<SEC-DOCUMENT>0001156039-23-000007.txt : 20230215
<SEC-HEADER>0001156039-23-000007.hdr.sgml : 20230215
<ACCEPTANCE-DATETIME>20230215164430
ACCESSION NUMBER:		0001156039-23-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		156
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230215
DATE AS OF CHANGE:		20230215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elevance Health, Inc.
		CENTRAL INDEX KEY:			0001156039
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				352145715
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16751
		FILM NUMBER:		23635983

	BUSINESS ADDRESS:	
		STREET 1:		220 VIRGINIA AVENUE
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46204
		BUSINESS PHONE:		8003311476

	MAIL ADDRESS:	
		STREET 1:		220 VIRGINIA AVENUE
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46204

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anthem, Inc.
		DATE OF NAME CHANGE:	20141202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WELLPOINT, INC
		DATE OF NAME CHANGE:	20100105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WELLPOINT INC
		DATE OF NAME CHANGE:	20041130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>elv-20221231.htm
<DESCRIPTION>FORM10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:454c8386-f90e-4c1e-9f8b-5fb66238439f,g:9bb273fb-a44f-4fa9-8c35-d6fee14cceb5,d:09daec87c4c344c8b0454b84b1a4fe73--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:elv="http://www.elevancehealth.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>elv-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV8yLTEtMS0xLTc4MDQ5_ae07ea1e-3be4-4fb7-bf31-96ac8de65b7f">false</ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV80LTEtMS0xLTc4MDQ5_a9a0b5a9-1dcc-480a-89c9-50b93e719eae">2022</ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV81LTEtMS0xLTc4MDQ5_3d63efd6-6c59-4b93-b994-930c3e4f8cdb">FY</ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV84LTEtMS0xLTc4MDQ5_9edc624a-13c5-44f1-b366-aeb7f4b1cc92">0001156039</ix:nonNumeric><ix:nonNumeric contextRef="i64441609cdbc496fa38247c4ed248dd7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3">P15Y</ix:nonNumeric><ix:nonNumeric contextRef="if9ced248bb284327b4df64ad260e211a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i22f60e8bbf864a89ba6d0bb4ef9e07bf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_afeade16-dee4-4795-8b19-99581c96cde5">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_346f76ea-dead-4d60-b08d-54ad913c9f6f">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_72ace3e9-597b-4518-a22f-101187f15e20">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="INF" name="elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDYvZnJhZzpmNTNiMDBmMzcyOWY0NjU1YjQ2MjQ3ZTFlMGEzY2NiZC90YWJsZTo5ODcyYzIzMmY3MTc0M2I2ODNkMjc1NDk1ZWQ2ZDk3MC90YWJsZXJhbmdlOjk4NzJjMjMyZjcxNzQzYjY4M2QyNzU0OTVlZDZkOTcwXzEtMy0xLTEtNzgwNDk_ae9b7ae2-9237-4e54-9e61-665571808d65">102</ix:nonFraction><ix:nonNumeric contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="if10138f4228d48388824633025312afe_D20210101-20211231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="if10138f4228d48388824633025312afe_D20210101-20211231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="if10138f4228d48388824633025312afe_D20210101-20211231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i647110a052c44104b85f07f28a55e14a_D20200101-20201231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i647110a052c44104b85f07f28a55e14a_D20200101-20201231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i647110a052c44104b85f07f28a55e14a_D20200101-20201231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</ix:nonNumeric><ix:nonNumeric contextRef="i19b75bd9929846879cf5eaddd4752c76_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad">http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib5abc1365f064e1ea869ec15ff3abcd3_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib3def97b16324c25b53915d44aa74ac6_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0">http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic1cb710db79d409384335a6604d0729f_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76">http://fasb.org/us-gaap/2022#ProfitLoss</ix:nonNumeric><ix:nonNumeric contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b">http://fasb.org/us-gaap/2022#ProfitLoss</ix:nonNumeric><ix:nonNumeric contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c">http://fasb.org/us-gaap/2022#ProfitLoss</ix:nonNumeric><ix:nonNumeric contextRef="i6c426fec08424ce089096359689f3d77_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzItMC0xLTEtNzgwNDk_81251d13-252e-4522-999f-5409e341d5c7">01/01/2032</ix:nonNumeric><ix:nonNumeric contextRef="i8676a9f8039043f9a4adf4d85b99b12f_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzMtMC0xLTEtNzgwNDk_59d065ae-7d75-42ea-aaff-941ce7d876b4">12/31/2042</ix:nonNumeric><ix:nonNumeric contextRef="i8837dd9386e64e11b2b5a657d243c739_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzctMC0xLTEtNzgwNDk_78a12783-16d6-446c-9d05-552cfd079ba5">01/01/2023</ix:nonNumeric><ix:nonNumeric contextRef="i6e4adbddcdea43adb30ab20715a88be5_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzgtMC0xLTEtNzgwNDk_21f091bb-c0b9-46db-8bc0-09486de219f4">12/31/2042</ix:nonNumeric><ix:nonNumeric contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="elv-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2398c42e085f4920a603bf9b3ed00ec1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i79090320ca5f4e8f812187d03517a85e_I20230201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2310c7de653445608cb615a91fde33b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf5b071c02144445ae1940007287f05f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8589c07204d749bbace5042c6b65cc69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f221c1344f471085a849bbadf705e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f53fa30766f4027ac9f51d714b28ca5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30274a1261ef49b2b0ed74d1f2f4ffd0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e30683b4044476b165b02ff7db9ad5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2672b85aeaa43e380a7c111f5228b73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793efbc5c7714f92b8248295269327af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if94c1fcb18c342dc8db391ef68ac66d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a79074187a456ab3c3c9edc81fd430_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if93412ca87a24e1a8d15a5d209e51bbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d4349f67ff4c61980f48af218a4394_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a827868fc64ccfacc19325aa44c171_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a2241770974cd59c85ae10194b94f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d68c3e5edf94c9cbe296449811771a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if422755e3e354c5f865ec51e2e1db51d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6946927fb5b546f5b3d2eaef12758789_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e4608246614931930218a735fc0cbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2494f99710864bc7a90c0848d3e5fde2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b6d6da5eaa4137b9f2ce6c292546d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad2035d69cb4c4bb3a71c39d076f734_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab35b50f371d4e109ef6e82fb6162116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4923e0fc5164066835e075d6d5a4675_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55f913977d34ea8ae0f65c274b41526_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62707788a92840b2a900639d9bb21b20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61b9bc047c24fe089b47010fc8c5147_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="individuals"><xbrli:measure>elv:individuals</xbrli:measure></xbrli:unit><xbrli:unit id="counties"><xbrli:measure>elv:counties</xbrli:measure></xbrli:unit><xbrli:unit id="states"><xbrli:measure>elv:states</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i64441609cdbc496fa38247c4ed248dd7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b94430fac3410384b74a0089cca3b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ced248bb284327b4df64ad260e211a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cdeae00e15947f2b19d9c357486c5be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4af8f693284287a7966314732d1b9d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf37da992005431c9ad91f291589bab4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f60e8bbf864a89ba6d0bb4ef9e07bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if071474e71e54a499f11bedc93cff54d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i842be0164ef642f19cf764709db72fe4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83026d2c318c405b900c3c41a9e37cc7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c555ed090374b7b9aa02f28d95d625c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de08eefaeef475eacfe40d3fec4420a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74006674df2c4b7198d31e2b3985d5af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652f2991b53941a1ac659bcb35e66d54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1938794b003c4dd68259f49f8b875e81_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66ac29085ee41519cfd744c0ac8e03c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bdd480b33d48f7a527eb0cb95e6c5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7079cee400b941a48ccb1dbed22219ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11008b88eee44f57a4919c3d0effdc63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92993e9e6dc54ce8b4394a223f436cb2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5647eb933f9e401e971742cbdc4d882d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:LeaseImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76840fe11a4246adb33e2fc35f9dce5c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:PPEImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720085721492466da1460ae790fd044c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b56ea1be96f4c70a8c1e7c9144fc68a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:LeaseImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66c129efd394897bd946da50f16dfa9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:PPEImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff881db619a457a91ac84f1aefaed9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:LeaseImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f02a690e784ac385d21cd667d6d637_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:PPEImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie891e0f02de14c5b99b6e50667fa8c9a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d0aff55fa54fd2a9a2a30c2e6c6a2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2229f739c29e4879809a6429e83712f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4fcad706e1b4867b404702dd922e926_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99433158fc54e1e93f623489413f8de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2df902d3b34cf4a36058a667c1980e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575634935f9d42e19be485bc9862c0f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f081e73a6c44fa88baccf8ed778d26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ec68f2e8874c1095494d4e367728a8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80df43e3b8244694a103a6571a73884c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba1560cbbed45a88ea28c07d58f145d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89cfda63370a45baa262eae4cf193a82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2fac999a95e4a5cb79ad594faeeb86b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7da5fca7f08493dbf6109531d652055_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e206452b4b4525ba8295deb406a4ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e00c7e161a54ca296d8ca502242628b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec50b6ddc92544c49b1a002b6bec5470_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c3b964b82147128c282f3d7907d1fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b44a4216564a04ab613dc30466a108_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b05263cbe6467f97da7e76b69399cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65761e7270d477bbc88316eeb1f57e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfcbc3060b964c0eb745c3af7c301df1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia153a0252f0c4f25a894df66b87f8a12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2334e7c069664e34bdb994a9760d559a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bf6477caab241859e5cf0650ec3947c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0418a7408fb4b69aee3f6404d135a23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i498cff72f8f34a2ab008f70e24959c30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="securities"><xbrli:measure>elv:securities</xbrli:measure></xbrli:unit><xbrli:context id="i76781baf46eb4f6ea9f326720c56d24c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f7d5ce1d5854f9ab123aec1ba08a66c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a0491ff0494ee48b5b1055821af090_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b47b4ff361f4031989f83a3333a82d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c623535470d4d61ab37acba9cfad54c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d18fbff221e4d46b9e4768147f370b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53403b97747a43718fc787ec172de61a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb31ce1cd8a2411fb9513a02d3ed3cf9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b0aede65fd4dd29e1f856a933eb6ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313a7fbc748841a6a6f1211fc6c0b559_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib727fd184c464a5092079464e697cc0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if532c3e8149744e285dc513d9e69b523_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:ThirdPartyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9313f67506114bbb8c5bc5b22dd2012f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:ThirdPartyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ad5cb59a1e44c5bef8850e5117517c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:RatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie118092ebec04fe3afe79f4870f4ed4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:RatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea80de425e5d4008bbefd6978deb3701_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9974d46da761480e8fd7c0dfc0115459_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d4050ea7e946fb83bc63f84f887ce0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf228ebc5ee4ed9ac397e8420d1727c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf0e0041e444850986706abfccd14c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349488ab238e4f40b2b347c93c7e1a52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d0c3a19c29c4b649862b0b586cdef34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie74879d09949481ca3d9a43e6f898eb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:EquitySecuritiesotherAssetsotherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c85d8180b384c1b902ff87d3cee955d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6479287b4fdd42e685cd3c578fd33e14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ce009ab57443fd98fe415da6193a1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09dd408e89d54981af41dcf162ba1bc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:EquitySecuritiesotherAssetsotherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81542d413fa4945bbc09e8c29161193_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f20343c2c574345836f7ccda1cb4891_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2fb9b4d38545ababb8320a29faa28d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFivePointFiveZeroPercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e594917ec14e3681954b85197676eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFivePointFiveZeroPercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56e8a6011ed4fdc85d7e0cfa580e4a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFivePointFiveZeroPercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie552404ba61c47b389e3c8fc6a697712_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459958d874344214bb9cac08d7d757ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia50a6cc46d6248a397c24a2ad0c2c744_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02888f49341a44d4941c9b1b6fb319ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida52dad48cef4deba690de9747f68ee8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7ee2dc635204bbf8650d842aeb2bac7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6d874468aa4ce6bcf71bd25597b297_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f4135503874ad1943ea10cbe7602f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06f61dafe7046c7a1f76c38c5fc05ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0d380b589e4106bb438dadcea77ccf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdeec77a2e849ab99853223554b64b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf6c3723dd347668da304307c4a44a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ccb539d68746d59161c8870f4d4df0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a4ad028b9a441cb7f6ba9a6e59341a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5be7d9b2d014385b6e19a6db3d6a4ec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ed18d384274ea3a14a91f034c105cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3411db499754ed98b66e11164278b68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a83586d8464e20bb8ad68eb2540321_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2303e464443d492f83362a773fe17a1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedThreePointThreeZeroPercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie189000e9d504c47b363ff6e09fccc11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedThreePointThreeZeroPercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61cdc82bcb443a8bf3d68ac1f8fb21c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedThreePointThreeZeroPercentageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272bebf1c8d949a8be406568bd0c2793_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c8de26adbc407f960803fd1f108a21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d7b5c7de1a49d48dd9569c22788930_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6fb48bbe5b4149b5d3e9962701d8e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c16b45922c4bc795ba956462757098_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="elv:HedgingStatusAxis">elv:TerminationsDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763517f93d014233863645c9d2bb0185_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="elv:HedgingStatusAxis">elv:TerminationsDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948573928d0f465a94e16e23831957af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8cd1ce29634691bf5ec4a6493a4478_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22c58671ad6415a8c5e55c98cb16b5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:NetGainsLossesOnFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ca95f113844a1a84afeef54a926515_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387703b787a3494b9ce325988abfd1f6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72f11ca13104ea894df74d97337dea2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b9f4d2b3cae4c11bac411a49ddb6174_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if10138f4228d48388824633025312afe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:NetGainsLossesOnFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34017a6ceea74441bb34336674de31f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26b5329fa2db4a9582fa955c6c09aa5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a12478c233d4cb4a3af16a5ece03ad5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a54e76eb8e745a0bcc186bff383f66b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647110a052c44104b85f07f28a55e14a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:NetGainsLossesOnFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic81edd70f3ec4b3ab957edfc0bf60938_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c774f65870474b9ff9c262bc7ac889_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3650a094504772a0bf73a6172f2a67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9096a0c9b14b4c9fa7be9af938dcc3ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99009b08fecf44cd93c279adb331703f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009bcd76d73148e5a865a59956651a7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b44c05131d4056a2f7c3c898130a7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72bd0d75b5c431692b8edb1c1c0d1dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id293b24cef6f4af1a37865b3f65c5128_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4723ab4fdb2541989a926b6fa4fa981e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c3b00e889545ffb01d1e62bf2b6746_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a55bb1adcf5446f8c1b805d8f31144e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd1383cc1874b88a8aa6f742ec27422_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206bf39a6a2e4283b7d98c5e5aba95be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica4de37099734e248456f4b9bcd0d11e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46e01dc3c644cd08544f306992b1cec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f78627f2e9a4f66a5c0bcdfdccb0aaf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ceef5d05b49498c84bc7a5735c400aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca8984787184bbbaefef048ae2a7ed2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c6a19fa0fd4060aabf6478982ccf36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0160f1f3dab24f569a23d2ba07f095d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb2feacd11c4565bfc6b5b6a3e279ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a873585c11f450d9fd9cf3c29c105f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51990bde857d4a5db236e8926558a29b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0441844ced744791a772d411eed7ca9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i904c347e51a64fb59bc57777f21d4ac5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f260a809bb49cb9e77ad6f5c2904a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f714be3d7a47ffa4d705a6678f8d4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069417d1b9bb426dbfd0f19f51c445ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca89489e7414de0a4fed48d20415ea2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if117aa6b760a48b191a9336dd1386d0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdae597d08f410ca9c02ca9b55441e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b75bd9929846879cf5eaddd4752c76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1417f5c20d04886b4a1c28630457c0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b78fb8e9294d4091b91dfb2f7b8dfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d2e3cdf76fb4346a9739172b0a28be0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5abc1365f064e1ea869ec15ff3abcd3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ebaa3e81cfc4ec9b580beed5caa48af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d91da7322044ebeb41aac5b19dd9fa5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aaff6ca3964450bafa714cc0aaec6db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41132adfcfc49268da644c34fda294a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92581736a99943b98dfe57570a7dba53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de34994aae94c3fa1fe238756f73e72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1333f2613ac4700882b9aa88ce86e8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dac1ad1470b43dab49c726357aa7ff8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c02d35e75f4475c925518ec594b0833_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3876e659055149f7a703040ca62a38d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea83cb6a8de4fa3949218ca98d32023_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if19a9ee228de40aa8494169d2d2d10e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0894905483914d83a324be50305c8544_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf99af398d9f47d5a429fe1dcacc1f44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4120bc1c539494db1a281d2596d5086_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3257f7fe574daa85e3967b1d116931_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04fa6f9d293449e69c6dc3044ca3c4d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731f097a1855416da64a94d30b7089d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7534f37a1c0488aa47b62fc88cc8dc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc437a887c994868be66d15b5875523e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib859e237e46b490d97c83b2fbc6eb7c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29501ab2755d404f9726f590112ae654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3039f8072e324d98beb39105271bc417_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39da1e7e5b0d4e3faac6f5afb10e8022_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fcb396e62c4b998da85a181a469648_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1831bed7a9a940b7b66b76e245b8018c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa94f2b63b1149839f52e2f831a1edef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16eafcfee2cb4d9b8e93262638fce1f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie822cce3164245ebb93dd26d240e4175_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11de76f442c4431cada80f558aa8ffc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2414d6cfbbd4765bf4121c62ca67493_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3def97b16324c25b53915d44aa74ac6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d3e183cefc842978e11387775c98361_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44e5a8e93e844062b0f224b3e55aed8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f9bbbaabb04060a11a6fd22a348392_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1cb710db79d409384335a6604d0729f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bede030acd1445e92925c2eb16fa9a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f18267c023f408a99a89907537030c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9d8f64f3ad45a084579266e307020c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4ecb9767514086a037990f8b694328_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f47d433c9f44b894af80bfe9cba63a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1c35519dba4644a3fb343be2411cac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3211a2672ef480891cfd22783436bf0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa94c0104acc4bf89ee5934a42f0fbc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d998702002443e1bdceee7c1cd3cda9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i360abcc2cf914906ae4e38a91bc64c5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e9582cb2ed44069090ba97e16cd18e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79df65678198415585bd1eadb7bbe9b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb612f5a191c437cb13598e31f479571_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865d332876a146d48476c774263e9f01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i876b8cfa43904577b851c227ca0f5cf5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8098a79a2da540da9b0adddcc15af4af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac255a2c1404484817fa038dbd46f96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686937bb287f43208495ac30ebad9562_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29275f18d1a443b99c9691261dec2159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib761ace65d4940a186ff76782f95901f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f400c669aa243fc80d850a5a79e4aab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813b76aca5e84f95975d45509f90c61a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe7e2d076a6470199f2cd23ff79750c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817dd5ae5155486e828b00cf52760c8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida04d4221bb546bc95004ba270b1eebb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaae7271d9499404cbd33f47b9000a9f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b12cb75dff40b3bf086b65a329faee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e3f09e2780b43d58044eb37c7023411_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">elv:DeferredTaxLiabilitiesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f3311caed27499f9d192299b6eb8a0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">elv:DeferredTaxLiabilitiesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e18d5b222e4195ad3fcd596a9a4307_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">elv:HealthInsuranceProviderfeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb438ebee364c309fc5d5bf8993c811_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99d2d66da9844cab49602099b561dda_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i725fb0d8346e4b058763cea8f52dbda8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6360a309b9734213b5078c4fb29519ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">elv:LimitedCarryforwardPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608f90ce9dc149a3bbb7d2041635b146_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">elv:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c426fec08424ce089096359689f3d77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8676a9f8039043f9a4adf4d85b99b12f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8837dd9386e64e11b2b5a657d243c739_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e4adbddcdea43adb30ab20715a88be5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5dcccaf6344690b4d7278e78ed1c0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6370e321e07c4309a9e458991006a124_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bbfdb76686848eba1f8e4e3f910ddd7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">elv:DataProcessingEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2273513928e9447ea6f22d1ef1546380_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">elv:DataProcessingEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c1eace13124235af0ad332c211c0f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299992abfe3a42a19dbf532c6dfc8e3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96687506b8f94774b0749011a7e8cc30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04cdfc65ff948fc912a66ca626eb27e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d2136218984fc386824cc3db496a1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42cda9b6c29f4c1188c4b091bb78bbdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc64eab57fde4787b3c18d688b193ef3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie605a92d69da478bba8a4d5a934346aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414a136e0db84003bf078b0578623a1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878444205e1c46049c539d9fd06405ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6addc423352741bab0b178cdde51da3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5282ee6fb6643008a314c4a693905e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1719b8ce5348aca152c341aa0c2afd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd5af0076694b48bcfd411f1a1d2e11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i307c5528ab3a457cbfb9833f2f43c891_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62dc3c697d8430b8c0877a6bd308c20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d28adfc0a54bd9baceff349c99b744_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c60676ab036430ab5cabf0a0d051ae4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i363acffb9a824cb3994c18c156fa9f14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef9f77b3653474080b83cf476ebe688_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8591443e8521443493e922d924cd9752_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666bee6f945341f288f2ce40ac054956_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i899c188b277246f88a96c04a8b0e3a2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4626139b5a5432daffd219066037e28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb27c8fb2e64bcca33419af780e6ad8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a7d829139842f08030a894802ebb5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09884f298c34bfc8b99687d69272ecc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399e8b1e21f5426486fa66186ca7a17e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba97ae25e674ac09265ecbdcc7c49a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e00926518a047ec902e830460f86c18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7eae151120d438b8aa81ae6d01ed182_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c987896cca46c88648cd9e0c631ac2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34e126013bd4bdd9dcbc1e1560410d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PreMedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28bb80744cf5451abb433b7a2ae2b2ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PreMedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af3c75b085341f79aae1e5b4a9109ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PostMedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i411e095557594f3599b08db79d9385d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PostMedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0439546d944cc89a588764266c7975_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecc2f49500d45e9a24a291a9d799fff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c312959f4143d697939a1225baf4a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd444af0664e4c1298d3fa8d8b705ead_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05d6861eb1d4839b34b143297bc3b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073e475229744657ac73e9da590e83f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc1af1b98554725ab989022f0630a0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3304b8d471184ac39be41951a5853e03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857507cd2bed48a9b9fe3fbc5b737056_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ace04bb2beb40b5a516c227c3ea00a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60a7d2ba705a4df69942c441186b72ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40578ab1c8b414884a39f3c0dae2822_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cc7418cfc74f5ba17ab4369f714947_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20102145585646cab0be477d78b18a73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6ab942bd2841168cdf7a7b4a3187a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda9b4fba37e447fb4c9600c624c8dc0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f81cdb55ce4e638a62241e00ebf0de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8d73bdd3b14402d844c2c0c59694668_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f28b66f26ff499d8c7bd3a51827b9ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4724ad9e28e04afa90e6467a8712ebf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62f9bcc18dfb447fb775b32088b6531d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf38d6a8dac24b72b1557ce07935c19e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3757024d2c6475cb1979d3770868e66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc490491d76a485b890f14584a038a3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d53728a1d54d7b9516dd30a8bdda03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c392f7e463f4339b291aa741cf0be26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2290abd15315443bb3b678c9c9e06e50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bca97fbdff84230a99f35c1a1dce85d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5847c45467bd4402971d8c43f9e23685_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8fa58a7f71b41e5ba27e355644a55ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6d48987cd74ff3be80bbd508db4661_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37817d0ad4574456871358f331c06a5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717a210731b940ee939db3c1dbba5956_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb399901683c4c35b4197be484a877d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc920e05c21b44d7961db2b67b504016_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac85b6a86c64d77b811c48e62a14bb5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89014b28ae34bfeabe6689041e3ca5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1a53d49d5c4867aa039a46e7568ed3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fec0c29d10b4a398f12075276df4a35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea2c0b2ce6a4178bc52bfce6465f76d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290e040e29e44712bfeb543bae80308f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingPartnershipInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218998b309404346862bc9cdba62f2cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4f2b19fc0245a59b7962eec5c99085_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f55d4ef714f45e2a97aae94dc3b7ded_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f648bcd3ed4b2299ff8051a9d130f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ce52d351384652a25cea41d5bf10d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e83d370570483a84584b1ba51b4a0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e1af2b6d3041098336c9393584e9cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab89283ade174a0bb7fe3b2918c3c835_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c28c3b58eff4d8e83e797a3c9dc86ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a52d405845744e3a22ff6418d046838_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica846717e1184bacb54d96b42ff8bfb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdd588c1a32a4b318e8824b9e80e833f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42abf7d75b0f4617992ff04363b8de28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3186402fca52479e94b30bea316112da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68819c4736484941b4667da3db092246_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fac223fbf12427cb4c55b80a18072a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic57c573544eb42bea430ba41085525f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8827a2fb2e7457595d626050de42f28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8708828d7a476587098de587d22948_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15ac02c8fcd427fae5b76de3ef93c01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2625252753fb4190bc4ba5269f5706d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b02994b45b43a6a51141e64ad4bd6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c345c140c9d4fc3ab7c4965bae458b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae1d87ac95d463f9fa59da4bbf23bce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacb113e118e7452c88560640a9b79b47_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4dd465b3a644ffba70709abd0e98ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8f6315c869439fbc63a0932a14c1b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142cfd8898984756ad60bc4f86418961_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f46381d5d84ab897c5e33368443242_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02fd6baa57ae461bbf3b32faaeb4ca35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id668c24327e44ed49160b1d70e4edf8e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9ca1afbe084ad2b78b08a5a7a9ab88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b4418327794b1ea9613fab77ce0af0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71836a62a044a1a972a740f6319ef84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c7dc7c1587494599625760bf34889e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549a8c00f0d749c38e43fa24e8a68fc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64aa8a2e665348d281dbb4b93dab7c26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5aaee2e719474ebec4de5223a6b859_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc72fc42cfa546b9b9e91cd582c83266_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84c581ad8f34d408c44634c9e7d0f91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64dcb287d7ec41c48e54b1306c36a88c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5524db3a83e64bfe85a82d222a654d8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37480e91464c49dd98f091245e025713_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90158ecd8c3e413386c593b81c9ec032_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26ec646267f4e85948a6ab2df7b23a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f8dc92496214bc1a120c9a3281fc5e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60a6a69355e3453493947ac5e9722c59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if820e1dc7ba1477ab9046f6f9fa76088_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bc64d208594f82a7ea1b06af17e59d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19857bfc8f948f1a850a6668ed7d8a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a5b59f05da4d839616ac13e1467ef1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81c850442314891a6ae5cc1a2f882f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e8077800b44d75af0b74ead71c6510_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c99e708c60467094ebc0103c16902b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2432a93c2642648f67e1ecff14d557_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401d253c03d541b2b15b77b43f0fd1df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48af28deba5435bbd08534c18358b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09876f128a94429b9227814e8df6c80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619c68bb39df4437a5e73314f08f8e67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6632e89a64e494ba984e898352b2f9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8c406fd2c74fdfafe3a57ed54a171f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ca6e2453404a48a52750e3e90e1c47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8105dc0c76f840128a4f6f87b9a897eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2552bb36ef2c4777893433a656282c25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a5175770b84cb4bab9529b3ce7bec7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1e3d70c034b4a9085ff1de6d2ce55f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131d7dc36ccb49a299712a5e82f3de3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9ec8958dad4e25b4dec1bdef155303_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666be2a8dc0345ef89405b86d686e7dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60bbfca782904064adf3f965eb407772_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c793768fac34476a639c2429c54308f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718358de146a4a6c93c1a4fe8ea02b90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4b302cec1d435aa72e21490d245992_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0301f217169748b8b9564b716734656d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3486851087a1461cbc7cdbd886031e0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824079b6e48d4bb5800315785acae403_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8acd54cdd7834f65b9fd34a3eecb83ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ff876d8f4d4e13bfb398ce15c78dfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingPartnershipInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da33ae4440b4e3e9858280b13b26b86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df6e9e072f7410bbe91dd8464dc1559_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b4a5ab5d5945078778d6bf6cb1a8c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81f254578c34d74b6c7ee4044f8bdda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6ac436f09047b58b9afbeeb2bfe737_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f7e00faf9c423987fb23403b1098bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc47fc0ad92542a9bae68627e6bef5ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25321d10a7f6437fbb4bcfce57f68be4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea480fece154d2f860656f2677bdfd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3ca81f42d6d4bab8cfeaf80de0cb1b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2ebfa875334d19ad5216074deb2d4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a519ff398f494e846042ee96a98679_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a64acd001884c8e9e9bb3b1a965529e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib46c9cd33130445a91236aacb780d027_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfe1e0781264622a6679afeb0a9c720_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bce5bacf7c24b4f9dc864afd7e4ca87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917c455132fb4e1e9f340d3bad48d102_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icefbd8bbbac7446baf3a38dca505dfea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie579e5cdf455475b9502356566def862_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6eee54cd694a2ca132251fbf4a7f5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a66d7e68f44e50981c5465d04e22bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7b6dd2b55348cba5836b9c067d3c29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia263eb55917d4d3fa6a60e7db1c48a3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4974aa0eb2c24470b0039864c0415900_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ded0fd871644ff591de8addd589219a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c81070f0b3b443c8f18a8f1214732bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d680746121d4419b3c54ef8acb7b9fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20a6873d906447385de48452526511e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc7ea082cf84448a7ec7762124b2a4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4376d31b137c4d3a8e1c905705497935_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52db6dff7f164d5e890ff1578cbcb759_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4b5962d9e5e4af890e2358bb3edbb03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bcdd3e9146f4beca1f89cb52fea78f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id541168132e04301912466c96cf4ad90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15061749f3f2485aa1798b8186e3f2c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087044734b154901b0cfed0b0f5d93dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e196f381254b4da2543763f22de2fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id05c5e1befde4b3d876502ebb2794242_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53abc6af4dd045279ea54e62550af65d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib689e1a2aa1847a19d4aa925acdcc69e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3aa30468184cb8b88f01ef4d14e83b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5874492cbb402d81d69b55109ae43c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7580de5335c2453fbc6266565e5baa9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48a8bf89b7b4def9e1a900fde56e8da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80355d52e2674470b51aa353a404d82c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f8ffbfbcd842e88af9bfbc67f7e567_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ad54fe654c42efbd77c7bb585d643d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib360e9af4b21497d82c013681a5dadae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd65a74e5704da5920113ea7aece196_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99956a06c7e46e1849e1ddf398be5df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6904393673c940ae893924fc97c16cda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932bd361ffbc47c298c90d616e0667b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe4907f34814d2baa614ba2fc07e320_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d6ceec20cd424fa94e7a6386ac5a78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id885b4e505b34b40bce2c6278117709a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55238bc0d8524816beff8ed796471899_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4334628ce145889a7e9f45088dbc5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253166758c5642418ac341338d564041_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i056128fedb8c4604822fdacd5c2f6272_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4172e7e04f43ae913e486aafb0c782_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aef76e4813e4606b8d70440c92f269a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23463b26e20041c888dd2c51a2181294_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44d7cf6e14d4446b34dd7ca19bc223b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6fbed5f4b7543ab8092cf310b884173_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1ab83b37e744c8899d7e3adb51c2939_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcabc74836324dbfa6c75eefd131bc85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifab00825672c4350bb49fbe11bbfb810_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9e96e08f9e4d9eab2889e9f25825de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b1e52956f34852bb67f516ba0647b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4efbc97b18234003842819922bc3113a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefeea68ef91044dc982120c3a3a950bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2066eaf9a484ad59e9589c14525a5c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e702d4536f4799a919aec9da8593e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4c9f11d99845b8921be755ddf836f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d1014df09f4661bc24d1661e77bfc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b68b45f4914e09ab526057a219f954_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id063c136e8d646d9a71a21018eada61b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cf1a9340bcf4268a0cbab4e753cb90e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53292eeae2a246e58c5a7bcb2a4337ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac5c44b376048bbae8a2f0719d42263_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949d008a3d0b4b8d93c2d6a4799ec855_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec6bfd612d64307b2a756760684ffe0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaea1bc60c1634bd889b51a318197368d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1c710fc55e47898c1d2f197e749108_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c611a7c74d4ab8ac5a98a6fe0e2728_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7636254161774196bf8c04399ddf133f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4154a06006b4cafa5cbd1a889726e29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e53d3ac9be45f58795982cc797e03c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a05e7eaeb64ad58b3d1f47ad49fa73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2607b444454d46e39b6286f9c8ea6e3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c77106efdf14a58abf9fc4127c8b091_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811d733c6b02495580c52c781054171e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e70d3f0aa9435ea3f59013c328d36f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90d8e2c8f9446bfbdb944daa4c9681b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3de8e0b39443b7b0385091bc11bf77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db25862eb95484085247b52a174b160_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2272113d58402ba5f389923853a07f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5aadb40cfa4a7c8342724cdc2f58c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb71d9d282b643fd8703d9459d16e56d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091a2bb4b5f242c3ad68068b656e90f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b72b535fce46bf8f61743fb9e18481_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70a6a0be4d643d3927176d45192c141_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134f72e11a1649b7934274f86bea6020_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf998fc82656469e90d336c2b880f377_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6946a35fa850465fa36f14fc4f52f7bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67736d5753d44699b20adb0618b589fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4f13755a194230acb1ec087846b505_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a828e106b94047928ff146300d2ed0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba93ec717e94394a8955cf9f5de9f90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e6cd38e3e84d5580d856acbad97133_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie323f9332ece4230a9778b8c7d487528_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4c77f05ea246d1b396cda16a6f5b1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353e9848174344adab8b80f569e38864_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22dd705e96640c28ac4a3b93dc44cb7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9c543ff2b843e8964521415571c09a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i928bec5ee982461199847da9ac96d68b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ffc1ca7d414bbd94fbe98e6dac3891_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc050557e394d4bb08e2383bcb0c73e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightZeroZeroPercentDueTwoThousandFortyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029531456f0742b18198f12d8893bbdd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightZeroZeroPercentDueTwoThousandFortyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice205a4939054c86b0d0fab99c58c6de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4c04d831ec4f03aa3ef7b1e8fae480_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4301f61a56d4a5981fa5a8be60c5456_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886b4f01b01343e99f882cbfedb38b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c8b1a203e04bc98e13209d268178e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12d2d5430234b8da43f315a70dbda73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11833466f4c4e66b1df0bdb5615948b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e99111afc84fa281a0286ba240fd53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188c10cfbcd14ea593ae781c8b7d8219_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86370035d0f94594abe20431af0befa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6caa66b97514d68ba837991fe14dbdf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe622a0dd5c41d5bb15002f914046be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba76da0d560460cb028e0c65f72ea97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3ed97bbfa0946bc8f76958f0fc5eb16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6bb5890f644dc2a4785a6cd8b1b0c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d118ac360bd4e3aad70d1189c447897_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74f9a1abba844ef9912af38aac619e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ffc9a6ff1d499eb81b8fc7cd50feeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc6cdf9d6fe436c9e1912baf09467ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic855e040017843f28f7041b2bc021f66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c3fc9281644847a3ab3c94cd2f8927_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b0fd92b63040658ab461c35f466977_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1151ddbe0ece40b18eadc2621477a0ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871498f5fef9430a894e75b1f70e1af1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00522144e96b43829be3251cd73df914_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SurplusNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic08004c17645430d9704d5e79d29fccc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SurplusNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80cee633ac84a32ac44408267eda7b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice43633ad18f45a3bf5610792f8e0e92_I20230208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9fbf8cc11e742c2b3eb7b913dbc0f53_I20230208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38626e3e281747b1864dc478c857e132_I20230208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3702fa1806f4f55afc1809dce531453_I20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad77e559c2a94999bb397fa384a544e9_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f2459563994824a4b0a6fe56121a68_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0933651ffe04b7bbdbc822cd8b57555_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14c797d21b24b8e925b9f7f60a8b208_I20220516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73dc0aa91534a999012a5f25833b272_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333b97a4235d45a5a86902df2d17954a_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ce9e81a0d3461dab8dbc07066d500d_I20210515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac73002099334b069811ed521ffc2f61_D20210515-20210515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-15</xbrli:startDate><xbrli:endDate>2021-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc2487f523740c69014d98ef48fc2ae_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429662b30ae84f4fb822ecd377e98b9c_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cffe8dccdc4ee6945a8e5fea7b55b4_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325bf58af121477aaabb4ba211cc0a8b_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:OtherSeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f86ebcddede41c59e36155926d5c738_I20201123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb1aa80db82419e86533f0ed7493781_I20200817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:OtherSeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca42aa1e7484753ae2809b124a577da_I20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41649eb783044c5eb58218b8fa152592_I20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6256919a6f740e9a7538e63d97e56c3_I20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ac997eed1f49e1bc4fbe2c7718e08f_I20190909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad3cc9878d194c6ab4cfcad7ad636235_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A5YearFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ac0254b163e4965ada5424581be8b2f_I20220418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A5YearFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83efaab7af2c47789e213ba327cae52f_D20220418-20220418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A2021364DayFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-18</xbrli:startDate><xbrli:endDate>2022-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99dac9a626014a259743a75faf51bbc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A2021364DayFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78ee27d7ced94e33a81e7cf47376711f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111f1669cf354c22bca3fe927cfeb62c_I20121009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3deab0f622924f9085bea8fcbe5ee03c_D20221015-20221015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-15</xbrli:startDate><xbrli:endDate>2022-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac96933216134d7b8897d64076389449_D20230213-20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-13</xbrli:startDate><xbrli:endDate>2023-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6cc8a906b734cbb88951da261ef5f76_D20121001-20121002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-10-01</xbrli:startDate><xbrli:endDate>2012-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168f8f6c7055487690a43cb967e499b1_I20121002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2e9b364d454a189b9c63aaf27ed9ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">elv:PharmacypricingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">elv:AnthemInc.v.ExpressScriptsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530e77d500e24332972b126eb61ad553_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">elv:OperationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">elv:AnthemInc.v.ExpressScriptsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb67e7d15ec40d393dc4ea0b4156be1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">elv:AnthemInc.v.ExpressScriptsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f482fd60e844e1aa802036bfbb28f7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94919fea365f4bf3810bbae7fae7bb53_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e9f319025d420eb32e7522fd74ed84_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie674fb9fe21244e6a1ce2872735af01d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91235d6e1c7c4af2b57d1b5d2854972a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:PerformancemeasurementperiodAxis">elv:A2022To2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic773a96084d446cc8f83053d1d3e03dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8aebf8ee5444e509fd8796f5ae27e76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f291e82852495c91f39ae516cb5961_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd001b0d68c34a668c7fde379c754978_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f7a4356b364dabba6bc38e7490c8bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id765367318fd412f9615ba9f41b69d33_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f793b028bf243b29bbcb6a44fa763f0_I20230124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia027da647af941768a3f104492aa7231_D20230124-20230124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6527b2d9fe44bd9c916d8863257a5b_I20210126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e95a8c856b14a5a8cf3fd92402ef4e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e698e227c346ae9586de0d8e1b1dbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95514d7548341cba52815d3f07c28d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08958ab7b46246489adf526e350f151f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcebd1544ec64ec6974e038a69b087db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a792ee17bd44f596cabc8ef3e8b4b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1482b2c7c0ff472fb0c9110009b806b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47960b8964ab402a942e197e579d8542_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4bd3fce911457baee6a8c050e6b70e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e36ba6bb351437bb13a37f1503ac813_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653b1eb3d81f4ca192dd6d3ffca11785_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246d9c069b344181a326be72f32bf256_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5723b60554294bebac94c904566db3f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98cc61d631e54bd68ab0e26a98a4905b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c01f7b130a4ac4a08d21b45fed6866_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b85f7bcceb24f4585583cc791c6fd0e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id351a075bd634b1598a879fd2e805740_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c5ae1b587c4de3a0abc993e1f65329_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9aefa095e5f4dd99aff2909fbcde15c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54dc7a29f571431296c8be227f11aabb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94ead6cf6db4e7fae98eafe846f769d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9323e18f92640a2a7c38e4273db90ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d3abd401b24655a17b8c74f5dd40a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfbd0421f60f4e64bc47776a3602ab89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2395d6d373c34b2ebab39d8aba7606e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa38daf500d4a73ac08682fa99f7730_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a127625ab7b4d44a9d9ad36c6e50197_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a1b61e2bc84caba4a714fd57739c74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd38742893d7416999e954ec984556f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798cec4e64e04bffbeed267a216429e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b77786d1b5c4248b0483a8990b79b0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59f5a3300a74c28a300c63349dea8cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae88b41165f46938384528eba3e864a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>elv:segment</xbrli:measure></xbrli:unit><xbrli:context id="iae176fbb87f54bac94b2e4ab0685d43a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98132071c63744ada30c2775fc5af988_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55d196caf5f45cfb07e66b8da2097ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df81813ee544edea31e2c74936bff4e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ba170c8f794d3bb4ca06d264b4e57d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d0c0663315405099698864eb3c19b8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2baaad3463642b18170d3f49e7ddc87_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8429825b5f7e40ca8d6e68d3bb26eab2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:SegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7278c60e164f14b96b13c3df65ba4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f05b417fd04be8a1aeab8299b5c69e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10db0a695d24e41bdf7833886001b71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c8e72dc40f4442b092502acb15a96c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie412ebaf29714d329b7b8b83c7ba69e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:SegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bef8962735044b1acb083bc20e63486_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icece7f971bda47f8bc76865f9659c5da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ebc5e9f4d1042a38e45cd00bce22554_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4cd355c6dc4109bc5041d9057f2121_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0d2a7152494f90b39b3fac5d9264ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:SegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c68969e3f114ff69c401be9bc37c2dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e22951986404675bbf5fbfa2839786c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i894b5d431a7047808e5ff7ebf443d016_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f62da538ba41f789a6a73b38e537d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123ffb166421487082a09f78c1725ebc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6364bd9ed8464178afda9d8855f8538c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8365100e5c9406a9883eb34ce369cba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:DentalVisionProductsAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ac17248d75456fb25896b8926586fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:DentalVisionProductsAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e94cb6360045ddb9b224a2f973d9d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:DentalVisionProductsAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3efe3527b82f45b4924c08cd2aeadf1f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cca4acaaa048e6904800f45ff39923_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735ef38ab9e648319f8e6b267c9164a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5157a3ffc8b8454a9197a5de365fbaf8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162dcb32162845ee8019a58aa859ae61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647d737a8abe4da3b8caeb6484d9b75d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42d0d2379bd40ba99bb0908ac993e6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c132f1b799e4a88b13c0fa30393e947_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79df8d34415c4640aa3a9d6958c599d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2abac369da1f4652a7813e0cd7aa350f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:PharmacyProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9d4685e2e749a2bc8254783454a3a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:PharmacyProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd36a7c95104275aee23983a5df35b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:PharmacyProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0dd4f771c744f2831d7f9d4dc1c0a0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:IntegratedHealthServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i458aaaae8b4c42abaaad6c6a529cf94d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:IntegratedHealthServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f95fe1cae3741118461bf71f33280c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:IntegratedHealthServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i096ee1cf57a8446eadfaff116cd44804_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0624a80296bd435499ecbb5c951564b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18cf6ebd6bf46c08192134b8ce7cfcf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417b0315d1f946278154f230d44ba1b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">elv:APCPasseLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f82c8853704ae1861ff012a8a6a705_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">elv:APCPasseLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4356376bd2bb4161b623b19b110ab07e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">elv:APCPasseLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b88a75959a3413fbf01add2bd34bcb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i725512778bd442a6b242345331bb3a06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6bc2c55daf14d049cede53415aaef62_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18e88e0db7ff4756a456b1a7ffd88b77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6ef69580834645b272fe1032c1d97a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2684dcf65c140fca76ea400241c2590_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088d91ca9c3148788190accbb142e04e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac9df3234b44acd9d0fc7e8d58b001f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida62205932654bdd82996ed0187717df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001156039</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMw_a12c5ad1-ffee-4d9a-b7e9-b95c28ce86c3">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6YWE1MDBmNGIxNDAyNDQyMmI5YzdmMzdkMjFiMzE4NTYvdGFibGVyYW5nZTphYTUwMGY0YjE0MDI0NDIyYjljN2YzN2QyMWIzMTg1Nl8wLTAtMS0xLTc4MDQ5_3480fae8-a7e4-42a7-90ce-638033378c93">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE<br/>SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8xMTU0NDg3MjExMzY5MA_e408e793-3f5a-44ad-b621-76ebaf7c275a"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8xMTU0NDg3MjExMzY5MA_33a5b539-aa45-4923-9215-1a2144167298">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MTU5M2IxNGI4ZDcxNDZlZGJiNGU0OWZhYWMwMGJiYmMvdGFibGVyYW5nZToxNTkzYjE0YjhkNzE0NmVkYmI0ZTQ5ZmFhYzAwYmJiY18wLTAtMS0xLTc4MDQ5_dc8ed8ea-20d0-4f05-a4ed-b43b3c2740fb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE <br/>SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI1_80e0d06d-9a94-4e92-9178-3b8b15a916a3">001-16751</ix:nonNumeric> </span></div><div style="text-align:center"><img src="elv-20221231_g1.jpg" alt="elv-20221231_g1.jpg" style="height:40px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMz_cd323c05-fa8a-4a5b-b2b6-ebe879a5f432">ELEVANCE HEALTH, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6ZmI2ZTczZTYyMmY1NGMyMmEzMGIwOWE5MThmNTY0MjAvdGFibGVyYW5nZTpmYjZlNzNlNjIyZjU0YzIyYTMwYjA5YTkxOGY1NjQyMF8wLTAtMS0xLTc4MDQ5_95dab6d8-ac42-4236-a223-e149680dfc1c">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6ZmI2ZTczZTYyMmY1NGMyMmEzMGIwOWE5MThmNTY0MjAvdGFibGVyYW5nZTpmYjZlNzNlNjIyZjU0YzIyYTMwYjA5YTkxOGY1NjQyMF8wLTItMS0xLTc4MDQ5_4831da9d-c732-486b-a16a-a137df2f5298">35-2145715</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of <br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM0_a22b3656-2ab5-4e06-92dc-f64af6b48e3a">220 Virginia Avenue</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM3_f6f29eb0-cc1a-4f36-8693-5a31d19c687a">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI2_3b9377fc-96b8-4420-9e55-322aa0486dc8">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI3_9f7cd8ac-c3e4-413e-8d09-d783ad7a7034">46204</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM4_e649c6d5-35cc-4d4c-a4e2-d8cca1042938" continuedAt="i2325c08e95d44e00921e74c820ea936f">(</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i2325c08e95d44e00921e74c820ea936f">833)</ix:continuation>&#160;<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM1_8e61f054-ce81-4af1-959a-55fe1d27c530">401-1577</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MWQ5NjQ0ZTg5MGE5NDE3MWExNmU3NmMwYWE3NjE4ZjQvdGFibGVyYW5nZToxZDk2NDRlODkwYTk0MTcxYTE2ZTc2YzBhYTc2MThmNF8xLTAtMS0xLTc4MDQ5_92c790d2-7ac0-4f5c-ac1f-c4cf1d48a443">Common Stock, Par Value $0.01</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MWQ5NjQ0ZTg5MGE5NDE3MWExNmU3NmMwYWE3NjE4ZjQvdGFibGVyYW5nZToxZDk2NDRlODkwYTk0MTcxYTE2ZTc2YzBhYTc2MThmNF8xLTItMS0xLTc4MDQ5_c8af7136-4206-43bc-963f-b9353d8f32d0">ELV</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MWQ5NjQ0ZTg5MGE5NDE3MWExNmU3NmMwYWE3NjE4ZjQvdGFibGVyYW5nZToxZDk2NDRlODkwYTk0MTcxYTE2ZTc2YzBhYTc2MThmNF8xLTQtMS0xLTc4MDQ5_beb58414-cb7f-477d-a4b4-1eac4779f50c">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: NONE</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM2_b0d7cfce-8de9-43cf-ad70-2ccd48e7ac28">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI4_e11c3acb-e28c-426d-b5a5-d8f794f33e76">No</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMx_21e7ee74-bfc4-43c6-8166-2d651ffae15b">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM5_a890c954-68de-4920-bffa-ac244c69a589">Yes</ix:nonNumeric> &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:24.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6N2NkZGJiNzUxZThmNGRiYzk1OWRhOWI1NzhiMzEwZmEvdGFibGVyYW5nZTo3Y2RkYmI3NTFlOGY0ZGJjOTU5ZGE5YjU3OGIzMTBmYV8wLTAtMS0xLTc4MDQ5_984100cc-56bd-4c4c-8ada-d118553a0cd2">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6N2NkZGJiNzUxZThmNGRiYzk1OWRhOWI1NzhiMzEwZmEvdGFibGVyYW5nZTo3Y2RkYmI3NTFlOGY0ZGJjOTU5ZGE5YjU3OGIzMTBmYV8xLTUtMS0xLTc4MDQ5_f4405613-50d9-44f0-88e9-3b271cae9631">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6N2NkZGJiNzUxZThmNGRiYzk1OWRhOWI1NzhiMzEwZmEvdGFibGVyYW5nZTo3Y2RkYmI3NTFlOGY0ZGJjOTU5ZGE5YjU3OGIzMTBmYV8yLTEtMS0xLTc4MDQ5_b78d9fbe-d792-44fc-96b6-23e42e1f7d5b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMy_c7f3ea68-1b26-49cc-a8b0-ee8884200cb6">x</ix:nonNumeric></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrants&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b) </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#168;</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;&#160;&#160;<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjQw_efa152eb-83a6-4fae-95ac-3de640403e1f">&#9744;</ix:nonNumeric>&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (assuming solely for the purposes of this calculation that all directors and executive officers of the registrant are &#8220;affiliates&#8221;) as of June&#160;30, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2398c42e085f4920a603bf9b3ed00ec1_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8yOTIw_da8404de-e69d-4768-be8b-4ad412e7566d">115,691,972,993</ix:nonFraction>.</span></div><div style="margin-bottom:3pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of February 1, 2023, <ix:nonFraction unitRef="shares" contextRef="i79090320ca5f4e8f812187d03517a85e_I20230201" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8yOTM0_e975f108-6fcc-46c0-836b-f14293b5bdbd">237,457,776</ix:nonFraction> shares of the registrant&#8217;s common stock were outstanding.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI5_c6265b9b-7d5b-4e13-b2fc-afd6816e0f4f" escape="true">Part III of this Annual Report on Form 10-K incorporates by reference information from the registrant&#8217;s Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 10, 2023.</ix:nonNumeric></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:12.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_13">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_16">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_16">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_19">UNRESOLVED </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_19">STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_19">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_22">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_22">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_25">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_25">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_28">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_28">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_31">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_34">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_34">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_37">[RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_37">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_40">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_40">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_58">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_58">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_61">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_61">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_181">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_181">136</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_184">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_184">136</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_187">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_187">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_190">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_190">139</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_193">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_196">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_196">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_199">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_199">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_202">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_202">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_205">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_205">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_208">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_208">140</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_211">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_214">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_214">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FORM 10-K SUMMARY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_217">146</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_262">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i09daec87c4c344c8b0454b84b1a4fe73_262">153</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-1-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol &#8220;ELV&#8221; on June 28, 2022. References in this Annual Report on Form 10-K to the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Elevance Health&#8221; or the &#8220;Company&#8221; refer to Elevance Health, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries. References to the term &#8220;states&#8221; include the District of Columbia and Puerto Rico, unless the context otherwise requires. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as &#8220;expect,&#8221; &#8220;feel,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;plan&#8221; and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not undertake to update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including healthcare laws and regulations, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing pharmacy benefit management (&#8220;PBM&#8221;), healthcare and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_13"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. BUSINESS.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Elevance Health, our purpose </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to improve the health of humanity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is central to who we are. It inspires all we do and is the driving force behind our unique approach to health. We know to meaningfully improve health we must take a broader view. That is why our foundational approach looks at whole health and its most critical drivers: social, behavioral and physical. We believe in working together to achieve our mission of improving lives and communities, simplifying healthcare and expecting more. We strive to deliver on our mission by maximizing the power of partnerships, innovating to fuel growth and health equity, and having a high-performance culture. Our strategy is to become a lifetime, trusted health partner through the following four core focus areas:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Whole Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Partner to address physical, behavioral, social, and pharmacy needs to improve health, affordability, quality, equity, and access for individuals and communities.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Exceptional Experiences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Put the people we serve at the center of all that we do, to exceed expectations and optimize health outcomes.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Care Provider Enablement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Be the easiest payer to work with by supporting care provider partners with data, insights, and tools they need to deliver exceptional care for our consumers.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Digital Platform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Use digital technologies to improve efficiency and experiences, convert data into insights, and create a platform that connects stakeholders from across the health ecosystem. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With an unyielding commitment to meeting the needs of our diverse customers, we are guided by the following values:</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Leadership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Redefine what is possible</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Community</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Committed, connected, invested</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Integrity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Do the right thing, with a spirit of excellence</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Agility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Delivery today, transform tomorrow</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Diversity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Open our hearts and minds</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members through our affiliated health plans as of December&#160;31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products &amp; Services business, which administers the Federal Employees Health Benefits (&#8220;FEHB&#8221;) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (&#8220;PBM&#8221;) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are an independent licensee of the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#8220;BCBS&#8221;) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer PBM services through our CarelonRx, Inc. (&#8220;CarelonRx&#8221;) subsidiary, which was named IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all 50&#160;states, the District of Columbia and Puerto Rico through our subsidiaries. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield &#8212; represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellpoint &#8212; we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Carelon &#8212; this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we managed our operations by customer type through four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. As we continue our journey to evolve our business from a traditional health insurance company into a lifetime, trusted health partner, we are evaluating and making changes to how we manage our business. This included a review of the products in each of our operating segments, which resulted in restructurings between some of our operating segments. Therefore, our reportable segment presentation in 2023 and its composition will reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources on January 1, 2023. For additional discussion, see &#8220;Reportable Segments&#8221; below in this &#8220;Business&#8221; section and Note 20, &#8220;Segment Information,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe healthcare is local and that we have the strong local presence required to understand and meet local customer needs with regard to any product they are enrolled in with us. Further, we believe we are well-positioned to deliver what customers want: innovative, choice-based and affordable products; distinctive service; simplified transactions; and better access to information for quality care. Our local presence, combined with our national expertise, has created opportunities for collaborative programs that reward physicians and hospitals for clinical quality and excellence. We feel that our commitment to health improvement and care management provides added value to customers and healthcare professionals. Ultimately, we believe that practical and sustainable improvements in healthcare must focus on improving healthcare quality while managing costs for total affordability. We have implemented initiatives driving payment innovation and partnered with providers to lower cost and improve the quality of healthcare for our members, and we continue to develop new and innovative ways to effectively manage risk and engage our members. Further, we continue to expand our financial arrangements with providers to implement payment models that advance value-based care. We believe focusing on quality of care rather than volume of care is the foundation for improving patient outcomes. Our value-based payment model supports patient-centered care by improving collaboration between providers and health partners and delivering to our patients the right care, at the right time, in the right place. In addition, we are focused on achieving efficiencies from our national scale while optimizing service performance for our customers. Finally, we expect to continue to rationalize our portfolio of businesses and products and align our investments to optimize our core businesses, invest in high-growth opportunities, and accelerate capabilities and services.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact on Our Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective contracting with providers of care to our members, product pricing, medical management and health and wellness programs, including service coordination and case management for addressing complex and specialized healthcare needs, innovative product design and our ability to maintain or achieve improvement in our Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) Star ratings. CMS Star ratings affect Medicare Advantage plan reimbursements as well as our eligibility to earn quality-based bonus payments for those plans. See &#8220;Regulation&#8221; below in this &#8220;Business&#8221; section for additional information on our CMS Star ratings.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information on our networks and provider relations, product pricing and healthcare cost management programs, see &#8220;Pricing and Underwriting of Our Products,&#8221; &#8220;Networks and Provider Relations,&#8221; &#8220;Medical Management Programs,&#8221; &#8220;Care Management and Wellness Products and Programs&#8221; and &#8220;Healthcare Quality Initiatives&#8221; below in this &#8220;Business&#8221; section.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advances in medical technology, including new specialty drugs, the aging population, other demographic characteristics and the COVID-19 pandemic continue to contribute to rising healthcare costs. Our managed care plans and products are designed to encourage providers and members to participate in quality, cost-effective health benefit programs by using the full range of our innovative medical management services, health-outcomes based initiatives and health quality-based </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial incentives. We believe our market position and high business retention rates will enable us to realize the long-term benefits of investing in preventive and early detection programs. Our ability to provide cost-effective health benefits products and services is enhanced through a disciplined approach to internal cost containment, prudent management of our risk exposure and successful integration of acquired businesses. In addition, our ability to manage general and administrative costs continues to be a driver of our overall profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future results of operations will also be impacted by certain external forces and resulting changes in our business model and strategy. Changes to our business environment will continue as elected officials at the national and state levels enact, and both elected officials and candidates for election propose, modifications to existing laws and regulations, including changes to taxes and fees. For additional discussion, see &#8220;Regulation&#8221; below in this &#8220;Business&#8221; section and Part I, Item&#160;1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are also impacted by levels and mix of membership, which can change as a result of the quality and pricing of our health benefits products and services, an aging population, economic conditions, changes in unemployment, the continued and future impact of the COVID-19 pandemic, acquisitions, entry into new markets and expansions in or exits from existing markets. These membership trends could be negatively impacted by various factors that could have a material adverse effect on our future results of operations such as general economic downturns that result in business failures, failure to obtain new customers or retain existing customers, premium increases, benefit changes, membership impacts caused by COVID-19, including how our members access healthcare services, or our exit from a specific market. See Part I, Item&#160;1A &#8220;Risk Factors&#8221; and Part II, Item&#160;7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to enhance interactions with customers, providers, brokers, agents, employees and other stakeholders through digital technology and improvements to internal operations. Our approach includes not only the sales and distribution of health benefits products through digital technology, but also implementing advanced capabilities that improve services benefiting customers, agents, brokers and providers while optimizing administrative costs. These enhancements can also help improve the quality, coordination and safety of healthcare through increased communications between patients and their physicians.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our participation in various federal government programs, we generated approximately 28% of our total consolidated revenues from agencies of the U.S. government for each of the years ended December&#160;31, 2022, 2021 and 2020. The majority of these revenues are contained in our Government Business segment as described below. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly evaluate the appropriateness of our reportable segments, particularly in light of organizational changes, merger and acquisition activity and changing laws and regulations. As discussed in the &#8220;General&#8221; section above, we are in the process of organizing our brand portfolio into three core go-to-market brands, and are reviewing and modifying how we will manage our businesses in the future. In 2022, we managed our operations by customer type through four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Commercial &amp; Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members. The Commercial &amp; Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits as described below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services (&#8220;NGS&#8221;) and services provided to the federal government in connection with the FEHB business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CarelonRx (formerly IngenioRx) segment includes our PBM business. CarelonRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, a prescription drug database, member services and mail order capabilities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other segment includes our Diversified Business Group, now known as Carelon Services, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain intercompany eliminations and corporate expenses not allocated to our other reportable segments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue our journey to evolve our business from a traditional health insurance company into a lifetime, trusted health partner, we are evaluating and making changes to how we manage our business. This included a review of the products in each of our operating segments, which resulted in restructurings between some of our operating segments. Therefore, our reportable segment presentation in 2023 and its composition will reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources on January 1, 2023. As a result of these changes, beginning with our Quarterly Report on Form 10-Q for the first quarter of 2023, we will report our results in the following four reportable segments: (i) Health Benefits, which will combine our existing Commercial &amp; Specialty Business and Government Business segments; (ii) our existing CarelonRx segment; (iii) Carelon Services (our former Diversified Business Group), which will be carved out from our existing Other segment; and (iv) Corporate and Other, which will include businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments. We expect to reclassify previously reported information to conform to the new presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 20, &#8220;Segment Information,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Membership</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical membership includes seven different customer types: Individual, Group risk-based, Group fee-based, BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare, Medicaid and FEHB. In addition, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are generally developed and marketed with an emphasis on the differing needs of our customers. In particular, our product development and marketing efforts take into account the differing characteristics between the various customers served by us, as well as the unique needs of educational and public entities, labor groups, the FEHB program, national employers and state-run programs servicing low-income, high-risk and underserved markets. Overall, we seek to establish pricing and product designs to provide value for our customers while achieving an appropriate level of profitability for each of our customer categories balanced with the competitive objective to grow market share. We believe that one of the keys to our success has been our focus on these distinct customer types, which better enables us to develop benefit plans and services that meet our customers&#8217; unique needs. Further, CarelonRx was built to simplify pharmacy care and focus on the whole person, and we expect it will make it easier for our customers to achieve better health outcomes at a lower total cost of care.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our Individual, Medicare and certain Group products with a smaller employee base through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships. Products for Commercial customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual markets, we offer on-exchange products through state- or federally-facilitated marketplaces (the &#8220;Public Exchange&#8221;) in compliance with the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the &#8220;ACA&#8221;) and off-exchange products. Federal subsidies are available for certain members, subject to income and family size, who purchase Public Exchange products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we made the decision to expand our participation in the Public Exchange market for 2023 after also expanding in 2022.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, for 2023 we are offering Individual Public Exchange products in 138 of the 143 rating regions in which we operate, in comparison to 122 of 143 rating regions in 2022.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment and underlying market characteristics.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Being a licensee of the BCBS association of companies, of which there were 34 independent primary licensees including us as of December&#160;31, 2022, provides significant market value, especially when competing for very large multi-state </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employer groups. For example, each BCBS member company is able to utilize other BCBS licensees&#8217; substantial provider networks and discounts when any BCBS member works or travels outside of the state in which their policy is written. This program is referred to as BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> host members are generally members who reside in or travel to a state in which an Elevance Health subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer-sponsored health plan serviced by a non-Elevance Health controlled BCBS licensee, which is the &#8220;home&#8221; plan. We perform certain administrative functions for BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">host members, including claims pricing and administration, for which we receive administrative fees from the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members&#8217; home plan. Other administrative functions, including maintenance of enrollment information and customer services, are performed by the home plan. See &#8220;BCBSA Licenses&#8221; below in this &#8220;Business&#8221; section for additional information on our BCBSA licenses. We refer to members in our service areas licensed by the BCBSA as our BCBS-branded, or Anthem BCBS, business. Non-BCBS-branded business refers to members in our non-BCBS-branded, or Wellpoint plans, which include Amerigroup, Freedom Health, HealthSun, MMM, Optimum Healthcare and Simply Healthcare plans, as well as HealthLink and UniCare members.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information describing each of our customer types and changes in medical membership over the last three years, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Membership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; included in Part II, Item 7 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product and Service Descriptions</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various forms of managed care products have been developed to contain the cost of healthcare by negotiating contracts with hospitals, physicians and other providers to deliver high-quality healthcare to members at favorable rates. These products usually feature medical management and other quality and cost optimization measures such as pre-admission review and approval for certain non-emergency services, pre-authorization of outpatient surgical procedures, network credentialing to determine that network physicians and hospitals have the required certifications and expertise, and various levels of care management programs to help members better understand and navigate the healthcare system. In addition, providers may have incentives to achieve certain quality measures, may share medical cost risk or may have other incentives to deliver quality medical services in a cost-effective manner. Also, certain plans offer members incentives for healthy behaviors, such as smoking cessation and weight management. Members are charged periodic, prepaid premiums and generally pay copayments, coinsurance and/or deductibles when they receive services.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial &amp; Specialty Business</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial Risk-Based Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Commercial &amp; Specialty Business offers employer groups a diversified mix of managed care risk-based products including: Preferred Provider Organization (&#8220;PPO&#8221;), Health Maintenance Organization (&#8220;HMO&#8221;), Consumer-Driven Health Plans (&#8220;CDHP&#8221;), Traditional Indemnity and Point-of-Service (&#8220;POS&#8221;) plans. PPO plans generally provide members the freedom to choose any healthcare provider, but require the member to pay a greater portion of the provider&#8217;s fee in the event the member chooses not to use a provider participating in the PPO&#8217;s network. HMOs include comprehensive managed care benefits generally through a participating network of physicians, hospitals and other providers. CDHPs generally combine a high-deductible PPO plan with an employer-funded and/or employee-funded personal care account, which may result in tax benefits to the employee and allow some or all of the dollars remaining in the personal care account at year-end to be rolled over to the next year for future healthcare needs. Traditional indemnity plans offer the member an option to select any healthcare provider for covered services, with coverage subject to deductibles and coinsurance and with member cost-sharing usually limited by out-of-pocket maximums. POS products blend the characteristics of HMO, PPO and indemnity plans. In general, POS plans allow members to choose to seek care from a provider within the plan&#8217;s network or outside the network, subject to, among other things, certain deductibles and coinsurance.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer Individual risk-based products on and off the Public Exchange, covering essential health benefits (as defined in the ACA) along with many other requirements and cost-sharing features.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial Fee-Based Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Commercial &amp; Specialty Business provides a broad array of managed care services to fee-based groups, including claims processing, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. Fee-based health plans are also able to use our provider networks and to realize savings through our negotiated provider arrangements, while allowing employers the ability to design certain health benefit plans in accordance with their own requirements and objectives. We </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also charge a premium to underwrite stop loss insurance for employers that maintain fee-based plans but want to limit their retained risk.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we perform certain administrative functions for BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> host members, discussed under &#8220;Membership&#8221; above, including claims pricing and administration, for which we receive administrative fees from the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members&#8217; home plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Specialty Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer an array of products and services to both risk-based and fee-based customers in conjunction with our health plans as well as to unaffiliated healthcare plans that are not Elevance Health subsidiaries.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.46pt">Stop Loss Insurance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stop loss insurance arrangements are built around our clients&#8217; needs while assuming 100% of the risk. We offer specific and aggregate plans that will provide options to meet our clients&#8217; coverage terms, budget and risk tolerance; active claims management to help avoid errors and missing claims; as well as cost containment to assist our clients with claims and cost control.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.46pt">Dental.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our dental plans include networks in certain states in which we operate and are offered on both a risk-based and fee-based basis. Our members also have access to additional dental providers through our participation in the National Dental GRID, a national dental network developed by and for BCBS plans that offers in-network discounts across the country.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.46pt">Vision.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vision plans include networks within the states in which we operate and are offered on both a risk-based and fee-based basis.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.46pt">Life.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer an array of competitive individual and group term life insurance benefit products. The life insurance products include term life and accidental death and dismemberment.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.46pt">Disability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer short-term and long-term disability and leave of absence products.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.46pt">Supplemental Health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer supplemental health products, including accident, critical illness and hospital indemnity, which provide coverage for specific conditions or circumstances.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Business</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Medicare Plans.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a wide variety of plans, products and options to individuals age 65 and older such as Medicare Advantage, including Special Needs Plans (&#8220;SNPs&#8221;), dual-eligible programs through Medicare-Medicaid Plans (&#8220;MMPs&#8221;), Medicare Supplement plans and Medicare Part D Prescription Drug Plans (&#8220;Medicare Part D&#8221;). </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or have severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care, covering all the healthcare services considered medically necessary for members and often providing professional care coordination services, with personal guidance and programs that help members maintain their health. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree Solutions business who are retired members of Commercial accounts or groups who are not affiliated with our Commercial accounts that have selected a Medicare Advantage product through us. MMP is a demonstration program focused on serving members who are dually eligible for Medicaid and Medicare. Medicare Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts paid by the traditional Medicare Fee-For-Service program. Medicare Part D offers a prescription drug plan to Medicare and MMP beneficiaries. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Medicaid Plans and Other State-Sponsored Programs.   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicaid business includes our managed care alternatives through public-funded healthcare programs, including Medicaid; Medicaid expansion programs; Temporary Assistance for Needy Families (&#8220;TANF&#8221;); programs for seniors and people with disabilities (&#8220;SPD&#8221;); Children&#8217;s Health Insurance Programs (&#8220;CHIP&#8221;); and specialty programs such as those focused on long-term services and support (&#8220;LTSS&#8221;), HIV/AIDS, children living in foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities and/or developmental disabilities. The Medicaid program makes federal matching funds available to all states for the delivery of healthcare benefits for low income and/or high medical risk individuals. These programs are managed by the individual states based on broad federal guidelines. Our Medicaid plans also cover certain dual-eligible customers, as previously described above, who also receive Medicare benefits. As of December 31, 2022, we provide Medicaid and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other state sponsored services, such as administrative services, in Arkansas, California, Colorado, Florida, Georgia, Indiana, Iowa, Kentucky, Louisiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, North Carolina, Ohio, Puerto Rico, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia and Wisconsin.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Federal Employees Health Benefits Program.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FEHB members consist of United States government employees and their dependents within our geographic markets through our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Medicare Administrative Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our NGS subsidiary, we serve as a fiscal intermediary, carrier and Medicare administrative contractor for the federal government by providing administrative services for the Medicare program, Parts A and B, which generally provides coverage for persons who are 65 or older and for persons who are under 65 and disabled or with end-stage renal disease. Part A of the Medicare program provides coverage for services provided by hospitals, skilled nursing facilities and other healthcare facilities. Part B of the Medicare program provides coverage for services provided by physicians, physical and occupational therapists and other professional providers, as well as certain durable medical equipment and medical supplies.</span></div><div style="margin-bottom:3pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CarelonRx</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our subsidiary CarelonRx markets and offers PBM services to our affiliated health plan customers throughout the country in both our Commercial &amp; Specialty and our Government business segments, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes features such as formulary management, pharmacy networks, a prescription drug database, member services and mail order capabilities. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CarelonRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation (&#8220;CVS Health&#8221;), pursuant to a five-year agreement (the &#8220;CVS PBM Agreement&#8221;) that is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. From December 2009 through December 2019, we delegated certain PBM functions and administrative services to Express Scripts Inc. (&#8220;Express Scripts&#8221;). We transitioned existing members from Express Scripts to CarelonRx by January 1, 2020. </span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other segment includes our Diversified Business Group, now known as Carelon Services. Business units in Carelon Services offer a broad array of healthcare related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs. Key services offered include:</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Behavioral Health. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide comprehensive behavioral health management services through clinical and network administration. In a limited capacity, we also provide high-quality, evidence-based behavioral healthcare and counseling services through licensed clinicians in convenient and accessible locations.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Care Delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We provide highly integrated, personalized care to patients with chronic and complex conditions, whether in their home, care centers, mobile units, skilled nursing facilities, hospitals, or virtually. Additionally, we provide non-hospice, community based palliative care to deliver an extra layer of personalized support and whole-person care. </span></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Advanced Analytics and Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage data, analytics, and insights to help improve outcomes and lower the cost of care, by working to ensure that our members receive safe, appropriate, high-quality, cost-effective care and that our providers are reimbursed accurately and timely.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The managed care industry is highly competitive, both nationally and in our local markets. Competition continues to be intense due to aggressive marketing, pricing, bid activity for government-sponsored programs, business consolidations, new strategic alliances, new competitors in the market, a proliferation of new products, technological advancements, the impact of legislative reform, increased quality awareness and price sensitivity among customers and changing market practices, such as increased usage of telehealth.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that participants in the managed care industry compete for customers based on quality of service, price, access to provider networks, access to care management and wellness programs (including health information), innovation, effective use of digital technology, breadth and flexibility of products and benefits, expertise and reputation (including National Committee on Quality Assurance (&#8220;NCQA&#8221;) accreditation status as well as CMS Star ratings), brand recognition and financial stability. Our ability to attract and retain customers is substantially tied to our ability to distinguish ourselves from our competitors in these areas.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our exclusive right to market products under the most recognized brand in the industry, BCBS, in our most significant markets provides us with greater brand recognition over competitive product offerings. Typically, we are the largest participant in each of our BCBS branded markets, and thus are closely-watched by other health benefits companies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product pricing remains competitive and we strive to price our health benefit products and design our Medicare and Medicaid bids consistent with anticipated underlying medical trends. We believe our pricing and bid strategy, based on predictive modeling, proprietary research and data-driven processes, has positioned us to benefit from the potential growth opportunities available through entry into new markets, expansions in existing markets and as a result of any future changes to the current regulatory scheme. We believe that our pricing and bid strategy, brand name and network quality will provide a strong foundation for membership growth opportunities in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provider networks give us a highly competitive unit cost position and provide distinctive service levels which allow us to offer a broad range of affordable health benefit products to our customers. To build our provider networks, we compete with other health benefits plans for the best contracts with hospitals, physicians and other providers. We believe that physicians and other providers primarily consider customer volume, reimbursement rates, timeliness of reimbursement and administrative service capabilities along with the reduction of non-value added administrative tasks when deciding whether to contract with a health benefits plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the sales and distribution level, we compete for qualified agents and brokers to recommend and distribute our products. Strong competition exists among insurance companies and health benefits plans for agents and brokers with demonstrated ability to secure new business and maintain existing accounts. We believe that the quality and price of our products, support services, reputation and prior relationships, along with a reasonable commission structure, are the factors agents and brokers consider in choosing whether to market our products. We believe that we have good relationships with our agents and brokers, and that our products, support services and commission structure compare favorably to those of our competitors in all of our markets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the PBM industry is highly competitive, and CarelonRx is subject to competition from national, regional and local PBMs, insurers, health plans, large retail pharmacy chains, large retail stores, supermarkets, mail order pharmacies, web pharmacies and specialty pharmacies. Strong competition within the PBM industry has generated greater demand for lower product and service pricing, increased revenue sharing and enhanced product and service offerings.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing and Underwriting of Our Products</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We price our products based on our assessment of current healthcare claim costs and emerging healthcare cost trends, combined with charges for administrative expenses, risk and profit. We continually review our product designs and pricing guidelines on a national and regional basis so that our products remain competitive and consistent with our profitability goals and strategies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue on Medicare policies is based on annual bids submitted to CMS. We base the Commercial and Medicaid premiums we charge and our Medicare bids on our estimates of future medical costs over the fixed contract period. In applying our pricing to each employer group and customer, we aim to maintain consistent, competitive and disciplined underwriting standards. We employ our proprietary accumulated actuarial and financial data to determine underwriting and pricing parameters for both our risk-based and fee-based businesses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most circumstances, our pricing and underwriting decisions follow a prospective rating process in which a fixed premium is determined at the beginning of the contract period. For our risk-based business, any deviation, favorable or unfavorable, from the medical costs assumed in determining the premium is our responsibility. Some of our larger groups employ retrospective rating reviews, where positive experience is partially refunded to the group, and negative experience is charged against a rate stabilization fund established from the group&#8217;s favorable experience or charged against future favorable </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience. In addition, our ACA and government risk-based contracts may include minimum medical loss ratio, risk adjustment, or risk corridor arrangements, which also stabilize premiums based upon claims experience.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pharmacy pricing through CarelonRx is presented to market via discounts off the average wholesale price for drugs dispensed through the retail, mail and specialty channels as well as through rebate projections. We utilize group-specific script data, formulary, network and clinical care program selection combined with administrative expense, risk and profit guidance to set market competitive pricing discounts and rebate projections. Pharmacy pricing guidelines guide the underwriting process and undergo an annual external review process to ensure market competitiveness.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Networks and Provider Relations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our relationships with physicians, hospitals and professionals that render healthcare services to our members are guided by local, regional and national standards for network development, reimbursement and contract methodologies. While following industry standards, we are simultaneously seeking to lead transformation efforts within our healthcare system, moving from a fragmented model premised on episodic intervention to one based on proactive, coordinated care built around the needs of the patient. A key element of this transformation involves a transition from traditional fee-for-service payment models to models where providers are paid based on the value, both in quality and affordability, of the care they deliver.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish &#8220;market-based&#8221; hospital reimbursement payments that we believe are fair, but aggressive, and among the most competitive in the market. We also seek to ensure that physicians in our network are paid in a timely manner at appropriate rates. In many instances, we deploy multi-year contracting strategies, including case rates or fixed rates, to limit our exposure to medical cost inflation and to increase cost predictability. We maintain both broad and narrow provider networks to ensure member choice, based on both price and access needs, while implementing programs designed to improve the quality of care our members receive. Increasingly, we are supplementing our broad-based networks with smaller or more cost-effective networks that are designed to be attractive to a more price-sensitive customer segment, such as Public Exchange customers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reimbursement strategies vary across markets and depend on the degree of consolidation and integration of physician groups and hospitals. Under a fee-for-service reimbursement methodology for physicians, fee schedules are developed at the state level based on an assessment of several factors and conditions, including the CMS resource-based relative value system (&#8220;RBRVS&#8221;), medical practice cost inflation and physician supply. We utilize CMS RBRVS fee schedules as a reference point for fee schedule development and analysis. The RBRVS structure was developed, maintained, and updated by CMS and is used by the Medicare program and other major health plans. In addition, we have implemented and continue to expand physician incentive contracting, or &#8220;pay-for-performance,&#8221; which ties physician payment levels to performance on clinical measures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we generally do not delegate full financial responsibility to our physician providers in the form of capitation-based reimbursement, we maintain capitation-based arrangements in certain markets where we determine that market dynamics result in it being a useful method to lower costs and reduce underwriting risk. Our provider engagement and contracting strategies have evolved to include value-based contracting arrangements that meet providers where they are in the movement from traditional fee-for-service to value-based care. These programs are designed to support Commercial, Medicare and Medicaid programs and the unique characteristics of these populations. Our value-based contracting programs are designed to reward our contracted providers for improving the overall quality of care they deliver by adhering to evidence-based medicine. In addition, these value-based contracts also share with the providers total cost of care savings that are achieved by adhering to evidence-based medicine over time. For providers who contract in one of our value-based programs, we work with them to share gaps in care information and other important data to assist them in managing the care of their patients. Often providers will also grant us access to data to support the efficient administration of program components. This data can allow us to more efficiently capture information regarding the risk of our membership and the overall adherence to evidence-based medicine, as well as information to more efficiently perform utilization management administration.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospital contracts provide for a variety of reimbursement arrangements depending on local market dynamics and current hospital utilization efficiency. Most hospitals are reimbursed a fixed amount per day or reimbursed a per-case amount, per admission, for inpatient covered services. A small percentage of hospitals, primarily rural, sole community hospitals, are reimbursed on a discount from approved charge basis for covered services. Our &#8220;per-case&#8221; reimbursement </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methods utilize many of the same attributes contained in Medicare&#8217;s Diagnosis Related Groups methodology. Hospital outpatient services are reimbursed by fixed case rates, fee schedules or percent of approved charges. Our hospital contracts recognize unique hospital attributes, such as academic medical centers or community hospitals, and the volume of care performed for our members. To improve predictability of expected costs, we frequently use a multi-year contracting approach with providers. In addition, the majority of our hospital contracts include a pay-for-performance component where reimbursement levels are linked to improved clinical performance, patient safety and medical error reduction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experience seasonality in our Commercial &amp; Specialty Business and Government Business segments. While our premium revenues are not seasonal, our benefit costs typically increase during the year as our risk-based members pay their contractual portion of claims responsibility under annual deductibles and reach their out-of-pocket maximum limits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Medical Management Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a broad array of medical management activities that facilitate improvements in the quality of care provided to our members and promote cost-effective medical care. These medical management activities and programs are administered and directed by physicians and nurses with the goal of ensuring that the care delivered to our members is supported by appropriate medical and scientific evidence, is received on a timely basis and occurs in the most appropriate setting. The medical management programs available to our members may vary depending on the particular plan or product in which they participate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care coordination is one of the strategies we utilize and is based on nationally recognized criteria developed by third-party medical specialists to help coordinate inpatient as well as outpatient care and monitor appropriate utilization of such services. Our case management focuses on identifying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">membership that will require a high level of intervention and providing assistance to manage their healthcare needs. Precertification is utilized to assess appropriateness of certain hospitalizations and other medical services prior to the services being rendered. Our medical policy committee determines our national policies and guidelines for the application of medical technologies, procedures and services and reviews these policies and guidelines at least once a year or as new published clinical evidence becomes available. We are actively engaged with our hospital and physician networks to enable them to improve medical and surgical care and achieve better outcomes for our members. We also work with outside experts through a process of external review to provide our members scientifically and clinically, evidence-based medical care. Our web-based tools allow our members to obtain or compare cost estimates for care, including out-of-pocket costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to assisting our members in making informed and value-based healthcare decisions, providing for easier navigation of healthcare services and delivering a better healthcare experience. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Care Management and Wellness Products and Programs  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expand our suite of integrated care management programs and tools. Availability of these programs and tools to our members may depend on the particular plan or product in which they participate. Our care management tools and programs are designed to increase quality and reduce medical costs for our members and help them make better decisions about their well-being as they navigate the healthcare system. Our digital engagement platform, Sydney Health, is designed to give our members access to personalized health and wellness resources; medical, pharmacy, dental, vision, life, and disability benefits details; as well as virtual care services, all in one place. Our care management, infertility services and maternity management programs serve as adjuncts to physician care. Through these programs, medical professionals help to educate participants regarding their care and condition. Our 24/7 NurseLine offers access to qualified, registered nurses to allow our members to make informed decisions about the appropriate level of care and avoid unnecessary worry. Our CareMore subsidiary specializes in whole-person care for members with complex and chronic conditions to improve clinical outcomes and patient wellbeing. Our Aspire Health subsidiary engages with members near-end-of life and/or requiring palliative care to manage serious illnesses and improve quality of life during a difficult time. With our integrated information systems and sophisticated data analytics, we help our members improve their compliance with evidence-based care guidelines, provide personal care notes that alert members to potential gaps in care, enable more prudent healthcare choices and assist in the realization of member out-of-pocket cost savings. Our employee assistance programs provide 24/7 telephonic support for personal and crisis events and provide resources such as counseling and referral assistance with childcare, health and wellness, financial issues, legal issues, adoption and daily living. We have a comprehensive behavioral health case </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management program supporting a wide range of members who are impacted by their behavioral health condition, including specialty areas such as eating disorders, anxiety, depression and substance abuse. The program assists members and their families with obtaining appropriate behavioral health treatment, offering community resources, providing education and telephonic support, and promoting provider collaboration. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Quality Initiatives </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, the healthcare industry is able to define quality healthcare based on effective, safe, equitable and affordable care in preventive health, outcomes of care and optimal care management for chronic disease. A key to our success has been our ability to develop partnerships by working with our network physicians, hospitals, and social resources providers to improve the quality outcomes of the healthcare and social impact services provided to our members, their families, and the community-at-large. Our ability to promote quality medical care, address health-related social risks, and advance health equity has been recognized by NCQA, the largest and most respected national accreditation program for managed care health plans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several quality healthcare measures, including the Healthcare Effectiveness Data and Information Set (&#8220;HEDIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), have been incorporated into NCQA&#8217;s accreditation processes. HEDIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> measures range from preventive services, such as screening mammography and pediatric immunization, to elements of care, including decreasing the complications of diabetes, improving treatment for patients with heart disease, integration of behavioral health, and racial and ethnic stratification measurement to help close healthcare disparities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our AIM Specialty Health (&#8220;AIM&#8221;) subsidiary, we promote appropriate, safe and affordable member care in the areas of imaging, sleep disorders, cardiac testing, oncology drugs and musculoskeletal procedures. These expanded specialty benefit management solutions leverage clinical expertise and technology to engage provider communities and members in the more effective and efficient use of outpatient services and to promote the most appropriate use of clinical services to improve the quality of overall healthcare delivered to our members and members of other health plans that are covered under AIM&#8217;s programs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our myNEXUS, Inc. (&#8220;myNEXUS&#8221;) subsidiary, we perform management review for home health services provided to Medicare members, with the goal of ensuring they receive appropriate, high-quality care and supporting their transition back into the home. Effective management of these services can help reduce preventable hospital admissions and readmissions, thereby improving healthcare outcomes for patients. Additionally, myNEXUS has developed programs to address healthcare quality by identifying social determinants of health needs of our members and seeking to close gaps in care through an in-home assessment. Both AIM and myNEXUS programs are examples of how we facilitate improvements in the quality of care provided to our members and promote cost-effective medical care. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical aspects of health have been traditionally the focus and the priority for healthcare. However, unique life circumstances and experiences impact every individual and their health. We seek to understand our members' health-related social needs to create a healthcare system that synchronizes care delivery for physical, behavioral, social and pharmacy needs. We are advancing our efforts through consistent screening of our members for their social needs by using industry-standard tools such as the Protocol for Responding to &amp; Assessing Patients&#8217; Assets, Risks &amp; Experiences, co-creating social action plans with our members, connecting members to related social support services, and evaluating the entire process for continuous quality improvement. We are committed to ensuring that all people, regardless of age, race or ethnicity, sexual orientation, gender identity, disability, and geographic or financial access can receive individualized care. Harnessing data gives a more complete picture of each individual and their health needs and can help make healthcare more personalized and equitable. Strengthening communities has a positive effect on health therefore we value and nurture our local ties which are a key component of our whole-health approach and drive us to work closely with community organizations that create support networks. Using our data, we also identify the resources needed to support local residents, including the people who we serve, to ensure those resources can better meet local needs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BCBSA Licenses  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements with the BCBSA that entitle us to the exclusive, and in certain areas, non-exclusive, use of the Blue Cross and Blue Shield names and marks in assigned geographic territories. BCBSA is a national association of independent Blue Cross and Blue Shield companies, the primary function of which is to promote and preserve the integrity of the BCBS names and marks, as well as provide certain coordination among the member companies. Each BCBSA licensee </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an independent legal organization and is not responsible for obligations of other BCBSA member organizations. Although previously we did not have a right to sell products and services using the BCBS names and marks outside of the states in which we are licensed to sell BCBS products, under the terms of the subscriber settlement agreement and release (&#8220;Subscriber Settlement Agreement&#8221;) among the class of plaintiffs, BCBSA and Blue Cross and/or Blue Shield licensees, including us (the &#8220;Blue plans&#8221;), some large national employers with self-funded plans (specifically identified in the Subscriber Settlement Agreement) have a right to request a second Blue plan bid in addition to a bid from the local Blue plan. The Subscriber Settlement Agreement received final approval in August 2022. We are required to pay an annual license fee to the BCBSA based on enrollment and also to comply with various requirements and restrictions regarding our operations and our use of the BCBS names and marks. These requirements and restrictions include, among other things: minimum capital and liquidity requirements; enrollment and customer service performance requirements; participation in programs that provide portability of membership between plans; disclosures to the BCBSA relating to enrollment and financial conditions; disclosures as to the structure of the BCBS system in contracts with third parties and in public statements; plan governance requirements; cybersecurity requirements; a requirement that at least 80% (or, in the case of Blue Cross of California, substantially all) of a licensee&#8217;s annual combined local net revenue, as defined by the BCBSA, attributable to healthcare plans and related services within its service areas must be sold, marketed, administered or underwritten under the BCBS names and marks; a requirement that neither a plan nor any of its licensed affiliates may permit an entity other than a plan or a licensed affiliate to obtain control of the plan or the licensed affiliate or to acquire a substantial portion of its assets related to licensable services; governance requirements such as a requirement that we divide our Board of Directors into three classes serving staggered three-year terms; a requirement that we guarantee certain contractual and financial obligations of our licensed affiliates; and a requirement that we indemnify the BCBSA against any claims asserted against it resulting from the contractual and financial obligations of any subsidiary that serves as a fiscal intermediary providing administrative services for Medicare Parts A and B. In addition, a change of control or violation of the BCBSA ownership limitations on our capital stock, impending financial insolvency or the appointment of a trustee or receiver or the commencement of any action against us seeking our dissolution could cause a termination of our license agreements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we and our licensed affiliates are currently in compliance with these standards. The standards under the license agreements may be modified in certain instances by the BCBSA. See Part I, Item&#160;1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K for additional details on the impact if we were not to comply with these license agreements and Note 14, &#8220;Commitments and Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Regulatory Proceedings &#8211; Blue Cross Blue Shield Antitrust Litigation&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Notes to our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information on the Subscriber Settlement Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation </span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to comprehensive and detailed state, federal and international regulation throughout the jurisdictions in which we do business. These laws and regulations, which can vary significantly from jurisdiction to jurisdiction, restrict how we conduct our businesses and result in additional burdens and costs to us. Further, federal and state laws and regulations are subject to amendments and changing interpretations in each jurisdiction. The application of these complex legal and regulatory requirements to the detailed operation of our businesses creates areas of uncertainty. In addition, there are numerous proposed healthcare laws and regulations at the federal and state levels, including single payer, Medicare for All and public option proposals, some of which could materially adversely affect our businesses if they were to be enacted.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supervisory agencies, including federal and state regulators and departments of health, insurance and corporation, have broad authority to:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">grant, suspend and revoke licenses to transact business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulate our products and services in great detail;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulate, limit, or suspend our ability to market products, including participation in Medicare and the Public Exchanges;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determine through a procurement process our ability to participate in certain programs, including state Medicaid programs;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retroactively adjust premium rates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitor our solvency and reserve adequacy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">audit, and recovery of audit discrepancies, including risk adjustment data validation (&#8220;RADV&#8221;) audits;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scrutinize our investment activities on the basis of quality, diversification and other quantitative criteria; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose monetary and criminal sanctions for non-compliance with regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To carry out these tasks, these government entities periodically examine our operations and accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health benefits business also may be adversely impacted by court and regulatory decisions that expand or invalidate the interpretations of existing statutes and regulations. It is uncertain whether we could recoup, through higher premiums or other measures, the increased costs of mandated benefits or other increased costs caused by potential legislation, regulation or court rulings. See Part I, Item&#160;1A &#8220;Risk&#160;Factors&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the declaration of COVID-19 as a public health emergency (&#8220;PHE&#8221;), the federal and state governments have enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we expect will continue to have, a significant impact on health benefits, consumer eligibility for public programs and our cash flows for all lines of business, and which have introduced increased uncertainty around our cost structure. These actions, which are or have been in effect for various durations, provide, among other things: mandates to waive cost-sharing for COVID-19 testing, vaccines and related services; financial support to healthcare providers; and mandates related to prior authorizations, payment levels to providers, consumer enrollment windows and telehealth services. The Biden administration renewed the PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on May 11, 2023.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Consolidated Appropriations Act of 2023 (the &#8220;2023 Appropriations Act&#8221;), Congress decoupled Medicaid eligibility recertification from the PHE. As a result, states may begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023. When recertifications resume, we expect a decline in our Medicaid membership. At the same time, we expect growth in our Commercial risk-based and fee-based plans and Medicare, including through the Public Exchanges, as members exiting Medicaid in our 14 Commercial states seek coverage elsewhere.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Inflation Reduction Act of 2022</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 (the &#8220;Inflation Reduction Act&#8221;), which was signed into law in August 2022, contains a variety of provisions that impact our business including an extension of the American Rescue Plan Act of 2021's enhanced Premium Tax Credits (&#8220;PTC&#8221;) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on repurchases of stock made after December 31, 2022; allowing CMS to negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump Administration Medicare drug rebate rule to 2032. The extension of the enhanced PTC will likely allow for growth in Individual exchange market enrollment as Medicaid eligibility recertifications resume, supporting continuity of coverage for more people.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Consolidated Appropriations Act of 2021</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act of 2021 (the &#8220;2021 Appropriations Act&#8221;) has impacted us since passage and in the future may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the 2021 Appropriations Act applicable to us have varying effective dates, some of which were effective in December 2021 and during 2022, and others of which have been extended into 2023 since the enactment of the 2021 Appropriations Act.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Regulation of Insurance Companies and HMOs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance and HMO subsidiaries must obtain a certificate of authority and maintain that license in the jurisdictions in which they conduct business. The National Association of Insurance Commissioners (&#8220;NAIC&#8221;) has adopted model regulations that, where adopted by states, require expanded governance practices, risk and solvency assessment reporting and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the filing of periodic financial and operating reports. Most states have adopted these or similar measures to expand the scope of regulations relating to corporate governance and internal control activities of HMOs and insurance companies. Health insurers and HMOs are subject to state examination and periodic license renewal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are regulated as an insurance holding company and are subject to the insurance holding company acts of the states in which our insurance company and HMO subsidiaries are domiciled. These acts contain certain reporting requirements, as well as restrictions on transactions between an insurer or HMO and its affiliates, and may restrict the ability of our regulated subsidiaries to pay dividends to our holding companies. These holding company laws and regulations generally require registration with applicable state departments of insurance and the filing of reports describing capital structure, ownership, financial condition, certain intercompany transactions, enterprise risks, corporate governance and general business operations. State insurance holding company laws and regulations require notice or prior regulatory approval of transactions including acquisitions, material intercompany transfers of assets, guarantees and other transactions between the regulated companies and their affiliates, including parent holding companies. Applicable state insurance holding company acts also restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. &#8220;Control&#8221; is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or controls 10% or more of the voting securities of another person.&#160;Dispositions of control generally are also regulated under the state insurance holding company acts.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The states of domicile of our regulated subsidiaries have statutory risk-based capital (&#8220;RBC&#8221;) requirements for health and other insurance companies and HMOs based on the Risk-Based Capital (RBC) For Health Organizations Model Act. These RBC requirements are intended to assess the capital adequacy of life and health insurers and HMOs, taking into account the risk characteristics of a company&#8217;s investments and products. In general, under these laws, an insurance company or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile for each calendar year. The law requires increasing degrees of regulatory oversight and intervention as a company&#8217;s RBC declines. As of December&#160;31, 2022, the RBC levels of our insurance and HMO subsidiaries exceeded all applicable mandatory RBC requirements. For more information on RBC capital and additional liquidity and capital requirements for a licensee of the BCBSA, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Liquidity and Capital Resources&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; included in Part II, Item 7 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing Requirements and Changes Stemming from the ACA</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment in 2010, the ACA has introduced new risks, regulatory challenges and uncertainties, has impacted our business model and strategy and has required changes in the way our products are designed, underwritten, priced, distributed and administered. We expect the ACA will continue to significantly impact our business and results of operations, including pricing, minimum medical loss ratios (&#8220;MLRs&#8221;) and the geographies in which our products are available. We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways that could increase financial recoveries from plans. We will continue to evaluate the impact of the ACA as any further developments occur.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain significant provisions of the ACA include, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The creation of Public Exchanges for individuals and small group customers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The establishment of minimum MLR thresholds by line of business for the Commercial market (which may be subject to more restrictive MLR thresholds under state regulations, such as those in New York). Medicare Advantage or Medicare Part D prescription drug plans that do not meet the mandated threshold will have to pay a minimum MLR rebate, will be subject to restricted enrollment if MLR is below the threshold for three consecutive years, and are subject to contract termination if the plan&#8217;s MLR is below the threshold for five consecutive years. In addition, state Medicaid programs are required to set managed care capitation rates such that a minimum MLR is projected to be achieved; however, states are not required to collect remittances if the minimum MLR is not achieved.</span></div><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 52.3% and 17.5% of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of and for the year ended December&#160;31, 2022. Approximately 53.6% and 18.4% </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of and for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The creation of an incentive payment program for Medicare Advantage plans. CMS developed the Medicare Advantage Star ratings system, which awards between 1.0 and 5.0 Stars to Medicare Advantage plans based on performance in several categories, including quality of care and customer service. The Star ratings are used by CMS to award quality-based bonus payments to plans that receive a rating of 4.0 or higher. The methodology and measures included in the Star ratings system can be modified by CMS annually. For payment year 2023, we expect to have approximately 73% of our Medicare Advantage members in 4.0 or higher rated plans.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The implementation of a Medicare Advantage payment formula, which prevents reimbursement rates from increasing as much as otherwise would be expected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to evaluate our experience in the Public Exchange markets. Based on the viability of the Public Exchanges and availability of federal subsidies, we have made adjustments to our premium rates and geographic participation, including a modest expansion in the Public Exchange markets in 2022 and further expansion into a limited number of additional counties in 2023. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions utilized in setting premium rates could have a material adverse effect on our results of operations, financial position, and cash flows, and may require further adjustments to our rates and participation going forward. As a result, for 2023 we are offering Individual Public Exchange products in 138 of the 143 rating regions in which we operate, in comparison to 122 of 143 rating regions in 2022.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment and underlying market characteristics.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Benefit and Pharmacy Benefit Manager Regulation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacy benefit managers are regulated at both the federal and state levels and must comply with federal and state statutes and regulations governing labeling, packaging, advertising and adulteration of prescription drugs, dispensing of controlled substances and licensing.&#160;In recent years the federal government has banned certain business practices, including &#8220;gag clauses,&#8221; which prohibited pharmacists from informing patients when a lower cost drug was available as a substitute, and &#8220;clawbacks,&#8221; which occurred when pharmacy benefit managers sought to recoup the difference between the reimbursed cost of the drug and the patient&#8217;s copay when the drug itself was less expensive than the copay paid by the patient. Regulation in the states varies dramatically and ranges from licensure of PBMs as third-party administrators, licensure specifically as a pharmacy benefit manager, and licensure accompanied by additional disclosures and limitations of business practices to varying degrees.&#160;The NAIC finalized a PBM model law that, if adopted widely, could result in a more standardized approach to PBM regulation in the states in the future. Additionally, in December 2020, the U.S. Supreme Court let stand an Arkansas law regulating PBMs, which could be a precursor to greater state regulation of PBMs in the future. In June 2021, the NAIC announced a proposed white paper addressing PBMs and examining the impact of this Supreme Court case on its model law, which could result in expansion of the NAIC model law and additional regulatory oversight, which could materially affect current industry practices and our PBM business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of proposals are being considered at the federal and state levels that would increase regulation of drug benefits and pharmacy benefit managers. Such proposals under consideration include (1) regulation of rebates from drug manufacturers that would require rebate dollars to be applied at the point-of-sale, (2) federal policy changes to set the prices for a subset of drugs covered under the Medicare program, (3) reforms to the Medicare drug benefit, such as beneficiary cost-sharing changes that aim to lower consumer costs, (4) attempts at both the federal and state levels to prohibit the use of spread pricing contracts in both the Commercial and Medicaid markets, and (5) electronic prior authorizations of drugs. These reforms have the potential to have broad impacts on our PBM business and could materially adversely affect our business if they are enacted.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy, Confidentiality and Data Standards Regulation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and the administrative simplification provisions of HIPAA impose a number of requirements on covered entities (including insurers, HMOs, group health plans, providers and clearinghouses) and their business associates relating to the use, disclosure and safeguarding of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protected health information. These requirements include uniform standards of common electronic healthcare transactions; privacy and security regulations; and unique identifier rules for employers, health plans and providers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act provisions of the American Recovery and Reinvestment Act of 2009 and corresponding implementing regulations have imposed additional requirements on the use and disclosure of protected health information such as additional data breach notification and reporting requirements, contracting requirements for HIPAA business associate agreements, strengthened enforcement mechanisms and increased penalties for HIPAA violations. Federal consumer protection laws may also apply in some instances to privacy and security practices related to personally identifiable information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Gramm-Leach-Bliley Act generally places restrictions on the disclosure of non-public information to non-affiliated third parties, and requires financial institutions, including insurers, to provide customers with notice regarding how their non-public personal information is used, including an opportunity to &#8220;opt out&#8221; of certain disclosures. State departments of insurance and certain federal agencies adopted implementing regulations as required by federal law. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cybersecurity Information Sharing Act of 2015 encourages organizations to share cyber threat indicators with the federal government and, among other things, directed HHS to develop a set of voluntary cybersecurity best practices for organizations in the healthcare industry, which were issued in 2018.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Public Exchanges are required to adhere to privacy and security standards with respect to personally identifiable information and to impose privacy and security standards that are at least as protective as those the Public Exchange has implemented for itself on insurers offering plans through the Public Exchanges and their designated downstream entities, including pharmacy benefit managers and other business associates. These standards may differ from, and be more stringent than, HIPAA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, states have begun enacting more comprehensive privacy laws and regulations addressing consumer rights to data protection or transparency that may affect our privacy and security practices, such as state laws like the California Privacy Rights Act of 2020 that govern the use, disclosure and protection of member data and impose additional breach notification requirements. The NAIC is planning potential revisions to one or more of its privacy model acts, which could expand consumer privacy rights. State consumer protection laws may also apply to privacy and security practices related to personally identifiable information, including information related to consumers and care providers. Complying with conflicting cybersecurity regulations and varying enforcement philosophies, which may differ from state to state, requires significant resources and may materially and adversely affect our ability to standardize our products and services across state lines. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal regulations have been finalized in the following areas that will continue to materially impact our operations:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal regulations on data interoperability that require claims data to be made available to third parties unaffiliated with us; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal regulations requiring hospitals and health insurers to publish negotiated prices for services, including the health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human Services, Labor and Treasury (the &#8220;Health Plan Transparency Rule&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in July 2022, the Health Plan Transparency Rule required us to disclose, on a monthly basis, detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we are now required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items and services.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Retirement Income Security Act of 1974</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of services to certain employee welfare benefit plans is subject to the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), a complex set of laws and regulations subject to interpretation and enforcement by the Internal Revenue Service and the Department of Labor. ERISA regulates certain aspects of the relationships between us, the employers that maintain employee welfare benefit plans subject to ERISA and participants in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such plans. Some of our administrative services and other activities may also be subject to regulation under ERISA. In addition, certain states require licensure or registration of companies providing third-party claims administration services for benefit plans. We provide a variety of products and services to employee welfare benefit plans that are covered by ERISA. Plans subject to ERISA can also be subject to state laws, and the question of whether and to what extent ERISA preempts a state law has been, and will continue to be, interpreted by many courts.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guaranty Fund Assessments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under insolvency or guaranty association laws in most states, insurance companies and HMOs can be assessed for amounts paid by guaranty funds for policyholder losses incurred when an insurance company or HMO becomes insolvent. Most state insolvency or guaranty association laws currently provide for assessments based upon the amount of premiums received on insurance underwritten within such state (with a minimum amount payable even if no premium is received). Under many of these guaranty association laws, assessments are made retrospectively. Some states permit insurers or HMOs to recover assessments paid through full or partial premium tax offsets or through future policyholder surcharges. The amount and timing of any future assessments cannot be predicted with certainty; however, future assessments are likely to occur.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various international subsidiaries, which provide back-office services, that are subject to different, and sometimes more stringent, legal and regulatory requirements that vary widely by jurisdiction. In addition, our non-U.S. operations are subject to U.S. laws regulating the conduct and activities of U.S.-based businesses operating abroad, including but not limited to, the Foreign Corrupt Practices Act and corresponding foreign laws governing anti-bribery, anti-corruption and anti-money laundering. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foundation of our strategy starts with our culture, and our associates are critical to fulfilling our purpose of improving the health of humanity. As of December&#160;31, 2022, our employee population, including all full-time, part-time and temporary workers, consisted of approximately 102,300 individuals, 79,000 in the United States and 23,300 internationally. We have built a high-performance culture that we believe enhances our ability to deliver on our commitments and guides us to address the challenges of today. We believe that our culture allows us to attract and retain talented and experienced individuals to support the communities we serve. Our associates actively participate through associate engagement surveys and online feedback tools. We leverage and monitor associate feedback and take action on responses.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inclusion &amp; Diversity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diversity of our associates is central to achieving key strategies and improving performance. We strive to maintain a diverse and inclusive workforce comprised of a vast array of backgrounds, life experiences and cultures, which we believe enables a deeper connection with our members, allowing us to better serve our members and communities, and drives greater business results. As of December&#160;31, 2022, our U.S. associate population was approximately 77% female and 51% racially and ethnically diverse, while 65% of our managers are female and 36% are racially or ethnically diverse.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Pay</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is committed to a fair pay workplace. We were in the first cohort of companies certified by the Fair Pay Workplace (&#8220;FPW&#8221;), an independent certification that takes a holistic approach to pay equity, partnering to design an annual pay equity action plan that includes a perpetual review of all positions, new hires and promotions to effect meaningful and measurable change. This independent certification is based on a set of publicly available rules and standards and the endorsed methodology of a group of leading experts from forward-thinking corporations, academia, human resources, data science and the legal field. After partnering with and overseeing our review process, FPW has validated our analysis of our associate population, which found that pay for females is within 1% of their male counterparts and pay for people of color is equal to their white counterparts, after taking into account neutral job related factors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Development</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growing and developing our talent internally is key to our succession plans and our ability to lead at our best every day. To inspire a high-performance culture and promote talent excellence, we offer individual, career and leadership development </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">opportunities, encouraging associates to continually learn and grow. We offer various instructor-led and virtual instructor-led programs and maintain a vast curriculum of relevant, on-demand learning and development resources. </span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health &amp; Wellbeing</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the privilege of touching the lives of millions of people each day, starting with the health of our own associates. To improve the health and wellbeing of our associates, we offer a comprehensive compensation package, including competitive salaries, a 401(k) plan and medical, dental, vision and disability coverage. In addition, we offer our associates wellness and behavioral programs and tools to help them get and stay healthy and more easily manage their work and personal lives. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information About Our Executive Officers</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth certain information regarding our executive officers and Chief Accounting Officer as of February 1, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.005%"><tr><td style="width:1.0%"></td><td style="width:33.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gail K. Boudreaux</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John E. Gallina</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Haytaian</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Carelon and CarelonRx</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles M. Kendrick, Jr.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Commercial &amp; Specialty Business Division</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria M. McCarthy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Administrative Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Felicia F. Norwood</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Government Business Division</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blair W. Todt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Legal Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronald W. Penczek</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer and Controller</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms. Boudreaux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our President and Chief Executive Officer and a Director of the Company since November 2017. Prior to joining us, she served as Chief Executive Officer of GKB Global Health, LLC (healthcare consulting firm) from 2015 to November 2017. Prior thereto, Ms. Boudreaux was Executive Vice President of UnitedHealth Group Incorporated (diversified healthcare company) from 2008 to 2015, including roles as Chief Executive Officer of UnitedHealthCare (managed healthcare company), a subsidiary of UnitedHealth Group Incorporated from 2011 to 2014 and President of the Commercial Business of UnitedHealthCare from 2008 to 2011. Before joining United HealthCare, she worked at Health Care Service Corporation (&#8220;HCSC&#8221;) (health insurance company) as Executive Vice President of External Operations from 2005 to 2008 and President of Blue Cross and Blue Shield of Illinois from 2002 to 2005. Before joining HCSC, Ms. Boudreaux held various positions at Aetna, Inc. (&#8220;Aetna&#8221;) (managed healthcare company), including Senior Vice President, Group Insurance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Gallina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Executive Vice President and Chief Financial Officer since 2016. Mr. Gallina joined Elevance Health in 1994 and has held a variety of leadership roles across the organization. Prior to his current role, Mr. Gallina served as Elevance Health&#8217;s Chief Financial Officer for the Commercial &amp; Specialty Business Division from 2015 to 2016, and as Senior Vice President and Chief Accounting Officer from 2013 to 2015. Other leadership positions held during his tenure include Senior Vice President, Chief Accounting Officer and Chief Risk Officer from 2011 to 2013, while also holding the title of Controller from 2011 to 2013. Before joining the Company, Mr. Gallina spent 12 years with Coopers &amp; Lybrand in various positions, including as an Audit Senior Manager.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Haytaian</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Executive Vice President and President of Carelon (formerly known as our Diversified Business Group) and CarelonRx (formerly known as IngenioRx) since October 2021. Prior to his current role, Mr. Haytaian served as Executive Vice President and President of our Commercial &amp; Specialty Business Division beginning in April 2018. From June 2014 until April 2018, Mr. Haytaian served as our Executive Vice President and President of the Government Business Division. Mr. Haytaian joined the Company in 2012 with our acquisition of Amerigroup Corporation (&#8220;Amerigroup&#8221;) and served as President of our Medicaid business from 2013 until 2014. From 2005 to 2013, Mr. Haytaian </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held several leadership positions with Amerigroup, including serving as Chief Executive Officer of the North Region for Amerigroup&#8217;s Medicaid business from 2012 until 2013. Mr. Haytaian has extensive experience leading Medicare and Medicaid programs with Amerigroup and, prior thereto, with Oxford Health Plans, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Kendrick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as Executive Vice President and President of our Commercial &amp; Specialty Business Division since October 2021. From January 2021 until October 2021, Mr. Kendrick served as President of our Commercial Business West Markets (California, Colorado, Indiana, Kentucky, Missouri, Nevada, Ohio and Wisconsin). Mr. Kendrick joined us in 1995, and has held numerous leadership roles across the organization, including serving as President, Anthem National Accounts/Central Markets from 2015 until January 2021 and President of National Accounts and General Manager for Anthem Blue Cross and Blue Shield of Georgia from 2010 until 2015.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms. McCarthy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Executive Vice President and Chief Administrative Officer since 2013. She was Executive Vice President of Enterprise Execution and Efficiency from 2012 to 2013. Prior to that appointment, she served as Senior Vice President for Operational Excellence from 2008 to 2012, as Senior Vice President of Service Operations from 2006 to 2008 and as Senior Vice President and Chief Operating Officer of our East Region from 2005 to 2006. Prior to our acquisition of WellChoice, Inc. (&#8220;WellChoice&#8221;) in 2005, Ms. McCarthy served as Executive Vice President and Chief Operating Officer of WellChoice.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms. Norwood </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Executive Vice President and President of the Government Business Division since June 2018. Prior to joining us, she was Director of The Department of Healthcare and Family Services for the State of Illinois from 2015 to June 2018. Prior to that appointment, Ms. Norwood held a variety of leadership roles at Aetna, with her most recent role as President of the Mid-America Region for Aetna from 2010 until 2013.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Todt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Executive Vice President and Chief Legal Officer since November 2020 and our interim head of human resources and global security and safety team since January 2022. Prior to joining us, Mr. Todt served as Senior Vice President, Legal, Compliance &amp; Business Performance and Chief Legal Officer of HCSC from 2016 to July 2020. Prior to joining HCSC, Mr. Todt held a variety of leadership roles at WellCare Health Plans, Inc. (health insurance company), with his most recent role as Senior Vice President, Chief Legal and Administrative Officer and Secretary from 2010 until 2016.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Penczek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Controller since November 2015 and as our Chief Accounting Officer since December 2015. He served as our Vice President and Controller from 2013 to 2015. Prior to that appointment, Mr. Penczek served as Vice President and Assistant Controller from 2008 to 2013 and in various other roles in our finance department from 2006 until 2008. Before joining us in 2005, Mr. Penczek was a Staff Vice President with CNA Insurance from 2000 to 2005 and had various positions with PricewaterhouseCoopers LLP from 1992 to 2000, including as a Manager.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a large accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) and are required, pursuant to Item&#160;101 of Regulation S-K, to provide certain information regarding our website and the availability of certain documents filed with or furnished to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers at www.sec.gov. Our website is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.elevancehealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have included our website address throughout this Annual Report on Form 10-K as a textual reference only. The information contained on, or accessible through, our website is not incorporated into this Annual Report on Form 10-K. We make available through our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or furnish it to the SEC. We also include on our website our Corporate Governance Guidelines, our Code of Conduct and the charter of each standing committee of our Board of Directors. In addition, we intend to disclose on our website any amendments to, or waivers from, our Code of Conduct that are required to be publicly disclosed pursuant to rules of the SEC and the New York Stock Exchange (&#8220;NYSE&#8221;). Elevance Health, Inc. is an Indiana corporation incorporated on July&#160;17, 2001.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating our business, the risks described below, as well as the other information contained in this Annual Report on Form 10-K, should be carefully considered. Any one or more of such risks could materially and adversely affect our business, financial condition, results of operations and stock price and could cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS RISKS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to appropriately predict, price for and manage healthcare costs, the profitability of our products and services could decline, which could materially adversely affect our business, cash flows, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability depends on accurately predicting and pricing healthcare costs and our ability to manage future healthcare costs through medical management, product design, negotiation of favorable provider contracts and underwriting criteria. Total healthcare costs are affected by the type, number and cost of individual services rendered. Numerous factors affecting healthcare costs may adversely affect our ability to predict and manage healthcare costs, and may impact our business, cash flows, financial condition and results of operations. These factors include, among others, changes in healthcare practices, demographic characteristics including the aging population, medical cost inflation, increased labor costs, evolution of new technologies, drugs and treatments, increased cost of individual services, increased number and cost of prescription drugs, clusters of high cost cases, increased use of services, including resulting from pandemics, large-scale medical emergencies, increasing natural disasters in connection with climate change and other public health crises, new mandated benefits and treatment guidelines and changes to other regulations impacting our business.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Slight differences between predicted and actual medical costs or utilization rates as a percentage of premium revenues can result in significant changes in our results of operations. Generally, our premiums on Commercial policies and Medicaid contracts are fixed for a 12-month period and are determined based on data from several months prior to the commencement of the premium period. Our revenue from Medicare policies is based on bids submitted to CMS six months prior to the start of the contract year. CMS has explicit gain and loss margin requirements within the bids, as well as contract-specific federal MLR annual requirements. Accordingly, the costs we incur in excess of our benefit cost projections cannot be recovered in the contract year through higher premiums. Existing Medicaid contract rates are often established by the applicable state, and our actual costs may exceed those rates. Many factors, including those discussed above, may cause actual costs to exceed those estimated and reflected in our Commercial premiums and Medicare and Medicaid bids.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although federal and state premium and risk adjustment mechanisms could help offset health benefit costs above our projections if the assumptions we use to set our premium rates are significantly different than actual results, our results of operations and financial condition could still be adversely affected. The reserves that we establish for health insurance policy benefits and other contractual rights and benefits are based on assumptions concerning a number of factors, including trends in healthcare costs, expenses, general economic conditions and other factors. To the extent the actual claims experience is unfavorable compared to our underlying assumptions, our incurred losses would increase and future earnings could be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the challenge of managing healthcare costs, we face pressure to contain premium rates. Our customers may renegotiate their contracts to seek to contain their costs or may move to a competitor to obtain more favorable premiums. Further, federal and state regulatory agencies may restrict or prevent entirely our ability to implement changes in premium rates. A limitation on our ability to increase or maintain our premium or reimbursement levels or a significant loss of membership resulting from our need to increase or maintain premium or reimbursement levels could adversely affect our business, cash flows, financial condition and results of operations. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to evaluate our experience in the Public Exchange markets. Based on the viability of the Public Exchanges and availability of federal subsidies, we have made adjustments to our premium rates and geographic participation, including a modest expansion in the Public Exchange markets in 2022, and further expansion in a limited number of additional counties in 2023. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions utilized in setting premium rates could have a material adverse effect on our results of operations, financial position, and cash flows, and may require further adjustments to our rates and participation in Public Exchanges going forward.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant reduction in the enrollment in our health benefits programs or PBM products or services, particularly in states where we have large regional concentrations, could have an adverse effect on our business, cash flows, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant reduction in the number of enrollees in our health benefits programs or PBM products or services could adversely affect our business, cash flows, financial condition and results of operations. Factors that could contribute to a reduction in enrollment include: reductions in workforce by existing customers; the end of the temporary suspension of eligibility recertification for Medicaid recipients in response to the COVID-19 pandemic, which will likely result in a reduction in our Medicaid membership; a general economic upturn that results in fewer individuals being eligible for Medicaid programs; a general economic downturn that results in business failures and high unemployment rates; employers no longer offering certain healthcare coverage as an employee benefit or electing to offer coverage on a voluntary, employee-funded basis; participation on Public Exchanges; federal and state regulatory changes; failure to obtain new customers or retain existing customers; premium increases and benefit changes; our exit from a specific market; negative publicity and news coverage; and failure to attain or maintain nationally recognized accreditations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The states in which we operate with the largest concentrations of revenues include California, Virginia, Ohio, New York, Indiana, Texas, Florida and Georgia. Due to this concentration of business in these states, we are exposed to potential losses resulting from the risk of state-specific or regional economic downturns impacting these states. If any such negative economic conditions do not improve, we may experience a reduction in existing and new business, which could have a material adverse effect on our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A cyber-attack or other privacy or data security incident could result in an unauthorized disclosure of sensitive or confidential information, cause a loss of data, disrupt our operations, give rise to remediation or other expenses, expose us to liability under federal, state and international laws, and subject us to litigation and investigations, which could have an adverse effect on our business, cash flows, financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our normal operations, we collect, store, process, retain and analyze certain sensitive and confidential information, including protected personal information subject to privacy, security and data breach notification requirements. Some of the data we process, store and transmit is outside of the U.S. due to the structure of our information technology systems and our internal business operations. We are subject to a variety of continuously evolving federal, state and international laws and rules regarding the use and disclosure of certain sensitive or confidential information, that depending on the specific business and intended data use, include without limitation, HIPAA's privacy and security rules, HIPAA's  HITECH rule, the Gramm-Leach-Bliley Act, GDPR and numerous state laws governing personal information, including the California Consumer Privacy Act, as amended by the California Privacy Rights Act effective on January 1, 2023. Our facilities and systems, and those of our third-party service providers, are regularly the target of, and may be vulnerable to, cyber-attacks, security breaches, acts of vandalism, computer viruses, misplaced or lost data, programming and/or human errors, negligent or wrongful conduct by employees or others with permitted access to our systems and information, or other threats. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot ensure that we will be able to identify, prevent or contain the effects of cyber-attacks or other cybersecurity risks that bypass our security measures or disrupt our information technology systems or business. Hardware, software or applications we develop or procure from third parties may contain defects in design, manufacturer defects or other problems that could unexpectedly compromise information security. In addition, because the techniques used to obtain unauthorized access, disable, disrupt or degrade service or sabotage systems change frequently, are becoming increasingly sophisticated, and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques, timely discover or counter them or implement adequate preventative measures. Viruses, worms or other malicious software programs may be used to attack our systems or otherwise exploit any security vulnerabilities which may cause system disruptions or shutdowns, or may cause personal, proprietary or confidential information to be disclosed, misappropriated or compromised. As a result, cyber-security and the continued development and enhancement of our controls, processes and practices designed to protect our systems, computers, software, data and networks from attack, damage and unauthorized access remain a priority for us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been, and may in the future be, subject to litigation and governmental investigations related to cyber-attacks and security breaches. Any such future litigation or governmental investigation could divert the attention of management from the operation of our business, result in reputational damage and have a material adverse impact on our business, cash </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flows, financial condition, and results of operations. Moreover, our programs to detect, contain, and respond to data security incidents as well as contingency plans and insurance coverage for potential liabilities of this nature may not be sufficient to cover all claims and liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with any privacy, security or data protection laws and regulations, or any security breach, cyber-attack or cyber-security breach, and any incident involving the misappropriation, theft, loss or other unauthorized disclosure or use of, or access to, sensitive or confidential information, whether by us or by one of our third-party service providers, could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage. In addition, this could negatively affect our operations, cause system disruptions, damage our reputation, cause membership losses and contract breaches, and could also result in regulatory enforcement actions, material fines and penalties, litigation or other actions that could have a material adverse effect on our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks associated with pandemics, like the COVID-19 pandemic, as well as other extreme events, large-scale medical emergencies and public health crises, which could have a material adverse effect on our business, results of operations, and financial condition and financial performance.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to impact our business, providers, customers and communities. A new pandemic or other large-scale medical emergency or public health crisis, referred to collectively as &#8220;public health crises,&#8221; may cause illness, death, quarantines, business and school shutdowns, reductions in business activity, travel and financial transactions, unemployment, inflation, labor shortages, supply chain interruptions and overall economic and financial market instability. The following are some of the risks that we experienced, and are likely to continue experiencing, as a result of the COVID-19 pandemic and that we could experience as a result of future public health crises, all of which could have a material adverse effect on our business, cash flows, financial condition and results of operations:</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased healthcare costs due to higher utilization rates of medical facilities and services and behavioral health services, increased labor costs resulting from labor shortages and increases in medical expenses and associated hospital and pharmaceutical costs, including testing, treatment and the administration of vaccines and other therapeutics and costs due to care deferred during the public health crisis, which may lead to additional care resulting from missed treatments.</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased estimation uncertainty on our claims liability, as well as decreased predictability of Medicare and Medicaid rates due to changes in utilization of medical facilities and services, medical expenses and other costs. We experienced rate adjustments from certain Medicaid regulators in 2022 in response to decreased utilization. </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A reduction in enrollment in our health benefits, products and services or a change in membership mix to less profitable lines of business by existing customers due to reductions in workforce and other impacts of an economic downturn.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash flow volatility or shortfalls caused by delayed, delinquent or non-collectable payments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the COVID-19 pandemic continues for a prolonged period, or if any future public health crisis occurs and continues for a prolonged period, these risks could be exacerbated, and cause further impact to our business and operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, other extreme events such as natural disasters, war, terrorism and civil unrest could create public health crises or otherwise have a material adverse effect on our business, cash flows, financial condition and results of operations. Natural disasters, such as wildfires, hurricanes and snow and ice storms, have impacted and may in the future impact our customers, employees, facilities and third-party vendors located in the affected area. In the event of a public health crises, we may need to make temporary policy changes, such as waiving various medical requirements, assisting with replacement medications, transferring prescriptions and expanding our help line. Furthermore, climate change could result in certain types of natural disasters occurring more frequently or with more intense effects, which could have a long-term impact on general economic conditions and the healthcare and pharmacy industry in particular.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are various risks associated with participating in Medicare and Medicaid programs, including dependence upon government funding and the timing of payments, compliance with government contracts and increased regulatory oversight. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with various federal and state agencies, including CMS, to provide managed healthcare services, such as Medicare Advantage, Medicare Part D, Medicare Supplement, Medicaid, TANF, SPD, LTSS, CHIP, Medicaid expansion programs and various specialty programs, products and services. We also provide various administrative services for other entities offering medical and/or prescription drug plans to their Medicaid or Medicare eligible members, and we offer </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employer group waiver plans which provide medical and/or prescription drug coverage to retirees. We also participate in programs in several states for the care of dual-eligible members. Regulatory reform initiatives or changes in existing laws or regulations applicable to these programs, or their interpretations, are difficult to predict and could have a material adverse effect on our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments, and base premium rates paid by each state or federal agency differ depending upon a combination of factors such as defined upper payment limits, a member&#8217;s health status, age, gender, county or region, benefit mix, member eligibility category and risk scores. Future rates may be affected by continued government efforts to contain costs and federal and state budgetary constraints. Certain state contracts are subject to cancellation in the event of the unavailability of state funds. Additionally, ongoing CMS system changes related to the data it uses to calculate risk scores in the Medicare Advantage program may impact our federal funding. The federal government or any state in which we operate could decrease rates paid to us, pay us less than the amount necessary to keep pace with our cost trends, cancel our contracts retroactively or seek an adjustment to previously negotiated rates. In addition, various states&#8217; Medicare-Medicaid plans are still subject to uncertainty surrounding payment rates and other requirements, which could affect where we seek to participate in these programs. An unexpected reduction in payments, inadequate government funding or significantly delayed payments for these programs may adversely affect our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other potential risks associated with Medicare Advantage and Medicare Part D plans include increased medical or pharmaceutical costs, data corrections identified as a result of ongoing auditing and monitoring activities, potential uncollectability of receivables resulting from processing and/or verifying enrollment, inadequacy of underwriting assumptions, inability to receive and process correct information (including inability due to systems issues by the federal government, the applicable state government or us), uncollectability of premiums from members and limited enrollment periods. Actual results may be materially different than our assumptions and estimates and could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with CMS and state governmental agencies contain certain provisions regarding data submission, risk adjustment, provider network and directory maintenance, quality measures, claims payment, timely and accurate processing of appeals and grievances, oversight of service providers, encounter data, continuity of care, call center performance and other requirements specific to federal and state program regulations. We have been subject in the past, and may again be in the future, to administrative actions, fines, penalties, liquidated damages or retrospective adjustments in payments made to our health plans as a result of a failure to comply with those requirements, which has impacted and in the future could impact our profitability. Due to decreased utilization of medical facilities and services as a result of the COVID-19 pandemic, we experienced retroactive rate adjustments by certain state Medicaid agencies, and rate adjustments may continue in the future. As members have accessed care during the COVID-19 pandemic, we have experienced increased difficulty obtaining provider information required by CMS and state governmental agencies and, as a result, may have difficulty meeting these quality measures. Further, our existing CMS or state Medicaid contracts have not always been renewed, we have not always been awarded new contracts as a result of the competitive procurement process, and in some cases we have lost members under existing contracts as a result of a post-award challenge by unsuccessful bidders, each of which could take place again in the future and have a material adverse effect on our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Star Rating System utilized by CMS to evaluate Medicare Advantage Plans may have a significant effect on our revenue, as higher-rated plans tend to experience increased enrollment and plans with a Star rating of 4.0 or higher are eligible for quality-based bonus payments and plans with a Star rating of 5.0 can market to and enroll members year-round. If we do not maintain or continue to improve our Star ratings, fail to meet or exceed our competitors&#8217; Star ratings, or if quality-based bonus payments are reduced or eliminated, we may experience a negative impact on our revenues and the benefits that our plans can offer, which could materially and adversely affect the marketability of our plans, our membership levels, results of operations, financial condition and cash flows. Similarly, if we fail to meet or exceed any performance standards imposed by state Medicaid programs in which we participate, we may not receive performance-based bonus payments or may incur penalties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our failure to comply with federal and state healthcare laws and regulations applicable to our participation in Medicaid and Medicare programs, including those directed at preventing fraud, abuse and discrimination, could result in investigations, litigation, fines, restrictions on, or exclusions from, program participation, or the imposition of corporate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">integrity agreements or other agreements with a federal or state governmental agency, any of which could adversely impact our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are periodically subject to government audits, including CMS RADV audits of our Medicare Advantage Plans to validate diagnostic data, patient claims and financial reporting, and audits of our Medicare Part D plans by the Medicare Part D Recovery Audit Contractor (&#8220;RAC&#8221;), as well as state Medicaid RAC programs. These audits could result in significant adjustments in payments made to our health plans, which could adversely affect our financial condition and results of operations. If we fail to report and correct errors discovered through our own auditing procedures or during a RADV or RAC audit, or otherwise fail to comply with applicable laws and regulations, we could be subject to fines, civil penalties or other sanctions, which could have a material adverse effect on our ability to participate in these programs, and on our financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare and Medicaid contracts are also subject to various MLR rules, including minimum MLR thresholds, rebate requirements and audits, which could adversely affect our membership and revenues if any of our state Medicare or Medicaid plans do not meet an applicable minimum MLR threshold. If a Medicare Advantage, MMP or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A change in our healthcare product mix may impact our profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our healthcare products that involve greater potential risk generally tend to be more profitable than administrative services products and those healthcare products where the employer groups assume the underwriting risks. Individuals and small employer groups are more likely to purchase our higher-risk healthcare products because such purchasers are generally unable or unwilling to bear greater liability for healthcare expenditures. Typically, government-sponsored programs also involve our higher-risk healthcare products. A shift of enrollees from more profitable products to less profitable products could have a material adverse effect on our cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to develop and maintain satisfactory relationships with hospitals, physicians, PBM service providers and other healthcare providers, our business, cash flows, financial condition and results of operations may be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability is dependent in part upon our ability to contract on favorable terms with hospitals, physicians, PBM service providers and supply chain partners and other healthcare providers. These partners may elect not to contract with us, and the failure to secure or maintain cost-effective contracts on competitive terms may result in a loss of membership or higher medical costs, which could adversely affect our business. In addition, consolidation among healthcare providers, Accountable Care Organization practice management companies, and other organizational structures that physicians, hospitals and other care providers choose, as well as the ability of larger employers to contract directly with providers, may change the way that these providers interact with us and may change the competitive landscape. Such organizations or groups of physicians may compete directly with us, which may impact our relationship with these providers or affect the way that we price our products and estimate our costs. Such competition may require us to incur costs to change our operations, which could adversely affect our business, cash flows, financial condition, and results of operations. In addition, price transparency initiatives, such as the Health Plan Transparency Rule, may impact our ability to obtain or maintain favorable contract terms. For example, beginning in 2021, hospitals were required to publish online payer-specific negotiated charges for each item or service the hospital provides. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to contract with providers, or if providers attempt to use their market position to negotiate more favorable contracts or place us at a competitive disadvantage, or the inability of providers to provide adequate care, could adversely affect our business. In addition, we do not have contracts with all providers that render services to our members and, as a result, may not have a pre-established agreement about the amount of compensation those out-of-network providers will accept for the services they render. State and federal laws, such as the No Surprises Act, define the compensation that must be paid to out-of-network providers in certain scenarios, and related litigation has lessened the weight of the Qualifying Payment Amount during independent dispute resolution processes, which may result in an increase in rates we must pay to out-of-network providers. Both our lack of contracts with certain providers and the development of new federal and state laws could result in significant litigation or arbitration proceedings, provider attempts to obtain payment from our members for the difference between the amount we have paid and the amount they have charged, or other increases in rates paid to out-of-network providers.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the success of our relationships with third parties for various services and functions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with various third parties to perform certain functions and services and provide us with certain information technology systems. Certain of these third parties provide us with significant portions of our business infrastructure and operating requirements. For example, a single vendor can provide to us a wide range of technology infrastructure services, such as end user (help desk and field support), data center, mainframe, storage and database services and multi-cloud management services, and we are subject to the risks of any operational failure, termination or other restraints in such an arrangement. We could become overly dependent on key vendors, which could cause us to lose core competencies. A termination of our agreements with, or disruption in the performance of, one or more of these service providers could result in service disruptions or unavailability, reduced service quality and effectiveness, increased or duplicative costs or an inability to meet our obligations to our customers. In addition, we may also have to seek alternative service providers, which may be unavailable or only available on less favorable contract terms. Any of these outcomes could adversely affect our business, reputation, cash flows, financial condition and operating results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PBM services business would be adversely affected if we are unable to contract on favorable terms with third-party vendors, including pharmaceutical manufacturers. We delegate certain PBM administrative functions, such as claims processing and prescription fulfillment, to CVS Health pursuant to the CVS PBM Agreement. If CVS Health fails to provide PBM services as contractually required, we may not be able to meet the full demands of our customers, which could have a material adverse effect on our business, reputation and results of operations. For additional information on the CVS PBM Agreement, see &#8220;Business &#8212; Product and Service Descriptions,&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure to effectively maintain and upgrade our information systems, or the availability and integrity of our data, could adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends significantly on effective information systems, and we have many different information systems for our various businesses, including those that we have acquired as a result of our merger and acquisition activities. Our information systems require an ongoing investment, commitment of significant resources to maintain and enhance existing systems, and development of new systems to keep pace with continuing changes in information processing technology, emerging cyber-security risks, changing customer preferences, evolving industry and regulatory standards and legal requirements, including as a result of the ACA, the Health Plan Transparency Rule, the 2021 Appropriations Act and proposed federal data interoperability regulations. In addition, we may obtain significant portions of our systems-related or other services from independent third parties, which may make our operations vulnerable if such third parties fail to perform adequately.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to adequately implement, consolidate, integrate, streamline, maintain and upgrade effective and efficient information systems with sufficiently advanced technological capabilities could result in investigations, audits, fines and penalties, competitive and cost disadvantages to us compared to our competitors, could divert management&#8217;s time, and could have a material adverse effect on our business, financial condition and results of operations. Failure or disruption of our performance of, or our ability to perform, key business functions, including as a result of the unavailability or cyber-attack of our information technology systems or those of third parties (including cloud service providers), could decrease response times, lower levels of service satisfaction and harm our reputation. Our systems interface with and depend on third-party systems and we could experience service denials if demand for such service exceeds capacity or these systems fail or experience interruption. Despite our adoption and continued enhancement of business continuity and disaster recovery strategies, there is no guarantee that such efforts will be effective, which could interrupt the functionality of our information technology systems or those of third parties. Our failure to implement adequate business continuity and disaster recovery strategies could significantly reduce our ability to provide products and services to our customers and clients, which could have a material adverse effect on our business and results of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The volume of health care data generated and the uses of this data, including electronic health records, are rapidly expanding. Our ability to develop, implement, price, support new and existing products and services, provide service to our customers in an efficient and uninterrupted fashion, and report on our operations depends on the integrity of this data and our information systems. In addition, connectivity amongst technologies is becoming increasingly important, with recent trends bringing greater consumer engagement in healthcare; therefore, the pace at which our customers will need enhanced technologies with sophisticated applications for mobile interfaces will continue to expand. If the information systems we rely upon to run our business were found to be inaccurate or unreliable or if we fail to adequately maintain our information systems, security controls and data integrity effectively, we could experience problems in determining medical cost estimates </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and establishing appropriate pricing and reserves, have disputes with customers and providers, face regulatory problems, including sanctions and penalties, incur increases in operating expenses or suffer other adverse consequences, including a decrease in membership.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL, REGULATORY AND PUBLIC POLICY RISKS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to significant government regulation, and changes or proposed changes in the regulation of our business by federal and state regulators may adversely affect our business, cash flows, financial condition and results of operations and the market price of our securities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to significant state and federal regulation associated with many aspects of our business, including, but not limited to, licensing, premiums, marketing activities, provider contracting, access and payment standards, and corporate governance and financial reporting matters, as described in greater detail in Part I, Item 1, &#8220;Business&#8212;Regulation&#8221; in this Annual Report on Form 10-K. Further, the integration into our business of entities that we acquire, or the expansion of our business into new businesses or jurisdictions, may affect the way in which existing laws and rules apply to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to existing laws, rules and regulations or judicial interpretation, application or enforcement thereof, or development of new laws, rules, regulatory interpretations or judgments could force us to change how we conduct our business, affect the products and services we offer (and where we offer them), restrict revenue and enrollment growth, increase our costs, including operating, healthcare technology and administrative costs, restrict our ability to obtain new product approvals and implement changes in premium rates, and require enhancements to our compliance infrastructure and internal controls environment, which could adversely impact our business and results of operations. In addition, legislative and/or regulatory policies or proposals that seek to manage the healthcare industry or otherwise impact our business may cause the market price of our securities to decrease, even if such policies or proposals never become effective. In particular, further regulations and modifications to the ACA and federal and state laws and regulations stemming from the ACA could impact the market for our products, federal government funding for various ACA programs, the regulations applicable to us and the fees and taxes payable by us and otherwise affect our business and future operations, some of which may adversely affect our financial condition and results of operations.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are required to obtain and maintain insurance and other regulatory approvals to market certain of our products and services, to increase prices for certain regulated products and services and to consummate some of our acquisitions and dispositions. Delays in obtaining or failure to obtain or maintain these approvals, as well as future regulatory action by state or federal authorities, could have a material adverse effect on the profitability or marketability of our health benefits or managed care products or on our business, financial condition, and results of operations. For example, requirements in the Health Plan Transparency Rule and the 2021 Appropriations Act, such as the price comparison tool, have the potential to increase healthcare costs and our operating costs in order to comply and may impact provider negotiations and market pricing. In addition, changes in government regulations or policies that apply to government-sponsored programs such as Medicare and Medicaid including, among other things, reimbursement levels, eligibility and recertification requirements, benefit coverage requirements and additional governmental participation, could also adversely affect our business, cash flows, financial condition, and results of operations. The annual recertification process for Medicaid recipients was temporarily suspended in response to the COVID-19 pandemic; however, the 2023 Appropriations Act decoupled Medicaid redeterminations from the COVID-19 public health emergency, and states may begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023. Where states allow certain programs to expire or have not opted for Medicaid expansion under the ACA, we could experience reduced Medicaid enrollment and reduced growth opportunities. If future modifications to laws and regulations significantly reduce Medicaid enrollment, our Medicaid business will be negatively impacted.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced past assessments under state or federal insolvency or guaranty association laws applicable to insurance companies, HMOs and other payers, and may experience assessments in the future if, for example, premiums established by other companies for their health insurance products, including certain long-term care products, are inadequate to cover their costs. Any such assessment could expose us to the risk of paying a portion of an impaired or insolvent insurance company&#8217;s claims through state guaranty associations. We are not currently able to estimate our potential financial obligations, losses or the availability of offsets associated with potential guaranty association assessments; however, any significant increase in guaranty association assessments could have a material adverse effect on our business, cash flows, financial condition, and results of operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect state legislatures will continue to focus on healthcare delivery and financing issues, including actions to reduce or limit increases to premium payments, provider billing protections, greater access to care and broader reforms of state health insurance markets. State ballot initiatives could also be put to voters that could materially impair our operating environment. If enacted into law, these state proposals and actions could have a material adverse impact on our business, cash flows, operations or financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the past, Congress has considered, and may consider in the future, various forms of managed care reform legislation which, if adopted, could fundamentally alter the treatment of coverage decisions under ERISA and other laws and could increase our costs, expose us to expanded liability or require us to revise the ways in which we conduct business. There have been legislative attempts to limit ERISA&#8217;s preemptive effect on state laws and litigants&#8217; ability to seek damages beyond the benefits offered under their plans. If adopted, such limitations could increase our liability exposure, permit greater state regulation of our operations, and expand the scope of damages, including punitive damages, litigants could be awarded.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various risks associated with our international operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand and operate our business outside of the U.S., we are presented with different challenges, including challenges in adapting to new markets, languages, business, labor and cultural practices and regulatory environments. Adapting to these challenges could require us to devote significant senior management attention and other resources. If we are unable to successfully manage our international operations, our business, cash flows, financial condition and results of operations could be adversely affected. In the future, we may acquire or operate new businesses outside of the U.S., increasing our exposure to these risks.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate internationally and are subject to regulation in the jurisdictions in which they are organized or conduct business related to, among other things, local and cross border taxation, intellectual property, investment, management control, labor, anti-fraud, anti-corruption and privacy and data protection, which vary by jurisdiction. In addition, we are subject to U.S. laws that regulate the conduct and activities of U.S.-based businesses operating abroad, such as the Foreign Corrupt Practices Act. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees, restrictions or outright prohibitions on the conduct of our business and significant reputational harm and could adversely affect our ability to market our products and services, which may have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to litigation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and may in the future be, a party to a variety of legal actions that may affect our business, such as administrative charges before government agencies, employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims and intellectual property-related litigation. In addition, because of the nature of our business, we are subject to a variety of legal actions relating to our business operations, including the design, administration and offering of our products and services. These could include claims relating to the denial or limitation of health benefits; federal and state false claims act laws; dispensing of drugs associated with our PBM business; professional liability claims arising out of the delivery of healthcare and related services to the public; development or application of medical policies and coverage and clinical guidelines; medical malpractice actions; allegations of anti-competitive and unfair business activities; provider disputes over reimbursement and contracts; provider tiering programs; narrow networks; termination of provider contracts; the recovery of overpayments from providers; fee-based business; disputes over co-payment calculations; reimbursement of out-of-network claims; the failure to disclose certain business practices; the failure to comply with various state or federal laws, including but not limited to, ERISA and the Mental Health Parity Act; and customer audits and contract performance, including government contracts. These actions or proceedings could result in substantial costs to us, require management to spend substantial time focused on litigation, result in negative media attention, and may adversely affect our business, reputation, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in, or may in the future be party to, pending or threatened litigation incidental to the business we transact or arising out of our operations, including, but not limited to, breaches of security and violations of privacy requirements, shareholder actions, compliance with federal and state laws and regulations (including qui tam or &#8220;whistleblower&#8221; actions), or sales and acquisitions of businesses or assets. From time to time, we are involved as a party in various governmental investigations, audits, reviews and administrative proceedings, including challenges relating to the award of government contracts. These investigations, audits and reviews include routine and special investigations by state </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance departments, various federal regulators including CMS and the HHS Office of Inspector General, state attorneys general, the Department of Justice, and various offices of the U.S. Attorney General. Following an investigation, we may be subject to civil or criminal fines, penalties, and other sanctions if we are determined to be in violation of applicable laws or regulations. Liabilities that may result from these actions could have a material adverse effect on our cash flows, results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent court decisions and legislative activity may increase our exposure for any of these types of claims. In some cases, substantial non-economic (including injunctive relief), treble or punitive damages may be sought. Our international footprint also subjects us to additional potential disputes or differing interpretations related to contractual rights, tax positions, and regulatory oversight. Some liabilities and damages may not be covered by the insurance we carry, insurers may dispute coverage, or the amount of insurance may not be enough to cover the damages awarded. In addition, insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. Any adverse judgment against us resulting in such damage awards could result in negative publicity and have an adverse effect on our cash flows, results of operations and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are various risks associated with providing healthcare and other diversified products and services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evolve our business to offer products and services beyond traditional health insurance, including digital health technology, pharmacy, behavioral and clinical care services, which subjects us to litigation and regulatory risks that are different from our traditional product and services offerings and may materially affect our exposure to other risks. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The direct provision of healthcare services by certain of our subsidiaries involves risks of additional litigation brought against us or our associates for alleged malpractice or professional liability claims arising out of the delivery of healthcare and related services. In addition, liability may arise from maintaining healthcare premises that serve the public. Behavioral health services may also raise the risk profile of our business given the critical and sensitive nature of the services provided. In addition, we are, to a certain extent, self-insured with regard to litigation risks, including claims of medical malpractice against our affiliated physicians and us, and it is possible that the level of actual losses will significantly exceed the liabilities recorded for our estimates of the probable costs resulting from self-insured matters. The defense of any actions may result in significant expenses, and if we fail to maintain adequate insurance coverage for these liabilities, or if such insurance is not available, the resulting costs could adversely affect our business, cash flows, financial condition and results of operations. As we become more involved in direct care delivery and the provision of other services, such as crisis management services, there will be an increased possibility of litigation. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, many states in which certain of our subsidiaries operate limit the practice of medicine to licensed individuals or professional organizations comprised of licensed individuals. Business corporations generally may not exercise control over the medical decisions of physicians, and we are not licensed to practice medicine. Rules and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources, and similar issues vary from state to state, and any enforcement actions by governmental officials alleging non-compliance with these rules and regulations could adversely affect our business, cash flows, financial condition and results of operations. Further, in certain states we are required to use professional corporations that are not affiliates, which exposes us to risk in the event the physician owners of those professional corporations take actions that are in breach of the contractual obligations that exist between us. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our PBM services business and related operations are subject to risks and uncertainties that are in addition to those we face in our core healthcare business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide PBM services through our CarelonRx business and are responsible to regulators and our customers for the delivery of those PBM services that we contract to provide. Our PBM services business is subject to the risks inherent in the dispensing, packaging, fulfillment and distribution of pharmaceuticals and other healthcare products, including exposure to liabilities and reputational harm related to purported dispensing and other operational errors by us or our PBM services suppliers. Any failure by us or one of our PBM services suppliers to adhere to the laws and regulations applicable to the dispensing of pharmaceuticals could subject our PBM business to civil and criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PBM services business is subject to federal and state laws and regulations that govern its relationships with pharmaceutical manufacturers, physicians, pharmacies and customers, including without limitation, federal and state anti-kickback laws, beneficiary inducement laws, consumer protection laws, ERISA, HIPAA and laws related to the operation of internet and mail-service pharmacies, as well as an increasing number of licensure, registration and other laws and accreditation standards that impact the business practices of a PBM services business. In addition, the PBM services business </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the practice of pharmacy are subject to federal and state laws and regulations, including those of state boards of pharmacy, individual state-controlled substance authorities, the U.S. Drug Enforcement Agency and the U.S. Food and Drug Administration. Also, we and our third-party vendors are subject to registration requirements and state and federal laws concerning labeling, packaging, advertising, handling and adulteration of prescription drugs and dispensing of controlled substances. Noncompliance with applicable laws and regulations by us or our third-party vendors could have material adverse effects on our business, results of operations, financial condition, liquidity and reputation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state legislatures and regulators also regularly consider new laws and regulations and changes to existing regulations and policies for the industry that could materially affect current industry practices and our business, including the regulation implemented by HHS in November 2020 related to drug manufacturer rebates, spread pricing contract arrangements, the pricing of pharmaceuticals, the 2021 Appropriations Act and potential new regulations regarding rebates, fees from pharmaceutical companies, the development and use of formularies and other utilization management tools, the use of average wholesale prices or other pricing benchmarks, pricing for specialty pharmaceuticals, limited access to networks and pharmacy network reimbursement methodologies and reporting requirements. Recent case law, such as the 2020 U.S. Supreme Court reinstatement of an Arkansas law regulating PBMs, as well as industry publications like the 2021 NAIC white paper on the topic, may increase and impact greater state regulation of PBMs.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to license agreements with the BCBSA that entitle us to the exclusive and, in certain areas, non-exclusive use of the BCBS names and marks in our geographic territories. The termination of these license agreements or changes in the terms and conditions of these license agreements could adversely affect our business, cash flows, financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreements with the BCBSA contain certain requirements and restrictions regarding our operations and our use of the BCBS names and marks, and failure to comply with those requirements could result in a termination of the license agreements. The license agreements may be modified by the BCBSA, which could have a material adverse effect on our future expansion plans or results of operations. Further, BCBS licensees have certain requirements to perform administrative services for members of other BCBS licensees. As of December 31, 2022, we provided services to approximately 33 million Blue Cross and/or Blue Shield enrollees. If we or another BCBS licensee are not in compliance with all legal requirements or are unable to perform administrative services as required, this could have an adverse effect on our members and our ability to maintain our licenses, which could have a material adverse effect on our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of an event causing termination of the license agreements, we would no longer have the right to use the BCBS names and marks or to sell BCBS health insurance products and services in one or more of our service areas. Furthermore, the BCBSA would be free to issue a license to use the BCBS names and marks in these service areas to another entity. Our existing BCBS members would be provided with instructions for obtaining alternative products and services licensed by the BCBSA. We believe that the BCBS names and marks are valuable identifiers of our products and services in the marketplace.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon termination of either license agreement, the BCBSA would have the right to impose a &#8220;Re-establishment Fee&#8221; upon us, which would be used in part to fund the establishment of a replacement Blue Cross and/or Blue Shield licensee in the vacated service area. The fee is set at $98.33 per licensed enrollee. If the Re-establishment Fee was applied to our total Blue Cross and/or Blue Shield enrollees of approximately 33 million as of December 31, 2022, we would be assessed approximately $3 billion by the BCBSA. As a result, termination of the license agreements would have a material adverse effect on our business, cash flows, financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on the BCBSA license agreements, including requirements, restrictions and termination events set forth in these license agreements, see Part I, Item 1, &#8220;Business &#8212; BCBSA Licenses&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indiana law, other applicable laws, our articles of incorporation and bylaws, and provisions of our BCBSA license agreements may prevent or discourage takeovers and business combinations that our shareholders might consider to be in their best interest. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indiana law, other applicable laws and regulations and provisions in our articles of incorporation and bylaws may delay, defer, prevent or render more difficult a takeover attempt that our shareholders might consider to be in their best interests. For instance, they may prevent our shareholders from receiving the benefit from any premium to the market price of our common </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock offered by a bidder in a takeover context or adversely affect the price that some investors are willing to pay for our stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The insurance holding company system acts and certain health statutes of the states in which our insurance company or HMO subsidiaries are regulated restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Further, the Indiana Business Corporation Law contains business combination provisions that, in general, prohibit for five years any business combination with a beneficial owner of 10% or more of our common stock unless the holder&#8217;s acquisition of the stock was approved in advance by our Board of Directors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles of incorporation and bylaws contain provisions that could have anti-takeover effects and may delay, defer or prevent a takeover attempt that our shareholders might consider to be in their best interests. Our articles of incorporation provide that no person may beneficially own shares of voting capital stock beyond specified ownership limits, except with the prior approval of a majority of the &#8220;continuing directors.&#8221; The ownership limits, which may not be exceeded without the prior approval of the BCBSA, are the following: (1) for any institutional investor (as defined in our articles of incorporation), one share less than 10% of our outstanding voting securities; (2) for any non-institutional investor (as defined in our articles of incorporation), one share less than 5% of our outstanding voting securities; and (3) for any person, one share less than the number of shares of our common stock or other equity securities (or a combination thereof) representing a 20% ownership interest in us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our articles of incorporation and bylaws: divide our Board of Directors into three classes serving staggered three-year terms (which is required by our license agreements with the BCBSA); permit our Board of Directors to determine the terms of and issue one or more series of preferred stock without further action by shareholders; restrict the maximum number of directors and the ability to increase that number; limit the ability of shareholders to remove directors; impose restrictions on shareholders&#8217; ability to fill vacancies on our Board of Directors; impose advance notice requirements for shareholder proposals and nominations of directors to be considered at meetings of shareholders; prohibit shareholders from amending certain provisions of our bylaws; and impose restrictions on who may call a special meeting of shareholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The health benefits industry is subject to negative publicity, which could adversely affect our business, cash flows, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health benefits industry is subject to negative publicity, which can arise from, among other things, increases in premium rates, industry consolidation, cost of care initiatives and debate around existing or proposed legislation. Negative publicity may result in increased regulation and legislative review of industry practices, which may further increase our costs of doing business and adversely affect our profitability by limiting our ability to market or provide our products and services, requiring us to change our products and services, or increasing the regulatory oversight under which we operate. In addition, any negative publicity concerning the BCBSA or other BCBSA licensees may adversely affect us and the sale of our health benefits products and services. Negative public perception or publicity of the health benefits industry in general, the BCBSA, other BCBSA licensees, or us or our key vendors could adversely affect our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STRATEGIC RISKS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition in many of our markets, and if we fail to adequately adapt to changes in our industry and develop and implement strategic growth opportunities, our ability to compete and grow may be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a health benefits company, we operate in a highly competitive industry that is subject to significant changes from and competition due to legislative reform, business consolidations, new strategic alliances, new market entrants, aggressive marketing practices, technological advancements and changing market practices such as increasing usage of telehealth. We also must respond to pricing and other actions taken by existing competitors and potentially disruptive new entrants in the Public Exchanges and in our other lines of business. These factors have produced and will continue to produce significant pressures on our profitability and membership. Furthermore, decisions to buy our products and services are increasingly made or influenced by consumers, through means such as direct purchasing (for example, Medicare Advantage plans) and insurance exchanges that allow individual choice, or by large employers that may increasingly have the ability to contract directly with providers. To compete effectively under these unique market pressures in the consumer-driven marketplace, we will be required to develop and deliver innovative and potentially disruptive products and services to satisfy evolving market demands.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the PBM industry is highly competitive, and CarelonRx is subject to competition from national, regional and local PBMs, other insurers, health plans, large retail pharmacy chains, large retail stores, supermarkets, mail order and web pharmacies, discount cards and specialty pharmacies. Strong competition within the PBM business has generated greater demand for lower product and service pricing, increased revenue sharing and enhanced product and service offerings. Our inability to maintain positive trends, contract on favorable terms with pharmaceutical manufacturers for, among other things, rebates, discounts and administrative fees or a failure to identify and implement new ways to mitigate pricing pressures, could negatively impact our ability to attract or retain customers, negatively impact our margins and have a material adverse effect on our business and results of operations. In addition, legislative reforms such as the regulation recently issued by HHS related to rebates and the 2021 Appropriations Act, which requires reporting of plan spending, the cost of plan pharmacy benefits, enrollee premiums and any manufacturer rebates received by the plan or issuer, may adversely affect our competitive position, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to profitably grow our business in the future, we need to not only grow our profitable medical membership, but also continue to diversify our sources of revenue and earnings, including through the increased sale of our stand-alone PBM and other Carelon services, specialty products, such as dental, vision and other supplemental products, expansion of products, expansion of our non-insurance assets and establishment of new cost of care solutions, including innovations in PBM and health services. If we are unable to acquire or develop and successfully manage new opportunities that further our strategic objectives and differentiate our products and services from our competitors, our ability to profitably grow our business could be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently dependent on the non-exclusive services of independent agents and brokers in the marketing of our healthcare products, particularly with respect to individuals, seniors and certain group customers. We face intense competition for the services and allegiance of these independent agents and brokers, who may also market the products of our competitors. Our relationship with our brokers and independent agents could be adversely impacted by changes in our business practices to address legislative changes, including potential reductions in commissions and consulting fees paid to agents and brokers. We cannot ensure that we will be able to compete successfully against current and future competitors for these services or that competitive pressures faced by us will not materially and adversely affect our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;Business &#8212; Competition&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have built a significant portion of our current business through mergers and acquisitions, joint ventures, strategic alliances and investments, and although we expect to pursue such opportunities in the future, we are subject to risks resulting from such business combinations. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are some of the risks associated with mergers, acquisitions, divestitures, joint ventures and strategic alliances and investments, referred to collectively as business combinations, that could have a material adverse effect on our business, cash flows, financial condition and results of operations:</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">some business combinations may not achieve anticipated revenues, earnings or cash flow, business opportunities, synergies, growth prospects or other anticipated benefits; </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may assume liabilities that were not disclosed to us, or which were underestimated, and which could lead to legal challenges, investigations and enforcement actions, and we may not be able to adequately recover from sellers or insurance carriers for such assumed liabilities;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience difficulties in integrating business combinations, including into our internal control environment and culture, be unable to integrate business combinations successfully or as quickly as expected and be unable to realize anticipated economic, operational and other benefits in a timely manner or at all;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business combinations and proposed business combinations that are not completed could disrupt our ongoing business, lead to the incurrence of significant fees, distract management, result in the loss of key employees, divert resources, result in tax costs or inefficiencies and make it difficult to maintain our current business standards, controls, information technology systems, policies and procedures;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may finance future business combinations by issuing common stock for some or all of the purchase price, which could dilute the ownership interests of our shareholders;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may compete with other firms, some of which may have greater financial and other resources, to acquire attractive companies;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience disputes with or competition from our partners or former partners in our strategic alliances, investments and joint ventures, which could result in litigation or a loss of business; and</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future business combinations may make it difficult to comply with the requirements of the BCBSA and lead to a risk that our BCBSA license agreements may be terminated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition to attract and retain employees. Further, managing key executive succession and retention is critical to our success. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to attract, develop and retain qualified employees, including those with diverse backgrounds, experience and skill sets, to operate and expand our business. We face intense competition for experienced and highly skilled employees, and we may be unable to attract and retain such employees or competition among potential employers may result in increasing salaries. Adverse changes to our corporate culture could harm our business operations and our ability to retain key employees and executives. An inability to retain existing employees or attract additional employees could have a material adverse effect on our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are unable to attract, retain and effectively manage the succession plans for key employees and executives, including our President and Chief Executive Officer, our business, results of operations and future performance could be adversely affected. We may have difficulty in replacing key executives because of the limited number of qualified individuals with the breadth of skills and experience required to operate and successfully expand our business. The succession plans we have in place for members of our senior management and employment arrangements with certain key executives do not guarantee that the services of our senior executives will continue to be available to us or that we will be able to attract, transition and retain suitable successors. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restrictions on our ability to obtain funds from our regulated subsidiaries could limit our ability to repurchase shares, pay dividends and meet our obligations and materially adversely affect our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries. Among other restrictions, state insurance and HMO laws restrict the ability of most of our regulated subsidiaries to pay dividends. In some states, we have made special undertakings that may further limit the ability of our regulated subsidiaries to pay dividends. Our ability to repurchase shares, pay dividends to our shareholders and meet our obligations, including paying operating expenses and debt service on our outstanding and future indebtedness, will depend upon the receipt of dividends from our subsidiaries. An inability of our subsidiaries to pay dividends in the future in an amount sufficient for us to meet our financial obligations may materially adversely affect our business, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, most of our regulated subsidiaries are subject to minimum capital requirements and periodic financial reporting that require them to report their results of risk-based capital calculations to the departments of insurance and the NAIC. Failure to maintain these minimum standards could subject our regulated subsidiaries to corrective action, including state supervision or liquidation. We are also a party to license agreements with the BCBSA which contain additional minimum capital and liquidity requirements. Changes to existing minimum capital requirements could further restrict the ability of our regulated subsidiaries to pay dividends and adversely affect our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated subsidiaries are subject to state laws and regulations that require diversification of their investment portfolios and limit the amount of investments in certain investment categories. Failure to comply with these laws and regulations might cause investments exceeding regulatory limitations to be treated as non-admitted assets for purposes of measuring statutory surplus and risk-based capital, and in some instances, require the sale of those investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial indebtedness outstanding and may incur additional indebtedness in the future, which could adversely affect our ability to pursue desirable business opportunities and to react to changes in the economy or our industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt service obligations require us to use a portion of our cash flow to pay interest and principal on debt instead of for other corporate purposes, including funding future expansion. We are exposed to interest rate risk to the extent of our variable rate indebtedness. Increases in interest rates have increased our cost of borrowing, and volatility in U.S. and global financial markets could impact our access to, or further increase the cost of, financing. If our cash flow and capital resources are insufficient to service our debt obligations, we may be forced to seek extraordinary dividends from our subsidiaries, sell </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets, seek additional equity or debt capital or restructure our debt. However, these measures might be unsuccessful or inadequate to meet scheduled debt service obligations or may not be available on commercially reasonable terms.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also incur future debt obligations that might subject us to restrictive covenants that could affect our financial and operational flexibility. Our breach or failure to comply with any of these covenants could result in a default under our credit facilities or other indebtedness. If we default under our credit agreement, the lenders could cease to make further extensions of credit or cause all of our outstanding debt obligations under our credit agreement to become immediately due and payable, together with accrued and unpaid interest. If the indebtedness under our notes or our credit agreement or our other indebtedness is accelerated, we may be unable to repay or finance the amounts due, on commercially reasonable terms, or at all. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A downgrade in our credit ratings could have an adverse effect on our business, cash flows, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims-paying ability, financial strength and debt ratings by nationally recognized statistical rating organizations are important factors in establishing the competitive position of insurance and health benefits companies. We believe our strong credit ratings are an important factor in marketing our products to customers. In addition, if our credit ratings are downgraded or placed under review, our business, cash flows, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs. Each of the ratings organizations reviews our ratings periodically, and there can be no assurance that our current ratings will be maintained in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The value of our intangible assets may become impaired.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $35 billion of goodwill and other intangible assets, representing 34% of our total consolidated assets. In accordance with applicable accounting standards, we periodically evaluate our goodwill and other intangible assets for potential impairment, using assumptions and judgments regarding the estimated fair value of our reporting units. Estimated fair values might be significantly different if other reasonable assumptions and estimates were to be used. If estimated fair values are less than the carrying values of goodwill and other intangible assets with indefinite lives in future impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value we place on intangible assets may be adversely impacted if existing or future business combinations fail to perform in a manner consistent with our assumptions. In addition, from time to time we divest businesses, and any such divestiture could result in significant asset impairment and disposition charges, including those related to goodwill and other intangible assets. Further, the estimated value of our reporting units may be impacted because of business decisions we make associated with any future changes to laws and regulations, which could unfavorably affect the carrying value of certain goodwill and other intangible assets and result in impairment charges in future periods. Any future evaluations requiring an impairment of our goodwill and other intangible assets could materially affect our results of operations and shareholders&#8217; equity which could, in turn, negatively impact our debt ratings or potentially impact our compliance with existing debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The value of our investments is influenced by varying economic and market conditions, and a decrease in value may result in a loss charged to income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a significant investment portfolio of cash equivalents and short-term and long-term investments in a variety of securities, which are subject to general credit, liquidity, market and interest rate risks. As a result, we may experience a reduction in value or loss of our investments, which may have a negative adverse effect on our results of operations, liquidity and financial condition. Changes in the economic environment, including periods of increased volatility in the securities markets such as those experienced in connection with COVID-19 and recent increases in inflation and interest rates, can increase the difficulty of assessing investment impairment and increase the risk of potential impairment of these assets. There is continuing risk that declines in the fair value of our investments may occur and material impairments may be charged to income in future periods, resulting in recognized losses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISKS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We also face other risks that could adversely affect our business, financial condition or results of operations, which include:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse securities and credit market conditions, which could impact our ability to meet liquidity needs;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any requirement to restate financial results in the event of inappropriate application of accounting principles;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in tax laws and regulations or changes in the interpretation of tax laws and regulations by governmental authorities that could impact the future value of our deferred tax assets and deferred tax liabilities, or result in significant one-time charges in the current or future taxable years;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a significant failure of our internal control over financial reporting;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our prevention and control systems related to employee compliance with internal policies, including data security and data privacy;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provider fraud that is not prevented or detected and impacts our medical costs or those of self-insured customers;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to protect our proprietary information and other sensitive data; and</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our corporate governance policies or procedures.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_19"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_22"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;PROPERTIES. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our principal executive offices located at 220 Virginia Avenue, Indianapolis, Indiana. In addition to this location, we have operating facilities located in each state where we operate as licensees of the BCBSA, in each state where Amerigroup conducts business and in certain other states and countries where our other subsidiaries operate. A majority of these locations are also leased properties. Our facilities support our various business segments. We modified certain of our workforce practices in 2020 in response to the COVID-19 pandemic, including having the majority of our workforce work remotely. In the third quarter of 2020, our management introduced enterprise-wide initiatives to streamline our operations and optimize our business, including a reduction of our office space footprint. In 2021 and 2022, we identified additional reductions of office space. We believe that our properties are adequate and suitable for our business as presently conducted; however, we are continuing to evaluate our real estate strategy in response to the changing needs of our in-office, hybrid and remote workforce.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_25"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;LEGAL PROCEEDINGS.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding our legal proceedings, see Note 14, &#8220;Commitments and Contingencies - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Regulatory Proceedings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, which information is incorporated herein by reference.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_28"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_34"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER&#160;MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, par value $0.01 per share, is listed on the NYSE under the symbol &#8220;ELV.&#8221; </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2023, there were 50,958 shareholders of record of our common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning securities authorized for issuance under our equity compensation plans is set forth in Part III, Item&#160;12, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information related to our repurchases of common stock for the periods indicated (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in millions, except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:9.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased as</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Publicly</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of&#160;Shares&#160;that</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">May Yet Be</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Under the</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2022 to October&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November&#160;1, 2022 to November&#160;30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;1, 2022 to December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14pt">Total number of shares purchased includes 4,324 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders&#8217; equity are shown net of these shares purchased.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14pt">Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board evaluates periodically. During the year ended December&#160;31, 2022, we repurchased 4,834,939 shares at an aggregate cost of $2,316 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Performance Graph and related information compares the cumulative total return to shareholders of our common stock for the period from December&#160;31, 2017 through December&#160;31, 2022, with the cumulative total return over such period of (i)&#160;the Standard&#160;&amp; Poor&#8217;s 500 Stock Index (the &#8220;S&amp;P 500 Index&#8221;) and (ii) the Standard and Poor&#8217;s 500 Health Care Index (the &#8220;S&amp;P 500 Health Care Index&#8221;). We have also included the Standard&#160;&amp; Poor&#8217;s Managed Health Care Index (the &#8220;S&amp;P Managed Health Care Index&#8221;) that we have compared ourselves to in prior years. We believe the S&amp;P 500 Health Care Index provides for a more meaningful comparison as it contains a more comprehensive list of companies in the healthcare industry than the previous S&amp;P Managed Health Care Index. The graph assumes an investment of $100 on December&#160;31, 2017 in each of our common stock and these indices (and the reinvestment of all dividends).</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the graph below are based on historical data, and we caution that the stock price performance shown in the graph below is not indicative of, and is not intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from S&amp;P Global Market Intelligence, a source believed to be reliable, but we are not responsible for any errors or omissions in such information. The following graph and related information shall not be deemed &#8220;soliciting materials&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><img src="elv-20221231_g2.jpg" alt="elv-20221231_g2.jpg" style="height:412px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:4.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elevance Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Health Care Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P Managed Health Care Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon an initial investment of $100 on December&#160;31, 2017 with dividends reinvested.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_37"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. [RESERVED]</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In Millions, Except Per Share Data or As Otherwise Stated Herein)</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol &#8220;ELV&#8221; on June 28, 2022. References to the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Elevance Health&#8221; or the &#8220;Company&#8221; used throughout this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) refer to Elevance Health, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries. References to the &#8220;states&#8221; include the District of Columbia and Puerto Rico, unless the context otherwise requires.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This MD&amp;A should be read in conjunction with our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section of this Annual Report on Form 10-K generally discusses 2022 and 2021 items and year-over-year comparisons between 2022 and 2021. A detailed discussion of 2020 items and year-over-year comparisons between 2021 and 2020 that are not included in this Annual Report on Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_43"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members through our affiliated health plans as of December&#160;31, 2022. We are an independent licensee of the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#8220;BCBS&#8221;) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, Unicare and/or Wellpoint. We offer pharmacy benefits management (&#8220;PBM&#8221;) services through our CarelonRx, Inc. (&#8220;CarelonRx&#8221;) subsidiary, which was known as IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all 50&#160;states, the District of Columbia and Puerto Rico through our subsidiaries. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield &#8212; represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellpoint &#8212; we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Carelon &#8212; this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we managed our operations by customer type through four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. As we continue our journey to evolve our business from a traditional health insurance company into a lifetime, trusted health partner, we are evaluating and making changes to how we manage our business. This included a review of the products in each of our operating segments, which resulted in restructurings between some of our operating segments. Therefore, our reportable segment presentation in 2023 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and its composition will reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources on January 1, 2023. As a result of these changes, beginning with our Quarterly Report on Form 10-Q for the first quarter of 2023, we will report our results in the following four reportable segments: (i) Health Benefits, which will combine our existing Commercial &amp; Specialty Business and Government Business segments; (ii) our existing CarelonRx segment; (iii) Carelon Services (our former Diversified Business Group), which will be carved out from our existing Other segment; and (iv) Corporate and Other, which will include businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments. We expect to reclassify previously reported information to conform to the new presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations discussed throughout this MD&amp;A are determined in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;). We also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. Operating margin is calculated as operating gain divided by operating revenue. Our definition of operating gain and operating margin may not be comparable to similarly titled measures reported by other companies. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, net income or fully-diluted earnings per share (&#8220;EPS&#8221;) prepared in accordance with GAAP. For additional details on operating gain, see our &#8220;Reportable Segments Results of Operations&#8221; discussion included in this MD&amp;A. For a reconciliation of reportable segment operating revenue to the amounts of total revenue included in the consolidated statements of income and a reconciliation of reportable segment operating gain to income before income tax expense, see Note 20, &#8220;Segment Information,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating revenue consists of premiums, product revenue, and administrative fees and other revenue. Premium revenue is generated from risk-based contracts where we indemnify our policyholders against costs for covered health and life insurance benefits. Product revenue represents services performed by CarelonRx for unaffiliated PBM customers and includes ingredient costs (net of any rebates or discounts), including co-payments made by or on behalf of the customer, and administrative fees. Unaffiliated PBM customers include our fee-based groups that contract with CarelonRx for PBM services and external customers outside of the health plans we own. Administrative fees and other revenue come from fees from our fee-based customers for the processing of transactions or network discount savings realized, revenues from our Medicare processing business and revenues from other health-related businesses, including care management programs and miscellaneous other income. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit expense primarily includes costs of care for health services consumed by our risk-based members, such as outpatient care, inpatient hospital care, professional services (primarily physician care) and pharmacy benefit costs. All four components are affected both by unit costs and utilization rates. Unit costs include the cost of outpatient medical procedures per visit, inpatient hospital care per admission, physician fees per office visit and prescription drug prices. Utilization rates represent the volume of consumption of health services and typically vary with the age and health status of our members and their social and lifestyle choices, along with clinical protocols and medical practice patterns in each of our markets. A portion of benefit expense recognized in each reporting period consists of actuarial estimates of claims incurred but not yet paid by us. Any changes in these estimates are recorded in the period the need for such an adjustment arises. While we offer a diversified mix of managed care products and services through our managed care plans, our aggregate cost of care can fluctuate based on a change in the overall mix of these products and services. Our managed care plans include: Preferred Provider Organizations; Health Maintenance Organizations; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify certain quality improvement costs as benefit expense. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members. These quality improvement costs may be comprised of expenses incurred for: (i)&#160;medical management, including care coordination and case management; (ii)&#160;health and wellness, including disease management services for such conditions as diabetes, high-risk pregnancies, congestive heart failure and asthma management and wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii)&#160;clinical health policy, such as identification and use of best clinical practices to avoid harm, identifying clinical errors and safety concerns, and identifying potential adverse drug interactions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of products sold represents the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated PBM customers (net of rebates or discounts), including any co-payments made by or on behalf of the customer, per-claim administrative fees for prescription fulfillment and certain direct costs related to sales and administration of customer contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of fixed and variable costs. Examples of fixed costs are depreciation, amortization and certain facilities expenses. Certain variable costs, such as premium taxes, vary directly with premium volume. Commission expense generally varies with premium or membership volume. Other variable costs, such as salaries and benefits, do not vary directly with changes in premium but are more aligned with changes in membership. The acquisition or loss of a significant block of business would likely impact staffing levels and thus, associated compensation expense. Other variable costs include professional and consulting expenses and advertising. Other factors can impact our administrative cost structure, including systems efficiencies, inflation and changes in productivity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective contracting with providers of care to our members, product pricing, medical management and health and wellness programs, innovative product design and our ability to maintain or achieve improvement in our Centers for Medicare and Medicaid Services Star ratings. Several economic factors related to healthcare costs, such as regulatory mandates of coverage as well as direct-to-consumer advertising by providers and pharmaceutical companies, have a direct impact on the volume of care consumed by our members. The potential effect of escalating healthcare costs, any changes in our ability to negotiate competitive rates with our providers and any regulatory or market-driven restrictions on our ability to obtain adequate premium rates to offset overall inflation in healthcare costs, including increases in unit costs and utilization resulting from the aging of the population and other demographics, the impact of epidemics and pandemics, as well as advances in medical technology, may impose further risks to our ability to profitably underwrite our business and may have a material adverse impact on our results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to expand through a combination of organic growth, strategic acquisitions and efficient use of capital in both existing and new markets. Our growth strategy is designed to enable us to take advantage of additional economies of scale, as well as provide us access to new and evolving technologies and products. In addition, we believe geographic and product diversity reduces our exposure to local or regional regulatory, economic and competitive pressures and provides us with increased opportunities for growth. We use our subsidiary CarelonRx (formerly IngenioRx) to market and offer PBM services, and we expect CarelonRx to continue to improve our ability to integrate pharmacy benefits within our medical and specialty platform. We continued growing our government-sponsored business through organic growth and the acquisitions of MMM Holdings, LLC (&#8220;MMM&#8221;) in 2021 and Integra MLTC, Inc. (&#8220;Integra&#8221;) in 2022. In all other markets, we intend to maintain our position by delivering excellent service, offering competitively priced products, providing access to high-quality provider networks and effectively capitalizing on the brand strength of the Blue Cross and Blue Shield names and marks.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our business and reportable segments, see Part I, Item 1, &#8220;Business&#8221; and Note 20, &#8220;Segment Information&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve, putting pressure on the healthcare system, and it has impacted, and may continue to impact, our membership, benefit expense and member behavior. The full extent of the impact of the COVID-19 pandemic will depend on future developments, which remain uncertain and cannot be predicted at this time. We will continue to monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes to manage our response and assess and mitigate potential adverse impacts to our business. For additional discussion regarding the impact of and our risks and trends related to the COVID-19 pandemic, see &#8220;Business Trends&#8221; and Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we made the decision to modestly expand our participation in the Individual state- or federally-facilitated marketplaces (the &#8220;Public Exchange&#8221;) for 2023 after also expanding in 2022. As a result, for 2023 we are offering Individual Public Exchange products in 138 of the 143 rating regions in which we operate, in comparison to 122 of 143 rating regions in 2022.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment and underlying market characteristics. Changes to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, the continuing growth in our government-sponsored business exposes us to increased regulatory oversight.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CarelonRx subsidiary markets and offers PBM services to our affiliated health plan customers throughout the country, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes features such as formulary management, pharmacy networks, a prescription drug database, member services and mail order capabilities. CarelonRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement that is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Trends: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to price our health benefit products consistent with anticipated underlying medical cost trends. We continue to closely monitor the COVID-19 pandemic (including new COVID-19 variants, which may be more contagious or severe, or less responsive to treatment or vaccines) and the impacts it may have on our pricing, such as surges in COVID-19 related hospitalizations, infection rates, the cost of COVID-19 vaccines, testing and treatment and the return of non-COVID-19 healthcare utilization to our estimate of normal levels, based on historical utilization patterns. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial &amp; Specialty Business segment remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. The Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;)  imposed an annual Health Insurance Provider Fee (&#8220;HIP Fee&#8221;) on health insurers that write certain types of health insurance on U.S. risks. We priced our affected products to cover the impact of the HIP Fee when it was in effect. The HIP Fee was in effect for 2020 but was permanently repealed beginning in 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Cost Trends:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as care and condition management, program integrity and specialty pharmacy management and utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new high cost prescription drugs, provider contracting inflation, labor costs and healthcare provider or member fraud.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At its onset, the COVID-19 pandemic caused a decrease in utilization of non-COVID-19 health services, which decreased our claim costs in 2020. As the pandemic continued through 2021, our non-COVID-19 healthcare utilization experience gradually increased and largely normalized, and our COVID-19 related healthcare expenses increased as new variants (Delta and Omicron) emerged and vaccinations and boosters became available.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omicron variant increased confirmed COVID-19 cases to significant levels at the end of 2021 and the beginning of 2022. The COVID-19 surge quickly declined during the first quarter of 2022, with COVID-19 inpatient hospitalizations, provider-based tests, visits and vaccinations all decreasing to lower levels by the end of the first half of 2022; concurrently, non-COVID-19 healthcare utilization recovered from lower levels earlier in the year. Omicron sub-variant viruses as well as costs associated with updated bivalent vaccinations drove modest increases in COVID-19 related healthcare expenses in the second half of 2022, but the expected paid claims impact for the second half of 2022 are significantly lower than the winter surge experienced in each of the prior two years. The ongoing cost and volume of covered services related to the COVID-19 pandemic and a future shift of government supplied vaccinations and treatments to privatized, full cost price points may have an adverse effect on our future claim costs. We continue to closely monitor the COVID-19 pandemic and its impacts on our medical cost trends. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion regarding business trends, see Part I, Item&#160;1, &#8220;Business&#8221; of this Annual Report on Form 10-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Trends and Uncertainties</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the declaration of COVID-19 as a public health emergency (&#8220;PHE&#8221;), the federal and state governments enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we expect will continue to have, a significant impact on health benefits, consumer eligibility for public programs and our cash flows for all of our lines of business and which have introduced increased uncertainty around our cost structure. These actions, which are or have been in effect for various durations, provide, among other things: mandates to waive cost-sharing for COVID-19 testing, vaccines and related services; financial support to healthcare providers; and mandates related to prior authorizations, payment levels to providers, consumer enrollment windows and telehealth services. The Biden administration renewed the PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on May 11, 2023.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Consolidated Appropriations Act of 2023 (the &#8220;2023 Appropriations Act&#8221;), Congress decoupled Medicaid eligibility recertification from the PHE. As a result, states may begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023. When recertifications resume, we expect a decline in our Medicaid membership. At the same time, we expect growth in our Commercial risk-based and fee-based plans and Medicare, including through the Public Exchanges, as members exiting Medicaid in our 14 Commercial states seek coverage elsewhere.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that impact our business including an extension of the American Rescue Plan Act of 2021's enhanced Premium Tax Credits (&#8220;PTC&#8221;) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on repurchases of stock made after December 31, 2022; allowing the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) to negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump Administration Medicare drug rebate rule to 2032. The extension of the enhanced PTC will likely allow for growth in Individual exchange market enrollment as Medicaid eligibility recertifications resume, supporting continuity of coverage for more people.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act of 2021 (the &#8220;2021 Appropriations Act&#8221;) has impacted and in the future may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health parity reporting and reporting on pharmacy benefits and drug costs. The requirements of the 2021 Appropriations Act applicable to us have varying effective dates, some of which were effective in December 2021 and during 2022, and others of which have been extended into 2023 since the enactment of the 2021 Appropriations Act.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human Services, Labor and Treasury required us to begin disclosing in July 2022, on a monthly basis, detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we are now required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items and services.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since its enactment in 2010, the ACA has introduced new risks, regulatory challenges and uncertainties, has impacted our business model and strategy and has required changes in the way our products are designed, underwritten, priced, distributed and administered. We expect the ACA will continue to significantly impact our business and results of operations, including pricing, minimum medical loss ratios and the geographies in which our products are available. We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways that could increase financial recoveries from plans. We will continue to evaluate the impact of the ACA as any further developments occur.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion regarding regulatory trends and uncertainties, and risk factors that could cause actual results to differ materially from those contained in forward-looking statements made in this Annual Report on Form 10-K, see Part I, Item&#160;1, &#8220;Business &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and Part I, Item&#160;1A, &#8220;Risk Factors.&#8221;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Items</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business and Operational Matters</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, we began operating as Elevance Health on June 28, 2022. This name change is intended to better reflect our business and our journey from a traditional health benefits organization to a lifetime, trusted health partner. Elevance Health supports health at every stage, offering health plans and clinical, behavioral, pharmacy and complex-care solutions that promote whole health.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service &amp; Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable, and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, we announced our entrance into an agreement with CarepathRx Aggregator, LLC to acquire its specialty pharmacy division, which includes BioPlus Parent, LLC (&#8220;BioPlus&#8221;) and subsidiaries. BioPlus is one of the largest independent specialty pharmacy organizations in the United States and seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition closed on February 15, 2023, and initial purchase accounting has not been finalized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, we completed our acquisition of Integra. Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, we completed our acquisition of MMM, including its Medicare Advantage plan, Medicaid plan and other affiliated companies. MMM is a Puerto Rico-based integrated healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network of specialized clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2021, we completed our acquisition of myNEXUS, Inc. (&#8220;myNEXUS&#8221;). myNEXUS is a comprehensive home-based nursing management company for payors and, at the time of acquisition, delivered integrated clinical support services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy to manage integrated, whole person multi-site care and support by providing national, large-scale expertise to manage nursing services in the home and facilitate transitions of care.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information, see Note 3, &#8220;Business Acquisitions,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we introduced enterprise-wide initiatives to optimize our business and as a result, recorded a charge of $653 in selling, general and administrative expenses. We believe these initiatives largely represent the next step forward in our progression towards becoming a more agile organization, including process automation and a reduction in our office space footprint. In the fourth quarters of 2022 and 2021, we identified additional office space reductions and related fixed asset impairments due to the continuing COVID-19 pandemic and recorded net charges of $39 and $202, respectively, in selling, general and administrative expenses. For additional information, see Note 4, &#8220;Business Optimization Initiatives&#8221; and Note 18, &#8220;Leases,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Matters </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the &#8220;Court&#8221;) captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Blue Cross Blue Shield Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;BCBSA Litigation&#8221;), the BCBSA and Blue Cross and/or Blue Shield licensees, including us (the &#8220;Blue plans&#8221;) previously approved a settlement agreement and release with the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiffs representing a putative nationwide class of health plan subscribers (the &#8220;Subscriber Settlement Agreement&#8221;), which agreement required the Court&#8217;s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber Settlement Agreement applies only to the subscriber class. The defendants continue to contest the consolidated cases brought by the provider plaintiffs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the &#8220;Final Approval Order&#8221;). In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which was previously accrued in 2020. Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event all appellate rights are exhausted in a manner that affirms the Court&#8217;s Final Approval Order, the defendants&#8217; payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement. For additional information regarding the BCBSA Litigation, see Note 14, &#8220;Commitments and Contingencies &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Regulatory Proceedings &#8211; Blue Cross Blue Shield Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Operating Performance</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, total medical membership increased by 2.2 million, or 4.8%. The increase in medical membership was driven primarily by organic growth in our Government Business segment primarily driven by the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, as well as organic growth in our Commercial &amp; Specialty Business segment, and in particular in our Group fee-based membership.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating revenue for the year ended December&#160;31, 2022 was $155,660, an increase of $18,717, or 13.7%, from the year ended December&#160;31, 2021. The increase in operating revenue was primarily driven by higher premium revenue in our Medicaid business due to organic membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth in our Medicare Advantage and Commercial &amp; Specialty Business risk-based businesses, as well as premium rate increases to cover medical cost trends, also generated higher premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue in our CarelonRx segment, resulting from growth in membership and higher script volume. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income for the year ended December&#160;31, 2022 was $6,019, a decrease of $76, or 1.2%, from the year ended December&#160;31, 2021. The decrease in net income was primarily due to realized losses on financial instruments in 2022, as compared to gains in 2021, and increased intangible amortization in 2022 related to recent acquisitions and the rebranding of our products, as we expect to retire certain trade names in the future. These items were partially offset by operating gain increases in all of our business segments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fully-diluted shareholders' earnings per share (&#8220;EPS&#8221;) for the year ended December&#160;31, 2022 was $24.81, an increase of $0.08, or 0.3%, from the year ended December&#160;31, 2021. Our diluted shares for the year ended December&#160;31, 2022 were 242.8, a decrease of 4.0, or 1.6%, compared to the year ended December&#160;31, 2021. The increase in EPS resulted from lower average shares outstanding in 2022, partially offset by the decrease in net income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow for the year ended December&#160;31, 2022 was $8,399, or approximately 1.4 times net income. Operating cash flow for the year ended December&#160;31, 2021 was $8,364, or approximately 1.4 times net income. The slight increase in operating cash flow was primarily due to higher net income in 2022, when adjusted for the impact of investment losses and gains, partially offset by the timing of working capital changes and the payment pursuant to the Subscriber Settlement Agreement made in September 2022.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Membership </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical membership includes the following customer types: Individual, Group risk-based, Group fee-based, BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Medicare, Medicaid and our Federal Employees Health Benefits (&#8220;FEHB&#8221;) Program. We refer to members in our service areas licensed by the BCBSA as our BCBS-branded, or Anthem BCBS, business. Non-BCBS-branded business refers to members in our non-BCBS-branded, or Wellpoint plans, which include Amerigroup, Freedom Health, HealthSun, MMM, Optimum Healthcare and Simply Healthcare plans, as well as HealthLink and UniCare members. In addition to the above medical membership, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health business.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Individual consists of individual customers under age 65 and their covered dependents. Individual policies are generally sold through independent agents and brokers, retail partnerships, our in-house sales force or via the Public Exchanges. Individual business is sold on a risk-based basis. We offer on-exchange products through Public Exchanges and off-exchange products. Federal premium subsidies are available only for certain Public Exchange Individual products.&#160;Unsubsidized Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network and the efficiency of administration. Customer turnover is generally higher with Individual as compared to Group risk-based. Individual business accounted for 1.7%, 1.7% and 1.6% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Group risk-based consists of employer customers who purchase products on a full-risk basis, which are products for which we charge a premium and indemnify our policyholders against costs for health benefits. Group risk-based accounts include Local Group customers and National Accounts. Local Group consists of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees. In addition, Local Group includes Student Health members. National Accounts generally consist of multi-state employer groups primarily headquartered in an Elevance Health service area with at least 5% of the eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some exceptions are allowed based on broker and consultant relationships. Group risk-based accounts are generally sold through brokers or consultants who work with industry specialists from our in-house sales force and are offered both on and off the Public Exchanges. Group risk-based accounted for 8.4%, 8.8% and 8.9% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Group fee-based customers represent employer groups, Local Group, including UniCare members, and National Accounts, who purchase fee-based products and elect to retain most or all of the financial risk associated with their employees&#8217; healthcare costs. Some fee-based customers choose to purchase stop loss coverage to limit their retained risk. Group fee-based accounts are generally sold through independent brokers or consultants retained by the customer working with our in-house sales force. Group fee-based accounted for 42.4%, 42.7% and 45.5% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> host customers represent enrollees of Blue Cross and/or Blue Shield plans not owned by Elevance Health who receive healthcare services in our BCBSA licensed markets. BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> membership consists of estimated host members using the national BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program. Host members are generally members who reside in or travel to a state in which an Elevance Health subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer-sponsored health plan issued by a non-Elevance Health controlled BCBSA licensee (the &#8220;home plan&#8221;). We perform certain functions, including claims pricing and administration, for BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members, for which we receive administrative fees from the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members&#8217; home plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan. Host members are computed using, among other things, the average number of BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> claims received per month. BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> host membership accounted for 13.6%, 13.6% and 14.1% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Advantage, including Special Needs Plans (&#8220;SNPs&#8221;), also known as Medicare Advantage SNPs; dual-eligible programs through Medicare-Medicaid Plans (&#8220;MMPs&#8221;); Medicare Supplement plans; and Medicare Part D Prescription Drug Plans (&#8220;Medicare Part D&#8221;). Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or have severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care, covering all the healthcare services considered medically necessary for members and often providing professional care coordination services, with personal guidance and programs that help members maintain their health. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree Solutions business who are retired members of Commercial accounts or retired members of groups who are not affiliated with our Commercial accounts who have selected a Medicare Advantage product through us. Medicare Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts paid by Medicare. Medicare Part D offers a prescription drug plan to Medicare and MMP beneficiaries. MMP, which was established as a result of the passage of the ACA, is a demonstration program focused on serving members who are dually eligible for Medicaid and Medicare. Medicare Supplement and Medicare Advantage products are marketed in the same manner, primarily through independent agents and brokers. Medicare program business accounted for 6.2%, 6.2% and 5.5% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicaid membership represents eligible members who receive health benefits through publicly funded healthcare programs, including Medicaid, ACA-related Medicaid expansion programs, Temporary Assistance for Needy Families, programs for seniors and people with disabilities, Children&#8217;s Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities or developmental disabilities, among others. Total Medicaid program business accounted for 24.3%, 23.4% and 20.6% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FEHB members consist of United States government employees and their dependents who receive health benefits within our geographic markets through our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management. FEHB business accounted for 3.4%, 3.6% and 3.8% of our medical members at December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our medical membership by reportable segment and customer type as of December&#160;31, 2022, 2021 and 2020. Also included below is other membership by product. The medical membership and other membership presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Medical Membership</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Risk-Based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Risk-Based</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Fee-Based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Fee-Based</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,610&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Commercial &amp; Specialty Business</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Employees Health Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Government Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medical Membership</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Other Membership</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life and Disability Members</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dental Members</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dental Administration Members</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vision Members</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare Part D Standalone Members</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022 Compared to December&#160;31, 2021</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Membership </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total medical membership increased in both our Government Business and Commercial &amp; Specialty Business segments primarily due to organic growth. Our Government Business segment&#8217;s organic growth was primarily driven by the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic. In addition, Medicaid membership was positively impacted by the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 and the acquisition of Integra in the second quarter of 2022. Medicare Advantage organic growth due to sales exceeding lapses also contributed to the overall Government Business segment growth. Our Commercial &amp; Specialty Business segment growth included Group fee-based membership increases due to sales exceeding lapses and positive in-group changes. BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">membership increased due to membership activity at other BCBSA plans whose members reside in or travel to our licensed areas. Individual membership increased due to our Public Exchange expansion in 2022. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Membership</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. Life and disability membership increased primarily due to new sales of disability products, partially offset by declines in our life membership. Dental membership increased primarily due to new sales in our Group risk-based accounts and penetration increases in our FEHB program, partially offset by the loss of a significant Group fee-based account. Dental administration membership increased primarily due to increased sales to other BCBS plans associated with the FEHB program. Vision membership increased primarily due to the launch of a new entry-level vision product in our Group markets. Medicare Part D Standalone membership declined as we discontinued certain legacy products.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated summarized results of operations and other information for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:8.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(273.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income before income tax expense </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,925&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,019&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to noncontrolling interests </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shareholders&#8217; net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average diluted shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted shareholders' net income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit expense ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(280)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense as a percentage of total revenues</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholders&#8217; net income as a percentage of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the following definitions are also applicable to all other results of operations tables in this discussion:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NM   Not meaningful.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Includes interest expense, amortization of other intangible assets and loss on extinguishment of debt.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the years ended December&#160;31, 2022, 2021 and 2020 were $133,229, $117,373 and $104,109, respectively. Premiums are included in total operating revenue presented above.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">bp = basis point; one hundred basis points = 1%.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating revenue increased primarily as a result of higher premium revenue in our Medicaid business due to organic membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth in our Medicare Advantage and our Commercial &amp; Specialty Business risk-based businesses, as well as premium rate increases to cover medical cost trends also generated higher premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue in our CarelonRx segment, resulting from growth in membership and higher script volume. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by reduced investment income from alternative investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had net losses on financial instruments in 2022, as compared to net gains in 2021, as a result of increased net losses on the sale of fixed maturity securities, reduced gains on the sale of equity securities and lower net gains on other invested assets. These losses were partially offset by lower mark-to-market losses on equity securities still held.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit expense increased primarily due to healthcare costs associated with organic membership growth in our Medicaid and Medicare businesses and the acquisition of MMM in the second quarter of 2021. Membership growth and higher healthcare costs in our Commercial risk-based business, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 also contributed to higher benefit expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit expense ratio decreased slightly primarily due to the realignment during 2022 of certain quality improvement costs, from benefit expenses to administrative expenses, due to regulatory clarification. This decline was partially offset by the impact of continued membership increases in our Government Business segment, which has a higher benefit expense ratio than our Commercial &amp; Specialty Business segment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated PBM customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased primarily due to increased costs to support membership growth and from our acquisitions, partially offset by lower business optimization charges in 2022 as compared to 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expense ratio decreased primarily due to operating revenue growth in 2022 and lower business optimization charges in 2022 as compared to 2021, partially offset by increased costs to support membership growth and the impact of the realignment of certain quality improvement costs described above.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense increased primarily due to additional amortization of intangible assets related to recent acquisitions and the rebranding of our products. The amortization period of certain intangible assets was shortened to align with anticipated dates the new branding will take place. In addition, certain indefinite-lived intangible assets have been reclassified as definite-lived, and therefore, are now being amortized. For additional information regarding intangible asset amortization, see Note 10, "Goodwill and Other Intangible Assets" of the Notes to Consolidated Financial Statements included in Part II, Item 8, of this Annual Report on Form 10-K.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our effective income tax rate decreased primarily due to the impact of geographic changes in our mix of earnings in 2022.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shareholders' net income as a percentage of total revenues decreased in 2022 as compared to 2021 as a result of all the factors discussed above.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of our reportable segment financial information for the years ended December&#160;31, 2022, 2021 and 2020: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CarelonRx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Gain (Loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CarelonRx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</span></div></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</span></div></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CarelonRx</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40bp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM&#160;&#160;&#160;&#160;Not meaningful.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Includes expenses of $20 for business optimization initiatives in 2022; $106 for business optimization initiatives in 2021; $311 for business optimization initiatives and $524 for the BCBSA Litigation in 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;&#160;&#160;&#160;Includes expenses of $16 for business optimization initiatives in 2022; $47 for business optimization initiatives in 2021; $205 for business optimization initiatives and $24 for the BCBSA Litigation in 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3&#160;&#160;&#160;&#160;Includes expenses of $2 for business optimization initiatives in 2021; $4 for business optimization initiatives in 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4&#160;&#160;&#160;&#160;Includes expenses of $3 for business optimization initiatives in 2022; $32 for business optimization initiatives in 2021; $133 for business optimization initiatives in 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5&#160;&#160;&#160;&#160;bp = basis point; one hundred basis points = 1%.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial &amp; Specialty Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating revenue increased primarily due to higher premiums in our Commercial risk-based business due to membership growth, premium rate increases in our Commercial risk-based business to cover medical cost trends and increased administrative fees in our Commercial fee-based business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in operating gain was primarily due to improved medical underwriting performance in our Commercial risk-based business and reduced business optimization charges in 2022 as compared to 2021. These items were partially offset by increased costs to support membership growth.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating revenue increased primarily due to higher premium revenue in our Medicaid business, including due to organic membership growth from the continued temporary suspension of Medicaid eligibility recertification during the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic, the acquisition of MMM at the end of the second quarter of 2021, the acquisition of Integra during the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth and premium rate increases to cover medical cost trends in our Medicare Advantage business also contributed to higher premium revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in operating gain was primarily driven by premium rate increases to cover medical cost trends in our Medicare business, organic membership growth in our Medicaid business from the continued suspension of eligibility recertifications during the COVID-19 pandemic and the acquisition of MMM in the second quarter of 2021. These increases were partially offset by additional administrative spend to support the growth in our Government business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CarelonRx</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating revenue increased as a result of growth in membership and higher script volume. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in operating gain was primarily a result of higher script volume, driven by growth in integrated medical and pharmacy members in 2022 and favorable out-of-period adjustments to fee-based revenue in the second half of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating revenue increased primarily due to higher revenue for expanded services performed by Carelon Services for our Commercial &amp; Specialty Business segment in 2022 and the acquisition of myNEXUS in the second quarter of 2021. These increases were partially offset by the reduction of external revenue due to the loss of a behavioral health contract in 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in operating gain was driven by improved performance in Carelon Services, the acquisition of myNEXUS in the second quarter of 2021, and a decline in unallocated corporate expenses in 2022.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&amp;A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits, which are discussed below. Our other significant accounting policies are summarized in Note 2, &#8220;Basis of Presentation and Significant Accounting Policies,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In general, our estimates are based on historical experience, evaluation of current trends, information from third-party professionals and various other assumptions that we believe to be reasonable under the known facts and circumstances. Estimates can require a significant amount of judgment, and a different set of assumptions could result in material changes to our reported results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims Payable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. At December&#160;31, 2022, this liability was $15,596 and represented 23% of our total consolidated liabilities. We record this liability and the corresponding benefit expense for incurred but not paid claims, including the estimated costs of processing such claims. Incurred but not paid claims include (1)&#160;an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems, which approximated 94%, or $14,736, of our total medical claims liability as of December&#160;31, 2022; and (2)&#160;claims reported to us and processed through our systems but not yet paid, which approximated 6%, or $860, of the total medical claims payable as of December&#160;31, 2022. The level of claims payable processed through our systems but not yet paid may fluctuate from one period-end to the next, from approximately 1% to 6% of our total medical claims liability, due to timing of when claim payments are made.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into &#8220;claim triangles,&#8221; which compare claim incurred dates to the dates of claim payments. This information is analyzed to create &#8220;completion factors&#8221; that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels (&#8220;trend factors&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes. These adjustments are made by our actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed. Circumstances to be considered in developing our best estimate of reserves include changes in utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. A comparison of prior period liabilities to re-estimated claim liabilities based on subsequent claims development is also considered in making the liability determination. In our comparison to prior periods, the methods and assumptions are not changed as reserves are recalculated; rather, the availability of additional paid claims information drives changes in the re-estimate of the unpaid claim liability. To the extent appropriate, changes in such development are recorded as a change to current period benefit expense. We had increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that lead to the increased estimation uncertainty.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods. Adjustments of prior year estimates may result in additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the considerable variability of healthcare costs, adjustments to claim liabilities occur each period and are sometimes significant as compared to the net income recorded in that period. Prior period development is recognized immediately upon the actuary&#8217;s judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is reasonable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are many factors that are used as a part of the estimation of our medical claims payable liability, the two key assumptions having the most significant impact on our incurred but not paid claims liability as of December&#160;31, 2022 were the completion and trend factors. As discussed above, these two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is variation in the reasonable choice of completion factors by duration for durations of three months through twelve months where the completion factors have the most significant impact. As previously discussed, completion factors tend to be less reliable for the most recent months and therefore are not specifically utilized for months one and two. In our analysis for the claim liabilities at December&#160;31, 2022, the variability in months three to five was estimated to be between 40 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 90 basis points, while months six through twelve have much lower estimated variability ranging from 0 to 30 basis points.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference in completion factor assumptions results in variability of 2%, or approximately $266, in the December&#160;31, 2022 incurred but not paid claims liability, depending on the completion factors chosen. It is important to note that the completion factor methodology inherently assumes that historical completion rates will be reflective of the current period. However, it is possible that the actual completion rates for the current period will develop differently from historical patterns and therefore could fall outside the possible variations described herein.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other major assumption used in the establishment of the December&#160;31, 2022 incurred but not paid claim liability was the trend factors. In our analysis for the period ended December&#160;31, 2022, there was a 310 basis point differential in the high and low trend factors. This range of trend factors would imply variability of 3%, or approximately $522, in the incurred but not paid claims liability, depending upon the trend factors used. Because historical trend factors are often not representative of current claim trends, the trend experience for the most recent six to nine months, plus knowledge of recent events likely affecting current trends, have been taken into consideration in establishing the incurred but not paid claims liability at December&#160;31, 2022.&#160;The COVID-19 pandemic continues to have an impact on claim costs for recent dates of service, which could have an influence on our trend factors. We will continue to monitor emerging experience in order to better understand the possible implications to our reserves.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12, &#8220;Medical Claims Payable,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, for a reconciliation of the beginning and ending balance for medical claims payable for the years ended December&#160;31, 2022, 2021 and 2020. Components of the total incurred claims for each year include amounts accrued for current year estimated claims expense as well as adjustments to prior year estimated accruals. In Note 12, &#8220;Medical Claims Payable,&#8221; the line labeled &#8220;Net incurred medical claims: Prior years redundancies&#8221; accounts for those adjustments made to prior year estimates. The impact of any reduction of &#8220;Net incurred medical claims: Prior years redundancies&#8221; may be offset as we establish the estimate of &#8220;Net incurred medical claims: Current year.&#8221; Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for our claims. When we recognize a release of the redundancy, we disclose the amount that is not in the ordinary course of business, if material.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 87.3% for 2022, 87.8% for 2021 and 87.7% for 2020. This ratio serves as an indicator of claims processing speed whereby 2022 claims were processed at a slightly slower speed than 2021 and 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred claims payable less prior year redundancies in the current year in order to demonstrate the development of the prior year reserves. For the year ended December&#160;31, 2022, this metric was 7.0%, largely driven by favorable trend factor development at the end of 2021. For the year ended December&#160;31, 2021, this metric was 18.1%, reflecting the estimation uncertainty due to COVID-19 at the end of 2020, and was largely driven by favorable trend factor development at the end of 2020 as well as favorable completion factor development from 2020. For the year ended December&#160;31, 2020, this metric was 8.0%, largely driven by favorable trend factor development at the end of 2019 as well as favorable completion factor development from 2019. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the year ended December&#160;31, 2022, this metric was 0.9%, which was calculated using the redundancy of $869. This metric was 2.0% for 2021 and 0.8% for 2020. We believe these metrics support the reasonableness of our estimates. The 2021 metric was impacted by the estimation uncertainty due to COVID-19.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the variance between total net incurred medical claims as reported in Note 12, &#8220;Medical Claims Payable,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K, for each of 2021 and 2020 and the incurred claims for such years had it been determined retrospectively (computed as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the difference between &#8220;net incurred medical claims &#8211; current year&#8221; for the year shown and &#8220;net incurred medical claims &#8211; prior years redundancies&#8221; for the immediately following year):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims, as reported</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective basis, as described above</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(834)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variance to total net incurred medical claims, as reported</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that our business is primarily short tailed (which means that medical claims are generally paid within twelve months of the member receiving service from the provider), the variance to total net incurred medical claims, as reported above, is used to assess the reasonableness of our estimate of ultimate incurred medical claims for a given calendar year with the benefit of one year of experience. We expect that substantially all of the development of the 2022 estimate of medical claims payable will be known during 2023.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2021 variance to total net incurred medical claims, as reported of (0.8)% was less than the 2020 percentage of 1.3%.&#160;This was primarily driven by the fact that the change in the prior year redundancy reported for 2021 as compared to 2020 was less than the change in the prior year redundancy reported for 2020 as compared to 2019.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance, which requires, among other things, the separate recognition of deferred tax assets and deferred tax liabilities. Such deferred tax assets and deferred tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at tax rates enacted at the time the deferred tax asset or liability is recorded. A valuation allowance must be established for deferred tax assets if it is &#8220;more likely than not&#8221; that all or a portion may be unrealized. Our judgment is required in determining an appropriate valuation allowance.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each financial reporting date, we assess the adequacy of the valuation allowance by evaluating each of our deferred tax assets based on the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the types of temporary differences that created the deferred tax asset;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of taxes paid in prior periods and available for a carry-back claim;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the tax rate at which the deferred tax assets will likely be utilized in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the forecasted future taxable income, and therefore, likely future deduction of the deferred tax item; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of tax planning strategies to recover those deferred tax assets; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any significant other issues impacting the likely realization of the benefit of the temporary differences.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although realization is not assured, we believe it is more likely than not that the deferred tax assets will be realized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, like other companies, frequently face challenges from tax authorities regarding the amount of taxes due. These challenges include questions regarding the timing and amount of deductions that we have taken on our tax returns. In evaluating any additional tax liability associated with various positions taken in our tax return filings, we record additional liabilities for potential adverse tax outcomes. Based on our evaluation of our tax positions, we believe we have appropriately accrued for uncertain tax benefits, as required by the applicable guidance. To the extent we prevail in matters we have accrued for, our future effective tax rate would be reduced and net income would increase. If we are required to pay more than accrued, our future effective tax rate would increase and net income would decrease. Our effective tax rate and net income in any given future period could be materially impacted.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are regularly audited by federal and other tax authorities, and from time to time, these audits result in proposed assessments. We believe our tax positions comply with applicable tax law, and we intend to defend our positions vigorously through the federal, state and local, and foreign appeals processes. We believe we have </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequately provided for any reasonably foreseeable outcome related to these matters. Accordingly, although their ultimate resolution may require additional tax payments, we do not anticipate any material impact on our results of operations or financial condition from these matters.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 8, &#8220;Income Taxes,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated goodwill at December&#160;31, 2022 was $24,383 and other intangible assets were $10,315. The sum of goodwill and other intangible assets represented 33.8% of our total consolidated assets and 95.6% of our consolidated shareholders&#8217; equity at December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow FASB guidance for business combinations and goodwill and other intangible assets, which specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Under the guidance, goodwill and other intangible assets (with indefinite lives) are not amortized but are tested for impairment at least annually. Furthermore, goodwill and other intangible assets are allocated to reporting units for purposes of the annual impairment test. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, which include goodwill and other intangible assets. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. These tests involve the use of estimates related to the fair value of goodwill at the reporting unit level and other intangible assets with indefinite lives, and require a significant degree of management judgment and the use of subjective assumptions. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. We have the option of first performing a qualitative assessment for each reporting unit to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, which is an indication that our goodwill may be impaired. These qualitative impairment tests include assessing events and factors that could affect the fair value of the indefinite-lived intangible assets. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. If we determine that a reporting unit&#8217;s goodwill may be impaired after utilizing these qualitative impairment analysis procedures, we are required to perform a quantitative impairment test.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quantitative impairment test utilizes the projected income and market valuation approaches for goodwill and the projected income approach for our indefinite lived intangible assets. Use of the projected income and market valuation approaches for our goodwill impairment test reflects our view that both valuation methodologies provide a reasonable estimate of fair value. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. These estimated future cash flows are then discounted. Our assumed discount rate is based on our industry&#8217;s weighted-average cost of capital. Market valuations are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization; and book value of invested capital (debt and equity) and include market comparisons to publicly traded companies in our industry.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not incur any impairment losses as a result of our 2022 annual impairment tests, as it was determined that it is more likely than not that the estimated fair values of our reporting units were substantially in excess of the carrying values as of December&#160;31, 2022. Additionally, we do not believe that the estimated fair values of our reporting units are at risk of becoming impaired in the next twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If estimated fair values are less than the carrying values of goodwill and other intangibles with indefinite lives in future annual impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 3, &#8220;Business Acquisitions&#8221; and Note 10, &#8220;Goodwill and Other Intangible Assets,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and long-term marketable investment securities were $27,657 at December&#160;31, 2022 and represented 26.9% of our total consolidated assets at December&#160;31, 2022. We classify fixed maturity securities in our investment portfolio as &#8220;available-for-sale&#8221; and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our impairment review is subjective and requires a high degree of judgment. We conduct this review on a quarterly basis, using both qualitative and quantitative factors. Such factors considered include the extent to which a security&#8217;s market value has been less than its cost, the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors), financial condition and near term prospects of the issuer, including the credit ratings and changes in the credit ratings of the issuer, recommendations of investment advisors, and forecasts of economic, market or industry trends. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security&#8217;s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive (loss) income. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive (loss) income. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a committee of accounting and investment associates and management that is responsible for managing the impairment review process. We believe that we have adequately reviewed our investment securities for impairment and that our investment securities are carried at fair value. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is continuing risk that declines in fair value may occur and additional impairment losses on investments may be recorded in future periods. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to marketable investment securities, we held additional long-term investments of $5,685, or 5.5% of total consolidated assets, at December&#160;31, 2022. These long-term investments consisted primarily of certain other equity investments, the cash surrender value of corporate-owned life insurance policies and mortgage loans. Due to their less liquid nature, these investments are classified as long-term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our investing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity market valuations. We manage market risks through our investment policy, which establishes credit quality limits and limits on investments in individual issuers. Ineffective management of these risks could have an impact on our future results of operations and financial condition. Our investment portfolio includes fixed maturity securities with a fair value of $26,704 at December&#160;31, 2022. The weighted-average credit rating of these securities was &#8220;A&#8221; as of December&#160;31, 2022. Included in this balance are investments in fixed maturity securities of states, municipalities and political subdivisions of $890 that are guaranteed by third parties. With the exception of 16 securities with a fair value of $9, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these securities are all investment-grade and carry a weighted-average credit rating of &#8220;AA&#8221; as of December&#160;31, 2022. The securities are guaranteed by a number of different guarantors, and we do not have any material exposure to any single guarantor, neither indirectly through the guarantees, nor directly through investment in the guarantor. Further, due to the high underlying credit rating of the issuers, the weighted-average credit rating of the fixed maturity securities without a guarantee, for which such information is available, was &#8220;A&#8221; as of December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values of fixed maturity and equity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value in accordance with FASB guidance for fair value measurements and disclosures. We have controls in place to review the pricing services&#8217; qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services&#8217; pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain quoted market prices for each security from the pricing services, which are derived through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available market observable information. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in these valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and therefore, such inputs are estimated internally. Such securities are designated Level III in accordance with FASB guidance. Securities designated Level III at December&#160;31, 2022 totaled $581 and represented approximately 1.7% of our total assets measured at fair value on a recurring basis. Our Level III securities primarily consisted of certain corporate securities and equity securities for which observable inputs were not always available and the fair values of these securities were estimated using inputs including, but not limited to, prepayment speeds, credit spreads, default rates and benchmark yields.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Part II, Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures about Market Risk,&#8221; and Note 2, &#8220;Basis of Presentation and Significant Accounting Policies,&#8221; Note 5, &#8220;Investments,&#8221; and Note 7, &#8220;Fair Value,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Benefits</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pension Benefits</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor defined benefit pension plans for some of our employees. These plans are accounted for in accordance with FASB guidance for retirement benefits, which requires that amounts recognized in financial statements be determined on an actuarial basis. As permitted by the guidance, we calculate the value of plan assets as described below. Further, the difference between our expected rate of return and the actual performance of plan assets, as well as certain changes in pension liabilities, are amortized over future periods.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important factor in determining our pension expense is the assumption for expected long-term return on plan assets. As of our December&#160;31, 2022 measurement date, we selected a weighted-average long-term rate of return on plan assets of 6.58%. We use a total portfolio return analysis in the development of our assumption. Factors such as past market performance, the long-term relationship between fixed maturity and equity securities, interest rates, inflation and asset allocations are considered in the assumption. The assumption includes an estimate of the additional return expected from active management of the investment portfolio. Peer data and an average of historical returns are also reviewed for appropriateness of the selected assumption. We believe our assumption of future returns is reasonable. However, if we lower our expected long-term return on plan assets, future contributions to the pension plan and pension expense would likely increase.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assumed long-term rate of return on assets is applied to a calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years, producing the expected return on plan assets that is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in the determination of pension expense. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of pension expense. The net deferral of past asset gains or losses affects the calculated value of plan assets and, ultimately, future pension expense.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan&#8217;s cash flows to determine the plan&#8217;s obligation. At the December&#160;31, 2022 measurement date, the weighted-average discount rate under the annual spot rate approach was 5.18%, compared to 2.70% at the December&#160;31, 2021 measurement date. The net effect of changes in the discount rate, as well as the net effect of other changes in actuarial assumptions and experience, have been deferred and amortized as a component of pension expense in accordance with FASB guidance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing the plan assets, our objective is to be a responsible fiduciary while minimizing financial risk. Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across a range of sectors and levels of capitalization to maximize long-term return for a prudent level of risk.&#160;In addition to producing a reasonable return, the investment strategy seeks to minimize the volatility in our expense and cash flow.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Postretirement Benefits</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide some associates with certain medical, vision and dental benefits upon retirement. We use various actuarial assumptions, including a discount rate and the expected trend in healthcare costs, to estimate the costs and benefit obligations for our retiree benefits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our December&#160;31, 2022 measurement date, the selected discount rate for all plans was 5.12%, compared to a discount rate of 2.49% at the December&#160;31, 2021 measurement rate. We developed this rate using the annual spot rate approach as described above. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was 8.00% for 2023 with a gradual decline to 4.50% by the year 2035. The assumed healthcare cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was 6.50% for 2023 with a gradual decline to 4.50% by the year 2035. These estimated trend rates are subject to change in the future.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our retirement benefits, see Note 11, &#8220;Retirement Benefits,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding new accounting pronouncements that were issued or became effective during the year ended December&#160;31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations or financial statement disclosures, see the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Guidance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Guidance Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; sections of Note 2, &#8220;Basis of Presentation and Significant Accounting Policies,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_55"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash receipts result primarily from premiums, product revenue, administrative fees and other revenue, investment income, proceeds from the sale or maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our cash, investments and capital structure so we are able to meet the short-term and long-term obligations of our business while maintaining financial flexibility and liquidity. We forecast, analyze and monitor our cash flows to enable investment and financing within the overall constraints of our financial strategy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the assets held by our regulated subsidiaries are in the form of cash and cash equivalents and investments. After considering expected cash flows from operating activities, we generally invest cash that exceeds our near term obligations in longer term marketable fixed maturity securities to improve our overall investment income returns. Our investment strategy is to make investments consistent with insurance statutes and other regulatory requirements, while preserving our asset base. Our investments are generally available-for-sale to meet liquidity and other needs. Our subsidiaries pay out excess capital annually in the form of dividends to their respective parent companies for general corporate use, as permitted by applicable regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, debt ratings, contractual restrictions, regulatory requirements and market conditions. The securities and credit markets have in the past experienced higher than normal volatility. Interest rates on fixed debt income securities increased in 2022 and may continue to do so in 2023, which could increase our borrowing costs if we elect to issue debt. During recent years, the federal government and various governmental agencies have taken a number of steps to strengthen the regulation of the financial services market. In addition, governments around the world have developed their own plans to provide stability and security in the credit markets and to ensure adequate capital in certain financial institutions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our major sources and uses of cash and cash equivalents for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sources of Cash:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of commercial paper and short- and long-term debt, net of repayments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other sources of cash, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sources of cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,081)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Uses of Cash:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments, net of proceeds from sales, maturities, calls and redemptions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of commercial paper and short- and long-term debt, net of issuances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other uses of cash, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total uses of cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,684)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,382)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(861)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity&#8212;Year Ended December&#160;31, 2022 Compared to Year Ended December&#160;31, 2021</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The slight increase in cash provided by operating activities was primarily due to higher net income in 2022, when adjusted for the impact of investment losses and gains, partially offset by the timing of working capital changes and the payment pursuant to the Subscriber Settlement Agreement made in September 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other significant changes in sources and uses of cash year-over-year included lower amounts used for purchases of subsidiaries, net of cash acquired and reduced cash used for purchases of investments, net of proceeds from sales, maturities, calls and redemptions. These decreased uses of cash were partially offset by reduced net proceeds received from the issuance of commercial paper and short-term and long-term debt and increased use of cash for share repurchases.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Condition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $35,044 at December&#160;31, 2022. Since December&#160;31, 2021, total cash, cash equivalents and investments in fixed maturity and equity securities increased by $1,384, primarily due to cash generated from operations. This increase was partially offset by cash used for acquisitions, common stock repurchases, purchases of property and equipment and cash dividends paid to shareholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, or other regulatory requirements, could impact our subsidiaries&#8217; future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we held $1,209 of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we access capital markets and issue debt (&#8220;Notes&#8221;) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more information on our debt, including redemptions and issuances, see Note 13, &#8220;Debt&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our audited consolidated balance sheets included in Part II, Item 8 of this Annual Report on Form 10-K. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders&#8217; equity. Total debt is the sum of short-term borrowings, current portion of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 39.9% and 38.9% as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior debt is rated &#8220;A&#8221; by S&amp;P Global Ratings, &#8220;BBB&#8221; by Fitch Ratings, Inc., &#8220;Baa2&#8221; by Moody&#8217;s Investor Service, Inc. and &#8220;bbb+&#8221; by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a shelf registration statement on file with the Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries and the financing of possible acquisitions or business expansions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a senior revolving credit facility (the &#8220;5-Year Facility&#8221;) with a group of lenders for general corporate purposes. In April 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also in April 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December&#160;31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the &#8220;Subsidiary Credit Facilities&#8221;) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit up to $200. Our ability to borrow under the Subsidiary Credit Facilities is subject to compliance with certain covenants. At December&#160;31, 2022, we had no outstanding borrowings under the Subsidiary Credit Facilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash on hand and/or our 5-Year Facility, which provides for credit in the amount of $4,000, to redeem any outstanding commercial paper upon maturity. At December&#160;31, 2022, we had $0 outstanding under our commercial paper program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year Facility and Subsidiary Credit Facilities, if market conditions allow, would be willing to provide financing in accordance with their legal obligations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the &#8220;FHLBs&#8221;). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At December&#160;31, 2022, we had $265 of outstanding short-term borrowings from the FHLBs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above, many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid. Based upon these requirements, we currently estimate that approximately $3,500 of dividends will be paid to us by our subsidiaries during 2023. During 2022, we received $3,097 of dividends from our subsidiaries.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries&#8217; states of domicile have statutory risk-based capital (&#8220;RBC&#8221;) requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners (&#8220;NAIC&#8221;) Risk-Based Capital (RBC) For Health Organizations Model Act (&#8220;RBC Model Act&#8221;). These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer&#8217;s investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company&#8217;s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries&#8217; respective RBC levels as of December&#160;31, 2022, which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries. For additional information, see Note 22, &#8220;Statutory Information,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources and Uses of Liquidity</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Short-Term Liquidity Requirements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously described, our cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. We believe cash on hand, operating cash receipts, investments and amounts available under our commercial paper program, our 5-Year Facility and our Subsidiary Credit Facilities and borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Long-Term Liquidity Requirements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our long-term cash disbursements required under various contractual obligations and commitments were:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Debt and interest expense:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future debt and estimated interest payments were $25,804, with $2,674 due within the next twelve months. For additional information, see Note 13 &#8220;Debt&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Operating leases:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer equipment, for which the future estimated payments were $1,028, with $206 due within the next twelve months. For additional information, see Note 18 &#8220;Leases&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.85pt">Other liabilities:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These liabilities primarily consist of future policy reserves, projected other postretirement benefits, deferred compensation, supplemental executive retirement plan liabilities and certain other miscellaneous long-term obligations. Amounts due within twelve months were $26, with $1,040 due in future periods. Estimated future payments for funded pension benefits have been excluded from these numbers, as we had no funding requirements under the Employee Retirement Income Security Act of 1974, as amended, at December&#160;31, 2022, as a result of the value of the assets in the plans. In addition, gross liabilities for uncertain tax positions and interest for which we cannot reasonably estimate the timing of the resolutions with the respective taxing authorities have not been included. For further information, see Note 8, &#8220;Income Taxes,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.85pt">Purchase obligations:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These obligations include estimated payments for future services under contractual arrangements from third-party service vendors. Amounts due within the next twelve months for these purchase obligations were $1,124, while longer term payments were $2,927. For further information, see Note 14, &#8220;Commitments and Contingencies,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Investment commitments:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These include unfunded capital commitments for alternative investments and low-income housing tax credits. Estimated amounts due were $1,504, including $314 due within the next twelve months. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the contractual obligations and commitments discussed above, we have a variety of other contractual agreements related to acquiring materials and services used in our operations. However, we do not believe these other agreements contain material noncancelable commitments.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;24, 2023, our Audit Committee declared a quarterly cash dividend to shareholders of $1.48 per share on the outstanding shares of our common stock. This quarterly dividend is payable on March&#160;24, 2023 to the shareholders of record as of March&#160;10, 2023.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our Board of Directors&#8217; authorization, we maintain a common stock repurchase program. As of December&#160;31, 2022, we had Board authorization of $1,876 to repurchase our common stock. On January 24, 2023, our Audit Committee, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time. We intend to utilize this authorization over a multi-year period, subject to market and industry conditions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that funds from future operating cash flows, cash and investments and funds available under our credit facilities and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet derivative instruments, guarantee transactions, agreements or other contractual arrangements or any indemnification agreements that will require funding in future periods. We have not transferred assets to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not hold any variable interest in an unconsolidated entity where such entity provides us with financing, liquidity, market risk or credit risk support. See Note 2 &#8220;Subsidiary Transactions&#8221; of the Notes to Condensed Financial Statements included in Part IV, Item&#160;15 of this Annual Report on Form 10-K for additional detail on the Elevance Health, Inc. parent guarantees of certain subsidiaries.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_58"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In Millions, Except As Otherwise Stated Herein)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our investing and borrowing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in market valuations. Potential impacts discussed below are based upon sensitivity analyses performed on our financial position as of December&#160;31, 2022. Actual results could vary from these estimates. Our primary objectives with our investment portfolio are to provide safety and preservation of capital, sufficient liquidity to meet cash flow requirements, the integration of investment strategy with the business operations and an attainment of a competitive after-tax total return.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio is exposed to three primary sources of risk: credit quality risk, interest rate risk and market valuation risk.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary risks associated with our fixed maturity securities, which are classified as available-for-sale, are credit quality risk and interest rate risk. Credit quality risk is defined as the risk of a credit event, such as a ratings downgrade or default, to an individual fixed maturity security and the potential loss attributable to that event. Credit quality risk is managed through our investment policy, which establishes credit quality limitations on the overall portfolio as well as diversification and percentage limits on securities of individual issuers. The result is a well-diversified portfolio of fixed maturity securities, with an average credit rating of approximately &#8220;A.&#8221; Interest rate risk is defined as the potential for economic losses on fixed maturity securities due to a change in market interest rates. Our fixed maturity portfolio is invested primarily in U.S. government securities, corporate bonds, asset-backed bonds, mortgage-related securities and municipal bonds, all of which have exposure to changes in the level of market interest rates. Interest rate risk is managed by maintaining asset duration within a band based upon our liabilities, operating performance and liquidity needs. Additionally, we have the capability of holding any security to maturity, which would allow us to realize full par value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in fixed maturity securities include corporate securities, which account for 46.9% of our total fixed maturity securities at December&#160;31, 2022 and are subject to credit/default risk. In a declining economic environment, corporate yields will usually increase, prompted by concern over the ability of corporations to make interest payments, thus causing a decrease in the price of corporate securities, and the decline in value of the corporate fixed maturity portfolio. We manage this risk through fundamental credit analysis, diversification of issuers and industries and an average credit rating of our corporate fixed maturity portfolio of approximately &#8220;BBB.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk for fixed maturity securities is addressed by actively managing the duration, allocation and diversification of our investment portfolio. We have evaluated the impact on the fixed maturity portfolio&#8217;s fair value considering an immediate 100 basis point change in interest rates. A 100 basis point increase in interest rates would result in an approximate $1,088 decrease in fair value, whereas a 100 basis point decrease in interest rates would result in an approximate $1,154 increase in fair value. While we classify our fixed maturity securities as &#8220;available-for-sale&#8221; for accounting purposes, we believe our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows and the duration of our portfolio should allow us to hold securities to maturity, thereby avoiding the recognition of losses should interest rates rise significantly.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity portfolio is comprised of large capitalization and small capitalization domestic equities, foreign equities, exchange-traded funds and index mutual funds. Our equity portfolio is subject to the volatility inherent in the stock market, driven by concerns over economic conditions, earnings and sales growth, inflation, and consumer confidence. These systemic risks cannot be managed through diversification alone. However, more routine risks, such as stock/industry specific risks, are managed by investing in a diversified equity portfolio.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other invested assets, reported within our long-term investments, are primarily subject to private market exposures, including private equity and private credit investments. These investments are also indirectly subject to market valuation risk, as public market valuations will form a basis for valuations for these investments. Given their illiquid nature, we focus on appropriate sizing of these investments relative to our liquidity needs and risk tolerance. Our risk tolerance is formed by the level of illiquidity and short-term price movements from market valuation risk we are willing to accept relative to the higher long-term expected returns over the life of these investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 3.4% of our marketable investments were equity securities. An immediate 10% decrease in each equity investment&#8217;s value, arising from market movement, would result in a fair value decrease of $95. Alternatively, an immediate 10% increase in each equity investment&#8217;s value, attributable to the same factor, would result in a fair value increase of $95.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our investments, see Note 5, &#8220;Investments,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item 8 and &#8220;Critical Accounting Policies and Estimates - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; within Part II, Item&#160;7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total long-term debt at December&#160;31, 2022 consisted of senior unsecured notes, convertible debentures, commercial paper and subordinated surplus notes issued by one of our insurance subsidiaries. At December&#160;31, 2022, the carrying value and estimated fair value of our long-term debt was $23,849 and $22,324 respectively. This debt is subject to interest rate risk, as these instruments have fixed interest rates and the fair value is affected by changes in market interest rates. Should interest rates increase or decrease in the future, the estimated fair value of our fixed rate debt would decrease or increase accordingly. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our long-term debt, see Note 7, &#8220;Fair Value&#8221; and Note 13, &#8220;Debt,&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates.&#160;We attempt to mitigate our exposure to interest rate risk through the use of derivative financial instruments.&#160;These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge (on an economic basis) interest rate risks associated with variable rate debt.&#160;We have used these types of instruments as designated hedges against specific liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates will affect the estimated fair value of these derivatives.&#160;As of December&#160;31, 2022, we recorded a net liability of $57, the estimated fair value of the swaps at that date.&#160;We have evaluated the impact on the interest rate swaps&#8217; fair value considering an immediate 100 basis point change in interest rates.&#160;A 100&#160;basis point increase in interest rates would result in an approximate $39 decrease in fair value, whereas a 100 basis point decrease in interest rates would result in an approximate $39 increase in fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our derivatives, see Note 6, &#8220;Derivative Financial Instruments&#8221; of the Notes to Consolidated Financial Statements included in Part II, Item&#160;8 of this Annual Report on Form 10-K. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID:<ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M182MS9mcmFnOjU4ZmE1NjBhMmQwZTRiMTE5NjcxYmU4NDk0YmQ4NzVlL3RhYmxlOjYzYmJhODcxNTdhNzQzNDc5NjVkZWQwNjljMmE1YjYzL3RhYmxlcmFuZ2U6NjNiYmE4NzE1N2E3NDM0Nzk2NWRlZDA2OWMyYTViNjNfMC0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOmRlMGRlYjFkZTcwMjRlYTI5Y2ZlYWRlMGVhYjU2ZTQ5Xzcw_6c07d203-1ff8-4aee-a032-d4358ef1db9a">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_64">67</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audited Consolidated Financial Statements:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_70">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_76">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_79">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_82">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Shareholders&#8217; Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_85">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i09daec87c4c344c8b0454b84b1a4fe73_88">74</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Report of Independent Registered</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Elevance Health, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Elevance Health, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of income, comprehensive income, shareholders&#8217; equity, and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes and financial statement schedule listed in the Index at Item&#160;15(c) (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;15, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:42.907%"><div style="text-align:center"><span><br/></span></div></div><div style="display:inline-block;max-width:14.184%;min-width:13.184%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:42.909%"></div></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.290%"><tr><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Incurred but Not Paid Claims</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims payable was $15,596 million at December 31, 2022, a significant portion of which related to the Company&#8217;s estimate for claims that are incurred but not paid. As discussed in Note 2 to the consolidated financial statements, the Company&#8217;s liability for incurred but not paid claims is determined using actuarial methods that include a number of factors and assumptions, including completion factors, which represent the average percentage of total incurred claims that have been paid through a given date after being incurred based on historical paid claims data, and trend factors, which represent an estimate of claims expense based on recent claims expense levels and healthcare cost levels. There is significant uncertainty inherent in determining management&#8217;s best estimate of completion and trend factors, which are used to calculate actuarial estimates of incurred but not paid claims.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s estimate of incurred but not paid claims was complex and required the involvement of our actuarial specialists due to the highly judgmental nature of the completion and trend factor assumptions used in the valuation process. The significant judgment was primarily due to the sensitivity of management&#8217;s best estimate of completion and trend factor assumptions, which have a significant impact on the valuation of incurred but not paid claims.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s actuarial process for estimating the liability for incurred but not paid claims. These audit procedures included among others, testing management review controls over completion and trend factor assumptions and the review and approval processes that management has in place for estimating the liability for incurred but not paid claims.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company&#8217;s liability for incurred but not paid claims, our audit procedures included, among others, testing the completeness and accuracy of the underlying claims and membership data recorded in the source claims processing and disbursement systems to the data used by management in developing completion and trend factor assumptions and agreeing a sample of incurred and paid claims to source documentation. With the support of actuarial specialists, we analyzed the Company&#8217;s completion and trend factor assumptions based on historical claim experience and emerging cost trends, and independently calculated a range of reasonable reserve estimates for comparison to management&#8217;s best estimate of the liability for incurred but not paid claims. Additionally, we performed a review of the prior period liabilities for incurred but not paid claims to subsequent claims development.</span></td></tr></table></div><div style="text-indent:317.25pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M182NC9mcmFnOmE1OWNhNzVkZWYzODRkZTg4MGJmZWM3MjcxMDhkNmE4L3RleHRyZWdpb246YTU5Y2E3NWRlZjM4NGRlODgwYmZlYzcyNzEwOGQ2YThfMzU3NA_053d46ac-8fa9-440b-b309-5d524fb7ee72">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="text-indent:317.25pt"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:42.907%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1944.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M182NC9mcmFnOmE1OWNhNzVkZWYzODRkZTg4MGJmZWM3MjcxMDhkNmE4L3RleHRyZWdpb246YTU5Y2E3NWRlZjM4NGRlODgwYmZlYzcyNzEwOGQ2YThfMzU3Ng_5c6bf16a-5547-4b9d-9873-f6504339d2b3">Indianapolis, Indiana</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;15, 2023</span></div><div style="text-align:center"><span><br/></span></div></div><div style="display:inline-block;max-width:14.184%;min-width:13.184%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:42.909%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except share data)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNC0xLTEtMS03ODA0OQ_a13ae090-fb25-4ff6-abd0-6eb8b16be37a">7,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNC0zLTEtMS03ODA0OQ_75efa3d7-7355-4967-ac89-d8b52a488e1c">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed maturity securities (amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzQ5_7a293772-a36e-48bf-b0da-468950079ceb">28,226</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzU2_14e3e8b9-83b7-4725-aed4-9376e2887f73">25,641</ix:nonFraction>; allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzkx_4ed634e8-70cb-4eb0-a332-efb733d1b65c">9</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzk4_79e79961-8585-4078-b062-a0567a80275d">6</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0xLTEtMS03ODA0OQ_5a75812d-7031-4b6c-bf81-b3a73abe6a49">25,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0zLTEtMS03ODA0OQ_e9e0301e-30de-44d3-8b99-a2942fa0847f">26,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNi0xLTEtMS03ODA0OQ_69371ac1-6c8e-401f-9dcf-17809738f278">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNi0zLTEtMS03ODA0OQ_e4f32b20-eb39-4712-9220-2f87e3058da7">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Premium receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:PremiumsReceivableAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfOS0xLTEtMS03ODA0OQ_cfa1cf36-e61a-41df-87f8-294dad5adc17">7,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:PremiumsReceivableAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfOS0zLTEtMS03ODA0OQ_64732994-0674-493b-a051-ac92d5410d24">5,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Self-funded receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:SelfFundedReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTAtMS0xLTEtNzgwNDk_74995810-6c6f-4549-9847-229102db3179">4,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:SelfFundedReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTAtMy0xLTEtNzgwNDk_281c4366-6710-488d-bb31-b70a9266e7d1">4,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTEtMS0xLTEtNzgwNDk_867c6ee4-ec05-44e4-a6b3-fbae95455c9b">4,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTEtMy0xLTEtNzgwNDk_4bfb0ee1-a5b0-45a2-bec9-bec81173620c">3,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTQtMS0xLTEtNzgwNDk_76cf5b40-08df-4f59-8c7b-3b5d08368c4e">5,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTQtMy0xLTEtNzgwNDk_f83ca9fa-e9a2-4bfe-8862-cc346001fa65">4,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTYtMS0xLTEtNzgwNDk_4f8b07ca-60f7-4b9f-9997-351ee1a246f4">55,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTYtMy0xLTEtNzgwNDk_a27d7bda-0453-426e-824c-e7c58091288d">51,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed maturity securities (amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF80OQ_19396c61-7269-425f-a090-c248ac24f159">789</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF81Ng_2f96e5de-65f2-452b-a7f4-186e3208935b">616</ix:nonFraction>; allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF8xMTU0NDg3MjA5MTc1Nw_f67648c1-901d-43f1-90be-aec2c4076ad4">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF8xMTU0NDg3MjA5MTc2NA_a724dc89-a313-4dd6-86d7-5d025b38b7b4">0</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMS0xLTEtNzgwNDk_e7bfa1ff-94d5-48ea-b1a9-8515ea548704">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMy0xLTEtNzgwNDk_330443d7-88ae-4521-82d1-72d1396f8f45">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTktMS0xLTEtNzgwNDk_d9767ae1-30d8-4d57-b5dd-fa19bb45d327">5,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTktMy0xLTEtNzgwNDk_8afc1da3-7441-4b7b-bad5-0fc4cac2bd48">5,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjAtMS0xLTEtNzgwNDk_6e72843c-3429-4255-aa6e-3d6b27d788c2">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjAtMy0xLTEtNzgwNDk_e290cfce-2efd-49bb-bace-3755b8155cd9">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjEtMS0xLTEtNzgwNDk_2edc4bfd-3610-432d-b6ff-024de463af15">24,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjEtMy0xLTEtNzgwNDk_6895cb2f-9962-4312-ada8-9c1e87af7205">24,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjItMS0xLTEtNzgwNDk_21115a67-99e6-47dc-aa2a-30bde6f9b1a5">10,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjItMy0xLTEtNzgwNDk_3515863e-1e6f-41f1-9fe8-2d253c94ddd1">10,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjMtMS0xLTEtNzgwNDk_fd654b4e-dd09-426e-b7e0-f12c2551fd71">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjMtMy0xLTEtNzgwNDk_1155a921-185b-48ae-9e0b-9cba6b426bca">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjQtMS0xLTEtNzgwNDk_7ebe6098-3272-4c7a-a0f8-25df2fc79027">102,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjQtMy0xLTEtNzgwNDk_65ecba89-5f0c-4a85-b831-427331768a86">97,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical claims payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjktMS0xLTEtNzgwNDk_a4fb478b-f51e-4b28-8b29-52d95e9b2175">15,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjktMy0xLTEtNzgwNDk_2888087c-c4e0-4419-bdf9-b1e11b6b1ffd">13,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other policyholder liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherPolicyholderFunds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzEtMS0xLTEtNzgwNDk_1f6ba7be-1edb-49fa-ae9f-1a29b57ffa7d">5,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherPolicyholderFunds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzEtMy0xLTEtNzgwNDk_44ef46f3-7374-4441-a7bf-b35a67d81620">5,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:UnearnedPremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzItMS0xLTEtNzgwNDk_f564e231-2604-4568-8ff1-6d345a763884">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:UnearnedPremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzItMy0xLTEtNzgwNDk_aa9a5aef-99ea-45ff-a70b-21716ad2ca3c">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzMtMS0xLTEtNzgwNDk_24361379-e8b9-46fc-bf2d-d6fa44831ccc">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzMtMy0xLTEtNzgwNDk_6eaed8c6-a689-480d-a2e5-78d82c0dda1b">4,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzYtMS0xLTEtNzgwNDk_41021b7b-f847-42e7-a76c-b8d3cfee6787">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzYtMy0xLTEtNzgwNDk_60159915-0e2a-4e71-a979-8a7b3c903b06">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzctMS0xLTEtNzgwNDk_2e0e7278-a0e5-4567-91e8-b4f068f4aba9">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzctMy0xLTEtNzgwNDk_85284ab4-4a37-431d-8aa2-928d18fcd9d4">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzgtMS0xLTEtNzgwNDk_90c146f6-5307-4d6e-a7eb-f35edf409bfe">9,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzgtMy0xLTEtNzgwNDk_f360ef2e-f945-48f9-a7a4-2a1d63d41e3d">7,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDAtMS0xLTEtNzgwNDk_adf5515b-cc46-436a-b513-a6d2249ede48">39,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDAtMy0xLTEtNzgwNDk_9da8b320-7383-40b1-84dd-dda79470f767">34,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDEtMS0xLTEtNzgwNDk_8e8163ca-21d1-4ac6-a6c1-a2b635e319ec">22,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDEtMy0xLTEtNzgwNDk_d75ca6b8-6627-4252-b1a3-3a8627495e23">21,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserves for future policy benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDItMS0xLTEtNzgwNDk_10c28c5a-1acc-4801-bff9-0606e17eb0a9">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDItMy0xLTEtNzgwNDk_ed5b99cb-716b-487e-a0f2-b23f96dde153">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDMtMS0xLTEtNzgwNDk_ca4f9458-87ba-4b95-b7f8-ac3c1347e0f1">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDMtMy0xLTEtNzgwNDk_7899b948-e28c-4c27-930a-ee052634ade4">2,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDQtMS0xLTEtNzgwNDk_5832ed0b-11d1-4f2a-92a1-9e40c1cd5f74">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDQtMy0xLTEtNzgwNDk_68b5e4b3-74ed-4fd3-944c-01b7cf5ed657">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDUtMS0xLTEtNzgwNDk_9b965627-0406-42a2-b284-da11d7a63cbf">66,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDUtMy0xLTEtNzgwNDk_f99d9f59-1d72-4a97-a923-aa550b968386">61,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and Contingencies&#8212;Note 14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDYtMS0xLTEtNzgwNDk_4f3e05f2-b0a0-4064-98e3-6f66f2c9d089"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDYtMy0xLTEtNzgwNDk_76025412-9d6d-4406-8cb5-91377df29771"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, without par value, shares authorized - <ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo4NmFiOWNmZGFkZWQ0MGQ3YTUzYWFhOGNlNDgyZTE4ZV82MA_eb544ea1-fffa-4ef0-9fd6-6d7f79b19055">100,000,000</ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo4NmFiOWNmZGFkZWQ0MGQ3YTUzYWFhOGNlNDgyZTE4ZV85Ng_23165b7d-0ea1-40c0-97b0-f8fdfcd4e978"><ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo4NmFiOWNmZGFkZWQ0MGQ3YTUzYWFhOGNlNDgyZTE4ZV85Ng_b2232086-c8fc-4f6b-b02c-37306de2c93a">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMS0xLTEtNzgwNDk_f8a09341-8922-425e-9398-f5b1747f60d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMy0xLTEtNzgwNDk_8ee2590c-9d16-49f4-975a-de80ed3c6c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV8yOA_9abbb137-7a67-4a61-8687-05b06a42951d">0.01</ix:nonFraction>, shares authorized - <ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV81Mg_0448ee0c-285b-4f2a-ac3d-61e644b313d2">900,000,000</ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV84OA_df8b0844-2d33-46d6-8090-cdee67cd5426"><ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV84OA_e53fddbd-217d-4fec-a217-b407f38ebf4e">237,958,067</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV85NQ_2ef6ef86-69da-4dcf-b109-b95f1fb8f45d"><ix:nonFraction unitRef="shares" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV85NQ_bdc6c9b8-8018-4018-bd90-9aaffe1ba13e">241,770,746</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMS0xLTEtNzgwNDk_c04cdaff-2726-4a4c-98d8-36b3fbd4154f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMy0xLTEtNzgwNDk_6492ce41-3322-41e6-a6c1-7bbb309b993f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTAtMS0xLTEtNzgwNDk_36ed2f8f-8419-4c4b-b5fc-648e15c8b46b">9,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTAtMy0xLTEtNzgwNDk_ac172e9f-0b6f-4303-98d2-e8d21cf306b7">9,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTEtMS0xLTEtNzgwNDk_0c1ff5f9-002d-49d4-89e3-1e779cbe3985">29,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTEtMy0xLTEtNzgwNDk_af2ce513-6db0-4300-8545-7d309b1a00b8">27,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTItMS0xLTEtNzgwNDk_03c37718-0989-46a0-8f74-d363cb720e36">2,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTItMy0xLTEtNzgwNDk_f941901b-8215-4bab-852b-96ee892f6252">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTMtMS0xLTEtNzgwNDk_1ef17180-18af-4cf2-b29d-4b98421eee8d">36,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTMtMy0xLTEtNzgwNDk_c23c7a32-e36f-4575-87c4-791c8f04bf2f">36,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTQtMS0xLTEtNzgwNDk_f39c56a5-2795-466d-9a9b-a74e45ba2c17">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTQtMy0xLTEtNzgwNDk_c02ef039-bc1e-44e8-9dc4-c485f3001cf8">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTUtMS0xLTEtNzgwNDk_3c22796f-6f35-439a-8ae5-92fe6ef3abc4">36,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTUtMy0xLTEtNzgwNDk_b1333950-6bbf-474f-943b-5d0f1ecd7eb2">36,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTYtMS0xLTEtNzgwNDk_93f5549d-724a-4459-add7-0abb99a79ecf">102,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTYtMy0xLTEtNzgwNDk_916dff36-c091-469f-bbb8-a0aa3168bed1">97,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:61.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMy0xLTEtMS03ODA0OQ_9edb6dea-f1c6-49e6-85dd-71829689ec7e">133,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMy0zLTEtMS03ODA0OQ_46340efe-43a9-44d3-8d5d-4fb6d21f7464">117,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMy01LTEtMS03ODA0OQ_b21e9cbc-4397-47e3-9f30-2c4db1549370">104,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:ProductRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNC0xLTEtMS03ODA0OQ_4a773fea-7901-473b-be27-f0130c37829a">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:ProductRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNC0zLTEtMS03ODA0OQ_fd1dc17e-5076-408b-8650-97c6733db9f0">12,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:ProductRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNC01LTEtMS03ODA0OQ_e18b2f57-57cc-46db-a61b-785920763e2d">10,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative fees and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNS0xLTEtMS03ODA0OQ_42fec35d-a2b1-4043-8acd-06ab7c661c7d">7,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNS0zLTEtMS03ODA0OQ_02aae168-0bc9-4790-a650-d73fd3d67494">6,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNS01LTEtMS03ODA0OQ_f2fd5842-e0cb-4e86-b205-2cc102d0f04c">6,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:OperatingRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNi0xLTEtMS03ODA0OQ_74a7a9fd-c105-49bb-9298-385d7a522a88">155,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:OperatingRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNi0zLTEtMS03ODA0OQ_83a5905b-4f50-4d64-b1cb-88cd56b66928">136,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:OperatingRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNi01LTEtMS03ODA0OQ_405c36ca-c450-4fda-998f-d5802303208d">120,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNy0xLTEtMS03ODA0OQ_66590b24-e693-4272-a9b7-c58d95cda949">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNy0zLTEtMS03ODA0OQ_abc2f26e-19fd-4189-bce4-2eb19b4205d6">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNy01LTEtMS03ODA0OQ_6c78ea20-e677-4c25-9982-ed3ad66e64c8">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfOC0xLTEtMS03ODA0OQ_4902aa17-f59c-41b5-84bf-7040af3ebf8a">550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfOC0zLTEtMS03ODA0OQ_5d135a15-38d9-4175-bccb-fd16d0984e6a">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfOC01LTEtMS03ODA0OQ_df69068e-56c4-4385-8a16-91ff1599160b">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTMtMS0xLTEtNzgwNDk_ecb72255-94b9-46b2-a805-2f7cf0c0f903">156,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTMtMy0xLTEtNzgwNDk_3afb44c9-ec8b-49c4-9b5e-d03d8048dc94">138,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTMtNS0xLTEtNzgwNDk_25fe96df-445d-4d20-baf8-b79077c53e43">121,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTUtMS0xLTEtNzgwNDk_eca9bb18-c802-47f9-a44f-4295f27334b0">116,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTUtMy0xLTEtNzgwNDk_fdbe7840-1850-4818-b96a-84e4898c16b8">102,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTUtNS0xLTEtNzgwNDk_cf7d1859-95b1-49de-97ca-c5550ce37025">88,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTYtMS0xLTEtNzgwNDk_8da3b956-19a7-4c3f-bf3f-cf99d23d0d38">13,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTYtMy0xLTEtNzgwNDk_8dbbdb16-1d02-4755-86b2-1d4309db4047">10,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTYtNS0xLTEtNzgwNDk_bec38e4f-e51c-4cf4-9d1b-2ac6c45b2794">8,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTctMS0xLTEtNzgwNDk_7d430148-dc95-490d-8348-1e0714f3ec15">17,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTctMy0xLTEtNzgwNDk_e18f785c-75ae-4d7b-adc8-5735f5d21ab9">15,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTctNS0xLTEtNzgwNDk_d69ad7f7-c7d0-4416-961b-41e72c9f89c6">17,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTgtMS0xLTEtNzgwNDk_f0d58810-0315-46ce-932b-c0b1e28d75d0">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTgtMy0xLTEtNzgwNDk_df7dd294-3fe9-48e4-8710-e5e7042a763c">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTgtNS0xLTEtNzgwNDk_f5c6909e-08e8-4b16-9732-a409a763c2ae">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTktMS0xLTEtNzgwNDk_3c25d311-2f74-4977-8e4c-5a195d1b69d0">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTktMy0xLTEtNzgwNDk_0250d6cf-685e-48f7-bcd2-138d2cc00e0b">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTktNS0xLTEtNzgwNDk_64e56ea4-4a7a-45b5-9616-aeb68fd28338">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjAtMS0xLTEtNzgwNDk_6c58f80c-4c96-47b4-b6e0-bccec5af4f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjAtMy0xLTEtNzgwNDk_a156ae69-c7c2-4991-93b3-0d44eac7d362">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjAtNS0xLTEtNzgwNDk_7df27ec6-bf85-4615-86f6-7c147855c34d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjEtMS0xLTEtNzgwNDk_28d045ce-2760-4fea-b6e0-167afda4989b">148,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjEtMy0xLTEtNzgwNDk_742ac6e3-d0ee-4ca0-b56f-4a829519bc12">130,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjEtNS0xLTEtNzgwNDk_9cc12c73-bb9b-4927-a1c3-825d4b9c6202">115,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income tax expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjItMS0xLTEtNzgwNDk_b993ab26-3971-4641-b17c-dc9e57a7c7ef">7,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjItMy0xLTEtNzgwNDk_fab24414-fe21-45de-8b3f-8d27bf430596">7,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjItNS0xLTEtNzgwNDk_c0565c0f-8378-454f-981d-300668a6ccd6">6,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjMtMS0xLTEtNzgwNDk_90f5defe-caad-4c8b-9c33-85d8945372c9">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjMtMy0xLTEtNzgwNDk_32c79923-3a58-4d90-9b3e-2445a035a5e9">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjMtNS0xLTEtNzgwNDk_092d7be9-b373-4535-ac38-8d2fdf6d3c78">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjYtMS0xLTEtNzgwNDk_0de1fe70-5c9e-42a2-9d57-66d6bb5e9c5f">6,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjYtMy0xLTEtNzgwNDk_797230e0-715e-4537-b80b-ef97bdbee8e9">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjYtNS0xLTEtNzgwNDk_eb320102-4ebf-47b5-9aa2-2bc259a5eea0">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjctMS0xLTEtNzgwNDk_6e7a819b-4e82-451a-99f0-b5cd93f686d3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjctMy0xLTEtNzgwNDk_830647f2-0685-4c75-8d34-d0c31278f561">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjctNS0xLTEtNzgwNDk_899cba73-0f7c-4b74-ad3f-a354d8377fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjgtMS0xLTEtNzgwNDk_9d122537-640d-4407-967b-12387d706a16">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjgtMy0xLTEtNzgwNDk_867c4d15-7504-42da-b33e-bdc1411fc1df">6,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjgtNS0xLTEtNzgwNDk_532694ea-feb4-4aaa-a936-fe89f8683ef9">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; net income per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzItMS0xLTEtNzgwNDk_6fcc0178-6b95-4236-9706-9db07c191589">25.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzItMy0xLTEtNzgwNDk_007b7a8e-df9d-43b9-9732-e76408d27cc2">25.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzItNS0xLTEtNzgwNDk_4ac005a2-d357-4976-825e-5e62f961f670">18.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzYtMS0xLTEtNzgwNDk_88af60ea-ddf7-462a-a572-0b21dca7d163">24.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzYtMy0xLTEtNzgwNDk_2edda2f2-c86a-4fed-8136-9da8c04178dd">24.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzYtNS0xLTEtNzgwNDk_8b3287d0-11b6-4210-8ff3-68a932059dad">17.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzctMS0xLTEtNzgwNDk_f584c61f-2421-4f29-ae10-1944fb935429">5.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzctMy0xLTEtNzgwNDk_b35332b6-4b83-4293-8371-af9523d262e2">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzctNS0xLTEtNzgwNDk_8a564b8d-8041-43ce-afdf-bb77722d4211">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMi0xLTEtMS03ODA0OQ_02262665-be08-446d-a9b7-621868d78be4">6,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMi0zLTEtMS03ODA0OQ_00be9945-83b2-4ad5-980a-8b28c59dffb0">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMi01LTEtMS03ODA0OQ_0841befb-5f76-47af-8a10-255599038b44">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains/losses on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNC0xLTEtMS03ODA0OQ_9ab55749-4282-4a2d-8fac-ccd8c46d3fe3">2,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNC0zLTEtMS03ODA0OQ_f69dfbdc-137c-4172-b0f6-4412218789c8">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNC01LTEtMS03ODA0OQ_6a5c8332-6795-49b2-a710-37a95f3d7689">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-credit component of impairment losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNS0xLTEtMS03ODA0OQ_1ec4f3a5-d807-4007-b31c-bd3599ac5dc5">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNS0zLTEtMS03ODA0OQ_f7fa9017-67f5-4b96-91f7-9111d5775c56">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNS01LTEtMS03ODA0OQ_c35397ab-f5ae-43cf-a87b-e4cd5340b359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains/losses on cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNi0xLTEtMS03ODA0OQ_5e15746d-bb41-4eda-8536-6e6ca7555960">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNi0zLTEtMS03ODA0OQ_917baea9-7ad4-4375-8943-c4798be9198f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNi01LTEtMS03ODA0OQ_fa24f33e-506a-45c7-8209-0d6c28bf35bb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net periodic pension and postretirement costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNy0xLTEtMS03ODA0OQ_20bc2a18-a927-44c7-a74f-75ac7cfe55c1">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNy0zLTEtMS03ODA0OQ_928b28fe-3871-4ffd-a0f3-ea4ee1b829b9">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNy01LTEtMS03ODA0OQ_a39c0b0c-6a6d-456c-aa15-d8687b3567e1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOC0xLTEtMS03ODA0OQ_8675c848-5839-4dc7-a2af-55c8e588c23b">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOC0zLTEtMS03ODA0OQ_b79d4519-5c1f-43db-a966-62bf0447afbd">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOC01LTEtMS03ODA0OQ_a50c3d3b-caea-47cf-aa2b-1d3d31248fb2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOS0xLTEtMS03ODA0OQ_9f8e71ac-22f4-49cd-a1f2-a9754bf54bb2">2,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOS0zLTEtMS03ODA0OQ_637e9116-e437-4a0c-a0f7-274fb1122589">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOS01LTEtMS03ODA0OQ_45590d68-0aaf-4cf2-894f-447498db2c4e">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTAtMS0xLTEtNzgwNDk_26b9455d-6e70-48e3-954e-115de9ee0d09">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTAtMy0xLTEtNzgwNDk_5720df9b-39be-422c-ae65-7b29a09b37e8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTAtNS0xLTEtNzgwNDk_56ecde72-00ec-422a-83a2-05877bcf4a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTEtMS0xLTEtNzgwNDk_6e5fcd31-80d2-4eba-8cec-ac2269352d90">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTEtMy0xLTEtNzgwNDk_864e2c8f-f6a8-4c91-8276-318437178d2f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTEtNS0xLTEtNzgwNDk_d18c9eb5-9490-4b49-9d9a-4c3bed062282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTItMS0xLTEtNzgwNDk_c490bf09-3727-4a1c-83dd-cb296c79a5cd">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTItMy0xLTEtNzgwNDk_67165ce3-57b8-489c-9646-a512c7eb6ef3">5,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTItNS0xLTEtNzgwNDk_07f802f1-27cd-4aef-8ba7-a0b7d8804414">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:61.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Years Ended December&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMy0xLTEtMS03ODA0OQ_82ee0ea6-7430-487e-9b13-c551a4eca2e5">6,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMy0zLTEtMS03ODA0OQ_cea64bf8-d5ce-479b-a9ab-d1a7ed870031">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMy01LTEtMS03ODA0OQ_cedf23e0-deda-4801-92c2-a2f5934a192d">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net losses (gains) on financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNS0xLTEtMS03ODA0OQ_091697ed-b3a6-4353-a961-345c5eda9a67">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNS0zLTEtMS03ODA0OQ_313bb7e1-9da9-43dc-b8c8-91bbbfd1a541">318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNS01LTEtMS03ODA0OQ_606b14c4-d574-49b6-a7dd-130f9cef7ab0">182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Equity in net earnings of other invested assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNi0xLTEtMS03ODA0OQ_ee2d5532-e368-401f-989c-d42623b9fa01">293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNi0zLTEtMS03ODA0OQ_7053372e-457d-472f-89ea-931efed8c686">562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNi01LTEtMS03ODA0OQ_6d823d1b-6e7f-43da-a444-34b555e79ac8">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNy0xLTEtMS03ODA0OQ_f8d9e0ce-48b0-4b64-8f7c-a77ec7b649d2">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNy0zLTEtMS03ODA0OQ_4b238d07-acd8-4fe6-9d71-d5388506b541">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNy01LTEtMS03ODA0OQ_21c895cb-158e-403a-b5be-6e149b4821a2">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTAtMS0xLTEtNzgwNDk_1d959ccf-7501-4543-a8ab-7a0c140c5f27">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTAtMy0xLTEtNzgwNDk_0bf6f7ef-1f5a-4aec-9b97-498fcd744276">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTAtNS0xLTEtNzgwNDk_36c8a367-02c8-4038-bd5d-4e718293b6af">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impairment of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTEtMS0xLTEtNzgwNDk_5619c54c-972c-4cfc-977d-93eff7a09b21">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTEtMy0xLTEtNzgwNDk_fa42f62f-d24b-4a61-baa7-ef8c4e9cd956">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTEtNS0xLTEtNzgwNDk_ce72fd21-14c2-431c-8ebd-7e0e50b8a21d">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTItMS0xLTEtNzgwNDk_f06af2c3-ba2d-4af7-a99c-37b9b89c57b2">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTItMy0xLTEtNzgwNDk_4d2052be-ba6c-42b6-aac1-d0ce110b11f7">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTItNS0xLTEtNzgwNDk_c8b28cb6-6e1d-4f3a-a4cd-622e7139aaca">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTQtMS0xLTEtNzgwNDk_8f640333-45ca-4b97-b7fa-7ccf7d9f8249">2,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTQtMy0xLTEtNzgwNDk_a09e7952-64ae-4b4d-9e70-16baa4175d38">2,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTQtNS0xLTEtNzgwNDk_8ca3baaa-e762-4101-a1d3-142e0e2bd793">256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTUtMS0xLTEtNzgwNDk_5c7e4f23-c524-4b66-935d-43daf736c94f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTUtMy0xLTEtNzgwNDk_fa82f410-0806-4e3f-ad13-465f5a65eb95">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTUtNS0xLTEtNzgwNDk_cfc99851-f4bb-4f10-afbf-00f7713f834e">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTYtMS0xLTEtNzgwNDk_4118cb13-8aa7-46ff-aeb3-d759f5ea18ba">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTYtMy0xLTEtNzgwNDk_4c68cd07-9079-4445-b575-09ca4082a1fc">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTYtNS0xLTEtNzgwNDk_7cf619ef-4bec-49f4-8649-682f91122c9e">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Policy liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTctMS0xLTEtNzgwNDk_1986c57d-b293-4d39-a15d-d7ad88a0bb61">2,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTctMy0xLTEtNzgwNDk_deb9ce1b-cd7b-4d04-a3e6-732c419b7157">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTctNS0xLTEtNzgwNDk_186df51e-8a3a-4df8-bc8a-7c91069d37a5">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unearned income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTgtMS0xLTEtNzgwNDk_619cf515-4471-4345-ade8-22d08cf3174e">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTgtMy0xLTEtNzgwNDk_ba1a9c99-e37a-4142-949d-017eafe8a777">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTgtNS0xLTEtNzgwNDk_1544a374-e619-4767-b2b0-97c0fa61e757">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTktMS0xLTEtNzgwNDk_6217894d-459e-4899-a0d4-78aacf517568">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTktMy0xLTEtNzgwNDk_e9d05b4c-f352-42ea-a735-3b5686a974ab">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTktNS0xLTEtNzgwNDk_33b9e3a5-64c5-4efd-8472-e06a634d0db5">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjAtMS0xLTEtNzgwNDk_e46782d4-afb3-40e5-9cf2-357f42d17105">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjAtMy0xLTEtNzgwNDk_31c34b2e-1147-4a2b-afac-a399e78e3af7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjAtNS0xLTEtNzgwNDk_6cc07f85-9b7a-4004-921c-44d3d98dc244">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjEtMS0xLTEtNzgwNDk_dfa8654e-a0f2-4aba-877b-943f5af84e64">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjEtMy0xLTEtNzgwNDk_9e7d357a-daa7-4da8-a782-4ae1a7d5fff4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjEtNS0xLTEtNzgwNDk_3a35c3a7-481a-4cdb-9939-e48245407e41">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjItMS0xLTEtNzgwNDk_3f4bd336-4b9c-44f2-8767-6b703573e2f9">8,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjItMy0xLTEtNzgwNDk_e2199b1a-6884-4569-9b78-9e34e53846f3">8,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjItNS0xLTEtNzgwNDk_5a57002b-0139-45c2-bdcf-bd51b467638d">10,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjQtMS0xLTEtNzgwNDk_374281bf-dcc9-43f7-8bb8-8c768b90cbbf">24,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjQtMy0xLTEtNzgwNDk_430be08f-3554-4be5-89ee-df8d732362e6">18,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjQtNS0xLTEtNzgwNDk_97fad90f-fea9-43da-811c-c2ab945f9330">19,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from sale of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:Proceedsfromsaleofequityandfixedmaturitysecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjUtMS0xLTEtNzgwNDk_ffa50be0-f3dc-49e9-b63c-2be7e81f4c92">11,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:Proceedsfromsaleofequityandfixedmaturitysecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjUtMy0xLTEtNzgwNDk_8f5d6e6b-51fe-4414-b22b-14067d61616e">10,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:Proceedsfromsaleofequityandfixedmaturitysecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjUtNS0xLTEtNzgwNDk_308bf5c4-ec67-4316-90cf-407677511692">11,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities, calls and redemptions from investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjYtMS0xLTEtNzgwNDk_5a2b68a7-5563-49ab-a12f-e77c3a37008d">10,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjYtMy0xLTEtNzgwNDk_82181e9a-d68a-4b33-aedd-e41780fef4aa">4,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjYtNS0xLTEtNzgwNDk_1874cff3-26b8-42c8-9694-6c136c003b5f">4,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Changes in securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjgtMS0xLTEtNzgwNDk_2f44c81e-23f3-4157-915b-9debb0e91601">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjgtMy0xLTEtNzgwNDk_a192637a-3c02-462e-bc0e-2b77c20f9814">956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjgtNS0xLTEtNzgwNDk_015b447c-3b25-4d88-91e0-a42422aedad8">849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjktMS0xLTEtNzgwNDk_b42a1438-5a3f-4b90-9813-aa1e8d178612">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjktMy0xLTEtNzgwNDk_5d26293a-7ca3-4c6d-800e-d29960e548fd">3,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjktNS0xLTEtNzgwNDk_ac7c0500-3b88-4c1b-9500-3d53a825fc63">1,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzAtMS0xLTEtNzgwNDk_6b4b6233-0b5a-4c3e-bfc6-bc331ca6a3a2">1,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzAtMy0xLTEtNzgwNDk_496eeff8-012c-4a30-b6bc-27777390da86">1,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzAtNS0xLTEtNzgwNDk_064089dd-5eba-4576-afd7-9909bbd0d844">1,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzEtMS0xLTEtNzgwNDk_573dc9ba-d2d6-4df4-9973-64907e480ec0">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzEtMy0xLTEtNzgwNDk_5e5ca619-9048-45cd-9675-97f28749c8c6">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzEtNS0xLTEtNzgwNDk_c33f4ab4-c038-49f6-866b-c0de35f37f24">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzItMS0xLTEtNzgwNDk_8cc84263-8c86-4a51-bb8e-88916cc0bb69">4,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzItMy0xLTEtNzgwNDk_9d3d851d-c035-4d6e-afaf-e00df915b268">9,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzItNS0xLTEtNzgwNDk_c64edfd2-a833-4086-a3a2-ec5890ab1269">7,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net (repayments of) proceeds from commercial paper borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzQtMS0xLTEtNzgwNDk_861291f0-f187-450a-8602-c316a97b1996">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzQtMy0xLTEtNzgwNDk_0f162a20-e1b6-4cd8-bdab-7e60646203cb">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzQtNS0xLTEtNzgwNDk_cdd54720-baed-4c80-a23e-a1d8b7598cc5">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from long-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzUtMS0xLTEtNzgwNDk_88ee0a11-7aec-460e-8688-0d34d3b933ec">3,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzUtMy0xLTEtNzgwNDk_363bbe07-eb89-4f39-99c9-9a7fd9ad562e">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzUtNS0xLTEtNzgwNDk_7ec35c26-7c7b-4e3c-a416-65c0f0609c9a">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repayments of long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzYtMS0xLTEtNzgwNDk_19e9469b-3d85-4a37-9721-5e7784d43cc3">1,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzYtMy0xLTEtNzgwNDk_de6210dd-77ef-4b81-b4f3-bb8f1cbb9170">1,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzYtNS0xLTEtNzgwNDk_c1eb1bf9-69cc-4c34-bf82-afb936039d89">1,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzctMS0xLTEtNzgwNDk_80f11b1e-0b69-4f1c-b9ea-3b4d3305168b">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzctMy0xLTEtNzgwNDk_2114adc1-85e7-428c-8839-a0ed232a84ef">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzctNS0xLTEtNzgwNDk_448091d4-12e6-4919-ac0f-38d6b6fe5f6a">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repayments of short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzgtMS0xLTEtNzgwNDk_a63a1e1b-382e-4fa6-b77b-9fc47cbec70c">1,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzgtMy0xLTEtNzgwNDk_2165a91b-d0ca-4edd-8b30-62a9078be8a1">1,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzgtNS0xLTEtNzgwNDk_17258c0d-bc7a-479f-9b09-720a37841c32">1,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Changes in securities lending payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInSecuritiesLendingPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzktMS0xLTEtNzgwNDk_d43fe951-80fb-4e64-96ea-4c921211929b">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInSecuritiesLendingPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzktMy0xLTEtNzgwNDk_360803ce-5454-49e6-9ac2-51c8c9700c26">956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInSecuritiesLendingPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzktNS0xLTEtNzgwNDk_29021ac4-a4ad-4b17-9721-31683d48d665">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Changes in bank overdrafts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDAtMS0xLTEtNzgwNDk_078e5b5b-644b-4808-b46e-35e3391385fb">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDAtMy0xLTEtNzgwNDk_4ce53b30-3eb2-4be6-96ae-72d876749dbc">376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDAtNS0xLTEtNzgwNDk_c3e4c55a-df69-45f5-989e-8ab7f753b352">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDEtMS0xLTEtNzgwNDk_e4493865-2205-4ee2-b83f-c9a5c78bc5fa">2,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDEtMy0xLTEtNzgwNDk_350b3a60-61cb-45bb-bcc4-f57b58324577">1,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDEtNS0xLTEtNzgwNDk_771b5008-4cd1-4da0-b8ad-41c3c1076eac">2,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDItMS0xLTEtNzgwNDk_1951d566-916d-44d9-a1a4-001622ecd39c">1,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDItMy0xLTEtNzgwNDk_5061cb49-d144-407a-a100-5c1ceb277552">1,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDItNS0xLTEtNzgwNDk_8132ba37-38ae-42cf-a0bf-75d496efc060">954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDMtMS0xLTEtNzgwNDk_b7887e64-4679-47cc-aa69-644651c905dd">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDMtMy0xLTEtNzgwNDk_ab7e912e-73ab-4f3c-972b-593de4f9ea01">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDMtNS0xLTEtNzgwNDk_9a197455-873f-4a59-8f86-caea11e1b417">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Taxes paid through withholding of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDQtMS0xLTEtNzgwNDk_a481503c-a8b0-4e78-95d7-b4ba9f137b27">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDQtMy0xLTEtNzgwNDk_c275db17-6130-4916-8645-2c887ab05a70">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDQtNS0xLTEtNzgwNDk_57ffbb2f-37af-45f8-aef5-f900086ff9b5">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDUtMS0xLTEtNzgwNDk_704e6e96-1c94-4524-84ca-42913bda7794">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDUtMy0xLTEtNzgwNDk_92604e8a-df46-4df3-ad95-0e5a48457829">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDUtNS0xLTEtNzgwNDk_41333b33-55f7-41ad-9fb3-9ff1b8dfd6d3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDYtMS0xLTEtNzgwNDk_da462abc-436a-496b-966e-3ec760bd2875">1,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDYtMy0xLTEtNzgwNDk_c0e14b31-d5ed-448e-8601-e0f59c330441">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDYtNS0xLTEtNzgwNDk_d442e77e-754c-48e6-9157-fe8ebba2b8fb">2,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDctMS0xLTEtNzgwNDk_bee74fb0-b0f9-4b9a-b607-d1f4943e79a2">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDctMy0xLTEtNzgwNDk_e496386d-dc19-4f6f-b532-73d20e57a714">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDctNS0xLTEtNzgwNDk_dcf18809-a7f9-492c-bcda-f75044d12169">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDgtMS0xLTEtNzgwNDk_860cdccd-5383-4a86-ade8-ff3954853a04">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDgtMy0xLTEtNzgwNDk_d1c34a00-8d14-4219-b84c-f5669abade04">861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDgtNS0xLTEtNzgwNDk_24b2f40c-635d-4046-b36d-acb6b93999af">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDktMS0xLTEtNzgwNDk_87285be9-ea42-43d1-9fae-73dca58c7994">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDktMy0xLTEtNzgwNDk_5807a7f6-da6d-4509-8e5c-5bbe0bbab68b">5,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDktNS0xLTEtNzgwNDk_42370df1-057a-4ecf-8dba-61e6fb72b787">4,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNTAtMS0xLTEtNzgwNDk_85933eb0-5588-4fad-a023-2bd6e30485ee">7,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNTAtMy0xLTEtNzgwNDk_ea5012ce-7fb9-43ac-841b-7916ef551a8a">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNTAtNS0xLTEtNzgwNDk_22635d04-e677-4792-b108-cf964b6b7379">5,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf5b071c02144445ae1940007287f05f_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0xLTEtMS03ODA0OQ_316503c8-a9b4-414f-86a6-afc9be200138">252.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf5b071c02144445ae1940007287f05f_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0zLTEtMS03ODA0OQ_de06a947-3e2b-4e9b-a961-6ddb147fb330">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8589c07204d749bbace5042c6b65cc69_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi01LTEtMS03ODA0OQ_c699f17f-7fb1-46e6-9615-ff6e935fe873">9,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f221c1344f471085a849bbadf705e3_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi03LTEtMS03ODA0OQ_95d70456-bbdd-472b-bf91-5d3be859057d">22,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f53fa30766f4027ac9f51d714b28ca5_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi05LTEtMS03ODA0OQ_9d995d91-8966-43df-a7c2-8ad001fc72cb">296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30274a1261ef49b2b0ed74d1f2f4ffd0_I20191231" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0xMS0xLTEtNzgwNDk_c80c2764-64d5-46eb-8d24-10551fd22d80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0xMy0xLTEtNzgwNDk_5551ba0d-b6ff-4f83-985e-6e69c2645aaa">31,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMy03LTEtMS03ODA0OQ_6bf7fae2-97ee-4b1d-9a44-e5c29fbbe4b7">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMy0xMy0xLTEtNzgwNDk_d014bf8a-02fe-490c-b425-0260f1739ac9">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e30683b4044476b165b02ff7db9ad5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNC05LTEtMS03ODA0OQ_d2c7b72c-85be-490d-bbd4-746d0fe5a6bc">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNC0xMy0xLTEtNzgwNDk_c431bc24-cc2e-431c-a629-401068497bd7">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib2672b85aeaa43e380a7c111f5228b73_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy0xLTEtMS03ODA0OQ_e30a44de-d812-4b87-82da-9c30c8fa87af">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy01LTEtMS03ODA0OQ_46e3d87b-77ed-4463-806e-9d7b15afa43d">353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy03LTEtMS03ODA0OQ_6a3210bf-b219-4f52-ac78-95b29e9748f0">2,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy0xMy0xLTEtNzgwNDk_b86da9ad-90bf-4dbd-9462-4cc9308374f5">2,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends and dividend equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOC03LTEtMS03ODA0OQ_2b41047a-b4f0-4e2e-9239-ac5d5c11832f">961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOC0xMy0xLTEtNzgwNDk_c7e7e384-cff6-4fc1-9d38-3c99bc24157c">961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock plans, net of related tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2672b85aeaa43e380a7c111f5228b73_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOS0xLTEtMS03ODA0OQ_a7005d03-9596-4026-94cb-b541bd1a000c">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOS01LTEtMS03ODA0OQ_3a67a014-f0c6-4eba-b289-23d5d647ee63">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOS0xMy0xLTEtNzgwNDk_0efda3d8-b931-40c7-bbef-12f080da21d6">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible debenture repurchases and conversions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTAtNS0xLTEtNzgwNDk_dac4ff56-3b8d-4917-adc5-a266c1bb70f4">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTAtMTMtMS0xLTc4MDQ5_7c8e727b-0386-4167-8d27-2faab129477b">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i793efbc5c7714f92b8248295269327af_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMS0xLTEtNzgwNDk_2855dd29-4e68-4775-9e44-aac5c7c9df15">245.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793efbc5c7714f92b8248295269327af_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMy0xLTEtNzgwNDk_c9977cf3-07f9-4bab-8387-bcaa41fd0d10">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94c1fcb18c342dc8db391ef68ac66d1_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItNS0xLTEtNzgwNDk_8f4c0d79-4942-49b0-beca-1ee0ca7b7800">9,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a79074187a456ab3c3c9edc81fd430_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItNy0xLTEtNzgwNDk_21cbc2a8-dfea-4979-bdc6-ecb3410bcd4b">23,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93412ca87a24e1a8d15a5d209e51bbb_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItOS0xLTEtNzgwNDk_0212b2e3-2c76-49c0-a44a-22ff83896e73">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMTMtMS0xLTc4MDQ5_0d168656-bf76-4478-8b83-cfff3c38df54">33,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTUtNy0xLTEtNzgwNDk_fd5435b2-ed12-4560-a722-4109c235d602">6,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTUtMTEtMS0xLTc4MDQ5_c2beb34b-c3ac-457a-92b6-a737d86139b3">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTUtMTMtMS0xLTc4MDQ5_65d8c701-dcb8-42ce-98d7-c1a28fa130e3">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6d4349f67ff4c61980f48af218a4394_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTYtOS0xLTEtNzgwNDk_7e5f2a43-e1ae-437e-9093-20dc5876c747">328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTYtMTEtMS0xLTc4MDQ5_ed2dad3b-3c60-4b06-8e9a-a19d8e861b3b">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTYtMTMtMS0xLTc4MDQ5_18b3e3b0-a0b4-432e-a00d-873e8c1154c1">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMTEtMS0xLTgxNzM1_6ac53da8-a6ff-43ee-811a-e70eacc9beab">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMTMtMS0xLTgxNzQ0_1a90b496-e97b-49b8-afba-ddc601de9cd4">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMS0xLTEtNzgwNDk_dd55c83a-8f41-4531-9280-c7a6df3afd53">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMy0xLTEtNzgwNDk_99ee2285-fb65-441d-bf20-f5b84c81c945">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktNS0xLTEtNzgwNDk_60c31c2f-b1f3-48fd-b4ed-ae2766336a4e">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktNy0xLTEtNzgwNDk_c56782bc-d5f5-49cc-9a10-934a162384aa">1,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMTMtMS0xLTc4MDQ5_f7aaf7a6-e5cf-4f5a-8ac7-44357772c601">1,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends and dividend equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtNy0xLTEtNzgwNDk_7b4bf8cd-e105-4cc4-84df-e68a5e034819">1,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMTMtMS0xLTc4MDQ5_b744b695-797a-4609-8196-39f1a4e982fd">1,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock plans, net of related tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjEtMS0xLTEtNzgwNDk_7b6d2481-27bb-4b8d-b331-73661236f306">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjEtNS0xLTEtNzgwNDk_2f30a11c-ee6d-43b5-bd8a-58ac9cbc6cc3">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjEtMTMtMS0xLTc4MDQ5_b90937d2-6e67-4d11-87eb-7f82de6ef996">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible debenture repurchases and conversions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjItNS0xLTEtNzgwNDk_6201aca5-ab81-4612-a55e-fea3cb33b791">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjItMTMtMS0xLTc4MDQ5_6d89cf91-18e8-41b1-ae88-dba8c12d6b32">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMS0xLTEtNzgwNDk_087463d3-fd98-4765-83a7-0fc15324c8ce">241.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMy0xLTEtNzgwNDk_fb5a3e88-3c0e-44ba-8391-3c1843cfe5ed">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a827868fc64ccfacc19325aa44c171_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtNS0xLTEtNzgwNDk_cd3430f0-696e-4c1b-8107-55f9f0f38467">9,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a2241770974cd59c85ae10194b94f6_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtNy0xLTEtNzgwNDk_c88f9339-e895-4105-aeaa-e16e4cfe688a">27,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68c3e5edf94c9cbe296449811771a5_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtOS0xLTEtNzgwNDk_82256759-4dad-4ffb-acad-3b3db4176e02">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if422755e3e354c5f865ec51e2e1db51d_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMTEtMS0xLTc4MDQ5_e7e401f6-d719-4f17-b6bc-32de2af1db2e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMTMtMS0xLTc4MDQ5_9a8f2522-d404-4f9c-914c-417ec10192f4">36,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption of Accounting Standards Update 2020-06 (Note 2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktNy0xLTEtODQ3OTA_dc5f99ee-0333-4a04-bd4c-0fac46704fa3">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6946927fb5b546f5b3d2eaef12758789_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMTMtMS0xLTg0Nzk4_88d0f365-d563-4607-9371-cecdb58a310d">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMS0xLTEtODQ3OTA_a558ea2e-5aa5-49cd-93ea-ce64fc1dd204">241.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMy0xLTEtODQ3OTA_073a2416-06d2-4086-9410-0ff3887a3964">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a827868fc64ccfacc19325aa44c171_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtNS0xLTEtODQ3OTA_54d7e034-4b6a-41ed-a786-64463d338211">9,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e4608246614931930218a735fc0cbb_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtNy0xLTEtODQ3OTA_715edd72-9d72-40b5-af7c-a0acef49067c">27,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68c3e5edf94c9cbe296449811771a5_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtOS0xLTEtODQ3OTA_bce7b972-75d8-4542-a276-217b1e416060">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if422755e3e354c5f865ec51e2e1db51d_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMTEtMS0xLTg0Nzk4_90dc93c5-1e23-4605-b555-f19a2242b119">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2494f99710864bc7a90c0848d3e5fde2_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMTMtMS0xLTg0Nzk4_7bef698a-2432-4b43-8977-eedd0d783007">36,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjYtNy0xLTEtNzgwNDk_ae426ec1-7c6a-46d1-82d4-64f0e96bde3f">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjYtMTEtMS0xLTc4MDQ5_408e656b-bf99-4e63-80d9-d46120477ab3">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjYtMTMtMS0xLTc4MDQ5_cf9134d9-08a1-4020-9fd6-bd51b0ffd804">6,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42b6d6da5eaa4137b9f2ce6c292546d4_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjctOS0xLTEtNzgwNDk_28ece4f7-c5c0-407f-bd6b-cffe17495f7b">2,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjctMTEtMS0xLTc4MDQ5_351d9f45-0482-4f69-946f-8a484232278c">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjctMTMtMS0xLTc4MDQ5_d7fbeb94-eb91-4666-a031-24323b3fc3f3">2,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjgtMTEtMS0xLTc4MDQ5_7bae4aa1-a3b4-435c-967d-2ce15063a9e8">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjgtMTMtMS0xLTc4MDQ5_f4f712f0-8538-48c2-94b2-826447c926e8">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifad2035d69cb4c4bb3a71c39d076f734_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtMS0xLTEtNzgwNDk_9eff50ce-f886-4fac-85c6-4363c31acc20">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtNS0xLTEtNzgwNDk_15ac85c1-ae9e-43d5-b811-15ba6ff69d07">184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtNy0xLTEtNzgwNDk_e66a4475-67c6-4821-a211-c3f5d5cb6ec0">2,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtMTMtMS0xLTc4MDQ5_71a43c80-a54a-4d0e-beb1-4797e1681c6e">2,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends and dividend equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzItNy0xLTEtNzgwNDk_4f9031df-e716-40ed-9f4e-bcf914aacf79">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzItMTMtMS0xLTc4MDQ5_a4063499-c71d-4c6f-9663-461702e45a63">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock plans, net of related tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifad2035d69cb4c4bb3a71c39d076f734_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzMtMS0xLTEtNzgwNDk_cfb3b7ae-f81d-4f2b-8676-854e96cf6854">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzMtNS0xLTEtNzgwNDk_70986184-3fa1-4edf-a8a5-b9ace04193f3">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzMtMTMtMS0xLTc4MDQ5_5b035826-2bef-464e-a5ac-ba9a22a72830">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible debenture repurchases and conversions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzQtNS0xLTEtNzgwNDk_19d17629-c07c-4e03-8d43-81dec6a6614d">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzQtMTMtMS0xLTc4MDQ5_22561e72-6180-4b16-be75-7716aba76763">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab35b50f371d4e109ef6e82fb6162116_I20221231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMS0xLTEtNzgwNDk_7f66ad1b-1d55-4c66-b7ca-5c695d633b4a">238.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab35b50f371d4e109ef6e82fb6162116_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMy0xLTEtNzgwNDk_7ba55ebe-89ed-4428-8f80-52f84db76981">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4923e0fc5164066835e075d6d5a4675_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtNS0xLTEtNzgwNDk_cc15effb-a3b1-4d4f-8f8e-3b7c41c4c4aa">9,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55f913977d34ea8ae0f65c274b41526_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtNy0xLTEtNzgwNDk_74882761-7362-45d9-bd90-a76f7bc1e949">29,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62707788a92840b2a900639d9bb21b20_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtOS0xLTEtNzgwNDk_ff6e6973-1f51-45ae-9584-2995b8f1252b">2,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61b9bc047c24fe089b47010fc8c5147_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMTEtMS0xLTc4MDQ5_890dc19e-7d1b-4a37-a1c6-b1aa987081ee">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMTMtMS0xLTc4MDQ5_83d25093-e995-47fd-b7ec-573f55367454">36,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In Millions, Except Per Share Data or As Otherwise Stated Herein)</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_91"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfMTQ1Mg_fd1a77c2-f3d1-4863-b54c-75226a511bac" continuedAt="i02ab234826bc4eefa25ffd16e1119848" escape="true">Organization </ix:nonNumeric></span></div><ix:continuation id="i02ab234826bc4eefa25ffd16e1119848" continuedAt="i6b8cc48907614547b9a62d20a58edea2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol &#8220;ELV&#8221; on June 28, 2022. References to the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or &#8220;Elevance Health&#8221; used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the &#8220;states&#8221; include the District of Columbia and Puerto Rico, unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately <ix:nonFraction unitRef="individuals" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-5" name="elv:NumberOfMedicalMembersServed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfMzk3_0c55a02c-f1a9-4dc4-8b11-04554857fa36">47.5</ix:nonFraction> million medical members through our affiliated health plans as of December&#160;31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products &amp; Services business, which administers the Federal Employees Health Benefits (&#8220;FEHB&#8221;) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (&#8220;PBM&#8221;) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#8220;BCBS&#8221;) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding <ix:nonFraction unitRef="counties" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="elv:NumberOfCountiesInGeographicalRegionNotServed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfODE0_4b1f19f4-3a79-4443-abf7-2c4e2c1e3f5e">30</ix:nonFraction> counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer PBM services through our CarelonRx, Inc. (&#8220;CarelonRx&#8221;) subsidiary, which was named IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all <ix:nonFraction unitRef="states" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfMTM3Mg_43443adc-38f6-4299-a475-0fa396c25d35">50</ix:nonFraction>&#160;states, the District of Columbia and Puerto Rico through our subsidiaries.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield &#8212; represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellpoint &#8212; we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Carelon &#8212; this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes made to our segments in 2022 associated with this branding strategy. Through December 31, 2022, we managed our operations by customer types through four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. Our branding strategy reflects the evolution of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b8cc48907614547b9a62d20a58edea2">our business from a traditional health insurance company into a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our business in the future. For additional discussion, including the changes to our reportable segments for 2023, see Note 20, &#8220;Segment Information.&#8221;</ix:continuation> </span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMjM_54a3464a-dce5-4026-ad71-21c9126b5eb8" continuedAt="i6d77b922c5c5477ea7266c81e0550f58" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6d77b922c5c5477ea7266c81e0550f58" continuedAt="i601593ede1204607a47d679ece24bf0a"><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NzU_c2d696c2-bd9b-413b-8632-dd633fa2add4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements include the accounts of Elevance Health and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NDk_7ac941fd-7bf1-434c-adef-0977b499d1a4" escape="true">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (&#8220;USD&#8221;). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in &#8220;Foreign currency translation adjustments&#8221; in our consolidated statements of comprehensive income.</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NTA_adc0444e-5441-498c-b433-07b85e74bd17" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNDQ_a9bcb336-1c4a-4532-8331-60725eee6043" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMjY_d4bc4394-34d2-49d9-813b-14eec8ebc91f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTg0NA_983a461e-d81a-4369-967b-82fb2b5a1581">258</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTg1Mg_3091489a-79ad-46ea-ba94-6621ff95522a">173</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NTQ_6c62d250-4363-433a-8ed8-937e0ff4edd2" continuedAt="i39530703a2c74549848d2f46769f138d" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as &#8220;available-for-sale&#8221; and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security&#8217;s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i601593ede1204607a47d679ece24bf0a" continuedAt="i64a30ec65cc94c75bca1976b71839830"><ix:continuation id="i39530703a2c74549848d2f46769f138d" continuedAt="ie829f6fa9b784a59bdbca459ce04ee6f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie829f6fa9b784a59bdbca459ce04ee6f">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported in other current assets on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current liabilities. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders&#8217; equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions.&#160;To the extent the loaned securities&#8217; value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall.&#160;As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at <ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="INF" name="elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfODE0OQ_cbe8a9cc-4b95-4041-99bd-1a4681b8cc51">102</ix:nonFraction>% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</ix:continuation> </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzOTY_8cbf14f7-4b8c-4084-be67-6c56710a54dd" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfODg0MQ_ab93165a-5c30-49ba-97a7-f91042c1ebe2">152</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfODg0OA_93072fec-6d28-44ed-8930-294f046bb1ca">142</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:SelffundedReceivablesAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTA3MA_725d7dfd-fe4f-4eb5-bfc2-e1e1ab2e2fa1">68</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:SelffundedReceivablesAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTA3Nw_681a67c3-3e88-4968-ba7c-273a3929d9f9">50</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTQwOQ_49aed515-58b8-4c46-8763-7b2f5106716d">744</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTQxNg_eebefed7-42e2-44af-ab45-3ab339edd2a2">648</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzOTc_c06a002a-5a30-4751-b722-556a10d22a7f" continuedAt="ice11142d75fe416780f27d81a4b9fa81" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws and are reported net on our consolidated balance sheets. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i64a30ec65cc94c75bca1976b71839830" continuedAt="ibe8d65cc786b4537b6be9b3af98e850e"><ix:continuation id="ice11142d75fe416780f27d81a4b9fa81"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the &#8220;Corporate AMT&#8221;) that became effective for us beginning January 1, 2023. We have elected to account for the effects of the Corporate AMT on deferred tax assets and carryforwards and tax credits in the period they arise. Additionally, the Inflation Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31, 2022. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of operations, cash flows or related disclosures.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMzY_3ea749d8-2390-473e-86e7-f2a20098b16d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3">fifteen</span> to <ix:nonNumeric contextRef="i05b94430fac3410384b74a0089cca3b4_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMzA_71c6c4b6-bd06-46d7-aa57-0121bfcc5622">thirty years</ix:nonNumeric> for buildings and improvements, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5">three</span> to <ix:nonNumeric contextRef="i8cdeae00e15947f2b19d9c357486c5be_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzc_f77ff7b8-424d-48bf-80c1-15d4d1d7bf35">five years</ix:nonNumeric> for computer equipment and software, and the lesser of the remaining life of the building lease, if any, or <ix:nonNumeric contextRef="ibc4af8f693284287a7966314732d1b9d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTEyOTQ_5b611164-61f3-4752-a755-182defb9f863">seven years</ix:nonNumeric> for furniture and other equipment. <ix:nonNumeric contextRef="iaf37da992005431c9ad91f291589bab4_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NDY_8c4d7734-5e37-4114-ab74-b85e1c86a9e8">Leasehold improvements are depreciated over the term of the related lease.</ix:nonNumeric> Certain costs related to the development or purchase of internal-use software are capitalized and amortized over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea">three</span> to <ix:nonNumeric contextRef="if071474e71e54a499f11bedc93cff54d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1Njg_2a0889dc-fc50-4894-bcce-737ab7b8355c">ten years</ix:nonNumeric>.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0MzE_847a8cd8-a719-43f2-9ffb-35dbac700358" continuedAt="i0290c22acfeb4fb0b7d7e9b84303a46b" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable assumptions and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry&#8217;s weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ibe8d65cc786b4537b6be9b3af98e850e" continuedAt="id8b284f7d521460689aa280096dcf6c7"><ix:continuation id="i0290c22acfeb4fb0b7d7e9b84303a46b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies in our industry and are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;); and book value of invested capital. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset&#8217;s fair value. This determination consists of a one-step test comparing the fair value of a reporting unit, including goodwill, to its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit&#8217;s carrying amount over its fair value. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.</span></div></ix:continuation><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0MjU_ced987e5-a89f-48ab-bad4-7a8e3fe66cea" continuedAt="i13a2243baa3b487390e0dcfbd19f4a68" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December&#160;31, 2022, we believe there were no material concentrations of credit risk with any individual counterparty.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i13a2243baa3b487390e0dcfbd19f4a68">We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNTY_a62ba5c5-ef53-436c-94f3-9c04209b19d3" continuedAt="ie4399a279bdb4049ba3a57dd8e711d0f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="id8b284f7d521460689aa280096dcf6c7" continuedAt="id949a6b2e0ed4a5f9918e50f4adebb11"><ix:continuation id="ie4399a279bdb4049ba3a57dd8e711d0f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NjU_62f2d572-bed7-4be5-a10a-860cb5f8b25e">We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan&#8217;s cash flows to determine the plan&#8217;s obligations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.</span></div></ix:continuation><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMzc_f65edb34-1c4f-4fec-bd32-d83eae5470fa" continuedAt="i658dfb0926d14a56bd6eb9d3db32778f" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims Payable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1)&#160;an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2)&#160;claims reported to us and processed through our systems but not yet paid.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into &#8220;claim triangles,&#8221; which compare claim incurred dates to the dates of claim payments. This information is analyzed to create &#8220;completion factors&#8221; that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels (&#8220;trend factors&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December&#160;31, 2022 or 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="id949a6b2e0ed4a5f9918e50f4adebb11" continuedAt="i8b20d409d07a4d639042834419bcf98f"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i658dfb0926d14a56bd6eb9d3db32778f">Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:OtherPolicyholderLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NTY_3f347834-1d15-401f-9582-68743e34bec7" continuedAt="id72a92fa675e44289bac61f57d1ea0e8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Policyholder Liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (&#8220;MLR&#8221;), the relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.</span></ix:nonNumeric></div><ix:continuation id="id72a92fa675e44289bac61f57d1ea0e8"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively the &#8220;ACA&#8221;). If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with regulations issued by the Department of Health and Human Services (&#8220;HHS&#8221;). Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.</span></div></ix:continuation><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:FuturePolicyBenefitsLiabilityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzODY_21a94808-ab17-421e-8e0d-7b621a0d8077" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Future Policy Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNTI_27302c81-a3fb-4a18-ab9d-1e05f56a0af6" continuedAt="i686fbafe39df4d34927bc7563850dd97" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Premiums for risk-based contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other regulatory requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final amounts paid, the adjustments are included in earnings in the period of final settlement. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative fees and other revenue include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i8b20d409d07a4d639042834419bcf98f" continuedAt="i7a388a111fa74a60b40b7b30ae61d858"><ix:continuation id="i686fbafe39df4d34927bc7563850dd97"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">groups an administrative fee, which is based on the number of members in a group and the group&#8217;s claim experience. In addition, administrative fees and other revenue include amounts received for the administration of Medicare, certain other government programs, and administrative services arrangements of our Carelon (Diversified Business Group) subsidiaries, now known as Carelon. Generally, these fee-based arrangements include services which constitute a single suite of services provided and for which consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with premiums, these fee-based arrangements may include terms with retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable consideration within the transaction price. As such, these fee-based arrangements contain a single performance obligation that constitutes a series, and revenue is recognized over time as the services are performed. All benefit payments under these programs are excluded from benefit expense. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of whether services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be recognized requires significant judgment in the determination of the level of achievement of performance incentives, service level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue includes revenue for services performed by our CarelonRx PBM for unaffiliated PBM customers. Unaffiliated PBM customers include our fee-based groups that have contracted with CarelonRx for PBM services and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in consolidation. Product revenue for PBM services is recognized using the gross method at the negotiated contract price when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer. CarelonRx determined it is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary management); its control over establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the pricing for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling the promise to provide PBM services. Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments made by or on behalf of the customer, and administrative fees. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in exchange for the products or services provided.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at December&#160;31, 2022. Revenue recognized in 2022 and 2021 from performance obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNjI_b1ac9607-32d4-4679-b48c-cfdc5cd1a7ad" continuedAt="id933f91ae3a2404690e7a2a0d11e3e0f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id933f91ae3a2404690e7a2a0d11e3e0f">CarelonRx&#8217;s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated PBM customers (net of rebates or discounts). Cost of products sold includes per-claim administrative fees for prescription fulfillment by its vendor and certain CarelonRx direct costs related to sales and administration of customer contracts.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNDg_68fa1cf4-e7b6-490a-a710-0ea621f83208" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is <ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzE4NTg_3fd2d687-75be-4a84-b802-0d50987ce380">90</ix:nonFraction>% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in our consolidated statements of income based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the consolidated statements of income.</span></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMjg_46920f17-8da4-47ac-964c-080d8f78f270" continuedAt="i839773ad90334790ba8e2cec213bbaf3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i7a388a111fa74a60b40b7b30ae61d858" continuedAt="i772efb9f105a45c2a9bd5c4d4993d831"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i839773ad90334790ba8e2cec213bbaf3">agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Group risk-based customers with a smaller employee base. Products for Group risk-based customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual and Group markets, we offer products through state or federally facilitated marketplaces, or Public Exchanges, and off-exchange products.&#160;The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate image are expensed when first aired. Total advertising and marketing expense was $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:MarketingAndAdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzM1MTM_71d23c9e-cde1-4bf6-9904-be3ffdd22383">511</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:MarketingAndAdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzM1MTc_08ca19cc-25a6-4495-8044-1a30875f8431">588</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:MarketingAndAdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzM1MjQ_d729d227-9d51-49c0-90ae-24eac1d13fc7">558</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:HealthInsuranceProviderFeePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzOTg_32da1ea7-a81a-47ba-8047-c345024436c1" continuedAt="id7b51c83859d4572baa7885241aceb65" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Insurance Provider Fee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7b51c83859d4572baa7885241aceb65"> The ACA imposed an annual Health Insurance Provider Fee (&#8220;HIP Fee&#8221;) on health insurers that wrote certain types of health insurance on U.S. risks, which was permanently repealed effective January 1, 2021. The HIP Fee was non-deductible for federal income tax purposes.&#160;Our affected products were priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when it was in effect. The HIP Fee was $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:PatientProtectionAffordableCareActHealthInsuranceProviderFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzQxMTA_042b5f76-0abf-42f4-bd35-efee7e6b7d47">15,523</ix:nonFraction> for 2020 and was permanently eliminated beginning in 2021. For the year ended December 31, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzQyMjQ_7d883d73-8de8-4b29-b68d-74548d583b73">1,570</ix:nonFraction> as selling, general and administrative expense related to the HIP Fee.</ix:continuation> </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0Njg_e8a4dd24-8cf8-4db1-a6af-c83c70d0aa0e" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We recognize operating right-of-use (&#8220;ROU&#8221;) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized initial direct costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in selling, general and administrative expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of the ROU asset to its estimated undiscounted future cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is performed. An impairment loss is recorded for the difference of the ROU asset&#8217;s carrying value that exceeds its estimated discounted cash flows. During the years ended December 31, 2022, 2021 and 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODYxMzE2_95f09d79-8ff5-4748-854b-101bc6881966">34</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzY2NTg_feef23b7-2634-4715-a958-424c6945a92e">136</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzY2NjU_bfd5964d-b415-4c30-b8a5-adf089467c13">258</ix:nonFraction>, respectively, for impairment and abandonment of ROU assets. See Note 18, &#8220;Leases&#8221; for additional information about the ROU asset impairment and abandonment charges.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0MTk_b3d4f48a-b62a-43d9-9de1-3f34144b16f3" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and the number of shares assumed purchased represents the dilutive shares.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0ODE_0eb1a914-1400-439a-ad4c-d9567accd8cb" continuedAt="i2a3fc823f5f047c69362bf80f5550c61" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FASB issued Accounting Standards Update No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-01&#8221;). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of the </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i772efb9f105a45c2a9bd5c4d4993d831"><ix:continuation id="i2a3fc823f5f047c69362bf80f5550c61"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued Accounting Standards Update No. 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables&#8212;Nonrefundable Fees and Other Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-08&#8221;). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-06&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODcwNDg5_c9cc18c5-f288-489a-8d34-9d323f97f250">31</ix:nonFraction>, a decrease to our deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" sign="-" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODcwNDk3_d99a1e84-f3c4-4c63-8b79-564ca477ef90">8</ix:nonFraction>, and a corresponding cumulative-effect reduction to our opening retained earnings of $<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODcwNTA0_825540fa-6d43-43b7-855c-78be6212f72f">23</ix:nonFraction>, eliminating the bifurcation of the embedded conversion option; these amounts were not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services&#8212;Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-11&#8221;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services&#8212;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2018-12&#8221;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, with the amendments required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company&#8217;s reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#8217;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. The Company adopted the new standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the earliest period presented, January 1, 2021. The adoption did not have a material impact on our consolidated financial position, results of operations, cash flows, or related disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There were no other new accounting pronouncements that were issued or became effective during the year ended December&#160;31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMjgzNA_39da7a88-6598-411c-8246-ece9a4db7fe8" continuedAt="iabe158fda0204c268ba4e71f0f269c3d" escape="true">Business Acquisitions</ix:nonNumeric></span></div><ix:continuation id="iabe158fda0204c268ba4e71f0f269c3d" continuedAt="i044ee918aa7543ae9ceb3301c54ec9a3"><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completed Acquisitions</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we completed business combinations for total cash consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzA5Mw_9765111b-2c23-40f4-aceb-0522e046f739">752</ix:nonFraction>. These acquisitions included Integra MLTC, Inc. (&#8220;Integra&#8221;), acquired May 2022, which is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase prices for all business combinations were allocated to the tangible and intangible net assets acquired based on management&#8217;s initial estimates of their fair values, of which $<ix:nonFraction unitRef="usd" contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzA4NQ_3f3ba86e-7eec-4f49-a220-3ad916aa45b7">89</ix:nonFraction> was allocated to finite-lived intangible assets, $<ix:nonFraction unitRef="usd" contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231" decimals="-6" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzEwMg_4374b5dc-eccb-4382-8ae9-13c6a7cb413e">250</ix:nonFraction> to indefinite-lived intangible assets, and $<ix:nonFraction unitRef="usd" contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzExMQ_f948a009-37c4-480c-b093-078beca7999a">145</ix:nonFraction> to goodwill. The intangible assets and goodwill acquired were assigned to our Government Business reportable segment. The majority of goodwill is deductible for income tax purposes. As of December&#160;31, 2022, the initial accounting for the acquisitions completed in 2022 had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we completed business combinations for total cash consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTg0_bdf5565b-dfb4-4c76-a9d4-7e241e0576aa">4,021</ix:nonFraction>. These acquisitions included myNEXUS, Inc. (&#8220;myNEXUS&#8221;), acquired April 2021, a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (&#8220;MMM&#8221;), acquired June 2021, including its Medicare Advantage plan, Medicaid plan, and other affiliated companies. The purchase prices for all business combinations were allocated to the tangible and intangible net assets acquired based on management&#8217;s final estimates of their fair values, of which $<ix:nonFraction unitRef="usd" contextRef="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNTc5_28b7cb27-9541-405c-b55c-a4173a303d26">1,577</ix:nonFraction> was allocated to finite-lived intangible assets, $<ix:nonFraction unitRef="usd" contextRef="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231" decimals="-6" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNjM2_1f4e7f4c-5398-4748-bb79-d626bde9fc3a">20</ix:nonFraction> to indefinite-lived intangible assets, and $<ix:nonFraction unitRef="usd" contextRef="i842be0164ef642f19cf764709db72fe4_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzEyMA_054bda13-ffe9-42d5-b5ee-9f49c75fe0bf">2,531</ix:nonFraction> to goodwill, including measurement period adjustments of $<ix:nonFraction unitRef="usd" contextRef="i83026d2c318c405b900c3c41a9e37cc7_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzEzMQ_1e790c56-9feb-4841-9a1e-01754ccecd97">10</ix:nonFraction> during the year ended December 31, 2022. Of these amounts, $<ix:nonFraction unitRef="usd" contextRef="i4c555ed090374b7b9aa02f28d95d625c_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNTQ5NzU1ODM5NTg5_f8d78f6f-054a-44f5-a1b9-9b449e16e125">795</ix:nonFraction> was allocated to our Other reportable segment and $<ix:nonFraction unitRef="usd" contextRef="i4de08eefaeef475eacfe40d3fec4420a_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNTQ5NzU1ODM5NTk4_b770c873-afb8-468a-a5af-60878946bdde">3,333</ix:nonFraction> to our Government Business reportable segment.The majority of goodwill is not deductible for income tax purposes.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMjgzNg_50d4f42a-c721-4954-b8b7-c54f1933319b" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired tangible assets (liabilities) at the acquisition date were:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMS0xLTEtMS03ODA0OQ_d3b7ee52-d6f3-405d-921f-6f6c984a220c">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMS0zLTEtMS03ODA0OQ_773c0aac-872b-472e-9667-44e6d1f75758">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMi0xLTEtMS03ODA0OQ_a5b6c899-7059-4e61-98a9-cbbae682c9e5">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMi0zLTEtMS03ODA0OQ_d4a61a90-6470-49d0-8d91-a9af3492104b">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMy0xLTEtMS03ODA0OQ_bd8d14bc-6976-4bfe-9dcf-9c187ba5a512">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMy0zLTEtMS03ODA0OQ_1b388d59-4183-4f6e-a680-0196a80905b2">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical claims and other policyholder liabilities payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNC0xLTEtMS03ODA0OQ_8da8d760-48c1-47d6-a613-01c609358383">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNC0zLTEtMS03ODA0OQ_065139e2-a221-4b89-bf5f-2133547cb2ab">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNS0xLTEtMS03ODA0OQ_99940928-fbac-47ed-bcfa-dbee60f3a90b">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNS0zLTEtMS03ODA0OQ_a66c6423-1f51-4d99-b4da-c0b72f4916bf">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNi0xLTEtMS03ODA0OQ_f687bba4-3c85-4484-a286-8bc2f5094419">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNi0zLTEtMS03ODA0OQ_daa18c08-4ce3-431b-ae59-55efb45bbc9f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0xLTEtMS05OTczMw_80b6990b-e65a-49bc-a395-713c2ec2f6ac">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0zLTEtMS05OTczNQ_f0b911ed-0265-4bc1-bc0b-546cf4aa8043">556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net tangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0xLTEtMS03ODA0OQ_32b5b324-19c1-4329-9657-2986e06a0e1f">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0zLTEtMS03ODA0OQ_e9ebe1a9-fc69-400f-b093-d2de7d5d0b6d">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent and tax liabilities, are finalized. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i044ee918aa7543ae9ceb3301c54ec9a3"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMjgzNw_9554e889-698a-45fc-9cb9-eeaac9e257ac" escape="true"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74006674df2c4b7198d31e2b3985d5af_D20220101-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi0xLTEtMS03ODA0OQ_672cea0e-2125-48a7-a918-e48ca52dfc47">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74006674df2c4b7198d31e2b3985d5af_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi0zLTEtMS03ODA0OQ_9076fe2a-c609-4232-ac38-26002367b709">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652f2991b53941a1ac659bcb35e66d54_D20210101-20211231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi01LTEtMS03ODA0OQ_8f52f839-0d98-4367-9d56-1561a04856d6">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i652f2991b53941a1ac659bcb35e66d54_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi03LTEtMS03ODA0OQ_ce6024a0-80ee-42b4-a8fd-4892b47d1d09">13</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1938794b003c4dd68259f49f8b875e81_D20220101-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy0xLTEtMS03ODA0OQ_62cc4ada-98d7-4831-b211-dcfea3637f9f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1938794b003c4dd68259f49f8b875e81_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy0zLTEtMS03ODA0OQ_7fa6143c-01a5-410d-a715-6f3605b4a7e2">15</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66ac29085ee41519cfd744c0ac8e03c_D20210101-20211231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy01LTEtMS03ODA0OQ_abf41f21-3404-49aa-80ff-72bdb31f08f1">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia66ac29085ee41519cfd744c0ac8e03c_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy03LTEtMS03ODA0OQ_82f782ad-89f4-4382-a6fa-68c1ccad8bc6">14</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2bdd480b33d48f7a527eb0cb95e6c5f_D20220101-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC0xLTEtMS03ODA0OQ_7bcdecd3-ccef-40b4-919b-eb686d634d71">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2bdd480b33d48f7a527eb0cb95e6c5f_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC0zLTEtMS03ODA0OQ_aaefd938-5b5a-4f8a-987a-38dafeeed359">0.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7079cee400b941a48ccb1dbed22219ae_D20210101-20211231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC01LTEtMS03ODA0OQ_8533ea0c-ece2-4ca2-a89f-9a2c758aeb8c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7079cee400b941a48ccb1dbed22219ae_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC03LTEtMS03ODA0OQ_26e7259e-9aad-4538-8244-8dee741af40d">13</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11008b88eee44f57a4919c3d0effdc63_D20220101-20221231" decimals="-6" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNS0xLTEtMS03ODA0OQ_663af870-4ffb-405a-b105-a2fadf0e3334">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92993e9e6dc54ce8b4394a223f436cb2_D20210101-20211231" decimals="-6" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNS01LTEtMS03ODA0OQ_ae3d2816-fed2-440b-be38-f717cf99349c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:TotalIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNi0xLTEtMS03ODA0OQ_1db971d7-6a8b-4be9-af0e-40d57f1ed518">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:TotalIntangibleAssetsAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNi01LTEtMS03ODA0OQ_49ee51b3-78c9-4b7a-9cc9-df1389e5622b">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations and financial condition of acquired entities have been included in our consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through December&#160;31, 2022, the impact of the acquired entities on revenue and net earnings was not material. Unaudited pro forma revenues for the years ended December&#160;31, 2022 and 2021 as if the acquisitions had occurred on January 1, 2021 were immaterial for both periods. The pro forma effects of the acquisitions on net earnings were immaterial for both years.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Acquisitions</span></div><div style="margin-bottom:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Louisiana Health Service &amp; Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service &amp; Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.</span></div><div style="margin-bottom:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioPlus Parent, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, we announced our entrance into an agreement with CarepathRx Aggregator, LLC to acquire its specialty pharmacy division, which includes BioPlus Parent, LLC (&#8220;BioPlus&#8221;) and subsidiaries. BioPlus is one of the largest independent specialty pharmacy organizations in the United States and seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition was completed on February 15, 2023, and initial purchase accounting for the acquisition has not been finalized.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_100"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE5Mjk_2c3f1687-270d-420e-b057-99e463e2951d" continuedAt="ia8caec564d864eb889abf5c6a14eb59a" escape="true">Business Optimization Initiatives</ix:nonNumeric></span></div><ix:continuation id="ia8caec564d864eb889abf5c6a14eb59a" continuedAt="i94d4d61e9c9d41579440de740891a7a8"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our properties are adequate and suitable for our business as presently conducted; however, we are continuing to evaluate our real estate strategy as it relates to the changing needs of a more hybrid remote workforce. As a result, during 2022, we identified additional reductions of office space and recorded a net charge of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_afeade16-dee4-4795-8b19-99581c96cde5"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_36214dfe-378d-4d69-9ac2-8ebb491a71c0">39</ix:nonFraction></span> in selling, general and administrative expenses. This charge includes $<ix:nonFraction unitRef="usd" contextRef="i5647eb933f9e401e971742cbdc4d882d_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIyMQ_c70d9d58-630e-4897-a8cb-ffc7357df7db">34</ix:nonFraction> for impairment and abandonment of operating-lease related ROU assets and $<ix:nonFraction unitRef="usd" contextRef="i76840fe11a4246adb33e2fc35f9dce5c_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIxNA_8c6c25a8-6921-4eeb-914a-3ce5639640ef">7</ix:nonFraction> for impairment and abandonment of property and equipment. In addition, we released $<ix:nonFraction unitRef="usd" contextRef="i720085721492466da1460ae790fd044c_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgyMDM5NA_b79faf83-79ed-4808-9a26-e08036dc1a46">2</ix:nonFraction> of employee termination costs, as reflected in the table below. The net charges recognized in the Commercial &amp; Specialty Business, Government Business, CarelonRx and Other segments in 2022, were $<ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE3Ng_4066d32b-f491-4e77-ae85-9b9997d9670b">20</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE4NA_816d1ee7-da66-4515-9f52-1ffa7deff883">16</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE5Mg_02d410c2-38bd-425a-a879-15dbaaaec3c2">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE5OQ_9680a94c-07f1-4121-aa5d-6a8de299c3e8">3</ix:nonFraction>, respectively. See Note 20, &#8220;Segment Information&#8221; for a discussion of our segments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we identified reductions of office space and recorded a charge of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_346f76ea-dead-4d60-b08d-54ad913c9f6f"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_48e3b13c-0396-4ca8-8e45-ff99d4b11dfc">202</ix:nonFraction></span> in selling, general and administrative expenses. This charge included $<ix:nonFraction unitRef="usd" contextRef="i8b56ea1be96f4c70a8c1e7c9144fc68a_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzUwNg_8aa9c3bd-d958-4a42-ab22-4cabbc6ce944">136</ix:nonFraction> for impairment and abandonment of operating-lease related ROU assets and $<ix:nonFraction unitRef="usd" contextRef="ic66c129efd394897bd946da50f16dfa9_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU4Mg_24c8ead0-675d-4454-a6be-b63caa7db3f8">66</ix:nonFraction> for impairment and abandonment of property and equipment. The charges recognized in the Commercial &amp; Specialty Business, Government Business, CarelonRx and Other segments in 2021, were $<ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc3MA_893d033d-a5dc-4efb-a763-bba48deb1ffd">108</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc3NA_1d85d814-ee6a-4356-af47-ed4f24c9d9b8">60</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc3OA_53b2a90c-1f87-4255-9f15-873265c4e58a">1</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc4NQ_8653aeb0-8668-4136-9b74-d606b351bb37">33</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i94d4d61e9c9d41579440de740891a7a8"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, our management introduced enterprise-wide initiatives to optimize our business and, as a result, we recorded a charge of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_72ace3e9-597b-4518-a22f-101187f15e20"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_b990f510-0660-4560-a656-97599f031bde">653</ix:nonFraction></span> in selling, general and administrative expenses. This charge included $<ix:nonFraction unitRef="usd" contextRef="i5ff881db619a457a91ac84f1aefaed9c_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzEwNTE_1abc581e-64dc-48aa-9579-8cf08507b938">258</ix:nonFraction> for impairment and abandonment of operating-lease related ROU assets, $<ix:nonFraction unitRef="usd" contextRef="ia2f02a690e784ac385d21cd667d6d637_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzExMjQ_6e9bc11c-2fdb-4f2b-b785-c22d1eee207c">198</ix:nonFraction> for impairment and abandonment of property and equipment and $<ix:nonFraction unitRef="usd" contextRef="ie891e0f02de14c5b99b6e50667fa8c9a_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzExODg_fa86f02e-d9ac-47ad-af49-d13f2b9cfcab">197</ix:nonFraction> for future payments for employee termination costs in connection with the repositioning and reskilling of our workforce. The charges recognized in the Commercial &amp; Specialty Business, Government Business, CarelonRx and Other segments in 2020, were $<ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0Mzk_b9000c34-dd5b-436c-a32f-e9d4cbde4df3">311</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0NDM_058b0a0b-d8d0-4162-9897-20f55f9b87a3">205</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i77d0aff55fa54fd2a9a2a30c2e6c6a2d_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0NDc_c652b565-7135-40bc-bb4d-8ffdbf821030">4</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0NTQ_9115bdde-3942-4055-a9fa-7faefbca0e04">133</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE5MzA_5453926a-ba89-4369-b1e9-63d9e1232f97" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity for the year ended December 31, 2022 and ending balance at December&#160;31, 2022, related to the liability for employee termination costs previously incurred in 2020, is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Business Optimization Initiatives</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities for employee termination costs at January 1, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2229f739c29e4879809a6429e83712f6_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtMS0xLTEtNzgwNDk_ec0ec6c4-7a89-4d3d-a773-06addd6e3466">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4fcad706e1b4867b404702dd922e926_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtMy0xLTEtNzgwNDk_085a0acc-ebb2-4634-9445-a361f5e9b7e1">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99433158fc54e1e93f623489413f8de_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtNS0xLTEtNzgwNDk_6e9d7919-af63-4e03-9963-faf1543f0fa2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2df902d3b34cf4a36058a667c1980e_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtNy0xLTEtNzgwNDk_f716c40f-42ca-4b68-aea3-7eb397c8511a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575634935f9d42e19be485bc9862c0f3_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtOS0xLTEtNzgwNDk_599d0de7-1c5b-4ef4-90ae-175c30e51252">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9f081e73a6c44fa88baccf8ed778d26_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtMS0xLTEtNzgwNDk_5cdab9ad-35d3-46c7-9015-30816b1a99a3">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ec68f2e8874c1095494d4e367728a8_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtMy0xLTEtNzgwNDk_fa9196be-1147-4fbd-ab1d-10b580cc5572">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80df43e3b8244694a103a6571a73884c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtNS0xLTEtNzgwNDk_25254948-294c-4d4a-a848-7ef01b419990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba1560cbbed45a88ea28c07d58f145d_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtNy0xLTEtNzgwNDk_77d6a448-56c3-4e7f-aed7-b5e4217a136f">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i720085721492466da1460ae790fd044c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtOS0xLTEtNzgwNDk_0b240fd5-6978-481c-ae26-c86195d9ca16">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Releases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f081e73a6c44fa88baccf8ed778d26_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtMS0xLTEtNzgwNDk_41915665-4443-4e7e-aef2-f4efba7372f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ec68f2e8874c1095494d4e367728a8_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtMy0xLTEtNzgwNDk_3ae11b11-8d6d-4cd6-b3b7-734cca103f4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80df43e3b8244694a103a6571a73884c_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtNS0xLTEtNzgwNDk_5adf6928-cedd-4892-88ec-6dd0463a0a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba1560cbbed45a88ea28c07d58f145d_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtNy0xLTEtNzgwNDk_0ada9f9e-c93c-4629-b56d-11a14b204b14">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i720085721492466da1460ae790fd044c_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtOS0xLTEtNzgwNDk_4f967111-c716-4cf5-a3f8-88b55340c2d5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities for employee termination costs ending balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89cfda63370a45baa262eae4cf193a82_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtMS0xLTEtNzgwNDk_ccbc9398-8c10-432d-abd1-33a22cf7fe97">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2fac999a95e4a5cb79ad594faeeb86b_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtMy0xLTEtNzgwNDk_56a81db8-aead-45ce-993f-031142d30a14">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7da5fca7f08493dbf6109531d652055_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtNS0xLTEtNzgwNDk_2ffcc135-20a4-40d0-ba3c-9636f6add8a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e206452b4b4525ba8295deb406a4ff_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtNy0xLTEtNzgwNDk_c6a1cfd9-d6f4-4f1f-b43b-ffa033afa1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e00c7e161a54ca296d8ca502242628b_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtOS0xLTEtNzgwNDk_59de7e1b-4372-46e7-bc81-6f793766d26b">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MjU_d5733a59-6f5c-4ef0-b794-ea7ecf4cc91e" continuedAt="ib7917672dc58478788cc49cf6425c833" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="ib7917672dc58478788cc49cf6425c833" continuedAt="i2c5dfd535c7542fe8f85952ad50b065b"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year residential and commercial mortgage-backed securities have been reclassified throughout this Note 5 and Note 7, &#8220;Fair Value&#8221; to conform to the current year presentation.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgzNTUxOA_a156c3a3-bf5f-44c6-be65-2c5a971cde5e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at December&#160;31, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost&#160;or<br/>Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance For Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtMS0xLTEtNzgwNDk_11b5e721-a85d-41c4-b101-7b97f5147a62">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtMy0xLTEtNzgwNDk_8ad8d8c7-5f3c-4d39-be53-384b6d392bd7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtNS0xLTEtNzgwNDk_edec9fcd-cf5a-4aa4-8806-916d8ecd1af6">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtNy0xLTEtNzgwNDk_a4839c1a-e56c-48f8-9669-89e8fb34354f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtOS0xLTEtNzgwNDk_e034ac9c-5563-4ae2-993b-da26ffa70268">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtMS0xLTEtNzgwNDk_46ffca35-378e-41d5-8190-68a6d3df3d12">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtMy0xLTEtNzgwNDk_b2ee3385-6f0d-4d1c-897a-c85235bdff3a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtNS0xLTEtNzgwNDk_64d56c19-4ceb-4ddf-8a7e-667f300c0cc3">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtNy0xLTEtNzgwNDk_cab3c5b6-4d9d-49d6-a787-4912d9bc8eea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtOS0xLTEtNzgwNDk_d130b788-fa18-4bcc-bd9c-e6fad6da155a">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctMS0xLTEtNzgwNDk_b589254a-26dd-4ad7-befa-77cfb19cb2ee">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctMy0xLTEtNzgwNDk_ae14f663-d365-4270-9566-302418a2da5c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctNS0xLTEtNzgwNDk_5c5b298d-8297-47c5-8a1a-972e5c5f15e2">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctNy0xLTEtNzgwNDk_25250c81-03b5-4def-8c9c-2f690cb15875">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctOS0xLTEtNzgwNDk_4137fefd-1658-4762-a06d-e92ea0103289">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtMS0xLTEtNzgwNDk_70d833d7-66b6-47d8-a60a-c8639eade8a3">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtMy0xLTEtNzgwNDk_c10b6368-2214-4081-8470-ddbb20e11299">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtNS0xLTEtNzgwNDk_e1e8ed19-79c4-4f20-994c-48d89a10a8e8">265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtNy0xLTEtNzgwNDk_338d0554-7421-46f4-a91a-74ad0f8a23c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtOS0xLTEtNzgwNDk_116665f8-6228-46b2-aca2-6fe9978a4ea9">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktMS0xLTEtNzgwNDk_d514e784-0d13-4349-a97d-08752a541a0a">13,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktMy0xLTEtNzgwNDk_c41fac12-0f1f-49e7-bbe1-891ad06b8036">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktNS0xLTEtNzgwNDk_7b29d76b-f17d-4e10-bf94-74bc9e658528">1,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktNy0xLTEtNzgwNDk_09ecf4de-5b36-4de2-bebb-85f843ea44c7">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktOS0xLTEtNzgwNDk_8551a236-ac8a-4978-b2c9-79ed1b2b414e">12,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTEtMS0xLTc4MDQ5_efb34cdc-0ead-443e-a6f4-9f4c14ca32aa">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTMtMS0xLTc4MDQ5_6ceecae4-5153-48ce-be6b-40568ac8526d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTUtMS0xLTc4MDQ5_63a8d4ba-cd3e-467c-8f99-1d9d5f3d9f2b">324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTctMS0xLTc4MDQ5_7fe069c6-c06d-4085-aecf-449110848e20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTktMS0xLTc4MDQ5_7b7be651-e03b-4198-93d6-4cac4f19f325">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTEtMS0xLTc4MDQ5_393e8e3e-2d16-4e28-9978-0eefaad070e7">2,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTMtMS0xLTc4MDQ5_07ce051f-7299-46c8-865b-7150fcd000d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTUtMS0xLTc4MDQ5_fde2d65f-ba1d-413a-a70f-2b6f1cfc0a9c">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTctMS0xLTc4MDQ5_0cc77240-0e42-4975-ae44-dcbc33e51a65">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTktMS0xLTc4MDQ5_ad135f9c-b92d-4139-a4e1-3b87e85346d0">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTEtMS0xLTc4MDQ5_1e0e0dd5-70aa-4ce3-94c2-663ea21fb961">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTMtMS0xLTc4MDQ5_7539ee83-7722-4ffe-878d-f563d5c87565">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTUtMS0xLTc4MDQ5_ada17e19-f1d7-44d2-8d8a-e55d7cb3d665">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTctMS0xLTc4MDQ5_83584c39-4783-46bc-b8fa-bdd1b044a0ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTktMS0xLTc4MDQ5_d4afb735-7d06-455d-b6e2-2f551110c558">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTEtMS0xLTc4MDQ5_6452eca1-a897-4da9-81ca-8aa905b17fdd">29,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTMtMS0xLTc4MDQ5_9a5a67a7-954a-4c0a-97ae-57fd54516cd3">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTUtMS0xLTc4MDQ5_e548f982-9ff5-48c9-8377-0cc800b12706">2,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTctMS0xLTc4MDQ5_3ab155da-05d9-4acd-b4fd-bef64dd9b8ca">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTktMS0xLTc4MDQ5_bcedd1f4-aab6-4986-9c14-8d71ada0aab2">26,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTEtMS0xLTc4MDQ5_ab58ef43-c389-4922-afbc-faf01fe9e44b">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTMtMS0xLTc4MDQ5_e451a546-c66f-413f-8ce4-c4390f64ee0c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTUtMS0xLTc4MDQ5_683e0714-a9c5-499d-a7e6-9ae0f92f5cfa">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTctMS0xLTc4MDQ5_ae99eb3a-3592-4bde-a5a0-8d2c5280551d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTktMS0xLTc4MDQ5_232e3cea-91e3-4fe1-8ebb-1fcf36a978ce">1,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTEtMS0xLTc4MDQ5_9c81c19d-052d-4248-926a-ad036fa4b079">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTMtMS0xLTc4MDQ5_be0c9567-4ff6-4471-b21f-32629682d81a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTUtMS0xLTc4MDQ5_6a109d75-481c-42b7-bd9b-2ec5b0bd96f1">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTctMS0xLTc4MDQ5_cc9651bf-4c26-47bf-b0f2-a08f145fa78b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTktMS0xLTc4MDQ5_b831fd80-0430-4b69-af1e-65ab8f04fcc1">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTEtMS0xLTc4MDQ5_937445ce-db80-40dd-93f2-292bc9202ce1">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTMtMS0xLTc4MDQ5_613681f5-14cc-4db0-bb94-7e900d284068">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTUtMS0xLTc4MDQ5_13cc28b4-3e2a-48c6-a654-7920137a0038">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTctMS0xLTc4MDQ5_bc3fc49a-e68b-4c72-81b6-d602407b6ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTktMS0xLTc4MDQ5_819d38d1-3c35-45ed-8301-fbc253c9474d">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTEtMS0xLTc4MDQ5_50328285-ff4d-4edd-bb7e-9a3ac46e4bcd">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTMtMS0xLTc4MDQ5_71532c22-5e01-4f54-acd7-072f5546b935">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTUtMS0xLTc4MDQ5_31f5a55d-fd52-407c-abb4-c99201973ad6">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTctMS0xLTc4MDQ5_6dca5ecd-d6af-4367-b25a-afc052325e32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTktMS0xLTc4MDQ5_7a116e21-299a-46fb-8041-2eab1f667483">5,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTEtMS0xLTc4MDQ5_3fd9b9f0-1d11-4514-aeda-057dbf5e0f98">12,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTMtMS0xLTc4MDQ5_89410243-5569-42a3-8b4f-a3cc53e0579a">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTUtMS0xLTc4MDQ5_5e00c3ba-c7c4-4b17-b8b5-0efa9f5c1ca4">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTctMS0xLTc4MDQ5_49f343b1-1b16-4348-af63-422900969d8a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTktMS0xLTc4MDQ5_b4e4b786-3fda-48e0-81ba-270e1168934b">12,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTEtMS0xLTc4MDQ5_1d1d7b51-a033-4318-b59c-827b1865efea">2,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTMtMS0xLTc4MDQ5_8e3ba4a4-d772-48b4-bb5a-2e331d1f4d26">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTUtMS0xLTc4MDQ5_5f7ee117-d89c-4ed0-bb51-c01fd0764dd3">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTctMS0xLTc4MDQ5_03fba7e7-0501-43e7-9c44-0cf61b06d2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTktMS0xLTc4MDQ5_28160cfb-f250-4d60-94e7-45b70e746692">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTEtMS0xLTc4MDQ5_9f52b021-bc4b-401a-a27b-53f85838ea06">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTMtMS0xLTc4MDQ5_1041a9d5-bccd-4dae-b16f-544636ccc85d">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTUtMS0xLTc4MDQ5_148ade27-a9f0-4525-9f97-5b42f40efc89">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTctMS0xLTc4MDQ5_d6a67862-a2a2-4883-b3d4-1077f7421ac0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTktMS0xLTc4MDQ5_3c491fc2-6e47-47ea-8d90-729c1e03f892">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTEtMS0xLTc4MDQ5_4855851c-402c-4e52-a4ad-03c82ac96a91">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTMtMS0xLTc4MDQ5_5d49ef7c-3626-4831-a306-d81b0c9815ac">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTUtMS0xLTc4MDQ5_f7a40d9b-ff6b-487d-89fe-387853639d36">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTctMS0xLTc4MDQ5_2ecbd30d-64ef-4944-bbce-808f16b2537a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTktMS0xLTc4MDQ5_57768984-6b96-426a-81b7-2189c49c5a22">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTEtMS0xLTc4MDQ5_57dd2e5b-3ec1-4e4d-83a3-868ec2c27f82">26,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTMtMS0xLTc4MDQ5_26b6c555-d135-4a0f-874c-38d8b3b89f2c">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTUtMS0xLTc4MDQ5_6af50763-b0ae-49fc-85bb-e4f37cfc20ed">182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTctMS0xLTc4MDQ5_b1973a3e-6942-4b4c-a9c5-a8e8bc34ed44">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTktMS0xLTc4MDQ5_54bdf385-dc04-4899-8fc7-689f03abaafd">26,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other asset-backed securities primarily consist of collateralized loan obligations and other debt securities.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i2c5dfd535c7542fe8f85952ad50b065b" continuedAt="i167547671add44c3ab8cd598195bf6ac"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4NDY_5ae0a6b9-77fc-43b0-9d2e-7dbf3f4d8dad" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at December&#160;31, 2022 and 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtMS0xLTEtNzgwNDk_e982cdec-16ac-4596-8551-151211b21d9f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtMy0xLTEtNzgwNDk_871ad8a6-1c98-4dab-8f9d-d16e3e9bb15a">701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtNS0xLTEtNzgwNDk_8e97876d-e943-4901-926f-89dc52430ca3">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtNy0xLTEtNzgwNDk_3f9836df-8f2d-4da1-ab24-9bfea7010f76">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtOS0xLTEtNzgwNDk_db2a85e0-490b-4179-a3a1-6b24cbbd2289">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtMTEtMS0xLTc4MDQ5_0e8c75fe-f727-4f32-b9e3-845095d198af">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtMS0xLTEtNzgwNDk_3afbeaef-1573-4b77-a66a-0b040a153621">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtMy0xLTEtNzgwNDk_adf82d20-596b-49f4-8798-64fc80621a85">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtNS0xLTEtNzgwNDk_495d95aa-c4b8-4bf9-a986-37740c404ca1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtNy0xLTEtNzgwNDk_19ae164e-702e-4b5b-b2e7-77f91311f6e2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtOS0xLTEtNzgwNDk_2dcc8f33-2111-4757-b2d7-571a9fd3cbea">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtMTEtMS0xLTc4MDQ5_7a35cc3a-03c3-49d0-a1f8-606807e29ce7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctMS0xLTEtNzgwNDk_125ec300-9615-4eff-8855-c219de59a7a0">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctMy0xLTEtNzgwNDk_78459834-928d-4511-a289-c279a2ff8edf">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctNS0xLTEtNzgwNDk_c85294be-7f4e-4e40-b7ea-f2333eec009a">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctNy0xLTEtNzgwNDk_178a8d6a-0a14-475f-9513-cc52700310d7">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctOS0xLTEtNzgwNDk_963dba4b-20be-4ed8-9858-bd2813735732">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctMTEtMS0xLTc4MDQ5_2761baac-3702-4a5a-b883-9e43ee64a589">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtMS0xLTEtNzgwNDk_d3f84c6b-e041-49fb-9ed7-5fa0b5b42571">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtMy0xLTEtNzgwNDk_979b2c17-919f-43a6-bf56-d2eff77dd5ca">2,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtNS0xLTEtNzgwNDk_41bed6b8-10dc-40dd-ba18-51b85ba2133d">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtNy0xLTEtNzgwNDk_d4cde205-8028-4d99-8767-7f811cc00822">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtOS0xLTEtNzgwNDk_8614754a-582f-4481-b529-33618b250a88">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtMTEtMS0xLTc4MDQ5_9aad8929-499f-4fed-b8e1-00596b01540d">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktMS0xLTEtNzgwNDk_53443202-5621-44d8-bb1a-4eeb66f3500d">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktMy0xLTEtNzgwNDk_4fb5a5ab-d1d9-4b28-a6b9-ac3481830e5d">7,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktNS0xLTEtNzgwNDk_32ecdace-3b8f-4c6e-9c14-95eb95955a4c">549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktNy0xLTEtNzgwNDk_a2e1e45a-6385-4a94-8fa9-7df79dd8cc51">2,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktOS0xLTEtNzgwNDk_5eab4a2e-fe75-4f16-aa6c-2ae2edc27f0c">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktMTEtMS0xLTc4MDQ5_3a384230-3348-409d-86d3-a203539366d3">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTEtMS0xLTc4MDQ5_990a72b1-9c94-4fdd-ac10-749e636bc73b">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTMtMS0xLTc4MDQ5_6d94b78d-adbf-4c5b-afe3-30dcb7b50448">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTUtMS0xLTc4MDQ5_4d6d8ec0-75e3-497a-a8f6-49472738feab">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTctMS0xLTc4MDQ5_51ef1bbc-17ab-4117-8e7d-24c9e6e3c52d">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTktMS0xLTc4MDQ5_a847c54b-1cd8-4d1e-b4bd-ed72903401a1">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTExLTEtMS03ODA0OQ_eee7ee1d-22a1-45bf-84fd-503db9e0725e">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTEtMS0xLTc4MDQ5_016dca63-fbad-463e-b064-f69de311e86c">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTMtMS0xLTc4MDQ5_8c47b957-ae5d-4670-89cf-556ee16f876c">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTUtMS0xLTc4MDQ5_85a7f1bd-10bb-459e-bb09-1c85ff580725">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTctMS0xLTc4MDQ5_6e25d0b7-5a8c-4a3f-95a3-3a436d2f45de">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTktMS0xLTc4MDQ5_1e9dfbf6-5f8e-42a4-8753-abdff06fac08">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTExLTEtMS03ODA0OQ_afaf1551-65e5-4414-b75d-2e1e0a8dfb36">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTEtMS0xLTc4MDQ5_5ef18efe-75f0-4be8-a547-c3d5527327a2">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTMtMS0xLTc4MDQ5_d25cce19-d02e-4ff4-a83a-29326629d140">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTUtMS0xLTc4MDQ5_532924d1-a7e9-4446-b5e3-2030c3c35198">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTctMS0xLTc4MDQ5_5d8d30a3-16fd-4e60-88e2-6da398e4a1ab">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTktMS0xLTc4MDQ5_093907ed-3363-48ff-b6f0-523e324de1c1">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTExLTEtMS03ODA0OQ_5822c76e-76d6-4d10-a32b-89fec24a8a46">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTEtMS0xLTc4MDQ5_9bd8ce84-e3a7-4a33-8b75-26e7f64f2484">7,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTMtMS0xLTc4MDQ5_c9a56624-8d99-4111-b85e-b5973bf2e775">16,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTUtMS0xLTc4MDQ5_08e825ec-8139-49c9-baa2-c3ad1f3ca280">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTctMS0xLTc4MDQ5_4c6abe72-cd4e-4a69-a905-26f88461c16c">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTktMS0xLTc4MDQ5_b9c07fef-84a7-4aee-a36c-3de09f8eaed2">7,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTExLTEtMS03ODA0OQ_d4be4361-be19-4bbb-ba68-f880036424b6">1,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTEtMS0xLTc4MDQ5_74e75642-13be-4a23-a20e-53f6895e0ba5">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTMtMS0xLTc4MDQ5_1395d019-5e6d-4d5b-af44-d4d2aa6db828">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTUtMS0xLTc4MDQ5_456e2087-7d45-4356-9cb0-882cae0346e4">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTctMS0xLTc4MDQ5_5301ad63-3941-4611-83b1-a49f0a4cbae5">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTktMS0xLTc4MDQ5_5f432deb-22bc-4c1a-8966-7216801120ef">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTExLTEtMS03ODA0OQ_cd514eba-5483-451b-b13d-8335d06887b8">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTEtMS0xLTc4MDQ5_c1f13780-5ce7-4090-8f48-6a72e1b6b089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTMtMS0xLTc4MDQ5_b070947e-889f-411f-801b-4133acf1e6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTUtMS0xLTc4MDQ5_31231e2d-3b48-47ab-8920-2eec06ea8865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTctMS0xLTc4MDQ5_b945f6f6-f267-41a5-b340-de5ae7aab782">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTktMS0xLTc4MDQ5_f1711b03-192c-4f63-ad7f-4403ada0c489">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTExLTEtMS03ODA0OQ_86e64f61-d4da-42b8-a73b-e405a1dd4e18">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTEtMS0xLTc4MDQ5_d2a037ac-7df0-4d4a-8370-627da3ab2e94">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTMtMS0xLTc4MDQ5_cba4bc7a-7b3c-48a4-bd46-cf436496e63d">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTUtMS0xLTc4MDQ5_72c22322-74d3-4acc-9b27-4740b677e15c">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTctMS0xLTc4MDQ5_09626408-d209-4b91-8f65-373821cde89e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTktMS0xLTc4MDQ5_1b4c42c0-1369-4a7c-af49-3d02cba1bcf8">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTExLTEtMS03ODA0OQ_85fbb465-1360-44cb-acc8-642eab448d63">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTEtMS0xLTc4MDQ5_8e9cd009-ee73-4e67-a1ae-efbc8f154201">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTMtMS0xLTc4MDQ5_7837a2e1-b989-4003-98b8-738ca99b99bc">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTUtMS0xLTc4MDQ5_cf236a7d-322b-42f8-9bbd-6ac5960bf4b4">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTctMS0xLTc4MDQ5_792f788f-af7b-4a21-b29c-1f18cdecd61f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTktMS0xLTc4MDQ5_510811cb-7de7-46fe-ab15-0888ab17d785">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTExLTEtMS03ODA0OQ_b898a04a-f264-4135-909e-52572f2c8280">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTEtMS0xLTc4MDQ5_0f1a4bbb-70b3-43f7-a3cb-9c381a8bc04d">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTMtMS0xLTc4MDQ5_ca7f3273-6dd5-43e6-bbac-4f5fda4411ba">3,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTUtMS0xLTc4MDQ5_5b52e24e-98e3-40f8-835c-3d9517a23cbb">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTctMS0xLTc4MDQ5_eb1f40c4-6317-437c-b879-d044d2a8a130">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTktMS0xLTc4MDQ5_e9b2d062-5761-4add-ab4f-ce0995825280">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTExLTEtMS03ODA0OQ_3dc41316-6d1f-4f5c-ac6a-fc2e1c0459b7">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTEtMS0xLTc4MDQ5_535ce517-dc56-4c94-af23-a09385eade75">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTMtMS0xLTc4MDQ5_03f0a400-e25b-4206-98e3-c77ae2fc8c48">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTUtMS0xLTc4MDQ5_f4cfabb9-481f-43d6-a937-386a9fcdf36f">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTctMS0xLTc4MDQ5_83220c43-9900-4332-a97f-23aad01a5fe5">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTktMS0xLTc4MDQ5_7a4b16d1-8686-4296-92f2-d1a579c8a24a">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTExLTEtMS03ODA0OQ_913b8e78-abf0-438d-81b0-9f70937bf553">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTEtMS0xLTc4MDQ5_6c8f43f6-22c9-433a-95db-221d5a6c4a31">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTMtMS0xLTc4MDQ5_52999c55-8c5c-4639-8267-41d22759b89e">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTUtMS0xLTc4MDQ5_7a5e83eb-0c53-4fd3-988c-c22931bd60bd">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTctMS0xLTc4MDQ5_ecc954b1-545e-44aa-a2bf-1cbda0e93505">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTktMS0xLTc4MDQ5_4868d335-9190-42ee-91b7-8aa350e4455e">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTExLTEtMS03ODA0OQ_8482b852-8eea-4897-bfde-5ed88246a2d3">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTEtMS0xLTc4MDQ5_451bb1a1-1980-4ce3-af75-3fefda6cd1ff">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTMtMS0xLTc4MDQ5_9aef7cb2-f949-492e-824a-83b09a0531f7">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTUtMS0xLTc4MDQ5_c186100f-d52d-4457-9755-20e285fa97e9">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTctMS0xLTc4MDQ5_94611fee-b31c-42bf-9ca0-ac728dba30b7">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTktMS0xLTc4MDQ5_c0e19547-6657-41d0-9b44-4493f46fb301">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTExLTEtMS03ODA0OQ_abbb4fd3-fff6-4207-bdd8-c66c4a71a5a6">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTEtMS0xLTc4MDQ5_a7a55208-cf8a-4501-9932-cc3237f4c75e">3,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTMtMS0xLTc4MDQ5_467d4612-9de9-46ec-a4d0-bfca3f0172fb">8,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTUtMS0xLTc4MDQ5_38c230ec-90e4-46df-bf2e-9f6e90b5dc2c">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="securities" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTctMS0xLTc4MDQ5_bed02e8e-06b3-4529-a570-12eab093a1fd">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTktMS0xLTc4MDQ5_f30d7ad8-7ce4-45b1-950a-dd0b7a527c01">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTExLTEtMS03ODA0OQ_ec24e79f-a5a2-4051-a32b-d1b76f3af8bd">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses on our securities shown in the table above have not been recognized into income because, as of December&#160;31, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for credit losses have been recorded in the amounts of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzEwOTk1MTE2MzkyMjc_2e92bf03-f1b5-4bc2-8d59-bfac7959e3f5">9</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzEwOTk1MTE2MzkyMjQ_d3e0726f-3298-45a1-8bc4-40f8362dd178">6</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-88-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i167547671add44c3ab8cd598195bf6ac" continuedAt="ibd584599875a452d9d9c086057b694d0"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MTI_95a4419e-16c1-464d-a39e-5c54123fca85" escape="true"><div style="margin-bottom:3pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at December&#160;31, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzEtMS0xLTEtNzgwNDk_8bc5e2fd-b36f-4df6-905d-667d81d3143a">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzEtMy0xLTEtNzgwNDk_d2ac01f1-0553-49e3-9282-36887c47c701">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzItMS0xLTEtNzgwNDk_f774e94f-8c6e-431a-bb11-75b53e0b736f">7,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzItMy0xLTEtNzgwNDk_b14dcea9-b3af-4033-bde9-1fa8e738cd60">7,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzMtMS0xLTEtNzgwNDk_013f2929-e588-4149-be86-ca46ea4f9dd1">9,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzMtMy0xLTEtNzgwNDk_33a337ca-4357-401e-ae7c-ac9fded3a9e1">8,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzQtMS0xLTEtNzgwNDk_62150b88-8cd3-4c2b-b74a-55ef3c2b30ff">6,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzQtMy0xLTEtNzgwNDk_24141422-723d-4951-9835-13ab6022696f">5,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzUtMS0xLTEtNzgwNDk_46cc3712-07d4-459e-90e9-0b3b693da125">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzUtMy0xLTEtNzgwNDk_cc550e9e-4fac-4103-8867-513e0e2f079d">4,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzYtMS0xLTEtNzgwNDk_aeba6dfd-a395-4fa5-bf2a-a38f96fa160b">29,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzYtMy0xLTEtNzgwNDk_0e10a72e-a48b-4b91-93f2-6eb22bfe0c42">26,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:InvestmentsinequitysecuritiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MjI_f73a2d4a-f0da-46d9-ad8f-523b491e9d8a" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current equity securities at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76781baf46eb4f6ea9f326720c56d24c_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzItMS0xLTEtNzgwNDk_dce57593-9d0a-4b86-800a-404bc1b1f2f6">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7d5ce1d5854f9ab123aec1ba08a66c_I20211231" decimals="-6" name="elv:EquitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzItMy0xLTEtNzgwNDk_9c08756c-4830-4d3a-a898-5c1ceb210942">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0491ff0494ee48b5b1055821af090_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzQtMS0xLTEtNzgwNDk_8634963f-0bc4-4f73-b79a-25498fffe8d9">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b47b4ff361f4031989f83a3333a82d5_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzQtMy0xLTEtNzgwNDk_eb23369f-645b-48a1-a077-3fb8a2991c58">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c623535470d4d61ab37acba9cfad54c_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzUtMS0xLTEtNzgwNDk_7ee9951b-4fb9-4f9d-8d9e-7a0854a522fc">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d18fbff221e4d46b9e4768147f370b0_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzUtMy0xLTEtNzgwNDk_152768be-8aca-4edc-8ba1-eedac8b2cb6d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzYtMS0xLTEtNzgwNDk_c3499b6f-fa56-4af7-827a-013a34d2c0af">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:EquitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzYtMy0xLTEtNzgwNDk_c7db63dd-980c-4fed-95e4-b1b246e841c5">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Income</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:InvestmentIncomeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4NDE_413a4141-b120-40e3-9a89-367743c6e015" escape="true"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major categories of net investment income for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzEtMS0xLTEtNzgwNDk_01c5b41f-d87b-4f68-95d7-2d92c1c472a1">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzEtMy0xLTEtNzgwNDk_e2246bf6-b74e-41be-96a8-647d0fe3e9e9">755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzEtNS0xLTEtNzgwNDk_554cac39-69b7-4fcd-b0dc-61a97ad01a57">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzItMS0xLTEtNzgwNDk_6dff7196-768b-4888-8bd7-9b83bcedd0ed">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzItMy0xLTEtNzgwNDk_3c096679-18ad-43a1-82cf-dd271b01a11d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzItNS0xLTEtNzgwNDk_0ba6735e-be4e-400a-a242-c9fe68b74c99">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb31ce1cd8a2411fb9513a02d3ed3cf9_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzMtMS0xLTEtNzgwNDk_b94198dd-c7f6-47d5-a1f4-5d4a47d32d5b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b0aede65fd4dd29e1f856a933eb6ad_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzMtMy0xLTEtNzgwNDk_3d9089e4-23a0-433d-b946-c6da334bcde5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313a7fbc748841a6a6f1211fc6c0b559_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzMtNS0xLTEtNzgwNDk_d0467de9-c04d-44bf-a6d3-faab077d3d67">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzQtMS0xLTEtNzgwNDk_cb5ffcee-068c-4887-829e-85b5ec58df92">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzQtMy0xLTEtNzgwNDk_55057481-9041-4d67-86f2-7858c474c38a">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzQtNS0xLTEtNzgwNDk_ea4675dc-2703-4d7a-ad29-d047a134db7a">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzUtMS0xLTEtNzgwNDk_bc57912b-ad7a-4fbe-9245-ddb9a05f09c7">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzUtMy0xLTEtNzgwNDk_08d21099-431a-47b1-9ac8-3b7e8dbcb7b6">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzUtNS0xLTEtNzgwNDk_52d1864d-7d22-4a24-ba9c-34104432f959">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzYtMS0xLTEtNzgwNDk_63c4d85a-1d8e-432a-84ce-4e24d214957f">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzYtMy0xLTEtNzgwNDk_ad89d10d-0115-4251-9f62-34c2295a3627">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzYtNS0xLTEtNzgwNDk_9d48313f-b8fb-4137-a7f9-e2a628626a54">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzctMS0xLTEtNzgwNDk_2ba36f8c-82ec-4aa4-a8d4-061ed2127103">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzctMy0xLTEtNzgwNDk_2fd84e31-915a-464b-b3de-b8b9160feb27">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzctNS0xLTEtNzgwNDk_77f54583-13d2-42c5-9a4d-3dbdda355846">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-89-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ibd584599875a452d9d9c086057b694d0" continuedAt="i1785d2dab00d4c53bee52fca2e20b28d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment (Losses) Gains </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MDE_092a1f61-5d9a-4545-bb9d-4fe1ab4bcfa3" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzMtMS0xLTEtNzgwNDk_7b8f5cb2-6a8a-4ac2-9398-13a1bcc9f2c1">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzMtMy0xLTEtNzgwNDk_4ce2d8af-92eb-4edd-99d9-74092083b380">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzMtNS0xLTEtNzgwNDk_630992de-465d-4c98-bd1d-23c3c9fc64c6">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzQtMS0xLTEtNzgwNDk_123497c9-b4e7-4911-99a9-625c13eafc10">469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzQtMy0xLTEtNzgwNDk_9675cd51-05cb-4860-b067-efa62bb6498a">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzQtNS0xLTEtNzgwNDk_fcd7fc21-19cd-4815-bad1-d9578c131946">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231" decimals="-6" name="elv:Impairmentlossesreversalsoninvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzUtMS0xLTEtNzgwNDk_6911bcb2-6867-418a-9153-c6cfaeeac39b">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231" decimals="-6" sign="-" name="elv:Impairmentlossesreversalsoninvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzUtMy0xLTEtNzgwNDk_417e646c-ac16-47a2-9ba0-dd23c6b728ca">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231" decimals="-6" name="elv:Impairmentlossesreversalsoninvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzUtNS0xLTEtNzgwNDk_ba83ee58-c5ab-490a-823c-6ddf1a85f811">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains on fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzYtMS0xLTEtNzgwNDk_4d57866b-d2a0-401e-9161-c1dd5cdc6d7d">448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzYtMy0xLTEtNzgwNDk_75824dbf-2cf5-478f-a0e9-6c030c5a8913">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzYtNS0xLTEtNzgwNDk_d0c92fd6-4f8e-49b6-9f54-d80989633ed8">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains recognized on equity securities still held</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzgtMS0xLTEtNzgwNDk_2a296a5c-84fe-4445-b017-1d73588ca972">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzgtMy0xLTEtNzgwNDk_040ef380-3e51-4420-b73a-e072161db1ab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzgtNS0xLTEtNzgwNDk_89e31118-b4f6-4e09-9083-c184074419e5">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized (losses) gains recognized on equity securities sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzktMS0xLTEtNzgwNDk_21a0d432-229f-4b19-834f-2cea7e57eec6">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzktMy0xLTEtNzgwNDk_e085cac7-3670-4b3c-b644-5dbe4da346d2">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzktNS0xLTEtNzgwNDk_e7341f20-376a-4c25-8447-cfc74b56331e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEwLTEtMS0xLTc4MDQ5_79c08d03-ae18-424b-9a78-b719d1abde79">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEwLTMtMS0xLTc4MDQ5_27fe4be0-90d7-4fe1-b8ee-28c90dd97ca2">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEwLTUtMS0xLTc4MDQ5_3384eb2d-011e-4a77-a0f3-b6bd8783312a">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231" decimals="-6" name="elv:GainsFromOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEyLTEtMS0xLTc4MDQ5_048b81d5-d489-4b78-8665-91463d1c81f4">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231" decimals="-6" name="elv:GainsFromOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEyLTMtMS0xLTc4MDQ5_068e1112-18a4-47fa-bdc1-779c22e7bb50">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231" decimals="-6" name="elv:GainsFromOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEyLTUtMS0xLTc4MDQ5_50a12916-f107-4e75-a595-36c44bc5864c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231" decimals="-6" name="elv:GrossLossesFromOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEzLTEtMS0xLTc4MDQ5_adf16ffa-0423-4a40-a187-5062808f5f2c">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231" decimals="-6" name="elv:GrossLossesFromOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEzLTMtMS0xLTc4MDQ5_29dead5d-bac9-440a-be59-61c8d7c623dd">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231" decimals="-6" name="elv:GrossLossesFromOtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEzLTUtMS0xLTc4MDQ5_a923866d-b007-4b3a-938d-9b2f53ad60c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231" decimals="-6" name="elv:Impairmentlossesreversalsoninvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE0LTEtMS0xLTc4MDQ5_d067647a-178f-42f6-9637-3683c7a83622">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231" decimals="-6" name="elv:Impairmentlossesreversalsoninvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE0LTMtMS0xLTc4MDQ5_857e5d8f-2acb-41c7-926d-13fff29a86de">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231" decimals="-6" name="elv:Impairmentlossesreversalsoninvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE0LTUtMS0xLTc4MDQ5_9d934b0e-d8d5-4efe-83a7-43411d7d07e0">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE1LTEtMS0xLTc4MDQ5_4facfd33-4e25-441f-9014-ec1a197f6b21">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE1LTMtMS0xLTc4MDQ5_909e717a-f529-405a-bf2d-c8a0e2350d51">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE1LTUtMS0xLTc4MDQ5_901ef9b9-b3ea-4030-8a61-c5a05ef2db9b">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="elv:InvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE2LTEtMS0xLTc4MDQ5_105731b4-4aec-4b37-8894-8602ab4adb44">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:InvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE2LTMtMS0xLTc4MDQ5_52f5ecd4-645c-446a-ad4d-f41b6e15cfb0">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:InvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE2LTUtMS0xLTc4MDQ5_6496bc97-e08b-4811-8cc9-10cfe73f6184">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i)&#160;changes in the investment environment; (ii)&#160;expectations that the fair value could deteriorate further; (iii)&#160;desire to reduce exposure to an issuer or an industry; (iv)&#160;changes in credit quality; or (v)&#160;changes in expected cash flow.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds from sales, maturities, calls or redemptions of fixed maturity securities was $<ix:nonFraction unitRef="usd" contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzQyNjk_f352c688-a239-4826-8991-4ba0aba5e72d">22,048</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzQyNzM_aa94ad64-5ef9-47be-af29-b0c69f4b25ae">10,565</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzQyODA_aed3b358-9d41-4e03-868a-56a34ba45ce4">11,122</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant judgment in the valuation of investments is the determination of when a credit loss has occurred. We follow a consistent and systematic process for recognizing impairments on securities that sustain credit declines in value. We have established a committee responsible for the impairment review process. The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but not limited to: (i)&#160;the extent to which the fair value is less than book value, (ii)&#160;the financial condition and near term prospects of the issuer, (iii)&#160;our intent and ability to retain impaired investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv)&#160;our intent to sell or the likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v)&#160;whether the debtor is current on interest and principal payments, (vi)&#160;the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors) and (vii)&#160;general market conditions and industry or sector specific factors. When a decision has been made to sell an impaired security or it is more likely than not that the impaired security will be required to be disposed of prior to recovery of its cost basis, the security is written down to fair value at the reporting date. For all other impaired securities, if the impairment is deemed to be credit related, an allowance is created.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have a material adverse impact on our results of operations or shareholders&#8217; equity.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-90-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i1785d2dab00d4c53bee52fca2e20b28d" continuedAt="ia35ce9c13b0548b3b018176f85647a6a"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, there were no individual investments that exceeded 10% of shareholders&#8217; equity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="number" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="INF" name="elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzYxODE_ac166c21-a873-4966-8324-23e0ad1cb5cd">eight</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="INF" name="elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MDc_1851cd57-f7aa-41b5-8fb0-bd4f1e87e0e2">two</ix:nonFraction>, respectively, fixed maturity investments that did not produce income during the years then ended.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we had committed approximately $<ix:nonFraction unitRef="usd" contextRef="if532c3e8149744e285dc513d9e69b523_I20221231" decimals="-6" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzYzNDE_5181500e-39f2-4c5b-a147-bf392a9d23b0">1,504</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9313f67506114bbb8c5bc5b22dd2012f_I20211231" decimals="-6" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzYzNDg_edb477b6-d3a5-4532-91fe-9d6b1c4ccd08">1,558</ix:nonFraction>, respectively, to future capital calls from various third-party investments in exchange for an ownership interest in the related entities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we had committed approximately $<ix:nonFraction unitRef="usd" contextRef="i15ad5cb59a1e44c5bef8850e5117517c_I20221231" decimals="-6" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgzNTQ4Ng_3f5c5a27-bdc5-422a-af64-6d15556601bd">185</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie118092ebec04fe3afe79f4870f4ed4d_I20211231" decimals="-6" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgzNTQ5NQ_53244f26-87a1-4664-94be-0fa1ce084df8">329</ix:nonFraction>, respectively, to future investments in rated notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, securities with carrying values of approximately $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AssetsHeldByInsuranceRegulators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY1NTM_68464ae9-d4e3-4e7a-829e-ab63618ad31b">752</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AssetsHeldByInsuranceRegulators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY1NjA_4b9550b1-378a-49c9-b06f-9af19b93a5e6">632</ix:nonFraction>, respectively, were deposited by our insurance subsidiaries under requirements of regulatory authorities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Investment Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued investment income totaled $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AccruedInvestmentIncomeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY3Mjk_e1020dea-b14c-472f-a3af-b856d3ae0147">245</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AccruedInvestmentIncomeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY3MzY_811e54dc-7a3e-41f6-987b-9bb6f02da327">205</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. We recognize accrued investment income under the caption &#8220;Other receivables&#8221; on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Lending Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the collateral received at the time of the securities lending transactions amounted to $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:SecuritiesLoanedFairValueOfCollateral" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzcwMTQ_e6c88d5e-60da-43b8-b683-a0caff2412b9">2,457</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:SecuritiesLoanedFairValueOfCollateral" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzcwMjE_bc07e1e3-55a5-4259-b948-b69e9f5ecf0f">2,155</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. The value of the collateral represented <ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="INF" name="elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzcwOTI_cbe8a9cc-4b95-4041-99bd-1a4681b8cc51">102</ix:nonFraction>% of the market value of the securities on loan at each of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the collateral as an asset under the caption &#8220;Other current assets&#8221; in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption &#8220;Other current liabilities.&#8221; The securities on loan are reported in the applicable investment category on our consolidated balance sheets.</span></div></ix:continuation><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia35ce9c13b0548b3b018176f85647a6a">At December&#160;31, 2022 and 2021, the remaining contractual maturities of our securities lending transactions included overnight and continuous transactions of cash for $<ix:nonFraction unitRef="usd" contextRef="iea80de425e5d4008bbefd6978deb3701_I20221231" decimals="-6" name="us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc2ODk_b0121953-4733-4754-a787-27f2e438b564">2,221</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9974d46da761480e8fd7c0dfc0115459_I20211231" decimals="-6" name="us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc2OTY_86519263-52f0-4783-b92c-6eee3e05ede5">1,874</ix:nonFraction>, respectively, United States Government securities for $<ix:nonFraction unitRef="usd" contextRef="id6d4050ea7e946fb83bc63f84f887ce0_I20221231" decimals="-6" name="us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc3NTg_58abec7b-fa4b-41d3-8d8b-d7c7600487d5">224</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idaf228ebc5ee4ed9ac397e8420d1727c_I20211231" decimals="-6" name="us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc3NjU_ce09b5f3-569b-43d8-bdca-2ce7eb4f15a0">281</ix:nonFraction>, respectively, and residential mortgage-backed securities for $<ix:nonFraction unitRef="usd" contextRef="iccf0e0041e444850986706abfccd14c2_I20221231" decimals="-6" name="us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgyOTk3NA_80593de4-c522-4231-b647-73e234bb3886">12</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i349488ab238e4f40b2b347c93c7e1a52_I20211231" decimals="-6" name="us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgyOTk4Mg_6745af3a-ff1b-4541-ba27-e8a223a2b187">0</ix:nonFraction>, respectively.</ix:continuation> </span></div><div style="margin-bottom:12pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-91-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwNzk_6c3aafa1-f07d-4494-96ee-e62b5431b94f" continuedAt="i521706c1d791425485b8acecf0a4d738" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i521706c1d791425485b8acecf0a4d738" continuedAt="i43a0f8579e8b4f099f785ff71170a673"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. We also enter into master netting agreements which reduce credit risk by permitting net settlement of transactions. At December&#160;31, 2022 and 2021, we had received collateral of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzQwNw_cecc3fd3-3a82-45c0-9e43-ee87802e4911">57</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzQxNA_8207872a-69e8-487e-8689-acbd96c6e99a">18</ix:nonFraction>, respectively, related to our derivative financial instruments.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwODU_b3b36771-351a-4d90-88a3-fa37bb388d3c" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual/<br/>Notional<br/>Amount</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps - fixed to floating</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d0c3a19c29c4b649862b0b586cdef34_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzQtMS0xLTEtNzgwNDk_60094183-228d-4f24-b462-a245d12f4a5d">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d0c3a19c29c4b649862b0b586cdef34_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzQtNS0xLTEtNzgwNDk_b7752f2e-3e3b-4ec1-8a8b-48135f0a352a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d0c3a19c29c4b649862b0b586cdef34_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzQtNy0xLTEtNzgwNDk_04c26cf4-2a71-494b-9aed-7b79b5749774">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Non-hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives embedded in convertible fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74879d09949481ca3d9a43e6f898eb0_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzctMS0xLTEtOTAxODg_0a0f51f5-1f8c-48fd-9728-311b9a094d99">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Maturity Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74879d09949481ca3d9a43e6f898eb0_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzctNS0xLTEtOTAxOTc_dc82c733-0f21-410c-9128-565bb064cfdb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74879d09949481ca3d9a43e6f898eb0_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzctNy0xLTEtOTAyMDU_65fbc0f4-4a49-4c57-9745-f5db86e4a7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzktMS0xLTEtNzgwNDk_02b41909-1006-43d8-9c86-b4adf8131614">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities/other assets/other liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzktNS0xLTEtNzgwNDk_267e66a4-fc33-4f37-8fc6-d8488e5fc837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzktNy0xLTEtNzgwNDk_f562f9e3-e23c-422c-9235-27aa230de867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEwLTEtMS0xLTc4MDQ5_7bab022b-82b9-414f-a4b2-91138b8dc7b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEwLTUtMS0xLTc4MDQ5_1c51e847-b9e1-414b-a4ac-eff3befb0c60">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEwLTctMS0xLTc4MDQ5_69154ea1-23cf-4b02-9f74-34192bd9cbb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c85d8180b384c1b902ff87d3cee955d_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzExLTEtMS0xLTc4MDQ5_240755f0-3913-41d9-9dba-e0da5b419b05">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c85d8180b384c1b902ff87d3cee955d_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzExLTUtMS0xLTc4MDQ5_53ab7d92-6a5c-41a6-9584-82b4a13a4997">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c85d8180b384c1b902ff87d3cee955d_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzExLTctMS0xLTc4MDQ5_53644c38-24c7-4798-b51a-7cb8618f09c8">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6479287b4fdd42e685cd3c578fd33e14_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEyLTEtMS0xLTc4MDQ5_4de7dac7-9d89-4ab7-b160-8e0b31af7eb2">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6479287b4fdd42e685cd3c578fd33e14_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEyLTUtMS0xLTc4MDQ5_666a0f74-7e85-4aed-bd87-216582fb940b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6479287b4fdd42e685cd3c578fd33e14_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEyLTctMS0xLTc4MDQ5_3d0f6024-befa-418a-b9dc-1952033042c3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEzLTEtMS0xLTc4MDQ5_413d80ad-5d60-4928-a1dd-78d9852cf438">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEzLTUtMS0xLTc4MDQ5_25c75f23-2dd1-4a4d-8c74-abeada893f4f">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEzLTctMS0xLTc4MDQ5_2d440f8e-ffea-47f9-b43a-f77f984c7cff">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE0LTEtMS0xLTc4MDQ5_7b265b10-dad7-4c24-bcf8-b4ebd78a3beb">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE0LTUtMS0xLTc4MDQ5_9edc024a-665c-4227-a337-5116c2d452b0">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE0LTctMS0xLTc4MDQ5_ecbac8da-84b4-435f-bd6f-5559a842d208">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts netted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE1LTUtMS0xLTc4MDQ5_a96f715b-9394-439f-be6a-1132c2e95fc9">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE1LTctMS0xLTc4MDQ5_d4c2f24f-655c-4b1c-b0ad-19de8dab88fc">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE2LTUtMS0xLTc4MDQ5_6db2ab81-8460-4318-a443-5ebe909bde86">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE2LTctMS0xLTc4MDQ5_2b8db065-4a8f-42f3-a595-5feaac75bec6">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps - fixed to floating</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce009ab57443fd98fe415da6193a1d_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIwLTEtMS0xLTc4MDQ5_d765d60c-1fe3-4197-bef3-3f3b26da5aa7">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce009ab57443fd98fe415da6193a1d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIwLTUtMS0xLTc4MDQ5_91c7460e-0081-4144-8b42-a085c302c0a0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3ce009ab57443fd98fe415da6193a1d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIwLTctMS0xLTc4MDQ5_d11863fb-ea9b-4e2e-8fed-9a3e96b829ac">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Non-hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09dd408e89d54981af41dcf162ba1bc5_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIzLTEtMS0xLTc4MDQ5_76e65a1d-2c04-47e9-bc82-d60a8d4e2524">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities/other assets/other liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09dd408e89d54981af41dcf162ba1bc5_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIzLTUtMS0xLTc4MDQ5_8d719f0f-c387-45b8-a584-b3ed24842258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09dd408e89d54981af41dcf162ba1bc5_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIzLTctMS0xLTc4MDQ5_e1d0aa23-ee70-43e8-b68f-a7c68cf96155">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI0LTEtMS0xLTc4MDQ5_3c617f7d-37d0-4bbb-be8d-35885f2c403e">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI0LTUtMS0xLTc4MDQ5_a9b7293a-390d-4216-892b-3486a524b0b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI0LTctMS0xLTc4MDQ5_5ed84a33-d5c4-4174-9b94-cb71d7ddd567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81542d413fa4945bbc09e8c29161193_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTEtMS0xLTgyNjg3_4ceb3363-8152-4793-b5b4-a85d8853ae25">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81542d413fa4945bbc09e8c29161193_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTUtMS0xLTgyNjk1_f5719b14-b247-4846-9676-c2821fa79401">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81542d413fa4945bbc09e8c29161193_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTctMS0xLTgyNjk1_af93b36f-0fc8-4ebf-b92e-494f12b3a80e">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTEtMS0xLTc4MDQ5_d4569812-b6a3-40bc-997a-4894cf3dc7ce">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTUtMS0xLTc4MDQ5_6404e437-5b8d-477e-8bc4-ec45f1136213">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTctMS0xLTc4MDQ5_06d08615-28f2-4344-8132-1155834ab301">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20343c2c574345836f7ccda1cb4891_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI2LTEtMS0xLTc4MDQ5_1aade1b3-83f5-448b-991a-dae4f142417f">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20343c2c574345836f7ccda1cb4891_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI2LTUtMS0xLTc4MDQ5_c18890c4-49d9-47a2-b53e-06fc97569382">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20343c2c574345836f7ccda1cb4891_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI2LTctMS0xLTc4MDQ5_890a9099-520e-4784-ac3c-5884c4eef771">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI3LTEtMS0xLTc4MDQ5_ed91b459-c45c-4d2e-ae35-ae9e1e379373">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI3LTUtMS0xLTc4MDQ5_56d2e7db-7a63-4045-999f-c73fbe91585b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI3LTctMS0xLTc4MDQ5_d92481e4-94c0-4106-b0e2-659eae47d46f">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts netted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI4LTUtMS0xLTc4MDQ5_cc26957a-ea4b-4cf9-a020-73385d651658">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI4LTctMS0xLTc4MDQ5_a4e1b29b-6b2a-46b2-a156-98897f1cf85c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI5LTUtMS0xLTc4MDQ5_6d08c141-65dd-461c-8e58-0a77d535c016">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI5LTctMS0xLTc4MDQ5_643573ec-e532-4653-9640-7d83a2ccead5">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-92-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i43a0f8579e8b4f099f785ff71170a673" continuedAt="ia8e3bcaf6a5644e192ed8f34bf9f81da"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the LIBOR or the Secured Overnight Financing Rate. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwNjk_b3031810-62b0-4bb1-b954-e5cd45884e91" continuedAt="i9b5042f0582d4e09a60ddceb3f95f456" escape="true">A summary of our outstanding fair value hedges at December&#160;31, 2022 and 2021 is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt"><ix:continuation id="i9b5042f0582d4e09a60ddceb3f95f456"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.117%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Fair Value Hedges</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/>Entered<br/>Into</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding&#160;Notional&#160;Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate<br/>Received</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fb9b4d38545ababb8320a29faa28d_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNC0xLTEtOTYyNTE_5f46204c-46e1-4f38-9ca1-3cd9786f2c15">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e594917ec14e3681954b85197676eb_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNi0xLTEtOTYyNTk_947b7125-4bb7-4b9f-8ddf-e2a556de6b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e2fb9b4d38545ababb8320a29faa28d_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItOC0xLTEtOTYyNjk_b70985b0-7e31-4415-8197-2601801a1b87">5.500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic56e8a6011ed4fdc85d7e0cfa580e4a3_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItMTEtMS0xLTk2Mjkx_9371d36f-672b-4065-9df6-33222b56a3c8">April 15, 2032</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie552404ba61c47b389e3c8fc6a697712_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNC0xLTEtOTYyNTE_3545be1f-216f-451b-820f-060fc2986f3c">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459958d874344214bb9cac08d7d757ff_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNi0xLTEtOTYyNTk_e8ce7c45-6271-43f5-9716-e1b48925b5ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie552404ba61c47b389e3c8fc6a697712_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtOC0xLTEtOTYyNjk_cbbf8371-d16b-4210-bfaa-c537fd00107e">4.101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia50a6cc46d6248a397c24a2ad0c2c744_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtMTEtMS0xLTk2Mjkx_53402833-1887-4ca4-9b8e-3a54a3b4e77e">September 1, 2027</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02888f49341a44d4941c9b1b6fb319ed_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNC0xLTEtOTYyNTE_b0fdd2e3-84b8-465d-9d02-f106cbfd30c7">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida52dad48cef4deba690de9747f68ee8_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNi0xLTEtOTYyNTk_f29dce0c-6875-4dbd-81df-0dc8549f67cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02888f49341a44d4941c9b1b6fb319ed_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtOC0xLTEtOTYyNjk_8139f4fb-4b55-4a12-86ff-715577fd4917">2.250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7ee2dc635204bbf8650d842aeb2bac7_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtMTEtMS0xLTk2Mjkx_d99e26dd-ce0b-46f0-9bb3-5f7f229bfb09">November 15, 2029</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6d874468aa4ce6bcf71bd25597b297_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNC0xLTEtNzgwNDk_e08db5c8-8014-4377-944f-e90c5b39f4c6">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f4135503874ad1943ea10cbe7602f1_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNi0xLTEtNzgwNDk_b23ed9de-b32f-4049-81ec-00abcb5b44a5">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab6d874468aa4ce6bcf71bd25597b297_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItOC0xLTEtNzgwNDk_5f051f7c-a643-4729-8a8e-45987f8acee9"><ix:nonFraction unitRef="number" contextRef="i42f4135503874ad1943ea10cbe7602f1_I20211231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItOC0xLTEtNzgwNDk_a5df403e-e0c1-4de3-987d-6971973ea67d">2.550</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia06f61dafe7046c7a1f76c38c5fc05ae_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItMTEtMS0xLTc4MDQ5_653cc609-d368-4c7b-a29a-2d2b39ef24b5">September 15, 2030</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0d380b589e4106bb438dadcea77ccf_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNC0xLTEtNzgwNDk_d57ae329-7160-4c1c-812d-01c0181e436a">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdeec77a2e849ab99853223554b64b9_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNi0xLTEtNzgwNDk_13181cd4-2776-4bee-bcf6-aaa3d79db6b3">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e0d380b589e4106bb438dadcea77ccf_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtOC0xLTEtNzgwNDk_338a96e9-1929-4917-8885-b03c0d2c078d"><ix:nonFraction unitRef="number" contextRef="icfdeec77a2e849ab99853223554b64b9_I20211231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtOC0xLTEtNzgwNDk_a3c14751-edf9-4558-b1c9-7d372aefc7ce">2.250</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cf6c3723dd347668da304307c4a44a6_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtMTEtMS0xLTc4MDQ5_6cb934bb-9bcb-4904-94c8-2f50f3d4d0e9">November 15, 2029</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ccb539d68746d59161c8870f4d4df0_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNC0xLTEtNzgwNDk_39d72332-a8d0-406e-a7ca-14e3937ec73b">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a4ad028b9a441cb7f6ba9a6e59341a_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNi0xLTEtNzgwNDk_11301dc4-16c9-4c8a-981e-a7a407cc00c1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08a4ad028b9a441cb7f6ba9a6e59341a_I20211231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtOC0xLTEtNzgwNDk_d722656e-969e-4d58-9083-160e6e37388f"><ix:nonFraction unitRef="number" contextRef="if2ccb539d68746d59161c8870f4d4df0_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtOC0xLTEtNzgwNDk_f37deae4-3155-4352-865f-0afa26e5bb07">4.101</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5be7d9b2d014385b6e19a6db3d6a4ec_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtMTEtMS0xLTc4MDQ5_9ab600db-ba0e-4bad-9e50-848407580802">September 1, 2027</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ed18d384274ea3a14a91f034c105cd_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtNC0xLTEtNzgwNDk_81e61637-773d-4e19-b7ea-855aac3a82e7">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3411db499754ed98b66e11164278b68_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtNi0xLTEtNzgwNDk_1144839c-fa78-4f90-879b-88fda2c0e081">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01ed18d384274ea3a14a91f034c105cd_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtOC0xLTEtNzgwNDk_9628ef3d-307d-458b-a614-bbbf059f239d"><ix:nonFraction unitRef="number" contextRef="if3411db499754ed98b66e11164278b68_I20211231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtOC0xLTEtNzgwNDk_b42e0463-4c21-4f4e-8816-783c41ae49cc">4.101</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i39a83586d8464e20bb8ad68eb2540321_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtMTEtMS0xLTc4MDQ5_994c3812-0f6f-4ad6-a536-083e5da7167b">September 1, 2027</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2303e464443d492f83362a773fe17a1d_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtNC0xLTEtNzgwNDk_44c5294e-3d10-4eb2-bf6d-bc6622b3aff8">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie189000e9d504c47b363ff6e09fccc11_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtNi0xLTEtNzgwNDk_fd040f46-5a79-4bfb-a7a0-754902040f5e">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie189000e9d504c47b363ff6e09fccc11_I20211231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtOC0xLTEtNzgwNDk_757f4a2b-5a58-4135-a19b-46bea7fcf552"><ix:nonFraction unitRef="number" contextRef="i2303e464443d492f83362a773fe17a1d_I20221231" decimals="5" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtOC0xLTEtNzgwNDk_7850bef7-bea9-456b-9865-9f7937bf63a0">3.300</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61cdc82bcb443a8bf3d68ac1f8fb21c_D20220101-20221231" name="us-gaap:OpenOptionContractsWrittenExpirationDates" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtMTEtMS0xLTc4MDQ5_2b434c97-1fc2-4918-9aed-953d1a32076b">January 15, 2023</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amount outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272bebf1c8d949a8be406568bd0c2793_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzctNC0xLTEtNzgwNDk_c55bca3a-f275-4070-8d4d-a78afde0edc2">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c8de26adbc407f960803fd1f108a21_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzctNi0xLTEtNzgwNDk_c3d269e8-ab01-4dc6-8876-19ad3549ce63">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwODI_7e92781c-d411-4853-a594-d8edfc72900f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification in Which Hedged Item is Included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount of Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d7b5c7de1a49d48dd9569c22788930_I20221231" decimals="-6" name="us-gaap:DerivativeAmountOfHedgedItem" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtMi0xLTEtNzgwNDk_c216afcc-b375-423b-b0ca-fce1d98be590">22,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6fb48bbe5b4149b5d3e9962701d8e5_I20211231" decimals="-6" name="us-gaap:DerivativeAmountOfHedgedItem" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtNC0xLTEtNzgwNDk_b47354a5-404c-48b2-b4aa-66d0a850477a">21,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95d7b5c7de1a49d48dd9569c22788930_I20221231" decimals="-6" name="elv:Fairvaluehedgescumulativebasisadjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtNi0xLTEtNzgwNDk_a781e508-9a97-4ad2-b925-9c59ff6ea717">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6fb48bbe5b4149b5d3e9962701d8e5_I20211231" decimals="-6" sign="-" name="elv:Fairvaluehedgescumulativebasisadjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtOC0xLTEtNzgwNDk_66d5a4fe-73b8-491d-b6d2-12445ab3e8d0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the variability of cash flows in the interest payments on future financings that were anticipated at the time of entering into the swaps. During 2022 and 2021, swaps in the notional amount of $<ix:nonFraction unitRef="usd" contextRef="if6c16b45922c4bc795ba956462757098_D20220101-20221231" decimals="-6" name="elv:Notionalamountterminatedderivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE0NjI_0f6c0174-4119-48c6-9249-07670a0dccc0">700</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i763517f93d014233863645c9d2bb0185_D20210101-20211231" decimals="-6" name="elv:Notionalamountterminatedderivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE0Njk_b4afa975-5d44-4869-ab6a-3df78ad7f81e">450</ix:nonFraction>, respectively, were terminated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $<ix:nonFraction unitRef="usd" contextRef="i948573928d0f465a94e16e23831957af_I20221231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE2NDE_2aa5dcf5-8076-4530-954a-53f24f18ca6e">229</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ied8cd1ce29634691bf5ec4a6493a4478_I20211231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE2NDg_c1519656-43ff-4d87-9759-1941401a78e1">239</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, the total amount of amortization over the next twelve months for all cash flow hedges is estimated to increase interest expense by approximately $<ix:nonFraction unitRef="usd" contextRef="i948573928d0f465a94e16e23831957af_I20221231" decimals="-6" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE4MzQ_9ccd0723-681f-4ffe-9bac-16cc7f4956fa">13</ix:nonFraction>. No amounts were excluded from effectiveness testing.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-93-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ia8e3bcaf6a5644e192ed8f34bf9f81da"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Hedging Derivatives</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwNjE_0de992ab-95bf-4fac-90a5-23a43ed69b81" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Non-hedging Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location of<br/>Gain (Loss) Recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>(Loss) Gain<br/>Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives embedded in convertible securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d">(<ix:nonFraction unitRef="usd" contextRef="ia22c58671ad6415a8c5e55c98cb16b5f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_2325ae58-4c38-4a99-9761-7894482cf2bc">3</ix:nonFraction>)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635">(<ix:nonFraction unitRef="usd" contextRef="i66ca95f113844a1a84afeef54a926515_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_f9c28438-c4b5-4a04-afb1-624d72d3762c">4</ix:nonFraction>)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (including swaptions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16"><ix:nonFraction unitRef="usd" contextRef="i387703b787a3494b9ce325988abfd1f6_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_9b1fe79b-c34b-41dc-bb73-daa26b6359be">13</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db"><ix:nonFraction unitRef="usd" contextRef="ia72f11ca13104ea894df74d97337dea2_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_c2771006-00cb-4763-91d4-7d9b3ebf57c0">10</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2"><ix:nonFraction unitRef="usd" contextRef="i1b9f4d2b3cae4c11bac411a49ddb6174_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_b1e1d40e-d156-4f57-af08-d37cd2f1b481">64</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzctNC0xLTEtNzgwNDk_b3dfc1bd-7084-4966-aa1a-0fc7e4d87301">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27">(<ix:nonFraction unitRef="usd" contextRef="i34017a6ceea74441bb34336674de31f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_b1b2f5fd-eaf2-4aa9-9b7b-f96c9a8003cd">4</ix:nonFraction>)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf"><ix:nonFraction unitRef="usd" contextRef="i26b5329fa2db4a9582fa955c6c09aa5d_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_b297812e-5e9c-40bc-9527-59b6a37546a9">4</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142"><ix:nonFraction unitRef="usd" contextRef="i7a12478c233d4cb4a3af16a5ece03ad5_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5350f171-1059-4d20-9ad7-e614ddafb39c">7</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEyLTQtMS0xLTc4MDQ5_5efd18b3-2ef7-4855-8d5b-0da6df1b9470">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf">(<ix:nonFraction unitRef="usd" contextRef="i2a54e76eb8e745a0bcc186bff383f66b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_500e257d-a14a-4b22-8643-97a7f5a0114f">1</ix:nonFraction>)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663">(<ix:nonFraction unitRef="usd" contextRef="ic81edd70f3ec4b3ab957edfc0bf60938_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_92badae7-b44d-4799-96d5-0b03b415f6f1">5</ix:nonFraction>)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7"><ix:nonFraction unitRef="usd" contextRef="i74c774f65870474b9ff9c262bc7ac889_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_bc54490a-965f-4187-82a9-dfc1ed629782">4</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE4LTQtMS0xLTc4MDQ5_28e8742c-634d-4ba8-945e-83f8eba595c3">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_115"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjY3_52fa33d7-edf3-472e-90c3-04068c9e025b" continuedAt="i38aaedef98ba469da1d56540cf05ac65" escape="true">Fair Value </ix:nonNumeric></span></div><ix:continuation id="i38aaedef98ba469da1d56540cf05ac65" continuedAt="i56db5beacfb6460aa70fc5e1d43fb989"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:8.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;Input:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Input Definition:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;II</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed maturity securities, available-for-sale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-94-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i56db5beacfb6460aa70fc5e1d43fb989" continuedAt="icdc1de6ec4894a52bec38e318e08192b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services&#8217; qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services&#8217; pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security&#8217;s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities lending collateral:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan assets not defined above (see Note 11, &#8220;Retirement Benefits,&#8221; for fair values of benefit plan assets):</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Fair values are based on quoted market prices, which represent the net asset value (&#8220;NAV&#8221;) of the shares held.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Fair values are estimated based on the plan&#8217;s proportionate share of the undistributed partners&#8217; capital as reported in audited financial statements of the partnership. In accordance with FASB guidance, certain investments that are measured at fair value using the NAV per share as a practical expedient or the fair value measurement alternative have been classified in the fair value hierarchy. The fair value amounts presented are intended to permit reconciliation of the fair value hierarchy to the total investments of the master trust.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Commingled fund</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Fair value is based on NAV per fund share, primarily derived from the quoted prices in active markets on the underlying equity securities.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract with insurance company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Fair value of the contract in the insurance company general investment account is determined by the insurance company based on the fair value of the underlying investments of the account.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in DOL 103-12 trust:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Fair value is based on the plan&#8217;s proportionate share of the fair value of investments held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity (&#8220;DOL 103-12 trust&#8221;) as reported in the audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of the trust.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Life insurance contracts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Fair value is based on the cash surrender value of the policies as reported by the insurer.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-95-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:3pt;text-indent:18pt"><ix:continuation id="icdc1de6ec4894a52bec38e318e08192b" continuedAt="i25a382bd2893410f8ea59d509f3cc7ef"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjcy_cc010912-68ff-43fc-8e6e-a5048d1e1a7d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3650a094504772a0bf73a6172f2a67_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMtMS0xLTEtNzgwNDk_208bb5ba-ec33-4ed4-b100-8c537a421dec">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMtNy0xLTEtNzgwNDk_1efe60b0-0251-4ac8-a466-72d58745f3ed">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9096a0c9b14b4c9fa7be9af938dcc3ff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUtMy0xLTEtNzgwNDk_ba069c5b-e335-4d93-8292-1f416e406cc2">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUtNy0xLTEtNzgwNDk_37c6f665-40b2-4adb-9910-eefb72e01f14">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99009b08fecf44cd93c279adb331703f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzYtMy0xLTEtNzgwNDk_de92d874-75bc-45e8-ae94-8fcf18f8f17d">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzYtNy0xLTEtNzgwNDk_1ec87318-0eef-44f7-8b66-17c23d6ed4fc">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009bcd76d73148e5a865a59956651a7a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzctMy0xLTEtNzgwNDk_8816f979-6c57-4189-a33a-93d5e9a2b6cc">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzctNy0xLTEtNzgwNDk_2961fcba-20dc-4c7d-91b5-672e4100ce72">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b44c05131d4056a2f7c3c898130a7a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzgtMy0xLTEtNzgwNDk_53376f8e-31b7-43e7-9150-bee55f68a5f3">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzgtNy0xLTEtNzgwNDk_7305789d-d684-42df-99cb-b014d3041d2e">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72bd0d75b5c431692b8edb1c1c0d1dc_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzktMy0xLTEtNzgwNDk_fee7ae28-2a0b-4c11-a955-4bb51c1e9e37">12,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293b24cef6f4af1a37865b3f65c5128_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzktNS0xLTEtNzgwNDk_8ace46ec-c8d2-4d0c-8e66-3bcec1e97015">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b44a4216564a04ab613dc30466a108_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzktNy0xLTEtNzgwNDk_9b078c68-3c32-4157-98e3-768bfe08306f">12,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4723ab4fdb2541989a926b6fa4fa981e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEwLTMtMS0xLTc4MDQ5_d29fc26a-c19d-4881-ab8a-083ef913e311">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c3b00e889545ffb01d1e62bf2b6746_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEwLTUtMS0xLTc4MDQ5_5fc42932-ddd9-4c67-bc3c-82d6540cfa7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEwLTctMS0xLTc4MDQ5_94a5530c-7650-4ddd-8451-669097604dfb">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a55bb1adcf5446f8c1b805d8f31144e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzExLTMtMS0xLTc4MDQ5_579187fe-6f82-4801-b612-86dad2ef54ca">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzExLTctMS0xLTc4MDQ5_c2a430c7-b74e-428b-92d2-b009d44531c3">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd1383cc1874b88a8aa6f742ec27422_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEyLTMtMS0xLTc4MDQ5_cd366c87-b289-4ca4-8628-940414e38d5e">3,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206bf39a6a2e4283b7d98c5e5aba95be_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEyLTUtMS0xLTc4MDQ5_b4fe883c-3331-4904-9823-bd07c5d9e4d2">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4de37099734e248456f4b9bcd0d11e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEyLTctMS0xLTc4MDQ5_318a0aea-f072-4228-a18f-e12414663c68">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46e01dc3c644cd08544f306992b1cec_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEzLTMtMS0xLTc4MDQ5_4d86fa27-bad8-4dba-9959-3f03dcd7c1bb">26,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f78627f2e9a4f66a5c0bcdfdccb0aaf_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEzLTUtMS0xLTc4MDQ5_03975697-52e9-4ede-afed-507ec3e33f19">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEzLTctMS0xLTc4MDQ5_51fbed90-1dd0-4a89-a7dd-b87f05ba651a">26,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ceef5d05b49498c84bc7a5735c400aa_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE1LTEtMS0xLTc4MDQ5_d4a1a58b-0401-4c0c-86ac-f1be485da1f7">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca8984787184bbbaefef048ae2a7ed2_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE1LTctMS0xLTc4MDQ5_25386e38-46fa-46f3-9e87-dc3b435ab04a">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c6a19fa0fd4060aabf6478982ccf36_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE3LTEtMS0xLTc4MDQ5_9ad0969a-a839-48fb-8c23-878f436b3470">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0160f1f3dab24f569a23d2ba07f095d0_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE3LTMtMS0xLTc4MDQ5_675a3ef0-f819-4df3-a469-888a80d4afe0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb2feacd11c4565bfc6b5b6a3e279ec_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE3LTctMS0xLTc4MDQ5_9e2e5c33-afc8-466e-94d2-528524432dbe">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a873585c11f450d9fd9cf3c29c105f2_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE4LTUtMS0xLTc4MDQ5_4662d8e6-f2c5-4bf2-a8f3-0c3ae68b89d8">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51990bde857d4a5db236e8926558a29b_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE4LTctMS0xLTc4MDQ5_8729e7bf-628d-4f30-a9b5-98c680ee871f">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0441844ced744791a772d411eed7ca9f_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTEtMS0xLTc4MDQ5_ac96c4b7-d9e2-40bb-817e-d5b0eea0c5b4">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904c347e51a64fb59bc57777f21d4ac5_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTMtMS0xLTc4MDQ5_4a4919a3-e103-4109-8e99-3f2ba630f440">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f260a809bb49cb9e77ad6f5c2904a6_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTUtMS0xLTc4MDQ5_d85d8b4c-4423-420e-b317-5dc6a07824fb">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f714be3d7a47ffa4d705a6678f8d4e_I20221231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTctMS0xLTc4MDQ5_07ce8a74-2bd4-42d6-9308-6445a3f2e180">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069417d1b9bb426dbfd0f19f51c445ee_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIwLTEtMS0xLTc4MDQ5_d2f19960-0eb5-429b-bb3f-414d596ac9e7">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca89489e7414de0a4fed48d20415ea2_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIwLTMtMS0xLTc4MDQ5_a44ae722-4e28-44ab-84aa-334ef198815a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if117aa6b760a48b191a9336dd1386d0f_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTUtMS0xLTEwMTQzNA_17cb4aa5-ac31-4f0d-b36c-bff6b8d1ff93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdae597d08f410ca9c02ca9b55441e3_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIwLTctMS0xLTc4MDQ5_008f9e69-d2e6-472f-86b9-586ebe52b43b">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231" decimals="-6" name="us-gaap:SecuritiesHeldAsCollateralAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTMtMS0xLTc4MDQ5_f76728e6-f667-448f-8266-7940f54af6c0">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:SecuritiesHeldAsCollateralAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTctMS0xLTc4MDQ5_4cf40da9-cd51-4c35-a7ea-799ea9659fcb">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad">Derivatives - other assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1417f5c20d04886b4a1c28630457c0f_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIyLTMtMS0xLTc4MDQ5_c7654d69-7964-4bbc-90b6-6b06fd637a37">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b78fb8e9294d4091b91dfb2f7b8dfe_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIyLTctMS0xLTc4MDQ5_a1455335-8ccd-44a6-8f1d-8cdab5eb539e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3650a094504772a0bf73a6172f2a67_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTEtMS0xLTc4MDQ5_28f33d36-32c8-474e-be95-0c0327e047ef">4,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTMtMS0xLTc4MDQ5_470b07f6-0343-4721-a5b3-b1fde271ab7d">28,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2e3cdf76fb4346a9739172b0a28be0_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTUtMS0xLTc4MDQ5_b7a271cb-4c36-4dc9-b13f-77a52804f4be">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTctMS0xLTc4MDQ5_909c2878-0c3b-4cd8-8c0f-c8e5cce3938a">33,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c">Derivatives - other liabilities</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1417f5c20d04886b4a1c28630457c0f_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI1LTMtMS0xLTc4MDQ5_ab017599-1505-4542-b0d6-4e4ead934508">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6b78fb8e9294d4091b91dfb2f7b8dfe_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI1LTctMS0xLTc4MDQ5_4172e083-9126-4e11-87e1-7a8d52b15c22">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI2LTMtMS0xLTc4MDQ5_b0ccfed3-35e0-4c1a-9d1d-82533af18c0c">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI2LTctMS0xLTc4MDQ5_3269bf3b-d071-42e6-b4de-3c4bd9d666c5">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebaa3e81cfc4ec9b580beed5caa48af_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMwLTEtMS0xLTc4MDQ5_52b93e9c-e7a8-4768-97b7-456ea6f43d6d">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMwLTctMS0xLTc4MDQ5_5ce18132-aced-4bc7-8ebf-9c4fdb9030b9">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d91da7322044ebeb41aac5b19dd9fa5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMyLTMtMS0xLTc4MDQ5_d59ca069-954d-45b9-8c31-37c1b2d2a42d">1,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMyLTctMS0xLTc4MDQ5_c23c5763-e20e-4d8c-981b-7fbde70fedd5">1,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aaff6ca3964450bafa714cc0aaec6db_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMzLTMtMS0xLTc4MDQ5_d66df5ed-2eac-4611-840e-1798007c21a9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMzLTctMS0xLTc4MDQ5_92852ce3-41f2-4394-b037-8442e4424f1e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41132adfcfc49268da644c34fda294a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM0LTMtMS0xLTc4MDQ5_f2ef9ce9-57f3-4d2d-be76-4348d691b184">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM0LTctMS0xLTc4MDQ5_5b573335-a0e1-464f-bbd5-5961d3b0760b">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92581736a99943b98dfe57570a7dba53_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM1LTMtMS0xLTc4MDQ5_c0f42c14-c060-49f8-a1dd-d161b06a97b5">5,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM1LTctMS0xLTc4MDQ5_45f01846-5dfe-4242-8999-09a9ad38f7a4">5,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de34994aae94c3fa1fe238756f73e72_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM2LTMtMS0xLTc4MDQ5_3d46a43f-9734-4a31-b9b6-facc4825a88a">12,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1333f2613ac4700882b9aa88ce86e8b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM2LTUtMS0xLTc4MDQ5_4b4e3c30-3dc4-4ea1-ad48-6dfff1a66ec6">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM2LTctMS0xLTc4MDQ5_08ffa62f-e12a-4418-8611-cf6a6ba07684">12,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dac1ad1470b43dab49c726357aa7ff8_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM3LTMtMS0xLTc4MDQ5_2051ddce-ca72-45ed-97cd-68f3fece4fbd">2,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c02d35e75f4475c925518ec594b0833_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM3LTUtMS0xLTc4MDQ5_0e6225f8-c0f1-4347-98b8-3f10be67c87f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM3LTctMS0xLTc4MDQ5_c1b48eb1-0ec9-4c18-9e11-fad2eaa8e8c9">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3876e659055149f7a703040ca62a38d8_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM4LTMtMS0xLTc4MDQ5_461c1d61-6dfb-412b-a291-f6d2ad7b5b5e">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM4LTctMS0xLTc4MDQ5_e211eeae-61f8-41e6-8168-2f1a02abd281">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea83cb6a8de4fa3949218ca98d32023_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM5LTMtMS0xLTc4MDQ5_4a74fe09-5ec7-4a9f-8720-962c75f9b72a">2,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19a9ee228de40aa8494169d2d2d10e1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM5LTUtMS0xLTc4MDQ5_8bd44650-6403-450b-b6a8-efa13cc75f8c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0894905483914d83a324be50305c8544_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM5LTctMS0xLTc4MDQ5_35e8cd9a-b6cd-40a1-bd2f-949e7d455a9e">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99af398d9f47d5a429fe1dcacc1f44_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQwLTMtMS0xLTc4MDQ5_a80b33a3-6551-4589-ac4f-403809e753af">26,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4120bc1c539494db1a281d2596d5086_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQwLTUtMS0xLTc4MDQ5_2e2b239e-7154-45bf-8358-efee903c05aa">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQwLTctMS0xLTc4MDQ5_c39ef076-0eeb-4f43-a487-77e68c25204f">26,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3257f7fe574daa85e3967b1d116931_I20211231" decimals="-6" name="elv:EquitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQyLTEtMS0xLTc4MDQ5_8acb42f9-10b5-4879-af97-b36153e44af6">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04fa6f9d293449e69c6dc3044ca3c4d8_I20211231" decimals="-6" name="elv:EquitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQyLTctMS0xLTc4MDQ5_c649e94e-6d05-4ad5-933c-3cc60c884f9f">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i731f097a1855416da64a94d30b7089d4_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ0LTEtMS0xLTc4MDQ5_045962c2-7143-4262-b991-683b71ca13ac">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7534f37a1c0488aa47b62fc88cc8dc0_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ0LTMtMS0xLTc4MDQ5_912c1f65-f2e6-4676-8f8a-c38a20a66266">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc437a887c994868be66d15b5875523e_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ0LTctMS0xLTc4MDQ5_1d855260-3e4f-4d78-9fa4-dbf5f83e07f6">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib859e237e46b490d97c83b2fbc6eb7c2_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ1LTUtMS0xLTc4MDQ5_f04e9f8b-37fc-4e66-8387-757e985b7c36">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29501ab2755d404f9726f590112ae654_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ1LTctMS0xLTc4MDQ5_46b99150-67d4-4782-b05a-8fa7b54d307c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3039f8072e324d98beb39105271bc417_I20211231" decimals="-6" name="elv:EquitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTEtMS0xLTc4MDQ5_5c860649-8857-43e7-b15f-3cf83965a8e2">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39da1e7e5b0d4e3faac6f5afb10e8022_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTMtMS0xLTc4MDQ5_96ad58c6-9f4a-4f8d-8b37-322904ff4ac5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fcb396e62c4b998da85a181a469648_I20211231" decimals="-6" name="elv:EquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTUtMS0xLTc4MDQ5_a212fb80-16d2-421d-8660-5c1e1f550c00">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1831bed7a9a940b7b66b76e245b8018c_I20211231" decimals="-6" name="elv:EquitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTctMS0xLTc4MDQ5_3445bba4-ad02-481b-9678-5de1b31afdb9">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa94f2b63b1149839f52e2f831a1edef_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTEtMS0xLTc4MDQ5_fba17010-197b-46c0-b437-79701f73dbf6">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16eafcfee2cb4d9b8e93262638fce1f6_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTMtMS0xLTc4MDQ5_6c6e9c28-0a64-4c62-91f3-0a2a9c7b413a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie822cce3164245ebb93dd26d240e4175_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTUtMS0xLTc4MDQ5_800a906b-22c7-4952-9590-670dba8d07de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11de76f442c4431cada80f558aa8ffc8_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTctMS0xLTc4MDQ5_dbedc8b3-3a3b-4bfa-ade4-789d96811da7">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2414d6cfbbd4765bf4121c62ca67493_I20211231" decimals="-6" name="us-gaap:SecuritiesHeldAsCollateralAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ4LTMtMS0xLTc4MDQ5_293cf6be-c472-4e53-906a-972b872d4a27">2,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:SecuritiesHeldAsCollateralAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ4LTctMS0xLTc4MDQ5_77bb4580-148d-4f00-9ad9-3b8041fac057">2,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0">Derivatives - other assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e183cefc842978e11387775c98361_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ5LTMtMS0xLTc4MDQ5_d48d4b1f-3e0b-4a69-9818-f04b54392890">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e5a8e93e844062b0f224b3e55aed8e_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ5LTctMS0xLTc4MDQ5_77f449f6-83b8-440d-b4bc-bc403ca09ac3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebaa3e81cfc4ec9b580beed5caa48af_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTEtMS0xLTc4MDQ5_6f2cb143-81cd-4b61-af1b-18c781afe015">4,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2414d6cfbbd4765bf4121c62ca67493_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTMtMS0xLTc4MDQ5_bfa9f9fc-053d-4bfc-b507-0c3006108272">28,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f9bbbaabb04060a11a6fd22a348392_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTUtMS0xLTc4MDQ5_243a024d-f0a8-490d-abe2-fea63029db17">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTctMS0xLTc4MDQ5_29610c49-45fc-4b0e-9e7a-12682355e39c">33,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132">Derivatives - other liabilities</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3e183cefc842978e11387775c98361_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUyLTMtMS0xLTc4MDQ5_1e5d6c11-a297-4533-8a4a-993531d1986e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44e5a8e93e844062b0f224b3e55aed8e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUyLTctMS0xLTc4MDQ5_0793933a-d953-48a4-8ddf-8e7be743d8ec">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2414d6cfbbd4765bf4121c62ca67493_I20211231" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUzLTMtMS0xLTc4MDQ5_ea42e158-d0c2-4372-9dd1-00bb1fdbd6ec">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUzLTctMS0xLTc4MDQ5_3bf3e16a-a70c-415a-ab56-9e86d8a2fcf5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i25a382bd2893410f8ea59d509f3cc7ef" continuedAt="i0c3fe568c5814f8d86fca505c040dbd4"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjc4_82925a97-97fa-46b0-92fb-0ccb95cf7ad0" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset-Backed Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bede030acd1445e92925c2eb16fa9a7_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItMS0xLTEtNzgwNDk_24258be3-8f7e-4540-a35b-8d104fae534f">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f18267c023f408a99a89907537030c8_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItMy0xLTEtNzgwNDk_2418fe3b-7fdd-4cc0-a1ff-6c547a2afffb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9d8f64f3ad45a084579266e307020c_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItNy0xLTEtNzgwNDk_145b477c-90fa-4412-99b7-1f296a128c1e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4ecb9767514086a037990f8b694328_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItOS0xLTEtNzgwNDk_10aaabbf-9ae6-4998-9065-7cf1632d3db9">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItMTEtMS0xLTc4MDQ5_976d5749-b8f0-488d-8f3a-2784395a97d3">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMS0xLTEtNzgwNDk_2f66062f-12ba-409a-a389-d2f2dc8d6bde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMy0xLTEtNzgwNDk_327504fe-bf6a-4fb9-b234-93547d3ae483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtNy0xLTEtNzgwNDk_6e4fece4-4d8b-4cf2-bb6d-945f6f6228dd">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtOS0xLTEtNzgwNDk_9182893e-8e25-470f-aa99-5e9933f77e88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_08381840-48b3-4e34-92fa-1e0673785619">1</ix:nonFraction>)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtMS0xLTEtNzgwNDk_2cab41fc-0d56-48fb-9a7b-513f17f7eaee">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtMy0xLTEtNzgwNDk_0da04bb6-f63e-463e-8abc-e195fc2bcd87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtNy0xLTEtNzgwNDk_5ba83bac-ec1a-4b0b-ae0f-66029c53543b">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtOS0xLTEtNzgwNDk_6b199b3c-729a-4f65-b479-6bfc166723cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtMTEtMS0xLTc4MDQ5_079ac2e4-212f-4ae3-baca-c7879687592d">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtMS0xLTEtNzgwNDk_b3b3874e-85a5-468f-b7bc-b2ae9cace29b">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtMy0xLTEtNzgwNDk_1a008d8e-141a-4a74-960c-389c7c4fae7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtNy0xLTEtNzgwNDk_3a3ff631-2ab9-46ed-aa27-37000dcfae61">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtOS0xLTEtNzgwNDk_760d35ba-a1d4-4ed2-b530-a4e554a27ab2">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtMTEtMS0xLTc4MDQ5_27d10fd7-b4a5-420c-873d-9296ca996873">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctMS0xLTEtNzgwNDk_594dcef5-847f-4716-8d39-d2361922b6ad">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctMy0xLTEtNzgwNDk_6d697f96-6013-43ed-ad0b-95c0833181d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctNy0xLTEtNzgwNDk_fa887380-1e3d-4ff0-acca-797af079058b">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctOS0xLTEtNzgwNDk_d9af334a-6bda-475d-bde0-497b494dcf74">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctMTEtMS0xLTc4MDQ5_149bf339-00e7-4ba3-9ac2-1b5ec26b9035">242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtMS0xLTEtNzgwNDk_f758b09b-fa41-410b-aec8-b9ed6826ecb3">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtMy0xLTEtNzgwNDk_da351515-c8d8-4763-ab82-32fcac3c82d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtNy0xLTEtNzgwNDk_00b2c6c7-60bd-4538-be1b-789bd89a6bb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtOS0xLTEtNzgwNDk_e2ad9408-e921-440c-86b0-d22888a7a5d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtMTEtMS0xLTc4MDQ5_c4bf764f-89e3-43d0-82e6-a9880ddaf030">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktMS0xLTEtNzgwNDk_ec1fa303-d5fe-44d8-9f1c-883a90af8629">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktMy0xLTEtNzgwNDk_0e9d4dfb-9f65-4547-97ee-83b5693d16cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktNy0xLTEtNzgwNDk_1119c88c-6bab-419d-8a45-e0a5a612a360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktOS0xLTEtNzgwNDk_2c4e8081-1171-432e-827f-aaf72aaa86fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktMTEtMS0xLTc4MDQ5_5be1b2c9-df71-4a73-bc8f-c67835af0557">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTEtMS0xLTc4MDQ5_43816cb4-8fb2-4779-b78b-b52d62696118">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTMtMS0xLTc4MDQ5_a3bbcaec-0b50-4469-a156-e2736da8b4e0">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTctMS0xLTc4MDQ5_eb94360f-a942-4a89-89ba-b828c6b2b2b0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTktMS0xLTc4MDQ5_d2d12051-7da3-4dcb-a083-6bd7c1647731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTExLTEtMS03ODA0OQ_3c3a2056-1d8b-4827-8162-ba5ad9f12836">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f47d433c9f44b894af80bfe9cba63a_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTEtMS0xLTc4MDQ5_8851c7c2-0bcb-40c8-a4c8-d04635b5220d">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1c35519dba4644a3fb343be2411cac_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTMtMS0xLTc4MDQ5_913460f4-4c47-4a3a-b5b4-c3e0b0d15e62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3211a2672ef480891cfd22783436bf0_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTctMS0xLTc4MDQ5_efc0a8ca-720f-4195-8e1f-e2a1b9328e59">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa94c0104acc4bf89ee5934a42f0fbc5_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTktMS0xLTc4MDQ5_8e07e930-718c-4607-be57-08d6b8a9dbdc">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTExLTEtMS03ODA0OQ_a3833b62-43c9-4504-b2c6-0477510cbd93">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTEtMS0xLTc4MDQ5_1af6de6a-3e25-4409-a136-9f5cb669534f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTMtMS0xLTc4MDQ5_6c5b276d-4d20-423f-b533-e6434a9dd81d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTctMS0xLTc4MDQ5_170eb95a-7c85-4070-a18b-e3c67dfd7d78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTktMS0xLTc4MDQ5_61057be4-70bf-4e1f-ba6b-ff6e4de2df07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTExLTEtMS03ODA0OQ_f0368487-511e-495a-8071-2669167f8660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d998702002443e1bdceee7c1cd3cda9_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTEtMS0xLTc4MDQ5_cadd7826-8332-4fad-b14a-a0603bcace56">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i360abcc2cf914906ae4e38a91bc64c5f_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTMtMS0xLTc4MDQ5_84c9ce33-0ddb-43d1-b7c9-a67747bbcb5d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e9582cb2ed44069090ba97e16cd18e_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTctMS0xLTc4MDQ5_12ceface-24bd-4292-a3bc-46b0c4d7c232">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79df65678198415585bd1eadb7bbe9b7_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTktMS0xLTc4MDQ5_2fca4248-1132-482b-8b39-16edf4a8a51b">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTExLTEtMS03ODA0OQ_d97d0b93-ca79-46fe-8675-d378eed769bf">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTEtMS0xLTc4MDQ5_c7640a14-90dd-48bb-967e-bb956bf8a9a4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTMtMS0xLTc4MDQ5_cc956c11-add5-413e-9091-9964dfce8277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTctMS0xLTc4MDQ5_500e486b-fafb-4035-a0c0-403a16072368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTktMS0xLTc4MDQ5_674005f9-c5d1-4da8-9daa-e4fe8dbac91e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_394f7169-e315-45fa-b040-96f2a1de2f50">19</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTEtMS0xLTc4MDQ5_0bc7e392-b186-4fa2-ba8b-6c26d70ae83b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTMtMS0xLTc4MDQ5_4b4cde91-907c-4b9b-aced-5e6a9075b4fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTctMS0xLTc4MDQ5_4866b247-8b1e-4c9d-96e5-49a3da06b869">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTktMS0xLTc4MDQ5_538d06f6-cbc4-4e2c-80ef-c12e886ae5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTExLTEtMS03ODA0OQ_853558ca-eedf-4c4e-86ca-e68b77fc06a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTEtMS0xLTc4MDQ5_335e89b3-4ff8-4c49-94e8-0371df80c42a">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTMtMS0xLTc4MDQ5_14667765-335a-4995-b2aa-813fdad2d568">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTctMS0xLTc4MDQ5_b238d474-f6bd-4edc-8da3-1d17775d6a7a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTktMS0xLTc4MDQ5_ff22cea9-f770-47ed-960a-520b8858b774">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTExLTEtMS03ODA0OQ_7bdd5cc0-c0a6-4fe0-9e04-4f4d202df3e4">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTEtMS0xLTc4MDQ5_3f9421e9-7f1c-4902-b71d-7d141164ebd6">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTMtMS0xLTc4MDQ5_5e844f5d-f835-4fce-be15-1b60acb42f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTctMS0xLTc4MDQ5_cdd305f8-4338-489d-8de1-3a3d8fbe6405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTktMS0xLTc4MDQ5_ace083a3-4c15-4d1a-b288-1e4b9cb889b1">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTExLTEtMS03ODA0OQ_3a14a812-b3be-43f3-b942-9fcf35faab2c">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTEtMS0xLTc4MDQ5_6b202b37-ac19-4b2b-87ab-8f66fbd97999">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTMtMS0xLTc4MDQ5_1db8f01b-c8ed-4acc-8c4a-c4de80cae4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTctMS0xLTc4MDQ5_54b6d0ae-f8a6-49e4-a556-54fcc359037d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTktMS0xLTc4MDQ5_7eaf4254-52c4-4085-ae1d-ca419936380a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTExLTEtMS03ODA0OQ_0ea39b1c-b07e-4ee4-a65a-219868139a88">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTEtMS0xLTc4MDQ5_57b61985-56c6-4c78-ac4a-a7501981b0b7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTMtMS0xLTc4MDQ5_0761ad0f-07c9-4a33-801c-a3ed50bf3dda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTctMS0xLTc4MDQ5_4becb91a-7007-4d4f-99dd-1ddabb1d6e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTktMS0xLTc4MDQ5_11149410-4ff7-426e-95a6-d69453cfd247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTExLTEtMS03ODA0OQ_b0aa346f-f5c6-4d9b-a2d5-6b7f113cb8f4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTEtMS0xLTc4MDQ5_bd3be886-8213-4c45-8c96-b900912b80dd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTMtMS0xLTc4MDQ5_fbf26b01-9b14-4ce3-8ef0-25acc3fd5d3b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTctMS0xLTc4MDQ5_8e7907d5-ec72-4f26-9398-b6443f5c5ddc">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTktMS0xLTc4MDQ5_9348ebcb-e3a5-4eec-91f7-1e008ea93590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTExLTEtMS03ODA0OQ_bca3139f-0f05-482f-997b-1650be5d8eab">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bede030acd1445e92925c2eb16fa9a7_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTEtMS0xLTc4MDQ5_12169e64-ecde-426f-8257-13010cd144ee">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f18267c023f408a99a89907537030c8_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTMtMS0xLTc4MDQ5_f44a4452-9275-4848-994c-7b309aaeced0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9d8f64f3ad45a084579266e307020c_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTctMS0xLTc4MDQ5_145e5ca8-c562-4c5d-9f27-004a737edc70">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4ecb9767514086a037990f8b694328_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTktMS0xLTc4MDQ5_1f183ca9-b5bd-48a6-a0e1-a0b614d84dee">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTExLTEtMS03ODA0OQ_28b7dd4d-284b-483b-a5ce-fd1e0f83c332">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTEtMS0xLTc4MDQ5_d42c6893-dd02-414a-9ce8-239bd48a0e7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTMtMS0xLTc4MDQ5_825e3d2d-156a-4ce8-b9d5-0e9b3cf1801c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTctMS0xLTc4MDQ5_364a6467-7173-4a0b-823f-ff452a9706ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTktMS0xLTc4MDQ5_34414dff-c646-4abb-9397-8217352aa8a2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTExLTEtMS03ODA0OQ_b977a0ff-e2ab-489d-9a4d-b461f8279588">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876b8cfa43904577b851c227ca0f5cf5_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTEtMS0xLTc4MDQ5_c81a93e3-542e-4c88-8600-ac19f0dd857b">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8098a79a2da540da9b0adddcc15af4af_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTMtMS0xLTc4MDQ5_300e6ec8-4cc2-473b-bbb0-fe6a423f20a3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac255a2c1404484817fa038dbd46f96_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTctMS0xLTc4MDQ5_d60ae7ac-c485-44db-a79d-d9f9afdabb1f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686937bb287f43208495ac30ebad9562_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTktMS0xLTc4MDQ5_ad894ce5-b831-4826-9b10-147237a51515">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTExLTEtMS03ODA0OQ_0c0cf6fc-7b1f-4a62-9482-26b0180e379f">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTEtMS0xLTc4MDQ5_f8092390-6938-4286-8b31-c939dcd49f0d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTMtMS0xLTc4MDQ5_17cc2710-d8be-44b1-9b1c-4eb64bf5bea1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTctMS0xLTc4MDQ5_ac9da744-e27a-457a-928d-6c390ad34e52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTktMS0xLTc4MDQ5_db139a2c-5fff-4fbe-8fc6-744abe4b7c29">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_37c211b3-24e9-4a6b-8362-444fb8973753">22</ix:nonFraction>)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTEtMS0xLTc4MDQ5_dd550f98-80b0-48b0-8300-ec7f9638a26f">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTMtMS0xLTc4MDQ5_9c6f0659-090d-4a4a-96fb-16c137f3c7fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTctMS0xLTc4MDQ5_85440389-5cc1-42ea-829f-68aecc3efe98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTktMS0xLTc4MDQ5_5acc522f-3ad7-49c0-bd48-cd848023667c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTExLTEtMS03ODA0OQ_341b0730-3f2a-4139-b5d8-8425d7cebe61">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTEtMS0xLTc4MDQ5_7c111388-07a3-47dd-a58e-ac34c29abbff">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTMtMS0xLTc4MDQ5_1fb653e2-90b2-4cb7-a713-eafa94daef7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTctMS0xLTc4MDQ5_b186597f-cc42-4e15-a14a-d84fe5c80adc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTktMS0xLTc4MDQ5_53b85dea-9d89-4843-bde0-3abf12c3bc78">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTExLTEtMS03ODA0OQ_7ea4ac9e-1ee4-4f14-a163-98f2f0c1428d">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTEtMS0xLTc4MDQ5_4865ff51-01ce-4720-86ca-6d14920501f6">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTMtMS0xLTc4MDQ5_22eb3e04-571a-422c-a0c0-0b632a6c2fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTctMS0xLTc4MDQ5_45945831-ebf5-46fb-915c-fb3269c8a31d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTktMS0xLTc4MDQ5_3693d19a-a6ec-4fe0-8e8e-ddff8e470bcc">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTExLTEtMS03ODA0OQ_d84b7a55-3dde-45d8-a0b5-2ef88b7dcfd3">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTEtMS0xLTc4MDQ5_d8f891c9-1241-4618-9db9-faa958f5611e">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTMtMS0xLTc4MDQ5_d15e6b6a-b97a-4c1f-9354-d7b445c7d5ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTctMS0xLTc4MDQ5_28a0beb2-02ff-427e-a88e-1681065b5970">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTktMS0xLTc4MDQ5_c62f1db4-9b33-492e-8f38-0f954d2fe2bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTExLTEtMS03ODA0OQ_112719ba-301d-4305-912e-e00bcb04366d">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTEtMS0xLTc4MDQ5_88b6719d-4e1b-4ca7-9447-83d85e03339e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTMtMS0xLTc4MDQ5_a7eb97fb-8abe-4e02-8218-3cae2e060624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTctMS0xLTc4MDQ5_cad8ac79-6845-4db2-83ee-353fbd4ab361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTktMS0xLTc4MDQ5_2b025f94-29d0-49e4-a000-5b985b5f03d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTExLTEtMS03ODA0OQ_f7c9cc8f-e10f-444c-baea-8d328e4df313">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTEtMS0xLTc4MDQ5_4ae6a334-f00a-4808-a03c-0feeb85c10dd">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTMtMS0xLTc4MDQ5_7e5ebbc4-e579-436b-bdf2-8c4eccc07575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTctMS0xLTc4MDQ5_b2191fcf-9426-4276-9267-f9aa954ab85f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTktMS0xLTc4MDQ5_b1d8e567-1b0d-44aa-ba4f-8dcc79042785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTExLTEtMS03ODA0OQ_cea8fc55-a23b-4aa6-8747-de2b3bc91c62">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d998702002443e1bdceee7c1cd3cda9_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTEtMS0xLTc4MDQ5_e48345a5-16c8-4a52-8c93-8fcbb9235ca8">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i360abcc2cf914906ae4e38a91bc64c5f_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTMtMS0xLTc4MDQ5_a93db08f-b48e-4511-b75e-2ca156b468bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e9582cb2ed44069090ba97e16cd18e_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTctMS0xLTc4MDQ5_c6b4ed3b-0b0e-4ee9-8d68-f2e97cccd9fc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79df65678198415585bd1eadb7bbe9b7_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTktMS0xLTc4MDQ5_289962c6-3808-4be7-aff5-1bddf7981df4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTExLTEtMS03ODA0OQ_eef705fd-2e3b-454a-b9bb-5b746934ee46">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTEtMS0xLTc4MDQ5_261498b0-d1f2-423d-936a-7dcdad0ec475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTMtMS0xLTc4MDQ5_68dae3bb-ae2a-4281-9365-40de45ea3a5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTctMS0xLTc4MDQ5_2c83b6fc-4973-4e6b-84f1-39d9253fbbd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTktMS0xLTc4MDQ5_1b59a1c3-c563-436c-af94-d469539de223">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTExLTEtMS03ODA0OQ_564d2a6c-add6-4d71-8af6-857401f834e3">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no individually material transfers into or out of Level III during the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, &#8220;Business Acquisitions,&#8221; we completed our acquisition of Integra in 2022 and the acquisitions of myNEXUS and MMM </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-97-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i0c3fe568c5814f8d86fca505c040dbd4" continuedAt="i833ee46cf81e449a80d2e141913f2256"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during 2021. The net assets acquired in our acquisitions of Integra, myNEXUS, and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December&#160;31, 2022 or 2021.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value on the consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other invested assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Other invested assets primarily include our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities&#8217; undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-98-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i833ee46cf81e449a80d2e141913f2256"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt&#8212;commercial paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt&#8212;senior unsecured notes and surplus notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt&#8212;convertible debentures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjgx_86e7af94-0460-4d87-bd4b-705cec69c1e3" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29275f18d1a443b99c9691261dec2159_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtMS0xLTEtNzgwNDk_bf8e531f-8567-4d29-9d56-1341a6b1e267">5,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib761ace65d4940a186ff76782f95901f_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtNS0xLTEtNzgwNDk_f7374182-fd01-49a4-8c43-2634e8c4c7a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtNy0xLTEtNzgwNDk_c0d36179-cc20-4b01-9444-94a1decf9bcd">5,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtOS0xLTEtNzgwNDk_67039389-d5c2-449a-8334-08c43052092a">5,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29275f18d1a443b99c9691261dec2159_I20221231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctMS0xLTEtNzgwNDk_12609f38-8d1b-4376-b306-d090d23b90aa">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib761ace65d4940a186ff76782f95901f_I20221231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctNS0xLTEtNzgwNDk_1ab35014-1440-4bea-a82a-00316186edf0">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctNy0xLTEtNzgwNDk_6664ed04-4b87-466b-bb78-f0dea3580a1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctOS0xLTEtNzgwNDk_fc17ec43-ac63-4d84-b829-9a91416f2244">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29275f18d1a443b99c9691261dec2159_I20221231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktMS0xLTEtNzgwNDk_bd48f265-8901-4e2b-b91a-87ad55d0ca50">23,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib761ace65d4940a186ff76782f95901f_I20221231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktNS0xLTEtNzgwNDk_617d3f98-6dd6-419a-9a5a-bfca6e7353da">21,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktNy0xLTEtNzgwNDk_7fa19e82-bcb8-4889-aca7-5c6356a0c06e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktOS0xLTEtNzgwNDk_47e8b023-ca31-4a04-bd2a-93b2fa1066d0">21,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29275f18d1a443b99c9691261dec2159_I20221231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTEtMS0xLTc4MDQ5_b334438b-6afb-45a4-9d51-6c3b727e8881">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib761ace65d4940a186ff76782f95901f_I20221231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTUtMS0xLTc4MDQ5_ff8437a2-dcfc-44cd-9e07-d0b9192a8c00">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTctMS0xLTc4MDQ5_89c3675c-d9b5-4751-a1ce-2f5b64555cc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTktMS0xLTc4MDQ5_3f6c5208-4341-4c0f-aeae-1ccc8349eaac">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTEtMS0xLTc4MDQ5_7d443573-d8c5-4af9-8c5a-0e06ad81a1e9">5,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTUtMS0xLTc4MDQ5_1ac4cbb4-d364-4530-8bf2-1b6202debaa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTctMS0xLTc4MDQ5_d9a123d0-ccd4-4a45-99de-553a2c040ad8">5,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTktMS0xLTc4MDQ5_36a17a0f-f551-4009-b6fe-fd630d71ea07">5,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTEtMS0xLTc4MDQ5_a414d610-be7b-41ec-aec7-a77893d89e57">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida04d4221bb546bc95004ba270b1eebb_I20211231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTMtMS0xLTc4MDQ5_d0516923-1474-461d-bc5a-20265fdbbbf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTUtMS0xLTc4MDQ5_34b2120d-8012-4086-8215-ae7a80ec5b23">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTctMS0xLTc4MDQ5_3df5592d-9306-42bb-a180-f4eb1c803134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTktMS0xLTc4MDQ5_7542af30-3358-4e6d-a241-9e4371ce090f">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTEtMS0xLTc4MDQ5_08974f72-6f40-4cca-974c-e81bb128b8a5">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTUtMS0xLTc4MDQ5_da3a2430-4409-474c-aecf-bc8a984c55ec">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTctMS0xLTc4MDQ5_a1f6e9fc-f9a7-43af-9ef8-ef9519f9c1f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTktMS0xLTc4MDQ5_1fdea2dd-6aa4-43e6-94f6-27f02310f48a">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTEtMS0xLTc4MDQ5_34f3f1b8-10a6-43a6-9807-b5360979ec44">22,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTUtMS0xLTc4MDQ5_9774448f-c295-4dc5-a7ef-9931627b61bd">25,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTctMS0xLTc4MDQ5_5470b838-0ae0-4019-8ec3-2acefd1c5246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTktMS0xLTc4MDQ5_301f18d7-dc09-49d7-8d0a-f73b3fe1bbca">25,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTEtMS0xLTc4MDQ5_8b3b7be4-ebf1-44fa-a253-71ac88357197">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTUtMS0xLTc4MDQ5_e8605e6b-1fb7-454e-8e66-a2898ea348bd">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTctMS0xLTc4MDQ5_f12bd9da-37f0-487f-b1a8-2def28b0698a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTktMS0xLTc4MDQ5_c7ef72b6-e438-47f2-b8c4-7fa7672637ed">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-99-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUzMTE_ce458c4b-7f1a-44ba-ba9d-7e31b2e2ab00" continuedAt="id942401c996a4197bf8e4fd8d5ef829d" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="id942401c996a4197bf8e4fd8d5ef829d" continuedAt="i5251dd5d2b524e159ae891679660df0a"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUzMDA_a604556f-adec-47b5-8d70-1098933242a7" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income taxes at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzMtMS0xLTEtNzgwNDk_b4046b3b-4639-4a0c-b5b7-abbf7462a1db">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzMtMy0xLTEtNzgwNDk_1dc81b4c-474f-4ec9-afd3-4fdda02e8242">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzUtMS0xLTEtNzgwNDk_f77e70fb-c52e-44f2-8605-de34e0fc8402">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzUtMy0xLTEtNzgwNDk_831040dd-9783-4fb7-aaee-6b3f45e8433a">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzYtMS0xLTEtNzgwNDk_3c855650-75e3-4536-a589-81d0f7272cff">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzYtMy0xLTEtNzgwNDk_8972a387-cfbc-4084-ac55-f62df73967e7">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:DeferredTaxAssetsLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzktMS0xLTEtNzgwNDk_5b67b2c2-7d8c-4fb4-8fb2-bc6fa392a860">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:DeferredTaxAssetsLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzktMy0xLTEtNzgwNDk_2e36f1f3-a6c8-490b-b40a-ecf83d7018ad">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEwLTEtMS0xLTc4MDQ5_370345c1-779e-4128-bcc0-3100326eac1d">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEwLTMtMS0xLTc4MDQ5_27c8a35f-a05f-4339-aadd-3a877d218db1">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzExLTEtMS0xLTc4MDQ5_37fc8853-6cb1-4314-b5f0-69a8b375d602">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzExLTMtMS0xLTc4MDQ5_93c69f3e-709b-483a-a05e-6382b6fc8106">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEyLTEtMS0xLTc4MDQ5_e211c5b3-04ef-488d-9992-e4a2196ab329">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEyLTMtMS0xLTc4MDQ5_a0d1d39c-f7a9-4789-80a4-1576c5f55a19">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTEtMS0xLTk5OTg3_7d4317aa-153e-4200-b78c-c6ac00d337ff">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTMtMS0xLTk5OTg5_f6f59637-457b-4953-9f08-b46933ddd0ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTEtMS0xLTc4MDQ5_63ee1f87-7735-4d55-b032-2beff16620e3">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTMtMS0xLTc4MDQ5_c4213042-98f1-4ced-8ece-77f3c2d78a19">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE0LTEtMS0xLTc4MDQ5_9c613fde-b34a-4f00-b6a8-217cef077c8e">2,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE0LTMtMS0xLTc4MDQ5_23e82b1d-c11f-4eb5-8e0a-e4d2d78f5db7">1,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE1LTEtMS0xLTc4MDQ5_9a0903c7-cb69-4de4-b128-e320470b3105">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE1LTMtMS0xLTc4MDQ5_287049c8-803e-4cb2-9ee8-6a66f5e10d08">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE2LTEtMS0xLTc4MDQ5_11d2e523-19f6-4ed1-bd04-add48333e413">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE2LTMtMS0xLTc4MDQ5_5104c46e-190e-4fc0-b975-10506174cad9">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal and state intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE4LTEtMS0xLTc4MDQ5_e162f16c-f95f-4879-9b8a-e0056ac33f12">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE4LTMtMS0xLTc4MDQ5_d9df69c5-f824-4db4-a87e-ef343939e547">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (including Puerto Rico) intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:DeferredTaxLiabilitiesNonUSIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE5LTEtMS0xLTc4MDQ5_12358d94-63ec-4760-a38d-5ba4ca8ad3a0">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:DeferredTaxLiabilitiesNonUSIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE5LTMtMS0xLTc4MDQ5_4ffaccea-0520-4fe9-bee1-023415fc9c60">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIwLTEtMS0xLTc4MDQ5_83bc4c4a-76b7-444a-88f9-5b901d69b3bb">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIwLTMtMS0xLTc4MDQ5_cf02de20-27d2-49bc-a280-a2f9d209c6d4">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIxLTEtMS0xLTc4MDQ5_2fda6bfe-e314-49be-a5fe-571bcfc34e3e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIxLTMtMS0xLTc4MDQ5_10b88a4a-61fa-4b2e-8c63-5bc285218062">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIyLTEtMS0xLTc4MDQ5_5cb6f51c-2138-461b-8fb0-b0d38113e6aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIyLTMtMS0xLTc4MDQ5_3abdad48-4a4b-4766-a36a-80f1ad0254a4">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIzLTEtMS0xLTc4MDQ5_ef8126c9-8b4e-4e88-bb6c-c2e0e5e4b05b">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIzLTMtMS0xLTc4MDQ5_5209da76-55a8-417e-8b23-f98ba03a16e6">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI0LTEtMS0xLTc4MDQ5_6314aba5-be5d-4494-8786-1247c376a264">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI0LTMtMS0xLTc4MDQ5_6e5bf15b-c4aa-47d2-baa3-e5649d85116d">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI1LTEtMS0xLTc4MDQ5_a896095c-deee-45be-bc8a-5681a04a7a1d">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI1LTMtMS0xLTc4MDQ5_0b1dc0cb-77b7-476a-8fe3-17462ae0e9b0">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI3LTEtMS0xLTc4MDQ5_9719a708-c149-4480-9f9c-73b4118bd9fb">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI3LTMtMS0xLTc4MDQ5_49c066a6-1dba-4b88-a18b-c519938ec3fb">4,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI4LTEtMS0xLTc4MDQ5_fe7d7882-ca44-4c82-8571-2356902edf86">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI4LTMtMS0xLTc4MDQ5_905d7673-f1bc-4304-9fc2-9ab0043adc00">2,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognized $<ix:nonFraction unitRef="usd" contextRef="iaae7271d9499404cbd33f47b9000a9f2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzIzMw_6a5f3d3b-c692-421d-b8e3-476db57b77fd">137</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i47b12cb75dff40b3bf086b65a329faee_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI0MA_b5907e5f-3da0-4b29-a05e-af085f8ad118">103</ix:nonFraction> of deferred tax asset under the caption &#8220;Other noncurrent assets&#8221; at December 31, 2022 and 2021, respectively. We recognized $<ix:nonFraction unitRef="usd" contextRef="i1e3f09e2780b43d58044eb37c7023411_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzM2OA_40cc5a29-3099-4e18-b0a0-a846ab7a2145">2,034</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0f3311caed27499f9d192299b6eb8a0d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzM3NQ_17839084-8ee8-4809-8251-bd39702a7626">2,805</ix:nonFraction> of deferred tax liability under the caption &#8220;Deferred tax liabilities, net&#8221; at December 31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have established U.S. deferred taxes for undistributed earnings from certain non-U.S. subsidiaries, which are included in the Investment basis component above, consistent with prior years.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUzMTA_3ecdfd23-eb4f-4f08-9b9a-7f5d25fe6e5b" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020 consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzItMS0xLTEtNzgwNDk_c8d9a7e6-4bfb-404e-bcfd-e943a0aa9bf1">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzItMy0xLTEtNzgwNDk_5daada67-2c34-4826-bd4b-90da106798ca">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzItNS0xLTEtNzgwNDk_73e1b163-c279-4319-b8ba-cb920b4e13a7">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (including Puerto Rico)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMS0xLTEtOTk5OTE_90fd741a-c205-4687-bad6-da1d3fc4b69e">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMy0xLTEtOTk5OTM_9f9dd91e-5063-4960-b6ad-c849097931e2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtNS0xLTEtOTk5OTU_e2866072-f781-42a7-ae16-73fe36751171">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMS0xLTEtNzgwNDk_29d6b877-53f9-4f21-8982-7a4eabbefc41">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMy0xLTEtNzgwNDk_11f96892-d37b-4d41-8d22-743a67746b86">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtNS0xLTEtNzgwNDk_e9a3b578-95fc-47f8-9e20-8282f6b60f49">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzQtMS0xLTEtNzgwNDk_25facddc-7168-4320-a186-3973408d80d4">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzQtMy0xLTEtNzgwNDk_e8806cee-1a90-4a83-9966-5658d305642b">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzQtNS0xLTEtNzgwNDk_39d20f6a-bbae-45ec-b016-0138dbd91297">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzUtMS0xLTEtNzgwNDk_99730da8-837e-48aa-b0cf-47476727185d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzUtMy0xLTEtNzgwNDk_bd02b274-c8b0-49ff-a5b4-80a6bb29eed0">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzUtNS0xLTEtNzgwNDk_3b033f5c-fa01-437a-89ae-3812d0c0ba1c">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzYtMS0xLTEtNzgwNDk_f1f3ce53-e863-4bb3-8189-027fdeaac19b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzYtMy0xLTEtNzgwNDk_bdebfc45-c1fb-457e-8b42-2b7dc6a6124e">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzYtNS0xLTEtNzgwNDk_62003070-2041-4d1a-b38e-37832193aed5">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-100-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i5251dd5d2b524e159ae891679660df0a" continuedAt="i2367ea60663e4a589596fd3a40e3a496"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local current tax expense is reported gross of federal benefit in the preceding table, and includes amounts related to audit settlements, uncertain tax positions, state tax credits and true up of prior years&#8217; tax. Such items are included on a net of federal tax basis in multiple lines in the following rate reconciliation table.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyNzk_d4290e99-4c6e-480e-9042-7609dc6a5a19" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItMS0xLTEtNzgwNDk_a6505731-0964-47d8-87cd-65ad2add9a39">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItMy0xLTEtNzgwNDk_b9fd66e6-a5cf-473d-81f0-c13a7ebb9a91">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItNS0xLTEtNzgwNDk_87b6da50-8fad-4321-b32a-41ce3f1ef2ce">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItNy0xLTEtNzgwNDk_2ab250a2-d240-4039-bd54-e70ec31a94ff">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItOS0xLTEtNzgwNDk_08d2d992-cb18-49f1-99de-19dc644b266c">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItMTEtMS0xLTc4MDQ5_1f8eee1e-faee-4b19-a2b0-1ef41efee8dd">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax expense/benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtMS0xLTEtNzgwNDk_e2c8d0ff-a806-42c5-8f60-cff0b6f6200b">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtMy0xLTEtNzgwNDk_1ecce41e-30a2-4fb9-8185-d292b09c169a">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtNS0xLTEtNzgwNDk_9564021c-e058-4d10-885c-5bdc86cacbb9">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtNy0xLTEtNzgwNDk_3d9ec869-5dd0-4035-88a8-8eea366e5cf7">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtOS0xLTEtNzgwNDk_ff4525ef-08d3-4d18-a5f4-3ce4fd375345">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtMTEtMS0xLTc4MDQ5_9a9b4bd6-ee26-44cb-a0c2-293c5706a69c">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax exempt interest and dividends received deduction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtMS0xLTEtNzgwNDk_0ba22725-aabe-43c2-88c0-d1c4b9b01e3b">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtMy0xLTEtNzgwNDk_a2933643-d7df-426c-86c0-80f7cd0a37b4">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtNS0xLTEtNzgwNDk_7d05f882-124b-431b-808e-309033d2a0ab">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtNy0xLTEtNzgwNDk_1fffd569-9a7b-4471-84ed-d9598d8b2ae1">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtOS0xLTEtNzgwNDk_4384028a-c5b0-4c72-be72-bae540ce90ca">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtMTEtMS0xLTc4MDQ5_521045f3-448f-4e72-880c-ff07f95666f9">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIP fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtMS0xLTEtNzgwNDk_3695bb36-cc1c-42ff-adcf-5cc19cde5cc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtMy0xLTEtNzgwNDk_57fa06b4-706d-4de6-9fb5-b715b2cc637e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtNS0xLTEtNzgwNDk_867df56e-627b-4027-b8c7-dbfa0e4e735e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtNy0xLTEtNzgwNDk_c3852b9e-09ea-4cb1-b94b-1045a348af3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtOS0xLTEtNzgwNDk_aefabc4b-a122-41ad-902d-85554a7e83b5">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtMTEtMS0xLTc4MDQ5_9c13a54b-719f-44a3-9044-3f36873995de">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis adjustments from recent acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtMS0xLTEtNzgwNDk_0bcdbdb8-85e6-498c-b90f-588b4b6d974c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" name="elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtMy0xLTEtNzgwNDk_d066b9a6-dd89-433f-89fd-0a73741b9df7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtNS0xLTEtNzgwNDk_539d5875-1ddb-4684-9164-0f590d1ea359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" name="elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtNy0xLTEtNzgwNDk_2740054e-8bab-41fc-9dee-69adf63d9ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtOS0xLTEtNzgwNDk_9a088b1c-36d1-4dbf-9943-44532e929d20">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" sign="-" name="elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtMTEtMS0xLTc4MDQ5_ee775456-3eb3-40be-9a21-5a33b72d5027">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctMS0xLTEtNzgwNDk_c4732900-e895-4349-8480-bfd122cfd3d4">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctMy0xLTEtNzgwNDk_a3977f73-c8ae-4f38-92b9-503aa2c7ee99">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctNS0xLTEtNzgwNDk_9c48ce1a-750d-4d20-9efc-1620d4b288d4">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctNy0xLTEtNzgwNDk_7bdb446f-ee89-4c7e-a4ba-53772283a675">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctOS0xLTEtNzgwNDk_1e668590-7c42-41cb-9a8a-1a19698c6df5">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctMTEtMS0xLTc4MDQ5_c285a547-ad8a-46af-b691-f008a884331e">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtMS0xLTEtNzgwNDk_eaeee296-a09e-427a-878a-c3eea2d5dd6c">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtMy0xLTEtNzgwNDk_a3749448-fc38-4c6e-8b5b-178afaff693f">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtNS0xLTEtNzgwNDk_682042ad-d12c-4a27-b8b7-dde7e0a0bd24">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtNy0xLTEtNzgwNDk_3231713a-38a9-4b56-9cf9-b095a1bef131">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtOS0xLTEtNzgwNDk_2a67f385-b5ab-432f-a7c4-97bba23ebd60">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtMTEtMS0xLTc4MDQ5_b2bfbc1e-ca23-40ce-8270-86269e8ed839">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we recognized income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE2NDE_b6083573-cc1e-4449-85d0-4a2b4fd54e96">1,750</ix:nonFraction>, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE2NDg_4fa70528-0b12-4c23-98a7-b88bab91825e">7.21</ix:nonFraction> per diluted share. The decrease in effective income tax rate is primarily due to the impact of geographic changes in the mix of 2022 earnings.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzEwOTk1MTE2MzYyNDY_20563bb0-66dd-406e-a66c-103e49d36957">1,830</ix:nonFraction>, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="2" name="us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzEwOTk1MTE2MzYyNTc_2d313bba-ea1d-4632-b6fb-f6e95bc69a62">7.41</ix:nonFraction> per diluted share. The HIP Fee payment was eliminated beginning in 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recognized income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4MDE_e36d6637-a951-470b-ad08-1b867a906582">1,666</ix:nonFraction>, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="2" name="us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4MDg_114059e0-bb7f-465a-8486-440b0e2e882d">6.55</ix:nonFraction> per diluted share, which included income tax expense of $<ix:nonFraction unitRef="usd" contextRef="if2e18d5b222e4195ad3fcd596a9a4307_D20200101-20201231" decimals="-6" name="elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4Njc_a2affae9-3efd-4210-b4a5-d7a10fccf871">330</ix:nonFraction>, or $<ix:nonFraction unitRef="usdPerShare" contextRef="if2e18d5b222e4195ad3fcd596a9a4307_D20200101-20201231" decimals="2" name="us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4NzQ_2ee93b4b-a8ab-44e4-98e3-55641f074388">1.30</ix:nonFraction> per diluted share, as a result of the non-tax deductibility of the HIP Fee payment.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyODA_a975cbbf-71f8-480d-9488-8310b8f9287d" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzEtMS0xLTEtNzgwNDk_25deec56-3f1f-425c-ae00-5d300c014f50">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzEtMy0xLTEtNzgwNDk_e5e5ed1e-2311-470d-8e61-5a2886f6b9e5">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzMtMS0xLTEtNzgwNDk_cbf6ae79-5a99-44db-aed8-834f23f1652f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzMtMy0xLTEtNzgwNDk_c5a9a34a-4632-455a-8e7c-27029bce1013">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzQtMS0xLTEtNzgwNDk_a3bb6171-d9cf-40ca-ab27-ad125e905854">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzQtMy0xLTEtNzgwNDk_e5c7b07f-2a7e-439e-ade0-7711c0ee00aa">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzctMS0xLTEtNzgwNDk_a626cb22-9643-46ce-be6c-6766c902c37a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzctMy0xLTEtNzgwNDk_b635ae67-5009-438e-b3c3-ed69e3424cb1">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzktMS0xLTEtNzgwNDk_2be47abe-2d9e-402d-9371-368cc00a948a">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzktMy0xLTEtNzgwNDk_9ad5bdb0-2df0-45ad-bc8d-8d3bb55468c2">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is included in the amounts described in the following paragraph. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI2MjY_65e8d04a-801b-44aa-a44a-7df670cf2b12">328</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI2MzM_46b24838-7746-4886-9ea9-ac2bf642c70c">250</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. Also included in the table above, at December&#160;31, 2022, is $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI3MDg_021c8876-a79d-40da-b2ff-7c8aa914babb">2</ix:nonFraction> that would be recognized as an adjustment to additional paid-in capital, which would not affect our effective tax rate. In addition to the contingent liabilities included in the table above, we filed protective state income tax refund claims of approximately $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:IncomeTaxRefundClaimsFiled" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI5NzA_f6f181d9-ffe1-45e6-aef1-3226d914753a">92</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4eb438ebee364c309fc5d5bf8993c811_D20170101-20171231" decimals="-6" name="elv:IncomeTaxRefundClaimsFiled" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzU0OTc1NTgyODg3NA_099f9cf4-8111-44a8-832d-14fdde64a5e5">310</ix:nonFraction> for 2022 and 2017, respectively. There were no equivalent protective state income tax refund claims filed in 2021, 2020, 2019 or 2018.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-101-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i2367ea60663e4a589596fd3a40e3a496"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020 we recognized net interest expense of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMxNDU_76264629-77d0-4668-8e7b-1cdfd61ff769">13</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMyNDM_2e1ce07f-1ed8-468b-aa68-c0da3195f49a">9</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMyNTA_3cc5d38b-69fa-4529-8b6d-26be4b5ddea7">7</ix:nonFraction>, respectively. We had accrued approximately $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMyOTc_2a5d5dd1-d34b-421c-a84c-c891896acdf6">55</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMzMDQ_e86a4577-e430-4811-9168-5297ca0a2efc">42</ix:nonFraction> for the payment of interest at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, as further described below, certain tax years remain open to examination by the Internal Revenue Service (&#8220;IRS&#8221;) and various state, local and foreign authorities. As a result of these examinations and discussions with taxing agencies, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could be reduced within a range of approximately $<ix:nonFraction unitRef="usd" contextRef="ib99d2d66da9844cab49602099b561dda_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQyMDI_a1d58c18-62ea-4c77-b735-5dc7426084ec">33</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i725fb0d8346e4b058763cea8f52dbda8_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQyMDg_0c856095-dfd7-44cd-bafc-e0746130725a">143</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member of the IRS Compliance Assurance Process (&#8220;CAP&#8221;). The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the IRS examination of our 2022 and 2021 tax years continues to be in process.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported in selling, general and administrative expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i6360a309b9734213b5078c4fb29519ed_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQ3Njg_2f45c44b-ac40-43da-a990-1b163756e51d">160</ix:nonFraction> that will expire beginning 2032 through 2042 and $<ix:nonFraction unitRef="usd" contextRef="i608f90ce9dc149a3bbb7d2041635b146_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQ4MjA_37867e09-7e81-4f2f-87a3-4b8c784e521e">109</ix:nonFraction> that have an indefinite carryforward period. State net operating loss carryforwards expire beginning 2023 through 2042, with some having an indefinite carryforward period.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes receivable totaled $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:IncomeTaxReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUwMjc_78f04381-b3c3-4a4c-8b6c-edee93984f4b">440</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:IncomeTaxReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUwMzQ_81d7973c-d013-447a-8d40-f1ffe21adf6a">173</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. We recognize the income tax receivable as an asset under the caption &#8220;Other current assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, federal income taxes paid totaled $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzEwOTk1MTE2MzYyNjQ_381e11de-650e-40a5-be87-7d6501d6da7b">1,594</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyNTM_99d692fc-402c-43a0-a4f8-be1cdcaf5fa6">1,299</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyNjA_e10bb3ea-9607-4962-90d7-fa6d9f8e7463">1,790</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzEwNzA_89db9038-4405-4b15-912d-4f7a0db8772d" continuedAt="if9a73d2ae3a6479091654bc8039f754b" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="if9a73d2ae3a6479091654bc8039f754b" continuedAt="i8899adf2929744d495a0c10c9112412b"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzEwNjU_c4e989fb-3d87-4df4-a63f-ee39510b9c63" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of property and equipment at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5dcccaf6344690b4d7278e78ed1c0f_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzEtMS0xLTEtNzgwNDk_efc8b03d-d5f9-4c76-9bc3-0314e585dfdf">5,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6370e321e07c4309a9e458991006a124_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzEtMy0xLTEtNzgwNDk_bb31c3cb-19b5-46a0-adaa-ccf942418d90">6,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, furniture and other equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbfdb76686848eba1f8e4e3f910ddd7_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzItMS0xLTEtNzgwNDk_a44d8e17-1a69-460c-aefa-35f0b17b29f8">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2273513928e9447ea6f22d1ef1546380_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzItMy0xLTEtNzgwNDk_d2304314-5e07-4a0a-8498-126989779487">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c1eace13124235af0ad332c211c0f0_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzMtMS0xLTEtNzgwNDk_aa41cd15-dedc-46f7-87a7-faf31c359216">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299992abfe3a42a19dbf532c6dfc8e3f_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzMtMy0xLTEtNzgwNDk_2375a8cc-6925-42ff-afb9-67a1a1eda473">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96687506b8f94774b0749011a7e8cc30_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzQtMS0xLTEtNzgwNDk_0aa0cae4-db40-46c2-a39e-1eb7c6cfd387">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04cdfc65ff948fc912a66ca626eb27e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzQtMy0xLTEtNzgwNDk_4c9de0d5-645f-425c-966b-3b7adbaf089e">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d2136218984fc386824cc3db496a1b_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzUtMS0xLTEtNzgwNDk_7e69b14a-4340-4f82-8381-68f19c21a5dc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cda9b6c29f4c1188c4b091bb78bbdf_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzUtMy0xLTEtNzgwNDk_11b6a2c4-431b-4d32-89ee-f9ee653a8c2d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzYtMS0xLTEtNzgwNDk_d13b5951-0995-4e7f-bc0c-e0b1c93e3caa">7,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzYtMy0xLTEtNzgwNDk_635dbc78-5400-40c5-8811-204a436c529b">8,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzctMS0xLTEtNzgwNDk_018f0df9-d916-4944-8124-7b303f7179a8">2,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzctMy0xLTEtNzgwNDk_4e70d63f-6fec-4ec1-aecc-23521f25d563">4,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzgtMS0xLTEtNzgwNDk_7a076035-9914-466d-8769-ebda4c9cf752">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzgtMy0xLTEtNzgwNDk_58ead171-5ac6-4365-92de-8e71d7527297">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzE0MA_fb261f3b-5d4f-4a33-b988-dfbbc65ce47c">123</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzE0NA_fc42e7c7-525f-4b11-92a5-cf9d3ff73762">136</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzE1MQ_349f8006-2614-4926-84eb-1bb3b9b9e0ab">176</ix:nonFraction>, respectively. Amortization expense on computer software and leasehold improvements for 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzI2MA_a8e755b9-86d6-486f-b8fe-c28c2c2a9115">661</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzI2NA_887531d3-5af6-468a-9a39-bbf5307d2546">532</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzI3MQ_507d3d54-aab3-41be-9e01-e9a93d67c700">462</ix:nonFraction>, respectively, which includes amortization expense on computer software, both purchased and internally developed, for 2022, 2021 and 2020 of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzQwOQ_722b5ca7-ef1b-43ba-be5e-1c39d492d1e7">599</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzQxMw_3b23362c-d89c-4242-b24a-fd58d732144a">485</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzQyMA_e5b5d9f8-6bdb-4ff8-90ab-3d3fd916d1a9">412</ix:nonFraction>, respectively. Capitalized costs related to the internal development of software of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzUwNw_d7cde342-9e3c-449a-8de3-79c982c9d482">5,354</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzUxNA_bd3f2223-77b7-49c5-a1ca-67696faf5cd8">5,626</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively, are reported with computer software.</span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8899adf2929744d495a0c10c9112412b">Impairment of property and equipment for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzY1Mw_0b606859-62cf-4bba-b371-612cdd404802">7</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzY2MA_5af5ab06-c8ae-4b7b-ba1d-3604a66a5636">73</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzU0OTc1NTgxNTI3MQ_e498f626-a01b-4b3c-8528-5ab3f84732fc">198</ix:nonFraction>, respectively, which is included in selling, general and administrative expenses and primarily related to our activities disclosed in Note 4, &#8220;Business Optimization Initiatives.&#8221;</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-102-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3ODE_3ef2f347-1b61-4bb9-bb88-ddc8063238f9" continuedAt="i5419e345a3464dbbb28aca4757464a9c" escape="true">Goodwill and Other Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i5419e345a3464dbbb28aca4757464a9c"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3ODM_30d47143-118a-4d5e-a84d-d0b27ac7c400" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the change in the carrying amount of goodwill for our segments (see Note 20, &#8220;Segment Information&#8221;) for 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtMS0xLTEtNzgwNDk_899d44aa-1315-45d6-b9a0-a865065f2f2a">11,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtMy0xLTEtNzgwNDk_cff3f8e1-5464-47fd-8ba0-1c84278b1b06">8,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414a136e0db84003bf078b0578623a1e_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtNS0xLTEtNzgwNDk_76145b57-ed29-45eb-9231-a2fb3f9b36b0">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878444205e1c46049c539d9fd06405ae_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtNy0xLTEtNzgwNDk_6f5a5731-24c6-4e44-b563-f4335e4a516e">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtOS0xLTEtNzgwNDk_ae141754-d9b8-4b6c-abaf-e523c1f1b1f6">21,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtMS0xLTEtNzgwNDk_76ed2156-d469-485e-aa01-f4a82eb8355a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtMy0xLTEtNzgwNDk_a2708545-ef81-4330-88f0-ee643a0f7c8d">2,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtNS0xLTEtNzgwNDk_84fb5108-fd62-40e8-b1c7-47434313735c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6addc423352741bab0b178cdde51da3a_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtNy0xLTEtNzgwNDk_22af8e9b-98d4-4243-a63e-ec3bb8e7c788">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtOS0xLTEtNzgwNDk_3c7488d0-aa58-454a-a8c0-b4fec06185e7">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtMS0xLTEtNzgwNDk_cf580b2f-48c6-4f9a-bd0d-0648a78834b0">11,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtMy0xLTEtNzgwNDk_39ee0485-0038-4dc4-a10f-dee1890cb042">10,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1719b8ce5348aca152c341aa0c2afd_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtNS0xLTEtNzgwNDk_edeb9258-2486-41a2-ab71-a81e5644aa99">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd5af0076694b48bcfd411f1a1d2e11_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtNy0xLTEtNzgwNDk_ed607378-f4de-4b48-a474-3ed97a915ba8">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtOS0xLTEtNzgwNDk_6cb3de9c-09f7-4705-a455-fcecc313fcbd">24,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtMS0xLTEtNzgwNDk_4250532d-6f74-45e7-863a-25ed6f687dad">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtMy0xLTEtNzgwNDk_45afad12-9cfd-4f0b-aede-72797a4a4498">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtNS0xLTEtNzgwNDk_2da07ca1-7a62-4a86-98d2-b1c2b5de1163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307c5528ab3a457cbfb9833f2f43c891_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtNy0xLTEtNzgwNDk_a8a7a409-585a-40fa-ba69-9c522909b047">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtOS0xLTEtNzgwNDk_72dd4803-44e3-46fa-bae7-1eea3dba2dc8">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtMS0xLTEtNzgwNDk_b1615603-ae41-49de-8a2d-35a2d0c1f8d5">11,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtMy0xLTEtNzgwNDk_10363e98-9417-411f-8245-b1a758a74c45">10,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c60676ab036430ab5cabf0a0d051ae4_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtNS0xLTEtNzgwNDk_c7e78d63-cf35-4924-9fdb-a4280c73bfdc">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363acffb9a824cb3994c18c156fa9f14_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtNy0xLTEtNzgwNDk_a3d3fc5d-d969-48b2-a9fa-899ce9734512">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtOS0xLTEtNzgwNDk_ef543d0c-1ed7-44bf-9be1-59051d7ad514">24,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment as of December&#160;31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctMS0xLTEtNzgwNDk_09367dbe-154c-4760-91cc-01b681c74d6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctMy0xLTEtNzgwNDk_4ed3e622-36ed-4a0d-b5e0-4d717c14f473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c60676ab036430ab5cabf0a0d051ae4_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctNS0xLTEtNzgwNDk_26c1378c-9fde-4b2a-a036-99c2015f4b57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363acffb9a824cb3994c18c156fa9f14_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctNy0xLTEtNzgwNDk_86041cb4-a1e0-4545-9bf9-28ef6e4ecad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctOS0xLTEtNzgwNDk_d86a6537-9c30-4830-b4cc-bbf3cfc0280d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2022, 2021 and 2020. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. For quantitative testing, the fair values are estimated using the projected income and market valuation approaches, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections, income projections, cash flows and discount rates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not incur any impairment losses in 2022, 2021 or 2020, as the estimated fair values of our reporting units were substantially in excess of their carrying values.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3ODk_ef6bb875-20d6-4246-b03c-d6ad4973531f" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of other intangible assets as of December&#160;31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:35.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.858%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef9f77b3653474080b83cf476ebe688_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtMS0xLTEtNzgwNDk_5989eb14-831c-4a17-b740-eea50f04855c">5,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibef9f77b3653474080b83cf476ebe688_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtMy0xLTEtNzgwNDk_eab69383-0e91-45a3-8dc0-e4d683940407">3,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef9f77b3653474080b83cf476ebe688_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtNS0xLTEtNzgwNDk_0db385e6-cb35-425f-ad5c-3f67ff26b6d3">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtNy0xLTEtNzgwNDk_0d90797a-95f6-42ec-8c22-64ae1d820582">5,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtOS0xLTEtNzgwNDk_ab8fdcf9-a16d-4292-9189-1c86db3feb65">3,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtMTEtMS0xLTc4MDQ5_fa4fea16-a10d-4547-a5bc-00b1bddff3c7">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8591443e8521443493e922d924cd9752_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtMS0xLTEtNzgwNDk_4120a3f8-0565-489b-b569-b37d7949bbbc">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8591443e8521443493e922d924cd9752_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtMy0xLTEtNzgwNDk_ce394fd8-e63a-4732-becf-88ead8c268e8">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8591443e8521443493e922d924cd9752_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtNS0xLTEtNzgwNDk_84cbad60-d15b-44be-bafc-ebfe6e94bc45">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666bee6f945341f288f2ce40ac054956_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtNy0xLTEtNzgwNDk_1602e90c-b46b-492f-9da8-f940763a7e37">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i666bee6f945341f288f2ce40ac054956_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtOS0xLTEtNzgwNDk_3dc994cd-b20c-410f-9762-e1b9a1c2ea44">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666bee6f945341f288f2ce40ac054956_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtMTEtMS0xLTc4MDQ5_2e70b4c2-2131-43e0-9fdb-6ecbeb26fed5">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i899c188b277246f88a96c04a8b0e3a2d_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtMS0xLTEtNzgwNDk_2cf99f0e-31e9-4b29-bf16-c94e7dfaf373">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i899c188b277246f88a96c04a8b0e3a2d_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtMy0xLTEtNzgwNDk_d75dfefe-4f18-4b38-b004-342c593e9888">440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i899c188b277246f88a96c04a8b0e3a2d_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtNS0xLTEtNzgwNDk_21136a1f-9b25-4903-a7a1-5366f15442f8">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtNy0xLTEtNzgwNDk_469a3b58-559a-47cd-b448-00987b8a8104">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtOS0xLTEtNzgwNDk_f9262503-8e11-4cdc-a4e0-7d1e2dd8318a">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtMTEtMS0xLTc4MDQ5_a0f82eba-0e1b-4cf3-a132-5e1e95ff6966">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtMS0xLTEtNzgwNDk_bc803704-b630-4fe6-b73a-c8b879030917">7,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtMy0xLTEtNzgwNDk_f4cea572-b5e0-4dbb-b627-ddc15002ad16">4,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtNS0xLTEtNzgwNDk_f9b73d24-39b5-4bc9-bd53-202c9d5e01cf">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtNy0xLTEtNzgwNDk_cf126376-bf8c-4a14-a708-aaa4236e96b9">6,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtOS0xLTEtNzgwNDk_a2873f20-79dd-4529-806a-31cc02e480ad">3,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtMTEtMS0xLTc4MDQ5_cd5996bc-9862-45d8-b3c9-de4374946fea">3,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield and other trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4626139b5a5432daffd219066037e28_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtMS0xLTEtNzgwNDk_bb84919a-2a52-4656-9237-f284194f88ba">5,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4626139b5a5432daffd219066037e28_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtNS0xLTEtNzgwNDk_606b03ea-8f1d-4ef7-978f-c63acabfc8e9">5,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb27c8fb2e64bcca33419af780e6ad8_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtNy0xLTEtNzgwNDk_f3020a0c-f83a-466c-ad6f-46779b305c8a">6,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb27c8fb2e64bcca33419af780e6ad8_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtMTEtMS0xLTc4MDQ5_a392a9ae-30dc-4367-8231-0d97a2e4428d">6,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7d829139842f08030a894802ebb5b_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktMS0xLTEtNzgwNDk_8958a63b-3e48-4489-b233-34afc5aed482">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7d829139842f08030a894802ebb5b_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktNS0xLTEtNzgwNDk_c2c4fe28-55ec-4168-85f4-36f1b4f27b8e">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09884f298c34bfc8b99687d69272ecc_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktNy0xLTEtNzgwNDk_416acf1b-5a42-48d6-b25b-c381430ce911">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09884f298c34bfc8b99687d69272ecc_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktMTEtMS0xLTc4MDQ5_6763bf48-a0fb-4250-b0b6-13926d923307">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTEtMS0xLTc4MDQ5_6a422c7d-c974-4bc1-8b3e-1e46c7e69498">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTUtMS0xLTc4MDQ5_3901e4f4-ae72-4e68-9072-e4c25b0162e8">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTctMS0xLTc4MDQ5_e16ce479-07db-4560-a537-ef3443dfcdac">7,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTExLTEtMS03ODA0OQ_11708dd8-9fd3-40ac-b82a-5889f1f2bdc3">7,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTEtMS0xLTc4MDQ5_9405b7aa-77f6-4f25-b2f2-949a0aee2f61">14,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTMtMS0xLTc4MDQ5_92f468de-2f8a-46a2-a0c0-604e2a069b71">4,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTUtMS0xLTc4MDQ5_26f01875-cf15-4452-a3f5-7ec8bd286cc9">10,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTctMS0xLTc4MDQ5_b6ba51f4-acf4-4100-9c86-c97b0d7be99e">14,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTktMS0xLTc4MDQ5_ef74300c-199f-4c7b-8d50-794adf84a797">3,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTExLTEtMS03ODA0OQ_642f3829-fa31-4027-acfb-b7d25290cda7">10,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, due to our acquisition of Integra, we recorded intangible assets and due to our new branding strategy, reclassified $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzU0OTc1NTgxNjEzNw_2f4da479-4d3a-40db-8c56-4c4694e2aa5d"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzU0OTc1NTgxNjEzNw_53a11da8-c5b1-49dc-b79d-de683fe602c5">308</ix:nonFraction></ix:nonFraction> of trademarks with indefinite lives to Intangible assets with finite lives - Other. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the estimated amortization expense for each of the five succeeding years is as follows: 2023, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3MzI_87d9a7cb-945e-4961-87ce-062b3046a871">806</ix:nonFraction>; 2024, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3NDA_fd2deaa6-72dc-4601-825b-d7419a9207e2">370</ix:nonFraction>; 2025, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3NDg_67e8cfae-db40-42b4-a3ba-e92cfc68521c">311</ix:nonFraction>; 2026, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3NTY_bbf8ac70-f67e-4d75-a66d-6c1f926bcb15">258</ix:nonFraction>; and 2027, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3Njg_8a09f589-3a1c-4a1c-9788-57734c50c355">221</ix:nonFraction>.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-103-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0Nzc_8ebc305b-c747-4eeb-962b-c69993b5266d" continuedAt="i5108042bb0f243d19ec248ffc12326fc" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="i5108042bb0f243d19ec248ffc12326fc" continuedAt="i87b599f1926140e5827842cb87e4caec"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Elevance Health Cash Balance Plan A (formerly the Anthem Cash Balance Plan A) and the Elevance Health Cash Balance Plan B (formerly the Anthem Cash Balance Plan B) are cash balance pension plans covering certain eligible employees of the affiliated companies that participate in these plans. Effective January&#160;1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules continued to accrue benefits. Participants who did not receive credits and/or benefit accruals were included in the Elevance Health Cash Balance Plan A, while employees who were still receiving credits and/or benefits participated in the Elevance Health Cash Balance Plan B. Effective January 1, 2019, benefits under the Elevance Health Cash Balance Plan B were curtailed. All grandfathered participants no longer have pay credits added to their accounts but continue to earn interest on existing account balances. Participants continue to earn years of pension service for vesting purposes. Several pension plans acquired through various corporate mergers and acquisitions were merged into these plans in prior years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employees&#8217; Retirement Plan of Blue Cross of California (the &#8220;BCC Plan&#8221;) is a defined benefit pension plan that covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective January&#160;1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired or rehired after December&#160;31, 2006 are eligible to participate in the BCC Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the plans&#8217; assets consist primarily of equity securities, fixed maturity securities, investment funds and cash. The funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), as further amended by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to provide assets sufficient to meet the benefits to be paid to plan participants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables disclose consolidated &#8220;pension benefits,&#8221; which include the defined benefit pension plans described above, and consolidated &#8220;other benefits,&#8221; which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were computed using assumptions at the December&#160;31 measurement dates.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0Njc_3bab5c6c-82ac-4d1b-a23f-844896fddb53" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the benefit obligation is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItMS0xLTEtNzgwNDk_f6c07287-ee72-4602-9412-20d145001f92">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba97ae25e674ac09265ecbdcc7c49a4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItMy0xLTEtNzgwNDk_d6de7907-833b-4bad-9e9d-1fc43a2f841b">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItNS0xLTEtNzgwNDk_2690b69f-3a0b-4a8c-9adc-f602d9e5c01d">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7eae151120d438b8aa81ae6d01ed182_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItNy0xLTEtNzgwNDk_7b4dafff-a157-4e38-b140-dfa9087b65ab">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtMS0xLTEtNzgwNDk_850f7e77-3f6d-421f-a0b6-8fe035c493c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtMy0xLTEtNzgwNDk_8de8cc83-7a69-4a33-a65a-d08e0423e6e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtNS0xLTEtNzgwNDk_5647a0f6-9ea8-4c61-9c4a-163e241d4079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtNy0xLTEtNzgwNDk_34427b2f-5129-41da-8171-e4309941c9d2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtMS0xLTEtNzgwNDk_546b2275-aa66-4b6e-a2c9-a90dcb65e302">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtMy0xLTEtNzgwNDk_2959777f-d7e5-43fe-b0af-3cec49e0bed1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtNS0xLTEtNzgwNDk_e404b880-4e65-4195-a683-4703248d884e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtNy0xLTEtNzgwNDk_5920a9d9-06aa-49f7-8e82-b392abcfc3da">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtMS0xLTEtNzgwNDk_0b74fb8e-5c6e-45f5-8d0e-ef4e895bd906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtMy0xLTEtNzgwNDk_2452b416-758d-420b-aeaf-f34d22b33178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtNS0xLTEtNzgwNDk_6f7774b6-cfee-4140-834a-1db0039fbe8c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtNy0xLTEtNzgwNDk_0db68f93-bef0-4107-9728-91422be6f963">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtMS0xLTEtNzgwNDk_28869e3b-b845-4fed-bf87-bf0378041ec3">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtMy0xLTEtNzgwNDk_ee29b377-3bf2-4f5a-9429-c7e9722803d0">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtNS0xLTEtNzgwNDk_f59fcafe-046d-46a1-87c4-4974e7a3439c">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtNy0xLTEtNzgwNDk_dc8eba81-71ae-4f0f-bd5b-2efdb49ebd8a">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctMS0xLTEtNzgwNDk_2b77aefe-e3e2-4551-a898-71d4485c0c98">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctMy0xLTEtNzgwNDk_1b67cff0-104d-46ab-ba84-8571fe5b3262">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctNS0xLTEtNzgwNDk_42da0ec0-da95-4775-8ec9-dff6a5d734ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctNy0xLTEtNzgwNDk_d5b1c9d7-cb37-43fd-9139-4b30f4c92b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtMS0xLTEtNzgwNDk_79bbbe61-1b9a-4b72-8d9c-47d895c76876">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtMy0xLTEtNzgwNDk_acb1e7e9-0fa3-4c53-805a-7f0c3753d446">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtNS0xLTEtNzgwNDk_817b8692-4d77-49c1-91d7-f445c0fabff4">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtNy0xLTEtNzgwNDk_8515b09c-46fe-430e-a780-60a64abae914">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktMS0xLTEtNzgwNDk_30abaa12-c248-4cc8-9e76-2de3def162e8">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktMy0xLTEtNzgwNDk_75096223-c7d7-4c91-9f80-bef019024d95">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktNS0xLTEtNzgwNDk_15a97896-5043-4748-bdf8-758effeca5ba">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktNy0xLTEtNzgwNDk_6f95efca-df92-416e-900e-f1306a45aa24">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-104-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i87b599f1926140e5827842cb87e4caec" continuedAt="iae12d1e7aac94ccfaec29e5d6c967503"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0ODA_0d7b3ec4-4233-4a68-a67b-d3d43d4b32de" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of plan assets are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItMS0xLTEtNzgwNDk_2777c2be-bde1-47d4-83f8-bd350d49bce2">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba97ae25e674ac09265ecbdcc7c49a4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItMy0xLTEtNzgwNDk_b2d99392-ed6c-4185-a8b1-0d2c9acc0d67">2,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItNS0xLTEtNzgwNDk_a0e60902-922e-4229-a523-0770fee8488e">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7eae151120d438b8aa81ae6d01ed182_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItNy0xLTEtNzgwNDk_bf77e2cb-759f-4bd6-b03b-77c43a0d58ff">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtMS0xLTEtNzgwNDk_ab846130-20a5-452d-8fd0-7b6123ff10ce">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtMy0xLTEtNzgwNDk_a7b4157a-4818-42b8-b018-61225ba12691">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtNS0xLTEtNzgwNDk_e18e5ad2-cb79-44d6-9f05-aa3b807e1dbf">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtNy0xLTEtNzgwNDk_9a409e03-a1e6-49de-bfeb-81cfc617d7de">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtMS0xLTEtNzgwNDk_aaa5e7c6-86fa-4fb8-8648-8faf243f4136">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtMy0xLTEtNzgwNDk_a86e661b-85ba-48b7-9f28-581bb0667022">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtNS0xLTEtNzgwNDk_507b384c-71c7-4eba-84f9-401fc7c3dfc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtNy0xLTEtNzgwNDk_58b6463a-4a96-41e9-94fe-fbe2bfc0911f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtMS0xLTEtNzgwNDk_7e9283c0-231d-4a54-b387-b1cdac8597cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtMy0xLTEtNzgwNDk_2007249d-c45a-4aa9-9bcf-d2b81b17bc90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtNS0xLTEtNzgwNDk_bec417c3-a52b-496f-a24a-d50a3e20caaa">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtNy0xLTEtNzgwNDk_2933f2f4-9bab-4ee1-b1fa-1b407b5fde9a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtMS0xLTEtNzgwNDk_2124855e-daa2-41b6-90ed-360bf1150b8f">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtMy0xLTEtNzgwNDk_c5f4ace7-ff8f-44f1-8eab-69fabee7b277">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtNS0xLTEtNzgwNDk_1b90056c-964e-4bb3-81db-c010cf55fbe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtNy0xLTEtNzgwNDk_68d35431-5cda-4d51-8ceb-fb4162280a7e">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="elv:DefinedBenefitPlanBenefitsPaidFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctMS0xLTEtNzgwNDk_c379a4ae-2bbf-4b15-8d44-71c4f1e72f8b">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="elv:DefinedBenefitPlanBenefitsPaidFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctMy0xLTEtNzgwNDk_d17014e9-49a8-4225-b875-5c2e3863fee2">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="elv:DefinedBenefitPlanBenefitsPaidFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctNS0xLTEtNzgwNDk_9490768b-53fb-4f4f-aecf-31e57e996a16">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="elv:DefinedBenefitPlanBenefitsPaidFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctNy0xLTEtNzgwNDk_11fb4ece-34c7-4632-bb95-b242e9f07d38">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtMS0xLTEtNzgwNDk_9e8239c6-2345-4663-a9c2-28a9524b876e">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtMy0xLTEtNzgwNDk_ec2443b5-ef34-4d6c-98e8-f839948b8df5">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtNS0xLTEtNzgwNDk_56373190-89e1-4cf0-84a4-8d69f7621683">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtNy0xLTEtNzgwNDk_508885bc-db42-4308-b1a8-80140f0c0821">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0ODg_286af5ec-da9d-4254-9149-b5a0b400027c" continuedAt="if4528ad14b9844e2bd10520d4bfa02ad" escape="true">The net amount included in the consolidated balance sheets is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="if4528ad14b9844e2bd10520d4bfa02ad"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItMS0xLTEtNzgwNDk_62a19197-ae9b-4b81-a939-7257f83fba9a">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItMy0xLTEtNzgwNDk_e2a300d7-cdf6-4a08-9691-a064b2257b5c">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItNS0xLTEtNzgwNDk_fd5c1e8e-6df6-4583-9abf-3c457a460715">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItNy0xLTEtNzgwNDk_fa27368a-0219-47ce-8755-0c95aa415781">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtMS0xLTEtNzgwNDk_5dff2493-6c8d-4393-8f82-af14997fd8f9">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtMy0xLTEtNzgwNDk_b65b639e-5dae-4c1b-8cca-7daefe0db90e">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtNS0xLTEtNzgwNDk_ea16a7c5-db4e-4cf7-826a-8fe86b1d7f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtNy0xLTEtNzgwNDk_7aa02663-3c7b-4066-a054-686bb2d558ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtMS0xLTEtNzgwNDk_6f012021-9037-4546-8c6a-3a301102e1c2">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtMy0xLTEtNzgwNDk_47215e79-6930-49bd-a157-0c08570ecbd4">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtNS0xLTEtNzgwNDk_6fe263be-3b81-4119-a3bf-2bed3a90db0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtNy0xLTEtNzgwNDk_14c9d5ec-c36d-4596-afd9-dc789ab44cf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtMS0xLTEtNzgwNDk_1e239c11-1012-4267-9a0a-1996dd3ca1c5">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtMy0xLTEtNzgwNDk_4e033333-8956-4513-981a-58759b4acff9">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtNS0xLTEtNzgwNDk_cd8d9ee3-a318-42c0-b4f1-56595bdb38f8">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtNy0xLTEtNzgwNDk_c95c9158-c5b7-4f5c-9f8b-35a487f7045b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0NDQ_454062f2-2d8e-4dc9-8b4f-70eea3664969" continuedAt="i4d448b9e1b9a493c8d0f780d225a9593" escape="true">The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i4d448b9e1b9a493c8d0f780d225a9593"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (loss) gain</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItMS0xLTEtNzgwNDk_c32a5300-f7d2-4cbc-9e36-424fa93da8bb">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItMy0xLTEtNzgwNDk_f7ca7d70-daa3-4030-9e04-4c179d0f74c1">625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItNS0xLTEtNzgwNDk_7f67a2f6-37c7-44f9-8c8a-0bbbbea91cbb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItNy0xLTEtNzgwNDk_63d21df0-46ef-43b9-9b3e-e62c69ed82fb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtMS0xLTEtNzgwNDk_273ea093-93d3-4a10-b1cd-da40cc745b0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtMy0xLTEtNzgwNDk_19f51644-9b8b-48b3-9c48-6489c6390854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtNS0xLTEtNzgwNDk_394d04ef-dbd8-4eb2-a9dc-d7ebb7848420">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtNy0xLTEtNzgwNDk_0a77e289-b15e-44d2-bb94-b9183b7bd25e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount before tax at December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtMS0xLTEtNzgwNDk_00db536e-5c86-4882-b01c-9768339e7ccb">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtMy0xLTEtNzgwNDk_b31f2b5f-95c9-4f9c-861b-28f77633a083">625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtNS0xLTEtNzgwNDk_fbec64f3-8fab-4b8c-b925-18c0644cfcbc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtNy0xLTEtNzgwNDk_c73d68ca-deb6-4ae2-88a0-db5a6d7dceac">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation for the defined benefit pension plans was $<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMxNDY_eb72efe8-91b6-46f2-a6e5-f4794200b850">1,413</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMxNTM_8632c837-118e-4f1b-ad74-e8f9c3fadb82">1,857</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, certain pension plans had accumulated benefit obligations in excess of plan assets. Such plans had accumulated benefit obligation and fair value of plan assets of $<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMzNTg_b45641c5-31b8-42b2-a68d-5c349ecd4fd8">44</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMzNjU_1368135a-a4bf-4121-bdb1-a5c311b5f248">0</ix:nonFraction>, respectively. In addition, certain plans had projected benefit obligations in excess of plan assets. Such plans had projected benefit obligation and fair value of plan assets of $<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM1NDc_c39965de-3beb-43c6-b16b-bb2d60574cc0">44</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM1NTQ_64bee2d9-2e1a-432a-8500-e7384d4b1da7">0</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0ODE_2bde7b3e-2c24-4d78-b192-1fe985d7974b" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItMS0xLTEtNzgwNDk_a5c0c280-2835-45fd-804f-4507fa794c6e">5.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItMy0xLTEtNzgwNDk_b1f90a91-421e-4ece-aa90-0ac1f3b7263b">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItNS0xLTEtNzgwNDk_ce7bdcc3-d13f-45f3-b28e-23ef90955467">5.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItNy0xLTEtNzgwNDk_8895f7ed-a90c-4994-97a4-c61d69d7463d">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtMS0xLTEtNzgwNDk_5e6c8778-3832-4bcb-ac92-81b39433860d">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtMy0xLTEtNzgwNDk_870e0e78-94c4-4b58-884b-cafeaa33915f">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtNS0xLTEtNzgwNDk_bfbcb425-6538-44f3-a691-4a7cc8b61ea0">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtNy0xLTEtNzgwNDk_633e779f-5468-4324-b280-6e6e75f8ad8a">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="4" name="elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtMS0xLTEtNzgwNDk_cdc3b80b-18cf-4303-88ea-e266d91e8090">6.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="4" name="elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtMy0xLTEtNzgwNDk_6258ed41-36e9-4cb0-b4df-af31df04da35">5.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="4" name="elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtNS0xLTEtNzgwNDk_cbbe4ed3-b4ef-4fcc-bd5d-3fe251cf6c89">6.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="4" name="elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtNy0xLTEtNzgwNDk_78c78e26-c238-4279-9f81-5889aecc0b2d">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtMS0xLTEtNzgwNDk_4a292ade-3cd7-4078-bcf5-a6f1be77ab9e">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtMy0xLTEtNzgwNDk_01290fa5-f477-4566-8483-9f40acff9244">3.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtNS0xLTEtNzgwNDk_24d158c2-32db-4001-9b14-7a8aeed3036a">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e00926518a047ec902e830460f86c18_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtNy0xLTEtNzgwNDk_789553d7-a90f-4e8c-8d19-ff99880e881b">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-105-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="iae12d1e7aac94ccfaec29e5d6c967503" continuedAt="i2249ac6233704feea424a782777594ae"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0MDk_5bae0fa9-9a22-4707-aaa3-07a36405d2e6" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit credit included in the consolidated statements of income are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzMtMS0xLTEtNzgwNDk_6d6a1b68-2bae-46ce-b5e2-6424c5762b0f">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzMtMy0xLTEtNzgwNDk_823bf4e6-473b-4f40-833e-3fcb8568fe8f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzMtNS0xLTEtNzgwNDk_7881688e-edba-496d-9098-292eb0df68cd">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzQtMS0xLTEtNzgwNDk_167ae727-f1c8-4c40-8afa-e665513e09a0">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzQtMy0xLTEtNzgwNDk_1d14587b-6064-4430-a821-b6e78deb3953">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzQtNS0xLTEtNzgwNDk_1d06ff90-5190-4ca6-be05-6fe5d8b690fe">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzUtMS0xLTEtNzgwNDk_257c1bd3-f2b3-4ad5-8128-aa5fd657be7f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzUtMy0xLTEtNzgwNDk_5a19b953-7f05-45fb-a336-9e1a572e16b7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzUtNS0xLTEtNzgwNDk_58e67881-8bcf-425b-add1-41dd72b9d1d4">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a">Settlement loss</span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMS0xLTEtNzgwNDk_72fb9c4d-a2e0-4716-b9d9-545e381923fd">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMy0xLTEtNzgwNDk_38047b04-e878-4044-a21a-d231b5aa0a44">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctNS0xLTEtNzgwNDk_c46ae9f8-e21f-4f94-b533-a1766b3f0541">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit credit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzgtMS0xLTEtNzgwNDk_0135c77a-1b27-4e38-b3a4-afeef879f68c">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzgtMy0xLTEtNzgwNDk_094a675b-6f5d-42f5-82ec-4a14eee3ccb8">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzgtNS0xLTEtNzgwNDk_91fb39bf-b807-4819-8fe3-bf2ae9d4e9c5">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzExLTEtMS0xLTc4MDQ5_276bfd58-2b55-4993-872a-e44193c23d7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzExLTMtMS0xLTc4MDQ5_db521f23-a156-4fb9-b0e1-57e794cd39c4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzExLTUtMS0xLTc4MDQ5_be828dcb-2dbe-4528-9852-f1b6841162d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEyLTEtMS0xLTc4MDQ5_71959d66-83ea-4de4-8040-e92eafa3d091">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEyLTMtMS0xLTc4MDQ5_c5a82f75-9b1e-43c6-a6b6-837f97732839">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEyLTUtMS0xLTc4MDQ5_6077f9d9-be6a-41db-8809-b67fee6e70c7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEzLTEtMS0xLTc4MDQ5_b84dfe85-2dc8-4702-a7a1-4c7f4ac4ed80">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEzLTMtMS0xLTc4MDQ5_3cdc6966-93fa-484b-9902-2f287623968c">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEzLTUtMS0xLTc4MDQ5_dfdaa587-59d3-463f-8b78-6bfd388a6a75">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE1LTEtMS0xLTc4MDQ5_6eacf259-09b8-4de3-b04d-cf3a133db0a1">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE1LTMtMS0xLTc4MDQ5_f146666f-8a08-43b6-9dc2-4c7a251ea1da">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE1LTUtMS0xLTc4MDQ5_26c2ec10-ce45-445c-aa26-013958700cfd">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit credit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE2LTEtMS0xLTc4MDQ5_c1d5dcae-d791-4029-8cb9-7645e4182394">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE2LTMtMS0xLTc4MDQ5_8992bede-13cd-4280-a758-8deb0f7307f8">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE2LTUtMS0xLTc4MDQ5_4f72f2b8-8860-4349-82cd-4f4fa0e3f48e">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we incurred total settlement losses of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM4NzM_0866409c-b407-45f5-846b-55f7a90d7571">28</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM4Nzc_f62fe879-cef1-4cae-a418-6ae47f1ec2b5">26</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM4ODQ_b2f226c7-c42a-4daf-8bb0-7160cd4c8040">29</ix:nonFraction>, respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0MzM_12af0db6-da41-4f2b-9092-01102983d8f4" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzItMS0xLTEtNzgwNDk_a0cf276f-60bb-4aa4-a068-ba22c62757f4">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzItMy0xLTEtNzgwNDk_826bfe11-3779-48c4-9028-76e63bd60f43">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzItNS0xLTEtNzgwNDk_582e2155-4c4a-4bc8-a75f-9a2b8795cb3e">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzMtMS0xLTEtNzgwNDk_e7d06159-f8b0-4ac3-b94b-13f5ea47136c">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzMtMy0xLTEtNzgwNDk_33aeb050-4da8-4db9-ae0a-bce0505c5c66">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzMtNS0xLTEtNzgwNDk_cf9da7ff-9a3a-4e6b-b9d3-dc2be87c95aa">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzQtMS0xLTEtNzgwNDk_2f28c59c-524d-4bcf-b411-069bd952090a">5.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzQtMy0xLTEtNzgwNDk_9239017c-5e58-465c-b561-bd91006fea80">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzQtNS0xLTEtNzgwNDk_377e0c48-be36-4d07-964a-3f9c4ef2f273">7.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzUtMS0xLTEtNzgwNDk_7ed267e2-35ee-427b-b9dd-21b93ee097a5">3.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzUtMy0xLTEtNzgwNDk_347cc2d0-8325-4aa4-ab42-da81f7ed8764">3.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzUtNS0xLTEtNzgwNDk_a9cac238-d4dd-4ded-a59a-e578c220c736">3.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzgtMS0xLTEtNzgwNDk_7ad0e113-411d-46c0-b403-fa6a873107dc">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzgtMy0xLTEtNzgwNDk_1d810cfe-9307-40fe-9ac7-92383717e644">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzgtNS0xLTEtNzgwNDk_275862fe-f3d8-45dd-a5a1-c94d8c8c23f3">2.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzktMS0xLTEtNzgwNDk_77023b85-8ce2-4706-93b7-93ab799328c4">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzktMy0xLTEtNzgwNDk_4c720e6d-f926-4047-b648-4ecfbc424de0">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzktNS0xLTEtNzgwNDk_f6710b09-661b-4d87-bf84-07fadba730c9">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzEwLTEtMS0xLTc4MDQ5_ec846090-b84d-4c1f-a495-632fa502a1cf">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzEwLTMtMS0xLTc4MDQ5_a4d014dc-3763-4c0c-a038-d43a0eb6fd3e">6.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzEwLTUtMS0xLTc4MDQ5_2cf769cd-8492-456e-b058-cf8ccb124449">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzExLTEtMS0xLTc4MDQ5_60e6a956-4c45-4ea3-beb5-b7589b725cc9">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzExLTMtMS0xLTc4MDQ5_5b318a41-a3ea-4de9-9873-d427c945bbf1">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzExLTUtMS0xLTc4MDQ5_3b5e50ba-31c7-4c73-bd60-55cb35bbe743">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was <ix:nonFraction unitRef="number" contextRef="ic34e126013bd4bdd9dcbc1e1560410d4_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQzNDY_24a8c74b-497e-45cb-996d-a948458d3a09">8.00</ix:nonFraction>% for 2023, with a gradual decline to <ix:nonFraction unitRef="number" contextRef="ic34e126013bd4bdd9dcbc1e1560410d4_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQzODM_6b9e8f33-8fe8-47aa-ae6c-34ce24ab22ea">4.50</ix:nonFraction>% by the year <ix:nonNumeric contextRef="i28bb80744cf5451abb433b7a2ae2b2ea_D20220101-20221231" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQzOTg_6bf8856b-577d-4cff-8413-8f0a7e8c4cae">2035</ix:nonNumeric>. The assumed healthcare cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was <ix:nonFraction unitRef="number" contextRef="i1af3c75b085341f79aae1e5b4a9109ee_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQ1OTY_156a0946-f6d6-41ef-b4b9-0c7345ff1649">6.50</ix:nonFraction>% for 2023, with a gradual decline to <ix:nonFraction unitRef="number" contextRef="i1af3c75b085341f79aae1e5b4a9109ee_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQ2MzM_0c4dded3-a175-4b2c-a49b-a976fb93d0bf">4.50</ix:nonFraction>% by the year <ix:nonNumeric contextRef="i411e095557594f3599b08db79d9385d3_D20220101-20221231" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQ2NDg_214e7ab0-da39-43f3-8c62-9128ebd88b1d">2035</ix:nonNumeric>. These estimated trend rates are subject to change in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across a range of sectors and levels of capitalization to maximize long-term return for a prudent level of risk.&#160;The weighted-average target allocation for pension benefit plan assets is <ix:nonFraction unitRef="number" contextRef="ifa0439546d944cc89a588764266c7975_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzUwNDA_21026eb4-04b0-46ca-9426-0b784c1dd609">37</ix:nonFraction>% equity securities, <ix:nonFraction unitRef="number" contextRef="idecc2f49500d45e9a24a291a9d799fff_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzUwNjI_efbf039d-052d-4872-b2d3-25584eb146ae">58</ix:nonFraction>% fixed maturity securities, and <ix:nonFraction unitRef="number" contextRef="i35c312959f4143d697939a1225baf4a8_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzUwOTY_df21cae9-4d96-4274-add0-1d078b25e5fa">5</ix:nonFraction>% to all other types of investments.&#160;Equity securities primarily include a mix of domestic securities, foreign securities and mutual funds invested in equities.&#160;Fixed maturity securities primarily include treasury securities, corporate bonds and asset-backed investments issued by corporations and the U.S. government.&#160;Other types of investments include insurance contracts </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-106-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i2249ac6233704feea424a782777594ae" continuedAt="i8b326bc42fed48a5a5a86112dde1ea32"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed specifically for employee benefit plans, a commingled fund comprised primarily of equity securities and certain partnership interests.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partnerships hold various types of underlying assets such as real estate and investments in oil and gas companies. Generally, the partnership interests are not redeemable and are transferable only with the consent of the general partner. Unfunded commitments related to all partnership interests totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ibd444af0664e4c1298d3fa8d8b705ead_I20221231" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzU0OTc1NTgyMzMwNA_ea63762d-ef2e-4115-9991-ddb6e9d0aa49">2</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if05d6861eb1d4839b34b143297bc3b5a_I20211231" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzYwOTA_0f7ec18a-aa69-4c98-ba35-8f9736c08e6a">3</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were invested in Elevance Health common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-107-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="i8b326bc42fed48a5a5a86112dde1ea32" continuedAt="i503e4ff7388c4715bd249bb548b8b226"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0Njg_e2138289-fee6-4c8e-ba7b-c016189c2bc6" continuedAt="i021c2b2253c847a08aed575f7f2f378b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2022, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:DefinedBenefitFairValueDueFromBrokers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzY1MTY_2b7d0ff3-3c05-4716-9fd8-d60525bc898f">36</ix:nonFraction>, and excluding estimated claims settlements to be paid from other benefit assets of ($<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:ClaimsSettlementsToBePaidFromOtherBenefitAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzY2MDM_ace47ade-a75c-4349-8758-bb586ea89054">17</ix:nonFraction>), are as follows (see Note 7, &#8220;Fair Value,&#8221; for additional information regarding the definition of level inputs):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073e475229744657ac73e9da590e83f8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtMS0xLTEtNzgwNDk_ba802882-e11a-4540-bb92-ebbcf316cc60">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1af1b98554725ab989022f0630a0e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtMy0xLTEtNzgwNDk_df2d65f2-9562-4c89-9a65-54fdc285fc8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3304b8d471184ac39be41951a5853e03_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtNS0xLTEtNzgwNDk_06cf6bc6-b117-4ebb-9ffd-16b204f6d0f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857507cd2bed48a9b9fe3fbc5b737056_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtNy0xLTEtNzgwNDk_d832dba8-a7d6-433f-8e2d-bc855fca5285">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ace04bb2beb40b5a516c227c3ea00a5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtMS0xLTEtNzgwNDk_90dc25bc-bc25-454e-a464-11c6455e4233">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a7d2ba705a4df69942c441186b72ff_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtMy0xLTEtNzgwNDk_907f6242-1bce-4284-b47f-4cf3110bdeb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40578ab1c8b414884a39f3c0dae2822_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtNS0xLTEtNzgwNDk_e31ba4b5-0eae-43b1-87b5-c3a53cb6038a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cc7418cfc74f5ba17ab4369f714947_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtNy0xLTEtNzgwNDk_2dd02982-5b71-49e1-ae4a-aed171a5ef4c">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20102145585646cab0be477d78b18a73_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtMS0xLTEtNzgwNDk_c57df7bb-006e-4be5-9b68-2a2eb347aad3">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6ab942bd2841168cdf7a7b4a3187a4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtMy0xLTEtNzgwNDk_bc92078c-7b5e-4f24-896d-03a29ca53111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda9b4fba37e447fb4c9600c624c8dc0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtNS0xLTEtNzgwNDk_888c477c-3b67-490c-b6cb-e1663352ca27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f81cdb55ce4e638a62241e00ebf0de_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtNy0xLTEtNzgwNDk_541712b8-d8c8-4ba7-adbe-7bd5dcf9572e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d73bdd3b14402d844c2c0c59694668_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtMS0xLTEtNzgwNDk_4697e7b1-a0df-44cc-a43c-7b945f528cf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f28b66f26ff499d8c7bd3a51827b9ba_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtMy0xLTEtNzgwNDk_540b7ca8-b93a-4206-83ab-ef4fb02af338">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4724ad9e28e04afa90e6467a8712ebf7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtNS0xLTEtNzgwNDk_2bf70f4d-c4aa-4ea1-9604-bad3c9e28751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f9bcc18dfb447fb775b32088b6531d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtNy0xLTEtNzgwNDk_7e547279-9f61-42f2-9c21-516fb6286fa7">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf38d6a8dac24b72b1557ce07935c19e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktMS0xLTEtNzgwNDk_ce574c99-0856-4ab6-947a-8400d9be9311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3757024d2c6475cb1979d3770868e66_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktMy0xLTEtNzgwNDk_8c15f7ed-ec10-4bf0-9da7-603c12ada1ce">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc490491d76a485b890f14584a038a3d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktNS0xLTEtNzgwNDk_5c1c1451-a30f-4a13-9d0f-bc08c7f9e1d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d53728a1d54d7b9516dd30a8bdda03_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktNy0xLTEtNzgwNDk_8962d9ed-80da-407c-ad26-ea40ff88bee6">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c392f7e463f4339b291aa741cf0be26_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTEtMS0xLTc4MDQ5_2948a63e-cc51-4c6c-bf94-ebc7e9a3a131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2290abd15315443bb3b678c9c9e06e50_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTMtMS0xLTc4MDQ5_d673c159-a13f-4672-acc5-7e9fdfdad06b">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bca97fbdff84230a99f35c1a1dce85d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTUtMS0xLTc4MDQ5_b11716a7-0c12-41dd-8366-1ad476f8f1df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5847c45467bd4402971d8c43f9e23685_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTctMS0xLTc4MDQ5_94a2f558-1720-4434-aab6-4f07b34d3e3a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8fa58a7f71b41e5ba27e355644a55ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTEtMS0xLTc4MDQ5_9b55db3f-f990-42b6-8c7e-4c2423bf6040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6d48987cd74ff3be80bbd508db4661_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTMtMS0xLTc4MDQ5_a913473a-8993-4bed-9b05-e51d82eb9ef9">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37817d0ad4574456871358f331c06a5a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTUtMS0xLTc4MDQ5_cc10e0f8-4267-4d58-9d4d-60648f1d685b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717a210731b940ee939db3c1dbba5956_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTctMS0xLTc4MDQ5_6635973c-886a-49df-84bb-6e4db63b1554">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance company contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb399901683c4c35b4197be484a877d0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTEtMS0xLTc4MDQ5_6d60af66-0f1f-4e64-a646-645fe4b6cb27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc920e05c21b44d7961db2b67b504016_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTMtMS0xLTc4MDQ5_36f21a80-e082-49a9-b987-376d4fb1a9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac85b6a86c64d77b811c48e62a14bb5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTUtMS0xLTc4MDQ5_0e743d72-9226-41d5-97b8-4f710ad509dc">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89014b28ae34bfeabe6689041e3ca5c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTctMS0xLTc4MDQ5_146def5d-b036-4a5c-9fea-e9c7c9024487">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1a53d49d5c4867aa039a46e7568ed3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTEtMS0xLTc4MDQ5_ecbcae49-62b7-4500-9818-aa5d000ddf73">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fec0c29d10b4a398f12075276df4a35_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTMtMS0xLTc4MDQ5_24d1373b-b3de-4362-babc-f481ce8655e1">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea2c0b2ce6a4178bc52bfce6465f76d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTUtMS0xLTc4MDQ5_174a2a35-4bad-4e92-92d3-2469f23b3ce6">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290e040e29e44712bfeb543bae80308f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTctMS0xLTc4MDQ5_dcaa8502-c2d0-4fca-a43d-71d5156bdedd">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218998b309404346862bc9cdba62f2cf_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE3LTctMS0xLTc4MDQ5_dbdc75b2-67d6-49c8-9d40-97d8ab21ad14">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4f2b19fc0245a59b7962eec5c99085_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE4LTctMS0xLTc4MDQ5_dbd00221-3ab3-4ca7-a6b4-806d3fd9f239">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f55d4ef714f45e2a97aae94dc3b7ded_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTEtMS0xLTc4MDQ5_39e707d5-4e35-4e79-8dee-83b40379733a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f648bcd3ed4b2299ff8051a9d130f6_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTMtMS0xLTc4MDQ5_df2b0c3d-fcee-4f0a-b3e3-26921f28f185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ce52d351384652a25cea41d5bf10d9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTUtMS0xLTc4MDQ5_a6471805-47f4-4be9-bd74-abeadb1e83e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e83d370570483a84584b1ba51b4a0e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTctMS0xLTc4MDQ5_8fffac27-5a1b-4c08-8a67-d35ba8aebefd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e1af2b6d3041098336c9393584e9cd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTEtMS0xLTc4MDQ5_173e4a97-15d0-4247-8b05-42c5f4c24ffd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89283ade174a0bb7fe3b2918c3c835_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTMtMS0xLTc4MDQ5_83550cb9-49e0-42c9-bb7b-713330d5550c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c28c3b58eff4d8e83e797a3c9dc86ab_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTUtMS0xLTc4MDQ5_f60ed795-83fb-428b-93a1-70092afb1bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a52d405845744e3a22ff6418d046838_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTctMS0xLTc4MDQ5_bfc532be-b090-4d57-99ab-d18f2ea7310f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica846717e1184bacb54d96b42ff8bfb8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTEtMS0xLTc4MDQ5_9ef7c0da-322c-4ac5-976f-39d5ff3cfb6f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd588c1a32a4b318e8824b9e80e833f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTMtMS0xLTc4MDQ5_391386ee-c878-4d00-8fbb-a309a118f52d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42abf7d75b0f4617992ff04363b8de28_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTUtMS0xLTc4MDQ5_b9030939-a1b2-4c2c-970b-ace3ca48d988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3186402fca52479e94b30bea316112da_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTctMS0xLTc4MDQ5_eb69df4d-f275-4118-be6b-98e937741476">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68819c4736484941b4667da3db092246_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTEtMS0xLTc4MDQ5_e74a50a2-8ad5-4b11-8bc1-46bfa58811c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fac223fbf12427cb4c55b80a18072a8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTMtMS0xLTc4MDQ5_6040a76e-9afe-4dd8-8d58-b299c7e93302">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57c573544eb42bea430ba41085525f5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTUtMS0xLTc4MDQ5_4e59b62b-0c7b-457a-9582-2c482ce47c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8827a2fb2e7457595d626050de42f28_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTctMS0xLTc4MDQ5_fc8d70b8-c518-4008-9b99-91ae499c1d90">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8708828d7a476587098de587d22948_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTEtMS0xLTc4MDQ5_cf486321-29a6-4bb0-afa7-71282d95212e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15ac02c8fcd427fae5b76de3ef93c01_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTMtMS0xLTc4MDQ5_73950211-267b-4df7-95b2-c50938106913">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2625252753fb4190bc4ba5269f5706d8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTUtMS0xLTc4MDQ5_6eb13c31-52ae-45a0-847f-164bf924325c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b02994b45b43a6a51141e64ad4bd6f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTctMS0xLTc4MDQ5_eb518a41-7f43-45a1-86f4-11c652705a15">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c345c140c9d4fc3ab7c4965bae458b2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTEtMS0xLTc4MDQ5_e9c8cf2a-e0df-4e7a-86f3-1596235e08a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae1d87ac95d463f9fa59da4bbf23bce_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTMtMS0xLTc4MDQ5_a82dabc6-645c-4b7f-9bf3-08e0ba8f7d2c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb113e118e7452c88560640a9b79b47_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTUtMS0xLTc4MDQ5_ad8d436d-6f5f-4c54-b6d3-410afa33e004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4dd465b3a644ffba70709abd0e98ab_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTctMS0xLTc4MDQ5_0d898959-6f3d-4b16-83d1-5757779147cb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8f6315c869439fbc63a0932a14c1b9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTEtMS0xLTc4MDQ5_e40fa3ef-ae34-49ed-b47e-f292cba2a130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142cfd8898984756ad60bc4f86418961_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTMtMS0xLTc4MDQ5_46f46644-8e66-49d6-bdf6-e9455ecf538d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f46381d5d84ab897c5e33368443242_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTUtMS0xLTc4MDQ5_202fc615-e30d-4290-85b1-4b9829bec054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02fd6baa57ae461bbf3b32faaeb4ca35_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTctMS0xLTc4MDQ5_339874f0-fc74-4a22-966b-5cf064587c23">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id668c24327e44ed49160b1d70e4edf8e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTEtMS0xLTc4MDQ5_ea44333c-4d95-478e-a5f4-d9ac0f845769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9ca1afbe084ad2b78b08a5a7a9ab88_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTMtMS0xLTc4MDQ5_88f4e945-b622-4f62-8ab1-567f76f07f1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b4418327794b1ea9613fab77ce0af0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTUtMS0xLTc4MDQ5_978d2a3c-ef32-4386-9350-268f876ce837">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71836a62a044a1a972a740f6319ef84_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTctMS0xLTc4MDQ5_94aa9236-a73a-4a88-9cf9-93de79e4c328">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in DOL 103-12 trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c7dc7c1587494599625760bf34889e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTEtMS0xLTc4MDQ5_90665ed3-24a3-41b3-b3a9-b81c5b9512bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549a8c00f0d749c38e43fa24e8a68fc3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTMtMS0xLTc4MDQ5_c43eccbb-373f-4b2d-810c-5d71c56624ed">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64aa8a2e665348d281dbb4b93dab7c26_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTUtMS0xLTc4MDQ5_46100485-8c7b-4ff1-a846-ec8a73c5daaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5aaee2e719474ebec4de5223a6b859_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTctMS0xLTc4MDQ5_299385ea-00c2-4642-9931-6af7f94b068d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other benefit assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc72fc42cfa546b9b9e91cd582c83266_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTEtMS0xLTc4MDQ5_634eb68e-1565-4bd2-b348-2ec8321e94e2">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84c581ad8f34d408c44634c9e7d0f91_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTMtMS0xLTc4MDQ5_bf546637-fdfb-4f16-beb8-a5b360217071">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64dcb287d7ec41c48e54b1306c36a88c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTUtMS0xLTc4MDQ5_a5527e5a-8674-417a-b682-6ae9104cb934">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5524db3a83e64bfe85a82d222a654d8b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTctMS0xLTc4MDQ5_98db07ce-ca6f-47e7-ae60-c1e98dfb87a5">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-108-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="i503e4ff7388c4715bd249bb548b8b226" continuedAt="i3bbfe605d17c46fc81db300cada04cfb"><ix:continuation id="i021c2b2253c847a08aed575f7f2f378b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2021, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:DefinedBenefitFairValueDueFromBrokers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzY5Mzk_206f4e67-4f1c-4076-87f6-af3b2175b2e6">48</ix:nonFraction>, and excluding estimated claims settlements to be paid from other benefit assets of ($<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:ClaimsSettlementsToBePaidFromOtherBenefitAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzU0OTc1NTgyMjc3NA_23596a33-409d-49be-aea8-29f58f4e25ad">29</ix:nonFraction>), are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37480e91464c49dd98f091245e025713_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtMS0xLTEtNzgwNDk_d0911a01-d30f-4f22-8fb5-a8ebc76a0663">682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90158ecd8c3e413386c593b81c9ec032_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtMy0xLTEtNzgwNDk_8338550a-b320-42fc-827a-87f65183c444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26ec646267f4e85948a6ab2df7b23a3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtNS0xLTEtNzgwNDk_0c02cb8a-951f-47eb-837c-e886f8f02f1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f8dc92496214bc1a120c9a3281fc5e8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtNy0xLTEtNzgwNDk_2fd56f1e-2667-44c4-8d7a-24f94f50cc31">682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a6a69355e3453493947ac5e9722c59_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtMS0xLTEtNzgwNDk_69a19866-fc56-4b47-ae59-41791327a967">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if820e1dc7ba1477ab9046f6f9fa76088_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtMy0xLTEtNzgwNDk_41bfa1f0-71ea-4f10-8643-36cbc45a36e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bc64d208594f82a7ea1b06af17e59d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtNS0xLTEtNzgwNDk_0c75ea8d-180e-40d4-a873-67162b848998">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19857bfc8f948f1a850a6668ed7d8a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtNy0xLTEtNzgwNDk_4255e47a-e2c9-4b97-b9e3-d7a3aacfcc9a">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a5b59f05da4d839616ac13e1467ef1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtMS0xLTEtNzgwNDk_8c950b26-c53e-494a-ac35-a5ffa9ec0a28">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81c850442314891a6ae5cc1a2f882f9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtMy0xLTEtNzgwNDk_98ecb918-bd05-4e9c-9f9e-282018cf2209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e8077800b44d75af0b74ead71c6510_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtNS0xLTEtNzgwNDk_213f61e0-b48c-4dc4-a11e-efc9881a0dac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c99e708c60467094ebc0103c16902b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtNy0xLTEtNzgwNDk_9034a938-edd1-4f3a-ac97-eb5f6f5eacf3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2432a93c2642648f67e1ecff14d557_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtMS0xLTEtNzgwNDk_780fce28-5b7c-4151-a0f7-e29327f00296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401d253c03d541b2b15b77b43f0fd1df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtMy0xLTEtNzgwNDk_c101cd82-8c69-46e7-ab75-816966b03f7f">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48af28deba5435bbd08534c18358b09_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtNS0xLTEtNzgwNDk_9a7633b7-d305-44ae-9dac-9e101a0a8fe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09876f128a94429b9227814e8df6c80_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtNy0xLTEtNzgwNDk_5e1a9d44-5deb-45c1-8bf3-b6e791a43bd4">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619c68bb39df4437a5e73314f08f8e67_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktMS0xLTEtNzgwNDk_90a1c1bd-24c4-400e-9291-14d6c9898b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6632e89a64e494ba984e898352b2f9c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktMy0xLTEtNzgwNDk_9c907608-0796-41c5-b2f5-6c1be0d90d13">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8c406fd2c74fdfafe3a57ed54a171f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktNS0xLTEtNzgwNDk_7b3ae526-7a83-4b18-8030-6284e42d1a5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ca6e2453404a48a52750e3e90e1c47_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktNy0xLTEtNzgwNDk_49a876bb-19b6-41aa-9c66-1d23562b5b58">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8105dc0c76f840128a4f6f87b9a897eb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTEtMS0xLTc4MDQ5_8c3b799e-3750-43bd-9c44-7d2078d65c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2552bb36ef2c4777893433a656282c25_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTMtMS0xLTc4MDQ5_33a90283-a245-4980-ae1b-4347ab6c20b7">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a5175770b84cb4bab9529b3ce7bec7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTUtMS0xLTc4MDQ5_f14e5f1f-bbdf-4fe5-9f63-d654a5ab3c8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e3d70c034b4a9085ff1de6d2ce55f3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTctMS0xLTc4MDQ5_02ce1ee8-bbd2-4714-bf38-eb7ca00dd9be">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i131d7dc36ccb49a299712a5e82f3de3d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTEtMS0xLTc4MDQ5_6dc62e63-7260-40c2-8931-a95a24212e67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9ec8958dad4e25b4dec1bdef155303_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTMtMS0xLTc4MDQ5_14c0ffa1-80a3-4338-b366-fa3cf0ff868a">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666be2a8dc0345ef89405b86d686e7dc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTUtMS0xLTc4MDQ5_c02c32f9-c99e-46b7-98f2-f6fc39d5da15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bbfca782904064adf3f965eb407772_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTctMS0xLTc4MDQ5_045b7f0b-36e0-45d3-a49d-1ae6f6c66669">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance company contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c793768fac34476a639c2429c54308f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTEtMS0xLTc4MDQ5_efdd6186-f43e-4f4b-94f6-50f65c744640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718358de146a4a6c93c1a4fe8ea02b90_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTMtMS0xLTc4MDQ5_3d1e8756-36d4-49d4-bafc-26d945f681d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4b302cec1d435aa72e21490d245992_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTUtMS0xLTc4MDQ5_acc5ce21-8557-4e5d-8155-db4bdee50124">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0301f217169748b8b9564b716734656d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTctMS0xLTc4MDQ5_1b8bc268-bf15-41f3-9464-b3b19a5fad05">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3486851087a1461cbc7cdbd886031e0a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTEtMS0xLTc4MDQ5_a320f462-32e3-4c32-b677-e93148311c0e">935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824079b6e48d4bb5800315785acae403_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTMtMS0xLTc4MDQ5_98ec6bbf-ed8f-45ff-b935-c080fe8c7877">978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8acd54cdd7834f65b9fd34a3eecb83ba_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTUtMS0xLTc4MDQ5_13d68c7f-db93-4f71-9ec6-7374dbaa5834">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ff876d8f4d4e13bfb398ce15c78dfb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTctMS0xLTc4MDQ5_76bd923d-1c03-4494-82b9-8a1e626c6563">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da33ae4440b4e3e9858280b13b26b86_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE3LTctMS0xLTc4MDQ5_9e0ad4c2-b84b-483a-91d5-93756e891f29">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df6e9e072f7410bbe91dd8464dc1559_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE4LTctMS0xLTc4MDQ5_253c8f92-0934-406c-b0cb-da865b74dc8a">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b4a5ab5d5945078778d6bf6cb1a8c4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTEtMS0xLTc4MDQ5_468acddc-23c0-40cc-b3ff-4d25943460c6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81f254578c34d74b6c7ee4044f8bdda_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTMtMS0xLTc4MDQ5_2f8a1186-24e2-429e-b328-8108fd2dcc05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6ac436f09047b58b9afbeeb2bfe737_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTUtMS0xLTc4MDQ5_e0da5b6e-2600-47d7-97f1-efa7c299d448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f7e00faf9c423987fb23403b1098bd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTctMS0xLTc4MDQ5_64ec83ec-b513-4653-b144-e9200c5576ea">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc47fc0ad92542a9bae68627e6bef5ac_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTEtMS0xLTc4MDQ5_629f1a53-6b72-47c5-bf02-9b3ecaf2c179">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25321d10a7f6437fbb4bcfce57f68be4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTMtMS0xLTc4MDQ5_a266e327-82bd-491c-ba16-b7aeef01b631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea480fece154d2f860656f2677bdfd3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTUtMS0xLTc4MDQ5_26d508b6-bbe1-4658-bc29-4553405f854f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ca81f42d6d4bab8cfeaf80de0cb1b7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTctMS0xLTc4MDQ5_8b09acec-4f1b-48de-983b-e9903859b113">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2ebfa875334d19ad5216074deb2d4b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTEtMS0xLTc4MDQ5_10b9f530-c719-4721-94dd-a02801d6e88c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a519ff398f494e846042ee96a98679_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTMtMS0xLTc4MDQ5_e1db4022-dc02-478e-bcac-f342bdf2ddf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a64acd001884c8e9e9bb3b1a965529e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTUtMS0xLTc4MDQ5_63c8befc-294a-4c36-837a-970fd8b9187a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46c9cd33130445a91236aacb780d027_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTctMS0xLTc4MDQ5_117f74ef-24d6-44e9-bdd8-5d08b7fbe84f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfe1e0781264622a6679afeb0a9c720_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTEtMS0xLTc4MDQ5_a84a7665-8662-4736-895f-ef05a449b3cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bce5bacf7c24b4f9dc864afd7e4ca87_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTMtMS0xLTc4MDQ5_fe408c48-5e79-4b72-831b-4c81c762cf8b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917c455132fb4e1e9f340d3bad48d102_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTUtMS0xLTc4MDQ5_bc9deb61-37e8-4907-b905-6869dd63d2be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icefbd8bbbac7446baf3a38dca505dfea_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTctMS0xLTc4MDQ5_7043062c-2237-4257-895d-3ee05b4c72bc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie579e5cdf455475b9502356566def862_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTEtMS0xLTc4MDQ5_940774a9-259f-4000-9a44-d9e07a0f901f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6eee54cd694a2ca132251fbf4a7f5e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTMtMS0xLTc4MDQ5_60452f31-666d-42cb-8ab0-dda521547fce">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a66d7e68f44e50981c5465d04e22bb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTUtMS0xLTc4MDQ5_7f9fa6c9-6a64-4e2e-932e-855c7a9ed325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7b6dd2b55348cba5836b9c067d3c29_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTctMS0xLTc4MDQ5_a2a403b8-547d-498a-a029-1ae3e90d34f2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia263eb55917d4d3fa6a60e7db1c48a3a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTEtMS0xLTc4MDQ5_d7975c64-a20d-46a5-bb10-1230285c0005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4974aa0eb2c24470b0039864c0415900_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTMtMS0xLTc4MDQ5_e221705c-717a-487b-9e9c-b6c9e0c7b713">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ded0fd871644ff591de8addd589219a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTUtMS0xLTc4MDQ5_b32aa705-796f-4d12-85bf-8f50ec9b7d3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c81070f0b3b443c8f18a8f1214732bd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTctMS0xLTc4MDQ5_7667f800-1a72-4812-b87d-ff21f29879fc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d680746121d4419b3c54ef8acb7b9fe_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTEtMS0xLTc4MDQ5_3d5b96f7-6cd0-452f-9e6a-5d774301b1ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20a6873d906447385de48452526511e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTMtMS0xLTc4MDQ5_2769fb92-e66f-4492-8522-59d9eade3363">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc7ea082cf84448a7ec7762124b2a4e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTUtMS0xLTc4MDQ5_1ef66f8b-827e-45f8-b6c5-2fec55070420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4376d31b137c4d3a8e1c905705497935_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTctMS0xLTc4MDQ5_6526b724-603e-4350-8adc-2ea490e887a4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52db6dff7f164d5e890ff1578cbcb759_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTEtMS0xLTc4MDQ5_107b206e-c7c0-4756-a062-a8abe5c420e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b5962d9e5e4af890e2358bb3edbb03_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTMtMS0xLTc4MDQ5_c8a99c96-98e7-4e4b-aa9b-e7409430f1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcdd3e9146f4beca1f89cb52fea78f0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTUtMS0xLTc4MDQ5_470a735e-a19a-45ef-8c63-58030e8710cf">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id541168132e04301912466c96cf4ad90_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTctMS0xLTc4MDQ5_a0d8a397-b453-4ca0-9cac-779d6963b6d2">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in DOL 103-12 trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15061749f3f2485aa1798b8186e3f2c1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTEtMS0xLTc4MDQ5_ceb3d99b-4330-40bf-b45a-f3c8046d7daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087044734b154901b0cfed0b0f5d93dd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTMtMS0xLTc4MDQ5_91c78c44-30ca-4029-8819-2948d10f0bd5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e196f381254b4da2543763f22de2fa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTUtMS0xLTc4MDQ5_ae081e77-8249-46e2-8106-73502e716cc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05c5e1befde4b3d876502ebb2794242_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTctMS0xLTc4MDQ5_0a62aa93-d9f0-4cad-9763-dd4acac0eee8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other benefit assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53abc6af4dd045279ea54e62550af65d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTEtMS0xLTc4MDQ5_1c0f6511-8b74-43e5-b4e2-3ee9470c6091">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689e1a2aa1847a19d4aa925acdcc69e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTMtMS0xLTc4MDQ5_59c754ba-55fe-4d97-b5fb-f49de5e1398d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f3aa30468184cb8b88f01ef4d14e83b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTUtMS0xLTc4MDQ5_7f731323-39b5-426b-ac36-23c31887d90c">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5874492cbb402d81d69b55109ae43c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTctMS0xLTc4MDQ5_aaf42aa8-69e3-4a7a-8cbf-fff2f9457036">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-109-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i3bbfe605d17c46fc81db300cada04cfb" continuedAt="if97c737e18e74f82b13fd7104d2c91c8"><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0MTI_508ee40a-74af-43e8-b669-bb6b48bc9d03" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Company<br/>Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life<br/>Insurance<br/>Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7580de5335c2453fbc6266565e5baa9e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzItNS0xLTEtNzgwNDk_b21c5356-6494-4679-b4ad-80a4832d8236">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48a8bf89b7b4def9e1a900fde56e8da_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzItNy0xLTEtNzgwNDk_234b570f-2479-4560-87d5-937ced2f7c37">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f9bbbaabb04060a11a6fd22a348392_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzItOS0xLTEtNzgwNDk_4cd4c98e-84ab-47cf-be2d-afedb8b0541f">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80355d52e2674470b51aa353a404d82c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzMtNS0xLTEtNzgwNDk_76dabc98-fd64-43e2-ac19-0b2350d6adfa">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzMtNy0xLTEtNzgwNDk_0cb9e986-e6e7-433d-874e-62d6f1768192">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzMtOS0xLTEtNzgwNDk_84ad6c59-a795-4bc4-afe8-a9ee1cc69ecb">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80355d52e2674470b51aa353a404d82c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzQtNS0xLTEtNzgwNDk_00c838eb-4ecb-452d-828b-4bd416ffabb0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzQtNy0xLTEtNzgwNDk_641be110-ed01-4f57-b43b-6976bd1fd1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzQtOS0xLTEtNzgwNDk_76026161-8064-478e-8529-c3dcff54fc50">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80355d52e2674470b51aa353a404d82c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzUtNS0xLTEtNzgwNDk_00bbd057-e647-40b1-b473-5251a9c466af">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzUtNy0xLTEtNzgwNDk_90410a6f-76f4-45a3-964d-19618e9f9c3d">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzUtOS0xLTEtNzgwNDk_6d112535-3f21-4810-8e7f-53063dbb634b">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f8ffbfbcd842e88af9bfbc67f7e567_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzctNS0xLTEtNzgwNDk_8ed60615-ccd4-4eb2-97c6-76634a504ac9">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ad54fe654c42efbd77c7bb585d643d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzctNy0xLTEtNzgwNDk_c77ab60c-4660-474b-b83f-08e034ba8e43">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2e3cdf76fb4346a9739172b0a28be0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzctOS0xLTEtNzgwNDk_302f891b-173f-4e77-9d4e-2a5f570224c8">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib360e9af4b21497d82c013681a5dadae_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEwLTUtMS0xLTc4MDQ5_f1374b78-8b58-4e09-b6a8-4195f50d9d56">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd65a74e5704da5920113ea7aece196_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEwLTctMS0xLTc4MDQ5_f9afea62-71fc-4cc1-a242-36b4af6a8446">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia99956a06c7e46e1849e1ddf398be5df_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEwLTktMS0xLTc4MDQ5_66c53ed8-7f47-4d29-a8fd-cbd418943cc3">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzExLTUtMS0xLTc4MDQ5_34bce0f6-e0ae-41c1-b0a2-f25e97fbe5a7">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6904393673c940ae893924fc97c16cda_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzExLTctMS0xLTc4MDQ5_c3d20292-3a73-4f0c-9778-6375d708c2b7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzExLTktMS0xLTc4MDQ5_69e3dcf7-721e-4837-8ae7-7f131685954d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEyLTUtMS0xLTc4MDQ5_841b9b50-12d5-49c9-a1c6-ca650a7c65d3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6904393673c940ae893924fc97c16cda_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEyLTctMS0xLTc4MDQ5_38c8844c-40e2-46e0-b903-1c650bd65f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEyLTktMS0xLTc4MDQ5_2870c445-e51d-4c7f-aacc-0839a6b3b030">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEzLTUtMS0xLTc4MDQ5_7ccededb-a789-4948-ac8f-b29ba3acb41d">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6904393673c940ae893924fc97c16cda_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEzLTctMS0xLTc4MDQ5_e281c61a-fc07-4372-be76-90f3444850b4">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEzLTktMS0xLTc4MDQ5_ed12a4ba-7e2c-4e7a-b4c7-e6b2e6f62d58">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7580de5335c2453fbc6266565e5baa9e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE1LTUtMS0xLTc4MDQ5_ca04ed4b-38ab-44b1-b5a9-eb1b61bf0495">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48a8bf89b7b4def9e1a900fde56e8da_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE1LTctMS0xLTc4MDQ5_9f011050-56e3-4971-aabb-203293b87625">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f9bbbaabb04060a11a6fd22a348392_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE1LTktMS0xLTc4MDQ5_99b3632f-c158-4d75-9262-355d506e4dc0">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932bd361ffbc47c298c90d616e0667b0_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE4LTUtMS0xLTc4MDQ5_04c04b9e-ab68-49d7-bd5c-e570efcbf2ad">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe4907f34814d2baa614ba2fc07e320_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE4LTctMS0xLTc4MDQ5_ef360f93-0d60-4d35-bf97-51405032073f">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d6ceec20cd424fa94e7a6386ac5a78_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE4LTktMS0xLTc4MDQ5_61fd130d-173e-46df-89ec-89a74aeff05c">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE5LTUtMS0xLTc4MDQ5_cd018db8-1ab0-4ecb-8373-d55473cc56cf">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE5LTctMS0xLTc4MDQ5_2d900c2f-2a78-4b1c-9fe4-89359ca11250">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE5LTktMS0xLTc4MDQ5_5efd2e65-5b83-45d7-86b2-3e2206dae8da">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIwLTUtMS0xLTc4MDQ5_36a5de9a-df82-40d0-a924-b32e9c8f0813">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIwLTctMS0xLTc4MDQ5_c40011c9-3cd6-4ab9-9224-f8bebf4c6071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIwLTktMS0xLTc4MDQ5_e710e510-cfea-43aa-a2f6-e52db6148d1d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIxLTUtMS0xLTc4MDQ5_552c5932-0713-4b2c-8c58-32323fc7ccf5">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIxLTctMS0xLTc4MDQ5_f57e1cc1-be23-466a-a60c-4579948f61cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIxLTktMS0xLTc4MDQ5_37464b83-af7f-4c60-874e-f6e6537f3c01">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib360e9af4b21497d82c013681a5dadae_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIyLTUtMS0xLTc4MDQ5_75a3db35-f699-4e05-a9dc-58c56086890d">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd65a74e5704da5920113ea7aece196_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIyLTctMS0xLTc4MDQ5_7bbdbf8c-9875-4eab-9c71-d0497c66311e">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia99956a06c7e46e1849e1ddf398be5df_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIyLTktMS0xLTc4MDQ5_ea04b181-66a8-4ee7-b72d-dfbf3486acf0">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other transfers into or out of Level III during the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended December&#160;31, 2022, 2021 and 2020, no material contributions were necessary to meet ERISA required funding levels. However, during each of the years ended December&#160;31, 2022, 2021 and 2020, we made tax deductible discretionary contributions to the pension benefit plans of $<ix:nonFraction unitRef="usd" contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzc3NTc_1adb3d47-67fc-4fc4-b100-d06ae0667485">4</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzc3NjE_e670e416-7762-4669-ad23-9c38c938fcd1">7</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzc3Njk_d6a08429-8a21-4721-8067-d9a3f4050096">7</ix:nonFraction>, respectively. Employer contributions to other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0NDE_3d353c53-3f5c-4de9-a5d2-8df5d318a283" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as appropriate, are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzEtMS0xLTEtNzgwNDk_654e7655-fcd7-4a2d-b9b6-c5e520c8ee2e">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzEtMy0xLTEtNzgwNDk_ab368f45-4f26-405a-9d75-19556966cc7d">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzItMS0xLTEtNzgwNDk_ae436cbc-d0e4-49ef-b4f3-736755708393">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzItMy0xLTEtNzgwNDk_dd766852-7e29-4f50-8659-bddc76a43975">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzMtMS0xLTEtNzgwNDk_95df3257-2ee2-4eb0-a296-0fda36bebf45">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzMtMy0xLTEtNzgwNDk_10a020d8-6fee-47df-8b90-0290447f7fa3">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzQtMS0xLTEtNzgwNDk_79c84019-2c18-46d5-b3cf-2a76d5ffa616">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzQtMy0xLTEtNzgwNDk_3aac4b44-2565-4bfc-9ef0-dfe492efa0ef">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzUtMS0xLTEtNzgwNDk_36604a17-e69f-4bed-85f3-2cce30d41060">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzUtMy0xLTEtNzgwNDk_096bbf46-38c9-4782-b4cc-74244b555ec0">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzYtMS0xLTEtNzgwNDk_898dd901-dc46-4ca0-970f-cb92c9f914d8">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzYtMy0xLTEtNzgwNDk_30bec5eb-ea09-42a7-91d2-9cffc44f2dac">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-110-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if97c737e18e74f82b13fd7104d2c91c8">In addition to the defined benefit plans, we maintain the Elevance Health 401(k) Plan (formerly the Anthem 401(k) Plan), which is a qualified defined contribution plan covering substantially all employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzgzNTY_b8b77c41-dc6c-453f-9d6c-3ff5e424a09c">275</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzgzNjA_54705607-723c-4327-ba08-81c1301bffce">241</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzgzNjc_adf11c53-7ef9-47eb-aca2-886d955bc53d">221</ix:nonFraction> during 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0Mjc_7313191c-c3ce-4439-93ff-22b42e29c88d" continuedAt="id3f9ec246e2542df8f651ee8e9458be8" escape="true">Medical Claims Payable</ix:nonNumeric></span></div><ix:continuation id="id3f9ec246e2542df8f651ee8e9458be8" continuedAt="i3ff8e750fa9f4c8a8550dd8126ada435"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0NDc_732668df-0fe1-4969-b9ed-22dc83cddb31" continuedAt="i0db6afabe68d4328b74dd20d79f2aab2" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, &#8220;Segment Information&#8221;), for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtMS0xLTEtNzgwNDk_c9f88df5-9f78-49b5-b841-ef704b51daec">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtMy0xLTEtNzgwNDk_473684ff-3976-4551-a4cf-552b7dc0a4fc">9,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtNS0xLTEtNzgwNDk_eea592d3-e73c-4145-a1ad-2a37a712e6d2">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtNy0xLTEtNzgwNDk_15743ac0-c307-405e-b224-cf942e601c33">13,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItMS0xLTEtNzgwNDk_e6f5fc96-f5cc-46aa-b7ed-63c245ac3a58">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItMy0xLTEtNzgwNDk_6d31ccd1-0ce2-4bd3-8637-19f0149301d4">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItNS0xLTEtNzgwNDk_51262d2c-36ed-4f3d-ad3b-421094bf68ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItNy0xLTEtNzgwNDk_9b791b2b-8e8e-48f8-a0de-436e91e79be5">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtMS0xLTEtNzgwNDk_b4717aed-8279-4fa3-9b08-8741953f67c1">3,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtMy0xLTEtNzgwNDk_dfd541be-b1a1-4972-8a6b-5740d1578d30">9,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtNS0xLTEtNzgwNDk_af238d77-9a7b-45e4-bb7d-6c46c7d32e06">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtNy0xLTEtNzgwNDk_9a562c2a-dca9-48cf-bcea-231a0d88dacf">13,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtMS0xLTEtNzgwNDk_c0aac58b-e4ab-44c4-96ee-5969bae7163d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtMy0xLTEtNzgwNDk_75650159-6823-4eb3-b3c2-82022c4ce3f3">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtNS0xLTEtNzgwNDk_b35d826c-7880-4d67-ac16-b468d1226d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtNy0xLTEtNzgwNDk_e9dcb085-c4b0-40b9-9e65-f2d91988a3d0">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtMS0xLTEtNzgwNDk_4035e8ae-e0bc-400e-88b8-40f92b627d09">30,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtMy0xLTEtNzgwNDk_e479bf84-3911-41d6-bf01-f7d1b09f5245">81,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtNS0xLTEtNzgwNDk_12192e1e-ae6c-4f97-91c1-9af66b60a57a">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtNy0xLTEtNzgwNDk_dc30f4ac-582b-407a-a7a7-8fae4a92c321">113,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctMS0xLTEtNzgwNDk_65244866-65ca-4f27-a318-6c5d20a10343">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctMy0xLTEtNzgwNDk_09473bcf-1052-46f5-942f-ef0635a72288">630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctNS0xLTEtNzgwNDk_176d273e-644d-4d4f-b0b6-20378bd363dc">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctNy0xLTEtNzgwNDk_b7e239e2-0ebc-4c34-85d0-c4479cf359cb">869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtMS0xLTEtNzgwNDk_0e121e98-aaef-4df9-b551-1ddd687b1a01">29,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtMy0xLTEtNzgwNDk_cff2833f-51ba-473e-9e3b-298b79dd24f0">81,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtNS0xLTEtNzgwNDk_ee4a98c6-4e4d-4a5d-a1f8-d23cd1cb9220">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtNy0xLTEtNzgwNDk_dce2ac5c-43ad-4343-ba8a-9dd9de288d80">112,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTEtMS0xLTc4MDQ5_cd547c2f-7c51-49d4-94b9-1e7c24f6c129">26,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTMtMS0xLTc4MDQ5_9be13a16-d929-4ee3-8142-6bdf68099d96">71,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTUtMS0xLTc4MDQ5_a5bd5bb6-6c6d-4674-bbc9-4d58956981f3">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTctMS0xLTc4MDQ5_ac55247a-295d-42dd-aaf3-4f3a7add0a9f">98,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTEtMS0xLTc4MDQ5_68526f74-11ae-4488-8a11-dd35488f3a9c">3,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTMtMS0xLTc4MDQ5_842b6233-3796-47d7-85fd-c37ccb821093">8,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTUtMS0xLTc4MDQ5_167652e3-51aa-4a7b-a893-751cf8fd7548">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTctMS0xLTc4MDQ5_c27b80a9-d28e-45ad-8dc6-5cc714a8e601">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTEtMS0xLTc4MDQ5_4175c286-780e-41ee-bce8-8388e65fec20">29,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTMtMS0xLTc4MDQ5_4c68dafb-b663-46f7-bb0c-54e9705d3d51">79,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTUtMS0xLTc4MDQ5_ee00df20-3ff1-42a0-8065-ad57c4d4ee6f">1,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTctMS0xLTc4MDQ5_526ad9a0-27e2-486e-97ee-af0072d1dbda">110,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTEtMS0xLTc4MDQ5_a03214f3-6e07-4707-8df4-6df99338bba8">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTMtMS0xLTc4MDQ5_1bff7df0-4812-48a6-9043-e21918291d10">10,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTUtMS0xLTc4MDQ5_96aa4126-59dc-4097-95e7-d43308d7e650">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTctMS0xLTc4MDQ5_e2101353-ce2e-4022-9540-a69490fdeb77">15,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTEtMS0xLTc4MDQ5_e5e04b87-1969-46ce-9850-a812540cf1d7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTMtMS0xLTc4MDQ5_18d10bba-3835-4f2f-9a2e-721853489433">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTUtMS0xLTc4MDQ5_8a189fe4-36d2-41fd-ae1d-10129b035f85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTctMS0xLTc4MDQ5_26178fbf-a4aa-4bc1-ac56-b4346754bfe3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTEtMS0xLTc4MDQ5_5945ab92-6051-45a7-8379-549f959d1a61">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTMtMS0xLTc4MDQ5_b6c22f11-3948-47a4-a818-abb824781a8a">10,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTUtMS0xLTc4MDQ5_ef6c4be0-be8a-4576-8a55-2d49348838b9">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTctMS0xLTc4MDQ5_3fb444dc-a261-4884-a1b3-1b49cbb2edb8">15,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-111-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i3ff8e750fa9f4c8a8550dd8126ada435" continuedAt="i5245ad4b1745428eacbc38612ce25558"><ix:continuation id="i0db6afabe68d4328b74dd20d79f2aab2"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtMS0xLTEtNzgwNDk_da90dfbe-9259-4b3b-ab56-1583f7d452a2">3,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtMy0xLTEtNzgwNDk_73d296bd-1ca1-4fd7-bbd3-2c33d2bce635">7,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtNS0xLTEtNzgwNDk_49770dbb-bfce-4891-a450-49121a48ed57">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtNy0xLTEtNzgwNDk_bcba0060-b32f-4ecd-8171-f315e94204ff">11,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItMS0xLTEtNzgwNDk_c4fd2cee-01b7-4d11-8f3d-c23f16f449e6">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItMy0xLTEtNzgwNDk_fb216ce2-5bba-410e-92e4-717eb5aaaa79">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItNS0xLTEtNzgwNDk_b89619ec-1696-4179-8e5b-abec7859c07f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItNy0xLTEtNzgwNDk_9b057a5f-fe5c-4e88-9807-239c84183eec">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtMS0xLTEtNzgwNDk_8339ddb5-e0dd-4464-8fd4-ca7448fc82f2">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtMy0xLTEtNzgwNDk_b757efa5-5fc8-44a7-a1fa-829c17698948">7,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtNS0xLTEtNzgwNDk_902d5d07-d8f8-43c1-946a-fdc1b316ecb7">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtNy0xLTEtNzgwNDk_3f53e995-9102-45ed-a07a-27ec23073a51">11,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtMS0xLTEtNzgwNDk_e09f3e45-65c2-4a86-bc51-5583389b7cd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtMy0xLTEtNzgwNDk_f6c47d5c-ee3d-4fb3-b4ec-15648a200dac">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtNS0xLTEtNzgwNDk_0d7009d6-f8b6-48ba-ab96-1c8c7dcdb1d1">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtNy0xLTEtNzgwNDk_15121fa4-742c-4461-984b-7aa67539989e">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtMS0xLTEtNzgwNDk_a25aa15b-4507-4688-9c46-eb9e6b35921c">28,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtMy0xLTEtNzgwNDk_8f861b0e-2a04-40c5-becc-bf1389218fb3">70,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtNS0xLTEtNzgwNDk_9d22b1fa-a1ba-4e84-afb9-7e1f6c42a356">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtNy0xLTEtNzgwNDk_4e547b4a-7223-4dc0-8fd3-1af373eca79d">100,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctMS0xLTEtNzgwNDk_8a637b9e-7904-4fb4-8417-abc8db94de80">465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctMy0xLTEtNzgwNDk_e3c1f140-2fa6-4f93-89eb-1ce2cc6fc77f">1,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctNS0xLTEtNzgwNDk_3b75d2d3-2ff4-4b46-83f1-2fb29332f21c">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctNy0xLTEtNzgwNDk_257cb6cb-ede1-410a-ae2d-a44dcac3cbfd">1,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtMS0xLTEtNzgwNDk_87c70872-8a12-4b99-a27e-ba213e455d77">27,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtMy0xLTEtNzgwNDk_f668c715-6541-4adb-a4fd-10399cc312a4">69,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtNS0xLTEtNzgwNDk_6c30a8ee-6ca0-44b6-bc61-d292e2b5bf09">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtNy0xLTEtNzgwNDk_ff346aa6-f013-4bbb-8a4f-79a2a1c89d6b">98,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTEtMS0xLTc4MDQ5_3ea6fa33-ad6d-4cad-8b97-b85fad6373e7">24,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTMtMS0xLTc4MDQ5_57d777b2-d2d7-47bd-ad04-303ae6a3ec74">62,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTUtMS0xLTc4MDQ5_dfee6b89-2b74-459b-af12-4d30ace05d49">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTctMS0xLTc4MDQ5_77e28613-dbcb-44b1-b959-c249caa33a45">88,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTEtMS0xLTc4MDQ5_1ad7d0a2-7701-420b-a263-0bad3dc16f02">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTMtMS0xLTc4MDQ5_ee943de7-9c2f-4bf2-83d4-cc320bfdb7f5">6,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTUtMS0xLTc4MDQ5_1d79205f-faf3-4a01-8249-0b040f6d852c">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTctMS0xLTc4MDQ5_25bb69da-0bd6-4dbf-b6e9-cc4b1030ae6f">8,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTEtMS0xLTc4MDQ5_f2361c0e-b5c9-447f-988d-57aa445f652c">27,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTMtMS0xLTc4MDQ5_ffbc3fd3-d548-4aab-a17d-e07ce7c8f9b6">68,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTUtMS0xLTc4MDQ5_7567a6cf-61be-4707-ad4c-9820665378e0">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTctMS0xLTc4MDQ5_01d4208c-5221-409e-9301-a56459d81827">96,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTEtMS0xLTc4MDQ5_10a844d8-f8f0-48a8-8338-6eea6c43fdf7">3,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTMtMS0xLTc4MDQ5_95f8b61f-29f7-4be9-8ea3-7eb33e0cdc42">9,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTUtMS0xLTc4MDQ5_a95abbcd-096e-481f-90e7-ade56a206864">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTctMS0xLTc4MDQ5_93b8379a-4a04-47ca-a38d-52307eb46909">13,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTEtMS0xLTc4MDQ5_e8f9f2b4-695b-42c0-ba8e-fb0e2af489e8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTMtMS0xLTc4MDQ5_9ff04321-f39b-4a26-b852-f222689cf7bf">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTUtMS0xLTc4MDQ5_6b849e39-791d-4f8c-b011-b8517a115acc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTctMS0xLTc4MDQ5_96ff2914-6fe1-4a7d-bda0-7486651de0e3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTEtMS0xLTc4MDQ5_512c87be-31e6-47f2-9ebd-9bf5b0dfb230">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTMtMS0xLTc4MDQ5_d59ccee2-f0e2-4f18-b3e5-be166d640b17">9,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTUtMS0xLTc4MDQ5_fb08a7f9-2605-4c1a-97b2-8913f1317f6a">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTctMS0xLTc4MDQ5_a1b14c49-e102-4d53-91bd-d11976b77def">13,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4334628ce145889a7e9f45088dbc5d_I20191231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtMS0xLTEtNzgwNDk_7fd485a5-25e8-44ae-8365-ec3106313ec1">3,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253166758c5642418ac341338d564041_I20191231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtMy0xLTEtNzgwNDk_88d12b95-a083-484b-b973-eb4df7f28852">5,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056128fedb8c4604822fdacd5c2f6272_I20191231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtNS0xLTEtMTAwMDY2_5d20cc89-eb04-4ee6-9efd-4543eba3a18e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtNy0xLTEtNzgwNDk_f51f7f44-c891-4c9b-98ae-5f2b7c106bc1">8,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd4334628ce145889a7e9f45088dbc5d_I20191231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItMS0xLTEtNzgwNDk_fe0b764c-417a-43a1-9a33-daa3175dba34">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i253166758c5642418ac341338d564041_I20191231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItMy0xLTEtNzgwNDk_03ce4937-2ae9-4dc5-b555-9155b392efb3">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056128fedb8c4604822fdacd5c2f6272_I20191231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItNS0xLTEtMTAwMDY2_8435afc7-23ec-41dd-bf09-403dd1a442bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItNy0xLTEtNzgwNDk_a7574227-99cf-4e40-b060-b9286d86ab94">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4334628ce145889a7e9f45088dbc5d_I20191231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtMS0xLTEtNzgwNDk_39630ab7-7762-45c9-b50f-6d51a06e2548">3,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253166758c5642418ac341338d564041_I20191231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtMy0xLTEtNzgwNDk_853698f1-6454-4f65-9fd0-ce71436e27b2">5,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056128fedb8c4604822fdacd5c2f6272_I20191231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtNS0xLTEtMTAwMDY2_397ce15f-f326-4eab-be62-015c9466bb49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtNy0xLTEtNzgwNDk_a919199b-8889-4b2e-b774-0393dd77f242">8,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzQtMy0xLTEtNzgwNDk_0eb6792e-69f1-4bb7-8391-ed82718b2ac7">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzQtNS0xLTEtMTAwMDY2_bcaae81d-7ac6-4b4e-a787-6b9daa1ed462">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzQtNy0xLTEtNzgwNDk_7d0931d4-3ae6-45e7-b79a-c4d65cfd8790">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtMS0xLTEtNzgwNDk_3824e3b4-1149-4d32-82e6-336c627336a0">24,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtMy0xLTEtNzgwNDk_cd6a4d22-dc20-4b10-b221-bc4095268f50">58,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtNS0xLTEtMTAwMDY2_74448171-d2d1-4842-bee8-130145c6b335">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtNy0xLTEtNzgwNDk_e3b5e3e5-d6fd-48d8-8dbc-2e40b790f0f9">85,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctMS0xLTEtNzgwNDk_c3111af4-1cdf-4855-9dce-c562d25d7b08">375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctMy0xLTEtNzgwNDk_229dd8c3-7352-4423-8d99-51203fb852a0">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctNS0xLTEtMTAwMDY2_8889043b-09da-4e8a-b8c5-5ae9c5989381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctNy0xLTEtNzgwNDk_7b53fe9f-8fe0-4858-b421-6aa12071aba4">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtMS0xLTEtNzgwNDk_531134b0-8a44-478d-abb9-b657024e5955">24,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtMy0xLTEtNzgwNDk_e65831f8-dc6f-4ccc-9feb-e8f02f56450c">58,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtNS0xLTEtMTAwMDY2_108e8a02-836f-43db-a88c-d9612105841e">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtNy0xLTEtNzgwNDk_366fe1ab-11cc-40ec-aae9-4f37d0206356">84,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTEtMS0xLTc4MDQ5_e3b28c25-53ef-4250-a8b2-c154b29004c7">21,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTMtMS0xLTc4MDQ5_7cb08d10-1206-4680-8add-dc2a529aa45e">51,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTUtMS0xLTEwMDA2Ng_10055a0e-b557-4ed1-ae2b-93591cf4f50c">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTctMS0xLTc4MDQ5_774972f8-9905-4dba-bccb-9a07a48c1eb3">74,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTEtMS0xLTc4MDQ5_7a79b759-ddff-4772-b83b-c88f5acfb2aa">2,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTMtMS0xLTc4MDQ5_2b99663e-e0cc-45f2-8c27-52a060244a7a">5,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTUtMS0xLTEwMDA2Ng_a0513f43-93c3-4301-82b9-9c2449a09b23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTctMS0xLTc4MDQ5_15695346-097a-4947-8895-2071737b5913">7,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTEtMS0xLTc4MDQ5_32607ae4-7930-4066-9147-931a527a1561">24,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTMtMS0xLTc4MDQ5_31390980-753c-4b71-b48d-0fe99835e3ca">56,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTUtMS0xLTEwMDA2Ng_82f6978b-1468-4270-a54f-e0f733079a58">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTctMS0xLTc4MDQ5_52d27be9-0a61-4a24-b5c7-c32fb871a10f">82,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTEtMS0xLTc4MDQ5_334ce68d-d83d-4726-8918-a250f80841c3">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTMtMS0xLTc4MDQ5_a9f4ce60-7b66-43b0-b967-ebb34a191afe">7,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTUtMS0xLTEwMDA2Ng_86e20ff3-478c-4414-8c1e-f71c84a020ec">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTctMS0xLTc4MDQ5_11d9f914-e41b-4874-8004-34df3aae402c">11,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTEtMS0xLTc4MDQ5_63b1bc4d-cf37-4195-b46e-2e347d436ac8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTMtMS0xLTc4MDQ5_444fa72f-d613-4d21-a6cb-065123548f8a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTUtMS0xLTEwMDA2Ng_4dd6f068-3ef4-4498-9afd-ad17e980f430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTctMS0xLTc4MDQ5_12f0b603-12f4-4d0c-989c-1f66094508e3">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTEtMS0xLTc4MDQ5_c482b2b8-0e6c-4b59-9b6e-ea8ecc22f27f">3,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTMtMS0xLTc4MDQ5_226126e4-b1e4-4913-a5b6-590b89736eed">7,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55238bc0d8524816beff8ed796471899_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTUtMS0xLTEwMDA2Ng_357a5685-c1ec-41e9-b311-afac1e0c5501">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTctMS0xLTc4MDQ5_a3b590f7-fc7e-4e28-ac21-d3312cd774ae">11,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period-end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-112-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i5245ad4b1745428eacbc38612ce25558" continuedAt="ic74571375abc4d54bdf1a64c86e2f452"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated. The prior year redundancy of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzk5OQ_7960ba89-0c89-4ee1-8894-4a601bd20581">869</ix:nonFraction> shown above for the year ended December&#160;31, 2022 represents an estimate based on paid claim activity from January&#160;1, 2022 to December&#160;31, 2022. Medical claim liabilities are usually described as having a &#8220;short tail,&#8221; which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzEzMjM_7960ba89-0c89-4ee1-8894-4a601bd20581">869</ix:nonFraction> redundancy relates to claims incurred in calendar year 2021. </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0MTQ_1797b06d-8764-4652-a781-8b2ee1187575" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December&#160;31, 2022, 2021 and 2020, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. We had increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that lead to the increased estimation uncertainty.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Favorable Developments<br/>by&#160;Changes in Key Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed trend factors</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzItMS0xLTEtNzgwNDk_1611e9e7-98a2-472a-8d24-18db1eb79bdf">859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzItMy0xLTEtNzgwNDk_22851a74-e1e5-470c-b76d-1beea7473b4e">1,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzItNS0xLTEtNzgwNDk_4d964005-4f54-49e7-812f-bf1ff261c30d">599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed completion factors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzMtMS0xLTEtNzgwNDk_49c8b0b3-7df5-4a5d-b372-29b97105b6be">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzMtMy0xLTEtNzgwNDk_ff88dc96-c364-4d64-95a3-9f601f9c7661">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzMtNS0xLTEtNzgwNDk_6d4a0a45-541a-41a3-a428-ad2dfb7f50b2">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzQtMS0xLTEtNzgwNDk_adf08649-1858-4e2a-8910-5732f9bcee3f">869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzQtMy0xLTEtNzgwNDk_135beb97-5bfa-434f-b08e-8c996051bd29">1,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzQtNS0xLTEtNzgwNDk_46dbaae7-d266-48c7-8e9d-d58fc186e1da">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in 2022 resulted primarily from trend factors in late 2021 developing more favorably than originally expected as well as a smaller contribution from completion factor development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in 2021 resulted primarily from trend factors in late 2020 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in 2020 resulted primarily from trend factors in late 2019 developing more favorably than originally expected as well as a smaller contribution from completion factor development.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0NDI_d2abde21-cf8b-416c-b2fe-023d28aead60" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzMtMi0xLTEtNzgwNDk_0ec7b317-13cb-48ac-9370-5d6763f24b85">29,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzMtNC0xLTEtNzgwNDk_c0bbc201-04b3-4b74-a6d0-d097a07b46e9">27,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzMtNi0xLTEtNzgwNDk_2920bfc0-6eb9-4145-9e21-4a2e6942daa6">24,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzQtMi0xLTEtNzgwNDk_cfbbdb09-e285-42cb-b4cb-06585b32f4b7">81,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzQtNC0xLTEtNzgwNDk_4413275f-d88b-4181-9190-8903e774b5c3">69,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzQtNi0xLTEtNzgwNDk_b134cbfa-4943-45b5-acec-1619b2741f7b">58,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzUtMi0xLTEtNzgwNDk_dda3a31f-b25f-46e5-a608-9d6655b9ebe1">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzUtNC0xLTEtNzgwNDk_a6bffcab-186e-4f33-b2e3-4c334ae8173f">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzUtNi0xLTEtNzgwNDk_fa0bf960-159d-4ab5-a01e-eb8df200a542">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzYtMi0xLTEtNzgwNDk_4cee18c6-0b3f-469d-98b5-940c6bc22b35">112,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzYtNC0xLTEtNzgwNDk_a9108086-07cb-4c28-a945-68d7e00da2b6">98,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzYtNi0xLTEtNzgwNDk_91b23182-b862-4c49-b1e0-e706118bbee5">84,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:QualityImprovementAndOtherClaimsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzctMi0xLTEtNzgwNDk_b25b2940-8a5b-4b9b-ac72-560e37f57630">3,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:QualityImprovementAndOtherClaimsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzctNC0xLTEtNzgwNDk_3c561153-040c-4834-a42e-4c11fd748594">3,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:QualityImprovementAndOtherClaimsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzctNi0xLTEtNzgwNDk_8e3ac086-bcc4-45c7-878e-8c1fc35e0715">3,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzgtMi0xLTEtNzgwNDk_5fa0950d-2da0-4f88-a476-b325d510f00e">116,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzgtNC0xLTEtNzgwNDk_d3434912-f94d-4cc6-9355-a01dd2de2b55">102,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzgtNi0xLTEtNzgwNDk_2cb36518-34e4-4609-9cd9-6f18796d6d9f">88,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-113-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ic74571375abc4d54bdf1a64c86e2f452" continuedAt="if6dfa0a3dc7a4eff888e1979e60ad8b8"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0MjQ_b1e69bea-aa8e-47f6-808a-366e8e7b928c" continuedAt="i7f617c50418b4a688d26da4b2da5399f" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for the Commercial &amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4172e7e04f43ae913e486aafb0c782_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzMtMi0xLTEtNzgwNDk_d9afa624-44db-4b93-986c-1e8e69793425">27,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aef76e4813e4606b8d70440c92f269a_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzMtNC0xLTEtNzgwNDk_0e8a4803-2fda-4546-a289-88d6ab835a26">27,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23463b26e20041c888dd2c51a2181294_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzMtNi0xLTEtNzgwNDk_91f3d7dc-a810-41e6-8cb1-74bdde8e9070">27,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44d7cf6e14d4446b34dd7ca19bc223b_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzQtNC0xLTEtNzgwNDk_8e70eba4-db75-4591-82b2-dcaebd94b33c">28,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzQtNi0xLTEtNzgwNDk_745ca494-60b4-4fad-81e1-43b7111a6db9">27,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzUtNi0xLTEtNzgwNDk_2954f0a3-1484-4e82-9c1b-dfd2c8804f9f">30,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzYtNi0xLTEtNzgwNDk_0a2b6ace-7fe5-4ecc-93b2-c483d267b184">85,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for the Commercial &amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4172e7e04f43ae913e486aafb0c782_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzMtMi0xLTEtNzgwNDk_d5e0dfb1-6cc8-452d-869b-c649cc73eae0">24,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aef76e4813e4606b8d70440c92f269a_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzMtNC0xLTEtNzgwNDk_d2bc190b-ea35-4a84-af6d-65f7b92f780e">26,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23463b26e20041c888dd2c51a2181294_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzMtNi0xLTEtNzgwNDk_0a3ed7d4-d314-4098-a68c-bd20fa6a9d2d">27,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44d7cf6e14d4446b34dd7ca19bc223b_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzQtNC0xLTEtNzgwNDk_1b836bef-ea1f-47c6-a8d8-3432cfb98bc5">24,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzQtNi0xLTEtNzgwNDk_f514a6b2-8c42-4670-ac73-2be5ef210918">27,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzUtNi0xLTEtNzgwNDk_ab93d9f4-60fa-4420-be87-733d958b2128">26,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzYtNi0xLTEtNzgwNDk_b4b7efbe-0e52-4316-820b-5e0e5243511b">81,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp; Specialty Business was $<ix:nonFraction unitRef="usd" contextRef="i23463b26e20041c888dd2c51a2181294_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM1ODc_4dd084b4-c6b0-4707-bef2-6d8b1406ac9f">52</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM1OTE_7051623a-f637-44f5-a8b2-73c0260ddc52">266</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM1OTg_bc09c91b-71d7-46db-a35a-b61574725e8f">3,796</ix:nonFraction> for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for the Commercial &amp; Specialty Business was <ix:nonFraction unitRef="usd" contextRef="i23463b26e20041c888dd2c51a2181294_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM3NTI_dd965094-4ad0-45e0-b07a-6146dab1ca6c">80</ix:nonFraction>, <ix:nonFraction unitRef="usd" contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM3NTY_7a696926-b190-41fd-b22a-25453851bc95">87</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM3NjM_ac9eb1ce-8d0c-41c3-ac52-a9129136e4d8">81</ix:nonFraction> for the claim years 2020 and prior, 2021 and 2022, respectively. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcabc74836324dbfa6c75eefd131bc85_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzMtMi0xLTEtNzgwNDk_330973f8-d158-4b50-8306-e6d9eed416de">64,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab00825672c4350bb49fbe11bbfb810_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzMtNC0xLTEtNzgwNDk_c1f59fed-92a9-4897-9af8-742406ab5545">63,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzMtNi0xLTEtNzgwNDk_8d696ae5-1043-44b9-8712-59b319194131">63,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9e96e08f9e4d9eab2889e9f25825de_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzQtNC0xLTEtNzgwNDk_3f605086-871f-4fb6-bfcd-6b66146f659e">71,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzQtNi0xLTEtNzgwNDk_7cc254c9-f277-43e0-b6d4-1dc4caa3177e">70,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efbc97b18234003842819922bc3113a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzUtNi0xLTEtNzgwNDk_c8aaf54a-865c-456f-bb2d-289f85b814f1">81,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzYtNi0xLTEtNzgwNDk_8fb240fc-8671-4bcd-8647-564b47ca664c">215,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-114-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="if6dfa0a3dc7a4eff888e1979e60ad8b8" continuedAt="i29a850aa054e4a06abd34c56c5106193"><ix:continuation id="i7f617c50418b4a688d26da4b2da5399f"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcabc74836324dbfa6c75eefd131bc85_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzMtMi0xLTEtNzgwNDk_77f982f3-3597-4750-98f3-04f1730fe5b4">56,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab00825672c4350bb49fbe11bbfb810_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzMtNC0xLTEtNzgwNDk_33da5c09-134d-40f0-a989-2eb9aea6be31">62,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzMtNi0xLTEtNzgwNDk_a1575b64-21b1-422f-b79a-dec240b4d94a">62,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9e96e08f9e4d9eab2889e9f25825de_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzQtNC0xLTEtNzgwNDk_1a15ae7f-6d42-4795-b4f2-4a3465844b1c">62,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzQtNi0xLTEtNzgwNDk_e5d8bd84-6415-4ba3-9544-261fb5e55b57">70,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efbc97b18234003842819922bc3113a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzUtNi0xLTEtNzgwNDk_99d5b48e-dae2-4c19-92c1-d1ba93bf61e3">71,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzYtNi0xLTEtNzgwNDk_de1fbf4d-0973-418a-bb48-1cd1cbb50b12">204,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $<ix:nonFraction unitRef="usd" contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQyMzM_8dbb4dc4-d74a-425b-86b9-d7f809b23059">142</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQyMzc_d1551408-5b0f-4af4-9bd6-aa40b471d4f4">325</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4efbc97b18234003842819922bc3113a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQyNDQ_41244d25-5875-49e4-b9a5-5043ef5cf9f8">10,462</ix:nonFraction> for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for the Government Business was <ix:nonFraction unitRef="usd" contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQzODY_f469cd3a-4144-4d8f-aeef-2b21762defe3">251</ix:nonFraction>, <ix:nonFraction unitRef="usd" contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQzOTA_f4dbf0c3-48fb-4cb6-9dc4-28ff5d3756da">325</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="i4efbc97b18234003842819922bc3113a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQzOTc_82531e24-73f2-4d77-aad9-fbb8f0a1ef9c">298</ix:nonFraction> for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefeea68ef91044dc982120c3a3a950bb_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzMtMi0xLTEtNzgwNDk_a58fcfa8-e968-4866-9dbf-ab8be647d765">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2066eaf9a484ad59e9589c14525a5c8_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzMtNC0xLTEtNzgwNDk_90909078-449a-4147-aaf4-ff8252974c8c">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzMtNi0xLTEtNzgwNDk_75df0852-b0d6-4b95-ba15-df1141b7666e">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e702d4536f4799a919aec9da8593e1_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzQtNC0xLTEtNzgwNDk_f764135a-7afd-4c2a-89c4-90ef83ce6042">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzQtNi0xLTEtNzgwNDk_432936f0-4506-45fb-8413-d55662535dd0">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzUtNi0xLTEtNzgwNDk_fcad8305-2a39-47ec-a788-577d096e0290">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzYtNi0xLTEtNzgwNDk_633e93f3-f3a4-4928-997a-dfb701e88f77">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefeea68ef91044dc982120c3a3a950bb_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzMtMi0xLTEtNzgwNDk_6bc55473-58b2-4c4c-91d5-bfabd8840ac1">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2066eaf9a484ad59e9589c14525a5c8_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzMtNC0xLTEtNzgwNDk_da7f8d83-7b14-4a02-818f-f544ab305f7e">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzMtNi0xLTEtNzgwNDk_c237c076-d1f8-4312-bb7c-b2b5572c7d6e">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e702d4536f4799a919aec9da8593e1_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzQtNC0xLTEtNzgwNDk_077a9f45-673c-44fe-a682-67c27fe2b2b5">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzQtNi0xLTEtNzgwNDk_c8e24ac5-c964-4fd1-882a-622694a9c613">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzUtNi0xLTEtNzgwNDk_2878a76e-e3d6-4d21-ac67-0a46b177fb66">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzYtNi0xLTEtNzgwNDk_04929768-8b2a-4cad-a3a0-a73c80612831">4,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for Other was $<ix:nonFraction unitRef="usd" contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ4MTI_28a74765-9cdb-4e8d-9300-116473b38450">1</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ4MTY_4e856932-0660-4b3d-b42c-f5955ab63ab4">6</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ4MjM_8a6f56d6-0639-4e54-99aa-a8ec9c6d1623">292</ix:nonFraction> for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for Other was <ix:nonFraction unitRef="usd" contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ5NDc_ffd75c32-7a88-4f6d-90f8-7726fb6912ee">29</ix:nonFraction>, <ix:nonFraction unitRef="usd" contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ5NTE_2d7b728d-3480-4161-ab3b-dae6987309af">28</ix:nonFraction>, and <ix:nonFraction unitRef="usd" contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ5NTk_7558eba5-fcb0-4fd3-b3dc-dec17b124648">25</ix:nonFraction> for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred claims development, paid claims development and cumulative number of reported claims for the years ended December&#160;31, 2020 and 2021 for our Commercial &amp; Specialty Business, Government Business and Other is unaudited and presented as supplementary information. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative number of reported claims for each claim year for our Commercial &amp; Specialty Business, Government Business and Other have been developed using historical data captured by our claim payment systems. The provided claim </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-115-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i29a850aa054e4a06abd34c56c5106193"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are not a precise tool for understanding utilization of medical services. They could be impacted by a variety of factors, including changes in provider billing practices, provider reimbursement arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative number of reported claims may not be comparable to similar measures reported by other health benefits companies. </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0MzY_4d56753b-881a-4875-b78e-16e16d6ce15e" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the Commercial &amp; Specialty Business, Government Business and Other incurred and paid claims development information for the three years ended December&#160;31, 2022, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December&#160;31, 2022, is as follows: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtMS0xLTEtNzgwNDk_5b096b85-0966-427a-835f-d15e81da07b3">85,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtMy0xLTEtNzgwNDk_f6425fe1-d4f6-4949-89dd-53f0e5e16081">215,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtNS0xLTEtNzgwNDk_d443c909-dd1d-425b-8518-f74b150b75ed">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtNy0xLTEtNzgwNDk_76f2011d-f5bb-4d81-8c3e-d2781a0e6a7a">305,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItMS0xLTEtNzgwNDk_fe818166-4b04-466c-88ae-41beff189acc">81,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItMy0xLTEtNzgwNDk_d513e315-05cb-405d-a4e8-55f99f01818a">204,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItNS0xLTEtNzgwNDk_02cda3fe-514d-4457-916d-6534fb5d2fbf">4,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItNy0xLTEtNzgwNDk_495de0ee-bc0f-4485-aa78-dfaeba6a09a9">289,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtMS0xLTEtNzgwNDk_4059682d-7934-4cd2-8dac-21af0f7f548d">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtMy0xLTEtNzgwNDk_4af139ab-c81c-4314-9d27-df7d8c9b0306">10,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtNS0xLTEtNzgwNDk_a9293ade-67e4-469f-8ffb-425a4501da7b">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtNy0xLTEtNzgwNDk_c20a493e-e876-4c88-ad78-ce55ff349ecf">15,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtMS0xLTEtNzgwNDk_5742c3a1-e279-455e-8852-c245d48b4d50">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtMy0xLTEtNzgwNDk_295c1211-8985-4e1f-8830-41a756aa6310">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtNS0xLTEtNzgwNDk_7d593e00-c9b5-4022-ae9d-a609ba13f1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtNy0xLTEtNzgwNDk_bcf0936f-41dc-4091-bba7-a09e322f114c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtMS0xLTEtMTAwMDcx_21a84c43-dfe4-4c57-b21a-cce91534ba9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtMy0xLTEtNzgwNDk_60a6f558-0a40-4733-850f-574c1019e0c1">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtNS0xLTEtNzgwNDk_b4ea6113-83c8-4ccb-a787-583ab73b39fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtNy0xLTEtNzgwNDk_e310cef4-af41-49c9-972b-abd35f06f184">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtMS0xLTEtNzgwNDk_caf5a035-a5a5-448a-896a-79d91823defa">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtMy0xLTEtNzgwNDk_9b474e47-194d-48b6-b11a-03e9265a9f3d">11,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id885b4e505b34b40bce2c6278117709a_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtNS0xLTEtNzgwNDk_769d8bb1-9e11-4f61-af7a-43bc66788b7b">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtNy0xLTEtNzgwNDk_e1bee355-510f-474b-a194-18307c56a9b8">15,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_139"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNTQ0ODcyMTMyNzc3_e3c03f2d-f97a-4a9c-956e-5f031858563b" continuedAt="i19a98e233af74321955820dc94d1cb7f" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i19a98e233af74321955820dc94d1cb7f" continuedAt="i563a7c97483d48afa13a63d3e459b0f4"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Borrowings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the &#8220;FHLBs&#8221;). As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i33b68b45f4914e09ab526057a219f954_I20221231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQxNw_90386e64-4e58-49b4-bdd1-99c059b3e199">265</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id063c136e8d646d9a71a21018eada61b_I20211231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQyNA_943daaab-edd4-41e7-8ad7-c47f233c05cc">275</ix:nonFraction>, respectively, were outstanding under our short-term FHLB borrowings. Outstanding short-term FHLB borrowings at December&#160;31, 2022 had fixed interest rates of <ix:nonFraction unitRef="number" contextRef="i33b68b45f4914e09ab526057a219f954_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU3MA_2f86454b-189a-4db1-9af2-71126fe9b38c">4.240</ix:nonFraction>%.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the &#8220;Subsidiary Credit Facilities&#8221;) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $<ix:nonFraction unitRef="usd" contextRef="i2cf1a9340bcf4268a0cbab4e753cb90e_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzgxNQ_fc8ac9b1-01eb-447e-b503-9400ff192e22">200</ix:nonFraction>. The interest rate on each line of credit is based on the LIBOR rate plus a predetermined rate. Our ability to borrow under the lines of credit is subject to compliance with certain covenants. At each of December 31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i53292eeae2a246e58c5a7bcb2a4337ed_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNTA_85d87365-a565-42cb-aea9-3c82c75be943"><ix:nonFraction unitRef="usd" contextRef="i53292eeae2a246e58c5a7bcb2a4337ed_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNTA_d74ca337-c003-4850-98db-f30f7f37d309">0</ix:nonFraction></ix:nonFraction> was outstanding under our Subsidiary Credit Facilities.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-116-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i563a7c97483d48afa13a63d3e459b0f4" continuedAt="i9a6918f1fd0842fa8c9b2ca3d0606f1e"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTQ4_dc53c189-4f3d-447d-b619-4cdc2430ddb8" escape="true"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-term debt at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac5c44b376048bbae8a2f0719d42263_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo1NTU5MGUwYmI2YTg0ZWMyYmNiZTNkODM1OWEzOTgzYl80_03d185e1-a25a-4238-97a1-17be04b74c2c">2.950</ix:nonFraction>%, due 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac5c44b376048bbae8a2f0719d42263_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMtMS0xLTEtNzgwNDk_eeda209a-5698-4041-a9e4-5531087bdbf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i949d008a3d0b4b8d93c2d6a4799ec855_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMtMy0xLTEtNzgwNDk_391051e6-d79c-4476-b881-0f96a9962073">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ec6bfd612d64307b2a756760684ffe0_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpkZmNkMzFmZjhkMDc0OTUxOWFiNDg4MjE1MTFkMDA2N180_7e1d6b7f-4b94-43ff-a146-b0fe3cce7f0a">3.125</ix:nonFraction>%, due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec6bfd612d64307b2a756760684ffe0_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzQtMS0xLTEtNzgwNDk_f17d748a-6303-43ca-a145-28552a0d7edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea1bc60c1634bd889b51a318197368d_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzQtMy0xLTEtNzgwNDk_4f4fbae9-bf1e-4b96-b3c2-fcd6e8d4efc8">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa1c710fc55e47898c1d2f197e749108_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo1ZTJmYmQ2MzU5ZGU0NTk4YmQzMGVkNDNkZjhlZmU3M180_ae506fcf-8a5d-40e9-94f0-556b20d18d64">3.300</ix:nonFraction>%, due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1c710fc55e47898c1d2f197e749108_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzUtMS0xLTEtNzgwNDk_23e44077-cc14-4ca6-97ef-9c8e0c9d1455">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c611a7c74d4ab8ac5a98a6fe0e2728_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzUtMy0xLTEtNzgwNDk_bd4c1410-1c34-4980-a78d-3e2f8ac0e855">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7636254161774196bf8c04399ddf133f_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzYtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjoxYTNiMjEzZGE2MjM0NmNiOTY4NDY3NzBjYTM4OTU4N180_eff4c7a2-80f0-4751-beb4-6b83a3780ad8">0.450</ix:nonFraction>%, due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7636254161774196bf8c04399ddf133f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzYtMS0xLTEtNzgwNDk_d04baf47-8eba-4bec-afc4-382e228a7e13">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4154a06006b4cafa5cbd1a889726e29_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzYtMy0xLTEtNzgwNDk_59ad24c2-d24b-4cc8-bf7b-e8ad42ea13c6">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13e53d3ac9be45f58795982cc797e03c_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzctMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0NGJkNGU3ZWVkM2U0Zjg2OGFmYTI1YzdlMjczZWFmNV80_028a79b6-32db-4758-a4f4-385c43cfd876">3.350</ix:nonFraction>%, due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e53d3ac9be45f58795982cc797e03c_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzctMS0xLTEtNzgwNDk_0acc3c19-b31e-43c6-851c-dc6737e8308a">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a05e7eaeb64ad58b3d1f47ad49fa73_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzctMy0xLTEtNzgwNDk_0c9d130a-af49-4606-b8fc-f9174194505c">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2607b444454d46e39b6286f9c8ea6e3f_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphMTRjODE3MzdiNWY0NjdkYmM2ZDhiYmFkM2VkZmU1YV80_3a6b9526-cb88-49af-a322-efbc0cb386c3">3.500</ix:nonFraction>%, due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2607b444454d46e39b6286f9c8ea6e3f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzgtMS0xLTEtNzgwNDk_897f7eab-179f-4fc2-a6d3-c4f7a4ac8a7e">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c77106efdf14a58abf9fc4127c8b091_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzgtMy0xLTEtNzgwNDk_a06bbe7b-edf9-4f03-8e57-14ee95b264bd">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i811d733c6b02495580c52c781054171e_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0YzE2YjVjYTI0ODg0MzNmODRmOGQ5MjE4M2Y2MzA4Ml80_6f888968-8d0d-43fe-8ab8-6da920eb9a81">2.375</ix:nonFraction>%, due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811d733c6b02495580c52c781054171e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMS0xLTEtNzgwNDk_d20d2886-99ff-4d8b-9f33-0b5c650a1f47">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e70d3f0aa9435ea3f59013c328d36f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMy0xLTEtNzgwNDk_fc8109f6-2473-4525-8e23-c1a9bb327439">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id90d8e2c8f9446bfbdb944daa4c9681b_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMC0xLTEtMTAwMTE4L3RleHRyZWdpb246ZTVkZDIxODYxMzI3NDlhMThjZjNhZjk0ZmZmNzhjNjNfNTQ5NzU1ODEzOTI4_a5bc7866-0b34-4975-adbc-4dd7fd7384ac">5.350</ix:nonFraction>%, due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90d8e2c8f9446bfbdb944daa4c9681b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMS0xLTEtMTAwMTQ4_646c6de4-cb5b-4420-b486-7c75a94fd259">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3de8e0b39443b7b0385091bc11bf77_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMy0xLTEtMTAwMTUw_45e456c4-6c0c-486f-af1a-18530d2ee5af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9db25862eb95484085247b52a174b160_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjkyMzkyZDEzMzM4NDY1ZGI2MzQ4N2U5ODgyODg3MzVfNA_f184de93-e029-4a3b-bf74-9d468f9139f9">1.500</ix:nonFraction>%, due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db25862eb95484085247b52a174b160_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEwLTEtMS0xLTc4MDQ5_6e82b1eb-44ca-4105-8ca6-39c0fe0c3351">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2272113d58402ba5f389923853a07f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEwLTMtMS0xLTc4MDQ5_a2bdd42d-9e0c-4ddd-982a-2114de503348">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea5aadb40cfa4a7c8342724cdc2f58c5_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzExLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NjBmY2UxMGUxNTlmNDdjZDhhNzQyNDBkNDdhMzA5ZmRfNA_2f688b44-9f8a-48d6-9a8c-7aebba74e40f">3.650</ix:nonFraction>%, due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5aadb40cfa4a7c8342724cdc2f58c5_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzExLTEtMS0xLTc4MDQ5_e98f1430-99c4-4bb6-a478-f8804bcbae86">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb71d9d282b643fd8703d9459d16e56d_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzExLTMtMS0xLTc4MDQ5_7418d3a9-1833-449f-aec4-dd3ce0bc1479">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i091a2bb4b5f242c3ad68068b656e90f2_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEyLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MWRiYWFmMGEzNTliNDlmZGEzNDlhNzE5OTZkNzBiNDNfNA_c1b4ca3d-eb16-4f12-a464-4054a05d8672">4.101</ix:nonFraction>%, due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091a2bb4b5f242c3ad68068b656e90f2_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEyLTEtMS0xLTc4MDQ5_f506d8c8-46df-4291-bbcf-c212f8771fe2">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b72b535fce46bf8f61743fb9e18481_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEyLTMtMS0xLTc4MDQ5_aebf674c-3cb8-450a-b0f0-76ed6c9f259f">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic70a6a0be4d643d3927176d45192c141_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEzLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MzU1MDlkZmUzNjJjNDBmZDhhZWNkMDQyMmQ4NWNiZjJfNA_f43f2434-a1ef-49fe-b81b-3176f41c22d8">2.875</ix:nonFraction>%, due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70a6a0be4d643d3927176d45192c141_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEzLTEtMS0xLTc4MDQ5_6bbfba41-5191-4177-b87d-20189d5752db">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134f72e11a1649b7934274f86bea6020_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEzLTMtMS0xLTc4MDQ5_9627f4eb-9b90-47d3-bb57-7874bdeb5386">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf998fc82656469e90d336c2b880f377_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE0LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Mjk0ZmZiMWQ2MDIyNDRlZjlkNTVmY2Y0OGJjMjFiNjFfNA_be4a790b-d0f3-4224-ba52-3557ce07cc96">2.250</ix:nonFraction>%, due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf998fc82656469e90d336c2b880f377_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE0LTEtMS0xLTc4MDQ5_c733e037-362d-4f0b-a6a7-2a633576dd9e">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6946a35fa850465fa36f14fc4f52f7bc_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE0LTMtMS0xLTc4MDQ5_72873e4d-7144-4196-b16a-10fb03e3f3b8">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67736d5753d44699b20adb0618b589fa_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YWJlNmQ4NmZiNmFiNGE0ZTk0OTE1ZDBlMzIwYzE4M2FfNA_8310e791-3170-4a61-809a-93003e83bd3c">2.550</ix:nonFraction>%, due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67736d5753d44699b20adb0618b589fa_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE1LTEtMS0xLTc4MDQ5_72f03615-d40d-4813-874b-bc593ff71da6">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4f13755a194230acb1ec087846b505_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE1LTMtMS0xLTc4MDQ5_69e014f9-366f-4c8f-9ac9-48ffcd330d40">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66a828e106b94047928ff146300d2ed0_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTAtMS0xLTEwMDEzMy90ZXh0cmVnaW9uOjk0ZjIwNDlkZmVhNjQ5NjQ5OTBiMGU4MzUyYjQ3Y2U0XzU0OTc1NTgxMzkxNA_7e752a0f-c50e-437b-8541-4eb74304a77b">4.100</ix:nonFraction>%, due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a828e106b94047928ff146300d2ed0_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTEtMS0xLTEwMDE1Ng_4ef27ef5-5f8a-44d6-8dfd-be495b350356">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba93ec717e94394a8955cf9f5de9f90_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTMtMS0xLTEwMDE1OQ_83aab3ef-be9d-4f9d-a95d-0d3655784ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2e6cd38e3e84d5580d856acbad97133_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTAtMS0xLTEwMDEzNi90ZXh0cmVnaW9uOjc4MzgwNTU5MzQ2NzQ0MWE5MTI4MTRkYjkyYzA0ZTExXzU0OTc1NTgxMzkxNA_78148719-f9bc-46f2-80ec-081dd66228a0">5.500</ix:nonFraction>%, due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e6cd38e3e84d5580d856acbad97133_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTEtMS0xLTEwMDE2Mg_b0cf5ff9-f2c0-4c28-9a90-90aae99de578">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie323f9332ece4230a9778b8c7d487528_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTMtMS0xLTEwMDE2NQ_f4205d91-165e-4993-8431-cac4a1269d0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife4c77f05ea246d1b396cda16a6f5b1e_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MGIwY2I5NzU2OTcwNDExNGJkOWZiOTQ0ZGEyNGMyOWFfNA_99d9572a-7152-4b04-ad72-e220adf15831">5.950</ix:nonFraction>%, due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4c77f05ea246d1b396cda16a6f5b1e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTEtMS0xLTc4MDQ5_fe83ea1b-d85d-4ea2-b6dd-8b807820360e">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353e9848174344adab8b80f569e38864_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTMtMS0xLTc4MDQ5_306cb63b-679d-4e32-a47d-5a7bb9afbd7a">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia22dd705e96640c28ac4a3b93dc44cb7_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NzhmMTFjYzAxNGIwNGVlZTliZGI1MGJiYmU2ZWE4ZjNfNA_1d3c5bbf-a06e-4f46-b794-d86778e15d18">5.850</ix:nonFraction>%, due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22dd705e96640c28ac4a3b93dc44cb7_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTEtMS0xLTc4MDQ5_95dcf9f9-b237-4157-8a74-a2bd645aa99b">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9c543ff2b843e8964521415571c09a_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTMtMS0xLTc4MDQ5_40527fa4-7266-45a6-ae0c-dc41d2c12069">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i928bec5ee982461199847da9ac96d68b_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NzFiNjNlYTk3MmNhNGM1OGIxZjQ4ZjIyMGRjYzdlYmFfNA_11037536-1543-4773-9e7c-d5b712670ae5">6.375</ix:nonFraction>%, due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928bec5ee982461199847da9ac96d68b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE4LTEtMS0xLTc4MDQ5_2a72c5fe-c3e2-4912-a5ec-ca08071f2f39">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ffc1ca7d414bbd94fbe98e6dac3891_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE4LTMtMS0xLTc4MDQ5_b8c1f066-4061-4074-9dbe-8fc4dc42fcd0">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc050557e394d4bb08e2383bcb0c73e_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE5LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MTExODJiYjY2MzMxNDMwNjg3YmUxYjUxMTcxZTg1ODNfNA_8899ca4d-dc49-4f36-b157-6c7bab1cca9e">5.800</ix:nonFraction>%, due 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc050557e394d4bb08e2383bcb0c73e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE5LTEtMS0xLTc4MDQ5_619004bf-d130-4dfd-91f2-8049c8356170">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029531456f0742b18198f12d8893bbdd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE5LTMtMS0xLTc4MDQ5_356a2f82-7f9a-4a7a-b2e6-749c5207b02d">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice205a4939054c86b0d0fab99c58c6de_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NTU1ZmZlMTk1ZGZlNGYxNWEwYTAwZTBmY2JjYWI3OGZfNA_6a76d7f3-2feb-4884-ad9c-dde273c71b60">4.625</ix:nonFraction>%, due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice205a4939054c86b0d0fab99c58c6de_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIwLTEtMS0xLTc4MDQ5_6113c803-eaf9-4f2f-b6bb-3c8344058e9d">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4c04d831ec4f03aa3ef7b1e8fae480_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIwLTMtMS0xLTc4MDQ5_9f53fb89-52ca-42db-824f-1f44885e1c16">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4301f61a56d4a5981fa5a8be60c5456_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ODhmMThhMWJiMGY3NDk0NGI2NWJmNWY2NmMwZWM1MzdfNA_0d669dea-1ca9-42b1-ae30-93f0bc9ebc18">4.650</ix:nonFraction>%, due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4301f61a56d4a5981fa5a8be60c5456_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIxLTEtMS0xLTc4MDQ5_56abada4-b097-4b5d-ab29-c7e232c25d27">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886b4f01b01343e99f882cbfedb38b5a_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIxLTMtMS0xLTc4MDQ5_18142353-0fb0-4800-a3df-15c43bacdb43">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c8b1a203e04bc98e13209d268178e6_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIyLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MTg4NmJkM2RhMDU3NGJiYzk0MTI1MWNmMmRhMDMxODJfNA_43231e69-cf4b-468d-9981-6af75fe1ab86">4.650</ix:nonFraction>%, due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c8b1a203e04bc98e13209d268178e6_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIyLTEtMS0xLTc4MDQ5_a3cee6a1-d7da-48ec-bdbc-babede5d0fc4">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d2d5430234b8da43f315a70dbda73_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIyLTMtMS0xLTc4MDQ5_23ba0ade-6676-4bb3-8cc9-c18e9b68d474">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie11833466f4c4e66b1df0bdb5615948b_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIzLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk3NmQyY2EzNzFjNGE2ZWIwMGFjM2I3N2I3MzE5OTRfNA_3147ab90-bd5e-4828-9d43-1b939a3ca1da">5.100</ix:nonFraction>%, due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11833466f4c4e66b1df0bdb5615948b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIzLTEtMS0xLTc4MDQ5_224acbef-c9fe-48da-bf99-4ea5481abfc8">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e99111afc84fa281a0286ba240fd53_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIzLTMtMS0xLTc4MDQ5_4c91f253-bfed-4ab6-9f87-ee82b3677af2">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i188c10cfbcd14ea593ae781c8b7d8219_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI0LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTYwZmFiYzk2ZjQ5NDE4NDg5OTdmYTM2YjI0NmMzYThfNA_2e85b661-5938-4c6e-b7ba-d914ae48735a">4.375</ix:nonFraction>%, due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188c10cfbcd14ea593ae781c8b7d8219_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI0LTEtMS0xLTc4MDQ5_4464da61-70b2-4080-80d9-d95fe12a9bf3">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86370035d0f94594abe20431af0befa9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI0LTMtMS0xLTc4MDQ5_23928867-b4e0-4141-bb1c-46a4ea6301fa">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6caa66b97514d68ba837991fe14dbdf_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MGY5NGFjOTExMTllNDE4YWIxMDYzYjcyYTc2NGU4ZmFfNA_19e3fc18-031e-4aa1-a35b-c8ab48cff0f7">4.550</ix:nonFraction>%, due 2048</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6caa66b97514d68ba837991fe14dbdf_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI1LTEtMS0xLTc4MDQ5_776996d2-ac06-4a5c-886e-33aa520ac155">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe622a0dd5c41d5bb15002f914046be_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI1LTMtMS0xLTc4MDQ5_e5f35d7c-9c79-4da8-aa8a-9ef82b6e6033">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieba76da0d560460cb028e0c65f72ea97_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI2LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MTc0NjYxOTU4MjAzNGJiYmI0MmJhNDcwMDYzMWQzMzdfNA_70c4ed28-40ee-44a2-a93e-c74980c85e65">3.700</ix:nonFraction>%, due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba76da0d560460cb028e0c65f72ea97_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI2LTEtMS0xLTc4MDQ5_18eede23-abff-4986-ab22-6fe6c366365f">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ed97bbfa0946bc8f76958f0fc5eb16_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI2LTMtMS0xLTc4MDQ5_42fdc79b-7afa-420a-9c3b-7ac8770ab239">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d6bb5890f644dc2a4785a6cd8b1b0c5_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ODIyMWJkMTcwMTMyNDEyMWJlZDU4NDhmMTA3ZmMyMzdfNA_8759e7ca-2f03-47a6-b86f-2c8f31aa5028">3.125</ix:nonFraction>%, due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6bb5890f644dc2a4785a6cd8b1b0c5_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI3LTEtMS0xLTc4MDQ5_3442f2b8-7152-4326-8f9c-26c5b72dc942">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d118ac360bd4e3aad70d1189c447897_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI3LTMtMS0xLTc4MDQ5_1a302255-3c27-46ca-93af-ff3d62b7e2f8">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id74f9a1abba844ef9912af38aac619e7_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YjNhYmYyMTYzNmQ5NDEwZjhkMjAzMTYyNGMzZjc4ZGVfNA_8a74d63f-26e4-4e43-81ea-3016d0fed105">3.600</ix:nonFraction>%, due 2051</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74f9a1abba844ef9912af38aac619e7_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI4LTEtMS0xLTc4MDQ5_4a498849-599b-4f4b-a934-d8dbd022ba6d">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ffc9a6ff1d499eb81b8fc7cd50feeb_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI4LTMtMS0xLTc4MDQ5_b740eed3-a0de-4160-b998-795b6e764fbe">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fc6cdf9d6fe436c9e1912baf09467ae_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTAtMS0xLTEwMDE0MS90ZXh0cmVnaW9uOjMxNDE0Y2I5ZWVhYTQ5MjM4YWU0MjIyMDBiMzhmMTQ3XzU0OTc1NTgxMzkxNA_ff77a52f-7cc1-4fa0-9091-3487c938978e">4.550</ix:nonFraction>%, due 2052</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc6cdf9d6fe436c9e1912baf09467ae_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTEtMS0xLTEwMDE2OA_1d29bce8-e9ec-476f-8a94-07203aeb1d75">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic855e040017843f28f7041b2bc021f66_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTMtMS0xLTEwMDE3MQ_974999d1-f99f-4fec-8cd1-dc20db8d6ff3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3c3fc9281644847a3ab3c94cd2f8927_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMyLTAtMS0xLTEwMDE0NS90ZXh0cmVnaW9uOjY1YTkwYzA4ZmU2YjQ5NzU4ZTQ0NDU5NGJjNjk3MGEwXzU0OTc1NTgxMzkxNA_66fe64ce-719c-4ede-8a43-aa66cc7cbfc2">6.100</ix:nonFraction>%, due 2052</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c3fc9281644847a3ab3c94cd2f8927_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMyLTEtMS0xLTEwMDE3NA_ea8f748b-d3fe-4f27-a876-a3af7488610f">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b0fd92b63040658ab461c35f466977_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMyLTMtMS0xLTEwMDE3Nw_8485fe6b-b0ee-47db-a6b5-a8a6d144d629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1151ddbe0ece40b18eadc2621477a0ef_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI5LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQxMjE2NTVhMmM1NDAxNzg3ODk3YWQ0MzNkNjIwNDVfNA_6f48b655-e8bd-427d-aed4-9fa29afd69fd">4.850</ix:nonFraction>%, due 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1151ddbe0ece40b18eadc2621477a0ef_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI5LTEtMS0xLTc4MDQ5_cb3de81f-5e04-41ff-bffb-73789ee38b0e">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871498f5fef9430a894e75b1f70e1af1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI5LTMtMS0xLTc4MDQ5_0c6b4693-2516-40c2-a1f9-4359fe393860">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surplus note:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00522144e96b43829be3251cd73df914_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZWU4ZDNmZmY3NDY2YmJiYmI3Mzc2MTk1ZThlNTZfNA_37f7f559-def4-481c-bd3c-0df7046805df">9.000</ix:nonFraction>%, due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00522144e96b43829be3251cd73df914_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTEtMS0xLTc4MDQ5_f9351d28-c38b-4f0c-a039-84a067108c48">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic08004c17645430d9704d5e79d29fccc_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTMtMS0xLTc4MDQ5_8df84445-3d9b-46e7-bf5d-13184d71bf77">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior convertible debentures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMzLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MWNkZWM2ZjAyYjRiNDA4NGIxNWEzNzc4MDJkZGQ2ZWVfNA_cd3ef748-a856-45de-9049-76221aaf9bec">2.750</ix:nonFraction>%, due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMzLTEtMS0xLTc4MDQ5_554b8655-5b46-4cf2-93a0-c3b9ce51dff7">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80cee633ac84a32ac44408267eda7b4_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMzLTMtMS0xLTc4MDQ5_f8bd5afd-f3f6-491f-9138-e209e20b21e6">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable rate debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM1LTEtMS0xLTc4MDQ5_e79c7142-1c3c-4a05-9032-a7af5ab5ad35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM1LTMtMS0xLTc4MDQ5_b601533f-49ef-4779-89ff-a18c4023bf4a">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM2LTEtMS0xLTc4MDQ5_ce8ea9b2-7fd9-48b6-8304-2de5b07aebb6">23,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM2LTMtMS0xLTc4MDQ5_6004a06f-f342-48b0-a7f2-0d4d600498ab">22,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM3LTEtMS0xLTc4MDQ5_73f05564-1c55-44d9-9bab-ffd133dfa759">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM3LTMtMS0xLTc4MDQ5_5d832dac-024a-4fa0-8434-e731207359c2">1,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM4LTEtMS0xLTc4MDQ5_486aaf57-bb50-4df1-afd3-2fdcf1c8dc85">22,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM4LTMtMS0xLTc4MDQ5_d1ce8f19-6158-43cd-94ce-d301af1c0705">21,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-117-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i9a6918f1fd0842fa8c9b2ca3d0606f1e" continuedAt="if88f36533d174576859d1a8cba745bf4"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings and the Subsidiary Credit Facilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally issue senior unsecured notes (&#8220;Notes&#8221;) for long-term borrowing purposes. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, we issued $<ix:nonFraction unitRef="usd" contextRef="ice43633ad18f45a3bf5610792f8e0e92_I20230208" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzgyMw_6b9d8e8a-322b-4236-ad87-348cf64a4805">500</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ice43633ad18f45a3bf5610792f8e0e92_I20230208" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzgzMg_1f389ea6-4b86-4398-981d-d46b663c04d2">4.900</ix:nonFraction>% Notes due 2026 (the &#8220;2026 Notes&#8221;), $<ix:nonFraction unitRef="usd" contextRef="ie9fbf8cc11e742c2b3eb7b913dbc0f53_I20230208" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg1Nw_b0ddd0cd-21e3-4b90-b5c2-6e3995d11979">1,000</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ie9fbf8cc11e742c2b3eb7b913dbc0f53_I20230208" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg0MA_6c1b3410-a86e-4cc5-89f1-aa8186666877">4.750</ix:nonFraction>% Notes due 2033 (the &#8220;2033 Notes&#8221;), and $<ix:nonFraction unitRef="usd" contextRef="i38626e3e281747b1864dc478c857e132_I20230208" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg2OA_855494d3-4fd4-44c9-b50c-ce0b02c947cc">1,100</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i38626e3e281747b1864dc478c857e132_I20230208" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg0OA_970fe07c-ba88-4bbf-a517-ae6c6874a9ae">5.125</ix:nonFraction>% Notes due 2053 (the &#8220;2053 Notes&#8221;) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2022, we repaid, at maturity, the $<ix:nonFraction unitRef="usd" contextRef="id3702fa1806f4f55afc1809dce531453_I20221201" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MjE4Nw_85c16eec-71f4-41b2-8fe6-2361dda0b762">750</ix:nonFraction> outstanding balance of our <ix:nonFraction unitRef="number" contextRef="id3702fa1806f4f55afc1809dce531453_I20221201" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MjE5Ng_330aba20-6a84-4d6c-81f9-8815b8f12f62">2.950</ix:nonFraction>% senior unsecured notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2022, we issued $<ix:nonFraction unitRef="usd" contextRef="iad77e559c2a94999bb397fa384a544e9_I20221104" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg3OQ_769bff7c-eedc-41b6-99ac-05afad336d6d">400</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iad77e559c2a94999bb397fa384a544e9_I20221104" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg4OA_22e5f7b3-e933-4c7c-92ca-1c4fc7366435">5.350</ix:nonFraction>% Notes due 2025, $<ix:nonFraction unitRef="usd" contextRef="if0f2459563994824a4b0a6fe56121a68_I20221104" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzkyMQ_9159a86a-869a-4c20-9fd2-d8654c3b997c">650</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if0f2459563994824a4b0a6fe56121a68_I20221104" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzkwMg_7c940cf7-3fd1-4a95-a1e4-934ca4f4d369">5.500</ix:nonFraction>% Notes due 2032 and $<ix:nonFraction unitRef="usd" contextRef="id0933651ffe04b7bbdbc822cd8b57555_I20221104" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg5Ng_42afea95-3ad8-4410-9426-6a8d1b6e6795">750</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id0933651ffe04b7bbdbc822cd8b57555_I20221104" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzkxMw_7e96844d-f34c-4fb7-bf45-9c9bec7c4753">6.100</ix:nonFraction>% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on April 15 and October 15 of each year, commencing April 15, 2023. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, we repaid, at maturity, the $<ix:nonFraction unitRef="usd" contextRef="ib14c797d21b24b8e925b9f7f60a8b208_I20220516" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTg3OQ_aeef373b-7798-4c38-b166-667d62de3e72">850</ix:nonFraction> outstanding balance of our <ix:nonFraction unitRef="number" contextRef="ib14c797d21b24b8e925b9f7f60a8b208_I20220516" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTg4NQ_ace1ced9-3f1f-4201-8c40-a89e39e4d7f7">3.125</ix:nonFraction>% senior unsecured notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2022, we issued $<ix:nonFraction unitRef="usd" contextRef="if73dc0aa91534a999012a5f25833b272_I20220429" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTg5Ng_7af275db-4829-4055-9e1a-94fad20d70b3">600</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if73dc0aa91534a999012a5f25833b272_I20220429" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTkxNA_d3bb9514-7a46-42f8-9879-3d09a39c472d">4.100</ix:nonFraction>% Notes due 2032 and $<ix:nonFraction unitRef="usd" contextRef="i333b97a4235d45a5a86902df2d17954a_I20220429" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTkwNQ_9121dde9-b8d8-4cac-91a8-82ac97b9437d">700</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i333b97a4235d45a5a86902df2d17954a_I20220429" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTkyMg_d021af5d-07ff-4e0c-ac7f-884c0b1b2603">4.550</ix:nonFraction>% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2021, we redeemed the $<ix:nonFraction unitRef="usd" contextRef="i69ce9e81a0d3461dab8dbc07066d500d_I20210515" decimals="-6" name="elv:DebtRedemptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE3NTM_e98a4810-b98e-4221-a3b6-c6e95fe34438">700</ix:nonFraction> outstanding principal balance of our <ix:nonFraction unitRef="number" contextRef="i69ce9e81a0d3461dab8dbc07066d500d_I20210515" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE3OTM_a101e76f-d1a6-4f7c-9c28-29e151a69b3c">3.700</ix:nonFraction>% Notes due August 15, 2021 <ix:nonNumeric contextRef="iac73002099334b069811ed521ffc2f61_D20210515-20210515" name="us-gaap:DebtInstrumentRedemptionDescription" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTQ5_ac30b175-8687-4c62-9562-b398890e55a6">at a redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="i2bc2487f523740c69014d98ef48fc2ae_I20210317" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE5ODQ_1c42c6db-e2ca-4c72-a3fd-8c32f309b307">500</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2bc2487f523740c69014d98ef48fc2ae_I20210317" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIwMTc_5e382fbf-7907-4be2-91ef-67942a0eb2b3">0.450</ix:nonFraction>% Notes due 2023, $<ix:nonFraction unitRef="usd" contextRef="i429662b30ae84f4fb822ecd377e98b9c_I20210317" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIwNTU_e3ab166e-c6ff-40e5-af43-99c9537c3fd1">750</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i429662b30ae84f4fb822ecd377e98b9c_I20210317" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIwODg_f39f0787-1d5b-48dd-9d4e-172c7e29ddaf">1.500</ix:nonFraction>% Notes due 2026, $<ix:nonFraction unitRef="usd" contextRef="i54cffe8dccdc4ee6945a8e5fea7b55b4_I20210317" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIxMjY_8cda6117-daea-4f07-87ec-929d74c66fd6">1,000</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i54cffe8dccdc4ee6945a8e5fea7b55b4_I20210317" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIxNTk_e6d49a7e-5fd7-4804-ab4c-bf428214a3e0">2.550</ix:nonFraction>% Notes due 2031 and $<ix:nonFraction unitRef="usd" contextRef="i325bf58af121477aaabb4ba211cc0a8b_I20210317" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIyMDA_ca7dbd05-79f3-4fac-aa35-a147e3d3ab8e">1,250</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i325bf58af121477aaabb4ba211cc0a8b_I20210317" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIyMzM_570e5af5-51d5-44c0-94cf-5d99e343f035">3.600</ix:nonFraction>% Notes due 2051 under our shelf registration statement. Interest on these notes is payable semiannually in arrears on March 15 and September 15 of each year, commencing September 15, 2021. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the year ended December 31, 2021, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzI4MDE_dff800aa-1db5-4be6-b3f0-346f794acda3">52</ix:nonFraction> of outstanding principal amount of certain other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $<ix:nonFraction unitRef="usd" contextRef="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231" decimals="-6" name="us-gaap:EarlyRepaymentOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzI5NzQ_bd9145d0-c0db-4c2e-ba57-11fa971efb05">67</ix:nonFraction>. We recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMwMjg_653b4376-c156-4c6c-9374-184035ed5863">15</ix:nonFraction> for the repurchase of these notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 23, 2020, we repaid, at maturity, the $<ix:nonFraction unitRef="usd" contextRef="i8f86ebcddede41c59e36155926d5c738_I20201123" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMxMTY_f46e9e51-57b1-4de8-a979-b5b1a0adde58">900</ix:nonFraction> outstanding balance of our <ix:nonFraction unitRef="number" contextRef="i8f86ebcddede41c59e36155926d5c738_I20201123" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMxNDY_ebae2e16-6355-49b8-b10e-9b2e4463d008">2.500</ix:nonFraction>% senior unsecured notes. On August 17, 2020, we repaid, at maturity, the $<ix:nonFraction unitRef="usd" contextRef="i8eb1aa80db82419e86533f0ed7493781_I20200817" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMyMjE_91a120c4-dc0d-480f-bc9e-0d1458e1a925">700</ix:nonFraction> outstanding balance of our <ix:nonFraction unitRef="number" contextRef="i8eb1aa80db82419e86533f0ed7493781_I20200817" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMyNTE_0314ed73-edf9-438c-843c-97f8b88cc089">4.350</ix:nonFraction>% senior unsecured notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the year ended December 31, 2020, we repurchased $<ix:nonFraction unitRef="usd" contextRef="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMzNDk_8a2fbc33-d523-48eb-b35e-ad1d6ba0dcaa">79</ix:nonFraction> of outstanding principal amount of certain other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $<ix:nonFraction unitRef="usd" contextRef="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231" decimals="-6" name="us-gaap:EarlyRepaymentOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM1MjI_e284cec5-31d3-4c1d-a9a9-4e244473b3a1">109</ix:nonFraction>. We recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM1NzY_51f478da-e15b-497f-b319-0823be468e55">30</ix:nonFraction> for the repurchase of these notes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-118-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="if88f36533d174576859d1a8cba745bf4" continuedAt="i4e1fe5295bdb4bde91be70b78def4d75"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i4ca42aa1e7484753ae2809b124a577da_I20200505" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM2NDA_2ecb24ee-bd42-4ce2-b427-82878f782ed0">400</ix:nonFraction> aggregate principal amount of additional senior notes pursuant to a reopening of our existing <ix:nonFraction unitRef="number" contextRef="i4ca42aa1e7484753ae2809b124a577da_I20200505" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM3Mzc_d2a45b17-e93e-494a-aab9-6786b92efbdb">2.375</ix:nonFraction>% Notes due 2025 (the &#8220;2025 Notes&#8221;), $<ix:nonFraction unitRef="usd" contextRef="i41649eb783044c5eb58218b8fa152592_I20200505" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM3NzU_6e2936f8-d904-4c2f-b842-e20cd6a225ca">1,100</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i41649eb783044c5eb58218b8fa152592_I20200505" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM4MDg_88d28aa0-55cb-46ae-9a73-5912da49174f">2.250</ix:nonFraction>% Notes due 2030 (the &#8220;2030 Notes&#8221;), and $<ix:nonFraction unitRef="usd" contextRef="ic6256919a6f740e9a7538e63d97e56c3_I20200505" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM4NTA_41e26a1a-186c-4cff-90cf-a17641bd91fe">1,000</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ic6256919a6f740e9a7538e63d97e56c3_I20200505" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM4ODM_e2e7734a-b3cf-4572-a050-9bdf26c75752">3.125</ix:nonFraction>% Notes due 2050 (the &#8220;2050 Notes&#8221;) under our shelf registration statement. The 2025 Notes constitute an additional issuance of our <ix:nonFraction unitRef="number" contextRef="ib8ac997eed1f49e1bc4fbe2c7718e08f_I20190909" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQwMTY_7db21265-0d53-4fc3-ac12-818aa6e940b2">2.375</ix:nonFraction>% notes due 2025, of which $<ix:nonFraction unitRef="usd" contextRef="ib8ac997eed1f49e1bc4fbe2c7718e08f_I20190909" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQwNDQ_815476c7-146b-4a02-8972-ae9cff82c995">850</ix:nonFraction> aggregate principal amount was issued on September 9, 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 2025 Notes is deemed to have accrued from January 15, 2020 and is payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2020. Interest on the 2030 Notes and 2050 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2020. The proceeds were used for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc. (&#8220;Anthem Insurance&#8221;), a wholly owned subsidiary, and is subordinate in right of payment to all of Anthem Insurance&#8217;s existing and future indebtedness. Any payment of interest or principal on the surplus note may be made only with the prior approval of the Indiana Department of Insurance (&#8220;IDOI&#8221;) and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana insurance laws.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a senior revolving credit facility (the &#8220;5-Year Facility&#8221;) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $<ix:nonFraction unitRef="usd" contextRef="iad3cc9878d194c6ab4cfcad7ad636235_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzYyNzk_8663b6a4-a8c7-47fa-a38d-020677473bf8">2,500</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i4ac0254b163e4965ada5424581be8b2f_I20220418" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgzMDQ5Mw_c2462311-10ea-4705-8243-00383286f130">4,000</ix:nonFraction>. <ix:nonNumeric contextRef="i83efaab7af2c47789e213ba327cae52f_D20220418-20220418" name="us-gaap:LineOfCreditFacilityDescription" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NDk2OA_43687ded-4062-444d-8d02-f32b9c248bb3">Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i99dac9a626014a259743a75faf51bbc3_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NDk1OA_efdabf3a-c0ef-4e6e-80e0-4b0458bef016">1,000</ix:nonFraction>, which was scheduled to mature in June 2022</ix:nonNumeric> (the &#8220;2021 364-Day Facility&#8221;). In June 2021, we terminated our 364-day senior revolving credit facility (the &#8220;prior 364-Day Facility&#8221;), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. <ix:nonNumeric contextRef="i78ee27d7ced94e33a81e7cf47376711f_D20220101-20221231" name="us-gaap:DebtInstrumentCovenantDescription" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTYw_aeb8e1d3-52d9-4b6a-8ddf-db651ca36bf4">Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i78ee27d7ced94e33a81e7cf47376711f_D20220101-20221231" name="us-gaap:DebtInstrumentCovenantCompliance" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTU3_245a9ac0-6f23-4352-a0e7-b8ea24a0cd3e">As of December&#160;31, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.9%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December&#160;31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility.</ix:nonNumeric> There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the years ended December&#160;31, 2022 or 2021. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an authorized commercial paper program of up to $<ix:nonFraction unitRef="usd" contextRef="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231" decimals="-6" name="elv:CommercialPaperMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc2ODI_0c8205cc-cc28-4b26-8450-5e61663fd54d">4,000</ix:nonFraction>, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $<ix:nonFraction unitRef="usd" contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231" decimals="-6" name="elv:CommercialPaperMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NTAwNw_7648c462-9835-4316-a379-11d3c6f49a87">3,500</ix:nonFraction> to $4,000. At December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc3NjY_2a3b751b-6276-4eac-b3ba-85d2d2e93cb6">0</ix:nonFraction> outstanding under our commercial paper program. At December&#160;31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc4NzU_b601533f-49ef-4779-89ff-a18c4023bf4a">300</ix:nonFraction> outstanding under our commercial paper program with a weighted-average interest rate of <ix:nonFraction unitRef="number" contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231" decimals="INF" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc5NjY_9c07a493-90bf-499c-b225-88f6d1b6f4cf">0.150</ix:nonFraction>%. Commercial paper borrowings have been classified as long-term debt at December&#160;31, 2022 and 2021, as our general practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year, and we have the ability to redeem our commercial paper with borrowings under the credit facilities described above. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debentures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;9, 2012, we issued $<ix:nonFraction unitRef="usd" contextRef="i111f1669cf354c22bca3fe927cfeb62c_I20121009" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzg0NDc_19c0a1ef-1ba1-48f5-9464-5176566dc0a0">1,500</ix:nonFraction> of senior convertible debentures (the &#8220;Debentures&#8221;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Debentures are governed by an indenture dated as of October&#160;9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;Indenture&#8221;). The Debentures bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i111f1669cf354c22bca3fe927cfeb62c_I20121009" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzg4NTc_4076abb4-14e5-45f8-9136-ea67dcceebc0">2.750</ix:nonFraction>%&#160;per year, payable semi-annually in arrears in cash on April&#160;15 and October&#160;15 of each year, and mature on October&#160;15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. <ix:nonNumeric contextRef="i3deab0f622924f9085bea8fcbe5ee03c_D20221015-20221015" name="us-gaap:LongTermDebtContingentPaymentOfPrincipalOrInterest" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NDk5OA_dfeb384b-8734-4220-9080-61d6c10254ad">The Debentures also have a contingent interest feature that requires us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October&#160;15, 2022. As of October 15, 2022, one of these events had occurred and contingent interest began accruing on the Debentures at a rate of 0.50% of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest will be payable on April 15, 2023, to holders of the Debentures as of the April 1, 2023 record date.</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-119-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i4e1fe5295bdb4bde91be70b78def4d75" continuedAt="idff41e8ca6534f5f87b0e65f96fc098c"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April&#160;15, 2042, only under the following circumstances: (1)&#160;during any fiscal quarter if the last reported sale price of our common stock for at least <ix:nonFraction unitRef="number" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk1ODk_8c5aadc9-2551-4f05-beef-aa7d2b529d6a">20</ix:nonFraction> trading days during a period of <ix:nonNumeric contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" name="elv:NumberOfConsecutiveTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk2MjQ_85785ff7-2c3a-41ef-bc70-3727a19ad1bd">30</ix:nonNumeric> consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk3NDM_e1874775-1e68-4dc1-b9a7-2467ccb822f3">130</ix:nonFraction>% of the applicable conversion price on each applicable trading day; (2)&#160;during the five business day period after any <ix:nonNumeric contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" name="elv:MeasurementPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk4NjM_d15091c2-f438-478a-a562-8af8595be809">10</ix:nonNumeric> consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $<ix:nonFraction unitRef="usd" contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk5NTU_6490c636-7e21-4366-97c4-b4a0d8bf8667">1,000</ix:nonFraction> (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than <ix:nonFraction unitRef="number" contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231" decimals="INF" name="elv:PercentConversionToStockPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwMDY3_909b2482-50fc-4a1b-a5be-f9b18465990a">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the applicable conversion rate on each such day; (3)&#160;if we call any or all of the Debentures for redemption, at any time prior to the close of business on the business day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events, as defined in the Indenture. On and after <ix:nonNumeric contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleEarliestDate1" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNDU4_7a96e7e3-ae03-4d86-839d-8eadade5fa87">April 15, 2042</ix:nonNumeric> and until the close of business on the third scheduled trading day immediately preceding the Debentures&#8217; maturity date of <ix:nonNumeric contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNTgz_8344d886-ac8c-4695-8a76-01edc722c73a">October 15, 2042</ix:nonNumeric>, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after <ix:nonNumeric contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" name="elv:DateDebenturesReedemable" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNzY3_f9c6dcc7-4a48-41bd-96b2-c3d84df54d18">October 20, 2022</ix:nonNumeric>, upon the occurrence of certain events, as defined in the Indenture.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2023, we delivered notice to redeem all of the outstanding Debentures. The Debentures will be redeemed on <ix:nonNumeric contextRef="iac96933216134d7b8897d64076389449_D20230213-20230213" name="us-gaap:DebtInstrumentRedemptionPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NTI5Nw_0e379de8-3bdb-4789-b557-3832d28aaa5f">March 15, 2023</ix:nonNumeric> at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="iac96933216134d7b8897d64076389449_D20230213-20230213" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NTI0Mg_c87f2070-0999-4993-b1fd-170b2ee6d2eb">100</ix:nonFraction>% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock or a combination thereof based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures was <ix:nonFraction unitRef="number" contextRef="ie6cc8a906b734cbb88951da261ef5f76_D20121001-20121002" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExMzEw_6257c43d-6cfb-4af0-bb59-587ef23fd0c2">13.2319</ix:nonFraction>&#160;shares of our common stock per Debenture, which represented a <ix:nonFraction unitRef="number" contextRef="i168f8f6c7055487690a43cb967e499b1_I20121002" decimals="INF" name="elv:ConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExMzc1_9c486024-e006-4a56-ab29-5f9b91d13a26">25</ix:nonFraction>% conversion premium based on the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i168f8f6c7055487690a43cb967e499b1_I20121002" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNDI3_aa8ca409-c451-4186-b9a4-5909638b778e">60.46</ix:nonFraction> per share of our common stock on October&#160;2, 2012 (the date the Debentures&#8217; terms were finalized) and is equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i168f8f6c7055487690a43cb967e499b1_I20121002" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNTc5_f3ca1128-2ee5-4b58-af69-254797d160ab">75.575</ix:nonFraction>&#160;per share of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="-6" name="elv:DebtConversionDebtPrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MzM2MA_d1e91903-9f88-4cba-bfb0-78b0982dfcc6">41</ix:nonFraction> aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversion with cash for total payments of $<ix:nonFraction unitRef="usd" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MzM1MQ_fc78001b-a0bf-4309-bf16-f0c57e382e80">299</ix:nonFraction>. During the year ended December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231" decimals="-6" name="elv:DebtConversionDebtPrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNjU1_20a0bf01-f87d-48a2-af83-bfbdb088c681">54</ix:nonFraction> aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $<ix:nonFraction unitRef="usd" contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExOTIy_7740d92f-6c0b-4071-8361-0aac4056704f">302</ix:nonFraction>. We recognized a loss on the extinguishment of debt related to the Debentures of $<ix:nonFraction unitRef="usd" contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyMDA2_08291869-ab76-403a-a908-c26d55358635">6</ix:nonFraction>, based on the fair values of the debt on the conversion settlement dates. During the year ended December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231" decimals="-6" name="elv:DebtConversionDebtPrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyMTI0_a9ae873f-7756-4688-8f0c-5b778e87091a">56</ix:nonFraction> aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $<ix:nonFraction unitRef="usd" contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyMzkx_69ac0f38-cc21-4010-966e-9a31de9c79dd">222</ix:nonFraction>. We recognized a loss on the extinguishment of debt related to the Debentures of $<ix:nonFraction unitRef="usd" contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyNDc1_316e2f77-da31-432e-b5cc-be23b5415c68">6</ix:nonFraction>, based on the fair values of the debt on the conversion settlement dates.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our common stock was last traded at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEzMTA3_116ddd49-4fca-4ffc-bca8-241ab05f035f">512.97</ix:nonFraction> per share. If the remaining Debentures had been converted or matured at December&#160;31, 2022, we would have been obligated to pay the principal of the Debentures plus an amount in cash or shares equal to $<ix:nonFraction unitRef="usd" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="-6" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEzMjk2_215701c1-cc63-4e7a-b9c9-2280d2b48da6">402</ix:nonFraction>. The Debentures and underlying shares of our common stock have not been and will not be registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option, net of deferred taxes and equity issuance costs, was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets.We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Mzg4NQ_76d79920-de6a-47b2-afe5-88fbb635e800">31</ix:nonFraction>, a decrease of our deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" sign="-" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Mzg5Mw_137c3fd0-a672-499d-867f-bdef07372101">8</ix:nonFraction> and a corresponding cumulative-effect reduction to our opening retained earnings of $<ix:nonFraction unitRef="usd" contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MzkwMA_26efafb1-20f6-47d7-8153-7ab3a6ef6df9">23</ix:nonFraction>, eliminating the bifurcation of the embedded conversion option.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-120-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="idff41e8ca6534f5f87b0e65f96fc098c"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTYy_5090267d-c899-4a2a-8e23-60b3be6ab35e" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, at December&#160;31, 2022, the related balances, conversion rate and conversion price of the Debentures:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzAtMS0xLTEtNzgwNDk_d9c67f32-4290-475a-8823-69a21150d744">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net debt carrying amount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzItMS0xLTEtNzgwNDk_5bd96448-a922-483b-a9fd-c00d4d52b557">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion rate (shares of common stock per $1,000 of principal amount)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzQtMS0xLTEtNzgwNDk_00834302-a189-47da-a1d1-1aa2b60ba543">14.3238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective conversion price (per $1,000 of principal amount)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzUtMS0xLTEtNzgwNDk_25b30a1c-4740-4054-95ba-9a0b61db7def">69.8139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTAx_de248a67-2b0a-4d09-b093-d126f3869c3f">2</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTA1_64c07244-14fc-46c8-b55e-6cfc789eaf8f">4</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTEy_6c4df042-412f-413d-b333-614dbfb02ec9">6</ix:nonFraction>, respectively, of interest expense related to the Debentures, of which $<ix:nonFraction unitRef="usd" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTg2_20764559-82f8-47e1-9aee-ee824c8a0873">2</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTkw_7fada8d6-85ec-4270-8740-1aa013f85518">3</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTk3_6436ffd5-c0ec-4879-b9f6-f5646a39ae7a">5</ix:nonFraction>, respectively, represented interest expense recognized at the stated interest rate of <ix:nonFraction unitRef="number" contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0Njg2_24a1168e-f786-4be6-aa61-4d350543f960">2.750</ix:nonFraction>% and $<ix:nonFraction unitRef="usd" contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0Njkz_ccf88de1-409e-433f-8d14-aebba722a435">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0Njk3_ffa906da-6deb-4ce9-84a5-d3be8cf3a590">1</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NzA0_badccfde-69a3-48e3-aefc-ee1fafb20005">1</ix:nonFraction>, respectively, represented interest expense resulting from amortization of the debt discount. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid on our total outstanding debt during 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0ODcy_53550214-0bd5-48b7-bebb-5c28076b8269">878</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0ODc2_f5e2e7d5-b983-4cda-96e3-df3f020789fa">822</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0ODg0_267671a1-fc08-48c5-923f-ce90323aaf94">794</ix:nonFraction>, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all applicable covenants under all of our outstanding debt agreements at December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of all long-term debt outstanding at December&#160;31, 2022 are as follows: 2023, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MDky_c1c60cbe-b7e2-4394-8b4a-1fd07284481f">1,500</ix:nonFraction>; 2024, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTAw_bf403e4b-4b4f-4e86-b3ff-d3b65e300e0e">1,647</ix:nonFraction>; 2025, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTA4_398a030f-96be-43dc-af42-1c9dc28e9647">1,650</ix:nonFraction>; 2026, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTE2_b92dfe1f-a674-47de-82d2-18c5ba4350ec">746</ix:nonFraction>; 2027, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTI0_ee839c66-d227-4cf5-9fc9-df44bc6bbcad">1,592</ix:nonFraction> and thereafter, $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTQz_47eae9ac-f2a4-4121-b05b-46fc7161c595">16,714</ix:nonFraction>.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_145"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzIxMjM5_639153f3-713d-4c13-a0e4-16fc22ad267b" continuedAt="ice39fb88b08f445e9a1e15faaa346d75" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ice39fb88b08f445e9a1e15faaa346d75" continuedAt="ia1f8499903354a5ea415f04b4471d3d9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. </span></div><div style="margin-bottom:9pt;padding-right:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $<ix:nonFraction unitRef="usd" contextRef="ib99d2d66da9844cab49602099b561dda_I20221231" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzIyNzA_d6fe8956-88b3-40cd-9e34-3873d61b887e">0</ix:nonFraction> to approximately $<ix:nonFraction unitRef="usd" contextRef="i725fb0d8346e4b058763cea8f52dbda8_I20221231" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzIyOTA_08b2b01e-9718-4fe8-b3d4-106b770725b6">250</ix:nonFraction> at December&#160;31, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross Blue Shield Antitrust Litigation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the &#8220;Blue plans&#8221;) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Blue Cross Blue Shield Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is pending in the U.S. District Court for the Northern District of Alabama (the &#8220;Court&#8221;). Generally, the suits allege that the BCBSA and the Blue plans have </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-121-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ia1f8499903354a5ea415f04b4471d3d9" continuedAt="if6e6ce928b4a4a27b30ae388c502c8e8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (&#8220;Sherman Act&#8221;) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Court issued an order on the parties&#8217; cross motions for partial summary judgment, determining that the defendants&#8217; aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the &#8220;Subscriber Settlement Agreement&#8221;), which agreement required the Court&#8217;s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the &#8220;national best efforts&#8221; rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members. The notice process was completed in March 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the &#8220;Final Approval Order&#8221;). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzU0OTc1NTkyNTEwMA_8f35f27a-8a82-4b7c-ab48-845f75090f4e">506</ix:nonFraction> into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzU0OTc1NTg2MDEzMA_90b7c39b-24bf-4344-9b79-15018cfe6e52">596</ix:nonFraction>, which was previously accrued in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event that all appellate rights are exhausted in a manner that affirms the Court&#8217;s Final Approval Order, the defendants&#8217; payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to the providers&#8217; claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants&#8217; motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs&#8217; motion for partial summary judgment, holding that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio v. American Express Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants&#8217; motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the &#8220;national best efforts&#8221; rule, the rule of reason applies to the provider plaintiffs&#8217; market allocation conspiracy claims, and (ii) denying the provider plaintiffs&#8217; motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers&#8217; group boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to providers&#8217; renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-122-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="if6e6ce928b4a4a27b30ae388c502c8e8" continuedAt="id07698e757c047488e1a3f4222c981cb"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 2:21-cv-01209-AMM (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JetBlue Airways Corp., et al. v. Anthem, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00558-GMB (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00265-RDP (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bed Bath &amp; Beyond Inc. v. Anthem, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-01256-SGC (N.D. Ala.);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Hoover, et al. v. Blue Cross Blue Shield Association, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00261-RDP (N.D. Ala.); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VHS Liquidating Trust v. Blue Cross of California, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross of California Taxation Litigation</span></div><div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (&#8220;BCC&#8221;) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the &#8220;Superior Court&#8221;) captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael D. Myers v. State Board of Equalization, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an &#8220;insurer&#8221; for purposes of taxation despite acknowledging it is not an &#8220;insurer&#8221; under regulatory law. At the time, under California law, &#8220;insurers&#8221; were required to pay a gross premiums tax (&#8220;GPT&#8221;) calculated as <ix:nonFraction unitRef="number" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="4" name="elv:GrossPremiumTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzc4Mjg_df0aebb8-4b85-4f27-a6dc-8a535e54d7d3">2.35</ix:nonFraction>% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (&#8220;CFT&#8221;), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.</span></div><div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Superior Court denied BCC&#8217;s motion for judgment on the pleadings and similar motions brought by other entities. In December 2020, the Superior Court granted BCC&#8217;s motion for summary judgment, dismissing the plaintiff&#8217;s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. BCC&#8217;s responding brief was filed in March 2022 and Plaintiff&#8217;s reply was filed in May 2022. We estimate that the appeal will be heard in March 2023. We intend to vigorously defend the appeal of this lawsuit.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Express Scripts, Inc. Pharmacy Benefit Management Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we filed a lawsuit against Express Scripts, Inc. (&#8220;Express Scripts&#8221;), our vendor at the time for PBM services, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anthem, Inc. v. Express Scripts, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the Southern District of New York (the &#8220;District Court&#8221;). The lawsuit seeks to recover over $<ix:nonFraction unitRef="usd" contextRef="ide2e9b364d454a189b9c63aaf27ed9ed_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzk2MjA_2575dcfd-bb15-438d-af17-193a5df7434a">14,800</ix:nonFraction> in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the &#8220;ESI PBM Agreement&#8221;), over $<ix:nonFraction unitRef="usd" contextRef="i530e77d500e24332972b126eb61ad553_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzk3Nzc_ff442d6e-18d0-4cbb-a8f0-1b1b1748f473">158</ix:nonFraction> in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $<ix:nonFraction unitRef="usd" contextRef="idbb67e7d15ec40d393dc4ea0b4156be1_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzEwODY0_7453ee36-6371-4369-9e2c-3e8975dc441c">4,675</ix:nonFraction> at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts&#8217; counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts&#8217; only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts&#8217; motion for summary </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-123-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="id07698e757c047488e1a3f4222c981cb" continuedAt="i06db6c29c46c4e45af00c65fe53fd530"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Annual Report on Form 10-K are (i) our operational breach claim based on Express Scripts&#8217; prior authorization processes and (ii) Express Scripts&#8217; counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Risk Adjustment Litigation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. Department of Justice (&#8220;DOJ&#8221;) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the &#8220;New York District Court&#8221;) in a case captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Anthem, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The DOJ&#8217;s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in that court. In November 2022, we filed an answer. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investigations of CareMore and HealthSun</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (&#8220;CareMore&#8221;), one of our California subsidiaries, and HealthSun Health Plans, Inc. (&#8220;HealthSun&#8221;), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore&#8217;s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (&#8220;HMOs&#8221;) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-124-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i06db6c29c46c4e45af00c65fe53fd530"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at December&#160;31, 2022 is approximately $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzE5Mzk4_4eaa4786-55c0-46d0-9053-f74250a7b349">761</ix:nonFraction>. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, we began using our pharmacy benefits manager CarelonRx, formerly known as IngenioRx, to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. CarelonRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vulnerability from Concentrations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which we conduct business. As of December&#160;31, 2022, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_151"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5NzE_e7f98a45-5595-4da5-9862-77a4a80bfb87" continuedAt="i01e6732252ed433f879b6992b446215e" escape="true">Capital Stock</ix:nonNumeric></span></div><ix:continuation id="i01e6732252ed433f879b6992b446215e" continuedAt="i462dd6944f134a888cce2d54341cf6d5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted the 2017 Elevance Health Incentive Compensation Plan, formerly known as the 2017 Anthem Incentive Compensation Plan (&#8220;2017 Incentive Plan&#8221;), which has been approved by our shareholders. The term of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The 2017 Incentive Plan limits the number of available shares for issuance to <ix:nonFraction unitRef="shares" contextRef="i9f482fd60e844e1aa802036bfbb28f7d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzcxNw_faadff6c-1a25-44e6-ad7e-2f13b40f3502">37.5</ix:nonFraction> shares, subject to adjustment as set forth in the 2017 Incentive Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest over <ix:nonNumeric contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzk1OQ_7596c059-ed6e-4e7c-8517-c4abab14c495">three years</ix:nonNumeric> in equal annual installments and generally have a term of <ix:nonNumeric contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231" name="elv:StockOptionTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzEwMjA_4bdb4ee1-fc70-49b2-808a-e2aed783d7b0">ten years</ix:nonNumeric> from the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also include one or more performance measures that must be met for the award to vest. For restricted stock or restricted stock </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-125-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i462dd6944f134a888cce2d54341cf6d5" continuedAt="i26ff49a12df74c77a44861c1c84f56d8"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units without performance measures, the restrictions lapse in three equal annual installments. Restricted stock or restricted stock units with performance measures vest in three year installments. Performance units issued in 2022 will vest in 2025, based on certain revenue and earnings targets over the three year period of 2022 to 2024. Performance units issued in 2021 will vest in 2024, based on certain revenue and earnings targets over the three year period of 2021 to 2023. Performance units issued in 2020 will vest in 2023, based on certain revenue and earnings targets over the three year period of 2020 to 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, we recognized share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzIzNjg_14aed0df-e1a2-4a07-8fed-44fde96d3029">264</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzIzNzI_e5c1f099-324c-479e-b2cc-0a16c8ca1b8d">255</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzIzNzk_2120f65c-8023-4dac-9369-bb460ae0ec05">283</ix:nonFraction>, respectively, as well as related tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI0MzI_ee2830be-fbc1-463a-8d4a-3c5937e7c084">66</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI0MzY_4ead590f-3a37-4a8e-b265-e68a2bf162fe">65</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI0NDM_310e69a5-7406-46da-8aa3-2cc137479ee2">74</ix:nonFraction>, respectively. </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzkwMTg_07ae56b7-8da4-457d-908c-15f144000f2c" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Option Price <br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzEtMS0xLTEtNzgwNDk_8f6c8f21-68d8-4985-abc7-9b148742e7d1">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzEtMy0xLTEtNzgwNDk_a93fba8d-343b-4299-8990-eaa240aa29ad">255.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzItMS0xLTEtNzgwNDk_a8c7e467-b609-49b3-9a95-44dde847e4e0">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzItMy0xLTEtNzgwNDk_1fec798d-3311-4419-b0ed-d97dbc78a147">452.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzMtMS0xLTEtNzgwNDk_43871c0c-6e3e-4db8-8b64-34908ca7adc8">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzMtMy0xLTEtNzgwNDk_0067c27a-ab63-44d1-9ae4-a99bb94709b2">242.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzQtMS0xLTEtNzgwNDk_7c90dcb1-8b11-47e1-ae45-aa9e850522f9">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzQtMy0xLTEtNzgwNDk_99189ed9-56f5-45df-b925-f73f1536fd71">339.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtMS0xLTEtNzgwNDk_051c6c82-8300-4376-8d46-099700d784cd">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtMy0xLTEtNzgwNDk_07a9f254-d28c-46ac-a155-7d3712a5d554">293.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtNS0xLTEtNzgwNDk_93100053-ec8e-4afe-bb0f-c8efdda76ba6">6.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtNy0xLTEtNzgwNDk_ec79ac44-3693-4f6e-990a-42f9118e4c9c">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtMS0xLTEtNzgwNDk_8c6db72b-063e-48dc-b614-36a05dbf2bc9">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtMy0xLTEtNzgwNDk_ee640a2c-0426-4ac0-8dbf-cb9204fda1d3">239.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtNS0xLTEtNzgwNDk_1c29ecf6-d43c-4723-9ed9-097bbeb0880f">5.14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtNy0xLTEtNzgwNDk_95919305-24a9-4002-a1dc-6350d561e5f1">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 amounted to $<ix:nonFraction unitRef="usd" contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2MjY_0a08d881-b449-48be-8c65-d4611edac816">120</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2MzA_277943a1-6b51-4abe-a637-3012ea255e7e">121</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2Mzc_25879527-dc8f-4774-8817-4ad7c574a95d">147</ix:nonFraction>, respectively. We recognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231" decimals="-6" name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2ODU_fa37aa07-f10a-444e-9820-2a8a0f6f8e10">31</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231" decimals="-6" name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2ODk_e2e528e4-b8e5-4bf2-9b58-18abd9d70d98">32</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231" decimals="-6" name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2OTY_8551316e-f933-49e4-b909-35eb74430f6c">40</ix:nonFraction> during the years ended December&#160;31, 2022, 2021 and 2020, respectively, from option exercises and disqualifying dispositions. During the years ended December&#160;31, 2022, 2021 and 2020, we received cash of $<ix:nonFraction unitRef="usd" contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI4NjM_55d12f2f-1645-437f-87a2-39e6365a2c6b">120</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI4Njc_87867e9d-e889-49a3-b3f4-52e411864a08">148</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI4NzQ_3255d146-804b-430b-9149-e6262e9e10a8">129</ix:nonFraction>, respectively, from exercises of stock options.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock awards that vested during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i94919fea365f4bf3810bbae7fae7bb53_D20220101-20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMwMjY_4a2c7920-7165-41a9-84d4-2ef0a675c394">261</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i18e9f319025d420eb32e7522fd74ed84_D20210101-20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMwMzA_0da05ba2-00b4-4eef-ab68-aac5cf6ab061">287</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie674fb9fe21244e6a1ce2872735af01d_D20200101-20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMwMzc_50728d62-4a40-474e-97e7-5be2d358fbd3">335</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5OTI_75e34457-fd9f-41af-99ec-5812b20609a1" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock&#160;Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzEtMS0xLTEtNzgwNDk_a0f52ac1-2383-413a-b9e9-235631c5a4d9">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzEtMy0xLTEtNzgwNDk_5e8d9c5c-5c1c-43a6-852a-f8295c0102f2">299.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzItMS0xLTEtNzgwNDk_8c0c10a1-f110-44c5-b5c6-631ca6044dde">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzItMy0xLTEtNzgwNDk_f482be45-c978-42b2-a35a-dad27c02c2f2">453.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzMtMS0xLTEtNzgwNDk_f736dd63-4b6d-4509-b088-cdc33bb95d36">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzMtMy0xLTEtNzgwNDk_7bf4a20c-ad36-40a8-a7b7-d5816925cd11">301.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzQtMS0xLTEtNzgwNDk_35e5b7a8-90b1-401f-a96a-1b2924c941ca">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzQtMy0xLTEtNzgwNDk_fc380ce9-6d47-44c4-9c31-e0bfa66a65fc">347.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzUtMS0xLTEtNzgwNDk_ef4aa22f-67ed-417b-863f-38b48f7e7dc0">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzUtMy0xLTEtNzgwNDk_6985b558-676d-42ef-90c2-db03ee013f30">357.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we granted approximately <ix:nonFraction unitRef="shares" contextRef="i91235d6e1c7c4af2b57d1b5d2854972a_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMyNjU_c5c6844d-36b9-41b5-ac91-33f5a40159fe">0.2</ix:nonFraction> restricted stock units that are contingent upon us achieving certain revenue and earnings targets over the three year period of 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024, based on results in the three year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2022, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock, including restricted stock units and performance units, amounted to $<ix:nonFraction unitRef="usd" contextRef="ic773a96084d446cc8f83053d1d3e03dd_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM3NTI_a85877b0-a852-4917-9f12-a42a329cb1f7">35</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic8aebf8ee5444e509fd8796f5ae27e76_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM3NTk_54747b45-75c6-48ae-b19f-d3e08fea2aef">176</ix:nonFraction>, respectively, which will be amortized over the weighted-average remaining requisite service periods of <ix:nonNumeric contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM4NjY_99dd3a70-2e6d-462d-aad5-c05a3bc72080">9</ix:nonNumeric> months and <ix:nonNumeric contextRef="i94919fea365f4bf3810bbae7fae7bb53_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM4NzM_e255e93f-4271-481a-90d2-213dc1e59815">12</ix:nonNumeric> months, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were approximately <ix:nonFraction unitRef="shares" contextRef="i9f482fd60e844e1aa802036bfbb28f7d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM5MjY_8cdf552b-5a81-4654-8588-5abf63226cd5">14.0</ix:nonFraction> shares of common stock available for future grants under the 2017 Incentive Plan.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-126-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="i26ff49a12df74c77a44861c1c84f56d8" continuedAt="ie66dc155544c4c13b95eb1bc920efad4"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice model are based on an analysis of implied volatility of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the multiple-grant approach for recognizing compensation expense associated with each separately vesting portion of the share-based award.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5NzQ_c8c56876-5841-401c-93d7-91ddbb524e6e" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzEtMS0xLTEtNzgwNDk_a9e739d9-be90-458e-8286-61714326322a">1.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzEtMy0xLTEtNzgwNDk_0c372978-a8a6-4323-9ea4-265e70456b29">1.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzEtNS0xLTEtNzgwNDk_b8e80d4f-88e9-446f-aacb-99589ef50e72">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzItMS0xLTEtNzgwNDk_7a004aa0-495b-44eb-b596-3f444986ab33">29.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzItMy0xLTEtNzgwNDk_3866aa9e-b19b-4112-a7e2-fb3553ca1470">30.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzItNS0xLTEtNzgwNDk_17ae7c78-201c-4635-b65a-3c77388e68ee">26.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (annual)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzMtMS0xLTEtNzgwNDk_76d3d9bd-65df-4bae-92c3-c174fce82310">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzMtMy0xLTEtNzgwNDk_e6f6115f-1762-4f5c-8d33-f2d592fe96f8">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzMtNS0xLTEtNzgwNDk_201ad80e-c7e1-48d7-b98a-ddb36d94218a">1.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzQtMS0xLTEtNzgwNDk_6075b9e4-142c-4a56-ac7b-6904d804fa4d">5.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzQtMy0xLTEtNzgwNDk_6c2e084d-1a2a-41a2-8e9f-f659dc8d8fae">5.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzQtNS0xLTEtNzgwNDk_9f9351fa-147a-428f-bd58-6e4571dc02ce">4.30</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzkwMTM_6c507a22-b31e-4761-bf07-22b60cdef75f" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values were determined for the years ending December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzEtMS0xLTEtNzgwNDk_48e3dfc9-6d6c-421c-9c6d-3045e44d0fe2">116.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzEtMy0xLTEtNzgwNDk_6288cc8f-3c03-4e05-b9c1-657faa012581">79.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzEtNS0xLTEtNzgwNDk_71559073-2d45-4d48-a210-2bfc53c54bc1">54.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzItMS0xLTEtNzgwNDk_88e68808-b5a9-4b5f-ab71-8810e25b8398">453.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzItMy0xLTEtNzgwNDk_0625572d-4837-40d7-b7e2-ffe84d446fcb">317.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzItNS0xLTEtNzgwNDk_82cb9798-c86b-4164-a8b9-ca3a5d54e0d3">272.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The binomial lattice option-pricing model requires the input of subjective assumptions including the expected stock price volatility. Because our stock option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered <ix:nonFraction unitRef="shares" contextRef="i01f291e82852495c91f39ae516cb5961_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU3MTk_bdd8e68d-1360-4598-b8bf-cf73b17312a1">14.0</ix:nonFraction> shares of common stock for the Employee Stock Purchase Plan (the &#8220;Stock Purchase Plan&#8221;), which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in Elevance Health. Pursuant to the terms of the Stock Purchase Plan, an eligible employee is permitted to purchase no more than $<ix:nonFraction unitRef="usd" contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231" decimals="0" name="elv:SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzYwNDI_c316eebd-91ca-49b0-9f14-4276f49c831c">25,000</ix:nonFraction> (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter. Employees become participants by electing payroll deductions from <ix:nonFraction unitRef="number" contextRef="i01f291e82852495c91f39ae516cb5961_I20221231" decimals="INF" name="elv:SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzYyMzU_838f0cf6-6566-49b8-9473-e5a917e566bc">1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i01f291e82852495c91f39ae516cb5961_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzYyNDE_81cbb1c8-a207-4d50-b95d-0de482da4de4">15</ix:nonFraction>% of gross compensation. Once purchased, the stock is accumulated in the employee&#8217;s investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a discounted price per share of <ix:nonFraction unitRef="number" contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzY0NjQ_d92b388d-dd92-41f7-b7d3-779158d9ee01">90</ix:nonFraction>% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter purchase period. The Stock Purchase Plan discount was recognized as compensation expense for the year ended December&#160;31, 2022, based on GAAP guidance. During the years ended December&#160;31, 2022, 2021 and 2020, we issued <ix:nonFraction unitRef="shares" contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzY3MjU_25a4a511-66c9-4f52-a141-d34d2e595cdc">0.1</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ibd001b0d68c34a668c7fde379c754978_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDczOA_d25af217-dd81-43fe-a9af-33c9d1cb2665">0.1</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i74f7a4356b364dabba6bc38e7490c8bb_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDc0Ng_7d7e1d5e-ed1a-46d1-b3e0-c9fd45c63d06">0.2</ix:nonFraction> shares, respectively, under the Stock Purchase Plan, and we received cash of $<ix:nonFraction unitRef="usd" contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDcxNA_11554fb8-3eeb-4191-9e65-5dd2df39a255">62</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ibd001b0d68c34a668c7fde379c754978_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDcyMg_e9ef7192-3e98-42f2-ae6c-6673e2bf4a97">55</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i74f7a4356b364dabba6bc38e7490c8bb_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDczMA_c0985a2e-59c9-4b58-ad11-0714d1e99aa9">47</ix:nonFraction>, respectively, for such shares. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i01f291e82852495c91f39ae516cb5961_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzY3Nzg_25f9d62e-faa6-42a7-9fc4-de8d29360b38">4.3</ix:nonFraction> shares were available for issuance under the Stock Purchase Plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Capital and Stock Repurchase Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-127-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ie66dc155544c4c13b95eb1bc920efad4"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:DividendsDeclaredTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzkwMDg_ebeb5da2-ccaf-4087-9c00-d357fad43316" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the cash dividend activity for the years ended December&#160;31, 2022 and 2021 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Dividend <br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItMC0xLTEtNzgwNDk_8793af25-9558-44ff-9170-a2927246173c">January 25, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItMi0xLTEtNzgwNDk_0b2b3637-c3e8-422c-a393-3d1b2dc547b4">March 10, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItNC0xLTEtNzgwNDk_ad68dce1-9d4e-451f-afb6-90a694e43de8">March 25, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItNi0xLTEtNzgwNDk_5f068bb1-fb0b-49eb-9c8c-5bf5df85c5a6">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItOC0xLTEtNzgwNDk_6d106046-ec64-4143-afdc-abf75f315073">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtMC0xLTEtNzgwNDk_977625c6-a9da-403e-bb5f-be60c98832ec">April 19, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtMi0xLTEtNzgwNDk_211bd8b2-061b-46b3-abf3-61945a29571c">June 10, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtNC0xLTEtNzgwNDk_4e9f7215-793b-4483-952c-cff42f794023">June 24, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtNi0xLTEtNzgwNDk_87dd27a2-e764-4bea-a678-f225df8091c1">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtOC0xLTEtNzgwNDk_f1d8ec2d-501d-41f9-867d-a3642bde3b19">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtMC0xLTEtNzgwNDk_abfb45d7-7ef5-4442-a99c-7c4d348539e5">July 19, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtMi0xLTEtNzgwNDk_464ccadf-21d1-4f8f-b03b-31c242cd3648">September 9, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtNC0xLTEtNzgwNDk_2c34b5e7-e0e9-4ddf-beef-8697c499e89a">September 23, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtNi0xLTEtNzgwNDk_59e674cf-1a71-4e6c-8f3d-698633bc8faf">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtOC0xLTEtNzgwNDk_d1fcc67e-41c5-4997-b42a-92b626d885ac">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtMC0xLTEtNzgwNDk_412be21c-174a-482b-bce1-f4edd81f3e0e">October 18, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtMi0xLTEtNzgwNDk_cb2fb45b-029f-44f2-90ba-f541ce31c31b">December 5, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtNC0xLTEtNzgwNDk_0fad179f-dc60-46c4-b60a-3018b2756bcd">December 21, 2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtNi0xLTEtNzgwNDk_a035b565-b369-4785-b3c3-8e2b9c597ca2">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtOC0xLTEtNzgwNDk_7a42322a-f891-4586-b9ce-ed0d4ee49dba">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtMC0xLTEtNzgwNDk_44a99a79-4da9-4b87-be13-811f06eccf22">January 26, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtMi0xLTEtNzgwNDk_1bf2205e-0051-467a-9c4c-45729e0cda59">March 10, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtNC0xLTEtNzgwNDk_e5db3db3-526b-4d24-981d-97f289451d00">March 25, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtNi0xLTEtNzgwNDk_2620708d-4c75-49e0-9a08-a68e0b283629">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtOC0xLTEtNzgwNDk_a4c937bb-63de-41a2-902c-dac089fd70d4">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktMC0xLTEtNzgwNDk_f0f15808-c536-4abc-a14a-a6263d507ee4">April 20, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktMi0xLTEtNzgwNDk_bc18b053-29f8-4e7f-a88d-f03c0d220b0e">June 10, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktNC0xLTEtNzgwNDk_7fcc1eac-0283-4481-975d-37c6d021e2b6">June 25, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktNi0xLTEtNzgwNDk_b00fa2ac-06be-4157-9d31-eacd091aa32f">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktOC0xLTEtNzgwNDk_bfdcf321-5290-4b62-9a78-21cfba650341">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTAtMS0xLTc4MDQ5_804ebaf1-948a-4e60-8f00-ec001716202f">July 20, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTItMS0xLTc4MDQ5_5dc13d3b-a1ba-444f-a460-ef3a1d2ccc5b">September 10, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTQtMS0xLTc4MDQ5_4ba89e38-fcc8-44d8-a718-2fe3c643291a">September 24, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTYtMS0xLTc4MDQ5_cea1de51-5a81-483c-90b8-3bad5741658a">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTgtMS0xLTc4MDQ5_4a6580e1-66ba-4b13-a54f-cd37dbad6a89">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTAtMS0xLTc4MDQ5_7493d05e-edb0-48d3-8e4d-6ec31ca13de0">October 19, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTItMS0xLTc4MDQ5_d6f65a47-6ed8-48ee-b101-bc91cd334e62">December 3, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTQtMS0xLTc4MDQ5_d72a2b85-4f16-462e-890e-9ed7dfe00d20">December 21, 2021</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTYtMS0xLTc4MDQ5_8cdca687-02ab-4852-8c2f-0fc74e40f68c">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTgtMS0xLTc4MDQ5_cff5be75-e984-4f1a-bc6e-ca9380143f8c">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2023, our Audit Committee declared a quarterly cash dividend to shareholders of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f793b028bf243b29bbcb6a44fa763f0_I20230124" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc1MzM_0a7b4f44-97a3-47cd-b25c-54ae422ed858">1.48</ix:nonFraction> per share on the outstanding shares of our common stock. This quarterly dividend is payable on <ix:nonNumeric contextRef="ia027da647af941768a3f104492aa7231_D20230124-20230124" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc2MzE_39575f67-de1b-41b2-b026-31a45e25282d">March 24, 2023</ix:nonNumeric> to the shareholders of record as of <ix:nonNumeric contextRef="ia027da647af941768a3f104492aa7231_D20230124-20230124" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc2NzA_976a5d5a-6223-4a89-8f2b-086723f03cd0">March 10, 2023</ix:nonNumeric>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Board of Directors&#8217; authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $<ix:nonFraction unitRef="usd" contextRef="ice6527b2d9fe44bd9c916d8863257a5b_I20210126" decimals="-6" name="elv:IncreaseInStockRepurchaseProgramAuthorization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc4ODI_5810cde8-0b8e-421a-abaf-ac9308f56e97">5,000</ix:nonFraction> increase to our common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $<ix:nonFraction unitRef="usd" contextRef="i2f793b028bf243b29bbcb6a44fa763f0_I20230124" decimals="-6" name="elv:IncreaseInStockRepurchaseProgramAuthorization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzExNTQ0ODcyMTA0NDcx_7a42a969-5af4-4c9b-b97c-2510c91e3d70">5,000</ix:nonFraction> increase to our common stock repurchase program. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time. We intend to utilize this authorization over a multi-year period, subject to market and industry conditions. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5OTU_f7232184-b67c-4107-91c8-b6f40c915c4c" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the years ended December&#160;31, 2022 and 2021 is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzItMy0xLTEtNzgwNDk_625a48aa-49cf-4419-889f-072707ebf58d">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzItNS0xLTEtNzgwNDk_a7fe4082-2525-4e7e-8f36-196471e47dd6">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="2" name="elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzMtMy0xLTEtNzgwNDk_7785058c-cc65-44ff-9c4f-9565f422567e">478.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="2" name="elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzMtNS0xLTEtNzgwNDk_7436ada2-0600-47fb-9cc4-55f1fd146b27">371.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzQtMy0xLTEtNzgwNDk_efe6ccc4-0be8-4fd6-9ca9-21e95c618885">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzQtNS0xLTEtNzgwNDk_c993dab1-1ed0-4627-9dc0-eac0cdad5138">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at end of year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzUtMy0xLTEtNzgwNDk_6d0793dc-5d32-4a1c-a2f4-0876578254b4">1,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzUtNS0xLTEtNzgwNDk_5150c376-e00e-42df-b40c-f70eaca0ea16">4,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding the use of capital for debt security repurchases, see Note 13, &#8220;Debt.&#8221;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-128-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90ZXh0cmVnaW9uOjFmYjgxNmJlYWE1ODQxMjdhMTM1MjNiYTdiZDQxY2JlXzE4NQ_826eaea5-b216-43d8-92a6-0684048e2bf9" continuedAt="i6554ba8ae3df4ea19b325130f1a40638" escape="true">Accumulated Other Comprehensive (Loss) Income </ix:nonNumeric></span></div><ix:continuation id="i6554ba8ae3df4ea19b325130f1a40638"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90ZXh0cmVnaW9uOjFmYjgxNmJlYWE1ODQxMjdhMTM1MjNiYTdiZDQxY2JlXzE3Ng_cb4e7273-a09f-4778-bb7d-c8842fbbe261" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive (loss) income at December&#160;31, 2022, 2021, and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e95a8c856b14a5a8cf3fd92402ef4e3_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzItMS0xLTEtNzgwNDk_761a4224-5791-4c0d-8de9-188be60f5de8">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e698e227c346ae9586de0d8e1b1dbf_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzItMy0xLTEtNzgwNDk_70571985-a4de-4091-8fc3-c2daf010704f">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95514d7548341cba52815d3f07c28d2_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzItNS0xLTEtNzgwNDk_15963a0b-d0ee-4f96-8643-1ce3ef1b07cf">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $<ix:nonFraction unitRef="usd" contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpmYTIwOGE2NzQ1N2Q0OTBmYmMxNDg4NjY3ODQ4NDk1ZF85Ng_434ffab9-200e-44ae-814c-61517a85adc3">926</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpmYTIwOGE2NzQ1N2Q0OTBmYmMxNDg4NjY3ODQ4NDk1ZF8xMDA_0c67f93e-28e7-45a7-a4f0-ee0e874eb7dc">121</ix:nonFraction>, and $(<ix:nonFraction unitRef="usd" contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpmYTIwOGE2NzQ1N2Q0OTBmYmMxNDg4NjY3ODQ4NDk1ZF8xMDg_5f839d14-b5f6-41e4-9b20-34320699157b">160</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMS0xLTEtNzgwNDk_d29e805e-2dc2-4549-a4fe-50f4d0ce85f7">2,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMy0xLTEtNzgwNDk_e32a1760-8220-4ce9-a9a5-a43e0d630036">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtNS0xLTEtNzgwNDk_5bf121aa-20ca-43fb-bccf-2d032b1b6add">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income, net of tax benefit (expense) of $(<ix:nonFraction unitRef="usd" contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0OTY1ZWU2NWRkYzQ0YTYxYTllYTkzMTI3OTgwOTEzOF8xMDI_7bb05935-65c0-4722-ad26-d3cafee2fa00">94</ix:nonFraction>), $<ix:nonFraction unitRef="usd" contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0OTY1ZWU2NWRkYzQ0YTYxYTllYTkzMTI3OTgwOTEzOF8xMDY_202252a2-9d9f-4be3-894b-014f2464edac">27</ix:nonFraction>, and $(<ix:nonFraction unitRef="usd" contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0OTY1ZWU2NWRkYzQ0YTYxYTllYTkzMTI3OTgwOTEzOF8xMTQ_001e6fd9-34dc-4c3c-81c6-c7a103e87671">13</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMS0xLTEtNzgwNDk_ff28b9f6-1d3b-4771-9317-4a7258c63043">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMy0xLTEtNzgwNDk_ee573a3b-95dc-465d-8530-ddf896c3a430">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtNS0xLTEtNzgwNDk_af12915b-2a54-43df-aa0b-54aff31bb57d">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzUtMS0xLTEtNzgwNDk_ea63bc9f-c902-43d8-bbe8-503c3d7a20d4">2,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzUtMy0xLTEtNzgwNDk_fcfc2df3-6265-4da7-b521-e3cf5dd4e8e4">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzUtNS0xLTEtNzgwNDk_3f02a50f-e2ef-4a8f-a447-3a533fc8111e">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcebd1544ec64ec6974e038a69b087db_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzYtMS0xLTEtNzgwNDk_94a6fdba-388e-4d1e-804b-d51f3fbdae97">1,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e95a8c856b14a5a8cf3fd92402ef4e3_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzYtMy0xLTEtNzgwNDk_f699ef5f-4491-4361-a5f2-9de0724eea66">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e698e227c346ae9586de0d8e1b1dbf_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzYtNS0xLTEtNzgwNDk_0a484203-85a4-43c9-b8a5-92ec684245e1">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a792ee17bd44f596cabc8ef3e8b4b4_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzktMS0xLTEtNzgwNDk_a92f3da4-1be7-461c-b24b-00cf2dd76ecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1482b2c7c0ff472fb0c9110009b806b5_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzktMy0xLTEtNzgwNDk_60f09912-d6f4-496c-9155-598b1666c001">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47960b8964ab402a942e197e579d8542_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzktNS0xLTEtNzgwNDk_b5055f8b-9a19-4d81-abf3-d1ec9a80238b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) benefit of $<ix:nonFraction unitRef="usd" contextRef="icc4bd3fce911457baee6a8c050e6b70e_D20220101-20221231" decimals="-6" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjBkNWNjNjE1Mzc5NDU5NDg4OGNlOWQxYjRjZGViZDNfNjQ_f5699093-a4ca-4406-8eae-db4c39bae1e6">0</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i2e36ba6bb351437bb13a37f1503ac813_D20210101-20211231" decimals="-6" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjBkNWNjNjE1Mzc5NDU5NDg4OGNlOWQxYjRjZGViZDNfNjg_1f678250-c61b-42c4-b992-35447cd8f131">1</ix:nonFraction>),and $<ix:nonFraction unitRef="usd" contextRef="i653b1eb3d81f4ca192dd6d3ffca11785_D20200101-20201231" decimals="-6" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjBkNWNjNjE1Mzc5NDU5NDg4OGNlOWQxYjRjZGViZDNfNzU_11f11abf-4492-4014-9377-3de1672e6d9e">0</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc4bd3fce911457baee6a8c050e6b70e_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTEtMS0xLTc4MDQ5_7b81ccf8-66bc-43bb-909a-856306171ef8">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e36ba6bb351437bb13a37f1503ac813_D20210101-20211231" decimals="-6" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTMtMS0xLTc4MDQ5_ac10c5cc-66a9-4c01-8b40-3f9952f66677">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653b1eb3d81f4ca192dd6d3ffca11785_D20200101-20201231" decimals="-6" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTUtMS0xLTc4MDQ5_53d4399e-2981-42f2-a6f8-98df68c7c77e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i246d9c069b344181a326be72f32bf256_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzExLTEtMS0xLTc4MDQ5_a8bab7e5-9699-47e9-b0d6-cac6dd218d9d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a792ee17bd44f596cabc8ef3e8b4b4_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzExLTMtMS0xLTc4MDQ5_7b8c60ba-a699-46f6-923e-9aa79091ca7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1482b2c7c0ff472fb0c9110009b806b5_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzExLTUtMS0xLTc4MDQ5_8c4e63c9-78c6-4409-9247-597d797ab361">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5723b60554294bebac94c904566db3f7_I20211231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE0LTEtMS0xLTc4MDQ5_1878f038-e8ec-4e8f-85f3-7400b15a8c98">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98cc61d631e54bd68ab0e26a98a4905b_I20201231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE0LTMtMS0xLTc4MDQ5_14daaedc-5617-45c5-a5bf-cf97c37d8521">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24c01f7b130a4ac4a08d21b45fed6866_I20191231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE0LTUtMS0xLTc4MDQ5_2a213412-6766-4a53-bb59-01fa7e0224e1">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(<ix:nonFraction unitRef="usd" contextRef="i7b85f7bcceb24f4585583cc791c6fd0e_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTUzMDE1YTBkOTg1NGI0ZDlkODNiYWQxM2MxZTIyZWJfNzE_0161f18d-4788-4d64-b29b-35fe123eb1f5">6</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="id351a075bd634b1598a879fd2e805740_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTUzMDE1YTBkOTg1NGI0ZDlkODNiYWQxM2MxZTIyZWJfNzU_4ea2103e-945c-47f4-af8a-7eff5f8b5018">3</ix:nonFraction>), and $(<ix:nonFraction unitRef="usd" contextRef="ib4c5ae1b587c4de3a0abc993e1f65329_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTUzMDE1YTBkOTg1NGI0ZDlkODNiYWQxM2MxZTIyZWJfODM_67e27862-eff6-4324-ab93-a37b638403bf">3</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b85f7bcceb24f4585583cc791c6fd0e_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTEtMS0xLTc4MDQ5_1216ab0b-d94e-4956-a30c-890ea7c0dbf2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id351a075bd634b1598a879fd2e805740_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTMtMS0xLTc4MDQ5_8c060ac5-19e4-473e-a0ea-449ebf448d98">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c5ae1b587c4de3a0abc993e1f65329_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTUtMS0xLTc4MDQ5_aaf76506-a720-4815-a4d3-79e495484cc9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9aefa095e5f4dd99aff2909fbcde15c_I20221231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE2LTEtMS0xLTc4MDQ5_df44e749-0623-41c2-9129-520beca3af2f">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5723b60554294bebac94c904566db3f7_I20211231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE2LTMtMS0xLTc4MDQ5_2463371e-3149-457e-b589-7005d2c044e8">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98cc61d631e54bd68ab0e26a98a4905b_I20201231" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE2LTUtMS0xLTc4MDQ5_481679c7-3fdf-4fe0-93e2-8a808eb295d5">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54dc7a29f571431296c8be227f11aabb_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE5LTEtMS0xLTc4MDQ5_372fb501-132c-4b53-a47d-346c7d9ff3fb">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie94ead6cf6db4e7fae98eafe846f769d_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE5LTMtMS0xLTc4MDQ5_5b01bff9-3452-4d43-8140-deb7615ed5ad">552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9323e18f92640a2a7c38e4273db90ea_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE5LTUtMS0xLTc4MDQ5_b087f1b5-26ae-4341-bf47-09103a006484">551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax expense of $(<ix:nonFraction unitRef="usd" contextRef="ic3d3abd401b24655a17b8c74f5dd40a1_D20220101-20221231" decimals="-6" sign="-" name="elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MDQ0ZTRmMzUwYzIxNDJlYmFmN2VhMmUyYjA4NzQxYTVfNjE_a3cbb000-743a-4514-8c1f-cbbef08761ce">23</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="ibfbd0421f60f4e64bc47776a3602ab89_D20210101-20211231" decimals="-6" sign="-" name="elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MDQ0ZTRmMzUwYzIxNDJlYmFmN2VhMmUyYjA4NzQxYTVfNjU_3b4a206c-80d4-47b6-a5b5-c287f2c3eeb5">36</ix:nonFraction>), and $(<ix:nonFraction unitRef="usd" contextRef="i2395d6d373c34b2ebab39d8aba7606e9_D20200101-20201231" decimals="-6" sign="-" name="elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MDQ0ZTRmMzUwYzIxNDJlYmFmN2VhMmUyYjA4NzQxYTVfNzM_7226c077-1978-489d-b545-6f80b69def9e">2</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3d3abd401b24655a17b8c74f5dd40a1_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTEtMS0xLTc4MDQ5_98b15eff-9fba-46a8-856e-c043bead7a8f">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbd0421f60f4e64bc47776a3602ab89_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTMtMS0xLTc4MDQ5_f21cfc0b-b6a2-444d-bf6c-9b08e2a54e18">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2395d6d373c34b2ebab39d8aba7606e9_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTUtMS0xLTc4MDQ5_dca872b8-515b-48a0-af8e-5ee7d99e3d3a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fa38daf500d4a73ac08682fa99f7730_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIxLTEtMS0xLTc4MDQ5_8f914a07-0b50-422d-9797-cfdc3a35986e">499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54dc7a29f571431296c8be227f11aabb_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIxLTMtMS0xLTc4MDQ5_4a597979-1f7b-43ea-9bd5-e77079971fe9">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie94ead6cf6db4e7fae98eafe846f769d_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIxLTUtMS0xLTc4MDQ5_bb25a543-0195-4245-903a-17f7a937f1bf">552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a127625ab7b4d44a9d9ad36c6e50197_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI0LTEtMS0xLTc4MDQ5_8da9a375-81fe-486d-8725-1a367fc48969">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a1b61e2bc84caba4a714fd57739c74_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI0LTMtMS0xLTc4MDQ5_d8338b22-fbff-4e98-9141-6afdfa6c476f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd38742893d7416999e954ec984556f7_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI0LTUtMS0xLTc4MDQ5_96b9d8a5-adbe-4d6a-981f-867be281bd67">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax benefit (expense) of $<ix:nonFraction unitRef="usd" contextRef="i798cec4e64e04bffbeed267a216429e5_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk5Y2JjOTBmMjMyNDRmZWIwNGY1NTdhOTFhMjMyYjVfNzE_43c9d9c1-9257-4bc3-af5a-f6e103b4d914">6</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i7b77786d1b5c4248b0483a8990b79b0d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk5Y2JjOTBmMjMyNDRmZWIwNGY1NTdhOTFhMjMyYjVfNzU_2277b71b-3c19-4fd5-9732-825c6beb4a0b">2</ix:nonFraction>, and $(<ix:nonFraction unitRef="usd" contextRef="ie59f5a3300a74c28a300c63349dea8cc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk5Y2JjOTBmMjMyNDRmZWIwNGY1NTdhOTFhMjMyYjVfODM_c4390ee7-8873-49af-82de-54e1b2e08a7e">2</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i798cec4e64e04bffbeed267a216429e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTEtMS0xLTc4MDQ5_0568d349-9f14-4651-b775-224f4a09f5c4">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b77786d1b5c4248b0483a8990b79b0d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTMtMS0xLTc4MDQ5_90e248bf-65ec-4de7-9ee6-213628c7fcb9">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59f5a3300a74c28a300c63349dea8cc_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTUtMS0xLTc4MDQ5_0a3e8ada-9119-4e05-8be0-9232f93db5eb">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icae88b41165f46938384528eba3e864a_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI2LTEtMS0xLTc4MDQ5_bbe86c35-9283-450c-abfa-abccdf6334ac">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a127625ab7b4d44a9d9ad36c6e50197_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI2LTMtMS0xLTc4MDQ5_0df4b56c-2836-49cd-a93f-308d4e3ac6e0">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a1b61e2bc84caba4a714fd57739c74_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI2LTUtMS0xLTc4MDQ5_ba2b589f-01a4-48bb-9887-f95ae510beda">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI5LTEtMS0xLTc4MDQ5_34b9468a-e7a4-48dd-8585-5f414c31d72a">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI5LTMtMS0xLTc4MDQ5_8573615a-23b3-41fe-8fca-05d680d2a6f1">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI5LTUtMS0xLTc4MDQ5_a08702d6-2914-4d7a-a485-59a456d4841c">296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246OGIwNjJkYTllYzI3NDAxMjlkMTZlMGNjMmI2MTUzZTZfNzc_654e9691-563f-44b4-8789-68f2ad32dd2c">809</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246OGIwNjJkYTllYzI3NDAxMjlkMTZlMGNjMmI2MTUzZTZfODE_28a715d9-d02f-4609-a03a-3d9622fdc550">110</ix:nonFraction>, and $(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246OGIwNjJkYTllYzI3NDAxMjlkMTZlMGNjMmI2MTUzZTZfODk_34844967-85c2-4835-a3ce-7b718ff3877b">154</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTEtMS0xLTc4MDQ5_0186b639-cdf7-4011-ad43-3499d84e1146">2,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTMtMS0xLTc4MDQ5_1805500b-c3e8-469b-bd7f-798297b15062">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTUtMS0xLTc4MDQ5_676f239f-a8a9-40e8-b518-f66e0b93b6a1">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to noncontrolling interests, net of tax (expense) benefit of $(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZDg3MDE2NTVhNGJmNDRjMzk3NDNjMzMzN2E5ODlkMjZfOTk_4e71415f-436c-4cb0-86be-07ad56643203">3</ix:nonFraction>), $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZDg3MDE2NTVhNGJmNDRjMzk3NDNjMzMzN2E5ODlkMjZfMTAz_330c6525-29fc-4a1f-9258-1cf8b3cc13a1">1</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZDg3MDE2NTVhNGJmNDRjMzk3NDNjMzMzN2E5ODlkMjZfMTEx_8be13dcf-6bc7-482b-ac11-1e9a7370677d">0</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTEtMS0xLTc4MDQ5_0a03c7c5-f538-41bd-a9b1-aa37d9535dd6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTMtMS0xLTc4MDQ5_6cbbda5a-38cc-4a31-baf1-ca94124fd160">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTUtMS0xLTc4MDQ5_1361c9a0-9a21-494a-a6df-b18dad2b1fa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMyLTEtMS0xLTc4MDQ5_94b2a6ad-2cf8-4364-a89f-47edfe0eebb1">2,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMyLTMtMS0xLTc4MDQ5_9e76fcc1-8c36-4087-a101-074da5e07474">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMyLTUtMS0xLTc4MDQ5_17c40838-6d57-4298-a730-5ed8ac9344ca">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-129-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ReinsuranceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg5MA_4221a972-8116-45a2-932b-d8e6de9cc3a0" continuedAt="i5f414c13a81f4a449e069037f70292f8" escape="true">Reinsurance</ix:nonNumeric></span></div><ix:continuation id="i5f414c13a81f4a449e069037f70292f8"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations. </span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg3OQ_10fc3d4d-9fc2-4af8-83b4-05a8d0c14f8f" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzItMy0xLTEtNzgwNDk_7c94c14b-75ae-49c1-b865-3061fa00c347">128,867</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzItNy0xLTEtNzgwNDk_101d9c71-762b-42f4-b786-622e5fad440f">113,149</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzItMTEtMS0xLTc4MDQ5_84c642ea-b4cb-4e22-9df1-bfefd0a4ce17">100,832</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:AssumedPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzMtMy0xLTEtNzgwNDk_7b9ea8b8-1309-42d4-a89f-5a0225db3b09">4,426</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:AssumedPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzMtNy0xLTEtNzgwNDk_a85c368d-1138-4b36-85ca-8c9d55dccc08">4,298</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:AssumedPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzMtMTEtMS0xLTc4MDQ5_75de7dfa-17b2-4516-8b67-fc0e30928ebd">3,356</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzQtMy0xLTEtNzgwNDk_fbe70ee7-b50c-49c7-80c7-8c8b901bde2f">64</ix:nonFraction>)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzQtNy0xLTEtNzgwNDk_ef487987-f772-420f-b7e5-7247cc558f35">74</ix:nonFraction>)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzQtMTEtMS0xLTc4MDQ5_af665472-9214-4fb7-bd2f-d7e13ca3ec7d">79</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzUtMy0xLTEtNzgwNDk_09379301-2ebc-4b9b-8f1f-bddfa49c0382">133,229</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzUtNy0xLTEtNzgwNDk_28dc3dbf-a378-4859-900c-3237c6fa3813">117,373</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzUtMTEtMS0xLTc4MDQ5_6fd1cf53-eb39-4b6b-a13a-6d0f5753d650">104,109</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage&#8212;assumed to net premiums</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="3" name="us-gaap:PremiumsPercentageAssumedToNet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzYtMy0xLTEtNzgwNDk_dd6f33ef-358c-483d-b6b4-dea3d37d9caf">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="3" name="us-gaap:PremiumsPercentageAssumedToNet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzYtNy0xLTEtNzgwNDk_5126799e-db55-4d9b-8526-1fbec99e54f6">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="3" name="us-gaap:PremiumsPercentageAssumedToNet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzYtMTEtMS0xLTc4MDQ5_c8d9b028-83d3-4f14-9a07-6879991b32c7">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between written premiums and earned premiums is immaterial in each of the years presented above.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg2OQ_2cb0f629-2c42-4f7a-a1c7-bbc89f84e63f" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net premiums earned by segment (see Note 20, &#8220;Segment Information&#8221;) for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzMtMy0xLTEtNzgwNDk_863df310-e348-4090-987f-acda10ebbd77">35,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzMtNy0xLTEtNzgwNDk_d68b9cdc-e0ab-4a83-8794-0b83487fa27f">33,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzMtMTEtMS0xLTc4MDQ5_721c956b-1fd1-4ef1-9537-2fa9adca090a">31,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzQtMy0xLTEtNzgwNDk_4139e70f-7ae3-443b-91fc-de5fc5ab8c69">96,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzQtNy0xLTEtNzgwNDk_1368e690-9a74-42ae-a53a-5eb0ab271721">82,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzQtMTEtMS0xLTc4MDQ5_c099c019-b249-4a5a-bd61-c51cf927dfe0">71,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzUtMy0xLTEtNzgwNDk_0a446c04-866e-4a06-bde1-a8663f1884ea">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzUtNy0xLTEtNzgwNDk_fd476412-b9d8-4031-ab60-47764a3d6122">1,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzUtMTEtMS0xLTk5NDI1_027bbd2a-e685-4c5e-b77b-a412ef847074">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzYtMy0xLTEtNzgwNDk_c6f06ebb-d6e8-4a2f-9a46-132677a83b34">133,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzYtNy0xLTEtNzgwNDk_530c91f4-84f1-4271-a151-4979e4f50abc">117,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzYtMTEtMS0xLTc4MDQ5_dff39eab-9b35-42e3-a0f9-05e6d0873b74">104,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg3NA_89c4d7b2-7924-4604-8c24-7ad45a6e00ae" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of reinsurance on benefit expense for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzEtMS0xLTEtNzgwNDk_b5a2b717-a58b-49b5-9bf5-8e12007978c6">112,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzEtMy0xLTEtNzgwNDk_68606945-8db3-42f0-90df-0d4f30d71a9e">99,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzEtNS0xLTEtNzgwNDk_3ff837d0-2c5c-4b99-839e-5bbe1a0662fd">85,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzItMS0xLTEtNzgwNDk_a402a3e6-5644-405f-9da0-30b8c6b6b4e8">3,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzItMy0xLTEtNzgwNDk_43e6522d-cadb-4989-90c9-577726f22e50">3,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzItNS0xLTEtNzgwNDk_98ad4ba1-a4ce-40f1-93be-16994c0c127d">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzMtMS0xLTEtNzgwNDk_cb755582-5650-4e13-be68-69dc38f6fff0">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzMtMy0xLTEtNzgwNDk_24ed302a-6275-4816-a087-d28a0536085d">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzMtNS0xLTEtNzgwNDk_03b5a9ee-bdab-463d-99e5-ce5f9519b6bf">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzQtMS0xLTEtNzgwNDk_27abe6b7-bd32-40c3-9474-57a83fbda1b9">116,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzQtMy0xLTEtNzgwNDk_90fdf3a1-63a2-4adb-8a8f-1b12ab31b175">102,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzQtNS0xLTEtNzgwNDk_2ef4ad69-ae9e-4983-9feb-5a88550f8824">88,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_163"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0Xzc1Ng_6b2ce160-9cc5-4064-8351-66dfe360cf7f" continuedAt="i88f4ca4900694e3fb9139da3e51ceeb3" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i88f4ca4900694e3fb9139da3e51ceeb3" continuedAt="ibea4565fb2ca42abb512b023bdaa9c7d"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of <ix:nonNumeric contextRef="ib99d2d66da9844cab49602099b561dda_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzE2MQ_c65e011a-8598-4e37-bfd1-5bcad72e8216">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="i725fb0d8346e4b058763cea8f52dbda8_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzE3Mg_ca14260d-676b-4b30-9207-b244615b0cb0">12</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:LesseeOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0Xzc1NA_a8b0cc16-4369-422d-8b67-87ae4fab2f6a" continuedAt="i07b3bd493c4e473089d8876ce6f08040" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMy0xLTEtNzgwNDk_ebae1bba-829c-4ba1-a7d4-e416770899bd">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItNS0xLTEtNzgwNDk_eb4d6238-0671-42f7-bb4d-dbd43dc6f188">628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMy0xLTEtNzgwNDk_d27df54f-36be-4a38-a0f1-7c126f4c240e">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtNS0xLTEtNzgwNDk_ecc5c66b-7cbd-4cc6-9d76-34687bfad76f">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMy0xLTEtNzgwNDk_b645d2dc-99d8-4e3e-8746-b60dc26a9306">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtNS0xLTEtNzgwNDk_5d00ea20-642f-4173-9574-42608de1fcbc">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-130-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ibea4565fb2ca42abb512b023bdaa9c7d"><ix:continuation id="i07b3bd493c4e473089d8876ce6f08040"><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzMtMS0xLTEtNzgwNDk_120d11b9-382d-4bf6-ae3e-d4d87805a8df">143</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzMtMy0xLTEtNzgwNDk_6d24b40c-6d05-404e-810e-0d321c20ea07">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzMtNS0xLTEtNzgwNDk_ab4f4375-fe2b-4507-86b2-f536c690baab">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="elv:ShortTermAndVariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzQtMS0xLTEtNzgwNDk_664de9c8-63dc-40a2-9b09-d3f2845c35ba">35</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:ShortTermAndVariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzQtMy0xLTEtNzgwNDk_d63718aa-0245-4a25-b2c5-40c4bbf5bd91">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:ShortTermAndVariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzQtNS0xLTEtNzgwNDk_77cb5ebb-4a16-4ce4-8d7e-418e1472a015">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzUtMS0xLTEtNzgwNDk_5b875840-7c5f-4fd0-9406-097952b68b71">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzUtMy0xLTEtNzgwNDk_ac7e4b08-fb1b-4aa3-be09-06d688e26592">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzUtNS0xLTEtNzgwNDk_eea93d07-c769-4d2f-b10b-e9d32de14558">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzYtMS0xLTEtNzgwNDk_c6fd65bd-5f98-480d-8f26-1ef8231353f0">175</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzYtMy0xLTEtNzgwNDk_e6a79080-b99b-4935-9b30-2ec9c6efe254">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzYtNS0xLTEtNzgwNDk_6631da6d-de9c-4ace-8d9c-35ed55f6d3a0">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities as disclosed in Note 4, &#8220;Business Optimization Initiatives,&#8221; include reducing our office space footprint. As a result, we performed an interim impairment test during the years ended December 31, 2022, 2021 and 2020, and recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzQ4MQ_29a449ae-38ec-433c-98ec-36598d8b59bd">34</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzQ4OA_426b584b-d329-4415-b3c0-c88121d8ad5c">136</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzU0OTc1NTgxNTE2Mw_165c0521-e727-4395-928d-4feddd67d809">258</ix:nonFraction>, respectively, for impairment and abandonment of ROU assets which are included in the operating lease expense shown above.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.828%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzktNC0xLTEtNzgwNDk_895b5412-987e-43f7-8c6d-68712ba12d1c">204</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzktNi0xLTEtNzgwNDk_ee38f6b3-585f-49f1-b344-1ae72ecea485">198</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new lease liabilities, operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEwLTQtMS0xLTc4MDQ5_6847508a-4ee9-4126-b82a-781a74a35057">113</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEwLTYtMS0xLTc4MDQ5_97b1e3a6-729c-4f12-99bd-b367027dacfe">334</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years, operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzExLTQtMS0xLTc4MDQ5_0b262f5a-4a7c-4e04-bc37-864372078666">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzExLTYtMS0xLTc4MDQ5_1d0399c9-fe0b-4317-beb0-368b05abf512">7</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate, operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEyLTQtMS0xLTc4MDQ5_837b0e3c-db8a-43bd-bd0b-b2233b10843c">2.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEyLTYtMS0xLTc4MDQ5_170b36d7-0ea2-4f81-94d6-45f183420498">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0Xzc2MQ_ec2f0667-271d-47ee-8205-5f703c1d8614" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzAtMS0xLTEtNzgwNDk_9c9d76f1-e079-4acd-8de7-594a60ce7e2e">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzEtMS0xLTEtNzgwNDk_5f6155ba-81f2-4397-924b-f1248ba66b34">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzItMS0xLTEtNzgwNDk_b872d705-cc0a-4ad4-9781-944deb5e850c">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzMtMS0xLTEtNzgwNDk_9807ec2e-abd3-4407-a66b-022ee1492aa3">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzQtMS0xLTEtNzgwNDk_41025ef3-f6d3-40bd-b68b-f0360bfcc190">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzUtMS0xLTEtNzgwNDk_d4660815-8ad8-41eb-a618-f447eb74ec65">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzYtMS0xLTEtNzgwNDk_d6f766f1-1737-4f50-adbf-971da10a65c3">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzctMS0xLTEtNzgwNDk_20f3b50b-5a3e-4568-aec6-c6cfe3cfd1c1">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzgtMS0xLTEtNzgwNDk_fdaa713e-2de7-408f-bcd6-dfe946ff090d">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_169"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzExNTU_539047eb-6927-4b7b-8ff7-e2c84e06f983" continuedAt="i50b8bafd7125448f817ca5e980837edf" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="i50b8bafd7125448f817ca5e980837edf" continuedAt="i7b22447f3a7e4110880ee12cc4ef9a73"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzExNTM_e5009956-e3a9-42c7-ae8c-9fd80e40c954" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share at December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share&#8212;weighted-average shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzEtMS0xLTEtNzgwNDk_6963b292-54b1-436c-9189-e49e636118c7">240.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzEtMy0xLTEtNzgwNDk_a2fe7380-31d0-41fb-870a-d803101a78a9">243.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzEtNS0xLTEtNzgwNDk_45badf0c-871c-4b76-922a-4faeb6afdc1a">250.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities&#8212;employee stock options, non-vested restricted stock awards, convertible debentures and equity units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzItMS0xLTEtNzgwNDk_83945b49-f863-4d0a-83b3-caef8ef0cf42">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzItMy0xLTEtNzgwNDk_e84155ec-c89d-47e6-b0ff-b74ab4df24c1">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzItNS0xLTEtNzgwNDk_9892c961-6d4f-40af-b18f-19baf7be71ca">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzMtMS0xLTEtNzgwNDk_d15e0535-8af0-46c4-ad45-4e9baf25f5ef">242.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzMtMy0xLTEtNzgwNDk_e47d1d53-bcaf-4eff-9376-0ce01330ac38">246.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzMtNS0xLTEtNzgwNDk_a4625123-23fd-4ed9-916e-3464a0e68399">254.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, weighted-average shares related to certain stock options of <ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzIxNw_e1553f7a-9a35-4a1a-a52e-47ae72c6d7d8">0.4</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzIyMQ_25af7688-275a-4602-a2b3-f3240f09513e">0.2</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzIyOA_75875530-e21b-4cc8-a66f-c6f5394a135c">1.2</ix:nonFraction>, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-131-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b22447f3a7e4110880ee12cc4ef9a73">During the years ended December&#160;31, 2022, 2021 and 2020, we issued approximately <ix:nonFraction unitRef="shares" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-5" name="elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzQyMQ_491ca741-3d05-4a2b-99bc-10dbc7a5c840">0.2</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-5" name="elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzQyNQ_beb4a4ae-2d1b-4565-9391-2b89eb4db8e2">0.3</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-5" name="elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzQzMg_3a8bd0c6-2a79-4ae6-8f49-6d76f049cb54">0.3</ix:nonFraction> restricted stock units, respectively, of which vesting was contingent upon us meeting certain earnings targets. Contingent restricted stock units are excluded from the denominator for diluted earnings per share and are included only if and when the contingency is met. The 2022 contingent restricted stock units are being measured over the three year period of 2022 through 2024, the 2021 contingent restricted stock units are being measured over the three year period of 2021 through 2023 and the 2020 contingent restricted stock units are being measured over the three year period of 2020 through 2022. Contingent restricted stock units generally vest in March of the year following each measurement period.</ix:continuation></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_172"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2NDg_087134a4-41cc-4520-ac7d-be9e82aed4f9" continuedAt="if0ea587a4a3341d083505282795d20bf" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="if0ea587a4a3341d083505282795d20bf" continuedAt="if5c0aec2c7ec497481d031629818829d"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2022, we managed and presented our operations through <ix:nonFraction unitRef="segment" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzE5OA_427e6733-5a2b-49d3-a4db-a8ac9a608dec">four</ix:nonFraction> reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Commercial &amp; Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members. The Commercial &amp; Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services (&#8220;NGS&#8221;) and services provided to the federal government in connection with the FEHB business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CarelonRx segment includes our PBM business. CarelonRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other segment includes our Diversified Business Group, now known as Carelon Services, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 &#8220;Organization&#8221;, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. As we continue our journey to evolve our business from a traditional health insurance company into a lifetime, trusted health partner, we are evaluating and making changes to how we manage our business. This included a review of the products in each of our operating segments, which resulted in restructurings between some of our operating segments. Therefore, our reportable segment presentation in 2023 and its composition will reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources on January 1, 2023. As a result of these changes, beginning with our Quarterly Report on Form 10-Q for the first quarter of 2023, we will report our results in the following four reportable segments: (i) Health Benefits, which will combine our existing Commercial &amp; Specialty Business and Government Business segments; (ii) our existing CarelonRx segment; (iii) Carelon Services (our former Diversified Business Group), which will be carved out from our existing Other segment; and (iv) Corporate and Other, which will include businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments. We expect to reclassify previously reported information to conform to the new presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefit and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, as well as certain back-office services provided by our international businesses, and are recorded at cost or management&#8217;s estimate of fair market value. These affiliated revenues are eliminated in consolidation. For segment reporting, we present all capitation risk arrangements on a gross basis; therefore, eliminations also include adjustments for capitated risk arrangements that are recognized on a net basis under GAAP.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-132-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="if5c0aec2c7ec497481d031629818829d" continuedAt="ic05b7a50ffc34e84a7f9540347fb81ad"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our participation in various federal government programs, we generated approximately <ix:nonFraction unitRef="number" contextRef="iae176fbb87f54bac94b2e4ab0685d43a_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzI2ODk_a472107b-3439-4fab-8828-8a01a6345e8a"><ix:nonFraction unitRef="number" contextRef="i98132071c63744ada30c2775fc5af988_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzI2ODk_d775a868-0927-4e06-94fd-6a3a200c7c67"><ix:nonFraction unitRef="number" contextRef="ie55d196caf5f45cfb07e66b8da2097ef_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzI2ODk_dcb7b671-105d-443f-8c86-d2855a68e661">28</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of our total consolidated revenues from agencies of the U.S. government for each of the years ended December&#160;31, 2022, 2021, and 2020. The majority of these revenues are contained in our Government Business segment. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, &#8220;Basis of Presentation and Significant Accounting Policies,&#8221; except that all capitation risk arrangements are reported on a gross basis with an adjustment included in eliminations for capitated risk arrangements that are presented on a net basis under GAAP. We evaluate performance of the reportable segments based on operating gain or loss as defined above. We evaluate net investment income, net gains (losses) on financial instruments, interest expense, amortization expense, gain or loss on extinguishment of debt, income taxes and assets and liabilities on a consolidated basis, as these items are managed in a corporate shared service environment and are not the responsibility of segment operating management.</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2NDU_56b99a33-08d7-4ec1-b71f-fd1dd6bb3de6" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItMS0xLTEtNzgwNDk_7dd12231-1027-4b06-a9c7-3ae68268f6b8">41,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItMy0xLTEtNzgwNDk_540d5daa-d3c2-4450-b29e-04e23717f26e">96,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df81813ee544edea31e2c74936bff4e_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItNS0xLTEtNzgwNDk_ed369766-115a-4049-8d76-0a6794f69efb">14,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ba170c8f794d3bb4ca06d264b4e57d_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItNy0xLTEtNzgwNDk_8b021c5b-7259-4b86-a6fb-0edb23f3c994">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItMTEtMS0xLTc4MDQ5_650ad62b-05ff-4bb7-8184-039d8473bc97">155,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d0c0663315405099698864eb3c19b8_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzMtNS0xLTEtNzgwNDk_ea287991-7a82-442e-b2a0-4d199eb0e1c1">13,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2baaad3463642b18170d3f49e7ddc87_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzMtNy0xLTEtNzgwNDk_0220e042-e083-4122-8092-03c2d57528e4">11,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8429825b5f7e40ca8d6e68d3bb26eab2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzMtOS0xLTEtNzgwNDk_9b789887-88c0-45fc-b463-d4ef5c53c6dd">24,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtMS0xLTEtNzgwNDk_55a70c3b-461d-4135-8292-015c345c635f">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtMy0xLTEtNzgwNDk_ed8218bf-be6f-4dbe-8df8-03400ec6ceb7">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtNS0xLTEtNzgwNDk_015c08b9-678d-4712-ab19-aef72dcd8b3a">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtNy0xLTEtNzgwNDk_6e53e340-7ac9-4e91-8d0a-cc81be9bd6e8">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtMTEtMS0xLTc4MDQ5_d55bd377-7558-43d0-9872-ad2d9a502cf6">8,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtMS0xLTEtNzgwNDk_0074785e-57af-4aa3-b6f0-3560804a1cf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtMy0xLTEtNzgwNDk_e84d1d42-bcb0-4ab9-9650-4c084ea02f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtNy0xLTEtNzgwNDk_e82794e7-807c-4a58-99d0-ae28ed206c78">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtMTEtMS0xLTc4MDQ5_b937f77b-fdb9-4003-a7bf-30561eb49a9d">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctMS0xLTEtNzgwNDk_a5b1e7d0-e8c2-4aca-a799-d051c5eca60f">38,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctMy0xLTEtNzgwNDk_0d4d3c16-ed46-4007-92d8-0d98f08dbe32">82,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7278c60e164f14b96b13c3df65ba4e_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctNS0xLTEtNzgwNDk_a85ee116-531e-47c2-b526-b476f99de0d7">12,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f05b417fd04be8a1aeab8299b5c69e_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctNy0xLTEtNzgwNDk_02e34cac-2c92-4bef-9cdd-389c482cbcd4">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctMTEtMS0xLTc4MDQ5_a1057ae1-24b7-4251-a881-494bc26a7e2b">136,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10db0a695d24e41bdf7833886001b71_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzgtNS0xLTEtNzgwNDk_438b6e34-4c58-46fd-aa9d-a8d147d93f98">12,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c8e72dc40f4442b092502acb15a96c_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzgtNy0xLTEtNzgwNDk_7bb9968c-1fd3-4eb3-a873-4b27299a3369">7,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie412ebaf29714d329b7b8b83c7ba69e6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzgtOS0xLTEtNzgwNDk_0cf1a3a7-10dc-4444-aad1-ef574be042eb">20,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktMS0xLTEtNzgwNDk_6c9db1cb-0b54-47dc-bd27-813533af88e5">2,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktMy0xLTEtNzgwNDk_8659876e-aba7-4b22-9a33-8786a1bf5024">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktNS0xLTEtNzgwNDk_5ab327ac-6d6c-4153-bfdd-3e8a2973d26b">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktNy0xLTEtNzgwNDk_b69acc76-1f6b-45a2-a392-6e93a6f4beb0">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktMTEtMS0xLTc4MDQ5_b06704cb-720e-4b80-975e-dc31b7ac2fe0">7,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTEtMS0xLTc4MDQ5_7287fe46-3052-4c6c-83e7-f4437368489e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTMtMS0xLTc4MDQ5_65e3f5ad-f737-42df-90d9-4496a406670b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTctMS0xLTc4MDQ5_697eda43-0440-4be5-9dc5-136297fad803">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTExLTEtMS03ODA0OQ_2536644e-1ff8-42ba-b4f9-7b9df01f1e96">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTEtMS0xLTc4MDQ5_fdc0fe1e-f6f5-4e68-adff-7f97f2f8e014">36,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTMtMS0xLTc4MDQ5_04081aad-d25b-4711-a006-58b7e04bfb6a">71,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bef8962735044b1acb083bc20e63486_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTUtMS0xLTc4MDQ5_3a43f377-870d-4f33-9fb1-c05399c81c03">10,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icece7f971bda47f8bc76865f9659c5da_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTctMS0xLTc4MDQ5_bf84cafe-13c8-4ebe-82e9-e95c96872572">2,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTExLTEtMS03ODA0OQ_9ce61c24-bae9-43af-baa1-295f0a26b61f">120,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebc5e9f4d1042a38e45cd00bce22554_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEzLTUtMS0xLTc4MDQ5_da8d61ab-9076-47d5-ae66-b573b351ac2d">11,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf4cd355c6dc4109bc5041d9057f2121_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEzLTctMS0xLTc4MDQ5_4a47c83d-4a0f-4b60-bd7d-80e12e84b3f8">3,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb0d2a7152494f90b39b3fac5d9264ee_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEzLTktMS0xLTc4MDQ5_4ab46098-5332-4984-8bcc-496ab71b8b0b">15,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTEtMS0xLTc4MDQ5_bd4440c7-1337-420e-9ecc-c142b8170f89">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTMtMS0xLTc4MDQ5_96906e30-d40e-48ab-a2ba-dab80d4442c9">2,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d0aff55fa54fd2a9a2a30c2e6c6a2d_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTUtMS0xLTc4MDQ5_c67c7203-67a6-48c0-b483-4a7db111dcfe">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTctMS0xLTc4MDQ5_7db57a3d-f9df-4989-a63e-c1aa19f88937">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTExLTEtMS03ODA0OQ_47c27323-a518-4221-ae9c-0b2b908ff1eb">6,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTEtMS0xLTc4MDQ5_f29be88f-570d-4e8b-aa31-f9fba157be09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTMtMS0xLTc4MDQ5_b783b49e-5059-4a75-8663-83038e6dd786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTctMS0xLTc4MDQ5_b7d7d9cf-1620-4b87-8c6c-c9027b2240a5">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTExLTEtMS03ODA0OQ_b40e3104-ffe7-432f-be8e-9d1447d8dfe8">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-133-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ic05b7a50ffc34e84a7f9540347fb81ad" continuedAt="ieb2b4359bebe44d6bedcaa371ad07e06"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:MajorProductRevenueBySegmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2Mzc_695bf6bc-cf17-42b7-922b-b82b1de363f4" continuedAt="id5a94c7e7eb94d6ab6e1b1944b843bb8" escape="true">The major product revenues for each of the reportable segments for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="id5a94c7e7eb94d6ab6e1b1944b843bb8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c68969e3f114ff69c401be9bc37c2dd_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzItMS0xLTEtNzgwNDk_dfd55185-931d-4617-8664-62f3d17152d5">33,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e22951986404675bbf5fbfa2839786c_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzItMy0xLTEtNzgwNDk_f35e82b3-a657-4964-b94b-b53cb234d13c">31,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894b5d431a7047808e5ff7ebf443d016_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzItNS0xLTEtNzgwNDk_7c68141c-338a-40db-a88f-9d6fa64e95bd">29,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f62da538ba41f789a6a73b38e537d8_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzMtMS0xLTEtNzgwNDk_b034efc7-b5b9-485a-b2f3-fec040344a60">6,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123ffb166421487082a09f78c1725ebc_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzMtMy0xLTEtNzgwNDk_aa17f82a-3ec5-4fa9-8d24-b4e05252c28f">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6364bd9ed8464178afda9d8855f8538c_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzMtNS0xLTEtNzgwNDk_fed709b1-ef17-4ee7-a79b-926107ffc1d6">5,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental/Vision products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8365100e5c9406a9883eb34ce369cba_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzQtMS0xLTEtNzgwNDk_9dac0144-94a6-46e4-8d13-557b0d8fda50">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1ac17248d75456fb25896b8926586fa_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzQtMy0xLTEtNzgwNDk_9b843fc9-b099-4b9e-ab25-f62990150ed6">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e94cb6360045ddb9b224a2f973d9d6_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzQtNS0xLTEtNzgwNDk_05a41624-1cef-4cc3-a36d-4c8f47026c37">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efe3527b82f45b4924c08cd2aeadf1f_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzUtMS0xLTEtNzgwNDk_8fdf5cd7-7240-46cc-8948-c893630580f9">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cca4acaaa048e6904800f45ff39923_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzUtMy0xLTEtNzgwNDk_43d11e09-0aa8-4c09-aa8c-a87a890036db">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735ef38ab9e648319f8e6b267c9164a1_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzUtNS0xLTEtNzgwNDk_0a3de084-7f04-4ca7-9f7f-9583867d3c4e">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Commercial &amp; Specialty Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzYtMS0xLTEtNzgwNDk_baa8af4b-746f-48ce-9936-06dc4e6aa152">41,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzYtMy0xLTEtNzgwNDk_5b368fa6-5cd7-4847-9d85-f0684e521af9">38,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzYtNS0xLTEtNzgwNDk_aaf96542-f695-4443-8b39-9ce12983a706">36,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157a3ffc8b8454a9197a5de365fbaf8_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzgtMS0xLTEtNzgwNDk_05291b1a-44a3-458d-bbcb-9d46615d0840">96,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162dcb32162845ee8019a58aa859ae61_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzgtMy0xLTEtNzgwNDk_fcc9d87e-eabd-40cf-9cf7-1e96854e4df7">82,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647d737a8abe4da3b8caeb6484d9b75d_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzgtNS0xLTEtNzgwNDk_6a48846b-f979-4d28-b92b-ba1ce4d0911c">71,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42d0d2379bd40ba99bb0908ac993e6e_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzktMS0xLTEtNzgwNDk_8f6e311c-b40a-4c7b-af1f-a4fc3e0abf46">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c132f1b799e4a88b13c0fa30393e947_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzktMy0xLTEtNzgwNDk_24e24071-26d5-418b-83a7-985078668a5a">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79df8d34415c4640aa3a9d6958c599d3_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzktNS0xLTEtNzgwNDk_7e2d90e8-0792-4ab7-a6c1-b52dc4f03b63">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Government Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEwLTEtMS0xLTc4MDQ5_134f40ff-a350-4b5d-9096-e281a9b8727e">96,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEwLTMtMS0xLTc4MDQ5_06075331-1a17-48ab-9dc7-d8c76440ec92">82,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEwLTUtMS0xLTc4MDQ5_db3019e8-c96d-4533-9541-e0c12fb0dd3b">71,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abac369da1f4652a7813e0cd7aa350f_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEyLTEtMS0xLTc4MDQ5_c1308715-420d-44bc-89cf-06ec0ff02496">28,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9d4685e2e749a2bc8254783454a3a6_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEyLTMtMS0xLTc4MDQ5_f5f47953-e8f0-447a-8005-ad82b664b66f">25,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd36a7c95104275aee23983a5df35b0_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEyLTUtMS0xLTc4MDQ5_6666ce66-fd0d-4d5e-abb0-189bbab21e20">21,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated health services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0dd4f771c744f2831d7f9d4dc1c0a0_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE0LTEtMS0xLTc4MDQ5_1e758510-2a1f-4e90-bfe1-39780310d759">12,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458aaaae8b4c42abaaad6c6a529cf94d_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE0LTMtMS0xLTc4MDQ5_c3290f91-a656-4162-af5e-60748e35314a">9,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f95fe1cae3741118461bf71f33280c7_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE0LTUtMS0xLTc4MDQ5_cbcedb17-ae36-4e2b-92fd-828019a92366">5,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096ee1cf57a8446eadfaff116cd44804_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE1LTEtMS0xLTc4MDQ5_f55fa17d-07a0-4097-8542-22794a42df7a">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0624a80296bd435499ecbb5c951564b4_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE1LTMtMS0xLTc4MDQ5_42e1b4f2-9f58-43b0-b606-a4b0d73c956c">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18cf6ebd6bf46c08192134b8ce7cfcf_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE1LTUtMS0xLTc4MDQ5_80287221-98a0-4886-a78d-1e041ccdec9b">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE2LTEtMS0xLTc4MDQ5_93cc4899-0da6-4589-8401-8573448d9718">13,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE2LTMtMS0xLTc4MDQ5_ea08d3ad-9b96-4ea0-a02d-a19f37dea335">10,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE2LTUtMS0xLTc4MDQ5_0086e7a1-32bb-4e03-ace7-d945295188cd">6,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8429825b5f7e40ca8d6e68d3bb26eab2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE4LTEtMS0xLTc4MDQ5_e6374c40-e4ee-4c28-8a45-22cf43429550">24,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie412ebaf29714d329b7b8b83c7ba69e6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE4LTMtMS0xLTc4MDQ5_bb121077-8f07-440f-ac61-6c77da0d71a6">20,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb0d2a7152494f90b39b3fac5d9264ee_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE4LTUtMS0xLTc4MDQ5_b96c6f6b-8acc-431d-8f5c-bbe4ee605440">15,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE5LTEtMS0xLTc4MDQ5_77c219e9-4cd3-49e3-af77-7e8888271d22">155,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE5LTMtMS0xLTc4MDQ5_020384b3-005b-45e6-8d04-3169ef337ef2">136,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE5LTUtMS0xLTc4MDQ5_e8423b9a-e5b5-4e20-8e14-b4742eb9c8be">120,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent fee-based product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such information.&#160;</span></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2NjM_28a6429d-140e-4d54-a57d-de7d12fd4cec" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments&#8217; operating revenue to the amounts of total revenues included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments&#8217; operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzEtMS0xLTEtNzgwNDk_667e6fdc-9467-484f-a310-0bdd3a92d241">155,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzEtMy0xLTEtNzgwNDk_e4a37b33-ef66-4b15-a199-9750871b8fca">136,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzEtNS0xLTEtNzgwNDk_673507bb-3cc3-4e61-ab98-1c641becf74d">120,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzItMS0xLTEtNzgwNDk_66590b24-e693-4272-a9b7-c58d95cda949">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzItMy0xLTEtNzgwNDk_abc2f26e-19fd-4189-bce4-2eb19b4205d6">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzItNS0xLTEtNzgwNDk_6c78ea20-e677-4c25-9982-ed3ad66e64c8">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzMtMS0xLTEtNzgwNDk_247354b7-7596-4bee-9128-6c58707b237b">550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzMtMy0xLTEtNzgwNDk_05cf7bd3-fe88-4853-8797-71ff126f823d">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzMtNS0xLTEtNzgwNDk_15ffdb2d-f5d7-4ce8-b4d7-d5fa0c8aeaf0">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzQtMS0xLTEtNzgwNDk_e8cd083e-3dd7-4255-8416-78293823e560">156,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzQtMy0xLTEtNzgwNDk_41ea4148-dd0b-4bf4-a8ef-dafbb757f37a">138,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzQtNS0xLTEtNzgwNDk_f5c44fa8-2a3c-4173-99a9-238b8a416b0e">121,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-134-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><ix:continuation id="ieb2b4359bebe44d6bedcaa371ad07e06"><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2Njc_01517a8a-daa3-4a58-bdd8-cf78c7d9bf11" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments&#8217; operating gain to income before income tax expense included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzEtMS0xLTEtNzgwNDk_b993ab26-3971-4641-b17c-dc9e57a7c7ef">7,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzEtMy0xLTEtNzgwNDk_fab24414-fe21-45de-8b3f-8d27bf430596">7,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzEtNS0xLTEtNzgwNDk_c0565c0f-8378-454f-981d-300668a6ccd6">6,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzItMS0xLTEtNzgwNDk_c88b4e6c-c17c-4ab8-ac17-d468ef410f00">1,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzItMy0xLTEtNzgwNDk_9c022bb6-7997-4976-8351-43a51ff7f468">1,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzItNS0xLTEtNzgwNDk_9b212078-c503-48e5-b275-07526f632fa6">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" sign="-" name="elv:NetLossesGainsOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzMtMS0xLTEtNzgwNDk_3341dd81-9c87-43b1-b479-06dd1a3e72ca">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="elv:NetLossesGainsOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzMtMy0xLTEtNzgwNDk_3e7f0f9f-6b76-4c01-9f12-b644d41b3e38">318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="elv:NetLossesGainsOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzMtNS0xLTEtNzgwNDk_4a95d98d-9d79-4536-a50d-0865b0d4be57">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzQtMS0xLTEtNzgwNDk_7134bf53-db1a-4d26-b800-d9e71bc1feae">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzQtMy0xLTEtNzgwNDk_322f2e21-a04c-4388-ab96-527ddfe77ee3">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzQtNS0xLTEtNzgwNDk_d60000b7-b421-4351-9984-f235416bac13">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzUtMS0xLTEtNzgwNDk_145b70c6-699a-456d-8e62-04674e39f8ee">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzUtMy0xLTEtNzgwNDk_30f4865b-1b36-456b-b1a8-54ad02893b26">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzUtNS0xLTEtNzgwNDk_dd8b3987-9949-406f-9b30-6c4a2d623ac2">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzYtMS0xLTEtNzgwNDk_362cf3cc-372d-427f-82f7-dcf06455b8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzYtMy0xLTEtNzgwNDk_b31469d0-a0f7-44a8-b322-4a6cd4f10f0e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzYtNS0xLTEtNzgwNDk_b6dcb42f-e3c2-47ee-a560-ca684775e69f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments&#8217; operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzctMS0xLTEtNzgwNDk_cab115b0-924f-4d73-aab8-c4c6eb437688">8,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzctMy0xLTEtNzgwNDk_4a6cc23b-76e1-49d3-ae00-e7a4afdf665b">7,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzctNS0xLTEtNzgwNDk_338ad13c-819b-4c1b-bb2e-dc28a8dea256">6,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_175"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzM0NQ_e24b6385-07f5-473a-8240-5c233aa4d051" continuedAt="i42d8e6bba0b84119949f7101a502b0fb" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42d8e6bba0b84119949f7101a502b0fb">We have an equity investment in APC Passe, LLC, which offers Medicaid products in Arkansas. During the years ended December&#160;31, 2022, 2021 and 2020, in the normal course of business, we assumed premiums of $<ix:nonFraction unitRef="usd" contextRef="i417b0315d1f946278154f230d44ba1b0_D20220101-20221231" decimals="-6" name="us-gaap:AssumedPremiumsWritten" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzIxOQ_ffa1bd52-b627-4dbd-8ac2-6ec651607319">501</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie3f82c8853704ae1861ff012a8a6a705_D20210101-20211231" decimals="-6" name="us-gaap:AssumedPremiumsWritten" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzIyNg_7fe6d220-d029-48dc-becf-3491de12a024">462</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4356376bd2bb4161b623b19b110ab07e_D20200101-20201231" decimals="-6" name="us-gaap:AssumedPremiumsWritten" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzU0OTc1NTgxNDMyMg_a8667b35-d680-4b7f-bc17-d2d72673d20f">446</ix:nonFraction>, respectively, from APC Passe, LLC, which is included in our total assumed premiums (see Note 17, &#8220;Reinsurance&#8221;).</ix:continuation></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_178"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22. <ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="elv:StatutoryInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzM2NTg_bca9fb24-3bc5-466b-9e8e-01e67d456aa9" continuedAt="i15c31c2bed954827ad6b0673529bd5df" escape="true">Statutory Information</ix:nonNumeric></span></div><ix:continuation id="i15c31c2bed954827ad6b0673529bd5df" continuedAt="i3708ab7451724db9b1bdc4b05e8b2e38"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance regulatory authorities, commonly referred to as statutory accounting, which vary in certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc., Beacon Health Options of California, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care (&#8220;DMHC&#8221;) and report their accounts in conformity with GAAP (these entities are collectively referred to as the &#8220;DMHC regulated entities&#8221;). Typical differences of GAAP reporting as compared to statutory reporting are the recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of Insurance Commissioners (&#8220;NAIC&#8221;) developed a codified version of the statutory accounting principles, designed to foster more consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set forth in a variety of publications of the NAIC as well as state laws, regulations and general administrative rules.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital (&#8220;RBC&#8221;) requirements. RBC is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied to certain financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December&#160;31, 2022 and 2021, all of our regulated subsidiaries exceeded the minimum applicable mandatory RBC requirements and/or capital and solvency requirements of their applicable governmental regulator. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI0NTQ_05d09f9d-c830-4559-b89b-4f978b8ea738">7,900</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2310c7de653445608cb615a91fde33b6_I20211231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI0NjE_31a19be9-8ac1-41ee-9c11-2ae40fd504e9">6,962</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively. The tangible net equity required for the DMHC regulated entities was approximately $<ix:nonFraction unitRef="usd" contextRef="i3b88a75959a3413fbf01add2bd34bcb8_I20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI1Nzg_5cdad3f0-9a21-4221-8fd4-619665532d1c">710</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i725512778bd442a6b242345331bb3a06_I20211231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI1ODU_f6348903-e506-4df0-8f8a-9db7e13709b5">690</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively. Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC regulated entities, was $<ix:nonFraction unitRef="usd" contextRef="id6bc2c55daf14d049cede53415aaef62_I20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI3OTc_06c29833-ccab-4ab3-b5fc-fef31fce7cec">19,048</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i18e88e0db7ff4756a456b1a7ffd88b77_I20211231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI4MDQ_8a4d6d0e-6aa1-4ac9-94a8-90ad3be2356a">16,178</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. GAAP equity of the DMHC regulated entities was $<ix:nonFraction unitRef="usd" contextRef="i5e6ef69580834645b272fe1032c1d97a_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI4ODI_87504fb7-418a-4d56-98a7-6c6ed43f803b">3,795</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia2684dcf65c140fca76ea400241c2590_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI4ODk_a145d455-09d8-47fb-b7f5-71a64cd0179f">3,886</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary&#8217;s domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC. During 2022, our insurance and HMO </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-135-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements (continued)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3708ab7451724db9b1bdc4b05e8b2e38">subsidiaries paid aggregate cash dividends of $<ix:nonFraction unitRef="usd" contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzM0NDQ_43eea4cf-962d-4c60-960b-2d76106923ca">3,097</ix:nonFraction> to the parent company, including cash dividends which required prior approval from regulatory authorities. We currently estimate that approximately $<ix:nonFraction unitRef="usd" contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231" decimals="-6" name="elv:EstimatedFutureDividendPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzM1OTU_8fec8c97-14e0-4744-97df-34fa1be03725">3,500</ix:nonFraction> of dividends will be paid to the parent company in 2023.</ix:continuation></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_181"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in or disagreements with our independent registered public accounting firm on accounting or financial disclosures.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_184"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carried out an evaluation as of December&#160;31, 2022, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, under the supervision and with the participation of the principal executive officer and principal financial officer, of Elevance Health, Inc. (the &#8220;Company&#8221;) is responsible for establishing and maintaining effective internal control over financial reporting (&#8220;Internal Control&#8221;), as such term is defined in the Exchange Act. The Company&#8217;s Internal Control is designed to provide reasonable assurance regarding the reliability of the Company&#8217;s financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. The Company&#8217;s Internal Control includes those policies and procedures that (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of inherent limitations in any Internal Control, no matter how well designed, misstatements due to error or fraud may occur and not be detected. Accordingly, even effective Internal Control can provide only reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, under the supervision and with the participation of the principal executive officer and principal financial officer, assessed the effectiveness of the Company&#8217;s Internal Control as of December&#160;31, 2022. Management&#8217;s assessment was based on criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on management&#8217;s assessment, management has concluded that the Company&#8217;s Internal Control was effective as of December&#160;31, 2022 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-136-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP, the Company&#8217;s independent registered public accounting firm, has audited the consolidated financial statements of the Company for the year ended December&#160;31, 2022, and has also issued an audit report dated February&#160;15, 2023, on the effectiveness of the Company&#8217;s Internal Control as of December&#160;31, 2022, which is included in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:47.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AIL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OUDREAUX</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALLINA</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the three months ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Elevance Health, Inc.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Elevance Health, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control&#8211;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Elevance Health, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Elevance Health, Inc. as of December&#160;31, 2022 and 2021, the related consolidated statements of income, comprehensive income, shareholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes and financial statement schedule listed in the Index at Item 15(c) and our report dated February&#160;15, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-137-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;text-indent:317.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;Ernst &amp; Young LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;15, 2023</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-138-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B. OTHER INFORMATION.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_190"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_193"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_196"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning our Executive Officers is included in Part I, Item 1, &#8220;Business - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information about our Executive Officers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; The information required by this Item concerning our Directors and nominees for Director, information about our Audit Committee members and financial expert(s), disclosure of any delinquent filers under Section&#160;16(a) of the Exchange Act and our Code of Conduct is incorporated herein by reference from our definitive Proxy Statement for our 2023 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_199"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11. EXECUTIVE COMPENSATION.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning remuneration of our Executive Officers and Directors, material transactions involving such Executive Officers and Directors and Compensation Committee interlocks, as well as the Compensation and Talent Committee Report and the CEO pay ratio are incorporated herein by reference from our definitive Proxy Statement for our 2023 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_202"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities authorized for issuance under our equity compensation plans as of December&#160;31, 2022 are as follows: </span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;securities&#160;to&#160;be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">issued upon exercise of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise price of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">outstanding&#160;options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">remaining&#160;available&#160;for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">future&#160;issuance&#160;under&#160;equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">compensation plans (excluding securities reflected in column (a))</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">4 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(c)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by shareholders as of December&#160;31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,621,939</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$293.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,352,576</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">We have no equity compensation plans pursuant to which awards may be granted in the future that have not been approved by shareholders.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Includes shares that may be issued under the Elevance Health Incentive Compensation Plan (formerly the Anthem Incentive Compensation Plan) and the 2017 Elevance Health Incentive Compensation Plan pursuant to the following outstanding awards: 2,831,989 stock options, 526,536 unvested restricted stock units, and 1,263,414 performance stock units (assuming that the outstanding performance stock units are earned at the maximum award level). </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Represents the weighted average exercise price of outstanding stock options. Does not take into consideration outstanding restricted stock units or performance stock units, which, once vested, may be converted into shares of our common stock on a one-for-one basis upon distribution at no additional cost.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Excludes securities reflected in the first column, &#8220;Number of securities to be issued upon exercise of outstanding options, warrants and rights&#8221;. Includes 14,026,920 shares of common stock available for issuance as stock options, restricted stock awards, performance stock awards, performance awards and stock appreciation rights under the 2017 Elevance Health Incentive Compensation Plan at December&#160;31, 2022. Includes 4,325,656 shares of common stock available for issuance under the Stock Purchase Plan at December&#160;31, 2022. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-139-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning the stock ownership of management and five percent beneficial owners is incorporated herein by reference from our definitive Proxy Statement for our 2023 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_205"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning certain relationships and related person transactions and Director independence is incorporated herein by reference from our definitive Proxy Statement for our 2023 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_208"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning principal accountant fees and services is incorporated herein by reference from our definitive Proxy Statement for our 2023 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-140-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_214"></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) 1.&#160;Financial Statements:</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statements of the Company are set forth in Part II, Item&#160;8:</span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021 </span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Income for the years ended December&#160;31, 2022, 2021, and 2020 </span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020 </span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Shareholders&#8217; Equity for the years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:9pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  2. Financial Statement Schedule:</span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statement schedule of the Company is included in Item&#160;15(c):</span></div><div style="margin-bottom:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule II&#8212;Condensed Financial Information of Registrant (Parent Company Only).</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are inapplicable, or the required information is included in the consolidated financial statements, and therefore, have been omitted.</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  3. Exhibits required to be filed as part of this report:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex31.htm">Amended and Restated Articles of Incorporation of the Company, as amended and restated effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex31.htm">June 27, 2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex31.htm"> incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex31.htm">June 28, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex32.htm">Bylaws of the Company, as amended effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex32.htm">June 28, 2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex32.htm"> incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex32.htm">3.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex32.htm"> to the Company&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522183957/d359422dex32.htm">June 28, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312504213329/dex41.htm">Indenture, dated as of December 9, 2004, between the Company and The Bank of New York Trust Company, N.A., as trustee, including the Form of the Company&#8217;s 5.950% Notes due 2034, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on December 15, 2004.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312506004785/dex41.htm">Indenture, dated as of January 10, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.), as trustee, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on January 11, 2006.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312506004785/dex44.htm">Form of 5.85% Notes due 2036, incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K filed on January 11, 2006.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312507132564/dex43.htm">Form of 6.375% Notes due 2037, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on June&#160;8, 2007.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312510187031/dex43.htm">Form of 5.800% Notes due 2040, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on August&#160;12, 2010.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312512215126/d347251dex43.htm">Form of 4.625% Notes due 2042, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on May&#160;7, 2012.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312512386056/d408375dex44.htm">Form of 3.300% Notes due 2023, incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K filed on September&#160;10, 2012.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-141-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312512386056/d408375dex45.htm">Form of 4.650% Notes due 2043, incorporated by reference to Exhibit 4.5 to the Company&#8217;s Current Report on Form 8-K filed on September&#160;10, 2012.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312513312857/d577328dex43.htm">Form of 5.100% Notes due 2044, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on July 31, 2013.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312514306698/d774115dex43.htm">Form of 3.500% Notes due 2024, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on August 12, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312514306698/d774115dex44.htm">Form of 4.650% Notes due 2044, incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K filed on August 12, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312514306698/d774115dex45.htm">Form of 4.850% Notes due 2054, incorporated by reference to Exhibit 4.5 to the Company&#8217;s Current Report on Form 8-K filed on August 12, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312512418691/d422012dex41.htm">Indenture dated as of October 9, 2012 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee, including the Form of the 2.750% Senior Convertible Debentures due 2042, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 9, 2012.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312515184154/d924472dex41.htm">Subordinated Indenture, dated as of May 12, 2015, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on May 12, 2015.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312517349359/d464820dex41.htm">Indenture dated as of November 21, 2017 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312517349359/d464820dex44.htm">Form of 3.350% Notes due 2024, incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2017.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312517349359/d464820dex45.htm">Form of 3.650% Notes due 2027, incorporated by reference to Exhibit 4.5 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2017. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312517349359/d464820dex46.htm">Form of 4.375% Notes due 2047, incorporated by reference to Exhibit 4.6 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2017. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312518068715/d510480dex41.htm">Form of 4.101% Notes due 2028, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 2, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312518068715/d510480dex42.htm">Form of 4.550% Notes due 2048, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on March 2, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312519240850/d756383dex41.htm">Form of 2.375% Notes due 2025, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on September 9, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312519240850/d756383dex42.htm">Form of 2.875% Notes due 2029, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on September 9, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312519240850/d756383dex43.htm">Form of 3.700% Notes due 2049, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on September 9, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312520133805/d926925dex42.htm">Form of 2.250% Notes due 2030, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on May 5, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312520133805/d926925dex43.htm">Form of 3.125% Notes due 2050, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on May 5, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312521084138/d160823dex41.htm">Form of 0.450% Notes due 2023, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 17, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312521084138/d160823dex42.htm">Form of 1.500% Notes due 2026, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on March 17, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-142-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312521084138/d160823dex43.htm">Form of 2.550% Notes due 2031, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on March 17, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312521084138/d160823dex44.htm">Form of 3.600% Notes due 2051, incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K filed on March 17, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522133790/d274466dex41.htm">Form of 4.100% Notes due 2032, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 29, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522133790/d274466dex42.htm">Form of 4.550% Notes due 2052, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on April 29, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(q)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522277914/d416104dex41.htm">Form of 5.350% Notes due 2025, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on November 4, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(r)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522277914/d416104dex42.htm">Form of 5.500% Notes due 2032, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on November 4, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522277914/d416104dex43.htm">Form of 6.100% Notes due 2052, incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on November 4, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(t)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex41.htm">Form of 4.900% Notes due 2026, incorporated by reference to Exhibit 4.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522277914/d416104dex43.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex41.htm">s Current Report on Form 8-K filed on February 8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex41.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex41.htm"> 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(u)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex42.htm">Form of 4.750% Notes due 2033, incorporated by reference to Exhibit 4.2 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522277914/d416104dex43.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex42.htm">s Current Report on Form 8-K filed on February 8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex42.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex42.htm"> 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex43.htm">Form of 5.125% Notes due 2053, incorporated by reference to Exhibit 4.3 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312522277914/d416104dex43.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex43.htm">s Current Report on Form 8-K filed on February 8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex43.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000119312523028419/d413102dex43.htm"> 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the request of the Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit47-20221231forform1.htm">Description of the Company&#8217;s Securities Registered Pursuant to Section 12 of the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-20221231forform.htm">Elevance Health Incentive Compensation Plan, as amended and restated effective June 28, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603915000006/exhibit102n-20150331.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2015, incorporated by reference to Exhibit 10.2(n) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603916000020/exhibit102m-20160331.htm">Form of Amendment, dated March 9, 2016, to Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2014, incorporated by reference to Exhibit 10.2(m) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603916000020/exhibit102p-20160331.htm">Form of Amendment, dated March 9, 2016, to Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2015, incorporated by reference to Exhibit 10.2(p) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603916000020/exhibit102s-20160331.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2016 and 2017, incorporated by reference to Exhibit 10.2(s) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm">2017 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm"> Incentive Compensation Plan, as amended and restated effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm">June 28, 2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm"> incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm">June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm"> 30, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit1022017elevanceheal.htm">2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603918000005/exhibit102d-2018033110qq12.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2018, incorporated by reference to Exhibit 10.2(d) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603918000010/exhibit102h-2018063010qq22.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement commencing July 2018, incorporated by reference to Exhibit 10.2(h) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-143-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603919000007/exhibit102l-201933110qq120.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2019, incorporated by reference to Exhibit 10.2(l) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603919000007/exhibit102m-201933110qq120.htm">Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2019, incorporated by reference to Exhibit 10.2(m) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603919000007/exhibit102n-201933110qq120.htm">Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2019, incorporated by reference to Exhibit 10.2(n) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603920000028/exhibit102l-2020331for.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2020, incorporated by reference to Exhibit 10.2(l) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603920000028/exhibit102m-2020331for.htm">Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2020, incorporated by reference to Exhibit 10.2(m) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603920000028/exhibit102n-2020331for.htm">Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2020, incorporated by reference to Exhibit 10.2(n) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603921000041/exhibit102manthem2021stock.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2021, incorporated by reference to Exhibit 10.2(m) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603921000041/exhibit102nanthem2021restr.htm">Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2021, incorporated by reference to Exhibit 10.2(n) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603921000041/exhibit102oanthem2021perfo.htm">Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2021, incorporated by reference to Exhibit 10.2(o) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit102l2022stockoption.htm">Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2022, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.2(l) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit102m2022restricteds.htm">Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2022, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.2(m) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit102n2022performance.htm">Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2022, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.2(n) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm"> Comprehensive Nonqualified Deferred Compensation Plan, as amended and restated effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm">June 28, 2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm"> incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm">June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm"> 30, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit103elevancehealthco.htm">2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm"> Executive Agreement Plan, as amended and restated effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm">June 28, 2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm"> incorporated by reference to Exhibit 10.4 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm">10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm"> for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm">quarter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm"> ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit104elevancehealthex.htm">June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm"> Executive Salary Continuation Plan, as amended and restated effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">June 28, 2022,  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">incorporated by reference to Exhibit 10.5 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm"> for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">quarter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm"> ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit105elevancehealthex.htm">June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm"> Directed Executive Compensation </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">Plan, as</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm"> amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">and restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">June 28, 2022,  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">incorporated by reference to Exhibit 10.6 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">Company&#8217;s Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm"> for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">quarter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm"> ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit106elevancehealthdi.htm">June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-144-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm"> Board of Directors Compensation Program, as amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">and restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">June 28, 2022,  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">incorporated by reference to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">Exhibit 10.7 to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit107elevancehealthbo.htm">2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm">Elevance Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm"> Board of Directors&#8217; Deferred Compensation Plan, as amended and restated effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm">June 28, 2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm"> incorporated by reference to Exhibit 10.8 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm">10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm"> for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm">quarter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm"> ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603922000081/exhibit108elevancehealthbo.htm">June 30, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312507224760/dex1041.htm">Form of Employment Agreement between the Company and each of the following: John E. Gallina, Peter D. Haytaian, and Gloria McCarthy, incorporated by reference to Exhibit A to Exhibit 10.41 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312517333500/d332795dex101.htm">Form of Employment Agreement between the Company and Gail Boudreaux, incorporated by reference to Exhibit A to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 6, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000115603918000010/exhibit109d-2018063010qq22.htm">Form of Employment Agreement between the Company and each of the following: Charles Morgan Kendrick, Felicia F. Norwood, and Blair W. Todt incorporated by reference to Exhibit 10.9(d) to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1156039/000119312517333500/d332795dex101.htm">Offer Letter, by and between the Company and Gail Boudreaux, dated as of November 5, 2017, incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 6, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1011-primarybluecro.htm">Blue Cross License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by the Member Plans through </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1011-primarybluecro.htm">June 16, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-primaryblueshi.htm">Blue Shield License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by the Member Plans through </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-primaryblueshi.htm">June 16, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-20221231forform1.htm">Subsidiaries of the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23-20221231forform1.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-20221231for10xk.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-20221231for10xk.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-20221231for10xk.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-20221231for10xk.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Elevance Health, Inc.&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Shareholders&#8217; Equity; (vi) the Notes to Consolidated Financial Statements and (vii) Financial Statement Schedule II. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contracts or compensatory plans or arrangements.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-145-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Exhibits</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this portion of Item&#160;15 is set forth in paragraph (a) 3 above.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Financial Statement Schedule</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule II&#8212;Condensed Financial Information of Registrant (Parent Company Only).</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_217"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16. FORM 10-K SUMMARY.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-146-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_220"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II&#8212;Condensed Financial Information of Registrant</span></div><div><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_223"></div><ix:nonNumeric contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90ZXh0cmVnaW9uOmY3ZGFiMDhkZmMwODRjOWFhNzZmNjdhMjA1Y2ZhNjNhXzkz_c127ff48-c1dd-46ef-9f4f-76dbe4905d9b" continuedAt="i403fcf7de72d4623b0838d0da0f22df2" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMtMS0xLTEtNzgwNDk_84fc048a-4700-4736-a7ef-b3df489fa486">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMtMy0xLTEtNzgwNDk_40318b02-a8f4-42b5-9f0a-49ee56e86a2e">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed maturity securities (amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV80OQ_78a55cfe-b80c-4c2a-838d-490d02f1d736">175</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV81Ng_1f9f947c-fa88-48f8-951f-124aee112306">512</ix:nonFraction>; allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV85MQ_91ecfc0f-aeee-40a9-bf67-fc47a11980a9">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV85OA_91bb9782-70c2-4391-88ec-d3e7b642aa8f">1</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMS0xLTEtNzgwNDk_4319b4cf-1611-461a-ae14-3d082179c054">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMy0xLTEtNzgwNDk_2d3c6a1b-a58b-4497-b88f-48897c636384">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzYtMS0xLTEtNzgwNDk_30f7e459-62df-4bdb-8a2d-2f955306c74d">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzYtMy0xLTEtNzgwNDk_d1745acf-7844-46af-9e80-3b4724ab510d">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:OtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzgtMS0xLTEtNzgwNDk_1fc8117c-527f-4031-8c4a-411a757a647a">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:OtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzgtMy0xLTEtNzgwNDk_3df58c39-06d4-4315-a1a1-e4aade4fbea5">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net due from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:DueFromAffiliateCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEwLTEtMS0xLTc4MDQ5_d7774184-24ec-42a3-a1ef-0ceb02685a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:DueFromAffiliateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEwLTMtMS0xLTc4MDQ5_5d65b4b2-9408-4ae2-8135-6d4b2d5ab4b9">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEyLTEtMS0xLTc4MDQ5_934aa494-30d0-4e3e-a348-692bcfd9958d">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEyLTMtMS0xLTc4MDQ5_d1e9ee69-d831-4c53-9ca9-1eec58874782">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEzLTEtMS0xLTc4MDQ5_ae519e3b-84c0-4c08-922c-441e468186bf">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEzLTMtMS0xLTc4MDQ5_145b27d1-c028-4f21-83dc-a6c995afcd99">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE0LTEtMS0xLTc4MDQ5_53bc1b82-f16a-479c-8c81-fa73eb2d7adc">783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE0LTMtMS0xLTc4MDQ5_e057629a-0e8e-4565-9154-51c1b760f401">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE1LTEtMS0xLTc4MDQ5_8ecc12c7-014e-4d04-92ff-72c3c506f5e1">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE1LTMtMS0xLTc4MDQ5_e6ddd7e5-ace4-4871-9f6f-8f69611edf07">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE2LTEtMS0xLTc4MDQ5_d9455eed-3c41-4455-b333-246354c4c19f">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE2LTMtMS0xLTc4MDQ5_1fd4175d-a0d2-41f7-8dcd-50603eb23bcc">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="elv:InvestmentInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE3LTEtMS0xLTc4MDQ5_5994147b-ac70-4f1d-99ea-e17086663b69">59,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="elv:InvestmentInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE3LTMtMS0xLTc4MDQ5_09df18a6-b6a4-4f33-8fac-893ceaa85832">56,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE4LTEtMS0xLTc4MDQ5_a8b544b9-358e-4c2d-bb84-580fd36c0563">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE4LTMtMS0xLTc4MDQ5_1b3563f4-53f8-48ce-b5da-63ea2de2b066">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE5LTEtMS0xLTc4MDQ5_111501f8-8b5c-46f5-a253-8f4cb68f8f56">62,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE5LTMtMS0xLTc4MDQ5_e6f35e98-cc5d-4fff-8d11-e9fdbdd2217f">60,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzIzLTEtMS0xLTc4MDQ5_4526bb76-22f7-4c58-8a7d-78f9751355c0">894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzIzLTMtMS0xLTc4MDQ5_254559f8-e02c-49d4-9b7e-53d05b83786c">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net due to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:DueToAffiliateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI3LTEtMS0xLTc4MDQ5_a42ea61a-7b99-487c-8df1-f1745212b9f0">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:DueToAffiliateCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI3LTMtMS0xLTc4MDQ5_a0fe0cd1-bf37-45ac-889f-21f69f976424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI4LTEtMS0xLTc4MDQ5_38286de2-07f3-47c5-a881-90c82ec749af">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI4LTMtMS0xLTc4MDQ5_2f603b0c-ae0c-40e1-9b85-3a429aede436">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI5LTEtMS0xLTc4MDQ5_747a840b-aa09-4e72-bb98-c9ee6631d60b">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI5LTMtMS0xLTc4MDQ5_10759fd5-1dfd-4ba6-ae5d-8a8f210bedb8">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMwLTEtMS0xLTc4MDQ5_e0cd912c-585d-44f9-a4e9-dccb538af4f5">3,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMwLTMtMS0xLTc4MDQ5_e8d835d5-531d-425f-92ff-e101784b3035">2,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMxLTEtMS0xLTc4MDQ5_23c9a5c3-6226-4ba9-ac2f-1ecd6c18a8e5">22,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMxLTMtMS0xLTc4MDQ5_e2ae2486-5a63-43cd-a8d6-f6ee6dc0395c">21,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMzLTEtMS0xLTc4MDQ5_5416a8a1-ac01-4c1b-b7ed-ca244d056760">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMzLTMtMS0xLTc4MDQ5_769a6fc9-c6f6-4aa7-addb-13b109bd77c4">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM0LTEtMS0xLTc4MDQ5_3a79cc1f-bf2b-4881-b13d-791652cac8b1">26,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM0LTMtMS0xLTc4MDQ5_53fa2ddd-7e96-4f53-9ef9-f296e503d47c">24,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies&#8212;Note 5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM1LTEtMS0xLTc4MDQ5_7e5f173d-399c-43eb-8a8f-6cd5eb26a88c"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM1LTMtMS0xLTc4MDQ5_35b9e2df-8068-4370-a832-1add9a28aa35"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, without par value, shares authorized - <ix:nonFraction unitRef="shares" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZmY0ZTc2NDliNGYxNThiNTE4YjY0MTg3NjMzZjBfNjA_752db9ab-5251-4a74-b41e-8d8016fd71cc">100,000,000</ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZmY0ZTc2NDliNGYxNThiNTE4YjY0MTg3NjMzZjBfOTY_5254485b-6e69-42f8-b123-460db6f787a6"><ix:nonFraction unitRef="shares" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZmY0ZTc2NDliNGYxNThiNTE4YjY0MTg3NjMzZjBfOTY_bfcda4c4-8d3b-488f-a4de-6e659d351c1e">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTEtMS0xLTc4MDQ5_d32cafa5-b5e4-4c14-91e5-5ac7a7aa0023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTMtMS0xLTc4MDQ5_1d1401dd-d81d-4010-9382-7424a7737911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfMjg_6a1c4e9f-70e6-4a2a-b287-10567ce306e3">0.01</ix:nonFraction>, shares authorized - <ix:nonFraction unitRef="shares" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfNTI_717958c4-c51f-49ca-b5dc-c57c8afe50c5">900,000,000</ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfODg_0f7998de-bf80-40eb-a204-7c7e909f1669"><ix:nonFraction unitRef="shares" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfODg_7cbd6e35-7cf1-4a2d-b4f6-832ec5976880">237,958,067</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfOTU_1c6e4b4f-1d7e-4c96-b634-efa337dfafad"><ix:nonFraction unitRef="shares" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfOTU_efa972a7-d858-4038-a280-c04b9fe2866c">241,770,746</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTEtMS0xLTc4MDQ5_dfb892b5-f778-41f2-b983-dc549227f863">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTMtMS0xLTc4MDQ5_cbbacac6-d2bb-4393-aa5a-32d5fdf95075">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM5LTEtMS0xLTc4MDQ5_68f8c1bd-a190-4e13-bdb2-e7fbe51cb270">9,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM5LTMtMS0xLTc4MDQ5_508b03de-680e-46ca-abba-ecea83843367">9,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQwLTEtMS0xLTc4MDQ5_430bf418-9453-446e-ae13-681266fe634b">29,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQwLTMtMS0xLTc4MDQ5_0672c176-51dd-4a31-9b03-3cbc6c1eb11f">27,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQxLTEtMS0xLTc4MDQ5_90a3cd05-1858-4d5b-b0cb-43def1483787">2,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQxLTMtMS0xLTc4MDQ5_dbd7cd10-37ce-4917-bae1-9f3da347075d">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQyLTEtMS0xLTc4MDQ5_48140eb7-7d69-4499-b991-7d0df94e0bec">36,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQyLTMtMS0xLTc4MDQ5_93e7a9c5-fd5f-4de4-9e75-8830a07a35b2">36,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQzLTEtMS0xLTc4MDQ5_cd6030cc-054f-4a32-8439-4c46e1c2527b">62,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQzLTMtMS0xLTc4MDQ5_ddc24b7a-cf02-423a-a4a0-cc765052a9c6">60,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-147-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_229"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i403fcf7de72d4623b0838d0da0f22df2" continuedAt="i3eeb723a5ba54a839b33d924a9dbcaf5"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Income</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzMtMS0xLTEtNzgwNDk_7d4e356b-e54c-41e3-8fe1-0e352da4ddac">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzMtMy0xLTEtNzgwNDk_0f4d09fa-ad5e-4cc8-b372-a5ecf23ca36b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzMtNS0xLTEtNzgwNDk_d664ef3c-5b02-423f-8d76-bdafe4b3a826">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzQtMS0xLTEtNzgwNDk_e9c5159f-4e20-4f7a-9ef9-702563935e88">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzQtMy0xLTEtNzgwNDk_5399d725-f83c-45e2-b39e-1c55d9b1a0a2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="elv:NetGainsLossesOnFinancialInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzQtNS0xLTEtNzgwNDk_cf10a472-84ed-4ca6-b198-e62c989b9985">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative fees and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:OtherIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzktMS0xLTEtNzgwNDk_10af238c-d9c8-4a22-b29b-0423632fd13f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:OtherIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzktMy0xLTEtNzgwNDk_af941034-e9aa-4d33-a16e-20d338c812b3">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzktNS0xLTEtNzgwNDk_bfff3a31-9ec6-430d-a9c3-6617100d6c8a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEwLTEtMS0xLTc4MDQ5_55cd6c05-c97b-4516-bc80-b72bf48da3c0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEwLTMtMS0xLTc4MDQ5_eda902b1-e7ac-4639-a377-768dd3ecb425">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEwLTUtMS0xLTc4MDQ5_a76d8bbc-94dc-473f-a0c6-3778b3a74971">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEyLTEtMS0xLTc4MDQ5_6b87455a-abe2-42b1-8885-c02c352096f0">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEyLTMtMS0xLTc4MDQ5_28c1045d-9338-4519-a3c4-76dcb98d4075">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEyLTUtMS0xLTc4MDQ5_211dd8a1-103a-4794-88d8-4923db2abc49">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEzLTEtMS0xLTc4MDQ5_8d2333f6-2ce4-4c85-b9f2-15fc7616c5b7">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEzLTMtMS0xLTc4MDQ5_d72ce636-97f0-4134-bbd2-e81f0d554670">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEzLTUtMS0xLTc4MDQ5_ad2f7287-dc9d-496e-b11f-0e61efbc1254">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE0LTEtMS0xLTc4MDQ5_68f23d9a-325e-4cd7-b22c-d855ac3bb147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE0LTMtMS0xLTc4MDQ5_636d2050-2e64-48ed-8a15-2ae31cc46769">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE0LTUtMS0xLTc4MDQ5_a29863f6-705e-48ac-b88e-34b9c53e6841">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="elv:TotalExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE1LTEtMS0xLTc4MDQ5_d442c32f-ee27-45f4-87de-a2739c8cf4f1">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="elv:TotalExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE1LTMtMS0xLTc4MDQ5_7506a81c-8f7f-43f7-9f04-1a99c6774a59">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="elv:TotalExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE1LTUtMS0xLTc4MDQ5_d78f3f0d-6e06-4bde-af70-2faa8f3fcc74">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income tax credits and equity in net income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE2LTEtMS0xLTc4MDQ5_cd0f12ee-489c-498e-8799-31c747ddf3a8">1,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE2LTMtMS0xLTc4MDQ5_8ebe2e18-1c5f-4d6f-ab9d-f663c5b18450">898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE2LTUtMS0xLTc4MDQ5_06f0ad09-c095-4bc3-bd7f-c3c5864d98d7">869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE3LTEtMS0xLTc4MDQ5_e407c21e-6610-4760-bb20-3ce510b70321">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE3LTMtMS0xLTc4MDQ5_d987641b-e4cc-4728-8194-b98bff9b3f56">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE3LTUtMS0xLTc4MDQ5_beb209d1-7669-40db-a495-32d2774c8e17">386</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE4LTEtMS0xLTc4MDQ5_2219dc66-46c5-4b9c-895a-cff1ccb989a0">6,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE4LTMtMS0xLTc4MDQ5_d32e66bc-b744-4c49-84d9-ada64183a984">6,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE4LTUtMS0xLTc4MDQ5_7a87bd8a-7c83-4724-a370-cb88771f2224">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE5LTEtMS0xLTc4MDQ5_091e8638-0ce0-4104-9d38-a87bb956d5db">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE5LTMtMS0xLTc4MDQ5_325253c0-8caf-4e19-a74c-206949d07eee">6,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE5LTUtMS0xLTc4MDQ5_d4d03c68-0163-47a3-8352-9671d6b00613">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-148-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_232"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3eeb723a5ba54a839b33d924a9dbcaf5" continuedAt="i5b4f831f013340f8852f057bcb459440"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Comprehensive Income</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzItMS0xLTEtNzgwNDk_ddc77a99-b20d-41d4-a4e6-8601f6d3206b">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzItMy0xLTEtNzgwNDk_d9e4476b-30b3-4417-8bfe-a8d45ac8c97a">6,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzItNS0xLTEtNzgwNDk_f8b99f83-e328-46f4-83b5-9ff663acf03e">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains/losses on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzQtMS0xLTEtNzgwNDk_59807dd6-216c-4bfa-8e93-d30b19c2b103">2,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzQtMy0xLTEtNzgwNDk_904fc373-7168-4140-8791-b0a9773b3674">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzQtNS0xLTEtNzgwNDk_c45ffe33-0ea5-41d6-84b4-2ce6e374db52">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-credit component of impairment losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzUtMS0xLTEtNzgwNDk_abdd1f6e-200a-48ff-b88c-f1429c89e93d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzUtMy0xLTEtNzgwNDk_4d858797-0b9c-4641-a1c5-531da02d471b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzUtNS0xLTEtNzgwNDk_2b4a3e96-0a3a-4d0e-8f31-eeaeada105f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains/losses on cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzYtMS0xLTEtNzgwNDk_30dbd416-f593-4611-ad32-c36f5d27df19">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzYtMy0xLTEtNzgwNDk_01a3c1a6-16bf-4535-848f-a1020f58d94d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzYtNS0xLTEtNzgwNDk_68505901-d90e-4089-bf4c-8a59a31741ea">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net periodic pension and postretirement costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzctMS0xLTEtNzgwNDk_27dd5647-b29a-433d-a394-0d939ef9be37">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzctMy0xLTEtNzgwNDk_818cbf28-25c4-4516-91c6-e94e3d3ebbd6">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzctNS0xLTEtNzgwNDk_d98374f9-182d-469d-9489-f9233ac1dc94">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzgtMS0xLTEtNzgwNDk_f19a123a-8855-4933-82b3-f3ffb2242e16">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzgtMy0xLTEtNzgwNDk_5ee2be55-15d0-4368-8ae1-aaf0bb4229b0">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzgtNS0xLTEtNzgwNDk_654f6dd9-b9fe-445b-a359-e5e66e4129c1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzktMS0xLTEtNzgwNDk_bb7f88a0-f1b0-4de3-b476-4950a89086bd">2,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzktMy0xLTEtNzgwNDk_c0314f64-8657-44f7-818f-7b39a59e3b23">328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzktNS0xLTEtNzgwNDk_4a31e31f-8e32-4952-933b-16902ce159b2">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzEwLTEtMS0xLTc4MDQ5_87d99b26-561b-4413-8481-485a6b8a04ce">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzEwLTMtMS0xLTc4MDQ5_e1842ee5-1fad-4faf-80fe-f1ea186c0c88">5,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzEwLTUtMS0xLTc4MDQ5_32402916-59cc-437b-9d93-4bde42488c9f">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-149-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_235"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5b4f831f013340f8852f057bcb459440" continuedAt="i4b9d653602da469593158f2051523f83"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI2LTEtMS0xLTc4MDQ5_f04c1aa3-87fd-4b7b-9ba7-09921140071f">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI2LTMtMS0xLTc4MDQ5_8f291e9c-b1ff-4345-87a1-3c19bbc46270">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI2LTUtMS0xLTc4MDQ5_85cb106d-445f-4a5c-bcfb-1f3d7e1bb4bb">4,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI4LTEtMS0xLTc4MDQ5_1721b76f-7ca2-4400-bb0b-431a1754e820">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI4LTMtMS0xLTc4MDQ5_7adeb91c-ae1f-46fe-af12-385d482915ed">2,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI4LTUtMS0xLTc4MDQ5_d0d7705f-afbc-4773-aeff-6171b185f9e5">2,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales, maturities, calls and redemptions of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI5LTEtMS0xLTc4MDQ5_fd9b16e9-b13f-4a11-9325-5b23bfb32621">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI5LTMtMS0xLTc4MDQ5_1db0dfc3-b519-41b7-89d1-369d17f1d53a">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI5LTUtMS0xLTc4MDQ5_3097667e-1db2-46d1-b200-e4ed6ab17d78">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment (issuance) of note to subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:OriginationOfNotesReceivableFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMxLTEtMS0xLTc4MDQ5_ed909499-32fa-48e2-92dc-0454d2c3a8ce">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OriginationOfNotesReceivableFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMxLTMtMS0xLTc4MDQ5_41b86f0e-26cd-4151-be9a-fd3537e1f8c6">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:OriginationOfNotesReceivableFromRelatedParties" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMxLTUtMS0xLTc4MDQ5_c0cb6c46-bcc0-4994-83f7-0695c2106632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalization of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMyLTEtMS0xLTc4MDQ5_d66a183d-358c-445c-a46f-832d2f22d922">411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMyLTMtMS0xLTc4MDQ5_95c54c9e-8185-40d2-b4b0-e056214fbff1">807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMyLTUtMS0xLTc4MDQ5_62754425-8187-4152-a322-ea2842d14764">2,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in securities lending collateral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMzLTEtMS0xLTc4MDQ5_817d2cb3-5bb4-4293-8142-6b5234d39cb0">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMzLTMtMS0xLTc4MDQ5_c0bbccda-a8ce-42c2-87d6-b6f06ba6db27">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMzLTUtMS0xLTc4MDQ5_cacc91df-221c-4df9-b119-bff700e943d2">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment, net of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM1LTEtMS0xLTc4MDQ5_4426a2c9-29b8-43e0-8e63-b6f65f998e0f">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM1LTMtMS0xLTc4MDQ5_6fee94ad-172d-4bd5-b2eb-a85a17965fee">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM1LTUtMS0xLTc4MDQ5_fbd72d4e-dff0-4be3-a104-afe7c036059e">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM2LTEtMS0xLTc4MDQ5_ba250d05-b06e-47be-bd17-65c972235bb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM2LTMtMS0xLTc4MDQ5_a357a81c-22e5-40e4-bacb-0823f66cd8b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM2LTUtMS0xLTc4MDQ5_0942f0ff-5111-43fe-8080-24d685fc08df">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM3LTEtMS0xLTc4MDQ5_2f8d05ef-70b3-44b2-b9f5-b7cf46f95a0e">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM3LTMtMS0xLTc4MDQ5_27b3cb56-837f-4f1b-ac07-aadeeed0f8ec">1,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM3LTUtMS0xLTc4MDQ5_a01758b3-39e3-4bb9-b303-62e69b3fdc00">2,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (repayments of) proceeds from commercial paper borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM5LTEtMS0xLTc4MDQ5_9ae48288-62e9-47ff-81ea-41fcc612e96f">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM5LTMtMS0xLTc4MDQ5_e33cca3c-20e7-42e8-84ad-2e43834d5d24">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM5LTUtMS0xLTc4MDQ5_6b42148d-5bd4-4edc-9c06-99755efaa9c7">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQwLTEtMS0xLTc4MDQ5_17e8679a-3cc2-4150-aa50-487a084a8d6c">3,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQwLTMtMS0xLTc4MDQ5_dd69607a-1d8e-4357-bb35-e66e367a5c72">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQwLTUtMS0xLTc4MDQ5_9b5922a6-3041-4437-a95c-6a2452f9d0a9">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQxLTEtMS0xLTc4MDQ5_5175cd13-6019-4943-863c-9b3663a8e936">1,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQxLTMtMS0xLTc4MDQ5_0b61d92c-4624-4676-b46e-d5e5ee55eef3">1,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQxLTUtMS0xLTc4MDQ5_516976ff-26ca-4553-ab79-c615b6a84016">1,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in securities lending payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInSecuritiesLendingPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQyLTEtMS0xLTc4MDQ5_9ec45033-15d6-4d62-8e76-b14a5d9b0feb">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInSecuritiesLendingPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQyLTMtMS0xLTc4MDQ5_16a0555c-4438-4681-8497-ace7b629b724">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInSecuritiesLendingPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQyLTUtMS0xLTc4MDQ5_b6fd8d52-539d-4558-afb7-78cf1bfb72cb">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ3LTEtMS0xLTc4MDQ5_eaf0665d-9c7c-45d2-a3cd-9beb3cd41f79">2,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ3LTMtMS0xLTc4MDQ5_23dd8bc2-b822-44fb-b207-325d0ea48598">1,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ3LTUtMS0xLTc4MDQ5_a4f0bb2e-e9c9-402c-bbe4-798c82c3d350">2,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ5LTEtMS0xLTc4MDQ5_ef49660f-5a64-4e26-80c0-4170521ff13c">1,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ5LTMtMS0xLTc4MDQ5_51667ac0-d500-4134-93ae-8403836ed05f">1,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ5LTUtMS0xLTc4MDQ5_b6d332c3-bebe-48ec-a1f3-92b10771b301">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUwLTEtMS0xLTc4MDQ5_4128e11a-f599-4adf-a8b4-795f8f9dec87">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUwLTMtMS0xLTc4MDQ5_b2544a17-a275-4b04-bc61-2ec3e1e1d3db">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUwLTUtMS0xLTc4MDQ5_d6637474-0443-4fbf-a4b0-a893fd31418d">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid through withholding of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUxLTEtMS0xLTc4MDQ5_d327bf43-342c-4365-981b-c6c53b05cbe8">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUxLTMtMS0xLTc4MDQ5_b935296a-ed4a-48ad-96d7-ccdc202e87ca">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUxLTUtMS0xLTc4MDQ5_390096ad-e84b-42ca-a5bd-4ddbdb8bd076">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUyLTEtMS0xLTc4MDQ5_77660402-df75-4bc2-b7aa-98b858b7f45d">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUyLTMtMS0xLTc4MDQ5_f17474e7-4b8c-4fe1-b41a-88aaf31707b9">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUyLTUtMS0xLTc4MDQ5_3def8684-e7bc-4d4a-8939-deb978bac0d8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUzLTEtMS0xLTc4MDQ5_9475bf80-1010-44d1-84b9-0f54bae41648">2,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUzLTMtMS0xLTc4MDQ5_7980582a-469f-4d01-8448-e7b4bb31e18e">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUzLTUtMS0xLTc4MDQ5_e85da6e2-361f-46ef-980d-db8550b3219d">3,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU0LTEtMS0xLTc4MDQ5_b701c7cd-8996-4e9e-91ef-3e0fb95825e0">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU0LTMtMS0xLTc4MDQ5_825fc44c-ee96-432b-b1d2-da7697ca8f1d">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU0LTUtMS0xLTc4MDQ5_6a1bb649-d2f1-44cb-ba32-8e19b5be71e7">1,118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU1LTEtMS0xLTc4MDQ5_5b5136ae-d035-4140-9f49-d6d645c7cd65">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac9df3234b44acd9d0fc7e8d58b001f_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU1LTMtMS0xLTc4MDQ5_6f79c065-5ece-4751-ba95-908c92088434">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida62205932654bdd82996ed0187717df_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU1LTUtMS0xLTc4MDQ5_f44fd90f-2411-4ffb-a7d4-627e801bf04e">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU2LTEtMS0xLTc4MDQ5_703d7f91-f7f3-4346-8fbf-1173fd9209af">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU2LTMtMS0xLTc4MDQ5_cb4a17e2-fc68-4002-a120-68c4577eaf46">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac9df3234b44acd9d0fc7e8d58b001f_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU2LTUtMS0xLTc4MDQ5_82316d36-06aa-453f-a5a7-f6ffd3ccbecf">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-150-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Parent Company Only)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In Millions, Except Per Share Data)</span></div><div style="text-align:center"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_241"></div><ix:continuation id="i4b9d653602da469593158f2051523f83" continuedAt="i88f38952eab9463b83e1246e9134a70a"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;Basis of Presentation and Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the parent company only financial statements of Elevance Health, Inc. (&#8220;Elevance Health&#8221;), Elevance Health&#8217;s investment in subsidiaries is stated at cost plus equity in undistributed earnings of the subsidiaries. Elevance Health&#8217;s share of net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of Elevance Health.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health&#8217;s parent company only financial statements should be read in conjunction with Elevance Health&#8217;s audited consolidated financial statements and the accompanying notes included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_244"></div><ix:continuation id="i88f38952eab9463b83e1246e9134a70a" continuedAt="ic55b65e6d3f74957853678a84acb1c7e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;Subsidiary Transactions</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends from Subsidiaries</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health received cash dividends from subsidiaries of $<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompany" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzExMg_10084ff3-bf4d-40b5-bdc0-47485a20b084">3,097</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompany" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzExNg_242a285b-655f-477f-b515-e8f4f1d5ead8">3,134</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompany" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzEyMw_ce015193-3a22-40d9-b772-fc4181e24b86">3,618</ix:nonFraction> during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends to Subsidiaries</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Elevance Health own shares of Elevance Health common stock. Elevance Health paid cash dividends to subsidiaries related to these shares of common stock in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzM1NA_a202b0d4-ff4e-4730-bec6-30c256e5556b">61</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzM1OA_d034e5e6-5fdc-4e92-a73a-c62aaaf1be67">54</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzM2NQ_b8435a51-2751-41d1-a57e-0b7bfebb452e">46</ix:nonFraction> during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Subsidiaries</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital contributions to subsidiaries were $<ix:nonFraction unitRef="usd" contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231" decimals="-6" name="elv:CapitalContributionToSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzQ3NQ_1e5aac7c-76ea-41eb-b714-270e0dcf925f">411</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231" decimals="-6" name="elv:CapitalContributionToSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzQ3OQ_092abdf2-bf4c-4aeb-984a-52f5c7e9743a">3,271</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231" decimals="-6" name="elv:CapitalContributionToSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzQ4Ng_d82f85ac-b23f-40a8-a922-e53634a73fa7">2,460</ix:nonFraction> during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amounts Due From and To Subsidiaries</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, Elevance Health reported amounts due (to) from subsidiaries of $(<ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:DueToAffiliateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzYzMg_e589befb-9771-4080-9146-e9078d0377b6">789</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:DueFromAffiliateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzYzOQ_ef521d3c-403f-4aec-9d0e-81358a68aba6">446</ix:nonFraction>, respectively. The amounts due (to) and from subsidiaries primarily include amounts for allocated administrative expenses or daily cash management activities. These items are routinely settled, and as such, are classified as current liabilities or assets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Elevance Health entered into a short-term loan agreement with a subsidiary for the amount of $<ix:nonFraction unitRef="usd" contextRef="i088d91ca9c3148788190accbb142e04e_I20211231" decimals="-6" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzk5MQ_081ebfd0-82b6-479b-9470-8adf0f69eeb8">1,500</ix:nonFraction>, which is also included in amounts due from subsidiaries at December 31, 2021. This loan was repaid in February 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees on Behalf of Subsidiaries</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health guarantees contractual or financial obligations or solvency requirements for certain of its subsidiaries. These guarantees approximated $<ix:nonFraction unitRef="usd" contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231" decimals="-6" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzEyMzI_77185ec2-a353-42a7-b507-8185ae4179bc">550</ix:nonFraction> at December&#160;31, 2022. There were no payments made on these guarantees in 2022.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_250"></div><ix:continuation id="ic55b65e6d3f74957853678a84acb1c7e" continuedAt="i703b01f28a3c495b9aeca01c558cdd90"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Derivative Financial Instruments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding derivative financial instruments contained in Note 6, &#8220;Derivative Financial Instruments,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-151-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_253"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i703b01f28a3c495b9aeca01c558cdd90" continuedAt="ib08d039a9f4c41919606b0303da80c93"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Long-Term Debt</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding long-term debt contained in Note 13, &#8220;Debt,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_256"></div><ix:continuation id="ib08d039a9f4c41919606b0303da80c93" continuedAt="if37a840505ed489abf80276e36ca5430"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Commitments and Contingencies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding commitments and contingencies contained in Note 14, &#8220;Commitments and Contingencies,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div></ix:continuation><div id="i09daec87c4c344c8b0454b84b1a4fe73_259"></div><ix:continuation id="if37a840505ed489abf80276e36ca5430"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Capital Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding capital stock contained in Note 15, &#8220;Capital Stock,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-152-</span></div></div></div><div id="i09daec87c4c344c8b0454b84b1a4fe73_262"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.863%"><tr><td style="width:1.0%"></td><td style="width:5.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELEVANCE HEALTH, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;GAIL K. BOUDREAUX&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gail K. Boudreaux<br/>President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: February&#160;15, 2023 </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:31.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;GAIL K. BOUDREAUX</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer, Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gail K. Boudreaux</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN E. GALLINA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John E. Gallina</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;RONALD W. PENCZEK&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer and Controller (Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ronald W. Penczek</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ELIZABETH E. TALLETT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Elizabeth E. Tallett</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    R. KERRY CLARK&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R. Kerry Clark</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    SUSAN D. DEVORE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Susan D. DeVore</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    ROBERT L. DIXON, JR.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert L. Dixon, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;LEWIS HAY III&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lewis Hay III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;BAHIJA JALLAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bahija Jallal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANTONIO F. NERI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Antonio F. Neri</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;RAMIRO G. PERU&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ramiro G. Peru</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    RYAN M. SCHNEIDER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ryan M. Schneider</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    DEANNA D. STRABLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deanna D. Strable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-153-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>exhibit47-20221231forform1.htm
<DESCRIPTION>EX-4.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icc167e6ed7004cf1969edc1dbc4220d7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The common stock of Elevance Health, Inc. (&#8220;Elevance Health,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a summary of the general terms and provisions of our common stock. This summary does not purport to be complete and is subject to and qualified by reference to our amended and restated articles of incorporation, as amended (our &#8220;articles of incorporation&#8221;) and our bylaws, as amended (our &#8220;bylaws&#8221;), both of which are filed as exhibits to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). For additional information, please read our articles of incorporation, our bylaws and the applicable provisions of the Indiana Business Corporation Law, as amended (the &#8220;IBCL&#8221;).</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are authorized to issue up to 900,000,000 shares of common stock, par value $0.01 per share, as well as up to 100,000,000 shares of preferred stock, without par value.  We have no shares of preferred stock issued or outstanding.  </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each holder of our common stock is entitled to one vote per share of record on all matters to be voted upon by the shareholders. Holders do not have cumulative voting rights in the election of directors or any other matter.  Subject to the preferential rights of the holders of any preferred stock that may at the time be outstanding, each share of common stock will entitle the holder of that share to an equal and ratable right to receive dividends or other distributions (other than purchases, redemptions or other acquisitions of shares by us) if declared from time to time by our board of directors and if there are sufficient funds to legally pay a dividend. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of our liquidation, dissolution or winding up, whether voluntary or involuntary, the holders of common stock will be entitled to share ratably in all assets remaining after payments to creditors and after satisfaction of the liquidation preference, if any, of the holders of any preferred stock that may at the time be outstanding. Holders of common stock have no preemptive or redemption rights and will not be subject to further calls or assessments by us. </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our common stock trades on the New York Stock Exchange under the symbol &#8220;ELV.&#8221; Computershare Trust Company, N.A. is the registrar, transfer agent, conversion agent and dividend disbursing agent for the common stock. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized But Unissued Shares </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana law does not require shareholder approval for any issuance of authorized shares. Authorized but unissued shares may be used for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions. One of the effects of the existence of authorized but unissued shares may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of current management and possibly deprive the shareholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices. In addition, depending on the rights prescribed for any series of preferred stock that may be issued, the issuance of preferred stock could have an adverse effect on the voting power of the holders of common stock or could impose restrictions upon the payment of dividends and other distributions to the holders of common stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitations on Ownership of Our Common Stock in Articles of Incorporation </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As required under our licenses with the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), our articles of incorporation contain certain limitations on the ownership of our common stock. Our articles of incorporation provide that no person may beneficially own shares of voting capital stock in excess of specified ownership limits, except with the prior approval of a majority of the &#8220;continuing directors.&#8221; The ownership limits, which may not be exceeded without the prior approval of the BCBSA, are the following&#58; </font></div><div style="margin-top:6pt;padding-left:44.1pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;for any institutional investor (as defined in our articles of incorporation), one share less than 10% of our outstanding voting securities&#59; </font></div><div style="margin-top:6pt;padding-left:44.1pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;for any non-institutional investor (as defined in our articles of incorporation), one share less than 5% of our outstanding voting securities&#59; and </font></div><div style="margin-top:6pt;padding-left:44.1pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;for any person, one share less than the number of shares of our common stock or other equity securities (or a combination thereof) representing a 20% ownership interest in us. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.7</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any transfer of stock that would result in any person beneficially owning shares of capital stock in excess of any ownership limit will result in the intended transferee acquiring no rights in the shares exceeding such ownership limit (with certain exceptions) and the person&#8217;s excess shares will be deemed transferred to an escrow agent to be held until the shares are transferred to a person whose ownership of the shares will not violate the ownership limit. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Other Provisions of Our Articles of Incorporation and Bylaws </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain other provisions of our articles of incorporation and bylaws may delay or make more difficult unsolicited acquisitions or changes of control of us. These provisions could have the effect of discouraging third parties from making proposals involving an unsolicited acquisition or change in control of us, although these proposals, if made, might be considered desirable by a majority of our shareholders. These provisions may also have the effect of making it more difficult for third parties to cause the replacement of the current management without the concurrence of the board of directors. These provisions include&#58; </font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;the division of the board of directors into three classes serving staggered terms of office of three years&#59; </font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;provisions limiting the maximum number of directors to 19 and requiring that any increase in the number of directors then in effect must be approved by a majority of continuing directors&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;provisions requiring that, except in certain limited circumstances, the filling of any vacancy on the board of directors must be approved by a majority of continuing directors&#59; </font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.85pt">permitting a special meeting of shareholders to be called only by the board of directors, the Chair of the Board, the Lead Director, the Chief Executive Officer, the President, or upon the written demand of any one or more shareholders owning at least 20% of our outstanding common stock&#59; and</font></div><div style="margin-top:6pt;padding-left:44.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">requirements for advance notice for raising business or making nominations at shareholders&#8217; meetings. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our bylaws provide that if the requirement for a classified board structure set forth in our licenses with the BCBSA is eliminated or otherwise no longer applicable to the Company, the board of directors will take all necessary actions to implement the elimination of the classified board structure and the annual election of all directors, which shall be phased in over a three-year period commencing with the first annual meeting of shareholders occurring at least 90 days after the board of directors determines that such requirement is eliminated or is otherwise no longer applicable to the Company.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our bylaws establish an advance notice procedure with regard to business to be brought before an annual or special meeting of shareholders and advance notice and proxy access procedures with regard to the nomination of candidates for election as directors, other than by or at the direction of the board of directors. Although our bylaws do not give the board of directors any power to approve or disapprove shareholder nominations for the election of directors or proposals for action, they may have the effect of precluding a contest for the election of directors or the consideration of shareholder proposals if the established procedures are not followed, and of discouraging or deterring a third party from conducting a solicitation of proxies to elect its own slate of directors or to approve its proposal without regard to whether consideration of those nominees or proposals might be harmful or beneficial to us and our shareholders. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, our bylaws provide that, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (a)&#160;any derivative action or proceeding brought on our behalf, (b)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or certain specified constituents of ours,&#160;(c)&#160;any action asserting a claim arising pursuant to any provision of the IBCL or our articles of incorporation or bylaws, or (d)&#160;any action asserting a claim governed by the internal affairs doctrine, will be, to the fullest extent permitted by law, the Marion Superior Court in Marion County, Indiana or, if the Marion Superior Court lacks jurisdiction, the United States District Court for the Southern District of Indiana.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment and Repeal of Bylaws </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our articles of incorporation and bylaws provide that the bylaws may be altered, amended or repealed by either (1)&#160;the affirmative vote of a majority of the entire number of directors, or (2)&#160;except for certain provisions of the bylaws, the affirmative vote, at a shareholder meeting, of at least a majority of the votes entitled to be cast by the holders of the outstanding shares of all classes of our stock entitled to vote generally in the election of directors, considered for this purpose as a single voting group. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Provisions of the Indiana Business Corporation Law </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As an Indiana corporation, we are governed by the IBCL. The following are some of the more significant provisions of the IBCL that may delay, prevent or make more difficult certain unsolicited acquisitions or changes of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.7</font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">control of us. These provisions also may have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions which shareholders may otherwise deem to be in their best interest. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Control Share Acquisitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Under Chapter 42 of the IBCL, an acquiring person or group who acquires, directly or indirectly, ownership of, or the power to direct the exercise of voting power with respect to, issued and outstanding &#8220;control shares&#8221; in an &#8220;issuing public corporation&#8221; may not exercise voting rights on any control shares unless these voting rights are conferred by a majority vote of the disinterested shareholders of the issuing public corporation at a special meeting of those shareholders held upon the request and at the expense of the acquiring person or, if no such request is made, at the next special or annual meeting of shareholders. If the acquiring person has acquired control shares with a majority or more of the voting power, and the control shares are accorded full voting rights by the disinterested shareholders, all shareholders of the issuing public corporation have dissenters&#8217; rights to receive the fair value of their shares pursuant to Chapter 44 of the IBCL. We are an &#8220;issuing public corporation&#8221; as defined under Chapter 42. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Chapter 42, &#8220;control shares&#8221; means shares acquired by a person that, when added to all other shares of the issuing public corporation owned by that person or in respect to which that person may exercise or direct the exercise of voting power, would otherwise entitle that person to exercise voting power of the issuing public corporation in the election of directors within any of the following ranges&#58; (i)&#160;one-fifth or more but less than one-third&#59; (ii)&#160;one-third or more but less than a majority&#59; or (iii)&#160;a majority or more. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chapter 42 does not apply if, before a control share acquisition is made, the corporation&#8217;s articles of incorporation or bylaws, including a bylaw adopted by the corporation&#8217;s board of directors, provide that they do not apply. Our bylaws provide that we are not subject to Chapter 42&#59; however, our board of directors could amend our bylaws to rescind our election to opt out of Chapter 42.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Certain Business Combinations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Chapter 43 of the IBCL restricts the ability of an Indiana corporation that has 100 or more shareholders to engage in any business combinations with an &#8220;interested shareholder&#8221; for five years after the date the shareholder became an &#8220;interested shareholder&#8221; (such date, the &#8220;share acquisition date&#8221;), unless the business combination or the purchase of shares by the interested shareholder on the interested shareholder&#8217;s share acquisition date is approved by the board of directors of the corporation before the share acquisition date. If such prior approval is not obtained, the interested shareholder may effect a business combination after the five-year period only if that shareholder receives approval from a majority of the disinterested shareholders or the offer meets specified fair price criteria. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of Chapter 43, &#8220;interested shareholder&#8221; means any person, other than the corporation or its subsidiaries, who is (1)&#160;the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation or (2)&#160;an affiliate or associate of the corporation, which at any time within the five-year period immediately before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding shares of the corporation. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chapter 43 does not apply to corporations that elect not to be subject to Chapter 43 in an amendment to their articles of incorporation approved by a majority of the disinterested shareholders. That amendment, however, cannot become effective until 18 months after its passage and would apply only to share acquisitions occurring after its effective date. Our articles of incorporation do not exclude us from Chapter 43. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mandatory Classified Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Under Chapter 33 of the IBCL, a corporation with a class of voting shares registered with the SEC under Section&#160;12 of the Exchange Act must have a classified board of directors unless the corporation adopts a bylaw expressly electing not to be governed by this provision. Although our articles of incorporation and bylaws provide for a classified board of directors so long as we are required to do so under our licenses with the BCBSA, we adopted an amendment to our bylaws electing not to be subject to this mandatory requirement effective July&#160;29, 2009. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Unanimous Written Consent of Shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Under Chapter 29 of the IBCL, as well as our articles of incorporation and our bylaws, any action required or permitted to be taken by the holders of common stock may be effected only at an annual meeting or special meeting of such holders, and shareholders may act in lieu of such meetings only by unanimous written consent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exhibit101-20221231forform.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i960e5e8d0b8d44eba38547426f398fea_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2014 ELEVANCE HEALTH INCENTIVE COMPENSATION PLAN</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2022 RESTATEMENT)</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Elevance Health, Inc., an Indiana corporation formerly known as Anthem, Inc. (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) previously adopted the Anthem Incentive Compensation Plan (formerly named, the &#8220;WellPoint Incentive Compensation Plan&#8221;), which it hereby amends and restates as the 2014 Elevance Health Incentive Compensation Plan (2022 Restatement) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), for the benefit of non-employee directors of the Company and officers and eligible employees and consultants of the Company and any Subsidiaries and Affiliates (as each term defined below), as follows&#58;</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ARTICLE I.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">ESTABLISHMENT&#59; PURPOSES&#59; AND DURATION</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Establishment of the Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Board of Directors (defined below) originally established and adopted the incentive compensation plan known as the &#8220;WellPoint 2006 Incentive Compensation Plan&#8221; on March&#160;15, 2006,  effective on May&#160;16, 2006 upon approval by the Company&#8217;s shareholders, and previously amended and restated it, effective December 2, 2014, as the Anthem Incentive Compensation Plan. The Plan is hereby amended and restated, effective June 28, 2022, solely to update the names of the Company and the Plan as set forth above and the definition of &#8220;Committee&#8221; set forth below. The Plan&#160;permits the grant of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares, Cash-Based Awards and Other Stock-Based Awards. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Purposes of the Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The purposes of the Plan are to provide additional incentives to non-employee directors of the Company and to those officers, employees and consultants of the Company, Subsidiaries and Affiliates whose substantial contributions are essential to the continued growth and success of the business of the Company and the Subsidiaries and Affiliates, in order to strengthen their commitment to the Company and the Subsidiaries and Affiliates, and to attract and retain competent and dedicated individuals whose efforts will result in the long-term growth and profitability of the Company and to further align the interests of such non-employee directors, officers, employees and consultants with the interests of the shareholders of the Company. To accomplish such purposes, the Plan provides that the Company may grant Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares, Cash-Based Awards and Other Stock-Based Awards.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Duration of the Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Plan shall remain in effect, subject to the right of the Board of Directors to amend or terminate the Plan at any time pursuant to Article&#160;XVII, until all Shares subject to it shall have been delivered, and any restrictions on such Shares have lapsed, pursuant to the Plan&#8217;s provisions. However, in no event may an Award be granted under the Plan on or after ten years from May&#160;20, 2009 (the &#8220;Effective Date&#8221;), the date the shareholders most recently approved the Plan.</font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ARTICLE II.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Whenever used in the Plan, the following terms shall have the meanings set forth below, and when the meaning is intended, the initial letter of the word shall be capitalized&#58;</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.1 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Affiliate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means any entity other than the Company and any Subsidiary that is affiliated with the Company through stock or equity ownership or otherwise and is designated as an Affiliate for purposes of the Plan by the Committee&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that, notwithstanding any other provisions of the Plan to the contrary, for purposes of NQSOs and SARs, if an individual who otherwise qualifies as an Employee or Non-Employee Director provides services to such an entity and not to the Company or a Subsidiary, such entity may only be designated an Affiliate if the Company qualifies as a &#8220;service recipient,&#8221; within the meaning of Code Section&#160;409A, with respect to such individual&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;that such definition of &#8220;service recipient&#8221; shall be determined by (a)&#160;applying Code Section&#160;1563(a)(1), (2)&#160;and (3), for purposes of determining a controlled group of corporations under Code </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section&#160;414(b), using the language &#8220;at least 50 percent&#8221; instead of &#8220;at least 80 percent&#8221; each place it appears in Code Section&#160;1563(a)(1), (2)&#160;and (3), and by applying Treasury Regulations Section&#160;1.414(c)-2, for purposes of determining trades or businesses (whether or not incorporated) that are under common control for purposes of Code Section&#160;414(c), using the language &#8220;at least 50 percent&#8221; instead of &#8220;at least 80 percent&#8221; each place it appears in Treasury Regulations Section&#160;1.414(c)-2, and (b)&#160;where the use of Shares with respect to the grant of an Option or SAR to such an individual is based upon legitimate business criteria, by applying Code Section&#160;1563(a)(1), (2)&#160;and (3), for purposes of determining a controlled group of corporations under Code Section&#160;414(b), using the language &#8220;at least 20 percent&#8221; instead of &#8220;at least 80 percent&#8221; at each place it appears in Code Section&#160;1563(a)(1), (2)&#160;and (3), and by applying Treasury Regulations Section&#160;1.414(c)-2, for purposes of determining trades or businesses (whether or not incorporated) that are under common control for purposes of Code Section&#160;414(c), using the language &#8220;at least 20 percent&#8221; instead of &#8220;at least 80 percent&#8221; at each place it appears in Treasury Regulations Section&#160;1.414(c)-2.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Annual Meeting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the annual meeting of shareholders at which members of the Board are routinely elected.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Award</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means, individually or collectively, a&#160;grant under the Plan of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Performance Shares, Performance Units, Cash-Based Awards, and Other Stock-Based Awards.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Award Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means either&#58; (a)&#160;a written agreement entered into by the Company and a Participant setting forth the terms and provisions applicable to an Award granted under the Plan, or (b)&#160;a written or electronic statement issued by the Company to a Participant describing the terms and provisions of such Award, including any amendment or modification thereof. The Committee may provide for the use of electronic, internet or other non-paper Award Agreements, and the use of electronic, internet or other non-paper means for the acceptance thereof and actions thereunder by a Participant.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; or &#8220;Board of Directors&#8221; means the Board of Directors of the&#160;Company.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.6 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Cash-Based Award</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means an Award granted to a Participant, as described in Article IX.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.7 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Cause</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; shall have the definition given such term in a Participant&#8217;s Award Agreement, or in the absence of any such definition, as determined in good faith by the Committee.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.8 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the first to occur of the following events with respect to the Company&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a) any person (as such term is used in Rule 13d-5 of the SEC under the Exchange Act) or group (as such term is defined in Section&#160;13(d) of the Exchange Act), other than a subsidiary of the Company or any employee benefit plan (or any related trust) of the Company or a subsidiary or affiliate of the Company, becomes the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of 20% or more of the Shares or of other voting securities representing 20% or more of the combined voting power of all voting securities the Company&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that (1)&#160;no Change of Control shall be deemed to have occurred solely by reason of any such acquisition by a corporation with respect to which, after such acquisition, more than 80% of both the common stock of such corporation and the combined voting power of the voting securities of such corporation are then beneficially owned, directly or indirectly, by the persons who were the beneficial owners of the Shares and other voting securities of the Company immediately before such acquisition, in substantially the same proportion as their ownership of the Shares and other voting securities of the Company immediately before such acquisition&#59; (2)&#160;if any person or group owns 20% or more but less than 30% of the combined voting power of the Shares and other voting securities of the Company and such person or group has a No Change of Control Agreement with the Company, no Change of Control shall be deemed to have occurred solely by reason of such ownership for so long as the No Change of Control Agreement remains in effect and such person or group is not in violation of the No Change of Control Agreement&#59; and (3)&#160;once a Change of Control occurs under this Section&#160;2.8(a), the occurrence of the next Change of Control (if any) under this Section&#160;2.8(a) shall be determined by reference to a person or group other than the person or group whose acquisition of beneficial ownership created such prior Change of Control unless the original person or group has in the meantime ceased to own 20% or more of the Shares or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">other voting securities representing 20% or more of the combined voting power of all voting securities of the Company&#59; or</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b) within any period of thirty-six (36)&#160;or fewer consecutive months individuals who, as of the first day of such period were members of the Board (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Incumbent Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) cease for any reason to constitute at least 75% of the members of the Board&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that (1)&#160;any individual who becomes a member of the Board after the first day of such period whose nomination for election to the Board was approved by a vote or written consent of at least 75% of the members of the Board who are then Incumbent Directors shall be considered an Incumbent Director, but excluding, for this purpose, any such individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of the Company (as such terms are used in Rule 14a-11 of the SEC under the Exchange Act) or an Imminent Change of Control or other transaction described in Section&#160;2.8(a) or 2.8(c)&#59; and (2)&#160;once a Change of Control occurs under this Section&#160;2.8(b), the occurrence of the next Change of Control (if any) under this Section&#160;2.8(b) shall be determined by reference to a period of&#160;thirty-six&#160;(36)&#160;or fewer consecutive months beginning not earlier than the date immediately after the date of such prior Change of Control&#59; or</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</font></div><div style="padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c) closing of a transaction which is any of the following&#58;</font></div><div style="margin-top:6pt;padding-left:63.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) a merger, reorganization or consolidation of the Company (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Merger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), after which (A)&#160;the individuals and entities who were the respective beneficial owners of the Shares and other voting securities of the Company immediately before such Merger do not beneficially own, directly or indirectly, more than 60% of, respectively, the Shares or the combined voting power of the common stock and voting securities of the corporation resulting from such Merger, in substantially the same proportion as their ownership of the Shares and other voting securities of the Company immediately before such Merger&#59;</font></div><div style="margin-top:6pt;padding-left:63.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) a Merger after which individuals who were members of the Board of Directors immediately before the Merger do not comprise a majority of the members of the Board of Directors of the corporation resulting from such Merger&#59;</font></div><div style="margin-top:6pt;padding-left:63.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3) a sale or other disposition by the Company of all or substantially all of the assets owned by it (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Sale</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) after which the individuals and entities who were the respective beneficial owners of the Shares and other voting securities of the Company immediately before such Sale do not beneficially own, directly or indirectly, more than 60% of, respectively, the Shares or the combined voting power of the common stock and voting securities of the transferee of substantially all of the Company&#8217;s assets in such Sale in substantially the same proportion as their ownership of the Shares and other voting securities of the Company immediately before such Sale&#59;</font></div><div style="margin-top:6pt;padding-left:63.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4) a Sale after which individuals who were members of the Board of Directors immediately before the Sale do not comprise a majority of the members of the board of directors of the transferee corporation that acquired substantially all of the Company&#8217;s assets&#59; or</font></div><div style="margin-top:6pt;padding-left:63.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5) a liquidation of the Company.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Code</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the Internal Revenue Code of 1986, as it may be amended from time to time, including rules and regulations promulgated thereunder and successor provisions and rules and regulations thereto.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.10 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the Compensation and Talent Committee of the Board of Directors or a subcommittee thereof, or such other committee designated by the Board to administer the Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.11 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Consultant</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means an independent contractor or consultant who performs services for the Company or a Subsidiary or Affiliate in a capacity other than as an Employee or Director.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.12 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Covered Employee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any Employee who is or may become a &#8220;covered employee,&#8221; as defined in Code Section&#160;162(m), and who is designated, either as an individual Employee or a member of a class of Employees, by the Committee within the shorter of (i)&#160;ninety (90)&#160;days after the beginning of the Performance Period, or (ii)&#160;the first twenty-five percent (25%)&#160;of the Performance Period, as a &#8220;Covered Employee&#8221; under the Plan for such applicable Performance Period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.13 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Designated Percentage</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; has the meaning given such term in Section&#160;11.2.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.14 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Director</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means any individual who is a member of the Board of Directors of the Company.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.15 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Dividend Equivalents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the equivalent value (in cash or Shares) of dividends that would otherwise be paid on the Shares subject to or issued pursuant to an Award (including Restricted Stock Units) but that have not been issued or delivered, as described in Article XIII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.16 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; shall have the meaning ascribed to such term in Section&#160;1.3.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.17 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Employee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means any person designated as an employee of the Company, a Subsidiary and&#47;or an Affiliate on the payroll records thereof. An Employee shall not include any individual during any period he or she is classified or treated by the Company, a Subsidiary or an Affiliate as an independent contractor, a consultant, or any employee of an employment, consulting, or temporary agency or any other entity other than the Company, a Subsidiary and&#47;or an Affiliate without regard to whether such individual is subsequently determined to have been, or is subsequently retroactively reclassified as a common-law employee of the Company, a Subsidiary and&#47;or an Affiliate during such period. As further provided in Section&#160;21.4, for purposes of the Plan, upon approval by the Committee, the term Employee may also include Employees whose employment with the Company, a Subsidiary or an Affiliate has been terminated subsequent to being granted an Award under the Plan. For the avoidance of doubt, a Director who would otherwise be an &#8220;Employee&#8221; within the meaning of this Section&#160;2.17 shall be considered an Employee for purposes of the Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.18 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Exchange Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the Securities Exchange Act of 1934, as it may be amended from time to time, including the rules and regulations promulgated thereunder and successor provisions and rules and regulations thereto.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.19 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Fair Market Value</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the fair market value of the Shares as determined by the Committee by the reasonable application of such reasonable valuation method, consistently applied, as the Committee deems appropriate&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that, with respect to ISOs, for purposes of Section&#160;6.3 and 6.9(c), such fair market value shall be determined subject to Section&#160;422(c)(7) of the Code&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that (a)&#160;if the Shares are readily tradable on an established securities market, Fair Market Value on any date shall be the last sale price reported for the Shares on such market on such date or, if no sale is reported on such date, on the last date preceding such date on which a sale was reported, or (b)&#160;if the Shares are admitted for listing on the New York Stock Exchange or other comparable market, Fair Market Value on any date shall be the last sale price reported for the Shares on such market on such date or, if no sale is reported on such date, on the last day preceding such date on which a sale was reported. In each case, the Committee shall determine Fair Market Value in a manner that satisfies the applicable requirements of Code Section&#160;409A.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.20 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Fees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means all cash amounts payable to a Non-Employee Director for services rendered as a director, including retainer fees, meeting fees and committee fees, but excluding travel and other out-of-pocket expense reimbursements.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.21 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Fiscal Year</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the calendar year, or such other consecutive twelve-month period as the Committee may select.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.22 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Freestanding SAR</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an SAR that is granted independently of any Options, as described in Article VII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.23 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Grant Price</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the price established at the time of grant of an SAR pursuant to Article VII, used to determine whether there is any payment due upon exercise of the SAR.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.24 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Imminent Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means (a)&#160;the public announcement (whether by advertisement, press release, press interview, public statement, SEC filing or otherwise) of a proposal or offer which if consummated would be a Change of Control, (b)&#160;the making to a director or executive officer of the Company of a written proposal which if consummated would be a Change of Control, or (c)&#160;the approval by the Board of Directors or the stockholders of the Company of a transaction that upon closing would be a Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.25 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Incentive Stock Option</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">ISO</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a right to purchase Shares under the Plan in accordance with the terms and conditions set forth in Article VI and which is designated as an Incentive&#160;Stock Option and which is intended to meet the requirements of&#160;Section 422 of the Code.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.26 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Incumbent Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; has the meaning given such term in Section&#160;2.8(a)(ii).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.27 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Insider</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an individual who is, on the relevant date, an officer, director or ten percent (10%)&#160;beneficial owner of any class of the Company&#8217;s equity securities that is registered pursuant to Section&#160;12 of the Exchange Act, as determined by the Committee in accordance with Section&#160;16 of the Exchange Act.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.28 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Merger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; has the meaning given such term in Section&#160;2.8(c)(1).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.29 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Change of Control Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a legal, binding and enforceable agreement executed by and in effect between a person or all members of a group and the Company that provides that&#58; (1)&#160;such person or group shall be bound by the agreement for the time period of not less than five (5)&#160;years from its date of execution&#59; (2)&#160;such person or group shall not acquire beneficial ownership or voting control equal to a percentage of the Shares or the voting power of other voting securities of the Company that exceeds a percentage specified in the agreement which percentage shall in all events be less than 30%&#59; (3)&#160;such person or group may not designate for election as directors a number of directors in excess of 25% of the number of directors on the Board&#59; and (4)&#160;such person or group shall vote the Shares and other voting securities of the Company in all matters in the manner directed by the majority of the Incumbent Directors. If any agreement described in the preceding sentence is violated by such person or group or is amended in a fashion such that it no longer satisfies the requirements of the preceding sentence, such agreement shall, as of the date of such violation or amendment, be treated for purposes hereof as no longer constituting a No Change of Control Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.30 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Non-Employee Director</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a Director who is not an Employee.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.31 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Nonqualified Stock Option</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">NQSO</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a right to purchase Shares under the Plan in accordance with the terms and conditions set forth in Article VI and which is not intended to meet the requirements of Section&#160;422 of the Code or otherwise does not meet such requirements.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.32 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means notice provided by a Participant to the Company in a manner prescribed by the Committee.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.33 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Option</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Stock Option</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an Incentive Stock Option or a Nonqualified Stock&#160;Option, as described in Article VI.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.34 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Option Price</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the price at which a Share may be purchased by a Participant pursuant to an Option.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.35 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Other Stock-Based Award</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an equity-based or equity-related Award described in Section&#160;10.1, granted in accordance with the terms and conditions set forth in Article X.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.36 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Participant</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means any eligible individual as set forth in Article V who holds one or more outstanding Awards.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.37 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance-Based Compensation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means compensation under an Award that is intended to satisfy the requirements of Code Section&#160;162(m) for certain performance-based compensation paid to Covered Employees. Notwithstanding the foregoing, nothing in the Plan shall be construed to mean that an Award which does not satisfy the requirements for performance-based compensation under Code Section&#160;162(m) does not constitute performance-based compensation for other purposes, including Code Section&#160;409A.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.38 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance Measure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means performance criteria or measures as described in Section&#160;12.1 on which the performance goals described in Article XII are based and which are approved by the Company&#8217;s shareholders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">pursuant to the Plan in order to qualify certain Awards as Performance-Based Compensation in accordance with Article XII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.39 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the period of time during which the performance goals must be met in order to determine the degree of payout and&#47;or vesting with respect to, or the amount or entitlement to, an Award.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.40 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance Share</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an Award of a performance share granted to a Participant, as described in Article IX.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.41 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance Unit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an Award of a performance unit granted to a Participant, as described in Article IX.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.42 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Period of Restriction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the period during which Shares of Restricted Stock or Restricted Stock Units are subject to a substantial risk of forfeiture, and, in the case of Restricted Stock, the transfer of Shares of Restricted Stock is limited in some way, as provided in Article VIII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.43 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Prior Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the Anthem 2001 Stock Incentive Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.44 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Qualified Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a Change of Control that qualifies as a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the assets of the Company, within the meaning of Section&#160;409A(a)(2)(A)(v) of the Code.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.45 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Restricted Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an Award granted to a Participant pursuant to Article VIII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.46 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Restricted Stock Unit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an Award, whose value is equal to a Share, granted to a Participant pursuant to Article VIII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.47 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Rule 16b-3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means Rule 16b-3 under the Exchange Act, or any successor rule, as the same may be amended from time to time.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.48 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Sale</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; has the meaning given such term in Section&#160;2.8(c)(3).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.49 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">SEC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the Securities and Exchange Commission.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.50 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Securities Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the Securities Act of 1933, as it may be amended from time to time, including the rules and regulations promulgated thereunder and successor provisions and rules and regulations thereto.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.51 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Share</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a share of common stock of the Company (including any new, additional or different stock or securities resulting from any change in corporate capitalization as listed in Section&#160;4.3).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.52 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Stock Appreciation Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">SAR</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means an Award, granted alone (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Freestanding SAR</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;) or in connection with a related Option (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Tandem SAR</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;), designated as an SAR, pursuant to the terms of Article VII.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.53 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Stock Election</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; has the meaning given such term in Section&#160;11.2.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.54 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Subsidiary</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means any present or future corporation which is or would be a &#8220;subsidiary corporation&#8221; of the Company as the term is defined in Section&#160;424(f) of the Code.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.55 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Substitute Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, options or other awards previously granted, or the right or obligation to grant future options or other awards, by a company acquired by the Company, a Subsidiary and&#47;or an Affiliate or with which the Company, a Subsidiary and&#47;or an Affiliate combines, or otherwise in connection with any merger, consolidation, acquisition of property or stock, or reorganization involving the Company, a Subsidiary or an Affiliate, including a transaction described in Code Section&#160;424(a).</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.56 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Tandem SAR</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means a SAR that is granted in connection with a related Option pursuant to Article VII.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">2.57 &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221; means the time when a Participant ceases the performance of services for the Company, any Affiliate or Subsidiary, as applicable, for any reason, with or without Cause, including a Termination by resignation, discharge, death, disability or retirement, but excluding (a)&#160;a Termination where there is a simultaneous reemployment (or commencement of service) or continuing employment (or service) of a Participant by the Company, Affiliate or any Subsidiary, (b)&#160;at the discretion of the Committee, a Termination that results in a temporary severance, and (c)&#160;at the discretion of the Committee, a Termination of an Employee that is immediately followed by the Participant&#8217;s service as a Non-Employee Director.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE III.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">ADMINISTRATION</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">General</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Committee shall have exclusive authority to operate, manage and administer the Plan in accordance with its terms and conditions. Notwithstanding the foregoing, in its absolute discretion, the Board may at any time and from time to time exercise any and all rights, duties and responsibilities of the Committee under the Plan, including establishing procedures to be followed by the Committee, but excluding matters which under any applicable law, regulation or rule, including any exemptive rule under Section&#160;16 of the Exchange Act (including Rule 16b-3) or Section&#160;162(m) of the Code, are required to be determined in the sole discretion of the Committee. If and to the extent that the Committee does not exist or cannot function, the Board may take any action under the Plan that would otherwise be the responsibility of the Committee, subject to the limitations set forth in the immediately preceding sentence. Notwithstanding any other provision of the Plan to the contrary, any action or determination specifically affecting or relating to an Award granted to a Non-Employee Director, including under Article XI, shall be taken, or approved or ratified, by the Board.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The members of the Committee shall be appointed from time to time by, and shall serve at the discretion of, the Board of Directors. The Committee shall consist of not less than three (3)&#160;non-employee members of the Board, each of whom satisfies such criteria of independence as the Board may establish and such additional regulatory or listing requirements as the Board may determine to be applicable or appropriate. Appointment of Committee members shall be effective upon their acceptance of such appointment. Committee members may be removed by the Board at any time either with or without cause, and such members may resign at any time by delivering notice thereof to the Board. Any vacancy on the Committee, whether due to action of the Board or any other reason, shall be filled by the Board. The Committee shall keep minutes of its meetings. A majority of the Committee shall constitute a quorum and a majority of a quorum may authorize any action. Any decision reduced to writing and signed by a majority of the members of the Committee shall be fully effective as if it has been made at a meeting duly held.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Authority of the Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Committee shall have full discretionary authority to grant, pursuant to the terms of the Plan, Awards to those individuals who are eligible to receive Awards under the Plan. Except as limited by law or by the Certificate of Incorporation or By-Laws of the Company, and subject to the provisions herein, the Committee shall have full power, in accordance with the other terms and provisions of the Plan, to&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) select Employees, Non-Employee Directors and Consultants who may receive Awards under the Plan and become Participants&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) determine eligibility for participation in the Plan and decide all questions concerning eligibility for, and the amount of, Awards under the Plan&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) determine the sizes and types of Awards&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) determine the terms and conditions of Awards, including the Option Prices of Options and the Grant Prices of SARs&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) grant Awards as an alternative to, or as the form of payment for grants or rights earned or payable under, other bonus or compensation plans, arrangements or policies of the Company or a Subsidiary or Affiliate&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(f) grant Substitute Awards on such terms and conditions as the Committee may prescribe, subject to compliance with the ISO rules under Code Section&#160;422 and the nonqualified deferred compensation rules under Code Section&#160;409A, where applicable&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(g) make all determinations under the Plan concerning Termination of any Participant&#8217;s employment or service with the Company or a Subsidiary or Affiliate, including whether such Termination occurs by reason of Cause, disability or in connection with a Change of Control and whether a leave constitutes a Termination&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(h) determine whether or not a Change of Control or an Imminent Change of Control shall have occurred and whether or not a Change of Control is a Qualified Change of Control&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(i) construe and interpret the Plan and any agreement or instrument entered into under the Plan, including any Award Agreement&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(j) establish and administer any terms, conditions, restrictions, limitations, forfeiture, vesting or exercise schedule, and other provisions of or relating to any Award&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(k) establish and administer any performance goals in connection with any Awards, including related Performance Measures or performance criteria and applicable Performance Periods, determine the extent to which any performance goals and&#47;or other terms and conditions of an Award are attained or are not attained, and certify whether, and to what extent, any such performance goals and other material terms applicable to Awards intended to qualify as Performance-Based Compensation were in fact satisfied&#59;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(l) construe any ambiguous provisions, correct any defects, supply any omissions and reconcile any inconsistencies in the Plan and&#47;or any Award Agreement or any other instrument relating to any Awards&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(m) establish, adopt, amend, waive and&#47;or rescind rules, regulations, procedures, guidelines, forms and&#47;or instruments for the Plan&#8217;s operation or administration&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(n) make all valuation determinations relating to Awards and the payment or settlement thereof&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(o) grant waivers of terms, conditions, restrictions and limitations under the Plan or applicable to any Award, or accelerate the vesting or exercisability of any Award&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(p) subject to the provisions of Article XVII, amend or adjust the terms and conditions of any outstanding Award and&#47;or adjust the number and&#47;or class of shares of stock subject to any outstanding Award&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(q) at any time and from time to time after the granting of an Award, specify such additional terms, conditions and restrictions with respect to such Award as may be deemed necessary or appropriate to ensure compliance with any and all applicable laws or rules, including terms, restrictions and conditions for compliance with applicable securities laws or listing rules, methods of withholding or providing for the payment of required taxes and restrictions regarding a Participant&#8217;s ability to exercise Options through a cashless (broker-assisted) exercise&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(r) determine whether, and to what extent and under what circumstances Awards may be settled in cash, Shares or other property or canceled or suspended&#59; and</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(s) exercise all such other authorities, take all such other actions and make all such other determinations as it deems necessary or advisable for the proper operation and&#47;or administration of the Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Award Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Committee shall, subject to applicable laws and rules, determine the date an Award is granted. Each Award shall be evidenced by an Award Agreement&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, two or more Awards granted to a single Participant may be combined in a single Award Agreement. An Award Agreement shall not be a precondition to the granting of an Award&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that (a)&#160;the Committee may, but need not, require as a condition to any Award Agreement&#8217;s effectiveness, that such Award Agreement be executed on behalf of the Company and&#47;or by the Participant to whom the Award evidenced thereby shall have been granted (including by electronic signature or other electronic indication of acceptance), and such executed Award Agreement be delivered to the Company, and (b)&#160;no person shall have any rights under any Award unless and until the Participant to whom such Award shall have been granted has complied with the applicable terms and conditions of the Award. The Committee shall prescribe the form of all Award Agreements, and, subject to the terms and conditions of the Plan, shall determine the content of all Award Agreements. Any Award Agreement may be supplemented or amended in writing from time to time as approved by the Committee&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;that the terms and conditions of any such Award Agreement as supplemented or amended are not inconsistent with the provisions of the Plan. In the event of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">dispute or discrepancy concerning the terms of an Award, the records of the Committee or its designee shall be determinative.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Discretionary Authority&#59; Decisions Binding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Committee shall have full discretionary authority in all matters related to the discharge of its responsibilities and the exercise of its authority under the Plan. All determinations, decisions, actions and interpretations by the Committee with respect to the Plan and any Award Agreement, and all related orders and resolutions of the Committee shall be final, conclusive and binding on all Participants, the Company and its shareholders, any Subsidiary or Affiliate and all persons having or claiming to have any right or interest in or under the Plan and&#47;or any Award Agreement. The Committee shall consider such factors as it deems relevant to making or taking such decisions, determinations, actions and interpretations, including the recommendations or advice of any Director or officer or employee of the Company, any director, officer or employee of a Subsidiary or Affiliate and such attorneys, consultants and accountants as the Committee may select. A Participant or other holder of an Award may contest a decision or action by the Committee with respect to such person or Award only on the grounds that such decision or action was arbitrary or capricious or was unlawful, and any review of such decision or action shall be limited to determining whether the Committee&#8217;s decision or action was arbitrary or capricious or was unlawful.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Attorneys&#59; Consultants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Committee may consult with counsel who may be counsel to the Company. The Committee may, with the approval of the Board, employ such other attorneys and&#47;or consultants, accountants, appraisers, brokers, agents and other persons, any of whom may be an Employee, as the Committee deems necessary or appropriate. The Committee, the Company and its officers and Directors shall be entitled to rely upon the advice, opinions or valuations of any such persons. The Committee shall not incur any liability for any action taken in good faith in reliance upon the advice of such counsel or other persons.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">3.7&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Delegation of Administration</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Except to the extent prohibited by applicable law, including any applicable exemptive rule under Section&#160;16 of the Exchange Act (including Rule 16b-3) or Section&#160;162(m) of the Code, or the applicable rules of a stock exchange, the Committee may, in its discretion, allocate all or any portion of its responsibilities and powers under this Article III to any one or more of its members and&#47;or delegate all or any part of its responsibilities and powers under this Article III to any person or persons selected by it&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that the Committee may not delegate its authority to correct defects, omissions or inconsistencies in the Plan. Any such authority delegated or allocated by the Committee under this Section&#160;3.7 shall be exercised in accordance with the terms and conditions of the Plan and any rules, regulations or administrative guidelines that may from time to time be established by the Committee, and any such allocation or delegation may be revoked by the Committee at any time.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE IV.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">SHARES SUBJECT TO THE PLAN AND AWARD LIMITS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">4.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Number of Shares Available for Grants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The shares of stock subject to Awards granted under the Plan shall be Shares. Such Shares subject to the Plan may be either authorized and unissued shares (which will not be subject to preemptive rights) or previously issued shares acquired by the Company or any Subsidiary. Subject to adjustment as provided in Section&#160;4.3, the total number of Shares that may be delivered pursuant to Awards under the Plan as of the Effective Date shall be sixty million sixty-eight thousand three hundred and thirty-four (60,068,334)&#160;Shares (the &#8220;Share Reserve&#8221;), which represents the sum of (a)&#160;twenty million (20,000,000)&#160;Shares authorized under the original Plan,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">plus</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;(b)&#160;thirty-three million (33,000,000)&#160;Shares authorized under this amendment and restatement of the Plan,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">plus</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;(c)&#160;seven million sixty-eight thousand, three hundred and forty-four (7,068,344)&#160;Shares available for issuance pursuant to the Prior Plan, as previously approved by the shareholders of the Company, on May&#160;16, 2006. The Share Reserve shall be increased by any Shares allocable to outstanding stock options or other awards under the Prior Plan which expire, are forfeited or otherwise terminate unexercised after May&#160;16, 2006. For purposes of this Section&#160;4.1, (d)&#160;each Share delivered pursuant to an Option shall reduce the Share Reserve by one (1)&#160;Share&#59; (e)&#160;each Share subject to the exercised portion of a SAR (whether the distribution upon exercise is made in cash, Shares or a combination of cash and Shares) shall reduce the Share Reserve by one (1)&#160;Share,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">other</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">than</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;an SAR that, by its terms, from and after the grant date thereof, is payable only in cash, in which case the Share Reserve shall not be reduced&#59; (f)&#160;each Share delivered pursuant to a Restricted Stock Unit Award, Performance Share Award, Performance Unit Award, or Other Stock-Based Award shall reduce the Share </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Reserve by one and sixty-seven one hundredths (1.67)&#160;Shares for Awards granted on or after the Effective Date and by two (2)&#160;Shares for Awards granted prior to the Effective Date&#59; (g)&#160;each Share delivered pursuant to a Restricted Stock Award without a purchase price, or with a per-Share purchase price lower than one hundred percent (100%)&#160;of the Fair Market Value of a Share on the grant date of such Restricted Stock Award, shall reduce the Share Reserve by one and sixty-seven one hundredths (1.67)&#160;Shares for Awards granted on or after the Effective Date and by two (2)&#160;Shares for Awards granted prior to the Effective Date&#59; (h)&#160;each Share delivered pursuant to a Restricted Stock Award with a per-Share purchase price at least equal to one hundred percent (100%)&#160;of the Fair Market Value of a Share on the grant date of such Restricted Stock Award shall reduce the Share Reserve by one (1)&#160;Share&#59; and (i)&#160;to the extent that a distribution pursuant to an Award is made in cash,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">other</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">than</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;pursuant to an Award that by its terms, from and after the grant date thereof, is payable only in cash, the Share Reserve shall be reduced by the number of Shares subject to the redeemed, paid or exercised portion of such Award. Subject to the immediately preceding sentence and, in the case of ISOs, any limitations applicable thereto under the Code, any Shares that are subject to an Option, SAR, or other Award which for any reason expires or is terminated or canceled without having been fully exercised or satisfied, and any Shares that are subject to any Restricted Stock Award (including any Shares subject to a Participant&#8217;s Restricted Stock Award that are repurchased by the Company at the Participant&#8217;s cost), Restricted Stock Unit Award or other Award granted under the Plan which are forfeited, shall, to the extent of any such expiration, termination, cancellation or forfeiture, be available for delivery in connection with future Awards under the Plan. However, notwithstanding any other provisions of this Section&#160;4.1 to the contrary, (i)&#160;Shares withheld or tendered to pay the exercise price or withholding taxes with respect to an outstanding Award shall not again be made available for issuance pursuant to Awards under the Plan, and (ii)&#160;the payment of cash dividends or Dividend Equivalents in cash in connection with Awards shall not reduce the Share Reserve. Any Shares delivered under the Plan upon exercise or satisfaction of Substitute Awards shall not reduce the Shares available for delivery under the Plan&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that the total number of Shares that may be delivered pursuant to Incentive Stock Options granted under the Plan shall be equal to twenty-seven million (27,000,000)&#160;Shares, as adjusted pursuant to this Section&#160;4.1, but without application of the foregoing provisions of this sentence. From and after May&#160;16, 2006, no further grants or awards were made under the Prior Plan&#59; however, grants or awards made under the Prior Plan before May&#160;16, 2006 shall continue in effect in accordance with their terms.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">4.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Award Limits</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The following limits shall apply to grants of all Awards under the&#160;Plan&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#58; The maximum aggregate number of Shares that may be subject to Options granted in any two consecutive Fiscal Years to any one Participant shall be four million (4,000,000)&#160;Shares.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">SARs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#58; The maximum aggregate number of Shares that may be subject to Stock Appreciation Rights granted in any two consecutive Fiscal Years to any one Participant shall be four million (4,000,000)&#160;Shares. Any Shares covered by Options which include Tandem SARs granted to one Participant in any two consecutive Fiscal Years shall reduce this limit on the number of Shares subject to SARs that can be granted to such Participant in such two consecutive Fiscal Years.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Restricted Stock or Restricted Stock Units</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#58; The maximum aggregate number of Shares that may be subject to Awards of Restricted Stock or Restricted Stock Units granted in any two consecutive Fiscal Years to any one Participant shall be two million (2,000,000)&#160;Shares.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance Shares or Performance Units</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#58; The maximum aggregate grant with respect to Awards of Performance Shares or Performance Units granted in any two consecutive Fiscal Years to any one Participant shall be two million (2,000,000)&#160;Shares.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Cash-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#58; The maximum aggregate amount awarded with respect to Cash-Based Awards made in any two consecutive Fiscal Years to any one Participant shall not exceed fifteen million dollars ($15,000,000).</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(f)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Other Stock-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#58; The maximum aggregate grant with respect to Other Stock-Based Awards made in any two consecutive Fiscal Years to any one Participant shall be two million (2,000,000)&#160;Shares (or cash amounts based on the value of such number of Shares).</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent required by Section&#160;162(m) of the Code, Shares subject to Options or SARs which are canceled shall continue to be counted against the limits set forth in paragraphs (a)&#160;and (b)&#160;immediately preceding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">4.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Adjustments in Authorized Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. In the event of any corporate event or transaction (including a change in the Shares or the capitalization of the Company), such as a reclassification, recapitalization, merger, consolidation, reorganization (whether or not such reorganization comes within the definition of such term in Section&#160;368 of the Code), issuance of warrants or rights, dividend or other distribution (whether in the form of cash, stock or other property), stock split or reverse stock split, spin-off, split-up, combination or exchange of shares, repurchase of shares, or other like change in corporate structure, partial or complete liquidation of the Company or distribution (other than normal cash dividends) to shareholders of the Company, or any similar corporate event or transaction, the Committee, in order to prevent dilution or enlargement of Participants&#8217; rights under the Plan, shall substitute or adjust, as applicable, the number, class and kind of securities which may be delivered under Section&#160;4.1&#59; the number, class and kind, and&#47;or price (such as the Option Price of Options or the Grant Price of SARs) of securities subject to outstanding Awards&#59; the Award limits set forth in Section&#160;4.2&#59; and other value determinations applicable to outstanding Awards&#59; provided, however that the number of Shares subject to any Award shall always be a whole number. The Committee shall also make appropriate adjustments and modifications in the terms of any outstanding Awards to reflect or related to any such events, adjustments, substitutions or changes, including modifications of performance goals and changes in the length of Performance Periods, subject to the requirements of Article XII in the case of Awards intended to qualify as Performance-Based Compensation. Any adjustment, substitution or change pursuant to this Section&#160;4.3 made with respect to an Award intended to be an Incentive Stock Option shall be made only to the extent consistent with such intent, unless the Committee determines otherwise, and any such adjustment that is made with respect to an Award that provides for Performance-Based Compensation shall be made consistent with the intent that such Award qualify for the performance-based compensation exception under Section&#160;162(m) of the Code. The Committee shall not make any adjustment pursuant to this Section&#160;4.3 that would cause an Award that is otherwise exempt from Code Section&#160;409A to become subject to Code Section&#160;409A, or that would cause an Award that is subject to Code Section&#160;409A to fail to satisfy the requirements of Code Section&#160;409A. All determinations of the Committee as to adjustments or changes under this Section&#160;4.3 shall be conclusive and binding on the Participants.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">4.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Limitation on Corporate Actions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The existence of the Plan and any Awards granted hereunder shall not affect in any way the right or power of the Company, any Subsidiary or any Affiliate to make or authorize any adjustment, recapitalization, reorganization or other change in its capital structure or business structure, any merger or consolidation, any issuance of debt, preferred or prior preference stock ahead of or affecting the Shares, additional shares of capital stock or other securities or subscription rights thereto, any dissolution or liquidation, any sale or transfer of all or part of its assets or business or any other corporate act or proceeding. Further, except as expressly provided herein or by the Committee, (i)&#160;the issuance by the Company of Shares or any class of securities convertible into shares of stock of any class, for cash, property, labor or services, upon direct sale, upon the exercise of rights or warrants to subscribe therefor, or upon conversion of shares or obligations of the Company convertible into such shares or other securities, (ii)&#160;the payment of a dividend in property other than Shares, (iii)&#160;the occurrence of any capital change described in Section&#160;4.3 or (iv)&#160;the occurrence of any similar transaction, and in any case whether or not for fair value, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares subject to Awards theretofore granted or the Option Price, Grant Price or purchase price per share applicable to any Award, unless the Committee shall determine, in its discretion, that an adjustment is necessary or appropriate.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE V.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">ELIGIBILITY AND PARTICIPATION</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">5.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Eligibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Employees, Non-Employee Directors and Consultants shall be eligible to become Participants and receive Awards in accordance with the terms and conditions of the Plan, subject to the limitations on the granting of ISOs set forth in Section&#160;6.9(a).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">5.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Actual Participation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to the provisions of the Plan, the Committee may, from time to time, select Participants from all eligible Employees, Non-Employee Directors and Consultants and shall determine the nature and amount of each Award.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE VI.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">STOCK OPTIONS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Grant of Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to the terms and provisions of the Plan, Options may be granted to Participants in such number, and upon such terms, and at&#160;any time and from time to time as shall be determined by the Committee. The Committee may grant an Option or provide for the grant of an Option, either from time to time in the discretion of the Committee or automatically upon the occurrence of specified events, including the achievement of performance goals, the satisfaction of an event or condition within the control of the recipient of the Option or within the control of others. The granting of an Option shall take place when the Committee by resolution, written consent or other appropriate action determines to grant such Option for a particular number of Shares to a particular Participant at a particular Option Price.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Award Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Each Option grant shall be evidenced by an Award Agreement that shall specify the Option Price, the maximum duration of the Option, the number of Shares to which the Option pertains, the conditions upon which the Option shall become exercisable and such other provisions as the Committee shall determine, which are not inconsistent with the terms of the Plan. The Award Agreement also shall specify whether the Option is intended to be an ISO or an NQSO. To the extent that any Option does not qualify as an ISO (whether because of its provisions or the time or manner of its exercise or otherwise), such Option, or the portion thereof which does not so qualify, shall constitute a separate NQSO.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Option Price</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Option Price for each Option shall be determined by the Committee and set forth in the Award Agreement&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;that, subject to Section&#160;6.9(c), the Option Price of an Option shall be not less than one hundred percent (100%)&#160;of&#160;the Fair Market Value of a Share on the date the Option is granted&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that Substitute Awards or Awards granted in connection with an adjustment provided for in Section&#160;4.3, in the form of stock options, shall have an Option Price per Share that is intended to maintain the economic value of the Award that was replaced or adjusted, as determined by the Committee.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Duration of Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Each Option granted to a Participant shall expire at such time as the Committee shall determine at the time of grant and set forth in the Award Agreement&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that no Option shall be exercisable later than the tenth (10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:110%;position:relative;top:-2.97pt;vertical-align:baseline">th</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">)&#160;anniversary of its&#160;date of grant, subject to the respective last sentences of Sections 6.5 and 6.9(c).</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Exercise of Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Options shall be exercisable at such times and be subject to such restrictions and conditions as the Committee shall in each instance determine and set forth in the Award Agreement, which need not be the same for each grant or for each Option or Participant. An Agreement may provide that the period of time over which an Option other than an ISO may be exercised shall be automatically extended if on the scheduled expiration date of such Option the Optionee&#8217;s exercise of such Option would violate applicable securities laws&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that during such extended exercise period the Option may only be exercised to the extent the Option was exercisable in accordance with its terms immediately prior to such scheduled expiration date&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that such extended exercise period shall end not later than thirty (30)&#160;days after the exercise of such Option first would no longer violate such laws.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Options shall be exercised by the delivery of a written notice of exercise to the Company, in a form specified or accepted by the Committee, or by complying with any alternative exercise procedures that may be authorized by the Committee, setting forth the number of Shares with respect to which the Option is to be exercised, accompanied by full payment for such Shares, which shall include applicable taxes, if any, in accordance with Article XVIII. The Option Price upon exercise of any Option shall be payable to the Company in full either&#58; (a)&#160;in cash or its equivalent&#59; (b)&#160;subject to such terms, conditions and limitations as the Committee may prescribe, by tendering (either by actual delivery or attestation) unencumbered Shares previously acquired by the Participant exercising such Option having an aggregate Fair Market Value at the time of exercise equal to the total Option Price, (c)&#160;by a combination of (a)&#160;and (b)&#59; or (d)&#160;by any other method approved or accepted by the Committee in its sole discretion, including, if the Committee so determines, a cashless (broker-assisted) exercise that complies with all applicable laws. Subject to any governing rules or regulations, as soon as practicable after receipt of a written notification of exercise and full payment in accordance with the preceding provisions of this Section&#160;6.6, the Company shall deliver to the Participant exercising an Option, in the Participant&#8217;s name, evidence of book entry Shares, or, upon the Participant&#8217;s request, Share certificates, in an appropriate amount based upon the number of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Shares purchased under the Option, subject to Section&#160;21.9. Unless otherwise determined by the Committee, all payments under all of the methods described above shall be paid in United States dollars.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.7&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Rights as a Shareholder</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. No Participant or other person shall become the beneficial owner of any Shares subject to an Option, nor have any rights to dividends or other rights of a shareholder with respect to any such Shares, until the Participant has actually received such Shares following exercise of his or her Option in accordance with the provisions of the Plan and the applicable Award Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.8&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Termination of Employment or Service</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Except as otherwise provided in the Award Agreement, an Option may be exercised only to the extent that it is then exercisable, and if at all times during the period beginning with the date of granting of such Option and ending on the date of exercise of such Option the Participant is an Employee or Non-Employee Director, and shall terminate immediately upon a Termination of the Participant. An Option shall cease to become newly exercisable upon a Termination of the holder thereof. Notwithstanding the foregoing provisions of this Section&#160;6.8 to the contrary, the Committee may determine in its discretion that an Option may be exercised following any such Termination, whether or not exercisable at the time of such Termination&#59; provided, however, that in no event may an Option be exercised after the expiration date of such Option specified in the applicable Award Agreement, except as provided in the last sentence of Section&#160;6.5.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">6.9&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Limitations on Incentive Stock Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">General</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. No ISO shall be granted to any individual otherwise eligible to participate in the Plan who is not an Employee of the Company or a Subsidiary on the date of granting of such Option. Any ISO granted under the Plan shall contain such terms and conditions, consistent with the Plan, as the Committee may determine to be necessary to qualify such Option as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code. Any ISO granted under the Plan may be modified by the Committee to disqualify such Option from treatment as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">$100,000 Per Year Limitation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any intent to grant ISOs, an Option granted under the Plan will not be considered an ISO to the extent that it, together with any other &#8220;incentive stock options&#8221; (within the meaning of Section&#160;422 of the Code, but without regard to subsection (d)&#160;of such Section) under the Plan and any other &#8220;incentive stock option&#8221; plans of the Company, any Subsidiary and any &#8220;parent corporation&#8221; of the Company within the meaning of Section&#160;424(e) of the Code, are exercisable for the first time by any Participant during any calendar year with respect to Shares having an aggregate Fair Market Value in excess of $100,000 (or such other limit as may be required by the Code) as of the time the Option with respect to such Shares is granted. The rule set forth in the preceding sentence shall be applied by taking Options into account in the order in which they were granted.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Options Granted to Certain Shareholders</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. No ISO shall be granted to an individual otherwise eligible to participate in the Plan who owns (within the meaning of Section&#160;424(d) of the Code), at the time the Option is granted, more than ten percent (10%)&#160;of the total combined voting power of all classes of stock of the Company or a Subsidiary or any &#8220;parent corporation&#8221; of the Company within the meaning of Section&#160;424(e) of the Code. This restriction does not apply if at the time such ISO is granted the Option Price of the ISO is at least 110% of the Fair Market Value of a Share on the date such ISO is granted, and the ISO by its terms is not exercisable after the expiration of five years from such date of grant.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE VII.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">STOCK APPRECIATION RIGHTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Grant of SARs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to the terms and conditions of the Plan, SARs may be granted to Participants at any time and from time to time as shall be determined by the Committee. The Committee may grant an SAR (a)&#160;in connection and simultaneously with the grant of an Option (a Tandem SAR) or (b)&#160;independent of, and unrelated to, an Option (a Freestanding SAR). The Committee shall have complete discretion in determining the number of Shares to which a SAR pertains (subject to Article IV) and, consistent with the provisions of the Plan, in determining the terms and conditions pertaining to any SAR.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Grant Price</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Grant Price for each SAR shall be determined by the Committee and set forth in the Award Agreement, subject to the limitations of this Section&#160;7.2. The Grant Price for each Freestanding SAR shall be not less than one hundred percent (100%)&#160;of&#160;the Fair Market Value of a Share on the date such Freestanding SAR is granted, except in the case of Substitute Awards or Awards granted in connection with an adjustment provided for in Section&#160;4.3. The Grant Price of a Tandem SAR shall be equal to the Option Price of the related Option.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Exercise of Tandem SARs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Tandem SARs may be exercised for all or part of the Shares subject to the related Option upon the surrender of the right to exercise the equivalent portion of the related Option. A Tandem SAR shall be exercisable only when and to the extent the related Option is exercisable and may be exercised only with respect to the Shares for which the related Option is then exercisable. A Tandem SAR shall entitle a Participant to elect, in the manner set forth in the Plan and the applicable Award Agreement, in lieu of exercising his or her unexercised related Option for all or a portion of the Shares for which such Option is then exercisable pursuant to its terms, to surrender such Option to the Company with respect to any or all of such Shares and to receive from the Company in exchange therefor a payment described in Section&#160;7.7. An Option with respect to which a Participant has elected to exercise a Tandem SAR shall, to the extent of the Shares covered by such exercise, be canceled automatically and surrendered to the Company. Such Option shall thereafter remain exercisable according to its terms only with respect to the number of Shares as to which it would otherwise be exercisable, less the number of Shares with respect to which such Tandem SAR has been so exercised. Notwithstanding any other provision of the Plan to the contrary, with respect to a Tandem SAR granted in connection with an ISO&#58; (a)&#160;the Tandem SAR will expire no later than the expiration of the related ISO&#59; (b)&#160;the value of the payment with respect to the Tandem SAR may not exceed the difference between the Fair Market Value of the Shares subject to the related ISO at the time the Tandem SAR is exercised and the Option Price of the related ISO&#59; and (c)&#160;the Tandem SAR may be exercised only when the Fair Market Value of the Shares subject to the ISO exceeds the Option Price of the ISO.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Exercise of Freestanding SARs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Freestanding SARs may be exercised upon whatever terms and conditions the Committee, in its sole discretion, in accordance with the Plan, determines and sets forth in the Award Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Award Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Each SAR grant shall be evidenced by an Award Agreement that shall specify the number of Shares to which the SAR pertains, the Grant Price, the term of the SAR, and such other terms and conditions as the Committee shall determine in accordance with the Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Term of SARs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The term of a SAR granted under the Plan shall be determined by the Committee, in its sole discretion&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that the term of any Tandem SAR shall be the same as the related Option and no SAR shall be exercisable more than ten (10)&#160;years after it is granted, subject to the last sentence of Section&#160;6.5 in the case of a Tandem SAR.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.7&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Payment of SAR Amount</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. An election to exercise SARs shall be deemed to have been made on the date of Notice of such election to the Company. Upon exercise of a SAR, a Participant shall be entitled to receive payment from the Company in an amount determined by multiplying&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) The excess of the Fair Market Value of a Share on the date of exercise over the Grant Price of the SAR&#59; by</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) The number of Shares with respect to which the SAR is exercised.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Notwithstanding the foregoing provisions of this Section&#160;7.7 to the contrary, the Committee may establish and set forth in the applicable Award Agreement a maximum amount per Share that will be payable upon the exercise of a SAR. At the discretion of the Committee, such payment upon exercise of a SAR shall be in cash, in Shares of equivalent Fair Market Value, or in some combination thereof.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.8&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Rights as a Shareholder</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. A Participant receiving a SAR shall have the rights of a Shareholder only as to Shares, if any, actually issued to such Participant upon satisfaction or achievement of the terms and conditions of the Award, and in accordance with the provisions of the Plan and the applicable Award Agreement, and not with respect to Shares to which such Award relates but which are not actually issued to such Participant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7.9&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Termination of Employment or Service</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Each SAR Award Agreement shall set forth the extent to which the Participant shall have the right to exercise the SAR following such Participant&#8217;s Termination. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all SARs issued pursuant to the Plan, and may reflect distinctions based on the reasons for Termination.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE VIII.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">RESTRICTED STOCK AND RESTRICTED STOCK UNITS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Awards of Restricted Stock and Restricted Stock Units</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to the terms and provisions of the Plan, the Committee, at any time and from time to time, may grant Shares of Restricted Stock and&#47;or Restricted Stock Units to Participants in such amounts as the Committee shall determine. Subject to the terms and conditions of this Article VIII and the Award Agreement, upon delivery of Shares of Restricted Stock to a Participant, or creation of a book entry evidencing a Participant&#8217;s ownership of Shares of Restricted Stock, pursuant to Section&#160;8.6, the Participant shall have all of the rights of a shareholder with respect to such Shares, subject to the terms and restrictions set forth in this Article VIII or the applicable Award Agreement or as determined by the Committee. Restricted Stock Units shall be similar to Restricted Stock, except no Shares are actually awarded to a Participant who is granted Restricted Stock Units on the date of grant, and such Participant shall have no rights of a shareholder with respect to such Restricted Stock Units.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Award Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Each Restricted Stock and&#47;or Restricted Stock Unit Award shall be evidenced by an Award Agreement that shall specify the Period of Restriction, the number of Shares of Restricted Stock or the number of Restricted Stock Units granted, and such other provisions as the Committee shall determine in accordance with the Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Nontransferability of Restricted Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Except as provided in this Article VIII, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, encumbered, alienated, hypothecated or otherwise disposed of until the end of the applicable Period of Restriction established by the Committee and specified in the Restricted Stock Award Agreement.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Period of Restriction and Other Restrictions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Period of Restriction shall lapse based on continuing service as a Non-Employee Director or Consultant or continuing employment with the Company, a Subsidiary or an Affiliate, the achievement of performance goals, the satisfaction of other conditions or restrictions or upon the occurrence of other events, in each case, as determined by the Committee, at its discretion, and stated in the Award Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Delivery of Shares, Payment of Restricted Stock Units</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to Section&#160;21.9, after the last day of the Period of Restriction applicable to a Participant&#8217;s Shares of Restricted Stock, and after all conditions and restrictions applicable to such Shares of Restricted Stock have been satisfied or lapse (including satisfaction of any applicable withholding tax obligations), pursuant to the applicable Award Agreement, such Shares of Restricted Stock shall become freely transferable by such Participant. After the last day of the Period of Restriction applicable to a Participant&#8217;s Restricted Stock Units, and after all conditions and restrictions applicable to Restricted Stock Units have been satisfied or lapse (including satisfaction of any applicable withholding tax obligations), pursuant to the applicable Award Agreement, such Restricted Stock Units shall be settled by delivery of Shares, a cash payment determined by reference to the then-current Fair Market Value of Shares or a combination of Shares and such cash payment, as the Committee, in its sole discretion, shall determine, either by the terms of the Award Agreement or otherwise.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Forms of Restricted Stock Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Each Participant who receives an Award of Shares of Restricted Stock shall be issued a stock certificate or certificates evidencing the Shares covered by such Award registered in the name of such Participant, which certificate or certificates may contain an appropriate legend. The Committee may require a Participant who receives a certificate or certificates evidencing a Restricted Stock Award to immediately deposit such certificate or certificates, together with a stock power or other appropriate instrument of transfer, endorsed in blank by the Participant, with signatures guaranteed in accordance with the Exchange Act if required by the Committee, with the Secretary of the Company or an escrow holder as provided in the immediately following sentence. The Secretary of the Company or such escrow holder as the Committee may appoint shall retain physical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">custody of each certificate representing a Restricted Stock Award until the Period of Restriction and any other restrictions imposed by the Committee or under the Award Agreement with respect to the Shares evidenced by such certificate expire or shall have been removed. The foregoing to the contrary notwithstanding, the Committee may, in its discretion, provide that a Participant&#8217;s ownership of Shares of Restricted Stock prior to the lapse of the Period of Restriction or any other applicable restrictions shall, in lieu of such certificates, be evidenced by a &#8220;book entry&#8221; (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">i.e.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a computerized or manual entry) in the records of the Company or its designated agent in the name of the Participant who has received such Award. Such records of the Company or such agent shall, absent manifest error, be binding on all Participants who receive Restricted Stock Awards evidenced in such manner. The holding of Shares of Restricted Stock by the Company or such an escrow holder, or the use of book entries to evidence the ownership of Shares of Restricted Stock, in accordance with this Section&#160;8.6, shall not affect the rights of Participants as owners of the Shares of Restricted Stock awarded to them, nor affect the restrictions applicable to such shares under the Award Agreement or the Plan, including the Period of Restriction.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.7&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Voting Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Unless otherwise determined by the Committee and set forth in a Participant&#8217;s Award Agreement, to the extent permitted or required by law, as determined by the Committee, Participants holding Shares of Restricted Stock may be granted the right to exercise full voting rights with respect to those Shares during the Period of Restriction. A Participant shall have no voting rights with respect to any Restricted Stock Units.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.8&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Dividends and Other Distributions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. During the Period of Restriction, Participants holding Shares of Restricted Stock shall be credited with any cash dividends paid with respect to such Shares while they are so held, unless determined otherwise by the Committee and set forth in the Award Agreement. The Committee may apply any restrictions to such dividends that the Committee deems appropriate. Except as set forth in the Award Agreement, in the event of (a)&#160;any adjustment as provided in Section&#160;4.3, or (b)&#160;any shares or securities are received as a dividend, or an extraordinary dividend is paid in cash, on Shares of Restricted Stock, any new or additional Shares or securities or any extraordinary dividends paid in cash received by a recipient of Restricted Stock shall be subject to the same terms and conditions, including the Period of Restriction, as relate to the original Shares of Restricted Stock.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.9&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Termination of Employment or Service</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Except as otherwise provided in this Section&#160;8.9, during the Period of Restriction, any Restricted Stock Units and&#47;or Shares of Restricted Stock held by a Participant shall be forfeited and revert to the Company (or, if Shares of Restricted Sock were sold to the Participant, the Participant shall be required to resell such Shares to the Company at cost) upon the Participant&#8217;s Termination or the failure to meet or satisfy any applicable performance goals or other terms, conditions and restrictions to the extent set forth in the applicable Award Agreement. Each applicable Award Agreement shall set forth the extent to which, if any, the Participant shall have the right to retain Restricted Stock Units and&#47;or Shares of Restricted Stock following such Participant&#8217;s Termination. Such provisions shall be determined in the sole discretion of the Committee, shall be included in the applicable Award Agreement, need not be uniform among all such Awards issued pursuant to the Plan, and may reflect distinctions based on the reasons for, or circumstances of, such Termination.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">8.10&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Compliance With Section&#160;409A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Unless the Committee provides otherwise in an Award Agreement, each Restricted Stock Unit shall be paid in full to the Participant no later than the fifteenth day of the third month after the end of the first calendar year in which the Restricted Stock Unit is no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Code Section&#160;409A. If the Committee provides in an Award Agreement that a Restricted Stock Unit is intended to be subject to Code Section&#160;409A, the Award Agreement shall include terms that are intended to satisfy the requirements of Section&#160;409A.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE IX.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">PERFORMANCE UNITS, PERFORMANCE SHARES, AND CASH-BASED AWARDS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">9.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Grant of Performance Units, Performance Shares and Cash-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to the terms of the&#160;Plan, Performance Units, Performance Shares, and&#47;or Cash-Based Awards may be granted to Participants in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee, in accordance with the Plan. A Performance Unit, Performance Share or Cash-Based Award entitles the Participant who receives such Award to receive Shares or cash upon the attainment of performance goals and&#47;or satisfaction of other terms and conditions determined by the Committee when the Award is granted and set forth in the Award </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Agreement. Such entitlements of a Participant with respect to his or her outstanding Performance Unit, Performance Share or Cash-Based Award shall be reflected by a bookkeeping entry in the records of the Company, unless otherwise provided by the Award Agreement. The terms and conditions of such Awards shall be consistent with the Plan and set forth in the Award Agreement and need not be uniform among all such Awards or all Participants receiving such Awards.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Value of Performance Units, Performance Shares and Cash-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Each Performance Unit shall have&#160;an initial value that is established by the Committee at the time of grant. Each Performance Share shall have an initial value equal to the Fair Market Value of a Share on the date of grant. Each Cash-Based Award shall have a value as shall be determined by the Committee. The Committee shall set performance goals in its discretion which, depending on the extent to which they are met, will determine the number and&#47;or value of Performance Units and Performance Shares and Cash-Based Awards that will be paid out to the Participant.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Earning of Performance Units, Performance Shares and Cash-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Subject to the terms of the&#160;Plan, after the applicable Performance Period has ended, the holder of Performance Units, Performance Shares or Cash-Based Awards shall be entitled to receive payment on the number and value of Performance Units, Performance Shares or Cash-Based Awards earned by the Participant over the Performance Period, to be determined as a function of the extent to which the&#160;corresponding performance goals and&#47;or other terms and conditions have been achieved or satisfied. The Committee shall determine the extent to which any such pre-established performance goals and&#47;or other terms and conditions of a Performance Unit, Performance Share or Cash-Based Award are attained or not attained following conclusion of the applicable Performance Period. The Committee may, in its discretion, waive any such performance goals and&#47;or other terms and conditions relating to any such Award not intended to qualify as Performance-Based Compensation.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Form and Timing of Payment of Performance Units, Performance Shares and Cash-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Payment of earned Performance Units, Performance Shares and Cash-Based Awards shall be as determined by the Committee and as set forth in the Award Agreement. Subject to&#160;the&#160;terms of the Plan, the Committee, in its sole discretion, may pay earned&#160;Performance Units, Performance Shares and Cash-Based Awards in the form of cash or in Shares (or in a combination thereof) which have an aggregate Fair Market Value equal to the value of the earned Performance Units, Performance Shares or Cash-Based Awards as soon as practicable after the end of the Performance Period and following the Committee&#8217;s determination of actual performance against the performance goals and&#47;or other terms and conditions established by the Committee. Such Shares may be granted subject to any restrictions imposed by the Committee, including pursuant to Section&#160;21.9. The determination of the Committee with respect to the form of payment of such Awards shall be set forth in the Award Agreement pertaining to the grant of the Award.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Rights as a Shareholder</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. A Participant receiving a Performance Unit, Performance Share or Cash-Based Award shall have the rights of a shareholder only as to Shares, if any, actually received by the Participant upon satisfaction or achievement of the terms and conditions of such Award and not with respect to Shares subject to the Award but not actually issued to such Participant.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Termination of Employment or Service</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Each Award Agreement shall set forth the extent to which the Participant shall have the right to retain Performance Units, Performance Shares and&#47;or Cash-Based Award following such Participant&#8217;s Termination. Such provisions shall be determined in the sole discretion of the Committee, shall be included in the applicable Award Agreement, need not be uniform among all such Awards issued pursuant to the Plan, and may reflect distinctions based on the reasons for Termination.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9.7&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Compliance With Section&#160;409A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Unless the Committee provides otherwise in an Award Agreement, each Performance Unit, Performance Share and&#47;or Cash-Based Award shall be paid in full to the Participant no later than the fifteenth day of the third month after the end of the first calendar year in which such Award is no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Code Section&#160;409A. If the Committee provides in an Award Agreement that a Performance Share, Performance Unit or Cash-Based Award is intended to be subject to Code Section&#160;409A, the Award Agreement shall include terms that are intended to satisfy the requirements of Section&#160;409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">ARTICLE X.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline">OTHER STOCK-BASED AWARDS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Other Stock-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. The Committee may grant types of equity-based or equity-related Awards not otherwise described by the terms of the Plan (including the grant or offer for sale of unrestricted Shares), in such amounts (subject to Article IV) and subject to such terms and conditions, as the Committee shall determine. Such Other Stock-Based Awards may involve the transfer of actual Shares to Participants, or payment in cash or otherwise of amounts based on the value of Shares and may include Awards designed to comply with or take advantage of the applicable local laws of jurisdictions other than the United States.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Value of Other Stock-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Each Other Stock-Based Award shall be expressed in terms of Shares or units based on Shares, as determined by the Committee. The Committee may establish performance goals in its discretion, and any such performance goals shall be set forth in the applicable Award Agreement. If the Committee exercises its discretion to establish performance goals, the number and&#47;or value of Other Stock-Based Awards that will be paid out to the Participant will depend on the extent to which such performance goals are met.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Payment of Other Stock-Based Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Payment, if any, with respect to an Other Stock-Based Award shall be made in accordance with the terms of the Award, as set forth in the Award Agreement, in cash or Shares as the Committee determines.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Termination of Employment or Service</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. The Committee shall determine the extent to which the Participant shall have the right to receive Other Stock-Based Awards following the Participant&#8217;s Termination. Such provisions shall be determined in the sole discretion of the Committee, such provisions may be included in the applicable Award Agreement, but need not be uniform among all Other Stock-Based Awards issued pursuant to the Plan, and may reflect distinctions based on the reasons for Termination.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Compliance With Section&#160;409A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Unless the Committee provides otherwise in an Award Agreement, each Other Stock-Based Award shall be paid in full to the Participant no later than the fifteenth day of the third month after the end of the first calendar year in which the Other Stock-Based Award is no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Code Section&#160;409A. If the Committee provides in an Award Agreement that a Cash-Based Award or Other Stock-Based Award is intended to be subject to Code Section&#160;409A, the Award Agreement shall include terms that are intended to satisfy the requirements of Section&#160;409A.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">ARTICLE XI.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline">NON-EMPLOYEE DIRECTOR FEES IN SHARES OR OTHER AWARDS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">11.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Payment of Fees in Shares or Other Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. The Board may determine to pay a Non-Employee Director up to 100% of his or her Fees as an Other Stock-Based Award denominated in Shares, or another type of Award, or otherwise make Awards in lieu of all or any portion of his or her Fees. Except as otherwise provided in this Article XI, the percentage of Fees to be paid in such Shares or other Awards to Non-Employee Directors, or the amount of an Award in lieu of Fees, during each calendar quarter shall be determined by the Board on or prior to the first day of such quarter. If such an Award to be issued as Fees is based on a percentage of such Fees, the number of Shares subject to such Award shall be determined by multiplying such percentage by the amount of such Fees otherwise payable in cash for such quarter and dividing the product by the Fair Market Value of the Shares on the first day of such quarter. If this formula produces a fractional Share, the Non-Employee Director shall be paid in cash the Fair Market Value of the fractional Share.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">11.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Election to Receive Fees in Shares or Other Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. To the extent permitted by the Board, a Non-Employee Director may elect to receive up to 100% of his or her Fees (not otherwise payable in Shares or any other Award pursuant to Section&#160;11.1) as an Other Stock-Based Award denominated in Shares or another type of Award, or otherwise elect to receive an Award in lieu of all or any portion of his or her Fees (not otherwise payable in Shares or any other Award pursuant to Section&#160;11.1) (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Stock Election</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8221;). A Stock Election must be in writing and shall be delivered to the Corporate Secretary of the Company prior to the Annual Meeting. Except as provided in this Article XI, such a Stock Election shall apply to Fees payable to the Non-Employee Director in respect of Board </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and&#47;or committee service during the period commencing on the date of such Annual Meeting and ending on the day before the next Annual Meeting, and a Non-Employee Director may revoke a Stock Election by delivering written notice of such revocation to the Corporate Secretary of the Company prior to the last day of any calendar quarter with respect to all calendar quarters beginning after delivery of such notice of revocation. A Stock Election may specify the applicable percentage of the Fees that the Non-Employee Director wishes to receive in Shares or other applicable Award (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Designated Percentage</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;). If a Stock Election specifying a Designated Percentage is made, then not later than the first day of the applicable calendar quarter, the number of Shares subject to the Award to be issued in lieu of the Non-Employee Director&#8217;s Fees pursuant to such Stock Election shall be determined by multiplying the Designated Percentage by the amount of Fees otherwise payable in cash for such quarter and dividing that product by the Fair Market Value of the Shares on the first day of such quarter. If this formula produces a fractional Share, the Non-Employee Director shall be paid in cash the Fair Market Value of the fractional Share.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">11.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Timing of Determinations or Elections</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. If required by the Board, determinations or elections concerning the percentage of Fees payable in Awards other than Shares, or the amount of any such Awards payable in lieu of Fees, shall be made prior to the commencement of the calendar year in which an Non-Employee Director performs the services to which such Fees relate, and any such determination or election shall be irrevocable with respect to such Fees for services performed during such calendar year.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XII.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">PERFORMANCE MEASURES</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">12.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Performance Measures</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The objective performance goals upon which the granting, payment and&#47;or vesting of Awards to Covered Employees that are intended to qualify as Performance-Based Compensation may occur shall be based on any one or more of the following Performance Measures selected by the Committee&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) asset growth&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) combined net worth&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) debt to equity ratio&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) earnings per share&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) revenue growth&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(f) investment performance&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(g) operating income (with or without investment income or income taxes)&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(h) cash flow&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(i) margin&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(j) net income, before or after taxes&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(k) earnings before interest, taxes, depreciation and&#47;or amortization&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(l) return on total capital, equity, revenue or assets&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(m) medical loss ratio&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(n) number of medical or specialty policyholders, members or insured&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(o) quality of service metrics&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(p) customer service metrics&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(q) productivity&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(r) administrative expense management&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(s) improved health of members, including enrollment in disease management programs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(t) economic profit&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(u) shareholder value added&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(v) stock price appreciation or total shareholder return&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(w) medical and&#47;or specialty market share&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(x) medical and&#47;or specialty penetration rate or uninsured rate&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(y) specialty earnings as a percent of total earnings&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(z) associate perceptions or turnover&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(aa) consumer perceptions of the Company or the Company&#8217;s industry&#59; and</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(ab) merger integration synergies.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Such performance goals shall be established by the Committee within the time period prescribed by, and shall otherwise comply with the requirements of, Code Section&#160;162(m)(4)(C), or any successor provision thereto, and the regulations thereunder, for performance-based compensation, and may be set forth in the applicable Award Agreement. Any Performance Measures may be used to measure the performance of the Company, its Affiliates, and&#47;or Subsidiaries as a whole or any business unit of the Company, its Affiliates, and&#47;or Subsidiaries or any combination thereof, as the Committee may deem appropriate, or any of the above Performance Measures as compared to the performance of a group of comparator companies, or published or special index that the Committee, in its sole discretion, deems appropriate, or the Company may select any relevant Performance Measure as compared to various stock market indices, or growth rates, or trends. The Performance Measures shall not include or derive from the number or frequency of (i)&#160;denials of authorization for benefit coverage&#59; or (ii)&#160;reductions or limitations on hospital lengths of stay, medical services or charges. Performance Measures shall not be designed, construed or used to incentivize the withholding of medically necessary services or the denial of benefits to which members are entitled.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">12.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Evaluation of Performance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any other provision of the Plan, payment or vesting of any such Award that is intended to qualify as Performance-Based Compensation shall not be made until the Committee certifies in writing that the applicable performance goals and any other material terms of such Award were in fact satisfied, except as otherwise provided in Section&#160;12.3. The Committee may provide in any such Award that any evaluation of performance may include or exclude any of the following events that occurs during a Performance Period&#58; (a)&#160;gains or losses on sales or dispositions, (b)&#160;asset write-downs, (c)&#160;litigation or claim judgments or settlements, (d)&#160;historic environmental obligations, (e)&#160;changes in tax law or rate, including the impact on deferred tax liabilities, (f)&#160;uninsured catastrophic property losses, (g)&#160;the cumulative effect of changes in accounting principles, (h)&#160;extraordinary items described in Accounting Principles Board Opinion No.&#160;30 and&#47;or in management&#8217;s discussion and analysis of financial performance appearing in the Company&#8217;s Annual Report on Form 10-K, (i)&#160;acquisitions occurring after the start of a Performance Period or unbudgeted costs incurred related to future acquisitions, (j)&#160;operations discontinued, divested or restructured during the Performance Period, including severance costs, (k)&#160;gains or losses on refinancing or extinguishment of debt, and (l)&#160;foreign exchange gains and losses. To the extent such inclusions or exclusions affect Awards to Covered Employees, they shall be prescribed in a form that meets the requirements of Code Section&#160;162(m) for deductibility.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">12.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Adjustment of Performance-Based Compensation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any provision of the Plan to the contrary, with respect to any Award that is intended to qualify as Performance-Based Compensation, (a)&#160;the Committee may adjust downwards, but not upwards, any amount payable, or other benefits granted, issued, retained and&#47;or vested pursuant to such an Award on account of satisfaction of the applicable performance goals on the basis of such further considerations as the Committee in its discretion shall determine, and (b)&#160;the Committee may not waive the achievement of the applicable performance goals, except in the case of the Participant&#8217;s death, disability or a Change of Control.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">12.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Committee Discretion</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. In the event that applicable tax and&#47;or securities laws change to permit Committee discretion to alter the governing Performance Measures without obtaining shareholder approval of such changes, the Committee shall have sole discretion to make such changes without obtaining shareholder approval. In addition, in the event that the Committee determines that it is advisable to grant Awards that shall not qualify as Performance-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based Compensation, the Committee may make such grants without satisfying the requirements of Code Section&#160;162(m) and base vesting&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">of such Awards on performance measures</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;other than those set forth in Section&#160;12.1.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XIII.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">DIVIDEND EQUIVALENTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">13.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Dividend Equivalents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Unless otherwise provided by the Committee, no adjustment shall be made in the Shares issuable or taken into account under Awards on account of cash dividends that may be paid or other rights that may be issued to the holders of Shares prior to issuance of such Shares under such Award. The Committee may grant Dividend Equivalents based on the dividends declared on Shares that are subject to any Award, including any Award the payment or settlement of which is deferred pursuant to Section&#160;21.6. The Committee may also grant Dividend Equivalents based on the dividends that would have been declared on Restricted Stock Units or Performance Units had such Units been Shares of Restricted Stock or Performance Units, as the case may be. In the event that payment or settlement of an Award is contingent on achievement of performance goals, no Dividend Equivalents shall be paid on any unearned portion of the Award. Dividend Equivalents may be credited as of the dividend payment dates, during the period between the date the Award is granted and the date the Award becomes payable, terminates or expires. Dividend Equivalents may be subject to any limitations and&#47;or restrictions determined by the Committee. Dividend Equivalents shall be converted to cash or additional Shares by such formula and at such time, and shall be paid at such times, as may be determined by the Committee. Unless the Award Agreement provides otherwise, Dividend Equivalents shall be paid to the Participant at least annually, not later than the fifteenth day of the third month following the end of the calendar year in which the Dividend Equivalents are credited (or, if later, the fifteenth day of the third month following the end of the calendar year in which the Dividend Equivalents are no longer subject to a substantial risk of forfeiture within the meaning of Code Section&#160;409A). Any Dividend Equivalents that are accumulated and paid after the date specified in the preceding sentence shall be explicitly set forth in a separate arrangement that provides for the payment of the dividend equivalents at a time and in a manner that satisfies the requirements of Code Section&#160;409A. No Dividend Equivalents shall relate to Shares underlying an Option or SAR unless such Dividend Equivalent rights are explicitly set forth as a separate arrangement and do not cause any such Option or SAR to be subject to Code Section&#160;409A.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XIV.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">TRANSFERABILITY OF AWARDS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">14.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Transferability of Incentive Stock Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. No ISO or Tandem SAR granted in connection with an ISO may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution. Further, all ISOs and Tandem SARs granted in connection with ISOs granted to a Participant shall be exercisable during his or her lifetime only by such Participant.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">14.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">All Other Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Except as otherwise provided in Section&#160;8.5 or a Participant&#8217;s Award Agreement or otherwise determined at any time by the Committee, no Award granted under the Plan may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution&#59; provided that the Committee may permit further transferability, on a general or a specific basis, and may impose conditions and limitations on any permitted transferability, subject to Section&#160;14.1 and any applicable Period of Restriction&#59; provided further, however, that no Award may be transferred for value or other consideration without first obtaining approval thereof by the shareholders of the Company. Further, except as otherwise provided in a Participant&#8217;s Award Agreement or otherwise determined at any time by the Committee, or unless the Committee decides to permit further transferability, subject to Section&#160;14.1 and any applicable Period of Restriction, all Awards granted to a Participant under the Plan, and all rights with respect to such Awards, shall be exercisable or available during his or her lifetime only by or to such Participant. With respect to those Awards, if any, that are permitted to be transferred to another individual, references in the Plan to exercise or payment related to such Awards by or to the Participant shall be deemed to include, as determined by the Committee, the Participant&#8217;s permitted transferee. A Participant&#8217;s unexercised Option or SAR, or amounts due but remaining unpaid to such Participant, at the Participant&#8217;s death, shall be exercised or paid as designated by the Participant by will or by the laws of descent and distribution. In the event any Award is exercised by or otherwise paid to the executors, administrators, heirs or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">distributees of the estate of a deceased Participant, or the transferee of an Award, in any such case, pursuant to the terms and conditions of the Plan and the applicable Agreement and in accordance with such terms and conditions as may be specified from time to time by the Committee, the Company shall be under no obligation to issue Shares thereunder unless and until the Company is satisfied, as determined in the discretion of the Committee, that the person or persons exercising such Award, or to receive such payment, are the duly appointed legal representative of the deceased Participant&#8217;s estate or the proper legatees or distributees thereof, or the valid transferee of such Award, as applicable. Any purported assignment, transfer or encumbrance of an Award that does not comply with this Section&#160;14.2 shall be void and unenforceable against the Company.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XV.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">RIGHTS OF PARTICIPANTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">15.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Rights or Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. No individual shall have any rights or claims under the Plan except in accordance with the provisions of the Plan and any applicable Award Agreement. The grant of an Award under the Plan shall not confer any rights upon the Participant holding such Award other than such terms, and subject to such conditions, as are specified in the Plan as being applicable to such type of Award, or to all Awards, or as are expressly set forth in the Award Agreement evidencing such Award. Without limiting the generality of the foregoing, nothing contained in the Plan or in any Award Agreement shall be deemed to&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) Give any Employee or Non-Employee Director the right to be retained in the service of the Company, an Affiliate and&#47;or a Subsidiary, whether in any particular position, at any particular rate of compensation, for any particular period of time or otherwise&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) Restrict in any way the right of the Company, an Affiliate and&#47;or a Subsidiary to terminate, change or modify any Employee&#8217;s employment or any Non-Employee Director&#8217;s service as a Director at any time with or without Cause&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) Confer on any Consultant any right of continued relationship with the Company, an Affiliate and&#47;or a Subsidiary, or alter any relationship between them, including any right of the Company or an Affiliate or Subsidiary to terminate, change or modify its relationship with a Consultant&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) Give any Employee, Non-Employee Director or Consultant the right to receive any bonus, whether payable in cash or in Shares, or in any combination thereof, from the Company, an Affiliate and&#47;or a Subsidiary, nor be construed as limiting in any way the right of the Company, an Affiliate and&#47;or a Subsidiary to determine, in its sole discretion, whether or not it shall pay any Employee, Non-Employee Director or Consultant bonuses, and, if so paid, the amount thereof and the manner of such payment&#59; or</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) Give any Participant any rights whatsoever with respect to an Award except as specifically provided in the Plan and the Award Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">15.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Adoption of the Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The adoption of the Plan shall not be deemed to give any Employee, Non-Employee Director or Consultant or any other individual any right to be selected as a Participant or to be granted an Award, or, having been so selected, to be selected to receive a future Award.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">15.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Vesting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any other provision of the Plan, a Participant&#8217;s right or entitlement to exercise or otherwise vest in any Award not exercisable or vested at the time of grant shall only result from continued services as a Non-Employee Director or Consultant or continued employment, as the case may be, with the Company or any Subsidiary or Affiliate, or satisfaction of any other performance goals or other conditions or restrictions applicable, by its terms, to such Award.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">15.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Effects on Benefits</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Payments and other compensation received by a Participant under an Award are not part of such Participant&#8217;s normal or expected compensation or salary for any purpose, including calculating termination, indemnity, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments under any laws, plans, contracts, arrangements or otherwise. No claim or entitlement to compensation or damages arises from the termination of the Plan or diminution in value of any Award or Shares purchased or otherwise received under the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">15.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">One or More Types of Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. A particular type of Award may be granted to a Participant either alone or in addition to other Awards under the Plan.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XVI.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">CHANGE OF CONTROL</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">16.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Treatment of Outstanding Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. In the event of a Change of Control, unless otherwise specifically prohibited by any applicable laws, rules or regulations or otherwise provided in any applicable Award Agreement, as in effect prior to the occurrence of the Change of Control, specifically with respect to a Change of Control&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement or by resolution adopted prior to the occurrence of such Change of Control, that any Options, SARs and Other Stock-Based Awards (if applicable) which are outstanding shall become exercisable as determined by the Committee, notwithstanding anything to the contrary in the Award Agreement&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that if the surviving or successor corporation to the Company, or any parent or subsidiary thereof, or any other corporation that is a party to the transaction resulting in the Change of Control, does not agree to assume, or substitute equivalent options or other awards for, such Options, SARs or Other Stock-Based Awards, or in the event of a liquidation of the Company, then immediately prior to the occurrence of such Change of Control, or as of such earlier date as the Committee may prescribe, any and all Options, SARs and Other Stock-Based Awards (if applicable) which are outstanding shall immediately become fully exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the Award Agreement.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement or by resolution adopted prior to the occurrence of such Change of Control, that restrictions, performance goals or other conditions applicable to Restricted Stock Units, Shares of Restricted Stock and Other Stock-Based Awards previously awarded to Participants shall be canceled or deemed achieved, the Period of Restriction applicable thereto shall terminate, and restrictions on transfer, sale, assignment, pledge or other disposition applicable to any such Shares of Restricted Stock shall lapse, in each case, to the extent provided by the Committee, notwithstanding anything to the contrary in the Award Agreement&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that if the surviving or successor corporation to the Company, or any parent or subsidiary thereof, or any other corporation that is a party to the transaction resulting in the Change of Control does not agree to assume, or substitute equivalent awards for, any such Awards, or in the event of a liquidation of the Company, then immediately prior to the occurrence of such Change of Control, any restrictions, performance goals or other conditions applicable to Restricted Stock Units, Shares of Restricted Stock and Other Stock-Based Awards previously awarded to Participants shall be immediately canceled or deemed achieved, the Period of Restriction applicable thereto shall immediately terminate, and all restrictions on transfer, sale, assignment, pledge or other disposition applicable to any such Shares of Restricted Stock shall immediately lapse, notwithstanding anything to the contrary in the Plan or the Award Agreement.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement or by resolution adopted prior to the occurrence of such Change of Control, that any Awards which are outstanding shall, in whole or in part, immediately become vested and nonforfeitable&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that if the surviving or successor corporation to the Company, or any parent or subsidiary thereof, or any other corporation that is a party to the transaction resulting in the Change of Control does not agree to assume, or substitute equivalent awards for, any such Awards, or in the event of a liquidation of the Company, then immediately prior to the occurrence of such Change of Control, all Awards which are outstanding shall immediately become fully vested and nonforfeitable.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement or by resolution adopted prior to the occurrence of such Change of Control, that the target payment opportunities attainable under any outstanding Awards of Performance Units, Performance Shares, Cash-Based Awards and other Awards shall be deemed to have been fully or partially earned for any Performance Period(s), as determined by the Committee, immediately prior to the effective date of the Change of Control. Notwithstanding the immediately preceding sentence to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:31.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">the contrary, if the surviving or successor corporation to the Company, or any parent or subsidiary thereof, or any other corporation that is a party to the transaction resulting in the Change of Control does not agree to assume, or substitute equivalent awards for, any such Awards, or in the event of a liquidation of the Company, then the target payment opportunities attainable under any outstanding Awards of Performance Units, Performance Shares, Cash-Based Awards and other Awards shall be deemed to have been fully earned for the entire Performance Period(s) immediately prior to the effective date of the Change of Control, unless actual performance exceeds the target, in which case actual performance shall be used, and (i)&#160;there shall be paid out to each Participant holding such an Award denominated in Shares, not later than five (5)&#160;days prior to the effective date of the Change of Control, a&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">pro rata</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;number of Shares (or the equivalent Fair Market Value thereof, as determined by the Committee, in cash) based upon an assumed achievement of all relevant targeted performance goals, unless actual performance exceeds the target, in which case actual performance shall be used, and upon the length of time within the Performance Period which has elapsed prior to the Change of Control, and (ii)&#160;Awards denominated in cash shall be paid&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">pro rata</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;to applicable Participants in cash within thirty (30)&#160;days following the effective date of the Change of Control, with the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">pro-ration</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;determined as a function of the length of time within the Performance Period which has elapsed prior to the Change of Control, and based on an assumed achievement of all relevant targeted performance goals, unless actual performance exceeds the target, in which case actual performance shall be used.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement applicable to any Award or by resolution adopted prior to the occurrence of such Change of Control, that any Award the payment or settlement of which was deferred under Section&#160;21.6 or otherwise may be paid or distributed immediately prior to the Change of Control, except as otherwise provided by the Committee in accordance with Section&#160;16.1(f)&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that if the surviving or successor corporation to the Company, or any parent or subsidiary thereof, or any other corporation that is a party to the transaction resulting in the Change of Control does not agree to assume, or substitute equivalent awards for, any such Awards, or in the event of a liquidation of the Company, then any such Award shall be paid or distributed immediately prior to such Change of Control, except as otherwise provided by the Committee in accordance with Section&#160;16.1(f).</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(f) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement applicable to any Award or by resolution adopted prior to the occurrence of the Change of Control, that any outstanding Award shall be adjusted by substituting for each Share subject to such Award immediately prior to the transaction resulting in the Change of Control the consideration (whether stock or other securities of the surviving corporation or any successor corporation to the Company, or a parent or subsidiary thereof, or that may be issuable by another corporation that is a party to the transaction resulting in the Change of Control) received in such transaction by holders of Shares for each Share held on the closing or effective date of such transaction, in which event the aggregate Option Price or Grant Price, as applicable, of the Award shall remain the same&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that if such consideration received in such transaction is not solely stock of a successor, surviving or other corporation, the Committee may provide for the consideration to be received upon exercise or payment of an Award, for each Share subject to such Award, to be solely stock or other securities of the successor, surviving or other corporation, as applicable, equal in fair market value, as determined by the Committee, to the per-Share consideration received by holders of Shares in such transaction.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(g) In its discretion, and on such terms and conditions as it deems appropriate, the Committee may provide, either by the terms of the Award Agreement applicable to any Award or by resolution adopted prior to the occurrence of the Change of Control, that any outstanding Award (or portion thereof) shall be converted into a right to receive cash, on or as soon as practicable following the closing date or expiration date of the transaction resulting in the Change of Control in an amount equal to the highest value of the consideration to be received in connection with such transaction for one Share, or, if higher, the highest Fair Market Value of a Share during the thirty (30)&#160;consecutive business days immediately prior to the closing date or expiration date of such transaction, less the per-Share Option Price, Grant Price or outstanding unpaid purchase price, as applicable to the Award, multiplied by the number of Shares subject to such Award, or the applicable portion thereof.</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(h) The Committee may, in its discretion, provide that an Award can or cannot be exercised after, or will otherwise terminate or not terminate as of, a Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">16.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Implied Rights&#59; Other Limitations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. No Participant shall have any right to prevent the consummation of any of the acts described in Section&#160;4.3 or 16.1 affecting the number of Shares available to, or other entitlement of, such Participant under the Plan or such Participant&#8217;s Award. Any actions or determinations of the Committee under this Article XVI need not be uniform as to all outstanding Awards, nor treat all Participants identically. Notwithstanding any provision of Section&#160;16.1 to the contrary, no actions of the Committee under Section&#160;16.1 shall materially impair the previously accrued rights of a Participant under any outstanding Award without the written consent of such Participant unless otherwise provided in the applicable Award Agreement. Notwithstanding the adjustments described in Section&#160;16.1, in no event may any Option or SAR be exercised after ten (10)&#160;years from the date it was originally granted, and any changes to ISOs pursuant to this Article XVI shall, unless the Committee determines otherwise, only be effective to the extent such adjustments or changes do not cause a &#8220;modification&#8221; (within the meaning of Section&#160;424(h)(3) of the Code) of such ISOs or adversely affect the tax status of such ISOs.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">16.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Termination, Amendment, and Modifications of Change of Control Provisions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any other provision of the Plan (but subject to the limitations of Section 16.1(h), the last sentence of Section&#160;17.1 and Section&#160;17.2) or any Award Agreement provision, the provisions of this Article XVI may not be terminated, amended, or modified on or after the date of a Change of Control to materially impair any Participant&#8217;s Award theretofore granted and then outstanding under the Plan without the prior written consent of such Participant.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">16.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Compliance with Section&#160;409A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any other provisions of the Plan or any Award Agreement to the contrary, if a Change of Control that is not a Qualified Change of Control occurs, and payment or distribution of an Award constituting deferred compensation subject to Section&#160;409A of the Code would otherwise be made or commence on the date of such Change of Control (pursuant to the Plan, the Award Agreement or otherwise), (a)&#160;the vesting of such Award shall accelerate in accordance with the Plan and the Award Agreement, (b)&#160;such payment or distribution shall not be made or commence prior to the earliest date on which Code Section&#160;409A permits such payment or distribution to be made or commence without additional taxes or penalties under Section&#160;409A, and (c)&#160;in the event any such payment or distribution is deferred in accordance with the immediately preceding clause (b), such payment or distribution that would have been made prior to the deferred payment or commencement date, but for Code Section&#160;409A, shall be paid or distributed on such earliest payment or commencement date, together, if determined by the Committee, with interest at the rate established by the Committee. The Committee shall not extend the period to exercise an Option or Stock Appreciation Right to the extent that such extension would cause the Option or Stock Appreciation Right to become subject to Code Section&#160;409A. Additionally, the Committee shall not take any action pursuant to this Article XVI that would cause an Award that is otherwise exempt from Code Section&#160;409A to become subject to Code Section&#160;409A, or that would cause an Award that is subject to Code Section409A to fail to satisfy the requirements of Code Section&#160;409A.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XVII.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">AMENDMENT, MODIFICATION, AND TERMINATION</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">17.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Amendment, Modification, and Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Board may, at any time and with or without prior notice, amend, alter, suspend, or terminate the Plan, and the Committee may, to the extent permitted by the Plan, amend the terms of any Award theretofore granted, including any Award Agreement, in each case, retroactively or prospectively&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that no such amendment, alteration, suspension, or termination of the Plan shall be made which, without first obtaining approval of the shareholders of the Company (where such approval is necessary to satisfy (i)&#160;the then-applicable requirements of Rule 16b-3, (ii)&#160;any requirements under the Code relating to ISOs or for exemption from Section&#160;162(m) of the Code, or (iii)&#160;any applicable law, regulation or rule (including the applicable regulations and rules of the SEC and any national securities exchange)), would&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) except as is provided in Section&#160;4.3, increase the maximum number of Shares which may be sold or awarded under the Plan or increase the maximum limitations set forth in Section&#160;4.2&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) except as is provided in Section&#160;4.3, decrease the minimum Option Price or Grant Price requirements of Sections 6.3 and 7.2, respectively&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) change the class of persons eligible to receive Awards under the Plan&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) change the Performance Measures set forth in Section&#160;12.1&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font><br></font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) extend the duration of the Plan or the period during which Options or SARs may be exercised under Section&#160;6.4 or 7.6, as applicable&#59; or</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(f) otherwise require shareholder approval to comply with any applicable law, regulation or rule (including the applicable regulations and rules of the SEC and any national securities exchange).</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, (A)&#160;no such amendment, alteration, suspension or termination of the Plan or any Award theretofore granted, including any Award Agreement, shall be made which would materially impair the previously accrued rights of a Participant under any outstanding Award without the written consent of such Participant, provided, however, that the Board may amend or alter the Plan and the Committee may amend or alter any Award, including any Agreement, either retroactively or prospectively, without the consent of the applicable Participant, (x)&#160;so as to preserve or come within any exemptions from liability under Section&#160;16(b) of the Exchange Act, pursuant to the rules and releases promulgated by the SEC (including Rule 16b-3), and&#47;or so that any Award that is intended to qualify as Performance-Based Compensation shall qualify for the performance-based compensation exception under Code Section&#160;162(m) (or any successor provision), or (y)&#160;if the Board or the Committee determines in its discretion that such amendment or alteration either (I)&#160;is required or advisable for the Company, the Plan or the Award to satisfy, comply with or meet the requirements of any law, regulation, rule or accounting standard or (II) is not reasonably likely to significantly diminish the benefits provided under such Award, or that such diminishment has been or will be adequately compensated, and (B)&#160;except as is provided in Section&#160;4.3, but notwithstanding any other provisions of the Plan, neither the Board nor the Committee may take any action&#58; (1)&#160;to amend the terms of an outstanding Option or SAR to reduce the Option Price or Grant Price thereof, cancel an Option or SAR and replace it with a new Option or SAR with a lower Option Price or Grant Price, or that has an economic effect that is the same as any such reduction or cancellation&#59; or (2)&#160;to cancel an outstanding Option or SAR having an Option Price or Grant Price above the then-current Fair Market Value of the Shares in exchange for cash or the grant of another type of Award, without, in each such case, first obtaining approval of the shareholders of the Company of such action.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">17.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Adjustment of Awards Upon the Occurrence of Certain Unusual or Nonrecurring Events</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Board or the Committee shall make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events (including the events described in Section&#160;4.3) affecting the Company or the financial statements of the Company or of changes in applicable laws, regulations, or accounting principles in order to prevent unintended dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan. Any such adjustment with respect to an Award intended to be an ISO shall be made only to the extent consistent with such intent, unless the Board or the Committee determines otherwise, and any such adjustment that is made with respect to an Award that is intended to qualify as Performance-Based Compensation shall be made consistent with the intent that such Award qualify for the performance-based compensation exception under Code Section&#160;162(m) (or any successor provision). Additionally, neither the Board nor the Committee shall not make any adjustment pursuant to this Article XVII that would cause an Award that is otherwise exempt from Code Section&#160;409A to become subject to Code Section&#160;409A, or that would cause an Award that is subject to Code Section&#160;409A to fail to satisfy the requirements of Code Section&#160;409A. The determination of the Committee as to the foregoing adjustments shall be conclusive and binding on Participants under the Plan.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XVIII.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">TAX WITHHOLDING AND OTHER TAX MATTERS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">18.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Tax Withholding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Company and&#47;or any Subsidiary or Affiliate are authorized to withhold from any Award granted or payment due under the Plan the amount of all Federal, state, local and non-United States taxes due in respect of such Award or payment and take any such other action as may be necessary or appropriate, as determined by the Committee, to satisfy all obligations for the payment of such taxes. The recipient of any payment or distribution under the Plan shall make arrangements satisfactory to the Company, as determined in the Committee&#8217;s discretion, for the satisfaction of any tax obligations that arise by reason of any such payment or distribution. The Company shall not be required to make any payment or distribution under or relating to the Plan or any Award until such obligations are satisfied or such arrangements are made, as determined by the Committee in its discretion.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">18.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Withholding or Tendering Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Without limiting the generality of Section&#160;18.1, the Committee may in its discretion permit a Participant to satisfy or arrange to satisfy, in whole or in part, the tax obligations incident to an Award by&#58; (a)&#160;electing to have the Company withhold Shares or other property otherwise deliverable to such Participant pursuant to his or her Award (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy required Federal, state, local and non-United States withholding obligations using the minimum statutory withholding rates for Federal, state, local and&#47;or non-U.S. tax purposes, including payroll taxes, that are applicable to supplemental taxable income) and&#47;or (b)&#160;tendering to the Company Shares owned by such Participant (or by such Participant and his or her spouse jointly) and purchased or held for the requisite period of time as may be required to avoid the Company&#8217;s or the Affiliates&#8217; or Subsidiaries&#8217; incurring an adverse accounting charge, based, in each case, on the Fair Market Value of the Shares on the payment date as determined by the Committee. All such elections shall be irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">18.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Restrictions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The satisfaction of tax obligations pursuant to this Article XVIII shall be subject to such restrictions as the Committee may impose, including any restrictions required by applicable law or the rules and regulations of the SEC, and shall be construed consistent with an intent to comply with any such applicable laws, rule and regulations.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">18.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Special ISO Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Committee may require a Participant to give prompt written notice to the Company concerning any disposition of Shares received upon the exercise of an ISO within&#58; (i)&#160;two (2)&#160;years from the date of granting such ISO to such Participant or (ii)&#160;one (1)&#160;year from the transfer of such Shares to such Participant or (iii)&#160;such other period as the Committee may from time to time determine. The Committee may direct that a Participant with respect to an ISO undertake in the applicable Award Agreement to give such written notice described in the preceding sentence, at such time and containing such information as the Committee may prescribe, and&#47;or that the certificates evidencing Shares acquired by exercise of an ISO refer to such requirement to give such notice.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">18.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;83(b) Election</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. If a Participant makes an election under Section&#160;83(b) of the Code to be taxed with respect to an Award as of the date of transfer of Shares rather than as of the date or dates upon which the Participant would otherwise be taxable under Section&#160;83(a) of the Code, such Participant shall deliver a copy of such election to the Company immediately after filing such election with the Internal Revenue Service. Neither the Company nor any Subsidiary or Affiliate shall have any liability or responsibility relating to or arising out of the filing or not filing of any such election or any defects in its construction.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">18.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Guarantee of Favorable Tax Treatment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Although the Company intends to administer the Plan so that Awards will be exempt from, or will comply with, the requirements of Code Section&#160;409A, the Company does not warrant that any Award under the Plan will qualify for favorable tax treatment under Code Section&#160;409A or any other provision of federal, state, local, or non-United States law. The Company shall not be liable to any Participant for any tax, interest, or penalties the Participant might owe as a result of the grant, holding, vesting, exercise, or payment of any Award under the Plan.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XIX.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">LIMITS OF LIABILITY&#59; INDEMNIFICATION</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">19.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Limits of Liability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) Any liability of the Company or a Subsidiary or Affiliate to any Participant with respect to any Award shall be based solely upon contractual obligations created by the Plan and the Award Agreement.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) None of the Company, any Subsidiary, any Affiliate, any member of the Board or the Committee or any other person participating in any determination of any question under the Plan, or in the interpretation, administration or application of the Plan, shall have any liability, in the absence of bad faith, to any party for any action taken or not taken in connection with the Plan, except as may expressly be provided by statute.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:63.95pt"><font><br></font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) Each member of the Committee, while serving as such, shall be considered to be acting in his or her capacity as a director of the Company. Members of the Board of Directors and members of the Committee acting under the Plan shall be fully protected in relying in good faith upon the advice of counsel and shall incur no liability except for gross negligence or willful misconduct in the performance of their duties.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) The Company shall not be liable to a Participant or any other person as to&#58; (i)&#160;the non-issuance of Shares as to which the Company has been unable to obtain from any regulatory body having relevant jurisdiction the authority deemed by the Committee or the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, and (ii)&#160;any tax consequence expected, but not realized, by any Participant or other person due to the receipt, exercise or settlement of any Option or other Award.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">19.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Indemnification</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Subject to the requirements of Indiana law, each individual who is or shall have been a member of the Committee or of the Board, or an officer of the Company to whom authority was delegated in accordance with Article III, shall be indemnified and held harmless by the Company against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company&#8217;s approval, or paid by him or her in satisfaction of any judgment in any such action, suit, or proceeding against him or her,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to&#160;handle and defend it on his or her own behalf, unless such loss, cost, liability, or expense is a result of the individual&#8217;s own willful misconduct or except as provided by statute. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to&#160;which such individual may be entitled under the Company&#8217;s Certificate of Incorporation or By-Laws, as a matter of law, or otherwise, or any power that the Company may have to indemnify or hold harmless such individual.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XX.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">SUCCESSORS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">20.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Successors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. All obligations of the Company under the Plan with respect to Awards granted hereunder shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and&#47;or assets of the Company.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ARTICLE XXI.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.1&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Drafting Context</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine&#59; the plural shall include the singular and the singular shall include the plural. The words &#8220;Article,&#8221; &#8220;Section,&#8221; and &#8220;paragraph&#8221; herein shall refer to provisions of the Plan, unless expressly indicated otherwise. The words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; herein shall be deemed to be followed by &#8220;without limitation&#8221; whether or not they are in fact followed by such words or words of similar import, unless the context otherwise requires.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.2&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Forfeiture Events</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) Notwithstanding any provision of the Plan to the contrary, the Committee shall have the authority to determine (and may so provide in any Agreement) that a Participant&#8217;s (including his or her estate&#8217;s or transferee&#8217;s) rights (including the right to exercise any Option or SAR), payments and benefits with respect to any Award shall be subject to reduction, cancellation, forfeiture or recoupment in the event of the Participant&#8217;s Termination for Cause or due to voluntary resignation&#59; serious misconduct&#59; violation of the Company&#8217;s or a Subsidiary&#8217;s or Affiliate&#8217;s policies&#59; breach of fiduciary duty&#59; unauthorized disclosure of any trade secret or confidential information of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Company or a Subsidiary or Affiliate&#59; breach of applicable noncompetition, nonsolicitation, confidentiality or other restrictive covenants&#59; or other conduct or activity that is in competition with the business of the Company or any Subsidiary or Affiliate, or otherwise detrimental to the business, reputation or interests of the Company and&#47;or any Subsidiary or Affiliate&#59; or upon the occurrence of certain events specified in the applicable Award Agreement (in any such case, whether or not the Participant is then an Employee, Non-Employee Director or Consultant). The determination of whether a Participant&#8217;s conduct, activities or circumstances are described in the immediately preceding sentence shall be made by the Committee in its good faith discretion, and pending any such determination, the Committee shall have the authority to suspend the exercise, payment, delivery or settlement of all or any portion of such Participant&#8217;s outstanding Awards pending an investigation of the matter.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws, if the Participant knowingly or grossly negligently engaged in the misconduct, or knowingly or grossly negligently failed to prevent the misconduct, or if the Participant is one of the individuals subject to automatic forfeiture under Section&#160;304 of the Sarbanes-Oxley Act of 2002, the Participant shall reimburse the Company the amount of any payment in settlement of an Award earned or accrued during the twelve- (12-) month period following the first public issuance or filing with the SEC (whichever just occurred) of the financial document embodying such financial reporting requirement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.3&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Severability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.4&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Transfer, Leave of Absence</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. For purposes of the Plan, a transfer of an Employee from the Company to an Affiliate or Subsidiary (or, for purposes of any ISO granted under the Plan, only a Subsidiary), or vice versa, or from one Affiliate or Subsidiary to another (or in the case of an ISO, only from one Subsidiary to another), and a leave of absence, duly authorized in writing by the Company or a Subsidiary or Affiliate, shall not be deemed a Termination of the Employee for purposes of the Plan or with respect to any Award (in the case of ISOs, to the extent permitted by the Code). The Committee shall have the discretion to determine the effects upon any Award, upon an individual&#8217;s status as an Employee, Non-Employee Director or Consultant for purposes of the Plan (including whether a Participant shall be deemed to have experienced a Termination or other change in status) and upon the exercisability, vesting, termination or expiration of any Award in the case of&#58; (a)&#160;any Participant who is employed by an entity that ceases to be an Affiliate or Subsidiary (whether due to a spin-off or otherwise), (b)&#160;any transfer of a Participant between locations of employment with the Company, an Affiliate, and&#47;or Subsidiary or between the Company, an Affiliate or Subsidiary or between Affiliates or Subsidiaries, (c)&#160;any leave of absence of a Participant, (d)&#160;any change in a Participant&#8217;s status from an Employee to a Consultant or a Non-Employee Director, or vice versa&#59; and (e)&#160;upon approval by the Committee, any Employee who experiences a Termination but becomes employed by a partnership, joint venture, corporation or other entity not meeting the requirements of an Affiliate or Subsidiary, subject, in each case, to the requirements of Code Section&#160;422 applicable to any ISOs and Code Section&#160;409A applicable to any Options and SARs.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.5&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Exercise and Payment of Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. An Award shall be deemed exercised or claimed when the Secretary of the Company or any other Company official or other person designated by the Committee for such purpose receives appropriate written notice from a Participant, in form acceptable to the Committee, together with payment of the applicable Option Price, Grant Price or other purchase price, if any, and compliance with Article XVIII, in accordance with the Plan and such Participant&#8217;s Award Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.6&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Deferrals</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. To the extent provided in the Award Agreement, the Committee may permit or require a Participant to defer such Participant&#8217;s receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant by virtue of the lapse or waiver of the Period of Restriction or other restrictions with respect to Restricted Stock or the payment or satisfaction of Restricted Stock Units, Performance Units, Performance Shares, Cash-Based Awards or Other Stock-Based Awards. If any such deferral election is required or permitted, (a)&#160;such deferral shall represent an unfunded and unsecured obligation of the Company and shall not confer the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">rights of a shareholder unless and until Shares are issued thereunder&#59; (b)&#160;the number of Shares subject to such deferral shall, until settlement thereof, be subject to adjustment pursuant to Section&#160;4.3&#59; and (c)&#160;the Committee shall establish rules and procedures for such deferrals and payment or settlement thereof, which may be in cash, Shares or any combination thereof, and such deferrals may be governed by the terms and conditions of any deferred compensation plan of the Company or Affiliate specified by the Committee for such purpose. Notwithstanding any provisions of the Plan to the contrary, in no event shall any deferral under this Section&#160;21.6 be permitted if the Committee determines that such deferral would result in the imposition of additional tax under Code Section&#160;409A of the Code.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.7&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Effect on Other Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Neither the adoption of the Plan nor anything contained herein shall affect any other compensation or incentive plans or arrangements of the Company or any Subsidiary or Affiliate, or prevent or limit the right of the Company or any Subsidiary or Affiliate to establish any other forms of incentives or compensation for their directors, officers, eligible employees or consultants or grant or assume options or other rights otherwise than under the Plan.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.8&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;16 of Exchange Act and Code Section&#160;162(m)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Unless otherwise stated in the Award Agreement, notwithstanding any other provision of the Plan, any Award granted to an Insider shall be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including Rule 16b-3) that are requirements for the application of such exemptive rule, and the Plan and the Award Agreement shall be deemed amended to the extent necessary to conform to such limitations. Furthermore, notwithstanding any other provision of the Plan or an Award Agreement, any Award to a Covered Employee that is intended to qualify as Performance-Based Compensation shall be subject to any applicable limitations set forth in Code Section&#160;162(m) or any regulations or rulings issued thereunder (including any amendment to the foregoing) that are requirements for qualification as &#8220;other performance-based compensation&#8221; as described in Code Section&#160;162(m)(4)(C), and the Plan and the Award Agreement shall be deemed amended to the extent necessary to conform to such requirements and no action of the Committee that would cause such Award not to so qualify shall be effective.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.9&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Requirements of Law&#59; Limitations on Awards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) The granting of Awards and the issuance of Shares under the Plan shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) If at any time the Committee shall determine, in its discretion, that the listing, registration and&#47;or qualification of Shares upon any securities exchange or under any state, Federal or non-United States law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the sale or purchase of Shares hereunder, the Company shall have no obligation to allow the grant, exercise or payment of any Award, or to issue or deliver evidence of title for Shares issued under the Plan, in whole or in part, unless and until such listing, registration, qualification, consent and&#47;or approval shall have been effected or obtained, or otherwise provided for, free of any conditions not acceptable to the Committee.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) If at any time counsel to the Company shall be of the opinion that any sale or delivery of Shares pursuant to an Award is or may be in the circumstances unlawful or result in the imposition of excise taxes on the Company or any Subsidiary or Affiliate under the statutes, rules or regulations of any applicable jurisdiction, the Company shall have no obligation to make such sale or delivery, or to make any application or to effect or to maintain any qualification or registration under the Securities Act, or otherwise with respect to Shares or Awards and the right to exercise or payment of any Option or Award shall be suspended until, in the opinion of such counsel, such sale or delivery shall be lawful or will not result in the imposition of excise taxes on the Company or any Subsidiary or Affiliate.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) Upon termination of any period of suspension under this Section&#160;21.9, any Award affected by such suspension which shall not then have expired or terminated shall be reinstated as to all Shares available before such suspension and as to the Shares which would otherwise have become available during the period of such suspension, but no suspension shall extend the term of any Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:6pt;padding-left:63.95pt"><font><br></font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) The Committee may require each person receiving Shares in connection with any Award under the Plan to represent and agree with the Company in writing that such person is acquiring such Shares for investment without a view to the distribution thereof, and&#47;or provide such other representations and agreements as the Committee may prescribe. The Committee, in its absolute discretion, may impose such restrictions on the ownership and transferability of the Shares purchasable or otherwise receivable by any person under any Award as it deems appropriate. Any such restrictions shall be set forth in the applicable Award Agreement, and the certificates evidencing such shares may include any legend that the Committee deems appropriate to reflect any such restrictions.</font></div><div style="margin-top:6pt;padding-left:63.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(f) An Award and any Shares received upon the exercise or payment of an Award shall be subject to such other transfer and&#47;or ownership restrictions and&#47;or legending requirements as the Committee may establish in its discretion and may be referred to on the certificates evidencing such Shares, including restrictions under applicable Federal securities laws, under the requirements of any stock exchange or market upon which such Shares are then listed and&#47;or&#160;traded, and under any blue sky or state securities laws applicable to such Shares.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.10&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Participants Deemed to Accept Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. By accepting any benefit under the Plan, each Participant and each person claiming under or through any such Participant shall be conclusively deemed to have indicated their acceptance and ratification of, and consent to, all of the terms and conditions of the Plan and any action taken under the Plan by the Board, the Committee or the Company, in any case in accordance with the terms and conditions of the Plan.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.11&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Governing Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Plan and all Award Agreements and other agreements hereunder shall be construed in accordance with and governed by the laws of the state of Indiana, without giving effect to the choice of law principles thereof, except to the extent superseded by applicable United States federal law. Unless otherwise provided in the Award Agreement, Participants are deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of Indiana, to resolve any and all issues that may arise out of or relate to the Plan or any related Award Agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.12&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Plan Unfunded</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the issuance of Shares or the payment of cash upon exercise or payment of any Award. Proceeds from the sale of Shares pursuant to Options or other Awards granted under the Plan shall constitute general funds of the Company.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.13&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Administration Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The Company shall bear all costs and expenses incurred in administering the Plan, including expenses of issuing Shares pursuant to any Options or other Awards granted hereunder.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.14&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Uncertificated Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. To the extent that the Plan provides for issuance of certificates to reflect the transfer of Shares, the transfer of such Shares may nevertheless be effected on a noncertificated basis, to the extent not prohibited by applicable law or the rules of any stock exchange.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.15&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">No Fractional Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. An Option or other Award shall not be exercisable with respect to a fractional Share or the lesser of fifty (50)&#160;shares or the full number of Shares then subject to the Option or other Award. No fractional Shares shall be issued upon the exercise or payment of an Option or other Award.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.16&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Deferred Compensation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. If any Award would be considered deferred compensation as defined under Code Section&#160;409A and would fail to meet the requirements of Code Section&#160;409A, then such Award shall be null and void&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, that the Committee may permit deferrals of compensation pursuant to the terms of a Participant&#8217;s Award Agreement, a separate plan, or a subplan which (in each case) meets the requirements of Code Section&#160;409A. Additionally, to the extent any Award is subject to Code Section&#160;409A, notwithstanding any provision herein to the contrary, the Plan does not permit the acceleration of the time or schedule of any distribution related to such Award, except as permitted by Code Section&#160;409A.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">21.17&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline">Participants Based Outside of the United States</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws or practices of countries other than the United States in which the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Company, any Affiliate, and&#47;or any Subsidiary operates or has Employees, Consultants or Non-Employee Directors, the Committee, in its sole discretion, shall have the power and authority to&#58;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) Determine which Affiliates and Subsidiaries shall be covered by the Plan&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) Determine which Employees, Consultants and&#47;or Non-Employee Directors outside the United States are eligible to participate in the Plan&#59;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">&#160;</font></div><div style="padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) Grant Awards (including substitutes for Awards), and modify the terms and conditions of any Awards, on such terms and conditions as the Committee determines necessary or appropriate to permit participation in the Plan by individuals otherwise eligible to so participate who are non-United States nationals or employed outside the United States, or otherwise to comply with applicable non-United States laws or conform to applicable requirements or practices of jurisdictions outside the United States&#59;</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) Establish subplans and adopt or modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or advisable. Any subplans and modifications to Plan terms and procedures established under this Section&#160;21.17 by the Committee shall be attached to the Plan as appendices&#59; and</font></div><div style="margin-top:6pt;padding-left:31.95pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(e) Take any action, before or after an Award is made, that the Committee, in its discretion, deems advisable to obtain approval or comply with any necessary local government regulatory exemptions or approvals.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Notwithstanding the above, the Committee may not take any actions hereunder, and no Awards shall be granted, that would violate any applicable law.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>exhibit1011-primarybluecro.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5abcf6af21b34b3bbcae3a76cfb49bd7_1"></div><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:93.3pt;padding-right:93.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS LICENSE AGREEMENT</font></div><div style="margin-top:1.05pt;padding-left:50.2pt;padding-right:50.2pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Includes revisions, if any, adopted by Member Plans through their June 16, 2022 meeting)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:51pt;padding-right:49.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement by and between Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and The Blue Cross Plan, known as</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#34;Plan&#34;).</font></div><div style="margin-top:10.45pt;padding-left:102.25pt;padding-right:102.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Preamble</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:66.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Plan and&#47;or its predecessor(s) in interest (collectively the &#34;Plan&#34;) had the right to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the &#34;Licensed Marks&#34;) for health care plans in its service area, which was essentially local in nature&#59;</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:51pt;padding-right:46.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Plan was desirous of assuring nationwide protection of the Licensed Marks, maintaining uniform quality controls among Plans, facilitating the provision of cost effective health care services to the public and otherwise benefiting the public&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:51pt;padding-right:59.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, to better attain such ends, the Plan and the predecessor of BCBSA in 1972 simultaneously executed the BCA License Agreement (s) and the Ownership Agreement&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:51pt;padding-right:52.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, BCBSA and the Plan desire to supercede said Agreement(s) and to revise certain provisions of the Ownership Agreement to reflect their current practices and to assure the continued integrity of the Licensed Marks and of the BLUE CROSS system&#59;</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:51pt;padding-right:58.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-top:4pt;padding-left:131.1pt;padding-right:131.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Agreement</font></div><div style="margin-top:11.65pt;padding-left:51pt;padding-right:46.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;BCBSA hereby grants to the Plan, upon the terms and conditions of this License Agreement (&#8220;Agreement&#8221; or &#8220;Primary License Agreement&#8221;), the right to use BLUE CROSS in its trade and&#47;or corporate name (the &#34;Licensed Name&#34;), and the right to use the Licensed Marks, in the sale, marketing and administration of health care plans and related services in the Service Area set forth and defined in paragraph 5 below. As used herein, health care plans and related services shall include acting as a nonprofit health care plan, a for-profit health care plan, or mutual health insurer operating on a not-for-profit or for-profit basis, under state law&#59; financing access to health care services&#59; when working with a bank that holds the relevant license to use the Licensed Name and Marks, offering&#58; (i) tax- favored savings accounts for medical expenses and means for accessing such accounts, such as debit cards or checks, that are provided solely to support access to such tax- favored savings accounts, all pursuant to such license, or (ii) prepaid rewards cards that are provided for completion of a wellness program, all pursuant to such license&#59; providing health care management and administration&#59; administering, but not underwriting, non- health portions of Workers&#8217; Compensation Insurance&#59; delivering health care services, except hospital services (as defined in the Guidelines to Membership Standards Applicable to Regular Members)&#59; and performing the Eligibility and Enrollment functions of HR administration for all benefit plans offered by a group account to its members, including benefit plans not provided by the Plan, provided that the Plan has contracted to provide Health Coverage under the Licensed Marks to the account (as the terms &#8220;Health Coverage,&#8221; &#8220;Eligibility&#8221; and &#8220;Enrollment&#8221; are defined in Exhibit 4, Paragraph 2.t.).</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.5pt;padding-left:51pt;padding-right:48.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Plan may use the Licensed Marks and Name in connection with the offering of&#58; i) health care plans and related services in the Service Area through Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1 hereto (the &#34;Controlled Affiliate License Agreement&#34;)&#59; and ii) insurance coverages offered by life insurers under the applicable law in the Service Area, other than those which the Plan may offer in its own name, provided through Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1A hereto (the &#34;Controlled Affiliate License Agreement Applicable to Life Insurance Companies&#34;) or the Agreement attached as Exhibit 1A1 hereto (the &#8220;Controlled Affiliate Trademark License Agreement for Life and Disability Insurance Products&#8221;) and further provided that the offering of such services does not and will not dilute or tarnish the unique value of the Licensed Marks and Name&#59; and iii) administration and underwriting of Workers&#8217; Compensation Insurance Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1 hereto (the &#8220;Controlled Affiliate License&#8221;)&#59; and iv) regional Medicare Advantage PPO products in cooperation with one or more other Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1B hereto (the &#8220;Controlled Affiliate License Agreement Applicable to Regional Medicare Advantage PPO Products&#8221;)&#59; and v) regional Medicare Part D Prescription Drug Plan products in cooperation with one or more other Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1C hereto (the &#8220;Controlled Affiliate License Agreement Applicable to Regional Medicare Part D Prescription Drug Plan Products&#8221;). As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it is subject to the bona fide control of a Plan or Plans and, if the entity meets the standards of Paragraph 2a.B but not Paragraph 2a.A, the entity, its owners, and persons with authority to select or</font></div><div style="margin-top:8.05pt;padding-left:334.8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:8.05pt;padding-left:334.8pt"><font><br></font></div><div style="margin-top:5.45pt;padding-left:50.95pt;padding-right:52.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appoint members or board members, other than a Plan or Plans, have received written approval of BCBSA. Absent written approval by BCBSA of an alternative method of control, bona fide control shall have the meaning set forth in Paragraphs 2a. and 2b.</font></div><div style="margin-top:10pt;padding-left:86.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">2a. With respect to the Controlled Affiliate Licenses authorized in clauses i) through iii) of Paragraph 2, bona fide control shall mean that a Plan (the &#8220;Sponsoring Plan&#8221;) authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to this Primary License Agreement with BCBSA must have&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:132pt;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">A.&#160;&#160;&#160;&#160;The legal authority, directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-top:0.6pt;padding-left:108pt;padding-right:51.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) to select members of the Controlled Affiliate's governing body having more than 50% voting control thereof&#59; (b) to exercise control over the policy and operations of the Controlled Affiliate&#59; (c) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur. In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee&#59; or</font></div><div style="margin-top:9.5pt;padding-left:108pt;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">B.&#160;&#160;&#160;&#160;The legal authority directly or indirectly through wholly-owned subsidiaries</font></div><div style="margin-top:0.6pt;padding-left:108pt;padding-right:48.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:99%">(a) to select members of the Controlled Affiliate's governing body having not less than 50% voting control thereof&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur&#59; (c) to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring Plan. Notwithstanding anything to the contrary in through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can&#58;</font></div><div style="margin-top:11.65pt;padding-left:186.35pt;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Change its legal and&#47;or trade name&#59;</font></div><div><font><br></font></div><div style="padding-left:186.35pt;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Change the geographic area in which it operates&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:186.35pt;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Change any of the types of businesses in which it engages&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:186pt;padding-right:71.8pt;text-indent:-19.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the ordinary course of business&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:186pt;padding-right:49.2pt;text-indent:-19.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being replaced&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:186pt;padding-right:73.15pt;text-indent:-19.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Make any loans or advances except in the ordinary course of business&#59;</font></div><div style="padding-left:130.55pt;text-align:right;text-indent:13.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:102%">                                 Amended as of March 26, 2015    </font></div><div style="margin-top:3.55pt;padding-left:185.6pt;padding-right:62.95pt;text-indent:-19.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                         -2-  </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3.55pt;padding-left:185.6pt;padding-right:62.95pt;text-indent:-19.4pt"><font><br></font></div><div style="padding-left:184.5pt;padding-right:62.95pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;Enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners of the Controlled Affiliate or persons or entities with the authority to select or appoint members or board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate)&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:185.6pt;padding-right:57pt;text-indent:-19.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;Conduct any business other than under the Licensed Marks and Name&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:179.6pt;padding-right:60.3pt;text-indent:-13.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks or Names.</font></div><div><font><br></font></div><div style="padding-left:87pt;padding-right:48.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at least 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee&#59; or</font></div><div><font><br></font></div><div style="padding-left:123pt;padding-right:44.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services, the legal authority by the Sponsoring Plan together with such other Plans (a) to select all members of the Controlled Affiliate&#8217;s governing body&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; (c) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and such other Plans each having an ownership interest. Such 100% control and ownership by Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall execute the &#8220;Addendum to Controlled Affiliate License&#8221; attached as Exhibit B-1 to Exhibit 1 attached hereto&#59; or</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:284pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:284pt"><font><br></font></div><div style="margin-top:3.15pt;padding-left:123pt;padding-right:42.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-branded basis offers solely a Basic Medicare Part D Prescription Drug product, the legal authority by the Sponsoring Plan&#58; (a) to select all members of the Controlled Affiliate&#8217;s governing body&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; (c) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by the Plan shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and Participating Plan as defined on the Controlled Affiliate License Agreement shall execute the &#8220;Addendum to Controlled Affiliate License&#8221; attached as Exhibit B-2 to Exhibit 1 attached hereto.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:123pt;padding-right:44.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that operates as a clinic, the legal authority by the Sponsoring Plan to exercise control over the policy and operations of the Controlled Affiliate as defined in Exhibit 1, Standard 1(E) and the Guidelines to Administer Standard 1(E). In addition, if the clinic is for- profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:50.95pt;padding-right:54.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2b.&#160;&#160;&#160;&#160;With respect to the Controlled Affiliate License Agreements authorized in clauses iv) and v) of Paragraph 2, bona fide control shall mean that the Controlled Affiliate is organized and operated in such a manner that it meets the following requirements&#58;</font></div><div style="margin-top:11.6pt;padding-left:51pt;padding-right:56.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The Controlled Affiliate is owned or controlled by two or more Plans authorized to use the Licensed Marks pursuant to this License Agreement&#160;&#160;&#160;&#160;with BCBSA (for purposes of this subparagraph A. through subparagraph C., the &#8220;Controlling Plans&#8221;)&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:373.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:100pt;padding-right:100pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2a-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.6pt;padding-left:100pt;padding-right:100pt;text-align:center"><font><br></font></div><div style="margin-top:3.55pt;padding-left:123pt;padding-right:47.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to this Agreement to use the Licensed Marks in a geographic area in the Region (as that term is defined in such Controlled Affiliate License Agreements) and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:123pt;padding-right:42.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries (a) to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59; and (c) to exercise control over the policy and operations of the Controlled Affiliate. Notwithstanding anything to the contrary in (a) through (c) of this subparagraph E., the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div><font><br></font></div><div style="padding-left:195pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Change its legal and&#47;or trade names&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:195pt;padding-right:56.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:42.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:48.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:123pt;padding-right:60.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:11.1pt;padding-left:368.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 19, 2014</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.65pt;padding-right:46.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(The next page is page 3)</font></div><div style="padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2b-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font><br></font></div><div style="margin-top:3.55pt;padding-left:51pt;padding-right:52.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is not licensed to use the Licensed Marks and Name, the Plan may, in communications that contain the Licensed Marks or Name, indicate its corporate relationship to the Affiliate and permit such Affiliate to indicate its corporate relationship to the Plan, solely in the circumstances, style and manner specified by BCBSA from time-to-time in regulations of general application consistent with the avoidance of confusion or mistake or the dilution or tarnishment of the Licensed Marks and Name.&#160;&#160;&#160;&#160;No rights are hereby created in any Controlled Affiliate to use the Licensed Marks or Name in its own name or otherwise.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:46.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The Plan recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name. The Plan further recognizes that its actions within its Service Area may affect the value of the Licensed Marks and Name nationwide. The Plan agrees (a) to maintain in good standing its membership in BCBSA&#59; (b) promptly to pay its dues to BCBSA, said dues to represent the royalties for this License Agreement&#59; (c) materially to comply with all applicable laws&#59; (d) to comply with the Membership Standards Applicable to Regular Members of BCBSA, a current copy of which is attached as Exhibit 2 hereto&#59; and (e) reasonably to permit BCBSA, upon a written, good faith request and during reasonable business hours, to inspect the Plan's books and records necessary to ascertain compliance herewith. As to other Plans and third parties, BCBSA shall maintain the confidentiality of all documents and information furnished by the Plan pursuant hereto, or pursuant to the Membership Standards, and clearly designated by the Plan as containing proprietary information of the Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:51pt;padding-right:46.75pt;text-indent:40.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The rights hereby granted are exclusive to the Plan within the geographical area(s) served by the Plan on June 30, 1972, and&#47;or as to which the Plan has been granted a subsequent license, which is hereby defined as the &#34;Service Area,&#34; except that BCBSA reserves the right to use the Licensed Marks in said Service Area, and except to the extent that said Service Area may overlap areas served by one or more other licensed Blue Cross Plans as of said date or subsequent license, as to which overlapping areas the rights hereby granted are nonexclusive as to such other Plan or Plans only.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:373.2pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 19, 2014</font></div><div><font><br></font></div><div style="padding-left:100pt;padding-right:100pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:100pt;padding-right:100pt;text-align:center"><font><br></font></div><div style="margin-top:3.55pt;padding-left:51pt;padding-right:46.9pt;text-indent:40.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Except as expressly provided by BCBSA with respect to National Accounts, Government Programs and certain other necessary and collateral uses, the current rules and regulations governing which are attached as Exhibit 3 and Exhibit 4 hereto, and are contained in other documents referenced herein, or as expressly provided herein, the Plan may not use the Licensed Marks and Name outside the Service Area or in connection with other goods and services, nor may the Plan use the Licensed Marks or Name in a manner which is intended to transfer in the Service Area the goodwill associated therewith to another mark or name. Nothing herein shall be construed to prevent the Plan from engaging in lawful activity anywhere under other marks and names not confusingly similar to the Licensed Marks and Name, provided that engaging in such activity does and will not dilute or tarnish the unique value of the Licensed Marks and Name. In addition to any and all remedies available hereunder, BCBSA may impose monetary fines on the Plan for the Plan&#8217;s use of the Licensed Marks and Names outside the Service Area, and provided that the procedure used in imposing a fine is consistent with procedures specifically prescribed by BCBSA from time to time in regulations of general application. In the case of regional Medicare Advantage PPO and regional Medicare Part D Prescription Drug Plan products offered by consenting and participating Plans in a region that includes the Service Areas, or portions thereof, of more than one Plan, such fine may be imposed jointly on the consenting and participating Plans for use of the Licensed Marks and Name in any geographic area of the region in which a Plan having exclusive rights to the Licensed Marks and Name does not consent to and participate in such offering, provided that the basis for imposition of such fine is consistent with rules specifically prescribed by BCBSA from time to time in regulations of general application.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:69.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;The Plan agrees that it will display the Licensed Marks and Name only in such form, style and manner as shall be specifically prescribed by BCBSA from time-to-time in regulations of general application in order to prevent impairment of the distinctiveness of the Licensed Marks and Name and the goodwill pertaining thereto. The Plan shall cause to appear on all materials on or in connection with which the Licensed Marks or Name are used such legends, markings and notices as BCBSA may reasonably request in order to give appropriate notice of service mark or other proprietary rights therein or pertaining thereto.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:48.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;BCBSA agrees that&#58; (a) it will not grant any other license effective during the term of this License Agreement for the use of the Licensed Marks or Name which is inconsistent with the rights granted to the Plan hereunder&#59; and (b) it will not itself use the Licensed Marks in derogation of the rights of the Plan or in a manner to deprive the Plan of the full benefits of this License Agreement, provided that BCBSA shall have the right to use the Licensed Marks in conjunction with any national offering under the Federal Employees Health Benefits Program in the manner set forth in Exhibit 4, Paragraph 4 (including subparagraphs) to this License Agreement. The Plan agrees that it will not attack the title of BCBSA in and to the Licensed Marks or Name or attack the validity of the Licensed Marks or of this License Agreement. The Plan further agrees that all use by it of the Licensed Marks and Name or any similar mark or name shall inure to the benefit of BCBSA, and the Plan shall cooperate with BCBSA in effectuating the assignment to BCBSA of any service mark or trademark registrations of the Licensed Marks or any similar mark or name held by the Plan or a Controlled Affiliate of the Plan, all or any portion of which registration consists of the Licensed Marks.</font></div><div style="margin-top:0.05pt;padding-left:338pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 16, 2006</font></div><div style="padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3a-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font><br></font></div><div style="margin-top:3.55pt;padding-left:51pt;padding-right:47.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;(a).  Should the Plan fail to comply with the provisions of paragraphs 2-4, 6, 7 and&#47;or 12, and not cure such failure within thirty (30) days of receiving written notice thereof (or commence curing such failure within such thirty day period and continue diligent efforts to complete the curing of such failure if such curing cannot reasonably be completed within such thirty day period), BCBSA shall have the right to issue a notice that the Plan is in a state of noncompliance. Except as to the termination of a Plan's License Agreement or the merger of two or more Plans, disputes as to noncompliance, and all other disputes between or among BCBSA, the Plan, other Plans and&#47;or Controlled Affiliates, shall be submitted promptly to mediation and mandatory dispute resolution pursuant to the rules and regulations of BCBSA, a current copy of which is attached as Exhibit 5 hereto, and shall be timely presented and resolved. The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties. If a state of noncompliance as aforesaid is undisputed by the Plan or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the License Agreement. Except, however, as provided in paragraphs 9(d)(iii), 15(a)(i)-(viii), and 15(a)(x) below, no Plan's license to use the Licensed Marks and Name may be finally terminated for any reason without the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:49.25pt;text-indent:76.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b).&#160;&#160;&#160;&#160;Notwithstanding any other provision of this License Agreement, a Plan's license to use the Licensed Marks and Name may be forthwith terminated by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to Member Plans for&#58; (i) failure to comply with any minimum capital or liquidity requirement under the Membership Standard on Financial Responsibility&#59; or (ii) impending financial insolvency&#59; or (iii) the pendency of any action instituted against the Plan seeking its dissolution or liquidation or its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property of business, unless this License Agreement has been earlier terminated under paragraph 15(a)&#59; or (iv) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans and&#47;or the Licensed Marks.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:361.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 16, 2006</font></div><div><font><br></font></div><div style="padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font><br></font></div><div style="margin-top:3.55pt;padding-left:51pt;padding-right:47.15pt;text-indent:76.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c).&#160;&#160;&#160;&#160;To the extent not otherwise provided therein, neither&#58; (i) the Membership Standards Applicable to Regular Members of BCBSA&#59; nor (ii) the rules and regulations governing Government Programs and certain other uses&#59; nor (iii) the rules and regulations governing mediation and mandatory dispute resolution, may be amended unless and until each such amendment is first adopted by the affirmative vote of three-fourths of the Plans and of three-fourths of the total then current weighted vote of all the Plans. The rules and regulations governing National Accounts and other national programs required by the Membership Standards Applicable to Regular Members of BCBSA (Exhibit 2) are contained, in addition to those set forth in Exhibit 3, in the following documents, as amended from time to time&#58; (1) the Inter-Plan Programs Policies and Provisions&#59; (2) Inter- Plan Medicare Advantage Program Policies and Provisions. The voting requirements specified in rules and regulations governing such national programs may not be amended unless and until each such amendment is first adopted by the affirmative vote of three- fourths of the Plans and of three-fourths of the total then current weighted vote of all the Plans.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:281.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 21, 2014</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4a-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:102.27pt;padding-right:102.27pt;text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:50.95pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:113.8pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d).&#160;&#160;&#160;&#160;The Plan may operate as a for-profit company on the following conditions&#58;</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:175.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The Plan shall discharge all responsibilities which it has to the</font></div><div style="padding-left:50.95pt;padding-right:61.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Association and to other Plans by virtue of this Agreement and the Plan's membership in BCBSA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:51pt;padding-right:57.6pt;text-indent:90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The Plan shall not use the licensed Marks and Name, or any derivative thereof, as part of its legal name or any symbol used to identify the Plan in any securities market. The Plan shall use the licensed Marks and Name as part of its trade name within its service area for the sale, marketing and administration of health care and related services in the service area.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:47.45pt;text-indent:90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Plan's license to use the Licensed Marks and Name shall automatically terminate effective&#58; (a) thirty days after the Plan knows, or there is an SEC filing indicating that, any Institutional Investor, has become the Beneficial Owner of securities representing 10% or more of the voting power of the Plan (&#8220;Excess Institutional Voter&#8221;), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter prior to such automatic termination becoming effective&#59; (b) thirty days after the Plan knows, or there is an SEC filing indicating that, any Noninstitutional Investor has become the Beneficial Owner of securities representing 5% or more of the voting power of the Plan (&#8220;Excess Noninstitutional Voter&#8221;) unless such Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional Voter prior to such automatic termination becoming effective&#59; (c) thirty days after the Plan knows, or there is an SEC filing indicating that, any Person has become the Beneficial Owner of 20% or more of the Plan&#8217;s then outstanding common stock or other equity securities which (either by themselves or in combination) represent an ownership interest of 20% or more pursuant to determinations made under paragraph 9(d)(iv) below (&#8220;Excess Owner&#8221;), unless such Excess Owner shall cease to be an Excess Owner prior to such automatic termination becoming effective&#59; (d) ten business days after individuals who at the time the Plan went public constituted the Board of Directors of the Plan (together with any new directors whose election to the Board was approved by a vote of 2&#47;3 of the directors then still in office who were directors at the time the Plan went public or whose election or nomination was previously so approved) (the &#34;Continuing Directors&#34;) cease for any reason to constitute a majority of the Board of Directors&#59; or (e) ten business days after the Plan consolidates with or merges with or into any person or conveys, assigns, transfers or sells all or substantially all of its assets to any person other than a merger in which the Plan is the surviving entity and immediately after which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner&#58; provided that, if requested by the affected Plan in a writing received by BCBSA prior to such automatic termination becoming effective, the provisions of this paragraph 9(d)(iii) may be waived, in whole or in part,</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:334.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:114%">Amended as of September 17, 1997</font></div><div style="padding-left:90.1pt;padding-right:90.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">-5-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:90.1pt;padding-right:90.1pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:48.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans. Any waiver so granted may be conditioned upon such additional requirements (including but not limited to imposing new and independent grounds for termination of this License) as shall be approved by the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans. If a timely waiver request is received, no automatic termination shall become effective until the later of&#58; (1) the conclusion of the applicable time period specified in paragraphs 9(d)(iii)(a)-(d) above, or (2) the conclusion of the first Member Plan meeting after receipt of such a waiver request.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:52.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Plan's license to use the Licensed Marks and Name is terminated pursuant to this Paragraph 9(d)(iii), the license may be reinstated in BCBSA&#8217;s sole discretion if, within 30 days of the date of such termination, the Plan demonstrates that the Person referred to in clause (a), (b) or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:51pt;padding-right:60.1pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">(iv)&#160;&#160;&#160;&#160;The Plan shall not issue any class or series of security other than (i) shares of common stock having identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt securities or (iii) such other securities as the Plan may approve, provided that BCBSA receives notice at least thirty days prior to the issuance of such securities, including a description of the terms for such securities, and BCBSA shall have the authority to determine how such other securities will be counted in determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="margin-top:10.5pt;padding-left:153.7pt;text-indent:-30.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;For purposes of paragraph 9(d)(iii), the following definitions shall apply&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:105pt;padding-right:49.25pt;text-indent:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#34;Affiliate&#34; and &#34;Associate&#34; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on November 17, 1993 (the &#34;Exchange Act&#34;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:105pt;padding-right:79pt;text-indent:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;A Person shall be deemed the &#34;Beneficial Owner&#34; of and shall be deemed to &#34;beneficially own&#34; any securities&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:105pt;padding-right:95.85pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;which such Person or any of such Person's Affiliates or Associates beneficially owns, directly or indirectly&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5a-</font></div><div style="margin-top:4.6pt;padding-left:28.4pt"><font><br></font></div><div style="padding-left:28.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 17, 1997</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:28.4pt;text-align:right"><font><br></font></div><div style="margin-top:3.35pt;padding-left:87pt;padding-right:52.1pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;which such Person or any of such Person's Affiliates or Associates has (A) the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise&#59; or (B) the right to vote pursuant to any agreement, arrangement or understanding&#59; provided, however, that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement, arrangement or understanding to vote such security (1) arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report)&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:87pt;padding-right:47.1pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person (or any of such Person's Affiliates or Associates) has any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) relating to the acquisition, holding, voting (except to the extent contemplated by the proviso to (b)(ii)(B) above) or disposing of any securities of the Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:87pt;padding-right:48.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase &#34;then outstanding,&#34; when used with reference to a Person's Beneficial Ownership of securities of the Plan, shall mean the number of such securities then issued and outstanding together with the number of such securities not then actually issued and outstanding which such Person would be deemed to own beneficially hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:87pt;padding-right:51.6pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;A Person shall be deemed an &#8220;Institutional Investor&#8221; if (but only if) such Person (i) is an entity or group identified in the SEC&#8217;s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by such Person with the SEC under Regulation 13D-G (or any successor Regulation) with respect to such Person&#8217;s Beneficial Ownership of Plan securities shall have contained a certification identical to the one required by item 10 of SEC Schedule 13G as constituted on June 1, 1997.</font></div><div><font><br></font></div><div style="padding-left:87pt;padding-right:70.1pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;&#8220;Noninstitutional Investor&#8221; means any Person who is not an Institutional Investor.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:87pt;padding-right:49.55pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">(e)&#160;&#160;&#160;&#160;&#34;Person&#34; shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other entity, and shall include any successor (by merger or otherwise) of such entity.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:334.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 17, 1997</font></div><div style="margin-top:10.2pt;padding-left:297.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5b-&#160;&#160;&#160;&#160;(The next page is page 6)</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.2pt;padding-left:297.95pt"><font><br></font></div><div style="margin-top:3.3pt;padding-left:36.6pt;padding-right:61.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;This License Agreement shall remain in effect&#58; (a) until terminated as provided herein&#59; or (b) until this and all such other License Agreements are terminated by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans&#59; or (c) until termination of aforesaid Ownership Agreement&#59; or</font></div><div style="padding-left:36.6pt;padding-right:60.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;until terminated by the Plan upon eighteen (18) months written notice to BCBSA or upon a shorter notice period approved by BCBSA in writing at its sole discretion.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:55.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;Except as otherwise provided in paragraph 15 below or by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans, or unless this and all such other License Agreements are simultaneously terminated by force of law, the termination of this License Agreement for any reason whatsoever shall cause the reversion to BCBSA of all rights in and to the Licensed Marks and Name, and the Plan agrees that it will promptly discontinue all use of the Licensed Marks and Name, will not use them thereafter, and will promptly, upon written notice from BCBSA, change its corporate name so as to eliminate the Licensed Name therefrom.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:58.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;The license hereby granted to Plan to use the Licensed Marks and Name is and shall be personal to the Plan so licensed and shall not be assignable by any act of the Plan, directly or indirectly, without the written consent of BCBSA. Said license shall not be assignable by operation of law, nor shall Plan mortgage or part with possession or control of this license or any right hereunder, and the Plan shall have no right to grant any sublicense to use the Licensed Marks and Name.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:59.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;BCBSA shall maintain appropriate service mark registrations of the Licensed Marks and BCBSA shall take such lawful steps and proceedings as may be necessary or proper to prevent use of the Licensed Marks by any person who is not authorized to use the same. Any actions or proceedings undertaken by BCBSA under the provisions of this paragraph shall be at BCBSA's sole cost and expense. BCBSA shall have the sole right to determine whether or not any legal action shall be taken on account of unauthorized use of the Licensed Marks, such right not to be unreasonably exercised. The Plan shall report any unlawful usage of the Licensed Marks to BCBSA in writing and agrees, free of charge, to cooperate fully with BCBSA's program of enforcing and protecting the service mark rights, trade name rights and other rights in the Licensed Marks.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:56.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;The Plan hereby agrees to save, defend, indemnify and hold BCBSA and any other Plan(s) harmless from and against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of the activities of the Plan or of any hospital, medical group, clinic or other provider of health services that is owned or controlled directly or indirectly by Plan. BCBSA hereby agrees to save, defend, indemnify and hold the Plan and any other Plan(s) harmless from and against all claims, damages, liabilities And costs of every kind, nature and description which may arise exclusively and directly as a result of the activities of BCBSA.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:299.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 21, 2012</font></div><div style="margin-top:10.2pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.2pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.3pt;padding-left:36.6pt;padding-right:53.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;(a). This Agreement shall automatically terminate upon the occurrence of any of the following events&#58;  (i) a voluntary petition shall be filed by the Plan or by BCBSA seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against the Plan or BCBSA seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by the Plan or BCBSA or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Plan or BCBSA respectively, or (iii) an order for relief is entered against the Plan or BCBSA in any case under the bankruptcy laws of the United States, or the Plan or BCBSA is adjudged bankrupt or insolvent (as that term is defined in the Uniform Commercial Code as enacted in the state of Illinois) by any court of competent jurisdiction, or (iv) the Plan or BCBSA makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of the Plan or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by the Plan or BCBSA or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Plan or BCBSA respectively, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of the Plan's or BCBSA's property or business is appointed, or the Plan or BCBSA is ordered dissolved or liquidated, or (ix) the Plan shall fail to pay its dues and shall not cure such failure within thirty (30) days of receiving written notice thereof, or (x) if, due to regulatory action, the Plan together with any applicable Controlled Affiliate becomes unable to do business using the Names and Marks in any State or portion thereof included in its Service Area, provided that&#58; (i) automatic termination shall not occur prior to the exhaustion by any such Plan of its rights to appeal or challenge such regulatory action&#59; and (ii) in the event the Plan is licensed to do business using the Names and Marks in multiple States or portions of States, the termination of its License Agreement shall be solely limited to the State(s) or portions thereof in which the regulatory action applies. By not appealing or challenging such regulatory action within the time prescribed by law or regulation, and in any event no later than 120 days after such action is taken, a Plan shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination shall proceed.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.3pt;padding-left:36.6pt;padding-right:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Plan&#8217;s or BCBSA&#8217;s property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 15(a)(vii) and (viii) of this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:281.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7a-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.3pt;padding-left:72pt;padding-right:67.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b).&#160;&#160;&#160;&#160;BCBSA, or the Plans (as provided and in addition to the rights conferred in Paragraph 10(b) above), may terminate this Agreement immediately upon written notice upon the occurrence of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">either</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the following events&#58; (a) the Plan or BCBSA becomes insolvent (as that term is defined in the Uniform Commercial Code enacted in the state of Illinois), or (b) any final judgment against the Plan or BCBSA remains unsatisfied or unbonded of record for a period of sixty (60) days or longer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:65.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c).&#160;&#160;&#160;&#160;If this License Agreement is terminated as to BCBSA for any reason stated in subparagraphs 15(a) and (b) above, the ownership of the Licensed Marks shall revert to each of the Plans as provided in the Ownership Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:69.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d).&#160;&#160;&#160;&#160;Upon termination of this License Agreement or any Controlled Affiliate License Agreement of a Larger Controlled Affiliate, as defined in Exhibit 1 to this License Agreement, the following conditions shall apply, except that, in the event of a partial termination of this Agreement pursuant to Paragraph 15 (a)(x)(ii) of this Agreement, the notices, national account listing, payment and audit right listed below shall be applicable solely with respect to the geographic area for which the Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div><font><br></font></div><div style="padding-left:180pt;padding-right:83.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The terminated entity shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the terminated entity or its Controlled Affiliates under the Licensed Marks and Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA, subject to any conflicting state law and state regulatory requirements. This notice shall be mailed within 15 days after termination or, if termination is pursuant to paragraph 10(d) of this Agreement, within 15 days after the written notice to BCBSA described in paragraph 10(d).</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:180pt;padding-right:81.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The terminated entity shall deliver to BCBSA within five days of a request by BCBSA a listing of national accounts in which the terminated entity is involved (in a Control, Participating or Servicing capacity), identifying the national account and the terminated entity's role therein. For those accounts where the terminated entity is the Control Plan, the Plan must also indicate the Participating and Servicing Plans in the national account syndicate.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8-</font></div><div style="margin-top:4.6pt;padding-left:32.5pt"><font><br></font></div><div style="padding-left:32.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:32.5pt;text-align:right"><font><br></font></div><div style="margin-top:0.05pt;padding-left:180pt;padding-right:47.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Unless the cause of termination is an event stated in paragraph 15(a) or (b) above respecting BCBSA, the Plan and its Licensed Controlled Affiliates shall be jointly liable for payment to BCBSA of an amount equal to the Re-Establishment Fee (described below) multiplied by the number of Licensed Enrollees of the terminated entity and its Licensed Controlled Affiliates&#59; provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in the Service Area established by this Agreement, the Re-Establishment Fee shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the terminated entity and its Licensed Controlled Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service Area. The Re-Establishment Fee shall be indexed to a base fee of $80.  The Re-Establishment Fee through December 31, 2005 shall be $80. The Re-Establishment Fee for calendar years after December 31, 2005 shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall be the base fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans&#8217; gross administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31, 2004.  The adjustment shall end on January 1, 2011, at which time the Re-Establishment Fee shall be fixed at the then-current amount and no longer automatically adjusted. For example, if the Plans&#8217; gross administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be $83.27 (100% of the base fee plus $1.84 for calendar year 2005 and $1.43 for calendar year 2006). Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (a) the end of the last fiscal year of the terminated entity which ended prior to termination or (b) the fiscal year which ended before any transactions causing the termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph (d)(iii) shall be due only to the extent that, in </font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:333.6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="padding-left:98.97pt;padding-right:98.97pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8a-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.97pt;padding-right:98.97pt;text-align:center"><font><br></font></div><div style="margin-top:3.3pt;padding-left:180pt;padding-right:81.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BCBSA's opinion, it does not cause the net worth of the Plan to fall below 100% of the Health Risk-Based Capital formula or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this sub paragraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans), measured as of the date of termination and adjusted for the value of any transactions not made in the ordinary course of business. This payment shall not be due in connection with transactions exclusively by or among Plan or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage. At least 50% of the Re Establishment Fee shall be awarded to the Plan (or Plans) that receive the new license(s) for the service area(s) at issue&#59; provided, however, that such award shall not become due or payable until all disputes, if any, regarding the amount of and BCBSA&#8217;s right to such Re-Establishment Fee have been finally resolved&#59; and provided further that the award shall be based on the final amount actually received by BCBSA. The Board of Directors shall adopt a resolution which it may amend from time to time that shall govern BCBSA&#8217;s use of its portion of the award. In the event that the terminated entity&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Plan (and&#47;or its Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph only to the extent that such payments exceed the amounts due to BCBSA pursuant to subparagraph 15(d)(vi) and any costs associated with reestablishing the Service Area, including any payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of replacing the terminated entity.</font></div><div><font><br></font></div><div style="padding-left:180pt;padding-right:52.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;The terminated entity shall comply with all financial settlement procedures set forth in BCBSA&#8217;s License Termination Contingency Plan, as amended from time to time and shall work diligently and in good faith with BCBSA, any Alternative Control Licensee or Replacement Licensee and any existing or potential </font></div><div style="margin-top:4.65pt;padding-left:333.6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="padding-left:98.97pt;padding-right:98.97pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8b-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.97pt;padding-right:98.97pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:3.3pt;padding-left:182.8pt;padding-right:49.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">new account for Blue-branded products and services to minimize the disruption of termination, and honor, to the fullest extent possible, the desire of accounts to continue to receive or obtain Blue-branded products and services through a new Licensee (&#8220;Transition&#8221;). Such diligence and good faith on the part of the terminated entity shall include, but not be limited to&#58; (a) working cooperatively with BCBSA to protect the Names and Marks from potential harm&#59; (b) cooperating with BCBSA&#8217;s use of the Names and Marks in the terminated entity&#8217;s former service area during the termination and Transition&#59; (c) transmitting, upon the request of an existing Blue account or of BCBSA with consent and on behalf of an existing Blue account, all member and account-data relating to the Federal Employee Program to BCBSA, and all member and account data relating to other programs to an Alternative Control Licensee or Replacement Licensee&#59; (d) working with BCBSA and the Alternative Control or Replacement Licensee with respect to potential new Blue accounts headquartered in the terminated entity&#8217;s former service area&#59; (e) continuing to service Blue accounts during the Transition&#59; (f) continuing to comply with National Programs, Federal Employee Program and NASCO policies and procedures and all voluntary BCBSA programs, policies and performance standards, such as Away From Home Care, including being responsible for payment of all penalties for non-compliance duly levied in conformity with the License Agreements, Membership Standards, or the Federal Employee Program agreements, that may arise during the Transition&#59; (g) maintaining and providing access to its provider networks, as defined by Federal Employee Program agreements and National Account Program Policies and Provisions, and Inter-Plan Programs Policies and Provisions, and making those networks and discounts available to members and providers who participate in National Programs and the Federal Employee Program during the Transition&#59; (h) maintaining its technical connections and processing capabilities during the Transition&#59; and (i) working diligently to conclude all financial settlements and account reconciliations as negotiated in the termination transition agreement.</font></div><div style="margin-top:3.3pt;padding-left:182.8pt;padding-right:49.95pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:302.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 16, 2006</font></div><div style="padding-left:98.97pt;padding-right:98.97pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8c-</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:180pt;padding-right:83.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Notwithstanding any other provision in this Agreement, BCBSA shall have the right, with the approval of its Board of Directors, to assess additional fines against the terminated entity during the Transition in the event it fails to maintain and provide access to provider networks as defined by Federal Employee Program agreements, National Account Program Policies and Provisions, and Inter-Plan Programs Policies and Provisions, and&#47;or pass on applicable discounts. Such fines shall be in addition to any other assessments, fees or liquidated damages payable herein, or under existing policies and programs and shall be imposed to make whole BCBSA and&#47;or the Plans. Terminated entity shall pay any such fines to BCBSA no later than 30 days after they are approved by the Board of Directors.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:180pt;padding-right:96.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;BCBSA shall have the right to examine and audit and&#47;or hire at terminated entity&#8217;s expense a third-party auditor to examine and audit the books and records of the terminated entity and its Licensed Controlled Affiliates to verify compliance with the terms and requirements this paragraph 15(d).</font></div><div><font><br></font></div><div style="margin-top:4.1pt;padding-left:180pt;padding-right:85.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data that was acquired or accessed during the period this Agreement was in force, including but not limited to all confidential processes, pricing, provider, discount and other strategic and competitively sensitive information (&#8220;Blue Information&#8221;) from disclosure, and shall not, either alone or with another entity, disclose such Blue Information or use it in any manner to compete without the express written permission of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:180pt;padding-right:88.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;As to a breach of 15 (d) (i), (ii), (iii), (iv), (vi), or (vii) the parties agree that the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 15 (d) (i), (ii), (iv), (vi), or (vii) by the Plan, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div style="margin-top:4.6pt;padding-left:361.55pt"><font><br></font></div><div style="padding-left:140.4pt;padding-right:32.4pt;text-align:right;text-indent:-140.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 16, 2006</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8d-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div><font><br></font></div><div style="padding-left:180pt;padding-right:85.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;In the event that the terminated entity&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Plan and its Licensed Controlled Affiliates shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:65.25pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e).&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Plan or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this License Agreement unless the License Agreement has been terminated pursuant to paragraph 10 (d) of this Agreement upon the required six (6) month written notice.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:120.6pt;text-indent:-30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f).&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amended as of June 16, 2006</font></div><div style="padding-right:4.5pt;text-align:right"><font><br></font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8e-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="margin-top:3.3pt;padding-left:36.6pt;padding-right:63.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;This Agreement supersedes any and all other agreements between the parties with respect to the subject matter herein, and contains all of the covenants and agreements of the parties as to the licensing of the Licensed Marks and Name. This Agreement may be amended only by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:75.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;If any provision or any part of any provision of this Agreement is judicially declared unlawful, each and every other provision, or any part of any provision, shall continue in full force and effect notwithstanding such judicial declaration.</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:36.6pt;padding-right:56.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;No waiver by BCBSA or the Plan of any breach or default in performance on the part of BCBSA or the Plan or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:59.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19a.&#160;&#160;&#160;&#160;All notices provided for hereunder shall be in writing and shall be sent in duplicate by regular mail to BCBSA or the Plan at the address currently published for each by BCBSA and shall be marked respectively to the attention of the President and, if any, the General Counsel, of BCBSA or the Plan.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:54.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19b.&#160;&#160;&#160;&#160;Except as provided in paragraphs 9(b), 9(d)(iii), 15(a), and 15(b) above, this Agreement may be terminated for a breach only upon at least 30 days&#8217; written notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to the Member Plans.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:54.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19c.&#160;&#160;&#160;&#160;For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:112.87pt;padding-right:112.87pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8f-</font></div><div><font><br></font></div><div style="padding-right:53.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 16, 2006</font></div><div style="padding-right:53.7pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(The next page is page 9)</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-right:53.7pt;text-align:right"><font><br></font></div><div style="margin-top:3.3pt;padding-left:36.6pt;padding-right:54.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;Nothing herein contained shall be construed to constitute the parties hereto as partners or joint venturers, or either as the agent of the other, and Plan shall have no right to bind or obligate BCBSA in any way, nor shall it represent that it has any right to do so. BCBSA shall have no liability to third parties with respect to any aspect of the business, activities, operations, products, or services of the Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:57.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;This Agreement shall be governed, construed and interpreted in accordance with the laws of the State of Illinois.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:62.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last signature written below.</font></div><div><font><br></font></div><div style="margin-top:7.5pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By____________________________________</font></div><div><font><br></font></div><div style="margin-top:10.7pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title___________________________________</font></div><div><font><br></font></div><div style="margin-top:10.7pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date__________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.2pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PLAN&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By____________________________________</font></div><div><font><br></font></div><div style="margin-top:10.7pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title___________________________________</font></div><div><font><br></font></div><div style="margin-top:10.7pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date___________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div><div style="margin-top:2pt;padding-right:47.5pt;text-align:right"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:2pt;padding-right:47.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 1</font></div><div style="margin-top:4.1pt;padding-left:104.3pt;padding-right:117.2pt;text-align:right"><font><br></font></div><div style="margin-top:4.1pt;padding-left:110.75pt;padding-right:110.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS</font></div><div style="padding-left:71.62pt;padding-right:71.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CONTROLLED AFFILIATE LICENSE AGREEMENT</font></div><div style="padding-left:42.7pt;padding-right:42.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Includes revisions adopted by Member Plans through their June 16, 2022 meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:66.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and________(&#8220;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Cross Plan, known as _________ (&#34;Plan&#34; or &#8220;Sponsoring Plan&#8221;), which is also a Party signatory hereto.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:74.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks&#59;</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:60.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Plan and Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE CROSS in a trade name (&#34;Licensed Name&#34;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:75.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GRANT OF LICENSE</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:50pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with&#58; (i) health care plans and related services, as defined in BCBSA's License Agreement with Plan, and administering the non-health portion of workers&#8217; compensation insurance, and (ii) underwriting the indemnity portion of workers&#8217; compensation insurance, provided that Controlled Affiliate&#8217;s total premium revenue comprises less than 15 percent of the Sponsoring Plan&#8217;s net subscription revenue.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:49.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This grant of rights is non-exclusive and is limited to the Service Area served by the Plan Subject to paragraph 3A(3) of this Agreement, Controlled Affiliate may use the Licensed Marks and Name in its legal name on the following conditions&#58; (i) the legal name must be approved in advance, in writing, by BCBSA&#59; (ii) Controlled Affiliate shall not do business outside the Service Area under any name or mark&#59; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market, unless such Controlled Affiliate is a not-for-profit company which may use the Licensed Marks and Name, or an approved derivative therefor, to identify itself in debt securities markets. Controlled Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font><br></font></div><div style="margin-top:4.1pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">QUALITY CONTROL</font></div><div style="margin-top:6.85pt;padding-left:36.6pt;padding-right:69.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.</font></div><div style="margin-top:6.95pt;padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to comply with all applicable federal, state and local</font></div><div style="padding-left:36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">laws.</font></div><div style="margin-top:6.85pt;padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often</font></div><div style="padding-left:36.55pt;padding-right:65.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if reasonably required by Plan or by BCBSA) a report or reports to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.</font></div><div style="margin-top:6.95pt;padding-left:36.6pt;padding-right:62.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that Plan and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div style="margin-top:6.85pt;padding-left:36.6pt;padding-right:81.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that the Sponsoring Plan has&#58;</font></div><div style="margin-top:6.95pt;padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-top:9.15pt;padding-left:36.6pt;padding-right:64.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 50% voting control thereof&#59; and</font></div><div style="margin-top:6.95pt;padding-left:36.6pt;padding-right:73.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur&#59; and</font></div><div style="margin-top:6.85pt;padding-left:36.6pt;padding-right:65.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring Plan&#59; and</font></div><div style="margin-top:6.95pt;padding-left:36.6pt;padding-right:67.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can&#58;</font></div><div style="margin-top:9.1pt;padding-left:180.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div style="margin-top:9.25pt;padding-left:180.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates&#59;</font></div><div><font><br></font></div><div style="padding-left:180.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:331.9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="padding-left:29.47pt;padding-right:29.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.1pt;padding-left:180.6pt;padding-right:77.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the ordinary course of business&#59;</font></div><div style="margin-top:4.1pt;padding-left:180.6pt;padding-right:77.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being replaced&#59;</font></div><div><font><br></font></div><div style="padding-left:180.6pt;padding-right:78.8pt;text-indent:-32.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;make any loans or advances except in the ordinary course of business&#59;</font></div><div><font><br></font></div><div style="padding-left:180.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;enter into any arrangement or agreement with any</font></div><div style="padding-left:180.6pt;padding-right:51.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party directly or indirectly affiliated with any of the owners or persons or entities with the authority to select or appoint members or board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate)&#59;</font></div><div><font><br></font></div><div style="padding-left:180.6pt;padding-right:64.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;conduct any business other than under the Licensed Marks and Name&#59;</font></div><div><font><br></font></div><div style="padding-left:180.6pt;padding-right:66.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:51.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at least 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee.</font></div><div style="padding-left:278.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Or</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:60.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having more than 50% voting control thereof and&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:62.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur&#59; and</font></div><div style="margin-top:9.15pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div style="margin-top:9.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:9.2pt;padding-left:36.6pt;padding-right:54.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee.</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Or</font></div><div style="margin-top:3.35pt;padding-left:36.6pt;padding-right:54.65pt;text-indent:3.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services, the Sponsoring Plan has the legal authority together with such other Plans&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and</font></div><div style="margin-top:9.15pt;padding-left:108.6pt;padding-right:107.45pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="padding-left:36.6pt;padding-right:75.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:222%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit</font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:53.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate with the Sponsoring Plan and such other Plans each having an ownership interest. Such control and ownership by Plans must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall execute a separate Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-1 for each product noted in Paragraph 2E(3) that is licensed to use the Marks.</font></div><div style="padding-left:278.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Or</font></div><div style="margin-top:9.25pt;padding-left:36.6pt;padding-right:63.75pt;text-indent:3.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-branded basis, only offers a Basic Medicare Part D Prescription Drug Plan product, the Sponsoring Plan has the legal authority&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and</font></div><div><font><br></font></div><div style="padding-left:108.6pt;padding-right:107.45pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-right:49.35pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended June 20, 2019</font></div><div style="padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:36.6pt;padding-right:46.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Participating Plan as defined in Exhibit B-2 and the Sponsoring Plan shall execute the Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-2.</font></div><div><font><br></font></div><div style="padding-left:278.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Or</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:51.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that operates as a clinic, absent an alternative method of control approved in writing by BCBSA, the Sponsoring Plan shall have bona fide operational control over the Controlled Affiliate as specified in Exhibit A, Standard 1(E) and the Guidelines to Administer Standard 1(E). In addition, if the clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur.</font></div><div style="padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;FOR-PROFIT, PUBLICLY TRADED LICENSEES</font></div><div style="padding-left:36.6pt"><font><br></font></div><div style="margin-top:4.1pt;padding-left:108.6pt;padding-right:59.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The Controlled Affiliate may operate as a for-profit publicly traded company on the following conditions&#58;</font></div><div style="margin-top:9.25pt;padding-left:72.6pt;padding-right:72.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall discharge all responsibilities which it has to the Association and to other Plans by virtue of this Agreement.</font></div><div style="margin-top:9.1pt;padding-left:72.6pt;padding-right:56.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall provide 90 days advance written notice to BCBSA prior to the initial filing with the SEC.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:50.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of its legal name or any symbol used to identify the Controlled Affiliate in any securities market. The Controlled Affiliate shall use the Licensed Marks and Name as part of its trade name within its service area for the sale, marketing and administration of health care and related services in the service area.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:50.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Controlled Affiliate&#8217;s license to use the Licensed Marks and Name shall automatically terminate effective&#58; (a) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any Institutional Investor, has become the Beneficial Owner of securities representing 10% or more of the voting power of the Controlled Affiliate (&#8220;Excess Institutional Voter&#8221;), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter prior to such automatic termination becoming effective&#59; (b) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any Noninstitutional Investor, other than a Plan or Plans or Controlled Affiliate Licensee or Licensees has become the Beneficial Owner of securities representing 5% or more of the voting power of the Controlled Affiliate (&#8220;Excess Noninstitutional Voter&#8221;) unless such Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional Voter prior to such automatic termination becoming effective&#59; (c) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any Person has become the Beneficial Owner, other than a </font></div><div style="padding-left:72.6pt;padding-right:50.6pt"><font><br></font></div><div style="padding-left:72.6pt;padding-right:50.6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="padding-left:299.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:299.6pt"><font><br></font></div><div style="padding-left:72.6pt;padding-right:50.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan or Plans or Controlled Affiliate Licensee or Licensees, of 20% or more of the Controlled Affiliate&#8217;s then outstanding common stock or other equity securities which (either by themselves or in combination) represent an ownership interest of 20% or more pursuant to determinations made under paragraph 3A(4) below (&#8220;Excess Owner&#8221;), unless such Excess Owner shall cease to be an Excess Owner prior to such automatic termination becoming effective&#59; (d) ten business days after individuals who at the time the Controlled Affiliate went public constituted the Board of Directors of the Controlled Affiliate (together with any new directors whose election to the Board was approved by a vote of 2&#47;3 of the directors then still in office who were directors at the time the Controlled Affiliate went public or whose election or nomination was previously so approved) (the &#8220;Continuing Directors&#8221;) cease for any reason to constitute a majority of the Board of Directors&#59; or (e) ten business days after the Controlled Affiliate consolidates with or merges with or into any person or conveys, assigns, transfers or sells all or substantially all of its assets to any person other than a merger in which the Sponsoring Plan is the surviving entity and immediately after which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner&#58; provided that, if requested by the affected Controlled Affiliate in a writing received by BCBSA prior to such automatic termination becoming effective, the provisions of this paragraph 3A(4) may be waived, in whole or in part, upon the affirmative vote of a majority of the disinterested Plans and majority of the total then current weighted vote of the disinterested Plans. Any waiver so granted may be conditioned upon such additional requirements (including but not limited to imposing new and independent grounds for termination of this License) as shall be approved by the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans. If a timely waiver request is received, no automatic termination shall become effective until the later of&#58; (1) the conclusion of the applicable time period specified in paragraphs 3A(4) (a)-(d) above, or (2) the conclusion of the first Member Plan meeting after receipt of such a waiver request.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:49.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Controlled Affiliate&#8217;s license, or any other license, to use the Licensed Marks and Name is terminated pursuant to Paragraph 3A(4), the license may be reinstated in BCBSA&#8217;s sole discretion if, within 30 days of the date of such termination, the Controlled Affiliate demonstrates that the Person referred to in clause (a), (b), or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner.</font></div><div><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;The Controlled Affiliate shall not issue any class or series of security other than</font></div><div style="padding-left:72.6pt;padding-right:69.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) shares of common stock having identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt securities or (iii) such other securities as the Controlled Affiliate may approve, provided that BCBSA receives notice at least thirty days prior to the issuance of such securities, including a gdescription of the terms for such securities, and BCBSA shall have the authority to determine how such other securities will be counted in determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="padding-left:72.6pt;padding-right:69.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:29.47pt;padding-right:29.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:29.47pt;padding-right:29.47pt;text-align:center"><font><br></font></div><div style="padding-left:72.6pt;padding-right:69.15pt"><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;For purposes of paragraph 3A(4) above, the following definitions shall apply&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:58.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#8220;Affiliate&#8221; and &#8220;Associate&#8221; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on November 17, 1993 (the &#8220;Exchange Act&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72.6pt;padding-right:69.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;A Person shall be deemed the &#8220;Beneficial Owner&#8221; of and shall be deemed to &#8220;beneficially own&#8221; any securities&#58;</font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:84.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;which such Person or any of such Person&#8217;s Affiliates or Associates beneficially owns, directly or indirectly&#59;</font></div><div style="padding-left:29.47pt;padding-right:29.47pt;text-align:center"><font><br></font></div><div style="padding-left:144.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;which such Person or any of such Person&#8217;s Affiliates or Associates has</font></div><div style="margin-top:4.1pt;padding-left:72.6pt;padding-right:51.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or (B) the right to vote pursuant to any agreement, arrangement or understanding&#59; provided, however, that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement, arrangement or understanding to vote such security (1) arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report)&#59; or</font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:49.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person (or any of such Person&#8217;s Affiliates or Associates) has any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) relating to the acquisition, holding, voting (except to the extent contemplated by the proviso to (ii)2(B) above) or disposing of any securities of the Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:53.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase &#8220;then outstanding,&#8221; when used with reference to a Person&#8217;s Beneficial Ownership of securities of the Controlled Affiliate, shall mean the number of such securities then issued and outstanding together with the number of such securities not then actually issued and outstanding which such Person would be deemed to own beneficially hereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:257.6pt;text-align:right;text-indent:30.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:18.3pt;padding-right:18.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:18.3pt;padding-right:18.3pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="padding-left:72.6pt;padding-right:55.2pt;text-indent:39.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;A Person shall be deemed an &#8220;Institutional Investor&#8221; if (but only if) such Person (i) is an entity or group identified in the SEC&#8217;s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by such Person with the SEC under Regulation 13D-G (or any successor Regulation) with respect to such Person&#8217;s Beneficial Ownership of Plan securities shall have contained a certification identical to the one required by item 10 of SEC Schedule 13G as constituted on June 1, 1997.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:60.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#8220;Noninstitutional Investor&#8221; means any Person who is not an Institutional Investor.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72.6pt;padding-right:49.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#8220;Person&#8221; shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other entity, and shall include any successor (by merger or otherwise) of such entity.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SERVICE MARK USE</font></div><div style="padding-left:36.6pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt;padding-right:49.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed</font></div><div style="margin-top:4.1pt;padding-left:36.6pt;padding-right:46.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Marks and Name. The Controlled Affiliate further recognizes that its actions within its Service Area may affect the value of the Licensed Marks and Name nationwide.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:64.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:55.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is intended to transfer in the Service Area the goodwill associated therewith to another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:51.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;If Controlled Affiliate meets the standards of 2E(1) but not 2E(2) above and any of Controlled Affiliate's advertising or promotional material is reasonably determined by BCBSA and&#47;or the Plan to be in contravention of rules and regulations governing the use of the Licensed Marks and Name, Controlled Affiliate shall for ninety (90) days thereafter obtain prior approval from BCBSA of advertising and promotional efforts using the Licensed Marks and Name, approval or disapproval thereof to be forthcoming within five (5) business days of receipt of same by BCBSA or its designee. In all advertising and promotional efforts, Controlled Affiliate shall observe the Service Area limitations applicable to Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="padding-left:41.15pt;padding-right:73.4pt;text-indent:31.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Notwithstanding any other provision in the Plan&#8217;s License Agreement with BCBSA or in this Agreement, Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLICENSING AND ASSIGNMENT</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:36.55pt;padding-right:52.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INFRINGEMENT</font></div><div><font><br></font></div><div style="margin-top:4.1pt;padding-left:36.6pt;padding-right:57.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name. Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to Plan and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITY INDEMNIFICATION</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:49.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate and Plan hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to&#58; (i) Controlled Affiliate's rendering of services under the Licensed Marks and Name&#59; or (ii) the activities of any hospital, medical group, clinic or other provider of health services that is owned or controlled directly or indirectly by Plan or Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE TERM</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt;padding-right:72.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the provisions herein.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:50.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; (i) the Plan ceases to be authorized to use the Licensed Marks and Name&#59; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement the Plan ceases to be authorized to use the Licensed Names and Marks in the geographic area served by the Controlled Affiliate provided, however, that if the Controlled Affiliate is serving more than one State or portions thereof, the termination of this Agreement shall be limited to the State(s) or portions thereof in </font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:6.45pt;padding-right:6.45pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:50.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which the Plan&#8217;s license to use the Licensed Marks and Names is terminated. By not appealing or challenging such regulatory action within the time prescribed by law or regulation, and in any event no later than 120 days after such action is taken, a Plan shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination shall proceed.</font></div><div><font><br></font></div><div style="margin-top:4.1pt;padding-left:36.6pt;padding-right:52.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be forthwith terminated by the Plan or the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to the Board for&#58; (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control standards of this Agreement&#59; or (2) failure to comply with the &#34;Organization and Governance&#34; quality control standard of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement&#59; or (3) impending financial insolvency&#59; or (4) for a Smaller Controlled Affiliate (as defined in Exhibit A), failure to comply with any of the applicable requirements of Standards 2, 3, 4, 5 or 7 of attached Exhibit A&#59; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 8(E)&#59; or (6) failure by a Controlled Affiliate that meets the standards of 2E(1) but not 2E(2) above to obtain BCBSA's written consent to a change in the identity of any owner, in the extent of ownership, or in the identity of any person or entity with the authority to select or appoint members or board members, provided that as to publicly traded Controlled Affiliates this provision shall apply only if the change affects a person or entity that owns at least 5% of the Controlled Affiliate's stock before or after the change&#59; or (7) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans, any other licensee including Controlled Affiliate and&#47;or the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:51.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraphs 8(B), 8(C) or 8(E) herein, should Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the Plan shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 8(B), 8(C) or 8(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution. All other disputes between BCBSA, the Plan and&#47;or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution. The mandatory dispute resolution panel shall have authority to issue orders for </font></div><div style="padding-left:72.6pt;padding-right:51.15pt"><font><br></font></div><div style="padding-left:72.6pt;padding-right:51.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:51.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specific performance and assess monetary penalties. Except, however, as provided in Paragraphs 8(B) and 8(E) of this Agreement, this license to use the Licensed</font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:57.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:84.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate&#8217;s rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with item 2(E) above&#59;</font></div><div><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 10 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA&#59; or</font></div><div style="padding-left:36.6pt;padding-right:55.1pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:55.1pt;text-indent:35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Any of the following events occur&#58; (i) a voluntary petition shall be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate&#8217;s property or business shall not in itself be </font></div><div style="padding-left:36.6pt;padding-right:55.1pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:55.1pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div style="padding-left:36.6pt;padding-right:55.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 8(E)(3)(vii) and (viii) of this Agreement.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:50.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The for-profit, publicly traded Controlled Affiliate is terminated pursuant to Paragraph 3A(4) of this Agreement. In which case, the licenses of any Controlled Affiliates directly or indirectly owned by the terminated for-profit, publicly traded Controlled Affiliate also shall immediately terminate as provided for in paragraph 3A(4) of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:60pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name.</font></div><div><font><br></font></div><div style="margin-top:4.1pt;padding-left:36.6pt;padding-right:53.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers that it is no longer a licensee of BCBSA and, if directed by the Association&#8217;s Board of Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:58.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;In the event this Agreement terminates pursuant to 8(B) hereof, or in the event the Controlled Affiliate is a Larger Controlled Affiliate (as defined in Exhibit A), upon termination of this Agreement, the provisions of Paragraph 8.G. shall not apply and the following provisions shall apply, except that, in the event of a partial termination of this Agreement pursuant to Paragraph 8(B)(ii) of this Agreement, the notices, national account listing, payment, and audit right listed below shall be applicable solely with respect to the geographic area for which the Plan&#8217;s license to use the Licensed Names and Marks is terminated.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:50.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA, subject to any conflicting state law and state regulatory requirements. This notice shall be mailed within 15 days after termination.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:55.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the national account and the Controlled Affiliate&#8217;s role therein.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:51.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:51.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:51.25pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:51.25pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:51.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72.6pt;padding-right:51.25pt"><font><br></font></div><div style="padding-left:36.7pt;padding-right:51.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan&#8217;s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for payment to BCBSA of an amount equal to the Re-Establishment Fee (described below) multiplied by the number of Licensed Enrollees of the Controlled Affiliate&#59; provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in the Service Area established by this Agreement, the Re- Establishment Fee shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service Area.</font></div><div style="padding-left:36.7pt;padding-right:51.05pt"><font><br></font></div><div style="padding-left:36.7pt;padding-right:51.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Re-Establishment Fee shall be indexed to a base fee of $80. The Re-Establishment Fee through December 31, 2005 shall be $80. The Re-establishment Fee for calendar years after December 31, 2005 shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall be the base fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans&#8217; gross administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31, 2004. The adjustment shall end on January 1, 2011, at which time the Re-Establishment Fee shall be fixed at the then- current amount and no longer automatically adjusted. For example, if the Plans&#8217; gross administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be $83.27 (100% of base fee plus $1.84 for calendar year 2005 and $1.43 for calendar year 2006). Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA&#8217;s opinion, it does not cause the net worth of the Controlled Affiliate, the Plan or any other Licensed Controlled Affiliates of the Plan to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this sub paragraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans)&#59; measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course of business. This payment shall not be due in connection with transactions exclusively by or among Plans or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage. At least 50% of the Re- Establishment Fee shall be awarded to the Plan (or Plans) that receive the new license(s) for the service area(s) at issue&#59; provided, however, that such award shall not become due or payable until all disputes, if any, regarding the amount of and BCBSA&#8217;s right to such Re- Establishment Fee have been finally resolved&#59; and provided further that the award shall be </font></div><div style="padding-left:36.7pt;padding-right:51.05pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div style="padding-left:36.7pt;padding-right:51.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based on the final amount actually received by BCBSA. The Board of Directors shall adopt a resolution which it may amend from time to time that shall govern BCBSA&#8217;s use of its portion of the award. In the event that the Controlled Affiliate&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and&#47;or the Plan or its other Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph 8.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph 8.M. and any costs associated with reestablishing the Service Area, including payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of replacing the Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:4.1pt;padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;BCBSA shall have the right to examine and audit and&#47;or hire at</font></div><div style="padding-left:36.6pt;padding-right:51.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminated entity&#8217;s expense a third party auditor to examine and audit the books and records of the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan to verify compliance with this paragraph 8.H.</font></div><div><font><br></font></div><div style="padding-left:108.6pt;text-indent:-32.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;Subsequent to termination of this Agreement, the terminated entity</font></div><div style="padding-left:36.6pt;padding-right:49.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and its affiliates, agents, and employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data that was acquired or accessed during the period this Agreement was in force, including but not limited to all confidential processes, pricing, provider, discount and other strategic and competitively sensitive information (&#8220;Blue Information&#8221;) from disclosure, and shall not, either alone or with another entity, disclose such Blue Information or use it in any manner to compete without the express written permission of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:108.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;As to a breach of 8.H.(1), (2), (3), (4) or (5) the parties agree that</font></div><div style="padding-left:36.6pt;padding-right:55.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 8.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:49.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;This Agreement shall remain in effect until terminated by the Controlled Affiliate or the Plan upon not less than eighteen (18) months written notice to the Association or upon a shorter notice period approved by BCBSA in writing at its sole discretion, or until terminated as otherwise provided herein. The Plan&#8217;s right to terminate without cause upon such notice is unfettered and may be exercised in the Plan&#8217;s sole discretion.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:61.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;In the event the Controlled Affiliate is a Smaller Controlled Affiliate (as defined in Exhibit A), the Controlled Affiliate agrees to be jointly liable for the amount described in</font></div><div style="padding-left:36.6pt;padding-right:100.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.3. and M. hereof upon termination of the BCBSA license agreement of any Larger Controlled Affiliate of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:58.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this Agreement unless the Plan&#8217;s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of the Plan&#8217;s license agreement upon the required 18 months written notice.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:90.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L.&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:51.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">M.&#160;&#160;&#160;&#160;In the event that the Plan has more than 50 percent voting control of the Controlled Affiliate under Paragraph 2(E)(2) above and is a Larger Controlled Affiliate (as defined in Exhibit A), then the vote called for in Paragraphs 8(C) and 8(D) above shall require the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans.</font></div><div style="margin-top:4.1pt;padding-left:36.6pt;padding-right:56pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">N.&#160;&#160;&#160;&#160;In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DISPUTE RESOLUTION</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt;padding-right:49.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties agree that any disputes between them or between or among either of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross Marks and Name are subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of Plan's License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by reference as though fully set forth herein.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE FEE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:51.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit C.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JOINT VENTURE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:73.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in the Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between Plan and Controlled Affiliate or between either and BCBSA.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICES AND CORRESPONDENCE</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:36.55pt;padding-right:56.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPLETE AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:58.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div><font><br></font></div><div style="margin-top:4.1pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SEVERABILITY</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:51.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NONWAIVER</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:36.55pt;padding-right:51.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">VOTING</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt;padding-right:53.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:53.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:354.2pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:118.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:100%">THIS PAGE IS INTENTIONALLY BLANK.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.45pt;padding-left:118.4pt"><font><br></font></div><div style="margin-top:4.1pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:65.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div><font><br></font></div><div style="padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HEADINGS</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.55pt;padding-right:63.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation hereof.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:81.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last signature written below.</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled Affiliate&#58;</font></div><div><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; ______________________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_____________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan&#58;</font></div><div><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_______________________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_____________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_______________________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_____________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:4.6pt;padding-left:36.6pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS</font></div><div style="padding-left:36.6pt;padding-right:2.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">June 2022</font></div><div style="padding-left:36.6pt;padding-right:2.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of definition&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;padding-right:71.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.15pt">A &#34;smaller Controlled Affiliate&#58;&#34; (1) comprises less than fifteen percent (15%) of Sponsoring Plan's and its licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider and freestanding coverage, and treating an entity seeking licensure as licensed)&#59;* or (2) underwrites the indemnity portion of workers&#8217; compensation insurance and has total premium revenue less than 15 percent of the Sponsoring Plan&#8217;s net subscription revenue.</font></div><div><font><br></font></div><div style="padding-left:54pt;padding-right:63.3pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.65pt">A &#34;larger Controlled Affiliate&#34; comprises fifteen percent (15%) or more of Sponsoring Plan's and its licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider and freestanding coverage, and treating an entity seeking licensure as licensed.)*</font></div><div><font><br></font></div><div style="padding-left:36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Changes in Controlled Affiliate status&#58;</font></div><div><font><br></font></div><div style="padding-left:36.55pt;padding-right:79.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">any </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate's status changes regarding&#58; its Plan ownership level, its risk acceptance or direct delivery of medical care, the Controlled Affiliate shall notify BCBSA within thirty (30) days of such occurrence in writing and come into compliance with the applicable standards within six (6) months.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:52.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a smaller Controlled Affiliate&#8217;s health and workers&#8217; compensation administration business reaches or surpasses fifteen percent (15%) of the total member enrollment of the Sponsoring Plan and licensed Controlled Affiliates, the Controlled Affiliate shall&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.25pt;padding-left:331.9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:110.77pt;padding-right:110.77pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="padding-left:36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="padding-left:36.55pt"><font><br></font></div><div style="margin-top:3.9pt;padding-left:54.6pt;padding-right:63.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Within thirty (30) days, notify BCBSA of this fact in writing, including evidence that the Controlled Affiliate meets the minimum liquidity and capital (BCBSA &#8220;Health Risk-Based Capital (HRBC)&#8221; as defined by the NAIC and state-established minimum reserve) requirements of the larger Controlled Affiliate Financial Responsibility standard&#59; and</font></div><div><font><br></font></div><div style="padding-left:54.6pt;padding-right:73.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Within six (6) months after reaching or surpassing the fifteen percent (15%) threshold, demonstrate compliance with all license requirements for a larger Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:66.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Controlled Affiliate that underwrites the indemnity portion of workers&#8217; compensation insurance receives a change in rating or proposed change in rating, the Controlled Affiliate shall notify BCBSA within 30 days of notification by the external rating agency.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.3pt;padding-left:36.55pt;padding-right:371.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:232%">*For purposes of this calculation, The numerator equals&#58;</font></div><div style="padding-left:36.55pt;padding-right:100.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicant Controlled Affiliate's member enrollment, as defined in BCBSA's Quarterly Enrollment Report (excluding rider and freestanding coverage).</font></div><div><font><br></font></div><div style="padding-left:36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The denominator equals&#58;</font></div><div><font><br></font></div><div style="padding-left:36.55pt;padding-right:89.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Numerator PLUS Sponsoring Plan and all other licensed Controlled Affiliates' member enrollment, as reported in BCBSA's Quarterly Enrollment Report (excluding rider and freestanding coverage).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:331.9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:110.75pt;padding-right:110.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.75pt;padding-right:110.75pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="padding-left:36.55pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:112.8pt;padding-right:112.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">STANDARDS FOR LICENSED CONTROLLED AFFILIATES</font></div><div style="padding-left:32pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each licensed controlled affiliate shall be subject to certain standards as determined below&#58;</font></div><div style="padding-left:32pt"><font><br></font></div><div style="margin-top:3.65pt;padding-left:54.6pt;text-indent:-22.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;What percent of the licensed controlled affiliate is controlled by the Sponsoring Plan and other Plans&#63;</font></div><div style="padding-left:37.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.519%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.6pt;padding-right:12.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">More than 50% by Sponsoring Plan</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.57pt;padding-right:12.57pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1A, 4</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.2pt;padding-right:10.2pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50% by Sponsoring Plan</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10.2pt;padding-right:10.2pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1B, 4</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.3pt;padding-right:7.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% Plan control but less than 50% Sponsoring Plan Control and it offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.2pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.57pt;padding-right:3.57pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% Sponsoring Plan control and on a Blue- branded basis, it only offers a Basic Medicare Part D Prescription Drug Plan product</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.15pt;padding-right:5.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1D, 4</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.95pt;padding-right:3.95pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At least 50% by Sponsoring Plan or operational Control by Sponsoring Plan and it solely operates as a Clinic as defined in Standard 1E.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.17pt;padding-right:5.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1E, 4</font></div></td></tr></table></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:112.7pt;padding-right:112.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN ADDITION,</font></div><div style="margin-bottom:0.15pt;margin-top:0.2pt;padding-left:54.6pt;text-indent:-22.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Is risk being assumed&#63;</font></div><div style="padding-left:31.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.676%"><tr><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt 0 38.3pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:35.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Yes</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:37.3pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#248;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:37.3pt;padding-right:-1.45pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">No</font></div><div><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#160;&#160;&#242;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.8pt;padding-right:7.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate underwrites any indemnity portion of workers&#8217; compensation insurance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.05pt;padding-left:0.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 7A-7E, 11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.05pt;padding-right:4.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises &#60; 15% of total member enrollment of Sponsoring Plan and its licensed affiliates, and does not underwrite the indemnity portion of workers&#8217; compensation insurance</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Standard 2</font></div><div style="padding-left:4.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Guidelines 1.1,1.2)</font></div><div style="padding-left:4.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">and Standard 11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:8.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 15% of total member enrollment of Sponsoring Plan and its licensed affiliates, and does not underwrite the indemnity portion of workers&#8217; compensation insurance</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div><font><br></font></div><div style="padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 6H</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.75pt;padding-right:4.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises &#60; 15% of total member enrollment of Sponsoring Plan and its licensed affiliates</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Standard 2</font></div><div style="padding-left:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Guidelines 1.1,1.3)</font></div><div style="padding-left:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and Standard 11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:98.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 15% of total member enrollment of Sponsoring Plan and its licensed affiliates</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 6H</font></div></td></tr></table></div><div style="padding-right:49.5pt;text-align:right"><font><br></font></div><div style="padding-right:49.5pt;text-align:right"><font><br></font></div><div style="margin-top:0.05pt;padding-left:100.62pt;padding-right:100.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN ADDITION,</font></div><div style="margin-top:0.05pt;padding-left:100.62pt;padding-right:100.62pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">           3.  Is medical care being directly provided as a staff model HMO&#63;</font></div><div style="padding-left:27.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.863%"><tr><td style="width:1.0%"></td><td style="width:49.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:108.92pt;padding-right:108.92pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Yes</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div><font><br></font></div><div style="padding-left:109.05pt;padding-right:109.05pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Standard 3A</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:119.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Standard </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3B</font></div></td></tr></table></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-right:49.5pt;text-align:right"><font><br></font></div><div style="padding-right:49.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Amended June 20, 2019</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:110.75pt;padding-right:110.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.7pt;padding-left:110.75pt;padding-right:110.75pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="padding-left:36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:4.7pt;padding-left:110.75pt;padding-right:110.75pt;text-align:center"><font><br></font></div><div style="margin-top:0.1pt;padding-left:100.57pt;padding-right:100.57pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STANDARDS FOR LICENSED CONTROLLED AFFILIATES</font></div><div style="margin-top:0.05pt;padding-left:64.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each licensed controlled affiliate shall be subject to certain standards as determined below&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:100.62pt;padding-right:100.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN ADDITION,</font></div><div style="margin-top:0.2pt;padding-left:32pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.  Is the licensed controlled affiliate operating as a Clinic as defined in Standard 1(E</font></div><div style="margin-top:0.2pt;padding-left:32pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.863%"><tr><td style="width:1.0%"></td><td style="width:49.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:108.92pt;padding-right:108.92pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Yes</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div><font><br></font></div><div style="padding-left:55.45pt;padding-right:55.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Standard 3C and Standard 2, 1.4 (if organized as a health plan that also operates as a Clinic)</font></div></td></tr></table></div><div style="margin-top:0.2pt;padding-left:32pt"><font><br></font></div><div style="margin-top:4.15pt;padding-left:32pt;padding-right:73.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 5.  If the controlled affiliate has health or workers&#8217; compensation administration business, does such business comprise 15% or more of the total member enrollment of Plan and its licensed Controlled Affiliates&#63;</font></div><div style="margin-top:4.15pt;padding-left:32pt;padding-right:73.7pt"><font><br></font></div><div style="padding-left:27.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.448%"><tr><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:12.7pt;padding-right:12.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</font></div><div style="margin-top:4.15pt;padding-left:32pt;padding-right:73.7pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:4.15pt;padding-left:36.85pt;padding-right:36.85pt;text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:4.15pt;padding-left:36.85pt;padding-right:36.85pt;text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:0.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</font></div><div style="margin-top:4.15pt;padding-left:32pt;padding-right:73.7pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#248;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.8pt;padding-right:12.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 6A-6J</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.8pt;padding-right:24.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate is not a former</font></div><div style="padding-left:0.8pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">primary licensee and is not subject to Standard 1(C)</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 5,8,9B,10,11</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.8pt;padding-right:75.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate is a former primary licensee</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 5,8,9A,10,11</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:76.75pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate is not a former primary licensee and is subject to Standard 1(C)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:76.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 5,8,9B,11</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-right:56.7pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended June 20, 2019</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:69pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1A.) The Standard for more than 50% Plan control is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:56.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA , has the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; 1) to select members of the Controlled Affiliate&#8217;s governing body having more than 50% voting control thereof&#59; and 2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur&#59; and 3) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1B.)&#160;&#160;&#160;&#160;The Standard for 50% Plan control is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:74.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA has the legal authority, directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:68.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 50% voting control thereof&#59; and</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:69.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur&#59; and</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:62.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring Plan.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:285pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:66.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in 1) through 3) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by Sponsoring Plan before the Controlled Affiliate can&#58;</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;change the geographic area in which it operates</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;change its legal and&#47;or trade names</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;change any of the types of businesses in which it engages</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:80.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the ordinary course of business</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:75.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being replaced</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;make any loans or advances except in the ordinary course of business</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:63.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners or persons or entities with the authority to select or appoint members or board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate)</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;conduct any business other than under the Licensed Marks and Name</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:59.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o&#160;&#160;&#160;&#160;take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:116.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own at least 50% of any for-profit Controlled Affiliate.</font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:116.75pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt;padding-right:61.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1C.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and service and has 100% Plan control but less than 50% Sponsoring Plan Control is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:57.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized and operated in such a manner that (i) it offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services&#59; and (ii) a Plan authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA has the legal authority together with Other Plans&#58;</font></div><div style="margin-top:11.5pt;padding-left:356.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended September 19, 2014</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="padding-left:96pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and</font></div><div style="margin-top:9.25pt;padding-left:96pt;padding-right:116.6pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws, or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="margin-top:1.95pt;padding-left:69pt;padding-right:82.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate. </font></div><div style="padding-right:82.9pt"><font><br></font></div><div style="padding-left:72pt;padding-right:82.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and such other Plans each having an ownership interest. Such 100% control and ownership by Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall execute the Addendum to Controlled Affiliate License.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:61.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1D.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that on a Blue-branded basis only offers a Basic Medicare Part D Prescription Drug Plan product and has 100% Plan control is&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:71.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall be organized and operated in such a manner that (i) on a Blue-branded basis, it only offers a Basic Medicare Part D Prescription Drug Plan product&#59; and (ii) the Sponsoring Plan has the legal authority&#58;</font></div><div style="margin-top:9.15pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate's governing body&#59; and</font></div><div style="margin-top:9.2pt;padding-left:105pt;padding-right:111.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="margin-top:9.25pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:67.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:71.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the Sponsoring Plan and Participating Plan shall execute the Addendum to Controlled Affiliate License.</font></div><div style="padding-left:69pt;padding-right:71.35pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt;padding-right:101.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1E.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that operates as a Clinic and the Sponsoring Plan has control of the Clinic is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:66.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized in such a manner that it operates as a Clinic and the Sponsoring Plan exercises operation control over the Controlled Affiliate.</font></div><div style="padding-left:69pt;padding-right:61.4pt"><font><br></font></div><div style="padding-left:69pt;padding-right:61.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, if the Clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-right:56.55pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended June 20, 2019</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:98.2pt;padding-right:98.2pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.2pt;padding-right:98.2pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 2 &#8211; Financial Responsibility</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:60.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers. If a risk- assuming Controlled Affiliate ceases operations for any reason, Blue Cross and&#47;or Blue Cross Plan coverage will be offered to all Controlled Affiliate subscribers without exclusions, limitations or conditions based on health status. If a nonrisk-assuming Controlled Affiliate ceases operations for any reason, Sponsoring Plan will provide for services to its customers. The requirements of the preceding two sentences shall apply to all lines of business unless a line of business is specially exempted from the requirement(s) by the BCBSA Board of Directors.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 3 &#8211; State Licensure&#47;Certification</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:78.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3A.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that employs, owns or contracts on a substantially exclusive basis for medical services is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:58.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain unimpaired licensure or certification for its medical care providers to operate under applicable state laws.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:56.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3B.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that does not employ, own or contract on a substantially exclusive basis for medical services is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:78.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain unimpaired licensure or certification to operate under applicable state laws.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:73.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3C.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that operates as a Clinic as defined in Standard 1(E) is&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:102.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 4 &#8211; Certain Disclosures</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:56.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of 1) the structure of the Blue Cross and Blue Shield System&#59; and 2) the independent nature of every licensee&#59; and 3) the Controlled Affiliate's financial condition.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:358.8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 5 &#8211; Reports and Records for Certain Smaller Controlled Affiliates</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:82.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For a smaller Controlled Affiliate that does not underwrite the indemnity portion of workers&#8217; compensation insurance, the Standard is&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:57.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate and&#47;or its Sponsoring licensed Plan shall furnish, on a timely and accurate basis, reports and records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:160.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Standard 6 &#8211; Other Standards for Larger Controlled Affiliates </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Standards 6(A) &#8211; (I) that follow apply to larger Controlled Affiliates. Standard 6(A)&#58; Board of Directors</font></div><div style="padding-left:69pt;padding-right:59.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate Governing Board shall act in the interest of its Corporation in providing cost-effective health care services to its customers. A Controlled Affiliate shall maintain a governing Board, which shall control the Controlled Affiliate, composed of a majority of persons other than providers of health care services, who shall be known as public members. A public member shall not be an employee of or have a financial interest in a health care provider, nor be a member of a profession which provides health care services.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(B)&#58; Responsiveness to Customers</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:78.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner responsive to customer needs and requirements.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(C)&#58; Participation in National Programs</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:68.95pt;padding-right:63.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall effectively and efficiently participate in each national program as from time to time may be adopted by the Member Plans for the purposes of providing portability of membership between the licensees and ease of claims processing for customers receiving benefits outside of the Controlled Affiliate's Service Area.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:285pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:3.7pt;padding-left:69pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(C)&#58; Participation in National Programs (continued)</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such programs are applicable to licensees, and include&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;BlueCard Program&#59;</font></div><div style="padding-left:87pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Inter-Plan Teleprocessing System (ITS)&#59;</font></div><div style="padding-left:87pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;National Account Programs</font></div><div style="padding-left:87pt;padding-right:102.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April 14, 2003&#59; and</font></div><div style="padding-left:87pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div><font><br></font></div><div style="padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(D)&#58;&#160;&#160;&#160;&#160;Financial Performance Requirements</font></div><div><font><br></font></div><div style="padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to requirements under the national programs listed in</font></div><div style="padding-left:68.95pt;padding-right:58.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6C&#58; Participation in National Programs, a Controlled Affiliate shall take such action as required to ensure its financial performance in programs and contracts of an inter-licensee nature or where BCBSA is a party.</font></div><div><font><br></font></div><div style="padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(E)&#58; Cooperation with Plan Performance Response Process</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:65.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall cooperate with BCBSA's Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Plan Performance Response Process and in addressing Controlled Affiliate performance problems identified thereunder.</font></div><div><font><br></font></div><div style="padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(F)&#58; Independent Financial Rating</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:60.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall obtain a rating of its financial strength from an independent rating agency approved by BCBSA's Board of Directors for such purpose.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(G)&#58; Local Best Efforts</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:64.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provision in the Plan&#8217;s License Agreement with BCBSA or in this License Agreement, during each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Cross Mark.</font></div><div style="padding-left:69pt;padding-right:64.75pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(H)&#58; Financial Responsibility</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:64.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:328.05pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of April 27, 2021</font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(I)&#58; Reports and Records</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:58.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall furnish to BCBSA on a timely and accurate basis reports and records relating to compliance with these Standards and the License Agreements between BCBSA and Controlled Affiliate. Such reports and records are the following&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A)&#160;&#160;&#160;&#160;BCBSA Controlled Affiliate Licensure Information Request&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:100.85pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B)&#160;&#160;&#160;&#160;Triennial trade name and service mark usage material, including disclosure material&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141pt;padding-right:57.4pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C)&#160;&#160;&#160;&#160;Changes in the ownership and governance of the Controlled Affiliate, including changes in its charter, articles of incorporation, or bylaws, changes in a Controlled Affiliate's Board composition, or changes in the identity of the Controlled Affiliate's Principal Officers, and changes in risk acceptance, contract growth, or direct delivery of medical care&#59; and</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:63.45pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D)&#160;&#160;&#160;&#160;Semi-annual &#8220;Health Risk-Based Capital (HRBC) Report&#8221; as defined by the NAIC, Annual Certified Audit Report, Insurance Department Examination Report, Annual Statement filed with State Insurance Department (with all attachments), and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:328.05pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 17, 2011</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:98.2pt;padding-right:98.2pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3.7pt;padding-left:69pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6(J)&#58; Control by Unlicensed Entities Prohibited</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to obtain control of the Controlled Affiliate or to acquire a substantial portion of its assets related to licensable services.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:94.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 7 - Other Standards for Risk-Assuming Workers&#8217; Compensation Controlled Affiliates</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:93.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standards 7(A) - (E) that follow apply to Controlled Affiliates that underwrite the indemnity portion of workers&#8217; compensation insurance.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7 (A)&#58; Financial Responsibility</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:60.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7(B)&#58; Reports and Records</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:100.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall furnish, on a timely and accurate basis, reports and records relating to compliance with these Standards and the License Agreements between BCBSA and the Controlled Affiliate. Such reports and records are the following&#58;</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;BCBSA Controlled Affiliate Licensure Information Request&#59; and</font></div><div><font><br></font></div><div style="padding-left:85.65pt;padding-right:95pt;text-indent:-16.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Triennial trade name and service mark usage materials, including disclosure materials&#59; and</font></div><div><font><br></font></div><div style="padding-left:85.4pt;padding-right:71.5pt;text-indent:-16.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Annual Certified Audit Report, Annual Statement as filed with the State Insurance Department (with all attachments), Annual NAIC&#8217;s Risk-Based Capital Worksheets for Property and Casualty Insurers&#59; and</font></div><div><font><br></font></div><div style="padding-left:85.8pt;padding-right:97.5pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Quarterly Estimated Risk-Based Capital for Property and Casualty Insurers, Insurance Department Examination Report&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:328.2pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 17, 2011</font></div><div><font><br></font></div><div style="padding-left:98.2pt;padding-right:98.2pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.2pt;padding-right:98.2pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7(B)&#58; Reports and Records, continued</font></div><div><font><br></font></div><div style="padding-left:87pt;padding-right:111.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Notification of all changes and proposed changes to independent ratings within 30 days of receipt and submission of a copy of all rating reports&#59; and</font></div><div><font><br></font></div><div style="padding-left:87pt;padding-right:98.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Changes in the ownership and governance of the Controlled Affiliate including changes in its charter, articles of incorporation, or bylaws, changes in a Controlled Affiliate&#8217;s Board composition, Plan control, state license status, operating area, the Controlled Affiliate&#8217;s Principal Officers or direct delivery of medical care.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7(C)&#58; Loss Prevention</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:125.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall apply loss prevention protocol to both new and existing business.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7(D)&#58; Claims Administration</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:90.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain an effective claims administration process that includes all the necessary functions to assure prompt and proper resolution of medical and indemnity claims.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7(E)&#58; Disability and Provider Management</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:100.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall arrange for the provision of appropriate and necessary medical and rehabilitative services to facilitate early intervention by medical professionals and timely and appropriate return to work.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:328.05pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 16, 2000</font></div><div style="margin-top:3pt;padding-left:112.57pt;padding-right:112.57pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3pt;padding-left:112.57pt;padding-right:112.57pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:69pt;padding-right:106.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 8 - Cooperation with Controlled Affiliate License Performance Response Process Protocol</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:69pt;padding-right:100.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate and its Sponsoring Plan shall cooperate with BCBSA&#8217;s Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Controlled Affiliate License Performance Response Process Protocol (ALPRPP) and in addressing Controlled Affiliate compliance problems identified thereunder.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:99.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary Licensees</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:58.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A smaller controlled affiliate that formerly was a Primary Licensee shall effectively and efficiently participate in certain national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the Controlled Affiliate&#8217;s service area and be subject to certain relevant financial and reporting requirements.</font></div><div style="margin-top:6pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;National program requirements include&#58;</font></div><div style="margin-top:6pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">BlueCard Program&#59;</font></div><div style="margin-top:5.95pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">Inter-Plan Teleprocessing System (ITS)&#59;</font></div><div style="margin-top:5.85pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">National Account Programs.</font></div><div style="margin-top:5.9pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Financial Requirements include&#58;</font></div><div style="margin-top:6pt;padding-left:135pt;padding-right:86.25pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">Standard 6(D)&#58; Financial Performance Requirements and Standard 6(H)&#58; Financial Responsibility&#59; or</font></div><div style="margin-top:5.95pt;padding-left:135pt;padding-right:82.3pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">A financial guarantee covering the Controlled Affiliate&#8217;s Inter-Plan Programs obligations in a form, and from a guarantor, acceptable to BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:328.05pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 21, 2014</font></div><div style="margin-top:6pt;padding-left:104.12pt;padding-right:104.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:6pt;padding-left:104.12pt;padding-right:104.12pt;text-align:center"><font><br></font></div><div style="margin-top:3.5pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:69pt;padding-right:99.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary Licensees</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Reporting requirements include&#58;</font></div><div style="margin-top:6.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">The Semi-annual Health Risk-Based Capital (HRBC) Report.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:358.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 13, 2002</font></div><div style="margin-top:6pt;padding-left:112.55pt;padding-right:112.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3.7pt;padding-left:69pt"><font><br></font></div><div style="padding-left:0.69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:99.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 9(B) - Participation in National Programs by Smaller Controlled Affiliates</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:88.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A smaller controlled affiliate shall participate in national programs in accordance with BlueCard and other relevant Policies and Provisions shall effectively and efficiently participate in national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the controlled affiliate&#8217;s service area and be subject to certain relevant financial and reporting requirements.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:100.8pt;text-indent:-31.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;National program requirements include&#58;</font></div><div style="margin-top:2.95pt;padding-left:121.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">BlueCard Program&#59;</font></div><div style="margin-top:2.4pt;padding-left:121.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">Inter-Plan Teleprocessing System (ITS)&#59;</font></div><div style="margin-top:2.55pt;padding-left:121.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">National Account Programs.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:100.8pt;text-indent:-31.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Financial Requirements include&#58;</font></div><div style="margin-top:3.35pt;padding-left:121.5pt;padding-right:104.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:32.15pt">Standard 6(D)&#58; Financial Performance Requirements and Standard 6(H)&#58; Financial Responsibility&#59; or</font></div><div style="margin-top:3.3pt;padding-left:121.5pt;padding-right:100.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%;padding-left:32.15pt">A financial guarantee covering the Controlled Affiliate&#8217;s Inter-Plan Programs obligations in a form, and from a guarantor, acceptable to BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:356.95pt;text-align:right;text-indent:3.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 20, 2013</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3.5pt;padding-left:69pt"><font><br></font></div><div style="margin-top:3.5pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 10 - Participation in Inter-Plan Medicare Advantage Program</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:59.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A smaller controlled affiliate for which this standard applies pursuant to the Preamble section of Exhibit A of the Controlled Affiliate License Agreement shall effectively and efficiently participate in certain national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the controlled affiliate&#8217;s service area.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">National program requirements include&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:61.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 11&#58; Participation in Master Business Associate Agreement by Smaller Controlled Affiliate Licensees</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:65.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective April 14, 2003, all smaller controlled affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as defined by the Business Associate Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.2pt;padding-left:321pt;text-align:right;text-indent:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:112.55pt;padding-right:112.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3.7pt;padding-left:69pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B-1</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:69pt;padding-right:66.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1C.</font></div><div><font><br></font></div><div style="padding-left:74.62pt;padding-right:74.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:81.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Addendum is made to that certain Blue Cross Controlled Affiliate License Agreement executed by and among Blue Cross and Blue Shield Association (&#8220;Licensor&#8221;),___________________________(&#8220;Controlled Affiliate Licensee&#8221;) and</font></div><div style="margin-top:0.05pt;padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________________________________________(&#8220;Sponsoring Plan&#8221;) dated the            _______ day of_________,________(&#8220;Agreement&#8221;). The parties to this Addendum are Licensor, Controlled Affiliate Licensee, Sponsoring Plan, and the undersigned other Plans (&#8216;Other Plans&#8221;). This Addendum is made and shall be deemed effective as of the date of the Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:65.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Sponsoring Plan asserts that it can serve the Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans market in its Service Area more efficiently and with less risk through an enterprise jointly owned and controlled with other Plans than through a wholly owned and Controlled Affiliate Licensee.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:67.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, in such circumstance Controlled Affiliate License Standard 1C permits the licensing of a Controlled Affiliate that is less than 50% owned and controlled by the Sponsoring Plan but which is 100% owned and controlled by Plans including the Sponsoring Plan, subject to certain conditions&#59;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:59.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, one such condition is that the Sponsoring Plan and all such other owning and controlling Plans enter into this Addendum&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:60.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein, the parties agree as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;This Addendum is limited to &#91;identify product name&#93;.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:64.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Sponsoring Plan shall participate operationally in Controlled Affiliate&#8217;s business that is conducted under the Licensed Marks. The parties understand that participation may take many forms, one of which should be providing a network of providers in the Service Area of the Controlled Affiliate for the Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans services being offered under the Agreement and being involved in network development and provider engagement functions.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:95.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Each of the Other Plans agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to enable Sponsoring Plan and</font></div><div style="padding-left:87pt;padding-right:95.45pt"><font><br></font></div><div style="padding-left:89.22pt;padding-right:89.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:3.7pt;padding-left:105pt;padding-right:65.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it will not take any action, either individually or jointly with any of the Other Plans, that would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either individually or jointly with any of the Other Plans, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:58.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Each of the Other Plans acknowledges that it has reviewed the Agreement and understands that Sponsoring Plan has the right to terminate the Agreement without cause upon notice as provided in Paragraph 8 of the Agreement, and that such right is unfettered and may be exercised by Sponsoring Plan in its sole discretion.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:76.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BLUE CROSS BLUE SHIELD ASSOCIATION</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Controlled Affiliate Licensee&#93;</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Sponsoring Plan&#93;</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Other Plan 1&#93;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Other Plan 2&#93;</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _______________________________________</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:356.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended September 27, 2018</font></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:98.22pt;padding-right:98.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B-2</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:69pt;padding-right:66.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1D.</font></div><div style="margin-top:9.15pt;padding-left:74.62pt;padding-right:74.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE</font></div><div style="margin-top:9.2pt;padding-left:69pt;padding-right:100.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Addendum is made to that certain Blue Cross Controlled Affiliate License Agreement executed by and among Blue Cross and Blue Shield Association (&#8220;Licensor&#8221;),__________________________(&#8220;Controlled Affiliate Licensee&#8221;),</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________________________________(&#8220;Sponsoring Plan&#8221;) and __________________________________  (&#8220;Participating Plan&#8221;) dated the ____ day of__________,_______(&#8220;Agreement&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:94.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Participating Plan is defined as the Plan that holds the Primary License with BCBSA to use the Service Marks in the Service Area where the Controlled Affiliate will use the Service Marks&#59;</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:73.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Participating Plan asserts that it can offer a lower cost Basic Medicare Part D Prescription Drug Plan product more efficiently in the Participating Plan&#8217;s Service Area through the Controlled Affiliate Licensee&#59;</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:84.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Controlled Affiliate shall only use the Service Marks inside of the Participating Plan(s) Service Area subject to each Participating Plan signing a separate Addendum&#59;</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:74.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, in such circumstance Controlled Affiliate License Standard 1D permits the licensing of a Controlled Affiliate that is 100% owned and controlled by a Sponsoring Plan, subject to certain conditions&#59;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:71.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, one such condition is that the Sponsoring Plan, Controlled Affiliate and the Participating Plan enter into this Addendum&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:60.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein, the parties agree as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:105pt;padding-right:65.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Participating Plan shall participate in Controlled Affiliate&#8217;s business that is conducted under the Licensed Marks. The parties understand that the Participating Plan shall conduct sales support and marketing of the Controlled Affiliate&#8217;s Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan&#8217;s Service Area. Any other form of participation shall require BCBSA&#8217;s written approval.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:60.3pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Participating Plan agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to enable Sponsoring Plan and</font></div><div><font><br></font></div><div style="padding-left:89.22pt;padding-right:89.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:89.22pt;padding-right:89.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:105pt;padding-right:58.1pt;text-indent:-1.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it will not take any action that would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either individually or jointly with the Sponsoring Plan or Controlled Affiliate Licensee, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:60.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The Controlled Affiliate Licensee shall only use the Licensed Marks authorized by the Participating Plan in connection with the Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan&#8217;s Service Area.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:61.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The Sponsoring Plan and Controlled Affiliate acknowledge that it has reviewed the Agreement and understands that Participating Plan has the right to terminate this Agreement&#58; (i) immediately upon the expiration or termination of the Plan Participation Agreement by and between Participating Plan and Controlled Affiliate upon written notice to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, or (ii) without cause upon 18 months written notice to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, and that such right is unfettered and may be exercised by Participating Plan in its sole discretion. In the event that Participating Plan and Controlled Affiliate fail to execute the Plan Participation Agreement by __________(Date), Participating Plan may terminate this Agreement immediately upon notice to Sponsoring Plan, Controlled Affiliate Licensee and Licensor.</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:58.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate Licensee's rights hereunder shall immediately terminate without any further action by any party or entity in the event that the Sponsoring Plan or Participating Plan ceases to be authorized to use the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:76.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BLUE CROSS BLUE SHIELD ASSOCIATION</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ______________________</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Controlled Affiliate Licensee&#93;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ______________________</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Sponsoring Plan&#93;</font></div><div><font><br></font></div><div style="padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ______________________</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Participating Plan&#93;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ______________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:14.07pt;padding-right:14.07pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div><div style="margin-top:0.15pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:60.05pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended March 17, 2016</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:60.05pt;text-align:right"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT C</font></div><div style="padding-left:69pt;padding-right:234.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED AFFILIATE LICENSE AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:96.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOR RISK PRODUCTS&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:66.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For Controlled Affiliates not underwriting the indemnity portion of workers&#8217; compensation insurance&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An amount equal to its pro rata share of Sponsoring Plan's dues payable to BCBSA computed with the addition of the Controlled Affiliate's members using the Marks on health care plans and related services as reported on the Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:143.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For Controlled Affiliates underwriting the indemnity portion of workers&#8217; compensation insurance&#58;</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:88.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An amount equal to 0.35 percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks&#59; plus, an annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 7.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:295.9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.4pt;padding-left:112.57pt;padding-right:112.57pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.4pt;padding-left:112.57pt;padding-right:112.57pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT C (continued)</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOR NONRISK PRODUCTS&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:90.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For third-party administrative business, an amount equal to its pro rata share of Sponsoring Plan&#8217;s dues payable to BCBSA computed with the addition of the Controlled Affiliate&#8217;s members using the Marks on health care plans and related services as reported on the Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:103.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For non-third party administrative business (e.g., case management, provider networks, etc.), an amount equal to 0.24 percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks&#59; plus&#58;</font></div><div><font><br></font></div><div style="padding-left:96pt;padding-right:115.3pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;An annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 6 D.</font></div><div><font><br></font></div><div style="padding-left:96pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;An annual fee of $2,000 per license for all other Controlled Affiliates.</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:57.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing shall be reduced by one-half where both a BLUE CROSS&#174; and BLUE SHIELD&#174; License are issued to the same Controlled Affiliate. In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated. Royalties under this formula will be calculated, billed and paid in arrears.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:284.95pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:100.5pt;padding-right:100.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:100.5pt;padding-right:100.5pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-right:53.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 1A</font></div><div style="margin-top:11.65pt;padding-left:112.92pt;padding-right:112.92pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:101%">CONTROLLED AFFILIATE LICENSE AGREEMENT APPLICABLE TO LIFE INSURANCE COMPANIES</font></div><div style="margin-top:1.35pt;padding-left:78.15pt;padding-right:78.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Includes revisions adopted by Member Plans through their June 16, 2022 meeting)</font></div><div style="margin-top:1.35pt;padding-left:112.95pt;padding-right:112.95pt;text-align:center"><font><br></font></div><div style="margin-top:0.4pt;padding-left:72.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) _____________________________(&#34;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Cross Plan(s), known as______________________________________(&#34;Plan&#34;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:69.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:36.55pt;padding-right:60.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">WHEREAS, the Plan and the Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE CROSS in a trade name (&#34;Licensed Name&#34;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36.55pt;padding-right:106.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-top:10.45pt;padding-left:87pt;text-indent:-14.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GRANT OF LICENSE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.55pt;padding-right:53.65pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Controlled Affiliate the exclusive right to use the licensed Marks and Names in connection with and only in connection with those life insurance and related services authorized by applicable state law, other than health care plans and related services (as defined in the Plan's License Agreements with BCBSA) which services are not separately licensed to Controlled Affiliate by BCBSA, in the Service Area served by the Plan, except that BCBSA reserves the right to use the Licensed Marks and Name in said Service Area, and except to the extent that said Service Area may overlap the area or areas served by one or more other licensed Blue Cross Plans as of the date of this License as to which overlapping areas the rights hereby granted are non-exclusive as to such other Plan or Plans and their respective Licensed Controlled Affiliates only. Controlled Affiliate cannot use the Licensed Marks or Name outside the Service Area or in its legal or trade name&#59; provided, however, that if and only for so long as Controlled Affiliate also holds a Blue Cross Controlled Affiliate License Agreement applicable to health care plans and related services, Controlled Affiliate may use the Licensed Marks and Name in its legal and trade name according to the terms of such license agreement.</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:361.55pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 12, 2003</font></div><div style="margin-top:10.2pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.2pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">QUALITY CONTROL</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:41.15pt;padding-right:53.95pt;text-indent:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in relation to the sale, marketing and rendering of authorized products and further agrees to be bound by the conditions regarding quality control shown in Exhibit A as it may be amended by BCBSA from time-to-time.</font></div><div><font><br></font></div><div style="padding-left:36.6pt;padding-right:62.5pt;text-indent:40.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that Plan and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:58.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan or by BCBSA) a report to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of Exhibit A.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:36.6pt;padding-right:55.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it is subject to the bona fide control of a Plan or Plans. Absent written approval by BCBSA of an alternative method of control, bona fide control shall mean the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Controlled Affiliate's governing body having not less than 51% voting control thereof&#59; (b) to exercise operational control with respect to the governance thereof&#59; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate. In addition, a Plan or Plans shall own at least 51% of any for-profit Controlled Affiliate. If the Controlled Affiliate is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items (a) and (c) above, proxies representing 51% of the votes at any meeting of the policyholders and shall demonstrate that there is no reason to believe this such proxies shall be revoked by sufficient policyholders to reduce such percentage below 51%.</font></div><div style="margin-top:10.45pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SERVICE MARK USE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:36.55pt;padding-right:55.9pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks, and shall comply with such rules (applicable to all Controlled Affiliates licensed to use the Marks) relative to service mark use, as are issued from time-to-time by BCBSA. If there is any public reference to the affiliation between the Plan and the Controlled Affiliate, all of the Controlled Affiliate's licensed services in the Service Area of the Plan shall be rendered under the Licensed Marks. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:102%">-2-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:36.55pt;padding-right:67.85pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall not sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the option of Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div style="margin-top:10.45pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INFRINGEMENTS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:36.55pt;padding-right:53.15pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify Plan and BCBSA of any suspected acts of infringement, unfair competition or passing off which may occur in relation to the Licensed Marks. Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to Plan and BCBSA, free of charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks by BCBSA.</font></div><div style="margin-top:10.45pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITY INDEMNIFICATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:36.55pt;padding-right:69.9pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate hereby agrees to save, defend, indemnify and hold Plan and BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of Controlled Affiliate's rendering of health care services under the Licensed Marks.</font></div><div style="margin-top:10.45pt;padding-left:72.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE TERM</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:36.55pt;padding-right:53.85pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods upon evidence satisfactory to the Plan and BCBSA that Controlled Affiliate meets the then applicable quality control standards, unless one of the parties hereto notifies the other party of the termination hereof at least sixty (60) days prior to expiration of any license period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:36.6pt;padding-right:59.4pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be terminated by the Plan or by BCBSA for cause at any time provided that Controlled Affiliate has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period). By way of example and not for purposes of limitation, Controlled Affiliate's failure to abide by the quality control provisions of Paragraph 2, above, shall be considered a proper ground for cancellation of this Agreement.</font></div><div><font><br></font></div><div style="margin-top:11.1pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.1pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.7pt;padding-left:36.55pt;padding-right:59.6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:91.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with Standard No. 1 (Organization and Governance) of Exhibit A or, following an opportunity to cure, with the remaining quality control provisions of Exhibit A, as it may be amended from time-to-time&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:132pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Plan ceases to be authorized to use the Licensed Marks&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:89.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Appropriate dues for Controlled Affiliate pursuant to item 8 hereof, which are the royalties for this License Agreement are more than sixty (60) days in arrears to BCBSA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:105.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks including any use in its trade name.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:95.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any disagreement between Plan and BCBSA as to whether grounds exist for termination or as to any other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation or mandatory dispute resolution in effect between the parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:90.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon termination of this Agreement, Licensed Controlled Affiliate shall immediately notify all of its customers that it is no longer a licensee of the Blue Cross and Blue Shield Association and provide instruction on how the customer can contact the Blue Cross and Blue Shield Association or a designated licensee to obtain further information on securing coverage. The written notification required by this paragraph shall be in writing and in a form approved by the Association. The Association shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div><font><br></font></div><div style="margin-top:3.75pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DUES</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:91.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="margin-top:10.45pt;padding-left:105pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;An annual fee of five thousand dollars ($5,000) per license, plus</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:110.5pt;text-indent:-5.5pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;.05% of gross revenue per year from branded group products, plus</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:110.5pt;text-indent:-5.5pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;.5% of gross revenue per year from branded individual products plus</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:134.7pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.14% of gross revenue per year from branded individual annuity products.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amended as of November 20, 1997</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div><div style="padding-right:4.5pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:68.95pt;padding-right:86.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing percentages shall be reduced by one-half where both a BLUE CROSS&#174; and BLUE SHIELD&#174; license are issued to the same entity. In the event that any License period is greater or less than one (1) year, any amounts due shall be prorated. Royalties under this formula will be calculated, billed and paid in arrears.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:100.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan will promptly and timely transmit to BCBSA all dues owed by Controlled Affiliate as determined by the above formula and if Plan shall fail to do so, Controlled Affiliate shall pay such dues directly.</font></div><div><font><br></font></div><div style="margin-top:3.55pt;padding-left:103.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.  JOINT VENTURE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:89.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between Plan and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-top:10.45pt;padding-left:105pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">VOTING</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:90.15pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.95pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:102pt;padding-right:100.95pt;text-align:justify;text-indent:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICES AND CORRESPONDENCE</font></div><div style="margin-top:10.95pt;padding-left:69pt;padding-right:92.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:104%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:104%">Amended as of November 20, 1997</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3.75pt;padding-left:119.4pt;text-indent:-14.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPLETE AGREEMENT</font></div><div style="margin-top:10.9pt;padding-left:69pt;padding-right:93.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This Agreement may only be amended by a writing executed by all parties.</font></div><div style="margin-top:9.7pt;padding-left:119.4pt;text-indent:-14.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SEVERABILITY</font></div><div style="margin-top:10.95pt;padding-left:69pt;padding-right:99.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way effect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-top:9.6pt;padding-left:114pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NONWAIVER</font></div><div style="margin-top:11.05pt;padding-left:69pt;padding-right:90.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of the Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-top:9.6pt;padding-left:114pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-top:10.9pt;padding-left:69pt;padding-right:98.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amended as of June 16, 2005</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-  </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:5.2pt;padding-left:69pt;padding-right:102.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last signature written below.</font></div><div style="margin-top:9.7pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-top:10.4pt;padding-left:69pt;padding-right:216.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:204%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:204%">________________________</font></div><div style="padding-left:36pt;padding-right:216.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled Affiliate&#58;</font></div><div style="margin-top:10.4pt;padding-left:69pt;padding-right:215.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:204%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:204%">________________________</font></div><div style="padding-left:36pt;padding-right:215.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan&#58;</font></div><div style="margin-top:10.4pt;padding-left:69pt;padding-right:213.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:203%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:203%">________________________</font></div><div style="padding-left:36pt;padding-right:213.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.6pt;padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.75pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">EXHIBIT A</font></div><div style="margin-top:0.55pt;padding-left:69pt;padding-right:236.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">CONTROLLED AFFILIATE LICENSE STANDARDS LIFE INSURANCE COMPANIES</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Page 1 of 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:93.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The standards for licensing Life Insurance Companies (Life and Health Insurance companies, as defined by state statute) are established by BCBSA and are subject to change from time-to-time upon the affirmative vote of three- fourths (3&#47;4) of the Plans and three-fourths (3&#47;4) of the total weighted vote of all Plans. Each Licensed Plan is required to use a standard controlled affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Life Insurance Company maintains compliance with the license standards.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:90.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An organization meeting the following standards shall be eligible for a license to use the Licensed Marks within the service area of its sponsoring Licensed Plan to the extent and the manner authorized under the Controlled Affiliate License applicable to Life Insurance Companies and the principal license to the Plan.</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The LIC shall be organized and operated in such a manner that it is controlled by a licensed Plan or Plans which have, directly or indirectly&#58; 1) not less than 51% of the voting control of the LIC&#59; and 2) the legal ability to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the LIC with which it does not concur&#59; and 3) operational control of the LIC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:91.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the LIC is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items 1 and 2 above, proxies representing at least 51% of the votes at any policyholder meeting and shall demonstrate that there is no reason to believe such proxies shall be revoked by sufficient policyholders to reduce such percentage below 51%.</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 2 - State Licensure</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:89.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The LIC must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life and health insurance company in each state in which the LIC does business.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.75pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">EXHIBIT A</font></div><div style="margin-top:0.55pt;padding-left:69pt;padding-right:236.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">CONTROLLED AFFILIATE LICENSE STANDARDS LIFE INSURANCE COMPANIES</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Page 2 of 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 3 - Records and Examination</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:100.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The LIC and its sponsoring licensed Plan(s) shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the LIC as may be required in order to establish compliance with the license agreement. The LIC and its sponsoring licensed Plan(s) shall permit BCBSA to examine the affairs of the LIC and shall agree that BCBSA's board may submit a written report to the chief executive officer(s) and the board(s) of directors of the sponsoring Plan(s).</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 4 - Mediation</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:96.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The LIC and its sponsoring Plan(s) shall agree to use the then-current BCBSA mediation and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed controlled affiliate, a licensed Plan or BCBSA.</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 5 - Financial Responsibility</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The LIC shall maintain adequate financial resources to protect its customers and meet its business obligations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:109.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 6 - Cooperation with Affiliate License Performance Response Process Protocol</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:69pt;padding-right:115.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The LIC and its Sponsoring Plan(s) shall cooperate with BCBSA&#8217;s Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Affiliate License Performance Response Process Protocol (ALPRPP) and in addressing LIC compliance problems identified thereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-right:81.8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:111%">Exhibit 1A1</font></div><div style="margin-top:0.95pt;padding-left:185.17pt;padding-right:185.17pt;text-align:center;text-indent:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:101%">CONTROLLED AFFILIATE</font></div><div style="padding-left:97.32pt;padding-right:97.32pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRADEMARK LICENSE AGREEMENT</font></div><div style="padding-left:112.9pt;padding-right:112.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:103%">FOR LIFE AND DISABILITY INSURANCE PRODUCTS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt;padding-right:99.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and _______________________, (&#8220;Life and Disability Controlled Affiliate&#8221;) which is a company offering life and disability insurance products owned and controlled by____________________, ___________, ____________ (individually, &#8220;Sponsoring Plan&#8221; and when referred to collectively, &#8220;Sponsoring Plans&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:101.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, BCBSA is the owner of the BLUE CROSS and BLUE SHIELD word and design service marks and any derivatives thereof (&#8220;Licensed Marks&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:89.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, each Sponsoring Plan is licensed separately by BCBSA to use one or more of the Licensed Marks in a particular Service Area&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:68.95pt;padding-right:89.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">Whereas, the Sponsoring Plans and the Life and Disability Controlled Affiliate desire that the latter be entitled to use the appropriate Licensed Marks in connection with life and disability insurance products in some or all of such Sponsoring Plans&#8217; Service Areas and in the Service Areas of other Regular Member Plans, as defined in the BCBSA By-laws, (&#8220;Blue Plans&#8221;) consistent with the terms of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:91.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GRANT OF LICENSE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:88.2pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Life and Disability Controlled Affiliate the limited right to use the Licensed Marks in connection with and only in connection with the following life and disability insurance products authorized by state law&#58; (1) Group&#58; Term Life, Long Term Disability, Whole Life, Benefit Life, Universal Life&#59; (2) Individual&#58; Term Life, Whole Life, Dependent Life, S</font><font style="color:#000080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ouse Life&#59; (3) Other&#58; Disability Income, Short Term Disability, Long Term Disability, Income Replacement&#59; and (4) such other life and disability products approved by BCBSA in writing (&#8220;Licensed Products&#8221;) in the Service Areas served by the Sponsoring Plans or in the Service Area or Areas of one or more other licensed Blue Plans, provided that such Blue Plans have consented to such use as authorized by this Agreement. Life and Disability Controlled Affiliate may not use the Licensed Marks in its legal or trade name.</font></div><div style="padding-left:69pt;padding-right:87.6pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font><br></font></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font><br></font></div><div style="margin-top:3.3pt;padding-left:69pt;padding-right:95.4pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Notwithstanding that the license granted to Life and Disability Controlled Affiliate is a license to use all of the Licensed Marks, Life and Disability Controlled Affiliate may only use those of the Licensed Marks in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Service Area of a Sponsoring Plan or other consenting Blue Plan as described below that such Plan is authorized to use as a Blue Plan pursuant to its separate license agreements with BCBSA.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:90.9pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate may use the Licensed Marks in the Service Areas of Sponsoring Plans or in the Service Area of a Blue Plan that is not a signatory to this Agreement only after such Sponsoring Plan(s) or non-signatory Blue Plan consents to such use by executing a written consent in substantially the same form as the Consent Agreement attached as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:114.9pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;The following provisions apply with respect to Consent Agreements once such agreements have been fully and properly executed&#58;</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:84.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;All sales, marketing and advertising materials developed by and proposed for use by Life and Disability Controlled Affiliate in the Service Area of Sponsoring Plan or consenting Blue Plan (hereinafter, such consenting Sponsoring Plan or consenting Blue Plan collectively referred to &#8220;Consenting Plan(s)&#8221;) must clearly identify the Consenting Plan (for example, a statement on such materials that reads &#8220;This product is offered with the cooperation of Blue Cross and&#47;or Blue Shield of &#91;Geography&#93;&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:83.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;To the extent the Consenting Plan has separate divisions or other Affiliates that use the Licensed Marks in distinct geographic areas within its Service Area, consent obtained under this Agreement may be limited to one or more of such specific geographic areas as specified by the Consenting Plan in its signed Consent Agreement. For purposes of this entire Agreement, all references to the Service Area of a Sponsoring Plan, Blue Plan or Consenting Plan may include the entire Service Area or a distinct geographic area within such Service Area as specified in this Section 1 D (2)&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:105pt;padding-right:82.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Where BCBSA has licensed two or more Blue Plans to use the same Licensed Marks in the same Service Area, in addition to the requirements set forth in Section D (1) above, the sales, marketing and advertising materials referenced in such section above must be communicated to the Consenting Plan&#8217;s existing and prospective accounts through or with the approval of such Consenting Plan, and the personnel of such Consenting Plan must actively participate in all sales and marketing activities conducted by Life and Disability Controlled Affiliate in the same Service Area, including participating in meetings (whether in- person or via telephone, video or internet conference) with both existing and prospective accounts of the Consenting Plan&#59;</font></div><div style="margin-top:0.05pt;padding-right:82.85pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:82.85pt"><font><br></font></div><div style="padding-left:29.47pt;padding-right:29.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:29.47pt;padding-right:29.47pt;text-align:center"><font><br></font></div><div style="padding-left:105pt;padding-right:83.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks that the Consenting Plan has been granted by BCBSA the license to use under its Blue Plan license </font></div><div><font><br></font></div><div style="margin-top:3.3pt;padding-left:105pt;padding-right:82.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;agreements (for example, if a Consenting Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials used by Life and Disability Controlled Affiliate in that Service Area may only contain or reference the Blue Cross Marks and not the Blue Shield Marks).</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:85.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;If a Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless BCBSA and the Consenting Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products in the Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a licensee and provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in form approved by BCBSA.</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">QUALITY CONTROL</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:96.2pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate agrees to use the Licensed Marks only in relation to the sale, marketing and administration of the Licensed Products and further agrees to be bound by the conditions regarding quality control shown in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Guidelines to Administer the Standards for Trademark License Agreement for Life and Disability Insurance Products attached thereto.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:98.4pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate agrees that BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Life and Disability Controlled Affiliate's rendering of service and use of the Licensed Marks.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.85pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by BCBSA) a report to BCBSA demonstrating Life and Disability Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of Exhibit A.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:95.65pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;As used herein, a Life and Disability Controlled Affiliate is defined as&#58; An entity organized and operated in such a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by BCBSA of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Life and Disability Controlled Affiliate's governing body having not less than 100% voting control thereof&#59; (b) to exercise operational control with respect to the governance thereof&#59; and (c) to prevent any change in its articles of </font></div><div style="margin-top:9.3pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:9.3pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:118.55pt;padding-right:95.65pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:67.5pt;padding-right:95.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incorporation, bylaws or other governing documents deemed inappropriate. In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:3.75pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SERVICE MARK USE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:88.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and shall ensure all uses of the Licensed Marks comply with the BCBSA Brand Regulations, as amended by BCBSA from time to time. Life and Disability Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Life and Disability Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:120.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The license hereby granted to Life and Disability Controlled Affiliate to use the Licensed Marks is and shall be personal to Life and Disability Controlled Affiliate and shall not be assignable by any act of the Life and Disability Controlled Affiliate, directly or indirectly, without the written consent of BCBSA. Said license shall not be assignable by operation of law, nor shall Life and Disability Controlled Affiliate mortgage or part with possession or control of this license or any right hereunder, and the Life and Disability Controlled Affiliate shall have no right to grant any sublicense to use the Licensed Marks.</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INFRINGEMENTS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:88.25pt;text-indent:40.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off which may occur in relation to the Licensed Marks. Life and Disability Controlled Affiliate shall not be entitled to require BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties. Life and Disability Controlled Affiliate agrees to render to BCBSA, free of charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks by BCBSA. BCBSA shall have sole control of the defense and resolution of any claim of infringement brought or threatened by others.</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITY INDEMNIFICATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate hereby agrees to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of Life and Disability Controlled Affiliate's conduct.</font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.75pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.75pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.75pt;text-indent:36pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE TERM</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.6pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods, unless either BCBSA or Life and Disability Controlled Affiliate notifies the other party in writing of the termination hereof at least sixty (60) days prior to expiration of any license period.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:3.3pt;padding-left:69pt;padding-right:93.2pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement may be terminated by BCBSA for cause at any time provided that Life and Disability Controlled Affiliate has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period). By way of example and not for purposes of limitation, Life and Disability Controlled Affiliate's failure to abide by the conditions regarding use of the Licensed Marks set forth in Section 1 of this Agreement or the quality control provisions of Section 2 (other than with respect to Section 2 D which is subject to immediate termination as stated in Section 7 C (1) below) shall be considered proper grounds for termination of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:89.6pt;text-indent:49.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;This Agreement and all of Life and Disability Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:122.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall no longer comply with Section 2 D (or Standard No. 1 (Organization and Governance) of Exhibit A)&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:105pt;padding-right:99.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Any Sponsoring Plan ceases to be authorized to use the Licensed Marks&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:105pt;padding-right:95.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Appropriate fees for Life and Disability Controlled Affiliate pursuant to Section 8 of this Agreement are more than sixty (60) days in arrears to BCBSA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:105pt;padding-right:86.25pt;text-indent:31.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon termination of this Agreement for cause or otherwise, Life and Disability Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:104.95pt;padding-right:106.8pt;text-indent:31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any disagreement between Life and Disability Controlled Affiliate and BCBSA as to whether grounds exist for termination or as to any other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation or mandatory dispute resolution in effect between the parties.</font></div><div style="margin-top:0.05pt;padding-left:104.95pt;padding-right:106.8pt;text-indent:31.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:104.95pt;padding-right:106.8pt;text-indent:31.55pt"><font><br></font></div><div style="margin-top:9.3pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:9.3pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:9.3pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:104.95pt;padding-right:86.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon termination of this Agreement, Licensed Life and Disability Controlled Affiliate shall immediately notify all of its customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA. BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div><font><br></font></div><div style="margin-top:3.75pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROYALTIES</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:112.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="margin-top:9.65pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">An annual fee of five thousand dollars ($5,000) per license, plus</font></div><div style="margin-top:11.65pt;padding-left:141pt;padding-right:104.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">.05% of gross revenue per year from group products sold under the Licensed Marks, plus</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;padding-right:91.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">.5% of gross revenue per year from individual products sold under the Licensed Marks</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:69pt;padding-right:100.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated. Royalties under this formula will be calculated, billed and paid in arrears.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:89.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate will promptly and timely transmit to BCBSA all fees owed by Life and Disability Controlled Affiliate as determined by the above formula.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JOINT VENTURE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:96.35pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between any Sponsoring Plan and Life and Disability Controlled Affiliate or between among them and&#47;or BCBSA.</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">VOTING</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:90.15pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the </font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:90.15pt;text-indent:54pt"><font><br></font></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:90.15pt;text-indent:-1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div style="margin-top:3.55pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICES AND CORRESPONDENCE</font></div><div style="margin-top:10.9pt;padding-left:68.95pt;padding-right:92.75pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div style="margin-top:10.45pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPLETE AGREEMENT</font></div><div style="margin-top:11.05pt;padding-left:69pt;padding-right:87pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This Agreement may only be amended by&#58; </font></div><div style="padding-left:69pt;padding-right:90.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) a writing signed by all parties&#59; or (b) a writing approved by the affirmative vote of three-fourths of the Blue Plans and three-fourths of the total then current weighted vote of all the Blue Plans as officially recorded by the BCBSA Corporate Secretary. Upon such adoption by the Blue Plans, this Agreement and all other Trademark License Agreements for Life and Disability Insurance Products then in effect shall simultaneously be amended.</font></div><div style="margin-top:9.6pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SEVERABILITY</font></div><div style="margin-top:10.9pt;padding-left:69pt;padding-right:99.4pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-top:9.6pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NONWAIVER</font></div><div style="margin-top:11.05pt;padding-left:69pt;padding-right:88.75pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of the Life and Disability Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-top:9.6pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-top:10.95pt;padding-left:69pt;padding-right:97pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:3.3pt;padding-left:69pt;padding-right:102.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last signature written below.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-top:10.45pt;padding-left:69pt;padding-right:216.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:203%">By&#58;_______________________</font></div><div style="padding-left:36pt;padding-right:216.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_____________________</font></div><div style="padding-right:216.45pt"><font><br></font></div><div style="padding-left:36pt;padding-right:216.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Life and Disability Controlled Affiliate&#58;</font></div><div style="margin-top:10.45pt;padding-left:69pt;padding-right:215.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:203%">By&#58;_______________________</font></div><div style="padding-left:36pt;padding-right:215.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_____________________</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sponsoring Plan&#58;</font></div><div style="margin-top:10.3pt;padding-left:69pt;padding-right:211.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:204%">By&#58;_______________________</font></div><div style="padding-left:36pt;padding-right:211.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_____________________</font></div><div style="padding-right:211.35pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:211.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;_____________________</font></div><div style="padding-right:211.35pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:211.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sponsoring Plan&#58;</font></div><div style="padding-right:211.35pt;text-align:justify"><font><br></font></div><div style="padding-left:69pt;padding-right:211.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:203%">By&#58;_________________________</font></div><div style="padding-left:36pt;padding-right:211.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;_______________________</font></div><div style="padding-right:211.35pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:211.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;______________________</font></div><div style="padding-right:211.35pt;text-align:justify"><font><br></font></div><div style="padding-right:211.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Add other Sponsoring Plans as necessary&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.8pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:7.8pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:3.75pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:11.65pt;padding-left:69pt;padding-right:133.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:101%">LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:103%">Page 1 of 2</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any Life and Disability Controlled Affiliate licensed under the Trademark License Agreement for Life and Disability Insurance Products (&#8220;licensee&#8221;) shall be organized and operated in such a manner that it is an entity organized and operated in such a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by BCBSA of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Life and Disability Controlled Affiliate's governing body having not less than 100% voting control thereof&#59; (b) to exercise operational control with respect to the governance thereof&#59; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate.  In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 2 - State Licensure</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:89.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The licensee must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life company in each state in which the licensee does business.</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 3 - Records and Examination</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:86.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The licensee shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the licensee as may be required in order to establish compliance with the Agreement. The licensee shall permit BCBSA to examine the affairs of the licensee and shall agree that BCBSA's board may submit a written report to the chief executive officer(s) and the board(s) of directors of the Sponsoring Plan(s).</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 4 - Mediation</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:92.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The licensee, its Sponsoring Plan(s) and all consenting Blue Plans shall agree to use the then-current BCBSA mediation and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed Life and Disability Controlled Affiliate, a Sponsoring Plan and or consenting Blue Plan or BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:8.75pt;padding-right:8.75pt;text-align:center"><font><br></font></div><div style="margin-top:3.75pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:11.65pt;padding-left:69pt;padding-right:133.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:101%">LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:103%">Page 2 of 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 5 - Financial Responsibility</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:142.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The licensee shall maintain adequate financial resources to protect its customers and meet its business obligations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 6 - Cooperation with BCBSA Governance</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:69pt;padding-right:113.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The licensee shall cooperate with BCBSA&#8217;s Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of and in addressing licensee compliance problems that may be identified in connection with the operation or administration of the Trademark License Agreement for Life and Disability Insurance Products.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font><br></font></div><div style="margin-top:3.45pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-top:6.85pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSENT AGREEMENT</font></div><div style="margin-top:11.5pt;padding-left:51pt;padding-right:94.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Consent Agreement is made and entered into by and among the undersigned Blue Plan, and____________________(&#8220;Life and Disability Controlled Affiliate&#8221;), and the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;) and shall be deemed effective on_______________________(&#8220;Effective Date&#8221;).</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:86.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, BCBSA owns the Blue Cross and Blue Shield word and design service marks and any derivative mark thereof (the &#8220;Brands&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:97.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, the undersigned Blue Plan is licensed to use one or more of the Brands within a specific geographic area (&#8220;Service Area&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:92.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas Life and Disability Controlled Affiliate is licensed by BCBSA to use one or more of the Brands to offer life and disability insurance products (&#8220;Products&#8221;) as defined and authorized in the Trademark License Agreement for Life and Disability Insurance Products (&#8220;Life and Disability License Agreement&#8221;)&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:96.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas neither the Blue Plan nor its affiliates offer the Products under any of the Brands in such Blue Plan&#8217;s Service Area or portion thereof where Blue Plan has consented to sale of the Products by Life and Disability Controlled Affiliate&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:116.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas BCBSA and the undersigned Blue Plan desire to consent to Life and Disability Controlled Affiliate&#8217;s use of the Brands in Blue Plan&#8217;s Service Area consistent with the terms of the Life and Disability License Agreement and this Consent Agreement.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:95.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Now, therefore, in consideration of the obligations and conditions stated in this Agreement, Blue Plan, Life and Disability Controlled Affiliate and BCBSA agree as follows&#58;</font></div><div style="margin-top:11.4pt;padding-left:87pt;padding-right:92.1pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate may market, sell, administer and underwrite the Products in Blue Plan&#8217;s Service Area under the Brands licensed to Blue Plan in such Service Area subject to the terms of this Consent Agreement, the Life and Disability License Agreement and Blue Plan&#8217;s license agreement(s) with BCBSA. Life and Disability Controlled Affiliate&#8217;s rights under the Brands to offer the Products under the Brands are limited to offering the Products only under the Brand(s) licensed to the consenting Blue Plan.</font></div><div style="margin-top:11.55pt;padding-left:87pt;padding-right:94.2pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall work with the undersigned Blue Plan to develop a written sales and marketing agreement that identifies the relationship between it and Blue Plan for the sales, marketing and customer service for the Products. The term of the sales and marketing agreement shall be the same as the term of this Consent Agreement.</font></div><div style="margin-top:11.5pt;padding-left:2.47pt;padding-right:2.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:2.47pt;padding-right:2.47pt;text-align:center"><font><br></font></div><div style="margin-top:3.15pt;padding-left:105pt;padding-right:83.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;All sales, marketing and advertising materials developed by and proposed for use by Life and Disability Controlled Affiliate in a consenting Blue Plan&#8217;s Service Area must clearly identify the consenting Blue Plan (for example, a statement on such materials that reads &#8220;This product is offered with the cooperation of Blue Cross and&#47;or Blue Shield of &#91;Geography&#93;&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:86.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate may use the Brands to sell the Products in the following Service Area or portion thereof as designated by Blue Plan&#58;</font></div><div style="padding-left:72pt;padding-right:86.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________________________________________________</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:100.55pt;padding-right:82.05pt;text-indent:-31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;If two or more Blue Plans to use the same Licensed Marks in the same Service Area, Life and Disability Controlled Affiliate shall work with the consenting Blue Plan in the following manner&#58; (a) the sales, marketing and advertising materials must be communicated to the consenting Blue Plan&#8217;s existing and prospective accounts through or with the approval of such Blue Plan, and (b) the personnel of such Blue Plan must actively participate in all sales and marketing activities conducted by Life and Disability Controlled Affiliate in the same Service Area, including participating in meetings (whether in-person or via telephone, video or internet conference) with both existing and prospective accounts of the consenting Blue Plan&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:100.55pt;padding-right:95.4pt;text-indent:-31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks that the consenting Blue Plan has been granted by BCBSA the license to use under its license agreement (for example, if a consenting Blue Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials used by Life and Disability Controlled Affiliate in that Service Area may only contain or reference the Blue Cross Marks and not the Blue Shield Marks).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:100.55pt;padding-right:85.35pt;text-indent:-31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;If this Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless each BCBSA and the Blue Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products in the Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in form approved by BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.2pt;padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:9.2pt;padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font><br></font></div><div style="margin-top:3.15pt;padding-left:100.55pt;padding-right:86.1pt;text-indent:-31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;The term of this Consent Agreement shall be one year from the Effective Date. Unless either Blue Plan or Life and Disability Controlled Affiliate provides the other party with written notice of its desire not to renew this Consent Agreement at least 60 days prior to expiration of the term or any extended term or unless terminated as provided in Paragraph 9 below, this Consent Agreement shall automatically renew for subsequent one year periods.</font></div><div><font><br></font></div><div style="padding-left:100.55pt;text-indent:-31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;This Consent Agreement may be terminated as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:123pt;padding-right:96.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Upon mutual written consent of Life and Disability Controlled Affiliate and Blue Plan&#59;</font></div><div><font><br></font></div><div style="padding-left:123pt;padding-right:103.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;By Blue Plan or Life and Disability Controlled Affiliate upon 60 days advance written notice to the non-terminating party and BCBSA&#59; or</font></div><div><font><br></font></div><div style="padding-left:123pt;padding-right:87.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;By Blue Plan immediately if Life and Disability Controlled Affiliate does not comply with this Consent Agreement or the sales protocol agreement.</font></div><div><font><br></font></div><div style="padding-left:100.55pt;padding-right:105.3pt;text-indent:-31.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;This Consent Agreement shall automatically terminate if Blue Plan&#8217;s primary licensee agreement terminates for any reason or if the Life and Disability License Agreement terminates for any reason.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:396.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Agreed and Accepted by&#58; &#91;Blue Plan&#93;&#58;</font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_______________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;______________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_______________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;______________________</font></div><div style="margin-top:4.6pt;padding-left:51pt"><font><br></font></div><div style="padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LIFE AND DISABILITY CONTROLLED AFFILIATE&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_______________________</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;______________________</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.6pt;padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-right:124.95pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Exhibit 1B</font></div><div style="padding-left:106.15pt;padding-right:106.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:113%">BLUE CROSS</font></div><div style="padding-left:86.3pt;padding-right:86.3pt;text-align:center;text-indent:63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE AGREEMENT APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS</font></div><div style="margin-top:1.25pt;padding-left:74.45pt;padding-right:74.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Adopted by Member Plans at their June 16, 2022 meeting)</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:51pt;padding-right:109.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and________(&#8220;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Cross Plan(s), known as ________ (&#34;Controlling Plans&#34;), each of which is also a Party signatory hereto.</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:100.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks&#59;</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:88.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) to offer Medicare Advantage PPO products in geographic regions designated by CMS (hereafter &#8220;regional MAPPO products&#8221;).</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:86.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:84.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE CROSS in a trade name (&#34;Licensed Name&#34;) to offer regional MAPPO products in a region that includes the Service Areas, or portions thereof, of more than one Controlling Plan&#59;</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:87.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GRANT OF LICENSE</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:86.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of regional MAPPO products and related services.</font></div><div><font><br></font></div><div style="padding-left:87pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This grant of rights is non-exclusive and is limited to the following states&#58;</font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________ (the &#8220;Region&#8221;).  Controlled Affiliate may use the Licensed</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:81.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Marks and Name in its legal name on the following conditions&#58; (i) the legal name must be approved in advance, in writing, by BCBSA&#59; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the Service Area of such Controlling Plan&#59; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">QUALITY CONTROL</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:97.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to comply with all applicable federal, state and local laws.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:88.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:86.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that the Controlling Plans and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:90.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:159.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:104.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:133.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:91.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:93.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:107.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div><font><br></font></div><div style="padding-left:231pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:231pt;padding-right:94.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:231pt;padding-right:83.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:231pt;padding-right:94.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:132.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.35pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SERVICE MARK USE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:102.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:94.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:85.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:96.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in connection with the sale, marketing and administration of regional MAPPO products and related services.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLICENSING AND ASSIGNMENT</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INFRINGEMENT</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.  Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITY INDEMNIFICATION</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:86.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of services under the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE TERM</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:120.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the provisions herein.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:82.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; (i) any one of the Controlling Plans ceases to be authorized to use the Licensed Marks and Name&#59; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement any one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:82.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling Plans an opportunity to be heard and to present their response to the Board for&#58; (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control standards of this</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="padding-left:90.75pt"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:91.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement&#59; or (2) failure to comply with the &#34;Organization and Governance&#34; quality control standard of this Agreement&#59; or (3) impending financial insolvency&#59; or (4)&#160;&#160;&#160;&#160;failure to comply with any of the applicable requirements of Standards 2, 3, 4, or 5 of attached Exhibit A&#59; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E)&#59; or (6) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and&#47;or the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:82pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance.   If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution. All other disputes between or among BCBSA, any of the Controlling Plans and&#47;or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution. The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties. Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:95.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with item 2(E) above&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:113.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:82.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Any of the following events occur&#58; (i) a voluntary petition shall be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate&#8217;s property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii) and</font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii) of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:86.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:84.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a licensee of BCBSA and, if directed by the Association&#8217;s Board of Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan&#8217;s license pursuant to Paragraph 15(a)(x)(ii) of the Blue Cross License Agreement, the notices, national account listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the geographic area for which the Controlling Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:132.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers,</font></div><div style="padding-left:51pt;padding-right:93.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">providers, brokers and agents of products or services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA. This notice shall be mailed within 15 days after termination.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall deliver to BCBSA within five days</font></div><div style="padding-left:50.95pt;padding-right:86.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the national account and the Controlled Affiliate&#8217;s role therein.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Unless the cause of termination is an event respecting BCBSA</font></div><div style="padding-left:50.95pt;padding-right:85.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stated in paragraph 15(a) or (b) of the Plan&#8217;s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate&#59; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:83.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total number of Licensed Enrollees in such geographic area. Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA&#8217;s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this subparagraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans)&#59; measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course of business. This payment shall not be due in connection with transactions exclusively by or among Plans (including the Controlling Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage. In the event that the Controlled Affiliate&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and&#47;or the Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with reestablishing the terminated Controlling Plan&#8217;s Service Area or the Region, including any payments made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;BCBSA shall have the right to audit the books and records of</font></div><div style="padding-left:51pt;padding-right:106.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-32.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that</font></div><div style="padding-left:51pt;padding-right:88.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.55pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.55pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:86.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this Agreement unless a Controlling Plan&#8217;s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of such Controlling Plan&#8217;s license agreement upon the required 6 month written notice.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:134.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DISPUTE RESOLUTION</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt;padding-right:90.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties agree that any disputes between or among them or between or among any of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross Marks and Name are subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling Plan&#8217;s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by reference as though fully set forth herein.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE FEE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:120.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit B.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JOINT VENTURE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt;padding-right:102.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICES AND CORRESPONDENCE</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:88.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last</font></div><div><font><br></font></div><div style="padding-left:106.12pt;padding-right:106.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.12pt;padding-right:106.12pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:122.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPLETE AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:84.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SEVERABILITY</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:89.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NONWAIVER</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:83.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div><font><br></font></div><div style="padding-left:87pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">VOTING</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:89.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with</font></div><div style="padding-left:50.95pt;padding-right:90.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:101.8pt;padding-right:101.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:101.8pt;padding-right:101.8pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:116.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HEADINGS</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:95.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation hereof.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:106.12pt;padding-right:106.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.12pt;padding-right:106.12pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt;padding-right:103.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last signature written below.</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled Affiliate&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling Plan&#58;</font></div><div><font><br></font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling Plan&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div><font><br></font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:106.12pt;padding-right:106.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.65pt;padding-left:106.12pt;padding-right:106.12pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:234.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS</font></div><div style="padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">June 2022</font></div><div style="padding-left:49.5pt"><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:84.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The standards for licensing Controlled Affiliates for Medicare Advantage PPO Products are established by BCBSA and are subject to change from time-to-time upon the affirmative vote of three-fourths (3&#47;4) of the Plans and three-fourths (3&#47;4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the license standards.</font></div><div><font><br></font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:50.95pt;padding-right:121.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling</font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plans&#59;</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:87.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:82.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:94.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:101.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:84.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div><font><br></font></div><div style="padding-left:195pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:89.55pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:84.45pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:102.9pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:132.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 2 - Financial Responsibility</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:88.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 3 - State Licensure&#47;Certification</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.35pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 4 - Certain Disclosures</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:88.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of&#58;</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the structure of the Blue Cross and Blue Shield System&#59; and</font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the independent nature of every licensee.</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 5 - Reports and Records for Controlled Affiliates</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate and&#47;or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 6 - Best Efforts</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:100.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Cross Marks.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 7 - Participation in Certain National Programs</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:102.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall effectively and efficiently participate in certain national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the Controlled Affiliate&#8217;s service area.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">National program requirements include&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Inter-Plan Teleprocessing System (ITS)&#59; and</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 8 - Participation in Master Business Associate Agreement</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:88.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as defined by the Business Associate Agreement.</font></div><div><font><br></font></div><div style="padding-left:266.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 15, 2007</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:29.85pt;padding-right:29.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:29.85pt;padding-right:29.85pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:239.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED AFFILIATE LICENSE AGREEMENTS</font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:114.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div><font><br></font></div><div style="padding-left:50.95pt;padding-right:114.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the Controlled Affiliate's members using the Marks on regional MAPPO products and related services as reported on the Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:302.95pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 14, 2007</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:15.45pt;padding-right:15.45pt;text-align:center"><font><br></font></div><div style="margin-top:3.35pt;padding-right:124.3pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Exhibit 1C</font></div><div style="padding-left:106.15pt;padding-right:106.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:114%">BLUE CROSS</font></div><div style="padding-left:67.12pt;padding-right:67.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE AGREEMENT</font></div><div style="padding-left:67.12pt;padding-right:67.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS</font></div><div style="margin-top:1.25pt;padding-left:74.45pt;padding-right:74.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Adopted by Member Plans at their June 16, 2022 meeting)</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:51pt;padding-right:109.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and________(&#8220;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Cross Plan(s), known as ______ (&#34;Controlling Plans&#34;), each of which is also a Party signatory hereto.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:100.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:88.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) to offer Medicare Part D Prescription Drug Plan products in geographic regions designated by CMS (hereafter &#8220;regional PDP products).&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:86.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:83.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE CROSS in a trade name (&#34;Licensed Name&#34;) to offer regional PDP products in a region that includes the Service Areas, or portions thereof, of more than one Controlling Plan&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:87.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GRANT OF LICENSE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:86.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of regional PDP products and related services.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:87pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This grant of rights is non-exclusive and is limited to the following states&#58;</font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________ (the &#8220;Region&#8221;).  Controlled Affiliate may use the Licensed</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:87pt;padding-right:81.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Marks and Name in its legal name on the following conditions&#58; (i) the legal name must be approved in advance, in writing, by BCBSA&#59; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the Service Area of such Controlling Plan&#59; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">QUALITY CONTROL</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:97.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to comply with all applicable federal, state and local laws.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:88.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:86.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that the Controlling Plans and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:90.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt;padding-right:159.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:104.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt;padding-right:82.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:123.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing Body having not less than 100% voting control thereof&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation,</font></div><div style="padding-left:51pt;padding-right:92.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59;</font></div><div><font><br></font></div><div style="padding-left:49.5pt;padding-right:129.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div style="margin-top:0.1pt;padding-left:159pt;padding-right:154.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:266%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59; (ii)change the geographic area in which it operates</font></div><div style="margin-top:0.1pt;padding-left:87pt;padding-right:85.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:87pt;padding-right:84.2pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:87pt;padding-right:112.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:132.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div style="padding-left:51pt;padding-right:132.1pt"><font><br></font></div><div style="padding-left:51pt;padding-right:132.1pt"><font><br></font></div><div style="padding-left:51pt;padding-right:132.1pt"><font><br></font></div><div style="padding-left:51pt;padding-right:132.1pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:51pt;padding-right:132.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SERVICE MARK USE</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:102.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.</font></div><div><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt;padding-right:94.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:85.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:96.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in connection with the sale, marketing and administration of regional PDP products and related services.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLICENSING AND ASSIGNMENT</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INFRINGEMENT</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.  Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.</font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:82.3pt;text-indent:36pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITY INDEMNIFICATION</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51.1pt;padding-right:86.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of services under the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE TERM</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:120.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the provisions herein.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:82.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; (i) any one of the Controlling Plans ceases to be authorized to use the Licensed Marks and Name&#59; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement any one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:82.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling Plans an opportunity to be heard and to present their response to the Board for&#58; (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control standards of this Agreement&#59; or (2) failure to comply with the &#34;Organization and Governance&#34; quality control standard of this Agreement&#59; or (3) impending financial insolvency&#59; or</font></div><div style="padding-left:51pt;padding-right:84.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;failure to comply with any of the applicable requirements of Standards 2, 3, 4, or 5 of attached Exhibit A&#59; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E)&#59; or (6) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and&#47;or the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:82pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty day period and continue diligent efforts to </font></div><div style="margin-top:0.05pt;padding-left:87pt;padding-right:82pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:49.5pt;padding-right:82pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance.  If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution. All other disputes between or among BCBSA, any of the Controlling Plans and&#47;or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution. The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties.</font></div><div style="padding-left:51pt;padding-right:90.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:95.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with item 2(E) above&#59;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:113.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA&#59; or</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Any of the following events occur&#58; (i) a voluntary petition shall</font></div><div style="padding-left:50.95pt;padding-right:85.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its</font></div><div style="margin-top:0.05pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:50.95pt;padding-right:82.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate&#8217;s property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:86.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:84.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a licensee of BCBSA and, if directed by the Association&#8217;s Board of Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:85.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan&#8217;s license pursuant to Paragraph 15(a)(x)(ii) of the Blue Cross</font></div><div><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt;padding-right:84.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">License Agreement, the notices, national account listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the geographic area for which the Controlling Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:83.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA. This notice shall be mailed within 15 days after termination.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall deliver to BCBSA within five days</font></div><div style="padding-left:51pt;padding-right:86.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the national account and the Controlled Affiliate&#8217;s role therein.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Unless the cause of termination is an event respecting BCBSA</font></div><div style="padding-left:50.95pt;padding-right:83.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stated in paragraph 15(a) or (b) of the Plan&#8217;s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate&#59; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total number of Licensed Enrollees in such geographic area. Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA&#8217;s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this subparagraph by the affirmative vote of three-fourths</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:50.95pt;padding-right:84.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Plans and three-fourths of the total then current weighted vote of all the Plans)&#59; measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course of business. This payment shall not be due in connection with transactions exclusively by or among Plans (including the Controlling Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage. In the event that the Controlled Affiliate&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and&#47;or the Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with reestablishing the terminated Controlling Plan&#8217;s Service Area or the Region, including any payments made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;BCBSA shall have the right to audit the books and records of</font></div><div style="padding-left:51pt;padding-right:106.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.</font></div><div><font><br></font></div><div style="padding-left:123pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that</font></div><div style="padding-left:51pt;padding-right:88.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:86.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this Agreement unless a Controlling Plan&#8217;s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of such Controlling Plan&#8217;s license agreement upon the required 6 month written notice.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:51pt;padding-right:134.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51.1pt;padding-right:85.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the</font></div><div style="padding-left:51.1pt;padding-right:83.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="padding-left:51.1pt;padding-right:83.4pt"><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DISPUTE RESOLUTION</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt;padding-right:90.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties agree that any disputes between or among them or between or among any of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross Marks and Name are subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling Plan&#8217;s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by reference as though fully set forth herein.</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE FEE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:120.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit B.</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JOINT VENTURE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:102.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICES AND CORRESPONDENCE</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:88.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPLETE AGREEMENT</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:84.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.2pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-10-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:9.2pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SEVERABILITY</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:89.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NONWAIVER</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:51pt;padding-right:83.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">VOTING</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:89.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:116.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HEADINGS</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:51pt;padding-right:95.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation hereof.</font></div><div><font><br></font></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-11-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt;padding-right:103.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last signature written below.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled Affiliate&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_____________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;___________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling Plan&#58;</font></div><div><font><br></font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _____________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;____________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling Plan&#58;</font></div><div><font><br></font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _____________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;____________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div><font><br></font></div><div style="padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_____________________________</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:50.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;___________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-12-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.65pt;padding-left:106.17pt;padding-right:106.17pt;text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:234.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS APPLICABLE TO REGIONAL MEDICARE</font></div><div style="padding-left:51pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PART D PRESCRIPTION DRUG PLAN PRODUCTS</font></div><div style="padding-left:50.95pt;padding-right:-2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:232%">June 2022 </font></div><div style="padding-left:50.95pt;padding-right:-2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:232%">PREAMBLE</font></div><div style="padding-left:50.95pt;padding-right:84.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The standards for licensing Controlled Affiliates for Medicare Part D Prescription Drug Plan Products are established by BCBSA and are subject to change from time- to-time upon the affirmative vote of three-fourths (3&#47;4) of the Plans and three-fourths (3&#47;4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the license standards.</font></div><div><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:106.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:141.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:86.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:115.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:105.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:83.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59;</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:124.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:110.72pt;padding-right:110.72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-13-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:110.72pt;padding-right:110.72pt;text-align:center"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:82.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div><font><br></font></div><div style="padding-left:213pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div><font><br></font></div><div style="padding-left:213pt;padding-right:86.9pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:213pt;padding-right:86.95pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div><font><br></font></div><div style="padding-left:213pt;padding-right:84.9pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:114.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div style="padding-left:68.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 2 - Financial Responsibility</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:69pt;padding-right:84.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 3 - State Licensure&#47;Certification</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:90.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:110.72pt;padding-right:110.72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-14-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.72pt;padding-right:110.72pt;text-align:center"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 4 - Certain Disclosures</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:97.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of&#58;</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the structure of the Blue Cross and Blue Shield System&#59; and</font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the independent nature of every licensee.</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 5 - Reports and Records for Controlled Affiliates</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:89.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Controlled Affiliate and&#47;or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 6 - Best Efforts</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:82.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Cross Marks.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard 7 - Participation in Master Business Associate Agreement</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:85.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as defined by the Business Associate Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:110.72pt;padding-right:110.72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-15-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:110.72pt;padding-right:110.72pt;text-align:center"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:221.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED AFFILIATE LICENSE AGREEMENTS</font></div><div style="padding-left:69pt;padding-right:102.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:116.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div><font><br></font></div><div style="padding-left:68.95pt;padding-right:110.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the Controlled Affiliate's members using the Marks on regional PDP products and related services as reported on the Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:321pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 14, 2007</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-16-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Membership Standards</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Page 1 of 5</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:94.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Membership Standards apply to all organizations seeking to become or to continue as Regular Members of the Blue Cross and Blue Shield Association. Any organization seeking to become a Regular Member must be found to be in substantial compliance with all Membership Standards at the time membership is granted and the organization must be found to be in substantial compliance with all Membership Standards for a period of two (2) years preceding the date of its application. If Membership is sought by an entity which controls or is controlled by one or more Plans, such compliance shall be determined on the basis of compliance by such Plan or Plans.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Regular Member Plans shall have authority to interpret these Standards.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:86.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Regular Member Plan that operates as a &#8220;Shell Holding Company&#8221; is defined as an entity that assumes no underwriting risk and has less than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) and less than 5% of the consolidated enterprise net general and administrative expenses.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Regular Member Plan that operates as a &#8220;Hybrid Holding Company&#8221; is defined as an entity that assumes no underwriting risk and has either more than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) or more than 5% of the consolidated enterprise net general and administrative expenses.</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:168pt;padding-right:89.35pt;text-indent:-94.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 1&#58;&#160;&#160;&#160;&#160;A Plan shall maintain a governing Board, which shall control the Plan and ensure that the Plan follows appropriate practices of corporate governance. A Plan's Board shall not be controlled by any special interest group, shall make an annual determination that a majority of its directors are independent, and shall act in the best interest of its Corporation and its customers. The Board shall be composed of a majority of persons other than providers of health care services, who shall be known as public members. A public member shall not be an employee of or have a financial interest in a health care provider, nor be a member of a profession which provides health care services.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.25pt;padding-left:299.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 15, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.25pt;padding-left:299.4pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Membership Standards</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Page 2 of 5</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:168pt;padding-right:91.45pt;text-indent:-99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 2&#58;&#160;&#160;&#160;&#160;A Plan shall furnish to the Association on a timely and accurate basis reports and records relating to compliance with these Standards and the License Agreements between the Association and the Plans. Such reports and records are the following&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:195pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;BCBSA Membership Information Request&#59;</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:97.65pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Triennial trade name and service mark usage material, including disclosure material under Standard 7&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:195pt;padding-right:90.6pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Changes in the governance of the Plan, including changes in a Plan's Charter, Articles of Incorporation, or Bylaws, changes in a Plan's Board composition, or changes in the identity of the Plan's Principal Officers&#59;</font></div><div style="padding-left:141pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:195pt;padding-right:90.6pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Written notice to BCBSA as soon as practicable but no later than 30 days after receipt of notice of any litigation filed against the Plan or any of its licensed controlled affiliates that includes allegations or claims that directly reference and seeks to enjoin or otherwise challenge the License Agreements, the structure of the Blue system, exclusive service areas, BCBSA, or any BCBSA rule, regulation, policy or Standard (Qualifying Litigation).</font></div><div style="padding-left:141pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:252pt;padding-right:87.55pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:36.65pt">Notice of Qualifying Litigation to BCBSA must include (1) Name of the Case&#59; (2) Case Number&#59; (3) Location&#47;Where Case Pending&#59; and (4) Date Plan Received, and be provided to BCBSA Senior Vice President, General Counsel and Corporate Secretary.</font></div><div style="padding-left:298.4pt"><font><br></font></div><div style="padding-left:298.4pt"><font><br></font></div><div style="padding-left:298.4pt"><font><br></font></div><div style="padding-left:298.4pt"><font><br></font></div><div style="padding-left:298.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 17, 2022</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:298.4pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:114%">Membership Standards</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Page 3 of 5</font></div><div style="margin-top:0.05pt;padding-right:87.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:195pt;padding-right:87.55pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Quarterly Financial Report, Semi-annual &#8220;Health Risk- Based Capital (HRBC) Report&#8221; as defined by the NAIC, Annual Budget, Annual Certified Audit Report, Insurance Department Examination Report, Annual Statement filed with State Insurance Department (with all attachments), Plan, Subsidiary and Affiliate Report&#59; (new version starting for period ended 12&#47;31&#47;20 and thereafter)&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:249pt;padding-right:85.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:32.15pt">Plans that are a Shell Holding Company as defined in the Preamble hereto are required to furnish only a calendar year-end &#8220;Health Risk-Based Capital (HRBC) Report&#8221; as defined by the NAIC.</font></div><div><font><br></font></div><div style="padding-left:195pt;padding-right:90.25pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Quarterly Enrollment Report, Quarterly Member Touchpoint Measures Index (MTM) through 12&#47;31&#47;2011, and Semi-annual MTM Index starting 1&#47;1&#47;2012 and thereafter.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:249pt;padding-right:91.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:32.15pt">For purposes of MTM reporting only, a Plan shall file a separate MTM report for each Geographic Market.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:184.2pt;padding-right:129.25pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 3&#58;&#160;&#160;&#160;&#160;A Plan shall be operated in a manner that provides reasonable financial assurance that it can fulfill its contractual obligations to its customers.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:184.2pt;padding-right:126.6pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 4&#58;&#160;&#160;&#160;&#160;A Plan shall be operated in a manner responsive to customer needs and requirements.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:184.2pt;padding-right:91pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 5&#58;&#160;&#160;&#160;&#160;A Plan shall effectively and efficiently participate in each national program as from time to time may be adopted by the Member Plans for the purposes of providing portability of membership between the Plans and ease of claims processing for customers receiving benefits outside of the Plan's Service Area.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:184.2pt;padding-right:112.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such programs are applicable to Blue Cross and Blue Shield Plans, and include&#58;</font></div><div><font><br></font></div><div style="margin-top:7.5pt;padding-left:213pt;text-indent:-28.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:108%">A.&#160;&#160;&#160;&#160;Inter-Plan Teleprocessing System (ITS)&#59;</font></div><div style="padding-left:213pt;text-indent:-28.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;BlueCard Program&#59;</font></div><div style="padding-left:213pt;text-indent:-28.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;National Account Programs&#59;</font></div><div style="margin-top:0.55pt;padding-left:213pt;padding-right:96.2pt;text-indent:-28.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">D.&#160;&#160;&#160;&#160;Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April 14, 2003&#59; and</font></div><div style="padding-left:213pt;text-indent:-28.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">E.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div style="padding-left:286.3pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 17, 2022</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:286.3pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Membership Standards</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Page 4 of 5</font></div><div><font><br></font></div><div style="margin-top:8.8pt;padding-left:184.2pt;padding-right:94.45pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 6&#58;&#160;&#160;&#160;&#160;In addition to requirements under the national programs listed in Standard 5&#58; Participation in National Programs, a Plan shall take such action as required to ensure its financial performance in programs and contracts of an inter-Plan nature or where the Association is a party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:184.2pt;padding-right:92.6pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 7&#58;&#160;&#160;&#160;&#160;A Plan shall make adequate disclosure in contracting with third parties and in disseminating public statements of (i) the structure of the Blue Cross and Blue Shield System,</font></div><div style="padding-left:184.2pt;padding-right:118.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) the independent nature of every Plan, and (iii) the Plan's financial condition.</font></div><div><font><br></font></div><div style="margin-top:9.1pt;padding-left:184.15pt;padding-right:97.2pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 8&#58;&#160;&#160;&#160;&#160;A Plan shall cooperate with the Association's Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Plan Performance Response Process and in addressing Plan performance problems identified thereunder.</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:184.15pt;padding-right:89.1pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 9&#58;&#160;&#160;&#160;&#160;A Plan shall obtain a rating of its financial strength from an independent rating agency approved by the Association's Board of Directors for such purpose.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:184.15pt;padding-right:95.85pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 10&#58;&#160;&#160;&#160;&#160;Notwithstanding any other provision in this License Agreement, during each year, a Plan and its Controlled Affiliate(s) engaged in providing licensable services (excluding Life Insurance and Charitable Foundation Services) shall use their best efforts to promote and build the value of the Blue Cross Marks.</font></div><div><font><br></font></div><div style="padding-left:184.15pt;padding-right:97pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 11&#58;&#160;&#160;&#160;&#160;Neither a Plan nor any Larger Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to obtain control of the Plan or Larger Controlled Affiliate or to acquire a substantial portion of its assets related to licensable services.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.25pt;padding-left:319.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.25pt;padding-left:319.15pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Membership Standards</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Page 5 of 5</font></div><div><font><br></font></div><div style="margin-top:10.6pt;padding-left:184.2pt;padding-right:93.7pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 12&#58;&#160;&#160;&#160;&#160;No provider network, or portion thereof, shall be rented or otherwise made available to a National Competitor if the Licensed Marks or Names are used in any way with such network.</font></div><div><font><br></font></div><div style="padding-left:184.2pt;padding-right:94.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A provider network may be rented or otherwise made available, provided there is no use of the Licensed Marks or Names with respect to the network being rented.</font></div><div><font><br></font></div><div style="padding-left:184.2pt;padding-right:92.5pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard 13&#58;&#160;&#160;&#160;&#160;Each Plan shall operate in a manner to reasonably&#58; 1) protect the security and confidentiality of Personally Identifiable Information (PII) and Protected Health Information (PHI)&#59; 2) protect the Brands from reputational damage&#59; and 3) cooperate with BCBSA and other Plans if a data security incident or data breach occurs.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.55pt;padding-left:329.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 18, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:8.55pt;padding-left:329.15pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 3</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:108%">GUIDELINES WITH RESPECT TO USE OF</font></div><div style="margin-top:0.55pt;padding-left:69pt;padding-right:86.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:101%">LICENSED NAME AND MARKS IN CONNECTION WITH NATIONAL ACCOUNTS</font></div><div style="margin-top:10.55pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 1 of 3</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:88.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The strength of the Blue Cross&#47;Blue Cross National Accounts mechanism, and the continued provision of cost effective, quality health care benefits to National Accounts, are predicated on locally managed provider networks coordinated on a national scale in a manner consistent with effective service to National Account customers and consistent with the preservation of the integrity of the Blue Cross&#47;Blue Shield system and the Licensed Marks. These guidelines shall be interpreted in keeping with such ends.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;A National Account is an entity with employee and&#47;or retiree locations in more than one Plan's Service Area. Unless otherwise agreed, a National Account is deemed located in the Service Area in which the corporate headquarters of the National Account is located. A local plant, office or division headquarters of an entity may be deemed a separate National Account when that local plant, office or division headquarters 1) has employee locations in more than one Service Area, and 2) has independent health benefit decision- making authority for the employees working at such local plant, office or division headquarters and for employees working at other locations outside the Service Area.  In such a case, the local plant, office or division headquarters is a National Account that is deemed located in the Service Area in which such local plant, office or division headquarters is located. The Control Plan of a National Account is the Plan in whose Service Area the National Account is located. A participating (&#34;Par&#34;) Plan is a Plan in whose Service Area the National Account has employee and&#47;or retiree locations, but in which the National Account is not located. In the event that a National Account parent company consolidates health benefit-decision making for itself and its wholly-owned subsidiary companies, the parent company and the subsidiary companies shall be considered one National Account. The Control Plan for such a National Account shall be the Plan in whose Service Area the parent company headquarters is located.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:94.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The National Account Guidelines enunciated herein below shall be applicable only with respect to the business of new National Accounts acquired after January 1, 1991.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt;padding-right:98.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Control Plans shall utilize National Account identification cards complying with then currently effective BCBSA graphic standards in connection with all National Accounts business to facilitate administration thereof, to minimize subscriber and provider confusion, and to reflect a commitment to cooperation among Plans.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:299.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 12, 2003</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:299.4pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 3</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2 of 3</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Disputes among Plans and&#47;or BCBSA as to the interpretation or implementation of these Guidelines or as to other National Accounts issues shall be submitted to mediation and mandatory dispute resolution as provided in the License Agreement. For two years from the effective date of the License Agreement, however, such disputes shall be subject to mediation only, with the results of such mediation to be collected and reported in order to establish more definitive operating parameters for National Accounts business and to serve as ground rules for future binding dispute resolution.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:98.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;The Control Plan may use the BlueCard Program (as defined by IPPC) to deliver benefits to employees and non-Medicare eligible retirees in a Participating Plan&#8217;s service area if an alternative arrangement with the Participating Plan cannot be negotiated. The Participating Plan&#8217;s minimum servicing requirement for those employees and non-Medicare retirees in its service area is to deliver benefits using the BlueCard Program. Account delivery is subject to the policies, provisions and procedures of the BlueCard Program.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:94.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;For provider payments in a Participating Plan&#8217;s area (on non-BlueCard claims), payment to the provider may be made by the Participating Plan or the Control Plan at the Participating Plan's option. If the Participating Plan elects to pay the provider, it may not withhold payment of a claim verified by the Control Plan or its designated processor, and payment must be in conformity with service criteria established by the Board of Directors of BCBSA (or an authorized committee thereof) to assure prompt payment, good service and minimum confusion with providers and subscribers. The Control Plan, at the Participating Plan's request, will also assure that measures are taken to protect the confidentiality of the data pertaining to provider reimbursement levels and profiles.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:299.35pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 14, 1996</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:299.35pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 3</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3 of 3</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:107.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;The Control Plan, in its financial agreements with a National Account, is expected to reasonably reflect the aggregate amount of differentials passed along to the Control Plan by all Participating Plans in a National Account.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:94.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Other than in contracting with health care providers or soliciting such contracts in areas contiguous to a Plan's Service Area in order to serve its subscribers or those of its licensed Controlled Affiliate residing or working in its Service Area, a Control Plan may not use the Licensed Marks and&#47;or Name, as a tag line or otherwise, to negotiate directly with providers outside its Service Area.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:299.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 13, 2003</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:299.4pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GOVERNMENT PROGRAMS AND CERTAIN OTHER USES</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 1 of 14</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt;padding-right:87.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;A Plan and its licensed Controlled Affiliate may use the Licensed Marks and Name in bidding on and executing a contract to serve a Government Program, and in thereafter communicating with the Government concerning the Program. With respect, however, to such contracts entered into after the 1st day of January, 1991, the Licensed Marks and Name will not be used in communications or transactions with beneficiaries or providers in the Government Program located outside a Plan's Service Area, unless the Plan can demonstrate to the satisfaction of BCBSA's governing body that such a restriction on use of the Licensed Marks and Name will jeopardize its ability to procure the contract for the Government Program. As to both existing and future contracts for Government Programs, Plans will discontinue use of the Licensed Marks and Name as to beneficiaries and Providers outside their Service Area as expeditiously as circumstances reasonably permit. Effective January 1, 1995, except as provided in the first sentence above, all use by a Plan of the Licensed Marks and Name in Government Programs outside of the Plan's Service Area shall be discontinued. Incidental communications outside a Plan's Service Area with resident or former resident beneficiaries of the Plan, and other categories of necessary incidental communications approved by BCBSA, are not prohibited. For purposes of this Paragraph 1, the term &#8220;Government Programs&#8221; shall mean Medicare Part A, Medicare Part B and other non-risk government programs.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:86.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In connection with activity otherwise in furtherance of the License Agreement, a Plan and its Controlled Affiliates that are licensed to use the Licensed Marks and Name in its Service Area pursuant to the Controlled Affiliate License Agreements authorized in clauses a) through c) of Paragraph 2 of the Plan&#8217;s License Agreement with BCBSA may use the Licensed Marks and Name outside the Plan&#8217;s Service Area in the following circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Common Business Communications</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:98.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services)&#59;</font></div><div style="margin-top:10.35pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;distributing business cards other than in marketing and selling&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:141pt;padding-right:88.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;advertising in publications or electronic media solely to persons for employment&#59;</font></div><div><font><br></font></div><div style="padding-left:329.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 19, 2014</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:329.15pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2 of 14</font></div><div><font><br></font></div><div style="margin-top:8.8pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;Marketing Spillover</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:99.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;advertising in print, electronic or other media which serve, as a substantial market, the Service Area of the Plan or licensed Controlled Affiliate, provided that no Plan or Controlled Affiliate may advertise outside its Service Area on the national broadcast and cable networks and that advertisements in national print media are limited to the smallest regional edition encompassing the Service Area&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:102.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">b.&#160;&#160;&#160;&#160;advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Plan's Service Area or that of a licensed Controlled Affiliate&#59;</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;Provider Contracting</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:86.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;contracting with health care providers or soliciting such contracts in areas contiguous to the Plan's Service Area in order to serve its subscribers or those of such licensed Controlled Affiliates residing or working in its service area&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:92.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;issuing a small sign containing the legal name or trade name of the Plan or such licensed Controlled Affiliates for display by a provider to identify the latter as a participating provider of the Plan or Controlled Affiliate&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:92.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;negotiating case-specific reimbursement rates with a provider that does not have a contract applicable to a specific member&#8217;s services rendered or to be rendered with the Licensee (or any of the Licensees in the case of overlapping Service Areas) in whose Service Area the health care provider is located, so long as</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:91.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the Licensee engaging in the negotiations complies with all applicable Inter-Plan Programs Policies and Provisions and Brand Regulations related to case-specific rate negotiations, and</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:99.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the Licensee (or all Licensees in the case of overlapping Service Areas) in whose Service Area the health care provider is located provides consent before negotiations commence.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:311pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of January 22, 2019</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:311pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3 of 14</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:141pt;padding-right:90.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;contracting with a pharmacy management organization (&#8220;Pharmacy Intermediary&#8221;) to gain access to a national or regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in contracting with the pharmacy providers in such network&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.4pt;padding-left:315.55pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of January 22, 2019</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.4pt;padding-left:315.55pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 4 of 14</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:88.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided that (1) the Plan and the Controlled Affiliate may not contract directly with pharmacists or pharmacy stores outside the Plan&#8217;s Service Area, and (2) neither the Plan&#8217;s or the Controlled Affiliate&#8217;s name nor the Licensed Marks or Name may be posted or otherwise displayed at or by any pharmacy store outside the Plan&#8217;s Service Area&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:101.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;contracting with a dental management organization (&#8220;Dental Intermediary&#8221;) to gain access to a national or regional dental network to deliver a routine dental benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in contracting with the dental providers in such network&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:103.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;contracting with a vision management organization (&#8220;Vision Intermediary&#8221;) to gain access to a national or regional vision network to deliver a routine vision benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in contracting with the vision providers in such network&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:89pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are collected within the Plan&#8217;s Service Area&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:141pt;padding-right:98.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;contracting with a durable medical equipment or home medical equipment company for durable medical equipment and supplies and home medical equipment and supplies that are shipped to a location within the Plan&#8217;s Service Area&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:105.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;contracting with a specialty pharmaceutical company for non- routine biological therapeutics that are ordered by a health care professional located within the Plan&#8217;s Service Area&#59;</font></div><div style="padding-left:141pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:141pt;padding-right:87.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;contracting with a company that operates provider sites in the Plan&#8217;s Service Area, provided that the contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Plan&#8217;s Service Area&#59;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:141pt;padding-right:87.8pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:141pt;padding-right:105.6pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 5 of 14</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;contracting with a company that makes health care professionals available in the Plans&#8217; Service Area (e.g., traveling home health nurse), provided that the contract is solely for services rendered by health care professionals who are located within the Plan&#8217;s Service Area.</font></div><div style="padding-left:141pt;padding-right:87pt"><font><br></font></div><div style="padding-left:141pt;padding-right:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;permitting Control&#47;Home Plans&#8217; ability to resolve members&#8217; service issues requiring outreach to out-of-area providers as set forth in the Inter-Plan Programs and Inter-Plan Medicare Advantage Program Policies.</font></div><div style="padding-left:141pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:141pt;padding-right:87pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;contracting with national telemedicine and virtual healthcare (i.e., telehealth providers) companies nationally for all virtual-only health care services in accordance with Inter-Plan Programs Policies and Provisions.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;Services to National Accounts</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141pt;padding-right:82.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee (as those terms are defined in the Inter-Plan Programs Policies and Provisions (&#8220;IP Policies&#8221;)) to offer Blue-branded Health Coverage to the National Account, offering Blue-branded Health and Wellness Programs to all members of the National Account, including members who have not enrolled in the Blue-branded Health Coverage (&#8220;non-Blue Health Coverage members&#8221;), provided that&#58;</font></div><div><font><br></font></div><div style="padding-left:175.5pt;padding-right:83.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Plan and&#47;or licensed Controlled Affiliate has no contact or interaction with providers outside of the Plan&#8217;s Service Area, except as specifically provided in the IP Policies and in</font></div><div style="padding-left:177pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4 (b)&#59; and</font></div><div><font><br></font></div><div style="padding-left:177pt;padding-right:82.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if in accordance with IP Policies another Licensee is soliciting or servicing under the Brands a local plant, office or division of the account that is outside of the Plan&#8217;s Service Area, the Plan and&#47;or licensed Controlled Affiliate may not offer Blue-branded Health and Wellness Programs to any employees working at such local plant, office or division without the consent of such other Licensee&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:177pt;padding-right:84.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;if the Plan and&#47;or licensed Controlled Affiliate provides an information card to the non-Blue Health Coverage members, the card may not display the Symbols in the masthead, must contain a prominent disclosure conveying that it is not a health insurance card, and otherwise must be designed so that it is dissimilar to a Blue member identification card.</font></div><div style="padding-left:177pt;padding-right:84.9pt"><font><br></font></div><div style="padding-left:177pt;padding-right:84.9pt"><font><br></font></div><div style="padding-left:326.25pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of June 16, 2022</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:326.25pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 6 of 14</font></div><div><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;Services to National Accounts (continued)</font></div><div><font><br></font></div><div style="padding-left:141pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this subparagraph a, the following definitions apply&#58;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:81.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Health and Wellness Program&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean a program that includes at least one of the following elements or a related element&#58;</font></div><div><font><br></font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Health Risk Assessment and&#47;or Preventive Screenings</font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Exercise and Fitness Programs</font></div><div style="padding-left:159pt;padding-right:87.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Health and Wellness Events (e.g., attendance at a health fair, a 5K walk)</font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Nutrition and Weight Management</font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Health Education (e.g., smoking cessation classes)</font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Prenatal and Parenting Education</font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8211;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Disease or Chronic Condition Management</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:141pt;padding-right:85.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above listing is intended to represent examples of the types of programs that may be offered, and other programs, including those offered through different media such as the internet or telephonically, may also be deemed Health and Wellness programs.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:84.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Health Coverage&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean providing or administering medical, surgical, hospital, major medical, or catastrophic coverage, or any HMO, PPO, POS or other managed care plan for the foregoing services.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141pt;padding-right:82.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;as part of a Health and Wellness Program that is otherwise compliant with Brand Regulation 4.11.4(a), contracting with a health and wellness organization to gain access to providers to deliver a discrete health and wellness event (&#8220;Event&#8221;) held at a National Account&#8217;s worksite outside of the Licensee&#8217;s Service Area, provided that&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:141pt;padding-right:82.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the services delivered at the Event are limited to fingerstick screenings for cholesterol and glucose, seasonal flu immunizations, blood pressure measurements, body mass index measurements, and other routine screenings, immunizations and measurements&#59; and</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:98.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;neither such services nor their costs are applied as claims against any benefit plan&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141pt;padding-right:94.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Event is presented during one or more limited periods during a benefit year and is available to all employees at the worksite.                   </font></div><div style="padding-right:94.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:141pt;padding-right:94.4pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 7 of 14</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:90.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee to offer Blue-branded Health Coverage to the National Account, performing the Eligibility and Enrollment functions of HR administration for all benefit plans offered by the National Account to its members, including benefit plans that are not underwritten or administered by the Plan, provided that&#58;</font></div><div><font><br></font></div><div style="padding-left:175.5pt;padding-right:85.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;in performing such functions, the Plan and&#47;or licensed Controlled Affiliate does not use the Brands in any communications with health care providers outside of the Plan&#8217;s Service Area, and otherwise limits its use of the Brands outside of the Service Area to communications with the account&#8217;s members, the other benefit plan providers with which the account has contracted and other reasonably necessary communications to perform such functions&#59; and</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:175.5pt;padding-right:82.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if in accordance with IP Policies another Licensee is soliciting or servicing under the Brands a local plant, office or division of the account that is outside of the Plan&#8217;s Service Area, the Plan and&#47;or licensed Controlled Affiliate may not perform Eligibility and Enrollment functions for employees working at such local plant, office or division without the consent of such other Licensee&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:82.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee to perform or investigate fraud, waste and abuse investigation activities for a non- participating provider in a Par&#47;Host Plan&#8217;s service area, as long as the Control&#47;Home Plan is given permission to do so by the Par&#47;Host Plan and specific conditions are met in accordance with Inter-Plan Programs and Inter-Plan Medicare Advantage Program policies.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:68.95pt;padding-right:152.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:232%">For purposes of this subparagraph b, the following definitions apply&#58; &#8220;Health Coverage&#8221; has the meaning set forth in subparagraph 2.4.a.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:330.95pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended September 27, 2018</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.35pt;padding-left:330.95pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 8 of 14</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:84.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Eligibility&#8221; means services that manage the account&#8217;s eligibility data and determine or process determinations relating to eligibility for benefit plans offered by the account to its employees, including such services as&#58;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:102.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">monitoring and auditing data to ensure that only entitled individuals are enrolled in each such benefit plan&#59;</font></div><div style="padding-left:141pt;padding-right:119.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">review of eligibility documentation (e.g. marriage licenses, birth certificates, student status verification letters, employment records)&#59;</font></div><div style="padding-left:141pt;padding-right:108.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%;padding-left:32.15pt">identification of key member segments such as over-age dependents, part-time employees, employees reaching certain milestones (e.g. Medicare-eligible, retirees)&#59;</font></div><div style="padding-left:141pt;padding-right:89.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">termination of coverage for those individuals found to be ineligible for coverage under a benefit plan, and, if applicable, generation of a COBRA event&#59; and</font></div><div style="padding-left:141pt;padding-right:108.35pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">management of &#8220;hour-banking&#8221; for union environments in which union members can bank hours to remain eligible for benefits.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:88pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Enrollment&#8221; means services that enroll eligible individuals and their spouses&#47;dependents or terminate or change their enrollment in the account&#8217;s benefit plans on an ongoing basis and during open enrollment periods, including such services as&#58;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:90.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">the coordination of each step in open enrollment process from project planning and system set-up to the generation of confirmation statements&#59;</font></div><div style="padding-left:141pt;padding-right:94.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">ongoing enrollment support for new hires and changes due to life events and work status adjustments&#59;</font></div><div style="padding-left:141pt;padding-right:137.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">evidence of insurability (EOI) administration for life and disability coverage&#59;</font></div><div style="padding-left:141pt;padding-right:99.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">transmission of eligibility&#47;enrollment information to the account&#8217;s benefit plan providers&#59;</font></div><div style="margin-top:0.1pt;padding-left:141pt;padding-right:113.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:32.15pt">review and reconciliation of error reports received from the account&#8217;s benefit plan providers&#59; and</font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:96.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.15pt">transmission of information to the account&#8217;s payroll system (e.g., benefit deductions, employee demographic data).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:298.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:298.4pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 9 of 14</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;Knowledge Sharing</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:90.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;submitting scholarly articles authored or co-authored by the Plan or Controlled Affiliate or its respective employees for publication in peer-reviewed journals&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:88.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;permitting an internal representative of the Licensee (e.g., officer, employee) to speak or present at a conference or symposium outside of the Licensee&#8217;s Service Area regarding either (i) healthcare financing, administration, delivery or policy, or (ii) topics within the representative&#8217;s functional discipline or expertise at the Licensee, for which the event sponsor will issue communications to promote, administer, and&#47;or recap the event that will identify the Licensee&#8217;s representative as a participant. The communications outside of the Licensee&#8217;s Service Area that mention the Licensee&#8217;s representative shall be limited to materials and digital media provided to attendees, on-site signage, advertising in relevant trade publications, direct mail and email to attendees and prospective attendees, and the sponsor&#8217;s website. Participation in any conference or symposium outside of the Licensee&#8217;s Service Area may not be for the purpose of marketing or selling products or services.</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:86.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Licensee&#8217;s representative wishes to use the Brands in any manner, including use in his&#47;her title, when participating as a speaker or presenter outside of the Licensee&#8217;s Service Area about a topic that is not related to healthcare financing, administration, delivery, or policy, or to topics within the representative&#8217;s functional discipline or expertise at the Licensee, the Licensee must notify BCBSA and receive prior approval from BCBSA before participating&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.15pt;padding-left:326.25pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.15pt;padding-left:326.25pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 10 of 14</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;Other Uses</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:84.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;entering into a license agreement between and among BCBSA, the Plan and a debit card issuer located outside the Plan&#8217;s Service Area, and entering into a corresponding operating agreement or agreements, in order to offer a debit card bearing the Licensed Marks and Name to eligible persons as defined by the aforementioned license agreement&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:82.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;appearing in communications issued by an independent third party to recognize outstanding performance of the Plan or Controlled Affiliate or a member of the Plan&#8217;s or Controlled Affiliate&#8217;s senior management as part of an established program of the third party for which the Plan has provided information to be considered for the recognition, provided that such use complies with regulations of general application specifically prescribed by BCBSA from time to time&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:93.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;to identify itself as being a joint sponsor of an event, program or activity along with other Plans or such Plans&#8217; licensed Controlled Affiliates, provided that such use complies with regulations of general application specifically prescribed by BCBSA from time to time&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;hosting meetings or events (collectively, &#8220;events&#8221;) in Washington,</font></div><div style="padding-left:141pt;padding-right:82.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.C.  or a Plan&#8217;s State Capitol related to policy and business issues in the Licensee&#8217;s Service Area, or hosting events in conjunction with the assemblies or conventions of national political parties. Such events may not involve marketing or selling products or services.  Use of the Brands outside the Licensee&#8217;s Service Area in connection with such events shall be limited to materials and digital media provided to attendees and prospective attendees and onsite signage. For any such events in Washington, D.C. that are open to attendees other than government officials or their staffs, or are briefings open to all Congressional staff, or are otherwise likely to receive media coverage, the Licensee is required to provide advance notice to BCBSA. For events hosted outside of Washington, D.C. in conjunction with the assemblies or conventions of national political parties, the Licensee is required to provide advance notice to BCBSA and to the local Plan(s)&#59;</font></div><div style="padding-left:141pt;padding-right:82.2pt"><font><br></font></div><div style="padding-left:326.25pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:114%">Amended as of March 26, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:326.25pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 11 of 14</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:95.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;permitting an affiliate that is not licensed to use the Licensed Marks to identify its corporate relationship with the Plan, provided that such use complies with regulations of general application specifically prescribed by BCBSA from time to time.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:91.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In connection with activity otherwise in furtherance of the License Agreement, a Controlled Affiliate that is licensed to use the Licensed Marks and Name pursuant to a Controlled Affiliate License Agreement authorized in clauses d) or e) of Paragraph 2 of the Plan&#8217;s License Agreement with BCBSA may use the Licensed Marks and Name outside the Region (as that term is defined in such respective Controlled Affiliate License Agreements) in the following circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:98.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services)&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;distributing business cards other than in marketing and selling&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;padding-right:86.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;contracting with health care providers or soliciting such contracts in areas contiguous to the Region in order to serve its subscribers residing in the Region, provided that the Controlled Affiliate may not use the names of any of its Controlling Plans in connection with such contracting unless the provider is located in a geographic area that is also contiguous to such Controlling Plan&#8217;s Service Area&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:141pt;padding-right:88.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;issuing a small sign containing the legal name or trade name of the Controlled Affiliate for display by a provider to identify the latter as a participating provider of the Controlled Affiliate, provided that the Controlled Affiliate may not use the names of any of its Controlling Plans on such signs unless the provider is located in a geographic area that is also contiguous to such Controlling Plan&#8217;s Service Area&#59;</font></div><div style="margin-top:11.4pt;padding-left:141pt;padding-right:88.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;advertising in publications or electronic media solely to persons for employment&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:288pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:144pt;padding-right:144pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 12 of 14</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:92.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;advertising in print, electronic or other media which serve, as a substantial market, the Region, provided that the Controlled Affiliate may not advertise outside its Region on the national broadcast and cable networks and that advertisements in national print media are limited to the smallest regional edition encompassing the Region, and provided further that any such advertising by the Controlled Affiliate may not reference the name of any of its Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to advertise in such media&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:93.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Region, provided that such advertising by the Controlled Affiliate may not reference the name of any of its Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to send direct mail to such zip code plus 4.</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:88.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;&#91;Intentionally left blank, pending review by the Inter-Plan Programs Committee of the applicability of the case management rule to such Controlled Affiliates.&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:141pt;padding-right:86.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;contracting with a pharmacy management organization (&#8220;Pharmacy Intermediary&#8221;) to gain access to a national or regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for the Controlled Affiliate&#8217;s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License Agreements, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in contracting with the pharmacy providers in such network&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:141pt;padding-right:90.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit to the Controlled Affiliate&#8217;s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug members enrolled under the Licensed Marks pursuant to such respective</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:141pt;padding-right:90.15pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 13 of 14</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:86.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controlled Affiliate License Agreements, provided that (1) the Controlled Affiliate may not contract directly with pharmacists or pharmacy stores outside the Region, and (2) neither the Controlled Affiliate&#8217;s name nor the Licensed Marks or Name may be posted or otherwise displayed at or by any pharmacy store outside the Region&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:106.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;contracting with a dental management organization (&#8220;Dental Intermediary&#8221;) to gain access to a national or regional dental network to deliver a routine dental benefit for the Controlled Affiliate&#8217;s regional Medicare Advantage PPO members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License Agreement, provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in contracting with the dental providers in such network&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:92.35pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;contracting with a vision management organization (&#8220;Vision Intermediary&#8221;) to gain access to a national or regional vision network to deliver a routine vision benefit for the Controlled Affiliate&#8217;s regional Medicare Advantage members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License Agreement, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in contracting with the vision providers in such network&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:89pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are collected within the Controlled Affiliate&#8217;s Region&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:98.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;contracting with a durable medical equipment or home medical equipment company for durable medical equipment and supplies and home medical equipment and supplies that are shipped to a location within the Controlled Affiliate&#8217;s Region&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:141pt;padding-right:105.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o.&#160;&#160;&#160;&#160;contracting with a specialty pharmaceutical company for non- routine biological therapeutics that are ordered by a health care professional located within the Region&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:99.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">p.&#160;&#160;&#160;&#160;contracting with a company that operates provider sites in the Region, provided that the contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Region&#59;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:141pt;padding-right:99.55pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 14 of 14</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:92.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">q.&#160;&#160;&#160;&#160;contracting with a company that makes health care professionals available in the Region (e.g., traveling home health nurse), provided that the contract is solely for services rendered by health care professionals who are located within the Region.</font></div><div><font><br></font></div><div style="padding-left:96pt;padding-right:93.45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;BCBSA shall retain the right to use the Licensed Marks in conjunction with the Federal Employee Program and with any other national offering made to federal employees pursuant to the Federal Employees Health Benefits Program (FEHBP), including the right to license such use to its vendors, but only in the following manner.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;padding-right:96.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Licensed Marks may only be used by BCBSA with the term &#8220;Federal Employee Program&#8221;, &#8220;Federal&#8221;, &#8220;FEP&#8221;, or similar language identifying the program as a benefit program for federal employees&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141pt;padding-right:93.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Licensed Marks may not be used by BCBSA with the name(s) of a specific Plan or Plans and&#59;</font></div><div><font><br></font></div><div style="padding-left:141pt;padding-right:114.35pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;any use by BCBSA in conjunction with a new national FEHBP program proposed after the enactment of this amendment will require the approval of the BCBSA Board of Directors.</font></div><div><font><br></font></div><div style="padding-left:96pt;padding-right:83.25pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Where required by applicable state or local law or regulation, a Plan or its licensed Controlled Affiliate may submit documents that contain the Brands to, and file forms that contain the Brands with, state or local regulators in a state not included in its Service Area, provided that it gives reasonable advance notice to the local Plan of its intent to submit such documents or file such forms. Notwithstanding, in no event may a Plan or its licensed Controlled Affiliate use the Brands to register, or to obtain or maintain a license, a certificate of authority, or an equivalent document authorizing it to act as a risk-bearing entity or third party administrator in a state not included in its Service Area. If the local Plan advises BCBSA that it believes its License Agreement has been or would be violated by any submission or filing, BCBSA shall determine whether such submission or filing is required by state or local law or regulation and violates the License Agreement, subject to the Plan&#8217;s or licensed Controlled Affiliate&#8217;s rights to obtain an independent review of such determination under Paragraph 9(a) and Exhibit 5 of its License Agreement or Paragraph 8 of the Controlled Affiliate License. For purposes of this paragraph, &#8220;local Plan&#8221; is defined as each Plan whose Service Area includes all or part of the state in which the foregoing applicable state or local law or regulation has been enacted.</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:326.25pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:326.25pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 1 of 23</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEDIATION AND MANDATORY DISPUTE RESOLUTION (MMDR) RULES</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:69pt;padding-right:83.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Blue Cross and Blue Shield Plans (&#34;Plans&#34;) and the Blue Cross Blue Shield Association (&#34;BCBSA&#34;) recognize and acknowledge that the Blue Cross and Blue Shield system is a unique nonprofit and for-profit system offering cost effective health care financing and services. The Plans and BCBSA desire to utilize Mediation and Mandatory Dispute Resolution (&#8220;MMDR&#8221;) to avoid expensive and time-consuming litigation that may otherwise occur in the federal and state judicial systems. Even MMDR should be viewed, however, as methods of last resort, all other procedures for dispute resolution having failed. Except as otherwise provided in the License Agreements, the Plans, their Controlled Affiliates and BCBSA agree to submit all disputes to MMDR pursuant to these Rules and in lieu of litigation.</font></div><div><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Initiation of Proceedings</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pre-MMDR Efforts</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:102.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Before filing a Complaint to invoke the MMDR process, the CEO of a complaining party, or his&#47;her designated representative, shall undertake good faith efforts with the other side(s) to try to resolve any dispute.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Complaint</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:82.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To commence a proceeding, the complaining party (or parties) shall provide by certified mail, return receipt requested, a written Complaint to the BCBSA Corporate Secretary (which shall also constitute service on BCBSA if it is a respondent) and to any Plan(s) and&#47;or Controlled Affiliate(s) named therein.</font></div><div style="padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Complaint shall contain&#58;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:85.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;identification of the complaining party (or parties) requesting the proceeding&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;identification of the respondent(s)&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:159pt;padding-right:86.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;identification of any other persons or entities who are interested in a resolution of the dispute&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;a full statement describing the nature of the dispute&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:108.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;identification of all of the issues that are being submitted for resolution&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:298.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of November 21, 1996</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.6pt;padding-left:298.4pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2 of 23</font></div><div><font><br></font></div><div style="margin-top:8.35pt;padding-left:163.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;the remedy sought&#59;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:163.85pt;padding-right:107.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;a statement as to whether the complaining party (or parties) elect(s) first to pursue Mediation&#59;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:163.85pt;padding-right:110.8pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">viii.&#160;&#160;&#160;&#160;any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor&#59; and</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:163.85pt;padding-right:88.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ix.&#160;&#160;&#160;&#160;a statement signed by the CEO of the complaining party affirming that the CEO has undertaken efforts, or has directed efforts to be undertaken, to resolve the dispute before resorting to the MMDR process.</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt;padding-right:86.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The complaining party (or parties) shall file and serve with the Complaint copies of all documents which the party (or parties) intend(s) to offer at the Arbitration Hearing and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing, along with a summary of each witness' expected testimony.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Answer</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:98.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within twenty (20) days after receipt of the Complaint, each respondent shall serve on BCBSA and on the complaining party (or parties)&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;a full Answer to the aforesaid Complaint&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:85.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;a statement of any Counterclaims against the complaining party (or parties), providing with respect thereto the information specified in Paragraph 1.B., above&#59;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:91.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;a statement as to whether the respondent elects to first pursue Mediation&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:110.8pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:82.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The respondent(s) shall file and serve with the Answer or by the date of the Initial Conference set forth in Paragraph 3.C., below, copies of all documents which the respondent(s) intend(s) to offer at the Arbitration Hearing and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing, along with a summary of each witness' expected testimony.</font></div><div><font><br></font></div><div style="padding-left:285pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:285pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reply To Counterclaim</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:86.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within ten (10) days after receipt of any Counterclaim, the complaining party (or parties) shall serve on BCBSA and on the responding party (or parties), a Reply to the Counterclaim. Such Reply must provide the same information required by Paragraph 1.C., above.</font></div><div><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Mediation</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:68.95pt;padding-right:85.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To facilitate the mediation of disputes between or among BCBSA, the Plans and&#47;or their Controlled Affiliates, the BCBSA Board has provided for Mediation under these Rules. Mediation may be pursued in lieu of or in an effort to obviate the Mandatory Dispute Resolution process, and all parties are strongly urged, but not required, to exhaust the mediation procedure provided for herein. In the event any party refuses to proceed with Mediation, the parties shall proceed immediately to Mandatory Dispute Resolution, as provided in Section 3.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Selection of Mediators</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:87.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If all parties agree to pursue Mediation, they shall promptly attempt to agree upon&#58; (i) the number of mediators desired, not to exceed three mediators&#59; and (ii) the selection of experienced mediator(s) from an independent entity to mediate all disputes set forth in the Complaint and Answer (and Counterclaim and Reply, if any). In the event the parties are unable to agree upon the selection or number of mediators, both within five (5) days of the service of the Answer or Reply to Counterclaim, whichever is later, the BCBSA Corporate Secretary shall immediately refer the matter to a nationally recognized professional ADR organization (such as CPR or JAMS) for mediation by a single mediator to be selected by the ADR organization.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Binding Decision</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:82.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Before the Mediation Hearing described below, the BCBSA Corporate Secretary shall contact the parties to determine whether they wish to be bound by any recommendation of the selected mediator(s) for resolution of the disputes. If all wish to be bound, the Corporate Secretary will send appropriate documentation to them for their signatures before the Mediation Hearing begins.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 4 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mediation Procedure</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:84.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Mediator(s) shall apply the mediation procedures and processes provided for herein (not the rules of the ADR organization with which they are affiliated) and shall promptly advise the parties of a scheduled Mediation Hearing date.  Unless a party requests an expedited procedure, or unless all parties to the proceeding agree to one or more extensions of time, the Mediation Hearing set forth below shall be completed within forty (40) days of BCBSA's receipt of the Complaint. The selected mediator(s), unless the parties otherwise agree, shall adhere to the following procedure&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:90.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Each party must be represented by its CEO or other representative who has been delegated full authority to resolve the dispute. However, parties may send additional representatives as they see fit.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:159pt;padding-right:83pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Each party will be given one-half hour to present its case, beginning with the complaining party (or parties), followed by the other party or parties. The parties are free to structure their presentations as they see fit, using oral statements or direct examination of witnesses. However, neither cross-examination nor questioning of opposing representatives will be permitted.  At the close of each presentation, the selected mediator(s) will be given an opportunity to ask questions of the presenters and witnesses. All parties must be present throughout the Mediation Hearing. The selected mediator(s) may extend the time allowed for each party's presentation at the Mediation Hearing. The selected mediator(s) may meet in executive session, outside the</font></div><div style="padding-left:159pt;padding-right:81.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">presence of the parties, or may meet with the parties separately, to discuss the controversy.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:94.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;After the close of the presentations, the parties will attempt to negotiate a settlement of the dispute. If the parties desire, the selected mediator(s), or any one or more of the selected mediators, will sit in on the negotiations.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.5pt;padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.5pt;padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 5 of 23</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:159pt;padding-right:82.95pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;After the close of the presentations, the selected mediator(s) may meet privately to agree upon a recommendation for resolution of the dispute which would be submitted to the parties for their consideration and approval. If the parties have previously agreed to be bound by the results of this procedure, this recommendation shall be binding upon the parties.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:82.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;The purpose of the Mediation Hearing is to assist the parties to settle their grievances short of mandatory dispute resolution. As a result, the Mediation Hearing has been designed to be as informal as possible. Rules of evidence shall not apply. There will be no transcript of the proceedings, and no party may make a tape recording of the Mediation Hearing.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:86.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;In order to facilitate a free and open discussion, the Mediation proceeding shall remain confidential. A &#34;Stipulation to Confidentiality&#34; which prohibits future use of settlement offers, all position papers or other statements furnished to the selected mediator(s), and decisions or recommendations in any Mediation proceeding shall be executed by each party.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:86.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;Upon request of the selected mediator(s), or one of the parties, BCBSA staff may also submit documentation at any time during the proceedings.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination of Mediation</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:86.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Mediation cannot be completed within the prescribed or agreed time period due to the lack of cooperation of any party, as determined by the selected mediator(s), or if the Mediation does not result in a final resolution of all disputes at the Mediation Hearing or within ten (10) days after the Mediation Hearing, any party or any one of the selected mediators shall so notify the BCBSA Corporate Secretary, who shall promptly issue a Notice of Termination of Mediation to all parties, to the selected mediator(s), and to the MDR Administrator. Such notice shall serve to bring the Mediation to an end and to initiate Mandatory Dispute Resolution. Upon agreement of all parties and the mediator(s), the Mediation process may continue at the same time the MDR process is invoked. In such case, the Notice of Termination of Mediation described above serves to initiate the MDR proceeding, but does not terminate mediation proceedings, which may proceed simultaneous with the MDR proceeding.</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 6 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Mandatory Dispute Resolution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> (MDR)</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:81.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any party elects not to first pursue Mediation, or if a Notice of Termination of Mediation is issued as set forth in Paragraph 2.D., above, then the unresolved disputes set forth in any Complaint and Answer (and Counterclaim and Reply, if any) shall be subject to mandatory binding arbitration (herein referred to as &#8220;MDR&#8221;).</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MDR Administrator</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:81.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator for purposes of Mandatory Arbitration shall be an independent nationally recognized entity such as CPR or JAMS, specializing in alternative dispute resolution. In the event the parties pursued Mediation with CPR, JAMS or a similar organization, that organization also shall serve as the MDR Administrator, unless all parties notify the BCBSA Corporate Secretary in writing within two (2) days of receiving the Notice of Termination of Mediation that they wish to pursue MDR with another nationally recognized organization serving as MDR Administrator.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:82.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the parties (i) did not pursue Mediation, (ii) pursued mediation with a Mediator not affiliated with an ADR organization that offers a panel of arbitrators, or (iii) all parties that pursued Mediation notified the BCBSA Corporate Secretary that they wish to have an MDR Administrator that is different from the organization with which their mediator was affiliated, they shall promptly attempt to agree on a nationally recognized ADR entity that supplies a panel of arbitrators. If they reach such agreement within five (5) days of the Notice of Termination of Mediation or receipt of the Answer or Reply to Counterclaim (whichever is later), the parties shall promptly inform the BCBSA Corporate Secretary of their agreed upon ADR organization. In the event the parties are unable to reach agreement on an MDR Administrator within that timeframe, the BCBSA Corporate Secretary shall immediately refer the matter to CPR, JAMS or a similar organization for MDR.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:69pt;padding-right:93.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any person who served as a Mediator shall not serve as an arbitrator for the same or similar dispute for purposes of MDR.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rules for MDR</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:86.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The rules controlling all aspects of MDR shall be exclusively those provided for herein. The rules promulgated or otherwise used by the MDR Administrator organization shall not apply.</font></div><div><font><br></font></div><div style="padding-left:270.6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:270.6pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 7 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Conference</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:68.95pt;padding-right:82.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within seven (7) days after a Notice of Termination has issued or the matter has otherwise been referred to an MDR Administrator, or within five (5) days after the time for filing and serving the Answer or Reply to any Counterclaim (whichever is later) if the parties elect first not to mediate, the parties shall confer with the Administrator to discuss selecting a dispute resolution panel (&#34;the Panel&#34;). This conference (the &#8220;Initial Conference&#8221;) may be by telephone. The parties are encouraged to agree to the composition of the Panel and to present that agreement to the Administrator at the Initial Conference. If the parties do not agree on the composition of the Panel by the time of the Initial Conference, or by any extension thereof agreed to by all parties and the Administrator, then the Panel Selection Process set forth in subparagraph D, below, shall be followed.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Panel Selection Process</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:81.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator shall designate, prior to the Initial Conference, at least seven potential arbitrators. Each party shall be permitted to strike any designee for cause and the Administrator shall determine the sufficiency thereof in its sole discretion. The Administrator will designate a replacement for any designee so stricken. Each party shall then be permitted one peremptory strike from the list of designees. The Administrator shall set the dates for exercising all strikes, which shall be set to encourage the prompt selection of arbitrators.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:82.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">After the parties exercise any designee strikes for cause and their peremptory strike against any designee of their choice, the parties shall each rank the remaining panel members in order of preference and provide the Administrator, without serving on any other party, their ranked list. The Administrator shall not disclose any party&#8217;s ranked list to members of the panel or to other parties.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:84.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From the remaining designees, and after considering opportunities to maximize, so far as possible, the collectively stated arbitrator preferences provided by the parties on their ranked lists, the Administrator shall select a three member Panel. The Panel Selection Process shall be completed no later than ten (10) days after the Initial Conference.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:88.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Arbitrator shall be compensated at his or her normal hourly rate or, in the absence of an established rate, at a reasonable hourly rate to be promptly fixed by the Administrator for all time spent in connection with the proceedings and shall be reimbursed for any travel and other reasonable expenses.</font></div><div><font><br></font></div><div style="padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 8 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duties Of The Arbitrators</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:84.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Panel shall promptly designate a Presiding Arbitrator for the purposes reflected below, but shall retain the power to review and modify any ruling or other action of said Presiding Arbitrator. Each Arbitrator shall be an independent Arbitrator, shall be governed by the Code of Ethics for Arbitrators in Commercial Disputes and shall at or prior to the commencement of any Arbitration Hearing take an oath to that effect. Each Arbitrator shall promptly disclose in writing to the Panel and to the parties any circumstances, whenever arising, that might cause doubt as to such Arbitrator's compliance, or ability to comply, with said Code of Ethics, and, absent resignation by such Arbitrator, the remaining Arbitrators shall determine in their sole discretion whether the circumstances so disclosed constitute grounds for disqualification and for replacement. With respect to such circumstances arising or coming to the attention of a party after an Arbitrator's selection, a party may likewise request the Arbitrator's resignation or a determination as to disqualification by the remaining Arbitrators. With respect to a sole Arbitrator, the determination as to disqualification shall be made by the Administrator.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:104.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There shall be no </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ex</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">parte</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> communication between the parties or their counsel and any member of the Panel.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Panel's Jurisdiction And Authority</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:88.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Panel's jurisdiction and authority shall extend to all disputes between or among the Plans, their Controlled Affiliates, and&#47;or BCBSA, except for those disputes excepted from these MMDR procedures as set forth in the License Agreements.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:81.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With the exception of punitive or treble damages, the Panel shall have full authority to award the relief it deems appropriate to resolve the parties' disputes, including monetary awards and injunctions, mandatory or prohibitory. The Panel has no authority to award punitive or treble damages except that the Panel may allocate or assess responsibility for punitive or treble damages assessed by another tribunal. Subject to the above limitations, the Panel may, by way of example, but not of limitation&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.4pt;padding-left:285pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.4pt;padding-left:285pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 9 of 23</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:159pt;padding-right:93.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">i.&#160;&#160;&#160;&#160;interpret or construe the meaning of any terms, phrase or provision in any license between BCBSA and a Plan or a Controlled Affiliate relating to the use of the BLUE CROSS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or BLUE SHIELD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">service marks.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:159pt;padding-right:85.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">ii.&#160;&#160;&#160;&#160;determine whether BCBSA, a Plan or a Controlled Affiliate has violated the terms or conditions of any license between the BCBSA and a Plan or a Controlled Affiliate relating to the use of the BLUE CROSS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or BLUE SHIELD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">service marks.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;decide challenges as to its own jurisdiction.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:114.95pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;issue such orders for interim relief as it deems appropriate pending Hearing and Award in any Arbitration.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:84.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is understood that the Panel is expected to resolve issues based on governing principles of law, preserving to the maximum extent legally possible the continued integrity of the Licensed Marks and the BLUE CROSS&#47;BLUE SHIELD system.  The Panel shall apply federal law to all issues which, if asserted in the United States District Court, would give rise to federal question jurisdiction, 28 U.S.C. &#167; 1331. The Panel shall apply Illinois law to all issues involving interpretation, performance or construction of any License Agreement or Controlled Affiliate License Agreement unless the agreement otherwise provides. As to other issues, the Panel shall choose the applicable law based on conflicts of law principles of the State of Illinois.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Conference</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:83.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within five (5) days of the Panel being selected, the Presiding Arbitrator shall confer with the parties and the other members of the Panel and shall schedule, in writing, a conference in which the parties and the Panel shall participate (the &#8220;Administrative Conference&#8221;). The Administrative Conference shall take place no later than fifteen (15) days after the Panel is selected. At the Administrative Conference the parties and the Panel shall discuss the scheduling of the Arbitration Hearing and any other matter appropriate to be considered, including but not limited to&#58; any written discovery in the form of requests for production of documents or requests to admit facts&#59; the identity of any witness whose deposition a party may desire and a showing of exceptional good cause for the taking of any such deposition&#59; the desirability of bifurcation or other separation of the issues&#59; the need for and the type of record of conferences and hearings, including the need for transcripts&#59; the need for expert witnesses and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 10 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:69pt;padding-right:85.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">how expert testimony should be presented&#59; the appropriateness of motions to dismiss and&#47;or for full or partial summary judgment&#59; consideration of stipulations&#59; the desirability of presenting any direct testimony in writing&#59; and the necessity for any on-site inspection by the Panel. If the parties agree, the Administrative Conference may be by telephone.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discovery</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:159pt;padding-right:88.3pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Requests for Production of Documents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; All requests for the production of documents must be served no later than five (5) days after the date of the Initial Conference. Within twenty (20) days after receipt of a request for production of documents, a party shall (a) serve responses and objections to the request,</font></div><div style="padding-left:158.95pt;padding-right:84.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) produce all responsive, non-privileged documents to the requesting party, and (c) to the extent any responsive documents are withheld on the grounds of attorney-client privilege or work product, produce a log identifying such documents in the manner specified in Fed. R. Civ. P. 26(b)(5). If, after reviewing a privilege log, the requesting party believes attorney-client privilege or work product protection was improperly claimed by the producing party with respect to any document, the requesting party may ask the Presiding Arbitrator to conduct an in-camera inspection of the same.  With respect to documentary and other discovery produced in any MDR proceeding by BCBSA, the fact that a party&#8217;s CEO or other senior officers may serve on the BCBSA Board of Directors, BCBSA Board Committees or other BCBSA work groups, task forces and the like, shall not be a basis for defeating an otherwise valid claim of attorney-client privilege or work product protection over such documentary or other discovery materials by BCBSA.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:82.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Requests for Admissions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Requests for Admissions may be served up to twenty-one (21) days prior to the discovery cut-off set by the Presiding Arbitrator. A party served with Requests For Admissions must respond within twenty (20) days of receipt of said request. The good faith use of and response to Requests for Admissions is encouraged, and the Panel shall have full discretion, with reference to the Federal Rules of Civil Procedure, in awarding appropriate sanctions with respect to abuse of the procedure.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:299.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:299.5pt"><font><br></font></div><div style="margin-top:3.2pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 11 of 23</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:159pt;padding-right:82.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Depositions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As a general rule, the parties will not be permitted to take party or non-party deposition testimony for discovery purposes. The Presiding Arbitrator, in his or her sole discretion, shall have the authority to permit a party to take such deposition testimony upon a showing of exceptional good cause. The parties will be permitted to take de bene esse deposition</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a href="#i5abcf6af21b34b3bbcae3a76cfb49bd7_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none">1 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">testimony to the fullest extent permitted by law of any witness who cannot be compelled to testify at the Arbitration Hearing. No deposition, for discovery purposes or otherwise, shall exceed three (3) hours, excluding objections and colloquy of counsel. Depositions may be recorded in any manner recognized by the Federal Rules of Civil Procedure and the parties shall specify in each notice of deposition or request for permission to take deposition testimony the manner in which such deposition shall be recorded.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:90.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Expert witness(es)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; If a party intends to present the testimony of an expert witness during the oral hearing, it shall provide all other parties with a written statement setting forth the information required to be provided by Fed. R. Civ. P. 26(a)(2)</font></div><div style="padding-left:159pt;padding-right:84.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;ten (10) days prior to the discovery cut-off set by the Presiding Arbitrator. If a party intends to present the testimony of a rebuttal expert witness during the Arbitration Hearing, it shall provide all other parties with a written statement setting forth the information required to be provided by Fed. R. Civ. P. 26(a)(2)(B) within twenty (20) days after the date on which the written statement of the expert witness whose testimony is to be rebutted was produced.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:159pt;padding-right:87.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Discovery cut-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Presiding Arbitrator shall determine the date on which the discovery period will end, but the discovery period shall not exceed thirty (30) days from the date of the Administrative Conference without the agreement of all parties.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.25pt;padding-left:68.95pt;padding-right:81.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As used in these Rules, &#34;de bene esse deposition&#34; means a deposition that is not taken for discovery purposes, but is taken for the purpose of reading part or all of the deposition transcript into the record at the Arbitration Hearing, to the extent permitted by the Panel, because the witness cannot be compelled to testify at the Arbitration Hearing or has exercised a right provided under these Rules to provide deposition testimony in lieu of testimony at the Arbitration Hearing.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:4.25pt;padding-left:68.95pt;padding-right:81.15pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 12 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:159pt;padding-right:96.3pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Additional discovery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Any additional discovery will be at the discretion of the Presiding Arbitrator.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:159pt;padding-right:82.3pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Discovery Disputes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any discovery disputes shall be raised by motion to the Presiding Arbitrator, who is authorized to resolve all such disputes, and whose resolution will be binding on the parties unless modified by the Arbitration Panel. Prior to raising any discovery dispute with the Presiding Arbitrator, the parties shall meet and confer, telephonically or in person, in an attempt to resolve or narrow the dispute. If a party refuses to comply with a decision resolving a discovery dispute, the Panel, in keeping with Fed. R. Civ. P. 37, may refuse to allow that party to support or oppose designated claims or defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases, decide an issue submitted for resolution adversely to that party.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:83.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">viii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Extensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The time for responding to discovery requests may be extended by the Presiding Arbitrator for good and sufficient cause shown. Any request for such an extension shall be made in writing.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Panel Suggested Settlement&#47;Mediation</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:83.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any point during the proceedings, the Panel at the request of any party or on its own initiative, may suggest that the parties explore settlement and that they do so at or before the conclusion of the Arbitration Hearing, and the Panel shall give such assistance in settlement negotiations as the parties may request and the Panel may deem appropriate. Alternatively, the Panel may direct the parties to endeavor to mediate their disputes as provided above, or to explore a mini-trial proceeding, or to have an independent party render a neutral evaluation of the parties&#8217; respective positions. The Panel shall enter such sanctions as it deems appropriate with respect to any party failing to pursue in good faith such Mediation or other alternate dispute resolution methods.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.95pt;padding-left:285pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:7.95pt;padding-left:285pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 13 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subpoenas on Third Parties</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:68.95pt;padding-right:88.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. &#167; 9 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., and subject to Paragraph 3.G(iii) above, a party may request the issuance of a subpoena on any third party, including but not limited to any third party Blue Plan or any officer, employee or director of a third party Blue Plan, to compel deposition testimony or the production of documents, and, if good and sufficient cause is shown, the Panel shall issue such a subpoena.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration Hearing</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt;padding-right:82.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An Arbitration Hearing will be held within thirty (30) days after the Administrative Conference if no discovery is taken, or within thirty (30) days after the close of discovery, unless all parties and the Panel agree to extend the Arbitration Hearing date, or unless the parties agree in writing to waive the Arbitration Hearing. The parties may mutually agree on the location of the Arbitration Hearing. If the parties fail to agree, the Arbitration Hearing shall be held in Chicago, Illinois, or at such other location determined by the Presiding Arbitrator to be most convenient to the participants. The Panel will determine the date(s) and time(s) of the Arbitration Hearing(s) after consultation with all parties and shall provide reasonable notice thereof to all parties or their representatives.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration Hearing Memoranda</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:82.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Twenty (20) days prior to the Arbitration Hearing, each party shall submit to the other party (or parties) and to the Panel an Arbitration Hearing Memorandum which sets forth the applicable law and any argument as to any relevant issue. The Arbitration Hearing Memorandum will supplement, and not repeat, the allegations, information and documents contained in or with the Complaint, Answer, Counterclaim and Reply, if any. Ten (10) days prior to the Arbitration Hearing, each party shall submit to each other party a list of all expert and fact witnesses (but not including rebuttal fact witness) that such party intends to have testify at the Arbitration Hearing and a brief summary of the testimony each such witness is expected to give. In addition, no later than five (5) days prior to the Arbitration, each party may submit to each other party and to the Panel a Response Arbitration Hearing Memorandum which sets forth any response to another party's Arbitration Hearing Memorandum.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.25pt;padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.25pt;padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 14 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">M.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice For Testimony</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:68.95pt;padding-right:82.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ten (10) days prior to the Arbitration Hearing, any party may serve a Notice on any other party (or parties) requesting the attendance at the Arbitration Hearing of any officer, employee or director of the other party (or parties) for the purpose of providing noncumulative testimony. If a party fails to produce one of its officers, employees or directors whose noncumulative testimony during the Arbitration Hearing is reasonably requested by an adverse party, the Panel may refuse to allow that party to support or oppose designated claims or defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases, decide an issue submitted for mandatory dispute resolution adversely to that party&#59; provided, however, that a party may refuse to produce a director to testify if, within two (2) days of receiving a notice requesting the attendance of such director at the Arbitration Hearing, the party agrees to make the director available for a de bene esse deposition at a mutually convenient time at any location within fifty (50) miles of the director&#8217;s primary residence chosen by the party requesting the director&#8217;s testimony. This Rule may not be used for the purpose of burdening or harassing any party, and the Presiding Arbitrator may impose such orders as are appropriate so as to prevent or remedy any such burden or harassment.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:69pt;padding-right:82.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. &#167; 9 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, twenty (20) days or more prior to the Arbitration Hearing, a party may request the issuance of a subpoena on any third party, including but not limited to any third party Blue Plan, BCBSA or any officer, employee or director of a third party Blue Plan or BCBSA for the purpose of providing noncummulative testimony at the Arbitration Hearing, and, if good and sufficient cause is shown, the Panel shall issue such a subpoena&#59; provided however, that a director of a third party Blue Plan or BCBSA may refuse to testify if, within two (2) days of receiving a subpoena requesting the attendance of such director at the Arbitration Hearing, the director agrees to make him&#47;herself available for a de bene esse deposition at a mutually convenient time at any location within fifty</font></div><div style="padding-left:69pt;padding-right:88.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(50) miles of the director&#8217;s primary residence chosen by the party requesting the director&#8217;s testimony. Each Blue Plan agrees to waive, on its own behalf and on behalf of its directors and officers, any objection it otherwise might have to any such subpoena based on service, venue or extraterritoriality.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.4pt;padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:11.4pt;padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 15 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">N.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration Hearing Procedures</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:159pt;padding-right:97.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Attendance at Arbitration Hearing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Any person having a direct interest in the proceeding is entitled to attend the Arbitration Hearing. The Presiding Arbitrator shall otherwise have the power to require the exclusion of any witness, other than a party or other essential person, during the testimony of any other witness. It shall be discretionary with the Presiding Arbitrator to determine the propriety of the attendance of any other person.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:82.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Confidentiality</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Panel and all parties shall maintain the privacy of the Arbitration Proceeding. The parties and the Panel shall treat the Arbitration Hearing and any discovery or other proceedings or events related thereto, including any award resulting therefrom, as confidential except as otherwise necessary in connection with a judicial challenge to or enforcement of an award or unless otherwise required by law.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:95.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stenographic Record</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Any party, or if the parties do not object, the Panel, may request that a stenographic or other record be made of any Arbitration Hearing or portion thereof. The costs of the recording and&#47;or of preparing the transcript shall be borne by the requesting party and by any party who receives a copy thereof. If the Panel requests a recording and&#47;or a transcript, the costs thereof shall be borne equally by the parties.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:93.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Oaths</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Panel may require witnesses to testify under oath or affirmation administered by any duly qualified person and, if requested by any party, shall do so.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:159pt;padding-right:90.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Order of Arbitration Hearing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; An Arbitration Hearing shall be opened by the recording of the date, time, and place of the Arbitration Hearing, and the presence of the Panel, the parties, and their representatives, if any. The Panel may, at the beginning of the Arbitration Hearing, ask for statements clarifying the issues involved.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:285pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:285pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 16 of 23</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:159pt;padding-right:88.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise agreed, the complaining party (or parties) shall then present evidence to support their claim(s). The respondent(s) shall then present evidence supporting their defenses and Counterclaims, if any. The complaining party (or parties) shall then present evidence supporting defenses to the Counterclaims, if any, and rebuttal.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:94.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Witnesses for each party shall submit to questions by adverse parties and&#47;or the Panel.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:84.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Panel has the discretion to vary these procedures, but shall afford a full and equal opportunity to all parties for the presentation of any material and relevant evidence.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:83.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Evidence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The parties may offer such evidence as is relevant and material to the dispute and shall produce such evidence as the Panel may deem necessary to an understanding and resolution of the dispute. Unless good cause is shown, as determined by the Panel or agreed to by all other parties, no party shall be permitted to offer evidence at the Arbitration Hearing which was not disclosed prior to the Arbitration Hearing by that party.  The Panel may receive and consider the evidence of witnesses by affidavit upon such terms as the Panel deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:86.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Panel shall be the judge of the relevance and materiality of the evidence offered, and conformity to legal rules of evidence, other than enforcement of the attorney-client privilege and the work product protection, shall not be necessary. The Federal Rules of Evidence shall be considered by the Panel in conducting the Arbitration Hearing but those rules shall not be controlling. All evidence shall be taken in the presence of the Panel and all of the parties, except where any party is in default or has waived the right to be present.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:86.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Settlement offers by any party in connection with Mediation or MDR proceedings, decisions or recommendations of the selected mediators, and a party's position papers or statements furnished to the selected mediators shall not be admissible evidence or considered by the Panel without the consent of all parties.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:159pt;padding-right:86.5pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 17 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:159pt;padding-right:87.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Closing of Arbitration Hearing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Presiding Arbitrator shall specifically inquire of all parties whether they have any further proofs to offer or witnesses to be heard. Upon receiving negative replies or if he or she is satisfied that the record is complete, the Presiding Arbitrator shall declare the Arbitration Hearing closed with an appropriate notation made on the record. Subject to being reopened as provided below, the time within which the Panel is required to make the award shall commence to run, in the absence of contrary agreement by the parties, upon the closing of the Arbitration Hearing.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:84.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With respect to complex disputes, the Panel may, in its sole discretion, defer the closing of the Arbitration Hearing for a period of up to thirty (30) days after the presentation of proofs in order to permit the parties to submit post-hearing briefs and argument, as the Panel deems appropriate, prior to making an award.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:83.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For good cause, the Arbitration Hearing may be reopened for up to thirty (30) days on the Panel's initiative, or upon application of a party, at any time before the award is made</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">O.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Awards</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:86.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An Award must be in writing and shall be made promptly by the Panel and, unless otherwise agreed by the parties or specified by law, no later than thirty (30) days from the date of closing the Arbitration Hearing. If all parties so request, the Award shall contain findings of fact and conclusions of law. The Award, and all other rulings and determinations by the Panel, may be by a majority vote.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:83.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parties shall accept as legal delivery of the Award the placing of the Award or a true copy thereof in the mail addressed to a party or its representative at its last known address or personal service of the Award on a party or its representative.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:69pt;padding-right:106.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Awards are binding only on the parties to the Arbitration and are not binding on any non-parties to the Arbitration and may not be used or cited as precedent in any other proceeding.</font></div><div><font><br></font></div><div style="padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 18 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:69pt;padding-right:88.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">After the expiration of twenty (20) days from initial delivery, the Award (with corrections, if any) shall be final and binding on the parties, and the parties shall undertake to carry out the Award without delay.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:89.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proceedings to confirm, modify or vacate an Award shall be conducted in conformity with and controlled by the Federal Arbitration Act. 9 U.S.C. &#167; 1, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">P.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:88.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within sixty (60) days after the Award and the conclusion of any judicial proceedings with respect thereto, each party and the Panel shall return any documents produced by any other party, including all copies thereof. If a party receives a discovery request in any other proceeding which would require it to produce any documents produced to it by any other party in a proceeding hereunder, it shall not produce such documents without first notifying the producing party and giving said party reasonable time to respond, if appropriate, to the discovery request.</font></div><div><font><br></font></div><div style="padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Miscellaneous</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expedited Procedures</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:88.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any party to a Mediation may direct a request for an expedited Mediation Hearing to the Chairman of the Mediation Committee, to the selected Mediators, and to all other parties at any time. The Chairman of the Mediation Committee, or at his or her direction, the then selected Mediators, shall grant any request which is supported by good and sufficient reasons. If such a request is granted, the Mediation shall be completed within as short a period as practicable, as determined by the Chairman of the Mediation Committee or, at his or her direction, the then selected Mediators.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:68.95pt;padding-right:84.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any party to an Arbitration may direct a request for expedited proceedings to the Administrator, to the Panel, and to all other parties at any time. The Administrator, or the Presiding Arbitrator if the Panel has been selected, shall grant any such request which is supported by good and sufficient reasons. If such a request is granted, the Arbitration shall be completed within as short a time as practicable, as determined by the Administrator and&#47;or the Presiding Arbitrator.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:249pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="padding-left:249pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 19 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Temporary or Preliminary Injunctive Relief</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:82.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any party may seek temporary or preliminary injunctive relief with the filing of a Complaint or at any time thereafter. If such relief is sought prior to the time that an Arbitration Panel has been selected, then the Administrator shall select a single Arbitrator who is a lawyer who has no interest in the subject matter of the dispute, and no connection to any of the parties, to hear and determine the request for temporary or preliminary injunction. If such relief is sought after the time that an Arbitration Panel has been selected, then the Arbitration Panel will hear and determine the request. The request for temporary or preliminary injunctive relief will be determined with reference to the temporary or preliminary injunction standards set forth in Fed. R. Civ. P. 65.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Defaults and Proceedings in the Absence of a Party</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:96.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whenever a party fails to comply with the MDR Rules in a manner deemed material by the Panel, the Panel shall fix a reasonable time for compliance and, if the party does not comply within said period, the Panel may enter an Order of default or afford such other relief as it deems appropriate.</font></div><div style="padding-left:69pt;padding-right:96.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arbitration may proceed in the event of a default or in the absence of any party who, after due notice, fails to be present or fails to obtain an extension. An Award shall not be made solely on the default or absence of a party, but the Panel shall require the party who is present to submit such evidence as the Panel may require for the making of findings, determinations, conclusions, and Awards.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:92.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each party shall be deemed to have consented that any papers, notices, or process necessary or proper for the initiation or continuation of a proceeding under these rules or for any court action in connection therewith may be served on a party by mail addressed to the party or its representative at its last known address or by personal service, in or outside the state where the MDR proceeding is to be held.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:88.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Corporate Secretary and the parties may also use facsimile transmission, telex, telegram, or other written forms of electronic communication to give the notices required by these rules.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:88.15pt;text-indent:36pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 20 of 23</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:83.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The expenses of witnesses shall be paid by the party causing or requesting the appearance of such witnesses. All expenses of the MDR proceeding, including compensation, required travel and other reasonable expenses of the Panel, and the cost of any proof produced at the direct request of the Panel, shall be borne equally by the parties and shall be paid periodically on a timely basis, unless they agree otherwise or unless the Panel in the Award assesses such expenses, or any part thereof against any party (or parties). In exceptional cases, the Panel may award reasonable attorneys' fees as an item of expense, and the Panel shall promptly determine the amount of such fees based on affidavits or such other proofs as the Panel deems sufficient.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disqualification or Disability of A Panel Member</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:93.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that any Arbitrator of a Panel with more than one Arbitrator should become disqualified, resign, die, or refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the parties are unable to agree upon a replacement, the remaining Panel member(s)&#58;</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:93.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;shall designate a replacement, subject to the right of any party to challenge such replacement for cause.</font></div><div><font><br></font></div><div style="padding-left:159pt;padding-right:96.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;shall decide the extent to which previously held hearings shall be repeated.</font></div><div><font><br></font></div><div style="padding-left:69pt;padding-right:102.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the remaining Panel members consider the proceedings to have progressed to a stage as to make replacement impracticable, the parties may agree, as an alternative to the recommencement of the Mandatory Dispute Resolution process, to resolution of the dispute by the remaining Panel members.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that a single Arbitrator should become disqualified, resign, die, or refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the parties are unable to agree upon a replacement, the Administrator shall appoint a successor, subject to the right of any party to challenge such successor for cause, and the successor shall decide the extent to which previously held proceedings shall be repeated.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:0.05pt;padding-left:69pt;padding-right:100.1pt;text-indent:36pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 21 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extensions of Time</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:82.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the provisions of Paragraph 3.H.(viii.), any time limit set forth in these Rules may be extended upon agreement of the parties and approval of&#58; (1) the Mediator if the proceeding is then in Mediation&#59; (2) the Administrator if the proceeding is in Arbitration, but no Arbitration Panel has been selected&#59; or (3) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intervention</font></div><div><font><br></font></div><div style="margin-top:4.65pt;padding-left:69pt;padding-right:86.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plans, their Controlled Affiliates, and BCBSA, to the extent subject to MMDR pursuant to their License Agreements, shall have the right to move to intervene in any pending Arbitration. A written motion for intervention shall be made to&#58; (1) the Administrator, if the proceeding is in Arbitration, but no Arbitration Panel has been selected&#59; or (2) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected. The written motion for intervention shall be delivered to the BCBSA Corporate Secretary (which shall also constitute service on the BCBSA if it is a respondent) and to any Plan(s) and&#47;or Controlled Affiliate(s) which are parties to the proceeding. Any party to the proceeding can submit written objections to the motion to intervene. The motion for intervention shall be granted upon good cause shown. Intervention also may be allowed by stipulation of the parties to the Arbitration proceeding. Intervention shall be allowed upon such terms as the Arbitration Panel decides.</font></div><div><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">BCBSA Assistance in Resolution of Disputes</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:105.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The resources and personnel of the BCBSA may be requested by any member Plan at any time to try to resolve disputes with another Plan.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Neutral Evaluation</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:69pt;padding-right:82.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties can voluntarily agree at any time to have an independent party render a neutral evaluation of the parties&#8217; respective positions.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:299.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.35pt;padding-left:299.5pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 22 of 23</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:141pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recovery of Attorney Fees and Expenses</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Motions to Compel</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:82.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothwithstanding any other provisions of these Rules, any Party subject to the License Agreements (for purposes of this Section K and all of its sub- sections only hereinafter referred to collectively and individually as a &#8220;Party&#8221;) that initiates a court action or administrative proceeding solely to compel adherence to these Rules shall not be determined to have violated these Rules by initiating such action or proceeding.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii&#160;&#160;&#160;&#160;Recovery of Fees, Expenses and Costs</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:105pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Arbitration Panel may, in its sole discretion, award a Party its reasonable attorneys&#8217; fees, expenses and costs associated with a filing to compel adherence to these Rules and&#47;or reasonable attorneys&#8217; fees, expenses and costs incurred in responding to an action filed in violation of these Rules&#59; provided, however, that neither fees, expenses, nor costs shall be awarded by the Arbitration Panel if the Party from which the award is sought can demonstrate to the Arbitration panel, in its sole discretion, that it did not violate these Rules or that it had reasonable grounds for believing that its action did not violate these Rules.</font></div><div><font><br></font></div><div style="padding-left:159pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii&#160;&#160;&#160;&#160;Requests for Reimbursement</font></div><div><font><br></font></div><div style="padding-left:105pt;padding-right:81.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Section K, any Party may request reimbursement of fees, expenses and&#47;or costs by submitting said request in writing to the Arbitration Panel at any time before an award is delivered pursuant Paragraph to 3.O above with a copy to the Party from which reimbursement is sought, explaining why it is entitled to such reimbursement. The Party from which reimbursement is sought shall have twenty (20) days to submit a response to such request to the Arbitration Panel with a copy to the Party seeking reimbursement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.25pt;padding-left:285pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-top:10.25pt;padding-left:285pt"><font><br></font></div><div style="margin-top:3.4pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-top:10.45pt;padding-left:69pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 23 of 23</font></div><div><font><br></font></div><div style="margin-top:10.6pt;padding-left:105pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L.&#160;&#160;&#160;&#160;Calculation of Time and Deadlines</font></div><div><font><br></font></div><div style="padding-left:60pt;padding-right:83.7pt;text-indent:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In computing any period of time prescribed or allowed under these rules, the day of the act or event from which the designated period of time begins to run shall not be included. The last day of the period so computed shall be included, unless it is a Saturday, a Sunday, or a legal holiday, in which event the period runs until the end of the next day which is not one of the aforementioned days. When the period of time prescribed is less than six (6) days, intermediate Saturdays, Sundays and legal holidays shall be excluded in the computation. As used in this rule, &#8220;legal holiday&#8221; includes New Year&#8217;s Day, Martin Luther King, Jr. Day, Washington&#8217;s Birthday, Memorial Day, Independence Day, Labor Day, Columbus Day, Veterans Day, Thanksgiving Day, Christmas Day and any other day appointed as a holiday by the President or the Congress of the United States.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:299.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="margin-top:0.05pt;padding-left:299.5pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>5
<FILENAME>exhibit1012-primaryblueshi.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idba684c98d94459f8ec5ca0084dbdf6e_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE SHIELD LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Includes revisions, if any, adopted by Member Plans through their June 16, 2022 meeting)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This agreement by and between Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and The Blue Shield Plan, known as ______________ (the &#34;Plan&#34;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preamble</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Plan and&#47;or its predecessor(s) in interest (collectively the &#34;Plan&#34;) had the right to use the BLUE SHIELD and BLUE SHIELD Design service marks (collectively the &#34;Licensed Marks&#34;) for health care plans in its service area, which was essentially local in nature&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Plan was desirous of assuring nationwide protection of the Licensed Marks, maintaining uniform quality controls among Plans, facilitating the provision of cost effective health care services to the public and otherwise benefiting the public&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, to better attain such ends, the Plan and the predecessor of BCBSA executed the Agreement(s) Relating to the Collective Service Mark &#34;Blue Shield&#34;&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, BCBSA and the Plan desire to supercede said Agreement(s) to reflect their current practices and to assure the continued integrity of the Licensed Marks and of the BLUE SHIELD system&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-bottom:4pt;text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">1.&#160;&#160;&#160;&#160;BCBSA hereby grants to the Plan, upon the terms and conditions of this License Agreement (&#8220;Agreement&#8221; or &#8220;Primary License Agreement&#8221;), the right to use BLUE SHIELD in its trade and&#47;or corporate name (the &#34;Licensed Name&#34;), and the right to use the Licensed Marks, in the sale, marketing and administration of health care plans and related services in the Service Area set forth and defined in paragraph 5 below.  As used herein, health care plans and related services shall include acting as a nonprofit health care plan, a for-profit health care plan, or mutual health insurer operating on a not-for-profit or for-profit basis, under state law&#59; financing access to health care services&#59; when working with a bank that holds the relevant license to use the Licensed Name and Marks, offering&#58; (i) tax-favored savings accounts for medical expenses and means for accessing such accounts, such as debit cards or checks, that are provided solely to support access to such tax-favored savings accounts, all pursuant to such license, or (ii) prepaid rewards cards that are provided for completion of a wellness program, all pursuant to such license&#59; providing health care management and administration&#59; administering, but not underwriting, non-health portions of Workers&#8217; Compensation Insurance&#59; delivering health care services, except hospital services (as defined in the Guidelines to Membership Standards Applicable to Regular Members)&#59; and performing the Eligibility and Enrollment functions of HR administration for all benefit plans offered by a group account to its members, including benefit plans not provided by the Plan, provided that the Plan has contracted to provide Health Coverage under the Licensed Marks to the account (as the terms &#8220;Health Coverage&#8221;, &#8220;Eligibility&#8221; and &#8220;Enrollment&#8221; are defined in Exhibit 4, Paragraph 2.t.).</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">2.&#160;&#160;&#160;&#160;The Plan may use the Licensed Marks and Name in connection with the offering of&#58; <br>i) health care plans and related services in the Service Area through Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1 hereto (the &#34;Controlled Affiliate License Agreement&#34;)&#59; and ii) insurance coverages offered by life insurers under the applicable law in the Service Area, other than those which the Plan may offer in its own name, provided through Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1A hereto (the &#34;Controlled Affiliate License Agreement Applicable to Life Insurance Companies&#34;) or the Agreement attached as Exhibit 1A1 hereto (the &#8220;Controlled Affiliate Trademark License Agreement for Life and Disability Insurance Products&#8221;) and further provided that the offering of such services does not and will not dilute or tarnish the unique value of the Licensed Marks and Name&#59; and iii) administration and underwriting of Workers&#8217; Compensation Insurance Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1 hereto (the &#8220;Controlled Affiliate License&#8221;)&#59; and iv) regional Medicare Advantage PPO Products in cooperation with one or more other Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1B hereto (the &#8220;Controlled Affiliate License Agreement Applicable to Regional Medicare Advantage PPO Products&#8221;)&#59; and v) regional Medicare Part D Prescription Drug Plan products in cooperation with one or more other Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached as Exhibit 1C hereto (the &#8220;Controlled Affiliate License Agreement Applicable to Regional Medicare Part D Prescription Drug Plan Products&#8221;).  As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it is subject to the bona fide control of a Plan or Plans and, if the entity meets the standards of Paragraph 2a.B but not Paragraph 2a.A, the entity, its owners, and persons with </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:104%">Amended as of September 19, 2014</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">authority to select or appoint members or board members, other than a Plan or Plans,  have received written approval of BCBSA.  Absent written approval by BCBSA of an alternative method of control, bona fide control shall have the meaning set forth in Paragraphs 2a. and 2b.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2a.&#160;&#160;&#160;&#160;With respect to the Controlled Affiliate Licenses authorized in clauses i) through iii) of Paragraph 2, bona fide control shall mean that a Plan (the &#8220;Sponsoring Plan&#8221;) authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to this Primary License Agreement with BCBSA must have&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Controlled Affiliate's governing body having more than 50% voting control thereof&#59; (b) to exercise control over the policy and operations of the Controlled Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (c) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan do not concur.  In addition, the Sponsoring Plan  directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;The legal authority directly or indirectly through wholly-owned subsidiaries (a) to select members of the Controlled Affiliate's governing body having not less than 50% voting control thereof&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan do not concur&#59; (c) to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring  Plan.  Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Change its legal and&#47;or trade name&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Change the geographic area in which it operates&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Change any of the types of businesses in which it engages&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being replaced&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Make any loans or advances except in the ordinary course of business&#59; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;Enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners of the Controlled Affiliate or persons or entities with the authority to select or appoint members or board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;Conduct any business other than under the Licensed Marks and Name&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks or Names.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at least 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee&#59; or  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services, the legal authority by the Sponsoring Plan together with such other Plans (a) to select all members of the Controlled Affiliate&#8217;s governing body&#59; (b) to prevent any change in the articles of incorporation, bylaws, or other establishing or governing documents of the Controlled Affiliate&#59; (c) to exercise control over the policy and operations of the Controlled Affiliate.  In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and such other Plans each having an ownership interest.  Such 100% control and ownership by Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.  Further, the Sponsoring Plan and such other Plans shall execute the &#8220;Addendum to Controlled Affiliate License&#8221; attached as Exhibit B-1 to Exhibit 1 attached hereto&#59; or</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-branded basis, offers solely a Basic Medicare Part D Prescription Drug product, the legal authority by the Sponsoring Plan (a) to select all members of the Controlled Affiliate&#8217;s governing body&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; (c) to exercise control over the policy and operations of the Controlled Affiliate.  In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by the Plan shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and Participating Plan as defined on the Controlled Affiliate License Agreement shall execute the &#8220;Addendum to Controlled Affiliate License&#8221; attached as Exhibit B-2 to Exhibit 1 attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that operates as a clinic, the legal authority by the Sponsoring Plan to exercise control over the policy and operations of the Controlled Affiliate as defined in Exhibit 1, Standard 1(E) and the Guidelines to Administer Standard 1 (E).  In addition, if the clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur. </font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2b.&#160;&#160;&#160;&#160;With respect to the Controlled Affiliate License Agreements authorized in clauses iv) and v) of Paragraph 2, bona fide control shall mean that the Controlled Affiliate is organized and operated in such a manner that it meets the following requirements&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The Controlled Affiliate is owned or controlled by two or more Plans authorized to use the Licensed Marks pursuant to this License Agreement with BCBSA (for purposes of this subparagraph A. through subparagraph C., the &#8220;Controlling Plans&#8221;)&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2a-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to this Agreement to use the Licensed Marks in a geographic area in the Region (as that term is defined in such Controlled Affiliate License Agreements) and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries (a) to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59; and (c) to exercise control over the policy and operations of the Controlled Affiliate.   Notwithstanding anything to the contrary in (a) through (c) of this subparagraph E., the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Change its legal and&#47;or trade names&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly- owned  subsidiaries shall own 100% of any for-profit Controlled Affiliate. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the next page is 3)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2b-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is not licensed to use the Licensed Marks and Name, the Plan may, in communications that contain the Licensed Marks or Name, indicate its corporate relationship to the Affiliate and permit such Affiliate to indicate its corporate relationship to the Plan, solely in the circumstances, style and manner specified by BCBSA from time-to-time in regulations of general application consistent with the avoidance of confusion or mistake or the dilution or tarnishment of the Licensed Marks and Name.  No rights are hereby created in any Controlled Affiliate to use the Licensed Marks or Name in its own name or otherwise.  </font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The Plan recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name.  The Plan further recognizes that its actions within its Service Area may affect the value of the Licensed Marks and Name nationwide.  The Plan agrees (a) to maintain in good standing its membership in BCBSA&#59; (b) promptly to pay its dues to BCBSA, said dues to represent the royalties for this License Agreement&#59; (c)  materially to comply with all applicable laws&#59; (d) to comply with the Membership Standards Applicable to Regular Members of BCBSA, a current copy of which is attached as Exhibit 2 hereto&#59; and (e) reasonably to permit BCBSA, upon a written, good faith request and during reasonable business hours, to inspect the Plan's books and records necessary to ascertain compliance herewith.  As to other Plans and third parties, BCBSA shall maintain the confidentiality of all documents and information furnished by the Plan pursuant hereto, or pursuant to the Membership Standards, and clearly designated by the Plan as containing proprietary information of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The rights hereby granted are exclusive to the Plan within the geographical area(s) served by the Plan on June 30, 1972, and&#47;or as to which the Plan has been granted a subsequent license, which is hereby defined as the &#34;Service Area, except that BCBSA reserves the right to use the Licensed Marks in said Service Area, and except to the extent that said Service Area may overlap areas served by one or more other licensed Blue Shield Plans as of said date or subsequent license, as to which overlapping areas the rights hereby granted are nonexclusive as to such other Plan or Plans only.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Except as expressly provided by BCBSA with respect to National Accounts, Government Programs and certain other necessary and collateral uses, the current rules and regulations governing which are attached as Exhibit 3 and Exhibit 4 hereto, and are contained in other documents referenced herein, or as expressly provided herein, the Plan may not use the Licensed Marks and Name outside the Service Area or in connection with other goods and services, nor may the Plan use the Licensed Marks or Name in a manner which is intended to transfer in the Service Area the goodwill associated therewith to another mark or name.  Nothing herein shall be construed to prevent the Plan from engaging in lawful activity anywhere under other marks and names not confusingly similar to the Licensed Marks and Name, provided that engaging in such activity does and will not dilute or tarnish the unique value of the Licensed Marks and Name.  In addition to any and all remedies available hereunder, BCBSA may impose monetary fines on the Plan for the Plan&#8217;s use of the Licensed Marks and Names outside the Service Area, and provided that the procedure used in imposing a fine is consistent with procedures specifically prescribed by BCBSA from time to time in regulations of general application.  In the case of regional Medicare Advantage PPO and regional Medicare Part D Prescription Drug Plan products offered by consenting and participating Plans in a region that includes the Service Areas, or portions thereof, of more than one Plan, such fine may be imposed jointly on the consenting and participating Plans for use of the Licensed Marks and Name in any geographic area of the region in which a Plan having exclusive rights to the Licensed Marks and Name does not consent to and participate in such offering, provided that the basis for imposition of such fine is consistent with rules specifically prescribed by BCBSA from time to time in regulations of general application.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;The Plan agrees that it will display the Licensed Marks and Name only in such form, style and manner as shall be specifically prescribed by BCBSA from time-to-time in regulations of general application in order to prevent impairment of the distinctiveness of the Licensed Marks and Name and the goodwill pertaining thereto.  The Plan shall cause to appear on all materials on or in connection with which the Licensed Marks or Name are used such legends, markings and notices as BCBSA may reasonably request in order to give appropriate notice of service mark or other proprietary rights therein or pertaining thereto.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;BCBSA agrees that&#58; (a) it will not grant any other license effective during the term of this License Agreement for the use of the Licensed Marks or Name which is inconsistent with the rights granted to the Plan hereunder&#59; and (b) it will not itself use the Licensed Marks in derogation of the rights of the Plan or in a manner to deprive the Plan of the full benefits of this License Agreement, provided that BCBSA shall have the right to use the Licensed Marks in conjunction with any national offering under the  Federal Employees Health Benefits Program in the manner set forth in Exhibit 4, Paragraph 4 (including subparagraphs) to this License&#160;&#160;&#160;&#160;Agreement.  The Plan agrees that it will not attack the title of BCBSA in and to the Licensed Marks or Name or attack the validity of the Licensed Marks or of this License Agreement.  The Plan further agrees that all use by it of the Licensed Marks and Name or any similar mark or name shall inure to the benefit of BCBSA, and the Plan shall cooperate with BCBSA in effectuating the assignment to BCBSA of any service mark or trademark registrations of the Licensed Marks or any similar mark or name held by the Plan or a Controlled Affiliate of the Plan, all or any portion of which registration consists of the Licensed Marks.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 16, 2006</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3a-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;(a).&#160;&#160;&#160;&#160;Should the Plan fail to comply with the provisions of paragraphs 2-4, 6, 7 and&#47;or 12, and not cure such failure within thirty (30) days of receiving written notice thereof (or commence curing such failure within such thirty day period and continue diligent efforts to complete the curing of such failure if such curing cannot reasonably be completed within such thirty day period), BCBSA shall have the right to issue a notice that the Plan is in a state of noncompliance. Except as to the termination of a Plan's License Agreement or the merger of two or more Plans, disputes as to  noncompliance, and all other disputes between or among BCBSA, the Plan, other Plans and&#47;or Controlled Affiliates, shall be submitted promptly to mediation and mandatory dispute resolution pursuant to the rules and regulations of BCBSA, a current copy of which is attached as Exhibit 5 hereto, and shall be timely presented and resolved. The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties. If a state of noncompliance as aforesaid is undisputed by the Plan or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the License Agreement.  Except, however, as provided in paragraphs 9(d)(iii), 15(a)(i)-(viii), and 15(a)(x) below, no Plan's license to use the Licensed Marks and Name may be finally terminated for any reason without the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b).&#160;&#160;&#160;&#160;Notwithstanding any other provision of this License Agreement, a Plan's license to use the Licensed Marks and Name may be forthwith terminated by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to Member Plans for&#58; (i) failure to comply with any minimum capital or liquidity requirement under the Membership Standard on Financial Responsibility&#59; or (ii) impending financial insolvency&#59; or (iii) the pendency of any action instituted against the Plan seeking its dissolution or liquidation or its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property of business, unless this License Agreement has been earlier terminated under paragraph 15(a)&#59; or (iv) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans and&#47;or the Licensed Marks.   </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 16, 2006</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c).&#160;&#160;&#160;&#160;To the extent not otherwise provided therein, neither&#58; (i) the Membership Standards Applicable to Regular Members of BCBSA&#59; nor (ii) the rules and regulations governing Government Programs and certain other uses&#59; nor (iii) the rules and regulations governing mediation and mandatory dispute resolution, may be amended unless and until each such amendment is first adopted by the affirmative vote of three-fourths of the Plans and of three-fourths of the total then current weighted vote of all the Plans.  The rules and regulations governing National Accounts and other national programs required by the Membership Standards Applicable to Regular Members of BCBSA (Exhibit 2) are contained, in addition to those set forth in Exhibit 3, in the following documents, as amended from time to time&#58; (1) the Inter-Plan Programs Policies and Provisions&#59; (2) Inter-Plan Medicare Advantage Program Policies and Provisions.  The voting requirements specified in rules and regulations governing such national programs may not be amended unless and until each such amendment is first adopted  by the affirmative vote of three-fourths of the Plans and of three-fourths of the total then current weighted vote of all the Plans.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 21, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4a-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d).&#160;&#160;&#160;&#160;The Plan may operate as a for-profit company on the following conditions&#58;</font></div><div style="padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The Plan shall discharge all responsibilities which it has to  the Association and to other Plans by virtue of this Agreement and the Plan's membership in BCBSA.</font></div><div style="padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The Plan shall not use the licensed Marks and Name, or any derivative thereof, as part of its legal name or any symbol used to identify the Plan in any securities market.  The Plan shall use the Licensed Marks and Name as part of its trade name within its service area for the sale, marketing and administration of health care and related services in the service area.</font></div><div style="padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;The Plan's license to use the Licensed Marks and Name shall automatically terminate effective&#58; (a) thirty days after the Plan knows, or there is an SEC filing indicating that, any Institutional Investor, has become the Beneficial Owner of securities representing 10% or more of the voting power of the Plan (&#8220;Excess Institutional Voter&#8221;), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter prior to such automatic termination becoming effective&#59; (b) thirty days after the Plan knows, or there is an SEC filing indicating that, any Noninstitutional Investor has become the Beneficial Owner of securities representing 5% or more of the voting power of the Plan (&#8220;Excess Noninstitutional Voter&#8221;) unless such Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional Voter prior to such automatic termination becoming effective&#59; (c) thirty days after the Plan knows, or there is an SEC filing indicating that, any Person has become the Beneficial Owner of 20% or more of the Plan&#8217;s then outstanding common stock or other equity securities which (either by themselves or in combination) represent an ownership interest of 20% or more pursuant to determinations made under paragraph 9(d)(iv) below (&#8220;Excess Owner&#8221;), unless such Excess Owner shall cease to be an Excess Owner prior to such automatic termination becoming effective&#59; (d) ten business days after individuals who at the time the Plan went public constituted the Board of Directors of the Plan (together with any new directors whose election to the Board was approved by a vote of 2&#47;3 of the directors then still in office who were directors at the time the Plan went public or whose election or nomination was previously so approved) (the &#34;Continuing Directors&#34;) cease for any reason to constitute a majority of the Board of Directors&#59; or (e) ten business days after the Plan consolidates with or merges with or into any person or conveys, assigns, transfers or sells all or substantially all of its assets to any person other than a merger in which the Plan is the surviving entity and immediately after which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner&#58;  provided that, if requested by the affected Plan in a writing received by BCBSA prior to such automatic termination  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 17, 1997</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">becoming effective, the provisions of this paragraph 9(d)(iii) may be waived, in whole or in part, upon the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans.  Any waiver so granted may be conditioned upon such additional requirements (including but not limited to imposing new and independent grounds for termination of this License) as shall be approved by the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans.  If a timely waiver request is received, no automatic termination shall become effective until the later of&#58; (1) the conclusion of the applicable time period specified in paragraphs 9(d)(iii)(a)-(d) above, or (2) the conclusion of the first Member Plan meeting after receipt of such a waiver request.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Plan's license to use the Licensed Marks and Name  is terminated pursuant to this Paragraph 9(d)(iii), the license may be reinstated in BCBSA&#8217;s sole discretion if, within 30 days of the date of such termination, the Plan demonstrates that the Person referred to in clause (a), (b) or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;The Plan shall not issue any class or series of security other than (i) shares of common stock having identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt securities or (iii) such other securities as the Plan may approve, provided that BCBSA receives notice at least thirty days prior to the issuance of such securities, including a description of the terms for such securities, and BCBSA shall have the authority to determine how such other securities will be counted in determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;For purposes of paragraph 9(d)(iii), the following definitions shall apply&#58;</font></div><div style="padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#34;Affiliate&#34; and &#34;Associate&#34; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934,  as amended and in effect on November 17, 1993 (the &#34;Exchange Act&#34;).</font></div><div style="padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;A Person shall be deemed the &#34;Beneficial Owner&#34; of and shall be deemed to &#34;beneficially own&#34; any securities&#58;</font></div><div style="padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;which such Person or any of such Person's Affiliates or Associates beneficially owns, directly or indirectly&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 17, 1997</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5a-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:135.35pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;which such Person or any of such Person's Affiliates or Associates has (A) the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise&#59; or (B) the right to vote pursuant to any agreement, arrangement or understanding&#59; provided, however, that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement, arrangement or understanding to vote such security (1) arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:135.35pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;which are beneficially owned, directly  or indirectly, by any other Person (or any Affiliate or Associate thereof) with  which such Person (or any of such Person's Affiliates or Associates) has any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) relating to the acquisition, holding, voting (except to the extent contemplated by the proviso to (b)(ii)(B) above) or disposing of any securities of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:135.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase &#34;then outstanding,&#34; when used with reference to a Person's Beneficial Ownership of securities of the Plan, shall mean the number of such securities then issued and outstanding together with the number of such securities not then actually issued and outstanding which such Person would be deemed to own beneficially hereunder.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;A Person shall be deemed an &#8220;Institutional Investor&#8221; if (but only if) such Person (i) is an entity or group identified in the SEC&#8217;s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by such Person with the SEC under Regulation 13D-G (or any successor Regulation) with respect to such Person&#8217;s Beneficial Ownership of Plan securities shall have contained a certification identical to the one required by item 10 of SEC Schedule 13G as constituted on June 1, 1997.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;&#8220;Noninstitutional Investor&#8221; means any Person who is not an Institutional Investor.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Person&#34; shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other entity, and shall include any successor (by merger or otherwise) of such entity.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 17, 1997</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5b-</font></div><div style="text-align:right;text-indent:72pt"><font><br></font></div><div style="text-align:right;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(The next page is page 6)</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;This License Agreement shall remain in effect&#58; (a) until terminated as provided herein&#59; or (b) until this and all such other License Agreements are terminated by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans&#59; (c) until terminated by the Plan upon eighteen (18) months written notice to BCBSA or upon a shorter notice period approved by BCBSA in writing at its sole discretion.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;Except as otherwise provided in paragraph 15 below or by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans, or unless this and all such other License Agreements are simultaneously terminated by force of law, the termination of this License Agreement for any reason whatsoever shall cause the reversion to BCBSA of all rights in and to the Licensed Marks and Name, and the Plan agrees that it will promptly discontinue all use of the Licensed Marks and Name, will not use them thereafter, and will promptly, upon written notice from BCBSA, change its corporate name so as to eliminate the Licensed Name therefrom.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;The license hereby granted to Plan to use the Licensed Marks and Name is and shall be personal to the Plan so licensed and shall not be assignable by any act of the Plan, directly or indirectly, without the written consent of BCBSA.  Said license shall not be assignable by operation of law, nor shall Plan mortgage or part with possession or control of this license or any right hereunder, and the Plan shall have no right to grant any sublicense to use the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;BCBSA shall maintain appropriate service mark registrations of the Licensed Marks and BCBSA shall take such lawful steps and proceedings as may be necessary or proper to prevent use of the Licensed Marks by any person who is not authorized to use the same.  Any actions or proceedings undertaken by BCBSA under the provisions of this paragraph shall be at BCBSA's sole cost and expense.  BCBSA shall have the sole right to determine whether or not any legal action shall be taken on account of unauthorized use of the Licensed Marks, such right not to be unreasonably exercised.  The Plan shall report any unlawful usage of the Licensed Marks to BCBSA in writing and agrees, free of charge, to cooperate fully with BCBSA's program of enforcing and protecting the service mark rights, trade name rights and other rights in the Licensed Marks.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;The Plan hereby agrees to save, defend, indemnify and hold BCBSA And any other Plan(s) harmless from and against all claims, damages, liabilities and Costs of every kind, nature and description which may arise as a result of the activities of the Plan or of any hospital, medical group, clinic or other provider of health services that is owned or controlled directly or indirectly by Plan.  BCBSA hereby agrees to save, defend, indemnify and hold the Plan and any other Plan(s) harmless from and against all claims, damages, liabilities and costs of every kind, nature and description which may arise exclusively and directly as a result of the activities of BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 21, 2012</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-6-</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;(a).&#160;&#160;&#160;&#160;This Agreement shall automatically terminate upon the occurrence of any of the following events&#58;  (i) a voluntary petition shall be filed by the Plan or by BCBSA seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against the Plan or BCBSA seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by the Plan or BCBSA or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Plan or BCBSA respectively, or (iii) an order for relief is entered against the Plan or BCBSA in any case under the bankruptcy laws of the United States, or the Plan or BCBSA is adjudged bankrupt or insolvent (as that term is defined in the Uniform Commercial Code as enacted in the state of Illinois) by any court of competent jurisdiction, or (iv) the  Plan or BCBSA makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of the Plan or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an action is instituted by any governmental entity or officer against the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by the Plan or BCBSA or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Plan or BCBSA respectively, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of the Plan's or BCBSA's property or business is appointed, or the Plan or BCBSA is ordered dissolved or liquidated, or (ix) the Plan shall fail to pay its dues and shall not cure such failure within thirty (30) days of receiving written notice thereof, or (x) if, due to regulatory action, the Plan together with any applicable Controlled Affiliate becomes unable to do business using the Names and Marks in any State or portion thereof included in its Service Area, provided that&#58; (i) automatic termination shall not occur prior to the exhaustion by any such Plan of its rights to appeal or challenge such regulatory action&#59; and (ii) in the event the Plan is licensed to do business using the Names and Marks in multiple States or portions of States, the termination of its License Agreement shall be solely limited to the State(s) or portions thereof in which the regulatory action applies.  By not appealing or challenging such regulatory action within the time prescribed by law or regulation, and in any event no later than 120 days after such action is taken, a Plan shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination shall proceed.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Plan&#8217;s or BCBSA&#8217;s property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 15(a)(vii) and (viii) of this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7a-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b).&#160;&#160;&#160;&#160;BCBSA, or the Plans (as provided and in addition to the rights conferred in Paragraph 10(b) above), may terminate this Agreement immediately upon written notice upon the occurrence of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">either</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the following events&#58;  (a) the Plan or BCBSA becomes insolvent (as that term is defined in the Uniform Commercial Code enacted in the state of Illinois), or (b) any final judgment against the Plan or BCBSA remains unsatisfied or unbonded of record for a period of sixty (60) days or longer.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c).   &#160;&#160;&#160;&#160;If this License Agreement is terminated as to BCBSA for any reason stated in subparagraphs 15(a) and (b) above, the ownership of the Licensed Marks shall revert to each of the Plans.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d).   &#160;&#160;&#160;&#160;Upon termination of this License Agreement or any Controlled Affiliate  License Agreement of a Larger Controlled Affiliate, as defined in Exhibit 1 to this License Agreement, the following conditions shall apply, except  that, in the event of a partial termination of this Agreement pursuant to Paragraph 15 (a)(x)(ii) of this Agreement, the notices, national account listing, payment and audit right listed below shall be applicable solely with respect to the geographic area for which the Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The terminated entity shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the terminated entity or its Controlled Affiliates under the Licensed Marks and Name.  The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA, subject to any conflicting state law and state regulatory requirements.  This notice shall be mailed within 15 days after termination or, if termination is pursuant to paragraph&#160;10(d) of this Agreement, within 15 days after the written notice to BCBSA described in paragraph&#160;10(d).</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The terminated entity shall deliver to BCBSA within five days of a request by BCBSA a listing of national accounts in which the terminated entity is involved (in a Control, Participating or Servicing capacity), identifying the national account and the terminated entity's role therein.  For those accounts where the terminated entity is the Control Plan, the Plan must also indicate the Participating and Servicing Plans in the national account syndicate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="text-align:right"><font><br></font></div><div style="padding-left:70.2pt;padding-right:70.2pt;text-align:center;text-indent:-140.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Unless the cause of termination is an event stated in paragraph 15(a) or (b) above respecting BCBSA, the Plan and its Licensed Controlled Affiliates shall be jointly liable for payment to BCBSA of an amount equal to the Re-Establishment Fee (described below) multiplied by the number of Licensed Enrollees of the terminated entity and its Licensed Controlled Affiliates&#59;  provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in the Service Area established by this Agreement, the Re-Establishment Fee shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the terminated entity and its Licensed Controlled Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service Area.  The Re-Establishment Fee shall be indexed to a base fee of $80.  The Re-Establishment Fee through December 31, 2005 shall be $80.  The Re-Establishment Fee for calendar years after December 31, 2005 shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall be the base fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans&#8217; gross administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31, 2004.  The adjustment shall end on January 1, 2011, at which time the Re-Establishment Fee shall be fixed at the then-current amount and no longer automatically adjusted.  For example, if the Plans&#8217; gross administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be $83.27 (100% of the base fee plus $1.84 for calendar year 2005 and $1.43 for calendar year 2006).  Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (a) the end of the last fiscal year of the terminated entity which ended prior to termination or (b) the fiscal year which ended before any transactions causing the termination began.  Notwithstanding the foregoing, the amount payable pursuant to this subparagraph (d)(iii) shall be due only </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8a-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to the extent that, in BCBSA's opinion, it does not cause the net worth of the Plan to fall below 100% of the Health Risk-Based Capital formula or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this sub paragraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans), measured as of the date of termination and adjusted for the value of any transactions not made in the ordinary course of business.  This payment shall not be due in connection with transactions exclusively by or among Plan or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage.  At least 50% of the Re-Establishment Fee shall be awarded to the Plan (or Plans) that receive the new license(s) for the service area(s) at issue&#59; provided, however, that such award shall not become due or payable until all disputes, if any, regarding the amount of and BCBSA&#8217;s right to such Re-Establishment Fee have been finally resolved&#59; and provided further that the award shall be based on the final amount actually received by BCBSA.  The Board of Directors shall adopt a resolution which it may amend from time to time that shall govern BCBSA&#8217;s use of its portion of the award.  In the event that the terminated entity&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Plan (and&#47;or its Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph only to the extent that such payments exceed the amounts due to BCBSA pursuant to subparagraph 15(d)(vi) and any costs associated with reestablishing the Service Area, including any payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of replacing the terminated entity.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;The terminated entity shall comply with all financial settlement procedures set forth in BCBSA&#8217;s License Termination Contingency Plan, as amended from time to time and shall work diligently and in good faith with </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8b-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BCBSA, any Alternative Control Licensee or Replacement Licensee and any existing or potential new account for Blue-branded products and services to minimize the disruption of termination, and honor, to the fullest extent possible, the desire of accounts to continue to receive or obtain Blue-branded products and services through a new Licensee (&#8220;Transition&#8221;).  Such diligence and good faith on the part of the terminated entity shall include, but not be limited to&#58; (a) working cooperatively with BCBSA to protect the Names and Marks from potential harm&#59; (b) cooperating with BCBSA&#8217;s use of the Names and Marks in the terminated entity&#8217;s former service area during the termination and Transition&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) transmitting, upon the request of an existing Blue account or of BCBSA with consent and on behalf of an existing Blue account, all member and account-data relating to the Federal Employee Program</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to BCBSA, and all member and account data relating to other programs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to an Alternative Control Licensee or Replacement Licensee&#59; (d) working with BCBSA and the Alternative Control or Replacement Licensee with respect to potential new Blue accounts headquartered in the terminated entity&#8217;s former service area&#59; (e) continuing to service Blue accounts during the Transition&#59; (f) continuing to comply with National Programs, Federal Employee Program and NASCO policies and procedures and all voluntary BCBSA programs, policies and performance standards, such as Away From Home Care,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">including being responsible for payment of all penalties for non-compliance duly levied in conformity with the License Agreements, Membership Standards, or the Federal Employee Program agreements, that may arise during the Transition&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g) maintaining and providing access to its provider networks,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as defined by Federal Employee Program agreements and National Account Program Policies and Provisions, and Inter-Plan Programs Policies and Provisions,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and making those networks and discounts available to members and providers who participate in National Programs and the Federal Employee Program during the Transition&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h) maintaining its technical connections and processing capabilities during the Transition&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and (i) working diligently to conclude all financial settlements and account reconciliations as negotiated in the termination transition agreement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 16, 2006</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8c-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Notwithstanding any other provision in this Agreement, BCBSA shall have the right, with the approval of its Board of Directors, to assess additional fines against the terminated entity during the Transition in the event it fails to maintain and provide access to</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provider networks as defined by Federal Employee Program agreements, National Account Program Policies and Provisions,  and Inter-Plans Programs Policies and Provisions, and&#47;or pass on applicable discounts. Such fines shall be in addition to any other assessments, fees or liquidated damages payable herein, or under existing policies and programs and shall be imposed to make whole BCBSA and&#47;or the Plans.  Terminated entity shall pay any such fines to BCBSA no later than 30 days after they are approved by the Board of Directors. </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;BCBSA shall have the right to examine and audit and&#47;or hire at terminated entity&#8217;s expense a third-party auditor to examine and audit the books and records of the terminated entity and its Licensed Controlled Affiliates to verify compliance with the terms and requirements of this paragraph 15(d).</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data that was acquired or accessed during the period this Agreement was in force, including but not limited to all confidential</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">processes, pricing, provider, discount and other strategic and competitively sensitive information (&#8220;Blue Information&#8221;) from disclosure, and shall not, either alone or with another entity, disclose such Blue Information or use it in any manner to compete without the express written permission of BCBSA. </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;As to a breach of 15 (d) (i), (ii), (iii), (iv), (vi), or (vii) the parties agree that the obligations are immediately enforceable in a court of competent jurisdiction.  As to a breach of 15 (d) (i), (ii), (iv), (vi), or (vii) by the Plan, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 16, 2006</font></div><div style="padding-left:140.4pt;text-align:right;text-indent:-140.4pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8d-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;In the event that the terminated entity&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Plan and its Licensed Controlled Affiliates shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e).&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Plan or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this License Agreement unless the License Agreement has been terminated pursuant to paragraph 10 (d) of this Agreement upon the required six (6) month written notice.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f).&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2006</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8e-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;This Agreement supersedes any and all other agreements between the parties with respect to the subject matter herein and contains all of the covenants and agreements of the parties as to the licensing of the Licensed Marks and Name.  This Agreement may be amended only by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;If any provision or any part of any provision of this Agreement is judicially declared unlawful, each and every other provision, or any part of any provision, shall continue in full force and effect notwithstanding such judicial declaration.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;No waiver by BCBSA or the Plan of any breach or default in performance on the part of BCBSA or the Plan or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19a.&#160;&#160;&#160;&#160;All notices provided for hereunder shall be in writing and shall be sent in duplicate by regular mail to BCBSA or the Plan at the address currently published for each by BCBSA and shall be marked respectively to the attention of the President and, if any, the General Counsel, of BCBSA or the Plan.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19b.&#160;&#160;&#160;&#160;Except as provided in paragraphs 9(b), 9(d)(iii), 15(a), and 15(b) above, this Agreement may be terminated for a breach only upon at least 30 days&#8217; written notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to the Member Plans. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19c.&#160;&#160;&#160;&#160;For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan.  For all other votes of the Plans, the Plan shall have one vote.  For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.  Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2006</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8f-</font></div><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(The next page is page 9)</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;Nothing herein contained shall be construed to constitute the parties hereto as partners or joint venturers, or either as the agent of the other, and Plan shall have no right to bind or obligate BCBSA in any way, nor shall it represent that it has any right to do so.  BCBSA shall have no liability to third parties with respect to any aspect of the business, activities, operations, products, or services of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;This Agreement shall be governed, construed and interpreted in accordance with the laws of the State of Illinois.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last signature written below.</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By___________________________________</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title__________________________________</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date__________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan&#58;</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By___________________________________</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title__________________________________</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date__________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-9-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE SHIELD </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE AGREEMENT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Includes revisions adopted by Member Plans through their June 16, 2022 meeting)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and ______________ (&#8220;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Shield Plan, known as _____________  (&#34;Plan&#34; or &#8220;Sponsoring Plan&#8221;), which is also a Party signatory hereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Plan and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE SHIELD Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE SHIELD in a trade name (&#34;Licensed Name&#34;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;GRANT OF LICENSE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with&#58;  (i) health care plans and related services, as defined in BCBSA's License Agreement with Plan, and administering the non-health portion of workers&#8217; compensation insurance, and (ii) underwriting the indemnity portion of workers&#8217; compensation insurance, provided that Controlled Affiliate&#8217;s total premium revenue comprises less than 15 percent of the Sponsoring Plan&#8217;s net subscription revenue.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant of rights is non-exclusive and is limited to the Service Area served by the Plan.  Subject to Paragraph 3A(3) of this Agreement, Controlled Affiliate may use the Licensed Marks and Name in its legal name on the following conditions&#58; (i) the legal name must be approved in advance, in writing, by BCBSA&#59; (ii) Controlled Affiliate shall not do business outside the Service Area under any name or mark&#59; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market, unless such Controlled Affiliate is <br>a not-for-profit company which may use the Licensed Marks and Name, or an approved derivative therefor, to identify itself in debt securities markets. Controlled Affiliate may <br>use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;QUALITY CONTROL</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time. </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to comply with all applicable federal, state and local laws.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan or by BCBSA) a report or reports to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that Plan and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that the Sponsoring Plan has&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The legal authority directly or indirectly through wholly-owned subsidiaries&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 50% voting control thereof&#59; and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through">  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring Plan&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can&#58;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being replaced&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;make any loans or advances except in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners or persons or entities with the authority to select or appoint members or board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate)&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;conduct any business other than under the Licensed Marks <br>and Name&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;take any action that Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at least 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Or</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The legal authority directly or indirectly through wholly-owned subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having more than 50% voting control thereof and to&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan do not concur&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Or</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services, the Sponsoring Plan has the legal authority together with such <br>other Plans&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and such other Plans each having an ownership interest.  Such control and ownership by Plans must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.  Further, the Sponsoring Plan and such other Plans shall execute a separate Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-1 for each product noted in Paragraph 2E(3) that is licensed to use the Marks.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Or</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-branded basis offers solely a Basic Medicare Part D Prescription Drug product, the Sponsoring Plan has the legal authority&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended June 20, 2019</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA, Further, the Participating Plan as defined in Exhibit B-2 and the Sponsoring Plan shall execute the Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-2.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Or</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;With respect to a Controlled Affiliate that is operating as a clinic, absent an alternative method of control approved in writing by BCBSA, the Sponsoring Plan shall have bonafide operational control over the Controlled Affiliate as specified in Exhibit A, Standard 1 (E) and the Guidelines to Administer Standard 1 (E).  In addition, if the clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing documents of the Controlled Affiliate with which it does not concur. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;FOR-PROFIT, PUBLICLY TRADED LICENSEES</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The Controlled Affiliate may operate as a for-profit publicly traded company on the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall discharge all responsibilities which it has to the Association and to other Plans by virtue of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall provide 90 days advance written notice to BCBSA prior to the initial filing with the SEC.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of its legal name or any symbol used to identify the Controlled Affiliate in any securities market.  The Controlled Affiliate shall use the Licensed Marks and Name as part of its trade name within its service area for the sale, marketing and administration of health care and related services in the service area.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Controlled Affiliate&#8217;s license to use the Licensed Marks and Name shall automatically terminate effective&#58; (a) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any Institutional Investor, has become the Beneficial Owner of securities representing 10% or more of the voting power of the Controlled Affiliate (&#8220;Excess Institutional Voter&#8221;), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter prior to such automatic termination becoming effective&#59; (b) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any Noninstitutional Investor, other than a Plan or Plans or Controlled Affiliate licensee or licensees has become the Beneficial Owner of securities representing 5% or more of the voting power of the Controlled Affiliate (&#8220;Excess Noninstitutional Voter&#8221;) unless such Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional Voter prior to such automatic termination becoming effective&#59; (c) thirty days after</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Controlled Affiliate knows, or there is an SEC filing indicating that, any Person has become the Beneficial Owner, other than a Plan or Plans or Controlled Affiliate licensee or licensees, of 20% or more of the Controlled Affiliate&#8217;s then outstanding common stock or other equity securities which (either by themselves or in combination) represent an ownership interest of 20% or more pursuant to determinations made under Paragraph 3A(4) below (&#8220;Excess Owner&#8221;), unless such Excess Owner shall cease to be an Excess Owner prior to such automatic termination becoming effective&#59; (d) ten business days after individuals who at the time the Controlled Affiliate went public constituted the Board of Directors of the Controlled Affiliate (together with any new directors whose election to the Board was approved by a vote of 2&#47;3 of the directors then still in office who were directors at the time the Controlled Affiliate went public or whose election or nomination was previously so approved) (the &#8220;Continuing Directors&#8221;) cease for any reason to constitute a majority of the Board of Directors&#59; or (e) ten business days after the Controlled Affiliate consolidates with or merges with or into any person or conveys, assigns, transfers or sells all or substantially all of its assets to any person other than a merger in which the Sponsoring Plan is the surviving entity and immediately after which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner&#58; provided that, if requested by the affected Controlled Affiliate in a writing received by BCBSA prior to such automatic termination becoming effective, the provision of this paragraph 3A(4) may be waived, in whole or in part, upon the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans.  Any waiver so granted may be conditioned upon such additional requirements (including but not limited to imposing new and independent grounds for termination of this License) as shall be approved by the affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans.  If a timely waiver request is received, no automatic termination shall become effective until the later of&#58;  (1) the conclusion of the applicable time period specified in paragraphs 3A(4)(a)-(d) above, or (2) the conclusion of the first Member Plan meeting after receipt of such a waiver request.</font></div><div style="margin-bottom:12pt;padding-left:81.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Controlled Affiliate&#8217;s license, or any other license, to use the Licensed Marks and Name is terminated pursuant to Paragraph 3A(4), the license may be reinstated in BCBSA&#8217;s sole discretion if, within 30 days of the date of such termination, the Controlled Affiliate demonstrates that the Person referred to in clause (a), (b) or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="margin-bottom:12pt;padding-left:81.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;The Controlled Affiliate shall not issue any class or series of security other than (i) shares of common stock having identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt securities, or (iii) such other securities as the Controlled Affiliate may approve, provided that BCBSA receives notice at least thirty days prior to the issuance of such securities, including a description of the terms for such securities, and BCBSA shall have the authority to determine how such other securities will be counted in determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an Excess Owner.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;For purposes of paragraph 3(A) above, the following definitions shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#8220;Affiliate&#8221; and &#8220;Associate&#8221; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on November 17, 1993 (the &#8220;Exchange Act&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;A Person shall be deemed the &#8220;Beneficial Owner&#8221; of and shall be deemed to &#8220;beneficially own&#8221; any securities&#58;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;which such Person or any of such Person&#8217;s Affiliates or Associates beneficially owns, directly or indirectly&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;which such Person or any of such Person&#8217;s Affiliates or Associates has (A) the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise&#59; or (B) the right to vote pursuant to any agreement, arrangement or understanding&#59; provided, however, that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement, arrangement or understanding to vote such security (1) arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person (or any of such Person&#8217;s Affiliates or Associates) has any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) relating to the acquisition, holding, voting (except to the extent contemplated by the proviso to (ii)2(B) above) or disposing of any securities of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:135pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase &#8220;then outstanding&#8221;, when used with reference to a Person&#8217;s Beneficial Ownership of securities of the Controlled Affiliate, shall mean the number of such securities then issued and outstanding together with the number of such securities not then actually issued and outstanding which such Person would be deemed to own beneficially hereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;A Person shall be deemed an &#8220;Institutional Investor&#8221; if (but only if) such Person (i) is an entity or group identified in the SEC&#8217;s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by such Person with the SEC under Regulation 13D-G (or any successor Regulation) with respect to such Person&#8217;s Beneficial Ownership of Plan securities shall have contained a certification identical to the one required by item 1 of SEC Schedule 13G as constituted on June 1, 1997.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#8220;Noninstitutional Investor&#8221; means any Person who is not an Institutional Investor.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#8220;Person&#8221; shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other entity, and shall include any successor (by merger or otherwise) of such entity.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;SERVICE MARK USE</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name.  The Controlled Affiliate further recognizes that its actions within its Service Area may affect the value of the Licensed Marks and Name nationwide.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA.  Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is intended to transfer in the Service Area the goodwill associated therewith to another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;If Controlled Affiliate meets the standards of 2E(1) but not 2E(2) above and any of  Controlled Affiliate's advertising or promotional material is reasonably determined by BCBSA and&#47;or the Plan to be in contravention of rules and regulations governing the use of the Licensed Marks and Name, Controlled Affiliate shall for ninety (90) days thereafter obtain prior approval from BCBSA of advertising and promotional efforts using the Licensed Marks and Name, approval or disapproval thereof to be forthcoming within five (5) business days of receipt of same by BCBSA or its designee. In all advertising and promotional efforts, Controlled Affiliate shall observe the Service Area limitations applicable to Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Notwithstanding any other provision in the Plan&#8217;s License Agreement with BCBSA or in this Agreement, Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of Plan or BCBSA.  This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;INFRINGEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.  Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Controlled Affiliate agrees to render to Plan and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;LIABILITY INDEMNIFICATION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate and Plan hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to&#58; (i) Controlled Affiliate's rendering of services under the Licensed Marks and Name&#59; or (ii) the activities of any hospital, medical group, clinic or other provider of health services that is owned or controlled directly or indirectly by Plan or Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;LICENSE TERM</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the provisions herein.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; (i) the Plan ceases to be authorized to use the Licensed Marks and Name&#59; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement the Plan ceases to be authorized to use the Licensed Names and Marks in the geographic area served by the Controlled Affiliate provided, however, that if the Controlled Affiliate is serving more than one State or portions thereof, the termination of this Agreement shall be </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-9-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited to the State(s) or portions thereof in which the Plan&#8217;s license to use the Licensed Marks and Names is terminated.  By not appealing or challenging such regulatory action within the time prescribed by law or regulation, and in any event no later than 120 days after such action is taken, a Plan shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination shall proceed.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C. &#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be forthwith terminated by the Plan or the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to the Board for&#58;  (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control standards of this Agreement&#59; or (2) failure to comply with the &#34;Organization and Governance&#34; quality control standard of this Agreement&#59; or (3) impending financial insolvency&#59; or (4) for a Smaller Controlled Affiliate (as defined in Exhibit A), failure to comply with any of the applicable requirements of Standards 2, 3, 4, 5 or 7 of attached Exhibit A&#59; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 8(E)&#59; or (6) failure by a Controlled Affiliate that meets the standards of 2E(1) but not 2E(2) above to obtain BCBSA's written consent to a change in the identity of any owner, in the extent of ownership, or in the identity of any person or entity with the authority to select or appoint members or board members, provided that as to publicly traded Controlled Affiliates this provision shall apply only if the change affects a person or entity that owns at least 5% of the Controlled Affiliate's stock before or after the change&#59; or (7) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans, any other licensee including Controlled Affiliate and&#47;or the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraphs 8(B), 8(C) or 8(E) herein, should Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the Plan shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance.   If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof.   Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 8(B), 8(C) or 8(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution.  All other disputes between BCBSA, the Plan and&#47;or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute </font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-10-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">resolution.  The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties.  Except, however, as provided in Paragraphs 8(B) and 8(E) of this Agreement, this license to use the Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div style="margin-bottom:6pt;padding-left:81.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with item 2(E) above&#59;</font></div><div style="margin-bottom:6pt;padding-left:81.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 10 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA&#59; or</font></div><div style="margin-bottom:6pt;padding-left:81.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Any of the following events occur&#58;  (i) a voluntary petition shall be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.  Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate&#8217;s property or business shall not in itself be deemed to </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-11-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 8(E)(3)(vii) and (viii) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The for-profit, publicly traded Controlled Affiliate is terminated pursuant to Paragraph 3A(4) of this Agreement.  In which case, the licenses of any controlled Affiliates directly or indirectly owned by the terminated for profit, publicly traded Controlled Affiliate also shall immediately terminate as provided for in paragraph 3A(4) of this Agreement</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers that it is no longer a licensee of BCBSA and, if directed by the Association&#8217;s Board of Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage.  The notification required by this paragraph shall be in writing and in a form approved by BCBSA.  The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;In the event this Agreement terminates pursuant to 8(b) hereof, or in the event the Controlled Affiliate is a Larger Controlled Affiliate (as defined in Exhibit A), upon termination of this Agreement, the provisions of Paragraph 8.G. shall not apply and the following provisions shall apply, except that, in the event of a partial termination of this Agreement pursuant to Paragraph 8(B)(ii) of this Agreement, the notices, national account listing, payment, and audit right listed below shall be applicable solely with respect to the geographic area for which the Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name.  The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA, subject to any conflicting state law and state regulatory requirements.  This notice shall be mailed within 15 days after termination.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall deliver to BCBSA within five days of a  request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the national account and the Controlled Affiliate&#8217;s role therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-12-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:113%">(3)&#160;&#160;&#160;&#160;Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan&#8217;s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for payment to BCBSA of an amount equal to  the Re-Establishment Fee (described below) multiplied by the number of Licensed Enrollees of the Controlled Affiliate&#59; provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in the Service Area established by this Agreement, the  Re-Establishment Fee shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service Area.</font></div><div style="margin-bottom:9pt;padding-left:81.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:113%">The Re-Establishment Fee shall be indexed to a base fee of $80. The Re-Establishment Fee through December 31, 2005 shall be $80.  The Re-Establishment Fee for calendar years after December 31, 2005 shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall be the base fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans&#8217; gross administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31, 2004.  The adjustment shall end on January 1, 2011, at which time the Re-Establishment Fee shall be fixed at the then-current amount and no longer automatically adjusted.  For example, if the Plans&#8217; gross administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be $83.27</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:113%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:113%">(100% of base fee plus $1.84 for calendar year 2005 and $1.43 for calendar year 2006.  Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the termination began.  Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA&#8217;s opinion, it does not cause the net worth of the Controlled Affiliate, the Plan or any other Licensed Controlled Affiliates of the Plan to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this sub paragraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans)&#59; measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course of business.  This payment shall not be due in connection with transactions exclusively by or among Plans or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage.  At least 50% of the Re-Establishment Fee shall be awarded to the Plan (or Plans) that receive the new license(s) for the service area(s) at issue&#59; provided, however, that such award shall not become due or payable until all disputes, if any, regarding the amount of and BCBSA&#8217;s right to such Re-Establishment Fee have been finally resolved&#59; and provided </font></div><div style="margin-top:3pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-13-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:10pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">further that the award shall be based on the final amount actually received by BCBSA.  The Board of Directors shall adopt a resolution which it may amend from time to time that shall govern BCBSA&#8217;s use of its portion of the award.  In the event that the Controlled Affiliate&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and&#47;or the Plan or its other Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph 8.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph 8.M. and any cost associated with reestablishing the Service Area, including any payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of replacing the Controlled Affiliate.</font></div><div style="margin-bottom:10pt;padding-left:81pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;BCBSA shall have the right to examine and audit and&#47;or hire at terminated entity&#8217;s expense a third party auditor to examine and audit the books and records of the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan to verify compliance with this paragraph 8.H.</font></div><div style="margin-bottom:10pt;padding-left:81pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data that was acquired or accessed during the period this Agreement was in force, including but not limited to all confidential processes,  pricing, provider, discount and other strategic and competitively sensitive information (&#8220;Blue Information&#8221;) from disclosure, and shall not, either alone or with another entity, disclose such Blue Information or use it in any manner to compete without the express written permission of BCBSA.</font></div><div style="margin-bottom:10pt;padding-left:81pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;As to a breach of 8.H.(1), (2), (3), (4) or (5) the parties agree that the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 8.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;This Agreement shall remain in effect until terminated by the Controlled Affiliate or the Plan upon not less than eighteen (18) months written notice to the Association or upon a shorter notice period approved by BCBSA in writing at its sole discretion, or until terminated as otherwise provided herein.  The Plan&#8217;s right to terminate without cause upon such notice is unfettered and may be exercised in the Plan&#8217;s sole discretion.</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;In the event the Controlled Affiliate is a Smaller Controlled Affiliate (as defined in Exhibit A), the Controlled Affiliate agrees to be jointly liable for the amount described in H.3.and M. hereof upon termination of the BCBSA license agreement of any Larger Controlled Affiliate of the Plan.</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this Agreement unless the Plan&#8217;s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of the Plan&#8217;s license agreement upon the required 18 months written notice.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as March 26, 2015</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-14-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">L.&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">M.&#160;&#160;&#160;&#160;In the event that the Plan has more than 50 percent voting control of the Controlled Affiliate under Paragraph 2(E)(2) above and is a Larger Controlled Affiliate (as defined in Exhibit A), then the vote called for in Paragraphs 8(C) and 8(D) above shall require the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N.&#160;&#160;&#160;&#160;In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.  Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties agree that any disputes between them or between or among either of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of Plan's License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by reference as though fully set forth herein.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;LICENSE FEE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit C.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in the Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between Plan and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;NOTICES AND CORRESPONDENCE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-15-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;COMPLETE AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof.  This Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;SEVERABILITY</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;NONWAIVER</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15A.&#160;&#160;&#160;&#160;VOTING</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan.  For all other votes of the Plans, the Plan shall have one vote.  For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-16-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS PAGE IS INTENTIONALLY BLANK.</font></div><div style="padding-left:27pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">HEADINGS</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation hereof.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last signature written below.</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled Affiliate&#58; </font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;___________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;__________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan&#58; </font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;___________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;__________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;___________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;__________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-17-</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">June 2022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of definition&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    A &#34;smaller Controlled Affiliate&#58;&#34; (1) comprises less than fifteen percent (15%) of Sponsoring Plan's and its licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider and freestanding coverage, and treating an entity seeking licensure as licensed)&#59;* or (2) underwrites the indemnity portion of workers&#8217; compensation insurance and has total premium revenue less than 15 percent of the Sponsoring Plan&#8217;s net subscription revenue. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    A &#34;larger Controlled Affiliate&#34; comprises fifteen percent (15%) or more of Sponsoring Plan's and its licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider and freestanding coverage, and treating an entity seeking licensure as licensed.)*</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in Controlled Affiliate status&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">any</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Controlled Affiliate's status changes regarding&#58; its Plan ownership level, its risk acceptance or direct delivery of medical care, the Controlled Affiliate shall notify BCBSA within thirty (30) days of such occurrence in writing and come into compliance with the applicable standards within six (6) months.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a smaller Controlled Affiliate&#8217;s health and workers&#8217; compensation administration business reaches or surpasses fifteen percent (15%) of the total member enrollment of the Sponsoring Plan and licensed Controlled Affiliates, the Controlled Affiliate shall&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-18-</font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Within thirty (30) days, notify BCBSA of this fact in writing, including evidence that the Controlled Affiliate meets the minimum liquidity and capital (BCBSA &#8220;Health Risk-Based Capital (HRBC)&#8221; as defined by the NAIC and state-established minimum reserve) requirements of the larger Controlled Affiliate Financial Responsibility standard&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Within six (6) months after reaching or surpassing the fifteen percent (15%) threshold, demonstrate compliance with all license requirements for a larger Controlled Affiliate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Controlled Affiliate that underwrites the indemnity portion of workers&#8217; compensation insurance receives a change in rating or proposed change in rating, the Controlled Affiliate shall notify BCBSA within 30 days of notification by the external rating agency.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*For purposes of this calculation, </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The numerator equals&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Applicant Controlled Affiliate's member enrollment, as defined in BCBSA's Quarterly Enrollment Report (excluding rider and freestanding coverage).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The denominator equals&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Numerator PLUS Sponsoring Plan and all other licensed Controlled Affiliates' member enrollment, as reported in BCBSA's Quarterly Enrollment Report (excluding rider and freestanding coverage).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-19-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STANDARDS FOR LICENSED CONTROLLED AFFILIATES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each licensed controlled affiliate shall be subject to certain standards as determined below&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;What percent of the licensed controlled affiliate is controlled by the Sponsoring Plan and other Plans&#63;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">More than 50% by Sponsoring Plan</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1A, 4</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50% by Sponsoring Plan</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1B, 4</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% Plan Control but less than 50% Sponsoring Plan Control and it offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1C, 4</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% Sponsoring Plan control and on a Blue-branded basis, it only offers  Basic Medicare Part D Prescription Drug Plan product</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1D, 4</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At least 50% by Sponsoring Plan or operational Control by Sponsoring Plan and it solely operates as a Clinic as defined in Standard 1E.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 1E, 4</font></div></td></tr></table></div><div><font><br></font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN ADDITION,</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Is risk being assumed&#63;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#248;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate underwrites any indemnity portion of workers&#8217; compensation insurance</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 7A-7E, 11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises &#60; 15% of total member enrollment of Sponsoring Plan and its licensed affiliates, and does not underwrite the indemnity portion of workers&#8217; compensation insurance</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 2 (Guidelines 1.1,1.2) and Standard 11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 15% of total member enrollment of Sponsoring Plan and its licensed affiliates, and does not underwrite the indemnity portion of workers&#8217; compensation insurance</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 6H</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises &#60; 15% of total member enrollment of Sponsoring Plan and its licensed affiliates</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 2</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Guidelines 1.1,1.3) and Standard 11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate comprises </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 15% of total member enrollment of Sponsoring Plan and its licensed affiliates</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 6H</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN ADDITION,</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Is medical care being directly provided as a staff model HMO&#63;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 3A</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 3B</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-20-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STANDARDS FOR LICENSED CONTROLLED AFFILIATES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each licensed controlled affiliate shall be subject to certain standards as determined below&#58;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN ADDITION,</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Is the licensed controlled affiliate operating as a Clinic, as defined in Standard 1(E)&#63;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard 3C and Standard 2, 1.4 (if organized as a health plan that also operates as a Clinic.</font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;If the controlled affiliate has health or workers&#8217; compensation administration business, does such business comprise 15% or more of the total member enrollment of Plan and its licensed Controlled Affiliates&#63;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:-0.02pt;text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#247;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#248;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 6A-6J</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">is not a former</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">primary licensee and is not subject to Standard 1(C) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 5,8,9B,10,11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate is a former primary licensee</font></div><div style="padding-right:2.75pt"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 5,8,9A,10,11</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Controlled Affiliate is not a former primary licensee and is subject to Standard 1(C) </font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#242;</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards 5,8,9B,11</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-21-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1A.)&#160;&#160;&#160;&#160;The Standard for more than 50% Plan control is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA has the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; 1) to select members of the Controlled Affiliate&#8217;s governing body having more than 50% voting control thereof&#59; and 2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan do not concur&#59; and 3) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1B.)&#160;&#160;&#160;&#160;The Standard for 50% Plan control is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA has the legal authority, directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 50% voting control thereof&#59; and </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan do not concur&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-22-</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in 1) through 3) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can&#58;</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">change the geographic area in which it operates </font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">change its legal and&#47;or trade names</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">change any of the types of businesses in which it engages</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the ordinary course of business</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being replaced</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">make any loans or advances except in the ordinary course of business</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners or persons or entities with the authority to select or appoint members or board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate)</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">conduct any business other than under the Licensed Marks and Name</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own at least 50% of any for-profit Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1C.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and service and has100% Plan control but less than 50% Sponsoring Plan Control&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized and operated in such a manner that (i) it offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans products and services&#59; and (ii) a Plan authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA (the &#8220;Sponsoring Plan,) has the legal authority together with Other Plans&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended September 27, 2018</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-23-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws, or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and such other Plans each having an ownership interest.  Such 100% control and ownership by Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.  Further, the Sponsoring Plan and such other Plans shall execute the Addendum to Controlled Affiliate License.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1D).  The Standard for a Controlled Affiliate that on a Blue-branded basis, only offers a Basic Medicare Part D Prescription Drug product and has 100% Plan control is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized and operated in such a manner that (i) on a Blue-branded basis, it only offers a Basic Medicare Part D Prescription Drug  product&#59; and (ii) the Sponsoring Plan has the legal authority&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;to select all members of the Controlled Affiliate&#8217;s governing body&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Further, the Sponsoring Plan and Participating Plan shall execute the Addendum to Controlled Affiliate License.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1E).&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that operates as a Clinic and the Sponsoring Plan has control of the Clinic is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be organized in such a manner that it operates as a Clinic and Sponsoring Plan exercises operational control over the Controlled Affiliate.  </font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, if the Clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended June 20, 2019</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-24-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 2 - Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.  If a risk-assuming Controlled Affiliate ceases operations for any reason, Blue Cross and&#47;or Blue Cross Plan coverage will be offered to all Controlled Affiliate subscribers without exclusions, limitations or conditions based on health status.  If a nonrisk-assuming Controlled Affiliate ceases operations for any reason, Sponsoring Plan will provide for services to its customers. The requirements of the preceding two sentences shall apply to all lines of business unless a line of business is specially exempted from the requirement(s) by the BCBSA Board of Directors.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 3 - State Licensure&#47;Certification</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3A.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that employs, owns or contracts on a substantially exclusive basis for medical services is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain unimpaired licensure or certification for its medical care providers to operate under applicable state laws.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3B.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that does not employ, own or contract on a substantially exclusive basis for medical services is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain unimpaired licensure or certification to operate under applicable state laws.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3C.)&#160;&#160;&#160;&#160;The Standard for a Controlled Affiliate that operates as a Clinic as defined in Standard 1(E) is&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 4 - Certain Disclosures</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of 1) the structure of the Blue Cross and Blue Shield System&#59; and 2) the independent nature of every licensee&#59; and 3) the Controlled Affiliate's financial condition.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2019</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-25-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 5 - Reports and Records for Certain Smaller Controlled Affiliates</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For a smaller Controlled Affiliate that does not underwrite the indemnity portion of workers&#8217; compensation insurance, the Standard is&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate and&#47;or its Sponsoring licensed Plan shall furnish, on a timely and accurate basis, reports and records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 6 - Other Standards for Larger Controlled Affiliates </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standards 6(A) - (I) that follow apply to larger Controlled Affiliates.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(A)&#58;  Board of Directors</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate Governing Board shall act in the interest of its Corporation in providing cost-effective health care services to its customers.  A Controlled Affiliate shall maintain a governing Board, which shall control the Controlled Affiliate, composed of a majority of persons other than providers of health care services, who shall be known as public members.  A public member shall not be an employee of or have a financial interest in a health care provider, nor be a member of a profession which provides health care services.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(B)&#58;  Responsiveness to Customers</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner responsive to customer needs and requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(C)&#58;  Participation in National Programs</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall effectively and efficiently participate in each national program as from time to time may be adopted by the Member Plans for the purposes of providing portability of membership between the licensees and ease of claims processing for customers receiving benefits outside of the Controlled Affiliate's Service Area. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-26-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(C)&#58;  Participation in National Programs (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such programs are applicable to licensees, and include&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;BlueCard Program&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Inter-Plan Teleprocessing System (ITS).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;National Account Programs&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April 14, 2003&#59; and </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(D)&#58;   Financial Performance Requirements</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to requirements under the national programs listed in </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6C&#58;  Participation in National Programs, a Controlled Affiliate shall take such action as required to ensure its financial performance in programs and contracts of an inter-licensee nature or where BCBSA is a party.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(E)&#58;  Cooperation with Plan Performance Response Process</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall cooperate with BCBSA's Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Plan Performance Response Process and in addressing Controlled Affiliate performance problems identified thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(F)&#58;  Independent Financial Rating</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall obtain a rating of its financial strength from an independent rating agency approved by BCBSA's Board of Directors for such purpose.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(G)&#58;  Local Best Efforts</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any other provision in the Plan&#8217;s License Agreement with BCBSA or in this License Agreement, during each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Mark. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(H)&#58;  Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of April 27, 2021</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-27-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(I)&#58;  Reports and Records</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall furnish to BCBSA on a timely and accurate basis reports and records relating to compliance with these Standards and the License Agreements between BCBSA and Controlled Affiliate.  Such reports and records are the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A)&#160;&#160;&#160;&#160;BCBSA Controlled Affiliate Licensure Information Request&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B)&#160;&#160;&#160;&#160;Triennial trade name and service mark usage material, including disclosure material&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C)&#160;&#160;&#160;&#160;Changes in the ownership and governance of the Controlled Affiliate, including changes in its charter, articles of incorporation, or bylaws, changes in a Controlled Affiliate's Board composition, or changes in the identity of the Controlled Affiliate's Principal Officers, and changes in risk acceptance, contract growth, or direct delivery of medical care&#59; and </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D)&#160;&#160;&#160;&#160;Semi-annual &#8220;Health Risk-Based Capital (HRBC) Report&#8221; as defined by the NAIC, Annual Certified Audit Report, Insurance Department Examination Report, Annual Statement filed with State Insurance Department (with all attachments), and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 17, 2011</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-28-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6(J)&#58;  Control by Unlicensed Entities Prohibited</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to obtain control of the Controlled Affiliate or to acquire a substantial portion of its assets related to licensable services.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 7 - Other Standards for Risk-Assuming Workers&#8217; Compensation Controlled Affiliates</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standards 7(A) - (E) that follow apply to Controlled Affiliates that underwrite the indemnity portion of workers&#8217; compensation insurance.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 7 (A)&#58;  Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 7(B)&#58;  Reports and Records</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall furnish, on a timely and accurate basis, reports and records relating to compliance with these Standards and the License Agreements between BCBSA and the Controlled Affiliate.  Such reports and records are the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;BCBSA Controlled Affiliate Licensure Information Request&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Triennial trade name and service mark usage materials, including disclosure materials&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Annual Certified Audit Report, Annual Statement as filed with the State Insurance Department (with all attachments), Annual NAIC&#8217;s Risk-Based Capital Worksheets for Property and Casualty Insurers&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Quarterly Estimated Risk-Based Capital for Property and Casualty Insurers, Insurance Department Examination Report&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 17, 2011</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-29-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Notification of all changes and proposed changes to independent ratings within 30 days of receipt and submission of  a copy of all rating reports&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Changes in the ownership and governance of the Controlled Affiliate including changes in its charter, articles of incorporation, or bylaws, changes in a Controlled Affiliate&#8217;s Board composition, Plan control, state license status, operating area, the Controlled Affiliate&#8217;s Principal Officers or direct delivery of medical care.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 7(C)&#58;  Loss Prevention</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall apply loss prevention protocol to both new and existing business.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 7(D)&#58;  Claims Administration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain an effective claims administration process that includes all the necessary functions to assure prompt and proper resolution of medical and indemnity claims.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 7(E)&#58;  Disability and Provider Management</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall arrange for the provision of appropriate and necessary medical and rehabilitative services to facilitate early intervention by medical professionals and timely and appropriate return to work.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 16, 2000</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-30-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 8 - Cooperation with Controlled Affiliate License Performance Response Process Protocol</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate and its Sponsoring Plan shall cooperate with BCBSA&#8217;s Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Controlled Affiliate License Performance Response Process Protocol (ALPRPP) and in addressing Controlled Affiliate compliance problems identified thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary Licensees</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A smaller controlled affiliate that formerly was a Primary Licensee shall effectively and efficiently participate in certain national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the Controlled Affiliate&#8217;s service area and be subject to certain relevant financial and reporting requirements.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;National program requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">BlueCard Program&#59;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">Inter-Plan Teleprocessing System (ITS)&#59; </font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">National Account Programs.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Financial Requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">Standard 6(D)&#58; Financial Performance Requirements and Standard 6(H)&#58; Financial Responsibility&#59; or</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">A financial guarantee covering the Controlled Affiliate&#8217;s Inter-Plan Programs obligations in a form, and from a guarantor, acceptable to BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 21, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-31-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary Licensees</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Reporting requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:41.15pt">The Semi-annual Health Risk-Based Capital (HRBC) Report.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 13, 2002</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-32-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 9(B) - Participation in National Programs by Smaller Controlled Affiliates</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A smaller controlled affiliate shall participate in national programs in accordance with BlueCard and other relevant Policies and Provisions shall effectively and efficiently participate in national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the controlled affiliate&#8217;s service area and be subject to certain relevant financial and reporting requirements.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;National program requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">BlueCard Program&#59;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">Inter-Plan Teleprocessing System (ITS).</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">National Account Programs. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Financial Requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">Standard 6(D)&#58; Financial Performance Requirements and Standard 6(H)&#58; Financial Responsibility&#59; or </font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.65pt">A financial guarantee covering the Controlled Affiliate&#8217;s Inter-Plan Programs obligations in a form, and from a guarantor, acceptable to BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 20, 2013</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-33-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 10 - Participation in Inter-Plan Medicare Advantage Program</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A smaller controlled affiliate for which this standard applies pursuant to the Preamble section of Exhibit A of the Controlled Affiliate License Agreement shall effectively and efficiently participate in certain national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the controlled affiliate&#8217;s service area.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">National program requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-25.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 11&#58; Participation in Master Business Associate Agreement by Smaller Controlled Affiliate Licensees</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective April 14, 2003, all smaller controlled affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as defined by the Business Associate Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-34-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B-1</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1C.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Addendum is made to that certain Blue Shield Controlled Affiliate License Agreement executed by and among Blue Cross and Blue Shield Association (&#8220;Licensor&#8221;), __________________________ (&#8220;Controlled Affiliate Licensee&#8221;) and _________________________________________(&#8220;Sponsoring Plan&#8221;) dated the _____ day of ____________ , _____ (&#8220;Agreement&#8221;).  The parties to this Addendum are Licensor, Controlled Affiliate Licensee, Sponsoring Plan, and the undersigned other Plans (&#8216;Other Plans&#8221;).  This Addendum is made and shall be deemed effective as of the date of the Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Sponsoring Plan asserts that it can serve the Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans market in its Service Area more efficiently and with less risk through an enterprise jointly owned and controlled with other Plans than through a wholly owned and Controlled Affiliate Licensee&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, in such circumstance Controlled Affiliate License Standard 1C permits the licensing of a Controlled Affiliate that is less than 50% owned and controlled by the Sponsoring Plan but which is 100% owned and controlled by Plans including the Sponsoring Plan, subject to certain conditions&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, one such condition is that the Sponsoring Plan and all such other owning and controlling Plans enter into this Addendum&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein, the parties agree as follows&#58;</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;This Addendum is limited to &#91;identify product name&#93;.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Sponsoring Plan shall participate operationally in Controlled Affiliate&#8217;s business that is conducted under the Licensed Marks.  The parties understand that participation may take many forms, one of which should be providing a network of providers in the Service Area of the Controlled Affiliate for the Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and&#47;or Special Need Plans services being offered under the Agreement and being involved in network development and provider engagement functions.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Each of the Other Plans agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to enable Sponsoring Plan and Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-35-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">will not take any action, either individually or jointly with any of the Other Plans, that would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either individually or jointly with any of the Other Plans, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Each of the Other Plans acknowledges that it has reviewed the Agreement and understands that Sponsoring Plan has the right to terminate the Agreement without cause upon notice as provided in Paragraph 8 of the Agreement, and that such right is unfettered and may be exercised by Sponsoring Plan in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BLUE CROSS BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Controlled Affiliate Licensee&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Sponsoring Plan&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Other Plan 1&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Other Plan 2&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 27, 2018</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-36-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B-2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1D.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM TO CONTROLLED AFFILIATE LICENSE</font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Addendum is made to that certain Blue Shield Controlled Affiliate License Agreement executed by and among Blue Cross and Blue Shield Association (&#8220;Licensor&#8221;), __________________________ (&#8220;Controlled Affiliate Licensee&#8221;), _____________________________________(&#8220;Sponsoring Plan&#8221;) and                    ___________________________________  (&#8220;Participating Plan&#8221;) dated the _____ day of ____________ , _____ (&#8220;Agreement&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Participating Plan is defined as the Plan that holds the Primary License with BCBSA to use the Service Marks in the Service Area where the Controlled Affiliate will use the Service Marks&#59; </font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Participating Plan asserts that it can offer a lower cost Basic Medicare Part D Prescription Drug Plan product more efficiently in the Participating Plan&#8217;s Service Area through the Controlled Affiliate Licensee&#59;</font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Controlled Affiliate shall only use the Service Marks inside of the Participating Plan(s) Service Area subject to each Participating Plan signing a separate Addendum&#59;</font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, in such circumstance Controlled Affiliate License Standard 1D permits the licensing of a Controlled Affiliate that is 100% owned and controlled by a Sponsoring Plan, subject to certain conditions&#59;</font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, one such condition is that the Sponsoring Plan, Controlled Affiliate and the Participating Plan enter into this Addendum&#59;</font></div><div style="margin-bottom:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein, the parties agree as follows&#58;</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Participating Plan shall participate in Controlled Affiliate&#8217;s business that is conducted under the Licensed Marks.  The parties understand that the Participating Plan shall conduct sales support and marketing of the Controlled Affiliate&#8217;s Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan&#8217;s Service Area.  Any other form of participation shall require BCBSA&#8217;s written approval.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Participating Plan agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to enable Sponsoring Plan and </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it will not take any action that would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either individually or jointly with the Sponsoring Plan or Controlled Affiliate Licensee, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The Controlled Affiliate Licensee shall only use the Licensed Marks authorized by the Participating Plan in connection with the Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan&#8217;s Service Area.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The Sponsoring Plan and Controlled Affiliate acknowledge that it has reviewed the Agreement and understands that Participating Plan has the right to terminate this Agreement&#58; (i) immediately upon the expiration or termination of the Plan Participation Agreement by and between Participating Plan and Controlled Affiliate upon written notice to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, or (ii) without cause upon 18 months written notice to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, and that such right is unfettered and may be exercised by Participating Plan in its sole discretion.  In the event that Participating Plan and Controlled Affiliate fail to execute the Plan Participation Agreement by ____________(Date), Participating Plan may terminate this Agreement immediately upon notice to Sponsoring Plan, Controlled Affiliate Licensee and Licensor. </font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate Licensee's rights hereunder shall immediately terminate without any further action by any party or entity in the event that the Sponsoring Plan or Participating Plan ceases to be authorized to use the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BLUE CROSS BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Controlled Affiliate Licensee&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Sponsoring Plan&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Participating Plan&#93;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended March 17, 2016</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT C</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ROYALTY FORMULA FOR SECTION 9 OF THE <br>CONTROLLED AFFILIATE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FOR RISK PRODUCTS&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Controlled Affiliates not underwriting the indemnity portion of workers&#8217; compensation insurance&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An amount equal to its pro rata share of Sponsoring Plan's dues payable to BCBSA computed with the addition of the Controlled Affiliate's members using the Marks on health care plans and related services as reported on the Quarterly Enrollment Report with BCBSA.  The payment by Sponsoring Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Controlled Affiliates underwriting the indemnity portion of workers&#8217; compensation insurance&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An amount equal to 0.35 percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks&#59; plus, an annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 7. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September, 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-39-</font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT C (continued)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FOR NONRISK PRODUCTS&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For third-party administrative business, an amount equal to its pro rata share of Sponsoring Plan&#8217;s dues payable to BCBSA computed with the addition of the Controlled Affiliate&#8217;s members using the Marks on health care plans and related services as reported on the Quarterly Enrollment Report with BCBSA.  The payment by Sponsoring Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For non-third-party administrative business (e.g., case management, provider networks, etc.), an amount equal to 0.24 percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks&#59; plus&#58; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;An annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 6 D.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;An annual fee of $2,000 per license for all other Controlled Affiliates.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The foregoing shall be reduced by one-half where both a BLUE CROSS&#174; and BLUE SHIELD&#174; License are issued to the same Controlled Affiliate.  In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated.  Royalties under this formula will be calculated, billed and paid in arrears.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 19, 2014</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-40-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 1A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE AGREEMENT <br>APPLICABLE TO LIFE INSURANCE COMPANIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Includes revisions adopted by Member Plans through their June 16, 2022 meeting)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________________(&#34;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Shield Plan(s), known as _______________________________________(&#34;Plan&#34;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Plan and the Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE SHIELD Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE SHIELD in a trade name (&#34;Licensed Name&#34;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;GRANT OF LICENSE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Controlled Affiliate the exclusive right to use the licensed Marks and Names in connection with and only in connection with those life insurance and related services authorized by applicable state law, other than health care plans and related services (as defined in the Plan's License Agreements with BCBSA) which services are not separately licensed to Controlled Affiliate by BCBSA, in the Service Area served by the Plan, except that BCBSA reserves the right to use the Licensed Marks and Name in said Service Area, and except to the extent that said Service Area may overlap the area or areas served by one or more other licensed Blue Shield Plans as of the date of this License as to which overlapping areas the rights hereby granted are non-exclusive as to such other Plan or Plans and their respective Licensed Controlled Affiliates only.  Controlled Affiliate cannot use the Licensed Marks or Name outside the Service Area or in its legal or trade name&#59; provided, however, that if and only for so long as Controlled Affiliate also holds a Blue Shield Affiliate License Agreement applicable to health care plans and related services, Controlled Affiliate may use the Licensed Marks and Name in its legal and trade name according to the terms of such license agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 12, 2003</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;QUALITY CONTROL</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in relation to the sale, marketing and rendering of authorized products and further agrees to be bound by the conditions regarding quality control shown in Exhibit A as it may be amended by BCBSA from time-to-time.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that Plan and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan or by BCBSA) a report to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of Exhibit A.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it is subject to the bona fide control of a Plan or Plans.  Absent written approval by BCBSA of an alternative method of control, bona fide control shall mean the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Controlled Affiliate's governing body having not less than 51% voting control thereof&#59; (b) to exercise operational control with respect to the governance thereof&#59; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate.  In addition, a Plan or Plans shall own at least 51% of any for-profit Controlled Affiliate.  If the Controlled Affiliate is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items (a) and (c) above, proxies representing 51% of the votes at any meeting of the policyholders and shall demonstrate that there is no reason to believe this such proxies shall be revoked by sufficient policyholders to reduce such percentage below 51%.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;SERVICE MARK USE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks, and shall comply with such rules (applicable to all Controlled Affiliates licensed to use the Marks) relative to service mark use, as are issued from time-to-time by BCBSA.  If there is any public reference to the affiliation between the Plan and the Controlled Affiliate, all of the Controlled Affiliate's licensed services in the Service Area of the Plan shall be rendered under the Licensed Marks.  Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Controlled Affiliate shall inure to the benefit of BCBSA</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall not sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the option of Plan or BCBSA.  This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;INFRINGEMENTS</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify Plan and BCBSA of any suspected acts of infringement, unfair competition or passing off which may occur in relation to the Licensed Marks.  Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Controlled Affiliate agrees to render to Plan and BCBSA, free of charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks by BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;LIABILITY INDEMNIFICATION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate hereby agrees to save, defend, indemnify and hold Plan and BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of Controlled Affiliate's rendering of health care services under the Licensed Marks.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;LICENSE TERM</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods upon evidence satisfactory to the Plan and BCBSA that Controlled Affiliate meets the then applicable quality control standards, unless one of the parties hereto notifies the other party of the termination hereof at least sixty (60) days prior to expiration of any license period.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement may be terminated by the Plan or by BCBSA for cause at any time provided that Controlled Affiliate has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period).  By way of example and not for purposes of limitation, Controlled Affiliate's failure to abide by the quality control provisions of Paragraph 2, above, shall be considered a proper ground for cancellation of this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement and all of Controlled Affiliate&#8217;s rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A. &#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with Standard No. 1 (Organization and Governance) of Exhibit A or, following an opportunity to cure, with the remaining quality control provisions of Exhibit A, as it may be amended from time-to-time&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Plan ceases to be authorized to use the Licensed Marks&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Appropriate dues for Controlled Affiliate pursuant to item 8 hereof, which are the royalties for this License Agreement are more than sixty (60) days in arrears to BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks including any use in its trade name.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of any disagreement between Plan and BCBSA as to whether grounds exist for termination or as to any other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation or mandatory dispute resolution in effect between the parties.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon termination of this Agreement, Licensed Controlled Affiliate shall immediately notify all of its customers that it is no longer a licensee of the Blue Cross and Blue Shield Association and provide instruction on how the customer can contact the Blue Cross and Blue Shield Association or a designated licensee to obtain further information on securing coverage. The written notification required by this paragraph shall be in writing and in a form approved by the Association. The Association shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;DUES</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">An annual fee of five thousand dollars ($5,000) per license, plus</font></div><div style="padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">.05% of gross revenue per year from branded group products, plus</font></div><div style="padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">.5% of gross revenue per year from branded individual products plus</font></div><div style="padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">.14% of gross revenue per year from branded individual annuity products.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The foregoing percentages shall be reduced by one-half where both a BLUE CROSS&#174; and BLUE SHIELD&#174; license are issued to the same entity.  In the  event that any License period is greater or less than one (1) year, any amounts due shall be prorated.  Royalties under this formula will be calculated, billed and paid in arrears.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan will promptly and timely transmit to BCBSA all dues owed by Controlled Affiliate as determined by the above formula and if Plan shall fail to do so, Controlled Affiliate shall pay such dues directly.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between Plan and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VOTING</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan.  For all other votes of the Plans, the Plan shall have one vote.  For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.  Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;NOTICES AND CORRESPONDENCE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 20, 1997</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;COMPLETE AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof.  This Agreement may only be amended by a writing executed by all parties.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;SEVERABILITY</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way effect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;NONWAIVER</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of the Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GOVERNING LAW</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last signature written below.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled Affiliate</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;________________________________</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7-</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LIFE INSURANCE COMPANIES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 1 of 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The standards for licensing Life Insurance Companies (Life and Health Insurance companies, as defined by state statute) are established by BCBSA and are subject to change from time-to-time upon the affirmative vote of three-fourths (3&#47;4) of the Plans and three-fourths (3&#47;4) of the total weighted vote of all Plans.  Each Licensed Plan is required to use a standard controlled affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Life Insurance Company maintains compliance with the license standards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An organization meeting the following standards shall be eligible for a license to use the Licensed Marks within the service area of its sponsoring Licensed Plan to the extent and the manner authorized under the Controlled Affiliate License applicable to Life Insurance Companies and the principal license to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The LIC shall be organized and operated in such a manner that it is controlled by a licensed Plan or Plans which have, directly or indirectly&#58; 1) not less than 51% of the voting control of the LIC&#59; and 2) the legal ability to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the LIC with which it does not concur&#59; and 3) operational control of the LIC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the LIC is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items 1 and 2 above, proxies representing at least 51% of the votes at any policyholder meeting and shall demonstrate that there is no reason to believe such proxies shall be revoked by sufficient policyholders to reduce such percentage below 51%. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 2 - State Licensure</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The LIC must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life and health insurance company in each state in which the LIC does business.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LIFE INSURANCE COMPANIES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 2 of 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 3 - Records and Examination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The LIC and its sponsoring licensed Plan(s) shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the LIC as may be required in order to establish compliance with the license agreement. The LIC and its sponsoring licensed Plan(s) shall permit BCBSA to examine the affairs of the LIC and shall agree that BCBSA's board may submit a written report to the chief executive officer(s) and the board(s) of directors of the sponsoring Plan(s).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 4 - Mediation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The LIC and its sponsoring Plan(s) shall agree to use the then-current BCBSA mediation and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed controlled affiliate, a licensed Plan or BCBSA.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 5 - Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The LIC shall maintain adequate financial resources to protect its customers and meet its business obligations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 6 - Cooperation with Affiliate License Performance Response Process Protocol</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The LIC and its Sponsoring Plan(s) shall cooperate with BCBSA&#8217;s Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Affiliate License Performance Response Process Protocol (ALPRPP) and in addressing LIC compliance problems identified thereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 1A1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE<br>TRADEMARK LICENSE AGREEMENT<br>FOR LIFE AND DISABILTY INSURANCE PRODUCTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and  ___________________, (&#8220;Life and Disability Controlled Affiliate&#8221;) which is a company offering life and disability insurance products owned and controlled by __________________, ____________, _____________</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">( individually, &#8220;Sponsoring Plan&#8221; and when referred to collectively, &#8220;Sponsoring Plans&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas, BCBSA is the owner of the BLUE CROSS and BLUE SHIELD word and design service marks and any derivatives thereof (&#8220;Licensed Marks&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas, each Sponsoring Plan is licensed separately by BCBSA to use one or more of the Licensed Marks in a particular Service Area&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas, the Sponsoring Plans and the Life and Disability Controlled Affiliate desire that the latter be entitled to use the appropriate Licensed Marks in connection with life and disability insurance products in some or all of such Sponsoring Plans&#8217; Service Areas and in the Service Areas of other Regular Member Plans, as defined in the BCBSA By-laws, (&#8220;Blue Plans&#8221;) consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;GRANT OF LICENSE</font></div><div style="margin-bottom:6pt;padding-left:54.7pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Life and Disability Controlled Affiliate the limited right to use the Licensed Marks in connection with and only in connection with the following life and disability insurance products authorized by state law&#58;&#160; (1) Group&#58;&#160; &#160;Term Life, Long Term Disability, Whole Life, Benefit Life, Universal Life&#59; (2) Individual&#58;&#160; Term Life, Whole Life, Dependent Life, S</font><font style="color:#000080;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ouse Life&#59; (3) Other&#58;&#160; Disability Income, Short Term Disability, Long Term Disability, Income Replacement&#59; and (4) such other life and disability products approved by BCBSA in writing (&#8220;Licensed Products&#8221;) in the Service Areas served by the Sponsoring Plans or in the Service Area or Areas of one or more other licensed Blue Plans, provided that such Blue Plans have consented to such use as authorized by this Agreement. Life and Disability Controlled Affiliate may not use the Licensed Marks in its legal or trade name.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Notwithstanding that the license granted to Life and Disability Controlled Affiliate is a license to use all of the Licensed Marks, Life and Disability Controlled Affiliate may only use those of the Licensed Marks in the Service Area of a Sponsoring Plan or other consenting Blue Plan as described below that such Plan is authorized to use as a Blue Plan pursuant to its separate license agreements with BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate may use the Licensed Marks in the Service Areas of Sponsoring Plans or in the Service Area of a Blue Plan that is not a signatory to this Agreement only after such Sponsoring Plan(s) or non-signatory Blue Plan consents to such use by executing a written consent in substantially the same form as the Consent Agreement attached as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;The following provisions apply with respect to Consent Agreements once such agreements have been fully and properly executed&#58; </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;All sales, marketing and advertising materials developed by and proposed for use by Life and Disability Controlled Affiliate in the Service Area of Sponsoring Plan or consenting Blue Plan (hereinafter, such consenting Sponsoring Plan or consenting Blue Plan collectively referred to &#8220;Consenting Plan(s)&#8221;) must clearly identify the Consenting Plan (for example, a statement on such materials that reads &#8220;This product is offered with the cooperation of Blue Cross and&#47;or Blue Shield of &#91;Geography&#93;&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;To the extent the Consenting Plan has separate divisions or other Affiliates that use the Licensed Marks in distinct geographic areas within its Service Area, consent obtained under this Agreement may be limited to one or more of such specific geographic areas as specified by the Consenting Plan in its signed Consent Agreement.  For purposes of this entire Agreement, all references to the Service Area of a Sponsoring Plan, Blue Plan or Consenting Plan may include the entire Service Area or a distinct geographic area within such Service Area as specified in this Section 1 D (2)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Where BCBSA has licensed two or more Blue Plans to use the same Licensed Marks in the same Service Area, in addition to the requirements set forth in Section D (1) above, the sales, marketing and advertising materials referenced in such section above must be communicated to the Consenting Plan&#8217;s existing and prospective accounts through or with the approval of such Consenting Plan, and the personnel of such Consenting Plan must actively participate in all sales and marketing activities conducted by Life and Disability Controlled Affiliate in the same Service Area, including participating in meetings (whether in-person or via telephone, video or internet conference) with both existing and prospective accounts of the Consenting Plan&#59; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks that the Consenting Plan has been granted by BCBSA the license to use under its Blue Plan license agreements (for example, if a Consenting Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials used by Life and Disability Controlled Affiliate in that Service Area may only contain or reference the Blue Cross Marks and not the Blue Shield Marks).</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;If a Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless BCBSA and the Consenting Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products in the Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a licensee and provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage.  The notification required by this paragraph shall be in writing and in form approved by BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;QUALITY CONTROL</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate agrees to use the Licensed Marks only in relation to the sale, marketing and administration of the Licensed Products and further agrees to be bound by the conditions regarding quality control shown in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the Guidelines to Administer the Standards for Trademark License Agreement for Life and Disability Insurance Products attached thereto. </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate agrees that BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Life and Disability Controlled Affiliate's rendering of service and use of the Licensed Marks.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by  BCBSA) a report to BCBSA demonstrating Life and Disability Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of Exhibit A.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;As used herein, a Life and Disability Controlled Affiliate is defined as&#58;  An entity organized and operated in such a manner that it is 100% owned and controlled by Sponsoring Plans.  Absent written approval by BCBSA of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Life and Disability Controlled Affiliate's governing body having not less than 100% voting control thereof&#59; (b) to exercise operational control with respect to the governance </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">thereof&#59; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate.  In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;SERVICE MARK USE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and shall ensure all uses of the Licensed Marks comply with the BCBSA Brand Regulations, as amended by BCBSA from time to time.  Life and Disability Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Life and Disability Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The license hereby granted to Life and Disability Controlled Affiliate to use the Licensed Marks is and shall be personal to Life and Disability Controlled Affiliate and shall not be assignable by any act of the Life and Disability Controlled Affiliate, directly or indirectly, without the written consent of BCBSA.  Said license shall not be assignable by operation of law, nor shall Life and Disability Controlled Affiliate mortgage or part with possession or control of this license or any right hereunder, and the Life and Disability Controlled Affiliate shall have no right to grant any sublicense to use the Licensed Marks.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;INFRINGEMENTS</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off which may occur in relation to the Licensed Marks.  Life and Disability Controlled Affiliate shall not be entitled to require BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Life and Disability Controlled Affiliate agrees to render to BCBSA, free of charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks by BCBSA.  BCBSA shall have sole control of the defense and resolution of any claim of infringement brought or threatened by others.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;LIABILITY INDEMNIFICATION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate hereby agrees to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of Life and Disability Controlled Affiliate's conduct.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;LICENSE TERM</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods, unless either BCBSA or Life and Disability Controlled Affiliate notifies the other party in writing of the termination hereof at least sixty (60) days prior to expiration of any license period.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement may be terminated by BCBSA for cause at any time provided that Life and Disability Controlled Affiliate has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period).  By way of example and not for purposes of limitation, Life and Disability Controlled Affiliate's failure to abide by the conditions regarding use of the Licensed Marks set forth in Section 1 of this Agreement or the quality control provisions of Section 2 (other than with respect to Section 2 D which is subject to immediate termination as stated in Section 7 C (1) below) shall be considered proper grounds for termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;This Agreement and all of Life and Disability Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall no longer comply with Section 2 D (or Standard No. 1 (Organization and Governance) of Exhibit A)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Any Sponsoring Plan ceases to be authorized to use the Licensed Marks&#59; or</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Appropriate fees for Life and Disability Controlled Affiliate pursuant to Section 8 of this Agreement are more than sixty (60) days in arrears to BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon termination of this Agreement for cause or otherwise, Life and Disability Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of any disagreement between Life and Disability Controlled Affiliate and BCBSA as to whether grounds exist for termination or as to any other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation or mandatory dispute resolution in effect between the parties.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon termination of this Agreement, Licensed Life and Disability Controlled Affiliate shall immediately notify all of its customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA.  BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;ROYALTIES</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">An annual fee of five thousand dollars ($5,000) per license, plus</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">.05% of gross revenue per year from group products sold under the Licensed Marks, plus</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">.5% of gross revenue per year from individual products sold under the Licensed Marks</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated.  Royalties under this formula will be calculated, billed and paid in arrears. </font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life and Disability Controlled Affiliate will promptly and timely transmit to BCBSA all fees owed by Life and Disability Controlled Affiliate as determined by the above formula. </font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between any Sponsoring Plan and Life and Disability Controlled Affiliate or between among them and&#47;or BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VOTING </font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan.  For all other votes of the Plans, the </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.  Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;NOTICES AND CORRESPONDENCE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;COMPLETE AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof.  This Agreement may only be amended by&#58; (a) a writing signed by all parties&#59; or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) a writing approved by the affirmative vote of three-fourths of the Blue Plans and three-fourths of the total then current weighted vote of all the Blue Plans as officially recorded by the BCBSA Corporate Secretary. Upon such adoption by the Blue Plans, this Agreement and all other Trademark License Agreements for Life and Disability Insurance Products then in effect shall simultaneously be amended.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;SEVERABILITY</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;NONWAIVER</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of the Life and Disability Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GOVERNING LAW</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last signature written below.</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;_______________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life and Disability Controlled Affiliate&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;_______________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sponsoring Plan&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sponsoring Plan&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;_______________________________</font></div><div><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Add other Sponsoring Plans as necessary&#93; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE <br>AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FOR LIFE AND DISABILITY INSURANCE PRODUCTS<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 1 of 2</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any Life and Disability Controlled Affiliate licensed under the Trademark License Agreement for Life and Disability Insurance Products (&#8220;licensee&#8221;) shall be organized and operated in such a manner that it is an entity organized and operated in such a manner that it is 100% owned and controlled by Sponsoring Plans.  Absent written approval by BCBSA of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-owned subsidiaries&#58; (a) to select members of the Life and Disability Controlled Affiliate's governing body having not less than 100% voting control thereof&#59; (b) to exercise operational control with respect to the governance thereof&#59; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate.  In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 2 - State Licensure</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The licensee must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life company in each state in which the licensee does business.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 3 - Records and Examination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The licensee shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the licensee as may be required in order to establish compliance with the Agreement.  The licensee shall permit BCBSA to examine the affairs of the licensee and shall agree that BCBSA's board may submit a written report to the chief executive officer(s) and the board(s) of directors of the Sponsoring Plan(s).</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 4 - Mediation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The licensee, its Sponsoring Plan(s) and all consenting Blue Plans shall agree to use the then-current BCBSA mediation and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed Life and Disability Controlled Affiliate, a Sponsoring Plan and or consenting Blue Plan or BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE <br>AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS <br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 2 of 2</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 5 - Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The licensee shall maintain adequate financial resources to protect its customers and meet its business obligations.  </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 6 - Cooperation with BCBSA Governance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The licensee shall cooperate with BCBSA&#8217;s Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of and in addressing licensee compliance problems that may be identified in connection with the operation or administration of the Trademark License Agreement for Life and Disability Insurance Products. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Consent Agreement is made and entered into by and among the undersigned Blue Plan, and ____________________ (&#8220;Life and Disability Controlled Affiliate&#8221;), and the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;) and shall be deemed effective on ______________________ (&#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas, BCBSA owns the Blue Cross and Blue Shield word and design service marks and any derivative mark thereof (the &#8220;Brands&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas, the undersigned Blue Plan is licensed to use one or more of the Brands within a specific geographic area (&#8220;Service Area&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas Life and Disability Controlled Affiliate is licensed by BCBSA to use one or more of the Brands to offer life and disability insurance products (&#8220;Products&#8221;) as defined and authorized in the Trademark License Agreement for Life and Disability Insurance Products (&#8220;Life and Disability License Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas neither the Blue Plan nor its affiliates offer the Products under any of the Brands in such Blue Plan&#8217;s Service Area or portion thereof where Blue Plan has consented to sale of the Products by Life and Disability Controlled Affiliate&#59; and </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whereas BCBSA and the undersigned Blue Plan desire to consent to Life and Disability Controlled Affiliate&#8217;s use of the Brands in Blue Plan&#8217;s Service Area consistent with the terms of the Life and Disability License Agreement and this Consent Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Now, therefore, in consideration of the obligations and conditions stated in this Agreement, Blue Plan, Life and Disability Controlled Affiliate and BCBSA agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate may market, sell, administer and underwrite the Products in Blue Plan&#8217;s Service Area under the Brands licensed to Blue Plan in such Service Area subject to the terms of this Consent Agreement, the Life and Disability License Agreement and Blue Plan&#8217;s license agreement(s) with BCBSA.  Life and Disability Controlled Affiliate&#8217;s rights under the Brands to offer the Products under the Brands are limited to offering the Products only under the Brand(s) licensed to the consenting Blue Plan.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall work with the undersigned Blue Plan to develop a written sales and marketing agreement that identifies the relationship between it and Blue Plan for the sales, marketing and customer service for the Products.  The term of the sales and marketing agreement shall be the same as the term of this Consent Agreement. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;All sales, marketing and advertising materials developed by and proposed for use by Life and Disability Controlled Affiliate in a consenting Blue Plan&#8217;s Service Area must clearly identify the consenting Blue Plan (for example, a statement on such materials that reads &#8220;This product is offered with the cooperation of Blue Cross and&#47;or Blue Shield of &#91;Geography&#93;&#8221;)&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate may use the Brands to sell the Products in the following Service Area or portion thereof as designated by Blue Plan&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;___________________________________________________</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;If two or more Blue Plans to use the same Licensed Marks in the same Service Area, Life and Disability Controlled Affiliate shall work with the consenting Blue Plan in the following manner&#58;  (a) the sales, marketing and advertising materials must be communicated to the consenting Blue Plan&#8217;s existing and prospective accounts through or with the approval of such Blue Plan, and (b) the personnel of such Blue Plan must actively participate in all sales and marketing activities conducted by Life and Disability Controlled Affiliate in the same Service Area, including participating in meetings (whether in-person or via telephone, video or internet conference) with both existing and prospective accounts of the consenting Blue Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks that the consenting Blue Plan has been granted by BCBSA the license to use under its license agreement (for example, if a consenting Blue Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials used by Life and Disability Controlled Affiliate in that Service Area may only contain or reference the Blue Cross Marks and not the Blue Shield Marks). </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;If this Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless each BCBSA and the Blue Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products in the Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage.  The notification required by this paragraph shall be in writing and in form approved by BCBSA. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;The term of this Consent Agreement shall be one year from the Effective Date.  Unless either Blue Plan or Life and Disability Controlled Affiliate provides the other party with written notice of its desire not to renew this Consent Agreement at least 60 days prior to expiration of the term or any extended term or unless terminated as provided in Paragraph 9 below, this Consent Agreement shall automatically renew for subsequent one year periods. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;This Consent Agreement may be terminated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Upon mutual written consent of Life and Disability Controlled Affiliate and Blue Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;By Blue Plan or Life and Disability Controlled Affiliate upon 60 days advance written notice to the non-terminating party and BCBSA&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;By Blue Plan immediately if Life and Disability Controlled Affiliate does not comply with this Consent Agreement or the sales protocol agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;This Consent Agreement shall automatically terminate if Blue Plan&#8217;s primary licensee agreement terminates for any reason or if the Life and Disability License Agreement terminates for any reason. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreed and Accepted by&#58;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Blue Plan&#93;&#58;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_____________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;____________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION&#58;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LIFE AND DISABILITY CONTROLLED AFFILIATE&#58;</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_______________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;_____________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 1B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE SHIELD <br>CONTROLLED AFFILIATE LICENSE AGREEMENT<br>APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Adopted by Member Plans at their June 16, 2022 meeting)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) and __________ (&#8220;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Cross Plan(s), known as ____________  (&#34;Controlling Plans&#34;), each of which is also a Party signatory hereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) to offer Medicare Advantage PPO products in geographic regions designated by CMS (hereafter &#8220;regional MAPPO products&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE SHIELD Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE SHIELD in a trade name (&#34;Licensed Name&#34;) to offer regional MAPPO products in a region that includes the Service Areas, or portions thereof, of more than one Controlling Plan&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;GRANT OF LICENSE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of regional MAPPO products and related services.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant of rights is non-exclusive and is limited to the following states&#58; _________________ (the &#8220;Region&#8221;).  Controlled Affiliate may use the Licensed</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marks and Name in its legal name on the following conditions&#58; (i) the legal name must be approved in advance, in writing, by BCBSA&#59; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the Service Area of such Controlling Plan&#59; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;QUALITY CONTROL</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to comply with all applicable federal, state and local laws.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that the Controlling Plans and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160; to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through">  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div style="padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;SERVICE MARK USE</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name.  The Controlled Affiliate further recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA.  Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in connection with the sale, marketing and administration of regional MAPPO products and related services.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any Controlling Plan or BCBSA.  This Agreement and all rights and duties hereunder are personal to Controlled Affiliate. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;INFRINGEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.  Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;LIABILITY INDEMNIFICATION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of services under the Licensed Marks and Name.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;LICENSE TERM</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the provisions herein.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; (i) any one of the Controlling Plans ceases to be authorized to use the Licensed Marks and Name&#59; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Shield License Agreement any one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C. &#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling Plans an opportunity to be heard and to present their response to the Board for&#58;  (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control standards of this </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement&#59; or (2) failure to comply with the &#34;Organization and Governance&#34; quality control standard of this Agreement&#59; or (3) impending financial insolvency&#59; or (4) failure to comply with any of the applicable requirements of Standards 2, 3, 4, or 5 of attached Exhibit A&#59; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E)&#59; or (6) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and&#47;or the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance.   If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof.   Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution.  All other disputes between or among BCBSA, any of the Controlling Plans and&#47;or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution.  The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties.  Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with item 2(E) above&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA&#59; or</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Any of the following events occur&#58;  (i) a voluntary petition shall be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.  Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate&#8217;s property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a licensee of BCBSA and, if directed by the Association&#8217;s Board of Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage.  The notification required by this paragraph shall be in writing and in a form approved by BCBSA.  The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan&#8217;s license pursuant to Paragraph 15(a)(x)(ii) of the Blue Shield License Agreement, the notices, national account listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the geographic area for which the Controlling Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name.  The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA.  This notice shall be mailed within 15 days after termination.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the national account and the Controlled Affiliate&#8217;s role therein.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan&#8217;s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate&#59; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total number of Licensed Enrollees in such geographic area.  Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the termination began.  Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA&#8217;s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this subparagraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans)&#59; measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course of business.  This payment shall not be due in connection with transactions exclusively by or among Plans (including the Controlling Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage.  In the event that the Controlled Affiliate&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and&#47;or the Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with reestablishing the terminated Controlling Plan&#8217;s Service Area or the Region, including any payments made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable in a court of competent jurisdiction.  As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-9-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this Agreement unless a Controlling Plan&#8217;s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of such Controlling Plan&#8217;s license agreement upon the required 6 month written notice.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Controlling Plans, and any other </font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.  Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties agree that any disputes between or among them or between or among any of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are subject to the </font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling Plan&#8217;s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by reference as though fully set forth herein.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;LICENSE FEE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit B.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;NOTICES AND CORRESPONDENCE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-10-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;COMPLETE AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof.  This Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;SEVERABILITY</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;NONWAIVER</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14A.&#160;&#160;&#160;&#160;VOTING</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan.  For all other votes of the Plans, the Plan shall have one vote.  For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.  Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-11-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;GOVERNING LAW</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;HEADINGS</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation hereof.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-12-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last signature written below.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled Affiliate&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;________________________________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;______________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlling Plan&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;_______________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlling Plan&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;_______________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;________________________________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS <br>APPLICABLE TO REGIONAL MEDICARE<br>ADVANTAGE PPO PRODUCTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">June 2022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The standards for licensing Controlled Affiliates for Medicare Advantage PPO Products are established by BCBSA and are subject to change from time-to-time upon the affirmative vote of three-fourths (3&#47;4) of the Plans and three-fourths (3&#47;4) of the total weighted vote.  Each Controlling Plan is required to use a standard Controlled Affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the license standards.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through">  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 2 - Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.  </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 3 - State Licensure&#47;Certification</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 4 - Certain Disclosures</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the structure of the Blue Cross and Blue Shield System&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the independent nature of every licensee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 5 - Reports and Records for Controlled Affiliates</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate and&#47;or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 6 -  Best Efforts</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Marks.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 7 -  Participation in Certain National Programs </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall effectively and efficiently participate in certain national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the Controlled Affiliate&#8217;s service area.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">National program requirements include&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Inter-Plan Teleprocessing System (ITS)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 8 -  Participation in Master Business Associate Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as defined by the Business Associate Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of  November 15, 2007</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROYALTY FORMULA FOR SECTION 9 OF THE <br>CONTROLLED AFFILIATE LICENSE AGREEMENTS <br>APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the Controlled Affiliate's members using the Marks on regional MAPPO products and related services as reported on the Quarterly Enrollment Report with BCBSA.  The payment by each Controlling Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 14, 2007</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 1C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE SHIELD <br>CONTROLLED AFFILIATE LICENSE AGREEMENT<br>APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION <br>DRUG PLAN PRODUCTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Adopted by Member Plans at their June 16, 2022 meeting)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement by and among Blue Cross and Blue Shield Association (&#34;BCBSA&#34;) <br>and ___________ (&#8220;Controlled Affiliate&#34;), a Controlled Affiliate of the Blue Cross Plan(s), known as ____________  (&#34;Controlling Plans&#34;), each of which is also a Party signatory hereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) to offer Medicare Part D Prescription Drug Plan products in geographic regions designated by CMS (hereafter &#8220;regional PDP products&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE SHIELD Design service marks (collectively the &#34;Licensed Marks&#34;) as service marks and be entitled to use the term BLUE SHIELD in a trade name (&#34;Licensed Name&#34;) to offer regional PDP products in a region that includes the Service Areas, or portions thereof, of more than one Controlling Plan&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;GRANT OF LICENSE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of regional PDP products and related services.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant of rights is non-exclusive and is limited to the following states&#58; ___________________ (the &#8220;Region&#8221;).  Controlled Affiliate may use the Licensed</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marks and Name in its legal name on the following conditions&#58; (i) the legal name must be approved in advance, in writing, by BCBSA&#59; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the Service Area of such Controlling Plan&#59; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;QUALITY CONTROL</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate agrees to comply with all applicable federal, state and local laws.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate agrees that the Controlling Plans and&#47;or BCBSA may, from time-to-time, upon reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160; to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through">  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;SERVICE MARK USE</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name.  The Controlled Affiliate further recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA.  Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in connection with the sale, marketing and administration of regional PDP products and related services.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;SUBLICENSING AND ASSIGNMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any Controlling Plan or BCBSA.  This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;INFRINGEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.  Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.  Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;LIABILITY INDEMNIFICATION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of services under the Licensed Marks and Name.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;LICENSE TERM</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the provisions herein.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58; (i) any one of the Controlling Plans ceases to be authorized to use the Licensed Marks and Name&#59; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Shield License Agreement any one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C. &#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling Plans an opportunity to be heard and to present their response to the Board for&#58;  (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control standards of this Agreement&#59; or (2) failure to comply with the &#34;Organization and Governance&#34; quality control standard of this Agreement&#59; or (3) impending financial insolvency&#59; or (4) failure to comply with any of the applicable requirements of Standards 2, 3, 4, or 5 of attached Exhibit A&#59; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E)&#59; or (6) such other reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and&#47;or the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty day period and continue diligent efforts to </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance.   If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof.   Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution.  All other disputes between or among BCBSA, any of the Controlling Plans and&#47;or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution.  The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary penalties.  Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by any party or entity in the event that&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate shall no longer comply with item 2(E) above&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA&#59; or </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Any of the following events occur&#58;  (i) a voluntary petition shall be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-6-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association&#8217;s Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.  Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate&#8217;s property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a licensee of BCBSA and, if directed by the Association&#8217;s Board of Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage.  The notification required by this paragraph shall be in writing and in a form approved by BCBSA.  The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan&#8217;s license pursuant to Paragraph 15(a)(x)(ii) of the Blue Shield License Agreement, the notices, national account listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the geographic area for which the Controlling Plan&#8217;s license to use the Licensed Names and Marks is terminated&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-7-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name.  The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA.  This notice shall be mailed within 15 days after termination.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the national account and the Controlled Affiliate&#8217;s role therein.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan&#8217;s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate&#59; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total number of Licensed Enrollees in such geographic area.  Licensed Enrollee means each and every person and covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the termination began.  Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA&#8217;s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided such equivalent is approved for purposes of this subparagraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans)&#59; measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course of business.  This payment shall not be due in connection with transactions exclusively by or among Plans (including the Controlling Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-8-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage.  In the event that the Controlled Affiliate&#8217;s license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and&#47;or the Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with reestablishing the terminated Controlling Plan&#8217;s Service Area or the Region, including any payments made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable in a court of competent jurisdiction.  As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction from entry into any transaction which would result in a termination of this Agreement unless a Controlling Plan&#8217;s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of such Controlling Plan&#8217;s license agreement upon the required 6 month written notice.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal proceedings, including but not limited to&#58; outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.  Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-9-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties agree that any disputes between or among them or between or among any of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling Plan&#8217;s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by reference as though fully set forth herein.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;LICENSE FEE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit B.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;NOTICES AND CORRESPONDENCE</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;COMPLETE AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement contains the complete understandings of the parties in relation to the subject matter hereof.  This Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-10-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;SEVERABILITY</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;NONWAIVER</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14A.&#160;&#160;&#160;&#160;VOTING</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all provisions of this Agreement referring to voting, the term &#8216;Plans&#8217; shall mean all entities licensed under the Blue Cross License Agreement and&#47;or the Blue Shield License Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.  For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan.  For all other votes of the Plans, the Plan shall have one vote.  For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of&#58; (i) 6&#47;52 or more of the Plans (rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question&#59; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.  Notwithstanding the foregoing provision, if there are thirty-five (35) Plans, the requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;GOVERNING LAW</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Illinois.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;HEADINGS</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation hereof.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-11-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last signature written below.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled Affiliate&#58; </font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;______________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlling Plan&#58; </font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;_______________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlling Plan&#58; </font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;_______________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLUE CROSS AND BLUE SHIELD ASSOCIATION</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;________________________________________</font></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-12-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTROLLED AFFILIATE LICENSE STANDARDS <br>APPLICABLE TO REGIONAL MEDICARE<br>PART D PRESCRIPTION DRUG PLAN PRODUCTS <br>June 2022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The standards for licensing Controlled Affiliates for Medicare Part D Prescription Drug Plan Products are established by BCBSA and are subject to change from time-to-time upon the affirmative vote of three-fourths (3&#47;4) of the Plans and three-fourths (3&#47;4) of the total weighted vote.  Each Controlling Plan is required to use a standard Controlled Affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the license standards.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 1 - Organization and Governance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following requirements&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Controlled Affiliate is owned or controlled by two or more Controlling Plans&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160; to select members of the Controlled Affiliate&#8217;s governing body having not less than 100% voting control thereof&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through">  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not concur&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;exercise control over the policy and operations of the Controlled Affiliate&#59; and</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-13-</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate&#8217;s establishing or governing documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;change its legal and&#47;or trade names&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;change the geographic area in which it operates (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;change any of the type(s) of businesses in which it engages (except such approval shall not be required with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks and Name.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit Controlled Affiliate.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 2 - Financial Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its contractual obligations to its customers.  </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 3 - State Licensure&#47;Certification</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-14-</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A (continued)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 4 - Certain Disclosures</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the structure of the Blue Cross and Blue Shield System&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the independent nature of every licensee.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 5 - Reports and Records for Controlled Affiliates</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Controlled Affiliate and&#47;or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.    </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 6 -  Best Efforts</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Marks.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standard 7 -  Participation in Master Business Associate Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as defined by the Business Associate Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-15-</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROYALTY FORMULA FOR SECTION 9 OF THE <br>CONTROLLED AFFILIATE LICENSE AGREEMENTS <br>APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the Controlled Affiliate's members using the Marks on regional PDP products and related services as reported on the Quarterly Enrollment Report with BCBSA.  The payment by each Controlling Plan of its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 14, 2007</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-16-</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Membership Standards<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 1 of 5</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preamble</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Membership Standards apply to all organizations seeking to become or to continue as Regular Members of the Blue Cross and Blue Shield Association.  Any organization seeking to become a Regular Member must be found to be in substantial compliance with all Membership Standards at the time membership is granted and the organization must be found to be in substantial compliance with all Membership Standards for a period of two (2) years preceding the date of its application.  If Membership is sought by an entity which controls or is controlled by one or more Plans, such compliance shall be determined on the basis of compliance by such Plan or Plans.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Regular Member Plans shall have authority to interpret these Standards.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Regular Member Plan that operates as a &#8220;Shell Holding Company&#8221; is defined as an entity that assumes no underwriting risk and has less than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) and less than 5% of the consolidated enterprise net general and administrative expenses.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Regular Member Plan that operates as a &#8220;Hybrid Holding Company&#8221; is defined as an entity that assumes no underwriting risk and has either more than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) or more than 5% of the consolidated enterprise net general and administrative expenses.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 1&#58; &#160;&#160;&#160;&#160;A Plan shall maintain a governing Board, which shall control the Plan and ensure that the Plan follows appropriate practices of corporate governance.  A Plan's Board shall not be controlled by any special interest group, shall make an annual determination that a majority of its directors are independent, and shall act in the best interest of its Corporation and its customers.  The Board shall be composed of a majority of persons other than providers of health care services, who shall be known as public members.  A public member shall not be an employee of or have a financial interest in a health care provider, nor be a member of a profession which provides health care services.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 15, 2007</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Membership Standards<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 2 of 5</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 2&#58;&#160;&#160;&#160;&#160;A Plan shall furnish to the Association on a timely and accurate basis reports and records relating to compliance with these Standards and the License Agreements between the Association and the Plans.  Such reports and records are the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:99pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;BCBSA Membership Information Request&#59;</font></div><div style="margin-bottom:12pt;padding-left:99pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Triennial trade name and service mark usage material, including disclosure material under Standard 7&#59;</font></div><div style="margin-bottom:12pt;padding-left:99pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Changes in the governance of the Plan, including changes in a Plan's Charter, Articles of Incorporation, or Bylaws, changes in a Plan's Board composition, or changes in the identity of the Plan's Principal Officers&#59;</font></div><div style="margin-bottom:12pt;padding-left:99pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Written notice to BCBSA as soon as practicable but no later than 30 days after receipt of any litigation filed against the Plan or any of its licensed controlled affiliates that includes allegations or claims that directly reference and seeks to enjoin or otherwise challenge the License Agreements, the structure of the Blue system, exclusive service areas, BCBSA, or any BCBSA rule, regulation, policy or Standard (Qualifying Litigation).</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Notice of Qualifying Litigation to BCBSA must include (1) Name of the Case&#59; (2) Case Number&#59; (3) Location&#47;Where Case Pending&#59; and (4) Date Plan Received, and be provided to BCBSA Senior Vice President, General Counsel and Corporate Secretary.</font></div><div style="margin-bottom:12pt;padding-left:99pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Quarterly Financial Report, Semi-annual &#8220;Health Risk-Based Capital (HRBC) Report&#8221; as defined by the NAIC, Annual Budget, Annual Certified Audit Report, Insurance Department Examination Report, Annual Statement filed with State Insurance Department (with all attachments), Plan, Subsidiary and Affiliate Report (new version starting for period ended 12&#47;31&#47;20 and thereafter)&#59; and</font></div><div style="padding-left:135pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Plans that are a Shell Holding Company as defined in the Preamble hereto are required to furnish only a calendar year-end &#8220;Health Risk-Based Capital (HRBC) Report&#8221; as defined by the NAIC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 17, 2022</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Membership Standards<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3 of 5</font></div><div style="margin-bottom:12pt;padding-left:99pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Quarterly Enrollment Report, Quarterly Member Touchpoint Measures Index (MTM) through 12&#47;31&#47;2011, and Semi-annual MTM Index starting 1&#47;1&#47;2012 and thereafter. </font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of MTM reporting only, a Plan shall file a separate MTM report for each Geographic Market.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 3&#58;&#160;&#160;&#160;&#160;A Plan shall be operated in a manner that provides reasonable financial assurance that it can fulfill its contractual obligations to its customers.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 4&#58;&#160;&#160;&#160;&#160;A Plan shall be operated in a manner responsive to customer needs and requirements.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 5&#58;&#160;&#160;&#160;&#160;A Plan shall effectively and efficiently participate in each national program as from time to time may be adopted by the Member Plans for the purposes of providing portability of membership between the Plans and ease of claims processing for customers receiving benefits outside of the Plan's Service Area. </font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such programs are applicable to Blue Cross and Blue Shield Plans, and include&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Inter-Plan Teleprocessing System (ITS)&#59;  </font></div><div style="margin-bottom:12pt;padding-left:99.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;BlueCard Program&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;National Account Programs&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April 14, 2003&#59; and </font></div><div style="margin-bottom:12pt;padding-left:99.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Inter-Plan Medicare Advantage Program.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 17, 2022</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Membership Standards<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 4 of 5</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 6&#58;&#160;&#160;&#160;&#160;In addition to requirements under the national programs listed in Standard 5&#58; Participation in National Programs, a Plan shall take such action as required to ensure its financial performance in programs and contracts of an inter-Plan nature or where the Association is a party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 7&#58;&#160;&#160;&#160;&#160;A Plan shall make adequate disclosure in contracting with third parties and in disseminating public statements of (i) the structure of the Blue Cross and Blue Shield System, (ii) the independent nature of every Plan, and (iii) the Plan's financial condition.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 8&#58;&#160;&#160;&#160;&#160;A Plan shall cooperate with the Association's Board of Directors and its Brand Enhancement &#38; Protection Committee in the administration of the Plan Performance Response Process and in addressing Plan performance problems identified thereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 9&#58;&#160;&#160;&#160;&#160;A Plan shall obtain a rating of its financial strength from an independent rating agency approved by the Association's Board of Directors for such purpose.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 10&#58;&#160;&#160;&#160;&#160;Notwithstanding any other provision in this License Agreement, during each year, a Plan and its Controlled Affiliate(s) engaged in providing licensable services (excluding Life Insurance and Charitable Foundation Services) shall use their best efforts to promote and build the value of the Blue Shield Marks.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 11&#58;&#160;&#160;&#160;&#160;Neither a Plan nor any Larger Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to obtain control of the Plan or Larger Controlled Affiliate or to acquire a substantial portion of its assets related to licensable services.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2005</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Membership Standards<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 5 of 5</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 12&#58;&#160;&#160;&#160;&#160;No provider network, or portion thereof, shall be rented or otherwise made available to a National Competitor if the Licensed Marks or Names are used in any way with such network. </font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A provider network may be rented or otherwise made available, provided there is no use of the Licensed Marks or Names with respect to the network being rented.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Standard 13&#58;&#160;&#160;&#160;&#160;Each Plan shall operate in a manner to reasonably&#58; 1) protect the security and confidentiality of Personally Identifiable Information (PII) and Protected Health Information (PHI)&#59; 2) protect the Brands from reputational damage&#59; and 3) cooperate with BCBSA and other Plans if a data security incident or data breach occurs.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 18, 2015</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 3</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GUIDELINES WITH RESPECT TO USE OF <br>LICENSED NAME AND MARKS IN CONNECTION WITH NATIONAL ACCOUNTS<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 1 of 3</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The strength of the Blue Cross&#47;Blue Shield National Accounts mechanism, and the continued provision of cost effective, quality health care benefits to National Accounts, are predicated on locally managed provider networks coordinated on a national scale in a manner consistent with effective service to National Account customers and consistent with the preservation of the integrity of the Blue Cross&#47;Blue Shield system and the Licensed Marks. These guidelines shall be interpreted in keeping with such ends.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;A National Account is an entity with employee and&#47;or retiree locations in more than one Plan's Service Area. Unless otherwise agreed, a National Account is deemed located in the Service Area in which the corporate headquarters of the National Account is located. A local plant, office or division headquarters of an entity may be deemed a separate National Account when that local plant, office or division headquarters 1) has employee locations in more than one Service Area, and 2) has independent health benefit decision-making authority for the employees working at such local plant, office or division headquarters and for employees working at other locations outside the Service Area.  In such a case, the local plant, office or division headquarters is a National Account that is deemed located in the Service Area in which such local plant, office or division headquarters is located.  The Control Plan of a National Account is the Plan in whose Service Area the National Account is located. A participating (&#34;Par&#34;) Plan is a Plan in whose Service Area the National Account has employee and&#47;or retiree locations, but in which the National Account is not located.  In the event that a National Account parent company consolidates health benefit-decision making for itself and its wholly-owned subsidiary companies, the parent company and the subsidiary companies shall be considered one National Account.  The Control Plan for such a National Account shall be the Plan in whose Service Area the parent company headquarters is located.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The National Account Guidelines enunciated herein below shall be applicable only with respect to the business of new National Accounts acquired after January 1, 1991.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Control Plans shall utilize National Account identification cards complying with then currently effective BCBSA graphic standards in connection with all National Accounts business to facilitate administration thereof, to minimize subscriber and provider confusion, and to reflect a commitment to cooperation among Plans.&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 12, 2003</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 3</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 2 of 3</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Disputes among Plans and&#47;or BCBSA as to the interpretation or implementation of these Guidelines or as to other National Accounts issues shall be submitted to mediation and mandatory dispute resolution as provided in the License Agreement. For two years from the effective date of the License Agreement, however, such disputes shall be subject to mediation only, with the results of such mediation to be collected and reported in order to establish more definitive operating parameters for National Accounts business and to serve as ground rules for future binding dispute resolution.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;The Control Plan may use the BlueCard Program (as defined by IPPC) to deliver benefits to employees and non-Medicare eligible retirees in a Participating Plan&#8217;s service area if an alternative arrangement with the Participating Plan cannot be negotiated.  The Participating Plan&#8217;s minimum servicing requirement for those employees and non-Medicare retirees in its service area is to deliver benefits using the BlueCard Program.  Account delivery is subject to the policies, provisions and procedures of the BlueCard Program.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;For provider payments in a Participating Plan&#8217;s area (on non-BlueCard claims), payment to the provider may be made by the Participating Plan or the Control Plan at the Participating Plan's option. If the Participating Plan elects to pay the provider, it may not withhold payment of a claim verified by the Control Plan or its designated processor, and payment must be in conformity with service criteria established by the Board of Directors of BCBSA (or an authorized committee thereof) to assure prompt payment, good service and minimum confusion with providers and subscribers. The Control Plan, at the Participating Plan's request, will also assure that measures are taken to protect the confidentiality of the data pertaining to provider reimbursement levels and profiles.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 14, 1996</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 3</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3 of 3</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;The Control Plan, in its financial agreements with a National Account, is expected to reasonably reflect the aggregate amount of differentials passed along to the Control Plan by all Participating Plans in a National Account.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Other than in contracting with health care providers or soliciting such contracts in areas contiguous to a Plan's Service Area in order to serve its subscribers or those of its licensed Controlled Affiliate residing or working in its Service Area, a Control Plan may not use the Licensed Marks and&#47;or Name, as a tag line or otherwise, to negotiate directly with providers outside its Service Area.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 13, 2003</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GOVERNMENT PROGRAMS AND CERTAIN OTHER USES<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 1 of 14</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;A Plan and its licensed Controlled Affiliate may use the Licensed Marks and Name in bidding on and executing a contract to serve a Government Program, and in thereafter communicating with the Government concerning the Program. With respect, however, to such contracts entered into after the 1st day of January, 1991, the Licensed Marks and Name will not be used in communications or transactions with beneficiaries or providers in the Government Program located outside a Plan's Service Area, unless the Plan can demonstrate to the satisfaction of BCBSA's governing body that such a restriction on use of the Licensed Marks and Name will jeopardize its ability to procure the contract for the Government Program. As to both existing and future contracts for Government Programs, Plans will discontinue use of the Licensed Marks and Name as to beneficiaries and Providers outside their Service Area as expeditiously as circumstances reasonably permit. Effective January 1, 1995, except as provided in the first sentence above, all use by a Plan of the Licensed Marks and Name in Government Programs outside of the Plan's Service Area shall be discontinued. Incidental communications outside a Plan's Service Area with resident or former resident beneficiaries of the Plan, and other categories of necessary incidental communications approved by BCBSA, are not prohibited.  For purposes of this Paragraph 1, the term &#8220;Government Programs&#8221; shall mean Medicare Part A, Medicare Part B and other non-risk government programs.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In connection with activity otherwise in furtherance of the License Agreement, a Plan and its Controlled Affiliates that are licensed to use the Licensed Marks and Name in its Service Area pursuant to the Controlled Affiliate License Agreements authorized in clauses a) through c) of Paragraph 2 of the Plan&#8217;s License Agreement with BCBSA may use the Licensed Marks and Name outside the Plan&#8217;s Service Area in the following circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Common Business Communications</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services)&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;distributing business cards other than in marketing and selling&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c. &#160;&#160;&#160;&#160;advertising in publications or electronic media solely to persons for employment&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 19, 2014</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 2 of 14</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;Marketing Spillover</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a. &#160;&#160;&#160;&#160;advertising in print, electronic or other media which serve, as a substantial market, the Service Area of the Plan or licensed Controlled Affiliate, provided that no Plan or Controlled Affiliate may advertise outside its Service Area on the national broadcast and cable networks and that advertisements in national print media are limited to the smallest regional edition encompassing the Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b. &#160;&#160;&#160;&#160;advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Plan's Service Area or that of a licensed Controlled Affiliate&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;Provider Contracting</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;contracting with health care providers or soliciting such contracts in areas contiguous to the Plan's Service Area in order to serve its subscribers or those of such licensed Controlled Affiliates residing or working in its service area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b. &#160;&#160;&#160;&#160;issuing a small sign containing the legal name or trade name of the Plan or such licensed Controlled Affiliates for display by a provider to identify the latter as a participating provider of the Plan or Controlled Affiliate&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;negotiating case-specific reimbursement rates with a provider that does not have a contract applicable to a specific member&#8217;s services rendered or to be rendered with the Licensee (or any of the Licensees in the case of overlapping Service Areas) in whose Service Area the health care provider is located, so long as</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the Licensee engaging in the negotiations complies with all applicable Inter-Plan Programs Policies and Provisions and Brand Regulations related to case-specific rate negotiations, and </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the Licensee (or all Licensees in the case of overlapping Service Areas) in whose Service Area the health care provider is located provides consent before negotiations commence.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of January 22, 2019</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;contracting with a pharmacy management organization (&#8220;Pharmacy Intermediary&#8221;) to gain access to a national or regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in contracting with the pharmacy providers in such network.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of January 22, 2019</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 4 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided that (1) the Plan and the Controlled Affiliate may not contract directly with pharmacists or pharmacy stores outside the Plan&#8217;s Service Area, and (2) neither the Plan&#8217;s or the Controlled Affiliate&#8217;s name nor the Licensed Marks or Name may be posted or otherwise displayed at or by any pharmacy store outside the Plan&#8217;s Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;contracting with a dental management organization (&#8220;Dental Intermediary&#8221;) to gain access to a national or regional dental network to deliver a routine dental benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in contracting with the dental providers in such network&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;contracting with a vision management organization (&#8220;Vision Intermediary&#8221;) to gain access to a national or regional vision network to deliver a routine vision benefit for all of the Plan&#8217;s or licensed Controlled Affiliate&#8217;s members nationwide, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in contracting with the vision providers in such network&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are collected within the Plan&#8217;s Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;contracting with a durable medical equipment or home medical equipment company for durable medical equipment and supplies and home medical equipment and supplies that are shipped to a location within the Plan&#8217;s Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are ordered by a health care professional located within the Plan&#8217;s Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;contracting with a company that operates provider sites in the Plan&#8217;s Service Area, provided that the contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Plan&#8217;s Service Area&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 5 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;contracting with a company that makes health care professionals available in the Plan&#8217;s Service Area (e.g., traveling home health nurse), provided that the contract is solely for services rendered by health care professionals who are located within the Plan&#8217;s Service Area.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;Permitting Control&#47;Home Plans&#8217; ability to resolve members&#8217; service issues requiring outreach to out-of-area providers as set forth in the Inter-Plan Programs and Inter-Plan Medicare Advantage Program Policies.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;contracting with national telemedicine and virtual healthcare (i.e., telehealth providers) companies nationally for all virtual-only health care services in accordance with Inter-Plan Programs Policies and Provisions.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;Services to National Accounts</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee (as those terms are defined in the Inter-Plan Programs Policies and Provisions (&#8220;IP Policies&#8221;)) to offer Blue-branded Health Coverage to the National Account, offering Blue-branded Health and Wellness Programs to all members of the National Account, including members who have not enrolled in the Blue-branded Health Coverage (&#8220;non-Blue Health Coverage members&#8221;), provided that&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Plan and&#47;or Licensed Controlled Affiliate has no contact or interaction with providers outside of the Plan&#8217;s Service Area, except as specifically provided in the IP Policies and in 2.4(b)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if in accordance with IP Policies another Licensee is soliciting or servicing under the Brands a local plant, office or division of the account that is outside of the Plan&#8217;s Service Area, the Plan and&#47;or licensed Controlled Affiliate may not offer Blue-branded Health and Wellness Programs to any employees working at such local plant, office or division without the consent of such other Licensee&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;if the Plan and&#47;or licensed Controlled Affiliate provides an information card to the non-Blue Health Coverage members, the card may not display the Symbols in the masthead, must contain a prominent disclosure conveying that it is not a health insurance card, and otherwise must be designed so that it is dissimilar to a Blue member identification card. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of June 16, 2022</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 6 of 14</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;Services to National Accounts (continued)</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this subparagraph a, the following definitions apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Health and Wellness Program&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall mean a program that includes at least one of the following elements or a related element&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Health Risk Assessment and&#47;or Preventive Screenings</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Exercise and Fitness Programs</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Health and Wellness Events (e.g., attendance at a health fair, a 5K walk)</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Nutrition and Weight Management</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Health Education (e.g., smoking cessation classes)</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Prenatal and Parenting Education</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Disease or Chronic Condition Management </font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The above listing is intended to represent examples of the types of programs that may be offered, and other programs, including those offered through different media such as the internet or telephonically, may also be deemed Health and Wellness programs.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Health Coverage&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall mean providing or administering medical, surgical, hospital, major medical, or catastrophic coverage, or any HMO, PPO, POS or other managed care plan for the foregoing services.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;as part of a Health and Wellness Program that is otherwise compliant with Brand Regulation 4.11.4(a), contracting with a health and wellness organization to gain access to providers to deliver a discrete health and wellness event (&#8220;Event&#8221;) held at a National Account&#8217;s worksite outside of the Licensee&#8217;s Service Area, provided that&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the services delivered at the Event are limited to fingerstick screenings for cholesterol and glucose, seasonal flu immunizations, blood pressure measurements, body mass index measurements, and other routine screenings, immunizations and measurements&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;neither such services nor their costs are applied as claims against any benefit plan&#59; and </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the Event is presented during one or more limited periods during a benefit year and is available to all employees at the worksite.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 7 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee to offer Blue-branded Health Coverage to the National Account, performing the Eligibility and Enrollment functions of HR administration for all benefit plans offered by the National Account to its members, including benefit plans that are not underwritten or administered by the Plan, provided that&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;in performing such functions, the Plan and&#47;or licensed Controlled Affiliate does not use the Brands in any communications with health care providers outside of the Plan&#8217;s Service Area, and otherwise limits its use of the Brands outside of the Service Area to communications with the account&#8217;s members, the other benefit plan providers with which the account has contracted and other reasonably necessary communications to perform such functions&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if in accordance with IP Policies another Licensee is soliciting or servicing under the Brands a local plant, office or division of the account that is outside of the Plan&#8217;s Service Area, the Plan and&#47;or licensed Controlled Affiliate may not perform Eligibility and Enrollment functions for employees working at such local plant, office or division without the consent of such other Licensee&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee to perform or investigate fraud, waste and abuse investigation activities for a non-participating provider in a Par&#47;Host Plan&#8217;s service area, as long as the Control&#47;Home Plan is given permission to do so by the Par&#47;Host Plan and specific conditions are met in accordance with Inter-Plan Programs and Inter-Plan Medicare Advantage Program policies. </font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this subparagraph b, the following definitions apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Health Coverage&#8221; has the meaning set forth in subparagraph 2.4.a.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 27, 2018</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 8 of 14</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Eligibility&#8221; means services that manage the account&#8217;s eligibility data and determine or process determinations relating to eligibility for benefit plans offered by the account to its employees, including such services as&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">monitoring and auditing data to ensure that only entitled individuals are enrolled in each such benefit plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">review of eligibility documentation (e.g. marriage licenses, birth certificates, student status verification letters, employment records)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">identification of key member segments such as over-age dependents, part-time employees, employees reaching certain milestones (e.g. Medicare-eligible, retirees)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">termination of coverage for those individuals found to be ineligible for coverage under a benefit plan, and, if applicable, generation of a COBRA event&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">management of &#8220;hour-banking&#8221; for union environments in which union members can bank hours to remain eligible for benefits.</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Enrollment&#8221; means services that enroll eligible individuals and their spouses&#47;dependents or terminate or change their enrollment in the account&#8217;s benefit plans on an ongoing basis and during open enrollment periods, including such services as&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the coordination of each step in open enrollment process from project planning and system set-up to the generation of confirmation statements&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ongoing enrollment support for new hires and changes due to life events and work status adjustments&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">evidence of insurability (EOI) administration for life and disability coverage&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">transmission of eligibility&#47;enrollment information to the account&#8217;s benefit plan providers&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">review and reconciliation of error reports received from the account&#8217;s benefit plan providers&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-17.65pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">transmission of information to the account&#8217;s payroll system (e.g., benefit deductions, employee demographic data).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 9 of 14</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;Knowledge Sharing</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;submitting scholarly articles authored or co-authored by the Plan or Controlled Affiliate or its respective employees for publication in peer-reviewed journals&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;permitting an internal representative of the Licensee (e.g., officer, employee) to speak or present at a conference or symposium outside of the Licensee&#8217;s Service Area regarding either (i) healthcare financing, administration, delivery or policy, or (ii) topics within the representative&#8217;s functional discipline or expertise at the Licensee, for which the event sponsor will issue communications to promote, administer, and&#47;or recap the event that will identify the Licensee&#8217;s representative as a participant.  The communications outside of the Licensee&#8217;s Service Area that mention the Licensee&#8217;s representative shall be limited to materials and digital media provided to attendees, on-site signage, advertising in relevant trade publications, direct mail and email to attendees and prospective attendees, and the sponsor&#8217;s website, Participation in any conference or symposium outside of the Licensee&#8217;s Service Area may not be for the purpose of marketing or selling products or services.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Licensee&#8217;s representative wishes to use the Brands in any manner, including use in his&#47;her title, when participating as a speaker or presenter outside of the Licensee&#8217;s Service Area about a topic that is not related to healthcare financing, administration, delivery, or policy, or to topics within the representative&#8217;s functional discipline or expertise at the Licensee, the Licensee must notify BCBSA and receive prior approval from BCBSA before participating.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 10 of 14</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;Other Uses</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;entering into a license agreement between and among BCBSA, the Plan and a debit card issuer located outside the Plan&#8217;s Service Area, and entering into a corresponding operating agreement or agreements, in order to offer a debit card bearing the Licensed Marks and Name to eligible persons as defined by the aforementioned license agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;appearing in communications issued by an independent third party to recognize outstanding performance of the Plan or Controlled Affiliate or a member of the Plan&#8217;s or Controlled Affiliate&#8217;s senior management as part of an established program of the third party for which the Plan has provided information to be considered for the recognition, provided that such use complies with regulations of general application specifically prescribed by BCBSA from time to time&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;to identify itself as being a joint sponsor of an event, program or activity along with other Plans or such Plans&#8217; licensed Controlled Affiliates, provided that such use complies with regulations of general application specifically prescribed by BCBSA from time to time&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;hosting meetings or events (collectively, &#8220;events&#8221;) in Washington, D.C. or a Plan&#8217;s State Capitol related to policy and business issues in the Licensee&#8217;s Service Area, or hosting events in conjunction with the assemblies or conventions of national political parties. Such events may not involve marketing or selling products or services.  Use of the Brands outside the Licensee&#8217;s Service Area in connection with such events shall be limited to materials and digital media provided to attendees and prospective attendees and onsite signage.  For any such events in Washington, D.C. that are open to attendees other than government officials or their staffs, or are briefings open to all Congressional staff, or are otherwise likely to receive media coverage, the Licensee is required to provide advance notice to BCBSA.  For events hosted outside of Washington, D.C. in conjunction with the assemblies or conventions of national political parties, the Licensee is required to provide advance notice to BCGSA and to the local Plan(s)&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 11 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;permitting an affiliate that is not licensed to use the Licensed Marks to identify its corporate relationship with the Plan, provided that such use complies with regulations of general application specifically prescribed by BCBSA from time to time.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In connection with activity otherwise in furtherance of the License Agreement, a Controlled Affiliate that is licensed to use the Licensed Marks and Name pursuant to a Controlled Affiliate License Agreement authorized in clauses d) or e) of Paragraph 2 of the Plan&#8217;s License Agreement with BCBSA may use the Licensed Marks and Name outside the Region (as that term is defined in such respective Controlled Affiliate License Agreements) in the following circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;distributing business cards other than in marketing and selling&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;contracting with health care providers or soliciting such contracts in areas contiguous to the Region in order to serve its subscribers residing in the Region, provided that the Controlled Affiliate may not use the names of any of its Controlling Plans in connection with such contracting unless the provider is located in a geographic area that is also contiguous to such Controlling Plan&#8217;s Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d. &#160;&#160;&#160;&#160;issuing a small sign containing the legal name or trade name of the Controlled Affiliate for display by a provider to identify the latter as a participating provider of the Controlled Affiliate, provided that the Controlled Affiliate may not use the names of any of its Controlling Plans on such signs unless the provider is located in a geographic area that is also contiguous to such Controlling Plan&#8217;s Service Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e. &#160;&#160;&#160;&#160;advertising in publications or electronic media solely to persons for employment&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="text-align:right"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 12 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f. &#160;&#160;&#160;&#160;advertising in print, electronic or other media which serve, as a substantial market, the Region, provided that the Controlled Affiliate may not advertise outside its Region on the national broadcast and cable networks and that advertisements in national print media are limited to the smallest regional edition encompassing the Region, and provided further that any such advertising by the Controlled Affiliate may not reference the name of any of its Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to advertise in such media&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g. &#160;&#160;&#160;&#160;advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Region, provided that such advertising by the Controlled Affiliate may not reference the name of any of its Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to send direct mail to such zip code plus 4.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;&#91;Intentionally left blank, pending review by the Inter-Plan Programs Committee of the applicability of the case management rule to such Controlled Affiliates.&#93;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;contracting with a pharmacy management organization (&#8220;Pharmacy Intermediary&#8221;) to gain access to a national or regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for the Controlled Affiliate&#8217;s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License Agreements, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in contracting with the pharmacy providers in such network&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit to the Controlled Affiliate&#8217;s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug members enrolled under the Licensed Marks pursuant to such respective</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 13 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controlled Affiliate License Agreements, provided that (1) the Controlled Affiliate may not contract directly with pharmacists or pharmacy stores outside the Region, and (2) neither the Controlled Affiliate&#8217;s name nor the Licensed Marks or Name may be posted or otherwise displayed at or by any pharmacy store outside the Region&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;contracting with a dental management organization (&#8220;Dental Intermediary&#8221;) to gain access to a national or regional dental network to deliver a routine dental benefit for the Controlled Affiliate&#8217;s regional Medicare Advantage PPO members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License Agreement, provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in contracting with the dental providers in such network&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;contracting with a vision management organization (&#8220;Vision Intermediary&#8221;) to gain access to a national or regional vision network to deliver a routine vision benefit for the Controlled Affiliate&#8217;s regional Medicare Advantage members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License Agreement, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in contracting with the vision providers in such network&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are collected within the Controlled Affiliate&#8217;s Region&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;contracting with a durable medical equipment or home medical equipment company for durable medical equipment and supplies and home medical equipment and supplies that are shipped to a location within the Controlled Affiliate&#8217;s Region&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">o.&#160;&#160;&#160;&#160;contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are ordered by a health care professional located within the Region&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p.&#160;&#160;&#160;&#160;contracting with a company that operates provider sites in the Region, provided that the contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Region&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 14 of 14</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">q.&#160;&#160;&#160;&#160;contracting with a company that makes health care professionals available in the Region (e.g., traveling home health nurse), provided that the contract is solely for services rendered by health care professionals who are located within the Region.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;BCBSA shall retain the right to use the Licensed Marks in conjunction with the Federal Employee Program and with any other national offering made to federal employees pursuant to the Federal Employees Health Benefits Program (FEHBP), including the right to license such use to its vendors, but only in the following manner.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Licensed Marks may only be used by BCBSA with the term &#8220;Federal Employee Program&#8221;, &#8220;Federal&#8221;, &#8220;FEP&#8221;, or similar language identifying the program as a benefit program for federal employees&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Licensed Marks may not be used by BCBSA with the name(s) of a specific Plan or Plans and&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;any use by BCBSA in conjunction with a new national FEHBP program proposed after the enactment of this amendment will require the approval of the BCBSA Board of Directors.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Where required by applicable state or local law or regulation, a Plan or its licensed Controlled Affiliate may submit documents that contain the Brands to, and file forms that contain the Brands with, state or local regulators in a state not included in its Service Area, provided that it gives reasonable advance notice to the local Plan of its intent to submit such documents or file such forms.&#160; Notwithstanding, in no event may a Plan or its licensed Controlled Affiliate use the Brands to register, or to obtain or maintain a license, a certificate of authority, or an equivalent document authorizing it to act as a risk-bearing entity or third-party administrator in a state not included in its Service Area.&#160; If the local Plan advises BCBSA that it believes its License Agreement has been or would be violated by any submission or filing, BCBSA shall determine whether such submission or filing is required by state or local law or regulation and violates the License Agreement, subject to the Plan&#8217;s or licensed Controlled Affiliate&#8217;s rights to obtain an independent review of such determination under Paragraph 9(a) and Exhibit 5 of its License Agreement or Paragraph 8 of the Controlled Affiliate License.  For purposes of this paragraph, &#8220;local Plan&#8221; is defined as each Plan whose Service Area includes all or part of the state in which the foregoing applicable state or local law or regulation has been enacted.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of March 26, 2015</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 1 of 23</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIATION AND MANDATORY DISPUTE RESOLUTION (MMDR) RULES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Blue Cross and Blue Shield Plans (&#34;Plans&#34;) and the Blue Cross Blue Shield Association (&#34;BCBSA&#34;) recognize and acknowledge that the Blue Cross and Blue Shield system is a unique nonprofit and for-profit system offering cost effective health care financing and services.  The Plans and BCBSA desire to utilize Mediation and Mandatory Dispute Resolution (&#8220;MMDR&#8221;) to avoid expensive and time-consuming litigation that may otherwise occur in the federal and state judicial systems.  Even MMDR should be viewed, however, as methods of last resort, all other procedures for dispute resolution having failed.  Except as otherwise provided in the License Agreements, the Plans, their Controlled Affiliates and BCBSA agree to submit all disputes to MMDR pursuant to these Rules and in lieu of litigation.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Initiation of Proceedings</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Pre-MMDR Efforts</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Before filing a Complaint to invoke the MMDR process, the CEO of a complaining party, or his&#47;her designated representative, shall undertake good faith efforts with the other side(s) to try to resolve any dispute.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Complaint</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To commence a proceeding, the complaining party (or parties) shall provide by certified mail, return receipt requested, a written Complaint to the BCBSA Corporate Secretary (which shall also constitute service on BCBSA if it is a respondent) and to any Plan(s) and&#47;or Controlled Affiliate(s) named therein.  The Complaint shall contain&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;identification of the complaining party (or parties) requesting the proceeding&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;identification of the respondent(s)&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;identification of any other persons or entities who are interested in a resolution of the dispute&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;a full statement describing the nature of the dispute&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;identification of all of the issues that are being submitted for resolution&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of November 21, 1996</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 2 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;the remedy sought&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;a statement as to whether the complaining party (or parties) elect(s) first to pursue Mediation&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">viii.&#160;&#160;&#160;&#160;any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ix.&#160;&#160;&#160;&#160;a statement signed by the CEO of the complaining party affirming that the CEO has undertaken efforts, or has directed efforts to be undertaken, to resolve the dispute before resorting to the MMDR process.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The complaining party (or parties) shall file and serve with the Complaint copies of all documents which the party (or parties) intend(s) to offer at the Arbitration Hearing and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing, along with a summary of each witness' expected testimony.  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Answer</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within twenty (20) days after receipt of the Complaint, each respondent shall serve on BCBSA and on the complaining party (or parties)&#58; </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;a full Answer to the aforesaid Complaint&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;a statement of any Counterclaims against the complaining party (or parties), providing with respect thereto the information specified in Paragraph 1.B., above&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;a statement as to whether the respondent elects to first pursue Mediation&#59; and </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The respondent(s) shall file and serve with the Answer or by the date of the Initial Conference set forth in Paragraph 3.C., below, copies of all documents which the respondent(s) intend(s) to offer at the Arbitration Hearing and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing, along with a summary of each witness' expected testimony.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Reply To Counterclaim</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within ten (10) days after receipt of any Counterclaim, the complaining party (or parties) shall serve on BCBSA and on the responding party (or parties) a Reply to the Counterclaim.  Such Reply must provide the same information required by Paragraph 1.C., above.</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Mediation</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To facilitate the mediation of disputes between or among BCBSA, the Plans and&#47;or their Controlled Affiliates, the BCBSA Board has provided for Mediation under these Rules.  Mediation may be pursued in lieu of or in an effort to obviate the Mandatory Dispute Resolution process, and all parties are strongly urged, but not required, to exhaust the mediation procedure provided for herein.  In the event any party refuses to proceed with Mediation, the parties shall proceed immediately to Mandatory Dispute Resolution, as provided in Section 3.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Selection of Mediators</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If all parties agree to pursue Mediation, they shall promptly attempt to agree upon&#58; (i) the number of mediators desired, not to exceed three mediators&#59; and (ii) the selection of experienced mediator(s) from an independent entity to mediate all disputes set forth in the Complaint and Answer (and Counterclaim and Reply, if any).  In the event the parties are unable to  agree upon the selection or number of mediators, both within five (5) days of the service of the Answer or Reply to Counterclaim, whichever is later, the BCBSA Corporate Secretary shall immediately refer the matter to a nationally recognized professional ADR organization (such as CPR or JAMS) for mediation by a single mediator to be selected by the ADR organization.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Binding Decision</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Before the Mediation Hearing described below, the BCBSA Corporate Secretary shall contact the parties to determine whether they wish to be bound by any recommendation of the selected mediator(s) for resolution of the disputes.  If all wish to be bound, the Corporate Secretary will send appropriate documentation to them for their signatures before the Mediation Hearing begins.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 4 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Mediation Procedure</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Mediator(s) shall apply the mediation procedures and processes provided for herein (not the rules of the ADR organization with which they are affiliated) and shall promptly advise the parties of a scheduled Mediation Hearing date.  Unless a party requests an expedited procedure, or unless all parties to the proceeding agree to one or more extensions of time, the Mediation Hearing set forth below shall be completed within forty (40) days of BCBSA's receipt of the Complaint.  The selected mediator(s), unless the parties otherwise agree, shall adhere to the following procedure&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Each party must be represented by its CEO or other representative who has been delegated full authority to resolve the dispute.  However, parties may send additional representatives as they see fit.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Each party will be given one-half hour to present its case, beginning with the complaining party (or parties), followed by the other party or parties.   The parties are free to structure their presentations as they see fit, using oral statements or direct examination of witnesses.  However, neither cross-examination nor questioning of opposing representatives will be permitted.  At the close of each presentation, the selected mediator(s) will be given an opportunity to ask questions of the presenters and witnesses.  All parties must be present throughout the Mediation Hearing.  The selected mediator(s) may extend the time allowed for each party's presentation at the Mediation Hearing.  The selected mediator(s) may meet in executive session, outside the presence of the parties, or may meet with the parties separately, to discuss the controversy.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;After the close of the presentations, the parties will attempt to negotiate a settlement of the dispute.  If the parties desire, the selected mediators, or any one or more of the selected mediator(s), will sit in on the negotiations.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 5 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;After the close of the presentations, the selected mediator(s) may meet privately to agree upon a recommendation for resolution of the dispute which would be submitted to the parties for their consideration and approval.  If the parties have previously agreed to be bound by the results of this procedure, this recommendation shall be binding upon the parties.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;The purpose of the Mediation Hearing is to assist the parties to settle their grievances short of mandatory dispute resolution.  As a result, the Mediation Hearing has been designed to be as informal as possible.  Rules of evidence shall not apply.  There will be no transcript of the proceedings, and no party may make a tape recording of the Mediation Hearing.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;In order to facilitate a free and open discussion, the Mediation proceeding shall remain confidential.  A &#34;Stipulation to Confidentiality&#34; which prohibits future use of settlement offers, all position papers or other statements furnished to the selected mediator(s), and decisions or recommendations in any Mediation proceeding shall be executed by each party.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;Upon request of the selected mediator(s), or one of the parties, BCBSA staff may also submit documentation at any time during the proceedings.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Notice of Termination of Mediation</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Mediation cannot be completed within the prescribed or agreed time period due to the lack of cooperation of any party, as determined by the selected mediator(s), or if the Mediation does not result in a final resolution of all disputes at the Mediation Hearing or within ten (10) days after the Mediation Hearing, any party or any one of the selected mediator(s) shall so notify the BCBSA Corporate Secretary, who shall promptly issue a Notice of Termination of Mediation to all parties, to the selected mediator(s), and to the MDR Administrator.  Such notice shall serve to bring the Mediation to an end and to initiate Mandatory Dispute Resolution.  Upon agreement of all parties and the mediator(s), the Mediation process may continue at the same time the MDR process is invoked.  In such case, the Notice of Termination of Mediation described above serves to initiate the MDR proceeding, but does not terminate mediation proceedings, which may proceed simultaneous with the MDR proceeding.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 6 of 23</font></div><div style="margin-bottom:6pt;padding-left:27.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Mandatory Dispute Resolution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(MDR)</font></div><div style="margin-bottom:12pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any party elects not to first pursue Mediation, or if a Notice of Termination of Mediation is issued as set forth in Paragraph 2.D., above, then the unresolved disputes set forth in any Complaint and Answer (and Counterclaim and Reply, if any) shall be subject to mandatory binding arbitration (herein referred to as &#8220;MDR&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;MDR Administrator</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Administrator for purposes of Mandatory Arbitration shall be an independent nationally recognized entity such as CPR or JAMS, specializing in alternative dispute resolution.  In the event the parties pursued Mediation with CPR, JAMS or a similar organization, that organization also shall serve as the MDR Administrator, unless all parties notify the BCBSA Corporate Secretary in writing within two (2) days of receiving the Notice of Termination of Mediation that they wish to pursue MDR with another nationally recognized organization serving as MDR Administrator. </font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event the parties (i) did not pursue Mediation, (ii) pursued mediation with a Mediator not affiliated with an ADR organization that offers a panel of arbitrators, or (iii) all parties that pursued Mediation notified the BCBSA Corporate Secretary that they wish to have an MDR Administrator that is different from the organization with which their mediator was affiliated, they shall promptly attempt to agree on a nationally recognized ADR entity that supplies a panel of arbitrators.  If they reach such agreement within five (5) days of the Notice of Termination of Mediation or receipt of the Answer or Reply to Counterclaim (whichever is later), the parties shall promptly inform the BCBSA Corporate Secretary of their agreed upon ADR organization.  In the event the parties are unable to reach agreement on an MDR Administrator within that timeframe, the BCBSA Corporate Secretary shall immediately refer the matter to CPR, JAMS or a similar organization for MDR.  </font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any person who served as a Mediator shall not serve as an arbitrator for the same or similar dispute for purposes of MDR.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Rules for MDR</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The rules controlling all aspects of MDR shall be exclusively those provided for herein.  The rules promulgated or otherwise used by the MDR Administrator organization shall not apply.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 7 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Initial Conference</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within seven (7) days after a Notice of Termination has issued, or the matter has otherwise been referred to an MDR Administrator, or within five (5) days after the time for filing and serving the Answer or Reply to any Counterclaim (whichever is later) if the parties elect first not to mediate, the parties shall confer with the Administrator to discuss selecting a dispute resolution panel (&#34;the Panel&#34;).  This conference (the &#8220;Initial Conference&#8221;) may be by telephone.  The parties are encouraged to agree to the composition of the Panel and to present that agreement to the Administrator at the Initial Conference.  If the parties do not agree on the composition of the Panel by the time of the Initial Conference, or by any extension thereof agreed to by all parties and the Administrator, then the Panel Selection Process set forth in subparagraph D, below, shall be followed.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Panel Selection Process</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Administrator shall designate, prior to the Initial Conference, at least seven potential arbitrators.  Each party shall be permitted to strike any designee for cause and the Administrator shall determine the sufficiency thereof in its sole discretion.  The Administrator will designate a replacement for any designee so stricken.  Each party shall then be permitted one peremptory strike from the list of designees.  The Administrator shall set the dates for exercising all strikes, which shall be set to encourage the prompt selection of arbitrators.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the parties exercise any designee strikes for cause and their peremptory strike against any designee of their choice, the parties shall each rank the remaining panel members in order of preference and provide the Administrator, without serving on any other party, their ranked list.  The Administrator shall not disclose any party&#8217;s ranked list to members of the panel or to other parties.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">From the remaining designees, and after considering opportunities to maximize, so far as possible, the collectively stated arbitrator preferences provided by the parties on their ranked lists, the Administrator shall select a three member Panel.  The Panel Selection Process shall be completed no later than ten (10) days after the Initial Conference.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Arbitrator shall be compensated at his or her normal hourly rate or, in the absence of an established rate, at a reasonable hourly rate to be promptly fixed by the Administrator for all time spent in connection with the proceedings and shall be reimbursed for any travel and other reasonable expenses.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 8 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Duties Of The Arbitrators</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Panel shall promptly designate a Presiding Arbitrator for the purposes reflected below, but shall retain the power to review and modify any ruling or other action of said Presiding Arbitrator.  Each Arbitrator shall be an independent Arbitrator, shall be governed by the Code of Ethics for Arbitrators in Commercial Disputes, and shall at or prior to the commencement of any Arbitration Hearing take an oath to that effect.  Each Arbitrator shall promptly disclose in writing to the Panel and to the parties any circumstances, whenever arising, that might cause doubt as to such Arbitrator's compliance, or ability to comply, with said Code of Ethics, and, absent resignation by such Arbitrator, the remaining Arbitrators shall determine in their sole discretion whether the circumstances so disclosed constitute grounds for disqualification and for replacement.  With respect to such circumstances arising or coming to the attention of a party after an Arbitrator's selection, a party may likewise request the Arbitrator's resignation or a determination as to disqualification by the remaining Arbitrators.  With respect to a sole Arbitrator, the determination as to disqualification shall be made by the Administrator.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There shall be no </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ex</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">parte</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> communication between the parties or their counsel and any member of the Panel.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Panel's Jurisdiction And Authority</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Panel's jurisdiction and authority shall extend to all disputes between or among the Plans, their Controlled Affiliates, and&#47;or BCBSA, except for those disputes excepted from these MMDR procedures as set forth in the License Agreements.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With the exception of punitive or treble damages, the Panel shall have full authority to award the relief it deems appropriate to resolve the parties' disputes, including monetary awards and injunctions, mandatory or prohibitory.  The Panel has no authority to award punitive or treble damages except that the Panel may allocate or assess responsibility for punitive or treble damages assessed by another tribunal.  Subject to the above limitations, the Panel may, by way of example, but not of limitation&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 9 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;interpret or construe the meaning of any terms, phrase or provision in any license between BCBSA and a  Plan or a Controlled Affiliate relating to the use of the BLUE CROSS&#174; or BLUE SHIELD&#174; service marks.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;determine whether BCBSA, a Plan or a Controlled Affiliate has violated the terms or conditions of any license between the BCBSA and a Plan or a Controlled Affiliate relating to the use of the BLUE CROSS&#174; or BLUE SHIELD&#174; service marks.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;decide challenges as to its own jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;issue such orders for interim relief as it deems appropriate pending Hearing and Award in any Arbitration.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is understood that the Panel is expected to resolve issues based on governing principles of law, preserving to the maximum extent legally possible the continued integrity of the Licensed Marks and the BLUE CROSS&#47;BLUE SHIELD system.  The Panel shall apply federal law to all issues which, if asserted in the United States District Court, would give rise to federal question jurisdiction, 28 U.S.C. &#167;&#160;1331.  The Panel shall apply Illinois law to all issues involving interpretation, performance or construction of any License Agreement or Controlled Affiliate License Agreement unless the agreement otherwise provides.  As to other issues, the Panel shall choose the applicable law based on conflicts of law principles of the State of Illinois.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Administrative Conference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within five (5) days of the Panel being selected, the Presiding Arbitrator shall confer with the parties and the other members of the Panel and shall schedule, in writing, a conference in which the parties and the Panel shall participate (the &#8220;Administrative Conference&#8221;).  The Administrative Conference shall take place no later than fifteen (15) days after the Panel is selected.  At the Administrative Conference the parties and the Panel shall discuss the scheduling of the Arbitration Hearing and any other matter appropriate to be considered, including but not limited to&#58; any written discovery in the form of requests for production of documents or requests to admit facts&#59; the identity of any witness whose deposition a party may desire and a showing of exceptional good cause for the taking</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 10 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of any such deposition&#59; the desirability of bifurcation or other separation of the issues&#59; the need for and the type of record of conferences and hearings, including the need for transcripts&#59; the need for expert witnesses and how expert testimony should be presented&#59; the appropriateness of motions to dismiss and&#47;or for full or partial summary judgment&#59; consideration of stipulations&#59; the desirability of presenting any direct testimony in writing&#59; and the necessity for any on-site inspection by the Panel.  If the parties agree, the Administrative Conference may be by telephone.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;Discovery</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Requests for Production of Documents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  All requests for the production of documents must be served no later than five (5) days after the date of the Initial Conference.  Within twenty (20) days after receipt of a request for production of documents, a party shall (a) serve responses and objections to the request, (b) produce all responsive, non-privileged documents to the requesting party, and (c) to the extent any responsive documents are withheld on the grounds of attorney-client privilege or work product, produce a log identifying such documents in the manner specified in Fed. R. Civ. P. 26(b)(5). If, after reviewing a privilege log, the requesting party believes attorney-client privilege or work product protection was improperly claimed by the producing party with respect to any document, the requesting party may ask the Presiding Arbitrator to conduct an in-camera inspection of the same.  With respect to documentary and other discovery produced in any MDR proceeding by BCBSA, the fact that a party&#8217;s CEO or other senior officers may serve on the BCBSA Board of Directors, BCBSA Board Committees or other BCBSA work groups, task forces and the like, shall not be a basis for defeating an otherwise valid claim of attorney-client privilege or work product protection over such documentary or other discovery materials by BCBSA.  </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Requests for Admissions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Requests for Admissions may be served up to twenty-one (21) days prior to the discovery cut-off set by the Presiding Arbitrator.  A party served with Requests For Admissions must respond within twenty (20) days of receipt of said request. The good faith use of and response to Requests for Admissions is encouraged, and the Panel shall have full discretion, with reference to the Federal Rules of Civil Procedure, in awarding appropriate sanctions with respect to abuse of the procedure.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 11 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Depositions&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   As a general rule, the parties will not be permitted to take party or non-party deposition testimony for discovery purposes.  The Presiding Arbitrator, in his or her sole discretion, shall have the authority to permit a party to take such deposition testimony upon a showing of exceptional good cause. The parties will be permitted to take de bene esse deposition</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> testimony to the fullest extent permitted by law of any witness who cannot be compelled to testify at the Arbitration Hearing.  No deposition, for discovery purposes or otherwise, shall exceed three (3) hours, excluding objections and colloquy of counsel.  Depositions may be recorded in any manner recognized by the Federal Rules of Civil Procedure and the parties shall specify in each notice of deposition or request for permission to take deposition testimony the manner in which such deposition shall be recorded.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Expert witness(es)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; If a party intends to present the testimony of an expert witness during the oral hearing, it shall provide all other parties with a written statement setting forth the information required to be provided by Fed. R. Civ. P. 26(a)(2)(B) ten (10) days prior to the discovery cut-off set by the Presiding Arbitrator.  If a party intends to present the testimony of a rebuttal expert witness during the Arbitration Hearing, it shall provide all other parties with a written statement setting forth the information required to be provided by Fed. R. Civ. P. 26(a)(2)(B) within twenty (20) days after the date on which the written statement of the expert witness whose testimony is to be rebutted was produced.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Discovery cut-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Presiding Arbitrator shall determine the date on which the discovery period will end, but the discovery period shall not exceed thirty (30) days from the date of the Administrative Conference without the agreement of all parties.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As used in these Rules, &#34;de bene esse deposition&#34; means a deposition that is not taken for discovery purposes, but is taken for the purpose of reading part or all of the deposition transcript into the record at the Arbitration Hearing, to the extent permitted by the Panel, because the witness cannot be compelled to testify at the Arbitration Hearing or&#160;has exercised a right provided under these Rules to&#160;provide deposition testimony in lieu of testimony at the Arbitration Hearing.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 12 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Additional discovery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Any additional discovery will be at the discretion of the Presiding Arbitrator.  </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Discovery Disputes&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any discovery disputes shall be raised by motion to the Presiding Arbitrator, who is authorized to resolve all such disputes, and whose resolution will be binding on the parties unless modified by the Arbitration Panel.  Prior to raising any discovery dispute with the Presiding Arbitrator, the parties shall meet and confer, telephonically or in person, in an attempt to resolve or narrow the dispute.  If a party refuses to comply with a decision resolving a discovery dispute, the Panel, in keeping with Fed. R. Civ. P. 37, may refuse to allow that party to support or oppose designated claims or defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases, decide an issue submitted for resolution adversely to that party.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">viii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Extensions&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The time for responding to discovery requests may be extended by the Presiding Arbitrator for good and sufficient cause shown.  Any request for such an extension shall be made in writing.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;Panel Suggested Settlement&#47;Mediation</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At any point during the proceedings, the Panel at the request of any party or on its own initiative, may suggest that the parties explore settlement and that they do so at or before the conclusion of the Arbitration Hearing, and the Panel shall give such assistance in settlement negotiations as the parties may request and the Panel may deem appropriate.  Alternatively, the Panel may direct the parties to endeavor to mediate their disputes as provided above, or to explore a mini-trial proceeding, or to have an independent party render a neutral evaluation of the parties&#8217; respective positions.  The Panel shall enter such sanctions as it deems appropriate with respect to any party failing to pursue in good faith such Mediation or other alternate dispute resolution methods.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 13 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;Subpoenas on Third Parties  </font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. &#167;&#160;9 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., and subject to Paragraph 3.G(iii) above, a party may request the issuance of a subpoena on any third party, including but not limited to any third party Blue Plan or any officer, employee or director of a third party Blue Plan, to compel deposition testimony or the production of documents, and, if good and sufficient cause is shown, the Panel shall issue such a subpoena.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;Arbitration Hearing</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An Arbitration Hearing will be held within thirty (30) days after the Administrative Conference if no discovery is taken, or within thirty (30) days after the close of discovery, unless all parties and the Panel agree to extend the Arbitration Hearing date, or unless the parties agree in writing to waive the Arbitration Hearing.  The parties may mutually agree on the location of the Arbitration Hearing.  If the parties fail to agree, the Arbitration Hearing shall be held in Chicago, Illinois, or at such other location determined by the Presiding Arbitrator to be most convenient to the participants.  The Panel will determine the date(s) and time(s) of the Arbitration Hearing(s) after consultation with all parties and shall provide reasonable notice thereof to all parties or their representatives.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">L.&#160;&#160;&#160;&#160;Arbitration Hearing Memoranda</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Twenty (20) days prior to the Arbitration Hearing, each party shall submit to the other party (or parties) and to the Panel an Arbitration Hearing Memorandum which sets forth the applicable law and any argument as to any relevant issue.  The Arbitration Hearing Memorandum will supplement, and not repeat, the allegations, information and documents contained in or with the Complaint, Answer, Counterclaim and Reply, if any.  Ten (10) days prior to the Arbitration Hearing, each party shall submit to each other party a list of all expert and fact witnesses (but not including rebuttal fact witness) that such party intends to have testify at the Arbitration Hearing and a brief summary of the testimony each such witness is expected to give.  In addition, no later than five (5) days prior to the Arbitration, each party may submit to each other party and to the Panel a Response Arbitration Hearing Memorandum which sets forth any response to another party's Arbitration Hearing Memorandum.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 14 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">M.&#160;&#160;&#160;&#160;Notice For Testimony</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ten (10) days prior to the Arbitration Hearing, any party may serve a Notice on any other party (or parties) requesting the attendance at the Arbitration Hearing of any officer, employee or director of the other party (or parties) for the purpose of providing noncumulative testimony.  If a party fails to produce one of its officers, employees or directors whose noncumulative testimony during the Arbitration Hearing is reasonably requested by an adverse party, the Panel may refuse to allow that party to support or oppose designated claims or defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases, decide an issue submitted for mandatory dispute resolution adversely to that party&#59; provided, however, that a party may refuse to produce a director to testify if, within two (2) days of receiving a notice requesting the attendance of such director at the Arbitration Hearing, the party agrees to make the director available for a de bene esse deposition at a mutually convenient time at any location within fifty (50) miles of the director&#8217;s primary residence chosen by the party requesting the director&#8217;s testimony.  This Rule may not be used for the purpose of burdening or harassing any party, and the Presiding Arbitrator may impose such orders as are appropriate so as to prevent or remedy any such burden or harassment.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. &#167; 9 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, twenty (20) days or more prior to the Arbitration Hearing, a party may request the issuance of a subpoena on any third party, including but not limited to any third party Blue Plan, BCBSA or any officer, employee or director of a third party Blue Plan or BCBSA for the purpose of providing noncumulative testimony at the Arbitration Hearing, and, if good and sufficient cause is shown, the Panel shall issue such a subpoena&#59; provided however, that a director of a third party Blue Plan or BCBSA may refuse to testify if, within two (2) days of receiving a subpoena requesting the attendance of such director at the Arbitration Hearing, the director agrees to make him&#47;herself available for a de bene esse deposition at a mutually convenient time at any location within fifty (50) miles of the director&#8217;s primary residence chosen by the party requesting the director&#8217;s testimony.  Each Blue Plan agrees to waive, on its own behalf and on behalf of its directors and officers, any objection it otherwise might have to any such subpoena based on service, venue or extraterritoriality.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 15 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N.&#160;&#160;&#160;&#160;Arbitration Hearing Procedures</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Attendance at Arbitration Hearing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Any person having a direct interest in the proceeding is entitled to attend the Arbitration Hearing.  The Presiding Arbitrator shall otherwise have the power to require the exclusion of any witness, other than a party or other essential person, during the testimony of any other witness.  It shall be discretionary with the Presiding Arbitrator to determine the propriety of the attendance of any other person.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Confidentiality</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  The Panel and all parties shall maintain the privacy of the Arbitration Proceeding.  The parties and the Panel shall treat the Arbitration Hearing and any discovery or other proceedings or events related thereto, including any award resulting therefrom, as confidential except as otherwise necessary in connection with a judicial challenge to or enforcement of an award or unless otherwise required by law.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Stenographic Record</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Any party, or if the parties do not object, the Panel, may request that a stenographic or other record be made of any Arbitration Hearing or portion thereof.  The costs of the recording and&#47;or of preparing the transcript shall be borne by the requesting party and by any party who receives a copy thereof.  If the Panel requests a recording and&#47;or a transcript, the costs thereof shall be borne equally by the parties.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Oaths</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  The Panel may require witnesses to testify under oath or affirmation administered by any duly qualified person and, if requested by any party, shall do so.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Order of Arbitration Hearing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  An Arbitration Hearing shall be opened by the recording of the date, time, and place of the Arbitration Hearing, and the presence of the Panel, the parties, and their representatives, if any.  The Panel may, at the beginning of the Arbitration Hearing, ask for statements clarifying the issues involved.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 16 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise agreed, the complaining party (or parties) shall then present evidence to support their claim(s).  The respondent(s) shall then present evidence supporting their defenses and Counterclaims, if any.  The complaining party (or parties) shall then present evidence supporting defenses to the Counterclaims, if any, and rebuttal.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Witnesses for each party shall submit to questions by adverse parties and&#47;or the Panel.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Panel has the discretion to vary these procedures, but shall afford a full and equal opportunity to all parties for the presentation of any material and relevant evidence.</font></div><div style="padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Evidence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  The parties may offer such evidence as is relevant and material to the dispute and shall produce such evidence as the Panel may deem necessary to an understanding and resolution of the dispute.  Unless good cause is shown, as determined by the Panel or agreed to by all other parties, no party shall be permitted to offer evidence at the Arbitration Hearing which was not disclosed prior to the Arbitration Hearing by that party.  The Panel may receive and consider the evidence of witnesses by affidavit upon such terms as the Panel deems appropriate.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Panel shall be the judge of the relevance and materiality of the evidence offered, and conformity to legal rules of evidence, other than enforcement of the attorney-client privilege and the work product protection, shall not be necessary.  The Federal Rules of Evidence shall be considered by the Panel in conducting the Arbitration Hearing but those rules shall not be controlling.  All evidence shall be taken in the presence of the Panel and all of the parties, except where any party is in default or has waived the right to be present.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Settlement offers by any party in connection with Mediation or MDR proceedings, decisions or recommendations of the selected mediators, and a party's position papers or statements furnished to the selected mediators shall not be admissible evidence or considered by the Panel without the consent of all parties.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 17 of 23</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Closing of Arbitration Hearing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  The Presiding Arbitrator shall specifically inquire of all parties whether they have any further proofs to offer or witnesses to be heard.  Upon receiving negative replies or if he or she is satisfied that the record is complete, the Presiding Arbitrator shall declare the Arbitration Hearing closed with an appropriate notation made on the record.  Subject to being reopened as provided below, the time within which the Panel is required to make the award shall commence to run, in the absence of contrary agreement by the parties, upon the closing of the Arbitration Hearing.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to complex disputes, the Panel may, in its sole discretion, defer the closing of the Arbitration Hearing for a period of up to thirty (30) days after the presentation of proofs in order to permit the parties to submit post-hearing briefs and argument, as the Panel deems appropriate, prior to making an award.</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For good cause, the Arbitration Hearing may be reopened for up to thirty (30) days on the Panel's initiative, or upon application of a party, at any time before the award is made</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">O.&#160;&#160;&#160;&#160;Awards</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An Award must be in writing and shall be made promptly by the Panel and, unless otherwise agreed by the parties or specified by law, no later than thirty (30) days from the date of closing the Arbitration Hearing.  If all parties so request, the Award shall contain findings of fact and conclusions of law.  The Award, and all other rulings and determinations by the Panel, may be by a majority vote.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parties shall accept as legal delivery of the Award the placing of the Award or a true copy thereof in the mail addressed to a party or its representative at its last known address or personal service of the Award on a party or its representative.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Awards are binding only on the parties to the Arbitration and are not binding on any non-parties to the Arbitration and may not be used or cited as precedent in any other proceeding.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 18 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the expiration of twenty (20) days from initial delivery, the Award (with corrections, if any) shall be final and binding on the parties, and the parties shall undertake to carry out the Award without delay.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceedings to confirm, modify or vacate an Award shall be conducted in conformity with and controlled by the Federal Arbitration Act.  9 U.S.C. &#167; 1, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">P.&#160;&#160;&#160;&#160;Return of Documents&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within sixty (60) days after the Award and the conclusion of any judicial proceedings with respect thereto, each party and the Panel shall return any documents produced by any other party, including all copies thereof.  If a party receives a discovery request in any other proceeding which would require it to produce any documents produced to it by any other party in a proceeding hereunder, it shall not produce such documents without first notifying the producing party and giving said party reasonable time to respond, if appropriate, to the discovery request.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Expedited Procedures</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any party to a Mediation may direct a request for an expedited Mediation Hearing to the Chairman of the Mediation Committee, to the selected Mediators, and to all other parties at any time.  The Chairman of the Mediation Committee, or at his or her direction, the then selected Mediators, shall grant any request which is supported by good and sufficient reasons.  If such a request is granted, the Mediation shall be completed within as short a period as practicable, as determined by the Chairman of the Mediation Committee or, at his or her direction, the then selected Mediators.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any party to an Arbitration may direct a request for expedited proceedings to the Administrator, to the Panel, and to all other parties at any time.  The Administrator, or the Presiding Arbitrator if the Panel has been selected, shall grant any such request which is supported by good and sufficient reasons.  If such a request is granted, the Arbitration shall be completed within as short a time as practicable, as determined by the Administrator and&#47;or the Presiding Arbitrator.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 19 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Temporary or Preliminary Injunctive Relief</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any party may seek temporary or preliminary injunctive relief with the filing of a Complaint or at any time thereafter.  If such relief is sought prior to the time that an Arbitration Panel has been selected, then the Administrator shall select a single Arbitrator who is a lawyer who has no interest in the subject matter of the dispute, and no connection to any of the parties, to hear and determine the request for temporary or preliminary injunction.  If such relief is sought after the time that an Arbitration Panel has been selected, then the Arbitration Panel will hear and determine the request.  The request for temporary or preliminary injunctive relief will be determined with reference to the temporary or preliminary injunction standards set forth in Fed. R. Civ. P. 65.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Defaults and Proceedings in the Absence of a Party</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whenever a party fails to comply with the MDR Rules in a manner deemed material by the Panel, the Panel shall fix a reasonable time for compliance and, if the party does not comply within said period, the Panel may enter an Order of default or afford such other relief as it deems appropriate.  Arbitration may proceed in the event of a default or in the absence of any party who, after due notice, fails to be present or fails to obtain an extension.  An Award shall not be made solely on the default or absence of a party, but the Panel shall require the party who is present to submit such evidence as the Panel may require for the making of findings, determinations, conclusions, and Awards.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Notice</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each party shall be deemed to have consented that any papers, notices, or process necessary or proper for the initiation or continuation of a proceeding under these rules or for any court action in connection therewith may be served on a party by mail addressed to the party or its representative at its last known address or by personal service, in or outside the state where the MDR proceeding is to be held.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Corporate Secretary and the parties may also use facsimile transmission, telex, telegram, or other written forms of electronic communication to give the notices required by these rules.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 20 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;Expenses</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The expenses of witnesses shall be paid by the party causing or requesting the appearance of such witnesses.  All expenses of the MDR proceeding, including compensation, required travel and other reasonable expenses of the Panel, and the cost of any proof produced at the direct request of the Panel, shall be borne equally by the parties and shall be paid periodically on a timely basis, unless they agree otherwise or unless the Panel in the Award assesses such expenses, or any part thereof against any party (or parties).  In exceptional cases, the Panel may award reasonable attorneys' fees as an item of expense, and the Panel shall promptly determine the amount of such fees based on affidavits or such other proofs as the Panel deems sufficient.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Disqualification or Disability of A Panel Member</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that any Arbitrator of a Panel with more than one Arbitrator should become disqualified, resign, die, or refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the parties are unable to agree upon a replacement, the remaining Panel member(s)&#58; </font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;shall designate a replacement, subject to the right of any party to challenge such replacement for cause.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;shall decide the extent to which previously held hearings shall be repeated.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the remaining Panel members consider the proceedings to have progressed to a stage as to make replacement impracticable, the parties may agree, as an alternative to the recommencement of the Mandatory Dispute Resolution process, to resolution of the dispute by the remaining Panel members.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that a single Arbitrator should become disqualified, resign, die, or refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the parties are unable to agree upon a replacement, the Administrator shall appoint a successor, subject to the right of any party to challenge such successor for cause, and the successor shall decide the extent to which previously held proceedings shall be repeated.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 21 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Extensions of Time</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the provisions of Paragraph 3.H.(viii), any time limit set forth in these Rules may be extended upon agreement of the parties and approval of&#58;  (1) the Mediator if the proceeding is then in Mediation&#59; (2) the Administrator if the proceeding is in Arbitration, but no Arbitration Panel has been selected&#59; or (3) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;Intervention</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plans, their Controlled Affiliates, and BCBSA, to the extent subject to MMDR pursuant to their License Agreements, shall have the right to move to intervene in any pending Arbitration.  A written motion for intervention shall be made to&#58;  (1) the Administrator, if the proceeding is in Arbitration, but no Arbitration Panel has been selected&#59; or (2) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected.  The written motion for intervention shall be delivered to the BCBSA Corporate Secretary (which shall also constitute service on the BCBSA if it is a respondent) and to any Plan(s) and&#47;or Controlled Affiliate(s) which are parties to the proceeding.  Any party to the proceeding can submit written objections to the motion to intervene.  The motion for intervention shall be granted upon good cause shown.  Intervention also may be allowed by stipulation of the parties to the Arbitration proceeding.  Intervention shall be allowed upon such terms as the Arbitration Panel decides.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;BCBSA Assistance In Resolution of Disputes</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The resources and personnel of the BCBSA may be requested by any member Plan at any time to try to resolve disputes with another Plan.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J.&#160;&#160;&#160;&#160;Neutral Evaluation</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties can voluntarily agree at any time to have an independent party render a neutral evaluation of the parties&#8217; respective positions.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 22 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">K.&#160;&#160;&#160;&#160;Recovery of Attorney Fees and Expenses</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Motions to Compel</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any other provisions of these Rules, any Party subject to the License Agreements (for purposes of this Section K and all of its sub-sections only hereinafter referred to collectively and individually as a &#8220;Party&#8221;) that initiates a court action or administrative proceeding solely to compel adherence to these Rules shall not be determined to have violated these Rules by initiating such action or proceeding.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii&#160;&#160;&#160;&#160;Recovery of Fees, Expenses and Costs</font></div><div style="margin-bottom:12pt;padding-left:81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Arbitration Panel may, in its sole discretion, award a Party its reasonable attorneys&#8217; fees, expenses and costs associated with a filing to compel adherence to these Rules and&#47;or reasonable attorneys&#8217; fees, expenses and costs incurred in responding to an action filed in violation of these Rules&#59; provided, however, that neither fees, expenses, nor costs shall be awarded by the Arbitration Panel if the Party from which the award is sought can demonstrate to the Arbitration panel, in its sole discretion, that it did not violate these Rules or that it had reasonable grounds for believing that its action did not violate these Rules.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii&#160;&#160;&#160;&#160;Requests for Reimbursement</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Section K, any Party may request reimbursement of fees, expenses and&#47;or costs by submitting said request in writing to the Arbitration Panel at any time before an award is delivered pursuant to Paragraph 3.O above, with a copy to the Party from which reimbursement is sought, explaining why it is entitled to such reimbursement.  The Party from which reimbursement is sought shall have twenty (20) days to submit a response to such request to the Arbitration Panel with a copy to the Party seeking reimbursement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 5</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 23 of 23</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">L.&#160;&#160;&#160;&#160;Calculation of Time and Deadlines</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In computing any period of time prescribed or allowed under these rules, the day of the act or event from which the designated period of time begins to run shall not be included.  The last day of the period so computed shall be included, unless it is a Saturday, a Sunday, or a legal holiday, in which event the period runs until the end of the next day which is not one of the aforementioned days.  When the period of time prescribed is less than six (6) days, intermediate Saturdays, Sundays and legal holidays shall be excluded in the computation.  As used in this rule, &#8220;legal holiday&#8221; includes New Year&#8217;s Day, Martin Luther King, Jr. Day, Washington&#8217;s Birthday, Memorial Day, Independence Day, Labor Day, Columbus Day, Veterans Day, Thanksgiving Day, Christmas Day and any other day appointed as a holiday by the President or the Congress of the United States.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended as of September 20, 2007</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>6
<FILENAME>exhibit21-20221231forform1.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3f702957072444de831fe3e3e6e77994_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE COMPANY</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Legal Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Domestic Jurisdiction</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Doing Business As</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advantage Medical Group, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alianza Medicos del SurEste, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Care Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Imaging Management, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIM Specialty Health</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Community Care of New Mexico, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Corporation </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP CORPORATION&#59; AGP Corporation&#59; AMGP&#59; AMGP Corporation&#59; AMGP Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Delaware, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup District of Columbia, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">District of Columbia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Insurance Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Iowa, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup IPA of New York, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Mississippi, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mississippi</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP New Jersey, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Community Care</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Ohio, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Community Care</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Partnership Plan, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Pennsylvania, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Tennessee, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Community Care</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Texas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Community Care</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP Washington, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGP Georgia Managed Care Company, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMERIGROUP&#59; AMERIGROUP Community Care&#59; AMERIGROUP Georgia&#59; AMGP Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH Health, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maine</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH Health Plans of Maine, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maine</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross Life and Health Insurance Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Financial, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Health Plans of Kentucky, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Health Plans of Maine, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maine</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield&#59; Associated Hospital Service</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Health Plans of New Hampshire, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Hampshire</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Health Plans of Virginia, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Health Plans, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Holding Corp. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Properties, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Insurance Companies, Inc.  </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield&#59;  Blue Cross and Blue Shield of Indiana&#59; Empire Blue Cross-Retiree Solutions&#59; Empire Blue Cross Blue Shield-Retiree Solutions&#59;  Anthem BC Health Insurance Company</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Kentucky Managed Care Plan, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield Medicaid</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Life &#38; Disability Insurance Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Life Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Partnership Holding Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Southeast, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Workers' Compensation, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Pathways LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APR, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus Enterprises, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aspire Health, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Palliative Care, Inc.&#59; Aspire CareMore Health, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Associated Group, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATH Holding Company, LLC </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AUMSI UM Services, Inc. f&#47;k&#47;a Anthem UM Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon CBHM LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Financing LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Holdings LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Options, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Options Care Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Options Holdco, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Options of California, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Options of Ohio, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Options of Pennsylvania, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Strategies LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Health Vista Parent, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Plan Funding, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Best Transportation of PR LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHS IPA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross Blue Shield of Wisconsin </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross of California </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross of California Partnership Plan, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross Partnership Plan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BVO Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Digital Platforms, Inc. fka CareMarket, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sydney Care</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Digital Platforms Israel Ltd fka Anthem Innovation Israel Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Employment Company, LLC fka Anthem Services Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Global Solutions India LLP fka Legato Health Technologies LLP</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Global Solutions Ireland Limited fka Legato Health Technologies Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Global Solutions Philippines, Inc. fka Legato Health Technologies Philppines, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Global Solutions Puerto Rico, L.L.C. fka Legato Health Technologies Puerto Rico, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Global Solutions U.S., Inc. fka Legato Health Technologies U.S., Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Global Solutions U.S.&#160; </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Holdings, Inc. fka DBG Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Holdings I, Inc. fka Legato Holdings I, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Holdings II, LLC fka Legato Holdings II, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carelon Insights, Inc. fka Valus, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ingenio, Inc.&#59; IngenioRx Administrators</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CarelonRx, Inc. fka IngenioRx, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CarelonRx Pharmacy, Inc. fka ZipDrug, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health IPA of New York, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health of Arizona, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health Plan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health Plan of Arizona, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health Plan of Nevada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health Plan of Texas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore Health System</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareMore, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caribbean Accountable Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castellana Physician Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCHA, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado Community Health Alliance</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centros de Medicina Primaria Advantage del Norte, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centro Medicina Familiar del Norte, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centros Medicos Unidos del Oeste, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cerulean Companies, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHCS IPA, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claim Management Services, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinica Todo Salud - Aibonito, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinica Todo Salud, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Staff Solutions, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community Care Health Plan of Kansas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthy Blue</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community Care Health Plan of Louisiana, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthy Blue</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community Care Health Plan of Nebraska, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nebraska</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellCare of Nebraska&#59; Healthy Blue</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community Care Health Plan of Nevada, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield Healthcare Solutions&#59; AMERIGROUP Community Care</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community Insurance Company </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compcare Health Services Insurance Corporation </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consorcio MultiSalud del Norte, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consorcio MultiSalud del Oeste, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crossroads Acquisition Corp.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeCare Analytics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeCare Dental Health International, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeCare Dental Insurance Ireland, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeCare Dental Networks, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeCare Dental, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeCare Operations Ireland, Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delivery Network, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental Services Organization, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated Agent Company, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts Cutler Bay, LLC, EasyScripts Hialeah, LLC, EasyScripts Westchester, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts Cutler Bay, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts Hialeah, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts Westchester, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EasyScripts, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EHC Benefits Agency, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire HealthChoice Assurance, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire Blue Cross&#59; Empire Blue Cross Blue Shield </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire HealthChoice HMO, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire Blue Cross HMO&#59; Empire Blue Cross Blue Shield HMO</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Government Solutions, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FHC Health Systems, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freedom Health, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freedom SPV, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Golden West Health Plan, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GR Health Solutions, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Georgia Life Insurance Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Life</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Retiree Health Solutions, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grupo Advantage del Oeste, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grupo Advantage Metro, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Core, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Management Corporation </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Ventures Partner, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthKeepers, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthLink HMO, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthLink HMO</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthLink, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthPlus HP, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire BlueCross BlueShield HealthPlus&#59; Empire BlueCross HealthPlus</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthSun Health Plans, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthSun Physicians Network, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthSun Physicians Network I, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthy Alliance Life Insurance Company </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HEP AP Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Highland Acquisition Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Highland Intermediate Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Highland Investor Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HMO Colorado, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HMO Colorado&#59; HMO Nevada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HMO Missouri, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup Missouri&#59; Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IEC Group Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IEC Group, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmeriBen</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imaging Management Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InHealth Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Living Complete Technologies, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAI Software, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAPR Capital, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAPR Global, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAPR Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts Behavioral Health Partnership</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Thornton Health Plan, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Hampshire</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Dental Network Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meridian Resource Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri Care, Incorporated</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthy Blue&#59; Missouri Care&#59; Missouri Care Health Plan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMM Contact, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMM Healthcare, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMM Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMM Multi Health, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMM Transportation, LLC </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Momentum Health Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSO Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSO of Puerto Rico, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">myNEXUS Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyNexus, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">myNEXUS Management, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">myNEXUS NPHO of TEXAS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">myNEXUS NY IPA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nash Holding Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Government Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGS of Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New England Research Institutes, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summit  Community Care</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGS Federal, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optimum Healthcare, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPTIONS Health Care, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Bird Road, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Cutler Bay, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Group, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Hialeah Gardens, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Kendall, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Bird Road, LLC&#59; Pasteur Medical Center, LLC&#59; Pasteur Medical Cutler Bay, LLC&#59; Pasteur Medical Group, LLC&#59; Pasteur Medical Hialeah Gardens, LLC&#59; Pasteur Medical Kendall, LLC&#59; Pasteur Medical Miami Gardens, LLC&#59; Pasteur Medical North Miami Beach, LLC&#59; Pasteur Medical Partners, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Miami Gardens, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical North Miami Beach, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasteur Medical Center, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM Healthcare Solutions, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM IntraHospital Physician Group, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiDisciplinary Clinic Aguadilla LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiDisciplinary Clinic Arecibo LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiDisciplinary Clinic Cabo Rojo LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiDisciplinary Clinic Guayama LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiDisciplinary Clinic Maunabo LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiDisciplinary Clinic, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM MultiSalud, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHM Specialty Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Group Practices, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMC Medicare Choice, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RightCHOICE Managed Care, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RightCHOICE Benefit Administrators&#59; Anthem Blue Cross and Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rocky Mountain Hospital and Medical Service, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Blue Cross and Blue Shield&#59; Anthem Blue Cross Blue Shield</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SellCore, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SellCore Insurance Services, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simply Healthcare Plans, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clear Health Alliance&#59; Better Health&#59;  Amerigroup Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southeast Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Sponsored Services, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amerigroup GBD Disease Management Program&#59; Anthem GBD Disease Management Program&#59; Amerigroup GBD Behavioral Health&#59; Anthem GBD Behavioral  Health</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Elevance Health Companies of California, Inc. fka The Anthem Companies of California,  Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Elevance Health Companies, Inc. fka The Anthem Companies, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthem Health Plans&#59; Anthem Benefit Services&#59; Anthem Health Systems&#59; The Anthem Companies Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TrustSolutions, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UNICARE Health Plan of West Virginia, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Virginia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UNICARE Illinois Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UniCare Life &#38; Health Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UNICARE Adjuster</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UNICARE National Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UniCare Specialty Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ValueOptions Federal Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ValueOptions of New Jersey, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ValueOptions of Texas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VITA Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellmax Health Medical Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellmax Medical Center</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellmax Health Physicians Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint Acquisition, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint California Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint Dental Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellpoint Federal Corporation fka WellPoint Military Care Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint Health Solutions, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint Holding Corp.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellpoint Maryland, Inc. fka AMERIGROUP Maryland, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint Information Technology Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellPoint Insurance Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawaii</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin Collaborative Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>7
<FILENAME>exhibit23-20221231forform1.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i80b94f10a75942b3a4cbfbffac1a0d02_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Form S-8 No. 333-84906 and Form S-8 No. 333-129334 pertaining to the Elevance Health 401(k) Plan&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Form S-8 No. 333-156099 pertaining to the Elevance Health Employee Stock Purchase Plan&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Form S-8 No. 333-159830 pertaining to the Elevance Health Incentive Compensation Plan&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Form S-8 No. 333-218190 pertaining to the 2017 Elevance Health Incentive Compensation Plan&#59; and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Form S-3 No. 333-249877 pertaining to the Elevance Health, Inc. registration of senior debt securities, subordinated debt securities, preferred stock, common stock, depositary shares, warrants, rights, stock purchase contracts and stock purchase units</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">of our reports dated February 15, 2023, with respect to the consolidated financial statements and financial statement schedule listed in the Index at Item 15(c) of Elevance Health, Inc., and the effectiveness of internal control over financial reporting of Elevance Health, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;S&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 15, 2023</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>exhibit311-20221231for10xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifff7941765f245c6ac5f7ea0fc7cdb82_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gail K. Boudreaux, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this report on Form 10-K of Elevance Health, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:50.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 15, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; GAIL K. BOUDREAUX</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exhibit312-20221231for10xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i87ed3fbb054a4be9a77b6ce0e2b09c53_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John E. Gallina, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this report on Form 10-K of Elevance Health, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:50.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 15, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JOHN E. GALLINA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Executive Vice President and<br>&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>exhibit321-20221231for10xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia8f9b2f86d55468db2d07c9c408d3665_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Elevance Health, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:44.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; GAIL K. BOUDREAUX</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gail K. Boudreaux</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>exhibit322-20221231for10xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib8bda7749d534f70a49239ad5877cfdd_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Elevance Health, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John E. Gallina, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JOHN E. GALLINA</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John E. Gallina</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive&#160;Vice&#160;President&#160;and&#160;Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>elv-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:454c8386-f90e-4c1e-9f8b-5fb66238439f,g:9bb273fb-a44f-4fa9-8c35-d6fee14cceb5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:elv="http://www.elevancehealth.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.elevancehealth.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="elv-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="elv-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="elv-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="elv-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.elevancehealth.com/role/DocumentAndEntityInformation">
        <link:definition>0000001 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.elevancehealth.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.elevancehealth.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000005 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinEquity" roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity">
        <link:definition>0000008 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.elevancehealth.com/role/Organization">
        <link:definition>0000009 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Basis Of Presentation And Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitions" roleURI="http://www.elevancehealth.com/role/BusinessAcquisitions">
        <link:definition>0000011 - Disclosure - Business Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOptimizationInitiatives" roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiatives">
        <link:definition>0000012 - Disclosure - Business Optimization Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.elevancehealth.com/role/Investments">
        <link:definition>0000013 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstruments">
        <link:definition>0000014 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.elevancehealth.com/role/FairValue">
        <link:definition>0000015 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.elevancehealth.com/role/IncomeTaxes">
        <link:definition>0000016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.elevancehealth.com/role/PropertyAndEquipment">
        <link:definition>0000017 - Disclosure - Property And Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndOtherIntangibleAssets" roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets">
        <link:definition>0000018 - Disclosure - Goodwill And Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.elevancehealth.com/role/RetirementBenefits">
        <link:definition>0000019 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayable" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayable">
        <link:definition>0000020 - Disclosure - Medical Claims Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.elevancehealth.com/role/Debt">
        <link:definition>0000021 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.elevancehealth.com/role/CommitmentsAndContingencies">
        <link:definition>0000022 - Disclosure - Commitments And Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStock" roleURI="http://www.elevancehealth.com/role/CapitalStock">
        <link:definition>0000023 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLoss" roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss">
        <link:definition>0000024 - Disclosure - Accumulated Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Reinsurance" roleURI="http://www.elevancehealth.com/role/Reinsurance">
        <link:definition>0000025 - Disclosure - Reinsurance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.elevancehealth.com/role/Leases">
        <link:definition>0000026 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.elevancehealth.com/role/EarningsPerShare">
        <link:definition>0000027 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.elevancehealth.com/role/SegmentInformation">
        <link:definition>0000028 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.elevancehealth.com/role/RelatedPartyTransactions">
        <link:definition>0000029 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatutoryInformation" roleURI="http://www.elevancehealth.com/role/StatutoryInformation">
        <link:definition>0000030 - Disclosure - Statutory Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationOfRegistrant" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant">
        <link:definition>0000031 - Disclosure - Schedule II-Condensed Financial Information Of Registrant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesPolicy" roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy">
        <link:definition>0000032 - Disclosure - Basis Of Presentation And Significant Accounting Policies (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsTables" roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsTables">
        <link:definition>0000033 - Disclosure - Business Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOptimizationInitiativesTables" roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables">
        <link:definition>0000034 - Disclosure - Business Optimization Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.elevancehealth.com/role/InvestmentsTables">
        <link:definition>0000035 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>0000036 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.elevancehealth.com/role/FairValueTables">
        <link:definition>0000037 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.elevancehealth.com/role/IncomeTaxesTables">
        <link:definition>0000038 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentTables">
        <link:definition>0000039 - Disclosure - Property And Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndOtherIntangibleAssetsTables" roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables">
        <link:definition>0000040 - Disclosure - Goodwill And Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsTables">
        <link:definition>0000041 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableTables" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableTables">
        <link:definition>0000042 - Disclosure - Medical Claims Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.elevancehealth.com/role/DebtTables">
        <link:definition>0000043 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockTables" roleURI="http://www.elevancehealth.com/role/CapitalStockTables">
        <link:definition>0000044 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossTables" roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables">
        <link:definition>0000045 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceTables" roleURI="http://www.elevancehealth.com/role/ReinsuranceTables">
        <link:definition>0000046 - Disclosure - Reinsurance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.elevancehealth.com/role/LeasesTables">
        <link:definition>0000047 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.elevancehealth.com/role/EarningsPerShareTables">
        <link:definition>0000048 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.elevancehealth.com/role/SegmentInformationTables">
        <link:definition>0000049 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.elevancehealth.com/role/OrganizationDetails">
        <link:definition>0000050 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails">
        <link:definition>0000051 - Disclosure - Basis Of Presentation And Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails" roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails">
        <link:definition>0000052 - Disclosure - Business Acquisitions (Acquired tangible assets and liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsIntangibleAssetsAcquiredDetails" roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails">
        <link:definition>0000053 - Disclosure - Business Acquisitions (Intangible Assets Acquired) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsNarrativeDetails" roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails">
        <link:definition>0000054 - Disclosure - Business Acquisitions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails">
        <link:definition>0000055 - Disclosure - Business Optimization Initiatives (Employee Termination Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOptimizationInitiativesNarrativeDetails" roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails">
        <link:definition>0000056 - Disclosure - Business Optimization Initiatives (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails">
        <link:definition>0000057 - Disclosure - Investments (Current And Long-Term Investments, Available-For-Sale) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails">
        <link:definition>0000058 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails">
        <link:definition>0000059 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsCurrentEquitySecuritiesDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails">
        <link:definition>0000060 - Disclosure - Investments (Current Equity Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails">
        <link:definition>0000061 - Disclosure - Investments (Major Categories Of Net Investment Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNetGainsLossesOnInvestmentsDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails">
        <link:definition>0000062 - Disclosure - Investments (Net Gains/Losses On Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails">
        <link:definition>0000063 - Disclosure - Investments (Gains and Losses Recognized on Equity Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.elevancehealth.com/role/InvestmentsNarrativeDetails">
        <link:definition>0000064 - Disclosure - Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails">
        <link:definition>0000065 - Disclosure - Derivative Financial Instruments (Notional Amounts, Balance Sheet Location And Estimated Fair Values Of Derivative Financial Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails">
        <link:definition>0000066 - Disclosure - Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails">
        <link:definition>0000067 - Disclosure - Derivative Financial Instruments Derivative Financial Instruments (Fair Value Hedges, Financial Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails">
        <link:definition>0000068 - Disclosure - Derivative Financial Instruments (Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Gains (Losses) On Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsNarrativeDetails" roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails">
        <link:definition>0000069 - Disclosure - Derivative Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" roleURI="http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails">
        <link:definition>0000070 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" roleURI="http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails">
        <link:definition>0000071 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" roleURI="http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails">
        <link:definition>0000072 - Disclosure - Fair Value (Carrying and Fair Value By Level of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfDeferredIncomeTaxesDetails" roleURI="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails">
        <link:definition>0000073 - Disclosure - Income Taxes(Components Of Deferred Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>0000074 - Disclosure - Income Taxes (Components Of Provision For Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails" roleURI="http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails">
        <link:definition>0000075 - Disclosure - Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails" roleURI="http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails">
        <link:definition>0000076 - Disclosure - Income Taxes (Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000077 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
        <link:definition>0000078 - Disclosure - Property And Equipment (Summary Of Property And Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>0000079 - Disclosure - Property And Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails">
        <link:definition>0000080 - Disclosure - Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails">
        <link:definition>0000081 - Disclosure - Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails">
        <link:definition>0000082 - Disclosure - Goodwill And Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsReconciliationOfTheBenefitObligationDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails">
        <link:definition>0000083 - Disclosure - Retirement Benefits (Reconciliation Of The Benefit Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsChangesInFairValueOfPlanAssetsDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails">
        <link:definition>0000084 - Disclosure - Retirement Benefits (Changes In Fair Value Of Plan Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails">
        <link:definition>0000085 - Disclosure - Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails">
        <link:definition>0000086 - Disclosure - Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss That Have Not Been Recognized As Components Of Net Periodic Benefit Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails">
        <link:definition>0000087 - Disclosure - Retirement Benefits (Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails">
        <link:definition>0000088 - Disclosure - Retirement Benefits (Components Of Net Periodic Benefit Cost (Benefit Credit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails">
        <link:definition>0000089 - Disclosure - Retirement Benefits (Weighted-Average Assumptions Used In Calculating Net Periodic Benefit Cost For All Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails">
        <link:definition>0000090 - Disclosure - Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails">
        <link:definition>0000091 - Disclosure - Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails">
        <link:definition>0000092 - Disclosure - Retirement Benefits (Estimated Future Payments For Pension Benefits And Other Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNarrativeDetails" roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails">
        <link:definition>0000093 - Disclosure - Retirement Benefits (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails">
        <link:definition>0000094 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails">
        <link:definition>0000095 - Disclosure - Medical Claims Payable ((Favorable) Unfavorable Developments By Changes In Key Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails">
        <link:definition>0000096 - Disclosure - Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails">
        <link:definition>0000097 - Disclosure - Medical Claims Payable (Incurred and Paid Claims Development, Net of Reinsurance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails">
        <link:definition>0000098 - Disclosure - Medical Claims Payable (Reconciliation Of The Claims Development To The Claims Liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsPayableNarrativeDetails" roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails">
        <link:definition>0000099 - Disclosure - Medical Claims Payable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCarryingValueOfLongTermDebtDetails" roleURI="http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails">
        <link:definition>0000100 - Disclosure - Debt (Carrying Value Of Long-Term Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleDebentureTermsDetails" roleURI="http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails">
        <link:definition>0000101 - Disclosure - Debt (Convertible Debenture Terms) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.elevancehealth.com/role/DebtNarrativeDetails">
        <link:definition>0000102 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>0000103 - Disclosure - Commitments And Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockSummaryOfStockOptionActivityDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails">
        <link:definition>0000104 - Disclosure - Capital Stock (Summary Of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails">
        <link:definition>0000105 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails">
        <link:definition>0000106 - Disclosure - Capital Stock (Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockWeightedAverageFairValuesDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails">
        <link:definition>0000107 - Disclosure - Capital Stock (Weighted-Average Fair Values) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockCashDividendActivityDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails">
        <link:definition>0000108 - Disclosure - Capital Stock (Cash Dividend Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockShareRepurchasesDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails">
        <link:definition>0000109 - Disclosure - Capital Stock (Share Repurchases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockNarrativeDetails" roleURI="http://www.elevancehealth.com/role/CapitalStockNarrativeDetails">
        <link:definition>0000110 - Disclosure - Capital Stock (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000111 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails" roleURI="http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails">
        <link:definition>0000112 - Disclosure - Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Earned) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails" roleURI="http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails">
        <link:definition>0000113 - Disclosure - Reinsurance (Summary Of Net Premiums Earned By Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails" roleURI="http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails">
        <link:definition>0000114 - Disclosure - Reinsurance (Effect Of Reinsurance On Benefit Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseandOtherInformationDetails" roleURI="http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails">
        <link:definition>0000115 - Disclosure - Leases (Lease and Other Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" roleURI="http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails">
        <link:definition>0000116 - Disclosure - Leases Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesNarrativeDetails" roleURI="http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails">
        <link:definition>0000117 - Disclosure - Leases Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" roleURI="http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails">
        <link:definition>0000118 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>0000119 - Disclosure - Earnings Per Share (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationFinancialDataByReportableSegmentDetails" roleURI="http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails">
        <link:definition>0000120 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationMajorProductRevenuesDetails" roleURI="http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails">
        <link:definition>0000121 - Disclosure - Segment Information (Major Product Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails" roleURI="http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails">
        <link:definition>0000122 - Disclosure - Segment Information (Reconciliation Of Revenue From Reportable Segments To The Consolidated Statements Of Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails" roleURI="http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails">
        <link:definition>0000123 - Disclosure - Segment Information (Reconciliation Of Reportable Segment Operating Gain To Income Before Income Taxes In The Consolidated Statements Of Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000124 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000125 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatutoryInformationDetails" roleURI="http://www.elevancehealth.com/role/StatutoryInformationDetails">
        <link:definition>0000126 - Disclosure - Statutory Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails">
        <link:definition>0000127 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails">
        <link:definition>0000128 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Balance Sheets - Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails">
        <link:definition>0000129 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Statements Of Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails">
        <link:definition>0000130 - Disclosure - Schedule II-Condensed Financial Information of Registrant (Statement of Comprehensive Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails">
        <link:definition>0000131 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Statement Of Cash Flows) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails" roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails">
        <link:definition>0000132 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" abstract="true" name="IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_AffiliatedMember" abstract="true" name="AffiliatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DeferredTaxLiabilitiesNetMember" abstract="true" name="DeferredTaxLiabilitiesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_IngenioRxSegmentMember" abstract="true" name="IngenioRxSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" abstract="true" name="ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" abstract="true" name="FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DefinedBenefitAgeDomain" abstract="true" name="DefinedBenefitAgeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" abstract="false" name="ShortDurationContractLiabilityForClaimsAdjustmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" abstract="true" name="SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PartnershipInvestmentsMember" abstract="true" name="PartnershipInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ManagedCareProductsMember" abstract="true" name="ManagedCareProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_NetGainsLossesOnFinancialInstruments" abstract="false" name="NetGainsLossesOnFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_ManagedCareServicesMember" abstract="true" name="ManagedCareServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" abstract="true" name="CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" abstract="true" name="FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_A5YearFacilityMember" abstract="true" name="A5YearFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_CommercialPaperMaximumBorrowingCapacity" abstract="false" name="CommercialPaperMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" abstract="false" name="AmortizationExpenseOnSoftwareAndLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_A2022To2024Member" abstract="true" name="A2022To2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_IntangibleAssetsLineItems" abstract="true" name="IntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" abstract="true" name="ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" abstract="true" name="ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PPEImpairmentMember" abstract="true" name="PPEImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DebtRedemptionAmount" abstract="false" name="DebtRedemptionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_IntegratedHealthServicesMember" abstract="true" name="IntegratedHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_A2021364DayFacilityMember" abstract="true" name="A2021364DayFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_Notionalamountterminatedderivatives" abstract="false" name="Notionalamountterminatedderivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" abstract="true" name="NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" abstract="true" name="FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_NetLossesGainsOnFinancialInstruments" abstract="false" name="NetLossesGainsOnFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_MedicalClaimsPayableAbstract" abstract="true" name="MedicalClaimsPayableAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_TotalLevelIIIassetcategoriesAxis" abstract="true" name="TotalLevelIIIassetcategoriesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_OperationalMember" abstract="true" name="OperationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_AcquisitionYearDomain" abstract="true" name="AcquisitionYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_OtherSegmentMember" abstract="true" name="OtherSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" abstract="false" name="FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_ConversionPremium" abstract="false" name="ConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_InvestmentInSubsidiaries" abstract="false" name="InvestmentInSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_LimitedCarryforwardPeriodMember" abstract="true" name="LimitedCarryforwardPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" abstract="true" name="InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DataProcessingEquipmentAndSoftwareMember" abstract="true" name="DataProcessingEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" abstract="false" name="OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" abstract="false" name="PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_InvestmentInDOL10312TrustMember" abstract="true" name="InvestmentInDOL10312TrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_GainsFromOtherInvestments" abstract="false" name="GainsFromOtherInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_LifeInsuranceContractsMember" abstract="true" name="LifeInsuranceContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DebtConversionDebtPrincipalAmount" abstract="false" name="DebtConversionDebtPrincipalAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_NetGainsLossesOnFinancialInstrumentsMember" abstract="true" name="NetGainsLossesOnFinancialInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_InsuranceCompanyContractsMember" abstract="true" name="InsuranceCompanyContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PerformancemeasurementperiodAxis" abstract="true" name="PerformancemeasurementperiodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" abstract="false" name="ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" abstract="true" name="FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_StockOptionTerm" abstract="false" name="StockOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" abstract="false" name="PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" abstract="true" name="FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_UnaffiliatedMember" abstract="true" name="UnaffiliatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" abstract="false" name="DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" abstract="false" name="FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" abstract="false" name="CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_TerminationsDomain" abstract="true" name="TerminationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" abstract="true" name="InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" abstract="true" name="ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_DefinedBenefitPlanByAgeAxis" abstract="true" name="DefinedBenefitPlanByAgeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ShortdurationInsuranceContractsClaimYearTable" abstract="true" name="ShortdurationInsuranceContractsClaimYearTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_SelfFundedReceivablesNet" abstract="false" name="SelfFundedReceivablesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" abstract="true" name="ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" abstract="false" name="ClaimsSettlementsToBePaidFromOtherBenefitAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" abstract="true" name="FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_StatutoryInformationTextBlock" abstract="false" name="StatutoryInformationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_HedgingStatusDomain" abstract="true" name="HedgingStatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" abstract="true" name="InterestRateReceivedFourPointOneZeroOnePercentageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_OtherDerivativeInstrumentsMember" abstract="true" name="OtherDerivativeInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_MajorProductRevenueBySegmentTableTextBlock" abstract="false" name="MajorProductRevenueBySegmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" abstract="true" name="FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_DentalVisionProductsAndServicesMember" abstract="true" name="DentalVisionProductsAndServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_HealthInsuranceProviderFeePolicyTextBlock" abstract="false" name="HealthInsuranceProviderFeePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" abstract="true" name="TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" abstract="true" name="TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_LesseeOperatingLeasesTableTextBlock" abstract="false" name="LesseeOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_HedgingStatusAxis" abstract="true" name="HedgingStatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_CapitalContributionToSubsidiaries" abstract="false" name="CapitalContributionToSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_TotalExpenses" abstract="false" name="TotalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" abstract="true" name="ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" abstract="true" name="TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" abstract="true" name="TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ProductRevenue" abstract="false" name="ProductRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" abstract="false" name="SelffundedReceivablesAllowanceForDoubtfulAccounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_SurplusNotesMember" abstract="true" name="SurplusNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" abstract="true" name="SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_ShortTermAndVariableLeaseCost" abstract="false" name="ShortTermAndVariableLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" abstract="true" name="InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" abstract="true" name="FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_InterestRateReceivedFivePointFiveZeroPercentageMember" abstract="true" name="InterestRateReceivedFivePointFiveZeroPercentageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" abstract="false" name="ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_CaliforniaDepartmentofManagedHealthCareMember" abstract="true" name="CaliforniaDepartmentofManagedHealthCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_NetPremiumsWrittenAndEarnedBySegmentTable" abstract="true" name="NetPremiumsWrittenAndEarnedBySegmentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesNonUSIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" abstract="false" name="SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" abstract="true" name="ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" abstract="true" name="ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_InvestmentGainsLosses" abstract="false" name="InvestmentGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" abstract="true" name="FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" abstract="true" name="ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" abstract="false" name="FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_SeniorUnsecuredNotesMember" abstract="true" name="SeniorUnsecuredNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_CommonEquitySecuritiesMember" abstract="true" name="CommonEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_GrossLossesFromOtherInvestments" abstract="false" name="GrossLossesFromOtherInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_CommercialSpecialtyBusinessSegmentMember" abstract="true" name="CommercialSpecialtyBusinessSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" abstract="false" name="PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_PharmacyProductsAndServicesMember" abstract="true" name="PharmacyProductsAndServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" abstract="true" name="TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" abstract="true" name="FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_Proceedsfromsaleofequityandfixedmaturitysecurities" abstract="false" name="Proceedsfromsaleofequityandfixedmaturitysecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_DefinedBenefitFairValueDueFromBrokers" abstract="false" name="DefinedBenefitFairValueDueFromBrokers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_OperatingRevenue" abstract="false" name="OperatingRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_GovernmentBusinessSegmentMember" abstract="true" name="GovernmentBusinessSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_NumberOfConsecutiveTradingDays" abstract="false" name="NumberOfConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="elv_InvestmentsinequitysecuritiesTableTextBlock" abstract="false" name="InvestmentsinequitysecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_Impairmentlossesreversalsoninvestments" abstract="false" name="Impairmentlossesreversalsoninvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_StatutoryInformationAbstract" abstract="true" name="StatutoryInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" abstract="true" name="NonCreditComponentsOfImpairmentsOnInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_AcquisitionYearPriorDomain" abstract="true" name="AcquisitionYearPriorDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" abstract="true" name="FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_MajorProductRevenueBySegmentTable" abstract="true" name="MajorProductRevenueBySegmentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_EquitySecurities" abstract="false" name="EquitySecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" abstract="true" name="BasisOfPresentationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_OtherSeniorUnsecuredNotesMember" abstract="true" name="OtherSeniorUnsecuredNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" abstract="false" name="EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_GrossPremiumTaxRate" abstract="false" name="GrossPremiumTaxRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_PercentConversionToStockPrice" abstract="false" name="PercentConversionToStockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" abstract="true" name="TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_QualityImprovementAndOtherClaimsExpense" abstract="false" name="QualityImprovementAndOtherClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" abstract="true" name="EquitySecuritiesotherAssetsotherLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_IncreaseInStockRepurchaseProgramAuthorization" abstract="false" name="IncreaseInStockRepurchaseProgramAuthorization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" abstract="true" name="FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_SegmentEliminationsMember" abstract="true" name="SegmentEliminationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_OtherPolicyholderLiabilitiesPolicyTextBlock" abstract="false" name="OtherPolicyholderLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_DateDebenturesReedemable" abstract="false" name="DateDebenturesReedemable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="elv_TwoThousandTwentyMember" abstract="true" name="TwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoThousandTwentyTwoMember" abstract="true" name="TwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" abstract="false" name="PatientProtectionAffordableCareActHealthInsuranceProviderFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" abstract="true" name="TotalPlanAssetsExcludingPartnershipInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_MeasurementPeriod" abstract="false" name="MeasurementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="elv_TotalIntangibleAssetsAcquired" abstract="false" name="TotalIntangibleAssetsAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_APCPasseLLCMember" abstract="true" name="APCPasseLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" abstract="true" name="FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" abstract="true" name="ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_AnthemInc.v.ExpressScriptsInc.Member" abstract="true" name="AnthemInc.v.ExpressScriptsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_AcquisitionYearAxis" abstract="true" name="AcquisitionYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" abstract="true" name="TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_LeaseImpairmentMember" abstract="true" name="LeaseImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_IntangibleAssetsTable" abstract="true" name="IntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" abstract="false" name="ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" abstract="true" name="ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_MajorProductRevenueBySegmentLineItems" abstract="true" name="MajorProductRevenueBySegmentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" abstract="false" name="IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" abstract="true" name="ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_DefinedBenefitPlanBenefitsPaidFairValue" abstract="false" name="DefinedBenefitPlanBenefitsPaidFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_CapitalStockAxis" abstract="true" name="CapitalStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="elv_PreMedicareMember" abstract="true" name="PreMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PharmacypricingMember" abstract="true" name="PharmacypricingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" abstract="true" name="ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_NumberOfCountiesInGeographicalRegionNotServed" abstract="false" name="NumberOfCountiesInGeographicalRegionNotServed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" abstract="true" name="FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" abstract="true" name="TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" abstract="true" name="FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_CommingledFundDomain" abstract="true" name="CommingledFundDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_Fairvaluehedgescumulativebasisadjustments" abstract="false" name="Fairvaluehedgescumulativebasisadjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_InterestRateReceivedThreePointThreeZeroPercentageMember" abstract="true" name="InterestRateReceivedThreePointThreeZeroPercentageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" abstract="false" name="NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="elv_NumberOfMedicalMembersServed" abstract="false" name="NumberOfMedicalMembersServed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" abstract="false" name="ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" abstract="false" name="ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_EstimatedFutureDividendPayments" abstract="false" name="EstimatedFutureDividendPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" abstract="true" name="FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" abstract="true" name="FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" abstract="true" name="FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" abstract="false" name="StockRepurchasedAndRetiredDuringPeriodAveragePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" abstract="true" name="TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_CapitalStockDomain" abstract="true" name="CapitalStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" abstract="false" name="ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" abstract="true" name="ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_TwoThousandEighteenMember" abstract="true" name="TwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_ThirdPartyInvestmentsMember" abstract="true" name="ThirdPartyInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_HealthInsuranceProviderfeeMember" abstract="true" name="HealthInsuranceProviderfeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" abstract="true" name="BasisOfPresentationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" abstract="true" name="FivePointEightZeroZeroPercentDueTwoThousandFortyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_TwoThousandTwentyOneMember" abstract="true" name="TwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_RatedNotesMember" abstract="true" name="RatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_BusinessOptimizationInitiativesAbstract" abstract="true" name="BusinessOptimizationInitiativesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="elv_TotalLevelIIIassetcategoriesDomain" abstract="true" name="TotalLevelIIIassetcategoriesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PostMedicareMember" abstract="true" name="PostMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_IncomeTaxRefundClaimsFiled" abstract="false" name="IncomeTaxRefundClaimsFiled" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" abstract="true" name="OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_PerformancemeasurementperiodDomain" abstract="true" name="PerformancemeasurementperiodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" abstract="false" name="EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>elv-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:454c8386-f90e-4c1e-9f8b-5fb66238439f,g:9bb273fb-a44f-4fa9-8c35-d6fee14cceb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1090b4ec-1795-445f-91dd-a09c97bd7cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1090b4ec-1795-445f-91dd-a09c97bd7cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPolicyholderFunds_783f465f-8dac-40e3-b670-78c876ac9890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPolicyholderFunds"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_OtherPolicyholderFunds_783f465f-8dac-40e3-b670-78c876ac9890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_7ed7fa1c-9ca7-4421-bbaf-61737373426c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnearnedPremiums"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_UnearnedPremiums_7ed7fa1c-9ca7-4421-bbaf-61737373426c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_50f9d21e-2b00-499d-877b-2a91f21d9112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_50f9d21e-2b00-499d-877b-2a91f21d9112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_87097cc7-e7e4-43f5-aa33-10eb384c3771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_ShortTermBorrowings_87097cc7-e7e4-43f5-aa33-10eb384c3771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2c9df24a-afaf-45a2-8861-5ef25719df3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_LongTermDebtCurrent_2c9df24a-afaf-45a2-8861-5ef25719df3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ceba24c4-9485-4971-8a95-911e6084f278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4007d998-d626-4aca-94c0-d39793693cba" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ceba24c4-9485-4971-8a95-911e6084f278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f452c83b-a8f1-4b30-9a9e-79a76a5f2569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2ab2165e-b4c4-4c4d-a5f5-5b7d52b4d3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f452c83b-a8f1-4b30-9a9e-79a76a5f2569" xlink:to="loc_us-gaap_PreferredStockValue_2ab2165e-b4c4-4c4d-a5f5-5b7d52b4d3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b6a6eb4f-7eae-4444-a515-c87734526f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f452c83b-a8f1-4b30-9a9e-79a76a5f2569" xlink:to="loc_us-gaap_CommonStockValue_b6a6eb4f-7eae-4444-a515-c87734526f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_72f1f506-d04e-4a1d-bcb3-3603792fb406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f452c83b-a8f1-4b30-9a9e-79a76a5f2569" xlink:to="loc_us-gaap_AdditionalPaidInCapital_72f1f506-d04e-4a1d-bcb3-3603792fb406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_628edb8f-3e2e-487a-9027-73c61e54ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f452c83b-a8f1-4b30-9a9e-79a76a5f2569" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_628edb8f-3e2e-487a-9027-73c61e54ffbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_581f3c22-353e-41cf-a03f-939d79d59fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f452c83b-a8f1-4b30-9a9e-79a76a5f2569" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_581f3c22-353e-41cf-a03f-939d79d59fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5081ccb7-72f9-469e-a71c-cfa8c8206064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_AssetsCurrent_5081ccb7-72f9-469e-a71c-cfa8c8206064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f4ad2fa5-ecd8-4454-9180-08d663a49645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f4ad2fa5-ecd8-4454-9180-08d663a49645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_3058b34c-224d-49f7-bad6-834ddd886577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_OtherLongTermInvestments_3058b34c-224d-49f7-bad6-834ddd886577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_64edf9f2-98be-4cba-9fe6-f22a1e1bd9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_64edf9f2-98be-4cba-9fe6-f22a1e1bd9f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bbb88c8c-974b-40f3-9d6d-0302d76c7351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_Goodwill_bbb88c8c-974b-40f3-9d6d-0302d76c7351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0da98182-3997-434f-8081-e77420247856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0da98182-3997-434f-8081-e77420247856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8afa59ce-c77c-461f-8e13-e30a846715a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53e7800d-55ce-4486-8e4c-a1f2f30e0999" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8afa59ce-c77c-461f-8e13-e30a846715a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2562a575-eea9-4aa0-b395-4346ba5b39f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_587e48a7-826e-46c5-89ca-a4c52c64482e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2562a575-eea9-4aa0-b395-4346ba5b39f3" xlink:to="loc_us-gaap_LiabilitiesCurrent_587e48a7-826e-46c5-89ca-a4c52c64482e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6e5e58b9-f849-40a3-bcd9-29236c4de8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2562a575-eea9-4aa0-b395-4346ba5b39f3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6e5e58b9-f849-40a3-bcd9-29236c4de8b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_99facd16-553d-46bf-a90c-c4223a98bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2562a575-eea9-4aa0-b395-4346ba5b39f3" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_99facd16-553d-46bf-a90c-c4223a98bbb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3a19e301-9c3c-4d13-a5bf-e1908f7752c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2562a575-eea9-4aa0-b395-4346ba5b39f3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3a19e301-9c3c-4d13-a5bf-e1908f7752c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4e27bff4-4093-45a5-9e1b-bc0e480d4ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2562a575-eea9-4aa0-b395-4346ba5b39f3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4e27bff4-4093-45a5-9e1b-bc0e480d4ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3876c681-da52-41e0-966f-9254155489c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3876c681-da52-41e0-966f-9254155489c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2b066a7-6407-4cae-900e-3210e9717e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2b066a7-6407-4cae-900e-3210e9717e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_ba99a787-9eb1-4925-936f-b2bbe870a897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_ba99a787-9eb1-4925-936f-b2bbe870a897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_e66d4da6-0e29-41b6-afbf-572a5130ffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_e66d4da6-0e29-41b6-afbf-572a5130ffd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SelfFundedReceivablesNet_b2c55ffd-6d0b-4cd4-823e-9acb3f6215e9" xlink:href="elv-20221231.xsd#elv_SelfFundedReceivablesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_elv_SelfFundedReceivablesNet_b2c55ffd-6d0b-4cd4-823e-9acb3f6215e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_7c17928e-4756-494c-91b9-3cd186307654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_us-gaap_OtherReceivables_7c17928e-4756-494c-91b9-3cd186307654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d1ca6fd0-aeb5-424d-b51c-bb2dcffa0e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242e740f-ca27-4253-a860-d7ad1ddfffb7" xlink:to="loc_us-gaap_OtherAssetsCurrent_d1ca6fd0-aeb5-424d-b51c-bb2dcffa0e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e220179-2d06-4efa-a03a-9049e024c1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c1f7a806-e46c-4bbb-802a-f1438c56f503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e220179-2d06-4efa-a03a-9049e024c1d7" xlink:to="loc_us-gaap_Liabilities_c1f7a806-e46c-4bbb-802a-f1438c56f503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec332834-b13c-4327-9b45-86cc4ce7f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e220179-2d06-4efa-a03a-9049e024c1d7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec332834-b13c-4327-9b45-86cc4ce7f7a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c47ed591-30aa-40a4-91ee-b8488752345b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e220179-2d06-4efa-a03a-9049e024c1d7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c47ed591-30aa-40a4-91ee-b8488752345b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7e4e2dc-ef22-4543-afd9-6fb6274f86b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a18d91f7-9ac2-4b56-b7be-a39f514886d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7e4e2dc-ef22-4543-afd9-6fb6274f86b1" xlink:to="loc_us-gaap_MinorityInterest_a18d91f7-9ac2-4b56-b7be-a39f514886d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b93b90e9-1e24-4e4a-9f32-709b44bbdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7e4e2dc-ef22-4543-afd9-6fb6274f86b1" xlink:to="loc_us-gaap_StockholdersEquity_b93b90e9-1e24-4e4a-9f32-709b44bbdca3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c558ba4a-61e6-4051-a7d1-73c4d9b9e583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_79a29f59-e1c7-42a8-a527-ffb561fb1dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c558ba4a-61e6-4051-a7d1-73c4d9b9e583" xlink:to="loc_us-gaap_ProfitLoss_79a29f59-e1c7-42a8-a527-ffb561fb1dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3283b6dc-4e5e-4278-8fff-5de9ea50f451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c558ba4a-61e6-4051-a7d1-73c4d9b9e583" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3283b6dc-4e5e-4278-8fff-5de9ea50f451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fd5cab33-2cae-418c-9b0e-e47acbad6aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperatingRevenue_79b90627-aa29-428b-9fbf-f2f16292e52a" xlink:href="elv-20221231.xsd#elv_OperatingRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_fd5cab33-2cae-418c-9b0e-e47acbad6aa5" xlink:to="loc_elv_OperatingRevenue_79b90627-aa29-428b-9fbf-f2f16292e52a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_c9bf7b94-2f08-4adf-96eb-ea11eca485d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_fd5cab33-2cae-418c-9b0e-e47acbad6aa5" xlink:to="loc_us-gaap_NetInvestmentIncome_c9bf7b94-2f08-4adf-96eb-ea11eca485d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_339eab80-6ff7-4163-8bfb-5eda10931a4a" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_fd5cab33-2cae-418c-9b0e-e47acbad6aa5" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_339eab80-6ff7-4163-8bfb-5eda10931a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7758478-dd2c-4d84-b273-4053484e78cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_56e969d1-1091-4f01-b6e4-6f459c45a261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7758478-dd2c-4d84-b273-4053484e78cc" xlink:to="loc_us-gaap_Revenues_56e969d1-1091-4f01-b6e4-6f459c45a261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_7c76188c-a443-45e8-91f6-94b4b786d317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7758478-dd2c-4d84-b273-4053484e78cc" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_7c76188c-a443-45e8-91f6-94b4b786d317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_33a3092a-c113-48ad-8562-10c67251e8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_feff9cc9-3e29-4c20-8f5c-9401e6f2f47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_33a3092a-c113-48ad-8562-10c67251e8e4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_feff9cc9-3e29-4c20-8f5c-9401e6f2f47c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0f74783e-b814-4391-a5fe-b5bc618ed577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_33a3092a-c113-48ad-8562-10c67251e8e4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0f74783e-b814-4391-a5fe-b5bc618ed577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_10d45c84-578d-4685-aab3-efdab255e9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_10d45c84-578d-4685-aab3-efdab255e9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8803e407-d9de-4766-a271-11b7257b568d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8803e407-d9de-4766-a271-11b7257b568d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56070f82-f876-4941-9303-ee35434924cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56070f82-f876-4941-9303-ee35434924cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b2b2dde4-67f5-4d7f-8e88-a15414f6da7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:to="loc_us-gaap_InterestExpense_b2b2dde4-67f5-4d7f-8e88-a15414f6da7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3f1ca889-8e50-4cb5-af48-62c0475f9039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3f1ca889-8e50-4cb5-af48-62c0475f9039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_68a68945-8c10-440e-8c72-299241ca1036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_20f141f5-1f51-40c3-a1c8-0f92696dde5f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_68a68945-8c10-440e-8c72-299241ca1036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperatingRevenue_720ecbbf-1737-439c-80f3-4a2a74011223" xlink:href="elv-20221231.xsd#elv_OperatingRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_ffc4de58-0e6a-420a-9efb-7c298fef129a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_elv_OperatingRevenue_720ecbbf-1737-439c-80f3-4a2a74011223" xlink:to="loc_us-gaap_PremiumsEarnedNet_ffc4de58-0e6a-420a-9efb-7c298fef129a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_776f422b-1259-4eb6-9e97-33f488f9c913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_elv_OperatingRevenue_720ecbbf-1737-439c-80f3-4a2a74011223" xlink:to="loc_us-gaap_OtherIncome_776f422b-1259-4eb6-9e97-33f488f9c913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ProductRevenue_4beaec49-a3ec-4992-8807-d733cf304289" xlink:href="elv-20221231.xsd#elv_ProductRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_elv_OperatingRevenue_720ecbbf-1737-439c-80f3-4a2a74011223" xlink:to="loc_elv_ProductRevenue_4beaec49-a3ec-4992-8807-d733cf304289" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdf0cf00-0863-4c64-8ea7-77f7122ebd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d971a5ec-46f2-4afe-a456-229dc06215e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdf0cf00-0863-4c64-8ea7-77f7122ebd87" xlink:to="loc_us-gaap_ProfitLoss_d971a5ec-46f2-4afe-a456-229dc06215e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f04af23-1954-413a-8e6d-cf87c9f5c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdf0cf00-0863-4c64-8ea7-77f7122ebd87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f04af23-1954-413a-8e6d-cf87c9f5c47d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_18536cdd-a6b8-47f2-a76b-5435d4b33fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdf0cf00-0863-4c64-8ea7-77f7122ebd87" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_18536cdd-a6b8-47f2-a76b-5435d4b33fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_fbc62b96-ef8e-490f-b80c-9528d0cc817a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdf0cf00-0863-4c64-8ea7-77f7122ebd87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_fbc62b96-ef8e-490f-b80c-9528d0cc817a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_86da9a9e-a06e-4dd0-ade7-095222491ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1efd0425-adaa-4a4a-8cdf-7ae0276b0dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_86da9a9e-a06e-4dd0-ade7-095222491ded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1efd0425-adaa-4a4a-8cdf-7ae0276b0dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_0dc0dad0-b2f1-48b8-a8df-c06c35017d65" xlink:href="elv-20221231.xsd#elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_86da9a9e-a06e-4dd0-ade7-095222491ded" xlink:to="loc_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_0dc0dad0-b2f1-48b8-a8df-c06c35017d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bdaa6532-8675-4d09-8829-dab45868318c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_86da9a9e-a06e-4dd0-ade7-095222491ded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bdaa6532-8675-4d09-8829-dab45868318c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_970e4280-2e9a-40bd-b638-ab51defa3025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_86da9a9e-a06e-4dd0-ade7-095222491ded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_970e4280-2e9a-40bd-b638-ab51defa3025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_11a66b95-f978-44f6-b70a-a2d737dab268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_86da9a9e-a06e-4dd0-ade7-095222491ded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_11a66b95-f978-44f6-b70a-a2d737dab268" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98b916f4-6a63-4d94-a7ba-7e1271b1492c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_ProfitLoss_98b916f4-6a63-4d94-a7ba-7e1271b1492c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_f97367ae-2b40-422a-b69f-e93f625fbdcb" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_f97367ae-2b40-422a-b69f-e93f625fbdcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_827a1840-c949-4679-8cc3-61c689cbb202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_827a1840-c949-4679-8cc3-61c689cbb202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc5f4988-f268-467a-a189-1f61cd420d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc5f4988-f268-467a-a189-1f61cd420d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_28ab7490-f3fb-4a17-9f5e-3d09adb56e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_28ab7490-f3fb-4a17-9f5e-3d09adb56e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_60bd7d63-5262-4367-aa25-de125f112a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_ShareBasedCompensation_60bd7d63-5262-4367-aa25-de125f112a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_a92e141b-ef83-473d-bed5-8b30c6618894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_a92e141b-ef83-473d-bed5-8b30c6618894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_bb826958-6816-4b71-8b4d-d30317e7711f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTradingSecurities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInTradingSecurities_bb826958-6816-4b71-8b4d-d30317e7711f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1828c3df-eece-4a6c-95aa-058d54ed2f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1828c3df-eece-4a6c-95aa-058d54ed2f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_49c65696-fb40-4327-a4c7-280adcca8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_49c65696-fb40-4327-a4c7-280adcca8d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_190a4934-68e1-41f2-85ee-d243c7009936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_190a4934-68e1-41f2-85ee-d243c7009936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_e8418617-09fd-4340-87c1-7769b5b37851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_e8418617-09fd-4340-87c1-7769b5b37851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_9c2b9510-5d38-4de9-904d-d09d93151271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_9c2b9510-5d38-4de9-904d-d09d93151271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e45788ee-2492-4bd4-b056-d6e5d586cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e45788ee-2492-4bd4-b056-d6e5d586cd84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa02b8ab-87f1-4c23-a53f-ed14b21ab607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fda8adf-b082-4e3e-82b4-eed982159b59" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa02b8ab-87f1-4c23-a53f-ed14b21ab607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d287bd08-05f7-4298-bfa9-bdc668c95b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae494d42-f55b-4746-899c-f83581459f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d287bd08-05f7-4298-bfa9-bdc668c95b3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae494d42-f55b-4746-899c-f83581459f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d5e6f1-df33-47e0-9c46-9cbc0413df33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d287bd08-05f7-4298-bfa9-bdc668c95b3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d5e6f1-df33-47e0-9c46-9cbc0413df33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42d25210-afa2-4cbf-b8d3-c6b72e2860fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d287bd08-05f7-4298-bfa9-bdc668c95b3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42d25210-afa2-4cbf-b8d3-c6b72e2860fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_baf82c94-c1d8-4618-9cb0-3d0ef4d21803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d287bd08-05f7-4298-bfa9-bdc668c95b3c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_baf82c94-c1d8-4618-9cb0-3d0ef4d21803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_ee4ee50b-8f3f-4706-b31c-3f4f0ae47448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_ee4ee50b-8f3f-4706-b31c-3f4f0ae47448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_409868dc-05ba-44da-8f1b-e18faa4062b6" xlink:href="elv-20221231.xsd#elv_Proceedsfromsaleofequityandfixedmaturitysecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_409868dc-05ba-44da-8f1b-e18faa4062b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c7aab163-0ca7-41c8-9134-5096831ae7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c7aab163-0ca7-41c8-9134-5096831ae7ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_be00fa75-d856-4e54-bc7e-6586c508ea43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_be00fa75-d856-4e54-bc7e-6586c508ea43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_97470c84-ac56-4bf3-be89-f68a4eba20e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_97470c84-ac56-4bf3-be89-f68a4eba20e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85855dd5-dcf8-49a5-ac38-4761b79c289e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85855dd5-dcf8-49a5-ac38-4761b79c289e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fd7b2784-eafe-4117-a59f-78b36c2a5092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f755fd5-763a-49f6-b0f9-4e9d5ef68a30" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fd7b2784-eafe-4117-a59f-78b36c2a5092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_a8ccfc54-e9b2-426b-ae8b-a1fc7eb8d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_a8ccfc54-e9b2-426b-ae8b-a1fc7eb8d1ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_33507842-e165-410e-9dd0-bf4358ab5ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_33507842-e165-410e-9dd0-bf4358ab5ebc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_16a8a4dc-90a8-43d9-9cae-3861ac88e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_16a8a4dc-90a8-43d9-9cae-3861ac88e3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_e48f8b59-1ac3-4d98-9307-e19a5eafb52c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_e48f8b59-1ac3-4d98-9307-e19a5eafb52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_29de8b0d-4545-4585-8de3-c4243ef1a1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_29de8b0d-4545-4585-8de3-c4243ef1a1ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_4edbde4b-a627-40e0-b879-099a930bf7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecuritiesLendingPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_4edbde4b-a627-40e0-b879-099a930bf7c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b6e2d6bb-a2eb-4039-9caa-79508221fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b6e2d6bb-a2eb-4039-9caa-79508221fd18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities_0f9928b5-261d-4ba5-ac75-1ab2cb84f5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities_0f9928b5-261d-4ba5-ac75-1ab2cb84f5bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c6993051-0637-4af2-976f-2700ec40578e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_PaymentsOfDividends_c6993051-0637-4af2-976f-2700ec40578e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_116ef40e-32bb-4e33-a16e-2ebade2f9ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_116ef40e-32bb-4e33-a16e-2ebade2f9ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5f176c57-c209-466d-8163-53df32cdf51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5f176c57-c209-466d-8163-53df32cdf51a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42bfd72e-a933-42b3-adef-1a95966c0baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c95b1242-11e9-44c4-962c-5e3a48d1d406" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42bfd72e-a933-42b3-adef-1a95966c0baa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5377edc-4a6f-4472-8390-28a0c0fa9cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_07bc402c-e8bd-4583-bd20-4d48c7366284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5377edc-4a6f-4472-8390-28a0c0fa9cec" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_07bc402c-e8bd-4583-bd20-4d48c7366284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bcc5ef36-2af9-455b-a511-2345083b0bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5377edc-4a6f-4472-8390-28a0c0fa9cec" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bcc5ef36-2af9-455b-a511-2345083b0bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_07dcde35-e46d-492c-8d20-1df939558534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5377edc-4a6f-4472-8390-28a0c0fa9cec" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_07dcde35-e46d-492c-8d20-1df939558534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_262c5f67-8984-438a-9d03-0df38b009845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5377edc-4a6f-4472-8390-28a0c0fa9cec" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_262c5f67-8984-438a-9d03-0df38b009845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_6c928f2c-3ba0-4369-ae1c-329c5f914f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5377edc-4a6f-4472-8390-28a0c0fa9cec" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_6c928f2c-3ba0-4369-ae1c-329c5f914f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_919d1286-4221-4232-aff6-3ee713d80960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2c727921-c95f-4434-a949-2257920bf9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_919d1286-4221-4232-aff6-3ee713d80960" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2c727921-c95f-4434-a949-2257920bf9f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_908686e4-6927-4380-9ef9-ce0e8456f847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_919d1286-4221-4232-aff6-3ee713d80960" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_908686e4-6927-4380-9ef9-ce0e8456f847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_d970adc8-5129-4964-8c8b-9987f74dd01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_919d1286-4221-4232-aff6-3ee713d80960" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_d970adc8-5129-4964-8c8b-9987f74dd01e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_fa6ed0f2-2e53-43ac-ac33-f4b3386d71fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_919d1286-4221-4232-aff6-3ee713d80960" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_fa6ed0f2-2e53-43ac-ac33-f4b3386d71fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_32ba3d3b-b8c6-4d63-9ae0-24086f70898f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_919d1286-4221-4232-aff6-3ee713d80960" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_32ba3d3b-b8c6-4d63-9ae0-24086f70898f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fefae4aa-0877-4d9b-adfc-62294bb36210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_62cbdc50-ff27-44a3-a144-bb88f4a2f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fefae4aa-0877-4d9b-adfc-62294bb36210" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_62cbdc50-ff27-44a3-a144-bb88f4a2f43d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_f6820289-7d86-465d-b7c2-d19d9218af70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fefae4aa-0877-4d9b-adfc-62294bb36210" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_f6820289-7d86-465d-b7c2-d19d9218af70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4badd9e0-bd51-4dcf-b438-86c184a40a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0f00f994-2c4d-4bc4-969c-b841585f6653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4badd9e0-bd51-4dcf-b438-86c184a40a41" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0f00f994-2c4d-4bc4-969c-b841585f6653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cb91dd3c-6c3f-42be-8f18-3b23579e2ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4badd9e0-bd51-4dcf-b438-86c184a40a41" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cb91dd3c-6c3f-42be-8f18-3b23579e2ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a265aa2f-4357-4cee-84dc-b1d0c527845b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4badd9e0-bd51-4dcf-b438-86c184a40a41" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a265aa2f-4357-4cee-84dc-b1d0c527845b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9d45fb9b-d9db-4c35-914a-157673df54aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9d45fb9b-d9db-4c35-914a-157673df54aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a3b3d5f2-aa2f-4956-8c44-a5adcdf86c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a3b3d5f2-aa2f-4956-8c44-a5adcdf86c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_15a63418-fb02-402e-bb7a-0ccdbf7a9c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_15a63418-fb02-402e-bb7a-0ccdbf7a9c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_8e5355f3-622e-43f8-94b2-2769822de346" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:to="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_8e5355f3-622e-43f8-94b2-2769822de346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_400d7717-5d1e-401e-aab8-13c7ef01cd93" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:to="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_400d7717-5d1e-401e-aab8-13c7ef01cd93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a69e22a0-5586-47c6-a2f5-53ce17b0d038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_de7c953d-90de-4ad8-afa3-e147e65c86ec" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a69e22a0-5586-47c6-a2f5-53ce17b0d038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e4bfb75c-7a7d-4c15-9a8c-1d51685e4491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e4bfb75c-7a7d-4c15-9a8c-1d51685e4491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_70344238-9a08-4e64-b9b9-ac5273f58e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_70344238-9a08-4e64-b9b9-ac5273f58e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductions_056c3980-ac8b-4319-928a-41e0d3cf47a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductions_056c3980-ac8b-4319-928a-41e0d3cf47a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_54df3a02-c81e-4d85-94eb-f3a0dbe7d1eb" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:to="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_54df3a02-c81e-4d85-94eb-f3a0dbe7d1eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_7b1c64af-53d4-4d47-8ced-8cea2abac0fc" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:to="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_7b1c64af-53d4-4d47-8ced-8cea2abac0fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9e0c2ad8-fa2a-4561-b7e3-67eec8d3aaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_79a7fa1e-d75f-4dfe-8fbf-6cbcc0f3958e" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9e0c2ad8-fa2a-4561-b7e3-67eec8d3aaec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_54365d63-e115-4311-a8bf-7f0c245145c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5abb2f2f-44a3-418b-8cd3-86e336d600ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_54365d63-e115-4311-a8bf-7f0c245145c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5abb2f2f-44a3-418b-8cd3-86e336d600ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9f63f0e-961b-4810-961f-54856f2ab863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_54365d63-e115-4311-a8bf-7f0c245145c5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9f63f0e-961b-4810-961f-54856f2ab863" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aad58a7d-6a46-42e3-a638-c6e7d1639899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4c641f6-ef67-49ff-ab3e-cbb2a8673fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aad58a7d-6a46-42e3-a638-c6e7d1639899" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4c641f6-ef67-49ff-ab3e-cbb2a8673fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7db50123-6677-4864-b068-96f18bdef962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aad58a7d-6a46-42e3-a638-c6e7d1639899" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7db50123-6677-4864-b068-96f18bdef962" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c27d07e8-f3c8-4278-9325-0b5f17a94657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b8ebc199-469e-46cd-9f6e-62dbee89ed33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c27d07e8-f3c8-4278-9325-0b5f17a94657" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b8ebc199-469e-46cd-9f6e-62dbee89ed33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_550e4569-3753-4c52-84f1-5eed17e0e1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c27d07e8-f3c8-4278-9325-0b5f17a94657" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_550e4569-3753-4c52-84f1-5eed17e0e1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_7d1ddc98-f366-44c8-8438-9f51396002bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c27d07e8-f3c8-4278-9325-0b5f17a94657" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_7d1ddc98-f366-44c8-8438-9f51396002bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_23de4c84-1cce-4019-ae95-25c2fe7e6b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_50d09ee4-9867-4021-84a3-9de29cd124ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_23de4c84-1cce-4019-ae95-25c2fe7e6b89" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_50d09ee4-9867-4021-84a3-9de29cd124ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_9b95be71-d75b-4dab-a437-10bc8b8c753a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_23de4c84-1cce-4019-ae95-25c2fe7e6b89" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_9b95be71-d75b-4dab-a437-10bc8b8c753a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_614e8a4e-632a-4c6c-b031-754c5ee5bba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_614e8a4e-632a-4c6c-b031-754c5ee5bba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_201634fd-b2ee-4d9b-b9ad-b856009fa670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_201634fd-b2ee-4d9b-b9ad-b856009fa670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_81ba65f9-12e7-4b50-acbc-8be7d38afa33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_81ba65f9-12e7-4b50-acbc-8be7d38afa33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a1d05ad2-c854-4c46-97b3-4ac6def8d512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a1d05ad2-c854-4c46-97b3-4ac6def8d512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_71bae906-9931-4ab9-b721-dd7b8bb86c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_71bae906-9931-4ab9-b721-dd7b8bb86c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_ab2d278c-849d-49a5-b485-b3a040d87c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9298201b-200e-4236-81be-441d860a3819" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_ab2d278c-849d-49a5-b485-b3a040d87c20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_4bedd3aa-7b72-4245-8a95-2917e67d880f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_7cfc19b3-5094-4869-ad04-82247dc0a7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_4bedd3aa-7b72-4245-8a95-2917e67d880f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_7cfc19b3-5094-4869-ad04-82247dc0a7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_12179d4c-3c98-4449-a754-b80ac60a60ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_4bedd3aa-7b72-4245-8a95-2917e67d880f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_12179d4c-3c98-4449-a754-b80ac60a60ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_501b1591-7755-476b-a437-dff7e83500eb" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_20651f34-40e5-4606-88c1-8011cd59d9bf" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_501b1591-7755-476b-a437-dff7e83500eb" xlink:to="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_20651f34-40e5-4606-88c1-8011cd59d9bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_eaed940a-9682-4e80-bf04-4873a4f128cb" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_501b1591-7755-476b-a437-dff7e83500eb" xlink:to="loc_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_eaed940a-9682-4e80-bf04-4873a4f128cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_f57ce113-9d2b-4314-9025-eeaf60ec9af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_f3776fd0-30a3-492d-9734-759a9bf30f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_f57ce113-9d2b-4314-9025-eeaf60ec9af3" xlink:to="loc_us-gaap_DirectPremiumsEarned_f3776fd0-30a3-492d-9734-759a9bf30f1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_7cc5b355-caa8-4680-82df-da12626a9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_f57ce113-9d2b-4314-9025-eeaf60ec9af3" xlink:to="loc_us-gaap_AssumedPremiumsEarned_7cc5b355-caa8-4680-82df-da12626a9a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_44b11949-712e-4395-8c61-33bf2aa23faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededPremiumsEarned"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_f57ce113-9d2b-4314-9025-eeaf60ec9af3" xlink:to="loc_us-gaap_CededPremiumsEarned_44b11949-712e-4395-8c61-33bf2aa23faf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_02383bd1-f83b-44d4-8c9b-4a24c9b05207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_e159af3c-5f81-4f95-b67b-d627fcecbf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_02383bd1-f83b-44d4-8c9b-4a24c9b05207" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_e159af3c-5f81-4f95-b67b-d627fcecbf5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_35c960de-3dca-46fe-b829-dfcc4b09b176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_02383bd1-f83b-44d4-8c9b-4a24c9b05207" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_35c960de-3dca-46fe-b829-dfcc4b09b176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_17ca6ad3-3e3e-401f-9fdb-5956ee1b6074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_02383bd1-f83b-44d4-8c9b-4a24c9b05207" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_17ca6ad3-3e3e-401f-9fdb-5956ee1b6074" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>elv-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:454c8386-f90e-4c1e-9f8b-5fb66238439f,g:9bb273fb-a44f-4fa9-8c35-d6fee14cceb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="elv-20221231.xsd#DocumentAndEntityInformation"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DocumentAndEntityInformation" xlink:type="extended" id="i596d860fc53f4b8e9bed61df7af9c4a6_DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c0743279-b68c-4256-b74a-74ee039e99aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentType_c0743279-b68c-4256-b74a-74ee039e99aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_41ad5b97-dc60-4ee3-97c8-9d0d2c6c9c05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentAnnualReport_41ad5b97-dc60-4ee3-97c8-9d0d2c6c9c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e3f3ba03-f520-4564-bf49-b5bb3198289c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentTransitionReport_e3f3ba03-f520-4564-bf49-b5bb3198289c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c73b8bf6-586e-4aef-a08b-cc1541031fcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_AmendmentFlag_c73b8bf6-586e-4aef-a08b-cc1541031fcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_72451c30-1953-4a38-8156-486cf762811d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentFiscalPeriodFocus_72451c30-1953-4a38-8156-486cf762811d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7794560c-a35c-4c62-835b-6071cb386f54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentFiscalYearFocus_7794560c-a35c-4c62-835b-6071cb386f54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5fafd394-58fb-44b5-8e0c-32029b47b540" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_CurrentFiscalYearEndDate_5fafd394-58fb-44b5-8e0c-32029b47b540" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f5a862c9-6075-463e-9d0a-1b45c5d6d00f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentPeriodEndDate_f5a862c9-6075-463e-9d0a-1b45c5d6d00f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_53812164-d484-4113-84a6-86cc4001c346" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityCentralIndexKey_53812164-d484-4113-84a6-86cc4001c346" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bab06580-7230-4aae-a526-65e07078fec3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityFileNumber_bab06580-7230-4aae-a526-65e07078fec3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c77c23a3-ec9f-4bae-ac12-fd0919229509" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityRegistrantName_c77c23a3-ec9f-4bae-ac12-fd0919229509" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dc29cac3-01a8-46ca-9527-c1cb55072c2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dc29cac3-01a8-46ca-9527-c1cb55072c2c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b46b3dcc-b126-4328-a9f8-c23348de26fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityTaxIdentificationNumber_b46b3dcc-b126-4328-a9f8-c23348de26fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd6832d3-bfa4-4f13-aaca-0f859f876310" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressAddressLine1_fd6832d3-bfa4-4f13-aaca-0f859f876310" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_310f73dc-9406-4859-a2b0-8c2cc31e1b64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressCityOrTown_310f73dc-9406-4859-a2b0-8c2cc31e1b64" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f362d1b5-4f0c-473c-815f-5481a77cbb62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressStateOrProvince_f362d1b5-4f0c-473c-815f-5481a77cbb62" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b48ad045-4a59-499a-9d0b-1a70d4c08ed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressPostalZipCode_b48ad045-4a59-499a-9d0b-1a70d4c08ed7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4159c5ea-026d-4a8c-98a0-ee1f4ea00c6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_CityAreaCode_4159c5ea-026d-4a8c-98a0-ee1f4ea00c6c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_862ded43-dcb9-4813-b391-6fd9c9be6e88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_LocalPhoneNumber_862ded43-dcb9-4813-b391-6fd9c9be6e88" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a0ad4359-06cd-47c7-974a-25381741a8f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_Security12bTitle_a0ad4359-06cd-47c7-974a-25381741a8f8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fce41c73-e20e-4cdd-a122-1b6cbec2d31a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_TradingSymbol_fce41c73-e20e-4cdd-a122-1b6cbec2d31a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d617d553-7e02-4e85-9561-1bdbe9d4fd95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_SecurityExchangeName_d617d553-7e02-4e85-9561-1bdbe9d4fd95" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0f610d49-4103-47a4-b9fc-d05deb0ab89b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0f610d49-4103-47a4-b9fc-d05deb0ab89b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dfb674af-d8be-4785-9d73-559f0b55481f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityVoluntaryFilers_dfb674af-d8be-4785-9d73-559f0b55481f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e10eae1e-6da7-4cb4-9652-0984a45c4cc6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityCurrentReportingStatus_e10eae1e-6da7-4cb4-9652-0984a45c4cc6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cca6187d-6fed-49c0-a80a-576fd4547344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityInteractiveDataCurrent_cca6187d-6fed-49c0-a80a-576fd4547344" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3e440f9b-4ae7-4eff-901d-7ddc29a0bec8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityFilerCategory_3e440f9b-4ae7-4eff-901d-7ddc29a0bec8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a68baebf-9dc0-4003-9a84-8d1d00471423" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntitySmallBusiness_a68baebf-9dc0-4003-9a84-8d1d00471423" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2478e885-313f-4494-bf08-4fa11edadd96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityEmergingGrowthCompany_2478e885-313f-4494-bf08-4fa11edadd96" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_6990cb0e-f41b-49e4-b02b-deea402e5c1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_IcfrAuditorAttestationFlag_6990cb0e-f41b-49e4-b02b-deea402e5c1d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_436766e3-45be-4858-ab8a-4233517b06a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityShellCompany_436766e3-45be-4858-ab8a-4233517b06a1" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4c34a068-9d03-4567-a5dc-62b2011056b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityPublicFloat_4c34a068-9d03-4567-a5dc-62b2011056b5" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_df582704-979d-4c41-a1c9-decf3ecc0df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_df582704-979d-4c41-a1c9-decf3ecc0df5" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da44f5d0-a8aa-47f9-8647-b75c85ff7cea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da44f5d0-a8aa-47f9-8647-b75c85ff7cea" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:to="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_049fc8de-ec27-40c0-994e-b123209981a4_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:to="loc_dei_EntityDomain_049fc8de-ec27-40c0-994e-b123209981a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b73c94bb-c05d-4719-9947-e4ac2d0a28d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:to="loc_dei_EntityDomain_b73c94bb-c05d-4719-9947-e4ac2d0a28d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended" id="i7dbf8f9520f3416da441182acedc1016_ConsolidatedStatementsofChangesinEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6975e5e4-f29e-491c-9c3e-87ec2eba00a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_SharesOutstanding_6975e5e4-f29e-491c-9c3e-87ec2eba00a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ca0e6f3-93f9-4612-9fb7-9fe39ad477ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StockholdersEquity_5ca0e6f3-93f9-4612-9fb7-9fe39ad477ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e6bd75a4-7f50-4774-97eb-6b0ad52970bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_MinorityInterest_e6bd75a4-7f50-4774-97eb-6b0ad52970bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10834908-0c17-40b4-851c-4eeec0ce1d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10834908-0c17-40b4-851c-4eeec0ce1d8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c04817f5-a7cb-4020-bf69-e16fe91e049e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_NetIncomeLoss_c04817f5-a7cb-4020-bf69-e16fe91e049e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4bd45102-72c6-46c5-9124-edc12be767ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4bd45102-72c6-46c5-9124-edc12be767ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7603c46a-c309-43c1-8a6e-9e69c34d1aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_ProfitLoss_7603c46a-c309-43c1-8a6e-9e69c34d1aab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bf37b94a-3459-4188-bb10-0db3a5334d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bf37b94a-3459-4188-bb10-0db3a5334d55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4f95eb25-dfd9-4e78-a7d6-ee3958140f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4f95eb25-dfd9-4e78-a7d6-ee3958140f76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b6090d5-ff19-42ea-a594-38431d422991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b6090d5-ff19-42ea-a594-38431d422991" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_265b9a12-aa4c-405a-aa0b-e99461b47980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_265b9a12-aa4c-405a-aa0b-e99461b47980" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7e1e2d3f-4419-4fc2-896b-8564b555950b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7e1e2d3f-4419-4fc2-896b-8564b555950b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d284715d-42ab-4e91-b35d-8f1d7612d4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d284715d-42ab-4e91-b35d-8f1d7612d4f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_844c8afb-d936-4571-91a5-55890a5849cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_DividendsCommonStock_844c8afb-d936-4571-91a5-55890a5849cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3f3255b-d638-4078-bcb8-adf6b738e333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3f3255b-d638-4078-bcb8-adf6b738e333" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ddecdea-e32a-44ed-beb8-e87054ba8cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ddecdea-e32a-44ed-beb8-e87054ba8cb7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_cf00d882-a7e3-47f6-a219-96bfebb20aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_cf00d882-a7e3-47f6-a219-96bfebb20aa6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f9c94eab-8603-42f9-a8c1-c03777502099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13e80c37-e6d8-4928-a4cf-33458f805e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4a61262c-53cb-4e96-b869-eedb634ea5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1e98a98-47d9-480b-a3a2-6a18ae3a647a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e9eb6d5a-c83e-4858-ba98-a54e4d042b57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:to="loc_us-gaap_EquityComponentDomain_e9eb6d5a-c83e-4858-ba98-a54e4d042b57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:to="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6150ede5-8d2e-4565-bc20-253f07ed05a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_CommonStockMember_6150ede5-8d2e-4565-bc20-253f07ed05a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a3b7d893-0cd8-4e33-86e5-49694d300c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a3b7d893-0cd8-4e33-86e5-49694d300c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3fcc0a20-8bd8-4fac-bb0b-89c783893970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_RetainedEarningsMember_3fcc0a20-8bd8-4fac-bb0b-89c783893970" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63c616b2-26ef-447f-9bc8-ad4a38546c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63c616b2-26ef-447f-9bc8-ad4a38546c73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d1df5502-2f77-404c-8288-c4e677c23885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d1df5502-2f77-404c-8288-c4e677c23885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ad110697-fb24-4f14-914a-9cbf51a32af1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ad110697-fb24-4f14-914a-9cbf51a32af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ba02270-d5fa-4b27-8f32-32fb5697d26e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ba02270-d5fa-4b27-8f32-32fb5697d26e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_41cc7bbb-3d69-48c6-9585-dd9ec27873cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_41cc7bbb-3d69-48c6-9585-dd9ec27873cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_84a252b9-c613-4a26-9d35-ee6ebba5e926_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:to="loc_us-gaap_TypeOfAdoptionMember_84a252b9-c613-4a26-9d35-ee6ebba5e926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a59645ed-86db-48e8-bfaa-b5b5ce205425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a59645ed-86db-48e8-bfaa-b5b5ce205425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_b1b264ab-7a46-4d0e-beab-d37346950dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a59645ed-86db-48e8-bfaa-b5b5ce205425" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_b1b264ab-7a46-4d0e-beab-d37346950dec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" id="i376af52af6154c83af782a71750cb4eb_BasisOfPresentationAndSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:href="elv-20221231.xsd#elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a9743611-89cc-4d7c-aa51-5a750ed23a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a9743611-89cc-4d7c-aa51-5a750ed23a82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_90732dfe-71f9-4a08-9b46-60faaf8a6da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_90732dfe-71f9-4a08-9b46-60faaf8a6da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_ddc32274-3596-4a87-90b5-d75ccbfa897e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_ddc32274-3596-4a87-90b5-d75ccbfa897e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_5530f9f2-c765-43fa-9c95-558b0c3d096c" xlink:href="elv-20221231.xsd#elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_5530f9f2-c765-43fa-9c95-558b0c3d096c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c40a3cf8-fb28-46b8-b878-4f6918a307c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c40a3cf8-fb28-46b8-b878-4f6918a307c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_babd146e-599f-47b1-a9e9-f3510f038b29" xlink:href="elv-20221231.xsd#elv_SelffundedReceivablesAllowanceForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_babd146e-599f-47b1-a9e9-f3510f038b29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_8d481487-d9b2-4551-8bc0-292cf8473640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_8d481487-d9b2-4551-8bc0-292cf8473640" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses_8fc469fa-c59d-439c-af82-500feaafb45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses_8fc469fa-c59d-439c-af82-500feaafb45b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aaedf489-6f11-4868-9e71-ff39f536401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aaedf489-6f11-4868-9e71-ff39f536401a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingAndAdvertisingExpense_5c57dde4-fc10-4c74-91c5-a82b0aeeaef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_MarketingAndAdvertisingExpense_5c57dde4-fc10-4c74-91c5-a82b0aeeaef8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_25189702-b43e-469d-bbf3-cbad1c4b8a6f" xlink:href="elv-20221231.xsd#elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_25189702-b43e-469d-bbf3-cbad1c4b8a6f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_ce81ad9a-2aaa-4cbb-b397-ece5cd6ff0b5" xlink:href="elv-20221231.xsd#elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_ce81ad9a-2aaa-4cbb-b397-ece5cd6ff0b5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384dfa6d-0a3b-49c8-8140-e245683702d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384dfa6d-0a3b-49c8-8140-e245683702d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2862f95a-f509-4ab9-acbb-0d07ddfd4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2862f95a-f509-4ab9-acbb-0d07ddfd4cca" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f344de27-d1ee-45f5-bf49-4e328e03d9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_LongTermDebt_f344de27-d1ee-45f5-bf49-4e328e03d9b2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_d35107eb-e1e8-4516-91e2-fda491f8e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_d35107eb-e1e8-4516-91e2-fda491f8e302" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c8fda5f-de97-417f-9ba9-92185b3c7819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_StockholdersEquity_8c8fda5f-de97-417f-9ba9-92185b3c7819" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:href="elv-20221231.xsd#elv_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35fcf5ff-0783-4645-a72d-98259d3368fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:to="loc_srt_RangeMember_35fcf5ff-0783-4645-a72d-98259d3368fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:to="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_304b5ced-76b9-45b1-97b0-66d34170703e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:to="loc_srt_MinimumMember_304b5ced-76b9-45b1-97b0-66d34170703e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26c56ab8-1e3d-4798-ba5c-1495d1839440" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:to="loc_srt_MaximumMember_26c56ab8-1e3d-4798-ba5c-1495d1839440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a71c68fe-b9a3-4a02-8dc6-2907d0351b18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a71c68fe-b9a3-4a02-8dc6-2907d0351b18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_95d652fd-b189-4363-b68b-6e6cd282f609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_95d652fd-b189-4363-b68b-6e6cd282f609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:to="loc_us-gaap_ReceivableTypeDomain_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_914b496a-fc51-434c-a107-c97dba454f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:to="loc_us-gaap_ReceivableTypeDomain_914b496a-fc51-434c-a107-c97dba454f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70b943ed-b499-4462-a889-302e94a69c5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70b943ed-b499-4462-a889-302e94a69c5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_daddd2b7-d811-4018-b3d5-36a9ce853138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_daddd2b7-d811-4018-b3d5-36a9ce853138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ab07bc09-8feb-41be-8a52-d34f3fe3ebca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_ComputerEquipmentMember_ab07bc09-8feb-41be-8a52-d34f3fe3ebca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_43816fb8-4388-4af9-9404-22ab9b8f2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_43816fb8-4388-4af9-9404-22ab9b8f2e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_43ed3437-8dea-46e4-877e-3900739bd3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_43ed3437-8dea-46e4-877e-3900739bd3d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_484f7e06-edde-47ab-9262-50108f8a990a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_484f7e06-edde-47ab-9262-50108f8a990a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f1950372-d98f-4312-9f1f-81f611e982b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f1950372-d98f-4312-9f1f-81f611e982b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a41963b3-fbef-432f-943c-7fe4c396f003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a41963b3-fbef-432f-943c-7fe4c396f003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_f864733c-5efb-42a0-9590-34e26fbb3d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a41963b3-fbef-432f-943c-7fe4c396f003" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_f864733c-5efb-42a0-9590-34e26fbb3d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cb3c8031-f169-4557-a3d9-a6bc283a9e79_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cb3c8031-f169-4557-a3d9-a6bc283a9e79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a28d5ef5-06bc-4101-85c1-e62883f13e24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a28d5ef5-06bc-4101-85c1-e62883f13e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a49d28aa-889c-4324-9cd9-ea6ed7106345" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a28d5ef5-06bc-4101-85c1-e62883f13e24" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a49d28aa-889c-4324-9cd9-ea6ed7106345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b06499d-f22f-4fab-8630-fb1a59b65d16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:to="loc_us-gaap_EquityComponentDomain_8b06499d-f22f-4fab-8630-fb1a59b65d16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_368a0030-20a2-4a73-9603-5b377d6f0ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:to="loc_us-gaap_EquityComponentDomain_368a0030-20a2-4a73-9603-5b377d6f0ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1d0ef9ba-977b-4304-89be-64e5da495a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_368a0030-20a2-4a73-9603-5b377d6f0ce3" xlink:to="loc_us-gaap_RetainedEarningsMember_1d0ef9ba-977b-4304-89be-64e5da495a1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitionsIntangibleAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails" xlink:type="extended" id="i46a5b85c34d14ae59402080f07adc7db_BusinessAcquisitionsIntangibleAssetsAcquiredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0b352025-44f9-4c67-8f52-da361772225b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0b352025-44f9-4c67-8f52-da361772225b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5e748a11-ad21-47e3-a77d-d4940c331424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5e748a11-ad21-47e3-a77d-d4940c331424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_665f7b66-2223-4919-a4f4-fe1cf1e3079f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_665f7b66-2223-4919-a4f4-fe1cf1e3079f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalIntangibleAssetsAcquired_4bf36cdb-5e38-4675-99fa-88e783454e78" xlink:href="elv-20221231.xsd#elv_TotalIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_elv_TotalIntangibleAssetsAcquired_4bf36cdb-5e38-4675-99fa-88e783454e78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6e7fc10-c23b-41a3-8186-d5aeccb90b10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6e7fc10-c23b-41a3-8186-d5aeccb90b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c534e07a-c09d-4b5b-9c4f-2ed3e07f3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c534e07a-c09d-4b5b-9c4f-2ed3e07f3dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_a557c8bc-6d6b-4d62-870a-235208d8f2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:to="loc_us-gaap_ContractualRightsMember_a557c8bc-6d6b-4d62-870a-235208d8f2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_dc4e7e5e-8f3e-4222-8fd2-1bb19cc26025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_dc4e7e5e-8f3e-4222-8fd2-1bb19cc26025" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cca3711a-4469-4047-be4c-6157adba8a8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cca3711a-4469-4047-be4c-6157adba8a8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c0ab418-c768-4b81-8c5c-f9c5ee2c51f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c0ab418-c768-4b81-8c5c-f9c5ee2c51f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_04967ac3-e998-4b9c-a21d-ab6ac4742cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c0ab418-c768-4b81-8c5c-f9c5ee2c51f2" xlink:to="loc_us-gaap_LicensingAgreementsMember_04967ac3-e998-4b9c-a21d-ab6ac4742cda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="extended" id="i245c6f762cf04b3fa0c0ab0e61eeed42_BusinessAcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4a1af38-cf30-4e0a-ba55-ffcae89d88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4a1af38-cf30-4e0a-ba55-ffcae89d88c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a6d1fe20-4a5b-4448-8b79-5c04522acd89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a6d1fe20-4a5b-4448-8b79-5c04522acd89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_23831ed4-e825-4e28-b803-2affa8000fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_23831ed4-e825-4e28-b803-2affa8000fdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ef288fb3-a537-4ef2-bcbd-538a55844973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ef288fb3-a537-4ef2-bcbd-538a55844973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_33055185-bace-4b69-b57b-3c8f908647cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_33055185-bace-4b69-b57b-3c8f908647cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05ef200e-c8b4-459c-a49b-1eadc0d9a544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_Goodwill_05ef200e-c8b4-459c-a49b-1eadc0d9a544" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ad178703-3abd-4025-81a1-9a76fba1e558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ad178703-3abd-4025-81a1-9a76fba1e558" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17044f6c-9dba-4b90-8a38-97bc65c34e7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17044f6c-9dba-4b90-8a38-97bc65c34e7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e147ace-922a-4452-ba7b-059fd2331f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e147ace-922a-4452-ba7b-059fd2331f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_5704d185-7c9f-40dd-b262-58e3e36612a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e147ace-922a-4452-ba7b-059fd2331f56" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_5704d185-7c9f-40dd-b262-58e3e36612a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f1b120c9-67aa-4fec-ae7d-275830ab32b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:to="loc_us-gaap_SegmentDomain_f1b120c9-67aa-4fec-ae7d-275830ab32b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:to="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_000f47af-c1f8-45bb-86b9-316a3cd7440e" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:to="loc_elv_GovernmentBusinessSegmentMember_000f47af-c1f8-45bb-86b9-316a3cd7440e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_750e8c5f-751c-4701-9547-a35f5ffe0c21" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:to="loc_elv_OtherSegmentMember_750e8c5f-751c-4701-9547-a35f5ffe0c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_c9465697-3403-44be-b6f8-37fabdcfa07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_c9465697-3403-44be-b6f8-37fabdcfa07a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:href="elv-20221231.xsd#elv_AcquisitionYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearDomain_d5e0908b-7f52-44e5-830d-e26dbf65841f_default" xlink:href="elv-20221231.xsd#elv_AcquisitionYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:to="loc_elv_AcquisitionYearDomain_d5e0908b-7f52-44e5-830d-e26dbf65841f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearDomain_cefb2e0f-9992-4463-a226-78e767db9281" xlink:href="elv-20221231.xsd#elv_AcquisitionYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:to="loc_elv_AcquisitionYearDomain_cefb2e0f-9992-4463-a226-78e767db9281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearPriorDomain_98c8359e-27bf-4a0c-93b9-a7bc4c0039dc" xlink:href="elv-20221231.xsd#elv_AcquisitionYearPriorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_AcquisitionYearDomain_cefb2e0f-9992-4463-a226-78e767db9281" xlink:to="loc_elv_AcquisitionYearPriorDomain_98c8359e-27bf-4a0c-93b9-a7bc4c0039dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessOptimizationInitiativesEmployeeTerminationCostsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" xlink:type="extended" id="i90e3f9e270694c55b4299c5672dc82fa_BusinessOptimizationInitiativesEmployeeTerminationCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e02e857f-ff0c-4ac3-bd4b-dfaa2cce99f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_RestructuringReserve_e02e857f-ff0c-4ac3-bd4b-dfaa2cce99f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_3fea1116-1021-4b79-b92d-f1f66ef062d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_PaymentsForRestructuring_3fea1116-1021-4b79-b92d-f1f66ef062d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_54b1b66e-3568-43e2-867c-9eec2d188799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_54b1b66e-3568-43e2-867c-9eec2d188799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_d197f95d-c6ec-4d49-aae4-bd3846f2e6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:to="loc_us-gaap_SegmentDomain_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:to="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_a176896a-1bbc-4497-b1ca-b2c39ce6aef0" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_IngenioRxSegmentMember_a176896a-1bbc-4497-b1ca-b2c39ce6aef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_ca585a5b-ec77-4d6e-aad5-79f25648aaa4" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_OtherSegmentMember_ca585a5b-ec77-4d6e-aad5-79f25648aaa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_1b38ada8-afb6-496a-8dba-1da63c23c63c" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_GovernmentBusinessSegmentMember_1b38ada8-afb6-496a-8dba-1da63c23c63c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_bdb00513-5c02-4f3b-8c6b-9033ad80949c" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_bdb00513-5c02-4f3b-8c6b-9033ad80949c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d77ca120-f42d-4b55-99dd-f59b69e42726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d77ca120-f42d-4b55-99dd-f59b69e42726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_872ebb1c-b216-4976-8374-fdde705950a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d77ca120-f42d-4b55-99dd-f59b69e42726" xlink:to="loc_us-gaap_EmployeeSeveranceMember_872ebb1c-b216-4976-8374-fdde705950a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessOptimizationInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails" xlink:type="extended" id="i3fd51658556743499cc988b3ce0add24_BusinessOptimizationInitiativesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f920e92d-89e5-432d-ad00-2373af77057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f920e92d-89e5-432d-ad00-2373af77057b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1ed27a9d-1471-4230-86ec-88569dc7e972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1ed27a9d-1471-4230-86ec-88569dc7e972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_807784c1-a496-4209-ad66-f88992dfb081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_807784c1-a496-4209-ad66-f88992dfb081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e87a4ea6-bc4e-40c5-bcd2-2557038110e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:to="loc_us-gaap_SegmentDomain_e87a4ea6-bc4e-40c5-bcd2-2557038110e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:to="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b6da420-1f20-4a0a-9215-58ca90919bba" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b6da420-1f20-4a0a-9215-58ca90919bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_a6145005-1f15-4a1f-98c1-8e22dd7afd73" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_IngenioRxSegmentMember_a6145005-1f15-4a1f-98c1-8e22dd7afd73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_8bbeaf36-bf3e-4474-ba42-0a3fdbc3833c" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_OtherSegmentMember_8bbeaf36-bf3e-4474-ba42-0a3fdbc3833c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_591b3969-4c83-4edc-8336-365a6fcb0b07" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_GovernmentBusinessSegmentMember_591b3969-4c83-4edc-8336-365a6fcb0b07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_75c45707-92ab-413e-9f73-b32f213728ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_75c45707-92ab-413e-9f73-b32f213728ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b334a062-c301-48a7-94db-bee0d250a123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b334a062-c301-48a7-94db-bee0d250a123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PPEImpairmentMember_fc77a152-0e66-465d-bc4d-3c496270c389" xlink:href="elv-20221231.xsd#elv_PPEImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:to="loc_elv_PPEImpairmentMember_fc77a152-0e66-465d-bc4d-3c496270c389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LeaseImpairmentMember_75ea40b2-b4c4-48a2-99df-47b5baed7c5b" xlink:href="elv-20221231.xsd#elv_LeaseImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:to="loc_elv_LeaseImpairmentMember_75ea40b2-b4c4-48a2-99df-47b5baed7c5b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails" xlink:type="extended" id="i209ee6d5051c4adb990074c442838b3e_InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_96e87a7d-b1be-46cb-a0e3-cbde0a18f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_96e87a7d-b1be-46cb-a0e3-cbde0a18f5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3569ee3e-9b4e-45f0-8d03-3e8a5b2b64e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3569ee3e-9b4e-45f0-8d03-3e8a5b2b64e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ccd1ee2-4770-4c7b-9105-7a6d65fc830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ccd1ee2-4770-4c7b-9105-7a6d65fc830e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f6ec1fce-8b6f-4fd7-92ef-3264781186a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f6ec1fce-8b6f-4fd7-92ef-3264781186a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d1a8b9a-f0ab-4c5b-b8d4-a92ac5523264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d1a8b9a-f0ab-4c5b-b8d4-a92ac5523264" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:to="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_934dbc77-866f-4396-9345-ab0e80297ca2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_934dbc77-866f-4396-9345-ab0e80297ca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2a2173f7-c4e5-4383-93c1-fa95a8e05a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2a2173f7-c4e5-4383-93c1-fa95a8e05a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_f49aa5e0-2763-47f9-bd0b-47282284d13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a2173f7-c4e5-4383-93c1-fa95a8e05a41" xlink:to="loc_us-gaap_FixedMaturitiesMember_f49aa5e0-2763-47f9-bd0b-47282284d13c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2a45902-1b73-4beb-b137-cfca57ae4cd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2a45902-1b73-4beb-b137-cfca57ae4cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_96e585f4-2dc8-4d3c-b270-ff7b9ed525ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_96e585f4-2dc8-4d3c-b270-ff7b9ed525ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe654fd-ced3-4de3-aa8a-b8d19fea5cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe654fd-ced3-4de3-aa8a-b8d19fea5cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_ef74e2ad-240d-4a98-a912-e58a3020871c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_ef74e2ad-240d-4a98-a912-e58a3020871c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_84aeb0b6-1255-4edf-8fb2-c6acfa13b77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_84aeb0b6-1255-4edf-8fb2-c6acfa13b77b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d2adccb8-d5cb-4756-a444-b71d0bf4e666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d2adccb8-d5cb-4756-a444-b71d0bf4e666" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_b3fab263-bb1f-45d6-a7f6-b5b97bd630ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_b3fab263-bb1f-45d6-a7f6-b5b97bd630ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_455fd26c-20ed-4a44-8a1c-8d8af9ba2b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_455fd26c-20ed-4a44-8a1c-8d8af9ba2b2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_599a03d9-aacf-44e1-bbb9-67f35c4fc36a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_599a03d9-aacf-44e1-bbb9-67f35c4fc36a" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" xlink:type="extended" id="i8e0754a0bbad447898b12ca54fdf7902_InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_82e67279-512d-46af-9b60-1fa303f50179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_82e67279-512d-46af-9b60-1fa303f50179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_31a3f2e6-78e2-40fe-84f1-24ad5f1b42a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_31a3f2e6-78e2-40fe-84f1-24ad5f1b42a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_070c30d4-2aa4-4b29-93d4-2369ac8da6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_070c30d4-2aa4-4b29-93d4-2369ac8da6f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9e357af5-dbd2-48db-b1a0-9e4645c87747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9e357af5-dbd2-48db-b1a0-9e4645c87747" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_06ad6759-1ddb-4e9e-bb24-c6a4b4c12267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_06ad6759-1ddb-4e9e-bb24-c6a4b4c12267" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_474dbc62-18a1-4803-896a-f1266fc15376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_474dbc62-18a1-4803-896a-f1266fc15376" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:to="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_baf50345-9813-4043-9335-e5e6d9aca2dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_baf50345-9813-4043-9335-e5e6d9aca2dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46f4a0d7-ce42-42b3-9015-3a8285ed71af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46f4a0d7-ce42-42b3-9015-3a8285ed71af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_fa6e692b-e73e-43c0-9b77-09e781991c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46f4a0d7-ce42-42b3-9015-3a8285ed71af" xlink:to="loc_us-gaap_FixedMaturitiesMember_fa6e692b-e73e-43c0-9b77-09e781991c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_76ae6c60-509a-4efd-8192-c0c737739d2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_76ae6c60-509a-4efd-8192-c0c737739d2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f1f06c49-a09e-45b3-952a-a61e09a72df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f1f06c49-a09e-45b3-952a-a61e09a72df3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0b113b06-44fe-49e9-83e2-eb3de4638f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0b113b06-44fe-49e9-83e2-eb3de4638f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_ce309f23-b18c-4556-9801-2b3a98d655a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_ce309f23-b18c-4556-9801-2b3a98d655a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_8c96c3f6-0758-454c-a827-3f26e2916a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_8c96c3f6-0758-454c-a827-3f26e2916a57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e08e1f44-3dd8-40fd-ba83-0f3f9679106b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e08e1f44-3dd8-40fd-ba83-0f3f9679106b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_c490fd9a-1df7-482e-85f4-babb13d248b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_c490fd9a-1df7-482e-85f4-babb13d248b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_22b320ed-84a9-4c52-9276-f093469d4d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_22b320ed-84a9-4c52-9276-f093469d4d1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_f3d8327f-ad50-4e89-bfae-0831ba24e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_f3d8327f-ad50-4e89-bfae-0831ba24e88c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" xlink:type="extended" id="i0752daf59c8f4694a966332e243da1af_InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c14f32d1-4240-4fe1-a07a-d1ef178c9962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c14f32d1-4240-4fe1-a07a-d1ef178c9962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4128df69-2f72-4436-bb22-46eb590106de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4128df69-2f72-4436-bb22-46eb590106de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2be46a20-0406-41c1-8bff-a176ee28a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2be46a20-0406-41c1-8bff-a176ee28a1a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b28d066e-3949-4c5a-aa6d-d1ddb0e0881f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b28d066e-3949-4c5a-aa6d-d1ddb0e0881f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_64f7113f-dc2d-4ce1-a6c7-b5da89a8fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_64f7113f-dc2d-4ce1-a6c7-b5da89a8fd30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_514843a2-0d01-4dfe-b258-ba2669be3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_514843a2-0d01-4dfe-b258-ba2669be3aef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_47c6103f-f6c4-437a-9e1a-cbee7e5a0410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_47c6103f-f6c4-437a-9e1a-cbee7e5a0410" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_56a24d14-7010-4fc7-aeee-28713f10ec1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_56a24d14-7010-4fc7-aeee-28713f10ec1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_29f5605b-455e-4e80-b6b5-85c5dce5f558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_29f5605b-455e-4e80-b6b5-85c5dce5f558" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_b8a9c96e-3c3b-4edb-95e5-c421d22d99af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_b8a9c96e-3c3b-4edb-95e5-c421d22d99af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_24140f2e-cd99-45b0-a506-e4d1524987f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_24140f2e-cd99-45b0-a506-e4d1524987f6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ecdb607e-14c0-4551-8218-00aeae85fc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ecdb607e-14c0-4551-8218-00aeae85fc11" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:to="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c995dd25-c9c6-45b7-8b79-d9561c042189_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c995dd25-c9c6-45b7-8b79-d9561c042189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_75dbacc8-47da-4116-a0f8-42bc7571ad86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_75dbacc8-47da-4116-a0f8-42bc7571ad86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_97709ec1-b7e5-4ae2-812b-18875964fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_75dbacc8-47da-4116-a0f8-42bc7571ad86" xlink:to="loc_us-gaap_FixedMaturitiesMember_97709ec1-b7e5-4ae2-812b-18875964fbaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsCurrentEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" xlink:type="extended" id="iedc6a57870d74a39a8d253edf9139cb6_InvestmentsCurrentEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_b3bcb0eb-c3da-4cdb-b9a5-9491655863ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecurities_dfaea87f-70bd-4688-a246-743cf1eebcd0" xlink:href="elv-20221231.xsd#elv_EquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_b3bcb0eb-c3da-4cdb-b9a5-9491655863ec" xlink:to="loc_elv_EquitySecurities_dfaea87f-70bd-4688-a246-743cf1eebcd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_b3bcb0eb-c3da-4cdb-b9a5-9491655863ec" xlink:to="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad3358bd-dbae-4012-a746-4073d7474536_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad3358bd-dbae-4012-a746-4073d7474536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExchangeTradedFundsMember_e59b3441-4eb9-4ece-aa0a-738430bcae94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExchangeTradedFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:to="loc_us-gaap_ExchangeTradedFundsMember_e59b3441-4eb9-4ece-aa0a-738430bcae94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommonEquitySecuritiesMember_a5f80811-6a1b-44da-a45e-37f27fa9e88c" xlink:href="elv-20221231.xsd#elv_CommonEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:to="loc_elv_CommonEquitySecuritiesMember_a5f80811-6a1b-44da-a45e-37f27fa9e88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_7e92b2a6-544a-4af3-9d11-e6783a3fba32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:to="loc_us-gaap_PrivateEquityFundsMember_7e92b2a6-544a-4af3-9d11-e6783a3fba32" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails" xlink:type="extended" id="i65a4ff45cf104bbf928ddd994c910334_InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_1259753d-8480-47e8-a314-21b734eba224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_InvestmentIncomeNet_1259753d-8480-47e8-a314-21b734eba224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_6810d0f1-cc63-43e1-a846-548a712b1327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_6810d0f1-cc63-43e1-a846-548a712b1327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_f89e5013-c5ed-4276-9dfe-d50e5a86c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_NetInvestmentIncome_f89e5013-c5ed-4276-9dfe-d50e5a86c2bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:to="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_eb086102-55c4-4ee2-86c4-62e96e0dffb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_eb086102-55c4-4ee2-86c4-62e96e0dffb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_845976e3-01c4-457c-8e7c-2e7021dfc5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_FixedMaturitiesMember_845976e3-01c4-457c-8e7c-2e7021dfc5e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0d80b104-bea7-4dde-9e95-63d34de0c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_EquitySecuritiesMember_0d80b104-bea7-4dde-9e95-63d34de0c51f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_ea949dd4-2d4d-4d78-9444-77329f888533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_ea949dd4-2d4d-4d78-9444-77329f888533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_ff34358a-86e0-48e5-a860-58e54d5decbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_OtherInvestmentsMember_ff34358a-86e0-48e5-a860-58e54d5decbc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsNetGainsLossesOnInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails" xlink:type="extended" id="ifdf79b4bf4a04d7ca40e9bf6f38e3b9c_InvestmentsNetGainsLossesOnInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b11d24cc-eb18-4dcd-be04-890036b6a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b11d24cc-eb18-4dcd-be04-890036b6a6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_89dcb4ea-466b-4b72-aab4-a0b85e0e93d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_89dcb4ea-466b-4b72-aab4-a0b85e0e93d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Impairmentlossesreversalsoninvestments_664b5eb6-49d7-4aad-97f7-b4672654cd57" xlink:href="elv-20221231.xsd#elv_Impairmentlossesreversalsoninvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_Impairmentlossesreversalsoninvestments_664b5eb6-49d7-4aad-97f7-b4672654cd57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_020c37f3-1491-4cb4-b465-c2979c39830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_020c37f3-1491-4cb4-b465-c2979c39830e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_803c6993-1b10-4b5e-91a5-f1218fc84b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_803c6993-1b10-4b5e-91a5-f1218fc84b5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a331d39d-d238-49fd-9764-9da027c25fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a331d39d-d238-49fd-9764-9da027c25fb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_babf60c2-982a-45bb-8ce6-051fadf5feb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_babf60c2-982a-45bb-8ce6-051fadf5feb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GainsFromOtherInvestments_7b5ea17f-61f3-4de5-adbe-4727abf6d6bd" xlink:href="elv-20221231.xsd#elv_GainsFromOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_GainsFromOtherInvestments_7b5ea17f-61f3-4de5-adbe-4727abf6d6bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GrossLossesFromOtherInvestments_403fb3d2-af81-47d6-8f8f-816e71346271" xlink:href="elv-20221231.xsd#elv_GrossLossesFromOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_GrossLossesFromOtherInvestments_403fb3d2-af81-47d6-8f8f-816e71346271" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentGainsLosses_a02b537c-8563-45c9-912c-864f57e56b81" xlink:href="elv-20221231.xsd#elv_InvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_InvestmentGainsLosses_a02b537c-8563-45c9-912c-864f57e56b81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_c88320e2-55c0-4ac4-8327-751f79e406cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_c88320e2-55c0-4ac4-8327-751f79e406cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:to="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_35e031cb-556b-47e8-83e3-2020e47294e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_35e031cb-556b-47e8-83e3-2020e47294e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_70d26045-2b48-4c58-b7cc-7a8edd860377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:to="loc_us-gaap_FixedMaturitiesMember_70d26045-2b48-4c58-b7cc-7a8edd860377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d299b9eb-62ae-47a4-aa09-37daf0436158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:to="loc_us-gaap_EquitySecuritiesMember_d299b9eb-62ae-47a4-aa09-37daf0436158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_b337c5fb-d5ff-4296-ac91-cbbd64b2d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:to="loc_us-gaap_OtherInvestmentsMember_b337c5fb-d5ff-4296-ac91-cbbd64b2d46a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="i753801b294884acf9341e7a735c2a70a_InvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_88c56531-0e21-4fe5-89c1-cdfa60acd92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_88c56531-0e21-4fe5-89c1-cdfa60acd92c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_30e3f1ec-47c4-412a-a35e-e96f4816da55" xlink:href="elv-20221231.xsd#elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_30e3f1ec-47c4-412a-a35e-e96f4816da55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d5cee8a5-d6fc-4094-a288-4da5034994c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_ContractualObligation_d5cee8a5-d6fc-4094-a288-4da5034994c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators_e148b1e0-d37a-4a1e-9da6-c7b80863f519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_AssetsHeldByInsuranceRegulators_e148b1e0-d37a-4a1e-9da6-c7b80863f519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_c734d19d-e7a8-4500-bb69-24e58c999d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_c734d19d-e7a8-4500-bb69-24e58c999d34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedFairValueOfCollateral_85e43ee4-f56e-484f-83e9-47e23b8775a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedFairValueOfCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_SecuritiesLoanedFairValueOfCollateral_85e43ee4-f56e-484f-83e9-47e23b8775a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_bc6059e8-6070-4d6c-9a98-67cd4bd7db80" xlink:href="elv-20221231.xsd#elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_bc6059e8-6070-4d6c-9a98-67cd4bd7db80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue_fbfc513f-ac92-4e9b-a187-c4800c0131ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue_fbfc513f-ac92-4e9b-a187-c4800c0131ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4e175847-3403-43f4-a4f7-83ee82485cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4e175847-3403-43f4-a4f7-83ee82485cff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_8539d688-d0d7-4035-8f09-5c80e99639e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_8539d688-d0d7-4035-8f09-5c80e99639e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_9022466e-bc64-4506-9c89-55c6c4c2fbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_9022466e-bc64-4506-9c89-55c6c4c2fbae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturityOvernightMember_390da534-da1b-423a-90be-db7dba795d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturityOvernightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_9022466e-bc64-4506-9c89-55c6c4c2fbae" xlink:to="loc_us-gaap_MaturityOvernightMember_390da534-da1b-423a-90be-db7dba795d99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_8d418f1e-0447-4e64-9670-c491ccc30fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_FixedMaturitiesMember_8d418f1e-0447-4e64-9670-c491ccc30fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_bc2614ff-b8e6-4ea5-ab69-af3c73140a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_CashMember_bc2614ff-b8e6-4ea5-ab69-af3c73140a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_62dac1d3-3c54-47cc-a368-6bda74a22d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_62dac1d3-3c54-47cc-a368-6bda74a22d62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThirdPartyInvestmentsMember_6fbdf3c3-5281-49b6-ae6a-268c86c554e1" xlink:href="elv-20221231.xsd#elv_ThirdPartyInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_elv_ThirdPartyInvestmentsMember_6fbdf3c3-5281-49b6-ae6a-268c86c554e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_RatedNotesMember_b6c3e4ce-d83c-401f-8ab3-0703485370bf" xlink:href="elv-20221231.xsd#elv_RatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_elv_RatedNotesMember_b6c3e4ce-d83c-401f-8ab3-0703485370bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_20aec05b-6c09-4712-94e0-c7c85b88d696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_20aec05b-6c09-4712-94e0-c7c85b88d696" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThirdPartyInvestmentsMember_b291917f-692f-4f48-9f12-8fbcab007adf" xlink:href="elv-20221231.xsd#elv_ThirdPartyInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:to="loc_elv_ThirdPartyInvestmentsMember_b291917f-692f-4f48-9f12-8fbcab007adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_RatedNotesMember_bb639c63-2829-432d-9ffb-bde5db1bb477" xlink:href="elv-20221231.xsd#elv_RatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:to="loc_elv_RatedNotesMember_bb639c63-2829-432d-9ffb-bde5db1bb477" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails" xlink:type="extended" id="i9277036ed1c54ebfa3f353116ecc9981_DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0845f447-e9af-4d39-8d09-2e872b2c143a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0845f447-e9af-4d39-8d09-2e872b2c143a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d66b8dae-5ae3-41b8-981f-069ce535c13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d66b8dae-5ae3-41b8-981f-069ce535c13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_6b3cc22c-62ae-42fb-9661-d4a20b86904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_6b3cc22c-62ae-42fb-9661-d4a20b86904e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral_f842f72f-2870-4abe-95b9-b3ba2aac9ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral_f842f72f-2870-4abe-95b9-b3ba2aac9ab6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a67aad5b-1480-40ac-8a31-56a5bd1bd8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a67aad5b-1480-40ac-8a31-56a5bd1bd8aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_20f8bffc-b1b8-4570-8c97-32871b9dccf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_20f8bffc-b1b8-4570-8c97-32871b9dccf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_c4211c03-4044-481f-ad78-51fbb60a0b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_c4211c03-4044-481f-ad78-51fbb60a0b38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fadeb886-bb28-48ce-968c-65390a6e7ffe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:to="loc_us-gaap_HedgingDesignationDomain_fadeb886-bb28-48ce-968c-65390a6e7ffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:to="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_acca513d-6816-42f4-a4be-4a714f00285a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_acca513d-6816-42f4-a4be-4a714f00285a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bfee0b86-da17-48de-869b-e939077bc91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:to="loc_us-gaap_NondesignatedMember_bfee0b86-da17-48de-869b-e939077bc91c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37e01956-0be5-4c56-87a8-0bb305e77a85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_37e01956-0be5-4c56-87a8-0bb305e77a85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_c54e9e3b-9e89-4d0e-80e3-841000746a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_c54e9e3b-9e89-4d0e-80e3-841000746a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_1540a172-28d1-45f4-8a39-9fab3ef8a666" xlink:href="elv-20221231.xsd#elv_EquitySecuritiesotherAssetsotherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_1540a172-28d1-45f4-8a39-9fab3ef8a666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9f1dcd29-2cbe-46b4-9806-8e1695e6ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_us-gaap_EquitySecuritiesMember_9f1dcd29-2cbe-46b4-9806-8e1695e6ccdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_d56a376e-df2c-4f28-8f2a-93478c28a0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_us-gaap_FixedMaturitiesMember_d56a376e-df2c-4f28-8f2a-93478c28a0df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9daef2c0-071c-40f6-9289-a7cb8bdb828c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9daef2c0-071c-40f6-9289-a7cb8bdb828c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8aa538a0-c278-40d3-9703-d74aad5aa059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_InterestRateSwapMember_8aa538a0-c278-40d3-9703-d74aad5aa059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_5719467d-9288-4032-b337-d272deb6cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_OptionMember_5719467d-9288-4032-b337-d272deb6cabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_dbb91883-daaa-4228-9047-c7a614cb4e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_OtherContractMember_dbb91883-daaa-4228-9047-c7a614cb4e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FutureMember_47d9eee9-642d-45a3-a155-d344670856bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FutureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_FutureMember_47d9eee9-642d-45a3-a155-d344670856bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_64880175-95c0-4191-a3a2-29f57ffe5722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_64880175-95c0-4191-a3a2-29f57ffe5722" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails" xlink:type="extended" id="i80c8174f50114f9d9c612a4a9e33fb03_DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_3d6cc314-4069-4bc8-987d-6d88c62ccfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_DerivativeNotionalAmount_3d6cc314-4069-4bc8-987d-6d88c62ccfee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_16afbe45-6919-43bc-b48c-3f146bd30ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_16afbe45-6919-43bc-b48c-3f146bd30ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenExpirationDates_4ef565a3-3bf7-4378-b388-cc872ef253c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenExpirationDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_OpenOptionContractsWrittenExpirationDates_4ef565a3-3bf7-4378-b388-cc872ef253c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2e556ab5-4afb-44c4-9e76-976987145e38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:to="loc_us-gaap_HedgingDesignationDomain_2e556ab5-4afb-44c4-9e76-976987145e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a945c897-a1cb-40b6-81b3-871f82572ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:to="loc_us-gaap_HedgingDesignationDomain_a945c897-a1cb-40b6-81b3-871f82572ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7bfead0-592b-4655-904e-b1dd2e63354a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a945c897-a1cb-40b6-81b3-871f82572ba9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7bfead0-592b-4655-904e-b1dd2e63354a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d53ba8f3-f00e-4785-b43d-192e69bc59c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d53ba8f3-f00e-4785-b43d-192e69bc59c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_b778801a-23dc-4f06-a07c-703db3ae0906" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedFivePointFiveZeroPercentageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_b778801a-23dc-4f06-a07c-703db3ae0906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_8922e30d-f240-4d39-9b62-dde822a9d9a9" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedFourPointOneZeroOnePercentageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_8922e30d-f240-4d39-9b62-dde822a9d9a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_401f93ce-52ba-4188-a4fc-9102875490ec" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_401f93ce-52ba-4188-a4fc-9102875490ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_8b8b2e8b-cad6-44c3-ac4f-35e0820abb53" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_8b8b2e8b-cad6-44c3-ac4f-35e0820abb53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_25227d79-3406-4ba3-9d51-f670fe5a4794" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedThreePointThreeZeroPercentageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_25227d79-3406-4ba3-9d51-f670fe5a4794" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyTwoMember_6c9e989f-5a81-4772-a259-100a89862252" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandTwentyTwoMember_6c9e989f-5a81-4772-a259-100a89862252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyOneMember_45529e13-c3e9-4247-9b3f-a8924dae9112" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandTwentyOneMember_45529e13-c3e9-4247-9b3f-a8924dae9112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyMember_63ebbb14-6831-4d89-9bd4-579b2ecfb8e2" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandTwentyMember_63ebbb14-6831-4d89-9bd4-579b2ecfb8e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandEighteenMember_26a2b3c7-0a71-4be6-87e9-91ffe8984d91" xlink:href="elv-20221231.xsd#elv_TwoThousandEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandEighteenMember_26a2b3c7-0a71-4be6-87e9-91ffe8984d91" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails" xlink:type="extended" id="icba4a51c7bca44abb757f7260e78f225_DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAmountOfHedgedItem_8666c255-47c0-4b87-b67a-896430b9afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAmountOfHedgedItem"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:to="loc_us-gaap_DerivativeAmountOfHedgedItem_8666c255-47c0-4b87-b67a-896430b9afb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Fairvaluehedgescumulativebasisadjustments_eb804e15-ec36-4c89-907a-29c5eb669712" xlink:href="elv-20221231.xsd#elv_Fairvaluehedgescumulativebasisadjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:to="loc_elv_Fairvaluehedgescumulativebasisadjustments_eb804e15-ec36-4c89-907a-29c5eb669712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_696dd791-ad6b-4d41-98aa-633b3228a014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_696dd791-ad6b-4d41-98aa-633b3228a014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_28c8ae12-374f-4804-8096-3aaa1d3ef536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696dd791-ad6b-4d41-98aa-633b3228a014" xlink:to="loc_us-gaap_LongTermDebtMember_28c8ae12-374f-4804-8096-3aaa1d3ef536" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails" xlink:type="extended" id="i16feb8017eca4f52992af2a0016313f9_DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_7912df1c-2a27-4746-b733-5a96605a65a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_7912df1c-2a27-4746-b733-5a96605a65a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5285553c-6428-46f2-8053-1daaa7546e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5285553c-6428-46f2-8053-1daaa7546e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_76b0dd86-e286-4e43-a224-99e752c75e36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_76b0dd86-e286-4e43-a224-99e752c75e36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2e395b34-43af-486e-bb2b-c3344b0d6b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_InterestRateSwapMember_2e395b34-43af-486e-bb2b-c3344b0d6b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_a166c2cb-cbf9-467c-a717-ac9f2368c85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_OtherContractMember_a166c2cb-cbf9-467c-a717-ac9f2368c85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_4e16cfea-5a0d-40cb-85dc-85ddc87c5765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_OptionMember_4e16cfea-5a0d-40cb-85dc-85ddc87c5765" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FutureMember_c07f43ae-0241-451b-ad03-531ce4b08248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FutureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_FutureMember_c07f43ae-0241-451b-ad03-531ce4b08248" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_16fd056d-7e27-48c4-bc00-272e5d1852b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_16fd056d-7e27-48c4-bc00-272e5d1852b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_78253894-21f5-4cfd-aaba-ee67a53d34d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_78253894-21f5-4cfd-aaba-ee67a53d34d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_063227b6-20cf-40bd-bf79-d3e881ccaec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_063227b6-20cf-40bd-bf79-d3e881ccaec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstrumentsMember_03e22238-1cd6-43ee-bd25-2258ac568220" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_063227b6-20cf-40bd-bf79-d3e881ccaec4" xlink:to="loc_elv_NetGainsLossesOnFinancialInstrumentsMember_03e22238-1cd6-43ee-bd25-2258ac568220" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i9faf9ffb5700406bb6ca3ad1e459acca_DerivativeFinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Notionalamountterminatedderivatives_83ca8a94-56bd-4d6d-8a07-d90c80307bc0" xlink:href="elv-20221231.xsd#elv_Notionalamountterminatedderivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_elv_Notionalamountterminatedderivatives_83ca8a94-56bd-4d6d-8a07-d90c80307bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_9d10e514-d042-4dbe-828d-586abbece31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_9d10e514-d042-4dbe-828d-586abbece31a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_12619720-576e-4747-bf4e-5511e29fdac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_12619720-576e-4747-bf4e-5511e29fdac3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_923fbae6-eeff-424b-8e3a-6daa47280dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_923fbae6-eeff-424b-8e3a-6daa47280dab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4f0e8459-15ec-42bb-9164-82e670b89f0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:to="loc_us-gaap_HedgingDesignationDomain_4f0e8459-15ec-42bb-9164-82e670b89f0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6a3f6c7f-cd0c-4bf3-add5-2194ef642960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:to="loc_us-gaap_HedgingDesignationDomain_6a3f6c7f-cd0c-4bf3-add5-2194ef642960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_19d3d0d5-926e-422d-bb38-3bc6f372fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6a3f6c7f-cd0c-4bf3-add5-2194ef642960" xlink:to="loc_us-gaap_NondesignatedMember_19d3d0d5-926e-422d-bb38-3bc6f372fe53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5f937620-ea65-4f6e-ae98-125040e7e02e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5f937620-ea65-4f6e-ae98-125040e7e02e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cfaafffa-fc45-4fd1-ba52-11457984a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cfaafffa-fc45-4fd1-ba52-11457984a6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d7adbf65-6e47-4c3b-8617-4b6c5a03f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cfaafffa-fc45-4fd1-ba52-11457984a6cb" xlink:to="loc_us-gaap_CashFlowHedgingMember_d7adbf65-6e47-4c3b-8617-4b6c5a03f8bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:href="elv-20221231.xsd#elv_HedgingStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusDomain_f27fd4f8-44f1-4134-8875-e6f72eb16362_default" xlink:href="elv-20221231.xsd#elv_HedgingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:to="loc_elv_HedgingStatusDomain_f27fd4f8-44f1-4134-8875-e6f72eb16362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusDomain_8e0ef420-fad2-45d5-b37d-9a27f3994301" xlink:href="elv-20221231.xsd#elv_HedgingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:to="loc_elv_HedgingStatusDomain_8e0ef420-fad2-45d5-b37d-9a27f3994301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TerminationsDomain_3e1dd211-d938-4d86-a45c-efc24fa09afc" xlink:href="elv-20221231.xsd#elv_TerminationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_HedgingStatusDomain_8e0ef420-fad2-45d5-b37d-9a27f3994301" xlink:to="loc_elv_TerminationsDomain_3e1dd211-d938-4d86-a45c-efc24fa09afc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:type="extended" id="i042f891d54d941faa4418ce931683534_FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6519af9a-8eea-4f80-8b0c-d7fcbc7d7c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6519af9a-8eea-4f80-8b0c-d7fcbc7d7c60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e4c3ba0-8c6d-416d-bb5a-12d3d1c5032a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e4c3ba0-8c6d-416d-bb5a-12d3d1c5032a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecurities_1de850bb-745e-4f35-8840-de19f5ce0ec6" xlink:href="elv-20221231.xsd#elv_EquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_elv_EquitySecurities_1de850bb-745e-4f35-8840-de19f5ce0ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_ba11377c-b7c6-48dd-9d8a-bc35a38285e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_OtherLongTermInvestments_ba11377c-b7c6-48dd-9d8a-bc35a38285e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesHeldAsCollateralAtFairValue_df096f47-f8f9-443b-b4d2-f9217face852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesHeldAsCollateralAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_SecuritiesHeldAsCollateralAtFairValue_df096f47-f8f9-443b-b4d2-f9217face852" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c6e1886f-084f-453d-82cf-244ba5ffdee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_DerivativeAssets_c6e1886f-084f-453d-82cf-244ba5ffdee1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_06831274-6f6e-4d5e-87c2-f99ab4a1108f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssets_c6e1886f-084f-453d-82cf-244ba5ffdee1" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_06831274-6f6e-4d5e-87c2-f99ab4a1108f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c759db8f-8701-4d64-ae20-c84b1375d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c759db8f-8701-4d64-ae20-c84b1375d9ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_312278e0-6948-4599-8100-859638ededfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_DerivativeLiabilities_312278e0-6948-4599-8100-859638ededfa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4463ece2-e507-4dfc-9f81-f1b51cc59860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilities_312278e0-6948-4599-8100-859638ededfa" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4463ece2-e507-4dfc-9f81-f1b51cc59860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_6eb94391-ece4-4f12-a242-44154742b966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_6eb94391-ece4-4f12-a242-44154742b966" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9152afe6-de22-40c2-aac5-5f27eb39c25a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9152afe6-de22-40c2-aac5-5f27eb39c25a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_33d1d848-af1c-4a15-8e5d-23006f8c37e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_33d1d848-af1c-4a15-8e5d-23006f8c37e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1984cd6e-6492-4ec3-9c2d-433555e347bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1984cd6e-6492-4ec3-9c2d-433555e347bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ac63d4b9-a26c-4928-8113-8bd5d089de06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ac63d4b9-a26c-4928-8113-8bd5d089de06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_48143720-85b1-4eb8-a327-4b26954d2570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_us-gaap_FixedMaturitiesMember_48143720-85b1-4eb8-a327-4b26954d2570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_455cb97a-662d-4077-9509-b97c3dce5f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_us-gaap_EquitySecuritiesMember_455cb97a-662d-4077-9509-b97c3dce5f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherDerivativeInstrumentsMember_41eec92b-d51c-499b-b76a-3e5e438d3936" xlink:href="elv-20221231.xsd#elv_OtherDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_elv_OtherDerivativeInstrumentsMember_41eec92b-d51c-499b-b76a-3e5e438d3936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_03ddab7c-9691-4ad8-be97-ef95f3c589cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_us-gaap_OtherInvestmentsMember_03ddab7c-9691-4ad8-be97-ef95f3c589cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_257fa0b5-8b92-4210-953d-fbebac72c2c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_257fa0b5-8b92-4210-953d-fbebac72c2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a8930211-5b14-40d7-856f-00141c4ab77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a8930211-5b14-40d7-856f-00141c4ab77a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9519814d-cdd4-426b-a0a2-1c28b292ef56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9519814d-cdd4-426b-a0a2-1c28b292ef56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_65e419ff-572a-4630-be05-fdbbab0d04ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_65e419ff-572a-4630-be05-fdbbab0d04ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_9c0bafc4-d117-4020-9c28-b02f7640bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_9c0bafc4-d117-4020-9c28-b02f7640bb09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7f918a2c-123f-4088-9d7f-44eec53154dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7f918a2c-123f-4088-9d7f-44eec53154dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_67022225-65da-4f09-b252-0b5ee9eaf879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_67022225-65da-4f09-b252-0b5ee9eaf879" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_a56d1e04-a929-40d9-a650-e06366c90618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_a56d1e04-a929-40d9-a650-e06366c90618" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_343df932-ec71-4f10-ad88-21a02ca90535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_343df932-ec71-4f10-ad88-21a02ca90535" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExchangeTradedFundsMember_a87da013-3d36-4d44-b723-d462a181006c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExchangeTradedFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_ExchangeTradedFundsMember_a87da013-3d36-4d44-b723-d462a181006c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommonEquitySecuritiesMember_47d59f88-b888-4da7-9d8c-283039f94915" xlink:href="elv-20221231.xsd#elv_CommonEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_elv_CommonEquitySecuritiesMember_47d59f88-b888-4da7-9d8c-283039f94915" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_ebdeda73-4f83-4804-a0f3-99a20cb4583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_PrivateEquityFundsMember_ebdeda73-4f83-4804-a0f3-99a20cb4583b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_306a87f7-9ffa-45d4-919f-81338f4f056d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_306a87f7-9ffa-45d4-919f-81338f4f056d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_6d6c465f-0822-4092-998f-656b5047284f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:to="loc_us-gaap_OtherLiabilitiesMember_6d6c465f-0822-4092-998f-656b5047284f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_de73bdec-e099-4310-b0fb-9255490609a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:to="loc_us-gaap_OtherAssetsMember_de73bdec-e099-4310-b0fb-9255490609a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" xlink:type="extended" id="if1d2aff0e7694a5299d4d0c06d57e8b2_FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2632c37b-6c15-465d-8cb2-eb8095774d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2632c37b-6c15-465d-8cb2-eb8095774d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_03e06f2a-9a78-495a-a07c-4cb49c029723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_03e06f2a-9a78-495a-a07c-4cb49c029723" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_a19ea0c5-9a18-447d-a5f7-ba4b1d0d1175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_a19ea0c5-9a18-447d-a5f7-ba4b1d0d1175" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_5176dc8b-bf38-43b0-8416-e67adc33c254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_5176dc8b-bf38-43b0-8416-e67adc33c254" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c4b27984-e411-406e-8380-cd1066c990da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c4b27984-e411-406e-8380-cd1066c990da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_8b124a60-d125-4875-8b19-a5a109bb7725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_8b124a60-d125-4875-8b19-a5a109bb7725" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_dde3c449-618e-460c-8954-4e140a2f3ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_dde3c449-618e-460c-8954-4e140a2f3ab4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_e5ef5abf-a5cc-4421-aa05-098409b7bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_e5ef5abf-a5cc-4421-aa05-098409b7bc9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1b035ff7-336d-4ce7-b23f-3034afb0d6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1b035ff7-336d-4ce7-b23f-3034afb0d6a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3668c162-007f-456c-92a8-dd697fd15400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cac29ac6-bc12-4330-bba7-84636716cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cac29ac6-bc12-4330-bba7-84636716cef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7ca0a694-13c4-4a64-8757-721751bb8c50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7ca0a694-13c4-4a64-8757-721751bb8c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1139616c-60bd-411b-8c59-a7985bcdbb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1139616c-60bd-411b-8c59-a7985bcdbb84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_f382090e-a4a3-4d07-bf19-e2a77a556ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_f382090e-a4a3-4d07-bf19-e2a77a556ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3f17eaaa-8492-4dbb-bb91-1bd5f7802d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3f17eaaa-8492-4dbb-bb91-1bd5f7802d7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_742233f4-858e-4dcd-8000-f71308a14f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_742233f4-858e-4dcd-8000-f71308a14f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_eda22168-bcea-4780-ad93-3ccdc33d4980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_EquitySecuritiesMember_eda22168-bcea-4780-ad93-3ccdc33d4980" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" xlink:type="extended" id="i5591b6528c2a4ffc907f56561333905a_FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_fcc2f92d-9b61-4fad-b4e7-5785e47951e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_OtherLongTermInvestments_fcc2f92d-9b61-4fad-b4e7-5785e47951e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_5a088f30-1682-4132-94cd-a78436fc0fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_5a088f30-1682-4132-94cd-a78436fc0fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_e736b6a3-dba5-459d-b4f3-a8ee8b796034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_CommercialPaper_e736b6a3-dba5-459d-b4f3-a8ee8b796034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_1f50b14d-499d-4076-bca3-7dc269a952f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_NotesPayable_1f50b14d-499d-4076-bca3-7dc269a952f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_8f2ecffb-daa4-4c50-a030-001c87a0d77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_8f2ecffb-daa4-4c50-a030-001c87a0d77b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_63a4a611-fca0-4f35-8899-448e835e438e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_63a4a611-fca0-4f35-8899-448e835e438e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbb8fdaf-181d-47e2-bb12-ea5916e50a23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbb8fdaf-181d-47e2-bb12-ea5916e50a23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_7ee42980-4242-4fb7-8676-8f109e7af1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_7ee42980-4242-4fb7-8676-8f109e7af1d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_eeb1ced6-b4ef-4b0f-910e-7b7a84718e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_eeb1ced6-b4ef-4b0f-910e-7b7a84718e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e0e8d56b-e488-4daf-9b98-785c8d0ec9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e0e8d56b-e488-4daf-9b98-785c8d0ec9ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f7bee811-02e6-4c74-be80-bf0b99b50b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f7bee811-02e6-4c74-be80-bf0b99b50b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ab6cf955-b3b2-41eb-abd2-8f9e1a478d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ab6cf955-b3b2-41eb-abd2-8f9e1a478d06" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i9a1c3e19603a40dba7449b2def024868_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_74dda42b-b3f6-44b1-bdb8-e612d90c2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_DeferredTaxLiabilities_74dda42b-b3f6-44b1-bdb8-e612d90c2f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c69ee30f-b38c-4543-b0a9-62b45a50ca75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c69ee30f-b38c-4543-b0a9-62b45a50ca75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e55bef37-02c8-4e8d-8440-e6b8104777b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e55bef37-02c8-4e8d-8440-e6b8104777b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet_fe05023c-acd8-4b4e-8645-9e3ad54a2514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet_fe05023c-acd8-4b4e-8645-9e3ad54a2514" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_97484c26-7ef5-41bd-aca7-be6f244bb939" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_97484c26-7ef5-41bd-aca7-be6f244bb939" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e4181e59-9082-4716-b3a8-f46756b131ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e4181e59-9082-4716-b3a8-f46756b131ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_c423585c-f0ee-4463-a9df-ff253edb3549" xlink:href="elv-20221231.xsd#elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_c423585c-f0ee-4463-a9df-ff253edb3549" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncomeTaxRefundClaimsFiled_2794f6cf-2988-4a99-9bf5-06f2d361a1da" xlink:href="elv-20221231.xsd#elv_IncomeTaxRefundClaimsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_elv_IncomeTaxRefundClaimsFiled_2794f6cf-2988-4a99-9bf5-06f2d361a1da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_f97cbf31-180a-4ee0-8f31-728fc822831e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_f97cbf31-180a-4ee0-8f31-728fc822831e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6c596461-6df5-4648-bbfc-9da9a833753e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6c596461-6df5-4648-bbfc-9da9a833753e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3168ddc0-4041-49d5-9a06-91ad4166ae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3168ddc0-4041-49d5-9a06-91ad4166ae7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_da2bf6a5-122c-4f0b-8a1b-932724f51e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_OperatingLossCarryforwards_da2bf6a5-122c-4f0b-8a1b-932724f51e0c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_0c4d9426-513c-4314-a002-4e1602d6abb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxReceivable_0c4d9426-513c-4314-a002-4e1602d6abb1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_b66767ea-c61e-4181-bd7b-37d96655cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxesPaid_b66767ea-c61e-4181-bd7b-37d96655cca5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3f20da0f-0c3c-4b17-9765-eefd874e82fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3f20da0f-0c3c-4b17-9765-eefd874e82fb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_64b7c460-ebdb-43c2-8d3d-7216768567db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_64b7c460-ebdb-43c2-8d3d-7216768567db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1ba84300-51e4-4099-a254-dddf23b602ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1ba84300-51e4-4099-a254-dddf23b602ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxLiabilitiesNetMember_daba9f9f-9c68-466c-82aa-80199c3d40da" xlink:href="elv-20221231.xsd#elv_DeferredTaxLiabilitiesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:to="loc_elv_DeferredTaxLiabilitiesNetMember_daba9f9f-9c68-466c-82aa-80199c3d40da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_2a8877c7-2d1a-432e-924a-855b9dcad47e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:to="loc_us-gaap_TaxPeriodDomain_2a8877c7-2d1a-432e-924a-855b9dcad47e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:to="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IndefiniteMember_cefb7e69-b730-4216-9a4a-717a92b6964b" xlink:href="elv-20221231.xsd#elv_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_elv_IndefiniteMember_cefb7e69-b730-4216-9a4a-717a92b6964b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LimitedCarryforwardPeriodMember_96f2ad19-47f2-4016-8ace-c081dbf9e3f7" xlink:href="elv-20221231.xsd#elv_LimitedCarryforwardPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_elv_LimitedCarryforwardPeriodMember_96f2ad19-47f2-4016-8ace-c081dbf9e3f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_74409465-f888-4ff9-8ad9-44b0e86f7dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_us-gaap_EarliestTaxYearMember_74409465-f888-4ff9-8ad9-44b0e86f7dcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_529d80a8-2215-4dc0-a999-da14b24e0f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_us-gaap_LatestTaxYearMember_529d80a8-2215-4dc0-a999-da14b24e0f20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_17ddbe34-ade4-41b0-84c0-5362adb0f94f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_17ddbe34-ade4-41b0-84c0-5362adb0f94f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c8e62d15-aaf1-4083-b0a7-092f92e73296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c8e62d15-aaf1-4083-b0a7-092f92e73296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HealthInsuranceProviderfeeMember_d78bfc18-992b-4f55-86cc-72ed887d7bad" xlink:href="elv-20221231.xsd#elv_HealthInsuranceProviderfeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:to="loc_elv_HealthInsuranceProviderfeeMember_d78bfc18-992b-4f55-86cc-72ed887d7bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_96932bb4-9c2e-4dd8-b4cd-9db6852775b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:to="loc_us-gaap_DomesticCountryMember_96932bb4-9c2e-4dd8-b4cd-9db6852775b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_55cbc441-0eec-4c21-a7f5-00dabd422a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_55cbc441-0eec-4c21-a7f5-00dabd422a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97850d7f-d6fa-41cd-80b8-2ca440d3326f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:to="loc_srt_RangeMember_97850d7f-d6fa-41cd-80b8-2ca440d3326f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:to="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df0219fc-a467-45a6-9a56-92a55c29bf82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:to="loc_srt_MinimumMember_df0219fc-a467-45a6-9a56-92a55c29bf82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65f8143d-7074-44e2-9603-3db00aaf7e5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:to="loc_srt_MaximumMember_65f8143d-7074-44e2-9603-3db00aaf7e5a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="extended" id="id478421d878a46aeae6e4ea7b9d85ff5_PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_992fc583-4bfd-46c4-8fd1-78235e01cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_992fc583-4bfd-46c4-8fd1-78235e01cdf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1b53d49-ae3e-4e34-afbe-c0c25a2d5361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1b53d49-ae3e-4e34-afbe-c0c25a2d5361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6414a21e-8abc-42ae-b10c-4d3e73664506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6414a21e-8abc-42ae-b10c-4d3e73664506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3e54d52-fdf4-4891-a36d-e0d63eeeda48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3e54d52-fdf4-4891-a36d-e0d63eeeda48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6adce645-3aba-43d4-a0b7-75cb5f9261d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6adce645-3aba-43d4-a0b7-75cb5f9261d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DataProcessingEquipmentAndSoftwareMember_316a0351-9712-45c9-af07-7d30224cc4f9" xlink:href="elv-20221231.xsd#elv_DataProcessingEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_elv_DataProcessingEquipmentAndSoftwareMember_316a0351-9712-45c9-af07-7d30224cc4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_64a32db9-4ee6-4f50-acf3-b761760df42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_64a32db9-4ee6-4f50-acf3-b761760df42e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_510a955e-5344-4a2e-8cbb-d7aba57c7599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_510a955e-5344-4a2e-8cbb-d7aba57c7599" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_5e143b32-a5dd-41d7-9921-7581db4e69ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_5e143b32-a5dd-41d7-9921-7581db4e69ba" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" id="ia6e0c8abd5de4a4eaad73181963a16c3_PropertyAndEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_18e20fd3-d320-4a88-b686-e8f0cb8a17eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_Depreciation_18e20fd3-d320-4a88-b686-e8f0cb8a17eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_503da652-c027-4ebd-adef-a35c9eb4d62b" xlink:href="elv-20221231.xsd#elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_503da652-c027-4ebd-adef-a35c9eb4d62b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_faa1273a-c8c8-427e-9ede-e0fc95b148ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_faa1273a-c8c8-427e-9ede-e0fc95b148ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_413b79d0-35e7-48cd-814a-2dda1c6ac956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_413b79d0-35e7-48cd-814a-2dda1c6ac956" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_2f8b43a4-a95e-432f-b071-e44fa3b5971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_2f8b43a4-a95e-432f-b071-e44fa3b5971f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_718ad59c-206f-43ba-97b7-600b8f35bbe8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_718ad59c-206f-43ba-97b7-600b8f35bbe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_f42247c5-56ff-4bc3-9d17-1721aa526445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_f42247c5-56ff-4bc3-9d17-1721aa526445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9816d571-6ce9-4887-a0c9-7083e708d3d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9816d571-6ce9-4887-a0c9-7083e708d3d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_005c4685-6f5f-42f5-a4c9-4c6d7b90b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_005c4685-6f5f-42f5-a4c9-4c6d7b90b3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PPEImpairmentMember_4975fd35-fdb5-4470-8f95-ab62e333ef2e" xlink:href="elv-20221231.xsd#elv_PPEImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_005c4685-6f5f-42f5-a4c9-4c6d7b90b3a9" xlink:to="loc_elv_PPEImpairmentMember_4975fd35-fdb5-4470-8f95-ab62e333ef2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" xlink:type="extended" id="i515b4fdc764f4c4b9311f1c66b405e2e_GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_34de5761-3908-458e-b0d7-318730c923ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_34de5761-3908-458e-b0d7-318730c923ee" xlink:to="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b8e4fb78-d2ed-44d8-bef6-90bd1f961b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_Goodwill_b8e4fb78-d2ed-44d8-bef6-90bd1f961b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_d26aed4c-e209-441d-822a-716d1863236d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_d26aed4c-e209-441d-822a-716d1863236d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_2170d993-a9e3-410f-b15a-d5bd50931a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_2170d993-a9e3-410f-b15a-d5bd50931a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a6a92eb0-7792-409c-b9de-309e117a177d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2499d4df-f027-49b4-9dc2-54e68f69a9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2499d4df-f027-49b4-9dc2-54e68f69a9ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_34de5761-3908-458e-b0d7-318730c923ee" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1f9467bf-7325-416e-b7ed-ae410f9cd91e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:to="loc_us-gaap_SegmentDomain_1f9467bf-7325-416e-b7ed-ae410f9cd91e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:to="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_7389b2fc-562c-4b32-8cc3-13cc463ae05b" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_7389b2fc-562c-4b32-8cc3-13cc463ae05b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_614097a0-bb3e-4350-9630-60015de01a57" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_elv_GovernmentBusinessSegmentMember_614097a0-bb3e-4350-9630-60015de01a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_1fae0418-0513-46ab-9170-bc8b63dacc5a" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_elv_IngenioRxSegmentMember_1fae0418-0513-46ab-9170-bc8b63dacc5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_fcce1186-d16c-4043-9edf-c74031db62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_us-gaap_AllOtherSegmentsMember_fcce1186-d16c-4043-9edf-c74031db62f4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" xlink:type="extended" id="ie1f3a224c9d342ba9f73815d88ad1852_GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f11e832-4dad-4ee3-9ac5-a2896f755d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f11e832-4dad-4ee3-9ac5-a2896f755d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_982d7682-f842-4985-aef3-eb7b57cd816c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_982d7682-f842-4985-aef3-eb7b57cd816c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_810763ec-65b2-4321-aaa5-555634ac0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_810763ec-65b2-4321-aaa5-555634ac0d4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f8a775af-56e1-4323-ae6b-cfaaefafa9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f8a775af-56e1-4323-ae6b-cfaaefafa9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_41e6d2a5-b92c-4e43-85b8-a9972940d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d6c7edcb-00f1-48d4-b635-9f49d6d4da12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d6c7edcb-00f1-48d4-b635-9f49d6d4da12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_ef394a3a-4592-42a6-a6cf-ee248cbdc5c5" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_ef394a3a-4592-42a6-a6cf-ee248cbdc5c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1526d37-4bb0-443e-bdbd-4a47efbe44ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1526d37-4bb0-443e-bdbd-4a47efbe44ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_29ac9d0f-58cf-408d-b1a7-8c4a38212cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:to="loc_us-gaap_CustomerRelationshipsMember_29ac9d0f-58cf-408d-b1a7-8c4a38212cf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_ced69082-edef-4edb-9000-3bde5ccfb0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:to="loc_us-gaap_ContractualRightsMember_ced69082-edef-4edb-9000-3bde5ccfb0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_bd87b5d2-2f52-4b76-8197-75eab8772af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_bd87b5d2-2f52-4b76-8197-75eab8772af4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f902ea63-f32c-43c6-ba54-f095a80e962c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f902ea63-f32c-43c6-ba54-f095a80e962c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_c28a675c-92f0-420a-91c9-27d147a1ddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:to="loc_us-gaap_TrademarksMember_c28a675c-92f0-420a-91c9-27d147a1ddd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_dc6f95de-82e5-4cf7-a8ce-4220056e4f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:to="loc_us-gaap_LicensingAgreementsMember_dc6f95de-82e5-4cf7-a8ce-4220056e4f2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsReconciliationOfTheBenefitObligationDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails" xlink:type="extended" id="ia16ee4b2704d4d12b72e5e0d85bd8c82_RetirementBenefitsReconciliationOfTheBenefitObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_868e9965-43d5-4b05-9ccf-51de70f1314c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_868e9965-43d5-4b05-9ccf-51de70f1314c" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_49d8de03-f4f7-4ef2-aa08-362a0f97bfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_49d8de03-f4f7-4ef2-aa08-362a0f97bfdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ed9b9dfe-e384-4af7-8ca4-66f74913990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ed9b9dfe-e384-4af7-8ca4-66f74913990d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_211e8da3-6df6-42e0-b392-e74a342c598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_211e8da3-6df6-42e0-b392-e74a342c598d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_f7cb1dc5-884e-4de7-b795-be0ffc7c580f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_f7cb1dc5-884e-4de7-b795-be0ffc7c580f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4cd77865-c678-46e3-9c94-3214653c509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4cd77865-c678-46e3-9c94-3214653c509a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7d9e94f8-2dc7-4d20-a79c-151ebb74f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7d9e94f8-2dc7-4d20-a79c-151ebb74f81e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_fa90ca28-b8cb-4867-955b-995776d30ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_fa90ca28-b8cb-4867-955b-995776d30ab3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_66de601b-a7a9-42a3-8c5e-58143852a843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_868e9965-43d5-4b05-9ccf-51de70f1314c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_36909830-0091-4b4b-9909-8b456e9789c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_36909830-0091-4b4b-9909-8b456e9789c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_56a13493-7a7a-48b6-bfee-27b5b0382856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_56a13493-7a7a-48b6-bfee-27b5b0382856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_99fb6dab-3387-4781-ae9d-cfa6a07819b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_99fb6dab-3387-4781-ae9d-cfa6a07819b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails" xlink:type="extended" id="i3a1177593190411c9d52275ca76face4_RetirementBenefitsChangesInFairValueOfPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57de0981-af9d-454b-9d26-9590850314b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57de0981-af9d-454b-9d26-9590850314b1" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f3bdb3e7-9711-4c2f-9130-52f8a201d943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f3bdb3e7-9711-4c2f-9130-52f8a201d943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_a813d2df-c897-49a1-8b1d-ebd155c9bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_a813d2df-c897-49a1-8b1d-ebd155c9bec5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ce97a7af-1221-4057-9502-c77846a4cee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ce97a7af-1221-4057-9502-c77846a4cee5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d1ff0621-d24c-4f56-ae56-21acb6b0e0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d1ff0621-d24c-4f56-ae56-21acb6b0e0ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_dda8571f-e594-4451-bd2a-ce96eb03a415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_dda8571f-e594-4451-bd2a-ce96eb03a415" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanBenefitsPaidFairValue_09d689b1-782b-463e-be21-2bb052e3ba41" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanBenefitsPaidFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_elv_DefinedBenefitPlanBenefitsPaidFairValue_09d689b1-782b-463e-be21-2bb052e3ba41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_affbff1a-90e9-45a1-b656-51c0d215b8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57de0981-af9d-454b-9d26-9590850314b1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_61818696-46cf-4149-87eb-025b5f8a9ac7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_61818696-46cf-4149-87eb-025b5f8a9ac7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09bdc0b4-38f2-49f5-ba4b-6a17b07861e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09bdc0b4-38f2-49f5-ba4b-6a17b07861e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5e54b385-73b6-4b37-894b-42ecd8892ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5e54b385-73b6-4b37-894b-42ecd8892ddd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" xlink:type="extended" id="ifb514087c6e34638838881aa234c5ed8_RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0a9fc9a5-3f30-4737-a452-77a1bc60a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0a9fc9a5-3f30-4737-a452-77a1bc60a6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2bb064e1-44f9-43fd-ab84-5b5c5abb69cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2bb064e1-44f9-43fd-ab84-5b5c5abb69cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3526e8e8-3a96-49dc-902d-603d7aeaaf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3526e8e8-3a96-49dc-902d-603d7aeaaf8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4699a952-5395-4731-aeb2-9ae89399af99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4699a952-5395-4731-aeb2-9ae89399af99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ceb584a2-7525-4044-b866-40d512649a34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ceb584a2-7525-4044-b866-40d512649a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0b1aaa48-e120-48ff-81a8-58dcfd38c528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0b1aaa48-e120-48ff-81a8-58dcfd38c528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64925254-3097-49e7-ac52-71bd61114e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64925254-3097-49e7-ac52-71bd61114e96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" xlink:type="extended" id="ib2010634db754e63beb9249e5eda242e_RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e3da539d-032b-4aae-b661-e90b9413194e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e3da539d-032b-4aae-b661-e90b9413194e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d2805552-812e-475d-8386-c9f781835145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d2805552-812e-475d-8386-c9f781835145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a8c29c2a-3be4-4c12-b6ea-16a3cfcbb6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a8c29c2a-3be4-4c12-b6ea-16a3cfcbb6b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cc05236e-cf98-4c49-b506-d7f7f83eecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cc05236e-cf98-4c49-b506-d7f7f83eecbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6ebf4b04-ac6f-4e70-ac16-8ef666049d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6ebf4b04-ac6f-4e70-ac16-8ef666049d68" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails" xlink:type="extended" id="i44f531200d9147e3bb17d530ce7490a5_RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_2fea345c-35fc-4184-823f-4faab2e7280e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_2fea345c-35fc-4184-823f-4faab2e7280e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_9b5bea46-d3ea-48a9-b97c-b23d62d79fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_9b5bea46-d3ea-48a9-b97c-b23d62d79fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_1fb5374c-52a1-46d6-b722-560ca972eb4c" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_1fb5374c-52a1-46d6-b722-560ca972eb4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_31361069-951d-4fab-83e0-fee0a7f317b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_31361069-951d-4fab-83e0-fee0a7f317b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_06d363c5-ae8b-463c-9e56-c73cd99ab690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_06d363c5-ae8b-463c-9e56-c73cd99ab690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7822dcf1-8139-477b-913c-ac97e038f6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7822dcf1-8139-477b-913c-ac97e038f6d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_91366b51-d36f-4bf8-b8dd-694bd5c59ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_91366b51-d36f-4bf8-b8dd-694bd5c59ede" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" xlink:type="extended" id="ib75e0d2d58894036bb8f79a1a95433d9_RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_53601c22-a417-48a4-a210-7d0f77cc2839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_53601c22-a417-48a4-a210-7d0f77cc2839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_738ca39e-d099-4f39-a054-1d8d7b361491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_738ca39e-d099-4f39-a054-1d8d7b361491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1fcf52c1-c75a-4bec-a0b6-6e98ee639179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1fcf52c1-c75a-4bec-a0b6-6e98ee639179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cd1a003b-1ef5-4013-94da-f0772a750ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cd1a003b-1ef5-4013-94da-f0772a750ad8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b52c6fc0-42df-4712-92f4-6b761737245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b52c6fc0-42df-4712-92f4-6b761737245c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_b7ad5194-fc29-488e-9740-5d544bab9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_b7ad5194-fc29-488e-9740-5d544bab9c9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_023580cd-53d0-4679-aa7b-2f4af4ffed51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_023580cd-53d0-4679-aa7b-2f4af4ffed51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8296386b-e698-4bf1-806b-fabafbed9360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8296386b-e698-4bf1-806b-fabafbed9360" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_64b04ec8-68ab-4df5-9be8-3c54788e8c91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_64b04ec8-68ab-4df5-9be8-3c54788e8c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_bd98b2db-a420-4dc6-97e3-5861a1c471f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_bd98b2db-a420-4dc6-97e3-5861a1c471f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c80c1b8-5b0f-4048-bb2c-85190015fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c80c1b8-5b0f-4048-bb2c-85190015fd90" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails" xlink:type="extended" id="ib249618cb7244b2b93c9daf05557a748_RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5b1a8091-5748-488c-9e43-51769403c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5b1a8091-5748-488c-9e43-51769403c1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_3d02f3e4-5e7f-4ef6-8be5-dac5eb103fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_3d02f3e4-5e7f-4ef6-8be5-dac5eb103fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3db0b922-79fd-42df-a956-932614d38eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3db0b922-79fd-42df-a956-932614d38eb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_611c5aff-2911-40d1-ae90-db994be6f944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_611c5aff-2911-40d1-ae90-db994be6f944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_acb58bc1-a824-4dc6-ab20-eb7b98361e1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_acb58bc1-a824-4dc6-ab20-eb7b98361e1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_024dd4d7-0a89-4109-a3aa-a7ed0e24ac2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_024dd4d7-0a89-4109-a3aa-a7ed0e24ac2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64b0d73e-4bb8-4136-aa96-6816f9164280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64b0d73e-4bb8-4136-aa96-6816f9164280" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails" xlink:type="extended" id="iecea4c158e604b9b8a79d79d5f522565_RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2b880c18-1fea-4654-bad0-79b006793564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2b880c18-1fea-4654-bad0-79b006793564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5a8e2e17-91c5-453e-b407-1ba6ad3c2f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5a8e2e17-91c5-453e-b407-1ba6ad3c2f28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7e187731-410e-4130-b683-820c29309408_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7e187731-410e-4130-b683-820c29309408_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_85021a02-7de2-4260-ab25-df1a9d56f6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_85021a02-7de2-4260-ab25-df1a9d56f6a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e3246f15-93f0-4d4c-bf15-74c9566b5162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e3246f15-93f0-4d4c-bf15-74c9566b5162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_bb73002b-6e52-4a57-8729-d121501b087e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_bb73002b-6e52-4a57-8729-d121501b087e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a817d29d-56f7-4a72-be93-7005d7396d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a817d29d-56f7-4a72-be93-7005d7396d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f79327ad-1929-431e-bb47-7bc2eb3f3a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f79327ad-1929-431e-bb47-7bc2eb3f3a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MutualFundsMember_3113b047-7404-4312-b4fa-ba2e474aef64" xlink:href="elv-20221231.xsd#elv_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_MutualFundsMember_3113b047-7404-4312-b4fa-ba2e474aef64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_6d768052-3a06-471f-b21a-c268372cf1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_6d768052-3a06-471f-b21a-c268372cf1b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8d03d197-b0ac-40c9-9ac6-521262a36092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8d03d197-b0ac-40c9-9ac6-521262a36092" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_255e39d9-52b7-4552-805b-5353644fbf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_255e39d9-52b7-4552-805b-5353644fbf0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommingledFundDomain_c61591bb-1161-428b-be88-314d493c06c3" xlink:href="elv-20221231.xsd#elv_CommingledFundDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_CommingledFundDomain_c61591bb-1161-428b-be88-314d493c06c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceCompanyContractsMember_0007d64e-45a2-4932-82f8-eaf3d796028a" xlink:href="elv-20221231.xsd#elv_InsuranceCompanyContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_InsuranceCompanyContractsMember_0007d64e-45a2-4932-82f8-eaf3d796028a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LifeInsuranceContractsMember_f76ff557-1918-4784-a487-d9a06db48ffc" xlink:href="elv-20221231.xsd#elv_LifeInsuranceContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_LifeInsuranceContractsMember_f76ff557-1918-4784-a487-d9a06db48ffc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentInDOL10312TrustMember_42c30346-5865-40c2-8ffd-e092f0ad3cce" xlink:href="elv-20221231.xsd#elv_InvestmentInDOL10312TrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_InvestmentInDOL10312TrustMember_42c30346-5865-40c2-8ffd-e092f0ad3cce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_961badf5-e8c6-4393-a382-3b877ad2e85a" xlink:href="elv-20221231.xsd#elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_961badf5-e8c6-4393-a382-3b877ad2e85a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PartnershipInvestmentsMember_7cd39fac-a68b-4550-8c3d-9fb6a47b17ae" xlink:href="elv-20221231.xsd#elv_PartnershipInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_PartnershipInvestmentsMember_7cd39fac-a68b-4550-8c3d-9fb6a47b17ae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_b52bd24a-67f2-4951-9561-7d07cfdf42ab" xlink:href="elv-20221231.xsd#elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_b52bd24a-67f2-4951-9561-7d07cfdf42ab" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1c268ac-f03b-4c60-be39-9376d1d06232_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1c268ac-f03b-4c60-be39-9376d1d06232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_09ebda7a-f796-42f6-ab90-460e31683cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_09ebda7a-f796-42f6-ab90-460e31683cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_22a25f4e-2ce2-40aa-b8fe-556d68ff2450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_22a25f4e-2ce2-40aa-b8fe-556d68ff2450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_de1020df-8f43-4782-aa2f-e95504f62fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_de1020df-8f43-4782-aa2f-e95504f62fe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_9c4decdf-468d-4e38-8f07-05b07a812732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_9c4decdf-468d-4e38-8f07-05b07a812732" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails" xlink:type="extended" id="i7d56d314289048f6a9455560914019b2_RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0d29c3ba-e727-4510-8523-d608c80579bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0d29c3ba-e727-4510-8523-d608c80579bc" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_897c3658-5bce-464f-885f-3e4b36ded8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_897c3658-5bce-464f-885f-3e4b36ded8c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_6794f608-4a7e-4180-a97a-a2bda415ada2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_6794f608-4a7e-4180-a97a-a2bda415ada2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase_7f87500f-01d0-432e-b0fb-2c3a9724edef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase_7f87500f-01d0-432e-b0fb-2c3a9724edef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale_2586a95e-660f-45aa-839d-e2053adec7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale_2586a95e-660f-45aa-839d-e2053adec7d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3311166c-63e7-47ec-8979-118f738e1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0d29c3ba-e727-4510-8523-d608c80579bc" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesDomain_ab99d065-b252-4f1a-a93b-033d1952ad23_default" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:to="loc_elv_TotalLevelIIIassetcategoriesDomain_ab99d065-b252-4f1a-a93b-033d1952ad23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesDomain_0ef1dfea-4579-4caf-b326-2e3c03777404" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:to="loc_elv_TotalLevelIIIassetcategoriesDomain_0ef1dfea-4579-4caf-b326-2e3c03777404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10628d46-207f-42b2-9726-57bb22a229bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10628d46-207f-42b2-9726-57bb22a229bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bef2947-8762-47f3-ac62-a47f4e2331ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bef2947-8762-47f3-ac62-a47f4e2331ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8abbef6a-a575-4a28-837e-3b81b770e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bef2947-8762-47f3-ac62-a47f4e2331ac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8abbef6a-a575-4a28-837e-3b81b770e85b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cb353bb6-1515-4238-b444-de420e03bb9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cb353bb6-1515-4238-b444-de420e03bb9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6a7cfee0-4efd-4619-9cf0-07596ee55c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6a7cfee0-4efd-4619-9cf0-07596ee55c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_7af01bbe-88bd-47e4-bc85-7914667d6b82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_7af01bbe-88bd-47e4-bc85-7914667d6b82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommingledFundDomain_0534ed4e-3165-4245-9ed8-fbd7b5f5c203" xlink:href="elv-20221231.xsd#elv_CommingledFundDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:to="loc_elv_CommingledFundDomain_0534ed4e-3165-4245-9ed8-fbd7b5f5c203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceCompanyContractsMember_b1f8f0cb-ac39-4fca-b87e-90a7f23be40c" xlink:href="elv-20221231.xsd#elv_InsuranceCompanyContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:to="loc_elv_InsuranceCompanyContractsMember_b1f8f0cb-ac39-4fca-b87e-90a7f23be40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LifeInsuranceContractsMember_918c0304-9c66-49e8-a85a-a998fcd2e6ab" xlink:href="elv-20221231.xsd#elv_LifeInsuranceContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:to="loc_elv_LifeInsuranceContractsMember_918c0304-9c66-49e8-a85a-a998fcd2e6ab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails" xlink:type="extended" id="i73b505ec497644a69ea7c672d931b191_RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_dcd4b68f-22c4-49aa-bd80-220b6884c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_dcd4b68f-22c4-49aa-bd80-220b6884c0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_aafc0fe0-dd65-4b1f-a39a-e509b1822d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_aafc0fe0-dd65-4b1f-a39a-e509b1822d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb285a83-171d-4216-b463-b1d970e7c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb285a83-171d-4216-b463-b1d970e7c73a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ae38b217-997b-4ea1-aac5-784654ae03eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ae38b217-997b-4ea1-aac5-784654ae03eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_09177d83-2308-4a7d-b7dc-c7b1944dafe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_09177d83-2308-4a7d-b7dc-c7b1944dafe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_40e2fd47-1912-4f9e-8f1a-5d3a7c96b874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_40e2fd47-1912-4f9e-8f1a-5d3a7c96b874" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4d2bb903-343c-4341-9a49-d2a55968d6ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4d2bb903-343c-4341-9a49-d2a55968d6ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2f5d86ff-0701-45e3-9026-dbe3133b342c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2f5d86ff-0701-45e3-9026-dbe3133b342c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3ecebaeb-69b7-4269-910b-48a5875a39dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3ecebaeb-69b7-4269-910b-48a5875a39dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended" id="ifbb6284909ed4543b2ec6e4f2376b543_RetirementBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9eba7b18-eb5d-400e-bcb2-7903b5ca8ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9eba7b18-eb5d-400e-bcb2-7903b5ca8ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_d977007f-3f6e-4f65-b5d2-0cbacaaf7713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_d977007f-3f6e-4f65-b5d2-0cbacaaf7713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8c3f5374-62a4-4798-9e9a-0f8291546deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8c3f5374-62a4-4798-9e9a-0f8291546deb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_65a49250-00f2-446c-a05c-12d7aa60e171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_65a49250-00f2-446c-a05c-12d7aa60e171" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_36fe72ae-4c88-4fa0-a2bb-36d145f6a476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_36fe72ae-4c88-4fa0-a2bb-36d145f6a476" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2b8946c5-6cdd-4289-86bd-ec0cd0f64e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2b8946c5-6cdd-4289-86bd-ec0cd0f64e95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ab7a42bb-3ffe-4051-b975-12399bb1eef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ab7a42bb-3ffe-4051-b975-12399bb1eef9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_b5d0ead2-9274-4990-bb55-588c7babf9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_b5d0ead2-9274-4990-bb55-588c7babf9a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_9bc4806a-f488-47c2-a2e7-2ea1ad218581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_9bc4806a-f488-47c2-a2e7-2ea1ad218581" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_dc0969be-67a2-4077-b812-d268cb683635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_dc0969be-67a2-4077-b812-d268cb683635" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitFairValueDueFromBrokers_3161e56b-a293-46e2-b4e4-dba1b7789ac3" xlink:href="elv-20221231.xsd#elv_DefinedBenefitFairValueDueFromBrokers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_elv_DefinedBenefitFairValueDueFromBrokers_3161e56b-a293-46e2-b4e4-dba1b7789ac3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_a79af07a-dac7-42e7-9de5-66d5f9660e51" xlink:href="elv-20221231.xsd#elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_a79af07a-dac7-42e7-9de5-66d5f9660e51" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_7eaafaab-bee4-44d8-b73a-2d956f99e148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_7eaafaab-bee4-44d8-b73a-2d956f99e148" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_88898c71-97b9-4ded-a51d-10a8ad0de136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_88898c71-97b9-4ded-a51d-10a8ad0de136" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_991b1374-1537-4629-9535-4071e8e07fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_991b1374-1537-4629-9535-4071e8e07fb3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b93bc868-528a-45a7-90e8-b86acc6cab81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b93bc868-528a-45a7-90e8-b86acc6cab81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_06633162-736a-46f4-929c-5139c1b5cc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_us-gaap_EquitySecuritiesMember_06633162-736a-46f4-929c-5139c1b5cc10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c0555b70-0c0a-4d4b-95de-d54e8317df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_us-gaap_DebtSecuritiesMember_c0555b70-0c0a-4d4b-95de-d54e8317df5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4e3c169b-663f-4410-a2b9-c3306101a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4e3c169b-663f-4410-a2b9-c3306101a1ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PartnershipInvestmentsMember_cc900dab-8a7b-4c71-b99a-79f3454e6d41" xlink:href="elv-20221231.xsd#elv_PartnershipInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_elv_PartnershipInvestmentsMember_cc900dab-8a7b-4c71-b99a-79f3454e6d41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanByAgeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitAgeDomain_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b_default" xlink:href="elv-20221231.xsd#elv_DefinedBenefitAgeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:to="loc_elv_DefinedBenefitAgeDomain_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:href="elv-20221231.xsd#elv_DefinedBenefitAgeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:to="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PreMedicareMember_fe6edd7a-0d3a-4fa7-95ef-cfa008f97db7" xlink:href="elv-20221231.xsd#elv_PreMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:to="loc_elv_PreMedicareMember_fe6edd7a-0d3a-4fa7-95ef-cfa008f97db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PostMedicareMember_f7801776-0147-4db7-8b80-085b266f7b14" xlink:href="elv-20221231.xsd#elv_PostMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:to="loc_elv_PostMedicareMember_f7801776-0147-4db7-8b80-085b266f7b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7e965d52-3e0f-4b16-bd7e-5916c48e54ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7e965d52-3e0f-4b16-bd7e-5916c48e54ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fa426d04-fd57-45c5-91ba-d1a560105e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fa426d04-fd57-45c5-91ba-d1a560105e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3bcfc0ce-eafd-4475-9f94-8b1b65a63aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3bcfc0ce-eafd-4475-9f94-8b1b65a63aaa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" xlink:type="extended" id="i0ac7a74af57b4e12a4d9c04a7b385399_MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_5f1a9cc8-4c4b-4b8a-86ca-f2334e81df39" xlink:href="elv-20221231.xsd#elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_5f1a9cc8-4c4b-4b8a-86ca-f2334e81df39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_26e05e56-266f-43ad-a4f8-10549d9316b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_26e05e56-266f-43ad-a4f8-10549d9316b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_526eebb5-60e7-4160-8c23-ce05a572b97a" xlink:href="elv-20221231.xsd#elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_526eebb5-60e7-4160-8c23-ce05a572b97a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_ad25f75d-bd96-4e92-b52f-82a5921e8fda" xlink:href="elv-20221231.xsd#elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_ad25f75d-bd96-4e92-b52f-82a5921e8fda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ed6aad0c-1da1-4420-84ba-1f2d7a614a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ed6aad0c-1da1-4420-84ba-1f2d7a614a49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_196cffc0-565f-4e05-9f10-34eb7168e9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_196cffc0-565f-4e05-9f10-34eb7168e9b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_d99cf23d-7e49-4d70-b3c4-197532280396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_d99cf23d-7e49-4d70-b3c4-197532280396" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9ff61bb3-56c1-469b-addf-aa5d0919628e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9ff61bb3-56c1-469b-addf-aa5d0919628e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8e8be1c0-a745-45b4-a366-9f90614df093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8e8be1c0-a745-45b4-a366-9f90614df093" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_1e6e37ab-0816-4cd1-aeca-96da869336f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_1e6e37ab-0816-4cd1-aeca-96da869336f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_53fea60c-4d93-4cbf-87a8-032d17d1a331" xlink:href="elv-20221231.xsd#elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_d980c253-3962-4102-9697-fe7cbb21ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_e31970d8-d664-4e0a-ad15-0c9954c5097b" xlink:href="elv-20221231.xsd#elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a1d82090-2e33-45fd-a248-75e55ea77cca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:to="loc_us-gaap_SegmentDomain_a1d82090-2e33-45fd-a248-75e55ea77cca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:to="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_2133825c-42c2-4f86-9e6e-906081a2ff45" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_2133825c-42c2-4f86-9e6e-906081a2ff45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_d9c6471f-014c-4dae-983a-ff6157dbec6a" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:to="loc_elv_GovernmentBusinessSegmentMember_d9c6471f-014c-4dae-983a-ff6157dbec6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_b02b8fdc-8a1d-41ad-a7a6-58de3b3d2856" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:to="loc_elv_OtherSegmentMember_b02b8fdc-8a1d-41ad-a7a6-58de3b3d2856" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" xlink:type="extended" id="ifb01e7128f82486392106c1ca3eba785_MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:href="elv-20221231.xsd#elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_a307ffe0-c8f7-4ba0-a24a-6234cd25fcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_a307ffe0-c8f7-4ba0-a24a-6234cd25fcd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_QualityImprovementAndOtherClaimsExpense_af214ef3-9f5d-4292-a24b-b9bc7f7e6197" xlink:href="elv-20221231.xsd#elv_QualityImprovementAndOtherClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_elv_QualityImprovementAndOtherClaimsExpense_af214ef3-9f5d-4292-a24b-b9bc7f7e6197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_1c1999c1-0989-410b-b758-760ea780e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_1c1999c1-0989-410b-b758-760ea780e3fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:href="elv-20221231.xsd#elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a392557-a97a-4626-b118-6864ad1a5924_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:to="loc_us-gaap_SegmentDomain_8a392557-a97a-4626-b118-6864ad1a5924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:to="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_eef6dfd6-8714-4037-a00b-612d03d4f777" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_eef6dfd6-8714-4037-a00b-612d03d4f777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_2f38f6e7-aff4-45ba-8787-78d2d1ec6552" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:to="loc_elv_GovernmentBusinessSegmentMember_2f38f6e7-aff4-45ba-8787-78d2d1ec6552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_367bc3af-ad5c-4581-8e8d-541625b24440" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:to="loc_elv_OtherSegmentMember_367bc3af-ad5c-4581-8e8d-541625b24440" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails" xlink:type="extended" id="i5abcade6f87e487f86cc9f2a0137a19e_MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_f30e407f-4ed6-462c-bc8f-b13928be4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_f30e407f-4ed6-462c-bc8f-b13928be4e3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_31e9e00f-e850-4270-8516-f52094437b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_31e9e00f-e850-4270-8516-f52094437b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_58504bb7-2239-4ace-abea-d7ff7fabedca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:to="loc_us-gaap_SegmentDomain_58504bb7-2239-4ace-abea-d7ff7fabedca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:to="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_5f23411b-6424-4440-829f-f1924adb49dc" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_5f23411b-6424-4440-829f-f1924adb49dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_58b9109e-a4ef-4b58-868c-44f8ae2b7807" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:to="loc_elv_GovernmentBusinessSegmentMember_58b9109e-a4ef-4b58-868c-44f8ae2b7807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_5d03381e-b87f-4c61-a48a-a53ab882d193" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:to="loc_elv_OtherSegmentMember_5d03381e-b87f-4c61-a48a-a53ab882d193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_8909d421-a90d-4adf-a0f3-4a39c67b78e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_8909d421-a90d-4adf-a0f3-4a39c67b78e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_f7dd2635-bc08-4e3a-86fb-6026f82fccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_f7dd2635-bc08-4e3a-86fb-6026f82fccaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_b06f24ea-571e-4bb3-a038-a28d9b3a89ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_b06f24ea-571e-4bb3-a038-a28d9b3a89ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_4c3d09c4-4ab3-4f52-b8ad-0954a458780d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_4c3d09c4-4ab3-4f52-b8ad-0954a458780d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails" xlink:type="extended" id="ifd50d2b34af34784824ff86cd49a846e_MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_7ce8f17f-1c38-4821-bc2b-0503239c8d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_7ce8f17f-1c38-4821-bc2b-0503239c8d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d0085b18-9c96-4c5c-aded-fdf05799f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d0085b18-9c96-4c5c-aded-fdf05799f5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f1cb7ad7-83ac-4265-8f5a-e2899d67af14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f1cb7ad7-83ac-4265-8f5a-e2899d67af14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_fc529e1e-992b-491c-a8b8-49323e835231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_fc529e1e-992b-491c-a8b8-49323e835231" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_c686143c-bd51-4ddd-a9c1-1203877c88fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_c686143c-bd51-4ddd-a9c1-1203877c88fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_ba505fd3-e1f7-4e4a-9647-34d7b5941fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_ba505fd3-e1f7-4e4a-9647-34d7b5941fb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d74d2109-5600-455c-8ca4-b9173971791e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:to="loc_us-gaap_SegmentDomain_d74d2109-5600-455c-8ca4-b9173971791e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:to="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_afcbac92-8529-4f3d-86f7-cc9c5f731f4a" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_afcbac92-8529-4f3d-86f7-cc9c5f731f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_de445349-4832-4bfb-b98a-14c6e1c4b977" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:to="loc_elv_GovernmentBusinessSegmentMember_de445349-4832-4bfb-b98a-14c6e1c4b977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_137906d9-fa7b-4297-afa0-13cc672a1ccc" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:to="loc_elv_OtherSegmentMember_137906d9-fa7b-4297-afa0-13cc672a1ccc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" xlink:type="extended" id="i85737406005b42fe8fd86d5af282f274_MedicalClaimsPayableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_036be551-58ce-4676-b232-b3ff0f27eec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_036be551-58ce-4676-b232-b3ff0f27eec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_9e8eb19b-0535-40ce-bd6e-38ba55d2ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_9e8eb19b-0535-40ce-bd6e-38ba55d2ce8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_6a55a3d0-8613-4a13-a99b-f36f1785195e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_6a55a3d0-8613-4a13-a99b-f36f1785195e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:href="elv-20221231.xsd#elv_ShortdurationInsuranceContractsClaimYearTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_31e2639d-b7b2-491e-bf2b-8802575dbf04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_31e2639d-b7b2-491e-bf2b-8802575dbf04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_8d1e6fbf-281f-4b66-b89d-ef32d59e34e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_8d1e6fbf-281f-4b66-b89d-ef32d59e34e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_f27ea595-61b1-4e87-959c-1d77a25600ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_f27ea595-61b1-4e87-959c-1d77a25600ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_c1493a40-f2c5-4cd7-accc-277224660b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_c1493a40-f2c5-4cd7-accc-277224660b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4cf29a50-37ad-4365-8a62-71efd4579594_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:to="loc_us-gaap_SegmentDomain_4cf29a50-37ad-4365-8a62-71efd4579594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:to="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_264c1dc4-1f0d-4c8e-8679-6d71c9631268" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_264c1dc4-1f0d-4c8e-8679-6d71c9631268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_e19ebe81-46fd-4e48-a916-b9677bbeb2cd" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:to="loc_elv_GovernmentBusinessSegmentMember_e19ebe81-46fd-4e48-a916-b9677bbeb2cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_ce0cef54-ed21-4cac-aa63-e1c4245843b8" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:to="loc_elv_OtherSegmentMember_ce0cef54-ed21-4cac-aa63-e1c4245843b8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DebtCarryingValueOfLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails" xlink:type="extended" id="ia473e81ae53b40d4b3202decbdeb85ba_DebtCarryingValueOfLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3807aefa-d355-49da-b7ad-b4746eae8b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_LongTermDebt_3807aefa-d355-49da-b7ad-b4746eae8b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_841db74c-e321-4d10-94bf-2af359d17bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_841db74c-e321-4d10-94bf-2af359d17bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_5e864b39-e7db-4baf-a4ef-3133611fa6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_CommercialPaper_5e864b39-e7db-4baf-a4ef-3133611fa6cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_dba6ebf5-fe14-467d-b367-0c3944009c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_LongTermDebtCurrent_dba6ebf5-fe14-467d-b367-0c3944009c3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f25eaee2-05ae-444d-b09a-d64616b43dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f25eaee2-05ae-444d-b09a-d64616b43dcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86946dfd-b606-406b-8d3a-716fb773ccbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86946dfd-b606-406b-8d3a-716fb773ccbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SeniorUnsecuredNotesMember_8e4d3d51-b6fa-4511-ac22-bb0597e37483" xlink:href="elv-20221231.xsd#elv_SeniorUnsecuredNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_elv_SeniorUnsecuredNotesMember_8e4d3d51-b6fa-4511-ac22-bb0597e37483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SurplusNotesMember_d2d1c2ae-4dd2-44d3-b64d-86f974fad4b3" xlink:href="elv-20221231.xsd#elv_SurplusNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_elv_SurplusNotesMember_d2d1c2ae-4dd2-44d3-b64d-86f974fad4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7d6cdd48-326e-46da-8758-69c29bd9cc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_us-gaap_ConvertibleDebtMember_7d6cdd48-326e-46da-8758-69c29bd9cc4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc5bee42-e2ca-499f-b9b9-b35519bf6040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_us-gaap_CommercialPaperMember_cc5bee42-e2ca-499f-b9b9-b35519bf6040" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:to="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7966345-d93d-474d-9fc5-34794fc37430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7966345-d93d-474d-9fc5-34794fc37430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_5b5cfff9-716a-4ad2-9858-ed53f21cb848" xlink:href="elv-20221231.xsd#elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_5b5cfff9-716a-4ad2-9858-ed53f21cb848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_5f84a196-af78-48d1-bc22-12a65c4b59f5" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_5f84a196-af78-48d1-bc22-12a65c4b59f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_e79990a5-6315-411b-9d8d-4602637c2383" xlink:href="elv-20221231.xsd#elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_e79990a5-6315-411b-9d8d-4602637c2383" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_285b65d5-f909-4ee8-a8ed-e450eebe2483" xlink:href="elv-20221231.xsd#elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_285b65d5-f909-4ee8-a8ed-e450eebe2483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_1fbf7e46-8442-4e99-9387-428347e20749" xlink:href="elv-20221231.xsd#elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_1fbf7e46-8442-4e99-9387-428347e20749" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_392f2d51-3f49-4519-8ebb-ab72f7ea727d" xlink:href="elv-20221231.xsd#elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_392f2d51-3f49-4519-8ebb-ab72f7ea727d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_10cc4ba0-0d64-4fad-bb37-e810bb63cd1f" xlink:href="elv-20221231.xsd#elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_10cc4ba0-0d64-4fad-bb37-e810bb63cd1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_61ff5b08-bca6-490c-98a1-f0c91d5572c3" xlink:href="elv-20221231.xsd#elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_61ff5b08-bca6-490c-98a1-f0c91d5572c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_75551721-f8d1-4814-8ee0-0757d5429632" xlink:href="elv-20221231.xsd#elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_75551721-f8d1-4814-8ee0-0757d5429632" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_6944f921-249b-4e6a-beab-eaa8f2f72887" xlink:href="elv-20221231.xsd#elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_6944f921-249b-4e6a-beab-eaa8f2f72887" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_5e0d8c00-91ec-455c-a06a-dfbb7cc221ee" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_5e0d8c00-91ec-455c-a06a-dfbb7cc221ee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_49a9707f-0454-4607-9bbd-28e914b7efc3" xlink:href="elv-20221231.xsd#elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_49a9707f-0454-4607-9bbd-28e914b7efc3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_4958f79f-1672-4753-8f17-21c09b87e23f" xlink:href="elv-20221231.xsd#elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_4958f79f-1672-4753-8f17-21c09b87e23f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4c7a934d-e3cb-4512-be72-2051c077e196" xlink:href="elv-20221231.xsd#elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4c7a934d-e3cb-4512-be72-2051c077e196" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_931e0996-51e4-477c-adb6-5c8fb70f5e8c" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_931e0996-51e4-477c-adb6-5c8fb70f5e8c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_2a03704f-fd34-4254-b790-7483a5132154" xlink:href="elv-20221231.xsd#elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_2a03704f-fd34-4254-b790-7483a5132154" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_9ed09a3b-beec-4f9b-86cc-9a71564a1ab0" xlink:href="elv-20221231.xsd#elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_9ed09a3b-beec-4f9b-86cc-9a71564a1ab0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_7c1a3f31-fbe1-4535-810a-c26a6be74a95" xlink:href="elv-20221231.xsd#elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_7c1a3f31-fbe1-4535-810a-c26a6be74a95" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_1901ddd1-4c67-4a72-b230-c8ad2b653c91" xlink:href="elv-20221231.xsd#elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_1901ddd1-4c67-4a72-b230-c8ad2b653c91" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_85b298ec-54ad-424a-946c-60bf1bf45359" xlink:href="elv-20221231.xsd#elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_85b298ec-54ad-424a-946c-60bf1bf45359" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_d6781561-cc35-4847-863d-d9b2538707d9" xlink:href="elv-20221231.xsd#elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_d6781561-cc35-4847-863d-d9b2538707d9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_7f89e726-0b68-49ee-a650-b582f2377372" xlink:href="elv-20221231.xsd#elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_7f89e726-0b68-49ee-a650-b582f2377372" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_49774fa5-b296-46aa-be28-154d4a8c70e8" xlink:href="elv-20221231.xsd#elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_49774fa5-b296-46aa-be28-154d4a8c70e8" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_ebd43f8a-e9b8-4141-8d81-1d09bef9a9de" xlink:href="elv-20221231.xsd#elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_ebd43f8a-e9b8-4141-8d81-1d09bef9a9de" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_e1804375-1063-45a5-bd69-bee4fe897e06" xlink:href="elv-20221231.xsd#elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_e1804375-1063-45a5-bd69-bee4fe897e06" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_63131622-fa87-42e7-aac2-53670240638f" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_63131622-fa87-42e7-aac2-53670240638f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_443f04c9-ac3b-4a1a-8b5c-aef3e97e60d5" xlink:href="elv-20221231.xsd#elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_443f04c9-ac3b-4a1a-8b5c-aef3e97e60d5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_3b076a2a-0ade-4577-8a53-580c7f143108" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_3b076a2a-0ade-4577-8a53-580c7f143108" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_b065f5c1-8f93-4d86-b72c-ddad80042297" xlink:href="elv-20221231.xsd#elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_b065f5c1-8f93-4d86-b72c-ddad80042297" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_05e838ab-6726-4b0b-92fa-4e61b93b6438" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_05e838ab-6726-4b0b-92fa-4e61b93b6438" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_a4abe6d0-7842-45a3-8452-f24b3e37b805" xlink:href="elv-20221231.xsd#elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_a4abe6d0-7842-45a3-8452-f24b3e37b805" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_975538ff-878d-47e7-989f-52f9901b9a32" xlink:href="elv-20221231.xsd#elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_975538ff-878d-47e7-989f-52f9901b9a32" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_675443e9-3fb2-4193-b396-b8afc46b854a" xlink:href="elv-20221231.xsd#elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_675443e9-3fb2-4193-b396-b8afc46b854a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_3e75d9e9-f052-45b2-ba00-30e05d805805" xlink:href="elv-20221231.xsd#elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_3e75d9e9-f052-45b2-ba00-30e05d805805" xlink:type="arc" order="33"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/DebtNarrativeDetails" xlink:type="extended" id="i43614c1965744bb0af3d6a16cb319013_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_1ed9be15-eb13-4a74-aa8e-4d111d776dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_1ed9be15-eb13-4a74-aa8e-4d111d776dc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b467981-e0c6-4637-91d1-25339a19bd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b467981-e0c6-4637-91d1-25339a19bd35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a5ea3a4e-f743-4385-90b2-ab6d66477841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a5ea3a4e-f743-4385-90b2-ab6d66477841" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_c658fa3f-01ca-4380-8bf5-20b6175cb193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_c658fa3f-01ca-4380-8bf5-20b6175cb193" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DebtRedemptionAmount_b8d3ff2f-51c7-4060-a9aa-96c2441725c7" xlink:href="elv-20221231.xsd#elv_DebtRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_DebtRedemptionAmount_b8d3ff2f-51c7-4060-a9aa-96c2441725c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b977e21f-c62d-4067-b6b6-4f99211f18b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b977e21f-c62d-4067-b6b6-4f99211f18b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc5e48d4-baf6-465b-ac0a-082e093cc541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1eefeffd-1ee1-46c4-9b74-452cae56c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1eefeffd-1ee1-46c4-9b74-452cae56c4e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_9ed9b076-30e8-402e-8aba-d08a81f73c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_9ed9b076-30e8-402e-8aba-d08a81f73c4b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarlyRepaymentOfSeniorDebt_d1225957-a684-4f0f-8e1e-f4578c701462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarlyRepaymentOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_EarlyRepaymentOfSeniorDebt_d1225957-a684-4f0f-8e1e-f4578c701462" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d1e5e4cd-0c28-4427-b49b-ae9aa4f9e024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d1e5e4cd-0c28-4427-b49b-ae9aa4f9e024" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1297fb0f-7d8c-4e0e-a5a4-2925748e87b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1297fb0f-7d8c-4e0e-a5a4-2925748e87b3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_36fee2a3-981f-4792-9cc9-0328db7f7a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_36fee2a3-981f-4792-9cc9-0328db7f7a6c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_3deeb918-2c75-4d91-97e3-a74a35da173e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_3deeb918-2c75-4d91-97e3-a74a35da173e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialPaperMaximumBorrowingCapacity_f23ec80b-872a-47eb-9422-c6b3add4fe9a" xlink:href="elv-20221231.xsd#elv_CommercialPaperMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_CommercialPaperMaximumBorrowingCapacity_f23ec80b-872a-47eb-9422-c6b3add4fe9a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_a9ca3d29-5988-4aaf-90e1-7a39c45164dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_CommercialPaper_a9ca3d29-5988-4aaf-90e1-7a39c45164dd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_245a9979-a208-44c4-8909-10a920ba67a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_245a9979-a208-44c4-8909-10a920ba67a3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9c216fc9-03ed-4606-a440-9e7b6698b525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9c216fc9-03ed-4606-a440-9e7b6698b525" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfConsecutiveTradingDays_c7932791-bc5e-4bab-a754-ad885b9b8a25" xlink:href="elv-20221231.xsd#elv_NumberOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_NumberOfConsecutiveTradingDays_c7932791-bc5e-4bab-a754-ad885b9b8a25" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5a372056-c5f2-4200-80be-3e317a6ce2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5a372056-c5f2-4200-80be-3e317a6ce2d1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MeasurementPeriod_8130bc7e-7696-4db6-bd34-04f1354f0240" xlink:href="elv-20221231.xsd#elv_MeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_MeasurementPeriod_8130bc7e-7696-4db6-bd34-04f1354f0240" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PercentConversionToStockPrice_e44ce228-099a-4473-aaa9-516968f97064" xlink:href="elv-20221231.xsd#elv_PercentConversionToStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_PercentConversionToStockPrice_e44ce228-099a-4473-aaa9-516968f97064" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleEarliestDate1_5627f4b9-4081-40ee-8714-70bc906f0b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleEarliestDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleEarliestDate1_5627f4b9-4081-40ee-8714-70bc906f0b8f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_40e806e7-cd95-40a4-bcf9-e5c59ca933a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_40e806e7-cd95-40a4-bcf9-e5c59ca933a0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DateDebenturesReedemable_8f59a9d7-9528-4e98-a74b-f01a77d0e9be" xlink:href="elv-20221231.xsd#elv_DateDebenturesReedemable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_DateDebenturesReedemable_8f59a9d7-9528-4e98-a74b-f01a77d0e9be" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c8c5e8e1-8e47-4bac-bf9c-48c98985feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c8c5e8e1-8e47-4bac-bf9c-48c98985feb5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ConversionPremium_4650faa2-ac40-4dfd-b489-0038928d5ffa" xlink:href="elv-20221231.xsd#elv_ConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_ConversionPremium_4650faa2-ac40-4dfd-b489-0038928d5ffa" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6a5c3d2a-750a-4d99-8ec4-410880fd30c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_SharePrice_6a5c3d2a-750a-4d99-8ec4-410880fd30c8" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_75ccea1f-6cd7-4a82-8c81-e38b9dfb99ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_75ccea1f-6cd7-4a82-8c81-e38b9dfb99ba" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DebtConversionDebtPrincipalAmount_bd799c63-fc73-4f31-9ff9-dd8f92d6eb9b" xlink:href="elv-20221231.xsd#elv_DebtConversionDebtPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_DebtConversionDebtPrincipalAmount_bd799c63-fc73-4f31-9ff9-dd8f92d6eb9b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d38e73e6-bb95-4c31-af14-eff405eba25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d38e73e6-bb95-4c31-af14-eff405eba25b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_667943a7-14eb-4fbc-9379-5198b1dc98f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_667943a7-14eb-4fbc-9379-5198b1dc98f7" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_89f0820a-427d-47fd-8938-eaada47297fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_InterestExpenseDebt_89f0820a-427d-47fd-8938-eaada47297fc" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ccb95998-ed40-428f-816a-64b606a0d794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ccb95998-ed40-428f-816a-64b606a0d794" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2386eadf-fe49-4b45-9cc1-d743eaa89c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2386eadf-fe49-4b45-9cc1-d743eaa89c8c" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_8b6c70e6-ca86-4f47-ba7f-4e0172f7cec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_InterestPaid_8b6c70e6-ca86-4f47-ba7f-4e0172f7cec4" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_77906d32-1d50-4ec8-8659-6a05b73bc1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_77906d32-1d50-4ec8-8659-6a05b73bc1e0" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2dca459e-70a4-4488-90ae-51bae7a04625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2dca459e-70a4-4488-90ae-51bae7a04625" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f9e7d02a-e1b1-4b68-b384-15b139660457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f9e7d02a-e1b1-4b68-b384-15b139660457" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_856128c5-8ca4-417a-b724-0bc7df9ef237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_856128c5-8ca4-417a-b724-0bc7df9ef237" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b664bb00-5d84-4e36-b125-60539fa1cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b664bb00-5d84-4e36-b125-60539fa1cd9c" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f18dcdc-aaaf-4e04-8efe-f82c061f8ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f18dcdc-aaaf-4e04-8efe-f82c061f8ee1" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_1c812aa6-3f32-430e-b341-29f4bd96bac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_1c812aa6-3f32-430e-b341-29f4bd96bac6" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_746b7a72-22e8-4cba-b77a-e7b6f06a5df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_746b7a72-22e8-4cba-b77a-e7b6f06a5df3" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4fb91a48-44e1-4ecf-816f-86c47744791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebt_4fb91a48-44e1-4ecf-816f-86c47744791b" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8b3e5457-df3b-479a-b80a-f3c1fce39df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8b3e5457-df3b-479a-b80a-f3c1fce39df1" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c44a656-5b77-401a-9bd9-e4546f5b3bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_StockholdersEquity_1c44a656-5b77-401a-9bd9-e4546f5b3bf1" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_75d966fa-a56c-403e-87ce-03b85120e17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_75d966fa-a56c-403e-87ce-03b85120e17d" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodEndDate_85e2a15c-45b2-4f6e-8099-d30e462bb56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodEndDate_85e2a15c-45b2-4f6e-8099-d30e462bb56d" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_990f7e2a-fad5-472a-b555-2db017451c0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_990f7e2a-fad5-472a-b555-2db017451c0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember_6fc3aa69-77af-47a0-aa74-8e86b0f79458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMember_6fc3aa69-77af-47a0-aa74-8e86b0f79458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5d2f8f3e-5805-4fc5-b14c-6796500d1c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:to="loc_us-gaap_LineOfCreditMember_5d2f8f3e-5805-4fc5-b14c-6796500d1c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5241cc53-8811-4b2e-8af1-db481ca608e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5241cc53-8811-4b2e-8af1-db481ca608e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b552c055-5306-4c63-bca8-d20615220432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b552c055-5306-4c63-bca8-d20615220432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SeniorUnsecuredNotesMember_325e961d-4ea9-4018-a9d3-e0ed0aa529a2" xlink:href="elv-20221231.xsd#elv_SeniorUnsecuredNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_elv_SeniorUnsecuredNotesMember_325e961d-4ea9-4018-a9d3-e0ed0aa529a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSeniorUnsecuredNotesMember_48457635-a793-4295-b0e8-952334d52101" xlink:href="elv-20221231.xsd#elv_OtherSeniorUnsecuredNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_elv_OtherSeniorUnsecuredNotesMember_48457635-a793-4295-b0e8-952334d52101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29e72420-14ec-42bd-b989-f4759ac26cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_us-gaap_CommercialPaperMember_29e72420-14ec-42bd-b989-f4759ac26cb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_c352e168-b677-46ac-85d8-438848db6a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_us-gaap_ConvertibleDebtMember_c352e168-b677-46ac-85d8-438848db6a1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a01e450-ae84-43a1-a864-e0d4b6507ae2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:to="loc_us-gaap_CreditFacilityDomain_2a01e450-ae84-43a1-a864-e0d4b6507ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:to="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A5YearFacilityMember_587843d9-4c85-497d-ba19-e700f1ad1f78" xlink:href="elv-20221231.xsd#elv_A5YearFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:to="loc_elv_A5YearFacilityMember_587843d9-4c85-497d-ba19-e700f1ad1f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A2021364DayFacilityMember_0684f433-7a94-472f-a498-b0c389948782" xlink:href="elv-20221231.xsd#elv_A2021364DayFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:to="loc_elv_A2021364DayFacilityMember_0684f433-7a94-472f-a498-b0c389948782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42deb910-6692-4605-b82d-0907588a524c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42deb910-6692-4605-b82d-0907588a524c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_adfb48af-6103-40c6-81fd-deab0f748047" xlink:href="elv-20221231.xsd#elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_adfb48af-6103-40c6-81fd-deab0f748047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_c763bed4-a715-49b7-8015-a941b3267f9a" xlink:href="elv-20221231.xsd#elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_c763bed4-a715-49b7-8015-a941b3267f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_4533cf54-cd55-4667-8390-9c0617fb3c05" xlink:href="elv-20221231.xsd#elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_4533cf54-cd55-4667-8390-9c0617fb3c05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_dc78f668-82aa-4db0-89ca-addf5ee2101d" xlink:href="elv-20221231.xsd#elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_dc78f668-82aa-4db0-89ca-addf5ee2101d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4e29bc16-1cd9-496d-89b5-3f0de7526eb4" xlink:href="elv-20221231.xsd#elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4e29bc16-1cd9-496d-89b5-3f0de7526eb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_8e5904a0-5794-4dd5-897c-379d8d3e0c30" xlink:href="elv-20221231.xsd#elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_8e5904a0-5794-4dd5-897c-379d8d3e0c30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_dcc70537-1f65-4f2c-a85b-bf626e7c4a12" xlink:href="elv-20221231.xsd#elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_dcc70537-1f65-4f2c-a85b-bf626e7c4a12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_abce18ed-4ede-4942-85f8-db5fccfec4ad" xlink:href="elv-20221231.xsd#elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_abce18ed-4ede-4942-85f8-db5fccfec4ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_000cccf2-0e79-4a37-a0a2-2048e395d2aa" xlink:href="elv-20221231.xsd#elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_000cccf2-0e79-4a37-a0a2-2048e395d2aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_57043393-7f43-49fd-a036-ad41591a12cf" xlink:href="elv-20221231.xsd#elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_57043393-7f43-49fd-a036-ad41591a12cf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_2f804b69-6952-4232-9c15-70f24a4681b6" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_2f804b69-6952-4232-9c15-70f24a4681b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_33379b6a-e68b-476f-bfce-06136e04cc57" xlink:href="elv-20221231.xsd#elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_33379b6a-e68b-476f-bfce-06136e04cc57" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_fde632a4-9263-4d9e-8d3a-f2386ab97171" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_fde632a4-9263-4d9e-8d3a-f2386ab97171" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_8001fd5c-723b-47ed-938c-238f50d244c9" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_8001fd5c-723b-47ed-938c-238f50d244c9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_289fb76d-c23a-489a-b957-5734860931a8" xlink:href="elv-20221231.xsd#elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_289fb76d-c23a-489a-b957-5734860931a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_5a46b55e-6bbd-4942-b0da-be9fd137bbd1" xlink:href="elv-20221231.xsd#elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_5a46b55e-6bbd-4942-b0da-be9fd137bbd1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_77f52e65-4e36-440a-b81f-12a5217c59b3" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_77f52e65-4e36-440a-b81f-12a5217c59b3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_c5a12c05-fe30-418f-b165-f7fc65637a04" xlink:href="elv-20221231.xsd#elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_c5a12c05-fe30-418f-b165-f7fc65637a04" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_e9b830dd-144a-49a7-84e7-360904c1b0dc" xlink:href="elv-20221231.xsd#elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_e9b830dd-144a-49a7-84e7-360904c1b0dc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_fe45d769-4b20-4583-a432-151a68fc7690" xlink:href="elv-20221231.xsd#elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_fe45d769-4b20-4583-a432-151a68fc7690" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_30c7edf3-916f-4410-bfc6-f2642663a3af" xlink:href="elv-20221231.xsd#elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_30c7edf3-916f-4410-bfc6-f2642663a3af" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6794e1f7-f862-426a-b3c2-431662d02759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6794e1f7-f862-426a-b3c2-431662d02759" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b5ad7a6-d063-4deb-b7f7-95e0c5247030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b5ad7a6-d063-4deb-b7f7-95e0c5247030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a12bba5c-1e39-41ae-9878-48fef815c8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2b5ad7a6-d063-4deb-b7f7-95e0c5247030" xlink:to="loc_us-gaap_SubsequentEventMember_a12bba5c-1e39-41ae-9878-48fef815c8e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_69f17f7f-81bf-41fd-bf91-d4e9e83df98f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_69f17f7f-81bf-41fd-bf91-d4e9e83df98f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7de17460-36ae-4f8c-8d7b-1cbecdfd1e11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7de17460-36ae-4f8c-8d7b-1cbecdfd1e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3f70b0f1-b4d0-4baf-9cf5-6f8bdb3e0c7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7de17460-36ae-4f8c-8d7b-1cbecdfd1e11" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3f70b0f1-b4d0-4baf-9cf5-6f8bdb3e0c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_93582517-43d6-4036-bb23-d950c7cc7339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:to="loc_us-gaap_TypeOfAdoptionMember_93582517-43d6-4036-bb23-d950c7cc7339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_861c4014-0834-4ff7-8d84-e782682f0168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:to="loc_us-gaap_TypeOfAdoptionMember_861c4014-0834-4ff7-8d84-e782682f0168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_b6fa6d10-90c7-47db-be6b-decaeec866d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_861c4014-0834-4ff7-8d84-e782682f0168" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_b6fa6d10-90c7-47db-be6b-decaeec866d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_209adba0-935e-4677-998b-2fd3461d8557_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:to="loc_us-gaap_EquityComponentDomain_209adba0-935e-4677-998b-2fd3461d8557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb3a0e46-f153-4780-a30c-cb95a91761c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:to="loc_us-gaap_EquityComponentDomain_cb3a0e46-f153-4780-a30c-cb95a91761c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_98f572f9-5f90-4492-86ba-071a8b02de10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb3a0e46-f153-4780-a30c-cb95a91761c6" xlink:to="loc_us-gaap_RetainedEarningsMember_98f572f9-5f90-4492-86ba-071a8b02de10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CommitmentsAndContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" id="if95bb58e0aa64e99bf085a28d7ae6f9c_CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:href="elv-20221231.xsd#elv_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_de53b822-34ae-4fea-969d-9f7d8ce02577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_de53b822-34ae-4fea-969d-9f7d8ce02577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GrossPremiumTaxRate_d0acd014-bd01-4153-945a-8218d89a5cef" xlink:href="elv-20221231.xsd#elv_GrossPremiumTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_elv_GrossPremiumTaxRate_d0acd014-bd01-4153-945a-8218d89a5cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1edd09fc-7e32-4dfa-89c3-48203609b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1edd09fc-7e32-4dfa-89c3-48203609b00b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c89da3c3-1b91-4933-86c4-02076aa4e896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c89da3c3-1b91-4933-86c4-02076aa4e896" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_025247c0-c39e-41a4-af17-e678b4e251a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_025247c0-c39e-41a4-af17-e678b4e251a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_36077b45-b7a2-4ef1-a0ab-3d98d2198388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_36077b45-b7a2-4ef1-a0ab-3d98d2198388" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:href="elv-20221231.xsd#elv_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e581c515-0da7-46b1-8774-f83b4b78059f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:to="loc_srt_LitigationCaseTypeDomain_e581c515-0da7-46b1-8774-f83b4b78059f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7f64415a-1aa7-4188-b614-512ef1770d1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:to="loc_srt_LitigationCaseTypeDomain_7f64415a-1aa7-4188-b614-512ef1770d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AnthemInc.v.ExpressScriptsInc.Member_2e4dcfe1-a5e4-4352-baf8-f99dd764d3b3" xlink:href="elv-20221231.xsd#elv_AnthemInc.v.ExpressScriptsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7f64415a-1aa7-4188-b614-512ef1770d1b" xlink:to="loc_elv_AnthemInc.v.ExpressScriptsInc.Member_2e4dcfe1-a5e4-4352-baf8-f99dd764d3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0208bc54-20ff-446f-a89a-6962dc15932c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:to="loc_srt_RangeMember_0208bc54-20ff-446f-a89a-6962dc15932c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:to="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_30ca01ef-6444-4541-b1c2-635352bc0035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:to="loc_srt_MinimumMember_30ca01ef-6444-4541-b1c2-635352bc0035" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1bcff3fa-bd51-4e18-ab6d-340fd8ad4197" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:to="loc_srt_MaximumMember_1bcff3fa-bd51-4e18-ab6d-340fd8ad4197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:to="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PharmacypricingMember_ddca4aa8-1495-4bfe-b682-51e0b8b0e7bd" xlink:href="elv-20221231.xsd#elv_PharmacypricingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:to="loc_elv_PharmacypricingMember_ddca4aa8-1495-4bfe-b682-51e0b8b0e7bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperationalMember_1f82a253-f102-4c91-96ea-49d81e3e9a8b" xlink:href="elv-20221231.xsd#elv_OperationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:to="loc_elv_OperationalMember_1f82a253-f102-4c91-96ea-49d81e3e9a8b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails" xlink:type="extended" id="ie705d447efdc4e64a9f59d6b388e74a3_CapitalStockShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_785619f4-38b9-471a-a65b-f77fce2617e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_785619f4-38b9-471a-a65b-f77fce2617e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_e0fcc265-372f-493f-94c0-6ac394388c35" xlink:href="elv-20221231.xsd#elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_e0fcc265-372f-493f-94c0-6ac394388c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d1d23851-648a-46b3-aedd-92da99f68783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d1d23851-648a-46b3-aedd-92da99f68783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e4cee220-5463-42c4-8fa6-1059260036bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e4cee220-5463-42c4-8fa6-1059260036bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ab015bc-0b50-4d64-9872-98bc32b918cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ab015bc-0b50-4d64-9872-98bc32b918cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f7dbf348-8496-431b-9472-5e1fc4f56517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f7dbf348-8496-431b-9472-5e1fc4f56517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2e84d36e-33e9-4984-8a40-42673782ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f7dbf348-8496-431b-9472-5e1fc4f56517" xlink:to="loc_us-gaap_SubsequentEventMember_2e84d36e-33e9-4984-8a40-42673782ad63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" xlink:type="extended" id="ia138aee811bc48d6a80bfa42ba0f224c_CapitalStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5ec54c43-6220-49a6-907b-a6418f12640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5ec54c43-6220-49a6-907b-a6418f12640b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6c37caa6-1619-4a17-bb5e-8d0c4f21c51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6c37caa6-1619-4a17-bb5e-8d0c4f21c51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StockOptionTerm_caf7c98c-50f7-46bf-8461-ce8ec1c94d80" xlink:href="elv-20221231.xsd#elv_StockOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_StockOptionTerm_caf7c98c-50f7-46bf-8461-ce8ec1c94d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2a86db97-fad7-4e3d-944b-8d12af4a5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensation_2a86db97-fad7-4e3d-944b-8d12af4a5a43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d63bd422-8fe7-4ffc-a25c-4e0a32d60494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d63bd422-8fe7-4ffc-a25c-4e0a32d60494" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7719e74a-95e7-4046-adf8-b8922006b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7719e74a-95e7-4046-adf8-b8922006b45a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_b0a52328-a6f3-48b6-9ad0-8251eb892c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_b0a52328-a6f3-48b6-9ad0-8251eb892c65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f045f2b8-d9e6-42a8-bdbd-9e807da4b621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f045f2b8-d9e6-42a8-bdbd-9e807da4b621" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_392d8d09-72ff-4eae-b4c4-e16fae43015e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_392d8d09-72ff-4eae-b4c4-e16fae43015e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd5d68cc-21bc-4ee4-8cf8-71c274eb33ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd5d68cc-21bc-4ee4-8cf8-71c274eb33ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_43ad5223-c6d2-448a-ba8c-f8958818bba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_43ad5223-c6d2-448a-ba8c-f8958818bba7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b71c86de-8f16-4ac5-af08-6e1dfc44b1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b71c86de-8f16-4ac5-af08-6e1dfc44b1b1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58a5259a-cd0e-4ecf-ba5f-90a4ea62d8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58a5259a-cd0e-4ecf-ba5f-90a4ea62d8f9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_f9363011-55b0-47d5-978b-289d5dcff164" xlink:href="elv-20221231.xsd#elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_f9363011-55b0-47d5-978b-289d5dcff164" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_cecef482-2530-44bc-ad54-0fa662888672" xlink:href="elv-20221231.xsd#elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_cecef482-2530-44bc-ad54-0fa662888672" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2b1a6e5e-a86a-468a-8edf-e0160500c29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2b1a6e5e-a86a-468a-8edf-e0160500c29a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e0681c14-f41a-44e2-b650-1b3c631ae46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e0681c14-f41a-44e2-b650-1b3c631ae46e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f94b1480-16c9-4202-85ed-02dc81aa5fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f94b1480-16c9-4202-85ed-02dc81aa5fa6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_5ca5b2a2-8fbf-4b8e-a9b7-a91552ba2591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_5ca5b2a2-8fbf-4b8e-a9b7-a91552ba2591" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_397f312b-ce4a-4b7f-a60b-6ddf95382826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_397f312b-ce4a-4b7f-a60b-6ddf95382826" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_9e199d15-d036-4c39-a1d4-84883ad63b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_9e199d15-d036-4c39-a1d4-84883ad63b43" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncreaseInStockRepurchaseProgramAuthorization_ad19ac41-a84f-4b3b-867b-6716861a454d" xlink:href="elv-20221231.xsd#elv_IncreaseInStockRepurchaseProgramAuthorization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_IncreaseInStockRepurchaseProgramAuthorization_ad19ac41-a84f-4b3b-867b-6716861a454d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5d2d29a4-3412-4075-9879-afd0097813a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5d2d29a4-3412-4075-9879-afd0097813a0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_104941c8-579d-4dd5-9528-f01668472be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_104941c8-579d-4dd5-9528-f01668472be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_02610e1a-f459-4faa-af7d-ea54ed1758d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_104941c8-579d-4dd5-9528-f01668472be8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_02610e1a-f459-4faa-af7d-ea54ed1758d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodDomain_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8_default" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:to="loc_elv_PerformancemeasurementperiodDomain_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodDomain_15a1cb61-950b-4059-b018-00a94fda0eb8" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:to="loc_elv_PerformancemeasurementperiodDomain_15a1cb61-950b-4059-b018-00a94fda0eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A2022To2024Member_a80731ad-b477-4ae0-9ef7-80ff03cdb69c" xlink:href="elv-20221231.xsd#elv_A2022To2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_PerformancemeasurementperiodDomain_15a1cb61-950b-4059-b018-00a94fda0eb8" xlink:to="loc_elv_A2022To2024Member_a80731ad-b477-4ae0-9ef7-80ff03cdb69c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee3c3875-d241-46ee-952c-86d89b792eb0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:to="loc_srt_RangeMember_ee3c3875-d241-46ee-952c-86d89b792eb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:to="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a5a8fb0a-f6d5-40f4-8c28-becb8c899efb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:to="loc_srt_MinimumMember_a5a8fb0a-f6d5-40f4-8c28-becb8c899efb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f982b216-8766-4864-83d8-42af1ab0554c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:to="loc_srt_MaximumMember_f982b216-8766-4864-83d8-42af1ab0554c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3564ad71-695c-4208-bb9a-36c38c8f76ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:to="loc_us-gaap_PlanNameDomain_3564ad71-695c-4208-bb9a-36c38c8f76ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e0283d05-90cc-4f6d-a501-21ef6e42156b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:to="loc_us-gaap_PlanNameDomain_e0283d05-90cc-4f6d-a501-21ef6e42156b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EmployeeStockPurchasePlanMember_e48307f2-5f86-4e7a-b237-7d171fb2f9e1" xlink:href="elv-20221231.xsd#elv_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e0283d05-90cc-4f6d-a501-21ef6e42156b" xlink:to="loc_elv_EmployeeStockPurchasePlanMember_e48307f2-5f86-4e7a-b237-7d171fb2f9e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_407021d2-64b6-4bb7-826b-6b50328d168a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_407021d2-64b6-4bb7-826b-6b50328d168a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a0ad8fe5-a1c2-42ca-8512-1f83a91f0072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a0ad8fe5-a1c2-42ca-8512-1f83a91f0072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_42d1dcc9-d764-4db5-a8fe-88827b4c0b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a0ad8fe5-a1c2-42ca-8512-1f83a91f0072" xlink:to="loc_us-gaap_SubsequentEventMember_42d1dcc9-d764-4db5-a8fe-88827b4c0b5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:href="elv-20221231.xsd#elv_CapitalStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockDomain_517bf683-c473-44ec-9420-ada248e3e2f5_default" xlink:href="elv-20221231.xsd#elv_CapitalStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:to="loc_elv_CapitalStockDomain_517bf683-c473-44ec-9420-ada248e3e2f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:href="elv-20221231.xsd#elv_CapitalStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:to="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_a5c200f0-11ff-4413-93c0-ff161fd62040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:to="loc_us-gaap_StockCompensationPlanMember_a5c200f0-11ff-4413-93c0-ff161fd62040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7cc48397-f95e-43ea-8f23-dff5b0f46319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7cc48397-f95e-43ea-8f23-dff5b0f46319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_01222ff3-869a-40c4-9dd0-8a7921b3a029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:to="loc_us-gaap_StockOptionMember_01222ff3-869a-40c4-9dd0-8a7921b3a029" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i3fa900076ff144fba135fbfc7a43a1b9_AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d6c5322-81cf-4f67-b2e9-f5f9781fe757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d6c5322-81cf-4f67-b2e9-f5f9781fe757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92462da7-5302-4e37-b34d-6ccdee2ea149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92462da7-5302-4e37-b34d-6ccdee2ea149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e7336312-68b7-4d8c-ab17-7d0464f555ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e7336312-68b7-4d8c-ab17-7d0464f555ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0e21aae2-2f0b-4f96-a945-cdbfc0c65f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0e21aae2-2f0b-4f96-a945-cdbfc0c65f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0045f0d7-3344-4c3c-9b53-a8d40079ab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_c4ee8b71-3c11-40e7-9695-f6eee953395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_c4ee8b71-3c11-40e7-9695-f6eee953395f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_fbfa2a81-1492-4cfb-b4cf-c8097857fb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_fbfa2a81-1492-4cfb-b4cf-c8097857fb39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_73ca6e45-9b86-4154-8e94-ee65d6131e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9725388f-2c0f-475d-a57d-a5e02c63d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9725388f-2c0f-475d-a57d-a5e02c63d8c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2c7ca85e-8857-405a-af7c-7f1dd8ce9576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2c7ca85e-8857-405a-af7c-7f1dd8ce9576" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_634532dc-ea96-49ba-b17e-7f115ed4e74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_a88cdb0c-5a5b-4c06-9884-d40f4bad5963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_a88cdb0c-5a5b-4c06-9884-d40f4bad5963" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_937d4f69-9c36-4b22-8ba1-8b7c90e014a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_937d4f69-9c36-4b22-8ba1-8b7c90e014a1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_f5ce33b4-e616-4853-a398-2e8506f705e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ccf3081e-cb81-4e0a-b87a-5237af41d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ccf3081e-cb81-4e0a-b87a-5237af41d36b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c855aa3b-5ba5-4c60-9b54-4ffdc17c8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c855aa3b-5ba5-4c60-9b54-4ffdc17c8b04" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_8c79ca52-853c-45b7-b2c9-79a8085b91b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2fe96899-fd90-4607-9647-c00092a39c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2fe96899-fd90-4607-9647-c00092a39c4e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30ec7577-880d-4aac-ad8d-c4c05b865842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30ec7577-880d-4aac-ad8d-c4c05b865842" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_026f65a9-974d-4b32-a3ff-9a49e98b88a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_026f65a9-974d-4b32-a3ff-9a49e98b88a6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0a53139e-c55d-4bda-b8e0-119d11441f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_abac65b3-3906-471c-807a-a38530eeaf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_abac65b3-3906-471c-807a-a38530eeaf9e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_1459e806-d909-4919-b750-062ed9c5bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_1459e806-d909-4919-b750-062ed9c5bcb7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities_1032f19c-1df5-4cf7-903b-f4c9753195fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities_1032f19c-1df5-4cf7-903b-f4c9753195fb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_61d2a3de-3266-47b2-addc-62b723e73d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_61d2a3de-3266-47b2-addc-62b723e73d9d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f81c0f34-8ecb-45ab-81b4-d98d7ef1cf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f81c0f34-8ecb-45ab-81b4-d98d7ef1cf7d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_ba55501d-79e1-41e9-944e-060ecf10831a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_ba55501d-79e1-41e9-944e-060ecf10831a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_bcdac986-a3d0-44c7-9f86-0e56843e535d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_bcdac986-a3d0-44c7-9f86-0e56843e535d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_df959d62-7aa2-46c2-926d-ae093764638c" xlink:href="elv-20221231.xsd#elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_df959d62-7aa2-46c2-926d-ae093764638c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cd3fb835-92f6-4eaf-863c-fc951c1f34d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:to="loc_us-gaap_EquityComponentDomain_cd3fb835-92f6-4eaf-863c-fc951c1f34d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:to="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ecf24d4-13d2-4c64-965d-76b3bb81eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ecf24d4-13d2-4c64-965d-76b3bb81eb23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_e9c26820-75ca-435e-adbc-c11ab2fac195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_e9c26820-75ca-435e-adbc-c11ab2fac195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e3f708cf-fff9-4403-bdd4-0b6fb1f8c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e3f708cf-fff9-4403-bdd4-0b6fb1f8c106" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23ca2a51-9dd5-47da-827f-330f98feaadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23ca2a51-9dd5-47da-827f-330f98feaadc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_dbda5711-91b4-4f83-a07c-b56952a77bd1" xlink:href="elv-20221231.xsd#elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_dbda5711-91b4-4f83-a07c-b56952a77bd1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails" xlink:type="extended" id="i5c80f790d560447299f00c0fa7fd444f_ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems_38d7f800-b604-486c-8b8f-3110efc30492" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementaryInsuranceInformationBySegmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_2777d5b0-77b5-4cf7-8685-e682e4d42e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems_38d7f800-b604-486c-8b8f-3110efc30492" xlink:to="loc_us-gaap_PremiumsEarnedNet_2777d5b0-77b5-4cf7-8685-e682e4d42e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:href="elv-20221231.xsd#elv_NetPremiumsWrittenAndEarnedBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems_38d7f800-b604-486c-8b8f-3110efc30492" xlink:to="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a24376de-15fc-4ce4-b096-0fd699f94545_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:to="loc_us-gaap_SegmentDomain_a24376de-15fc-4ce4-b096-0fd699f94545_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:to="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_29475193-285c-46be-a8c3-4ef1ff051356" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_29475193-285c-46be-a8c3-4ef1ff051356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_213fa820-deec-49ad-9fce-658538c2a7e1" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:to="loc_elv_GovernmentBusinessSegmentMember_213fa820-deec-49ad-9fce-658538c2a7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_490fc6c3-4add-4af0-9546-9c32df6efbe8" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:to="loc_elv_OtherSegmentMember_490fc6c3-4add-4af0-9546-9c32df6efbe8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#LeasesLeaseandOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" xlink:type="extended" id="ia245c39ccd824207bc06a7c825d1c357_LeasesLeaseandOtherInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_118aee26-603f-40c1-9b73-5cbefec22f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_118aee26-603f-40c1-9b73-5cbefec22f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e12e673c-7be3-40b4-852d-66c2b40d6ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e12e673c-7be3-40b4-852d-66c2b40d6ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3d732531-3dc6-42cc-8889-3a9ca1dad946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3d732531-3dc6-42cc-8889-3a9ca1dad946" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_59eb4850-3810-4636-b645-d7ec63e5a898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseCost_59eb4850-3810-4636-b645-d7ec63e5a898" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortTermAndVariableLeaseCost_2585179a-8b13-42f7-972c-55acae1ba9fc" xlink:href="elv-20221231.xsd#elv_ShortTermAndVariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_elv_ShortTermAndVariableLeaseCost_2585179a-8b13-42f7-972c-55acae1ba9fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_a6059a96-5647-41d7-b788-ec55123929a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_SubleaseIncome_a6059a96-5647-41d7-b788-ec55123929a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c8dfb752-47db-4b31-8d7c-2604eadcfac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_LeaseCost_c8dfb752-47db-4b31-8d7c-2604eadcfac7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1071ca76-9aba-4a3d-a575-f40eac1bf8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeasePayments_1071ca76-9aba-4a3d-a575-f40eac1bf8c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f3789e92-9451-4a30-957b-5b2aac0de695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f3789e92-9451-4a30-957b-5b2aac0de695" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7df3e94-6f7c-468f-9208-8f0e7d31685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7df3e94-6f7c-468f-9208-8f0e7d31685a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8e08a2ea-88ae-424a-a765-724ea97bcf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8e08a2ea-88ae-424a-a765-724ea97bcf31" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06fa6dff-6d51-462f-abfb-610c9f917b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06fa6dff-6d51-462f-abfb-610c9f917b8f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_66e7f316-cdee-4289-8e51-4b7f60688737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_66e7f316-cdee-4289-8e51-4b7f60688737" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3bad14ce-6abe-4cd5-93c9-60d817bf7be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3bad14ce-6abe-4cd5-93c9-60d817bf7be4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a9292349-ee69-4509-9d63-dd21eaf495f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a9292349-ee69-4509-9d63-dd21eaf495f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c43361be-905d-41f4-b605-7ea7910597c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c43361be-905d-41f4-b605-7ea7910597c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_d6070631-109f-440b-86ce-46862d0494e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c43361be-905d-41f4-b605-7ea7910597c9" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_d6070631-109f-440b-86ce-46862d0494e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#LeasesLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails" xlink:type="extended" id="iced8343a161c4b5cae33a6cd4b3b72c6_LeasesLeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b55dc924-0bdb-4a0f-bedd-80c155ced8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b55dc924-0bdb-4a0f-bedd-80c155ced8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_c6c57c37-f208-4404-81a9-56025a86a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_c6c57c37-f208-4404-81a9-56025a86a6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:to="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:to="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82e5c2e3-2b94-47df-b884-a59d8ae9ec52_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:to="loc_srt_RangeMember_82e5c2e3-2b94-47df-b884-a59d8ae9ec52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:to="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46e47c90-1a28-4c95-9554-ae0587a41691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:to="loc_srt_MinimumMember_46e47c90-1a28-4c95-9554-ae0587a41691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a86e7bb8-defe-424a-ac39-523853b6d0eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:to="loc_srt_MaximumMember_a86e7bb8-defe-424a-ac39-523853b6d0eb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationFinancialDataByReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" xlink:type="extended" id="i2f05ada751a544428c63554a6e8f861b_SegmentInformationFinancialDataByReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_ed204099-4e71-4abb-a692-74109a2159a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_InsuranceServicesRevenue_ed204099-4e71-4abb-a692-74109a2159a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_74f0ca44-a98f-4cf8-87a7-5afad1c08ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_OperatingIncomeLoss_74f0ca44-a98f-4cf8-87a7-5afad1c08ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_b26db5ca-58ff-4b53-aafe-217779bf8af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_b26db5ca-58ff-4b53-aafe-217779bf8af3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1572e863-7a24-4fc1-af5f-471e781128a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:to="loc_us-gaap_SegmentDomain_1572e863-7a24-4fc1-af5f-471e781128a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:to="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_ea87e903-bb07-4942-8ce0-dc188ffbae73" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_ea87e903-bb07-4942-8ce0-dc188ffbae73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_d2998c6a-223f-484b-90a5-76250b646db8" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_GovernmentBusinessSegmentMember_d2998c6a-223f-484b-90a5-76250b646db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_b5743d2a-a552-4d31-991c-73d13d97c975" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_IngenioRxSegmentMember_b5743d2a-a552-4d31-991c-73d13d97c975" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_8629e610-4467-4ebb-9f3d-b0d5cc6504b1" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_OtherSegmentMember_8629e610-4467-4ebb-9f3d-b0d5cc6504b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SegmentEliminationsMember_abb6020b-7d0d-4144-8eb7-087a9ac8d7ca" xlink:href="elv-20221231.xsd#elv_SegmentEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_SegmentEliminationsMember_abb6020b-7d0d-4144-8eb7-087a9ac8d7ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:to="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:to="loc_srt_NameOfMajorCustomerDomain_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:to="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_UnaffiliatedMember_b1cb7ca1-bb7d-44ea-b8c8-7cc2f8dbc84e" xlink:href="elv-20221231.xsd#elv_UnaffiliatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:to="loc_elv_UnaffiliatedMember_b1cb7ca1-bb7d-44ea-b8c8-7cc2f8dbc84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AffiliatedMember_deae4330-9397-4f88-b4fb-de2d8e0a76b5" xlink:href="elv-20221231.xsd#elv_AffiliatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:to="loc_elv_AffiliatedMember_deae4330-9397-4f88-b4fb-de2d8e0a76b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationMajorProductRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails" xlink:type="extended" id="i3bd7801549ee4ade84c11806b2177dfa_SegmentInformationMajorProductRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentLineItems_b908c12d-599b-4aa2-8f12-7bfc0d2bf2f9" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_5c197c89-c58f-41af-a2f2-11c175b793a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elv_MajorProductRevenueBySegmentLineItems_b908c12d-599b-4aa2-8f12-7bfc0d2bf2f9" xlink:to="loc_us-gaap_InsuranceServicesRevenue_5c197c89-c58f-41af-a2f2-11c175b793a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_elv_MajorProductRevenueBySegmentLineItems_b908c12d-599b-4aa2-8f12-7bfc0d2bf2f9" xlink:to="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fab869fb-e961-4db0-b319-f2acd431857f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:to="loc_us-gaap_SegmentDomain_fab869fb-e961-4db0-b319-f2acd431857f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:to="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b35a868-0493-4e84-8099-43a5fc6fb6a0" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b35a868-0493-4e84-8099-43a5fc6fb6a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_592a609f-2996-4c93-a165-a090dc08969c" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_GovernmentBusinessSegmentMember_592a609f-2996-4c93-a165-a090dc08969c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_8851ef48-4804-4613-9fa5-85ef04689063" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_IngenioRxSegmentMember_8851ef48-4804-4613-9fa5-85ef04689063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_bd0d246c-019c-4ae6-a627-b1cad2abc631" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_OtherSegmentMember_bd0d246c-019c-4ae6-a627-b1cad2abc631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SegmentEliminationsMember_428c7592-2a8a-4661-89ad-d47b65f10989" xlink:href="elv-20221231.xsd#elv_SegmentEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_SegmentEliminationsMember_428c7592-2a8a-4661-89ad-d47b65f10989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:to="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bd0be0d-c029-48a7-a3df-e59e2b786a9d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:to="loc_srt_ProductsAndServicesDomain_8bd0be0d-c029-48a7-a3df-e59e2b786a9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:to="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ManagedCareProductsMember_4f074075-b90f-453e-b037-66f38c79eef2" xlink:href="elv-20221231.xsd#elv_ManagedCareProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_ManagedCareProductsMember_4f074075-b90f-453e-b037-66f38c79eef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ManagedCareServicesMember_b37a0c21-f875-4d76-a531-cc7ac1ace711" xlink:href="elv-20221231.xsd#elv_ManagedCareServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_ManagedCareServicesMember_b37a0c21-f875-4d76-a531-cc7ac1ace711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DentalVisionProductsAndServicesMember_aeed7c9d-5ec2-48b7-948d-bc93368865b8" xlink:href="elv-20221231.xsd#elv_DentalVisionProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_DentalVisionProductsAndServicesMember_aeed7c9d-5ec2-48b7-948d-bc93368865b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherProductsMember_3dda21c1-cd83-4fa8-be19-f1c74db8355f" xlink:href="elv-20221231.xsd#elv_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_OtherProductsMember_3dda21c1-cd83-4fa8-be19-f1c74db8355f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PharmacyProductsAndServicesMember_3656ee4d-fd79-46d0-853e-c40239451aa4" xlink:href="elv-20221231.xsd#elv_PharmacyProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_PharmacyProductsAndServicesMember_3656ee4d-fd79-46d0-853e-c40239451aa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntegratedHealthServicesMember_ecc9bc38-d7d6-4c1e-8c60-458b088c5d80" xlink:href="elv-20221231.xsd#elv_IntegratedHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_IntegratedHealthServicesMember_ecc9bc38-d7d6-4c1e-8c60-458b088c5d80" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="icab01f70a8484553af3b2ebc81f7efbc_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3bf9695a-8f1f-406a-97b2-655cf9b80657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:to="loc_us-gaap_NumberOfReportableSegments_3bf9695a-8f1f-406a-97b2-655cf9b80657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_849d7106-a12a-4575-883a-d5292fc075e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_849d7106-a12a-4575-883a-d5292fc075e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c2dab95b-8a03-44a6-913b-a55791c52800_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:to="loc_us-gaap_SegmentDomain_c2dab95b-8a03-44a6-913b-a55791c52800_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:to="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_9cd88b00-dcdf-4857-9469-24a9ed6fa0b5" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:to="loc_elv_GovernmentBusinessSegmentMember_9cd88b00-dcdf-4857-9469-24a9ed6fa0b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_b8d0d6b7-52b8-4201-8f4d-80d207876a56" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:to="loc_elv_IngenioRxSegmentMember_b8d0d6b7-52b8-4201-8f4d-80d207876a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0e0449d6-0472-49a9-8343-5855d1d165ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0e0449d6-0472-49a9-8343-5855d1d165ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2fa113ee-50de-4366-ba71-1eef4939b7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2fa113ee-50de-4366-ba71-1eef4939b7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_48f12134-0c1b-44a7-a3bc-684950a37703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2fa113ee-50de-4366-ba71-1eef4939b7b4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_48f12134-0c1b-44a7-a3bc-684950a37703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64df2351-9168-4b10-a8ae-192ae038d48b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64df2351-9168-4b10-a8ae-192ae038d48b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_caa32302-0840-4a79-8b61-c1d3ca7c1626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_caa32302-0840-4a79-8b61-c1d3ca7c1626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7d81472f-beb8-4377-94c3-de436a491a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_caa32302-0840-4a79-8b61-c1d3ca7c1626" xlink:to="loc_us-gaap_SalesRevenueNetMember_7d81472f-beb8-4377-94c3-de436a491a35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i30bd95fd181548d0bc7878df3017c01d_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c9e4bd2f-8ed5-4628-9857-a11b130fde68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten_7aac3b11-6d1b-4072-b097-e87dd4a4c137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c9e4bd2f-8ed5-4628-9857-a11b130fde68" xlink:to="loc_us-gaap_AssumedPremiumsWritten_7aac3b11-6d1b-4072-b097-e87dd4a4c137" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c9e4bd2f-8ed5-4628-9857-a11b130fde68" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2ea6db73-2316-4e29-9f6c-7e06b32461b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:to="loc_us-gaap_RelatedPartyDomain_2ea6db73-2316-4e29-9f6c-7e06b32461b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ff714aa0-698f-4c97-8082-42e2d13ccb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:to="loc_us-gaap_RelatedPartyDomain_ff714aa0-698f-4c97-8082-42e2d13ccb1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_APCPasseLLCMember_01c11964-9887-4820-bafc-7d265be7f183" xlink:href="elv-20221231.xsd#elv_APCPasseLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ff714aa0-698f-4c97-8082-42e2d13ccb1a" xlink:to="loc_elv_APCPasseLLCMember_01c11964-9887-4820-bafc-7d265be7f183" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/StatutoryInformationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#StatutoryInformationDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/StatutoryInformationDetails" xlink:type="extended" id="i4680c411dce14ac2b0b537ab1d4827de_StatutoryInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_147a39ca-ca7d-4d9f-84b0-20cae337bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_147a39ca-ca7d-4d9f-84b0-20cae337bb57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_0f908e41-80c1-479f-9459-efbc6179584f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_0f908e41-80c1-479f-9459-efbc6179584f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d93695bc-675b-4aff-9641-22ce5f4dd81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StockholdersEquity_d93695bc-675b-4aff-9641-22ce5f4dd81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency_a98defb1-1c08-426a-8eb8-bec387ad44bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency_a98defb1-1c08-426a-8eb8-bec387ad44bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EstimatedFutureDividendPayments_51a012b5-6b52-4195-a07a-93153cb563ba" xlink:href="elv-20221231.xsd#elv_EstimatedFutureDividendPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_elv_EstimatedFutureDividendPayments_51a012b5-6b52-4195-a07a-93153cb563ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:to="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ccb6e8a5-3dd9-4e06-988c-7c18c433a719_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:to="loc_dei_EntityDomain_ccb6e8a5-3dd9-4e06-988c-7c18c433a719_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:to="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CaliforniaDepartmentofManagedHealthCareMember_d91a77cf-6c96-4a4d-b57e-b43733bbacff" xlink:href="elv-20221231.xsd#elv_CaliforniaDepartmentofManagedHealthCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:to="loc_elv_CaliforniaDepartmentofManagedHealthCareMember_d91a77cf-6c96-4a4d-b57e-b43733bbacff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_6312635b-ab96-49a1-9ec7-f21204735f8a" xlink:href="elv-20221231.xsd#elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:to="loc_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_6312635b-ab96-49a1-9ec7-f21204735f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_54114465-5b6f-44fa-8c8d-1fa2e22f00e9" xlink:href="elv-20221231.xsd#elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:to="loc_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_54114465-5b6f-44fa-8c8d-1fa2e22f00e9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails" xlink:type="extended" id="i4824e3249b664df7ac6cb6cf7d1dc9ed_ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:to="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0232c0c2-0e2f-49a2-ab88-7712a2cb04b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0232c0c2-0e2f-49a2-ab88-7712a2cb04b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6084fd3c-e733-4641-a068-77cb4be947c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6084fd3c-e733-4641-a068-77cb4be947c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a24a92b1-4dab-4399-96f4-98b86ef16ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a24a92b1-4dab-4399-96f4-98b86ef16ec4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_ebbdd983-d2a8-46eb-be52-f4538c655b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_OtherReceivables_ebbdd983-d2a8-46eb-be52-f4538c655b67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_8f0c8627-cb89-4d67-bfc2-e527521fcefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_8f0c8627-cb89-4d67-bfc2-e527521fcefb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9f9efb36-a178-4144-a115-509608954b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_OtherAssetsCurrent_9f9efb36-a178-4144-a115-509608954b7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_28a004c8-60e3-4614-b521-db6701019081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_AssetsCurrent_28a004c8-60e3-4614-b521-db6701019081" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_f2b93954-f968-4046-98df-c6dd7fcfe967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_OtherLongTermInvestments_f2b93954-f968-4046-98df-c6dd7fcfe967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3545ac3c-fc17-4a49-addf-37fbfd16e597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3545ac3c-fc17-4a49-addf-37fbfd16e597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4df29eba-b512-4eca-bbe7-c3eec622a11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4df29eba-b512-4eca-bbe7-c3eec622a11c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentInSubsidiaries_a3db2f16-170f-4016-b988-6eb667a83a7f" xlink:href="elv-20221231.xsd#elv_InvestmentInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_elv_InvestmentInSubsidiaries_a3db2f16-170f-4016-b988-6eb667a83a7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb1ffbeb-a323-488d-b60d-5318cf222b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb1ffbeb-a323-488d-b60d-5318cf222b01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ea3e9937-8e73-4e9a-a5a5-7afb0bd2f820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_Assets_ea3e9937-8e73-4e9a-a5a5-7afb0bd2f820" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8ed45df2-d02e-4bf7-8b43-ce7d087ceb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8ed45df2-d02e-4bf7-8b43-ce7d087ceb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_3df1ead2-3906-42d0-8d3d-0bc3267e1dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_DueToAffiliateCurrent_3df1ead2-3906-42d0-8d3d-0bc3267e1dcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a60951ae-c003-44e6-8467-31158732ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_LongTermDebtCurrent_a60951ae-c003-44e6-8467-31158732ffdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_97ad2595-7b08-41c1-b165-80f069517203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_97ad2595-7b08-41c1-b165-80f069517203" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd9c022a-0899-42bb-a942-046c9922ad27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_LiabilitiesCurrent_bd9c022a-0899-42bb-a942-046c9922ad27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_22c43f7e-fc5d-4ed1-bc51-58fafea53f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_22c43f7e-fc5d-4ed1-bc51-58fafea53f8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_624266a0-a064-4659-8860-3254e3eed610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_624266a0-a064-4659-8860-3254e3eed610" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_67641822-af58-4754-9978-ab9bed2a3d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_Liabilities_67641822-af58-4754-9978-ab9bed2a3d84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02166ab3-5530-4bd9-8ccf-f3a963a6b92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02166ab3-5530-4bd9-8ccf-f3a963a6b92e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2321a489-6bb8-4cb8-b69d-95447381b67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_PreferredStockValue_2321a489-6bb8-4cb8-b69d-95447381b67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a2c01109-903d-48f0-a002-5c5ff87f5d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_CommonStockValue_a2c01109-903d-48f0-a002-5c5ff87f5d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5e496412-6c8d-42b9-970d-6730bb8a6d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5e496412-6c8d-42b9-970d-6730bb8a6d5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a523e94-de55-4955-9454-4dee6b9bc623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a523e94-de55-4955-9454-4dee6b9bc623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8b3009c-1874-48ce-8c49-6141b75f0e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8b3009c-1874-48ce-8c49-6141b75f0e07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e86ddd0-8058-4760-8c06-0d0abf97d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_StockholdersEquity_9e86ddd0-8058-4760-8c06-0d0abf97d600" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6be4a62-d81e-4f88-8d7d-f6833df3ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6be4a62-d81e-4f88-8d7d-f6833df3ba48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:to="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:to="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_db195ad2-ab64-4a5e-acd3-23a9944c8448_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:to="loc_srt_ConsolidatedEntitiesDomain_db195ad2-ab64-4a5e-acd3-23a9944c8448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5e7d1a46-ac91-4113-85a1-463c5cdc0caa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5e7d1a46-ac91-4113-85a1-463c5cdc0caa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_5a134f7a-7d39-4867-b3b4-e0d2954fec5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5e7d1a46-ac91-4113-85a1-463c5cdc0caa" xlink:to="loc_srt_ParentCompanyMember_5a134f7a-7d39-4867-b3b4-e0d2954fec5f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails" xlink:type="extended" id="i883d69cffc1b4214a6a52b413f736ffd_ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6356f762-8b3b-4244-9fe9-ac922fe05e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6356f762-8b3b-4244-9fe9-ac922fe05e32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_92b8f11a-4402-4e07-863a-19d317f4f8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_92b8f11a-4402-4e07-863a-19d317f4f8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_16a3b490-434e-4c6f-be61-383c4243bac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_16a3b490-434e-4c6f-be61-383c4243bac2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_efa8b013-3f44-49eb-b7da-b922bd4f950c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_efa8b013-3f44-49eb-b7da-b922bd4f950c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cbc063e4-eaa3-497f-8972-6fe46373ba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cbc063e4-eaa3-497f-8972-6fe46373ba1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_da8b0907-6847-4f4c-be48-acdbf88da469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_da8b0907-6847-4f4c-be48-acdbf88da469" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e8485db9-8912-4c23-bbfe-607b2920e98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e8485db9-8912-4c23-bbfe-607b2920e98a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e58d87e8-a7f4-478e-9182-b4f1bb832b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockSharesIssued_e58d87e8-a7f4-478e-9182-b4f1bb832b60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9187a069-f3b1-4b94-894e-f8726f174778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9187a069-f3b1-4b94-894e-f8726f174778" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:to="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_adec63db-f9b8-4215-8748-a36e94a28d14_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:to="loc_srt_ConsolidatedEntitiesDomain_adec63db-f9b8-4215-8748-a36e94a28d14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5a6da785-c4c0-4d77-a78c-c4c759cf7d98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5a6da785-c4c0-4d77-a78c-c4c759cf7d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f301583f-9eea-49e4-8b0c-e4ed35b3c944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5a6da785-c4c0-4d77-a78c-c4c759cf7d98" xlink:to="loc_srt_ParentCompanyMember_f301583f-9eea-49e4-8b0c-e4ed35b3c944" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails" xlink:type="extended" id="i7327cf747c2e4271aa5d70af66814738_ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_a0b83ae0-8797-47bf-915c-c79bd862e54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_NetInvestmentIncome_a0b83ae0-8797-47bf-915c-c79bd862e54a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_f6709948-2f60-4fd8-9644-016268fdf76c" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_f6709948-2f60-4fd8-9644-016268fdf76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_3179994a-dfe3-4f9d-ab5e-ab21f8a23bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_OtherIncome_3179994a-dfe3-4f9d-ab5e-ab21f8a23bc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5f61061-8376-4968-9611-df0d079ed521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_Revenues_f5f61061-8376-4968-9611-df0d079ed521" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_20384fcd-e651-486b-8432-bdde53118378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_20384fcd-e651-486b-8432-bdde53118378" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_68c7abc8-bc7c-4392-98f2-2f1bbd847ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_InterestExpense_68c7abc8-bc7c-4392-98f2-2f1bbd847ce6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5974b1bb-eab6-43b6-8ee0-03373a9efc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5974b1bb-eab6-43b6-8ee0-03373a9efc53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalExpenses_a02139d0-9e4d-4956-8956-d4cef8a8adaf" xlink:href="elv-20221231.xsd#elv_TotalExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_elv_TotalExpenses_a02139d0-9e4d-4956-8956-d4cef8a8adaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8583b948-9191-40f7-b509-8448b866356f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8583b948-9191-40f7-b509-8448b866356f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_99a292e0-209f-46c5-94a3-a5a24eae967b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_99a292e0-209f-46c5-94a3-a5a24eae967b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d6062211-7203-4db1-b624-c5085df47df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d6062211-7203-4db1-b624-c5085df47df4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c0456b4-648d-4def-9c1c-3808b12a272d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_NetIncomeLoss_8c0456b4-648d-4def-9c1c-3808b12a272d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8e6b69a0-e5c4-4638-9ae5-1a29195e462d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8e6b69a0-e5c4-4638-9ae5-1a29195e462d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_91f19984-d087-4a20-9e82-a6d637a2482c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_91f19984-d087-4a20-9e82-a6d637a2482c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_736eba9f-5a68-49f8-b869-d5bd48f167b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_91f19984-d087-4a20-9e82-a6d637a2482c" xlink:to="loc_srt_ParentCompanyMember_736eba9f-5a68-49f8-b869-d5bd48f167b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails" xlink:type="extended" id="ibb331795f1bb4d3db97a87d9e4f15572_ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb4f68fb-2ebe-4323-b572-4d49c3c7261c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_NetIncomeLoss_cb4f68fb-2ebe-4323-b572-4d49c3c7261c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_85dca222-55ed-4e1d-96e5-2442a0090453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_85dca222-55ed-4e1d-96e5-2442a0090453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_2a68654e-ea91-4313-97ed-f823431c1eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_2a68654e-ea91-4313-97ed-f823431c1eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_00c918ae-6786-414c-a925-e3ea78cdeeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_00c918ae-6786-414c-a925-e3ea78cdeeae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2e6b1e09-3db9-4749-8d0c-6dea4cecb639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2e6b1e09-3db9-4749-8d0c-6dea4cecb639" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e505b9a-4fdc-4031-9ce7-62256aed3f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e505b9a-4fdc-4031-9ce7-62256aed3f91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_45c83cac-21c2-4486-b6f9-2ed41ff905e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_45c83cac-21c2-4486-b6f9-2ed41ff905e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc224b3f-446f-45ca-a77c-b60a5e22269f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc224b3f-446f-45ca-a77c-b60a5e22269f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_869a990d-e788-47c4-87d5-411330d8e921_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:to="loc_srt_ConsolidatedEntitiesDomain_869a990d-e788-47c4-87d5-411330d8e921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10f1c1bd-24ea-463c-b9bc-d6f9380e88e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10f1c1bd-24ea-463c-b9bc-d6f9380e88e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_189d5315-b135-493e-bba2-c47363c43bf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10f1c1bd-24ea-463c-b9bc-d6f9380e88e4" xlink:to="loc_srt_ParentCompanyMember_189d5315-b135-493e-bba2-c47363c43bf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails" xlink:type="extended" id="i97adb2e3ad744186993959003ce89bf2_ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de20d3df-ea7f-4a64-a332-e8c57453e619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de20d3df-ea7f-4a64-a332-e8c57453e619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_449b3052-06ab-4e82-8a0f-79eaf35c6e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de20d3df-ea7f-4a64-a332-e8c57453e619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_449b3052-06ab-4e82-8a0f-79eaf35c6e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8b081e3f-040a-4297-b5e1-21e209061b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8b081e3f-040a-4297-b5e1-21e209061b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_55231b33-7985-4b34-8a80-a6c9617a5551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_55231b33-7985-4b34-8a80-a6c9617a5551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_b7c019a2-0d6a-4138-90e7-4858a3d64bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_b7c019a2-0d6a-4138-90e7-4858a3d64bc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_9e8e98f3-a623-410d-be19-12483d768bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_9e8e98f3-a623-410d-be19-12483d768bad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_bcd3128c-b30a-45ec-8f08-39e5a499ea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_bcd3128c-b30a-45ec-8f08-39e5a499ea1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_f1cf8e0b-f7a0-4635-930b-d823788e3ef1" xlink:href="elv-20221231.xsd#elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_f1cf8e0b-f7a0-4635-930b-d823788e3ef1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bfb37f55-ffbb-42ae-8093-47e058b8ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bfb37f55-ffbb-42ae-8093-47e058b8ce7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c6ff984-b64c-436b-a16b-8cbf2f2d42da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c6ff984-b64c-436b-a16b-8cbf2f2d42da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_692b34a6-2525-472f-8fb0-8a2f59b9a10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_692b34a6-2525-472f-8fb0-8a2f59b9a10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71480d4e-fc8c-4009-a469-422d26dcfefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71480d4e-fc8c-4009-a469-422d26dcfefd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d9adc063-41c0-4bf6-8bad-71fdd2995ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d9adc063-41c0-4bf6-8bad-71fdd2995ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_d88b036e-2b29-496c-9530-fc32b1f6d268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecuritiesLendingPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_d88b036e-2b29-496c-9530-fc32b1f6d268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6e9d7e77-ceb6-4460-9db6-3e271a27090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6e9d7e77-ceb6-4460-9db6-3e271a27090c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_01ee1547-c41a-4a14-a00b-4ff0eba3e4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_PaymentsOfDividends_01ee1547-c41a-4a14-a00b-4ff0eba3e4c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6fee0cfc-2ddc-46a9-8096-f8a4213d3829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6fee0cfc-2ddc-46a9-8096-f8a4213d3829" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3b0dadf5-17a3-4e50-b3df-9a5ceb81fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3b0dadf5-17a3-4e50-b3df-9a5ceb81fbf4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4f8b7683-ee11-4b6a-a32f-e0664030bb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4f8b7683-ee11-4b6a-a32f-e0664030bb70" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d988e94-5a1d-4de1-91e8-767877c0ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d988e94-5a1d-4de1-91e8-767877c0ecf3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d5b6314-f1df-45db-9961-7ba3f79d4205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d5b6314-f1df-45db-9961-7ba3f79d4205" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3b7659-3332-4bf6-95fc-f601507fd41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3b7659-3332-4bf6-95fc-f601507fd41f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e0861736-09c5-40ff-851c-a09db45103c4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e0861736-09c5-40ff-851c-a09db45103c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_bdad0c14-c023-4f97-a669-eb9c58e35832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_bdad0c14-c023-4f97-a669-eb9c58e35832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_077d6611-ff63-4e16-bb8b-9123b34f0463" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_bdad0c14-c023-4f97-a669-eb9c58e35832" xlink:to="loc_srt_ParentCompanyMember_077d6611-ff63-4e16-bb8b-9123b34f0463" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails" xlink:type="extended" id="if17d6b22a9e949a08203879caaad01c5_ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompany_59260165-f7ce-4f68-80a2-2f6bce320cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDividendsPaidToParentCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompany_59260165-f7ce-4f68-80a2-2f6bce320cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_3a0f400f-a1d6-44b0-8fc8-09d91df93a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_DividendsCommonStockCash_3a0f400f-a1d6-44b0-8fc8-09d91df93a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalContributionToSubsidiaries_9d7d13e9-df19-40f7-8c00-fc41202fbb93" xlink:href="elv-20221231.xsd#elv_CapitalContributionToSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_elv_CapitalContributionToSubsidiaries_9d7d13e9-df19-40f7-8c00-fc41202fbb93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_ca42d13d-31d7-4d44-b4d3-7081fd066a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_ca42d13d-31d7-4d44-b4d3-7081fd066a39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_67f7c352-4bbf-4517-9c5f-723aaba215c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_DueToAffiliateCurrent_67f7c352-4bbf-4517-9c5f-723aaba215c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_d788411c-5c22-48e2-9220-b6a5257a20f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_d788411c-5c22-48e2-9220-b6a5257a20f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_66e6e3e4-0f72-4277-b193-d5da5233f419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_66e6e3e4-0f72-4277-b193-d5da5233f419" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f9658b43-aef1-48c7-8328-7d77d7e5a6d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f9658b43-aef1-48c7-8328-7d77d7e5a6d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_98f11571-0804-44fc-b198-b841d3967a62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_98f11571-0804-44fc-b198-b841d3967a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d0c7523f-9900-4bd5-bd55-2a28c808d180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_98f11571-0804-44fc-b198-b841d3967a62" xlink:to="loc_srt_ParentCompanyMember_d0c7523f-9900-4bd5-bd55-2a28c808d180" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_6f4575ca-d0bd-45f1-a535-147ca0f953d5" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_6f4575ca-d0bd-45f1-a535-147ca0f953d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ProfitLoss" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>elv-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:454c8386-f90e-4c1e-9f8b-5fb66238439f,g:9bb273fb-a44f-4fa9-8c35-d6fee14cceb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c0e65b7a-e6fb-43d9-9ef7-ca6493b2b755_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_8d0e3c99-88aa-4060-9b50-37d90ec1c75b_terseLabel_en-US" xlink:label="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment, net of sales</link:label>
    <link:label id="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_label_en-US" xlink:label="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PurchasesOfProceedsFromSaleOfPropertyEquipmentNet</link:label>
    <link:label id="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_documentation_en-US" xlink:label="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net purchases of and proceeds from sale of property and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" xlink:href="elv-20221231.xsd#elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" xlink:to="lab_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_8014b427-1cb7-40b6-b03a-e55dec874095_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_32655d2f-80cb-4e7b-98bc-a1be1b8a34f4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_9fc25f98-1307-4bdc-bda0-47cdbee22e26_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ShortTermAndVariableLeaseCost_b98b7f84-b988-4b22-9985-e283f2a83c7f_terseLabel_en-US" xlink:label="lab_elv_ShortTermAndVariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and variable lease cost</link:label>
    <link:label id="lab_elv_ShortTermAndVariableLeaseCost_label_en-US" xlink:label="lab_elv_ShortTermAndVariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and variable lease cost</link:label>
    <link:label id="lab_elv_ShortTermAndVariableLeaseCost_documentation_en-US" xlink:label="lab_elv_ShortTermAndVariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of short-term and variable lease cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortTermAndVariableLeaseCost" xlink:href="elv-20221231.xsd#elv_ShortTermAndVariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ShortTermAndVariableLeaseCost" xlink:to="lab_elv_ShortTermAndVariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_96941f4c-72c8-4c84-aeef-88bf8b6d017f_verboseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit expense</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_6d984ceb-ba75-42b8-ad92-5366cb47677a_totalLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net benefit expense</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_c9a6939e-1881-4c6f-851f-7ad79c19da29_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9cf01c86-4182-41af-8c88-72b01691a3c8_terseLabel_en-US" xlink:label="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:href="elv-20221231.xsd#elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_HedgingStatusAxis_262e67bb-8934-43b9-b99f-275abf9ed8c2_terseLabel_en-US" xlink:label="lab_elv_HedgingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Status [Axis]</link:label>
    <link:label id="lab_elv_HedgingStatusAxis_label_en-US" xlink:label="lab_elv_HedgingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Status [Axis]</link:label>
    <link:label id="lab_elv_HedgingStatusAxis_documentation_en-US" xlink:label="lab_elv_HedgingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusAxis" xlink:href="elv-20221231.xsd#elv_HedgingStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_HedgingStatusAxis" xlink:to="lab_elv_HedgingStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7b29179c-a8f1-4af5-a232-7ab517bd583a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4b6a5d65-e6d9-43c0-870a-657153c32135_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_68bb427d-d237-4065-b7a6-4c794d5b7a36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy_2823a070-9695-4ce1-8a4f-10e141d50b6f_verboseLabel_en-US" xlink:label="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves For Future Policy Benefits</link:label>
    <link:label id="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy_label_en-US" xlink:label="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:to="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_016c1487-365b-450f-9e04-98de846619c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days in 30 day period greater than 130%</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_78fa09d3-3cc8-46f2-8333-9ebab2d04785_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CommercialPaperMaximumBorrowingCapacity_4def2e45-225c-40e9-a864-a0730abc929a_terseLabel_en-US" xlink:label="lab_elv_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper authorized</link:label>
    <link:label id="lab_elv_CommercialPaperMaximumBorrowingCapacity_label_en-US" xlink:label="lab_elv_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper Maximum Borrowing Capacity</link:label>
    <link:label id="lab_elv_CommercialPaperMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_elv_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialPaperMaximumBorrowingCapacity" xlink:href="elv-20221231.xsd#elv_CommercialPaperMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CommercialPaperMaximumBorrowingCapacity" xlink:to="lab_elv_CommercialPaperMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_657045c8-a395-44ce-b675-0364dc091762_terseLabel_en-US" xlink:label="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.350% due 2024 [Member]</link:label>
    <link:label id="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Zero Percent Due Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Zero Percent Due Two Thousand Twenty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" xlink:href="elv-20221231.xsd#elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" xlink:to="lab_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_bc52f6ae-8e9e-49b2-8f89-b00097c31474_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SeniorUnsecuredNotesMember_8e1f45a2-4773-42de-9bfb-0762c5a24be1_terseLabel_en-US" xlink:label="lab_elv_SeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes [Member]</link:label>
    <link:label id="lab_elv_SeniorUnsecuredNotesMember_label_en-US" xlink:label="lab_elv_SeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes [Member]</link:label>
    <link:label id="lab_elv_SeniorUnsecuredNotesMember_documentation_en-US" xlink:label="lab_elv_SeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SeniorUnsecuredNotesMember" xlink:href="elv-20221231.xsd#elv_SeniorUnsecuredNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SeniorUnsecuredNotesMember" xlink:to="lab_elv_SeniorUnsecuredNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_a2ca65de-d6e4-4c0d-af86-2d14235fe34b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpensesAbstract_15ddbef5-118d-4307-8f5a-fe900c46dcec_terseLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits, Losses and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:to="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DefinedBenefitPlanByAgeAxis_25415b3c-c220-4fc0-8e13-16c43583fe71_terseLabel_en-US" xlink:label="lab_elv_DefinedBenefitPlanByAgeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan By Age [Axis]</link:label>
    <link:label id="lab_elv_DefinedBenefitPlanByAgeAxis_label_en-US" xlink:label="lab_elv_DefinedBenefitPlanByAgeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan By Age [Axis]</link:label>
    <link:label id="lab_elv_DefinedBenefitPlanByAgeAxis_documentation_en-US" xlink:label="lab_elv_DefinedBenefitPlanByAgeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanByAgeAxis" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanByAgeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DefinedBenefitPlanByAgeAxis" xlink:to="lab_elv_DefinedBenefitPlanByAgeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses_355f2548-f4d1-469c-aef1-b101c00ac5e4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Method Used to Amortize Gain (Loss), Description</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Method Used to Amortize Gain (Loss), Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_aa7f7f94-556f-4482-8e18-c85ad2faefd4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_eb06bd61-7689-4573-8be6-6a11dba0914d_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_94104457-dc97-4879-a4e4-8602725c1103_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_55f7520b-5565-44ed-9aa7-9cf729741a18_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross medical claims payable, end of year</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4822059e-3f4c-4ab7-9ed7-b1f7f72f39a5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets_9c09bc3e-4395-424b-96dd-8820aac122f6_terseLabel_en-US" xlink:label="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S intangible assets</link:label>
    <link:label id="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets_label_en-US" xlink:label="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Non-U.S Intangible Assets</link:label>
    <link:label id="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets_documentation_en-US" xlink:label="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from non-U.S. intangible assets other than goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" xlink:href="elv-20221231.xsd#elv_DeferredTaxLiabilitiesNonUSIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" xlink:to="lab_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0339d14-d8ca-4190-bb26-7325557476da_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types of Fixed Maturity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a618b51-4022-47ac-b348-5bd9a426faa5_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstrumentsMember_f26aa45b-9829-451e-bbe5-721e00a3e520_terseLabel_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on financial instruments</link:label>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstrumentsMember_label_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) on financial instruments [Member]</link:label>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstrumentsMember_documentation_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) on financial instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstrumentsMember" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NetGainsLossesOnFinancialInstrumentsMember" xlink:to="lab_elv_NetGainsLossesOnFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cb686cdc-6d7c-44e8-86d2-53b9c9e6c781_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49616491-9405-4629-9ded-67aad0e7cd36_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Number of Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_af352555-f4d1-4b93-9b7b-d94cf9d104c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_435371a5-a123-4db7-9ff1-c89d364a0406_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_dabd519e-99fc-4b59-a1be-8b2d3df7c0a1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bb0003a-d0ac-4954-82f8-65266f6e557b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EquitySecurities_aaf5d986-24ed-43a9-883a-34bc4c384e3c_terseLabel_en-US" xlink:label="lab_elv_EquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_elv_EquitySecurities_label_en-US" xlink:label="lab_elv_EquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_elv_EquitySecurities_documentation_en-US" xlink:label="lab_elv_EquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments in equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecurities" xlink:href="elv-20221231.xsd#elv_EquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EquitySecurities" xlink:to="lab_elv_EquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_04467725-d6d8-40bd-83c7-3da76ae7b04d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_7531e65c-7c12-4b26-826c-d94949cd45af_terseLabel_en-US" xlink:label="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit (Expense)</link:label>
    <link:label id="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_label_en-US" xlink:label="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense</link:label>
    <link:label id="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_documentation_en-US" xlink:label="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" xlink:href="elv-20221231.xsd#elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" xlink:to="lab_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2ecaa552-c035-4dc0-b56d-aadd474ae8ea_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_1f6382a8-738b-491a-941e-91fac40036cd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_aa00c06c-85b9-4094-bea7-b85787d80c9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fb4efd82-04f2-48c1-86cb-853e68bb2229_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_efa7e7bd-4ab6-4a54-b6e2-96191dd7f904_terseLabel_en-US" xlink:label="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.100% due 2032 [Member]</link:label>
    <link:label id="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_label_en-US" xlink:label="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Due Two Thousand Thirty Two [Member]</link:label>
    <link:label id="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_documentation_en-US" xlink:label="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Due Two Thousand Thirty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" xlink:to="lab_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_085ce920-aa07-40bf-9093-b0310a2392c4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_d17121da-a5af-4acc-a8e9-bcb867012f73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_0c32cfb7-cbee-4130-935d-f599b4a69b97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturities, allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dec4e64c-1cd4-41bd-b03e-96bb4470af78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4d77299e-e703-48bb-8f91-6b13eb602cd3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments, Due Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_acf1b60f-377b-4a72-a65f-07c0a72adc18_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_5927200c-a42d-4801-a72d-5c24864d3b43_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which the Company is licensed to conduct insurance operations</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_41abcbb1-9294-4c0e-b331-8306a8936445_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_f6806782-e7c7-4cc4-be32-20b79952fd78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d4aa4f1f-3ad5-4c9a-8b6b-ac6e6ba3e847_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PharmacyProductsAndServicesMember_8d2c5b7f-b56d-44c5-9ac3-ea6bd07ec93a_terseLabel_en-US" xlink:label="lab_elv_PharmacyProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy products and services [Member]</link:label>
    <link:label id="lab_elv_PharmacyProductsAndServicesMember_label_en-US" xlink:label="lab_elv_PharmacyProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy products and services [Member]</link:label>
    <link:label id="lab_elv_PharmacyProductsAndServicesMember_documentation_en-US" xlink:label="lab_elv_PharmacyProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy products and services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PharmacyProductsAndServicesMember" xlink:href="elv-20221231.xsd#elv_PharmacyProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PharmacyProductsAndServicesMember" xlink:to="lab_elv_PharmacyProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_845db5db-1220-4241-958d-b5db9d9b3969_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_8ceb0d7a-65d3-469a-9ddd-8f2dfbaf7d25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636e614d-9b20-4ebe-84aa-51595665949c_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f283f344-dfc5-4a61-bfdc-7538d34c59c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Ending Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarlyRepaymentOfSeniorDebt_b44b2db1-81d7-4a0c-adc4-9213461c1c84_terseLabel_en-US" xlink:label="lab_us-gaap_EarlyRepaymentOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early repayment of senior debt</link:label>
    <link:label id="lab_us-gaap_EarlyRepaymentOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_EarlyRepaymentOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Repayment of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarlyRepaymentOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarlyRepaymentOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarlyRepaymentOfSeniorDebt" xlink:to="lab_us-gaap_EarlyRepaymentOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1f08e11e-e2c4-43c8-b47a-4c326cac14c0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_0b4a9050-6226-4b87-ae43-c153f50d2dcd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss on loss contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_b02d5018-6de1-4ae8-9810-5851b8812412_verboseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale_f7ac1591-f031-419a-9380-4eb1f95a437d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3984df75-c420-4c1e-a646-d4a17966a494_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4152aad0-7588-47fe-9a73-31731873bd41_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Foreign Currency Translation Adjustment, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2cb768c7-eb03-4e70-b631-79e760764fd6_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Foreign Currency Translation Adjustment, Ending Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_9afc49f0-5b7f-4918-82d2-14dcf7cdaacc_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Defined Benefit Plan, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_63fcbdae-98f6-4538-b441-4e72df44b50e_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Defined Benefit Plan, Ending Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8bf6b046-db48-42dd-8032-29ed34c514d1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a14dfa5f-cfeb-437c-b7fe-dde0f29a3534_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_ece507eb-7d66-4b09-8d88-8cdb976c24f7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9757ab65-58f3-44fe-9eb8-178494848f09_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_177695c1-1cc6-49f3-b1f9-ea9887db9ef5_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2c4a26b2-e829-49e7-a963-402f1213d077_netLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pension benefit assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_73e782f8-f084-4277-aa2a-04ca748bdf70_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PharmacypricingMember_8d0be567-73f7-4965-8589-5abaf044d577_terseLabel_en-US" xlink:label="lab_elv_PharmacypricingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy pricing [Member]</link:label>
    <link:label id="lab_elv_PharmacypricingMember_label_en-US" xlink:label="lab_elv_PharmacypricingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy pricing [Member]</link:label>
    <link:label id="lab_elv_PharmacypricingMember_documentation_en-US" xlink:label="lab_elv_PharmacypricingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy pricing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PharmacypricingMember" xlink:href="elv-20221231.xsd#elv_PharmacypricingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PharmacypricingMember" xlink:to="lab_elv_PharmacypricingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock_bbe2cfde-800c-4154-962a-8ee0637238c9_terseLabel_en-US" xlink:label="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Assumptions Used In Calculating The Benefit Obligations</link:label>
    <link:label id="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Assumptions Used In Calculating The Benefit Obligations [Table Text Block]</link:label>
    <link:label id="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock_documentation_en-US" xlink:label="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" xlink:href="elv-20221231.xsd#elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" xlink:to="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_005c8683-d556-4cbd-b8b6-f6ec6680452a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2b02471e-4bce-4440-a0e0-b993356b78f4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_111cb9b4-84f5-4833-ab99-9a089afae85e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_c8e412da-75e8-4384-9231-20d136125db3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level III</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10e7bc39-befe-4627-9af7-29e84c81d521_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d6adc20-d4ab-40a5-934e-c9c0d3608e10_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ad170938-80ef-4e85-bc56-338df6328d94_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period, Weighted-Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0247e5d9-bd66-4815-8eb5-5156b4b2cf0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefits</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_520b817f-bf61-4c14-8bfc-bd584ec7506b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b7a100e7-4ebf-4eb5-a0a3-c3b4492d7185_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_e3161b5d-91ac-4ddf-8b2b-c9934e36f27a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial loss (gain)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_bbf818e6-5b01-40b6-a2c4-5bb704b63842_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8e39d1e9-4b62-4c16-8c9f-37e74d454326_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d979dea1-3334-4b9a-8fd2-d58a8b0249eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CaliforniaDepartmentofManagedHealthCareMember_85b6deb8-2984-4409-a401-ceb1abffe58a_terseLabel_en-US" xlink:label="lab_elv_CaliforniaDepartmentofManagedHealthCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Department of Managed Health Care [Member]</link:label>
    <link:label id="lab_elv_CaliforniaDepartmentofManagedHealthCareMember_label_en-US" xlink:label="lab_elv_CaliforniaDepartmentofManagedHealthCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Department of Managed Health Care [Member]</link:label>
    <link:label id="lab_elv_CaliforniaDepartmentofManagedHealthCareMember_documentation_en-US" xlink:label="lab_elv_CaliforniaDepartmentofManagedHealthCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Department of Managed Health Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CaliforniaDepartmentofManagedHealthCareMember" xlink:href="elv-20221231.xsd#elv_CaliforniaDepartmentofManagedHealthCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CaliforniaDepartmentofManagedHealthCareMember" xlink:to="lab_elv_CaliforniaDepartmentofManagedHealthCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_01470e28-3b2a-4412-ae83-462aceb3d167_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds originally recevied from divestiture of business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f1e76882-c8a0-4b83-8e6b-afad6018e26c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_41dc442d-6f01-43bc-a993-76b58b09f4ea_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on other investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_55b93492-0334-43c5-8a14-67a51da2e8a0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_cc25a544-c553-4466-9c75-06de31fcd074_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bc7413b1-cc6c-4491-8c87-7facec1b67e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_01486cc1-4e66-45fc-8e02-77b6f80bb3d4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, purchase accounting adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_bc2902a0-b9ed-4ccf-8c11-926e22e2db4a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72ae3baa-69d8-4676-9f1c-b5f593992169_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_cca2fd18-0f81-4c82-8420-d848d43cee93_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Payments For Pension Benefits And Other Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_a786f8fb-8038-4284-8ad4-2027f6c84f31_terseLabel_en-US" xlink:label="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.850%, due 2036 [Member]</link:label>
    <link:label id="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_label_en-US" xlink:label="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Eight Five Zero Percent Due Two Thousand Thirty Six [Member]</link:label>
    <link:label id="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_documentation_en-US" xlink:label="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point eight Five Zero Percent Due Two Thousand Thirty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" xlink:href="elv-20221231.xsd#elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" xlink:to="lab_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_6e5802ff-d11f-4b73-b1fc-e859c75c25b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Projected Benefit Obligations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b1671ac2-9412-41e5-a2ea-83ebc77b6f66_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_c3d0a3cc-fc65-4a88-8cd2-6a2ba9213a4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_717bdfe1-74ea-4cba-b4b7-b065df8cd9aa_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a010e8d-4a9d-40e0-9e1d-d3c91cda7937_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_e7e947d1-acb9-40d6-90c4-ac83cd9adf65_terseLabel_en-US" xlink:label="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:href="elv-20221231.xsd#elv_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="lab_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_5932b4a9-9686-4f03-bf79-0f3d35dd7dd2_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fe26752a-994a-4950-ab34-b46b4fd03437_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6befcaa4-4c35-4ad9-98cb-c37ebcdbd083_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TotalLevelIIIassetcategoriesDomain_e203393e-fb92-49a1-9903-524feda7b4ff_terseLabel_en-US" xlink:label="lab_elv_TotalLevelIIIassetcategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Level III, asset categories [Domain]</link:label>
    <link:label id="lab_elv_TotalLevelIIIassetcategoriesDomain_label_en-US" xlink:label="lab_elv_TotalLevelIIIassetcategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Level III, asset categories [Domain]</link:label>
    <link:label id="lab_elv_TotalLevelIIIassetcategoriesDomain_documentation_en-US" xlink:label="lab_elv_TotalLevelIIIassetcategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Total Level III, asset categories [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesDomain" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TotalLevelIIIassetcategoriesDomain" xlink:to="lab_elv_TotalLevelIIIassetcategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DeferredTaxLiabilitiesNetMember_c737a294-6bd6-4662-876e-488ae91ea554_terseLabel_en-US" xlink:label="lab_elv_DeferredTaxLiabilitiesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net [Member]</link:label>
    <link:label id="lab_elv_DeferredTaxLiabilitiesNetMember_label_en-US" xlink:label="lab_elv_DeferredTaxLiabilitiesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net [Member]</link:label>
    <link:label id="lab_elv_DeferredTaxLiabilitiesNetMember_documentation_en-US" xlink:label="lab_elv_DeferredTaxLiabilitiesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxLiabilitiesNetMember" xlink:href="elv-20221231.xsd#elv_DeferredTaxLiabilitiesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DeferredTaxLiabilitiesNetMember" xlink:to="lab_elv_DeferredTaxLiabilitiesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1daa76fb-4a36-4028-ad17-9982be36857d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0b4a144e-f430-4f9c-a21c-910e8b1943f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized gains on fixed maturity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_fc61ebd9-6f41-4fb4-ad7f-b049fcc658c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ea1d406b-03f4-4ccb-8980-11161cff8208_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6a9823bf-e963-4f5f-9189-dc0186331eaf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_HealthInsuranceProviderfeeMember_cad252d3-7b3b-4b02-a205-1c1e62758801_terseLabel_en-US" xlink:label="lab_elv_HealthInsuranceProviderfeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider fee [Member]</link:label>
    <link:label id="lab_elv_HealthInsuranceProviderfeeMember_label_en-US" xlink:label="lab_elv_HealthInsuranceProviderfeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider fee [Member]</link:label>
    <link:label id="lab_elv_HealthInsuranceProviderfeeMember_documentation_en-US" xlink:label="lab_elv_HealthInsuranceProviderfeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider fee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HealthInsuranceProviderfeeMember" xlink:href="elv-20221231.xsd#elv_HealthInsuranceProviderfeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_HealthInsuranceProviderfeeMember" xlink:to="lab_elv_HealthInsuranceProviderfeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f4afb1e-3215-4ca6-afb2-52b7749fb2f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c681e50-4adf-4745-9b65-fe6127be9642_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OtherSegmentMember_03fc96ad-67af-4dbb-8345-7cb564cd0232_terseLabel_en-US" xlink:label="lab_elv_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segment [Member]</link:label>
    <link:label id="lab_elv_OtherSegmentMember_3e40a1c7-e3b7-4744-9a03-c8dd60dc25d0_verboseLabel_en-US" xlink:label="lab_elv_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_elv_OtherSegmentMember_label_en-US" xlink:label="lab_elv_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segment [Member]</link:label>
    <link:label id="lab_elv_OtherSegmentMember_documentation_en-US" xlink:label="lab_elv_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OtherSegmentMember" xlink:to="lab_elv_OtherSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_5fc1f5ee-f559-474d-bf3b-b642937491e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_0c415ce8-1ba9-42b1-b2ff-0761d3450937_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c68943d9-f883-4963-b8c2-e993377d4cb2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PostMedicareMember_13bc8368-6b40-449c-a678-f4cc194751e6_terseLabel_en-US" xlink:label="lab_elv_PostMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Medicare [Member]</link:label>
    <link:label id="lab_elv_PostMedicareMember_label_en-US" xlink:label="lab_elv_PostMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Medicare [Member]</link:label>
    <link:label id="lab_elv_PostMedicareMember_documentation_en-US" xlink:label="lab_elv_PostMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PostMedicareMember" xlink:href="elv-20221231.xsd#elv_PostMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PostMedicareMember" xlink:to="lab_elv_PostMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_LifeInsuranceContractsMember_3afccefe-26da-4ce2-8652-ce5d6fafca11_terseLabel_en-US" xlink:label="lab_elv_LifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance Contracts [Member]</link:label>
    <link:label id="lab_elv_LifeInsuranceContractsMember_label_en-US" xlink:label="lab_elv_LifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance Contracts [Member]</link:label>
    <link:label id="lab_elv_LifeInsuranceContractsMember_documentation_en-US" xlink:label="lab_elv_LifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LifeInsuranceContractsMember" xlink:href="elv-20221231.xsd#elv_LifeInsuranceContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_LifeInsuranceContractsMember" xlink:to="lab_elv_LifeInsuranceContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_91fbc5e6-b552-4c5d-a3e2-e4b9dbd481ee_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_de635561-3a99-4f98-978a-f1e07e1dd73f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned income</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_HedgingStatusDomain_37f8e36a-157a-4b94-af3c-45c8534b231f_terseLabel_en-US" xlink:label="lab_elv_HedgingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Status [Domain]</link:label>
    <link:label id="lab_elv_HedgingStatusDomain_label_en-US" xlink:label="lab_elv_HedgingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Status [Domain]</link:label>
    <link:label id="lab_elv_HedgingStatusDomain_documentation_en-US" xlink:label="lab_elv_HedgingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Hedging Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusDomain" xlink:href="elv-20221231.xsd#elv_HedgingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_HedgingStatusDomain" xlink:to="lab_elv_HedgingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_29a9337c-c4f8-44c3-b951-3391104ee403_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DentalVisionProductsAndServicesMember_98353729-52e4-49cf-bacc-8856ef8763ee_terseLabel_en-US" xlink:label="lab_elv_DentalVisionProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dental Vision Products And Services [Member]</link:label>
    <link:label id="lab_elv_DentalVisionProductsAndServicesMember_label_en-US" xlink:label="lab_elv_DentalVisionProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dental Vision Products And Services [Member]</link:label>
    <link:label id="lab_elv_DentalVisionProductsAndServicesMember_documentation_en-US" xlink:label="lab_elv_DentalVisionProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dental Vision Products And Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DentalVisionProductsAndServicesMember" xlink:href="elv-20221231.xsd#elv_DentalVisionProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DentalVisionProductsAndServicesMember" xlink:to="lab_elv_DentalVisionProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_0d726dc3-ae96-45ce-94ed-356b177a9b08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) recognized in net income</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_be928d2d-e31e-491f-b489-e54fdd6f71ee_terseLabel_en-US" xlink:label="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance, HMO Subsidiaries and Other Regulated Entities, Excluding the California Department of Managed Health Care [Member]</link:label>
    <link:label id="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_label_en-US" xlink:label="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance HMO Subsidiaries Regulated Entities Excluding California Department of Managed Health Care [Member]</link:label>
    <link:label id="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_documentation_en-US" xlink:label="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance, HMO Subsidiaries and Regulated Entities, Excluding California Department of Managed Health Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" xlink:href="elv-20221231.xsd#elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" xlink:to="lab_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PerformancemeasurementperiodDomain_9a2e8e5c-dadf-4fea-8380-027969c16cf7_terseLabel_en-US" xlink:label="lab_elv_PerformancemeasurementperiodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period [Domain]</link:label>
    <link:label id="lab_elv_PerformancemeasurementperiodDomain_label_en-US" xlink:label="lab_elv_PerformancemeasurementperiodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period [Domain]</link:label>
    <link:label id="lab_elv_PerformancemeasurementperiodDomain_documentation_en-US" xlink:label="lab_elv_PerformancemeasurementperiodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Performance measurement period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodDomain" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PerformancemeasurementperiodDomain" xlink:to="lab_elv_PerformancemeasurementperiodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_1b1502b2-fe48-48d3-b33a-cdd5d1e2f95e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CommitmentsAndContingenciesLineItems_5edd2e31-a4e7-491c-9352-c46013c36844_terseLabel_en-US" xlink:label="lab_elv_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_elv_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_elv_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_elv_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_elv_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommitmentsAndContingenciesLineItems" xlink:href="elv-20221231.xsd#elv_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems" xlink:to="lab_elv_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_LesseeOperatingLeasesTableTextBlock_134d2b5f-d598-49e8-a731-c13010d88b9f_terseLabel_en-US" xlink:label="lab_elv_LesseeOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_elv_LesseeOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_elv_LesseeOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_elv_LesseeOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_elv_LesseeOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LesseeOperatingLeasesTableTextBlock" xlink:href="elv-20221231.xsd#elv_LesseeOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_LesseeOperatingLeasesTableTextBlock" xlink:to="lab_elv_LesseeOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_f964862a-9b66-4cf5-acdf-21a430e9c9f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eeb99f9a-52eb-49ba-9399-2150f7ed5cfd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net tangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_b84bdd5d-306b-4d6a-b8b8-3f2cfe86d94e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b192f250-d6d0-41de-b0ea-494e17084a3b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_079d9a08-66c3-4053-b75a-7f0e5d3b1d5e_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_bcc4d89c-7809-4d72-8125-9a2ea5543dac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMember_6b2ef990-fcb9-443d-951b-fa4d79114394_terseLabel_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank Advances [Member]</link:label>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMember_label_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank Advances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:to="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1d8d449b-798b-4137-baf8-303f35264fd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_97cbe826-59f4-4b48-a457-f67ea4095dc1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in securities lending collateral</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_a737b22e-f978-461d-bedf-c01050486dc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in securities lending collateral</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Collateral Held under Securities Lending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" xlink:to="lab_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_27ba9511-f2bf-4920-8f6e-fd82a69a9cf4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_2609827d-1b20-400b-a148-56657ce13131_terseLabel_en-US" xlink:label="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.100% due 2052 [Member]</link:label>
    <link:label id="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_label_en-US" xlink:label="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Zero Zero Percent Due Two Thousand Fifty Two [Member]</link:label>
    <link:label id="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_documentation_en-US" xlink:label="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Zero Zero Percent Due Two Thousand Fifty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" xlink:href="elv-20221231.xsd#elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" xlink:to="lab_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_5e2014e5-1b39-4a1b-953a-d635794e58ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_bc468ec1-538f-412a-a087-fee01a42fca2_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IntangibleAssetsLineItems_bac76784-1396-425b-96e0-a758c7e3df56_terseLabel_en-US" xlink:label="lab_elv_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_elv_IntangibleAssetsLineItems_label_en-US" xlink:label="lab_elv_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_elv_IntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_elv_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsLineItems" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IntangibleAssetsLineItems" xlink:to="lab_elv_IntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_157390a7-b26f-42c8-9b06-34ffeb79948c_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c138f43-3dd8-4aa7-9659-e04cabdbb01d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_48be1f78-11a0-4394-9d99-17dd8a6ee6c9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1e0e05f3-28d5-467d-af81-c680b4a3fab0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_41befe5b-4918-4328-a38c-54b35e40761b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_97da7678-6be3-464a-a94d-8bd74f6f2869_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Credit Facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7fb1b674-3d58-4324-81f1-33e9ee6f4a0c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_8891faa3-02fc-4af3-979c-a62383224e9a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_05fe10ca-6587-4a67-8cd2-ff7cd44618f5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_48efa145-c8ca-437d-9200-1863e42a2dd4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_32a5593a-cddd-467a-abe9-7fca0edf8a19_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_a219761d-4862-448c-8d7e-148ef8cdc9c6_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivateEquityFundsMember_54f91420-ac56-4128-ae4b-4ae5314befd3_terseLabel_en-US" xlink:label="lab_us-gaap_PrivateEquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_PrivateEquityFundsMember_label_en-US" xlink:label="lab_us-gaap_PrivateEquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivateEquityFundsMember" xlink:to="lab_us-gaap_PrivateEquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_648a96e9-5bdb-4ef2-946e-17e700854b95_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_35f2d3d6-bdb5-42a8-9beb-6b65a031ed80_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted-Average Assumptions Used to Estimate the Fair Values of Options Granted During the Periods</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_bbd33974-e4ca-4cc0-ae4e-5383f6d4e3b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7ad1b0f1-a73c-469c-80a1-4c5d1280d5c0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6eb8cf6e-37ed-4b5a-bb0a-65e9854d5c96_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_889c57ca-1a03-4418-b29c-bcff0fb1df8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Aggregate Contractual Or Notional Amounts And Estimated Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_5e82663e-2d4e-4d44-bf7a-f3bbdbcd994a_terseLabel_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage-Backed Securities [Member]</link:label>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5aad0fac-dd03-440f-9310-e2b6219e270d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period, Weighted-Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_947fb3c0-7377-4b3a-82cf-a039ff25b544_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash considerations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_137d95fa-d1fe-41a7-bad5-4ddf6e78fd98_terseLabel_en-US" xlink:label="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% due 2020 [Member]</link:label>
    <link:label id="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_label_en-US" xlink:label="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Five Zero Zero Percent Due Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_documentation_en-US" xlink:label="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Five Zero Zero Percent Due Two Thousand Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" xlink:href="elv-20221231.xsd#elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" xlink:to="lab_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_806fbc2d-2b07-4aae-a344-8bd7c8e99656_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2f722d58-2a8e-4485-b285-f0c27093f070_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IncreaseInStockRepurchaseProgramAuthorization_8769ea64-6b48-4509-8850-a45e83ce900e_terseLabel_en-US" xlink:label="lab_elv_IncreaseInStockRepurchaseProgramAuthorization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in stock repurchase program authorization</link:label>
    <link:label id="lab_elv_IncreaseInStockRepurchaseProgramAuthorization_label_en-US" xlink:label="lab_elv_IncreaseInStockRepurchaseProgramAuthorization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Stock Repurchase Program Authorization</link:label>
    <link:label id="lab_elv_IncreaseInStockRepurchaseProgramAuthorization_documentation_en-US" xlink:label="lab_elv_IncreaseInStockRepurchaseProgramAuthorization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncreaseInStockRepurchaseProgramAuthorization" xlink:href="elv-20221231.xsd#elv_IncreaseInStockRepurchaseProgramAuthorization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IncreaseInStockRepurchaseProgramAuthorization" xlink:to="lab_elv_IncreaseInStockRepurchaseProgramAuthorization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_0f4965b7-6a5d-4584-b212-92be3d1e15fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTradingSecurities_c3d0cde0-6966-4751-b249-1595a843ceef_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTradingSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other invested assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTradingSecurities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTradingSecurities" xlink:to="lab_us-gaap_IncreaseDecreaseInTradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_23874a62-8d5a-4a9c-86a1-22c552fa711e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_9e09ad10-a1dd-4aa8-ae4e-722e7b1b8321_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_5e28670c-fc61-448f-8b4c-23571ae0de5e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_904a88a5-8dd9-4cc9-8f4e-41d9cd3a79d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contract, Cumulative Number of Reported Claims</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Cumulative Number of Reported Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fd845105-50b1-4191-abf9-03b44743eb78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (annual)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_8b919a1a-2f96-4a9a-93bb-d3f4e1d200ac_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_3181b71a-f141-46e5-b528-78c5e5ede828_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_1db982f7-d884-4852-93f2-07236837a627_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_ff10628b-08a4-434f-b303-37ead6c42a29_terseLabel_en-US" xlink:label="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.800%, due 2040 [Member]</link:label>
    <link:label id="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_label_en-US" xlink:label="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Eight Zero Zero Percent Due Two Thousand Forty [Member]</link:label>
    <link:label id="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_documentation_en-US" xlink:label="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Eight Zero Zero Percent Due Two Thousand Forty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" xlink:href="elv-20221231.xsd#elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" xlink:to="lab_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_635f259c-760e-4d9d-9c68-1f9804e259fc_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_369d2aa0-6358-40e3-8e35-c18a296a5c53_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a5b313b4-1b27-4bf9-b49a-11888a92e1a2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffe02609-b7df-480a-a421-5c13678c517f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11fd525b-fb32-40f8-b12b-9e8cf6518ee6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48e32048-23fc-45b7-8f18-e85cd454a94d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity, Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3e49b895-b7d1-4b3e-bc81-0f37254f35a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d0cb61ee-9e21-45d8-b00b-e4f293be006d_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_ec854b0b-67ee-4fdf-ba8b-78287b910141_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CommitmentsAndContingenciesTable_cc04f9de-a710-4480-af50-b2ebe0ecd631_terseLabel_en-US" xlink:label="lab_elv_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_elv_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_elv_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_elv_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_elv_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies [Table].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommitmentsAndContingenciesTable" xlink:href="elv-20221231.xsd#elv_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CommitmentsAndContingenciesTable" xlink:to="lab_elv_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_8c760e45-2297-429f-9ac6-ec21c5cac08b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion rate (shares of common stock per $1,000 of principal amount)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_8e45280a-dca1-4555-a1da-444d806af647_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio, Shares</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0b9407dc-db09-4eff-9b95-a10c396326c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d899c0cf-6e87-4974-b222-65d5afbac118_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_6eca4e20-279f-44cf-a72a-45f5d5d63e26_terseLabel_en-US" xlink:label="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities lending transactions, ratio of fair value of collateral on hold to fair value of securities on loan</link:label>
    <link:label id="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_label_en-US" xlink:label="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan</link:label>
    <link:label id="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_documentation_en-US" xlink:label="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" xlink:href="elv-20221231.xsd#elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" xlink:to="lab_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_13dbbaf0-ccff-4155-b1be-5ed2be805b8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_StatutoryInformationTextBlock_d5c91cbd-dc75-4804-8865-d0852fa428c0_terseLabel_en-US" xlink:label="lab_elv_StatutoryInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Information</link:label>
    <link:label id="lab_elv_StatutoryInformationTextBlock_label_en-US" xlink:label="lab_elv_StatutoryInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Information [Text Block]</link:label>
    <link:label id="lab_elv_StatutoryInformationTextBlock_documentation_en-US" xlink:label="lab_elv_StatutoryInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StatutoryInformationTextBlock" xlink:href="elv-20221231.xsd#elv_StatutoryInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_StatutoryInformationTextBlock" xlink:to="lab_elv_StatutoryInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_04188563-d15f-4806-b363-cd531d3ccc10_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a5563813-f96b-49c4-8122-b13b1e446e5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a7921763-22a0-4f7e-9efb-a271bf9c927c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0b8aa720-5e54-4134-80c2-0da36b7a37df_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_ffdeb4ad-65f1-4e8c-88da-b393608375d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_StatutoryInformationAbstract_a848af80-11a1-4e39-8211-719396dd598e_terseLabel_en-US" xlink:label="lab_elv_StatutoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Information [Abstract]</link:label>
    <link:label id="lab_elv_StatutoryInformationAbstract_label_en-US" xlink:label="lab_elv_StatutoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Information [Abstract]</link:label>
    <link:label id="lab_elv_StatutoryInformationAbstract_documentation_en-US" xlink:label="lab_elv_StatutoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StatutoryInformationAbstract" xlink:href="elv-20221231.xsd#elv_StatutoryInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_StatutoryInformationAbstract" xlink:to="lab_elv_StatutoryInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract_ef8a04a6-263d-4889-8240-3b99d02203a2_terseLabel_en-US" xlink:label="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred and Paid Claims Development, Net of Reinsurance [Abstract]</link:label>
    <link:label id="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract_label_en-US" xlink:label="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred and Paid Claims Development, Net of Reinsurance [Abstract]</link:label>
    <link:label id="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract_documentation_en-US" xlink:label="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred and Paid Claims Development, Net of Reinsurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" xlink:href="elv-20221231.xsd#elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" xlink:to="lab_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_457f23fd-f1db-4212-8144-8409f4d7482a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Operating Activities Segment [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_db6dcc6a-649b-410f-9de1-63cd1d51783d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract_01b98ae4-27a1-468e-8045-797e2fb22612_terseLabel_en-US" xlink:label="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Claims Development To The Claims Liability [Abstract]</link:label>
    <link:label id="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract_label_en-US" xlink:label="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Claims Development To The Claims Liability [Abstract]</link:label>
    <link:label id="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract_documentation_en-US" xlink:label="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Claims Development To The Claims Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" xlink:href="elv-20221231.xsd#elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" xlink:to="lab_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TotalLevelIIIassetcategoriesAxis_959622da-06ca-4455-9784-210a61b42626_terseLabel_en-US" xlink:label="lab_elv_TotalLevelIIIassetcategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Level III, asset categories [Axis]</link:label>
    <link:label id="lab_elv_TotalLevelIIIassetcategoriesAxis_label_en-US" xlink:label="lab_elv_TotalLevelIIIassetcategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Level III, asset categories [Axis]</link:label>
    <link:label id="lab_elv_TotalLevelIIIassetcategoriesAxis_documentation_en-US" xlink:label="lab_elv_TotalLevelIIIassetcategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Level III, asset categories [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesAxis" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TotalLevelIIIassetcategoriesAxis" xlink:to="lab_elv_TotalLevelIIIassetcategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_A2022To2024Member_f68cd077-136e-4397-a743-69513c5d81eb_terseLabel_en-US" xlink:label="lab_elv_A2022To2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 to 2024 [Member]</link:label>
    <link:label id="lab_elv_A2022To2024Member_label_en-US" xlink:label="lab_elv_A2022To2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 to 2024 [Member]</link:label>
    <link:label id="lab_elv_A2022To2024Member_documentation_en-US" xlink:label="lab_elv_A2022To2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 to 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A2022To2024Member" xlink:href="elv-20221231.xsd#elv_A2022To2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_A2022To2024Member" xlink:to="lab_elv_A2022To2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e26225ba-b255-4890-a234-37f0b15edcca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock_8aa3d0f7-0e1f-432c-8645-76e8598a9adc_terseLabel_en-US" xlink:label="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Policyholder Liabilities</link:label>
    <link:label id="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Policyholder Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Policyholder Liabilities Policy Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherPolicyholderLiabilitiesPolicyTextBlock" xlink:href="elv-20221231.xsd#elv_OtherPolicyholderLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OtherPolicyholderLiabilitiesPolicyTextBlock" xlink:to="lab_elv_OtherPolicyholderLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_62fac5ba-cdf0-4396-ae91-972eb1168168_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_bd40a16e-af52-4603-b980-ea680281446d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_09815e2a-1deb-48cd-bafb-60137f0b51ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Restricted Stock Shares and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a9331ec7-28df-4531-8c15-95083749ab22_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8fde2abb-9d7e-4ed6-b717-d8d93ebdb491_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6dac24ad-34f3-4c82-b329-f8eb9ba4306a_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use Of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsEarned_5bbdcd26-c09a-491a-bb2f-1eca4af0251f_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed - Premium earned</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsEarned" xlink:to="lab_us-gaap_AssumedPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_536b9360-ac81-48b2-ae45-a23e5859a54f_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_00f8c08d-378d-463c-9f3b-9aa080c06804_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3dabe0e0-15ed-4c2e-9e6f-930f109b0ffd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue generated from participation in various federal government programs</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingAndAdvertisingExpense_e2c490c5-9efd-4325-a6e5-c1db3275eb16_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingAndAdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and marketing expense</link:label>
    <link:label id="lab_us-gaap_MarketingAndAdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_MarketingAndAdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing and Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingAndAdvertisingExpense" xlink:to="lab_us-gaap_MarketingAndAdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_32763668-9522-4bc2-98d9-5cd8f4978159_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d0922c3c-749f-4b2e-a374-e340d2dfa9b3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_a4ffe921-594a-4c0b-975c-0933566f0e50_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7875cd7c-c176-4ded-99e2-e47e5a452b3b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, Total Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_54ebf1e6-2f42-4381-84d5-8c4dc82cb173_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable_13e07765-e836-4056-8d72-77d2948a3916_terseLabel_en-US" xlink:label="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Premiums Earned By Segment [Table]</link:label>
    <link:label id="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable_label_en-US" xlink:label="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Premiums Written And Earned By Segment [Table]</link:label>
    <link:label id="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable_documentation_en-US" xlink:label="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Premiums Written And Earned By Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable" xlink:href="elv-20221231.xsd#elv_NetPremiumsWrittenAndEarnedBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable" xlink:to="lab_elv_NetPremiumsWrittenAndEarnedBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_69e5faa4-6d71-4207-828a-4d41cfbef920_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_1e4146f6-60ff-42ba-9473-863b0a282bd9_terseLabel_en-US" xlink:label="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deductions, percent of gross compensation, minimum</link:label>
    <link:label id="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_documentation_en-US" xlink:label="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:href="elv-20221231.xsd#elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_fa69dfe7-e96f-48ce-97f2-9676bc99c700_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate amount of damages sought for operational breaches</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_55b4647f-f805-43f0-9bcf-a5b9357921c3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_1cb4515e-0fbd-49e7-b0a0-2df399ef7bcb_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_9f4df11d-eda0-4ce1-8549-53ef8bb15e3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Maturity Securities, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_9f9ec8aa-04ef-4eb2-aadf-ec8647b14250_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Maturity Securities, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_724ff167-6fab-4eed-93cd-7e5f2b451c6c_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain" xlink:to="lab_us-gaap_GainContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_80d328fd-83bc-4d7c-92e3-651c6341b76f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_04b895ba-4718-417b-bef5-635b49f1af92_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededPremiumsEarned_b024c88b-5f77-4ba6-bdfc-d19e96935dc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CededPremiumsEarned" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded - Premium earned</link:label>
    <link:label id="lab_us-gaap_CededPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_CededPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededPremiumsEarned" xlink:to="lab_us-gaap_CededPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb9bba6-ac4b-443a-92ad-40599df1de71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4074f840-80e5-4337-af4d-9b77ffb7dbe7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f9a8f8e9-6a54-41cd-855e-447622220fdc_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Investments [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_7ee9e066-291a-49c0-a763-394ac17b5503_terseLabel_en-US" xlink:label="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250%, due 2030 [Member]</link:label>
    <link:label id="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_label_en-US" xlink:label="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Zero Percent Due Two Thousand Thirty [Member]</link:label>
    <link:label id="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_documentation_en-US" xlink:label="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Zero Percent Due Two Thousand Thirty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" xlink:href="elv-20221231.xsd#elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" xlink:to="lab_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDeductions_ed466b67-903d-49a8-84f2-b140af50f260_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax exempt interest and dividends received deduction, amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDeductions" xlink:to="lab_us-gaap_IncomeTaxReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TotalIntangibleAssetsAcquired_f2522631-98e2-4ec6-a1a4-7b0780c898e6_terseLabel_en-US" xlink:label="lab_elv_TotalIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_elv_TotalIntangibleAssetsAcquired_label_en-US" xlink:label="lab_elv_TotalIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangible Assets Acquired</link:label>
    <link:label id="lab_elv_TotalIntangibleAssetsAcquired_documentation_en-US" xlink:label="lab_elv_TotalIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalIntangibleAssetsAcquired" xlink:href="elv-20221231.xsd#elv_TotalIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TotalIntangibleAssetsAcquired" xlink:to="lab_elv_TotalIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_497b3375-e973-4087-882c-21fcc0223495_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deductions, percent of gross compensation, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4839bf11-b183-4611-9517-193ac8209a86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_2a0864a0-3483-4046-9119-c5bd615978c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable by Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_149d5e66-949c-4a90-8d07-6e4fe685892b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3dd0e1fc-380c-4e8c-9ded-67320f51870f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_f0da4151-6394-43f2-84a6-bf7965500ffc_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_8c97b307-519e-4621-97c9-5001f3ea0fca_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_8a7b6f6f-edf1-4dbe-919c-b57d5ab7530c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future maturities of debt Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_58194254-8dbb-4307-aa6e-342fa1e88674_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_A2021364DayFacilityMember_45edfdff-46ca-4f34-a805-b18eaeb6e1a9_terseLabel_en-US" xlink:label="lab_elv_A2021364DayFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 364-Day Facility</link:label>
    <link:label id="lab_elv_A2021364DayFacilityMember_label_en-US" xlink:label="lab_elv_A2021364DayFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 364-Day Facility [Member]</link:label>
    <link:label id="lab_elv_A2021364DayFacilityMember_documentation_en-US" xlink:label="lab_elv_A2021364DayFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 364-Day Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A2021364DayFacilityMember" xlink:href="elv-20221231.xsd#elv_A2021364DayFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_A2021364DayFacilityMember" xlink:to="lab_elv_A2021364DayFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IntangibleAssetsTable_8cf3257a-121c-4baf-b041-88e257a87132_terseLabel_en-US" xlink:label="lab_elv_IntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_elv_IntangibleAssetsTable_label_en-US" xlink:label="lab_elv_IntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_elv_IntangibleAssetsTable_documentation_en-US" xlink:label="lab_elv_IntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsTable" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IntangibleAssetsTable" xlink:to="lab_elv_IntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_e0dd0eca-4e48-4a4d-9311-3c9a6f4d3b8c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables, allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Loss, Receivable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3ee59d33-a34a-4e63-88bb-7c2819189ff6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_457fd9a4-cd79-4e4e-8d3e-9fc9c964a8b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense (benefit)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CommingledFundDomain_284fcaa8-8466-4974-8731-447bed969547_verboseLabel_en-US" xlink:label="lab_elv_CommingledFundDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled fund</link:label>
    <link:label id="lab_elv_CommingledFundDomain_d8eedbe8-106d-411d-86ef-db90e85c1b58_terseLabel_en-US" xlink:label="lab_elv_CommingledFundDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled fund</link:label>
    <link:label id="lab_elv_CommingledFundDomain_label_en-US" xlink:label="lab_elv_CommingledFundDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled Fund [Domain]</link:label>
    <link:label id="lab_elv_CommingledFundDomain_documentation_en-US" xlink:label="lab_elv_CommingledFundDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommingledFundDomain" xlink:href="elv-20221231.xsd#elv_CommingledFundDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CommingledFundDomain" xlink:to="lab_elv_CommingledFundDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_32f3b6e3-8cf7-488d-b545-5ca4206085fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized (losses) gains recognized on equity securities sold</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a5a0634e-7f4e-4f9f-b38b-3dc07b201727_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized gains (losses) recognized on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f375215e-da50-49ee-ad69-7586c611e354_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cd3b3f7c-1076-4e57-87cc-cb9b5d81a6a4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_69968a0d-f552-4dc3-afae-5ff7dbdfa9b3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers into Level III</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_0f37372d-6570-49c0-9c4c-facbe4d417ad_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6a9b8739-147d-48e3-910f-17fd2cc772bf_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_GovernmentBusinessSegmentMember_97066caf-5b77-4fb9-aee6-9c27da3a8457_verboseLabel_en-US" xlink:label="lab_elv_GovernmentBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Business Segment [Member]</link:label>
    <link:label id="lab_elv_GovernmentBusinessSegmentMember_f66b734d-d8ba-4779-a218-52112348fc14_terseLabel_en-US" xlink:label="lab_elv_GovernmentBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Business [Member]</link:label>
    <link:label id="lab_elv_GovernmentBusinessSegmentMember_label_en-US" xlink:label="lab_elv_GovernmentBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Business Segment [Member]</link:label>
    <link:label id="lab_elv_GovernmentBusinessSegmentMember_documentation_en-US" xlink:label="lab_elv_GovernmentBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Business Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_GovernmentBusinessSegmentMember" xlink:to="lab_elv_GovernmentBusinessSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EstimatedFutureDividendPayments_457f33a7-fb8e-49e1-81dd-e302f25eedc4_terseLabel_en-US" xlink:label="lab_elv_EstimatedFutureDividendPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Dividend Payments</link:label>
    <link:label id="lab_elv_EstimatedFutureDividendPayments_label_en-US" xlink:label="lab_elv_EstimatedFutureDividendPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Dividend Payments</link:label>
    <link:label id="lab_elv_EstimatedFutureDividendPayments_documentation_en-US" xlink:label="lab_elv_EstimatedFutureDividendPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of dividends expected to be paid during the following twelve months subject to regulatory approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EstimatedFutureDividendPayments" xlink:href="elv-20221231.xsd#elv_EstimatedFutureDividendPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EstimatedFutureDividendPayments" xlink:to="lab_elv_EstimatedFutureDividendPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_fdffdbc7-782c-400c-ad5b-1aee088c94dd_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Cross And Blue Shield And Other Trademarks [Member]</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2a9b8273-ea68-4592-8764-ce8eca9da905_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_fa0e8e1b-e271-444a-b950-6be5eef25e8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_10faa655-5b81-4345-b516-2e4a9a93fa46_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period, Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_124a3cd4-1ec1-46b1-9ef4-9b5be9f0fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_5085337e-7d73-4fe0-b5b4-d723c7af2e7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0d1e43eb-1df8-45e0-bf7b-86353a5c671b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value, Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3df5ef96-b1e9-4222-9420-64d92b96f565_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_a68e6510-9d91-4d4a-a656-42119ea62d69_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f3646cc-d627-4bed-9a72-13ce3650825c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_244ddf8d-7c1d-4cf5-9848-bb88d030a876_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_96d072c1-d8d2-45fc-8d9c-836a4dfee444_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_8db7dea8-aa26-4615-8cfa-7cd78675f150_terseLabel_en-US" xlink:label="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Two Point Five Five Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_label_en-US" xlink:label="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Two Point Five Five Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_documentation_en-US" xlink:label="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Two Point Five Five Zero Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" xlink:to="lab_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InsuranceCompanyContractsMember_c0912812-e49a-40c1-be01-86e243c9069e_terseLabel_en-US" xlink:label="lab_elv_InsuranceCompanyContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Company Contracts [Member]</link:label>
    <link:label id="lab_elv_InsuranceCompanyContractsMember_label_en-US" xlink:label="lab_elv_InsuranceCompanyContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Company Contracts [Member]</link:label>
    <link:label id="lab_elv_InsuranceCompanyContractsMember_documentation_en-US" xlink:label="lab_elv_InsuranceCompanyContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Company Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceCompanyContractsMember" xlink:href="elv-20221231.xsd#elv_InsuranceCompanyContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InsuranceCompanyContractsMember" xlink:to="lab_elv_InsuranceCompanyContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_c749cc6e-976b-46e9-be33-bc6f5dbd2d83_terseLabel_en-US" xlink:label="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations and purchase adjustments</link:label>
    <link:label id="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_label_en-US" xlink:label="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments</link:label>
    <link:label id="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_documentation_en-US" xlink:label="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" xlink:href="elv-20221231.xsd#elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" xlink:to="lab_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPolicyholderFunds_80217db8-db9e-48c7-8124-4f8ff52ab2c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other policyholder liabilities</link:label>
    <link:label id="lab_us-gaap_OtherPolicyholderFunds_label_en-US" xlink:label="lab_us-gaap_OtherPolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Policyholder Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPolicyholderFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPolicyholderFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPolicyholderFunds" xlink:to="lab_us-gaap_OtherPolicyholderFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_db9cc839-ad9f-4877-9682-c1045bb257d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3cc36462-caeb-45fc-9aee-e0bc4683dc5f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5fd2c6dd-cb94-4fe1-9c1e-b902528b2f59_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, after measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_Goodwill_72000d78-3df3-4256-a7c3-7f87158b9950_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_349479bb-af50-4260-9643-43f04612ff69_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AffiliatedMember_1fbb719f-8489-4d9c-b744-d2522023c673_terseLabel_en-US" xlink:label="lab_elv_AffiliatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated [Member]</link:label>
    <link:label id="lab_elv_AffiliatedMember_label_en-US" xlink:label="lab_elv_AffiliatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated [Member]</link:label>
    <link:label id="lab_elv_AffiliatedMember_documentation_en-US" xlink:label="lab_elv_AffiliatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AffiliatedMember" xlink:href="elv-20221231.xsd#elv_AffiliatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AffiliatedMember" xlink:to="lab_elv_AffiliatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_MajorProductRevenueBySegmentTableTextBlock_f9d2745a-a984-4e02-a936-364ee8d22738_terseLabel_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenues</link:label>
    <link:label id="lab_elv_MajorProductRevenueBySegmentTableTextBlock_label_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenue By Segment [Table Text Block]</link:label>
    <link:label id="lab_elv_MajorProductRevenueBySegmentTableTextBlock_documentation_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Major Product Revenue By Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentTableTextBlock" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_MajorProductRevenueBySegmentTableTextBlock" xlink:to="lab_elv_MajorProductRevenueBySegmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d831e71a-81f9-4925-825f-46c1cccca9db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_38888c0a-ef67-4877-8927-2a7eeb22aacb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_75d9fe2e-d3db-4f03-b5d3-324819cd6595_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a2d8af54-7cf1-4147-9316-d8bad5706a9d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized investment gains</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_ea50171f-8dbf-4ec2-8b77-785ac08862a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c8edd7b0-8142-4c68-b514-63ddc76f9177_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3cf3a2d4-798b-42eb-a68e-767a9164e10e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_04c0593c-089b-4f0e-b789-419b8f368a92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0b723dcb-21c8-46dd-af42-2f7671d99b84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0b4857ac-b493-4fd7-955a-494a2ce80196_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_1e8ce24f-bb02-4f9a-ace6-103c031d3adf_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_902933a1-d98f-4546-b17c-7ca0e1556770_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_1f0d4185-9e48-42e4-8e67-e7600dcb94b4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6b5153cc-a724-4071-aab7-da0b33dcd7f3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_073b17f3-609a-4c66-9057-4ef64ba02d3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_4921ad6b-79c9-4ee8-b23d-d80ff458d30d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_948acd48-5444-422c-9a7e-4385ab7d9ac2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_8e13c316-f9ba-457c-8790-018b95634ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Favorable) Unfavorable Developments By Changes In Key Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:to="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_0492ceee-968a-46e7-9265-27ff50b73d0f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_992598f9-7687-45ee-9c15-fa4c153037fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debentures</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_9f0b8b57-61fa-4837-916f-8aceb15c14c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt carrying amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_115b3108-6654-402b-871d-dd98c9015135_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_23e9555d-86b3-4a48-9d4e-e6a0a08eb08f_terseLabel_en-US" xlink:label="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.350%, due 2020 [Member]</link:label>
    <link:label id="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_label_en-US" xlink:label="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Five Zero Percent Due Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_documentation_en-US" xlink:label="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Five Zero Percent Due Two Thousand Twenty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" xlink:href="elv-20221231.xsd#elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" xlink:to="lab_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5abd27d2-f7e0-4d68-9d37-6bbb8fa94965_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_b7e2abd9-d0ee-49f8-8c11-9f1e54697e23_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_feb3bba3-b0aa-45f4-900b-9d576c38caa6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_7ea9fb4d-32d3-4f08-a9a9-930df3c7885c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_84ffd43d-a354-4894-b648-cda47f9a4132_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_1d5ae2bd-597c-4078-ae62-48972af77719_terseLabel_en-US" xlink:label="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.300%, due 2023 [Member]</link:label>
    <link:label id="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Zero Percent Due Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Zero Percent Due Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" xlink:href="elv-20221231.xsd#elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" xlink:to="lab_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_ca5a6a1d-1498-43a1-8907-03de9374328e_terseLabel_en-US" xlink:label="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.650%, due 2044 [Member]</link:label>
    <link:label id="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_label_en-US" xlink:label="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Five Zero Percent Due Two Thousand Forty Four [Member]</link:label>
    <link:label id="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_documentation_en-US" xlink:label="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Five Zero Percent Due Two Thousand Forty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" xlink:href="elv-20221231.xsd#elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" xlink:to="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_RatedNotesMember_48eb9d41-f047-4710-a15c-7825554b5816_terseLabel_en-US" xlink:label="lab_elv_RatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rated notes</link:label>
    <link:label id="lab_elv_RatedNotesMember_label_en-US" xlink:label="lab_elv_RatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rated notes [Member]</link:label>
    <link:label id="lab_elv_RatedNotesMember_documentation_en-US" xlink:label="lab_elv_RatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rated notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_RatedNotesMember" xlink:href="elv-20221231.xsd#elv_RatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_RatedNotesMember" xlink:to="lab_elv_RatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_cddeceb4-0442-4d6a-bcd5-319b236eddbb_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective conversion price (per $1,000 of principal amount) per share</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_73917b6b-3d37-4175-9c00-4602b37bab4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_bd1d49f0-11db-4e64-9b57-4dc2621e1239_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1210c017-87df-4b98-8105-91ec12d816a7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_e772f9fb-2717-42b6-9410-4badc0ee0c4f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative fees and other revenue</link:label>
    <link:label id="lab_us-gaap_OtherIncome_1cb1a198-7d22-46b4-93a5-97101b0b3a08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative fees and other revenue</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults_4f7b253d-2a1d-4458-b38b-f1b711da6e09_terseLabel_en-US" xlink:label="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units excluded from the denominator for diluted earnings per share</link:label>
    <link:label id="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults_label_en-US" xlink:label="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially Dilutive Restricted Stock Units Contingent On Operating Results</link:label>
    <link:label id="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults_documentation_en-US" xlink:label="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially Dilutive Restricted Stock Units Contingent On Operating Results</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" xlink:href="elv-20221231.xsd#elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" xlink:to="lab_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1039c0c-9e65-4f58-909d-86054fa7adbf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_411afbe1-fcdd-4d0d-af88-d54c3c4e61a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_475e66fd-caf7-4087-8c95-ff4a786e0b5b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_99901aad-fb66-498a-9bf7-adac3837edf5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_046bfc1b-2a93-46df-b057-73dcefcd3674_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_67ae43f2-60d0-40d7-bcb5-6446b5ee6993_terseLabel_en-US" xlink:label="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500%, due 2024 [Member]</link:label>
    <link:label id="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Zero Zero Percent Due Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Zero Zero Percent Due Two Thousand Twenty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" xlink:href="elv-20221231.xsd#elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" xlink:to="lab_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock_d1673f96-f289-408f-9ca2-036acf3b91df_verboseLabel_en-US" xlink:label="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans</link:label>
    <link:label id="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock_label_en-US" xlink:label="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Assumptions Used In Calculating The Net Periodic Benefit Cost [Table Text Block]</link:label>
    <link:label id="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock_documentation_en-US" xlink:label="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" xlink:href="elv-20221231.xsd#elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" xlink:to="lab_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_44992aab-ceaa-401c-9e5a-9300fc1870f7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Reinsurance On Benefit Expense</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_857a58a4-2b74-4692-8cba-68bd8d6fd7f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9bcd0b29-1dbb-437b-ae7b-3a5f8fbf53e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0a20b4bd-ab90-4df9-b8be-86119badcf93_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ShortdurationInsuranceContractsClaimYearTable_4af5adc7-4d87-4546-80fa-82f77cf0f66c_terseLabel_en-US" xlink:label="lab_elv_ShortdurationInsuranceContractsClaimYearTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year [Table]</link:label>
    <link:label id="lab_elv_ShortdurationInsuranceContractsClaimYearTable_label_en-US" xlink:label="lab_elv_ShortdurationInsuranceContractsClaimYearTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year [Table]</link:label>
    <link:label id="lab_elv_ShortdurationInsuranceContractsClaimYearTable_documentation_en-US" xlink:label="lab_elv_ShortdurationInsuranceContractsClaimYearTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationInsuranceContractsClaimYearTable" xlink:href="elv-20221231.xsd#elv_ShortdurationInsuranceContractsClaimYearTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ShortdurationInsuranceContractsClaimYearTable" xlink:to="lab_elv_ShortdurationInsuranceContractsClaimYearTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_58ccfb75-a064-4d4b-b170-ef455f1d1d9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_8e171133-80b4-450d-b7fc-438ad8996309_terseLabel_en-US" xlink:label="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.550%, due 2048 [Member]</link:label>
    <link:label id="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_label_en-US" xlink:label="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Five Zero Percent Due Two Thousand Forty Eight [Member]</link:label>
    <link:label id="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_documentation_en-US" xlink:label="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Five Zero Percent Due Two Thousand Forty Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" xlink:to="lab_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_d8d1b3cf-d668-4a53-af52-899b3c76af31_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_612cd790-80fb-4271-87b6-76753db92bf1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_519f75ff-d929-4e5c-adcd-a01a991aa0b5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dd0e2519-dcd8-42e9-ab44-9ce4a46ed6ab_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0399e825-5d77-4f27-af5f-c2afc00cef94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_e03dd183-40be-4cd0-aa3b-af415a9e3d9c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_2d2016ac-f1c4-4925-b5b2-a18b2dd76c1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If-converted value per dollar above the conversion price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d5dde1da-0693-4ea0-a770-68424d10dbec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81e82ef9-2b65-48c2-971e-116fafc245bf_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_78e0dba8-dce3-4268-9020-af9ed35c90f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_39ae9d9f-89e3-45f0-8733-718809bb5375_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_e74e6a41-9728-419f-a59f-154178ed91e2_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7241f952-6394-4fcf-b419-69d0c8cee48f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3f49cc2d-4ed5-442c-a066-ade05acf67ae_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1812c3ff-e645-41c7-a347-95f15be9903c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bab1d977-783a-4468-89b6-35b47328583f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_c6f2eb24-4860-44cd-ae94-40cfa9253d63_terseLabel_en-US" xlink:label="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Protection Affordable Care Act Health Insurance Provider Fee, amount paid</link:label>
    <link:label id="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_label_en-US" xlink:label="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid</link:label>
    <link:label id="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_documentation_en-US" xlink:label="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount paid for the annual Health Insurance Provider Fee assessed in accordance with Section 9010 of the Patient Protection Affordable Care Act.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" xlink:href="elv-20221231.xsd#elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" xlink:to="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e1f779b3-f38a-4336-8629-087170a51579_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_277c34d7-a69e-4137-a15f-bbcd637ec810_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_1e353cf2-736a-430d-a6fb-5e4ecf985f42_terseLabel_en-US" xlink:label="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.700%, due 2049 [Member]</link:label>
    <link:label id="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_label_en-US" xlink:label="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seven Zero Zero Percent Due Two Thousand Forty Nine [Member]</link:label>
    <link:label id="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_documentation_en-US" xlink:label="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seven Zero Zero Percent Due Two Thousand Forty Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" xlink:href="elv-20221231.xsd#elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" xlink:to="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_34552c50-5827-43a3-9393-68e3c8ac1989_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan, purchase price per share as a percent of closing price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_bd3eacc4-1ba2-4da0-83fa-3849768d8e43_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4c5d57b3-c52d-48df-b720-ae7bec6467e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_UnaffiliatedMember_a6d591d1-9a2f-442b-bfc5-af2fce53a99d_terseLabel_en-US" xlink:label="lab_elv_UnaffiliatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaffiliated [Member]</link:label>
    <link:label id="lab_elv_UnaffiliatedMember_label_en-US" xlink:label="lab_elv_UnaffiliatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaffiliated [Member]</link:label>
    <link:label id="lab_elv_UnaffiliatedMember_documentation_en-US" xlink:label="lab_elv_UnaffiliatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaffiliated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_UnaffiliatedMember" xlink:href="elv-20221231.xsd#elv_UnaffiliatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_UnaffiliatedMember" xlink:to="lab_elv_UnaffiliatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_GrossPremiumTaxRate_3dadc145-078e-47ab-a662-04c3af438df8_terseLabel_en-US" xlink:label="lab_elv_GrossPremiumTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross premium tax rate, state of California</link:label>
    <link:label id="lab_elv_GrossPremiumTaxRate_label_en-US" xlink:label="lab_elv_GrossPremiumTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Premium Tax Rate</link:label>
    <link:label id="lab_elv_GrossPremiumTaxRate_documentation_en-US" xlink:label="lab_elv_GrossPremiumTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross premium tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GrossPremiumTaxRate" xlink:href="elv-20221231.xsd#elv_GrossPremiumTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_GrossPremiumTaxRate" xlink:to="lab_elv_GrossPremiumTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_3826282f-adff-4c6a-ac2b-12f137b121ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SupplementaryInsuranceInformationBySegmentLineItems_1d31c2c6-2ece-4264-8cfd-02afb6aec87f_terseLabel_en-US" xlink:label="lab_srt_SupplementaryInsuranceInformationBySegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Premiums Earned By Segment [Line Items]</link:label>
    <link:label id="lab_srt_SupplementaryInsuranceInformationBySegmentLineItems_label_en-US" xlink:label="lab_srt_SupplementaryInsuranceInformationBySegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementaryInsuranceInformationBySegmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems" xlink:to="lab_srt_SupplementaryInsuranceInformationBySegmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_6a712d53-3220-40f2-8048-7cc67a0d28ba_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_59ac91ed-760a-49c9-8c83-754870ab1c8e_terseLabel_en-US" xlink:label="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Incurred Medical Claims to Benefit Expense [Line Items]</link:label>
    <link:label id="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_label_en-US" xlink:label="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">reconciliation of net incurred medical claims to benefit expense [Line Items]</link:label>
    <link:label id="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_documentation_en-US" xlink:label="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" xlink:href="elv-20221231.xsd#elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" xlink:to="lab_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_06e2b22f-4a0c-44c2-88da-7c4f93c15695_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Securities, Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fd279182-98b0-4ec2-acf4-7e7bc8cc4ef9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_41e85119-8fa6-4533-b4c2-a46f9ed40429_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_ec6797ae-d309-4a7b-b2ac-63fbe716559b_terseLabel_en-US" xlink:label="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-credit components of impairments on investments</link:label>
    <link:label id="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_label_en-US" xlink:label="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-credit components of impairments on investments [Member]</link:label>
    <link:label id="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_documentation_en-US" xlink:label="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-credit components of impairments on investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" xlink:href="elv-20221231.xsd#elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" xlink:to="lab_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InvestmentInDOL10312TrustMember_5b658a26-424a-491c-aaca-90e9ca8b3942_terseLabel_en-US" xlink:label="lab_elv_InvestmentInDOL10312TrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In DOL 103-12 Trust [Member]</link:label>
    <link:label id="lab_elv_InvestmentInDOL10312TrustMember_label_en-US" xlink:label="lab_elv_InvestmentInDOL10312TrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In D O L10312 Trust [Member]</link:label>
    <link:label id="lab_elv_InvestmentInDOL10312TrustMember_documentation_en-US" xlink:label="lab_elv_InvestmentInDOL10312TrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In D O L 103-12 Trust [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentInDOL10312TrustMember" xlink:href="elv-20221231.xsd#elv_InvestmentInDOL10312TrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InvestmentInDOL10312TrustMember" xlink:to="lab_elv_InvestmentInDOL10312TrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_51116958-bbb1-4b41-9b9e-dc8d1c1962a3_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_63d3591a-c135-481a-a0d0-58363d4c2d08_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b9ccc0f2-a63c-4188-b1f9-44a041e4ac7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_0c293540-8373-49a3-9eaf-ec380f421d27_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Dividend Activity</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_3fafc24e-a9b2-48c6-af0c-6050f3c6f44c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_93873409-4251-4d92-9311-68d0bd10c286_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net periodic pension and postretirement costs</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_b7f3542d-751c-49aa-a552-88327fe82816_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory-basis capital and surplus</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus, Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_02f655ab-8855-4277-a04e-dac24c83bf61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility factor</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase_d6eba8be-2529-43e7-ad76-4f05690fc591_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_14ee6db8-cef7-4f17-9f0e-e8dacd176ba9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DebtRedemptionAmount_60230e83-057c-4f93-9f35-9e694e798941_terseLabel_en-US" xlink:label="lab_elv_DebtRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Redemption amount</link:label>
    <link:label id="lab_elv_DebtRedemptionAmount_label_en-US" xlink:label="lab_elv_DebtRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Redemption amount</link:label>
    <link:label id="lab_elv_DebtRedemptionAmount_documentation_en-US" xlink:label="lab_elv_DebtRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Redemption amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DebtRedemptionAmount" xlink:href="elv-20221231.xsd#elv_DebtRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DebtRedemptionAmount" xlink:to="lab_elv_DebtRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions_8c06d0da-fcc5-4a64-9c78-4d77289f1fb9_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b9873680-f16a-427b-94b3-d8931d67ca90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock plans, net of related tax benefits</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_834fdd3f-93b6-4666-907e-cd91c204daca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains/losses on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2f512f41-5d4c-4e7c-ae53-fac7d341fd98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_03b3d324-3cf0-4f91-a304-c437c86e6e94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_000a6979-dfa6-4564-aaca-7dedd4599f67_verboseLabel_en-US" xlink:label="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_label_en-US" xlink:label="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Of Expected Rate Of Return On Plan Assets</link:label>
    <link:label id="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_documentation_en-US" xlink:label="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Of Expected Rate Of Return On Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" xlink:to="lab_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_d362a2d4-ce80-4506-9152-b48a1017097e_terseLabel_en-US" xlink:label="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis adjustments from recent acquisitions, amount</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_label_en-US" xlink:label="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Recent Acquisitions, amount</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_documentation_en-US" xlink:label="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense as a result of the basis adjustments from recent acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" xlink:to="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_df8914ba-9b2b-4fcc-abbc-390ac5aa6795_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency_b090c52e-0310-4f15-adcd-ae3e84f213ec_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Dividends Paid with Approval of Regulatory Agency</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Dividends Paid with Approval of Regulatory Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency" xlink:to="lab_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_APCPasseLLCMember_ff0e4bc4-ae82-46c1-ac7c-0cb192dfc9a8_terseLabel_en-US" xlink:label="lab_elv_APCPasseLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Passe, LLC [Member]</link:label>
    <link:label id="lab_elv_APCPasseLLCMember_label_en-US" xlink:label="lab_elv_APCPasseLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Passe, LLC [Member]</link:label>
    <link:label id="lab_elv_APCPasseLLCMember_documentation_en-US" xlink:label="lab_elv_APCPasseLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Passe, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_APCPasseLLCMember" xlink:href="elv-20221231.xsd#elv_APCPasseLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_APCPasseLLCMember" xlink:to="lab_elv_APCPasseLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_300ab4a7-d7fa-4d0c-82a5-dae8fdf32e32_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II-Condensed Financial Information Of Registrant</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PPEImpairmentMember_c3b1f02a-c0bb-424c-93b5-846f96a8ee25_terseLabel_en-US" xlink:label="lab_elv_PPEImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment Impairment and Abandonment [Member]</link:label>
    <link:label id="lab_elv_PPEImpairmentMember_label_en-US" xlink:label="lab_elv_PPEImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPE Impairment [Member]</link:label>
    <link:label id="lab_elv_PPEImpairmentMember_documentation_en-US" xlink:label="lab_elv_PPEImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPE Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PPEImpairmentMember" xlink:href="elv-20221231.xsd#elv_PPEImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PPEImpairmentMember" xlink:to="lab_elv_PPEImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130dafdb-babf-43e1-8267-ac0c7ae50b34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions[Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_06499818-9b15-4f34-8869-f788ff0378f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Realized Gains (Losses) On Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_625bf213-546e-47bc-8787-990c58b0d3c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_52589ffd-a299-4e97-b918-fb2b45316730_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate cost</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e00ee5f1-1a5f-46ab-8e90-1116ec4bff69_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_e51b20c5-63ef-4608-9eb7-5a7ae622d3de_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_d68cf901-db82-4f1c-bde4-7eaa95f899df_terseLabel_en-US" xlink:label="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.500% due 2032 [Member]</link:label>
    <link:label id="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_label_en-US" xlink:label="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Zero Percent Due Two Thousand Thirty Two [Member]</link:label>
    <link:label id="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_documentation_en-US" xlink:label="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Zero Percent Due Two Thousand Thirty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" xlink:href="elv-20221231.xsd#elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" xlink:to="lab_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1109537a-176c-4aa2-90b9-ed2151133c81_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_cd11b976-922e-4d79-b016-c44216a3d348_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_d76520e4-3a71-49c2-8d99-972576fc87bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_344c7f12-f292-4ccb-a977-1428e54c60ed_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_03bfc65c-805f-492f-a8a6-325a66e53955_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_3bbf2726-a986-408f-a4ff-724034ebfdf7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_MajorProductRevenueBySegmentTable_79eb7c8b-636f-4655-a017-7271599eaa76_terseLabel_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenue By Segment [Table]</link:label>
    <link:label id="lab_elv_MajorProductRevenueBySegmentTable_label_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenue By Segment [Table]</link:label>
    <link:label id="lab_elv_MajorProductRevenueBySegmentTable_documentation_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenue By Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentTable" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_MajorProductRevenueBySegmentTable" xlink:to="lab_elv_MajorProductRevenueBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bbd094c1-2b30-44af-8196-fa62bac03a91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e717e795-c54b-466e-a680-8604ca927131_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_588e536e-4bbb-4b01-b3c0-35835e2ef9e3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Net Periodic Benefit Cost (Credit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenOptionContractsWrittenExpirationDates_3cba0f55-31fe-4333-873a-fe1dc8d29478_terseLabel_en-US" xlink:label="lab_us-gaap_OpenOptionContractsWrittenExpirationDates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_us-gaap_OpenOptionContractsWrittenExpirationDates_label_en-US" xlink:label="lab_us-gaap_OpenOptionContractsWrittenExpirationDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Option Contracts Written, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenExpirationDates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenExpirationDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenOptionContractsWrittenExpirationDates" xlink:to="lab_us-gaap_OpenOptionContractsWrittenExpirationDates" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock_a386ca52-e5a7-4763-b870-ef6801c4a9f4_terseLabel_en-US" xlink:label="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet</link:label>
    <link:label id="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block]</link:label>
    <link:label id="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock_documentation_en-US" xlink:label="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" xlink:href="elv-20221231.xsd#elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" xlink:to="lab_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_50a1d230-ae5d-4c6b-b257-a047cb0bfae8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DefinedBenefitFairValueDueFromBrokers_cc3e5b5a-3a15-4a53-bcdb-d18fd4f5b9a9_terseLabel_en-US" xlink:label="lab_elv_DefinedBenefitFairValueDueFromBrokers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount of assets (liabilities) of cash, investment income receivable and amounts due to/from brokers, excluded from fair values of pension benefit assets and other benefit assets</link:label>
    <link:label id="lab_elv_DefinedBenefitFairValueDueFromBrokers_label_en-US" xlink:label="lab_elv_DefinedBenefitFairValueDueFromBrokers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Fair Value Due From Brokers</link:label>
    <link:label id="lab_elv_DefinedBenefitFairValueDueFromBrokers_documentation_en-US" xlink:label="lab_elv_DefinedBenefitFairValueDueFromBrokers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Fair Value Due From Brokers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitFairValueDueFromBrokers" xlink:href="elv-20221231.xsd#elv_DefinedBenefitFairValueDueFromBrokers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DefinedBenefitFairValueDueFromBrokers" xlink:to="lab_elv_DefinedBenefitFairValueDueFromBrokers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_d43e0ef4-46b5-4a90-b875-a3d49e4ffeed_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_fcdbaa87-9a83-4384-9b84-6fcc2fe20390_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other invested assets, long-term</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_24104095-78c6-4ab4-8108-8218a355e088_negatedTerseLabel_en-US" xlink:label="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, Total Intangible Assets</link:label>
    <link:label id="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_label_en-US" xlink:label="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Accumulated Amortization Excluding Goodwill</link:label>
    <link:label id="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_documentation_en-US" xlink:label="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Accumulated Amortization Excluding Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:to="lab_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_5a3e402f-a1f9-4762-ae41-1a2868c98363_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6f6aaa6f-6a9f-4cce-a636-de9f88304573_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_c039b8f3-d156-4424-a586-1e1f5a37a1a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f06790d0-ff14-47a0-9921-2196d0d0668f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b02c7336-9690-40a8-b95f-b4470257dd87_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_365b0dec-6151-40ca-b14c-56c48054c50e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_70a775a6-45d3-420a-b261-21ab01085c46_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_652d0d3f-f979-4aaf-9dd4-b00bc3704c04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_2bf10c65-5586-49d0-be08-7142d70020ec_terseLabel_en-US" xlink:label="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_label_en-US" xlink:label="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity and fixed maturity securities</link:label>
    <link:label id="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_documentation_en-US" xlink:label="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity and fixed maturity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Proceedsfromsaleofequityandfixedmaturitysecurities" xlink:href="elv-20221231.xsd#elv_Proceedsfromsaleofequityandfixedmaturitysecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_Proceedsfromsaleofequityandfixedmaturitysecurities" xlink:to="lab_elv_Proceedsfromsaleofequityandfixedmaturitysecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesTable_701d14f2-5709-4e4b-990a-d97aa3cc23fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Table]</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesTable_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable" xlink:to="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_77834220-cf2a-4654-949c-0b925006982e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_Impairmentlossesreversalsoninvestments_80bfe5cf-8dee-4eb5-b12a-7beef21481c0_negatedTerseLabel_en-US" xlink:label="lab_elv_Impairmentlossesreversalsoninvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment (losses) recoveries recognized in income</link:label>
    <link:label id="lab_elv_Impairmentlossesreversalsoninvestments_label_en-US" xlink:label="lab_elv_Impairmentlossesreversalsoninvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment (losses) reversals on investments</link:label>
    <link:label id="lab_elv_Impairmentlossesreversalsoninvestments_documentation_en-US" xlink:label="lab_elv_Impairmentlossesreversalsoninvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Impairmentlossesreversalsoninvestments" xlink:href="elv-20221231.xsd#elv_Impairmentlossesreversalsoninvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_Impairmentlossesreversalsoninvestments" xlink:to="lab_elv_Impairmentlossesreversalsoninvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_955381e7-5e09-4cb7-bc4b-d2cc9e69f236_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7447c88e-298e-482d-a1bf-4b1b68aab7d6_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_6b4f042c-c4a3-4c6a-a6dc-62672551634b_terseLabel_en-US" xlink:label="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-funded receivables, allowance for doubtful accounts</link:label>
    <link:label id="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-funded Receivables, Allowance For Doubtful Accounts</link:label>
    <link:label id="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_documentation_en-US" xlink:label="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" xlink:href="elv-20221231.xsd#elv_SelffundedReceivablesAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" xlink:to="lab_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_e4245e2d-3c1d-4a0b-966b-d4911dd5f5a3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ManagedCareProductsMember_5018b3a4-72a0-44d1-a674-f0ede014ced3_terseLabel_en-US" xlink:label="lab_elv_ManagedCareProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care Products [Member]</link:label>
    <link:label id="lab_elv_ManagedCareProductsMember_label_en-US" xlink:label="lab_elv_ManagedCareProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care Products [Member]</link:label>
    <link:label id="lab_elv_ManagedCareProductsMember_documentation_en-US" xlink:label="lab_elv_ManagedCareProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ManagedCareProductsMember" xlink:href="elv-20221231.xsd#elv_ManagedCareProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ManagedCareProductsMember" xlink:to="lab_elv_ManagedCareProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_a3bf7abf-8484-48f8-9301-66a4d4d7ef76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1a1fa005-851d-41c9-945d-7163c138f3b7_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, 12 Months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_60afbeb8-5481-4f0e-868f-9e77f88a4bb4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_df835b2e-02db-48aa-9138-7792bcd2e894_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50f06d6b-af27-4431-9909-ecf6c7293f0c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders' equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_1caec88f-d6ca-479e-9d88-c0bde3e700ea_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Securities [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67ddc6c2-a15e-4c5a-b15f-a6c4a48d1d0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d639fbf0-1eb5-4993-8550-fe6ce0c96171_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired, Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_343b12c1-2caa-45c9-b1bd-ea644d19afee_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ManagedCareServicesMember_0a76d323-eaa9-4e64-ac1e-0a5b97c5cf07_terseLabel_en-US" xlink:label="lab_elv_ManagedCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care Services [Member]</link:label>
    <link:label id="lab_elv_ManagedCareServicesMember_label_en-US" xlink:label="lab_elv_ManagedCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care Services [Member]</link:label>
    <link:label id="lab_elv_ManagedCareServicesMember_documentation_en-US" xlink:label="lab_elv_ManagedCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ManagedCareServicesMember" xlink:href="elv-20221231.xsd#elv_ManagedCareServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ManagedCareServicesMember" xlink:to="lab_elv_ManagedCareServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_79c8b83d-f776-40b1-b8c5-44a0504689ee_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider And Hospital Relationships [Member]</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9a6f3697-1f03-484d-a96c-b3e962db29a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_fafe7cdf-1a48-43c8-af23-0ec30f85f700_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product of Conversion to Stock Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_1ae4dafa-d7b6-40d4-81f3-a0c0eec6515a_terseLabel_en-US" xlink:label="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.900 % due 2026 [Member]</link:label>
    <link:label id="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_label_en-US" xlink:label="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" xlink:href="elv-20221231.xsd#elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" xlink:to="lab_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eeba75a1-e67f-4ce4-b19f-eea4e3331969_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic earnings per share&#8212;weighted-average shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0223dfd3-63b2-445f-a6b6-4915c70dc00e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_aef6914a-8ec7-4173-8237-b50c5d588b58_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_c903b40c-8199-4b09-aca8-751188fb6a79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net incurred medical claims in prior years redundancies</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCashAbstract_ca5fe377-58c8-48b5-9bbd-e484bfc5e5cc_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash [Abstract]</link:label>
    <link:label id="lab_us-gaap_DividendsCashAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCashAbstract" xlink:to="lab_us-gaap_DividendsCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fb121814-d98c-4780-a871-05a56fe4818b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_c65e6094-64bb-479c-8f00-ba7c48fbb243_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average target allocation for plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_2bf6e69e-3e9b-4b14-bd8e-dd6e184935ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_2f0cb775-c70a-4431-9bbc-b0bb63f895de_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4bc85565-57b1-400c-9c5d-32cc2b65b647_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_0fc03ef7-e31d-4f3b-8085-2a62bc7ec39d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_c946b992-426e-4bb5-8da0-72cdf699f8f8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed health care cost trend rate to be used for next year to measure expected cost of other benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_e5e94575-f4cc-4549-97bd-02d9f99350c2_terseLabel_en-US" xlink:label="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625%, due 2042 [Member]</link:label>
    <link:label id="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_label_en-US" xlink:label="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent Due Two Thousand Forty Two [Member]</link:label>
    <link:label id="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_documentation_en-US" xlink:label="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent Due Two Thousand Forty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" xlink:href="elv-20221231.xsd#elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" xlink:to="lab_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_f067d87e-b406-4b47-bbc4-e4ef8c63262b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1da1e74f-326f-46ca-ac93-c57094ccd41c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1e0c9425-59e2-4a71-88f4-768f78abf6b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Carrying Value Of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_effe569a-0a13-4da1-a89c-948e87d47fc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_a32e0cf0-f430-4c6a-9beb-31fb325077d1_terseLabel_en-US" xlink:label="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Date</link:label>
    <link:label id="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_5c5d90d7-def9-4176-8e9e-c48bf56a6580_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Date to be Paid</link:label>
    <link:label id="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_label_en-US" xlink:label="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Date to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:to="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a668a8c9-3a7d-475f-a167-a16c324eb56e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_fac100ba-7c09-4647-8207-698362e51cf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) recognized in accumulated other comprehensive loss/income</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_76b2e4fc-ae8b-487d-b16a-d593c0aeaeb9_terseLabel_en-US" xlink:label="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.375%, due 2025 [Member]</link:label>
    <link:label id="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_label_en-US" xlink:label="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Seven Five Percent Due Two Thousand Twenty Five [Member]</link:label>
    <link:label id="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_documentation_en-US" xlink:label="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Seven Five Percent Due Two Thousand Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" xlink:href="elv-20221231.xsd#elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" xlink:to="lab_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_02de78f7-459f-4fe6-99d4-f623fec81626_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_2d42db73-2a05-4277-ba78-567a6e19c8a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_27405df4-0c67-48df-aa35-bb3c66195e1d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5acce0ff-d1c1-4fd7-8050-925f211f728c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level III [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b2350b27-aebf-424b-a492-4864f3176c5e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_444941b4-b75b-4116-9deb-b063c1e50655_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax credits and equity in net income of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a554114b-856d-4856-a6e8-62b888f0657c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturity securities, long-term</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_2f1660e1-1a15-46fd-9353-4995a7b3a6fb_terseLabel_en-US" xlink:label="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% due 2050 [Member]</link:label>
    <link:label id="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_label_en-US" xlink:label="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Due Two Thousand Fifty [Member]</link:label>
    <link:label id="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_documentation_en-US" xlink:label="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Due Two Thousand Fifty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" xlink:to="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedMaturitiesMember_ad71760f-9e56-4cdc-82b2-7255c82497fc_terseLabel_en-US" xlink:label="lab_us-gaap_FixedMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Maturity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_FixedMaturitiesMember_label_en-US" xlink:label="lab_us-gaap_FixedMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedMaturitiesMember" xlink:to="lab_us-gaap_FixedMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_cae6bb13-0b45-4414-95e1-d8dd8cf0500c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_835ca09c-0060-4c65-bbcb-a088f6fe1a2b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PercentConversionToStockPrice_86b8e1ec-10ef-4758-88c7-69d80cea380d_terseLabel_en-US" xlink:label="lab_elv_PercentConversionToStockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Conversion Price to Closing Price</link:label>
    <link:label id="lab_elv_PercentConversionToStockPrice_label_en-US" xlink:label="lab_elv_PercentConversionToStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Conversion To Stock Price</link:label>
    <link:label id="lab_elv_PercentConversionToStockPrice_documentation_en-US" xlink:label="lab_elv_PercentConversionToStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PercentConversionToStockPrice" xlink:href="elv-20221231.xsd#elv_PercentConversionToStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PercentConversionToStockPrice" xlink:to="lab_elv_PercentConversionToStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_ceb0d91d-a1bb-4fda-8cff-57daaa4b643f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_cae294c3-3cf8-4186-8212-827e7a9ad920_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business optimization initiatives, incurred cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_2389c01c-422b-4bcf-b23e-55b24e352148_terseLabel_en-US" xlink:label="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.101%, due 2028 [Member]</link:label>
    <link:label id="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_label_en-US" xlink:label="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero One Percent Due Two Thousand Twenty Eight [Member]</link:label>
    <link:label id="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_documentation_en-US" xlink:label="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero One Percent Due Two Thousand Twenty Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" xlink:to="lab_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b7c65de-e32a-45d8-beeb-164e27e632e2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e2519bb-5b5e-4375-809c-e0b8ee9f8122_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e3b1f704-c218-4e1d-9f33-3facc68d6a2d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill by reportable segment</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_70f7c1bc-88f5-489c-937c-b06e3f48b544_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_9db90704-c5e6-46a7-9234-5431da0280c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7f60551-90b0-47f7-a800-dad507cc04d2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_bccec277-9314-486c-9df0-a0d6afa468f9_verboseLabel_en-US" xlink:label="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share</link:label>
    <link:label id="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_label_en-US" xlink:label="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period Average Price</link:label>
    <link:label id="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_documentation_en-US" xlink:label="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period Average Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" xlink:href="elv-20221231.xsd#elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" xlink:to="lab_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8c3f867c-ec03-4ed2-b94e-90f6c3ea44cd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of subsidiaries, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_170462e3-5ba4-425a-839f-fef7caa8c58f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level II [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d2f38326-58aa-4e5a-a9a7-70b5a0fcaf0a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_9e10a1b0-5c05-4688-940f-551bd6835561_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_9951014c-1bd6-41f4-a560-bfd032ca79bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_96614cd3-27ce-48bc-9318-818be339538b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b1ab5ef6-9e72-4a1c-a20c-021a5fe78fbc_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount, Total Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets_39f503bd-dc77-48bd-9fad-4758915d0ab8_terseLabel_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and other long-term assets</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets_label_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property And Equipment and Other Long Term Assets</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets_documentation_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property And Equipment and Other Long Term Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" xlink:to="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_f4bb8bff-b1e3-4d69-bbd6-345e294314ce_terseLabel_en-US" xlink:label="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.650% due 2027 [Member]</link:label>
    <link:label id="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_label_en-US" xlink:label="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Five Zero Percent Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label id="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_documentation_en-US" xlink:label="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Five Zero Percent Due Two Thousand Twenty Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" xlink:href="elv-20221231.xsd#elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" xlink:to="lab_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_543659cf-bf57-4145-a7fa-ec2e9df9d88e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_1cb88bc0-b151-45e2-9d92-fbb8fd5785ba_terseLabel_en-US" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</link:label>
    <link:label id="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_label_en-US" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_505ecb7b-1003-47c2-9dc5-30215a243f6d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_72323b08-94ef-437d-934d-cbc9e908892a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_38abf32b-4aad-41dd-abe2-92b34d018d51_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6f8cc16b-cf29-4953-8276-a249d638648f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ConversionPremium_d5bb2fa6-dd4c-4601-b5e4-cbc6ffabf847_terseLabel_en-US" xlink:label="lab_elv_ConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium (%)</link:label>
    <link:label id="lab_elv_ConversionPremium_label_en-US" xlink:label="lab_elv_ConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Premium</link:label>
    <link:label id="lab_elv_ConversionPremium_documentation_en-US" xlink:label="lab_elv_ConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium to the closing market price of common stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ConversionPremium" xlink:href="elv-20221231.xsd#elv_ConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ConversionPremium" xlink:to="lab_elv_ConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_de40a2fb-ee92-494f-a906-9adee89293eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amounts Included In Accumulated Other Comprehensive Loss (Income) That Have Not Been Recognized As Components Of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_f8110963-61a1-4bc0-9bc5-48c567262486_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_7fe7dcaa-4f2c-46da-9dbb-ee310fb37f97_terseLabel_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider fee, percent</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_label_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Patient Protection Affordable Care Act Health Insurance Provider Fee, Percent</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_documentation_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider Fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" xlink:to="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_c829be50-6410-4ef8-865e-0a2fe1934d54_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net medical claims payable, end of year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_214d6ca1-4127-4df4-80e7-e9f7309d8dae_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_3ce721e6-6787-4fd0-92cd-fb931b2f5fe5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization Initiatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_0b5ea36f-1c34-469e-934e-9714d0cc1784_terseLabel_en-US" xlink:label="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact additional paid-in capital in future periods, if recognized</link:label>
    <link:label id="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_label_en-US" xlink:label="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate in future periods, if recognized</link:label>
    <link:label id="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_documentation_en-US" xlink:label="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" xlink:href="elv-20221231.xsd#elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" xlink:to="lab_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_QualityImprovementAndOtherClaimsExpense_7e4cdc70-959c-48e3-a99e-9bfce8c4c06b_terseLabel_en-US" xlink:label="lab_elv_QualityImprovementAndOtherClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality improvement and other claims expense</link:label>
    <link:label id="lab_elv_QualityImprovementAndOtherClaimsExpense_label_en-US" xlink:label="lab_elv_QualityImprovementAndOtherClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Improvement And Other Claims Expense</link:label>
    <link:label id="lab_elv_QualityImprovementAndOtherClaimsExpense_documentation_en-US" xlink:label="lab_elv_QualityImprovementAndOtherClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Improvement And Other Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_QualityImprovementAndOtherClaimsExpense" xlink:href="elv-20221231.xsd#elv_QualityImprovementAndOtherClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_QualityImprovementAndOtherClaimsExpense" xlink:to="lab_elv_QualityImprovementAndOtherClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a572b5b2-f340-4334-b0c7-5c72bbd85397_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate in future periods, if recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_2f7218b7-6dfb-4d6e-964e-a78409362561_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Outstanding Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_54ae8519-88f3-4660-9105-68fcf31fed9b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized in income on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_39b03850-e962-4743-8a14-f51ea6afaf8f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Securities [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionMember_a8076de9-f141-445f-8c15-2d885c2f265d_terseLabel_en-US" xlink:label="lab_us-gaap_OptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options [Member]</link:label>
    <link:label id="lab_us-gaap_OptionMember_label_en-US" xlink:label="lab_us-gaap_OptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Held [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionMember" xlink:to="lab_us-gaap_OptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock_0f09b492-fd7d-44e9-bf8f-8173e5bc8f8a_terseLabel_en-US" xlink:label="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Net Premiums Earned By Segment</link:label>
    <link:label id="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock_label_en-US" xlink:label="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Summary Of Net Premiums Written And Earned By Segment [Table Text Block]</link:label>
    <link:label id="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock_documentation_en-US" xlink:label="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Summary Of Net Premiums Written And Earned By Segment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" xlink:href="elv-20221231.xsd#elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" xlink:to="lab_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_86a0c548-dc7b-4293-ab44-637c7bcdfc33_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_label_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceTextBlock" xlink:to="lab_us-gaap_ReinsuranceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_17542cde-08d9-4fcf-baa9-23b1b766d472_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_fb7ba6b6-22a0-4dee-9529-6a17fdc1113a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_41be8715-02d6-4e06-999e-d59df464ff3c_terseLabel_en-US" xlink:label="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Three Point Three Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_label_en-US" xlink:label="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Three Point Three Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_documentation_en-US" xlink:label="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Three Point Three Zero Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedThreePointThreeZeroPercentageMember" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedThreePointThreeZeroPercentageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InterestRateReceivedThreePointThreeZeroPercentageMember" xlink:to="lab_elv_InterestRateReceivedThreePointThreeZeroPercentageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_40dbbbbe-e0f4-4eb1-a284-8a81d2a188f9_terseLabel_en-US" xlink:label="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]</link:label>
    <link:label id="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_label_en-US" xlink:label="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]</link:label>
    <link:label id="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_documentation_en-US" xlink:label="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net incurred medical claims to benefit expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" xlink:href="elv-20221231.xsd#elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" xlink:to="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CommercialSpecialtyBusinessSegmentMember_461f76e8-975b-467b-94c4-9ef340531825_terseLabel_en-US" xlink:label="lab_elv_CommercialSpecialtyBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Specialty Business [Member]</link:label>
    <link:label id="lab_elv_CommercialSpecialtyBusinessSegmentMember_cc63a835-bf13-4d95-a70d-e1f53c828381_verboseLabel_en-US" xlink:label="lab_elv_CommercialSpecialtyBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Specialty Business Segment [Member]</link:label>
    <link:label id="lab_elv_CommercialSpecialtyBusinessSegmentMember_label_en-US" xlink:label="lab_elv_CommercialSpecialtyBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Specialty Business Segment [Member]</link:label>
    <link:label id="lab_elv_CommercialSpecialtyBusinessSegmentMember_documentation_en-US" xlink:label="lab_elv_CommercialSpecialtyBusinessSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Specialty Business Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CommercialSpecialtyBusinessSegmentMember" xlink:to="lab_elv_CommercialSpecialtyBusinessSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_388a0c75-bbd2-4adb-9056-c2dfaf7d2d90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_11aedcb9-9e6a-4a29-82f1-19670f72a185_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net incurred medical claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_cb8bdf5c-9481-44f5-8dbc-6aa156289370_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net incurred medical claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0e51847d-29b0-4255-a139-b5a2125ec1d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8de662e0-f5a4-468c-b23f-16b82e299203_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fc42d07d-0d60-4b9a-aa7d-f96c7e7934e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains/losses on investments, before reclassification</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_579c8618-fb5e-4d1c-b606-732859889d51_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherContractMember_3399cadd-9b7c-4795-ac61-433f15bd8c22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collars [Member]</link:label>
    <link:label id="lab_us-gaap_OtherContractMember_label_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherContractMember" xlink:to="lab_us-gaap_OtherContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DateDebenturesReedemable_f8abc712-9610-4c89-b14d-bd0cebaf02b6_terseLabel_en-US" xlink:label="lab_elv_DateDebenturesReedemable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date debentures redeemable at our option</link:label>
    <link:label id="lab_elv_DateDebenturesReedemable_label_en-US" xlink:label="lab_elv_DateDebenturesReedemable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Debentures Reedemable</link:label>
    <link:label id="lab_elv_DateDebenturesReedemable_documentation_en-US" xlink:label="lab_elv_DateDebenturesReedemable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DateDebenturesReedemable" xlink:href="elv-20221231.xsd#elv_DateDebenturesReedemable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DateDebenturesReedemable" xlink:to="lab_elv_DateDebenturesReedemable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d5b95755-73b5-4a82-8d38-33f82fd26be9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, Restricted Stock Shares and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2906a4b2-635c-43f5-9c20-479d954a3953_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_37a395ed-77aa-4810-8986-b1f3134cb91b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of registered shares for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedFairValueOfCollateral_8c8cea78-5c28-44c8-8c90-ab7640238269_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedFairValueOfCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned, Fair Value of Collateral</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedFairValueOfCollateral_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedFairValueOfCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned, Fair Value of Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedFairValueOfCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedFairValueOfCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedFairValueOfCollateral" xlink:to="lab_us-gaap_SecuritiesLoanedFairValueOfCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_e2297291-34f6-4a35-907c-e8ac9629590a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Fair Values Determined For the Periods</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_e53b4aa7-933d-4163-a3b0-69f713d9e662_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_Notionalamountterminatedderivatives_4fb704b3-2980-472f-accc-cf89d984258a_terseLabel_en-US" xlink:label="lab_elv_Notionalamountterminatedderivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_elv_Notionalamountterminatedderivatives_label_en-US" xlink:label="lab_elv_Notionalamountterminatedderivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount, terminated derivatives</link:label>
    <link:label id="lab_elv_Notionalamountterminatedderivatives_documentation_en-US" xlink:label="lab_elv_Notionalamountterminatedderivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents notional amount of terminated derivatives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Notionalamountterminatedderivatives" xlink:href="elv-20221231.xsd#elv_Notionalamountterminatedderivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_Notionalamountterminatedderivatives" xlink:to="lab_elv_Notionalamountterminatedderivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_b59786ce-16ee-4c95-aab0-b7ccd1f2d9f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_38790b19-25d3-401a-8cef-3e8417c37e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:to="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_55970bad-0196-4013-b1da-299343c62e3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Security Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAggregatedInvestmentsMember" xlink:to="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3cb1095f-8f8f-45c9-bba5-8a9a7623968a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesHeldAsCollateralAtFairValue_dd503cf9-b815-4c05-a36c-a62f24144729_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesHeldAsCollateralAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities lending collateral</link:label>
    <link:label id="lab_us-gaap_SecuritiesHeldAsCollateralAtFairValue_label_en-US" xlink:label="lab_us-gaap_SecuritiesHeldAsCollateralAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Held as Collateral, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesHeldAsCollateralAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesHeldAsCollateralAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesHeldAsCollateralAtFairValue" xlink:to="lab_us-gaap_SecuritiesHeldAsCollateralAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_6a5fbed7-c852-45d1-b795-ef9151a8c59b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_e0148c16-26e9-46d0-b17f-67b9da48cb5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_78e38f89-bccb-40e5-b19e-d563a786af27_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial (loss) gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_793e09ac-826d-43be-9ad5-4a2b4b98cc6d_terseLabel_en-US" xlink:label="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Plan Assets Excluding Partnership Investments [Member]</link:label>
    <link:label id="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_label_en-US" xlink:label="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Plan Assets Excluding Partnership Investments [Member]</link:label>
    <link:label id="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_documentation_en-US" xlink:label="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Plan Assets excluding Partnership Investments[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" xlink:href="elv-20221231.xsd#elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" xlink:to="lab_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_aae0048c-1db1-42e3-afb4-7a52f376fc7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16b5a84e-2ef1-4fb8-9848-481a637b5ac0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2359729-447a-4c1d-8a14-4ce0c348bc9b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6c8a1a13-0c5a-46a0-9a58-c855718a8ba1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income taxes net of federal tax expense/benefit, amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_25a1b92a-c966-4c41-8e5d-be524170da12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b353df86-5551-4eb1-865c-5867145d37c3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_146bc53d-691a-4701-9c07-73d94b678b91_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_e6051346-743f-44db-845f-6da9419ba564_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Plan Assets, Level III Reconciliation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_MajorProductRevenueBySegmentLineItems_3ed70f40-435f-4695-970f-6df0e8894249_terseLabel_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenue By Segment [Line Items]</link:label>
    <link:label id="lab_elv_MajorProductRevenueBySegmentLineItems_label_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Product Revenue By Segment [Line Items]</link:label>
    <link:label id="lab_elv_MajorProductRevenueBySegmentLineItems_documentation_en-US" xlink:label="lab_elv_MajorProductRevenueBySegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Major Product Revenue By Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentLineItems" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_MajorProductRevenueBySegmentLineItems" xlink:to="lab_elv_MajorProductRevenueBySegmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2c5db489-9a3a-4ad4-92be-e8e80833fd72_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_dccc654e-cd22-4a3d-883e-58e916886ec3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0d5d853c-4001-4270-9702-91de5ce24408_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d38a2e89-51e2-40a9-aa4a-aa1fbb8789e1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_608bd2df-5bc4-487b-8a97-b2e20b106316_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Releases</link:label>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6b78dcc7-da87-4d2e-8e54-f898dd7606c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_f11c143f-11df-45c7-b765-7fd204fea64a_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_d3ba110a-4139-4225-8d64-56b1ce85243a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Values And Gross Unrealized Losses For Fixed Maturity Securities In An Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_1dbb7be5-598b-4673-bdde-c6ac5ce62f18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Unfunded Commitment</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e32c84cb-2f81-49a8-8cd6-5a3e25501ec9_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount at December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AcquisitionYearAxis_4dd40b79-746b-4a82-a92a-7f260d2e69dc_terseLabel_en-US" xlink:label="lab_elv_AcquisitionYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year [Axis]</link:label>
    <link:label id="lab_elv_AcquisitionYearAxis_label_en-US" xlink:label="lab_elv_AcquisitionYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year [Axis]</link:label>
    <link:label id="lab_elv_AcquisitionYearAxis_documentation_en-US" xlink:label="lab_elv_AcquisitionYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearAxis" xlink:href="elv-20221231.xsd#elv_AcquisitionYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AcquisitionYearAxis" xlink:to="lab_elv_AcquisitionYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_7bb1c03e-dfe9-47a6-b589-e276bfcf38cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_0e89b985-6410-4e1b-97f3-664f7b2d8eb8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_403db23d-f594-45de-8265-07f4604ce401_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_5d54145f-66c3-4a3c-906c-df64470ae1a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0ea2c78c-2f9a-453b-9195-9c88bce36b2d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee735367-d416-4c97-89b2-c5616f3632b6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future maturities of debt in 2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_56c0401b-547c-4947-ba83-b30d659a9eef_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ff423d9b-5a60-4257-9784-a3442ec3dcb5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a34c3502-5035-4e88-8017-e8cb83511c11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b6cccf85-ac80-4c5a-bb19-605ef0bdc97d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DefinedBenefitAgeDomain_85ac3621-8a8b-4d83-966c-16cf10e4a4c4_terseLabel_en-US" xlink:label="lab_elv_DefinedBenefitAgeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Age [Domain]</link:label>
    <link:label id="lab_elv_DefinedBenefitAgeDomain_label_en-US" xlink:label="lab_elv_DefinedBenefitAgeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Age [Domain]</link:label>
    <link:label id="lab_elv_DefinedBenefitAgeDomain_documentation_en-US" xlink:label="lab_elv_DefinedBenefitAgeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitAgeDomain" xlink:href="elv-20221231.xsd#elv_DefinedBenefitAgeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DefinedBenefitAgeDomain" xlink:to="lab_elv_DefinedBenefitAgeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7bfae5e7-5384-4672-8ee9-884667a2a4ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_e704a20f-f863-419b-8527-e99c32ad8441_terseLabel_en-US" xlink:label="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.950% due 2022 [Member]</link:label>
    <link:label id="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Nine Five Zero Percent Due Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Nine Five Zero Percent Due Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" xlink:href="elv-20221231.xsd#elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" xlink:to="lab_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8974370d-3c41-4a7d-8dad-2efca5267536_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net earnings of other invested assets</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_92484c3a-40b4-4c48-8ec9-a2eb0b3c4953_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_3470989a-c3ca-4914-ad16-7afc0e07f7ce_terseLabel_en-US" xlink:label="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.500% due 2026 [Member]</link:label>
    <link:label id="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_label_en-US" xlink:label="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Five Zero Zero Percent Due Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Five Zero Zero Percent Due Two Thousand Twenty Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" xlink:href="elv-20221231.xsd#elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" xlink:to="lab_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a131fd6c-7425-446f-998a-a56862db2505_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_e65048c6-db59-4b18-bb9a-d858d503fc81_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities_2426f10f-c8d4-403f-9d71-6414e59b1a75_negatedTerseLabel_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and other policyholder liabilities payable</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities_label_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Medical claims and Other Policyholder liabilities</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities_documentation_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Medical claims and Other Policyholder liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" xlink:to="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5a2e1580-5c9f-48c7-8574-de06d9a155f7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_865b77e6-ae64-4089-aa5f-f2637b85e5a4_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_acff8096-63f6-44cf-b2b9-057cd022ddc2_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAmountOfHedgedItem_5050f1a2-67e4-454e-8c2e-4f7e5ea8b052_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAmountOfHedgedItem" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Hedged Item</link:label>
    <link:label id="lab_us-gaap_DerivativeAmountOfHedgedItem_label_en-US" xlink:label="lab_us-gaap_DerivativeAmountOfHedgedItem" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Hedged Item</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAmountOfHedgedItem" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAmountOfHedgedItem"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAmountOfHedgedItem" xlink:to="lab_us-gaap_DerivativeAmountOfHedgedItem" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_881ab811-5b3c-4cdd-8bca-bba52c333c39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator For Basic And Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2f383cb6-40b8-42a4-b9a8-9239c4b257af_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_865f2c38-c904-4800-b0ef-523ba518e14b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized losses from sales</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnearnedPremiums_b60b4987-210a-4e6f-8439-ecceab720564_verboseLabel_en-US" xlink:label="lab_us-gaap_UnearnedPremiums" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned income</link:label>
    <link:label id="lab_us-gaap_UnearnedPremiums_label_en-US" xlink:label="lab_us-gaap_UnearnedPremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnearnedPremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnearnedPremiums" xlink:to="lab_us-gaap_UnearnedPremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b1aa87bb-6ef3-4cc1-9619-b08d1795a2a4_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_06e9b837-d8b5-494f-a7a4-0d8f5071fc22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefits [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c9774da8-f650-46a0-b13d-8809d0818d09_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2af0922e-e5b7-4ce2-ab27-564fcaa31f63_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7b1b6a4-1120-4f07-9463-a91f417dcd25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_7743969d-fa35-4805-9e87-85479d850503_terseLabel_en-US" xlink:label="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.600% due 2051 [Member]</link:label>
    <link:label id="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_label_en-US" xlink:label="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Zero Percent Due Two Thousand Fifty One [Member]</link:label>
    <link:label id="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_documentation_en-US" xlink:label="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Zero Percent Due Two Thousand Fifty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" xlink:href="elv-20221231.xsd#elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" xlink:to="lab_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_81860159-f8bc-401a-b8ae-cfeff1071161_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_60a984f8-1c26-4eb6-9b66-0ed814ae5ee1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a605a433-5fab-4646-a9d7-c9d4e461e52c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_bc7fec88-c344-47bf-9c1c-44be146d474c_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_addf5310-6085-4e4e-8908-4ec5786a9d17_terseLabel_en-US" xlink:label="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.850%, due 2054 [Member]</link:label>
    <link:label id="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_label_en-US" xlink:label="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Eight Five Zero Percent Due Two Thousand Fifty Four [Member]</link:label>
    <link:label id="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_documentation_en-US" xlink:label="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Eight Five Zero Percent Due Two Thousand Fifty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" xlink:href="elv-20221231.xsd#elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" xlink:to="lab_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_5f208999-c9ae-4514-b7d8-aae66454e32c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance lines other than short duration</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantDescription_cc841841-7b85-4c10-813b-bb3e88a2ea8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantDescription" xlink:to="lab_us-gaap_DebtInstrumentCovenantDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c9d38b13-86aa-4524-abb9-09665f254147_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRollForwardsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRollForwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Roll Forwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRollForwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanRollForwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_b7db2823-2250-45db-80a5-e1339756e60c_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Non-credit component of impairments on investments, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_aea4996d-48f9-4682-9231-e38af0e6c358_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Non-credit component of impairments on investments, Ending Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_80847240-9655-4536-a39f-c05233b2d0e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future maturities of debt in 2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c8a30db-8c44-434d-ad80-18bbdee1ab68_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in carrying amount of gross unrecognized tax benefits from uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_637462b0-91aa-406f-b6b4-2fd8f0674c3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member]</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_48a6d5a5-0f70-4f33-9355-0e41e0787e47_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d64cf6dd-b6f6-4eed-bc04-b9beb851201a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_d744d9bf-1081-44f7-b769-6cfde22990c6_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_484db5ba-c7b0-428d-9aff-d4af8469e42e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_654e2f79-3a4b-4d21-95b3-b9d8ab7b86d8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_2747e8ff-952f-4234-a0ec-bbd30c0ffd9e_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for employee termination costs, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_f3d79d97-777b-438f-87c3-3d738ed59c42_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for employee termination costs, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AuditInformationAbstract_915d5d8b-f5bc-422a-aba7-1a127daae7f8_terseLabel_en-US" xlink:label="lab_elv_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_elv_AuditInformationAbstract_label_en-US" xlink:label="lab_elv_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_elv_AuditInformationAbstract_documentation_en-US" xlink:label="lab_elv_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AuditInformationAbstract" xlink:href="elv-20221231.xsd#elv_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AuditInformationAbstract" xlink:to="lab_elv_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock_3741aec6-22a2-475e-8578-4307c62a61c2_terseLabel_en-US" xlink:label="lab_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Insurance Profits [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock" xlink:to="lab_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_92ca5609-9ba4-44ab-80b9-fb3437a7a2f4_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Purchased and Internally Developed [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldByInsuranceRegulators_5af60de9-6928-4f40-bdec-e3fa03963059_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities on deposit under regulatory requirements</link:label>
    <link:label id="lab_us-gaap_AssetsHeldByInsuranceRegulators_label_en-US" xlink:label="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held by Insurance Regulators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldByInsuranceRegulators" xlink:to="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_329d41ed-8c11-408e-a7f4-3e16d67909c4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral received</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:to="lab_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_3fe00a7d-24ce-4775-9e2a-c019d59ff0fe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and equipment</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_86867b34-506f-4793-83fa-306df325458b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2e4d69a9-d7c6-4972-b72f-e7f3e1503862_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bcf446d2-60b1-4dd0-bd20-152a54a3dc4d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2bd04eb7-a302-43b1-beb8-9f076eb3098f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_b49e9966-7685-431b-9b20-ed18ce1b9929_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense resulting from the stated interest rate</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_4d11f48a-077e-4dc9-8f55-f43c7cfafcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoThousandTwentyOneMember_b78f9023-d6f4-4494-8877-669ad3afb852_terseLabel_en-US" xlink:label="lab_elv_TwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 [Member]</link:label>
    <link:label id="lab_elv_TwoThousandTwentyOneMember_label_en-US" xlink:label="lab_elv_TwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_elv_TwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_elv_TwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyOneMember" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoThousandTwentyOneMember" xlink:to="lab_elv_TwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NumberOfMedicalMembersServed_2c24801f-4553-4e1e-900e-27d2a43854b6_terseLabel_en-US" xlink:label="lab_elv_NumberOfMedicalMembersServed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medical Members Served</link:label>
    <link:label id="lab_elv_NumberOfMedicalMembersServed_label_en-US" xlink:label="lab_elv_NumberOfMedicalMembersServed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medical Members Served</link:label>
    <link:label id="lab_elv_NumberOfMedicalMembersServed_documentation_en-US" xlink:label="lab_elv_NumberOfMedicalMembersServed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of medical members served</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfMedicalMembersServed" xlink:href="elv-20221231.xsd#elv_NumberOfMedicalMembersServed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NumberOfMedicalMembersServed" xlink:to="lab_elv_NumberOfMedicalMembersServed" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SelfFundedReceivablesNet_c1cc32f6-286c-41dd-b1ca-aa2b0d942b41_terseLabel_en-US" xlink:label="lab_elv_SelfFundedReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-funded receivables</link:label>
    <link:label id="lab_elv_SelfFundedReceivablesNet_label_en-US" xlink:label="lab_elv_SelfFundedReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Funded Receivables, Net</link:label>
    <link:label id="lab_elv_SelfFundedReceivablesNet_documentation_en-US" xlink:label="lab_elv_SelfFundedReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SelfFundedReceivablesNet" xlink:href="elv-20221231.xsd#elv_SelfFundedReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SelfFundedReceivablesNet" xlink:to="lab_elv_SelfFundedReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cf7be653-e0f8-4465-b183-5daf6fe4d9f7_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_65e04659-4b25-41ba-899e-d1fa39784441_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TotalExpenses_faa4cf06-9dfe-4697-bd80-592739d47b2b_terseLabel_en-US" xlink:label="lab_elv_TotalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_elv_TotalExpenses_label_en-US" xlink:label="lab_elv_TotalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expenses</link:label>
    <link:label id="lab_elv_TotalExpenses_documentation_en-US" xlink:label="lab_elv_TotalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalExpenses" xlink:href="elv-20221231.xsd#elv_TotalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TotalExpenses" xlink:to="lab_elv_TotalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9a7a49db-85c6-497f-8cf9-109db52956fc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_12300a4d-3712-4a2c-b91e-c1c62868fe44_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0a3de7e4-cae3-4473-b5b6-8c39f26d600e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_d89eae90-16e4-4ac0-8259-339c400c7c88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Maturity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_48cca19d-3a0b-46ea-97e7-1b179a9da4e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_4fd3cf19-b679-476d-998f-4ae29ba5db92_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bc8ef299-711e-4aa9-8512-143c1c83c9fb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6a49936b-15bd-478f-a75c-f1e6d7168b8a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_92d36b38-f5b5-4b5e-8848-51ca336dff33_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_41ec20e4-0141-40e4-8114-c621d8271806_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_81373752-7abd-42ac-bd1d-630dbf9310c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax Benefit (Expense), Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_001d37b6-1146-4efc-8b46-abcf33221433_terseLabel_en-US" xlink:label="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Four Point One Zero One Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_label_en-US" xlink:label="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Four Point One Zero One Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_documentation_en-US" xlink:label="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Four Point One Zero One Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedFourPointOneZeroOnePercentageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" xlink:to="lab_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_76075d0e-f7a6-4612-8f1d-93a01552e241_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NumberOfConsecutiveTradingDays_2230d3a7-5915-4e82-a1b9-d193a026c450_terseLabel_en-US" xlink:label="lab_elv_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days exceeding 130%</link:label>
    <link:label id="lab_elv_NumberOfConsecutiveTradingDays_label_en-US" xlink:label="lab_elv_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Trading Days</link:label>
    <link:label id="lab_elv_NumberOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_elv_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfConsecutiveTradingDays" xlink:href="elv-20221231.xsd#elv_NumberOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NumberOfConsecutiveTradingDays" xlink:to="lab_elv_NumberOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d72bc569-cf7c-419d-adf8-b46bdc2f072f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_LeaseImpairmentMember_63da8b8c-2dff-4179-b0e7-34aa505f25ed_terseLabel_en-US" xlink:label="lab_elv_LeaseImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Impairment and Abandonment [Member]</link:label>
    <link:label id="lab_elv_LeaseImpairmentMember_label_en-US" xlink:label="lab_elv_LeaseImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment [Member]</link:label>
    <link:label id="lab_elv_LeaseImpairmentMember_documentation_en-US" xlink:label="lab_elv_LeaseImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LeaseImpairmentMember" xlink:href="elv-20221231.xsd#elv_LeaseImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_LeaseImpairmentMember" xlink:to="lab_elv_LeaseImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_369ab0e3-b033-4ec7-a842-e9a56bdf7ab2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4cbbaed3-30d2-48fa-b4e2-a54072f1a386_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_98876bb3-f8ab-493a-8de8-86f65a524dbd_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, Municipalities And Political Subdivisions, Tax-Exempt [Member]</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_98693107-fc57-40ed-b039-53d66d7f3f6c_terseLabel_en-US" xlink:label="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense on computer software and leasehold improvements</link:label>
    <link:label id="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_label_en-US" xlink:label="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Expense On Software And Leasehold Improvements</link:label>
    <link:label id="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_documentation_en-US" xlink:label="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For each income statement presented, the amount charged to expense for amortization of capitalized computer software and leasehold improvement costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" xlink:href="elv-20221231.xsd#elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" xlink:to="lab_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_2b13affd-d8f7-4e2e-b8ae-a1b1df8d396a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_03ff1bc8-3eda-4f33-a240-8ecc4c82d482_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_001b8877-1f71-4931-97a0-3b36f2f74413_terseLabel_en-US" xlink:label="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Protection Affordable Care Act Health Insurance Provider Fee, annual amount to be collected by the Government through assessments to all health insurers subject to the fee</link:label>
    <link:label id="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_label_en-US" xlink:label="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Protection Affordable Care Act Health Insurance Provider Fee</link:label>
    <link:label id="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_documentation_en-US" xlink:label="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fee imposed on covered entities engaged in the business of providing health insurance for United States health risks. This fee is imposed by section 9010 of the Patient Protection and Affordable Care Act, as amended. The regulations affect persons engaged in the business of providing health insurance for United States health risks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:href="elv-20221231.xsd#elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:to="lab_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_8b88ab14-14bb-4639-9786-ae7ed2214557_terseLabel_en-US" xlink:label="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of fixed maturity investments that did not produce income</link:label>
    <link:label id="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_label_en-US" xlink:label="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Fixed Maturity Investments That Did Not Produce Income</link:label>
    <link:label id="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_documentation_en-US" xlink:label="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in fixed maturities, mortgage loans on real estate, investment real estate, and other long-term investments that have been non-income producing the for the twelve months preceding the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" xlink:href="elv-20221231.xsd#elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" xlink:to="lab_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_6341735c-7bdd-4757-9532-c0b9d15df6b0_periodStartLabel_en-US" xlink:label="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross medical claims payable, beginning of year</link:label>
    <link:label id="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_99efd34d-cf35-44f2-9451-1d36ca8ee6d8_periodEndLabel_en-US" xlink:label="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross medical claims payable, end of year</link:label>
    <link:label id="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_label_en-US" xlink:label="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Duration Contract Liability For Claims Adjustment Expense</link:label>
    <link:label id="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_documentation_en-US" xlink:label="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:href="elv-20221231.xsd#elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:to="lab_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1dba02dc-83a8-46a9-80b0-dc6ffda8ed29_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IngenioRxSegmentMember_2f79fb45-ca8b-4bca-92ee-0bbb63ba37b1_terseLabel_en-US" xlink:label="lab_elv_IngenioRxSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CarelonRx Segment [Member]</link:label>
    <link:label id="lab_elv_IngenioRxSegmentMember_label_en-US" xlink:label="lab_elv_IngenioRxSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IngenioRx Segment [Member]</link:label>
    <link:label id="lab_elv_IngenioRxSegmentMember_documentation_en-US" xlink:label="lab_elv_IngenioRxSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IngenioRx Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IngenioRxSegmentMember" xlink:to="lab_elv_IngenioRxSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstruments_aab7dca3-a438-4ff1-a057-36b61ec07251_terseLabel_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on financial instruments</link:label>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstruments_6462357f-cebb-4b3d-a3a2-e55415b2d893_negatedTerseLabel_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses (gains) on financial instruments</link:label>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstruments_1f409b81-b88c-4916-a56d-0a3ddfbbbd6d_verboseLabel_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on financial instruments</link:label>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstruments_label_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) on financial instruments</link:label>
    <link:label id="lab_elv_NetGainsLossesOnFinancialInstruments_documentation_en-US" xlink:label="lab_elv_NetGainsLossesOnFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) on financial instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NetGainsLossesOnFinancialInstruments" xlink:to="lab_elv_NetGainsLossesOnFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e56c1787-6495-4b20-b288-a4d5169797fd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f77032b2-524d-4ed2-8aad-b648b45a3ba9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_StockOptionTerm_1eb39322-c343-4c50-835a-21fa8198f778_terseLabel_en-US" xlink:label="lab_elv_StockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option term, years</link:label>
    <link:label id="lab_elv_StockOptionTerm_label_en-US" xlink:label="lab_elv_StockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Term</link:label>
    <link:label id="lab_elv_StockOptionTerm_documentation_en-US" xlink:label="lab_elv_StockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StockOptionTerm" xlink:href="elv-20221231.xsd#elv_StockOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_StockOptionTerm" xlink:to="lab_elv_StockOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OtherProductsMember_b722475c-dac1-4457-ad6a-e926c607407b_terseLabel_en-US" xlink:label="lab_elv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_elv_OtherProductsMember_label_en-US" xlink:label="lab_elv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_elv_OtherProductsMember_documentation_en-US" xlink:label="lab_elv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherProductsMember" xlink:href="elv-20221231.xsd#elv_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OtherProductsMember" xlink:to="lab_elv_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c38ab7ac-9d9d-4bf0-856b-3581eae22768_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level I [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_b86f54fb-5436-42d5-b1cd-3af97e327dd1_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Additional Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAdditionalInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_a7cae04d-fa4c-4773-baae-3a7940a65cad_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities_04319ef4-228d-4525-b0cb-50845bf4825a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-credit component of other-than-temporary impairments on investments, tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Tax, Portion Attributable to Parent, Available-for-Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_83b4de5a-f2cb-4b15-be86-27a853947da9_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_a50bb4c9-150b-41b4-aee5-94ac70660106_terseLabel_en-US" xlink:label="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.350% due 2025 [Member]</link:label>
    <link:label id="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_label_en-US" xlink:label="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Five Zero Percent Due Two Thousand Twenty Five [Member]</link:label>
    <link:label id="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_documentation_en-US" xlink:label="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Five Zero Percent Due Two Thousand Twenty Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" xlink:href="elv-20221231.xsd#elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" xlink:to="lab_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ab57138-3a73-4207-926a-557cb38a43c2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f76021c1-524e-43bc-97a8-cff641f2ba19_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_c3405c4a-4c8a-4689-8af3-955b59d7047a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_7a031584-7b2d-4e97-9314-e80c4e22a7d9_terseLabel_en-US" xlink:label="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.750% due 2033 [Member]</link:label>
    <link:label id="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_label_en-US" xlink:label="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Seven Five Zero Percent Due Two Thousand Thirty Three [Member]</link:label>
    <link:label id="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_documentation_en-US" xlink:label="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Seven Five Zero Percent Due Two Thousand Thirty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" xlink:href="elv-20221231.xsd#elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" xlink:to="lab_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5973034d-21d0-4598-914d-c274312b2d6a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_c2596e0c-addf-43b4-b10c-cbefb2b6218f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred and Paid Claims Development, Net of Reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_1ae4bd36-6371-406a-a1b3-667f0652cd00_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of amortization over the next twelve months for all cash flow hedges</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2b23153-831c-4a84-8b9d-a6ca6b41b38f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_f3292e61-0554-4299-b6ff-ff2593a6bb5b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs related to the internal development of software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a0de0643-67e1-47d8-ac57-463aa6250e37_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4f9f4da0-5df3-4ec5-9068-2d626e7205f2_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_c66bdc2e-f939-4ffd-be98-3056a7d5c8c4_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1bad8436-142b-4928-ab71-7d9da812c3cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_6c124901-e72d-426b-b66e-b5e4a45cd4ef_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net payments attributable to prior years medical claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_73dbdc3f-0f54-48a6-9427-c1ba02fba8ad_terseLabel_en-US" xlink:label="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Five Point Five Zero Percentage</link:label>
    <link:label id="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_label_en-US" xlink:label="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Five Point Five Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_documentation_en-US" xlink:label="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Five Point Five Zero Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedFivePointFiveZeroPercentageMember" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedFivePointFiveZeroPercentageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InterestRateReceivedFivePointFiveZeroPercentageMember" xlink:to="lab_elv_InterestRateReceivedFivePointFiveZeroPercentageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_624939eb-7a23-4cbb-82b5-57d3368967c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturities, amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_c71102eb-2b3a-4f7c-8ab1-d6f34557ac6d_terseLabel_en-US" xlink:label="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-credit component of impairment losses on investments, net of tax</link:label>
    <link:label id="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_label_en-US" xlink:label="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-credit component of impairment losses on investments net of tax</link:label>
    <link:label id="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-credit component of impairment losses on investments, net of tax effect.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" xlink:href="elv-20221231.xsd#elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" xlink:to="lab_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PreMedicareMember_bb86acab-45f9-4d65-a0d4-479e74a594b4_terseLabel_en-US" xlink:label="lab_elv_PreMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Medicare [Member]</link:label>
    <link:label id="lab_elv_PreMedicareMember_label_en-US" xlink:label="lab_elv_PreMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Medicare [Member]</link:label>
    <link:label id="lab_elv_PreMedicareMember_documentation_en-US" xlink:label="lab_elv_PreMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PreMedicareMember" xlink:href="elv-20221231.xsd#elv_PreMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PreMedicareMember" xlink:to="lab_elv_PreMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_dd58fac1-91c0-430d-9e19-1690a4b4e819_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_208d132a-6431-49d9-be5f-d983bd33b5ab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturities, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_528798a4-6757-4356-9e2c-882008902a6c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturity securities, current, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4111d395-3a49-419f-9da1-8fe97d6c59a0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FutureMember_e784c618-5063-4b99-8582-f37b496d5c85_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Futures [Member]</link:label>
    <link:label id="lab_us-gaap_FutureMember_label_en-US" xlink:label="lab_us-gaap_FutureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FutureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FutureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMember" xlink:to="lab_us-gaap_FutureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_416e275d-7216-48f8-bba3-524041db16b9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c02330c5-1775-409b-88f3-c443764077dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Shares and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_126b287a-1cfb-47a2-928c-ddd0b47bc79a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_95255ff2-572f-4bbf-8255-75c92554d1c8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization Initiative Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_84d715e9-d34f-4062-895a-cde569fceb8b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoThousandTwentyMember_5b071130-ee44-48ba-9a47-df621589551c_terseLabel_en-US" xlink:label="lab_elv_TwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 [Member]</link:label>
    <link:label id="lab_elv_TwoThousandTwentyMember_label_en-US" xlink:label="lab_elv_TwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_elv_TwoThousandTwentyMember_documentation_en-US" xlink:label="lab_elv_TwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyMember" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoThousandTwentyMember" xlink:to="lab_elv_TwoThousandTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d8021d24-bbbb-465a-b3a8-33b27cb2e099_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_85f5a0f1-4c95-428e-b836-c07c3856fa0a_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_97ac2f7c-da47-4f36-8783-c5e454ab4467_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b6be3cb1-2ecc-48b9-9d18-f87406059403_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_98186170-58ce-4791-85e1-6c4e701f9839_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OperationalMember_284af661-d4bf-4665-b7dc-e0bada46d5b6_terseLabel_en-US" xlink:label="lab_elv_OperationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational [Member]</link:label>
    <link:label id="lab_elv_OperationalMember_label_en-US" xlink:label="lab_elv_OperationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational [Member]</link:label>
    <link:label id="lab_elv_OperationalMember_documentation_en-US" xlink:label="lab_elv_OperationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperationalMember" xlink:href="elv-20221231.xsd#elv_OperationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OperationalMember" xlink:to="lab_elv_OperationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6bc3a90b-7f71-4774-8387-0453d5b6dd6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions related to tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectPremiumsEarned_ae750af1-87d4-44cb-8d55-74478691e691_terseLabel_en-US" xlink:label="lab_us-gaap_DirectPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct - Premiums earned</link:label>
    <link:label id="lab_us-gaap_DirectPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_DirectPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectPremiumsEarned" xlink:to="lab_us-gaap_DirectPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_103c9326-c162-4aa5-ad1e-968b832ed92f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Categories Of Net Investment Income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeTextBlock" xlink:to="lab_us-gaap_InvestmentIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_11fc51fe-9f7f-40bb-be48-aa89839e2f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:to="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3b7118b3-b965-48ea-abe2-6147cca81fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Pension Benefit Assets and Other Benefit Assets by Asset Category and Level Inputs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_fbceca13-5a3e-4204-909b-002425c6e07e_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_829ed629-1f2a-48cd-bb1b-de7529fab5d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments, Due 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_cb2e78f9-2250-47a3-ba62-1086f2ba9e8b_terseLabel_en-US" xlink:label="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.875%, due 2029 [Member]</link:label>
    <link:label id="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_label_en-US" xlink:label="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Eight Seven Five Percent Due Two Thousand Twenty Nine [Member]</link:label>
    <link:label id="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_documentation_en-US" xlink:label="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Eight Seven Five Percent Due Two Thousand Twenty Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" xlink:href="elv-20221231.xsd#elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" xlink:to="lab_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_172b1f61-37b7-412e-acf3-b27c956dc671_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types Of Debt And Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6e4543bd-4003-46b8-ace2-a02334939783_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d58f405d-3bd1-4770-81d0-46ec9bac39f3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future maturities of debt in 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_6e5b8c14-4569-4f17-9ac8-e246f74e5f6c_terseLabel_en-US" xlink:label="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Two Point Two Five Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_label_en-US" xlink:label="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Two Point Two Five Zero Percentage [Member]</link:label>
    <link:label id="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_documentation_en-US" xlink:label="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Received Two Point Two Five Zero Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" xlink:to="lab_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_a29c7e65-0854-4926-a976-a62829281e84_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TerminationsDomain_b46f5c05-f25b-497d-a04d-86f9c9656ce7_terseLabel_en-US" xlink:label="lab_elv_TerminationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminations [Domain]</link:label>
    <link:label id="lab_elv_TerminationsDomain_label_en-US" xlink:label="lab_elv_TerminationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminations [Domain]</link:label>
    <link:label id="lab_elv_TerminationsDomain_documentation_en-US" xlink:label="lab_elv_TerminationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of derivatives terminated [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TerminationsDomain" xlink:href="elv-20221231.xsd#elv_TerminationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TerminationsDomain" xlink:to="lab_elv_TerminationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtMember_5e76d8c2-6d66-44d2-a230-5ec9174fc196_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Government Securities [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Government Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f9d8de1f-a0a5-4b58-bde2-2259d7d7ff88_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d67fdd0b-2f3f-4789-b671-153fcc2cc14d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dd24312e-b74a-4095-a7eb-ea54ab19edc1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_294104e7-f591-4ab6-8e55-37d214f6810c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Components of Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e937d20c-9097-4871-a57d-cf6dbb89a7dd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_537540cd-422f-4fa7-845b-729fcd7970f2_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturityOvernightMember_e223dacf-4278-4c11-bbae-fe36814acefc_terseLabel_en-US" xlink:label="lab_us-gaap_MaturityOvernightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Overnight [Member]</link:label>
    <link:label id="lab_us-gaap_MaturityOvernightMember_label_en-US" xlink:label="lab_us-gaap_MaturityOvernightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Overnight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturityOvernightMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturityOvernightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturityOvernightMember" xlink:to="lab_us-gaap_MaturityOvernightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c2f05fc9-1187-4c3c-9691-6f8859bfbe97_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_9a37e718-fc2a-4f83-8504-0f0e918c582f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_12dd8219-789d-4fc6-a921-d766f2a4fe9b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_3eb47ab3-7a78-426f-bf07-141717f133e7_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b7d0df61-8a33-4772-9c0f-c650a621967c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c2775b6c-455f-471b-9fc6-ac2fdef7d557_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Optimization Initiatives and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ffd3fec3-43f7-44c3-8ef1-896a54b6eda2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments, Due 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_32a5ca05-b6fa-4f3e-80f6-a705004e8681_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_ea404834-12be-4338-a347-473a769deef6_terseLabel_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_28c686ce-3287-43c1-a5bd-2ced7d43b6a6_verboseLabel_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term FHLB borrowings outstanding</link:label>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_label_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank, Advance, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" xlink:to="lab_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ProductRevenue_3e86927d-42b9-4d79-a982-2c7717718824_terseLabel_en-US" xlink:label="lab_elv_ProductRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_elv_ProductRevenue_label_en-US" xlink:label="lab_elv_ProductRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_elv_ProductRevenue_documentation_en-US" xlink:label="lab_elv_ProductRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue recognized from goods sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ProductRevenue" xlink:href="elv-20221231.xsd#elv_ProductRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ProductRevenue" xlink:to="lab_elv_ProductRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_89f0b595-1216-4995-b0c7-55532d5d2d0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_42ea2c54-55c2-470d-8f8e-4bb170fa096c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_caad04f3-0b71-489b-a027-90113c51a74e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7e02d73c-70f8-497d-8e53-f4b132f77fc7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1c5d0c49-ec88-4347-8cb7-7c9923ce61c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_da4b92b4-beaf-4fbf-912f-687aa85a416e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_27bc8130-24d7-4271-8810-af7bf8a323ee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_542cb7e7-f8a5-4dfc-bf5c-eae9a090aa84_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CapitalContributionToSubsidiaries_21fda80f-afc8-4020-9d29-33c1fd1195d8_terseLabel_en-US" xlink:label="lab_elv_CapitalContributionToSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution to subsidiaries</link:label>
    <link:label id="lab_elv_CapitalContributionToSubsidiaries_label_en-US" xlink:label="lab_elv_CapitalContributionToSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Contribution To Subsidiaries</link:label>
    <link:label id="lab_elv_CapitalContributionToSubsidiaries_documentation_en-US" xlink:label="lab_elv_CapitalContributionToSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution to subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalContributionToSubsidiaries" xlink:href="elv-20221231.xsd#elv_CapitalContributionToSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CapitalContributionToSubsidiaries" xlink:to="lab_elv_CapitalContributionToSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_29dcfeaf-854a-4cad-b8d1-bc97f04ae523_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded medical claims payable, beginning of year</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_a1186108-522d-47c4-8be9-e56633f98f9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded medical claims payable, end of year</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_4b08d7d8-9081-4bd0-a38f-e7e341c78552_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded medical claims payable, end of year</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a96c816a-48f6-4f6d-90cd-041a6fe26cb7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_bd528483-83a4-4738-9054-8883623b7f7d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c2246f4-4a1b-4568-8c07-6d4a82821dae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_08a4049f-58da-4e46-8c04-7c0d63fc7a68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_eefe67a6-e5b3-4df6-b404-e0a9dbbb220b_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_50c6c039-949b-4e1e-81b7-0ca1baedd814_periodStartLabel_en-US" xlink:label="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net medical claims payable, beginning of year</link:label>
    <link:label id="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_f760a20c-f925-436a-96d1-bc28f03cf809_periodEndLabel_en-US" xlink:label="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net medical claims payable, end of year</link:label>
    <link:label id="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_label_en-US" xlink:label="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short duration contract liability for unpaid claims and adjustment expense, Net</link:label>
    <link:label id="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_documentation_en-US" xlink:label="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:href="elv-20221231.xsd#elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:to="lab_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_86ed4ace-95a8-4ae6-b293-ec6f48543422_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_8b39ae9c-1ced-44d0-9ed0-e2ea21573bac_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_76c15fbb-4f89-40f2-b473-b3e2fc3a1b9f_negatedLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Ceded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6481cef6-225a-4e9d-98ed-01d36ff29e60_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities_cf1aa048-1659-4608-9e19-f0a4de03fdf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in bank overdrafts</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Outstanding Checks, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities" xlink:to="lab_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_78cb1c25-4252-405c-b14e-b2c2eef79734_negatedLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized losses for all terminated cash flow hedges included in accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_22b61d7f-77d9-451b-bd8c-ba6a78091957_periodStartLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedges, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_7910634a-462e-42f4-99fc-b3bc166a9bbf_periodEndLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedges, Ending Balance</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_6ea8f0b1-f72f-4d60-bdb1-bbf9bd3761cf_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IndefiniteMember_350961bb-ebc7-4b35-ac47-9b7796abb928_terseLabel_en-US" xlink:label="lab_elv_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Carryforward Period</link:label>
    <link:label id="lab_elv_IndefiniteMember_label_en-US" xlink:label="lab_elv_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_elv_IndefiniteMember_documentation_en-US" xlink:label="lab_elv_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IndefiniteMember" xlink:href="elv-20221231.xsd#elv_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IndefiniteMember" xlink:to="lab_elv_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_aa265b97-6052-46e1-bc3a-f11a7e9ac1a8_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer-related [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0049a0eb-31bd-443d-85e3-225002a692e9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_76b89402-345a-48c7-8b81-3db51ec8ed9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CapitalStockAxis_9eaf834e-4d39-4f4b-b575-63e276ec3b75_terseLabel_en-US" xlink:label="lab_elv_CapitalStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock [Axis]</link:label>
    <link:label id="lab_elv_CapitalStockAxis_label_en-US" xlink:label="lab_elv_CapitalStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock [Axis]</link:label>
    <link:label id="lab_elv_CapitalStockAxis_documentation_en-US" xlink:label="lab_elv_CapitalStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockAxis" xlink:href="elv-20221231.xsd#elv_CapitalStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CapitalStockAxis" xlink:to="lab_elv_CapitalStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_255fc51a-2ce0-4855-866c-a2ea361e5a48_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_19c0d831-f962-468a-97d0-15b3ff608ec1_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory risk-based capital necessary to satisfy regulatory requirements</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_27b76e50-d3ad-4843-9047-c8d5a41dbda3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 - 2032</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InvestmentInSubsidiaries_e88521c1-fbe1-4fd5-9ea0-88c944eba4e8_terseLabel_en-US" xlink:label="lab_elv_InvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in subsidiaries</link:label>
    <link:label id="lab_elv_InvestmentInSubsidiaries_label_en-US" xlink:label="lab_elv_InvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Subsidiaries</link:label>
    <link:label id="lab_elv_InvestmentInSubsidiaries_documentation_en-US" xlink:label="lab_elv_InvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentInSubsidiaries" xlink:href="elv-20221231.xsd#elv_InvestmentInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InvestmentInSubsidiaries" xlink:to="lab_elv_InvestmentInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c56dda51-cd4d-449e-85e3-375d8ec59347_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_2b0d4128-62ef-465f-97a7-37fe32482208_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_b83b9877-12d7-48b1-8d0a-e752525588a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ending Balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_88cc229b-67c6-4b0b-a9c3-c90f24b104d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_3100e082-cdf9-449b-a1c2-724943e7a2e9_terseLabel_en-US" xlink:label="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member]</link:label>
    <link:label id="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_label_en-US" xlink:label="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member]</link:label>
    <link:label id="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_documentation_en-US" xlink:label="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" xlink:href="elv-20221231.xsd#elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" xlink:to="lab_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_7f57e116-164b-4df4-8d21-ae1e69f1a07f_terseLabel_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_label_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:to="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_89feea35-ae47-4161-a6cd-224ac6163b30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a2ca5d64-869e-4bba-be9b-819c876b1efd_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_8297d814-06bf-4b23-826f-5eb016e8854e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefits [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2c23c9e1-2393-4ec3-ac4d-138bbcd2a0f2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_2766c692-0c25-4fe8-ad22-c6a5d6562152_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Price Company Stock</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b11a0512-8ef7-490f-bfd7-7d9cd472c013_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_99f7a924-c6e5-42b0-8949-f3b1cde47872_terseLabel_en-US" xlink:label="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims settlements to be paid from other benefit assets</link:label>
    <link:label id="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_label_en-US" xlink:label="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims settlements to be paid from other benefit assets</link:label>
    <link:label id="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_documentation_en-US" xlink:label="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims settlements to be paid from other benefit assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" xlink:href="elv-20221231.xsd#elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" xlink:to="lab_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract_93dbbb01-83b6-4085-8b44-f763badd9766_terseLabel_en-US" xlink:label="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Net Incurred Medical Claims To Benefit Expense [Abstract]</link:label>
    <link:label id="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract_label_en-US" xlink:label="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Net Incurred Medical Claims To Benefit Expense [Abstract]</link:label>
    <link:label id="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract_documentation_en-US" xlink:label="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Net Incurred Medical Claims To Benefit Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" xlink:href="elv-20221231.xsd#elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" xlink:to="lab_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_f582be72-84b7-49fc-ad0a-3ee163115d57_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Contingent Payment of Principal or Interest</link:label>
    <link:label id="lab_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_label_en-US" xlink:label="lab_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Contingent Payment of Principal or Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:to="lab_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent_89f64918-f15e-41c0-a469-48fc401f89d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturities, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1bc43742-ded1-4508-8fc9-d2d54b885784_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_ae8be6f9-45ce-46d8-90e5-74b3b2a0b04f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_0039efed-f36a-48cc-a86d-36364e0e5859_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7201937d-9260-4efd-8ceb-f5e25e98c08d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_927827b3-c015-491c-a0d2-5728bcda3df6_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_893d0797-1293-4f3a-ad14-2d41a6d7eab7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets, relating to assets still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a0b12502-da83-4c17-879a-b0eba6319a4c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_3f1e538e-f716-4435-86d6-c176fb87b3f6_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets_7c80d856-4585-49f6-a722-df30c6f6d329_terseLabel_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and other current assets</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets_label_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Accounts Receivables and Other Current Assets</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Accounts Receivables and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" xlink:to="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_078bad01-0d8f-4cb6-952c-294599e12b7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Fair Value Of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_GrossLossesFromOtherInvestments_c7125f62-7081-48c0-aa37-1aa05f10a8b4_negatedTerseLabel_en-US" xlink:label="lab_elv_GrossLossesFromOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross losses from other investments</link:label>
    <link:label id="lab_elv_GrossLossesFromOtherInvestments_label_en-US" xlink:label="lab_elv_GrossLossesFromOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Losses From Other Investments</link:label>
    <link:label id="lab_elv_GrossLossesFromOtherInvestments_documentation_en-US" xlink:label="lab_elv_GrossLossesFromOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Losses From Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GrossLossesFromOtherInvestments" xlink:href="elv-20221231.xsd#elv_GrossLossesFromOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_GrossLossesFromOtherInvestments" xlink:to="lab_elv_GrossLossesFromOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_b1994fcf-70b9-4833-be93-af27137b4803_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_2a884025-47d1-48ba-8332-4b2b2d56db75_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_7848f919-75c1-47c8-87d5-3cd1aee676b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains/losses on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_14dafd93-5bd5-49ec-920f-07d144b30ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Securities, 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_f1d80fe2-cbba-4dca-8749-ee5575e8ff0d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_c94ee007-c9b7-4f1b-9552-839f43072352_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_MutualFundsMember_4cbc9d40-66b7-46ae-9119-1071f7a19b4d_terseLabel_en-US" xlink:label="lab_elv_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_elv_MutualFundsMember_label_en-US" xlink:label="lab_elv_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_elv_MutualFundsMember_documentation_en-US" xlink:label="lab_elv_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MutualFundsMember" xlink:href="elv-20221231.xsd#elv_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_MutualFundsMember" xlink:to="lab_elv_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68f6552d-5647-4f47-8963-156b450520ea_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value, 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_57dfbd51-413b-4434-b45b-3fa5e0e3fef4_terseLabel_en-US" xlink:label="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.950%, due 2034 [Member]</link:label>
    <link:label id="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_label_en-US" xlink:label="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Nine Five Zero Percent Due Two Thousand Thirty Four [Member]</link:label>
    <link:label id="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_documentation_en-US" xlink:label="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Nine Five Zero Percent Due two Thousand Thirty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" xlink:href="elv-20221231.xsd#elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" xlink:to="lab_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_9142e31b-19db-4c26-8327-66412849c44e_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Record Date</link:label>
    <link:label id="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_7cb85ee0-07bf-4c52-83df-709f481d061e_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Date of Record</link:label>
    <link:label id="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_label_en-US" xlink:label="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Date of Record</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f4a0b1ce-011a-4337-8423-d3f58912a442_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of other intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_7ea4bdde-2868-4b90-be8c-b8b70b7fa369_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9e89f9e-56a1-4e31-a63c-6609d0720691_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments, Due 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_290e65a2-07c5-4ede-98aa-051da54b4916_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_0922f48a-531c-4553-96af-5ece8351c8a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_4a276878-e723-4ec5-a4e6-eeb92007cd34_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (repayments of) proceeds from commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_9e32095d-a028-497e-ac8d-a2f4e4410db6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (repayments of) proceeds from commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_839a8c50-f48a-4652-8350-240f7ad37917_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_e1a10caa-5016-4deb-9182-5cf95dbbbd5d_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_dce097a8-31c2-4290-bd47-6a83fd1a3c2a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e4ec3f45-23cd-4fff-82a7-c09c3783151c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5f34e753-029b-424f-be6c-684598afd652_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholders' Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_eaa8227a-841d-494c-9dad-0bf6b8cc92b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholders' Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1cfbced3-2de7-4373-acdc-403889633e96_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c22a24dc-85d4-4127-aed0-05c20c9c92f3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAAP equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CommonEquitySecuritiesMember_06482aec-5b0c-43d2-82f8-d1ca9be251e0_terseLabel_en-US" xlink:label="lab_elv_CommonEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Equity Securities [Member]</link:label>
    <link:label id="lab_elv_CommonEquitySecuritiesMember_label_en-US" xlink:label="lab_elv_CommonEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Equity Securities [Member]</link:label>
    <link:label id="lab_elv_CommonEquitySecuritiesMember_documentation_en-US" xlink:label="lab_elv_CommonEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommonEquitySecuritiesMember" xlink:href="elv-20221231.xsd#elv_CommonEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CommonEquitySecuritiesMember" xlink:to="lab_elv_CommonEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5aef5e54-d7d1-41e6-9660-1eec29ce1a22_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_49033a95-5c99-4abb-83f7-785b8ca1834a_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net due to subsidiaries</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_be7a6ff7-c153-4084-86dd-30169647ebcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted-Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_9c4448a8-5ccd-4080-a145-d96e11d791be_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends and dividend equivalents</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesLineItems_c56dc1db-d08e-43ef-ab9a-7c9dd4a83d9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesLineItems_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d794e6f2-f72e-4511-bde8-b4074e5fd0bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_199f6f91-066e-4bdf-b9aa-17207c4ff931_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage-Backed Securities [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d0fdd4e6-5c9a-4175-a911-68c5dbb5402c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, Finite Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_39e442c7-17ac-4576-8739-9a3d22c9b0ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Current [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2e12d0b6-a278-4696-a650-36f19d56a2ac_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Sponsored Securities [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3ed83ac4-c2e7-4523-bf1e-2a1a2020891f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_e9c30b5f-ab2c-454c-8ce5-662d3cf9d116_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_169b888c-793f-48ad-bd50-57fb1776bfed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future maturities of debt in 2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_75e36d17-1421-40ca-9343-c25f41eb814b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_86c2c200-6329-4f0e-807e-6678924a5098_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_57eeb372-8181-47d1-8d74-50144f56d554_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_b856e731-2807-4377-ac62-20acb4190519_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_6311d5be-0936-49c9-850f-f1dc729bb553_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_ce15fb30-d600-4a43-af78-eec16c828bec_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid to subsidiaries</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b1b82277-1de6-480b-b890-ce3a1741f881_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_3371a30e-fc22-4f57-873c-7e0d125be841_terseLabel_en-US" xlink:label="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Direct, Assumed And Ceded Premiums Earned</link:label>
    <link:label id="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_label_en-US" xlink:label="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:to="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_378719c9-7e65-4845-8138-9e03b5a9552a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_A5YearFacilityMember_f9f97450-133d-4d2b-ae1f-b237d32dbb32_terseLabel_en-US" xlink:label="lab_elv_A5YearFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5-Year Facility [Member]</link:label>
    <link:label id="lab_elv_A5YearFacilityMember_label_en-US" xlink:label="lab_elv_A5YearFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5-Year Facility [Member]</link:label>
    <link:label id="lab_elv_A5YearFacilityMember_documentation_en-US" xlink:label="lab_elv_A5YearFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5-Year Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A5YearFacilityMember" xlink:href="elv-20221231.xsd#elv_A5YearFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_A5YearFacilityMember" xlink:to="lab_elv_A5YearFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_13bbf5b6-45af-4244-89c2-525f83c03831_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IntegratedHealthServicesMember_bd8c5fab-90f8-4fea-ba2c-c8a3c7743aa9_terseLabel_en-US" xlink:label="lab_elv_IntegratedHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integrated health services [Member]</link:label>
    <link:label id="lab_elv_IntegratedHealthServicesMember_label_en-US" xlink:label="lab_elv_IntegratedHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integrated health services [Member]</link:label>
    <link:label id="lab_elv_IntegratedHealthServicesMember_documentation_en-US" xlink:label="lab_elv_IntegratedHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integrated health services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntegratedHealthServicesMember" xlink:href="elv-20221231.xsd#elv_IntegratedHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IntegratedHealthServicesMember" xlink:to="lab_elv_IntegratedHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NumberOfCountiesInGeographicalRegionNotServed_2f7e284a-fc5b-453f-998f-82b83b2bb77d_terseLabel_en-US" xlink:label="lab_elv_NumberOfCountiesInGeographicalRegionNotServed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of counties in the Kansas City area the Company does not serve</link:label>
    <link:label id="lab_elv_NumberOfCountiesInGeographicalRegionNotServed_label_en-US" xlink:label="lab_elv_NumberOfCountiesInGeographicalRegionNotServed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfCountiesInGeographicalRegionNotServed</link:label>
    <link:label id="lab_elv_NumberOfCountiesInGeographicalRegionNotServed_documentation_en-US" xlink:label="lab_elv_NumberOfCountiesInGeographicalRegionNotServed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of counties in a geographical region for which services are not provided.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfCountiesInGeographicalRegionNotServed" xlink:href="elv-20221231.xsd#elv_NumberOfCountiesInGeographicalRegionNotServed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NumberOfCountiesInGeographicalRegionNotServed" xlink:to="lab_elv_NumberOfCountiesInGeographicalRegionNotServed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsReceivableAtCarryingValue_33a98e90-1e4f-4188-a43a-94e3cf5b5dc6_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium receivables</link:label>
    <link:label id="lab_us-gaap_PremiumsReceivableAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsReceivableAtCarryingValue" xlink:to="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_c45e0a40-28be-4e0d-99f8-ab6e7b1966ad_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f1f9c3af-5b57-4355-a049-a0b10e8c51ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_61b409bf-0180-4347-a201-b8430c9610b2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_88bcd097-d3bc-42e7-a434-bc023e4ab016_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities_7b002a95-f9af-4199-a3c0-2fa7f3e9a285_negatedTerseLabel_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, CurrentLiabilities, Accounts Payable and Other Current Liabilities</link:label>
    <link:label id="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, CurrentLiabilities, Accounts Payable and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" xlink:to="lab_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8afb936e-98dd-451f-bdaf-a50a9f5ee420_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_531a8718-b6f1-42f9-84b3-f1437d9e1efc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments basis</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3c98471a-945f-4556-a694-fc83b16a407e_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Other Equipment [Member]</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4becebb9-7df9-43a3-a1e3-5f4cf27381ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_d49d306a-39dc-4422-96d5-d6824e092c80_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c807235a-fa35-4c37-84ef-58c4453423ac_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions made to 401k retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d01149fe-5a31-496b-af27-f0f75aebb2a3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8fc31bfa-6326-4dc2-8e57-876f8038057c_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, Indefinite Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4ebd9fcd-680f-4edf-95e1-55959fba0903_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount, Indefinite Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b4a43d62-2729-4bd4-8fda-f6ef505ae03d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DeferredTaxAssetsLeasingArrangements_01db96d0-777c-4407-9006-f5ccf9e57bc0_terseLabel_en-US" xlink:label="lab_elv_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_elv_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_elv_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_elv_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_elv_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax asset attributable to taxable temporary differences from leasing arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxAssetsLeasingArrangements" xlink:href="elv-20221231.xsd#elv_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_elv_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a1419e44-3e9f-4918-aa10-cc7264c52cfa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_8525aaff-72ad-4b92-a40d-69bda8bcb366_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount Included In Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_fb29c819-674e-4936-bccb-b31218fbcad9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized losses included in net income related to assets still held</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_55ab7aee-a78c-43cc-a69e-493c0063836b_terseLabel_en-US" xlink:label="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Department of Managed Health Care Regulated Entities [Member]</link:label>
    <link:label id="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_label_en-US" xlink:label="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Department Of Managed Health Care Regulated Entities [Member]</link:label>
    <link:label id="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_documentation_en-US" xlink:label="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Department of Managed Health Care Regulated Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" xlink:href="elv-20221231.xsd#elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" xlink:to="lab_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_5bc0e18e-3004-4ca7-8e84-a99b5235fa85_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_fe9dea77-22ae-4634-9362-59ec7ba74449_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue_2607d162-7355-4754-a78f-02104b3217bb_negatedTerseLabel_en-US" xlink:label="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue_label_en-US" xlink:label="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Benefits Paid Fair Value</link:label>
    <link:label id="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue_documentation_en-US" xlink:label="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Benefits Paid Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanBenefitsPaidFairValue" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanBenefitsPaidFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DefinedBenefitPlanBenefitsPaidFairValue" xlink:to="lab_elv_DefinedBenefitPlanBenefitsPaidFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_57f13b30-6449-4b67-9d41-c387ab8c4918_terseLabel_en-US" xlink:label="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.550% due 2052 [Member]</link:label>
    <link:label id="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_label_en-US" xlink:label="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Five Zero Due Two Thousand Fifty Two [Member]</link:label>
    <link:label id="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_documentation_en-US" xlink:label="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Five Zero Due Two Thousand Fifty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" xlink:to="lab_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b20b4ee9-006e-47be-8ff1-bbabaf57641b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_4186f88e-f657-4b82-8880-8fbe75dd131e_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Direct</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_b74e500f-bfee-447b-a326-9dce1050d137_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_23a48190-9c55-445f-b860-5b6fc5a11167_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period, Restricted Stock Shares and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e0dce554-f2f1-4df5-96ef-7fcbe76f637d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period, Restricted Stock Shares and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_CapitalStockDomain_2d90938c-d401-4628-9dde-f3f91fa8990f_terseLabel_en-US" xlink:label="lab_elv_CapitalStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock [Domain]</link:label>
    <link:label id="lab_elv_CapitalStockDomain_label_en-US" xlink:label="lab_elv_CapitalStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock [Domain]</link:label>
    <link:label id="lab_elv_CapitalStockDomain_documentation_en-US" xlink:label="lab_elv_CapitalStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockDomain" xlink:href="elv-20221231.xsd#elv_CapitalStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_CapitalStockDomain" xlink:to="lab_elv_CapitalStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_5755d512-64b5-48c7-a7a1-ffabd8e53d65_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_374dc114-50f8-44be-b7b9-71e366f105b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, Finite Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6addc26b-8207-4392-9214-fd15a6e282b2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_35ec8650-6a63-40e0-9f91-cef3c3a72c5a_terseLabel_en-US" xlink:label="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.000%, due 2027 [Member]</link:label>
    <link:label id="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_label_en-US" xlink:label="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nine Point Zero Zero Zero Percent Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label id="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_documentation_en-US" xlink:label="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nine Point Zero Zero Zero Percent Due Two Thousand Twenty Seven [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" xlink:href="elv-20221231.xsd#elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" xlink:to="lab_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_1b79d975-6627-462d-b6b9-2becdbede090_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Claim Year 2022 [Member]</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_f15eb7d2-c38a-4683-9186-10338ea6f288_verboseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed premiums</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsWritten" xlink:to="lab_us-gaap_AssumedPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_523ee432-0e90-4ab1-8955-9fba8b9e482e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax exempt interest and dividends received deduction, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8631239e-086a-4750-a3d9-5f566ec3818f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2fe1ea9-f28a-4409-9db1-a5dfb5e32e53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InvestmentsinequitysecuritiesTableTextBlock_64fc2b56-5fde-4bc7-93f7-dc50f43c6b60_terseLabel_en-US" xlink:label="lab_elv_InvestmentsinequitysecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Securities</link:label>
    <link:label id="lab_elv_InvestmentsinequitysecuritiesTableTextBlock_label_en-US" xlink:label="lab_elv_InvestmentsinequitysecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity securities [Table Text Block]</link:label>
    <link:label id="lab_elv_InvestmentsinequitysecuritiesTableTextBlock_documentation_en-US" xlink:label="lab_elv_InvestmentsinequitysecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentsinequitysecuritiesTableTextBlock" xlink:href="elv-20221231.xsd#elv_InvestmentsinequitysecuritiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InvestmentsinequitysecuritiesTableTextBlock" xlink:to="lab_elv_InvestmentsinequitysecuritiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4661a15f-d39b-4fa1-a0eb-dd7eeaa5ccb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceServicesRevenue_b33f0f24-c755-470e-9c22-0b7f014c76e2_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segments operating revenues</link:label>
    <link:label id="lab_us-gaap_InsuranceServicesRevenue_67d77898-ca4f-4a34-a591-c1879ca65970_verboseLabel_en-US" xlink:label="lab_us-gaap_InsuranceServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue</link:label>
    <link:label id="lab_us-gaap_InsuranceServicesRevenue_label_en-US" xlink:label="lab_us-gaap_InsuranceServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceServicesRevenue" xlink:to="lab_us-gaap_InsuranceServicesRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_7e8a59ef-257d-4b38-97c5-30830daf065f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_b40d655e-fe73-48c5-a597-916e962c7486_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_de232be3-a18f-4fcb-ada1-61df9c4e2a82_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Business Optimization Initiative [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ba5a0074-879a-4edd-9ffd-add4786fa910_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_8152f826-c5e0-4ea0-9089-78a4417a42e2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_876d9343-afe3-44bb-93b7-7463b278fd4a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2561d6fa-5110-493c-b7c8-1b613f47dec8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating gain (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6d249893-b2bc-441b-b5ed-3384a9af850c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segments operating gain</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a8088859-33aa-4355-811d-62909bdc727b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DocumentAndEntityInformationAbstract_e64876d1-4be0-4b03-85e2-8bb7e83595d0_terseLabel_en-US" xlink:label="lab_elv_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_elv_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_elv_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_elv_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_elv_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DocumentAndEntityInformationAbstract" xlink:href="elv-20221231.xsd#elv_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DocumentAndEntityInformationAbstract" xlink:to="lab_elv_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22b0d533-3135-4a1c-b012-22f9613ec7b9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_d229b194-a883-4c12-9668-8a8f198254f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales, maturities, calls and redemptions of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsPercentageAssumedToNet_d2ea57b2-ec8b-4222-88e0-f103b4c06b64_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsPercentageAssumedToNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage - assumed to net premiums - earned</link:label>
    <link:label id="lab_us-gaap_PremiumsPercentageAssumedToNet_label_en-US" xlink:label="lab_us-gaap_PremiumsPercentageAssumedToNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsPercentageAssumedToNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsPercentageAssumedToNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsPercentageAssumedToNet" xlink:to="lab_us-gaap_PremiumsPercentageAssumedToNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3921fc65-4a68-4734-9e54-16f242cb6837_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_81f299a6-87a3-41f1-ab66-0fec6d1952ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OtherSeniorUnsecuredNotesMember_21d238c1-ff45-42b6-ba44-4d4b8c1f587c_terseLabel_en-US" xlink:label="lab_elv_OtherSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other senior unsecured notes [Member]</link:label>
    <link:label id="lab_elv_OtherSeniorUnsecuredNotesMember_label_en-US" xlink:label="lab_elv_OtherSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other senior unsecured notes [Member]</link:label>
    <link:label id="lab_elv_OtherSeniorUnsecuredNotesMember_documentation_en-US" xlink:label="lab_elv_OtherSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other senior unsecured notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSeniorUnsecuredNotesMember" xlink:href="elv-20221231.xsd#elv_OtherSeniorUnsecuredNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OtherSeniorUnsecuredNotesMember" xlink:to="lab_elv_OtherSeniorUnsecuredNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_MedicalClaimsPayableAbstract_e74f5fbf-0526-4ff4-88d0-fa3b58cada5a_terseLabel_en-US" xlink:label="lab_elv_MedicalClaimsPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable [Abstract]</link:label>
    <link:label id="lab_elv_MedicalClaimsPayableAbstract_label_en-US" xlink:label="lab_elv_MedicalClaimsPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable [Abstract]</link:label>
    <link:label id="lab_elv_MedicalClaimsPayableAbstract_documentation_en-US" xlink:label="lab_elv_MedicalClaimsPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MedicalClaimsPayableAbstract" xlink:href="elv-20221231.xsd#elv_MedicalClaimsPayableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_MedicalClaimsPayableAbstract" xlink:to="lab_elv_MedicalClaimsPayableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_008393fd-e2fb-4201-8fcb-85a36d7f1c94_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Gain (Loss) Recognized</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_22abd2d3-b94d-4cbc-b0f7-f9ce6cd593f0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f28743ee-be4f-4fb1-94fa-fe62bd6ace87_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be05b81c-2ece-4dc8-abf2-9afecc83694b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_7925959b-9359-4de9-8f2b-40455b8cf8c1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Crediting Rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue_e7fdc48c-69a0-4b16-ab51-90ad79c241e7_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral received for securities loaned, at carrying value</link:label>
    <link:label id="lab_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Received for Securities Loaned, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue" xlink:to="lab_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_21a52ba5-6612-4c8b-8f29-3f6c801c5a50_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6b63c052-bfd7-4ea6-b534-7cb62e39344f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments, Due 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_cccd4e9d-92bb-4eee-9136-a2076f324689_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b908b444-aab3-4794-b32d-4ea64cc9901a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a6006c17-b847-4274-850a-b8451fa35b91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate number of performance restricted stock units granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_0fb45ab0-ac47-4401-a6aa-3e3f7a77b10d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock option exercises and disqualifying dispositions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Expense from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:to="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d444ba8a-82f5-4c6b-8e26-ff862168ba5b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid In Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_46b3f2bd-40b7-47f5-b0f3-13564f418831_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of property and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_23f33d0e-7a01-4f27-a7b2-84e18898cf96_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Medicaid Licenses [Member]</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_05781612-dafa-409f-9394-1cdbe39ef24c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_21e95417-01e6-4927-9372-6205c36d3fb3_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4e8b5b66-225b-4f08-9005-23785d3114bd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3d342dd1-f7cc-4945-8c91-cdcaf1659040_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c4b734c8-a4cf-425d-97e3-ea7134cc8466_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b169c3e-df82-4ce0-9bfc-b72254a08610_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_8d3bcfd2-b68a-44a4-b201-01c61e9f9184_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_069bd4df-637a-49fb-95ff-01387ec6752b_terseLabel_en-US" xlink:label="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.375%, due 2037 [Member]</link:label>
    <link:label id="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_label_en-US" xlink:label="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Due Two Thousand Thirty Seven [Member]</link:label>
    <link:label id="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_documentation_en-US" xlink:label="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Due Two thousand Thirty seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" xlink:href="elv-20221231.xsd#elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" xlink:to="lab_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_1d6d8285-b6d7-487c-b5cc-9707ed3cd14b_terseLabel_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider fee, amount</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_ab18cf26-81e1-4930-a78a-8890265a8ab1_verboseLabel_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_label_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_documentation_en-US" xlink:label="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider fee payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:to="lab_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_932fcc44-2fc2-4904-a8bd-d35e7ddf82a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_95883679-3bc9-4e4e-a9e0-f479311a7871_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_7c8dfd9a-1079-4d6c-afc0-024c4def6772_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_a95ed83b-60eb-4944-9c3a-15f138f21059_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Long-term Fixed Maturity Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_8bd2fa15-597d-4452-bb72-c434407369b0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Dividend per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b0756723-44f9-4da8-af73-f5ffbe3c4cfd_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AcquisitionYearDomain_710a112e-3c64-469a-a207-30469fc0b88b_terseLabel_en-US" xlink:label="lab_elv_AcquisitionYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year [Domain]</link:label>
    <link:label id="lab_elv_AcquisitionYearDomain_label_en-US" xlink:label="lab_elv_AcquisitionYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year [Domain]</link:label>
    <link:label id="lab_elv_AcquisitionYearDomain_documentation_en-US" xlink:label="lab_elv_AcquisitionYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearDomain" xlink:href="elv-20221231.xsd#elv_AcquisitionYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AcquisitionYearDomain" xlink:to="lab_elv_AcquisitionYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties_126b2449-6804-43e3-97ec-dadd2f42c8a9_terseLabel_en-US" xlink:label="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of note to subsidiary</link:label>
    <link:label id="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Origination of Notes Receivable from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:to="lab_us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantCompliance_64c65267-cacd-475a-9825-8d9ff8d46372_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantCompliance_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantCompliance" xlink:to="lab_us-gaap_DebtInstrumentCovenantCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock_abc883fe-35ee-42bb-8314-f4b8e1da53a3_terseLabel_en-US" xlink:label="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Incurred Medical Claims to Benefit Expense</link:label>
    <link:label id="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock_label_en-US" xlink:label="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block]</link:label>
    <link:label id="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock_documentation_en-US" xlink:label="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" xlink:href="elv-20221231.xsd#elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" xlink:to="lab_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDividendsPaidToParentCompany_1c28213e-8404-4512-b801-cb768a8dc057_terseLabel_en-US" xlink:label="lab_us-gaap_CashDividendsPaidToParentCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends received from subsidiaries</link:label>
    <link:label id="lab_us-gaap_CashDividendsPaidToParentCompany_label_en-US" xlink:label="lab_us-gaap_CashDividendsPaidToParentCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Subsidiaries and Equity Method Investees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompany" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDividendsPaidToParentCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDividendsPaidToParentCompany" xlink:to="lab_us-gaap_CashDividendsPaidToParentCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_5933a5e2-d430-40b3-abd3-46f0da1ec4fc_terseLabel_en-US" xlink:label="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.0450% due 2023 [Member]</link:label>
    <link:label id="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Four Five Zero Percent Due Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Four Five Zero Percent Due Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" xlink:href="elv-20221231.xsd#elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" xlink:to="lab_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet_f0532c0b-090c-4358-87a2-f6273d6ba1b9_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) per diluted share</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both, Earnings Per Share Impact, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet" xlink:to="lab_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67b26192-2692-4f70-819f-2b880dd1f252_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81d4abd3-43da-4944-86cd-bd29f1d4adcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock and stock awards granted during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_154ba1d0-5c61-4815-a946-26cf989892f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_b6166134-b83e-4800-9641-f0af42a9d640_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Debentures [Member]</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityDescription_7580a940-8fe3-4f5a-aaac-4817c9d3d862_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Description</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityDescription_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityDescription" xlink:to="lab_us-gaap_LineOfCreditFacilityDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f206d139-81fb-4902-8923-d8ec2e0f8b87_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_ff0591dd-5596-47ad-9ebb-3524ceadb7ee_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit change reasonably possible due to tax settlements - lower amount</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45003811-69e9-4f48-adc7-8ebdf009199d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cb702f61-ca93-4820-ac5c-37ae4431259e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed70350f-6b17-4dae-b9d5-8412c2c6a748_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_8e176372-5323-491e-9f32-333ef7c5e941_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment as of December 31</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9a93e412-eadc-429c-a4e8-3084636a60c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_86816237-6c65-4c5a-848b-b230a267d7ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DebtConversionDebtPrincipalAmount_7f37019f-c962-4f71-b17a-81a8823c9128_terseLabel_en-US" xlink:label="lab_elv_DebtConversionDebtPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of convertible debentures surrendered for conversion</link:label>
    <link:label id="lab_elv_DebtConversionDebtPrincipalAmount_label_en-US" xlink:label="lab_elv_DebtConversionDebtPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Debt Principal Amount</link:label>
    <link:label id="lab_elv_DebtConversionDebtPrincipalAmount_documentation_en-US" xlink:label="lab_elv_DebtConversionDebtPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate principal amount of the original debt instrument that was surrendered for conversion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DebtConversionDebtPrincipalAmount" xlink:href="elv-20221231.xsd#elv_DebtConversionDebtPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DebtConversionDebtPrincipalAmount" xlink:to="lab_elv_DebtConversionDebtPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_0f049992-bf89-40e5-ae9d-100979623ae5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges, holding gain (loss), tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_5bbd0598-ccb3-4b6d-8798-cba06913841d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4c2ab56d-8c19-43fc-a8a4-1868f6814b50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e559765a-c2fd-447d-b748-17ad0e2c6e01_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_11cbd522-6887-44fd-b4fb-abc76023abfd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_483eccc9-5f03-44ec-bd93-bc12f39fcfcb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_33b5c617-a31d-46aa-b2d8-2015188a9a65_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AnthemInc.v.ExpressScriptsInc.Member_9df2ee08-e5b7-49fb-8096-03ddf0c8ec91_terseLabel_en-US" xlink:label="lab_elv_AnthemInc.v.ExpressScriptsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anthem, Inc. v. Express Scripts, Inc. [Member]</link:label>
    <link:label id="lab_elv_AnthemInc.v.ExpressScriptsInc.Member_label_en-US" xlink:label="lab_elv_AnthemInc.v.ExpressScriptsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anthem, Inc. v. Express Scripts, Inc. [Member]</link:label>
    <link:label id="lab_elv_AnthemInc.v.ExpressScriptsInc.Member_documentation_en-US" xlink:label="lab_elv_AnthemInc.v.ExpressScriptsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anthem, Inc. v. Express Scripts, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AnthemInc.v.ExpressScriptsInc.Member" xlink:href="elv-20221231.xsd#elv_AnthemInc.v.ExpressScriptsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AnthemInc.v.ExpressScriptsInc.Member" xlink:to="lab_elv_AnthemInc.v.ExpressScriptsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_c5e5b5c6-89e8-4573-bf4c-7ff580f8935f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5e8fda16-ebd9-4119-ac2e-b45791e09063_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c8ac30fe-6ac1-4ffb-adff-3188dcb99654_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_8c03fd60-0106-4678-87e9-3ee5319512d7_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parental Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_077d0ab0-e05e-40e1-86d9-6c3c04a460c4_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_Fairvaluehedgescumulativebasisadjustments_f25ae018-7106-4ebf-8eb3-87d702dc6c94_negatedTerseLabel_en-US" xlink:label="lab_elv_Fairvaluehedgescumulativebasisadjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative basis adjustments for fair value hedges</link:label>
    <link:label id="lab_elv_Fairvaluehedgescumulativebasisadjustments_label_en-US" xlink:label="lab_elv_Fairvaluehedgescumulativebasisadjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges, cumulative basis adjustments</link:label>
    <link:label id="lab_elv_Fairvaluehedgescumulativebasisadjustments_documentation_en-US" xlink:label="lab_elv_Fairvaluehedgescumulativebasisadjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative basis adjustments for fair value hedges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Fairvaluehedgescumulativebasisadjustments" xlink:href="elv-20221231.xsd#elv_Fairvaluehedgescumulativebasisadjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_Fairvaluehedgescumulativebasisadjustments" xlink:to="lab_elv_Fairvaluehedgescumulativebasisadjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_678b78a9-370f-416d-bcaa-9261c50ddb9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Claims Development To The Claims Liability</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_31e57371-bb20-4b14-a37e-eafd3d2d6416_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Data By Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_bcbbfe0a-0c8e-4773-b7e8-b7de3e294570_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of property and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2e4f07b1-2caa-4b99-88d1-819c533c3fc2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_1e5d0293-7824-401a-8d4b-2f8bc33abed6_terseLabel_en-US" xlink:label="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis adjustments from recent acquisitions, percent</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_label_en-US" xlink:label="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Recent Acquisitions, percent</link:label>
    <link:label id="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_documentation_en-US" xlink:label="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) resulting from basis adjustments due to recent acquistions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" xlink:to="lab_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_24c07594-a06d-4fe7-a49b-f4790b80b227_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_label_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_37249591-1bdb-46d0-b758-03b5489baa89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_fe6c354f-0964-419b-85fa-c3ddacf33225_terseLabel_en-US" xlink:label="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.650%, due 2043 [Member]</link:label>
    <link:label id="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_label_en-US" xlink:label="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Five Zero Percent Due Two Thousand Forty Three [Member]</link:label>
    <link:label id="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_documentation_en-US" xlink:label="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" xlink:href="elv-20221231.xsd#elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" xlink:to="lab_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6675cbae-b701-462e-8a60-9b10311669e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoThousandEighteenMember_c93cf707-9146-4893-a23d-c8db7c461992_terseLabel_en-US" xlink:label="lab_elv_TwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 [Member]</link:label>
    <link:label id="lab_elv_TwoThousandEighteenMember_label_en-US" xlink:label="lab_elv_TwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen [Member]</link:label>
    <link:label id="lab_elv_TwoThousandEighteenMember_documentation_en-US" xlink:label="lab_elv_TwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandEighteenMember" xlink:href="elv-20221231.xsd#elv_TwoThousandEighteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoThousandEighteenMember" xlink:to="lab_elv_TwoThousandEighteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodEndDate_b8d2f0dd-0066-45e2-86ff-5f455abbd858_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period, End Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodEndDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period, End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_277fa3eb-ca2c-435b-bd9b-f22b849d50e4_terseLabel_en-US" xlink:label="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities/other assets/other liabilities [Member]</link:label>
    <link:label id="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_label_en-US" xlink:label="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities/other assets/other liabilities [Member]</link:label>
    <link:label id="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_documentation_en-US" xlink:label="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities/other assets/other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" xlink:href="elv-20221231.xsd#elv_EquitySecuritiesotherAssetsotherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" xlink:to="lab_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c518395a-9da1-421f-89ba-fb10411ad470_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount at statutory rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_11543269-fa7b-486d-87d6-d07920f248eb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Termination [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_470ab084-09ed-4941-9acf-3279fe9784f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_e170b0b9-c207-4149-b11f-761503c2dd34_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_label_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableAmountPerShare" xlink:to="lab_us-gaap_DividendsPayableAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a7da7758-f8d9-496d-9489-34b493e1e500_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3ff1592b-6900-43b0-b06a-41c0359bcdd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_6fe88143-b055-400f-b6f5-38a09eced1a7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits_01bb82cd-17f8-444f-988f-428395c3e79d_terseLabel_en-US" xlink:label="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement assets</link:label>
    <link:label id="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits_label_en-US" xlink:label="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax liabilities, Deferred Expense, Retirement benefits</link:label>
    <link:label id="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits_documentation_en-US" xlink:label="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax liabilities, Deferred Expense, Retirement benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" xlink:href="elv-20221231.xsd#elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" xlink:to="lab_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f89ac94-bbd2-4fa0-8caf-8ac996f2a295_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6adc7f0a-a533-4921-93f3-a82120ed5da1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral_e55d4b20-1a02-4820-8196-fc4532cd4524_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_03c0ed48-1ced-4b34-9ef0-eedd43cb8d5d_terseLabel_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a66d403e-430c-4238-8ec1-1dd677ff2a40_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income taxes net of federal tax expense/benefit, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_75e9d305-f227-47bd-8641-736ac53d3992_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_c76f1ca0-eb7d-423b-801c-49f36a8b0f3f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_79c6361e-4ccf-4d95-9ea3-c1e68dea0ee8_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68ddc595-3e60-426a-99ea-a06d23d98fb6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_400fdfb2-12cc-41cf-94b5-23bb49002c82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cb5f2385-2b7a-4ecd-a9be-38a2b74f3313_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_f318ec3f-baae-4c25-8805-50fe7b47f667_terseLabel_en-US" xlink:label="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% due 2053 [Member]</link:label>
    <link:label id="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_label_en-US" xlink:label="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Two Five Percent Due Two Thousand Fifty Three [Member]</link:label>
    <link:label id="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_documentation_en-US" xlink:label="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Two Five Percent Due Two Thousand Fifty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" xlink:href="elv-20221231.xsd#elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" xlink:to="lab_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PerformancemeasurementperiodAxis_692932f7-a8ad-463f-92ed-41dd311fa46c_terseLabel_en-US" xlink:label="lab_elv_PerformancemeasurementperiodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period [Axis]</link:label>
    <link:label id="lab_elv_PerformancemeasurementperiodAxis_label_en-US" xlink:label="lab_elv_PerformancemeasurementperiodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period [Axis]</link:label>
    <link:label id="lab_elv_PerformancemeasurementperiodAxis_documentation_en-US" xlink:label="lab_elv_PerformancemeasurementperiodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodAxis" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PerformancemeasurementperiodAxis" xlink:to="lab_elv_PerformancemeasurementperiodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LatestTaxYearMember_c11780a3-a809-4777-95ef-d9d9e0f813a5_terseLabel_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:label id="lab_us-gaap_LatestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_033df425-d67d-4f9e-8c82-4dd2ee23197d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_6ee35f5d-fc78-4905-bb2c-87d157d8643a_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_143f17b0-9e28-4d61-a201-80cda184b14c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_MeasurementPeriod_1bbb0293-bc0e-4c19-b003-8b3cf30430a6_terseLabel_en-US" xlink:label="lab_elv_MeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period for testing</link:label>
    <link:label id="lab_elv_MeasurementPeriod_label_en-US" xlink:label="lab_elv_MeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period</link:label>
    <link:label id="lab_elv_MeasurementPeriod_documentation_en-US" xlink:label="lab_elv_MeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MeasurementPeriod" xlink:href="elv-20221231.xsd#elv_MeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_MeasurementPeriod" xlink:to="lab_elv_MeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_7dae7052-de2b-4cb7-bc49-bd004b3d1d60_terseLabel_en-US" xlink:label="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125%, due 2022 [Member]</link:label>
    <link:label id="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Due Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Due Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" xlink:to="lab_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a3e6f0e-e08f-4933-bc2d-d0ca1cd43413_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Restricted Stock Shares and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_4abc5253-8933-452e-b613-9b59806abfc0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f7fb6cc8-ef6b-420b-b260-2b14eaddc754_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_803e4d42-31e3-47f6-bbee-a1600f56e6b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claim Year 2021 [Member]</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_07924fc9-0d34-4d2b-8f0d-11cfd878e01f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f8c68e9-dc8d-4784-a2a4-006058de8821_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_a8cc1ce8-96b1-478f-914c-3236867ab816_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Loss, Statement of Income or Comprehensive Income Location</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_1b255b10-83c1-406b-ae1d-8e00db258f56_terseLabel_en-US" xlink:label="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.550% due 2031 [Member]</link:label>
    <link:label id="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_label_en-US" xlink:label="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Five Five Zero Percent Due Two Thousand Thirty One [Member]</link:label>
    <link:label id="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_documentation_en-US" xlink:label="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Five Five Zero Percent Due Two Thousand Thirty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" xlink:href="elv-20221231.xsd#elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" xlink:to="lab_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_1d83fda1-3dd6-40aa-9c38-8b7c2a052eb6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year in which ultimate trend rate reached</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_837a26ec-91d9-4c3f-ae25-47fff6ad976e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_525fabe4-f018-4f8b-ac24-ffc56b5164b9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e65cac4-34ff-4a54-9c2f-eafcbf413333_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d5f922c-0aeb-4bd3-9355-8f1758221d17_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_07e14692-6bef-451b-9110-103a4a80d852_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionDescription_7b928a79-bbfe-4da1-a412-4dcf550db479_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:to="lab_us-gaap_DebtInstrumentRedemptionDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_d96d6c6c-7722-4334-83f2-9dbf0498b2b9_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net due from subsidiaries</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_af9820b5-24e3-45c8-b8da-0b48dbf1d047_verboseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from subsidiaries</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_a406bd85-1175-4842-946c-3093676a21e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_4a37c40e-a1b4-4e84-b747-94b97dba5d64_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Compensation Plan [Member]</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_3abf0e04-b079-4c97-8160-d244def13a97_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_label_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9cc0ba64-f91f-417a-955c-17f2f8747348_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_b68337a5-6d2a-4ba9-91be-8f1c51439475_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_45b32b0e-67b3-40cf-9781-595ec07ec705_terseLabel_en-US" xlink:label="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of stock employees are permitted to purchase per calender year (whole dollars)</link:label>
    <link:label id="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_label_en-US" xlink:label="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Amount</link:label>
    <link:label id="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_documentation_en-US" xlink:label="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" xlink:href="elv-20221231.xsd#elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" xlink:to="lab_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_dec9b5b4-d9d1-4b16-8444-8b55532abcf0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity date on long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_80792cff-85d2-4160-9599-2c1c771d9eb4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_9f67dfbd-5574-45f9-92b8-6fcac85bb6ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_80139dd8-4eeb-41da-9064-fcd55fb4d0c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_08229e4d-5ce2-4239-ad2d-9918e7ecf774_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends per share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a91d603f-3873-46bf-88a7-416b53866cb1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6713e26a-8aaa-4635-9015-e64437e351d5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount, Finite Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_4f36107e-9e76-4313-a6a6-69ec7efada94_verboseLabel_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims Payable</link:label>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:to="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_BusinessOptimizationInitiativesAbstract_label_en-US" xlink:label="lab_elv_BusinessOptimizationInitiativesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization Initiatives [Abstract]</link:label>
    <link:label id="lab_elv_BusinessOptimizationInitiativesAbstract_documentation_en-US" xlink:label="lab_elv_BusinessOptimizationInitiativesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessOptimizationInitiativesAbstract" xlink:href="elv-20221231.xsd#elv_BusinessOptimizationInitiativesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_BusinessOptimizationInitiativesAbstract" xlink:to="lab_elv_BusinessOptimizationInitiativesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_088c8c64-5801-47ab-a03e-4fd28272c5d6_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_fbe67242-e2a3-47c7-af57-294b70e872ea_totalLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_2c5adb98-5841-427e-a860-2b87aec17e9b_verboseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned Net</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1d636601-d91b-44ff-8f01-21d1f09d62a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_dafec5e4-474e-42df-984d-5ea2f3d5a695_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8891b412-531a-4ccd-80e9-ace023a6ecec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c94487c8-f0be-462d-bdcc-49cab4b4fff4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_dabbdbd0-ee87-41d2-8501-d190d4092ad2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense resulting from amortization of the debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1323ebdb-f31c-4351-880e-beb23e17306a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d710fe-0a2b-4806-a9f9-bed93fbc4dac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_89928489-cfad-4aa5-a3cc-b534509d5965_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f984c3de-ec57-4f7a-86d0-5e3ba5815280_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e9f6937e-70ca-4cd5-979c-75e441c2f1a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoThousandTwentyTwoMember_85b848d2-6343-44a0-8cef-c36f554b93f8_terseLabel_en-US" xlink:label="lab_elv_TwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 [Member]</link:label>
    <link:label id="lab_elv_TwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_elv_TwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_elv_TwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_elv_TwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyTwoMember" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoThousandTwentyTwoMember" xlink:to="lab_elv_TwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_579fd01b-f046-45a7-9bc5-80ac00650935_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock plans, net of related tax benefits (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2c67f9bd-20d6-46c0-b51b-f09a65a80cef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f4aa7e89-c575-4899-a875-b86a9bcd70a9_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Government Securities [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c4b9e923-dc89-4af0-a752-e9df2213e8d4_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Government Securities [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SegmentEliminationsMember_705e7aa0-b483-4b56-a722-34a02e98282e_terseLabel_en-US" xlink:label="lab_elv_SegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Eliminations [Member]</link:label>
    <link:label id="lab_elv_SegmentEliminationsMember_label_en-US" xlink:label="lab_elv_SegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Eliminations [Member]</link:label>
    <link:label id="lab_elv_SegmentEliminationsMember_documentation_en-US" xlink:label="lab_elv_SegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SegmentEliminationsMember" xlink:href="elv-20221231.xsd#elv_SegmentEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SegmentEliminationsMember" xlink:to="lab_elv_SegmentEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b4ab0ba9-3622-403a-8233-bb685cd9b033_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_DataProcessingEquipmentAndSoftwareMember_5d08773a-ef83-41a4-be1c-c4a825881fb2_verboseLabel_en-US" xlink:label="lab_elv_DataProcessingEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment, Furniture and Other Equipment [Member]</link:label>
    <link:label id="lab_elv_DataProcessingEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_elv_DataProcessingEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Data Processing Equipment And Software [Member]</link:label>
    <link:label id="lab_elv_DataProcessingEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_elv_DataProcessingEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Data Processing Equipment and Computer Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DataProcessingEquipmentAndSoftwareMember" xlink:href="elv-20221231.xsd#elv_DataProcessingEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_DataProcessingEquipmentAndSoftwareMember" xlink:to="lab_elv_DataProcessingEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_5207f0b5-7a2c-4bcc-8769-799bc5584b9d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ultimate health care cost trend rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_47de3f2c-d680-4601-aff0-55db2eb14a27_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_996c54fd-0ad4-4ffe-87a9-3d8e4cd7e8de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Gain (Loss) Recognized</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_af40f2b9-14b3-4b42-8d7f-447dc9ebec27_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a33a12fd-3004-49ef-963c-e77c79cd71b4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost or Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_535ab65b-33dc-48d4-b4c4-7889914d28b0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4c9673e4-c228-4f93-99ad-23755f5e8d1b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale fixed maturity securities investments, current, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleEarliestDate1_ac7860b7-5364-4b23-8b1a-c5be5d848a1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleEarliestDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Date for Conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleEarliestDate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleEarliestDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Earliest Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleEarliestDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleEarliestDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleEarliestDate1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleEarliestDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_AcquisitionYearPriorDomain_74afba69-6d1d-4c43-bc98-756ae2a4354d_terseLabel_en-US" xlink:label="lab_elv_AcquisitionYearPriorDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year, Prior Year</link:label>
    <link:label id="lab_elv_AcquisitionYearPriorDomain_label_en-US" xlink:label="lab_elv_AcquisitionYearPriorDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year, Prior [Domain]</link:label>
    <link:label id="lab_elv_AcquisitionYearPriorDomain_documentation_en-US" xlink:label="lab_elv_AcquisitionYearPriorDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Year, Prior</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearPriorDomain" xlink:href="elv-20221231.xsd#elv_AcquisitionYearPriorDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_AcquisitionYearPriorDomain" xlink:to="lab_elv_AcquisitionYearPriorDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_aa1096c9-2572-4fb8-9b7e-cd09be20a596_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets relating to:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_64fdd683-5088-484f-aab8-bd119e321a42_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_label_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c7ab62e8-ca1e-4dfa-8afd-68227ea193e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_HealthInsuranceProviderFeePolicyTextBlock_54c8c2ae-86c1-4b4d-8566-9e963d2e7cef_terseLabel_en-US" xlink:label="lab_elv_HealthInsuranceProviderFeePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider Fee</link:label>
    <link:label id="lab_elv_HealthInsuranceProviderFeePolicyTextBlock_label_en-US" xlink:label="lab_elv_HealthInsuranceProviderFeePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider Fee [Policy Text Block]</link:label>
    <link:label id="lab_elv_HealthInsuranceProviderFeePolicyTextBlock_documentation_en-US" xlink:label="lab_elv_HealthInsuranceProviderFeePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Provider Fee [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HealthInsuranceProviderFeePolicyTextBlock" xlink:href="elv-20221231.xsd#elv_HealthInsuranceProviderFeePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_HealthInsuranceProviderFeePolicyTextBlock" xlink:to="lab_elv_HealthInsuranceProviderFeePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cd501188-17c9-4a62-8a7e-a4def94b6a7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future maturities of debt in 2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7190a631-9ce9-40d7-96c0-440250a12891_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bbe2e6c2-2ba1-431b-9b66-584f062c3f7c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_1c88f73a-f4f5-4b0c-bb5a-b206baabe255_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_1aa653e7-8dd6-4fa5-adca-623a7add3c45_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_f1fc1e36-7060-47d2-b2a7-7faa8ff57181_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b9c2cc68-5d0a-4f56-a17a-6e4c81436a77_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_6647ac0e-ae35-40a7-b934-ddc25bcddd08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts netted</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_fcbbb77a-b3fa-49e3-9f54-d51400969f2c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable_61398b9e-0e31-44cd-b92d-0a93115eafa7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gain (Loss) on Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_507c7717-02bd-47e8-89dc-f4c5230a56b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies&#8212;Note 14</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3d12ce77-efbc-4055-b48d-a749f686dbfc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies-Note 5</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_3786f948-f4d8-4e8a-82bb-ab2a23b559f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-credit component of impairment losses on investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f083a066-2c32-4f2c-b3cd-c2696a036a8d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7930a9b8-c866-477a-bf16-8192581ecb7b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period, Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36c8049d-56cf-436a-9759-ec0d37d84fae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period, Weighted-Average Option Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_3e3203df-d0e8-4f77-8df0-385b0b187df7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in securities lending payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Securities Lending Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecuritiesLendingPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_816da931-2d00-46b3-9b19-9c170d63be4a_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets amortization period, years</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_54beaa6b-d01d-43f6-ba8a-de7d73ea2a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Reportable Segment Operating Revenues To The Consolidated Statements Of Income</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3dd06f36-6644-4e19-897a-69323ff31784_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Optimization, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_InvestmentGainsLosses_98a2bdca-455d-40ab-87c7-43e6418aa8cc_verboseLabel_en-US" xlink:label="lab_elv_InvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on investments</link:label>
    <link:label id="lab_elv_InvestmentGainsLosses_label_en-US" xlink:label="lab_elv_InvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Gains (Losses)</link:label>
    <link:label id="lab_elv_InvestmentGainsLosses_documentation_en-US" xlink:label="lab_elv_InvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentGainsLosses" xlink:href="elv-20221231.xsd#elv_InvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_InvestmentGainsLosses" xlink:to="lab_elv_InvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_4236a17a-4be5-46ca-9740-a9ea1ab6aee5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_5e31ca75-009e-4849-94b1-5bdbed826f33_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_f9517dcb-d24c-4a4f-9b62-684c0308216d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_debd7382-fd9e-4e32-8a60-bf745cc0aa4c_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Declaration Date</link:label>
    <link:label id="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_label_en-US" xlink:label="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Date Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:to="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_2af35fb2-091e-48cc-b7e2-df921719c02b_negatedTerseLabel_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed trend factors</link:label>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_label_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (Unfavorable) Developments by Changes in Trend Factors Assumptions</link:label>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_documentation_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (Unfavorable) Developments by Changes in Trend Factors Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" xlink:to="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_8aa0adec-d49a-4d6f-9551-ae7ed4f17420_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_a35fc1d3-7784-491a-a1ad-3c4da05b7c66_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d6963eac-57e9-4463-88a1-1bf1cf6e62b2_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_NetLossesGainsOnFinancialInstruments_1f5d54c1-0e07-4dc2-bd04-18a99aa50fb0_negatedTerseLabel_en-US" xlink:label="lab_elv_NetLossesGainsOnFinancialInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on financial instruments</link:label>
    <link:label id="lab_elv_NetLossesGainsOnFinancialInstruments_label_en-US" xlink:label="lab_elv_NetLossesGainsOnFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on financial instruments</link:label>
    <link:label id="lab_elv_NetLossesGainsOnFinancialInstruments_documentation_en-US" xlink:label="lab_elv_NetLossesGainsOnFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (losses) gains on financial instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetLossesGainsOnFinancialInstruments" xlink:href="elv-20221231.xsd#elv_NetLossesGainsOnFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_NetLossesGainsOnFinancialInstruments" xlink:to="lab_elv_NetLossesGainsOnFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_SurplusNotesMember_76e182f2-3c69-4c49-a250-ad04f830499e_terseLabel_en-US" xlink:label="lab_elv_SurplusNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surplus Notes [Member]</link:label>
    <link:label id="lab_elv_SurplusNotesMember_label_en-US" xlink:label="lab_elv_SurplusNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surplus Notes [Member]</link:label>
    <link:label id="lab_elv_SurplusNotesMember_documentation_en-US" xlink:label="lab_elv_SurplusNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surplus Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SurplusNotesMember" xlink:href="elv-20221231.xsd#elv_SurplusNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_SurplusNotesMember" xlink:to="lab_elv_SurplusNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_926bafed-a5cc-4949-8380-644ead97ec16_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_d69458ad-f6b7-4ac8-bf6c-327863288195_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_10fa8054-5da0-4ec4-a0db-9f805850c0b5_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_4831d312-44b1-4905-adfc-15bc8d8409d6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_66ac0f5d-92a8-41f9-989e-ecd267d2f341_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums receivable, allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_f9f24be2-690c-44dd-bd9d-449824f38940_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future capital calls or investment obligations</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1d615ce5-f762-4758-a18f-b9fdbc9abde3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_60ac3670-f3df-4ab4-8a54-e4b41f25d805_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan by Plan Asset Categories [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_8922cf4b-fb36-48f6-98c9-12c88e6d7e74_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_16d756bf-1ddc-42ef-8a15-7854e17ef24e_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_74f9b9b7-4a3b-4bef-be5c-393283a2049e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1ab39c4f-5af7-4838-8f5c-a1e09adf4dd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid through withholding of common stock under employee stock plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2b3f939d-e057-4472-a437-c0c485870540_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a0b76688-2bfe-46a0-b3eb-af5ff010845e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_aea389c1-3453-4ef6-b97a-91198e70857f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net payments attributable to current year medical claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_3a793956-eb61-4f15-98ab-1db2554c653d_terseLabel_en-US" xlink:label="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.700%, due 2021 [Member]</link:label>
    <link:label id="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seven Zero Zero Percent Due Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seven Zero Zero Percent Due Two Thousand Twenty One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" xlink:href="elv-20221231.xsd#elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" xlink:to="lab_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_daaeba6f-57fd-4f45-91e3-2ee936a25726_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_dda36e66-ad64-4f9c-bd63-67359e3fa524_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorization remaining at the end of each period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_f8afa4f2-f69d-4aab-b662-d1f7507ae156_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_56cfa852-ed0e-46d9-b9ce-f70f8fcdfecf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_e8da6fdc-1480-46b5-aa94-ebebc80d0896_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_991eb031-c3bc-4a95-bda5-77a6279d58d9_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Hedging Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_4f496eb2-b8da-45f7-aa7c-7fe713aa5f53_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_735bbd17-f188-4127-9312-535fe23b21bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debenture repurchases and conversions</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d7392933-7eb6-45d6-bbc9-23313d7ddc5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_0f411b55-31e1-4af7-8d8b-e260d8a7e936_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Reportable Segment Operating Gain To Income From Continuing Operations Before Income Taxes In The Consolidated Statements Of Income</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_6a17957e-6a1c-4972-9008-3afcca3d6480_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_742e53f0-8c30-45b1-8138-2f2597c3020a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_892de3f9-824c-4977-87c7-1aa7b1dc505f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized gains from sales</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9fd69185-04ce-43a4-bad7-4626279fca0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5341be36-a6c7-4a24-afa6-27d924c9587a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_GainsFromOtherInvestments_44d61dab-70ed-4c05-b0c6-fbb065e8086f_terseLabel_en-US" xlink:label="lab_elv_GainsFromOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross gains from other investments</link:label>
    <link:label id="lab_elv_GainsFromOtherInvestments_label_en-US" xlink:label="lab_elv_GainsFromOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains From Other Investments</link:label>
    <link:label id="lab_elv_GainsFromOtherInvestments_documentation_en-US" xlink:label="lab_elv_GainsFromOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains From Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GainsFromOtherInvestments" xlink:href="elv-20221231.xsd#elv_GainsFromOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_GainsFromOtherInvestments" xlink:to="lab_elv_GainsFromOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_0542a5ea-0b2b-4732-a906-8541051568a3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation for the defined benefit pension plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fd13c6c3-1d6e-4781-8cae-3b1f852aa6a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan vesting period, years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_d4b8eda6-5b87-4285-8970-612a948afc18_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed maturities, amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1ed808cc-df6d-4cb7-a396-ff2e7454aa83_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments, Due 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6ae166f9-06c1-4dfa-b2af-c4f91ca3df54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_d7ff5023-1a14-428f-b6bd-49171407f218_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_fcdaa42f-709e-4a55-ba81-4768313ded14_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer funds and cash and cash equivalents on deposit for regulatory requirements</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9b7b91a4-429f-44ae-91fe-127d0ba3fa47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f500eda2-0fc2-4eeb-80b3-0beae72879ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_37f36951-c0f5-4f2c-be0f-5bbced483caa_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_f637b897-8c9f-4ddd-b8f2-0176615438d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ebbc38df-e650-46bf-a481-76ea11b098ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_fcadb8a0-2bc2-453e-8e78-2a52dfec3e6c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_6631b05b-070a-4c82-8fbb-3ff1fecbc3dc_negatedTerseLabel_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed completion factors</link:label>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_label_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (Unfavorable) Developments by Changes in Completion Factors Assumptions</link:label>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_documentation_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (Unfavorable) Developments by Changes in Completion Factors Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" xlink:to="lab_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_e19dc143-d872-45d4-86b5-eeeb6677a6cb_terseLabel_en-US" xlink:label="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.375%, due 2025 [Member]</link:label>
    <link:label id="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_label_en-US" xlink:label="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Seven Five Due Two Thousand Twenty Five [Member]</link:label>
    <link:label id="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_documentation_en-US" xlink:label="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Seven Five Due Two Thousand Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" xlink:href="elv-20221231.xsd#elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" xlink:to="lab_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c38394d2-42c0-4261-95ec-e458a4024fc3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Securities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_245b9353-8658-4fda-91b8-b869e6a42aa3_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment expense</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Investment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6adc3ad2-37f1-446e-9021-7f9ae02c251a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_bed0734c-3dcd-464e-805a-2d20897fc38b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_b5c8b31a-67fc-4507-a7a9-1ec842ca24b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts netted</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Asset Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_08fa3571-473e-41d4-8ce6-324e9415133a_terseLabel_en-US" xlink:label="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.750%, due 2042 [Member]</link:label>
    <link:label id="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_label_en-US" xlink:label="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Five Zero Percent Due Two Thousand Forty Two [Member]</link:label>
    <link:label id="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_documentation_en-US" xlink:label="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" xlink:href="elv-20221231.xsd#elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" xlink:to="lab_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_d8d90f3b-2728-48fc-bdac-50ab8cdc556c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_51b4f373-95f4-4f92-b4ab-da576b32559d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7f0ba8e5-2914-4ada-89f0-cdf1eccd9272_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_805d7a33-743d-43c8-9cc6-f4fd745df666_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_32b18898-d767-4b4b-a48d-47e1ffd57ae3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_3621006d-4bc7-4d13-a471-b1da9f073682_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain (loss) realized in other comprehensive loss, tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_71d303e1-f42c-4ccf-be54-7abbf5470689_totalLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits, Losses and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses" xlink:to="lab_us-gaap_BenefitsLossesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_be56b6b8-1a6e-4a7c-8bea-02e3b4d49cb0_terseLabel_en-US" xlink:label="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.100%, due 2044 [Member]</link:label>
    <link:label id="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_label_en-US" xlink:label="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Zero Zero Percent Due Two Thousand Forty Four [Member]</link:label>
    <link:label id="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_documentation_en-US" xlink:label="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Zero Zero Percent Due Two Thousand Forty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" xlink:href="elv-20221231.xsd#elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" xlink:to="lab_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d3a143b7-f3b0-4575-977f-422f323c9ef4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_3664a9da-5251-412a-9865-bd29470d1f26_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities relating to:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2ac6966e-584e-4117-861a-c0d1242d35b4_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_bb0ddf5a-51a1-4427-a0b6-fbc747d4c52d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization of subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Fund Long-Term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_16d19d19-2f78-4fec-bb76-3e383a4f8b79_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_dcfc468b-24a3-4ee9-809b-3b928d9bc344_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_d476fbec-3eca-4d9f-809b-4ae5816006d4_terseLabel_en-US" xlink:label="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% due 2047 [Member]</link:label>
    <link:label id="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_label_en-US" xlink:label="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Seven Five Percent Due Two Thousand Forty Seven [Member]</link:label>
    <link:label id="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_documentation_en-US" xlink:label="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Seven Five Percent Due Two Thousand Forty Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" xlink:href="elv-20221231.xsd#elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" xlink:to="lab_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_59c8cb70-54da-4725-b193-a5bcd108cf0a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_8f626c85-d456-4291-9337-534983003161_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_35c1dcbf-70b2-4beb-839b-aa421faf79ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalAbstract_09be9280-3285-4d7e-bb16-1877cc869005_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital [Abstract]</link:label>
    <link:label id="lab_us-gaap_CapitalAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banking Regulation, Total Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalAbstract" xlink:to="lab_us-gaap_CapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_0939e335-3ddd-4b9f-a5f0-9bd1454a1532_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9dd7edc8-0529-4cdd-aeab-b2dbe63eff85_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExchangeTradedFundsMember_1b2ff4f4-6c38-40fc-ab15-5c823bee57e0_terseLabel_en-US" xlink:label="lab_us-gaap_ExchangeTradedFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Traded Funds [Member]</link:label>
    <link:label id="lab_us-gaap_ExchangeTradedFundsMember_label_en-US" xlink:label="lab_us-gaap_ExchangeTradedFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Traded Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExchangeTradedFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExchangeTradedFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExchangeTradedFundsMember" xlink:to="lab_us-gaap_ExchangeTradedFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_PartnershipInvestmentsMember_b64e18d8-89d3-4890-971b-b0c24297bc82_terseLabel_en-US" xlink:label="lab_elv_PartnershipInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership investments [Member]</link:label>
    <link:label id="lab_elv_PartnershipInvestmentsMember_label_en-US" xlink:label="lab_elv_PartnershipInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership investments [Member]</link:label>
    <link:label id="lab_elv_PartnershipInvestmentsMember_documentation_en-US" xlink:label="lab_elv_PartnershipInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PartnershipInvestmentsMember" xlink:href="elv-20221231.xsd#elv_PartnershipInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_PartnershipInvestmentsMember" xlink:to="lab_elv_PartnershipInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_1e33771a-20cf-4fa4-bb44-b9da868de060_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_EmployeeStockPurchasePlanMember_03df860b-2e6f-44bf-abb2-c9a30cb864a8_terseLabel_en-US" xlink:label="lab_elv_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_elv_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_elv_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_elv_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_elv_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EmployeeStockPurchasePlanMember" xlink:href="elv-20221231.xsd#elv_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_EmployeeStockPurchasePlanMember" xlink:to="lab_elv_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_7de132e5-9706-4cf8-a7d4-6169b5e256de_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_d638129e-db30-4f74-ab00-6491200e9771_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued investment income</link:label>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_label_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Investment Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_63cdd8d3-2be5-4c70-9e39-35240ba28d09_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities&#8212;employee stock options, non-vested restricted stock awards, convertible debentures and equity units</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_5e2dcb5f-dae4-408a-9e11-ca71a935ed59_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_daffcd47-7e8d-463f-8a35-93793ea9a846_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_a1f9d94e-f9fa-4a4f-a6a3-c840a2ee17f0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_7f2e83ef-2e01-47bc-b01e-1e589314c521_negatedTotalLabel_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_label_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (Unfavorable) Developments by Changes in Total Assumptions</link:label>
    <link:label id="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_documentation_en-US" xlink:label="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (Unfavorable) Developments by Changes in Total Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" xlink:to="lab_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5db4be8d-2221-4f42-ae79-1971e48e2216_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ac3d52a2-bdb4-4616-b637-aad055087c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_2c23da3a-bc4b-4b06-a7b0-e30e1aab78db_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_9069be95-601e-42c8-b781-0adf55fcd7a0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8f5e03e4-0edc-4cac-9203-dfe1275609fe_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_ad833c08-350f-4bb9-b516-f681a5bf2beb_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount before tax at December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9c6ae324-7da3-45bc-aa4c-c759d88de12f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_84c46c67-90c8-4b46-8f01-f5054c2a5e24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_60caf824-c1b1-41bd-967c-c6e8d69d90bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_29953e02-021f-48df-a6e8-9e414fef1609_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_ThirdPartyInvestmentsMember_7e9cd9b8-977e-4c8d-b0ae-cbcfcfebfd1e_terseLabel_en-US" xlink:label="lab_elv_ThirdPartyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party investments</link:label>
    <link:label id="lab_elv_ThirdPartyInvestmentsMember_label_en-US" xlink:label="lab_elv_ThirdPartyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party investments [Member]</link:label>
    <link:label id="lab_elv_ThirdPartyInvestmentsMember_documentation_en-US" xlink:label="lab_elv_ThirdPartyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThirdPartyInvestmentsMember" xlink:href="elv-20221231.xsd#elv_ThirdPartyInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_ThirdPartyInvestmentsMember" xlink:to="lab_elv_ThirdPartyInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_71629474-4737-4483-b23c-e01fa7f542bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_53b8907c-3144-4a20-b953-7988decaa0b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9c471c2d-ece8-4de2-8458-a453d6db582d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount at statutory rate, amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_ab0b1ae2-9484-45e9-a48f-f13ee1f58751_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bbc86caa-5bd9-4411-a9b6-769ab1cec3ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities, calls and redemptions from investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b23b809e-4559-480f-a426-0c847d567ca5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_1238082c-3a95-4075-bd4b-663c1cb7bb62_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Gains/Losses</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OperatingRevenue_4ca5aac0-68da-4e76-94d7-ae19ab14dd32_totalLabel_en-US" xlink:label="lab_elv_OperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating revenue</link:label>
    <link:label id="lab_elv_OperatingRevenue_label_en-US" xlink:label="lab_elv_OperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Revenue</link:label>
    <link:label id="lab_elv_OperatingRevenue_documentation_en-US" xlink:label="lab_elv_OperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from insurance services and products sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperatingRevenue" xlink:href="elv-20221231.xsd#elv_OperatingRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OperatingRevenue" xlink:to="lab_elv_OperatingRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_OtherDerivativeInstrumentsMember_f7633d3f-1acb-447d-ab9a-ed16f75b54a3_terseLabel_en-US" xlink:label="lab_elv_OtherDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Member]</link:label>
    <link:label id="lab_elv_OtherDerivativeInstrumentsMember_label_en-US" xlink:label="lab_elv_OtherDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Derivative Instruments [Member]</link:label>
    <link:label id="lab_elv_OtherDerivativeInstrumentsMember_documentation_en-US" xlink:label="lab_elv_OtherDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherDerivativeInstrumentsMember" xlink:href="elv-20221231.xsd#elv_OtherDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_OtherDerivativeInstrumentsMember" xlink:to="lab_elv_OtherDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_0f57f02e-1ef3-48cb-91f8-32f40b84f724_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_IncomeTaxRefundClaimsFiled_97970120-0e23-480e-b492-c41296897b90_terseLabel_en-US" xlink:label="lab_elv_IncomeTaxRefundClaimsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protective state income tax refund claims filed</link:label>
    <link:label id="lab_elv_IncomeTaxRefundClaimsFiled_label_en-US" xlink:label="lab_elv_IncomeTaxRefundClaimsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Refund Claims Filed</link:label>
    <link:label id="lab_elv_IncomeTaxRefundClaimsFiled_documentation_en-US" xlink:label="lab_elv_IncomeTaxRefundClaimsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of income tax refund claims filed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncomeTaxRefundClaimsFiled" xlink:href="elv-20221231.xsd#elv_IncomeTaxRefundClaimsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_IncomeTaxRefundClaimsFiled" xlink:to="lab_elv_IncomeTaxRefundClaimsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_elv_LimitedCarryforwardPeriodMember_ab4c85b3-4a2d-4b83-80da-f8e657dab412_terseLabel_en-US" xlink:label="lab_elv_LimitedCarryforwardPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Carryforward Period</link:label>
    <link:label id="lab_elv_LimitedCarryforwardPeriodMember_label_en-US" xlink:label="lab_elv_LimitedCarryforwardPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Carryforward Period [Member]</link:label>
    <link:label id="lab_elv_LimitedCarryforwardPeriodMember_documentation_en-US" xlink:label="lab_elv_LimitedCarryforwardPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Carryforward Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LimitedCarryforwardPeriodMember" xlink:href="elv-20221231.xsd#elv_LimitedCarryforwardPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_elv_LimitedCarryforwardPeriodMember" xlink:to="lab_elv_LimitedCarryforwardPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0ef3b11d-e067-48d0-9799-6b9f9c60c7ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment, tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_1568abcf-b6ba-4d40-bd4c-3cca11d80ebb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debenture Terms</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_37105829-386a-42e3-8d51-148008f03368_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_ce7886b6-9a3a-4279-813f-cd046e0a8759_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>elv-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:454c8386-f90e-4c1e-9f8b-5fb66238439f,g:9bb273fb-a44f-4fa9-8c35-d6fee14cceb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="elv-20221231.xsd#DocumentAndEntityInformation"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_DocumentAndEntityInformationAbstract_81be641c-6a77-4b1d-9dbb-8e6dcd088e11" xlink:href="elv-20221231.xsd#elv_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_DocumentAndEntityInformationAbstract_81be641c-6a77-4b1d-9dbb-8e6dcd088e11" xlink:to="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:to="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b73c94bb-c05d-4719-9947-e4ac2d0a28d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_049fc8de-ec27-40c0-994e-b123209981a4" xlink:to="loc_dei_EntityDomain_b73c94bb-c05d-4719-9947-e4ac2d0a28d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ffdd26b6-c278-433c-af29-5d3c2707d04d" xlink:to="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c0743279-b68c-4256-b74a-74ee039e99aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentType_c0743279-b68c-4256-b74a-74ee039e99aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_41ad5b97-dc60-4ee3-97c8-9d0d2c6c9c05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentAnnualReport_41ad5b97-dc60-4ee3-97c8-9d0d2c6c9c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e3f3ba03-f520-4564-bf49-b5bb3198289c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentTransitionReport_e3f3ba03-f520-4564-bf49-b5bb3198289c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c73b8bf6-586e-4aef-a08b-cc1541031fcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_AmendmentFlag_c73b8bf6-586e-4aef-a08b-cc1541031fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_72451c30-1953-4a38-8156-486cf762811d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentFiscalPeriodFocus_72451c30-1953-4a38-8156-486cf762811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7794560c-a35c-4c62-835b-6071cb386f54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentFiscalYearFocus_7794560c-a35c-4c62-835b-6071cb386f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5fafd394-58fb-44b5-8e0c-32029b47b540" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_CurrentFiscalYearEndDate_5fafd394-58fb-44b5-8e0c-32029b47b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f5a862c9-6075-463e-9d0a-1b45c5d6d00f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentPeriodEndDate_f5a862c9-6075-463e-9d0a-1b45c5d6d00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_53812164-d484-4113-84a6-86cc4001c346" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityCentralIndexKey_53812164-d484-4113-84a6-86cc4001c346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bab06580-7230-4aae-a526-65e07078fec3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityFileNumber_bab06580-7230-4aae-a526-65e07078fec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c77c23a3-ec9f-4bae-ac12-fd0919229509" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityRegistrantName_c77c23a3-ec9f-4bae-ac12-fd0919229509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dc29cac3-01a8-46ca-9527-c1cb55072c2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dc29cac3-01a8-46ca-9527-c1cb55072c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b46b3dcc-b126-4328-a9f8-c23348de26fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityTaxIdentificationNumber_b46b3dcc-b126-4328-a9f8-c23348de26fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd6832d3-bfa4-4f13-aaca-0f859f876310" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressAddressLine1_fd6832d3-bfa4-4f13-aaca-0f859f876310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_310f73dc-9406-4859-a2b0-8c2cc31e1b64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressCityOrTown_310f73dc-9406-4859-a2b0-8c2cc31e1b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f362d1b5-4f0c-473c-815f-5481a77cbb62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressStateOrProvince_f362d1b5-4f0c-473c-815f-5481a77cbb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b48ad045-4a59-499a-9d0b-1a70d4c08ed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityAddressPostalZipCode_b48ad045-4a59-499a-9d0b-1a70d4c08ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4159c5ea-026d-4a8c-98a0-ee1f4ea00c6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_CityAreaCode_4159c5ea-026d-4a8c-98a0-ee1f4ea00c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_862ded43-dcb9-4813-b391-6fd9c9be6e88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_LocalPhoneNumber_862ded43-dcb9-4813-b391-6fd9c9be6e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a0ad4359-06cd-47c7-974a-25381741a8f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_Security12bTitle_a0ad4359-06cd-47c7-974a-25381741a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fce41c73-e20e-4cdd-a122-1b6cbec2d31a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_TradingSymbol_fce41c73-e20e-4cdd-a122-1b6cbec2d31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d617d553-7e02-4e85-9561-1bdbe9d4fd95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_SecurityExchangeName_d617d553-7e02-4e85-9561-1bdbe9d4fd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0f610d49-4103-47a4-b9fc-d05deb0ab89b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0f610d49-4103-47a4-b9fc-d05deb0ab89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dfb674af-d8be-4785-9d73-559f0b55481f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityVoluntaryFilers_dfb674af-d8be-4785-9d73-559f0b55481f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e10eae1e-6da7-4cb4-9652-0984a45c4cc6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityCurrentReportingStatus_e10eae1e-6da7-4cb4-9652-0984a45c4cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cca6187d-6fed-49c0-a80a-576fd4547344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityInteractiveDataCurrent_cca6187d-6fed-49c0-a80a-576fd4547344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3e440f9b-4ae7-4eff-901d-7ddc29a0bec8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityFilerCategory_3e440f9b-4ae7-4eff-901d-7ddc29a0bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a68baebf-9dc0-4003-9a84-8d1d00471423" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntitySmallBusiness_a68baebf-9dc0-4003-9a84-8d1d00471423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2478e885-313f-4494-bf08-4fa11edadd96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityEmergingGrowthCompany_2478e885-313f-4494-bf08-4fa11edadd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_6990cb0e-f41b-49e4-b02b-deea402e5c1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_IcfrAuditorAttestationFlag_6990cb0e-f41b-49e4-b02b-deea402e5c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_436766e3-45be-4858-ab8a-4233517b06a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityShellCompany_436766e3-45be-4858-ab8a-4233517b06a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4c34a068-9d03-4567-a5dc-62b2011056b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityPublicFloat_4c34a068-9d03-4567-a5dc-62b2011056b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_df582704-979d-4c41-a1c9-decf3ecc0df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_df582704-979d-4c41-a1c9-decf3ecc0df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da44f5d0-a8aa-47f9-8647-b75c85ff7cea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_81c6f150-0775-4cbd-8f19-00b5e5631437" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da44f5d0-a8aa-47f9-8647-b75c85ff7cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/AuditInformation" xlink:type="simple" xlink:href="elv-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_AuditInformationAbstract_69e43884-fde3-4e2a-a14b-c68fba278fc3" xlink:href="elv-20221231.xsd#elv_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_7e103fe0-abe4-4252-9ca8-4a0c36087e47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_AuditInformationAbstract_69e43884-fde3-4e2a-a14b-c68fba278fc3" xlink:to="loc_dei_AuditorFirmId_7e103fe0-abe4-4252-9ca8-4a0c36087e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6f427048-8ded-4b9e-9242-5f0fcb98eb65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_AuditInformationAbstract_69e43884-fde3-4e2a-a14b-c68fba278fc3" xlink:to="loc_dei_AuditorName_6f427048-8ded-4b9e-9242-5f0fcb98eb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_007c7d36-fd14-4712-9932-dfa66746cefd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_AuditInformationAbstract_69e43884-fde3-4e2a-a14b-c68fba278fc3" xlink:to="loc_dei_AuditorLocation_007c7d36-fd14-4712-9932-dfa66746cefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a9671d22-41e9-44ad-911a-c9564c2e4896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a9671d22-41e9-44ad-911a-c9564c2e4896" xlink:to="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14e83db2-c514-411b-a864-9dad8d967313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14e83db2-c514-411b-a864-9dad8d967313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e765ad07-41d2-46c2-a58a-dbd6196af919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e765ad07-41d2-46c2-a58a-dbd6196af919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_59f8e1ac-ca56-4b63-ade4-1a0704780153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_59f8e1ac-ca56-4b63-ade4-1a0704780153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_5b1a0632-5400-4c61-85a5-e8d630c82f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_5b1a0632-5400-4c61-85a5-e8d630c82f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SelfFundedReceivablesNet_2bcf01d2-b5fb-43ac-9c58-fad7677ab0fc" xlink:href="elv-20221231.xsd#elv_SelfFundedReceivablesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_elv_SelfFundedReceivablesNet_2bcf01d2-b5fb-43ac-9c58-fad7677ab0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_3c4337e4-dc58-4e39-9717-e7d1e72a4f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_OtherReceivables_3c4337e4-dc58-4e39-9717-e7d1e72a4f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d113b0ea-fcb4-4ada-b116-b31582446d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_OtherAssetsCurrent_d113b0ea-fcb4-4ada-b116-b31582446d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2f4c24e8-5c64-4906-9c35-cf5d0b28b900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_AssetsCurrent_2f4c24e8-5c64-4906-9c35-cf5d0b28b900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9a404169-62fb-4ff8-9f21-2f2642578724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dbd08f7a-66e5-441e-86ea-1b64e7bfad33" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9a404169-62fb-4ff8-9f21-2f2642578724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_edd73241-76a6-44d6-937e-35efce509cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_OtherLongTermInvestments_edd73241-76a6-44d6-937e-35efce509cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b556e47a-f01c-4cea-8082-c9dabef7f8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b556e47a-f01c-4cea-8082-c9dabef7f8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5045ca6b-8bca-4541-984a-27d61b47f165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_Goodwill_5045ca6b-8bca-4541-984a-27d61b47f165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5454cd52-8983-468f-a830-963a54234394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5454cd52-8983-468f-a830-963a54234394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f133d906-a2ce-4261-b008-ada7c5e3fd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f133d906-a2ce-4261-b008-ada7c5e3fd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ba6eb074-69ea-4ed8-b089-d6fbf6978109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d5dfe1a-7695-4e18-8762-67a9bfcfac02" xlink:to="loc_us-gaap_Assets_ba6eb074-69ea-4ed8-b089-d6fbf6978109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a9671d22-41e9-44ad-911a-c9564c2e4896" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_00e4b35d-0a95-4e47-ac38-868f08bdb509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_00e4b35d-0a95-4e47-ac38-868f08bdb509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPolicyholderFunds_9a2b0f8c-08bc-4fb4-9bbc-3d78009cd247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPolicyholderFunds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_OtherPolicyholderFunds_9a2b0f8c-08bc-4fb4-9bbc-3d78009cd247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_7ec79441-4891-42c4-8e32-c09f7ecb8458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnearnedPremiums"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_UnearnedPremiums_7ec79441-4891-42c4-8e32-c09f7ecb8458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c37a311a-6eae-48f4-bdb8-5c53caec7fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c37a311a-6eae-48f4-bdb8-5c53caec7fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_3fca2708-3bd6-4267-958a-585ebfbd9de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_ShortTermBorrowings_3fca2708-3bd6-4267-958a-585ebfbd9de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_54698a88-4306-4920-97ec-af67b146f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_LongTermDebtCurrent_54698a88-4306-4920-97ec-af67b146f28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_47b2a8d1-87d6-40a7-8356-b95d1d6c79eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_47b2a8d1-87d6-40a7-8356-b95d1d6c79eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4a0fda6-f446-4128-ab2d-82306b9b07b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_LiabilitiesCurrent_e4a0fda6-f446-4128-ab2d-82306b9b07b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_64631cda-0422-44f0-b986-883ea0be8164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_64631cda-0422-44f0-b986-883ea0be8164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_aa718fb8-a729-4f40-9bea-d240c3579cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_aa718fb8-a729-4f40-9bea-d240c3579cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c7439c68-9672-43d4-9edf-7ec338d90845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c7439c68-9672-43d4-9edf-7ec338d90845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_33820a81-ed15-4e39-8d0a-3362dead1bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_33820a81-ed15-4e39-8d0a-3362dead1bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_062fce85-4766-45b3-bf78-c35bffe70d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_Liabilities_062fce85-4766-45b3-bf78-c35bffe70d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ccfdf5b9-0a08-4bcc-8347-50fc44495c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ccfdf5b9-0a08-4bcc-8347-50fc44495c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_64f0c047-3b5f-4253-a38f-420801f8cc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_PreferredStockValue_64f0c047-3b5f-4253-a38f-420801f8cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e23e413f-198b-4e8f-a92e-3b7eb0c7ddee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_CommonStockValue_e23e413f-198b-4e8f-a92e-3b7eb0c7ddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_674a032f-a718-48ce-9c5d-ae618cbcd876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_674a032f-a718-48ce-9c5d-ae618cbcd876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ca091fa6-7853-47cf-be2e-ed18b312900d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ca091fa6-7853-47cf-be2e-ed18b312900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc21892d-20e6-48d3-8a35-bf6eefc39bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc21892d-20e6-48d3-8a35-bf6eefc39bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd96af58-3223-4382-b39a-5fd6d958ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_StockholdersEquity_cd96af58-3223-4382-b39a-5fd6d958ec6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2db5cf8b-21aa-463e-bcc1-dc531ae6b0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_MinorityInterest_2db5cf8b-21aa-463e-bcc1-dc531ae6b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3096eef9-001f-4498-ae06-65f9e2a448b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ded61427-577a-4b37-8da0-16fc60c439d5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3096eef9-001f-4498-ae06-65f9e2a448b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_06656ba5-c36c-40fe-b5cb-d7086a593d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3853727b-ac3f-4e30-8376-8a79fac523b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_06656ba5-c36c-40fe-b5cb-d7086a593d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_33416a75-8c5e-46c3-83bd-37aeb8018822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_33416a75-8c5e-46c3-83bd-37aeb8018822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_46c415b3-f1b8-4e64-b0e0-fbb9412c48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_46c415b3-f1b8-4e64-b0e0-fbb9412c48ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_6ce83fa6-e086-4c0f-80f9-61485d30c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_6ce83fa6-e086-4c0f-80f9-61485d30c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent_f5815a08-f57e-4ae6-8597-69e892026d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent_f5815a08-f57e-4ae6-8597-69e892026d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2f02fbab-1a44-43ca-9b14-def72bd6a4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2f02fbab-1a44-43ca-9b14-def72bd6a4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c5dee180-5c08-465b-a7c1-2741260cc52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c5dee180-5c08-465b-a7c1-2741260cc52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_38cb662c-285b-465b-9072-bd389763b8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_38cb662c-285b-465b-9072-bd389763b8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f64079e0-94ab-4189-9334-306ce170f91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f64079e0-94ab-4189-9334-306ce170f91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_515b0998-9a52-48da-855c-f85854114312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_515b0998-9a52-48da-855c-f85854114312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_87b106fa-2b86-4f24-8e7a-6db27fede6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_CommonStockSharesIssued_87b106fa-2b86-4f24-8e7a-6db27fede6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28a00ae4-6306-468d-8420-c4896a4eee75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e67c9d-556a-4886-85ee-d9d35957e666" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_28a00ae4-6306-468d-8420-c4896a4eee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_305e9732-4aa7-4191-bacb-5a8d8dc143b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_us-gaap_PremiumsEarnedNet_305e9732-4aa7-4191-bacb-5a8d8dc143b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ProductRevenue_de724c90-3fb7-40e0-833e-68410c7125dd" xlink:href="elv-20221231.xsd#elv_ProductRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_elv_ProductRevenue_de724c90-3fb7-40e0-833e-68410c7125dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_7457b61e-98dc-40c2-a990-6e8fa374384c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_us-gaap_OtherIncome_7457b61e-98dc-40c2-a990-6e8fa374384c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperatingRevenue_097e6f5f-def2-418d-b986-7c4fb99889c5" xlink:href="elv-20221231.xsd#elv_OperatingRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_elv_OperatingRevenue_097e6f5f-def2-418d-b986-7c4fb99889c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_0b93e1d8-9ed0-43cd-9c93-483096f0176d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_us-gaap_NetInvestmentIncome_0b93e1d8-9ed0-43cd-9c93-483096f0176d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_956a7ecf-e63b-4695-8909-ab92fda989e4" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_956a7ecf-e63b-4695-8909-ab92fda989e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5a66c96-1190-4514-bce2-88b4e26a5221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3b0c0afd-74aa-43bf-a308-6ae4600b821f" xlink:to="loc_us-gaap_Revenues_f5a66c96-1190-4514-bce2-88b4e26a5221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_a8a90165-6a4a-4895-b0a0-7d6809164b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_a8a90165-6a4a-4895-b0a0-7d6809164b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_053ff523-0258-49cf-8e46-dd0a364d3821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_053ff523-0258-49cf-8e46-dd0a364d3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5966bcfd-e9f2-4342-9fda-b4197a405a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5966bcfd-e9f2-4342-9fda-b4197a405a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9dd07749-1dc2-4cd1-a2be-ca68a9f80ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_InterestExpense_9dd07749-1dc2-4cd1-a2be-ca68a9f80ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ca7efb02-d2a3-4935-ab87-32048ba19459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ca7efb02-d2a3-4935-ab87-32048ba19459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_266af2e1-d1a9-4bb4-b460-2c1075416914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_266af2e1-d1a9-4bb4-b460-2c1075416914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_a59946d8-9744-4552-8b69-282ad9f0b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_b25c9e98-641f-47a5-b3dd-a771728be6fc" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_a59946d8-9744-4552-8b69-282ad9f0b8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8eccf8d-2d8c-47b8-83b6-6418b12fbfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8eccf8d-2d8c-47b8-83b6-6418b12fbfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b3ff5b40-23fa-4a0d-8a0f-6769d62c1bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b3ff5b40-23fa-4a0d-8a0f-6769d62c1bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f3ef2a49-fd0f-4b36-a225-77237c3d48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_ProfitLoss_f3ef2a49-fd0f-4b36-a225-77237c3d48ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f28496cc-682e-4dbb-8652-eea941811732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f28496cc-682e-4dbb-8652-eea941811732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58f34da4-cc4e-4243-a3cd-082bfda42d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_NetIncomeLoss_58f34da4-cc4e-4243-a3cd-082bfda42d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_69d51928-0cf2-4aaa-85b7-474a20cf94a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_69d51928-0cf2-4aaa-85b7-474a20cf94a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6ec51cba-8728-4568-b797-95723dd2d633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_69d51928-0cf2-4aaa-85b7-474a20cf94a3" xlink:to="loc_us-gaap_EarningsPerShareBasic_6ec51cba-8728-4568-b797-95723dd2d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c1f0fa19-7524-41be-b9fa-6442a88f7318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_69d51928-0cf2-4aaa-85b7-474a20cf94a3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c1f0fa19-7524-41be-b9fa-6442a88f7318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8726a93c-e2c1-4c5e-8805-a9ab39caeef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_510e86dd-f3c4-417f-beb8-5f29807d2bcc" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8726a93c-e2c1-4c5e-8805-a9ab39caeef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2dacac0-aaf9-45b3-b327-1acda300d04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:to="loc_us-gaap_ProfitLoss_f2dacac0-aaf9-45b3-b327-1acda300d04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2df22c36-505b-4e3a-9c26-676cce5aeb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2df22c36-505b-4e3a-9c26-676cce5aeb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_863ad5f9-0b11-4bbe-a7d0-7b36726145cf" xlink:href="elv-20221231.xsd#elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:to="loc_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax_863ad5f9-0b11-4bbe-a7d0-7b36726145cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1efaae06-5867-47a0-a79d-cb40ebd0acf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1efaae06-5867-47a0-a79d-cb40ebd0acf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f89e3b5f-89f3-4d5e-82d0-c6e17164cd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f89e3b5f-89f3-4d5e-82d0-c6e17164cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ddfec726-3d8e-4e9f-b458-248aa5021f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85f77704-9fa8-4e38-8e06-6a7982acc360" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ddfec726-3d8e-4e9f-b458-248aa5021f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c99993ca-a013-4a32-bf93-ec77b056eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c99993ca-a013-4a32-bf93-ec77b056eea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_98a10b1e-3015-4ea1-ae9b-e128f70ad565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_98a10b1e-3015-4ea1-ae9b-e128f70ad565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_5a427f6a-2369-4d6d-89ab-224ec675d66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_5a427f6a-2369-4d6d-89ab-224ec675d66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_83021d67-eb94-49a1-8926-135da9e159f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a11cac8f-4438-48f8-a453-a8269f682f46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_83021d67-eb94-49a1-8926-135da9e159f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cce6f96f-b141-4ca1-a23e-e799c46f9549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cce6f96f-b141-4ca1-a23e-e799c46f9549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ab817899-055b-40f6-8acd-5e2ad5e15540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cce6f96f-b141-4ca1-a23e-e799c46f9549" xlink:to="loc_us-gaap_ProfitLoss_ab817899-055b-40f6-8acd-5e2ad5e15540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cce6f96f-b141-4ca1-a23e-e799c46f9549" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_4d9e06f4-31ef-446f-a86a-b8ff564444c6" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_4d9e06f4-31ef-446f-a86a-b8ff564444c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a8e48663-4e9f-4bf1-90a1-06c98499e92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a8e48663-4e9f-4bf1-90a1-06c98499e92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_a12cf4fa-d97d-44a3-9ac6-522695d995bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_a12cf4fa-d97d-44a3-9ac6-522695d995bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_247a4e68-f5b7-46de-aa01-70d86078a784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_247a4e68-f5b7-46de-aa01-70d86078a784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_39ac7bdc-d23f-452d-8d07-67dab4ecd9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_39ac7bdc-d23f-452d-8d07-67dab4ecd9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_68f36219-666d-4cb0-ad8e-eca20eb88cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_us-gaap_ShareBasedCompensation_68f36219-666d-4cb0-ad8e-eca20eb88cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_498b9a08-7d47-4a18-82b9-37dc2667ab9f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_f3ffcacb-583b-422b-a48a-45cf91f032c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_f3ffcacb-583b-422b-a48a-45cf91f032c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_1344001e-7297-45ec-84c9-9fd90306ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTradingSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInTradingSecurities_1344001e-7297-45ec-84c9-9fd90306ea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_98e7337c-0916-4860-b226-85d7eb077ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_98e7337c-0916-4860-b226-85d7eb077ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_078d402e-676e-4880-acf4-8d4873093008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_078d402e-676e-4880-acf4-8d4873093008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4c5e5255-59ad-4929-9b5d-a792e7194634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4c5e5255-59ad-4929-9b5d-a792e7194634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_5d8352b9-c00b-4792-8fec-76b3f853c8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_5d8352b9-c00b-4792-8fec-76b3f853c8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_8e752316-ff37-4b61-a7f6-9a8c9f64868c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_8e752316-ff37-4b61-a7f6-9a8c9f64868c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_90bd77fc-a6aa-4d8a-9c29-19bba2e3b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b40d710-6cb2-4176-a52c-179b5b23717d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_90bd77fc-a6aa-4d8a-9c29-19bba2e3b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_473b68b9-4326-4d4e-ada2-e63264899b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cce6f96f-b141-4ca1-a23e-e799c46f9549" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_473b68b9-4326-4d4e-ada2-e63264899b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5cc036c2-6f43-4fd2-8bba-cd16dd5e4aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5cc036c2-6f43-4fd2-8bba-cd16dd5e4aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_f37ef408-1212-4674-ac59-a3469f70721a" xlink:href="elv-20221231.xsd#elv_Proceedsfromsaleofequityandfixedmaturitysecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_elv_Proceedsfromsaleofequityandfixedmaturitysecurities_f37ef408-1212-4674-ac59-a3469f70721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9888091f-ec8c-4743-b2d5-0567969dede9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9888091f-ec8c-4743-b2d5-0567969dede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_a53cc39c-1411-4347-a818-194d98fd785a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_a53cc39c-1411-4347-a818-194d98fd785a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_187a18ea-a2a1-41ec-8dae-ff9eb858c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_187a18ea-a2a1-41ec-8dae-ff9eb858c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f4875f5-59bd-4871-bde1-bf3be3b2eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f4875f5-59bd-4871-bde1-bf3be3b2eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0cb0c582-410e-41f3-9c23-3a0d5e1b1f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0cb0c582-410e-41f3-9c23-3a0d5e1b1f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20e4c67a-747f-4b51-ae16-67062cd5b334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0378f89-f405-4558-8139-3f51e8d6badf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20e4c67a-747f-4b51-ae16-67062cd5b334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_89220290-4d0e-4a23-9961-ab366354c535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_89220290-4d0e-4a23-9961-ab366354c535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6121dabf-d4cc-4822-a58a-e52c97cdc216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6121dabf-d4cc-4822-a58a-e52c97cdc216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_dfbe9498-aa9c-4286-b722-a2e4f9c5cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_dfbe9498-aa9c-4286-b722-a2e4f9c5cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_845bac65-3385-4272-b795-a817910f64b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_845bac65-3385-4272-b795-a817910f64b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_2025788e-8b4c-4de3-a83a-7f779900d6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_2025788e-8b4c-4de3-a83a-7f779900d6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_5d1989e1-d00c-49a3-8b61-a39e55407ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecuritiesLendingPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_5d1989e1-d00c-49a3-8b61-a39e55407ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities_5388e787-b00f-423c-8d9b-a28ffea2f927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities_5388e787-b00f-423c-8d9b-a28ffea2f927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_86d80025-e324-42f7-82cc-a0cffbee2a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_86d80025-e324-42f7-82cc-a0cffbee2a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_5c1f5485-5ccd-416e-b520-b17ce48bd37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_PaymentsOfDividends_5c1f5485-5ccd-416e-b520-b17ce48bd37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8ac7aeba-0c0c-4c44-8dde-f2a08be4d665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8ac7aeba-0c0c-4c44-8dde-f2a08be4d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_27d83770-6767-4404-b511-bfd22e535788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_27d83770-6767-4404-b511-bfd22e535788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3966fe2f-8e1e-41d0-8242-dcdf00ca0e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3966fe2f-8e1e-41d0-8242-dcdf00ca0e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_401286f6-e41e-4f8c-8248-b5c84e948bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3d8547-bd26-4a49-af13-7bca3a76529d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_401286f6-e41e-4f8c-8248-b5c84e948bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5763a315-8f23-4fb1-a6c5-386a30c56250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5763a315-8f23-4fb1-a6c5-386a30c56250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9fac1ad5-5117-437e-9f39-63f683dada04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9fac1ad5-5117-437e-9f39-63f683dada04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bca09635-c7e7-4c08-bf69-8eb2ce5a7eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bca09635-c7e7-4c08-bf69-8eb2ce5a7eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b46b2a3-a97b-4a3c-a35c-93570b1d5725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59b30057-1968-40b1-a66a-9e99a4f7ac3f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b46b2a3-a97b-4a3c-a35c-93570b1d5725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="elv-20221231.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f8a29c5-970f-4340-897c-e244d0071709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f8a29c5-970f-4340-897c-e244d0071709" xlink:to="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e9eb6d5a-c83e-4858-ba98-a54e4d042b57" xlink:to="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6150ede5-8d2e-4565-bc20-253f07ed05a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_CommonStockMember_6150ede5-8d2e-4565-bc20-253f07ed05a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a3b7d893-0cd8-4e33-86e5-49694d300c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a3b7d893-0cd8-4e33-86e5-49694d300c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3fcc0a20-8bd8-4fac-bb0b-89c783893970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_RetainedEarningsMember_3fcc0a20-8bd8-4fac-bb0b-89c783893970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63c616b2-26ef-447f-9bc8-ad4a38546c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63c616b2-26ef-447f-9bc8-ad4a38546c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d1df5502-2f77-404c-8288-c4e677c23885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3320efd-99e2-4245-9f18-8e1c151196c1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d1df5502-2f77-404c-8288-c4e677c23885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ad110697-fb24-4f14-914a-9cbf51a32af1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ba02270-d5fa-4b27-8f32-32fb5697d26e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ba02270-d5fa-4b27-8f32-32fb5697d26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_41cc7bbb-3d69-48c6-9585-dd9ec27873cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b99cc72e-b803-4925-85bc-5ec46d818984" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_41cc7bbb-3d69-48c6-9585-dd9ec27873cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a59645ed-86db-48e8-bfaa-b5b5ce205425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_84a252b9-c613-4a26-9d35-ee6ebba5e926" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a59645ed-86db-48e8-bfaa-b5b5ce205425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_b1b264ab-7a46-4d0e-beab-d37346950dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a59645ed-86db-48e8-bfaa-b5b5ce205425" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_b1b264ab-7a46-4d0e-beab-d37346950dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df3ead97-d818-46e6-8139-c57412f6aa16" xlink:to="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6975e5e4-f29e-491c-9c3e-87ec2eba00a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_SharesOutstanding_6975e5e4-f29e-491c-9c3e-87ec2eba00a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ca0e6f3-93f9-4612-9fb7-9fe39ad477ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StockholdersEquity_5ca0e6f3-93f9-4612-9fb7-9fe39ad477ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e6bd75a4-7f50-4774-97eb-6b0ad52970bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_MinorityInterest_e6bd75a4-7f50-4774-97eb-6b0ad52970bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10834908-0c17-40b4-851c-4eeec0ce1d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10834908-0c17-40b4-851c-4eeec0ce1d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c04817f5-a7cb-4020-bf69-e16fe91e049e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_NetIncomeLoss_c04817f5-a7cb-4020-bf69-e16fe91e049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4bd45102-72c6-46c5-9124-edc12be767ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4bd45102-72c6-46c5-9124-edc12be767ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7603c46a-c309-43c1-8a6e-9e69c34d1aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_ProfitLoss_7603c46a-c309-43c1-8a6e-9e69c34d1aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bf37b94a-3459-4188-bb10-0db3a5334d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bf37b94a-3459-4188-bb10-0db3a5334d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4f95eb25-dfd9-4e78-a7d6-ee3958140f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4f95eb25-dfd9-4e78-a7d6-ee3958140f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b6090d5-ff19-42ea-a594-38431d422991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b6090d5-ff19-42ea-a594-38431d422991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_265b9a12-aa4c-405a-aa0b-e99461b47980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_265b9a12-aa4c-405a-aa0b-e99461b47980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7e1e2d3f-4419-4fc2-896b-8564b555950b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7e1e2d3f-4419-4fc2-896b-8564b555950b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d284715d-42ab-4e91-b35d-8f1d7612d4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d284715d-42ab-4e91-b35d-8f1d7612d4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_844c8afb-d936-4571-91a5-55890a5849cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_DividendsCommonStock_844c8afb-d936-4571-91a5-55890a5849cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3f3255b-d638-4078-bcb8-adf6b738e333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3f3255b-d638-4078-bcb8-adf6b738e333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ddecdea-e32a-44ed-beb8-e87054ba8cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ddecdea-e32a-44ed-beb8-e87054ba8cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_cf00d882-a7e3-47f6-a219-96bfebb20aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e78ba9-aa61-4c2c-872f-9c95c2758e24" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_cf00d882-a7e3-47f6-a219-96bfebb20aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f9c94eab-8603-42f9-a8c1-c03777502099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_SharesOutstanding_f9c94eab-8603-42f9-a8c1-c03777502099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13e80c37-e6d8-4928-a4cf-33458f805e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StockholdersEquity_13e80c37-e6d8-4928-a4cf-33458f805e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4a61262c-53cb-4e96-b869-eedb634ea5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_MinorityInterest_4a61262c-53cb-4e96-b869-eedb634ea5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1e98a98-47d9-480b-a3a2-6a18ae3a647a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bd67a794-d2b5-4593-936a-0fb53c2e0e97" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1e98a98-47d9-480b-a3a2-6a18ae3a647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/Organization" xlink:type="simple" xlink:href="elv-20221231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17ebea52-2315-4971-a945-1a62b350a91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_0410af15-7100-4fe7-a101-ff73b22c4ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17ebea52-2315-4971-a945-1a62b350a91b" xlink:to="loc_us-gaap_NatureOfOperations_0410af15-7100-4fe7-a101-ff73b22c4ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="elv-20221231.xsd#BasisOfPresentationAndSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1271d1fb-845f-4772-8ee7-b830523feac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8cacf131-94a4-4429-b2f4-ddc0aa69ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1271d1fb-845f-4772-8ee7-b830523feac3" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8cacf131-94a4-4429-b2f4-ddc0aa69ba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitions" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitions"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1694e40a-8622-486b-998d-dfc46382a99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_69f3e68f-fb16-4a06-8845-08a1a1c8f241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1694e40a-8622-486b-998d-dfc46382a99e" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_69f3e68f-fb16-4a06-8845-08a1a1c8f241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiatives" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessOptimizationInitiatives"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessOptimizationInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessOptimizationInitiativesAbstract_da351675-5858-4d87-8ef6-eda4efd0bfab" xlink:href="elv-20221231.xsd#elv_BusinessOptimizationInitiativesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1b9a373c-9c75-418a-88c5-6ff8bad6dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BusinessOptimizationInitiativesAbstract_da351675-5858-4d87-8ef6-eda4efd0bfab" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1b9a373c-9c75-418a-88c5-6ff8bad6dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/Investments" xlink:type="simple" xlink:href="elv-20221231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_b007f52c-9991-496c-bd99-2e1d1f3254c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_eeeebcf6-0af6-42b5-8f3b-3e2a9fabcbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b007f52c-9991-496c-bd99-2e1d1f3254c8" xlink:to="loc_us-gaap_InvestmentTextBlock_eeeebcf6-0af6-42b5-8f3b-3e2a9fabcbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fa86bb85-f3db-43b0-8479-930036b62cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1e7b0eb0-1453-4b3e-9293-9563a855b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fa86bb85-f3db-43b0-8479-930036b62cb7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1e7b0eb0-1453-4b3e-9293-9563a855b07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValue" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c061a90b-a3e9-489f-903b-60f71c08781f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_cbc64ad8-f451-4a20-a4bb-aa3b6e0c3bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c061a90b-a3e9-489f-903b-60f71c08781f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_cbc64ad8-f451-4a20-a4bb-aa3b6e0c3bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94461fa2-fde7-4622-98f8-9c3a96edb36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d22cd08f-8fdf-46d5-9027-82a06ebbb58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94461fa2-fde7-4622-98f8-9c3a96edb36f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d22cd08f-8fdf-46d5-9027-82a06ebbb58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipment"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_050ab3df-89a2-49f3-8834-c4ba0ec514df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_20882da4-3f51-4d6b-9bf3-6bc160a67755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_050ab3df-89a2-49f3-8834-c4ba0ec514df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_20882da4-3f51-4d6b-9bf3-6bc160a67755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc66ab3c-b79d-4b2e-8eb8-8ca491aaa866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_123c5206-c71b-4aac-b99b-e3c19b67bc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc66ab3c-b79d-4b2e-8eb8-8ca491aaa866" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_123c5206-c71b-4aac-b99b-e3c19b67bc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefits" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3aab5483-3718-404f-bc27-f00a39a4791f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_841d7979-4955-4ea4-af17-8ced4510f99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3aab5483-3718-404f-bc27-f00a39a4791f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_841d7979-4955-4ea4-af17-8ced4510f99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayable" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayable"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_MedicalClaimsPayableAbstract_0d77a76f-c13c-48d5-af28-f0e6229c098f" xlink:href="elv-20221231.xsd#elv_MedicalClaimsPayableAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_4e56a7d7-6498-40b8-9934-772952d817aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_0d77a76f-c13c-48d5-af28-f0e6229c098f" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_4e56a7d7-6498-40b8-9934-772952d817aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/Debt" xlink:type="simple" xlink:href="elv-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_36c6d8c0-f61d-4a4a-8bcb-1c91fbdf4fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3aa2d12a-97f8-47a4-a1eb-5f8c5a5b9c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_36c6d8c0-f61d-4a4a-8bcb-1c91fbdf4fad" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3aa2d12a-97f8-47a4-a1eb-5f8c5a5b9c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="elv-20221231.xsd#CommitmentsAndContingencies"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea6f0ccd-863f-419e-8d92-fd36de35de6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1fcaa7dc-1b03-46e4-822a-d779ff14f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea6f0ccd-863f-419e-8d92-fd36de35de6e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1fcaa7dc-1b03-46e4-822a-d779ff14f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStock" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStock"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_475a421c-6548-4dd4-aa74-d30ea87a1076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_65e106a5-28f5-469b-beef-517761ae1b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_475a421c-6548-4dd4-aa74-d30ea87a1076" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_65e106a5-28f5-469b-beef-517761ae1b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="elv-20221231.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6575bb9d-dd65-447c-8b0b-82caf43ddb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_1c928436-776c-4d5b-ab27-6a44eaf72750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6575bb9d-dd65-447c-8b0b-82caf43ddb83" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_1c928436-776c-4d5b-ab27-6a44eaf72750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/Reinsurance" xlink:type="simple" xlink:href="elv-20221231.xsd#Reinsurance"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/Reinsurance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_f566aeb5-5d81-481b-8b9c-7306f2107897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock_c5f6a8d9-e9f1-4bca-82fd-2a914276126c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_f566aeb5-5d81-481b-8b9c-7306f2107897" xlink:to="loc_us-gaap_ReinsuranceTextBlock_c5f6a8d9-e9f1-4bca-82fd-2a914276126c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/Leases" xlink:type="simple" xlink:href="elv-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_5ee914ba-f653-4434-8aa5-0c69e1e261a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_04425a6b-80e1-404e-a184-1a4c0b03ab84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_5ee914ba-f653-4434-8aa5-0c69e1e261a8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_04425a6b-80e1-404e-a184-1a4c0b03ab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/EarningsPerShare" xlink:type="simple" xlink:href="elv-20221231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d1211c82-5ba0-4bc3-8bcd-baa4051e3c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_86830803-8fdf-4fdf-b37f-8e45971a94c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d1211c82-5ba0-4bc3-8bcd-baa4051e3c87" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_86830803-8fdf-4fdf-b37f-8e45971a94c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformation" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0fc648b1-085a-4e0a-9d46-154379d17984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_13a5c653-45f6-4f96-9504-8ce5598b7307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0fc648b1-085a-4e0a-9d46-154379d17984" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_13a5c653-45f6-4f96-9504-8ce5598b7307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="elv-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b96f2003-ca03-465d-a550-b06006141a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_04cf12ec-aa4f-4078-88cd-917b89a9b411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b96f2003-ca03-465d-a550-b06006141a53" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_04cf12ec-aa4f-4078-88cd-917b89a9b411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/StatutoryInformation" xlink:type="simple" xlink:href="elv-20221231.xsd#StatutoryInformation"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/StatutoryInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_StatutoryInformationAbstract_ac283dab-41e9-4907-ba21-b496ec1e9af7" xlink:href="elv-20221231.xsd#elv_StatutoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StatutoryInformationTextBlock_2f7138f2-93e9-45cd-afba-e36aa1db61dc" xlink:href="elv-20221231.xsd#elv_StatutoryInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_StatutoryInformationAbstract_ac283dab-41e9-4907-ba21-b496ec1e9af7" xlink:to="loc_elv_StatutoryInformationTextBlock_2f7138f2-93e9-45cd-afba-e36aa1db61dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrant"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_35ef3708-c7a4-49c5-935b-5d8bfa3d719d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_fab2beb7-89c3-4570-ac55-a7f20e2a111b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_35ef3708-c7a4-49c5-935b-5d8bfa3d719d" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_fab2beb7-89c3-4570-ac55-a7f20e2a111b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy" xlink:type="simple" xlink:href="elv-20221231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicy"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_edcdd5d4-3a32-47c1-b428-afff994e61c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_edcdd5d4-3a32-47c1-b428-afff994e61c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7522bd9b-8b1f-48dc-a5bf-9d35a063fadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7522bd9b-8b1f-48dc-a5bf-9d35a063fadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_500451b1-eb2e-47cd-9c93-221b535aa4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_500451b1-eb2e-47cd-9c93-221b535aa4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_46035354-ca43-45b8-af7e-32d21e3ae255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_UseOfEstimates_46035354-ca43-45b8-af7e-32d21e3ae255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6c0eb43b-3ac9-4a72-86b5-4fd1cf9d22d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6c0eb43b-3ac9-4a72-86b5-4fd1cf9d22d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_5f9709ae-1384-4181-8dfc-a16d2ca63f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_5f9709ae-1384-4181-8dfc-a16d2ca63f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_7b5eee5e-b3ee-4b8f-b3c5-41c359fec2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_7b5eee5e-b3ee-4b8f-b3c5-41c359fec2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_240e32d7-3574-4cb8-8ec7-11afbeac24c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_240e32d7-3574-4cb8-8ec7-11afbeac24c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_52fbff2b-7a4a-4be4-8e51-0c8c5b9bc83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_52fbff2b-7a4a-4be4-8e51-0c8c5b9bc83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_363b77a2-b0a6-40b6-9a39-5b5ee4b94733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_363b77a2-b0a6-40b6-9a39-5b5ee4b94733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_098ed69c-910a-459e-a565-4eacf6916166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_098ed69c-910a-459e-a565-4eacf6916166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_25d84493-b7fe-4fc7-8955-83cb01c0746c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_25d84493-b7fe-4fc7-8955-83cb01c0746c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_04f59972-de34-4b47-abd1-b02b02d75564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_04f59972-de34-4b47-abd1-b02b02d75564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherPolicyholderLiabilitiesPolicyTextBlock_bd4a2a5e-4f8a-429f-96cd-a8ee9a038389" xlink:href="elv-20221231.xsd#elv_OtherPolicyholderLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_elv_OtherPolicyholderLiabilitiesPolicyTextBlock_bd4a2a5e-4f8a-429f-96cd-a8ee9a038389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy_7dc5a23f-25a2-46b6-9a02-e9d289ad90da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy_7dc5a23f-25a2-46b6-9a02-e9d289ad90da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_47bde0ed-1edf-4845-8745-58fa61e7923a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_47bde0ed-1edf-4845-8745-58fa61e7923a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_3beedb0f-1256-4a08-b47b-e17b0a2b86e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_3beedb0f-1256-4a08-b47b-e17b0a2b86e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0ccd547e-4223-4e7c-82dd-cbb347d6ab87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0ccd547e-4223-4e7c-82dd-cbb347d6ab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_7693f00f-f610-4702-af7d-1237f4dfaf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_7693f00f-f610-4702-af7d-1237f4dfaf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HealthInsuranceProviderFeePolicyTextBlock_cd126ecd-8572-47f4-92f9-43012a0fe0ce" xlink:href="elv-20221231.xsd#elv_HealthInsuranceProviderFeePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_elv_HealthInsuranceProviderFeePolicyTextBlock_cd126ecd-8572-47f4-92f9-43012a0fe0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9e1dd4f3-4729-4c1b-90f2-61c10e06fc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9e1dd4f3-4729-4c1b-90f2-61c10e06fc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f00e5ebc-cdfe-47e0-beb5-6cd045555df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f00e5ebc-cdfe-47e0-beb5-6cd045555df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c9e4115-d0ba-4dbd-ba49-eacb56d38617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d96947b-d9d6-45aa-a3ac-813eeab504f6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c9e4115-d0ba-4dbd-ba49-eacb56d38617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsTables" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2d693a9d-407c-4738-9dba-5bbd06b09257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_877b1680-ed8b-40a0-b198-836c0c589fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2d693a9d-407c-4738-9dba-5bbd06b09257" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_877b1680-ed8b-40a0-b198-836c0c589fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_7cf11a7a-99e7-41bb-bc12-99f544424cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2d693a9d-407c-4738-9dba-5bbd06b09257" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_7cf11a7a-99e7-41bb-bc12-99f544424cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessOptimizationInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessOptimizationInitiativesAbstract_7fe678e4-023b-497f-9855-1595f436c51f" xlink:href="elv-20221231.xsd#elv_BusinessOptimizationInitiativesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_c55fe3dd-f9f2-4b63-a6ea-2eb458a366cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BusinessOptimizationInitiativesAbstract_7fe678e4-023b-497f-9855-1595f436c51f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_c55fe3dd-f9f2-4b63-a6ea-2eb458a366cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsTables" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_4208a1da-408b-4e7d-afd3-0e31a2d1e1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_4208a1da-408b-4e7d-afd3-0e31a2d1e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_27925d15-c882-4d73-a094-8945c51c207b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_27925d15-c882-4d73-a094-8945c51c207b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6484bfed-a114-4e48-8656-75f8e54ec566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6484bfed-a114-4e48-8656-75f8e54ec566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentsinequitysecuritiesTableTextBlock_c1692f03-8ffc-4d32-a387-1f041b0f9012" xlink:href="elv-20221231.xsd#elv_InvestmentsinequitysecuritiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:to="loc_elv_InvestmentsinequitysecuritiesTableTextBlock_c1692f03-8ffc-4d32-a387-1f041b0f9012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock_fcab5f0f-6f86-4376-aa9c-a93a7670686f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:to="loc_us-gaap_InvestmentIncomeTextBlock_fcab5f0f-6f86-4376-aa9c-a93a7670686f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_8c34b3fd-651b-4104-b33c-a80dc5ee25ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ff40ae76-221a-425e-9534-6d818ee818ac" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_8c34b3fd-651b-4104-b33c-a80dc5ee25ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_049ccd28-4d96-4810-93b8-45dc06408d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ea598364-fb75-497e-a182-59c14fc16d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_049ccd28-4d96-4810-93b8-45dc06408d7a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ea598364-fb75-497e-a182-59c14fc16d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_aacfdc02-061f-4380-880c-975aa1294238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_049ccd28-4d96-4810-93b8-45dc06408d7a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_aacfdc02-061f-4380-880c-975aa1294238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_abe57f20-8321-4c1b-8710-a5fada5b691b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_049ccd28-4d96-4810-93b8-45dc06408d7a" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_abe57f20-8321-4c1b-8710-a5fada5b691b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_72a76336-a461-41f7-8ed0-72a603706b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_049ccd28-4d96-4810-93b8-45dc06408d7a" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_72a76336-a461-41f7-8ed0-72a603706b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueTables" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_409461ed-46c6-4316-892c-bdffe8a2bd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ec27f197-f785-488a-98fe-a1ed4e35067d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_409461ed-46c6-4316-892c-bdffe8a2bd3c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ec27f197-f785-488a-98fe-a1ed4e35067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a123a5b0-9896-4cf5-ba3b-034128814997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_409461ed-46c6-4316-892c-bdffe8a2bd3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a123a5b0-9896-4cf5-ba3b-034128814997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock_c0a9cdab-c8b4-4d8e-9447-9ee34526dbd2" xlink:href="elv-20221231.xsd#elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_409461ed-46c6-4316-892c-bdffe8a2bd3c" xlink:to="loc_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock_c0a9cdab-c8b4-4d8e-9447-9ee34526dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6715a916-98d8-45fe-ad49-80ecbb914927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_493043d5-6dd9-43d2-9e9b-45ccd6f6bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6715a916-98d8-45fe-ad49-80ecbb914927" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_493043d5-6dd9-43d2-9e9b-45ccd6f6bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6682d521-66e9-41b1-846e-ec4bb18b1129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6715a916-98d8-45fe-ad49-80ecbb914927" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6682d521-66e9-41b1-846e-ec4bb18b1129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b2b1bd71-a6b2-4d90-91da-942959b48719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6715a916-98d8-45fe-ad49-80ecbb914927" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b2b1bd71-a6b2-4d90-91da-942959b48719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_4325cbe0-2f11-43a6-b7d5-5d397bd7fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6715a916-98d8-45fe-ad49-80ecbb914927" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_4325cbe0-2f11-43a6-b7d5-5d397bd7fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95038220-0252-40e3-9061-b79b3e7ad986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ae27d149-6328-4fb5-a32c-25f461f27b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95038220-0252-40e3-9061-b79b3e7ad986" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ae27d149-6328-4fb5-a32c-25f461f27b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_680a9f64-2054-4e9c-b9b1-a4a796f634e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_63295a01-57a8-4163-94d6-9156f1a32641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_680a9f64-2054-4e9c-b9b1-a4a796f634e4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_63295a01-57a8-4163-94d6-9156f1a32641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock_6f8c290c-1d1d-43ec-9b6e-7c5b318c96e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_680a9f64-2054-4e9c-b9b1-a4a796f634e4" xlink:to="loc_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock_6f8c290c-1d1d-43ec-9b6e-7c5b318c96e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_5d89d5e6-c9dc-4e88-9f2f-bab54eb8c42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_5d89d5e6-c9dc-4e88-9f2f-bab54eb8c42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_d8bb728f-5de7-438c-98b3-f34069dd2f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_d8bb728f-5de7-438c-98b3-f34069dd2f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_091d6cb2-3f01-4885-9236-c52d9331286a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_091d6cb2-3f01-4885-9236-c52d9331286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_01660f84-c1da-439e-bb69-5dd01c2bfc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_01660f84-c1da-439e-bb69-5dd01c2bfc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock_5aa84eae-868c-442a-856b-36aaa4d735c6" xlink:href="elv-20221231.xsd#elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock_5aa84eae-868c-442a-856b-36aaa4d735c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_87d6c7e3-9a9a-45dc-a8d8-79978adc9efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_87d6c7e3-9a9a-45dc-a8d8-79978adc9efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock_289aa432-e915-4c42-bf42-4c0e9d317a0d" xlink:href="elv-20221231.xsd#elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock_289aa432-e915-4c42-bf42-4c0e9d317a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_c731305c-ab53-4fcf-86d8-d7b9bff7c9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_c731305c-ab53-4fcf-86d8-d7b9bff7c9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_454a26f2-5217-4aa4-8b21-75c3c758dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_454a26f2-5217-4aa4-8b21-75c3c758dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d96cf73a-d0dd-46f0-ac59-47e9c03aab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d2991a8-c869-45ed-b3e5-debbf072590a" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d96cf73a-d0dd-46f0-ac59-47e9c03aab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableTables" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_MedicalClaimsPayableAbstract_a43d0d62-6959-4e42-844d-064bec022897" xlink:href="elv-20221231.xsd#elv_MedicalClaimsPayableAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_8174d91a-90ea-4a80-a9cb-fcb6d4556ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a43d0d62-6959-4e42-844d-064bec022897" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_8174d91a-90ea-4a80-a9cb-fcb6d4556ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_af5ab48e-7055-4bfa-b970-b46c3daa8aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a43d0d62-6959-4e42-844d-064bec022897" xlink:to="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_af5ab48e-7055-4bfa-b970-b46c3daa8aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock_ec546f7b-8fda-4a7b-9aad-b8ce63135180" xlink:href="elv-20221231.xsd#elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a43d0d62-6959-4e42-844d-064bec022897" xlink:to="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock_ec546f7b-8fda-4a7b-9aad-b8ce63135180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_1b99fb35-a760-4394-be3d-ccf56332d134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a43d0d62-6959-4e42-844d-064bec022897" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_1b99fb35-a760-4394-be3d-ccf56332d134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_788c5ae9-729e-42a1-a273-b118dd493ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a43d0d62-6959-4e42-844d-064bec022897" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_788c5ae9-729e-42a1-a273-b118dd493ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DebtTables" xlink:type="simple" xlink:href="elv-20221231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e74c7f5b-3883-4833-a18c-a479bf9c033b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_081fdd1a-9182-47c7-9558-31eb9d01a65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e74c7f5b-3883-4833-a18c-a479bf9c033b" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_081fdd1a-9182-47c7-9558-31eb9d01a65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_bb619ab8-e5b0-445c-a5e5-4f57ee960721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e74c7f5b-3883-4833-a18c-a479bf9c033b" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_bb619ab8-e5b0-445c-a5e5-4f57ee960721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockTables" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8af2baae-7eb4-41c8-b0ee-576d0a08d4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8af2baae-7eb4-41c8-b0ee-576d0a08d4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2009e426-c45b-4859-b5a9-4aa250cccbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2009e426-c45b-4859-b5a9-4aa250cccbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b656f9e-7e3f-4c42-bfb0-99441c620988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b656f9e-7e3f-4c42-bfb0-99441c620988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_57e2898c-41a8-4d9d-8009-9e179d948343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_57e2898c-41a8-4d9d-8009-9e179d948343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_71f309ae-e792-4a44-b577-cf2a3e7f6cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_71f309ae-e792-4a44-b577-cf2a3e7f6cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_abea1683-8bb7-46b0-a3d5-5ea1909c1449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_3d2cee2f-4e73-4f28-a5f1-2ade0db0cf4b" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_abea1683-8bb7-46b0-a3d5-5ea1909c1449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="elv-20221231.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_77ee8c17-60a5-443c-8de7-e00b3dc959f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8c750049-edb0-4b3f-b3b6-45b0798f1b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_77ee8c17-60a5-443c-8de7-e00b3dc959f1" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8c750049-edb0-4b3f-b3b6-45b0798f1b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceTables" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_891185b2-9551-4b91-a930-4c5afbed4f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_900c044e-e79e-4bdf-af54-8fe942526ccd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_891185b2-9551-4b91-a930-4c5afbed4f44" xlink:to="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_900c044e-e79e-4bdf-af54-8fe942526ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock_0b14d889-0c31-4835-890c-76f86712d878" xlink:href="elv-20221231.xsd#elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_891185b2-9551-4b91-a930-4c5afbed4f44" xlink:to="loc_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock_0b14d889-0c31-4835-890c-76f86712d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_335e8a25-e011-466d-8b3d-d0e8aa4f3096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_891185b2-9551-4b91-a930-4c5afbed4f44" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_335e8a25-e011-466d-8b3d-d0e8aa4f3096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/LeasesTables" xlink:type="simple" xlink:href="elv-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_d6997398-ed26-417a-a47d-597aed3b7399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LesseeOperatingLeasesTableTextBlock_43d6be83-df07-4fc1-b06f-cd47e8764770" xlink:href="elv-20221231.xsd#elv_LesseeOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_d6997398-ed26-417a-a47d-597aed3b7399" xlink:to="loc_elv_LesseeOperatingLeasesTableTextBlock_43d6be83-df07-4fc1-b06f-cd47e8764770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da3067f4-888c-46b3-ab75-132b5a90a4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_d6997398-ed26-417a-a47d-597aed3b7399" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da3067f4-888c-46b3-ab75-132b5a90a4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="elv-20221231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e4f2e473-7958-49e2-99dc-514f86f53895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f38ec12f-48aa-4a05-b865-ebec726de801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e4f2e473-7958-49e2-99dc-514f86f53895" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f38ec12f-48aa-4a05-b865-ebec726de801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6339ee23-6fe9-42fc-aa4b-34696bb09b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f494cdac-4190-4fde-a5d8-44ef73891524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6339ee23-6fe9-42fc-aa4b-34696bb09b43" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f494cdac-4190-4fde-a5d8-44ef73891524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentTableTextBlock_6c145280-9e46-4ada-9da0-402aad4e0a5f" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6339ee23-6fe9-42fc-aa4b-34696bb09b43" xlink:to="loc_elv_MajorProductRevenueBySegmentTableTextBlock_6c145280-9e46-4ada-9da0-402aad4e0a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_d422aac8-1169-4735-8d4c-4d0e74138880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6339ee23-6fe9-42fc-aa4b-34696bb09b43" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_d422aac8-1169-4735-8d4c-4d0e74138880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_adba0369-e7f3-4289-a215-fd1ebf134731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6339ee23-6fe9-42fc-aa4b-34696bb09b43" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_adba0369-e7f3-4289-a215-fd1ebf134731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f597d33c-36c9-4682-a834-b5f4298088b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfCountiesInGeographicalRegionNotServed_381014f5-6232-4df5-99d5-ab399476b52b" xlink:href="elv-20221231.xsd#elv_NumberOfCountiesInGeographicalRegionNotServed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f597d33c-36c9-4682-a834-b5f4298088b0" xlink:to="loc_elv_NumberOfCountiesInGeographicalRegionNotServed_381014f5-6232-4df5-99d5-ab399476b52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_6175a819-65bf-411f-ac29-6cb2020118b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f597d33c-36c9-4682-a834-b5f4298088b0" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_6175a819-65bf-411f-ac29-6cb2020118b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfMedicalMembersServed_33fac871-de38-4381-927a-e20666edc5e4" xlink:href="elv-20221231.xsd#elv_NumberOfMedicalMembersServed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f597d33c-36c9-4682-a834-b5f4298088b0" xlink:to="loc_elv_NumberOfMedicalMembersServed_33fac871-de38-4381-927a-e20666edc5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_122f58d9-f544-42a7-9a0f-f4f7764e6af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:href="elv-20221231.xsd#elv_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_122f58d9-f544-42a7-9a0f-f4f7764e6af2" xlink:to="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_35fcf5ff-0783-4645-a72d-98259d3368fe" xlink:to="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_304b5ced-76b9-45b1-97b0-66d34170703e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:to="loc_srt_MinimumMember_304b5ced-76b9-45b1-97b0-66d34170703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26c56ab8-1e3d-4798-ba5c-1495d1839440" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75b20ffb-5836-497c-83d5-c9c2eab75456" xlink:to="loc_srt_MaximumMember_26c56ab8-1e3d-4798-ba5c-1495d1839440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_95d652fd-b189-4363-b68b-6e6cd282f609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a71c68fe-b9a3-4a02-8dc6-2907d0351b18" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_95d652fd-b189-4363-b68b-6e6cd282f609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_914b496a-fc51-434c-a107-c97dba454f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d9ac488a-3900-4034-aeeb-0b0ad6e1bbd0" xlink:to="loc_us-gaap_ReceivableTypeDomain_914b496a-fc51-434c-a107-c97dba454f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70b943ed-b499-4462-a889-302e94a69c5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_daddd2b7-d811-4018-b3d5-36a9ce853138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_daddd2b7-d811-4018-b3d5-36a9ce853138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ab07bc09-8feb-41be-8a52-d34f3fe3ebca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_ComputerEquipmentMember_ab07bc09-8feb-41be-8a52-d34f3fe3ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_43816fb8-4388-4af9-9404-22ab9b8f2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_43816fb8-4388-4af9-9404-22ab9b8f2e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_43ed3437-8dea-46e4-877e-3900739bd3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_43ed3437-8dea-46e4-877e-3900739bd3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_484f7e06-edde-47ab-9262-50108f8a990a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ab923d1-027c-4990-9ea1-ce0826baad04" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_484f7e06-edde-47ab-9262-50108f8a990a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a41963b3-fbef-432f-943c-7fe4c396f003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f1950372-d98f-4312-9f1f-81f611e982b5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a41963b3-fbef-432f-943c-7fe4c396f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_f864733c-5efb-42a0-9590-34e26fbb3d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a41963b3-fbef-432f-943c-7fe4c396f003" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_f864733c-5efb-42a0-9590-34e26fbb3d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a28d5ef5-06bc-4101-85c1-e62883f13e24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cb3c8031-f169-4557-a3d9-a6bc283a9e79" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a28d5ef5-06bc-4101-85c1-e62883f13e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a49d28aa-889c-4324-9cd9-ea6ed7106345" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a28d5ef5-06bc-4101-85c1-e62883f13e24" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a49d28aa-889c-4324-9cd9-ea6ed7106345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_368a0030-20a2-4a73-9603-5b377d6f0ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b06499d-f22f-4fab-8630-fb1a59b65d16" xlink:to="loc_us-gaap_EquityComponentDomain_368a0030-20a2-4a73-9603-5b377d6f0ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1d0ef9ba-977b-4304-89be-64e5da495a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_368a0030-20a2-4a73-9603-5b377d6f0ce3" xlink:to="loc_us-gaap_RetainedEarningsMember_1d0ef9ba-977b-4304-89be-64e5da495a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:href="elv-20221231.xsd#elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesTable_86dfc322-9af2-4712-8890-dbfdd58dc517" xlink:to="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a9743611-89cc-4d7c-aa51-5a750ed23a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a9743611-89cc-4d7c-aa51-5a750ed23a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_90732dfe-71f9-4a08-9b46-60faaf8a6da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_90732dfe-71f9-4a08-9b46-60faaf8a6da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_ddc32274-3596-4a87-90b5-d75ccbfa897e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_ddc32274-3596-4a87-90b5-d75ccbfa897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_5530f9f2-c765-43fa-9c95-558b0c3d096c" xlink:href="elv-20221231.xsd#elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_5530f9f2-c765-43fa-9c95-558b0c3d096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c40a3cf8-fb28-46b8-b878-4f6918a307c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c40a3cf8-fb28-46b8-b878-4f6918a307c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_babd146e-599f-47b1-a9e9-f3510f038b29" xlink:href="elv-20221231.xsd#elv_SelffundedReceivablesAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts_babd146e-599f-47b1-a9e9-f3510f038b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_8d481487-d9b2-4551-8bc0-292cf8473640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_8d481487-d9b2-4551-8bc0-292cf8473640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses_8fc469fa-c59d-439c-af82-500feaafb45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses_8fc469fa-c59d-439c-af82-500feaafb45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aaedf489-6f11-4868-9e71-ff39f536401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aaedf489-6f11-4868-9e71-ff39f536401a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingAndAdvertisingExpense_5c57dde4-fc10-4c74-91c5-a82b0aeeaef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_MarketingAndAdvertisingExpense_5c57dde4-fc10-4c74-91c5-a82b0aeeaef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_25189702-b43e-469d-bbf3-cbad1c4b8a6f" xlink:href="elv-20221231.xsd#elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee_25189702-b43e-469d-bbf3-cbad1c4b8a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_ce81ad9a-2aaa-4cbb-b397-ece5cd6ff0b5" xlink:href="elv-20221231.xsd#elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid_ce81ad9a-2aaa-4cbb-b397-ece5cd6ff0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384dfa6d-0a3b-49c8-8140-e245683702d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384dfa6d-0a3b-49c8-8140-e245683702d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2862f95a-f509-4ab9-acbb-0d07ddfd4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2862f95a-f509-4ab9-acbb-0d07ddfd4cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f344de27-d1ee-45f5-bf49-4e328e03d9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_LongTermDebt_f344de27-d1ee-45f5-bf49-4e328e03d9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_d35107eb-e1e8-4516-91e2-fda491f8e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_d35107eb-e1e8-4516-91e2-fda491f8e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c8fda5f-de97-417f-9ba9-92185b3c7819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_9d9cb0bc-4c5a-4d5c-9643-e573e1258788" xlink:to="loc_us-gaap_StockholdersEquity_8c8fda5f-de97-417f-9ba9-92185b3c7819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_45fff46d-24e7-40f1-af01-2395d6264a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_45fff46d-24e7-40f1-af01-2395d6264a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets_71210fa3-e04d-4c3a-9237-6b3f946608ae" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets_71210fa3-e04d-4c3a-9237-6b3f946608ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets_9ece7805-e5ba-4f93-ae74-cd0fd6ea1fda" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets_9ece7805-e5ba-4f93-ae74-cd0fd6ea1fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities_7beced70-a52c-452c-aa2f-a6f9f4b1827d" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities_7beced70-a52c-452c-aa2f-a6f9f4b1827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities_2ca55221-515b-4769-9ebd-86ced3326592" xlink:href="elv-20221231.xsd#elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities_2ca55221-515b-4769-9ebd-86ced3326592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_96c462cb-6ab7-4558-8f05-988ca5d1b32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_96c462cb-6ab7-4558-8f05-988ca5d1b32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7a6103fb-6359-4c4b-acf2-e6f4e86d7032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7a6103fb-6359-4c4b-acf2-e6f4e86d7032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1fbef057-13e9-4761-8453-ca7aa458597b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aef5ade6-dc24-4c83-a477-3d029e817e34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1fbef057-13e9-4761-8453-ca7aa458597b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitionsIntangibleAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b1a90b4d-4458-4ac1-85f0-41b40d20d9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b1a90b4d-4458-4ac1-85f0-41b40d20d9b0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d6e7fc10-c23b-41a3-8186-d5aeccb90b10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c534e07a-c09d-4b5b-9c4f-2ed3e07f3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c534e07a-c09d-4b5b-9c4f-2ed3e07f3dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_a557c8bc-6d6b-4d62-870a-235208d8f2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:to="loc_us-gaap_ContractualRightsMember_a557c8bc-6d6b-4d62-870a-235208d8f2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_dc4e7e5e-8f3e-4222-8fd2-1bb19cc26025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_667b6d1f-cd51-451e-a470-2ab58631104c" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_dc4e7e5e-8f3e-4222-8fd2-1bb19cc26025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c0ab418-c768-4b81-8c5c-f9c5ee2c51f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cca3711a-4469-4047-be4c-6157adba8a8e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c0ab418-c768-4b81-8c5c-f9c5ee2c51f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_04967ac3-e998-4b9c-a21d-ab6ac4742cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c0ab418-c768-4b81-8c5c-f9c5ee2c51f2" xlink:to="loc_us-gaap_LicensingAgreementsMember_04967ac3-e998-4b9c-a21d-ab6ac4742cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5b6271b4-59bf-4a10-9f83-79a93147507d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0b352025-44f9-4c67-8f52-da361772225b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0b352025-44f9-4c67-8f52-da361772225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5e748a11-ad21-47e3-a77d-d4940c331424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5e748a11-ad21-47e3-a77d-d4940c331424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_665f7b66-2223-4919-a4f4-fe1cf1e3079f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_665f7b66-2223-4919-a4f4-fe1cf1e3079f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalIntangibleAssetsAcquired_4bf36cdb-5e38-4675-99fa-88e783454e78" xlink:href="elv-20221231.xsd#elv_TotalIntangibleAssetsAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebe9d4b1-f691-472e-ba9b-ad9c80ecf81b" xlink:to="loc_elv_TotalIntangibleAssetsAcquired_4bf36cdb-5e38-4675-99fa-88e783454e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessAcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_61347e5b-0441-448d-82a3-397d97e83c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_61347e5b-0441-448d-82a3-397d97e83c0d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e147ace-922a-4452-ba7b-059fd2331f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17044f6c-9dba-4b90-8a38-97bc65c34e7c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e147ace-922a-4452-ba7b-059fd2331f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_5704d185-7c9f-40dd-b262-58e3e36612a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e147ace-922a-4452-ba7b-059fd2331f56" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_5704d185-7c9f-40dd-b262-58e3e36612a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f1b120c9-67aa-4fec-ae7d-275830ab32b8" xlink:to="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_000f47af-c1f8-45bb-86b9-316a3cd7440e" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:to="loc_elv_GovernmentBusinessSegmentMember_000f47af-c1f8-45bb-86b9-316a3cd7440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_750e8c5f-751c-4701-9547-a35f5ffe0c21" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:to="loc_elv_OtherSegmentMember_750e8c5f-751c-4701-9547-a35f5ffe0c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_c9465697-3403-44be-b6f8-37fabdcfa07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec01fe05-40d0-4361-ba31-35b5d0a61c5a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_c9465697-3403-44be-b6f8-37fabdcfa07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:href="elv-20221231.xsd#elv_AcquisitionYearAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearDomain_cefb2e0f-9992-4463-a226-78e767db9281" xlink:href="elv-20221231.xsd#elv_AcquisitionYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_AcquisitionYearAxis_d5e0908b-7f52-44e5-830d-e26dbf65841f" xlink:to="loc_elv_AcquisitionYearDomain_cefb2e0f-9992-4463-a226-78e767db9281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AcquisitionYearPriorDomain_98c8359e-27bf-4a0c-93b9-a7bc4c0039dc" xlink:href="elv-20221231.xsd#elv_AcquisitionYearPriorDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_AcquisitionYearDomain_cefb2e0f-9992-4463-a226-78e767db9281" xlink:to="loc_elv_AcquisitionYearPriorDomain_98c8359e-27bf-4a0c-93b9-a7bc4c0039dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_97250ef1-f295-40f3-8937-14ce2763febf" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4a1af38-cf30-4e0a-ba55-ffcae89d88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4a1af38-cf30-4e0a-ba55-ffcae89d88c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a6d1fe20-4a5b-4448-8b79-5c04522acd89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a6d1fe20-4a5b-4448-8b79-5c04522acd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_23831ed4-e825-4e28-b803-2affa8000fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_23831ed4-e825-4e28-b803-2affa8000fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ef288fb3-a537-4ef2-bcbd-538a55844973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ef288fb3-a537-4ef2-bcbd-538a55844973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_33055185-bace-4b69-b57b-3c8f908647cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_33055185-bace-4b69-b57b-3c8f908647cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05ef200e-c8b4-459c-a49b-1eadc0d9a544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_Goodwill_05ef200e-c8b4-459c-a49b-1eadc0d9a544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ad178703-3abd-4025-81a1-9a76fba1e558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12dd4642-e7c4-43ba-ad89-5ef6400624b0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ad178703-3abd-4025-81a1-9a76fba1e558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessOptimizationInitiativesEmployeeTerminationCostsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f9e3045e-e680-4505-a54b-7f30af58f9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f9e3045e-e680-4505-a54b-7f30af58f9e2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16f464d8-aa3c-45b8-950e-3d4d2bb3ae4d" xlink:to="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_a176896a-1bbc-4497-b1ca-b2c39ce6aef0" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_IngenioRxSegmentMember_a176896a-1bbc-4497-b1ca-b2c39ce6aef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_ca585a5b-ec77-4d6e-aad5-79f25648aaa4" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_OtherSegmentMember_ca585a5b-ec77-4d6e-aad5-79f25648aaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_1b38ada8-afb6-496a-8dba-1da63c23c63c" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_GovernmentBusinessSegmentMember_1b38ada8-afb6-496a-8dba-1da63c23c63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_bdb00513-5c02-4f3b-8c6b-9033ad80949c" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e8248dce-016f-43c0-8e27-4ea4bdc7912d" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_bdb00513-5c02-4f3b-8c6b-9033ad80949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d77ca120-f42d-4b55-99dd-f59b69e42726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a4f17cda-77ab-44dd-8fb6-52e49a7f02e0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d77ca120-f42d-4b55-99dd-f59b69e42726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_872ebb1c-b216-4976-8374-fdde705950a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d77ca120-f42d-4b55-99dd-f59b69e42726" xlink:to="loc_us-gaap_EmployeeSeveranceMember_872ebb1c-b216-4976-8374-fdde705950a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_da0e7385-c035-45b2-a684-aa2c033198a5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e02e857f-ff0c-4ac3-bd4b-dfaa2cce99f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_RestructuringReserve_e02e857f-ff0c-4ac3-bd4b-dfaa2cce99f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_3fea1116-1021-4b79-b92d-f1f66ef062d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_PaymentsForRestructuring_3fea1116-1021-4b79-b92d-f1f66ef062d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_54b1b66e-3568-43e2-867c-9eec2d188799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_54b1b66e-3568-43e2-867c-9eec2d188799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_d197f95d-c6ec-4d49-aae4-bd3846f2e6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ec5ce47-bcad-4df8-b15e-c630aa8fb87f" xlink:to="loc_us-gaap_RestructuringReserve_d197f95d-c6ec-4d49-aae4-bd3846f2e6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#BusinessOptimizationInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ba4da3b-0f48-461a-932e-ab213ddccc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ba4da3b-0f48-461a-932e-ab213ddccc67" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e87a4ea6-bc4e-40c5-bcd2-2557038110e2" xlink:to="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b6da420-1f20-4a0a-9215-58ca90919bba" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b6da420-1f20-4a0a-9215-58ca90919bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_a6145005-1f15-4a1f-98c1-8e22dd7afd73" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_IngenioRxSegmentMember_a6145005-1f15-4a1f-98c1-8e22dd7afd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_8bbeaf36-bf3e-4474-ba42-0a3fdbc3833c" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_OtherSegmentMember_8bbeaf36-bf3e-4474-ba42-0a3fdbc3833c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_591b3969-4c83-4edc-8336-365a6fcb0b07" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7152b6d-dc45-49e6-963f-d21384b5aab3" xlink:to="loc_elv_GovernmentBusinessSegmentMember_591b3969-4c83-4edc-8336-365a6fcb0b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_75c45707-92ab-413e-9f73-b32f213728ff" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b334a062-c301-48a7-94db-bee0d250a123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b334a062-c301-48a7-94db-bee0d250a123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PPEImpairmentMember_fc77a152-0e66-465d-bc4d-3c496270c389" xlink:href="elv-20221231.xsd#elv_PPEImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:to="loc_elv_PPEImpairmentMember_fc77a152-0e66-465d-bc4d-3c496270c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LeaseImpairmentMember_75ea40b2-b4c4-48a2-99df-47b5baed7c5b" xlink:href="elv-20221231.xsd#elv_LeaseImpairmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7dc790d0-1120-43a2-abcb-10a3ca0383fb" xlink:to="loc_elv_LeaseImpairmentMember_75ea40b2-b4c4-48a2-99df-47b5baed7c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e66d054a-68f1-4e10-9165-9df4d9e81fc4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f920e92d-89e5-432d-ad00-2373af77057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f920e92d-89e5-432d-ad00-2373af77057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1ed27a9d-1471-4230-86ec-88569dc7e972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1ed27a9d-1471-4230-86ec-88569dc7e972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_807784c1-a496-4209-ad66-f88992dfb081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6133eb73-c9fa-404b-a0ff-3a614e8c151d" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_807784c1-a496-4209-ad66-f88992dfb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_4ec46a87-4897-446b-ac25-157160a26e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4ec46a87-4897-446b-ac25-157160a26e1e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:to="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2a2173f7-c4e5-4383-93c1-fa95a8e05a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_934dbc77-866f-4396-9345-ab0e80297ca2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2a2173f7-c4e5-4383-93c1-fa95a8e05a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_f49aa5e0-2763-47f9-bd0b-47282284d13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a2173f7-c4e5-4383-93c1-fa95a8e05a41" xlink:to="loc_us-gaap_FixedMaturitiesMember_f49aa5e0-2763-47f9-bd0b-47282284d13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f2a45902-1b73-4beb-b137-cfca57ae4cd7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_96e585f4-2dc8-4d3c-b270-ff7b9ed525ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_96e585f4-2dc8-4d3c-b270-ff7b9ed525ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe654fd-ced3-4de3-aa8a-b8d19fea5cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe654fd-ced3-4de3-aa8a-b8d19fea5cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_ef74e2ad-240d-4a98-a912-e58a3020871c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_ef74e2ad-240d-4a98-a912-e58a3020871c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_84aeb0b6-1255-4edf-8fb2-c6acfa13b77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_84aeb0b6-1255-4edf-8fb2-c6acfa13b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d2adccb8-d5cb-4756-a444-b71d0bf4e666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d2adccb8-d5cb-4756-a444-b71d0bf4e666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_b3fab263-bb1f-45d6-a7f6-b5b97bd630ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_b3fab263-bb1f-45d6-a7f6-b5b97bd630ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_455fd26c-20ed-4a44-8a1c-8d8af9ba2b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_455fd26c-20ed-4a44-8a1c-8d8af9ba2b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_599a03d9-aacf-44e1-bbb9-67f35c4fc36a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d98c12f-a610-4bbd-99b8-32ff5c4f1ddc" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_599a03d9-aacf-44e1-bbb9-67f35c4fc36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6e69a2fc-1196-4091-b52c-031aa9c4db82" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_96e87a7d-b1be-46cb-a0e3-cbde0a18f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_96e87a7d-b1be-46cb-a0e3-cbde0a18f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3569ee3e-9b4e-45f0-8d03-3e8a5b2b64e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3569ee3e-9b4e-45f0-8d03-3e8a5b2b64e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ccd1ee2-4770-4c7b-9105-7a6d65fc830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ccd1ee2-4770-4c7b-9105-7a6d65fc830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f6ec1fce-8b6f-4fd7-92ef-3264781186a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f6ec1fce-8b6f-4fd7-92ef-3264781186a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d1a8b9a-f0ab-4c5b-b8d4-a92ac5523264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fc0c1f2-6801-4e08-9518-59d73a913c8c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d1a8b9a-f0ab-4c5b-b8d4-a92ac5523264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_0ab6f370-4f24-4cd9-9961-676565cc1b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0ab6f370-4f24-4cd9-9961-676565cc1b28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:to="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46f4a0d7-ce42-42b3-9015-3a8285ed71af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_baf50345-9813-4043-9335-e5e6d9aca2dd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46f4a0d7-ce42-42b3-9015-3a8285ed71af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_fa6e692b-e73e-43c0-9b77-09e781991c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46f4a0d7-ce42-42b3-9015-3a8285ed71af" xlink:to="loc_us-gaap_FixedMaturitiesMember_fa6e692b-e73e-43c0-9b77-09e781991c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_76ae6c60-509a-4efd-8192-c0c737739d2e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f1f06c49-a09e-45b3-952a-a61e09a72df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f1f06c49-a09e-45b3-952a-a61e09a72df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0b113b06-44fe-49e9-83e2-eb3de4638f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0b113b06-44fe-49e9-83e2-eb3de4638f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_ce309f23-b18c-4556-9801-2b3a98d655a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_ce309f23-b18c-4556-9801-2b3a98d655a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_8c96c3f6-0758-454c-a827-3f26e2916a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_8c96c3f6-0758-454c-a827-3f26e2916a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e08e1f44-3dd8-40fd-ba83-0f3f9679106b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e08e1f44-3dd8-40fd-ba83-0f3f9679106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_c490fd9a-1df7-482e-85f4-babb13d248b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_c490fd9a-1df7-482e-85f4-babb13d248b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_22b320ed-84a9-4c52-9276-f093469d4d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_22b320ed-84a9-4c52-9276-f093469d4d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_f3d8327f-ad50-4e89-bfae-0831ba24e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9573dc1d-2479-4114-afe5-a2006faef143" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_f3d8327f-ad50-4e89-bfae-0831ba24e88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_6e7d6f7e-51f6-4fdd-ad53-c7d52fc45bfb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_82e67279-512d-46af-9b60-1fa303f50179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_82e67279-512d-46af-9b60-1fa303f50179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_31a3f2e6-78e2-40fe-84f1-24ad5f1b42a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_31a3f2e6-78e2-40fe-84f1-24ad5f1b42a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_070c30d4-2aa4-4b29-93d4-2369ac8da6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_070c30d4-2aa4-4b29-93d4-2369ac8da6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9e357af5-dbd2-48db-b1a0-9e4645c87747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9e357af5-dbd2-48db-b1a0-9e4645c87747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_06ad6759-1ddb-4e9e-bb24-c6a4b4c12267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_06ad6759-1ddb-4e9e-bb24-c6a4b4c12267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_474dbc62-18a1-4803-896a-f1266fc15376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b6bd7d4-422e-40d6-8b11-a4a2aa4c1f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_474dbc62-18a1-4803-896a-f1266fc15376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_6341ee76-4f72-4bd1-aa0a-56d7f8b1a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_6341ee76-4f72-4bd1-aa0a-56d7f8b1a0d8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:to="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_75dbacc8-47da-4116-a0f8-42bc7571ad86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c995dd25-c9c6-45b7-8b79-d9561c042189" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_75dbacc8-47da-4116-a0f8-42bc7571ad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_97709ec1-b7e5-4ae2-812b-18875964fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_75dbacc8-47da-4116-a0f8-42bc7571ad86" xlink:to="loc_us-gaap_FixedMaturitiesMember_97709ec1-b7e5-4ae2-812b-18875964fbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cfbe8421-aef0-4a7b-b54f-c7d38b037bb9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c14f32d1-4240-4fe1-a07a-d1ef178c9962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c14f32d1-4240-4fe1-a07a-d1ef178c9962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4128df69-2f72-4436-bb22-46eb590106de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4128df69-2f72-4436-bb22-46eb590106de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2be46a20-0406-41c1-8bff-a176ee28a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2be46a20-0406-41c1-8bff-a176ee28a1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b28d066e-3949-4c5a-aa6d-d1ddb0e0881f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b28d066e-3949-4c5a-aa6d-d1ddb0e0881f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_64f7113f-dc2d-4ce1-a6c7-b5da89a8fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_64f7113f-dc2d-4ce1-a6c7-b5da89a8fd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_514843a2-0d01-4dfe-b258-ba2669be3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_514843a2-0d01-4dfe-b258-ba2669be3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_47c6103f-f6c4-437a-9e1a-cbee7e5a0410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_47c6103f-f6c4-437a-9e1a-cbee7e5a0410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_56a24d14-7010-4fc7-aeee-28713f10ec1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_56a24d14-7010-4fc7-aeee-28713f10ec1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_29f5605b-455e-4e80-b6b5-85c5dce5f558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_29f5605b-455e-4e80-b6b5-85c5dce5f558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_b8a9c96e-3c3b-4edb-95e5-c421d22d99af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_b8a9c96e-3c3b-4edb-95e5-c421d22d99af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_24140f2e-cd99-45b0-a506-e4d1524987f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_24140f2e-cd99-45b0-a506-e4d1524987f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ecdb607e-14c0-4551-8218-00aeae85fc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3268ba2-ab2d-491b-a958-c574482b6e3b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ecdb607e-14c0-4551-8218-00aeae85fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsCurrentEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_b4f1aa9d-e31c-4a93-8b99-e5330c4a114c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b4f1aa9d-e31c-4a93-8b99-e5330c4a114c" xlink:to="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad3358bd-dbae-4012-a746-4073d7474536" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExchangeTradedFundsMember_e59b3441-4eb9-4ece-aa0a-738430bcae94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExchangeTradedFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:to="loc_us-gaap_ExchangeTradedFundsMember_e59b3441-4eb9-4ece-aa0a-738430bcae94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommonEquitySecuritiesMember_a5f80811-6a1b-44da-a45e-37f27fa9e88c" xlink:href="elv-20221231.xsd#elv_CommonEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:to="loc_elv_CommonEquitySecuritiesMember_a5f80811-6a1b-44da-a45e-37f27fa9e88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_7e92b2a6-544a-4af3-9d11-e6783a3fba32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71be561-0b29-462d-8958-e638dfcc0362" xlink:to="loc_us-gaap_PrivateEquityFundsMember_7e92b2a6-544a-4af3-9d11-e6783a3fba32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_b3bcb0eb-c3da-4cdb-b9a5-9491655863ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_8591595e-ea4b-43bd-b34a-e0e3b5fe786d" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_b3bcb0eb-c3da-4cdb-b9a5-9491655863ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecurities_dfaea87f-70bd-4688-a246-743cf1eebcd0" xlink:href="elv-20221231.xsd#elv_EquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_b3bcb0eb-c3da-4cdb-b9a5-9491655863ec" xlink:to="loc_elv_EquitySecurities_dfaea87f-70bd-4688-a246-743cf1eebcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_aa44463d-839c-4991-a52c-a989792000c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_aa44463d-839c-4991-a52c-a989792000c4" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:to="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_eb086102-55c4-4ee2-86c4-62e96e0dffb7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_845976e3-01c4-457c-8e7c-2e7021dfc5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_FixedMaturitiesMember_845976e3-01c4-457c-8e7c-2e7021dfc5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0d80b104-bea7-4dde-9e95-63d34de0c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_EquitySecuritiesMember_0d80b104-bea7-4dde-9e95-63d34de0c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_ea949dd4-2d4d-4d78-9444-77329f888533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_ea949dd4-2d4d-4d78-9444-77329f888533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_ff34358a-86e0-48e5-a860-58e54d5decbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_71e36e92-dfab-478a-971b-af8c3e8eb53e" xlink:to="loc_us-gaap_OtherInvestmentsMember_ff34358a-86e0-48e5-a860-58e54d5decbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53eb8b4b-484b-49ea-bf8c-e92636cbe55c" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_1259753d-8480-47e8-a314-21b734eba224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_InvestmentIncomeNet_1259753d-8480-47e8-a314-21b734eba224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_6810d0f1-cc63-43e1-a846-548a712b1327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_6810d0f1-cc63-43e1-a846-548a712b1327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_f89e5013-c5ed-4276-9dfe-d50e5a86c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_40403ab5-93e4-4a1f-a476-1c37b5507ef7" xlink:to="loc_us-gaap_NetInvestmentIncome_f89e5013-c5ed-4276-9dfe-d50e5a86c2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsNetGainsLossesOnInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_3e64f089-bb71-4537-8e34-1ed25957285b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3e64f089-bb71-4537-8e34-1ed25957285b" xlink:to="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:to="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_35e031cb-556b-47e8-83e3-2020e47294e8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_70d26045-2b48-4c58-b7cc-7a8edd860377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:to="loc_us-gaap_FixedMaturitiesMember_70d26045-2b48-4c58-b7cc-7a8edd860377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d299b9eb-62ae-47a4-aa09-37daf0436158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:to="loc_us-gaap_EquitySecuritiesMember_d299b9eb-62ae-47a4-aa09-37daf0436158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_b337c5fb-d5ff-4296-ac91-cbbd64b2d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e1359702-6c1e-4886-8e1c-b22f7ce8e48e" xlink:to="loc_us-gaap_OtherInvestmentsMember_b337c5fb-d5ff-4296-ac91-cbbd64b2d46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_8780971d-669b-4bba-977c-cccd85bb406b" xlink:to="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b11d24cc-eb18-4dcd-be04-890036b6a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b11d24cc-eb18-4dcd-be04-890036b6a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_89dcb4ea-466b-4b72-aab4-a0b85e0e93d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_89dcb4ea-466b-4b72-aab4-a0b85e0e93d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Impairmentlossesreversalsoninvestments_664b5eb6-49d7-4aad-97f7-b4672654cd57" xlink:href="elv-20221231.xsd#elv_Impairmentlossesreversalsoninvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_Impairmentlossesreversalsoninvestments_664b5eb6-49d7-4aad-97f7-b4672654cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_020c37f3-1491-4cb4-b465-c2979c39830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_020c37f3-1491-4cb4-b465-c2979c39830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_803c6993-1b10-4b5e-91a5-f1218fc84b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_803c6993-1b10-4b5e-91a5-f1218fc84b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a331d39d-d238-49fd-9764-9da027c25fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a331d39d-d238-49fd-9764-9da027c25fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_babf60c2-982a-45bb-8ce6-051fadf5feb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_babf60c2-982a-45bb-8ce6-051fadf5feb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GainsFromOtherInvestments_7b5ea17f-61f3-4de5-adbe-4727abf6d6bd" xlink:href="elv-20221231.xsd#elv_GainsFromOtherInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_GainsFromOtherInvestments_7b5ea17f-61f3-4de5-adbe-4727abf6d6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GrossLossesFromOtherInvestments_403fb3d2-af81-47d6-8f8f-816e71346271" xlink:href="elv-20221231.xsd#elv_GrossLossesFromOtherInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_GrossLossesFromOtherInvestments_403fb3d2-af81-47d6-8f8f-816e71346271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentGainsLosses_a02b537c-8563-45c9-912c-864f57e56b81" xlink:href="elv-20221231.xsd#elv_InvestmentGainsLosses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_elv_InvestmentGainsLosses_a02b537c-8563-45c9-912c-864f57e56b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_c88320e2-55c0-4ac4-8327-751f79e406cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_2d85e751-860f-4779-a2a4-888cc7c9fce8" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_c88320e2-55c0-4ac4-8327-751f79e406cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract_f3636d5d-bff7-4f46-85c8-5ff34d91ca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_91b01255-e77a-4c3d-81a8-c083fd2acff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract_f3636d5d-bff7-4f46-85c8-5ff34d91ca1c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_91b01255-e77a-4c3d-81a8-c083fd2acff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_07ad48ae-3b51-42ab-a9e7-e012008f42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract_f3636d5d-bff7-4f46-85c8-5ff34d91ca1c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_07ad48ae-3b51-42ab-a9e7-e012008f42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_92f4c37e-38ea-467b-97ff-7fb1caa1b83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract_f3636d5d-bff7-4f46-85c8-5ff34d91ca1c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_92f4c37e-38ea-467b-97ff-7fb1caa1b83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_5833f82f-9a06-4a0f-ad84-130145b20fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_5833f82f-9a06-4a0f-ad84-130145b20fc8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_9022466e-bc64-4506-9c89-55c6c4c2fbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_8539d688-d0d7-4035-8f09-5c80e99639e1" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_9022466e-bc64-4506-9c89-55c6c4c2fbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturityOvernightMember_390da534-da1b-423a-90be-db7dba795d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturityOvernightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_9022466e-bc64-4506-9c89-55c6c4c2fbae" xlink:to="loc_us-gaap_MaturityOvernightMember_390da534-da1b-423a-90be-db7dba795d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_8bd90e6f-bbfe-479e-8bee-14ab627fc0b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_8d418f1e-0447-4e64-9670-c491ccc30fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_FixedMaturitiesMember_8d418f1e-0447-4e64-9670-c491ccc30fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_bc2614ff-b8e6-4ea5-ab69-af3c73140a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_CashMember_bc2614ff-b8e6-4ea5-ab69-af3c73140a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_62dac1d3-3c54-47cc-a368-6bda74a22d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_62dac1d3-3c54-47cc-a368-6bda74a22d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThirdPartyInvestmentsMember_6fbdf3c3-5281-49b6-ae6a-268c86c554e1" xlink:href="elv-20221231.xsd#elv_ThirdPartyInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_elv_ThirdPartyInvestmentsMember_6fbdf3c3-5281-49b6-ae6a-268c86c554e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_RatedNotesMember_b6c3e4ce-d83c-401f-8ab3-0703485370bf" xlink:href="elv-20221231.xsd#elv_RatedNotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_elv_RatedNotesMember_b6c3e4ce-d83c-401f-8ab3-0703485370bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_20aec05b-6c09-4712-94e0-c7c85b88d696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ead056a-a4ef-4b52-b8ff-e342a16f5b40" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_20aec05b-6c09-4712-94e0-c7c85b88d696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_78752fbb-ecb0-49d6-8afb-7ee1e4cf4f8d" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThirdPartyInvestmentsMember_b291917f-692f-4f48-9f12-8fbcab007adf" xlink:href="elv-20221231.xsd#elv_ThirdPartyInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:to="loc_elv_ThirdPartyInvestmentsMember_b291917f-692f-4f48-9f12-8fbcab007adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_RatedNotesMember_bb639c63-2829-432d-9ffb-bde5db1bb477" xlink:href="elv-20221231.xsd#elv_RatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2e9b662d-c7a8-4c0b-a719-bda2d3492af6" xlink:to="loc_elv_RatedNotesMember_bb639c63-2829-432d-9ffb-bde5db1bb477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4b298b2c-eb00-4a86-aa3e-a2f95b6260cd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_88c56531-0e21-4fe5-89c1-cdfa60acd92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_88c56531-0e21-4fe5-89c1-cdfa60acd92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_30e3f1ec-47c4-412a-a35e-e96f4816da55" xlink:href="elv-20221231.xsd#elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome_30e3f1ec-47c4-412a-a35e-e96f4816da55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d5cee8a5-d6fc-4094-a288-4da5034994c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_ContractualObligation_d5cee8a5-d6fc-4094-a288-4da5034994c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators_e148b1e0-d37a-4a1e-9da6-c7b80863f519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_AssetsHeldByInsuranceRegulators_e148b1e0-d37a-4a1e-9da6-c7b80863f519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_c734d19d-e7a8-4500-bb69-24e58c999d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_c734d19d-e7a8-4500-bb69-24e58c999d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedFairValueOfCollateral_85e43ee4-f56e-484f-83e9-47e23b8775a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedFairValueOfCollateral"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_SecuritiesLoanedFairValueOfCollateral_85e43ee4-f56e-484f-83e9-47e23b8775a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_bc6059e8-6070-4d6c-9a98-67cd4bd7db80" xlink:href="elv-20221231.xsd#elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan_bc6059e8-6070-4d6c-9a98-67cd4bd7db80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue_fbfc513f-ac92-4e9b-a187-c4800c0131ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue_fbfc513f-ac92-4e9b-a187-c4800c0131ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4e175847-3403-43f4-a4f7-83ee82485cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84f02583-f831-4bfd-b7ae-d1ad6dff1ebe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4e175847-3403-43f4-a4f7-83ee82485cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3e5472da-3299-41d3-925b-5247b09d22cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3e5472da-3299-41d3-925b-5247b09d22cb" xlink:to="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_fadeb886-bb28-48ce-968c-65390a6e7ffe" xlink:to="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_acca513d-6816-42f4-a4be-4a714f00285a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_acca513d-6816-42f4-a4be-4a714f00285a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bfee0b86-da17-48de-869b-e939077bc91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e6ca0d3a-c073-4d94-8676-b2821a4297cf" xlink:to="loc_us-gaap_NondesignatedMember_bfee0b86-da17-48de-869b-e939077bc91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_37e01956-0be5-4c56-87a8-0bb305e77a85" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_c54e9e3b-9e89-4d0e-80e3-841000746a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_c54e9e3b-9e89-4d0e-80e3-841000746a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_1540a172-28d1-45f4-8a39-9fab3ef8a666" xlink:href="elv-20221231.xsd#elv_EquitySecuritiesotherAssetsotherLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_elv_EquitySecuritiesotherAssetsotherLiabilitiesMember_1540a172-28d1-45f4-8a39-9fab3ef8a666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9f1dcd29-2cbe-46b4-9806-8e1695e6ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_us-gaap_EquitySecuritiesMember_9f1dcd29-2cbe-46b4-9806-8e1695e6ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_d56a376e-df2c-4f28-8f2a-93478c28a0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dc601113-c01e-4010-8252-3906dbecdbcc" xlink:to="loc_us-gaap_FixedMaturitiesMember_d56a376e-df2c-4f28-8f2a-93478c28a0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9daef2c0-071c-40f6-9289-a7cb8bdb828c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8aa538a0-c278-40d3-9703-d74aad5aa059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_InterestRateSwapMember_8aa538a0-c278-40d3-9703-d74aad5aa059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_5719467d-9288-4032-b337-d272deb6cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_OptionMember_5719467d-9288-4032-b337-d272deb6cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_dbb91883-daaa-4228-9047-c7a614cb4e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_OtherContractMember_dbb91883-daaa-4228-9047-c7a614cb4e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FutureMember_47d9eee9-642d-45a3-a155-d344670856bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FutureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_FutureMember_47d9eee9-642d-45a3-a155-d344670856bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_64880175-95c0-4191-a3a2-29f57ffe5722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e508e7ab-5ce6-485d-8063-6cb328443b8f" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_64880175-95c0-4191-a3a2-29f57ffe5722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cae987cd-ed0e-49f5-9ed5-b07bfd57a4d3" xlink:to="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0845f447-e9af-4d39-8d09-2e872b2c143a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0845f447-e9af-4d39-8d09-2e872b2c143a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d66b8dae-5ae3-41b8-981f-069ce535c13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d66b8dae-5ae3-41b8-981f-069ce535c13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_6b3cc22c-62ae-42fb-9661-d4a20b86904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_6b3cc22c-62ae-42fb-9661-d4a20b86904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral_f842f72f-2870-4abe-95b9-b3ba2aac9ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral_f842f72f-2870-4abe-95b9-b3ba2aac9ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a67aad5b-1480-40ac-8a31-56a5bd1bd8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a67aad5b-1480-40ac-8a31-56a5bd1bd8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_20f8bffc-b1b8-4570-8c97-32871b9dccf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_20f8bffc-b1b8-4570-8c97-32871b9dccf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_c4211c03-4044-481f-ad78-51fbb60a0b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b56d1509-a9a7-410d-8710-eced90872a66" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_c4211c03-4044-481f-ad78-51fbb60a0b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d092ae97-344b-4974-8d8f-3ed9638d29b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d092ae97-344b-4974-8d8f-3ed9638d29b4" xlink:to="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a945c897-a1cb-40b6-81b3-871f82572ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2e556ab5-4afb-44c4-9e76-976987145e38" xlink:to="loc_us-gaap_HedgingDesignationDomain_a945c897-a1cb-40b6-81b3-871f82572ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7bfead0-592b-4655-904e-b1dd2e63354a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a945c897-a1cb-40b6-81b3-871f82572ba9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7bfead0-592b-4655-904e-b1dd2e63354a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d53ba8f3-f00e-4785-b43d-192e69bc59c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_b778801a-23dc-4f06-a07c-703db3ae0906" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedFivePointFiveZeroPercentageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedFivePointFiveZeroPercentageMember_b778801a-23dc-4f06-a07c-703db3ae0906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_8922e30d-f240-4d39-9b62-dde822a9d9a9" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedFourPointOneZeroOnePercentageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedFourPointOneZeroOnePercentageMember_8922e30d-f240-4d39-9b62-dde822a9d9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_401f93ce-52ba-4188-a4fc-9102875490ec" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember_401f93ce-52ba-4188-a4fc-9102875490ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_8b8b2e8b-cad6-44c3-ac4f-35e0820abb53" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember_8b8b2e8b-cad6-44c3-ac4f-35e0820abb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_25227d79-3406-4ba3-9d51-f670fe5a4794" xlink:href="elv-20221231.xsd#elv_InterestRateReceivedThreePointThreeZeroPercentageMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e75ee6ec-52d4-4734-8ca5-2498fef97e10" xlink:to="loc_elv_InterestRateReceivedThreePointThreeZeroPercentageMember_25227d79-3406-4ba3-9d51-f670fe5a4794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_61f93c93-95ca-425c-bf97-d5aa6bc3ddd2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyTwoMember_6c9e989f-5a81-4772-a259-100a89862252" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandTwentyTwoMember_6c9e989f-5a81-4772-a259-100a89862252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyOneMember_45529e13-c3e9-4247-9b3f-a8924dae9112" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandTwentyOneMember_45529e13-c3e9-4247-9b3f-a8924dae9112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandTwentyMember_63ebbb14-6831-4d89-9bd4-579b2ecfb8e2" xlink:href="elv-20221231.xsd#elv_TwoThousandTwentyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandTwentyMember_63ebbb14-6831-4d89-9bd4-579b2ecfb8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoThousandEighteenMember_26a2b3c7-0a71-4be6-87e9-91ffe8984d91" xlink:href="elv-20221231.xsd#elv_TwoThousandEighteenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2eab952-65a4-4cc9-a63e-4062eadc1fb7" xlink:to="loc_elv_TwoThousandEighteenMember_26a2b3c7-0a71-4be6-87e9-91ffe8984d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_18b4af51-8e08-4834-b0bf-9ae12fa42e32" xlink:to="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_3d6cc314-4069-4bc8-987d-6d88c62ccfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_DerivativeNotionalAmount_3d6cc314-4069-4bc8-987d-6d88c62ccfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_16afbe45-6919-43bc-b48c-3f146bd30ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_16afbe45-6919-43bc-b48c-3f146bd30ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenExpirationDates_4ef565a3-3bf7-4378-b388-cc872ef253c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenExpirationDates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc8bf97-f5a9-4998-87ac-8382614a791f" xlink:to="loc_us-gaap_OpenOptionContractsWrittenExpirationDates_4ef565a3-3bf7-4378-b388-cc872ef253c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f931feab-7b42-4ccb-b31d-32fde85a1be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f931feab-7b42-4ccb-b31d-32fde85a1be3" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_696dd791-ad6b-4d41-98aa-633b3228a014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1b5b3baf-9f37-4602-8bc2-f0f74fc53f96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_696dd791-ad6b-4d41-98aa-633b3228a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_28c8ae12-374f-4804-8096-3aaa1d3ef536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696dd791-ad6b-4d41-98aa-633b3228a014" xlink:to="loc_us-gaap_LongTermDebtMember_28c8ae12-374f-4804-8096-3aaa1d3ef536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_47c6604a-9584-48a3-9f15-e03237fef5a5" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAmountOfHedgedItem_8666c255-47c0-4b87-b67a-896430b9afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAmountOfHedgedItem"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:to="loc_us-gaap_DerivativeAmountOfHedgedItem_8666c255-47c0-4b87-b67a-896430b9afb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Fairvaluehedgescumulativebasisadjustments_eb804e15-ec36-4c89-907a-29c5eb669712" xlink:href="elv-20221231.xsd#elv_Fairvaluehedgescumulativebasisadjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7f0f68b3-56c8-4942-96f7-8c05ce05a9ea" xlink:to="loc_elv_Fairvaluehedgescumulativebasisadjustments_eb804e15-ec36-4c89-907a-29c5eb669712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_26dcffa0-5ac2-487f-b81f-63d4b57071a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_26dcffa0-5ac2-487f-b81f-63d4b57071a5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76b0dd86-e286-4e43-a224-99e752c75e36" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2e395b34-43af-486e-bb2b-c3344b0d6b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_InterestRateSwapMember_2e395b34-43af-486e-bb2b-c3344b0d6b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_a166c2cb-cbf9-467c-a717-ac9f2368c85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_OtherContractMember_a166c2cb-cbf9-467c-a717-ac9f2368c85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_4e16cfea-5a0d-40cb-85dc-85ddc87c5765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_OptionMember_4e16cfea-5a0d-40cb-85dc-85ddc87c5765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FutureMember_c07f43ae-0241-451b-ad03-531ce4b08248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FutureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_FutureMember_c07f43ae-0241-451b-ad03-531ce4b08248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_16fd056d-7e27-48c4-bc00-272e5d1852b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4790f148-9685-4c93-8109-ff230d0d5b47" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_16fd056d-7e27-48c4-bc00-272e5d1852b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_063227b6-20cf-40bd-bf79-d3e881ccaec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_78253894-21f5-4cfd-aaba-ee67a53d34d4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_063227b6-20cf-40bd-bf79-d3e881ccaec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstrumentsMember_03e22238-1cd6-43ee-bd25-2258ac568220" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_063227b6-20cf-40bd-bf79-d3e881ccaec4" xlink:to="loc_elv_NetGainsLossesOnFinancialInstrumentsMember_03e22238-1cd6-43ee-bd25-2258ac568220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ee00515c-ccb1-4021-9bd9-622385dff7e0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_7912df1c-2a27-4746-b733-5a96605a65a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_7912df1c-2a27-4746-b733-5a96605a65a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5285553c-6428-46f2-8053-1daaa7546e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_37503785-9bb4-46e9-9b4b-3f1eff9dd550" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5285553c-6428-46f2-8053-1daaa7546e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DerivativeFinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c855cc8-3bf7-4968-95df-efca5534c628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c855cc8-3bf7-4968-95df-efca5534c628" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6a3f6c7f-cd0c-4bf3-add5-2194ef642960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4f0e8459-15ec-42bb-9164-82e670b89f0c" xlink:to="loc_us-gaap_HedgingDesignationDomain_6a3f6c7f-cd0c-4bf3-add5-2194ef642960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_19d3d0d5-926e-422d-bb38-3bc6f372fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6a3f6c7f-cd0c-4bf3-add5-2194ef642960" xlink:to="loc_us-gaap_NondesignatedMember_19d3d0d5-926e-422d-bb38-3bc6f372fe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cfaafffa-fc45-4fd1-ba52-11457984a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5f937620-ea65-4f6e-ae98-125040e7e02e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cfaafffa-fc45-4fd1-ba52-11457984a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d7adbf65-6e47-4c3b-8617-4b6c5a03f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cfaafffa-fc45-4fd1-ba52-11457984a6cb" xlink:to="loc_us-gaap_CashFlowHedgingMember_d7adbf65-6e47-4c3b-8617-4b6c5a03f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:href="elv-20221231.xsd#elv_HedgingStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HedgingStatusDomain_8e0ef420-fad2-45d5-b37d-9a27f3994301" xlink:href="elv-20221231.xsd#elv_HedgingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_HedgingStatusAxis_f27fd4f8-44f1-4134-8875-e6f72eb16362" xlink:to="loc_elv_HedgingStatusDomain_8e0ef420-fad2-45d5-b37d-9a27f3994301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TerminationsDomain_3e1dd211-d938-4d86-a45c-efc24fa09afc" xlink:href="elv-20221231.xsd#elv_TerminationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_HedgingStatusDomain_8e0ef420-fad2-45d5-b37d-9a27f3994301" xlink:to="loc_elv_TerminationsDomain_3e1dd211-d938-4d86-a45c-efc24fa09afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d6e62e48-775b-49d6-a40d-3d7ec968a7b2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_Notionalamountterminatedderivatives_83ca8a94-56bd-4d6d-8a07-d90c80307bc0" xlink:href="elv-20221231.xsd#elv_Notionalamountterminatedderivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_elv_Notionalamountterminatedderivatives_83ca8a94-56bd-4d6d-8a07-d90c80307bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_9d10e514-d042-4dbe-828d-586abbece31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_9d10e514-d042-4dbe-828d-586abbece31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_12619720-576e-4747-bf4e-5511e29fdac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_12619720-576e-4747-bf4e-5511e29fdac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_923fbae6-eeff-424b-8e3a-6daa47280dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5603540d-f83c-41e4-8c20-fddb3012c74e" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_923fbae6-eeff-424b-8e3a-6daa47280dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d69f4c07-0e8d-4b84-b6fa-839f4a2f211e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d69f4c07-0e8d-4b84-b6fa-839f4a2f211e" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9152afe6-de22-40c2-aac5-5f27eb39c25a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_33d1d848-af1c-4a15-8e5d-23006f8c37e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_33d1d848-af1c-4a15-8e5d-23006f8c37e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1984cd6e-6492-4ec3-9c2d-433555e347bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1984cd6e-6492-4ec3-9c2d-433555e347bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ac63d4b9-a26c-4928-8113-8bd5d089de06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c72c2365-9099-4305-a0dc-326154467fd8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ac63d4b9-a26c-4928-8113-8bd5d089de06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0b49f5fd-3c79-42e6-93a3-3f7d16ab1526" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedMaturitiesMember_48143720-85b1-4eb8-a327-4b26954d2570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_us-gaap_FixedMaturitiesMember_48143720-85b1-4eb8-a327-4b26954d2570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_455cb97a-662d-4077-9509-b97c3dce5f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_us-gaap_EquitySecuritiesMember_455cb97a-662d-4077-9509-b97c3dce5f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherDerivativeInstrumentsMember_41eec92b-d51c-499b-b76a-3e5e438d3936" xlink:href="elv-20221231.xsd#elv_OtherDerivativeInstrumentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_elv_OtherDerivativeInstrumentsMember_41eec92b-d51c-499b-b76a-3e5e438d3936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_03ddab7c-9691-4ad8-be97-ef95f3c589cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4a305f9-4231-4ac3-a670-78b7cfa9b689" xlink:to="loc_us-gaap_OtherInvestmentsMember_03ddab7c-9691-4ad8-be97-ef95f3c589cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_257fa0b5-8b92-4210-953d-fbebac72c2c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a8930211-5b14-40d7-856f-00141c4ab77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a8930211-5b14-40d7-856f-00141c4ab77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9519814d-cdd4-426b-a0a2-1c28b292ef56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9519814d-cdd4-426b-a0a2-1c28b292ef56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_65e419ff-572a-4630-be05-fdbbab0d04ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_65e419ff-572a-4630-be05-fdbbab0d04ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_9c0bafc4-d117-4020-9c28-b02f7640bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_9c0bafc4-d117-4020-9c28-b02f7640bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7f918a2c-123f-4088-9d7f-44eec53154dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7f918a2c-123f-4088-9d7f-44eec53154dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_67022225-65da-4f09-b252-0b5ee9eaf879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_67022225-65da-4f09-b252-0b5ee9eaf879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_a56d1e04-a929-40d9-a650-e06366c90618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_a56d1e04-a929-40d9-a650-e06366c90618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_343df932-ec71-4f10-ad88-21a02ca90535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_343df932-ec71-4f10-ad88-21a02ca90535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExchangeTradedFundsMember_a87da013-3d36-4d44-b723-d462a181006c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExchangeTradedFundsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_ExchangeTradedFundsMember_a87da013-3d36-4d44-b723-d462a181006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommonEquitySecuritiesMember_47d59f88-b888-4da7-9d8c-283039f94915" xlink:href="elv-20221231.xsd#elv_CommonEquitySecuritiesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_elv_CommonEquitySecuritiesMember_47d59f88-b888-4da7-9d8c-283039f94915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_ebdeda73-4f83-4804-a0f3-99a20cb4583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f10bce9-0768-461f-8da1-8dde053c5f73" xlink:to="loc_us-gaap_PrivateEquityFundsMember_ebdeda73-4f83-4804-a0f3-99a20cb4583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_306a87f7-9ffa-45d4-919f-81338f4f056d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_6d6c465f-0822-4092-998f-656b5047284f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:to="loc_us-gaap_OtherLiabilitiesMember_6d6c465f-0822-4092-998f-656b5047284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_de73bdec-e099-4310-b0fb-9255490609a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8199e25d-a865-4880-9714-ce59e957eb37" xlink:to="loc_us-gaap_OtherAssetsMember_de73bdec-e099-4310-b0fb-9255490609a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_73787d43-9106-4b44-b565-b1034e79b65b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6519af9a-8eea-4f80-8b0c-d7fcbc7d7c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6519af9a-8eea-4f80-8b0c-d7fcbc7d7c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e4c3ba0-8c6d-416d-bb5a-12d3d1c5032a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e4c3ba0-8c6d-416d-bb5a-12d3d1c5032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EquitySecurities_1de850bb-745e-4f35-8840-de19f5ce0ec6" xlink:href="elv-20221231.xsd#elv_EquitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_elv_EquitySecurities_1de850bb-745e-4f35-8840-de19f5ce0ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_ba11377c-b7c6-48dd-9d8a-bc35a38285e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_OtherLongTermInvestments_ba11377c-b7c6-48dd-9d8a-bc35a38285e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesHeldAsCollateralAtFairValue_df096f47-f8f9-443b-b4d2-f9217face852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesHeldAsCollateralAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_SecuritiesHeldAsCollateralAtFairValue_df096f47-f8f9-443b-b4d2-f9217face852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c6e1886f-084f-453d-82cf-244ba5ffdee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_DerivativeAssets_c6e1886f-084f-453d-82cf-244ba5ffdee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_06831274-6f6e-4d5e-87c2-f99ab4a1108f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssets_c6e1886f-084f-453d-82cf-244ba5ffdee1" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_06831274-6f6e-4d5e-87c2-f99ab4a1108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c759db8f-8701-4d64-ae20-c84b1375d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c759db8f-8701-4d64-ae20-c84b1375d9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_312278e0-6948-4599-8100-859638ededfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_DerivativeLiabilities_312278e0-6948-4599-8100-859638ededfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4463ece2-e507-4dfc-9f81-f1b51cc59860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilities_312278e0-6948-4599-8100-859638ededfa" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4463ece2-e507-4dfc-9f81-f1b51cc59860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_6eb94391-ece4-4f12-a242-44154742b966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_345a7276-9a52-4875-8f7d-6f525c93458b" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_6eb94391-ece4-4f12-a242-44154742b966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e2516eff-12e2-44c4-85f9-c63d8edd456b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2516eff-12e2-44c4-85f9-c63d8edd456b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7ca0a694-13c4-4a64-8757-721751bb8c50" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1139616c-60bd-411b-8c59-a7985bcdbb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1139616c-60bd-411b-8c59-a7985bcdbb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_f382090e-a4a3-4d07-bf19-e2a77a556ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_f382090e-a4a3-4d07-bf19-e2a77a556ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3f17eaaa-8492-4dbb-bb91-1bd5f7802d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3f17eaaa-8492-4dbb-bb91-1bd5f7802d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_742233f4-858e-4dcd-8000-f71308a14f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_742233f4-858e-4dcd-8000-f71308a14f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_eda22168-bcea-4780-ad93-3ccdc33d4980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a2b5fcf-88b5-41e9-adf3-b4a790ca1927" xlink:to="loc_us-gaap_EquitySecuritiesMember_eda22168-bcea-4780-ad93-3ccdc33d4980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_97a4089a-3f02-4e2c-a194-87cbd5cb5526" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2632c37b-6c15-465d-8cb2-eb8095774d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2632c37b-6c15-465d-8cb2-eb8095774d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_03e06f2a-9a78-495a-a07c-4cb49c029723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_03e06f2a-9a78-495a-a07c-4cb49c029723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_a19ea0c5-9a18-447d-a5f7-ba4b1d0d1175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_a19ea0c5-9a18-447d-a5f7-ba4b1d0d1175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_5176dc8b-bf38-43b0-8416-e67adc33c254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_5176dc8b-bf38-43b0-8416-e67adc33c254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c4b27984-e411-406e-8380-cd1066c990da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c4b27984-e411-406e-8380-cd1066c990da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_8b124a60-d125-4875-8b19-a5a109bb7725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_8b124a60-d125-4875-8b19-a5a109bb7725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_dde3c449-618e-460c-8954-4e140a2f3ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_dde3c449-618e-460c-8954-4e140a2f3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_e5ef5abf-a5cc-4421-aa05-098409b7bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_e5ef5abf-a5cc-4421-aa05-098409b7bc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1b035ff7-336d-4ce7-b23f-3034afb0d6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1b035ff7-336d-4ce7-b23f-3034afb0d6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3668c162-007f-456c-92a8-dd697fd15400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffa9724a-ffad-40e5-83d1-d04fb770e377" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3668c162-007f-456c-92a8-dd697fd15400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cac29ac6-bc12-4330-bba7-84636716cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bf7372-bb4d-4f0a-af5a-6b12f0d45255" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cac29ac6-bc12-4330-bba7-84636716cef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4450bb43-0140-4c78-9d23-2a6a61878c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4450bb43-0140-4c78-9d23-2a6a61878c2f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bbb8fdaf-181d-47e2-bb12-ea5916e50a23" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_7ee42980-4242-4fb7-8676-8f109e7af1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_7ee42980-4242-4fb7-8676-8f109e7af1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_eeb1ced6-b4ef-4b0f-910e-7b7a84718e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11292c4d-158c-44fd-a660-3f102636401c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_eeb1ced6-b4ef-4b0f-910e-7b7a84718e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0affba2b-7d7d-4673-83f1-4c8b49d8a1a6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e0e8d56b-e488-4daf-9b98-785c8d0ec9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e0e8d56b-e488-4daf-9b98-785c8d0ec9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f7bee811-02e6-4c74-be80-bf0b99b50b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f7bee811-02e6-4c74-be80-bf0b99b50b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ab6cf955-b3b2-41eb-abd2-8f9e1a478d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_266e673e-58de-4735-94eb-f54a45b2171f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ab6cf955-b3b2-41eb-abd2-8f9e1a478d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_df64ba40-9cc1-4aaf-89c4-feda0be87649" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_fcc2f92d-9b61-4fad-b4e7-5785e47951e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_OtherLongTermInvestments_fcc2f92d-9b61-4fad-b4e7-5785e47951e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_5a088f30-1682-4132-94cd-a78436fc0fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_5a088f30-1682-4132-94cd-a78436fc0fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_e736b6a3-dba5-459d-b4f3-a8ee8b796034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_CommercialPaper_e736b6a3-dba5-459d-b4f3-a8ee8b796034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_1f50b14d-499d-4076-bca3-7dc269a952f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_NotesPayable_1f50b14d-499d-4076-bca3-7dc269a952f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_8f2ecffb-daa4-4c50-a030-001c87a0d77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_8f2ecffb-daa4-4c50-a030-001c87a0d77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_63a4a611-fca0-4f35-8899-448e835e438e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66ab630b-ba0c-48ae-b966-aa0c54427487" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_63a4a611-fca0-4f35-8899-448e835e438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f4577970-ca6d-47c6-affe-5ceb03528268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f4577970-ca6d-47c6-affe-5ceb03528268" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_84578660-fa97-4771-9cc3-44edfc926c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_84578660-fa97-4771-9cc3-44edfc926c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_95b3df41-b825-4691-be3a-1ed2e00a29a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_95b3df41-b825-4691-be3a-1ed2e00a29a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_cec4faf3-ce24-4d3e-94a6-93a9696ee4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_cec4faf3-ce24-4d3e-94a6-93a9696ee4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxAssetsLeasingArrangements_d427512d-ee11-4ff1-abf1-0ac59d7eecc0" xlink:href="elv-20221231.xsd#elv_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_elv_DeferredTaxAssetsLeasingArrangements_d427512d-ee11-4ff1-abf1-0ac59d7eecc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_80bcc083-7d33-40c5-a29b-0e38b54427db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_80bcc083-7d33-40c5-a29b-0e38b54427db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_cc80f7cb-b2e9-4b6b-945c-60c79a492aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_cc80f7cb-b2e9-4b6b-945c-60c79a492aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4f17e9fc-a33c-4816-b076-12517f8351c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4f17e9fc-a33c-4816-b076-12517f8351c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_8f75e787-4590-4bf7-b923-7659a703cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_8f75e787-4590-4bf7-b923-7659a703cfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7c58d17c-9f37-44c0-b66b-b62fb6ea786b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7c58d17c-9f37-44c0-b66b-b62fb6ea786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7b685678-21c7-4c45-9c40-eb79d8a5a642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7b685678-21c7-4c45-9c40-eb79d8a5a642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_29a4afc3-fdbd-42dc-b620-6548a9af1099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_29a4afc3-fdbd-42dc-b620-6548a9af1099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7df3c8f4-0eea-4bdf-a677-651ac35e698d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_675774c4-2cde-425c-a6c7-0c61d11910d3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7df3c8f4-0eea-4bdf-a677-651ac35e698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f4577970-ca6d-47c6-affe-5ceb03528268" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_86437bb2-db73-4ab0-a2ab-a9ad3c2a7285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_86437bb2-db73-4ab0-a2ab-a9ad3c2a7285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets_c3319de4-5366-4520-83ab-f8220c9ccb83" xlink:href="elv-20221231.xsd#elv_DeferredTaxLiabilitiesNonUSIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets_c3319de4-5366-4520-83ab-f8220c9ccb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_d2ea936c-5b03-44ca-9ecb-84eb2e921baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_d2ea936c-5b03-44ca-9ecb-84eb2e921baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d05259de-a46c-46ca-b4b5-fcaf92889c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d05259de-a46c-46ca-b4b5-fcaf92889c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_8fdc8178-a490-4a2d-ac2a-846657b68dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_8fdc8178-a490-4a2d-ac2a-846657b68dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits_4cfd2293-4d25-4666-8131-f650a09e1067" xlink:href="elv-20221231.xsd#elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits_4cfd2293-4d25-4666-8131-f650a09e1067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d723a489-dca2-48c4-a4d3-5fd3a3704e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d723a489-dca2-48c4-a4d3-5fd3a3704e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_94c59eb4-d2c0-42a1-81cc-22fe86b91dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_94c59eb4-d2c0-42a1-81cc-22fe86b91dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cebe42d5-2b8b-44ad-b049-12ad4d7a8847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_cebe42d5-2b8b-44ad-b049-12ad4d7a8847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3e00d710-d70f-400f-816f-290cd6a0ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f8095a59-30e4-4eba-9a97-a19c0f33edf1" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3e00d710-d70f-400f-816f-290cd6a0ddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_913e2eb1-7d31-428c-b9c7-81ddc581a562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb2ace3e-70bf-499c-9f92-dbeba02aa3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_913e2eb1-7d31-428c-b9c7-81ddc581a562" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb2ace3e-70bf-499c-9f92-dbeba02aa3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fc7d26ad-8c91-444c-a538-a6d1227a8af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb2ace3e-70bf-499c-9f92-dbeba02aa3e7" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fc7d26ad-8c91-444c-a538-a6d1227a8af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_907225f9-893f-4972-9263-758639be50e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb2ace3e-70bf-499c-9f92-dbeba02aa3e7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_907225f9-893f-4972-9263-758639be50e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a896fba8-4dc4-465e-a9f7-834b3c7a10bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb2ace3e-70bf-499c-9f92-dbeba02aa3e7" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a896fba8-4dc4-465e-a9f7-834b3c7a10bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0490d709-8668-45be-aa49-d7f926cde82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb2ace3e-70bf-499c-9f92-dbeba02aa3e7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0490d709-8668-45be-aa49-d7f926cde82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_cabe1f4a-041b-4235-a106-f78f28bf4f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_913e2eb1-7d31-428c-b9c7-81ddc581a562" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_cabe1f4a-041b-4235-a106-f78f28bf4f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d1b2a17a-91cd-4cba-b62d-63db0c4f7ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_913e2eb1-7d31-428c-b9c7-81ddc581a562" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d1b2a17a-91cd-4cba-b62d-63db0c4f7ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8c1d6bfc-15ec-43d4-a8fc-e3a9c59e71b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8c1d6bfc-15ec-43d4-a8fc-e3a9c59e71b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5a5f9bf5-67fe-4ee9-8a59-ab69b4120d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5a5f9bf5-67fe-4ee9-8a59-ab69b4120d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_522481a6-65f4-4477-bac3-53b2c2dfff02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_522481a6-65f4-4477-bac3-53b2c2dfff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1b4d9b12-ca44-4dcf-a8a3-ee3a50b89792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1b4d9b12-ca44-4dcf-a8a3-ee3a50b89792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductions_e49218a4-f95a-4de9-b9ff-3098b53cee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductions_e49218a4-f95a-4de9-b9ff-3098b53cee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_0f6db98d-3104-40eb-ae47-5e6bc2d9bc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_0f6db98d-3104-40eb-ae47-5e6bc2d9bc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_9cd9d52d-5331-474e-967f-6a99fe7a0771" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_9cd9d52d-5331-474e-967f-6a99fe7a0771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_ad646a42-ea39-4385-be82-00179ac019d7" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent_ad646a42-ea39-4385-be82-00179ac019d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_b52e2385-ca12-49ae-865b-427cc9f51e0a" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount_b52e2385-ca12-49ae-865b-427cc9f51e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_36fe6174-df61-4fef-8ee2-0875abab2c99" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent_36fe6174-df61-4fef-8ee2-0875abab2c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_396dedf7-af74-4229-9e12-154fe257b959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_396dedf7-af74-4229-9e12-154fe257b959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ba62381-9fcc-44ff-ac4e-59432c0316ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ba62381-9fcc-44ff-ac4e-59432c0316ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ffb80fba-4bd8-49c1-9387-683eac228b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ffb80fba-4bd8-49c1-9387-683eac228b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e9377fc-52b6-4faa-8869-634b40792eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_834a2a35-c83b-45fe-bd1a-35c216e4d68d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e9377fc-52b6-4faa-8869-634b40792eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec1e228f-e5e5-448a-a32d-ca42845c03c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec1e228f-e5e5-448a-a32d-ca42845c03c0" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_894ddf41-be69-4452-9a44-a872ebc66338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_894ddf41-be69-4452-9a44-a872ebc66338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_647620f3-bbfd-4730-8757-0bd179b10c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_647620f3-bbfd-4730-8757-0bd179b10c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_78e5aee5-f749-4b66-b3c1-7bc5dd6838b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_78e5aee5-f749-4b66-b3c1-7bc5dd6838b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_ffca9b06-0db2-49ab-814e-8cf44f06d832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_ffca9b06-0db2-49ab-814e-8cf44f06d832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2ca0ff94-06ca-428b-9bd7-ac1ea263781f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_01ebf993-afbe-463f-9712-e5e4174458bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2ca0ff94-06ca-428b-9bd7-ac1ea263781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1b3fd717-1c44-4613-8624-207a7afa0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1b3fd717-1c44-4613-8624-207a7afa0ece" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_64b7c460-ebdb-43c2-8d3d-7216768567db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1ba84300-51e4-4099-a254-dddf23b602ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1ba84300-51e4-4099-a254-dddf23b602ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DeferredTaxLiabilitiesNetMember_daba9f9f-9c68-466c-82aa-80199c3d40da" xlink:href="elv-20221231.xsd#elv_DeferredTaxLiabilitiesNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_275e9026-6964-4c61-9ead-afe7a2c93707" xlink:to="loc_elv_DeferredTaxLiabilitiesNetMember_daba9f9f-9c68-466c-82aa-80199c3d40da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_2a8877c7-2d1a-432e-924a-855b9dcad47e" xlink:to="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IndefiniteMember_cefb7e69-b730-4216-9a4a-717a92b6964b" xlink:href="elv-20221231.xsd#elv_IndefiniteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_elv_IndefiniteMember_cefb7e69-b730-4216-9a4a-717a92b6964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LimitedCarryforwardPeriodMember_96f2ad19-47f2-4016-8ace-c081dbf9e3f7" xlink:href="elv-20221231.xsd#elv_LimitedCarryforwardPeriodMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_elv_LimitedCarryforwardPeriodMember_96f2ad19-47f2-4016-8ace-c081dbf9e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_74409465-f888-4ff9-8ad9-44b0e86f7dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_us-gaap_EarliestTaxYearMember_74409465-f888-4ff9-8ad9-44b0e86f7dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_529d80a8-2215-4dc0-a999-da14b24e0f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_abe78fff-2678-4d91-b806-b2ec91e358c9" xlink:to="loc_us-gaap_LatestTaxYearMember_529d80a8-2215-4dc0-a999-da14b24e0f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c8e62d15-aaf1-4083-b0a7-092f92e73296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_17ddbe34-ade4-41b0-84c0-5362adb0f94f" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c8e62d15-aaf1-4083-b0a7-092f92e73296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e45928e8-ecb9-4565-95c7-6f43d3a7a0cb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_HealthInsuranceProviderfeeMember_d78bfc18-992b-4f55-86cc-72ed887d7bad" xlink:href="elv-20221231.xsd#elv_HealthInsuranceProviderfeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:to="loc_elv_HealthInsuranceProviderfeeMember_d78bfc18-992b-4f55-86cc-72ed887d7bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_96932bb4-9c2e-4dd8-b4cd-9db6852775b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:to="loc_us-gaap_DomesticCountryMember_96932bb4-9c2e-4dd8-b4cd-9db6852775b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_55cbc441-0eec-4c21-a7f5-00dabd422a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2f45427d-2c90-4871-b09e-1a53cb7a6145" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_55cbc441-0eec-4c21-a7f5-00dabd422a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_97850d7f-d6fa-41cd-80b8-2ca440d3326f" xlink:to="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df0219fc-a467-45a6-9a56-92a55c29bf82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:to="loc_srt_MinimumMember_df0219fc-a467-45a6-9a56-92a55c29bf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65f8143d-7074-44e2-9603-3db00aaf7e5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18f53195-6470-4b39-af02-647f2bf80712" xlink:to="loc_srt_MaximumMember_65f8143d-7074-44e2-9603-3db00aaf7e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_970ae7be-c631-4a00-a1cd-dc1a983ae412" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_74dda42b-b3f6-44b1-bdb8-e612d90c2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_DeferredTaxLiabilities_74dda42b-b3f6-44b1-bdb8-e612d90c2f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c69ee30f-b38c-4543-b0a9-62b45a50ca75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c69ee30f-b38c-4543-b0a9-62b45a50ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e55bef37-02c8-4e8d-8440-e6b8104777b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e55bef37-02c8-4e8d-8440-e6b8104777b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet_fe05023c-acd8-4b4e-8645-9e3ad54a2514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet_fe05023c-acd8-4b4e-8645-9e3ad54a2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_97484c26-7ef5-41bd-aca7-be6f244bb939" xlink:href="elv-20221231.xsd#elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee_97484c26-7ef5-41bd-aca7-be6f244bb939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e4181e59-9082-4716-b3a8-f46756b131ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e4181e59-9082-4716-b3a8-f46756b131ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_c423585c-f0ee-4463-a9df-ff253edb3549" xlink:href="elv-20221231.xsd#elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized_c423585c-f0ee-4463-a9df-ff253edb3549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncomeTaxRefundClaimsFiled_2794f6cf-2988-4a99-9bf5-06f2d361a1da" xlink:href="elv-20221231.xsd#elv_IncomeTaxRefundClaimsFiled"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_elv_IncomeTaxRefundClaimsFiled_2794f6cf-2988-4a99-9bf5-06f2d361a1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_f97cbf31-180a-4ee0-8f31-728fc822831e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_f97cbf31-180a-4ee0-8f31-728fc822831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6c596461-6df5-4648-bbfc-9da9a833753e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6c596461-6df5-4648-bbfc-9da9a833753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3168ddc0-4041-49d5-9a06-91ad4166ae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3168ddc0-4041-49d5-9a06-91ad4166ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_da2bf6a5-122c-4f0b-8a1b-932724f51e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_OperatingLossCarryforwards_da2bf6a5-122c-4f0b-8a1b-932724f51e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_0c4d9426-513c-4314-a002-4e1602d6abb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxReceivable_0c4d9426-513c-4314-a002-4e1602d6abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_b66767ea-c61e-4181-bd7b-37d96655cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_IncomeTaxesPaid_b66767ea-c61e-4181-bd7b-37d96655cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3f20da0f-0c3c-4b17-9765-eefd874e82fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7b26081c-096c-41bc-a9d4-dccffc5c2a49" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3f20da0f-0c3c-4b17-9765-eefd874e82fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d61c5194-fcb8-4544-bf89-c52b432d2259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d61c5194-fcb8-4544-bf89-c52b432d2259" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3e54d52-fdf4-4891-a36d-e0d63eeeda48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6adce645-3aba-43d4-a0b7-75cb5f9261d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6adce645-3aba-43d4-a0b7-75cb5f9261d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DataProcessingEquipmentAndSoftwareMember_316a0351-9712-45c9-af07-7d30224cc4f9" xlink:href="elv-20221231.xsd#elv_DataProcessingEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_elv_DataProcessingEquipmentAndSoftwareMember_316a0351-9712-45c9-af07-7d30224cc4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_64a32db9-4ee6-4f50-acf3-b761760df42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_64a32db9-4ee6-4f50-acf3-b761760df42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_510a955e-5344-4a2e-8cbb-d7aba57c7599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_510a955e-5344-4a2e-8cbb-d7aba57c7599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_5e143b32-a5dd-41d7-9921-7581db4e69ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beee3a6c-b3bc-4a3d-9247-7f1f1cf7075f" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_5e143b32-a5dd-41d7-9921-7581db4e69ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3369fd3b-479b-44cf-95b9-d14a9dcd538d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_992fc583-4bfd-46c4-8fd1-78235e01cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_992fc583-4bfd-46c4-8fd1-78235e01cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1b53d49-ae3e-4e34-afbe-c0c25a2d5361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1b53d49-ae3e-4e34-afbe-c0c25a2d5361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6414a21e-8abc-42ae-b10c-4d3e73664506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e144e2b-cff7-45f4-8237-3fb66ac3dc08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6414a21e-8abc-42ae-b10c-4d3e73664506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#PropertyAndEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7be47a2-875c-4453-8b96-e366785749ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7be47a2-875c-4453-8b96-e366785749ed" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_f42247c5-56ff-4bc3-9d17-1721aa526445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_718ad59c-206f-43ba-97b7-600b8f35bbe8" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_f42247c5-56ff-4bc3-9d17-1721aa526445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_005c4685-6f5f-42f5-a4c9-4c6d7b90b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9816d571-6ce9-4887-a0c9-7083e708d3d2" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_005c4685-6f5f-42f5-a4c9-4c6d7b90b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PPEImpairmentMember_4975fd35-fdb5-4470-8f95-ab62e333ef2e" xlink:href="elv-20221231.xsd#elv_PPEImpairmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_005c4685-6f5f-42f5-a4c9-4c6d7b90b3a9" xlink:to="loc_elv_PPEImpairmentMember_4975fd35-fdb5-4470-8f95-ab62e333ef2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4de5c183-0487-42be-bbf5-dc5e4426898a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_18e20fd3-d320-4a88-b686-e8f0cb8a17eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_Depreciation_18e20fd3-d320-4a88-b686-e8f0cb8a17eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_503da652-c027-4ebd-adef-a35c9eb4d62b" xlink:href="elv-20221231.xsd#elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements_503da652-c027-4ebd-adef-a35c9eb4d62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_faa1273a-c8c8-427e-9ede-e0fc95b148ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_faa1273a-c8c8-427e-9ede-e0fc95b148ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_413b79d0-35e7-48cd-814a-2dda1c6ac956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_413b79d0-35e7-48cd-814a-2dda1c6ac956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_2f8b43a4-a95e-432f-b071-e44fa3b5971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fff843e9-3648-48aa-aa63-10fe1bed7189" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_2f8b43a4-a95e-432f-b071-e44fa3b5971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9df24361-caa0-4727-a7ca-652486623646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9df24361-caa0-4727-a7ca-652486623646" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1f9467bf-7325-416e-b7ed-ae410f9cd91e" xlink:to="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_7389b2fc-562c-4b32-8cc3-13cc463ae05b" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_7389b2fc-562c-4b32-8cc3-13cc463ae05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_614097a0-bb3e-4350-9630-60015de01a57" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_elv_GovernmentBusinessSegmentMember_614097a0-bb3e-4350-9630-60015de01a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_1fae0418-0513-46ab-9170-bc8b63dacc5a" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_elv_IngenioRxSegmentMember_1fae0418-0513-46ab-9170-bc8b63dacc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_fcce1186-d16c-4043-9edf-c74031db62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e51fb041-7b12-4a02-9584-9b51311c3482" xlink:to="loc_us-gaap_AllOtherSegmentsMember_fcce1186-d16c-4043-9edf-c74031db62f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_34de5761-3908-458e-b0d7-318730c923ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a15aab0a-e09a-4377-91c7-e73768c725c5" xlink:to="loc_us-gaap_GoodwillLineItems_34de5761-3908-458e-b0d7-318730c923ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_34de5761-3908-458e-b0d7-318730c923ee" xlink:to="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b8e4fb78-d2ed-44d8-bef6-90bd1f961b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_Goodwill_b8e4fb78-d2ed-44d8-bef6-90bd1f961b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_d26aed4c-e209-441d-822a-716d1863236d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_d26aed4c-e209-441d-822a-716d1863236d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_2170d993-a9e3-410f-b15a-d5bd50931a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_2170d993-a9e3-410f-b15a-d5bd50931a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a6a92eb0-7792-409c-b9de-309e117a177d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_Goodwill_a6a92eb0-7792-409c-b9de-309e117a177d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2499d4df-f027-49b4-9dc2-54e68f69a9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d6e22ef-8caa-4704-986f-1c8684432174" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2499d4df-f027-49b4-9dc2-54e68f69a9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2ab32f7f-fe2e-40dc-a4c7-47557ad79fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2ab32f7f-fe2e-40dc-a4c7-47557ad79fed" xlink:to="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5c56433f-e6a8-4cd0-bbdf-7e6c684c8e84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_29ac9d0f-58cf-408d-b1a7-8c4a38212cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:to="loc_us-gaap_CustomerRelationshipsMember_29ac9d0f-58cf-408d-b1a7-8c4a38212cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_ced69082-edef-4edb-9000-3bde5ccfb0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:to="loc_us-gaap_ContractualRightsMember_ced69082-edef-4edb-9000-3bde5ccfb0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_bd87b5d2-2f52-4b76-8197-75eab8772af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_efe1cbcb-b5b3-4e9d-a209-6fd08c2cfe39" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_bd87b5d2-2f52-4b76-8197-75eab8772af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f902ea63-f32c-43c6-ba54-f095a80e962c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_c28a675c-92f0-420a-91c9-27d147a1ddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:to="loc_us-gaap_TrademarksMember_c28a675c-92f0-420a-91c9-27d147a1ddd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_dc6f95de-82e5-4cf7-a8ce-4220056e4f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc06f17c-9510-4f37-b71c-876cb3b14544" xlink:to="loc_us-gaap_LicensingAgreementsMember_dc6f95de-82e5-4cf7-a8ce-4220056e4f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsTable_f0480bc7-1490-4adc-bf04-0e16925ee781" xlink:to="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f11e832-4dad-4ee3-9ac5-a2896f755d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f11e832-4dad-4ee3-9ac5-a2896f755d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_982d7682-f842-4985-aef3-eb7b57cd816c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_982d7682-f842-4985-aef3-eb7b57cd816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_810763ec-65b2-4321-aaa5-555634ac0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_810763ec-65b2-4321-aaa5-555634ac0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f8a775af-56e1-4323-ae6b-cfaaefafa9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f8a775af-56e1-4323-ae6b-cfaaefafa9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_41e6d2a5-b92c-4e43-85b8-a9972940d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_41e6d2a5-b92c-4e43-85b8-a9972940d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d6c7edcb-00f1-48d4-b635-9f49d6d4da12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d6c7edcb-00f1-48d4-b635-9f49d6d4da12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_ef394a3a-4592-42a6-a6cf-ee248cbdc5c5" xlink:href="elv-20221231.xsd#elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_ef394a3a-4592-42a6-a6cf-ee248cbdc5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1526d37-4bb0-443e-bdbd-4a47efbe44ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IntangibleAssetsLineItems_e887a386-5b77-4fcf-b3f2-0f19f1eb368b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1526d37-4bb0-443e-bdbd-4a47efbe44ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#GoodwillAndOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_ff166f75-0aa0-4701-b0e3-b4ec388ce69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_ff166f75-0aa0-4701-b0e3-b4ec388ce69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_8cd8a774-f015-43e9-8436-a2ce8e7e44ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_8cd8a774-f015-43e9-8436-a2ce8e7e44ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_117f7442-c411-4069-b29f-65265cf565d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_117f7442-c411-4069-b29f-65265cf565d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_04c3e908-1a6f-4236-9320-bcc213987fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_04c3e908-1a6f-4236-9320-bcc213987fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_acd11001-94bf-4a9e-82fe-051e966b02d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_acd11001-94bf-4a9e-82fe-051e966b02d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_933ab880-a06c-451d-b204-5b60dc6d500d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_933ab880-a06c-451d-b204-5b60dc6d500d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e2b853f5-b7ac-4039-9205-6fbf8356618b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10cbd857-8b40-4b3a-9e93-651c8bbd685e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e2b853f5-b7ac-4039-9205-6fbf8356618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsReconciliationOfTheBenefitObligationDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract_dabfc3a8-ff0e-4c17-b958-81d4ee842918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRollForwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract_dabfc3a8-ff0e-4c17-b958-81d4ee842918" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_36909830-0091-4b4b-9909-8b456e9789c8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_56a13493-7a7a-48b6-bfee-27b5b0382856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_56a13493-7a7a-48b6-bfee-27b5b0382856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_99fb6dab-3387-4781-ae9d-cfa6a07819b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ae8ed375-ad04-4162-a4c0-3e65dc2ef4af" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_99fb6dab-3387-4781-ae9d-cfa6a07819b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_868e9965-43d5-4b05-9ccf-51de70f1314c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_440e0b42-4ab7-4aa2-8949-c4898e555776" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_868e9965-43d5-4b05-9ccf-51de70f1314c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_868e9965-43d5-4b05-9ccf-51de70f1314c" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_49d8de03-f4f7-4ef2-aa08-362a0f97bfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_49d8de03-f4f7-4ef2-aa08-362a0f97bfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ed9b9dfe-e384-4af7-8ca4-66f74913990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ed9b9dfe-e384-4af7-8ca4-66f74913990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_211e8da3-6df6-42e0-b392-e74a342c598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_211e8da3-6df6-42e0-b392-e74a342c598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_f7cb1dc5-884e-4de7-b795-be0ffc7c580f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_f7cb1dc5-884e-4de7-b795-be0ffc7c580f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4cd77865-c678-46e3-9c94-3214653c509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4cd77865-c678-46e3-9c94-3214653c509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7d9e94f8-2dc7-4d20-a79c-151ebb74f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7d9e94f8-2dc7-4d20-a79c-151ebb74f81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_fa90ca28-b8cb-4867-955b-995776d30ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_fa90ca28-b8cb-4867-955b-995776d30ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_66de601b-a7a9-42a3-8c5e-58143852a843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_2ade09b0-6e00-4230-b58b-2f168eac3f18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_66de601b-a7a9-42a3-8c5e-58143852a843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract_e1f3861d-b874-4dce-be67-1fbf2e5a9bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRollForwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract_e1f3861d-b874-4dce-be67-1fbf2e5a9bc1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61818696-46cf-4149-87eb-025b5f8a9ac7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09bdc0b4-38f2-49f5-ba4b-6a17b07861e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09bdc0b4-38f2-49f5-ba4b-6a17b07861e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5e54b385-73b6-4b37-894b-42ecd8892ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_42f55f9a-65a9-448a-9d01-c52c46a996de" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5e54b385-73b6-4b37-894b-42ecd8892ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57de0981-af9d-454b-9d26-9590850314b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_53c01e27-e9f5-4b69-9e9d-aa141c9c931f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57de0981-af9d-454b-9d26-9590850314b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57de0981-af9d-454b-9d26-9590850314b1" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f3bdb3e7-9711-4c2f-9130-52f8a201d943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f3bdb3e7-9711-4c2f-9130-52f8a201d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_a813d2df-c897-49a1-8b1d-ebd155c9bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_a813d2df-c897-49a1-8b1d-ebd155c9bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ce97a7af-1221-4057-9502-c77846a4cee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ce97a7af-1221-4057-9502-c77846a4cee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d1ff0621-d24c-4f56-ae56-21acb6b0e0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d1ff0621-d24c-4f56-ae56-21acb6b0e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_dda8571f-e594-4451-bd2a-ce96eb03a415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_dda8571f-e594-4451-bd2a-ce96eb03a415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanBenefitsPaidFairValue_09d689b1-782b-463e-be21-2bb052e3ba41" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanBenefitsPaidFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_elv_DefinedBenefitPlanBenefitsPaidFairValue_09d689b1-782b-463e-be21-2bb052e3ba41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_affbff1a-90e9-45a1-b656-51c0d215b8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bce1244a-f176-4497-baf2-4d7c0e862f46" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_affbff1a-90e9-45a1-b656-51c0d215b8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7360fe53-312f-46e3-8d2f-c2ee21e814fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7360fe53-312f-46e3-8d2f-c2ee21e814fe" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ceb584a2-7525-4044-b866-40d512649a34" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0b1aaa48-e120-48ff-81a8-58dcfd38c528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0b1aaa48-e120-48ff-81a8-58dcfd38c528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64925254-3097-49e7-ac52-71bd61114e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e6ae3be0-207b-4cab-836d-32c8e84913e6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64925254-3097-49e7-ac52-71bd61114e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eda180b0-2d03-4368-bb8e-6b5129683c27" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0a9fc9a5-3f30-4737-a452-77a1bc60a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0a9fc9a5-3f30-4737-a452-77a1bc60a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2bb064e1-44f9-43fd-ab84-5b5c5abb69cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2bb064e1-44f9-43fd-ab84-5b5c5abb69cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3526e8e8-3a96-49dc-902d-603d7aeaaf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3526e8e8-3a96-49dc-902d-603d7aeaaf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4699a952-5395-4731-aeb2-9ae89399af99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5336a825-d1aa-4d37-8074-9160b629ea7d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4699a952-5395-4731-aeb2-9ae89399af99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_035e6efb-d1d2-4008-b109-e370aea004f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_035e6efb-d1d2-4008-b109-e370aea004f8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3d9bae5e-4909-4b0e-8aea-4d94e3598b6f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cc05236e-cf98-4c49-b506-d7f7f83eecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cc05236e-cf98-4c49-b506-d7f7f83eecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6ebf4b04-ac6f-4e70-ac16-8ef666049d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e174766a-69d8-453a-b592-d4eaaaca48f1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6ebf4b04-ac6f-4e70-ac16-8ef666049d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e858f4be-8c8a-4f75-b797-a538d5c41b22" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e3da539d-032b-4aae-b661-e90b9413194e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e3da539d-032b-4aae-b661-e90b9413194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d2805552-812e-475d-8386-c9f781835145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d2805552-812e-475d-8386-c9f781835145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a8c29c2a-3be4-4c12-b6ea-16a3cfcbb6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_934ff4c2-0265-437e-99fe-7d27227a22bd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a8c29c2a-3be4-4c12-b6ea-16a3cfcbb6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_3280ad80-8625-45a3-86af-318ec5fbe026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_3280ad80-8625-45a3-86af-318ec5fbe026" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_06d363c5-ae8b-463c-9e56-c73cd99ab690" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7822dcf1-8139-477b-913c-ac97e038f6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7822dcf1-8139-477b-913c-ac97e038f6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_91366b51-d36f-4bf8-b8dd-694bd5c59ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3b80f06d-b50a-4e63-9f9f-f3283c083fc6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_91366b51-d36f-4bf8-b8dd-694bd5c59ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2d63466f-9509-4e35-9f02-a3ce520d52c7" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_2fea345c-35fc-4184-823f-4faab2e7280e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_2fea345c-35fc-4184-823f-4faab2e7280e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_9b5bea46-d3ea-48a9-b97c-b23d62d79fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_9b5bea46-d3ea-48a9-b97c-b23d62d79fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_1fb5374c-52a1-46d6-b722-560ca972eb4c" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets_1fb5374c-52a1-46d6-b722-560ca972eb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_31361069-951d-4fab-83e0-fee0a7f317b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_139b1299-6fdf-4eb3-8d64-b1245fc3196f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_31361069-951d-4fab-83e0-fee0a7f317b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0cf44663-7f2d-4da3-9655-2b57e1e53969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0cf44663-7f2d-4da3-9655-2b57e1e53969" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_64b04ec8-68ab-4df5-9be8-3c54788e8c91" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_bd98b2db-a420-4dc6-97e3-5861a1c471f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_bd98b2db-a420-4dc6-97e3-5861a1c471f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c80c1b8-5b0f-4048-bb2c-85190015fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b5a1bb5c-3ebf-4416-aaca-63a2854a5810" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c80c1b8-5b0f-4048-bb2c-85190015fd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3f8f6f64-b4ec-49a9-b407-018dc38c656f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_53601c22-a417-48a4-a210-7d0f77cc2839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_53601c22-a417-48a4-a210-7d0f77cc2839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_738ca39e-d099-4f39-a054-1d8d7b361491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_738ca39e-d099-4f39-a054-1d8d7b361491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1fcf52c1-c75a-4bec-a0b6-6e98ee639179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1fcf52c1-c75a-4bec-a0b6-6e98ee639179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cd1a003b-1ef5-4013-94da-f0772a750ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cd1a003b-1ef5-4013-94da-f0772a750ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b52c6fc0-42df-4712-92f4-6b761737245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b52c6fc0-42df-4712-92f4-6b761737245c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_b7ad5194-fc29-488e-9740-5d544bab9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_b7ad5194-fc29-488e-9740-5d544bab9c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_023580cd-53d0-4679-aa7b-2f4af4ffed51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_023580cd-53d0-4679-aa7b-2f4af4ffed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8296386b-e698-4bf1-806b-fabafbed9360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1e16147a-8f66-4e56-acd4-a375f4c91039" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8296386b-e698-4bf1-806b-fabafbed9360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_56a60075-72ee-4ab2-b6c9-76d918ed0aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_56a60075-72ee-4ab2-b6c9-76d918ed0aeb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_acb58bc1-a824-4dc6-ab20-eb7b98361e1f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_024dd4d7-0a89-4109-a3aa-a7ed0e24ac2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_024dd4d7-0a89-4109-a3aa-a7ed0e24ac2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64b0d73e-4bb8-4136-aa96-6816f9164280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6d738abb-e9a0-431b-a220-2940cf372f3c" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64b0d73e-4bb8-4136-aa96-6816f9164280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d31b1d-24f8-4132-86e1-c87135ab8dc3" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5b1a8091-5748-488c-9e43-51769403c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5b1a8091-5748-488c-9e43-51769403c1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_3d02f3e4-5e7f-4ef6-8be5-dac5eb103fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_3d02f3e4-5e7f-4ef6-8be5-dac5eb103fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3db0b922-79fd-42df-a956-932614d38eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3db0b922-79fd-42df-a956-932614d38eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_611c5aff-2911-40d1-ae90-db994be6f944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_72e900cd-7bd0-487e-8236-d6212347d091" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_611c5aff-2911-40d1-ae90-db994be6f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8ee7b556-dfcc-4b8c-b71b-7d6cabfd9bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8ee7b556-dfcc-4b8c-b71b-7d6cabfd9bf0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e187731-410e-4130-b683-820c29309408" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_85021a02-7de2-4260-ab25-df1a9d56f6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_85021a02-7de2-4260-ab25-df1a9d56f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e3246f15-93f0-4d4c-bf15-74c9566b5162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6dae3cc0-fb58-48ca-8f21-d31fb036bdc0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e3246f15-93f0-4d4c-bf15-74c9566b5162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bb73002b-6e52-4a57-8729-d121501b087e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a817d29d-56f7-4a72-be93-7005d7396d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a817d29d-56f7-4a72-be93-7005d7396d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f79327ad-1929-431e-bb47-7bc2eb3f3a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f79327ad-1929-431e-bb47-7bc2eb3f3a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MutualFundsMember_3113b047-7404-4312-b4fa-ba2e474aef64" xlink:href="elv-20221231.xsd#elv_MutualFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_MutualFundsMember_3113b047-7404-4312-b4fa-ba2e474aef64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_6d768052-3a06-471f-b21a-c268372cf1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_6d768052-3a06-471f-b21a-c268372cf1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8d03d197-b0ac-40c9-9ac6-521262a36092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8d03d197-b0ac-40c9-9ac6-521262a36092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_255e39d9-52b7-4552-805b-5353644fbf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_255e39d9-52b7-4552-805b-5353644fbf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommingledFundDomain_c61591bb-1161-428b-be88-314d493c06c3" xlink:href="elv-20221231.xsd#elv_CommingledFundDomain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_CommingledFundDomain_c61591bb-1161-428b-be88-314d493c06c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceCompanyContractsMember_0007d64e-45a2-4932-82f8-eaf3d796028a" xlink:href="elv-20221231.xsd#elv_InsuranceCompanyContractsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_InsuranceCompanyContractsMember_0007d64e-45a2-4932-82f8-eaf3d796028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LifeInsuranceContractsMember_f76ff557-1918-4784-a487-d9a06db48ffc" xlink:href="elv-20221231.xsd#elv_LifeInsuranceContractsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_LifeInsuranceContractsMember_f76ff557-1918-4784-a487-d9a06db48ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentInDOL10312TrustMember_42c30346-5865-40c2-8ffd-e092f0ad3cce" xlink:href="elv-20221231.xsd#elv_InvestmentInDOL10312TrustMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_InvestmentInDOL10312TrustMember_42c30346-5865-40c2-8ffd-e092f0ad3cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_961badf5-e8c6-4393-a382-3b877ad2e85a" xlink:href="elv-20221231.xsd#elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember_961badf5-e8c6-4393-a382-3b877ad2e85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PartnershipInvestmentsMember_7cd39fac-a68b-4550-8c3d-9fb6a47b17ae" xlink:href="elv-20221231.xsd#elv_PartnershipInvestmentsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_PartnershipInvestmentsMember_7cd39fac-a68b-4550-8c3d-9fb6a47b17ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_b52bd24a-67f2-4951-9561-7d07cfdf42ab" xlink:href="elv-20221231.xsd#elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_34ef907b-d94e-4bca-a6b2-6eab8494dfb0" xlink:to="loc_elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember_b52bd24a-67f2-4951-9561-7d07cfdf42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1c268ac-f03b-4c60-be39-9376d1d06232" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_09ebda7a-f796-42f6-ab90-460e31683cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_09ebda7a-f796-42f6-ab90-460e31683cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_22a25f4e-2ce2-40aa-b8fe-556d68ff2450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_22a25f4e-2ce2-40aa-b8fe-556d68ff2450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_de1020df-8f43-4782-aa2f-e95504f62fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_de1020df-8f43-4782-aa2f-e95504f62fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_9c4decdf-468d-4e38-8f07-05b07a812732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45a9e44f-5b09-42f5-9a7c-7abd1a21e73a" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_9c4decdf-468d-4e38-8f07-05b07a812732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_136a9c82-8e9f-46ca-9e3c-e64d5a4081c2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2b880c18-1fea-4654-bad0-79b006793564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2b880c18-1fea-4654-bad0-79b006793564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5a8e2e17-91c5-453e-b407-1ba6ad3c2f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2b65ada0-2868-4fd0-b790-072f9c52f7db" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5a8e2e17-91c5-453e-b407-1ba6ad3c2f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract_8d9f43f0-ba42-432a-9d2c-9c742998a3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRollForwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanRollForwardsAbstract_8d9f43f0-ba42-432a-9d2c-9c742998a3f7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalLevelIIIassetcategoriesDomain_0ef1dfea-4579-4caf-b326-2e3c03777404" xlink:href="elv-20221231.xsd#elv_TotalLevelIIIassetcategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_TotalLevelIIIassetcategoriesAxis_ab99d065-b252-4f1a-a93b-033d1952ad23" xlink:to="loc_elv_TotalLevelIIIassetcategoriesDomain_0ef1dfea-4579-4caf-b326-2e3c03777404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bef2947-8762-47f3-ac62-a47f4e2331ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10628d46-207f-42b2-9726-57bb22a229bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bef2947-8762-47f3-ac62-a47f4e2331ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8abbef6a-a575-4a28-837e-3b81b770e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bef2947-8762-47f3-ac62-a47f4e2331ac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8abbef6a-a575-4a28-837e-3b81b770e85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6a7cfee0-4efd-4619-9cf0-07596ee55c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cb353bb6-1515-4238-b444-de420e03bb9e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6a7cfee0-4efd-4619-9cf0-07596ee55c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7af01bbe-88bd-47e4-bc85-7914667d6b82" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommingledFundDomain_0534ed4e-3165-4245-9ed8-fbd7b5f5c203" xlink:href="elv-20221231.xsd#elv_CommingledFundDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:to="loc_elv_CommingledFundDomain_0534ed4e-3165-4245-9ed8-fbd7b5f5c203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceCompanyContractsMember_b1f8f0cb-ac39-4fca-b87e-90a7f23be40c" xlink:href="elv-20221231.xsd#elv_InsuranceCompanyContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:to="loc_elv_InsuranceCompanyContractsMember_b1f8f0cb-ac39-4fca-b87e-90a7f23be40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LifeInsuranceContractsMember_918c0304-9c66-49e8-a85a-a998fcd2e6ab" xlink:href="elv-20221231.xsd#elv_LifeInsuranceContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1fa5401a-9611-4e13-91e3-5c79466bfde9" xlink:to="loc_elv_LifeInsuranceContractsMember_918c0304-9c66-49e8-a85a-a998fcd2e6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0d29c3ba-e727-4510-8523-d608c80579bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_37a7bb65-b58e-4a6f-9e7b-dcaf53d59d6d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0d29c3ba-e727-4510-8523-d608c80579bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0d29c3ba-e727-4510-8523-d608c80579bc" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_897c3658-5bce-464f-885f-3e4b36ded8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_897c3658-5bce-464f-885f-3e4b36ded8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_6794f608-4a7e-4180-a97a-a2bda415ada2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_6794f608-4a7e-4180-a97a-a2bda415ada2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase_7f87500f-01d0-432e-b0fb-2c3a9724edef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase_7f87500f-01d0-432e-b0fb-2c3a9724edef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale_2586a95e-660f-45aa-839d-e2053adec7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale_2586a95e-660f-45aa-839d-e2053adec7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3311166c-63e7-47ec-8979-118f738e1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_7611a4a6-1a9c-43a9-b778-43acfe3c4402" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3311166c-63e7-47ec-8979-118f738e1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d1e10ebb-1f9a-46b0-93c2-77e38505d66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d1e10ebb-1f9a-46b0-93c2-77e38505d66f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4d2bb903-343c-4341-9a49-d2a55968d6ce" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2f5d86ff-0701-45e3-9026-dbe3133b342c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2f5d86ff-0701-45e3-9026-dbe3133b342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3ecebaeb-69b7-4269-910b-48a5875a39dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_98ed45bc-38d7-44f9-8766-1ff72a67f549" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3ecebaeb-69b7-4269-910b-48a5875a39dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f274a300-7332-4537-8833-79af0546e35e" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_dcd4b68f-22c4-49aa-bd80-220b6884c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_dcd4b68f-22c4-49aa-bd80-220b6884c0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_aafc0fe0-dd65-4b1f-a39a-e509b1822d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_aafc0fe0-dd65-4b1f-a39a-e509b1822d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb285a83-171d-4216-b463-b1d970e7c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb285a83-171d-4216-b463-b1d970e7c73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ae38b217-997b-4ea1-aac5-784654ae03eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ae38b217-997b-4ea1-aac5-784654ae03eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_09177d83-2308-4a7d-b7dc-c7b1944dafe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_09177d83-2308-4a7d-b7dc-c7b1944dafe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_40e2fd47-1912-4f9e-8f1a-5d3a7c96b874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_00a246c3-14ff-4d97-b54a-e65a2f23d797" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_40e2fd47-1912-4f9e-8f1a-5d3a7c96b874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract_6dac9090-a2ce-4b20-8020-3c9a91230927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAdditionalInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAdditionalInformationAbstract_6dac9090-a2ce-4b20-8020-3c9a91230927" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b93bc868-528a-45a7-90e8-b86acc6cab81" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_06633162-736a-46f4-929c-5139c1b5cc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_us-gaap_EquitySecuritiesMember_06633162-736a-46f4-929c-5139c1b5cc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c0555b70-0c0a-4d4b-95de-d54e8317df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_us-gaap_DebtSecuritiesMember_c0555b70-0c0a-4d4b-95de-d54e8317df5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4e3c169b-663f-4410-a2b9-c3306101a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4e3c169b-663f-4410-a2b9-c3306101a1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PartnershipInvestmentsMember_cc900dab-8a7b-4c71-b99a-79f3454e6d41" xlink:href="elv-20221231.xsd#elv_PartnershipInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_9b030cbc-7cc8-4f81-ae48-43dc113c6a79" xlink:to="loc_elv_PartnershipInvestmentsMember_cc900dab-8a7b-4c71-b99a-79f3454e6d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:href="elv-20221231.xsd#elv_DefinedBenefitPlanByAgeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:href="elv-20221231.xsd#elv_DefinedBenefitAgeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_DefinedBenefitPlanByAgeAxis_eb31aa2c-8b9d-4293-83bb-09f5f0f87a7b" xlink:to="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PreMedicareMember_fe6edd7a-0d3a-4fa7-95ef-cfa008f97db7" xlink:href="elv-20221231.xsd#elv_PreMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:to="loc_elv_PreMedicareMember_fe6edd7a-0d3a-4fa7-95ef-cfa008f97db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PostMedicareMember_f7801776-0147-4db7-8b80-085b266f7b14" xlink:href="elv-20221231.xsd#elv_PostMedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_DefinedBenefitAgeDomain_fd09e861-ffcc-499a-a527-b5fb5a0f8b49" xlink:to="loc_elv_PostMedicareMember_f7801776-0147-4db7-8b80-085b266f7b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e965d52-3e0f-4b16-bd7e-5916c48e54ad" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fa426d04-fd57-45c5-91ba-d1a560105e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fa426d04-fd57-45c5-91ba-d1a560105e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3bcfc0ce-eafd-4475-9f94-8b1b65a63aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35c95595-1e0d-4503-976c-8c45ec522f2a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3bcfc0ce-eafd-4475-9f94-8b1b65a63aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b729d9aa-086b-496b-9dd6-1d445bac6697" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9eba7b18-eb5d-400e-bcb2-7903b5ca8ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9eba7b18-eb5d-400e-bcb2-7903b5ca8ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_d977007f-3f6e-4f65-b5d2-0cbacaaf7713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_d977007f-3f6e-4f65-b5d2-0cbacaaf7713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8c3f5374-62a4-4798-9e9a-0f8291546deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8c3f5374-62a4-4798-9e9a-0f8291546deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_65a49250-00f2-446c-a05c-12d7aa60e171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_65a49250-00f2-446c-a05c-12d7aa60e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_36fe72ae-4c88-4fa0-a2bb-36d145f6a476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_36fe72ae-4c88-4fa0-a2bb-36d145f6a476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2b8946c5-6cdd-4289-86bd-ec0cd0f64e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2b8946c5-6cdd-4289-86bd-ec0cd0f64e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ab7a42bb-3ffe-4051-b975-12399bb1eef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ab7a42bb-3ffe-4051-b975-12399bb1eef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_b5d0ead2-9274-4990-bb55-588c7babf9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_b5d0ead2-9274-4990-bb55-588c7babf9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_9bc4806a-f488-47c2-a2e7-2ea1ad218581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_9bc4806a-f488-47c2-a2e7-2ea1ad218581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_dc0969be-67a2-4077-b812-d268cb683635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_dc0969be-67a2-4077-b812-d268cb683635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DefinedBenefitFairValueDueFromBrokers_3161e56b-a293-46e2-b4e4-dba1b7789ac3" xlink:href="elv-20221231.xsd#elv_DefinedBenefitFairValueDueFromBrokers"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_elv_DefinedBenefitFairValueDueFromBrokers_3161e56b-a293-46e2-b4e4-dba1b7789ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_a79af07a-dac7-42e7-9de5-66d5f9660e51" xlink:href="elv-20221231.xsd#elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets_a79af07a-dac7-42e7-9de5-66d5f9660e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_7eaafaab-bee4-44d8-b73a-2d956f99e148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_7eaafaab-bee4-44d8-b73a-2d956f99e148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_88898c71-97b9-4ded-a51d-10a8ad0de136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_88898c71-97b9-4ded-a51d-10a8ad0de136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_991b1374-1537-4629-9535-4071e8e07fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_111b440e-0e70-496c-accb-6aa342cb1962" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_991b1374-1537-4629-9535-4071e8e07fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_39207ffd-ddea-4cd1-9af8-46c121968a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_39207ffd-ddea-4cd1-9af8-46c121968a7e" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a1d82090-2e33-45fd-a248-75e55ea77cca" xlink:to="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_2133825c-42c2-4f86-9e6e-906081a2ff45" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_2133825c-42c2-4f86-9e6e-906081a2ff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_d9c6471f-014c-4dae-983a-ff6157dbec6a" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:to="loc_elv_GovernmentBusinessSegmentMember_d9c6471f-014c-4dae-983a-ff6157dbec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_b02b8fdc-8a1d-41ad-a7a6-58de3b3d2856" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ace6c6c7-0f5d-474f-bd37-4070dc4ce76d" xlink:to="loc_elv_OtherSegmentMember_b02b8fdc-8a1d-41ad-a7a6-58de3b3d2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_642ee9d3-e52c-4be4-9636-1d3f9b797748" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_5f1a9cc8-4c4b-4b8a-86ca-f2334e81df39" xlink:href="elv-20221231.xsd#elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_5f1a9cc8-4c4b-4b8a-86ca-f2334e81df39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_26e05e56-266f-43ad-a4f8-10549d9316b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_26e05e56-266f-43ad-a4f8-10549d9316b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_526eebb5-60e7-4160-8c23-ce05a572b97a" xlink:href="elv-20221231.xsd#elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_526eebb5-60e7-4160-8c23-ce05a572b97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_ad25f75d-bd96-4e92-b52f-82a5921e8fda" xlink:href="elv-20221231.xsd#elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments_ad25f75d-bd96-4e92-b52f-82a5921e8fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ed6aad0c-1da1-4420-84ba-1f2d7a614a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ed6aad0c-1da1-4420-84ba-1f2d7a614a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_196cffc0-565f-4e05-9f10-34eb7168e9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_196cffc0-565f-4e05-9f10-34eb7168e9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_d99cf23d-7e49-4d70-b3c4-197532280396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_d99cf23d-7e49-4d70-b3c4-197532280396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9ff61bb3-56c1-469b-addf-aa5d0919628e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9ff61bb3-56c1-469b-addf-aa5d0919628e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8e8be1c0-a745-45b4-a366-9f90614df093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8e8be1c0-a745-45b4-a366-9f90614df093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_1e6e37ab-0816-4cd1-aeca-96da869336f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_1e6e37ab-0816-4cd1-aeca-96da869336f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_53fea60c-4d93-4cbf-87a8-032d17d1a331" xlink:href="elv-20221231.xsd#elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet_53fea60c-4d93-4cbf-87a8-032d17d1a331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_d980c253-3962-4102-9697-fe7cbb21ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_d980c253-3962-4102-9697-fe7cbb21ed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_e31970d8-d664-4e0a-ad15-0c9954c5097b" xlink:href="elv-20221231.xsd#elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b39a7f41-06c1-486f-898e-fa8df376034d" xlink:to="loc_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense_e31970d8-d664-4e0a-ad15-0c9954c5097b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_MedicalClaimsPayableAbstract_a3c11b55-bad1-4eb2-a1c3-6faf95e985df" xlink:href="elv-20221231.xsd#elv_MedicalClaimsPayableAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_c7cb55ff-38f3-48b7-b95d-c0f1b74c6553" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a3c11b55-bad1-4eb2-a1c3-6faf95e985df" xlink:to="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions_c7cb55ff-38f3-48b7-b95d-c0f1b74c6553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_900ea1eb-d64e-43ee-8824-bc6adcd66d72" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a3c11b55-bad1-4eb2-a1c3-6faf95e985df" xlink:to="loc_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions_900ea1eb-d64e-43ee-8824-bc6adcd66d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_dbd7580c-f076-437c-b009-4114fca96339" xlink:href="elv-20221231.xsd#elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_a3c11b55-bad1-4eb2-a1c3-6faf95e985df" xlink:to="loc_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions_dbd7580c-f076-437c-b009-4114fca96339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract_2debd833-72c7-4c87-831e-927b06d8b851" xlink:href="elv-20221231.xsd#elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:href="elv-20221231.xsd#elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract_2debd833-72c7-4c87-831e-927b06d8b851" xlink:to="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a392557-a97a-4626-b118-6864ad1a5924" xlink:to="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_eef6dfd6-8714-4037-a00b-612d03d4f777" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_eef6dfd6-8714-4037-a00b-612d03d4f777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_2f38f6e7-aff4-45ba-8787-78d2d1ec6552" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:to="loc_elv_GovernmentBusinessSegmentMember_2f38f6e7-aff4-45ba-8787-78d2d1ec6552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_367bc3af-ad5c-4581-8e8d-541625b24440" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81414d43-df64-4937-81ed-a0688e831f87" xlink:to="loc_elv_OtherSegmentMember_367bc3af-ad5c-4581-8e8d-541625b24440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:href="elv-20221231.xsd#elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable_69920369-c0d8-4376-a33b-d8c3f53a2956" xlink:to="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_a307ffe0-c8f7-4ba0-a24a-6234cd25fcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_a307ffe0-c8f7-4ba0-a24a-6234cd25fcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_QualityImprovementAndOtherClaimsExpense_af214ef3-9f5d-4292-a24b-b9bc7f7e6197" xlink:href="elv-20221231.xsd#elv_QualityImprovementAndOtherClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_elv_QualityImprovementAndOtherClaimsExpense_af214ef3-9f5d-4292-a24b-b9bc7f7e6197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_1c1999c1-0989-410b-b758-760ea780e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems_cfd69571-ea12-4e20-8319-922f258f22c7" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_1c1999c1-0989-410b-b758-760ea780e3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract_5ad2d0c4-bd98-40ce-b8ce-96456f3bf817" xlink:href="elv-20221231.xsd#elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract_5ad2d0c4-bd98-40ce-b8ce-96456f3bf817" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_58504bb7-2239-4ace-abea-d7ff7fabedca" xlink:to="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_5f23411b-6424-4440-829f-f1924adb49dc" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_5f23411b-6424-4440-829f-f1924adb49dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_58b9109e-a4ef-4b58-868c-44f8ae2b7807" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:to="loc_elv_GovernmentBusinessSegmentMember_58b9109e-a4ef-4b58-868c-44f8ae2b7807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_5d03381e-b87f-4c61-a48a-a53ab882d193" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_068881bf-634d-4654-80ee-0c06e7696b43" xlink:to="loc_elv_OtherSegmentMember_5d03381e-b87f-4c61-a48a-a53ab882d193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_8909d421-a90d-4adf-a0f3-4a39c67b78e0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_f7dd2635-bc08-4e3a-86fb-6026f82fccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_f7dd2635-bc08-4e3a-86fb-6026f82fccaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_b06f24ea-571e-4bb3-a038-a28d9b3a89ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_b06f24ea-571e-4bb3-a038-a28d9b3a89ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_4c3d09c4-4ab3-4f52-b8ad-0954a458780d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_215ee891-81d2-4fc7-b93a-26cc28efce9a" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_4c3d09c4-4ab3-4f52-b8ad-0954a458780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_db4a8776-4895-4000-a07a-54c505dd8ef0" xlink:to="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_f30e407f-4ed6-462c-bc8f-b13928be4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_f30e407f-4ed6-462c-bc8f-b13928be4e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_31e9e00f-e850-4270-8516-f52094437b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_37dc2203-560f-49fd-96d0-64fd507ec053" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_31e9e00f-e850-4270-8516-f52094437b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract_dc6fa0c8-3902-40c4-b4eb-1d1521dcdba0" xlink:href="elv-20221231.xsd#elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract_dc6fa0c8-3902-40c4-b4eb-1d1521dcdba0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d74d2109-5600-455c-8ca4-b9173971791e" xlink:to="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_afcbac92-8529-4f3d-86f7-cc9c5f731f4a" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_afcbac92-8529-4f3d-86f7-cc9c5f731f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_de445349-4832-4bfb-b98a-14c6e1c4b977" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:to="loc_elv_GovernmentBusinessSegmentMember_de445349-4832-4bfb-b98a-14c6e1c4b977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_137906d9-fa7b-4297-afa0-13cc672a1ccc" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1446365c-3011-4d29-9d3e-14e0d9537d35" xlink:to="loc_elv_OtherSegmentMember_137906d9-fa7b-4297-afa0-13cc672a1ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_18c63be0-8603-4600-b2c1-002ed5a39177" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_7ce8f17f-1c38-4821-bc2b-0503239c8d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_7ce8f17f-1c38-4821-bc2b-0503239c8d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d0085b18-9c96-4c5c-aded-fdf05799f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d0085b18-9c96-4c5c-aded-fdf05799f5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f1cb7ad7-83ac-4265-8f5a-e2899d67af14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f1cb7ad7-83ac-4265-8f5a-e2899d67af14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_fc529e1e-992b-491c-a8b8-49323e835231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_fc529e1e-992b-491c-a8b8-49323e835231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_c686143c-bd51-4ddd-a9c1-1203877c88fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_c686143c-bd51-4ddd-a9c1-1203877c88fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_ba505fd3-e1f7-4e4a-9647-34d7b5941fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_28e28fd1-83f3-49d7-ba1a-88fc84c595ea" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_ba505fd3-e1f7-4e4a-9647-34d7b5941fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#MedicalClaimsPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_MedicalClaimsPayableAbstract_cfeba900-f2a5-46c9-b4da-df68368fd259" xlink:href="elv-20221231.xsd#elv_MedicalClaimsPayableAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:href="elv-20221231.xsd#elv_ShortdurationInsuranceContractsClaimYearTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MedicalClaimsPayableAbstract_cfeba900-f2a5-46c9-b4da-df68368fd259" xlink:to="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_31e2639d-b7b2-491e-bf2b-8802575dbf04" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_8d1e6fbf-281f-4b66-b89d-ef32d59e34e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member_8d1e6fbf-281f-4b66-b89d-ef32d59e34e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_f27ea595-61b1-4e87-959c-1d77a25600ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:to="loc_us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member_f27ea595-61b1-4e87-959c-1d77a25600ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_c1493a40-f2c5-4cd7-accc-277224660b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_2d811892-0446-4f82-979b-e36137cf2874" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_c1493a40-f2c5-4cd7-accc-277224660b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4cf29a50-37ad-4365-8a62-71efd4579594" xlink:to="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_264c1dc4-1f0d-4c8e-8679-6d71c9631268" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_264c1dc4-1f0d-4c8e-8679-6d71c9631268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_e19ebe81-46fd-4e48-a916-b9677bbeb2cd" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:to="loc_elv_GovernmentBusinessSegmentMember_e19ebe81-46fd-4e48-a916-b9677bbeb2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_ce0cef54-ed21-4cac-aa63-e1c4245843b8" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4f0e0562-c4e6-4372-ae6f-79babfe96f39" xlink:to="loc_elv_OtherSegmentMember_ce0cef54-ed21-4cac-aa63-e1c4245843b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_ShortdurationInsuranceContractsClaimYearTable_5fec561c-1195-4be4-b0d5-fbaa1da0ebe8" xlink:to="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_036be551-58ce-4676-b232-b3ff0f27eec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_036be551-58ce-4676-b232-b3ff0f27eec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_9e8eb19b-0535-40ce-bd6e-38ba55d2ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_9e8eb19b-0535-40ce-bd6e-38ba55d2ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_6a55a3d0-8613-4a13-a99b-f36f1785195e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_e8ba955b-53d4-4f87-90c7-a865b79f1f64" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_6a55a3d0-8613-4a13-a99b-f36f1785195e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DebtCarryingValueOfLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1cf535ae-a1c9-4abe-9598-11a0f2a25fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1cf535ae-a1c9-4abe-9598-11a0f2a25fae" xlink:to="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86946dfd-b606-406b-8d3a-716fb773ccbc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SeniorUnsecuredNotesMember_8e4d3d51-b6fa-4511-ac22-bb0597e37483" xlink:href="elv-20221231.xsd#elv_SeniorUnsecuredNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_elv_SeniorUnsecuredNotesMember_8e4d3d51-b6fa-4511-ac22-bb0597e37483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SurplusNotesMember_d2d1c2ae-4dd2-44d3-b64d-86f974fad4b3" xlink:href="elv-20221231.xsd#elv_SurplusNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_elv_SurplusNotesMember_d2d1c2ae-4dd2-44d3-b64d-86f974fad4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7d6cdd48-326e-46da-8758-69c29bd9cc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_us-gaap_ConvertibleDebtMember_7d6cdd48-326e-46da-8758-69c29bd9cc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc5bee42-e2ca-499f-b9b9-b35519bf6040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4c4a943-6688-4c8b-a8f9-45add2441979" xlink:to="loc_us-gaap_CommercialPaperMember_cc5bee42-e2ca-499f-b9b9-b35519bf6040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:to="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7966345-d93d-474d-9fc5-34794fc37430" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_5b5cfff9-716a-4ad2-9858-ed53f21cb848" xlink:href="elv-20221231.xsd#elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_5b5cfff9-716a-4ad2-9858-ed53f21cb848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_5f84a196-af78-48d1-bc22-12a65c4b59f5" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_5f84a196-af78-48d1-bc22-12a65c4b59f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_e79990a5-6315-411b-9d8d-4602637c2383" xlink:href="elv-20221231.xsd#elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember_e79990a5-6315-411b-9d8d-4602637c2383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_285b65d5-f909-4ee8-a8ed-e450eebe2483" xlink:href="elv-20221231.xsd#elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_285b65d5-f909-4ee8-a8ed-e450eebe2483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_1fbf7e46-8442-4e99-9387-428347e20749" xlink:href="elv-20221231.xsd#elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember_1fbf7e46-8442-4e99-9387-428347e20749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_392f2d51-3f49-4519-8ebb-ab72f7ea727d" xlink:href="elv-20221231.xsd#elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember_392f2d51-3f49-4519-8ebb-ab72f7ea727d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_10cc4ba0-0d64-4fad-bb37-e810bb63cd1f" xlink:href="elv-20221231.xsd#elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember_10cc4ba0-0d64-4fad-bb37-e810bb63cd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_61ff5b08-bca6-490c-98a1-f0c91d5572c3" xlink:href="elv-20221231.xsd#elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_61ff5b08-bca6-490c-98a1-f0c91d5572c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_75551721-f8d1-4814-8ee0-0757d5429632" xlink:href="elv-20221231.xsd#elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_75551721-f8d1-4814-8ee0-0757d5429632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_6944f921-249b-4e6a-beab-eaa8f2f72887" xlink:href="elv-20221231.xsd#elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember_6944f921-249b-4e6a-beab-eaa8f2f72887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_5e0d8c00-91ec-455c-a06a-dfbb7cc221ee" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember_5e0d8c00-91ec-455c-a06a-dfbb7cc221ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_49a9707f-0454-4607-9bbd-28e914b7efc3" xlink:href="elv-20221231.xsd#elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember_49a9707f-0454-4607-9bbd-28e914b7efc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_4958f79f-1672-4753-8f17-21c09b87e23f" xlink:href="elv-20221231.xsd#elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_4958f79f-1672-4753-8f17-21c09b87e23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4c7a934d-e3cb-4512-be72-2051c077e196" xlink:href="elv-20221231.xsd#elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4c7a934d-e3cb-4512-be72-2051c077e196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_931e0996-51e4-477c-adb6-5c8fb70f5e8c" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_931e0996-51e4-477c-adb6-5c8fb70f5e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_2a03704f-fd34-4254-b790-7483a5132154" xlink:href="elv-20221231.xsd#elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_2a03704f-fd34-4254-b790-7483a5132154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_9ed09a3b-beec-4f9b-86cc-9a71564a1ab0" xlink:href="elv-20221231.xsd#elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember_9ed09a3b-beec-4f9b-86cc-9a71564a1ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_7c1a3f31-fbe1-4535-810a-c26a6be74a95" xlink:href="elv-20221231.xsd#elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember_7c1a3f31-fbe1-4535-810a-c26a6be74a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_1901ddd1-4c67-4a72-b230-c8ad2b653c91" xlink:href="elv-20221231.xsd#elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember_1901ddd1-4c67-4a72-b230-c8ad2b653c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_85b298ec-54ad-424a-946c-60bf1bf45359" xlink:href="elv-20221231.xsd#elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember_85b298ec-54ad-424a-946c-60bf1bf45359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_d6781561-cc35-4847-863d-d9b2538707d9" xlink:href="elv-20221231.xsd#elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember_d6781561-cc35-4847-863d-d9b2538707d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_7f89e726-0b68-49ee-a650-b582f2377372" xlink:href="elv-20221231.xsd#elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember_7f89e726-0b68-49ee-a650-b582f2377372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_49774fa5-b296-46aa-be28-154d4a8c70e8" xlink:href="elv-20221231.xsd#elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember_49774fa5-b296-46aa-be28-154d4a8c70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_ebd43f8a-e9b8-4141-8d81-1d09bef9a9de" xlink:href="elv-20221231.xsd#elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember_ebd43f8a-e9b8-4141-8d81-1d09bef9a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_e1804375-1063-45a5-bd69-bee4fe897e06" xlink:href="elv-20221231.xsd#elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember_e1804375-1063-45a5-bd69-bee4fe897e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_63131622-fa87-42e7-aac2-53670240638f" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember_63131622-fa87-42e7-aac2-53670240638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_443f04c9-ac3b-4a1a-8b5c-aef3e97e60d5" xlink:href="elv-20221231.xsd#elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember_443f04c9-ac3b-4a1a-8b5c-aef3e97e60d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_3b076a2a-0ade-4577-8a53-580c7f143108" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_3b076a2a-0ade-4577-8a53-580c7f143108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_b065f5c1-8f93-4d86-b72c-ddad80042297" xlink:href="elv-20221231.xsd#elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_b065f5c1-8f93-4d86-b72c-ddad80042297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_05e838ab-6726-4b0b-92fa-4e61b93b6438" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_05e838ab-6726-4b0b-92fa-4e61b93b6438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_a4abe6d0-7842-45a3-8452-f24b3e37b805" xlink:href="elv-20221231.xsd#elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_a4abe6d0-7842-45a3-8452-f24b3e37b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_975538ff-878d-47e7-989f-52f9901b9a32" xlink:href="elv-20221231.xsd#elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember_975538ff-878d-47e7-989f-52f9901b9a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_675443e9-3fb2-4193-b396-b8afc46b854a" xlink:href="elv-20221231.xsd#elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember_675443e9-3fb2-4193-b396-b8afc46b854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_3e75d9e9-f052-45b2-ba00-30e05d805805" xlink:href="elv-20221231.xsd#elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22128c9c-a968-462b-89a4-41f717763069" xlink:to="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_3e75d9e9-f052-45b2-ba00-30e05d805805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_43960f79-fa2d-48dc-b894-8412cd8d3f89" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3807aefa-d355-49da-b7ad-b4746eae8b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_LongTermDebt_3807aefa-d355-49da-b7ad-b4746eae8b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_841db74c-e321-4d10-94bf-2af359d17bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_841db74c-e321-4d10-94bf-2af359d17bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_5e864b39-e7db-4baf-a4ef-3133611fa6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_CommercialPaper_5e864b39-e7db-4baf-a4ef-3133611fa6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_dba6ebf5-fe14-467d-b367-0c3944009c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_LongTermDebtCurrent_dba6ebf5-fe14-467d-b367-0c3944009c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f25eaee2-05ae-444d-b09a-d64616b43dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c13579fe-900f-4cee-a356-b230dfcafb8c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f25eaee2-05ae-444d-b09a-d64616b43dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DebtConvertibleDebentureTermsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d06c42d9-d257-4063-8033-e64e3b74acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b167aee9-4dd2-4d5c-b91b-b2bf1749f304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d06c42d9-d257-4063-8033-e64e3b74acc2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b167aee9-4dd2-4d5c-b91b-b2bf1749f304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_502081fc-9a33-40c3-85d8-2d6b81fe5d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d06c42d9-d257-4063-8033-e64e3b74acc2" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_502081fc-9a33-40c3-85d8-2d6b81fe5d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_82a733a5-0338-40e0-9097-e9f6484a1ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d06c42d9-d257-4063-8033-e64e3b74acc2" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_82a733a5-0338-40e0-9097-e9f6484a1ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_a8ccbb86-852f-4831-a6ab-ba946a489b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d06c42d9-d257-4063-8033-e64e3b74acc2" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_a8ccbb86-852f-4831-a6ab-ba946a489b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ab7057b6-9dd7-4e9c-bee5-f4efee88520c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ab7057b6-9dd7-4e9c-bee5-f4efee88520c" xlink:to="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_990f7e2a-fad5-472a-b555-2db017451c0c" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember_6fc3aa69-77af-47a0-aa74-8e86b0f79458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMember_6fc3aa69-77af-47a0-aa74-8e86b0f79458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5d2f8f3e-5805-4fc5-b14c-6796500d1c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:to="loc_us-gaap_LineOfCreditMember_5d2f8f3e-5805-4fc5-b14c-6796500d1c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5241cc53-8811-4b2e-8af1-db481ca608e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_961d6408-75a3-4d5b-9721-cbd152066b90" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5241cc53-8811-4b2e-8af1-db481ca608e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b552c055-5306-4c63-bca8-d20615220432" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SeniorUnsecuredNotesMember_325e961d-4ea9-4018-a9d3-e0ed0aa529a2" xlink:href="elv-20221231.xsd#elv_SeniorUnsecuredNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_elv_SeniorUnsecuredNotesMember_325e961d-4ea9-4018-a9d3-e0ed0aa529a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSeniorUnsecuredNotesMember_48457635-a793-4295-b0e8-952334d52101" xlink:href="elv-20221231.xsd#elv_OtherSeniorUnsecuredNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_elv_OtherSeniorUnsecuredNotesMember_48457635-a793-4295-b0e8-952334d52101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29e72420-14ec-42bd-b989-f4759ac26cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_us-gaap_CommercialPaperMember_29e72420-14ec-42bd-b989-f4759ac26cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_c352e168-b677-46ac-85d8-438848db6a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86ff5caa-d55c-40fe-9887-e52a3a5daab8" xlink:to="loc_us-gaap_ConvertibleDebtMember_c352e168-b677-46ac-85d8-438848db6a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2a01e450-ae84-43a1-a864-e0d4b6507ae2" xlink:to="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A5YearFacilityMember_587843d9-4c85-497d-ba19-e700f1ad1f78" xlink:href="elv-20221231.xsd#elv_A5YearFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:to="loc_elv_A5YearFacilityMember_587843d9-4c85-497d-ba19-e700f1ad1f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A2021364DayFacilityMember_0684f433-7a94-472f-a498-b0c389948782" xlink:href="elv-20221231.xsd#elv_A2021364DayFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5d734800-d895-49eb-9ab7-8b55b9400f8f" xlink:to="loc_elv_A2021364DayFacilityMember_0684f433-7a94-472f-a498-b0c389948782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_42deb910-6692-4605-b82d-0907588a524c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_adfb48af-6103-40c6-81fd-deab0f748047" xlink:href="elv-20221231.xsd#elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember_adfb48af-6103-40c6-81fd-deab0f748047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_c763bed4-a715-49b7-8015-a941b3267f9a" xlink:href="elv-20221231.xsd#elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember_c763bed4-a715-49b7-8015-a941b3267f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_4533cf54-cd55-4667-8390-9c0617fb3c05" xlink:href="elv-20221231.xsd#elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember_4533cf54-cd55-4667-8390-9c0617fb3c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_dc78f668-82aa-4db0-89ca-addf5ee2101d" xlink:href="elv-20221231.xsd#elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember_dc78f668-82aa-4db0-89ca-addf5ee2101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4e29bc16-1cd9-496d-89b5-3f0de7526eb4" xlink:href="elv-20221231.xsd#elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember_4e29bc16-1cd9-496d-89b5-3f0de7526eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_8e5904a0-5794-4dd5-897c-379d8d3e0c30" xlink:href="elv-20221231.xsd#elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember_8e5904a0-5794-4dd5-897c-379d8d3e0c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_dcc70537-1f65-4f2c-a85b-bf626e7c4a12" xlink:href="elv-20221231.xsd#elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember_dcc70537-1f65-4f2c-a85b-bf626e7c4a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_abce18ed-4ede-4942-85f8-db5fccfec4ad" xlink:href="elv-20221231.xsd#elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember_abce18ed-4ede-4942-85f8-db5fccfec4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_000cccf2-0e79-4a37-a0a2-2048e395d2aa" xlink:href="elv-20221231.xsd#elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember_000cccf2-0e79-4a37-a0a2-2048e395d2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_57043393-7f43-49fd-a036-ad41591a12cf" xlink:href="elv-20221231.xsd#elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember_57043393-7f43-49fd-a036-ad41591a12cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_2f804b69-6952-4232-9c15-70f24a4681b6" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember_2f804b69-6952-4232-9c15-70f24a4681b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_33379b6a-e68b-476f-bfce-06136e04cc57" xlink:href="elv-20221231.xsd#elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember_33379b6a-e68b-476f-bfce-06136e04cc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_fde632a4-9263-4d9e-8d3a-f2386ab97171" xlink:href="elv-20221231.xsd#elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember_fde632a4-9263-4d9e-8d3a-f2386ab97171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_8001fd5c-723b-47ed-938c-238f50d244c9" xlink:href="elv-20221231.xsd#elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember_8001fd5c-723b-47ed-938c-238f50d244c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_289fb76d-c23a-489a-b957-5734860931a8" xlink:href="elv-20221231.xsd#elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember_289fb76d-c23a-489a-b957-5734860931a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_5a46b55e-6bbd-4942-b0da-be9fd137bbd1" xlink:href="elv-20221231.xsd#elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember_5a46b55e-6bbd-4942-b0da-be9fd137bbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_77f52e65-4e36-440a-b81f-12a5217c59b3" xlink:href="elv-20221231.xsd#elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember_77f52e65-4e36-440a-b81f-12a5217c59b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_c5a12c05-fe30-418f-b165-f7fc65637a04" xlink:href="elv-20221231.xsd#elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember_c5a12c05-fe30-418f-b165-f7fc65637a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_e9b830dd-144a-49a7-84e7-360904c1b0dc" xlink:href="elv-20221231.xsd#elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember_e9b830dd-144a-49a7-84e7-360904c1b0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_fe45d769-4b20-4583-a432-151a68fc7690" xlink:href="elv-20221231.xsd#elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember_fe45d769-4b20-4583-a432-151a68fc7690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_30c7edf3-916f-4410-bfc6-f2642663a3af" xlink:href="elv-20221231.xsd#elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember_30c7edf3-916f-4410-bfc6-f2642663a3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6794e1f7-f862-426a-b3c2-431662d02759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3d3e552b-94d4-4472-a673-feccd8327d93" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6794e1f7-f862-426a-b3c2-431662d02759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b5ad7a6-d063-4deb-b7f7-95e0c5247030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6aa8e572-f3fc-4a9c-9c1a-fc1647fed4a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b5ad7a6-d063-4deb-b7f7-95e0c5247030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a12bba5c-1e39-41ae-9878-48fef815c8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2b5ad7a6-d063-4deb-b7f7-95e0c5247030" xlink:to="loc_us-gaap_SubsequentEventMember_a12bba5c-1e39-41ae-9878-48fef815c8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7de17460-36ae-4f8c-8d7b-1cbecdfd1e11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_69f17f7f-81bf-41fd-bf91-d4e9e83df98f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7de17460-36ae-4f8c-8d7b-1cbecdfd1e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3f70b0f1-b4d0-4baf-9cf5-6f8bdb3e0c7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7de17460-36ae-4f8c-8d7b-1cbecdfd1e11" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3f70b0f1-b4d0-4baf-9cf5-6f8bdb3e0c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_861c4014-0834-4ff7-8d84-e782682f0168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_93582517-43d6-4036-bb23-d950c7cc7339" xlink:to="loc_us-gaap_TypeOfAdoptionMember_861c4014-0834-4ff7-8d84-e782682f0168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_b6fa6d10-90c7-47db-be6b-decaeec866d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_861c4014-0834-4ff7-8d84-e782682f0168" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_b6fa6d10-90c7-47db-be6b-decaeec866d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb3a0e46-f153-4780-a30c-cb95a91761c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_209adba0-935e-4677-998b-2fd3461d8557" xlink:to="loc_us-gaap_EquityComponentDomain_cb3a0e46-f153-4780-a30c-cb95a91761c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_98f572f9-5f90-4492-86ba-071a8b02de10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb3a0e46-f153-4780-a30c-cb95a91761c6" xlink:to="loc_us-gaap_RetainedEarningsMember_98f572f9-5f90-4492-86ba-071a8b02de10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3874aec-5980-4627-ab1c-b48a7917ed22" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_1ed9be15-eb13-4a74-aa8e-4d111d776dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate_1ed9be15-eb13-4a74-aa8e-4d111d776dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b467981-e0c6-4637-91d1-25339a19bd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b467981-e0c6-4637-91d1-25339a19bd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a5ea3a4e-f743-4385-90b2-ab6d66477841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a5ea3a4e-f743-4385-90b2-ab6d66477841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_c658fa3f-01ca-4380-8bf5-20b6175cb193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_c658fa3f-01ca-4380-8bf5-20b6175cb193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DebtRedemptionAmount_b8d3ff2f-51c7-4060-a9aa-96c2441725c7" xlink:href="elv-20221231.xsd#elv_DebtRedemptionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_DebtRedemptionAmount_b8d3ff2f-51c7-4060-a9aa-96c2441725c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b977e21f-c62d-4067-b6b6-4f99211f18b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b977e21f-c62d-4067-b6b6-4f99211f18b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc5e48d4-baf6-465b-ac0a-082e093cc541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1eefeffd-1ee1-46c4-9b74-452cae56c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1eefeffd-1ee1-46c4-9b74-452cae56c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_9ed9b076-30e8-402e-8aba-d08a81f73c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionDescription"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_9ed9b076-30e8-402e-8aba-d08a81f73c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarlyRepaymentOfSeniorDebt_d1225957-a684-4f0f-8e1e-f4578c701462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarlyRepaymentOfSeniorDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_EarlyRepaymentOfSeniorDebt_d1225957-a684-4f0f-8e1e-f4578c701462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d1e5e4cd-0c28-4427-b49b-ae9aa4f9e024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d1e5e4cd-0c28-4427-b49b-ae9aa4f9e024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1297fb0f-7d8c-4e0e-a5a4-2925748e87b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1297fb0f-7d8c-4e0e-a5a4-2925748e87b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_36fee2a3-981f-4792-9cc9-0328db7f7a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_36fee2a3-981f-4792-9cc9-0328db7f7a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_3deeb918-2c75-4d91-97e3-a74a35da173e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_3deeb918-2c75-4d91-97e3-a74a35da173e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialPaperMaximumBorrowingCapacity_f23ec80b-872a-47eb-9422-c6b3add4fe9a" xlink:href="elv-20221231.xsd#elv_CommercialPaperMaximumBorrowingCapacity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_CommercialPaperMaximumBorrowingCapacity_f23ec80b-872a-47eb-9422-c6b3add4fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_a9ca3d29-5988-4aaf-90e1-7a39c45164dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_CommercialPaper_a9ca3d29-5988-4aaf-90e1-7a39c45164dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_245a9979-a208-44c4-8909-10a920ba67a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_245a9979-a208-44c4-8909-10a920ba67a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9c216fc9-03ed-4606-a440-9e7b6698b525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9c216fc9-03ed-4606-a440-9e7b6698b525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NumberOfConsecutiveTradingDays_c7932791-bc5e-4bab-a754-ad885b9b8a25" xlink:href="elv-20221231.xsd#elv_NumberOfConsecutiveTradingDays"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_NumberOfConsecutiveTradingDays_c7932791-bc5e-4bab-a754-ad885b9b8a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5a372056-c5f2-4200-80be-3e317a6ce2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5a372056-c5f2-4200-80be-3e317a6ce2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MeasurementPeriod_8130bc7e-7696-4db6-bd34-04f1354f0240" xlink:href="elv-20221231.xsd#elv_MeasurementPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_MeasurementPeriod_8130bc7e-7696-4db6-bd34-04f1354f0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PercentConversionToStockPrice_e44ce228-099a-4473-aaa9-516968f97064" xlink:href="elv-20221231.xsd#elv_PercentConversionToStockPrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_PercentConversionToStockPrice_e44ce228-099a-4473-aaa9-516968f97064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleEarliestDate1_5627f4b9-4081-40ee-8714-70bc906f0b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleEarliestDate1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleEarliestDate1_5627f4b9-4081-40ee-8714-70bc906f0b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_40e806e7-cd95-40a4-bcf9-e5c59ca933a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_40e806e7-cd95-40a4-bcf9-e5c59ca933a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DateDebenturesReedemable_8f59a9d7-9528-4e98-a74b-f01a77d0e9be" xlink:href="elv-20221231.xsd#elv_DateDebenturesReedemable"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_DateDebenturesReedemable_8f59a9d7-9528-4e98-a74b-f01a77d0e9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c8c5e8e1-8e47-4bac-bf9c-48c98985feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c8c5e8e1-8e47-4bac-bf9c-48c98985feb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ConversionPremium_4650faa2-ac40-4dfd-b489-0038928d5ffa" xlink:href="elv-20221231.xsd#elv_ConversionPremium"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_ConversionPremium_4650faa2-ac40-4dfd-b489-0038928d5ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6a5c3d2a-750a-4d99-8ec4-410880fd30c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_SharePrice_6a5c3d2a-750a-4d99-8ec4-410880fd30c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_75ccea1f-6cd7-4a82-8c81-e38b9dfb99ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_75ccea1f-6cd7-4a82-8c81-e38b9dfb99ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DebtConversionDebtPrincipalAmount_bd799c63-fc73-4f31-9ff9-dd8f92d6eb9b" xlink:href="elv-20221231.xsd#elv_DebtConversionDebtPrincipalAmount"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_elv_DebtConversionDebtPrincipalAmount_bd799c63-fc73-4f31-9ff9-dd8f92d6eb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d38e73e6-bb95-4c31-af14-eff405eba25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d38e73e6-bb95-4c31-af14-eff405eba25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_667943a7-14eb-4fbc-9379-5198b1dc98f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_667943a7-14eb-4fbc-9379-5198b1dc98f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_89f0820a-427d-47fd-8938-eaada47297fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_InterestExpenseDebt_89f0820a-427d-47fd-8938-eaada47297fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ccb95998-ed40-428f-816a-64b606a0d794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ccb95998-ed40-428f-816a-64b606a0d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2386eadf-fe49-4b45-9cc1-d743eaa89c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2386eadf-fe49-4b45-9cc1-d743eaa89c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_8b6c70e6-ca86-4f47-ba7f-4e0172f7cec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_InterestPaid_8b6c70e6-ca86-4f47-ba7f-4e0172f7cec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_77906d32-1d50-4ec8-8659-6a05b73bc1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_77906d32-1d50-4ec8-8659-6a05b73bc1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2dca459e-70a4-4488-90ae-51bae7a04625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2dca459e-70a4-4488-90ae-51bae7a04625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f9e7d02a-e1b1-4b68-b384-15b139660457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f9e7d02a-e1b1-4b68-b384-15b139660457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_856128c5-8ca4-417a-b724-0bc7df9ef237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_856128c5-8ca4-417a-b724-0bc7df9ef237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b664bb00-5d84-4e36-b125-60539fa1cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b664bb00-5d84-4e36-b125-60539fa1cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f18dcdc-aaaf-4e04-8efe-f82c061f8ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f18dcdc-aaaf-4e04-8efe-f82c061f8ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_1c812aa6-3f32-430e-b341-29f4bd96bac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_1c812aa6-3f32-430e-b341-29f4bd96bac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_746b7a72-22e8-4cba-b77a-e7b6f06a5df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_746b7a72-22e8-4cba-b77a-e7b6f06a5df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4fb91a48-44e1-4ecf-816f-86c47744791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_LongTermDebt_4fb91a48-44e1-4ecf-816f-86c47744791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8b3e5457-df3b-479a-b80a-f3c1fce39df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8b3e5457-df3b-479a-b80a-f3c1fce39df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c44a656-5b77-401a-9bd9-e4546f5b3bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_StockholdersEquity_1c44a656-5b77-401a-9bd9-e4546f5b3bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_75d966fa-a56c-403e-87ce-03b85120e17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_75d966fa-a56c-403e-87ce-03b85120e17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodEndDate_85e2a15c-45b2-4f6e-8099-d30e462bb56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodEndDate"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0ec4c53f-a33e-45aa-b023-6497f8716361" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodEndDate_85e2a15c-45b2-4f6e-8099-d30e462bb56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CommitmentsAndContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4edd21b0-e560-4048-95a4-74e44ffcec24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:href="elv-20221231.xsd#elv_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4edd21b0-e560-4048-95a4-74e44ffcec24" xlink:to="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7f64415a-1aa7-4188-b614-512ef1770d1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e581c515-0da7-46b1-8774-f83b4b78059f" xlink:to="loc_srt_LitigationCaseTypeDomain_7f64415a-1aa7-4188-b614-512ef1770d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AnthemInc.v.ExpressScriptsInc.Member_2e4dcfe1-a5e4-4352-baf8-f99dd764d3b3" xlink:href="elv-20221231.xsd#elv_AnthemInc.v.ExpressScriptsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7f64415a-1aa7-4188-b614-512ef1770d1b" xlink:to="loc_elv_AnthemInc.v.ExpressScriptsInc.Member_2e4dcfe1-a5e4-4352-baf8-f99dd764d3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0208bc54-20ff-446f-a89a-6962dc15932c" xlink:to="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_30ca01ef-6444-4541-b1c2-635352bc0035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:to="loc_srt_MinimumMember_30ca01ef-6444-4541-b1c2-635352bc0035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1bcff3fa-bd51-4e18-ab6d-340fd8ad4197" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65bdfa86-2a02-480f-b8da-303a15510c2a" xlink:to="loc_srt_MaximumMember_1bcff3fa-bd51-4e18-ab6d-340fd8ad4197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_7cecba7a-fb3d-4edf-932b-d4dd700a2f2c" xlink:to="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PharmacypricingMember_ddca4aa8-1495-4bfe-b682-51e0b8b0e7bd" xlink:href="elv-20221231.xsd#elv_PharmacypricingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:to="loc_elv_PharmacypricingMember_ddca4aa8-1495-4bfe-b682-51e0b8b0e7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OperationalMember_1f82a253-f102-4c91-96ea-49d81e3e9a8b" xlink:href="elv-20221231.xsd#elv_OperationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_894e65e4-5b0c-4411-b113-3ade56c9d2f0" xlink:to="loc_elv_OperationalMember_1f82a253-f102-4c91-96ea-49d81e3e9a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:href="elv-20221231.xsd#elv_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesTable_f2043aac-9bd6-439c-bd06-0cade6f57edc" xlink:to="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_de53b822-34ae-4fea-969d-9f7d8ce02577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_de53b822-34ae-4fea-969d-9f7d8ce02577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GrossPremiumTaxRate_d0acd014-bd01-4153-945a-8218d89a5cef" xlink:href="elv-20221231.xsd#elv_GrossPremiumTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_elv_GrossPremiumTaxRate_d0acd014-bd01-4153-945a-8218d89a5cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1edd09fc-7e32-4dfa-89c3-48203609b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1edd09fc-7e32-4dfa-89c3-48203609b00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c89da3c3-1b91-4933-86c4-02076aa4e896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c89da3c3-1b91-4933-86c4-02076aa4e896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_025247c0-c39e-41a4-af17-e678b4e251a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_025247c0-c39e-41a4-af17-e678b4e251a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_36077b45-b7a2-4ef1-a0ab-3d98d2198388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CommitmentsAndContingenciesLineItems_25a28dd9-f640-403b-9b00-24497db39810" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_36077b45-b7a2-4ef1-a0ab-3d98d2198388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockSummaryOfStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3b3e37b-a2a6-4ec9-bc8f-4071b7adf5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3b3e37b-a2a6-4ec9-bc8f-4071b7adf5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f7435b87-ef65-4236-955f-af9a38f69f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f7435b87-ef65-4236-955f-af9a38f69f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c73091c8-fe73-4254-ba3b-7d6c2358ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c73091c8-fe73-4254-ba3b-7d6c2358ec18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_57386443-de2d-45cb-b94e-8947b56141a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_57386443-de2d-45cb-b94e-8947b56141a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9e0cea7-98f4-437c-8c61-43b9cf5e57e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c1d18c4-8d1b-4e8b-8592-a310003a3803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9e0cea7-98f4-437c-8c61-43b9cf5e57e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_53651dea-f5fa-42ff-93ed-a58482392efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_53651dea-f5fa-42ff-93ed-a58482392efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7b675af-ec24-4f5b-a38b-d797d495e6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7b675af-ec24-4f5b-a38b-d797d495e6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef7a72eb-aae9-4ba3-859c-eaf44483da5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef7a72eb-aae9-4ba3-859c-eaf44483da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24690aa1-3e78-4174-9f96-a3c15eece71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24690aa1-3e78-4174-9f96-a3c15eece71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_fdf84c98-e5e2-4e42-bbe8-df2f4854c837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_fdf84c98-e5e2-4e42-bbe8-df2f4854c837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e60e844-fa2f-4474-bde1-f7800ca15b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d944112-798c-4c48-a87b-f1eae5beed01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e60e844-fa2f-4474-bde1-f7800ca15b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_aef84f84-a476-4285-8656-01237f0ca514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_aef84f84-a476-4285-8656-01237f0ca514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c63f5269-ab3f-4055-96d1-35ea10337118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c63f5269-ab3f-4055-96d1-35ea10337118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67569690-e12a-4494-b294-6f6bd6f6e436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67569690-e12a-4494-b294-6f6bd6f6e436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ba8fa95b-a834-4976-bd82-1919b7ddbf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ba8fa95b-a834-4976-bd82-1919b7ddbf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25db4168-1b00-43a6-9d75-daa95c11f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_07ce5089-1f0f-4cd3-9d28-89d9027a014a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25db4168-1b00-43a6-9d75-daa95c11f96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_23bae35e-682b-420c-ab63-35490f29c5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_23bae35e-682b-420c-ab63-35490f29c5fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf88f2e7-c176-49cd-9c9a-cfe99d593d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf88f2e7-c176-49cd-9c9a-cfe99d593d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f8e5c3a-57ec-435e-a537-2dbd1c83e77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f8e5c3a-57ec-435e-a537-2dbd1c83e77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7c18f6b2-3efa-451d-9932-b965fc76cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7c18f6b2-3efa-451d-9932-b965fc76cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35c772e1-8ec4-4e40-b099-abea90482cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35c772e1-8ec4-4e40-b099-abea90482cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_73914ee1-efd8-4f36-845f-2dfaebeee6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d3dcc43e-6493-4100-853a-c87cc67e9b78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_73914ee1-efd8-4f36-845f-2dfaebeee6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_23bae35e-682b-420c-ab63-35490f29c5fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_548f47db-9b66-4994-ab93-5c0c08170d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_548f47db-9b66-4994-ab93-5c0c08170d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e6884b6-26e9-42a4-88ea-0d9c520a1e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e6884b6-26e9-42a4-88ea-0d9c520a1e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_03a8fef8-79bc-4ff4-98fb-80135cfeefee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_03a8fef8-79bc-4ff4-98fb-80135cfeefee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_beb994a9-39a3-40c9-8217-5afae5d5bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_beb994a9-39a3-40c9-8217-5afae5d5bb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b610df4-a9c8-46c4-84c7-accc8404ce3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8905f90e-1517-4ac5-911b-e1f124989d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b610df4-a9c8-46c4-84c7-accc8404ce3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_4fe4a50d-4a4d-4ce7-b5ba-dc4f66d7bc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eecac788-6ca8-42ef-aa1d-90b31b9be19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_4fe4a50d-4a4d-4ce7-b5ba-dc4f66d7bc33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eecac788-6ca8-42ef-aa1d-90b31b9be19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3a48a65-d352-4798-9a50-9906a209bff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_4fe4a50d-4a4d-4ce7-b5ba-dc4f66d7bc33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3a48a65-d352-4798-9a50-9906a209bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75364a8e-4279-41ec-8ef6-91ad7a8233b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_4fe4a50d-4a4d-4ce7-b5ba-dc4f66d7bc33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75364a8e-4279-41ec-8ef6-91ad7a8233b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_caf76431-3b2c-406d-ab89-9973df70e9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_4fe4a50d-4a4d-4ce7-b5ba-dc4f66d7bc33" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_caf76431-3b2c-406d-ab89-9973df70e9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockWeightedAverageFairValuesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_ae49ef55-63cb-456c-ad6b-58725603ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68fc58b9-4cca-4796-8678-6a6ed9f5cd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_ae49ef55-63cb-456c-ad6b-58725603ee05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68fc58b9-4cca-4796-8678-6a6ed9f5cd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b6b0548c-9da4-4943-a5e3-2dfac5e7035e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_ae49ef55-63cb-456c-ad6b-58725603ee05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b6b0548c-9da4-4943-a5e3-2dfac5e7035e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockCashDividendActivityDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract_7b80b0d6-0757-492c-be05-ec9e58ddd080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_3225a295-d700-414a-a693-1626a44a8e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_7b80b0d6-0757-492c-be05-ec9e58ddd080" xlink:to="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_3225a295-d700-414a-a693-1626a44a8e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_e73df5f5-9c68-48e7-9310-7769646c2d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_7b80b0d6-0757-492c-be05-ec9e58ddd080" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_e73df5f5-9c68-48e7-9310-7769646c2d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_af589c40-4a02-46d9-9112-28b0e9142565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_7b80b0d6-0757-492c-be05-ec9e58ddd080" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_af589c40-4a02-46d9-9112-28b0e9142565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_08eeaca1-dc84-4eaa-9847-7fed617015cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_7b80b0d6-0757-492c-be05-ec9e58ddd080" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_08eeaca1-dc84-4eaa-9847-7fed617015cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_723e07d4-4ee6-4e65-be83-ff0f0aafa7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_7b80b0d6-0757-492c-be05-ec9e58ddd080" xlink:to="loc_us-gaap_PaymentsOfDividends_723e07d4-4ee6-4e65-be83-ff0f0aafa7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_441c8877-58c9-4886-8546-057596983d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_441c8877-58c9-4886-8546-057596983d56" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f7dbf348-8496-431b-9472-5e1fc4f56517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7ab015bc-0b50-4d64-9872-98bc32b918cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f7dbf348-8496-431b-9472-5e1fc4f56517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2e84d36e-33e9-4984-8a40-42673782ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f7dbf348-8496-431b-9472-5e1fc4f56517" xlink:to="loc_us-gaap_SubsequentEventMember_2e84d36e-33e9-4984-8a40-42673782ad63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3d5ecdc2-fd67-4f2a-b5a5-1b2a7fbd569f" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_785619f4-38b9-471a-a65b-f77fce2617e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_785619f4-38b9-471a-a65b-f77fce2617e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_e0fcc265-372f-493f-94c0-6ac394388c35" xlink:href="elv-20221231.xsd#elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice_e0fcc265-372f-493f-94c0-6ac394388c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d1d23851-648a-46b3-aedd-92da99f68783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d1d23851-648a-46b3-aedd-92da99f68783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e4cee220-5463-42c4-8fa6-1059260036bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6f25d80c-ea9d-459d-94db-76a9420a45b9" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e4cee220-5463-42c4-8fa6-1059260036bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#CapitalStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAbstract_f1ab638a-2421-4e7f-9511-784cca01d8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalAbstract_f1ab638a-2421-4e7f-9511-784cca01d8ce" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_104941c8-579d-4dd5-9528-f01668472be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9bc5225f-d3ff-4cfa-97dd-0a58378f4fa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_104941c8-579d-4dd5-9528-f01668472be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_02610e1a-f459-4faa-af7d-ea54ed1758d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_104941c8-579d-4dd5-9528-f01668472be8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_02610e1a-f459-4faa-af7d-ea54ed1758d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PerformancemeasurementperiodDomain_15a1cb61-950b-4059-b018-00a94fda0eb8" xlink:href="elv-20221231.xsd#elv_PerformancemeasurementperiodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_PerformancemeasurementperiodAxis_ba5abfef-ce39-4e6a-b77e-72e0ca6376c8" xlink:to="loc_elv_PerformancemeasurementperiodDomain_15a1cb61-950b-4059-b018-00a94fda0eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_A2022To2024Member_a80731ad-b477-4ae0-9ef7-80ff03cdb69c" xlink:href="elv-20221231.xsd#elv_A2022To2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_PerformancemeasurementperiodDomain_15a1cb61-950b-4059-b018-00a94fda0eb8" xlink:to="loc_elv_A2022To2024Member_a80731ad-b477-4ae0-9ef7-80ff03cdb69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ee3c3875-d241-46ee-952c-86d89b792eb0" xlink:to="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a5a8fb0a-f6d5-40f4-8c28-becb8c899efb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:to="loc_srt_MinimumMember_a5a8fb0a-f6d5-40f4-8c28-becb8c899efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f982b216-8766-4864-83d8-42af1ab0554c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d2f7e33-980b-4bde-a84b-175c56fd280b" xlink:to="loc_srt_MaximumMember_f982b216-8766-4864-83d8-42af1ab0554c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e0283d05-90cc-4f6d-a501-21ef6e42156b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3564ad71-695c-4208-bb9a-36c38c8f76ea" xlink:to="loc_us-gaap_PlanNameDomain_e0283d05-90cc-4f6d-a501-21ef6e42156b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EmployeeStockPurchasePlanMember_e48307f2-5f86-4e7a-b237-7d171fb2f9e1" xlink:href="elv-20221231.xsd#elv_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e0283d05-90cc-4f6d-a501-21ef6e42156b" xlink:to="loc_elv_EmployeeStockPurchasePlanMember_e48307f2-5f86-4e7a-b237-7d171fb2f9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a0ad8fe5-a1c2-42ca-8512-1f83a91f0072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_407021d2-64b6-4bb7-826b-6b50328d168a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a0ad8fe5-a1c2-42ca-8512-1f83a91f0072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_42d1dcc9-d764-4db5-a8fe-88827b4c0b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a0ad8fe5-a1c2-42ca-8512-1f83a91f0072" xlink:to="loc_us-gaap_SubsequentEventMember_42d1dcc9-d764-4db5-a8fe-88827b4c0b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:href="elv-20221231.xsd#elv_CapitalStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:href="elv-20221231.xsd#elv_CapitalStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CapitalStockAxis_517bf683-c473-44ec-9420-ada248e3e2f5" xlink:to="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_a5c200f0-11ff-4413-93c0-ff161fd62040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:to="loc_us-gaap_StockCompensationPlanMember_a5c200f0-11ff-4413-93c0-ff161fd62040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7cc48397-f95e-43ea-8f23-dff5b0f46319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7cc48397-f95e-43ea-8f23-dff5b0f46319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_01222ff3-869a-40c4-9dd0-8a7921b3a029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_CapitalStockDomain_3ed4c3d6-79c9-49c4-87c1-5583389c37e0" xlink:to="loc_us-gaap_StockOptionMember_01222ff3-869a-40c4-9dd0-8a7921b3a029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0f7f07c-525d-4e3e-8993-4de4c088de3c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5ec54c43-6220-49a6-907b-a6418f12640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5ec54c43-6220-49a6-907b-a6418f12640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6c37caa6-1619-4a17-bb5e-8d0c4f21c51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6c37caa6-1619-4a17-bb5e-8d0c4f21c51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_StockOptionTerm_caf7c98c-50f7-46bf-8461-ce8ec1c94d80" xlink:href="elv-20221231.xsd#elv_StockOptionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_StockOptionTerm_caf7c98c-50f7-46bf-8461-ce8ec1c94d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2a86db97-fad7-4e3d-944b-8d12af4a5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensation_2a86db97-fad7-4e3d-944b-8d12af4a5a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d63bd422-8fe7-4ffc-a25c-4e0a32d60494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d63bd422-8fe7-4ffc-a25c-4e0a32d60494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7719e74a-95e7-4046-adf8-b8922006b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7719e74a-95e7-4046-adf8-b8922006b45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_b0a52328-a6f3-48b6-9ad0-8251eb892c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_b0a52328-a6f3-48b6-9ad0-8251eb892c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f045f2b8-d9e6-42a8-bdbd-9e807da4b621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f045f2b8-d9e6-42a8-bdbd-9e807da4b621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_392d8d09-72ff-4eae-b4c4-e16fae43015e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_392d8d09-72ff-4eae-b4c4-e16fae43015e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd5d68cc-21bc-4ee4-8cf8-71c274eb33ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd5d68cc-21bc-4ee4-8cf8-71c274eb33ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_43ad5223-c6d2-448a-ba8c-f8958818bba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_43ad5223-c6d2-448a-ba8c-f8958818bba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b71c86de-8f16-4ac5-af08-6e1dfc44b1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b71c86de-8f16-4ac5-af08-6e1dfc44b1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58a5259a-cd0e-4ecf-ba5f-90a4ea62d8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58a5259a-cd0e-4ecf-ba5f-90a4ea62d8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_f9363011-55b0-47d5-978b-289d5dcff164" xlink:href="elv-20221231.xsd#elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount_f9363011-55b0-47d5-978b-289d5dcff164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_cecef482-2530-44bc-ad54-0fa662888672" xlink:href="elv-20221231.xsd#elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_cecef482-2530-44bc-ad54-0fa662888672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2b1a6e5e-a86a-468a-8edf-e0160500c29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2b1a6e5e-a86a-468a-8edf-e0160500c29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e0681c14-f41a-44e2-b650-1b3c631ae46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e0681c14-f41a-44e2-b650-1b3c631ae46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f94b1480-16c9-4202-85ed-02dc81aa5fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f94b1480-16c9-4202-85ed-02dc81aa5fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_5ca5b2a2-8fbf-4b8e-a9b7-a91552ba2591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_5ca5b2a2-8fbf-4b8e-a9b7-a91552ba2591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_397f312b-ce4a-4b7f-a60b-6ddf95382826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_397f312b-ce4a-4b7f-a60b-6ddf95382826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_9e199d15-d036-4c39-a1d4-84883ad63b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_9e199d15-d036-4c39-a1d4-84883ad63b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IncreaseInStockRepurchaseProgramAuthorization_ad19ac41-a84f-4b3b-867b-6716861a454d" xlink:href="elv-20221231.xsd#elv_IncreaseInStockRepurchaseProgramAuthorization"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_elv_IncreaseInStockRepurchaseProgramAuthorization_ad19ac41-a84f-4b3b-867b-6716861a454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5d2d29a4-3412-4075-9879-afd0097813a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd2d55c4-37f7-4be5-93f1-3348d0f4b8ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5d2d29a4-3412-4075-9879-afd0097813a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_25bff3ec-dd7b-416d-8132-da42edecfd02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_25bff3ec-dd7b-416d-8132-da42edecfd02" xlink:to="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd3fb835-92f6-4eaf-863c-fc951c1f34d6" xlink:to="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ecf24d4-13d2-4c64-965d-76b3bb81eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ecf24d4-13d2-4c64-965d-76b3bb81eb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_e9c26820-75ca-435e-adbc-c11ab2fac195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_e9c26820-75ca-435e-adbc-c11ab2fac195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e3f708cf-fff9-4403-bdd4-0b6fb1f8c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e3f708cf-fff9-4403-bdd4-0b6fb1f8c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23ca2a51-9dd5-47da-827f-330f98feaadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23ca2a51-9dd5-47da-827f-330f98feaadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_dbda5711-91b4-4f83-a07c-b56952a77bd1" xlink:href="elv-20221231.xsd#elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe385577-f46f-409e-88f5-532221fe3fd8" xlink:to="loc_elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember_dbda5711-91b4-4f83-a07c-b56952a77bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3c8140b1-2502-4491-9675-7b8bbbca9894" xlink:to="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d6c5322-81cf-4f67-b2e9-f5f9781fe757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d6c5322-81cf-4f67-b2e9-f5f9781fe757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92462da7-5302-4e37-b34d-6ccdee2ea149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92462da7-5302-4e37-b34d-6ccdee2ea149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e7336312-68b7-4d8c-ab17-7d0464f555ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e7336312-68b7-4d8c-ab17-7d0464f555ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0e21aae2-2f0b-4f96-a945-cdbfc0c65f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0e21aae2-2f0b-4f96-a945-cdbfc0c65f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0045f0d7-3344-4c3c-9b53-a8d40079ab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0045f0d7-3344-4c3c-9b53-a8d40079ab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_c4ee8b71-3c11-40e7-9695-f6eee953395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_c4ee8b71-3c11-40e7-9695-f6eee953395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_fbfa2a81-1492-4cfb-b4cf-c8097857fb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_fbfa2a81-1492-4cfb-b4cf-c8097857fb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_73ca6e45-9b86-4154-8e94-ee65d6131e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_73ca6e45-9b86-4154-8e94-ee65d6131e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9725388f-2c0f-475d-a57d-a5e02c63d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9725388f-2c0f-475d-a57d-a5e02c63d8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2c7ca85e-8857-405a-af7c-7f1dd8ce9576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2c7ca85e-8857-405a-af7c-7f1dd8ce9576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_634532dc-ea96-49ba-b17e-7f115ed4e74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_634532dc-ea96-49ba-b17e-7f115ed4e74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_a88cdb0c-5a5b-4c06-9884-d40f4bad5963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_a88cdb0c-5a5b-4c06-9884-d40f4bad5963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_937d4f69-9c36-4b22-8ba1-8b7c90e014a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_937d4f69-9c36-4b22-8ba1-8b7c90e014a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_f5ce33b4-e616-4853-a398-2e8506f705e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_f5ce33b4-e616-4853-a398-2e8506f705e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ccf3081e-cb81-4e0a-b87a-5237af41d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ccf3081e-cb81-4e0a-b87a-5237af41d36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c855aa3b-5ba5-4c60-9b54-4ffdc17c8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c855aa3b-5ba5-4c60-9b54-4ffdc17c8b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_8c79ca52-853c-45b7-b2c9-79a8085b91b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_8c79ca52-853c-45b7-b2c9-79a8085b91b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2fe96899-fd90-4607-9647-c00092a39c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2fe96899-fd90-4607-9647-c00092a39c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30ec7577-880d-4aac-ad8d-c4c05b865842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30ec7577-880d-4aac-ad8d-c4c05b865842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_026f65a9-974d-4b32-a3ff-9a49e98b88a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_026f65a9-974d-4b32-a3ff-9a49e98b88a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0a53139e-c55d-4bda-b8e0-119d11441f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0a53139e-c55d-4bda-b8e0-119d11441f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_abac65b3-3906-471c-807a-a38530eeaf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_abac65b3-3906-471c-807a-a38530eeaf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_1459e806-d909-4919-b750-062ed9c5bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_1459e806-d909-4919-b750-062ed9c5bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities_1032f19c-1df5-4cf7-903b-f4c9753195fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities_1032f19c-1df5-4cf7-903b-f4c9753195fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_61d2a3de-3266-47b2-addc-62b723e73d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_61d2a3de-3266-47b2-addc-62b723e73d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f81c0f34-8ecb-45ab-81b4-d98d7ef1cf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f81c0f34-8ecb-45ab-81b4-d98d7ef1cf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_ba55501d-79e1-41e9-944e-060ecf10831a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_ba55501d-79e1-41e9-944e-060ecf10831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_bcdac986-a3d0-44c7-9f86-0e56843e535d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_bcdac986-a3d0-44c7-9f86-0e56843e535d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_df959d62-7aa2-46c2-926d-ae093764638c" xlink:href="elv-20221231.xsd#elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e333ec87-c766-432c-8e98-05fdf60aad1b" xlink:to="loc_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense_df959d62-7aa2-46c2-926d-ae093764638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_efed37d0-eab2-4d0b-adfb-4fac26e2df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_31450a28-37b4-40fe-aca8-c19590da18ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_efed37d0-eab2-4d0b-adfb-4fac26e2df9c" xlink:to="loc_us-gaap_DirectPremiumsEarned_31450a28-37b4-40fe-aca8-c19590da18ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_00c5488a-b258-4d1b-a227-fcb32d0246c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_efed37d0-eab2-4d0b-adfb-4fac26e2df9c" xlink:to="loc_us-gaap_AssumedPremiumsEarned_00c5488a-b258-4d1b-a227-fcb32d0246c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_724725f5-138b-4c51-988d-d3be7c78d5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededPremiumsEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_efed37d0-eab2-4d0b-adfb-4fac26e2df9c" xlink:to="loc_us-gaap_CededPremiumsEarned_724725f5-138b-4c51-988d-d3be7c78d5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_19291f6f-4147-44e0-9f3b-a5438e5d3e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_efed37d0-eab2-4d0b-adfb-4fac26e2df9c" xlink:to="loc_us-gaap_PremiumsEarnedNet_19291f6f-4147-44e0-9f3b-a5438e5d3e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsPercentageAssumedToNet_d2ae1be7-9f90-42fd-83e0-216b185d786d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsPercentageAssumedToNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_efed37d0-eab2-4d0b-adfb-4fac26e2df9c" xlink:to="loc_us-gaap_PremiumsPercentageAssumedToNet_d2ae1be7-9f90-42fd-83e0-216b185d786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_ce160001-9b12-4133-b118-a2ff14acd19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:href="elv-20221231.xsd#elv_NetPremiumsWrittenAndEarnedBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_ce160001-9b12-4133-b118-a2ff14acd19f" xlink:to="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a24376de-15fc-4ce4-b096-0fd699f94545" xlink:to="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_29475193-285c-46be-a8c3-4ef1ff051356" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_29475193-285c-46be-a8c3-4ef1ff051356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_213fa820-deec-49ad-9fce-658538c2a7e1" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:to="loc_elv_GovernmentBusinessSegmentMember_213fa820-deec-49ad-9fce-658538c2a7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_490fc6c3-4add-4af0-9546-9c32df6efbe8" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ea9e53e3-13e4-4c50-b49a-7731e1292253" xlink:to="loc_elv_OtherSegmentMember_490fc6c3-4add-4af0-9546-9c32df6efbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems_38d7f800-b604-486c-8b8f-3110efc30492" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementaryInsuranceInformationBySegmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_NetPremiumsWrittenAndEarnedBySegmentTable_1f13bb27-30a2-4e65-87dd-fe3090ea78d5" xlink:to="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems_38d7f800-b604-486c-8b8f-3110efc30492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_2777d5b0-77b5-4cf7-8685-e682e4d42e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SupplementaryInsuranceInformationBySegmentLineItems_38d7f800-b604-486c-8b8f-3110efc30492" xlink:to="loc_us-gaap_PremiumsEarnedNet_2777d5b0-77b5-4cf7-8685-e682e4d42e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_d760625e-4c8f-4da9-8a75-29d2a195eb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_69039027-7413-4ded-891e-f4a89d963432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_d760625e-4c8f-4da9-8a75-29d2a195eb4f" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_69039027-7413-4ded-891e-f4a89d963432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_c9a6e84b-8be0-4865-9e8e-075f148c04ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_d760625e-4c8f-4da9-8a75-29d2a195eb4f" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_c9a6e84b-8be0-4865-9e8e-075f148c04ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_5171ba84-239e-487f-9b00-399d048bc793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_d760625e-4c8f-4da9-8a75-29d2a195eb4f" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_5171ba84-239e-487f-9b00-399d048bc793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_d29c9543-0e8d-4731-ac54-abb6c422fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_d760625e-4c8f-4da9-8a75-29d2a195eb4f" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_d29c9543-0e8d-4731-ac54-abb6c422fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#LeasesLeaseandOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_020a5682-19be-4f64-8098-22b3dac8dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_020a5682-19be-4f64-8098-22b3dac8dbe2" xlink:to="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c43361be-905d-41f4-b605-7ea7910597c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9292349-ee69-4509-9d63-dd21eaf495f5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c43361be-905d-41f4-b605-7ea7910597c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_d6070631-109f-440b-86ce-46862d0494e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c43361be-905d-41f4-b605-7ea7910597c9" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_d6070631-109f-440b-86ce-46862d0494e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8cf5c9a9-6c8d-4c7c-9e8f-f0f7ce40401e" xlink:to="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_118aee26-603f-40c1-9b73-5cbefec22f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_118aee26-603f-40c1-9b73-5cbefec22f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e12e673c-7be3-40b4-852d-66c2b40d6ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e12e673c-7be3-40b4-852d-66c2b40d6ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3d732531-3dc6-42cc-8889-3a9ca1dad946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3d732531-3dc6-42cc-8889-3a9ca1dad946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_59eb4850-3810-4636-b645-d7ec63e5a898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseCost_59eb4850-3810-4636-b645-d7ec63e5a898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ShortTermAndVariableLeaseCost_2585179a-8b13-42f7-972c-55acae1ba9fc" xlink:href="elv-20221231.xsd#elv_ShortTermAndVariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_elv_ShortTermAndVariableLeaseCost_2585179a-8b13-42f7-972c-55acae1ba9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_a6059a96-5647-41d7-b788-ec55123929a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_SubleaseIncome_a6059a96-5647-41d7-b788-ec55123929a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c8dfb752-47db-4b31-8d7c-2604eadcfac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_LeaseCost_c8dfb752-47db-4b31-8d7c-2604eadcfac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1071ca76-9aba-4a3d-a575-f40eac1bf8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeasePayments_1071ca76-9aba-4a3d-a575-f40eac1bf8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f3789e92-9451-4a30-957b-5b2aac0de695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f3789e92-9451-4a30-957b-5b2aac0de695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7df3e94-6f7c-468f-9208-8f0e7d31685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7df3e94-6f7c-468f-9208-8f0e7d31685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8e08a2ea-88ae-424a-a765-724ea97bcf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8e08a2ea-88ae-424a-a765-724ea97bcf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06fa6dff-6d51-462f-abfb-610c9f917b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06fa6dff-6d51-462f-abfb-610c9f917b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_66e7f316-cdee-4289-8e51-4b7f60688737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_66e7f316-cdee-4289-8e51-4b7f60688737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3bad14ce-6abe-4cd5-93c9-60d817bf7be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8279d8-7d3b-4f9d-938e-84f97b1259cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3bad14ce-6abe-4cd5-93c9-60d817bf7be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f66523b0-894e-4b22-9849-dea2a9bf7456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f66523b0-894e-4b22-9849-dea2a9bf7456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61df6ad9-32a4-4b26-bd92-9d6f37094904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61df6ad9-32a4-4b26-bd92-9d6f37094904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2bcfc75d-e3ae-45fd-a522-5f3557ba7983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2bcfc75d-e3ae-45fd-a522-5f3557ba7983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5873654a-5e7e-44b6-b2a5-506c2933767c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5873654a-5e7e-44b6-b2a5-506c2933767c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_92b12dbc-f447-4085-b20e-d5950f4e5764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_92b12dbc-f447-4085-b20e-d5950f4e5764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3836fc29-1178-4b90-abf7-604f32f2287d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3836fc29-1178-4b90-abf7-604f32f2287d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13b6e7f6-175d-4811-8879-029e8ba95e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13b6e7f6-175d-4811-8879-029e8ba95e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d96bf07b-c85a-4745-bd0a-1ed4220e3f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d96bf07b-c85a-4745-bd0a-1ed4220e3f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aefc965e-9287-4c97-bbf4-6a3c34c0d0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_449a5d6d-9785-4bfa-a582-7ea6fa3c6e7b" xlink:to="loc_us-gaap_OperatingLeaseLiability_aefc965e-9287-4c97-bbf4-6a3c34c0d0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#LeasesLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_971b7540-8fab-42e1-a815-763f1c4c9439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971b7540-8fab-42e1-a815-763f1c4c9439" xlink:to="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:to="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82e5c2e3-2b94-47df-b884-a59d8ae9ec52" xlink:to="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46e47c90-1a28-4c95-9554-ae0587a41691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:to="loc_srt_MinimumMember_46e47c90-1a28-4c95-9554-ae0587a41691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a86e7bb8-defe-424a-ac39-523853b6d0eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_993310f3-20c2-4a53-abd1-cf40b3d311f4" xlink:to="loc_srt_MaximumMember_a86e7bb8-defe-424a-ac39-523853b6d0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_997a7031-7915-4cc6-b7d0-a802ae7988b4" xlink:to="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b55dc924-0bdb-4a0f-bedd-80c155ced8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b55dc924-0bdb-4a0f-bedd-80c155ced8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_c6c57c37-f208-4404-81a9-56025a86a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8041e925-3951-450e-9f80-c1509e5385f7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_c6c57c37-f208-4404-81a9-56025a86a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e70942d3-0208-46ee-884b-f04ac9724648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85e19811-7196-49cc-9e81-b0f37e6e8f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e70942d3-0208-46ee-884b-f04ac9724648" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85e19811-7196-49cc-9e81-b0f37e6e8f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ba1df02c-79df-4d13-a7b1-7e1e96104699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e70942d3-0208-46ee-884b-f04ac9724648" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ba1df02c-79df-4d13-a7b1-7e1e96104699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54509387-019c-48d3-ab15-b9baa5642d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e70942d3-0208-46ee-884b-f04ac9724648" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54509387-019c-48d3-ab15-b9baa5642d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_768b8c41-a37a-47b6-b8e7-7c1285b89418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fe863eb7-64d7-49b7-bfbd-1ddfa6d16752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_768b8c41-a37a-47b6-b8e7-7c1285b89418" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fe863eb7-64d7-49b7-bfbd-1ddfa6d16752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults_2650d91f-5edf-4232-814d-04c7f58c590f" xlink:href="elv-20221231.xsd#elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_768b8c41-a37a-47b6-b8e7-7c1285b89418" xlink:to="loc_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults_2650d91f-5edf-4232-814d-04c7f58c590f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationFinancialDataByReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3bf9b5aa-afdc-404b-b6fc-62c628e004b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3bf9b5aa-afdc-404b-b6fc-62c628e004b4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1572e863-7a24-4fc1-af5f-471e781128a3" xlink:to="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_ea87e903-bb07-4942-8ce0-dc188ffbae73" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_ea87e903-bb07-4942-8ce0-dc188ffbae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_d2998c6a-223f-484b-90a5-76250b646db8" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_GovernmentBusinessSegmentMember_d2998c6a-223f-484b-90a5-76250b646db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_b5743d2a-a552-4d31-991c-73d13d97c975" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_IngenioRxSegmentMember_b5743d2a-a552-4d31-991c-73d13d97c975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_8629e610-4467-4ebb-9f3d-b0d5cc6504b1" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_OtherSegmentMember_8629e610-4467-4ebb-9f3d-b0d5cc6504b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SegmentEliminationsMember_abb6020b-7d0d-4144-8eb7-087a9ac8d7ca" xlink:href="elv-20221231.xsd#elv_SegmentEliminationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c6aae7cf-2ff7-48cd-9bd8-624277a6a445" xlink:to="loc_elv_SegmentEliminationsMember_abb6020b-7d0d-4144-8eb7-087a9ac8d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:to="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_98ad2fc6-08ba-4d86-8b1b-6b95671fcec7" xlink:to="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_UnaffiliatedMember_b1cb7ca1-bb7d-44ea-b8c8-7cc2f8dbc84e" xlink:href="elv-20221231.xsd#elv_UnaffiliatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:to="loc_elv_UnaffiliatedMember_b1cb7ca1-bb7d-44ea-b8c8-7cc2f8dbc84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_AffiliatedMember_deae4330-9397-4f88-b4fb-de2d8e0a76b5" xlink:href="elv-20221231.xsd#elv_AffiliatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b56d5bd3-79ab-4af2-adc2-3fcbd40beec3" xlink:to="loc_elv_AffiliatedMember_deae4330-9397-4f88-b4fb-de2d8e0a76b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82a4f6e3-dd04-498f-a6e6-1b6936b7c71a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_ed204099-4e71-4abb-a692-74109a2159a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_InsuranceServicesRevenue_ed204099-4e71-4abb-a692-74109a2159a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_74f0ca44-a98f-4cf8-87a7-5afad1c08ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_OperatingIncomeLoss_74f0ca44-a98f-4cf8-87a7-5afad1c08ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_b26db5ca-58ff-4b53-aafe-217779bf8af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d90e46b0-98d1-4887-a335-4d8d0aabc087" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_b26db5ca-58ff-4b53-aafe-217779bf8af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationMajorProductRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_28330e70-90c4-4140-9baf-d43dc3da0234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28330e70-90c4-4140-9baf-d43dc3da0234" xlink:to="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fab869fb-e961-4db0-b319-f2acd431857f" xlink:to="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b35a868-0493-4e84-8099-43a5fc6fb6a0" xlink:href="elv-20221231.xsd#elv_CommercialSpecialtyBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_CommercialSpecialtyBusinessSegmentMember_3b35a868-0493-4e84-8099-43a5fc6fb6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_592a609f-2996-4c93-a165-a090dc08969c" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_GovernmentBusinessSegmentMember_592a609f-2996-4c93-a165-a090dc08969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_8851ef48-4804-4613-9fa5-85ef04689063" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_IngenioRxSegmentMember_8851ef48-4804-4613-9fa5-85ef04689063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherSegmentMember_bd0d246c-019c-4ae6-a627-b1cad2abc631" xlink:href="elv-20221231.xsd#elv_OtherSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_OtherSegmentMember_bd0d246c-019c-4ae6-a627-b1cad2abc631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_SegmentEliminationsMember_428c7592-2a8a-4661-89ad-d47b65f10989" xlink:href="elv-20221231.xsd#elv_SegmentEliminationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e27b7983-9ba3-421a-b04f-c591fc4fc120" xlink:to="loc_elv_SegmentEliminationsMember_428c7592-2a8a-4661-89ad-d47b65f10989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:to="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8bd0be0d-c029-48a7-a3df-e59e2b786a9d" xlink:to="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ManagedCareProductsMember_4f074075-b90f-453e-b037-66f38c79eef2" xlink:href="elv-20221231.xsd#elv_ManagedCareProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_ManagedCareProductsMember_4f074075-b90f-453e-b037-66f38c79eef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_ManagedCareServicesMember_b37a0c21-f875-4d76-a531-cc7ac1ace711" xlink:href="elv-20221231.xsd#elv_ManagedCareServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_ManagedCareServicesMember_b37a0c21-f875-4d76-a531-cc7ac1ace711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_DentalVisionProductsAndServicesMember_aeed7c9d-5ec2-48b7-948d-bc93368865b8" xlink:href="elv-20221231.xsd#elv_DentalVisionProductsAndServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_DentalVisionProductsAndServicesMember_aeed7c9d-5ec2-48b7-948d-bc93368865b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_OtherProductsMember_3dda21c1-cd83-4fa8-be19-f1c74db8355f" xlink:href="elv-20221231.xsd#elv_OtherProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_OtherProductsMember_3dda21c1-cd83-4fa8-be19-f1c74db8355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PharmacyProductsAndServicesMember_3656ee4d-fd79-46d0-853e-c40239451aa4" xlink:href="elv-20221231.xsd#elv_PharmacyProductsAndServicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_PharmacyProductsAndServicesMember_3656ee4d-fd79-46d0-853e-c40239451aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IntegratedHealthServicesMember_ecc9bc38-d7d6-4c1e-8c60-458b088c5d80" xlink:href="elv-20221231.xsd#elv_IntegratedHealthServicesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d91a348-e789-4a3b-91ed-fde545bb421b" xlink:to="loc_elv_IntegratedHealthServicesMember_ecc9bc38-d7d6-4c1e-8c60-458b088c5d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_MajorProductRevenueBySegmentLineItems_b908c12d-599b-4aa2-8f12-7bfc0d2bf2f9" xlink:href="elv-20221231.xsd#elv_MajorProductRevenueBySegmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MajorProductRevenueBySegmentTable_3f77b83d-582b-4e19-8f3f-a8aa46034ca2" xlink:to="loc_elv_MajorProductRevenueBySegmentLineItems_b908c12d-599b-4aa2-8f12-7bfc0d2bf2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_5c197c89-c58f-41af-a2f2-11c175b793a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_MajorProductRevenueBySegmentLineItems_b908c12d-599b-4aa2-8f12-7bfc0d2bf2f9" xlink:to="loc_us-gaap_InsuranceServicesRevenue_5c197c89-c58f-41af-a2f2-11c175b793a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_581ab4f9-87cf-44f8-b521-5c7271d7613c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_46369bd9-3db3-499c-92d1-a3e728dfb165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_581ab4f9-87cf-44f8-b521-5c7271d7613c" xlink:to="loc_us-gaap_InsuranceServicesRevenue_46369bd9-3db3-499c-92d1-a3e728dfb165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_acb74fed-d983-4d11-9d5d-a39eb698a7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_581ab4f9-87cf-44f8-b521-5c7271d7613c" xlink:to="loc_us-gaap_NetInvestmentIncome_acb74fed-d983-4d11-9d5d-a39eb698a7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_b4887680-8896-4f88-83fb-6eaec7d140f5" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_581ab4f9-87cf-44f8-b521-5c7271d7613c" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_b4887680-8896-4f88-83fb-6eaec7d140f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_94dded8a-b65d-4c0c-b299-414f3e0bd06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_581ab4f9-87cf-44f8-b521-5c7271d7613c" xlink:to="loc_us-gaap_Revenues_94dded8a-b65d-4c0c-b299-414f3e0bd06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2075bf9e-b6bb-4964-94cf-a2438d47df27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2075bf9e-b6bb-4964-94cf-a2438d47df27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_8a66561c-4263-4368-9210-3265072c95b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_us-gaap_NetInvestmentIncome_8a66561c-4263-4368-9210-3265072c95b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetLossesGainsOnFinancialInstruments_a336e9a5-301f-4c98-93fc-362502123693" xlink:href="elv-20221231.xsd#elv_NetLossesGainsOnFinancialInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_elv_NetLossesGainsOnFinancialInstruments_a336e9a5-301f-4c98-93fc-362502123693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6cc9287e-f5ca-41d0-9a28-807962635a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_us-gaap_InterestExpense_6cc9287e-f5ca-41d0-9a28-807962635a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_14c70ade-c2f4-48bf-ac0f-e09c3e67762c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_14c70ade-c2f4-48bf-ac0f-e09c3e67762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9994aa8a-73d9-4907-8f4e-e0da7f420f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9994aa8a-73d9-4907-8f4e-e0da7f420f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbd7a5ab-b56e-4887-866e-623b5e888987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_adaad360-ab8a-4276-93b2-30dbbc4f6e25" xlink:to="loc_us-gaap_OperatingIncomeLoss_cbd7a5ab-b56e-4887-866e-623b5e888987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8e9f5158-2d74-40b3-88c7-6a88cb2178d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8e9f5158-2d74-40b3-88c7-6a88cb2178d2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c2dab95b-8a03-44a6-913b-a55791c52800" xlink:to="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_GovernmentBusinessSegmentMember_9cd88b00-dcdf-4857-9469-24a9ed6fa0b5" xlink:href="elv-20221231.xsd#elv_GovernmentBusinessSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:to="loc_elv_GovernmentBusinessSegmentMember_9cd88b00-dcdf-4857-9469-24a9ed6fa0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_IngenioRxSegmentMember_b8d0d6b7-52b8-4201-8f4d-80d207876a56" xlink:href="elv-20221231.xsd#elv_IngenioRxSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_305b2ade-4dda-445d-9f9d-ef969521c23d" xlink:to="loc_elv_IngenioRxSegmentMember_b8d0d6b7-52b8-4201-8f4d-80d207876a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2fa113ee-50de-4366-ba71-1eef4939b7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0e0449d6-0472-49a9-8343-5855d1d165ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2fa113ee-50de-4366-ba71-1eef4939b7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_48f12134-0c1b-44a7-a3bc-684950a37703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2fa113ee-50de-4366-ba71-1eef4939b7b4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_48f12134-0c1b-44a7-a3bc-684950a37703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_caa32302-0840-4a79-8b61-c1d3ca7c1626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64df2351-9168-4b10-a8ae-192ae038d48b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_caa32302-0840-4a79-8b61-c1d3ca7c1626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7d81472f-beb8-4377-94c3-de436a491a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_caa32302-0840-4a79-8b61-c1d3ca7c1626" xlink:to="loc_us-gaap_SalesRevenueNetMember_7d81472f-beb8-4377-94c3-de436a491a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_261d812b-6681-4b18-a9ab-de4514ae18b7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3bf9695a-8f1f-406a-97b2-655cf9b80657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:to="loc_us-gaap_NumberOfReportableSegments_3bf9695a-8f1f-406a-97b2-655cf9b80657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_849d7106-a12a-4575-883a-d5292fc075e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcab824d-6dea-45f3-9fdd-92a77f329f42" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_849d7106-a12a-4575-883a-d5292fc075e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ec8d2978-9ed9-4c80-b3d3-f2d41fd40b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ec8d2978-9ed9-4c80-b3d3-f2d41fd40b9e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ff714aa0-698f-4c97-8082-42e2d13ccb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ea6db73-2316-4e29-9f6c-7e06b32461b1" xlink:to="loc_us-gaap_RelatedPartyDomain_ff714aa0-698f-4c97-8082-42e2d13ccb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_APCPasseLLCMember_01c11964-9887-4820-bafc-7d265be7f183" xlink:href="elv-20221231.xsd#elv_APCPasseLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ff714aa0-698f-4c97-8082-42e2d13ccb1a" xlink:to="loc_elv_APCPasseLLCMember_01c11964-9887-4820-bafc-7d265be7f183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c9e4bd2f-8ed5-4628-9857-a11b130fde68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_07e4c19b-e0ba-47b4-a8dd-0e74ba7936be" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c9e4bd2f-8ed5-4628-9857-a11b130fde68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten_7aac3b11-6d1b-4072-b097-e87dd4a4c137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c9e4bd2f-8ed5-4628-9857-a11b130fde68" xlink:to="loc_us-gaap_AssumedPremiumsWritten_7aac3b11-6d1b-4072-b097-e87dd4a4c137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/StatutoryInformationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#StatutoryInformationDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/StatutoryInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_elv_StatutoryInformationAbstract_96ad9e31-95ca-4d22-98b9-16955abd9eff" xlink:href="elv-20221231.xsd#elv_StatutoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elv_StatutoryInformationAbstract_96ad9e31-95ca-4d22-98b9-16955abd9eff" xlink:to="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:to="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ccb6e8a5-3dd9-4e06-988c-7c18c433a719" xlink:to="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CaliforniaDepartmentofManagedHealthCareMember_d91a77cf-6c96-4a4d-b57e-b43733bbacff" xlink:href="elv-20221231.xsd#elv_CaliforniaDepartmentofManagedHealthCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:to="loc_elv_CaliforniaDepartmentofManagedHealthCareMember_d91a77cf-6c96-4a4d-b57e-b43733bbacff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_6312635b-ab96-49a1-9ec7-f21204735f8a" xlink:href="elv-20221231.xsd#elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:to="loc_elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember_6312635b-ab96-49a1-9ec7-f21204735f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_54114465-5b6f-44fa-8c8d-1fa2e22f00e9" xlink:href="elv-20221231.xsd#elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a638cc24-1b26-4b96-8c26-0c858426f8c5" xlink:to="loc_elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember_54114465-5b6f-44fa-8c8d-1fa2e22f00e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_48c9aff7-4cba-4add-a699-6457ed6510d3" xlink:to="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_147a39ca-ca7d-4d9f-84b0-20cae337bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_147a39ca-ca7d-4d9f-84b0-20cae337bb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_0f908e41-80c1-479f-9459-efbc6179584f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_0f908e41-80c1-479f-9459-efbc6179584f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d93695bc-675b-4aff-9641-22ce5f4dd81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StockholdersEquity_d93695bc-675b-4aff-9641-22ce5f4dd81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency_a98defb1-1c08-426a-8eb8-bec387ad44bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency_a98defb1-1c08-426a-8eb8-bec387ad44bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_EstimatedFutureDividendPayments_51a012b5-6b52-4195-a07a-93153cb563ba" xlink:href="elv-20221231.xsd#elv_EstimatedFutureDividendPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_58f52745-6a6c-4408-8a9e-05384e93f957" xlink:to="loc_elv_EstimatedFutureDividendPayments_51a012b5-6b52-4195-a07a-93153cb563ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_e13d6f8a-45a2-41e7-b643-fd43d210b17e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_e13d6f8a-45a2-41e7-b643-fd43d210b17e" xlink:to="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:to="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5e7d1a46-ac91-4113-85a1-463c5cdc0caa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_db195ad2-ab64-4a5e-acd3-23a9944c8448" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5e7d1a46-ac91-4113-85a1-463c5cdc0caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_5a134f7a-7d39-4867-b3b4-e0d2954fec5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5e7d1a46-ac91-4113-85a1-463c5cdc0caa" xlink:to="loc_srt_ParentCompanyMember_5a134f7a-7d39-4867-b3b4-e0d2954fec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1adf0ed2-1a19-4845-ab07-5ada88016443" xlink:to="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:to="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0232c0c2-0e2f-49a2-ab88-7712a2cb04b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0232c0c2-0e2f-49a2-ab88-7712a2cb04b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6084fd3c-e733-4641-a068-77cb4be947c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6084fd3c-e733-4641-a068-77cb4be947c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a24a92b1-4dab-4399-96f4-98b86ef16ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a24a92b1-4dab-4399-96f4-98b86ef16ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_ebbdd983-d2a8-46eb-be52-f4538c655b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_OtherReceivables_ebbdd983-d2a8-46eb-be52-f4538c655b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_8f0c8627-cb89-4d67-bfc2-e527521fcefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_8f0c8627-cb89-4d67-bfc2-e527521fcefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9f9efb36-a178-4144-a115-509608954b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_OtherAssetsCurrent_9f9efb36-a178-4144-a115-509608954b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_28a004c8-60e3-4614-b521-db6701019081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d794743a-b189-4dda-baa2-b77fc964c4fa" xlink:to="loc_us-gaap_AssetsCurrent_28a004c8-60e3-4614-b521-db6701019081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_f2b93954-f968-4046-98df-c6dd7fcfe967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_OtherLongTermInvestments_f2b93954-f968-4046-98df-c6dd7fcfe967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3545ac3c-fc17-4a49-addf-37fbfd16e597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3545ac3c-fc17-4a49-addf-37fbfd16e597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4df29eba-b512-4eca-bbe7-c3eec622a11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4df29eba-b512-4eca-bbe7-c3eec622a11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_InvestmentInSubsidiaries_a3db2f16-170f-4016-b988-6eb667a83a7f" xlink:href="elv-20221231.xsd#elv_InvestmentInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_elv_InvestmentInSubsidiaries_a3db2f16-170f-4016-b988-6eb667a83a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb1ffbeb-a323-488d-b60d-5318cf222b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb1ffbeb-a323-488d-b60d-5318cf222b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ea3e9937-8e73-4e9a-a5a5-7afb0bd2f820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a56300-8aa1-49eb-8b4b-024cfff8e95a" xlink:to="loc_us-gaap_Assets_ea3e9937-8e73-4e9a-a5a5-7afb0bd2f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c4819eb6-8e09-4fae-be44-40d7ffb88fe9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8ed45df2-d02e-4bf7-8b43-ce7d087ceb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8ed45df2-d02e-4bf7-8b43-ce7d087ceb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_3df1ead2-3906-42d0-8d3d-0bc3267e1dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_DueToAffiliateCurrent_3df1ead2-3906-42d0-8d3d-0bc3267e1dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a60951ae-c003-44e6-8467-31158732ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_LongTermDebtCurrent_a60951ae-c003-44e6-8467-31158732ffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_97ad2595-7b08-41c1-b165-80f069517203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_97ad2595-7b08-41c1-b165-80f069517203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd9c022a-0899-42bb-a942-046c9922ad27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45f9ce32-1947-4bd8-b7f4-0e629f7c34e2" xlink:to="loc_us-gaap_LiabilitiesCurrent_bd9c022a-0899-42bb-a942-046c9922ad27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_22c43f7e-fc5d-4ed1-bc51-58fafea53f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_22c43f7e-fc5d-4ed1-bc51-58fafea53f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_624266a0-a064-4659-8860-3254e3eed610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_624266a0-a064-4659-8860-3254e3eed610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_67641822-af58-4754-9978-ab9bed2a3d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_49d2ce1b-62f5-49f0-9203-539ace943154" xlink:to="loc_us-gaap_Liabilities_67641822-af58-4754-9978-ab9bed2a3d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02166ab3-5530-4bd9-8ccf-f3a963a6b92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02166ab3-5530-4bd9-8ccf-f3a963a6b92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2321a489-6bb8-4cb8-b69d-95447381b67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_PreferredStockValue_2321a489-6bb8-4cb8-b69d-95447381b67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a2c01109-903d-48f0-a002-5c5ff87f5d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_CommonStockValue_a2c01109-903d-48f0-a002-5c5ff87f5d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5e496412-6c8d-42b9-970d-6730bb8a6d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5e496412-6c8d-42b9-970d-6730bb8a6d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a523e94-de55-4955-9454-4dee6b9bc623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a523e94-de55-4955-9454-4dee6b9bc623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8b3009c-1874-48ce-8c49-6141b75f0e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8b3009c-1874-48ce-8c49-6141b75f0e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e86ddd0-8058-4760-8c06-0d0abf97d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ed477edb-8fd7-47a1-a689-e5001b2da7d3" xlink:to="loc_us-gaap_StockholdersEquity_9e86ddd0-8058-4760-8c06-0d0abf97d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6be4a62-d81e-4f88-8d7d-f6833df3ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25cfbc12-17e2-48b7-b668-312971894b3a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6be4a62-d81e-4f88-8d7d-f6833df3ba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_f4903dd8-0887-44e4-b380-fd32a451da10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_f4903dd8-0887-44e4-b380-fd32a451da10" xlink:to="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:to="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5a6da785-c4c0-4d77-a78c-c4c759cf7d98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_adec63db-f9b8-4215-8748-a36e94a28d14" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5a6da785-c4c0-4d77-a78c-c4c759cf7d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f301583f-9eea-49e4-8b0c-e4ed35b3c944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5a6da785-c4c0-4d77-a78c-c4c759cf7d98" xlink:to="loc_srt_ParentCompanyMember_f301583f-9eea-49e4-8b0c-e4ed35b3c944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bec36e8-2666-4438-a77d-046297473299" xlink:to="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6356f762-8b3b-4244-9fe9-ac922fe05e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6356f762-8b3b-4244-9fe9-ac922fe05e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_92b8f11a-4402-4e07-863a-19d317f4f8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_92b8f11a-4402-4e07-863a-19d317f4f8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_16a3b490-434e-4c6f-be61-383c4243bac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_16a3b490-434e-4c6f-be61-383c4243bac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_efa8b013-3f44-49eb-b7da-b922bd4f950c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_efa8b013-3f44-49eb-b7da-b922bd4f950c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cbc063e4-eaa3-497f-8972-6fe46373ba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cbc063e4-eaa3-497f-8972-6fe46373ba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_da8b0907-6847-4f4c-be48-acdbf88da469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_da8b0907-6847-4f4c-be48-acdbf88da469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e8485db9-8912-4c23-bbfe-607b2920e98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e8485db9-8912-4c23-bbfe-607b2920e98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e58d87e8-a7f4-478e-9182-b4f1bb832b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockSharesIssued_e58d87e8-a7f4-478e-9182-b4f1bb832b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9187a069-f3b1-4b94-894e-f8726f174778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cad0cd87-fa12-4f29-8eb9-85afc80f417a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9187a069-f3b1-4b94-894e-f8726f174778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_00a265c2-ab8d-480a-ac61-d2e6e2fc1b97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_00a265c2-ab8d-480a-ac61-d2e6e2fc1b97" xlink:to="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_91f19984-d087-4a20-9e82-a6d637a2482c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8e6b69a0-e5c4-4638-9ae5-1a29195e462d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_91f19984-d087-4a20-9e82-a6d637a2482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_736eba9f-5a68-49f8-b869-d5bd48f167b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_91f19984-d087-4a20-9e82-a6d637a2482c" xlink:to="loc_srt_ParentCompanyMember_736eba9f-5a68-49f8-b869-d5bd48f167b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8e4ad36-25fb-41a8-b13d-b33b794b5c4b" xlink:to="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_a0b83ae0-8797-47bf-915c-c79bd862e54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_NetInvestmentIncome_a0b83ae0-8797-47bf-915c-c79bd862e54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_NetGainsLossesOnFinancialInstruments_f6709948-2f60-4fd8-9644-016268fdf76c" xlink:href="elv-20221231.xsd#elv_NetGainsLossesOnFinancialInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_elv_NetGainsLossesOnFinancialInstruments_f6709948-2f60-4fd8-9644-016268fdf76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_3179994a-dfe3-4f9d-ab5e-ab21f8a23bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_OtherIncome_3179994a-dfe3-4f9d-ab5e-ab21f8a23bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5f61061-8376-4968-9611-df0d079ed521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_Revenues_f5f61061-8376-4968-9611-df0d079ed521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_20384fcd-e651-486b-8432-bdde53118378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_20384fcd-e651-486b-8432-bdde53118378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_68c7abc8-bc7c-4392-98f2-2f1bbd847ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_InterestExpense_68c7abc8-bc7c-4392-98f2-2f1bbd847ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5974b1bb-eab6-43b6-8ee0-03373a9efc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5974b1bb-eab6-43b6-8ee0-03373a9efc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_TotalExpenses_a02139d0-9e4d-4956-8956-d4cef8a8adaf" xlink:href="elv-20221231.xsd#elv_TotalExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_elv_TotalExpenses_a02139d0-9e4d-4956-8956-d4cef8a8adaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8583b948-9191-40f7-b509-8448b866356f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8583b948-9191-40f7-b509-8448b866356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_99a292e0-209f-46c5-94a3-a5a24eae967b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_99a292e0-209f-46c5-94a3-a5a24eae967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d6062211-7203-4db1-b624-c5085df47df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d6062211-7203-4db1-b624-c5085df47df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c0456b4-648d-4def-9c1c-3808b12a272d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa115aea-1cdf-4888-8e8b-d608b63944e3" xlink:to="loc_us-gaap_NetIncomeLoss_8c0456b4-648d-4def-9c1c-3808b12a272d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e806c17d-cacc-4dd0-8bfe-954bfe3332f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e806c17d-cacc-4dd0-8bfe-954bfe3332f5" xlink:to="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10f1c1bd-24ea-463c-b9bc-d6f9380e88e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_869a990d-e788-47c4-87d5-411330d8e921" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10f1c1bd-24ea-463c-b9bc-d6f9380e88e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_189d5315-b135-493e-bba2-c47363c43bf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10f1c1bd-24ea-463c-b9bc-d6f9380e88e4" xlink:to="loc_srt_ParentCompanyMember_189d5315-b135-493e-bba2-c47363c43bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5198fca6-eacb-4aeb-bed3-4a276df9ffa0" xlink:to="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb4f68fb-2ebe-4323-b572-4d49c3c7261c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_NetIncomeLoss_cb4f68fb-2ebe-4323-b572-4d49c3c7261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_85dca222-55ed-4e1d-96e5-2442a0090453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_85dca222-55ed-4e1d-96e5-2442a0090453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_2a68654e-ea91-4313-97ed-f823431c1eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities_2a68654e-ea91-4313-97ed-f823431c1eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_00c918ae-6786-414c-a925-e3ea78cdeeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_00c918ae-6786-414c-a925-e3ea78cdeeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2e6b1e09-3db9-4749-8d0c-6dea4cecb639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2e6b1e09-3db9-4749-8d0c-6dea4cecb639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e505b9a-4fdc-4031-9ce7-62256aed3f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e505b9a-4fdc-4031-9ce7-62256aed3f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_45c83cac-21c2-4486-b6f9-2ed41ff905e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0569e56-ed65-45a8-9293-8231274c3a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_45c83cac-21c2-4486-b6f9-2ed41ff905e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc224b3f-446f-45ca-a77c-b60a5e22269f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_08437dbf-70cf-47fa-8cd0-43ac7a5cbe66" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc224b3f-446f-45ca-a77c-b60a5e22269f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_e33d13ee-1624-4645-b102-8ae2c2a66db4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_e33d13ee-1624-4645-b102-8ae2c2a66db4" xlink:to="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_bdad0c14-c023-4f97-a669-eb9c58e35832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e0861736-09c5-40ff-851c-a09db45103c4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_bdad0c14-c023-4f97-a669-eb9c58e35832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_077d6611-ff63-4e16-bb8b-9123b34f0463" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_bdad0c14-c023-4f97-a669-eb9c58e35832" xlink:to="loc_srt_ParentCompanyMember_077d6611-ff63-4e16-bb8b-9123b34f0463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc022ab6-8795-4161-a679-6e27c10e3755" xlink:to="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de20d3df-ea7f-4a64-a332-e8c57453e619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de20d3df-ea7f-4a64-a332-e8c57453e619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_449b3052-06ab-4e82-8a0f-79eaf35c6e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de20d3df-ea7f-4a64-a332-e8c57453e619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_449b3052-06ab-4e82-8a0f-79eaf35c6e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8b081e3f-040a-4297-b5e1-21e209061b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8b081e3f-040a-4297-b5e1-21e209061b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_55231b33-7985-4b34-8a80-a6c9617a5551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_55231b33-7985-4b34-8a80-a6c9617a5551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_b7c019a2-0d6a-4138-90e7-4858a3d64bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_OriginationOfNotesReceivableFromRelatedParties_b7c019a2-0d6a-4138-90e7-4858a3d64bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_9e8e98f3-a623-410d-be19-12483d768bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_9e8e98f3-a623-410d-be19-12483d768bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_bcd3128c-b30a-45ec-8f08-39e5a499ea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending_bcd3128c-b30a-45ec-8f08-39e5a499ea1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_f1cf8e0b-f7a0-4635-930b-d823788e3ef1" xlink:href="elv-20221231.xsd#elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet_f1cf8e0b-f7a0-4635-930b-d823788e3ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bfb37f55-ffbb-42ae-8093-47e058b8ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bfb37f55-ffbb-42ae-8093-47e058b8ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c6ff984-b64c-436b-a16b-8cbf2f2d42da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8373a001-3fcd-47c5-b351-1a6809d5a7cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c6ff984-b64c-436b-a16b-8cbf2f2d42da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_692b34a6-2525-472f-8fb0-8a2f59b9a10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_692b34a6-2525-472f-8fb0-8a2f59b9a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71480d4e-fc8c-4009-a469-422d26dcfefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71480d4e-fc8c-4009-a469-422d26dcfefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d9adc063-41c0-4bf6-8bad-71fdd2995ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d9adc063-41c0-4bf6-8bad-71fdd2995ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_d88b036e-2b29-496c-9530-fc32b1f6d268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecuritiesLendingPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable_d88b036e-2b29-496c-9530-fc32b1f6d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6e9d7e77-ceb6-4460-9db6-3e271a27090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6e9d7e77-ceb6-4460-9db6-3e271a27090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_01ee1547-c41a-4a14-a00b-4ff0eba3e4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_PaymentsOfDividends_01ee1547-c41a-4a14-a00b-4ff0eba3e4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6fee0cfc-2ddc-46a9-8096-f8a4213d3829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6fee0cfc-2ddc-46a9-8096-f8a4213d3829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3b0dadf5-17a3-4e50-b3df-9a5ceb81fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3b0dadf5-17a3-4e50-b3df-9a5ceb81fbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4f8b7683-ee11-4b6a-a32f-e0664030bb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4f8b7683-ee11-4b6a-a32f-e0664030bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d988e94-5a1d-4de1-91e8-767877c0ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00f3e49b-c4c2-489f-b2d1-9e289169a5bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d988e94-5a1d-4de1-91e8-767877c0ecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d5b6314-f1df-45db-9961-7ba3f79d4205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d5b6314-f1df-45db-9961-7ba3f79d4205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3b7659-3332-4bf6-95fc-f601507fd41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f59249c-581d-4fbb-b5c9-c912ee6eba54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3b7659-3332-4bf6-95fc-f601507fd41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails" xlink:type="simple" xlink:href="elv-20221231.xsd#ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_b746f4f1-123d-4454-8a84-1c024ee453af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_b746f4f1-123d-4454-8a84-1c024ee453af" xlink:to="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_98f11571-0804-44fc-b198-b841d3967a62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f9658b43-aef1-48c7-8328-7d77d7e5a6d3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_98f11571-0804-44fc-b198-b841d3967a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d0c7523f-9900-4bd5-bd55-2a28c808d180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_98f11571-0804-44fc-b198-b841d3967a62" xlink:to="loc_srt_ParentCompanyMember_d0c7523f-9900-4bd5-bd55-2a28c808d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bef6a86b-58c0-4f06-8bca-65a7c4391003" xlink:to="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompany_59260165-f7ce-4f68-80a2-2f6bce320cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDividendsPaidToParentCompany"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompany_59260165-f7ce-4f68-80a2-2f6bce320cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_3a0f400f-a1d6-44b0-8fc8-09d91df93a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_DividendsCommonStockCash_3a0f400f-a1d6-44b0-8fc8-09d91df93a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_elv_CapitalContributionToSubsidiaries_9d7d13e9-df19-40f7-8c00-fc41202fbb93" xlink:href="elv-20221231.xsd#elv_CapitalContributionToSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_elv_CapitalContributionToSubsidiaries_9d7d13e9-df19-40f7-8c00-fc41202fbb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_ca42d13d-31d7-4d44-b4d3-7081fd066a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_ca42d13d-31d7-4d44-b4d3-7081fd066a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_67f7c352-4bbf-4517-9c5f-723aaba215c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_DueToAffiliateCurrent_67f7c352-4bbf-4517-9c5f-723aaba215c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_d788411c-5c22-48e2-9220-b6a5257a20f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_d788411c-5c22-48e2-9220-b6a5257a20f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_66e6e3e4-0f72-4277-b193-d5da5233f419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f1beb07-4300-482c-a744-6564fb4ca87d" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_66e6e3e4-0f72-4277-b193-d5da5233f419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>elv-20221231_g1.jpg
<DESCRIPTION>ELEVANCE HEALTH LOGO
<TEXT>
begin 644 elv-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #. >8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_/UXN_Y&O6O^
MOV;_ -&-64JEV"CJ3BM7Q=_R->M?]?LW_HQJS(/]<G^\*_7([(^.>Y]H1_\
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M1_%&BVFLV$RX,=S&"5]U;JI'8@@U\Y'/_>]ZGIZZGIO+M-):GX$Y(Z45[_\
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M^H#_ .# _P#Q%?K#9_\ 'G!_US7^535\'_;>*\ON/H/J-'S/R8_X=D_&+_J
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MN)6F<1KM4%B2<#L.>E??/_#IN_\ ^BAVW_@M;_XNC_ATW?\ _10[;_P6M_\
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MD)M-,A8-<W;=E1/3/5CP.YK5^$/Q7T/XU> =,\5^'YM]G>)\\+$&2WE'WXG
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M/;(OEH,C+ ]0:_5BBNS!XR>"FYP2=U;4QK48UXJ,F?BE_P ,4_&[_HGNI_\
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MR)!:.D>/7>P"_K7V+\!?^"8-[)>6^K?%+4(X+9#O_L'39=[R>TLPX4>R9/\
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M][K_ -$M7V5'"4)9=[5P7-RO7[SQ)UJBQ/(GI='[#4445\:>V%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7Y)?\%,/^3FI_^P3:?R:OUMK\DO\ @IA_R<U/_P!@FT_D
MU?09'_O3]'^AYV/_ (/S+G_!,3_DXR?_ + US_Z%'7ZPU^(W[+/Q[A_9T^)4
MGBF?1WUM&LI;3[-'.(CERIW;B#_=].]?7/\ P]DTW_HG=U_X,U_^-UW9I@,1
MB,1STHW5EU1SX3$4J=/EF[,_0"OS$_X*L_\ )5_"'_8&/_HYZ[O_ (>R:;_T
M3NZ_\&:__&Z^6OVMOVE(/VF/%VC:U;Z%)H2Z?9?9#%)<"8N=[-NR%&/O5.68
M#$X?$JI5C9:]4/%8BE4I.,7J;'_!/C_DZ?PK_P!<[G_T0]?L;7XY?\$^/^3I
M_"O_ %SN?_1#U^MGQ!\<:9\-?!.M>*-8D\K3=*MGN9B.K8'"C_:8X4#U(KGS
MN+EBHQ6[2_-FF =J3;[F3\6/C-X1^"?APZUXNU>+3K8DK##]Z>X8#.V.,<L?
MT'<BOB+QQ_P5>N1>R1>#_ \/V13A+G6KEB[^YCCQC_OLU\;_ !P^-7B'X[^/
M;[Q-K]PS&1BEI9ACY5I#GY8D'H.YZDY)KUC]G;]@_P ;?'K1(_$,MS!X7\-S
M$_9[R]C9Y+G!P6CC&,KG(W$@<<9KT*6687"4O:8QW?X?AN<\\55K3Y:*/6?#
MW_!5_P 30WB?V[X&TF[M,_-_9]S+ X'J-^\']*^PO@'^UMX!_:$C^SZ'>OI^
MNHF^31M0PEQ@=2F"1(!ZJ>.X%?$?Q/\ ^"7WC+PGX?N-3\+Z]:^*Y;="[Z=Y
M!MYW &3Y>6(8_P"SD9[9Z5\=:3JVJ>$=>M]0T^YN-*U:PF$D4T1,<L,BG\P0
M:MY?@<=!O#.S7:_XID_6,1AY)55=']!5%>(_LA_M +^T-\)+76+KRT\06#_8
MM5BC&!YP (D [!U(;V.X=JY3]N[]HZX^!/PO2RT.X\CQ7KY>VLY5(W6T0'[R
M8>XR%7W;/:OE(X6K*O\ 5K>]>Q[#K15/VO0M_M!?MT> ?@/>3Z.#)XG\31\/
MINGNH6!L=)93PI]@"1Z5\KZA_P %7?&LETS6/@K0;>VSQ'<2SROCW8,H_2OA
M^:::]N'EE=YYY6+.[DLSL3DDD]237TI\,?\ @GK\6?B1HMOJ\EE9>&K&X4/#
M_;,S1S2*1D,(U5F /^U@U]@LNP.#@G7U?=O\D>*\3B*TK4_P/IKX0_\ !4?P
M_P"(M2@T[QYX>;PSYK!!J=C*9[=2>[H0&4>XW5O?%#_@I5X:^''CS5?#L7A:
MZUR&R=!'J5G?1^3<*R*X=.#QAO6OAOXW?L>?$KX#6 U/7M+AO=$W;6U32Y3-
M#&2< /P&3/J1C/&:\2))Z\TX97@:S]K3UCY/04L7B*:Y9;G[._LN?M;:;^T]
M<>(XK#P_=:&=%6W9S<SK)YGFF0#& ,8\L_G7CW_!5G_DDO@__L-'_P!$/7$?
M\$E?^0A\3O\ KEIW\[FNW_X*L_\ ))?!_P#V&C_Z(>O'C1AA\UC3IJR37Y':
MZDJF$<I;_P#!/@'X _\ );O G_8:M/\ T:M?LU\>OC!;? GX::AXPN].FU6"
MSDBC-K#($9M[A<Y/IFOQE^ /_);O G_8:M/_ $:M?KQ^UU\+]=^,?P-UGPMX
M;C@EU:ZF@>-;B41)A) S98^P-=F;J$L3153X>OI<PP3DJ4W'<_/[]KK]MG2O
MVE/ .E^'K#PS>:++9ZBM\9[BY216 CD3:  .?GS^%?,W@7Q"GA'QMX>UV6%K
MB/2]1M[UH5."XCE5RH/8G;BO2?C7^R9X_P#@#X?LM9\6V]A#97ES]DB-K=B9
MO,VEN0!P,*:\HT/1[GQ%K>GZ59A6N[ZXCM80YP"[L%7)[#)%>_AH8>%'EH/W
M->M_4\^K*I*=ZFY^C7_#V+PY_P!"#JG_ ('1_P#Q-?5_P"^,5K\>?ACIOC.S
MTZ;2H+V2:,6L\@=E\N1D)R!WVYK\T?\ AVK\:O\ GQT;_P &2_X5^A?[(/PL
MU[X,_ ?1/"GB2."+5[2:Y>1;>42)AYG=<,/9A7R.84<#3HIX9IROWOH>QAIX
MB4[55IZ'QI_P5>_Y*-X'_P"P3+_Z.->,_L)>)-+\'_M$:3K6MW\&F:596=W-
M<7=P^U(U$+<D_P!.^:]F_P""KW_)1O __8)E_P#1QKX9BC>:18XU9W<A551D
ML3T %?18&FJV7QIOJFOS/-Q$N3$N79GZ+?$[_@JK;6.IRVO@/PDNHVL;$#4=
M9E:,2>ZPIR!]6!]A7,^&?^"KWB.+4(_^$A\#Z7=61/S_ -FW$D,BCU&\N#].
M/K7FW@?_ ()N?%OQAH,.J74>E^'A.GF16FJ7#+<8/3<J(VS/H3D=P*\9^,_P
M"\:? /7(M,\7:7]E^T M;7D#^9;W &,E''7&1D'!&1D<BL*6$RR;]E"S?KK_
M %Z&DZV*C[\KI>A^QWP-_:"\'_M!>&FU;PM>LTD.%N]/N0$N;5CT#KD\'G#
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M_#V#PK_T(FL?^!<7^%?"?Q]\?:%\4?BQKWBOP]I$VAV&JRBX:RF96*2E1YC
MKQAF!;ZL:_0G_AUE\-O^A@\0?]_(O_B*/^'67PV_Z&#Q!_W\B_\ B*\[#XO+
M<+)RI73?J=-2CBJRM.QXM_P2G\2SV?Q2\7:%O;[)?:2MT4[>9%*H4_\ ?,KU
MR'_!3+Q3/K?[1ATQI&-MI&F6\$<>> S@R,?QWK^0K[F_9_\ V+O"'[._C"[\
M1:%J>J7UY<6;692^="BJSJQ("J.?D _$U\'?\%)_#\NC_M,7MXZ$0ZGIUK<Q
MMC@X4QD?@8ZK"UZ6)S)U:>W+^.@JU.=+"J,NXS_@G7\)=/\ B=\>!>ZM EUI
MWAVT.I>1(N5DFWJD0([@%BW_  "OUVK\G?\ @F?\1K'P7\=KK1]0F6"/Q%8&
MR@=S@?:%<.B_B ZCW(K]8J\S.W/ZU:6UE;^O4Z\#;V6FY2UK1;'Q%I%YI>IV
ML=[I]Y$T%Q;S+N21&&&4CZ&OPJ^./@%?A;\7O%OA2-F>#2]0E@A9NK19S&3[
M[2M?N[=74-E;2W%Q*D,$*&2220A510,DDGH *_"W]H;QY;?$SXW>,_$UD<V.
MH:C(]LV/O1*=B'\54'\:ZLA<^>:^S;\?ZN8YA;ECW/L'_@DK_P A#XG?]<M.
M_G<UV_\ P59_Y)+X/_[#1_\ 1#UQ'_!)7_D(?$[_ *Y:=_.YKM_^"K/_ "27
MP?\ ]AH_^B'JJG_(Y7R_])%'_<G_ %U/@'X _P#);O G_8:M/_1JU^[M?A%\
M ?\ DMW@3_L-6G_HU:_=VIS_ /B4_1CR[X9'Q/\ \%5O^2-^%?\ L.#_ -$2
MU^='PD_Y*MX,_P"PU9?^CTK]%_\ @JMG_A37A4]O[='_ *(EK\Y_A*<?%7P8
M3P/[:LO_ $>E>IE7^X?><F,_WC[C]\****^!/HC\S?\ @J]_R4;P/_V"9?\
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MV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]M_ZL+"U*\YWD[H^8?\ @J]_R4;P/_V"9?\ T<:\K_X)W_\ )TWAS_KWNO\
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@/RKW\ZQ-+$1I^S=[7[^1YV!I3IN7,C1HHHKY<]8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>elv-20221231_g2.jpg
<DESCRIPTION>PERFORMANCE GRAPH
<TEXT>
begin 644 elv-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4E!WT# 2(  A$! Q$!_\0
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M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.
M^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A
M_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\
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M_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\
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M_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\
M_A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2
M]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8_
M_&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJ
MC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X
M9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O
M@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?
M]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&
M_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?
M_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\
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M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.
M^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A
M_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\
M1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1O
MX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_
M /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^
M$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V
M/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\
M:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/
M^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD
M[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"
M'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T
M1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^
M'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__
M .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A
M+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C
M_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\
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M_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\
M_A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2
M]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8_
M_&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJ
MC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X
M9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O
M@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?
M]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&
M_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?
M_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\
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M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.
M^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A
M_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\
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M_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\J_\ @N=_S1/_ +C?_MA7ZJ5^5?\ P7._YHG_ -QO_P!L* /O_P#9
M._Y-9^#?_8F:-_Z0PUZK7E7[)W_)K/P;_P"Q,T;_ -(8:]5H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "ORK_X+G?\T3_[C?\ [85^JE?E7_P7._YHG_W&_P#V
MPH ^_P#]D[_DUGX-_P#8F:-_Z0PUZK7E7[)W_)K/P;_[$S1O_2&&O5: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#PUJUIKFB7@8VVH6,HEAE"L4;:PX.&5A]0:V: "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX?%3_@H?\>+/1M*MKN[@NKIXO#WA6"0+!9PC)WOR%+[ 6DE;T/10 /IK2?\
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M3^W[\-M"\7^)?'%OX=\(Z391Z-X;L;R&22)H;:-8-\4*L%528RK2$EF96X(
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M5X3^P_\ &;4OCW^R[X&\8:TPDUR>VDM+^7_GK-!*\#2G'&7\L.0. 7(KW:@
MJIJ>K66BV;W>HWEO86D?WY[J58XU^K,0!7$_'[XS:3^S[\'_ !/X^UE#/::/
M:^8ELK!6N)F8)%$#V+R,JY[9)[5^'&CVOQP_X*9?'"XM7U/^T+E5-U)]JF:'
M2M%M@VT;4&=H^8* H9W)).[YFH _>KP_X]\,^+II(M#\1:3K4L>=Z:??13LN
M#@Y",<8/'UK=9@JDDX Y)-?@]^T1_P $Z/BW^R'X9@^(EKKUGJ^F:;+&T^J>
M'IYH+K379@JR$$*P7>P4.A)!(R%K[B_X)J_MG:S^TWX&\1?#;QK>K=^.='TY
MI+;5)>'U"S;]WODQUDC9T#-_$'4\MN) /!/^"UOQ$DUCQM\.?"]EJBW.CV^G
M3ZG);V\P:,SO*8PS8."P6,@9Y 9O[U:W[$O_  3;^&OQ*^&/P[^)/B'QGJ9\
M27=RNI_V+:3VZV^R*X;;"R,AD)81C<0P^\0!WKXL_:Q_9.\1?LB^,M'\-^)-
M8TO6;K4]/_M".72S)L5/,>/:=ZJ<Y0G@=Q7U]_P3Q_X)^>,?^$G^%7QW_P"$
MCT/_ (1WS&U#^S<S?:]F)8MOW-F<\_>Z4 ?KU4=Q<1VL$DTSK%#&I=W8X"J!
MDDGTQ4E>0?M?>./^%<_LN_%#7UD\J>WT"ZBMWSC;-+&88C_WW(M 'X/^#OAY
MXE_;2_:<U72O#DUG;:YXMU/4=6%QJLCQV\0)EN6,C(CL.!M&%/) ]Z^EO^'*
MGQO_ .AI^'__ (,;[_Y#KY8_9G\7_%/P5\19+[X/:=?ZAXSFL9;6,Z;I?]H3
MP1.5#R)'L8*< +O*D ,>G6OI'PY_P4<_:>_9W^(T-G\4$O\ 5X5VO=^'/%&E
M)8321'(WQ2+$KKGG:WS(<=&H _53]C/X*ZY^SM^S9X/^'OB2ZT^]UK1_MGGS
MZ7)));MYMY/.NQG1&.%E4'*CD'J.3[77#?!'XQ:!\?/A=H'CKPU,9-+U:W$O
ME.1YEO(.)(9,='1PRGMQD9!!KN: /S6_X*\_LC_\)?X7C^-/AFRSK.BPK;^(
M(84^:XLP<)<8'5HB<,?^>9!) CKBO^".W[5GV6ZN_@?XBN\0S&34/#4DK?=?
ME[BU'U^:51ZB7U%?JMJ&GVNK:?<V-[;QW=E=1-!/;S*&26-@596!X(()!!]:
M_ ']L7]G_7OV'_VEH+GPW/<6.D/=+K?A75$)+1JD@81%CU>%\*<]5V,?OXH
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M7._YHG_W&_\ VPH ^_\ ]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\
M[$S1O_2&&O5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY7_X*<> [SQY^QCX
MZCL(VFNM*%OJXC5<DQP3*TQ]ML7F-_P&OJBH+ZQM]4L;BSO(([FTN(VAFAE4
M,DB,"&5@>H()!'O0!^+?_!&CXF6'A']HK7O#&H7$=M_PE&CF*S:0@>9<P2"1
M8QGN8S,?^ @5^U=?B!^V-_P3?\?_ +/OC>Z\7?"_3M4\0>!_/^V6DVD;Y+_1
MFW;A&ZJ?,*H?NRKG 'S$$9/'6G_!43]I33]!/AYO&$<URJ_9EO;C2+=KY,#;
MC=Y?+_[3*6SR230!^CO[57_!33PW^RW\;K+P)=>&9O%-NMA'=:I=Z;?(D]A(
M[-MB\IEP[>6%?!9.)%YYK6_:R^)EO\</^"</C;QMX8M=0T_3]:T5+RWAU. 1
M7 MQ<Q[RR*S !D5B""000>0:_-7]EW]@_P"*7[7'Q#A\2^,K;6=)\'7ETUWJ
M_BC5]RW-]ELN(/,^:61SD>9@JO))) 4_N'=?#S0+SX=2^!7T^,>%Y-*.BG3U
M&$%H8O)\L>@V<4 ?D)_P13N-.C_:.\7QW!1=2D\+R"U+$ E1=6YD ]3]P\=@
M:_9/6+BRM=(OIM3>*/38X'>Y>?'EK$%)<MG^';G/M7X0?&3]E7XU_L#_ !>3
MQCX3AU.YT72[A[C2?%^EVYGB6$Y&RZ4*1&Q0[75QL;+8+"K'Q/\ ^"DGQ]_:
M2\'S?#V*VTZUAU:,VMU!X5TR;[9?QD$-$<R2':P."$"Y''0D$ \]_8/CN+C]
MM+X6#1UE7_B>JZJ>7$ 5S)G'_3(/G\:^AO\ @MA_R<EX-_[%*'_TLNJ^@/\
M@F#^P%KGP;U1OBM\2+#^S?$TML]OHVB2X,MC'(,23S?W967*!,Y57?=R<+X9
M_P %HM$U'4_VC?!\EG875W&OA2%2\$+. ?MEUQD#K0!^BO[!-FEC^QS\)HT
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M([EG^(4_]FM;\AF.HGRRFW^$M@KCL17Z#_\ !;S_ ))9\-/^PS<?^B!7GO\
MP31_X)Y>)X/'ND_%OXFZ1/H6GZ2XNM$T6_CV7-S<X^2XEC(S&B$[E#88N%.
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M??$CX]?\%+OB1H]E%H?]J_82T5II^BVK0Z;IHD(WRRR.S;<A5RTC_P ( ]*
M/O7_ ((HWE[-^SCXPMY5S80^*93 _P#MM:6Q=?H,(?\ @1K]"J\B_93_ &?-
M/_9C^!^@>!+.6.\N[96N-1OHT*B[O)#F63!YQT5<\[44&O7: "O@K_@LUI-E
M=?LKZ1?S6L4E[:>);9;>X9!YD2O#.'"MU ;:N1T.T>@K[UKX<_X+"V%UJ7[)
MMI%:6TUU+_PDMFWEPH7;'E7'.!0!X9_P0YT>QD;XO:JUK$VI0C3+6.Z*@R)$
M_P!I9T![!FC0D=RB^@K]5J_,#_@B'I-]I>E_&$7MG<6A>;2=OGQ,F["W><9'
M/45^G] '\X7QOL==_P"&SO'5K9SQVWB)O'EZEM<3, B7!U!_+<ELC;N*G)R,
M5]_?\*G_ ."C'_10=/\ _ NQ_P#C%<?_ ,%1OV%?%7_"Q[SXP_#O1+G6=+U1
M5EUNQTN,O<6=TH -PL:_,R. I8J"58,QX;(\UTW_ (*]?&W2_AP?"$VF:/<^
M)8X/L">))[>3[:K<KO:+=L:8<<[0,C)4\T =I\#?^";?[0O@O]I'P5\0O$-M
MHKQ6?B2VU;5+B#5(_,:/[0'N&"*H!)4O\HQG..*^O?\ @H3^WH_[(NFZ/H7A
MK3+76/'.MPM<PB_+&VL;=6V^;(JD,Y9@RJH('R,2> K?-W_!+/\ 9I^,/_"9
M6_Q#\9:MXH\,^"+*-S9:'>7US;_VO,ZD*[P%AF!=V_+##MMQN&ZM;_@L1^S#
MXO\ '&L>&OBKX8TJZUVQTW2_[(U6VL8FEFM8TEDFCGV+DE/WL@9@/EPN>#P
M<3\/-%_;I_;2\,VWB2#Q])X.\(:CN-K>-=KI$<T8)!,:6D?G,N00"XPWJ1S7
MQ%\=OA?JGP9_: USP9K>MKXCU?2[V%+K5%+D3R.D<C'+DL<%\9/)QVKZD_9O
M_P""GGQ7^'GPNT;X5>'? -CXRUK3XOL.C7"QSO<!,G8CP1\RE<@#:4X4 Y/-
M?./[0WPG^+W@SXH/J/Q*TF^D\8:]%'X@GD*&9CYS,0'*#:K H5*#A<;>,8H
M_:O_ (*0_P#)DOQ2_P"O*W_]*X*_/S_@B=ID<W[07C:_9 SV_AAHE8_P[[J
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MUD ,<_Q(FB;<,C#:B0<COUK]\/BS_P DK\9?]@6]_P#1#U^$_P 4O#NK2?\
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M^]PZOM"!G+EF0E>?F XJC_P5MT'4]0_;#U&:UTZ[N8O[&L1YD,#.N=C<9 H
M_6?X%^&]/\8_LD_#W0-6MUN]*U3P/IUC=V[=)(9+"-'4_56(K\9/@+J6I?L0
M_M_6&D:Q.8[;2==?0=2F;Y4FL9SY8G(_N['CG'^ZM?MC^S3$\/[.7PJCD1HY
M$\*:4K(PP5(LXL@CUK\V_P#@LS^SU=1>-/"GQ4T/3IKB/5H?['U86T18BXB!
M:"1L#JT>],]A OK0!\W?%V^U']NC]OZ]TW2YVFL]<U]='L)HSN6'38#L,P'H
M(HWF/N6K]/\ _@I9X;3P_P#L >,=&T*!;33-+ATJWCMH\@);1WMLJH/90%_
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M*?*7@@]*]GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "ORK_X+G?\ -$_^XW_[85^JE?E7_P %SO\
MFB?_ '&__;"@#[__ &3O^36?@W_V)FC?^D,->JUY5^R=_P FL_!O_L3-&_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\J_P#@N=_S1/\
M[C?_ +85^JE?E7_P7._YHG_W&_\ VPH ^_\ ]D[_ )-9^#?_ &)FC?\ I##7
MJM>5?LG?\FL_!O\ [$S1O_2&&O5: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\J_^"YW_ #1/_N-_^V%?JI7Y5_\ !<[_ )HG_P!QO_VPH ^__P!D[_DUGX-_
M]B9HW_I##7JM>5?LG?\ )K/P;_[$S1O_ $AAKU6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_*O\ X+G?\T3_ .XW_P"V%?JI7Y5_\%SO^:)_]QO_ -L* /O_
M /9._P"36?@W_P!B9HW_ *0PUZK7E7[)W_)K/P;_ .Q,T;_TAAKU6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *_*O_@N=_P T3_[C?_MA7ZJ5^5?_  7._P":
M)_\ <;_]L* /O_\ 9._Y-9^#?_8F:-_Z0PUZK7E7[)W_ ":S\&_^Q,T;_P!(
M8:]5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_ ."YW_-$_P#N-_\ MA7Z
MJ5^5?_!<[_FB?_<;_P#;"@#[_P#V3O\ DUGX-_\ 8F:-_P"D,->JUY5^R=_R
M:S\&_P#L3-&_](8:]5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_X+G?\
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M6\=Q;31W%O(H9)8F#*ZGH01P14M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF7]G'7_%>EM&OB*Y>/2]',JAE6ZFSA\'@[$620 @@F, \$U^4_[+W["/CO\
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M7=MW+G'3</6@#J:*\J_X:Q^"'_19/A__ .%18_\ QVC_ (:Q^"'_ $63X?\
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M_P#':/\ AK'X(?\ 19/A_P#^%18__': /5:*\J_X:Q^"'_19/A__ .%18_\
MQVC_ (:Q^"'_ $63X?\ _A46/_QV@#U6BO*O^&L?@A_T63X?_P#A46/_ ,=H
M_P"&L?@A_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?]%D^'_\ X5%C_P#':/\
MAK'X(?\ 19/A_P#^%18__': /5:*\J_X:Q^"'_19/A__ .%18_\ QVC_ (:Q
M^"'_ $63X?\ _A46/_QV@#U6BO*O^&L?@A_T63X?_P#A46/_ ,=H_P"&L?@A
M_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\
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M=H ]5HKRK_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\ 19/A_P#^%18__':
M/5:*\J_X:Q^"'_19/A__ .%18_\ QVC_ (:Q^"'_ $63X?\ _A46/_QV@#U6
MBO*O^&L?@A_T63X?_P#A46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\=H ]5HKR
MK_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\ 19/A_P#^%18__': /5:*\J_X
M:Q^"'_19/A__ .%18_\ QVC_ (:Q^"'_ $63X?\ _A46/_QV@#U6BO*O^&L?
M@A_T63X?_P#A46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?
M]%D^'_\ X5%C_P#':/\ AK'X(?\ 19/A_P#^%18__': /5:*\J_X:Q^"'_19
M/A__ .%18_\ QVC_ (:Q^"'_ $63X?\ _A46/_QV@#U6BO*O^&L?@A_T63X?
M_P#A46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?]%D^'_\
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M_P#^%18__': /5:*\J_X:Q^"'_19/A__ .%18_\ QVC_ (:Q^"'_ $63X?\
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M_P#':/\ AK'X(?\ 19/A_P#^%18__': /5:*\J_X:Q^"'_19/A__ .%18_\
MQVC_ (:Q^"'_ $63X?\ _A46/_QV@#U6BO*O^&L?@A_T63X?_P#A46/_ ,=H
M_P"&L?@A_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?]%D^'_\ X5%C_P#':/\
MAK'X(?\ 19/A_P#^%18__': /5:*\J_X:Q^"'_19/A__ .%18_\ QVC_ (:Q
M^"'_ $63X?\ _A46/_QV@#U6BO*O^&L?@A_T63X?_P#A46/_ ,=H_P"&L?@A
M_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\
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M=H ]5HKRK_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\ 19/A_P#^%18__':
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M_P#A46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\=H ]5HKRK_AK'X(?]%D^'_\
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MR:S\&_\ L3-&_P#2&&O5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJUY5XC_Y.F^'G_8F>)O_ $NT&@#U6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\J\.?\G3?$/_ +$SPS_Z7:]7JM>5>'/^3IOB
M'_V)GAG_ -+M>H ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "ORK_ ."YW_-$_P#N-_\ MA7ZJ5^5?_!<[_FB?_<;_P#;
M"@#[_P#V3O\ DUGX-_\ 8F:-_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O*O$?_ "=-\//^Q,\3?^EV@UZK7E7B/_DZ
M;X>?]B9XF_\ 2[0: /5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KRKPY_R=-\0_\ L3/#/_I=KU>JUY5X<_Y.F^(?_8F>&?\
MTNUZ@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *_*O\ X+G?\T3_ .XW_P"V%?JI7Y5_\%SO^:)_]QO_ -L* /O_ /9.
M_P"36?@W_P!B9HW_ *0PUZK7E7[)W_)K/P;_ .Q,T;_TAAKU6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\J\1_\ )TWP\_[$SQ-_Z7:#7JM>5>(_^3IOAY_V)GB;
M_P!+M!H ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRKPY_R=-\0_\
ML3/#/_I=KU>JUY5X<_Y.F^(?_8F>&?\ TNUZ@#U6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*O\ X+G?\T3_ .XW_P"V
M%?JI7Y5_\%SO^:)_]QO_ -L* /O_ /9._P"36?@W_P!B9HW_ *0PUZK7E7[)
MW_)K/P;_ .Q,T;_TAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\J\1_\ )TWP
M\_[$SQ-_Z7:#7JM>5>(_^3IOAY_V)GB;_P!+M!H ]5HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O*O#G_)TWQ#_P"Q,\,_^EVO
M5ZK7E7AS_DZ;XA_]B9X9_P#2[7J /5:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\J_P#@N=_S1/\ [C?_ +85^JE?E7_P
M7._YHG_W&_\ VPH ^_\ ]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&^ C5OO>7SM9E2@#[QHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "ORK_P""YW_-$_\ N-_^V%?JI7Y5_P#!<[_FB?\ W&__
M &PH ^__ -D[_DUGX-_]B9HW_I##7JM>5?LG?\FL_!O_ +$S1O\ TAAKU6@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<EF/)))-=30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB?\ W&__ &PH ^__ -D[_DUGX-_]B9HW_I##7JM>5?LG?\FL_!O_ +$S1O\
MTAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\J\1_\G3?#S_L3/$W_ *7:#7JM
M>5>(_P#DZ;X>?]B9XF_]+M!H ]5HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(?\ V)GAG_TNUZ@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_*O_@N=_P T3_[C?_MA7ZJ5^5?_  7._P":)_\ <;_]
ML* /O_\ 9._Y-9^#?_8F:-_Z0PUZK7E7[)W_ ":S\&_^Q,T;_P!(8:]5H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O*O$?_)TWP\_[$SQ-_Z7:#7JM>5>(_\ DZ;X
M>?\ 8F>)O_2[0: /5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBO _VX_BYXY^"/[.?B'Q3\/=";6=
M=@VQ/<!!(-,@8-YEX8_^6@CP..0"P9@55A0!\2?MY?%?1_V+_CW-XB^"7B9-
M$\?^)K61?%?A>&W6?3OG0F&]D3.V.YW-O"X.[[S !V$OY]_"K]I#X@?!WXM?
M\+'T'7[B3Q/+,\M]/?.TRZB';=(EP"<R*QY.3D$ @@@$<!KFN:CXFUF^U?5[
MVXU+5+Z9KBZO+J0R2S2,<L[,>223G)JC0!^E/P'_ &Z?A!\#-"/Q0\2CQ!\4
MOCOXQ:9M<O)((X/[+16 6UC9VVQQ%=I7RPVX* 0@54&GXL_X+A:]<,R^&?A7
MIM@!PLFK:M)=9YZE8XX\<=MQ^M?F7IVG7>L:A;6%A;37M[=2K#!;6\9>261B
M J*HY+$D  <DFOT=^$?_  16\7^)-)T[4_'OCBR\*-<PI/)I.G6;7ES#N /E
M2.S(BNN<';O (."1S0!['K'_  69\"_\*32\LM'U-/BA=Z9*%TV*T$EA97V&
M5#)([H6BW!7^3<=K '!SC\Z_%G[;_P ?O'UQ(M_\5?$ZFX8@V^EWC62-NXVA
M(-@P>F,5^KOP[_X)$_ +P7Y4NL66M>-;E>2=8U%HXMWLEN(^/9BWOFOI_P"'
MWP-^'GPHC5?!W@C0/#3*,&;3=.BAE;C&6D"[F..Y)- 'X:?"/X1_M>>-;JZO
M?!=G\2+0ZI'Y5QJ4NH7.FQW,><X:>:2-7&?]H]_4U[?X-_X(V_&'QU??VEX^
M\;:+X?>X.Z9S++JE[GU8?(A_[^FOV4HH _/GP+_P1;^$>AQVTGB?Q/XG\47<
M; R)%+%8VLHSTV*C2 'VE_*OJ?X??LA?!;X6PHGAOX9^'+.15V"ZN+);JYVX
MP1YTV^0@]_FYKU^B@#G?#?PY\)^#6W>'_#&C:$WKINGQ6Y_\<4>I_.NBHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHIDTT=O#)+*ZQ11J6>1R JJ!DDD]!0 ^J]_?VVEV-S>WD\=K:6T;333S
M,%2-%!+,Q/0  DGVKX-_:J_X*U>!?A-]LT#X9QV_Q \5)F,WZN?[)M6]3(IS
M.1Z1D+_M@C%<7\'/^"ID5G^S_K>L?'C3[6ZURZG:#1M'TFV"3ZS:NGS,\+,5
MCA!)7S6PKC<%#LC @' _M3_\%?M8\1W%WX6^!UA+IEJ[& ^)[Z$/=S]LVT'(
MC![,^YB#]U#7RO\  W]N;XE_L_R^-KRVURX\4:OXFM?*<:Y=/>V\$Y8$W;*S
M$23!05 SMP_S9V[:PO!?PJ\6_M:?$W4]-^#_ ,.8O#NE7,Q>6SLIYI+33X6;
M(%Q=S,3MXSMR Q7Y8\C%?JS^R3_P2[^'_P  /L?B#Q>(/'WCF/$BW%U%_H%B
M_7]Q"WWF!_Y:29/ *A#0!^4E]^QU\9]0^$6J?%^[\$W5KX863[3*3 EO,T+Y
M9KF.U4 K O'S!0H5@5&T$KXEIVG7>L:A;6%A;37M[=2K#!;6\9>261B J*HY
M+$D  <DFOZGI(TFC:.15=&!5E89!!Z@BOG7X5?L"_"#X.?&C6/B7X>T-X]8O
M27L[*9E>STEFSYC6L>T;"V>Y.T$A-JG% 'R_^Q+_ ,$S?&'P3\5?#WXGZUKV
MF6?B*&2:35_#MYIZW0MK62+")%+GY;D'[SCA=Y +!2)/TLHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O*O#G_)TWQ#_ .Q,\,_^EVO5ZK7E7AS_ ).F^(?_ &)G
MAG_TNUZ@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_*O_@N=_S1/_N-_P#MA7ZJ5^5?_!<[_FB?_<;_ /;"@#[_ /V3
MO^36?@W_ -B9HW_I##7JM>5?LG?\FL_!O_L3-&_](8:]5H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHI&8*I). .230!5U;5+70]*O=2OI?
M(LK.%[B>7:6V1HI9C@ DX / &:Y?X2?&'PA\=/!=OXM\#ZO_ &WX?N)9(8[S
M[--;[G1MKC9*B,,'U%?B_P#$KXK_ !6_X*/?'+Q1H^AZ[-I?@C2;.\U*WTMI
MWCL[;3;?_EK*B#][,^4Y;/S2!054<>;_  F\'_'/X/\ @_P1\7OA==:Q-:ZU
M>W5M';Z#'-<,LUNVUH[FW52KHZ\C((.ULX*C(!_0W17D^C_'*6R_9G7XJ^,/
M#]]X9NK+P_)J^K:'>6\EO<6\T43-+ $E 89="$W#D%3WK\@/#OB3]HS_ (*9
M_%W6-/TKQ3)I>G6T;WCV3W\MGI.EV[-M2,K$I,C'.T$JSM@DG ) !^Z]%?A+
MXGUK]HO_ ()F_%[1K/4_%<FI65S"MU':QW\MYI.IVX?#Q[)5!1AC:2%5UR"#
M@@G]@]2_:*\/:7^S/_PNF:.1- /AZ/7TM2Z^:=\(=+?/3S"[+'Z;C0!ZO17X
M4>#5_:/_ ."FWQ*\2S6'BO[#8Z?&D\]O-J$]GI&GJS-Y$*11AR6.QL,59CL)
M9N*[?]E3]JSXL?LC_M.1_"#XK:S>:KX?EU6+2-1M=4O&NO[/>3:L-S;RL25B
M^>-ROW2C$[0V#0!^T%%>-?M=?M!P?LQ_ 7Q'XZ,,5WJ5NJVNEV<V=D]Y*=L2
ML 02J\NP!!VHV.:_(SX5_"+]IK_@H(WB7QW:>-9I8-.NR%FU75IK6W-UM#^1
M:Q1*5C*JR'@(HWKSR: /W8HK\E/^";G[:7Q!\.?'!?@;\4]4O=6M[NXN;"TF
MUB8S7FFZA%N)@:5B69&*.@4DX<IM(&17ZUT %%%% !7E7B/_ ).F^'G_ &)G
MB;_TNT&O5:\J\1_\G3?#S_L3/$W_ *7:#0!ZK1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 5Y5X<_Y.F^(?_8F>&?_ $NUZO5:\J\.?\G3?$/_ +$SPS_Z7:]0!ZK1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_P7
M._YHG_W&_P#VPK]5*_*O_@N=_P T3_[C?_MA0!]__LG?\FL_!O\ [$S1O_2&
M&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2,H92",@\$&EJCKNK1^']#U#5)HIIX;*WDN7BMTWR.J*6*H
MO=B!P.YH _!3XP_#WXF_\$Z_V@-?FT>WDMM!U2*\L--U*>#S;34],GSF%R.
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MPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z
M=E_WZ% '1T5SG_"N?#'_ $ [+_OT*/\ A7/AC_H!V7_?H4 ='17.?\*Y\,?]
M .R_[]"C_A7/AC_H!V7_ 'Z% '1T5SG_  KGPQ_T [+_ +]"C_A7/AC_ * =
ME_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z =E_WZ% '1T5SG_"N?#'_ $ [
M+_OT*/\ A7/AC_H!V7_?H4 ='17.?\*Y\,?] .R_[]"C_A7/AC_H!V7_ 'Z%
M '1T5SG_  KGPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^
M_0H_X5SX8_Z =E_WZ% '1T5SG_"N?#'_ $ [+_OT*/\ A7/AC_H!V7_?H4 =
M'17.?\*Y\,?] .R_[]"C_A7/AC_H!V7_ 'Z% '1T5SG_  KGPQ_T [+_ +]"
MC_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z =E_WZ% '1T5S
MG_"N?#'_ $ [+_OT*/\ A7/AC_H!V7_?H4 ='17.?\*Y\,?] .R_[]"C_A7/
MAC_H!V7_ 'Z% '1T5SG_  KGPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG
M_"N?#'_0#LO^_0H_X5SX8_Z =E_WZ% '1T5SG_"N?#'_ $ [+_OT*/\ A7/A
MC_H!V7_?H4 ='17.?\*Y\,?] .R_[]"C_A7/AC_H!V7_ 'Z% '1T5SG_  KG
MPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z
M=E_WZ% '1T5SG_"N?#'_ $ [+_OT*/\ A7/AC_H!V7_?H4 ='17.?\*Y\,?]
M .R_[]"C_A7/AC_H!V7_ 'Z% '1T5SG_  KGPQ_T [+_ +]"C_A7/AC_ * =
ME_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z =E_WZ% '1T5SG_"N?#'_ $ [
M+_OT*/\ A7/AC_H!V7_?H4 ='17.?\*Y\,?] .R_[]"C_A7/AC_H!V7_ 'Z%
M '1T5SG_  KGPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^
M_0H_X5SX8_Z =E_WZ% '1T5SG_"N?#'_ $ [+_OT*/\ A7/AC_H!V7_?H4 =
M'17.?\*Y\,?] .R_[]"C_A7/AC_H!V7_ 'Z% '1T5SG_  KGPQ_T [+_ +]"
MC_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z =E_WZ% '1T5S
MG_"N?#'_ $ [+_OT*/\ A7/AC_H!V7_?H4 ='17.?\*Y\,?] .R_[]"C_A7/
MAC_H!V7_ 'Z% '1T5SG_  KGPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG
M_"N?#'_0#LO^_0H_X5SX8_Z =E_WZ% '1T5SG_"N?#'_ $ [+_OT*/\ A7/A
MC_H!V7_?H4 ='17.?\*Y\,?] .R_[]"C_A7/AC_H!V7_ 'Z% '1T5SG_  KG
MPQ_T [+_ +]"C_A7/AC_ * =E_WZ% '1T5SG_"N?#'_0#LO^_0H_X5SX8_Z
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M<^&/^@'9?]^A1_PKGPQ_T [+_OT* .CHKG/^%<^&/^@'9?\ ?H4?\*Y\,?\
M0#LO^_0H Z.BN<_X5SX8_P"@'9?]^A1_PKGPQ_T [+_OT* .CHKG/^%<^&/^
M@'9?]^A1_P *Y\,?] .R_P"_0H Z.BN<_P"%<^&/^@'9?]^A1_PKGPQ_T [+
M_OT* .CHKG/^%<^&/^@'9?\ ?H4?\*Y\,?\ 0#LO^_0H Z.BN<_X5SX8_P"@
M'9?]^A1_PKGPQ_T [+_OT* .CHKG/^%<^&/^@'9?]^A1_P *Y\,?] .R_P"_
M0H Z.BN<_P"%<^&/^@'9?]^A1_PKGPQ_T [+_OT* .CHKG/^%<^&/^@'9?\
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M"O@7H,_PU_9*\)1:+%.PM[KQK=6WFW^H29P&A5P7<DGAI>FXA8UX-:W[-/\
MP2S\??';6AX]^.VJZIH=A?N+J2QNIC)K6HD]YF?/D \??R_!&U>&H \N\2?&
MSXW_ +>VL0?#+X7>%?\ A&/A_:A4A\(^&4%MI]I!GA[R<!5(SSAMJ9 VINZ_
M=_[)'_!*OP-\$?L7B/X@&W\?>-(]LB12QYTRQ<8(\N-AF5@?XY!CH0BD9KZ^
M^&'PG\(_!CPG;>&O!6@6?A[18.1;VB8+MW>1SEI'.!EF))QUKK: $50J@ 8
MX %+110 4444 %%%% !7Y2?\%R;F87GP=MQ*X@,>K2&+<=I8&T ;'3.">?>O
MU;K\H/\ @N5_R%?@W_UQU;_T*SH _+:BBB@ K^D']C"XENOV3?A%+/*\TA\,
M6 +R,6)Q"H')]A7\WU?T>_L4_P#)H_PA_P"Q9L?_ $4M 'M=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7E7AS_DZ;XA_P#8F>&?_2[7J]5KRKPY_P G3?$/_L3/#/\
MZ7:]0!ZK1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?E7_P7._YHG_W&_\ VPK]5*_*O_@N=_S1/_N-_P#MA0!]_P#[)W_)
MK/P;_P"Q,T;_ -(8:]5KRK]D[_DUGX-_]B9HW_I##7JM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Y5XC_P"3IOAY_P!B9XF_]+M!KU6O*O$?_)TWP\_[$SQ-_P"E
MV@T >JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ."YW_-$_P#N-_\ MA7ZJ5^5?_!<[_FB?_<;_P#;"@#[_P#V3O\ DUGX-_\
M8F:-_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O*O$?_ "=-\//^Q,\3?^EV@UZK7E7B/_DZ;X>?]B9XF_\ 2[0: /5:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGD_$6)4VCIM!O1@?@*/^%;?\%#+5=WVOX@,(QG_D8HI"<?\ ;<[OUS7[544
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MGAXI&,((]>N0,#IC,(Q^E!_X)T?MAV7^D0:_(T\7SH(?%KJ^X<C:2P .?<4
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M_N-_^V% 'W_^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Y5XC_ .3IOAY_V)GB;_TNT&O5:\J\1_\
M)TWP\_[$SQ-_Z7:#0!ZK1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445$UU#'<) TL:SR LD98!F ZD#OB@"
M6O"?C)^V_P#!CX#>*K+PWXN\9VUMK=Q*L<MG9QO=/9@D?/<>6#Y0Y!PWS8Y
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MA8$J?=2#7QQ\6_\ @CK\'/&_G7/@^^U?X?7[Y*QVTIOK,$]S%,=_7LLJCV]
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MW=__ !ROJCP?X3TOP'X3T;PUHEN;/1M'LX;"RMS(TACAB0(B[F)9L*H&22:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.@212R,PXY)C'TKS^/\ :!_;3_8OD6#Q9%X@N-$MSLV^*K7^U;!L<!5O%).
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^_X)R_%O]K?Q,/B'\9]9U;P_HNH,)Y+G5"9-7U%#@@11O_J8\9PSC &-J,M
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M2.-1T55' 'L*L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>)O_ $NT&@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6_ACXF^#?P%\(>#_ !AXA;Q1XBTNV9+K4&D>09:1G6)7?YF2-6$:DXR$' Z
M _(?PC\%_P!I/_@IAXNA\2^)M0N+7PHLA\O6-41K?3+5">5L[=<>8V.,J.2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -B9HW_I##7JM>5?LG?\FL_!O_L3-&_](8:]5H **** "BBB@ HHHH ****
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M_P )=<_]"QK7_?$'_P =H_X2ZY_Z%C6O^^(/_CM '1T5SG_"77/_ $+&M?\
M?$'_ ,=H_P"$NN?^A8UK_OB#_P".T ='17.?\)=<_P#0L:U_WQ!_\=H_X2ZY
M_P"A8UK_ +X@_P#CM '1T5SG_"77/_0L:U_WQ!_\=H_X2ZY_Z%C6O^^(/_CM
M '1T5SG_  EUS_T+&M?]\0?_ !VC_A+KG_H6-:_[X@_^.T ='17.?\)=<_\
M0L:U_P!\0?\ QVC_ (2ZY_Z%C6O^^(/_ ([0!T=%<Y_PEUS_ -"QK7_?$'_Q
MVC_A+KG_ *%C6O\ OB#_ ..T ='17.?\)=<_]"QK7_?$'_QVC_A+KG_H6-:_
M[X@_^.T ='17.?\ "77/_0L:U_WQ!_\ ':/^$NN?^A8UK_OB#_X[0!T=%<Y_
MPEUS_P!"QK7_ 'Q!_P#':/\ A+KG_H6-:_[X@_\ CM '1T5SG_"77/\ T+&M
M?]\0?_':/^$NN?\ H6-:_P"^(/\ X[0!T=%<Y_PEUS_T+&M?]\0?_':/^$NN
M?^A8UK_OB#_X[0!T=%<Y_P )=<_]"QK7_?$'_P =H_X2ZY_Z%C6O^^(/_CM
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M^A8UK_OB#_X[0!T=%<Y_PEUS_P!"QK7_ 'Q!_P#':/\ A+KG_H6-:_[X@_\
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M_P )=<_]"QK7_?$'_P =H_X2ZY_Z%C6O^^(/_CM '1T5SG_"77/_ $+&M?\
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M&D<^VZG2=)X79E#;E VL"O*D'J,$\X^)O^"EG[3G[1_@WXK:WX<M;C7?A_\
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M_P#CM'_"77/_ $+&M?\ ?$'_ ,=H Z.BN<_X2ZY_Z%C6O^^(/_CM'_"77/\
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M=<_]"QK7_?$'_P =H Z.BN<_X2ZY_P"A8UK_ +X@_P#CM'_"77/_ $+&M?\
M?$'_ ,=H Z.BN<_X2ZY_Z%C6O^^(/_CM'_"77/\ T+&M?]\0?_': .CHKG/^
M$NN?^A8UK_OB#_X[1_PEUS_T+&M?]\0?_': .CK\H/\ @N5_R%?@W_UQU;_T
M*SK]//\ A+KG_H6-:_[X@_\ CM<9\1_ W@WXP1V$?C?X5-XJ6P+M:_VM86LY
M@+XW["TAV[MJYQUVCT% '\UM%?T-_P##*_P._P"C>M)_\$UG_P#'*XWP7^RK
M\%]:_:$\=:;<?![P_9:;9^%] N+?3[S2H-J2RW>L++*JJ6 +K#"I/4^4OH*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HI&8*I). .237D/Q=_:U^$WP3\.ZEJ?B/QQHHN+.)I%TBSOX9K^X8=(XH
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MI+1AN?\ IY:+Z_YQ7B/C#_@N%IL1DC\+?"FZN@1\ESK&KK#@Y[Q1Q/GC_;%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5>'/\ DZ;X
MA_\ 8F>&?_2[7J]5KRKPY_R=-\0_^Q,\,_\ I=KU 'JM%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^5?\ P7._YHG_ -QO
M_P!L*_52ORK_ ."YW_-$_P#N-_\ MA0!]_\ [)W_ ":S\&_^Q,T;_P!(8:]5
MKRK]D[_DUGX-_P#8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5>(_^
M3IOAY_V)GB;_ -+M!KU6O*O$?_)TWP\_[$SQ-_Z7:#0!ZK1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW?[E)',8_!10!\*^+O\ @MA\1M9F\CPA\._#VC-*=B+J,T^HRY/ V[#""W_
M3]*YG_AHS]O'XZ_+H.G^++/3YN%;1O#BV, ^ERT0(_[^5^L,C?![]GNSW/\
M\(1\-K;;QQ9Z6I&.WW,UB_#W]L7X,?%;Q\/!7A+X@:7KGB5HWECL[82;9E4%
MF\N0H(Y"%!8JK$X!., F@#\N?^'>/[8?QO._QSKDUNDWSG_A+O%3W0]LI$TY
M'';''3CI7I7@S_@A[J,NR3Q9\5+6V (WVVBZ2TVX=\2R2)C_ +X-?3G[=7_!
M0J#]CW6=%\.6/@^3Q/X@U6R-^LMQ=?9K2"+>R DA6:1MR-E1MP,'=SBOS_\
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MXC:;HOAWQU9LLD6FZWJ.C(\\021E=%\^,21X=6XP/7OF@#\LHO\ @J!^U/\
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M4M2TF"XF;:,(69U.2H  )Y&!CH*[;2-%T_P_8I9Z786NFV:<K;V<*Q1CZ*H
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MKVIQ@X]2D'FN/H5!KZ1\!?\ !#^,+%-XU^*#,?\ EI9Z#IH&/I-*_/\ W[H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_\ )TWP\_[$SQ-_Z7:#7JM>5>(_^3IOAY_V)GB;_P!+M!H ]5HHHH ****
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M?W+M]/2>Y7Z32AG_ /'J]950BA5 50, #H*6B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRKPY
M_P G3?$/_L3/#/\ Z7:]7JM>5>'/^3IOB'_V)GAG_P!+M>H ]5HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ_M2^./$\7C;PK80>$8+'[5:ZSI=C+;P07'F(HM@SNPDW*SMU+#8<G!%<?\
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M&?M5_P#!-'XY?M#?M">(_$8\=Z+>>$[RY\W3CK%[<![" @8MT@6)E7820-I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E
M7AS_ ).F^(?_ &)GAG_TNUZO5:\J\.?\G3?$/_L3/#/_ *7:]0!ZK1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_ ,%S
MO^:)_P#<;_\ ;"OU4K\J_P#@N=_S1/\ [C?_ +84 ??_ .R=_P FL_!O_L3-
M&_\ 2&&O5:\J_9._Y-9^#?\ V)FC?^D,->JT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7E7B/_DZ;X>?]B9XF_P#2[0:]5KRKQ'_R=-\//^Q,\3?^EV@T >JT444
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M^"[U[4PN/K#$AS_W\KV+P'_P1Q^!OAGRI->NO$GC"8??CO+\6T#?18%1P/\
M@9KZ+\!_L=_!+X:>6WA[X7^&K6>/[EU<6*W5POTEFWN/^^J /RTF_P""B?[7
MGQZF:'P#HDMI%(=FSP?X9>[P.^9)5F*GU8$8Z\4S_ACG]MK]H;=_PF.I:Y;:
M=-_#XJ\2;(.>H^S([LO_ '[%?M;#"EO$D42+'$BA51!@*!P !V%/H _)?P'_
M ,$0=:N!%+XT^)]A8D8,EKH.G/<Y]0)96CQ]?+/TKZ,\!_\ !('X ^$V236+
M?Q!XRE')75M3,4>?9;98CCV)-?;E>-?%']L;X+?!LS1^*OB-H=G>P_?T^UG^
MUW:GT,$(=Q^(% &GX$_9;^$'PS6(^&OAKX9TN>/[MTNFQ27''_39P9#^+5ZE
M7YN_%'_@M=X$T7S;?P%X(UCQ/.HVK=ZM,FGV^?[RJ/,=A[$(?YU\XZC_ ,%!
M/VM?VF;R73_AUI%SIULS>6\/@O1'G9 >GF7$@D9#T^8,GX4 ?L]X@\2:1X3T
MN34M<U6RT;3H_OW>H7"00K]7<@#\Z^8?BC_P5!_9\^&0FBC\72>,+^/_ )=/
M#%L;O=])B5A/X25\$>'_ /@E_P#M,?'K4H]8^)GB&/1F?YFN/%&L/J5[M/\
M=2,R =OE9UQ^E?3WPM_X(O\ PK\,>3/XV\2:YXVNEQNMX2NG6C^H*H6E_*44
M >.?$[_@MKK]^TMK\.OAW9::&^6.^\0W+W4AST(ABV!3_P #89]>E>9#5_VZ
MOVO#BV_X2^UT6XX!MU7P_IYC/7Y_W0E7ZES]:_6SX7_LR_"KX,+$?!?@'0M"
MN8QA;V*T62[_ !N'W2'\6KTV@#\A_AG_ ,$4?&&M3)>?$3X@Z;HJN?,DM=%@
M>^G?/)#2R>6JM[@./K7UW\+_ /@E9^S]\-_)FN_#EWXTOX\'[1XDO&F7/?\
M<QA(B/9D-?7M% &/X7\'Z#X'TM--\.:)IN@:<GW;/2[2.VA7Z(@ 'Y5L444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY5X<_P"3IOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"EVO4 >JT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5_P#!
M<[_FB?\ W&__ &PK]5*_*O\ X+G?\T3_ .XW_P"V% 'W_P#LG?\ )K/P;_[$
MS1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I##7JM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !14%]?6^FV5Q>7<R6]K;QM++-(<*B*"68G
ML  36-X&^('AOXF>'HM=\)ZY8^(M&E=HTOM.G6:%F4X8!EXR#P: .@HHHH *
M*** "BBB@ HHHH **** "BBB@ KRKQ'_ ,G3?#S_ +$SQ-_Z7:#7JM>5>(_^
M3IOAY_V)GB;_ -+M!H ]5HHHH **** "BBB@ HHHH **** "BBO/_&'[0?PP
M^'^\>)?B'X7T.1.L-]J\$<I]@A?<3[ 4 >@45\F^,/\ @J3^SCX1WI'XWFU^
MX3.8-'TRXES]'9%C/_?5>'>,/^"W'@#3_,'A?X=^(M;*Y"MJES!8*WOE#,<?
MA^':@#](Z*_&_P 4?\%J/BKKTWV;PIX#\-:093A!="XOYA_N[7C!/U4_2L+_
M (: _;V^-WRZ-8>,+2QERJMI/AQ-/@'?BX:)3TQUD]/6@#]K:X#Q=^T#\,?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&\72>&_ XU+2M,OM*@B6PO/):*ZEM)9&8?:\E@UE%M(( #/D'((^(** /O\
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M5O\ 4HC?W(;^\))RY4G_ &<#VKW*B@!%4(H50%4#  Z"EHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG/L/[17[ GQC_96^)>L>,OA%;:CJO@W;<RVUYHK^;=6-HZD26US%]YU"%E)
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M\<GE.L3%3U.QL ;A\HP <U\5[0?$;_@J!J%AIH\[[5\1+>RZ;@#'=1QR$X[
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ML_VDOV?[^;RHOCGHBMC.9O&*Q+^;R@5MV/Q>^"^IQM)9_&C0[M%.TM!XVB<
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M[>,1QHOHJ@8 ^E 'XP^'O^"7_P"TQ\>M1BUCXF>(8]&9OF:X\4:Q)J5[M/\
M=2,R#T^5G7^E?3GPQ_X(N_"SPVL4WC3Q-KWC.[7&Z&W*Z=:-ZY1=\GY2BOT+
MHH \5^'7[&_PC^$LB3>#_"4&@7:# O+61Q<_C,29#^+5Z/\ \(/;?]!/6O\
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M  @]M_T$]:_\&D__ ,51_P (/;?]!/6O_!I/_P#%5T=% '.?\(/;?]!/6O\
MP:3_ /Q5'_"#VW_03UK_ ,&D_P#\571T4 <Y_P (/;?]!/6O_!I/_P#%4?\
M"#VW_03UK_P:3_\ Q5='10!SG_"#VW_03UK_ ,&D_P#\51_P@]M_T$]:_P#!
MI/\ _%5T=% '.?\ "#VW_03UK_P:3_\ Q5'_  @]M_T$]:_\&D__ ,571T4
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M3UK_ ,&D_P#\571T4 <Y_P (/;?]!/6O_!I/_P#%4?\ "#VW_03UK_P:3_\
MQ5='10!SG_"#VW_03UK_ ,&D_P#\51_P@]M_T$]:_P#!I/\ _%5T=% '.?\
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M3UK_ ,&D_P#\51_P@]M_T$]:_P#!I/\ _%5T=% '.?\ "#VW_03UK_P:3_\
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M_03UK_P:3_\ Q5='10!SG_"#VW_03UK_ ,&D_P#\51_P@]M_T$]:_P#!I/\
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M 4444 %%%% !7Y5_\%SO^:)_]QO_ -L*_52ORK_X+G?\T3_[C?\ [84 ??\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OSU_X+8?\FV^#?^QMA_\ 2.ZK]"J\7_:L_98\-_M;?#^P\*>)
MM2U/2;:QU%-3AN=+:,2>8L<D>T[U8%2LK=LY Y]0#^;^BOV3_P"')?PL_P"A
MZ\8?]]6O_P 9H_X<E_"S_H>O&'_?5K_\9H _&ROWH_X)/_\ )DOA#_K]U'_T
MKEKRK_AR7\+/^AZ\8?\ ?5K_ /&:^ROV=/@/HO[-?PETGP!X?O;[4=-T]YY5
MNM19#-(TLK2-G8JK@%L# Z =3S0!Z71110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5X<_P"3IOB'_P!B
M9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"EVO4 >JT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5_P#!<[_FB?\ W&__ &PK
M]5*_*O\ X+G?\T3_ .XW_P"V% 'W_P#LG?\ )K/P;_[$S1O_ $AAKU6O*OV3
MO^36?@W_ -B9HW_I##7JM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5XC_Y.F^'G
M_8F>)O\ TNT&O5:\J\1_\G3?#S_L3/$W_I=H- 'JM%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y5X<_P"3IOB'_P!B9X9_]+M>
MKU6O*O#G_)TWQ#_[$SPS_P"EVO4 >JT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7Y5_P#!<[_FB?\ W&__ &PK]5*_*O\
MX+G?\T3_ .XW_P"V% 'W_P#LG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_
M -B9HW_I##7JM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5XC_Y.F^'G_8F>)O\
MTNT&O5:\J\1_\G3?#S_L3/$W_I=H- 'JM%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y5X<_P"3IOB'_P!B9X9_]+M>KU6O*O#G
M_)TWQ#_[$SPS_P"EVO4 >JT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7Y5_P#!<[_FB?\ W&__ &PK]5*_*O\ X+G?\T3_
M .XW_P"V% 'W_P#LG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I
M##7JM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y5XC_Y.F^'G_8F>)O\ TNT&O5:\
MJ\1_\G3?#S_L3/$W_I=H- 'JM%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5Y5X<_P"3IOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[
M$SPS_P"EVO4 >JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7Y5_P#!<[_FB?\ W&__ &PK]5*_*O\ X+G?\T3_ .XW_P"V
M% 'W_P#LG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I##7JM !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y5XC_Y.F^'G_8F>)O\ TNT&O5:\J\1_\G3?
M#S_L3/$W_I=H- 'JM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Y5X<_P"3IOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"E
MVO4 >JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7Y5_P#!<[_FB?\ W&__ &PK]5*_*O\ X+G?\T3_ .XW_P"V% 'W_P#L
MG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I##7JM !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y5XC_Y.F^'G_8F>)O\ TNT&O5:\J\1_\G3?#S_L3/$W
M_I=H- 'JM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%)K;Q)I]K*=(N/%<WBJ7S$_U-E!.9XQ)Z9VQ1_[SBOWCH **** "O@K]M_\
M;L\/?LO_ !_\%7FFZ;;^.=?TO1M8TC5M#CU(V4EA]K?2;F"1W\J3.Y+<X7'(
M;.1C!^]:_$O]JS2;'7O^"OUIIFIV5OJ.FWOBWPM;75G=Q++#/$\&GJ\;HP(9
M64D%2,$$@T >P?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7W_\
M\,G?!#_HC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /SO\
MJB?_ )=?_P!Q4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-_#__ ,)>Q_\
MC5'_  R=\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__ '%1_P /SO\
MJB?_ )=?_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP0_Z(W\/_ /PE
M['_XU0!\ ?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7W_\ \,G?
M!#_HC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /SO\ JB?_
M )=?_P!Q4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-_#__ ,)>Q_\ C5'_
M  R=\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__ '%1_P /SO\ JB?_
M )=?_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP0_Z(W\/_ /PE['_X
MU0!\ ?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7W_\ \,G?!#_H
MC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /SO\ JB?_ )=?
M_P!Q4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-_#__ ,)>Q_\ C5'_  R=
M\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__ '%1_P /SO\ JB?_ )=?
M_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP0_Z(W\/_ /PE['_XU0!\
M ?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7W_\ \,G?!#_HC?P_
M_P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /SO\ JB?_ )=?_P!Q
M4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-_#__ ,)>Q_\ C5'_  R=\$/^
MB-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__ '%1_P /SO\ JB?_ )=?_P!Q
M5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP0_Z(W\/_ /PE['_XU0!\ ?\
M#\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7W_\ \,G?!#_HC?P__P#"
M7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /SO\ JB?_ )=?_P!Q4?\
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MP0_Z(W\/_P#PE['_ .-4 ? '_#\[_JB?_EU__<5'_#\[_JB?_EU__<5??_\
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M?_EU_P#W%7W_ /\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\
MC5 'P!_P_._ZHG_Y=?\ ]Q4?\/SO^J)_^77_ /<5??\ _P ,G?!#_HC?P_\
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M\/SO^J)_^77_ /<5??\ _P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
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M_P#PE['_ .-4 ? '_#\[_JB?_EU__<5'_#\[_JB?_EU__<5??_\ PR=\$/\
MHC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5 'P!_P_._ZHG_Y=?_W%
M1_P_._ZHG_Y=?_W%7W__ ,,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__
M /"7L?\ XU0!\ ?\/SO^J)_^77_]Q4?\/SO^J)_^77_]Q5]__P##)WP0_P"B
M-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-4 ? '_#\[_JB?_EU__<5'
M_#\[_JB?_EU__<5??_\ PR=\$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\
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M_P"J)_\ EU__ '%7W_\ \,G?!#_HC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\
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M/^B-_#__ ,)>Q_\ C5'_  R=\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\
MEU__ '%1_P /SO\ JB?_ )=?_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\
M#)WP0_Z(W\/_ /PE['_XU0!\ ?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\
MEU__ '%7W_\ \,G?!#_HC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5
M 'P!_P /SO\ JB?_ )=?_P!Q4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-
M_#__ ,)>Q_\ C5'_  R=\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__
M '%1_P /SO\ JB?_ )=?_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP
M0_Z(W\/_ /PE['_XU0!\ ?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__
M '%7W_\ \,G?!#_HC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!
M_P /SO\ JB?_ )=?_P!Q4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-_#__
M ,)>Q_\ C5'_  R=\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__ '%1
M_P /SO\ JB?_ )=?_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP0_Z(
MW\/_ /PE['_XU0!\ ?\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7
MW_\ \,G?!#_HC?P__P#"7L?_ (U1_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /
MSO\ JB?_ )=?_P!Q4?\ #\[_ *HG_P"77_\ <5??_P#PR=\$/^B-_#__ ,)>
MQ_\ C5'_  R=\$/^B-_#_P#\)>Q_^-4 ? '_  _._P"J)_\ EU__ '%1_P /
MSO\ JB?_ )=?_P!Q5]__ /#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP0_Z(W\/_
M /PE['_XU0!\ ?\ #\[_ *HG_P"77_\ <5>O_L0?MV>'OVH/C_XUO-2TVW\#
M:_JFC:/I&DZ')J1O9+_[(^K7,\B/Y4>-J7 RN. N<G.!]0?\,G?!#_HC?P__
M /"7L?\ XU7Y0?LIZ38Z#_P5^N],TRRM].TVR\6^*;:UL[2)8H8(D@U!4C1%
M "JJ@ *!@  "@#]M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K\J_^"YW_ #1/_N-_^V%?JI7Y5_\ !<[_ )HG_P!QO_VP
MH ^__P!D[_DUGX-_]B9HW_I##7JM>5?LG?\ )K/P;_[$S1O_ $AAKU6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/+]O#_@F
MUX \1>"?&7Q(\!Z!K5IX[CA^U1Z%X;C\VWU&=I '/V81LVXAB3Y14<9QG)K]
M#:* /A']AW_@G+\-_A[X/\$?$/Q/X?U74/B#-80W\UCXE7;'I=TRAB$MBB[7
M0]/,W,IY&"!C[LDC66-D=0Z,,,K#((]#3J* /ACXN?\ !('X,?$37KK6-!N]
M:\!SW+;WL=)DCDL0Q.25BD0LF?[JN%'917H'[-/_  3C^$O[,^OQ>)--@O\
MQ-XJA!^SZMKDB2&UR""88T540D'&XAFZX(!(KZGHH KZAI]KJ^GW-C?6T-Y9
M74303VUP@>.6-@59&4\%2"00>"#7P=\0/^"-?P=\6>*9-5T36O$/A&QGDWRZ
M392Q30)GJ(3(A9!_O%P.V!Q7WS10!XQ^S7^R/\.?V5=!N;#P1IDQO;S'VS6M
M2=9KZZ .0KR!5 4=E157/.,\U[/110 4444 %?/7B_\ 83^%?CCX_0?&/5+3
M5'\:PZA8ZFDL5^RP>=:+$L)\O&, 01Y'?GUKZ%HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KYZ\=?L)_"OXB?'2W^+FL6FJ/XQ@O+.^26&_9(/-M1&(3Y>,
M8_=)D=^:^A:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^>O'7["?PK^(GQT
MM_BYK%IJC^,8+RSODEAOV2#S;41B$^7C&/W29'?FOH6B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OGK1_V$_A7H?Q^D^,=K::H/&KZA/J9E:_8P>=*KJY\O
M&,8=N*^A:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^>M'_ &$_A7H?Q^D^
M,=K::H/&KZA/J9E:_8P>=*KJY\O&,8=N*^A:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^>O"'["?PK\#_'Z?XQZ7::HGC6;4+[4WEEOV:#SKM95F/EXQ@B
M>3 [<>E?0M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !15'7-;L/#>BW^KZK=PV&F6$#W5U=7#!8X8D4L[L3T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD,->JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*BO0O^"S7Q$^&?B_3O 6GZ'JNEZYXZL[B9YI],G2<V]BR?ZN5T)P6DV,JDY
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MK98ZTFF6RWQD.6,XB429/KNS704 %%%% !1110 4444 %%%% !1110 4444
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M)=H%TI9-X [GR%8GJ22>IK]QKZ^MM,LKB\O+B*TM+>-IIKB=PD<:*,LS,>
M 22> !7XC_\ !7RX,/[9=M)-N,46@V!''\(DE)QZ\YKH?V\OV]=;_:D\4)\(
MOA"E[<^$+BZ6T>2QC;[3XAGW8554?,(-V-J]6(W-V  /V7L;ZVU.RM[RSN(K
MNTN(UFAN('#QR(PRK*PX(((((X(-3U\Z_L'? 7QC^SK\ -+\+^-?$<VM:JSF
MY73RXD@TA' /V6)^K ')/.W<QVC'+?15 !1110 4444 %%%% !1110 4444
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M6K](K?\ 9N\!V?QZ;XP6NCI:^-9--DTV>XAPL<X<I^^=<<RA4V;QR58@YP,
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M=@!_>="Y]2[5^XMY>6^G6<]W=SQVMK!&TLL\SA$C11EF9CP  "23TQ7XA_\
M!3V_CLO^"@ N;QPEI;0Z0[,PX6,*K,?I]ZNE_;T_;TUS]J+Q4OPA^$*WMSX0
MGNEM'DL4;[1XAGW8554<^1NQM7JY^9N,  '>_P#!8KX >(/%7Q*^''CKPQI=
MSK:ZW;)X:,-A$96-T)'EMP,=3(LL@'_7*OI#_@G[_P $_=,_9@T.+Q7XKBM]
M4^)]_#B248DBTF-AS!">A<CAY!UY5?ER6]3_ &(_@SXV^!_[/GA_PO\ $'Q"
MWB#6[?,L5NVV1=*B*C9:)+UD"<_,3@;BJ_*JU[[0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5_\%SO^:)_]QO_ -L*
M_52ORK_X+G?\T3_[C?\ [84 ??\ ^R=_R:S\&_\ L3-&_P#2&&O5:\J_9._Y
M-9^#?_8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?FI\>/\ @J=X@^"?[8U[X-U#PL$^'F@R
M?V?J=N5!O[EG".+R-LX 52"D?1E8[B"R^7^AO@7QUH'Q,\(Z7XH\+ZI;ZSH.
MIPB>UO;9LJZGMZA@005."I!! ((K\3/VBOAW<_MC?\%+O'GA+PM?6UI<WUU+
M9Q7<^6A66PTT(P<KR TEJ4R <;LX.,&C^RO^U/\ $#_@GO\ %_5/!'C?2[[_
M (1C[9Y6N>&YO]9;2<#[5;9.W=MP>#ME7'/W64 _1/\ X*=?LF_\-$?!=O$6
M@V?G>.?",<EW9K&OSWEKC,]MQ]XX7>@Y^92HQO-._P""8_[67_#1/P73P_KU
MYYWCKPDD=G>M*V9+RUQB"YYY)P-CGGYEW'&\"OJSP+XZT#XF>$=+\4>%]4M]
M9T'4X1/:WMLV5=3V]0P((*G!4@@@$$5^4?[4?@W6/^"='[9FA?&?P992'P!X
MFN)&N]/M_EC!<@WED>P##][%G@$<#]T: /UZKE/'GPJ\(?%#^Q_^$M\.:?X@
M_L>]34+#[=")/L\Z]'7/Z@\' R#@5J>$?%6F>.O"NC^(]%N1>:1JUG%?6=P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKT_5M*T?QYX6N].OHK;6-!UBS:":,D20W5O*A!&1PRLK=1U!K\E/@QK6J_\
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M /9._P"36?@W_P!B9HW_ *0PUZK7E7[)W_)K/P;_ .Q,T;_TAAKU6@ HHHH
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MJQ$^FY\>]?9_[%?[:WAW]LSP;JJ_V5_8?B?252/5M%F<31,D@(66)B!OC;#
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M[1/'-Q;^0U_CY0W(:98_NB9E.TR8W%1C/+9]4H **** "BBB@ HHHH ****
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M6?BII?A>TM?&FK1".>]4?*K'/F2QI]U)) 0'<#+8_P!I]WJE !1110 4444
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MOFS_ '&8D_(HH _0/3-+LM%TVVT[3[.WL-/MHUA@M;6)8XHHU&%144 *H'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P""BEIH/PJ2WMG.NZ5/!I]ECR;+4))(F,* ?= D*MM'W=Q4 !<#]X:_/O\
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MM9+NX=#POGR;U4$]<(HQTW-UH _0S]O']EN#]JCX%ZAH]I#&/%^D[M0T&X;
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MS\&_^Q,T;_TAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX/T;5)8E U*PAN7C(R/WD88CZ<U^//\ P6P_Y.2\&_\ 8I0_^EEU7KO[;/\
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MS0?^$9^'T=TVDVFL7&1=6MU'(R/+=+DJ(G;CCF/:"206V@'HW_!6[6M<T?\
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MZM7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !145S-]FMY9BCR"-"^R-=S-@9P!W/M7YW_L^_\
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M/]G/:O:?^"9>C^ ]8_8M\.0Z'HUJ\=\MQ:^(H[FV#?;+L,RRB;<,2J590,Y
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M$S1O_2&&O5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS^_X*,?\$YX/C7:WWQ)^&UC';>/X4,FHZ5" J:T@'WE["X '!_CZ'G!KYO\
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M>2HCSD@D@'PA_P $X_\ @HY)\/YM/^$_Q8U!AX=#"UT;7[QCNTULX6VN&/\
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M]Y"LAM;E595E3/1@&.#V.#U (W: "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#B?C=XCL_"'P9\=ZW?NJ6>GZ'>W,I8XRJP.<?4X
MP/<BOYV_ O[//C;XA?"?Q;\1O#=@VHZ1X3N88]2CM\FXB1T=S.J@<HFP;B.5
M# XP&(_HX^(GP_T/XJ>"-9\)>);(:AH6KV[6MW;EBI9#W##D$$ @CD$ UY=^
MR/\ LJ:)^R9\-=2\):7?2:R+_5;C4)[ZYB"R2*Y"11L!P=L2(IQ@%MY &[%
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M#?\ V)FC?^D,->JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#LG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I##7JM !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5^5?_!<[_FB?_<;_ /;"OU4K\J_^"YW_ #1/
M_N-_^V% 'W_^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5^5?\ P7._YHG_ -QO_P!L*_52ORK_
M ."YW_-$_P#N-_\ MA0!]_\ [)W_ ":S\&_^Q,T;_P!(8:]5KRK]D[_DUGX-
M_P#8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI\(_]!?X@?\ AQ_$/_R=7JM% 'E7_#-/A'_H+_$#_P ./XA_^3J/^&:?"/\
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MM% 'E7_#-/A'_H+_ ! _\./XA_\ DZC_ (9I\(_]!?X@?^''\0__ "=7JM%
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M'\0__)U>JT4 >5?\,T^$?^@O\0/_  X_B'_Y.H_X9I\(_P#07^('_AQ_$/\
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M_$#_ ,./XA_^3J/^&:?"/_07^('_ (<?Q#_\G5ZK10!Y5_PS3X1_Z"_Q _\
M#C^(?_DZC_AFGPC_ -!?X@?^''\0_P#R=7JM% 'E7_#-/A'_ *"_Q _\./XA
M_P#DZC_AFGPC_P!!?X@?^''\0_\ R=7JM% 'E7_#-/A'_H+_ ! _\./XA_\
MDZC_ (9I\(_]!?X@?^''\0__ "=7JM% 'E7_  S3X1_Z"_Q _P##C^(?_DZC
M_AFGPC_T%_B!_P"''\0__)U>JT4 >5?\,T^$?^@O\0/_  X_B'_Y.H_X9I\(
M_P#07^('_AQ_$/\ \G5ZK10!Y5_PS3X1_P"@O\0/_#C^(?\ Y.H_X9I\(_\
M07^('_AQ_$/_ ,G5ZK10!Y5_PS3X1_Z"_P 0/_#C^(?_ ).H_P"&:?"/_07^
M('_AQ_$/_P G5ZK10!Y5_P ,T^$?^@O\0/\ PX_B'_Y.H_X9I\(_]!?X@?\
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M_P#R=7JM% 'E7_#-/A'_ *"_Q _\./XA_P#DZC_AFGPC_P!!?X@?^''\0_\
MR=7JM% 'E7_#-/A'_H+_ ! _\./XA_\ DZC_ (9I\(_]!?X@?^''\0__ "=7
MJM% 'E7_  S3X1_Z"_Q _P##C^(?_DZC_AFGPC_T%_B!_P"''\0__)U>JT4
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M_P#)U>JT4 >5?\,T^$?^@O\ $#_PX_B'_P"3J/\ AFGPC_T%_B!_X<?Q#_\
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MV^0/7.[VH ^M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGBZU\ >!_$7BB^4O9:)IUQJ4Z@X)CAB:1AGMPIH W:*_,#_A^-H?_1)-0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_#-/_!0S_H+_$#_ ,./#_\ )U '[4T5^*W_  S3_P %#/\ H+_$#_PX\/\
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MW\2:1^R;^S18W5Q<LC7NK6^G^0MPJ%ECDFM[9$$:99B"\H)W'(!S0!K? ?\
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MWF _&OWPK^>_PQ\(--^/G[?VM> =8O;K3M-UKQ=K$4US8[?.0+)<2 KN!'5
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M2\N+F:QL+IF$\UQ?B-6,TY?),2;XQL7!/(!4*,\=\!_VC_B/_P $WOB/\0/
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MTA7C><8#$!><T ?;-?,O_!27QM_P@W[%_P 1[A'V7&H6L6DQ#/WOM$R1./\
MOVTA_"OIJO+?VCOV?_"'[27PZ_X13QO/?6VAQ7<=^9+"Z%NXD1752692-OSD
MX(Z@>E 'X]_L3?M!?LX?!'X;:O!\7?AX/'_B?4M69X2?#MEJ(L[18HPGSW+K
MMW.9253/09[5^HG[)7BS]G#XM6L_BOX->%O">BZS:H8+R.PT&VT[4[17/W9
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M HHHH **** "BBB@ KRK]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\
M[$S1O_2&&@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*O_
M (+G?\T3_P"XW_[85^JE?E7_ ,%SO^:)_P#<;_\ ;"@#[_\ V3O^36?@W_V)
MFC?^D,->JUY5^R=_R:S\&_\ L3-&_P#2&&O5: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OV:?^2=:O_V.?BS_
M -2'4:]5KRK]FG_DG6K_ /8Y^+/_ %(=1KU6@ HHHH **** "BBB@ HHHH *
M^6/VYOV%M _:W\)B\LC;Z)\1=-B*Z9K+J0DRC)^S7. 2T9).&P2A)(R"RM]3
MT4 ?*/["O["&A?LE^%SJ6I&VUSXCZC%MU#5XU)CMD//V>VW $)D#<V 7(R<
M!1]7444 %%%% !1110 4444 %?B%^VI\&/C&?VYO&/CCP=\,O%^M06NKV6H:
M=J5CX=N[JUE>&"!E*ND95P'3!P>Q%?M[10!^0'_#9'[>O_1+?$'_ (;^[_\
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M1[Z/4L<(SJHXBF(X+CH22 IP1^Q=% 'R1^Q?\$OC#I?P%\267QM\9ZQJNO\
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M_P#"W_\ A,O!OB#PE]N_L?[)_;NESV7VC9]MW^7YJ+NV[TSC.-RYZBOTJHH
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M?$/A&ST?619^5;ZM=W45Q&8K2&!@PCMW7!,1(PW0BO$_^'*GQO\ ^AI^'_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>5?LG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I##0!ZK11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_P %SO\ FB?_ '&_
M_;"OU4K\J_\ @N=_S1/_ +C?_MA0!]__ +)W_)K/P;_[$S1O_2&&O5:\J_9.
M_P"36?@W_P!B9HW_ *0PUZK0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!Y5^S3_R3K5_^QS\6?\ J0ZC7JM>5?LT
M_P#).M7_ .QS\6?^I#J->JT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP$\':O)HN@6^I0Z%#9)=-;17UV^T22W+KRR!F*A>0 @(4L:_9&ORW_X*+?\
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M%U'44*3W>GB+R0JHF2L;-YK?,ZDC;\N#R/CW]AK_ )2EG_L,^(O_ $1=TO\
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MMXC_ ."HW[56J2>-/%LOAKPG9137\<#RJ5TZR$BI';6Z,0GF-N3<^.=K,0<
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MFRW(],Q^U 'Y]^!;*>U\=>$)9HFCCN;^VEA9APZ"XV%A[;D8?@:_J"K^?O\
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M[Q-=>*?#NE6'VKPU=70PR64SL#&!D[=LD;KM!QQN &[% ']"\<B31K)&RNC
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MGXE:U+XJT71[B75X7C2""^LO*/VN- IRJ^7O;8Y<,%QUP:R_^"'W_(_?%/\
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M0^ZFO>/^&*?@)_T2'P?_ ."F+_"O4?!_@O0/A[X=M- \,:-8Z!HEH&$&GZ=
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M_:._8:_9S_9H_97UKQ0WB2Z\5^+[^S6/0-0N-379=73,HWV\,!"L@&YCN+@
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M,;O,9<@C)"Y'*GMZ_P#LD_L(^$OV/]:\1:EX:\0:UK4NM6\5O,FJF':BQLS
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M'_P1R^%'@/Q)#JWBG6M5\>QP,6BTR\1+6T8Y^4R*A+/CTW!3W!'%>I_LK_\
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M*N4^)_PK\*?&;P;>^%?&>B6VO:%> >9:W (PP^ZZ,"&1QV92".QH \0^"O\
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M?NI7R#\ O^":?@;]GOXU6WQ*T;Q1XAU+58/M6VTOC!Y!\]&1L[8PW <XY[4
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MS\&_^Q,T;_TAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#RK]FG_ ))UJ_\ V.?BS_U(=1KU6O*OV:?^2=:O
M_P!CGXL_]2'4:]5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *J:MI-EK^EWFF:E:0W^G7D+V]S:W"!XYHV!
M5D93P5()!!]:MT4 ?"'CC_@C;\#_ !/K%S?Z/J/BGPFDS;AI^GWL4UK$.X03
M1/)S[R$#TKO?V>?^"9OP<_9Y\36WB:TM]2\6>([5Q):7WB&9)5M'!X>*)$1
MPX(9@S C((KZRHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O*OV3O^36?@W_V)FC?^D,->JUY5^R=
M_P FL_!O_L3-&_\ 2&&@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#R=1_PS3X1_P"@O\0/_#C^(?\ Y.H ]5HKRK_AFGPC_P!!?X@?^''\0_\
MR=1_PS3X1_Z"_P 0/_#C^(?_ ).H ]5HKRK_ (9I\(_]!?X@?^''\0__ "=1
M_P ,T^$?^@O\0/\ PX_B'_Y.H ]5HKRK_AFGPC_T%_B!_P"''\0__)U'_#-/
MA'_H+_$#_P ./XA_^3J /5:*\J_X9I\(_P#07^('_AQ_$/\ \G4?\,T^$?\
MH+_$#_PX_B'_ .3J /5:*\J_X9I\(_\ 07^('_AQ_$/_ ,G4?\,T^$?^@O\
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M ! _\./XA_\ DZ@#U6BO*O\ AFGPC_T%_B!_X<?Q#_\ )U'_  S3X1_Z"_Q
M_P##C^(?_DZ@#U6BO*O^&:?"/_07^('_ (<?Q#_\G4?\,T^$?^@O\0/_  X_
MB'_Y.H ]5HKRK_AFGPC_ -!?X@?^''\0_P#R=1_PS3X1_P"@O\0/_#C^(?\
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M_P#)U'_#-/A'_H+_ ! _\./XA_\ DZ@#U6BO*O\ AFGPC_T%_B!_X<?Q#_\
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M_$#_ ,./XA_^3J /5:*\J_X9I\(_]!?X@?\ AQ_$/_R=1_PS3X1_Z"_Q _\
M#C^(?_DZ@#U6BO*O^&:?"/\ T%_B!_X<?Q#_ /)U'_#-/A'_ *"_Q _\./XA
M_P#DZ@#U6BO*O^&:?"/_ $%_B!_X<?Q#_P#)U'_#-/A'_H+_ ! _\./XA_\
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MOV'1M(LX=/L;4.S^3!$@CC3<Q+'"J!EB2<<DT :M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^5?\ P7._YHG_ -QO_P!L*_52ORK_ ."YW_-$
M_P#N-_\ MA0!]_\ [)W_ ":S\&_^Q,T;_P!(8:]5KRK]D[_DUGX-_P#8F:-_
MZ0PUZK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_P7._YHG_W&_P#VPK]5
M*_*O_@N=_P T3_[C?_MA0!S'PL_X+'_\*J^&/A#P5_PJ+^U/^$;T>ST;[=_P
MDOD_:/L\"0^9L^R-LW;,[=QQG&3UKJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$
M_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!4
M3_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_
M %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U
M1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'Y
MG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9
M_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^
M'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A
M^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH
M/^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C
M_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHH
MH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N
M*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[B
MHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z_
M_N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\
M[BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K
M_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P N
MO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__
M "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#R
MZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_
M /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/
M_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\
M5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$
M_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?
M]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_
M %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?
MF?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'Y
MG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _
MX?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^
M'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@
M _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ
M/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*B
MB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^
MXJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N
M*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_
M .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z_
M_N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\
M+K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K
M_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\
M\NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__
M "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!4
M3_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_
M /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A^9_U
M1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?F?\
M5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #_A^9
M_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_X?F?
M]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ** #_A
M^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[BH_X?
MF?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ** #
M_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\ [BH_
MX?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^XJ**
M #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P NO_[B
MH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_ .XJ
M** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#RZ_\
M[BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\ +K_^
MXJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/_P N
MO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\ \NO_
M .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$_P#R
MZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!43_\
M+K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_ %1/
M_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U1/\
M\NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'YG_5$
M_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9_P!4
M3_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^'YG_
M %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A^9_U
M1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH /^'Y
MG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C_A^9
M_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHHH /^
M'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N*C_A
M^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[BHHH
M/^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z__N*C
M_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\ [BHH
MH /^'YG_ %1/_P NO_[BH_X?F?\ 5$__ "Z__N*BB@ _X?F?]43_ /+K_P#N
M*C_A^9_U1/\ \NO_ .XJ** #_A^9_P!43_\ +K_^XJ/^'YG_ %1/_P NO_[B
MHHH /^'YG_5$_P#RZ_\ [BH_X?F?]43_ /+K_P#N*BB@ _X?F?\ 5$__ "Z_
M_N*C_A^9_P!43_\ +K_^XJ** #_A^9_U1/\ \NO_ .XJ/^'YG_5$_P#RZ_\
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-L_\ M9W]L<E% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888874288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001156039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELEVANCE HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-2145715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">220 Virginia Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-1577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,691,972,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,457,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part III of this Annual Report on Form 10-K incorporates by reference information from the registrant&#8217;s Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 10, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887846048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Indianapolis, Indiana<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887900176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,387<span></span>
</td>
<td class="nump">$ 4,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fixed maturities, current</a></td>
<td class="nump">25,952<span></span>
</td>
<td class="nump">26,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAtCarryingValue', window );">Premium receivables</a></td>
<td class="nump">7,083<span></span>
</td>
<td class="nump">5,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_SelfFundedReceivablesNet', window );">Self-funded receivables</a></td>
<td class="nump">4,663<span></span>
</td>
<td class="nump">4,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">4,298<span></span>
</td>
<td class="nump">3,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">5,281<span></span>
</td>
<td class="nump">4,654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,617<span></span>
</td>
<td class="nump">51,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fixed maturity securities, long-term</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">3,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">24,383<span></span>
</td>
<td class="nump">24,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">10,315<span></span>
</td>
<td class="nump">10,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,772<span></span>
</td>
<td class="nump">97,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims payable</a></td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">13,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPolicyholderFunds', window );">Other policyholder liabilities</a></td>
<td class="nump">5,933<span></span>
</td>
<td class="nump">5,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnearnedPremiums', window );">Unearned income</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">9,683<span></span>
</td>
<td class="nump">7,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">39,696<span></span>
</td>
<td class="nump">34,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">22,349<span></span>
</td>
<td class="nump">21,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Reserves for future policy benefits</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">66,378<span></span>
</td>
<td class="nump">61,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 14</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,084<span></span>
</td>
<td class="nump">9,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">29,724<span></span>
</td>
<td class="nump">27,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,503)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,307<span></span>
</td>
<td class="nump">36,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">36,394<span></span>
</td>
<td class="nump">36,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 102,772<span></span>
</td>
<td class="nump">$ 97,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_SelfFundedReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_SelfFundedReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 55<br> -Paragraph 29E<br> -URI https://asc.fasb.org/extlink&amp;oid=126561865&amp;loc=SL117819541-158441<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPolicyholderFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPolicyholderFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnearnedPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnearnedPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888722624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Fixed maturities, amortized cost, current</a></td>
<td class="nump">$ 28,226<span></span>
</td>
<td class="nump">$ 25,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent', window );">Fixed maturities, allowance for credit loss, current</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Fixed maturities, amortized cost, noncurrent</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent', window );">Fixed maturities, allowance for credit loss, noncurrent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">237,958,067<span></span>
</td>
<td class="nump">241,770,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">237,958,067<span></span>
</td>
<td class="nump">241,770,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887905952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 133,229<span></span>
</td>
<td class="nump">$ 117,373<span></span>
</td>
<td class="nump">$ 104,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ProductRevenue', window );">Product revenue</a></td>
<td class="nump">14,978<span></span>
</td>
<td class="nump">12,657<span></span>
</td>
<td class="nump">10,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Administrative fees and other revenue</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">6,913<span></span>
</td>
<td class="nump">6,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_OperatingRevenue', window );">Total operating revenue</a></td>
<td class="nump">155,660<span></span>
</td>
<td class="nump">136,943<span></span>
</td>
<td class="nump">120,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NetGainsLossesOnFinancialInstruments', window );">Net (losses) gains on financial instruments</a></td>
<td class="num">(550)<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">156,595<span></span>
</td>
<td class="nump">138,639<span></span>
</td>
<td class="nump">121,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Benefit expense</a></td>
<td class="nump">116,487<span></span>
</td>
<td class="nump">102,645<span></span>
</td>
<td class="nump">88,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">13,035<span></span>
</td>
<td class="nump">10,895<span></span>
</td>
<td class="nump">8,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">17,686<span></span>
</td>
<td class="nump">15,914<span></span>
</td>
<td class="nump">17,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other intangible assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Total expenses</a></td>
<td class="nump">148,826<span></span>
</td>
<td class="nump">130,714<span></span>
</td>
<td class="nump">115,629<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">7,769<span></span>
</td>
<td class="nump">7,925<span></span>
</td>
<td class="nump">6,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,019<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">$ 6,025<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 4,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Shareholders&#8217; net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share</a></td>
<td class="nump">$ 25.10<span></span>
</td>
<td class="nump">$ 25.04<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share</a></td>
<td class="nump">24.81<span></span>
</td>
<td class="nump">24.73<span></span>
</td>
<td class="nump">17.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends per share</a></td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="nump">$ 4.52<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NetGainsLossesOnFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net gains (losses) on financial instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NetGainsLossesOnFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_OperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from insurance services and products sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_OperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5,6,7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886414080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">$ 6,019<span></span>
</td>
<td class="nump">$ 6,095<span></span>
</td>
<td class="nump">$ 4,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in net unrealized gains/losses on investments</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax', window );">Change in non-credit component of impairment losses on investments, net of tax</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in net unrealized gains/losses on cash flow hedges</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Change in net periodic pension and postretirement costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(2,336)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss attributable to noncontrolling interests</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total shareholders&#8217; comprehensive income</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 5,776<span></span>
</td>
<td class="nump">$ 5,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in non-credit component of impairment losses on investments, net of tax effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885842224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">$ 6,019<span></span>
</td>
<td class="nump">$ 6,095<span></span>
</td>
<td class="nump">$ 4,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NetGainsLossesOnFinancialInstruments', window );">Net losses (gains) on financial instruments</a></td>
<td class="nump">550<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net earnings of other invested assets</a></td>
<td class="num">(293)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">1,675<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables, net</a></td>
<td class="num">(2,510)<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTradingSecurities', window );">Other invested assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Policy liabilities</a></td>
<td class="nump">2,254<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">3,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned income</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">1,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income taxes</a></td>
<td class="num">(338)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">8,399<span></span>
</td>
<td class="nump">8,364<span></span>
</td>
<td class="nump">10,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(24,946)<span></span>
</td>
<td class="num">(18,669)<span></span>
</td>
<td class="num">(19,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_Proceedsfromsaleofequityandfixedmaturitysecurities', window );">Proceeds from sale of investments</a></td>
<td class="nump">11,988<span></span>
</td>
<td class="nump">10,269<span></span>
</td>
<td class="nump">11,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities, calls and redemptions from investments</a></td>
<td class="nump">10,620<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
<td class="nump">4,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending', window );">Changes in securities lending collateral</a></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
<td class="num">(849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchases of subsidiaries, net of cash acquired</a></td>
<td class="num">(649)<span></span>
</td>
<td class="num">(3,476)<span></span>
</td>
<td class="num">(1,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,152)<span></span>
</td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">(1,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,560)<span></span>
</td>
<td class="num">(9,638)<span></span>
</td>
<td class="num">(7,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Net (repayments of) proceeds from commercial paper borrowings</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowings</a></td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term borrowings</a></td>
<td class="num">(1,899)<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
<td class="num">(1,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short-term borrowings</a></td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(1,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable', window );">Changes in securities lending payable</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities', window );">Changes in bank overdrafts</a></td>
<td class="nump">933<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(2,316)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
<td class="num">(2,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Cash dividends</a></td>
<td class="num">(1,229)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
<td class="num">(954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock under employee stock plans</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid through withholding of common stock under employee stock plans</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="num">(861)<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">4,880<span></span>
</td>
<td class="nump">5,741<span></span>
</td>
<td class="nump">4,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 7,387<span></span>
</td>
<td class="nump">$ 4,880<span></span>
</td>
<td class="nump">$ 5,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NetGainsLossesOnFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net gains (losses) on financial instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NetGainsLossesOnFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_Proceedsfromsaleofequityandfixedmaturitysecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of equity and fixed maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_Proceedsfromsaleofequityandfixedmaturitysecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in cash during the period due to the net increase or decrease in outstanding checks, the liability that represents checks that have been issued but that have not cleared. The entity may classify these cash flows as financing or operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecuritiesLendingPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883624096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Balance, beginning at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 9,448<span></span>
</td>
<td class="nump">$ 22,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest, Beginning Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity, Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 31,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(2,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(353)<span></span>
</td>
<td class="num">(2,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends and dividend equivalents</a></td>
<td class="num">(961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock plans, net of related tax benefits (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under employee stock plans, net of related tax benefits</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Convertible debenture repurchases and conversions</a></td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Balance, ending at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">9,244<span></span>
</td>
<td class="nump">23,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity, Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">33,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">6,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">6,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling Interest, Period Increase (Decrease)</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock, shares</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">$ (1,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(1,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends and dividend equivalents</a></td>
<td class="num">(1,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock plans, net of related tax benefits (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under employee stock plans, net of related tax benefits</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Convertible debenture repurchases and conversions</a></td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Balance, ending at Dec. 31, 2021</a></td>
<td class="nump">36,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,148<span></span>
</td>
<td class="nump">27,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,065<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Balance, ending (Accounting Standards Update 2020-06) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">36,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity, Ending Balance (Accounting Standards Update 2020-06) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">6,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">6,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(2,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling Interest, Period Increase (Decrease)</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock, shares</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">$ (2,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(2,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends and dividend equivalents</a></td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock plans, net of related tax benefits (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under employee stock plans, net of related tax benefits</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Convertible debenture repurchases and conversions</a></td>
<td class="num">(232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Balance, ending at Dec. 31, 2022</a></td>
<td class="nump">36,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 9,084<span></span>
</td>
<td class="nump">$ 29,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest, Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity, Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 36,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890682064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text">Organization <div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol &#8220;ELV&#8221; on June 28, 2022. References to the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or &#8220;Elevance Health&#8221; used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the &#8220;states&#8221; include the District of Columbia and Puerto Rico, unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members through our affiliated health plans as of December&#160;31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products &amp; Services business, which administers the Federal Employees Health Benefits (&#8220;FEHB&#8221;) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (&#8220;PBM&#8221;) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#8220;BCBS&#8221;) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer PBM services through our CarelonRx, Inc. (&#8220;CarelonRx&#8221;) subsidiary, which was named IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all 50&#160;states, the District of Columbia and Puerto Rico through our subsidiaries.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield &#8212; represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellpoint &#8212; we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Carelon &#8212; this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes made to our segments in 2022 associated with this branding strategy. Through December 31, 2022, we managed our operations by customer types through four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. Our branding strategy reflects the evolution of </span></div>our business from a traditional health insurance company into a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our business in the future. For additional discussion, including the changes to our reportable segments for 2023, see Note 20, &#8220;Segment Information.&#8221;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890688192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis Of Presentation And Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis Of Presentation And Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements include the accounts of Elevance Health and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (&#8220;USD&#8221;). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in &#8220;Foreign currency translation adjustments&#8221; in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $258 and $173 at December&#160;31, 2022 and 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as &#8220;available-for-sale&#8221; and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security&#8217;s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported in other current assets on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current liabilities. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders&#8217; equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions.&#160;To the extent the loaned securities&#8217; value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall.&#160;As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $152 and $142 at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $68 and $50 at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $744 and $648 at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws and are reported net on our consolidated balance sheets. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the &#8220;Corporate AMT&#8221;) that became effective for us beginning January 1, 2023. We have elected to account for the effects of the Corporate AMT on deferred tax assets and carryforwards and tax credits in the period they arise. Additionally, the Inflation Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31, 2022. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of operations, cash flows or related disclosures.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3">fifteen</span> to thirty years for buildings and improvements, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5">three</span> to five years for computer equipment and software, and the lesser of the remaining life of the building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea">three</span> to ten years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable assumptions and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry&#8217;s weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies in our industry and are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;); and book value of invested capital. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset&#8217;s fair value. This determination consists of a one-step test comparing the fair value of a reporting unit, including goodwill, to its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit&#8217;s carrying amount over its fair value. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December&#160;31, 2022, we believe there were no material concentrations of credit risk with any individual counterparty.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan&#8217;s cash flows to determine the plan&#8217;s obligations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims Payable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1)&#160;an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2)&#160;claims reported to us and processed through our systems but not yet paid.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into &#8220;claim triangles,&#8221; which compare claim incurred dates to the dates of claim payments. This information is analyzed to create &#8220;completion factors&#8221; that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels (&#8220;trend factors&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December&#160;31, 2022 or 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Policyholder Liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (&#8220;MLR&#8221;), the relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively the &#8220;ACA&#8221;). If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with regulations issued by the Department of Health and Human Services (&#8220;HHS&#8221;). Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Future Policy Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Premiums for risk-based contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other regulatory requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final amounts paid, the adjustments are included in earnings in the period of final settlement. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative fees and other revenue include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">groups an administrative fee, which is based on the number of members in a group and the group&#8217;s claim experience. In addition, administrative fees and other revenue include amounts received for the administration of Medicare, certain other government programs, and administrative services arrangements of our Carelon (Diversified Business Group) subsidiaries, now known as Carelon. Generally, these fee-based arrangements include services which constitute a single suite of services provided and for which consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with premiums, these fee-based arrangements may include terms with retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable consideration within the transaction price. As such, these fee-based arrangements contain a single performance obligation that constitutes a series, and revenue is recognized over time as the services are performed. All benefit payments under these programs are excluded from benefit expense. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of whether services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be recognized requires significant judgment in the determination of the level of achievement of performance incentives, service level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue includes revenue for services performed by our CarelonRx PBM for unaffiliated PBM customers. Unaffiliated PBM customers include our fee-based groups that have contracted with CarelonRx for PBM services and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in consolidation. Product revenue for PBM services is recognized using the gross method at the negotiated contract price when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer. CarelonRx determined it is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary management); its control over establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the pricing for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling the promise to provide PBM services. Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments made by or on behalf of the customer, and administrative fees. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in exchange for the products or services provided.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at December&#160;31, 2022. Revenue recognized in 2022 and 2021 from performance obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CarelonRx&#8217;s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated PBM customers (net of rebates or discounts). Cost of products sold includes per-claim administrative fees for prescription fulfillment by its vendor and certain CarelonRx direct costs related to sales and administration of customer contracts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in our consolidated statements of income based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Group risk-based customers with a smaller employee base. Products for Group risk-based customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual and Group markets, we offer products through state or federally facilitated marketplaces, or Public Exchanges, and off-exchange products.&#160;The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate image are expensed when first aired. Total advertising and marketing expense was $511, $588 and $558 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Insurance Provider Fee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA imposed an annual Health Insurance Provider Fee (&#8220;HIP Fee&#8221;) on health insurers that wrote certain types of health insurance on U.S. risks, which was permanently repealed effective January 1, 2021. The HIP Fee was non-deductible for federal income tax purposes.&#160;Our affected products were priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when it was in effect. The HIP Fee was $15,523 for 2020 and was permanently eliminated beginning in 2021. For the year ended December 31, 2020, we recognized $1,570 as selling, general and administrative expense related to the HIP Fee. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We recognize operating right-of-use (&#8220;ROU&#8221;) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized initial direct costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in selling, general and administrative expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of the ROU asset to its estimated undiscounted future cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is performed. An impairment loss is recorded for the difference of the ROU asset&#8217;s carrying value that exceeds its estimated discounted cash flows. During the years ended December 31, 2022, 2021 and 2020, we recorded $34, $136 and $258, respectively, for impairment and abandonment of ROU assets. See Note 18, &#8220;Leases&#8221; for additional information about the ROU asset impairment and abandonment charges.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and the number of shares assumed purchased represents the dilutive shares.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FASB issued Accounting Standards Update No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-01&#8221;). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued Accounting Standards Update No. 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables&#8212;Nonrefundable Fees and Other Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-08&#8221;). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-06&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option; these amounts were not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services&#8212;Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-11&#8221;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services&#8212;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2018-12&#8221;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, with the amendments required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company&#8217;s reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#8217;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. The Company adopted the new standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the earliest period presented, January 1, 2021. The adoption did not have a material impact on our consolidated financial position, results of operations, cash flows, or related disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There were no other new accounting pronouncements that were issued or became effective during the year ended December&#160;31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890700096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Business Acquisitions</a></td>
<td class="text">Business Acquisitions<div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completed Acquisitions</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we completed business combinations for total cash consideration of approximately $752. These acquisitions included Integra MLTC, Inc. (&#8220;Integra&#8221;), acquired May 2022, which is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase prices for all business combinations were allocated to the tangible and intangible net assets acquired based on management&#8217;s initial estimates of their fair values, of which $89 was allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $145 to goodwill. The intangible assets and goodwill acquired were assigned to our Government Business reportable segment. The majority of goodwill is deductible for income tax purposes. As of December&#160;31, 2022, the initial accounting for the acquisitions completed in 2022 had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we completed business combinations for total cash consideration of approximately $4,021. These acquisitions included myNEXUS, Inc. (&#8220;myNEXUS&#8221;), acquired April 2021, a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (&#8220;MMM&#8221;), acquired June 2021, including its Medicare Advantage plan, Medicaid plan, and other affiliated companies. The purchase prices for all business combinations were allocated to the tangible and intangible net assets acquired based on management&#8217;s final estimates of their fair values, of which $1,577 was allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,531 to goodwill, including measurement period adjustments of $10 during the year ended December 31, 2022. Of these amounts, $795 was allocated to our Other reportable segment and $3,333 to our Government Business reportable segment.The majority of goodwill is not deductible for income tax purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired tangible assets (liabilities) at the acquisition date were:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical claims and other policyholder liabilities payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net tangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent and tax liabilities, are finalized. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations and financial condition of acquired entities have been included in our consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through December&#160;31, 2022, the impact of the acquired entities on revenue and net earnings was not material. Unaudited pro forma revenues for the years ended December&#160;31, 2022 and 2021 as if the acquisitions had occurred on January 1, 2021 were immaterial for both periods. The pro forma effects of the acquisitions on net earnings were immaterial for both years.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Acquisitions</span></div><div style="margin-bottom:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Louisiana Health Service &amp; Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service &amp; Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.</span></div><div style="margin-bottom:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioPlus Parent, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, we announced our entrance into an agreement with CarepathRx Aggregator, LLC to acquire its specialty pharmacy division, which includes BioPlus Parent, LLC (&#8220;BioPlus&#8221;) and subsidiaries. BioPlus is one of the largest independent specialty pharmacy organizations in the United States and seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition was completed on February 15, 2023, and initial purchase accounting for the acquisition has not been finalized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890688192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Optimization Initiatives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BusinessOptimizationInitiativesAbstract', window );"><strong>Business Optimization Initiatives [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Business Optimization Initiatives</a></td>
<td class="text">Business Optimization Initiatives<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our properties are adequate and suitable for our business as presently conducted; however, we are continuing to evaluate our real estate strategy as it relates to the changing needs of a more hybrid remote workforce. As a result, during 2022, we identified additional reductions of office space and recorded a net charge of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_afeade16-dee4-4795-8b19-99581c96cde5">39</span> in selling, general and administrative expenses. This charge includes $34 for impairment and abandonment of operating-lease related ROU assets and $7 for impairment and abandonment of property and equipment. In addition, we released $2 of employee termination costs, as reflected in the table below. The net charges recognized in the Commercial &amp; Specialty Business, Government Business, CarelonRx and Other segments in 2022, were $20, $16, $0 and $3, respectively. See Note 20, &#8220;Segment Information&#8221; for a discussion of our segments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we identified reductions of office space and recorded a charge of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_346f76ea-dead-4d60-b08d-54ad913c9f6f">202</span> in selling, general and administrative expenses. This charge included $136 for impairment and abandonment of operating-lease related ROU assets and $66 for impairment and abandonment of property and equipment. The charges recognized in the Commercial &amp; Specialty Business, Government Business, CarelonRx and Other segments in 2021, were $108, $60, $1 and $33, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, our management introduced enterprise-wide initiatives to optimize our business and, as a result, we recorded a charge of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_72ace3e9-597b-4518-a22f-101187f15e20">653</span> in selling, general and administrative expenses. This charge included $258 for impairment and abandonment of operating-lease related ROU assets, $198 for impairment and abandonment of property and equipment and $197 for future payments for employee termination costs in connection with the repositioning and reskilling of our workforce. The charges recognized in the Commercial &amp; Specialty Business, Government Business, CarelonRx and Other segments in 2020, were $311, $205, $4 and $133, respectively.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity for the year ended December 31, 2022 and ending balance at December&#160;31, 2022, related to the liability for employee termination costs previously incurred in 2020, is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Business Optimization Initiatives</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities for employee termination costs at January 1, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Releases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities for employee termination costs ending balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BusinessOptimizationInitiativesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Optimization Initiatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BusinessOptimizationInitiativesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894932928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investment [Text Block]</a></td>
<td class="text">Investments <div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year residential and commercial mortgage-backed securities have been reclassified throughout this Note 5 and Note 7, &#8220;Fair Value&#8221; to conform to the current year presentation.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at December&#160;31, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost&#160;or<br/>Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance For Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other asset-backed securities primarily consist of collateralized loan obligations and other debt securities.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at December&#160;31, 2022 and 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses on our securities shown in the table above have not been recognized into income because, as of December&#160;31, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for credit losses have been recorded in the amounts of $9 and $6 at December&#160;31, 2022 and 2021, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest. </span></div><div style="margin-bottom:3pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at December&#160;31, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current equity securities at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Income</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major categories of net investment income for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment (Losses) Gains </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains on fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains recognized on equity securities still held</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized (losses) gains recognized on equity securities sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i)&#160;changes in the investment environment; (ii)&#160;expectations that the fair value could deteriorate further; (iii)&#160;desire to reduce exposure to an issuer or an industry; (iv)&#160;changes in credit quality; or (v)&#160;changes in expected cash flow.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds from sales, maturities, calls or redemptions of fixed maturity securities was $22,048, $10,565 and $11,122 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant judgment in the valuation of investments is the determination of when a credit loss has occurred. We follow a consistent and systematic process for recognizing impairments on securities that sustain credit declines in value. We have established a committee responsible for the impairment review process. The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but not limited to: (i)&#160;the extent to which the fair value is less than book value, (ii)&#160;the financial condition and near term prospects of the issuer, (iii)&#160;our intent and ability to retain impaired investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv)&#160;our intent to sell or the likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v)&#160;whether the debtor is current on interest and principal payments, (vi)&#160;the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors) and (vii)&#160;general market conditions and industry or sector specific factors. When a decision has been made to sell an impaired security or it is more likely than not that the impaired security will be required to be disposed of prior to recovery of its cost basis, the security is written down to fair value at the reporting date. For all other impaired securities, if the impairment is deemed to be credit related, an allowance is created.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have a material adverse impact on our results of operations or shareholders&#8217; equity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, there were no individual investments that exceeded 10% of shareholders&#8217; equity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, there were eight and two, respectively, fixed maturity investments that did not produce income during the years then ended.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we had committed approximately $1,504 and $1,558, respectively, to future capital calls from various third-party investments in exchange for an ownership interest in the related entities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we had committed approximately $185 and $329, respectively, to future investments in rated notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, securities with carrying values of approximately $752 and $632, respectively, were deposited by our insurance subsidiaries under requirements of regulatory authorities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Investment Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued investment income totaled $245 and $205 at December&#160;31, 2022 and 2021, respectively. We recognize accrued investment income under the caption &#8220;Other receivables&#8221; on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Lending Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the collateral received at the time of the securities lending transactions amounted to $2,457 and $2,155 at December&#160;31, 2022 and 2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the collateral as an asset under the caption &#8220;Other current assets&#8221; in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption &#8220;Other current liabilities.&#8221; The securities on loan are reported in the applicable investment category on our consolidated balance sheets.</span></div>At December&#160;31, 2022 and 2021, the remaining contractual maturities of our securities lending transactions included overnight and continuous transactions of cash for $2,221 and $1,874, respectively, United States Government securities for $224 and $281, respectively, and residential mortgage-backed securities for $12 and $0, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890903968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. We also enter into master netting agreements which reduce credit risk by permitting net settlement of transactions. At December&#160;31, 2022 and 2021, we had received collateral of $57 and $18, respectively, related to our derivative financial instruments.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual/<br/>Notional<br/>Amount</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps - fixed to floating</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Non-hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives embedded in convertible fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Maturity Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities/other assets/other liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts netted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps - fixed to floating</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Non-hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities/other assets/other liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts netted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the LIBOR or the Secured Overnight Financing Rate. A summary of our outstanding fair value hedges at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Fair Value Hedges</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/>Entered<br/>Into</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding&#160;Notional&#160;Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate<br/>Received</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 15, 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amount outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification in Which Hedged Item is Included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount of Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the variability of cash flows in the interest payments on future financings that were anticipated at the time of entering into the swaps. During 2022 and 2021, swaps in the notional amount of $700 and $450, respectively, were terminated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $229 and $239 at December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, the total amount of amortization over the next twelve months for all cash flow hedges is estimated to increase interest expense by approximately $13. No amounts were excluded from effectiveness testing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Hedging Derivatives</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Non-hedging Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location of<br/>Gain (Loss) Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>(Loss) Gain<br/>Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives embedded in convertible securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d">(3)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635">(4)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (including swaptions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16">13</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db">10</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2">64</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27">(4)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf">4</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142">7</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf">(1)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663">(5)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7">4</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886443376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;Input:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Input Definition:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;II</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed maturity securities, available-for-sale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services&#8217; qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services&#8217; pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security&#8217;s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities lending collateral:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan assets not defined above (see Note 11, &#8220;Retirement Benefits,&#8221; for fair values of benefit plan assets):</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Fair values are based on quoted market prices, which represent the net asset value (&#8220;NAV&#8221;) of the shares held.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Fair values are estimated based on the plan&#8217;s proportionate share of the undistributed partners&#8217; capital as reported in audited financial statements of the partnership. In accordance with FASB guidance, certain investments that are measured at fair value using the NAV per share as a practical expedient or the fair value measurement alternative have been classified in the fair value hierarchy. The fair value amounts presented are intended to permit reconciliation of the fair value hierarchy to the total investments of the master trust.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Commingled fund</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Fair value is based on NAV per fund share, primarily derived from the quoted prices in active markets on the underlying equity securities.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract with insurance company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Fair value of the contract in the insurance company general investment account is determined by the insurance company based on the fair value of the underlying investments of the account.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in DOL 103-12 trust:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Fair value is based on the plan&#8217;s proportionate share of the fair value of investments held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity (&#8220;DOL 103-12 trust&#8221;) as reported in the audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of the trust.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Life insurance contracts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Fair value is based on the cash surrender value of the policies as reported by the insurer.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad">Derivatives - other assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c">Derivatives - other liabilities</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0">Derivatives - other assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132">Derivatives - other liabilities</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset-Backed Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76">(1)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b">19</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c">(22)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no individually material transfers into or out of Level III during the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, &#8220;Business Acquisitions,&#8221; we completed our acquisition of Integra in 2022 and the acquisitions of myNEXUS and MMM </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during 2021. The net assets acquired in our acquisitions of Integra, myNEXUS, and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December&#160;31, 2022 or 2021.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value on the consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other invested assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Other invested assets primarily include our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities&#8217; undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt&#8212;commercial paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt&#8212;senior unsecured notes and surplus notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt&#8212;convertible debentures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887897216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income taxes at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal and state intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (including Puerto Rico) intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognized $137 and $103 of deferred tax asset under the caption &#8220;Other noncurrent assets&#8221; at December 31, 2022 and 2021, respectively. We recognized $2,034 and $2,805 of deferred tax liability under the caption &#8220;Deferred tax liabilities, net&#8221; at December 31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have established U.S. deferred taxes for undistributed earnings from certain non-U.S. subsidiaries, which are included in the Investment basis component above, consistent with prior years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020 consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (including Puerto Rico)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local current tax expense is reported gross of federal benefit in the preceding table, and includes amounts related to audit settlements, uncertain tax positions, state tax credits and true up of prior years&#8217; tax. Such items are included on a net of federal tax basis in multiple lines in the following rate reconciliation table.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax expense/benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax exempt interest and dividends received deduction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIP fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis adjustments from recent acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we recognized income tax expense of $1,750, or $7.21 per diluted share. The decrease in effective income tax rate is primarily due to the impact of geographic changes in the mix of 2022 earnings.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized income tax expense of $1,830, or $7.41 per diluted share. The HIP Fee payment was eliminated beginning in 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recognized income tax expense of $1,666, or $6.55 per diluted share, which included income tax expense of $330, or $1.30 per diluted share, as a result of the non-tax deductibility of the HIP Fee payment.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is included in the amounts described in the following paragraph. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was $328 and $250 at December&#160;31, 2022 and 2021, respectively. Also included in the table above, at December&#160;31, 2022, is $2 that would be recognized as an adjustment to additional paid-in capital, which would not affect our effective tax rate. In addition to the contingent liabilities included in the table above, we filed protective state income tax refund claims of approximately $92 and $310 for 2022 and 2017, respectively. There were no equivalent protective state income tax refund claims filed in 2021, 2020, 2019 or 2018.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020 we recognized net interest expense of $13, $9 and $7, respectively. We had accrued approximately $55 and $42 for the payment of interest at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, as further described below, certain tax years remain open to examination by the Internal Revenue Service (&#8220;IRS&#8221;) and various state, local and foreign authorities. As a result of these examinations and discussions with taxing agencies, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could be reduced within a range of approximately $33 to $143.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member of the IRS Compliance Assurance Process (&#8220;CAP&#8221;). The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the IRS examination of our 2022 and 2021 tax years continues to be in process.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported in selling, general and administrative expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal net operating loss carryforwards of $160 that will expire beginning 2032 through 2042 and $109 that have an indefinite carryforward period. State net operating loss carryforwards expire beginning 2023 through 2042, with some having an indefinite carryforward period.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes receivable totaled $440 and $173 at December&#160;31, 2022 and 2021, respectively. We recognize the income tax receivable as an asset under the caption &#8220;Other current assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, federal income taxes paid totaled $1,594, $1,299 and $1,790, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937895276384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property And Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of property and equipment at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, furniture and other equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2022, 2021 and 2020 was $123, $136 and $176, respectively. Amortization expense on computer software and leasehold improvements for 2022, 2021 and 2020 was $661, $532 and $462, respectively, which includes amortization expense on computer software, both purchased and internally developed, for 2022, 2021 and 2020 of $599, $485 and $412, respectively. Capitalized costs related to the internal development of software of $5,354 and $5,626 at December&#160;31, 2022 and 2021, respectively, are reported with computer software.</span></div>Impairment of property and equipment for the years ended December&#160;31, 2022, 2021 and 2020 was $7, $73, and $198, respectively, which is included in selling, general and administrative expenses and primarily related to our activities disclosed in Note 4, &#8220;Business Optimization Initiatives.&#8221;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886497472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill And Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill And Other Intangible Assets</a></td>
<td class="text">Goodwill and Other Intangible Assets<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the change in the carrying amount of goodwill for our segments (see Note 20, &#8220;Segment Information&#8221;) for 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment as of December&#160;31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2022, 2021 and 2020. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. For quantitative testing, the fair values are estimated using the projected income and market valuation approaches, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections, income projections, cash flows and discount rates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not incur any impairment losses in 2022, 2021 or 2020, as the estimated fair values of our reporting units were substantially in excess of their carrying values.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of other intangible assets as of December&#160;31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:35.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.858%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield and other trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, due to our acquisition of Integra, we recorded intangible assets and due to our new branding strategy, reclassified $308 of trademarks with indefinite lives to Intangible assets with finite lives - Other. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the estimated amortization expense for each of the five succeeding years is as follows: 2023, $806; 2024, $370; 2025, $311; 2026, $258; and 2027, $221.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894870000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Elevance Health Cash Balance Plan A (formerly the Anthem Cash Balance Plan A) and the Elevance Health Cash Balance Plan B (formerly the Anthem Cash Balance Plan B) are cash balance pension plans covering certain eligible employees of the affiliated companies that participate in these plans. Effective January&#160;1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules continued to accrue benefits. Participants who did not receive credits and/or benefit accruals were included in the Elevance Health Cash Balance Plan A, while employees who were still receiving credits and/or benefits participated in the Elevance Health Cash Balance Plan B. Effective January 1, 2019, benefits under the Elevance Health Cash Balance Plan B were curtailed. All grandfathered participants no longer have pay credits added to their accounts but continue to earn interest on existing account balances. Participants continue to earn years of pension service for vesting purposes. Several pension plans acquired through various corporate mergers and acquisitions were merged into these plans in prior years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employees&#8217; Retirement Plan of Blue Cross of California (the &#8220;BCC Plan&#8221;) is a defined benefit pension plan that covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective January&#160;1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired or rehired after December&#160;31, 2006 are eligible to participate in the BCC Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the plans&#8217; assets consist primarily of equity securities, fixed maturity securities, investment funds and cash. The funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), as further amended by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to provide assets sufficient to meet the benefits to be paid to plan participants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables disclose consolidated &#8220;pension benefits,&#8221; which include the defined benefit pension plans described above, and consolidated &#8220;other benefits,&#8221; which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were computed using assumptions at the December&#160;31 measurement dates.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the benefit obligation is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of plan assets are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net amount included in the consolidated balance sheets is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (loss) gain</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount before tax at December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation for the defined benefit pension plans was $1,413 and $1,857 at December&#160;31, 2022 and 2021, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, certain pension plans had accumulated benefit obligations in excess of plan assets. Such plans had accumulated benefit obligation and fair value of plan assets of $44 and $0, respectively. In addition, certain plans had projected benefit obligations in excess of plan assets. Such plans had projected benefit obligation and fair value of plan assets of $44 and $0, respectively.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit credit included in the consolidated statements of income are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a">Settlement loss</span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit credit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit credit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we incurred total settlement losses of $28, $26 and $29, respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was 8.00% for 2023, with a gradual decline to 4.50% by the year 2035. The assumed healthcare cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was 6.50% for 2023, with a gradual decline to 4.50% by the year 2035. These estimated trend rates are subject to change in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across a range of sectors and levels of capitalization to maximize long-term return for a prudent level of risk.&#160;The weighted-average target allocation for pension benefit plan assets is 37% equity securities, 58% fixed maturity securities, and 5% to all other types of investments.&#160;Equity securities primarily include a mix of domestic securities, foreign securities and mutual funds invested in equities.&#160;Fixed maturity securities primarily include treasury securities, corporate bonds and asset-backed investments issued by corporations and the U.S. government.&#160;Other types of investments include insurance contracts </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed specifically for employee benefit plans, a commingled fund comprised primarily of equity securities and certain partnership interests.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partnerships hold various types of underlying assets such as real estate and investments in oil and gas companies. Generally, the partnership interests are not redeemable and are transferable only with the consent of the general partner. Unfunded commitments related to all partnership interests totaled approximately $2 and $3 at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were invested in Elevance Health common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2022, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $36, and excluding estimated claims settlements to be paid from other benefit assets of ($17), are as follows (see Note 7, &#8220;Fair Value,&#8221; for additional information regarding the definition of level inputs):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance company contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in DOL 103-12 trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other benefit assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2021, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $48, and excluding estimated claims settlements to be paid from other benefit assets of ($29), are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance company contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in DOL 103-12 trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other benefit assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Company<br/>Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life<br/>Insurance<br/>Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other transfers into or out of Level III during the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended December&#160;31, 2022, 2021 and 2020, no material contributions were necessary to meet ERISA required funding levels. However, during each of the years ended December&#160;31, 2022, 2021 and 2020, we made tax deductible discretionary contributions to the pension benefit plans of $4, $7, and $7, respectively. Employer contributions to other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as appropriate, are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>In addition to the defined benefit plans, we maintain the Elevance Health 401(k) Plan (formerly the Anthem 401(k) Plan), which is a qualified defined contribution plan covering substantially all employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled $275, $241 and $221 during 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937895276384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MedicalClaimsPayableAbstract', window );"><strong>Medical Claims Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Claims Payable</a></td>
<td class="text">Medical Claims Payable<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, &#8220;Segment Information&#8221;), for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,515&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period-end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated. The prior year redundancy of $869 shown above for the year ended December&#160;31, 2022 represents an estimate based on paid claim activity from January&#160;1, 2022 to December&#160;31, 2022. Medical claim liabilities are usually described as having a &#8220;short tail,&#8221; which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the $869 redundancy relates to claims incurred in calendar year 2021. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December&#160;31, 2022, 2021 and 2020, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. We had increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that lead to the increased estimation uncertainty.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Favorable Developments<br/>by&#160;Changes in Key Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed trend factors</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed completion factors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,703)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in 2022 resulted primarily from trend factors in late 2021 developing more favorably than originally expected as well as a smaller contribution from completion factor development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in 2021 resulted primarily from trend factors in late 2020 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in 2020 resulted primarily from trend factors in late 2019 developing more favorably than originally expected as well as a smaller contribution from completion factor development.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for the Commercial &amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for the Commercial &amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp; Specialty Business was $52, $266 and $3,796 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for the Commercial &amp; Specialty Business was 80, 87 and 81 for the claim years 2020 and prior, 2021 and 2022, respectively. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $142, $325 and $10,462 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for the Government Business was 251, 325 and 298 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for Other was $1, $6 and $292 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for Other was 29, 28, and 25 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred claims development, paid claims development and cumulative number of reported claims for the years ended December&#160;31, 2020 and 2021 for our Commercial &amp; Specialty Business, Government Business and Other is unaudited and presented as supplementary information. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative number of reported claims for each claim year for our Commercial &amp; Specialty Business, Government Business and Other have been developed using historical data captured by our claim payment systems. The provided claim </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are not a precise tool for understanding utilization of medical services. They could be impacted by a variety of factors, including changes in provider billing practices, provider reimbursement arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative number of reported claims may not be comparable to similar measures reported by other health benefits companies. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the Commercial &amp; Specialty Business, Government Business and Other incurred and paid claims development information for the three years ended December&#160;31, 2022, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December&#160;31, 2022, is as follows: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_MedicalClaimsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_MedicalClaimsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890874544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Borrowings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the &#8220;FHLBs&#8221;). As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At December&#160;31, 2022 and 2021, $265 and $275, respectively, were outstanding under our short-term FHLB borrowings. Outstanding short-term FHLB borrowings at December&#160;31, 2022 had fixed interest rates of 4.240%.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the &#8220;Subsidiary Credit Facilities&#8221;) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200. The interest rate on each line of credit is based on the LIBOR rate plus a predetermined rate. Our ability to borrow under the lines of credit is subject to compliance with certain covenants. At each of December 31, 2022 and 2021, $0 was outstanding under our Subsidiary Credit Facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-term debt at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.950%, due 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125%, due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300%, due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.450%, due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.350%, due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500%, due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.375%, due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.350%, due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.500%, due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.650%, due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101%, due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.875%, due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250%, due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.550%, due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.100%, due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.500%, due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.950%, due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.850%, due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375%, due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.800%, due 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625%, due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650%, due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650%, due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.100%, due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375%, due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%, due 2048</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.700%, due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125%, due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.600%, due 2051</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%, due 2052</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.100%, due 2052</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.850%, due 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surplus note:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.000%, due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior convertible debentures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.750%, due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable rate debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,349&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings and the Subsidiary Credit Facilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally issue senior unsecured notes (&#8220;Notes&#8221;) for long-term borrowing purposes. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the &#8220;2026 Notes&#8221;), $1,000 aggregate principal amount of 4.750% Notes due 2033 (the &#8220;2033 Notes&#8221;), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the &#8220;2053 Notes&#8221;) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2022, we repaid, at maturity, the $750 outstanding balance of our 2.950% senior unsecured notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2022, we issued $400 aggregate principal amount of 5.350% Notes due 2025, $650 aggregate principal amount of 5.500% Notes due 2032 and $750 aggregate principal amount of 6.100% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on April 15 and October 15 of each year, commencing April 15, 2023. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 and $700 aggregate principal amount of 4.550% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2021, we redeemed the $700 outstanding principal balance of our 3.700% Notes due August 15, 2021 at a redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, we issued $500 aggregate principal amount of 0.450% Notes due 2023, $750 aggregate principal amount of 1.500% Notes due 2026, $1,000 aggregate principal amount of 2.550% Notes due 2031 and $1,250 aggregate principal amount of 3.600% Notes due 2051 under our shelf registration statement. Interest on these notes is payable semiannually in arrears on March 15 and September 15 of each year, commencing September 15, 2021. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the year ended December 31, 2021, we repurchased $52 of outstanding principal amount of certain other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $67. We recognized a loss on extinguishment of debt of $15 for the repurchase of these notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 23, 2020, we repaid, at maturity, the $900 outstanding balance of our 2.500% senior unsecured notes. On August 17, 2020, we repaid, at maturity, the $700 outstanding balance of our 4.350% senior unsecured notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the year ended December 31, 2020, we repurchased $79 of outstanding principal amount of certain other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $109. We recognized a loss on extinguishment of debt of $30 for the repurchase of these notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2020, we issued $400 aggregate principal amount of additional senior notes pursuant to a reopening of our existing 2.375% Notes due 2025 (the &#8220;2025 Notes&#8221;), $1,100 aggregate principal amount of 2.250% Notes due 2030 (the &#8220;2030 Notes&#8221;), and $1,000 aggregate principal amount of 3.125% Notes due 2050 (the &#8220;2050 Notes&#8221;) under our shelf registration statement. The 2025 Notes constitute an additional issuance of our 2.375% notes due 2025, of which $850 aggregate principal amount was issued on September 9, 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 2025 Notes is deemed to have accrued from January 15, 2020 and is payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2020. Interest on the 2030 Notes and 2050 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2020. The proceeds were used for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc. (&#8220;Anthem Insurance&#8221;), a wholly owned subsidiary, and is subordinate in right of payment to all of Anthem Insurance&#8217;s existing and future indebtedness. Any payment of interest or principal on the surplus note may be made only with the prior approval of the Indiana Department of Insurance (&#8220;IDOI&#8221;) and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana insurance laws.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a senior revolving credit facility (the &#8220;5-Year Facility&#8221;) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the &#8220;2021 364-Day Facility&#8221;). In June 2021, we terminated our 364-day senior revolving credit facility (the &#8220;prior 364-Day Facility&#8221;), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.&#160;As of December&#160;31, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.9%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December&#160;31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the years ended December&#160;31, 2022 or 2021. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. At December&#160;31, 2022, we had $0 outstanding under our commercial paper program. At December&#160;31, 2021, we had $300 outstanding under our commercial paper program with a weighted-average interest rate of 0.150%. Commercial paper borrowings have been classified as long-term debt at December&#160;31, 2022 and 2021, as our general practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year, and we have the ability to redeem our commercial paper with borrowings under the credit facilities described above. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debentures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;9, 2012, we issued $1,500 of senior convertible debentures (the &#8220;Debentures&#8221;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Debentures are governed by an indenture dated as of October&#160;9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;Indenture&#8221;). The Debentures bear interest at a rate of 2.750%&#160;per year, payable semi-annually in arrears in cash on April&#160;15 and October&#160;15 of each year, and mature on October&#160;15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. The Debentures also have a contingent interest feature that requires us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October&#160;15, 2022. As of October 15, 2022, one of these events had occurred and contingent interest began accruing on the Debentures at a rate of 0.50% of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest will be payable on April 15, 2023, to holders of the Debentures as of the April 1, 2023 record date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April&#160;15, 2042, only under the following circumstances: (1)&#160;during any fiscal quarter if the last reported sale price of our common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2)&#160;during the five business day period after any 10 consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the applicable conversion rate on each such day; (3)&#160;if we call any or all of the Debentures for redemption, at any time prior to the close of business on the business day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events, as defined in the Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately preceding the Debentures&#8217; maturity date of October 15, 2042, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2023, we delivered notice to redeem all of the outstanding Debentures. The Debentures will be redeemed on March 15, 2023 at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock or a combination thereof based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures was 13.2319&#160;shares of our common stock per Debenture, which represented a 25% conversion premium based on the closing price of $60.46 per share of our common stock on October&#160;2, 2012 (the date the Debentures&#8217; terms were finalized) and is equivalent to an initial conversion price of $75.575&#160;per share of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, $41 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversion with cash for total payments of $299. During the year ended December&#160;31, 2021, $54 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $302. We recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on the conversion settlement dates. During the year ended December&#160;31, 2020, $56 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $222. We recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on the conversion settlement dates.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our common stock was last traded at a price of $512.97 per share. If the remaining Debentures had been converted or matured at December&#160;31, 2022, we would have been obligated to pay the principal of the Debentures plus an amount in cash or shares equal to $402. The Debentures and underlying shares of our common stock have not been and will not be registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option, net of deferred taxes and equity issuance costs, was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets.We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, at December&#160;31, 2022, the related balances, conversion rate and conversion price of the Debentures:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net debt carrying amount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion rate (shares of common stock per $1,000 of principal amount)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective conversion price (per $1,000 of principal amount)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.8139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $2, $4 and $6, respectively, of interest expense related to the Debentures, of which $2, $3 and $5, respectively, represented interest expense recognized at the stated interest rate of 2.750% and $0, $1 and $1, respectively, represented interest expense resulting from amortization of the debt discount. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid on our total outstanding debt during 2022, 2021 and 2020 was $878, $822, and $794, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all applicable covenants under all of our outstanding debt agreements at December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of all long-term debt outstanding at December&#160;31, 2022 are as follows: 2023, $1,500; 2024, $1,647; 2025, $1,650; 2026, $746; 2027, $1,592 and thereafter, $16,714.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890706672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments And Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. </span></div><div style="margin-bottom:9pt;padding-right:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at December&#160;31, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross Blue Shield Antitrust Litigation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the &#8220;Blue plans&#8221;) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Blue Cross Blue Shield Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is pending in the U.S. District Court for the Northern District of Alabama (the &#8220;Court&#8221;). Generally, the suits allege that the BCBSA and the Blue plans have </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (&#8220;Sherman Act&#8221;) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Court issued an order on the parties&#8217; cross motions for partial summary judgment, determining that the defendants&#8217; aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the &#8220;Subscriber Settlement Agreement&#8221;), which agreement required the Court&#8217;s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the &#8220;national best efforts&#8221; rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members. The notice process was completed in March 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the &#8220;Final Approval Order&#8221;). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which was previously accrued in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event that all appellate rights are exhausted in a manner that affirms the Court&#8217;s Final Approval Order, the defendants&#8217; payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to the providers&#8217; claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants&#8217; motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs&#8217; motion for partial summary judgment, holding that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio v. American Express Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants&#8217; motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the &#8220;national best efforts&#8221; rule, the rule of reason applies to the provider plaintiffs&#8217; market allocation conspiracy claims, and (ii) denying the provider plaintiffs&#8217; motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers&#8217; group boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to providers&#8217; renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 2:21-cv-01209-AMM (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JetBlue Airways Corp., et al. v. Anthem, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00558-GMB (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00265-RDP (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bed Bath &amp; Beyond Inc. v. Anthem, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-01256-SGC (N.D. Ala.);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Hoover, et al. v. Blue Cross Blue Shield Association, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00261-RDP (N.D. Ala.); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VHS Liquidating Trust v. Blue Cross of California, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross of California Taxation Litigation</span></div><div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (&#8220;BCC&#8221;) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the &#8220;Superior Court&#8221;) captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael D. Myers v. State Board of Equalization, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an &#8220;insurer&#8221; for purposes of taxation despite acknowledging it is not an &#8220;insurer&#8221; under regulatory law. At the time, under California law, &#8220;insurers&#8221; were required to pay a gross premiums tax (&#8220;GPT&#8221;) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (&#8220;CFT&#8221;), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.</span></div><div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Superior Court denied BCC&#8217;s motion for judgment on the pleadings and similar motions brought by other entities. In December 2020, the Superior Court granted BCC&#8217;s motion for summary judgment, dismissing the plaintiff&#8217;s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. BCC&#8217;s responding brief was filed in March 2022 and Plaintiff&#8217;s reply was filed in May 2022. We estimate that the appeal will be heard in March 2023. We intend to vigorously defend the appeal of this lawsuit.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Express Scripts, Inc. Pharmacy Benefit Management Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we filed a lawsuit against Express Scripts, Inc. (&#8220;Express Scripts&#8221;), our vendor at the time for PBM services, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anthem, Inc. v. Express Scripts, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the Southern District of New York (the &#8220;District Court&#8221;). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the &#8220;ESI PBM Agreement&#8221;), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts&#8217; counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts&#8217; only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts&#8217; motion for summary </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Annual Report on Form 10-K are (i) our operational breach claim based on Express Scripts&#8217; prior authorization processes and (ii) Express Scripts&#8217; counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Risk Adjustment Litigation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. Department of Justice (&#8220;DOJ&#8221;) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the &#8220;New York District Court&#8221;) in a case captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Anthem, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The DOJ&#8217;s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in that court. In November 2022, we filed an answer. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investigations of CareMore and HealthSun</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (&#8220;CareMore&#8221;), one of our California subsidiaries, and HealthSun Health Plans, Inc. (&#8220;HealthSun&#8221;), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore&#8217;s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (&#8220;HMOs&#8221;) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at December&#160;31, 2022 is approximately $761. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, we began using our pharmacy benefits manager CarelonRx, formerly known as IngenioRx, to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. CarelonRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vulnerability from Concentrations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which we conduct business. As of December&#160;31, 2022, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890900400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalAbstract', window );"><strong>Banking Regulation, Total Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text">Capital Stock<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted the 2017 Elevance Health Incentive Compensation Plan, formerly known as the 2017 Anthem Incentive Compensation Plan (&#8220;2017 Incentive Plan&#8221;), which has been approved by our shareholders. The term of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The 2017 Incentive Plan limits the number of available shares for issuance to 37.5 shares, subject to adjustment as set forth in the 2017 Incentive Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest over three years in equal annual installments and generally have a term of ten years from the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also include one or more performance measures that must be met for the award to vest. For restricted stock or restricted stock </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units without performance measures, the restrictions lapse in three equal annual installments. Restricted stock or restricted stock units with performance measures vest in three year installments. Performance units issued in 2022 will vest in 2025, based on certain revenue and earnings targets over the three year period of 2022 to 2024. Performance units issued in 2021 will vest in 2024, based on certain revenue and earnings targets over the three year period of 2021 to 2023. Performance units issued in 2020 will vest in 2023, based on certain revenue and earnings targets over the three year period of 2020 to 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, we recognized share-based compensation expense of $264, $255 and $283, respectively, as well as related tax benefits of $66, $65 and $74, respectively. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Option Price <br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 amounted to $120, $121 and $147, respectively. We recognized tax benefits of $31, $32 and $40 during the years ended December&#160;31, 2022, 2021 and 2020, respectively, from option exercises and disqualifying dispositions. During the years ended December&#160;31, 2022, 2021 and 2020, we received cash of $120, $148 and $129, respectively, from exercises of stock options.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock awards that vested during the years ended December&#160;31, 2022, 2021 and 2020 was $261, $287 and $335, respectively.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock&#160;Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we granted approximately 0.2 restricted stock units that are contingent upon us achieving certain revenue and earnings targets over the three year period of 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024, based on results in the three year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2022, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock, including restricted stock units and performance units, amounted to $35 and $176, respectively, which will be amortized over the weighted-average remaining requisite service periods of 9 months and 12 months, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were approximately 14.0 shares of common stock available for future grants under the 2017 Incentive Plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice model are based on an analysis of implied volatility of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the multiple-grant approach for recognizing compensation expense associated with each separately vesting portion of the share-based award.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (annual)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values were determined for the years ending December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The binomial lattice option-pricing model requires the input of subjective assumptions including the expected stock price volatility. Because our stock option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan (the &#8220;Stock Purchase Plan&#8221;), which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in Elevance Health. Pursuant to the terms of the Stock Purchase Plan, an eligible employee is permitted to purchase no more than $25,000 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter. Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the employee&#8217;s investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a discounted price per share of 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter purchase period. The Stock Purchase Plan discount was recognized as compensation expense for the year ended December&#160;31, 2022, based on GAAP guidance. During the years ended December&#160;31, 2022, 2021 and 2020, we issued 0.1, 0.1 and 0.2 shares, respectively, under the Stock Purchase Plan, and we received cash of $62, $55 and $47, respectively, for such shares. As of December&#160;31, 2022, 4.3 shares were available for issuance under the Stock Purchase Plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Capital and Stock Repurchase Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the cash dividend activity for the years ended December&#160;31, 2022 and 2021 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Dividend <br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 19, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 18, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 5, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 26, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 24, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 19, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2023, our Audit Committee declared a quarterly cash dividend to shareholders of $1.48 per share on the outstanding shares of our common stock. This quarterly dividend is payable on March 24, 2023 to the shareholders of record as of March 10, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Board of Directors&#8217; authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time. We intend to utilize this authorization over a multi-year period, subject to market and industry conditions. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the years ended December&#160;31, 2022 and 2021 is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at end of year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding the use of capital for debt security repurchases, see Note 13, &#8220;Debt.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894928176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated Other Comprehensive (Loss) Income <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive (loss) income at December&#160;31, 2022, 2021, and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $926, $121, and $(160), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income, net of tax benefit (expense) of $(94), $27, and $(13), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) benefit of $0, $(1),and $0, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(6), $(3), and $(3), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax expense of $(23), $(36), and $(2), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax benefit (expense) of $6, $2, and $(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $809, $110, and $(154), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to noncontrolling interests, net of tax (expense) benefit of $(3), $1, and $0, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139938006345536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceTextBlock', window );">Reinsurance</a></td>
<td class="text">Reinsurance<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,867</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,149</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,298</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,229</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,373</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,109</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage&#8212;assumed to net premiums</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between written premiums and earned premiums is immaterial in each of the years presented above.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net premiums earned by segment (see Note 20, &#8220;Segment Information&#8221;) for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of reinsurance on benefit expense for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27830-158548<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6816-158387<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27758-158548<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937893412448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 1 year to 12 years.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities as disclosed in Note 4, &#8220;Business Optimization Initiatives,&#8221; include reducing our office space footprint. As a result, we performed an interim impairment test during the years ended December 31, 2022, 2021 and 2020, and recorded impairment charges of $34, $136 and $258, respectively, for impairment and abandonment of ROU assets which are included in the operating lease expense shown above.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.828%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new lease liabilities, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937893384720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings per Share<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share at December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share&#8212;weighted-average shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities&#8212;employee stock options, non-vested restricted stock awards, convertible debentures and equity units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, weighted-average shares related to certain stock options of 0.4, 0.2 and 1.2, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. </span></div>During the years ended December&#160;31, 2022, 2021 and 2020, we issued approximately 0.2, 0.3 and 0.3 restricted stock units, respectively, of which vesting was contingent upon us meeting certain earnings targets. Contingent restricted stock units are excluded from the denominator for diluted earnings per share and are included only if and when the contingency is met. The 2022 contingent restricted stock units are being measured over the three year period of 2022 through 2024, the 2021 contingent restricted stock units are being measured over the three year period of 2021 through 2023 and the 2020 contingent restricted stock units are being measured over the three year period of 2020 through 2022. Contingent restricted stock units generally vest in March of the year following each measurement period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937893311600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2022, we managed and presented our operations through four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Commercial &amp; Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members. The Commercial &amp; Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services (&#8220;NGS&#8221;) and services provided to the federal government in connection with the FEHB business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CarelonRx segment includes our PBM business. CarelonRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other segment includes our Diversified Business Group, now known as Carelon Services, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 &#8220;Organization&#8221;, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. As we continue our journey to evolve our business from a traditional health insurance company into a lifetime, trusted health partner, we are evaluating and making changes to how we manage our business. This included a review of the products in each of our operating segments, which resulted in restructurings between some of our operating segments. Therefore, our reportable segment presentation in 2023 and its composition will reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources on January 1, 2023. As a result of these changes, beginning with our Quarterly Report on Form 10-Q for the first quarter of 2023, we will report our results in the following four reportable segments: (i) Health Benefits, which will combine our existing Commercial &amp; Specialty Business and Government Business segments; (ii) our existing CarelonRx segment; (iii) Carelon Services (our former Diversified Business Group), which will be carved out from our existing Other segment; and (iv) Corporate and Other, which will include businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments. We expect to reclassify previously reported information to conform to the new presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefit and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, as well as certain back-office services provided by our international businesses, and are recorded at cost or management&#8217;s estimate of fair market value. These affiliated revenues are eliminated in consolidation. For segment reporting, we present all capitation risk arrangements on a gross basis; therefore, eliminations also include adjustments for capitated risk arrangements that are recognized on a net basis under GAAP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our participation in various federal government programs, we generated approximately 28% of our total consolidated revenues from agencies of the U.S. government for each of the years ended December&#160;31, 2022, 2021, and 2020. The majority of these revenues are contained in our Government Business segment. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, &#8220;Basis of Presentation and Significant Accounting Policies,&#8221; except that all capitation risk arrangements are reported on a gross basis with an adjustment included in eliminations for capitated risk arrangements that are presented on a net basis under GAAP. We evaluate performance of the reportable segments based on operating gain or loss as defined above. We evaluate net investment income, net gains (losses) on financial instruments, interest expense, amortization expense, gain or loss on extinguishment of debt, income taxes and assets and liabilities on a consolidated basis, as these items are managed in a corporate shared service environment and are not the responsibility of segment operating management.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major product revenues for each of the reportable segments for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental/Vision products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Commercial &amp; Specialty Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Government Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,810&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated health services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent fee-based product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such information.&#160;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments&#8217; operating revenue to the amounts of total revenues included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments&#8217; operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,639&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,867&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments&#8217; operating gain to income before income tax expense included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments&#8217; operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937893362896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsWe have an equity investment in APC Passe, LLC, which offers Medicaid products in Arkansas. During the years ended December&#160;31, 2022, 2021 and 2020, in the normal course of business, we assumed premiums of $501, $462 and $446, respectively, from APC Passe, LLC, which is included in our total assumed premiums (see Note 17, &#8220;Reinsurance&#8221;).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894928176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statutory Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_StatutoryInformationAbstract', window );"><strong>Statutory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_StatutoryInformationTextBlock', window );">Statutory Information</a></td>
<td class="text">Statutory Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance regulatory authorities, commonly referred to as statutory accounting, which vary in certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc., Beacon Health Options of California, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care (&#8220;DMHC&#8221;) and report their accounts in conformity with GAAP (these entities are collectively referred to as the &#8220;DMHC regulated entities&#8221;). Typical differences of GAAP reporting as compared to statutory reporting are the recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of Insurance Commissioners (&#8220;NAIC&#8221;) developed a codified version of the statutory accounting principles, designed to foster more consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set forth in a variety of publications of the NAIC as well as state laws, regulations and general administrative rules.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital (&#8220;RBC&#8221;) requirements. RBC is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied to certain financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December&#160;31, 2022 and 2021, all of our regulated subsidiaries exceeded the minimum applicable mandatory RBC requirements and/or capital and solvency requirements of their applicable governmental regulator. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately $7,900 and $6,962 as of December&#160;31, 2022 and 2021, respectively. The tangible net equity required for the DMHC regulated entities was approximately $710 and $690 as of December&#160;31, 2022 and 2021, respectively. Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC regulated entities, was $19,048 and $16,178 at December&#160;31, 2022 and 2021, respectively. GAAP equity of the DMHC regulated entities was $3,795 and $3,886 at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary&#8217;s domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC. During 2022, our insurance and HMO </span></div>subsidiaries paid aggregate cash dividends of $3,097 to the parent company, including cash dividends which required prior approval from regulatory authorities. We currently estimate that approximately $3,500 of dividends will be paid to the parent company in 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_StatutoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_StatutoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_StatutoryInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory Information [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_StatutoryInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888602512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information Of Registrant<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Schedule II-Condensed Financial Information Of Registrant</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed maturity securities (amortized cost of $175 and $512; allowance for credit losses of $0 and $1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net due from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net due to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies&#8212;Note 5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Income</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative fees and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income tax credits and equity in net income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Comprehensive Income</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains/losses on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-credit component of impairment losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains/losses on cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net periodic pension and postretirement costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevance Health, Inc. (Parent Company Only)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales, maturities, calls and redemptions of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment (issuance) of note to subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalization of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in securities lending collateral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment, net of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,821)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,926)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (repayments of) proceeds from commercial paper borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in securities lending payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid through withholding of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,464)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,002)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;Basis of Presentation and Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the parent company only financial statements of Elevance Health, Inc. (&#8220;Elevance Health&#8221;), Elevance Health&#8217;s investment in subsidiaries is stated at cost plus equity in undistributed earnings of the subsidiaries. Elevance Health&#8217;s share of net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of Elevance Health.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health&#8217;s parent company only financial statements should be read in conjunction with Elevance Health&#8217;s audited consolidated financial statements and the accompanying notes included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;Subsidiary Transactions</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends from Subsidiaries</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health received cash dividends from subsidiaries of $3,097, $3,134 and $3,618 during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends to Subsidiaries</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Elevance Health own shares of Elevance Health common stock. Elevance Health paid cash dividends to subsidiaries related to these shares of common stock in the amount of $61, $54 and $46 during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Subsidiaries</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital contributions to subsidiaries were $411, $3,271 and $2,460 during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amounts Due From and To Subsidiaries</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, Elevance Health reported amounts due (to) from subsidiaries of $(789) and $446, respectively. The amounts due (to) and from subsidiaries primarily include amounts for allocated administrative expenses or daily cash management activities. These items are routinely settled, and as such, are classified as current liabilities or assets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Elevance Health entered into a short-term loan agreement with a subsidiary for the amount of $1,500, which is also included in amounts due from subsidiaries at December 31, 2021. This loan was repaid in February 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees on Behalf of Subsidiaries</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health guarantees contractual or financial obligations or solvency requirements for certain of its subsidiaries. These guarantees approximated $550 at December&#160;31, 2022. There were no payments made on these guarantees in 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Derivative Financial Instruments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding derivative financial instruments contained in Note 6, &#8220;Derivative Financial Instruments,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Long-Term Debt</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding long-term debt contained in Note 13, &#8220;Debt,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Commitments and Contingencies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding commitments and contingencies contained in Note 14, &#8220;Commitments and Contingencies,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Capital Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information regarding capital stock contained in Note 15, &#8220;Capital Stock,&#8221; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI https://asc.fasb.org/extlink&amp;oid=126898705&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937879377136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis Of Presentation And Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis Of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements include the accounts of Elevance Health and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (&#8220;USD&#8221;). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in &#8220;Foreign currency translation adjustments&#8221; in our consolidated statements of comprehensive income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use Of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $258 and $173 at December&#160;31, 2022 and 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as &#8220;available-for-sale&#8221; and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security&#8217;s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption &#8220;Other invested assets&#8221; in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div>We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported in other current assets on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current liabilities. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders&#8217; equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions.&#160;To the extent the loaned securities&#8217; value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall.&#160;As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $152 and $142 at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $68 and $50 at December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $744 and $648 at December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws and are reported net on our consolidated balance sheets. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact </span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the &#8220;Corporate AMT&#8221;) that became effective for us beginning January 1, 2023. We have elected to account for the effects of the Corporate AMT on deferred tax assets and carryforwards and tax credits in the period they arise. Additionally, the Inflation Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31, 2022. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of operations, cash flows or related disclosures.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property And Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3">fifteen</span> to thirty years for buildings and improvements, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5">three</span> to five years for computer equipment and software, and the lesser of the remaining life of the building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea">three</span> to ten years.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill And Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable assumptions and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry&#8217;s weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies in our industry and are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;); and book value of invested capital. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset&#8217;s fair value. This determination consists of a one-step test comparing the fair value of a reporting unit, including goodwill, to its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit&#8217;s carrying amount over its fair value. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December&#160;31, 2022, we believe there were no material concentrations of credit risk with any individual counterparty.</span></div>We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Retirement Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension </span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan&#8217;s cash flows to determine the plan&#8217;s obligations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy', window );">Medical Claims Payable</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims Payable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1)&#160;an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2)&#160;claims reported to us and processed through our systems but not yet paid.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into &#8220;claim triangles,&#8221; which compare claim incurred dates to the dates of claim payments. This information is analyzed to create &#8220;completion factors&#8221; that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels (&#8220;trend factors&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December&#160;31, 2022 or 2021.</span></div>Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_OtherPolicyholderLiabilitiesPolicyTextBlock', window );">Other Policyholder Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Policyholder Liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (&#8220;MLR&#8221;), the relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively the &#8220;ACA&#8221;). If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with regulations issued by the Department of Health and Human Services (&#8220;HHS&#8221;). Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy', window );">Reserves For Future Policy Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Future Policy Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Premiums for risk-based contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other regulatory requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final amounts paid, the adjustments are included in earnings in the period of final settlement. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative fees and other revenue include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">groups an administrative fee, which is based on the number of members in a group and the group&#8217;s claim experience. In addition, administrative fees and other revenue include amounts received for the administration of Medicare, certain other government programs, and administrative services arrangements of our Carelon (Diversified Business Group) subsidiaries, now known as Carelon. Generally, these fee-based arrangements include services which constitute a single suite of services provided and for which consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with premiums, these fee-based arrangements may include terms with retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable consideration within the transaction price. As such, these fee-based arrangements contain a single performance obligation that constitutes a series, and revenue is recognized over time as the services are performed. All benefit payments under these programs are excluded from benefit expense. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of whether services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be recognized requires significant judgment in the determination of the level of achievement of performance incentives, service level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue includes revenue for services performed by our CarelonRx PBM for unaffiliated PBM customers. Unaffiliated PBM customers include our fee-based groups that have contracted with CarelonRx for PBM services and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in consolidation. Product revenue for PBM services is recognized using the gross method at the negotiated contract price when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer. CarelonRx determined it is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary management); its control over establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the pricing for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling the promise to provide PBM services. Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments made by or on behalf of the customer, and administrative fees. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in exchange for the products or services provided.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at December&#160;31, 2022. Revenue recognized in 2022 and 2021 from performance obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Products Sold</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span>CarelonRx&#8217;s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated PBM customers (net of rebates or discounts). Cost of products sold includes per-claim administrative fees for prescription fulfillment by its vendor and certain CarelonRx direct costs related to sales and administration of customer contracts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in our consolidated statements of income based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the consolidated statements of income.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent </span>agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Group risk-based customers with a smaller employee base. Products for Group risk-based customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual and Group markets, we offer products through state or federally facilitated marketplaces, or Public Exchanges, and off-exchange products.&#160;The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate image are expensed when first aired. Total advertising and marketing expense was $511, $588 and $558 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_HealthInsuranceProviderFeePolicyTextBlock', window );">Health Insurance Provider Fee</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Insurance Provider Fee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span> The ACA imposed an annual Health Insurance Provider Fee (&#8220;HIP Fee&#8221;) on health insurers that wrote certain types of health insurance on U.S. risks, which was permanently repealed effective January 1, 2021. The HIP Fee was non-deductible for federal income tax purposes.&#160;Our affected products were priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when it was in effect. The HIP Fee was $15,523 for 2020 and was permanently eliminated beginning in 2021. For the year ended December 31, 2020, we recognized $1,570 as selling, general and administrative expense related to the HIP Fee.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We recognize operating right-of-use (&#8220;ROU&#8221;) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized initial direct costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in selling, general and administrative expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of the ROU asset to its estimated undiscounted future cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is performed. An impairment loss is recorded for the difference of the ROU asset&#8217;s carrying value that exceeds its estimated discounted cash flows. During the years ended December 31, 2022, 2021 and 2020, we recorded $34, $136 and $258, respectively, for impairment and abandonment of ROU assets. See Note 18, &#8220;Leases&#8221; for additional information about the ROU asset impairment and abandonment charges.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and the number of shares assumed purchased represents the dilutive shares.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FASB issued Accounting Standards Update No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-01&#8221;). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of the </span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued Accounting Standards Update No. 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables&#8212;Nonrefundable Fees and Other Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-08&#8221;). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-06&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option; these amounts were not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services&#8212;Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-11&#8221;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services&#8212;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2018-12&#8221;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, with the amendments required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company&#8217;s reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#8217;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. The Company adopted the new standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the earliest period presented, January 1, 2021. The adoption did not have a material impact on our consolidated financial position, results of operations, cash flows, or related disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There were no other new accounting pronouncements that were issued or became effective during the year ended December&#160;31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_HealthInsuranceProviderFeePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Insurance Provider Fee [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_HealthInsuranceProviderFeePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_OtherPolicyholderLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Policyholder Liabilities Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_OtherPolicyholderLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14937-158439<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FuturePolicyBenefitsLiabilityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14754-158437<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14784-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890688064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired tangible assets (liabilities) at the acquisition date were:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical claims and other policyholder liabilities payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net tangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890770912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Optimization Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BusinessOptimizationInitiativesAbstract', window );"><strong>Business Optimization Initiatives [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Business Optimization Initiatives</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity for the year ended December 31, 2022 and ending balance at December&#160;31, 2022, related to the liability for employee termination costs previously incurred in 2020, is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Business Optimization Initiatives</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities for employee termination costs at January 1, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Releases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities for employee termination costs ending balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BusinessOptimizationInitiativesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Optimization Initiatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BusinessOptimizationInitiativesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887011344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Current And Long-term Fixed Maturity Securities, Available-for-sale</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at December&#160;31, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost&#160;or<br/>Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance For Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Aggregate Fair Values And Gross Unrealized Losses For Fixed Maturity Securities In An Unrealized Loss Position</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at December&#160;31, 2022 and 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at December&#160;31, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_InvestmentsinequitysecuritiesTableTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current equity securities at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeTextBlock', window );">Major Categories Of Net Investment Income</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major categories of net investment income for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Net Investment Gains/Losses</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains on fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains recognized on equity securities still held</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized (losses) gains recognized on equity securities sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_InvestmentsinequitysecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments in equity securities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_InvestmentsinequitysecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885833168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary Of Aggregate Contractual Or Notional Amounts And Estimated Fair Values</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual/<br/>Notional<br/>Amount</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps - fixed to floating</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Non-hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives embedded in convertible fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Maturity Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities/other assets/other liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts netted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps - fixed to floating</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Non-hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities/other assets/other liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets/other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal non-hedging</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts netted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary Of Outstanding Fair Value Hedges</a></td>
<td class="text">A summary of our outstanding fair value hedges at December&#160;31, 2022 and 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Fair Value Hedges</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/>Entered<br/>Into</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding&#160;Notional&#160;Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate<br/>Received</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 15, 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amount outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification in Which Hedged Item is Included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount of Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Realized Gains (Losses) On Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Non-hedging Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location of<br/>Gain (Loss) Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>(Loss) Gain<br/>Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives embedded in convertible securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d">(3)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635">(4)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (including swaptions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16">13</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db">10</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2">64</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27">(4)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collars</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf">4</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142">7</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf">(1)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663">(5)</span></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Futures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7">4</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937891012704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad">Derivatives - other assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c">Derivatives - other liabilities</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0">Derivatives - other assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132">Derivatives - other liabilities</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset-Backed Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76">(1)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b">19</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c">(22)</span></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains or losses included in net income related to assets still held at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock', window );">Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885788720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components Of Deferred Income Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income taxes at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal and state intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (including Puerto Rico) intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components Of Provision For Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020 consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (including Puerto Rico)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax expense/benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax exempt interest and dividends received deduction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIP fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis adjustments from recent acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885782976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of property and equipment at December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, furniture and other equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894932928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill And Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the change in the carrying amount of goodwill for our segments (see Note 20, &#8220;Segment Information&#8221;) for 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment as of December&#160;31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock', window );">Components Of Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of other intangible assets as of December&#160;31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:35.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.858%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield and other trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of present value of future profits of insurance contract acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122135039&amp;loc=d3e569990-122904<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887907104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock', window );">Reconciliation Of The Benefit Obligation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the benefit obligation is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Changes In The Fair Value Of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of plan assets are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Net Amount Included In Consolidated Balance Sheets</a></td>
<td class="text">The net amount included in the consolidated balance sheets is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock', window );">Net Amounts Included In Accumulated Other Comprehensive Loss (Income) That Have Not Been Recognized As Components Of Net Periodic Benefit Costs</a></td>
<td class="text">The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (loss) gain</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount before tax at December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock', window );">Schedule Of Assumptions Used In Calculating The Benefit Obligations</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components Of Net Periodic Benefit Cost (Credit)</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit credit included in the consolidated statements of income are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a">Settlement loss</span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit credit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit credit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock', window );">Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Fair Values of Pension Benefit Assets and Other Benefit Assets by Asset Category and Level Inputs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2022, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $36, and excluding estimated claims settlements to be paid from other benefit assets of ($17), are as follows (see Note 7, &#8220;Fair Value,&#8221; for additional information regarding the definition of level inputs):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance company contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in DOL 103-12 trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other benefit assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2021, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $48, and excluding estimated claims settlements to be paid from other benefit assets of ($29), are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance company contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension benefit assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other types of investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in DOL 103-12 trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other benefit assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock', window );">Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Company<br/>Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life<br/>Insurance<br/>Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets relating to assets still held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Estimated Future Payments For Pension Benefits And Other Benefits</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as appropriate, are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888690448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MedicalClaimsPayableAbstract', window );"><strong>Medical Claims Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, &#8220;Segment Information&#8221;), for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,515&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock', window );">(Favorable) Unfavorable Developments By Changes In Key Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December&#160;31, 2022, 2021 and 2020, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. We had increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that lead to the increased estimation uncertainty.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Favorable Developments<br/>by&#160;Changes in Key Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed trend factors</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed completion factors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,703)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock', window );">Reconciliation of Net Incurred Medical Claims to Benefit Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock', window );">Incurred and Paid Claims Development, Net of Reinsurance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for the Commercial &amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for the Commercial &amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp; Specialty Business was $52, $266 and $3,796 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for the Commercial &amp; Specialty Business was 80, 87 and 81 for the claim years 2020 and prior, 2021 and 2022, respectively. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $142, $325 and $10,462 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for the Government Business was 251, 325 and 298 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claim Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for Other was $1, $6 and $292 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the cumulative number of reported claims for Other was 29, 28, and 25 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock', window );">Reconciliation Of Claims Development To The Claims Liability</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the Commercial &amp; Specialty Business, Government Business and Other incurred and paid claims development information for the three years ended December&#160;31, 2022, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December&#160;31, 2022, is as follows: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_MedicalClaimsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_MedicalClaimsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reasons for the change in incurred claims and claim adjustment expenses recognized in the income statement attributable to insured events of prior fiscal years. Also includes disclosures of additional premiums or return premiums accrued as a result of changes in incurred claims and claim adjustment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.W)<br> -URI https://asc.fasb.org/extlink&amp;oid=27015833&amp;loc=d3e570705-122907<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885766000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">The Carrying Value Of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-term debt at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.950%, due 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125%, due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300%, due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.450%, due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.350%, due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500%, due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.375%, due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.350%, due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.500%, due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.650%, due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.101%, due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.875%, due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250%, due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.550%, due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.100%, due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.500%, due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.950%, due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.850%, due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375%, due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.800%, due 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625%, due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650%, due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650%, due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.100%, due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375%, due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%, due 2048</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.700%, due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125%, due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.600%, due 2051</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%, due 2052</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.100%, due 2052</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.850%, due 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surplus note:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.000%, due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior convertible debentures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.750%, due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable rate debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,349&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debenture Terms</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, at December&#160;31, 2022, the related balances, conversion rate and conversion price of the Debentures:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net debt carrying amount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion rate (shares of common stock per $1,000 of principal amount)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective conversion price (per $1,000 of principal amount)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.8139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894803280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalAbstract', window );"><strong>Banking Regulation, Total Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Option Price <br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock&#160;Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used to Estimate the Fair Values of Options Granted During the Periods</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (annual)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of Weighted-Average Fair Values Determined For the Periods</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values were determined for the years ending December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Summary of Cash Dividend Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the cash dividend activity for the years ended December&#160;31, 2022 and 2021 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Dividend <br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 19, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 18, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 5, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 26, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 24, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 19, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Summary of Share Repurchases</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the years ended December&#160;31, 2022 and 2021 is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at end of year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890747200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Reconciliation of Components of Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive (loss) income at December&#160;31, 2022, 2021, and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $926, $121, and $(160), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income, net of tax benefit (expense) of $(94), $27, and $(13), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) benefit of $0, $(1),and $0, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(6), $(3), and $(3), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax expense of $(23), $(36), and $(2), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax benefit (expense) of $6, $2, and $(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $809, $110, and $(154), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to noncontrolling interests, net of tax (expense) benefit of $(3), $1, and $0, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890707200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock', window );">Summary Of Direct, Assumed And Ceded Premiums Earned</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,867</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,149</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,298</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,229</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,373</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,109</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage&#8212;assumed to net premiums</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock', window );">Summary Of Net Premiums Earned By Segment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net premiums earned by segment (see Note 20, &#8220;Segment Information&#8221;) for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Effect Of Reinsurance On Benefit Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of reinsurance on benefit expense for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Net Premiums Written And Earned By Segment [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17)<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883576096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_LesseeOperatingLeasesTableTextBlock', window );">Lessee, Operating Leases [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities as disclosed in Note 4, &#8220;Business Optimization Initiatives,&#8221; include reducing our office space footprint. As a result, we performed an interim impairment test during the years ended December 31, 2022, 2021 and 2020, and recorded impairment charges of $34, $136 and $258, respectively, for impairment and abandonment of ROU assets which are included in the operating lease expense shown above.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.828%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new lease liabilities, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate, operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_LesseeOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_LesseeOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890954400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Denominator For Basic And Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share at December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share&#8212;weighted-average shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities&#8212;employee stock options, non-vested restricted stock awards, convertible debentures and equity units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888679008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Financial Data By Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentTableTextBlock', window );">Major Product Revenues</a></td>
<td class="text">The major product revenues for each of the reportable segments for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental/Vision products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Commercial &amp; Specialty Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Government Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,810&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated health services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Business</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation Of Reportable Segment Operating Revenues To The Consolidated Statements Of Income</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments&#8217; operating revenue to the amounts of total revenues included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments&#8217; operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,639&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,867&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation Of Reportable Segment Operating Gain To Income From Continuing Operations Before Income Taxes In The Consolidated Statements Of Income</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments&#8217; operating gain to income before income tax expense included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments&#8217; operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_MajorProductRevenueBySegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Major Product Revenue By Segment [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_MajorProductRevenueBySegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883563056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details)<br> individuals in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>individuals </div>
<div>counties </div>
<div>states</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NumberOfCountiesInGeographicalRegionNotServed', window );">Number of counties in the Kansas City area the Company does not serve | counties</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which the Company is licensed to conduct insurance operations | states</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NumberOfMedicalMembersServed', window );">Number Of Medical Members Served | individuals</a></td>
<td class="nump">47.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NumberOfCountiesInGeographicalRegionNotServed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of counties in a geographical region for which services are not provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NumberOfCountiesInGeographicalRegionNotServed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NumberOfMedicalMembersServed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of medical members served</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NumberOfMedicalMembersServed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885546144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis Of Presentation And Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Customer funds and cash and cash equivalents on deposit for regulatory requirements</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan', window );">Securities lending transactions, ratio of fair value of collateral on hold to fair value of securities on loan</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts', window );">Premiums receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts', window );">Self-funded receivables, allowance for doubtful accounts</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent', window );">Other receivables, allowance for doubtful accounts</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses', window );">Defined Benefit Plan, Alternative Method Used to Amortize Gain (Loss), Description</a></td>
<td class="text">We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee stock purchase plan, purchase price per share as a percent of closing price</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and marketing expense</a></td>
<td class="nump">$ 511<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">$ 558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee', window );">Patient Protection Affordable Care Act Health Insurance Provider Fee, annual amount to be collected by the Government through assessments to all health insurers subject to the fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid', window );">Patient Protection Affordable Care Act Health Insurance Provider Fee, amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="nump">29,724<span></span>
</td>
<td class="nump">27,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating Lease, Impairment Loss</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">23,849<span></span>
</td>
<td class="nump">22,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,307<span></span>
</td>
<td class="nump">36,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">$ 29,724<span></span>
</td>
<td class="nump">27,088<span></span>
</td>
<td class="nump">$ 23,802<span></span>
</td>
<td class="nump">$ 22,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred Tax and Other Liabilities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, Plant and Equipment, Depreciation Methods</a></td>
<td class="text">Leasehold improvements are depreciated over the term of the related lease.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Buildings and Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Internal-use software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Buildings and Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture And Other Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Internal-use software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis Of Presentation And Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual fee imposed on covered entities engaged in the business of providing health insurance for United States health risks. This fee is imposed by section 9010 of the Patient Protection and Affordable Care Act, as amended. The regulations affect persons engaged in the business of providing health insurance for United States health risks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for the annual Health Insurance Provider Fee assessed in accordance with Section 9010 of the Patient Protection Affordable Care Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_SelffundedReceivablesAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_SelffundedReceivablesAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on receivable, classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of alternative method used to amortize gain (loss) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885338368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisitions (Acquired tangible assets and liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets', window );">Accounts receivable and other current assets</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets', window );">Property, equipment and other long-term assets</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities', window );">Medical claims and other policyholder liabilities payable</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net tangible assets</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="num">$ (107)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Accounts Receivables and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, CurrentLiabilities, Accounts Payable and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Medical claims and Other Policyholder liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property And Equipment and Other Long Term Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888805584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions (Intangible Assets Acquired) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_TotalIntangibleAssetsAcquired', window );">Total intangible assets</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 1,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">State Medicaid Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived Intangible Assets Acquired</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer-related [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets amortization period, years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Provider And Hospital Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets amortization period, years</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets amortization period, years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_TotalIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Intangible Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_TotalIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888008096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, after measurement period adjustments</a></td>
<td class="nump">$ 24,383<span></span>
</td>
<td class="nump">$ 24,228<span></span>
</td>
<td class="nump">$ 21,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, after measurement period adjustments</a></td>
<td class="nump">10,477<span></span>
</td>
<td class="nump">10,349<span></span>
</td>
<td class="nump">8,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, after measurement period adjustments</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash considerations</a></td>
<td class="nump">752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived Intangible Assets Acquired</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Acquired During Period</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Acquisition Year, Prior Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, purchase accounting adjustments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, after measurement period adjustments</a></td>
<td class="nump">2,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Government Business Segment [Member] | Acquisition Year, Prior Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible Assets, Net (Including Goodwill)</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Other [Member] | Acquisition Year, Prior Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible Assets, Net (Including Goodwill)</a></td>
<td class="nump">$ 795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_AcquisitionYearAxis=elv_AcquisitionYearPriorDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_AcquisitionYearAxis=elv_AcquisitionYearPriorDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882047456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Optimization Initiatives (Employee Termination Costs) (Details) - Employee Termination [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, beginning balance</a></td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, ending balance</a></td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, beginning balance</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, ending balance</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, beginning balance</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, ending balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, beginning balance</a></td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, ending balance</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, beginning balance</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities for employee termination costs, ending balance</a></td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the accrual for restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884627456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Optimization Initiatives (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Business Optimization, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative expense<span></span>
</td>
<td class="text">Selling, general and administrative expense<span></span>
</td>
<td class="text">Selling, general and administrative expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=elv_PPEImpairmentMember', window );">Property and Equipment Impairment and Abandonment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=elv_LeaseImpairmentMember', window );">Operating Lease Impairment and Abandonment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member] | Employee Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member] | Employee Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member] | Employee Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Business optimization initiatives, incurred cost</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business [Member] | Employee Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Business Optimization Initiatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Releases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the accrual for restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=elv_PPEImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=elv_PPEImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=elv_LeaseImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=elv_LeaseImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885167872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Current And Long-Term Investments, Available-For-Sale) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">29,015<span></span>
</td>
<td class="nump">26,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,378)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,704<span></span>
</td>
<td class="nump">26,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | United States Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Government Sponsored Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Foreign Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | States, Municipalities And Political Subdivisions, Tax-Exempt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">4,389<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">4,143<span></span>
</td>
<td class="nump">5,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">13,721<span></span>
</td>
<td class="nump">12,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">12,529<span></span>
</td>
<td class="nump">12,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(324)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Commercial Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Other Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or Amortized Cost</a></td>
<td class="nump">3,967<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="nump">$ 2,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherAggregatedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherAggregatedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883794272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) - Fixed Maturity Securities [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>securities</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>securities</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">7,781<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 16,035<span></span>
</td>
<td class="nump">$ 8,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (1,071)<span></span>
</td>
<td class="num">$ (131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 7,537<span></span>
</td>
<td class="nump">$ 985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (1,307)<span></span>
</td>
<td class="num">$ (51)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">United States Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 442<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Government Sponsored Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Foreign Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">States, Municipalities And Political Subdivisions, Tax-Exempt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 2,615<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (147)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 652<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (118)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 7,826<span></span>
</td>
<td class="nump">$ 3,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (549)<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 3,521<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (669)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">$ 1,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (121)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (203)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Commercial Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Other Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 Months | securities</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value, Less than 12 Months</a></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss, less than 12 months</a></td>
<td class="num">$ (124)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, 12 Months or Greater | securities</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Estimated Fair Value, 12 Months or Greater</a></td>
<td class="nump">$ 1,074<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss, 12 Months or greater</a></td>
<td class="num">$ (117)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherAggregatedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherAggregatedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894655952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) - Fixed Maturity Securities [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, Estimated Fair Value</a></td>
<td class="nump">$ 720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">7,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years, Estimated Fair Value</a></td>
<td class="nump">8,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years, Estimated Fair Value</a></td>
<td class="nump">5,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Mortgage-backed securities, Estimated Fair Value</a></td>
<td class="nump">4,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities Fair Value</a></td>
<td class="nump">26,704<span></span>
</td>
<td class="nump">$ 26,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, Amortized Cost</a></td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">7,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years, Amortized Cost</a></td>
<td class="nump">9,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years, Amortized Cost</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost', window );">Mortgage-backed securities, Amortized Cost</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available For Sale Securities, Amortized Cost</a></td>
<td class="nump">$ 29,015<span></span>
</td>
<td class="nump">$ 26,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883628640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Current Equity Securities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Equity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">$ 1,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ExchangeTradedFundsMember', window );">Exchange Traded Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Equity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=elv_CommonEquitySecuritiesMember', window );">Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Equity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PrivateEquityFundsMember', window );">Private Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Equity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investments in equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ExchangeTradedFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ExchangeTradedFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=elv_CommonEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=elv_CommonEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PrivateEquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PrivateEquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885691584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Major Categories Of Net Investment Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">$ 1,528<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Investment expense</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">$ 432<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885522480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Net Gains/Losses On Investments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_InvestmentGainsLosses', window );">Net (losses) gains on investments</a></td>
<td class="num">$ (630)<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains from sales</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses from sales</a></td>
<td class="num">(469)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_Impairmentlossesreversalsoninvestments', window );">Impairment (losses) recoveries recognized in income</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Net realized gains on fixed maturity securities</a></td>
<td class="num">(448)<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized in income on equity securities</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net realized (losses) gains recognized on equity securities sold</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (losses) gains on equity securities</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_Impairmentlossesreversalsoninvestments', window );">Impairment (losses) recoveries recognized in income</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_GainsFromOtherInvestments', window );">Gross gains from other investments</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_GrossLossesFromOtherInvestments', window );">Gross losses from other investments</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Net (losses) gains on other investments</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_GainsFromOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains From Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_GainsFromOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_GrossLossesFromOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Losses From Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_GrossLossesFromOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_Impairmentlossesreversalsoninvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_Impairmentlossesreversalsoninvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_InvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Gains (Losses)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_InvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884547056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome', window );">Number of fixed maturity investments that did not produce income</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldByInsuranceRegulators', window );">Securities on deposit under regulatory requirements</a></td>
<td class="nump">$ 752<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued investment income</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesLoanedFairValueOfCollateral', window );">Securities Loaned, Fair Value of Collateral</a></td>
<td class="nump">$ 2,457<span></span>
</td>
<td class="nump">$ 2,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan', window );">Securities lending transactions, ratio of fair value of collateral on hold to fair value of securities on loan</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds</a></td>
<td class="nump">22,048<span></span>
</td>
<td class="nump">10,565<span></span>
</td>
<td class="nump">$ 11,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=elv_ThirdPartyInvestmentsMember', window );">Third party investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Future capital calls or investment obligations</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=elv_RatedNotesMember', window );">Rated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Future capital calls or investment obligations</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOvernightMember', window );">Maturity Overnight [Member] | Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue', window );">Collateral received for securities loaned, at carrying value</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">1,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOvernightMember', window );">Maturity Overnight [Member] | United States Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue', window );">Collateral received for securities loaned, at carrying value</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOvernightMember', window );">Maturity Overnight [Member] | Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue', window );">Collateral received for securities loaned, at carrying value</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in fixed maturities, mortgage loans on real estate, investment real estate, and other long-term investments that have been non-income producing the for the twelve months preceding the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldByInsuranceRegulators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123600598&amp;loc=SL75763979-209797<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldByInsuranceRegulators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received as security in return for loaning securities to another party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesLoanedFairValueOfCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the securities pledged as collateral against securities loaned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226013-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesLoanedFairValueOfCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=elv_ThirdPartyInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=elv_ThirdPartyInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=elv_RatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=elv_RatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOvernightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOvernightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885478992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments (Notional Amounts, Balance Sheet Location And Estimated Fair Values Of Derivative Financial Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Amounts netted</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral', window );">Net derivative assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Amounts netted</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral', window );">Net derivative liabilities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Hedging Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Hedging Instruments [Member] | Other Noncurrent Assets [Member] | Interest Rate Swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Non-Hedging Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Non-Hedging Instruments [Member] | Other Noncurrent Assets [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Non-Hedging Instruments [Member] | Equity securities/other assets/other liabilities [Member] | Interest Rate Swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Non-Hedging Instruments [Member] | Equity Securities [Member] | Collars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Non-Hedging Instruments [Member] | Equity Securities [Member] | Futures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Non-Hedging Instruments [Member] | Fixed Maturity Securities [Member] | Embedded Derivative Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226006-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226006-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=elv_EquitySecuritiesotherAssetsotherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=elv_EquitySecuritiesotherAssetsotherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FutureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FutureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885474288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Five Point Five Zero Percentage | 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Apr. 15,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Four Point One Zero One Percentage [Member] | 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">4.101%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Sep.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Four Point One Zero One Percentage [Member] | 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">4.101%<span></span>
</td>
<td class="nump">4.101%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Sep.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Four Point One Zero One Percentage [Member] | 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">4.101%<span></span>
</td>
<td class="nump">4.101%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Sep.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Two Point Two Five Zero Percentage [Member] | 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Nov. 15,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Two Point Two Five Zero Percentage [Member] | 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Nov. 15,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Two Point Five Five Zero Percentage [Member] | 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Sep. 15,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest Rate Swaps [Member] | Interest Rate Received Three Point Three Zero Percentage [Member] | 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest Rate Received</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenOptionContractsWrittenExpirationDates', window );">Expiration Date</a></td>
<td class="text">Jan. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenOptionContractsWrittenExpirationDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the open option contracts written on the investment, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column F))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611282-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenOptionContractsWrittenExpirationDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedFivePointFiveZeroPercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedFivePointFiveZeroPercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=elv_TwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=elv_TwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedFourPointOneZeroOnePercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedFourPointOneZeroOnePercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=elv_TwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=elv_TwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=elv_TwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=elv_TwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=elv_TwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=elv_TwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedThreePointThreeZeroPercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=elv_InterestRateReceivedThreePointThreeZeroPercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890740480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments Derivative Financial Instruments (Fair Value Hedges, Financial Position) (Details) - Long-term Debt [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAmountOfHedgedItem', window );">Derivative, Amount of Hedged Item</a></td>
<td class="nump">$ 22,349<span></span>
</td>
<td class="nump">$ 21,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_Fairvaluehedgescumulativebasisadjustments', window );">Cumulative basis adjustments for fair value hedges</a></td>
<td class="num">$ (57)<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_Fairvaluehedgescumulativebasisadjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative basis adjustments for fair value hedges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_Fairvaluehedgescumulativebasisadjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAmountOfHedgedItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of hedged item in hedging relationship. Excludes hedged asset or liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAmountOfHedgedItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888771488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Gains (Losses) On Investments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=elv_NetGainsLossesOnFinancialInstrumentsMember', window );">Net (losses) gains on financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="text">Net (losses) gains on financial instruments<span></span>
</td>
<td class="text">Net (losses) gains on financial instruments<span></span>
</td>
<td class="text">Net (losses) gains on financial instruments<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember', window );">Collars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FutureMember', window );">Futures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Embedded Derivative Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain (Loss) Recognized</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=elv_NetGainsLossesOnFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=elv_NetGainsLossesOnFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FutureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FutureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886464912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset', window );">Collateral received</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Unrecognized losses for all terminated cash flow hedges included in accumulated other comprehensive loss</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Total amount of amortization over the next twelve months for all cash flow hedges</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Terminations [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_Notionalamountterminatedderivatives', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_Notionalamountterminatedderivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents notional amount of terminated derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_Notionalamountterminatedderivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_HedgingStatusAxis=elv_TerminationsDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_HedgingStatusAxis=elv_TerminationsDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882490272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 3,567<span></span>
</td>
<td class="nump">$ 2,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesHeldAsCollateralAtFairValue', window );">Securities lending collateral</a></td>
<td class="nump">2,457<span></span>
</td>
<td class="nump">2,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">33,787<span></span>
</td>
<td class="nump">33,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="num">$ (60)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities, Other noncurrent liabilities<span></span>
</td>
<td class="text">Other current liabilities, Other noncurrent liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets, Other noncurrent assets<span></span>
</td>
<td class="text">Other current assets, Other noncurrent assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ExchangeTradedFundsMember', window );">Exchange Traded Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=elv_CommonEquitySecuritiesMember', window );">Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PrivateEquityFundsMember', window );">Private Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,704<span></span>
</td>
<td class="nump">26,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | United States Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Government Sponsored Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Foreign Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | States, Municipalities And Political Subdivisions, Tax-Exempt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">4,143<span></span>
</td>
<td class="nump">5,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">12,529<span></span>
</td>
<td class="nump">12,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Commercial Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember', window );">Fixed Maturity Securities [Member] | Other Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,738<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Exchange Traded Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Private Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=elv_OtherDerivativeInstrumentsMember', window );">Derivatives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,494<span></span>
</td>
<td class="nump">4,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I [Member] | Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I [Member] | Equity Securities [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I [Member] | Other Investments [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesHeldAsCollateralAtFairValue', window );">Securities lending collateral</a></td>
<td class="nump">2,457<span></span>
</td>
<td class="nump">2,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">28,712<span></span>
</td>
<td class="nump">28,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,211<span></span>
</td>
<td class="nump">26,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | United States Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | Government Sponsored Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | Foreign Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | States, Municipalities And Political Subdivisions, Tax-Exempt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">4,143<span></span>
</td>
<td class="nump">5,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">12,392<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">2,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | Commercial Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Fixed Maturity Securities [Member] | Other Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Equity Securities [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Derivatives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level II [Member] | Other Investments [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Fixed Maturity Securities [Member] | Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Fixed Maturity Securities [Member] | Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Fixed Maturity Securities [Member] | Other Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Equity Securities [Member] | Private Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EquitySecurities', window );">Equity Securities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member] | Other Investments [Member] | Common Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investments in equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesHeldAsCollateralAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount (fair value) as of the balance sheet date of securities held that had been pledged by counterparties under financing and lending arrangements, pursuant to which the entity has the right by agreement or custom to sell or re-pledge such securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5086-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesHeldAsCollateralAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ExchangeTradedFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ExchangeTradedFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=elv_CommonEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=elv_CommonEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PrivateEquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PrivateEquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_FixedMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=elv_OtherDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=elv_OtherDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882249808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) recognized in net income</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Net Income<span></span>
</td>
<td class="text">Net Income<span></span>
</td>
<td class="text">Net Income<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains (losses) recognized in accumulated other comprehensive loss/income</a></td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level III</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level III</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in unrealized losses included in net income related to assets still held</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) recognized in net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains (losses) recognized in accumulated other comprehensive loss/income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level III</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level III</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in unrealized losses included in net income related to assets still held</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential Mortgage-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) recognized in net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains (losses) recognized in accumulated other comprehensive loss/income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level III</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level III</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in unrealized losses included in net income related to assets still held</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) recognized in net income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains (losses) recognized in accumulated other comprehensive loss/income</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level III</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level III</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in unrealized losses included in net income related to assets still held</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) recognized in net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains (losses) recognized in accumulated other comprehensive loss/income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level III</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level III</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in unrealized losses included in net income related to assets still held</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882376208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Carrying and Fair Value By Level of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">$ 5,685<span></span>
</td>
<td class="nump">$ 5,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debentures</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) recognized in net income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">5,582<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate', window );">Short-term borrowings</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes</a></td>
<td class="nump">23,786<span></span>
</td>
<td class="nump">22,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debentures</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">5,582<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate', window );">Short-term borrowings</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes</a></td>
<td class="nump">21,861<span></span>
</td>
<td class="nump">25,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debentures</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate', window );">Short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate', window );">Short-term borrowings</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes</a></td>
<td class="nump">21,861<span></span>
</td>
<td class="nump">25,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debentures</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">5,582<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debentures</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of advance from Federal Home Loan Bank (FHLBank) maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6479118&amp;loc=d3e64650-112822<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894660256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes(Components Of Deferred Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets relating to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Bad debt reserves</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Insurance reserves</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DeferredTaxAssetsLeasingArrangements', window );">Lease liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Retirement liabilities</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Deferred compensation</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state operating loss carryforwards</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Deferred Tax Assets, Investments</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">2,049<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities relating to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Federal and state intangible assets</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets', window );">Non-U.S intangible assets</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware', window );">Capitalized software</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits', window );">Retirement assets</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease right-of-use assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">3,743<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="nump">$ 2,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DeferredTaxLiabilitiesNonUSIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from non-U.S. intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DeferredTaxLiabilitiesNonUSIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax liabilities, Deferred Expense, Retirement benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884460160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components Of Provision For Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 1,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current Foreign Tax Expense (Benefit)</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">2,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885693184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Amount at statutory rate, amount</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 1,664<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Amount at statutory rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes net of federal tax expense/benefit, amount</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes net of federal tax expense/benefit, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductions', window );">Tax exempt interest and dividends received deduction, amount</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Tax exempt interest and dividends received deduction, percent</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee', window );">Health Insurance Provider fee, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent', window );">Health Insurance Provider fee, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount', window );">Basis adjustments from recent acquisitions, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent', window );">Basis adjustments from recent acquisitions, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net amount</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net percent</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense, percent</a></td>
<td class="nump">22.50%<span></span>
</td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">26.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax expense as a result of the basis adjustments from recent acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) resulting from basis adjustments due to recent acquistions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider fee payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider Fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883494080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Change in carrying amount of gross unrecognized tax benefits from uncertain tax positions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior years</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions related to tax positions of prior years</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885297216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="nump">$ 2,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet', window );">Income tax expense (benefit) per diluted share</a></td>
<td class="nump">$ 7.21<span></span>
</td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee', window );">Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate in future periods, if recognized</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized', window );">Unrecognized tax benefits that would impact additional paid-in capital in future periods, if recognized</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IncomeTaxRefundClaimsFiled', window );">Protective state income tax refund claims filed</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense (benefit)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest accrued</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income Taxes Receivable</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit change reasonably possible due to tax settlements - lower amount</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit change reasonably possible due to tax settlements - lower amount</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=elv_HealthInsuranceProviderfeeMember', window );">Health Insurance Provider fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet', window );">Income tax expense (benefit) per diluted share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee', window );">Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=elv_IndefiniteMember', window );">Indefinite Carryforward Period | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=elv_LimitedCarryforwardPeriodMember', window );">Limited Carryforward Period | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Jan.  01,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member] | State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Dec. 31,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year [Member] | State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Dec. 31,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets, Net</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=elv_DeferredTaxLiabilitiesNetMember', window );">Deferred tax liabilities, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">$ 2,034<span></span>
</td>
<td class="nump">$ 2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider fee payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_IncomeTaxRefundClaimsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax refund claims filed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_IncomeTaxRefundClaimsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of earnings, after tax, of an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=SL124452875-109257<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1311-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125520798&amp;loc=SL114871939-224231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=elv_HealthInsuranceProviderfeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=elv_HealthInsuranceProviderfeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=elv_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=elv_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=elv_LimitedCarryforwardPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=elv_LimitedCarryforwardPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=elv_DeferredTaxLiabilitiesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=elv_DeferredTaxLiabilitiesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894409152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property And Equipment (Summary Of Property And Equipment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,119<span></span>
</td>
<td class="nump">$ 8,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(2,803)<span></span>
</td>
<td class="num">(4,340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">3,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software, Purchased and Internally Developed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,604<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=elv_DataProcessingEquipmentAndSoftwareMember', window );">Computer Equipment, Furniture and Other Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=elv_DataProcessingEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=elv_DataProcessingEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882045824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements', window );">Amortization expense on computer software and leasehold improvements</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Computer software amortization</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized costs related to the internal development of software</a></td>
<td class="nump">5,354<span></span>
</td>
<td class="nump">5,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each income statement presented, the amount charged to expense for amortization of capitalized computer software and leasehold improvement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886897824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill by reportable segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 24,228<span></span>
</td>
<td class="nump">$ 21,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">24,383<span></span>
</td>
<td class="nump">24,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment as of December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill by reportable segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">11,593<span></span>
</td>
<td class="nump">11,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">11,611<span></span>
</td>
<td class="nump">11,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment as of December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill by reportable segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">10,349<span></span>
</td>
<td class="nump">8,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">10,477<span></span>
</td>
<td class="nump">10,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment as of December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill by reportable segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment as of December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill by reportable segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">2,227<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">$ 2,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment as of December 31</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885860848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">$ 7,127<span></span>
</td>
<td class="nump">$ 6,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization, Finite Lived Intangibles</a></td>
<td class="num">(4,279)<span></span>
</td>
<td class="num">(3,506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="nump">3,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount, Indefinite Lived Intangibles</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">7,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount, Indefinite Lived Intangibles</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">7,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount, Total Intangible Assets</a></td>
<td class="nump">14,594<span></span>
</td>
<td class="nump">14,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill', window );">Accumulated Amortization, Total Intangible Assets</a></td>
<td class="num">(4,279)<span></span>
</td>
<td class="num">(3,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount, Total Intangible Assets</a></td>
<td class="nump">10,315<span></span>
</td>
<td class="nump">10,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Blue Cross And Blue Shield And Other Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount, Indefinite Lived Intangibles</a></td>
<td class="nump">5,991<span></span>
</td>
<td class="nump">6,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount, Indefinite Lived Intangibles</a></td>
<td class="nump">5,991<span></span>
</td>
<td class="nump">6,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">State Medicaid Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount, Indefinite Lived Intangibles</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount, Indefinite Lived Intangibles</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">5,791<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization, Finite Lived Intangibles</a></td>
<td class="num">(3,693)<span></span>
</td>
<td class="num">(3,236)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Provider And Hospital Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization, Finite Lived Intangibles</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization, Finite Lived Intangibles</a></td>
<td class="num">(440)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount, Finite Lived Intangibles</a></td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Accumulated Amortization Excluding Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884502832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill And Other Intangible Assets (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Finite-Lived Intangible Assets, Period Increase (Decrease)</a></td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Indefinite-Lived Intangible Assets, Period Increase (Decrease)</a></td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated amortization expense 2023</a></td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated amortization expense 2024</a></td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated amortization expense 2025</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated amortization expense 2026</a></td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated amortization expense 2027</a></td>
<td class="nump">$ 221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883921696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Reconciliation Of The Benefit Obligation) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Reconciliation of benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">$ 1,859<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial loss (gain)</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement', window );">Settlements</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">1,415<span></span>
</td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Reconciliation of benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial loss (gain)</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894662368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Changes In Fair Value Of Plan Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">$ 2,216<span></span>
</td>
<td class="nump">$ 2,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(352)<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitPlanBenefitsPaidFairValue', window );">Benefits paid</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitPlanBenefitsPaidFairValue', window );">Benefits paid</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DefinedBenefitPlanBenefitsPaidFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan Benefits Paid Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DefinedBenefitPlanBenefitsPaidFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885430640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">$ 363<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount at December 31</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount at December 31</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894707312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss That Have Not Been Recognized As Components Of Net Periodic Benefit Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial (loss) gain</a></td>
<td class="num">$ (672)<span></span>
</td>
<td class="num">$ (625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Net amount before tax at December 31</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial (loss) gain</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Net amount before tax at December 31</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894898496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.18%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">6.58%<span></span>
</td>
<td class="nump">5.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest Crediting Rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.12%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">6.57%<span></span>
</td>
<td class="nump">6.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest Crediting Rate</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">1.56%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Of Expected Rate Of Return On Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894905632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Components Of Net Periodic Benefit Cost (Benefit Credit) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList', window );">Settlement Loss, Statement of Income or Comprehensive Income Location</a></td>
<td class="text">Selling, general and administrative expense<span></span>
</td>
<td class="text">Selling, general and administrative expense<span></span>
</td>
<td class="text">Selling, general and administrative expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on assets</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial loss</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit credit</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on assets</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit credit</a></td>
<td class="num">$ (23)<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894657344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Weighted-Average Assumptions Used In Calculating Net Periodic Benefit Cost For All Plans) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
<td class="nump">3.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">5.02%<span></span>
</td>
<td class="nump">6.72%<span></span>
</td>
<td class="nump">7.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
<td class="nump">2.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">6.43%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">1.56%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">1.81%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937875786160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InsuranceCompanyContractsMember', window );">Insurance Company Contracts [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_LifeInsuranceContractsMember', window );">Life Insurance Contracts [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | U.S. Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | U.S. Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | U.S. Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | U.S. Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Foreign Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Foreign Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Foreign Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Foreign Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Mutual Funds [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Mutual Funds [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Mutual Funds [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Government Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Government Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Government Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Corporate Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Corporate Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Corporate Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Asset-Backed Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Asset-Backed Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Asset-Backed Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Commingled fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Commingled fund | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Commingled fund | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Commingled fund | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Insurance Company Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Insurance Company Contracts [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Insurance Company Contracts [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Insurance Company Contracts [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Total Plan Assets Excluding Partnership Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">1,627<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Partnership investments [Member] | Fair Value Measured at Net Asset Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member] | Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | U.S. Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | U.S. Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | U.S. Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | U.S. Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Foreign Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Foreign Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Foreign Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Foreign Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Mutual Funds [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Mutual Funds [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Mutual Funds [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Government Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Government Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Government Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Corporate Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Corporate Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Corporate Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Asset-Backed Securities [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Asset-Backed Securities [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Asset-Backed Securities [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Commingled fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Commingled fund | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Commingled fund | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Commingled fund | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Life Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Life Insurance Contracts [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Life Insurance Contracts [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Life Insurance Contracts [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Investment In DOL 103-12 Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Investment In DOL 103-12 Trust [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Investment In DOL 103-12 Trust [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Investment In DOL 103-12 Trust [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member] | Level I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member] | Level II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member] | Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member] | Level III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total pension benefit assets</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment within defined benefit plan asset category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InsuranceCompanyContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InsuranceCompanyContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_LifeInsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_LifeInsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_CommingledFundDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_CommingledFundDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_PartnershipInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_PartnershipInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InvestmentInDOL10312TrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InvestmentInDOL10312TrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884982544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs) (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Change in Fair Value of Plan Assets, Level III Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Actual return on plan assets, relating to assets still held at the reporting date</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase', window );">Purchases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale', window );">Sales</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Insurance Company Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Change in Fair Value of Plan Assets, Level III Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Actual return on plan assets, relating to assets still held at the reporting date</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase', window );">Purchases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale', window );">Sales</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Life Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Change in Fair Value of Plan Assets, Level III Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Actual return on plan assets, relating to assets still held at the reporting date</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase', window );">Purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale', window );">Sales</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of decrease in plan asset of defined benefit plan from sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase in plan asset of defined benefit plan from purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InsuranceCompanyContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_InsuranceCompanyContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_LifeInsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_LifeInsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885269232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Estimated Future Payments For Pension Benefits And Other Benefits) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028 - 2032</a></td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028 - 2032</a></td>
<td class="nump">$ 110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887929456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitFairValueDueFromBrokers', window );">Net amount of assets (liabilities) of cash, investment income receivable and amounts due to/from brokers, excluded from fair values of pension benefit assets and other benefit assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets', window );">Claims settlements to be paid from other benefit assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions made to 401k retirement benefit plans</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation for the defined benefit pension plans</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Payment for Pension and Other Postretirement Benefits</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitPlanByAgeAxis=elv_PreMedicareMember', window );">Pre-Medicare [Member] | Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Assumed health care cost trend rate to be used for next year to measure expected cost of other benefits</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Ultimate health care cost trend rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Year in which ultimate trend rate reached</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DefinedBenefitPlanByAgeAxis=elv_PostMedicareMember', window );">Post-Medicare [Member] | Other Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Assumed health care cost trend rate to be used for next year to measure expected cost of other benefits</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Ultimate health care cost trend rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Year in which ultimate trend rate reached</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Weighted-average target allocation for plan assets</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember', window );">Fixed Maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Weighted-average target allocation for plan assets</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MoneyMarketFundsMember', window );">All Other Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Weighted-average target allocation for plan assets</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_PartnershipInvestmentsMember', window );">Partnership investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Defined Benefit Plan, Unfunded Commitment</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claims settlements to be paid from other benefit assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DefinedBenefitFairValueDueFromBrokers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Fair Value Due From Brokers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DefinedBenefitFairValueDueFromBrokers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year ultimate health care cost trend rate is expected to be reached, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DefinedBenefitPlanByAgeAxis=elv_PreMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DefinedBenefitPlanByAgeAxis=elv_PreMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DefinedBenefitPlanByAgeAxis=elv_PostMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DefinedBenefitPlanByAgeAxis=elv_PostMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_PartnershipInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=elv_PartnershipInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885899696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Medical Claims Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, beginning of year</a></td>
<td class="nump">$ 13,282<span></span>
</td>
<td class="nump">$ 11,135<span></span>
</td>
<td class="nump">$ 8,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, beginning of year</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, beginning of year</a></td>
<td class="nump">13,261<span></span>
</td>
<td class="nump">11,089<span></span>
</td>
<td class="nump">8,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments', window );">Business combinations and purchase adjustments</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current Year Claims and Claims Adjustment Expense</a></td>
<td class="nump">113,414<span></span>
</td>
<td class="nump">100,440<span></span>
</td>
<td class="nump">85,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(869)<span></span>
</td>
<td class="num">(1,703)<span></span>
</td>
<td class="num">(637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total net incurred medical claims</a></td>
<td class="nump">112,545<span></span>
</td>
<td class="nump">98,737<span></span>
</td>
<td class="nump">84,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Net payments attributable to current year medical claims</a></td>
<td class="nump">98,997<span></span>
</td>
<td class="nump">88,156<span></span>
</td>
<td class="nump">74,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Net payments attributable to prior years medical claims</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">8,829<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total net payments</a></td>
<td class="nump">110,597<span></span>
</td>
<td class="nump">96,985<span></span>
</td>
<td class="nump">82,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">15,342<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
<td class="nump">11,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">15,348<span></span>
</td>
<td class="nump">13,282<span></span>
</td>
<td class="nump">11,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Medical Claims Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, beginning of year</a></td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
<td class="nump">3,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, beginning of year</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, beginning of year</a></td>
<td class="nump">3,834<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments', window );">Business combinations and purchase adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current Year Claims and Claims Adjustment Expense</a></td>
<td class="nump">30,067<span></span>
</td>
<td class="nump">28,132<span></span>
</td>
<td class="nump">24,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total net incurred medical claims</a></td>
<td class="nump">29,913<span></span>
</td>
<td class="nump">27,667<span></span>
</td>
<td class="nump">24,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Net payments attributable to current year medical claims</a></td>
<td class="nump">26,274<span></span>
</td>
<td class="nump">24,502<span></span>
</td>
<td class="nump">21,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Net payments attributable to prior years medical claims</a></td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">2,612<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total net payments</a></td>
<td class="nump">29,636<span></span>
</td>
<td class="nump">27,114<span></span>
</td>
<td class="nump">24,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">4,114<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">4,119<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Medical Claims Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, beginning of year</a></td>
<td class="nump">9,157<span></span>
</td>
<td class="nump">7,646<span></span>
</td>
<td class="nump">5,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, beginning of year</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, beginning of year</a></td>
<td class="nump">9,149<span></span>
</td>
<td class="nump">7,613<span></span>
</td>
<td class="nump">5,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments', window );">Business combinations and purchase adjustments</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current Year Claims and Claims Adjustment Expense</a></td>
<td class="nump">81,795<span></span>
</td>
<td class="nump">70,670<span></span>
</td>
<td class="nump">58,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total net incurred medical claims</a></td>
<td class="nump">81,165<span></span>
</td>
<td class="nump">69,448<span></span>
</td>
<td class="nump">58,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Net payments attributable to current year medical claims</a></td>
<td class="nump">71,463<span></span>
</td>
<td class="nump">62,233<span></span>
</td>
<td class="nump">51,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Net payments attributable to prior years medical claims</a></td>
<td class="nump">8,052<span></span>
</td>
<td class="nump">6,054<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total net payments</a></td>
<td class="nump">79,515<span></span>
</td>
<td class="nump">68,287<span></span>
</td>
<td class="nump">56,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">10,929<span></span>
</td>
<td class="nump">9,149<span></span>
</td>
<td class="nump">7,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">10,930<span></span>
</td>
<td class="nump">9,157<span></span>
</td>
<td class="nump">7,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Medical Claims Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, beginning of year</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, beginning of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, beginning of year</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments', window );">Business combinations and purchase adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current Year Claims and Claims Adjustment Expense</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total net incurred medical claims</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Net payments attributable to current year medical claims</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Net payments attributable to prior years medical claims</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total net payments</a></td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894876816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims Payable ((Favorable) Unfavorable Developments By Changes In Key Assumptions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MedicalClaimsPayableAbstract', window );"><strong>Medical Claims Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions', window );">Assumed trend factors</a></td>
<td class="num">$ (859)<span></span>
</td>
<td class="num">$ (1,429)<span></span>
</td>
<td class="num">$ (599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions', window );">Assumed completion factors</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions', window );">Total</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (1,703)<span></span>
</td>
<td class="num">$ (637)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Favorable (Unfavorable) Developments by Changes in Completion Factors Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Favorable (Unfavorable) Developments by Changes in Total Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Favorable (Unfavorable) Developments by Changes in Trend Factors Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_MedicalClaimsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_MedicalClaimsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886903616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems', window );"><strong>Reconciliation of Net Incurred Medical Claims to Benefit Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Net incurred medical claims</a></td>
<td class="nump">$ 112,545<span></span>
</td>
<td class="nump">$ 98,737<span></span>
</td>
<td class="nump">$ 84,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_QualityImprovementAndOtherClaimsExpense', window );">Quality improvement and other claims expense</a></td>
<td class="nump">3,942<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
<td class="nump">3,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Benefit expense</a></td>
<td class="nump">116,487<span></span>
</td>
<td class="nump">102,645<span></span>
</td>
<td class="nump">88,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems', window );"><strong>Reconciliation of Net Incurred Medical Claims to Benefit Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Net incurred medical claims</a></td>
<td class="nump">29,913<span></span>
</td>
<td class="nump">27,667<span></span>
</td>
<td class="nump">24,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems', window );"><strong>Reconciliation of Net Incurred Medical Claims to Benefit Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Net incurred medical claims</a></td>
<td class="nump">81,165<span></span>
</td>
<td class="nump">69,448<span></span>
</td>
<td class="nump">58,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems', window );"><strong>Reconciliation of Net Incurred Medical Claims to Benefit Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Net incurred medical claims</a></td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_QualityImprovementAndOtherClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quality Improvement And Other Claims Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_QualityImprovementAndOtherClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884839536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims Payable (Incurred and Paid Claims Development, Net of Reinsurance) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">$ 305,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">289,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">85,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">81,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member] | Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">27,101<span></span>
</td>
<td class="nump">$ 27,080<span></span>
</td>
<td class="nump">$ 27,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">27,049<span></span>
</td>
<td class="nump">26,876<span></span>
</td>
<td class="nump">24,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member] | Short-duration Insurance Contracts, Claim Year 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">27,957<span></span>
</td>
<td class="nump">28,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">27,691<span></span>
</td>
<td class="nump">24,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business [Member] | Short-Duration Insurance Contract, Claim Year 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">30,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">26,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">215,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">204,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member] | Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">63,123<span></span>
</td>
<td class="nump">63,158<span></span>
</td>
<td class="nump">64,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">62,981<span></span>
</td>
<td class="nump">62,821<span></span>
</td>
<td class="nump">56,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member] | Short-duration Insurance Contracts, Claim Year 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">70,450<span></span>
</td>
<td class="nump">71,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">70,125<span></span>
</td>
<td class="nump">62,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member] | Short-Duration Insurance Contract, Claim Year 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">81,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">71,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">4,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member] | Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member] | Short-duration Insurance Contracts, Claim Year 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member] | Short-Duration Insurance Contract, Claim Year 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">$ 1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClaimsDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClaimsDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886169856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims Payable (Reconciliation Of The Claims Development To The Claims Liability) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems', window );"><strong>Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">$ 305,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">289,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">15,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem', window );">Insurance lines other than short duration</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">13,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems', window );"><strong>Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">85,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">81,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">4,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem', window );">Insurance lines other than short duration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">4,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems', window );"><strong>Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">215,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">204,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">10,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem', window );">Insurance lines other than short duration</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">11,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems', window );"><strong>Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance</a></td>
<td class="nump">4,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Net medical claims payable, end of year</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Ceded medical claims payable, end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem', window );">Insurance lines other than short duration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Gross medical claims payable, end of year</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894242208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims Payable (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (1,703)<span></span>
</td>
<td class="num">$ (637)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Net incurred medical claims in prior years redundancies</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member', window );">Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member] | Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member', window );">Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member] | Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member', window );">Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member] | Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member', window );">Short-duration Insurance Contracts, Claim Year 2021 [Member] | Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member', window );">Short-duration Insurance Contracts, Claim Year 2021 [Member] | Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member', window );">Short-duration Insurance Contracts, Claim Year 2021 [Member] | Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member', window );">Short-Duration Insurance Contract, Claim Year 2022 [Member] | Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 3,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member', window );">Short-Duration Insurance Contract, Claim Year 2022 [Member] | Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 10,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member', window );">Short-Duration Insurance Contract, Claim Year 2022 [Member] | Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Short-duration Insurance Contract, Cumulative Number of Reported Claims</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClaimsDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClaimsDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671321-158438<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671317-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative number of reported claims for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671317-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937877422064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Carrying Value Of Long-Term Debt) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 01, 2022</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>May 05, 2020</div></th>
<th class="th"><div>Oct. 09, 2012</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 23,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">22,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.950% due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.125%, due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.300%, due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | .0450% due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.350% due 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.500%, due 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.375%, due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.350% due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">5.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 1.500% due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.650% due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.101%, due 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.101%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.875%, due 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">2.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.250%, due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.550% due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.100% due 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.500% due 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.950%, due 2034 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.850%, due 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 6.375%, due 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.800%, due 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.625%, due 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.650%, due 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.650%, due 2044 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.100%, due 2044 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.375% due 2047 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.550%, due 2048 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.700%, due 2049 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.125% due 2050 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.600% due 2051 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.550% due 2052 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 6.100% due 2052 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.850%, due 2054 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SurplusNotesMember', window );">Surplus Notes [Member] | 9.000%, due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Senior Convertible Debentures [Member] | 2.750%, due 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on long-term debt</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=elv_SurplusNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=elv_SurplusNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884423280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Convertible Debenture Terms) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding principal amount</a></td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net debt carrying amount</a></td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate (shares of common stock per $1,000 of principal amount)</a></td>
<td class="nump">14.3238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Effective conversion price (per $1,000 of principal amount) per share | $ / shares</a></td>
<td class="nump">$ 69.8139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937864968880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Oct. 15, 2022</div></th>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2012 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 04, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 16, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 09, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 09, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (21,000,000)<span></span>
</td>
<td class="num">$ (36,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.3238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.8139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,899,000,000<span></span>
</td>
<td class="nump">1,068,000,000<span></span>
</td>
<td class="nump">1,932,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,000,000<span></span>
</td>
<td class="nump">822,000,000<span></span>
</td>
<td class="nump">794,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Future maturities of debt in 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Future maturities of debt in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Future maturities of debt in 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Future maturities of debt in 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Future maturities of debt in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Future maturities of debt Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,714,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,849,000,000<span></span>
</td>
<td class="nump">22,756,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,307,000,000<span></span>
</td>
<td class="nump">36,060,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,724,000,000<span></span>
</td>
<td class="nump">27,088,000,000<span></span>
</td>
<td class="nump">23,802,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,538,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred Tax and Other Liabilities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=elv_A5YearFacilityMember', window );">5-Year Facility [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=elv_A2021364DayFacilityMember', window );">2021 364-Day Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of Credit Facility, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=elv_A2021364DayFacilityMember', window );">2021 364-Day Facility | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.700%, due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DebtRedemptionAmount', window );">Debt, Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument, Redemption, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">at a redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.950% due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">749,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | .0450% due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">499,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 1.500% due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 746,000,000<span></span>
</td>
<td class="nump">745,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.550% due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 968,000,000<span></span>
</td>
<td class="nump">992,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.600% due 2051 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233,000,000<span></span>
</td>
<td class="nump">1,232,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.500% due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.350%, due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.375%, due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 2.250%, due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,071,000,000<span></span>
</td>
<td class="nump">1,089,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.125% due 2050 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 988,000,000<span></span>
</td>
<td class="nump">987,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 3.125%, due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.100% due 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.350% due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.500% due 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.550% due 2052 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 6.100% due 2052 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 741,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.900 % due 2026 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 4.750% due 2033 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember', window );">Senior Unsecured Notes [Member] | 5.125% due 2053 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=elv_OtherSeniorUnsecuredNotesMember', window );">Other senior unsecured notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000,000<span></span>
</td>
<td class="nump">79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarlyRepaymentOfSeniorDebt', window );">Early repayment of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">109,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="num">(30,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommercialPaperMaximumBorrowingCapacity', window );">Commercial paper authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="nump">3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on commercial paper borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Senior Convertible Debentures [Member] | 2.750%, due 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,000,000)<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days in 30 day period greater than 130%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NumberOfConsecutiveTradingDays', window );">Number of trading days exceeding 130%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Product of Conversion to Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MeasurementPeriod', window );">Measurement Period for testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_PercentConversionToStockPrice', window );">Percent of Conversion Price to Closing Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleEarliestDate1', window );">Earliest Date for Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 15,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DateDebenturesReedemable', window );">Date debentures redeemable at our option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 20,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.2319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ConversionPremium', window );">Conversion premium (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing Price Company Stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.46<span></span>
</td>
<td class="nump">$ 512.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_DebtConversionDebtPrincipalAmount', window );">Aggregate principal amount of convertible debentures surrendered for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="nump">54,000,000<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,000,000<span></span>
</td>
<td class="nump">302,000,000<span></span>
</td>
<td class="nump">222,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">If-converted value per dollar above the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense resulting from the stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Interest expense resulting from amortization of the debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest', window );">Long-Term Debt, Contingent Payment of Principal or Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Debentures also have a contingent interest feature that requires us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October&#160;15, 2022. As of October 15, 2022, one of these events had occurred and contingent interest began accruing on the Debentures at a rate of 0.50% of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest will be payable on April 15, 2023, to holders of the Debentures as of the April 1, 2023 record date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Senior Convertible Debentures [Member] | 2.750%, due 2042 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodEndDate', window );">Debt Instrument, Redemption Period, End Date</a></td>
<td class="text">Mar. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember', window );">Federal Home Loan Bank Advances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate', window );">Short-term FHLB borrowings outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Subsidiary Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt Instrument, Covenant Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt Instrument, Covenant Compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of December&#160;31, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.9%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December&#160;31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CommercialPaperMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Paper, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CommercialPaperMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion premium to the closing market price of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DateDebenturesReedemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DateDebenturesReedemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DebtConversionDebtPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate principal amount of the original debt instrument that was surrendered for conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DebtConversionDebtPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_DebtRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt, Redemption amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_DebtRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_MeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_MeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_PercentConversionToStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_PercentConversionToStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleEarliestDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date when the debt instrument can be converted into equity, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleEarliestDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of debt instrument redemption period, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarlyRepaymentOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarlyRepaymentOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of advance from Federal Home Loan Bank (FHLBank) maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6479118&amp;loc=d3e64650-112822<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conditions, facts and circumstances that would trigger a payment of principal or interest which was not otherwise immediately due and payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=elv_A5YearFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=elv_A5YearFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=elv_A2021364DayFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=elv_A2021364DayFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=elv_SeniorUnsecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=elv_OtherSeniorUnsecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=elv_OtherSeniorUnsecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888768144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss on loss contingencies</a></td>
<td class="nump">$ 596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_GrossPremiumTaxRate', window );">Gross premium tax rate, state of California</a></td>
<td class="nump">2.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term Purchase Commitment, Amount</a></td>
<td class="nump">$ 761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss on loss contingencies</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss on loss contingencies</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=elv_AnthemInc.v.ExpressScriptsInc.Member', window );">Anthem, Inc. v. Express Scripts, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds originally recevied from divestiture of business</a></td>
<td class="nump">4,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=elv_AnthemInc.v.ExpressScriptsInc.Member', window );">Anthem, Inc. v. Express Scripts, Inc. [Member] | Pharmacy pricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Approximate amount of damages sought for operational breaches</a></td>
<td class="nump">14,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=elv_AnthemInc.v.ExpressScriptsInc.Member', window );">Anthem, Inc. v. Express Scripts, Inc. [Member] | Operational [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Approximate amount of damages sought for operational breaches</a></td>
<td class="nump">$ 158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_GrossPremiumTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross premium tax rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_GrossPremiumTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=elv_AnthemInc.v.ExpressScriptsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=elv_AnthemInc.v.ExpressScriptsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=elv_PharmacypricingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=elv_PharmacypricingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=elv_OperationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=elv_OperationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937888792448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Summary Of Stock Option Activity) (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period, Number of Shares | shares</a></td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted, Number of Shares | shares</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Number of Shares | shares</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired, Number of Shares | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period, Number of Shares | shares</a></td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period, Number of Shares | shares</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Option Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period, Weighted-Average Option Price per Share | $ / shares</a></td>
<td class="nump">$ 255.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted-Average Option Price per Share | $ / shares</a></td>
<td class="nump">452.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted-Average Option Price per Share | $ / shares</a></td>
<td class="nump">242.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired, Weighted-Average Option Price per Share | $ / shares</a></td>
<td class="nump">339.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period, Weighted-Average Option Price per Share | $ / shares</a></td>
<td class="nump">293.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period, Weighted-Average Option Price per Share | $ / shares</a></td>
<td class="nump">$ 239.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">5 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable at end of period, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886979344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Shares and Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period, Restricted Stock Shares and Units</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Restricted Stock Shares and Units</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Restricted Stock Shares and Units</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Restricted Stock Shares and Units</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period, Restricted Stock Shares and Units</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share</a></td>
<td class="nump">$ 299.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted-Average Grant Date Fair Value per Share</a></td>
<td class="nump">453.70<span></span>
</td>
<td class="nump">$ 317.70<span></span>
</td>
<td class="nump">$ 272.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted-Average Grant Date Fair Value per Share</a></td>
<td class="nump">301.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted-Average Grant Date Fair Value Per Share</a></td>
<td class="nump">347.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share</a></td>
<td class="nump">$ 357.21<span></span>
</td>
<td class="nump">$ 299.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937895409024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalAbstract', window );"><strong>Banking Regulation, Total Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.97%<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (annual)</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life (years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937890767648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Weighted-Average Fair Values) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalAbstract', window );"><strong>Banking Regulation, Total Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted during the year</a></td>
<td class="nump">$ 116.92<span></span>
</td>
<td class="nump">$ 79.91<span></span>
</td>
<td class="nump">$ 54.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock and stock awards granted during the year</a></td>
<td class="nump">$ 453.70<span></span>
</td>
<td class="nump">$ 317.70<span></span>
</td>
<td class="nump">$ 272.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937885260192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Cash Dividend Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Dividends, Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear', window );">Declaration Date</a></td>
<td class="text">Oct. 18,  2022<span></span>
</td>
<td class="text">Jul. 19,  2022<span></span>
</td>
<td class="text">Apr. 19,  2022<span></span>
</td>
<td class="text">Jan. 25,  2022<span></span>
</td>
<td class="text">Oct. 19,  2021<span></span>
</td>
<td class="text">Jul. 20,  2021<span></span>
</td>
<td class="text">Apr. 20,  2021<span></span>
</td>
<td class="text">Jan. 26,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Record Date</a></td>
<td class="text">Dec.  05,  2022<span></span>
</td>
<td class="text">Sep.  09,  2022<span></span>
</td>
<td class="text">Jun. 10,  2022<span></span>
</td>
<td class="text">Mar. 10,  2022<span></span>
</td>
<td class="text">Dec.  03,  2021<span></span>
</td>
<td class="text">Sep. 10,  2021<span></span>
</td>
<td class="text">Jun. 10,  2021<span></span>
</td>
<td class="text">Mar. 10,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Payment Date</a></td>
<td class="text">Dec. 21,  2022<span></span>
</td>
<td class="text">Sep. 23,  2022<span></span>
</td>
<td class="text">Jun. 24,  2022<span></span>
</td>
<td class="text">Mar. 25,  2022<span></span>
</td>
<td class="text">Dec. 21,  2021<span></span>
</td>
<td class="text">Sep. 24,  2021<span></span>
</td>
<td class="text">Jun. 25,  2021<span></span>
</td>
<td class="text">Mar. 25,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash Dividend per Share</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Total</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the dividend to be paid was declared, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateDeclaredDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886915216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Share Repurchases) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice', window );">Average price per share</a></td>
<td class="nump">$ 478.99<span></span>
</td>
<td class="nump">$ 371.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Aggregate cost</a></td>
<td class="nump">$ 2,316<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Authorization remaining at the end of each period</a></td>
<td class="nump">$ 1,876<span></span>
</td>
<td class="nump">$ 4,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased and Retired During Period Average Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884307440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000,000<span></span>
</td>
<td class="nump">$ 255,000,000<span></span>
</td>
<td class="nump">$ 283,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit from share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">74,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,000,000<span></span>
</td>
<td class="nump">203,000,000<span></span>
</td>
<td class="nump">176,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee stock purchase plan, purchase price per share as a percent of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividends Payable, Date to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2022<span></span>
</td>
<td class="text">Sep. 23,  2022<span></span>
</td>
<td class="text">Jun. 24,  2022<span></span>
</td>
<td class="text">Mar. 25,  2022<span></span>
</td>
<td class="text">Dec. 21,  2021<span></span>
</td>
<td class="text">Sep. 24,  2021<span></span>
</td>
<td class="text">Jun. 25,  2021<span></span>
</td>
<td class="text">Mar. 25,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividends Payable, Date of Record</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  05,  2022<span></span>
</td>
<td class="text">Sep.  09,  2022<span></span>
</td>
<td class="text">Jun. 10,  2022<span></span>
</td>
<td class="text">Mar. 10,  2022<span></span>
</td>
<td class="text">Dec.  03,  2021<span></span>
</td>
<td class="text">Sep. 10,  2021<span></span>
</td>
<td class="text">Jun. 10,  2021<span></span>
</td>
<td class="text">Mar. 10,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IncreaseInStockRepurchaseProgramAuthorization', window );">Increase in stock repurchase program authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CapitalStockAxis=us-gaap_StockCompensationPlanMember', window );">Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of registered shares for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CapitalStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="nump">287,000,000<span></span>
</td>
<td class="nump">335,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average remaining requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CapitalStockAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock incentive plan vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_StockOptionTerm', window );">Stock option term, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">121,000,000<span></span>
</td>
<td class="nump">147,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit from stock option exercises and disqualifying dispositions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">$ 148,000,000<span></span>
</td>
<td class="nump">$ 129,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average remaining requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividends Payable, Date to be Paid</a></td>
<td class="text">Mar. 24,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividends Payable, Date of Record</a></td>
<td class="text">Mar. 10,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_IncreaseInStockRepurchaseProgramAuthorization', window );">Increase in stock repurchase program authorization</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=elv_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of registered shares for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount', window );">Maximum amount of stock employees are permitted to purchase per calender year (whole dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Payroll deductions, percent of gross compensation, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Payroll deductions, percent of gross compensation, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee stock purchase plan, purchase price per share as a percent of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="nump">$ 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | 2022 to 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Approximate number of performance restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_IncreaseInStockRepurchaseProgramAuthorization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_IncreaseInStockRepurchaseProgramAuthorization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_StockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Option Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_StockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CapitalStockAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CapitalStockAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CapitalStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CapitalStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CapitalStockAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CapitalStockAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=elv_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=elv_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_PerformancemeasurementperiodAxis=elv_A2022To2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_PerformancemeasurementperiodAxis=elv_A2022To2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882242144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in net unrealized gains/losses on investments</a></td>
<td class="num">$ (2,260)<span></span>
</td>
<td class="num">$ (457)<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in net unrealized gains/losses on cash flow hedges</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Change in net periodic pension and postretirement costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning</a></td>
<td class="num">(178)<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(2,336)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss attributable to noncontrolling interests</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending</a></td>
<td class="num">(2,503)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Net gain (loss) realized in other comprehensive loss, tax (expense) benefit</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest', window );">Other Comprehensive Income (Loss), Tax Benefit (Expense), Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Net unrealized investment gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">AOCI, Debt Securities, Beginning Balance</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in net unrealized gains/losses on investments, before reclassification</a></td>
<td class="num">(2,614)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</a></td>
<td class="nump">354<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in net unrealized gains/losses on investments</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">AOCI, Debt Securities, Ending Balance</a></td>
<td class="num">(1,768)<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Net cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">AOCI, Cash Flow Hedges, Beginning Balance</a></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in net unrealized gains/losses on cash flow hedges</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">AOCI, Cash Flow Hedges, Ending Balance</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Cash flow hedges, holding gain (loss), tax (expense) benefit</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Pension and other postretirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">AOCI, Defined Benefit Plan, Beginning Balance</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Change in net periodic pension and postretirement costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">AOCI, Defined Benefit Plan, Ending Balance</a></td>
<td class="num">(499)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense', window );">Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit (Expense)</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">AOCI, Foreign Currency Translation Adjustment, Beginning Balance</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">AOCI, Foreign Currency Translation Adjustment, Ending Balance</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment, tax (expense) benefit</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember', window );">Non-credit components of impairments on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities', window );">AOCI, Non-credit component of impairments on investments, Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities', window );">Change in non-credit component of impairment losses on investments, net of tax</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities', window );">AOCI, Non-credit component of impairments on investments, Ending Balance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities', window );">Non-credit component of other-than-temporary impairments on investments, tax (expense) benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of accumulated other comprehensive loss related to that portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized either as available-for-sale or held-to-maturity that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284427-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other than temporary impairment (OTTI) loss on investment in available-for-sale debt security, recognized in other comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 35<br> -URI https://asc.fasb.org/extlink&amp;oid=124260725&amp;loc=d3e25362-111560<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of other than temporary impairment (OTTI) on investment in available-for-sale debt security, recognized in other comprehensive loss, attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894434752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Earned) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectPremiumsEarned', window );">Direct - Premiums earned</a></td>
<td class="nump">$ 128,867<span></span>
</td>
<td class="nump">$ 113,149<span></span>
</td>
<td class="nump">$ 100,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssumedPremiumsEarned', window );">Assumed - Premium earned</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
<td class="nump">3,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededPremiumsEarned', window );">Ceded - Premium earned</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 133,229<span></span>
</td>
<td class="nump">$ 117,373<span></span>
</td>
<td class="nump">$ 104,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsPercentageAssumedToNet', window );">Percentage - assumed to net premiums - earned</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earned premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earned premiums ceded to other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167274&amp;loc=d3e27175-158546<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsPercentageAssumedToNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of assumed premium earned to premium earned after effects of reinsurance, as disclosed in supplementary reinsurance information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column F))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsPercentageAssumedToNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894707312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Summary Of Net Premiums Earned By Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_SupplementaryInsuranceInformationBySegmentLineItems', window );"><strong>Net Premiums Earned By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums Earned Net</a></td>
<td class="nump">$ 133,229<span></span>
</td>
<td class="nump">$ 117,373<span></span>
</td>
<td class="nump">$ 104,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_SupplementaryInsuranceInformationBySegmentLineItems', window );"><strong>Net Premiums Earned By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums Earned Net</a></td>
<td class="nump">35,633<span></span>
</td>
<td class="nump">33,209<span></span>
</td>
<td class="nump">31,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_SupplementaryInsuranceInformationBySegmentLineItems', window );"><strong>Net Premiums Earned By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums Earned Net</a></td>
<td class="nump">96,323<span></span>
</td>
<td class="nump">82,520<span></span>
</td>
<td class="nump">71,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_SupplementaryInsuranceInformationBySegmentLineItems', window );"><strong>Net Premiums Earned By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums Earned Net</a></td>
<td class="nump">$ 1,273<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_SupplementaryInsuranceInformationBySegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_SupplementaryInsuranceInformationBySegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894406544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Effect Of Reinsurance On Benefit Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross', window );">Direct</a></td>
<td class="nump">$ 112,809<span></span>
</td>
<td class="nump">$ 99,007<span></span>
</td>
<td class="nump">$ 85,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed', window );">Assumed</a></td>
<td class="nump">3,730<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded', window );">Ceded</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Net benefit expense</a></td>
<td class="nump">$ 116,487<span></span>
</td>
<td class="nump">$ 102,645<span></span>
</td>
<td class="nump">$ 88,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of policy benefits and costs incurred for policies assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of provision for policy benefits and costs incurred for policies ceded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883710896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Lease and Other Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_ShortTermAndVariableLeaseCost', window );">Short-term and variable lease cost</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, Cost</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">2.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other noncurrent assets<span></span>
</td>
<td class="text">Other noncurrent assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other noncurrent liabilities<span></span>
</td>
<td class="text">Other noncurrent liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_ShortTermAndVariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and variable lease cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_ShortTermAndVariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937882398912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Future Minimum Payments, Due 2023</a></td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Future Minimum Payments, Due 2024</a></td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Future Minimum Payments, Due 2025</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Future Minimum Payments, Due 2026</a></td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Future Minimum Payments, Due 2027</a></td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Future Minimum Payments, Due Thereafter</a></td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed Interest</a></td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937879310736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating Lease, Impairment Loss</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937895343264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic earnings per share&#8212;weighted-average shares</a></td>
<td class="nump">240.0<span></span>
</td>
<td class="nump">243.8<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities&#8212;employee stock options, non-vested restricted stock awards, convertible debentures and equity units</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted earnings per share</a></td>
<td class="nump">242.8<span></span>
</td>
<td class="nump">246.8<span></span>
</td>
<td class="nump">254.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887853632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Narrative) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults', window );">Restricted stock units excluded from the denominator for diluted earnings per share</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potentially Dilutive Restricted Stock Units Contingent On Operating Results</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937887001728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Financial Data By Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">$ 155,660<span></span>
</td>
<td class="nump">$ 136,943<span></span>
</td>
<td class="nump">$ 120,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating gain (loss)</a></td>
<td class="nump">8,452<span></span>
</td>
<td class="nump">7,489<span></span>
</td>
<td class="nump">6,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">41,674<span></span>
</td>
<td class="nump">38,809<span></span>
</td>
<td class="nump">36,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating gain (loss)</a></td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">96,810<span></span>
</td>
<td class="nump">82,919<span></span>
</td>
<td class="nump">71,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating gain (loss)</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating gain (loss)</a></td>
<td class="nump">1,868<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member] | Unaffiliated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">14,974<span></span>
</td>
<td class="nump">12,655<span></span>
</td>
<td class="nump">10,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member] | Affiliated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">13,552<span></span>
</td>
<td class="nump">12,776<span></span>
</td>
<td class="nump">11,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">13,294<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating gain (loss)</a></td>
<td class="nump">354<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other [Member] | Unaffiliated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">2,202<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other [Member] | Affiliated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">11,092<span></span>
</td>
<td class="nump">7,690<span></span>
</td>
<td class="nump">3,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_SegmentEliminationsMember', window );">Segment Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="num">$ (24,644)<span></span>
</td>
<td class="num">$ (20,466)<span></span>
</td>
<td class="num">$ (15,431)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.1,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=elv_UnaffiliatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=elv_UnaffiliatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=elv_AffiliatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=elv_AffiliatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_SegmentEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_SegmentEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886183776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Major Product Revenues) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">$ 155,660<span></span>
</td>
<td class="nump">$ 136,943<span></span>
</td>
<td class="nump">$ 120,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">41,674<span></span>
</td>
<td class="nump">38,809<span></span>
</td>
<td class="nump">36,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member] | Managed Care Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">33,927<span></span>
</td>
<td class="nump">31,564<span></span>
</td>
<td class="nump">29,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member] | Managed Care Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">6,152<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member] | Dental Vision Products And Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember', window );">Commercial and Specialty Business Segment [Member] | Other Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">96,810<span></span>
</td>
<td class="nump">82,919<span></span>
</td>
<td class="nump">71,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member] | Managed Care Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">96,322<span></span>
</td>
<td class="nump">82,519<span></span>
</td>
<td class="nump">71,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business Segment [Member] | Managed Care Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember', window );">CarelonRx Segment [Member] | Pharmacy products and services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">28,526<span></span>
</td>
<td class="nump">25,431<span></span>
</td>
<td class="nump">21,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">13,294<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member] | Other Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember', window );">Other Segment [Member] | Integrated health services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="nump">12,274<span></span>
</td>
<td class="nump">9,645<span></span>
</td>
<td class="nump">5,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_SegmentEliminationsMember', window );">Segment Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_MajorProductRevenueBySegmentLineItems', window );"><strong>Major Product Revenue By Segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Insurance Services Revenue</a></td>
<td class="num">$ (24,644)<span></span>
</td>
<td class="num">$ (20,466)<span></span>
</td>
<td class="num">$ (15,431)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_MajorProductRevenueBySegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Major Product Revenue By Segment [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_MajorProductRevenueBySegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.1,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_CommercialSpecialtyBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elv_ManagedCareProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elv_ManagedCareProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elv_ManagedCareServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elv_ManagedCareServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elv_DentalVisionProductsAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elv_DentalVisionProductsAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elv_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elv_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_IngenioRxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elv_PharmacyProductsAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elv_PharmacyProductsAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elv_IntegratedHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elv_IntegratedHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_SegmentEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_SegmentEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883946688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Reconciliation Of Revenue From Reportable Segments To The Consolidated Statements Of Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Reportable segments operating revenues</a></td>
<td class="nump">$ 155,660<span></span>
</td>
<td class="nump">$ 136,943<span></span>
</td>
<td class="nump">$ 120,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NetGainsLossesOnFinancialInstruments', window );">Net (losses) gains on financial instruments</a></td>
<td class="num">(550)<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 156,595<span></span>
</td>
<td class="nump">$ 138,639<span></span>
</td>
<td class="nump">$ 121,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NetGainsLossesOnFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net gains (losses) on financial instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NetGainsLossesOnFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.1,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937886979280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Reconciliation Of Reportable Segment Operating Gain To Income Before Income Taxes In The Consolidated Statements Of Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 7,769<span></span>
</td>
<td class="nump">$ 7,925<span></span>
</td>
<td class="nump">$ 6,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net Investment Income</a></td>
<td class="num">(1,485)<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NetLossesGainsOnFinancialInstruments', window );">Net (losses) gains on financial instruments</a></td>
<td class="nump">550<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other intangible assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segments operating gain</a></td>
<td class="nump">$ 8,452<span></span>
</td>
<td class="nump">$ 7,489<span></span>
</td>
<td class="nump">$ 6,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NetLossesGainsOnFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net (losses) gains on financial instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NetLossesGainsOnFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894406544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details) - segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember', window );">Government Business [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue generated from participation in various federal government programs</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=elv_GovernmentBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937883679520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=elv_APCPasseLLCMember', window );">APC Passe, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssumedPremiumsWritten', window );">Assumed premiums</a></td>
<td class="nump">$ 501<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=elv_APCPasseLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=elv_APCPasseLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894625024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statutory Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Statutory risk-based capital necessary to satisfy regulatory requirements</a></td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="nump">$ 6,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">GAAP equity</a></td>
<td class="nump">36,307<span></span>
</td>
<td class="nump">36,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency', window );">Statutory Accounting Practices, Dividends Paid with Approval of Regulatory Agency</a></td>
<td class="nump">3,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_EstimatedFutureDividendPayments', window );">Estimated Future Dividend Payments</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=elv_CaliforniaDepartmentofManagedHealthCareMember', window );">California Department of Managed Health Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Statutory risk-based capital necessary to satisfy regulatory requirements</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember', window );">Insurance, HMO Subsidiaries and Other Regulated Entities, Excluding the California Department of Managed Health Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Statutory-basis capital and surplus</a></td>
<td class="nump">19,048<span></span>
</td>
<td class="nump">16,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember', window );">California Department of Managed Health Care Regulated Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">GAAP equity</a></td>
<td class="nump">$ 3,795<span></span>
</td>
<td class="nump">$ 3,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_EstimatedFutureDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends expected to be paid during the following twelve months subject to regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_EstimatedFutureDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends paid subject to regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=elv_CaliforniaDepartmentofManagedHealthCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=elv_CaliforniaDepartmentofManagedHealthCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937864950848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,387<span></span>
</td>
<td class="nump">$ 4,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fixed maturity securities, current, amortized cost</a></td>
<td class="nump">25,952<span></span>
</td>
<td class="nump">26,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">4,298<span></span>
</td>
<td class="nump">3,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">5,281<span></span>
</td>
<td class="nump">4,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,617<span></span>
</td>
<td class="nump">51,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">3,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,772<span></span>
</td>
<td class="nump">97,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">9,683<span></span>
</td>
<td class="nump">7,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">39,696<span></span>
</td>
<td class="nump">34,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">22,349<span></span>
</td>
<td class="nump">21,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">66,378<span></span>
</td>
<td class="nump">61,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies-Note 5</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,084<span></span>
</td>
<td class="nump">9,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">29,724<span></span>
</td>
<td class="nump">27,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,503)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">$ (296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,307<span></span>
</td>
<td class="nump">36,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">102,772<span></span>
</td>
<td class="nump">97,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fixed maturity securities, current, amortized cost</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Net due from subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other invested assets, long-term</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_InvestmentInSubsidiaries', window );">Investment in subsidiaries</a></td>
<td class="nump">59,042<span></span>
</td>
<td class="nump">56,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">62,550<span></span>
</td>
<td class="nump">60,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Net due to subsidiaries</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,544<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">22,324<span></span>
</td>
<td class="nump">21,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,243<span></span>
</td>
<td class="nump">24,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies-Note 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,084<span></span>
</td>
<td class="nump">9,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">29,724<span></span>
</td>
<td class="nump">27,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,503)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,307<span></span>
</td>
<td class="nump">36,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 62,550<span></span>
</td>
<td class="nump">$ 60,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_InvestmentInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_InvestmentInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937894163936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information Of Registrant (Balance Sheets - Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">237,958,067<span></span>
</td>
<td class="nump">241,770,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">237,958,067<span></span>
</td>
<td class="nump">241,770,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale fixed maturity securities investments, current, amortized cost</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Fixed Maturity Securities, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">237,958,067<span></span>
</td>
<td class="nump">241,770,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">237,958,067<span></span>
</td>
<td class="nump">241,770,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937864852976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information Of Registrant (Statements Of Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">$ 1,485<span></span>
</td>
<td class="nump">$ 1,378<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NetGainsLossesOnFinancialInstruments', window );">Net (losses) gains on financial instruments</a></td>
<td class="num">(550)<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Administrative fees and other revenue</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">6,913<span></span>
</td>
<td class="nump">6,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">156,595<span></span>
</td>
<td class="nump">138,639<span></span>
</td>
<td class="nump">121,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">6,025<span></span>
</td>
<td class="nump">6,104<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_NetGainsLossesOnFinancialInstruments', window );">Net (losses) gains on financial instruments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Administrative fees and other revenue</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">794<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_TotalExpenses', window );">Total expenses</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income tax credits and equity in net income of subsidiaries</a></td>
<td class="num">(1,020)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Income tax credits</a></td>
<td class="num">(461)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Equity in net income of subsidiaries</a></td>
<td class="nump">6,584<span></span>
</td>
<td class="nump">6,758<span></span>
</td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">$ 6,025<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 4,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_NetGainsLossesOnFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net gains (losses) on financial instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_NetGainsLossesOnFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_TotalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_TotalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937874229008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information of Registrant (Statement of Comprehensive Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">$ 6,025<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 4,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in net unrealized gains/losses on investments</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in net unrealized gains/losses on cash flow hedges</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Change in net periodic pension and postretirement costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">5,776<span></span>
</td>
<td class="nump">5,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Shareholders&#8217; net income</a></td>
<td class="nump">6,025<span></span>
</td>
<td class="nump">6,104<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in net unrealized gains/losses on investments</a></td>
<td class="num">(2,249)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities', window );">Change in non-credit component of impairment losses on investments, net of tax</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in net unrealized gains/losses on cash flow hedges</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Change in net periodic pension and postretirement costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 5,776<span></span>
</td>
<td class="nump">$ 5,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other than temporary impairment (OTTI) loss on investment in available-for-sale debt security, recognized in other comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 35<br> -URI https://asc.fasb.org/extlink&amp;oid=124260725&amp;loc=d3e25362-111560<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937884144448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information Of Registrant (Statement Of Cash Flows) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,399<span></span>
</td>
<td class="nump">$ 8,364<span></span>
</td>
<td class="nump">$ 10,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,946)<span></span>
</td>
<td class="num">(18,669)<span></span>
</td>
<td class="num">(19,492)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending', window );">Changes in securities lending collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
<td class="num">(849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,560)<span></span>
</td>
<td class="num">(9,638)<span></span>
</td>
<td class="num">(7,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Net (repayments of) proceeds from commercial paper borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,899)<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
<td class="num">(1,932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable', window );">Changes in securities lending payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and retirement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,316)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
<td class="num">(2,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Cash dividends</a></td>
<td class="num">$ (305)<span></span>
</td>
<td class="num">$ (306)<span></span>
</td>
<td class="num">$ (309)<span></span>
</td>
<td class="num">$ (309)<span></span>
</td>
<td class="num">$ (273)<span></span>
</td>
<td class="num">$ (276)<span></span>
</td>
<td class="num">$ (278)<span></span>
</td>
<td class="num">$ (277)<span></span>
</td>
<td class="num">(1,229)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
<td class="num">(954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock under employee stock plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid through withholding of common stock under employee stock plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
<td class="num">(861)<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</a></td>
<td class="nump">7,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,387<span></span>
</td>
<td class="nump">4,880<span></span>
</td>
<td class="nump">5,741<span></span>
</td>
<td class="nump">$ 4,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
<td class="nump">4,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(2,059)<span></span>
</td>
<td class="num">(2,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments', window );">Proceeds from sales, maturities, calls and redemptions of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OriginationOfNotesReceivableFromRelatedParties', window );">Issuance of note to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Capitalization of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending', window );">Changes in securities lending collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet', window );">Purchases of property and equipment, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="num">(1,821)<span></span>
</td>
<td class="num">(2,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Net (repayments of) proceeds from commercial paper borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,899)<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
<td class="num">(1,932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable', window );">Changes in securities lending payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and retirement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,316)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
<td class="num">(2,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Cash dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock under employee stock plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid through withholding of common stock under employee stock plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,464)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="num">(3,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(1,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</a></td>
<td class="nump">$ 942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net purchases of and proceeds from sale of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecuritiesLendingPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecuritiesLendingPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OriginationOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OriginationOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139937891367184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details) - Parent Company [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDividendsPaidToParentCompany', window );">Cash dividends received from subsidiaries</a></td>
<td class="nump">$ 3,097<span></span>
</td>
<td class="nump">$ 3,134<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid to subsidiaries</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elv_CapitalContributionToSubsidiaries', window );">Capital contribution to subsidiaries</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">3,271<span></span>
</td>
<td class="nump">$ 2,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Amounts due from subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Net due to subsidiaries</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Parental Guarantees</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Notes Receivable, Related Parties, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elv_CapitalContributionToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital contribution to subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elv_CapitalContributionToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDividendsPaidToParentCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents disclosure of the total aggregate cash dividends paid to the entity by consolidated subsidiaries, by unconsolidated subsidiaries, and by 50 percent or less owned persons accounted for using the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDividendsPaidToParentCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>elv-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:elv="http://www.elevancehealth.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="elv-20221231.xsd" xlink:type="simple"/>
    <context id="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2398c42e085f4920a603bf9b3ed00ec1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i79090320ca5f4e8f812187d03517a85e_I20230201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2310c7de653445608cb615a91fde33b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6715d3ccc7ea4563a72cd62894c7df53_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf5b071c02144445ae1940007287f05f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8589c07204d749bbace5042c6b65cc69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i99f221c1344f471085a849bbadf705e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f53fa30766f4027ac9f51d714b28ca5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30274a1261ef49b2b0ed74d1f2f4ffd0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32e30683b4044476b165b02ff7db9ad5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2672b85aeaa43e380a7c111f5228b73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i793efbc5c7714f92b8248295269327af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if94c1fcb18c342dc8db391ef68ac66d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35a79074187a456ab3c3c9edc81fd430_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if93412ca87a24e1a8d15a5d209e51bbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6d4349f67ff4c61980f48af218a4394_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65a827868fc64ccfacc19325aa44c171_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67a2241770974cd59c85ae10194b94f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d68c3e5edf94c9cbe296449811771a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if422755e3e354c5f865ec51e2e1db51d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6946927fb5b546f5b3d2eaef12758789_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1e4608246614931930218a735fc0cbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2494f99710864bc7a90c0848d3e5fde2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42b6d6da5eaa4137b9f2ce6c292546d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifad2035d69cb4c4bb3a71c39d076f734_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab35b50f371d4e109ef6e82fb6162116_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4923e0fc5164066835e075d6d5a4675_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic55f913977d34ea8ae0f65c274b41526_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62707788a92840b2a900639d9bb21b20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib61b9bc047c24fe089b47010fc8c5147_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64441609cdbc496fa38247c4ed248dd7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05b94430fac3410384b74a0089cca3b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9ced248bb284327b4df64ad260e211a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8cdeae00e15947f2b19d9c357486c5be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc4af8f693284287a7966314732d1b9d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaf37da992005431c9ad91f291589bab4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22f60e8bbf864a89ba6d0bb4ef9e07bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if071474e71e54a499f11bedc93cff54d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i842be0164ef642f19cf764709db72fe4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83026d2c318c405b900c3c41a9e37cc7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c555ed090374b7b9aa02f28d95d625c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4de08eefaeef475eacfe40d3fec4420a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:AcquisitionYearAxis">elv:AcquisitionYearPriorDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i74006674df2c4b7198d31e2b3985d5af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i652f2991b53941a1ac659bcb35e66d54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1938794b003c4dd68259f49f8b875e81_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia66ac29085ee41519cfd744c0ac8e03c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2bdd480b33d48f7a527eb0cb95e6c5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7079cee400b941a48ccb1dbed22219ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11008b88eee44f57a4919c3d0effdc63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i92993e9e6dc54ce8b4394a223f436cb2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5647eb933f9e401e971742cbdc4d882d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:LeaseImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76840fe11a4246adb33e2fc35f9dce5c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:PPEImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i720085721492466da1460ae790fd044c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b56ea1be96f4c70a8c1e7c9144fc68a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:LeaseImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic66c129efd394897bd946da50f16dfa9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:PPEImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ff881db619a457a91ac84f1aefaed9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:LeaseImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2f02a690e784ac385d21cd667d6d637_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">elv:PPEImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie891e0f02de14c5b99b6e50667fa8c9a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77d0aff55fa54fd2a9a2a30c2e6c6a2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2229f739c29e4879809a6429e83712f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4fcad706e1b4867b404702dd922e926_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic99433158fc54e1e93f623489413f8de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e2df902d3b34cf4a36058a667c1980e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i575634935f9d42e19be485bc9862c0f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9f081e73a6c44fa88baccf8ed778d26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie7ec68f2e8874c1095494d4e367728a8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80df43e3b8244694a103a6571a73884c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idba1560cbbed45a88ea28c07d58f145d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89cfda63370a45baa262eae4cf193a82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2fac999a95e4a5cb79ad594faeeb86b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7da5fca7f08493dbf6109531d652055_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2e206452b4b4525ba8295deb406a4ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e00c7e161a54ca296d8ca502242628b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec50b6ddc92544c49b1a002b6bec5470_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82c3b964b82147128c282f3d7907d1fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56b44a4216564a04ab613dc30466a108_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2b05263cbe6467f97da7e76b69399cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id65761e7270d477bbc88316eeb1f57e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfcbc3060b964c0eb745c3af7c301df1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia153a0252f0c4f25a894df66b87f8a12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2334e7c069664e34bdb994a9760d559a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bf6477caab241859e5cf0650ec3947c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0418a7408fb4b69aee3f6404d135a23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i498cff72f8f34a2ab008f70e24959c30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ef64ace9ef94f91a76ea258c74686c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76781baf46eb4f6ea9f326720c56d24c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f7d5ce1d5854f9ab123aec1ba08a66c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19a0491ff0494ee48b5b1055821af090_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b47b4ff361f4031989f83a3333a82d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c623535470d4d61ab37acba9cfad54c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d18fbff221e4d46b9e4768147f370b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53403b97747a43718fc787ec172de61a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb31ce1cd8a2411fb9513a02d3ed3cf9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78b0aede65fd4dd29e1f856a933eb6ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i313a7fbc748841a6a6f1211fc6c0b559_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib727fd184c464a5092079464e697cc0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if532c3e8149744e285dc513d9e69b523_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:ThirdPartyInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9313f67506114bbb8c5bc5b22dd2012f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:ThirdPartyInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15ad5cb59a1e44c5bef8850e5117517c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:RatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie118092ebec04fe3afe79f4870f4ed4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:RatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea80de425e5d4008bbefd6978deb3701_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9974d46da761480e8fd7c0dfc0115459_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6d4050ea7e946fb83bc63f84f887ce0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idaf228ebc5ee4ed9ac397e8420d1727c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccf0e0041e444850986706abfccd14c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i349488ab238e4f40b2b347c93c7e1a52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d0c3a19c29c4b649862b0b586cdef34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie74879d09949481ca3d9a43e6f898eb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:EquitySecuritiesotherAssetsotherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c85d8180b384c1b902ff87d3cee955d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6479287b4fdd42e685cd3c578fd33e14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3ce009ab57443fd98fe415da6193a1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09dd408e89d54981af41dcf162ba1bc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:EquitySecuritiesotherAssetsotherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie81542d413fa4945bbc09e8c29161193_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f20343c2c574345836f7ccda1cb4891_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e2fb9b4d38545ababb8320a29faa28d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFivePointFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34e594917ec14e3681954b85197676eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFivePointFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic56e8a6011ed4fdc85d7e0cfa580e4a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFivePointFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie552404ba61c47b389e3c8fc6a697712_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i459958d874344214bb9cac08d7d757ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia50a6cc46d6248a397c24a2ad0c2c744_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i02888f49341a44d4941c9b1b6fb319ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida52dad48cef4deba690de9747f68ee8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7ee2dc635204bbf8650d842aeb2bac7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab6d874468aa4ce6bcf71bd25597b297_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42f4135503874ad1943ea10cbe7602f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia06f61dafe7046c7a1f76c38c5fc05ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointFiveFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e0d380b589e4106bb438dadcea77ccf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfdeec77a2e849ab99853223554b64b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cf6c3723dd347668da304307c4a44a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedTwoPointTwoFiveZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if2ccb539d68746d59161c8870f4d4df0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08a4ad028b9a441cb7f6ba9a6e59341a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5be7d9b2d014385b6e19a6db3d6a4ec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01ed18d384274ea3a14a91f034c105cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3411db499754ed98b66e11164278b68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39a83586d8464e20bb8ad68eb2540321_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedFourPointOneZeroOnePercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2303e464443d492f83362a773fe17a1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedThreePointThreeZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie189000e9d504c47b363ff6e09fccc11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedThreePointThreeZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib61cdc82bcb443a8bf3d68ac1f8fb21c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">elv:InterestRateReceivedThreePointThreeZeroPercentageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:TwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i272bebf1c8d949a8be406568bd0c2793_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04c8de26adbc407f960803fd1f108a21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95d7b5c7de1a49d48dd9569c22788930_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f6fb48bbe5b4149b5d3e9962701d8e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6c16b45922c4bc795ba956462757098_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:HedgingStatusAxis">elv:TerminationsDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i763517f93d014233863645c9d2bb0185_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:HedgingStatusAxis">elv:TerminationsDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i948573928d0f465a94e16e23831957af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied8cd1ce29634691bf5ec4a6493a4478_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia22c58671ad6415a8c5e55c98cb16b5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:NetGainsLossesOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66ca95f113844a1a84afeef54a926515_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i387703b787a3494b9ce325988abfd1f6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia72f11ca13104ea894df74d97337dea2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1b9f4d2b3cae4c11bac411a49ddb6174_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if10138f4228d48388824633025312afe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:NetGainsLossesOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34017a6ceea74441bb34336674de31f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26b5329fa2db4a9582fa955c6c09aa5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a12478c233d4cb4a3af16a5ece03ad5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a54e76eb8e745a0bcc186bff383f66b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i647110a052c44104b85f07f28a55e14a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">elv:NetGainsLossesOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic81edd70f3ec4b3ab957edfc0bf60938_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74c774f65870474b9ff9c262bc7ac889_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:FutureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c3650a094504772a0bf73a6172f2a67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9096a0c9b14b4c9fa7be9af938dcc3ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99009b08fecf44cd93c279adb331703f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i009bcd76d73148e5a865a59956651a7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27b44c05131d4056a2f7c3c898130a7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic72bd0d75b5c431692b8edb1c1c0d1dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id293b24cef6f4af1a37865b3f65c5128_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4723ab4fdb2541989a926b6fa4fa981e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9c3b00e889545ffb01d1e62bf2b6746_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a55bb1adcf5446f8c1b805d8f31144e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bd1383cc1874b88a8aa6f742ec27422_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i206bf39a6a2e4283b7d98c5e5aba95be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica4de37099734e248456f4b9bcd0d11e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia46e01dc3c644cd08544f306992b1cec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f78627f2e9a4f66a5c0bcdfdccb0aaf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ceef5d05b49498c84bc7a5735c400aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ca8984787184bbbaefef048ae2a7ed2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4c6a19fa0fd4060aabf6478982ccf36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0160f1f3dab24f569a23d2ba07f095d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebb2feacd11c4565bfc6b5b6a3e279ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a873585c11f450d9fd9cf3c29c105f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51990bde857d4a5db236e8926558a29b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0441844ced744791a772d411eed7ca9f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i904c347e51a64fb59bc57777f21d4ac5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7f260a809bb49cb9e77ad6f5c2904a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89f714be3d7a47ffa4d705a6678f8d4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i069417d1b9bb426dbfd0f19f51c445ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifca89489e7414de0a4fed48d20415ea2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if117aa6b760a48b191a9336dd1386d0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bdae597d08f410ca9c02ca9b55441e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19b75bd9929846879cf5eaddd4752c76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1417f5c20d04886b4a1c28630457c0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6b78fb8e9294d4091b91dfb2f7b8dfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d2e3cdf76fb4346a9739172b0a28be0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5abc1365f064e1ea869ec15ff3abcd3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ebaa3e81cfc4ec9b580beed5caa48af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d91da7322044ebeb41aac5b19dd9fa5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2aaff6ca3964450bafa714cc0aaec6db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie41132adfcfc49268da644c34fda294a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92581736a99943b98dfe57570a7dba53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7de34994aae94c3fa1fe238756f73e72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1333f2613ac4700882b9aa88ce86e8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dac1ad1470b43dab49c726357aa7ff8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c02d35e75f4475c925518ec594b0833_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3876e659055149f7a703040ca62a38d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ea83cb6a8de4fa3949218ca98d32023_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if19a9ee228de40aa8494169d2d2d10e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0894905483914d83a324be50305c8544_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf99af398d9f47d5a429fe1dcacc1f44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4120bc1c539494db1a281d2596d5086_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:FixedMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e3257f7fe574daa85e3967b1d116931_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04fa6f9d293449e69c6dc3044ca3c4d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ExchangeTradedFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i731f097a1855416da64a94d30b7089d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7534f37a1c0488aa47b62fc88cc8dc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc437a887c994868be66d15b5875523e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib859e237e46b490d97c83b2fbc6eb7c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29501ab2755d404f9726f590112ae654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3039f8072e324d98beb39105271bc417_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39da1e7e5b0d4e3faac6f5afb10e8022_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8fcb396e62c4b998da85a181a469648_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1831bed7a9a940b7b66b76e245b8018c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa94f2b63b1149839f52e2f831a1edef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16eafcfee2cb4d9b8e93262638fce1f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie822cce3164245ebb93dd26d240e4175_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11de76f442c4431cada80f558aa8ffc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">elv:CommonEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2414d6cfbbd4765bf4121c62ca67493_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3def97b16324c25b53915d44aa74ac6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d3e183cefc842978e11387775c98361_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44e5a8e93e844062b0f224b3e55aed8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">elv:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5f9bbbaabb04060a11a6fd22a348392_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1cb710db79d409384335a6604d0729f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bede030acd1445e92925c2eb16fa9a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f18267c023f408a99a89907537030c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf9d8f64f3ad45a084579266e307020c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b4ecb9767514086a037990f8b694328_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e4c774172504b819ea779511e90e19c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72f47d433c9f44b894af80bfe9cba63a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb1c35519dba4644a3fb343be2411cac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3211a2672ef480891cfd22783436bf0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa94c0104acc4bf89ee5934a42f0fbc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d998702002443e1bdceee7c1cd3cda9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i360abcc2cf914906ae4e38a91bc64c5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50e9582cb2ed44069090ba97e16cd18e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79df65678198415585bd1eadb7bbe9b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb612f5a191c437cb13598e31f479571_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i865d332876a146d48476c774263e9f01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i876b8cfa43904577b851c227ca0f5cf5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8098a79a2da540da9b0adddcc15af4af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ac255a2c1404484817fa038dbd46f96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i686937bb287f43208495ac30ebad9562_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29275f18d1a443b99c9691261dec2159_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib761ace65d4940a186ff76782f95901f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f400c669aa243fc80d850a5a79e4aab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i813b76aca5e84f95975d45509f90c61a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfe7e2d076a6470199f2cd23ff79750c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i817dd5ae5155486e828b00cf52760c8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida04d4221bb546bc95004ba270b1eebb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaae7271d9499404cbd33f47b9000a9f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47b12cb75dff40b3bf086b65a329faee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e3f09e2780b43d58044eb37c7023411_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">elv:DeferredTaxLiabilitiesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f3311caed27499f9d192299b6eb8a0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">elv:DeferredTaxLiabilitiesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2e18d5b222e4195ad3fcd596a9a4307_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">elv:HealthInsuranceProviderfeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4eb438ebee364c309fc5d5bf8993c811_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib99d2d66da9844cab49602099b561dda_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i725fb0d8346e4b058763cea8f52dbda8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6360a309b9734213b5078c4fb29519ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">elv:LimitedCarryforwardPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i608f90ce9dc149a3bbb7d2041635b146_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">elv:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c426fec08424ce089096359689f3d77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8676a9f8039043f9a4adf4d85b99b12f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8837dd9386e64e11b2b5a657d243c739_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e4adbddcdea43adb30ab20715a88be5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife5dcccaf6344690b4d7278e78ed1c0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6370e321e07c4309a9e458991006a124_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bbfdb76686848eba1f8e4e3f910ddd7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">elv:DataProcessingEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2273513928e9447ea6f22d1ef1546380_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">elv:DataProcessingEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6c1eace13124235af0ad332c211c0f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i299992abfe3a42a19dbf532c6dfc8e3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96687506b8f94774b0749011a7e8cc30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib04cdfc65ff948fc912a66ca626eb27e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19d2136218984fc386824cc3db496a1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42cda9b6c29f4c1188c4b091bb78bbdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc64eab57fde4787b3c18d688b193ef3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie605a92d69da478bba8a4d5a934346aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i414a136e0db84003bf078b0578623a1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i878444205e1c46049c539d9fd06405ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6addc423352741bab0b178cdde51da3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i854e5f6c800a408a8b83bac7c2f66e50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5282ee6fb6643008a314c4a693905e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f1719b8ce5348aca152c341aa0c2afd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecd5af0076694b48bcfd411f1a1d2e11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i307c5528ab3a457cbfb9833f2f43c891_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if62dc3c697d8430b8c0877a6bd308c20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5d28adfc0a54bd9baceff349c99b744_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c60676ab036430ab5cabf0a0d051ae4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i363acffb9a824cb3994c18c156fa9f14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibef9f77b3653474080b83cf476ebe688_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8591443e8521443493e922d924cd9752_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i666bee6f945341f288f2ce40ac054956_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i899c188b277246f88a96c04a8b0e3a2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4626139b5a5432daffd219066037e28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cb27c8fb2e64bcca33419af780e6ad8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1a7d829139842f08030a894802ebb5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic09884f298c34bfc8b99687d69272ecc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i399e8b1e21f5426486fa66186ca7a17e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifba97ae25e674ac09265ecbdcc7c49a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e00926518a047ec902e830460f86c18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7eae151120d438b8aa81ae6d01ed182_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72b759f5ad9048f5a21e88c5835d93b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10c987896cca46c88648cd9e0c631ac2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c42f530033b47d8829379b411ebac86_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic34e126013bd4bdd9dcbc1e1560410d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PreMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28bb80744cf5451abb433b7a2ae2b2ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PreMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1af3c75b085341f79aae1e5b4a9109ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PostMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i411e095557594f3599b08db79d9385d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:DefinedBenefitPlanByAgeAxis">elv:PostMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa0439546d944cc89a588764266c7975_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idecc2f49500d45e9a24a291a9d799fff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35c312959f4143d697939a1225baf4a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd444af0664e4c1298d3fa8d8b705ead_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if05d6861eb1d4839b34b143297bc3b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i073e475229744657ac73e9da590e83f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4bc1af1b98554725ab989022f0630a0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3304b8d471184ac39be41951a5853e03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i857507cd2bed48a9b9fe3fbc5b737056_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ace04bb2beb40b5a516c227c3ea00a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60a7d2ba705a4df69942c441186b72ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id40578ab1c8b414884a39f3c0dae2822_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30cc7418cfc74f5ba17ab4369f714947_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20102145585646cab0be477d78b18a73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb6ab942bd2841168cdf7a7b4a3187a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibda9b4fba37e447fb4c9600c624c8dc0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3f81cdb55ce4e638a62241e00ebf0de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8d73bdd3b14402d844c2c0c59694668_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f28b66f26ff499d8c7bd3a51827b9ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4724ad9e28e04afa90e6467a8712ebf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62f9bcc18dfb447fb775b32088b6531d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf38d6a8dac24b72b1557ce07935c19e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3757024d2c6475cb1979d3770868e66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc490491d76a485b890f14584a038a3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32d53728a1d54d7b9516dd30a8bdda03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c392f7e463f4339b291aa741cf0be26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2290abd15315443bb3b678c9c9e06e50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bca97fbdff84230a99f35c1a1dce85d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5847c45467bd4402971d8c43f9e23685_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8fa58a7f71b41e5ba27e355644a55ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide6d48987cd74ff3be80bbd508db4661_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37817d0ad4574456871358f331c06a5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i717a210731b940ee939db3c1dbba5956_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb399901683c4c35b4197be484a877d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc920e05c21b44d7961db2b67b504016_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icac85b6a86c64d77b811c48e62a14bb5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if89014b28ae34bfeabe6689041e3ca5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d1a53d49d5c4867aa039a46e7568ed3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5fec0c29d10b4a398f12075276df4a35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idea2c0b2ce6a4178bc52bfce6465f76d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i290e040e29e44712bfeb543bae80308f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingPartnershipInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i218998b309404346862bc9cdba62f2cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief4f2b19fc0245a59b7962eec5c99085_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f55d4ef714f45e2a97aae94dc3b7ded_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4f648bcd3ed4b2299ff8051a9d130f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9ce52d351384652a25cea41d5bf10d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58e83d370570483a84584b1ba51b4a0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4e1af2b6d3041098336c9393584e9cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab89283ade174a0bb7fe3b2918c3c835_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c28c3b58eff4d8e83e797a3c9dc86ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a52d405845744e3a22ff6418d046838_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica846717e1184bacb54d96b42ff8bfb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifdd588c1a32a4b318e8824b9e80e833f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42abf7d75b0f4617992ff04363b8de28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3186402fca52479e94b30bea316112da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68819c4736484941b4667da3db092246_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fac223fbf12427cb4c55b80a18072a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic57c573544eb42bea430ba41085525f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8827a2fb2e7457595d626050de42f28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee8708828d7a476587098de587d22948_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if15ac02c8fcd427fae5b76de3ef93c01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2625252753fb4190bc4ba5269f5706d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86b02994b45b43a6a51141e64ad4bd6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c345c140c9d4fc3ab7c4965bae458b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieae1d87ac95d463f9fa59da4bbf23bce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacb113e118e7452c88560640a9b79b47_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb4dd465b3a644ffba70709abd0e98ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec8f6315c869439fbc63a0932a14c1b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i142cfd8898984756ad60bc4f86418961_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5f46381d5d84ab897c5e33368443242_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02fd6baa57ae461bbf3b32faaeb4ca35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id668c24327e44ed49160b1d70e4edf8e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e9ca1afbe084ad2b78b08a5a7a9ab88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1b4418327794b1ea9613fab77ce0af0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia71836a62a044a1a972a740f6319ef84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92c7dc7c1587494599625760bf34889e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i549a8c00f0d749c38e43fa24e8a68fc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64aa8a2e665348d281dbb4b93dab7c26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd5aaee2e719474ebec4de5223a6b859_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc72fc42cfa546b9b9e91cd582c83266_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia84c581ad8f34d408c44634c9e7d0f91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64dcb287d7ec41c48e54b1306c36a88c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5524db3a83e64bfe85a82d222a654d8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37480e91464c49dd98f091245e025713_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90158ecd8c3e413386c593b81c9ec032_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie26ec646267f4e85948a6ab2df7b23a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f8dc92496214bc1a120c9a3281fc5e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60a6a69355e3453493947ac5e9722c59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if820e1dc7ba1477ab9046f6f9fa76088_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9bc64d208594f82a7ea1b06af17e59d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic19857bfc8f948f1a850a6668ed7d8a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92a5b59f05da4d839616ac13e1467ef1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic81c850442314891a6ae5cc1a2f882f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45e8077800b44d75af0b74ead71c6510_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47c99e708c60467094ebc0103c16902b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a2432a93c2642648f67e1ecff14d557_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i401d253c03d541b2b15b77b43f0fd1df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie48af28deba5435bbd08534c18358b09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id09876f128a94429b9227814e8df6c80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i619c68bb39df4437a5e73314f08f8e67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6632e89a64e494ba984e898352b2f9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e8c406fd2c74fdfafe3a57ed54a171f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61ca6e2453404a48a52750e3e90e1c47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8105dc0c76f840128a4f6f87b9a897eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2552bb36ef2c4777893433a656282c25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23a5175770b84cb4bab9529b3ce7bec7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1e3d70c034b4a9085ff1de6d2ce55f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i131d7dc36ccb49a299712a5e82f3de3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f9ec8958dad4e25b4dec1bdef155303_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i666be2a8dc0345ef89405b86d686e7dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60bbfca782904064adf3f965eb407772_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c793768fac34476a639c2429c54308f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i718358de146a4a6c93c1a4fe8ea02b90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c4b302cec1d435aa72e21490d245992_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0301f217169748b8b9564b716734656d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3486851087a1461cbc7cdbd886031e0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i824079b6e48d4bb5800315785acae403_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8acd54cdd7834f65b9fd34a3eecb83ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4ff876d8f4d4e13bfb398ce15c78dfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingPartnershipInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2da33ae4440b4e3e9858280b13b26b86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:PartnershipInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df6e9e072f7410bbe91dd8464dc1559_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89b4a5ab5d5945078778d6bf6cb1a8c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if81f254578c34d74b6c7ee4044f8bdda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b6ac436f09047b58b9afbeeb2bfe737_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64f7e00faf9c423987fb23403b1098bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc47fc0ad92542a9bae68627e6bef5ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25321d10a7f6437fbb4bcfce57f68be4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ea480fece154d2f860656f2677bdfd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3ca81f42d6d4bab8cfeaf80de0cb1b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a2ebfa875334d19ad5216074deb2d4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0a519ff398f494e846042ee96a98679_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a64acd001884c8e9e9bb3b1a965529e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib46c9cd33130445a91236aacb780d027_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:MutualFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdfe1e0781264622a6679afeb0a9c720_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bce5bacf7c24b4f9dc864afd7e4ca87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i917c455132fb4e1e9f340d3bad48d102_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icefbd8bbbac7446baf3a38dca505dfea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie579e5cdf455475b9502356566def862_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e6eee54cd694a2ca132251fbf4a7f5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7a66d7e68f44e50981c5465d04e22bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd7b6dd2b55348cba5836b9c067d3c29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia263eb55917d4d3fa6a60e7db1c48a3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4974aa0eb2c24470b0039864c0415900_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ded0fd871644ff591de8addd589219a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c81070f0b3b443c8f18a8f1214732bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d680746121d4419b3c54ef8acb7b9fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id20a6873d906447385de48452526511e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cc7ea082cf84448a7ec7762124b2a4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4376d31b137c4d3a8e1c905705497935_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:CommingledFundDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52db6dff7f164d5e890ff1578cbcb759_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4b5962d9e5e4af890e2358bb3edbb03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bcdd3e9146f4beca1f89cb52fea78f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id541168132e04301912466c96cf4ad90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15061749f3f2485aa1798b8186e3f2c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i087044734b154901b0cfed0b0f5d93dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46e196f381254b4da2543763f22de2fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id05c5e1befde4b3d876502ebb2794242_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InvestmentInDOL10312TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53abc6af4dd045279ea54e62550af65d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib689e1a2aa1847a19d4aa925acdcc69e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f3aa30468184cb8b88f01ef4d14e83b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice5874492cbb402d81d69b55109ae43c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7580de5335c2453fbc6266565e5baa9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic48a8bf89b7b4def9e1a900fde56e8da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80355d52e2674470b51aa353a404d82c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic2f8ffbfbcd842e88af9bfbc67f7e567_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31ad54fe654c42efbd77c7bb585d643d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib360e9af4b21497d82c013681a5dadae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedd65a74e5704da5920113ea7aece196_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia99956a06c7e46e1849e1ddf398be5df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6904393673c940ae893924fc97c16cda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i932bd361ffbc47c298c90d616e0667b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5fe4907f34814d2baa614ba2fc07e320_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89d6ceec20cd424fa94e7a6386ac5a78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:InsuranceCompanyContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">elv:LifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id885b4e505b34b40bce2c6278117709a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55238bc0d8524816beff8ed796471899_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd4334628ce145889a7e9f45088dbc5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i253166758c5642418ac341338d564041_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i056128fedb8c4604822fdacd5c2f6272_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c4172e7e04f43ae913e486aafb0c782_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7aef76e4813e4606b8d70440c92f269a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23463b26e20041c888dd2c51a2181294_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib44d7cf6e14d4446b34dd7ca19bc223b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6fbed5f4b7543ab8092cf310b884173_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1ab83b37e744c8899d7e3adb51c2939_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcabc74836324dbfa6c75eefd131bc85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifab00825672c4350bb49fbe11bbfb810_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad9e96e08f9e4d9eab2889e9f25825de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2b1e52956f34852bb67f516ba0647b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4efbc97b18234003842819922bc3113a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefeea68ef91044dc982120c3a3a950bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2066eaf9a484ad59e9589c14525a5c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14e702d4536f4799a919aec9da8593e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e4c9f11d99845b8921be755ddf836f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84d1014df09f4661bc24d1661e77bfc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33b68b45f4914e09ab526057a219f954_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id063c136e8d646d9a71a21018eada61b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cf1a9340bcf4268a0cbab4e753cb90e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53292eeae2a246e58c5a7bcb2a4337ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieac5c44b376048bbae8a2f0719d42263_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i949d008a3d0b4b8d93c2d6a4799ec855_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ec6bfd612d64307b2a756760684ffe0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaea1bc60c1634bd889b51a318197368d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa1c710fc55e47898c1d2f197e749108_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i45c611a7c74d4ab8ac5a98a6fe0e2728_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7636254161774196bf8c04399ddf133f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4154a06006b4cafa5cbd1a889726e29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13e53d3ac9be45f58795982cc797e03c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7a05e7eaeb64ad58b3d1f47ad49fa73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2607b444454d46e39b6286f9c8ea6e3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c77106efdf14a58abf9fc4127c8b091_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i811d733c6b02495580c52c781054171e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7e70d3f0aa9435ea3f59013c328d36f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id90d8e2c8f9446bfbdb944daa4c9681b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b3de8e0b39443b7b0385091bc11bf77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9db25862eb95484085247b52a174b160_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf2272113d58402ba5f389923853a07f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea5aadb40cfa4a7c8342724cdc2f58c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb71d9d282b643fd8703d9459d16e56d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i091a2bb4b5f242c3ad68068b656e90f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30b72b535fce46bf8f61743fb9e18481_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic70a6a0be4d643d3927176d45192c141_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i134f72e11a1649b7934274f86bea6020_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf998fc82656469e90d336c2b880f377_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6946a35fa850465fa36f14fc4f52f7bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67736d5753d44699b20adb0618b589fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb4f13755a194230acb1ec087846b505_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66a828e106b94047928ff146300d2ed0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifba93ec717e94394a8955cf9f5de9f90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2e6cd38e3e84d5580d856acbad97133_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie323f9332ece4230a9778b8c7d487528_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife4c77f05ea246d1b396cda16a6f5b1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i353e9848174344adab8b80f569e38864_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia22dd705e96640c28ac4a3b93dc44cb7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd9c543ff2b843e8964521415571c09a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i928bec5ee982461199847da9ac96d68b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88ffc1ca7d414bbd94fbe98e6dac3891_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadc050557e394d4bb08e2383bcb0c73e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightZeroZeroPercentDueTwoThousandFortyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i029531456f0742b18198f12d8893bbdd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointEightZeroZeroPercentDueTwoThousandFortyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice205a4939054c86b0d0fab99c58c6de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f4c04d831ec4f03aa3ef7b1e8fae480_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4301f61a56d4a5981fa5a8be60c5456_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i886b4f01b01343e99f882cbfedb38b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5c8b1a203e04bc98e13209d268178e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib12d2d5430234b8da43f315a70dbda73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie11833466f4c4e66b1df0bdb5615948b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24e99111afc84fa281a0286ba240fd53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i188c10cfbcd14ea593ae781c8b7d8219_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86370035d0f94594abe20431af0befa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6caa66b97514d68ba837991fe14dbdf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibbe622a0dd5c41d5bb15002f914046be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieba76da0d560460cb028e0c65f72ea97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3ed97bbfa0946bc8f76958f0fc5eb16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d6bb5890f644dc2a4785a6cd8b1b0c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d118ac360bd4e3aad70d1189c447897_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id74f9a1abba844ef9912af38aac619e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69ffc9a6ff1d499eb81b8fc7cd50feeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fc6cdf9d6fe436c9e1912baf09467ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic855e040017843f28f7041b2bc021f66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3c3fc9281644847a3ab3c94cd2f8927_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29b0fd92b63040658ab461c35f466977_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1151ddbe0ece40b18eadc2621477a0ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i871498f5fef9430a894e75b1f70e1af1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00522144e96b43829be3251cd73df914_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SurplusNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic08004c17645430d9704d5e79d29fccc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SurplusNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c84a9462da54835ae2f9e76a4f4376c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if80cee633ac84a32ac44408267eda7b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice43633ad18f45a3bf5610792f8e0e92_I20230208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-08</instant>
        </period>
    </context>
    <context id="ie9fbf8cc11e742c2b3eb7b913dbc0f53_I20230208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-08</instant>
        </period>
    </context>
    <context id="i38626e3e281747b1864dc478c857e132_I20230208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-08</instant>
        </period>
    </context>
    <context id="id3702fa1806f4f55afc1809dce531453_I20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="iad77e559c2a94999bb397fa384a544e9_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="if0f2459563994824a4b0a6fe56121a68_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="id0933651ffe04b7bbdbc822cd8b57555_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="ib14c797d21b24b8e925b9f7f60a8b208_I20220516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="if73dc0aa91534a999012a5f25833b272_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i333b97a4235d45a5a86902df2d17954a_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i69ce9e81a0d3461dab8dbc07066d500d_I20210515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-15</instant>
        </period>
    </context>
    <context id="iac73002099334b069811ed521ffc2f61_D20210515-20210515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-15</startDate>
            <endDate>2021-05-15</endDate>
        </period>
    </context>
    <context id="i2bc2487f523740c69014d98ef48fc2ae_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i429662b30ae84f4fb822ecd377e98b9c_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i54cffe8dccdc4ee6945a8e5fea7b55b4_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i325bf58af121477aaabb4ba211cc0a8b_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:OtherSeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8f86ebcddede41c59e36155926d5c738_I20201123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-23</instant>
        </period>
    </context>
    <context id="i8eb1aa80db82419e86533f0ed7493781_I20200817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-17</instant>
        </period>
    </context>
    <context id="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:OtherSeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ca42aa1e7484753ae2809b124a577da_I20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-05</instant>
        </period>
    </context>
    <context id="i41649eb783044c5eb58218b8fa152592_I20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-05</instant>
        </period>
    </context>
    <context id="ic6256919a6f740e9a7538e63d97e56c3_I20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:ThreePointOneTwoFivePercentDueTwoThousandFiftyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-05</instant>
        </period>
    </context>
    <context id="ib8ac997eed1f49e1bc4fbe2c7718e08f_I20190909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">elv:SeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-09</instant>
        </period>
    </context>
    <context id="iad3cc9878d194c6ab4cfcad7ad636235_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A5YearFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ac0254b163e4965ada5424581be8b2f_I20220418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A5YearFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-18</instant>
        </period>
    </context>
    <context id="i83efaab7af2c47789e213ba327cae52f_D20220418-20220418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A2021364DayFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-18</startDate>
            <endDate>2022-04-18</endDate>
        </period>
    </context>
    <context id="i99dac9a626014a259743a75faf51bbc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">elv:A2021364DayFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78ee27d7ced94e33a81e7cf47376711f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i111f1669cf354c22bca3fe927cfeb62c_I20121009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-10-09</instant>
        </period>
    </context>
    <context id="i3deab0f622924f9085bea8fcbe5ee03c_D20221015-20221015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-15</startDate>
            <endDate>2022-10-15</endDate>
        </period>
    </context>
    <context id="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac96933216134d7b8897d64076389449_D20230213-20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="ie6cc8a906b734cbb88951da261ef5f76_D20121001-20121002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-10-01</startDate>
            <endDate>2012-10-02</endDate>
        </period>
    </context>
    <context id="i168f8f6c7055487690a43cb967e499b1_I20121002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-10-02</instant>
        </period>
    </context>
    <context id="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide2e9b364d454a189b9c63aaf27ed9ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">elv:AnthemInc.v.ExpressScriptsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">elv:PharmacypricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i530e77d500e24332972b126eb61ad553_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">elv:AnthemInc.v.ExpressScriptsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">elv:OperationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idbb67e7d15ec40d393dc4ea0b4156be1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">elv:AnthemInc.v.ExpressScriptsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f482fd60e844e1aa802036bfbb28f7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94919fea365f4bf3810bbae7fae7bb53_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18e9f319025d420eb32e7522fd74ed84_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie674fb9fe21244e6a1ce2872735af01d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91235d6e1c7c4af2b57d1b5d2854972a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="elv:PerformancemeasurementperiodAxis">elv:A2022To2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic773a96084d446cc8f83053d1d3e03dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8aebf8ee5444e509fd8796f5ae27e76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elv:CapitalStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01f291e82852495c91f39ae516cb5961_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibd001b0d68c34a668c7fde379c754978_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74f7a4356b364dabba6bc38e7490c8bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elv:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id765367318fd412f9615ba9f41b69d33_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f793b028bf243b29bbcb6a44fa763f0_I20230124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="ia027da647af941768a3f104492aa7231_D20230124-20230124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="ice6527b2d9fe44bd9c916d8863257a5b_I20210126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="i9e95a8c856b14a5a8cf3fd92402ef4e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81e698e227c346ae9586de0d8e1b1dbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if95514d7548341cba52815d3f07c28d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08958ab7b46246489adf526e350f151f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcebd1544ec64ec6974e038a69b087db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58a792ee17bd44f596cabc8ef3e8b4b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1482b2c7c0ff472fb0c9110009b806b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47960b8964ab402a942e197e579d8542_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc4bd3fce911457baee6a8c050e6b70e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e36ba6bb351437bb13a37f1503ac813_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i653b1eb3d81f4ca192dd6d3ffca11785_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i246d9c069b344181a326be72f32bf256_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5723b60554294bebac94c904566db3f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98cc61d631e54bd68ab0e26a98a4905b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24c01f7b130a4ac4a08d21b45fed6866_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b85f7bcceb24f4585583cc791c6fd0e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id351a075bd634b1598a879fd2e805740_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4c5ae1b587c4de3a0abc993e1f65329_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9aefa095e5f4dd99aff2909fbcde15c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54dc7a29f571431296c8be227f11aabb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie94ead6cf6db4e7fae98eafe846f769d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9323e18f92640a2a7c38e4273db90ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3d3abd401b24655a17b8c74f5dd40a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibfbd0421f60f4e64bc47776a3602ab89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2395d6d373c34b2ebab39d8aba7606e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fa38daf500d4a73ac08682fa99f7730_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a127625ab7b4d44a9d9ad36c6e50197_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4a1b61e2bc84caba4a714fd57739c74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd38742893d7416999e954ec984556f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i798cec4e64e04bffbeed267a216429e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b77786d1b5c4248b0483a8990b79b0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie59f5a3300a74c28a300c63349dea8cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icae88b41165f46938384528eba3e864a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae176fbb87f54bac94b2e4ab0685d43a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98132071c63744ada30c2775fc5af988_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie55d196caf5f45cfb07e66b8da2097ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1df81813ee544edea31e2c74936bff4e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17ba170c8f794d3bb4ca06d264b4e57d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7d0c0663315405099698864eb3c19b8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id2baaad3463642b18170d3f49e7ddc87_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8429825b5f7e40ca8d6e68d3bb26eab2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:SegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1b7278c60e164f14b96b13c3df65ba4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4f05b417fd04be8a1aeab8299b5c69e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie10db0a695d24e41bdf7833886001b71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1c8e72dc40f4442b092502acb15a96c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie412ebaf29714d329b7b8b83c7ba69e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:SegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7bef8962735044b1acb083bc20e63486_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icece7f971bda47f8bc76865f9659c5da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:UnaffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ebc5e9f4d1042a38e45cd00bce22554_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf4cd355c6dc4109bc5041d9057f2121_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">elv:AffiliatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb0d2a7152494f90b39b3fac5d9264ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:SegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c68969e3f114ff69c401be9bc37c2dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e22951986404675bbf5fbfa2839786c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i894b5d431a7047808e5ff7ebf443d016_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98f62da538ba41f789a6a73b38e537d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i123ffb166421487082a09f78c1725ebc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6364bd9ed8464178afda9d8855f8538c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8365100e5c9406a9883eb34ce369cba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:DentalVisionProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia1ac17248d75456fb25896b8926586fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:DentalVisionProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08e94cb6360045ddb9b224a2f973d9d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:DentalVisionProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3efe3527b82f45b4924c08cd2aeadf1f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i41cca4acaaa048e6904800f45ff39923_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i735ef38ab9e648319f8e6b267c9164a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:CommercialSpecialtyBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5157a3ffc8b8454a9197a5de365fbaf8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i162dcb32162845ee8019a58aa859ae61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i647d737a8abe4da3b8caeb6484d9b75d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if42d0d2379bd40ba99bb0908ac993e6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c132f1b799e4a88b13c0fa30393e947_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79df8d34415c4640aa3a9d6958c599d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:ManagedCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:GovernmentBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2abac369da1f4652a7813e0cd7aa350f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:PharmacyProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a9d4685e2e749a2bc8254783454a3a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:PharmacyProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9cd36a7c95104275aee23983a5df35b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:PharmacyProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:IngenioRxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d0dd4f771c744f2831d7f9d4dc1c0a0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:IntegratedHealthServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i458aaaae8b4c42abaaad6c6a529cf94d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:IntegratedHealthServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f95fe1cae3741118461bf71f33280c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:IntegratedHealthServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i096ee1cf57a8446eadfaff116cd44804_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0624a80296bd435499ecbb5c951564b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if18cf6ebd6bf46c08192134b8ce7cfcf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elv:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">elv:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i417b0315d1f946278154f230d44ba1b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">elv:APCPasseLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3f82c8853704ae1861ff012a8a6a705_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">elv:APCPasseLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4356376bd2bb4161b623b19b110ab07e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">elv:APCPasseLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b88a75959a3413fbf01add2bd34bcb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i725512778bd442a6b242345331bb3a06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6bc2c55daf14d049cede53415aaef62_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18e88e0db7ff4756a456b1a7ffd88b77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e6ef69580834645b272fe1032c1d97a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2684dcf65c140fca76ea400241c2590_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">elv:CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i088d91ca9c3148788190accbb142e04e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4274554137b941b8b61ab51e740d5503_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaac9df3234b44acd9d0fc7e8d58b001f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida62205932654bdd82996ed0187717df_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001156039</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="individuals">
        <measure>elv:individuals</measure>
    </unit>
    <unit id="counties">
        <measure>elv:counties</measure>
    </unit>
    <unit id="states">
        <measure>elv:states</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="securities">
        <measure>elv:securities</measure>
    </unit>
    <unit id="segment">
        <measure>elv:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV8yLTEtMS0xLTc4MDQ5_ae07ea1e-3be4-4fb7-bf31-96ac8de65b7f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV80LTEtMS0xLTc4MDQ5_a9a0b5a9-1dcc-480a-89c9-50b93e719eae">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV81LTEtMS0xLTc4MDQ5_3d63efd6-6c59-4b93-b994-930c3e4f8cdb">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M180L2ZyYWc6MmJhMmMwNDIyYWE4NDk3OWI0Y2U4YzYxMzNmYTI1MGYvdGFibGU6ZjcyMzc3MDQwMTY1NDZmZTg4Yzg4NjZhMGI3ZWM5YjUvdGFibGVyYW5nZTpmNzIzNzcwNDAxNjU0NmZlODhjODg2NmEwYjdlYzliNV84LTEtMS0xLTc4MDQ5_9edc624a-13c5-44f1-b366-aeb7f4b1cc92">0001156039</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i64441609cdbc496fa38247c4ed248dd7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if9ced248bb284327b4df64ad260e211a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i22f60e8bbf864a89ba6d0bb4ef9e07bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_afeade16-dee4-4795-8b19-99581c96cde5">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_346f76ea-dead-4d60-b08d-54ad913c9f6f">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_72ace3e9-597b-4518-a22f-101187f15e20">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDYvZnJhZzpmNTNiMDBmMzcyOWY0NjU1YjQ2MjQ3ZTFlMGEzY2NiZC90YWJsZTo5ODcyYzIzMmY3MTc0M2I2ODNkMjc1NDk1ZWQ2ZDk3MC90YWJsZXJhbmdlOjk4NzJjMjMyZjcxNzQzYjY4M2QyNzU0OTVlZDZkOTcwXzEtMy0xLTEtNzgwNDk_ae9b7ae2-9237-4e54-9e61-665571808d65"
      unitRef="number">1.02</elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i20f6180cce7c443190ecf1bee3a73783_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="if10138f4228d48388824633025312afe_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="if10138f4228d48388824633025312afe_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="if10138f4228d48388824633025312afe_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i647110a052c44104b85f07f28a55e14a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i647110a052c44104b85f07f28a55e14a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i647110a052c44104b85f07f28a55e14a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7">http://www.elevancehealth.com/20221231#NetGainsLossesOnFinancialInstruments</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i19b75bd9929846879cf5eaddd4752c76_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad">http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ib5abc1365f064e1ea869ec15ff3abcd3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ib3def97b16324c25b53915d44aa74ac6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0">http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ic1cb710db79d409384335a6604d0729f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76">http://fasb.org/us-gaap/2022#ProfitLoss</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b">http://fasb.org/us-gaap/2022#ProfitLoss</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c">http://fasb.org/us-gaap/2022#ProfitLoss</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i6c426fec08424ce089096359689f3d77_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzItMC0xLTEtNzgwNDk_81251d13-252e-4522-999f-5409e341d5c7">2032-01-01</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i8676a9f8039043f9a4adf4d85b99b12f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzMtMC0xLTEtNzgwNDk_59d065ae-7d75-42ea-aaff-941ce7d876b4">2042-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i8837dd9386e64e11b2b5a657d243c739_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzctMC0xLTEtNzgwNDk_78a12783-16d6-446c-9d05-552cfd079ba5">2023-01-01</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i6e4adbddcdea43adb30ab20715a88be5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjEvZnJhZzo0NTNmODIyY2ExOGE0MDg0YmM4YmZlYzM3N2Y5NDZhMy90YWJsZTpjYmY2MzcxNDc0MzQ0Yzc3OGU2MWQ3Y2MzNTQ4NjkyYi90YWJsZXJhbmdlOmNiZjYzNzE0NzQzNDRjNzc4ZTYxZDdjYzM1NDg2OTJiXzgtMC0xLTEtNzgwNDk_21f091bb-c0b9-46db-8bc0-09486de219f4">2042-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMw_a12c5ad1-ffee-4d9a-b7e9-b95c28ce86c3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6YWE1MDBmNGIxNDAyNDQyMmI5YzdmMzdkMjFiMzE4NTYvdGFibGVyYW5nZTphYTUwMGY0YjE0MDI0NDIyYjljN2YzN2QyMWIzMTg1Nl8wLTAtMS0xLTc4MDQ5_3480fae8-a7e4-42a7-90ce-638033378c93">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8xMTU0NDg3MjExMzY5MA_e408e793-3f5a-44ad-b621-76ebaf7c275a">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8xMTU0NDg3MjExMzY5MA_33a5b539-aa45-4923-9215-1a2144167298">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MTU5M2IxNGI4ZDcxNDZlZGJiNGU0OWZhYWMwMGJiYmMvdGFibGVyYW5nZToxNTkzYjE0YjhkNzE0NmVkYmI0ZTQ5ZmFhYzAwYmJiY18wLTAtMS0xLTc4MDQ5_dc8ed8ea-20d0-4f05-a4ed-b43b3c2740fb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI1_80e0d06d-9a94-4e92-9178-3b8b15a916a3">001-16751</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMz_cd323c05-fa8a-4a5b-b2b6-ebe879a5f432">ELEVANCE HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6ZmI2ZTczZTYyMmY1NGMyMmEzMGIwOWE5MThmNTY0MjAvdGFibGVyYW5nZTpmYjZlNzNlNjIyZjU0YzIyYTMwYjA5YTkxOGY1NjQyMF8wLTAtMS0xLTc4MDQ5_95dab6d8-ac42-4236-a223-e149680dfc1c">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6ZmI2ZTczZTYyMmY1NGMyMmEzMGIwOWE5MThmNTY0MjAvdGFibGVyYW5nZTpmYjZlNzNlNjIyZjU0YzIyYTMwYjA5YTkxOGY1NjQyMF8wLTItMS0xLTc4MDQ5_4831da9d-c732-486b-a16a-a137df2f5298">35-2145715</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM0_a22b3656-2ab5-4e06-92dc-f64af6b48e3a">220 Virginia Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM3_f6f29eb0-cc1a-4f36-8693-5a31d19c687a">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI2_3b9377fc-96b8-4420-9e55-322aa0486dc8">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI3_9f7cd8ac-c3e4-413e-8d09-d783ad7a7034">46204</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM4_e649c6d5-35cc-4d4c-a4e2-d8cca1042938">(833)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM1_8e61f054-ce81-4af1-959a-55fe1d27c530">401-1577</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MWQ5NjQ0ZTg5MGE5NDE3MWExNmU3NmMwYWE3NjE4ZjQvdGFibGVyYW5nZToxZDk2NDRlODkwYTk0MTcxYTE2ZTc2YzBhYTc2MThmNF8xLTAtMS0xLTc4MDQ5_92c790d2-7ac0-4f5c-ac1f-c4cf1d48a443">Common Stock, Par Value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MWQ5NjQ0ZTg5MGE5NDE3MWExNmU3NmMwYWE3NjE4ZjQvdGFibGVyYW5nZToxZDk2NDRlODkwYTk0MTcxYTE2ZTc2YzBhYTc2MThmNF8xLTItMS0xLTc4MDQ5_c8af7136-4206-43bc-963f-b9353d8f32d0">ELV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6MWQ5NjQ0ZTg5MGE5NDE3MWExNmU3NmMwYWE3NjE4ZjQvdGFibGVyYW5nZToxZDk2NDRlODkwYTk0MTcxYTE2ZTc2YzBhYTc2MThmNF8xLTQtMS0xLTc4MDQ5_beb58414-cb7f-477d-a4b4-1eac4779f50c">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM2_b0d7cfce-8de9-43cf-ad70-2ccd48e7ac28">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI4_e11c3acb-e28c-426d-b5a5-d8f794f33e76">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMx_21e7ee74-bfc4-43c6-8166-2d651ffae15b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjM5_a890c954-68de-4920-bffa-ac244c69a589">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6N2NkZGJiNzUxZThmNGRiYzk1OWRhOWI1NzhiMzEwZmEvdGFibGVyYW5nZTo3Y2RkYmI3NTFlOGY0ZGJjOTU5ZGE5YjU3OGIzMTBmYV8wLTAtMS0xLTc4MDQ5_984100cc-56bd-4c4c-8ada-d118553a0cd2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6N2NkZGJiNzUxZThmNGRiYzk1OWRhOWI1NzhiMzEwZmEvdGFibGVyYW5nZTo3Y2RkYmI3NTFlOGY0ZGJjOTU5ZGE5YjU3OGIzMTBmYV8xLTUtMS0xLTc4MDQ5_f4405613-50d9-44f0-88e9-3b271cae9631">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGFibGU6N2NkZGJiNzUxZThmNGRiYzk1OWRhOWI1NzhiMzEwZmEvdGFibGVyYW5nZTo3Y2RkYmI3NTFlOGY0ZGJjOTU5ZGE5YjU3OGIzMTBmYV8yLTEtMS0xLTc4MDQ5_b78d9fbe-d792-44fc-96b6-23e42e1f7d5b">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjMy_c7f3ea68-1b26-49cc-a8b0-ee8884200cb6">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjQw_efa152eb-83a6-4fae-95ac-3de640403e1f">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i2398c42e085f4920a603bf9b3ed00ec1_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8yOTIw_da8404de-e69d-4768-be8b-4ad412e7566d"
      unitRef="usd">115691972993</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i79090320ca5f4e8f812187d03517a85e_I20230201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8yOTM0_e975f108-6fcc-46c0-836b-f14293b5bdbd"
      unitRef="shares">237457776</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xL2ZyYWc6MmEzNjg1MDY2M2UwNGM0NjlhYTgxMjhlODRlNDhiNzAvdGV4dHJlZ2lvbjoyYTM2ODUwNjYzZTA0YzQ2OWFhODEyOGU4NGU0OGI3MF8zMjI5_c6265b9b-7d5b-4e13-b2fc-afd6816e0f4f">Part III of this Annual Report on Form 10-K incorporates by reference information from the registrant&#x2019;s Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 10, 2023.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M182MS9mcmFnOjU4ZmE1NjBhMmQwZTRiMTE5NjcxYmU4NDk0YmQ4NzVlL3RhYmxlOjYzYmJhODcxNTdhNzQzNDc5NjVkZWQwNjljMmE1YjYzL3RhYmxlcmFuZ2U6NjNiYmE4NzE1N2E3NDM0Nzk2NWRlZDA2OWMyYTViNjNfMC0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOmRlMGRlYjFkZTcwMjRlYTI5Y2ZlYWRlMGVhYjU2ZTQ5Xzcw_6c07d203-1ff8-4aee-a032-d4358ef1db9a">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M182NC9mcmFnOmE1OWNhNzVkZWYzODRkZTg4MGJmZWM3MjcxMDhkNmE4L3RleHRyZWdpb246YTU5Y2E3NWRlZjM4NGRlODgwYmZlYzcyNzEwOGQ2YThfMzU3NA_053d46ac-8fa9-440b-b309-5d524fb7ee72">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M182NC9mcmFnOmE1OWNhNzVkZWYzODRkZTg4MGJmZWM3MjcxMDhkNmE4L3RleHRyZWdpb246YTU5Y2E3NWRlZjM4NGRlODgwYmZlYzcyNzEwOGQ2YThfMzU3Ng_5c6bf16a-5547-4b9d-9873-f6504339d2b3">Indianapolis, Indiana</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNC0xLTEtMS03ODA0OQ_a13ae090-fb25-4ff6-abd0-6eb8b16be37a"
      unitRef="usd">7387000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNC0zLTEtMS03ODA0OQ_75efa3d7-7355-4967-ac89-d8b52a488e1c"
      unitRef="usd">4880000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzQ5_7a293772-a36e-48bf-b0da-468950079ceb"
      unitRef="usd">28226000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzU2_14e3e8b9-83b7-4725-aed4-9376e2887f73"
      unitRef="usd">25641000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzkx_4ed634e8-70cb-4eb0-a332-efb733d1b65c"
      unitRef="usd">-9000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0wLTEtMS03ODA0OS90ZXh0cmVnaW9uOjNkOWVkYTIwNGQ0ZjRjMDFhZWY1ZWJiOTdhM2Y3ZDViXzk4_79e79961-8585-4078-b062-a0567a80275d"
      unitRef="usd">-6000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0xLTEtMS03ODA0OQ_5a75812d-7031-4b6c-bf81-b3a73abe6a49"
      unitRef="usd">25952000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNS0zLTEtMS03ODA0OQ_e9e0301e-30de-44d3-8b99-a2942fa0847f"
      unitRef="usd">26267000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNi0xLTEtMS03ODA0OQ_69371ac1-6c8e-401f-9dcf-17809738f278"
      unitRef="usd">953000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNi0zLTEtMS03ODA0OQ_e4f32b20-eb39-4712-9220-2f87e3058da7"
      unitRef="usd">1881000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:PremiumsReceivableAtCarryingValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfOS0xLTEtMS03ODA0OQ_cfa1cf36-e61a-41df-87f8-294dad5adc17"
      unitRef="usd">7083000000</us-gaap:PremiumsReceivableAtCarryingValue>
    <us-gaap:PremiumsReceivableAtCarryingValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfOS0zLTEtMS03ODA0OQ_64732994-0674-493b-a051-ac92d5410d24"
      unitRef="usd">5681000000</us-gaap:PremiumsReceivableAtCarryingValue>
    <elv:SelfFundedReceivablesNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTAtMS0xLTEtNzgwNDk_74995810-6c6f-4549-9847-229102db3179"
      unitRef="usd">4663000000</elv:SelfFundedReceivablesNet>
    <elv:SelfFundedReceivablesNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTAtMy0xLTEtNzgwNDk_281c4366-6710-488d-bb31-b70a9266e7d1"
      unitRef="usd">4010000000</elv:SelfFundedReceivablesNet>
    <us-gaap:OtherReceivables
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTEtMS0xLTEtNzgwNDk_867c6ee4-ec05-44e4-a6b3-fbae95455c9b"
      unitRef="usd">4298000000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTEtMy0xLTEtNzgwNDk_4bfb0ee1-a5b0-45a2-bec9-bec81173620c"
      unitRef="usd">3749000000</us-gaap:OtherReceivables>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTQtMS0xLTEtNzgwNDk_76cf5b40-08df-4f59-8c7b-3b5d08368c4e"
      unitRef="usd">5281000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTQtMy0xLTEtNzgwNDk_f83ca9fa-e9a2-4bfe-8862-cc346001fa65"
      unitRef="usd">4654000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTYtMS0xLTEtNzgwNDk_4f8b07ca-60f7-4b9f-9997-351ee1a246f4"
      unitRef="usd">55617000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTYtMy0xLTEtNzgwNDk_a27d7bda-0453-426e-824c-e7c58091288d"
      unitRef="usd">51122000000</us-gaap:AssetsCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF80OQ_19396c61-7269-425f-a090-c248ac24f159"
      unitRef="usd">789000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF81Ng_2f96e5de-65f2-452b-a7f4-186e3208935b"
      unitRef="usd">616000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF8xMTU0NDg3MjA5MTc1Nw_f67648c1-901d-43f1-90be-aec2c4076ad4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpiMDdkNDRkZGU5NWY0MmI2ODhiNGY2ZGUwN2M0NWU0OF8xMTU0NDg3MjA5MTc2NA_a724dc89-a313-4dd6-86d7-5d025b38b7b4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMS0xLTEtNzgwNDk_e7bfa1ff-94d5-48ea-b1a9-8515ea548704"
      unitRef="usd">752000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTgtMy0xLTEtNzgwNDk_330443d7-88ae-4521-82d1-72d1396f8f45"
      unitRef="usd">632000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTktMS0xLTEtNzgwNDk_d9767ae1-30d8-4d57-b5dd-fa19bb45d327"
      unitRef="usd">5685000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMTktMy0xLTEtNzgwNDk_8afc1da3-7441-4b7b-bad5-0fc4cac2bd48"
      unitRef="usd">5225000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjAtMS0xLTEtNzgwNDk_6e72843c-3429-4255-aa6e-3d6b27d788c2"
      unitRef="usd">4316000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjAtMy0xLTEtNzgwNDk_e290cfce-2efd-49bb-bace-3755b8155cd9"
      unitRef="usd">3919000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjEtMS0xLTEtNzgwNDk_2edc4bfd-3610-432d-b6ff-024de463af15"
      unitRef="usd">24383000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjEtMy0xLTEtNzgwNDk_6895cb2f-9962-4312-ada8-9c1e87af7205"
      unitRef="usd">24228000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjItMS0xLTEtNzgwNDk_21115a67-99e6-47dc-aa2a-30bde6f9b1a5"
      unitRef="usd">10315000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjItMy0xLTEtNzgwNDk_3515863e-1e6f-41f1-9fe8-2d253c94ddd1"
      unitRef="usd">10615000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjMtMS0xLTEtNzgwNDk_fd654b4e-dd09-426e-b7e0-f12c2551fd71"
      unitRef="usd">1704000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjMtMy0xLTEtNzgwNDk_1155a921-185b-48ae-9e0b-9cba6b426bca"
      unitRef="usd">1719000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjQtMS0xLTEtNzgwNDk_7ebe6098-3272-4c7a-a0f8-25df2fc79027"
      unitRef="usd">102772000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjQtMy0xLTEtNzgwNDk_65ecba89-5f0c-4a85-b831-427331768a86"
      unitRef="usd">97460000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjktMS0xLTEtNzgwNDk_a4fb478b-f51e-4b28-8b29-52d95e9b2175"
      unitRef="usd">15596000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMjktMy0xLTEtNzgwNDk_2888087c-c4e0-4419-bdf9-b1e11b6b1ffd"
      unitRef="usd">13518000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:OtherPolicyholderFunds
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzEtMS0xLTEtNzgwNDk_1f6ba7be-1edb-49fa-ae9f-1a29b57ffa7d"
      unitRef="usd">5933000000</us-gaap:OtherPolicyholderFunds>
    <us-gaap:OtherPolicyholderFunds
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzEtMy0xLTEtNzgwNDk_44ef46f3-7374-4441-a7bf-b35a67d81620"
      unitRef="usd">5521000000</us-gaap:OtherPolicyholderFunds>
    <us-gaap:UnearnedPremiums
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzItMS0xLTEtNzgwNDk_f564e231-2604-4568-8ff1-6d345a763884"
      unitRef="usd">1112000000</us-gaap:UnearnedPremiums>
    <us-gaap:UnearnedPremiums
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzItMy0xLTEtNzgwNDk_aa9a5aef-99ea-45ff-a70b-21716ad2ca3c"
      unitRef="usd">1153000000</us-gaap:UnearnedPremiums>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzMtMS0xLTEtNzgwNDk_24361379-e8b9-46fc-bf2d-d6fa44831ccc"
      unitRef="usd">5607000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzMtMy0xLTEtNzgwNDk_6eaed8c6-a689-480d-a2e5-78d82c0dda1b"
      unitRef="usd">4970000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzYtMS0xLTEtNzgwNDk_41021b7b-f847-42e7-a76c-b8d3cfee6787"
      unitRef="usd">265000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzYtMy0xLTEtNzgwNDk_60159915-0e2a-4e71-a979-8a7b3c903b06"
      unitRef="usd">275000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzctMS0xLTEtNzgwNDk_2e0e7278-a0e5-4567-91e8-b4f068f4aba9"
      unitRef="usd">1500000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzctMy0xLTEtNzgwNDk_85284ab4-4a37-431d-8aa2-928d18fcd9d4"
      unitRef="usd">1599000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzgtMS0xLTEtNzgwNDk_90c146f6-5307-4d6e-a7eb-f35edf409bfe"
      unitRef="usd">9683000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfMzgtMy0xLTEtNzgwNDk_f360ef2e-f945-48f9-a7a4-2a1d63d41e3d"
      unitRef="usd">7849000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDAtMS0xLTEtNzgwNDk_adf5515b-cc46-436a-b513-a6d2249ede48"
      unitRef="usd">39696000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDAtMy0xLTEtNzgwNDk_9da8b320-7383-40b1-84dd-dda79470f767"
      unitRef="usd">34885000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDEtMS0xLTEtNzgwNDk_8e8163ca-21d1-4ac6-a6c1-a2b635e319ec"
      unitRef="usd">22349000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDEtMy0xLTEtNzgwNDk_d75ca6b8-6627-4252-b1a3-3a8627495e23"
      unitRef="usd">21157000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDItMS0xLTEtNzgwNDk_10c28c5a-1acc-4801-bff9-0606e17eb0a9"
      unitRef="usd">737000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDItMy0xLTEtNzgwNDk_ed5b99cb-716b-487e-a0f2-b23f96dde153"
      unitRef="usd">802000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDMtMS0xLTEtNzgwNDk_ca4f9458-87ba-4b95-b7f8-ac3c1347e0f1"
      unitRef="usd">2034000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDMtMy0xLTEtNzgwNDk_7899b948-e28c-4c27-930a-ee052634ade4"
      unitRef="usd">2805000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDQtMS0xLTEtNzgwNDk_5832ed0b-11d1-4f2a-92a1-9e40c1cd5f74"
      unitRef="usd">1562000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDQtMy0xLTEtNzgwNDk_68b5e4b3-74ed-4fd3-944c-01b7cf5ed657"
      unitRef="usd">1683000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDUtMS0xLTEtNzgwNDk_9b965627-0406-42a2-b284-da11d7a63cbf"
      unitRef="usd">66378000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDUtMy0xLTEtNzgwNDk_f99d9f59-1d72-4a97-a923-aa550b968386"
      unitRef="usd">61332000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDYtMS0xLTEtNzgwNDk_4f3e05f2-b0a0-4064-98e3-6f66f2c9d089"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDYtMy0xLTEtNzgwNDk_76025412-9d6d-4406-8cb5-91377df29771"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo4NmFiOWNmZGFkZWQ0MGQ3YTUzYWFhOGNlNDgyZTE4ZV82MA_eb544ea1-fffa-4ef0-9fd6-6d7f79b19055"
      unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo4NmFiOWNmZGFkZWQ0MGQ3YTUzYWFhOGNlNDgyZTE4ZV85Ng_23165b7d-0ea1-40c0-97b0-f8fdfcd4e978"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo4NmFiOWNmZGFkZWQ0MGQ3YTUzYWFhOGNlNDgyZTE4ZV85Ng_b2232086-c8fc-4f6b-b02c-37306de2c93a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMS0xLTEtNzgwNDk_f8a09341-8922-425e-9398-f5b1747f60d6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDgtMy0xLTEtNzgwNDk_8ee2590c-9d16-49f4-975a-de80ed3c6c7c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV8yOA_9abbb137-7a67-4a61-8687-05b06a42951d"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV81Mg_0448ee0c-285b-4f2a-ac3d-61e644b313d2"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV84OA_df8b0844-2d33-46d6-8090-cdee67cd5426"
      unitRef="shares">237958067</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV84OA_e53fddbd-217d-4fec-a217-b407f38ebf4e"
      unitRef="shares">237958067</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV85NQ_2ef6ef86-69da-4dcf-b109-b95f1fb8f45d"
      unitRef="shares">241770746</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo2ODAzZTUxMWQ1NDU0ZTE3ODdiZmE3YzAyYWZlOTY4ZV85NQ_bdc6c9b8-8018-4018-bd90-9aaffe1ba13e"
      unitRef="shares">241770746</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMS0xLTEtNzgwNDk_c04cdaff-2726-4a4c-98d8-36b3fbd4154f"
      unitRef="usd">2000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNDktMy0xLTEtNzgwNDk_6492ce41-3322-41e6-a6c1-7bbb309b993f"
      unitRef="usd">2000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTAtMS0xLTEtNzgwNDk_36ed2f8f-8419-4c4b-b5fc-648e15c8b46b"
      unitRef="usd">9084000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTAtMy0xLTEtNzgwNDk_ac172e9f-0b6f-4303-98d2-e8d21cf306b7"
      unitRef="usd">9148000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTEtMS0xLTEtNzgwNDk_0c1ff5f9-002d-49d4-89e3-1e779cbe3985"
      unitRef="usd">29724000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTEtMy0xLTEtNzgwNDk_af2ce513-6db0-4300-8545-7d309b1a00b8"
      unitRef="usd">27088000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTItMS0xLTEtNzgwNDk_03c37718-0989-46a0-8f74-d363cb720e36"
      unitRef="usd">-2503000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTItMy0xLTEtNzgwNDk_f941901b-8215-4bab-852b-96ee892f6252"
      unitRef="usd">-178000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTMtMS0xLTEtNzgwNDk_1ef17180-18af-4cf2-b29d-4b98421eee8d"
      unitRef="usd">36307000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTMtMy0xLTEtNzgwNDk_c23c7a32-e36f-4575-87c4-791c8f04bf2f"
      unitRef="usd">36060000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTQtMS0xLTEtNzgwNDk_f39c56a5-2795-466d-9a9b-a74e45ba2c17"
      unitRef="usd">87000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTQtMy0xLTEtNzgwNDk_c02ef039-bc1e-44e8-9dc4-c485f3001cf8"
      unitRef="usd">68000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTUtMS0xLTEtNzgwNDk_3c22796f-6f35-439a-8ae5-92fe6ef3abc4"
      unitRef="usd">36394000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTUtMy0xLTEtNzgwNDk_b1333950-6bbf-474f-943b-5d0f1ecd7eb2"
      unitRef="usd">36128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTYtMS0xLTEtNzgwNDk_93f5549d-724a-4459-add7-0abb99a79ecf"
      unitRef="usd">102772000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183MC9mcmFnOjM3NDY3N2Q3N2E2ZTQ2NTc4N2MxYWIyMGNjOGUyNDU4L3RhYmxlOmRiYjY1ODc2NGEyMzRjMWJhYTdlNTg1ZGFjMTQ0YzI0L3RhYmxlcmFuZ2U6ZGJiNjU4NzY0YTIzNGMxYmFhN2U1ODVkYWMxNDRjMjRfNTYtMy0xLTEtNzgwNDk_916dff36-c091-469f-bbb8-a0aa3168bed1"
      unitRef="usd">97460000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PremiumsEarnedNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMy0xLTEtMS03ODA0OQ_9edb6dea-f1c6-49e6-85dd-71829689ec7e"
      unitRef="usd">133229000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMy0zLTEtMS03ODA0OQ_46340efe-43a9-44d3-8d5d-4fb6d21f7464"
      unitRef="usd">117373000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMy01LTEtMS03ODA0OQ_b21e9cbc-4397-47e3-9f30-2c4db1549370"
      unitRef="usd">104109000000</us-gaap:PremiumsEarnedNet>
    <elv:ProductRevenue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNC0xLTEtMS03ODA0OQ_4a773fea-7901-473b-be27-f0130c37829a"
      unitRef="usd">14978000000</elv:ProductRevenue>
    <elv:ProductRevenue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNC0zLTEtMS03ODA0OQ_fd1dc17e-5076-408b-8650-97c6733db9f0"
      unitRef="usd">12657000000</elv:ProductRevenue>
    <elv:ProductRevenue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNC01LTEtMS03ODA0OQ_e18b2f57-57cc-46db-a61b-785920763e2d"
      unitRef="usd">10384000000</elv:ProductRevenue>
    <us-gaap:OtherIncome
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNS0xLTEtMS03ODA0OQ_42fec35d-a2b1-4043-8acd-06ab7c661c7d"
      unitRef="usd">7453000000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNS0zLTEtMS03ODA0OQ_02aae168-0bc9-4790-a650-d73fd3d67494"
      unitRef="usd">6913000000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNS01LTEtMS03ODA0OQ_f2fd5842-e0cb-4e86-b205-2cc102d0f04c"
      unitRef="usd">6315000000</us-gaap:OtherIncome>
    <elv:OperatingRevenue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNi0xLTEtMS03ODA0OQ_74a7a9fd-c105-49bb-9298-385d7a522a88"
      unitRef="usd">155660000000</elv:OperatingRevenue>
    <elv:OperatingRevenue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNi0zLTEtMS03ODA0OQ_83a5905b-4f50-4d64-b1cb-88cd56b66928"
      unitRef="usd">136943000000</elv:OperatingRevenue>
    <elv:OperatingRevenue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNi01LTEtMS03ODA0OQ_405c36ca-c450-4fda-998f-d5802303208d"
      unitRef="usd">120808000000</elv:OperatingRevenue>
    <us-gaap:NetInvestmentIncome
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNy0xLTEtMS03ODA0OQ_66590b24-e693-4272-a9b7-c58d95cda949"
      unitRef="usd">1485000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNy0zLTEtMS03ODA0OQ_abc2f26e-19fd-4189-bce4-2eb19b4205d6"
      unitRef="usd">1378000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfNy01LTEtMS03ODA0OQ_6c78ea20-e677-4c25-9982-ed3ad66e64c8"
      unitRef="usd">877000000</us-gaap:NetInvestmentIncome>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfOC0xLTEtMS03ODA0OQ_4902aa17-f59c-41b5-84bf-7040af3ebf8a"
      unitRef="usd">-550000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfOC0zLTEtMS03ODA0OQ_5d135a15-38d9-4175-bccb-fd16d0984e6a"
      unitRef="usd">318000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfOC01LTEtMS03ODA0OQ_df69068e-56c4-4385-8a16-91ff1599160b"
      unitRef="usd">182000000</elv:NetGainsLossesOnFinancialInstruments>
    <us-gaap:Revenues
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTMtMS0xLTEtNzgwNDk_ecb72255-94b9-46b2-a805-2f7cf0c0f903"
      unitRef="usd">156595000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTMtMy0xLTEtNzgwNDk_3afb44c9-ec8b-49c4-9b5e-d03d8048dc94"
      unitRef="usd">138639000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTMtNS0xLTEtNzgwNDk_25fe96df-445d-4d20-baf8-b79077c53e43"
      unitRef="usd">121867000000</us-gaap:Revenues>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTUtMS0xLTEtNzgwNDk_eca9bb18-c802-47f9-a44f-4295f27334b0"
      unitRef="usd">116487000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTUtMy0xLTEtNzgwNDk_fdbe7840-1850-4818-b96a-84e4898c16b8"
      unitRef="usd">102645000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTUtNS0xLTEtNzgwNDk_cf7d1859-95b1-49de-97ca-c5550ce37025"
      unitRef="usd">88045000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTYtMS0xLTEtNzgwNDk_8da3b956-19a7-4c3f-bf3f-cf99d23d0d38"
      unitRef="usd">13035000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTYtMy0xLTEtNzgwNDk_8dbbdb16-1d02-4755-86b2-1d4309db4047"
      unitRef="usd">10895000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTYtNS0xLTEtNzgwNDk_bec38e4f-e51c-4cf4-9d1b-2ac6c45b2794"
      unitRef="usd">8953000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTctMS0xLTEtNzgwNDk_7d430148-dc95-490d-8348-1e0714f3ec15"
      unitRef="usd">17686000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTctMy0xLTEtNzgwNDk_e18f785c-75ae-4d7b-adc8-5735f5d21ab9"
      unitRef="usd">15914000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTctNS0xLTEtNzgwNDk_d69ad7f7-c7d0-4416-961b-41e72c9f89c6"
      unitRef="usd">17450000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InterestExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTgtMS0xLTEtNzgwNDk_f0d58810-0315-46ce-932b-c0b1e28d75d0"
      unitRef="usd">851000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTgtMy0xLTEtNzgwNDk_df7dd294-3fe9-48e4-8710-e5e7042a763c"
      unitRef="usd">798000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTgtNS0xLTEtNzgwNDk_f5c6909e-08e8-4b16-9732-a409a763c2ae"
      unitRef="usd">784000000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTktMS0xLTEtNzgwNDk_3c25d311-2f74-4977-8e4c-5a195d1b69d0"
      unitRef="usd">767000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTktMy0xLTEtNzgwNDk_0250d6cf-685e-48f7-bcd2-138d2cc00e0b"
      unitRef="usd">441000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMTktNS0xLTEtNzgwNDk_64e56ea4-4a7a-45b5-9616-aeb68fd28338"
      unitRef="usd">361000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjAtMS0xLTEtNzgwNDk_6c58f80c-4c96-47b4-b6e0-bccec5af4f25"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjAtMy0xLTEtNzgwNDk_a156ae69-c7c2-4991-93b3-0d44eac7d362"
      unitRef="usd">-21000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjAtNS0xLTEtNzgwNDk_7df27ec6-bf85-4615-86f6-7c147855c34d"
      unitRef="usd">-36000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:BenefitsLossesAndExpenses
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjEtMS0xLTEtNzgwNDk_28d045ce-2760-4fea-b6e0-167afda4989b"
      unitRef="usd">148826000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjEtMy0xLTEtNzgwNDk_742ac6e3-d0ee-4ca0-b56f-4a829519bc12"
      unitRef="usd">130714000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjEtNS0xLTEtNzgwNDk_9cc12c73-bb9b-4927-a1c3-825d4b9c6202"
      unitRef="usd">115629000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjItMS0xLTEtNzgwNDk_b993ab26-3971-4641-b17c-dc9e57a7c7ef"
      unitRef="usd">7769000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjItMy0xLTEtNzgwNDk_fab24414-fe21-45de-8b3f-8d27bf430596"
      unitRef="usd">7925000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjItNS0xLTEtNzgwNDk_c0565c0f-8378-454f-981d-300668a6ccd6"
      unitRef="usd">6238000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjMtMS0xLTEtNzgwNDk_90f5defe-caad-4c8b-9c33-85d8945372c9"
      unitRef="usd">1750000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjMtMy0xLTEtNzgwNDk_32c79923-3a58-4d90-9b3e-2445a035a5e9"
      unitRef="usd">1830000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjMtNS0xLTEtNzgwNDk_092d7be9-b373-4535-ac38-8d2fdf6d3c78"
      unitRef="usd">1666000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjYtMS0xLTEtNzgwNDk_0de1fe70-5c9e-42a2-9d57-66d6bb5e9c5f"
      unitRef="usd">6019000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjYtMy0xLTEtNzgwNDk_797230e0-715e-4537-b80b-ef97bdbee8e9"
      unitRef="usd">6095000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjYtNS0xLTEtNzgwNDk_eb320102-4ebf-47b5-9aa2-2bc259a5eea0"
      unitRef="usd">4572000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjctMS0xLTEtNzgwNDk_6e7a819b-4e82-451a-99f0-b5cd93f686d3"
      unitRef="usd">-6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjctMy0xLTEtNzgwNDk_830647f2-0685-4c75-8d34-d0c31278f561"
      unitRef="usd">-9000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjctNS0xLTEtNzgwNDk_899cba73-0f7c-4b74-ad3f-a354d8377fad"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjgtMS0xLTEtNzgwNDk_9d122537-640d-4407-967b-12387d706a16"
      unitRef="usd">6025000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjgtMy0xLTEtNzgwNDk_867c4d15-7504-42da-b33e-bdc1411fc1df"
      unitRef="usd">6104000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMjgtNS0xLTEtNzgwNDk_532694ea-feb4-4aaa-a936-fe89f8683ef9"
      unitRef="usd">4572000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzItMS0xLTEtNzgwNDk_6fcc0178-6b95-4236-9706-9db07c191589"
      unitRef="usdPerShare">25.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzItMy0xLTEtNzgwNDk_007b7a8e-df9d-43b9-9732-e76408d27cc2"
      unitRef="usdPerShare">25.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzItNS0xLTEtNzgwNDk_4ac005a2-d357-4976-825e-5e62f961f670"
      unitRef="usdPerShare">18.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzYtMS0xLTEtNzgwNDk_88af60ea-ddf7-462a-a572-0b21dca7d163"
      unitRef="usdPerShare">24.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzYtMy0xLTEtNzgwNDk_2edda2f2-c86a-4fed-8136-9da8c04178dd"
      unitRef="usdPerShare">24.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzYtNS0xLTEtNzgwNDk_8b3287d0-11b6-4210-8ff3-68a932059dad"
      unitRef="usdPerShare">17.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzctMS0xLTEtNzgwNDk_f584c61f-2421-4f29-ae10-1944fb935429"
      unitRef="usdPerShare">5.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzctMy0xLTEtNzgwNDk_b35332b6-4b83-4293-8371-af9523d262e2"
      unitRef="usdPerShare">4.52</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183Ni9mcmFnOmU4ODM4OTE4NGVjNTQ5ZTE4N2Q0Nzg2NjU1NGM0ZjkyL3RhYmxlOmE0NzA2ODkxOWQ4OTQ2MDZhYzY5MDBjYTNjZGZiNDBiL3RhYmxlcmFuZ2U6YTQ3MDY4OTE5ZDg5NDYwNmFjNjkwMGNhM2NkZmI0MGJfMzctNS0xLTEtNzgwNDk_8a564b8d-8041-43ce-afdf-bb77722d4211"
      unitRef="usdPerShare">3.80</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMi0xLTEtMS03ODA0OQ_02262665-be08-446d-a9b7-621868d78be4"
      unitRef="usd">6019000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMi0zLTEtMS03ODA0OQ_00be9945-83b2-4ad5-980a-8b28c59dffb0"
      unitRef="usd">6095000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMi01LTEtMS03ODA0OQ_0841befb-5f76-47af-8a10-255599038b44"
      unitRef="usd">4572000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNC0xLTEtMS03ODA0OQ_9ab55749-4282-4a2d-8fac-ccd8c46d3fe3"
      unitRef="usd">-2260000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNC0zLTEtMS03ODA0OQ_f69dfbdc-137c-4172-b0f6-4412218789c8"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNC01LTEtMS03ODA0OQ_6a5c8332-6795-49b2-a710-37a95f3d7689"
      unitRef="usd">428000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNS0xLTEtMS03ODA0OQ_1ec4f3a5-d807-4007-b31c-bd3599ac5dc5"
      unitRef="usd">-3000000</elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax>
    <elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNS0zLTEtMS03ODA0OQ_f7fa9017-67f5-4b96-91f7-9111d5775c56"
      unitRef="usd">2000000</elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax>
    <elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNS01LTEtMS03ODA0OQ_c35397ab-f5ae-43cf-a87b-e4cd5340b359"
      unitRef="usd">0</elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNi0xLTEtMS03ODA0OQ_5e15746d-bb41-4eda-8536-6e6ca7555960"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNi0zLTEtMS03ODA0OQ_917baea9-7ad4-4375-8943-c4798be9198f"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNi01LTEtMS03ODA0OQ_fa24f33e-506a-45c7-8209-0d6c28bf35bb"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNy0xLTEtMS03ODA0OQ_20bc2a18-a927-44c7-a74f-75ac7cfe55c1"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNy0zLTEtMS03ODA0OQ_928b28fe-3871-4ffd-a0f3-ea4ee1b829b9"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfNy01LTEtMS03ODA0OQ_a39c0b0c-6a6d-456c-aa15-d8687b3567e1"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOC0xLTEtMS03ODA0OQ_8675c848-5839-4dc7-a2af-55c8e588c23b"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOC0zLTEtMS03ODA0OQ_b79d4519-5c1f-43db-a966-62bf0447afbd"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOC01LTEtMS03ODA0OQ_a50c3d3b-caea-47cf-aa2b-1d3d31248fb2"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOS0xLTEtMS03ODA0OQ_9f8e71ac-22f4-49cd-a1f2-a9754bf54bb2"
      unitRef="usd">-2336000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOS0zLTEtMS03ODA0OQ_637e9116-e437-4a0c-a0f7-274fb1122589"
      unitRef="usd">-330000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfOS01LTEtMS03ODA0OQ_45590d68-0aaf-4cf2-894f-447498db2c4e"
      unitRef="usd">446000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTAtMS0xLTEtNzgwNDk_26b9455d-6e70-48e3-954e-115de9ee0d09"
      unitRef="usd">-6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTAtMy0xLTEtNzgwNDk_5720df9b-39be-422c-ae65-7b29a09b37e8"
      unitRef="usd">-9000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTAtNS0xLTEtNzgwNDk_56ecde72-00ec-422a-83a2-05877bcf4a79"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTEtMS0xLTEtNzgwNDk_6e5fcd31-80d2-4eba-8cec-ac2269352d90"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTEtMy0xLTEtNzgwNDk_864e2c8f-f6a8-4c91-8276-318437178d2f"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTEtNS0xLTEtNzgwNDk_d18c9eb5-9490-4b49-9d9a-4c3bed062282"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTItMS0xLTEtNzgwNDk_c490bf09-3727-4a1c-83dd-cb296c79a5cd"
      unitRef="usd">3700000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTItMy0xLTEtNzgwNDk_67165ce3-57b8-489c-9646-a512c7eb6ef3"
      unitRef="usd">5776000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M183OS9mcmFnOmU5MzUwZGIzMzkyMzQxZGRiNDI3NWU1ZTM5MmQ5ZTIzL3RhYmxlOmYzNzA2MDllOTkxNTQ2MTE5ZWVjYzBkMDQ3Njk2OWUyL3RhYmxlcmFuZ2U6ZjM3MDYwOWU5OTE1NDYxMTllZWNjMGQwNDc2OTY5ZTJfMTItNS0xLTEtNzgwNDk_07f802f1-27cd-4aef-8ba7-a0b7d8804414"
      unitRef="usd">5018000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMy0xLTEtMS03ODA0OQ_82ee0ea6-7430-487e-9b13-c551a4eca2e5"
      unitRef="usd">6019000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMy0zLTEtMS03ODA0OQ_cea64bf8-d5ce-479b-a9ab-d1a7ed870031"
      unitRef="usd">6095000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMy01LTEtMS03ODA0OQ_cedf23e0-deda-4801-92c2-a2f5934a192d"
      unitRef="usd">4572000000</us-gaap:ProfitLoss>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNS0xLTEtMS03ODA0OQ_091697ed-b3a6-4353-a961-345c5eda9a67"
      unitRef="usd">-550000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNS0zLTEtMS03ODA0OQ_313bb7e1-9da9-43dc-b8c8-91bbbfd1a541"
      unitRef="usd">318000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNS01LTEtMS03ODA0OQ_606b14c4-d574-49b6-a7dd-130f9cef7ab0"
      unitRef="usd">182000000</elv:NetGainsLossesOnFinancialInstruments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNi0xLTEtMS03ODA0OQ_ee2d5532-e368-401f-989c-d42623b9fa01"
      unitRef="usd">293000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNi0zLTEtMS03ODA0OQ_7053372e-457d-472f-89ea-931efed8c686"
      unitRef="usd">562000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNi01LTEtMS03ODA0OQ_6d823d1b-6e7f-43da-a444-34b555e79ac8"
      unitRef="usd">51000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNy0xLTEtMS03ODA0OQ_f8d9e0ce-48b0-4b64-8f7c-a77ec7b649d2"
      unitRef="usd">1675000000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNy0zLTEtMS03ODA0OQ_4b238d07-acd8-4fe6-9d71-d5388506b541"
      unitRef="usd">1302000000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNy01LTEtMS03ODA0OQ_21c895cb-158e-403a-b5be-6e149b4821a2"
      unitRef="usd">1154000000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTAtMS0xLTEtNzgwNDk_1d959ccf-7501-4543-a8ab-7a0c140c5f27"
      unitRef="usd">-76000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTAtMy0xLTEtNzgwNDk_0bf6f7ef-1f5a-4aec-9b97-498fcd744276"
      unitRef="usd">326000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTAtNS0xLTEtNzgwNDk_36c8a367-02c8-4038-bd5d-4e718293b6af"
      unitRef="usd">-540000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTEtMS0xLTEtNzgwNDk_5619c54c-972c-4cfc-977d-93eff7a09b21"
      unitRef="usd">7000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTEtMy0xLTEtNzgwNDk_fa42f62f-d24b-4a61-baa7-ef8c4e9cd956"
      unitRef="usd">73000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTEtNS0xLTEtNzgwNDk_ce72fd21-14c2-431c-8ebd-7e0e50b8a21d"
      unitRef="usd">198000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ShareBasedCompensation
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTItMS0xLTEtNzgwNDk_f06af2c3-ba2d-4af7-a99c-37b9b89c57b2"
      unitRef="usd">264000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTItMy0xLTEtNzgwNDk_4d2052be-ba6c-42b6-aac1-d0ce110b11f7"
      unitRef="usd">255000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTItNS0xLTEtNzgwNDk_c8b28cb6-6e1d-4f3a-a4cd-622e7139aaca"
      unitRef="usd">283000000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTQtMS0xLTEtNzgwNDk_8f640333-45ca-4b97-b7fa-7ccf7d9f8249"
      unitRef="usd">2510000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTQtMy0xLTEtNzgwNDk_a09e7952-64ae-4b4d-9e70-16baa4175d38"
      unitRef="usd">2138000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTQtNS0xLTEtNzgwNDk_8ca3baaa-e762-4101-a1d3-142e0e2bd793"
      unitRef="usd">256000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTUtMS0xLTEtNzgwNDk_5c7e4f23-c524-4b66-935d-43daf736c94f"
      unitRef="usd">-11000000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTUtMy0xLTEtNzgwNDk_fa82f410-0806-4e3f-ad13-465f5a65eb95"
      unitRef="usd">70000000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTUtNS0xLTEtNzgwNDk_cfc99851-f4bb-4f10-afbf-00f7713f834e"
      unitRef="usd">32000000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTYtMS0xLTEtNzgwNDk_4118cb13-8aa7-46ff-aeb3-d759f5ea18ba"
      unitRef="usd">-120000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTYtMy0xLTEtNzgwNDk_4c68cd07-9079-4445-b575-09ca4082a1fc"
      unitRef="usd">-37000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTYtNS0xLTEtNzgwNDk_7cf619ef-4bec-49f4-8649-682f91122c9e"
      unitRef="usd">283000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTctMS0xLTEtNzgwNDk_1986c57d-b293-4d39-a15d-d7ad88a0bb61"
      unitRef="usd">2254000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTctMy0xLTEtNzgwNDk_deb9ce1b-cd7b-4d04-a3e6-732c419b7157"
      unitRef="usd">2597000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTctNS0xLTEtNzgwNDk_186df51e-8a3a-4df8-bc8a-7c91069d37a5"
      unitRef="usd">3528000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTgtMS0xLTEtNzgwNDk_619cf515-4471-4345-ade8-22d08cf3174e"
      unitRef="usd">-42000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTgtMy0xLTEtNzgwNDk_ba1a9c99-e37a-4142-949d-017eafe8a777"
      unitRef="usd">-113000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTgtNS0xLTEtNzgwNDk_1544a374-e619-4767-b2b0-97c0fa61e757"
      unitRef="usd">202000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTktMS0xLTEtNzgwNDk_6217894d-459e-4899-a0d4-78aacf517568"
      unitRef="usd">824000000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTktMy0xLTEtNzgwNDk_e9d05b4c-f352-42ea-a735-3b5686a974ab"
      unitRef="usd">719000000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMTktNS0xLTEtNzgwNDk_33b9e3a5-64c5-4efd-8472-e06a634d0db5"
      unitRef="usd">1978000000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjAtMS0xLTEtNzgwNDk_e46782d4-afb3-40e5-9cf2-357f42d17105"
      unitRef="usd">-338000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjAtMy0xLTEtNzgwNDk_31c34b2e-1147-4a2b-afac-a399e78e3af7"
      unitRef="usd">140000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjAtNS0xLTEtNzgwNDk_6cc07f85-9b7a-4004-921c-44d3d98dc244"
      unitRef="usd">72000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjEtMS0xLTEtNzgwNDk_dfa8654e-a0f2-4aba-877b-943f5af84e64"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjEtMy0xLTEtNzgwNDk_9e7d357a-daa7-4da8-a782-4ae1a7d5fff4"
      unitRef="usd">-21000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjEtNS0xLTEtNzgwNDk_3a35c3a7-481a-4cdb-9939-e48245407e41"
      unitRef="usd">-45000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjItMS0xLTEtNzgwNDk_3f4bd336-4b9c-44f2-8767-6b703573e2f9"
      unitRef="usd">8399000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjItMy0xLTEtNzgwNDk_e2199b1a-6884-4569-9b78-9e34e53846f3"
      unitRef="usd">8364000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjItNS0xLTEtNzgwNDk_5a57002b-0139-45c2-bdcf-bd51b467638d"
      unitRef="usd">10688000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjQtMS0xLTEtNzgwNDk_374281bf-dcc9-43f7-8bb8-8c768b90cbbf"
      unitRef="usd">24946000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjQtMy0xLTEtNzgwNDk_430be08f-3554-4be5-89ee-df8d732362e6"
      unitRef="usd">18669000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjQtNS0xLTEtNzgwNDk_97fad90f-fea9-43da-811c-c2ab945f9330"
      unitRef="usd">19492000000</us-gaap:PaymentsToAcquireInvestments>
    <elv:Proceedsfromsaleofequityandfixedmaturitysecurities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjUtMS0xLTEtNzgwNDk_ffa50be0-f3dc-49e9-b63c-2be7e81f4c92"
      unitRef="usd">11988000000</elv:Proceedsfromsaleofequityandfixedmaturitysecurities>
    <elv:Proceedsfromsaleofequityandfixedmaturitysecurities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjUtMy0xLTEtNzgwNDk_8f5d6e6b-51fe-4414-b22b-14067d61616e"
      unitRef="usd">10269000000</elv:Proceedsfromsaleofequityandfixedmaturitysecurities>
    <elv:Proceedsfromsaleofequityandfixedmaturitysecurities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjUtNS0xLTEtNzgwNDk_308bf5c4-ec67-4316-90cf-407677511692"
      unitRef="usd">11318000000</elv:Proceedsfromsaleofequityandfixedmaturitysecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjYtMS0xLTEtNzgwNDk_5a2b68a7-5563-49ab-a12f-e77c3a37008d"
      unitRef="usd">10620000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjYtMy0xLTEtNzgwNDk_82181e9a-d68a-4b33-aedd-e41780fef4aa"
      unitRef="usd">4344000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjYtNS0xLTEtNzgwNDk_1874cff3-26b8-42c8-9694-6c136c003b5f"
      unitRef="usd">4741000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjgtMS0xLTEtNzgwNDk_2f44c81e-23f3-4157-915b-9debb0e91601"
      unitRef="usd">301000000</us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending>
    <us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjgtMy0xLTEtNzgwNDk_a192637a-3c02-462e-bc0e-2b77c20f9814"
      unitRef="usd">956000000</us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending>
    <us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjgtNS0xLTEtNzgwNDk_015b447c-3b25-4d88-91e0-a42422aedad8"
      unitRef="usd">849000000</us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjktMS0xLTEtNzgwNDk_b42a1438-5a3f-4b90-9813-aa1e8d178612"
      unitRef="usd">649000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjktMy0xLTEtNzgwNDk_5d26293a-7ca3-4c6d-800e-d29960e548fd"
      unitRef="usd">3476000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMjktNS0xLTEtNzgwNDk_ac7c0500-3b88-4c1b-9500-3d53a825fc63"
      unitRef="usd">1976000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzAtMS0xLTEtNzgwNDk_6b4b6233-0b5a-4c3e-bfc6-bc331ca6a3a2"
      unitRef="usd">1152000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzAtMy0xLTEtNzgwNDk_496eeff8-012c-4a30-b6bc-27777390da86"
      unitRef="usd">1087000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzAtNS0xLTEtNzgwNDk_064089dd-5eba-4576-afd7-9909bbd0d844"
      unitRef="usd">1021000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzEtMS0xLTEtNzgwNDk_573dc9ba-d2d6-4df4-9973-64907e480ec0"
      unitRef="usd">120000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzEtMy0xLTEtNzgwNDk_5e5ca619-9048-45cd-9675-97f28749c8c6"
      unitRef="usd">63000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzEtNS0xLTEtNzgwNDk_c33f4ab4-c038-49f6-866b-c0de35f37f24"
      unitRef="usd">45000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzItMS0xLTEtNzgwNDk_8cc84263-8c86-4a51-bb8e-88916cc0bb69"
      unitRef="usd">-4560000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzItMy0xLTEtNzgwNDk_9d3d851d-c035-4d6e-afaf-e00df915b268"
      unitRef="usd">-9638000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzItNS0xLTEtNzgwNDk_c64edfd2-a833-4086-a3a2-ec5890ab1269"
      unitRef="usd">-7324000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzQtMS0xLTEtNzgwNDk_861291f0-f187-450a-8602-c316a97b1996"
      unitRef="usd">-300000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzQtMy0xLTEtNzgwNDk_0f162a20-e1b6-4cd8-bdab-7e60646203cb"
      unitRef="usd">50000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzQtNS0xLTEtNzgwNDk_cdd54720-baed-4c80-a23e-a1d8b7598cc5"
      unitRef="usd">-150000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzUtMS0xLTEtNzgwNDk_88ee0a11-7aec-460e-8688-0d34d3b933ec"
      unitRef="usd">3071000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzUtMy0xLTEtNzgwNDk_363bbe07-eb89-4f39-99c9-9a7fd9ad562e"
      unitRef="usd">3462000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzUtNS0xLTEtNzgwNDk_7ec35c26-7c7b-4e3c-a416-65c0f0609c9a"
      unitRef="usd">2484000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzYtMS0xLTEtNzgwNDk_19e9469b-3d85-4a37-9721-5e7784d43cc3"
      unitRef="usd">1899000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzYtMy0xLTEtNzgwNDk_de6210dd-77ef-4b81-b4f3-bb8f1cbb9170"
      unitRef="usd">1068000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzYtNS0xLTEtNzgwNDk_c1eb1bf9-69cc-4c34-bf82-afb936039d89"
      unitRef="usd">1932000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzctMS0xLTEtNzgwNDk_80f11b1e-0b69-4f1c-b9ea-3b4d3305168b"
      unitRef="usd">1365000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzctMy0xLTEtNzgwNDk_2114adc1-85e7-428c-8839-a0ed232a84ef"
      unitRef="usd">1325000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzctNS0xLTEtNzgwNDk_448091d4-12e6-4919-ac0f-38d6b6fe5f6a"
      unitRef="usd">970000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzgtMS0xLTEtNzgwNDk_a63a1e1b-382e-4fa6-b77b-9fc47cbec70c"
      unitRef="usd">1375000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzgtMy0xLTEtNzgwNDk_2165a91b-d0ca-4edd-8b30-62a9078be8a1"
      unitRef="usd">1050000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzgtNS0xLTEtNzgwNDk_17258c0d-bc7a-479f-9b09-720a37841c32"
      unitRef="usd">1670000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:IncreaseDecreaseInSecuritiesLendingPayable
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzktMS0xLTEtNzgwNDk_d43fe951-80fb-4e64-96ea-4c921211929b"
      unitRef="usd">302000000</us-gaap:IncreaseDecreaseInSecuritiesLendingPayable>
    <us-gaap:IncreaseDecreaseInSecuritiesLendingPayable
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzktMy0xLTEtNzgwNDk_360803ce-5454-49e6-9ac2-51c8c9700c26"
      unitRef="usd">956000000</us-gaap:IncreaseDecreaseInSecuritiesLendingPayable>
    <us-gaap:IncreaseDecreaseInSecuritiesLendingPayable
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfMzktNS0xLTEtNzgwNDk_29021ac4-a4ad-4b17-9721-31683d48d665"
      unitRef="usd">849000000</us-gaap:IncreaseDecreaseInSecuritiesLendingPayable>
    <us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDAtMS0xLTEtNzgwNDk_078e5b5b-644b-4808-b46e-35e3391385fb"
      unitRef="usd">933000000</us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities>
    <us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDAtMy0xLTEtNzgwNDk_4ce53b30-3eb2-4be6-96ae-72d876749dbc"
      unitRef="usd">-376000000</us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities>
    <us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDAtNS0xLTEtNzgwNDk_c3e4c55a-df69-45f5-989e-8ab7f753b352"
      unitRef="usd">486000000</us-gaap:IncreaseDecreaseInOutstandingChecksFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDEtMS0xLTEtNzgwNDk_e4493865-2205-4ee2-b83f-c9a5c78bc5fa"
      unitRef="usd">2316000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDEtMy0xLTEtNzgwNDk_350b3a60-61cb-45bb-bcc4-f57b58324577"
      unitRef="usd">1900000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDEtNS0xLTEtNzgwNDk_771b5008-4cd1-4da0-b8ad-41c3c1076eac"
      unitRef="usd">2700000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDItMS0xLTEtNzgwNDk_1951d566-916d-44d9-a1a4-001622ecd39c"
      unitRef="usd">1229000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDItMy0xLTEtNzgwNDk_5061cb49-d144-407a-a100-5c1ceb277552"
      unitRef="usd">1104000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDItNS0xLTEtNzgwNDk_8132ba37-38ae-42cf-a0bf-75d496efc060"
      unitRef="usd">954000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDMtMS0xLTEtNzgwNDk_b7887e64-4679-47cc-aa69-644651c905dd"
      unitRef="usd">182000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDMtMy0xLTEtNzgwNDk_ab7e912e-73ab-4f3c-972b-593de4f9ea01"
      unitRef="usd">203000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDMtNS0xLTEtNzgwNDk_9a197455-873f-4a59-8f86-caea11e1b417"
      unitRef="usd">176000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDQtMS0xLTEtNzgwNDk_a481503c-a8b0-4e78-95d7-b4ba9f137b27"
      unitRef="usd">93000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDQtMy0xLTEtNzgwNDk_c275db17-6130-4916-8645-2c887ab05a70"
      unitRef="usd">102000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDQtNS0xLTEtNzgwNDk_57ffbb2f-37af-45f8-aef5-f900086ff9b5"
      unitRef="usd">128000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDUtMS0xLTEtNzgwNDk_704e6e96-1c94-4524-84ca-42913bda7794"
      unitRef="usd">41000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDUtMy0xLTEtNzgwNDk_92604e8a-df46-4df3-ad95-0e5a48457829"
      unitRef="usd">27000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDUtNS0xLTEtNzgwNDk_41333b33-55f7-41ad-9fb3-9ff1b8dfd6d3"
      unitRef="usd">2000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDYtMS0xLTEtNzgwNDk_da462abc-436a-496b-966e-3ec760bd2875"
      unitRef="usd">-1318000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDYtMy0xLTEtNzgwNDk_c0e14b31-d5ed-448e-8601-e0f59c330441"
      unitRef="usd">423000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDYtNS0xLTEtNzgwNDk_d442e77e-754c-48e6-9157-fe8ebba2b8fb"
      unitRef="usd">-2567000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDctMS0xLTEtNzgwNDk_bee74fb0-b0f9-4b9a-b607-d1f4943e79a2"
      unitRef="usd">-14000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDctMy0xLTEtNzgwNDk_e496386d-dc19-4f6f-b532-73d20e57a714"
      unitRef="usd">-10000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDctNS0xLTEtNzgwNDk_dcf18809-a7f9-492c-bcda-f75044d12169"
      unitRef="usd">7000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDgtMS0xLTEtNzgwNDk_860cdccd-5383-4a86-ade8-ff3954853a04"
      unitRef="usd">2507000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDgtMy0xLTEtNzgwNDk_d1c34a00-8d14-4219-b84c-f5669abade04"
      unitRef="usd">-861000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDgtNS0xLTEtNzgwNDk_24b2f40c-635d-4046-b36d-acb6b93999af"
      unitRef="usd">804000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDktMS0xLTEtNzgwNDk_87285be9-ea42-43d1-9fae-73dca58c7994"
      unitRef="usd">4880000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDktMy0xLTEtNzgwNDk_5807a7f6-da6d-4509-8e5c-5bbe0bbab68b"
      unitRef="usd">5741000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNDktNS0xLTEtNzgwNDk_42370df1-057a-4ecf-8dba-61e6fb72b787"
      unitRef="usd">4937000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNTAtMS0xLTEtNzgwNDk_85933eb0-5588-4fad-a023-2bd6e30485ee"
      unitRef="usd">7387000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNTAtMy0xLTEtNzgwNDk_ea5012ce-7fb9-43ac-841b-7916ef551a8a"
      unitRef="usd">4880000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184Mi9mcmFnOjMyMzVmM2Q3NWNhMjRlNTBiODI3NTUzYzRkMzUzNTY2L3RhYmxlOjM4OGEzZGM3Y2NkNTQ1NjhhYWZlZmNiMGYwZWNlZTRlL3RhYmxlcmFuZ2U6Mzg4YTNkYzdjY2Q1NDU2OGFhZmVmY2IwZjBlY2VlNGVfNTAtNS0xLTEtNzgwNDk_22635d04-e677-4792-b108-cf964b6b7379"
      unitRef="usd">5741000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="ibf5b071c02144445ae1940007287f05f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0xLTEtMS03ODA0OQ_316503c8-a9b4-414f-86a6-afc9be200138"
      unitRef="shares">252900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibf5b071c02144445ae1940007287f05f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0zLTEtMS03ODA0OQ_de06a947-3e2b-4e9b-a961-6ddb147fb330"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8589c07204d749bbace5042c6b65cc69_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi01LTEtMS03ODA0OQ_c699f17f-7fb1-46e6-9615-ff6e935fe873"
      unitRef="usd">9448000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99f221c1344f471085a849bbadf705e3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi03LTEtMS03ODA0OQ_95d70456-bbdd-472b-bf91-5d3be859057d"
      unitRef="usd">22538000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f53fa30766f4027ac9f51d714b28ca5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi05LTEtMS03ODA0OQ_9d995d91-8966-43df-a7c2-8ad001fc72cb"
      unitRef="usd">-296000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i30274a1261ef49b2b0ed74d1f2f4ffd0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0xMS0xLTEtNzgwNDk_c80c2764-64d5-46eb-8d24-10551fd22d80"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMi0xMy0xLTEtNzgwNDk_5551ba0d-b6ff-4f83-985e-6e69c2645aaa"
      unitRef="usd">31693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMy03LTEtMS03ODA0OQ_6bf7fae2-97ee-4b1d-9a44-e5c29fbbe4b7"
      unitRef="usd">4572000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMy0xMy0xLTEtNzgwNDk_d014bf8a-02fe-490c-b425-0260f1739ac9"
      unitRef="usd">4572000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32e30683b4044476b165b02ff7db9ad5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNC05LTEtMS03ODA0OQ_d2c7b72c-85be-490d-bbd4-746d0fe5a6bc"
      unitRef="usd">446000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNC0xMy0xLTEtNzgwNDk_c431bc24-cc2e-431c-a629-401068497bd7"
      unitRef="usd">446000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ib2672b85aeaa43e380a7c111f5228b73_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy0xLTEtMS03ODA0OQ_e30a44de-d812-4b87-82da-9c30c8fa87af"
      unitRef="shares">9400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy01LTEtMS03ODA0OQ_46e3d87b-77ed-4463-806e-9d7b15afa43d"
      unitRef="usd">353000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy03LTEtMS03ODA0OQ_6a3210bf-b219-4f52-ac78-95b29e9748f0"
      unitRef="usd">2347000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfNy0xMy0xLTEtNzgwNDk_b86da9ad-90bf-4dbd-9462-4cc9308374f5"
      unitRef="usd">2700000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:DividendsCommonStock
      contextRef="i1b75ba78b5dd43a9b426763c1a6c525b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOC03LTEtMS03ODA0OQ_2b41047a-b4f0-4e2e-9239-ac5d5c11832f"
      unitRef="usd">961000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOC0xMy0xLTEtNzgwNDk_c7e7e384-cff6-4fc1-9d38-3c99bc24157c"
      unitRef="usd">961000000</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib2672b85aeaa43e380a7c111f5228b73_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOS0xLTEtMS03ODA0OQ_a7005d03-9596-4026-94cb-b541bd1a000c"
      unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOS01LTEtMS03ODA0OQ_3a67a014-f0c6-4eba-b289-23d5d647ee63"
      unitRef="usd">330000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfOS0xMy0xLTEtNzgwNDk_0efda3d8-b931-40c7-bbef-12f080da21d6"
      unitRef="usd">330000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="icf34ad0909de434bb6091ebb2fba3633_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTAtNS0xLTEtNzgwNDk_dac4ff56-3b8d-4917-adc5-a266c1bb70f4"
      unitRef="usd">-181000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTAtMTMtMS0xLTc4MDQ5_7c8e727b-0386-4167-8d27-2faab129477b"
      unitRef="usd">-181000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:SharesOutstanding
      contextRef="i793efbc5c7714f92b8248295269327af_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMS0xLTEtNzgwNDk_2855dd29-4e68-4775-9e44-aac5c7c9df15"
      unitRef="shares">245400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i793efbc5c7714f92b8248295269327af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMy0xLTEtNzgwNDk_c9977cf3-07f9-4bab-8387-bcaa41fd0d10"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if94c1fcb18c342dc8db391ef68ac66d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItNS0xLTEtNzgwNDk_8f4c0d79-4942-49b0-beca-1ee0ca7b7800"
      unitRef="usd">9244000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35a79074187a456ab3c3c9edc81fd430_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItNy0xLTEtNzgwNDk_21cbc2a8-dfea-4979-bdc6-ecb3410bcd4b"
      unitRef="usd">23802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if93412ca87a24e1a8d15a5d209e51bbb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItOS0xLTEtNzgwNDk_0212b2e3-2c76-49c0-a44a-22ff83896e73"
      unitRef="usd">150000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMTMtMS0xLTc4MDQ5_0d168656-bf76-4478-8b83-cfff3c38df54"
      unitRef="usd">33199000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTUtNy0xLTEtNzgwNDk_fd5435b2-ed12-4560-a722-4109c235d602"
      unitRef="usd">6104000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTUtMTEtMS0xLTc4MDQ5_c2beb34b-c3ac-457a-92b6-a737d86139b3"
      unitRef="usd">-9000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTUtMTMtMS0xLTc4MDQ5_65d8c701-dcb8-42ce-98d7-c1a28fa130e3"
      unitRef="usd">6095000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib6d4349f67ff4c61980f48af218a4394_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTYtOS0xLTEtNzgwNDk_7e5f2a43-e1ae-437e-9093-20dc5876c747"
      unitRef="usd">-328000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTYtMTEtMS0xLTc4MDQ5_ed2dad3b-3c60-4b06-8e9a-a19d8e861b3b"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTYtMTMtMS0xLTc4MDQ5_18b3e3b0-a0b4-432e-a00d-873e8c1154c1"
      unitRef="usd">-330000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="icdcdbe42d42d4b9bace1d99bcc7fa484_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMTEtMS0xLTgxNzM1_6ac53da8-a6ff-43ee-811a-e70eacc9beab"
      unitRef="usd">79000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTItMTMtMS0xLTgxNzQ0_1a90b496-e97b-49b8-afba-ddc601de9cd4"
      unitRef="usd">79000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMS0xLTEtNzgwNDk_dd55c83a-8f41-4531-9280-c7a6df3afd53"
      unitRef="shares">5100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMy0xLTEtNzgwNDk_99ee2285-fb65-441d-bf20-f5b84c81c945"
      unitRef="usd">1000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktNS0xLTEtNzgwNDk_60c31c2f-b1f3-48fd-b4ed-ae2766336a4e"
      unitRef="usd">192000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktNy0xLTEtNzgwNDk_c56782bc-d5f5-49cc-9a10-934a162384aa"
      unitRef="usd">1707000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMTMtMS0xLTc4MDQ5_f7aaf7a6-e5cf-4f5a-8ac7-44357772c601"
      unitRef="usd">1900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:DividendsCommonStock
      contextRef="i131da8df58324ff596e25526f7fee2d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtNy0xLTEtNzgwNDk_7b4bf8cd-e105-4cc4-84df-e68a5e034819"
      unitRef="usd">1111000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMTMtMS0xLTc4MDQ5_b744b695-797a-4609-8196-39f1a4e982fd"
      unitRef="usd">1111000000</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7389831c37e246a2955996cb6f3484e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjEtMS0xLTEtNzgwNDk_7b6d2481-27bb-4b8d-b331-73661236f306"
      unitRef="shares">1500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjEtNS0xLTEtNzgwNDk_2f30a11c-ee6d-43b5-bd8a-58ac9cbc6cc3"
      unitRef="usd">355000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjEtMTMtMS0xLTc4MDQ5_b90937d2-6e67-4d11-87eb-7f82de6ef996"
      unitRef="usd">355000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i593f9d61679e453c9e2b598bd1243cb4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjItNS0xLTEtNzgwNDk_6201aca5-ab81-4612-a55e-fea3cb33b791"
      unitRef="usd">-259000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjItMTMtMS0xLTc4MDQ5_6d89cf91-18e8-41b1-ae88-dba8c12d6b32"
      unitRef="usd">-259000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:SharesOutstanding
      contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMS0xLTEtNzgwNDk_087463d3-fd98-4765-83a7-0fc15324c8ce"
      unitRef="shares">241800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMy0xLTEtNzgwNDk_fb5a3e88-3c0e-44ba-8391-3c1843cfe5ed"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65a827868fc64ccfacc19325aa44c171_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtNS0xLTEtNzgwNDk_cd3430f0-696e-4c1b-8107-55f9f0f38467"
      unitRef="usd">9148000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67a2241770974cd59c85ae10194b94f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtNy0xLTEtNzgwNDk_c88f9339-e895-4105-aeaa-e16e4cfe688a"
      unitRef="usd">27088000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d68c3e5edf94c9cbe296449811771a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtOS0xLTEtNzgwNDk_82256759-4dad-4ffb-acad-3b3db4176e02"
      unitRef="usd">-178000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if422755e3e354c5f865ec51e2e1db51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMTEtMS0xLTc4MDQ5_e7e401f6-d719-4f17-b6bc-32de2af1db2e"
      unitRef="usd">68000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjMtMTMtMS0xLTc4MDQ5_9a8f2522-d404-4f9c-914c-417ec10192f4"
      unitRef="usd">36128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktNy0xLTEtODQ3OTA_dc5f99ee-0333-4a04-bd4c-0fac46704fa3"
      unitRef="usd">-23000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6946927fb5b546f5b3d2eaef12758789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMTktMTMtMS0xLTg0Nzk4_88d0f365-d563-4607-9371-cecdb58a310d"
      unitRef="usd">-23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMS0xLTEtODQ3OTA_a558ea2e-5aa5-49cd-93ea-ce64fc1dd204"
      unitRef="shares">241800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i70f48fcd3c1d4ee0bfa8537689643e3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMy0xLTEtODQ3OTA_073a2416-06d2-4086-9410-0ff3887a3964"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65a827868fc64ccfacc19325aa44c171_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtNS0xLTEtODQ3OTA_54d7e034-4b6a-41ed-a786-64463d338211"
      unitRef="usd">9148000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1e4608246614931930218a735fc0cbb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtNy0xLTEtODQ3OTA_715edd72-9d72-40b5-af7c-a0acef49067c"
      unitRef="usd">27065000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d68c3e5edf94c9cbe296449811771a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtOS0xLTEtODQ3OTA_bce7b972-75d8-4542-a276-217b1e416060"
      unitRef="usd">-178000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if422755e3e354c5f865ec51e2e1db51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMTEtMS0xLTg0Nzk4_90dc93c5-1e23-4605-b555-f19a2242b119"
      unitRef="usd">68000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2494f99710864bc7a90c0848d3e5fde2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjAtMTMtMS0xLTg0Nzk4_7bef698a-2432-4b43-8977-eedd0d783007"
      unitRef="usd">36105000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjYtNy0xLTEtNzgwNDk_ae426ec1-7c6a-46d1-82d4-64f0e96bde3f"
      unitRef="usd">6025000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjYtMTEtMS0xLTc4MDQ5_408e656b-bf99-4e63-80d9-d46120477ab3"
      unitRef="usd">-6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjYtMTMtMS0xLTc4MDQ5_cf9134d9-08a1-4020-9fd6-bd51b0ffd804"
      unitRef="usd">6019000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i42b6d6da5eaa4137b9f2ce6c292546d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjctOS0xLTEtNzgwNDk_28ece4f7-c5c0-407f-bd6b-cffe17495f7b"
      unitRef="usd">-2325000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjctMTEtMS0xLTc4MDQ5_351d9f45-0482-4f69-946f-8a484232278c"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjctMTMtMS0xLTc4MDQ5_d7fbeb94-eb91-4666-a031-24323b3fc3f3"
      unitRef="usd">-2336000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i376b189203a148f5b6b1e0845eb73611_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjgtMTEtMS0xLTc4MDQ5_7bae4aa1-a3b4-435c-967d-2ce15063a9e8"
      unitRef="usd">36000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMjgtMTMtMS0xLTc4MDQ5_f4f712f0-8538-48c2-94b2-826447c926e8"
      unitRef="usd">36000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ifad2035d69cb4c4bb3a71c39d076f734_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtMS0xLTEtNzgwNDk_9eff50ce-f886-4fac-85c6-4363c31acc20"
      unitRef="shares">4800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtNS0xLTEtNzgwNDk_15ac85c1-ae9e-43d5-b811-15ba6ff69d07"
      unitRef="usd">184000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtNy0xLTEtNzgwNDk_e66a4475-67c6-4821-a211-c3f5d5cb6ec0"
      unitRef="usd">2132000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzEtMTMtMS0xLTc4MDQ5_71a43c80-a54a-4d0e-beb1-4797e1681c6e"
      unitRef="usd">2316000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:DividendsCommonStock
      contextRef="ic9f925d983e547bfbd92a260aa342ab5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzItNy0xLTEtNzgwNDk_4f9031df-e716-40ed-9f4e-bcf914aacf79"
      unitRef="usd">1234000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzItMTMtMS0xLTc4MDQ5_a4063499-c71d-4c6f-9663-461702e45a63"
      unitRef="usd">1234000000</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifad2035d69cb4c4bb3a71c39d076f734_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzMtMS0xLTEtNzgwNDk_cfb3b7ae-f81d-4f2b-8676-854e96cf6854"
      unitRef="shares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzMtNS0xLTEtNzgwNDk_70986184-3fa1-4edf-a8a5-b9ace04193f3"
      unitRef="usd">352000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzMtMTMtMS0xLTc4MDQ5_5b035826-2bef-464e-a5ac-ba9a22a72830"
      unitRef="usd">352000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i1d2d8b8e74e84bb39f048da4e83cc29a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzQtNS0xLTEtNzgwNDk_19d17629-c07c-4e03-8d43-81dec6a6614d"
      unitRef="usd">-232000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzQtMTMtMS0xLTc4MDQ5_22561e72-6180-4b16-be75-7716aba76763"
      unitRef="usd">-232000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:SharesOutstanding
      contextRef="iab35b50f371d4e109ef6e82fb6162116_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMS0xLTEtNzgwNDk_7f66ad1b-1d55-4c66-b7ca-5c695d633b4a"
      unitRef="shares">238000000.0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iab35b50f371d4e109ef6e82fb6162116_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMy0xLTEtNzgwNDk_7ba55ebe-89ed-4428-8f80-52f84db76981"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4923e0fc5164066835e075d6d5a4675_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtNS0xLTEtNzgwNDk_cc15effb-a3b1-4d4f-8f8e-3b7c41c4c4aa"
      unitRef="usd">9084000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic55f913977d34ea8ae0f65c274b41526_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtNy0xLTEtNzgwNDk_74882761-7362-45d9-bd90-a76f7bc1e949"
      unitRef="usd">29724000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62707788a92840b2a900639d9bb21b20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtOS0xLTEtNzgwNDk_ff6e6973-1f51-45ae-9584-2995b8f1252b"
      unitRef="usd">-2503000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib61b9bc047c24fe089b47010fc8c5147_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMTEtMS0xLTc4MDQ5_890dc19e-7d1b-4a37-a1c6-b1aa987081ee"
      unitRef="usd">87000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M184NS9mcmFnOjliYTEzMDFkMmIzMzQyMWE5N2U1NmE2NzEyNDI1MjZhL3RhYmxlOjFiZjlkMTkzNWM0ODQ4OTQ5MzEzMmM2Yzg5MTBiNGI5L3RhYmxlcmFuZ2U6MWJmOWQxOTM1YzQ4NDg5NDkzMTMyYzZjODkxMGI0YjlfMzUtMTMtMS0xLTc4MDQ5_83d25093-e995-47fd-b7ec-573f55367454"
      unitRef="usd">36394000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NatureOfOperations
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfMTQ1Mg_fd1a77c2-f3d1-4863-b54c-75226a511bac">Organization &lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol &#x201c;ELV&#x201d; on June 28, 2022. References to the terms &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or &#x201c;Elevance Health&#x201d; used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the &#x201c;states&#x201d; include the District of Columbia and Puerto Rico, unless the context otherwise requires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members through our affiliated health plans as of December&#160;31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products &amp;amp; Services business, which administers the Federal Employees Health Benefits (&#x201c;FEHB&#x201d;) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (&#x201c;PBM&#x201d;) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are an independent licensee of the Blue Cross and Blue Shield Association (&#x201c;BCBSA&#x201d;), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#x201c;BCBS&#x201d;) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer PBM services through our CarelonRx, Inc. (&#x201c;CarelonRx&#x201d;) subsidiary, which was named IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all 50&#160;states, the District of Columbia and Puerto Rico through our subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Anthem Blue Cross/Anthem Blue Cross and Blue Shield &#x2014; represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Wellpoint &#x2014; we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Carelon &#x2014; this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes made to our segments in 2022 associated with this branding strategy. Through December 31, 2022, we managed our operations by customer types through four reportable segments: Commercial &amp;amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. Our branding strategy reflects the evolution of &lt;/span&gt;&lt;/div&gt;our business from a traditional health insurance company into a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our business in the future. For additional discussion, including the changes to our reportable segments for 2023, see Note 20, &#x201c;Segment Information.&#x201d;</us-gaap:NatureOfOperations>
    <elv:NumberOfMedicalMembersServed
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfMzk3_0c55a02c-f1a9-4dc4-8b11-04554857fa36"
      unitRef="individuals">47500000</elv:NumberOfMedicalMembersServed>
    <elv:NumberOfCountiesInGeographicalRegionNotServed
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfODE0_4b1f19f4-3a79-4443-abf7-2c4e2c1e3f5e"
      unitRef="counties">30</elv:NumberOfCountiesInGeographicalRegionNotServed>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185MS9mcmFnOjg1ODI3MzVjNjM5ODRhMDE4NzE3M2Q0N2U5ZWM1MWI5L3RleHRyZWdpb246ODU4MjczNWM2Mzk4NGEwMTg3MTczZDQ3ZTllYzUxYjlfMTM3Mg_43443adc-38f6-4299-a475-0fa396c25d35"
      unitRef="states">50</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMjM_54a3464a-dce5-4026-ad71-21c9126b5eb8">Basis of Presentation and Significant Accounting Policies&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying consolidated financial statements include the accounts of Elevance Health and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (&#x201c;USD&#x201d;). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in &#x201c;Foreign currency translation adjustments&#x201d; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $258 and $173 at December&#160;31, 2022 and 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify fixed maturity securities in our investment portfolio as &#x201c;available-for-sale&#x201d; and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security&#x2019;s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption &#x201c;Other invested assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption &#x201c;Other invested assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption &#x201c;Other invested assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported in other current assets on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current liabilities. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders&#x2019; equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions.&#160;To the extent the loaned securities&#x2019; value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall.&#160;As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $152 and $142 at December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $68 and $50 at December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $744 and $648 at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws and are reported net on our consolidated balance sheets. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the &#x201c;Corporate AMT&#x201d;) that became effective for us beginning January 1, 2023. We have elected to account for the effects of the Corporate AMT on deferred tax assets and carryforwards and tax credits in the period they arise. Additionally, the Inflation Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31, 2022. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of operations, cash flows or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3"&gt;fifteen&lt;/span&gt; to thirty years for buildings and improvements, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5"&gt;three&lt;/span&gt; to five years for computer equipment and software, and the lesser of the remaining life of the building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea"&gt;three&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable assumptions and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry&#x2019;s weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;companies in our industry and are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;); and book value of invested capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset&#x2019;s fair value. This determination consists of a one-step test comparing the fair value of a reporting unit, including goodwill, to its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit&#x2019;s carrying amount over its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December&#160;31, 2022, we believe there were no material concentrations of credit risk with any individual counterparty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Retirement Benefits:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan&#x2019;s cash flows to determine the plan&#x2019;s obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Claims Payable:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1)&#160;an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2)&#160;claims reported to us and processed through our systems but not yet paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into &#x201c;claim triangles,&#x201d; which compare claim incurred dates to the dates of claim payments. This information is analyzed to create &#x201c;completion factors&#x201d; that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels (&#x201c;trend factors&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Policyholder Liabilities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (&#x201c;MLR&#x201d;), the relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively the &#x201c;ACA&#x201d;). If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with regulations issued by the Department of Health and Human Services (&#x201c;HHS&#x201d;). Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Future Policy Benefits:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Premiums for risk-based contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other regulatory requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final amounts paid, the adjustments are included in earnings in the period of final settlement. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative fees and other revenue include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;groups an administrative fee, which is based on the number of members in a group and the group&#x2019;s claim experience. In addition, administrative fees and other revenue include amounts received for the administration of Medicare, certain other government programs, and administrative services arrangements of our Carelon (Diversified Business Group) subsidiaries, now known as Carelon. Generally, these fee-based arrangements include services which constitute a single suite of services provided and for which consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with premiums, these fee-based arrangements may include terms with retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable consideration within the transaction price. As such, these fee-based arrangements contain a single performance obligation that constitutes a series, and revenue is recognized over time as the services are performed. All benefit payments under these programs are excluded from benefit expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of whether services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be recognized requires significant judgment in the determination of the level of achievement of performance incentives, service level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue includes revenue for services performed by our CarelonRx PBM for unaffiliated PBM customers. Unaffiliated PBM customers include our fee-based groups that have contracted with CarelonRx for PBM services and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in consolidation. Product revenue for PBM services is recognized using the gross method at the negotiated contract price when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer. CarelonRx determined it is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary management); its control over establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the pricing for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling the promise to provide PBM services. Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments made by or on behalf of the customer, and administrative fees. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in exchange for the products or services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at December&#160;31, 2022. Revenue recognized in 2022 and 2021 from performance obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CarelonRx&#x2019;s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated PBM customers (net of rebates or discounts). Cost of products sold includes per-claim administrative fees for prescription fulfillment by its vendor and certain CarelonRx direct costs related to sales and administration of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in our consolidated statements of income based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Group risk-based customers with a smaller employee base. Products for Group risk-based customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual and Group markets, we offer products through state or federally facilitated marketplaces, or Public Exchanges, and off-exchange products.&#160;The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate image are expensed when first aired. Total advertising and marketing expense was $511, $588 and $558 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Insurance Provider Fee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The ACA imposed an annual Health Insurance Provider Fee (&#x201c;HIP Fee&#x201d;) on health insurers that wrote certain types of health insurance on U.S. risks, which was permanently repealed effective January 1, 2021. The HIP Fee was non-deductible for federal income tax purposes.&#160;Our affected products were priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when it was in effect. The HIP Fee was $15,523 for 2020 and was permanently eliminated beginning in 2021. For the year ended December 31, 2020, we recognized $1,570 as selling, general and administrative expense related to the HIP Fee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We recognize operating right-of-use (&#x201c;ROU&#x201d;) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized initial direct costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in selling, general and administrative expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of the ROU asset to its estimated undiscounted future cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is performed. An impairment loss is recorded for the difference of the ROU asset&#x2019;s carrying value that exceeds its estimated discounted cash flows. During the years ended December 31, 2022, 2021 and 2020, we recorded $34, $136 and $258, respectively, for impairment and abandonment of ROU assets. See Note 18, &#x201c;Leases&#x201d; for additional information about the ROU asset impairment and abandonment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per Share:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and the number of shares assumed purchased represents the dilutive shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Guidance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the FASB issued Accounting Standards Update No. 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-01&#x201d;). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued Accounting Standards Update No. 2020-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Subtopic 310-20, Receivables&#x2014;Nonrefundable Fees and Other Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-08&#x201d;). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued Accounting Standards Update No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2020-06&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option; these amounts were not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance Not Yet Adopted: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the FASB issued Accounting Standards Update No. 2020-11,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Services&#x2014;Insurance (Topic 944): Effective Date and Early Application &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2020-11&#x201d;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Services&#x2014;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2018-12&#x201d;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, with the amendments required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company&#x2019;s reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#x2019;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. The Company adopted the new standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the earliest period presented, January 1, 2021. The adoption did not have a material impact on our consolidated financial position, results of operations, cash flows, or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;There were no other new accounting pronouncements that were issued or became effective during the year ended December&#160;31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NzU_c2d696c2-bd9b-413b-8632-dd633fa2add4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying consolidated financial statements include the accounts of Elevance Health and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NDk_7ac941fd-7bf1-434c-adef-0977b499d1a4">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (&#x201c;USD&#x201d;). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in &#x201c;Foreign currency translation adjustments&#x201d; in our consolidated statements of comprehensive income.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NTA_adc0444e-5441-498c-b433-07b85e74bd17">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/span&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNDQ_a9bcb336-1c4a-4532-8331-60725eee6043">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMjY_d4bc4394-34d2-49d9-813b-14eec8ebc91f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $258 and $173 at December&#160;31, 2022 and 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTg0NA_983a461e-d81a-4369-967b-82fb2b5a1581"
      unitRef="usd">258000000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTg1Mg_3091489a-79ad-46ea-ba94-6621ff95522a"
      unitRef="usd">173000000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NTQ_6c62d250-4363-433a-8ed8-937e0ff4edd2">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify fixed maturity securities in our investment portfolio as &#x201c;available-for-sale&#x201d; and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security&#x2019;s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption &#x201c;Other invested assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption &#x201c;Other invested assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption &#x201c;Other invested assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.&lt;/span&gt;&lt;/div&gt;We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported in other current assets on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current liabilities. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders&#x2019; equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions.&#160;To the extent the loaned securities&#x2019; value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall.&#160;As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</us-gaap:InvestmentPolicyTextBlock>
    <elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfODE0OQ_cbe8a9cc-4b95-4041-99bd-1a4681b8cc51"
      unitRef="number">1.02</elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzOTY_8cbf14f7-4b8c-4084-be67-6c56710a54dd">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $152 and $142 at December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $68 and $50 at December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $744 and $648 at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfODg0MQ_ab93165a-5c30-49ba-97a7-f91042c1ebe2"
      unitRef="usd">152000000</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfODg0OA_93072fec-6d28-44ed-8930-294f046bb1ca"
      unitRef="usd">142000000</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <elv:SelffundedReceivablesAllowanceForDoubtfulAccounts
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTA3MA_725d7dfd-fe4f-4eb5-bfc2-e1e1ab2e2fa1"
      unitRef="usd">68000000</elv:SelffundedReceivablesAllowanceForDoubtfulAccounts>
    <elv:SelffundedReceivablesAllowanceForDoubtfulAccounts
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTA3Nw_681a67c3-3e88-4968-ba7c-273a3929d9f9"
      unitRef="usd">50000000</elv:SelffundedReceivablesAllowanceForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTQwOQ_49aed515-58b8-4c46-8763-7b2f5106716d"
      unitRef="usd">744000000</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfOTQxNg_eebefed7-42e2-44af-ab45-3ab339edd2a2"
      unitRef="usd">648000000</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzOTc_c06a002a-5a30-4751-b722-556a10d22a7f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws and are reported net on our consolidated balance sheets. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact &lt;/span&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the &#x201c;Corporate AMT&#x201d;) that became effective for us beginning January 1, 2023. We have elected to account for the effects of the Corporate AMT on deferred tax assets and carryforwards and tax credits in the period they arise. Additionally, the Inflation Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31, 2022. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of operations, cash flows or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMzY_3ea749d8-2390-473e-86e7-f2a20098b16d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMjQ_03931d0a-8679-41d4-96b8-3bd8460818c3"&gt;fifteen&lt;/span&gt; to thirty years for buildings and improvements, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzE_62a72357-1649-491e-96a9-cc9d3358f1f5"&gt;three&lt;/span&gt; to five years for computer equipment and software, and the lesser of the remaining life of the building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1NjI_e7e61c5c-1ac1-45d9-98ce-c5d8635426ea"&gt;three&lt;/span&gt; to ten years.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i05b94430fac3410384b74a0089cca3b4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExMzA_71c6c4b6-bd06-46d7-aa57-0121bfcc5622">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8cdeae00e15947f2b19d9c357486c5be_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTExNzc_f77ff7b8-424d-48bf-80c1-15d4d1d7bf35">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibc4af8f693284287a7966314732d1b9d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTEyOTQ_5b611164-61f3-4752-a755-182defb9f863">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods
      contextRef="iaf37da992005431c9ad91f291589bab4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NDY_8c4d7734-5e37-4114-ab74-b85e1c86a9e8">Leasehold improvements are depreciated over the term of the related lease.</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if071474e71e54a499f11bedc93cff54d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMTE1Njg_2a0889dc-fc50-4894-bcce-737ab7b8355c">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0MzE_847a8cd8-a719-43f2-9ffb-35dbac700358">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable assumptions and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry&#x2019;s weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;companies in our industry and are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;); and book value of invested capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset&#x2019;s fair value. This determination consists of a one-step test comparing the fair value of a reporting unit, including goodwill, to its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit&#x2019;s carrying amount over its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0MjU_ced987e5-a89f-48ab-bad4-7a8e3fe66cea">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December&#160;31, 2022, we believe there were no material concentrations of credit risk with any individual counterparty.&lt;/span&gt;&lt;/div&gt;We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNTY_a62ba5c5-ef53-436c-94f3-9c04209b19d3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Retirement Benefits:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension &lt;/span&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan&#x2019;s cash flows to determine the plan&#x2019;s obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NjU_62f2d572-bed7-4be5-a10a-860cb5f8b25e">We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.</us-gaap:DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses>
    <us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMzc_f65edb34-1c4f-4fec-bd32-d83eae5470fa">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Claims Payable:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1)&#160;an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2)&#160;claims reported to us and processed through our systems but not yet paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into &#x201c;claim triangles,&#x201d; which compare claim incurred dates to the dates of claim payments. This information is analyzed to create &#x201c;completion factors&#x201d; that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels (&#x201c;trend factors&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members.</us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy>
    <elv:OtherPolicyholderLiabilitiesPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0NTY_3f347834-1d15-401f-9582-68743e34bec7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Policyholder Liabilities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (&#x201c;MLR&#x201d;), the relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.&lt;/span&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively the &#x201c;ACA&#x201d;). If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with regulations issued by the Department of Health and Human Services (&#x201c;HHS&#x201d;). Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.&lt;/span&gt;&lt;/div&gt;</elv:OtherPolicyholderLiabilitiesPolicyTextBlock>
    <us-gaap:FuturePolicyBenefitsLiabilityPolicy
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzODY_21a94808-ab17-421e-8e0d-7b621a0d8077">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Future Policy Benefits:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FuturePolicyBenefitsLiabilityPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNTI_27302c81-a3fb-4a18-ab9d-1e05f56a0af6">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Premiums for risk-based contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other regulatory requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final amounts paid, the adjustments are included in earnings in the period of final settlement. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative fees and other revenue include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;groups an administrative fee, which is based on the number of members in a group and the group&#x2019;s claim experience. In addition, administrative fees and other revenue include amounts received for the administration of Medicare, certain other government programs, and administrative services arrangements of our Carelon (Diversified Business Group) subsidiaries, now known as Carelon. Generally, these fee-based arrangements include services which constitute a single suite of services provided and for which consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with premiums, these fee-based arrangements may include terms with retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable consideration within the transaction price. As such, these fee-based arrangements contain a single performance obligation that constitutes a series, and revenue is recognized over time as the services are performed. All benefit payments under these programs are excluded from benefit expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of whether services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be recognized requires significant judgment in the determination of the level of achievement of performance incentives, service level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue includes revenue for services performed by our CarelonRx PBM for unaffiliated PBM customers. Unaffiliated PBM customers include our fee-based groups that have contracted with CarelonRx for PBM services and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in consolidation. Product revenue for PBM services is recognized using the gross method at the negotiated contract price when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer. CarelonRx determined it is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary management); its control over establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the pricing for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling the promise to provide PBM services. Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments made by or on behalf of the customer, and administrative fees. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in exchange for the products or services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at December&#160;31, 2022. Revenue recognized in 2022 and 2021 from performance obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNjI_b1ac9607-32d4-4679-b48c-cfdc5cd1a7ad">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;CarelonRx&#x2019;s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated PBM customers (net of rebates or discounts). Cost of products sold includes per-claim administrative fees for prescription fulfillment by its vendor and certain CarelonRx direct costs related to sales and administration of customer contracts.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzNDg_68fa1cf4-e7b6-490a-a710-0ea621f83208">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in our consolidated statements of income based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the consolidated statements of income.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzE4NTg_3fd2d687-75be-4a84-b802-0d50987ce380"
      unitRef="number">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzMjg_46920f17-8da4-47ac-964c-080d8f78f270">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent &lt;/span&gt;agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Group risk-based customers with a smaller employee base. Products for Group risk-based customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual and Group markets, we offer products through state or federally facilitated marketplaces, or Public Exchanges, and off-exchange products.&#160;The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate image are expensed when first aired. Total advertising and marketing expense was $511, $588 and $558 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzM1MTM_71d23c9e-cde1-4bf6-9904-be3ffdd22383"
      unitRef="usd">511000000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzM1MTc_08ca19cc-25a6-4495-8044-1a30875f8431"
      unitRef="usd">588000000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzM1MjQ_d729d227-9d51-49c0-90ae-24eac1d13fc7"
      unitRef="usd">558000000</us-gaap:MarketingAndAdvertisingExpense>
    <elv:HealthInsuranceProviderFeePolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDUzOTg_32da1ea7-a81a-47ba-8047-c345024436c1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Insurance Provider Fee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt; The ACA imposed an annual Health Insurance Provider Fee (&#x201c;HIP Fee&#x201d;) on health insurers that wrote certain types of health insurance on U.S. risks, which was permanently repealed effective January 1, 2021. The HIP Fee was non-deductible for federal income tax purposes.&#160;Our affected products were priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when it was in effect. The HIP Fee was $15,523 for 2020 and was permanently eliminated beginning in 2021. For the year ended December 31, 2020, we recognized $1,570 as selling, general and administrative expense related to the HIP Fee.</elv:HealthInsuranceProviderFeePolicyTextBlock>
    <elv:PatientProtectionAffordableCareActHealthInsuranceProviderFee
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzQxMTA_042b5f76-0abf-42f4-bd35-efee7e6b7d47"
      unitRef="usd">15523000000</elv:PatientProtectionAffordableCareActHealthInsuranceProviderFee>
    <elv:PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzQyMjQ_7d883d73-8de8-4b29-b68d-74548d583b73"
      unitRef="usd">1570000000</elv:PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0Njg_e8a4dd24-8cf8-4db1-a6af-c83c70d0aa0e">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We recognize operating right-of-use (&#x201c;ROU&#x201d;) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized initial direct costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in selling, general and administrative expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of the ROU asset to its estimated undiscounted future cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is performed. An impairment loss is recorded for the difference of the ROU asset&#x2019;s carrying value that exceeds its estimated discounted cash flows. During the years ended December 31, 2022, 2021 and 2020, we recorded $34, $136 and $258, respectively, for impairment and abandonment of ROU assets. See Note 18, &#x201c;Leases&#x201d; for additional information about the ROU asset impairment and abandonment charges.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODYxMzE2_95f09d79-8ff5-4748-854b-101bc6881966"
      unitRef="usd">34000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzY2NTg_feef23b7-2634-4715-a958-424c6945a92e"
      unitRef="usd">136000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfMzY2NjU_bfd5964d-b415-4c30-b8a5-adf089467c13"
      unitRef="usd">258000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0MTk_b3d4f48a-b62a-43d9-9de1-3f34144b16f3">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per Share:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and the number of shares assumed purchased represents the dilutive shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNDU0ODE_0eb1a914-1400-439a-ad4c-d9567accd8cb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Guidance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the FASB issued Accounting Standards Update No. 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-01&#x201d;). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of the &lt;/span&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued Accounting Standards Update No. 2020-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Subtopic 310-20, Receivables&#x2014;Nonrefundable Fees and Other Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-08&#x201d;). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued Accounting Standards Update No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2020-06&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option; these amounts were not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance Not Yet Adopted: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the FASB issued Accounting Standards Update No. 2020-11,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Services&#x2014;Insurance (Topic 944): Effective Date and Early Application &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2020-11&#x201d;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Services&#x2014;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2018-12&#x201d;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, with the amendments required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company&#x2019;s reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#x2019;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. The Company adopted the new standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the earliest period presented, January 1, 2021. The adoption did not have a material impact on our consolidated financial position, results of operations, cash flows, or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;There were no other new accounting pronouncements that were issued or became effective during the year ended December&#160;31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODcwNDg5_c9cc18c5-f288-489a-8d34-9d323f97f250"
      unitRef="usd">31000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODcwNDk3_d99a1e84-f3c4-4c63-8b79-564ca477ef90"
      unitRef="usd">-8000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185NC9mcmFnOjVhYzIxZWJiZjY4MTQ1ODNiNWNhOGRhM2JjMjIyZjk5L3RleHRyZWdpb246NWFjMjFlYmJmNjgxNDU4M2I1Y2E4ZGEzYmMyMjJmOTlfNTQ5NzU1ODcwNTA0_825540fa-6d43-43b7-855c-78be6212f72f"
      unitRef="usd">-23000000</us-gaap:StockholdersEquity>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMjgzNA_39da7a88-6598-411c-8246-ece9a4db7fe8">Business Acquisitions&lt;div style="margin-bottom:9pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Completed Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, we completed business combinations for total cash consideration of approximately $752. These acquisitions included Integra MLTC, Inc. (&#x201c;Integra&#x201d;), acquired May 2022, which is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase prices for all business combinations were allocated to the tangible and intangible net assets acquired based on management&#x2019;s initial estimates of their fair values, of which $89 was allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $145 to goodwill. The intangible assets and goodwill acquired were assigned to our Government Business reportable segment. The majority of goodwill is deductible for income tax purposes. As of December&#160;31, 2022, the initial accounting for the acquisitions completed in 2022 had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, we completed business combinations for total cash consideration of approximately $4,021. These acquisitions included myNEXUS, Inc. (&#x201c;myNEXUS&#x201d;), acquired April 2021, a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (&#x201c;MMM&#x201d;), acquired June 2021, including its Medicare Advantage plan, Medicaid plan, and other affiliated companies. The purchase prices for all business combinations were allocated to the tangible and intangible net assets acquired based on management&#x2019;s final estimates of their fair values, of which $1,577 was allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,531 to goodwill, including measurement period adjustments of $10 during the year ended December 31, 2022. Of these amounts, $795 was allocated to our Other reportable segment and $3,333 to our Government Business reportable segment.The majority of goodwill is not deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired tangible assets (liabilities) at the acquisition date were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical claims and other policyholder liabilities payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent and tax liabilities, are finalized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider and hospital relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State Medicaid licenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations and financial condition of acquired entities have been included in our consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through December&#160;31, 2022, the impact of the acquired entities on revenue and net earnings was not material. Unaudited pro forma revenues for the years ended December&#160;31, 2022 and 2021 as if the acquisitions had occurred on January 1, 2021 were immaterial for both periods. The pro forma effects of the acquisitions on net earnings were immaterial for both years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pending Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Louisiana Health Service &amp;amp; Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service &amp;amp; Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BioPlus Parent, LLC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2022, we announced our entrance into an agreement with CarepathRx Aggregator, LLC to acquire its specialty pharmacy division, which includes BioPlus Parent, LLC (&#x201c;BioPlus&#x201d;) and subsidiaries. BioPlus is one of the largest independent specialty pharmacy organizations in the United States and seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition was completed on February 15, 2023, and initial purchase accounting for the acquisition has not been finalized.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzA5Mw_9765111b-2c23-40f4-aceb-0522e046f739"
      unitRef="usd">752000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzA4NQ_3f3ba86e-7eec-4f49-a220-3ad916aa45b7"
      unitRef="usd">89000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzEwMg_4374b5dc-eccb-4382-8ae9-13c6a7cb413e"
      unitRef="usd">250000000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzExMQ_f948a009-37c4-480c-b093-078beca7999a"
      unitRef="usd">145000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTg0_bdf5565b-dfb4-4c76-a9d4-7e241e0576aa"
      unitRef="usd">4021000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNTc5_28b7cb27-9541-405c-b55c-a4173a303d26"
      unitRef="usd">1577000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i15c5536514f64495bfe94e56b9bbd3dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNjM2_1f4e7f4c-5398-4748-bb79-d626bde9fc3a"
      unitRef="usd">20000000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:Goodwill
      contextRef="i842be0164ef642f19cf764709db72fe4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzEyMA_054bda13-ffe9-42d5-b5ee-9f49c75fe0bf"
      unitRef="usd">2531000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i83026d2c318c405b900c3c41a9e37cc7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMTA5OTUxMTY1MzEzMQ_1e790c56-9feb-4841-9a1e-01754ccecd97"
      unitRef="usd">10000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i4c555ed090374b7b9aa02f28d95d625c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNTQ5NzU1ODM5NTg5_f8d78f6f-054a-44f5-a1b9-9b449e16e125"
      unitRef="usd">795000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i4de08eefaeef475eacfe40d3fec4420a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfNTQ5NzU1ODM5NTk4_b770c873-afb8-468a-a5af-60878946bdde"
      unitRef="usd">3333000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMjgzNg_50d4f42a-c721-4954-b8b7-c54f1933319b">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired tangible assets (liabilities) at the acquisition date were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical claims and other policyholder liabilities payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMS0xLTEtMS03ODA0OQ_d3b7ee52-d6f3-405d-921f-6f6c984a220c"
      unitRef="usd">170000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMS0zLTEtMS03ODA0OQ_773c0aac-872b-472e-9667-44e6d1f75758"
      unitRef="usd">808000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMi0xLTEtMS03ODA0OQ_a5b6c899-7059-4e61-98a9-cbbae682c9e5"
      unitRef="usd">240000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMi0zLTEtMS03ODA0OQ_d4a61a90-6470-49d0-8d91-a9af3492104b"
      unitRef="usd">295000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMy0xLTEtMS03ODA0OQ_bd8d14bc-6976-4bfe-9dcf-9c187ba5a512"
      unitRef="usd">109000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfMy0zLTEtMS03ODA0OQ_1b388d59-4183-4f6e-a680-0196a80905b2"
      unitRef="usd">102000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNC0xLTEtMS03ODA0OQ_8da8d760-48c1-47d6-a613-01c609358383"
      unitRef="usd">185000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNC0zLTEtMS03ODA0OQ_065139e2-a221-4b89-bf5f-2133547cb2ab"
      unitRef="usd">571000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNS0xLTEtMS03ODA0OQ_99940928-fbac-47ed-bcfa-dbee60f3a90b"
      unitRef="usd">20000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities>
    <elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNS0zLTEtMS03ODA0OQ_a66c6423-1f51-4d99-b4da-c0b72f4916bf"
      unitRef="usd">179000000</elv:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNi0xLTEtMS03ODA0OQ_f687bba4-3c85-4484-a286-8bc2f5094419"
      unitRef="usd">15000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNi0zLTEtMS03ODA0OQ_daa18c08-4ce3-431b-ae59-55efb45bbc9f"
      unitRef="usd">6000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0xLTEtMS05OTczMw_80b6990b-e65a-49bc-a395-713c2ec2f6ac"
      unitRef="usd">32000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0zLTEtMS05OTczNQ_f0b911ed-0265-4bc1-bc0b-546cf4aa8043"
      unitRef="usd">556000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0xLTEtMS03ODA0OQ_32b5b324-19c1-4329-9657-2986e06a0e1f"
      unitRef="usd">267000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjg2YjdjNzg1NzM0ZTQ5ZWJiYjZjZjk0ZjNlNGM4NjU0L3RhYmxlcmFuZ2U6ODZiN2M3ODU3MzRlNDllYmJiNmNmOTRmM2U0Yzg2NTRfNy0zLTEtMS03ODA0OQ_e9ebe1a9-fc69-400f-b093-d2de7d5d0b6d"
      unitRef="usd">-107000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RleHRyZWdpb246N2JiYjIxNGRhMzE3NDlkMzkzOTdkY2JkZjBiNDYwMGVfMjgzNw_9554e889-698a-45fc-9cb9-eeaac9e257ac">&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider and hospital relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State Medicaid licenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i74006674df2c4b7198d31e2b3985d5af_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi0xLTEtMS03ODA0OQ_672cea0e-2125-48a7-a918-e48ca52dfc47"
      unitRef="usd">85000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i74006674df2c4b7198d31e2b3985d5af_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi0zLTEtMS03ODA0OQ_9076fe2a-c609-4232-ac38-26002367b709">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i652f2991b53941a1ac659bcb35e66d54_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi01LTEtMS03ODA0OQ_8f52f839-0d98-4367-9d56-1561a04856d6"
      unitRef="usd">1313000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i652f2991b53941a1ac659bcb35e66d54_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMi03LTEtMS03ODA0OQ_ce6024a0-80ee-42b4-a8fd-4892b47d1d09">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i1938794b003c4dd68259f49f8b875e81_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy0xLTEtMS03ODA0OQ_62cc4ada-98d7-4831-b211-dcfea3637f9f"
      unitRef="usd">2000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1938794b003c4dd68259f49f8b875e81_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy0zLTEtMS03ODA0OQ_7fa6143c-01a5-410d-a715-6f3605b4a7e2">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ia66ac29085ee41519cfd744c0ac8e03c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy01LTEtMS03ODA0OQ_abf41f21-3404-49aa-80ff-72bdb31f08f1"
      unitRef="usd">240000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia66ac29085ee41519cfd744c0ac8e03c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfMy03LTEtMS03ODA0OQ_82f782ad-89f4-4382-a6fa-68c1ccad8bc6">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="if2bdd480b33d48f7a527eb0cb95e6c5f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC0xLTEtMS03ODA0OQ_7bcdecd3-ccef-40b4-919b-eb686d634d71"
      unitRef="usd">2000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if2bdd480b33d48f7a527eb0cb95e6c5f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC0zLTEtMS03ODA0OQ_aaefd938-5b5a-4f8a-987a-38dafeeed359">P0Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i7079cee400b941a48ccb1dbed22219ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC01LTEtMS03ODA0OQ_8533ea0c-ece2-4ca2-a89f-9a2c758aeb8c"
      unitRef="usd">24000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7079cee400b941a48ccb1dbed22219ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNC03LTEtMS03ODA0OQ_26e7259e-9aad-4538-8244-8dee741af40d">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i11008b88eee44f57a4919c3d0effdc63_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNS0xLTEtMS03ODA0OQ_663af870-4ffb-405a-b105-a2fadf0e3334"
      unitRef="usd">250000000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i92993e9e6dc54ce8b4394a223f436cb2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNS01LTEtMS03ODA0OQ_ae3d2816-fed2-440b-be38-f717cf99349c"
      unitRef="usd">20000000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <elv:TotalIntangibleAssetsAcquired
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNi0xLTEtMS03ODA0OQ_1db971d7-6a8b-4be9-af0e-40d57f1ed518"
      unitRef="usd">339000000</elv:TotalIntangibleAssetsAcquired>
    <elv:TotalIntangibleAssetsAcquired
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M185Ny9mcmFnOjdiYmIyMTRkYTMxNzQ5ZDM5Mzk3ZGNiZGYwYjQ2MDBlL3RhYmxlOjFhNjVmZmFiNmUwNzQ4Y2M4MGYzNjg5MzEyOWFlMmM0L3RhYmxlcmFuZ2U6MWE2NWZmYWI2ZTA3NDhjYzgwZjM2ODkzMTI5YWUyYzRfNi01LTEtMS03ODA0OQ_49ee51b3-78c9-4b7a-9cc9-df1389e5622b"
      unitRef="usd">1597000000</elv:TotalIntangibleAssetsAcquired>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE5Mjk_2c3f1687-270d-420e-b057-99e463e2951d">Business Optimization Initiatives&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our properties are adequate and suitable for our business as presently conducted; however, we are continuing to evaluate our real estate strategy as it relates to the changing needs of a more hybrid remote workforce. As a result, during 2022, we identified additional reductions of office space and recorded a net charge of $&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_afeade16-dee4-4795-8b19-99581c96cde5"&gt;39&lt;/span&gt; in selling, general and administrative expenses. This charge includes $34 for impairment and abandonment of operating-lease related ROU assets and $7 for impairment and abandonment of property and equipment. In addition, we released $2 of employee termination costs, as reflected in the table below. The net charges recognized in the Commercial &amp;amp; Specialty Business, Government Business, CarelonRx and Other segments in 2022, were $20, $16, $0 and $3, respectively. See Note 20, &#x201c;Segment Information&#x201d; for a discussion of our segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we identified reductions of office space and recorded a charge of $&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_346f76ea-dead-4d60-b08d-54ad913c9f6f"&gt;202&lt;/span&gt; in selling, general and administrative expenses. This charge included $136 for impairment and abandonment of operating-lease related ROU assets and $66 for impairment and abandonment of property and equipment. The charges recognized in the Commercial &amp;amp; Specialty Business, Government Business, CarelonRx and Other segments in 2021, were $108, $60, $1 and $33, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, our management introduced enterprise-wide initiatives to optimize our business and, as a result, we recorded a charge of $&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_72ace3e9-597b-4518-a22f-101187f15e20"&gt;653&lt;/span&gt; in selling, general and administrative expenses. This charge included $258 for impairment and abandonment of operating-lease related ROU assets, $198 for impairment and abandonment of property and equipment and $197 for future payments for employee termination costs in connection with the repositioning and reskilling of our workforce. The charges recognized in the Commercial &amp;amp; Specialty Business, Government Business, CarelonRx and Other segments in 2020, were $311, $205, $4 and $133, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity for the year ended December 31, 2022 and ending balance at December&#160;31, 2022, related to the liability for employee termination costs previously incurred in 2020, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Business Optimization Initiatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities for employee termination costs at January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Releases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities for employee termination costs ending balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIwNg_36214dfe-378d-4d69-9ac2-8ebb491a71c0"
      unitRef="usd">39000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5647eb933f9e401e971742cbdc4d882d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIyMQ_c70d9d58-630e-4897-a8cb-ffc7357df7db"
      unitRef="usd">34000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i76840fe11a4246adb33e2fc35f9dce5c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODIxNA_8c6c25a8-6921-4eeb-914a-3ce5639640ef"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i720085721492466da1460ae790fd044c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgyMDM5NA_b79faf83-79ed-4808-9a26-e08036dc1a46"
      unitRef="usd">2000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE3Ng_4066d32b-f491-4e77-ae85-9b9997d9670b"
      unitRef="usd">20000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE4NA_816d1ee7-da66-4515-9f52-1ffa7deff883"
      unitRef="usd">16000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE5Mg_02d410c2-38bd-425a-a879-15dbaaaec3c2"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU0OTc1NTgxODE5OQ_9680a94c-07f1-4121-aa5d-6a8de299c3e8"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzQzMw_48e3b13c-0396-4ca8-8e45-ff99d4b11dfc"
      unitRef="usd">202000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8b56ea1be96f4c70a8c1e7c9144fc68a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzUwNg_8aa9c3bd-d958-4a42-ab22-4cabbc6ce944"
      unitRef="usd">136000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic66c129efd394897bd946da50f16dfa9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzU4Mg_24c8ead0-675d-4454-a6be-b63caa7db3f8"
      unitRef="usd">66000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc3MA_893d033d-a5dc-4efb-a763-bba48deb1ffd"
      unitRef="usd">108000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc3NA_1d85d814-ee6a-4356-af47-ed4f24c9d9b8"
      unitRef="usd">60000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc3OA_53b2a90c-1f87-4255-9f15-873265c4e58a"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzc4NQ_8653aeb0-8668-4136-9b74-d606b351bb37"
      unitRef="usd">33000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzk3OA_b990f510-0660-4560-a656-97599f031bde"
      unitRef="usd">653000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5ff881db619a457a91ac84f1aefaed9c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzEwNTE_1abc581e-64dc-48aa-9579-8cf08507b938"
      unitRef="usd">258000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia2f02a690e784ac385d21cd667d6d637_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzExMjQ_6e9bc11c-2fdb-4f2b-b785-c22d1eee207c"
      unitRef="usd">198000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie891e0f02de14c5b99b6e50667fa8c9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzExODg_fa86f02e-d9ac-47ad-af49-d13f2b9cfcab"
      unitRef="usd">197000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0Mzk_b9000c34-dd5b-436c-a32f-e9d4cbde4df3"
      unitRef="usd">311000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0NDM_058b0a0b-d8d0-4162-9897-20f55f9b87a3"
      unitRef="usd">205000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i77d0aff55fa54fd2a9a2a30c2e6c6a2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0NDc_c652b565-7135-40bc-bb4d-8ffdbf821030"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE0NTQ_9115bdde-3942-4055-a9fa-7faefbca0e04"
      unitRef="usd">133000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90ZXh0cmVnaW9uOmMzZDY0OGUwZDFkMTRmODM5MDU2OWEyYjNmMjQ4NmNmXzE5MzA_5453926a-ba89-4369-b1e9-63d9e1232f97">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity for the year ended December 31, 2022 and ending balance at December&#160;31, 2022, related to the liability for employee termination costs previously incurred in 2020, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Business Optimization Initiatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities for employee termination costs at January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Releases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities for employee termination costs ending balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i2229f739c29e4879809a6429e83712f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtMS0xLTEtNzgwNDk_ec0ec6c4-7a89-4d3d-a773-06addd6e3466"
      unitRef="usd">61000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic4fcad706e1b4867b404702dd922e926_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtMy0xLTEtNzgwNDk_085a0acc-ebb2-4634-9445-a361f5e9b7e1"
      unitRef="usd">57000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic99433158fc54e1e93f623489413f8de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtNS0xLTEtNzgwNDk_6e9d7919-af63-4e03-9963-faf1543f0fa2"
      unitRef="usd">1000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2e2df902d3b34cf4a36058a667c1980e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtNy0xLTEtNzgwNDk_f716c40f-42ca-4b68-aea3-7eb397c8511a"
      unitRef="usd">3000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i575634935f9d42e19be485bc9862c0f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzMtOS0xLTEtNzgwNDk_599d0de7-1c5b-4ef4-90ae-175c30e51252"
      unitRef="usd">122000000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="ia9f081e73a6c44fa88baccf8ed778d26_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtMS0xLTEtNzgwNDk_5cdab9ad-35d3-46c7-9015-30816b1a99a3"
      unitRef="usd">20000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ie7ec68f2e8874c1095494d4e367728a8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtMy0xLTEtNzgwNDk_fa9196be-1147-4fbd-ab1d-10b580cc5572"
      unitRef="usd">18000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i80df43e3b8244694a103a6571a73884c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtNS0xLTEtNzgwNDk_25254948-294c-4d4a-a848-7ef01b419990"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="idba1560cbbed45a88ea28c07d58f145d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtNy0xLTEtNzgwNDk_77d6a448-56c3-4e7f-aed7-b5e4217a136f"
      unitRef="usd">1000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i720085721492466da1460ae790fd044c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzQtOS0xLTEtNzgwNDk_0b240fd5-6978-481c-ae26-c86195d9ca16"
      unitRef="usd">39000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="ia9f081e73a6c44fa88baccf8ed778d26_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtMS0xLTEtNzgwNDk_41915665-4443-4e7e-aef2-f4efba7372f3"
      unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="ie7ec68f2e8874c1095494d4e367728a8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtMy0xLTEtNzgwNDk_3ae11b11-8d6d-4cd6-b3b7-734cca103f4e"
      unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i80df43e3b8244694a103a6571a73884c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtNS0xLTEtNzgwNDk_5adf6928-cedd-4892-88ec-6dd0463a0a87"
      unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="idba1560cbbed45a88ea28c07d58f145d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtNy0xLTEtNzgwNDk_0ada9f9e-c93c-4629-b56d-11a14b204b14"
      unitRef="usd">2000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i720085721492466da1460ae790fd044c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzUtOS0xLTEtNzgwNDk_4f967111-c716-4cf5-a3f8-88b55340c2d5"
      unitRef="usd">2000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReserve
      contextRef="i89cfda63370a45baa262eae4cf193a82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtMS0xLTEtNzgwNDk_ccbc9398-8c10-432d-abd1-33a22cf7fe97"
      unitRef="usd">41000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id2fac999a95e4a5cb79ad594faeeb86b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtMy0xLTEtNzgwNDk_56a81db8-aead-45ce-993f-031142d30a14"
      unitRef="usd">39000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie7da5fca7f08493dbf6109531d652055_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtNS0xLTEtNzgwNDk_2ffcc135-20a4-40d0-ba3c-9636f6add8a7"
      unitRef="usd">1000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia2e206452b4b4525ba8295deb406a4ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtNy0xLTEtNzgwNDk_c6a1cfd9-d6f4-4f1f-b43b-ffa033afa1ea"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i4e00c7e161a54ca296d8ca502242628b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDAvZnJhZzpjM2Q2NDhlMGQxZDE0ZjgzOTA1NjlhMmIzZjI0ODZjZi90YWJsZTowMzA1NWI1N2NiZTM0MjgxYTAyNTUxMzViNTA2MzMzNy90YWJsZXJhbmdlOjAzMDU1YjU3Y2JlMzQyODFhMDI1NTEzNWI1MDYzMzM3XzYtOS0xLTEtNzgwNDk_59de7e1b-4372-46e7-bc81-6f793766d26b"
      unitRef="usd">81000000</us-gaap:RestructuringReserve>
    <us-gaap:InvestmentTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MjU_d5733a59-6f5c-4ef0-b794-ea7ecf4cc91e">Investments &lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year residential and commercial mortgage-backed securities have been reclassified throughout this Note 5 and Note 7, &#x201c;Fair Value&#x201d; to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of current and long-term fixed maturity securities, available-for-sale, at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&#160;or&lt;br/&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance For Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other asset-backed securities primarily consist of collateralized loan obligations and other debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For fixed maturity securities in an unrealized loss position at December&#160;31, 2022 and 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Securities are whole amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized losses on our securities shown in the table above have not been recognized into income because, as of December&#160;31, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for credit losses have been recorded in the amounts of $9 and $6 at December&#160;31, 2022 and 2021, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and fair value of fixed maturity securities at December&#160;31, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of current equity securities at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange traded funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major categories of net investment income for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment (Losses) Gains &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment (losses) gains for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized gains from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized losses from sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment (losses) recoveries recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains on fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains recognized on equity securities still held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized (losses) gains recognized on equity securities sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i)&#160;changes in the investment environment; (ii)&#160;expectations that the fair value could deteriorate further; (iii)&#160;desire to reduce exposure to an issuer or an industry; (iv)&#160;changes in credit quality; or (v)&#160;changes in expected cash flow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total proceeds from sales, maturities, calls or redemptions of fixed maturity securities was $22,048, $10,565 and $11,122 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant judgment in the valuation of investments is the determination of when a credit loss has occurred. We follow a consistent and systematic process for recognizing impairments on securities that sustain credit declines in value. We have established a committee responsible for the impairment review process. The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but not limited to: (i)&#160;the extent to which the fair value is less than book value, (ii)&#160;the financial condition and near term prospects of the issuer, (iii)&#160;our intent and ability to retain impaired investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv)&#160;our intent to sell or the likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v)&#160;whether the debtor is current on interest and principal payments, (vi)&#160;the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors) and (vii)&#160;general market conditions and industry or sector specific factors. When a decision has been made to sell an impaired security or it is more likely than not that the impaired security will be required to be disposed of prior to recovery of its cost basis, the security is written down to fair value at the reporting date. For all other impaired securities, if the impairment is deemed to be credit related, an allowance is created.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have a material adverse impact on our results of operations or shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, there were no individual investments that exceeded 10% of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, there were eight and two, respectively, fixed maturity investments that did not produce income during the years then ended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, we had committed approximately $1,504 and $1,558, respectively, to future capital calls from various third-party investments in exchange for an ownership interest in the related entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, we had committed approximately $185 and $329, respectively, to future investments in rated notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, securities with carrying values of approximately $752 and $632, respectively, were deposited by our insurance subsidiaries under requirements of regulatory authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Investment Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued investment income totaled $245 and $205 at December&#160;31, 2022 and 2021, respectively. We recognize accrued investment income under the caption &#x201c;Other receivables&#x201d; on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Lending Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the collateral received at the time of the securities lending transactions amounted to $2,457 and $2,155 at December&#160;31, 2022 and 2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the collateral as an asset under the caption &#x201c;Other current assets&#x201d; in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption &#x201c;Other current liabilities.&#x201d; The securities on loan are reported in the applicable investment category on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;At December&#160;31, 2022 and 2021, the remaining contractual maturities of our securities lending transactions included overnight and continuous transactions of cash for $2,221 and $1,874, respectively, United States Government securities for $224 and $281, respectively, and residential mortgage-backed securities for $12 and $0, respectively.</us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgzNTUxOA_a156c3a3-bf5f-44c6-be65-2c5a971cde5e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of current and long-term fixed maturity securities, available-for-sale, at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&#160;or&lt;br/&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance For Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtMS0xLTEtNzgwNDk_11b5e721-a85d-41c4-b101-7b97f5147a62"
      unitRef="usd">1502000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtMy0xLTEtNzgwNDk_8ad8d8c7-5f3c-4d39-be53-384b6d392bd7"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtNS0xLTEtNzgwNDk_edec9fcd-cf5a-4aa4-8806-916d8ecd1af6"
      unitRef="usd">103000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtNy0xLTEtNzgwNDk_a4839c1a-e56c-48f8-9669-89e8fb34354f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzUtOS0xLTEtNzgwNDk_e034ac9c-5563-4ae2-993b-da26ffa70268"
      unitRef="usd">1401000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtMS0xLTEtNzgwNDk_46ffca35-378e-41d5-8190-68a6d3df3d12"
      unitRef="usd">82000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtMy0xLTEtNzgwNDk_b2ee3385-6f0d-4d1c-897a-c85235bdff3a"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtNS0xLTEtNzgwNDk_64d56c19-4ceb-4ddf-8a7e-667f300c0cc3"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtNy0xLTEtNzgwNDk_cab3c5b6-4d9d-49d6-a787-4912d9bc8eea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzYtOS0xLTEtNzgwNDk_d130b788-fa18-4bcc-bd9c-e6fad6da155a"
      unitRef="usd">78000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctMS0xLTEtNzgwNDk_b589254a-26dd-4ad7-befa-77cfb19cb2ee"
      unitRef="usd">321000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctMy0xLTEtNzgwNDk_ae14f663-d365-4270-9566-302418a2da5c"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctNS0xLTEtNzgwNDk_5c5b298d-8297-47c5-8a1a-972e5c5f15e2"
      unitRef="usd">46000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctNy0xLTEtNzgwNDk_25250c81-03b5-4def-8c9c-2f690cb15875"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzctOS0xLTEtNzgwNDk_4137fefd-1658-4762-a06d-e92ea0103289"
      unitRef="usd">274000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtMS0xLTEtNzgwNDk_70d833d7-66b6-47d8-a60a-c8639eade8a3"
      unitRef="usd">4389000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtMy0xLTEtNzgwNDk_c10b6368-2214-4081-8470-ddbb20e11299"
      unitRef="usd">19000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtNS0xLTEtNzgwNDk_e1e8ed19-79c4-4f20-994c-48d89a10a8e8"
      unitRef="usd">265000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtNy0xLTEtNzgwNDk_338d0554-7421-46f4-a91a-74ad0f8a23c7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzgtOS0xLTEtNzgwNDk_116665f8-6228-46b2-aca2-6fe9978a4ea9"
      unitRef="usd">4143000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktMS0xLTEtNzgwNDk_d514e784-0d13-4349-a97d-08752a541a0a"
      unitRef="usd">13721000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktMy0xLTEtNzgwNDk_c41fac12-0f1f-49e7-bbe1-891ad06b8036"
      unitRef="usd">31000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktNS0xLTEtNzgwNDk_7b29d76b-f17d-4e10-bf94-74bc9e658528"
      unitRef="usd">1218000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktNy0xLTEtNzgwNDk_09ecf4de-5b36-4de2-bebb-85f843ea44c7"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzktOS0xLTEtNzgwNDk_8551a236-ac8a-4978-b2c9-79ed1b2b414e"
      unitRef="usd">12529000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTEtMS0xLTc4MDQ5_efb34cdc-0ead-443e-a6f4-9f4c14ca32aa"
      unitRef="usd">2978000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTMtMS0xLTc4MDQ5_6ceecae4-5153-48ce-be6b-40568ac8526d"
      unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTUtMS0xLTc4MDQ5_63a8d4ba-cd3e-467c-8f99-1d9d5f3d9f2b"
      unitRef="usd">324000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTctMS0xLTc4MDQ5_7fe069c6-c06d-4085-aecf-449110848e20"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEwLTktMS0xLTc4MDQ5_7b7be651-e03b-4198-93d6-4cac4f19f325"
      unitRef="usd">2663000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTEtMS0xLTc4MDQ5_393e8e3e-2d16-4e28-9978-0eefaad070e7"
      unitRef="usd">2055000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTMtMS0xLTc4MDQ5_07ce051f-7299-46c8-865b-7150fcd000d0"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTUtMS0xLTc4MDQ5_fde2d65f-ba1d-413a-a70f-2b6f1cfc0a9c"
      unitRef="usd">176000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTctMS0xLTc4MDQ5_0cc77240-0e42-4975-ae44-dcbc33e51a65"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzExLTktMS0xLTc4MDQ5_ad135f9c-b92d-4139-a4e1-3b87e85346d0"
      unitRef="usd">1878000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTEtMS0xLTc4MDQ5_1e0e0dd5-70aa-4ce3-94c2-663ea21fb961"
      unitRef="usd">3967000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTMtMS0xLTc4MDQ5_7539ee83-7722-4ffe-878d-f563d5c87565"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTUtMS0xLTc4MDQ5_ada17e19-f1d7-44d2-8d8a-e55d7cb3d665"
      unitRef="usd">241000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTctMS0xLTc4MDQ5_83584c39-4783-46bc-b8fa-bdd1b044a0ac"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEyLTktMS0xLTc4MDQ5_d4afb735-7d06-455d-b6e2-2f551110c558"
      unitRef="usd">3738000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTEtMS0xLTc4MDQ5_6452eca1-a897-4da9-81ca-8aa905b17fdd"
      unitRef="usd">29015000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTMtMS0xLTc4MDQ5_9a5a67a7-954a-4c0a-97ae-57fd54516cd3"
      unitRef="usd">76000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTUtMS0xLTc4MDQ5_e548f982-9ff5-48c9-8377-0cc800b12706"
      unitRef="usd">2378000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTctMS0xLTc4MDQ5_3ab155da-05d9-4acd-b4fd-bef64dd9b8ca"
      unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzEzLTktMS0xLTc4MDQ5_bcedd1f4-aab6-4986-9c14-8d71ada0aab2"
      unitRef="usd">26704000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTEtMS0xLTc4MDQ5_ab58ef43-c389-4922-afbc-faf01fe9e44b"
      unitRef="usd">1443000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTMtMS0xLTc4MDQ5_e451a546-c66f-413f-8ce4-c4390f64ee0c"
      unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTUtMS0xLTc4MDQ5_683e0714-a9c5-499d-a7e6-9ae0f92f5cfa"
      unitRef="usd">18000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTctMS0xLTc4MDQ5_ae99eb3a-3592-4bde-a5a0-8d2c5280551d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE4LTktMS0xLTc4MDQ5_232e3cea-91e3-4fe1-8ebb-1fcf36a978ce"
      unitRef="usd">1432000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTEtMS0xLTc4MDQ5_9c81c19d-052d-4248-926a-ad036fa4b079"
      unitRef="usd">65000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTMtMS0xLTc4MDQ5_be0c9567-4ff6-4471-b21f-32629682d81a"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTUtMS0xLTc4MDQ5_6a109d75-481c-42b7-bd9b-2ec5b0bd96f1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTctMS0xLTc4MDQ5_cc9651bf-4c26-47bf-b0f2-a08f145fa78b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzE5LTktMS0xLTc4MDQ5_b831fd80-0430-4b69-af1e-65ab8f04fcc1"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTEtMS0xLTc4MDQ5_937445ce-db80-40dd-93f2-292bc9202ce1"
      unitRef="usd">353000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTMtMS0xLTc4MDQ5_613681f5-14cc-4db0-bb94-7e900d284068"
      unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTUtMS0xLTc4MDQ5_13cc28b4-3e2a-48c6-a654-7920137a0038"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTctMS0xLTc4MDQ5_bc3fc49a-e68b-4c72-81b6-d602407b6ffa"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIwLTktMS0xLTc4MDQ5_819d38d1-3c35-45ed-8301-fbc253c9474d"
      unitRef="usd">347000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTEtMS0xLTc4MDQ5_50328285-ff4d-4edd-bb7e-9a3ac46e4bcd"
      unitRef="usd">5321000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTMtMS0xLTc4MDQ5_71532c22-5e01-4f54-acd7-072f5546b935"
      unitRef="usd">310000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTUtMS0xLTc4MDQ5_31f5a55d-fd52-407c-abb4-c99201973ad6"
      unitRef="usd">10000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTctMS0xLTc4MDQ5_6dca5ecd-d6af-4367-b25a-afc052325e32"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIxLTktMS0xLTc4MDQ5_7a116e21-299a-46fb-8041-2eab1f667483"
      unitRef="usd">5621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTEtMS0xLTc4MDQ5_3fd9b9f0-1d11-4514-aeda-057dbf5e0f98"
      unitRef="usd">12044000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTMtMS0xLTc4MDQ5_89410243-5569-42a3-8b4f-a3cc53e0579a"
      unitRef="usd">401000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTUtMS0xLTc4MDQ5_5e00c3ba-c7c4-4b17-b8b5-0efa9f5c1ca4"
      unitRef="usd">78000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTctMS0xLTc4MDQ5_49f343b1-1b16-4348-af63-422900969d8a"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIyLTktMS0xLTc4MDQ5_b4e4b786-3fda-48e0-81ba-270e1168934b"
      unitRef="usd">12363000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTEtMS0xLTc4MDQ5_1d1d7b51-a033-4318-b59c-827b1865efea"
      unitRef="usd">2492000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTMtMS0xLTc4MDQ5_8e3ba4a4-d772-48b4-bb5a-2e331d1f4d26"
      unitRef="usd">48000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTUtMS0xLTc4MDQ5_5f7ee117-d89c-4ed0-bb51-c01fd0764dd3"
      unitRef="usd">22000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTctMS0xLTc4MDQ5_03fba7e7-0501-43e7-9c44-0cf61b06d2ba"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzIzLTktMS0xLTc4MDQ5_28160cfb-f250-4d60-94e7-45b70e746692"
      unitRef="usd">2518000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTEtMS0xLTc4MDQ5_9f52b021-bc4b-401a-a27b-53f85838ea06"
      unitRef="usd">1632000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTMtMS0xLTc4MDQ5_1041a9d5-bccd-4dae-b16f-544636ccc85d"
      unitRef="usd">29000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTUtMS0xLTc4MDQ5_148ade27-a9f0-4525-9f97-5b42f40efc89"
      unitRef="usd">16000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTctMS0xLTc4MDQ5_d6a67862-a2a2-4883-b3d4-1077f7421ac0"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI0LTktMS0xLTc4MDQ5_3c491fc2-6e47-47ea-8d90-729c1e03f892"
      unitRef="usd">1643000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTEtMS0xLTc4MDQ5_4855851c-402c-4e52-a4ad-03c82ac96a91"
      unitRef="usd">2907000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTMtMS0xLTc4MDQ5_5d49ef7c-3626-4831-a306-d81b0c9815ac"
      unitRef="usd">24000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTUtMS0xLTc4MDQ5_f7a40d9b-ff6b-487d-89fe-387853639d36"
      unitRef="usd">24000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTctMS0xLTc4MDQ5_2ecbd30d-64ef-4944-bbce-808f16b2537a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI1LTktMS0xLTc4MDQ5_57768984-6b96-426a-81b7-2189c49c5a22"
      unitRef="usd">2907000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTEtMS0xLTc4MDQ5_57dd2e5b-3ec1-4e4d-83a3-868ec2c27f82"
      unitRef="usd">26257000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTMtMS0xLTc4MDQ5_26b6c555-d135-4a0f-874c-38d8b3b89f2c"
      unitRef="usd">830000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTUtMS0xLTc4MDQ5_6af50763-b0ae-49fc-85bb-e4f37cfc20ed"
      unitRef="usd">182000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTctMS0xLTc4MDQ5_b1973a3e-6942-4b4c-a9c5-a8e8bc34ed44"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo4MTUzOTQxYmQ5YTM0YjM4YjkwNDZmNzljOTZiNGNiMS90YWJsZXJhbmdlOjgxNTM5NDFiZDlhMzRiMzhiOTA0NmY3OWM5NmI0Y2IxXzI2LTktMS0xLTc4MDQ5_54bdf385-dc04-4899-8fc7-689f03abaafd"
      unitRef="usd">26899000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4NDY_5ae0a6b9-77fc-43b0-9d2e-7dbf3f4d8dad">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For fixed maturity securities in an unrealized loss position at December&#160;31, 2022 and 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Securities are whole amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtMS0xLTEtNzgwNDk_e982cdec-16ac-4596-8551-151211b21d9f"
      unitRef="securities">61</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtMy0xLTEtNzgwNDk_871ad8a6-1c98-4dab-8f9d-d16e3e9bb15a"
      unitRef="usd">701000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtNS0xLTEtNzgwNDk_8e97876d-e943-4901-926f-89dc52430ca3"
      unitRef="usd">40000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtNy0xLTEtNzgwNDk_3f9836df-8f2d-4da1-ab24-9bfea7010f76"
      unitRef="securities">38</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtOS0xLTEtNzgwNDk_db2a85e0-490b-4179-a3a1-6b24cbbd2289"
      unitRef="usd">442000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzUtMTEtMS0xLTc4MDQ5_0e8c75fe-f727-4f32-b9e3-845095d198af"
      unitRef="usd">63000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtMS0xLTEtNzgwNDk_3afbeaef-1573-4b77-a66a-0b040a153621"
      unitRef="securities">39</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtMy0xLTEtNzgwNDk_adf82d20-596b-49f4-8798-64fc80621a85"
      unitRef="usd">73000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtNS0xLTEtNzgwNDk_495d95aa-c4b8-4bf9-a986-37740c404ca1"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtNy0xLTEtNzgwNDk_19ae164e-702e-4b5b-b2e7-77f91311f6e2"
      unitRef="securities">6</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtOS0xLTEtNzgwNDk_2dcc8f33-2111-4757-b2d7-571a9fd3cbea"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzYtMTEtMS0xLTc4MDQ5_7a35cc3a-03c3-49d0-a1f8-606807e29ce7"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctMS0xLTEtNzgwNDk_125ec300-9615-4eff-8855-c219de59a7a0"
      unitRef="securities">150</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctMy0xLTEtNzgwNDk_78459834-928d-4511-a289-c279a2ff8edf"
      unitRef="usd">100000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctNS0xLTEtNzgwNDk_c85294be-7f4e-4e40-b7ea-f2333eec009a"
      unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctNy0xLTEtNzgwNDk_178a8d6a-0a14-475f-9513-cc52700310d7"
      unitRef="securities">198</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctOS0xLTEtNzgwNDk_963dba4b-20be-4ed8-9858-bd2813735732"
      unitRef="usd">142000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzctMTEtMS0xLTc4MDQ5_2761baac-3702-4a5a-b883-9e43ee64a589"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtMS0xLTEtNzgwNDk_d3f84c6b-e041-49fb-9ed7-5fa0b5b42571"
      unitRef="securities">1398</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtMy0xLTEtNzgwNDk_979b2c17-919f-43a6-bf56-d2eff77dd5ca"
      unitRef="usd">2615000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtNS0xLTEtNzgwNDk_41bed6b8-10dc-40dd-ba18-51b85ba2133d"
      unitRef="usd">147000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtNy0xLTEtNzgwNDk_d4cde205-8028-4d99-8767-7f811cc00822"
      unitRef="securities">396</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtOS0xLTEtNzgwNDk_8614754a-582f-4481-b529-33618b250a88"
      unitRef="usd">652000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzgtMTEtMS0xLTc4MDQ5_9aad8929-499f-4fed-b8e1-00596b01540d"
      unitRef="usd">118000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktMS0xLTEtNzgwNDk_53443202-5621-44d8-bb1a-4eeb66f3500d"
      unitRef="securities">3551</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktMy0xLTEtNzgwNDk_4fb5a5ab-d1d9-4b28-a6b9-ac3481830e5d"
      unitRef="usd">7826000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktNS0xLTEtNzgwNDk_32ecdace-3b8f-4c6e-9c14-95eb95955a4c"
      unitRef="usd">549000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktNy0xLTEtNzgwNDk_a2e1e45a-6385-4a94-8fa9-7df79dd8cc51"
      unitRef="securities">2204</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktOS0xLTEtNzgwNDk_5eab4a2e-fe75-4f16-aa6c-2ae2edc27f0c"
      unitRef="usd">3521000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzktMTEtMS0xLTc4MDQ5_3a384230-3348-409d-86d3-a203539366d3"
      unitRef="usd">669000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTEtMS0xLTc4MDQ5_990a72b1-9c94-4fdd-ac10-749e636bc73b"
      unitRef="securities">1341</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTMtMS0xLTc4MDQ5_6d94b78d-adbf-4c5b-afe3-30dcb7b50448"
      unitRef="usd">1435000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTUtMS0xLTc4MDQ5_4d6d8ec0-75e3-497a-a8f6-49472738feab"
      unitRef="usd">121000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTctMS0xLTc4MDQ5_51ef1bbc-17ab-4117-8e7d-24c9e6e3c52d"
      unitRef="securities">496</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTktMS0xLTc4MDQ5_a847c54b-1cd8-4d1e-b4bd-ed72903401a1"
      unitRef="usd">982000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEwLTExLTEtMS03ODA0OQ_eee7ee1d-22a1-45bf-84fd-503db9e0725e"
      unitRef="usd">203000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTEtMS0xLTc4MDQ5_016dca63-fbad-463e-b064-f69de311e86c"
      unitRef="securities">457</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTMtMS0xLTc4MDQ5_8c47b957-ae5d-4670-89cf-556ee16f876c"
      unitRef="usd">1082000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTUtMS0xLTc4MDQ5_85a7f1bd-10bb-459e-bb09-1c85ff580725"
      unitRef="usd">76000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTctMS0xLTc4MDQ5_6e25d0b7-5a8c-4a3f-95a3-3a436d2f45de"
      unitRef="securities">324</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTktMS0xLTc4MDQ5_1e9dfbf6-5f8e-42a4-8753-abdff06fac08"
      unitRef="usd">719000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzExLTExLTEtMS03ODA0OQ_afaf1551-65e5-4414-b75d-2e1e0a8dfb36"
      unitRef="usd">100000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTEtMS0xLTc4MDQ5_5ef18efe-75f0-4be8-a547-c3d5527327a2"
      unitRef="securities">784</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTMtMS0xLTc4MDQ5_d25cce19-d02e-4ff4-a83a-29326629d140"
      unitRef="usd">2203000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTUtMS0xLTc4MDQ5_532924d1-a7e9-4446-b5e3-2030c3c35198"
      unitRef="usd">124000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTctMS0xLTc4MDQ5_5d8d30a3-16fd-4e60-88e2-6da398e4a1ab"
      unitRef="securities">398</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTktMS0xLTc4MDQ5_093907ed-3363-48ff-b6f0-523e324de1c1"
      unitRef="usd">1074000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id65761e7270d477bbc88316eeb1f57e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEyLTExLTEtMS03ODA0OQ_5822c76e-76d6-4d10-a32b-89fec24a8a46"
      unitRef="usd">117000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTEtMS0xLTc4MDQ5_9bd8ce84-e3a7-4a33-8b75-26e7f64f2484"
      unitRef="securities">7781</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTMtMS0xLTc4MDQ5_c9a56624-8d99-4111-b85e-b5973bf2e775"
      unitRef="usd">16035000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTUtMS0xLTc4MDQ5_08e825ec-8139-49c9-baa2-c3ad1f3ca280"
      unitRef="usd">1071000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTctMS0xLTc4MDQ5_4c6abe72-cd4e-4a69-a905-26f88461c16c"
      unitRef="securities">4060</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTktMS0xLTc4MDQ5_b9c07fef-84a7-4aee-a36c-3de09f8eaed2"
      unitRef="usd">7537000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzEzLTExLTEtMS03ODA0OQ_d4be4361-be19-4bbb-ba68-f880036424b6"
      unitRef="usd">1307000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTEtMS0xLTc4MDQ5_74e75642-13be-4a23-a20e-53f6895e0ba5"
      unitRef="securities">51</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTMtMS0xLTc4MDQ5_1395d019-5e6d-4d5b-af44-d4d2aa6db828"
      unitRef="usd">990000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTUtMS0xLTc4MDQ5_456e2087-7d45-4356-9cb0-882cae0346e4"
      unitRef="usd">11000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTctMS0xLTc4MDQ5_5301ad63-3941-4611-83b1-a49f0a4cbae5"
      unitRef="securities">27</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTktMS0xLTc4MDQ5_5f432deb-22bc-4c1a-8966-7216801120ef"
      unitRef="usd">176000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE4LTExLTEtMS03ODA0OQ_cd514eba-5483-451b-b13d-8335d06887b8"
      unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTEtMS0xLTc4MDQ5_c1f13780-5ce7-4090-8f48-6a72e1b6b089"
      unitRef="securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTMtMS0xLTc4MDQ5_b070947e-889f-411f-801b-4133acf1e6ba"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTUtMS0xLTc4MDQ5_31231e2d-3b48-47ab-8920-2eec06ea8865"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTctMS0xLTc4MDQ5_b945f6f6-f267-41a5-b340-de5ae7aab782"
      unitRef="securities">1</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTktMS0xLTc4MDQ5_f1711b03-192c-4f63-ad7f-4403ada0c489"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzE5LTExLTEtMS03ODA0OQ_86e64f61-d4da-42b8-a73b-e405a1dd4e18"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTEtMS0xLTc4MDQ5_d2a037ac-7df0-4d4a-8370-627da3ab2e94"
      unitRef="securities">188</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTMtMS0xLTc4MDQ5_cba4bc7a-7b3c-48a4-bd46-cf436496e63d"
      unitRef="usd">143000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTUtMS0xLTc4MDQ5_72c22322-74d3-4acc-9b27-4740b677e15c"
      unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTctMS0xLTc4MDQ5_09626408-d209-4b91-8f65-373821cde89e"
      unitRef="securities">68</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTktMS0xLTc4MDQ5_1b4c42c0-1369-4a7c-af49-3d02cba1bcf8"
      unitRef="usd">41000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIwLTExLTEtMS03ODA0OQ_85fbb465-1360-44cb-acc8-642eab448d63"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTEtMS0xLTc4MDQ5_8e9cd009-ee73-4e67-a1ae-efbc8f154201"
      unitRef="securities">281</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTMtMS0xLTc4MDQ5_7837a2e1-b989-4003-98b8-738ca99b99bc"
      unitRef="usd">634000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTUtMS0xLTc4MDQ5_cf236a7d-322b-42f8-9bbd-6ac5960bf4b4"
      unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTctMS0xLTc4MDQ5_792f788f-af7b-4a21-b29c-1f18cdecd61f"
      unitRef="securities">8</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTktMS0xLTc4MDQ5_510811cb-7de7-46fe-ab15-0888ab17d785"
      unitRef="usd">16000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIxLTExLTEtMS03ODA0OQ_b898a04a-f264-4135-909e-52572f2c8280"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTEtMS0xLTc4MDQ5_0f1a4bbb-70b3-43f7-a3cb-9c381a8bc04d"
      unitRef="securities">1846</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTMtMS0xLTc4MDQ5_ca7f3273-6dd5-43e6-bbac-4f5fda4411ba"
      unitRef="usd">3310000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTUtMS0xLTc4MDQ5_5b52e24e-98e3-40f8-835c-3d9517a23cbb"
      unitRef="usd">57000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTctMS0xLTc4MDQ5_eb1f40c4-6317-437c-b879-d044d2a8a130"
      unitRef="securities">403</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTktMS0xLTc4MDQ5_e9b2d062-5761-4add-ab4f-ce0995825280"
      unitRef="usd">485000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIyLTExLTEtMS03ODA0OQ_3dc41316-6d1f-4f5c-ac6a-fc2e1c0459b7"
      unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTEtMS0xLTc4MDQ5_535ce517-dc56-4c94-af23-a09385eade75"
      unitRef="securities">422</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTMtMS0xLTc4MDQ5_03f0a400-e25b-4206-98e3-c77ae2fc8c48"
      unitRef="usd">1295000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTUtMS0xLTc4MDQ5_f4cfabb9-481f-43d6-a937-386a9fcdf36f"
      unitRef="usd">19000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTctMS0xLTc4MDQ5_83220c43-9900-4332-a97f-23aad01a5fe5"
      unitRef="securities">63</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTktMS0xLTc4MDQ5_7a4b16d1-8686-4296-92f2-d1a579c8a24a"
      unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzIzLTExLTEtMS03ODA0OQ_913b8e78-abf0-438d-81b0-9f70937bf553"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTEtMS0xLTc4MDQ5_6c8f43f6-22c9-433a-95db-221d5a6c4a31"
      unitRef="securities">272</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTMtMS0xLTc4MDQ5_52999c55-8c5c-4639-8267-41d22759b89e"
      unitRef="usd">676000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTUtMS0xLTc4MDQ5_7a5e83eb-0c53-4fd3-988c-c22931bd60bd"
      unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTctMS0xLTc4MDQ5_ecc954b1-545e-44aa-a2bf-1cbda0e93505"
      unitRef="securities">66</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTktMS0xLTc4MDQ5_4868d335-9190-42ee-91b7-8aa350e4455e"
      unitRef="usd">137000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI0LTExLTEtMS03ODA0OQ_8482b852-8eea-4897-bfde-5ed88246a2d3"
      unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTEtMS0xLTc4MDQ5_451bb1a1-1980-4ce3-af75-3fefda6cd1ff"
      unitRef="securities">511</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTMtMS0xLTc4MDQ5_9aef7cb2-f949-492e-824a-83b09a0531f7"
      unitRef="usd">1707000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTUtMS0xLTc4MDQ5_c186100f-d52d-4457-9755-20e285fa97e9"
      unitRef="usd">19000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTctMS0xLTc4MDQ5_94611fee-b31c-42bf-9ca0-ac728dba30b7"
      unitRef="securities">50</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTktMS0xLTc4MDQ5_c0e19547-6657-41d0-9b44-4493f46fb301"
      unitRef="usd">85000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i498cff72f8f34a2ab008f70e24959c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI1LTExLTEtMS03ODA0OQ_abbb4fd3-fff6-4207-bdd8-c66c4a71a5a6"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTEtMS0xLTc4MDQ5_a7a55208-cf8a-4501-9932-cc3237f4c75e"
      unitRef="securities">3571</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTMtMS0xLTc4MDQ5_467d4612-9de9-46ec-a4d0-bfca3f0172fb"
      unitRef="usd">8755000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTUtMS0xLTc4MDQ5_38c230ec-90e4-46df-bf2e-9f6e90b5dc2c"
      unitRef="usd">131000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTctMS0xLTc4MDQ5_bed02e8e-06b3-4529-a570-12eab093a1fd"
      unitRef="securities">686</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTktMS0xLTc4MDQ5_f30d7ad8-7ce4-45b1-950a-dd0b7a527c01"
      unitRef="usd">985000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyOTdjYzhkYzZlZGU0MWE1YTkyMjVjYzVkMjk4ODMzZi90YWJsZXJhbmdlOjI5N2NjOGRjNmVkZTQxYTVhOTIyNWNjNWQyOTg4MzNmXzI2LTExLTEtMS03ODA0OQ_ec24e79f-a5a2-4051-a32b-d1b76f3af8bd"
      unitRef="usd">51000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzEwOTk1MTE2MzkyMjc_2e92bf03-f1b5-4bc2-8d59-bfac7959e3f5"
      unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzEwOTk1MTE2MzkyMjQ_d3e0726f-3298-45a1-8bc4-40f8362dd178"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MTI_95a4419e-16c1-464d-a39e-5c54123fca85">&lt;div style="margin-bottom:3pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and fair value of fixed maturity securities at December&#160;31, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzEtMS0xLTEtNzgwNDk_8bc5e2fd-b36f-4df6-905d-667d81d3143a"
      unitRef="usd">726000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzEtMy0xLTEtNzgwNDk_d2ac01f1-0553-49e3-9282-36887c47c701"
      unitRef="usd">720000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzItMS0xLTEtNzgwNDk_f774e94f-8c6e-431a-bb11-75b53e0b736f"
      unitRef="usd">7489000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzItMy0xLTEtNzgwNDk_b14dcea9-b3af-4033-bde9-1fa8e738cd60"
      unitRef="usd">7095000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzMtMS0xLTEtNzgwNDk_013f2929-e588-4149-be86-ca46ea4f9dd1"
      unitRef="usd">9512000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzMtMy0xLTEtNzgwNDk_33a337ca-4357-401e-ae7c-ac9fded3a9e1"
      unitRef="usd">8703000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzQtMS0xLTEtNzgwNDk_62150b88-8cd3-4c2b-b74a-55ef3c2b30ff"
      unitRef="usd">6255000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzQtMy0xLTEtNzgwNDk_24141422-723d-4951-9835-13ab6022696f"
      unitRef="usd">5645000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzUtMS0xLTEtNzgwNDk_46cc3712-07d4-459e-90e9-0b3b693da125"
      unitRef="usd">5033000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzUtMy0xLTEtNzgwNDk_cc550e9e-4fac-4103-8867-513e0e2f079d"
      unitRef="usd">4541000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzYtMS0xLTEtNzgwNDk_aeba6dfd-a395-4fa5-bf2a-a38f96fa160b"
      unitRef="usd">29015000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2MzhjNDIwNTJhN2Q0ZjRkODQ5YzIyZWNmMTMzNWQxZS90YWJsZXJhbmdlOjYzOGM0MjA1MmE3ZDRmNGQ4NDljMjJlY2YxMzM1ZDFlXzYtMy0xLTEtNzgwNDk_0e10a72e-a48b-4b91-93f2-6eb22bfe0c42"
      unitRef="usd">26704000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <elv:InvestmentsinequitysecuritiesTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MjI_f73a2d4a-f0da-46d9-ad8f-523b491e9d8a">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of current equity securities at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange traded funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:InvestmentsinequitysecuritiesTableTextBlock>
    <elv:EquitySecurities
      contextRef="i76781baf46eb4f6ea9f326720c56d24c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzItMS0xLTEtNzgwNDk_dce57593-9d0a-4b86-800a-404bc1b1f2f6"
      unitRef="usd">822000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i7f7d5ce1d5854f9ab123aec1ba08a66c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzItMy0xLTEtNzgwNDk_9c08756c-4830-4d3a-a898-5c1ceb210942"
      unitRef="usd">1750000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i19a0491ff0494ee48b5b1055821af090_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzQtMS0xLTEtNzgwNDk_8634963f-0bc4-4f73-b79a-25498fffe8d9"
      unitRef="usd">43000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i7b47b4ff361f4031989f83a3333a82d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzQtMy0xLTEtNzgwNDk_eb23369f-645b-48a1-a077-3fb8a2991c58"
      unitRef="usd">42000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i3c623535470d4d61ab37acba9cfad54c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzUtMS0xLTEtNzgwNDk_7ee9951b-4fb9-4f9d-8d9e-7a0854a522fc"
      unitRef="usd">88000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i6d18fbff221e4d46b9e4768147f370b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzUtMy0xLTEtNzgwNDk_152768be-8aca-4edc-8ba1-eedac8b2cb6d"
      unitRef="usd">89000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzYtMS0xLTEtNzgwNDk_c3499b6f-fa56-4af7-827a-013a34d2c0af"
      unitRef="usd">953000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo1YTEyMzU3MGU0N2E0MDg2OTUyMWZlYzA2NjllNjExYi90YWJsZXJhbmdlOjVhMTIzNTcwZTQ3YTQwODY5NTIxZmVjMDY2OWU2MTFiXzYtMy0xLTEtNzgwNDk_c7db63dd-980c-4fed-95e4-b1b246e841c5"
      unitRef="usd">1881000000</elv:EquitySecurities>
    <us-gaap:InvestmentIncomeTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4NDE_413a4141-b120-40e3-9a89-367743c6e015">&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major categories of net investment income for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentIncomeTextBlock>
    <us-gaap:InvestmentIncomeNet
      contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzEtMS0xLTEtNzgwNDk_01c5b41f-d87b-4f68-95d7-2d92c1c472a1"
      unitRef="usd">971000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzEtMy0xLTEtNzgwNDk_e2246bf6-b74e-41be-96a8-647d0fe3e9e9"
      unitRef="usd">755000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzEtNS0xLTEtNzgwNDk_554cac39-69b7-4fcd-b0dc-61a97ad01a57"
      unitRef="usd">725000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzItMS0xLTEtNzgwNDk_6dff7196-768b-4888-8bd7-9b83bcedd0ed"
      unitRef="usd">48000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzItMy0xLTEtNzgwNDk_3c096679-18ad-43a1-82cf-dd271b01a11d"
      unitRef="usd">43000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzItNS0xLTEtNzgwNDk_0ba6735e-be4e-400a-a242-c9fe68b74c99"
      unitRef="usd">71000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="idb31ce1cd8a2411fb9513a02d3ed3cf9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzMtMS0xLTEtNzgwNDk_b94198dd-c7f6-47d5-a1f4-5d4a47d32d5b"
      unitRef="usd">77000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i78b0aede65fd4dd29e1f856a933eb6ad_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzMtMy0xLTEtNzgwNDk_3d9089e4-23a0-433d-b946-c6da334bcde5"
      unitRef="usd">5000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i313a7fbc748841a6a6f1211fc6c0b559_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzMtNS0xLTEtNzgwNDk_d0467de9-c04d-44bf-a6d3-faab077d3d67"
      unitRef="usd">28000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzQtMS0xLTEtNzgwNDk_cb5ffcee-068c-4887-829e-85b5ec58df92"
      unitRef="usd">432000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzQtMy0xLTEtNzgwNDk_55057481-9041-4d67-86f2-7858c474c38a"
      unitRef="usd">616000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzQtNS0xLTEtNzgwNDk_ea4675dc-2703-4d7a-ad29-d047a134db7a"
      unitRef="usd">91000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzUtMS0xLTEtNzgwNDk_bc57912b-ad7a-4fbe-9245-ddb9a05f09c7"
      unitRef="usd">1528000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzUtMy0xLTEtNzgwNDk_08d21099-431a-47b1-9ac8-3b7e8dbcb7b6"
      unitRef="usd">1419000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzUtNS0xLTEtNzgwNDk_52d1864d-7d22-4a24-ba9c-34104432f959"
      unitRef="usd">915000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzYtMS0xLTEtNzgwNDk_63c4d85a-1d8e-432a-84ce-4e24d214957f"
      unitRef="usd">43000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzYtMy0xLTEtNzgwNDk_ad89d10d-0115-4251-9f62-34c2295a3627"
      unitRef="usd">41000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzYtNS0xLTEtNzgwNDk_9d48313f-b8fb-4137-a7f9-e2a628626a54"
      unitRef="usd">38000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:NetInvestmentIncome
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzctMS0xLTEtNzgwNDk_2ba36f8c-82ec-4aa4-a8d4-061ed2127103"
      unitRef="usd">1485000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzctMy0xLTEtNzgwNDk_2fd84e31-915a-464b-b3de-b8b9160feb27"
      unitRef="usd">1378000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZToyNWEwNGRkNjI0NDk0YTQwYjU5YmE0YTM4MzQyNzhlZi90YWJsZXJhbmdlOjI1YTA0ZGQ2MjQ0OTRhNDBiNTliYTRhMzgzNDI3OGVmXzctNS0xLTEtNzgwNDk_77f54583-13d2-42c5-9a4d-3dbdda355846"
      unitRef="usd">877000000</us-gaap:NetInvestmentIncome>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MDE_092a1f61-5d9a-4545-bb9d-4fe1ab4bcfa3">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment (losses) gains for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized gains from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized losses from sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment (losses) recoveries recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains on fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains recognized on equity securities still held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized (losses) gains recognized on equity securities sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzMtMS0xLTEtNzgwNDk_7b8f5cb2-6a8a-4ac2-9398-13a1bcc9f2c1"
      unitRef="usd">52000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzMtMy0xLTEtNzgwNDk_4ce2d8af-92eb-4edd-99d9-74092083b380"
      unitRef="usd">170000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzMtNS0xLTEtNzgwNDk_630992de-465d-4c98-bd1d-23c3c9fc64c6"
      unitRef="usd">175000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzQtMS0xLTEtNzgwNDk_123497c9-b4e7-4911-99a9-625c13eafc10"
      unitRef="usd">-469000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzQtMy0xLTEtNzgwNDk_9675cd51-05cb-4860-b067-efa62bb6498a"
      unitRef="usd">-44000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzQtNS0xLTEtNzgwNDk_fcd7fc21-19cd-4815-bad1-d9578c131946"
      unitRef="usd">-105000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <elv:Impairmentlossesreversalsoninvestments
      contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzUtMS0xLTEtNzgwNDk_6911bcb2-6867-418a-9153-c6cfaeeac39b"
      unitRef="usd">31000000</elv:Impairmentlossesreversalsoninvestments>
    <elv:Impairmentlossesreversalsoninvestments
      contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzUtMy0xLTEtNzgwNDk_417e646c-ac16-47a2-9ba0-dd23c6b728ca"
      unitRef="usd">-1000000</elv:Impairmentlossesreversalsoninvestments>
    <elv:Impairmentlossesreversalsoninvestments
      contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzUtNS0xLTEtNzgwNDk_ba83ee58-c5ab-490a-823c-6ddf1a85f811"
      unitRef="usd">7000000</elv:Impairmentlossesreversalsoninvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzYtMS0xLTEtNzgwNDk_4d57866b-d2a0-401e-9161-c1dd5cdc6d7d"
      unitRef="usd">-448000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzYtMy0xLTEtNzgwNDk_75824dbf-2cf5-478f-a0e9-6c030c5a8913"
      unitRef="usd">127000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzYtNS0xLTEtNzgwNDk_d0c92fd6-4f8e-49b6-9f54-d80989633ed8"
      unitRef="usd">63000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzgtMS0xLTEtNzgwNDk_2a296a5c-84fe-4445-b017-1d73588ca972"
      unitRef="usd">-78000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzgtMy0xLTEtNzgwNDk_040ef380-3e51-4420-b73a-e072161db1ab"
      unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzgtNS0xLTEtNzgwNDk_89e31118-b4f6-4e09-9083-c184074419e5"
      unitRef="usd">133000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzktMS0xLTEtNzgwNDk_21a0d432-229f-4b19-834f-2cea7e57eec6"
      unitRef="usd">102000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzktMy0xLTEtNzgwNDk_e085cac7-3670-4b3c-b644-5dbe4da346d2"
      unitRef="usd">73000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzktNS0xLTEtNzgwNDk_e7341f20-376a-4c25-8447-cfc74b56331e"
      unitRef="usd">-61000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="icd86e477548543548f2c1d7cf19ea45c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEwLTEtMS0xLTc4MDQ5_79c08d03-ae18-424b-9a78-b719d1abde79"
      unitRef="usd">-180000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i53403b97747a43718fc787ec172de61a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEwLTMtMS0xLTc4MDQ5_27fe4be0-90d7-4fe1-b8ee-28c90dd97ca2"
      unitRef="usd">-71000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if668c5280a0f4693bd25c8bcd4489abd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEwLTUtMS0xLTc4MDQ5_3384eb2d-011e-4a77-a0f3-b6bd8783312a"
      unitRef="usd">194000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <elv:GainsFromOtherInvestments
      contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEyLTEtMS0xLTc4MDQ5_048b81d5-d489-4b78-8665-91463d1c81f4"
      unitRef="usd">96000000</elv:GainsFromOtherInvestments>
    <elv:GainsFromOtherInvestments
      contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEyLTMtMS0xLTc4MDQ5_068e1112-18a4-47fa-bdc1-779c22e7bb50"
      unitRef="usd">293000000</elv:GainsFromOtherInvestments>
    <elv:GainsFromOtherInvestments
      contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEyLTUtMS0xLTc4MDQ5_50a12916-f107-4e75-a595-36c44bc5864c"
      unitRef="usd">18000000</elv:GainsFromOtherInvestments>
    <elv:GrossLossesFromOtherInvestments
      contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEzLTEtMS0xLTc4MDQ5_adf16ffa-0423-4a40-a187-5062808f5f2c"
      unitRef="usd">64000000</elv:GrossLossesFromOtherInvestments>
    <elv:GrossLossesFromOtherInvestments
      contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEzLTMtMS0xLTc4MDQ5_29dead5d-bac9-440a-be59-61c8d7c623dd"
      unitRef="usd">22000000</elv:GrossLossesFromOtherInvestments>
    <elv:GrossLossesFromOtherInvestments
      contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzEzLTUtMS0xLTc4MDQ5_a923866d-b007-4b3a-938d-9b2f53ad60c0"
      unitRef="usd">0</elv:GrossLossesFromOtherInvestments>
    <elv:Impairmentlossesreversalsoninvestments
      contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE0LTEtMS0xLTc4MDQ5_d067647a-178f-42f6-9637-3683c7a83622"
      unitRef="usd">34000000</elv:Impairmentlossesreversalsoninvestments>
    <elv:Impairmentlossesreversalsoninvestments
      contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE0LTMtMS0xLTc4MDQ5_857e5d8f-2acb-41c7-926d-13fff29a86de"
      unitRef="usd">16000000</elv:Impairmentlossesreversalsoninvestments>
    <elv:Impairmentlossesreversalsoninvestments
      contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE0LTUtMS0xLTc4MDQ5_9d934b0e-d8d5-4efe-83a7-43411d7d07e0"
      unitRef="usd">91000000</elv:Impairmentlossesreversalsoninvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i578386e9c69d4211b5fbe45b12c0dd8b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE1LTEtMS0xLTc4MDQ5_4facfd33-4e25-441f-9014-ec1a197f6b21"
      unitRef="usd">-2000000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="ib727fd184c464a5092079464e697cc0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE1LTMtMS0xLTc4MDQ5_909e717a-f529-405a-bf2d-c8a0e2350d51"
      unitRef="usd">255000000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i4d03ab0797204bee81ce3c5ede7e3680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE1LTUtMS0xLTc4MDQ5_901ef9b9-b3ea-4030-8a61-c5a05ef2db9b"
      unitRef="usd">-73000000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <elv:InvestmentGainsLosses
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE2LTEtMS0xLTc4MDQ5_105731b4-4aec-4b37-8894-8602ab4adb44"
      unitRef="usd">-630000000</elv:InvestmentGainsLosses>
    <elv:InvestmentGainsLosses
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE2LTMtMS0xLTc4MDQ5_52f5ecd4-645c-446a-ad4d-f41b6e15cfb0"
      unitRef="usd">311000000</elv:InvestmentGainsLosses>
    <elv:InvestmentGainsLosses
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90YWJsZTo2OTRhNDAxOGZjM2E0NmE5ODNmOWZkNDIyNGY5NTM1NS90YWJsZXJhbmdlOjY5NGE0MDE4ZmMzYTQ2YTk4M2Y5ZmQ0MjI0Zjk1MzU1XzE2LTUtMS0xLTc4MDQ5_6496bc97-e08b-4811-8cc9-10cfe73f6184"
      unitRef="usd">184000000</elv:InvestmentGainsLosses>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="icac0faa7cb804ea9bcfeb8dd18f2bea3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzQyNjk_f352c688-a239-4826-8991-4ba0aba5e72d"
      unitRef="usd">22048000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4a5068cdfe96418f892972ceea8b8e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzQyNzM_aa94ad64-5ef9-47be-af29-b0c69f4b25ae"
      unitRef="usd">10565000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ia0f92f317ab548fda3536bb47daf4e98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzQyODA_aed3b358-9d41-4e03-868a-56a34ba45ce4"
      unitRef="usd">11122000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzYxODE_ac166c21-a873-4966-8324-23e0ad1cb5cd"
      unitRef="number">8</elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome>
    <elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc4MDc_1851cd57-f7aa-41b5-8fb0-bd4f1e87e0e2"
      unitRef="number">2</elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome>
    <us-gaap:ContractualObligation
      contextRef="if532c3e8149744e285dc513d9e69b523_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzYzNDE_5181500e-39f2-4c5b-a147-bf392a9d23b0"
      unitRef="usd">1504000000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i9313f67506114bbb8c5bc5b22dd2012f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzYzNDg_edb477b6-d3a5-4532-91fe-9d6b1c4ccd08"
      unitRef="usd">1558000000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i15ad5cb59a1e44c5bef8850e5117517c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgzNTQ4Ng_3f5c5a27-bdc5-422a-af64-6d15556601bd"
      unitRef="usd">185000000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="ie118092ebec04fe3afe79f4870f4ed4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgzNTQ5NQ_53244f26-87a1-4664-94be-0fa1ce084df8"
      unitRef="usd">329000000</us-gaap:ContractualObligation>
    <us-gaap:AssetsHeldByInsuranceRegulators
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY1NTM_68464ae9-d4e3-4e7a-829e-ab63618ad31b"
      unitRef="usd">752000000</us-gaap:AssetsHeldByInsuranceRegulators>
    <us-gaap:AssetsHeldByInsuranceRegulators
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY1NjA_4b9550b1-378a-49c9-b06f-9af19b93a5e6"
      unitRef="usd">632000000</us-gaap:AssetsHeldByInsuranceRegulators>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY3Mjk_e1020dea-b14c-472f-a3af-b856d3ae0147"
      unitRef="usd">245000000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzY3MzY_811e54dc-7a3e-41f6-987b-9bb6f02da327"
      unitRef="usd">205000000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:SecuritiesLoanedFairValueOfCollateral
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzcwMTQ_e6c88d5e-60da-43b8-b683-a0caff2412b9"
      unitRef="usd">2457000000</us-gaap:SecuritiesLoanedFairValueOfCollateral>
    <us-gaap:SecuritiesLoanedFairValueOfCollateral
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzcwMjE_bc07e1e3-55a5-4259-b948-b69e9f5ecf0f"
      unitRef="usd">2155000000</us-gaap:SecuritiesLoanedFairValueOfCollateral>
    <elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzcwOTI_cbe8a9cc-4b95-4041-99bd-1a4681b8cc51"
      unitRef="number">1.02</elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan>
    <us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue
      contextRef="iea80de425e5d4008bbefd6978deb3701_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc2ODk_b0121953-4733-4754-a787-27f2e438b564"
      unitRef="usd">2221000000</us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue>
    <us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue
      contextRef="i9974d46da761480e8fd7c0dfc0115459_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc2OTY_86519263-52f0-4783-b92c-6eee3e05ede5"
      unitRef="usd">1874000000</us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue>
    <us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue
      contextRef="id6d4050ea7e946fb83bc63f84f887ce0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc3NTg_58abec7b-fa4b-41d3-8d8b-d7c7600487d5"
      unitRef="usd">224000000</us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue>
    <us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue
      contextRef="idaf228ebc5ee4ed9ac397e8420d1727c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzc3NjU_ce09b5f3-569b-43d8-bdca-2ce7eb4f15a0"
      unitRef="usd">281000000</us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue>
    <us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue
      contextRef="iccf0e0041e444850986706abfccd14c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgyOTk3NA_80593de4-c522-4231-b647-73e234bb3886"
      unitRef="usd">12000000</us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue>
    <us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue
      contextRef="i349488ab238e4f40b2b347c93c7e1a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDMvZnJhZzowMmU1MWJmMDZiMjY0MTgxODVmYjZkZjZlYjliMTgxMi90ZXh0cmVnaW9uOjAyZTUxYmYwNmIyNjQxODE4NWZiNmRmNmViOWIxODEyXzU0OTc1NTgyOTk4Mg_6745af3a-ff1b-4541-ba27-e8a223a2b187"
      unitRef="usd">0</us-gaap:DepositsReceivedForSecuritiesLoanedAtCarryingValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwNzk_6c3aafa1-f07d-4494-96ee-e62b5431b94f">Derivative Financial Instruments&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants. We also enter into master netting agreements which reduce credit risk by permitting net settlement of transactions. At December&#160;31, 2022 and 2021, we had received collateral of $57 and $18, respectively, related to our derivative financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual/&lt;br/&gt;Notional&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Liability)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps - fixed to floating&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Non-hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives embedded in convertible fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed Maturity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities/other assets/other liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts netted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps - fixed to floating&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Non-hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities/other assets/other liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts netted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the LIBOR or the Secured Overnight Financing Rate. A summary of our outstanding fair value hedges at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Fair Value Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;br/&gt;Entered&lt;br/&gt;Into&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&#160;Notional&#160;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;br/&gt;Received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 15, 2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 1, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 15, 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 1, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 1, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 15, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amount outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification in Which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount of Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the variability of cash flows in the interest payments on future financings that were anticipated at the time of entering into the swaps. During 2022 and 2021, swaps in the notional amount of $700 and $450, respectively, were terminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $229 and $239 at December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, the total amount of amortization over the next twelve months for all cash flow hedges is estimated to increase interest expense by approximately $13. No amounts were excluded from effectiveness testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Hedging Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Non-hedging Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location of&lt;br/&gt;Gain (Loss) Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;(Loss) Gain&lt;br/&gt;Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives embedded in convertible securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d"&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635"&gt;(4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options (including swaptions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16"&gt;13&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db"&gt;10&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2"&gt;64&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27"&gt;(4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf"&gt;4&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142"&gt;7&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7"&gt;4&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzQwNw_cecc3fd3-3a82-45c0-9e43-ee87802e4911"
      unitRef="usd">57000000</us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset>
    <us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzQxNA_8207872a-69e8-487e-8689-acbd96c6e99a"
      unitRef="usd">18000000</us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwODU_b3b36771-351a-4d90-88a3-fa37bb388d3c">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual/&lt;br/&gt;Notional&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Liability)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps - fixed to floating&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Non-hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives embedded in convertible fixed maturity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed Maturity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities/other assets/other liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts netted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps - fixed to floating&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Non-hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities/other assets/other liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets/other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal non-hedging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts netted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2d0c3a19c29c4b649862b0b586cdef34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzQtMS0xLTEtNzgwNDk_60094183-228d-4f24-b462-a245d12f4a5d"
      unitRef="usd">1125000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2d0c3a19c29c4b649862b0b586cdef34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzQtNS0xLTEtNzgwNDk_b7752f2e-3e3b-4ec1-8a8b-48135f0a352a"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2d0c3a19c29c4b649862b0b586cdef34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzQtNy0xLTEtNzgwNDk_04c26cf4-2a71-494b-9aed-7b79b5749774"
      unitRef="usd">60000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie74879d09949481ca3d9a43e6f898eb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzctMS0xLTEtOTAxODg_0a0f51f5-1f8c-48fd-9728-311b9a094d99"
      unitRef="usd">18000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie74879d09949481ca3d9a43e6f898eb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzctNS0xLTEtOTAxOTc_dc82c733-0f21-410c-9128-565bb064cfdb"
      unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie74879d09949481ca3d9a43e6f898eb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzctNy0xLTEtOTAyMDU_65fbc0f4-4a49-4c57-9745-f5db86e4a7cb"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzktMS0xLTEtNzgwNDk_02b41909-1006-43d8-9c86-b4adf8131614"
      unitRef="usd">5000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzktNS0xLTEtNzgwNDk_267e66a4-fc33-4f37-8fc6-d8488e5fc837"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7c5b76a9e6c6483eb6fa7325e27cc2e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzktNy0xLTEtNzgwNDk_f562f9e3-e23c-422c-9235-27aa230de867"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEwLTEtMS0xLTc4MDQ5_7bab022b-82b9-414f-a4b2-91138b8dc7b4"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEwLTUtMS0xLTc4MDQ5_1c51e847-b9e1-414b-a4ac-eff3befb0c60"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic18fe432bd9246a9bc2b1517ddd862b2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEwLTctMS0xLTc4MDQ5_69154ea1-23cf-4b02-9f74-34192bd9cbb9"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1c85d8180b384c1b902ff87d3cee955d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzExLTEtMS0xLTc4MDQ5_240755f0-3913-41d9-9dba-e0da5b419b05"
      unitRef="usd">19000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1c85d8180b384c1b902ff87d3cee955d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzExLTUtMS0xLTc4MDQ5_53ab7d92-6a5c-41a6-9584-82b4a13a4997"
      unitRef="usd">23000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1c85d8180b384c1b902ff87d3cee955d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzExLTctMS0xLTc4MDQ5_53644c38-24c7-4798-b51a-7cb8618f09c8"
      unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6479287b4fdd42e685cd3c578fd33e14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEyLTEtMS0xLTc4MDQ5_4de7dac7-9d89-4ab7-b160-8e0b31af7eb2"
      unitRef="usd">358000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6479287b4fdd42e685cd3c578fd33e14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEyLTUtMS0xLTc4MDQ5_666a0f74-7e85-4aed-bd87-216582fb940b"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6479287b4fdd42e685cd3c578fd33e14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEyLTctMS0xLTc4MDQ5_3d0f6024-befa-418a-b9dc-1952033042c3"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEzLTEtMS0xLTc4MDQ5_413d80ad-5d60-4928-a1dd-78d9852cf438"
      unitRef="usd">400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEzLTUtMS0xLTc4MDQ5_25c75f23-2dd1-4a4d-8c74-abeada893f4f"
      unitRef="usd">30000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i87e201fc1a0b4a65aaf8eb4353f9873e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzEzLTctMS0xLTc4MDQ5_2d440f8e-ffea-47f9-b43a-f77f984c7cff"
      unitRef="usd">11000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE0LTEtMS0xLTc4MDQ5_7b265b10-dad7-4c24-bcf8-b4ebd78a3beb"
      unitRef="usd">1525000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE0LTUtMS0xLTc4MDQ5_9edc024a-665c-4227-a337-5116c2d452b0"
      unitRef="usd">33000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE0LTctMS0xLTc4MDQ5_ecbac8da-84b4-435f-bd6f-5559a842d208"
      unitRef="usd">71000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE1LTUtMS0xLTc4MDQ5_a96f715b-9394-439f-be6a-1132c2e95fc9"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE1LTctMS0xLTc4MDQ5_d4c2f24f-655c-4b1c-b0ad-19de8dab88fc"
      unitRef="usd">12000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE2LTUtMS0xLTc4MDQ5_6db2ab81-8460-4318-a443-5ebe909bde86"
      unitRef="usd">21000000</us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzE2LTctMS0xLTc4MDQ5_2b8db065-4a8f-42f3-a595-5feaac75bec6"
      unitRef="usd">59000000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie3ce009ab57443fd98fe415da6193a1d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIwLTEtMS0xLTc4MDQ5_d765d60c-1fe3-4197-bef3-3f3b26da5aa7"
      unitRef="usd">825000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie3ce009ab57443fd98fe415da6193a1d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIwLTUtMS0xLTc4MDQ5_91c7460e-0081-4144-8b42-a085c302c0a0"
      unitRef="usd">23000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie3ce009ab57443fd98fe415da6193a1d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIwLTctMS0xLTc4MDQ5_d11863fb-ea9b-4e2e-8fed-9a3e96b829ac"
      unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i09dd408e89d54981af41dcf162ba1bc5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIzLTEtMS0xLTc4MDQ5_76e65a1d-2c04-47e9-bc82-d60a8d4e2524"
      unitRef="usd">119000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i09dd408e89d54981af41dcf162ba1bc5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIzLTUtMS0xLTc4MDQ5_8d719f0f-c387-45b8-a584-b3ed24842258"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i09dd408e89d54981af41dcf162ba1bc5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzIzLTctMS0xLTc4MDQ5_e1d0aa23-ee70-43e8-b68f-a7c68cf96155"
      unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI0LTEtMS0xLTc4MDQ5_3c617f7d-37d0-4bbb-be8d-35885f2c403e"
      unitRef="usd">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI0LTUtMS0xLTc4MDQ5_a9b7293a-390d-4216-892b-3486a524b0b5"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia0dcc3f192c44866b9b21d496d17e8a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI0LTctMS0xLTc4MDQ5_5ed84a33-d5c4-4174-9b94-cb71d7ddd567"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie81542d413fa4945bbc09e8c29161193_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTEtMS0xLTgyNjg3_4ceb3363-8152-4793-b5b4-a85d8853ae25"
      unitRef="usd">19000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie81542d413fa4945bbc09e8c29161193_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTUtMS0xLTgyNjk1_f5719b14-b247-4846-9676-c2821fa79401"
      unitRef="usd">21000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie81542d413fa4945bbc09e8c29161193_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTctMS0xLTgyNjk1_af93b36f-0fc8-4ebf-b92e-494f12b3a80e"
      unitRef="usd">17000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTEtMS0xLTc4MDQ5_d4569812-b6a3-40bc-997a-4894cf3dc7ce"
      unitRef="usd">344000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTUtMS0xLTc4MDQ5_6404e437-5b8d-477e-8bc4-ec45f1136213"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia8ba1a987a2e4fabb7b7ec25b311a267_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI1LTctMS0xLTc4MDQ5_06d08615-28f2-4344-8132-1155834ab301"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1f20343c2c574345836f7ccda1cb4891_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI2LTEtMS0xLTc4MDQ5_1aade1b3-83f5-448b-991a-dae4f142417f"
      unitRef="usd">582000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1f20343c2c574345836f7ccda1cb4891_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI2LTUtMS0xLTc4MDQ5_c18890c4-49d9-47a2-b53e-06fc97569382"
      unitRef="usd">24000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1f20343c2c574345836f7ccda1cb4891_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI2LTctMS0xLTc4MDQ5_890a9099-520e-4784-ac3c-5884c4eef771"
      unitRef="usd">24000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI3LTEtMS0xLTc4MDQ5_ed91b459-c45c-4d2e-ae35-ae9e1e379373"
      unitRef="usd">1407000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI3LTUtMS0xLTc4MDQ5_56d2e7db-7a63-4045-999f-c73fbe91585b"
      unitRef="usd">47000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI3LTctMS0xLTc4MDQ5_d92481e4-94c0-4106-b0e2-659eae47d46f"
      unitRef="usd">29000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI4LTUtMS0xLTc4MDQ5_cc26957a-ea4b-4cf9-a020-73385d651658"
      unitRef="usd">21000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI4LTctMS0xLTc4MDQ5_a4e1b29b-6b2a-46b2-a156-98897f1cf85c"
      unitRef="usd">21000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI5LTUtMS0xLTc4MDQ5_6d08c141-65dd-461c-8e58-0a77d535c016"
      unitRef="usd">26000000</us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTpjN2NiYzkxYmQxODE0YWQzYjg3ZmJjYTY4MmIxMWE0YS90YWJsZXJhbmdlOmM3Y2JjOTFiZDE4MTRhZDNiODdmYmNhNjgyYjExYTRhXzI5LTctMS0xLTc4MDQ5_643573ec-e532-4653-9640-7d83a2ccead5"
      unitRef="usd">8000000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwNjk_b3031810-62b0-4bb1-b954-e5cd45884e91">A summary of our outstanding fair value hedges at December&#160;31, 2022 and 2021 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Fair Value Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;br/&gt;Entered&lt;br/&gt;Into&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&#160;Notional&#160;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;br/&gt;Received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 15, 2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 1, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 15, 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 1, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 1, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 15, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amount outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2e2fb9b4d38545ababb8320a29faa28d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNC0xLTEtOTYyNTE_5f46204c-46e1-4f38-9ca1-3cd9786f2c15"
      unitRef="usd">150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i34e594917ec14e3681954b85197676eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNi0xLTEtOTYyNTk_947b7125-4bb7-4b9f-8ddf-e2a556de6b3e"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i2e2fb9b4d38545ababb8320a29faa28d_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItOC0xLTEtOTYyNjk_b70985b0-7e31-4415-8197-2601801a1b87"
      unitRef="number">0.05500</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="ic56e8a6011ed4fdc85d7e0cfa580e4a3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItMTEtMS0xLTk2Mjkx_9371d36f-672b-4065-9df6-33222b56a3c8">2032-04-15</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie552404ba61c47b389e3c8fc6a697712_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNC0xLTEtOTYyNTE_3545be1f-216f-451b-820f-060fc2986f3c"
      unitRef="usd">75000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i459958d874344214bb9cac08d7d757ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNi0xLTEtOTYyNTk_e8ce7c45-6271-43f5-9716-e1b48925b5ec"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ie552404ba61c47b389e3c8fc6a697712_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtOC0xLTEtOTYyNjk_cbbf8371-d16b-4210-bfaa-c537fd00107e"
      unitRef="number">0.04101</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="ia50a6cc46d6248a397c24a2ad0c2c744_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtMTEtMS0xLTk2Mjkx_53402833-1887-4ca4-9b8e-3a54a3b4e77e">2027-09-01</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i02888f49341a44d4941c9b1b6fb319ed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNC0xLTEtOTYyNTE_b0fdd2e3-84b8-465d-9d02-f106cbfd30c7"
      unitRef="usd">75000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ida52dad48cef4deba690de9747f68ee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNi0xLTEtOTYyNTk_f29dce0c-6875-4dbd-81df-0dc8549f67cf"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i02888f49341a44d4941c9b1b6fb319ed_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtOC0xLTEtOTYyNjk_8139f4fb-4b55-4a12-86ff-715577fd4917"
      unitRef="number">0.02250</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="ie7ee2dc635204bbf8650d842aeb2bac7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtMTEtMS0xLTk2Mjkx_d99e26dd-ce0b-46f0-9bb3-5f7f229bfb09">2029-11-15</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iab6d874468aa4ce6bcf71bd25597b297_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNC0xLTEtNzgwNDk_e08db5c8-8014-4377-944f-e90c5b39f4c6"
      unitRef="usd">150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i42f4135503874ad1943ea10cbe7602f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItNi0xLTEtNzgwNDk_b23ed9de-b32f-4049-81ec-00abcb5b44a5"
      unitRef="usd">150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="iab6d874468aa4ce6bcf71bd25597b297_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItOC0xLTEtNzgwNDk_5f051f7c-a643-4729-8a8e-45987f8acee9"
      unitRef="number">0.02550</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i42f4135503874ad1943ea10cbe7602f1_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItOC0xLTEtNzgwNDk_a5df403e-e0c1-4de3-987d-6971973ea67d"
      unitRef="number">0.02550</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="ia06f61dafe7046c7a1f76c38c5fc05ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzItMTEtMS0xLTc4MDQ5_653cc609-d368-4c7b-a29a-2d2b39ef24b5">2030-09-15</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6e0d380b589e4106bb438dadcea77ccf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNC0xLTEtNzgwNDk_d57ae329-7160-4c1c-812d-01c0181e436a"
      unitRef="usd">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icfdeec77a2e849ab99853223554b64b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtNi0xLTEtNzgwNDk_13181cd4-2776-4bee-bcf6-aaa3d79db6b3"
      unitRef="usd">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i6e0d380b589e4106bb438dadcea77ccf_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtOC0xLTEtNzgwNDk_338a96e9-1929-4917-8885-b03c0d2c078d"
      unitRef="number">0.02250</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="icfdeec77a2e849ab99853223554b64b9_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtOC0xLTEtNzgwNDk_a3c14751-edf9-4558-b1c9-7d372aefc7ce"
      unitRef="number">0.02250</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="i1cf6c3723dd347668da304307c4a44a6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzMtMTEtMS0xLTc4MDQ5_6cb934bb-9bcb-4904-94c8-2f50f3d4d0e9">2029-11-15</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if2ccb539d68746d59161c8870f4d4df0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNC0xLTEtNzgwNDk_39d72332-a8d0-406e-a7ca-14e3937ec73b"
      unitRef="usd">75000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i08a4ad028b9a441cb7f6ba9a6e59341a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtNi0xLTEtNzgwNDk_11301dc4-16c9-4c8a-981e-a7a407cc00c1"
      unitRef="usd">75000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i08a4ad028b9a441cb7f6ba9a6e59341a_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtOC0xLTEtNzgwNDk_d722656e-969e-4d58-9083-160e6e37388f"
      unitRef="number">0.04101</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="if2ccb539d68746d59161c8870f4d4df0_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtOC0xLTEtNzgwNDk_f37deae4-3155-4352-865f-0afa26e5bb07"
      unitRef="number">0.04101</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="ib5be7d9b2d014385b6e19a6db3d6a4ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzQtMTEtMS0xLTc4MDQ5_9ab600db-ba0e-4bad-9e50-848407580802">2027-09-01</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i01ed18d384274ea3a14a91f034c105cd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtNC0xLTEtNzgwNDk_81e61637-773d-4e19-b7ea-855aac3a82e7"
      unitRef="usd">50000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if3411db499754ed98b66e11164278b68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtNi0xLTEtNzgwNDk_1144839c-fa78-4f90-879b-88fda2c0e081"
      unitRef="usd">50000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i01ed18d384274ea3a14a91f034c105cd_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtOC0xLTEtNzgwNDk_9628ef3d-307d-458b-a614-bbbf059f239d"
      unitRef="number">0.04101</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="if3411db499754ed98b66e11164278b68_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtOC0xLTEtNzgwNDk_b42e0463-4c21-4f4e-8816-783c41ae49cc"
      unitRef="number">0.04101</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="i39a83586d8464e20bb8ad68eb2540321_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzUtMTEtMS0xLTc4MDQ5_994c3812-0f6f-4ad6-a536-083e5da7167b">2027-09-01</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2303e464443d492f83362a773fe17a1d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtNC0xLTEtNzgwNDk_44c5294e-3d10-4eb2-bf6d-bc6622b3aff8"
      unitRef="usd">450000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie189000e9d504c47b363ff6e09fccc11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtNi0xLTEtNzgwNDk_fd040f46-5a79-4bfb-a7a0-754902040f5e"
      unitRef="usd">450000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ie189000e9d504c47b363ff6e09fccc11_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtOC0xLTEtNzgwNDk_757f4a2b-5a58-4135-a19b-46bea7fcf552"
      unitRef="number">0.03300</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i2303e464443d492f83362a773fe17a1d_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtOC0xLTEtNzgwNDk_7850bef7-bea9-456b-9865-9f7937bf63a0"
      unitRef="number">0.03300</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:OpenOptionContractsWrittenExpirationDates
      contextRef="ib61cdc82bcb443a8bf3d68ac1f8fb21c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzYtMTEtMS0xLTc4MDQ5_2b434c97-1fc2-4918-9aed-953d1a32076b">2023-01-15</us-gaap:OpenOptionContractsWrittenExpirationDates>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i272bebf1c8d949a8be406568bd0c2793_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzctNC0xLTEtNzgwNDk_c55bca3a-f275-4070-8d4d-a78afde0edc2"
      unitRef="usd">1125000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i04c8de26adbc407f960803fd1f108a21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTplYmM3NGQwNTcwNWM0MzNhYTU5NjA1MTgwYTYwYjAxZC90YWJsZXJhbmdlOmViYzc0ZDA1NzA1YzQzM2FhNTk2MDUxODBhNjBiMDFkXzctNi0xLTEtNzgwNDk_c3d269e8-ab01-4dc6-8876-19ad3549ce63"
      unitRef="usd">825000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwODI_7e92781c-d411-4853-a594-d8edfc72900f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification in Which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount of Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeAmountOfHedgedItem
      contextRef="i95d7b5c7de1a49d48dd9569c22788930_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtMi0xLTEtNzgwNDk_c216afcc-b375-423b-b0ca-fce1d98be590"
      unitRef="usd">22349000000</us-gaap:DerivativeAmountOfHedgedItem>
    <us-gaap:DerivativeAmountOfHedgedItem
      contextRef="i0f6fb48bbe5b4149b5d3e9962701d8e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtNC0xLTEtNzgwNDk_b47354a5-404c-48b2-b4aa-66d0a850477a"
      unitRef="usd">21157000000</us-gaap:DerivativeAmountOfHedgedItem>
    <elv:Fairvaluehedgescumulativebasisadjustments
      contextRef="i95d7b5c7de1a49d48dd9569c22788930_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtNi0xLTEtNzgwNDk_a781e508-9a97-4ad2-b925-9c59ff6ea717"
      unitRef="usd">57000000</elv:Fairvaluehedgescumulativebasisadjustments>
    <elv:Fairvaluehedgescumulativebasisadjustments
      contextRef="i0f6fb48bbe5b4149b5d3e9962701d8e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZToxYmI5MjRhM2Q2MDE0MmI5OWE2MGQwZDRhMTNlNjFjOS90YWJsZXJhbmdlOjFiYjkyNGEzZDYwMTQyYjk5YTYwZDBkNGExM2U2MWM5XzMtOC0xLTEtNzgwNDk_66d5a4fe-73b8-491d-b6d2-12445ab3e8d0"
      unitRef="usd">-18000000</elv:Fairvaluehedgescumulativebasisadjustments>
    <elv:Notionalamountterminatedderivatives
      contextRef="if6c16b45922c4bc795ba956462757098_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE0NjI_0f6c0174-4119-48c6-9249-07670a0dccc0"
      unitRef="usd">700000000</elv:Notionalamountterminatedderivatives>
    <elv:Notionalamountterminatedderivatives
      contextRef="i763517f93d014233863645c9d2bb0185_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE0Njk_b4afa975-5d44-4869-ab6a-3df78ad7f81e"
      unitRef="usd">450000000</elv:Notionalamountterminatedderivatives>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i948573928d0f465a94e16e23831957af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE2NDE_2aa5dcf5-8076-4530-954a-53f24f18ca6e"
      unitRef="usd">-229000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="ied8cd1ce29634691bf5ec4a6493a4478_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE2NDg_c1519656-43ff-4d87-9759-1941401a78e1"
      unitRef="usd">-239000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i948573928d0f465a94e16e23831957af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzE4MzQ_9ccd0723-681f-4ffe-9bac-16cc7f4956fa"
      unitRef="usd">13000000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90ZXh0cmVnaW9uOjA2ZGMyNWIxOThhYTRkZTFhNDYzZDQ1ODgzMDZmYjNiXzIwNjE_0de992ab-95bf-4fac-90a5-23a43ed69b81">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Non-hedging Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location of&lt;br/&gt;Gain (Loss) Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;(Loss) Gain&lt;br/&gt;Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives embedded in convertible securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_794b96f1-069c-4028-b57a-fd7a3f3ea07d"&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_2449a8b6-f507-4903-962f-09245ae0c635"&gt;(4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options (including swaptions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_13c4cad6-925f-4f34-90db-994506b9df16"&gt;13&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_1c8096af-838d-4e27-b2ff-617a1ab349db"&gt;10&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_0503c4be-950e-4d02-ae9d-920626532de2"&gt;64&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_85ba5d29-ce95-4c80-8e8d-02e8db1c5f27"&gt;(4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_85859062-9ef4-4e4d-be92-dce6cc970bcf"&gt;4&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5d97bbff-2e5c-49fd-9578-13c48157d142"&gt;7&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_a2ec27ec-9f6a-4343-b32c-c0fc78915bdf"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_42fce7da-55d4-4dfb-9f88-871d7e8b8663"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Futures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_45ab1ca1-08d8-42b8-a92d-188b250166a7"&gt;4&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia22c58671ad6415a8c5e55c98cb16b5f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzItNC0xLTEtOTAzNTE_2325ae58-4c38-4a99-9761-7894482cf2bc"
      unitRef="usd">-3000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i66ca95f113844a1a84afeef54a926515_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzMtNC0xLTEtNzgwNDk_f9c28438-c4b5-4a04-afb1-624d72d3762c"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i387703b787a3494b9ce325988abfd1f6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzQtNC0xLTEtNzgwNDk_9b1fe79b-c34b-41dc-bb73-daa26b6359be"
      unitRef="usd">13000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia72f11ca13104ea894df74d97337dea2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtOTAzNzg_c2771006-00cb-4763-91d4-7d9b3ebf57c0"
      unitRef="usd">10000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i1b9f4d2b3cae4c11bac411a49ddb6174_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzUtNC0xLTEtNzgwNDk_b1e1d40e-d156-4f57-af08-d37cd2f1b481"
      unitRef="usd">64000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzctNC0xLTEtNzgwNDk_b3dfc1bd-7084-4966-aa1a-0fc7e4d87301"
      unitRef="usd">80000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i34017a6ceea74441bb34336674de31f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzktNC0xLTEtNzgwNDk_b1b2f5fd-eaf2-4aa9-9b7b-f96c9a8003cd"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i26b5329fa2db4a9582fa955c6c09aa5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEwLTQtMS0xLTc4MDQ5_b297812e-5e9c-40bc-9527-59b6a37546a9"
      unitRef="usd">4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7a12478c233d4cb4a3af16a5ece03ad5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzExLTQtMS0xLTc4MDQ5_5350f171-1059-4d20-9ad7-e614ddafb39c"
      unitRef="usd">7000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzEyLTQtMS0xLTc4MDQ5_5efd18b3-2ef7-4855-8d5b-0da6df1b9470"
      unitRef="usd">7000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2a54e76eb8e745a0bcc186bff383f66b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE1LTQtMS0xLTc4MDQ5_500e257d-a14a-4b22-8643-97a7f5a0114f"
      unitRef="usd">-1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ic81edd70f3ec4b3ab957edfc0bf60938_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE2LTQtMS0xLTc4MDQ5_92badae7-b44d-4799-96d5-0b03b415f6f1"
      unitRef="usd">-5000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i74c774f65870474b9ff9c262bc7ac889_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE3LTQtMS0xLTc4MDQ5_bc54490a-965f-4187-82a9-dfc1ed629782"
      unitRef="usd">4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMDkvZnJhZzowNmRjMjViMTk4YWE0ZGUxYTQ2M2Q0NTg4MzA2ZmIzYi90YWJsZTo5OTc2OGExZmM2OTU0MDhkODUyMDNjMGEwMTdiNjk5OC90YWJsZXJhbmdlOjk5NzY4YTFmYzY5NTQwOGQ4NTIwM2MwYTAxN2I2OTk4XzE4LTQtMS0xLTc4MDQ5_28e8742c-634d-4ba8-945e-83f8eba595c3"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjY3_52fa33d7-edf3-472e-90c3-04068c9e025b">Fair Value &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;Input:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Input Definition:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs that reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed maturity securities, available-for-sale:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services&#x2019; qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services&#x2019; pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security&#x2019;s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities lending collateral:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan assets not defined above (see Note 11, &#x201c;Retirement Benefits,&#x201d; for fair values of benefit plan assets):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Fair values are based on quoted market prices, which represent the net asset value (&#x201c;NAV&#x201d;) of the shares held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Partnership investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Fair values are estimated based on the plan&#x2019;s proportionate share of the undistributed partners&#x2019; capital as reported in audited financial statements of the partnership. In accordance with FASB guidance, certain investments that are measured at fair value using the NAV per share as a practical expedient or the fair value measurement alternative have been classified in the fair value hierarchy. The fair value amounts presented are intended to permit reconciliation of the fair value hierarchy to the total investments of the master trust.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Commingled fund&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: Fair value is based on NAV per fund share, primarily derived from the quoted prices in active markets on the underlying equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract with insurance company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Fair value of the contract in the insurance company general investment account is determined by the insurance company based on the fair value of the underlying investments of the account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in DOL 103-12 trust:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Fair value is based on the plan&#x2019;s proportionate share of the fair value of investments held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity (&#x201c;DOL 103-12 trust&#x201d;) as reported in the audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of the trust.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Life insurance contracts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Fair value is based on the cash surrender value of the policies as reported by the insurer.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange traded funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets - common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities lending collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad"&gt;Derivatives - other assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c"&gt;Derivatives - other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange traded funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets - common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities lending collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0"&gt;Derivatives - other assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132"&gt;Derivatives - other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Residential&lt;br/&gt;Mortgage-&lt;br/&gt;backed&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Asset-Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrealized gains or losses included in net income related to assets still held at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b"&gt;19&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrealized gains or losses included in net income related to assets still held at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c"&gt;(22)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrealized gains or losses included in net income related to assets still held at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no individually material transfers into or out of Level III during the years ended December&#160;31, 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, &#x201c;Business Acquisitions,&#x201d; we completed our acquisition of Integra in 2022 and the acquisitions of myNEXUS and MMM &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during 2021. The net assets acquired in our acquisitions of Integra, myNEXUS, and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the years ended December&#160;31, 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value on the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other invested assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Other invested assets primarily include our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities&#x2019; undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term borrowings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term debt&#x2014;commercial paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term debt&#x2014;senior unsecured notes and surplus notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term debt&#x2014;convertible debentures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debentures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debentures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjcy_cc010912-68ff-43fc-8e6e-a5048d1e1a7d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange traded funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets - common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities lending collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTAtMS0xLTk5Mjcy_1674fffa-3ba9-42f0-995f-ff7a205f1bad"&gt;Derivatives - other assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI0LTAtMS0xLTk5MjY2_fb613156-ea85-48a5-9c67-c4562e7e059c"&gt;Derivatives - other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government sponsored securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions, tax-exempt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fixed maturity securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange traded funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets - common equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities lending collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTAtMS0xLTk5Mjcw_c25dea45-1a37-468f-8057-3f1eb42a37d0"&gt;Derivatives - other assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTAtMS0xLTk5MjY4_b88c4d22-45b1-4a49-bd8a-86ace5dd4132"&gt;Derivatives - other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c3650a094504772a0bf73a6172f2a67_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMtMS0xLTEtNzgwNDk_208bb5ba-ec33-4ed4-b100-8c537a421dec"
      unitRef="usd">3567000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMtNy0xLTEtNzgwNDk_1efe60b0-0251-4ac8-a466-72d58745f3ed"
      unitRef="usd">3567000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9096a0c9b14b4c9fa7be9af938dcc3ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUtMy0xLTEtNzgwNDk_ba069c5b-e335-4d93-8292-1f416e406cc2"
      unitRef="usd">1401000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec50b6ddc92544c49b1a002b6bec5470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUtNy0xLTEtNzgwNDk_37c6f665-40b2-4adb-9910-eefb72e01f14"
      unitRef="usd">1401000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99009b08fecf44cd93c279adb331703f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzYtMy0xLTEtNzgwNDk_de92d874-75bc-45e8-ae94-8fcf18f8f17d"
      unitRef="usd">78000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i312cadd2c3fd4ad48fd80f9ea6f3388d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzYtNy0xLTEtNzgwNDk_1ec87318-0eef-44f7-8b66-17c23d6ed4fc"
      unitRef="usd">78000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i009bcd76d73148e5a865a59956651a7a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzctMy0xLTEtNzgwNDk_8816f979-6c57-4189-a33a-93d5e9a2b6cc"
      unitRef="usd">274000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82c3b964b82147128c282f3d7907d1fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzctNy0xLTEtNzgwNDk_2961fcba-20dc-4c7d-91b5-672e4100ce72"
      unitRef="usd">274000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27b44c05131d4056a2f7c3c898130a7a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzgtMy0xLTEtNzgwNDk_53376f8e-31b7-43e7-9150-bee55f68a5f3"
      unitRef="usd">4143000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bfb0dd90e6e452eaeb64c9e550a52e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzgtNy0xLTEtNzgwNDk_7305789d-d684-42df-99cb-b014d3041d2e"
      unitRef="usd">4143000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic72bd0d75b5c431692b8edb1c1c0d1dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzktMy0xLTEtNzgwNDk_fee7ae28-2a0b-4c11-a955-4bb51c1e9e37"
      unitRef="usd">12392000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id293b24cef6f4af1a37865b3f65c5128_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzktNS0xLTEtNzgwNDk_8ace46ec-c8d2-4d0c-8e66-3bcec1e97015"
      unitRef="usd">137000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56b44a4216564a04ab613dc30466a108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzktNy0xLTEtNzgwNDk_9b078c68-3c32-4157-98e3-768bfe08306f"
      unitRef="usd">12529000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4723ab4fdb2541989a926b6fa4fa981e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEwLTMtMS0xLTc4MDQ5_d29fc26a-c19d-4881-ab8a-083ef913e311"
      unitRef="usd">2663000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9c3b00e889545ffb01d1e62bf2b6746_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEwLTUtMS0xLTc4MDQ5_5fc42932-ddd9-4c67-bc3c-82d6540cfa7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2b05263cbe6467f97da7e76b69399cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEwLTctMS0xLTc4MDQ5_94a5530c-7650-4ddd-8451-669097604dfb"
      unitRef="usd">2663000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a55bb1adcf5446f8c1b805d8f31144e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzExLTMtMS0xLTc4MDQ5_579187fe-6f82-4801-b612-86dad2ef54ca"
      unitRef="usd">1878000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9cec8d3ec14408c96aeec604e4b7bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzExLTctMS0xLTc4MDQ5_c2a430c7-b74e-428b-92d2-b009d44531c3"
      unitRef="usd">1878000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bd1383cc1874b88a8aa6f742ec27422_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEyLTMtMS0xLTc4MDQ5_cd366c87-b289-4ca4-8628-940414e38d5e"
      unitRef="usd">3382000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i206bf39a6a2e4283b7d98c5e5aba95be_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEyLTUtMS0xLTc4MDQ5_b4fe883c-3331-4904-9823-bd07c5d9e4d2"
      unitRef="usd">356000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica4de37099734e248456f4b9bcd0d11e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEyLTctMS0xLTc4MDQ5_318a0aea-f072-4228-a18f-e12414663c68"
      unitRef="usd">3738000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia46e01dc3c644cd08544f306992b1cec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEzLTMtMS0xLTc4MDQ5_4d86fa27-bad8-4dba-9959-3f03dcd7c1bb"
      unitRef="usd">26211000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f78627f2e9a4f66a5c0bcdfdccb0aaf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEzLTUtMS0xLTc4MDQ5_03975697-52e9-4ede-afed-507ec3e33f19"
      unitRef="usd">493000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzEzLTctMS0xLTc4MDQ5_51fbed90-1dd0-4a89-a7dd-b87f05ba651a"
      unitRef="usd">26704000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <elv:EquitySecurities
      contextRef="i6ceef5d05b49498c84bc7a5735c400aa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE1LTEtMS0xLTc4MDQ5_d4a1a58b-0401-4c0c-86ac-f1be485da1f7"
      unitRef="usd">822000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i6ca8984787184bbbaefef048ae2a7ed2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE1LTctMS0xLTc4MDQ5_25386e38-46fa-46f3-9e87-dc3b435ab04a"
      unitRef="usd">822000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="if4c6a19fa0fd4060aabf6478982ccf36_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE3LTEtMS0xLTc4MDQ5_9ad0969a-a839-48fb-8c23-878f436b3470"
      unitRef="usd">2000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i0160f1f3dab24f569a23d2ba07f095d0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE3LTMtMS0xLTc4MDQ5_675a3ef0-f819-4df3-a469-888a80d4afe0"
      unitRef="usd">41000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="iebb2feacd11c4565bfc6b5b6a3e279ec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE3LTctMS0xLTc4MDQ5_9e2e5c33-afc8-466e-94d2-528524432dbe"
      unitRef="usd">43000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i8a873585c11f450d9fd9cf3c29c105f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE4LTUtMS0xLTc4MDQ5_4662d8e6-f2c5-4bf2-a8f3-0c3ae68b89d8"
      unitRef="usd">88000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i51990bde857d4a5db236e8926558a29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE4LTctMS0xLTc4MDQ5_8729e7bf-628d-4f30-a9b5-98c680ee871f"
      unitRef="usd">88000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i0441844ced744791a772d411eed7ca9f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTEtMS0xLTc4MDQ5_ac96c4b7-d9e2-40bb-817e-d5b0eea0c5b4"
      unitRef="usd">824000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i904c347e51a64fb59bc57777f21d4ac5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTMtMS0xLTc4MDQ5_4a4919a3-e103-4109-8e99-3f2ba630f440"
      unitRef="usd">41000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="if7f260a809bb49cb9e77ad6f5c2904a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTUtMS0xLTc4MDQ5_d85d8b4c-4423-420e-b317-5dc6a07824fb"
      unitRef="usd">88000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i89f714be3d7a47ffa4d705a6678f8d4e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTctMS0xLTc4MDQ5_07ce8a74-2bd4-42d6-9308-6445a3f2e180"
      unitRef="usd">953000000</elv:EquitySecurities>
    <us-gaap:OtherLongTermInvestments
      contextRef="i069417d1b9bb426dbfd0f19f51c445ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIwLTEtMS0xLTc4MDQ5_d2f19960-0eb5-429b-bb3f-414d596ac9e7"
      unitRef="usd">103000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ifca89489e7414de0a4fed48d20415ea2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIwLTMtMS0xLTc4MDQ5_a44ae722-4e28-44ab-84aa-334ef198815a"
      unitRef="usd">0</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="if117aa6b760a48b191a9336dd1386d0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzE5LTUtMS0xLTEwMTQzNA_17cb4aa5-ac31-4f0d-b36c-bff6b8d1ff93"
      unitRef="usd">0</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i9bdae597d08f410ca9c02ca9b55441e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIwLTctMS0xLTc4MDQ5_008f9e69-d2e6-472f-86b9-586ebe52b43b"
      unitRef="usd">103000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:SecuritiesHeldAsCollateralAtFairValue
      contextRef="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTMtMS0xLTc4MDQ5_f76728e6-f667-448f-8266-7940f54af6c0"
      unitRef="usd">2457000000</us-gaap:SecuritiesHeldAsCollateralAtFairValue>
    <us-gaap:SecuritiesHeldAsCollateralAtFairValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIxLTctMS0xLTc4MDQ5_4cf40da9-cd51-4c35-a7ea-799ea9659fcb"
      unitRef="usd">2457000000</us-gaap:SecuritiesHeldAsCollateralAtFairValue>
    <us-gaap:DerivativeAssets
      contextRef="ic1417f5c20d04886b4a1c28630457c0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIyLTMtMS0xLTc4MDQ5_c7654d69-7964-4bbc-90b6-6b06fd637a37"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie6b78fb8e9294d4091b91dfb2f7b8dfe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIyLTctMS0xLTc4MDQ5_a1455335-8ccd-44a6-8f1d-8cdab5eb539e"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c3650a094504772a0bf73a6172f2a67_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTEtMS0xLTc4MDQ5_28f33d36-32c8-474e-be95-0c0327e047ef"
      unitRef="usd">4494000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTMtMS0xLTc4MDQ5_470b07f6-0343-4721-a5b3-b1fde271ab7d"
      unitRef="usd">28712000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d2e3cdf76fb4346a9739172b0a28be0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTUtMS0xLTc4MDQ5_b7a271cb-4c36-4dc9-b13f-77a52804f4be"
      unitRef="usd">581000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzIzLTctMS0xLTc4MDQ5_909c2878-0c3b-4cd8-8c0f-c8e5cce3938a"
      unitRef="usd">33787000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ic1417f5c20d04886b4a1c28630457c0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI1LTMtMS0xLTc4MDQ5_ab017599-1505-4542-b0d6-4e4ead934508"
      unitRef="usd">60000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie6b78fb8e9294d4091b91dfb2f7b8dfe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI1LTctMS0xLTc4MDQ5_4172e083-9126-4e11-87e1-7a8d52b15c22"
      unitRef="usd">60000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i9e4b14e380af4e6f8c25a0531eca80ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI2LTMtMS0xLTc4MDQ5_b0ccfed3-35e0-4c1a-9d1d-82533af18c0c"
      unitRef="usd">60000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzI2LTctMS0xLTc4MDQ5_3269bf3b-d071-42e6-b4de-3c4bd9d666c5"
      unitRef="usd">60000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6ebaa3e81cfc4ec9b580beed5caa48af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMwLTEtMS0xLTc4MDQ5_52b93e9c-e7a8-4768-97b7-456ea6f43d6d"
      unitRef="usd">2415000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMwLTctMS0xLTc4MDQ5_5ce18132-aced-4bc7-8ebf-9c4fdb9030b9"
      unitRef="usd">2415000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d91da7322044ebeb41aac5b19dd9fa5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMyLTMtMS0xLTc4MDQ5_d59ca069-954d-45b9-8c31-37c1b2d2a42d"
      unitRef="usd">1432000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5cdcbbe5e2c4cc38bd73ff06c8b9f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMyLTctMS0xLTc4MDQ5_c23c5763-e20e-4d8c-981b-7fbde70fedd5"
      unitRef="usd">1432000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2aaff6ca3964450bafa714cc0aaec6db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMzLTMtMS0xLTc4MDQ5_d66df5ed-2eac-4611-840e-1798007c21a9"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfcbc3060b964c0eb745c3af7c301df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzMzLTctMS0xLTc4MDQ5_92852ce3-41f2-4394-b037-8442e4424f1e"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie41132adfcfc49268da644c34fda294a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM0LTMtMS0xLTc4MDQ5_f2ef9ce9-57f3-4d2d-be76-4348d691b184"
      unitRef="usd">347000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i911d18133f3a43c88a4a1ef0ca5fcbbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM0LTctMS0xLTc4MDQ5_5b573335-a0e1-464f-bbd5-5961d3b0760b"
      unitRef="usd">347000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92581736a99943b98dfe57570a7dba53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM1LTMtMS0xLTc4MDQ5_c0f42c14-c060-49f8-a1dd-d161b06a97b5"
      unitRef="usd">5621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia153a0252f0c4f25a894df66b87f8a12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM1LTctMS0xLTc4MDQ5_45f01846-5dfe-4242-8999-09a9ad38f7a4"
      unitRef="usd">5621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7de34994aae94c3fa1fe238756f73e72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM2LTMtMS0xLTc4MDQ5_3d46a43f-9734-4a31-b9b6-facc4825a88a"
      unitRef="usd">12027000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1333f2613ac4700882b9aa88ce86e8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM2LTUtMS0xLTc4MDQ5_4b4e3c30-3dc4-4ea1-ad48-6dfff1a66ec6"
      unitRef="usd">336000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2334e7c069664e34bdb994a9760d559a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM2LTctMS0xLTc4MDQ5_08ffa62f-e12a-4418-8611-cf6a6ba07684"
      unitRef="usd">12363000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3dac1ad1470b43dab49c726357aa7ff8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM3LTMtMS0xLTc4MDQ5_2051ddce-ca72-45ed-97cd-68f3fece4fbd"
      unitRef="usd">2513000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c02d35e75f4475c925518ec594b0833_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM3LTUtMS0xLTc4MDQ5_0e6225f8-c0f1-4347-98b8-3f10be67c87f"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bf6477caab241859e5cf0650ec3947c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM3LTctMS0xLTc4MDQ5_c1b48eb1-0ec9-4c18-9e11-fad2eaa8e8c9"
      unitRef="usd">2518000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3876e659055149f7a703040ca62a38d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM4LTMtMS0xLTc4MDQ5_461c1d61-6dfb-412b-a291-f6d2ad7b5b5e"
      unitRef="usd">1643000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0418a7408fb4b69aee3f6404d135a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM4LTctMS0xLTc4MDQ5_e211eeae-61f8-41e6-8168-2f1a02abd281"
      unitRef="usd">1643000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ea83cb6a8de4fa3949218ca98d32023_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM5LTMtMS0xLTc4MDQ5_4a74fe09-5ec7-4a9f-8720-962c75f9b72a"
      unitRef="usd">2888000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if19a9ee228de40aa8494169d2d2d10e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM5LTUtMS0xLTc4MDQ5_8bd44650-6403-450b-b6a8-efa13cc75f8c"
      unitRef="usd">19000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0894905483914d83a324be50305c8544_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzM5LTctMS0xLTc4MDQ5_35e8cd9a-b6cd-40a1-bd2f-949e7d455a9e"
      unitRef="usd">2907000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf99af398d9f47d5a429fe1dcacc1f44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQwLTMtMS0xLTc4MDQ5_a80b33a3-6551-4589-ac4f-403809e753af"
      unitRef="usd">26539000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4120bc1c539494db1a281d2596d5086_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQwLTUtMS0xLTc4MDQ5_2e2b239e-7154-45bf-8358-efee903c05aa"
      unitRef="usd">360000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ef64ace9ef94f91a76ea258c74686c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQwLTctMS0xLTc4MDQ5_c39ef076-0eeb-4f43-a487-77e68c25204f"
      unitRef="usd">26899000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <elv:EquitySecurities
      contextRef="i6e3257f7fe574daa85e3967b1d116931_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQyLTEtMS0xLTc4MDQ5_8acb42f9-10b5-4879-af97-b36153e44af6"
      unitRef="usd">1750000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i04fa6f9d293449e69c6dc3044ca3c4d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQyLTctMS0xLTc4MDQ5_c649e94e-6d05-4ad5-933c-3cc60c884f9f"
      unitRef="usd">1750000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i731f097a1855416da64a94d30b7089d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ0LTEtMS0xLTc4MDQ5_045962c2-7143-4262-b991-683b71ca13ac"
      unitRef="usd">8000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="ie7534f37a1c0488aa47b62fc88cc8dc0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ0LTMtMS0xLTc4MDQ5_912c1f65-f2e6-4676-8f8a-c38a20a66266"
      unitRef="usd">34000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="ibc437a887c994868be66d15b5875523e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ0LTctMS0xLTc4MDQ5_1d855260-3e4f-4d78-9fa4-dbf5f83e07f6"
      unitRef="usd">42000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="ib859e237e46b490d97c83b2fbc6eb7c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ1LTUtMS0xLTc4MDQ5_f04e9f8b-37fc-4e66-8387-757e985b7c36"
      unitRef="usd">89000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i29501ab2755d404f9726f590112ae654_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ1LTctMS0xLTc4MDQ5_46b99150-67d4-4782-b05a-8fa7b54d307c"
      unitRef="usd">89000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i3039f8072e324d98beb39105271bc417_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTEtMS0xLTc4MDQ5_5c860649-8857-43e7-b15f-3cf83965a8e2"
      unitRef="usd">1758000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i39da1e7e5b0d4e3faac6f5afb10e8022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTMtMS0xLTc4MDQ5_96ad58c6-9f4a-4f8d-8b37-322904ff4ac5"
      unitRef="usd">34000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="if8fcb396e62c4b998da85a181a469648_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTUtMS0xLTc4MDQ5_a212fb80-16d2-421d-8660-5c1e1f550c00"
      unitRef="usd">89000000</elv:EquitySecurities>
    <elv:EquitySecurities
      contextRef="i1831bed7a9a940b7b66b76e245b8018c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ2LTctMS0xLTc4MDQ5_3445bba4-ad02-481b-9678-5de1b31afdb9"
      unitRef="usd">1881000000</elv:EquitySecurities>
    <us-gaap:OtherLongTermInvestments
      contextRef="iaa94f2b63b1149839f52e2f831a1edef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTEtMS0xLTc4MDQ5_fba17010-197b-46c0-b437-79701f73dbf6"
      unitRef="usd">138000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i16eafcfee2cb4d9b8e93262638fce1f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTMtMS0xLTc4MDQ5_6c6e9c28-0a64-4c62-91f3-0a2a9c7b413a"
      unitRef="usd">0</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ie822cce3164245ebb93dd26d240e4175_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTUtMS0xLTc4MDQ5_800a906b-22c7-4952-9590-670dba8d07de"
      unitRef="usd">0</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i11de76f442c4431cada80f558aa8ffc8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ3LTctMS0xLTc4MDQ5_dbedc8b3-3a3b-4bfa-ade4-789d96811da7"
      unitRef="usd">138000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:SecuritiesHeldAsCollateralAtFairValue
      contextRef="id2414d6cfbbd4765bf4121c62ca67493_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ4LTMtMS0xLTc4MDQ5_293cf6be-c472-4e53-906a-972b872d4a27"
      unitRef="usd">2155000000</us-gaap:SecuritiesHeldAsCollateralAtFairValue>
    <us-gaap:SecuritiesHeldAsCollateralAtFairValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ4LTctMS0xLTc4MDQ5_77bb4580-148d-4f00-9ad9-3b8041fac057"
      unitRef="usd">2155000000</us-gaap:SecuritiesHeldAsCollateralAtFairValue>
    <us-gaap:DerivativeAssets
      contextRef="i9d3e183cefc842978e11387775c98361_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ5LTMtMS0xLTc4MDQ5_d48d4b1f-3e0b-4a69-9818-f04b54392890"
      unitRef="usd">19000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i44e5a8e93e844062b0f224b3e55aed8e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzQ5LTctMS0xLTc4MDQ5_77f449f6-83b8-440d-b4bc-bc403ca09ac3"
      unitRef="usd">19000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6ebaa3e81cfc4ec9b580beed5caa48af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTEtMS0xLTc4MDQ5_6f2cb143-81cd-4b61-af1b-18c781afe015"
      unitRef="usd">4311000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id2414d6cfbbd4765bf4121c62ca67493_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTMtMS0xLTc4MDQ5_bfa9f9fc-053d-4bfc-b507-0c3006108272"
      unitRef="usd">28747000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5f9bbbaabb04060a11a6fd22a348392_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTUtMS0xLTc4MDQ5_243a024d-f0a8-490d-abe2-fea63029db17"
      unitRef="usd">449000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUwLTctMS0xLTc4MDQ5_29610c49-45fc-4b0e-9e7a-12682355e39c"
      unitRef="usd">33507000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i9d3e183cefc842978e11387775c98361_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUyLTMtMS0xLTc4MDQ5_1e5d6c11-a297-4533-8a4a-993531d1986e"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i44e5a8e93e844062b0f224b3e55aed8e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUyLTctMS0xLTc4MDQ5_0793933a-d953-48a4-8ddf-8e7be743d8ec"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="id2414d6cfbbd4765bf4121c62ca67493_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUzLTMtMS0xLTc4MDQ5_ea42e158-d0c2-4372-9dd1-00bb1fdbd6ec"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1OWVmMDBkODk0MWU0Y2E2Yjk0NGFkNTljOGQ1NzJiZi90YWJsZXJhbmdlOjU5ZWYwMGQ4OTQxZTRjYTZiOTQ0YWQ1OWM4ZDU3MmJmXzUzLTctMS0xLTc4MDQ5_3bf3e16a-a70c-415a-ab56-9e86d8a2fcf5"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjc4_82925a97-97fa-46b0-92fb-0ccb95cf7ad0">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Residential&lt;br/&gt;Mortgage-&lt;br/&gt;backed&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Asset-Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_bc7b057c-e40d-4ec0-a595-106ef6f5cf76"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrealized gains or losses included in net income related to assets still held at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_d05ba9e2-dc62-4342-bf97-3e510ed1fe1b"&gt;19&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrealized gains or losses included in net income related to assets still held at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_2ba07e4b-fcdc-4676-b0c8-d954b5d1651c"&gt;(22)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized in accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrealized gains or losses included in net income related to assets still held at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i9bede030acd1445e92925c2eb16fa9a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItMS0xLTEtNzgwNDk_24258be3-8f7e-4540-a35b-8d104fae534f"
      unitRef="usd">336000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i0f18267c023f408a99a89907537030c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItMy0xLTEtNzgwNDk_2418fe3b-7fdd-4cc0-a1ff-6c547a2afffb"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="icf9d8f64f3ad45a084579266e307020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItNy0xLTEtNzgwNDk_145b477c-90fa-4412-99b7-1f296a128c1e"
      unitRef="usd">19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2b4ecb9767514086a037990f8b694328_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItOS0xLTEtNzgwNDk_10aaabbf-9ae6-4998-9065-7cf1632d3db9"
      unitRef="usd">89000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzItMTEtMS0xLTc4MDQ5_976d5749-b8f0-488d-8f3a-2784395a97d3"
      unitRef="usd">449000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMS0xLTEtNzgwNDk_2f66062f-12ba-409a-a389-d2f2dc8d6bde"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMy0xLTEtNzgwNDk_327504fe-bf6a-4fb9-b234-93547d3ae483"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtNy0xLTEtNzgwNDk_6e4fece4-4d8b-4cf2-bb6d-945f6f6228dd"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtOS0xLTEtNzgwNDk_9182893e-8e25-470f-aa99-5e9933f77e88"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzQtMTEtMS0xLTc4MDQ5_08381840-48b3-4e34-92fa-1e0673785619"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtMS0xLTEtNzgwNDk_2cab41fc-0d56-48fb-9a7b-513f17f7eaee"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtMy0xLTEtNzgwNDk_0da04bb6-f63e-463e-8abc-e195fc2bcd87"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtNy0xLTEtNzgwNDk_5ba83bac-ec1a-4b0b-ae0f-66029c53543b"
      unitRef="usd">-16000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtOS0xLTEtNzgwNDk_6b199b3c-729a-4f65-b479-6bfc166723cc"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzUtMTEtMS0xLTc4MDQ5_079ac2e4-212f-4ae3-baca-c7879687592d"
      unitRef="usd">-17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtMS0xLTEtNzgwNDk_b3b3874e-85a5-468f-b7bc-b2ae9cace29b"
      unitRef="usd">56000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtMy0xLTEtNzgwNDk_1a008d8e-141a-4a74-960c-389c7c4fae7e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtNy0xLTEtNzgwNDk_3a3ff631-2ab9-46ed-aa27-37000dcfae61"
      unitRef="usd">370000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtOS0xLTEtNzgwNDk_760d35ba-a1d4-4ed2-b530-a4e554a27ab2"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzYtMTEtMS0xLTc4MDQ5_27d10fd7-b4a5-420c-873d-9296ca996873"
      unitRef="usd">443000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctMS0xLTEtNzgwNDk_594dcef5-847f-4716-8d39-d2361922b6ad"
      unitRef="usd">210000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctMy0xLTEtNzgwNDk_6d697f96-6013-43ed-ad0b-95c0833181d4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctNy0xLTEtNzgwNDk_fa887380-1e3d-4ff0-acca-797af079058b"
      unitRef="usd">14000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctOS0xLTEtNzgwNDk_d9af334a-6bda-475d-bde0-497b494dcf74"
      unitRef="usd">18000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzctMTEtMS0xLTc4MDQ5_149bf339-00e7-4ba3-9ac2-1b5ec26b9035"
      unitRef="usd">242000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtMS0xLTEtNzgwNDk_f758b09b-fa41-410b-aec8-b9ed6826ecb3"
      unitRef="usd">41000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtMy0xLTEtNzgwNDk_da351515-c8d8-4763-ab82-32fcac3c82d5"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtNy0xLTEtNzgwNDk_00b2c6c7-60bd-4538-be1b-789bd89a6bb4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtOS0xLTEtNzgwNDk_e2ad9408-e921-440c-86b0-d22888a7a5d6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzgtMTEtMS0xLTc4MDQ5_c4bf764f-89e3-43d0-82e6-a9880ddaf030"
      unitRef="usd">41000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktMS0xLTEtNzgwNDk_ec1fa303-d5fe-44d8-9f1c-883a90af8629"
      unitRef="usd">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktMy0xLTEtNzgwNDk_0e9d4dfb-9f65-4547-97ee-83b5693d16cc"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktNy0xLTEtNzgwNDk_1119c88c-6bab-419d-8a45-e0a5a612a360"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktOS0xLTEtNzgwNDk_2c4e8081-1171-432e-827f-aaf72aaa86fd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzktMTEtMS0xLTc4MDQ5_5be1b2c9-df71-4a73-bc8f-c67835af0557"
      unitRef="usd">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTEtMS0xLTc4MDQ5_43816cb4-8fb2-4779-b78b-b52d62696118"
      unitRef="usd">12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTMtMS0xLTc4MDQ5_a3bbcaec-0b50-4469-a156-e2736da8b4e0"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTctMS0xLTc4MDQ5_eb94360f-a942-4a89-89ba-b828c6b2b2b0"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTktMS0xLTc4MDQ5_d2d12051-7da3-4dcb-a083-6bd7c1647731"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEwLTExLTEtMS03ODA0OQ_3c3a2056-1d8b-4827-8162-ba5ad9f12836"
      unitRef="usd">19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i72f47d433c9f44b894af80bfe9cba63a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTEtMS0xLTc4MDQ5_8851c7c2-0bcb-40c8-a4c8-d04635b5220d"
      unitRef="usd">137000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="idb1c35519dba4644a3fb343be2411cac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTMtMS0xLTc4MDQ5_913460f4-4c47-4a3a-b5b4-c3e0b0d15e62"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id3211a2672ef480891cfd22783436bf0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTctMS0xLTc4MDQ5_efc0a8ca-720f-4195-8e1f-e2a1b9328e59"
      unitRef="usd">356000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="iaa94c0104acc4bf89ee5934a42f0fbc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTktMS0xLTc4MDQ5_8e07e930-718c-4607-be57-08d6b8a9dbdc"
      unitRef="usd">88000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzExLTExLTEtMS03ODA0OQ_a3833b62-43c9-4504-b2c6-0477510cbd93"
      unitRef="usd">581000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="ib0da50324473475ca1c74bc7dbcbb9a5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTEtMS0xLTc4MDQ5_1af6de6a-3e25-4409-a136-9f5cb669534f"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i3e4c774172504b819ea779511e90e19c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTMtMS0xLTc4MDQ5_6c5b276d-4d20-423f-b533-e6434a9dd81d"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i280f35f8b5b04f319af791b8a03f056f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTctMS0xLTc4MDQ5_170eb95a-7c85-4070-a18b-e3c67dfd7d78"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="ia2de0609594c41d68360c2841dd434b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTktMS0xLTc4MDQ5_61057be4-70bf-4e1f-ba6b-ff6e4de2df07"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzEyLTExLTEtMS03ODA0OQ_f0368487-511e-495a-8071-2669167f8660"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i5d998702002443e1bdceee7c1cd3cda9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTEtMS0xLTc4MDQ5_cadd7826-8332-4fad-b14a-a0603bcace56"
      unitRef="usd">325000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i360abcc2cf914906ae4e38a91bc64c5f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTMtMS0xLTc4MDQ5_84c9ce33-0ddb-43d1-b7c9-a67747bbcb5d"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i50e9582cb2ed44069090ba97e16cd18e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTctMS0xLTc4MDQ5_12ceface-24bd-4292-a3bc-46b0c4d7c232"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i79df65678198415585bd1eadb7bbe9b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTktMS0xLTc4MDQ5_2fca4248-1132-482b-8b39-16edf4a8a51b"
      unitRef="usd">60000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE1LTExLTEtMS03ODA0OQ_d97d0b93-ca79-46fe-8675-d378eed769bf"
      unitRef="usd">392000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTEtMS0xLTc4MDQ5_c7640a14-90dd-48bb-967e-bb956bf8a9a4"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTMtMS0xLTc4MDQ5_cc956c11-add5-413e-9091-9964dfce8277"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTctMS0xLTc4MDQ5_500e486b-fafb-4035-a0c0-403a16072368"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTktMS0xLTc4MDQ5_674005f9-c5d1-4da8-9daa-e4fe8dbac91e"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE3LTExLTEtMS03ODA0OQ_394f7169-e315-45fa-b040-96f2a1de2f50"
      unitRef="usd">19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTEtMS0xLTc4MDQ5_0bc7e392-b186-4fa2-ba8b-6c26d70ae83b"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTMtMS0xLTc4MDQ5_4b4cde91-907c-4b9b-aced-5e6a9075b4fc"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTctMS0xLTc4MDQ5_4866b247-8b1e-4c9d-96e5-49a3da06b869"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTktMS0xLTc4MDQ5_538d06f6-cbc4-4e2c-80ef-c12e886ae5b9"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE4LTExLTEtMS03ODA0OQ_853558ca-eedf-4c4e-86ca-e68b77fc06a8"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTEtMS0xLTc4MDQ5_335e89b3-4ff8-4c49-94e8-0371df80c42a"
      unitRef="usd">179000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTMtMS0xLTc4MDQ5_14667765-335a-4995-b2aa-813fdad2d568"
      unitRef="usd">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTctMS0xLTc4MDQ5_b238d474-f6bd-4edc-8da3-1d17775d6a7a"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTktMS0xLTc4MDQ5_ff22cea9-f770-47ed-960a-520b8858b774"
      unitRef="usd">16000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzE5LTExLTEtMS03ODA0OQ_7bdd5cc0-c0a6-4fe0-9e04-4f4d202df3e4"
      unitRef="usd">216000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTEtMS0xLTc4MDQ5_3f9421e9-7f1c-4902-b71d-7d141164ebd6"
      unitRef="usd">18000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTMtMS0xLTc4MDQ5_5e844f5d-f835-4fce-be15-1b60acb42f9c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTctMS0xLTc4MDQ5_cdd305f8-4338-489d-8de1-3a3d8fbe6405"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTktMS0xLTc4MDQ5_ace083a3-4c15-4d1a-b288-1e4b9cb889b1"
      unitRef="usd">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIwLTExLTEtMS03ODA0OQ_3a14a812-b3be-43f3-b942-9fcf35faab2c"
      unitRef="usd">22000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTEtMS0xLTc4MDQ5_6b202b37-ac19-4b2b-87ab-8f66fbd97999"
      unitRef="usd">157000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTMtMS0xLTc4MDQ5_1db8f01b-c8ed-4acc-8c4a-c4de80cae4c8"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTctMS0xLTc4MDQ5_54b6d0ae-f8a6-49e4-a556-54fcc359037d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTktMS0xLTc4MDQ5_7eaf4254-52c4-4085-ae1d-ca419936380a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIxLTExLTEtMS03ODA0OQ_0ea39b1c-b07e-4ee4-a65a-219868139a88"
      unitRef="usd">157000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTEtMS0xLTc4MDQ5_57b61985-56c6-4c78-ac4a-a7501981b0b7"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTMtMS0xLTc4MDQ5_0761ad0f-07c9-4a33-801c-a3ed50bf3dda"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTctMS0xLTc4MDQ5_4becb91a-7007-4d4f-99dd-1ddabb1d6e3f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTktMS0xLTc4MDQ5_11149410-4ff7-426e-95a6-d69453cfd247"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIyLTExLTEtMS03ODA0OQ_b0aa346f-f5c6-4d9b-a2d5-6b7f113cb8f4"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTEtMS0xLTc4MDQ5_bd3be886-8213-4c45-8c96-b900912b80dd"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTMtMS0xLTc4MDQ5_fbf26b01-9b14-4ce3-8ef0-25acc3fd5d3b"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTctMS0xLTc4MDQ5_8e7907d5-ec72-4f26-9398-b6443f5c5ddc"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTktMS0xLTc4MDQ5_9348ebcb-e3a5-4eec-91f7-1e008ea93590"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzIzLTExLTEtMS03ODA0OQ_bca3139f-0f05-482f-997b-1650be5d8eab"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i9bede030acd1445e92925c2eb16fa9a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTEtMS0xLTc4MDQ5_12169e64-ecde-426f-8257-13010cd144ee"
      unitRef="usd">336000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i0f18267c023f408a99a89907537030c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTMtMS0xLTc4MDQ5_f44a4452-9275-4848-994c-7b309aaeced0"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="icf9d8f64f3ad45a084579266e307020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTctMS0xLTc4MDQ5_145e5ca8-c562-4c5d-9f27-004a737edc70"
      unitRef="usd">19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2b4ecb9767514086a037990f8b694328_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTktMS0xLTc4MDQ5_1f183ca9-b5bd-48a6-a0e1-a0b614d84dee"
      unitRef="usd">89000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI0LTExLTEtMS03ODA0OQ_28b7dd4d-284b-483b-a5ce-fd1e0f83c332"
      unitRef="usd">449000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="idb612f5a191c437cb13598e31f479571_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTEtMS0xLTc4MDQ5_d42c6893-dd02-414a-9ce8-239bd48a0e7b"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="id0fba3646e8b47bc99e4143d8caab96e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTMtMS0xLTc4MDQ5_825e3d2d-156a-4ce8-b9d5-0e9b3cf1801c"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i865d332876a146d48476c774263e9f01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTctMS0xLTc4MDQ5_364a6467-7173-4a0b-823f-ff452a9706ec"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i8a3e6302e3b14226b542816533c905f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTktMS0xLTc4MDQ5_34414dff-c646-4abb-9397-8217352aa8a2"
      unitRef="usd">18000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI1LTExLTEtMS03ODA0OQ_b977a0ff-e2ab-489d-9a4d-b461f8279588"
      unitRef="usd">18000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i876b8cfa43904577b851c227ca0f5cf5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTEtMS0xLTc4MDQ5_c81a93e3-542e-4c88-8600-ac19f0dd857b"
      unitRef="usd">303000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i8098a79a2da540da9b0adddcc15af4af_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTMtMS0xLTc4MDQ5_300e6ec8-4cc2-473b-bbb0-fe6a423f20a3"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i7ac255a2c1404484817fa038dbd46f96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTctMS0xLTc4MDQ5_d60ae7ac-c485-44db-a79d-d9f9afdabb1f"
      unitRef="usd">7000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i686937bb287f43208495ac30ebad9562_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTktMS0xLTc4MDQ5_ad894ce5-b831-4826-9b10-147237a51515"
      unitRef="usd">85000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzI4LTExLTEtMS03ODA0OQ_0c0cf6fc-7b1f-4a62-9482-26b0180e379f"
      unitRef="usd">397000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTEtMS0xLTc4MDQ5_f8092390-6938-4286-8b31-c939dcd49f0d"
      unitRef="usd">-3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTMtMS0xLTc4MDQ5_17cc2710-d8be-44b1-9b1c-4eb64bf5bea1"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTctMS0xLTc4MDQ5_ac9da744-e27a-457a-928d-6c390ad34e52"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTktMS0xLTc4MDQ5_db139a2c-5fff-4fbe-8fc6-744abe4b7c29"
      unitRef="usd">-19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMwLTExLTEtMS03ODA0OQ_37c211b3-24e9-4a6b-8362-444fb8973753"
      unitRef="usd">-22000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTEtMS0xLTc4MDQ5_dd550f98-80b0-48b0-8300-ec7f9638a26f"
      unitRef="usd">-5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTMtMS0xLTc4MDQ5_9c6f0659-090d-4a4a-96fb-16c137f3c7fb"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTctMS0xLTc4MDQ5_85440389-5cc1-42ea-829f-68aecc3efe98"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTktMS0xLTc4MDQ5_5acc522f-3ad7-49c0-bd48-cd848023667c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMxLTExLTEtMS03ODA0OQ_341b0730-3f2a-4139-b5d8-8425d7cebe61"
      unitRef="usd">-5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTEtMS0xLTc4MDQ5_7c111388-07a3-47dd-a58e-ac34c29abbff"
      unitRef="usd">85000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTMtMS0xLTc4MDQ5_1fb653e2-90b2-4cb7-a713-eafa94daef7b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTctMS0xLTc4MDQ5_b186597f-cc42-4e15-a14a-d84fe5c80adc"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTktMS0xLTc4MDQ5_53b85dea-9d89-4843-bde0-3abf12c3bc78"
      unitRef="usd">16000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMyLTExLTEtMS03ODA0OQ_7ea4ac9e-1ee4-4f14-a163-98f2f0c1428d"
      unitRef="usd">101000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTEtMS0xLTc4MDQ5_4865ff51-01ce-4720-86ca-6d14920501f6"
      unitRef="usd">19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTMtMS0xLTc4MDQ5_22eb3e04-571a-422c-a0c0-0b632a6c2fca"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTctMS0xLTc4MDQ5_45945831-ebf5-46fb-915c-fb3269c8a31d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTktMS0xLTc4MDQ5_3693d19a-a6ec-4fe0-8e8e-ddff8e470bcc"
      unitRef="usd">22000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzMzLTExLTEtMS03ODA0OQ_d84b7a55-3dde-45d8-a0b5-2ef88b7dcfd3"
      unitRef="usd">41000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTEtMS0xLTc4MDQ5_d8f891c9-1241-4618-9db9-faa958f5611e"
      unitRef="usd">44000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTMtMS0xLTc4MDQ5_d15e6b6a-b97a-4c1f-9354-d7b445c7d5ca"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTctMS0xLTc4MDQ5_28a0beb2-02ff-427e-a88e-1681065b5970"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTktMS0xLTc4MDQ5_c62f1db4-9b33-492e-8f38-0f954d2fe2bd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM0LTExLTEtMS03ODA0OQ_112719ba-301d-4305-912e-e00bcb04366d"
      unitRef="usd">46000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTEtMS0xLTc4MDQ5_88b6719d-4e1b-4ca7-9447-83d85e03339e"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTMtMS0xLTc4MDQ5_a7eb97fb-8abe-4e02-8218-3cae2e060624"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTctMS0xLTc4MDQ5_cad8ac79-6845-4db2-83ee-353fbd4ab361"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTktMS0xLTc4MDQ5_2b025f94-29d0-49e4-a000-5b985b5f03d4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM1LTExLTEtMS03ODA0OQ_f7c9cc8f-e10f-444c-baea-8d328e4df313"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTEtMS0xLTc4MDQ5_4ae6a334-f00a-4808-a03c-0feeb85c10dd"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTMtMS0xLTc4MDQ5_7e5ebbc4-e579-436b-bdf2-8c4eccc07575"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTctMS0xLTc4MDQ5_b2191fcf-9426-4276-9267-f9aa954ab85f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTktMS0xLTc4MDQ5_b1d8e567-1b0d-44aa-ba4f-8dcc79042785"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM2LTExLTEtMS03ODA0OQ_cea8fc55-a23b-4aa6-8747-de2b3bc91c62"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i5d998702002443e1bdceee7c1cd3cda9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTEtMS0xLTc4MDQ5_e48345a5-16c8-4a52-8c93-8fcbb9235ca8"
      unitRef="usd">325000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i360abcc2cf914906ae4e38a91bc64c5f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTMtMS0xLTc4MDQ5_a93db08f-b48e-4511-b75e-2ca156b468bf"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i50e9582cb2ed44069090ba97e16cd18e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTctMS0xLTc4MDQ5_c6b4ed3b-0b0e-4ee9-8d68-f2e97cccd9fc"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i79df65678198415585bd1eadb7bbe9b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTktMS0xLTc4MDQ5_289962c6-3808-4be7-aff5-1bddf7981df4"
      unitRef="usd">60000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM3LTExLTEtMS03ODA0OQ_eef705fd-2e3b-454a-b9bb-5b746934ee46"
      unitRef="usd">392000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i440208aefdbd4ff9a3000ae1f540666c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTEtMS0xLTc4MDQ5_261498b0-d1f2-423d-936a-7dcdad0ec475"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="ic9f8371a966846ba984db6812d5fee42_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTMtMS0xLTc4MDQ5_68dae3bb-ae2a-4281-9365-40de45ea3a5c"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i42b600fabff64389bc7e8c01fda0d53e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTctMS0xLTc4MDQ5_2c83b6fc-4973-4e6b-84f1-39d9253fbbd5"
      unitRef="usd">0</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i299822b39f5f4e19910510482e4c5dcb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTktMS0xLTc4MDQ5_1b59a1c3-c563-436c-af94-d469539de223"
      unitRef="usd">-19000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTo1NWMzMTNhYjhjNDE0OWUwYjczZWU2ZmNjZGZmYzcyOS90YWJsZXJhbmdlOjU1YzMxM2FiOGM0MTQ5ZTBiNzNlZTZmY2NkZmZjNzI5XzM4LTExLTEtMS03ODA0OQ_564d2a6c-add6-4d71-8af6-857401f834e3"
      unitRef="usd">-19000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90ZXh0cmVnaW9uOjQzNjAwMzJiNzQ5MDRmZTA4ZjJmNGZmYTc5NjRiMGQ1XzEzMjgx_86e7af94-0460-4d87-bd4b-705cec69c1e3">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debentures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debentures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock>
    <us-gaap:OtherLongTermInvestments
      contextRef="i29275f18d1a443b99c9691261dec2159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtMS0xLTEtNzgwNDk_bf8e531f-8567-4d29-9d56-1341a6b1e267"
      unitRef="usd">5582000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ib761ace65d4940a186ff76782f95901f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtNS0xLTEtNzgwNDk_f7374182-fd01-49a4-8c43-2634e8c4c7a0"
      unitRef="usd">0</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtNy0xLTEtNzgwNDk_c0d36179-cc20-4b01-9444-94a1decf9bcd"
      unitRef="usd">5582000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzQtOS0xLTEtNzgwNDk_67039389-d5c2-449a-8334-08c43052092a"
      unitRef="usd">5582000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="i29275f18d1a443b99c9691261dec2159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctMS0xLTEtNzgwNDk_12609f38-8d1b-4376-b306-d090d23b90aa"
      unitRef="usd">265000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="ib761ace65d4940a186ff76782f95901f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctNS0xLTEtNzgwNDk_1ab35014-1440-4bea-a82a-00316186edf0"
      unitRef="usd">265000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctNy0xLTEtNzgwNDk_6664ed04-4b87-466b-bb78-f0dea3580a1f"
      unitRef="usd">0</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzctOS0xLTEtNzgwNDk_fc17ec43-ac63-4d84-b829-9a91416f2244"
      unitRef="usd">265000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:NotesPayable
      contextRef="i29275f18d1a443b99c9691261dec2159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktMS0xLTEtNzgwNDk_bd48f265-8901-4e2b-b91a-87ad55d0ca50"
      unitRef="usd">23786000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="ib761ace65d4940a186ff76782f95901f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktNS0xLTEtNzgwNDk_617d3f98-6dd6-419a-9a5a-bfca6e7353da"
      unitRef="usd">21861000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktNy0xLTEtNzgwNDk_7fa19e82-bcb8-4889-aca7-5c6356a0c06e"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzktOS0xLTEtNzgwNDk_47e8b023-ca31-4a04-bd2a-93b2fa1066d0"
      unitRef="usd">21861000000</us-gaap:NotesPayable>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i29275f18d1a443b99c9691261dec2159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTEtMS0xLTc4MDQ5_b334438b-6afb-45a4-9d51-6c3b727e8881"
      unitRef="usd">63000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ib761ace65d4940a186ff76782f95901f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTUtMS0xLTc4MDQ5_ff8437a2-dcfc-44cd-9e07-d0b9192a8c00"
      unitRef="usd">463000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i8f400c669aa243fc80d850a5a79e4aab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTctMS0xLTc4MDQ5_89c3675c-d9b5-4751-a1ce-2f5b64555cc4"
      unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i813b76aca5e84f95975d45509f90c61a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzEwLTktMS0xLTc4MDQ5_3f6c5208-4341-4c0f-aeae-1ccc8349eaac"
      unitRef="usd">463000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTEtMS0xLTc4MDQ5_7d443573-d8c5-4af9-8c5a-0e06ad81a1e9"
      unitRef="usd">5087000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTUtMS0xLTc4MDQ5_1ac4cbb4-d364-4530-8bf2-1b6202debaa5"
      unitRef="usd">0</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTctMS0xLTc4MDQ5_d9a123d0-ccd4-4a45-99de-553a2c040ad8"
      unitRef="usd">5087000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE0LTktMS0xLTc4MDQ5_36a17a0f-f551-4009-b6fe-fd630d71ea07"
      unitRef="usd">5087000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTEtMS0xLTc4MDQ5_a414d610-be7b-41ec-aec7-a77893d89e57"
      unitRef="usd">275000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="ida04d4221bb546bc95004ba270b1eebb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTMtMS0xLTc4MDQ5_d0516923-1474-461d-bc5a-20265fdbbbf3"
      unitRef="usd">0</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTUtMS0xLTc4MDQ5_34b2120d-8012-4086-8215-ae7a80ec5b23"
      unitRef="usd">275000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTctMS0xLTc4MDQ5_3df5592d-9306-42bb-a180-f4eb1c803134"
      unitRef="usd">0</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE3LTktMS0xLTc4MDQ5_7542af30-3358-4e6d-a241-9e4371ce090f"
      unitRef="usd">275000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:CommercialPaper
      contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTEtMS0xLTc4MDQ5_08974f72-6f40-4cca-974c-e81bb128b8a5"
      unitRef="usd">300000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTUtMS0xLTc4MDQ5_da3a2430-4409-474c-aecf-bc8a984c55ec"
      unitRef="usd">300000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTctMS0xLTc4MDQ5_a1f6e9fc-f9a7-43af-9ef8-ef9519f9c1f3"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE4LTktMS0xLTc4MDQ5_1fdea2dd-6aa4-43e6-94f6-27f02310f48a"
      unitRef="usd">300000000</us-gaap:CommercialPaper>
    <us-gaap:NotesPayable
      contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTEtMS0xLTc4MDQ5_34f3f1b8-10a6-43a6-9807-b5360979ec44"
      unitRef="usd">22384000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTUtMS0xLTc4MDQ5_9774448f-c295-4dc5-a7ef-9931627b61bd"
      unitRef="usd">25150000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTctMS0xLTc4MDQ5_5470b838-0ae0-4019-8ec3-2acefd1c5246"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzE5LTktMS0xLTc4MDQ5_301f18d7-dc09-49d7-8d0a-f73b3fe1bbca"
      unitRef="usd">25150000000</us-gaap:NotesPayable>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="icfe7e2d076a6470199f2cd23ff79750c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTEtMS0xLTc4MDQ5_8b3b7be4-ebf1-44fa-a253-71ac88357197"
      unitRef="usd">72000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i817dd5ae5155486e828b00cf52760c8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTUtMS0xLTc4MDQ5_e8605e6b-1fb7-454e-8e66-a2898ea348bd"
      unitRef="usd">687000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ica9f2caf38d34d74b88b90af6bdd4c44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTctMS0xLTc4MDQ5_f12bd9da-37f0-487f-b1a8-2def28b0698a"
      unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i616b40ce7f3445a1aec6b99aa1a6e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTUvZnJhZzo0MzYwMDMyYjc0OTA0ZmUwOGYyZjRmZmE3OTY0YjBkNS90YWJsZTpiY2JmYjE2ZDIxZDY0MjgyOGI4NzMwNDliOTM3NjQzZi90YWJsZXJhbmdlOmJjYmZiMTZkMjFkNjQyODI4Yjg3MzA0OWI5Mzc2NDNmXzIwLTktMS0xLTc4MDQ5_c7ef72b6-e438-47f2-b8c4-7fa7672637ed"
      unitRef="usd">687000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUzMTE_ce458c4b-7f1a-44ba-ba9d-7e31b2e2ab00">Income Taxes&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred income taxes at December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debt reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal and state intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign (including Puerto Rico) intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognized $137 and $103 of deferred tax asset under the caption &#x201c;Other noncurrent assets&#x201d; at December 31, 2022 and 2021, respectively. We recognized $2,034 and $2,805 of deferred tax liability under the caption &#x201c;Deferred tax liabilities, net&#x201d; at December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we have established U.S. deferred taxes for undistributed earnings from certain non-U.S. subsidiaries, which are included in the Investment basis component above, consistent with prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign (including Puerto Rico)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local current tax expense is reported gross of federal benefit in the preceding table, and includes amounts related to audit settlements, uncertain tax positions, state tax credits and true up of prior years&#x2019; tax. Such items are included on a net of federal tax basis in multiple lines in the following rate reconciliation table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income taxes net of federal tax expense/benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax exempt interest and dividends received deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HIP fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis adjustments from recent acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, we recognized income tax expense of $1,750, or $7.21 per diluted share. The decrease in effective income tax rate is primarily due to the impact of geographic changes in the mix of 2022 earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we recognized income tax expense of $1,830, or $7.41 per diluted share. The HIP Fee payment was eliminated beginning in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we recognized income tax expense of $1,666, or $6.55 per diluted share, which included income tax expense of $330, or $1.30 per diluted share, as a result of the non-tax deductibility of the HIP Fee payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is included in the amounts described in the following paragraph. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was $328 and $250 at December&#160;31, 2022 and 2021, respectively. Also included in the table above, at December&#160;31, 2022, is $2 that would be recognized as an adjustment to additional paid-in capital, which would not affect our effective tax rate. In addition to the contingent liabilities included in the table above, we filed protective state income tax refund claims of approximately $92 and $310 for 2022 and 2017, respectively. There were no equivalent protective state income tax refund claims filed in 2021, 2020, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020 we recognized net interest expense of $13, $9 and $7, respectively. We had accrued approximately $55 and $42 for the payment of interest at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, as further described below, certain tax years remain open to examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) and various state, local and foreign authorities. As a result of these examinations and discussions with taxing agencies, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could be reduced within a range of approximately $33 to $143.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a member of the IRS Compliance Assurance Process (&#x201c;CAP&#x201d;). The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the IRS examination of our 2022 and 2021 tax years continues to be in process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported in selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had federal net operating loss carryforwards of $160 that will expire beginning 2032 through 2042 and $109 that have an indefinite carryforward period. State net operating loss carryforwards expire beginning 2023 through 2042, with some having an indefinite carryforward period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes receivable totaled $440 and $173 at December&#160;31, 2022 and 2021, respectively. We recognize the income tax receivable as an asset under the caption &#x201c;Other current assets&#x201d; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020, federal income taxes paid totaled $1,594, $1,299 and $1,790, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUzMDA_a604556f-adec-47b5-8d70-1098933242a7">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred income taxes at December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debt reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal and state intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign (including Puerto Rico) intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzMtMS0xLTEtNzgwNDk_b4046b3b-4639-4a0c-b5b7-abbf7462a1db"
      unitRef="usd">379000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzMtMy0xLTEtNzgwNDk_1dc81b4c-474f-4ec9-afd3-4fdda02e8242"
      unitRef="usd">511000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzUtMS0xLTEtNzgwNDk_f77e70fb-c52e-44f2-8605-de34e0fc8402"
      unitRef="usd">301000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzUtMy0xLTEtNzgwNDk_831040dd-9783-4fb7-aaee-6b3f45e8433a"
      unitRef="usd">246000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzYtMS0xLTEtNzgwNDk_3c855650-75e3-4536-a589-81d0f7272cff"
      unitRef="usd">147000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzYtMy0xLTEtNzgwNDk_8972a387-cfbc-4084-ac55-f62df73967e7"
      unitRef="usd">156000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <elv:DeferredTaxAssetsLeasingArrangements
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzktMS0xLTEtNzgwNDk_5b67b2c2-7d8c-4fb4-8fb2-bc6fa392a860"
      unitRef="usd">200000000</elv:DeferredTaxAssetsLeasingArrangements>
    <elv:DeferredTaxAssetsLeasingArrangements
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzktMy0xLTEtNzgwNDk_2e36f1f3-a6c8-490b-b40a-ecf83d7018ad"
      unitRef="usd">216000000</elv:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEwLTEtMS0xLTc4MDQ5_370345c1-779e-4128-bcc0-3100326eac1d"
      unitRef="usd">173000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEwLTMtMS0xLTc4MDQ5_27c8a35f-a05f-4339-aadd-3a877d218db1"
      unitRef="usd">170000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzExLTEtMS0xLTc4MDQ5_37fc8853-6cb1-4314-b5f0-69a8b375d602"
      unitRef="usd">34000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzExLTMtMS0xLTc4MDQ5_93c69f3e-709b-483a-a05e-6382b6fc8106"
      unitRef="usd">35000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEyLTEtMS0xLTc4MDQ5_e211c5b3-04ef-488d-9992-e4a2196ab329"
      unitRef="usd">208000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEyLTMtMS0xLTc4MDQ5_a0d1d39c-f7a9-4789-80a4-1576c5f55a19"
      unitRef="usd">201000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTEtMS0xLTk5OTg3_7d4317aa-153e-4200-b78c-c6ac00d337ff"
      unitRef="usd">340000000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTMtMS0xLTk5OTg5_f6f59637-457b-4953-9f08-b46933ddd0ad"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTEtMS0xLTc4MDQ5_63ee1f87-7735-4d55-b032-2beff16620e3"
      unitRef="usd">267000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzEzLTMtMS0xLTc4MDQ5_c4213042-98f1-4ced-8ece-77f3c2d78a19"
      unitRef="usd">207000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE0LTEtMS0xLTc4MDQ5_9c613fde-b34a-4f00-b6a8-217cef077c8e"
      unitRef="usd">2049000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE0LTMtMS0xLTc4MDQ5_23e82b1d-c11f-4eb5-8e0a-e4d2d78f5db7"
      unitRef="usd">1742000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE1LTEtMS0xLTc4MDQ5_9a0903c7-cb69-4de4-b128-e320470b3105"
      unitRef="usd">203000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE1LTMtMS0xLTc4MDQ5_287049c8-803e-4cb2-9ee8-6a66f5e10d08"
      unitRef="usd">212000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE2LTEtMS0xLTc4MDQ5_11d2e523-19f6-4ed1-bd04-add48333e413"
      unitRef="usd">1846000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE2LTMtMS0xLTc4MDQ5_5104c46e-190e-4fc0-b975-10506174cad9"
      unitRef="usd">1530000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE4LTEtMS0xLTc4MDQ5_e162f16c-f95f-4879-9b8a-e0056ac33f12"
      unitRef="usd">2059000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE4LTMtMS0xLTc4MDQ5_d9df69c5-f824-4db4-a87e-ef343939e547"
      unitRef="usd">2071000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <elv:DeferredTaxLiabilitiesNonUSIntangibleAssets
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE5LTEtMS0xLTc4MDQ5_12358d94-63ec-4760-a38d-5ba4ca8ad3a0"
      unitRef="usd">380000000</elv:DeferredTaxLiabilitiesNonUSIntangibleAssets>
    <elv:DeferredTaxLiabilitiesNonUSIntangibleAssets
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzE5LTMtMS0xLTc4MDQ5_4ffaccea-0520-4fe9-bee1-023415fc9c60"
      unitRef="usd">452000000</elv:DeferredTaxLiabilitiesNonUSIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIwLTEtMS0xLTc4MDQ5_83bc4c4a-76b7-444a-88f9-5b901d69b3bb"
      unitRef="usd">601000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIwLTMtMS0xLTc4MDQ5_cf02de20-27d2-49bc-a280-a2f9d209c6d4"
      unitRef="usd">777000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIxLTEtMS0xLTc4MDQ5_2fda6bfe-e314-49be-a5fe-571bcfc34e3e"
      unitRef="usd">62000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIxLTMtMS0xLTc4MDQ5_10b88a4a-61fa-4b2e-8c63-5bc285218062"
      unitRef="usd">45000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIyLTEtMS0xLTc4MDQ5_5cb6f51c-2138-461b-8fb0-b0d38113e6aa"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIyLTMtMS0xLTc4MDQ5_3abdad48-4a4b-4766-a36a-80f1ad0254a4"
      unitRef="usd">295000000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <elv:DeferredTaxliabilitiesDeferredExpenseRetirementbenefits
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIzLTEtMS0xLTc4MDQ5_ef8126c9-8b4e-4e88-bb6c-c2e0e5e4b05b"
      unitRef="usd">317000000</elv:DeferredTaxliabilitiesDeferredExpenseRetirementbenefits>
    <elv:DeferredTaxliabilitiesDeferredExpenseRetirementbenefits
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzIzLTMtMS0xLTc4MDQ5_5209da76-55a8-417e-8b23-f98ba03a16e6"
      unitRef="usd">314000000</elv:DeferredTaxliabilitiesDeferredExpenseRetirementbenefits>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI0LTEtMS0xLTc4MDQ5_6314aba5-be5d-4494-8786-1247c376a264"
      unitRef="usd">123000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI0LTMtMS0xLTc4MDQ5_6e5bf15b-c4aa-47d2-baa3-e5649d85116d"
      unitRef="usd">126000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI1LTEtMS0xLTc4MDQ5_a896095c-deee-45be-bc8a-5681a04a7a1d"
      unitRef="usd">201000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI1LTMtMS0xLTc4MDQ5_0b1dc0cb-77b7-476a-8fe3-17462ae0e9b0"
      unitRef="usd">152000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI3LTEtMS0xLTc4MDQ5_9719a708-c149-4480-9f9c-73b4118bd9fb"
      unitRef="usd">3743000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI3LTMtMS0xLTc4MDQ5_49c066a6-1dba-4b88-a18b-c519938ec3fb"
      unitRef="usd">4232000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI4LTEtMS0xLTc4MDQ5_fe7d7882-ca44-4c82-8571-2356902edf86"
      unitRef="usd">1897000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZToxNzYzMmMxZGQ1Y2E0MTRhOTg4MTY2MWIwNWE0OWM0ZC90YWJsZXJhbmdlOjE3NjMyYzFkZDVjYTQxNGE5ODgxNjYxYjA1YTQ5YzRkXzI4LTMtMS0xLTc4MDQ5_905d7673-f1bc-4304-9fc2-9ab0043adc00"
      unitRef="usd">2702000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iaae7271d9499404cbd33f47b9000a9f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzIzMw_6a5f3d3b-c692-421d-b8e3-476db57b77fd"
      unitRef="usd">137000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i47b12cb75dff40b3bf086b65a329faee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI0MA_b5907e5f-3da0-4b29-a05e-af085f8ad118"
      unitRef="usd">103000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i1e3f09e2780b43d58044eb37c7023411_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzM2OA_40cc5a29-3099-4e18-b0a0-a846ab7a2145"
      unitRef="usd">2034000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0f3311caed27499f9d192299b6eb8a0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzM3NQ_17839084-8ee8-4809-8251-bd39702a7626"
      unitRef="usd">2805000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUzMTA_3ecdfd23-eb4f-4f08-9b9a-7f5d25fe6e5b">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign (including Puerto Rico)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzItMS0xLTEtNzgwNDk_c8d9a7e6-4bfb-404e-bcfd-e943a0aa9bf1"
      unitRef="usd">1469000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzItMy0xLTEtNzgwNDk_5daada67-2c34-4826-bd4b-90da106798ca"
      unitRef="usd">1467000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzItNS0xLTEtNzgwNDk_73e1b163-c279-4319-b8ba-cb920b4e13a7"
      unitRef="usd">1724000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMS0xLTEtOTk5OTE_90fd741a-c205-4687-bad6-da1d3fc4b69e"
      unitRef="usd">98000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMy0xLTEtOTk5OTM_9f9dd91e-5063-4960-b6ad-c849097931e2"
      unitRef="usd">18000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtNS0xLTEtOTk5OTU_e2866072-f781-42a7-ae16-73fe36751171"
      unitRef="usd">7000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMS0xLTEtNzgwNDk_29d6b877-53f9-4f21-8982-7a4eabbefc41"
      unitRef="usd">179000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtMy0xLTEtNzgwNDk_11f96892-d37b-4d41-8d22-743a67746b86"
      unitRef="usd">165000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzMtNS0xLTEtNzgwNDk_e9a3b578-95fc-47f8-9e20-8282f6b60f49"
      unitRef="usd">461000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzQtMS0xLTEtNzgwNDk_25facddc-7168-4320-a186-3973408d80d4"
      unitRef="usd">1746000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzQtMy0xLTEtNzgwNDk_e8806cee-1a90-4a83-9966-5658d305642b"
      unitRef="usd">1650000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzQtNS0xLTEtNzgwNDk_39d20f6a-bbae-45ec-b016-0138dbd91297"
      unitRef="usd">2192000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzUtMS0xLTEtNzgwNDk_99730da8-837e-48aa-b0cf-47476727185d"
      unitRef="usd">4000000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzUtMy0xLTEtNzgwNDk_bd02b274-c8b0-49ff-a5b4-80a6bb29eed0"
      unitRef="usd">180000000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzUtNS0xLTEtNzgwNDk_3b033f5c-fa01-437a-89ae-3812d0c0ba1c"
      unitRef="usd">-526000000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzYtMS0xLTEtNzgwNDk_f1f3ce53-e863-4bb3-8189-027fdeaac19b"
      unitRef="usd">1750000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzYtMy0xLTEtNzgwNDk_bdebfc45-c1fb-457e-8b42-2b7dc6a6124e"
      unitRef="usd">1830000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTpmN2I3ZGJiN2YzNWU0NzNiODcwYzQ3OGFkZTQyMDJkNy90YWJsZXJhbmdlOmY3YjdkYmI3ZjM1ZTQ3M2I4NzBjNDc4YWRlNDIwMmQ3XzYtNS0xLTEtNzgwNDk_62003070-2041-4d1a-b38e-37832193aed5"
      unitRef="usd">1666000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyNzk_d4290e99-4c6e-480e-9042-7609dc6a5a19">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income taxes net of federal tax expense/benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax exempt interest and dividends received deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HIP fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis adjustments from recent acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItMS0xLTEtNzgwNDk_a6505731-0964-47d8-87cd-65ad2add9a39"
      unitRef="usd">1631000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItMy0xLTEtNzgwNDk_b9fd66e6-a5cf-473d-81f0-c13a7ebb9a91"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItNS0xLTEtNzgwNDk_87b6da50-8fad-4321-b32a-41ce3f1ef2ce"
      unitRef="usd">1664000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItNy0xLTEtNzgwNDk_2ab250a2-d240-4039-bd54-e70ec31a94ff"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItOS0xLTEtNzgwNDk_08d2d992-cb18-49f1-99de-19dc644b266c"
      unitRef="usd">1310000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzItMTEtMS0xLTc4MDQ5_1f8eee1e-faee-4b19-a2b0-1ef41efee8dd"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtMS0xLTEtNzgwNDk_e2c8d0ff-a806-42c5-8f60-cff0b6f6200b"
      unitRef="usd">238000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtMy0xLTEtNzgwNDk_1ecce41e-30a2-4fb9-8185-d292b09c169a"
      unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtNS0xLTEtNzgwNDk_9564021c-e058-4d10-885c-5bdc86cacbb9"
      unitRef="usd">258000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtNy0xLTEtNzgwNDk_3d9ec869-5dd0-4035-88a8-8eea366e5cf7"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtOS0xLTEtNzgwNDk_ff4525ef-08d3-4d18-a5f4-3ce4fd375345"
      unitRef="usd">235000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzMtMTEtMS0xLTc4MDQ5_9a9b4bd6-ee26-44cb-a0c2-293c5706a69c"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationDeductions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtMS0xLTEtNzgwNDk_0ba22725-aabe-43c2-88c0-d1c4b9b01e3b"
      unitRef="usd">19000000</us-gaap:IncomeTaxReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtMy0xLTEtNzgwNDk_a2933643-d7df-426c-86c0-80f7cd0a37b4"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:IncomeTaxReconciliationDeductions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtNS0xLTEtNzgwNDk_7d05f882-124b-431b-808e-309033d2a0ab"
      unitRef="usd">22000000</us-gaap:IncomeTaxReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtNy0xLTEtNzgwNDk_1fffd569-9a7b-4471-84ed-d9598d8b2ae1"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:IncomeTaxReconciliationDeductions
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtOS0xLTEtNzgwNDk_4384028a-c5b0-4c72-be72-bae540ce90ca"
      unitRef="usd">22000000</us-gaap:IncomeTaxReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzQtMTEtMS0xLTc4MDQ5_521045f3-448f-4e72-880c-ff07f95666f9"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtMS0xLTEtNzgwNDk_3695bb36-cc1c-42ff-adcf-5cc19cde5cc8"
      unitRef="usd">0</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtMy0xLTEtNzgwNDk_57fa06b4-706d-4de6-9fb5-b715b2cc637e"
      unitRef="number">0</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtNS0xLTEtNzgwNDk_867df56e-627b-4027-b8c7-dbfa0e4e735e"
      unitRef="usd">0</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtNy0xLTEtNzgwNDk_c3852b9e-09ea-4cb1-b94b-1045a348af3f"
      unitRef="number">0</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtOS0xLTEtNzgwNDk_aefabc4b-a122-41ad-902d-85554a7e83b5"
      unitRef="usd">330000000</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzUtMTEtMS0xLTc4MDQ5_9c13a54b-719f-44a3-9044-3f36873995de"
      unitRef="number">0.053</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent>
    <elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtMS0xLTEtNzgwNDk_0bcdbdb8-85e6-498c-b90f-588b4b6d974c"
      unitRef="usd">0</elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount>
    <elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtMy0xLTEtNzgwNDk_d066b9a6-dd89-433f-89fd-0a73741b9df7"
      unitRef="number">0</elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent>
    <elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtNS0xLTEtNzgwNDk_539d5875-1ddb-4684-9164-0f590d1ea359"
      unitRef="usd">0</elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount>
    <elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtNy0xLTEtNzgwNDk_2740054e-8bab-41fc-9dee-69adf63d9ee3"
      unitRef="number">0</elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent>
    <elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtOS0xLTEtNzgwNDk_9a088b1c-36d1-4dbf-9943-44532e929d20"
      unitRef="usd">-110000000</elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount>
    <elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzYtMTEtMS0xLTc4MDQ5_ee775456-3eb3-40be-9a21-5a33b72d5027"
      unitRef="number">-0.018</elv:EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctMS0xLTEtNzgwNDk_c4732900-e895-4349-8480-bfd122cfd3d4"
      unitRef="usd">-100000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctMy0xLTEtNzgwNDk_a3977f73-c8ae-4f38-92b9-503aa2c7ee99"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctNS0xLTEtNzgwNDk_9c48ce1a-750d-4d20-9efc-1620d4b288d4"
      unitRef="usd">-70000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctNy0xLTEtNzgwNDk_7bdb446f-ee89-4c7e-a4ba-53772283a675"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctOS0xLTEtNzgwNDk_1e668590-7c42-41cb-9a8a-1a19698c6df5"
      unitRef="usd">-77000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzctMTEtMS0xLTc4MDQ5_c285a547-ad8a-46af-b691-f008a884331e"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtMS0xLTEtNzgwNDk_eaeee296-a09e-427a-878a-c3eea2d5dd6c"
      unitRef="usd">1750000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtMy0xLTEtNzgwNDk_a3749448-fc38-4c6e-8b5b-178afaff693f"
      unitRef="number">0.225</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtNS0xLTEtNzgwNDk_682042ad-d12c-4a27-b8b7-dde7e0a0bd24"
      unitRef="usd">1830000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtNy0xLTEtNzgwNDk_3231713a-38a9-4b56-9cf9-b095a1bef131"
      unitRef="number">0.231</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtOS0xLTEtNzgwNDk_2a67f385-b5ab-432f-a7c4-97bba23ebd60"
      unitRef="usd">1666000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTo1YzNiMmIyZmJjOTA0YTk5YWUyZTUzYmNkMTkzNGJhOC90YWJsZXJhbmdlOjVjM2IyYjJmYmM5MDRhOTlhZTJlNTNiY2QxOTM0YmE4XzgtMTEtMS0xLTc4MDQ5_b2bfbc1e-ca23-40ce-8270-86269e8ed839"
      unitRef="number">0.267</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE2NDE_b6083573-cc1e-4449-85d0-4a2b4fd54e96"
      unitRef="usd">1750000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE2NDg_4fa70528-0b12-4c23-98a7-b88bab91825e"
      unitRef="usdPerShare">7.21</us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzEwOTk1MTE2MzYyNDY_20563bb0-66dd-406e-a66c-103e49d36957"
      unitRef="usd">1830000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzEwOTk1MTE2MzYyNTc_2d313bba-ea1d-4632-b6fb-f6e95bc69a62"
      unitRef="usdPerShare">7.41</us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4MDE_e36d6637-a951-470b-ad08-1b867a906582"
      unitRef="usd">1666000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4MDg_114059e0-bb7f-465a-8486-440b0e2e882d"
      unitRef="usdPerShare">6.55</us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet>
    <elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee
      contextRef="if2e18d5b222e4195ad3fcd596a9a4307_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4Njc_a2affae9-3efd-4210-b4a5-d7a10fccf871"
      unitRef="usd">330000000</elv:EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee>
    <us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet
      contextRef="if2e18d5b222e4195ad3fcd596a9a4307_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzE4NzQ_2ee93b4b-a8ab-44e4-98e3-55641f074388"
      unitRef="usdPerShare">1.30</us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyODA_a975cbbf-71f8-480d-9488-8310b8f9287d">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzEtMS0xLTEtNzgwNDk_25deec56-3f1f-425c-ae00-5d300c014f50"
      unitRef="usd">271000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzEtMy0xLTEtNzgwNDk_e5e5ed1e-2311-470d-8e61-5a2886f6b9e5"
      unitRef="usd">249000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzMtMS0xLTEtNzgwNDk_cbf6ae79-5a99-44db-aed8-834f23f1652f"
      unitRef="usd">22000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzMtMy0xLTEtNzgwNDk_c5a9a34a-4632-455a-8e7c-27029bce1013"
      unitRef="usd">10000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzQtMS0xLTEtNzgwNDk_a3bb6171-d9cf-40ca-ab27-ad125e905854"
      unitRef="usd">57000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzQtMy0xLTEtNzgwNDk_e5c7b07f-2a7e-439e-ade0-7711c0ee00aa"
      unitRef="usd">17000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzctMS0xLTEtNzgwNDk_a626cb22-9643-46ce-be6c-6766c902c37a"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzctMy0xLTEtNzgwNDk_b635ae67-5009-438e-b3c3-ed69e3424cb1"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzktMS0xLTEtNzgwNDk_2be47abe-2d9e-402d-9371-368cc00a948a"
      unitRef="usd">349000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90YWJsZTplNTAwYTI1NjMxMzQ0NGFhODE1MDE5NjVmNjgwMjkxYS90YWJsZXJhbmdlOmU1MDBhMjU2MzEzNDQ0YWE4MTUwMTk2NWY2ODAyOTFhXzktMy0xLTEtNzgwNDk_9ad5bdb0-2df0-45ad-bc8d-8d3bb55468c2"
      unitRef="usd">271000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI2MjY_65e8d04a-801b-44aa-a44a-7df670cf2b12"
      unitRef="usd">328000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI2MzM_46b24838-7746-4886-9ea9-ac2bf642c70c"
      unitRef="usd">250000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <elv:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI3MDg_021c8876-a79d-40da-b2ff-7c8aa914babb"
      unitRef="usd">2000000</elv:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized>
    <elv:IncomeTaxRefundClaimsFiled
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzI5NzA_f6f181d9-ffe1-45e6-aef1-3226d914753a"
      unitRef="usd">92000000</elv:IncomeTaxRefundClaimsFiled>
    <elv:IncomeTaxRefundClaimsFiled
      contextRef="i4eb438ebee364c309fc5d5bf8993c811_D20170101-20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzU0OTc1NTgyODg3NA_099f9cf4-8111-44a8-832d-14fdde64a5e5"
      unitRef="usd">310000000</elv:IncomeTaxRefundClaimsFiled>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMxNDU_76264629-77d0-4668-8e7b-1cdfd61ff769"
      unitRef="usd">-13000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMyNDM_2e1ce07f-1ed8-468b-aa68-c0da3195f49a"
      unitRef="usd">-9000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMyNTA_3cc5d38b-69fa-4529-8b6d-26be4b5ddea7"
      unitRef="usd">-7000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMyOTc_2a5d5dd1-d34b-421c-a84c-c891896acdf6"
      unitRef="usd">55000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzMzMDQ_e86a4577-e430-4811-9168-5297ca0a2efc"
      unitRef="usd">42000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ib99d2d66da9844cab49602099b561dda_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQyMDI_a1d58c18-62ea-4c77-b735-5dc7426084ec"
      unitRef="usd">33000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i725fb0d8346e4b058763cea8f52dbda8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQyMDg_0c856095-dfd7-44cd-bafc-e0746130725a"
      unitRef="usd">143000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6360a309b9734213b5078c4fb29519ed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQ3Njg_2f45c44b-ac40-43da-a990-1b163756e51d"
      unitRef="usd">160000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i608f90ce9dc149a3bbb7d2041635b146_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzQ4MjA_37867e09-7e81-4f2f-87a3-4b8c784e521e"
      unitRef="usd">109000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxReceivable
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUwMjc_78f04381-b3c3-4a4c-8b6c-edee93984f4b"
      unitRef="usd">440000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUwMzQ_81d7973c-d013-447a-8d40-f1ffe21adf6a"
      unitRef="usd">173000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxesPaid
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzEwOTk1MTE2MzYyNjQ_381e11de-650e-40a5-be87-7d6501d6da7b"
      unitRef="usd">1594000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyNTM_99d692fc-402c-43a0-a4f8-be1cdcaf5fa6"
      unitRef="usd">1299000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMTgvZnJhZzpkOWNlMDkwYTVkYjY0ZmY1YjYwYWU5NzFlMTQ0NDhiYS90ZXh0cmVnaW9uOmQ5Y2UwOTBhNWRiNjRmZjViNjBhZTk3MWUxNDQ0OGJhXzUyNjA_e10bb3ea-9607-4962-90d7-fa6d9f8e7463"
      unitRef="usd">1790000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzEwNzA_89db9038-4405-4b15-912d-4f7a0db8772d">Property and Equipment&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of property and equipment at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software, purchased and internally developed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, furniture and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for 2022, 2021 and 2020 was $123, $136 and $176, respectively. Amortization expense on computer software and leasehold improvements for 2022, 2021 and 2020 was $661, $532 and $462, respectively, which includes amortization expense on computer software, both purchased and internally developed, for 2022, 2021 and 2020 of $599, $485 and $412, respectively. Capitalized costs related to the internal development of software of $5,354 and $5,626 at December&#160;31, 2022 and 2021, respectively, are reported with computer software.&lt;/span&gt;&lt;/div&gt;Impairment of property and equipment for the years ended December&#160;31, 2022, 2021 and 2020 was $7, $73, and $198, respectively, which is included in selling, general and administrative expenses and primarily related to our activities disclosed in Note 4, &#x201c;Business Optimization Initiatives.&#x201d;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzEwNjU_c4e989fb-3d87-4df4-a63f-ee39510b9c63">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of property and equipment at December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software, purchased and internally developed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, furniture and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife5dcccaf6344690b4d7278e78ed1c0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzEtMS0xLTEtNzgwNDk_efc8b03d-d5f9-4c76-9bc3-0314e585dfdf"
      unitRef="usd">5604000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6370e321e07c4309a9e458991006a124_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzEtMy0xLTEtNzgwNDk_bb31c3cb-19b5-46a0-adaa-ccf942418d90"
      unitRef="usd">6115000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5bbfdb76686848eba1f8e4e3f910ddd7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzItMS0xLTEtNzgwNDk_a44d8e17-1a69-460c-aefa-35f0b17b29f8"
      unitRef="usd">828000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2273513928e9447ea6f22d1ef1546380_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzItMy0xLTEtNzgwNDk_d2304314-5e07-4a0a-8498-126989779487"
      unitRef="usd">1314000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib6c1eace13124235af0ad332c211c0f0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzMtMS0xLTEtNzgwNDk_aa41cd15-dedc-46f7-87a7-faf31c359216"
      unitRef="usd">648000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i299992abfe3a42a19dbf532c6dfc8e3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzMtMy0xLTEtNzgwNDk_2375a8cc-6925-42ff-afb9-67a1a1eda473"
      unitRef="usd">641000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i96687506b8f94774b0749011a7e8cc30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzQtMS0xLTEtNzgwNDk_0aa0cae4-db40-46c2-a39e-1eb7c6cfd387"
      unitRef="usd">38000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib04cdfc65ff948fc912a66ca626eb27e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzQtMy0xLTEtNzgwNDk_4c9de0d5-645f-425c-966b-3b7adbaf089e"
      unitRef="usd">172000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19d2136218984fc386824cc3db496a1b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzUtMS0xLTEtNzgwNDk_7e69b14a-4340-4f82-8381-68f19c21a5dc"
      unitRef="usd">1000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i42cda9b6c29f4c1188c4b091bb78bbdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzUtMy0xLTEtNzgwNDk_11b6a2c4-431b-4d32-89ee-f9ee653a8c2d"
      unitRef="usd">17000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzYtMS0xLTEtNzgwNDk_d13b5951-0995-4e7f-bc0c-e0b1c93e3caa"
      unitRef="usd">7119000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzYtMy0xLTEtNzgwNDk_635dbc78-5400-40c5-8811-204a436c529b"
      unitRef="usd">8259000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzctMS0xLTEtNzgwNDk_018f0df9-d916-4944-8124-7b303f7179a8"
      unitRef="usd">2803000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzctMy0xLTEtNzgwNDk_4e70d63f-6fec-4ec1-aecc-23521f25d563"
      unitRef="usd">4340000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzgtMS0xLTEtNzgwNDk_7a076035-9914-466d-8769-ebda4c9cf752"
      unitRef="usd">4316000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90YWJsZTo3NTRhYjk1ZTIwMzc0NmZiYTFlMDU0MmNkZDBiNmYzOC90YWJsZXJhbmdlOjc1NGFiOTVlMjAzNzQ2ZmJhMWUwNTQyY2RkMGI2ZjM4XzgtMy0xLTEtNzgwNDk_58ead171-5ac6-4365-92de-8e71d7527297"
      unitRef="usd">3919000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzE0MA_fb261f3b-5d4f-4a33-b988-dfbbc65ce47c"
      unitRef="usd">123000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzE0NA_fc42e7c7-525f-4b11-92a5-cf9d3ff73762"
      unitRef="usd">136000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzE1MQ_349f8006-2614-4926-84eb-1bb3b9b9e0ab"
      unitRef="usd">176000000</us-gaap:Depreciation>
    <elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzI2MA_a8e755b9-86d6-486f-b8fe-c28c2c2a9115"
      unitRef="usd">661000000</elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements>
    <elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzI2NA_887531d3-5af6-468a-9a39-bbf5307d2546"
      unitRef="usd">532000000</elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements>
    <elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzI3MQ_507d3d54-aab3-41be-9e01-e9a93d67c700"
      unitRef="usd">462000000</elv:AmortizationExpenseOnSoftwareAndLeaseholdImprovements>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzQwOQ_722b5ca7-ef1b-43ba-be5e-1c39d492d1e7"
      unitRef="usd">599000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzQxMw_3b23362c-d89c-4242-b24a-fd58d732144a"
      unitRef="usd">485000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzQyMA_e5b5d9f8-6bdb-4ff8-90ab-3d3fd916d1a9"
      unitRef="usd">412000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzUwNw_d7cde342-9e3c-449a-8de3-79c982c9d482"
      unitRef="usd">5354000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzUxNA_bd3f2223-77b7-49c5-a1ca-67696faf5cd8"
      unitRef="usd">5626000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzY1Mw_0b606859-62cf-4bba-b371-612cdd404802"
      unitRef="usd">7000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzY2MA_5af5ab06-c8ae-4b7b-ba1d-3604a66a5636"
      unitRef="usd">73000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjQvZnJhZzowNzY2N2UzOTNhY2M0NTE5ODc2ZTI5ZmRjYjJjZjFmNS90ZXh0cmVnaW9uOjA3NjY3ZTM5M2FjYzQ1MTk4NzZlMjlmZGNiMmNmMWY1XzU0OTc1NTgxNTI3MQ_e498f626-a01b-4b3c-8528-5ab3f84732fc"
      unitRef="usd">198000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3ODE_3ef2f347-1b61-4bb9-bb88-ddc8063238f9">Goodwill and Other Intangible Assets&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the change in the carrying amount of goodwill for our segments (see Note 20, &#x201c;Segment Information&#x201d;) for 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2022, 2021 and 2020. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. For quantitative testing, the fair values are estimated using the projected income and market valuation approaches, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections, income projections, cash flows and discount rates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not incur any impairment losses in 2022, 2021 or 2020, as the estimated fair values of our reporting units were substantially in excess of their carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of other intangible assets as of December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider and hospital relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Cross and Blue Shield and other trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State Medicaid licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, due to our acquisition of Integra, we recorded intangible assets and due to our new branding strategy, reclassified $308 of trademarks with indefinite lives to Intangible assets with finite lives - Other. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the estimated amortization expense for each of the five succeeding years is as follows: 2023, $806; 2024, $370; 2025, $311; 2026, $258; and 2027, $221.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3ODM_30d47143-118a-4d5e-a84d-d0b27ac7c400">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the change in the carrying amount of goodwill for our segments (see Note 20, &#x201c;Segment Information&#x201d;) for 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtMS0xLTEtNzgwNDk_899d44aa-1315-45d6-b9a0-a865065f2f2a"
      unitRef="usd">11593000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtMy0xLTEtNzgwNDk_cff3f8e1-5464-47fd-8ba0-1c84278b1b06"
      unitRef="usd">8331000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i414a136e0db84003bf078b0578623a1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtNS0xLTEtNzgwNDk_76145b57-ed29-45eb-9231-a2fb3f9b36b0"
      unitRef="usd">48000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i878444205e1c46049c539d9fd06405ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtNy0xLTEtNzgwNDk_6f5a5731-24c6-4e44-b563-f4335e4a516e"
      unitRef="usd">1719000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzEtOS0xLTEtNzgwNDk_ae141754-d9b8-4b6c-abaf-e523c1f1b1f6"
      unitRef="usd">21691000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtMS0xLTEtNzgwNDk_76ed2156-d469-485e-aa01-f4a82eb8355a"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtMy0xLTEtNzgwNDk_a2708545-ef81-4330-88f0-ee643a0f7c8d"
      unitRef="usd">2018000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtNS0xLTEtNzgwNDk_84fb5108-fd62-40e8-b1c7-47434313735c"
      unitRef="usd">11000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i6addc423352741bab0b178cdde51da3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtNy0xLTEtNzgwNDk_22af8e9b-98d4-4243-a63e-ec3bb8e7c788"
      unitRef="usd">508000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzMtOS0xLTEtNzgwNDk_3c7488d0-aa58-454a-a8c0-b4fec06185e7"
      unitRef="usd">2537000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtMS0xLTEtNzgwNDk_cf580b2f-48c6-4f9a-bd0d-0648a78834b0"
      unitRef="usd">11593000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtMy0xLTEtNzgwNDk_39ee0485-0038-4dc4-a10f-dee1890cb042"
      unitRef="usd">10349000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4f1719b8ce5348aca152c341aa0c2afd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtNS0xLTEtNzgwNDk_edeb9258-2486-41a2-ab71-a81e5644aa99"
      unitRef="usd">59000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iecd5af0076694b48bcfd411f1a1d2e11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtNy0xLTEtNzgwNDk_ed607378-f4de-4b48-a474-3ed97a915ba8"
      unitRef="usd">2227000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzQtOS0xLTEtNzgwNDk_6cb3de9c-09f7-4705-a455-fcecc313fcbd"
      unitRef="usd">24228000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtMS0xLTEtNzgwNDk_4250532d-6f74-45e7-863a-25ed6f687dad"
      unitRef="usd">18000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtMy0xLTEtNzgwNDk_45afad12-9cfd-4f0b-aede-72797a4a4498"
      unitRef="usd">128000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtNS0xLTEtNzgwNDk_2da07ca1-7a62-4a86-98d2-b1c2b5de1163"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i307c5528ab3a457cbfb9833f2f43c891_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtNy0xLTEtNzgwNDk_a8a7a409-585a-40fa-ba69-9c522909b047"
      unitRef="usd">9000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzUtOS0xLTEtNzgwNDk_72dd4803-44e3-46fa-bae7-1eea3dba2dc8"
      unitRef="usd">155000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtMS0xLTEtNzgwNDk_b1615603-ae41-49de-8a2d-35a2d0c1f8d5"
      unitRef="usd">11611000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtMy0xLTEtNzgwNDk_10363e98-9417-411f-8245-b1a758a74c45"
      unitRef="usd">10477000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0c60676ab036430ab5cabf0a0d051ae4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtNS0xLTEtNzgwNDk_c7e78d63-cf35-4924-9fdb-a4280c73bfdc"
      unitRef="usd">59000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i363acffb9a824cb3994c18c156fa9f14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtNy0xLTEtNzgwNDk_a3d3fc5d-d969-48b2-a9fa-899ce9734512"
      unitRef="usd">2236000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzYtOS0xLTEtNzgwNDk_ef543d0c-1ed7-44bf-9be1-59051d7ad514"
      unitRef="usd">24383000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctMS0xLTEtNzgwNDk_09367dbe-154c-4760-91cc-01b681c74d6c"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctMy0xLTEtNzgwNDk_4ed3e622-36ed-4a0d-b5e0-4d717c14f473"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i0c60676ab036430ab5cabf0a0d051ae4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctNS0xLTEtNzgwNDk_26c1378c-9fde-4b2a-a036-99c2015f4b57"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i363acffb9a824cb3994c18c156fa9f14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctNy0xLTEtNzgwNDk_86041cb4-a1e0-4545-9bf9-28ef6e4ecad7"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTplZDc3ZGE2ZWI1OTE0NjE5OWEwOWU5YzI3OTFkZTIxOC90YWJsZXJhbmdlOmVkNzdkYTZlYjU5MTQ2MTk5YTA5ZTljMjc5MWRlMjE4XzctOS0xLTEtNzgwNDk_d86a6537-9c30-4830-b4cc-bbf3cfc0280d"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3ODk_ef6bb875-20d6-4246-b03c-d6ad4973531f">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of other intangible assets as of December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider and hospital relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Cross and Blue Shield and other trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State Medicaid licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibef9f77b3653474080b83cf476ebe688_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtMS0xLTEtNzgwNDk_5989eb14-831c-4a17-b740-eea50f04855c"
      unitRef="usd">5791000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibef9f77b3653474080b83cf476ebe688_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtMy0xLTEtNzgwNDk_eab69383-0e91-45a3-8dc0-e4d683940407"
      unitRef="usd">3693000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibef9f77b3653474080b83cf476ebe688_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtNS0xLTEtNzgwNDk_0db385e6-cb35-425f-ad5c-3f67ff26b6d3"
      unitRef="usd">2098000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtNy0xLTEtNzgwNDk_0d90797a-95f6-42ec-8c22-64ae1d820582"
      unitRef="usd">5598000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtOS0xLTEtNzgwNDk_ab8fdcf9-a16d-4292-9189-1c86db3feb65"
      unitRef="usd">3236000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib1e5f69f7dd145fc9725e8aa852ecb01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzMtMTEtMS0xLTc4MDQ5_fa4fea16-a10d-4547-a5bc-00b1bddff3c7"
      unitRef="usd">2362000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8591443e8521443493e922d924cd9752_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtMS0xLTEtNzgwNDk_4120a3f8-0565-489b-b569-b37d7949bbbc"
      unitRef="usd">326000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8591443e8521443493e922d924cd9752_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtMy0xLTEtNzgwNDk_ce394fd8-e63a-4732-becf-88ead8c268e8"
      unitRef="usd">146000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8591443e8521443493e922d924cd9752_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtNS0xLTEtNzgwNDk_84cbad60-d15b-44be-bafc-ebfe6e94bc45"
      unitRef="usd">180000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i666bee6f945341f288f2ce40ac054956_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtNy0xLTEtNzgwNDk_1602e90c-b46b-492f-9da8-f940763a7e37"
      unitRef="usd">324000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i666bee6f945341f288f2ce40ac054956_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtOS0xLTEtNzgwNDk_3dc994cd-b20c-410f-9762-e1b9a1c2ea44"
      unitRef="usd">129000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i666bee6f945341f288f2ce40ac054956_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzQtMTEtMS0xLTc4MDQ5_2e70b4c2-2131-43e0-9fdb-6ecbeb26fed5"
      unitRef="usd">195000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i899c188b277246f88a96c04a8b0e3a2d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtMS0xLTEtNzgwNDk_2cf99f0e-31e9-4b29-bf16-c94e7dfaf373"
      unitRef="usd">1010000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i899c188b277246f88a96c04a8b0e3a2d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtMy0xLTEtNzgwNDk_d75dfefe-4f18-4b38-b004-342c593e9888"
      unitRef="usd">440000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i899c188b277246f88a96c04a8b0e3a2d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtNS0xLTEtNzgwNDk_21136a1f-9b25-4903-a7a1-5366f15442f8"
      unitRef="usd">570000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtNy0xLTEtNzgwNDk_469a3b58-559a-47cd-b448-00987b8a8104"
      unitRef="usd">610000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtOS0xLTEtNzgwNDk_f9262503-8e11-4cdc-a4e0-7d1e2dd8318a"
      unitRef="usd">141000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3bd259ec818f4fd4bc66415b3f749e3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzUtMTEtMS0xLTc4MDQ5_a0f82eba-0e1b-4cf3-a132-5e1e95ff6966"
      unitRef="usd">469000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtMS0xLTEtNzgwNDk_bc803704-b630-4fe6-b73a-c8b879030917"
      unitRef="usd">7127000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtMy0xLTEtNzgwNDk_f4cea572-b5e0-4dbb-b627-ddc15002ad16"
      unitRef="usd">4279000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtNS0xLTEtNzgwNDk_f9b73d24-39b5-4bc9-bd53-202c9d5e01cf"
      unitRef="usd">2848000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtNy0xLTEtNzgwNDk_cf126376-bf8c-4a14-a708-aaa4236e96b9"
      unitRef="usd">6532000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtOS0xLTEtNzgwNDk_a2873f20-79dd-4529-806a-31cc02e480ad"
      unitRef="usd">3506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzYtMTEtMS0xLTc4MDQ5_cd5996bc-9862-45d8-b3c9-de4374946fea"
      unitRef="usd">3026000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib4626139b5a5432daffd219066037e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtMS0xLTEtNzgwNDk_bb84919a-2a52-4656-9237-f284194f88ba"
      unitRef="usd">5991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib4626139b5a5432daffd219066037e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtNS0xLTEtNzgwNDk_606b03ea-8f1d-4ef7-978f-c63acabfc8e9"
      unitRef="usd">5991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5cb27c8fb2e64bcca33419af780e6ad8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtNy0xLTEtNzgwNDk_f3020a0c-f83a-466c-ad6f-46779b305c8a"
      unitRef="usd">6299000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5cb27c8fb2e64bcca33419af780e6ad8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzgtMTEtMS0xLTc4MDQ5_a392a9ae-30dc-4367-8231-0d97a2e4428d"
      unitRef="usd">6299000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if1a7d829139842f08030a894802ebb5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktMS0xLTEtNzgwNDk_8958a63b-3e48-4489-b233-34afc5aed482"
      unitRef="usd">1476000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if1a7d829139842f08030a894802ebb5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktNS0xLTEtNzgwNDk_c2c4fe28-55ec-4168-85f4-36f1b4f27b8e"
      unitRef="usd">1476000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic09884f298c34bfc8b99687d69272ecc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktNy0xLTEtNzgwNDk_416acf1b-5a42-48d6-b25b-c381430ce911"
      unitRef="usd">1290000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic09884f298c34bfc8b99687d69272ecc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzktMTEtMS0xLTc4MDQ5_6763bf48-a0fb-4250-b0b6-13926d923307"
      unitRef="usd">1290000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTEtMS0xLTc4MDQ5_6a422c7d-c974-4bc1-8b3e-1e46c7e69498"
      unitRef="usd">7467000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTUtMS0xLTc4MDQ5_3901e4f4-ae72-4e68-9072-e4c25b0162e8"
      unitRef="usd">7467000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTctMS0xLTc4MDQ5_e16ce479-07db-4560-a537-ef3443dfcdac"
      unitRef="usd">7589000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzEwLTExLTEtMS03ODA0OQ_11708dd8-9fd3-40ac-b82a-5889f1f2bdc3"
      unitRef="usd">7589000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTEtMS0xLTc4MDQ5_9405b7aa-77f6-4f25-b2f2-949a0aee2f61"
      unitRef="usd">14594000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <elv:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTMtMS0xLTc4MDQ5_92f468de-2f8a-46a2-a0c0-604e2a069b71"
      unitRef="usd">4279000000</elv:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTUtMS0xLTc4MDQ5_26f01875-cf15-4452-a3f5-7ec8bd286cc9"
      unitRef="usd">10315000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTctMS0xLTc4MDQ5_b6ba51f4-acf4-4100-9c86-c97b0d7be99e"
      unitRef="usd">14121000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <elv:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTktMS0xLTc4MDQ5_ef74300c-199f-4c7b-8d50-794adf84a797"
      unitRef="usd">3506000000</elv:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90YWJsZTpjZjdiNGIwNGNmMGQ0OGE2OWE3Y2I5NGNmZjAwOGFmMy90YWJsZXJhbmdlOmNmN2I0YjA0Y2YwZDQ4YTY5YTdjYjk0Y2ZmMDA4YWYzXzExLTExLTEtMS03ODA0OQ_642f3829-fa31-4027-acfb-b7d25290cda7"
      unitRef="usd">10615000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzU0OTc1NTgxNjEzNw_2f4da479-4d3a-40db-8c56-4c4694e2aa5d"
      unitRef="usd">-308000000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzU0OTc1NTgxNjEzNw_53a11da8-c5b1-49dc-b79d-de683fe602c5"
      unitRef="usd">308000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3MzI_87d9a7cb-945e-4961-87ce-062b3046a871"
      unitRef="usd">806000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3NDA_fd2deaa6-72dc-4601-825b-d7419a9207e2"
      unitRef="usd">370000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3NDg_67e8cfae-db40-42b4-a3ba-e92cfc68521c"
      unitRef="usd">311000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3NTY_bbf8ac70-f67e-4d75-a66d-6c1f926bcb15"
      unitRef="usd">258000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMjcvZnJhZzo5MDczZGY4NmM0NGU0YTM3YmUwZmYzMTkyYzA3MzUyMi90ZXh0cmVnaW9uOjkwNzNkZjg2YzQ0ZTRhMzdiZTBmZjMxOTJjMDczNTIyXzE3Njg_8a09f589-3a1c-4a1c-9788-57734c50c355"
      unitRef="usd">221000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0Nzc_8ebc305b-c747-4eeb-962b-c69993b5266d">Retirement Benefits&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Elevance Health Cash Balance Plan A (formerly the Anthem Cash Balance Plan A) and the Elevance Health Cash Balance Plan B (formerly the Anthem Cash Balance Plan B) are cash balance pension plans covering certain eligible employees of the affiliated companies that participate in these plans. Effective January&#160;1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules continued to accrue benefits. Participants who did not receive credits and/or benefit accruals were included in the Elevance Health Cash Balance Plan A, while employees who were still receiving credits and/or benefits participated in the Elevance Health Cash Balance Plan B. Effective January 1, 2019, benefits under the Elevance Health Cash Balance Plan B were curtailed. All grandfathered participants no longer have pay credits added to their accounts but continue to earn interest on existing account balances. Participants continue to earn years of pension service for vesting purposes. Several pension plans acquired through various corporate mergers and acquisitions were merged into these plans in prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Employees&#x2019; Retirement Plan of Blue Cross of California (the &#x201c;BCC Plan&#x201d;) is a defined benefit pension plan that covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective January&#160;1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired or rehired after December&#160;31, 2006 are eligible to participate in the BCC Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the plans&#x2019; assets consist primarily of equity securities, fixed maturity securities, investment funds and cash. The funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended (&#x201c;ERISA&#x201d;), as further amended by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to provide assets sufficient to meet the benefits to be paid to plan participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables disclose consolidated &#x201c;pension benefits,&#x201d; which include the defined benefit pension plans described above, and consolidated &#x201c;other benefits,&#x201d; which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were computed using assumptions at the December&#160;31 measurement dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the benefit obligation is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the fair value of plan assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net amount included in the consolidated balance sheets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (loss) gain&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount before tax at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accumulated benefit obligation for the defined benefit pension plans was $1,413 and $1,857 at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, certain pension plans had accumulated benefit obligations in excess of plan assets. Such plans had accumulated benefit obligation and fair value of plan assets of $44 and $0, respectively. In addition, certain plans had projected benefit obligations in excess of plan assets. Such plans had projected benefit obligation and fair value of plan assets of $44 and $0, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit credit included in the consolidated statements of income are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a"&gt;Settlement loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we incurred total settlement losses of $28, $26 and $29, respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was 8.00% for 2023, with a gradual decline to 4.50% by the year 2035. The assumed healthcare cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December&#160;31, 2022 measurement date was 6.50% for 2023, with a gradual decline to 4.50% by the year 2035. These estimated trend rates are subject to change in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across a range of sectors and levels of capitalization to maximize long-term return for a prudent level of risk.&#160;The weighted-average target allocation for pension benefit plan assets is 37% equity securities, 58% fixed maturity securities, and 5% to all other types of investments.&#160;Equity securities primarily include a mix of domestic securities, foreign securities and mutual funds invested in equities.&#160;Fixed maturity securities primarily include treasury securities, corporate bonds and asset-backed investments issued by corporations and the U.S. government.&#160;Other types of investments include insurance contracts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;designed specifically for employee benefit plans, a commingled fund comprised primarily of equity securities and certain partnership interests.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partnerships hold various types of underlying assets such as real estate and investments in oil and gas companies. Generally, the partnership interests are not redeemable and are transferable only with the consent of the general partner. Unfunded commitments related to all partnership interests totaled approximately $2 and $3 at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were invested in Elevance Health common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2022, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $36, and excluding estimated claims settlements to be paid from other benefit assets of ($17), are as follows (see Note 7, &#x201c;Fair Value,&#x201d; for additional information regarding the definition of level inputs):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance company contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in DOL 103-12 trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2021, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $48, and excluding estimated claims settlements to be paid from other benefit assets of ($29), are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance company contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in DOL 103-12 trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Company&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life&lt;br/&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets relating to assets still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets relating to assets still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets relating to assets still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other transfers into or out of Level III during the years ended December&#160;31, 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended December&#160;31, 2022, 2021 and 2020, no material contributions were necessary to meet ERISA required funding levels. However, during each of the years ended December&#160;31, 2022, 2021 and 2020, we made tax deductible discretionary contributions to the pension benefit plans of $4, $7, and $7, respectively. Employer contributions to other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as appropriate, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 - 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In addition to the defined benefit plans, we maintain the Elevance Health 401(k) Plan (formerly the Anthem 401(k) Plan), which is a qualified defined contribution plan covering substantially all employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled $275, $241 and $221 during 2022, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0Njc_3bab5c6c-82ac-4d1b-a23f-844896fddb53">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the benefit obligation is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItMS0xLTEtNzgwNDk_f6c07287-ee72-4602-9412-20d145001f92"
      unitRef="usd">1859000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ifba97ae25e674ac09265ecbdcc7c49a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItMy0xLTEtNzgwNDk_d6de7907-833b-4bad-9e9d-1fc43a2f841b"
      unitRef="usd">2009000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItNS0xLTEtNzgwNDk_2690b69f-3a0b-4a8c-9adc-f602d9e5c01d"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ic7eae151120d438b8aa81ae6d01ed182_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzItNy0xLTEtNzgwNDk_7b4dafff-a157-4e38-b140-dfa9087b65ab"
      unitRef="usd">399000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtMS0xLTEtNzgwNDk_850f7e77-3f6d-421f-a0b6-8fe035c493c9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtMy0xLTEtNzgwNDk_8de8cc83-7a69-4a33-a65a-d08e0423e6e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtNS0xLTEtNzgwNDk_5647a0f6-9ea8-4c61-9c4a-163e241d4079"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzMtNy0xLTEtNzgwNDk_34427b2f-5129-41da-8171-e4309941c9d2"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtMS0xLTEtNzgwNDk_546b2275-aa66-4b6e-a2c9-a90dcb65e302"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtMy0xLTEtNzgwNDk_2959777f-d7e5-43fe-b0af-3cec49e0bed1"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtNS0xLTEtNzgwNDk_e404b880-4e65-4195-a683-4703248d884e"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzQtNy0xLTEtNzgwNDk_5920a9d9-06aa-49f7-8e82-b392abcfc3da"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtMS0xLTEtNzgwNDk_0b74fb8e-5c6e-45f5-8d0e-ef4e895bd906"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtMy0xLTEtNzgwNDk_2452b416-758d-420b-aeaf-f34d22b33178"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtNS0xLTEtNzgwNDk_6f7774b6-cfee-4140-834a-1db0039fbe8c"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzUtNy0xLTEtNzgwNDk_0db68f93-bef0-4107-9728-91422be6f963"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtMS0xLTEtNzgwNDk_28869e3b-b845-4fed-bf87-bf0378041ec3"
      unitRef="usd">362000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtMy0xLTEtNzgwNDk_ee29b377-3bf2-4f5a-9429-c7e9722803d0"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtNS0xLTEtNzgwNDk_f59fcafe-046d-46a1-87c4-4974e7a3439c"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzYtNy0xLTEtNzgwNDk_dc8eba81-71ae-4f0f-bd5b-2efdb49ebd8a"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctMS0xLTEtNzgwNDk_2b77aefe-e3e2-4551-a898-71d4485c0c98"
      unitRef="usd">-74000000</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctMy0xLTEtNzgwNDk_1b67cff0-104d-46ab-ba84-8571fe5b3262"
      unitRef="usd">-90000000</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctNS0xLTEtNzgwNDk_42da0ec0-da95-4775-8ec9-dff6a5d734ea"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzctNy0xLTEtNzgwNDk_d5b1c9d7-cb37-43fd-9139-4b30f4c92b18"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtMS0xLTEtNzgwNDk_79bbbe61-1b9a-4b72-8d9c-47d895c76876"
      unitRef="usd">60000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtMy0xLTEtNzgwNDk_acb1e7e9-0fa3-4c53-805a-7f0c3753d446"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtNS0xLTEtNzgwNDk_817b8692-4d77-49c1-91d7-f445c0fabff4"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzgtNy0xLTEtNzgwNDk_8515b09c-46fe-430e-a780-60a64abae914"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktMS0xLTEtNzgwNDk_30abaa12-c248-4cc8-9e76-2de3def162e8"
      unitRef="usd">1415000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktMy0xLTEtNzgwNDk_75096223-c7d7-4c91-9f80-bef019024d95"
      unitRef="usd">1859000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktNS0xLTEtNzgwNDk_15a97896-5043-4748-bdf8-758effeca5ba"
      unitRef="usd">277000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplMTBjNTY4MDdlZjM0OGZjOTJkNTgxYjY2MjUxMzI0ZC90YWJsZXJhbmdlOmUxMGM1NjgwN2VmMzQ4ZmM5MmQ1ODFiNjYyNTEzMjRkXzktNy0xLTEtNzgwNDk_6f95efca-df92-416e-900e-f1306a45aa24"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0ODA_0d7b3ec4-4233-4a68-a67b-d3d43d4b32de">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the fair value of plan assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItMS0xLTEtNzgwNDk_2777c2be-bde1-47d4-83f8-bd350d49bce2"
      unitRef="usd">2216000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifba97ae25e674ac09265ecbdcc7c49a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItMy0xLTEtNzgwNDk_b2d99392-ed6c-4185-a8b1-0d2c9acc0d67"
      unitRef="usd">2186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItNS0xLTEtNzgwNDk_a0e60902-922e-4229-a523-0770fee8488e"
      unitRef="usd">371000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7eae151120d438b8aa81ae6d01ed182_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzItNy0xLTEtNzgwNDk_bf77e2cb-759f-4bd6-b03b-77c43a0d58ff"
      unitRef="usd">391000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtMS0xLTEtNzgwNDk_ab846130-20a5-452d-8fd0-7b6123ff10ce"
      unitRef="usd">-352000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtMy0xLTEtNzgwNDk_a7b4157a-4818-42b8-b018-61225ba12691"
      unitRef="usd">174000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtNS0xLTEtNzgwNDk_e18e5ad2-cb79-44d6-9f05-aa3b807e1dbf"
      unitRef="usd">-61000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzMtNy0xLTEtNzgwNDk_9a409e03-a1e6-49de-bfeb-81cfc617d7de"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtMS0xLTEtNzgwNDk_aaa5e7c6-86fa-4fb8-8648-8faf243f4136"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtMy0xLTEtNzgwNDk_a86e661b-85ba-48b7-9f28-581bb0667022"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtNS0xLTEtNzgwNDk_507b384c-71c7-4eba-84f9-401fc7c3dfc3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzQtNy0xLTEtNzgwNDk_58b6463a-4a96-41e9-94fe-fbe2bfc0911f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtMS0xLTEtNzgwNDk_7e9283c0-231d-4a54-b387-b1cdac8597cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtMy0xLTEtNzgwNDk_2007249d-c45a-4aa9-9bcf-d2b81b17bc90"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtNS0xLTEtNzgwNDk_bec417c3-a52b-496f-a24a-d50a3e20caaa"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzUtNy0xLTEtNzgwNDk_2933f2f4-9bab-4ee1-b1fa-1b407b5fde9a"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtMS0xLTEtNzgwNDk_2124855e-daa2-41b6-90ed-360bf1150b8f"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtMy0xLTEtNzgwNDk_c5f4ace7-ff8f-44f1-8eab-69fabee7b277"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtNS0xLTEtNzgwNDk_1b90056c-964e-4bb3-81db-c010cf55fbe7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzYtNy0xLTEtNzgwNDk_68d35431-5cda-4d51-8ceb-fb4162280a7e"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <elv:DefinedBenefitPlanBenefitsPaidFairValue
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctMS0xLTEtNzgwNDk_c379a4ae-2bbf-4b15-8d44-71c4f1e72f8b"
      unitRef="usd">60000000</elv:DefinedBenefitPlanBenefitsPaidFairValue>
    <elv:DefinedBenefitPlanBenefitsPaidFairValue
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctMy0xLTEtNzgwNDk_d17014e9-49a8-4225-b875-5c2e3863fee2"
      unitRef="usd">61000000</elv:DefinedBenefitPlanBenefitsPaidFairValue>
    <elv:DefinedBenefitPlanBenefitsPaidFairValue
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctNS0xLTEtNzgwNDk_9490768b-53fb-4f4f-aecf-31e57e996a16"
      unitRef="usd">28000000</elv:DefinedBenefitPlanBenefitsPaidFairValue>
    <elv:DefinedBenefitPlanBenefitsPaidFairValue
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzctNy0xLTEtNzgwNDk_11fb4ece-34c7-4632-bb95-b242e9f07d38"
      unitRef="usd">41000000</elv:DefinedBenefitPlanBenefitsPaidFairValue>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtMS0xLTEtNzgwNDk_9e8239c6-2345-4663-a9c2-28a9524b876e"
      unitRef="usd">1734000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtMy0xLTEtNzgwNDk_ec2443b5-ef34-4d6c-98e8-f839948b8df5"
      unitRef="usd">2216000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtNS0xLTEtNzgwNDk_56373190-89e1-4cf0-84a4-8d69f7621683"
      unitRef="usd">299000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZToxMDhjMTI4YTJjYmY0NTQ4YjNiYTA1OTJmN2EyOWE1ZS90YWJsZXJhbmdlOjEwOGMxMjhhMmNiZjQ1NDhiM2JhMDU5MmY3YTI5YTVlXzgtNy0xLTEtNzgwNDk_508885bc-db42-4308-b1a8-80140f0c0821"
      unitRef="usd">371000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0ODg_286af5ec-da9d-4254-9149-b5a0b400027c">The net amount included in the consolidated balance sheets is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItMS0xLTEtNzgwNDk_62a19197-ae9b-4b81-a939-7257f83fba9a"
      unitRef="usd">363000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItMy0xLTEtNzgwNDk_e2a300d7-cdf6-4a08-9691-a064b2257b5c"
      unitRef="usd">415000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItNS0xLTEtNzgwNDk_fd5c1e8e-6df6-4583-9abf-3c457a460715"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzItNy0xLTEtNzgwNDk_fa27368a-0219-47ce-8755-0c95aa415781"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtMS0xLTEtNzgwNDk_5dff2493-6c8d-4393-8f82-af14997fd8f9"
      unitRef="usd">6000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtMy0xLTEtNzgwNDk_b65b639e-5dae-4c1b-8cca-7daefe0db90e"
      unitRef="usd">6000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtNS0xLTEtNzgwNDk_ea16a7c5-db4e-4cf7-826a-8fe86b1d7f0e"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzMtNy0xLTEtNzgwNDk_7aa02663-3c7b-4066-a054-686bb2d558ab"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtMS0xLTEtNzgwNDk_6f012021-9037-4546-8c6a-3a301102e1c2"
      unitRef="usd">38000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtMy0xLTEtNzgwNDk_47215e79-6930-49bd-a157-0c08570ecbd4"
      unitRef="usd">52000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtNS0xLTEtNzgwNDk_6fe263be-3b81-4119-a3bf-2bed3a90db0f"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzQtNy0xLTEtNzgwNDk_14c9d5ec-c36d-4596-afd9-dc789ab44cf6"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtMS0xLTEtNzgwNDk_1e239c11-1012-4267-9a0a-1996dd3ca1c5"
      unitRef="usd">319000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtMy0xLTEtNzgwNDk_4e033333-8956-4513-981a-58759b4acff9"
      unitRef="usd">357000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtNS0xLTEtNzgwNDk_cd8d9ee3-a318-42c0-b4f1-56595bdb38f8"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZmQ5ZDAwNmJjYzE0ZmM1OTQzMDA3NGY1YmIzZWM1Ni90YWJsZXJhbmdlOmFmZDlkMDA2YmNjMTRmYzU5NDMwMDc0ZjViYjNlYzU2XzUtNy0xLTEtNzgwNDk_c95c9158-c5b7-4f5c-9f8b-35a487f7045b"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0NDQ_454062f2-2d8e-4dc9-8b4f-70eea3664969">The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (loss) gain&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount before tax at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItMS0xLTEtNzgwNDk_c32a5300-f7d2-4cbc-9e36-424fa93da8bb"
      unitRef="usd">672000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItMy0xLTEtNzgwNDk_f7ca7d70-daa3-4030-9e04-4c179d0f74c1"
      unitRef="usd">625000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItNS0xLTEtNzgwNDk_7f67a2f6-37c7-44f9-8c8a-0bbbbea91cbb"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzItNy0xLTEtNzgwNDk_63d21df0-46ef-43b9-9b3e-e62c69ed82fb"
      unitRef="usd">-36000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtMS0xLTEtNzgwNDk_273ea093-93d3-4a10-b1cd-da40cc745b0b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtMy0xLTEtNzgwNDk_19f51644-9b8b-48b3-9c48-6489c6390854"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtNS0xLTEtNzgwNDk_394d04ef-dbd8-4eb2-a9dc-d7ebb7848420"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzMtNy0xLTEtNzgwNDk_0a77e289-b15e-44d2-bb94-b9183b7bd25e"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtMS0xLTEtNzgwNDk_00db536e-5c86-4882-b01c-9768339e7ccb"
      unitRef="usd">-672000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtMy0xLTEtNzgwNDk_b31f2b5f-95c9-4f9c-861b-28f77633a083"
      unitRef="usd">-625000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtNS0xLTEtNzgwNDk_fbec64f3-8fab-4b8c-b925-18c0644cfcbc"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphZTg4MjQ1MTRjYWU0YjhhYTdkOGNkNzkzZTEyMTk3OC90YWJsZXJhbmdlOmFlODgyNDUxNGNhZTRiOGFhN2Q4Y2Q3OTNlMTIxOTc4XzQtNy0xLTEtNzgwNDk_c73d68ca-deb6-4ae2-88a0-db5a6d7dceac"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMxNDY_eb72efe8-91b6-46f2-a6e5-f4794200b850"
      unitRef="usd">1413000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMxNTM_8632c837-118e-4f1b-ad74-e8f9c3fadb82"
      unitRef="usd">1857000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMzNTg_b45641c5-31b8-42b2-a68d-5c349ecd4fd8"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzMzNjU_1368135a-a4bf-4121-bdb1-a5c311b5f248"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM1NDc_c39965de-3beb-43c6-b16b-bb2d60574cc0"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM1NTQ_64bee2d9-2e1a-432a-8500-e7384d4b1da7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <elv:ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0ODE_2bde7b3e-2c24-4d78-b192-1fe985d7974b">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItMS0xLTEtNzgwNDk_a5c0c280-2835-45fd-804f-4507fa794c6e"
      unitRef="number">0.0518</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItMy0xLTEtNzgwNDk_b1f90a91-421e-4ece-aa90-0ac1f3b7263b"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItNS0xLTEtNzgwNDk_ce7bdcc3-d13f-45f3-b28e-23ef90955467"
      unitRef="number">0.0512</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzItNy0xLTEtNzgwNDk_8895f7ed-a90c-4994-97a4-c61d69d7463d"
      unitRef="number">0.0249</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtMS0xLTEtNzgwNDk_5e6c8778-3832-4bcb-ac92-81b39433860d"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtMy0xLTEtNzgwNDk_870e0e78-94c4-4b58-884b-cafeaa33915f"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtNS0xLTEtNzgwNDk_bfbcb425-6538-44f3-a691-4a7cc8b61ea0"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzMtNy0xLTEtNzgwNDk_633e779f-5468-4324-b280-6e6e75f8ad8a"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtMS0xLTEtNzgwNDk_cdc3b80b-18cf-4303-88ea-e266d91e8090"
      unitRef="number">0.0658</elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets>
    <elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtMy0xLTEtNzgwNDk_6258ed41-36e9-4cb0-b4df-af31df04da35"
      unitRef="number">0.0502</elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets>
    <elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtNS0xLTEtNzgwNDk_cbbe4ed3-b4ef-4fcc-bd5d-3fe251cf6c89"
      unitRef="number">0.0657</elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets>
    <elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzQtNy0xLTEtNzgwNDk_78c78e26-c238-4279-9f81-5889aecc0b2d"
      unitRef="number">0.0643</elv:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtMS0xLTEtNzgwNDk_4a292ade-3cd7-4078-bcf5-a6f1be77ab9e"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i399e8b1e21f5426486fa66186ca7a17e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtMy0xLTEtNzgwNDk_01290fa5-f477-4566-8483-9f40acff9244"
      unitRef="number">0.0382</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtNS0xLTEtNzgwNDk_24d158c2-32db-4001-9b14-7a8aeed3036a"
      unitRef="number">0.0389</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i1e00926518a047ec902e830460f86c18_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTo5YjE1MWZkZGU0OTg0NTAxOTQxN2RkYWZiOTFmMTc3ZC90YWJsZXJhbmdlOjliMTUxZmRkZTQ5ODQ1MDE5NDE3ZGRhZmI5MWYxNzdkXzUtNy0xLTEtNzgwNDk_789553d7-a90f-4e8c-8d19-ff99880e881b"
      unitRef="number">0.0156</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0MDk_5bae0fa9-9a22-4707-aaa3-07a36405d2e6">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit credit included in the consolidated statements of income are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_266a0113-a418-4fd2-b309-7d4374f83696"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_4712e8a5-7a3a-451c-b0df-750df7b521ae"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMC0xLTEtOTk0NzY_c58261d9-660f-4963-aad2-3ac6538c668a"&gt;Settlement loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzMtMS0xLTEtNzgwNDk_6d6a1b68-2bae-46ce-b5e2-6424c5762b0f"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzMtMy0xLTEtNzgwNDk_823bf4e6-473b-4f40-833e-3fcb8568fe8f"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzMtNS0xLTEtNzgwNDk_7881688e-edba-496d-9098-292eb0df68cd"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzQtMS0xLTEtNzgwNDk_167ae727-f1c8-4c40-8afa-e665513e09a0"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzQtMy0xLTEtNzgwNDk_1d14587b-6064-4430-a821-b6e78deb3953"
      unitRef="usd">134000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzQtNS0xLTEtNzgwNDk_1d06ff90-5190-4ca6-be05-6fe5d8b690fe"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzUtMS0xLTEtNzgwNDk_257c1bd3-f2b3-4ad5-8128-aa5fd657be7f"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzUtMy0xLTEtNzgwNDk_5a19b953-7f05-45fb-a336-9e1a572e16b7"
      unitRef="usd">-25000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzUtNS0xLTEtNzgwNDk_58e67881-8bcf-425b-add1-41dd72b9d1d4"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMS0xLTEtNzgwNDk_72fb9c4d-a2e0-4716-b9d9-545e381923fd"
      unitRef="usd">-28000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctMy0xLTEtNzgwNDk_38047b04-e878-4044-a21a-d231b5aa0a44"
      unitRef="usd">-26000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzctNS0xLTEtNzgwNDk_c46ae9f8-e21f-4f94-b533-a1766b3f0541"
      unitRef="usd">-29000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzgtMS0xLTEtNzgwNDk_0135c77a-1b27-4e38-b3a4-afeef879f68c"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzgtMy0xLTEtNzgwNDk_094a675b-6f5d-42f5-82ec-4a14eee3ccb8"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzgtNS0xLTEtNzgwNDk_91fb39bf-b807-4819-8fe3-bf2ae9d4e9c5"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzExLTEtMS0xLTc4MDQ5_276bfd58-2b55-4993-872a-e44193c23d7c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzExLTMtMS0xLTc4MDQ5_db521f23-a156-4fb9-b0e1-57e794cd39c4"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzExLTUtMS0xLTc4MDQ5_be828dcb-2dbe-4528-9852-f1b6841162d0"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEyLTEtMS0xLTc4MDQ5_71959d66-83ea-4de4-8040-e92eafa3d091"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEyLTMtMS0xLTc4MDQ5_c5a82f75-9b1e-43c6-a6b6-837f97732839"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEyLTUtMS0xLTc4MDQ5_6077f9d9-be6a-41db-8809-b67fee6e70c7"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEzLTEtMS0xLTc4MDQ5_b84dfe85-2dc8-4702-a7a1-4c7f4ac4ed80"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEzLTMtMS0xLTc4MDQ5_3cdc6966-93fa-484b-9902-2f287623968c"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzEzLTUtMS0xLTc4MDQ5_dfdaa587-59d3-463f-8b78-6bfd388a6a75"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE1LTEtMS0xLTc4MDQ5_6eacf259-09b8-4de3-b04d-cf3a133db0a1"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE1LTMtMS0xLTc4MDQ5_f146666f-8a08-43b6-9dc2-4c7a251ea1da"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE1LTUtMS0xLTc4MDQ5_26c2ec10-ce45-445c-aa26-013958700cfd"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE2LTEtMS0xLTc4MDQ5_c1d5dcae-d791-4029-8cb9-7645e4182394"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE2LTMtMS0xLTc4MDQ5_8992bede-13cd-4280-a758-8deb0f7307f8"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTphNDViNTM5ZGVlNjA0YjZhOGI4ODM4ODM0ZjYwZGYzZC90YWJsZXJhbmdlOmE0NWI1MzlkZWU2MDRiNmE4Yjg4Mzg4MzRmNjBkZjNkXzE2LTUtMS0xLTc4MDQ5_4f72f2b8-8860-4349-82cd-4f4fa0e3f48e"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM4NzM_0866409c-b407-45f5-846b-55f7a90d7571"
      unitRef="usd">-28000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM4Nzc_f62fe879-cef1-4cae-a418-6ae47f1ec2b5"
      unitRef="usd">-26000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzM4ODQ_b2f226c7-c42a-4daf-8bb0-7160cd4c8040"
      unitRef="usd">-29000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <elv:ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0MzM_12af0db6-da41-4f2b-9092-01102983d8f4">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzItMS0xLTEtNzgwNDk_a0cf276f-60bb-4aa4-a068-ba22c62757f4"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzItMy0xLTEtNzgwNDk_826bfe11-3779-48c4-9028-76e63bd60f43"
      unitRef="number">0.0224</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzItNS0xLTEtNzgwNDk_582e2155-4c4a-4bc8-a75f-9a2b8795cb3e"
      unitRef="number">0.0311</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzMtMS0xLTEtNzgwNDk_e7d06159-f8b0-4ac3-b94b-13f5ea47136c"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzMtMy0xLTEtNzgwNDk_33aeb050-4da8-4db9-ae0a-bce0505c5c66"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzMtNS0xLTEtNzgwNDk_cf9da7ff-9a3a-4e6b-b9d3-dc2be87c95aa"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzQtMS0xLTEtNzgwNDk_2f28c59c-524d-4bcf-b411-069bd952090a"
      unitRef="number">0.0502</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzQtMy0xLTEtNzgwNDk_9239017c-5e58-465c-b561-bd91006fea80"
      unitRef="number">0.0672</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzQtNS0xLTEtNzgwNDk_377e0c48-be36-4d07-964a-3f9c4ef2f273"
      unitRef="number">0.0733</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzUtMS0xLTEtNzgwNDk_7ed267e2-35ee-427b-b9dd-21b93ee097a5"
      unitRef="number">0.0382</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzUtMy0xLTEtNzgwNDk_347cc2d0-8325-4aa4-ab42-da81f7ed8764"
      unitRef="number">0.0382</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzUtNS0xLTEtNzgwNDk_a9cac238-d4dd-4ded-a59a-e578c220c736"
      unitRef="number">0.0382</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzgtMS0xLTEtNzgwNDk_7ad0e113-411d-46c0-b403-fa6a873107dc"
      unitRef="number">0.0249</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzgtMy0xLTEtNzgwNDk_1d810cfe-9307-40fe-9ac7-92383717e644"
      unitRef="number">0.0199</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzgtNS0xLTEtNzgwNDk_275862fe-f3d8-45dd-a5a1-c94d8c8c23f3"
      unitRef="number">0.0293</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzktMS0xLTEtNzgwNDk_77023b85-8ce2-4706-93b7-93ab799328c4"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzktMy0xLTEtNzgwNDk_4c720e6d-f926-4047-b648-4ecfbc424de0"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzktNS0xLTEtNzgwNDk_f6710b09-661b-4d87-bf84-07fadba730c9"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzEwLTEtMS0xLTc4MDQ5_ec846090-b84d-4c1f-a495-632fa502a1cf"
      unitRef="number">0.0643</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzEwLTMtMS0xLTc4MDQ5_a4d014dc-3763-4c0c-a038-d43a0eb6fd3e"
      unitRef="number">0.0660</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzEwLTUtMS0xLTc4MDQ5_2cf769cd-8492-456e-b058-cf8ccb124449"
      unitRef="number">0.0700</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="iae84c4a7fc5c45f9ae54f7c42dd1cc58_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzExLTEtMS0xLTc4MDQ5_60e6a956-4c45-4ea3-beb5-b7589b725cc9"
      unitRef="number">0.0156</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ib94d156a0b914d599dbd6a5d038e0b79_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzExLTMtMS0xLTc4MDQ5_5b318a41-a3ea-4de9-9873-d427c945bbf1"
      unitRef="number">0.0087</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i55dbd821dfe84d9ea2d1908d9f358d80_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTozMTdmMTgyMGFmODE0MjU0YmNhMmM5NDI4YzhmMmNlNC90YWJsZXJhbmdlOjMxN2YxODIwYWY4MTQyNTRiY2EyYzk0MjhjOGYyY2U0XzExLTUtMS0xLTc4MDQ5_3b5e50ba-31c7-4c73-bd60-55cb35bbe743"
      unitRef="number">0.0181</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="ic34e126013bd4bdd9dcbc1e1560410d4_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQzNDY_24a8c74b-497e-45cb-996d-a948458d3a09"
      unitRef="number">0.0800</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="ic34e126013bd4bdd9dcbc1e1560410d4_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQzODM_6b9e8f33-8fe8-47aa-ae6c-34ce24ab22ea"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i28bb80744cf5451abb433b7a2ae2b2ea_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQzOTg_6bf8856b-577d-4cff-8413-8f0a7e8c4cae">2035</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i1af3c75b085341f79aae1e5b4a9109ee_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQ1OTY_156a0946-f6d6-41ef-b4b9-0c7345ff1649"
      unitRef="number">0.0650</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i1af3c75b085341f79aae1e5b4a9109ee_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQ2MzM_0c4dded3-a175-4b2c-a49b-a976fb93d0bf"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i411e095557594f3599b08db79d9385d3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzQ2NDg_214e7ab0-da39-43f3-8c62-9128ebd88b1d">2035</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ifa0439546d944cc89a588764266c7975_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzUwNDA_21026eb4-04b0-46ca-9426-0b784c1dd609"
      unitRef="number">0.37</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="idecc2f49500d45e9a24a291a9d799fff_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzUwNjI_efbf039d-052d-4872-b2d3-25584eb146ae"
      unitRef="number">0.58</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i35c312959f4143d697939a1225baf4a8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzUwOTY_df21cae9-4d96-4274-add0-1d078b25e5fa"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="ibd444af0664e4c1298d3fa8d8b705ead_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzU0OTc1NTgyMzMwNA_ea63762d-ef2e-4115-9991-ddb6e9d0aa49"
      unitRef="usd">2000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="if05d6861eb1d4839b34b143297bc3b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzYwOTA_0f7ec18a-aa69-4c98-ba35-8f9736c08e6a"
      unitRef="usd">3000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0Njg_e2138289-fee6-4c8e-ba7b-c016189c2bc6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2022, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $36, and excluding estimated claims settlements to be paid from other benefit assets of ($17), are as follows (see Note 7, &#x201c;Fair Value,&#x201d; for additional information regarding the definition of level inputs):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance company contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in DOL 103-12 trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December&#160;31, 2021, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $48, and excluding estimated claims settlements to be paid from other benefit assets of ($29), are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance company contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other types of investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in DOL 103-12 trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other benefit assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <elv:DefinedBenefitFairValueDueFromBrokers
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzY1MTY_2b7d0ff3-3c05-4716-9fd8-d60525bc898f"
      unitRef="usd">36000000</elv:DefinedBenefitFairValueDueFromBrokers>
    <elv:ClaimsSettlementsToBePaidFromOtherBenefitAssets
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzY2MDM_ace47ade-a75c-4349-8758-bb586ea89054"
      unitRef="usd">17000000</elv:ClaimsSettlementsToBePaidFromOtherBenefitAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i073e475229744657ac73e9da590e83f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtMS0xLTEtNzgwNDk_ba802882-e11a-4540-bb92-ebbcf316cc60"
      unitRef="usd">489000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4bc1af1b98554725ab989022f0630a0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtMy0xLTEtNzgwNDk_df2d65f2-9562-4c89-9a65-54fdc285fc8f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3304b8d471184ac39be41951a5853e03_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtNS0xLTEtNzgwNDk_06cf6bc6-b117-4ebb-9ffd-16b204f6d0f5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i857507cd2bed48a9b9fe3fbc5b737056_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzQtNy0xLTEtNzgwNDk_d832dba8-a7d6-433f-8e2d-bc855fca5285"
      unitRef="usd">489000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i8ace04bb2beb40b5a516c227c3ea00a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtMS0xLTEtNzgwNDk_90dc25bc-bc25-454e-a464-11c6455e4233"
      unitRef="usd">145000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i60a7d2ba705a4df69942c441186b72ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtMy0xLTEtNzgwNDk_907f6242-1bce-4284-b47f-4cf3110bdeb6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id40578ab1c8b414884a39f3c0dae2822_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtNS0xLTEtNzgwNDk_e31ba4b5-0eae-43b1-87b5-c3a53cb6038a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i30cc7418cfc74f5ba17ab4369f714947_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzUtNy0xLTEtNzgwNDk_2dd02982-5b71-49e1-ae4a-aed171a5ef4c"
      unitRef="usd">145000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i20102145585646cab0be477d78b18a73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtMS0xLTEtNzgwNDk_c57df7bb-006e-4be5-9b68-2a2eb347aad3"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ibb6ab942bd2841168cdf7a7b4a3187a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtMy0xLTEtNzgwNDk_bc92078c-7b5e-4f24-896d-03a29ca53111"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ibda9b4fba37e447fb4c9600c624c8dc0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtNS0xLTEtNzgwNDk_888c477c-3b67-490c-b6cb-e1663352ca27"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ib3f81cdb55ce4e638a62241e00ebf0de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzYtNy0xLTEtNzgwNDk_541712b8-d8c8-4ba7-adbe-7bd5dcf9572e"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if8d73bdd3b14402d844c2c0c59694668_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtMS0xLTEtNzgwNDk_4697e7b1-a0df-44cc-a43c-7b945f528cf8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i9f28b66f26ff499d8c7bd3a51827b9ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtMy0xLTEtNzgwNDk_540b7ca8-b93a-4206-83ab-ef4fb02af338"
      unitRef="usd">247000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4724ad9e28e04afa90e6467a8712ebf7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtNS0xLTEtNzgwNDk_2bf70f4d-c4aa-4ea1-9604-bad3c9e28751"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i62f9bcc18dfb447fb775b32088b6531d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzgtNy0xLTEtNzgwNDk_7e547279-9f61-42f2-9c21-516fb6286fa7"
      unitRef="usd">247000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="iaf38d6a8dac24b72b1557ce07935c19e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktMS0xLTEtNzgwNDk_ce574c99-0856-4ab6-947a-8400d9be9311"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ia3757024d2c6475cb1979d3770868e66_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktMy0xLTEtNzgwNDk_8c15f7ed-ec10-4bf0-9da7-603c12ada1ce"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="idc490491d76a485b890f14584a038a3d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktNS0xLTEtNzgwNDk_5c1c1451-a30f-4a13-9d0f-bc08c7f9e1d6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i32d53728a1d54d7b9516dd30a8bdda03_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzktNy0xLTEtNzgwNDk_8962d9ed-80da-407c-ad26-ea40ff88bee6"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i0c392f7e463f4339b291aa741cf0be26_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTEtMS0xLTc4MDQ5_2948a63e-cc51-4c6c-bf94-ebc7e9a3a131"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i2290abd15315443bb3b678c9c9e06e50_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTMtMS0xLTc4MDQ5_d673c159-a13f-4672-acc5-7e9fdfdad06b"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3bca97fbdff84230a99f35c1a1dce85d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTUtMS0xLTc4MDQ5_b11716a7-0c12-41dd-8366-1ad476f8f1df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i5847c45467bd4402971d8c43f9e23685_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEwLTctMS0xLTc4MDQ5_94a2f558-1720-4434-aab6-4f07b34d3e3a"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ic8fa58a7f71b41e5ba27e355644a55ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTEtMS0xLTc4MDQ5_9b55db3f-f990-42b6-8c7e-4c2423bf6040"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ide6d48987cd74ff3be80bbd508db4661_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTMtMS0xLTc4MDQ5_a913473a-8993-4bed-9b05-e51d82eb9ef9"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i37817d0ad4574456871358f331c06a5a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTUtMS0xLTc4MDQ5_cc10e0f8-4267-4d58-9d4d-60648f1d685b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i717a210731b940ee939db3c1dbba5956_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzEzLTctMS0xLTc4MDQ5_6635973c-886a-49df-84bb-6e4db63b1554"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ibb399901683c4c35b4197be484a877d0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTEtMS0xLTc4MDQ5_6d60af66-0f1f-4e64-a646-645fe4b6cb27"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ifc920e05c21b44d7961db2b67b504016_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTMtMS0xLTc4MDQ5_36f21a80-e082-49a9-b987-376d4fb1a9e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="icac85b6a86c64d77b811c48e62a14bb5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTUtMS0xLTc4MDQ5_0e743d72-9226-41d5-97b8-4f710ad509dc"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if89014b28ae34bfeabe6689041e3ca5c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE0LTctMS0xLTc4MDQ5_146def5d-b036-4a5c-9fea-e9c7c9024487"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d1a53d49d5c4867aa039a46e7568ed3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTEtMS0xLTc4MDQ5_ecbcae49-62b7-4500-9818-aa5d000ddf73"
      unitRef="usd">673000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5fec0c29d10b4a398f12075276df4a35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTMtMS0xLTc4MDQ5_24d1373b-b3de-4362-babc-f481ce8655e1"
      unitRef="usd">800000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idea2c0b2ce6a4178bc52bfce6465f76d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTUtMS0xLTc4MDQ5_174a2a35-4bad-4e92-92d3-2469f23b3ce6"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i290e040e29e44712bfeb543bae80308f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE2LTctMS0xLTc4MDQ5_dcaa8502-c2d0-4fca-a43d-71d5156bdedd"
      unitRef="usd">1627000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i218998b309404346862bc9cdba62f2cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE3LTctMS0xLTc4MDQ5_dbdc75b2-67d6-49c8-9d40-97d8ab21ad14"
      unitRef="usd">71000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ief4f2b19fc0245a59b7962eec5c99085_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzE4LTctMS0xLTc4MDQ5_dbd00221-3ab3-4ca7-a6b4-806d3fd9f239"
      unitRef="usd">1698000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i0f55d4ef714f45e2a97aae94dc3b7ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTEtMS0xLTc4MDQ5_39e707d5-4e35-4e79-8dee-83b40379733a"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ia4f648bcd3ed4b2299ff8051a9d130f6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTMtMS0xLTc4MDQ5_df2b0c3d-fcee-4f0a-b3e3-26921f28f185"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id9ce52d351384652a25cea41d5bf10d9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTUtMS0xLTc4MDQ5_a6471805-47f4-4be9-bd74-abeadb1e83e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i58e83d370570483a84584b1ba51b4a0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIyLTctMS0xLTc4MDQ5_8fffac27-5a1b-4c08-8a67-d35ba8aebefd"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie4e1af2b6d3041098336c9393584e9cd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTEtMS0xLTc4MDQ5_173e4a97-15d0-4247-8b05-42c5f4c24ffd"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="iab89283ade174a0bb7fe3b2918c3c835_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTMtMS0xLTc4MDQ5_83550cb9-49e0-42c9-bb7b-713330d5550c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3c28c3b58eff4d8e83e797a3c9dc86ab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTUtMS0xLTc4MDQ5_f60ed795-83fb-428b-93a1-70092afb1bbd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i9a52d405845744e3a22ff6418d046838_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzIzLTctMS0xLTc4MDQ5_bfc532be-b090-4d57-99ab-d18f2ea7310f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ica846717e1184bacb54d96b42ff8bfb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTEtMS0xLTc4MDQ5_9ef7c0da-322c-4ac5-976f-39d5ff3cfb6f"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ifdd588c1a32a4b318e8824b9e80e833f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTMtMS0xLTc4MDQ5_391386ee-c878-4d00-8fbb-a309a118f52d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i42abf7d75b0f4617992ff04363b8de28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTUtMS0xLTc4MDQ5_b9030939-a1b2-4c2c-970b-ace3ca48d988"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3186402fca52479e94b30bea316112da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI0LTctMS0xLTc4MDQ5_eb69df4d-f275-4118-be6b-98e937741476"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i68819c4736484941b4667da3db092246_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTEtMS0xLTc4MDQ5_e74a50a2-8ad5-4b11-8bc1-46bfa58811c6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4fac223fbf12427cb4c55b80a18072a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTMtMS0xLTc4MDQ5_6040a76e-9afe-4dd8-8d58-b299c7e93302"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ic57c573544eb42bea430ba41085525f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTUtMS0xLTc4MDQ5_4e59b62b-0c7b-457a-9582-2c482ce47c05"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if8827a2fb2e7457595d626050de42f28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI2LTctMS0xLTc4MDQ5_fc8d70b8-c518-4008-9b99-91ae499c1d90"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="iee8708828d7a476587098de587d22948_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTEtMS0xLTc4MDQ5_cf486321-29a6-4bb0-afa7-71282d95212e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if15ac02c8fcd427fae5b76de3ef93c01_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTMtMS0xLTc4MDQ5_73950211-267b-4df7-95b2-c50938106913"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i2625252753fb4190bc4ba5269f5706d8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTUtMS0xLTc4MDQ5_6eb13c31-52ae-45a0-847f-164bf924325c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i86b02994b45b43a6a51141e64ad4bd6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI3LTctMS0xLTc4MDQ5_eb518a41-7f43-45a1-86f4-11c652705a15"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i6c345c140c9d4fc3ab7c4965bae458b2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTEtMS0xLTc4MDQ5_e9c8cf2a-e0df-4e7a-86f3-1596235e08a3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ieae1d87ac95d463f9fa59da4bbf23bce_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTMtMS0xLTc4MDQ5_a82dabc6-645c-4b7f-9bf3-08e0ba8f7d2c"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="iacb113e118e7452c88560640a9b79b47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTUtMS0xLTc4MDQ5_ad8d436d-6f5f-4c54-b6d3-410afa33e004"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="idb4dd465b3a644ffba70709abd0e98ab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzI4LTctMS0xLTc4MDQ5_0d898959-6f3d-4b16-83d1-5757779147cb"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="iec8f6315c869439fbc63a0932a14c1b9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTEtMS0xLTc4MDQ5_e40fa3ef-ae34-49ed-b47e-f292cba2a130"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i142cfd8898984756ad60bc4f86418961_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTMtMS0xLTc4MDQ5_46f46644-8e66-49d6-bdf6-e9455ecf538d"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ia5f46381d5d84ab897c5e33368443242_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTUtMS0xLTc4MDQ5_202fc615-e30d-4290-85b1-4b9829bec054"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i02fd6baa57ae461bbf3b32faaeb4ca35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMxLTctMS0xLTc4MDQ5_339874f0-fc74-4a22-966b-5cf064587c23"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id668c24327e44ed49160b1d70e4edf8e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTEtMS0xLTc4MDQ5_ea44333c-4d95-478e-a5f4-d9ac0f845769"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4e9ca1afbe084ad2b78b08a5a7a9ab88_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTMtMS0xLTc4MDQ5_88f4e945-b622-4f62-8ab1-567f76f07f1e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ia1b4418327794b1ea9613fab77ce0af0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTUtMS0xLTc4MDQ5_978d2a3c-ef32-4386-9350-268f876ce837"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ia71836a62a044a1a972a740f6319ef84_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMyLTctMS0xLTc4MDQ5_94aa9236-a73a-4a88-9cf9-93de79e4c328"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i92c7dc7c1587494599625760bf34889e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTEtMS0xLTc4MDQ5_90665ed3-24a3-41b3-b3a9-b81c5b9512bf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i549a8c00f0d749c38e43fa24e8a68fc3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTMtMS0xLTc4MDQ5_c43eccbb-373f-4b2d-810c-5d71c56624ed"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i64aa8a2e665348d281dbb4b93dab7c26_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTUtMS0xLTc4MDQ5_46100485-8c7b-4ff1-a846-ec8a73c5daaf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="icd5aaee2e719474ebec4de5223a6b859_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzMzLTctMS0xLTc4MDQ5_299385ea-00c2-4642-9931-6af7f94b068d"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc72fc42cfa546b9b9e91cd582c83266_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTEtMS0xLTc4MDQ5_634eb68e-1565-4bd2-b348-2ec8321e94e2"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia84c581ad8f34d408c44634c9e7d0f91_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTMtMS0xLTc4MDQ5_bf546637-fdfb-4f16-beb8-a5b360217071"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64dcb287d7ec41c48e54b1306c36a88c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTUtMS0xLTc4MDQ5_a5527e5a-8674-417a-b682-6ae9104cb934"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i5524db3a83e64bfe85a82d222a654d8b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowNjYwN2Q4Y2Y1MTA0MjIzYWFiYjUzNmNiMjFmNjc5Ny90YWJsZXJhbmdlOjA2NjA3ZDhjZjUxMDQyMjNhYWJiNTM2Y2IyMWY2Nzk3XzM0LTctMS0xLTc4MDQ5_98db07ce-ca6f-47e7-ae60-c1e98dfb87a5"
      unitRef="usd">316000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <elv:DefinedBenefitFairValueDueFromBrokers
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzY5Mzk_206f4e67-4f1c-4076-87f6-af3b2175b2e6"
      unitRef="usd">48000000</elv:DefinedBenefitFairValueDueFromBrokers>
    <elv:ClaimsSettlementsToBePaidFromOtherBenefitAssets
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzU0OTc1NTgyMjc3NA_23596a33-409d-49be-aea8-29f58f4e25ad"
      unitRef="usd">29000000</elv:ClaimsSettlementsToBePaidFromOtherBenefitAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i37480e91464c49dd98f091245e025713_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtMS0xLTEtNzgwNDk_d0911a01-d30f-4f22-8fb5-a8ebc76a0663"
      unitRef="usd">682000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i90158ecd8c3e413386c593b81c9ec032_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtMy0xLTEtNzgwNDk_8338550a-b320-42fc-827a-87f65183c444"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie26ec646267f4e85948a6ab2df7b23a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtNS0xLTEtNzgwNDk_0c02cb8a-951f-47eb-837c-e886f8f02f1c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i7f8dc92496214bc1a120c9a3281fc5e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzQtNy0xLTEtNzgwNDk_2fd56f1e-2667-44c4-8d7a-24f94f50cc31"
      unitRef="usd">682000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i60a6a69355e3453493947ac5e9722c59_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtMS0xLTEtNzgwNDk_69a19866-fc56-4b47-ae59-41791327a967"
      unitRef="usd">204000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if820e1dc7ba1477ab9046f6f9fa76088_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtMy0xLTEtNzgwNDk_41bfa1f0-71ea-4f10-8643-36cbc45a36e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ic9bc64d208594f82a7ea1b06af17e59d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtNS0xLTEtNzgwNDk_0c75ea8d-180e-40d4-a873-67162b848998"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ic19857bfc8f948f1a850a6668ed7d8a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzUtNy0xLTEtNzgwNDk_4255e47a-e2c9-4b97-b9e3-d7a3aacfcc9a"
      unitRef="usd">204000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i92a5b59f05da4d839616ac13e1467ef1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtMS0xLTEtNzgwNDk_8c950b26-c53e-494a-ac35-a5ffa9ec0a28"
      unitRef="usd">49000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ic81c850442314891a6ae5cc1a2f882f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtMy0xLTEtNzgwNDk_98ecb918-bd05-4e9c-9f9e-282018cf2209"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i45e8077800b44d75af0b74ead71c6510_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtNS0xLTEtNzgwNDk_213f61e0-b48c-4dc4-a11e-efc9881a0dac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i47c99e708c60467094ebc0103c16902b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzYtNy0xLTEtNzgwNDk_9034a938-edd1-4f3a-ac97-eb5f6f5eacf3"
      unitRef="usd">49000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i8a2432a93c2642648f67e1ecff14d557_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtMS0xLTEtNzgwNDk_780fce28-5b7c-4151-a0f7-e29327f00296"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i401d253c03d541b2b15b77b43f0fd1df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtMy0xLTEtNzgwNDk_c101cd82-8c69-46e7-ab75-816966b03f7f"
      unitRef="usd">395000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie48af28deba5435bbd08534c18358b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtNS0xLTEtNzgwNDk_9a7633b7-d305-44ae-9dac-9e101a0a8fe0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id09876f128a94429b9227814e8df6c80_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzgtNy0xLTEtNzgwNDk_5e1a9d44-5deb-45c1-8bf3-b6e791a43bd4"
      unitRef="usd">395000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i619c68bb39df4437a5e73314f08f8e67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktMS0xLTEtNzgwNDk_90a1c1bd-24c4-400e-9291-14d6c9898b2f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ib6632e89a64e494ba984e898352b2f9c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktMy0xLTEtNzgwNDk_9c907608-0796-41c5-b2f5-6c1be0d90d13"
      unitRef="usd">379000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3e8c406fd2c74fdfafe3a57ed54a171f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktNS0xLTEtNzgwNDk_7b3ae526-7a83-4b18-8030-6284e42d1a5b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i61ca6e2453404a48a52750e3e90e1c47_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzktNy0xLTEtNzgwNDk_49a876bb-19b6-41aa-9c66-1d23562b5b58"
      unitRef="usd">379000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i8105dc0c76f840128a4f6f87b9a897eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTEtMS0xLTc4MDQ5_8c3b799e-3750-43bd-9c44-7d2078d65c2e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i2552bb36ef2c4777893433a656282c25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTMtMS0xLTc4MDQ5_33a90283-a245-4980-ae1b-4347ab6c20b7"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i23a5175770b84cb4bab9529b3ce7bec7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTUtMS0xLTc4MDQ5_f14e5f1f-bbdf-4fe5-9f63-d654a5ab3c8a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie1e3d70c034b4a9085ff1de6d2ce55f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEwLTctMS0xLTc4MDQ5_02ce1ee8-bbd2-4714-bf38-eb7ca00dd9be"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i131d7dc36ccb49a299712a5e82f3de3d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTEtMS0xLTc4MDQ5_6dc62e63-7260-40c2-8931-a95a24212e67"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i2f9ec8958dad4e25b4dec1bdef155303_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTMtMS0xLTc4MDQ5_14c0ffa1-80a3-4338-b366-fa3cf0ff868a"
      unitRef="usd">106000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i666be2a8dc0345ef89405b86d686e7dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTUtMS0xLTc4MDQ5_c02c32f9-c99e-46b7-98f2-f6fc39d5da15"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i60bbfca782904064adf3f965eb407772_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzEzLTctMS0xLTc4MDQ5_045b7f0b-36e0-45d3-a49d-1ae6f6c66669"
      unitRef="usd">106000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4c793768fac34476a639c2429c54308f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTEtMS0xLTc4MDQ5_efdd6186-f43e-4f4b-94f6-50f65c744640"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i718358de146a4a6c93c1a4fe8ea02b90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTMtMS0xLTc4MDQ5_3d1e8756-36d4-49d4-bafc-26d945f681d0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i6c4b302cec1d435aa72e21490d245992_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTUtMS0xLTc4MDQ5_acc5ce21-8557-4e5d-8155-db4bdee50124"
      unitRef="usd">179000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i0301f217169748b8b9564b716734656d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE0LTctMS0xLTc4MDQ5_1b8bc268-bf15-41f3-9464-b3b19a5fad05"
      unitRef="usd">179000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3486851087a1461cbc7cdbd886031e0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTEtMS0xLTc4MDQ5_a320f462-32e3-4c32-b677-e93148311c0e"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i824079b6e48d4bb5800315785acae403_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTMtMS0xLTc4MDQ5_98ec6bbf-ed8f-45ff-b935-c080fe8c7877"
      unitRef="usd">978000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8acd54cdd7834f65b9fd34a3eecb83ba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTUtMS0xLTc4MDQ5_13d68c7f-db93-4f71-9ec6-7374dbaa5834"
      unitRef="usd">179000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ib4ff876d8f4d4e13bfb398ce15c78dfb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE2LTctMS0xLTc4MDQ5_76bd923d-1c03-4494-82b9-8a1e626c6563"
      unitRef="usd">2092000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i2da33ae4440b4e3e9858280b13b26b86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE3LTctMS0xLTc4MDQ5_9e0ad4c2-b84b-483a-91d5-93756e891f29"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i1df6e9e072f7410bbe91dd8464dc1559_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzE4LTctMS0xLTc4MDQ5_253c8f92-0934-406c-b0cb-da865b74dc8a"
      unitRef="usd">2170000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i89b4a5ab5d5945078778d6bf6cb1a8c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTEtMS0xLTc4MDQ5_468acddc-23c0-40cc-b3ff-4d25943460c6"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if81f254578c34d74b6c7ee4044f8bdda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTMtMS0xLTc4MDQ5_2f8a1186-24e2-429e-b328-8108fd2dcc05"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3b6ac436f09047b58b9afbeeb2bfe737_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTUtMS0xLTc4MDQ5_e0da5b6e-2600-47d7-97f1-efa7c299d448"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i64f7e00faf9c423987fb23403b1098bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIyLTctMS0xLTc4MDQ5_64ec83ec-b513-4653-b144-e9200c5576ea"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="idc47fc0ad92542a9bae68627e6bef5ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTEtMS0xLTc4MDQ5_629f1a53-6b72-47c5-bf02-9b3ecaf2c179"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i25321d10a7f6437fbb4bcfce57f68be4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTMtMS0xLTc4MDQ5_a266e327-82bd-491c-ba16-b7aeef01b631"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3ea480fece154d2f860656f2677bdfd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTUtMS0xLTc4MDQ5_26d508b6-bbe1-4658-bc29-4553405f854f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if3ca81f42d6d4bab8cfeaf80de0cb1b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzIzLTctMS0xLTc4MDQ5_8b09acec-4f1b-48de-983b-e9903859b113"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i7a2ebfa875334d19ad5216074deb2d4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTEtMS0xLTc4MDQ5_10b9f530-c719-4721-94dd-a02801d6e88c"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie0a519ff398f494e846042ee96a98679_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTMtMS0xLTc4MDQ5_e1db4022-dc02-478e-bcac-f342bdf2ddf0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i7a64acd001884c8e9e9bb3b1a965529e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTUtMS0xLTc4MDQ5_63c8befc-294a-4c36-837a-970fd8b9187a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ib46c9cd33130445a91236aacb780d027_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI0LTctMS0xLTc4MDQ5_117f74ef-24d6-44e9-bdd8-5d08b7fbe84f"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="icdfe1e0781264622a6679afeb0a9c720_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTEtMS0xLTc4MDQ5_a84a7665-8662-4736-895f-ef05a449b3cf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4bce5bacf7c24b4f9dc864afd7e4ca87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTMtMS0xLTc4MDQ5_fe408c48-5e79-4b72-831b-4c81c762cf8b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i917c455132fb4e1e9f340d3bad48d102_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTUtMS0xLTc4MDQ5_bc9deb61-37e8-4907-b905-6869dd63d2be"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="icefbd8bbbac7446baf3a38dca505dfea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI2LTctMS0xLTc4MDQ5_7043062c-2237-4257-895d-3ee05b4c72bc"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie579e5cdf455475b9502356566def862_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTEtMS0xLTc4MDQ5_940774a9-259f-4000-9a44-d9e07a0f901f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i6e6eee54cd694a2ca132251fbf4a7f5e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTMtMS0xLTc4MDQ5_60452f31-666d-42cb-8ab0-dda521547fce"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ic7a66d7e68f44e50981c5465d04e22bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTUtMS0xLTc4MDQ5_7f9fa6c9-6a64-4e2e-932e-855c7a9ed325"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="icd7b6dd2b55348cba5836b9c067d3c29_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI3LTctMS0xLTc4MDQ5_a2a403b8-547d-498a-a029-1ae3e90d34f2"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ia263eb55917d4d3fa6a60e7db1c48a3a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTEtMS0xLTc4MDQ5_d7975c64-a20d-46a5-bb10-1230285c0005"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4974aa0eb2c24470b0039864c0415900_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTMtMS0xLTc4MDQ5_e221705c-717a-487b-9e9c-b6c9e0c7b713"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i1ded0fd871644ff591de8addd589219a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTUtMS0xLTc4MDQ5_b32aa705-796f-4d12-85bf-8f50ec9b7d3b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i8c81070f0b3b443c8f18a8f1214732bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzI4LTctMS0xLTc4MDQ5_7667f800-1a72-4812-b87d-ff21f29879fc"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3d680746121d4419b3c54ef8acb7b9fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTEtMS0xLTc4MDQ5_3d5b96f7-6cd0-452f-9e6a-5d774301b1ce"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id20a6873d906447385de48452526511e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTMtMS0xLTc4MDQ5_2769fb92-e66f-4492-8522-59d9eade3363"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i5cc7ea082cf84448a7ec7762124b2a4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTUtMS0xLTc4MDQ5_1ef66f8b-827e-45f8-b6c5-2fec55070420"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i4376d31b137c4d3a8e1c905705497935_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMxLTctMS0xLTc4MDQ5_6526b724-603e-4350-8adc-2ea490e887a4"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i52db6dff7f164d5e890ff1578cbcb759_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTEtMS0xLTc4MDQ5_107b206e-c7c0-4756-a062-a8abe5c420e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ie4b5962d9e5e4af890e2358bb3edbb03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTMtMS0xLTc4MDQ5_c8a99c96-98e7-4e4b-aa9b-e7409430f1ea"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i3bcdd3e9146f4beca1f89cb52fea78f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTUtMS0xLTc4MDQ5_470a735e-a19a-45ef-8c63-58030e8710cf"
      unitRef="usd">338000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id541168132e04301912466c96cf4ad90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMyLTctMS0xLTc4MDQ5_a0d8a397-b453-4ca0-9cac-779d6963b6d2"
      unitRef="usd">338000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i15061749f3f2485aa1798b8186e3f2c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTEtMS0xLTc4MDQ5_ceb3d99b-4330-40bf-b45a-f3c8046d7daa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i087044734b154901b0cfed0b0f5d93dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTMtMS0xLTc4MDQ5_91c78c44-30ca-4029-8819-2948d10f0bd5"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i46e196f381254b4da2543763f22de2fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTUtMS0xLTc4MDQ5_ae081e77-8249-46e2-8106-73502e716cc7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="id05c5e1befde4b3d876502ebb2794242_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzMzLTctMS0xLTc4MDQ5_0a62aa93-d9f0-4cad-9763-dd4acac0eee8"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53abc6af4dd045279ea54e62550af65d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTEtMS0xLTc4MDQ5_1c0f6511-8b74-43e5-b4e2-3ee9470c6091"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib689e1a2aa1847a19d4aa925acdcc69e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTMtMS0xLTc4MDQ5_59c754ba-55fe-4d97-b5fb-f49de5e1398d"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f3aa30468184cb8b88f01ef4d14e83b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTUtMS0xLTc4MDQ5_7f731323-39b5-426b-ac36-23c31887d90c"
      unitRef="usd">338000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="ice5874492cbb402d81d69b55109ae43c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTpkMDc4YjU1N2JiYmU0ZjQxYjZlYjE1ZGFkY2ZkYjAzYi90YWJsZXJhbmdlOmQwNzhiNTU3YmJiZTRmNDFiNmViMTVkYWRjZmRiMDNiXzM0LTctMS0xLTc4MDQ5_aaf42aa8-69e3-4a7a-8cbf-fff2f9457036"
      unitRef="usd">398000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0MTI_508ee40a-74af-43e8-b669-bb6b48bc9d03">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Company&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life&lt;br/&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets relating to assets still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets relating to assets still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets relating to assets still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7580de5335c2453fbc6266565e5baa9e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzItNS0xLTEtNzgwNDk_b21c5356-6494-4679-b4ad-80a4832d8236"
      unitRef="usd">179000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic48a8bf89b7b4def9e1a900fde56e8da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzItNy0xLTEtNzgwNDk_234b570f-2479-4560-87d5-937ced2f7c37"
      unitRef="usd">338000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5f9bbbaabb04060a11a6fd22a348392_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzItOS0xLTEtNzgwNDk_4cd4c98e-84ab-47cf-be2d-afedb8b0541f"
      unitRef="usd">517000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i80355d52e2674470b51aa353a404d82c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzMtNS0xLTEtNzgwNDk_76dabc98-fd64-43e2-ac19-0b2350d6adfa"
      unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzMtNy0xLTEtNzgwNDk_0cb9e986-e6e7-433d-874e-62d6f1768192"
      unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzMtOS0xLTEtNzgwNDk_84ad6c59-a795-4bc4-afe8-a9ee1cc69ecb"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="i80355d52e2674470b51aa353a404d82c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzQtNS0xLTEtNzgwNDk_00c838eb-4ecb-452d-828b-4bd416ffabb0"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzQtNy0xLTEtNzgwNDk_641be110-ed01-4f57-b43b-6976bd1fd1a3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzQtOS0xLTEtNzgwNDk_76026161-8064-478e-8529-c3dcff54fc50"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="i80355d52e2674470b51aa353a404d82c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzUtNS0xLTEtNzgwNDk_00bbd057-e647-40b1-b473-5251a9c466af"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="ic5c78fc9d73b4ec386aae7232ff68f85_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzUtNy0xLTEtNzgwNDk_90410a6f-76f4-45a3-964d-19618e9f9c3d"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="i087a822a1c0e4d969893b0be9331987c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzUtOS0xLTEtNzgwNDk_6d112535-3f21-4810-8e7f-53063dbb634b"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic2f8ffbfbcd842e88af9bfbc67f7e567_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzctNS0xLTEtNzgwNDk_8ed60615-ccd4-4eb2-97c6-76634a504ac9"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i31ad54fe654c42efbd77c7bb585d643d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzctNy0xLTEtNzgwNDk_c77ab60c-4660-474b-b83f-08e034ba8e43"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d2e3cdf76fb4346a9739172b0a28be0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzctOS0xLTEtNzgwNDk_302f891b-173f-4e77-9d4e-2a5f570224c8"
      unitRef="usd">424000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib360e9af4b21497d82c013681a5dadae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEwLTUtMS0xLTc4MDQ5_f1374b78-8b58-4e09-b6a8-4195f50d9d56"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iedd65a74e5704da5920113ea7aece196_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEwLTctMS0xLTc4MDQ5_f9afea62-71fc-4cc1-a242-36b4af6a8446"
      unitRef="usd">323000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia99956a06c7e46e1849e1ddf398be5df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEwLTktMS0xLTc4MDQ5_66c53ed8-7f47-4d29-a8fd-cbd418943cc3"
      unitRef="usd">512000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzExLTUtMS0xLTc4MDQ5_34bce0f6-e0ae-41c1-b0a2-f25e97fbe5a7"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i6904393673c940ae893924fc97c16cda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzExLTctMS0xLTc4MDQ5_c3d20292-3a73-4f0c-9778-6375d708c2b7"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzExLTktMS0xLTc4MDQ5_69e3dcf7-721e-4837-8ae7-7f131685954d"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEyLTUtMS0xLTc4MDQ5_841b9b50-12d5-49c9-a1c6-ca650a7c65d3"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="i6904393673c940ae893924fc97c16cda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEyLTctMS0xLTc4MDQ5_38c8844c-40e2-46e0-b903-1c650bd65f69"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEyLTktMS0xLTc4MDQ5_2870c445-e51d-4c7f-aacc-0839a6b3b030"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="i01607854d2954557b3c9dc56a08ba4e8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEzLTUtMS0xLTc4MDQ5_7ccededb-a789-4948-ac8f-b29ba3acb41d"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="i6904393673c940ae893924fc97c16cda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEzLTctMS0xLTc4MDQ5_e281c61a-fc07-4372-be76-90f3444850b4"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="i6291c323cd2947f99a66560c9237a8e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzEzLTktMS0xLTc4MDQ5_ed12a4ba-7e2c-4e7a-b4c7-e6b2e6f62d58"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7580de5335c2453fbc6266565e5baa9e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE1LTUtMS0xLTc4MDQ5_ca04ed4b-38ab-44b1-b5a9-eb1b61bf0495"
      unitRef="usd">179000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic48a8bf89b7b4def9e1a900fde56e8da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE1LTctMS0xLTc4MDQ5_9f011050-56e3-4971-aabb-203293b87625"
      unitRef="usd">338000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5f9bbbaabb04060a11a6fd22a348392_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE1LTktMS0xLTc4MDQ5_99b3632f-c158-4d75-9262-355d506e4dc0"
      unitRef="usd">517000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i932bd361ffbc47c298c90d616e0667b0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE4LTUtMS0xLTc4MDQ5_04c04b9e-ab68-49d7-bd5c-e570efcbf2ad"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5fe4907f34814d2baa614ba2fc07e320_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE4LTctMS0xLTc4MDQ5_ef360f93-0d60-4d35-bf97-51405032073f"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89d6ceec20cd424fa94e7a6386ac5a78_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE4LTktMS0xLTc4MDQ5_61fd130d-173e-46df-89ec-89a74aeff05c"
      unitRef="usd">469000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE5LTUtMS0xLTc4MDQ5_cd018db8-1ab0-4ecb-8373-d55473cc56cf"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE5LTctMS0xLTc4MDQ5_2d900c2f-2a78-4b1c-9fe4-89359ca11250"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzE5LTktMS0xLTc4MDQ5_5efd2e65-5b83-45d7-86b2-3e2206dae8da"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIwLTUtMS0xLTc4MDQ5_36a5de9a-df82-40d0-a924-b32e9c8f0813"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIwLTctMS0xLTc4MDQ5_c40011c9-3cd6-4ab9-9224-f8bebf4c6071"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase
      contextRef="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIwLTktMS0xLTc4MDQ5_e710e510-cfea-43aa-a2f6-e52db6148d1d"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="icf7dc602cbbc414c8d26989876c4f4bc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIxLTUtMS0xLTc4MDQ5_552c5932-0713-4b2c-8c58-32323fc7ccf5"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="if4965ff9ee98482180cfc461f8aaa27f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIxLTctMS0xLTc4MDQ5_f57e1cc1-be23-466a-a60c-4579948f61cc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale
      contextRef="i0a87bd6f94554c7fb4c2de39612adede_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIxLTktMS0xLTc4MDQ5_37464b83-af7f-4c60-874e-f6e6537f3c01"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib360e9af4b21497d82c013681a5dadae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIyLTUtMS0xLTc4MDQ5_75a3db35-f699-4e05-a9dc-58c56086890d"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iedd65a74e5704da5920113ea7aece196_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIyLTctMS0xLTc4MDQ5_7bbdbf8c-9875-4eab-9c71-d0497c66311e"
      unitRef="usd">323000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia99956a06c7e46e1849e1ddf398be5df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTowMmIxZWMzNmJiNzY0ZmQ1YjhkNjIyMzkzNDk1MzMzNi90YWJsZXJhbmdlOjAyYjFlYzM2YmI3NjRmZDViOGQ2MjIzOTM0OTUzMzM2XzIyLTktMS0xLTc4MDQ5_ea04b181-66a8-4ee7-b72d-dfbf3486acf0"
      unitRef="usd">512000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzc3NTc_1adb3d47-67fc-4fc4-b100-d06ae0667485"
      unitRef="usd">4000000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="ib0ab691ad28642da93046ef891be4bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzc3NjE_e670e416-7762-4669-ad23-9c38c938fcd1"
      unitRef="usd">7000000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="i9c42f530033b47d8829379b411ebac86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzc3Njk_d6a08429-8a21-4721-8067-d9a3f4050096"
      unitRef="usd">7000000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzg0NDE_3d353c53-3f5c-4de9-a5d2-8df5d318a283">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as appropriate, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 - 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzEtMS0xLTEtNzgwNDk_654e7655-fcd7-4a2d-b9b6-c5e520c8ee2e"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzEtMy0xLTEtNzgwNDk_ab368f45-4f26-405a-9d75-19556966cc7d"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzItMS0xLTEtNzgwNDk_ae436cbc-d0e4-49ef-b4f3-736755708393"
      unitRef="usd">120000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzItMy0xLTEtNzgwNDk_dd766852-7e29-4f50-8659-bddc76a43975"
      unitRef="usd">30000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzMtMS0xLTEtNzgwNDk_95df3257-2ee2-4eb0-a296-0fda36bebf45"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzMtMy0xLTEtNzgwNDk_10a020d8-6fee-47df-8b90-0290447f7fa3"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzQtMS0xLTEtNzgwNDk_79c84019-2c18-46d5-b3cf-2a76d5ffa616"
      unitRef="usd">116000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzQtMy0xLTEtNzgwNDk_3aac4b44-2565-4bfc-9ef0-dfe492efa0ef"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzUtMS0xLTEtNzgwNDk_36604a17-e69f-4bed-85f3-2cce30d41060"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzUtMy0xLTEtNzgwNDk_096bbf46-38c9-4782-b4cc-74244b555ec0"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i72b759f5ad9048f5a21e88c5835d93b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzYtMS0xLTEtNzgwNDk_898dd901-dc46-4ca0-970f-cb92c9f914d8"
      unitRef="usd">526000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i10c987896cca46c88648cd9e0c631ac2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90YWJsZTplNjQ1NzUyOTA1MmQ0NTAwOTBkOTZmODYxNjE4MTdjYS90YWJsZXJhbmdlOmU2NDU3NTI5MDUyZDQ1MDA5MGQ5NmY4NjE2MTgxN2NhXzYtMy0xLTEtNzgwNDk_30bec5eb-ea09-42a7-91d2-9cffc44f2dac"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzgzNTY_b8b77c41-dc6c-453f-9d6c-3ff5e424a09c"
      unitRef="usd">275000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzgzNjA_54705607-723c-4327-ba08-81c1301bffce"
      unitRef="usd">241000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzAvZnJhZzozYWExYzFlODY3M2M0NTMzODJjMzYyYTQ0NjUwMTVkZC90ZXh0cmVnaW9uOjNhYTFjMWU4NjczYzQ1MzM4MmMzNjJhNDQ2NTAxNWRkXzgzNjc_adf11c53-7ef9-47eb-aca2-886d955bc53d"
      unitRef="usd">221000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0Mjc_7313191c-c3ce-4439-93ff-22b42e29c88d">Medical Claims Payable&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, &#x201c;Segment Information&#x201d;), for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business combinations and purchase adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years redundancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net payments attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business combinations and purchase adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years redundancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net payments attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business combinations and purchase adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years redundancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net payments attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period-end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated. The prior year redundancy of $869 shown above for the year ended December&#160;31, 2022 represents an estimate based on paid claim activity from January&#160;1, 2022 to December&#160;31, 2022. Medical claim liabilities are usually described as having a &#x201c;short tail,&#x201d; which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the $869 redundancy relates to claims incurred in calendar year 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December&#160;31, 2022, 2021 and 2020, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. We had increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that lead to the increased estimation uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Favorable Developments&lt;br/&gt;by&#160;Changes in Key Assumptions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed trend factors&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed completion factors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable development recognized in 2022 resulted primarily from trend factors in late 2021 developing more favorably than originally expected as well as a smaller contribution from completion factor development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable development recognized in 2021 resulted primarily from trend factors in late 2020 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable development recognized in 2020 resulted primarily from trend factors in late 2019 developing more favorably than originally expected as well as a smaller contribution from completion factor development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality improvement and other claims expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incurred claims development, net of reinsurance, for the Commercial &amp;amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paid claims development, net of reinsurance, for the Commercial &amp;amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp;amp; Specialty Business was $52, $266 and $3,796 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the cumulative number of reported claims for the Commercial &amp;amp; Specialty Business was 80, 87 and 81 for the claim years 2020 and prior, 2021 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $142, $325 and $10,462 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the cumulative number of reported claims for the Government Business was 251, 325 and 298 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incurred claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paid claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for Other was $1, $6 and $292 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the cumulative number of reported claims for Other was 29, 28, and 25 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information about incurred claims development, paid claims development and cumulative number of reported claims for the years ended December&#160;31, 2020 and 2021 for our Commercial &amp;amp; Specialty Business, Government Business and Other is unaudited and presented as supplementary information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cumulative number of reported claims for each claim year for our Commercial &amp;amp; Specialty Business, Government Business and Other have been developed using historical data captured by our claim payment systems. The provided claim &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are not a precise tool for understanding utilization of medical services. They could be impacted by a variety of factors, including changes in provider billing practices, provider reimbursement arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative number of reported claims may not be comparable to similar measures reported by other health benefits companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the Commercial &amp;amp; Specialty Business, Government Business and Other incurred and paid claims development information for the three years ended December&#160;31, 2022, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December&#160;31, 2022, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance lines other than short duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0NDc_732668df-0fe1-4969-b9ed-22dc83cddb31">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, &#x201c;Segment Information&#x201d;), for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business combinations and purchase adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years redundancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net payments attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business combinations and purchase adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years redundancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net payments attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business combinations and purchase adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years redundancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net payments attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtMS0xLTEtNzgwNDk_c9f88df5-9f78-49b5-b841-ef704b51daec"
      unitRef="usd">3847000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtMy0xLTEtNzgwNDk_473684ff-3976-4551-a4cf-552b7dc0a4fc"
      unitRef="usd">9157000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtNS0xLTEtNzgwNDk_eea592d3-e73c-4145-a1ad-2a37a712e6d2"
      unitRef="usd">278000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEtNy0xLTEtNzgwNDk_15743ac0-c307-405e-b224-cf942e601c33"
      unitRef="usd">13282000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItMS0xLTEtNzgwNDk_e6f5fc96-f5cc-46aa-b7ed-63c245ac3a58"
      unitRef="usd">13000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItMy0xLTEtNzgwNDk_6d31ccd1-0ce2-4bd3-8637-19f0149301d4"
      unitRef="usd">8000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItNS0xLTEtNzgwNDk_51262d2c-36ed-4f3d-ad3b-421094bf68ee"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzItNy0xLTEtNzgwNDk_9b791b2b-8e8e-48f8-a0de-436e91e79be5"
      unitRef="usd">21000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtMS0xLTEtNzgwNDk_b4717aed-8279-4fa3-9b08-8741953f67c1"
      unitRef="usd">3834000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtMy0xLTEtNzgwNDk_dfd541be-b1a1-4972-8a6b-5740d1578d30"
      unitRef="usd">9149000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtNS0xLTEtNzgwNDk_af238d77-9a7b-45e4-bb7d-6c46c7d32e06"
      unitRef="usd">278000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzMtNy0xLTEtNzgwNDk_9a562c2a-dca9-48cf-bcea-231a0d88dacf"
      unitRef="usd">13261000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtMS0xLTEtNzgwNDk_c0aac58b-e4ab-44c4-96ee-5969bae7163d"
      unitRef="usd">3000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtMy0xLTEtNzgwNDk_75650159-6823-4eb3-b3c2-82022c4ce3f3"
      unitRef="usd">130000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtNS0xLTEtNzgwNDk_b35d826c-7880-4d67-ac16-b468d1226d5e"
      unitRef="usd">0</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzQtNy0xLTEtNzgwNDk_e9dcb085-c4b0-40b9-9e65-f2d91988a3d0"
      unitRef="usd">133000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtMS0xLTEtNzgwNDk_4035e8ae-e0bc-400e-88b8-40f92b627d09"
      unitRef="usd">30067000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtMy0xLTEtNzgwNDk_e479bf84-3911-41d6-bf01-f7d1b09f5245"
      unitRef="usd">81795000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtNS0xLTEtNzgwNDk_12192e1e-ae6c-4f97-91c1-9af66b60a57a"
      unitRef="usd">1552000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzYtNy0xLTEtNzgwNDk_dc30f4ac-582b-407a-a7a7-8fae4a92c321"
      unitRef="usd">113414000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctMS0xLTEtNzgwNDk_65244866-65ca-4f27-a318-6c5d20a10343"
      unitRef="usd">154000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctMy0xLTEtNzgwNDk_09473bcf-1052-46f5-942f-ef0635a72288"
      unitRef="usd">630000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctNS0xLTEtNzgwNDk_176d273e-644d-4d4f-b0b6-20378bd363dc"
      unitRef="usd">85000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzctNy0xLTEtNzgwNDk_b7e239e2-0ebc-4c34-85d0-c4479cf359cb"
      unitRef="usd">869000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtMS0xLTEtNzgwNDk_0e121e98-aaef-4df9-b551-1ddd687b1a01"
      unitRef="usd">29913000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtMy0xLTEtNzgwNDk_cff2833f-51ba-473e-9e3b-298b79dd24f0"
      unitRef="usd">81165000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtNS0xLTEtNzgwNDk_ee4a98c6-4e4d-4a5d-a1f8-d23cd1cb9220"
      unitRef="usd">1467000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzgtNy0xLTEtNzgwNDk_dce2ac5c-43ad-4343-ba8a-9dd9de288d80"
      unitRef="usd">112545000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTEtMS0xLTc4MDQ5_cd547c2f-7c51-49d4-94b9-1e7c24f6c129"
      unitRef="usd">26274000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTMtMS0xLTc4MDQ5_9be13a16-d929-4ee3-8142-6bdf68099d96"
      unitRef="usd">71463000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTUtMS0xLTc4MDQ5_a5bd5bb6-6c6d-4674-bbc9-4d58956981f3"
      unitRef="usd">1260000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEwLTctMS0xLTc4MDQ5_ac55247a-295d-42dd-aaf3-4f3a7add0a9f"
      unitRef="usd">98997000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTEtMS0xLTc4MDQ5_68526f74-11ae-4488-8a11-dd35488f3a9c"
      unitRef="usd">3362000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTMtMS0xLTc4MDQ5_842b6233-3796-47d7-85fd-c37ccb821093"
      unitRef="usd">8052000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTUtMS0xLTc4MDQ5_167652e3-51aa-4a7b-a893-751cf8fd7548"
      unitRef="usd">186000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzExLTctMS0xLTc4MDQ5_c27b80a9-d28e-45ad-8dc6-5cc714a8e601"
      unitRef="usd">11600000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTEtMS0xLTc4MDQ5_4175c286-780e-41ee-bce8-8388e65fec20"
      unitRef="usd">29636000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTMtMS0xLTc4MDQ5_4c68dafb-b663-46f7-bb0c-54e9705d3d51"
      unitRef="usd">79515000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTUtMS0xLTc4MDQ5_ee00df20-3ff1-42a0-8065-ad57c4d4ee6f"
      unitRef="usd">1446000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEyLTctMS0xLTc4MDQ5_526ad9a0-27e2-486e-97ee-af0072d1dbda"
      unitRef="usd">110597000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTEtMS0xLTc4MDQ5_a03214f3-6e07-4707-8df4-6df99338bba8"
      unitRef="usd">4114000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTMtMS0xLTc4MDQ5_1bff7df0-4812-48a6-9043-e21918291d10"
      unitRef="usd">10929000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTUtMS0xLTc4MDQ5_96aa4126-59dc-4097-95e7-d43308d7e650"
      unitRef="usd">299000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzEzLTctMS0xLTc4MDQ5_e2101353-ce2e-4022-9540-a69490fdeb77"
      unitRef="usd">15342000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTEtMS0xLTc4MDQ5_e5e04b87-1969-46ce-9850-a812540cf1d7"
      unitRef="usd">5000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTMtMS0xLTc4MDQ5_18d10bba-3835-4f2f-9a2e-721853489433"
      unitRef="usd">1000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTUtMS0xLTc4MDQ5_8a189fe4-36d2-41fd-ae1d-10129b035f85"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE0LTctMS0xLTc4MDQ5_26178fbf-a4aa-4bc1-ac56-b4346754bfe3"
      unitRef="usd">6000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTEtMS0xLTc4MDQ5_5945ab92-6051-45a7-8379-549f959d1a61"
      unitRef="usd">4119000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTMtMS0xLTc4MDQ5_b6c22f11-3948-47a4-a818-abb824781a8a"
      unitRef="usd">10930000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTUtMS0xLTc4MDQ5_ef6c4be0-be8a-4576-8a55-2d49348838b9"
      unitRef="usd">299000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToxNGU5YmQwNWYzMDQ0YjVjYjcxNGY2MGQ1MmZjZjA0YS90YWJsZXJhbmdlOjE0ZTliZDA1ZjMwNDRiNWNiNzE0ZjYwZDUyZmNmMDRhXzE1LTctMS0xLTc4MDQ5_3fb444dc-a261-4884-a1b3-1b49cbb2edb8"
      unitRef="usd">15348000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtMS0xLTEtNzgwNDk_da90dfbe-9259-4b3b-ab56-1583f7d452a2"
      unitRef="usd">3294000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtMy0xLTEtNzgwNDk_73d296bd-1ca1-4fd7-bbd3-2c33d2bce635"
      unitRef="usd">7646000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtNS0xLTEtNzgwNDk_49770dbb-bfce-4891-a450-49121a48ed57"
      unitRef="usd">195000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEtNy0xLTEtNzgwNDk_bcba0060-b32f-4ecd-8171-f315e94204ff"
      unitRef="usd">11135000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItMS0xLTEtNzgwNDk_c4fd2cee-01b7-4d11-8f3d-c23f16f449e6"
      unitRef="usd">13000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItMy0xLTEtNzgwNDk_fb216ce2-5bba-410e-92e4-717eb5aaaa79"
      unitRef="usd">33000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItNS0xLTEtNzgwNDk_b89619ec-1696-4179-8e5b-abec7859c07f"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzItNy0xLTEtNzgwNDk_9b057a5f-fe5c-4e88-9807-239c84183eec"
      unitRef="usd">46000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtMS0xLTEtNzgwNDk_8339ddb5-e0dd-4464-8fd4-ca7448fc82f2"
      unitRef="usd">3281000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtMy0xLTEtNzgwNDk_b757efa5-5fc8-44a7-a1fa-829c17698948"
      unitRef="usd">7613000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtNS0xLTEtNzgwNDk_902d5d07-d8f8-43c1-946a-fdc1b316ecb7"
      unitRef="usd">195000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzMtNy0xLTEtNzgwNDk_3f53e995-9102-45ed-a07a-27ec23073a51"
      unitRef="usd">11089000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtMS0xLTEtNzgwNDk_e09f3e45-65c2-4a86-bc51-5583389b7cd7"
      unitRef="usd">0</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtMy0xLTEtNzgwNDk_f6c47d5c-ee3d-4fb3-b4ec-15648a200dac"
      unitRef="usd">375000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtNS0xLTEtNzgwNDk_0d7009d6-f8b6-48ba-ab96-1c8c7dcdb1d1"
      unitRef="usd">45000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzQtNy0xLTEtNzgwNDk_15121fa4-742c-4461-984b-7aa67539989e"
      unitRef="usd">420000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtMS0xLTEtNzgwNDk_a25aa15b-4507-4688-9c46-eb9e6b35921c"
      unitRef="usd">28132000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtMy0xLTEtNzgwNDk_8f861b0e-2a04-40c5-becc-bf1389218fb3"
      unitRef="usd">70670000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtNS0xLTEtNzgwNDk_9d22b1fa-a1ba-4e84-afb9-7e1f6c42a356"
      unitRef="usd">1638000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzYtNy0xLTEtNzgwNDk_4e547b4a-7223-4dc0-8fd3-1af373eca79d"
      unitRef="usd">100440000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctMS0xLTEtNzgwNDk_8a637b9e-7904-4fb4-8417-abc8db94de80"
      unitRef="usd">465000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctMy0xLTEtNzgwNDk_e3c1f140-2fa6-4f93-89eb-1ce2cc6fc77f"
      unitRef="usd">1222000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctNS0xLTEtNzgwNDk_3b75d2d3-2ff4-4b46-83f1-2fb29332f21c"
      unitRef="usd">16000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzctNy0xLTEtNzgwNDk_257cb6cb-ede1-410a-ae2d-a44dcac3cbfd"
      unitRef="usd">1703000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtMS0xLTEtNzgwNDk_87c70872-8a12-4b99-a27e-ba213e455d77"
      unitRef="usd">27667000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtMy0xLTEtNzgwNDk_f668c715-6541-4adb-a4fd-10399cc312a4"
      unitRef="usd">69448000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtNS0xLTEtNzgwNDk_6c30a8ee-6ca0-44b6-bc61-d292e2b5bf09"
      unitRef="usd">1622000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzgtNy0xLTEtNzgwNDk_ff346aa6-f013-4bbb-8a4f-79a2a1c89d6b"
      unitRef="usd">98737000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTEtMS0xLTc4MDQ5_3ea6fa33-ad6d-4cad-8b97-b85fad6373e7"
      unitRef="usd">24502000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTMtMS0xLTc4MDQ5_57d777b2-d2d7-47bd-ad04-303ae6a3ec74"
      unitRef="usd">62233000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTUtMS0xLTc4MDQ5_dfee6b89-2b74-459b-af12-4d30ace05d49"
      unitRef="usd">1421000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEwLTctMS0xLTc4MDQ5_77e28613-dbcb-44b1-b959-c249caa33a45"
      unitRef="usd">88156000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTEtMS0xLTc4MDQ5_1ad7d0a2-7701-420b-a263-0bad3dc16f02"
      unitRef="usd">2612000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTMtMS0xLTc4MDQ5_ee943de7-9c2f-4bf2-83d4-cc320bfdb7f5"
      unitRef="usd">6054000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTUtMS0xLTc4MDQ5_1d79205f-faf3-4a01-8249-0b040f6d852c"
      unitRef="usd">163000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzExLTctMS0xLTc4MDQ5_25bb69da-0bd6-4dbf-b6e9-cc4b1030ae6f"
      unitRef="usd">8829000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTEtMS0xLTc4MDQ5_f2361c0e-b5c9-447f-988d-57aa445f652c"
      unitRef="usd">27114000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTMtMS0xLTc4MDQ5_ffbc3fd3-d548-4aab-a17d-e07ce7c8f9b6"
      unitRef="usd">68287000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTUtMS0xLTc4MDQ5_7567a6cf-61be-4707-ad4c-9820665378e0"
      unitRef="usd">1584000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEyLTctMS0xLTc4MDQ5_01d4208c-5221-409e-9301-a56459d81827"
      unitRef="usd">96985000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTEtMS0xLTc4MDQ5_10a844d8-f8f0-48a8-8338-6eea6c43fdf7"
      unitRef="usd">3834000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTMtMS0xLTc4MDQ5_95f8b61f-29f7-4be9-8ea3-7eb33e0cdc42"
      unitRef="usd">9149000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTUtMS0xLTc4MDQ5_a95abbcd-096e-481f-90e7-ade56a206864"
      unitRef="usd">278000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzEzLTctMS0xLTc4MDQ5_93b8379a-4a04-47ca-a38d-52307eb46909"
      unitRef="usd">13261000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTEtMS0xLTc4MDQ5_e8f9f2b4-695b-42c0-ba8e-fb0e2af489e8"
      unitRef="usd">13000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTMtMS0xLTc4MDQ5_9ff04321-f39b-4a26-b852-f222689cf7bf"
      unitRef="usd">8000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTUtMS0xLTc4MDQ5_6b849e39-791d-4f8c-b011-b8517a115acc"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE0LTctMS0xLTc4MDQ5_96ff2914-6fe1-4a7d-bda0-7486651de0e3"
      unitRef="usd">21000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i854e5f6c800a408a8b83bac7c2f66e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTEtMS0xLTc4MDQ5_512c87be-31e6-47f2-9ebd-9bf5b0dfb230"
      unitRef="usd">3847000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ia5282ee6fb6643008a314c4a693905e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTMtMS0xLTc4MDQ5_d59ccee2-f0e2-4f18-b3e5-be166d640b17"
      unitRef="usd">9157000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i94d1d3eac4f542b8a5d44ca575abb5f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTUtMS0xLTc4MDQ5_fb08a7f9-2605-4c1a-97b2-8913f1317f6a"
      unitRef="usd">278000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZToyNDA3NTkyMTlmOTE0MDU5YjMzNThjYjM2YTdmYmRkMy90YWJsZXJhbmdlOjI0MDc1OTIxOWY5MTQwNTliMzM1OGNiMzZhN2ZiZGQzXzE1LTctMS0xLTc4MDQ5_a1b14c49-e102-4d53-91bd-d11976b77def"
      unitRef="usd">13282000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="idd4334628ce145889a7e9f45088dbc5d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtMS0xLTEtNzgwNDk_7fd485a5-25e8-44ae-8365-ec3106313ec1"
      unitRef="usd">3039000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i253166758c5642418ac341338d564041_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtMy0xLTEtNzgwNDk_88d12b95-a083-484b-b973-eb4df7f28852"
      unitRef="usd">5608000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i056128fedb8c4604822fdacd5c2f6272_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtNS0xLTEtMTAwMDY2_5d20cc89-eb04-4ee6-9efd-4543eba3a18e"
      unitRef="usd">0</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEtNy0xLTEtNzgwNDk_f51f7f44-c891-4c9b-98ae-5f2b7c106bc1"
      unitRef="usd">8647000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="idd4334628ce145889a7e9f45088dbc5d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItMS0xLTEtNzgwNDk_fe0b764c-417a-43a1-9a33-daa3175dba34"
      unitRef="usd">14000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i253166758c5642418ac341338d564041_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItMy0xLTEtNzgwNDk_03ce4937-2ae9-4dc5-b555-9155b392efb3"
      unitRef="usd">19000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i056128fedb8c4604822fdacd5c2f6272_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItNS0xLTEtMTAwMDY2_8435afc7-23ec-41dd-bf09-403dd1a442bc"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzItNy0xLTEtNzgwNDk_a7574227-99cf-4e40-b060-b9286d86ab94"
      unitRef="usd">33000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="idd4334628ce145889a7e9f45088dbc5d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtMS0xLTEtNzgwNDk_39630ab7-7762-45c9-b50f-6d51a06e2548"
      unitRef="usd">3025000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i253166758c5642418ac341338d564041_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtMy0xLTEtNzgwNDk_853698f1-6454-4f65-9fd0-ce71436e27b2"
      unitRef="usd">5589000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i056128fedb8c4604822fdacd5c2f6272_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtNS0xLTEtMTAwMDY2_397ce15f-f326-4eab-be62-015c9466bb49"
      unitRef="usd">0</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzMtNy0xLTEtNzgwNDk_a919199b-8889-4b2e-b774-0393dd77f242"
      unitRef="usd">8614000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzQtMy0xLTEtNzgwNDk_0eb6792e-69f1-4bb7-8391-ed82718b2ac7"
      unitRef="usd">141000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzQtNS0xLTEtMTAwMDY2_bcaae81d-7ac6-4b4e-a787-6b9daa1ed462"
      unitRef="usd">198000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzQtNy0xLTEtNzgwNDk_7d0931d4-3ae6-45e7-b79a-c4d65cfd8790"
      unitRef="usd">339000000</elv:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtMS0xLTEtNzgwNDk_3824e3b4-1149-4d32-82e6-336c627336a0"
      unitRef="usd">24894000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtMy0xLTEtNzgwNDk_cd6a4d22-dc20-4b10-b221-bc4095268f50"
      unitRef="usd">58912000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtNS0xLTEtMTAwMDY2_74448171-d2d1-4842-bee8-130145c6b335"
      unitRef="usd">1288000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzYtNy0xLTEtNzgwNDk_e3b5e3e5-d6fd-48d8-8dbc-2e40b790f0f9"
      unitRef="usd">85094000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctMS0xLTEtNzgwNDk_c3111af4-1cdf-4855-9dce-c562d25d7b08"
      unitRef="usd">375000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctMy0xLTEtNzgwNDk_229dd8c3-7352-4423-8d99-51203fb852a0"
      unitRef="usd">262000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctNS0xLTEtMTAwMDY2_8889043b-09da-4e8a-b8c5-5ae9c5989381"
      unitRef="usd">0</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzctNy0xLTEtNzgwNDk_7b53fe9f-8fe0-4858-b421-6aa12071aba4"
      unitRef="usd">637000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtMS0xLTEtNzgwNDk_531134b0-8a44-478d-abb9-b657024e5955"
      unitRef="usd">24519000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtMy0xLTEtNzgwNDk_e65831f8-dc6f-4ccc-9feb-e8f02f56450c"
      unitRef="usd">58650000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtNS0xLTEtMTAwMDY2_108e8a02-836f-43db-a88c-d9612105841e"
      unitRef="usd">1288000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzgtNy0xLTEtNzgwNDk_366fe1ab-11cc-40ec-aae9-4f37d0206356"
      unitRef="usd">84457000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTEtMS0xLTc4MDQ5_e3b28c25-53ef-4250-a8b2-c154b29004c7"
      unitRef="usd">21736000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTMtMS0xLTc4MDQ5_7cb08d10-1206-4680-8add-dc2a529aa45e"
      unitRef="usd">51602000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTUtMS0xLTEwMDA2Ng_10055a0e-b557-4ed1-ae2b-93591cf4f50c"
      unitRef="usd">1291000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEwLTctMS0xLTc4MDQ5_774972f8-9905-4dba-bccb-9a07a48c1eb3"
      unitRef="usd">74629000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTEtMS0xLTc4MDQ5_7a79b759-ddff-4772-b83b-c88f5acfb2aa"
      unitRef="usd">2527000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTMtMS0xLTc4MDQ5_2b99663e-e0cc-45f2-8c27-52a060244a7a"
      unitRef="usd">5165000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTUtMS0xLTEwMDA2Ng_a0513f43-93c3-4301-82b9-9c2449a09b23"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzExLTctMS0xLTc4MDQ5_15695346-097a-4947-8895-2071737b5913"
      unitRef="usd">7692000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTEtMS0xLTc4MDQ5_32607ae4-7930-4066-9147-931a527a1561"
      unitRef="usd">24263000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTMtMS0xLTc4MDQ5_31390980-753c-4b71-b48d-0fe99835e3ca"
      unitRef="usd">56767000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTUtMS0xLTEwMDA2Ng_82f6978b-1468-4270-a54f-e0f733079a58"
      unitRef="usd">1291000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEyLTctMS0xLTc4MDQ5_52d27be9-0a61-4a24-b5c7-c32fb871a10f"
      unitRef="usd">82321000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTEtMS0xLTc4MDQ5_334ce68d-d83d-4726-8918-a250f80841c3"
      unitRef="usd">3281000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTMtMS0xLTc4MDQ5_a9f4ce60-7b66-43b0-b967-ebb34a191afe"
      unitRef="usd">7613000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTUtMS0xLTEwMDA2Ng_86e20ff3-478c-4414-8c1e-f71c84a020ec"
      unitRef="usd">195000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzEzLTctMS0xLTc4MDQ5_11d9f914-e41b-4874-8004-34df3aae402c"
      unitRef="usd">11089000000</elv:ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTEtMS0xLTc4MDQ5_63b1bc4d-cf37-4195-b46e-2e347d436ac8"
      unitRef="usd">13000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTMtMS0xLTc4MDQ5_444fa72f-d613-4d21-a6cb-065123548f8a"
      unitRef="usd">33000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTUtMS0xLTEwMDA2Ng_4dd6f068-3ef4-4498-9afd-ad17e980f430"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE0LTctMS0xLTc4MDQ5_12f0b603-12f4-4d0c-989c-1f66094508e3"
      unitRef="usd">46000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ifc64eab57fde4787b3c18d688b193ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTEtMS0xLTc4MDQ5_c482b2b8-0e6c-4b59-9b6e-ea8ecc22f27f"
      unitRef="usd">3294000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="ie605a92d69da478bba8a4d5a934346aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTMtMS0xLTc4MDQ5_226126e4-b1e4-4913-a5b6-590b89736eed"
      unitRef="usd">7646000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i55238bc0d8524816beff8ed796471899_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTUtMS0xLTEwMDA2Ng_357a5685-c1ec-41e9-b311-afac1e0c5501"
      unitRef="usd">195000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTowMzNjMGUwYzY3Zjc0MjhhODc4YjBkMDAyYWRiY2QzNi90YWJsZXJhbmdlOjAzM2MwZTBjNjdmNzQyOGE4NzhiMGQwMDJhZGJjZDM2XzE1LTctMS0xLTc4MDQ5_a3b590f7-fc7e-4e28-ac21-d3312cd774ae"
      unitRef="usd">11135000000</elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzk5OQ_7960ba89-0c89-4ee1-8894-4a601bd20581"
      unitRef="usd">869000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzEzMjM_7960ba89-0c89-4ee1-8894-4a601bd20581"
      unitRef="usd">869000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0MTQ_1797b06d-8764-4652-a781-8b2ee1187575">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December&#160;31, 2022, 2021 and 2020, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. We had increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that lead to the increased estimation uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Favorable Developments&lt;br/&gt;by&#160;Changes in Key Assumptions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed trend factors&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed completion factors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock>
    <elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzItMS0xLTEtNzgwNDk_1611e9e7-98a2-472a-8d24-18db1eb79bdf"
      unitRef="usd">859000000</elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzItMy0xLTEtNzgwNDk_22851a74-e1e5-470c-b76d-1beea7473b4e"
      unitRef="usd">1429000000</elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzItNS0xLTEtNzgwNDk_4d964005-4f54-49e7-812f-bf1ff261c30d"
      unitRef="usd">599000000</elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzMtMS0xLTEtNzgwNDk_49c8b0b3-7df5-4a5d-b372-29b97105b6be"
      unitRef="usd">10000000</elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzMtMy0xLTEtNzgwNDk_ff88dc96-c364-4d64-95a3-9f601f9c7661"
      unitRef="usd">274000000</elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzMtNS0xLTEtNzgwNDk_6d4a0a45-541a-41a3-a428-ad2dfb7f50b2"
      unitRef="usd">38000000</elv:FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzQtMS0xLTEtNzgwNDk_adf08649-1858-4e2a-8910-5732f9bcee3f"
      unitRef="usd">869000000</elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzQtMy0xLTEtNzgwNDk_135beb97-5bfa-434f-b08e-8c996051bd29"
      unitRef="usd">1703000000</elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions>
    <elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTozNGJkODliM2MwNDA0Y2FhOTE1NWRkMTg3MTU3MjEwZi90YWJsZXJhbmdlOjM0YmQ4OWIzYzA0MDRjYWE5MTU1ZGQxODcxNTcyMTBmXzQtNS0xLTEtNzgwNDk_46dbaae7-d266-48c7-8e9d-d58fc186e1da"
      unitRef="usd">637000000</elv:FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions>
    <elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0NDI_d2abde21-cf8b-416c-b2fe-023d28aead60">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net incurred medical claims:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net incurred medical claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality improvement and other claims expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzMtMi0xLTEtNzgwNDk_0ec7b317-13cb-48ac-9370-5d6763f24b85"
      unitRef="usd">29913000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzMtNC0xLTEtNzgwNDk_c0bbc201-04b3-4b74-a6d0-d097a07b46e9"
      unitRef="usd">27667000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzMtNi0xLTEtNzgwNDk_2920bfc0-6eb9-4145-9e21-4a2e6942daa6"
      unitRef="usd">24519000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzQtMi0xLTEtNzgwNDk_cfbbdb09-e285-42cb-b4cb-06585b32f4b7"
      unitRef="usd">81165000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzQtNC0xLTEtNzgwNDk_4413275f-d88b-4181-9190-8903e774b5c3"
      unitRef="usd">69448000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzQtNi0xLTEtNzgwNDk_b134cbfa-4943-45b5-acec-1619b2741f7b"
      unitRef="usd">58650000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzUtMi0xLTEtNzgwNDk_dda3a31f-b25f-46e5-a608-9d6655b9ebe1"
      unitRef="usd">1467000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzUtNC0xLTEtNzgwNDk_a6bffcab-186e-4f33-b2e3-4c334ae8173f"
      unitRef="usd">1622000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzUtNi0xLTEtNzgwNDk_fa0bf960-159d-4ab5-a01e-eb8df200a542"
      unitRef="usd">1288000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzYtMi0xLTEtNzgwNDk_4cee18c6-0b3f-469d-98b5-940c6bc22b35"
      unitRef="usd">112545000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzYtNC0xLTEtNzgwNDk_a9108086-07cb-4c28-a945-68d7e00da2b6"
      unitRef="usd">98737000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzYtNi0xLTEtNzgwNDk_91b23182-b862-4c49-b1e0-e706118bbee5"
      unitRef="usd">84457000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <elv:QualityImprovementAndOtherClaimsExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzctMi0xLTEtNzgwNDk_b25b2940-8a5b-4b9b-ac72-560e37f57630"
      unitRef="usd">3942000000</elv:QualityImprovementAndOtherClaimsExpense>
    <elv:QualityImprovementAndOtherClaimsExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzctNC0xLTEtNzgwNDk_3c561153-040c-4834-a42e-4c11fd748594"
      unitRef="usd">3908000000</elv:QualityImprovementAndOtherClaimsExpense>
    <elv:QualityImprovementAndOtherClaimsExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzctNi0xLTEtNzgwNDk_8e3ac086-bcc4-45c7-878e-8c1fc35e0715"
      unitRef="usd">3588000000</elv:QualityImprovementAndOtherClaimsExpense>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzgtMi0xLTEtNzgwNDk_5fa0950d-2da0-4f88-a476-b325d510f00e"
      unitRef="usd">116487000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzgtNC0xLTEtNzgwNDk_d3434912-f94d-4cc6-9355-a01dd2de2b55"
      unitRef="usd">102645000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphNzBhNDFjY2U4NTg0OGQ1Yjc5NWViMDY0OGM2NTMyYS90YWJsZXJhbmdlOmE3MGE0MWNjZTg1ODQ4ZDViNzk1ZWIwNjQ4YzY1MzJhXzgtNi0xLTEtNzgwNDk_2cb36518-34e4-4609-9cd9-6f18796d6d9f"
      unitRef="usd">88045000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0MjQ_b1e69bea-aa8e-47f6-808a-366e8e7b928c">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incurred claims development, net of reinsurance, for the Commercial &amp;amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paid claims development, net of reinsurance, for the Commercial &amp;amp; Specialty Business for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp;amp; Specialty Business was $52, $266 and $3,796 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the cumulative number of reported claims for the Commercial &amp;amp; Specialty Business was 80, 87 and 81 for the claim years 2020 and prior, 2021 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $142, $325 and $10,462 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the cumulative number of reported claims for the Government Business was 251, 325 and 298 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incurred claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paid claims development, net of reinsurance, for Other as of and for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claim Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims for Other was $1, $6 and $292 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the cumulative number of reported claims for Other was 29, 28, and 25 for the claim years 2020 and prior, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i5c4172e7e04f43ae913e486aafb0c782_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzMtMi0xLTEtNzgwNDk_d9afa624-44db-4b93-986c-1e8e69793425"
      unitRef="usd">27545000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i7aef76e4813e4606b8d70440c92f269a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzMtNC0xLTEtNzgwNDk_0e8a4803-2fda-4546-a289-88d6ab835a26"
      unitRef="usd">27080000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i23463b26e20041c888dd2c51a2181294_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzMtNi0xLTEtNzgwNDk_91f3d7dc-a810-41e6-8cb1-74bdde8e9070"
      unitRef="usd">27101000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ib44d7cf6e14d4446b34dd7ca19bc223b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzQtNC0xLTEtNzgwNDk_8e70eba4-db75-4591-82b2-dcaebd94b33c"
      unitRef="usd">28132000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzQtNi0xLTEtNzgwNDk_745ca494-60b4-4fad-81e1-43b7111a6db9"
      unitRef="usd">27957000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzUtNi0xLTEtNzgwNDk_2954f0a3-1484-4e82-9c1b-dfd2c8804f9f"
      unitRef="usd">30070000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo4MWI1OWRiYzM4NzM0NTAxYTg3MTc3Yjk4YzA3ODJlMC90YWJsZXJhbmdlOjgxYjU5ZGJjMzg3MzQ1MDFhODcxNzdiOThjMDc4MmUwXzYtNi0xLTEtNzgwNDk_0a2b6ace-7fe5-4ecc-93b2-c483d267b184"
      unitRef="usd">85128000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i5c4172e7e04f43ae913e486aafb0c782_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzMtMi0xLTEtNzgwNDk_d5e0dfb1-6cc8-452d-869b-c649cc73eae0"
      unitRef="usd">24263000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i7aef76e4813e4606b8d70440c92f269a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzMtNC0xLTEtNzgwNDk_d2bc190b-ea35-4a84-af6d-65f7b92f780e"
      unitRef="usd">26876000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i23463b26e20041c888dd2c51a2181294_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzMtNi0xLTEtNzgwNDk_0a3ed7d4-d314-4098-a68c-bd20fa6a9d2d"
      unitRef="usd">27049000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ib44d7cf6e14d4446b34dd7ca19bc223b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzQtNC0xLTEtNzgwNDk_1b836bef-ea1f-47c6-a8d8-3432cfb98bc5"
      unitRef="usd">24502000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzQtNi0xLTEtNzgwNDk_f514a6b2-8c42-4670-ac73-2be5ef210918"
      unitRef="usd">27691000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzUtNi0xLTEtNzgwNDk_ab93d9f4-60fa-4420-be87-733d958b2128"
      unitRef="usd">26274000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiZjYyZGQ4YmNmMjQ0NGU1OGEzNWVmMTQyMWZlNWY2MS90YWJsZXJhbmdlOmJmNjJkZDhiY2YyNDQ0ZTU4YTM1ZWYxNDIxZmU1ZjYxXzYtNi0xLTEtNzgwNDk_b4b7efbe-0e52-4316-820b-5e0e5243511b"
      unitRef="usd">81014000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="i23463b26e20041c888dd2c51a2181294_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM1ODc_4dd084b4-c6b0-4707-bef2-6d8b1406ac9f"
      unitRef="usd">52000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM1OTE_7051623a-f637-44f5-a8b2-73c0260ddc52"
      unitRef="usd">266000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM1OTg_bc09c91b-71d7-46db-a35a-b61574725e8f"
      unitRef="usd">3796000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i23463b26e20041c888dd2c51a2181294_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM3NTI_dd965094-4ad0-45e0-b07a-6146dab1ca6c"
      unitRef="usd">80000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="ia6fbed5f4b7543ab8092cf310b884173_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM3NTY_7a696926-b190-41fd-b22a-25453851bc95"
      unitRef="usd">87000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="ib1ab83b37e744c8899d7e3adb51c2939_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzM3NjM_ac9eb1ce-8d0c-41c3-ac52-a9129136e4d8"
      unitRef="usd">81000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="idcabc74836324dbfa6c75eefd131bc85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzMtMi0xLTEtNzgwNDk_330973f8-d158-4b50-8306-e6d9eed416de"
      unitRef="usd">64379000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ifab00825672c4350bb49fbe11bbfb810_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzMtNC0xLTEtNzgwNDk_c1f59fed-92a9-4897-9af8-742406ab5545"
      unitRef="usd">63158000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzMtNi0xLTEtNzgwNDk_8d696ae5-1043-44b9-8712-59b319194131"
      unitRef="usd">63123000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="iad9e96e08f9e4d9eab2889e9f25825de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzQtNC0xLTEtNzgwNDk_3f605086-871f-4fb6-bfcd-6b66146f659e"
      unitRef="usd">71045000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzQtNi0xLTEtNzgwNDk_7cc254c9-f277-43e0-b6d4-1dc4caa3177e"
      unitRef="usd">70450000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i4efbc97b18234003842819922bc3113a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzUtNi0xLTEtNzgwNDk_c8aaf54a-865c-456f-bb2d-289f85b814f1"
      unitRef="usd">81925000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTplNDYxMzRiNjAzZDM0MTA3OTkyZjU4Y2JlODI2ZjE5YS90YWJsZXJhbmdlOmU0NjEzNGI2MDNkMzQxMDc5OTJmNThjYmU4MjZmMTlhXzYtNi0xLTEtNzgwNDk_8fb240fc-8671-4bcd-8647-564b47ca664c"
      unitRef="usd">215498000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="idcabc74836324dbfa6c75eefd131bc85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzMtMi0xLTEtNzgwNDk_77f982f3-3597-4750-98f3-04f1730fe5b4"
      unitRef="usd">56767000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ifab00825672c4350bb49fbe11bbfb810_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzMtNC0xLTEtNzgwNDk_33da5c09-134d-40f0-a989-2eb9aea6be31"
      unitRef="usd">62821000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzMtNi0xLTEtNzgwNDk_a1575b64-21b1-422f-b79a-dec240b4d94a"
      unitRef="usd">62981000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="iad9e96e08f9e4d9eab2889e9f25825de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzQtNC0xLTEtNzgwNDk_1a15ae7f-6d42-4795-b4f2-4a3465844b1c"
      unitRef="usd">62233000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzQtNi0xLTEtNzgwNDk_e5d8bd84-6415-4ba3-9544-261fb5e55b57"
      unitRef="usd">70125000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i4efbc97b18234003842819922bc3113a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzUtNi0xLTEtNzgwNDk_99d5b48e-dae2-4c19-92c1-d1ba93bf61e3"
      unitRef="usd">71463000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpjYzc5ZTc4NmQ3ZTI0Y2ExOTNlOTc5M2YzNWY2NTViMS90YWJsZXJhbmdlOmNjNzllNzg2ZDdlMjRjYTE5M2U5NzkzZjM1ZjY1NWIxXzYtNi0xLTEtNzgwNDk_de1fbf4d-0973-418a-bb48-1cd1cbb50b12"
      unitRef="usd">204569000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQyMzM_8dbb4dc4-d74a-425b-86b9-d7f809b23059"
      unitRef="usd">142000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQyMzc_d1551408-5b0f-4af4-9bd6-aa40b471d4f4"
      unitRef="usd">325000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="i4efbc97b18234003842819922bc3113a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQyNDQ_41244d25-5875-49e4-b9a5-5043ef5cf9f8"
      unitRef="usd">10462000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i99c59a694d1a41f09f4a701a27ed7e6d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQzODY_f469cd3a-4144-4d8f-aeef-2b21762defe3"
      unitRef="usd">251000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="ic2b1e52956f34852bb67f516ba0647b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQzOTA_f4dbf0c3-48fb-4cb6-9dc4-28ff5d3756da"
      unitRef="usd">325000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i4efbc97b18234003842819922bc3113a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQzOTc_82531e24-73f2-4d77-aad9-fbb8f0a1ef9c"
      unitRef="usd">298000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="iefeea68ef91044dc982120c3a3a950bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzMtMi0xLTEtNzgwNDk_a58fcfa8-e968-4866-9dbf-ab8be647d765"
      unitRef="usd">1486000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia2066eaf9a484ad59e9589c14525a5c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzMtNC0xLTEtNzgwNDk_90909078-449a-4147-aaf4-ff8252974c8c"
      unitRef="usd">1470000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzMtNi0xLTEtNzgwNDk_75df0852-b0d6-4b95-ba15-df1141b7666e"
      unitRef="usd">1459000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i14e702d4536f4799a919aec9da8593e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzQtNC0xLTEtNzgwNDk_f764135a-7afd-4c2a-89c4-90ef83ce6042"
      unitRef="usd">1683000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzQtNi0xLTEtNzgwNDk_432936f0-4506-45fb-8413-d55662535dd0"
      unitRef="usd">1609000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzUtNi0xLTEtNzgwNDk_fcad8305-2a39-47ec-a788-577d096e0290"
      unitRef="usd">1552000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTpiN2E4MWI4ODkyYjM0MzU5YTQ5M2E2N2I3YTNiYzM1Ni90YWJsZXJhbmdlOmI3YTgxYjg4OTJiMzQzNTlhNDkzYTY3YjdhM2JjMzU2XzYtNi0xLTEtNzgwNDk_633e93f3-f3a4-4928-997a-dfb701e88f77"
      unitRef="usd">4620000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="iefeea68ef91044dc982120c3a3a950bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzMtMi0xLTEtNzgwNDk_6bc55473-58b2-4c4c-91d5-bfabd8840ac1"
      unitRef="usd">1292000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia2066eaf9a484ad59e9589c14525a5c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzMtNC0xLTEtNzgwNDk_da7f8d83-7b14-4a02-818f-f544ab305f7e"
      unitRef="usd">1454000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzMtNi0xLTEtNzgwNDk_c237c076-d1f8-4312-bb7c-b2b5572c7d6e"
      unitRef="usd">1458000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i14e702d4536f4799a919aec9da8593e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzQtNC0xLTEtNzgwNDk_077a9f45-673c-44fe-a682-67c27fe2b2b5"
      unitRef="usd">1421000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzQtNi0xLTEtNzgwNDk_c8e24ac5-c964-4fd1-882a-622694a9c613"
      unitRef="usd">1603000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzUtNi0xLTEtNzgwNDk_2878a76e-e3d6-4d21-ac67-0a46b177fb66"
      unitRef="usd">1260000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTphMWQxNWFlODgwMWE0NWQ5OTI5ZDdjMWNhZmFjZjg3My90YWJsZXJhbmdlOmExZDE1YWU4ODAxYTQ1ZDk5MjlkN2MxY2FmYWNmODczXzYtNi0xLTEtNzgwNDk_04929768-8b2a-4cad-a3a0-a73c80612831"
      unitRef="usd">4321000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ4MTI_28a74765-9cdb-4e8d-9300-116473b38450"
      unitRef="usd">1000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ4MTY_4e856932-0660-4b3d-b42c-f5955ab63ab4"
      unitRef="usd">6000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ4MjM_8a6f56d6-0639-4e54-99aa-a8ec9c6d1623"
      unitRef="usd">292000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i636b16b8c6fd4d57a55a97e38bd5bcb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ5NDc_ffd75c32-7a88-4f6d-90f8-7726fb6912ee"
      unitRef="usd">29000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i3e4c9f11d99845b8921be755ddf836f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ5NTE_2d7b728d-3480-4161-ab3b-dae6987309af"
      unitRef="usd">28000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i84d1014df09f4661bc24d1661e77bfc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzQ5NTk_7558eba5-fcb0-4fd3-b3dc-dec17b124648"
      unitRef="usd">25000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90ZXh0cmVnaW9uOmRhM2Y3MThmOTlmZjQxMTNhNDk3YTg4OThiZmYwMWJkXzY0MzY_4d56753b-881a-4875-b78e-16e16d6ce15e">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the Commercial &amp;amp; Specialty Business, Government Business and Other incurred and paid claims development information for the three years ended December&#160;31, 2022, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December&#160;31, 2022, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial&lt;br/&gt;&amp;amp; Specialty&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government&lt;br/&gt;Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance lines other than short duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross medical claims payable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtMS0xLTEtNzgwNDk_5b096b85-0966-427a-835f-d15e81da07b3"
      unitRef="usd">85128000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtMy0xLTEtNzgwNDk_f6425fe1-d4f6-4949-89dd-53f0e5e16081"
      unitRef="usd">215498000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtNS0xLTEtNzgwNDk_d443c909-dd1d-425b-8518-f74b150b75ed"
      unitRef="usd">4620000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzEtNy0xLTEtNzgwNDk_76f2011d-f5bb-4d81-8c3e-d2781a0e6a7a"
      unitRef="usd">305246000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItMS0xLTEtNzgwNDk_fe818166-4b04-466c-88ae-41beff189acc"
      unitRef="usd">81014000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItMy0xLTEtNzgwNDk_d513e315-05cb-405d-a4e8-55f99f01818a"
      unitRef="usd">204569000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItNS0xLTEtNzgwNDk_02cda3fe-514d-4457-916d-6534fb5d2fbf"
      unitRef="usd">4321000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzItNy0xLTEtNzgwNDk_495de0ee-bc0f-4485-aa78-dfaeba6a09a9"
      unitRef="usd">289904000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtMS0xLTEtNzgwNDk_4059682d-7934-4cd2-8dac-21af0f7f548d"
      unitRef="usd">4114000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtMy0xLTEtNzgwNDk_4af139ab-c81c-4314-9d27-df7d8c9b0306"
      unitRef="usd">10929000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtNS0xLTEtNzgwNDk_a9293ade-67e4-469f-8ffb-425a4501da7b"
      unitRef="usd">299000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzMtNy0xLTEtNzgwNDk_c20a493e-e876-4c88-ad78-ce55ff349ecf"
      unitRef="usd">15342000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtMS0xLTEtNzgwNDk_5742c3a1-e279-455e-8852-c245d48b4d50"
      unitRef="usd">5000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtMy0xLTEtNzgwNDk_295c1211-8985-4e1f-8830-41a756aa6310"
      unitRef="usd">1000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtNS0xLTEtNzgwNDk_7d593e00-c9b5-4022-ae9d-a609ba13f1db"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzQtNy0xLTEtNzgwNDk_bcf0936f-41dc-4091-bba7-a09e322f114c"
      unitRef="usd">6000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtMS0xLTEtMTAwMDcx_21a84c43-dfe4-4c57-b21a-cce91534ba9e"
      unitRef="usd">0</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtMy0xLTEtNzgwNDk_60a6f558-0a40-4733-850f-574c1019e0c1"
      unitRef="usd">248000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtNS0xLTEtNzgwNDk_b4ea6113-83c8-4ccb-a787-583ab73b39fb"
      unitRef="usd">0</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzUtNy0xLTEtNzgwNDk_e310cef4-af41-49c9-972b-abd35f06f184"
      unitRef="usd">248000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if62dc3c697d8430b8c0877a6bd308c20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtMS0xLTEtNzgwNDk_caf5a035-a5a5-448a-896a-79d91823defa"
      unitRef="usd">4119000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia5d28adfc0a54bd9baceff349c99b744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtMy0xLTEtNzgwNDk_9b474e47-194d-48b6-b11a-03e9265a9f3d"
      unitRef="usd">11178000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id885b4e505b34b40bce2c6278117709a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtNS0xLTEtNzgwNDk_769d8bb1-9e11-4f61-af7a-43bc66788b7b"
      unitRef="usd">299000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzYvZnJhZzpkYTNmNzE4Zjk5ZmY0MTEzYTQ5N2E4ODk4YmZmMDFiZC90YWJsZTo5Mzk1ZTRiNDMyM2Q0MzU1OTNiMDZiOGQ5YWNmZDVkOC90YWJsZXJhbmdlOjkzOTVlNGI0MzIzZDQzNTU5M2IwNmI4ZDlhY2ZkNWQ4XzYtNy0xLTEtNzgwNDk_e1bee355-510f-474b-a194-18307c56a9b8"
      unitRef="usd">15596000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNTQ0ODcyMTMyNzc3_e3c03f2d-f97a-4a9c-956e-5f031858563b">Debt&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the &#x201c;FHLBs&#x201d;). As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At December&#160;31, 2022 and 2021, $265 and $275, respectively, were outstanding under our short-term FHLB borrowings. Outstanding short-term FHLB borrowings at December&#160;31, 2022 had fixed interest rates of 4.240%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the &#x201c;Subsidiary Credit Facilities&#x201d;) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200. The interest rate on each line of credit is based on the LIBOR rate plus a predetermined rate. Our ability to borrow under the lines of credit is subject to compliance with certain covenants. At each of December 31, 2022 and 2021, $0 was outstanding under our Subsidiary Credit Facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our long-term debt at December&#160;31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior unsecured notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.950%, due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125%, due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.300%, due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.450%, due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.350%, due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500%, due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.375%, due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.350%, due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.500%, due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.650%, due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101%, due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.875%, due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250%, due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.550%, due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.100%, due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.500%, due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.950%, due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.850%, due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375%, due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.800%, due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625%, due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.650%, due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.650%, due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.100%, due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375%, due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.550%, due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.700%, due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125%, due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.600%, due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.550%, due 2052&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.100%, due 2052&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.850%, due 2054&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surplus note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.000%, due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior convertible debentures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.750%, due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable rate debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings and the Subsidiary Credit Facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally issue senior unsecured notes (&#x201c;Notes&#x201d;) for long-term borrowing purposes. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the &#x201c;2026 Notes&#x201d;), $1,000 aggregate principal amount of 4.750% Notes due 2033 (the &#x201c;2033 Notes&#x201d;), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the &#x201c;2053 Notes&#x201d;) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 1, 2022, we repaid, at maturity, the $750 outstanding balance of our 2.950% senior unsecured notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 4, 2022, we issued $400 aggregate principal amount of 5.350% Notes due 2025, $650 aggregate principal amount of 5.500% Notes due 2032 and $750 aggregate principal amount of 6.100% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on April 15 and October 15 of each year, commencing April 15, 2023. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 and $700 aggregate principal amount of 4.550% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2021, we redeemed the $700 outstanding principal balance of our 3.700% Notes due August 15, 2021 at a redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, we issued $500 aggregate principal amount of 0.450% Notes due 2023, $750 aggregate principal amount of 1.500% Notes due 2026, $1,000 aggregate principal amount of 2.550% Notes due 2031 and $1,250 aggregate principal amount of 3.600% Notes due 2051 under our shelf registration statement. Interest on these notes is payable semiannually in arrears on March 15 and September 15 of each year, commencing September 15, 2021. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the year ended December 31, 2021, we repurchased $52 of outstanding principal amount of certain other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $67. We recognized a loss on extinguishment of debt of $15 for the repurchase of these notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 23, 2020, we repaid, at maturity, the $900 outstanding balance of our 2.500% senior unsecured notes. On August 17, 2020, we repaid, at maturity, the $700 outstanding balance of our 4.350% senior unsecured notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the year ended December 31, 2020, we repurchased $79 of outstanding principal amount of certain other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $109. We recognized a loss on extinguishment of debt of $30 for the repurchase of these notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2020, we issued $400 aggregate principal amount of additional senior notes pursuant to a reopening of our existing 2.375% Notes due 2025 (the &#x201c;2025 Notes&#x201d;), $1,100 aggregate principal amount of 2.250% Notes due 2030 (the &#x201c;2030 Notes&#x201d;), and $1,000 aggregate principal amount of 3.125% Notes due 2050 (the &#x201c;2050 Notes&#x201d;) under our shelf registration statement. The 2025 Notes constitute an additional issuance of our 2.375% notes due 2025, of which $850 aggregate principal amount was issued on September 9, 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on the 2025 Notes is deemed to have accrued from January 15, 2020 and is payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2020. Interest on the 2030 Notes and 2050 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2020. The proceeds were used for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc. (&#x201c;Anthem Insurance&#x201d;), a wholly owned subsidiary, and is subordinate in right of payment to all of Anthem Insurance&#x2019;s existing and future indebtedness. Any payment of interest or principal on the surplus note may be made only with the prior approval of the Indiana Department of Insurance (&#x201c;IDOI&#x201d;) and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana insurance laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a senior revolving credit facility (the &#x201c;5-Year Facility&#x201d;) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the &#x201c;2021 364-Day Facility&#x201d;). In June 2021, we terminated our 364-day senior revolving credit facility (the &#x201c;prior 364-Day Facility&#x201d;), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.&#160;As of December&#160;31, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.9%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December&#160;31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the years ended December&#160;31, 2022 or 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. At December&#160;31, 2022, we had $0 outstanding under our commercial paper program. At December&#160;31, 2021, we had $300 outstanding under our commercial paper program with a weighted-average interest rate of 0.150%. Commercial paper borrowings have been classified as long-term debt at December&#160;31, 2022 and 2021, as our general practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year, and we have the ability to redeem our commercial paper with borrowings under the credit facilities described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Debentures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;9, 2012, we issued $1,500 of senior convertible debentures (the &#x201c;Debentures&#x201d;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The Debentures are governed by an indenture dated as of October&#160;9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#x201c;Indenture&#x201d;). The Debentures bear interest at a rate of 2.750%&#160;per year, payable semi-annually in arrears in cash on April&#160;15 and October&#160;15 of each year, and mature on October&#160;15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. The Debentures also have a contingent interest feature that requires us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October&#160;15, 2022. As of October 15, 2022, one of these events had occurred and contingent interest began accruing on the Debentures at a rate of 0.50% of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest will be payable on April 15, 2023, to holders of the Debentures as of the April 1, 2023 record date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April&#160;15, 2042, only under the following circumstances: (1)&#160;during any fiscal quarter if the last reported sale price of our common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2)&#160;during the five business day period after any 10 consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the applicable conversion rate on each such day; (3)&#160;if we call any or all of the Debentures for redemption, at any time prior to the close of business on the business day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events, as defined in the Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately preceding the Debentures&#x2019; maturity date of October 15, 2042, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2023, we delivered notice to redeem all of the outstanding Debentures. The Debentures will be redeemed on March 15, 2023 at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock or a combination thereof based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures was 13.2319&#160;shares of our common stock per Debenture, which represented a 25% conversion premium based on the closing price of $60.46 per share of our common stock on October&#160;2, 2012 (the date the Debentures&#x2019; terms were finalized) and is equivalent to an initial conversion price of $75.575&#160;per share of our common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, $41 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversion with cash for total payments of $299. During the year ended December&#160;31, 2021, $54 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $302. We recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on the conversion settlement dates. During the year ended December&#160;31, 2020, $56 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $222. We recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on the conversion settlement dates.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our common stock was last traded at a price of $512.97 per share. If the remaining Debentures had been converted or matured at December&#160;31, 2022, we would have been obligated to pay the principal of the Debentures plus an amount in cash or shares equal to $402. The Debentures and underlying shares of our common stock have not been and will not be registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option, net of deferred taxes and equity issuance costs, was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets.We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, at December&#160;31, 2022, the related balances, conversion rate and conversion price of the Debentures:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net debt carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion rate (shares of common stock per $1,000 of principal amount)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective conversion price (per $1,000 of principal amount)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.8139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $2, $4 and $6, respectively, of interest expense related to the Debentures, of which $2, $3 and $5, respectively, represented interest expense recognized at the stated interest rate of 2.750% and $0, $1 and $1, respectively, represented interest expense resulting from amortization of the debt discount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid on our total outstanding debt during 2022, 2021 and 2020 was $878, $822, and $794, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We were in compliance with all applicable covenants under all of our outstanding debt agreements at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of all long-term debt outstanding at December&#160;31, 2022 are as follows: 2023, $1,500; 2024, $1,647; 2025, $1,650; 2026, $746; 2027, $1,592 and thereafter, $16,714.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="i33b68b45f4914e09ab526057a219f954_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQxNw_90386e64-4e58-49b4-bdd1-99c059b3e199"
      unitRef="usd">265000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate
      contextRef="id063c136e8d646d9a71a21018eada61b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQyNA_943daaab-edd4-41e7-8ad7-c47f233c05cc"
      unitRef="usd">275000000</us-gaap:FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i33b68b45f4914e09ab526057a219f954_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU3MA_2f86454b-189a-4db1-9af2-71126fe9b38c"
      unitRef="number">0.04240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2cf1a9340bcf4268a0cbab4e753cb90e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzgxNQ_fc8ac9b1-01eb-447e-b503-9400ff192e22"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="i53292eeae2a246e58c5a7bcb2a4337ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNTA_85d87365-a565-42cb-aea9-3c82c75be943"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="i53292eeae2a246e58c5a7bcb2a4337ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNTA_d74ca337-c003-4850-98db-f30f7f37d309"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTQ4_dc53c189-4f3d-447d-b619-4cdc2430ddb8">&lt;div style="margin-bottom:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our long-term debt at December&#160;31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior unsecured notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.950%, due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125%, due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.300%, due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.450%, due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.350%, due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500%, due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.375%, due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.350%, due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.500%, due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.650%, due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.101%, due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.875%, due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250%, due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.550%, due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.100%, due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.500%, due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.950%, due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.850%, due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375%, due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.800%, due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625%, due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.650%, due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.650%, due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.100%, due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375%, due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.550%, due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.700%, due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125%, due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.600%, due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.550%, due 2052&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.100%, due 2052&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.850%, due 2054&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surplus note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.000%, due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior convertible debentures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.750%, due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable rate debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieac5c44b376048bbae8a2f0719d42263_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo1NTU5MGUwYmI2YTg0ZWMyYmNiZTNkODM1OWEzOTgzYl80_03d185e1-a25a-4238-97a1-17be04b74c2c"
      unitRef="number">0.02950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ieac5c44b376048bbae8a2f0719d42263_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMtMS0xLTEtNzgwNDk_eeda209a-5698-4041-a9e4-5531087bdbf5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i949d008a3d0b4b8d93c2d6a4799ec855_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMtMy0xLTEtNzgwNDk_391051e6-d79c-4476-b881-0f96a9962073"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ec6bfd612d64307b2a756760684ffe0_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpkZmNkMzFmZjhkMDc0OTUxOWFiNDg4MjE1MTFkMDA2N180_7e1d6b7f-4b94-43ff-a146-b0fe3cce7f0a"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0ec6bfd612d64307b2a756760684ffe0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzQtMS0xLTEtNzgwNDk_f17d748a-6303-43ca-a145-28552a0d7edd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaea1bc60c1634bd889b51a318197368d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzQtMy0xLTEtNzgwNDk_4f4fbae9-bf1e-4b96-b3c2-fcd6e8d4efc8"
      unitRef="usd">850000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa1c710fc55e47898c1d2f197e749108_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo1ZTJmYmQ2MzU5ZGU0NTk4YmQzMGVkNDNkZjhlZmU3M180_ae506fcf-8a5d-40e9-94f0-556b20d18d64"
      unitRef="number">0.03300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iaa1c710fc55e47898c1d2f197e749108_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzUtMS0xLTEtNzgwNDk_23e44077-cc14-4ca6-97ef-9c8e0c9d1455"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i45c611a7c74d4ab8ac5a98a6fe0e2728_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzUtMy0xLTEtNzgwNDk_bd4c1410-1c34-4980-a78d-3e2f8ac0e855"
      unitRef="usd">1014000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7636254161774196bf8c04399ddf133f_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzYtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjoxYTNiMjEzZGE2MjM0NmNiOTY4NDY3NzBjYTM4OTU4N180_eff4c7a2-80f0-4751-beb4-6b83a3780ad8"
      unitRef="number">0.00450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i7636254161774196bf8c04399ddf133f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzYtMS0xLTEtNzgwNDk_d04baf47-8eba-4bec-afc4-382e228a7e13"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic4154a06006b4cafa5cbd1a889726e29_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzYtMy0xLTEtNzgwNDk_59ad24c2-d24b-4cc8-bf7b-e8ad42ea13c6"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i13e53d3ac9be45f58795982cc797e03c_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzctMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0NGJkNGU3ZWVkM2U0Zjg2OGFmYTI1YzdlMjczZWFmNV80_028a79b6-32db-4758-a4f4-385c43cfd876"
      unitRef="number">0.03350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i13e53d3ac9be45f58795982cc797e03c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzctMS0xLTEtNzgwNDk_0acc3c19-b31e-43c6-851c-dc6737e8308a"
      unitRef="usd">849000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie7a05e7eaeb64ad58b3d1f47ad49fa73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzctMy0xLTEtNzgwNDk_0c9d130a-af49-4606-b8fc-f9174194505c"
      unitRef="usd">848000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2607b444454d46e39b6286f9c8ea6e3f_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzgtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphMTRjODE3MzdiNWY0NjdkYmM2ZDhiYmFkM2VkZmU1YV80_3a6b9526-cb88-49af-a322-efbc0cb386c3"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2607b444454d46e39b6286f9c8ea6e3f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzgtMS0xLTEtNzgwNDk_897f7eab-179f-4fc2-a6d3-c4f7a4ac8a7e"
      unitRef="usd">798000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0c77106efdf14a58abf9fc4127c8b091_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzgtMy0xLTEtNzgwNDk_a06bbe7b-edf9-4f03-8e57-14ee95b264bd"
      unitRef="usd">797000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i811d733c6b02495580c52c781054171e_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0YzE2YjVjYTI0ODg0MzNmODRmOGQ5MjE4M2Y2MzA4Ml80_6f888968-8d0d-43fe-8ab8-6da920eb9a81"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i811d733c6b02495580c52c781054171e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMS0xLTEtNzgwNDk_d20d2886-99ff-4d8b-9f33-0b5c650a1f47"
      unitRef="usd">1252000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if7e70d3f0aa9435ea3f59013c328d36f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMy0xLTEtNzgwNDk_fc8109f6-2473-4525-8e23-c1a9bb327439"
      unitRef="usd">1253000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id90d8e2c8f9446bfbdb944daa4c9681b_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMC0xLTEtMTAwMTE4L3RleHRyZWdpb246ZTVkZDIxODYxMzI3NDlhMThjZjNhZjk0ZmZmNzhjNjNfNTQ5NzU1ODEzOTI4_a5bc7866-0b34-4975-adbc-4dd7fd7384ac"
      unitRef="number">0.05350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id90d8e2c8f9446bfbdb944daa4c9681b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMS0xLTEtMTAwMTQ4_646c6de4-cb5b-4420-b486-7c75a94fd259"
      unitRef="usd">398000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3b3de8e0b39443b7b0385091bc11bf77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzktMy0xLTEtMTAwMTUw_45e456c4-6c0c-486f-af1a-18530d2ee5af"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9db25862eb95484085247b52a174b160_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjkyMzkyZDEzMzM4NDY1ZGI2MzQ4N2U5ODgyODg3MzVfNA_f184de93-e029-4a3b-bf74-9d468f9139f9"
      unitRef="number">0.01500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9db25862eb95484085247b52a174b160_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEwLTEtMS0xLTc4MDQ5_6e82b1eb-44ca-4105-8ca6-39c0fe0c3351"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaf2272113d58402ba5f389923853a07f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEwLTMtMS0xLTc4MDQ5_a2bdd42d-9e0c-4ddd-982a-2114de503348"
      unitRef="usd">745000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iea5aadb40cfa4a7c8342724cdc2f58c5_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzExLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NjBmY2UxMGUxNTlmNDdjZDhhNzQyNDBkNDdhMzA5ZmRfNA_2f688b44-9f8a-48d6-9a8c-7aebba74e40f"
      unitRef="number">0.03650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iea5aadb40cfa4a7c8342724cdc2f58c5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzExLTEtMS0xLTc4MDQ5_e98f1430-99c4-4bb6-a478-f8804bcbae86"
      unitRef="usd">1592000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icb71d9d282b643fd8703d9459d16e56d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzExLTMtMS0xLTc4MDQ5_7418d3a9-1833-449f-aec4-dd3ce0bc1479"
      unitRef="usd">1592000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i091a2bb4b5f242c3ad68068b656e90f2_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEyLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MWRiYWFmMGEzNTliNDlmZGEzNDlhNzE5OTZkNzBiNDNfNA_c1b4ca3d-eb16-4f12-a464-4054a05d8672"
      unitRef="number">0.04101</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i091a2bb4b5f242c3ad68068b656e90f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEyLTEtMS0xLTc4MDQ5_f506d8c8-46df-4291-bbcf-c212f8771fe2"
      unitRef="usd">1234000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i30b72b535fce46bf8f61743fb9e18481_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEyLTMtMS0xLTc4MDQ5_aebf674c-3cb8-450a-b0f0-76ed6c9f259f"
      unitRef="usd">1251000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic70a6a0be4d643d3927176d45192c141_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEzLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MzU1MDlkZmUzNjJjNDBmZDhhZWNkMDQyMmQ4NWNiZjJfNA_f43f2434-a1ef-49fe-b81b-3176f41c22d8"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ic70a6a0be4d643d3927176d45192c141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEzLTEtMS0xLTc4MDQ5_6bbfba41-5191-4177-b87d-20189d5752db"
      unitRef="usd">820000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i134f72e11a1649b7934274f86bea6020_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzEzLTMtMS0xLTc4MDQ5_9627f4eb-9b90-47d3-bb57-7874bdeb5386"
      unitRef="usd">820000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf998fc82656469e90d336c2b880f377_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE0LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Mjk0ZmZiMWQ2MDIyNDRlZjlkNTVmY2Y0OGJjMjFiNjFfNA_be4a790b-d0f3-4224-ba52-3557ce07cc96"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idf998fc82656469e90d336c2b880f377_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE0LTEtMS0xLTc4MDQ5_c733e037-362d-4f0b-a6a7-2a633576dd9e"
      unitRef="usd">1071000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6946a35fa850465fa36f14fc4f52f7bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE0LTMtMS0xLTc4MDQ5_72873e4d-7144-4196-b16a-10fb03e3f3b8"
      unitRef="usd">1089000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i67736d5753d44699b20adb0618b589fa_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YWJlNmQ4NmZiNmFiNGE0ZTk0OTE1ZDBlMzIwYzE4M2FfNA_8310e791-3170-4a61-809a-93003e83bd3c"
      unitRef="number">0.02550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i67736d5753d44699b20adb0618b589fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE1LTEtMS0xLTc4MDQ5_72f03615-d40d-4813-874b-bc593ff71da6"
      unitRef="usd">968000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ieb4f13755a194230acb1ec087846b505_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE1LTMtMS0xLTc4MDQ5_69e014f9-366f-4c8f-9ac9-48ffcd330d40"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i66a828e106b94047928ff146300d2ed0_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTAtMS0xLTEwMDEzMy90ZXh0cmVnaW9uOjk0ZjIwNDlkZmVhNjQ5NjQ5OTBiMGU4MzUyYjQ3Y2U0XzU0OTc1NTgxMzkxNA_7e752a0f-c50e-437b-8541-4eb74304a77b"
      unitRef="number">0.04100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i66a828e106b94047928ff146300d2ed0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTEtMS0xLTEwMDE1Ng_4ef27ef5-5f8a-44d6-8dfd-be495b350356"
      unitRef="usd">595000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifba93ec717e94394a8955cf9f5de9f90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTMtMS0xLTEwMDE1OQ_83aab3ef-be9d-4f9d-a95d-0d3655784ed5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie2e6cd38e3e84d5580d856acbad97133_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTAtMS0xLTEwMDEzNi90ZXh0cmVnaW9uOjc4MzgwNTU5MzQ2NzQ0MWE5MTI4MTRkYjkyYzA0ZTExXzU0OTc1NTgxMzkxNA_78148719-f9bc-46f2-80ec-081dd66228a0"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie2e6cd38e3e84d5580d856acbad97133_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTEtMS0xLTEwMDE2Mg_b0cf5ff9-f2c0-4c28-9a90-90aae99de578"
      unitRef="usd">644000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie323f9332ece4230a9778b8c7d487528_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTMtMS0xLTEwMDE2NQ_f4205d91-165e-4993-8431-cac4a1269d0c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ife4c77f05ea246d1b396cda16a6f5b1e_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MGIwY2I5NzU2OTcwNDExNGJkOWZiOTQ0ZGEyNGMyOWFfNA_99d9572a-7152-4b04-ad72-e220adf15831"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ife4c77f05ea246d1b396cda16a6f5b1e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTEtMS0xLTc4MDQ5_fe83ea1b-d85d-4ea2-b6dd-8b807820360e"
      unitRef="usd">334000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i353e9848174344adab8b80f569e38864_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE2LTMtMS0xLTc4MDQ5_306cb63b-679d-4e32-a47d-5a7bb9afbd7a"
      unitRef="usd">334000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia22dd705e96640c28ac4a3b93dc44cb7_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NzhmMTFjYzAxNGIwNGVlZTliZGI1MGJiYmU2ZWE4ZjNfNA_1d3c5bbf-a06e-4f46-b794-d86778e15d18"
      unitRef="number">0.05850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia22dd705e96640c28ac4a3b93dc44cb7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTEtMS0xLTc4MDQ5_95dcf9f9-b237-4157-8a74-a2bd645aa99b"
      unitRef="usd">396000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibd9c543ff2b843e8964521415571c09a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE3LTMtMS0xLTc4MDQ5_40527fa4-7266-45a6-ae0c-dc41d2c12069"
      unitRef="usd">396000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i928bec5ee982461199847da9ac96d68b_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NzFiNjNlYTk3MmNhNGM1OGIxZjQ4ZjIyMGRjYzdlYmFfNA_11037536-1543-4773-9e7c-d5b712670ae5"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i928bec5ee982461199847da9ac96d68b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE4LTEtMS0xLTc4MDQ5_2a72c5fe-c3e2-4912-a5ec-ca08071f2f39"
      unitRef="usd">364000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i88ffc1ca7d414bbd94fbe98e6dac3891_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE4LTMtMS0xLTc4MDQ5_b8c1f066-4061-4074-9dbe-8fc4dc42fcd0"
      unitRef="usd">364000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iadc050557e394d4bb08e2383bcb0c73e_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE5LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MTExODJiYjY2MzMxNDMwNjg3YmUxYjUxMTcxZTg1ODNfNA_8899ca4d-dc49-4f36-b157-6c7bab1cca9e"
      unitRef="number">0.05800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iadc050557e394d4bb08e2383bcb0c73e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE5LTEtMS0xLTc4MDQ5_619004bf-d130-4dfd-91f2-8049c8356170"
      unitRef="usd">114000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i029531456f0742b18198f12d8893bbdd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzE5LTMtMS0xLTc4MDQ5_356a2f82-7f9a-4a7a-b2e6-749c5207b02d"
      unitRef="usd">114000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ice205a4939054c86b0d0fab99c58c6de_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246NTU1ZmZlMTk1ZGZlNGYxNWEwYTAwZTBmY2JjYWI3OGZfNA_6a76d7f3-2feb-4884-ad9c-dde273c71b60"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ice205a4939054c86b0d0fab99c58c6de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIwLTEtMS0xLTc4MDQ5_6113c803-eaf9-4f2f-b6bb-3c8344058e9d"
      unitRef="usd">859000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6f4c04d831ec4f03aa3ef7b1e8fae480_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIwLTMtMS0xLTc4MDQ5_9f53fb89-52ca-42db-824f-1f44885e1c16"
      unitRef="usd">859000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie4301f61a56d4a5981fa5a8be60c5456_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ODhmMThhMWJiMGY3NDk0NGI2NWJmNWY2NmMwZWM1MzdfNA_0d669dea-1ca9-42b1-ae30-93f0bc9ebc18"
      unitRef="number">0.04650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie4301f61a56d4a5981fa5a8be60c5456_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIxLTEtMS0xLTc4MDQ5_56abada4-b097-4b5d-ab29-c7e232c25d27"
      unitRef="usd">974000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i886b4f01b01343e99f882cbfedb38b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIxLTMtMS0xLTc4MDQ5_18142353-0fb0-4800-a3df-15c43bacdb43"
      unitRef="usd">974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie5c8b1a203e04bc98e13209d268178e6_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIyLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MTg4NmJkM2RhMDU3NGJiYzk0MTI1MWNmMmRhMDMxODJfNA_43231e69-cf4b-468d-9981-6af75fe1ab86"
      unitRef="number">0.04650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie5c8b1a203e04bc98e13209d268178e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIyLTEtMS0xLTc4MDQ5_a3cee6a1-d7da-48ec-bdbc-babede5d0fc4"
      unitRef="usd">767000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib12d2d5430234b8da43f315a70dbda73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIyLTMtMS0xLTc4MDQ5_23ba0ade-6676-4bb3-8cc9-c18e9b68d474"
      unitRef="usd">767000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie11833466f4c4e66b1df0bdb5615948b_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIzLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk3NmQyY2EzNzFjNGE2ZWIwMGFjM2I3N2I3MzE5OTRfNA_3147ab90-bd5e-4828-9d43-1b939a3ca1da"
      unitRef="number">0.05100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie11833466f4c4e66b1df0bdb5615948b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIzLTEtMS0xLTc4MDQ5_224acbef-c9fe-48da-bf99-4ea5481abfc8"
      unitRef="usd">548000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i24e99111afc84fa281a0286ba240fd53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzIzLTMtMS0xLTc4MDQ5_4c91f253-bfed-4ab6-9f87-ee82b3677af2"
      unitRef="usd">548000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i188c10cfbcd14ea593ae781c8b7d8219_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI0LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTYwZmFiYzk2ZjQ5NDE4NDg5OTdmYTM2YjI0NmMzYThfNA_2e85b661-5938-4c6e-b7ba-d914ae48735a"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i188c10cfbcd14ea593ae781c8b7d8219_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI0LTEtMS0xLTc4MDQ5_4464da61-70b2-4080-80d9-d95fe12a9bf3"
      unitRef="usd">1388000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i86370035d0f94594abe20431af0befa9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI0LTMtMS0xLTc4MDQ5_23928867-b4e0-4141-bb1c-46a4ea6301fa"
      unitRef="usd">1387000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if6caa66b97514d68ba837991fe14dbdf_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MGY5NGFjOTExMTllNDE4YWIxMDYzYjcyYTc2NGU4ZmFfNA_19e3fc18-031e-4aa1-a35b-c8ab48cff0f7"
      unitRef="number">0.04550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if6caa66b97514d68ba837991fe14dbdf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI1LTEtMS0xLTc4MDQ5_776996d2-ac06-4a5c-886e-33aa520ac155"
      unitRef="usd">840000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibbe622a0dd5c41d5bb15002f914046be_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI1LTMtMS0xLTc4MDQ5_e5f35d7c-9c79-4da8-aa8a-9ef82b6e6033"
      unitRef="usd">839000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieba76da0d560460cb028e0c65f72ea97_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI2LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MTc0NjYxOTU4MjAzNGJiYmI0MmJhNDcwMDYzMWQzMzdfNA_70c4ed28-40ee-44a2-a93e-c74980c85e65"
      unitRef="number">0.03700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ieba76da0d560460cb028e0c65f72ea97_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI2LTEtMS0xLTc4MDQ5_18eede23-abff-4986-ab22-6fe6c366365f"
      unitRef="usd">812000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia3ed97bbfa0946bc8f76958f0fc5eb16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI2LTMtMS0xLTc4MDQ5_42fdc79b-7afa-420a-9c3b-7ac8770ab239"
      unitRef="usd">812000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d6bb5890f644dc2a4785a6cd8b1b0c5_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ODIyMWJkMTcwMTMyNDEyMWJlZDU4NDhmMTA3ZmMyMzdfNA_8759e7ca-2f03-47a6-b86f-2c8f31aa5028"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1d6bb5890f644dc2a4785a6cd8b1b0c5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI3LTEtMS0xLTc4MDQ5_3442f2b8-7152-4326-8f9c-26c5b72dc942"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4d118ac360bd4e3aad70d1189c447897_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI3LTMtMS0xLTc4MDQ5_1a302255-3c27-46ca-93af-ff3d62b7e2f8"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id74f9a1abba844ef9912af38aac619e7_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YjNhYmYyMTYzNmQ5NDEwZjhkMjAzMTYyNGMzZjc4ZGVfNA_8a74d63f-26e4-4e43-81ea-3016d0fed105"
      unitRef="number">0.03600</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id74f9a1abba844ef9912af38aac619e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI4LTEtMS0xLTc4MDQ5_4a498849-599b-4f4b-a934-d8dbd022ba6d"
      unitRef="usd">1233000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i69ffc9a6ff1d499eb81b8fc7cd50feeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI4LTMtMS0xLTc4MDQ5_b740eed3-a0de-4160-b998-795b6e764fbe"
      unitRef="usd">1232000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8fc6cdf9d6fe436c9e1912baf09467ae_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTAtMS0xLTEwMDE0MS90ZXh0cmVnaW9uOjMxNDE0Y2I5ZWVhYTQ5MjM4YWU0MjIyMDBiMzhmMTQ3XzU0OTc1NTgxMzkxNA_ff77a52f-7cc1-4fa0-9091-3487c938978e"
      unitRef="number">0.04550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8fc6cdf9d6fe436c9e1912baf09467ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTEtMS0xLTEwMDE2OA_1d29bce8-e9ec-476f-8a94-07203aeb1d75"
      unitRef="usd">689000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic855e040017843f28f7041b2bc021f66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTMtMS0xLTEwMDE3MQ_974999d1-f99f-4fec-8cd1-dc20db8d6ff3"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia3c3fc9281644847a3ab3c94cd2f8927_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMyLTAtMS0xLTEwMDE0NS90ZXh0cmVnaW9uOjY1YTkwYzA4ZmU2YjQ5NzU4ZTQ0NDU5NGJjNjk3MGEwXzU0OTc1NTgxMzkxNA_66fe64ce-719c-4ede-8a43-aa66cc7cbfc2"
      unitRef="number">0.06100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia3c3fc9281644847a3ab3c94cd2f8927_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMyLTEtMS0xLTEwMDE3NA_ea8f748b-d3fe-4f27-a876-a3af7488610f"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i29b0fd92b63040658ab461c35f466977_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMyLTMtMS0xLTEwMDE3Nw_8485fe6b-b0ee-47db-a6b5-a8a6d144d629"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1151ddbe0ece40b18eadc2621477a0ef_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI5LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQxMjE2NTVhMmM1NDAxNzg3ODk3YWQ0MzNkNjIwNDVfNA_6f48b655-e8bd-427d-aed4-9fa29afd69fd"
      unitRef="number">0.04850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1151ddbe0ece40b18eadc2621477a0ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI5LTEtMS0xLTc4MDQ5_cb3de81f-5e04-41ff-bffb-73789ee38b0e"
      unitRef="usd">247000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i871498f5fef9430a894e75b1f70e1af1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzI5LTMtMS0xLTc4MDQ5_0c6b4693-2516-40c2-a1f9-4359fe393860"
      unitRef="usd">247000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i00522144e96b43829be3251cd73df914_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZWU4ZDNmZmY3NDY2YmJiYmI3Mzc2MTk1ZThlNTZfNA_37f7f559-def4-481c-bd3c-0df7046805df"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i00522144e96b43829be3251cd73df914_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTEtMS0xLTc4MDQ5_f9351d28-c38b-4f0c-a039-84a067108c48"
      unitRef="usd">25000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic08004c17645430d9704d5e79d29fccc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMxLTMtMS0xLTc4MDQ5_8df84445-3d9b-46e7-bf5d-13184d71bf77"
      unitRef="usd">25000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMzLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MWNkZWM2ZjAyYjRiNDA4NGIxNWEzNzc4MDJkZGQ2ZWVfNA_cd3ef748-a856-45de-9049-76221aaf9bec"
      unitRef="number">0.02750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMzLTEtMS0xLTc4MDQ5_554b8655-5b46-4cf2-93a0-c3b9ce51dff7"
      unitRef="usd">63000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if80cee633ac84a32ac44408267eda7b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzMzLTMtMS0xLTc4MDQ5_f8bd5afd-f3f6-491f-9138-e209e20b21e6"
      unitRef="usd">72000000</us-gaap:LongTermDebt>
    <us-gaap:CommercialPaper
      contextRef="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM1LTEtMS0xLTc4MDQ5_e79c7142-1c3c-4a05-9032-a7af5ab5ad35"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM1LTMtMS0xLTc4MDQ5_b601533f-49ef-4779-89ff-a18c4023bf4a"
      unitRef="usd">300000000</us-gaap:CommercialPaper>
    <us-gaap:LongTermDebt
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM2LTEtMS0xLTc4MDQ5_ce8ea9b2-7fd9-48b6-8304-2de5b07aebb6"
      unitRef="usd">23849000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM2LTMtMS0xLTc4MDQ5_6004a06f-f342-48b0-a7f2-0d4d600498ab"
      unitRef="usd">22756000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM3LTEtMS0xLTc4MDQ5_73f05564-1c55-44d9-9bab-ffd133dfa759"
      unitRef="usd">1500000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM3LTMtMS0xLTc4MDQ5_5d832dac-024a-4fa0-8434-e731207359c2"
      unitRef="usd">1599000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM4LTEtMS0xLTc4MDQ5_486aaf57-bb50-4df1-afd3-2fdcf1c8dc85"
      unitRef="usd">22349000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZTo5MGNiNmY2ZTNmNzc0MDQyYTEwZDc5MmM0N2Y4YmY0MS90YWJsZXJhbmdlOjkwY2I2ZjZlM2Y3NzQwNDJhMTBkNzkyYzQ3ZjhiZjQxXzM4LTMtMS0xLTc4MDQ5_d1ce8f19-6158-43cd-94ce-d301af1c0705"
      unitRef="usd">21157000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ice43633ad18f45a3bf5610792f8e0e92_I20230208"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzgyMw_6b9d8e8a-322b-4236-ad87-348cf64a4805"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ice43633ad18f45a3bf5610792f8e0e92_I20230208"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzgzMg_1f389ea6-4b86-4398-981d-d46b663c04d2"
      unitRef="number">0.04900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie9fbf8cc11e742c2b3eb7b913dbc0f53_I20230208"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg1Nw_b0ddd0cd-21e3-4b90-b5c2-6e3995d11979"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9fbf8cc11e742c2b3eb7b913dbc0f53_I20230208"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg0MA_6c1b3410-a86e-4cc5-89f1-aa8186666877"
      unitRef="number">0.04750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i38626e3e281747b1864dc478c857e132_I20230208"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg2OA_855494d3-4fd4-44c9-b50c-ce0b02c947cc"
      unitRef="usd">1100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38626e3e281747b1864dc478c857e132_I20230208"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg0OA_970fe07c-ba88-4bbf-a517-ae6c6874a9ae"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="id3702fa1806f4f55afc1809dce531453_I20221201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MjE4Nw_85c16eec-71f4-41b2-8fe6-2361dda0b762"
      unitRef="usd">750000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3702fa1806f4f55afc1809dce531453_I20221201"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MjE5Ng_330aba20-6a84-4d6c-81f9-8815b8f12f62"
      unitRef="number">0.02950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iad77e559c2a94999bb397fa384a544e9_I20221104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg3OQ_769bff7c-eedc-41b6-99ac-05afad336d6d"
      unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iad77e559c2a94999bb397fa384a544e9_I20221104"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg4OA_22e5f7b3-e933-4c7c-92ca-1c4fc7366435"
      unitRef="number">0.05350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if0f2459563994824a4b0a6fe56121a68_I20221104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzkyMQ_9159a86a-869a-4c20-9fd2-d8654c3b997c"
      unitRef="usd">650000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0f2459563994824a4b0a6fe56121a68_I20221104"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzkwMg_7c940cf7-3fd1-4a95-a1e4-934ca4f4d369"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id0933651ffe04b7bbdbc822cd8b57555_I20221104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Nzg5Ng_42afea95-3ad8-4410-9426-6a8d1b6e6795"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id0933651ffe04b7bbdbc822cd8b57555_I20221104"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0NzkxMw_7e96844d-f34c-4fb7-bf45-9c9bec7c4753"
      unitRef="number">0.06100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ib14c797d21b24b8e925b9f7f60a8b208_I20220516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTg3OQ_aeef373b-7798-4c38-b166-667d62de3e72"
      unitRef="usd">850000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib14c797d21b24b8e925b9f7f60a8b208_I20220516"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTg4NQ_ace1ced9-3f1f-4201-8c40-a89e39e4d7f7"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if73dc0aa91534a999012a5f25833b272_I20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTg5Ng_7af275db-4829-4055-9e1a-94fad20d70b3"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if73dc0aa91534a999012a5f25833b272_I20220429"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTkxNA_d3bb9514-7a46-42f8-9879-3d09a39c472d"
      unitRef="number">0.04100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i333b97a4235d45a5a86902df2d17954a_I20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTkwNQ_9121dde9-b8d8-4cac-91a8-82ac97b9437d"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i333b97a4235d45a5a86902df2d17954a_I20220429"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgyOTkyMg_d021af5d-07ff-4e0c-ac7f-884c0b1b2603"
      unitRef="number">0.04550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <elv:DebtRedemptionAmount
      contextRef="i69ce9e81a0d3461dab8dbc07066d500d_I20210515"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE3NTM_e98a4810-b98e-4221-a3b6-c6e95fe34438"
      unitRef="usd">700000000</elv:DebtRedemptionAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i69ce9e81a0d3461dab8dbc07066d500d_I20210515"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE3OTM_a101e76f-d1a6-4f7c-9c28-29e151a69b3c"
      unitRef="number">0.03700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionDescription
      contextRef="iac73002099334b069811ed521ffc2f61_D20210515-20210515"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTQ5_ac30b175-8687-4c62-9562-b398890e55a6">at a redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2bc2487f523740c69014d98ef48fc2ae_I20210317"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE5ODQ_1c42c6db-e2ca-4c72-a3fd-8c32f309b307"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2bc2487f523740c69014d98ef48fc2ae_I20210317"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIwMTc_5e382fbf-7907-4be2-91ef-67942a0eb2b3"
      unitRef="number">0.00450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i429662b30ae84f4fb822ecd377e98b9c_I20210317"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIwNTU_e3ab166e-c6ff-40e5-af43-99c9537c3fd1"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i429662b30ae84f4fb822ecd377e98b9c_I20210317"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIwODg_f39f0787-1d5b-48dd-9d4e-172c7e29ddaf"
      unitRef="number">0.01500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i54cffe8dccdc4ee6945a8e5fea7b55b4_I20210317"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIxMjY_8cda6117-daea-4f07-87ec-929d74c66fd6"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i54cffe8dccdc4ee6945a8e5fea7b55b4_I20210317"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIxNTk_e6d49a7e-5fd7-4804-ab4c-bf428214a3e0"
      unitRef="number">0.02550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i325bf58af121477aaabb4ba211cc0a8b_I20210317"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIyMDA_ca7dbd05-79f3-4fac-aa35-a147e3d3ab8e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i325bf58af121477aaabb4ba211cc0a8b_I20210317"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzIyMzM_570e5af5-51d5-44c0-94cf-5d99e343f035"
      unitRef="number">0.03600</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzI4MDE_dff800aa-1db5-4be6-b3f0-346f794acda3"
      unitRef="usd">52000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:EarlyRepaymentOfSeniorDebt
      contextRef="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzI5NzQ_bd9145d0-c0db-4c2e-ba57-11fa971efb05"
      unitRef="usd">67000000</us-gaap:EarlyRepaymentOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8d35aa89d0a9487fa31388ceeb25d3b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMwMjg_653b4376-c156-4c6c-9374-184035ed5863"
      unitRef="usd">15000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i8f86ebcddede41c59e36155926d5c738_I20201123"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMxMTY_f46e9e51-57b1-4de8-a979-b5b1a0adde58"
      unitRef="usd">900000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f86ebcddede41c59e36155926d5c738_I20201123"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMxNDY_ebae2e16-6355-49b8-b10e-9b2e4463d008"
      unitRef="number">0.02500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i8eb1aa80db82419e86533f0ed7493781_I20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMyMjE_91a120c4-dc0d-480f-bc9e-0d1458e1a925"
      unitRef="usd">700000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8eb1aa80db82419e86533f0ed7493781_I20200817"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMyNTE_0314ed73-edf9-438c-843c-97f8b88cc089"
      unitRef="number">0.04350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzMzNDk_8a2fbc33-d523-48eb-b35e-ad1d6ba0dcaa"
      unitRef="usd">79000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:EarlyRepaymentOfSeniorDebt
      contextRef="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM1MjI_e284cec5-31d3-4c1d-a9a9-4e244473b3a1"
      unitRef="usd">109000000</us-gaap:EarlyRepaymentOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic8b566d6f47b4daf8a672af08bc43ea8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM1NzY_51f478da-e15b-497f-b319-0823be468e55"
      unitRef="usd">-30000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4ca42aa1e7484753ae2809b124a577da_I20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM2NDA_2ecb24ee-bd42-4ce2-b427-82878f782ed0"
      unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4ca42aa1e7484753ae2809b124a577da_I20200505"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM3Mzc_d2a45b17-e93e-494a-aab9-6786b92efbdb"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i41649eb783044c5eb58218b8fa152592_I20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM3NzU_6e2936f8-d904-4c2f-b842-e20cd6a225ca"
      unitRef="usd">1100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41649eb783044c5eb58218b8fa152592_I20200505"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM4MDg_88d28aa0-55cb-46ae-9a73-5912da49174f"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic6256919a6f740e9a7538e63d97e56c3_I20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM4NTA_41e26a1a-186c-4cff-90cf-a17641bd91fe"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic6256919a6f740e9a7538e63d97e56c3_I20200505"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzM4ODM_e2e7734a-b3cf-4572-a050-9bdf26c75752"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib8ac997eed1f49e1bc4fbe2c7718e08f_I20190909"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQwMTY_7db21265-0d53-4fc3-ac12-818aa6e940b2"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib8ac997eed1f49e1bc4fbe2c7718e08f_I20190909"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzQwNDQ_815476c7-146b-4a02-8972-ae9cff82c995"
      unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iad3cc9878d194c6ab4cfcad7ad636235_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzYyNzk_8663b6a4-a8c7-47fa-a38d-020677473bf8"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4ac0254b163e4965ada5424581be8b2f_I20220418"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTgzMDQ5Mw_c2462311-10ea-4705-8243-00383286f130"
      unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityDescription
      contextRef="i83efaab7af2c47789e213ba327cae52f_D20220418-20220418"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NDk2OA_43687ded-4062-444d-8d02-f32b9c248bb3">Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i99dac9a626014a259743a75faf51bbc3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NDk1OA_efdabf3a-c0ef-4e6e-80e0-4b0458bef016"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCovenantDescription
      contextRef="i78ee27d7ced94e33a81e7cf47376711f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTYw_aeb8e1d3-52d9-4b6a-8ddf-db651ca36bf4">Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.</us-gaap:DebtInstrumentCovenantDescription>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="i78ee27d7ced94e33a81e7cf47376711f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTU3_245a9ac0-6f23-4352-a0e7-b8ea24a0cd3e">As of December&#160;31, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.9%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December&#160;31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility.</us-gaap:DebtInstrumentCovenantCompliance>
    <elv:CommercialPaperMaximumBorrowingCapacity
      contextRef="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc2ODI_0c8205cc-cc28-4b26-8450-5e61663fd54d"
      unitRef="usd">4000000000</elv:CommercialPaperMaximumBorrowingCapacity>
    <elv:CommercialPaperMaximumBorrowingCapacity
      contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NTAwNw_7648c462-9835-4316-a379-11d3c6f49a87"
      unitRef="usd">3500000000</elv:CommercialPaperMaximumBorrowingCapacity>
    <us-gaap:CommercialPaper
      contextRef="i59654c1f0eec4aada0e2b8e3073ae6a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc3NjY_2a3b751b-6276-4eac-b3ba-85d2d2e93cb6"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc4NzU_b601533f-49ef-4779-89ff-a18c4023bf4a"
      unitRef="usd">300000000</us-gaap:CommercialPaper>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i36a0a42c323145ef81b27d49ee1f9e8b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzc5NjY_9c07a493-90bf-499c-b225-88f6d1b6f4cf"
      unitRef="number">0.00150</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i111f1669cf354c22bca3fe927cfeb62c_I20121009"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzg0NDc_19c0a1ef-1ba1-48f5-9464-5176566dc0a0"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i111f1669cf354c22bca3fe927cfeb62c_I20121009"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzg4NTc_4076abb4-14e5-45f8-9136-ea67dcceebc0"
      unitRef="number">0.02750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtContingentPaymentOfPrincipalOrInterest
      contextRef="i3deab0f622924f9085bea8fcbe5ee03c_D20221015-20221015"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NDk5OA_dfeb384b-8734-4220-9080-61d6c10254ad">The Debentures also have a contingent interest feature that requires us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October&#160;15, 2022. As of October 15, 2022, one of these events had occurred and contingent interest began accruing on the Debentures at a rate of 0.50% of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest will be payable on April 15, 2023, to holders of the Debentures as of the April 1, 2023 record date.</us-gaap:LongTermDebtContingentPaymentOfPrincipalOrInterest>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk1ODk_8c5aadc9-2551-4f05-beef-aa7d2b529d6a"
      unitRef="number">20</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <elv:NumberOfConsecutiveTradingDays
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk2MjQ_85785ff7-2c3a-41ef-bc70-3727a19ad1bd">P30D</elv:NumberOfConsecutiveTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk3NDM_e1874775-1e68-4dc1-b9a7-2467ccb822f3"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <elv:MeasurementPeriod
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk4NjM_d15091c2-f438-478a-a562-8af8595be809">P10D</elv:MeasurementPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzk5NTU_6490c636-7e21-4366-97c4-b4a0d8bf8667"
      unitRef="usd">1000</us-gaap:DebtInstrumentFaceAmount>
    <elv:PercentConversionToStockPrice
      contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwMDY3_909b2482-50fc-4a1b-a5be-f9b18465990a"
      unitRef="number">0.98</elv:PercentConversionToStockPrice>
    <us-gaap:DebtInstrumentConvertibleEarliestDate1
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNDU4_7a96e7e3-ae03-4d86-839d-8eadade5fa87">2042-04-15</us-gaap:DebtInstrumentConvertibleEarliestDate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNTgz_8344d886-ac8c-4695-8a76-01edc722c73a">2042-10-15</us-gaap:DebtInstrumentMaturityDate>
    <elv:DateDebenturesReedemable
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEwNzY3_f9c6dcc7-4a48-41bd-96b2-c3d84df54d18">2022-10-20</elv:DateDebenturesReedemable>
    <us-gaap:DebtInstrumentRedemptionPeriodEndDate
      contextRef="iac96933216134d7b8897d64076389449_D20230213-20230213"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NTI5Nw_0e379de8-3bdb-4789-b557-3832d28aaa5f">2023-03-15</us-gaap:DebtInstrumentRedemptionPeriodEndDate>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="iac96933216134d7b8897d64076389449_D20230213-20230213"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg1NTI0Mg_c87f2070-0999-4993-b1fd-170b2ee6d2eb"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ie6cc8a906b734cbb88951da261ef5f76_D20121001-20121002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExMzEw_6257c43d-6cfb-4af0-bb59-587ef23fd0c2"
      unitRef="number">13.2319</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <elv:ConversionPremium
      contextRef="i168f8f6c7055487690a43cb967e499b1_I20121002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExMzc1_9c486024-e006-4a56-ab29-5f9b91d13a26"
      unitRef="number">0.25</elv:ConversionPremium>
    <us-gaap:SharePrice
      contextRef="i168f8f6c7055487690a43cb967e499b1_I20121002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNDI3_aa8ca409-c451-4186-b9a4-5909638b778e"
      unitRef="usdPerShare">60.46</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i168f8f6c7055487690a43cb967e499b1_I20121002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNTc5_f3ca1128-2ee5-4b58-af69-254797d160ab"
      unitRef="usdPerShare">75.575</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <elv:DebtConversionDebtPrincipalAmount
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MzM2MA_d1e91903-9f88-4cba-bfb0-78b0982dfcc6"
      unitRef="usd">41000000</elv:DebtConversionDebtPrincipalAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MzM1MQ_fc78001b-a0bf-4309-bf16-f0c57e382e80"
      unitRef="usd">299000000</us-gaap:RepaymentsOfLongTermDebt>
    <elv:DebtConversionDebtPrincipalAmount
      contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExNjU1_20a0bf01-f87d-48a2-af83-bfbdb088c681"
      unitRef="usd">54000000</elv:DebtConversionDebtPrincipalAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzExOTIy_7740d92f-6c0b-4071-8361-0aac4056704f"
      unitRef="usd">302000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyMDA2_08291869-ab76-403a-a908-c26d55358635"
      unitRef="usd">-6000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <elv:DebtConversionDebtPrincipalAmount
      contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyMTI0_a9ae873f-7756-4688-8f0c-5b778e87091a"
      unitRef="usd">56000000</elv:DebtConversionDebtPrincipalAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyMzkx_69ac0f38-cc21-4010-966e-9a31de9c79dd"
      unitRef="usd">222000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEyNDc1_316e2f77-da31-432e-b5cc-be23b5415c68"
      unitRef="usd">-6000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:SharePrice
      contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEzMTA3_116ddd49-4fca-4ffc-bca8-241ab05f035f"
      unitRef="usdPerShare">512.97</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzEzMjk2_215701c1-cc63-4e7a-b9c9-2280d2b48da6"
      unitRef="usd">402000000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:LongTermDebt
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Mzg4NQ_76d79920-de6a-47b2-afe5-88fbb635e800"
      unitRef="usd">31000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0Mzg5Mw_137c3fd0-a672-499d-867f-bdef07372101"
      unitRef="usd">-8000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity
      contextRef="i36339a5e9f2a4183be7baf0bbf242dd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzU0OTc1NTg0MzkwMA_26efafb1-20f6-47d7-8153-7ab3a6ef6df9"
      unitRef="usd">-23000000</us-gaap:StockholdersEquity>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTYy_5090267d-c899-4a2a-8e23-60b3be6ab35e">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, at December&#160;31, 2022, the related balances, conversion rate and conversion price of the Debentures:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net debt carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion rate (shares of common stock per $1,000 of principal amount)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective conversion price (per $1,000 of principal amount)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.8139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzAtMS0xLTEtNzgwNDk_d9c67f32-4290-475a-8823-69a21150d744"
      unitRef="usd">63000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzItMS0xLTEtNzgwNDk_5bd96448-a922-483b-a9fd-c00d4d52b557"
      unitRef="usd">63000000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzQtMS0xLTEtNzgwNDk_00834302-a189-47da-a1d1-1aa2b60ba543"
      unitRef="number">14.3238</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90YWJsZToyNjJjZGI1MmRjMmI0ODA2YTliOTI0ZDI2OGE0YjE4MC90YWJsZXJhbmdlOjI2MmNkYjUyZGMyYjQ4MDZhOWI5MjRkMjY4YTRiMTgwXzUtMS0xLTEtNzgwNDk_25b30a1c-4740-4054-95ba-9a0b61db7def"
      unitRef="usdPerShare">69.8139</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestExpenseDebt
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTAx_de248a67-2b0a-4d09-b093-d126f3869c3f"
      unitRef="usd">2000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTA1_64c07244-14fc-46c8-b55e-6cfc789eaf8f"
      unitRef="usd">4000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTEy_6c4df042-412f-413d-b333-614dbfb02ec9"
      unitRef="usd">6000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTg2_20764559-82f8-47e1-9aee-ee824c8a0873"
      unitRef="usd">2000000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTkw_7fada8d6-85ec-4270-8740-1aa013f85518"
      unitRef="usd">3000000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NTk3_6436ffd5-c0ec-4879-b9f6-f5646a39ae7a"
      unitRef="usd">5000000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c84a9462da54835ae2f9e76a4f4376c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0Njg2_24a1168e-f786-4be6-aa61-4d350543f960"
      unitRef="number">0.02750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i578c26b85f61435e86dc64890acdacd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0Njkz_ccf88de1-409e-433f-8d14-aebba722a435"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i014b2a7989874672999bda1d7e4f0158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0Njk3_ffa906da-6deb-4ce9-84a5-d3be8cf3a590"
      unitRef="usd">1000000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic527b011d56d490c86fc7e4e28f15beb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0NzA0_badccfde-69a3-48e3-aefc-ee1fafb20005"
      unitRef="usd">1000000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestPaid
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0ODcy_53550214-0bd5-48b7-bebb-5c28076b8269"
      unitRef="usd">878000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0ODc2_f5e2e7d5-b983-4cda-96e3-df3f020789fa"
      unitRef="usd">822000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE0ODg0_267671a1-fc08-48c5-923f-ce90323aaf94"
      unitRef="usd">794000000</us-gaap:InterestPaid>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MDky_c1c60cbe-b7e2-4394-8b4a-1fd07284481f"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTAw_bf403e4b-4b4f-4e86-b3ff-d3b65e300e0e"
      unitRef="usd">1647000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTA4_398a030f-96be-43dc-af42-1c9dc28e9647"
      unitRef="usd">1650000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTE2_b92dfe1f-a674-47de-82d2-18c5ba4350ec"
      unitRef="usd">746000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTI0_ee839c66-d227-4cf5-9fc9-df44bc6bbcad"
      unitRef="usd">1592000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xMzkvZnJhZzowYzY3ZGU0YzM5ZGM0ZjQ1YWQ1ZDRkNzI3MThmYmY5Mi90ZXh0cmVnaW9uOjBjNjdkZTRjMzlkYzRmNDVhZDVkNGQ3MjcxOGZiZjkyXzE1MTQz_47eae9ac-f2a4-4121-b05b-46fc7161c595"
      unitRef="usd">16714000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzIxMjM5_639153f3-713d-4c13-a0e4-16fc22ad267b">Commitments and Contingencies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation and Regulatory Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at December&#160;31, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Blue Cross Blue Shield Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the &#x201c;Blue plans&#x201d;) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Blue Cross Blue Shield Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that is pending in the U.S. District Court for the Northern District of Alabama (the &#x201c;Court&#x201d;). Generally, the suits allege that the BCBSA and the Blue plans have &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (&#x201c;Sherman Act&#x201d;) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Court issued an order on the parties&#x2019; cross motions for partial summary judgment, determining that the defendants&#x2019; aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the &#x201c;Subscriber Settlement Agreement&#x201d;), which agreement required the Court&#x2019;s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the &#x201c;national best efforts&#x201d; rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members. The notice process was completed in March 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the &#x201c;Final Approval Order&#x201d;). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which was previously accrued in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event that all appellate rights are exhausted in a manner that affirms the Court&#x2019;s Final Approval Order, the defendants&#x2019; payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to the providers&#x2019; claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants&#x2019; motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs&#x2019; motion for partial summary judgment, holding that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ohio v. American Express Co&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants&#x2019; motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the &#x201c;national best efforts&#x201d; rule, the rule of reason applies to the provider plaintiffs&#x2019; market allocation conspiracy claims, and (ii) denying the provider plaintiffs&#x2019; motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers&#x2019; group boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to providers&#x2019; renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are:  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No. 2:21-cv-01209-AMM (N.D. Ala.); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;JetBlue Airways Corp., et al. v. Anthem, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 2:22-cv-00558-GMB (N.D. Ala.); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 2:22-cv-00265-RDP (N.D. Ala.); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bed Bath &amp;amp; Beyond Inc. v. Anthem, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 2:22-cv-01256-SGC (N.D. Ala.);&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Hoover, et al. v. Blue Cross Blue Shield Association, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 2:22-cv-00261-RDP (N.D. Ala.); and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VHS Liquidating Trust v. Blue Cross of California, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Blue Cross of California Taxation Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (&#x201c;BCC&#x201d;) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the &#x201c;Superior Court&#x201d;) captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Michael D. Myers v. State Board of Equalization, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an &#x201c;insurer&#x201d; for purposes of taxation despite acknowledging it is not an &#x201c;insurer&#x201d; under regulatory law. At the time, under California law, &#x201c;insurers&#x201d; were required to pay a gross premiums tax (&#x201c;GPT&#x201d;) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (&#x201c;CFT&#x201d;), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Superior Court denied BCC&#x2019;s motion for judgment on the pleadings and similar motions brought by other entities. In December 2020, the Superior Court granted BCC&#x2019;s motion for summary judgment, dismissing the plaintiff&#x2019;s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. BCC&#x2019;s responding brief was filed in March 2022 and Plaintiff&#x2019;s reply was filed in May 2022. We estimate that the appeal will be heard in March 2023. We intend to vigorously defend the appeal of this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Express Scripts, Inc. Pharmacy Benefit Management Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, we filed a lawsuit against Express Scripts, Inc. (&#x201c;Express Scripts&#x201d;), our vendor at the time for PBM services, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Anthem, Inc. v. Express Scripts, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the U.S. District Court for the Southern District of New York (the &#x201c;District Court&#x201d;). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the &#x201c;ESI PBM Agreement&#x201d;), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts&#x2019; counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts&#x2019; only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts&#x2019; motion for summary &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Annual Report on Form 10-K are (i) our operational breach claim based on Express Scripts&#x2019; prior authorization processes and (ii) Express Scripts&#x2019; counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Risk Adjustment Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. Department of Justice (&#x201c;DOJ&#x201d;) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the &#x201c;New York District Court&#x201d;) in a case captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States v. Anthem, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The DOJ&#x2019;s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in that court. In November 2022, we filed an answer. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investigations of CareMore and HealthSun&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (&#x201c;CareMore&#x201d;), one of our California subsidiaries, and HealthSun Health Plans, Inc. (&#x201c;HealthSun&#x201d;), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore&#x2019;s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Other Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (&#x201c;HMOs&#x201d;) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations and Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at December&#160;31, 2022 is approximately $761. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2019, we began using our pharmacy benefits manager CarelonRx, formerly known as IngenioRx, to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. CarelonRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vulnerability from Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which we conduct business. As of December&#160;31, 2022, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib99d2d66da9844cab49602099b561dda_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzIyNzA_d6fe8956-88b3-40cd-9e34-3873d61b887e"
      unitRef="usd">0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i725fb0d8346e4b058763cea8f52dbda8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzIyOTA_08b2b01e-9718-4fe8-b3d4-106b770725b6"
      unitRef="usd">250000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzU0OTc1NTkyNTEwMA_8f35f27a-8a82-4b7c-ab48-845f75090f4e"
      unitRef="usd">506000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzU0OTc1NTg2MDEzMA_90b7c39b-24bf-4344-9b79-15018cfe6e52"
      unitRef="usd">596000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <elv:GrossPremiumTaxRate
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzc4Mjg_df0aebb8-4b85-4f27-a6dc-8a535e54d7d3"
      unitRef="number">0.0235</elv:GrossPremiumTaxRate>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ide2e9b364d454a189b9c63aaf27ed9ed_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzk2MjA_2575dcfd-bb15-438d-af17-193a5df7434a"
      unitRef="usd">14800000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i530e77d500e24332972b126eb61ad553_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzk3Nzc_ff442d6e-18d0-4cbb-a8f0-1b1b1748f473"
      unitRef="usd">158000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="idbb67e7d15ec40d393dc4ea0b4156be1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzEwODY0_7453ee36-6371-4369-9e2c-3e8975dc441c"
      unitRef="usd">4675000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNDUvZnJhZzpiNTU1NWIyYTZiNmQ0MjYzYWZmZjYyNjIyYmI2YzljZC90ZXh0cmVnaW9uOmI1NTU1YjJhNmI2ZDQyNjNhZmZmNjI2MjJiYjZjOWNkXzE5Mzk4_4eaa4786-55c0-46d0-9053-f74250a7b349"
      unitRef="usd">761000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5NzE_e7f98a45-5595-4da5-9862-77a4a80bfb87">Capital Stock&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors has adopted the 2017 Elevance Health Incentive Compensation Plan, formerly known as the 2017 Anthem Incentive Compensation Plan (&#x201c;2017 Incentive Plan&#x201d;), which has been approved by our shareholders. The term of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The 2017 Incentive Plan limits the number of available shares for issuance to 37.5 shares, subject to adjustment as set forth in the 2017 Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest over three years in equal annual installments and generally have a term of ten years from the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also include one or more performance measures that must be met for the award to vest. For restricted stock or restricted stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;units without performance measures, the restrictions lapse in three equal annual installments. Restricted stock or restricted stock units with performance measures vest in three year installments. Performance units issued in 2022 will vest in 2025, based on certain revenue and earnings targets over the three year period of 2022 to 2024. Performance units issued in 2021 will vest in 2024, based on certain revenue and earnings targets over the three year period of 2021 to 2023. Performance units issued in 2020 will vest in 2023, based on certain revenue and earnings targets over the three year period of 2020 to 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, we recognized share-based compensation expense of $264, $255 and $283, respectively, as well as related tax benefits of $66, $65 and $74, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Option Price &lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 amounted to $120, $121 and $147, respectively. We recognized tax benefits of $31, $32 and $40 during the years ended December&#160;31, 2022, 2021 and 2020, respectively, from option exercises and disqualifying dispositions. During the years ended December&#160;31, 2022, 2021 and 2020, we received cash of $120, $148 and $129, respectively, from exercises of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of restricted stock awards that vested during the years ended December&#160;31, 2022, 2021 and 2020 was $261, $287 and $335, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock&#160;Shares&lt;br/&gt;and Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, we granted approximately 0.2 restricted stock units that are contingent upon us achieving certain revenue and earnings targets over the three year period of 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024, based on results in the three year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of December&#160;31, 2022, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock, including restricted stock units and performance units, amounted to $35 and $176, respectively, which will be amortized over the weighted-average remaining requisite service periods of 9 months and 12 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there were approximately 14.0 shares of common stock available for future grants under the 2017 Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice model are based on an analysis of implied volatility of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the multiple-grant approach for recognizing compensation expense associated with each separately vesting portion of the share-based award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (annual)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average fair values were determined for the years ending December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The binomial lattice option-pricing model requires the input of subjective assumptions including the expected stock price volatility. Because our stock option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan (the &#x201c;Stock Purchase Plan&#x201d;), which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in Elevance Health. Pursuant to the terms of the Stock Purchase Plan, an eligible employee is permitted to purchase no more than $25,000 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter. Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the employee&#x2019;s investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a discounted price per share of 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter purchase period. The Stock Purchase Plan discount was recognized as compensation expense for the year ended December&#160;31, 2022, based on GAAP guidance. During the years ended December&#160;31, 2022, 2021 and 2020, we issued 0.1, 0.1 and 0.2 shares, respectively, under the Stock Purchase Plan, and we received cash of $62, $55 and $47, respectively, for such shares. As of December&#160;31, 2022, 4.3 shares were available for issuance under the Stock Purchase Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Capital and Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the cash dividend activity for the years ended December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Declaration Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Record Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Dividend &lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 25, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 10, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 25, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 19, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 10, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 19, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 23, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 18, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 5, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 21, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 26, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 25, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 25, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 24, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 19, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2023, our Audit Committee declared a quarterly cash dividend to shareholders of $1.48 per share on the outstanding shares of our common stock. This quarterly dividend is payable on March 24, 2023 to the shareholders of record as of March 10, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Board of Directors&#x2019; authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time. We intend to utilize this authorization over a multi-year period, subject to market and industry conditions. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock repurchases for the years ended December&#160;31, 2022 and 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Authorization remaining at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information regarding the use of capital for debt security repurchases, see Note 13, &#x201c;Debt.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9f482fd60e844e1aa802036bfbb28f7d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzcxNw_faadff6c-1a25-44e6-ad7e-2f13b40f3502"
      unitRef="shares">37500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzk1OQ_7596c059-ed6e-4e7c-8517-c4abab14c495">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <elv:StockOptionTerm
      contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzEwMjA_4bdb4ee1-fc70-49b2-808a-e2aed783d7b0">P10Y</elv:StockOptionTerm>
    <us-gaap:ShareBasedCompensation
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzIzNjg_14aed0df-e1a2-4a07-8fed-44fde96d3029"
      unitRef="usd">264000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzIzNzI_e5c1f099-324c-479e-b2cc-0a16c8ca1b8d"
      unitRef="usd">255000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzIzNzk_2120f65c-8023-4dac-9369-bb460ae0ec05"
      unitRef="usd">283000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI0MzI_ee2830be-fbc1-463a-8d4a-3c5937e7c084"
      unitRef="usd">66000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI0MzY_4ead590f-3a37-4a8e-b265-e68a2bf162fe"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI0NDM_310e69a5-7406-46da-8aa3-2cc137479ee2"
      unitRef="usd">74000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzkwMTg_07ae56b7-8da4-457d-908c-15f144000f2c">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Option Price &lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzEtMS0xLTEtNzgwNDk_8f6c8f21-68d8-4985-abc7-9b148742e7d1"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzEtMy0xLTEtNzgwNDk_a93fba8d-343b-4299-8990-eaa240aa29ad"
      unitRef="usdPerShare">255.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzItMS0xLTEtNzgwNDk_a8c7e467-b609-49b3-9a95-44dde847e4e0"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzItMy0xLTEtNzgwNDk_1fec798d-3311-4419-b0ed-d97dbc78a147"
      unitRef="usdPerShare">452.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzMtMS0xLTEtNzgwNDk_43871c0c-6e3e-4db8-8b64-34908ca7adc8"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzMtMy0xLTEtNzgwNDk_0067c27a-ab63-44d1-9ae4-a99bb94709b2"
      unitRef="usdPerShare">242.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzQtMS0xLTEtNzgwNDk_7c90dcb1-8b11-47e1-ae45-aa9e850522f9"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzQtMy0xLTEtNzgwNDk_99189ed9-56f5-45df-b925-f73f1536fd71"
      unitRef="usdPerShare">339.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtMS0xLTEtNzgwNDk_051c6c82-8300-4376-8d46-099700d784cd"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtMy0xLTEtNzgwNDk_07a9f254-d28c-46ac-a155-7d3712a5d554"
      unitRef="usdPerShare">293.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtNS0xLTEtNzgwNDk_93100053-ec8e-4afe-bb0f-c8efdda76ba6">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzUtNy0xLTEtNzgwNDk_ec79ac44-3693-4f6e-990a-42f9118e4c9c"
      unitRef="usd">622000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtMS0xLTEtNzgwNDk_8c6db72b-063e-48dc-b614-36a05dbf2bc9"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtMy0xLTEtNzgwNDk_ee640a2c-0426-4ac0-8dbf-cb9204fda1d3"
      unitRef="usdPerShare">239.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtNS0xLTEtNzgwNDk_1c29ecf6-d43c-4723-9ed9-097bbeb0880f">P5Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTpjMDBjOTIzYjE2OTk0ZGFiOTVjNDJlYTMyY2U3NDc2Yi90YWJsZXJhbmdlOmMwMGM5MjNiMTY5OTRkYWI5NWM0MmVhMzJjZTc0NzZiXzYtNy0xLTEtNzgwNDk_95919305-24a9-4002-a1dc-6350d561e5f1"
      unitRef="usd">448000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2MjY_0a08d881-b449-48be-8c65-d4611edac816"
      unitRef="usd">120000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2MzA_277943a1-6b51-4abe-a637-3012ea255e7e"
      unitRef="usd">121000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2Mzc_25879527-dc8f-4774-8817-4ad7c574a95d"
      unitRef="usd">147000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2ODU_fa37aa07-f10a-444e-9820-2a8a0f6f8e10"
      unitRef="usd">31000000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2ODk_e2e528e4-b8e5-4bf2-9b58-18abd9d70d98"
      unitRef="usd">32000000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI2OTY_8551316e-f933-49e4-b909-35eb74430f6c"
      unitRef="usd">40000000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI4NjM_55d12f2f-1645-437f-87a2-39e6365a2c6b"
      unitRef="usd">120000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3043a56e4f044e9880867fcd09c8c685_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI4Njc_87867e9d-e889-49a3-b3f4-52e411864a08"
      unitRef="usd">148000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if302dcaa62374b57b23069ad02e225dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzI4NzQ_3255d146-804b-430b-9149-e6262e9e10a8"
      unitRef="usd">129000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i94919fea365f4bf3810bbae7fae7bb53_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMwMjY_4a2c7920-7165-41a9-84d4-2ef0a675c394"
      unitRef="usd">261000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i18e9f319025d420eb32e7522fd74ed84_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMwMzA_0da05ba2-00b4-4eef-ab68-aac5cf6ab061"
      unitRef="usd">287000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ie674fb9fe21244e6a1ce2872735af01d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMwMzc_50728d62-4a40-474e-97e7-5be2d358fbd3"
      unitRef="usd">335000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5OTI_75e34457-fd9f-41af-99ec-5812b20609a1">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock&#160;Shares&lt;br/&gt;and Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzEtMS0xLTEtNzgwNDk_a0f52ac1-2383-413a-b9e9-235631c5a4d9"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzEtMy0xLTEtNzgwNDk_5e8d9c5c-5c1c-43a6-852a-f8295c0102f2"
      unitRef="usdPerShare">299.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzItMS0xLTEtNzgwNDk_8c0c10a1-f110-44c5-b5c6-631ca6044dde"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzItMy0xLTEtNzgwNDk_f482be45-c978-42b2-a35a-dad27c02c2f2"
      unitRef="usdPerShare">453.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzMtMS0xLTEtNzgwNDk_f736dd63-4b6d-4509-b088-cdc33bb95d36"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzMtMy0xLTEtNzgwNDk_7bf4a20c-ad36-40a8-a7b7-d5816925cd11"
      unitRef="usdPerShare">301.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzQtMS0xLTEtNzgwNDk_35e5b7a8-90b1-401f-a96a-1b2924c941ca"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzQtMy0xLTEtNzgwNDk_fc380ce9-6d47-44c4-9c31-e0bfa66a65fc"
      unitRef="usdPerShare">347.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzUtMS0xLTEtNzgwNDk_ef4aa22f-67ed-417b-863f-38b48f7e7dc0"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTozNDM5Zjc5MGVkNzY0Y2E0OTYyMjdhZDM2ZTExZDlkNi90YWJsZXJhbmdlOjM0MzlmNzkwZWQ3NjRjYTQ5NjIyN2FkMzZlMTFkOWQ2XzUtMy0xLTEtNzgwNDk_6985b558-676d-42ef-90c2-db03ee013f30"
      unitRef="usdPerShare">357.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i91235d6e1c7c4af2b57d1b5d2854972a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzMyNjU_c5c6844d-36b9-41b5-ac91-33f5a40159fe"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic773a96084d446cc8f83053d1d3e03dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM3NTI_a85877b0-a852-4917-9f12-a42a329cb1f7"
      unitRef="usd">35000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic8aebf8ee5444e509fd8796f5ae27e76_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM3NTk_54747b45-75c6-48ae-b19f-d3e08fea2aef"
      unitRef="usd">176000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i296faf20b4e64788b0b32e47f8e45d43_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM4NjY_99dd3a70-2e6d-462d-aad5-c05a3bc72080">P9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i94919fea365f4bf3810bbae7fae7bb53_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM4NzM_e255e93f-4271-481a-90d2-213dc1e59815">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9f482fd60e844e1aa802036bfbb28f7d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzM5MjY_8cdf552b-5a81-4654-8588-5abf63226cd5"
      unitRef="shares">14000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5NzQ_c8c56876-5841-401c-93d7-91ddbb524e6e">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (annual)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzEtMS0xLTEtNzgwNDk_a9e739d9-be90-458e-8286-61714326322a"
      unitRef="number">0.0197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzEtMy0xLTEtNzgwNDk_0c372978-a8a6-4323-9ea4-265e70456b29"
      unitRef="number">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzEtNS0xLTEtNzgwNDk_b8e80d4f-88e9-446f-aacb-99589ef50e72"
      unitRef="number">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzItMS0xLTEtNzgwNDk_7a004aa0-495b-44eb-b596-3f444986ab33"
      unitRef="number">0.2900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzItMy0xLTEtNzgwNDk_3866aa9e-b19b-4112-a7e2-fb3553ca1470"
      unitRef="number">0.3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzItNS0xLTEtNzgwNDk_17ae7c78-201c-4635-b65a-3c77388e68ee"
      unitRef="number">0.2600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzMtMS0xLTEtNzgwNDk_76d3d9bd-65df-4bae-92c3-c174fce82310"
      unitRef="number">0.0110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzMtMy0xLTEtNzgwNDk_e6f6115f-1762-4f5c-8d33-f2d592fe96f8"
      unitRef="number">0.0150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzMtNS0xLTEtNzgwNDk_201ad80e-c7e1-48d7-b98a-ddb36d94218a"
      unitRef="number">0.0140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzQtMS0xLTEtNzgwNDk_6075b9e4-142c-4a56-ac7b-6904d804fa4d">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzQtMy0xLTEtNzgwNDk_6c2e084d-1a2a-41a2-8e9f-f659dc8d8fae">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTowOTIxZjExZDEwZWY0OWUyYWYyNjc2YmNkYmRmODkwMC90YWJsZXJhbmdlOjA5MjFmMTFkMTBlZjQ5ZTJhZjI2NzZiY2RiZGY4OTAwXzQtNS0xLTEtNzgwNDk_9f9351fa-147a-428f-bd58-6e4571dc02ce">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzkwMTM_6c507a22-b31e-4761-bf07-22b60cdef75f">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average fair values were determined for the years ending December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzEtMS0xLTEtNzgwNDk_48e3dfc9-6d6c-421c-9c6d-3045e44d0fe2"
      unitRef="usdPerShare">116.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzEtMy0xLTEtNzgwNDk_6288cc8f-3c03-4e05-b9c1-657faa012581"
      unitRef="usdPerShare">79.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzEtNS0xLTEtNzgwNDk_71559073-2d45-4d48-a210-2bfc53c54bc1"
      unitRef="usdPerShare">54.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzItMS0xLTEtNzgwNDk_88e68808-b5a9-4b5f-ab71-8810e25b8398"
      unitRef="usdPerShare">453.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzItMy0xLTEtNzgwNDk_0625572d-4837-40d7-b7e2-ffe84d446fcb"
      unitRef="usdPerShare">317.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTo2NGY3NTlmNTU2Y2U0NmI4YjBmMDhlODlmZDQ1MDk2ZC90YWJsZXJhbmdlOjY0Zjc1OWY1NTZjZTQ2YjhiMGYwOGU4OWZkNDUwOTZkXzItNS0xLTEtNzgwNDk_82cb9798-c86b-4164-a8b9-ca3a5d54e0d3"
      unitRef="usdPerShare">272.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i01f291e82852495c91f39ae516cb5961_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU3MTk_bdd8e68d-1360-4598-b8bf-cf73b17312a1"
      unitRef="shares">14000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <elv:SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount
      contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzYwNDI_c316eebd-91ca-49b0-9f14-4276f49c831c"
      unitRef="usd">25000</elv:SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount>
    <elv:SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="i01f291e82852495c91f39ae516cb5961_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzYyMzU_838f0cf6-6566-49b8-9473-e5a917e566bc"
      unitRef="number">0.01</elv:SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i01f291e82852495c91f39ae516cb5961_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzYyNDE_81cbb1c8-a207-4d50-b95d-0de482da4de4"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzY0NjQ_d92b388d-dd92-41f7-b7d3-779158d9ee01"
      unitRef="number">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzY3MjU_25a4a511-66c9-4f52-a141-d34d2e595cdc"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibd001b0d68c34a668c7fde379c754978_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDczOA_d25af217-dd81-43fe-a9af-33c9d1cb2665"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i74f7a4356b364dabba6bc38e7490c8bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDc0Ng_7d7e1d5e-ed1a-46d1-b3e0-c9fd45c63d06"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i39207efb6f5c43c181ca8bd5ff40436d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDcxNA_11554fb8-3eeb-4191-9e65-5dd2df39a255"
      unitRef="usd">62000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibd001b0d68c34a668c7fde379c754978_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDcyMg_e9ef7192-3e98-42f2-ae6c-6673e2bf4a97"
      unitRef="usd">55000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i74f7a4356b364dabba6bc38e7490c8bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzU0OTc1NTgyNDczMA_c0985a2e-59c9-4b58-ad11-0714d1e99aa9"
      unitRef="usd">47000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i01f291e82852495c91f39ae516cb5961_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzY3Nzg_25f9d62e-faa6-42a7-9fc4-de8d29360b38"
      unitRef="shares">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzkwMDg_ebeb5da2-ccaf-4087-9c00-d357fad43316">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the cash dividend activity for the years ended December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Declaration Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Record Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Dividend &lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 25, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 10, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 25, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 19, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 10, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 19, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 23, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 18, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 5, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 21, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 26, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 25, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 25, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 24, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 19, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItMC0xLTEtNzgwNDk_8793af25-9558-44ff-9170-a2927246173c">2022-01-25</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItMi0xLTEtNzgwNDk_0b2b3637-c3e8-422c-a393-3d1b2dc547b4">2022-03-10</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItNC0xLTEtNzgwNDk_ad68dce1-9d4e-451f-afb6-90a694e43de8">2022-03-25</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItNi0xLTEtNzgwNDk_5f068bb1-fb0b-49eb-9c8c-5bf5df85c5a6"
      unitRef="usdPerShare">1.28</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i8782dcc74d2a4c5eaeeb40ab02f13a30_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzItOC0xLTEtNzgwNDk_6d106046-ec64-4143-afdc-abf75f315073"
      unitRef="usd">309000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtMC0xLTEtNzgwNDk_977625c6-a9da-403e-bb5f-be60c98832ec">2022-04-19</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtMi0xLTEtNzgwNDk_211bd8b2-061b-46b3-abf3-61945a29571c">2022-06-10</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtNC0xLTEtNzgwNDk_4e9f7215-793b-4483-952c-cff42f794023">2022-06-24</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtNi0xLTEtNzgwNDk_87dd27a2-e764-4bea-a678-f225df8091c1"
      unitRef="usdPerShare">1.28</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i097b18150f734cccb22442fd46d93fb5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzMtOC0xLTEtNzgwNDk_f1d8ec2d-501d-41f9-867d-a3642bde3b19"
      unitRef="usd">309000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtMC0xLTEtNzgwNDk_abfb45d7-7ef5-4442-a99c-7c4d348539e5">2022-07-19</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtMi0xLTEtNzgwNDk_464ccadf-21d1-4f8f-b03b-31c242cd3648">2022-09-09</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtNC0xLTEtNzgwNDk_2c34b5e7-e0e9-4ddf-beef-8697c499e89a">2022-09-23</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtNi0xLTEtNzgwNDk_59e674cf-1a71-4e6c-8f3d-698633bc8faf"
      unitRef="usdPerShare">1.28</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="id765367318fd412f9615ba9f41b69d33_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzQtOC0xLTEtNzgwNDk_d1fcc67e-41c5-4997-b42a-92b626d885ac"
      unitRef="usd">306000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtMC0xLTEtNzgwNDk_412be21c-174a-482b-bce1-f4edd81f3e0e">2022-10-18</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtMi0xLTEtNzgwNDk_cb2fb45b-029f-44f2-90ba-f541ce31c31b">2022-12-05</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtNC0xLTEtNzgwNDk_0fad179f-dc60-46c4-b60a-3018b2756bcd">2022-12-21</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtNi0xLTEtNzgwNDk_a035b565-b369-4785-b3c3-8e2b9c597ca2"
      unitRef="usdPerShare">1.28</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i9f1d6a035065442988901aa213d9e12b_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzUtOC0xLTEtNzgwNDk_7a42322a-f891-4586-b9ce-ed0d4ee49dba"
      unitRef="usd">305000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtMC0xLTEtNzgwNDk_44a99a79-4da9-4b87-be13-811f06eccf22">2021-01-26</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtMi0xLTEtNzgwNDk_1bf2205e-0051-467a-9c4c-45729e0cda59">2021-03-10</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtNC0xLTEtNzgwNDk_e5db3db3-526b-4d24-981d-97f289451d00">2021-03-25</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtNi0xLTEtNzgwNDk_2620708d-4c75-49e0-9a08-a68e0b283629"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i87ac583d2ea14598ae987b16b473e3b3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzgtOC0xLTEtNzgwNDk_a4c937bb-63de-41a2-902c-dac089fd70d4"
      unitRef="usd">277000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktMC0xLTEtNzgwNDk_f0f15808-c536-4abc-a14a-a6263d507ee4">2021-04-20</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktMi0xLTEtNzgwNDk_bc18b053-29f8-4e7f-a88d-f03c0d220b0e">2021-06-10</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktNC0xLTEtNzgwNDk_7fcc1eac-0283-4481-975d-37c6d021e2b6">2021-06-25</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktNi0xLTEtNzgwNDk_b00fa2ac-06be-4157-9d31-eacd091aa32f"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i0bc637bb050f48de91332547b96c57d2_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzktOC0xLTEtNzgwNDk_bfdcf321-5290-4b62-9a78-21cfba650341"
      unitRef="usd">278000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTAtMS0xLTc4MDQ5_804ebaf1-948a-4e60-8f00-ec001716202f">2021-07-20</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTItMS0xLTc4MDQ5_5dc13d3b-a1ba-444f-a460-ef3a1d2ccc5b">2021-09-10</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTQtMS0xLTc4MDQ5_4ba89e38-fcc8-44d8-a718-2fe3c643291a">2021-09-24</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTYtMS0xLTc4MDQ5_cea1de51-5a81-483c-90b8-3bad5741658a"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i6e60d573c86047969da37e7fdce78f1d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzEwLTgtMS0xLTc4MDQ5_4a6580e1-66ba-4b13-a54f-cd37dbad6a89"
      unitRef="usd">276000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear
      contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTAtMS0xLTc4MDQ5_7493d05e-edb0-48d3-8e4d-6ec31ca13de0">2021-10-19</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTItMS0xLTc4MDQ5_d6f65a47-6ed8-48ee-b101-bc91cd334e62">2021-12-03</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTQtMS0xLTc4MDQ5_d72a2b85-4f16-462e-890e-9ed7dfe00d20">2021-12-21</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTYtMS0xLTc4MDQ5_8cdca687-02ab-4852-8c2f-0fc74e40f68c"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividends
      contextRef="i7cbe97f526914b52a6688b82ded70008_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZToyMDE0Y2NjOWVmM2E0NmNlYmRhMjc1ODIyZjFmMjM1My90YWJsZXJhbmdlOjIwMTRjY2M5ZWYzYTQ2Y2ViZGEyNzU4MjJmMWYyMzUzXzExLTgtMS0xLTc4MDQ5_cff5be75-e984-4f1a-bc6e-ca9380143f8c"
      unitRef="usd">273000000</us-gaap:PaymentsOfDividends>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i2f793b028bf243b29bbcb6a44fa763f0_I20230124"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc1MzM_0a7b4f44-97a3-47cd-b25c-54ae422ed858"
      unitRef="usdPerShare">1.48</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="ia027da647af941768a3f104492aa7231_D20230124-20230124"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc2MzE_39575f67-de1b-41b2-b026-31a45e25282d">2023-03-24</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="ia027da647af941768a3f104492aa7231_D20230124-20230124"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc2NzA_976a5d5a-6223-4a89-8f2b-086723f03cd0">2023-03-10</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <elv:IncreaseInStockRepurchaseProgramAuthorization
      contextRef="ice6527b2d9fe44bd9c916d8863257a5b_I20210126"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzc4ODI_5810cde8-0b8e-421a-abaf-ac9308f56e97"
      unitRef="usd">5000000000</elv:IncreaseInStockRepurchaseProgramAuthorization>
    <elv:IncreaseInStockRepurchaseProgramAuthorization
      contextRef="i2f793b028bf243b29bbcb6a44fa763f0_I20230124"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzExNTQ0ODcyMTA0NDcx_7a42a969-5af4-4c9b-b97c-2510c91e3d70"
      unitRef="usd">5000000</elv:IncreaseInStockRepurchaseProgramAuthorization>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90ZXh0cmVnaW9uOjExNmI4Mjg0NWQxMjRkMWFiOTc4MzdiZTA3YjVjNTdkXzg5OTU_f7232184-b67c-4107-91c8-b6f40c915c4c">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock repurchases for the years ended December&#160;31, 2022 and 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Authorization remaining at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzItMy0xLTEtNzgwNDk_625a48aa-49cf-4419-889f-072707ebf58d"
      unitRef="shares">4800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzItNS0xLTEtNzgwNDk_a7fe4082-2525-4e7e-8f36-196471e47dd6"
      unitRef="shares">5100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzMtMy0xLTEtNzgwNDk_7785058c-cc65-44ff-9c4f-9565f422567e"
      unitRef="usdPerShare">478.99</elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice>
    <elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzMtNS0xLTEtNzgwNDk_7436ada2-0600-47fb-9cc4-55f1fd146b27"
      unitRef="usdPerShare">371.46</elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzQtMy0xLTEtNzgwNDk_efe6ccc4-0be8-4fd6-9ca9-21e95c618885"
      unitRef="usd">2316000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzQtNS0xLTEtNzgwNDk_c993dab1-1ed0-4627-9dc0-eac0cdad5138"
      unitRef="usd">1900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzUtMy0xLTEtNzgwNDk_6d0793dc-5d32-4a1c-a2f4-0876578254b4"
      unitRef="usd">1876000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTEvZnJhZzoxMTZiODI4NDVkMTI0ZDFhYjk3ODM3YmUwN2I1YzU3ZC90YWJsZTplYzlkZTEwNmMzZjU0ZGQ3YmY0ZTAxODBkNjFkMThkNy90YWJsZXJhbmdlOmVjOWRlMTA2YzNmNTRkZDdiZjRlMDE4MGQ2MWQxOGQ3XzUtNS0xLTEtNzgwNDk_5150c376-e00e-42df-b40c-f70eaca0ea16"
      unitRef="usd">4192000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90ZXh0cmVnaW9uOjFmYjgxNmJlYWE1ODQxMjdhMTM1MjNiYTdiZDQxY2JlXzE4NQ_826eaea5-b216-43d8-92a6-0684048e2bf9">Accumulated Other Comprehensive (Loss) Income &lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the components of accumulated other comprehensive (loss) income at December&#160;31, 2022, 2021, and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net unrealized investment gains:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $926, $121, and $(160), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income, net of tax benefit (expense) of $(94), $27, and $(13), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-credit components of impairments on investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax (expense) benefit of $0, $(1),and $0, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax expense of $(6), $(3), and $(3), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension and other postretirement benefits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax expense of $(23), $(36), and $(2), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign currency translation adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax benefit (expense) of $6, $2, and $(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total beginning of year accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive (loss) income, net of tax benefit (expense) of $809, $110, and $(154), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to noncontrolling interests, net of tax (expense) benefit of $(3), $1, and $0, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total end of year accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90ZXh0cmVnaW9uOjFmYjgxNmJlYWE1ODQxMjdhMTM1MjNiYTdiZDQxY2JlXzE3Ng_cb4e7273-a09f-4778-bb7d-c8842fbbe261">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the components of accumulated other comprehensive (loss) income at December&#160;31, 2022, 2021, and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net unrealized investment gains:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $926, $121, and $(160), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income, net of tax benefit (expense) of $(94), $27, and $(13), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-credit components of impairments on investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax (expense) benefit of $0, $(1),and $0, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax expense of $(6), $(3), and $(3), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension and other postretirement benefits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax expense of $(23), $(36), and $(2), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign currency translation adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax benefit (expense) of $6, $2, and $(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total beginning of year accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive (loss) income, net of tax benefit (expense) of $809, $110, and $(154), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to noncontrolling interests, net of tax (expense) benefit of $(3), $1, and $0, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total end of year accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9e95a8c856b14a5a8cf3fd92402ef4e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzItMS0xLTEtNzgwNDk_761a4224-5791-4c0d-8de9-188be60f5de8"
      unitRef="usd">492000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i81e698e227c346ae9586de0d8e1b1dbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzItMy0xLTEtNzgwNDk_70571985-a4de-4091-8fc3-c2daf010704f"
      unitRef="usd">949000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if95514d7548341cba52815d3f07c28d2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzItNS0xLTEtNzgwNDk_15963a0b-d0ee-4f96-8643-1ce3ef1b07cf"
      unitRef="usd">521000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpmYTIwOGE2NzQ1N2Q0OTBmYmMxNDg4NjY3ODQ4NDk1ZF85Ng_434ffab9-200e-44ae-814c-61517a85adc3"
      unitRef="usd">-926000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpmYTIwOGE2NzQ1N2Q0OTBmYmMxNDg4NjY3ODQ4NDk1ZF8xMDA_0c67f93e-28e7-45a7-a4f0-ee0e874eb7dc"
      unitRef="usd">-121000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjpmYTIwOGE2NzQ1N2Q0OTBmYmMxNDg4NjY3ODQ4NDk1ZF8xMDg_5f839d14-b5f6-41e4-9b20-34320699157b"
      unitRef="usd">160000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMS0xLTEtNzgwNDk_d29e805e-2dc2-4549-a4fe-50f4d0ce85f7"
      unitRef="usd">-2614000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtMy0xLTEtNzgwNDk_e32a1760-8220-4ce9-a9a5-a43e0d630036"
      unitRef="usd">-357000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMtNS0xLTEtNzgwNDk_5bf121aa-20ca-43fb-bccf-2d032b1b6add"
      unitRef="usd">478000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0OTY1ZWU2NWRkYzQ0YTYxYTllYTkzMTI3OTgwOTEzOF8xMDI_7bb05935-65c0-4722-ad26-d3cafee2fa00"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0OTY1ZWU2NWRkYzQ0YTYxYTllYTkzMTI3OTgwOTEzOF8xMDY_202252a2-9d9f-4be3-894b-014f2464edac"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjo0OTY1ZWU2NWRkYzQ0YTYxYTllYTkzMTI3OTgwOTEzOF8xMTQ_001e6fd9-34dc-4c3c-81c6-c7a103e87671"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMS0xLTEtNzgwNDk_ff28b9f6-1d3b-4771-9317-4a7258c63043"
      unitRef="usd">354000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtMy0xLTEtNzgwNDk_ee573a3b-95dc-465d-8530-ddf896c3a430"
      unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzQtNS0xLTEtNzgwNDk_af12915b-2a54-43df-aa0b-54aff31bb57d"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i08958ab7b46246489adf526e350f151f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzUtMS0xLTEtNzgwNDk_ea63bc9f-c902-43d8-bbe8-503c3d7a20d4"
      unitRef="usd">-2260000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icdc06973c7064f6099c73d75a1caca78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzUtMy0xLTEtNzgwNDk_fcfc2df3-6265-4da7-b521-e3cf5dd4e8e4"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i49f27ae4124743f8a2f202be3a842ab1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzUtNS0xLTEtNzgwNDk_3f02a50f-e2ef-4a8f-a447-3a533fc8111e"
      unitRef="usd">428000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibcebd1544ec64ec6974e038a69b087db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzYtMS0xLTEtNzgwNDk_94a6fdba-388e-4d1e-804b-d51f3fbdae97"
      unitRef="usd">-1768000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9e95a8c856b14a5a8cf3fd92402ef4e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzYtMy0xLTEtNzgwNDk_f699ef5f-4491-4361-a5f2-9de0724eea66"
      unitRef="usd">492000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i81e698e227c346ae9586de0d8e1b1dbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzYtNS0xLTEtNzgwNDk_0a484203-85a4-43c9-b8a5-92ec684245e1"
      unitRef="usd">949000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities
      contextRef="i58a792ee17bd44f596cabc8ef3e8b4b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzktMS0xLTEtNzgwNDk_a92f3da4-1be7-461c-b24b-00cf2dd76ecb"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities
      contextRef="i1482b2c7c0ff472fb0c9110009b806b5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzktMy0xLTEtNzgwNDk_60f09912-d6f4-496c-9155-598b1666c001"
      unitRef="usd">2000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities
      contextRef="i47960b8964ab402a942e197e579d8542_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzktNS0xLTEtNzgwNDk_b5055f8b-9a19-4d81-abf3-d1ec9a80238b"
      unitRef="usd">2000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities
      contextRef="icc4bd3fce911457baee6a8c050e6b70e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjBkNWNjNjE1Mzc5NDU5NDg4OGNlOWQxYjRjZGViZDNfNjQ_f5699093-a4ca-4406-8eae-db4c39bae1e6"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities
      contextRef="i2e36ba6bb351437bb13a37f1503ac813_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjBkNWNjNjE1Mzc5NDU5NDg4OGNlOWQxYjRjZGViZDNfNjg_1f678250-c61b-42c4-b992-35447cd8f131"
      unitRef="usd">1000000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities
      contextRef="i653b1eb3d81f4ca192dd6d3ffca11785_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZjBkNWNjNjE1Mzc5NDU5NDg4OGNlOWQxYjRjZGViZDNfNzU_11f11abf-4492-4014-9377-3de1672e6d9e"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities
      contextRef="icc4bd3fce911457baee6a8c050e6b70e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTEtMS0xLTc4MDQ5_7b81ccf8-66bc-43bb-909a-856306171ef8"
      unitRef="usd">-3000000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities
      contextRef="i2e36ba6bb351437bb13a37f1503ac813_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTMtMS0xLTc4MDQ5_ac10c5cc-66a9-4c01-8b40-3f9952f66677"
      unitRef="usd">2000000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities
      contextRef="i653b1eb3d81f4ca192dd6d3ffca11785_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzEwLTUtMS0xLTc4MDQ5_53d4399e-2981-42f2-a6f8-98df68c7c77e"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities
      contextRef="i246d9c069b344181a326be72f32bf256_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzExLTEtMS0xLTc4MDQ5_a8bab7e5-9699-47e9-b0d6-cac6dd218d9d"
      unitRef="usd">3000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities
      contextRef="i58a792ee17bd44f596cabc8ef3e8b4b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzExLTMtMS0xLTc4MDQ5_7b8c60ba-a699-46f6-923e-9aa79091ca7a"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities
      contextRef="i1482b2c7c0ff472fb0c9110009b806b5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzExLTUtMS0xLTc4MDQ5_8c4e63c9-78c6-4409-9247-597d797ab361"
      unitRef="usd">2000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i5723b60554294bebac94c904566db3f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE0LTEtMS0xLTc4MDQ5_1878f038-e8ec-4e8f-85f3-7400b15a8c98"
      unitRef="usd">-239000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i98cc61d631e54bd68ab0e26a98a4905b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE0LTMtMS0xLTc4MDQ5_14daaedc-5617-45c5-a5bf-cf97c37d8521"
      unitRef="usd">-250000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i24c01f7b130a4ac4a08d21b45fed6866_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE0LTUtMS0xLTc4MDQ5_2a213412-6766-4a53-bb59-01fa7e0224e1"
      unitRef="usd">-262000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i7b85f7bcceb24f4585583cc791c6fd0e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTUzMDE1YTBkOTg1NGI0ZDlkODNiYWQxM2MxZTIyZWJfNzE_0161f18d-4788-4d64-b29b-35fe123eb1f5"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="id351a075bd634b1598a879fd2e805740_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTUzMDE1YTBkOTg1NGI0ZDlkODNiYWQxM2MxZTIyZWJfNzU_4ea2103e-945c-47f4-af8a-7eff5f8b5018"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ib4c5ae1b587c4de3a0abc993e1f65329_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YTUzMDE1YTBkOTg1NGI0ZDlkODNiYWQxM2MxZTIyZWJfODM_67e27862-eff6-4324-ab93-a37b638403bf"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7b85f7bcceb24f4585583cc791c6fd0e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTEtMS0xLTc4MDQ5_1216ab0b-d94e-4956-a30c-890ea7c0dbf2"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id351a075bd634b1598a879fd2e805740_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTMtMS0xLTc4MDQ5_8c060ac5-19e4-473e-a0ea-449ebf448d98"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib4c5ae1b587c4de3a0abc993e1f65329_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE1LTUtMS0xLTc4MDQ5_aaf76506-a720-4815-a4d3-79e495484cc9"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="if9aefa095e5f4dd99aff2909fbcde15c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE2LTEtMS0xLTc4MDQ5_df44e749-0623-41c2-9129-520beca3af2f"
      unitRef="usd">-229000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i5723b60554294bebac94c904566db3f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE2LTMtMS0xLTc4MDQ5_2463371e-3149-457e-b589-7005d2c044e8"
      unitRef="usd">-239000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i98cc61d631e54bd68ab0e26a98a4905b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE2LTUtMS0xLTc4MDQ5_481679c7-3fdf-4fe0-93e2-8a808eb295d5"
      unitRef="usd">-250000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i54dc7a29f571431296c8be227f11aabb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE5LTEtMS0xLTc4MDQ5_372fb501-132c-4b53-a47d-346c7d9ff3fb"
      unitRef="usd">429000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ie94ead6cf6db4e7fae98eafe846f769d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE5LTMtMS0xLTc4MDQ5_5b01bff9-3452-4d43-8140-deb7615ed5ad"
      unitRef="usd">552000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ia9323e18f92640a2a7c38e4273db90ea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzE5LTUtMS0xLTc4MDQ5_b087f1b5-26ae-4341-bf47-09103a006484"
      unitRef="usd">551000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense
      contextRef="ic3d3abd401b24655a17b8c74f5dd40a1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MDQ0ZTRmMzUwYzIxNDJlYmFmN2VhMmUyYjA4NzQxYTVfNjE_a3cbb000-743a-4514-8c1f-cbbef08761ce"
      unitRef="usd">-23000000</elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense>
    <elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense
      contextRef="ibfbd0421f60f4e64bc47776a3602ab89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MDQ0ZTRmMzUwYzIxNDJlYmFmN2VhMmUyYjA4NzQxYTVfNjU_3b4a206c-80d4-47b6-a5b5-c287f2c3eeb5"
      unitRef="usd">-36000000</elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense>
    <elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense
      contextRef="i2395d6d373c34b2ebab39d8aba7606e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246MDQ0ZTRmMzUwYzIxNDJlYmFmN2VhMmUyYjA4NzQxYTVfNzM_7226c077-1978-489d-b545-6f80b69def9e"
      unitRef="usd">-2000000</elv:OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic3d3abd401b24655a17b8c74f5dd40a1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTEtMS0xLTc4MDQ5_98b15eff-9fba-46a8-856e-c043bead7a8f"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ibfbd0421f60f4e64bc47776a3602ab89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTMtMS0xLTc4MDQ5_f21cfc0b-b6a2-444d-bf6c-9b08e2a54e18"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i2395d6d373c34b2ebab39d8aba7606e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIwLTUtMS0xLTc4MDQ5_dca872b8-515b-48a0-af8e-5ee7d99e3d3a"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i7fa38daf500d4a73ac08682fa99f7730_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIxLTEtMS0xLTc4MDQ5_8f914a07-0b50-422d-9797-cfdc3a35986e"
      unitRef="usd">499000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i54dc7a29f571431296c8be227f11aabb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIxLTMtMS0xLTc4MDQ5_4a597979-1f7b-43ea-9bd5-e77079971fe9"
      unitRef="usd">429000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ie94ead6cf6db4e7fae98eafe846f769d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzIxLTUtMS0xLTc4MDQ5_bb25a543-0195-4245-903a-17f7a937f1bf"
      unitRef="usd">552000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i8a127625ab7b4d44a9d9ad36c6e50197_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI0LTEtMS0xLTc4MDQ5_8da9a375-81fe-486d-8725-1a367fc48969"
      unitRef="usd">-4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ib4a1b61e2bc84caba4a714fd57739c74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI0LTMtMS0xLTc4MDQ5_d8338b22-fbff-4e98-9141-6afdfa6c476f"
      unitRef="usd">5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ibd38742893d7416999e954ec984556f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI0LTUtMS0xLTc4MDQ5_96b9d8a5-adbe-4d6a-981f-867be281bd67"
      unitRef="usd">-2000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i798cec4e64e04bffbeed267a216429e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk5Y2JjOTBmMjMyNDRmZWIwNGY1NTdhOTFhMjMyYjVfNzE_43c9d9c1-9257-4bc3-af5a-f6e103b4d914"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i7b77786d1b5c4248b0483a8990b79b0d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk5Y2JjOTBmMjMyNDRmZWIwNGY1NTdhOTFhMjMyYjVfNzU_2277b71b-3c19-4fd5-9732-825c6beb4a0b"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ie59f5a3300a74c28a300c63349dea8cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246Zjk5Y2JjOTBmMjMyNDRmZWIwNGY1NTdhOTFhMjMyYjVfODM_c4390ee7-8873-49af-82de-54e1b2e08a7e"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i798cec4e64e04bffbeed267a216429e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTEtMS0xLTc4MDQ5_0568d349-9f14-4651-b775-224f4a09f5c4"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7b77786d1b5c4248b0483a8990b79b0d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTMtMS0xLTc4MDQ5_90e248bf-65ec-4de7-9ee6-213628c7fcb9"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie59f5a3300a74c28a300c63349dea8cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI1LTUtMS0xLTc4MDQ5_0a3e8ada-9119-4e05-8be0-9232f93db5eb"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="icae88b41165f46938384528eba3e864a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI2LTEtMS0xLTc4MDQ5_bbe86c35-9283-450c-abfa-abccdf6334ac"
      unitRef="usd">-17000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i8a127625ab7b4d44a9d9ad36c6e50197_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI2LTMtMS0xLTc4MDQ5_0df4b56c-2836-49cd-a93f-308d4e3ac6e0"
      unitRef="usd">-4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ib4a1b61e2bc84caba4a714fd57739c74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI2LTUtMS0xLTc4MDQ5_ba2b589f-01a4-48bb-9887-f95ae510beda"
      unitRef="usd">5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI5LTEtMS0xLTc4MDQ5_34b9468a-e7a4-48dd-8585-5f414c31d72a"
      unitRef="usd">-178000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI5LTMtMS0xLTc4MDQ5_8573615a-23b3-41fe-8fca-05d680d2a6f1"
      unitRef="usd">150000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6715d3ccc7ea4563a72cd62894c7df53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzI5LTUtMS0xLTc4MDQ5_a08702d6-2914-4d7a-a485-59a456d4841c"
      unitRef="usd">-296000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246OGIwNjJkYTllYzI3NDAxMjlkMTZlMGNjMmI2MTUzZTZfNzc_654e9691-563f-44b4-8789-68f2ad32dd2c"
      unitRef="usd">-809000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246OGIwNjJkYTllYzI3NDAxMjlkMTZlMGNjMmI2MTUzZTZfODE_28a715d9-d02f-4609-a03a-3d9622fdc550"
      unitRef="usd">-110000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246OGIwNjJkYTllYzI3NDAxMjlkMTZlMGNjMmI2MTUzZTZfODk_34844967-85c2-4835-a3ce-7b718ff3877b"
      unitRef="usd">154000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTEtMS0xLTc4MDQ5_0186b639-cdf7-4011-ad43-3499d84e1146"
      unitRef="usd">-2336000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTMtMS0xLTc4MDQ5_1805500b-c3e8-469b-bd7f-798297b15062"
      unitRef="usd">-330000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMwLTUtMS0xLTc4MDQ5_676f239f-a8a9-40e8-b518-f66e0b93b6a1"
      unitRef="usd">446000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZDg3MDE2NTVhNGJmNDRjMzk3NDNjMzMzN2E5ODlkMjZfOTk_4e71415f-436c-4cb0-86be-07ad56643203"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZDg3MDE2NTVhNGJmNDRjMzk3NDNjMzMzN2E5ODlkMjZfMTAz_330c6525-29fc-4a1f-9258-1cf8b3cc13a1"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZDg3MDE2NTVhNGJmNDRjMzk3NDNjMzMzN2E5ODlkMjZfMTEx_8be13dcf-6bc7-482b-ac11-1e9a7370677d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTEtMS0xLTc4MDQ5_0a03c7c5-f538-41bd-a9b1-aa37d9535dd6"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTMtMS0xLTc4MDQ5_6cbbda5a-38cc-4a31-baf1-ca94124fd160"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMxLTUtMS0xLTc4MDQ5_1361c9a0-9a21-494a-a6df-b18dad2b1fa8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMyLTEtMS0xLTc4MDQ5_94b2a6ad-2cf8-4364-a89f-47edfe0eebb1"
      unitRef="usd">-2503000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMyLTMtMS0xLTc4MDQ5_9e76fcc1-8c36-4087-a101-074da5e07474"
      unitRef="usd">-178000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNTQvZnJhZzoxZmI4MTZiZWFhNTg0MTI3YTEzNTIzYmE3YmQ0MWNiZS90YWJsZTo4ZjljY2NlZTYwMDM0MDM3ODZiODk4NzIyZTNlMjQyNC90YWJsZXJhbmdlOjhmOWNjY2VlNjAwMzQwMzc4NmI4OTg3MjJlM2UyNDI0XzMyLTUtMS0xLTc4MDQ5_17c40838-6d57-4298-a730-5ed8ac9344ca"
      unitRef="usd">150000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReinsuranceTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg5MA_4221a972-8116-45a2-932b-d8e6de9cc3a0">Reinsurance&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,867&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,832&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,109&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Percentage&#x2014;assumed to net premiums&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between written premiums and earned premiums is immaterial in each of the years presented above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of net premiums earned by segment (see Note 20, &#x201c;Segment Information&#x201d;) for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect of reinsurance on benefit expense for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReinsuranceTextBlock>
    <srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg3OQ_10fc3d4d-9fc2-4af8-83b4-05a8d0c14f8f">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,867&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,832&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,109&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Percentage&#x2014;assumed to net premiums&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock>
    <us-gaap:DirectPremiumsEarned
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzItMy0xLTEtNzgwNDk_7c94c14b-75ae-49c1-b865-3061fa00c347"
      unitRef="usd">128867000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzItNy0xLTEtNzgwNDk_101d9c71-762b-42f4-b786-622e5fad440f"
      unitRef="usd">113149000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzItMTEtMS0xLTc4MDQ5_84c642ea-b4cb-4e22-9df1-bfefd0a4ce17"
      unitRef="usd">100832000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzMtMy0xLTEtNzgwNDk_7b9ea8b8-1309-42d4-a89f-5a0225db3b09"
      unitRef="usd">4426000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzMtNy0xLTEtNzgwNDk_a85c368d-1138-4b36-85ca-8c9d55dccc08"
      unitRef="usd">4298000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzMtMTEtMS0xLTc4MDQ5_75de7dfa-17b2-4516-8b67-fc0e30928ebd"
      unitRef="usd">3356000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:CededPremiumsEarned
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzQtMy0xLTEtNzgwNDk_fbe70ee7-b50c-49c7-80c7-8c8b901bde2f"
      unitRef="usd">64000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzQtNy0xLTEtNzgwNDk_ef487987-f772-420f-b7e5-7247cc558f35"
      unitRef="usd">74000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzQtMTEtMS0xLTc4MDQ5_af665472-9214-4fb7-bd2f-d7e13ca3ec7d"
      unitRef="usd">79000000</us-gaap:CededPremiumsEarned>
    <us-gaap:PremiumsEarnedNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzUtMy0xLTEtNzgwNDk_09379301-2ebc-4b9b-8f1f-bddfa49c0382"
      unitRef="usd">133229000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzUtNy0xLTEtNzgwNDk_28dc3dbf-a378-4859-900c-3237c6fa3813"
      unitRef="usd">117373000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzUtMTEtMS0xLTc4MDQ5_6fd1cf53-eb39-4b6b-a13a-6d0f5753d650"
      unitRef="usd">104109000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsPercentageAssumedToNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzYtMy0xLTEtNzgwNDk_dd6f33ef-358c-483d-b6b4-dea3d37d9caf"
      unitRef="number">0.033</us-gaap:PremiumsPercentageAssumedToNet>
    <us-gaap:PremiumsPercentageAssumedToNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzYtNy0xLTEtNzgwNDk_5126799e-db55-4d9b-8526-1fbec99e54f6"
      unitRef="number">0.037</us-gaap:PremiumsPercentageAssumedToNet>
    <us-gaap:PremiumsPercentageAssumedToNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTo2NDUyOTk4YmY2NzE0ZmE3OGZhZWFkM2QwYmQ3MDMwZS90YWJsZXJhbmdlOjY0NTI5OThiZjY3MTRmYTc4ZmFlYWQzZDBiZDcwMzBlXzYtMTEtMS0xLTc4MDQ5_c8d9b028-83d3-4f14-9a07-6879991b32c7"
      unitRef="number">0.032</us-gaap:PremiumsPercentageAssumedToNet>
    <elv:ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg2OQ_2cb0f629-2c42-4f7a-a1c7-bbc89f84e63f">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of net premiums earned by segment (see Note 20, &#x201c;Segment Information&#x201d;) for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock>
    <us-gaap:PremiumsEarnedNet
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzMtMy0xLTEtNzgwNDk_863df310-e348-4090-987f-acda10ebbd77"
      unitRef="usd">35633000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzMtNy0xLTEtNzgwNDk_d68b9cdc-e0ab-4a83-8794-0b83487fa27f"
      unitRef="usd">33209000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzMtMTEtMS0xLTc4MDQ5_721c956b-1fd1-4ef1-9537-2fa9adca090a"
      unitRef="usd">31471000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzQtMy0xLTEtNzgwNDk_4139e70f-7ae3-443b-91fc-de5fc5ab8c69"
      unitRef="usd">96323000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzQtNy0xLTEtNzgwNDk_1368e690-9a74-42ae-a53a-5eb0ab271721"
      unitRef="usd">82520000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzQtMTEtMS0xLTc4MDQ5_c099c019-b249-4a5a-bd61-c51cf927dfe0"
      unitRef="usd">71188000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzUtMy0xLTEtNzgwNDk_0a446c04-866e-4a06-bde1-a8663f1884ea"
      unitRef="usd">1273000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzUtNy0xLTEtNzgwNDk_fd476412-b9d8-4031-ab60-47764a3d6122"
      unitRef="usd">1644000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzUtMTEtMS0xLTk5NDI1_027bbd2a-e685-4c5e-b77b-a412ef847074"
      unitRef="usd">1450000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzYtMy0xLTEtNzgwNDk_c6f06ebb-d6e8-4a2f-9a46-132677a83b34"
      unitRef="usd">133229000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzYtNy0xLTEtNzgwNDk_530c91f4-84f1-4271-a151-4979e4f50abc"
      unitRef="usd">117373000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZToxMGI3MzM5ZmQyYzg0NjE3YTEzMjNhOTNlNDdlOTBjOS90YWJsZXJhbmdlOjEwYjczMzlmZDJjODQ2MTdhMTMyM2E5M2U0N2U5MGM5XzYtMTEtMS0xLTc4MDQ5_dff39eab-9b35-42e3-a0f9-05e6d0873b74"
      unitRef="usd">104109000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:EffectsOfReinsuranceTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90ZXh0cmVnaW9uOjBjNGZlNjRhMTU3YjQ3YTQ5ZjlhNGMzNDNhNTBjZDA2Xzg3NA_89c4d7b2-7924-4604-8c24-7ad45a6e00ae">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect of reinsurance on benefit expense for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredGross
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzEtMS0xLTEtNzgwNDk_b5a2b717-a58b-49b5-9bf5-8e12007978c6"
      unitRef="usd">112809000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredGross>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredGross
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzEtMy0xLTEtNzgwNDk_68606945-8db3-42f0-90df-0d4f30d71a9e"
      unitRef="usd">99007000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredGross>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredGross
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzEtNS0xLTEtNzgwNDk_3ff837d0-2c5c-4b99-839e-5bbe1a0662fd"
      unitRef="usd">85168000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredGross>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzItMS0xLTEtNzgwNDk_a402a3e6-5644-405f-9da0-30b8c6b6b4e8"
      unitRef="usd">3730000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzItMy0xLTEtNzgwNDk_43e6522d-cadb-4989-90c9-577726f22e50"
      unitRef="usd">3719000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzItNS0xLTEtNzgwNDk_98ad4ba1-a4ce-40f1-93be-16994c0c127d"
      unitRef="usd">2967000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzMtMS0xLTEtNzgwNDk_cb755582-5650-4e13-be68-69dc38f6fff0"
      unitRef="usd">52000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzMtMy0xLTEtNzgwNDk_24ed302a-6275-4816-a087-d28a0536085d"
      unitRef="usd">81000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzMtNS0xLTEtNzgwNDk_03b5a9ee-bdab-463d-99e5-ce5f9519b6bf"
      unitRef="usd">90000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzQtMS0xLTEtNzgwNDk_27abe6b7-bd32-40c3-9474-57a83fbda1b9"
      unitRef="usd">116487000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzQtMy0xLTEtNzgwNDk_90fdf3a1-63a2-4adb-8a8f-1b12ab31b175"
      unitRef="usd">102645000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjAvZnJhZzowYzRmZTY0YTE1N2I0N2E0OWY5YTRjMzQzYTUwY2QwNi90YWJsZTpjNjc1NjAxMGNlYTA0MGU2OWRlMDUzYWNmYWE4ZWQ1Ny90YWJsZXJhbmdlOmM2NzU2MDEwY2VhMDQwZTY5ZGUwNTNhY2ZhYThlZDU3XzQtNS0xLTEtNzgwNDk_2ef4ad69-ae9e-4983-9feb-5a88550f8824"
      unitRef="usd">88045000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0Xzc1Ng_6b2ce160-9cc5-4064-8351-66dfe360cf7f">Leases&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 1 year to 12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information related to our leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our activities as disclosed in Note 4, &#x201c;Business Optimization Initiatives,&#x201d; include reducing our office space footprint. As a result, we performed an interim impairment test during the years ended December 31, 2022, 2021 and 2020, and recorded impairment charges of $34, $136 and $258, respectively, for impairment and abandonment of ROU assets which are included in the operating lease expense shown above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash paid for amounts included in the measurement of lease liabilities, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for new lease liabilities, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term in years, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib99d2d66da9844cab49602099b561dda_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzE2MQ_c65e011a-8598-4e37-bfd1-5bcad72e8216">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i725fb0d8346e4b058763cea8f52dbda8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzE3Mg_ca14260d-676b-4b30-9207-b244615b0cb0">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <elv:LesseeOperatingLeasesTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0Xzc1NA_a8b0cc16-4369-422d-8b67-87ae4fab2f6a">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information related to our leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_1f6c7192-af22-4750-8d4c-430f5920bc66"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMS0xLTEtNzgwNDk_c58fac8e-c2e6-4a53-929d-8cccfb87cbd1"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_964b4c5a-866c-4561-b525-ab1ad01fdce2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMS0xLTEtNzgwNDk_e293b572-51b8-48dc-bbfb-97d0e18ce16c"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_2f28e6ae-bb85-4e62-bf98-e856531b2483"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMS0xLTEtNzgwNDk_dcdafd1c-3bcf-4c16-b744-306639d37f8c"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our activities as disclosed in Note 4, &#x201c;Business Optimization Initiatives,&#x201d; include reducing our office space footprint. As a result, we performed an interim impairment test during the years ended December 31, 2022, 2021 and 2020, and recorded impairment charges of $34, $136 and $258, respectively, for impairment and abandonment of ROU assets which are included in the operating lease expense shown above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash paid for amounts included in the measurement of lease liabilities, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for new lease liabilities, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term in years, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate, operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</elv:LesseeOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItMy0xLTEtNzgwNDk_ebae1bba-829c-4ba1-a7d4-e416770899bd"
      unitRef="usd">604000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzItNS0xLTEtNzgwNDk_eb4d6238-0671-42f7-bb4d-dbd43dc6f188"
      unitRef="usd">628000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtMy0xLTEtNzgwNDk_d27df54f-36be-4a38-a0f1-7c126f4c240e"
      unitRef="usd">181000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzMtNS0xLTEtNzgwNDk_ecc5c66b-7cbd-4cc6-9d76-34687bfad76f"
      unitRef="usd">133000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtMy0xLTEtNzgwNDk_b645d2dc-99d8-4e3e-8746-b60dc26a9306"
      unitRef="usd">751000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTo2NGI5NmM2MmYyMDI0ZjY5YjE3NDI4NWI2NDhkNTdkOC90YWJsZXJhbmdlOjY0Yjk2YzYyZjIwMjRmNjliMTc0Mjg1YjY0OGQ1N2Q4XzQtNS0xLTEtNzgwNDk_5d00ea20-642f-4173-9574-42608de1fcbc"
      unitRef="usd">864000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzMtMS0xLTEtNzgwNDk_120d11b9-382d-4bf6-ae3e-d4d87805a8df"
      unitRef="usd">143000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzMtMy0xLTEtNzgwNDk_6d24b40c-6d05-404e-810e-0d321c20ea07"
      unitRef="usd">261000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzMtNS0xLTEtNzgwNDk_ab4f4375-fe2b-4507-86b2-f536c690baab"
      unitRef="usd">438000000</us-gaap:OperatingLeaseCost>
    <elv:ShortTermAndVariableLeaseCost
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzQtMS0xLTEtNzgwNDk_664de9c8-63dc-40a2-9b09-d3f2845c35ba"
      unitRef="usd">35000000</elv:ShortTermAndVariableLeaseCost>
    <elv:ShortTermAndVariableLeaseCost
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzQtMy0xLTEtNzgwNDk_d63718aa-0245-4a25-b2c5-40c4bbf5bd91"
      unitRef="usd">45000000</elv:ShortTermAndVariableLeaseCost>
    <elv:ShortTermAndVariableLeaseCost
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzQtNS0xLTEtNzgwNDk_77cb5ebb-4a16-4ce4-8d7e-418e1472a015"
      unitRef="usd">50000000</elv:ShortTermAndVariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzUtMS0xLTEtNzgwNDk_5b875840-7c5f-4fd0-9406-097952b68b71"
      unitRef="usd">3000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzUtMy0xLTEtNzgwNDk_ac7e4b08-fb1b-4aa3-be09-06d688e26592"
      unitRef="usd">4000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzUtNS0xLTEtNzgwNDk_eea93d07-c769-4d2f-b10b-e9d32de14558"
      unitRef="usd">9000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzYtMS0xLTEtNzgwNDk_c6fd65bd-5f98-480d-8f26-1ef8231353f0"
      unitRef="usd">175000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzYtMy0xLTEtNzgwNDk_e6a79080-b99b-4935-9b30-2ec9c6efe254"
      unitRef="usd">302000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToxZWNhZWJhZDE4ZTQ0ZTA0YWYzZDY0OWJiMTg5ZDdmYy90YWJsZXJhbmdlOjFlY2FlYmFkMThlNDRlMDRhZjNkNjQ5YmIxODlkN2ZjXzYtNS0xLTEtNzgwNDk_6631da6d-de9c-4ace-8d9c-35ed55f6d3a0"
      unitRef="usd">479000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzQ4MQ_29a449ae-38ec-433c-98ec-36598d8b59bd"
      unitRef="usd">34000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzQ4OA_426b584b-d329-4415-b3c0-c88121d8ad5c"
      unitRef="usd">136000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0XzU0OTc1NTgxNTE2Mw_165c0521-e727-4395-928d-4feddd67d809"
      unitRef="usd">258000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeasePayments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzktNC0xLTEtNzgwNDk_895b5412-987e-43f7-8c6d-68712ba12d1c"
      unitRef="usd">204000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzktNi0xLTEtNzgwNDk_ee38f6b3-585f-49f1-b344-1ae72ecea485"
      unitRef="usd">198000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEwLTQtMS0xLTc4MDQ5_6847508a-4ee9-4126-b82a-781a74a35057"
      unitRef="usd">113000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEwLTYtMS0xLTc4MDQ5_97b1e3a6-729c-4f12-99bd-b367027dacfe"
      unitRef="usd">334000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzExLTQtMS0xLTc4MDQ5_0b262f5a-4a7c-4e04-bc37-864372078666">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzExLTYtMS0xLTc4MDQ5_1d0399c9-fe0b-4317-beb0-368b05abf512">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEyLTQtMS0xLTc4MDQ5_837b0e3c-db8a-43bd-bd0b-b2233b10843c"
      unitRef="number">0.0298</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZTpkMjQ5ZmNkNDJlNTk0NTQ3YWM0OWIyMDAwMzZjNmNiMy90YWJsZXJhbmdlOmQyNDlmY2Q0MmU1OTQ1NDdhYzQ5YjIwMDAzNmM2Y2IzXzEyLTYtMS0xLTc4MDQ5_170b36d7-0ea2-4f81-94d6-45f183420498"
      unitRef="number">0.0269</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90ZXh0cmVnaW9uOjVmZGE3MzlkMzc5ZTRmOTE4OWQ4MTY2NTc0MmE4YjQ0Xzc2MQ_ec2f0667-271d-47ee-8205-5f703c1d8614">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzAtMS0xLTEtNzgwNDk_9c9d76f1-e079-4acd-8de7-594a60ce7e2e"
      unitRef="usd">206000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzEtMS0xLTEtNzgwNDk_5f6155ba-81f2-4397-924b-f1248ba66b34"
      unitRef="usd">179000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzItMS0xLTEtNzgwNDk_b872d705-cc0a-4ad4-9781-944deb5e850c"
      unitRef="usd">145000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzMtMS0xLTEtNzgwNDk_9807ec2e-abd3-4407-a66b-022ee1492aa3"
      unitRef="usd">111000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzQtMS0xLTEtNzgwNDk_41025ef3-f6d3-40bd-b68b-f0360bfcc190"
      unitRef="usd">77000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzUtMS0xLTEtNzgwNDk_d4660815-8ad8-41eb-a618-f447eb74ec65"
      unitRef="usd">310000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzYtMS0xLTEtNzgwNDk_d6f766f1-1737-4f50-adbf-971da10a65c3"
      unitRef="usd">1028000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzctMS0xLTEtNzgwNDk_20f3b50b-5a3e-4568-aec6-c6cfe3cfd1c1"
      unitRef="usd">96000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjMvZnJhZzo1ZmRhNzM5ZDM3OWU0ZjkxODlkODE2NjU3NDJhOGI0NC90YWJsZToyOWVkY2QyNWU5ODg0MWViOGUzYTc5M2IzYWM1M2VhMi90YWJsZXJhbmdlOjI5ZWRjZDI1ZTk4ODQxZWI4ZTNhNzkzYjNhYzUzZWEyXzgtMS0xLTEtNzgwNDk_fdaa713e-2de7-408f-bcd6-dfe946ff090d"
      unitRef="usd">932000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzExNTU_539047eb-6927-4b7b-8ff7-e2c84e06f983">Earnings per Share&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The denominator for basic and diluted earnings per share at December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for basic earnings per share&#x2014;weighted-average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&#x2014;employee stock options, non-vested restricted stock awards, convertible debentures and equity units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, weighted-average shares related to certain stock options of 0.4, 0.2 and 1.2, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. &lt;/span&gt;&lt;/div&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we issued approximately 0.2, 0.3 and 0.3 restricted stock units, respectively, of which vesting was contingent upon us meeting certain earnings targets. Contingent restricted stock units are excluded from the denominator for diluted earnings per share and are included only if and when the contingency is met. The 2022 contingent restricted stock units are being measured over the three year period of 2022 through 2024, the 2021 contingent restricted stock units are being measured over the three year period of 2021 through 2023 and the 2020 contingent restricted stock units are being measured over the three year period of 2020 through 2022. Contingent restricted stock units generally vest in March of the year following each measurement period.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzExNTM_e5009956-e3a9-42c7-ae8c-9fd80e40c954">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The denominator for basic and diluted earnings per share at December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for basic earnings per share&#x2014;weighted-average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&#x2014;employee stock options, non-vested restricted stock awards, convertible debentures and equity units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzEtMS0xLTEtNzgwNDk_6963b292-54b1-436c-9189-e49e636118c7"
      unitRef="shares">240000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzEtMy0xLTEtNzgwNDk_a2fe7380-31d0-41fb-870a-d803101a78a9"
      unitRef="shares">243800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzEtNS0xLTEtNzgwNDk_45badf0c-871c-4b76-922a-4faeb6afdc1a"
      unitRef="shares">250800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzItMS0xLTEtNzgwNDk_83945b49-f863-4d0a-83b3-caef8ef0cf42"
      unitRef="shares">2800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzItMy0xLTEtNzgwNDk_e84155ec-c89d-47e6-b0ff-b74ab4df24c1"
      unitRef="shares">3000000.0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzItNS0xLTEtNzgwNDk_9892c961-6d4f-40af-b18f-19baf7be71ca"
      unitRef="shares">3500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzMtMS0xLTEtNzgwNDk_d15e0535-8af0-46c4-ad45-4e9baf25f5ef"
      unitRef="shares">242800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzMtMy0xLTEtNzgwNDk_e47d1d53-bcaf-4eff-9376-0ce01330ac38"
      unitRef="shares">246800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90YWJsZToyOGIwYjRmYjkzOTU0MDRiOTk2MjZhMDRlZmFlYTZjOS90YWJsZXJhbmdlOjI4YjBiNGZiOTM5NTQwNGI5OTYyNmEwNGVmYWVhNmM5XzMtNS0xLTEtNzgwNDk_a4625123-23fd-4ed9-916e-3464a0e68399"
      unitRef="shares">254300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzIxNw_e1553f7a-9a35-4a1a-a52e-47ae72c6d7d8"
      unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzIyMQ_25af7688-275a-4602-a2b3-f3240f09513e"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzIyOA_75875530-e21b-4cc8-a66f-c6f5394a135c"
      unitRef="shares">1200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzQyMQ_491ca741-3d05-4a2b-99bc-10dbc7a5c840"
      unitRef="shares">200000</elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults>
    <elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzQyNQ_beb4a4ae-2d1b-4565-9391-2b89eb4db8e2"
      unitRef="shares">300000</elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults>
    <elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNjkvZnJhZzplMzg1Nzc1MmEwZWM0MWIyOThiOThlZmM5ZTJiZjM1My90ZXh0cmVnaW9uOmUzODU3NzUyYTBlYzQxYjI5OGI5OGVmYzllMmJmMzUzXzQzMg_3a8bd0c6-2a79-4ae6-8f49-6d76f049cb54"
      unitRef="shares">300000</elv:PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2NDg_087134a4-41cc-4520-ac7d-be9e82aed4f9">Segment Information&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2022, we managed and presented our operations through four reportable segments: Commercial &amp;amp; Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Commercial &amp;amp; Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; members. The Commercial &amp;amp; Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services (&#x201c;NGS&#x201d;) and services provided to the federal government in connection with the FEHB business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our CarelonRx segment includes our PBM business. CarelonRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Other segment includes our Diversified Business Group, now known as Carelon Services, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1 &#x201c;Organization&#x201d;, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. As we continue our journey to evolve our business from a traditional health insurance company into a lifetime, trusted health partner, we are evaluating and making changes to how we manage our business. This included a review of the products in each of our operating segments, which resulted in restructurings between some of our operating segments. Therefore, our reportable segment presentation in 2023 and its composition will reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources on January 1, 2023. As a result of these changes, beginning with our Quarterly Report on Form 10-Q for the first quarter of 2023, we will report our results in the following four reportable segments: (i) Health Benefits, which will combine our existing Commercial &amp;amp; Specialty Business and Government Business segments; (ii) our existing CarelonRx segment; (iii) Carelon Services (our former Diversified Business Group), which will be carved out from our existing Other segment; and (iv) Corporate and Other, which will include businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments. We expect to reclassify previously reported information to conform to the new presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefit and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, as well as certain back-office services provided by our international businesses, and are recorded at cost or management&#x2019;s estimate of fair market value. These affiliated revenues are eliminated in consolidation. For segment reporting, we present all capitation risk arrangements on a gross basis; therefore, eliminations also include adjustments for capitated risk arrangements that are recognized on a net basis under GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through our participation in various federal government programs, we generated approximately 28% of our total consolidated revenues from agencies of the U.S. government for each of the years ended December&#160;31, 2022, 2021, and 2020. The majority of these revenues are contained in our Government Business segment. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, &#x201c;Basis of Presentation and Significant Accounting Policies,&#x201d; except that all capitation risk arrangements are reported on a gross basis with an adjustment included in eliminations for capitated risk arrangements that are presented on a net basis under GAAP. We evaluate performance of the reportable segments based on operating gain or loss as defined above. We evaluate net investment income, net gains (losses) on financial instruments, interest expense, amortization expense, gain or loss on extinguishment of debt, income taxes and assets and liabilities on a consolidated basis, as these items are managed in a corporate shared service environment and are not the responsibility of segment operating management.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial data by reportable segment for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - unaffiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - affiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - unaffiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - affiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating gain (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - unaffiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - affiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating gain (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major product revenues for each of the reportable segments for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dental/Vision products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Integrated health services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent fee-based product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such information.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of reportable segments&#x2019; operating revenue to the amounts of total revenues included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segments&#x2019; operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of reportable segments&#x2019; operating gain to income before income tax expense included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segments&#x2019; operating gain&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzE5OA_427e6733-5a2b-49d3-a4db-a8ac9a608dec"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iae176fbb87f54bac94b2e4ab0685d43a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzI2ODk_a472107b-3439-4fab-8828-8a01a6345e8a"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i98132071c63744ada30c2775fc5af988_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzI2ODk_d775a868-0927-4e06-94fd-6a3a200c7c67"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie55d196caf5f45cfb07e66b8da2097ef_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzI2ODk_dcb7b671-105d-443f-8c86-d2855a68e661"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2NDU_56b99a33-08d7-4ec1-b71f-fd1dd6bb3de6">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial data by reportable segment for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - unaffiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - affiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - unaffiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - affiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating gain (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - unaffiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating revenue - affiliated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating gain (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItMS0xLTEtNzgwNDk_7dd12231-1027-4b06-a9c7-3ae68268f6b8"
      unitRef="usd">41674000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItMy0xLTEtNzgwNDk_540d5daa-d3c2-4450-b29e-04e23717f26e"
      unitRef="usd">96810000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i1df81813ee544edea31e2c74936bff4e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItNS0xLTEtNzgwNDk_ed369766-115a-4049-8d76-0a6794f69efb"
      unitRef="usd">14974000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i17ba170c8f794d3bb4ca06d264b4e57d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItNy0xLTEtNzgwNDk_8b021c5b-7259-4b86-a6fb-0edb23f3c994"
      unitRef="usd">2202000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzItMTEtMS0xLTc4MDQ5_650ad62b-05ff-4bb7-8184-039d8473bc97"
      unitRef="usd">155660000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ic7d0c0663315405099698864eb3c19b8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzMtNS0xLTEtNzgwNDk_ea287991-7a82-442e-b2a0-4d199eb0e1c1"
      unitRef="usd">13552000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="id2baaad3463642b18170d3f49e7ddc87_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzMtNy0xLTEtNzgwNDk_0220e042-e083-4122-8092-03c2d57528e4"
      unitRef="usd">11092000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i8429825b5f7e40ca8d6e68d3bb26eab2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzMtOS0xLTEtNzgwNDk_9b789887-88c0-45fc-b463-d4ef5c53c6dd"
      unitRef="usd">-24644000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtMS0xLTEtNzgwNDk_55a70c3b-461d-4135-8292-015c345c635f"
      unitRef="usd">2933000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtMy0xLTEtNzgwNDk_ed8218bf-be6f-4dbe-8df8-03400ec6ceb7"
      unitRef="usd">3297000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcd4e88199154a60b03416fb7594180f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtNS0xLTEtNzgwNDk_015c08b9-678d-4712-ab19-aef72dcd8b3a"
      unitRef="usd">1868000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtNy0xLTEtNzgwNDk_6e53e340-7ac9-4e91-8d0a-cc81be9bd6e8"
      unitRef="usd">354000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzQtMTEtMS0xLTc4MDQ5_d55bd377-7558-43d0-9872-ad2d9a502cf6"
      unitRef="usd">8452000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtMS0xLTEtNzgwNDk_0074785e-57af-4aa3-b6f0-3560804a1cf7"
      unitRef="usd">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtMy0xLTEtNzgwNDk_e84d1d42-bcb0-4ab9-9650-4c084ea02f0a"
      unitRef="usd">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtNy0xLTEtNzgwNDk_e82794e7-807c-4a58-99d0-ae28ed206c78"
      unitRef="usd">784000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzUtMTEtMS0xLTc4MDQ5_b937f77b-fdb9-4003-a7bf-30561eb49a9d"
      unitRef="usd">784000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctMS0xLTEtNzgwNDk_a5b1e7d0-e8c2-4aca-a799-d051c5eca60f"
      unitRef="usd">38809000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctMy0xLTEtNzgwNDk_0d4d3c16-ed46-4007-92d8-0d98f08dbe32"
      unitRef="usd">82919000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i1b7278c60e164f14b96b13c3df65ba4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctNS0xLTEtNzgwNDk_a85ee116-531e-47c2-b526-b476f99de0d7"
      unitRef="usd">12655000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ia4f05b417fd04be8a1aeab8299b5c69e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctNy0xLTEtNzgwNDk_02e34cac-2c92-4bef-9cdd-389c482cbcd4"
      unitRef="usd">2560000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzctMTEtMS0xLTc4MDQ5_a1057ae1-24b7-4251-a881-494bc26a7e2b"
      unitRef="usd">136943000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie10db0a695d24e41bdf7833886001b71_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzgtNS0xLTEtNzgwNDk_438b6e34-4c58-46fd-aa9d-a8d147d93f98"
      unitRef="usd">12776000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie1c8e72dc40f4442b092502acb15a96c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzgtNy0xLTEtNzgwNDk_7bb9968c-1fd3-4eb3-a873-4b27299a3369"
      unitRef="usd">7690000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie412ebaf29714d329b7b8b83c7ba69e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzgtOS0xLTEtNzgwNDk_0cf1a3a7-10dc-4444-aad1-ef574be042eb"
      unitRef="usd">-20466000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktMS0xLTEtNzgwNDk_6c9db1cb-0b54-47dc-bd27-813533af88e5"
      unitRef="usd">2753000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktMy0xLTEtNzgwNDk_8659876e-aba7-4b22-9a33-8786a1bf5024"
      unitRef="usd">3061000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6aaa78c2d9d4204bf48e9cfdaba7020_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktNS0xLTEtNzgwNDk_5ab327ac-6d6c-4153-bfdd-3e8a2973d26b"
      unitRef="usd">1684000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktNy0xLTEtNzgwNDk_b69acc76-1f6b-45a2-a392-6e93a6f4beb0"
      unitRef="usd">-9000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzktMTEtMS0xLTc4MDQ5_b06704cb-720e-4b80-975e-dc31b7ac2fe0"
      unitRef="usd">7489000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTEtMS0xLTc4MDQ5_7287fe46-3052-4c6c-83e7-f4437368489e"
      unitRef="usd">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTMtMS0xLTc4MDQ5_65e3f5ad-f737-42df-90d9-4496a406670b"
      unitRef="usd">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTctMS0xLTc4MDQ5_697eda43-0440-4be5-9dc5-136297fad803"
      unitRef="usd">668000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEwLTExLTEtMS03ODA0OQ_2536644e-1ff8-42ba-b4f9-7b9df01f1e96"
      unitRef="usd">668000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTEtMS0xLTc4MDQ5_fdc0fe1e-f6f5-4e68-adff-7f97f2f8e014"
      unitRef="usd">36699000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTMtMS0xLTc4MDQ5_04081aad-d25b-4711-a006-58b7e04bfb6a"
      unitRef="usd">71572000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i7bef8962735044b1acb083bc20e63486_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTUtMS0xLTc4MDQ5_3a43f377-870d-4f33-9fb1-c05399c81c03"
      unitRef="usd">10384000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="icece7f971bda47f8bc76865f9659c5da_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTctMS0xLTc4MDQ5_bf84cafe-13c8-4ebe-82e9-e95c96872572"
      unitRef="usd">2153000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEyLTExLTEtMS03ODA0OQ_9ce61c24-bae9-43af-baa1-295f0a26b61f"
      unitRef="usd">120808000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i1ebc5e9f4d1042a38e45cd00bce22554_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEzLTUtMS0xLTc4MDQ5_da8d61ab-9076-47d5-ae66-b573b351ac2d"
      unitRef="usd">11527000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="iaf4cd355c6dc4109bc5041d9057f2121_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEzLTctMS0xLTc4MDQ5_4a47c83d-4a0f-4b60-bd7d-80e12e84b3f8"
      unitRef="usd">3904000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="icb0d2a7152494f90b39b3fac5d9264ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzEzLTktMS0xLTc4MDQ5_4ab46098-5332-4984-8bcc-496ab71b8b0b"
      unitRef="usd">-15431000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTEtMS0xLTc4MDQ5_bd4440c7-1337-420e-9ecc-c142b8170f89"
      unitRef="usd">2681000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTMtMS0xLTc4MDQ5_96906e30-d40e-48ab-a2ba-dab80d4442c9"
      unitRef="usd">2444000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i77d0aff55fa54fd2a9a2a30c2e6c6a2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTUtMS0xLTc4MDQ5_c67c7203-67a6-48c0-b483-4a7db111dcfe"
      unitRef="usd">1361000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTctMS0xLTc4MDQ5_7db57a3d-f9df-4989-a63e-c1aa19f88937"
      unitRef="usd">-126000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE0LTExLTEtMS03ODA0OQ_47c27323-a518-4221-ae9c-0b2b908ff1eb"
      unitRef="usd">6360000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTEtMS0xLTc4MDQ5_f29be88f-570d-4e8b-aa31-f9fba157be09"
      unitRef="usd">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTMtMS0xLTc4MDQ5_b783b49e-5059-4a75-8663-83038e6dd786"
      unitRef="usd">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTctMS0xLTc4MDQ5_b7d7d9cf-1620-4b87-8c6c-c9027b2240a5"
      unitRef="usd">638000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo3Zjk3MjYwMDA3OTY0NmM0YWViYTc0ZDYyOTJhZjI3NC90YWJsZXJhbmdlOjdmOTcyNjAwMDc5NjQ2YzRhZWJhNzRkNjI5MmFmMjc0XzE1LTExLTEtMS03ODA0OQ_b40e3104-ffe7-432f-be8e-9d1447d8dfe8"
      unitRef="usd">638000000</us-gaap:OtherDepreciationAndAmortization>
    <elv:MajorProductRevenueBySegmentTableTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2Mzc_695bf6bc-cf17-42b7-922b-b82b1de363f4">The major product revenues for each of the reportable segments for the years ended December&#160;31, 2022, 2021 and 2020 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dental/Vision products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Commercial &amp;amp; Specialty Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Government Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CarelonRx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Integrated health services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other Business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</elv:MajorProductRevenueBySegmentTableTextBlock>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i4c68969e3f114ff69c401be9bc37c2dd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzItMS0xLTEtNzgwNDk_dfd55185-931d-4617-8664-62f3d17152d5"
      unitRef="usd">33927000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i6e22951986404675bbf5fbfa2839786c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzItMy0xLTEtNzgwNDk_f35e82b3-a657-4964-b94b-b53cb234d13c"
      unitRef="usd">31564000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i894b5d431a7047808e5ff7ebf443d016_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzItNS0xLTEtNzgwNDk_7c68141c-338a-40db-a88f-9d6fa64e95bd"
      unitRef="usd">29815000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i98f62da538ba41f789a6a73b38e537d8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzMtMS0xLTEtNzgwNDk_b034efc7-b5b9-485a-b2f3-fec040344a60"
      unitRef="usd">6152000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i123ffb166421487082a09f78c1725ebc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzMtMy0xLTEtNzgwNDk_aa17f82a-3ec5-4fa9-8d24-b4e05252c28f"
      unitRef="usd">5711000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i6364bd9ed8464178afda9d8855f8538c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzMtNS0xLTEtNzgwNDk_fed709b1-ef17-4ee7-a79b-926107ffc1d6"
      unitRef="usd">5296000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="if8365100e5c9406a9883eb34ce369cba_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzQtMS0xLTEtNzgwNDk_9dac0144-94a6-46e4-8d13-557b0d8fda50"
      unitRef="usd">1434000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ia1ac17248d75456fb25896b8926586fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzQtMy0xLTEtNzgwNDk_9b843fc9-b099-4b9e-ab25-f62990150ed6"
      unitRef="usd">1363000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i08e94cb6360045ddb9b224a2f973d9d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzQtNS0xLTEtNzgwNDk_05a41624-1cef-4cc3-a36d-4c8f47026c37"
      unitRef="usd">1231000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i3efe3527b82f45b4924c08cd2aeadf1f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzUtMS0xLTEtNzgwNDk_8fdf5cd7-7240-46cc-8948-c893630580f9"
      unitRef="usd">161000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i41cca4acaaa048e6904800f45ff39923_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzUtMy0xLTEtNzgwNDk_43d11e09-0aa8-4c09-aa8c-a87a890036db"
      unitRef="usd">171000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i735ef38ab9e648319f8e6b267c9164a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzUtNS0xLTEtNzgwNDk_0a3de084-7f04-4ca7-9f7f-9583867d3c4e"
      unitRef="usd">357000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzYtMS0xLTEtNzgwNDk_baa8af4b-746f-48ce-9936-06dc4e6aa152"
      unitRef="usd">41674000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i770384facf4c4469817f6cffe71f71ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzYtMy0xLTEtNzgwNDk_5b368fa6-5cd7-4847-9d85-f0684e521af9"
      unitRef="usd">38809000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i6d7d4c96af0f4fda828da7f3ef5ff027_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzYtNS0xLTEtNzgwNDk_aaf96542-f695-4443-8b39-9ce12983a706"
      unitRef="usd">36699000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i5157a3ffc8b8454a9197a5de365fbaf8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzgtMS0xLTEtNzgwNDk_05291b1a-44a3-458d-bbcb-9d46615d0840"
      unitRef="usd">96322000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i162dcb32162845ee8019a58aa859ae61_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzgtMy0xLTEtNzgwNDk_fcc9d87e-eabd-40cf-9cf7-1e96854e4df7"
      unitRef="usd">82519000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i647d737a8abe4da3b8caeb6484d9b75d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzgtNS0xLTEtNzgwNDk_6a48846b-f979-4d28-b92b-ba1ce4d0911c"
      unitRef="usd">71188000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="if42d0d2379bd40ba99bb0908ac993e6e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzktMS0xLTEtNzgwNDk_8f6e311c-b40a-4c7b-af1f-a4fc3e0abf46"
      unitRef="usd">488000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i9c132f1b799e4a88b13c0fa30393e947_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzktMy0xLTEtNzgwNDk_24e24071-26d5-418b-83a7-985078668a5a"
      unitRef="usd">400000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i79df8d34415c4640aa3a9d6958c599d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzktNS0xLTEtNzgwNDk_7e2d90e8-0792-4ab7-a6c1-b52dc4f03b63"
      unitRef="usd">384000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i64cc4da4939041a7b25fc8e63e2fd72c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEwLTEtMS0xLTc4MDQ5_134f40ff-a350-4b5d-9096-e281a9b8727e"
      unitRef="usd">96810000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i6d2ef3b7e8734b4bbd1e7f987608e323_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEwLTMtMS0xLTc4MDQ5_06075331-1a17-48ab-9dc7-d8c76440ec92"
      unitRef="usd">82919000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie88b98efd2d44c629f173f817e570f05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEwLTUtMS0xLTc4MDQ5_db3019e8-c96d-4533-9541-e0c12fb0dd3b"
      unitRef="usd">71572000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i2abac369da1f4652a7813e0cd7aa350f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEyLTEtMS0xLTc4MDQ5_c1308715-420d-44bc-89cf-06ec0ff02496"
      unitRef="usd">28526000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i9a9d4685e2e749a2bc8254783454a3a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEyLTMtMS0xLTc4MDQ5_f5f47953-e8f0-447a-8005-ad82b664b66f"
      unitRef="usd">25431000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i9cd36a7c95104275aee23983a5df35b0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzEyLTUtMS0xLTc4MDQ5_6666ce66-fd0d-4d5e-abb0-189bbab21e20"
      unitRef="usd">21911000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i8d0dd4f771c744f2831d7f9d4dc1c0a0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE0LTEtMS0xLTc4MDQ5_1e758510-2a1f-4e90-bfe1-39780310d759"
      unitRef="usd">12274000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i458aaaae8b4c42abaaad6c6a529cf94d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE0LTMtMS0xLTc4MDQ5_c3290f91-a656-4162-af5e-60748e35314a"
      unitRef="usd">9645000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i2f95fe1cae3741118461bf71f33280c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE0LTUtMS0xLTc4MDQ5_cbcedb17-ae36-4e2b-92fd-828019a92366"
      unitRef="usd">5787000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i096ee1cf57a8446eadfaff116cd44804_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE1LTEtMS0xLTc4MDQ5_f55fa17d-07a0-4097-8542-22794a42df7a"
      unitRef="usd">1020000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i0624a80296bd435499ecbb5c951564b4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE1LTMtMS0xLTc4MDQ5_42e1b4f2-9f58-43b0-b606-a4b0d73c956c"
      unitRef="usd">605000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="if18cf6ebd6bf46c08192134b8ce7cfcf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE1LTUtMS0xLTc4MDQ5_80287221-98a0-4886-a78d-1e041ccdec9b"
      unitRef="usd">270000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i940cdadbe7e345b28e1ce08bf9987988_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE2LTEtMS0xLTc4MDQ5_93cc4899-0da6-4589-8401-8573448d9718"
      unitRef="usd">13294000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie37a2fd92330495eb52aaa1b10dd6476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE2LTMtMS0xLTc4MDQ5_ea08d3ad-9b96-4ea0-a02d-a19f37dea335"
      unitRef="usd">10250000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i1af0fb1bf3ad4196b70f6a6a7fd4c582_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE2LTUtMS0xLTc4MDQ5_0086e7a1-32bb-4e03-ace7-d945295188cd"
      unitRef="usd">6057000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i8429825b5f7e40ca8d6e68d3bb26eab2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE4LTEtMS0xLTc4MDQ5_e6374c40-e4ee-4c28-8a45-22cf43429550"
      unitRef="usd">-24644000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ie412ebaf29714d329b7b8b83c7ba69e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE4LTMtMS0xLTc4MDQ5_bb121077-8f07-440f-ac61-6c77da0d71a6"
      unitRef="usd">-20466000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="icb0d2a7152494f90b39b3fac5d9264ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE4LTUtMS0xLTc4MDQ5_b96c6f6b-8acc-431d-8f5c-bbe4ee605440"
      unitRef="usd">-15431000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE5LTEtMS0xLTc4MDQ5_77c219e9-4cd3-49e3-af77-7e8888271d22"
      unitRef="usd">155660000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE5LTMtMS0xLTc4MDQ5_020384b3-005b-45e6-8d04-3169ef337ef2"
      unitRef="usd">136943000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTpiYzViODYwYjU5NjA0NDhkODBjOGQwNjVkZTQxMDA4ZC90YWJsZXJhbmdlOmJjNWI4NjBiNTk2MDQ0OGQ4MGM4ZDA2NWRlNDEwMDhkXzE5LTUtMS0xLTc4MDQ5_e8423b9a-e5b5-4e20-8e14-b4742eb9c8be"
      unitRef="usd">120808000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2NjM_28a6429d-140e-4d54-a57d-de7d12fd4cec">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of reportable segments&#x2019; operating revenue to the amounts of total revenues included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segments&#x2019; operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (losses) gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzEtMS0xLTEtNzgwNDk_667e6fdc-9467-484f-a310-0bdd3a92d241"
      unitRef="usd">155660000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzEtMy0xLTEtNzgwNDk_e4a37b33-ef66-4b15-a199-9750871b8fca"
      unitRef="usd">136943000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzEtNS0xLTEtNzgwNDk_673507bb-3cc3-4e61-ab98-1c641becf74d"
      unitRef="usd">120808000000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:NetInvestmentIncome
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzItMS0xLTEtNzgwNDk_66590b24-e693-4272-a9b7-c58d95cda949"
      unitRef="usd">1485000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzItMy0xLTEtNzgwNDk_abc2f26e-19fd-4189-bce4-2eb19b4205d6"
      unitRef="usd">1378000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzItNS0xLTEtNzgwNDk_6c78ea20-e677-4c25-9982-ed3ad66e64c8"
      unitRef="usd">877000000</us-gaap:NetInvestmentIncome>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzMtMS0xLTEtNzgwNDk_247354b7-7596-4bee-9128-6c58707b237b"
      unitRef="usd">-550000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzMtMy0xLTEtNzgwNDk_05cf7bd3-fe88-4853-8797-71ff126f823d"
      unitRef="usd">318000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzMtNS0xLTEtNzgwNDk_15ffdb2d-f5d7-4ce8-b4d7-d5fa0c8aeaf0"
      unitRef="usd">182000000</elv:NetGainsLossesOnFinancialInstruments>
    <us-gaap:Revenues
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzQtMS0xLTEtNzgwNDk_e8cd083e-3dd7-4255-8416-78293823e560"
      unitRef="usd">156595000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzQtMy0xLTEtNzgwNDk_41ea4148-dd0b-4bf4-a8ef-dafbb757f37a"
      unitRef="usd">138639000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo2MWQ2N2MwM2I2ZjQ0ZWM2ODY3NWI0NDVjNzE3MDNjZS90YWJsZXJhbmdlOjYxZDY3YzAzYjZmNDRlYzY4Njc1YjQ0NWM3MTcwM2NlXzQtNS0xLTEtNzgwNDk_f5c44fa8-2a3c-4173-99a9-238b8a416b0e"
      unitRef="usd">121867000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90ZXh0cmVnaW9uOmIyOWUwMjYzODBiNTRkYzQ4ZDJkNmRkMGU5ZjMxNjRmXzU2Njc_01517a8a-daa3-4a58-bdd8-cf78c7d9bf11">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of reportable segments&#x2019; operating gain to income before income tax expense included in our consolidated statements of income for the years ended December&#160;31, 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segments&#x2019; operating gain&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzEtMS0xLTEtNzgwNDk_b993ab26-3971-4641-b17c-dc9e57a7c7ef"
      unitRef="usd">7769000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzEtMy0xLTEtNzgwNDk_fab24414-fe21-45de-8b3f-8d27bf430596"
      unitRef="usd">7925000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzEtNS0xLTEtNzgwNDk_c0565c0f-8378-454f-981d-300668a6ccd6"
      unitRef="usd">6238000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetInvestmentIncome
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzItMS0xLTEtNzgwNDk_c88b4e6c-c17c-4ab8-ac17-d468ef410f00"
      unitRef="usd">1485000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzItMy0xLTEtNzgwNDk_9c022bb6-7997-4976-8351-43a51ff7f468"
      unitRef="usd">1378000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzItNS0xLTEtNzgwNDk_9b212078-c503-48e5-b275-07526f632fa6"
      unitRef="usd">877000000</us-gaap:NetInvestmentIncome>
    <elv:NetLossesGainsOnFinancialInstruments
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzMtMS0xLTEtNzgwNDk_3341dd81-9c87-43b1-b479-06dd1a3e72ca"
      unitRef="usd">-550000000</elv:NetLossesGainsOnFinancialInstruments>
    <elv:NetLossesGainsOnFinancialInstruments
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzMtMy0xLTEtNzgwNDk_3e7f0f9f-6b76-4c01-9f12-b644d41b3e38"
      unitRef="usd">318000000</elv:NetLossesGainsOnFinancialInstruments>
    <elv:NetLossesGainsOnFinancialInstruments
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzMtNS0xLTEtNzgwNDk_4a95d98d-9d79-4536-a50d-0865b0d4be57"
      unitRef="usd">182000000</elv:NetLossesGainsOnFinancialInstruments>
    <us-gaap:InterestExpense
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzQtMS0xLTEtNzgwNDk_7134bf53-db1a-4d26-b800-d9e71bc1feae"
      unitRef="usd">851000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzQtMy0xLTEtNzgwNDk_322f2e21-a04c-4388-ab96-527ddfe77ee3"
      unitRef="usd">798000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzQtNS0xLTEtNzgwNDk_d60000b7-b421-4351-9984-f235416bac13"
      unitRef="usd">784000000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzUtMS0xLTEtNzgwNDk_145b70c6-699a-456d-8e62-04674e39f8ee"
      unitRef="usd">767000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzUtMy0xLTEtNzgwNDk_30f4865b-1b36-456b-b1a8-54ad02893b26"
      unitRef="usd">441000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzUtNS0xLTEtNzgwNDk_dd8b3987-9949-406f-9b30-6c4a2d623ac2"
      unitRef="usd">361000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzYtMS0xLTEtNzgwNDk_362cf3cc-372d-427f-82f7-dcf06455b8e0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzYtMy0xLTEtNzgwNDk_b31469d0-a0f7-44a8-b322-4a6cd4f10f0e"
      unitRef="usd">-21000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzYtNS0xLTEtNzgwNDk_b6dcb42f-e3c2-47ee-a560-ca684775e69f"
      unitRef="usd">-36000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OperatingIncomeLoss
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzctMS0xLTEtNzgwNDk_cab115b0-924f-4d73-aab8-c4c6eb437688"
      unitRef="usd">8452000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i68c5618278594510a5fcb2076da6fa1c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzctMy0xLTEtNzgwNDk_4a6cc23b-76e1-49d3-ae00-e7a4afdf665b"
      unitRef="usd">7489000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzIvZnJhZzpiMjllMDI2MzgwYjU0ZGM0OGQyZDZkZDBlOWYzMTY0Zi90YWJsZTo4N2Q5MzU2YjdmYTE0OGMyOTY1YmQ5ZmU0NmUwNTJjYy90YWJsZXJhbmdlOjg3ZDkzNTZiN2ZhMTQ4YzI5NjViZDlmZTQ2ZTA1MmNjXzctNS0xLTEtNzgwNDk_338ad13c-819b-4c1b-bb2e-dc28a8dea256"
      unitRef="usd">6360000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzM0NQ_e24b6385-07f5-473a-8240-5c233aa4d051">Related Party TransactionsWe have an equity investment in APC Passe, LLC, which offers Medicaid products in Arkansas. During the years ended December&#160;31, 2022, 2021 and 2020, in the normal course of business, we assumed premiums of $501, $462 and $446, respectively, from APC Passe, LLC, which is included in our total assumed premiums (see Note 17, &#x201c;Reinsurance&#x201d;).</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i417b0315d1f946278154f230d44ba1b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzIxOQ_ffa1bd52-b627-4dbd-8ac2-6ec651607319"
      unitRef="usd">501000000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="ie3f82c8853704ae1861ff012a8a6a705_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzIyNg_7fe6d220-d029-48dc-becf-3491de12a024"
      unitRef="usd">462000000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i4356376bd2bb4161b623b19b110ab07e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzUvZnJhZzo2NDdiMjQ2ZGY3NGQ0NmMxOWU3OWViZmFmYjMwMTcwZi90ZXh0cmVnaW9uOjY0N2IyNDZkZjc0ZDQ2YzE5ZTc5ZWJmYWZiMzAxNzBmXzU0OTc1NTgxNDMyMg_a8667b35-d680-4b7f-bc17-d2d72673d20f"
      unitRef="usd">446000000</us-gaap:AssumedPremiumsWritten>
    <elv:StatutoryInformationTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzM2NTg_bca9fb24-3bc5-466b-9e8e-01e67d456aa9">Statutory Information&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance regulatory authorities, commonly referred to as statutory accounting, which vary in certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc., Beacon Health Options of California, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care (&#x201c;DMHC&#x201d;) and report their accounts in conformity with GAAP (these entities are collectively referred to as the &#x201c;DMHC regulated entities&#x201d;). Typical differences of GAAP reporting as compared to statutory reporting are the recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of Insurance Commissioners (&#x201c;NAIC&#x201d;) developed a codified version of the statutory accounting principles, designed to foster more consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set forth in a variety of publications of the NAIC as well as state laws, regulations and general administrative rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital (&#x201c;RBC&#x201d;) requirements. RBC is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied to certain financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December&#160;31, 2022 and 2021, all of our regulated subsidiaries exceeded the minimum applicable mandatory RBC requirements and/or capital and solvency requirements of their applicable governmental regulator. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately $7,900 and $6,962 as of December&#160;31, 2022 and 2021, respectively. The tangible net equity required for the DMHC regulated entities was approximately $710 and $690 as of December&#160;31, 2022 and 2021, respectively. Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC regulated entities, was $19,048 and $16,178 at December&#160;31, 2022 and 2021, respectively. GAAP equity of the DMHC regulated entities was $3,795 and $3,886 at December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary&#x2019;s domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC. During 2022, our insurance and HMO &lt;/span&gt;&lt;/div&gt;subsidiaries paid aggregate cash dividends of $3,097 to the parent company, including cash dividends which required prior approval from regulatory authorities. We currently estimate that approximately $3,500 of dividends will be paid to the parent company in 2023.</elv:StatutoryInformationTextBlock>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI0NTQ_05d09f9d-c830-4559-b89b-4f978b8ea738"
      unitRef="usd">7900000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
      contextRef="i2310c7de653445608cb615a91fde33b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI0NjE_31a19be9-8ac1-41ee-9c11-2ae40fd504e9"
      unitRef="usd">6962000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
      contextRef="i3b88a75959a3413fbf01add2bd34bcb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI1Nzg_5cdad3f0-9a21-4221-8fd4-619665532d1c"
      unitRef="usd">710000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
      contextRef="i725512778bd442a6b242345331bb3a06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI1ODU_f6348903-e506-4df0-8f8a-9db7e13709b5"
      unitRef="usd">690000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
      contextRef="id6bc2c55daf14d049cede53415aaef62_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI3OTc_06c29833-ccab-4ab3-b5fc-fef31fce7cec"
      unitRef="usd">19048000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
      contextRef="i18e88e0db7ff4756a456b1a7ffd88b77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI4MDQ_8a4d6d0e-6aa1-4ac9-94a8-90ad3be2356a"
      unitRef="usd">16178000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StockholdersEquity
      contextRef="i5e6ef69580834645b272fe1032c1d97a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI4ODI_87504fb7-418a-4d56-98a7-6c6ed43f803b"
      unitRef="usd">3795000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2684dcf65c140fca76ea400241c2590_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzI4ODk_a145d455-09d8-47fb-b7f5-71a64cd0179f"
      unitRef="usd">3886000000</us-gaap:StockholdersEquity>
    <us-gaap:StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzM0NDQ_43eea4cf-962d-4c60-960b-2d76106923ca"
      unitRef="usd">3097000000</us-gaap:StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency>
    <elv:EstimatedFutureDividendPayments
      contextRef="i4a75db76b76e4786aa3fcd8ba8940b14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18xNzgvZnJhZzoyZjFkMzU0YzY3OTE0ZGQ0ODAzYzM0ZmJmYWE2NmUwNy90ZXh0cmVnaW9uOjJmMWQzNTRjNjc5MTRkZDQ4MDNjMzRmYmZhYTY2ZTA3XzM1OTU_8fec8c97-14e0-4744-97df-34fa1be03725"
      unitRef="usd">3500000000</elv:EstimatedFutureDividendPayments>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
      contextRef="ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90ZXh0cmVnaW9uOmY3ZGFiMDhkZmMwODRjOWFhNzZmNjdhMjA1Y2ZhNjNhXzkz_c127ff48-c1dd-46ef-9f4f-76dbe4905d9b">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Elevance Health, Inc. (Parent Company Only)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed maturity securities (amortized cost of $175 and $512; allowance for credit losses of $0 and $1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net due from subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other invested assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities and shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net due to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&#x2014;Note 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total liabilities and shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Elevance Health, Inc. (Parent Company Only)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Statements of Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Administrative fees and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before income tax credits and equity in net income of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shareholders&#x2019; net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Elevance Health, Inc. (Parent Company Only)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Statements of Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other comprehensive (loss) income, net of tax:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in net unrealized gains/losses on investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-credit component of impairment losses on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in net unrealized gains/losses on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in net periodic pension and postretirement costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shareholders&#x2019; comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Elevance Health, Inc. (Parent Company Only)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from sales, maturities, calls and redemptions of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment (issuance) of note to subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalization of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in securities lending collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment, net of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash provided by (used in) investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (repayments of) proceeds from commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from long-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayments of long-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in securities lending payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repurchase and retirement of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from issuance of common stock under employee stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes paid through withholding of common stock under employee stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash used in financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1.&#160;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the parent company only financial statements of Elevance Health, Inc. (&#x201c;Elevance Health&#x201d;), Elevance Health&#x2019;s investment in subsidiaries is stated at cost plus equity in undistributed earnings of the subsidiaries. Elevance Health&#x2019;s share of net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of Elevance Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Elevance Health&#x2019;s parent company only financial statements should be read in conjunction with Elevance Health&#x2019;s audited consolidated financial statements and the accompanying notes included in Part II, Item 8 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.&#160;Subsidiary Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends from Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Elevance Health received cash dividends from subsidiaries of $3,097, $3,134 and $3,618 during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends to Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Elevance Health own shares of Elevance Health common stock. Elevance Health paid cash dividends to subsidiaries related to these shares of common stock in the amount of $61, $54 and $46 during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital contributions to subsidiaries were $411, $3,271 and $2,460 during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amounts Due From and To Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, Elevance Health reported amounts due (to) from subsidiaries of $(789) and $446, respectively. The amounts due (to) and from subsidiaries primarily include amounts for allocated administrative expenses or daily cash management activities. These items are routinely settled, and as such, are classified as current liabilities or assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 Elevance Health entered into a short-term loan agreement with a subsidiary for the amount of $1,500, which is also included in amounts due from subsidiaries at December 31, 2021. This loan was repaid in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees on Behalf of Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Elevance Health guarantees contractual or financial obligations or solvency requirements for certain of its subsidiaries. These guarantees approximated $550 at December&#160;31, 2022. There were no payments made on these guarantees in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3. Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information regarding derivative financial instruments contained in Note 6, &#x201c;Derivative Financial Instruments,&#x201d; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4. Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information regarding long-term debt contained in Note 13, &#x201c;Debt,&#x201d; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5. Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information regarding commitments and contingencies contained in Note 14, &#x201c;Commitments and Contingencies,&#x201d; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6. Capital Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information regarding capital stock contained in Note 15, &#x201c;Capital Stock,&#x201d; of the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.&lt;/span&gt;&lt;/div&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMtMS0xLTEtNzgwNDk_84fc048a-4700-4736-a7ef-b3df489fa486"
      unitRef="usd">942000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMtMy0xLTEtNzgwNDk_40318b02-a8f4-42b5-9f0a-49ee56e86a2e"
      unitRef="usd">630000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV80OQ_78a55cfe-b80c-4c2a-838d-490d02f1d736"
      unitRef="usd">175000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV81Ng_1f9f947c-fa88-48f8-951f-124aee112306"
      unitRef="usd">512000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV85MQ_91ecfc0f-aeee-40a9-bf67-fc47a11980a9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMC0xLTEtNzgwNDkvdGV4dHJlZ2lvbjphYTk3Y2E0NGUzM2Q0ZTBiYjQ4OTdkYjVlNGZlZjA5OV85OA_91bb9782-70c2-4391-88ec-d3e7b642aa8f"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMS0xLTEtNzgwNDk_4319b4cf-1611-461a-ae14-3d082179c054"
      unitRef="usd">163000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzUtMy0xLTEtNzgwNDk_2d3c6a1b-a58b-4497-b88f-48897c636384"
      unitRef="usd">515000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzYtMS0xLTEtNzgwNDk_30f7e459-62df-4bdb-8a2d-2f955306c74d"
      unitRef="usd">104000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzYtMy0xLTEtNzgwNDk_d1745acf-7844-46af-9e80-3b4724ab510d"
      unitRef="usd">49000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:OtherReceivables
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzgtMS0xLTEtNzgwNDk_1fc8117c-527f-4031-8c4a-411a757a647a"
      unitRef="usd">55000000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzgtMy0xLTEtNzgwNDk_3df58c39-06d4-4315-a1a1-e4aade4fbea5"
      unitRef="usd">40000000</us-gaap:OtherReceivables>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEwLTEtMS0xLTc4MDQ5_d7774184-24ec-42a3-a1ef-0ceb02685a46"
      unitRef="usd">0</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEwLTMtMS0xLTc4MDQ5_5d65b4b2-9408-4ae2-8135-6d4b2d5ab4b9"
      unitRef="usd">446000000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEyLTEtMS0xLTc4MDQ5_934aa494-30d0-4e3e-a348-692bcfd9958d"
      unitRef="usd">721000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEyLTMtMS0xLTc4MDQ5_d1e9ee69-d831-4c53-9ca9-1eec58874782"
      unitRef="usd">655000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEzLTEtMS0xLTc4MDQ5_ae519e3b-84c0-4c08-922c-441e468186bf"
      unitRef="usd">1985000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzEzLTMtMS0xLTc4MDQ5_145b27d1-c028-4f21-83dc-a6c995afcd99"
      unitRef="usd">2335000000</us-gaap:AssetsCurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE0LTEtMS0xLTc4MDQ5_53bc1b82-f16a-479c-8c81-fa73eb2d7adc"
      unitRef="usd">783000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE0LTMtMS0xLTc4MDQ5_e057629a-0e8e-4565-9154-51c1b760f401"
      unitRef="usd">808000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE1LTEtMS0xLTc4MDQ5_8ecc12c7-014e-4d04-92ff-72c3c506f5e1"
      unitRef="usd">187000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE1LTMtMS0xLTc4MDQ5_e6ddd7e5-ace4-4871-9f6f-8f69611edf07"
      unitRef="usd">207000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE2LTEtMS0xLTc4MDQ5_d9455eed-3c41-4455-b333-246354c4c19f"
      unitRef="usd">313000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE2LTMtMS0xLTc4MDQ5_1fd4175d-a0d2-41f7-8dcd-50603eb23bcc"
      unitRef="usd">77000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <elv:InvestmentInSubsidiaries
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE3LTEtMS0xLTc4MDQ5_5994147b-ac70-4f1d-99ea-e17086663b69"
      unitRef="usd">59042000000</elv:InvestmentInSubsidiaries>
    <elv:InvestmentInSubsidiaries
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE3LTMtMS0xLTc4MDQ5_09df18a6-b6a4-4f33-8fac-893ceaa85832"
      unitRef="usd">56375000000</elv:InvestmentInSubsidiaries>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE4LTEtMS0xLTc4MDQ5_a8b544b9-358e-4c2d-bb84-580fd36c0563"
      unitRef="usd">240000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE4LTMtMS0xLTc4MDQ5_1b3563f4-53f8-48ce-b5da-63ea2de2b066"
      unitRef="usd">265000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE5LTEtMS0xLTc4MDQ5_111501f8-8b5c-46f5-a253-8f4cb68f8f56"
      unitRef="usd">62550000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzE5LTMtMS0xLTc4MDQ5_e6f35e98-cc5d-4fff-8d11-e9fdbdd2217f"
      unitRef="usd">60067000000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzIzLTEtMS0xLTc4MDQ5_4526bb76-22f7-4c58-8a7d-78f9751355c0"
      unitRef="usd">894000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzIzLTMtMS0xLTc4MDQ5_254559f8-e02c-49d4-9b7e-53d05b83786c"
      unitRef="usd">559000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI3LTEtMS0xLTc4MDQ5_a42ea61a-7b99-487c-8df1-f1745212b9f0"
      unitRef="usd">789000000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI3LTMtMS0xLTc4MDQ5_a0fe0cd1-bf37-45ac-889f-21f69f976424"
      unitRef="usd">0</us-gaap:DueToAffiliateCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI4LTEtMS0xLTc4MDQ5_38286de2-07f3-47c5-a881-90c82ec749af"
      unitRef="usd">1500000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI4LTMtMS0xLTc4MDQ5_2f603b0c-ae0c-40e1-9b85-3a429aede436"
      unitRef="usd">1599000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI5LTEtMS0xLTc4MDQ5_747a840b-aa09-4e72-bb98-c9ee6631d60b"
      unitRef="usd">361000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzI5LTMtMS0xLTc4MDQ5_10759fd5-1dfd-4ba6-ae5d-8a8f210bedb8"
      unitRef="usd">344000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMwLTEtMS0xLTc4MDQ5_e0cd912c-585d-44f9-a4e9-dccb538af4f5"
      unitRef="usd">3544000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMwLTMtMS0xLTc4MDQ5_e8d835d5-531d-425f-92ff-e101784b3035"
      unitRef="usd">2502000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMxLTEtMS0xLTc4MDQ5_23c9a5c3-6226-4ba9-ac2f-1ecd6c18a8e5"
      unitRef="usd">22324000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMxLTMtMS0xLTc4MDQ5_e2ae2486-5a63-43cd-a8d6-f6ee6dc0395c"
      unitRef="usd">21132000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMzLTEtMS0xLTc4MDQ5_5416a8a1-ac01-4c1b-b7ed-ca244d056760"
      unitRef="usd">375000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzMzLTMtMS0xLTc4MDQ5_769a6fc9-c6f6-4aa7-addb-13b109bd77c4"
      unitRef="usd">373000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM0LTEtMS0xLTc4MDQ5_3a79cc1f-bf2b-4881-b13d-791652cac8b1"
      unitRef="usd">26243000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM0LTMtMS0xLTc4MDQ5_53fa2ddd-7e96-4f53-9ef9-f296e503d47c"
      unitRef="usd">24007000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM1LTEtMS0xLTc4MDQ5_7e5f173d-399c-43eb-8a8f-6cd5eb26a88c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM1LTMtMS0xLTc4MDQ5_35b9e2df-8068-4370-a832-1add9a28aa35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZmY0ZTc2NDliNGYxNThiNTE4YjY0MTg3NjMzZjBfNjA_752db9ab-5251-4a74-b41e-8d8016fd71cc"
      unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZmY0ZTc2NDliNGYxNThiNTE4YjY0MTg3NjMzZjBfOTY_5254485b-6e69-42f8-b123-460db6f787a6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246ZWQ0ZmY0ZTc2NDliNGYxNThiNTE4YjY0MTg3NjMzZjBfOTY_bfcda4c4-8d3b-488f-a4de-6e659d351c1e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTEtMS0xLTc4MDQ5_d32cafa5-b5e4-4c14-91e5-5ac7a7aa0023"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM3LTMtMS0xLTc4MDQ5_1d1401dd-d81d-4010-9382-7424a7737911"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfMjg_6a1c4e9f-70e6-4a2a-b287-10567ce306e3"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfNTI_717958c4-c51f-49ca-b5dc-c57c8afe50c5"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfODg_0f7998de-bf80-40eb-a204-7c7e909f1669"
      unitRef="shares">237958067</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfODg_7cbd6e35-7cf1-4a2d-b4f6-832ec5976880"
      unitRef="shares">237958067</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfOTU_1c6e4b4f-1d7e-4c96-b634-efa337dfafad"
      unitRef="shares">241770746</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTAtMS0xLTc4MDQ5L3RleHRyZWdpb246YmQzOGY2ZjNiN2NjNGM0ZThkYzM0ODhjZDY1OTA4M2VfOTU_efa972a7-d858-4038-a280-c04b9fe2866c"
      unitRef="shares">241770746</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTEtMS0xLTc4MDQ5_dfb892b5-f778-41f2-b983-dc549227f863"
      unitRef="usd">2000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM4LTMtMS0xLTc4MDQ5_cbbacac6-d2bb-4393-aa5a-32d5fdf95075"
      unitRef="usd">2000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM5LTEtMS0xLTc4MDQ5_68f8c1bd-a190-4e13-bdb2-e7fbe51cb270"
      unitRef="usd">9084000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzM5LTMtMS0xLTc4MDQ5_508b03de-680e-46ca-abba-ecea83843367"
      unitRef="usd">9148000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQwLTEtMS0xLTc4MDQ5_430bf418-9453-446e-ae13-681266fe634b"
      unitRef="usd">29724000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQwLTMtMS0xLTc4MDQ5_0672c176-51dd-4a31-9b03-3cbc6c1eb11f"
      unitRef="usd">27088000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQxLTEtMS0xLTc4MDQ5_90a3cd05-1858-4d5b-b0cb-43def1483787"
      unitRef="usd">-2503000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQxLTMtMS0xLTc4MDQ5_dbd7cd10-37ce-4917-bae1-9f3da347075d"
      unitRef="usd">-178000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQyLTEtMS0xLTc4MDQ5_48140eb7-7d69-4499-b991-7d0df94e0bec"
      unitRef="usd">36307000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQyLTMtMS0xLTc4MDQ5_93e7a9c5-fd5f-4de4-9e75-8830a07a35b2"
      unitRef="usd">36060000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQzLTEtMS0xLTc4MDQ5_cd6030cc-054f-4a32-8439-4c46e1c2527b"
      unitRef="usd">62550000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjMvZnJhZzpmN2RhYjA4ZGZjMDg0YzlhYTc2ZjY3YTIwNWNmYTYzYS90YWJsZTpkOThkMTQ4YTdlYjY0NzM5OGVhZDZlNWUyZWZiZTAxZC90YWJsZXJhbmdlOmQ5OGQxNDhhN2ViNjQ3Mzk4ZWFkNmU1ZTJlZmJlMDFkXzQzLTMtMS0xLTc4MDQ5_ddc24b7a-cf02-423a-a4a0-cc765052a9c6"
      unitRef="usd">60067000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:NetInvestmentIncome
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzMtMS0xLTEtNzgwNDk_7d4e356b-e54c-41e3-8fe1-0e352da4ddac"
      unitRef="usd">4000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzMtMy0xLTEtNzgwNDk_0f4d09fa-ad5e-4cc8-b372-a5ecf23ca36b"
      unitRef="usd">6000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzMtNS0xLTEtNzgwNDk_d664ef3c-5b02-423f-8d76-bdafe4b3a826"
      unitRef="usd">65000000</us-gaap:NetInvestmentIncome>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzQtMS0xLTEtNzgwNDk_e9c5159f-4e20-4f7a-9ef9-702563935e88"
      unitRef="usd">2000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzQtMy0xLTEtNzgwNDk_5399d725-f83c-45e2-b39e-1c55d9b1a0a2"
      unitRef="usd">6000000</elv:NetGainsLossesOnFinancialInstruments>
    <elv:NetGainsLossesOnFinancialInstruments
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzQtNS0xLTEtNzgwNDk_cf10a472-84ed-4ca6-b198-e62c989b9985"
      unitRef="usd">28000000</elv:NetGainsLossesOnFinancialInstruments>
    <us-gaap:OtherIncome
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzktMS0xLTEtNzgwNDk_10af238c-d9c8-4a22-b29b-0423632fd13f"
      unitRef="usd">7000000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzktMy0xLTEtNzgwNDk_af941034-e9aa-4d33-a16e-20d338c812b3"
      unitRef="usd">24000000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzktNS0xLTEtNzgwNDk_bfff3a31-9ec6-430d-a9c3-6617100d6c8a"
      unitRef="usd">22000000</us-gaap:OtherIncome>
    <us-gaap:Revenues
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEwLTEtMS0xLTc4MDQ5_55cd6c05-c97b-4516-bc80-b72bf48da3c0"
      unitRef="usd">13000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEwLTMtMS0xLTc4MDQ5_eda902b1-e7ac-4639-a377-768dd3ecb425"
      unitRef="usd">36000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEwLTUtMS0xLTc4MDQ5_a76d8bbc-94dc-473f-a0c6-3778b3a74971"
      unitRef="usd">115000000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEyLTEtMS0xLTc4MDQ5_6b87455a-abe2-42b1-8885-c02c352096f0"
      unitRef="usd">188000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEyLTMtMS0xLTc4MDQ5_28c1045d-9338-4519-a3c4-76dcb98d4075"
      unitRef="usd">119000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEyLTUtMS0xLTc4MDQ5_211dd8a1-103a-4794-88d8-4923db2abc49"
      unitRef="usd">169000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InterestExpense
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEzLTEtMS0xLTc4MDQ5_8d2333f6-2ce4-4c85-b9f2-15fc7616c5b7"
      unitRef="usd">845000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEzLTMtMS0xLTc4MDQ5_d72ce636-97f0-4134-bbd2-e81f0d554670"
      unitRef="usd">794000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzEzLTUtMS0xLTc4MDQ5_ad2f7287-dc9d-496e-b11f-0e61efbc1254"
      unitRef="usd">779000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE0LTEtMS0xLTc4MDQ5_68f23d9a-325e-4cd7-b22c-d855ac3bb147"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE0LTMtMS0xLTc4MDQ5_636d2050-2e64-48ed-8a15-2ae31cc46769"
      unitRef="usd">-21000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE0LTUtMS0xLTc4MDQ5_a29863f6-705e-48ac-b88e-34b9c53e6841"
      unitRef="usd">-36000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <elv:TotalExpenses
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE1LTEtMS0xLTc4MDQ5_d442c32f-ee27-45f4-87de-a2739c8cf4f1"
      unitRef="usd">1033000000</elv:TotalExpenses>
    <elv:TotalExpenses
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE1LTMtMS0xLTc4MDQ5_7506a81c-8f7f-43f7-9f04-1a99c6774a59"
      unitRef="usd">934000000</elv:TotalExpenses>
    <elv:TotalExpenses
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE1LTUtMS0xLTc4MDQ5_d78f3f0d-6e06-4bde-af70-2faa8f3fcc74"
      unitRef="usd">984000000</elv:TotalExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE2LTEtMS0xLTc4MDQ5_cd0f12ee-489c-498e-8799-31c747ddf3a8"
      unitRef="usd">-1020000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE2LTMtMS0xLTc4MDQ5_8ebe2e18-1c5f-4d6f-ab9d-f663c5b18450"
      unitRef="usd">-898000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE2LTUtMS0xLTc4MDQ5_06f0ad09-c095-4bc3-bd7f-c3c5864d98d7"
      unitRef="usd">-869000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE3LTEtMS0xLTc4MDQ5_e407c21e-6610-4760-bb20-3ce510b70321"
      unitRef="usd">-461000000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE3LTMtMS0xLTc4MDQ5_d987641b-e4cc-4728-8194-b98bff9b3f56"
      unitRef="usd">-244000000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE3LTUtMS0xLTc4MDQ5_beb209d1-7669-40db-a495-32d2774c8e17"
      unitRef="usd">-386000000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE4LTEtMS0xLTc4MDQ5_2219dc66-46c5-4b9c-895a-cff1ccb989a0"
      unitRef="usd">6584000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE4LTMtMS0xLTc4MDQ5_d32e66bc-b744-4c49-84d9-ada64183a984"
      unitRef="usd">6758000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE4LTUtMS0xLTc4MDQ5_7a87bd8a-7c83-4724-a370-cb88771f2224"
      unitRef="usd">5055000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:NetIncomeLoss
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE5LTEtMS0xLTc4MDQ5_091e8638-0ce0-4104-9d38-a87bb956d5db"
      unitRef="usd">6025000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE5LTMtMS0xLTc4MDQ5_325253c0-8caf-4e19-a74c-206949d07eee"
      unitRef="usd">6104000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMjkvZnJhZzpiZGY0Mjg0NjJhZTM0OWY1YjBmMjk4YWU5MmJiMmFiOS90YWJsZToyMWNjOGM2ZWNiNWY0NTA4ODk2YmRlYzVkYTNlOTdlNy90YWJsZXJhbmdlOjIxY2M4YzZlY2I1ZjQ1MDg4OTZiZGVjNWRhM2U5N2U3XzE5LTUtMS0xLTc4MDQ5_d4d03c68-0163-47a3-8352-9671d6b00613"
      unitRef="usd">4572000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzItMS0xLTEtNzgwNDk_ddc77a99-b20d-41d4-a4e6-8601f6d3206b"
      unitRef="usd">6025000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzItMy0xLTEtNzgwNDk_d9e4476b-30b3-4417-8bfe-a8d45ac8c97a"
      unitRef="usd">6104000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzItNS0xLTEtNzgwNDk_f8b99f83-e328-46f4-83b5-9ff663acf03e"
      unitRef="usd">4572000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzQtMS0xLTEtNzgwNDk_59807dd6-216c-4bfa-8e93-d30b19c2b103"
      unitRef="usd">-2249000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzQtMy0xLTEtNzgwNDk_904fc373-7168-4140-8791-b0a9773b3674"
      unitRef="usd">-455000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzQtNS0xLTEtNzgwNDk_c45ffe33-0ea5-41d6-84b4-2ce6e374db52"
      unitRef="usd">428000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzUtMS0xLTEtNzgwNDk_abdd1f6e-200a-48ff-b88c-f1429c89e93d"
      unitRef="usd">-3000000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzUtMy0xLTEtNzgwNDk_4d858797-0b9c-4641-a1c5-531da02d471b"
      unitRef="usd">-2000000</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzUtNS0xLTEtNzgwNDk_2b4a3e96-0a3a-4d0e-8f31-eeaeada105f4"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzYtMS0xLTEtNzgwNDk_30dbd416-f593-4611-ad32-c36f5d27df19"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzYtMy0xLTEtNzgwNDk_01a3c1a6-16bf-4535-848f-a1020f58d94d"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzYtNS0xLTEtNzgwNDk_68505901-d90e-4089-bf4c-8a59a31741ea"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzctMS0xLTEtNzgwNDk_27dd5647-b29a-433d-a394-0d939ef9be37"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzctMy0xLTEtNzgwNDk_818cbf28-25c4-4516-91c6-e94e3d3ebbd6"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzctNS0xLTEtNzgwNDk_d98374f9-182d-469d-9489-f9233ac1dc94"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzgtMS0xLTEtNzgwNDk_f19a123a-8855-4933-82b3-f3ffb2242e16"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzgtMy0xLTEtNzgwNDk_5ee2be55-15d0-4368-8ae1-aaf0bb4229b0"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzgtNS0xLTEtNzgwNDk_654f6dd9-b9fe-445b-a359-e5e66e4129c1"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzktMS0xLTEtNzgwNDk_bb7f88a0-f1b0-4de3-b476-4950a89086bd"
      unitRef="usd">-2325000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzktMy0xLTEtNzgwNDk_c0314f64-8657-44f7-818f-7b39a59e3b23"
      unitRef="usd">-328000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzktNS0xLTEtNzgwNDk_4a31e31f-8e32-4952-933b-16902ce159b2"
      unitRef="usd">446000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzEwLTEtMS0xLTc4MDQ5_87d99b26-561b-4413-8481-485a6b8a04ce"
      unitRef="usd">3700000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzEwLTMtMS0xLTc4MDQ5_e1842ee5-1fad-4faf-80fe-f1ea186c0c88"
      unitRef="usd">5776000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzIvZnJhZzoyYjYwODA1MzVkZmI0YWE4YjlhOGYyNmE4NDExNjRkMS90YWJsZTozNjI3NTA4YzlmOWQ0NWZlYjU1OTVjOTY2NzgwM2U5Ny90YWJsZXJhbmdlOjM2Mjc1MDhjOWY5ZDQ1ZmViNTU5NWM5NjY3ODAzZTk3XzEwLTUtMS0xLTc4MDQ5_32402916-59cc-437b-9d93-4bde42488c9f"
      unitRef="usd">5018000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI2LTEtMS0xLTc4MDQ5_f04c1aa3-87fd-4b7b-9ba7-09921140071f"
      unitRef="usd">1447000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI2LTMtMS0xLTc4MDQ5_8f291e9c-b1ff-4345-87a1-3c19bbc46270"
      unitRef="usd">2038000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI2LTUtMS0xLTc4MDQ5_85cb106d-445f-4a5c-bcfb-1f3d7e1bb4bb"
      unitRef="usd">4810000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI4LTEtMS0xLTc4MDQ5_1721b76f-7ca2-4400-bb0b-431a1754e820"
      unitRef="usd">367000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI4LTMtMS0xLTc4MDQ5_7adeb91c-ae1f-46fe-af12-385d482915ed"
      unitRef="usd">2059000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI4LTUtMS0xLTc4MDQ5_d0d7705f-afbc-4773-aeff-6171b185f9e5"
      unitRef="usd">2729000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI5LTEtMS0xLTc4MDQ5_fd9b16e9-b13f-4a11-9325-5b23bfb32621"
      unitRef="usd">618000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI5LTMtMS0xLTc4MDQ5_1db0dfc3-b519-41b7-89d1-369d17f1d53a"
      unitRef="usd">2449000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzI5LTUtMS0xLTc4MDQ5_3097667e-1db2-46d1-b200-e4ed6ab17d78"
      unitRef="usd">2593000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:OriginationOfNotesReceivableFromRelatedParties
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMxLTEtMS0xLTc4MDQ5_ed909499-32fa-48e2-92dc-0454d2c3a8ce"
      unitRef="usd">1500000000</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
    <us-gaap:OriginationOfNotesReceivableFromRelatedParties
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMxLTMtMS0xLTc4MDQ5_41b86f0e-26cd-4151-be9a-fd3537e1f8c6"
      unitRef="usd">-1500000000</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
    <us-gaap:OriginationOfNotesReceivableFromRelatedParties
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMxLTUtMS0xLTc4MDQ5_c0cb6c46-bcc0-4994-83f7-0695c2106632"
      unitRef="usd">0</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMyLTEtMS0xLTc4MDQ5_d66a183d-358c-445c-a46f-832d2f22d922"
      unitRef="usd">411000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMyLTMtMS0xLTc4MDQ5_95c54c9e-8185-40d2-b4b0-e056214fbff1"
      unitRef="usd">807000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMyLTUtMS0xLTc4MDQ5_62754425-8187-4152-a322-ea2842d14764"
      unitRef="usd">2460000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMzLTEtMS0xLTc4MDQ5_817d2cb3-5bb4-4293-8142-6b5234d39cb0"
      unitRef="usd">-36000000</us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending>
    <us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMzLTMtMS0xLTc4MDQ5_c0bbccda-a8ce-42c2-87d6-b6f06ba6db27"
      unitRef="usd">-173000000</us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending>
    <us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzMzLTUtMS0xLTc4MDQ5_cacc91df-221c-4df9-b119-bff700e943d2"
      unitRef="usd">234000000</us-gaap:IncreaseDecreaseInCollateralHeldUnderSecuritiesLending>
    <elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM1LTEtMS0xLTc4MDQ5_4426a2c9-29b8-43e0-8e63-b6f65f998e0f"
      unitRef="usd">-47000000</elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet>
    <elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM1LTMtMS0xLTc4MDQ5_6fee94ad-172d-4bd5-b2eb-a85a17965fee"
      unitRef="usd">-77000000</elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet>
    <elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM1LTUtMS0xLTc4MDQ5_fbd72d4e-dff0-4be3-a104-afe7c036059e"
      unitRef="usd">-107000000</elv:PurchasesOfProceedsFromSaleOfPropertyEquipmentNet>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM2LTEtMS0xLTc4MDQ5_ba250d05-b06e-47be-bd17-65c972235bb9"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM2LTMtMS0xLTc4MDQ5_a357a81c-22e5-40e4-bacb-0823f66cd8b7"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM2LTUtMS0xLTc4MDQ5_0942f0ff-5111-43fe-8080-24d685fc08df"
      unitRef="usd">-11000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM3LTEtMS0xLTc4MDQ5_2f8d05ef-70b3-44b2-b9f5-b7cf46f95a0e"
      unitRef="usd">1329000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM3LTMtMS0xLTc4MDQ5_27b3cb56-837f-4f1b-ac07-aadeeed0f8ec"
      unitRef="usd">-1821000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM3LTUtMS0xLTc4MDQ5_a01758b3-39e3-4bb9-b303-62e69b3fdc00"
      unitRef="usd">-2926000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM5LTEtMS0xLTc4MDQ5_9ae48288-62e9-47ff-81ea-41fcc612e96f"
      unitRef="usd">-300000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM5LTMtMS0xLTc4MDQ5_e33cca3c-20e7-42e8-84ad-2e43834d5d24"
      unitRef="usd">50000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzM5LTUtMS0xLTc4MDQ5_6b42148d-5bd4-4edc-9c06-99755efaa9c7"
      unitRef="usd">-150000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQwLTEtMS0xLTc4MDQ5_17e8679a-3cc2-4150-aa50-487a084a8d6c"
      unitRef="usd">3071000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQwLTMtMS0xLTc4MDQ5_dd69607a-1d8e-4357-bb35-e66e367a5c72"
      unitRef="usd">3462000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQwLTUtMS0xLTc4MDQ5_9b5922a6-3041-4437-a95c-6a2452f9d0a9"
      unitRef="usd">2484000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQxLTEtMS0xLTc4MDQ5_5175cd13-6019-4943-863c-9b3663a8e936"
      unitRef="usd">1899000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQxLTMtMS0xLTc4MDQ5_0b61d92c-4624-4676-b46e-d5e5ee55eef3"
      unitRef="usd">1068000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQxLTUtMS0xLTc4MDQ5_516976ff-26ca-4553-ab79-c615b6a84016"
      unitRef="usd">1932000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:IncreaseDecreaseInSecuritiesLendingPayable
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQyLTEtMS0xLTc4MDQ5_9ec45033-15d6-4d62-8e76-b14a5d9b0feb"
      unitRef="usd">-36000000</us-gaap:IncreaseDecreaseInSecuritiesLendingPayable>
    <us-gaap:IncreaseDecreaseInSecuritiesLendingPayable
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQyLTMtMS0xLTc4MDQ5_16a0555c-4438-4681-8497-ace7b629b724"
      unitRef="usd">-173000000</us-gaap:IncreaseDecreaseInSecuritiesLendingPayable>
    <us-gaap:IncreaseDecreaseInSecuritiesLendingPayable
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQyLTUtMS0xLTc4MDQ5_b6fd8d52-539d-4558-afb7-78cf1bfb72cb"
      unitRef="usd">234000000</us-gaap:IncreaseDecreaseInSecuritiesLendingPayable>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ3LTEtMS0xLTc4MDQ5_eaf0665d-9c7c-45d2-a3cd-9beb3cd41f79"
      unitRef="usd">2316000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ3LTMtMS0xLTc4MDQ5_23dd8bc2-b822-44fb-b207-325d0ea48598"
      unitRef="usd">1900000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ3LTUtMS0xLTc4MDQ5_a4f0bb2e-e9c9-402c-bbe4-798c82c3d350"
      unitRef="usd">2700000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ5LTEtMS0xLTc4MDQ5_ef49660f-5a64-4e26-80c0-4170521ff13c"
      unitRef="usd">1290000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ5LTMtMS0xLTc4MDQ5_51667ac0-d500-4134-93ae-8403836ed05f"
      unitRef="usd">1158000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzQ5LTUtMS0xLTc4MDQ5_b6d332c3-bebe-48ec-a1f3-92b10771b301"
      unitRef="usd">1000000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUwLTEtMS0xLTc4MDQ5_4128e11a-f599-4adf-a8b4-795f8f9dec87"
      unitRef="usd">182000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUwLTMtMS0xLTc4MDQ5_b2544a17-a275-4b04-bc61-2ec3e1e1d3db"
      unitRef="usd">203000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUwLTUtMS0xLTc4MDQ5_d6637474-0443-4fbf-a4b0-a893fd31418d"
      unitRef="usd">176000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUxLTEtMS0xLTc4MDQ5_d327bf43-342c-4365-981b-c6c53b05cbe8"
      unitRef="usd">93000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUxLTMtMS0xLTc4MDQ5_b935296a-ed4a-48ad-96d7-ccdc202e87ca"
      unitRef="usd">102000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUxLTUtMS0xLTc4MDQ5_390096ad-e84b-42ca-a5bd-4ddbdb8bd076"
      unitRef="usd">128000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUyLTEtMS0xLTc4MDQ5_77660402-df75-4bc2-b7aa-98b858b7f45d"
      unitRef="usd">217000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUyLTMtMS0xLTc4MDQ5_f17474e7-4b8c-4fe1-b41a-88aaf31707b9"
      unitRef="usd">399000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUyLTUtMS0xLTc4MDQ5_3def8684-e7bc-4d4a-8939-deb978bac0d8"
      unitRef="usd">14000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUzLTEtMS0xLTc4MDQ5_9475bf80-1010-44d1-84b9-0f54bae41648"
      unitRef="usd">-2464000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUzLTMtMS0xLTc4MDQ5_7980582a-469f-4d01-8448-e7b4bb31e18e"
      unitRef="usd">-287000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzUzLTUtMS0xLTc4MDQ5_e85da6e2-361f-46ef-980d-db8550b3219d"
      unitRef="usd">-3002000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU0LTEtMS0xLTc4MDQ5_b701c7cd-8996-4e9e-91ef-3e0fb95825e0"
      unitRef="usd">312000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU0LTMtMS0xLTc4MDQ5_825fc44c-ee96-432b-b1d2-da7697ca8f1d"
      unitRef="usd">-70000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU0LTUtMS0xLTc4MDQ5_6a1bb649-d2f1-44cb-ba32-8e19b5be71e7"
      unitRef="usd">-1118000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU1LTEtMS0xLTc4MDQ5_5b5136ae-d035-4140-9f49-d6d645c7cd65"
      unitRef="usd">630000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaac9df3234b44acd9d0fc7e8d58b001f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU1LTMtMS0xLTc4MDQ5_6f79c065-5ece-4751-ba95-908c92088434"
      unitRef="usd">700000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida62205932654bdd82996ed0187717df_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU1LTUtMS0xLTc4MDQ5_f44fd90f-2411-4ffb-a7d4-627e801bf04e"
      unitRef="usd">1818000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU2LTEtMS0xLTc4MDQ5_703d7f91-f7f3-4346-8fbf-1173fd9209af"
      unitRef="usd">942000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU2LTMtMS0xLTc4MDQ5_cb4a17e2-fc68-4002-a120-68c4577eaf46"
      unitRef="usd">630000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaac9df3234b44acd9d0fc7e8d58b001f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yMzUvZnJhZzo0ODdlNDM5ODNhMWQ0YTdjOTQxYmY0NjBmZGEyMmE1ZS90YWJsZTpkZDVjMGMyYzhlZGM0YzAyYTI4ZmYyYTI3N2JhMzBlNi90YWJsZXJhbmdlOmRkNWMwYzJjOGVkYzRjMDJhMjhmZjJhMjc3YmEzMGU2XzU2LTUtMS0xLTc4MDQ5_82316d36-06aa-453f-a5a7-f6ffd3ccbecf"
      unitRef="usd">700000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashDividendsPaidToParentCompany
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzExMg_10084ff3-bf4d-40b5-bdc0-47485a20b084"
      unitRef="usd">3097000000</us-gaap:CashDividendsPaidToParentCompany>
    <us-gaap:CashDividendsPaidToParentCompany
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzExNg_242a285b-655f-477f-b515-e8f4f1d5ead8"
      unitRef="usd">3134000000</us-gaap:CashDividendsPaidToParentCompany>
    <us-gaap:CashDividendsPaidToParentCompany
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzEyMw_ce015193-3a22-40d9-b772-fc4181e24b86"
      unitRef="usd">3618000000</us-gaap:CashDividendsPaidToParentCompany>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzM1NA_a202b0d4-ff4e-4730-bec6-30c256e5556b"
      unitRef="usd">61000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzM1OA_d034e5e6-5fdc-4e92-a73a-c62aaaf1be67"
      unitRef="usd">54000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzM2NQ_b8435a51-2751-41d1-a57e-0b7bfebb452e"
      unitRef="usd">46000000</us-gaap:DividendsCommonStockCash>
    <elv:CapitalContributionToSubsidiaries
      contextRef="i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzQ3NQ_1e5aac7c-76ea-41eb-b714-270e0dcf925f"
      unitRef="usd">411000000</elv:CapitalContributionToSubsidiaries>
    <elv:CapitalContributionToSubsidiaries
      contextRef="i4274554137b941b8b61ab51e740d5503_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzQ3OQ_092abdf2-bf4c-4aeb-984a-52f5c7e9743a"
      unitRef="usd">3271000000</elv:CapitalContributionToSubsidiaries>
    <elv:CapitalContributionToSubsidiaries
      contextRef="i5e3f07d0dd694509af53bfd76d9cb592_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzQ4Ng_d82f85ac-b23f-40a8-a922-e53634a73fa7"
      unitRef="usd">2460000000</elv:CapitalContributionToSubsidiaries>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzYzMg_e589befb-9771-4080-9146-e9078d0377b6"
      unitRef="usd">789000000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzYzOQ_ef521d3c-403f-4aec-9d0e-81358a68aba6"
      unitRef="usd">446000000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i088d91ca9c3148788190accbb142e04e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzk5MQ_081ebfd0-82b6-479b-9470-8adf0f69eeb8"
      unitRef="usd">1500000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5ZGFlYzg3YzRjMzQ0YzhiMDQ1NGI4NGIxYTRmZTczL3NlYzowOWRhZWM4N2M0YzM0NGM4YjA0NTRiODRiMWE0ZmU3M18yNDQvZnJhZzpmZWZmY2UyMzEzMGY0N2Q4YTMzZGZiOWFkMTk4MWJlMy90ZXh0cmVnaW9uOmZlZmZjZTIzMTMwZjQ3ZDhhMzNkZmI5YWQxOTgxYmUzXzEyMzI_77185ec2-a353-42a7-b507-8185ae4179bc"
      unitRef="usd">550000000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>151
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (F%3U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " ")A4]6%7!6D>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>NG\&$E'7"]-.("$Q"<0M<KPMHFFCQ*C=VY.&K1."!^ 8^Y?/
MGR4WZ"0.GI[]X,BSH7 SV:X/$MU:')F=! AX)*M"'A-];.X';Q7'IS^ 4_BA
M#@154=R!)59:L8(9F+F%*-I&HT1/B@=_QFM<\.[3=PFF$:@C2ST'*/,21#M/
M=*>I:^ *F&%,WH;O NF%F*I_8E,'Q#DY!;.DQG',QSKEX@XEO#T]OJ1U,],'
M5CU2_!6,Y).CM;A,?JT?-KNM:*NBJK.BRLK;757*52U7]^^SZP^_J[ =M-F;
M?VQ\$6P;^'47[1=02P,$%     @ B85/5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"D_\P6$ _5O*ZM'4-Z P "4Q=5(F:$9([I$V(0>'F3.>*-%JUMX+DY)"APK
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MN+;KZK1=-:S:E ?6!V7Q^%M>YOB& MH%X/.54O:YX<[ S3M/\A]02P,$%
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MT4$: +Y?":&?%^8#S=0_^Q=02P,$%     @ B85/5M8GT80L"0  C2T  !@
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MGYN&."A@.4<*V$T!6RK@'8O@- 4<J<#0.U+ ;0JX4@';/E+ :PIX4@%G>*3
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MMR^/Y*?ZFO06#-27 *4%)[5'"(T906D$2J-0&D/11,6T?@,/MH^!K10+U'H
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M6-?+I:F, *0WIZFT#5PM.! \+C*9R\4=MV30:+7P3I<J-,BF[VK>;ZGE]GW
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M9HRGO6A>$.&:6A[ @!.I (HQZ!KI@WDOU']<&[CSV< !CM3 /%'J/-.&W6U
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M 4?@@3?@]Z5S;7KA _)'Y(O_ U!+ P04    " ")A4]6IM]3<?XH  #@A0
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M30_="[2E$YW:MNO:P+5D93AV!IL1"@>S5&FPFO6'2S01%M[U/3SIS]KN4_+
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M2&?N]O&'L3MB212RC=V!_[D/)=T5'J"_;[MNM!^P <^.!'BO_S]02P,$%
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MRO;%#RE+C4_W5-UDK6K<?WEU>7L1COQ%8 Y$G#5I7PCXICN$,AHS*HF^Z1>
MO.CTJ=P6-]TLJ/PK=UUK6@]G^9I#NAH2/+3?:!] W0M3OTH@3]YI?OT)+68J
MV&/LG:0WF?U03-8=*[(^]/4=$Z0K#0 _6]46$F!J-=M.'R,+)U'LV1/(4<Q4
MK'$H [6W"F5QV*%8\_N1 .VNZK!$W1? =Z@8<896BG:FQ<HDC9PYS()QWX A
M()N>$HB"#;Y;.3UX,Y$N84FL>,. =3'DZD!(Y',4O(&LN-3V!GX0-Y*ZC'!
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M$-$$C,^M+9L;VJ#]/G7^'U!+ P04    " ")A4]6*LK%N $$  "$"0  &0
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MRP'>7SBN*YN)*.A_O.;_ E!+ P04    " ")A4]60Y%D\-$0  !,+P  &0
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M,Y?P0L(WQ(ZKMMGSGMCEV./_C)F>]\LIN2*4!U]!=4P<-/M]/AE!H9,X880
MZA-FXWR="Z;)!&['M3&%L GLF$SA2N1)+W3!!-D H&Q&#H@342-1.D<O]KTH
MB\0$VF8-3(#T,O[ZM->E(3E]-L[<F0AN8CI]WMT08AG9>QIDJ?.V."3-D[5G
M4[Z2XL+/)WD=Y:1NS9"47=4/G+6I4+CJ(><PLLOO5=WT75.]K)B4KM#NZ I]
M%W54N6PM=2.6\O%)@@W$@Q)%S72P3\'TV&Q56=)Y*"AZT.R18Z %0>M2ZF\*
M!05EHB$"#QKK'2M@Y-=6D_->IN.:1=>3H=Q)V)[<CT*(Q( #[V[%5XA;H!5$
M\\D5^* RHG24TBR)AZ)5PLD+75HJL20'>KM&& ['PN@M%#3?L097>DD69Q>%
M0G2U**6KXCTZ0&7^IAHJG0771."#OA6CELV(W/5BWF8'K6MM"C:!J^NNL-%!
MUS,^X7KR'%P YQO%4Z1R%_!IY[70"=Y6"[E%R)%CY"C;2[>0VUW'YJ\M1?:.
M[M)@0AG@)9U;9SV]WN :.QU%@;6<.CR: A]RKGDSKL!L%:<)YPA>R\Y2DD*/
MO2^G3I86#%C%YLNQ<DX? 9F+L LQW%)D^XT!V][%Q)R&?;?BNT?2UYXXT5Q+
M.(9>+$!R8>KU.5*TS$<'*TM;VRK#MJ*? P:)&-N8KAL:P)'>-T9M<&, ,.$F
MO18&_7E+SH_ 5F[L (.6!+%0<J()?XYYC5P0J.J7^<$']+9U5ZB&)>AGLV",
M'+C?,5C0[4$8^RLS= (192$DW/V6_7T"XBFU*$D*A'<Q>:8HFLBW08K"\1M:
M2=\U?H>$@#4#Z'=VV*+<LF<\X^($Y73E:0D_X>0>WN."1L _*'(7;560$-,H
MX@8T0]*G"H,,<<H@*BKPW6<D&$HGI_=1=6$QIS$D_C1FDE,4SL$P[I/+U!1%
M:_D+91<06]:&"$ ]E6H&R;/+ZY07R!V=&14-1L]%$4OM-3;FT!FJC+7$2_CV
M18!#O',Y<\4LB]).DT-=3$D=6/91VA7K K'/Z3[+@)VC;G[A9,%!7'1)ARC,
M0 ^S Z5X,4- 50)Z"6#B##XU6*$0]A6EWU$24^N,<CJ*4=%_/*LOGB5PX0UI
MLD$&!EL#<B,W6 ,0DQJ]XA&54>GO+OGN_X?VZ41'O3OL_BG(Z?JI'CYXOBC7
MT?213):R V=C_DR/-_C:-=@Q2J@A&"5 UT#D #F?4!JT.93?UV<R^ 'BZ/0\
M(IP3,J(E@8[X0Q!=3APX>4KSCXRPW8E_W0_!TI$Y!IR<#5/D8N"0E2H+-V<!
MD$0Z.^#OMU*LB58XCJ"K#.Z'/I/('5$YNW443L>TB_0T2PZ"@M%19UI' EU6
M-(N!W_U5;[;1A*PTG/D,C.777+ /FY=&/;/PY@+3]3%/;B"+X&=ASV\:+N?N
M>DS3G#CDK@O=VWL_M*&2^8L#.!U.6<L*=:<#'@1%CKR$8LAK$MU%@Q#2M:4"
M@#J\EH]Z#2GQG=*L4=A#2(Q@W=8CI$*9<D?0L-0.SW1MSAYLX18.*.B(2JD"
MQ?P3/<U;:;7EL0T]?%C6L@RZO$6H '"7/8&@K/R&\"ZV +.0A>0X@9%4^H]5
M*^H-280&S/%D :?AJ_B/3LL-M\!\AR^^<* RVEZJBB9= , ;4Q=MKHYCS3V[
M(".Q**1G8%-=D05RZ-@RD_/6$K2TW >02 S9#VNP=",B2GI25/ULA^ V]X1P
MK;(%Y2506]MP'U#") WW /=BI&^.@>E ?E5MM:FY87V-I5BK&,_YF1UC5)Z@
M[=$DN(?."T5(UO6:B]:07ID *!3H* V;'@"85 .2M6W=)5EYJ$?FH!]5T=K&
M[&CS]H#30_C\FM:/#E>H#GKF5/,6#$==M8=1<G*C08(-!L@SP(ZR9(_ (=1.
M.P=Y"B<_P"FN(QH93P-Q'8Z#=.(>A%V'81"BEOPW5>FPW^#'8!I)8X'6'\;Y
MI2V6OHHR9=*_ZY:X==H'O'9S3+;)&C[6K7E8 6K*8;\$) TY<P9]Q:WX=S<;
MI55NE-L]>+,[?(<B=.ZTZ5VP2VO<Z?5)CU/00%GL-Q:&E7M##OLH]B0^GI$]
M!$$#I>V*< D_L=1-HQ0KA[BBYJI3[_Y0W-[2*P&>O;YGY6$)-Z6\%!0]9SM.
MPWY"@O8#V8#<"_UOX[)5CD7P:LD*<(XG?:9TKT;PB/;K4UST2<,>1.L"W4]M
M[$N"E814CVP'R/"PTOGJ. 1I!-#/B>EM"'<]<!',B^$%%0]E^@3(0E7<W-#C
M5/#+GM>W7"XL Q_$5 9X(N&\H>M#.:C9JDX#7-WVCNB2U(8R0]&/QFV[@$-K
M+Y!D=^.%U>[L\.&PT0Y<8ACPTTTVO$/P,$2OZKHX&HBHP11$7HAL*B+@1>T/
MI]"B8<MA1SV7B(V $Q""BJN(B[@YS$KVZ-HH+L5^ ,*3O+YK1[O*2B(JWDH^
MA_>^[4.DCQ"(?JMN@RZ"U)9.0'ALI)_P]%4SZ"I2M]:]OD,OFJB*W<TQF._@
M6[[E<D,8<SBPZ3SUAKD'IV"U(WU:4MTDPF5P(@6MDC[(L2B)=<00Z2X3]=%)
M:8AG-FNT?7LK#=RJ-Q!QR%.O-=EI/_JJ.'KZ"G6ZD;W@:"2&GX5&4K&J\#,5
M-PH[-O_0Z(-YQ([X>#"4G2I1T!0$>P>!Z7DQBE %I<@"*G7/MR1YK(,?1YQR
M0=*+X^R&DPH%6-;Q[0W+T$H5 2E+]J\HD ?R@Z'B=MA6#9&$\878$=Q*B-X"
MIFK[#<?;%EE&VD-?"#J+\WLD?/PMSS'\^QPE'+)D+ (B!,QJ9!R*Y >-S)K[
M=U/T>79HU#FDT59^ Y3L9>172 ZA2S_0.DLU\)X"*5W18.\X)&&58W>?D9GP
M/C$Z?,-U25*^H()0$K94!-JZ@9T;%$-5;>E2:+WI@"('P@KZ7@&<8A/W"-EK
M#Z%1Y)]]8$F/YNBCHL$JC?\+FIP-$RT+ADA&CH.>PO&?B84_YE!^Q\W9YZ$^
M&8@>9M$3E@I=<%AVJ-CW/066,XS?S\H00(R1P-KYV?B NP?""44/#%".-CC@
MD4=\2 ;7],9,XL%8D*;38ZXI2-N&$&@N-YH HL-_C Z[2$"/88I72*U'<C'0
M]"G3E2V!P(>*5WJSCQ?O1IWGT@,5]VS[#Y!NZH%F',TN2W;$LF$V8 KFX6GC
M#U$N1ZXTAOLU/^\'_T<L96GDY^EQ=,P2.U&A^)$V6)CO?.U&!\"IRK9S "0M
M>8K!S6&7H3V2I-YFV4*/-?*Q;)M5W;TG\#[/30N:I^.[[L[IZ(G[4MRYCA*O
MQFB<_I:G  Q3^VX>3>FEDYPL//F7W%%T[\:Y(0-(*+VE!P6V>T7.9Q&"C.BI
M"S;97)9.3?2Z)S6=>^/\@( ALWPV]=+(M64D>CCGY]/[%S'\F>12KC Q'CL=
ML9>>< ,+69G[VLY/3UP6OHX">GKLU!>$Z6]4X-=AYCYAT;\)R'DL^G.WQ)>>
M@VT#EJ$Z?L.$TJ#,5T_'V)$)CSB0EFLIS16>LV'_9B(/(3HSZF?-&# K#P=^
MA/7&-3C%<#:RZ]'@_MF&A]TT63GBW5?B.4C5"+R7\C\8Q-QV4GR]H&#3X9G!
M@[7-ID2+2A5V$ 9^<+Y[B5N?>Z'V;O"&\UJ9);_'35 ,;NA>=NZO]J^*OW=O
M2.^7N_?,_R'-DJ8PI5I@Z_@V2Z_<HZ/N1U-O^'UI](!-O>:O*^!E96@![B]J
M9$[_@P[H7Z!_]W]02P,$%     @ B85/5I>UZ4%F"   +1D  !D   !X;"]W
M;W)K<VAE971S+W-H965T,30N>&ULI5EM;]NV%OXKA)<-,9#:EFS'298$R$N#
M96B;HNE=,5S<#[1,VUPE42.I.-FOO\\A]>98=NL.B&-)Y#GG.>^'\OE*Z:]F
M*81ESTF<FHO.TMKLK-\WT5(DW/14)E*LS)5.N,6M7O1-I@6?.:(D[H>#P7$_
MX3+M7)Z[9Q_UY;G*;2Q3\5$SDR<)UR_7(E:KBT[0*1]\DHNEI0?]R_.,+\2C
ML/_)/FK<]2LN,YF(U$B5,BWF%YVKX.QZ1/O=AC^D6)G&-2--IDI]I9O[V45G
M0(!$+")+'#B^GL2-B&-B!!A_%SP[E4@B;%Z7W.^<[M!ERHVX4?$7.;/+B\Y)
MA\W$G.>Q_:16OXE"GS'QBU1LW'^V\GN/L3G*C55)00P$B4S]-W\N[- @.!EL
M(0@+@M#A]H(<REMN^>6Y5BNF:3>XT853U5$#G$S)*8]68U6"SE[>"BV?.%F&
MW<F4IY'D,;M/C=4Y3&_->=]""NWM1P7':\\QW,(Q"-E[E=JE86_3F9BM,^@#
M7H4Q+#%>ASLYWHJHQX;!$0L'8;B#W[#2>>CX#;^M<T-3QM,9^TW,%C)=L"L*
M%FFE,.Q6FBA6)M>"_?=JBNT(I/^UF<4+';4+I>0Z,QF/Q$4'V6.$?A*=RU]^
M"HX'O^Y0:52I--K%_8?<^.\XLB^"95HBDV7\PF3Z)(S%%[-+P>8J1K*3'>U+
M!A.J.1*E8C>OV,F:W1ENK-#$1',KF%GQS!RQ>6YA>+I0>L7UC$4(+?( 'F6Y
M=3Z+>!PSE5&2XRD2(N8:%\2A>":2J9@A%ALHO+O!4G-([Y$V/#:*"4)!6!2R
MS-!U*JPE5?A""^%57RUEM$1)FN618!&^)5!+\Y5-7U@F="(]!2B9 77LR,@*
M@)X:[NH19%Y9AM F<+H*;P<+%[A=";;D,XB)! #/O&9 !,.!U<%XXO8>!"='
MV&,RX>I;_$)WM&_&H(/*]3=-#R!E3788X4"^@+(+\D-I[YRDPAB*L..:)RHO
MDP9.0QR0Q#F7FCWQ.(=]&RB^A8#Q799@$AM,$50(E)L:4I]=\QC\!'MT'>R=
MBK@K]F\K2'<$Z0^"Q*X,O,$.WTD^E;&T+]T6H64!:**[WXQ,]@::/'OMYK'B
MSM\'+#@*PC%[@ DU($.:Z2MW$Q<RJ: <L"$^A\>#+ON@TC?+%HFWC3BM@A?)
M!6\\"6WE-!:%?"B9:^B"0(OH@@0$)TA96GQ?+C[6BR/VRT\G81#^VJK6F+W]
M.U]G5VBP59V27?G]X+.NOM]-'E0;;WSFLN!T$P0+A^SPM,ON?#U@P_%)VR9V
M&';98SZURB+"TH9U1X-!^\)PP Z#H,L^NY5F@2!WCN'.S94AP$Q <U4D 94(
MF/LP@'2TOP^(LG5&"&)X?'RZ&7'!OXRXD^^)M] %W'A[O+7)"]K\\+W!0,+*
M0 A@^F] ?!U#NT,A@*4GC5@8C5IV#;?'PO@D;%\(1R :;8N%T6#2LC*:@.9T
M,Q9"Q >0ML3",3GCI-NL3!0#PK74)4>1=$W(93R<_80.JW+3TA_K9DA!4=0&
MQEFFM"N"*.94_]<)Q7/FAQG:@-58I8LWV)  YM2RN59)$6BTW:R%FWO28Y^I
MQ:\]8QE_X524:,Z.XU)RW0[8TFO((7@JTFB);O/5!S/UFW?WUP^?J+_0C2M6
M6'N .BD-U>4  FF?(.U5OR)!.&T8BWY!6UJ$[M-=/F-B(;:;WOE3<,T>&I(^
ME,W0^[[.(D+)WCYG4OMN=$OW3JJ3N)EM?A%!-A[@?YD%X]X8J?,SN\*<%6.-
MD _#K>23<44YZ@6# (;,K-?:*SWY'M*P%P+$!_544#JIX>D6TL!!ID_8&^-_
M0Z2'.]A."-WHLY_  6'%WUX:HB%"!/[VI1H1#3[#WA!(?^=I3D%70!P6U>#5
M3+06C.5(X OUY[79N!RA5A!-4Y[2U.6+M$0V&Q7+F9MAIL60XXYY:Y-5E"=Y
M["<KG$TIE&=_X=#HJSIFYGVSX>S50'43HV;+N2S&*HP@7]SLZU)BQNYA1TJ@
M^S2*<T)_@X'ZQ1V@"EO,RZW5U,5N:LSUKE?IYEA4JM3\BP-&BQAZO"&JSKGZ
MZMUZP4-!#H^&HU/7I8\"3-74*M%>#FB.NN%FR>[@L)TEFJ/Q:.D/.N5!!2&@
M78%$:2P*:LL)!Z=]NW38U?0O/\$3$Q%+G/5]@:5%Z@&E3EB."-6<ZE5ID(HU
MI'GGPUO^\%2.W.D"Q7P)[[MXPZE'1C)S<81GQ ,3LQ=.O/R$4)1G![7';G/W
M^-4QQ>M1X-C(!1Q4)D@==U)!)KT^JC@LY S25LQ\;\E3RH9%*O\!.!R]?213
M7Q%44PDQV-54M3W*&)>->.%1D2247&[RB%2"(_B2WBS!W"3@R)W5*(KX,T"A
M'QR$*$$.=3@\W9TSZSJA.[DXV-A_Y(WL2D9M'5PA3/[QZ84:Z%M@*I[ADY6(
M@2_Q+U-*$VSJ:AH',#@,NFO!32,F8#7H*NATRK-,JV>W&:?V@V#80^5=KT3B
MN;"=&P7$?.XU2P7\8$E2NNBY0;+,T^9A9>,DZ>GIKCEH-2>BMH*'Y+'%61N4
MT$@EPEF 6+X(&@T%O5QJL[)+\L(W@VW=O3D(-_'?>U&/I?SZ1.E<6AUCW2RP
M!<)WG=X:DRJ-B(<4A<)TV8)C+G?)VWI01FT:=EO']7VX'([JZ?S0YPH9HGIC
MTMV+6S"LYO6]R ;5!+\/V?&H:+MHJ8-=?FB;L_8V-@SU([J-?DBU2:799)=B
M;2/5WHH%=03L%3GC[@^I5CL-I[*V]YW]QBOL1.B%>U%OD#(H3/YM=O6T^BW@
MRK\"K[?['Q+><[T@,+&8@W30FXP[3/N7\_[&JLR]$)\J:U7B+I>"HR;1!JS/
ME;+E#0FH?B&Y_#]02P,$%     @ B85/5OJ[Z)$X%@  LD\  !D   !X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULW5SK;]NXEO]7A-SBH@64Q)+MV$D?0-I.
M=[MH9XIV9NZ]6.P'6J)M3F710TI)??_Z/>?P(>KE.)W9^;! &^O!QWG^>$@>
MZL6]5%_UEO,J^K8K2OWR;%M5^YO+2YUM^8[I"[GG);Q92[5C%=RJS:7>*\YR
MJK0K+M/)Y.IRQT1Y]NH%/?ND7KV0=56(DG]2D:YW.Z8.KWDA[U^>)6?NP6>Q
MV5;XX/+5BSW;\"^\^F7_2<'=I6\E%SM>:B'+2/'UR[/;Y.;U#,M3@5\%O]?!
M=82<K*3\BC?O\Y=G$R2(%SRKL 4&/W?\#2\*; C(^-VV>>:[Q(KAM6O]'?$.
MO*R8YF]D\0^15]N79\NS*.=K5A?59WG_G]SR,\?V,EEH^AO=F[+3V5F4U;J2
M.UL9*-B)TORR;U8.087E9*1":BND1+?IB*A\RRKVZH62]Y'"TM :7A"K5!N(
M$R4JY4NEX*V >M6K=TRHZ%=6U/S%907MX=/+S-9];>JF(W63-/HHRVJKHQ_*
MG.?M!BZ!$$]-ZJAYG1YM\2W/+J)I$D?I)$V/M#?UW$VIO>F#W$5OA<X*J6O%
M=?3?MRM=*3"(_QEBVC0Y&VX2G>1&[UG&7YZ!%VBN[OC9J[__+;F:/#]"\,P3
M/#O6^@/J.%IWF+)  K=:\TI'K,RC0K"5*$0E0!B*9U*!^B)616LL?4>E11E5
M6QYELM2R$#FKH,2*%:S,>$3F!BTI> \O-E*)?]-K#7_KO315"W['BTBNH]_J
M? -^7$5,:YD):NI>5%LJ)<I]#6W56+62T8XSU!&^ E(:>BZB#]2<*1Y#4^A[
M( 'H]A"]N_WR.MK40":2!U 5<F*;1 H,]WEC"C$Q 8VM90'XI&]L-^^QFQOS
M$[W%C@2"B']MWA@1U"7+?P-/Y7D<_5Y+Y&ZO1,8U$2)RZ%=DK$#N46KP+!2_
M<,@$7JV^DE@K$DQ =H3B=Q)X[SN74$Q!659V^A5E5M2H4FC<$0S%*B)7KM T
MV*HP@L*NB+*0L ,\5K+>;$'_2LF55(PPE+1FZ$2:V,.TOH]^*8,>K;:)&(!?
MQ&9HKP3XQ[I__]LR31;/=;3BNHK@OP#8Y6A"]UC!=KQG"@0J]@SU>2_K(D?K
M05Z1?5%NQG@:)?;G+;<&@+5WO-K*G&P,AJH],F[LQA)_SU'IUEYS7G$%N$P6
M&UH=$,U9!@(LH!F\JUJ=L#_9&6^B-TQO(_Y[+: *FGK_"<H'9"B* [4D0,9
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M^5FDS!?BS$TE]_15MI6L*KFCRRT'=U98 -ZO)7!O;[ #_YF^5_\+4$L#!!0
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M8'QE4-B%!]J@_X^#B_\#4$L#!!0    ( (F%3U8J>+=$E@,  *,(   9
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;)56VX[;-A#]E8%J% D@6%=K[:UM
MP-Y-T0()8"1H^U#T@9;&%A%*5$AJM9NO[Y"R%>W&ZZ8/-B\S<^;,A:26G52?
M=8EHX+$2M5YYI3'-;1#HO,2*Z:ELL";)0:J*&5JJ8Z ;A:QP1I4(XC#,@HKQ
MVELOW=Y.K9>R-8+7N%.@VZIBZFF+0G8K+_+.&Q_YL31V(U@O&W;$3VC^:':*
M5L& 4O *:\UE#0H/*V\3W6Y3J^\4_N38Z=$<;"1[*3_;Q>_%R@LM(128&XO
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M#('&E33CC\7KU4HR2(F_QT4#B!1L -YLY,1=B3M)1#9$0";3$= ";-.46&(
MD9DD+ZO.3 6Z 4>V6U 3)XENB(=V0"RPH*5612-%70H9ZP*4U9@'@X#YMB7W
MQ1A;Z(BFIC2M)84T:BQNK6#Z4S?+?X$MZ@"PRBR'RUBOT91(H<5T(BTQIN[W
MO]N4(H=W6FLT7,74@'KI)I-52WE*PQL"6X+'XMW^.*E*H=LUA)5(HB+1,F76
MBO0*/#FEYH'BS$I;%4G6 -;L>CU&E;$N&]53#)J=1ZMJE666 %:F01*JKJ)\
MP<PW1[7(7W2TJ %,ZT=;4%_GQN(:#'16@U2B*^BB%%E9K#'!)@85V_AAQV2:
MFJ5"/Z5)SF53/$8)Y;V"X$A93!=GHON+?##( S[9+)TM$Q J\+8BN)-FT&VC
MMV5%@WV0L/$XV[/\./FC4<2GPSF'DTF)CIIL&0@#CGD93?-*4=1A58B?TC(:
MUIW)T[H::V(R+5(ZG?GK7^:!'ST7'<SF!0$S-QE8O-5EQ:S=QID".X6*Q06M
M*74,O.<WM[?<@;_ZSR^% GF' -[AU* 'XUQU!-V.SDP*S@!*O6G\!TQVQ.#7
M6DJ#&,<@+SH*>1W==0P.@R#4\"BQ.Y8VO*Y8 2W-;;R"U@G$'S)?XB:T$,R\
MM2+!,AX">4N/L1#K"GBAW5+&526-EE:*(%HK1,(*K@F-)92F?H!^@E7HCJQ&
M8J7N01%"3_JE_T@5I+RL%"M(Q"@>.2^C1/0;:W:9@4CP2>H>@RJKT%H:/+8N
M'AXK-Y8(P64R!FU5 Q^&K@4C=T[[ V('(:C*F[R=0$LV#2($4(]&F B+X0#+
MA0T='7Y;P"5*6%IBN+J&;P#[_B*:C" @4"(IB!075HU?OW_[X=KI,+=801?(
M3;B62^/:WUE-?J?+VL;\=FSC0TE"JF $T2GC&^N-,O34\3V863=9S'8[@J0:
M<E[)AE"+C1FXT(K)R+" FE05J2UIA"X_J52Z13XBP%:M\>.2T%$Q(++Y=6'4
MKB,,J+PC0=?QDAQ>JJHD U:Q#F%Q4_8/5E3.EMT<(RLV\D;)QCDR)N,4#& 6
M6250##*')>S9R&YH1N.O/S,?L+76.P78&$]#0][);$5R;(5BNA"_.3Q&$F<C
M\4DQ8=0\17<L0MNZ!'IHXU#:F,Q9]ICL/7'+:4$$L5A#U#<5XU"%K>C6/(_-
MZG3L'A3$56-I)J;MDL!UET7"X1W19<W<R;%< B/,$\5J8E:P>M:J9QMW_\JR
M:[_23H<^_,[=S>&H('0IUZI@),7DY#G$.6!S/EW@&HP\CZ[A)*3/Q0*&9AQ>
M0D$A U'P_.#JPRRMM^5VTP CB$A,#<!V%','&BRW@X$B^H/= <P5UNJ"0/\2
M 0$P^"*<!9?X#/$QG="=?PGRZCJS^'$1T:\+[_)@V)M=6 1[N9BAR<7,IR%F
M^)C,+X^("@#1$]+$GW:%%4565+2PR29&U%(Y[%K%BC9$Y$(H?" Q6,LFC?W6
ME7US?/3A!0Y&@3_CJS^G:QCYO,"^$3:%E' 3A7"NW(YV$4XA<S^:&'F%H<-D
MO;>0M-K[4O^JM3^]H!?!XO+X:@9S6DW<G13/_J)&4-6.@!8+*QY:U *P:T#[
M(([OX9G;\G$FI?H>MOL+4*+1FM##D@ZJ9F251@G1#A]S<6L; 5"60!5R[Y#&
M)?_O2[@S9J]Y2'*CA3[HL&,?@NNB&XCQ65#3J$-,7V153V9PG$U.@$H!$_-/
M>(JXB83S23I'>D&V?FEB,-X T(9K*67!R+DNU+_)K53<N2Q83;"8-.D6.[L2
MJ-^"*4'1]S$WEL,.E R)!$U@^V(607)T#:9TG?)"(8R@P-QM%\P.YD"^H9AW
M9;R4"'],+'$@[OUIYJ0)$Y9X5[(#CH1BM\_[[#O(Z)P0+F1?>4X@%^V18?)I
M_)S$,J* >6L"\.P!82LOQ4'[4>M=^S-NXO0SI#.8RGL*DO;L&%LM"JT>.Q"3
M?!R1\?4<LF2^O7VNWA9M!-?AI)T881OE)[Z5_E/#? OUI!]WG%N6Z=.8=J=K
MV8M<FLJ89^+"'0H6!R.2H5W MQK6#XA'6?5Y%SP=^W/Q1 3CR,,%WP+^-EG@
M\IX:@%6R>TQD8Z0"AA4CG W''G49O+R^WQK):CO$L*N;C:=SGM6C6?$MX@N\
M^Y-.=,-VS#L7&FPR#J8\T3PP%Z+4'T]GN'!,\ B0,LAPTKM4-2ZY&\8"Y;[X
M>^+U#E>C'Z&=4XQ&P0O!2-2142L;%P'X'KE6/YSP)SS%^PX.MYC($1H<*.01
M3#I.W#R :PCP;,%@=TP$P#9&MHO)@B\TUYX*]8+1\Q9&X<7YO\\BA9^^=XJU
M@/RD^<#,USGVGNK?;5R^'4+P"Q(#_4>7GV,F")F-8&(ND.(/C7;F91)+9@,Z
M@)B\CA9G8=-W[![)==-NA38Q55_")KMR'LQ'^)@9+ @6?3#@S6\&PW\*ZZ>\
MFM$HPB?)>360574%;':\79$^TNDR4+0YV94H&^V2U%^-1Z<G.XY*GS.+/@)9
MZ G&4&(R:-__.NAY).:T8!/1)1J'I\!FAS*=RYZ![',S,8"T6#!3B_!/Y<:"
MY6P\\Y@;[GN,&XN2WG@>,8ESWV(F*P/F,OO\Q"0%T;_6%+A37ZLDG!;A/38K
MB'1$<FNV7_GT9TX#H,5%O:&TATLS4E!I0^'L89>8(U5JN[@\P:7HIRDH*"*-
M/@R,]K?\'%3-(8<G/#+:A+;D$E,&/*5]5RH3*KT1-Y/Q%"UM.HJW)X$73L??
M62JX'A7+?T@D,V;T&T4"LBG_GK.'[(J!".U6C7A?WF[+&VBN')N]J=5;EVB*
M1:HH=ZU6BO*FZOY(7K63/"62Y?%$*T.H$57]L)76?;O>5!G@['(,RHE&/$7?
MNK2%@$P"MKE/$F\54-\Y)UKC^%[E\,%<*WD*$\N=43(<0OF;E)T#C<$FJZJ/
M1^"WCO6:-B% S&2W9=C+!O8L'?O;,'HR))OI_,FIO#.Q-7W"U3;*<1^5S%B\
MWA^[D^[>+9A=I!0!$70AZ:>_L9=2ZV)_.?*&\QTF[6VF-!Z'N>&*\YNCZWE(
M0ZU9P_ML[@H[R])EUUET3Y=Q\I&GVRF!@FF;-+3K9E**MDC]^_C#6*RI+%*8
MHL>OQ_7)$:4*D,0)"4ZY($SCI"RD0=$D$ $J#@<+-FBEV^I\KRH_X@),G@.Q
MJ6Y"\C([=E69*NZ)VD.O*$L9H )FM5';-IRPD4#G$;9!99:VI;&6/:[79 \V
MX6HRXY14KZ#O6$;)L;$-5;J"$*7*^.>U319P%7TL_@8>-;$^,O65(>):%P&7
M)65.J7.SA 2JD&NUPA#T8UE  &WYB&)VLCF;TUV;F=P48_%[04(T1?U<64JU
M-)M6:Q+#]'#,1_'V%OO$>\8\3'QNMN+GX7?:IG,UUJ2ZBU*0MK":F,1=(DF1
MC&H>:)T1Y1Y@N.VI[CN+=@?\2]G#%%LLW]GC?FV9I$85V+I,@&3OAF?; >[>
M \H>:1(^9-792YM#&[5<EYIW-'1$*Q7-MC0\M?#YKR9=YS895R;F;$:[\*K8
M-O6@_\4\N\EL3:;]7K6Q\1?R0L51NG.4/^S<A:-E2"-&%.O;^@C5^GJ>S.XJ
MS<F"G<;;1%[*-?&KE2YSL=3E1VCHR)9+:31*[YG$'Y-%6Y'0ELQV4^Z\=9+%
M*J\Z>YA>.8LG&>0;XUZ<^Q&5\7I1OKBH@%Z_E "":.1J2YP#_@?)N:TKL6O<
M5>-484XEF@."ZUBG;K/!J3+E-H)=P5X^$S_QU[?NNKMY*W[CO=FA*>[M.F""
MQ,^S0R?WS,!]!TFQ/9\O>GO=W1T]>7/HY?S)]#"YCM]^[GJ^<'&8C5P<]WS/
MQ-]:%]2=R_4-)E'O_K;U@$.-HVGO_KKK&@?:^_-I[_ZX!WR&B?LNR_7#WJ=S
M^[;C(,DU/'0<Y8'HIA/^-XM[S%9[J'(N9A&EZN?8 IV; 4:S(.+#)CMTWR$H
M51M.C4YEBMEBWM_M?9D614=T*!K4H($*7T][_,-J#W[Z:NT).W<G-:?;\'-:
MTVW[-1H3=.Y^4JOAJ&I?"D'D\?_;+K**'W[]2?A>^-0/$#\TG4*J[W5OC0X,
M0M\Y9=;PX7/=T>/ZR^S_UI_X_U%_,IG_2?XD6!SXDZ_ >/_;,'XV#X[8)ST9
ML-# FQSJ'G[K6>GD$.,GWX#QX6+:NS]MJ=&B=_\Y:P6Z=6Z_QEY];]:[_R*,
M!X7T_T48OPC))!<1E>*H<S#R%L%QC)]_#N.#D0_+_@:,][TC2H0'0SITJ$%]
M_0D&=&SR]?HSZ=R=U)UNP_^7*!^&<_Y_+,K[W=N3*!_R&02JRM#X=$)C+JZ/
M'AIRYSP8&,V).G>R=;]*:#<E^_L?<Y1IAVX6[EW-^$O*%/NG'G;VQW(U;/\7
MY?".C >E=PRY\Q0@MG>RDP\:D*TY^4S=<:%C)UAX?\UQ?=DF$/@,]49FJ3NW
MI>66:C]HQ3G*BX .&DWIH%$TO13O&IUL8JJQ["!M(3[$=*#NPJ>F_I1J2-$E
MO<"R1_XAER8@=&Y\@L4^(13_,4+AZA?O$L(@9*$$?X)09I=<Q/,Z\MCY@ZF3
MQX+$P8=QO,>(PQ]8SQ/B\!XC#HZY(PZ7%ES?G"V^OS@B*F?2.8]6&'YGD]**
M8]XYNS1_C$"\@;7\K9>8L5E3FX>JS+%PRK(T'"GM;#G]LG*C2<=[8_$K0DAW
M3L@=U*57G1 ;/I"18SJ&4!)@>SC('/N5?Y"4[<L=[K"O/>2;MH/%E(VDG#6?
M1S$GLOF<KDFI\/EF_-:"'2>[,1 =C $'35)S:<(&DV-Z!2F/J69A4_YY_%'R
M45<Z-HJMOG[8.WK6;%L:[="6D<[H!(&=P[V[0_YOO@(;1[1P%*QRL;Q/C%G7
M[E%@/NUK!'(@.U,4&(L?RSMZV6#D5EG&R<8YAB\N+N=4Q=B3[BGY6>$-E0CL
M>921.(],P$[7?@+RR!'"NMQSBF8XV!V]?T:+<X(B/M];<M*V/3?L*MP8V)P?
MM@?9G6[OWO0AC=]M)TR-:-=_H!HRL)FJ1O;<LI8K5L2V]&;'L[5U<TJ=$KE;
M37G$P\V'VTF8<(9*9(0)O/\+N98]P3=/A![=3Q%2S F+<#_#_8P/6WA!A/L0
M/H;NY^(IU<T",>4FGAAZR?"J\Q8HOW!"[[I2ZAQV85X(;7]M7Z>]-F^1[IJ;
M=W%_CC5 NH*NKM#5&T?3,Z'-^ZWF2UUN^9W295G79<ZW&PD=U-0 SU=E6;LO
M-$'[DO&K_P502P,$%     @ B85/5N18AEZI#0  -C,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C N>&ULU5MI<]M&$OTK4PHK95<A$FX"OJID.]GU5@YO
MG*.VMO;#$!R)B'%P,0,IS*_?UST#$))(6K2=V/M%A A,W_VFNP=\<MUV;_5*
M*2-^KZM&/SU9&;-^=':FBY6JI3YMUZK!G8NVJZ7!O]WEF5YW2BYY45V=A;Z?
MGM6R;$Z>/>'O7G?/GK2]J<I&O>Z$[NM:=IOGJFJOGYX$)\,7/Y:7*T-?G#U[
MLI:7ZHTR/Z]?=_CO;*2R+&O5Z+)M1*<NGIZ<!X^>Q_0\/_!+J:[UY%J0)HNV
M?4O_O%H^/?%)(%6IPA %B8\K]4)5%1&"&/]U-$]&EK1P>CU0_X9UARX+J=6+
MMOJU7)K5TY/L1"S5A>PK\V-[_7?E]$F(7M%6FO^*:_ML%)^(HM>FK=UB2%"7
MC?V4OSL[3!9D_IX%H5L0LMR6$4OY4AKY[$G77HN.G@8UNF!5>36$*QMRRAO3
MX6Z)=>;9=VI9%K(2+RI9UEJ\EANYJ-23,P/:],19X>@\MW3"/72"4'S7-F:E
MQ=?-4BUO$CB#4*-DX2#9\_ @Q9>J.!51X(G0#\,#]*)1TXCI14=I*OY]OM"F
M0W#\9Y?2EF2\FR0ES".]EH5Z>H*,T*J[4B?/OOPB2/W'!P2.1X'C0]2/<,U!
M.KNEW&.-<R1:T39%6962LZ:]$&:EQ$)=EDU3-I="-DNAFB5=+F0EFT)I 6P0
MM2-86()K2] 3BXW0ZA)I;,0#K93XOC4*+O7$EU]D8>@_?N-NOFHLPH IWPD>
M/_28,+'?*-D15[44" M5+U0WAH8HM9 D0P6 T8_$B[:N55>4D.5O[97J&B;_
M \ATXJ?6T-==J_5^@4=5H3LSGHG(R^(Y/G,O2.@SG&?X&T1>F(7BA2*Y[D_N
M01 ]% ^RAVR!('PL'H3!0_$] /C^-"!0%),X<<["D"AI()[W&LZ'<D5;+\J&
MK:G99>N^*U9 +R&7OP%5R"9:1%CGCV($4<12E$W1=]T=E6!9^AJVM!+XGI_.
M119X\SP1@9<DH0@@1AS$XG57PG'TF$8\+?MFB3@I$2@/@B2&[FGDDP42^I/F
M#YU;FOV\19A[>1 1MR E;C%8!T'H)7'",L-45B5I3%<N>L/1;-I;0M^FFGKA
M/!9SH@=;P(2^R#,OS^<W5+BU*O*B-!29YY/&60HYO-3W)TJ,PD#J-$K%//>2
M@*6.Z6G?2\#@D+\1Z:.G8R^ 1;$H#^'J/!=!XD7QNZ)N2@&<1Q^G[PC^Z;H9
M\\XIT,$=@3)C_C,K0?:G8L6]4C_X:U(_S&-\SKT4WH/RB/89^3R(DO=,_2B:
MY'Z<'I_[81:0/$@(D@:R^%E^;.X/ D3S1"")XM _(OG##.J'8NY[Z=Q'8*<1
M(,CW$>#^@>2/4\IXI%D8TF?*_\S]Z%X  'V1\VD.'AEQ!/ C5>?1_$/R/_82
M/Q1IZ(41Y7^,D,J@6I(>RO\0EL<BY#_R$KB1>1E2<U?ZSSEWTPP.FQ-$9H#L
MU,NSY-[9OP?G[Y_\!)JCKZ'>,>E_<-?[Y-GO_S79[T<$>0D@GI0?+#F#UU,8
MYW@ H/TOR"< 0&AP+ #X80*1$F3]0 ;B(-3>$P.". "29"*"KD> 0.QE@,8$
M&R;R 6F=92)+/#\_5   ;F" , TG%DBC^;T@ -F*[0C\TL0?^,5>G'P0! "!
ML$4GM(>S$CF@-0:\Y(<A( GG\  5(X,: *@\W D#,7(V$DGJS:EJ8199Z$7(
MQOO#P$[(/PH&@'"#J/%Q9<#!+?"\;GO2<O1:IRII\&E:L9Y8\ HMO[CHVAK?
MJJNR[76U$4J;LN:G@2(+0(FA($%24^X[H62G!%IL?JXBB#"F4LM3\>UTA4&0
M;\1:@>'R*Y*>5@&>3-GTLL(RXJFNP8B2H5-?;3E+DGWL/7#O4G8,6N@)^QNV
M87=Z BIU?=/VAG(3B0;^;YOVNCD5/ZW*F\1*SL2U[*P]2*NV*Y'/+!-D@+E+
M-._+$>A&0VQ.$1V7DF860CH;=VK==B0SP>.^--EC?W1^L*+U@'MRH4A-9U"F
M.3"J"$/,2C:WQ+4F(T75A/@VQ3<4-3/4]$*O8!$A%P#B^W5QT(V:4T[@9N3%
M$Q?$8@/[ETLKN)WDP$)6F7](N!BQ-1""WG>HGXKOID:Z&6T47]I&R5+I MAA
MHV(EKS@,ADX5*G5&&%E6GNM0Q?6J+%9P@&S87(;4W##%2]6HCFFRX->E696-
M,->J@D%J.REQ.V9M9<5VJLHKZY'NJBR45<^PJ=NK<JFZ4W%>%"U'9[7Q[&+Y
M&UQD-@,Q-O[$'S8:-%G%>7V,&\@#B\ ?TKF12FKK6[NGDBP619T ,-8PO1OX
MF>M6O"6=-6ZL[7[C#,?BM=H(75XVY07,#PPND0V%(8>V_22& =>B:8TUUI@"
M8QCH&S&D]P61ZPHHQ:E \)Q_R!\,*$C%2MEA(!XQ'>7;!<1I.\UZZ]WZ0'#D
M"B5VU2N4,4LJ57H#$?^P:5ZI*U4!&?JF-."B"27J\G>RT<+MR(05C;K _35*
M(0HT& 7?#JZ%H\IZT7=:<=4R4,1ME$V:HV*CC:H)U%#;Z'%CQZ[>7"H\:B.[
MQ-T&"FU&$O;[":$U-DA41^,MW2_J4O.4=;C%E%O *>M':6.Y.!0A*AR<BUWU
MQJGX52$&*,"*3G'^.C\2BQX&[)!$#<7LGB@8<6X;"<BMNYA!4MYI"D_%&\3N
M$O"C.<1MU.]3<I"1G[WK4XZ[%S_\\NKE5R@]#.GA*EM$C^0R:@PO ")GAHLH
M"PB5DB/TO\L>I^(;>=5VG'$OB7V[=A4$*<NAS77O.<6FNA7 V)$?9 D*RQEU
M57%HKY(<G\/SD_@?%CT(:!(3SJDJC;*A"INYN<QL;-!F0Y5&X# *N=P*R=T
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MYKF3YQV'@DK)6E1#@.6B2O_9X6[BBR0M264[K:F40="L;]B)<0695S&)!JA
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M/Z[%FM'._(C]Z+I>>/VQ)+4,5,UDI(9SWRHIB)([,D<ZY>T=1(  <Y6%0KE
MI3+:CFW GD2=UMR8;08<+?,YG+'I#5X=1#&T.G[%%_L*P;P([V;VB7[:+!T)
MMQHAPT9G.U$Y 8ST^!VAPU0+ !V"PG:30G4H K/SP#YY!2LBR1SLG@3B3L@
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M&\:-RP+-)[:SD63A<1U-'F'.401+(R::ESP&BR+KG@[O<]2$N2%(?M>B5I>
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M2H1Q@';\J\R.&%?KP1X>9(N^#]"OR)3B/:RR[P!CZX[S6L(+1Y/BT,Y.K$E
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MU^QL/]:*MMG3LZ=Z!TDFC#Q%(%.#G)U@N*QS@8AZI(7(5*IW3&QDPMG%5AM
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M#ZH%A,4+^'?)#K8^"+N#3YE)'@P81*1+&M?399<*OZ$5AK-O: ;DYZH:9,!
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M2M,T.^'?N:<-QVHQ6UL^*Q&L DD;&AUV-&TN+@9"6B0'UIPQ#WSOM+;#_/%
MH";:SX.:%!ZDY75!;CFAO8@2W&H"WO(A/W;NZ!Z<)RO4"W]J-@1/NTA]M-R]
MW1W,I_5Y=&]>G^H_<DW%8:#$.2V-+OJ] '1]4JX?K%KYT^E,63KK^MLE_7.!
MVAG0][E2=OO@'.S^79G\!U!+ P04    " ")A4]6RS(J8F($   !"@  &0
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MDR%,-_1&0^,%Z/]*4XKW"W_ \.I;_ =02P,$%     @ B85/5D%O%3?S!
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M\_2WBP3<V-''!=D^=M&5)>[)<=KR3Q!=,.#SQEK:+X*#Z;>Z_ =02P,$%
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MP8[=?M=/ZU\8>_X-M1[3ZB&M$B^1R[V>^$),PF VG^##8A;$X4B$DV#!WZ,
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M!HZ*A_H< $"P0ILVT)YCV9['$@\1B"A4DI8"55#T>%$ET!6Q&2H'O(T KL0
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MC<ENN/ZESD]<KNG+D$*L,-5>1,$)D_K7+_I-6V_5+TZ6==O6I;K=8.L@) W
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M\0 9I#L%<Q4!^1J(J0(MA@V8<P#A?$]OY6:BH5DF=H <3!AKVS;_A(4A;G:
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MW9>A*AQ5 /TORBT!%;=9G'/K:+G!BF$3FPUL9E4NS:D5 0 K!:V6B!<Z0'%
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M8U,!"80 K0-4%,8,[76Y"&S + .I7 (!)N# D<&@>$<8=-T"J :?-$O4KP1
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M*')VJ5)?PPBEYU6N+S.BQH(<V8I:V'"[$RIOX8J(6,[T<@07ZW32@@37H5+
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M4F80UJCPTNVD?81PQ71^# D] <ETQ01EI5T&.I?*G!A4!?!RA=H4;ND(PF%
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M'[CXDD/=5+!AI2<-+GA>RRQW-Q?\0Z=]P/% R-O%!<^:M(QX$Y YVN:" _P
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M7"X9A3T))\!X)(0N;]! ]7)V^A]02P,$%     @ B85/5FM(;6U5"   FAT
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M.13BCP)X^]6<,_XM_.(VZ$B>I#@UA9MZY;1#%7P21 M@DS3B:(M%']V)HF[
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MW%+3UZRS ]L9K;:]'1TK#E0:BO__2F!DJOW=T(^>>S"PE":C['G5*^+=8?7
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ME!C.T@;A,]XI"KJCE85</X-A5K!20@9H>R^+"C9AI_?AA W'5C$1Q\3>WV?
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M]& @;8=4^6X;A5O\G@Z_BX.<N-ZLJ^756]%S9"21YRK+%9"G/$QS&\,K6V$
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M)Z,9^Z5/3=R=O_GMXN6? +":]&C7;T1/:A:+/KS6=68RHXTH/$O)D3"$KLR
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MQ:&*WPTNP<?6: -ERP!*=5XT""*O9(OS/;-7XC<TCBXT_?=D*%V^\'NN=QS
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M$]G:3%X.-2[LA'MNB)N9K3W/!RC9%?:&<BON<BL^^/Z^8M*PL:S0/_@YN;<
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M"Y45H/VEI$/9+:R!_B$W^0]02P,$%     @ B85/5CQ<G*KD!   O0L  !D
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MMJ3Y&K4CH.^N>ZX/3L%F8I_^!U!+ P04    " ")A4]6?';%<]P"  !U!@
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MTKGTZWM(R;*==9SL(@]]L2B)',Z<.7.&UM&=5%_T3 A#[JNRUL>]F3'S@\%
MYS-1<?U6SD6--Q.I*FYPJZ8#/5>"C]VBJAPPWX\'%2_JWO#(/;M4PR.Y,&51
MBTM%]**JN'HX%:6\.^[1WO+!53&=&?M@,#R:\ZFX%N;W^:7"W:"S,BXJ4>M"
MUD2)R7'OA!Z<)G:^F_"Y$'=Z;4QL)",IO]B;\_%QS[<.B5+DQEK@N-R*,U&6
MUA#<^-K:['5;VH7KXZ7U#RYVQ#+B6IS)\H]B;&;'O;1'QF+"%Z6YDG>_B#:>
MR-K+9:G=+[EKY_H]DB^TD56[&!Y41=U<^7V+PTL6L'8!<WXW&SDOWW'#AT=*
MWA%E9\.:';A0W6HX5]0V*==&X6V!=69X+:: V)#SNDFP1:I_PT>ET/M' X,=
M[+Q!WEH[;:RQ)ZQ11BYD;6::O*_'8KQI8 #7.O_8TK]3MM/B.Y&_)0'U"/,9
MVV$OZ.(-G+W@F7BOQ%PJ4]13\M?)2!L%=OR]+=[&6KC=FJV8 SWGN3CNH22T
M4+>B-WSS$XW]PQV^AIVOX2[KPP]%S>N\X"6QJ26G#ZW7-CND#62;SSNM;O=Y
MM=78;C5Z0,%U6^D6,S"$F)D@#X(K383-,$%^1#42JLN1^Z6$UV,[\$FA"==8
M6J+\]0$YDU4EE-OI#:_FA^1Z+NR=>2"G"PU7M28?Y:U0M=NR>W;&%02DOKHG
MG^""(N_+ M7@^*K)C32P]R?<>LHK\FDN%'?Y5N)6U M!?B:+FD\F15EP@R5[
M)*1>G(089+&74I_0T,O</?-@ M<W/Z6,LD.,:!1Y<>QOM;IF<[E@>:6!%T6,
M4.KY&2-]%GIQ&.YWKU?6IE!3;)L% 0D\EB6$>FF<DB *N\FI%\+4.X$< K]&
MX8 YKRRM_VT>R F9*^BW KKVI?BZ*.8.U\>>+:])&FZ,=V!*7X)ID'JIGV&0
M(AJ:$<J\.(H<IA'PV\ TB+TL#+X;4^8E24P2+\Y\0.I[81P_"6F_E%KO8_,D
MLLCZ,06R,>+L9ZLUB1>FV:LC&R-_Z^,=R&[GU6-D8T1LD4VH%R4@E>\%:<-6
MBN VD 4JJ9]^-[(PS!+ E/D B$9>&-#GD8U3BM\P#(%L 'S[E*WE(\8S__6Q
M#=*-\0[MC3KMC79J[P7_!VIWJ>1XD=MNX?#2V]1VIYWM:GL#$:W<!O-V@S8A
MVFFLX/G,HF"U]EL9UC^FP]#/#2%VJNBFN-<OT>4+7N.<-B:YM=5ZKBT501$0
M9<_N'<6.@QD4--I<8&,O<H08@Z",1%Y"*7Y9%L/Y&@(^^%RXHUYGV?K>K:*@
M7\.I +\LH&TCH+:&$PIM3-H^\))06JUOY:FMI6U]9WO,Z! !X(.H11 U5"!-
MTR>B#?$F]'UBB[/Q;]LV;<MI5;(MZ57/NYQQ',[RAR>P82DJ-2;,E2AA%$:6
M\)S71DR5J^^9  :S-431UX!!AB84V72DR1)2SS(B]B/"$K]UNGG3^4MM6PJM
MZ+ (4ST?Z&^TY(V;KM-U^MS)26/]FS)8M=A58U@)V8[ZCKOZCG?6]Y7()0X\
M92M"GR9;SE9K&K<4 /A+;/6>(2Q9%F,'[+7!I2E-V#FO<UF);4JQTZ/M2G$"
M2#8<A2QLD00G?LDAD=\HO)%.*B"P"^N?516'>(=T4>?EPBH(1%PN%,G7(].K
MR+"R<)&]RC'PD?I<?4=(SY'C-_R3+>I;H8W+8>LTY".-K'PD*4F3Q,UR/0O_
M<UP'0X0UF73'8#PP:M&$WH\B?Q^1I82FK&7LAC.Q%V61<R;UXB!SSM@36[*+
MJ4G'U.0UF?K1=F.PM*$A^:!D9=F*=PO[NIUHJ_)4()-B.?&&WR.:\_K'Z;TS
MC%>FMSMS@-MM=D=-*.V=X?=$W,]%K<7_@][GSWF)4YR7Q.XTAU9JJ12CQ3W%
MY;XCLQ512V=<0>A]-[<A-.D[0N\_S6@0FO1!:&LC9?NN2R IIG,HC2A)LM3]
M!SAY=#B3KA44:-GUM+!IXM@41A/P/0S1B=&1?X4C=GMQ;].U*/3,!8#58S%:
M'>28G?VRZG<9WVO_]NRUA_2]]D"YK<P&:Q]%<!Z8ND\_&@2 $#;?1[JGW=>E
MD^:CRFIZ\VGJ@JNI58A23+#4?YO@S*>:SSW-C9%S]XEE)(V1E1NBVXZ%LA/P
M?B*E6=[8#;IO;L/_ %!+ P04    " ")A4]6 6GZ1IX"  #R!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,"YX;6R-E&UOTS 0Q[_**4@(I*E)TW:#T4;:
M.DV@J:Q:!;Q O'"3:V/-L8-]:3?$A^?L=%$WNFEO$C_<_?W[^^'&6V-O78E(
M<%<I[291252?QK'+2ZR$ZYD:-<^LC*T$<=>N8U=;%$5(JE2<)LEQ7 FIHVP<
MQN8V&YN&E-0XM^":JA+V_AR5V4ZB?O0P<"/7)?F!.!O78HT+I&_UW'(O[E0*
M6:%VTFBPN)I$9_W3\Y&/#P'?)6[=7AN\DZ4QM[[SI9A$B0="A3EY!<&_#4Y1
M*2_$&+]WFE&WI$_<;S^H7P;O[&4I'$Z-^B$+*B?1AP@*7(E&T8W9?L:=GP"8
M&^7"%[:[V"2"O'%DJETR$U12MW]QM]N'O81A^DQ"NDM( W>[4*"\$"2RL35;
ML#Z:U7PC6 W9#">U/Y0%69Z5G$?9M5T++?^(L$7O+I"$5.X]2%W(C2P:H1RW
M82:5X@ WCHG7])EQOM,_;_739_0O,._!H'\$:9*FCV1STVB2Z,"1('PB';.-
MSDO:>4G#6H-7>#F"*?,:)8O6FM %S"TZU-0.F!5<2BUT+H6"A4?@JT8.?IXM
M'5F^++\.F6T!AH<!_ ,Z=;7(<1+5?BV[P2A[^Z9_G'QZP=Z@LS=X23W[VE1+
MM!Z\VSH^&BH1KH1VPL%4TCT(?IIA<&JJ6NA[* P':D,0>.!OEWW(7TMP' C\
M>]YD@V0<;PY0#SOJX2NIVW/VS-M2YN4C2.E R9S?.A9 AA%UT>3$L:ZQ?$8(
M7(5L.#C'#@[=F)9_^!__Z!G^4<<_>@W_]0IF6,B<+\L,_8B#A=_/@G'V;O4A
MIE;_XQ[3\*0W>D(5[SUA7PUGPJ[9/2A<<5K2.V$5VU:8MD.F#J]Z:8AK1&B6
M7)31^@">7QE##QU?*+HRG_T#4$L#!!0    ( (F%3U9SDB7K$@L  !E2   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;,5<76_C-A;]*T2VNSL#.+$E
M^2.9S01(+$T[0+(33)KM0[$/C$3;[$BB2U+Y*/KC]Y)R+-/2T'%S%WE)))L\
M).\A+^\]E'7Z(.0WM6!,D\<B+]7'@X76RP_]ODH7K*#J2"Q9"=_,A"RHAELY
M[ZNE9#2SE8J\'PX&XWY!>7EP=FH_NY9GIZ+2.2_9M22J*@HJGRY8+AX^'@0'
MSQ]\Y?.%-A_TSTZ7=,YNF+Y=7DNXZZ]1,EZP4G%1$LEF'P_.@P_)\,14L"7^
MP]F#VK@F9BAW0GPS-Y^SCP<#TR.6LU0;" K_[MF4Y;E!@G[\O@(]6+=I*FY>
M/Z-_LH.'P=Q1Q:8B_X5G>O'QX/B 9&Q&JUQ_%0\_L=6 1@8O%;FR?\G#JNS@
M@*25TJ)8588>%+RL_]/'E2%>4B%<50BW*@3#[U2(5A6BEU88KBH,7UIAM*I@
MA]ZOQVX-%U--STZE>"#2E 8T<V&M;VN#O7AI)LJ-EO MAWKZ[((JKLB7&;F6
M3+%24TO?>9F1&SXO^8RGM-3D/$U%56I>SLFUR'G*F2+O8J8IS]5[<DAN;V+R
M[H?WY ?"2W+%\QQ U&E?0P=-,_UTU9F+NC/A=SH3A.1*E'JA2%)F+',!^C"R
M]?#"Y^%=A%[$F*5') IZ)!R$84>'IB^O'G14CU]>?=!1/7EQ]>#$8XQHS75D
M\2)TKG^]!"CR6;-"_;>+UKK=87>[QM=]4$N:LH\'2].RO&<'9__X6S >_*N+
M$DRP&!,L00)SR!NNR1OZT,^FUA<P2695F2E"@;64JD5SP7ZO^#W-@5=%@-:,
M+87BFL!> @Y]7N54"_D$EU!,LL(4ZV*R[L3(=L)L,O=GX>CXM'^_25"[3#")
MW#*Q=S#[VAT)S+'[:&WWD=?N-RRM)-=F%8!M,[,LM*2EHG:C4STBS3(B8D9F
ME$L"#%3,W(%C!I,S27/#QD+D&=%BJXQJL*%,+FC914G=OV"P:>^C0;A%RHM*
MQ=ZQ[DL+$IA#RWA-R]A+"[BP@E>%@@F=,ICW=SGK$9I#W$/+E-E9GXGJ3L^J
M'((1Z]$ZY_NX/9='VZ;M*#/<-JRWM_L:%@G,,>QD;=C)COF>SPZ-CV'9AFW5
M7S)NW=)XPW#C;5_2+C(:;)G6V]]]38L$YICV>&W:8Z]IO^@%DZ\VZG%K-DZ&
MPRVK'K<-/]RR?.SMZ[YF10)SS'JR-NN)UZPQF\$G&;E@)5QI<IW3LD?.<W"^
M)35I"+EB>B$R<JN8=<+GA9":_\'(CY!(D7>70JGW/1(SE4J^-%Z]R^S^/OS"
M8,.%!@L3)P'-A#TN(16R:TA7LC3^?0G](E0I!AMTI>Q& @53FJ=F<X:BZWUA
MHV2//"QXNC"S1D",]@=L%>F"EG/X#WTW .Z6LMD(%*!$/2D(V\ .*:0-90D3
M4-S#'[V0C)$G1J4Z(M![NESF3U \%5+R#.8B?" %A9;!8/398%6Y[D=F<KR*
M2@X;W!SL"%N8A"T,6@; 6W ?I@T(-Y]Q>F "TT*:5L5JO"7DP=\%,;UGCRE3
MR@PK&/S=_#/CG4,^K,TPZEM _ZVV]-V*?W&7\WD=VPJYPT14LO7HLF?+P$=P
M 6DR6-WDVH8J,VDY+%/3/SYC&I+EYQZ83!A6+WQ)E;5@L10EQ%?F>S/$)9-<
M9&#_YPZF0NFCKLC7.\?VC7PQP1(D,&=]!X,F1QUX5U=2+'/Q!/,50N#T&UE6
M$M: 8I;)WL:M- R!N8E:6&(-'7";KLA(8689+FVYSNQTT ZB!D<G6\[5W]E]
M:4)%2[#07*(VQ(3 2]1Y!@M'<VMEDY@45'YC-I4T_K!4W58/6CO:* BVC1ZT
M X7C[2VM"VD[>TG\0_BK)@H;$X7^P!4\DYF/UU+HE5AV/@/WD9F(@$S-O#U/
M-?F)T5POR.=25=+&!U#^GANO^HF92+<L*_"9X+H@3# N^H[9C&/E"9^L8_K1
M^+/2I'K&W8MJOK!N3RF;_5G'GN=D4;?$34M,*J*J.^-0S=?6=[)NTKRCW#?E
M7Z&-G3!\%&XGE:B-)EAH[D1HQ)C *Q=@381Z!BPISSII0E5F5F@N39/M>!VU
MS00+S66I45T"O^SRU8B<)KI,J#2!@"+OSC="&!-[IER_[[3]L&6M\&02;L?J
M7<4F@[9O0U54L-!<JS::2N 75;[ KDSMOG#)8.?ND<\%S&!I794)QSO-.6K9
M*6K9LETFB,;;EFP7:FE<B7\ ?]5 C;H1^.6-2U'.#TT^ 6G%G>XTQ[@]BNAX
MV I6.HJ%DU'+)JCZ!1:::[Q&P0C\$L;/0L/>:&- H[O!IO9/JX[JITY#MB6(
M:!P-)MN&["HV&+><'ZI:@87F&K+1*P*_8-%V?K]>L>*.R<Y# #_8WGL-)EJ,
MBI9@H;FT-'I'</)&YS@!9M(X146+4=$2+#3W5++):$-_1KN?BUJ!C79$$JMB
MNR*)+K3H>/NH(.DJ%HZB!LT=>I,CACMRQ&9>WFA($JG,%+E=9A!/V7/2P\&8
M_$FF=8AEU+MD-H/XN$>NK8YB$OGS3%B=K@=7OU5*V[CA3[*?N_)W<]^YCHH6
MHZ(E6&@NX4W&&X9OY*Y"U"04%2U&14NPT%P*FUPU].>JN\-1/\#>5+03S2C8
M=F.H:286FFO@)LT,_6DFY)%,2G!=/]-'JYS59T67G-[QW)X0]\B_19E64*CL
M)@ S/YR&[:3TL+6/H&:D6&@N 4U&&OHSTCTW9,QS].D*;7.G/6QI7ZA-)EAH
MKK6;]#;<D=Z:K-\^$P&)OQ3W]?,H_NT:,T.=HJ+%J&@)%IK+39,]AY.WVJXQ
M<^,I*EJ,BI9@H;D4-GE[Z,_;KZ58,JF?>O8L7-L-)0%GMC3+S)QT0ZLIKXFM
MS\8[%;<=K32+F&\N8B-<9\\M;!ZJVOAA=68J6:V?Y@:C\RS4W_C>]*+F_UAH
M+KU-_A_Z'S:XXB4OJF+M+B'UN:AXGMF4QW#]<J>*FN^CHL6H: D6FOO@;9/O
M1X,W<JH1YOGQ%!4M1D5+L-!<"AO=(O+K%CN<ZJUBYLFM2S[K/"_= 1Z,ZF=Q
M.CE!E190T1(L-)>31EJ(_(?I'9YP*HIE99X/6G-CF;H1,_U@MB:?._2WMO=:
M0M434-$2+#27MXT?(KS9+Q%P?XJ ^UL$W!\C_#\4BZA1+"*_8O%*=^@'CSS>
M$%-UB%'1$BPTEY)&PXC\&D:'-_Q<VJ=@\\-*,:)>Y -1I0U4M!@5+<%"<]EJ
M-)!H_%8^$%4J046+4=$2+#27PD8JB?P/&KS2!_K!?3X05?I 14NPT%Q*&NDC
M\HL25_01*3?V-[3W*D*5,U#1$BPTE[)&SHC>ZG&&"%7>0$6+4=$2+#3WIZF-
MO#'T/\[P.D>X SP:?-\3^JONRPDJ6H*%YG+2Z!5#OZ30X0E?DQO[6]MW+:&B
MQ:AH"1::RUNC:0S?ZG&)(:J\@8H6HZ(E6&@NA8V\,=SQ:/_KW*$?W*,4^FON
M30FJ7(&%YE*R\?8$OZ+0X0T_5;+DNC*_LU@_<-$X1J\O1'W6 A4M1D5+L-!<
MUAI%8SAZ*U^(*G.@HL6H: D6FDMA(W,,=[VHX56^T \^\?A"5-D"%2W!0G,I
M:62+H5]9Z/"%^^N$_C;V7D"HB@8J6H*%YK+5*!K#X[?R@:@*!RI:C(J68*&Y
M%#8*Q]#_P,8K?: ?//"EQZB2!2I:@H56<]+?> 5>P>3<OGM0$;LHZM?%K3]=
MO]_PW+[5;^OSB^!#7+^EL(&I7YIX1>7<O*(B9S. '!Q-8&.5]7L(ZQLMEO9%
M>W=":U'8RP6C&9.F 'P_$T(_WY@&UF^#//L?4$L#!!0    ( (F%3U;615V\
M6 ,  $ *   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*V636_;.!"&
M_PJA%D4*)-&'+<M.;0&.C6+W$&S0;'</BSW0TM@B2HDJ2=O)O]\AI:B*S#@Y
M[$7BQ\SPF5<CDO.CD#]4 :#)8\DKM? *K>L;WU=9 255UZ*&"F>V0I948U?N
M?%5+H+EU*KD?!<'$+RFKO'1NQ^YE.A=[S5D%]Y*H?5E2^70+7!P77N@]#WQC
MNT*; 3^=UW0'#Z"_U_<2>WX7)6<E5(J)BDC8+KQE>+,* ^-@+?YB<%2]-C&I
M;(3X83J_YPLO,$3 (=,F!,77 5; N8F$'#_;H%ZWIG'LMY^C?[7)8S(;JF E
M^-\LU\7"FWHDARW=<_U-''^#-J'8Q,L$5_9)CJUMX)%LK[0H6V<D*%G5O.EC
M*T3/(1R_XA"U#M%['4:MP\@FVI#9M-94TW0NQ9%(8XW13,-J8[TQ&U:9S_B@
M)<XR]-/I[5[AB%)DF?W<,\6,MHI<V)Z$G&A:[=B& Z%*@5:$5CGAC&X81U-0
MG\G%&C1E'%M7Y/O#FEQ\_$P^$E:1.\:Y"3;W-7*:U?RL9;IMF*)7F-:079-1
M>$FB((H<[JOWNX<OW7U4IY,HZB2*;+S16Q*M1+EA%6W*#W58&DGZPI%_EANE
M)9;FOZZLFV7&[F7,_WJC:IK!PL,?4H$\@)=^^A!.@B\N#?ZG8"\4&76*C,Y%
M3U=4%9<DPR<!3/Y .51M;:A"2'VE0998 P=0NC13+C6:)6*[A-EL#FF8!'/_
MT$_RU&8:3#N;%^SCCGU\EGV996)O:"5D@.BVMA%<Z (D_G%2(G!;[2[L)OJD
MAQ2-A]@.FUGLQHX[[/@L]KW$G5OJITNK>%U:R Z;BVK7B/XZ>'P"%0:S ;C+
M)G*#3SKPR5GP.\A91CG).&6EZC'7@K/LJ1 \-PG\VE)(39_,5W'E,#GANPJG
M\2 )AU&<A.XLDBZ+Y'U5T\(Y2J:7@@L].:6*AG7CL F3F9M\VI%/SY+_,2B0
M-S"G#H2AP Z;B1MRUD'.SD*N80NR.6X>WR*<G:X^B@:$#ILX?H4Q#'X=E<%9
MRC^%QD*N<,\?G(K.(RXXV;NB23+@=!A=A4$R /5[Q[NY6]U1N6-X2G/8HEMP
MG:"_;*XK34>+VI[X&Z'Q_F";!5[Q0!H#G-\*H9\[YA+171K3_P!02P,$%
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MX-?DP^_,Q=*T'L]KB8=-/-R9C*7I*?%,,_>MW?;,="R#G7("IF'[]H[]26U
MG$1&NZ.N]6RZMM^_,!]]JRYT3<#H@&\7@O,3\E@^@I9R,/+AV_7#2LAC.>BU
MU9_1 ]\N"%9&CD[61]^T==_:=\]-R?&I30.;SHWMG?LWO@/!<CY616\CIMU=
MQ[K&IH=C_\+$Q%:1Z)J $05L%X6S$Q,?*TE_V%(51DJP74ILS,3'PM#S1RT1
MC31@NS38J%F:GE+WIL-C^X?Y>9F)C[_EVS[EL>GAV-[#[WB2@ @IB1%A$5JD
MD(W5ZXE$M3KO6N>FM^/AI8EJ%8^N"1BMP':M.#]1CP5FT*)HV @,M@N,E:C'
M<M'#+<0)C& $=L&P$34X_FIOBV<Z?F#_:C\O4<M@]?_Q;_Y]"&[MBDH3<)U?
MQ$D=8\M4<5M5S5:7?>^+*RZSO+@I?"1"5X9$,:RTJ7<]U(%%<?E6/"B>YA=>
M2ZX43_+A!D@$(EN@WZ\X5X>'+$!U!3K[#E!+ P04    " ")A4]62;#@X#H&
M   N,@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6RU6UMOVS84_BN$
M5PPMD-8BY6OF&&C"= O0K$&\;@_%'A2;L85*HDO223KLQX^Z1#0EF;6RHY=$
MEW,^BI]X#L]G4K-'+K[*#6,*/<51(L]Z&Z6VI_V^7&Y8',AW?,L2?>>>BSA0
M^E2L^W(K6+#*G.*H3SQOU(^#,.G-9]FU&S&?\9V*PH3=""1W<1R([^<LXH]G
M/=Q[OG ;KC<JO="?S[;!FBV8^KR]$?JL7Z*LPI@E,N0)$NS^K/<>GU)_FCID
M%G^&[%'N':.T*W><?TU/KE9G/2]](A:QI4HA OWO@5VP*$J1]'-\*T![99NI
MX_[Q,_J'K/.Z,W>!9!<\^BM<J<U9;])#*W8?[")URQ]_8T6'ABG>DD<R^XL>
M"UNOAY8[J7A<..LGB,,D_Q\\%43L.0P&!QQ(X4".=? +!_]8AT'A,,B8R;N2
M\4 #%<QG@C\BD5IKM/0@(S/SUMT/D_2]+Y30=T/MI^;G.ZFO2(D^;548A_\$
MV=NX2D(5!ND;D>CU[X$0V?$;])HR%821?(/>HL\+BEZ_>H->H3!!UV$4:4<Y
MZRO]4"ET?UD\P'G^ .3  V""KGFB-A)=)BNVL@'ZNC=EE\ASE\Z)$Y&RY3OD
MXQ-$/$(:'NCB>'?<X$Z/=_<<O?'+%^1G>/Z+7]"7C]H 72D6R[^;^,_Q!\WX
M:5XYE=M@R<YZ.G%()AY8;_[S3WCD_=+$'208!0*S>!V4O Y<Z(97OL]K:'@]
MT2?+G1!LA99<JB9F\Q:&60MI@GV8^]-9_V&?K[J)'A>V#:W;C(9^:6/U;ECV
M;GA<[_9'S8D>-D6/+G2/3M!"!7K4L$0A?I_>XS%#7.B;L29\DR;W!_9\_<OE
MDTJOW$5,1^HN9B+#;!QQ[F=;Z"0?)NL3M&:)1HE0D*Q0L-+)+90JSS2(/>F)
M3;*F$=@E..T(W'J'H_(=CIRM7<;;B']G#/W!A&XB'Z!?KEE\QT0C[4ZXMH$.
M"4:!P"P:QR6-XXX3Z!B25T@P"@1F\3HI>9UTGD"=+;1E%A*,3FHY&4_'S3EY
M6A(V=1)VJXM=7:$VUDC36G-O*[/$A1.\;?> P"P>L&=J3L_)Q(W0ND6H[UG^
MO/RV"[?9)'05;X-09(?IC?=W^B]/LG-7VG,WUG84@:)1*#2;Z+WB'G><^XH&
MH,B%1*-0:#:YQ)!+.D^ 11.CO< ?5^*^,+'*PU&E@FR P=-)<[K"1GE@9P$^
M_[3-BKQDC3ZFB>O%\0DJ0$#1*!2:S;#1('C0=7PZ54YK<B'1*!2:3:Z10/A(
M#?1_XG-8"RQ_4 W0N@WV:Q%:-R+#0Q%J% )V2P2MU+006X:%%%EL67JL)]:R
M[\[ !!4,H&@4"LTFUF@&W+5HP*"J 12-0J'9Y!KA@+M7#D435CQYU<"LVV!O
M4@W,NI&/\8' -*4^=M?ZQP<F^A>U%OKNQEN/+5!E 85F__1KI 7Q.@Y< BHG
M0-$H%)I-KI$3Q%E1.Q5LX;H?1]5X=*.WYJ*+ZI^8ZI^XJ_^+0+"()[=/:,'6
M/ZR!W6"M!Q4D&H5"LXDT*H-TO<!!0 4&*!J%0K/)-0*#=+_*433AC.RZ":[,
MLPTF@^99EI@*G[@K_,,Q^))9U=U8ZV$$B4:AT&RBC<X@HZYC%%1K@*)1*#2;
M7*,UB+/<=L^JXQ_''J@T@$*SN3#2@+BEP2>U8>*X&15T[0 4C4*AV20:\4&F
M74<KJ,  1:-0:/9N#",P?/?:!<2,6C1A:<Y*5#>95&QH@PWV#VP<\$V1[[N+
M_.80?,F$ZFZH]<X34/4 A6:3;-2#3[K>U0.J*$#1*!2:3>[>CBGWNH5K0BU<
M]V.FMM+JAF]-1A<*P#<*P'<K@%_Y Q/Y(LU1/PJ[X5J/*] %!2@TFTHC-_QA
MUT$+*C% T2@4FDVND1B^>RD#9%X=U2?$436X1_7E5*\ZL=9MB#<\,+&:.M]W
MU_FN2'S1] JZP@"*1J'0;*J-C/ G74<JJ+P 1:-0:#:Y1E[X+]_'Y-<W,E7U
MJAN]-1>@:J"_MY$^9F*=?9 @=;[9)2K?@%Y>+3]Z>)]M]:]</\>G-/]TP<#D
M7U)<!V(=)A)%[%Y#>N_&FBN1?YR0GRB^S;;KWW&E>)P=;EBP8B(UT/?O.5?/
M)VD#Y2<B\_\ 4$L#!!0    ( (F%3U8/H@M%  @  '$V   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4W+GAM;+U;:V_;-A3]*X17#"U0U^+3=I<82-.F*]!@
M0=-V'XI]4&S&$:J')]%..NS'C[)=4^)KHJOT2^+'X=6]$G7.N11]<E^47ZL[
MS@5XR-*\.AW<";%Z.1I5\SN>Q=6+8L5S^<UM46:QD&_+Y:A:E3Q>; =EZ0A%
M$1ME<9(/9B?;SZ[*V4FQ%FF2\ZL25.LLB\MOKWA:W)\.X.#[!Q^2Y9VH/QC-
M3E;QDE]S\6EU5<IWHT.419+QO$J*')3\]G1P!E^>,U8/V"(^)_R^:KP&=2DW
M1?&U?O-N<3J(ZHQXRN>B#A'+?QM^SM.TCB3S^'L?=' X9CVP^?I[](MM\;*8
MF[CBYT7Z9[(0=Z>#R0 L^&V\3L6'XOYWOB^(UO'F15IM_X+[/38:@/FZ$D6V
M'RPSR))\]S]^V)^(Q@!(' /0?@#J.@#O!^!MH;O,MF6]CD4\.RF+>U#6:!FM
M?K$]-]O1LIHDKR_CM2CEMXD<)V;O\@VOA+PNH@)/S]=E*5^!LWP!WA?Y<OB1
MEQEH0)Z#LTV<I/%-RH?R+ ZOXY0_ T]?<R$_K9Z!(?AT_1H\??(,/ %)#BZ3
M-)77JCH9"9EJ?<#1?)_6JUU:R)'6:SY_ 3!\#E"$D&7X>??AL#U\)$_0X2RA
MPUE"VWCX?\\2^/)>?@?>"9Y5?]GJV@4B]D#U3?FR6L5S?CJ0=UW%RPT?S'[]
M!;+H-UN5/05KU8P/-6-?]-E%\L 7X#(6ZS(1W\ UG]<O$EY/@E3>_7$^YT#R
M"#@O^2(1<L)4U@N].PK='J4FE<UL.#T9;9IE6B#L &DE3P[)D^.2!U\N>7;#
M2^NU\\8,O78]!6N53P_ET[[F*^VSYIZ"M6IFAYJ9]Y*?%Y4 <CJ>944IDG_D
MY:\_L96\B\,:TPU-(TBU26E!,43']GDY/B0Y]B;YMI1W"?B42\5-MSF^E4IK
MO6W&QN''3,O0A$QP9,]O<LAO$I9??5=S:X(3X^A#A,<3+4<+"DZ0/<GI(<GI
M3V&FJ9F;SDP6B(.98*04-_*F_Z82B?0?LH2+."G!YSA=<ZM"1I89.(Z(EJ(5
M-IE.'6DVC '\00H%_\J9DM2%7 M93P7>%AM>YEO:Z<BX_AQ"Z:>O:.TSIDP"
M[,TEP%YM0E_1VG4KHP#]3J$[\^X#-><JI!'29[0%10AV3&AE":#?$W3GWGV@
MUBVEYVA"'-( E6A#KSZ&D.\^4IM7(ZPG:4--'&DJG85^H>V+?J&IL)%>@ _2
M3E\I,/1+<&?Z->45D@CJ&=I0V"%P4,DP].MP)_)MTNU*MEE%65-Q1^+U'C^8
M@'J*UCY;R@_ :6_$Z[46P77W%*W=E"HG@?Q.HCOQ(M,D3'1*LV 8M4]DI%P$
M\KN([J2[#]2ZD_0,30AQ)-CH[+WB&$*Z^T@M.M6[!AL&.G)4 HM^3BN.3&'5
M&=<+::>OA!?YA;<KXR*+INK]A 7#'(J&E/ BO_!V8ML+2:_),C_"Y/J/'KPF
M]!A--E+JCUAO2V%>'Q%<=T_1VG4KVX#\MB& :TU+@)%!9180=5A<I&P#"FS?
MW6QK-N9&BB;$87&14FKD;]U#V-;2>Q-]"<0&@H[3B)6N8K^N]K;T:2KJ4%==
M"\9!N%B)+O:+;E?"Q::>HK&^OF !8>*8"%C)+O;+;B?*W2TK/ >7ZSR9)RLY
M9;:(^O'$55&_F<<IN%[?+))-4C]7DM"/\</PS0//5L)+R?[L0JFIKVCM<]E8
MJ,=]43+V&HW@NGN*UJY;^0KL]Q7=*1F;KH'@B?$8PD31)G.WTU3N @>V]4Y2
MQF:_#HTD30R&+L90JH[]/7T +V.S)Q\BIOM@&\J9IA)A[!?AWHC95%_="'LA
M[?25/&._/'?F95-Y"23ZZHX%19ESNBJ)QD>NKC>9^;PH5T4I2^GJ@?T'#2:>
MQ^B[B?(').J+<(G7:00_4^PI6KMNY2N(WU=T)UQB:>;QV'#!-AB*B*.I)\I=
MD,"FWDFYQ.S7L9&EB6DN!+9S5*I-_$U] .42LRD?0@3UWM@&&SN:8])XDG[D
MH_1 SB6FNAJK)S:,:S(H_25^_>W*NL2BOH@B78"M,,P<30=1$DR.7%9O\NX'
M7B4+R3N)-+Z7\B9<QDL^?!7/OW9?^?6G$<Q(C]&5$V4(R+@W)O9:B^"Z>XK6
MKELY">)W$@%,;+H$-#66U6PH,G4\QB#*2Y# =M_-PV8C;]QX)H0XV(TJ*:?^
M5C^ A:FEF\=(;Y=M*.0XD50I+SWR87P@"5-3<'7CZX6TTU=Z3/UZW)6"J:FT
MB#'=^-I0U/5<DRI!ID>NLK>-;Y;Q<OX#_.O/(GC'U6.TX%29 TKZXE_:Z^ZZ
MOJ*UZV[LK_-[BN[\2TV[@"*J&Q\+"C+78V2J/ 4-;.N=_$O-?EVWP18(<NPR
MHDK :>"&. __FAWY$!J;XJPHQYXMJO26'OD\/I1_;;OF] J\F'8!2HFI7XD[
M,[ ILG!BV 4;BKEVZ# EQNS(=?<F _\A[KB\\>0L$8',ZS]Z* /U%:U]KI0C
M8+ OYF6];K+K*UJ[;F4EF-]*!&SSM;3V4S;6IK(%A::1X_D&4V:"!7;W3N9E
MEMUN.B58,,C1%S.EW2QP/YR;>IFE+T=$%P@[RI&FDEIVY,/Y0.IEIL3JUM<+
M::??V)7NE^"NQ+L/T_P1!!YCG7@M*,ML'35^#U3_&.LR+I=R]H&4W\IAT8NQ
M'%_N?M^T>R.*U?8G0C>%$$6V?7G'XP4O:X#\_K8HQ/<W]:^.#K\RF_T'4$L#
M!!0    ( (F%3U8#8._D:P@  .H\   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4X+GAM;+U;76_;.!;]*X1WL&B!IA8_)7<2 VTZG2W0;(-FVWD8S(-B,[90
M6?)(=))9S(\?RE9-BU^-*\HOB64?7MU+4?=<7AV=/Y35UWK)N0"/J[RH+T9+
M(=:OQN-ZMN2KM'Y9KGDA?[DKJU4JY&&U&-?KBJ?S[:!5/D91Q,:K-"M&T_/M
M=]?5]+S<B#PK^'4%ZLUJE59_O>%Y^7 Q@J-O7WS*%DO1?#&>GJ_3!;_AXO/Z
MNI)'X[V5>;;B19V5!:CXW<7H-7QU&:-FP!;Q)>,/]<%GT(1R6Y9?FX/W\XM1
MU'C$<SX3C8E4_KOGESS/&TO2CS];HZ/].9N!AY^_67^W#5X&<YO6_++,?\OF
M8GDQ2D9@SN_232X^E0__X6U M+$W*_-Z^Q<\M-AH!&:;6I2K=K#T8)45N__I
M8SL1!P,P=@Q [0#TU &X'8"W@>X\VX;U-A7I]+PJ'T#5H*6UYL-V;K:C9319
MT5S&&U')7S,Y3DS?%_>\%O*ZB!H\>[U85'R1"@[>I5D%OJ3YAH/7Q1S\6I5U
M#3X7<J'DV?_Y''QHCC_>@7?9HSRZ2L6FRL1?X(;/F@\9K\'[0HXTAER7==9<
MON?@V5LNTBROGX,SCY7?K_CJEE=_@)] 5H"K+,_EX/I\+&3H30#C61OFFUV8
MR!'F6SY["3!\ 5"$$/A\\Q8\^^DYJ/<GLEB\?+I%^%V+8WE9]M<&[:\-VIX"
M?_?:@-\_R-_ >\%7]1^VZ'>&B-U0DPI>U>MTQB]&\EZO>77/1]-__PNRZ&=;
MX(&,=6+&^YBQS_KTOYOF>H/R[F 5O  ?N%P[8ID6 ")P519B68.__9?OS>X\
M;'N>)IG=3^,X@>?C^\-031"FL0)U0B#[$(@WA%]JD<G\(E>TNHNL(=B\WIFF
M!P[)B<54<]M$)3&E=K?IWFWJ=7MWCV_4#9O+XQ<@/_1[Y?2;&AZ=P2C6I]N&
MPH[I9GN_V0^L&+5.RDJF+RZO1_7=)<.,U4 B%FDQF""6,'L(\3Z$^ =6C"T$
MF]>Q,:DQQ;'FM0F:)(X%D^R]3GYDP73<7KC=3FQK(=+]MJ"H8\%,]GY/O'Y_
M+K)FJF^$]*P&OY;WO"JV2=;".S;'O=:/S;6!C'4F D:*_*-0#--:"A1V*&O=
MN ^*'G@BEFE/U$D'>M:S8%QK&*K: 'IIN!_+M+8[.2,RW#9!DTGD\%OQ._03
M?#^::8UW\@'1,[0-!%T3KE@=^FD](,^T9^J4'8D>A(E!L2,&1?'0S_']B ::
M]$T(TOTV03!V\"-4' _])-^3:UKKG17!L.ZY!>2:<<7LT$_MA_2REEN7LFJH
MYVE$XS=]=,H-9*T[$:I8@$DPJO'6'4?''<A:-VY5;$!_M1&0:B9FUICH:]C$
M.#(V4D4"\I)Q/Z9I;7>81K_Q+!B7TXKAD9_A^]%,:[Q+,[K7)L;E]<&&WT_J
M 3FF/5.G,-$C,"$.ED2*WI&?WOLQ##*96]_Z6B NIQ6U(S^U]V079&['S_1B
MRH_I^JWH'/GI_)UDDVQ1_, >QF_XZ(91(&O=:5#% 6+!^F3>,N/HN -9Z\:M
M:@ODKRW"44M[HDXFH'I9;0,EB6,-J[H ^;L(_=C%; _ R/#; B+8X;?B=>3G
M]9X$,['URW3'+2#'?&/%YMC/Y@$IICU39T%,]'V,!<1<02AVQWYV[\<RV&1N
M:.QC+"#B2-A8\3OV\WM/HL'FCOP,ZZQN SDZ??B@*^^G]5VS[ 6XVA39+%M+
M[[<4TSP;NBZ;@UF:@YO-[3R[SYHG?!+ZO_3Q[)='OEH++Q/Y3WQL1@YEK3M-
MJI# )!0386])<G3<@:QUXU:%"/87(@&?VE SIV SJ9@HE+CN3E5'8'^3H1<5
M8;-[@!C4JU<+BF'B<%P5 O@[389>7(3-9P-GD.B->!MJXG!<D3_VDW](,DHL
MNV,C-YH@%Q>I0@#["X&>7&1R/*,&%YD@Z&BI$54($'\AT).+B+EI/X-0OU&M
M*(?GBOV)G_TORVI=5HU,X8F[';^]8W-M*&O=Z%4-08*I DA064 H:]VX50E"
M3J4,(+:G_E3?L5M0,"&NV^Y '#"D.L#L(L0)TK.<!84Q=#2GB")Y,J1 @%B>
M_5.B]R^M*$<3GBAB)R>3"!#S\3]"D=X;M*!(Y-AR$D7S9$B9 #$)'%-DK'H3
M15Q" :)XG@PJ%2 6%0!CQMJQH)"+;!2]$S^]?^)U-I?)-I,;G*NR$HMTP<_>
MI+.O3W^.XS_#T6EX",D 564##289H$$E Z&L=>-610<]E62 FG( B(DAE3)1
M!"'[:J:J>* #J@:HV5F Q-"FV5!HXA*G*?JG0^H&J$T28"0_*\JQR:&*\>G)
MA /4% 408Y-C 3$']] #<>"0R@%JTOHDT7<Y%A!Q;(VIHGXZJ'" 6C0!*-(?
M8-I0KAE7;$_];']9KE:\FO7@'?\)CLZ_0^@'J"HA:##]  VJ'PAEK1NWJC_H
MJ?0#U-0&$*JW>2P@%#MHAZFB@0TH(6!F#P%&1O:PH)A+=\04Z[,A903,(B.(
M]71M SF:4DSQ/#N9D("9*@&,] V/!<1<DZ\HGPVI)6 FF<=0WS-80! []IM,
M,3X;5$_ ;%H!X[&F#>5:-XKFF9_F/XJE7!*OZYJ+(\G&;_C8I!O*6G<:#EXI
M"*8H8$$5!:&L=>-6-0<[E:* F6*!.#&RA@FB+J$N4Y4"&U!1P,PF C(+/@L*
MQI$K;RBN9T-J"IA-4V!F:AO*L<>)%<'')U,5Q*9@P'P : %11X,S5F0?#ZDJ
MB"VJ@BC6I]^"<K778L7V\:"R@MBB&(#0>(/H";J"\<&+J,U;P%=IM<B*6J[@
M.SDH>AG+T=7NQ=K=@2C7VW=3;TLARM7VXY*G<UXU /G[75F*;P?-ZZ[[UYNG
M_P!02P,$%     @ B85/5H 7+!BH P  /0\  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&ULK9=?;^(X$,"_BI5;G5IIM_E#$D@7(K5PU58Z=-6BW7U8
M[8,) UA-8LXVT-ZGOW%(0TBR*8WZ G8\,YZ?)QG/#/=</,HU@")/29S*D;%6
M:G-MFC):0T+E%=] BBM++A*J<"I6IMP(H(M,*8E-Q[)\,Z$L-<)A]NQ!A$.^
M53%+X4$0N4T2*IYO(>;[D6$;+P^^LM5:Z0=F.-S0%<Q ?=L\")R9A94%2R"5
MC*=$P')DW-C78]O5"IG$=P9[61H3C3+G_%%/[A<CP](>00R1TB8H_NU@#'&L
M+:$?_^9&C6)/K5@>OUB_R^ 19DXEC'G\@RW4>F0,#+* )=W&ZBO??X$<R-/V
M(A[+[)?L<UG+(-%6*I[DRNA!PM+#/WW*#Z*D@*#-"DZNX)RKT,L5>AGHP;,,
M:T(5#8>"[XG0TFA-#[*SR;21AJ4ZC#,E<)6AG@KOTQU(A7%1DES<)%PH]A\L
MR)A+16[2!;FC3)#O--X"^6=)[M@3+DZIV@JFGLD,(CU@(#^2VV=42I7 N&QI
M7,A<DHL)*,IB>4D^_5Z?_)Q",@?Q"X6^S2;DXL,E^4!82J8LCC'<<F@JI-4^
MFU%.=GL@<WY#-H'HBO3LC\2Q'*=!?7R^NGVJ;N(9%P?M% ?M9/9ZKQXT^?DW
MKI%[!8G\U<1U,.0V&]+?];7<T A&!GZX$L0.C/#//VS?^MQ$^4[&3IA[!7.O
MS7HXP;<&8\B1]AFH(%R0&"2^+'])Q? 3A/+[U702!_->9EXGI%W8=ZRAN2L#
MMKK0$= M -U7 >E2@3@RJK7@V]6:+#$[94_>@'O8S"_C6H%7X6WUJ".O5_!Z
M9_(>\0IB!>E;@;T:\*!O]2K K2YU!/8+8/],X YT?HW.\]UJ.%OW[TC7+^CZ
MK7133/<KO*P_S6GTB#BRE,_/A>S7(%W/M2N0K6YTA!P4D(-6R)L=WCYT'@/!
MHH=(BH,CYRMP@QJ<X_<MMT(WJ&4IQQ\$02%UXG90N!UTRYVGEW23UT$]C3A^
MQ>?6S3M&Q+:.18?U'GGS==1\GQ-6=Q!48-N]Z4I;*K'L=\F:9^#:-=S LYTJ
M;JL[77&/A8[=6E,TY\PSV)P:F^]XU739OG=7MF-!8[=7-&T9\PS$7OU&L'K5
M^Z[=A:Z(QY+&;J]ICOD2^R0RT_ER]C9*MYX/ \NN1;)!# />KZ1-L]3;Z,9R
M2L6*I1*3X1+UK*L^&A"'7NTP47R3M3MSKK!YRH9K[&]!: %<7W*N7B:Z@RHZ
MYO!_4$L#!!0    ( (F%3U:\3LG<[P(  -4,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;*U776^;,!3]*Q:KID[:RE=(2$>0UF35*JU2U*S;P[0'
M!VZ"5<#4-DG[[V<#I=!0U*B\@ WW'-_C>X"+MZ?LCD<  CTD<<IG6B1$=J[K
M/(@@P?R,9I#*.QO*$BSDE&UUGC' 80%*8MTRC+&>8))JOE=<6S+?H[F(20I+
MAGB>))@]7D!,]S/-U)XNW)!M)-0%W?<RO(45B-MLR>1,KUE"DD#*"4T1@\U,
M^V:>STU+ 8J(WP3VO#%&2LJ:TCLUN0IGFJ$R@A@"H2BP/.U@#G&LF&0>]Q6I
M5J^I@,WQ$_ME(5Z*66,.<QK_(:&(9IJKH1 V.(_%#=W_@$J0H_@"&O/BB/9E
M[&2DH2#G@B856&:0D+0\XX=J(QH \S6 50&LMP+L"F 70LO,"ED+++#O,;I'
M3$5+-C4H]J9 2S4D565<"2;O$HD3_E6Z RYD701'I_.<,3E"W^]S(A[1"H*<
M$4& ?T*G"Q"8Q'+T!=VN%NCTY!,Z021%UR2.93VXIPN9CB+5@VKIBW)IZY6E
M%Q"<(=O\C"S#LCK@\[?#S39<EYM0[X15[X15\-FO\!V(1G]_RA!T)2#A_[KD
ME7RC;C[U_)WS# <PT^0#QH'M0/,_?C#'QM<NL0.1M:3;M72[C_U0>I?:DL(I
M*-3+8>=/'=O3=TT1AS&FZYIU4"NY49W<J#^YAR#"Z1;0+X9#"-%EGH:R-M>0
MK(%UUJ67[]BZ#$36DN[4TIV!+>D,*7T@LI;T<2U]_'Y+EA3CAMU<]29I6?(P
MQIPX1K<E)W5RD][DYC1)Y">HHSP]KNRE/+8T Y&UU+NU>G=@5[I#2A^(K"5]
M6DN?OM^5TP/'C5Z^)SM"K&Y+FL;SA]SHS6W)R X+.-*5_:3'UF8HMO86-'H9
M<V!G5H1#R1^(K2W_N8$Q>YN$M[FSXFA^HUWWA3V[8J8O_*DW>D[5\%]CMB4I
M1S%L),@XFT@T*WOH<B)H5K2A:RID4UL,(_G? 4P%R/L;2L731'6V]9^,_Q]0
M2P,$%     @ B85/5MNGQ+3_ P  B14  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C$N>&ULK5A=;]LV%/TKA%8,";!&HB3;<F8;:,P6#3"O08-N#\4>&/G:
MUBJ)+DG;Z;\?*2GZCF:C?+$IZ=PCGD-=ZNK.3HQ_$SL B9Z3.!5S:R?E_M:V
M1;B#A(H;MH=47=DPGE"I#OG6%GL.=)T%);'M.L[83FB46HM9=NZ!+V;L(.,H
MA0>.Q"%)*/]Q!S$[S2ULO9SX'&UW4I^P%[,]W<(CR"_[!ZZ.[))E'260BHBE
MB,-F;KW#MP0'.B!#_!7!2=3&2$MY8NR;/KA?SRU'SPAB"*6FH.KO"$N(8\VD
MYO&](+7*>^K ^OB%_4,F7HEYH@*6+/X[6LO=W HLM(8-/<3R,SM]A$+02/.%
M+!;9+SH56,="X4%(EA3!:@9)E.;_]+DPHA: QZ\$N$6 VP[P7PGPB@#OW "_
M"/ S9W(IF0^$2KJ8<79"7*,5FQYD9F;12GZ4ZG5_E%Q=C52<7-RG1Q!2+:04
MZ&I%_V4<+:F$+>,1"/1I@_Y4SUX%4L.0)7"-K@A(&L7B&KU%7QX)NGISC=Z@
M*$6K*([5@HJ9+=7T]$WLL)C*73X5]Y6I8!>M6"IW KU/U[!N$MA*5RG.?1%W
MYPXR$@AOD(=_0Z[CNCT36IX?CGO"R?GASH :KUPJ+^/S_G>IBE5 7_]0$'0O
M(1'_]/F=\_G]?'I'N15[&L+<4EN& 'X$:_'K+WCL_-[GE4DR8HBLX:-?^N@/
ML==]C#(?^ZS+*489A=X[CPL\<H.9?:Q;T@/R\;0)(EW0%(]*3$/!J%0P.E<!
M/*LW@.B5D'.,:S=^ZWLM!7T8W!+0@_&"?@'C4L!X4(#>5*)SEF'<N3?V@U%+
M1 _(F[36BG1!P632KV)2JI@,JO@0/<,:K:@\\$C^0(\0ZH'>-[^N('D"WIN4
M@YR7)J5),F*(K.%E4'H9&-[< I,^FB0CAL@:/DY+'Z<_O[E-.[DPG;2R?MG%
M3$:MQ",]&/>5K0T[54'B#"IX__UP038-DUWZ&!AE(Z;8FD;6*CML.*4*0E-F
MFF0CIMB:9KJ5F>[/YU7!44\(OUTS]&%:;V72@ZGE9U-!53WBP:)JL:1BAW1R
M'6F<E?N#:66T=#3*1DRQ-7VLJD?LFTZKP7KT8C--LA%3;$TSJT(6GUW)#J15
MMP*ME6Z%*UU,^VW5 W%?J6-Q5<CBX4KVD]P!1_6OZ,&T&B2[^$DPR49,L36-
MK&II/#&=5D8K::-LQ!1;T\RJF,:#->:9:15TODQ]SVWG51<TQN-V9G5!T_;[
MRJ[UJ!+@VZS7)U#(#JG,.SKEV;*?^"[KHK7.W^D^8];[JFCR)N6*\FV4"A3#
M1E$Z-Q,U(9[W_?(#R?99)^R)2<F2;+@#N@:N >KZAC'Y<J!O4'9?%_\!4$L#
M!!0    ( (F%3U:PU@#LLP0  -X7   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8R+GAM;*U876^C.!3]*Q8[6K72MF!#2-)-D*9E/BI-=JJINOLPV@=*G 0-
MX(SM))W]]6M#PH=Q2"+YI35P[HG/M>_EX,F.T!]LA3$';UF:LZFUXGQ]9]LL
M7N$L8K=DC7/Q9$%H%G%Q29<V6U,<S8N@++61X_AV%B6Y%4R*>T\TF) -3Y,<
M/U' -ED6T5_W."6[J06MPXUOR7+%Y0T[F*RC)7[&_&7]1,657;',DPSG+"$Y
MH'@QM=[#NQ 5 07B[P3O6&,,I)170G[(B\?YU'+DC'"*8RXI(O%OBQ]PFDHF
M,8^?>U*K^DT9V!P?V#\6XH68UXCA!Y+^D\SY:FJ-+##'BVB3\F]D]QGO!0TD
M7TQ25OP%NSW6L4"\89QD^V Q@RS)R__1VSX1C0#H'PE ^P"D!GA' MQ]@'MN
M@+</\(K,E%**/(01CX())3M )5JPR4&1S"):R$]RN>[/G(JGB8CCP6.^Q8R+
MA>0,7/TE]MDGL5>8_84PAAGXFH,&X!I<A9A'22I&-^#E.017[Z[!.Y#D8):D
MJ5A&-K&YF)2DMN/]!.[+": C$X (S$C.5PQ\R.=XWB:PA9I*$CI(ND>]C"&.
M;X$+_P#(04@SH8?SPZ$F/#P_W.E1XU8+Y!9\[LD% M^_B&?@D>.,_:M+=$GD
MZ8ED [ECZRC&4TMT"(;I%EO![[]!W_E3ER239*$ALE8"O2J!7A][(#?U55KL
MYVNPE+L;B'Z3U-M:E\J2<E!0RM:Y#6Y\5RSGMIFB+LB%L(T)NQ@X\BI,2]"@
M$C3H%?0Q><-S,(OXAB;\%WC&L1PDHER_SW#VBJEV<_1R7KHY3)*%ALA:N?2K
M7/JFJLLWF4"39*$ALE8"AU4"A[V;\1,5E24,0)0F_XE=6=;7@I(,L"C%VMHJ
M"?U&20R04EE="!PJU1?J, -]98TJ,:-+Q)1-XX2:46<:-YX_5O3H0)ZB1X.!
MSA%!XTK0N%?08[:.$EIL[ZH%4AR3+::R7\CA,B^T)K(EQB3#.HWC[M1<I=$]
M=#%J*]2P#/7RH%.[%^=D<U<VGVCNBZ)#9H<.R:H.J;4GCFYQ1HH\#0JBH:)0
M _+=(Q(;!@WV2OSP<W-!F^\GN[1-&64+3;&U$XGJ1")3O7[/9"J+)ME"4VSM
M+-9V%/::M> E5^JMU5C4;B*K$9<;^$05NIKNT"G"+@BI)=B%0/=8#=86$I[V
MD)5LQ4PV9.O$ D;2N5:QIVOXZIM0AQJZJN@NR(='--<N$_;;3+UO/F\Q!QII
M(]4^ZU!#]:6A <'Q$0,-:]<'>SU1\)6O,&U^VO;W5*/6SRA;:(JMG<C:_<&A
ML9[::R0OSJ))MM 46SN+M>V$_;[3D$V#&@OI>FK5Z7RFKU:=!C0^UE%J,PK[
MW6AIKQN?"*0HPQ.?XK#K&\>^*JJ+0>-.E]18U)%>$ZH-*.HWH*6FYI?"6:*0
MQG3ZZE+I0$A]X6E SA%1M>5$_993W_K/$P:[)R?J.TV#08.!JDM#-%1?Y';C
MX#/#=%D<(#,0DTW.RP/#ZFYU2/V^.)I5[M_#N[ \:JYIRI/O6427,@$I7@A*
MYW8H9D3+P^3R@I-U<;SZ2C@G63%<X6B.J02(YPM"^.%"_D!UI!_\#U!+ P04
M    " ")A4]6M,$I5-4%   K(P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6RU6EUOVS84_2N$5PP)D,8B_9G,,9!$2U>@Z8)DZ1Z*/3#2M4U$$EV2
M<AI@/WZDK$B6S+*.Q[S8^K@\Y#WDO3RD.'GBXE$N !3ZGB:9/.LLE%J>=KLR
M6D!*Y3%?0J;?S+A(J=*W8MZ52P$T+@JE29<$P;";4I9UII/BV8V83GBN$I;!
MC4 R3U,JGB\@X4]G'=QY>7#+Y@ME'G2GDR6=PQVH^^6-T'?="B5F*622\0P)
MF)UUSO%I2,:F0&'QA<&3W+A&QI4'SA_-S<?XK!.8%D$"D3(05/^MX!*2Q"#I
M=GPK03M5G:;@YO4+^E7AO';F@4JXY,G?+%:+L\ZX@V*8T3Q1M_SI#R@=&AB\
MB">R^$5/I6W005$N%4_+PKH%*<O6__1[2<1& 4)^4("4!<BN!7IE@=ZN!?IE
M@7[!S-J5@H>0*CJ="/Z$A+'6:.:B(+,HK=UGF>GW.R7T6Z;+J>G'; 52Z8Y4
M$AU\ID)0TP^'Z" $15DB#]$[Q#)TS9)$=Y.<=)6NU!3M1F4%%^L*R \JP 1=
M\TPM)/H]BR%N G1U:ZLFDY<F7Q G8@C1,>KA(T0"0M#]78@.WAU:&G:Y.PQV
MP(2[PP1VF(:7O:IC>@5N[Z<=@[Y^TN_01P6I_,?6 6N@OAW()(Y3N:01G'5T
M9I @5M"9_OH+'@:_V4CS"19Z FL0V*\([+O0IY_S] $$XC,T8]\AUD&C<L'4
MLQ[.]9!7"ZI0S&*4<866@L=Y!-H@XBG8F%[7."QJ-!EU-1U/NJM-^K8M2-,B
M=+9Z3TX&%2<#)R=W$!D.&$BD<VX,2RZ90KD.3*&3^#Q/J.+B65]^RYF @B(;
M#>M*!AM.C@8M-R^W;8:]-A7.QNY)Q;"B8NBDXCR*1*Z'13T:'/T^W.[5_J#E
ML,4F:-F$SB;MZ?"H<GBT:]]_XC2#^ A=42;0%YKD8,)$3YVZ_T'0Q$;!:*L_
M-06C%@<6(SQHD^!LYIXDC"L2QKN2D$ 6LVR.E*"9I(4*D4?(S'^\2!J&F]4+
M-U'%C0F<!4]BI'C+1C:"*]$<VWA<MP\'&QSAXZ =/3M9A4Y?]V3RI&+RQ,GD
M59%4KU^2:DWL$3I/M)JDF<ZD6I>B2P&Q3C*?N+3FDI.M(?/^I$6&Q6388L+9
MUCV9P$&MH8+]N$!?K\',0M9IVPWZVGG;*UKH"ZU)Z(8HQ;[$3XGDBT6?:*$O
MM":+I&:1.(?EC> 10&P7[61[NB)!ORUG+&8X& S;*;TTVPQ1C#&I\U73@UH#
M8Z="])9DRFJ&KBQCLVFG&7=S]^W06M%BMZ3]:\%$C)94-%6LU6-/,K/DQB=:
MZ NMR6*M@?' 6W+QI%!+%GVBA;[0FBS6\AF[]?-5KH,24$273&E5%-$DT;I'
M;.II_I"P.54_W#?85LQX$/3;86FS&HS;@?D6RAK7TAJ[M?6MUH;%&A+LGGJ2
MO"4C/M%"7VA-YFH]CL?>@M&3W"U9](D6^D)KLEAK<?P3,?[_@_%D.\S&[26N
MQ:A'3MJA^!9:G-1:G+BU>"46_ER!R,RN;R7"T;_HDLJ%4Y2[T5\[R+RBA;[0
MFLS6HIQX$^7$JRCWBA;Z0FNR6(MRXA;E]2X+$A !6^F)PRC8C=V#I-R>H4I'
MLA#/9I>BV&6P4FT3\@2W(M=BA<>CUEP;NIN^+S6UVB=NM>\.W?N,F4GV3FGV
M)/K C4TQ&'=<;KLK?_68]+I/[@NM27R]KB!];Y'M=5WA%2WTA=9DL5Y7$/?F
MNO?('E@BNRV/;49CW([KMU@JD'JI0-Q+!7=<WX)DL1YZ3/-VS86:TSF\OZ#1
MHPGV'4/;D_HO*?6)%OI":W)?KTS(R%MH>UVE>$4+?:$U6:Q7*<3]V<![:(^W
M]\O:GP L-D$[KKVN.KH;IPA2$//B-(9$$<\SM?XZ7SVM3GR<%^<<6L\O\&FX
M/K=1PZR/D5Q3,6>9^?8RTY#!\4A[)]8G,]8WBB^+LPH/7"F>%I<+H#$(8Z#?
MS[A>8Y<WIH+J?,ST/U!+ P04    " ")A4]6%AO>\0P&  !-*0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V-"YX;6RUFEEOVS@0Q[\*X2T6*9!$YN$C6<=
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M>\GH-T>HQ6@P1O8ABA1T(&=Q[S+?2T_:?#=$FC:(M&BLO6N[ :'KA$=F[3^
M3?2W&;5*58" W("P:\:_#A)N5OF0<:\3;B&=]Q5^!Q@@!0;(&Q@@KV#@RYL>
MMP(#Y!4,D%GRC0EH88?:4J+K5%2 O%$!,DN^,?5,DS:%"@J07RA 9KTW4NDR
MT64J(D!O(P(Y^3_\6'/Q$V1,K@^%_" I5HQMRLN36G1O>;MPJ^T\F7X';" %
M&\@;;""OL.'+F[XKJV #>X4-;.&(YJZL:0)AR[X85JB!O:$&-C&B.3N=)KI"
M!1K8+VA@DR$,F1;,:'FOP+6-^#=31KF*S*I5I'[S/ E#FKJ7!K>$KE/$ES<]
M88HOL#>^P%[YPI<W/6[%%]@K7V +/#2W?=TVND[%%]@;7V#GED*IT?D#A:Y1
M$0;V2QC8LJ-@)--B UM^7L(*,K OR+ O#Y=KL4[9CN7!*SGX\J8G3)$#]D8.
MV"LY^/*F_TZJR(%X)0=B8@$>C!M#VF9$6MZKB6('XHT=B&4+HJG1LI/1HE"Q
M _'+#L2V_]#4B8R?QP]:=GR(@@?R9GBXY,]L :ZIR!>'ME7B@SQ8+*3=KN]!
MK-%[I0M?WO2,UKXW\$87Q"M=^/*FQZWH@GBE"V(A!V/U</;XJQ$I#B'>.(28
MC$&:P3@[^]5@%+ 0O\!2NJNO-LVW&7>/72,*:M^ZY1\:7M-4KDH9"-F#=-\_
M'$DIZ?;;O>V)2%;%YV_WB1!)5!PN&941Y@;R_D.2B)>3_(NZZ@O*Z?]02P,$
M%     @ B85/5FYALG/H!0  S"P  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C4N>&ULS9IM;]LV$,>_"N$50PIDD4C*=I(Y!MJD03,L:Y"L';!B+QB;L87J
MP:/HN /VX4<]6!0CA9+L,[ W"64=_[HCC^>?14XVL?B6+#F7Z'L81,G%8"GE
MZMQQDMF2ARPYB5<\4G>>8A$RJ2[%PDE6@K-YUBD,'.*Z(R=D?C283K+/[L1T
M$J]EX$?\3J!D'89,_/.>!_'F8H 'VP_N_<52IA\XT\F*+?@#EY]7=T)=.:7*
MW ]YE/AQA 1_NAB\P^>7WCCMD%E\\?DFJ;11&LIC'']++V[F%P,W]8@'?"93
M":;^/?-+'@2IDO+C[T)T4#XS[5AM;]6OL^!5,(\LX9=Q\(<_E\N+P>D S?D3
M6P?R/MY\Y$5 PU1O%@=)]A=M"EMW@&;K1,9AT5EY$/I1_I]]+P:BT@&/7NE
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M;_^(T*9N:/7$Z67H"3/MJ,.$X8+^ 6A\ .V76KOGB6\S[5\E^PM02P,$%
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MUR6R$C$-3T$'?@0H0*CE@:[>;@Y;S/';S0.+-YUR]#L9K_/ZZ-?&_&,V4OE
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MP?W=%([>',,;X!)NN!"T*6846HK)(8?I>OV+:OWDE?7C!&Z4M+F!WV6&V2Y
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M/I>/_Z2[*PH[?8MR56_^=1YWLN[,6=S73;G>'=Q:L,Z+[?_9T\X3W %AI#G
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MP7'^P7$^I/WL/*MO'?K7??Z0K;I@4UWL5D.XT=#=EQ[._#"*3^8/_$7(0EY
MPH.08%QP,"X C7O?VM7\=*ZZP=D,HLJZK8J(.W$:^CWC9!F2)$1M7'@P+@2-
M^Z.YI56;1 ^T;MJHRC91]\)9E<7-RX96:Y6MH61'&"5ASUB%D.=I/!D=C(U
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M9*)$DPO<'"0,THQRX:(-_ORF..+) )_=>C#'J SZ##+ZP;0R 15L8FD3G<?
MIC]0!S3-!'D.UHO[:$DAY >:*4:?03H?AG1&N; %22^<R_LB7^1WV6[@W[1#
M_*GLOBRRE7-U?[W,'_)NQ4\K^B5[>OG^B:[O&CA74$MW6-I$7S+<Z<?3RA54
M"(JE370>@Z ^7%8TSI5$+OL0J3BDD HC3S/K[3.HY\-0SRA;SLOJKJRZ*I+I
M P.UOH>E35Q"PX!F,*T9\@ 5=V)I$YW'<&< EQ]-DV"G1GA)\$(O[:]#4HGY
MD:]9)L407@ C/*,T^$SK?-G"IF[:\+*LFIOLAKY\FRU^F+]3P&98C^T8I<&
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MB#\(Q_Q!)D;]07"Y/]#4]1S(H5 ,^@^BX/909(8LI,\,#N8-4("H,L-T+_.
M;OOA&J4.R7&!D(F1@1!<-A T=3T'<CAR@!#$:$\S4?!\2"_9"AG=KF;",8&0
M 2H0\WW->TWP(C&EE*[0S/%O$)BC0IF6^"NL!ZRPC[]1H!S'O$&\B4$YF K$
MWH&C0#F.%80,T((<L])ZKY// 2E/0)F>N1RN@ZDK#FD"+[4>T&(]2J/P:1".
M4(/X$\-E,,.'O0/'H0;FN8&?M\%X?[PP@YA(F$PA%02ZIQ3'L4%@'@I%6!^]
M3'C@5/9#-PI&XR@TB#\QC 9S>M@[<!2,QA%\D &&#^-2E2]#L""5@)I"RH^T
MMW8.J<'\$L?FP%%S[;C$&6CJ>K[CT*,_K060!.;RL'?@*#B2H_4@ [P>YCFB
M:N?2WXFCDO+]2),C'+4&@>DGGI$C&!/MN$P;:.IZWN3 9#"Q)9$P^8>] T>!
MI1P+"!F@ 3'.FD!>["B],"AD-'O7",>Y06!>BF=DS#-F"W&9-]#4]9S(P=-@
M8NL=83(0>P>.@F$Y7A R0 QBGBB*]G]A)*6*>0= PC%Q$)BM0ITKE@4F7'H-
M-'4]GW"H-)C8*D:8\</>@:- 4X[\@PRP?YC-B 3RTD2IC:M22!OV'/:#:2EL
MP_[HSL8#=M@/[2BU0XYN@X036Z@(\W]8.Q!+7<^!' "UY0)17[6\_%#.#960
M+C<XQ@X"LUJH<V.$>0E<J@XT=3V_<; SG-AJ1)@]Q-Z!HT!.CDR$#+")'#4O
ML=,90J\9H,S6W'E]2VGS+FNRLY.[]CWY,JMN\J)KUO&]/<9]U341K/*;V\.7
MIKQKKV[F7)=-4ZXW'V]IMJ15)]#^_7M9-OLO\U;_8UG]V)SC[']02P,$%
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M:9#*RW>@J"7?44-?%*>O#@BF "5Y$ R)? @&3;$6_PUQ49RX#H%@ZA.32XZ
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M&@N[BZP')@^*C&T]877%<;F#QZ.CB%I0D^@HI!94',<=,=T53]A=/77)<>]
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M/V[YUPU_^ 9_$,*=%";7\)M(,#D4\"D974;"?4;6X5G%&XPO81Q\@' 4A@-
MF^]W#\[@C+L"C9W>^ V]MB24I'A?#M:40Z:0N7+4_7(82OEV7X[4EJ/NRF'W
MJGTYAG+=H$R&46Q#N=(5BW'E4<?0J)[1BW[^*9B-?AW*TP\2.\C:I,O:Y)QZ
MM&8%H["!&?B#B9KZ$P1# 3<J4Z=B&]YS%,[)\+D?QX#-Y)?.Y@!OVN%-S^)=
M)TE3!* ^?%@6:HT%,[:0DMY_I9 J_8I,#=$W#YGUR<(C^%.38#3,/NO89S^"
MO5*<MBWYX$F;G7!-YT?HIR;!?!A]WJ'/SZ(_8%+')Z2'(=!;]3_H\Q.NC\='
M9L!D.HR^Z- 7WWN@J<-@N45%768(;W%R7,>]X]KPG=KTCWT#Z/<NE1)5YNY:
M#;'M/4TW[5:[Z_S:W6)'ZVNZYIM;^3^9YAOACJF,4\X+3$ER=#DG(M7<N\W$
MR,I=75MIZ")TPYP^55!9 ]I/I33[B7U ]_$3?0-02P,$%     @ B85/5G%(
M?U+<"   %$L  !D   !X;"]W;W)K<VAE971S+W-H965T-S8N>&ULQ9QK;]LX
M%H;_"N$=#%J@C2U*OG62 *G%P721=()VNXO%8#XP$AT3HXN7I)-TL3]^2%D1
M34FAX^1X]DMCN^0CZGVE(YXC2J?WI?A#KAA3Z"'/"GDV6"FU_C <RF3%<BI/
MRC4K]/\L2Y%3I;^*VZ%<"T;3JE.>#?%H-!GFE!>#\]/JMVMQ?EIN5,8+=BV0
MW.0Y%=\_LJR\/QL$@\<?OO#;E3(_#,]/U_26?67JV_I:Z&_#AI+RG!62EP42
M;'DVN @^D&AF.E0M_LG9O=SYC,RNW)3E'^;+I_1L,#(C8AE+E$%0_>>.+5B6
M&9(>QW]JZ*#9INFX^_F1_G.U\WIG;JADBS+[%T_5ZFPP&Z"4+>DF4U_*^U]8
MO4-CPTO*3%;_HONZ[6B DHU495YWUB/(>;']2Q]J(78Z!),G.N"Z VYWB)[H
M$-8=PN=VB.H.T7,[C.L.U:X/M_M>"1=31<]/17F/A&FM:>9#I7[56^O%"W.@
M?%5"_R_7_=3YIR(I<X;^01^81&\^4R&H<>XM>A,S17DFWZ+WZ-O7&+WYX2WZ
M 0V17%&AF_("?2NXDN_TC_KS%<\R[;L\'2H]*(,>)O4 /FX'@)\80(#155FH
ME42D2%GJ H9Z;YI=PH^[]!%[B3%+3E 8O$-XA''/@!;/[Q[T=(^?WWW4TYT\
MNWLP]8@1-OZ&%2_<ZR]::)EY<<N*Y#OZ[5*W0Y\4R^7O?9YMH5$_U 2O#W)-
M$W8VT-%),G''!N<__BV8C'[JTQL2%D/""!#,<29JG(E\=.WTD@G!TLJ;2TYO
M>,859_J,^LQ4GR=;W+C"F?A_=Q[,YOH8N=O5NML(3T?8;11[!W:HAD P1\-Q
MH^'8JV%]="NM('O0UT[)^H0;=X6;CD<MX7H:S<)6H[BGT60R<1L1[Y!?*,BD
M$61RH"#HS0TKV)*KMVC-!$IYME'ZH*O">)]86_YT9Q>G)R8..F+U-8I:C>)N
MH\G)>-P2R[L[+Q1KVH@U]8I%EDM6S5/03I3\PI*R2/2Y2*N)S+7^PPJ%KD6I
MZKG-Q5+/SU)ZDS&TT"*BBT2A7QC-U$ISY$;0(F&F_1U/M> _LUZ9IYTCJ7U
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M]AP:M#H 2B-0-%=T6QW _NK )<^YN;Z_(GZ!U@Y :3$HC4#17*ML[0 ?I7:
M06L'H+08E$:@:.[*/UL["/VU@Q?%K[![XU4/J!6__!L^>$D?: T BN:*;FL
MH;\&0*C(N+F/:DZ+?S,JFECUS/#EYQ^\]A*T% !*(U TURE;"@B/4@H(04L!
MH+08E$:@:*X_.RN7_:6 7YO0=6E"U^Z$0+Y#Y&'-Q38;C:GJS2;W\/].BQ.$
M1L$[A/ H[%TI[B<<[ [LVN5CE E"6R8(]Y0)?''N:[5JR1OE0#-]4%H,2B-0
M--<G6Q((QT>)<J!% %!:#$HC4#37'UL$"/TKME\?Y?Q\)\KAL-<=T!( *(U
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M$A!7* @LOY[(@@2!0I)Q_)>"&MF8RO'T^HC^6YR\3&:%.5G0X"_?$]N),32
M1]9X'XA'>OB#I DY"L^E 8\_P2&UM0S@[KF@8>HL(PC]*/G&SRD1)PZPW^"
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MOUQP)%Q) ;-A7=B#2D!6*63MV#\X@X=99D-M9@L:AH2Y/@X EDJ\W!%U+5[
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MVXB6VR?PMJ/%*GU%SH3&-VG:7.)G TAC@/-S(?2N8QZF^8?(X ]02P,$%
M  @ B85/5IQCW7Q3 P  V L  !D   !X;"]W;W)K<VAE971S+W-H965T.#4N
M>&ULM59=;QH[$/TKHVU5$>DV^\%'2 I(":AJI*9%R6W[4/7![ ZL5:]-;2^D
M_?5W;#9[(5EH*M$7L'?G',X9SY@9K)7^;G)$"_>%D&88Y-8N+\+0I#D6S)RJ
M)4IZ,U>Z8):V>A&:I4:6>5 APB2*>F'!N Q& _]LJD<#55K!)4XUF+(HF/YY
MA4*MAT$</#RXY8O<N@?A:+!D"[Q#^VDYU;0+:Y:,%R@-5Q(TSH?!97PQCCW
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MT8>77.V^*M]Y*8V#// ,*5VYSGPB!$C1)FW<&N*1XS;$M>."<0,7MN/&7H?
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M@(O-T,/>;N&>S1?:+OC18$GG\ #Z<3F19N:741*60J:8R)"$V="[PI<CW+6
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MZZ@J?-*/:GMIEQJ*Z[I,KG=U&W[K JT.D[GQXV,H8X!*&/HF8QL6!)B;6RL
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ML@&HWV^*HG[XT-S@^.[OXE]02P,$%     @ B85/5IT/,<G; @  5 @  !D
M  !X;"]W;W)K<VAE971S+W-H965T.30N>&ULK59=;]HP%/TK5E9-5%J;3T+;
M020@JU9-2*A=MX=I#R:YD&B.G=D&RK^?[804HA0QJ2_$=LXYW'.ON9?AEO$_
M(@.0Z*4@5(RL3,KRSK9%DD&!Q34K@:HW2\8++-66KVQ1<L"I(17$]APGM N<
M4RL:FK,YCX9L+4E.8<Z16!<%YKL)$+8=6:ZU/WC,5YG4!W8T+/$*GD ^EW.N
M=G:CDN8%4)$SBC@L1];8O8M#C3> 'SELQ<$::2<+QO[HS4,ZLAP=$!!(I%;
MZK&!*1"BA508?VM-J_E*33Q<[]7OC7?E98$%3!GYF:<R&UDW%DIAB==$/K+M
M5ZC]]+5>PH@PGVA;8QT+)6LA65&3501%3JLG?JGS<$!PPS<(7DWPVH3@#8)?
M$_QS"4%-"$QF*BLF#S&6.!IRMD5<HY6:7IAD&K:RGU-=]B?)U=M<\60T@S1/
M,$%3@O-"H#G>X04!U.O=XPWC>GV)GNEROT$Q;-15*57AI4"3'9IFF*Y H >*
MOL$.C86Z/Z6NJ+A$O1@DSHE:7:'GIQCU+B[1!<HIFN6$:,C0ELJ"#L1.ZG G
M5;C>&^&Z'IHQ*C.!OM 4TF,!6WEO$N#M$S#Q3BK&D%PCW_V$/,?S.@*:GD]W
M.^CQ^73GA!N_*:=O]/S_*^>O\4)(KGYCO[M27DD&W9*Z[]R)$B<PLE1C$< W
M8$4?/[BA\[DK7>\I%K^3V%$J@R:5P2GUR%QE2)'D0%.T5,ECO//&5C)](Z.[
M[":ZNNG?#NW-85HZ0&[@M5!Q!ZI_^PHZ\M%O?/3/\I&PHB1@FNT),Y56>!2G
MT_+2@?$&0<M*!\B_Z782-D["DTZ^,XE)5]!A1P7"=@4Z0.[ \5MA=Z!"?]"*
MVS[HMP7PE9E;0F5X3675>9K39C2.S41HG4_4R*PFW*M,-6]GF*]R*A"!I9)T
MK@<J)%[-L&HC66FZ^H))-2/,,E-C'[@&J/=+QN1^H[^@^2,1_0-02P,$%
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M@ 0+@< T3KT]IQZTF'J01$*"A4!@&I'^GDA_)&+JMY9]X&(2&*O>VFU?8H'
M-&*#/;'!"+0T:).*'6Q*J;73OJ0"@6FDSO:DSH"D%/V'KM>Y*-^L)'FUU;AX
MY!$M\JP4TGE(EFL=07_Q2-27>;O+7A'GPJK)UB;[2@DD6 @$IAT<["A3X4"K
M<H,(Q"4H6@B%IK-Y8-'P2*2Y:42[)/.ECA@RTI2Y6ID3.'I9V%GF,G=?IO.A
M_!.VNHIG4M2F"9T+A\U,+CK*O,#W3"XZRACQZ!$NE 7"3WB@88406^7/WEOO
M-0MJGZ#0]..B#!1FX H(:706H&@A%)K.IC).^ GG]'P*Z':L^IGKFZN^HRS
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M*% FLC_'C7U,FDN0/=_>7D&JA5!JIE<UCF,K%#X1#Y1)&#YA!S=YP)YK;Y]
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M+W HOLADG;_28)%(F43YQQ7W?"ZR!NKWMTDBMU^R&U2OT9C]!U!+ P04
M" ")A4]6B ^=  @8  #;M0$ &0   'AL+W=O<FMS:&5E=',O<VAE970Y.2YX
M;6RMW5US&\>5QO&O@N(F6W:536+> :^DJH33KQ4GKGB=O4CE I)&$LLDP05
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MFJ4TOWE=>EOC@\#U\5<'Q_^\CT:S9U85:%6):@K5-*H95+.4YG5UXT+79NR
M;W4Y[W^,OTSN]]/5AFYH4*U%-8%J$M44JFE4,ZAF*<U?/2[S;=@!WP8=\$6U
M%M4$JDE44ZBF4<V@FJ4T?WFXZ+@9.^#;Q .^1?3LGW25P7V.IKRH)E%--?&
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M&@RG^*55W3;KB9&5:U4K:;#QN6&!?QI0=@.NYU*:_<0&:/]=R6]02P,$%
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M"-5B5$M0+:6T9J94=?EC<5U^E#_M-[.';)O/7YW<1XOR44U!-175-%334<U
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MSG(&RYDL9[&<S7(.R[DLY[&<SW(!RX4L%[%<S'()RZ48UXJC82V.ANRM *^
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M1DJ,+@3*^:+O!YV3[2:[E1;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7L%R*<:U
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M62Y@N9#E(I:+62YAN13C6JE2ZTXP$A>P1_E3]J,\L=F6*5(]LT"Y>(\TVYL
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MZH').[M2B>*49#RF&6+DI6]=N9?S;AZO OZ*R8;O7*,\DV=*W_*;:=2WG'Q
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M.J=)L7E#8GO."2KG!."\/9*0LJC6-#"LMESD %4WA 74XPYR(-O  NJ!QW4
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MY7HUU#VKH9$@S\K'@AC9@BX$[3UY>T65 ./J,]E\,.KK!_-%E8INE!T2=7I
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MY&0BB1)=#M1[.9F<2L)<#M2[N3*1A+F\?;V;R]I;O3X!31+G/3Z!UQ40QOF
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M,RAK@.=+*<UV82_H^GWR!U!+ P04    " "*A4]6/6:'AV &  !=+0  &@
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MG2J:O;S- <NW]>[6NYRQ/*U_;FBTI$4%X-=7><Z>#JH;=#NJY_\#4$L#!!0
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M.1,4[S/*41:F_=K%KD];^FA'[Y*D&Z;'1G'8E?;8)LRB?FG#5MKPH+0[:5#
MH30;]J19FIQV8]-C%F=I?-J1T&,6A5G:#9"_5WLJ4 M7PS4IY%J8^KYM1]MG
MPKFKCIWQ"WP^U-7^'TW]]KBF:F$CR6&.E,')$#>EZGI>=XQ<N0HWDP;KI6LN
M\0D$RAK@_%Q*L^O8!=I'5?X74$L#!!0    ( (J%3U8E:7GPRP,  .,+   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$R,BYX;6RM5MMNXS80_15"710)T$17
M2W)J&XBM7A9HND&<;1^*/M#2V!*6$EV2OK1?WZ$D:QV)<?*P+[9(G3F<,S,:
MSN3 Q1>9 RAR+%DEIU:NU/;.MF6:0TGE+=]"A6_67)14X5)L;+D50+/:J&2V
MYSBA7=*BLF:3>N]1S"9\IUA1P:,@<E>65/P[!\8/4\NU3AM/Q297>L.>3;9T
M TM0G[>/ E=VQY(5)52RX!41L)Y:]^Y=XCK:H$;\4<!!GCT3+67%^1>]^)A-
M+4=[! Q2I2DH_NUA 8QI)O3CGY;4ZL[4AN?/)_:?:_$H9D4E+#C[L\A4/K5B
MBV2PICNFGOCA5V@%C31?RIFL?\FAQ3H627=2\;(U1@_*HFK^Z;$-Q)F!&[YB
MX+4&7M\@>,7 ;PW\]QH$K4%01Z:14L<AH8K.)H(?B-!H9-,/=3!K:Y1?5#KO
M2R7P;8%V:K:$#691D8]54T,Z%U=/D/(J+5C1K#^MR1-LN5!TQ8"<+#YM0>#[
M:D-^P?(BSQPY4EX"F0-2P6GU3(\@<4&><R +7DG.BHPJR,A2X9^FDOJ$!GY-
MKA)0M&#RFMR0S\N$7'VX)A\('O!0,(;>R(FM4+?VWDY;C?-&H_>*1M<C#[Q2
MN20_51ED+PEL#%@7->\4M;EWD3&!]);X[@_$<SS/X-#B_>:NP3QYO[ES08W?
MU8!?\_EOU$"39)W1O^Y74@G\)O\V1;MA"\QLNE'=R2U-86IA)Y(@]F#-OO_.
M#9T?39'ZEF3)-R)[$<6@BV)PB7W6UONJJ?ZB62E=_:88-ERCFDOWYOTLBL+Q
MQ-Z?Q\8 &GNCEZ!D" H]/^Y +[2,.BVCBUI^!]T1]B!5VQRT&).,AB8\._S&
M#>*>BPL3RH_BGA #*HXBLY"P$Q*^*>2*<2D!&\H&^Y0DV-#6146QOU&&:<(Z
MW]5-R"0O'+@T&CD]<4/,C>_VM1E ;NR9M46=MNB-@E. 9:P(''$*D,;\1(-S
MXY';$S#$1..^_P9,')C=CSOWXXONWY>ZV?S77#%\3;C*06!"%*TVA;YH*&;-
MG)9XZ$T8]50-,4'04YX,,7[HFE6-.U7CBZI^PUK3)09'W4AWA<SK+PCU9;!2
M)C'C@1/]"ALBO+Z2(<0/S4)<Y^MDX%R4<G;GR^:&0&7=I:\_)N-5[ SZ41R,
MO)XD RH*XE[_2PRHT ^=GC#[;/HI06SJ*5*2E.\JU5SIW6XWJ=[7\UEO?ZXG
MV'JJ^DK3C+\/5&QT[V"P1DKG-D*71#-1-@O%M_6,M>(*)[;Z,<<I'(0&X/LU
MY^JTT =T<_WL?U!+ P04    " "*A4]6T(7.(10#  #1"@  &@   'AL+W=O
M<FMS:&5E=',O<VAE970Q,C,N>&ULM59;;]HP%/XK5B9-K;21"Q2J#B(5LDNE
MM4)4VQZJ/ICD)+&:V)GM0"?MQ\^7D$*54BJQ%_#E?)^/OW-\<L9KQA]$#B#1
M8UE0,7%R*:L+UQ5Q#B46/58!53LIXR66:LHS5U0<<&) 9>$&GC=T2TRH$X[-
MVIR'8U;+@E"8<R3JLL3\SQ0*MIXXOK-96) LEWK!#<<5SN 6Y(]JSM7,;5D2
M4@(5A%'$(9TXE_Y%--+VQN G@;78&B-]DR5C#WIRE4P<3SL$!<12,V#UMX(9
M%(4F4F[\;CB=]D@-W!YOV+^8NZN[++& &2M^D43F$^?<00FDN"[D@JV_07.?
M,\T7LT*87[1N;#T'Q;60K&S RH.24/N/'QL=M@#^\ 5 T ""YX#!"X!^ ^@?
M"A@T@(%1QE[%Z!!AB<,Q9VO$M;5BTP,CID&KZQ.JPWXKN=HE"B?#6\A4$"6Z
MHC:%="Q.;C#G6,?C%)U$(#$IQ"GZB(2U';M2':SA;MP<,K6'!"\<X@?HFE&9
M"_29)I#L$KC*X];M8./V--C+&$'<0WW_ PJ\(.AP:'8XW.^ 1X?#O3VWZ;=!
MZ!N^_BM!6$#%N"0TVPG'W7=ECJXDE.*^2WO+/>CFUF7C0E0XAHFCZH( O@(G
M?/_.'WJ?NG0[)EET)+(=30>MIH-][.%-72Z!(Y8VJN)E :@16G3):.F&ADX7
MRU4X&+NK;6WV'OA6;8Y$MJ/-6:O-V5YMOK(5<&I2;EH+M2D$NKL&+=@]^HMF
MINPH\6:,QLJ(VSQ<$/&P;;: %= :T!1HG*MOQM-FE[Q[/7IKEAZ3+#H2V4XD
MAFTDAO_QY0^/J>DQR:(CD>UH.FHU'>W-[CEPG;6J:=&OGS=9F@$%E<B0H)2S
M$E58R1V3R@I-*%IA3E@M4 J)LBM0]O1&*LXRCLO.JF%=\;VMLN'U@O-GE>,@
MJ^@U*ZN&N_6Q5X\T,TV30#&KJ;0?T':U[<LN33OR;'VJ^C7;7CW1V&;O&O.,
M4($*2!6EUQNI)\)M V4GDE6FI5@RJ2J%&>:JYP2N#=1^RIC<3/0!;1<;_@-0
M2P,$%     @ BH5/5MG['!:- @  S@<  !H   !X;"]W;W)K<VAE971S+W-H
M965T,3(T+GAM;*U5;6_:,!#^*U963:W4-2\$-G40J9!-JP02:M?M0[4/)CF(
M53MFMH'VW^_LA RZ@#J)+XG/ON>YN\?)77\CU9,N  QY%KS4 Z\P9GGM^SHK
M0%!])9=0XLE<*D$-FFKAZZ4"FCN0X'X4!#U?4%9Z2=_M3572ERO#60E31?1*
M"*I>AL#E9N"%WG;CCBT*8S?\I+^D"[@'\["<*K3\AB5G DK-9$D4S ?>37B=
M=JV_<_C!8*-WUL16,I/RR1JW^< +;$+ (3.6@>)K#2/@W!)A&K]K3J\):8&[
MZRW[5U<[UC*C&D:2_V2Y*0;>)X_D,*<K;N[DYAO4];@$,\FU>Y)-Y=O#B-E*
M&REJ,-J"E=6;/M<Z[ #"W@% 5 .BUX#X *!3 SIO!<0U(';*5*4X'5)J:-)7
M<D.4]48VNW!B.C26STI[[?=&X2E#G$GN@%,#.9E295[(=T5+3=V-:'*>@J&,
MZPOR@3S<I^3\[(*<$5:2">/<>O1]@QE8'C^KHPVK:-&!:&%$)K(TA29?RASR
M?0(?4V_RC[;Y#Z.CC"ED5Z037I(HB**6A$9OAX<M\/3M\.!(-9WF-CJ.+S[
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MD,8 ?Y\+H3<W)D#Y>F3P/U!+ P04    " "*A4]6$]W\B-4*  #O50  &@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,C8N>&ULS9Q=;]LX%H;_"N$M=CM 4HM?
MDMU) K26BRVPG2F:F=F+Q5XH,A,+E26/)"?M_OJE9,>TR%-:#"CL7K21[<.C
MHY<4R8<\TM5367VMUT(TZ-LF+^KKR;IIMF^GTSI=BTU2ORFWHI"_W)?5)FGD
MQ^IA6F\KD:RZ0IM\2H(@G&Z2K)C<7'7??:YNKLI=DV>%^%RA>K?9)-7W]R(O
MGZXG>/+\Q9?L8=VT7TQOKK;)@[@5S>_;SY7\-#UZ664;4=196:!*W%]/WN&W
MRY"T!3J+/S+Q5)\<H_92[LKR:_OAX^IZ$K01B5RD3>LBD7\>Q4+D>>M)QO'G
MP>GD>,ZVX.GQL_</W<7+B[E+:K$H\W]FJV9]/9E-T$K<)[N\^5(^_5T<+HBW
M_M(RK[O_T=/!-IB@=%<WY>906$:PR8K]W^3;08B3 IC]H  Y%"!#"]!# 3JT
M #L48$,+\$.![M*G^VOOA(N3)KFYJLHG5+76TEM[T*G?E99Z947;4&Z;2OZ:
MR7+-S:UL>:M=+M#'CY>+LEC))B!6Z$-6)$6:)3GZ6.P;8UNIO]ZC+^(AJYLJ
M*1KT^GV22R.!;MN3US^AU[%HDBR71Y?H]]L8O7[U$WJ%L@)]RO)<EJ^OIHV,
MN#WO-#U$]WX?'?E!=+%(WR"*+Q )" &*+X87QT#Q>'CQ "B^'%P<S_O%I[*6
MCE5%CE5%.G_T!_X6NZH24OBDKJ7>;R$U]PX8[*#M<][6VR05UQ/9J=2B>A23
MF[_^!8?!SY"V/IW%/ITM/3GKU0(]U@*U>;]9)/4:)<4*I>V!^'.7/2:YK!:P
M=>]=\<Y5VV4_WD1T%EU-'T]U-HW8;!;TC6)K4*[Z>7+6TX\=]6-6_3YDWV0'
M(WN4794UWU$MTO8@$_6%[.ZZ!GZ!DDU9-=E_I%U:U@TD[/X<X8EFA,\YT90%
MK$(2:OK'UGA=I?7DK"<M/TK+K=(N96/L20HIQPU-YIQJNIDV>#;#FFS66%QE
M\^2L)UMXE"VTRO9KLQ:5G/2D0M[*=SDL6VA(PLA\INEF&M&(S37=K,&XZN;)
M64^WZ*A;-$"WM#<J0=)%ABJ<Z*UI81JQD#--.FL\KM)Y<M:3;G:4;F:5[K>R
MD7.K\]+-3.EXB/4!!+#"F&B=86R-R%4\3\YZXLV/XLT'M+NL>!1U(X>(O7H7
M*"^+A\M&5!M(R+DI43CCFHZ $2&:46R-S55&3\YZ,N) 3?T#JY"?*\F;E1PQ
MVNE,.Y/9;KKAMQ#@F'OPUKM'*0XU$0$K.L=Z)VB/S%5&7][Z.IX@%![0((NR
M.']#'SSUAM8H8+J&D)6IH34J9PT]>>MKJ-@&6R?MAQ[1(APQ)0E(%.E3/L!N
M'K%0GT[;HW'6;@P@P8I(,!T$AGF6W&5Y-_,#Z1#[A(B%5V^Q5V]+7][Z%:(0
M!]L9YUV:ECN)A&B;?&]GE%T'FZ1IM9/CE?BV;1=9X%9N$@L/ WV\!ZS8/#*:
MN%>N\>6MKZ@B&VQ'F^<FOFW!L"Q0>:_&>[02=_" !7 ,#P)=3<AJ;G2V7G''
ME[>^F@IX\!#B2<UN U31I)IY.-.1$;"*9@;[V.-R5G$,^L$*?["=?_J3^',J
MFH!#Y^'<F#T!9FRFSU1C>V3..HZ!0EBQ$+;#T#]Z-[*<R(NZ/LIZN.%!24WN
M(83J;6X!F6',]54@>Y#.DHX!2%@1$AZ"2"<STG.MTT0?S$-C;@58&3U!; _-
M6<@Q$(DH1")V1-K?XV?4(R;RA"&-]-4AR Q3JG.Z/2+GI?(QT(@H-")V-%J4
MFTW6M%A9[Q?-RZ+)B@=1I%++RU_*1B .2OH"&D'@)H8G1_%+'%FJ90S:(B<[
M2?:MI-MU4HEUF:]$5?^M0__F.U@-?C>4_.XH^=U2&@/AB$(X8M]5^ER)>R&[
MZA6JFS+]>H&>LF9=[N3XEU3H,<EWX@+5;:7)VV@G?ZFZW9%+A(/@(MC_^_G9
M(*OKEC/:VTUZJ!MY(&\Y:2S' P'6,C4Z)GV2?-XDME^A<WV,07!$$1RQ$US;
M;TG,.%3&L1+0J^!-@.&JF+M4!:'1Q9S/+H(PZGXE#%]$47 1L1"L(6 G2Z^A
MLR:Q_9J=:V@,(B2*"(F="-^M5ED[,Y3#\S;)5I=9@=)DF\GA&A00V/8*9OJZ
M&V2%V4R7T2L*^O+6EU&A(+&CX)<V9Z-HER62JI!M$Y[@F'!'YA$QY /,HF!F
MZ.<5 GUYZ^NG()#8(?!=FNXVNSQI=R+*/5:7&WFF=9M+]2A07M:PI";H71(>
MZ%@-F6%]9AD?K$Y3"##7^N<E8'1)3@"T+X"B-S)D*ZL>.J$P88R&U%CA LT"
M8Q77'IIS2QJ#V8AB-F)G-@,UNH%AL+  FT'KXX =M#YNC]59V3$@CBJ(HV?V
MN9*.@>68ODV*[^A?G\3F3E3_!A-V?,+7PJNWV*NWI2]O_3I18$CQH#T+2S(;
M]4E<"Z_>8J_>EKZ\]>M"T2"U[[VYI;0!&VQ,[V4 (]G+ZREM7@'.E[>^AB=9
M@7: \Y/61DW,PJ$^)P",.-97B.WA.HL[!HU116/43F.#$MNH"4#8V%D'C(Q-
M"GLPSM*-@4E481*U8]*@Y#9J<@_7DV, &V;<T5[)R)>WOG**C*B=C'X1#5I)
MY+^OR@VJ=W=UMLJ2ZD>-ST0??0D%,&$LU!7TRD:^O/455&Q$_20(4A-R(J(G
M" )&H=Y(8WM SO*-L2]&%5E1/TF"U(0E/#>2VP K0JDAH%>B\N6M+Z B*NH_
M49":?!09F]V T2S0H=P>G+.48R 44PC%O*8*,G.K"QO//0!&1%\)B.UQ.6?G
MCP$]3$$/L^^&Q<^+_$WR[=@<?R2AF0-(L=X0 :/(4- KJOCRUE=0H0JSH\K'
M[F9NVU[[8-FY49F9&,+G@4$KD%E(([UOM(?F+.08O,(4KS [KSCDK#*3-X@^
M]5M 1J&AH%<H\>6MK^#)<TQV*#F7L<I,U @)UY=E%Y!9$)@/*7F%$E_>^M(I
M*&%\T.+/N815YI,G%EZ]Q5Z]+7UYZU>(8AUF9YT7)ZPR$VIF<QVZ 2/.=>JV
M1^BLYQCDPQ3Y,#OY/+-C4YX?HP#XF>DY;("1SM[VB)SU&P-]F$(?9D>?%Z7[
M,H"#S'1?T,I(][7'YZSF&!S$% >Q(1PT,!60F6Q#0QW&(2.F/ZUGC\I9PS$
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M:N5C04%IU,JG"0K\L;UZPHIEV _+B*@$K6 *(NB':VJE&C;BPW6>%@BNL;1
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M-"O.UX5VEV?;:DZZW?+\8.O813N>:[=97FVFZC/HGD*YO<$]!9)F06DVE.9
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MTZSD6IEIQ?ZVB-=QE/\@%0EU5T%I%I1F0VD.E.9":1Z4YD-I 9-=4?I$*GQ
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M.!U4:L7I_9Q2Y2US+JJA/U>J_!0$U71.<U)=%245&LD*F1.ENW(65*6D)*V
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M3@=C;-[B&/[<:I@W8&!Y(-/+YAI?;;Q"]M<!MJ;[*@0;*5Z)V$CQN0;$/6_
M2!+W:F-Y@(&M E8[D-^=!VK*S8DB6%7,&W8%XTB28 C4HKM&XQB9G1B^[O7!
MKI(H2A(W IC;011A"%R-.((Y  \8$D7F.;CS/ J:YU2P_E_TZ"]02P,$%
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M;W!S+V%P<"YX;6Q02P$"% ,4    " ")A4]6%7!6D>\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ")A4]6
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( (F%3U;!N9G,F <  #(O   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ")A4]6
MO%AD=#@"  "]!0  &               @('<#P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ B85/5AB(J]9:!P  3R   !@
M     ("!2A(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M (F%3U;2#>FJ<0,  /\,   8              " @=H9  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " ")A4]6E'H^Y/<%   /&@  &
M            @(&!'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ B85/5I]?-LM!!    1   !@              ("!KB,  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (F%3U;6)]&$+ D  (TM
M   8              " @24H  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " ")A4]61G+7#N$.  #IPP  &               @(&',0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ B85/5C[.0 A
M"0  4!8  !@              ("!GD   'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( (F%3U:FWU-Q_B@  ."%   9              "
M@11*  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ B85/
M5BL^\E>X"0  JQH  !D              ("!27,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " ")A4]6*LK%N $$  "$"0  &0
M        @($X?0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( (F%3U9#D63PT1   $PO   9              " @7"!  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ B85/5I>UZ4%F"   +1D
M !D              ("!>)(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " ")A4]6^KOHD3@6  "R3P  &0              @($5FP
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (F%3U9?7V50
M_PL  'T@   9              " @82Q  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ B85/5BIXMT26 P  HP@  !D
M ("!NKT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " ")
MA4]6?ER@%H0'  ">$0  &0              @(&'P0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( (F%3U9ZS1]?[Q$  ' \   9
M          " @4+)  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#
M%     @ B85/5N18AEZI#0  -C,  !D              ("!:-L  'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ")A4]6@O@[#+ 6  !(
M3P  &0              @(%(Z0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+ 0(4 Q0    ( (F%3U:KG/7B8Q\  -M<   9              " @2\
M 0!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ B85/5E<_
M!)#]$   [C$  !D              ("!R1\! 'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " ")A4]6:F 6UI8$  "Z#   &0
M    @('], $ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M (F%3U;+,BIB8@0   $*   9              " @<HU 0!X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ B85/5D%O%3?S!   I@L  !D
M             ("!8SH! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " ")A4]6'CH_VAX#  !B!P  &0              @(&-/P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (F%3U;80',A5 X
M -<H   9              " @>)" 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ B85/5M7Y.)O" @  )@8  !D              ("!
M;5$! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " ")A4]6
M6KUZ_#('  "2$@  &0              @(%F5 $ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( (F%3U8$UA96NPP  (XD   9
M      " @<]; 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ B85/5A@NPG*'-0  0[L  !D              ("!P6@! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ")A4]63CT/,?T#  !P"0
M&0              @(%_G@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( (F%3U8W[RXN P,  #$'   9              " @;.B 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ B85/5CLRF#5<
M"0  @1P  !D              ("![:4! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " ")A4]6 =PY^Y8&  "H%0  &0
M@(& KP$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (F%
M3U9K2&UM50@  )H=   9              " @4VV 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ B85/5N')Q+IZ!@  RQ   !D
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M=#0R+GAM;%!+ 0(4 Q0    ( (F%3U9$(@1AS00  *X+   9
M  " @4_D 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MB85/5DW^+>L)!@  HQ$  !D              ("!4^D! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " ")A4]6&;"?*J $  "U#   &0
M            @(&3[P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( (F%3U9C<UG-[@,  -0)   9              " @6KT 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ B85/5CQ<G*KD!
MO0L  !D              ("!C_@! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " ")A4]6?';%<]P"  !U!@  &0              @(&J
M_0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (F%3U8L
M.F0?B 8  '\3   9              " @;T  @!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ B85/5@%I^D:> @  \@4  !D
M     ("!? <" 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (F%3U:YY5ZG'P0   X5   9              "
M@0,C @!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ B85/
M5DFPX. Z!@  +C(  !D              ("!62<" 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " ")A4]6#Z(+10 (  !Q-@  &0
M        @('*+0( >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( (F%3U8#8._D:P@  .H\   9              " @0$V @!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ B85/5H 7+!BH P  /0\
M !D              ("!HSX" 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " ")A4]6O$[)W.\"  #5#   &0              @(&"0@(
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( (F%3U;;I\2T
M_P,  (D5   9              " @:A% @!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ B85/5K#6 .RS!   WA<  !D
M ("!WDD" 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " ")
MA4]6M,$I5-4%   K(P  &0              @('(3@( >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( (F%3U86&][Q# 8  $TI   9
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M970V."YX;6Q02P$"% ,4    " ")A4]647AC%\L.  #!FP  &0
M    @(&7; ( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M (F%3U8KCG8U\P@  /4[   9              " @9E[ @!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ B85/5L)Y5:XI!@  -2P  !D
M             ("!PX0" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " ")A4]6^7Y/4<,$  #;$P  &0              @($CBP( >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( (F%3U9A356B,0,
M ($*   9              " @1V0 @!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ B85/5KIQ?3R8!   S!(  !D              ("!
MA9," 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " ")A4]6
MT9\-:3 #   ("0  &0              @(%4F ( >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( (F%3U9Q2']2W @  !1+   9
M      " @;N; @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ B85/5BJ%/R?] P  6A0  !D              ("!SJ0" 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " ")A4]6%%/!!5 #  !("@
M&0              @($"J0( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( (F%3U9>/7>T&@4  -X;   9              " @8FL @!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ B85/5IJ0V"(K
M!0  8QX  !D              ("!VK$" 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    " ")A4]6JK&4WMP"  !;"   &0
M@($\MP( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( (F%
M3U91#7M1=P0  /D7   9              " @4^Z @!X;"]W;W)K<VAE971S
M+W-H965T.#(N>&UL4$L! A0#%     @ B85/5G!R9$4"!   X1   !D
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M=#@W+GAM;%!+ 0(4 Q0    ( (F%3U8:]?O1X0,  +<0   9
M  " @?#2 @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @
MB85/5IYA*VW]&@  8YX! !D              ("!"-<" 'AL+W=O<FMS:&5E
M=',O<VAE970X.2YX;6Q02P$"% ,4    " ")A4]6:2SFY>@$  # %P  &0
M            @($\\@( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4
M Q0    ( (F%3U8!\IPL#0,  "(+   9              " @5OW @!X;"]W
M;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ B85/5MH1]A=0!P
M(#$  !D              ("!G_H" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX
M;6Q02P$"% ,4    " ")A4]61QSH9!X)   '/   &0              @($F
M @, >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( (F%3U:=
M#S')VP(  %0(   9              " @7L+ P!X;"]W;W)K<VAE971S+W-H
M965T.30N>&UL4$L! A0#%     @ B85/5O<-7B\$!   A!,  !D
M     ("!C0X# 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (F%3U93]T5AR0(  ,<&   :              "
M@75  P!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( (J%
M3U:.B;-E3#D  -I_!  :              " @79# P!X;"]W;W)K<VAE971S
M+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( (J%3U8KCD^/&@0   X1   :
M          " @?I\ P!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;%!+ 0(4
M Q0    ( (J%3U;82T\0^0,   00   :              " @4R! P!X;"]W
M;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( (J%3U90*^$.W@,
M $83   :              " @7V% P!X;"]W;W)K<VAE971S+W-H965T,3 T
M+GAM;%!+ 0(4 Q0    ( (J%3U8.#PK8.0,  *,)   :              "
M@9.) P!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0    ( (J%
M3U;A:Q5IP@(  )\'   :              " @02- P!X;"]W;W)K<VAE971S
M+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( (J%3U9&;<)6?P0  ! :   :
M          " @?Z/ P!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM;%!+ 0(4
M Q0    ( (J%3U9:6%XN) ,  *X)   :              " @;64 P!X;"]W
M;W)K<VAE971S+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( (J%3U9$23-83@\
M  #(   :              " @1&8 P!X;"]W;W)K<VAE971S+W-H965T,3 Y
M+GAM;%!+ 0(4 Q0    ( (J%3U:-!)O<%P@  -\J   :              "
M@9>G P!X;"]W;W)K<VAE971S+W-H965T,3$P+GAM;%!+ 0(4 Q0    ( (J%
M3U81Y;LO+ ,  /8)   :              " @>:O P!X;"]W;W)K<VAE971S
M+W-H965T,3$Q+GAM;%!+ 0(4 Q0    ( (J%3U:Z-]NED0,   81   :
M          " @4JS P!X;"]W;W)K<VAE971S+W-H965T,3$R+GAM;%!+ 0(4
M Q0    ( (J%3U9M<>W?\P(  -D(   :              " @1.W P!X;"]W
M;W)K<VAE971S+W-H965T,3$S+GAM;%!+ 0(4 Q0    ( (J%3U;+" .?;00
M ),3   :              " @3ZZ P!X;"]W;W)K<VAE971S+W-H965T,3$T
M+GAM;%!+ 0(4 Q0    ( (J%3U8TI3BOWP(  +$(   :              "
M@>.^ P!X;"]W;W)K<VAE971S+W-H965T,3$U+GAM;%!+ 0(4 Q0    ( (J%
M3U9>WQ[#U@(  #T*   :              " @?K! P!X;"]W;W)K<VAE971S
M+W-H965T,3$V+GAM;%!+ 0(4 Q0    ( (J%3U:M]10(*0,   0)   :
M          " @0C% P!X;"]W;W)K<VAE971S+W-H965T,3$W+GAM;%!+ 0(4
M Q0    ( (J%3U8),*M]S0(  /L'   :              " @6G( P!X;"]W
M;W)K<VAE971S+W-H965T,3$X+GAM;%!+ 0(4 Q0    ( (J%3U8]9H>'8 8
M %TM   :              " @6[+ P!X;"]W;W)K<VAE971S+W-H965T,3$Y
M+GAM;%!+ 0(4 Q0    ( (J%3U;[%I&<I@8  ',U   :              "
M@0;2 P!X;"]W;W)K<VAE971S+W-H965T,3(P+GAM;%!+ 0(4 Q0    ( (J%
M3U8HH'/I- ,  & )   :              " @>38 P!X;"]W;W)K<VAE971S
M+W-H965T,3(Q+GAM;%!+ 0(4 Q0    ( (J%3U8E:7GPRP,  .,+   :
M          " @5#< P!X;"]W;W)K<VAE971S+W-H965T,3(R+GAM;%!+ 0(4
M Q0    ( (J%3U;0A<XA% ,  -$*   :              " @5/@ P!X;"]W
M;W)K<VAE971S+W-H965T,3(S+GAM;%!+ 0(4 Q0    ( (J%3U;9^QP6C0(
M ,X'   :              " @9_C P!X;"]W;W)K<VAE971S+W-H965T,3(T
M+GAM;%!+ 0(4 Q0    ( (J%3U89/V8"' 0  "H1   :              "
M@63F P!X;"]W;W)K<VAE971S+W-H965T,3(U+GAM;%!+ 0(4 Q0    ( (J%
M3U83W?R(U0H  .]5   :              " @;CJ P!X;"]W;W)K<VAE971S
M+W-H965T,3(V+GAM;%!+ 0(4 Q0    ( (J%3U8<57AM_@,  %02   :
M          " @<7U P!X;"]W;W)K<VAE971S+W-H965T,3(W+GAM;%!+ 0(4
M Q0    ( (J%3U8=?;!N) 4  &<5   :              " @?OY P!X;"]W
M;W)K<VAE971S+W-H965T,3(X+GAM;%!+ 0(4 Q0    ( (J%3U9O71R$S00
M /$4   :              " @5?_ P!X;"]W;W)K<VAE971S+W-H965T,3(Y
M+GAM;%!+ 0(4 Q0    ( (J%3U9^NT%V<0X  (ZL   :              "
M@5P$! !X;"]W;W)K<VAE971S+W-H965T,3,P+GAM;%!+ 0(4 Q0    ( (J%
M3U;:L+=>? ,  &(+   :              " @043! !X;"]W;W)K<VAE971S
M+W-H965T,3,Q+GAM;%!+ 0(4 Q0    ( (J%3U:XF$3<8 ,  )@6   -
M          "  ;D6! !X;"]S='EL97,N>&UL4$L! A0#%     @ BH5/5I>*
MNQS     $P(   L              ( !1!H$ %]R96QS+RYR96QS4$L! A0#
M%     @ BH5/5DIM#H/K"   O54   \              ( !+1L$ 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( (J%3U:)X*8'CP,  -),   :
M      "  44D! !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( (J%3U8L^_TJNP(  'E)   3              "  0PH! !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    "+ (L 9"8  /@J!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>819</ContextCount>
  <ElementCount>720</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>202</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis Of Presentation And Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis Of Presentation And Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Business Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessAcquisitions</Role>
      <ShortName>Business Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Business Optimization Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessOptimizationInitiatives</Role>
      <ShortName>Business Optimization Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Property And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/PropertyAndEquipment</Role>
      <ShortName>Property And Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Goodwill And Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets</Role>
      <ShortName>Goodwill And Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Medical Claims Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayable</Role>
      <ShortName>Medical Claims Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Commitments And Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments And Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Accumulated Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss</Role>
      <ShortName>Accumulated Other Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Reinsurance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/Reinsurance</Role>
      <ShortName>Reinsurance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Statutory Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/StatutoryInformation</Role>
      <ShortName>Statutory Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Schedule II-Condensed Financial Information Of Registrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant</Role>
      <ShortName>Schedule II-Condensed Financial Information Of Registrant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Basis Of Presentation And Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Basis Of Presentation And Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Business Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessAcquisitionsTables</Role>
      <ShortName>Business Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessAcquisitions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Business Optimization Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables</Role>
      <ShortName>Business Optimization Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessOptimizationInitiatives</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/Investments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/FairValue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property And Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property And Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/PropertyAndEquipment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Goodwill And Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill And Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefits</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Medical Claims Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</Role>
      <ShortName>Medical Claims Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/Debt</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStock</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Reinsurance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ReinsuranceTables</Role>
      <ShortName>Reinsurance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/Reinsurance</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/Leases</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/EarningsPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/SegmentInformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/Organization</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Basis Of Presentation And Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis Of Presentation And Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Business Acquisitions (Acquired tangible assets and liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails</Role>
      <ShortName>Business Acquisitions (Acquired tangible assets and liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessAcquisitionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Business Acquisitions (Intangible Assets Acquired) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Business Acquisitions (Intangible Assets Acquired) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessAcquisitionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Business Acquisitions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails</Role>
      <ShortName>Business Acquisitions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessAcquisitionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Business Optimization Initiatives (Employee Termination Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails</Role>
      <ShortName>Business Optimization Initiatives (Employee Termination Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Business Optimization Initiatives (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails</Role>
      <ShortName>Business Optimization Initiatives (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Investments (Current And Long-Term Investments, Available-For-Sale) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails</Role>
      <ShortName>Investments (Current And Long-Term Investments, Available-For-Sale) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails</Role>
      <ShortName>Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails</Role>
      <ShortName>Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Investments (Current Equity Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails</Role>
      <ShortName>Investments (Current Equity Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Investments (Major Categories Of Net Investment Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails</Role>
      <ShortName>Investments (Major Categories Of Net Investment Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Investments (Net Gains/Losses On Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails</Role>
      <ShortName>Investments (Net Gains/Losses On Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/InvestmentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Derivative Financial Instruments (Notional Amounts, Balance Sheet Location And Estimated Fair Values Of Derivative Financial Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments (Notional Amounts, Balance Sheet Location And Estimated Fair Values Of Derivative Financial Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Derivative Financial Instruments Derivative Financial Instruments (Fair Value Hedges, Financial Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails</Role>
      <ShortName>Derivative Financial Instruments Derivative Financial Instruments (Fair Value Hedges, Financial Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Derivative Financial Instruments (Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Gains (Losses) On Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails</Role>
      <ShortName>Derivative Financial Instruments (Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Gains (Losses) On Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Derivative Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Derivative Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/FairValueTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails</Role>
      <ShortName>Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/FairValueTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Fair Value (Carrying and Fair Value By Level of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails</Role>
      <ShortName>Fair Value (Carrying and Fair Value By Level of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/FairValueTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Income Taxes(Components Of Deferred Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes(Components Of Deferred Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Income Taxes (Components Of Provision For Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Components Of Provision For Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Income Taxes (Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes (Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Property And Equipment (Summary Of Property And Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property And Equipment (Summary Of Property And Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Property And Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property And Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails</Role>
      <ShortName>Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Goodwill And Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill And Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Retirement Benefits (Reconciliation Of The Benefit Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails</Role>
      <ShortName>Retirement Benefits (Reconciliation Of The Benefit Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Retirement Benefits (Changes In Fair Value Of Plan Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails</Role>
      <ShortName>Retirement Benefits (Changes In Fair Value Of Plan Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss That Have Not Been Recognized As Components Of Net Periodic Benefit Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails</Role>
      <ShortName>Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss That Have Not Been Recognized As Components Of Net Periodic Benefit Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Retirement Benefits (Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails</Role>
      <ShortName>Retirement Benefits (Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Retirement Benefits (Components Of Net Periodic Benefit Cost (Benefit Credit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails</Role>
      <ShortName>Retirement Benefits (Components Of Net Periodic Benefit Cost (Benefit Credit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Retirement Benefits (Weighted-Average Assumptions Used In Calculating Net Periodic Benefit Cost For All Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails</Role>
      <ShortName>Retirement Benefits (Weighted-Average Assumptions Used In Calculating Net Periodic Benefit Cost For All Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails</Role>
      <ShortName>Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails</Role>
      <ShortName>Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Retirement Benefits (Estimated Future Payments For Pension Benefits And Other Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails</Role>
      <ShortName>Retirement Benefits (Estimated Future Payments For Pension Benefits And Other Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Retirement Benefits (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails</Role>
      <ShortName>Retirement Benefits (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RetirementBenefitsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails</Role>
      <ShortName>Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Medical Claims Payable ((Favorable) Unfavorable Developments By Changes In Key Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails</Role>
      <ShortName>Medical Claims Payable ((Favorable) Unfavorable Developments By Changes In Key Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails</Role>
      <ShortName>Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Medical Claims Payable (Incurred and Paid Claims Development, Net of Reinsurance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails</Role>
      <ShortName>Medical Claims Payable (Incurred and Paid Claims Development, Net of Reinsurance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Medical Claims Payable (Reconciliation Of The Claims Development To The Claims Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails</Role>
      <ShortName>Medical Claims Payable (Reconciliation Of The Claims Development To The Claims Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Medical Claims Payable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails</Role>
      <ShortName>Medical Claims Payable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/MedicalClaimsPayableTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Debt (Carrying Value Of Long-Term Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails</Role>
      <ShortName>Debt (Carrying Value Of Long-Term Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DebtTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Debt (Convertible Debenture Terms) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails</Role>
      <ShortName>Debt (Convertible Debenture Terms) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DebtTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/DebtTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Commitments And Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments And Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Capital Stock (Summary Of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Capital Stock (Summary Of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails</Role>
      <ShortName>Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Capital Stock (Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails</Role>
      <ShortName>Capital Stock (Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Capital Stock (Weighted-Average Fair Values) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails</Role>
      <ShortName>Capital Stock (Weighted-Average Fair Values) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Capital Stock (Cash Dividend Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails</Role>
      <ShortName>Capital Stock (Cash Dividend Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Capital Stock (Share Repurchases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails</Role>
      <ShortName>Capital Stock (Share Repurchases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Capital Stock (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/CapitalStockNarrativeDetails</Role>
      <ShortName>Capital Stock (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/CapitalStockTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Earned) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails</Role>
      <ShortName>Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Earned) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ReinsuranceTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - Reinsurance (Summary Of Net Premiums Earned By Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails</Role>
      <ShortName>Reinsurance (Summary Of Net Premiums Earned By Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ReinsuranceTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - Reinsurance (Effect Of Reinsurance On Benefit Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails</Role>
      <ShortName>Reinsurance (Effect Of Reinsurance On Benefit Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ReinsuranceTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - Leases (Lease and Other Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails</Role>
      <ShortName>Leases (Lease and Other Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/LeasesTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - Leases Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails</Role>
      <ShortName>Leases Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - Leases Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails</Role>
      <ShortName>Leases Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/EarningsPerShareTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - Earnings Per Share (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/EarningsPerShareTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails</Role>
      <ShortName>Segment Information (Financial Data By Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/SegmentInformationTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000121 - Disclosure - Segment Information (Major Product Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails</Role>
      <ShortName>Segment Information (Major Product Revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/SegmentInformationTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>0000122 - Disclosure - Segment Information (Reconciliation Of Revenue From Reportable Segments To The Consolidated Statements Of Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails</Role>
      <ShortName>Segment Information (Reconciliation Of Revenue From Reportable Segments To The Consolidated Statements Of Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/SegmentInformationTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>0000123 - Disclosure - Segment Information (Reconciliation Of Reportable Segment Operating Gain To Income Before Income Taxes In The Consolidated Statements Of Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails</Role>
      <ShortName>Segment Information (Reconciliation Of Reportable Segment Operating Gain To Income Before Income Taxes In The Consolidated Statements Of Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/SegmentInformationTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>0000124 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/SegmentInformationTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>0000125 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/RelatedPartyTransactions</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>0000126 - Disclosure - Statutory Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/StatutoryInformationDetails</Role>
      <ShortName>Statutory Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/StatutoryInformation</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>0000127 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails</Role>
      <ShortName>Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>0000128 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Balance Sheets - Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails</Role>
      <ShortName>Schedule II-Condensed Financial Information Of Registrant (Balance Sheets - Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>0000129 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Statements Of Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails</Role>
      <ShortName>Schedule II-Condensed Financial Information Of Registrant (Statements Of Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>0000130 - Disclosure - Schedule II-Condensed Financial Information of Registrant (Statement of Comprehensive Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails</Role>
      <ShortName>Schedule II-Condensed Financial Information of Registrant (Statement of Comprehensive Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>0000131 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Statement Of Cash Flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails</Role>
      <ShortName>Schedule II-Condensed Financial Information Of Registrant (Statement Of Cash Flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant</ParentRole>
      <Position>130</Position>
    </Report>
    <Report instance="elv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>0000132 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails</Role>
      <ShortName>Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant</ParentRole>
      <Position>131</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: elv:SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan, us-gaap:OperatingLossCarryforwardsExpirationDate, us-gaap:PropertyPlantAndEquipmentUsefulLife -  elv-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="elv-20221231.htm">elv-20221231.htm</File>
    <File>elv-20221231.xsd</File>
    <File>elv-20221231_cal.xml</File>
    <File>elv-20221231_def.xml</File>
    <File>elv-20221231_lab.xml</File>
    <File>elv-20221231_pre.xml</File>
    <File>exhibit101-20221231forform.htm</File>
    <File>exhibit1011-primarybluecro.htm</File>
    <File>exhibit1012-primaryblueshi.htm</File>
    <File>exhibit21-20221231forform1.htm</File>
    <File>exhibit23-20221231forform1.htm</File>
    <File>exhibit311-20221231for10xk.htm</File>
    <File>exhibit312-20221231for10xk.htm</File>
    <File>exhibit321-20221231for10xk.htm</File>
    <File>exhibit322-20221231for10xk.htm</File>
    <File>exhibit47-20221231forform1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>elv-20221231_g1.jpg</File>
    <File>elv-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="2935">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>157
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "elv-20221231.htm": {
   "axisCustom": 5,
   "axisStandard": 41,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 2935,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 819,
   "dts": {
    "calculationLink": {
     "local": [
      "elv-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "elv-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "elv-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "elv-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "elv-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "elv-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 1160,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 37,
    "http://www.elevancehealth.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 42
   },
   "keyCustom": 81,
   "keyStandard": 639,
   "memberCustom": 103,
   "memberStandard": 91,
   "nsprefix": "elv",
   "nsuri": "http://www.elevancehealth.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.elevancehealth.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis Of Presentation And Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis Of Presentation And Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Debt (Convertible Debenture Terms) (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails",
     "shortName": "Debt (Convertible Debenture Terms) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Debt (Narrative) (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.elevancehealth.com/role/DebtNarrativeDetails",
     "shortName": "Debt (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Commitments And Contingencies (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments And Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Capital Stock (Summary Of Stock Option Activity) (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails",
     "shortName": "Capital Stock (Summary Of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails",
     "shortName": "Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Capital Stock (Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted) (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
     "shortName": "Capital Stock (Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Capital Stock (Weighted-Average Fair Values) (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails",
     "shortName": "Capital Stock (Weighted-Average Fair Values) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i9f1d6a035065442988901aa213d9e12b_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Capital Stock (Cash Dividend Activity) (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails",
     "shortName": "Capital Stock (Cash Dividend Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i9f1d6a035065442988901aa213d9e12b_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Capital Stock (Share Repurchases) (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails",
     "shortName": "Capital Stock (Share Repurchases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Capital Stock (Narrative) (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
     "shortName": "Capital Stock (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Business Acquisitions",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.elevancehealth.com/role/BusinessAcquisitions",
     "shortName": "Business Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DirectPremiumsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Earned) (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails",
     "shortName": "Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Earned) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DirectPremiumsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - Reinsurance (Summary Of Net Premiums Earned By Segment) (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails",
     "shortName": "Reinsurance (Summary Of Net Premiums Earned By Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i20d839c65c244c4589c68cc00b4be3b7_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PolicyholderBenefitsAndClaimsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - Reinsurance (Effect Of Reinsurance On Benefit Expense) (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails",
     "shortName": "Reinsurance (Effect Of Reinsurance On Benefit Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PolicyholderBenefitsAndClaimsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:LesseeOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - Leases (Lease and Other Information) (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails",
     "shortName": "Leases (Lease and Other Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:LesseeOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - Leases Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails",
     "shortName": "Leases Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - Leases Leases (Narrative) (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails",
     "shortName": "Leases Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ib99d2d66da9844cab49602099b561dda_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails",
     "shortName": "Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - Earnings Per Share (Narrative) (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceServicesRevenue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
     "shortName": "Segment Information (Financial Data By Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Business Optimization Initiatives",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiatives",
     "shortName": "Business Optimization Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i3e539c32012849dc97ee77c6fe12eeca_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceServicesRevenue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000121 - Disclosure - Segment Information (Major Product Revenues) (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails",
     "shortName": "Segment Information (Major Product Revenues) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4c68969e3f114ff69c401be9bc37c2dd_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InsuranceServicesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceServicesRevenue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000122 - Disclosure - Segment Information (Reconciliation Of Revenue From Reportable Segments To The Consolidated Statements Of Income) (Details)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails",
     "shortName": "Segment Information (Reconciliation Of Revenue From Reportable Segments To The Consolidated Statements Of Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000123 - Disclosure - Segment Information (Reconciliation Of Reportable Segment Operating Gain To Income Before Income Taxes In The Consolidated Statements Of Income) (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails",
     "shortName": "Segment Information (Reconciliation Of Reportable Segment Operating Gain To Income Before Income Taxes In The Consolidated Statements Of Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "elv:NetLossesGainsOnFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000124 - Disclosure - Segment Information (Narrative) (Details)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i417b0315d1f946278154f230d44ba1b0_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000125 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i417b0315d1f946278154f230d44ba1b0_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000126 - Disclosure - Statutory Information (Details)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://www.elevancehealth.com/role/StatutoryInformationDetails",
     "shortName": "Statutory Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000127 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
     "shortName": "Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000128 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Balance Sheets - Additional Information) (Details)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails",
     "shortName": "Schedule II-Condensed Financial Information Of Registrant (Balance Sheets - Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i0cb7a5f59d934fa688ffd6000b53fdc9_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetInvestmentIncome",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000129 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Statements Of Income) (Details)",
     "menuCat": "Details",
     "order": "128",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
     "shortName": "Schedule II-Condensed Financial Information Of Registrant (Statements Of Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetInvestmentIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000130 - Disclosure - Schedule II-Condensed Financial Information of Registrant (Statement of Comprehensive Income) (Details)",
     "menuCat": "Details",
     "order": "129",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails",
     "shortName": "Schedule II-Condensed Financial Information of Registrant (Statement of Comprehensive Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.elevancehealth.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000131 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Statement Of Cash Flows) (Details)",
     "menuCat": "Details",
     "order": "130",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails",
     "shortName": "Schedule II-Condensed Financial Information Of Registrant (Statement Of Cash Flows) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashDividendsPaidToParentCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000132 - Disclosure - Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details)",
     "menuCat": "Details",
     "order": "131",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails",
     "shortName": "Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8bc72ccf9de2441db57f2b01ba1a7ccc_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashDividendsPaidToParentCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Derivative Financial Instruments",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.elevancehealth.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.elevancehealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Property And Equipment",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.elevancehealth.com/role/PropertyAndEquipment",
     "shortName": "Property And Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Goodwill And Other Intangible Assets",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets",
     "shortName": "Goodwill And Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Retirement Benefits",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.elevancehealth.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.elevancehealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Medical Claims Payable",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayable",
     "shortName": "Medical Claims Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.elevancehealth.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Commitments And Contingencies",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.elevancehealth.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments And Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Capital Stock",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.elevancehealth.com/role/CapitalStock",
     "shortName": "Capital Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Accumulated Other Comprehensive Loss",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss",
     "shortName": "Accumulated Other Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReinsuranceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Reinsurance",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.elevancehealth.com/role/Reinsurance",
     "shortName": "Reinsurance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReinsuranceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.elevancehealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.elevancehealth.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Segment Information",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.elevancehealth.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.elevancehealth.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PremiumsReceivableAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elv:StatutoryInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Statutory Information",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.elevancehealth.com/role/StatutoryInformation",
     "shortName": "Statutory Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elv:StatutoryInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Schedule II-Condensed Financial Information Of Registrant",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant",
     "shortName": "Schedule II-Condensed Financial Information Of Registrant",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Basis Of Presentation And Significant Accounting Policies (Policy)",
     "menuCat": "Policies",
     "order": "32",
     "role": "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy",
     "shortName": "Basis Of Presentation And Significant Accounting Policies (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Business Acquisitions (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsTables",
     "shortName": "Business Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Business Optimization Initiatives (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables",
     "shortName": "Business Optimization Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.elevancehealth.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Derivative Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.elevancehealth.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.elevancehealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property And Equipment (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.elevancehealth.com/role/PropertyAndEquipmentTables",
     "shortName": "Property And Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Goodwill And Other Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables",
     "shortName": "Goodwill And Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Retirement Benefits (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Medical Claims Payable (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableTables",
     "shortName": "Medical Claims Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.elevancehealth.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Capital Stock (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.elevancehealth.com/role/CapitalStockTables",
     "shortName": "Capital Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables",
     "shortName": "Accumulated Other Comprehensive Loss (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Reinsurance (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.elevancehealth.com/role/ReinsuranceTables",
     "shortName": "Reinsurance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elv:LesseeOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.elevancehealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elv:LesseeOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.elevancehealth.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Segment Information (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://www.elevancehealth.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Income",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "elv:ProductRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "elv:NumberOfCountiesInGeographicalRegionNotServed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "counties",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Organization (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.elevancehealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "elv:NumberOfCountiesInGeographicalRegionNotServed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "counties",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndInvestmentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Basis Of Presentation And Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
     "shortName": "Basis Of Presentation And Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndInvestmentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Business Acquisitions (Acquired tangible assets and liabilities) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails",
     "shortName": "Business Acquisitions (Acquired tangible assets and liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:TotalIntangibleAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Business Acquisitions (Intangible Assets Acquired) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
     "shortName": "Business Acquisitions (Intangible Assets Acquired) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:TotalIntangibleAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Business Acquisitions (Narrative) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
     "shortName": "Business Acquisitions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i42368d14ad324be6931badb1eb7a8a52_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i575634935f9d42e19be485bc9862c0f3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Business Optimization Initiatives (Employee Termination Costs) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
     "shortName": "Business Optimization Initiatives (Employee Termination Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i575634935f9d42e19be485bc9862c0f3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Business Optimization Initiatives (Narrative) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
     "shortName": "Business Optimization Initiatives (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Investments (Current And Long-Term Investments, Available-For-Sale) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
     "shortName": "Investments (Current And Long-Term Investments, Available-For-Sale) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "securities",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
     "shortName": "Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "securities",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
     "shortName": "Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "icafc8ed72ff645f5a69ea33ced3d0fe6_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "elv:ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:InvestmentsinequitysecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:EquitySecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Investments (Current Equity Securities) (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails",
     "shortName": "Investments (Current Equity Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Investments (Major Categories Of Net Investment Income) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
     "shortName": "Investments (Major Categories Of Net Investment Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:InvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Investments (Net Gains/Losses On Investments) (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails",
     "shortName": "Investments (Net Gains/Losses On Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:InvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Investments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "elv:NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Derivative Financial Instruments (Notional Amounts, Balance Sheet Location And Estimated Fair Values Of Derivative Financial Instruments) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
     "shortName": "Derivative Financial Instruments (Notional Amounts, Balance Sheet Location And Estimated Fair Values Of Derivative Financial Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails",
     "shortName": "Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2e2fb9b4d38545ababb8320a29faa28d_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i95d7b5c7de1a49d48dd9569c22788930_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAmountOfHedgedItem",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Derivative Financial Instruments Derivative Financial Instruments (Fair Value Hedges, Financial Position) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails",
     "shortName": "Derivative Financial Instruments Derivative Financial Instruments (Fair Value Hedges, Financial Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i95d7b5c7de1a49d48dd9569c22788930_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAmountOfHedgedItem",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Derivative Financial Instruments (Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Gains (Losses) On Investments) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
     "shortName": "Derivative Financial Instruments (Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Gains (Losses) On Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Derivative Financial Instruments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
     "shortName": "Derivative Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
     "shortName": "Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
     "shortName": "Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i6715d3ccc7ea4563a72cd62894c7df53_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Fair Value (Carrying and Fair Value By Level of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
     "shortName": "Fair Value (Carrying and Fair Value By Level of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i29275f18d1a443b99c9691261dec2159_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherLongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Income Taxes(Components Of Deferred Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails",
     "shortName": "Income Taxes(Components Of Deferred Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Income Taxes (Components Of Provision For Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes (Components Of Provision For Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails",
     "shortName": "Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Income Taxes (Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails",
     "shortName": "Income Taxes (Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i6f69d9e10ab049a0bdec5b6baf1996c5_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemEarningsPerShareImpactNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Property And Equipment (Summary Of Property And Equipment) (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails",
     "shortName": "Property And Equipment (Summary Of Property And Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Property And Equipment (Narrative) (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails",
     "shortName": "Property And Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails",
     "shortName": "Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ibf5b071c02144445ae1940007287f05f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Changes in Equity",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ibf5b071c02144445ae1940007287f05f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails",
     "shortName": "Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Goodwill And Other Intangible Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill And Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i399e8b1e21f5426486fa66186ca7a17e_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Retirement Benefits (Reconciliation Of The Benefit Obligation) (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
     "shortName": "Retirement Benefits (Reconciliation Of The Benefit Obligation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i399e8b1e21f5426486fa66186ca7a17e_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Retirement Benefits (Changes In Fair Value Of Plan Assets) (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
     "shortName": "Retirement Benefits (Changes In Fair Value Of Plan Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
     "shortName": "Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss That Have Not Been Recognized As Components Of Net Periodic Benefit Costs) (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
     "shortName": "Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss That Have Not Been Recognized As Components Of Net Periodic Benefit Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Retirement Benefits (Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans) (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails",
     "shortName": "Retirement Benefits (Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Retirement Benefits (Components Of Net Periodic Benefit Cost (Benefit Credit) (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
     "shortName": "Retirement Benefits (Components Of Net Periodic Benefit Cost (Benefit Credit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Retirement Benefits (Weighted-Average Assumptions Used In Calculating Net Periodic Benefit Cost For All Plans) (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
     "shortName": "Retirement Benefits (Weighted-Average Assumptions Used In Calculating Net Periodic Benefit Cost For All Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i8f2d0cbb82ad4a3c8e6c6ff1a073194f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i9d2e3cdf76fb4346a9739172b0a28be0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
     "shortName": "Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4d1a53d49d5c4867aa039a46e7568ed3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.elevancehealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ia5f9bbbaabb04060a11a6fd22a348392_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs) (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails",
     "shortName": "Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i087a822a1c0e4d969893b0be9331987c_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Retirement Benefits (Estimated Future Payments For Pension Benefits And Other Benefits) (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
     "shortName": "Retirement Benefits (Estimated Future Payments For Pension Benefits And Other Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i72b759f5ad9048f5a21e88c5835d93b0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Retirement Benefits (Narrative) (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
     "shortName": "Retirement Benefits (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "elv:DefinedBenefitFairValueDueFromBrokers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i2310c7de653445608cb615a91fde33b6_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
     "shortName": "Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i6715d3ccc7ea4563a72cd62894c7df53_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Medical Claims Payable ((Favorable) Unfavorable Developments By Changes In Key Assumptions) (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails",
     "shortName": "Medical Claims Payable ((Favorable) Unfavorable Developments By Changes In Key Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "elv:FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
     "shortName": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "elv:QualityImprovementAndOtherClaimsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Medical Claims Payable (Incurred and Paid Claims Development, Net of Reinsurance) (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
     "shortName": "Medical Claims Payable (Incurred and Paid Claims Development, Net of Reinsurance) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i23463b26e20041c888dd2c51a2181294_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Medical Claims Payable (Reconciliation Of The Claims Development To The Claims Liability) (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails",
     "shortName": "Medical Claims Payable (Reconciliation Of The Claims Development To The Claims Liability) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "ided38cf943eb4d0680c68d45403f03b2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Medical Claims Payable (Narrative) (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
     "shortName": "Medical Claims Payable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i23463b26e20041c888dd2c51a2181294_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "i4a75db76b76e4786aa3fcd8ba8940b14_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Debt (Carrying Value Of Long-Term Debt) (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
     "shortName": "Debt (Carrying Value Of Long-Term Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "elv-20221231.htm",
      "contextRef": "iaa1c710fc55e47898c1d2f197e749108_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 202,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1091"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation",
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r1097"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r1098"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation",
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1092"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "elv_A2021364DayFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 364-Day Facility [Member]",
        "label": "2021 364-Day Facility [Member]",
        "terseLabel": "2021 364-Day Facility"
       }
      }
     },
     "localname": "A2021364DayFacilityMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_A2022To2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 to 2024",
        "label": "2022 to 2024 [Member]",
        "terseLabel": "2022 to 2024 [Member]"
       }
      }
     },
     "localname": "A2022To2024Member",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_A5YearFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5-Year Facility [Member]",
        "label": "5-Year Facility [Member]",
        "terseLabel": "5-Year Facility [Member]"
       }
      }
     },
     "localname": "A5YearFacilityMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_APCPasseLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC Passe, LLC [Member]",
        "label": "APC Passe, LLC [Member]",
        "terseLabel": "APC Passe, LLC [Member]"
       }
      }
     },
     "localname": "APCPasseLLCMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_AcquisitionYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Year",
        "label": "Acquisition Year [Axis]",
        "terseLabel": "Acquisition Year [Axis]"
       }
      }
     },
     "localname": "AcquisitionYearAxis",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_AcquisitionYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Year [Domain]",
        "label": "Acquisition Year [Domain]",
        "terseLabel": "Acquisition Year [Domain]"
       }
      }
     },
     "localname": "AcquisitionYearDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_AcquisitionYearPriorDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Year, Prior",
        "label": "Acquisition Year, Prior [Domain]",
        "terseLabel": "Acquisition Year, Prior Year"
       }
      }
     },
     "localname": "AcquisitionYearPriorDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_AffiliatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliated [Member]",
        "label": "Affiliated [Member]",
        "terseLabel": "Affiliated [Member]"
       }
      }
     },
     "localname": "AffiliatedMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_AmortizationExpenseOnSoftwareAndLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each income statement presented, the amount charged to expense for amortization of capitalized computer software and leasehold improvement costs.",
        "label": "Amortization Expense On Software And Leasehold Improvements",
        "terseLabel": "Amortization expense on computer software and leasehold improvements"
       }
      }
     },
     "localname": "AmortizationExpenseOnSoftwareAndLeaseholdImprovements",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_AnthemInc.v.ExpressScriptsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anthem, Inc. v. Express Scripts, Inc. [Member]",
        "label": "Anthem, Inc. v. Express Scripts, Inc. [Member]",
        "terseLabel": "Anthem, Inc. v. Express Scripts, Inc. [Member]"
       }
      }
     },
     "localname": "AnthemInc.v.ExpressScriptsInc.Member",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_BasisOfPresentationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Of Presentation And Significant Accounting Policies [Line Items]",
        "label": "Basis Of Presentation And Significant Accounting Policies [Line Items]",
        "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_BasisOfPresentationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Of Presentation And Significant Accounting Policies [Table]",
        "label": "Basis Of Presentation And Significant Accounting Policies [Table]",
        "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Accounts Receivables and Other Current Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Accounts Receivables and Other Current Assets",
        "terseLabel": "Accounts receivable and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, CurrentLiabilities, Accounts Payable and Other Current Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, CurrentLiabilities, Accounts Payable and Other Current Liabilities",
        "negatedTerseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Medical claims and Other Policyholder liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Medical claims and Other Policyholder liabilities",
        "negatedTerseLabel": "Medical claims and other policyholder liabilities payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property And Equipment and Other Long Term Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property And Equipment and Other Long Term Assets",
        "terseLabel": "Property, equipment and other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_BusinessOptimizationInitiativesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Optimization Initiatives",
        "label": "Business Optimization Initiatives [Abstract]"
       }
      }
     },
     "localname": "BusinessOptimizationInitiativesAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Department of Managed Health Care Regulated Entities",
        "label": "California Department Of Managed Health Care Regulated Entities [Member]",
        "terseLabel": "California Department of Managed Health Care Regulated Entities [Member]"
       }
      }
     },
     "localname": "CaliforniaDepartmentOfManagedHealthCareRegulatedEntitiesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_CaliforniaDepartmentofManagedHealthCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Department of Managed Health Care [Member]",
        "label": "California Department of Managed Health Care [Member]",
        "terseLabel": "California Department of Managed Health Care [Member]"
       }
      }
     },
     "localname": "CaliforniaDepartmentofManagedHealthCareMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_CapitalContributionToSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital contribution to subsidiaries",
        "label": "Capital Contribution To Subsidiaries",
        "terseLabel": "Capital contribution to subsidiaries"
       }
      }
     },
     "localname": "CapitalContributionToSubsidiaries",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_CapitalStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Stock [Axis]",
        "label": "Capital Stock [Axis]",
        "terseLabel": "Capital Stock [Axis]"
       }
      }
     },
     "localname": "CapitalStockAxis",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_CapitalStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Stock [Domain]",
        "label": "Capital Stock [Domain]",
        "terseLabel": "Capital Stock [Domain]"
       }
      }
     },
     "localname": "CapitalStockDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block]",
        "terseLabel": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet"
       }
      }
     },
     "localname": "CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in non-credit component of impairment losses on investments, net of tax effect.",
        "label": "Change in non-credit component of impairment losses on investments net of tax",
        "terseLabel": "Change in non-credit component of impairment losses on investments, net of tax"
       }
      }
     },
     "localname": "ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_ClaimsSettlementsToBePaidFromOtherBenefitAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claims settlements to be paid from other benefit assets",
        "label": "Claims settlements to be paid from other benefit assets",
        "terseLabel": "Claims settlements to be paid from other benefit assets"
       }
      }
     },
     "localname": "ClaimsSettlementsToBePaidFromOtherBenefitAssets",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_CommercialPaperMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Paper, Maximum Borrowing Capacity",
        "label": "Commercial Paper Maximum Borrowing Capacity",
        "terseLabel": "Commercial paper authorized"
       }
      }
     },
     "localname": "CommercialPaperMaximumBorrowingCapacity",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_CommercialSpecialtyBusinessSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial and Specialty Business Segment",
        "label": "Commercial Specialty Business Segment [Member]",
        "terseLabel": "Commercial and Specialty Business [Member]",
        "verboseLabel": "Commercial and Specialty Business Segment [Member]"
       }
      }
     },
     "localname": "CommercialSpecialtyBusinessSegmentMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_CommingledFundDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commingled Fund",
        "label": "Commingled Fund [Domain]",
        "terseLabel": "Commingled fund",
        "verboseLabel": "Commingled fund"
       }
      }
     },
     "localname": "CommingledFundDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies [Table].",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_CommonEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Equity Securities [Member]",
        "label": "Common Equity Securities [Member]",
        "terseLabel": "Common Equity Securities [Member]"
       }
      }
     },
     "localname": "CommonEquitySecuritiesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion premium to the closing market price of common stock",
        "label": "Conversion Premium",
        "terseLabel": "Conversion premium (%)"
       }
      }
     },
     "localname": "ConversionPremium",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_DataProcessingEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Data Processing Equipment and Computer Software [Member]",
        "label": "Data Processing Equipment And Software [Member]",
        "verboseLabel": "Computer Equipment, Furniture and Other Equipment [Member]"
       }
      }
     },
     "localname": "DataProcessingEquipmentAndSoftwareMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_DateDebenturesReedemable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Date Debentures Reedemable",
        "terseLabel": "Date debentures redeemable at our option"
       }
      }
     },
     "localname": "DateDebenturesReedemable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "elv_DebtConversionDebtPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate principal amount of the original debt instrument that was surrendered for conversion.",
        "label": "Debt Conversion Debt Principal Amount",
        "terseLabel": "Aggregate principal amount of convertible debentures surrendered for conversion"
       }
      }
     },
     "localname": "DebtConversionDebtPrincipalAmount",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DebtRedemptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt, Redemption amount",
        "label": "Debt, Redemption amount",
        "terseLabel": "Debt, Redemption amount"
       }
      }
     },
     "localname": "DebtRedemptionAmount",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DeferredTaxLiabilitiesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, net",
        "label": "Deferred tax liabilities, net [Member]",
        "terseLabel": "Deferred tax liabilities, net [Member]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_DeferredTaxLiabilitiesNonUSIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from non-U.S. intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Non-U.S Intangible Assets",
        "terseLabel": "Non-U.S intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNonUSIntangibleAssets",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DeferredTaxliabilitiesDeferredExpenseRetirementbenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax liabilities, Deferred Expense, Retirement benefits",
        "label": "Deferred Tax liabilities, Deferred Expense, Retirement benefits",
        "terseLabel": "Retirement assets"
       }
      }
     },
     "localname": "DeferredTaxliabilitiesDeferredExpenseRetirementbenefits",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DefinedBenefitAgeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Defined Benefit Age [Domain]",
        "terseLabel": "Defined Benefit Age [Domain]"
       }
      }
     },
     "localname": "DefinedBenefitAgeDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_DefinedBenefitFairValueDueFromBrokers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Fair Value Due From Brokers",
        "label": "Defined Benefit Fair Value Due From Brokers",
        "terseLabel": "Net amount of assets (liabilities) of cash, investment income receivable and amounts due to/from brokers, excluded from fair values of pension benefit assets and other benefit assets"
       }
      }
     },
     "localname": "DefinedBenefitFairValueDueFromBrokers",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Of Expected Rate Of Return On Plan Assets",
        "label": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Of Expected Rate Of Return On Plan Assets",
        "verboseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationOfExpectedRateOfReturnOnPlanAssets",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_DefinedBenefitPlanBenefitsPaidFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan Benefits Paid Fair Value",
        "label": "Defined Benefit Plan Benefits Paid Fair Value",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitsPaidFairValue",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_DefinedBenefitPlanByAgeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Defined Benefit Plan By Age [Axis]",
        "terseLabel": "Defined Benefit Plan By Age [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByAgeAxis",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_DentalVisionProductsAndServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dental Vision Products And Services [Member]",
        "label": "Dental Vision Products And Services [Member]",
        "terseLabel": "Dental Vision Products And Services [Member]"
       }
      }
     },
     "localname": "DentalVisionProductsAndServicesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Document and Entity Information",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense as a result of the basis adjustments from recent acquisitions",
        "label": "Effective Income Tax Rate Reconciliation Recent Acquisitions, amount",
        "terseLabel": "Basis adjustments from recent acquisitions, amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) resulting from basis adjustments due to recent acquistions",
        "label": "Effective Income Tax Rate Reconciliation Recent Acquisitions, percent",
        "terseLabel": "Basis adjustments from recent acquisitions, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider fee payments.",
        "label": "Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee",
        "terseLabel": "Health Insurance Provider fee, amount",
        "verboseLabel": "Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the income tax expense as a result of the non-tax deductibility of the Patient Protection Affordable Care Act Health Insurance Provider Fee.",
        "label": "Effective Income Tax Reconciliation, Patient Protection Affordable Care Act Health Insurance Provider Fee, Percent",
        "terseLabel": "Health Insurance Provider fee, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_EquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investments in equity securities.",
        "label": "Equity Securities",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecurities",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_EquitySecuritiesotherAssetsotherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities/other assets/other liabilities",
        "label": "Equity securities/other assets/other liabilities [Member]",
        "terseLabel": "Equity securities/other assets/other liabilities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesotherAssetsotherLiabilitiesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_EstimatedFutureDividendPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividends expected to be paid during the following twelve months subject to regulatory approval.",
        "label": "Estimated Future Dividend Payments",
        "terseLabel": "Estimated Future Dividend Payments"
       }
      }
     },
     "localname": "EstimatedFutureDividendPayments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_Fairvaluehedgescumulativebasisadjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative basis adjustments for fair value hedges.",
        "label": "Fair value hedges, cumulative basis adjustments",
        "negatedTerseLabel": "Cumulative basis adjustments for fair value hedges"
       }
      }
     },
     "localname": "Fairvaluehedgescumulativebasisadjustments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails": {
       "order": 2.0,
       "parentTag": "elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Favorable (Unfavorable) Developments by Changes in Completion Factors Assumptions",
        "label": "Favorable (Unfavorable) Developments by Changes in Completion Factors Assumptions",
        "negatedTerseLabel": "Assumed completion factors"
       }
      }
     },
     "localname": "FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Favorable (Unfavorable) Developments by Changes in Total Assumptions",
        "label": "Favorable (Unfavorable) Developments by Changes in Total Assumptions",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails": {
       "order": 1.0,
       "parentTag": "elv_FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Favorable (Unfavorable) Developments by Changes in Trend Factors Assumptions",
        "label": "Favorable (Unfavorable) Developments by Changes in Trend Factors Assumptions",
        "negatedTerseLabel": "Assumed trend factors"
       }
      }
     },
     "localname": "FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableFavorableUnfavorableDevelopmentsByChangesInKeyAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point eight Five Zero Percent Due Two Thousand Thirty Six [Member]",
        "label": "Five Point Eight Five Zero Percent Due Two Thousand Thirty Six [Member]",
        "terseLabel": "5.850%, due 2036 [Member]"
       }
      }
     },
     "localname": "FivePointEightFiveZeroPercentDueTwoThousandThirtySixMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FivePointEightZeroZeroPercentDueTwoThousandFortyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Eight Zero Zero Percent Due Two Thousand Forty",
        "label": "Five Point Eight Zero Zero Percent Due Two Thousand Forty [Member]",
        "terseLabel": "5.800%, due 2040 [Member]"
       }
      }
     },
     "localname": "FivePointEightZeroZeroPercentDueTwoThousandFortyMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Five Zero Zero Percent Due Two Thousand Thirty Two",
        "label": "Five Point Five Zero Zero Percent Due Two Thousand Thirty Two [Member]",
        "terseLabel": "5.500% due 2032 [Member]"
       }
      }
     },
     "localname": "FivePointFiveZeroZeroPercentDueTwoThousandThirtyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Nine Five Zero Percent Due two Thousand Thirty Four [Member]",
        "label": "Five Point Nine Five Zero Percent Due Two Thousand Thirty Four [Member]",
        "terseLabel": "5.950%, due 2034 [Member]"
       }
      }
     },
     "localname": "FivePointNineFiveZeroPercentDueTwoThousandThirtyFourMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Two Five Percent Due Two Thousand Fifty Three",
        "label": "Five Point One Two Five Percent Due Two Thousand Fifty Three [Member]",
        "terseLabel": "5.125% due 2053 [Member]"
       }
      }
     },
     "localname": "FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Zero Zero Percent Due Two Thousand Forty Four [Member]",
        "label": "Five Point One Zero Zero Percent Due Two Thousand Forty Four [Member]",
        "terseLabel": "5.100%, due 2044 [Member]"
       }
      }
     },
     "localname": "FivePointOneZeroZeroPercentDueTwoThousandFortyFourMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Three Five Zero Percent Due Two Thousand Twenty Five",
        "label": "Five Point Three Five Zero Percent Due Two Thousand Twenty Five [Member]",
        "terseLabel": "5.350% due 2025 [Member]"
       }
      }
     },
     "localname": "FivePointThreeFiveZeroPercentDueTwoThousandTwentyFiveMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Eight Five Zero Percent Due Two Thousand Fifty Four [Member]",
        "label": "Four Point Eight Five Zero Percent Due Two Thousand Fifty Four [Member]",
        "terseLabel": "4.850%, due 2054 [Member]"
       }
      }
     },
     "localname": "FourPointEightFiveZeroPercentDueTwoThousandFiftyFourMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Five Zero Due Two Thousand Fifty Two",
        "label": "Four Point Five Five Zero Due Two Thousand Fifty Two [Member]",
        "terseLabel": "4.550% due 2052 [Member]"
       }
      }
     },
     "localname": "FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Five Zero Percent Due Two Thousand Forty Eight [Member]",
        "label": "Four Point Five Five Zero Percent Due Two Thousand Forty Eight [Member]",
        "terseLabel": "4.550%, due 2048 [Member]"
       }
      }
     },
     "localname": "FourPointFiveFiveZeroPercentDueTwoThousandFortyEightMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six",
        "label": "Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six [Member]",
        "terseLabel": "4.900 % due 2026 [Member]"
       }
      }
     },
     "localname": "FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point One Zero One Percent Due Two Thousand Twenty Eight [Member]",
        "label": "Four Point One Zero One Percent Due Two Thousand Twenty Eight [Member]",
        "terseLabel": "4.101%, due 2028 [Member]"
       }
      }
     },
     "localname": "FourPointOneZeroOnePercentDueTwoThousandTwentyEightMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point One Zero Percent Due Two Thousand Thirty Two",
        "label": "Four Point One Zero Percent Due Two Thousand Thirty Two [Member]",
        "terseLabel": "4.100% due 2032 [Member]"
       }
      }
     },
     "localname": "FourPointOneZeroPercentDueTwoThousandThirtyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Seven Five Zero Percent Due Two Thousand Thirty Three",
        "label": "Four Point Seven Five Zero Percent Due Two Thousand Thirty Three [Member]",
        "terseLabel": "4.750% due 2033 [Member]"
       }
      }
     },
     "localname": "FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Five Zero Percent Due Two Thousand Forty Four [Member]",
        "label": "Four Point Six Five Zero Percent Due Two Thousand Forty Four [Member]",
        "terseLabel": "4.650%, due 2044 [Member]"
       }
      }
     },
     "localname": "FourPointSixFiveZeroPercentDueTwoThousandFortyFourMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Four Point Six Five Zero Percent Due Two Thousand Forty Three [Member]",
        "terseLabel": "4.650%, due 2043 [Member]"
       }
      }
     },
     "localname": "FourPointSixFiveZeroPercentDueTwoThousandFortyThreeMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Two Five Percent Due Two Thousand Forty Two",
        "label": "Four Point Six Two Five Percent Due Two Thousand Forty Two [Member]",
        "terseLabel": "4.625%, due 2042 [Member]"
       }
      }
     },
     "localname": "FourPointSixTwoFivePercentDueTwoThousandFortyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Three Five Zero Percent Due Two Thousand Twenty",
        "label": "Four Point Three Five Zero Percent Due Two Thousand Twenty [Member]",
        "terseLabel": "4.350%, due 2020 [Member]"
       }
      }
     },
     "localname": "FourPointThreeFiveZeroPercentDueTwoThousandTwentyMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Three Seven Five Percent Due Two Thousand Forty Seven [Member]",
        "label": "Four Point Three Seven Five Percent Due Two Thousand Forty Seven [Member]",
        "terseLabel": "4.375% due 2047 [Member]"
       }
      }
     },
     "localname": "FourPointThreeSevenFivePercentDueTwoThousandFortySevenMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_GainsFromOtherInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains From Other Investments",
        "label": "Gains From Other Investments",
        "terseLabel": "Gross gains from other investments"
       }
      }
     },
     "localname": "GainsFromOtherInvestments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_GovernmentBusinessSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Business Segment",
        "label": "Government Business Segment [Member]",
        "terseLabel": "Government Business [Member]",
        "verboseLabel": "Government Business Segment [Member]"
       }
      }
     },
     "localname": "GovernmentBusinessSegmentMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails",
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_GrossLossesFromOtherInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Losses From Other Investments",
        "label": "Gross Losses From Other Investments",
        "negatedTerseLabel": "Gross losses from other investments"
       }
      }
     },
     "localname": "GrossLossesFromOtherInvestments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_GrossPremiumTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross premium tax rate",
        "label": "Gross Premium Tax Rate",
        "terseLabel": "Gross premium tax rate, state of California"
       }
      }
     },
     "localname": "GrossPremiumTaxRate",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_HealthInsuranceProviderFeePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Insurance Provider Fee [Policy Text Block]",
        "label": "Health Insurance Provider Fee [Policy Text Block]",
        "terseLabel": "Health Insurance Provider Fee"
       }
      }
     },
     "localname": "HealthInsuranceProviderFeePolicyTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_HealthInsuranceProviderfeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Insurance Provider fee [Member]",
        "label": "Health Insurance Provider fee [Member]",
        "terseLabel": "Health Insurance Provider fee [Member]"
       }
      }
     },
     "localname": "HealthInsuranceProviderfeeMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_HedgingStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging Status [Axis]",
        "label": "Hedging Status [Axis]",
        "terseLabel": "Hedging Status [Axis]"
       }
      }
     },
     "localname": "HedgingStatusAxis",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_HedgingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Hedging Status [Axis]",
        "label": "Hedging Status [Domain]",
        "terseLabel": "Hedging Status [Domain]"
       }
      }
     },
     "localname": "HedgingStatusDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_Impairmentlossesreversalsoninvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Impairment (losses) reversals on investments",
        "negatedTerseLabel": "Impairment (losses) recoveries recognized in income"
       }
      }
     },
     "localname": "Impairmentlossesreversalsoninvestments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_IncomeTaxRefundClaimsFiled": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax refund claims filed.",
        "label": "Income Tax Refund Claims Filed",
        "terseLabel": "Protective state income tax refund claims filed"
       }
      }
     },
     "localname": "IncomeTaxRefundClaimsFiled",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_IncreaseInStockRepurchaseProgramAuthorization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program.",
        "label": "Increase In Stock Repurchase Program Authorization",
        "terseLabel": "Increase in stock repurchase program authorization"
       }
      }
     },
     "localname": "IncreaseInStockRepurchaseProgramAuthorization",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incurred and Paid Claims Development, Net of Reinsurance [Abstract]",
        "label": "Incurred and Paid Claims Development, Net of Reinsurance [Abstract]",
        "terseLabel": "Incurred and Paid Claims Development, Net of Reinsurance [Abstract]"
       }
      }
     },
     "localname": "IncurredandPaidClaimsDevelopmentNetofReinsuranceAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite Carryforward Period"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_IngenioRxSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IngenioRx Segment",
        "label": "IngenioRx Segment [Member]",
        "terseLabel": "CarelonRx Segment [Member]"
       }
      }
     },
     "localname": "IngenioRxSegmentMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails",
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InsuranceCompanyContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Company Contracts [Member]",
        "label": "Insurance Company Contracts [Member]",
        "terseLabel": "Insurance Company Contracts [Member]"
       }
      }
     },
     "localname": "InsuranceCompanyContractsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance, HMO Subsidiaries and Regulated Entities, Excluding California Department of Managed Health Care",
        "label": "Insurance HMO Subsidiaries Regulated Entities Excluding California Department of Managed Health Care [Member]",
        "terseLabel": "Insurance, HMO Subsidiaries and Other Regulated Entities, Excluding the California Department of Managed Health Care [Member]"
       }
      }
     },
     "localname": "InsuranceHMOSubsidiariesRegulatedEntitiesExcludingCaliforniaDepartmentofManagedHealthCareMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Accumulated Amortization Excluding Goodwill",
        "label": "Intangible Assets Accumulated Amortization Excluding Goodwill",
        "negatedTerseLabel": "Accumulated Amortization, Total Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsAccumulatedAmortizationExcludingGoodwill",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_IntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets [Line Items]",
        "label": "Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsLineItems",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_IntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets [Table]",
        "label": "Intangible Assets [Table]",
        "terseLabel": "Intangible Assets [Table]"
       }
      }
     },
     "localname": "IntangibleAssetsTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_IntegratedHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrated health services",
        "label": "Integrated health services [Member]",
        "terseLabel": "Integrated health services [Member]"
       }
      }
     },
     "localname": "IntegratedHealthServicesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InterestRateReceivedFivePointFiveZeroPercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Received Five Point Five Zero Percentage",
        "label": "Interest Rate Received Five Point Five Zero Percentage [Member]",
        "terseLabel": "Interest Rate Received Five Point Five Zero Percentage"
       }
      }
     },
     "localname": "InterestRateReceivedFivePointFiveZeroPercentageMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InterestRateReceivedFourPointOneZeroOnePercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Received Four Point One Zero One Percentage",
        "label": "Interest Rate Received Four Point One Zero One Percentage [Member]",
        "terseLabel": "Interest Rate Received Four Point One Zero One Percentage [Member]"
       }
      }
     },
     "localname": "InterestRateReceivedFourPointOneZeroOnePercentageMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InterestRateReceivedThreePointThreeZeroPercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Received Three Point Three Zero Percentage",
        "label": "Interest Rate Received Three Point Three Zero Percentage [Member]",
        "terseLabel": "Interest Rate Received Three Point Three Zero Percentage [Member]"
       }
      }
     },
     "localname": "InterestRateReceivedThreePointThreeZeroPercentageMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InterestRateReceivedTwoPointFiveFiveZeroPercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Received Two Point Five Five Zero Percentage",
        "label": "Interest Rate Received Two Point Five Five Zero Percentage [Member]",
        "terseLabel": "Interest Rate Received Two Point Five Five Zero Percentage [Member]"
       }
      }
     },
     "localname": "InterestRateReceivedTwoPointFiveFiveZeroPercentageMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InterestRateReceivedTwoPointTwoFiveZeroPercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Received Two Point Two Five Zero Percentage",
        "label": "Interest Rate Received Two Point Two Five Zero Percentage [Member]",
        "terseLabel": "Interest Rate Received Two Point Two Five Zero Percentage [Member]"
       }
      }
     },
     "localname": "InterestRateReceivedTwoPointTwoFiveZeroPercentageMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InvestmentGainsLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Gains (Losses)",
        "label": "Investment Gains (Losses)",
        "verboseLabel": "Net (losses) gains on investments"
       }
      }
     },
     "localname": "InvestmentGainsLosses",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_InvestmentInDOL10312TrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In D O L 103-12 Trust [Member]",
        "label": "Investment In D O L10312 Trust [Member]",
        "terseLabel": "Investment In DOL 103-12 Trust [Member]"
       }
      }
     },
     "localname": "InvestmentInDOL10312TrustMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_InvestmentInSubsidiaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in Subsidiaries",
        "label": "Investment in Subsidiaries",
        "terseLabel": "Investment in subsidiaries"
       }
      }
     },
     "localname": "InvestmentInSubsidiaries",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_InvestmentsinequitysecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in equity securities [Table Text Block]",
        "label": "Investments in equity securities [Table Text Block]",
        "terseLabel": "Investments in Equity Securities"
       }
      }
     },
     "localname": "InvestmentsinequitysecuritiesTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_LeaseImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Impairment",
        "label": "Lease Impairment [Member]",
        "terseLabel": "Operating Lease Impairment and Abandonment [Member]"
       }
      }
     },
     "localname": "LeaseImpairmentMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_LesseeOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases [Table Text Block]",
        "label": "Lessee, Operating Leases [Table Text Block]",
        "terseLabel": "Lessee, Operating Leases [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments",
        "terseLabel": "Business combinations and purchase adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_LifeInsuranceContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Life Insurance Contracts [Member]",
        "label": "Life Insurance Contracts [Member]",
        "terseLabel": "Life Insurance Contracts [Member]"
       }
      }
     },
     "localname": "LifeInsuranceContractsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_LimitedCarryforwardPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited Carryforward Period",
        "label": "Limited Carryforward Period [Member]",
        "terseLabel": "Limited Carryforward Period"
       }
      }
     },
     "localname": "LimitedCarryforwardPeriodMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_MajorProductRevenueBySegmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Major Product Revenue By Segment [Table]",
        "label": "Major Product Revenue By Segment [Line Items]",
        "terseLabel": "Major Product Revenue By Segment [Line Items]"
       }
      }
     },
     "localname": "MajorProductRevenueBySegmentLineItems",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_MajorProductRevenueBySegmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Product Revenue By Segment [Table]",
        "label": "Major Product Revenue By Segment [Table]",
        "terseLabel": "Major Product Revenue By Segment [Table]"
       }
      }
     },
     "localname": "MajorProductRevenueBySegmentTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_MajorProductRevenueBySegmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Major Product Revenue By Segment [Table]",
        "label": "Major Product Revenue By Segment [Table Text Block]",
        "terseLabel": "Major Product Revenues"
       }
      }
     },
     "localname": "MajorProductRevenueBySegmentTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_ManagedCareProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care Products [Member]",
        "label": "Managed Care Products [Member]",
        "terseLabel": "Managed Care Products [Member]"
       }
      }
     },
     "localname": "ManagedCareProductsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ManagedCareServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care Services [Member]",
        "label": "Managed Care Services [Member]",
        "terseLabel": "Managed Care Services [Member]"
       }
      }
     },
     "localname": "ManagedCareServicesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_MeasurementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Period",
        "label": "Measurement Period",
        "terseLabel": "Measurement Period for testing"
       }
      }
     },
     "localname": "MeasurementPeriod",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elv_MedicalClaimsPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims Payable [Abstract]",
        "label": "Medical Claims Payable [Abstract]",
        "terseLabel": "Medical Claims Payable [Abstract]"
       }
      }
     },
     "localname": "MedicalClaimsPayableAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual Funds [Member]",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual Funds [Member]"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_NetGainsLossesOnFinancialInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net gains (losses) on financial instruments",
        "label": "Net gains (losses) on financial instruments",
        "negatedTerseLabel": "Net losses (gains) on financial instruments",
        "terseLabel": "Net (losses) gains on financial instruments",
        "verboseLabel": "Net (losses) gains on financial instruments"
       }
      }
     },
     "localname": "NetGainsLossesOnFinancialInstruments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_NetGainsLossesOnFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net gains (losses) on financial instruments",
        "label": "Net gains (losses) on financial instruments [Member]",
        "terseLabel": "Net (losses) gains on financial instruments"
       }
      }
     },
     "localname": "NetGainsLossesOnFinancialInstrumentsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_NetLossesGainsOnFinancialInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net (losses) gains on financial instruments",
        "label": "Net (losses) gains on financial instruments",
        "negatedTerseLabel": "Net (losses) gains on financial instruments"
       }
      }
     },
     "localname": "NetLossesGainsOnFinancialInstruments",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_NetPremiumsWrittenAndEarnedBySegmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Premiums Written And Earned By Segment [Table]",
        "label": "Net Premiums Written And Earned By Segment [Table]",
        "terseLabel": "Net Premiums Earned By Segment [Table]"
       }
      }
     },
     "localname": "NetPremiumsWrittenAndEarnedBySegmentTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nine Point Zero Zero Zero Percent Due Two Thousand Twenty Seven [member]",
        "label": "Nine Point Zero Zero Zero Percent Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "9.000%, due 2027 [Member]"
       }
      }
     },
     "localname": "NinePointZeroZeroZeroPercentDueTwoThousandTwentySevenMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-credit components of impairments on investments",
        "label": "Non-credit components of impairments on investments [Member]",
        "terseLabel": "Non-credit components of impairments on investments"
       }
      }
     },
     "localname": "NonCreditComponentsOfImpairmentsOnInvestmentsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_Notionalamountterminatedderivatives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents notional amount of terminated derivatives.",
        "label": "Notional amount, terminated derivatives",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "Notionalamountterminatedderivatives",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_NumberOfConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Number Of Consecutive Trading Days",
        "terseLabel": "Number of trading days exceeding 130%"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDays",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elv_NumberOfCountiesInGeographicalRegionNotServed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of counties in a geographical region for which services are not provided.",
        "label": "NumberOfCountiesInGeographicalRegionNotServed",
        "terseLabel": "Number of counties in the Kansas City area the Company does not serve"
       }
      }
     },
     "localname": "NumberOfCountiesInGeographicalRegionNotServed",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "elv_NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in fixed maturities, mortgage loans on real estate, investment real estate, and other long-term investments that have been non-income producing the for the twelve months preceding the balance sheet date.",
        "label": "Number Of Fixed Maturity Investments That Did Not Produce Income",
        "terseLabel": "Number of fixed maturity investments that did not produce income"
       }
      }
     },
     "localname": "NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "elv_NumberOfMedicalMembersServed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of medical members served",
        "label": "Number Of Medical Members Served",
        "terseLabel": "Number Of Medical Members Served"
       }
      }
     },
     "localname": "NumberOfMedicalMembersServed",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "elv_OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Five Zero Zero Percent Due Two Thousand Twenty Six",
        "label": "One Point Five Zero Zero Percent Due Two Thousand Twenty Six [Member]",
        "terseLabel": "1.500% due 2026 [Member]"
       }
      }
     },
     "localname": "OnePointFiveZeroZeroPercentDueTwoThousandTwentySixMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_OperatingRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from insurance services and products sold.",
        "label": "Operating Revenue",
        "totalLabel": "Total operating revenue"
       }
      }
     },
     "localname": "OperatingRevenue",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_OperationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operational [Member]",
        "label": "Operational [Member]",
        "terseLabel": "Operational [Member]"
       }
      }
     },
     "localname": "OperationalMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_OtherDerivativeInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Derivative Instruments",
        "label": "Other Derivative Instruments [Member]",
        "terseLabel": "Derivatives [Member]"
       }
      }
     },
     "localname": "OtherDerivativeInstrumentsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense",
        "terseLabel": "Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit (Expense)"
       }
      }
     },
     "localname": "OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_OtherPolicyholderLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Policyholder Liabilities Policy Text Block",
        "label": "Other Policyholder Liabilities [Policy Text Block]",
        "terseLabel": "Other Policyholder Liabilities"
       }
      }
     },
     "localname": "OtherPolicyholderLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other Products [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_OtherSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other segment",
        "label": "Other Segment [Member]",
        "terseLabel": "Other Segment [Member]",
        "verboseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherSegmentMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_OtherSeniorUnsecuredNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other senior unsecured notes",
        "label": "Other senior unsecured notes [Member]",
        "terseLabel": "Other senior unsecured notes [Member]"
       }
      }
     },
     "localname": "OtherSeniorUnsecuredNotesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PPEImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPE Impairment",
        "label": "PPE Impairment [Member]",
        "terseLabel": "Property and Equipment Impairment and Abandonment [Member]"
       }
      }
     },
     "localname": "PPEImpairmentMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PartnershipInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partnership investments",
        "label": "Partnership investments [Member]",
        "terseLabel": "Partnership investments [Member]"
       }
      }
     },
     "localname": "PartnershipInvestmentsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PatientProtectionAffordableCareActHealthInsuranceProviderFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual fee imposed on covered entities engaged in the business of providing health insurance for United States health risks. This fee is imposed by section 9010 of the Patient Protection and Affordable Care Act, as amended. The regulations affect persons engaged in the business of providing health insurance for United States health risks.",
        "label": "Patient Protection Affordable Care Act Health Insurance Provider Fee",
        "terseLabel": "Patient Protection Affordable Care Act Health Insurance Provider Fee, annual amount to be collected by the Government through assessments to all health insurers subject to the fee"
       }
      }
     },
     "localname": "PatientProtectionAffordableCareActHealthInsuranceProviderFee",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for the annual Health Insurance Provider Fee assessed in accordance with Section 9010 of the Patient Protection Affordable Care Act.",
        "label": "Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid",
        "terseLabel": "Patient Protection Affordable Care Act Health Insurance Provider Fee, amount paid"
       }
      }
     },
     "localname": "PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_PercentConversionToStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Percent Conversion To Stock Price",
        "terseLabel": "Percent of Conversion Price to Closing Price"
       }
      }
     },
     "localname": "PercentConversionToStockPrice",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_PerformancemeasurementperiodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance measurement period [Axis]",
        "label": "Performance measurement period [Axis]",
        "terseLabel": "Performance measurement period [Axis]"
       }
      }
     },
     "localname": "PerformancemeasurementperiodAxis",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_PerformancemeasurementperiodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Performance measurement period [Axis]",
        "label": "Performance measurement period [Domain]",
        "terseLabel": "Performance measurement period [Domain]"
       }
      }
     },
     "localname": "PerformancemeasurementperiodDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PharmacyProductsAndServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy products and services",
        "label": "Pharmacy products and services [Member]",
        "terseLabel": "Pharmacy products and services [Member]"
       }
      }
     },
     "localname": "PharmacyProductsAndServicesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PharmacypricingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy pricing [Member]",
        "label": "Pharmacy pricing [Member]",
        "terseLabel": "Pharmacy pricing [Member]"
       }
      }
     },
     "localname": "PharmacypricingMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PostMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Post Medicare [Member]",
        "terseLabel": "Post-Medicare [Member]"
       }
      }
     },
     "localname": "PostMedicareMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potentially Dilutive Restricted Stock Units Contingent On Operating Results",
        "label": "Potentially Dilutive Restricted Stock Units Contingent On Operating Results",
        "terseLabel": "Restricted stock units excluded from the denominator for diluted earnings per share"
       }
      }
     },
     "localname": "PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "elv_PreMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Pre Medicare [Member]",
        "terseLabel": "Pre-Medicare [Member]"
       }
      }
     },
     "localname": "PreMedicareMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_Proceedsfromsaleofequityandfixedmaturitysecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of equity and fixed maturity securities.",
        "label": "Proceeds from sale of equity and fixed maturity securities",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofequityandfixedmaturitysecurities",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_ProductRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "elv_OperatingRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold.",
        "label": "Product Revenue",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductRevenue",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_PurchasesOfProceedsFromSaleOfPropertyEquipmentNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net purchases of and proceeds from sale of property and equipment.",
        "label": "PurchasesOfProceedsFromSaleOfPropertyEquipmentNet",
        "terseLabel": "Purchases of property and equipment, net of sales"
       }
      }
     },
     "localname": "PurchasesOfProceedsFromSaleOfPropertyEquipmentNet",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_QualityImprovementAndOtherClaimsExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quality Improvement And Other Claims Expense",
        "label": "Quality Improvement And Other Claims Expense",
        "terseLabel": "Quality improvement and other claims expense"
       }
      }
     },
     "localname": "QualityImprovementAndOtherClaimsExpense",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_RatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rated notes",
        "label": "Rated notes [Member]",
        "terseLabel": "Rated notes"
       }
      }
     },
     "localname": "RatedNotesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Net Incurred Medical Claims To Benefit Expense [Abstract]",
        "label": "Reconciliation Of Net Incurred Medical Claims To Benefit Expense [Abstract]",
        "terseLabel": "Reconciliation Of Net Incurred Medical Claims To Benefit Expense [Abstract]"
       }
      }
     },
     "localname": "ReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]",
        "label": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]",
        "terseLabel": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]"
       }
      }
     },
     "localname": "ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of net incurred medical claims to benefit expense [Table]",
        "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]",
        "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]"
       }
      }
     },
     "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense.",
        "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block]",
        "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense"
       }
      }
     },
     "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table]",
        "label": "reconciliation of net incurred medical claims to benefit expense [Line Items]",
        "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Line Items]"
       }
      }
     },
     "localname": "ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.",
        "label": "Schedule Of Assumptions Used In Calculating The Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule Of Assumptions Used In Calculating The Benefit Obligations"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedInCalculatingTheBenefitObligationsTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.",
        "label": "Schedule Of Assumptions Used In Calculating The Net Periodic Benefit Cost [Table Text Block]",
        "verboseLabel": "Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedInCalculatingTheNetPeriodicBenefitCostTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Summary Of Net Premiums Written And Earned By Segment [Text Block]",
        "label": "Schedule Of Summary Of Net Premiums Written And Earned By Segment [Table Text Block]",
        "terseLabel": "Summary Of Net Premiums Earned By Segment"
       }
      }
     },
     "localname": "ScheduleOfSummaryOfNetPremiumsWrittenAndEarnedBySegmentTableTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions.",
        "label": "Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan",
        "terseLabel": "Securities lending transactions, ratio of fair value of collateral on hold to fair value of securities on loan"
       }
      }
     },
     "localname": "SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_SegmentEliminationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Eliminations [Member]",
        "label": "Segment Eliminations [Member]",
        "terseLabel": "Segment Eliminations [Member]"
       }
      }
     },
     "localname": "SegmentEliminationsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_SelfFundedReceivablesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts.",
        "label": "Self-Funded Receivables, Net",
        "terseLabel": "Self-funded receivables"
       }
      }
     },
     "localname": "SelfFundedReceivablesNet",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_SelffundedReceivablesAllowanceForDoubtfulAccounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value.",
        "label": "Self-funded Receivables, Allowance For Doubtful Accounts",
        "terseLabel": "Self-funded receivables, allowance for doubtful accounts"
       }
      }
     },
     "localname": "SelffundedReceivablesAllowanceForDoubtfulAccounts",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_SeniorUnsecuredNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes [Member]",
        "label": "Senior Unsecured Notes [Member]",
        "terseLabel": "Senior Unsecured Notes [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Amount",
        "terseLabel": "Maximum amount of stock employees are permitted to purchase per calender year (whole dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumSharesPerEmployeeAmount",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "terseLabel": "Payroll deductions, percent of gross compensation, minimum"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration.",
        "label": "Short Duration Contract Liability For Claims Adjustment Expense",
        "periodEndLabel": "Gross medical claims payable, end of year",
        "periodStartLabel": "Gross medical claims payable, beginning of year"
       }
      }
     },
     "localname": "ShortDurationContractLiabilityForClaimsAdjustmentExpense",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_ShortTermAndVariableLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and variable lease cost",
        "label": "Short-term and variable lease cost",
        "terseLabel": "Short-term and variable lease cost"
       }
      }
     },
     "localname": "ShortTermAndVariableLeaseCost",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_ShortdurationInsuranceContractsClaimYearTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-duration Insurance Contracts, Claim Year [Table]",
        "label": "Short-duration Insurance Contracts, Claim Year [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Claim Year [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsClaimYearTable",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims.",
        "label": "Short duration contract liability for unpaid claims and adjustment expense, Net",
        "periodEndLabel": "Net medical claims payable, end of year",
        "periodStartLabel": "Net medical claims payable, beginning of year"
       }
      }
     },
     "localname": "ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point One Zero Zero Percent Due Two Thousand Fifty Two",
        "label": "Six Point One Zero Zero Percent Due Two Thousand Fifty Two [Member]",
        "terseLabel": "6.100% due 2052 [Member]"
       }
      }
     },
     "localname": "SixPointOneZeroZeroPercentDueTwoThousandFiftyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Three Seven Five Percent Due Two thousand Thirty seven [Member]",
        "label": "Six Point Three Seven Five Percent Due Two Thousand Thirty Seven [Member]",
        "terseLabel": "6.375%, due 2037 [Member]"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentDueTwoThousandThirtySevenMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_StatutoryInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statutory information [Abstract]",
        "label": "Statutory Information [Abstract]",
        "terseLabel": "Statutory Information [Abstract]"
       }
      }
     },
     "localname": "StatutoryInformationAbstract",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "elv_StatutoryInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statutory Information [Text Block]",
        "label": "Statutory Information [Text Block]",
        "terseLabel": "Statutory Information"
       }
      }
     },
     "localname": "StatutoryInformationTextBlock",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elv_StockOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Term",
        "label": "Stock Option Term",
        "terseLabel": "Stock option term, years"
       }
      }
     },
     "localname": "StockOptionTerm",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchased and Retired During Period Average Price",
        "label": "Stock Repurchased and Retired During Period Average Price",
        "verboseLabel": "Average price per share"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodAveragePrice",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "elv_SurplusNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surplus Notes [Member]",
        "label": "Surplus Notes [Member]",
        "terseLabel": "Surplus Notes [Member]"
       }
      }
     },
     "localname": "SurplusNotesMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TerminationsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of derivatives terminated [Domain]",
        "label": "Terminations [Domain]",
        "terseLabel": "Terminations [Domain]"
       }
      }
     },
     "localname": "TerminationsDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThirdPartyInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third party investments",
        "label": "Third party investments [Member]",
        "terseLabel": "Third party investments"
       }
      }
     },
     "localname": "ThirdPartyInvestmentsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Five Zero Zero Percent Due Two Thousand Twenty Four [Member]",
        "label": "Three Point Five Zero Zero Percent Due Two Thousand Twenty Four [Member]",
        "terseLabel": "3.500%, due 2024 [Member]"
       }
      }
     },
     "localname": "ThreePointFiveZeroZeroPercentDueTwoThousandTwentyFourMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointOneTwoFivePercentDueTwoThousandFiftyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Two Five Percent Due Two Thousand Fifty",
        "label": "Three Point One Two Five Percent Due Two Thousand Fifty [Member]",
        "terseLabel": "3.125% due 2050 [Member]"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentDueTwoThousandFiftyMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Two Five Percent Due Two Thousand Twenty Two",
        "label": "Three Point One Two Five Percent Due Two Thousand Twenty Two [Member]",
        "terseLabel": "3.125%, due 2022 [Member]"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Seven Zero Zero Percent Due Two Thousand Forty Nine [Member]",
        "label": "Three Point Seven Zero Zero Percent Due Two Thousand Forty Nine [Member]",
        "terseLabel": "3.700%, due 2049 [Member]"
       }
      }
     },
     "localname": "ThreePointSevenZeroZeroPercentDueTwoThousandFortyNineMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Seven Zero Zero Percent Due Two Thousand Twenty One [Member]",
        "label": "Three Point Seven Zero Zero Percent Due Two Thousand Twenty One [Member]",
        "terseLabel": "3.700%, due 2021 [Member]"
       }
      }
     },
     "localname": "ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Five Zero Percent Due Two Thousand Twenty Seven [Member]",
        "label": "Three Point Six Five Zero Percent Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "3.650% due 2027 [Member]"
       }
      }
     },
     "localname": "ThreePointSixFiveZeroPercentDueTwoThousandTwentySevenMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Zero Zero Percent Due Two Thousand Fifty One",
        "label": "Three Point Six Zero Zero Percent Due Two Thousand Fifty One [Member]",
        "terseLabel": "3.600% due 2051 [Member]"
       }
      }
     },
     "localname": "ThreePointSixZeroZeroPercentDueTwoThousandFiftyOneMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Five Zero Percent Due Two Thousand Twenty Four [Member]",
        "label": "Three Point Three Five Zero Percent Due Two Thousand Twenty Four [Member]",
        "terseLabel": "3.350% due 2024 [Member]"
       }
      }
     },
     "localname": "ThreePointThreeFiveZeroPercentDueTwoThousandTwentyFourMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Zero Zero Percent Due Two Thousand Twenty Three",
        "label": "Three Point Three Zero Zero Percent Due Two Thousand Twenty Three [Member]",
        "terseLabel": "3.300%, due 2023 [Member]"
       }
      }
     },
     "localname": "ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TotalExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Expenses",
        "label": "Total Expenses",
        "terseLabel": "Total expenses"
       }
      }
     },
     "localname": "TotalExpenses",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_TotalIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Intangible Assets Acquired",
        "label": "Total Intangible Assets Acquired",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "TotalIntangibleAssetsAcquired",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_TotalLevelIIIassetcategoriesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Level III, asset categories [Axis]",
        "label": "Total Level III, asset categories [Axis]",
        "terseLabel": "Total Level III, asset categories [Axis]"
       }
      }
     },
     "localname": "TotalLevelIIIassetcategoriesAxis",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elv_TotalLevelIIIassetcategoriesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Total Level III, asset categories [Axis]",
        "label": "Total Level III, asset categories [Domain]",
        "terseLabel": "Total Level III, asset categories [Domain]"
       }
      }
     },
     "localname": "TotalLevelIIIassetcategoriesDomain",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers",
        "label": "Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member]",
        "terseLabel": "Total Plan Assets Excluding Cash, Investment Income Receivable And Amounts Due (To) From Brokers [Member]"
       }
      }
     },
     "localname": "TotalPlanAssetsExcludingCashInvestmentIncomeReceivableAndAmountsDueToFromBrokersMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TotalPlanAssetsExcludingPartnershipInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Plan Assets excluding Partnership Investments[Member]",
        "label": "Total Plan Assets Excluding Partnership Investments [Member]",
        "terseLabel": "Total Plan Assets Excluding Partnership Investments [Member]"
       }
      }
     },
     "localname": "TotalPlanAssetsExcludingPartnershipInvestmentsMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Eight Seven Five Percent Due Two Thousand Twenty Nine [Member]",
        "label": "Two Point Eight Seven Five Percent Due Two Thousand Twenty Nine [Member]",
        "terseLabel": "2.875%, due 2029 [Member]"
       }
      }
     },
     "localname": "TwoPointEightSevenFivePercentDueTwoThousandTwentyNineMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Five Five Zero Percent Due Two Thousand Thirty One",
        "label": "Two Point Five Five Zero Percent Due Two Thousand Thirty One [Member]",
        "terseLabel": "2.550% due 2031 [Member]"
       }
      }
     },
     "localname": "TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Five Zero Zero Percent Due Two Thousand Twenty [Member]",
        "label": "Two Point Five Zero Zero Percent Due Two Thousand Twenty [Member]",
        "terseLabel": "2.500% due 2020 [Member]"
       }
      }
     },
     "localname": "TwoPointFiveZeroZeroPercentDueTwoThousandTwentyMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Nine Five Zero Percent Due Two Thousand Twenty Two [Member]",
        "label": "Two Point Nine Five Zero Percent Due Two Thousand Twenty Two [Member]",
        "terseLabel": "2.950% due 2022 [Member]"
       }
      }
     },
     "localname": "TwoPointNineFiveZeroPercentDueTwoThousandTwentyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Two Point Seven Five Zero Percent Due Two Thousand Forty Two [Member]",
        "terseLabel": "2.750%, due 2042 [Member]"
       }
      }
     },
     "localname": "TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Three Seven Five Due Two Thousand Twenty Five [Member]",
        "label": "Two Point Three Seven Five Due Two Thousand Twenty Five [Member]",
        "terseLabel": "2.375%, due 2025 [Member]"
       }
      }
     },
     "localname": "TwoPointThreeSevenFiveDueTwoThousandTwentyFiveMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Three Seven Five Percent Due Two Thousand Twenty Five [Member]",
        "label": "Two Point Three Seven Five Percent Due Two Thousand Twenty Five [Member]",
        "terseLabel": "2.375%, due 2025 [Member]"
       }
      }
     },
     "localname": "TwoPointThreeSevenFivePercentDueTwoThousandTwentyFiveMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Five Zero Percent Due Two Thousand Thirty",
        "label": "Two Point Two Five Zero Percent Due Two Thousand Thirty [Member]",
        "terseLabel": "2.250%, due 2030 [Member]"
       }
      }
     },
     "localname": "TwoPointTwoFiveZeroPercentDueTwoThousandThirtyMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoThousandEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen",
        "label": "Two Thousand Eighteen [Member]",
        "terseLabel": "2018 [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty",
        "label": "Two Thousand Twenty [Member]",
        "terseLabel": "2020 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty One",
        "label": "Two Thousand Twenty One [Member]",
        "terseLabel": "2021 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_TwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two",
        "label": "Two Thousand Twenty Two [Member]",
        "terseLabel": "2022 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_UnaffiliatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaffiliated [Member]",
        "label": "Unaffiliated [Member]",
        "terseLabel": "Unaffiliated [Member]"
       }
      }
     },
     "localname": "UnaffiliatedMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elv_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate.",
        "label": "Unrecognized tax benefits that would not impact effective tax rate in future periods, if recognized",
        "terseLabel": "Unrecognized tax benefits that would impact additional paid-in capital in future periods, if recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Four Five Zero Percent Due Two Thousand Twenty Three",
        "label": "Zero Point Four Five Zero Percent Due Two Thousand Twenty Three [Member]",
        "terseLabel": ".0450% due 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.elevancehealth.com/20221231",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]",
        "terseLabel": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r433",
      "r797",
      "r798",
      "r802",
      "r803",
      "r892",
      "r1034",
      "r1037",
      "r1182",
      "r1185",
      "r1186",
      "r1278",
      "r1279",
      "r1280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r433",
      "r797",
      "r798",
      "r802",
      "r803",
      "r892",
      "r1034",
      "r1037",
      "r1182",
      "r1185",
      "r1186",
      "r1278",
      "r1279",
      "r1280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r1102",
      "r1130",
      "r1131",
      "r1158",
      "r1223",
      "r1224",
      "r1225",
      "r1231",
      "r1232",
      "r1240",
      "r1241",
      "r1242",
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount after cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r367",
      "r437",
      "r444",
      "r450",
      "r523",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r811",
      "r814",
      "r816",
      "r817",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r367",
      "r437",
      "r444",
      "r450",
      "r523",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r811",
      "r814",
      "r816",
      "r817",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r367",
      "r437",
      "r444",
      "r450",
      "r523",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r811",
      "r814",
      "r816",
      "r817",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r501",
      "r1059",
      "r1189",
      "r1267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r712",
      "r926",
      "r986",
      "r1035",
      "r1036",
      "r1057",
      "r1070",
      "r1082",
      "r1187",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r712",
      "r926",
      "r986",
      "r1035",
      "r1036",
      "r1057",
      "r1070",
      "r1082",
      "r1187",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r501",
      "r1059",
      "r1189",
      "r1267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The registrant that controls, directly or indirectly, another entity (or entities). The usual condition for control is ownership of a majority (over 50 percent) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.",
        "label": "Parent Company [Member]",
        "terseLabel": "Parent Company [Member]"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r498",
      "r927",
      "r1058",
      "r1080",
      "r1178",
      "r1179",
      "r1189",
      "r1266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r498",
      "r927",
      "r1058",
      "r1080",
      "r1178",
      "r1179",
      "r1189",
      "r1266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r660",
      "r712",
      "r740",
      "r741",
      "r742",
      "r901",
      "r926",
      "r986",
      "r1035",
      "r1036",
      "r1057",
      "r1070",
      "r1082",
      "r1174",
      "r1187",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r660",
      "r712",
      "r740",
      "r741",
      "r742",
      "r901",
      "r926",
      "r986",
      "r1035",
      "r1036",
      "r1057",
      "r1070",
      "r1082",
      "r1174",
      "r1187",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock": {
     "auth_ref": [
      "r976",
      "r1038"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue.",
        "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block]",
        "terseLabel": "Summary Of Direct, Assumed And Ceded Premiums Earned"
       }
      }
     },
     "localname": "SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SupplementaryInsuranceInformationBySegmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]",
        "terseLabel": "Net Premiums Earned By Segment [Line Items]"
       }
      }
     },
     "localname": "SupplementaryInsuranceInformationBySegmentLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable by Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r287",
      "r323",
      "r1105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.",
        "label": "Accrued Investment Income Receivable",
        "terseLabel": "Accrued investment income"
       }
      }
     },
     "localname": "AccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r41",
      "r47",
      "r241",
      "r1108",
      "r1109",
      "r1110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Pension and other postretirement benefits"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r145",
      "r378"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r39",
      "r47",
      "r241",
      "r412",
      "r1109",
      "r1110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r404",
      "r412",
      "r801",
      "r1109",
      "r1110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Net cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r404",
      "r412",
      "r1109",
      "r1110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Net unrealized investment gains"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r1107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "periodEndLabel": "AOCI, Debt Securities, Ending Balance",
        "periodStartLabel": "AOCI, Debt Securities, Beginning Balance"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r42",
      "r47",
      "r1195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "negatedPeriodEndLabel": "AOCI, Defined Benefit Plan, Ending Balance",
        "negatedPeriodStartLabel": "AOCI, Defined Benefit Plan, Beginning Balance"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r396",
      "r401",
      "r403",
      "r404",
      "r834"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "periodEndLabel": "AOCI, Foreign Currency Translation Adjustment, Ending Balance",
        "periodStartLabel": "AOCI, Foreign Currency Translation Adjustment, Beginning Balance"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r47",
      "r387",
      "r963",
      "r994",
      "r998"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending",
        "periodStartLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities": {
     "auth_ref": [
      "r47",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of accumulated other comprehensive loss related to that portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized either as available-for-sale or held-to-maturity that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.",
        "label": "Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities",
        "negatedPeriodEndLabel": "AOCI, Non-credit component of impairments on investments, Ending Balance",
        "negatedPeriodStartLabel": "AOCI, Non-credit component of impairments on investments, Beginning Balance"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r47",
      "r241",
      "r884",
      "r989",
      "r990",
      "r1108",
      "r1109",
      "r1110",
      "r1127",
      "r1128",
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Intangible assets amortization period, years"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r12",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r1127",
      "r1128",
      "r1129",
      "r1241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r438",
      "r439",
      "r440",
      "r441",
      "r450",
      "r503",
      "r504",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r746",
      "r747",
      "r748",
      "r775",
      "r776",
      "r777",
      "r778",
      "r792",
      "r793",
      "r794",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r857",
      "r858",
      "r861",
      "r862",
      "r863",
      "r864",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r929",
      "r930",
      "r931",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "terseLabel": "Convertible debenture repurchases and conversions"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r470",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.",
        "label": "Allowance for Credit Loss, Receivable, Other, Current",
        "terseLabel": "Other receivables, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulOtherReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r58",
      "r79",
      "r278",
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Interest expense resulting from amortization of the debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r79",
      "r129",
      "r137"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of other intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedLabel": "Unrecognized losses for all terminated cash flow hedges included in accumulated other comprehensive loss",
        "periodEndLabel": "AOCI, Cash Flow Hedges, Ending Balance",
        "periodStartLabel": "AOCI, Cash Flow Hedges, Beginning Balance"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r1060",
      "r1146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-Backed Securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r288",
      "r316",
      "r382",
      "r427",
      "r482",
      "r488",
      "r494",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r797",
      "r802",
      "r836",
      "r1078",
      "r1183",
      "r1184",
      "r1254"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r373",
      "r389",
      "r427",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r797",
      "r802",
      "r836",
      "r1078",
      "r1183",
      "r1184",
      "r1254"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldByInsuranceRegulators": {
     "auth_ref": [
      "r1008"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.",
        "label": "Assets Held by Insurance Regulators",
        "verboseLabel": "Securities on deposit under regulatory requirements"
       }
      }
     },
     "localname": "AssetsHeldByInsuranceRegulators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": {
     "auth_ref": [
      "r431",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]",
        "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": {
     "auth_ref": [
      "r431",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]",
        "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssumedPremiumsEarned": {
     "auth_ref": [
      "r330",
      "r973",
      "r1003",
      "r1006"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earned premiums assumed from other entities.",
        "label": "Assumed Premiums Earned",
        "terseLabel": "Assumed - Premium earned"
       }
      }
     },
     "localname": "AssumedPremiumsEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssumedPremiumsWritten": {
     "auth_ref": [
      "r1003"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums assumed from other entities.",
        "label": "Assumed Premiums Written",
        "verboseLabel": "Assumed premiums"
       }
      }
     },
     "localname": "AssumedPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r506",
      "r531"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Cost or Amortized Cost",
        "totalLabel": "Available For Sale Securities, Amortized Cost",
        "verboseLabel": "Available-for-sale fixed maturity securities investments, current, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "verboseLabel": "Due after five years through ten years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r113",
      "r510",
      "r954"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "verboseLabel": "Due after five years through ten years, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r113",
      "r509",
      "r953"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "verboseLabel": "Due after ten years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r113",
      "r511",
      "r955"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "verboseLabel": "Due after ten years, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r113",
      "r508",
      "r952"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost",
        "verboseLabel": "Mortgage-backed securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r119",
      "r956"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value",
        "verboseLabel": "Mortgage-backed securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r110",
      "r505",
      "r531",
      "r946"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Available for sale securities Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r107",
      "r531"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Fixed maturities, current",
        "verboseLabel": "Fixed maturity securities, current, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r107",
      "r376",
      "r531"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Fixed maturity securities, long-term"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r252",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis Of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis Of Presentation And Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BenefitsLossesAndExpenses": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.",
        "label": "Benefits, Losses and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "BenefitsLossesAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BenefitsLossesAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benefits, Losses and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "BenefitsLossesAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r791",
      "r1064",
      "r1067"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r791",
      "r1064",
      "r1067"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total net tangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsAcquiredtangibleassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking Regulation, Total Capital [Abstract]",
        "terseLabel": "Capital [Abstract]"
       }
      }
     },
     "localname": "CapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Computer software amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r1270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Capitalized costs related to the internal development of software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r81",
      "r375",
      "r1039"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r81",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r277"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDividendsPaidToParentCompany": {
     "auth_ref": [
      "r1126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents disclosure of the total aggregate cash dividends paid to the entity by consolidated subsidiaries, by unconsolidated subsidiaries, and by 50 percent or less owned persons accounted for using the equity method.",
        "label": "SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Subsidiaries and Equity Method Investees",
        "terseLabel": "Cash dividends received from subsidiaries"
       }
      }
     },
     "localname": "CashDividendsPaidToParentCompany",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash [Member]"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CededPremiumsEarned": {
     "auth_ref": [
      "r330",
      "r972",
      "r1000",
      "r1001",
      "r1004",
      "r1006"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earned premiums ceded to other entities.",
        "label": "Ceded Premiums Earned",
        "negatedTerseLabel": "Ceded - Premium earned"
       }
      }
     },
     "localname": "CededPremiumsEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClaimsDevelopmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Claims Development [Line Items]",
        "terseLabel": "Claims Development [Line Items]"
       }
      }
     },
     "localname": "ClaimsDevelopmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r119",
      "r1192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage-Backed Securities [Member]",
        "terseLabel": "Commercial Mortgage-Backed Securities [Member]"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r1",
      "r289",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails",
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r296",
      "r325"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 14",
        "verboseLabel": "Commitments and contingencies-Note 5"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r572",
      "r574",
      "r1030",
      "r1181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments And Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "verboseLabel": "Cash Dividend per Share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends per share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r1127",
      "r1128",
      "r1241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746",
        "verboseLabel": "Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and 241,770,746"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r408",
      "r410",
      "r418",
      "r949",
      "r967"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Total comprehensive income",
        "totalLabel": "Total shareholders\u2019 comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r62",
      "r417",
      "r948",
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment and Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r275",
      "r276",
      "r501",
      "r1029"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r92",
      "r93",
      "r275",
      "r276",
      "r501",
      "r1009",
      "r1029"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r92",
      "r93",
      "r275",
      "r276",
      "r501",
      "r1029",
      "r1269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r92",
      "r93",
      "r275",
      "r276",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenue generated from participation in various federal government programs"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r275",
      "r276",
      "r501",
      "r1029"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r433",
      "r1101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "terseLabel": "Schedule II-Condensed Financial Information Of Registrant"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrant"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Future capital calls or investment obligations"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Provider And Hospital Relationships [Member]"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r159",
      "r591",
      "r592",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Senior Convertible Debentures [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible debentures",
        "verboseLabel": "Net debt carrying amount"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails",
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Convertible Debenture Terms"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r1060",
      "r1062",
      "r1268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r54",
      "r927"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r1190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Products Sold"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r1124",
      "r1230",
      "r1233"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r1124",
      "r1230"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current Foreign Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r223",
      "r772",
      "r782",
      "r1124"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current tax expense:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r1124",
      "r1230",
      "r1233"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r91",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships [Member]",
        "verboseLabel": "Customer-related [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r425",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r607",
      "r614",
      "r615",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r290",
      "r292",
      "r313",
      "r433",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r860",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r160",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Effective conversion price (per $1,000 of principal amount) per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r25",
      "r166",
      "r167",
      "r169",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio, Shares",
        "verboseLabel": "Conversion rate (shares of common stock per $1,000 of principal amount)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleEarliestDate1": {
     "auth_ref": [
      "r26",
      "r166",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest date when the debt instrument can be converted into equity, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Convertible, Earliest Date",
        "terseLabel": "Earliest Date for Conversion"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleEarliestDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "If-converted value per dollar above the conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Number of trading days in 30 day period greater than 130%"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Product of Conversion to Stock Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r6",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument, Covenant Compliance",
        "terseLabel": "Debt Instrument, Covenant Compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r6",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument, Covenant Description",
        "terseLabel": "Debt Instrument, Covenant Description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r279",
      "r281",
      "r591",
      "r860",
      "r1053",
      "r1054"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Outstanding principal amount",
        "verboseLabel": "Long-term debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtConvertibleDebentureTermsDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate",
        "verboseLabel": "Interest rate on long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r390",
      "r1052",
      "r1243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date on long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r26",
      "r433",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r860",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Description",
        "terseLabel": "Debt Instrument, Redemption, Description"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodEndDate": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of debt instrument redemption period, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Redemption Period, End Date",
        "terseLabel": "Debt Instrument, Redemption Period, End Date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodEndDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt Instrument, Redemption Price, Percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased face amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r26",
      "r166",
      "r168",
      "r169",
      "r170",
      "r278",
      "r279",
      "r281",
      "r307",
      "r433",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r860",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r507",
      "r531",
      "r536",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "negatedTerseLabel": "Fixed Maturity Securities, Allowance for Credit Loss",
        "terseLabel": "Fixed Maturity Securities, Allowance for Credit Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current",
        "negatedTerseLabel": "Fixed maturities, allowance for credit loss, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Fixed maturities, allowance for credit loss, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r531",
      "r1145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Fixed maturities, amortized cost, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r531",
      "r1145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Fixed maturities, amortized cost, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r515",
      "r534",
      "r1050"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "verboseLabel": "Estimated Fair Value, 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r515",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Gross unrealized loss, 12 Months or greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r1162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of Securities, 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r515",
      "r534",
      "r1050"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "verboseLabel": "Estimated Fair Value, Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r515",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Gross unrealized loss, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r1162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of Securities, Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "terseLabel": "Gross realized gains from sales"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r1148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Net realized gains on fixed maturity securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Gross realized losses from sales"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r532",
      "r1050"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Investment [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Fixed Maturity Securities [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Unrecognized tax benefit change reasonably possible due to tax settlements - lower amount"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r755",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r79",
      "r223",
      "r773",
      "r781",
      "r782",
      "r1124"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r8",
      "r9",
      "r291",
      "r312",
      "r767"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "terseLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r755",
      "r756"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r219",
      "r222",
      "r1124"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred Tax and Other Liabilities, Noncurrent"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset, Current [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r768"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Deferred Tax Assets, Investments"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r1228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred Tax Assets, Net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets relating to:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Federal and state operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Retirement liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Bad debt reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "terseLabel": "Insurance reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r769"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.",
        "label": "Deferred Tax Expense from Stock Options Exercised",
        "terseLabel": "Tax benefit from stock option exercises and disqualifying dispositions"
       }
      }
     },
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r207",
      "r1228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized software.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Software",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Federal and state intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "terseLabel": "Investments basis"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities relating to:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r218",
      "r1229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r669"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation for the defined benefit pension plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r42",
      "r47",
      "r1195"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "totalLabel": "Net amount before tax at December 31"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r47",
      "r681"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedLabel": "Net actuarial (loss) gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r47",
      "r681"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r651",
      "r1062"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r665",
      "r1062"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Actual return on plan assets, relating to assets still held at the reporting date"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial loss (gain)"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAdditionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Additional Information [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAdditionalInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of alternative method used to amortize gain (loss) for defined benefit plan.",
        "label": "Defined Benefit Plan, Alternative Method Used to Amortize Gain (Loss), Description",
        "terseLabel": "Defined Benefit Plan, Alternative Method Used to Amortize Gain (Loss), Description"
       }
      }
     },
     "localname": "DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r637",
      "r676",
      "r700",
      "r1062",
      "r1063"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r637",
      "r677",
      "r701",
      "r1062",
      "r1063"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r179",
      "r182"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Net amount at December 31"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r287",
      "r315",
      "r635",
      "r636",
      "r659",
      "r1062"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest Crediting Rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r684",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r639"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation at end of year",
        "periodStartLabel": "Benefit obligation at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r646",
      "r708"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": {
     "auth_ref": [
      "r1191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.",
        "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r687",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan by Plan Asset Categories [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Reconciliation of benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]",
        "terseLabel": "Change in Fair Value of Plan Assets, Level III Reconciliation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r653",
      "r663",
      "r704",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2028 - 2032"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r637",
      "r675",
      "r699",
      "r1062",
      "r1063"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r650",
      "r661",
      "r663",
      "r664",
      "r1060",
      "r1061",
      "r1062"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "netLabel": "Total pension benefit assets",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Assumed health care cost trend rate to be used for next year to measure expected cost of other benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r637",
      "r642",
      "r674",
      "r698",
      "r1062",
      "r1063"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r672",
      "r696",
      "r1062",
      "r1063"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": {
     "auth_ref": [
      "r672",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Settlement Loss, Statement of Income or Comprehensive Income Location"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "auth_ref": [
      "r694",
      "r1062"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": {
     "auth_ref": [
      "r694",
      "r1062"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r694",
      "r695",
      "r1062"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r1196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount": {
     "auth_ref": [
      "r1192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment within defined benefit plan asset category.",
        "label": "Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale": {
     "auth_ref": [
      "r1194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of decrease in plan asset of defined benefit plan from sale.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale",
        "negatedTerseLabel": "Sales"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase": {
     "auth_ref": [
      "r1194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase in plan asset of defined benefit plan from purchase.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r660",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Weighted-average target allocation for plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r638",
      "r679",
      "r703"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedLabel": "Settlement loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRollForwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Roll Forwards [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanRollForwardsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r640",
      "r673",
      "r697",
      "r1062",
      "r1063"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r658"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Ultimate health care cost trend rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format.",
        "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate",
        "terseLabel": "Year in which ultimate trend rate reached"
       }
      }
     },
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r709"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contributions made to 401k retirement benefit plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received as security in return for loaning securities to another party.",
        "label": "Deposits Received for Securities Loaned, at Carrying Value",
        "terseLabel": "Collateral received for securities loaned, at carrying value"
       }
      }
     },
     "localname": "DepositsReceivedForSecuritiesLoanedAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAmountOfHedgedItem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of hedged item in hedging relationship. Excludes hedged asset or liability.",
        "label": "Derivative, Amount of Hedged Item",
        "terseLabel": "Derivative, Amount of Hedged Item"
       }
      }
     },
     "localname": "DerivativeAmountOfHedgedItem",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset": {
     "auth_ref": [
      "r32",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements offset against derivative assets.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset",
        "terseLabel": "Collateral received"
       }
      }
     },
     "localname": "DerivativeAssetCollateralObligationToReturnCashOffset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r32",
      "r36",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "negatedTerseLabel": "Amounts netted"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset.",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r393",
      "r394",
      "r835",
      "r1042"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "verboseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]",
        "verboseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r35",
      "r254",
      "r285",
      "r392",
      "r1042"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total derivative assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": {
     "auth_ref": [
      "r33",
      "r34",
      "r37",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral",
        "terseLabel": "Net derivative assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r35",
      "r254",
      "r285",
      "r392",
      "r1042"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "negatedTerseLabel": "Total derivative liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": {
     "auth_ref": [
      "r33",
      "r34",
      "r37",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral",
        "negatedTerseLabel": "Net derivative liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "verboseLabel": "Interest Rate Received"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r1237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Derivative Gain (Loss) Recognized"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r1237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.",
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative Gain (Loss) Recognized"
       }
      }
     },
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r253",
      "r255",
      "r260",
      "r261",
      "r1042"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument Risk [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r250",
      "r253",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r250",
      "r253",
      "r260",
      "r261",
      "r266",
      "r267",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r393",
      "r394",
      "r835",
      "r1042"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedTerseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r32",
      "r36",
      "r254",
      "r1041"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset",
        "terseLabel": "Amounts netted"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r1235",
      "r1236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount",
        "verboseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r257",
      "r260",
      "r262",
      "r265",
      "r267",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r247",
      "r250",
      "r251",
      "r263",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Hedging Instruments [Member]",
        "verboseLabel": "Interest Rate Swaps [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DirectPremiumsEarned": {
     "auth_ref": [
      "r330",
      "r971",
      "r1002",
      "r1005"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Direct Premiums Earned",
        "terseLabel": "Direct - Premiums earned"
       }
      }
     },
     "localname": "DirectPremiumsEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.",
        "label": "Dividends Payable, Date to be Paid",
        "terseLabel": "Payment Date",
        "verboseLabel": "Dividends Payable, Date to be Paid"
       }
      }
     },
     "localname": "DividendPayableDateToBePaidDayMonthAndYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DividendsCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Cash [Abstract]",
        "terseLabel": "Dividends, Cash [Abstract]"
       }
      }
     },
     "localname": "DividendsCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r171",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "negatedLabel": "Dividends and dividend equivalents"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Cash dividends paid to subsidiaries"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Summary of Cash Dividend Activity"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Dividends Payable, Amount Per Share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format.",
        "label": "Dividends Payable, Date Declared",
        "verboseLabel": "Declaration Date"
       }
      }
     },
     "localname": "DividendsPayableDateDeclaredDayMonthAndYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.",
        "label": "Dividends Payable, Date of Record",
        "terseLabel": "Dividends Payable, Date of Record",
        "verboseLabel": "Record Date"
       }
      }
     },
     "localname": "DividendsPayableDateOfRecordDayMonthAndYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromAffiliateCurrent": {
     "auth_ref": [
      "r282",
      "r889",
      "r893"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Net due from subsidiaries",
        "verboseLabel": "Amounts due from subsidiaries"
       }
      }
     },
     "localname": "DueFromAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r2",
      "r282",
      "r362",
      "r1125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Net due to subsidiaries"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r1227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year [Member]"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarlyRepaymentOfSeniorDebt": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.",
        "label": "Early Repayment of Senior Debt",
        "terseLabel": "Early repayment of senior debt"
       }
      }
     },
     "localname": "EarlyRepaymentOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r419",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r451",
      "r453",
      "r455",
      "r456",
      "r457",
      "r461",
      "r817",
      "r818",
      "r950",
      "r968",
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Shareholders\u2019 net income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r419",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r453",
      "r455",
      "r456",
      "r457",
      "r461",
      "r817",
      "r818",
      "r950",
      "r968",
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r846"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r758"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total income tax expense, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r428",
      "r758",
      "r783"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Amount at statutory rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r1226",
      "r1234"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "negatedTerseLabel": "Tax exempt interest and dividends received deduction, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1226",
      "r1234"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1226",
      "r1234"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income taxes net of federal tax expense/benefit, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.",
        "label": "Effects of Reinsurance [Table Text Block]",
        "terseLabel": "Effect Of Reinsurance On Benefit Expense"
       }
      }
     },
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument embedded in host contract.",
        "label": "Embedded Derivative Financial Instruments [Member]",
        "terseLabel": "Embedded Derivative Financial Instruments"
       }
      }
     },
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r745"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit from share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Termination [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r165",
      "r367",
      "r412",
      "r413",
      "r414",
      "r434",
      "r435",
      "r436",
      "r439",
      "r447",
      "r449",
      "r463",
      "r523",
      "r634",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r816",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r854",
      "r884",
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r383",
      "r833",
      "r1040"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r1153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Net (losses) gains on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r969",
      "r1153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Net realized (losses) gains recognized on equity securities sold",
        "terseLabel": "Net realized gains (losses) recognized on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r969",
      "r1153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains (losses) recognized in income on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsGainsandLossesRecognizedonEquitySecuritiesDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss) [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r125",
      "r314",
      "r1086",
      "r1087",
      "r1088"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExchangeTradedFundsMember": {
     "auth_ref": [
      "r1192",
      "r1244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange.",
        "label": "Exchange Traded Funds [Member]",
        "terseLabel": "Exchange Traded Funds [Member]"
       }
      }
     },
     "localname": "ExchangeTradedFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r821",
      "r822",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r828"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "verboseLabel": "Change in unrealized losses included in net income related to assets still held"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r605",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r822",
      "r898",
      "r899",
      "r900",
      "r1053",
      "r1054",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r605",
      "r663",
      "r668",
      "r822",
      "r898",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level I [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r605",
      "r663",
      "r668",
      "r822",
      "r899",
      "r1053",
      "r1054",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level II [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r605",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r822",
      "r900",
      "r1053",
      "r1054",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level III [Member]",
        "verboseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Defined Benefit Plan, Unfunded Commitment"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r663",
      "r820",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r825"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Gains (losses) recognized in net income"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "auth_ref": [
      "r826"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Gains (losses) recognized in accumulated other comprehensive loss/income"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales",
        "negatedLabel": "Sales"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r827"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "verboseLabel": "Transfers into Level III"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r827"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedLabel": "Transfers out of Level III"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r605",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r898",
      "r899",
      "r900",
      "r1053",
      "r1054",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r829",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r830",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate": {
     "auth_ref": [
      "r157",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advance from Federal Home Loan Bank (FHLBank) maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Federal Home Loan Bank, Advance, Maturity, Year One",
        "terseLabel": "Short-term borrowings",
        "verboseLabel": "Short-term FHLB borrowings outstanding"
       }
      }
     },
     "localname": "FederalHomeLoanBankAdvancesMaturitiesSummaryDueWithinOneYearOfBalanceSheetDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails",
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalHomeLoanBankAdvancesMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans.",
        "label": "Federal Home Loan Bank Advances [Member]",
        "terseLabel": "Federal Home Loan Bank Advances [Member]"
       }
      }
     },
     "localname": "FederalHomeLoanBankAdvancesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r513",
      "r514",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r535",
      "r538",
      "r616",
      "r632",
      "r806",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r1050",
      "r1150",
      "r1151",
      "r1152",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Major Types Of Debt And Equity Securities [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "negatedTerseLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r380",
      "r555"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization, Finite Lived Intangibles"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated amortization expense 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Estimated amortization expense 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated amortization expense 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated amortization expense 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated amortization expense 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r551",
      "r554",
      "r555",
      "r557",
      "r928",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r136",
      "r932"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount, Finite Lived Intangibles"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r130",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r136",
      "r928"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount, Finite Lived Intangibles"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedMaturitiesMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element provides types of investments that may be contained within the fixed maturity category which are securities having a stated final repayment date. Examples of items within this category may include bonds, including convertibles and bonds with warrants, and redeemable preferred stocks.",
        "label": "Fixed Maturities [Member]",
        "terseLabel": "Fixed Maturity Securities [Member]"
       }
      }
     },
     "localname": "FixedMaturitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignGovernmentDebtMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.",
        "label": "Foreign Government Debt [Member]",
        "terseLabel": "Foreign Government Securities [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r1192",
      "r1268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign Securities [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture And Other Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FutureMember": {
     "auth_ref": [
      "r1239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Futures contracts are forward-based contracts to make or take delivery of a specified financial instrument, foreign currency, or commodity at a specified future date or during a specified period at as specified price or yield. Futures are standardized contracts traded on an organized exchange.",
        "label": "Future [Member]",
        "terseLabel": "Futures [Member]"
       }
      }
     },
     "localname": "FutureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FuturePolicyBenefitsLiabilityPolicy": {
     "auth_ref": [
      "r982",
      "r984",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption.",
        "label": "Liability for Future Policy Benefit [Policy Text Block]",
        "verboseLabel": "Reserves For Future Policy Benefits"
       }
      }
     },
     "localname": "FuturePolicyBenefitsLiabilityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r1180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r1180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Net Investment Gains/Losses"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "terseLabel": "Net (losses) gains on other investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r79",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r379",
      "r539",
      "r945",
      "r1051",
      "r1078",
      "r1163",
      "r1170"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill, after measurement period adjustments"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r541",
      "r1051"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Acquired During Period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill And Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill And Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r540",
      "r547",
      "r1051"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "negatedTerseLabel": "Accumulated impairment as of December 31"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r1171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r224",
      "r1169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, purchase accounting adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill by reportable segment"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Current Carrying Value",
        "terseLabel": "Parental Guarantees"
       }
      }
     },
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r250",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r79",
      "r142",
      "r148"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of property and equipment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r79",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of property and equipment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r286",
      "r298",
      "r333",
      "r482",
      "r487",
      "r493",
      "r496",
      "r951",
      "r1049"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r482",
      "r487",
      "r493",
      "r496",
      "r1049"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "verboseLabel": "Loss before income tax credits and equity in net income of subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r52",
      "r79",
      "r126",
      "r297",
      "r331",
      "r479"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in net earnings of other invested assets"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Equity in net income of subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r558",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Income tax credits"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r428",
      "r759",
      "r765",
      "r771",
      "r779",
      "r784",
      "r788",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r429",
      "r448",
      "r449",
      "r480",
      "r757",
      "r780",
      "r786",
      "r970"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r411",
      "r753",
      "r754",
      "r765",
      "r766",
      "r770",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r310",
      "r1105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Income Taxes Receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDeductions": {
     "auth_ref": [
      "r1226"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Amount",
        "negatedLabel": "Tax exempt interest and dividends received deduction, amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r758"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Amount at statutory rate, amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1226"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, net amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1226"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State and local income taxes net of federal tax expense/benefit, amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseComputedAtTheStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r75",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r1119"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments.",
        "label": "Increase (Decrease) in Collateral Held under Securities Lending",
        "negatedLabel": "Changes in securities lending collateral",
        "negatedTerseLabel": "Changes in securities lending collateral"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollateralHeldUnderSecuritiesLending",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r1043"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Unearned income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "auth_ref": [
      "r1119"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in insurance liability balances during the period.",
        "label": "Increase (Decrease) in Insurance Liabilities",
        "terseLabel": "Policy liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in cash during the period due to the net increase or decrease in outstanding checks, the liability that represents checks that have been issued but that have not cleared. The entity may classify these cash flows as financing or operating activities.",
        "label": "Increase (Decrease) in Outstanding Checks, Financing Activities",
        "terseLabel": "Changes in bank overdrafts"
       }
      }
     },
     "localname": "IncreaseDecreaseInOutstandingChecksFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecuritiesLendingPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction.",
        "label": "Increase (Decrease) in Securities Lending Payable",
        "terseLabel": "Changes in securities lending payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecuritiesLendingPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTradingSecurities": {
     "auth_ref": [
      "r73",
      "r78"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income.",
        "label": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI",
        "negatedLabel": "Other invested assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r553",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount, Indefinite Lived Intangibles",
        "verboseLabel": "Gross Carrying Amount, Indefinite Lived Intangibles"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r132",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-Lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceServicesRevenue": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.",
        "label": "Insurance Services Revenue",
        "terseLabel": "Reportable segments operating revenues",
        "verboseLabel": "Insurance Services Revenue"
       }
      }
     },
     "localname": "InsuranceServicesRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount, Total Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r128",
      "r134"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets",
        "verboseLabel": "Net Carrying Amount, Total Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible Assets, Net (Including Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r280",
      "r300",
      "r415",
      "r476",
      "r859"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r58",
      "r611",
      "r619",
      "r1055",
      "r1056"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r60",
      "r612",
      "r1055",
      "r1056"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Interest expense resulting from the stated interest rate"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r1121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Total amount of amortization over the next twelve months for all cash flow hedges"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swaps [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "auth_ref": [
      "r59",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the generation of investment income.",
        "label": "Investment Income, Investment Expense",
        "negatedLabel": "Investment expense"
       }
      }
     },
     "localname": "InvestmentIncomeInvestmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeTextBlock": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table Text Block]",
        "terseLabel": "Major Categories Of Net Investment Income"
       }
      }
     },
     "localname": "InvestmentIncomeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r518",
      "r1264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r1149",
      "r1154",
      "r1156",
      "r1157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "Investment [Text Block]"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and Improvements [Member]"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r1227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year [Member]"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r876",
      "r1077"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "terseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total future minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Future Minimum Payments, Due Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Future Minimum Payments, Due 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Future Minimum Payments, Due 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Future Minimum Payments, Due 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Future Minimum Payments, Due 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Future Minimum Payments, Due 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lessee, Operating Leases [Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r427",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r798",
      "r802",
      "r803",
      "r836",
      "r1048",
      "r1183",
      "r1254",
      "r1255"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r294",
      "r322",
      "r1078",
      "r1123",
      "r1155",
      "r1245"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and shareholders' equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity",
        "verboseLabel": "Liabilities and shareholders' equity [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r374",
      "r427",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r798",
      "r802",
      "r803",
      "r836",
      "r1078",
      "r1183",
      "r1254",
      "r1255"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r339",
      "r342"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "terseLabel": "Gross medical claims payable, end of year",
        "verboseLabel": "Medical claims payable"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "terseLabel": "Medical Claims Payable [Line Items]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "terseLabel": "Medical Claims Payable"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefits": {
     "auth_ref": [
      "r960",
      "r981",
      "r983",
      "r992",
      "r1081"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.",
        "label": "Liability for Future Policy Benefit, before Reinsurance",
        "terseLabel": "Reserves for future policy benefits"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Claims Payable"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Net payments attributable to current year medical claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Net payments attributable to prior years medical claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "terseLabel": "Total net incurred medical claims",
        "verboseLabel": "Net incurred medical claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": {
     "auth_ref": [
      "r311",
      "r339",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net",
        "terseLabel": "Net medical claims payable, end of year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "State Medicaid Licenses [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityDescription": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.",
        "label": "Line of Credit Facility, Description",
        "terseLabel": "Line of Credit Facility, Description"
       }
      }
     },
     "localname": "LineOfCreditFacilityDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r835"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Subsidiary Credit Facilities"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r6",
      "r292",
      "r318",
      "r604",
      "r618",
      "r1053",
      "r1054"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conditions, facts and circumstances that would trigger a payment of principal or interest which was not otherwise immediately due and payable.",
        "label": "Long-Term Debt, Contingent Payment of Principal or Interest",
        "terseLabel": "Long-Term Debt, Contingent Payment of Principal or Interest"
       }
      }
     },
     "localname": "LongTermDebtContingentPaymentOfPrincipalOrInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r157",
      "r433",
      "r1188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Future maturities of debt Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r157",
      "r433",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "Future maturities of debt in 2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r157",
      "r433",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "Future maturities of debt in 2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r157",
      "r433",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "Future maturities of debt in 2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r157",
      "r433",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "Future maturities of debt in 2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r157",
      "r433",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "Future maturities of debt in 2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDerivativeFinancialInstrumentsFairValueHedgesFinancialPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Long-term Purchase Commitment, Amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r26",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtCarryingValueOfLongTermDebtDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on commercial paper borrowings"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r1175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r1175",
      "r1176",
      "r1177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Approximate amount of damages sought for operational breaches"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r577",
      "r578",
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss on loss contingencies"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Equity Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Equity Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.",
        "label": "Marketing and Advertising Expense",
        "terseLabel": "Advertising and marketing expense"
       }
      }
     },
     "localname": "MarketingAndAdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaturityOvernightMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of the day after the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.",
        "label": "Maturity Overnight [Member]",
        "terseLabel": "Maturity Overnight [Member]"
       }
      }
     },
     "localname": "MaturityOvernightMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Business Acquisitions"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r31",
      "r293",
      "r321",
      "r427",
      "r519",
      "r582",
      "r584",
      "r585",
      "r586",
      "r589",
      "r590",
      "r836"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Noncontrolling Interest, Ending Balance",
        "periodStartLabel": "Noncontrolling Interest, Beginning Balance",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r1192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "All Other Investments [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r464",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Net cash (used in) provided by financing activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r53",
      "r80",
      "r299",
      "r332",
      "r372",
      "r406",
      "r409",
      "r414",
      "r427",
      "r438",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r454",
      "r482",
      "r487",
      "r493",
      "r496",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r818",
      "r836",
      "r1049",
      "r1183"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Shareholders\u2019 net income",
        "totalLabel": "Shareholders\u2019 net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r239",
      "r243",
      "r406",
      "r409",
      "r448",
      "r449",
      "r1110"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interests",
        "terseLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r966"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "negatedTerseLabel": "Net Investment Income",
        "terseLabel": "Net investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r235",
      "r634",
      "r1127",
      "r1128",
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Non-Hedging Instruments [Member]",
        "verboseLabel": "Non-hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r6",
      "r292",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r282",
      "r386",
      "r1125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Notes Receivable, Related Parties, Current"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which the Company is licensed to conduct insurance operations"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenOptionContractsWrittenExpirationDates": {
     "auth_ref": [
      "r1020"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the open option contracts written on the investment, in YYYY-MM-DD format.",
        "label": "Open Option Contracts Written, Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "OpenOptionContractsWrittenExpirationDates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsSummaryOfOutstandingFairValueHedgesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r482",
      "r487",
      "r493",
      "r496",
      "r1049"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Reportable segments operating gain",
        "verboseLabel": "Operating gain (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentOperatingGainToIncomeBeforeIncomeTaxesInTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r870",
      "r1077"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r1248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating Lease, Impairment Loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r866"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r866"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r866"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r868",
      "r872"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r875",
      "r1077"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r874",
      "r1077"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Operating Loss Carryforwards, Expiration Date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Options Held [Member]",
        "terseLabel": "Options [Member]"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OriginationOfNotesReceivableFromRelatedParties": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Origination of Notes Receivable from Related Parties",
        "terseLabel": "Issuance of note to subsidiary"
       }
      }
     },
     "localname": "OriginationOfNotesReceivableFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAggregatedInvestmentsMember": {
     "auth_ref": [
      "r1012",
      "r1015",
      "r1018"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.",
        "label": "Other Security Investments [Member]",
        "terseLabel": "Other Asset-Backed Securities [Member]"
       }
      }
     },
     "localname": "OtherAggregatedInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r388",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r252",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets [Member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r398",
      "r399",
      "r401"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Change in net unrealized gains/losses on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r398",
      "r399",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "negatedLabel": "Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r397",
      "r401"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Change in net unrealized gains/losses on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "negatedTerseLabel": "Cash flow hedges, holding gain (loss), tax (expense) benefit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r38",
      "r45",
      "r845",
      "r853"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustment, tax (expense) benefit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r50",
      "r165",
      "r407",
      "r410",
      "r417",
      "r847",
      "r852",
      "r854",
      "r948",
      "r965",
      "r1108",
      "r1109"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of tax:",
        "verboseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r237",
      "r238",
      "r240",
      "r407",
      "r410"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Other comprehensive loss attributable to noncontrolling interests",
        "terseLabel": "Other comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r237",
      "r238",
      "r240",
      "r407",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Change in net periodic pension and postretirement costs"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r44",
      "r48",
      "r124",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r45",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r45",
      "r412",
      "r417",
      "r757",
      "r785",
      "r787",
      "r847",
      "r850",
      "r854",
      "r948",
      "r965"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Net gain (loss) realized in other comprehensive loss, tax (expense) benefit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r237",
      "r238",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax Benefit (Expense), Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r398",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in net unrealized gains/losses on investments, before reclassification"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherContractMember": {
     "auth_ref": [
      "r1042",
      "r1060",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is classified as other.",
        "label": "Other Contract [Member]",
        "terseLabel": "Collars [Member]"
       }
      }
     },
     "localname": "OtherContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsEffectOfNonHedgingDerivativesOnIncomeStatementAndIncludedInNetGainsLossesOnInvestmentsDetails",
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r1147",
      "r1161",
      "r1192",
      "r1244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other Asset-Backed Securities [Member]"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r55",
      "r79",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization of property and equipment"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "elv_OperatingRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Administrative fees and other revenue",
        "verboseLabel": "Administrative fees and other revenue"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "terseLabel": "Other Investments [Member]"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails",
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r252",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities [Member]"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r327",
      "r1104"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "terseLabel": "Other invested assets, long-term"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/FairValueCarryingandFairValueByLevelofFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails",
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsNotionalAmountsBalanceSheetLocationAndEstimatedFairValuesOfDerivativeFinancialInstrumentsDetails",
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPolicyholderFunds": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.",
        "label": "Other Policyholder Funds",
        "terseLabel": "Other policyholder liabilities"
       }
      }
     },
     "localname": "OtherPolicyholderFunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r178",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r687",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r709",
      "r710",
      "r711",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Benefits [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities": {
     "auth_ref": [
      "r40",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other than temporary impairment (OTTI) loss on investment in available-for-sale debt security, recognized in other comprehensive loss.",
        "label": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-Sale Securities",
        "terseLabel": "Change in non-credit component of impairment losses on investments, net of tax"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities": {
     "auth_ref": [
      "r40",
      "r45",
      "r238",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of other than temporary impairment (OTTI) on investment in available-for-sale debt security, recognized in other comprehensive loss, attributable to the parent entity.",
        "label": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Tax, Portion Attributable to Parent, Available-for-Sale Securities",
        "negatedTerseLabel": "Non-credit component of other-than-temporary impairments on investments, tax (expense) benefit"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r76",
      "r341"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total net payments"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r1111",
      "r1113"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase and retirement of common stock",
        "negatedTerseLabel": "Repurchase and retirement of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r562",
      "r1118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Cash dividends",
        "negatedTerseLabel": "Cash dividends",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockCashDividendActivityDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid through withholding of common stock under employee stock plans"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r66",
      "r795"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total cash considerations"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Purchases of subsidiaries, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r1112",
      "r1252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "negatedTerseLabel": "Capitalization of subsidiaries"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributions": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.",
        "label": "Payment for Pension and Other Postretirement Benefits",
        "terseLabel": "Payment for Pension and Other Postretirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r660",
      "r662",
      "r668",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r706",
      "r707",
      "r709",
      "r714",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r5",
      "r635",
      "r636",
      "r659",
      "r1062"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r635",
      "r636",
      "r659",
      "r1062"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r188",
      "r193",
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "verboseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r177",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r687",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r709",
      "r710",
      "r713",
      "r1062",
      "r1063",
      "r1067",
      "r1068",
      "r1069"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefits [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r687",
      "r1060",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredGross": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred.",
        "label": "Policyholder Benefits and Claims Incurred, Direct",
        "terseLabel": "Direct"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": {
     "auth_ref": [
      "r308",
      "r337"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0
      },
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.",
        "label": "Policyholder Benefits and Claims Incurred, Net",
        "totalLabel": "Net benefit expense",
        "verboseLabel": "Benefit expense"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r10",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none",
        "verboseLabel": "Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r947",
      "r964",
      "r974",
      "r1007"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "elv_OperatingRevenue",
       "weight": 1.0
      },
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premiums",
        "totalLabel": "Premiums",
        "verboseLabel": "Premiums Earned Net"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsPercentageAssumedToNet": {
     "auth_ref": [
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of assumed premium earned to premium earned after effects of reinsurance, as disclosed in supplementary reinsurance information.",
        "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net",
        "terseLabel": "Percentage - assumed to net premiums - earned"
       }
      }
     },
     "localname": "PremiumsPercentageAssumedToNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfDirectAssumedAndCededPremiumsEarnedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r961",
      "r1138",
      "r1140",
      "r1159",
      "r1160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.",
        "label": "Premium Receivable, Allowance for Credit Loss",
        "terseLabel": "Premiums receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsReceivableAtCarryingValue": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.",
        "label": "Premiums Receivable, Net",
        "terseLabel": "Premium receivables"
       }
      }
     },
     "localname": "PremiumsReceivableAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of present value of future profits of insurance contract acquired in business combination.",
        "label": "Present Value of Future Insurance Profits [Table Text Block]",
        "terseLabel": "Components Of Other Intangible Assets"
       }
      }
     },
     "localname": "PresentValueOfFutureInsuranceProfitsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrivateEquityFundsMember": {
     "auth_ref": [
      "r1192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments held in private equity funds.",
        "label": "Private Equity Funds [Member]",
        "terseLabel": "Private Equity Securities [Member]"
       }
      }
     },
     "localname": "PrivateEquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Proceeds originally recevied from divestiture of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "verboseLabel": "Proceeds from long-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r106",
      "r420",
      "r421"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities, calls and redemptions from investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": {
     "auth_ref": [
      "r1111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments",
        "terseLabel": "Proceeds from sales, maturities, calls and redemptions of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r1115",
      "r1117"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": {
     "auth_ref": [
      "r1114",
      "r1116",
      "r1120"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.",
        "label": "Proceeds from (Repayments of) Commercial Paper",
        "terseLabel": "Net (repayments of) proceeds from commercial paper borrowings",
        "verboseLabel": "Net (repayments of) proceeds from commercial paper borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfCommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r63",
      "r106",
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r205"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock under employee stock plans",
        "verboseLabel": "Cash received from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r372",
      "r406",
      "r409",
      "r423",
      "r427",
      "r438",
      "r448",
      "r449",
      "r482",
      "r487",
      "r493",
      "r496",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r796",
      "r799",
      "r800",
      "r818",
      "r836",
      "r951",
      "r1049",
      "r1073",
      "r1074",
      "r1110",
      "r1183"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net Income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.",
        "label": "Property, Plant and Equipment, Depreciation Methods",
        "terseLabel": "Property, Plant and Equipment, Depreciation Methods"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationMethods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r1031",
      "r1032",
      "r1033"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r144",
      "r377"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r147",
      "r324",
      "r957",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r1031",
      "r1032"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable Type [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r1139",
      "r1141",
      "r1142",
      "r1143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation Of Reportable Segment Operating Gain To Income From Continuing Operations Before Income Taxes In The Consolidated Statements Of Income"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation Of Reportable Segment Operating Revenues To The Consolidated Statements Of Income"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Change in carrying amount of gross unrecognized tax benefits from uncertain tax positions"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.",
        "label": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]",
        "terseLabel": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reinsurance Disclosures [Abstract]",
        "terseLabel": "Reinsurance Disclosures [Abstract]"
       }
      }
     },
     "localname": "ReinsuranceDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of policy benefits and costs incurred for policies assumed.",
        "label": "Policyholder Benefits and Claims Incurred, Assumed",
        "terseLabel": "Assumed"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded.",
        "label": "Policyholder Benefits and Claims Incurred, Ceded",
        "negatedLabel": "Ceded"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ReinsuranceEffectOfReinsuranceOnBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "auth_ref": [
      "r339",
      "r342",
      "r1263",
      "r1265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "negatedPeriodStartLabel": "Ceded medical claims payable, beginning of year",
        "periodEndLabel": "Ceded medical claims payable, end of year",
        "terseLabel": "Ceded medical claims payable, end of year"
       }
      }
     },
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceTextBlock": {
     "auth_ref": [
      "r958",
      "r959",
      "r1010",
      "r1083",
      "r1084"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.",
        "label": "Reinsurance [Text Block]",
        "terseLabel": "Reinsurance"
       }
      }
     },
     "localname": "ReinsuranceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/Reinsurance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r687",
      "r887",
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r687",
      "r887",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r1253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r885",
      "r886",
      "r888",
      "r890",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term borrowings",
        "negatedTerseLabel": "Repayments of long-term borrowings",
        "terseLabel": "Repayments of Long-term Debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayments of short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResidentialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r1144",
      "r1192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by residential real estate mortgage loans.",
        "label": "Residential Mortgage-Backed Securities [Member]",
        "terseLabel": "Residential Mortgage-Backed Securities [Member]"
       }
      }
     },
     "localname": "ResidentialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r1027",
      "r1028",
      "r1106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Customer funds and cash and cash equivalents on deposit for regulatory requirements"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r560",
      "r562",
      "r565",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Business Optimization Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r561",
      "r564",
      "r567",
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Business optimization initiatives, incurred cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r561",
      "r562",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Business Optimization Initiative Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Business Optimization Initiatives [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r1099",
      "r1100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.",
        "label": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Business Optimization, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r562",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Liabilities for employee termination costs, ending balance",
        "periodStartLabel": "Liabilities for employee termination costs, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReservePeriodIncreaseDecrease": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the accrual for restructuring costs.",
        "label": "Restructuring Reserve, Period Increase (Decrease)",
        "negatedTerseLabel": "Releases"
       }
      }
     },
     "localname": "RestructuringReservePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r171",
      "r319",
      "r993",
      "r998",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r367",
      "r434",
      "r435",
      "r436",
      "r439",
      "r447",
      "r449",
      "r523",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r816",
      "r989",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r687",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r709",
      "r710",
      "r711",
      "r713",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r687",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r709",
      "r710",
      "r711",
      "r713",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r1044",
      "r1045"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r416",
      "r427",
      "r473",
      "r474",
      "r486",
      "r491",
      "r492",
      "r498",
      "r499",
      "r501",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r836",
      "r951",
      "r1183"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfRevenueFromReportableSegmentsToTheConsolidatedStatementsOfIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r873",
      "r1077"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r501",
      "r1136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r47",
      "r1246",
      "r1247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Reconciliation of Components of Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Fair Values of Pension Benefit Assets and Other Benefit Assets by Asset Category and Level Inputs"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "verboseLabel": "Net Amount Included In Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Investment [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Current And Long-term Fixed Maturity Securities, Available-for-sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r114",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Investment [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Business Acquisitions[Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsIntangibleAssetsAcquiredDetails",
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock": {
     "auth_ref": [
      "r343",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reasons for the change in incurred claims and claim adjustment expenses recognized in the income statement attributable to insured events of prior fiscal years. Also includes disclosures of additional premiums or return premiums accrued as a result of changes in incurred claims and claim adjustment expenses.",
        "label": "Schedule of Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "(Favorable) Unfavorable Developments By Changes In Key Assumptions"
       }
      }
     },
     "localname": "ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "verboseLabel": "Changes In The Fair Value Of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.",
        "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]",
        "verboseLabel": "Reconciliation Of The Benefit Obligation"
       }
      }
     },
     "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Components Of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "verboseLabel": "The Carrying Value Of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Components Of Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsChangesInFairValueOfPlanAssetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostBenefitCreditDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsEstimatedFuturePaymentsForPensionBenefitsAndOtherBenefitsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountIncludedInConsolidatedBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsNetAmountsIncludedInAccumulatedOtherComprehensiveLossThatHaveNotBeenRecognizedAsComponentsOfNetPeriodicBenefitCostsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBeginningAndEndingBalancesOfPlanAssetsMeasuredAtFairValueUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsReconciliationOfTheBenefitObligationDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostForAllPlansDetails",
      "http://www.elevancehealth.com/role/RetirementBenefitsWeightedAverageAssumptionsUsedInCalculatingTheBenefitObligationsForAllPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary Of Aggregate Contractual Or Notional Amounts And Estimated Fair Values"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r257",
      "r260",
      "r262",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "verboseLabel": "Summary Of Outstanding Fair Value Hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r1133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Denominator For Basic And Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r1193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.",
        "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]",
        "verboseLabel": "Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs"
       }
      }
     },
     "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "verboseLabel": "Estimated Future Payments For Pension Benefits And Other Benefits"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": {
     "auth_ref": [
      "r1079",
      "r1085",
      "r1268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset supporting separate account.",
        "label": "Fair Value, Separate Account Investment [Table]",
        "terseLabel": "Fair Value, Separate Account Investment [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain (Loss) on Securities [Line Items]",
        "terseLabel": "Investment [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGainLossOnInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about realized and unrealized gain (loss) on investment in security.",
        "label": "Schedule of Gain (Loss) on Securities [Table]",
        "terseLabel": "Investment [Table]"
       }
      }
     },
     "localname": "ScheduleOfGainLossOnInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNetGainsLossesOnInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r1051",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Investment Income [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r57",
      "r58",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]",
        "terseLabel": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsMajorCategoriesOfNetInvestmentIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components Of Net Periodic Benefit Cost (Credit)"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.",
        "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]",
        "verboseLabel": "Net Amounts Included In Accumulated Other Comprehensive Loss (Income) That Have Not Been Recognized As Components Of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r259",
      "r1238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Effect Of Non-Hedging Derivatives On Income Statement And Included In Net Realized Gains (Losses) On Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Business Optimization Initiatives and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Business Optimization Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r101",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r101",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Financial Data By Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of Weighted-Average Assumptions Used to Estimate the Fair Values of Options Granted During the Periods"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "verboseLabel": "Summary of Share Repurchases"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Aggregate Fair Values And Gross Unrealized Losses For Fixed Maturity Securities In An Unrealized Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesHeldAsCollateralAtFairValue": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount (fair value) as of the balance sheet date of securities held that had been pledged by counterparties under financing and lending arrangements, pursuant to which the entity has the right by agreement or custom to sell or re-pledge such securities.",
        "label": "Securities Held as Collateral, at Fair Value",
        "verboseLabel": "Securities lending collateral"
       }
      }
     },
     "localname": "SecuritiesHeldAsCollateralAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuritiesLoanedFairValueOfCollateral": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the securities pledged as collateral against securities loaned.",
        "label": "Securities Loaned, Fair Value of Collateral",
        "terseLabel": "Securities Loaned, Fair Value of Collateral"
       }
      }
     },
     "localname": "SecuritiesLoanedFairValueOfCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r501",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r564",
      "r569",
      "r1051",
      "r1266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails",
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Segment, Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r482",
      "r485",
      "r490",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Weighted-average remaining requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock incentive plan vesting period, years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited, Restricted Stock Shares and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Weighted-Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted, Restricted Stock Shares and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock and stock awards granted during the year",
        "verboseLabel": "Granted, Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails",
      "http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period, Restricted Stock Shares and Units",
        "periodStartLabel": "Nonvested at beginning of period, Restricted Stock Shares and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Shares and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share",
        "periodStartLabel": "Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested, Restricted Stock Shares and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested, Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield (annual)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility factor"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Payroll deductions, percent of gross compensation, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r1072"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of registered shares for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable at end of period, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable at end of period, Weighted-Average Option Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r1203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r1203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited or expired, Weighted-Average Option Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r1204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "verboseLabel": "Granted, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Approximate number of performance restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Options granted during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Fair Values Determined For the Periods"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at end of period, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period, Number of Shares",
        "periodStartLabel": "Outstanding at beginning of period, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period, Weighted-Average Option Price per Share",
        "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Option Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Option Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r736"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Exercisable at end of period, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised, Weighted-Average Option Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted, Weighted-Average Option Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r718",
      "r737",
      "r738",
      "r739",
      "r740",
      "r743",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing Price Company Stock"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted-average expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of period, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of period, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Employee stock purchase plan, purchase price per share as a percent of closing price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2019Member": {
     "auth_ref": [
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2019 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contract, Accident Year 2019 [Member]",
        "terseLabel": "Short-Duration Insurance Contract, Claim Year 2022 [Member]"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractAccidentYear2019Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2017 in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year 2017 [Member]",
        "terseLabel": "Short-duration Insurance Contracts, Claim Year 2020 and Prior [Member]"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractsAccidentYear2017Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member": {
     "auth_ref": [
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2018 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year 2018 [Member]",
        "terseLabel": "Short-duration Insurance Contracts, Claim Year 2021 [Member]"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractsAccidentYear2018Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r3",
      "r290",
      "r317",
      "r1078"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year [Axis]",
        "terseLabel": "Short-duration Insurance Contracts, Claim Year [Axis]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsAccidentYearAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year [Domain]",
        "terseLabel": "Short-duration Insurance Contracts, Claim Year [Domain]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsAccidentYearDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]",
        "terseLabel": "Incurred and Paid Claims Development, Net of Reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net",
        "terseLabel": "Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net",
        "terseLabel": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net",
        "terseLabel": "Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item",
        "terseLabel": "Insurance lines other than short duration"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative number of reported claims for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contract, Cumulative Number of Reported Claims",
        "terseLabel": "Short-duration Insurance Contract, Cumulative Number of Reported Claims"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsNumberOfReportedClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]",
        "terseLabel": "Reconciliation Of Claims Development To The Claims Liability"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer Software, Purchased and Internally Developed [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internal-use software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r371",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r501",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r559",
      "r564",
      "r569",
      "r1051",
      "r1266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Business Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessAcquisitionsNarrativeDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableIncurredandPaidClaimsDevelopmentNetofReinsuranceDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails",
      "http://www.elevancehealth.com/role/ReinsuranceSummaryOfNetPremiumsEarnedBySegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails",
      "http://www.elevancehealth.com/role/SegmentInformationMajorProductRevenuesDetails",
      "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r165",
      "r367",
      "r412",
      "r413",
      "r414",
      "r434",
      "r435",
      "r436",
      "r439",
      "r447",
      "r449",
      "r463",
      "r523",
      "r634",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r816",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r854",
      "r884",
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Statement, Operating Activities Segment [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r463",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails",
      "http://www.elevancehealth.com/role/LeasesLeasesNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsAdditionalInformationDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementOfCashFlowsDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantStatementsOfIncomeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationofRegistrantStatementofComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividends paid subject to regulatory approval.",
        "label": "Statutory Accounting Practices, Dividends Paid with Approval of Regulatory Agency",
        "terseLabel": "Statutory Accounting Practices, Dividends Paid with Approval of Regulatory Agency"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statutory Accounting Practices [Line Items]",
        "terseLabel": "Statutory Accounting Practices [Line Items]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": {
     "auth_ref": [
      "r320",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance",
        "terseLabel": "Statutory-basis capital and surplus"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "terseLabel": "Statutory risk-based capital necessary to satisfy regulatory requirements"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesTable": {
     "auth_ref": [
      "r329",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail by state, country, or other jurisdiction of domicile in which financial statements are filed reflecting statutory capital and surplus, net income and the differences between financial reports which are in conformity with generally accepted accounting principles and the statutory financial statements which also use state permitted or prescribed accounting practices.",
        "label": "Statutory Accounting Practices [Table]",
        "terseLabel": "Statutory Accounting Practices [Table]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r1134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r10",
      "r11",
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock Issued During Period, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r165",
      "r171",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, Number of Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r165",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "verboseLabel": "Authorization remaining at the end of each period"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r10",
      "r11",
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchase and retirement of common stock, shares",
        "verboseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r10",
      "r11",
      "r165",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchase and retirement of common stock",
        "verboseLabel": "Aggregate cost"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r14",
      "r15",
      "r104",
      "r1078",
      "r1123",
      "r1155",
      "r1245"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Total Shareholders' Balance, ending",
        "periodStartLabel": "Total Shareholders' Balance, beginning",
        "terseLabel": "Total shareholders' equity",
        "totalLabel": "Total shareholders' equity",
        "verboseLabel": "GAAP equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails",
      "http://www.elevancehealth.com/role/StatutoryInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ScheduleIICondensedFinancialInformationOfRegistrantBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r235",
      "r236",
      "r242",
      "r367",
      "r368",
      "r413",
      "r434",
      "r435",
      "r436",
      "r439",
      "r447",
      "r523",
      "r634",
      "r746",
      "r747",
      "r748",
      "r777",
      "r778",
      "r816",
      "r847",
      "r848",
      "r854",
      "r884",
      "r990",
      "r991",
      "r1123",
      "r1155",
      "r1245"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Total equity, Ending Balance",
        "periodStartLabel": "Total equity, Beginning Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r426",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r871",
      "r1077"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease Income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r855",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r855",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r855",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails",
      "http://www.elevancehealth.com/role/CapitalStockShareRepurchasesDetails",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r209",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "verboseLabel": "Change In The Carrying Amount Of Gross Unrecognized Tax Benefits From Uncertain Tax Positions"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current Year Claims and Claims Adjustment Expense"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "negatedTerseLabel": "Net incurred medical claims in prior years redundancies"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails",
      "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Blue Cross And Blue Shield And Other Trademarks [Member]"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r513",
      "r514",
      "r616",
      "r632",
      "r806",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r1150",
      "r1151",
      "r1152",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Major Types of Fixed Maturity Securities [Domain]",
        "verboseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r438",
      "r439",
      "r440",
      "r441",
      "r450",
      "r503",
      "r504",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r746",
      "r747",
      "r748",
      "r775",
      "r776",
      "r777",
      "r778",
      "r792",
      "r793",
      "r794",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r857",
      "r858",
      "r861",
      "r862",
      "r863",
      "r864",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r929",
      "r930",
      "r931",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.elevancehealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r561",
      "r562",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Business Optimization Initiative [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails",
      "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesNarrativeDetails",
      "http://www.elevancehealth.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r1046",
      "r1060",
      "r1262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "United States Government Securities [Member]",
        "verboseLabel": "United States Government Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails",
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r1262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "Government Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r1192",
      "r1262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government Sponsored Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r1060",
      "r1268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "States, Municipalities And Political Subdivisions, Tax-Exempt [Member]"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermInvestmentsAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r1046",
      "r1060",
      "r1062",
      "r1262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "U.S. Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/RetirementBenefitsFairValuesOfPensionBenefitAssetsAndOtherBenefitAssetsByAssetCategoryAndLevelInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "auth_ref": [
      "r572",
      "r573",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement.",
        "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]",
        "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]"
       }
      }
     },
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnearnedPremiums": {
     "auth_ref": [
      "r962"
     ],
     "calculation": {
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.",
        "label": "Unearned Premiums",
        "verboseLabel": "Unearned income"
       }
      }
     },
     "localname": "UnearnedPremiums",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": {
     "auth_ref": [
      "r977",
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]",
        "verboseLabel": "Medical Claims Payable"
       }
      }
     },
     "localname": "UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r752",
      "r761"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r762"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions related to tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r760"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "negatedTerseLabel": "Net interest expense (benefit)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r763"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r762"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesChangeInTheCarryingAmountOfGrossUnrecognizedTaxBenefitsFromUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r764"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate in future periods, if recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemEarningsPerShareImpactNet": {
     "auth_ref": [
      "r61",
      "r1132",
      "r1135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of earnings, after tax, of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both, Earnings Per Share Impact, Net",
        "terseLabel": "Income tax expense (benefit) per diluted share"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemEarningsPerShareImpactNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use Of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r1133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Effect of dilutive securities\u2014employee stock options, non-vested restricted stock awards, convertible debentures and equity units"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r452",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Denominator for diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r451",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic earnings per share\u2014weighted-average shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=84167274&loc=d3e27175-158546",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(a)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600598&loc=SL75763979-209797",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5086-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1037": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1038": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260725&loc=d3e25362-111560",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1074": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1075": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1076": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1077": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1078": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1079": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284427-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1080": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1081": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819541-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1082": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1083": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1084": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1085": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1086": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1087": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1088": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1089": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1090": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1091": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1092": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1093": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1094": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1095": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1096": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1097": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1098": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1099": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1311-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=SL124452875-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1271": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1272": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1273": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1274": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1275": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1276": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1277": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1278": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1279": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1280": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=122135039&loc=d3e569990-122904",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),5)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.14)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.23(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.1,4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.5)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.5,6,7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671321-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "40",
   "Subparagraph": "(SAB Topic 5.W)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=27015833&loc=d3e570705-122907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24938-158530",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24959-158530",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(11))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=126898705&loc=d3e5864-122674",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226013-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25383-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=125520798&loc=SL114871939-224231",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3095-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6816-158387",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14754-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14784-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)(6)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14937-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/subtopic&trid=2560295",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>158
<FILENAME>0001156039-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001156039-23-000007-xbrl.zip
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MZJ@&_Q5J/IV,ZW#6,+KE5<X;5JT$JUH,^N#LW3XSN[UU3VT_^Z,H)_$"MZD
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MEP- SRKO;2HVU/BM9NAO2/33Q\G>)UQ9SB.>?B%%?<MU__-T7F) :/;#O [
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M%>]#\<7;L&Z0WJ8$7@J@')-F): 6UD NIY0]N[:RM4K$^B[7ZYH NJSA_:4
MZTLH0,EC515$$D43"X9JN8I95J9+/;4+L<V2.F_,*7(MI@"0-ZGJ8*M$L>R"
M]&FW7A@O*[99"K0A%(6U.E?12?<UF-"@5638D\=W2R/6!MI;CFV6@JANECCK
M7"T6T,EGZ:(>O=ADL=,NFO5"]!9CFZ6@:8Q8VV 3F<30IF=40@_R2[1!FTX5
M++U!K]I)[78S]8N@$I:@/.L,T8<,"H*H[I*,X636@R\WMK_Q[M D);!6NUC)
M 6M.MGIC(2;0(NP*KSY-;@RB;NF-FREAQZ;4)%;#9@M4 :U7+J($ZZ3% W6
M'8M5#LLGY:HPPP7G+:3Y,ELPK%,65>(RI>@-J6I7GQEK#Q&FJJ+F8-$30$6)
MW9&H1BXAQ&+\>BWON9O2<?G+CC@P^5@-QQB M$H.$A1@ZT,P$==L$=F=$IS+
M)U=4I8)EFZ-IRV4 M1)KYH+&8&/<[ 7HGDQ=/J=*QH8NY<P%G'A%1A-)A2(Q
MD ;7I3U@&W&[ GR*\P5 WMJ@$%Q&--XPLH1+.EF,9BT22=U-=74C>9R*J4@I
M)4R. 1WED+"X!"T368X^KP5?[I1.NA&:<"CH*F&0($[B[)*K;^+:ZN*=4:X#
MM3DWBN?FV(&&C?+@3(8L/\7M1)-<X0S*(]2Z^NS8:)<;RFO)2E%@[34Z(#3)
METCHY!8@PB1VP+VL/41,3F5?"B7CVD[HE#4J9;+/<@1"!^K%/AR.I+U%!CX>
M-:S:IS^&YN6+#PK@GEA8&O)TB_/L!9/ VDIL+JI#/QZ]$;ZT^WRA$M+PC$L?
M9]>[Y:K0PVI#6%JF[EH 6SZQ$E5-C+Y:&V-9,WJ\.!F/IN,)EP>M..W)9#C=
M4.7:L:>0)"</.1H-09M()IIJ2T@J%%T[D,3XJU1Y*-08[H\^\*5Q8\.(OYR7
MRS6K4I)BSR(,&3E[H,3.*91?[1HPXN6+N7:<BBQX.CX2< B/7ISFENYYNLC\
MYVM(#I\!$(SVS@,JP.RU+605>(]:Q34@Q_WQY&0\$7IL7,@U%P"9K)SQEC)[
M\*&F4#!P\-DGFQ)U(%Y8'":+HZ'$*Y=?#8_ZX\EL'_?Y5Z377*Y-R57A!R9B
MBL4R:0 5VP8/9O(*N%7XH!6N,?0--N-J</L[L;K#YJ-X%[SF8((J$$+.%*/5
MGCGKZ@+K-:#'?!CJWO[^A/?%KY0/&&YH\==>!5O:KQ),K1Y<=>@E?K66N-BB
M*OO5I\7Z85(<E3;K[=@0$-F82["U*D\QIZHZL&1O,^ST&3T6N!*\4I90P*LV
MH$"*<P!'%FN0-W6I>LWH<?>&G19'E:1UT5%;6RV"%8^/@)JKHC9CF7-= ZK<
MB6&G!:XUULZB,LX(": :AS%!J=[G&&I$;=: $7=MV&F!NTBL!0ZD?/(>V$(N
M.27 %+PJSB5< W+<D6&GQ7$"L@0&(1!B-J"C2^Q(I*A33#9!H-7GQ&;8Z4;5
MJ!)68  5:X;L$S);88R"HJU#LP[!RMT;=EJ@^4B1:@VFQFH!#68E1 F*#227
M)&!9 WK<G6&GQ='"LM@()$Y<$]2D,7A&XR(%\-%3!V3H6F!R.AI> C)];\K>
MM_<QX_1TPO,%?A\.7UWHZNC5[^U*7T0Z^!!UQ@J>,U1!.55K?#"*G"\&5KC4
M^+4-P(,S.L#1/N],L'!Y>#HJ71EI##441ZR+BTZZ(6;! 9D$+]4VCW= W*T<
M.(NSD3JA@J1KE9_ ##&[K)5ST;2$0:G+JP^O=JJ,1P_^YU2>N'.3K2&#_*G5
M>EU!69UBJM&BE?\PFN(ZW'&6A,T"M05Y8YUM"W0+%*\QVX"4,5'%XM;"XSR=
M#-^(UKP$J$L.QQ<M<6*MTOX,!7Q.#,%'#:':H/(ZA .WC,T"(WDD51$#Y:A
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M*YVG^IJAE3EU&32D[(KEE+P)2I?('<@%ND*P+*ZW5$_:9W#)&(),(;F,TEU
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M,:*K3\ZE\*$3(SR=)V?*!=FE4%2LH)4$\:2,_,S.2:S/':CUMC%6"^4#0];
M-BJLP&W_@G&HG-4L+E;E#JQ#N0U/NBIHZ92#RR4EDR+X&!)5D3NE% C.4.A
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M \;'2$Y%C*30<@4$@C@U&&C&V2102K" P]:%MI;>%.I=A_;.FE+NTF."U%1
M2Q$,'#&TQ L([<M5J.M<9G,A6TL;_^0"X )IA'D8P9XA!BPEE;Z (X69PK3I
MV$/O*B"FQJE+\@:E%2I64PTEF$/JJTO'-C=YIX4%CBT,H- :0ZME?$8CJ1]_
M6DH$"X#I:#7DW2ZW9??3[K&PAJ38U8:N[>Q%6C7/WBEKV+K#S=<S;EC_PCVP
MFH9X3:V,C TB!5$0+JE2+RU46X"W/EKUN&']\UACE9"(0* (9*Y<8H3H%=A
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M!(FT0 ZX'>+<!2EO39EX\9+/7L]R?,I2E&7;%;[9=)^-@:M2ULC0'9U#$EI
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MB1B;=CWTQ<44N&++1F'$^9:QF -"2275$N,"2%ZN=EW'LIH+R46U.0=,VA$
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M0P@9(6$D2DDTQYC74?:Q5*A^928Z%Z:\NW-%[Q0#@"GA "AHYLPTJ?8M^3N
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M= =MK8?B4W<;BY)I^!B.E6LOLN3ZV6])>7>'C!TI*RVUWN,Q3\E.TWE.@PS
MQC)<2NBEDF?$"BMP*L>-RAY['Z1DUH93H5HA:$)6X"R430%4%KP?^RTJN\W[
M6["RSO*E/4X0--("N?<D"$/84H62(L126M2PA,G-&RKOR:M00G$M/J+0T"HQ
M3IV/FS&Q4K6*"Z[)'Y:_]?V--ZBLM'QICWV-L7>-RB/EB2##RT"7 8Y78\VX
MY$N$&RS[URNFH801<CP3V, EH*>,652"MKR&+&@7A'XQ8?[D?)V'@WN\F)RH
MY BE]M @R=3S#7M,4Q.X/%S,@LMG-TSV6>7F*10&RA0**%8)%CK+-"04M=J2
MO<G-9OZ(0;_4(7#'R#JWWO98C])! QCFZ H]9.;LO4ET[.R :SCS.5Y,]GCJ
M SG$7B.7:L"%,'8N/#*A&D;B7.HZO,DOIL=O.%EI]ZY]ICQ5AB.)$F*&[$0=
M,:ET-\DH9<E;*1LI^_4I15$BIY ]@.A(BV-.@2Q5C&WDR,?B4U:ZD;_'W=F1
MW20K(P2E//7/9\@]Q\(MF-BB>[QMH.S7H\2(.4.=1"UXK1*M!S$I-1:")>_-
M?IL:7Q<P'24H^_,H"88PB3%R5X3."2.'-(0+)PC=RI(]R@;*7GO1(FH,VD4M
M@H_$)[,WC$.X-,,4%S#@\IVAYQ8[^#M6UKJ!O\?4I^860BX6^M3. %@\!<C#
MRP3QS@MN<KW!LO^:MZK,0Z)0*Q&F@V/&W$90ZCX^%5MP+]IO87GGW8T=*FN]
ML+['_$>\IL3!K"A$*R*QA) Z10A0Q5?@5XX;E3UF0,*MVD!EF!!J4!FRUH/6
M,MUB9UIPS=M;O76FV/)N;;O2^^I[;.Z6W:B)= XTW(AB;Y4*]FE:E$NLRW4K
M&RM[SX.LRG3W./0*8)H8&A:N:BA1PCKZN[UCX-PG)WV5)0=['!]F,2)KKD$,
M/#-;"].72&&:/;?@%K1'#\D>NZ0TZ,21920\ -Y'RI.X9V36&LG7H5!._O'+
M,6>B9)U7UO?9*:5W):Z]1P,B%XR"79M:"=U=UN!-CAB4/4[?Z#J$2">KW2%7
M)8_#IPCW2=8V7D.EV]OI\4\0LL[JI3UVG,52/,"P74/(/8U,)T"4)#HX['7!
MF<YQ$[+'VONL>42;A''D-PB-,TM6 K74D=("5,E>S?*[N;RY'O+.4\C;P3D7
M1Y)(0C=*4O-P)W6:"@8U:BX=:J4E#-G8,'D?NR6Q1#/Q,'6^"!+1V335%*$U
M#KZ&LYUW7R?=V6RE!09[/#-N$0A[Z2,3AAP8";P5B4.A>.2^X!N"&RK[[H4?
MRG : $Y5(..(19Y3B6HMVW06N%RO,FV_[U"Y"0(SF9OPZN+EZ:O+);D3#1@"
M:&P5IGI9HY'H6/%&EJBK+KB][+$SLL=>D(K !#49%\!<V%,G;Y6A0VYUR?/5
MKYN&?EN@](XK&G>=%-\\^M'YV3=^<74BISX]82&^I&-0]YHS3\#DQ H  5-M
M;MQDP:V6-D[VZ4\*U3)"3@_N"LPV,IPDZ#FTS%YY 6?#[[+*BQ>#C1,^_9S'
MV[*0U9LK!YY&)J6I68!WC)*: ;G'X>UQ <<G\['*/F_E0YX\JD7L4#A++S6&
M1JFC!Z<W\ZQR2 'G:I5WIGN34'N_$Q6?O))+_]^OQJM^//SY3[#R@R>L,,O,
M]T*Z%W /A#IUZ:@:H[?A/I)DER84LXF&?GTU9MF$OCOL7[=MW><5W@W2/4*:
ML:;JV=/4![1)Q JFT%"QM.D6\?PA/10.M[DW]LX"I[7>;=\?H)9;2)TCAMJA
ME\)=Q\=DZKO>3=]V20^S55_ORIW>W:5V%^;7>?"\D^EA/TW?6O-22!,3$)%(
MIM8YCXR[3%N]UZ#$ $L#Y5N/LO,6MT!E>LHZ68GW NQC0R;T!(5*S42 "1@D
M<.T^4H@4N>(*6#GJAOK[(\4"Y5Q+['UJK=)$AGC'E*9R_=)**?,G9:M3> ^8
M2 1MU"Q%22#HE(I0;[T&1AGB^0TFH<0Z5TQ^=\'^NE5**/=BW4?D:=DT,%,L
M&7C(E! 3EYX*YBRI78]A#Y!H:: <_62H 0G<2[0'2/)@@1I#RL6@3.T!*X5D
M/5EL5(!7 ,E15MGNCY!*ZN13LQW+4.,TO&7:56RA5BLA7+<N'O&F+(V07W/C
M]$W(6>NMCBGDE'TDQMIR""G04+(CSZF$,;J5-#2MIE[C?S^X8>7>!LT"H1E@
M7%P]X"O_"6R^>^Q;@]K///7FD=] 6!)-@*V7E!L$'<$J@A%Z!QR(7=\;BB''
MMC2P=A3MXM4(7+?9I%OI?NY@)=^+;0_>:(B66I/DP([0H<O(IETMM^:$0KI<
M5AZ?W7;G9=_'MJL$I8#V[FBJIN!>:2AA]-*=FY1R4S2U1%"VB=Q[!26G(KT@
M]_CF6@BS" BG&%6G[9<%@[)=;]XG*&BY,"-98)KD"N>8$=5=4K$L=2>$4X@A
MWEMFG=TN"ET]]XL#",_I%.^M@[Q?$IX_*,W['<(3.U87-7-SB%K(<XVE4!I9
M\,AZWFR[AJDV;ZZ&O$V,N(686.&Z#]/F?,K[6/<N<:S[8$-K0B3'6G+NP:T!
MY89O;H:%@,L+$-_O)GJ+_&25G 3<3WQ0E%*KU0Y-P+@CUY:X!Q2%[(S7&R77
M\6&!%;^'C _Q]O$A[BT^@#(DYJD $Z&5S)XPD,0$7%HSOE[Y)2QOQ^LZ/GR_
MC? 1%8.$:?<J[&-_%&(%<FF8 \#4L+%@BBC8.994KBO)EPW)FV/;=^29&R2_
M%!MJ*I7BU$6K07#BX4W0:S9J7JKF!4-R[!WY]@>)("L-(-QB'RXE#MW0Q9.V
M%M$#[KI51 KC_XN#Y,C#3:1[8?IG'\=QEE4)&UHDT,H"VI6ML=5<4R[SOT[V
M4Y#<//:%?W-^^LW)V;./AEE.KCYA/3D]V9_;^/ZK?L?#_?*5\\4M?]KOW8_:
M6Y=7UI *2*S9@6KAZ1IY@H)1'"7UFS*/.-N[%\=-PJZ<(^[CD@-F[\S2N">%
MUI \Q2R<4U/V,DAX<$/"O;DC\;-VF99.KO" 7]^=<7ZX(_FV>7YY1_)[3_T=
M&2>1\=1K-=40@4?ZT" /K=BYERBB>?Y7N.>XIM\'.W=R=[RA>VK6U(W <V:,
MWK1#RZVV&/N"CAR>/#^_N'KZL[?(?QL:BSQUB,-PL5;2G@MH2J*<N]-PUMVE
MIET)0TPQ+%?F'W$[CP%)#/M1^MF<)?2:$B7H%+"(,W85+^XAZYO%/]9^N7?S
MP0;,0H#Y@1<:R-RNZ.X'3_T=7J@TU%0%2Z\1<G&LIA60 NN0( 8+"BT;7;.+
M<4/$5LHYQ1HS6!-$:E8AM)J1 &A'5YYDV;V;#S:Z;BVE9M7!XC!4[SH$Q'P;
MJG_PU-]!M5=59 I56@:5B>H2C5.-WDMONPJ@G7*;?.;N@[11O4"ZKD7<;7SF
M]5/3/O*"BAU[U19* 6QUA&+(*E2; Y'$;_."#:JE0/6CO.!;3GY/^^$(DK@1
M$C:H+4W-*HRC#4SZR &65&>R 3.[FA<MJ<FPM95J0$&Q=AUD><(>1P(J.[K"
M#5UAHVNI=(7;TQ7V1I=Y<I)<P:  1R0AK9FYI^9&;@O*.O_,)V?#8E<G9\_\
M3$_\\D^O'_'5JXNWCID_?\X7+UA?O[P8+W7V[/=2='EQ]>%G)U<GS_AJ?/X1
M7[[UH^Z?78TWX=,S_>,W?_SX'R\O_/+RB5Z<O+RZG+ZVQA2SY."M3=>5/<%(
M-:DEB:FZU,A62EX72H_'.[,S.Y]N&.T3(Q,9 KM9+*X0+%.>[HMQ$!AV%H\+
MP&@SZ/>.4#M@ZE:#3V--=Y7[*>0J762:-V?S/4*=[/41OSRYXM,G5^?ZMQ]L
MZDQ?^NC\Q<OQ])VA/S_E=\U5F,LY9J+:1XP?B\HK-$0)DI-#Z^A0#);@JV]A
MG,<O)[.L<4WE )E+G1+,J1<B8L#:NEH@1:U8%I!RSL5^!TGJ>@[)E+E.'1:D
M-$DY5&(+R5,J9@M(ZN9BOX.D3004J3OG6CI(SQB#"'OKXU^116C=7[;?%S[2
M]!.]<ML]^.79R=7E%T^^7*,OC>C4<Z0P%AZDX%,D;"4-R=+ #6'QOO0PMCR(
M7_7:H,M8F6/)C<!8.:HG;*GEPCW$Y?O5P]CR,#XV3OWRJD=M"D.LCC!I48HE
M+$ M\4)\[.=^T<\O7O"9CA_,EZ\N?/KF-^_#]TLBT]/S\5_8U][F_;_SA?U4
M8=_1>'9M+3/5@&  TU%QQQQ*MFC90[9E9YYW):[N:,X\NXSDT@L,MUP"=<,V
M<M!IQ%[S5I=JB?>VF.[$*B'V1-%Q>-0$5)1BS\1>8E4I5.-\K7+S_D];+H_X
MQ5O[:Q^_>'EZ_MI]9X_/7UWH<[[T!>W,9$JA>9>Q-A2R1HS**%9ZAY'SUR4=
MR!S4.(>//F+C795@%34#U_%'Z^:YD;9)P"RI+& ^ECQ(5C%RBL:02]T=E/+(
M]*MH1F^[\WA9TA'\?"QYD)P"&R93;6")I]X0["X06$+J,7,./_"N(=^])>_4
MEX6\G_<MT#1++);0IT)+54DCO4[=H!KE+N7F0N/-^U9SF.'[!K=_W^J]'/;P
MOEFK)=>6(X[W*J8^1%41I@Y1*EF^V2=L-^\;S?)]:[=_WV@_[QOU:)5#+J&.
MC"$1(H7(G&(V\ICDYJK->U1!O_Y]NVW)ZCX;Z#76@MF2<X1"(^LB'"NW"K3L
M6?(/-,<<_=NOBO![\V^B-3>1,#P<H#G%G%.!)E2U-$O7[QO<O&\S]&_Q]OXM
M[LV_5:_!2LN*-<!(Z,DXCWR^FWK#?KW?&F_\6YRC?XNW]V]Q;_ZMJ3A-#=8K
M19"2IO0 96@3MS;^>M>YP8U_>R^YP:]_WV[MW_:GQ%-OE(=:0^D)LB024:D,
MT+G5W,/U>-.89CN^:\]WA7[?MD6>?&W:Q\ L#JD95VC<"6*KR+D/?PF4F-N@
M]_I^V3#,O<U"OVJ=_<!&[[A8]?93?\_.N=>I[#P9=0<0(Z58#;&.J-BXW/3@
MCNG.YY_].J!WXB'M8[ 7.16>QB97B3"-;-*>NU&"D+R#Y_FW=7IR-8P_?<_'
M__O5^+VF2K7SL_'IY?=IOJ_ZZL6KT_%<>^17GYY]XY=7TW=--;"?G5].98FG
MK^SD[-GGYQ?3B</]JZN+$WEUQ7+J3\\?G9]-;]O%^>GI>,JGXPV\&-]_ITYK
M?PV;,'HE])2:9JA#*Q>LYL'0HT23?MUN>K/Q>[=QV)N-.Y42P5H!S!!5N"2,
MQ896:)K0TIL>?IN-W[N-(^WO' O'RF5I C7!U#.!;9+6GD<V%\NRNO*LR=B'
M/X-1TU!IY*<M5.@U$&G+PQEP5%9>U!G,>LDX3"MQZJFQPTA$&N2.G/IX??',
M"(DE+NA,9[UD'.2,2-3%8@%PK=._U,!#1JXD 9O)_*LB5@7$G519#+G0*+G'
M)@;0"U5E4?2>'05NAI$MV,;3R>ZPT)OF?=\]^+A_^N(EGUR\V'UR]IW-[WKF
MT[X,%P&3)&T:>H>6N@2E:9\TD&"H4A:?LLW+</O+PZ;3@2!(%5@@)"9('J=F
M^XT,"RP_#YN5X?:87*F"C'19?:PS*$W8O3)J*,&KM.#K2:YF8,'#9TS)<YWJ
MFR27"-.1Z%07TT8:'3(KQA^>(&_F7G8:5$N6Z)(-8P?E2,FLCN7>Q\>Q75\D
M744:-#=S'R2W25/!UK0E(AD@8N2<JOC043E)3V7&=?C+L?+=)"PM9:E3([I$
M("ZL!$H!I@%WDGM;?,+R$TGI31[Z$5\^_^3T_.]_<7OFWR:EBSYY(E2MT6J.
M7H:\JL@2/%4F9*!P?;ZZ9&^[!'/N+[E)H"'V-K128& %#F@I"I3NP[:U+CZY
M68 Y]YCRM*D+=Q-5EP0="I:"6;51U-IM32G/;.UZ^$3(1@+$H97AG3-(G(II
ML5&WY!A*@[">1&@9$!PD/1+0PAZE8%,PSQQ8E"A[["-S2K2>]&@9$!PD:>K$
MWCE0\=+!C(A[3Q2HBYK'HHM/FF9K^[M)I<"T<:)>6H0<$U5%F8K >HS,(FM,
MI1YX/SES^Y.?C0^NIMM]E_?MZU=O<N#9G?/M+\]R F>KVD>6#+OV3(3.W1%J
M;Y5LC7G6LFR]OR2,*:<1F+%3JA X<9ONZ$)JV82"\QJ3L$79>I^'4MDRBT&(
M(T.KI7 <.9LVZ,7&%WD)36)7;?3#IV_2Q0*DH=-#GYJ<RC2(M57.-206I%6G
M;TLCY""Y7<I4IK.NEG4D^,F%)9,A"[<:JJ\[MUL:(0=)_(9>S&C<2P@&W#)K
MP(JI,U%O+8<U)GX+ .-.LD+DF%I-97>-P "8C-ARU>IE*)=5'K!]<G[A)\_.
M/GIU<>%G^GK&=MY?1BC 46KT)(J@P]F/A1VA6QD+FH:"7&-&N!P[[R\;%,O8
M("%E:Q KT72A$UP)H93ZYL!\;=G@8NR\S[,Z0G6=%+X'D-[%W5)MG&*%1%Y6
MG0G.W."'SP*;C*0/Z]0W6"$!2@#,C$1!&DFP56>!2Z+C,-W""_7".8? #30A
MCX^TY@QDSJBZZ@QP270<)/M3=D2!&*<9#Y4RYB$=$KIP=JS :\S^9@[%OC*_
M5V<G;XQ\_<._->!UA_9=&>GU8S<O<?/0S>?3:_ST.83'5KL(MEY@5Z@IR8$E
M5)Q&*_$28\Z?7EV>G$VCRMZ\Q%O%MG\^_\8OSG[B.>^P_JU_AX\&6^/EW@S;
M^^+D\F]_>OT3DSH'IN<O_.)'3[[#W^)/8X4\?\$7/VS.SJ=^^<4TR?25/_)5
MQDW"F%-H<>J9!\ VXJ:FUDK7PIT0EQ@W-\)G2OA!8K^78G&Z%-Q'["_:)32O
M5= X!6J^R(XB&^$S)?PP4Z^L8QQ^?#>2PT>^DZ,G;4#39,X.2ZAQGL:L/N2O
MSR]NR'D+Z2_/N/>3TY-)U.Z+GUNLI$^G@<$GYU_\XW8+:)GD-.'8@F)O!)9%
M0#E42Q4$O+0E3:BXA44?7SWWBSVYPST!NTAJM%G04&O.L4 H@:@.I5C!)6LD
MP751\RO]P.\BY_ZJN;$DS&P9:JZ0IB$$+5CN0-[,%-NZN'E?WF;=S. T,2 5
M*;TY!&6TZA6G4)6JLZ1U,7/]E8]/3UZ<G.VT[2H;4T1IJ:'6X+%"CR!4)6;-
MUFL1OA:L\]Y6VP3K0;:K&'HH K%U"R".''EX 4Q$4K32$LB980AYCX+U,(>#
M,9@$KE0L@4,4ZPUS'IIU&NO6XKJH6:5@/1 WBMZ2*80.,"1KH%1"8I58F*JN
MBYO5"=;#, -QJC_OB5H$RXFD"0IF;3(<D-=U,?/^!>MAID:*=Z0ZS9X/ !*'
M!PB815/PF@'K D[)-L%ZF,H35V]]^ (QAM91M%6LI5,MI,5X >3,,(2\1\%Z
M$&JBBQ:G#A8#))[NOA:U$$0]I5)@7=2L4K >A!ONH);+2(6'9HV!!D4!HE$H
MK:>8%MD)__#>9MW,#"ECB5LL"0@Z!<DDN?,(3M/E>_=U,?/^!>M!C I:AUXE
MSSU&Z+V23O?K?3B$W#39R@YV/SI_,5:LGO#IDY<^_7'U>L_5+Y-[^/SBW%[I
MU>/A<BZ^&<+NNY__D,_XF=M'?.'73UKEMGT=XH-*)*P0H+8BTDN7S@DS-5S;
M=LCQ0760U!H)9*JECMP"- SHI??FT@&RA;B$U'J#:F[AC[#79%PR"D/L#8DK
MMRPCD2JYV<HJ5&8$U?5CJPQ_@Y+>)=8**0*V@(D##;8TME1&PKZ%OV5#=9BA
M#;E.,YG=$"K$AMR-R1!+Z3C<UR+O+6Y0';K+*>9:8@A>E"!,K>@QNV10SR,3
M%%Y ^/ME.SX8+\*G_WDR/?=&Q]P_LUO:=%9$+S(4<N0IZ@%.PYA+[9(*4A6D
M5 O6OH1[D1M@<PZ+(PTD4!G1,00H9D*2$G#JU+*1+2$KW ";<XC,WCV7U 13
MAR) T]P/5$OL;'V9<\;GJ[MV)S5KWAJ%J#J-BV'F .B5QG]#&&3UGHG2(D?M
M;3@=KMXH%^\96<@K8([4!U.2:E.*%7AEY[C'A--!@EV)I?$T"!(%H0!3I,;%
M1C98NG!?V7;HG5V!G]O6^F%V06LRE9S&GX,E=PR1N" S%F*O*ZNE/QJ6#K/Y
M"<U:;CP"G8-Q%E1V&1$/C*056U>8.QJ6#K/G"<F"I=QHFB4A3"02*"#O9GS5
M)33!6!1+:S[I(XTY]2B-R($1I\NIH7,>=LY.T+88MTB6#I/*D76T:41W49B&
M&7%FLDH%M1!9WF+<(EDZS,AW%M9<R3AVJ"5QF[H^!;4VJ"IA99N6=W$MX.<1
M^OPY7[Q@??WK-^.7&>*&$X**Q9,W()Y&**0"#?.T/Y!Y9=<4CP6EP[005<N5
MFU*9+BNUPNXI$V8NUG.1L*X(=RPH'23 X4CA#'IK41M 3YBCM3X\E6G4P&%=
M 6[?]Y=^'J.IC?>SB^D&TU^<3Z^>KSFRP;09R>PHH# I)IZFQE8NB;03+').
MQ!$S=)AY@IU*]ZCLN4&,$:%&Z2WVG!,&;>L*::MGZ""Q+%#U@5 OC1&@3F4E
MW'N,50T  VRQ;/ZGM0<)8*$F8 R)JACD D2N(F72UV5JS+L%L/F#<Y"HU2-J
MKRY6I4/5@)%2S""HWK1KWZ+6_,$YS&WQV"3D6"P.@5Q3PUA&\I7#"%3"49:4
M=GWAN^%'GX^W[?73"SZ[9-U=\O_3Z[<?>:NWP^<??<Z7E_[99Q^M,99X[I@4
ML>06@#UBC;V/E<\X78@,94&Q9+Z6/8BS'\J@YC8D0A*!.-*3FK)$DA@#3R-.
M%N3LYVO9PY2F"R*W0H4X0\Q=QH)E&W:V$<M5<+[#ZLQ//OS,G_'IQ[O?YZT*
M3SX]Z><79R?\P%^.]W!ZO?-^?6KW)A6<SN[V;\T[F2_>4BDQM89#GT/B*@E2
MAI)S%,D<ZGSGB\_:0/L;##X$L"8MQ;A'L "D;E[&8BK,WFM:X KZ].SRU7"-
MZG]Y^/C)*[D\L1.^.)DF&SU[,^YQ]PWC"Q__XWJZXQQ,NK\U%]$1/9BTWJ&5
MRE"J1!Z?&:*TML UMTR3[F^5%J]C,5+!@!DJ%$DM=8\A)XU&;<9#67^5&WW\
M8P/]R,(+682<*H)IKT4CA*[<JC.$D"!J*A06N AG:;']K;&@TKCT0D89.E?$
MX3#K>&^EY&Y*\UUCTY;,1R,).#\]L;??^#>FVVW8#+N<74V3D/GL]4)64$ T
MBLJD>>HA@Q@IL*I(A.0!?+XK:$[VV-_ZF/HQ)]5.Y@D@FDR-4B5$X:$M]'IL
M_+QWO@YNF,/O<D%J4,K(E9L01$&ID:5$;Q"LE+"$V[?SLN)!=K2*YQ[:5 %4
M"4H@[B5+MU:-5 JE!>QHS<N*AVE!S4K6<\H@ *Q&-H1B<[2",M[KOHMPF_'>
M$>'"_O9"N(X 5BBG6D#,IEE9U2U$;"TVV]DCTF:/7[1'I-]FCW\Y^<>'%WYY
M_NI"_?+-I\^=;??[V,DW__YOXS\WU2+&KM@4- /H6"LPS(73K!'HWO)_3^;Y
M[GLNKUZ?#D.\.#F[]]Q/GCV_^C#'/Y:75__Z]Q.[>OYA#.'__,/NF?_^;Y?C
MS?GW?Y.+?QG?_^;C-R_SHQ>;?N5[(QUZ=O;A-%O;+_[PYIMO'M?ST_.+#_^/
ML/O?O_;Q=[S7^<7)Z>L/_\?38;7+#Q[YWS_XXOP%G_V/_WG)9Y?W+L>[TM\\
M\?+DG_YAK.,7W'WZ]S>_<QNO<WIRYC=_AYBF7_O+1Y\^_?C!!T^>WG_Z\9/O
M_\XS_&V??/S1EU]\^O33CY]\</_1@P\^_O\^^LO]1W_^^(./'C]\^.F3)Y\^
M?G3 OT*ZU5_AO_CR^<G9LZOSL__YP8,_?O3'#X:_ )K].__)XR\>?O!O8TF=
MG9\]>O5BO(A^<+WROO ^N3ZWC%/-9W8!"Q6#5K2QKL(0&OFG9X=^<,:3AYOV
M"QZ<ZZO)5TSC[?]P[4SS?[Z6!^???):^^.:K_/"5??WQ-W_],WW]^.O[Y:]_
M_N3TJW\^RU_]\XNO'_[S/\)7_WQ^\O#!?\1'?_X4QK__^.KI%R_^^E3_^5E^
M-)YW_O?'__7%\[_^UT-XE!Z.YSX,C_[\$+[Z^GYX]/2+D\</OCAY^%\?A[^^
M^#(_C/B/S])?7W_U7UH?OOCXGX^^?A8?/O@J/4Q?_GU\3WCT]>GSKYX^^\?#
MKY^?CN\[??3@^<FC?][_QO[\GV!_^5^G?TVGW\C7YZ^_>OHP/7XPON?KK_[Y
MUZ?WQ\_\C_3XOSYY_OC!QZ\?__G+\3M^&1[_^=/\\!/\Y\.O'_[]OSDF+6SQ
M7N_N]\"([TESNB=4-*$Z5LU_^/<8[OV_.\?VG17^_8,?L;-O0L(-(;M7_/#D
M:O"HWV,&?I*9_^LA7_SM@\=G_G__+-XO^.+9<*M7YR\_' YUL'W%<NHWC\KY
MQ7#?]\;?X)1?7OJ'-Q_\JYU<OCSEUR,T['[J[IO^]?JUY/SJZOS%]'+_^HU?
M7)THGUXOH-U:>O/PM>LF^B.6/'GOJQ$EKNSF!U\[]C_N'/N_7-F/'X,_ME)_
M]M'PQ_BSC_W2JU+^8P"XU<O^R^XW?O-;C_=E>G__GS_D/]Q\PTNV:1/[P_3R
M'Q_$\5:\Y4=.O?_XK3E_>7O'<O_BA$\_^/+L1,_-/WCXY)W<_!PE;P+GW3N5
M^V=GK_CT"W]Y?G'UAP_Z^<4+OAJO/MZ1H:@^E//S4^'3T_/_G[TW;VX:V_I&
MOXJ*YWV?2U?9.9XR-?>ERB0&<@X9.@YPZ5NWNF1IVQ'(DA_)3G!_^KO&O;=D
M!P(T) &?/TZ31,/6'M;X6[\U'^4?'Z3L>9Z,7KS>>?=V -<_F^(83@[[RY/#
M/Y;'TZ/M=W_'T^._XP_'[Y\GQW\/>B<7[^2>-_"N[>S/BQD\]_7U\8MWK7?O
M!ZWCPZ/6R>'1\MW[]/U)Y]W?)QUXSMNCOX\O)NV3=._ZU45_?CQL?7QU$?7@
MN[?_ZO;V6N/0[#7#7=-K]CKA;G._%9GF3G>OU>UV=_>B?9!=__U?^[N]G2=U
M\65%@VSX+]O+K!._:3=_J1"\24W29NZ?G+SNOPK.!V>GYQ?!V>OSX>O^R45P
M<1J Z7(!]DG0[@:GYT%[^W'\6W#Z/+AX.2!ST;-LK%73/[C 2]K[W5YEENCH
M_XN$WIU8#)\]UVPQY$4POS3!."EA98*E"8L 7%T3_P@SXHQ\A %[UI4C_SNZ
M-\TIO/,2;VO&X;*)8VN:[$&>_:^V.SX>7[R&<S[I'K\??#S^^]WV<?\OTVOM
MF=W];K,[W@Z;O5X8-T<[G79S=P>[;.Y&6'#X727VP:) +_,Y[9EWL"RW7<+-
MZO7_ZG;#[=%V=[\9AKWM9F^_TVWN=]K;S7;8:?=Z[9W=SO[>HZ>')B(O_;__
MJ[W3>H)N=E4@-P)<F,];F?=-WIR>KS&$-^;DQIS\YWU4A$TFB)K\V4U*$#+;
MQQTP)V$<?QY&8%;^F?[YXM\)":*W?UZ^>WL,9N._DW?3XYI)F7\\N?CP-YJ3
M[]Y??CCY>] ZF;[Y\&YZU/KSXH_M/Z?/+]_]W;]^-X5[VVM,RCC:,_&>"6$=
MXE:S-VYM-\.> 6W4ZXZZH(9ZK?%(3,K>3VY27ISW3X9'9#M^D5D9_.1VY=R>
MPH CPL&XR*<!J[4?___S_,Y>?>]5,W+.)B4F&L ; 'V<+=  ^?U[.@(,/7H.
M;SNAESU((?PM,<6C]E][+0/2<R=N[H?[X)>;_4YSO[V[U^R.]D;M[7"_O1-V
M,8_4;H)MN+UB"'Z9R9=,)T%91/_GD4FO[(K\-6EOO9]-'@5A.K_A+_+(2]T_
MLX]?8WF!J)Q]?/2O3T<8>^L$_8^7ZIWO;*;PUC\WDZ1$&3D_@;_\<MO_^.^_
MHKC;Z49@.8S#/7!FP3=JCCJCG:89F;W=_7![W.MV'CT=O!J\Z9\<#(*7@_ZK
MBY>-X.CD8.L>>3][M]I.CP<?PVA.FR#(QT%A%S\(RZ!$HN]Q8N(@R8)D7@;1
M95C 4%?#\@_(8=K=VN_M_>,>4V=K>^?FOW[M4WL[6^W]SG?VP^Z;W?K=)=Q1
M%N4%^%_46)IJF _R138OE@?@1Z[Z9"5>,2OR*WS. PT7L5?VY_2H@^_]\^+=
M\GCZ#L9SO,3G'+\X@C$,MH\O+J<G%^]:Q^_[]4#_]-W[/].3OT_2D_='RS_?
MOX9Q'J%DO89Q;K^[^/#Q] 4\[_T?2Y"BJU[9_G8<CG;BO688]3K-7J>[TPP[
MG6[3M'O[L(;Q.&I'CYX>97$29N$_ZY6MBS*P*/G> G=]F*%F>?\4GN9W/[$7
MX<<CP2A%=&H?L&W^HX_B4?4H8J,2;%[9C':[<!3W=D;-$.QY^+_N;CSNC+<I
MUMO=;G;:O>W=]O8G3Z,HG9HMCH"61RO;NLBO^=^=>[7%/VLFT0Y_3&HBR(L@
M1YJ)X/VB2,HXH0IHM)LH9)+X>H6N+29AEOQ-/_^V$6/W?8V/MLZWAEO!8#I+
M\R4L<E7D!"QS?KO% =A9M_]K\]'"V7ATJZFK7'K?8FUWY*7VX[@P92G_>04#
M:#](;?!-KFKK+["B1MV=[9UF)QQM-WNFM=/<[\11<[S3"\<[H]Z>Z8:/GL)L
M!F\2=+*2,.A?F6QA[I&C>L^VU '\\[2XR*\?IJ7_31NJ^]=X9]S9-Z-6,XK:
M8;,W!DM];V>_V]P.P6QH[\.T[H;64I_E:5*NIH%_U$J13CY%SJ<K4+T_J>?V
M3:'<SE_=T7YW=W<<-;'Q;[/7Z[2:^V9[N]GM=*@)XDX<[=WH>?VPE3S+8:G2
M/Y,9>^"_VC)U_]H?[T;Q7A@UHRXBX=I=T]R+6_O->'>O&\:[X6ZKVWOTM+?3
M:?7ND>3^K*G((4999+239P6<U&06IH'Y:*+%/+G"L.,8V45_"Q[#!@AP!]P,
M^[TORL@%R?_[O_8Z[=TG93 WJ9E=YIEFJ1H!?"HS0@1A8<( 40J_V]6ZBW3:
M]\1?X6&&K_PE#_!Q[R^STP/E&(-@W8ZB9B_N18@[Z#3CO2@*D7%_O[OWB&8\
M >LK[J.6ZG0[VQ'VT-Z.>V"ZM?8[6 P;[75:)MSO[HSAZ-SD?=^5 28?P X1
MDS!_]B/VNMW?Z#O\F]6!_'X[\E4./N49'L@''"SZIEW9_FO/[+3'K>U>,S)[
M[2:X!.TF$I8UMY$W.^[L1MO=%J@53.1N[^[>(\URRRTY!!U24+FA9*Y,8>)@
MMBC*!::PYGD 5^!VX]W6[CP>_89J"&$@_6C^^P/.8W6[6ZWV[2!Z7_:W[>[M
M$DY?E!W;W^JT=A_(8&EFM^\DZ?9](GK[MX.+)?.4<L FC"Z#* W+\@O">U\0
MSGH8LU&$9+F5R^DH3Q^77Q*^_=GF G$@+$#S,?\7MXC\ZV-T&683_;L(VNO+
M1"]P<GE=X/2F^1'!B^ ;F)Z JLL#_=#[$%*^>U"QZ+YENS.BH_L@[1M!"[_]
M8_OD_1^M/R\FV\<O!MLGAX,N//OC"3S[9'I\_>[MH'OR?M#[\_T?*VCA/P\_
M=$[@F:>''Z[?77QH'5]$\!T#3*YUWOW]#-X;=2B9]AS&N)*7[D2[^ZVXT]P-
M(T0+;X/5'K7'S:@7C=MQ;R_L];J,0@1S=SC/HP^-X"PL@C=ANC#!_VIMM5;
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MV-.SL)@'1T='UA[J9]DB3(-S&U1]#M(T:+>:_PE<WP78*F"%%3KK\!>6N=1
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M=O>W]F_92_X+&]]WOJ$SXLZW=:C_Y_?>;5NMA3_VC3P=X*5*6RNT9<RCX+)
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M[T;.W(<D:7M#G7$?A$RGU7GT5&IOW@6G;T_ O'EY=(:85+!T+OI')\&SP<D
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M  . ?;8KR6E0F>I()GV1B6:S0TK%Q6(BN6)V%F;Y3,YL0XGHS!3G?G:91!@
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M!F%H5TA ?9?K"G1>G* #B5NB$F\%^?I%\;W&)KCW#4O5>'B3=J<=/F[@?\%
MT9JJOW6$==B/T+;&)KK=@GK@6?./](\+EGHA!"[>I$OG!I/5$:C2D)BH*Y"H
M!QZPJN#L!4U$4%TJN96(/D>BM. WS"I>'[5R)/'"3J37_\,KCSSR&U1+(U);
M747OLO4@_#8IV*1R5&KCR&Y)1'25M9?6BQ34TN?&\)PV=YN"-DG,,/]J< PN
ME]Z3]C,,#-$':W*O;H2720$E%<$&1'0H9144R)24?,.KEV>42J'][4&]-HN%
MPT++UJ.T87X-VP/+!AI<NVEKF9GC@#_ 0M1.&>_;X*9@Y@,Y@24:5$EY62D@
MJA:TE3[BFNO=5PI;!0_BBF@1Y.'RJPP[I*Z0/MBX A#PGQ>@^3?)D6PP&(4I
M(UEL"-BV$T?W=?1>P-\P2*Q=51@[=;BO8-RY[M^1:7\P2QL=%7@V!2U'1AC$
M;5$]>T#*K%#3C6I#"XT"P^%+P<-K37J%)+:60*,&Y&A/5V940&.5G>85I#L7
M YDD1XLD)0M8VWNZV*B-XOM?(]U*P3@O42Y*,;T8TLE<L[=XG.;<TZM8L^9>
M&U+Y^%J#.,0QAU+LKT"*<JY%H _0P'ZK7.(K.<]*PD1C4FP66=FI,;$IG$+<
M*8)'HY(?#^)5X"(XZ>:A2IBSA$+S'$]7]O :,_$ZZ!9!---*5]8M5TK'E,'6
M&_;.-8^9BH?K0Z[J O .7#V%/QH=12X=V=)YB.X"8T9==R=[JJ@[L&T;!T^"
M/X!"U7+<<NY5Y6,T&<2V@NH(OT]:!)_HUD>%(,D^9G7-LZ;Y*"CG%9P=BUT<
ML22FTB5LJ B%%OD__#@B%@ ?W@-FG+'<'\B3;?*+DEEX-"F$9B79F3 OP#K,
M/6![WQ&[4"5D7\JQ\18)<BAI;3!0S0-.%4QO1$D>_+'/,.A.J]TB]15.&7CU
M&"D9M*J[X:-*^@?]2K8.)FIUCK8L2[M0P@H**[R"[45#)C(6.0&VP!LN?B]>
M.JLLEDET2 ,\@HVJ%5:;2/?ZAR<TJ@"7F,%',6SF4@(1'IO("IR/=DEM+D0$
MX3QS2'%,_#UHV?*CI+J*.BY\PC(WIK/;Z7U/F,)=N@5>%+/AYDJ"T;G:A)Z,
MN&G+X52VNWMJ-K1[72DK1[B6U@=('$WYEYF#A$+E8)3Q,K<['7S&^OM_[;6J
M=/)6&TSLDDJU%%6R4;-:@E/72GAKTWJ-$7K+#G:318IA0+!L42Z3*<;&GLVJ
M4P,6S"N'U#&">*@L,Y.T;K:%"8S&QA@F)J X@MFPM1V:S68["U&C-HQ6"> +
M"C OEI6Z,6O8ITM7>E)W:AZ@?'QFN-'[2N\&)*NO]5_@Y!-Y5/ 3'[JY+#/\
M7[=7L3Q@J:?HBSO&>U="LOATIYJ&0R>A#T15<IF:9>P%-<![8ILD16HMDZEC
M0HF*(J#<*+.N3+&4L,D5?!M@@046[#P08,$=S8^& B1LP)65YF.(N?(&^\UT
M1@368A.SL+/1#D.NPWG"/%)KNC^H@XEF'%KD)(9J;8ELF0J%4TK>Y?@._[U\
M(2;YBI"*"VLX(=[V5D=* 48. Z&Q(MD(^#.2XY4P!_ZA,*"CA;0Q+#<AY6_8
M25N;V?L6T^B26'2TUK#B]>IOT7D!8Q.W/5>+\F&@O5L_ ? %M3X'?MNI9%WW
MGQO8Z=F+PG=S(<P5L? )@75F8XG-<H;9NZ*&_9,0%'G@(3&KUX=%!"U,<%H1
M'AX2R?,?+\&MT_0AOH ;<K%E8SW"&G)XO,BDE&\LG_B0=^F=&M'^+EW;D\X%
M>/U%P  @SKWU8 HPB(B1H[921LN^='L^Y)6Z#^A]U<!X;N3 G*YKUF?/B+^J
M1"EG,N[Y,Q8B8@$;.I@#12,UL.95X!?V8+H G#<,CZN-FRV\XH/_==S8G^=K
MJW1T8%0':7]N&\\25HK[*BVY7!,(^09^D'#6X0_:_(/JP+6C"/R^X:7D3J2G
MA&T4XA'>C"7071M%5KN%'N_:2DA#P JLN=+J:GTGJT]UKZ*E7&E@I6_RTE.N
M*980NG&#*ZT8>7C^X2=8\J0J@Y* Z])(E*!QM795&C0/!F&["*5A.9<2."I6
MK5"6?,>*_J#YO57'%S7Z78=UN;.&)C6B@RJT:/<VT*)[CRR2/ R?<1%PAZZ.
MX0&6W;[1,O1<.Q!7"/PTM$J1.4JX.BB!$ .&$OW6E&$5FYZ924X,>43:RGRS
MDJVRM/"-.F&\Q7$X5FYEWZ?\N2+A?9(!)_K#>3 .K_*"G&LB0%-^ _LYBY+A
MD6,3$BO+#2RV/ Z?2(<_DMD46+1-0;TA_XJ-&LX*TT3#@*6- *#)F,.HYA6S
M5UDS&Q64H2+D+%IZFI^>LIA?YH6^B&3F7#G X9V3A,G]<W -F %&TXP1>!"&
M(@7"RXU4;<44<;44.M7K;N3IMVT:;$,&'*]'027$.]HQ ']49(8P%RF#\!I2
M4V;Q3V=VQ20K7>OXD(57R42+P'W*F&4)$J4&&7*;91HNA0_?4NCY&7"=>%U5
M7;\&W4AH!+L=:+4)K(% (WVNECKZ3]?MZ9[*3W!D=AD5655H\&!J,NJ<DY9Y
MPPZ,H0><_'36C'T9;AZ>#.Q:# -*<L[;267E-&>\/IA%SK1D$>"MQ59P[+G)
M&)O&,P_KF>0QLB_!]ILA0$M8@7C!G3<]@[F(<N401B(05W<@7G",4)MY0A@+
M"D=1+P[U6;ZUH_%W50$WJN#U2N$6Z/1;?N5.O6L9*H9JU[*[BW+^F*9E7V3^
M5"=K6[J8N>5 .JCF,RII/JOGI>_"? CN/'EWFTH**4ZM1;6)>M,5/B@IG6\M
M.*2QGY,51_AW6 (-%%L.ZE./E<,U7#\[=:V])<!U['G1:V]Z>>S=A!AX;&S<
M/$36E\RVNR?):AG9#U^>N5LNO%*J(^2@RU3EGZ&GV,S'337X[#A/7=&T<*?#
MT$5^>[)2$'F6T1@K9<2M1!/J,L?R.@S65YO1T QQHE*T,-TJP7SB1<9PX(0:
M]7#["3$3I-2*'F ]H+&Q3"/$Y>H_C,? 11V8C<#QN!R#AW5@O )A'7B1Z-%B
M3FP%L BVO*!645S9*+9@W\V2(WBMOLY#3CEKI>&9*FOLQ:T U]9_NE85A6P_
M.MUD5\S'PG(L=KS09J2HSA11I;]F2![:".3S,XY5(PEH*CBJOGGXT7VQ%+%8
M@)86?%U+'5M!K:!E$6-LRE)@> .C2-[LKWT[&K[H##>E'^<(3B3'A-EMUO*9
MCWP961+"2EAOF[!5.0^)/0^^;>+M'RH@TG(=:0!ZPX:6%E(< '?FKE27(O)U
M8GP0DF]&L %>L33X1IM8 _,*+3C.&[.)KPE^\$7 ?,9S/,LCS U/PX\8NL%3
M>SIT @O>) BN.@P9%@4V>(.V#%4'5J>%#%+9<@U^)H-(:74]/G,Y\315Y@,O
MH11TVEG"S]*UAJ?4CQJ3)7+VCA>5?NW#MQI(D(4%B=)N"&LFG9'YB6G]$I-L
MQ5BY.[PGP:IX9WI8H74J26QBN'8=:JO!VY!"567)7M0*X=]C8AH9*YD9/J9_
MT/\-!I%KO>44#X 6Q)'XGEINN\I&%1_TUJ;PQDC\9XW$YR#4[Y.->*<9C]O:
MB#<S#MU(,>3HA;2Z8DWJBRC0"*!5AS@(=^RZCD.-E4A#N+[O$$CS14CD@15J
MD7Q=,L=ZJ+1!>. 5)A5+VVQ!'*710I@UX R/=+\,K[B;LL</J7$RX[6/\1O5
M-;1R0TNL7?T)<>0YVGGI;J22OMX6@\:.T0@P&HJX G-."N2&6157MG:#,SX;
M8)0%1NT^!&#46H5Q1S-&!X;#3<P!1)S3VNT5(4;&D8-Y9!9C9X(K^;;MU>4$
M"V]N])BP*RLUL$3K3_:V+61 H^ A6CGU&LE?"K)Q;X!%#8_MDQ$\MF^6IN(L
M]3CS?&X@'O=W96^">)0_!N/Q68C'QBGX<4Z!LW/OAR=PIZ[ 6RW PWH,->[7
MLWIBK F;VWC.MG29J?.)"EGD>SE$CIFH:EE7" X7V0HEHM=<SM;U8^SR1K3F
M)XD"JR>I6S])W9W[=)+V=UN=>WV2>CMTE-"&>X4VW)&-*]UY\F.=85EI!DZQ
M:2K1#JG?*(.44FI*H!J"J03$&2O+Q105 %KI&K0EZS*PQ\?V,"%E/YD4AG+:
MWNZERBG-$G <5:!L6FM>'8$-DV).'ZN'%_'$L,]+N>IYCMV?X>.><$VR4;/#
M<Y U Q]>Y4D<F*+(M>]B(@UVZ98G51:H:F,UQON725D9I81R^8T6,B$ Y8=R
M"+\0A/5@CN4A,2C_PEH-Q0 S3MM("&>K;*PF<:$3*@=86S5JV?7IC#.%)ZG
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M0$*W%)_8L1=9G<\,&#=N]C7#X;HK6_=)A2S6*"U-M*#.2=<NT""X&ZZOM4I
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M'4!&S7?%/82BY&35+&U+_=AXE#2L12K%8C8ICQ91D[:!JQG?"IXAFP-*:#J
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MFZ>=FL:RW$NC X*M[<[!C<*;VQ/+(QP]]D\A X[&=X3M1+T2MFT.:;@_@N-
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M&"$D87HD'';[>L!=B=Z)44'1=!!&X^ I_G*JMPSWND]0#'5PWB24GZ\1DU#
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M8=N9\+/P219%:BHN1]*X_'=5?[A_&(% )Z2ALR;40I<=<_2L#[SRZFRS"H2
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MP?7TBM2!T+O@'V%_O\B*>O0VV\/M_#R8:!R*JN+7R/DF *)L-*=W W- V&G
M>C,=.;"F@BHI:E!57(CR2\QKB.QH;MP!.E*C7_1J5G]X\?875WV@^'\6-AM&
M:)1(:@NO2S@O:$N&(!=4*4E;/#TOA0W$YD)G6LFH21SFA#4">PRK7,2OZNF#
M8B?N(9T[#6M+K?)U*Z"R,/AD9!:1 BGL7U(KN"B40" \S+(RI+$0*RWSC)SU
MX#8Y&CQD*1BU20%ZT>QX]<)Q!!JDF.'JM&6MY,D]/](=*YA,36:&"U>@CO"L
M?+"9W(E'M9X\8XY],I)*FB%43 >4?_G X$26C>/7SZ;9+%\6V9B=S(CC&@M;
M_I1IQO0Q.-@+BV-![$Y4 O!3Q3D=\BY@)7+U<67T(5U-:M9AU2"W>IFI"#<.
M)*<WDQQ0B2_+AAZ^.<\WK04P(L.(X3"3=-/17R4W5)"]H_FB'$I8$W#>N2+$
MOV7M=MX&"Y3,:7EEJH 4?L]<!?X"8?#P_D,"3V7>XC3]=S4Q9)\P$'VRZ>3R
M$#%P%?/-K;6F[^'FAC/.% OVSZ[^6 O,CLYT?A%=P>S%:]P"D%T#]TCXT)IV
M2DM;+5%D>7 A">W/D40/:!S(T7^&".,]E6*;%95T=@0_T43E^D0D/$4!"W%6
M70FGF@LMQL"/2N&#'H!Y=+VRQ%T9U)5!O[\K@^XD:[:.*3B_VJ;#5)P63@C-
M?<%4K[3L:DYFA:/J"HX(+].8OF2MU*H^6$B@?%G4.+<['T4&^W+FPPS$#53+
M*,)6:9?<W XO:4T0K(-PQLD&T+S;+-D"=NQ]-FKM-MEB<0LY;/TEF <0LNR?
M/=:DD%"A7(80YIP5[:IV>J%YL@6"+RAB+!;:ZBL'.EH1@H$=<\;.?)0TOP:@
M]%69]L94$NKF_LLH ^N ]@-I9X*S3N\(_2O\I_ S@-4M$4;"Y]3;0RB";"')
M^VST^,'1O0_WV;UE[Q.<Z 0B#(L__*^ DJ2;6(\;%*BR\[R36K?'ZR0 Z)V,
MKV22AU$O*E#3^/V&%!&X3_(%B,Z6H_-\K?[J1L9(N**I2$ DO8N-A)KJ1Q%:
M$.>8]FEB_O8@H^U[%D\F),5+";GG'U6 XPVJ*O4>EL;?)TT&J$Z&5XWUPBWX
M5&;%U=>OY/6Y1?^BR.?*;D+?E<$1$OX7^:1N*<_,.9!'O[*-;"WRS.)^U,')
M.2!=D6S5Y#_H?QP3%^(BV_Q0(/-Y@!\=I]=_$JX/DL6PP\0?P>WX8SG OW]T
M^.#!$SK#UW7XOYG>6([W0QSO?UO/^I\]>G3X_>/M'S\X/-KZV:[+/CS\_L%O
M?]7'A]\]W)MG_?[& _LW3!I/7%@:M.S^SU\>_25Z=L#^__!P]7%TE$9@[)EV
MUP<OC=_?)&$4?\Z6N6T=>?,=+_6 7NDO-_KJ?KS_R?F?^O7?2H"5C,$U"SSF
MU _D,4/@FL_GQV(WU]7JA_#FHQ"Q%;,1O</QCD&A%IFO-"2]HPQ#\F-6+$;_
M.!P]K=I9B,_:CS=8'UN'Y!,6SF\[K%]UK0T/[#</]W(D;]T"?1M"3?0&.S^I
MYT/^N@T]Q__;JU'Y>W51CIX?CG[,"!B1?=92Z[SV9RVUZX?N-F[-1[=XO&[=
M4HN;[5\$@AO:CU'L_C?9CQT;>,-!"G;N:YFHG,H:SPY'/V6;$/YEY=>V_/NU
M'9]\WG;\<N,UPO\^&%AR2<_W]_W@]_9N5/O7>'2:U?E",F#RW^\^?HT3].OM
MV-.+K*;2Y^O#T3_R<E87TP_CT=\=:/OVG0NW<>-^>\O&ZX^^<2-S-Y<JSD@B
M(ENL-Z.G"J%Z5G!^^\]U O\8;E-DM)U?3X-)6U]L;MF1<LMW\K</;MEX_1%W
MLN3XTP;8KQC ?KWM^B)?D&+"Z,7AZ.>JOJJJV2T[2&[Y=KUU >P?<;NZ@_?'
M2(EZ*P[:KSIH3Q>$;OV%*OZS]2T[-F[YOGWRY!:/UZU;:#<X3%\!7?MG30*_
M(SC(C+;BV[R<_D_^X9:="K=]-WYWB\?KUBVV[0@5VHV5"&4.;,*_ 3ARR^ ]
M6P&"PX"?U\U A?1K((_0!8 NJQF@022?=9,"&;=&!Z>%>-NK6JFD3H4B(_@T
MP<+^'-P<44H\^O:0>)!9TO#?%8L*$L54<Y&[^V^[6[C\C_]X.@IA^<1D1\:C
M5Z].1_<<=QQX>Q=83/.B7M[G!@SPV8>[#C\-\:!33WDR(^CYVGI<4!\[^FH%
MYODC^C^(.(P;.X@=3)K]T,23/"'&QY[LP7?T9/2$'HH85G[>7#,<_@DHZ3JZ
MQRB_P=N-1;T.I 2;F[R CMR1/-_CU(5U\ZT9)'-DAQZN^[I'8;!)W2VWM2"=
MRO$WO#30!PW0OCPK+J?L9Z>QE2:*T)R>G9H$S3W/!.I)7.Z/KIGAYQ^%<>U-
MY#_0MWC";Q'>IC<H3Q=M>"QP)--G^.?9!77KT*<OJ;A:%?%*#^5*3WKC0:_1
M7947=!G%;%L+%0W.2;XNLS%-X:$-!/X61V+G\HAK[RPO:5^D S*V)2+#>$NY
M13_5"M>]@O<ML<&?4R,5HQMVUS>'(_=J6%+ATKVFQ9)T[GACTQ-@=26D8JY=
M14P2LW_3SO<J&\ZT4Q^>2J_2;\;)D\27[#R,R2UO>[<YV^I/2EFGYI_&A;N%
MP^T'5_ENX*Q>[)%:[,/1&S":N5&*>Q*#.6N9FSB,R3HO6[1^LJC9EEVVVR?"
MA^^*YD/OF=1*/](^8Q"T$9&18O37Q9K;ZZ)GU?]USPBY([TSD2L:KZ.'HDX.
M2/]I13PNC<S+J\VDYI[SOL5*^##(4(Y.PC_6.BJB:W\[I2T^P\1TJ_C[8&.2
M0TT+O/<(A$ZDOJ,/);=KX$+/G*]CFQ 'QOVT)CQT@9=$8E14[S[>%_OEV+./
MKC4L.K3>LMSXM>C9/\F>)%3*)ZNZ6+!:T.@%[211W0ZN$FW>A?O"UF?]M&F@
MW;@K<WB8WD;,OG?+6=[H8:1?R*;_:0O>E70':/-Q._.0:Q4_3N10X_OTAM?$
M@(V2(9I1'B4:,!G Z%F1(4O>Y:Y#TCHD'SZXZY#<-4 X>1M0Z"R&SV:L_KB6
M_6D$1C8^E7;$7E"L1W_.NV 1R-$(-BK=''!FMJ_^AW'U/^IL6S+4($9%UUKD
M6S%V =,/I[UGM[!&L<[;L>;:*@UV\9TW'\-CSSRM?L,1Q!_EW%4DSBTZ=[_@
MX31T>O*YE)5H]:(_R;+SWV)+JV.URY@/!?N_4!O]:U9Z']V+HE<$+@DCG,TJ
M6E.SL+##G\)-UNWT _F214/]OL4XC/-E-@N?O;DH*HS"+T4#SK/R_F'Z9'*>
MH5V9(I<GXS1T*4FRB?S,FX8M6S:^\\=/2C19_JS$CN*9-W\[%;(F??,8:?
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MX-\IV:G4*G[*.S<:L@#]VH"K=NPZ2^)PNKL,W.&D(3)KTJOMW\L<R4>C3N&
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MBWZSSIVFH!NL\,.IBHNKLP.GN[_!:D0,J>NGOMA'$JLA9^%<8,'!M)35DKQ
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M*+9E2Q3D/ABNWI4A8QGRT9^^#+ES@+9G-L:[RD*O0W!*>T2ATW(445=TOD:
M+BZ+76552=?T8/JJZ8* "Z(3#Q'(BJB4Q ..!$I2.2!;Z#*H13R_$!\3 T"&
MW:U.P(2B6*%97#.^BH[L;&&P.B"7XX7VT,[^7)73R)F% (..^GZF0G.)<I:1
M@8HQ>>Q*8+(%[RRP%1WW4I6=8UB_QCD9EZH,!E62!&0>DY->XO9\'E80)QW5
M ]J:S*RE=\210B >O&&2X.HBQ_5#@,:=EA-I<+U1K*I95T:BM *?IHQ#IPRL
M9&J"Z5.XU+*:A= &!3)V270_K278MF@DX^VC:56F&>"#HN.D2U6"'DP3_&EA
MV.?4MKEWYIDP6$</)_V! ]1)X4)R:PQV=S&WM>BB)=4?>%:9RTO4@]D[F\KM
M[<2;6^],&-9LL0:P*SVN!:PD-687ZMS5&G;DB/MI/>E,;IIJREXWIR=<PU7Q
M(=]6-7<&7)/]:UJM(P0ZUW=K\10/]EG]FO+1%J#9-GQZ^O=5I!B\Z0P_NCTG
MP?NAB3+STPA:M]\KZ>V;5<5Y(R^7;<D'X^@$-3Z[K&W#7=,,2]>?XP+S-,]K
M0:U+EE\,5Z.D6H.+0QA,7/19+!;\'K,\(R*3$'#7%,&#*"9)^C;3BZI:^# V
MA:K$+]/# $ 9[%MXJLXR08;>+)='5(Q]NR8W:3;A$*,,!T6)[6JU #(!5%YA
M15MTC<P\>L)<=3>]*R,)R"_2YF7NG9B'T:NND*>D[>V*#"[S=>4E"215DB$.
M N#%'U/VO7!)SANK&5?QN-X:XPA<& NP;7W9.+V"!&##.Y]>/WSGJ]2/?]BZ
MXT6>\X"T.']X^&UGQQ]\Q2V/W?#-\5?D-$O&YNCQX1,:BY?6Y]MK_Y;JE;32
M]3M!@=YG*](M,"@&C@$X85T456V-[8,]RZY-NHNTZ&Q."3D4XT,-%6K+I(;-
M6R:>E1=5LZ*SE\^QBRP<&].\7<=.UZ1$DP,J,7:-PD;4YPA=.6<0_/:I.4&:
M^ ^K=(7+JVEV@SGEAE,QJ*)>AK;10=,;DWU$;HL<HD.>9T9V8F-%5'^Y;Q_?
M?CC>;97/WBK2>4F+(!+%;-3 2;QJT(G$ 9OE>A%IP'9M$L.=F;S9=/W$SAV_
M(:_?BN/A7:*=>,V:J\GNY,&-$^@^5IA6>AV(4\(%:Z;H@CGC.[MGWE$9NUN9
MG[@R3W8@?8< S..(6$[,-;JTI*P#NVJAY++XB+0ON5S*RK(@GZ3D@\#\L4'D
ML*[>;7#CN!+9Z\4EJ8#;!<_=U-7_AK*H=ZOHTU;1J;IC!/G-UF*6Y.2=!W^O
M83<>L(19OL@VY)Z"0@,%0/IN694'$B-P<V.VN>88NK79NI?;7.@8IC&O1-@/
M0&+/A/,!Z:Z"P9Q;76A"#!&)44S/[+XD5S<]E]N$K'5P9.I)+*ERF*5M5Q)"
M"F8AB:]NDA_Y^O. -L;(SP8^D($$!I>+LJ;/)!,\J*P.@P<D2-%P6_\T!(R+
M<'#7C$Y&XP3Y2\.13EJB_?W25B1AU7T9?<^K8C&;%S6=ZA=M3<(?ZH,V9=B^
M<)"IB+ZF4O58J(&Q&(0LHE_?<^D&,]L1\$]/G_H5/OL:)F%&Q_^BF@J7+[O+
MRE@57)H,F5!@0BZEM)MM2RE)44!:?\'W&SM-A$Y _" W)%F!O+6RPZNWXW%]
MY(@U<C8A?U;G !0)N<-,$2!C3AN0DRZME,:=Q"^/_E#C\P8+!*U;Z^!> @'9
MH2SJPH#5D2(B+TQ^GP<)%@+/P#WCAK0 D(G> '\'0LX6X7!6CLS) ?'<N/KD
M=;P'-%T7J5Z.1$^T>F9AF=181K%O[=8;DT^ 8]V:;/![]/_1#.CBWI8-MC8<
MUL_=+6/I@UZ&8B('U*YH940Y)FKUT=8!EKD&N(=HG^1L9WB%KVJYGZ>T=S'>
M=T6&"MK&X7WW%2RGM16\N\Y1O^,I\^1G,O"GK\\2]0!&*23)F!C!J:VS>3V9
M769@X1K'O[TEI/8S]X<S2F4*;:$N@O'H_<G/+\:CL[?AFZ_>GX6'./WIY=OX
M!=<";R5D>A-]N\9D,N-R&HPI(HFXOJ)>(DOE<1HOP26G?'"*I&8L'6YJU07F
MV6.UDZ(T8ZX+UYQGC7K4Y*/M>Q+?L.M$+4SH?KN#:$2(QN,[B,:N =)NS!'K
M #.1O*Q!/H-M7U^W< TY@3"9"%R2O6.F/6?2%MF20-PS/YVTY*F W93YS$;4
MMWK07?&'*F!"YK<F^1[JFBQ 8'K)+J]+-%D\#PQ"E1(C.F8TWG5-[DP"/TPA
M;0PK:@71*A_E00L"?) [U"$2O;TEXMMR[+S3%DK#LEVC6<UY9S[E4?L*"Y3D
MS*I:/;@Q'_W"Y*?'OEU?SS-WMLMB[I+CN:^(;246KPXCR0JD<QO3?5CC4>S0
MY)(D<YRY1A%^0O(W)D7IV':Y$U[/1]4-"@<?;4=V4[A)A!Y(=H%IB&M5(CP$
MZ>#A.#T'8>Z8\<*;V-$YMG[B9?%Q+%=*&MXI!#H'3Y,RR#73"@CB%T)/CO<7
M:+!G]8V@6#?&8;%#1<0Q3D4^X[Z/,6EGYXSI)6KX<+86Z&<ZU?8<?"FER'0H
M@RFY<(N%,;$D\1J:?\HNM0]?D59+XZG4$:J73-P" DN&L:A5<9A0:[$JJ%50
M<#C9@L*)=>X'4!^H[_WH*N]R#.OPR%J6&FQ_'2N*:BWFM=?3;.S=3$+E5C!8
MX(FY QBE!<OL9!+_+FGQA$"6@$\T)>'+'_)\%;ZMCC+#FYNU$-6-908B[!FS
M%,QF765:=0?'1/Z!.R2-FY MZ&7!O5[&8#938J\$AV1>',X,V0@VL ?1>C#$
MCQ8): '=4O%UCR8$J978"]UMD=]'R71]'.X#5($_&<N)$JQUSKST:"&8L&N7
M2//?,3 )1D)A_0,A#8UDRJG(24V[@)ZF30?3_\5(/?;O('K#S2P&]1P.30?V
M;#RF+&B1]:;=?3%85.^)/*?!\BT,2+ 2M5%L<FM2P3*)'M2@5BEK9X7UQ"^K
MDDCZF(\+@!+$:?&UPG+7K+:9/J(V*2[IW.N5K*51P76D7=+P@NDQ5F?B^ISB
M@@DI?$((&;X72?CXOI*/X1OINR>=&_=BF!E_+Y48[3^!$ENC?89]VS@>I+_M
M&,^VN3\>'"'CG>7:-#N? N1E2C57JN),-VB#$YT0.2F=3$*'^A0<A8X.#1DZ
MX<9M?H4_^8<G1'J3G#(LPAG.ZNA-),T6QCMI?H@X%8AQF@ZM'8/)B<>ZX>ZM
M#IENQ+)I^XUT%;.\UX9I5'+HB0$HMO =@&,MLHNEMEXO(#]$',+O0LHW!V^0
M.'S0KU(7K*E%,8JFGQS+O0?:A;>6IC%N-Q4W3<4:T4HT!4X=L;I')FXY_V*C
M<]B)0Q3$[,VX,"LJ_%&/CIW#XA&1%D[LV\G \SW)TP3_F,$C2<K%<'%S1N E
M*-[PN,R>SVAC)=^I*WIX_KF#!KA3ERD=I>@DOK4X$JDESCQ_#E*(&V6/8?V\
MOL= ?.9)(2,M8O ^=QY@(B!BY#"#>(0;P9EN@+ ;=P!\WGOK0RK([4]\<_.]
M8K80-J?[0^T]!0XP&05TX*FM99L'Z#WI1R *C*"CX8?';_P;Q(/8(O:-=)0*
M)P-OY%3L4Y3RPAO>Q*B$SQ,$([.@XU'<39=Y[HASNE;!,>@*R1/G+>C^Y.NE
M QPM'^Y"32B<M^(]1C3 5U17U1'I?B$C-LJ<^71<1-5?(DH"#$HI[B;F T\)
M)60A P\*^8U(]D>Q@<XE,[!$=,6V>V;$T+D^P/,YRF1JHRA#B$SWI/[W23$3
M T<A> ?*N::J&XIC8D_2C;:K_^TN/?.7_VOKD,;L+,3CHW=<E3GC.-@86V5W
M>'K> 5\9JO5Q0Z1,REWV5B2&L)<8N7G 0I"2&1>%S(3_UV!MT1F#;\EY3+0I
M\4O4HH W'ST^?$!;2K"A25:=8B;9F0=,WSZIRK:)Y\-UUWX2KDT*(H*B1I>W
M/IQM!E)[.$#4">(LZMEG5JQ(2UTG_3S"EH5!<C=$99L%P<BXH-^'118X!E?^
M;HN2T]\RTF/WZP*E25WM,Z;;HP(:0S:&B+N,^2OM(S7.-*W#&1DET-PX[#"F
M-'(H9&Q7&2L':"G1[X4![^J9T579H/K6(J$HOI8L.-W?T08<CL[".(!(9$Q#
MZ(39.O. %CGG4T$D-I@V> *5P)$ZMMTGR"V;XQ(*$650K2V><C<9GDGII&?Q
M$G.6]M \)<D@9,J&';&^;^KJDD,=B9UR -9/E]XY>C@^ S!4E59YE%I@)&OE
M9N X.T3PP<Q-/"%1S7N+V^$Z>(LNY5AL5#,'6-GTF46!Z5S"*ERT'-VP0+"Z
MYQT2<JF[8$T6ZE":$.]=5=%5%9_<515W#1#%O>=,EW%>Y[G9'NFEC'^3XU-W
MJ;FX?0^;,.CEINODQ4/@-Q;FVS^+*!V7G(,2O727[?9%+\H;=C$<HW<GS_XE
M'^G!N=6/@Z3M M%U,%K9>5D1+XZ2684A!&XF-KW'L6=)>6[VHD-\^'Y),E4R
M>]T/W[&,UF9T0M<@(C+$$F$)J0;YNY-3E2!/&A@Z)VWXFDO*OT=<)L_5-<#>
M:?W4W,%XR\)U^?=/3->E8K \LI(LY%0JLX<9>Q!DMUA<#)W:5V5,(2.2FQDU
M%0?8&2^*\ <:(WQWG())]>;^R'4'Z'#+O_7M39+2G9Q@C&TUWR2:C; Y--OS
MZ2U[7N]S5U5&9-'*;?/A;<H?RGR\\?LO*<"GM5: .=RL:2&.)/2$FS#:%<K5
M+=LE/B0ZN>:B6LS@I4R80-ME%*,YN,%.<7X\3X+2,<_UE !YTCJ)1A.J<Y@6
M#;C(7:=B9%RY@T_.!,?#X+77;Q.$EA@I ]:M*.GB+\I#H/6Y<""BW)U/6T1.
M%!O22*Z5L6Y*F94P:1JB4@#,X21T0A44L^7YKG\TUEEWSS2GQ]CY2"/6G,S6
ME@381Z*"$]<M%$VV.O2@5Z3.H4Y=/LW*WI'Q?K*IZ0^SI &8OR5X@.AGZ-9E
M%?!-7>22!Z+"6E5'*?-%+G*"6\"9"<:3X[.AA^%B/N C"42NX4)=+F 25^Y$
MW?@0'.\JMH"H<XDV^^Y%:GGLV!._:NNP%!O.[VCBB]YYZ/&4+!'[5G]9\W7C
M& G+(!4X2]JUHI$P(9U1'>#(CQW%#Z?")$^8I37GI=]O5NQ4CITK>8 .R:K.
M/4R+#@B=Q1N\"I$]!$,^7Z>Z)5QO[4QL7"K]1C[[[%/<@C\5)TOJ+RI!*!?=
M)./8A+=K&(RV88@3O6PX9B54TSYT*K5=;)K@1L&S)0697MW1E0[3:=>RY&\4
MJQD0;;MDY)UAOK%A3DXV8@4WR*6B+!G"V'&JS9L@@1P3AB0/X7-73L)?0O<M
MKU]3&K[9UY&;)D@'_#S_G'BHUABD<Y] !,M8JM1(*)V#2%,=?6*P-L;J&+^Q
MZ%J:K,^ 5&0L/22*Y3?P?2,3<)($)5^M0DR.W;*L4EU1M^](U)KT<&B&3NFS
M-_5Y5FH163E)/=TD5%]+*^7R!%3N5T!O"SV\'.1^EFWR?<=^\E0C8LMI\B1.
M!VXGIO+!_5,[_2 _G9QBU1#4O2RJS.SAT?6NL@T_GH5]<G_ N]W",#""^[&?
MZ! _S)IIMLH/1V=T!OO10- J!SUAB&PDI.9-5\D[C]PF7!G.U?16V*1IDD<G
M\&<L@=@;@O"_B*QOT>M1:)&!-QMY"7O!JDQ4$)E[CJL&IN0M ],E?;OQ^KW6
MY.\DB4S6/K\G6AY)G;A$=Y\U \2V(QJ?GS@G0XFLT7O_BW>@T.^,OC-Q0D#M
MK8+719:%" -P.'J!O'M&W,P$N [VOI26MH</'A[Y'7&5UQ8),_UORUK454D6
MFL(S(CY4O(W#Q88)('TB^&VH@!=KIH16@XKN1V6.D?6RMS"O!$"8FG'O4Z":
MZ4Z2-37>,MZW435D*<M:F2-\& 63.]K&SM+7 B<@X[!VTL@%$!Y-%K,!6DDI
M$R2A/I-KEC-LKX"P/MGJQZHQ'-X.%HXB#W=?%FX#!L/"(<E4.F3C (C%KD]]
M_?F!Z:5324N3^:04WZX];!S5HR51M0@/-^LTM.N#:GZ@D+GX>$@K$- G3)?V
M ,7'O,@W\NR'5, 6U0\M'+!FC]_F/U?!I-4K;H"'* 7W5$1#'A\K#,NR;<#@
MJI#XK4_I4(/--"\I^Z4 )^D(</21!/:B."4'LS<9YUQA>O2O_Z*B.T-JWPKH
M_(2'3A*PM//4^PHKC C 0?>Y:.6H%C)Q?W0D*DVF.ETHY155C>E=">^_XST/
M1T\K0?<OP, Z[ZZM!#MI7AMZ(1PA.C6%!QO0+\,B-;PKOYZR<&;UI%#6*KQV
M/F/X@D&W9*<WSE0KDM\$C'65Z_)2&"[I1881($R46[\*85IIJ==]AO7(6PY6
M>.:$,Q)FK[338NMPWQ578W'UFS]]<?7SR%:CK5 U(H;*:3I\()Y/U4!H6UAC
MC2? F[=2>ME'YV%K?WOZ\G0J,WS&3)N]=I\24 _PMF,-=PNYQ#8V/@'@D?B'
MZ%[6&T043D5_,F'#"?>LLZC.Y<AQ*"N9J((E;BF!\,KSX.,P^PEP5_H \)?"
M-Z[H'S4[^G/_1IV;]EO\*3T;7*YZ= _L(L'S_""UX'S!T7UXG_O:^ *+,X9G
M':Z[S%FC3+MLZ#OHP$SF8$G]*@?31=7.?+ :'T6:XCLM@I&LM))JD885P$TC
M"S"VXD;" @UT#1H2<5KA3<,Y6V. Z.9 N6MQ$S4;RI6B+\OMS0^Y,<ZD\1+G
M=$5ND)PE:AO4@!$H8\J6)H_&:Z$#J1@[?2'7".DQ:. T+SG)4=5Y7)#];$SO
ME)9O= 1;TL[*L2$&]>N*=48$JID4#@0C@!/%9U$RNE0:3W0WI@$ (^PH] R.
MJ.ITB"]K[#]]7QG=!92@QM&-5 _U(2Y$.^YRX/6];S5Q_:.<5P]!6KAB_$O)
M>>GM@>$)ER=YK(,[0(ODADK;*5/Z]=E2;P000^]I6=KE")MH]:X40M#/^PH:
MD_9]U%FZ-D,YP >5Z#:F;7M>&HN;6V;Y@H"O41N2GKM3A;(3)=I);0-*^NU2
M>H5YNY@7VG 77N7T7V>:QEBU==-FI1DV^HCN>Z(& 35A]P,R<$D(FHRN"&30
M.+4B^\R)B01NZ@34L \95A^BMUF^I+28R1Y%&JY?Q[*NZWY70HB.-D<MZP]B
M<8=Z8T,Z#KD2@#_5A068],/CT5LI_](]S\0J/',\6L8.3E-->?&7X]%+RL <
MF4+("3,1O&-H3GB,%^1>'#TX^,<^UH_>IUERL^&+3<R(T6"U*U9>ZPK;F9:5
M1%])(SYWD"AL4!:0MJO=("NRGZ;-K!G[!TVGFSL,6JPY# ZEN#C84DNH=EAG
MZ<#WF9FHC5Z^WC^%[7"B1I/(TH E"<IN+S*B:B3FN7$Q?$VR:K$-F24\AYY'
M$\R$^)>N9@8Y\_8D38!BK8F$K:(GR>I3K1/K,DK&:B WH<_2YS;0/DEJ58ID
M,OX]G-6.OO&8)0GPLU2U!F[GF"_FZ67)W$LB@KJ95,'&&.H<A(X*L[%_ (W(
MX=3IL@3&N1SHYCHY/1G?)!5.7Z%L]>C$2^BP8JO$0-R]H-D=)L$@3QZ&679V
MT@0ZY)!)MF97K"-S=* YM@@*-,XMRO'X?%D26'DG#G2,:=7"R[T&WP%'<R<T
MEJJYAHB:N%UL;CUAX(MHLN-31]E(7SF$,#'98/QG0QSL2[K@>-C 1]LD/KUH
M7PWM= YG31]K 0J*#,V9MG.X#)JMHM36=1T0"A@<U/'Q^?E,:.R31'TC82[*
MFU)]Z?1,Z>DCFGPQS#3N'6K;]E)$7[A'7V<S#?"TTZD;X-4]\"M_8XP8U$X?
MYY;NM!Q=\IRZ(]-U(UUPG/ZBV)QN,D?WP%%]+QB[;_-A3#;&TDY[AH2]K@C4
MA.8NWPYOR!8=7W+G.P)4?$X9L009LKD=!GQZ0'T+_J23[G)2RD.:)!8OYV5!
M%;]@8=A1QG$,8Z-?X8:Q!IM@*D,L8;F>X&2(D,5Q[8]1W.607-15(;7=;%:M
M8N>:D3-U%$IM&3A> &E' HLKM9<QU!YQ3'Z.W;4&0(YD\*K1.:O@Y.(TX)64
M]DG1HF8LTF# 'EZB"%Z(F>_?^]SUI,KA9OX&I'(_Y]WER5-7C;,=O>TF0=8P
M67TW7\'3M"CZ#$.?9E0^![:VY; :RHSO@W--L4IPHUK6)U)^9F3)R4EAB*12
M,,"T-4[9D>..:(T (:JK,E(]T[*H9\("6&>K@O2NC5295YY;!^)VCOVQ"]#"
M6#.A<$5QC*K?.KAFK. 5B_S=1<25OW@:X\0N;9^1OY8U%PY?H<%IQR?2D$2B
MYR0XLU'B1-.P=]\'*)6Y:%TQ/HE8P^SL)^>ZV2*]32V)=7!ZPZ@)Z_44+AXH
MQT83JI72;Q322@Y-NP3]ZKEFA<.H1#34,5NO.4BNF7^$.I?7LN?2\80! Y>W
MV,U9^M3LV7AQ\%2,?8X4:U@+>3Q2Y*J^NYL7#](U/-P#/A0==P3K73%HH6X[
M^QY8DCFUE LR.O@62B6##&WX>:&IR[1EV;F&L?]\6P!O 8T*6UN6WBT3EQ\8
M#YZ+IA\/Q7G.:GN*7/AKD0;IKD0:2Z3?_NE+I#L'2$!N#%*!+QOEWF%W-<T:
M#LE@1G-5&!",A=;TDG/9%03@%+IX7!>R/S*L6ZT;E3"*+L$(Q$2]*1O!,01U
MJ/3,RH&/CARBT)^F*9LL>L2)[,VMR#/NS"J^>O[CR:OQZ-WS'__YZN3]FW?_
M/3KY^=GH[3^?OGIY.GK[)OS__SUZ]_+L'V>WX4U^M0JJ3W*XEMR8(Y%04M)-
M(%J6+(M+0:&$:3_I%80GFP' C1.Y^I($D.90*<B.(:B2QN%SH]A/%.+NV6QZ
MH#0W0UTV2:1J,_"0]>KY;EN3I"A#UY5MD,2GP]HC^6GZ6.D)QS+</?I'14=I
M58<[KQD6 L,D$"E+*6HJ0UD?>)$:%=Q )S=%)2SN N)B*I!,6$)%_;%PN).7
MT:N3C+NU%RF]O+.!<R66ZPHJHX2Q2--87/WNZ@>ATTB8^37-+1ENJTY$^8 ^
MW@* T2N7/:<?_3LL[6961(WI31>6;50N*1\Y]A*USL)OW'!2:@]KM:=BH.#,
MNA<<Z]MUF%8P9K-BRK+IGEU][#UH%C"/*MYPW26[-9#.=W<<^T.ZP]\N=S]G
MT 3[IBSEUGIT^T5UQ;YKB5I@ND_=] X'^*;(< ^Y(>4'YK^%GRWO1\86;6)V
M5%%XK?.ZNB)$AT$Y#;3OSW]S(<:^Z<-E2Y@R*2E&RT7L 8;Q[A!BUE(HN5&7
MVL<1TRGN:$HXTC7"Y"*/2SLU/M4JNBL#,";,6<D'#\<9>7E9A$"<(^@;,X'<
MN)%@D9\7S2+3E/'?HE1 I<I-A3^6:2@XY264SYP@[NH.62$G(4\8>M"H-'W]
M&>J)(,=@.;?BQ?"3EB2TH, D"\\P!%$ :6SB:PDK$N&MJAD..P/;2#$I.?0Z
M"-_NGJ< <IFP\M,%$M9+]^):KM3=-1[B/C>>?X=>I(M&2H?47>I2/+719YGG
M2D^6?01J=X,O33;ZI3AY UZ30"6Q>GU'C*IDQQ+4;\'^L=V!^OK' >I.XB[Y
MUA8Q*4G+:5$V;=VCFK4]%TT.=A>6Q32"*'N]33%1QAU+;#.Q@S@5HS^6>W#K
M\H#MSDJ1BZ=<$KJE=!YA)V.AN]&$L282&DK"+XA5@9[12$:K)!<]T$W$B7Y[
MX:073I:5'Q@N91ASG->>:-<755UH%>QF"60YQ5SS9Z6=,AT^O8X4*W^/19_2
M)G7@XZXO=^WL\TH0JPEAB,1!.XO8MK.WU+'3GA&VLUP-+!KDV*J%I ;PN7$1
M^+754QW7E&@,Z_GOF&YRQB-ACC89BNESA-+<CA1M;SP)D%].,ZOQ^!V,*?D8
MT",!YY5YFKN;^7MZ70DSC(M3N-]4]<.Y-:/.B^6D#:N,Q4N$;]$KC?"\TXZT
M@Z4#9%"M$A,7ZG/&1,Q7PAK6(;<3+X&PGU^P*Y'*#B(_TWTOY;F?>QJ:\*5B
M53!NEQ:AB$06X.YJ &5 ).6UJ =ICX_)4Z7CW6 ;CX9@&\%=J-JPE;PX=ZZY
M5\U7Z\D<;Y*H7 +<HHQL,U5M8GCL.9YU60E\Q>AJ>!K#0-:%4_SQ\F9QR:TS
M#BM/PJ,O*$BDESD<_0+O6>Z6+4CDU[4@\6\YC5YP>=PHCRLN>OAQC\$=4Q(;
M+&8H3ZU YOCKE&56/V=//=R.@M.VE#S'R[D:[Y[_-.PA#945!VX]=I1I)$1D
M-0"IMRH+JWG$C@_ACU[]^V6  IPHYBD/$\:(C0?/?._P+ @,<XD3A+JXN;*]
ML0P.K1F>M\2)C%Z,ZY7_Z?4;W_&.3MXFTMQ[TESW7!U5VQ#HSOT9:(H4O@LS
M> '25:]WUQZWPL[K^(C1G7: "]E+464U.<NYT.G$:'"&7>9Z#^DB)W2[G!GZ
M0G$_5=;;H"T8HL')"6S!?(EP.JU9N(V0]^(I6?>&>6,P'(%1*\&=T$@.S)YH
MTM5L&TB=5N!(2JOEF^/CB1]/ M=Q, :S0]X,(EKI:)C/FWP]H'-JEQU<7VXU
M.+L.@2>7</2]G===YC.Q2;_F*+PKU\5RW7=[4JZ[1?:;=;$TE2!I&;"+]"KG
M\VK: J;@//%9<#T VW%):W))(!:4%,ZF=APKA*?F;+NKT;$T&?):49G+G/6)
M,&N%/ZQS3?]J[EMR[9"$$_]Y4E?9#%$NE=:;J$'7,]3L]3?:\3XAMV?MJ2V\
M6TO=ZRUS,E9KZ_?O<:>S8>T$*"ZM!H\E+UF@!*GN<-R-%86F\BZ246+,-X_@
M;A.3<L$/FQA71:H&\R%[F!1/!043N9O3<-36M#@NN.VFH=5$K39&/2-_2UV"
M*'YGRR<)OT4-U5*9E50=0%(/1"#=0S+>P0G*.&"B(Y#ZX' G0OX:[MYBKQ ]
MB$H2^T[/W[T\.W$.COFS"NWK9ZP3-X A+Z!,<#F'E'2&% $;X^Y)Z? U*Q^[
M0-XC2(@R0TD^UQ$$\ ;'\YL'L:*NH!6^&L_#3BJ320G"]E<M!9<O1PI8I88F
M^:8J.S('2/N39(^&'(5H$S!OI\X,_"<\8.8W5C*:<< PH%@5*PKBUF9XDJJO
M*V/YS"3CS5::)&FFX4-([O);).UO"&@((Z&?V5A$-E\1E+D5H(-?7:K?+57/
MV"CI&T7V8;^5U$X:47V"2;?NT;Q3.&W79)$4#_[/P[/#L;9:4LLBN5DR0+$1
MR01\TH##_@K$XBQ;K86>$HRV?/*-B6<K.+?X;3PT@H]=<<,1B2JU->B-F+8L
M":@I3^J.-NB[QOOPD>:>0[L-O/V9Y72:II7^O"PLY\E9@#7\>>V[U5YQ[E!2
MHNZT'37*& %QAZK1KC7UV]$E3K<WSB*OZ$\:;9GFVC@2NK(LNO7OH841,9RB
M9L6F*HX]4Z;NWV8Y30L0P6B$EY?DE@Y0,I&J69-:&&><Y81/, 3QK /;#%-8
M@V6.P^+N\3>*FL3#"=E%)0+NHVE-C(0324=G'R5)2L\,!<R6"</"JZSAM<26
MO(05$$59V8YTFJR+ Q4UH?\F'OHV-B"LZN*2=$(-*QH=9JWE7I+(\&23C$._
M::PSC+38^(@6ABLN[ C34VE-O!$80Q-'OU*1'+>.S27.X*:G!8(751V601D\
M-VY9>&M&YV0:'.=_%94EW+7%?S#'UVUK4NI[%G]9>/ @29<U:] #XO0F6+>0
M_@D38E_VA;S[\$]BF@I#?%%,I$XE51X#,\S[Y<NTQU(;8\(CH5TF^G:#.73/
MS\#UBAWEN5@-O36JIK?)&6&,*5P/)S4>2;'VT<=@'RO&-VFF<P)*&FZI(D Z
M'+!<N#_1XVJQ.AC;LBWU&]VP7;2+L"5. /M/]%!,IY)WE"7VW3]3:2;K0VU:
MM!_J3HSE*F0C@\M2JS2AT4^89.F:(&Q.)&70^![T6>4Z]E"9P.7D+3/&'W0Q
MA7VSN6. .1O'7E+J_SE_Q/>+4VQ(IF.<C+KZ0^0(BC+>5H.@U+T6[$! 6X;'
M/P_?K"Q8+BC&2:[/1R.NXP%4RCQ;-'9=F@\RT,<HWS.H$O%/W9X/N_S$'Z&C
M<8QZ>0YU8.(@M)A,KQZV+_L^UD!I:2E[6,L*V9)RW6'(%:#X=IQ"W>H4(!=U
M7ZW*RZ9: G?I*ROQE?.VH,<(;W!L/UMF"^/]E45P3$6V_#R>9W*DISVU;3FG
M;%(\0^R,/8X),H/5HV"0EH6U,Q',@NXWX1*U)-50VSL.*[NNJRO56@Y_Z/ @
M];"NS;$@?Z2#CY9?^ ]3ZE&=<X;UTV+).P[!<>?1I]6! F;#J$WU/#_NO!/6
M>4+TQRN"G\>!0,BJ,,^3.)0VCA;.]'[CI7:,K*U;Q&(09-RA0S#BF+U90UX)
M57-%4V1HX0E>S;&$64)4(,)(?M9\U[&_I[.P-B.FKQ1=%<?FV&>:"HXUM7T5
M2H_->"T#@GAOE&(J=.?Z'U%3,.>'<[3M>L6\>!L3K*3MD,5HSBE2WYR9:;!.
MLATJ[_0D]_5 3R0?R':/H\YD>L#;Z0ZE[IF@HDC^)JS?,N5.#0NIF/&B%$OH
MVMR8ZQD)Y;IK9[M)KFO0]'Q$Y](L+GUM-#.7B3>OP4L*3VF"4Y&3-! R_7)#
MAVG=HD$Y&!2X[O=PBQ"5@<M9$/)7U%VXR"=H;U=4O-SQ/L:[R11CG6#37'\W
MURFI*@@J0( P:'_0\(+$0'P$FTDP /"4A9E48Y.@;+81,E#:-K]2A$[BB"7T
MK8/YH.YQSSK0X4UVF93A)Y%1YH=1KZ(.*X6H@#$A1*S=>Y$(J[LK8\8RYO=[
M4L;\:JJ76K>;Y;1KQ$98M29M"ZKJQJU^%9@'HO&GL]$;Q/FTYE^6:!,*._='
MUO49:ZM1>-VZS#>-"OXP].N9W9M^_?>6FI(EYM(GX21"XY-UHQ.YFMZ%D)<$
MLN).R71[6%XP%?!CY3Y*3&D>0_(:KOLQYD=CCB.R]2D2+8_]R]$,PP?M: M6
M"4K]</2JB-PQ%B7*0:^H,^=^?*Y4T/;C_(]1M'S'_?5A>.JUJ_JA N8K:MK-
M+YK2L3YEJ=XY\O2.\G*]6?'*8Y<8P2R U=.L8?K8Z+V5(=(.SGM9+8NI/QZ+
M\M_@";E$/WR1S\,)N*YSZ6OO5JILI1(P:*U<9#[+/J^J=3C?*1IQZH:-5  <
MP#3B=F)<4$NE@Q\L[3%RF1M'JSA":HXR -E'$R&P7ADK7-!9UQ1XY#,:H(5;
MVYQ"C:\GK(PJ\RF2J=$@74%AH$8NMP%E)7ZFG/(:*$9J/F/P]V $NT]> F3E
M,6#V.%H#3+,4'K@E02F6QH(-AA(N:T$[QM(\>>A8Z5"O6FH3&$?NG&:>/.=T
M,B1-=[0V?+FTJNQE$>= [HC?A%^D'Y-8L,"!N7J+;$3*KV@\;DWVDHOP9,]W
MEU Y]"Y2G:)X0(!RJRGFQ;86C3U-@2:D'U$FSZ(;RKFA07"X+T61!75F9JF+
M&_)N]:PXA_R+?,>S% JC[89RB&'Y%I4&*98JPHQT4_8=\^A"MHX!XUGG=H,Z
M=P5ATV/P+[%R=*OVLIHZC'),#LGD0G%?6I3R*ZLQWO8FJ?<7*@3%VT$;CMV.
MB#._Z78^)85'"=L:1VX>3RXW2Q,@9!,;J#QQND$;-<XYH8I\<I#M[A=+>G;;
M,9-C@"Z=BS"D]$QUC = >DUN/9FU-N[ 5!^.GL9U+OO!!M>8P>M,\49 **,E
M:M%+J(_.B;R<RVG4::6%U88.(1P/,1&_ODCE1RG?V#T?KZ0T@KR\SG)8HL)2
MO)@?\,$]4P*D<PJ)T^TG[**>1 ]3XM+#29Y7YA\S'R*"!9MFIU:&!*\X)H2'
M;,A;:0J16.5.3;3U8+&Q;R. :( TTU8&YK;C'SE7AIFTI$$#>]D8?V3LB%Y%
MN-0I!1@/;"R%9'"$BH ;<6;YG,A4E.9?G?Y4),<7/)5]1=XXX4>*!)B*@-_B
MTDC9-[ZABE+!MX@_ G/>.G+':YNJOAR_[&^AH[:K.,JP'W&P( 3@\GAJF?J(
M6IF6:*]2-E;';D[FH!F69V &0>U7<6I%,UEG4?KO)F7/S^MAN27G0 H3!3V(
MM#H9"&27[5?0">,:>7;48LONA_95)>0AF-ZH4]RUZJF8(>4SR?3.>"KZOP^&
M-=(H,G$(?AB%B#5VR#_F];1H<L6.C"Q\4 L5H\U$.3$1\^ 4KCP'L-DJ62DO
M>HCFSWZ*M9M8'!JD,>I S2JL.7Q5A:$Z=A&$S720",I+FN'"^"^R6G#F#&=A
M*[66IAG\!W^9)MD36ZB!"N=\DF-%N@;,H3B1Z:$H,NZFF052-?CB7]J,&/>*
MET=;J^!8MPV\9?G*N-Z256,.(\RC'DSF?C*"6+U/G-$2\>670@\2YVI474$'
M%B=)M?NV1 N=( PX%^YJ^ *>L3@^T1ZA7X#VQ%9,^QG^YZ=VW-V:H&^[4(?W
M\WS V\'"<8B(DK*LH)C%DYE0=XFW+TWGE0!EA*P0<CG.']QG>8!?C/8X'5?M
M<*/W)?7>156^^YB.-N\W= P7 C=U26=M3X_T=B:'YQQU'M_.G9DI*4K:&,$M
M9]6&Y[]HAM67BO)"A0KX[@;!&!,?YX?L'/_IQ$^4:&%=%Y/6ROZ)+LMVA>A>
MQZ./&;NYM3[TS:7R5BV9#?J'0XW$VWHYJ7!$T) S@8CXM\DH0>6Z@,M*B2JM
M\\<?E!9Z#/^.,Y3PI&1T!XN+:;=J.MQ#HR@4QS)O7>1+S/8SF%32_9;GW\.4
M]TW7[PV+N=@K?(J/BK5Z'HGVWBY!H50D7;YIL)XHJQ-7,UV28NX(B!H//"LP
M/!^*Z8<)\;4S2B3VYF] 5"3>"']H5+H1JRN? #XR'OWT\NT)HT@P#FZ;T"*S
MO<"I9$JZYVOE?UD<&+^[O6!">A)# O@\+9%:1A\4 /6:RA$)V"SM1,JFX?<S
MA8A%X0S,CR,<Z@-O$#8.+XE.[$Z_'UXZ=\5C*QX_>G!7/+Z.LK8;DFB"MNLK
MW<P&]15]K-%T4F$3N%N,73S'7SJ0$&V1&Z2*DD:>6LB*Q\_J]GSTW(4R)R (
ML50!OO2BJKBS"-\^27"BX?1;-!6GP<0]&9!C&^B?B)N_1PS3)^04S6'R+TLF
M)YP0$#+U-Q DK0OV0R["SQ=ZO&>SEAHD'>#0:;0)9+2<=0[6H5$,!N3G\!2=
M^*U;V^X>*8D3,30ZKIJ]I9;=#(FK#01T6U!LBR(,\2P2]YANQOX=]R_Z6\CW
MF">5C$82P_@WB7E:7Z[R3?;=K3+R]7HZS.YW#*ZK+K@Q!0XW;TO<+JP5\=MI
M]]L6-MD.#U[D;^2*,<%.@BO^<W!:<- ^?/#P@3_/:84G7DKX<,*1>1.V0C8S
M9NV(=8_*J&(N]"M]E_,&>E-6?:=Q3_,ZE [G 99' I4?(WQ3/\OQLZP[8N6<
M[X:=I$HTS;;Z7.Q6A$LL)"V60D\K?7[Y>28)X:N+:I$3,D\9Z$RX2@<B>%_3
M"^J6:<;V-\C","XM[+7>."EZ,5(+*"::ATE/#04?I^#D91XL^$S%"V0C"Y-O
M*A:L*)",VYC25BBL#MCULY;*+OGH%&B1<+,2&TH12&%OG]0?"*W9T%5LWDCT
M_NGKU.&+ZQD%&YG=1?$ACXOCYY.7IY0*(AZ";)77VM6TKE;%=)Q"49#&9R=O
M5ULT/8?9L %K-)]_86NTISU*J.+%CAU)R7;%B#$[3T^?GIU(DHR8EQ>>"BC_
M&"Q4(RT%20XQHWD<,Q#(ON2Z7>BRHS);YI$EK]%DT'E.G0.KBV)*G0(UR7D5
MTF?2;1W0FDWO^0F;DM*NLV"LX-]G$62[]1)?./6Z8]E^T47QJQ?R;?$$WH!.
MX;J52T=:YA9FS]M,.C#C>=31U-'3^9HES/6!+4T?[,LG#]#%*&4#"WS@)7DO
M#+R\(.:8L"[BR3 4GR-,)0T D74/M!>,WMQ=3\#HR!/F#=]N< X2;<8$;QXE
M(JDK@94Q8LDRO0$*HN&S9^'H@Q/TB/D''R(TT=I]TJ,%OM:/J%B'&7KT:+0D
M.J#PCD\7;3@4T6B=,94T_G)V4>0+)?++(ST @)(#SV2E$%I]W9 A')M]^4_N
MB?!D ]>-3&9*K#-R8XH4&;L-U*9CJ8LZ:?]U$D+R)LVO4X'^]29R?VS2/U?B
MU%13=O6G@F*0&A=U?++F[ UV.98NJZ67%?C]\CIRVG*;N!3EMAZI5<T,-V&]
MX?.ME((I?(L60(FE#6B!,9ASU@^'N^WUI8EQL<4U??=YG3/%(M54PXK1-[SN
MF8U1.;D?MJSL,W@B&ZY=6(B&:^G2MH>PK8]]1RXN\=07JN\569[!H51:I\O
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M%D&8.&Y32G4<Q[,P3H7FYA9C.4J'PSI9G8XWSB (13^1;DKO5S6I4>F*.0N
M(!DM[KL8'\_IDH?@);:=K<9TRB@<,\(< TR)1UTDXW]3><68P$ 2[A&/^H$*
MX*SK<Y;3H/#!8B9H),L"Q-<UX0*W*CT;?5<FF3(4]NTXR]A3+R*I/]*@DEPV
M[F6_I!!(179>RD)V?E'.4[T/WLFM^N#DUQ$8XEQQ6)T4QZ*;TDF&9?0-:K]
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M5912=IS4TO$,;!G6.=@3@^=D2!D+*]HN"BP8LX)]\7+KQ9$:!_@/!I8AR9J
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M10Z"@'^-$*P<_G(.M(["V S$@/M@-^C>,"PU.T9J"@L0!KAF(KH#&)/<FEM
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M8&D&IFBE%82FZ#QM!,T <^]N5**7"C>JLU0[/UT<A)-[0Y5V6%Z)"IN_UE'
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ML8)H&,YFJ '(^9UR/_N!W!<-S\ &CBQL8*406%)E(M@OOBK@IG1^K6?A@[H
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MFXO6XNB)2-0YVCB=\YG(HQ>0<W4V'JMA%EYSWY8DR+X+87C_F+O=?JFYRG4
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MSI!H\;%1E(&H+KVU <^7Z1,WLD1)6"G^"\P!),=1>!8D,\ O1TC%><H;BP9
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M&]X[ !$O[AZ\"DKX<[AAE(;?^0;?PE5X;=_[G__7;[>;3Y]1' H0YSV<'3;
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M(R9ZE!4XGY'E$0C'(<>BM=G.1K>+BK!O$B.N3TR<:=JSSD08(H:D4S)\JK0
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MV/('JTBY P^528Z6I>E2#K:[Y27%*[I:E%OKR31%^'%GFV=)M=J2U45Y3#^
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M: /:((2G@R&HR9Q:R(:O9$2R?P3VC)DZF!D)Z 4T.,PE_D$01E$E,=%"DAQ
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M9885P(-P1$PS$Q7ZV?-G)T?T([,6Z'BG%%#!@I=SHILB?=L3.HJFB/SGH,3
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MRF'0"'M@-.;O;  3''$,26%\DKS-K+"N4F!9?O=F^9&][;^-),SG@JN&XB3
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MDHT?)5CG"6"J/'$.H9!+?#&VM!(OH.TN:%NW\0MH6P5MW>07+' 13-IDC33
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M<@@+1MH>^].29271L#V.>M80"D1YQ+@+0*3(;8>#60@%+*2)WC"M=.XMP-1
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M3 !)O))")N/1YA(&2W5B+I#N\ :]!JE0@+P"(#=;G03F.#?@8\X#YI&#5CJ
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MZ0;?691DNW'T/ 1O8R\G8 QX8SSPGVSL%#N8ZCG<"'@Z&D_8_"G^XO^[&'X
M-AE_9>/81^S,V0U+*)'L.#QO"/4;T.EXC "(_W^^),]O?C:?#NW<.WSC<.Q6
M7^A],B/?C9!O<XRU 5'&@RF(*8(BW"A-C"@D<31P/ )2::P.O4W-6?;=[C*[
MWU]GV<SN.\#N%^OMWY1@M7#$68I3ZT4@IF(ED<R5A:^DEI1C[E9F]T?$[@\9
MJLE,_O!,OF'-V$#KNE!$2Y3IJK3$6*=)D%7!N:,E%6KO8)=BLM]9..=+<RQP
MC,7=VB7?JXOF(;/!;@5@K^"!)VZS'[<=+9 (?:A,\)F=.W<'AYMCN&M16&>M
M(Q6K&>&Z%D0[7Y,0F*IX73%=\.C<*6X-B=D#_'C@93>,I&\--!E+;H8E:_:3
MHY9Q712D=I037H(196IN2:B$4-H KB"6U&(S;77WW,091!ZWZ96A8Z>A8V.^
M(#=EX(4E@E6.\((+8IAP1%LCC&)**1T .K9TX=M1)>0["S-]H=_O-E-MH.<#
MXT^&XW%3[G_A]?1'BRO= /X S@HKG1<5X[P210W'GE9:T> \8T:\?7&]Q)E;
MNI:RH757"+<YQ;R695T9KXC7O"2<.4I4P)EFS%E=U5:J6-*S7]>;_N5<#_#]
ML+H(0CGEP4PR!5>Z,,!@%0@Y':A2PE:1U>];P<FL?J>LOMY4N"ZDED$0,(!!
MF:D*16I?65(9XPMCM!&UV3NH]F4NX/N^65W2RC%KK03,KP33LK1.E+7B(.M#
MQ9#5J<JL_HA8?:,XJ&2R<(&2HI*:<&\#J9W11% O@I&ED;5$J:Y8CBA]XQRX
M+QHG'EZ_Q"RYINF8'NXG!B1PDX49^<Y\O)T?9_>LO/_U@#OT_0@#KK$QD!3P
MG^>R%EJS8%UM-(B#PE >];[[#KYE87!GPN#-YCCZNE*,>5.0JJIKPH-V1!<E
M(Z5QPK."UY7W>P=RG]5W'$N[ TY[8#]Y!MT,NMFOED'W&J"[GK2IJX*6UA,9
MC"*<:4MJ3@V1B@H?JHKJ6M^17RV#;@;=#+K9P_GC@>Y&N+;$.&W!B1=2$BY5
M20PM:F*#$AQ(+9E4=^3AW!G0C4Z3O\XUW!3^=<,/!_\G_DC/8:9_/>B>J7VS
M?:HS/3T9CMO%TS*B\'?PO6N\>6= 18L6I^(5?QK.@4CVR\A5(G*]]GZ@K9V<
MP6HN,!P]GLS][,FEF]!\6<+3_^U\,AOBH?UIBKU7AQ_\WSX.W?RTQ<3>MYH]
M*Y9?T0;.X&)^^5=ZQ\\"9/GI76/[<LN^N$%$EF1U-_H_<<$1(POEM+>UM-R"
M,FUK />*FYH;JGGPDH'YN]=^Z73:/L2Y/O'$3+U^3W2 9_Q)CS[JB]G>7U</
M'IRZ_KZO;]GE!VV#?/>_J^55[L>XJ\]'_D,<A_8/KT?ST_W!B[&]_-"M<IY:
M590>]#F>3L812['U\.#U'/Z)'<?0>QK;#F,78C^=_>__KRZI_-L 1?#\X@;/
MV;R"N%U%O(D(NV2KB.KPL"-]/O,_M;_\S0UGYR-]\=-P')<<O_2WU:NC8K.&
MZ'%3T]O+,_:D2.>L<8@W=V[>?A+?6I-2Z;V2/9$5O?3MXLGE[WWILO))R=A7
M7?7+[U6<_]!KK9_4\O)W\UJ_=JVT>%(77W?9O-@O+E8]H?+:Z]GB$&@Q$K1O
M?_-/7A$DO#K^+S<^>U,GP+<4Z_6U@HIO)J!V7EOP?6''K]R^'?KHG9RC-?6Z
M,2Z^O+8'=1JM'XCM?I'MUFSW3&KIG;O,/OU25#T=]8=YWDNBZFEN5YQG=^E3
MLQL\]9?.WW3R<2.7Z/O8QD-8*UJ)>A1MFE=ZZ,AP'']_JL_1MKWWS=V=BWS'
M9+9V<;:(8ULB;6.3YD3ER=DYR! _G@T_^/C*7_XUF<W^!\W$R9F_!O6_<F<?
MU?Z]G(S1M3P%JP\]-R]P?7[VA5+P'VM[HC82#\^:]O%M97E)OR#+=SN9K+ZY
M4S'5Q[X8#^ ^(YSGNE&\>!. ?'20]G)Q9AH,FX2D_41U^#H\>:U=N(VX>72[
M^4JGK?RW'BWN"O2__J./8LM^\W,-+R:!^EQ/L<3LK@3"[IM1C[.@4%W+EOJG
M'B_T]&) ]P<8(;Y-O>"CJ:6^WLY<&GV?1>A="\";4)E"4EN4E,/_*NVI@NL6
MLJQE**IP2=U!M1Z 3[A^O)C/YGJ,.[8S<?.7K]NX^6CXYYOGGX^>_?+^Z.S%
M9[C/!7RN>EG^3E^>/2]??GY^\?+9"WKT[C^GR[CY+\/_O!N]/WKS_O/+/XZ*
MXV>_\N,WOU9'G^$Z9T<EK+DZ>O/S$-98;<3-__CGV?$?OWXZ?G-$__S\*W_Y
M[*1Z^>S]YZ,W1Q=_?O[/N^-G[S\=_?U%\>>[43@:IICYT>N"'3\[+(Y_?<NH
MP#&_-='*<,(I#Z066A =K#(>Z]M9O7=05N43=4?5 CN3BG1%U=#]\O.N =WU
M\XQN_/B/$\8VDXB^$L,VDHBBHZIQU28C*8/8S4#L\QJ(.5\(K;@DS)>&<*\,
MP)F@1#AG*)?!,%;L'=QZ7D &L Q@CQG ZJI6%N"JX$YR96!G?%7PT@HC*FN%
MN@V /8;4QD>";G0-W8 R*E 9,)V<$BYPV(&@%0E!>,6JX&O)]@[4/N>;@Y R
MPF6$^X$0#ABE+*FEC// )2WJ2M<1Z5R01>6O7=Z>$>Y>$8ZM(9RJG"QX)8@Q
MSA$N08DS05%2.69\7:FBD@Z,T'*_8AGB,L1]?Q!WD]ZF-%0L:%9((0(O2JFM
M"A5UDG)3UE97EV/<)2U-LSUZ6SRKUO',*8 T +!:"8&-M0+1TI:DUJXH:+"R
MM#B>2HG;CVW(.)9Q;'>>^R;M50&ZN*:EH#Z BE::PH-5ZF@H P_!%==5U8Z&
MX\D4,*M-Q%A5U,+PDW?DLY].,J;=,%"PWDK"UH4MI>!$<%>A&6I([4I.:%%5
M-+BR='6!R8=U2<N_92TMH]N/C&YWU6=M4S?K6CZ_FDQQ%8?S^71H%K':Z,UD
M-3MM.R9FX_66P+C>6Q'PS^C"$2-"(#S4C*BZ\D1XH6PI>*6UWCM@=%^H1QZ"
M^,;I(KN4E7<]A'CIYX/AE[-EK]%U__$E@S12_^OJZ'>H_4BF4J92IE*FTIWJ
M@M3(RFA9F\HYSC#/JA12,$NUL%59F1L/$@$IDTHRL#PCZW9WIMM=; 0FA DR
M:%\2'/Y"N*&.*,TY\94M53#&<Q-[Z5:RO*.F,IF!,\QF*F4J/2HJ/>14K5?3
M21C.LR2\8TFXX>5P!>4FU)H490!1J I+0)&IX$]1!"J9TE8]%E&8RUZN8.A8
M%#RP_8+@V_@U=G"VQGV*GSP!)5,I4RE3*5,I4^GA%>[2LT+4S/""<RZ%H:(R
MH,,%Z8S2KKJQPAUU@Y5>(4MGU$L_/PYO]*>ML<E7>NK'NS.7]C$HXB^?;N26
MN=)*(TM+<'0CZN$.LV8YD5RX(OA*"V-!#^>;N669IW>:IS/R/@8J/:2KXSK(
MF^'U9O"ZX>>PG%%C2TZL+0%?&;5$BU(1#H020$=IG'P<^+H3V1J)J8LM[H[X
M]W#L0"?XB:C-QL@/R>6_^?/%U)[JF8_C^J9^/IS&)M/88]JF?H.S+_8;_"[]
MO)>7*6QO^E$*69JZTEYKSCRK"RTMI31495D;R:X"P,WN'[CE2]JX.&T#2>.>
M+::8$@=/-7&OF[5D(+P^$%YL- 8!JT%S[CQQ-2T)-[4D=>DT 8E6V#KH6NJP
M=Z">\%O4,.0XS6-0,3.5=@5E-W5,&QC7KE"%<IXS;HPH%/7&E,%H)MB5$+L]
MX?A*B(V]X3+"W@QAU^OZN?#,U=(0*;TCH%$R4A?"$^6DH94.(#/=W@&K-I.&
M,\)^#[Q[YWEA-^+='"N_,\;>R!K3K*2%"<24% Q'4'>)MK(FJC*E\DKR.A1[
M!^4^XYM#=S-K[RIK9^4I4RE3Z=N+R3MWHV8Q^4 >AG57JZF%TTH[HE!8<F?@
M-RY*PJU5K*B9!-&)<E(6FW.2=TA.[D0VV>/TLSX;?AC"PMPLNEE=\]? +X?F
MYGRS'8@DY!A@IE*F4J;2]^8PZ<1/&B$6%<.LU=U JSM^NN'\* VG!9>:&!X*
MPGWIB2J9(MI6KK*4UJS$N)'8G,)^X]Y7F4DSE&8J92H]*BH]J.LC"[S;"[S-
MC#'II6<U)S8$07BPE"C':L*L4IA)1BMI=U[BY62QK^;H%[/90H^M7\\- \YV
M?CKP9^>CR87WS8NP=^/9_F#L8R[9U,=)G(.Y_C0P?NS#\"M='H_6%;P+*65(
MP6TY9/'GS^@CQJQ;/YYI7&(&S)L YNN-S#(MBZ)R!2.J4H"712F(XM804W%J
M'-5PW  OZ>T'3N6HSF-00#.5=@1POU5VV2;:QEA;?._X'-<T>_[)3^T0<#=C
M[<VP=CW'C&DA=4$Y"84%K/5&$U/6BI3,54YPL"<$VSM@;#/ EKEXI[DX8VVF
M4J92IM*/0Z4'3QG*>LL]VHCK3K7"!Z>9JXE1C(*1:"4QQ@="RU#4A=,E=>)Q
M*"XY/>BK6?[I9!Q78T8>V-/ $A=3/YAVJ7LI;<C&3\V0_W*VT ZXDG/ )U/I
MT5'I&Q?=73**[="]6\SF6&@^>S,YA#W$I>C1*SUT+\9/]?EPKD=I# @ZI$%,
MC.?'H8>2S[R9OUZ8F?_O M[J72WK(S=I?_GF</YR;?J1TY:'4 G"3.T(5U02
M[6Q%="F$I<;((O"] UKO=) O\WQ&YDRE3*5,I1^42M\X^2AK.3NNY<#K\S3G
MT7)X]NJMM+67I32D8+4@G J)0QXE*8/6AI:*2VEV7LW9B5RF76[O_<Q;?V;\
M=,#H_@"9]S8I1Y?.HGN$^'BS9"2IF _&5E9*RH,J35WRNE15*10KI0XXY/%:
M.4CQXL>+^6RNQ[AC&<=NA&,OYNNS:LNZJIS#KGU>U 1 JR+*<TZT1FI9Y0+%
MRE)>;6E?]77^X^MQP2,*$/T0;+VI]7PE3U]C<&MFZILR]7J>M5*@?P9&"AF
MLXTVI&:U),9JS6EPA:/%WL&M1ZQFAOZN&#HH;FFPAM:6\=+9VAFFJ ^BUE8(
M1V_#T+DYQ-UQ^[K#M0[<%DX"HRM>P@]3$ -6)Z'>%U9+(^L"N%WMESR+\,SQ
M*XZ+2DM52$YKB;/7M6&66>6!]4%(<%9DCM\1CE^3[R6UQI:Z)BYX#1P/O&^<
M%<1;PS@MC'7<@-+.]NOBKD:,99;_/E@^*#@AI<6FQ"7W5->.5KIR9:%\18TQ
M66O_9EQ]O";'BY*6IO2,E%8*X&I;$,VY)F49 JCO2GC)]@YH=5>)7)FE=YBE
M;Y5IFRF[PY2] 5B+()13GA;:%%SIP@ B5T88':A2PE9?#]8OQG:TP(W;.G_J
MY62,ZYA.1K#\DQ>PHJF?S;-.=Z<^F_6 4N&HJ$4EB D(_US6I#8UPUKY 'IY
M[4+%,8]W'VC_B"5 3O+]:N1XZ>=YMNSN!$]SQD2F4J92IM+#ZHB44:=1.:A9
MB7FW8":6556*((/WI:,Q^8BVR4?T:F41I,QR6%[6^>Y.Y_M]PX\77,5994KB
M'4Z.J@18_+*$WVBA;,DJ)XIR[T#LT^+6GOO,P1EG,Y5N5<OBK#.>EP[_,PIV
MP5.'?<NL#)K7_!I >TF6YPKB7L\2S\![(^ ]2KT^EL:V+8TWC!MBF;: O%(3
M51H!\,NDJP5ERK"]@TT[>X=R-S,K?[5;K;:5H'4IZTKQBA:Z"M:4A11.BZ"I
MO;'*]&HZ"<-YUI?NGFW7?&2B<K650!=G34UX:3U1M9/$4EW60#I6>(8*4Z&J
MG5>8=B+W^G$ZPN)X;^P@N9SO/1@!]_U8_2!S,Y9,I4RE3*5,I4RE7:+238QJ
M(QQG7 4A0^!64%47@=<ZE+36G*E;&-511WC:5Q&6-C88W,?AC?ZT-?C]2D]!
MY\FZ^HUT]3\WLIFDKT()-"2>:D\XDZ"J%XH!&9VM:BFLY'+O@)7U+@^LRYR]
M@^ZRK^;L[$R[$T[?<*9Y5SKMF"',BH)P4PA2>Z6)ILK5OA;4,$Q'SHS^73+Z
M'7C3;L'HF7MOS+UK/C5:&^:9*8@N# =!77KXK7"DELS7EM**6[J]?^0.\6_.
M*OMJ7C^T=G&V2,-5QBL2<C!L1&1.-]L!?W&.]V0J92IE*F4J92IE*NTLE;ZM
MBV358#H:CB?36-V3]+;4>Q^,IJG7,__,IW^SR73C4IW6X7'RZ>7G(_I6:%LQ
MIVL"%FX D\E[4E.JB9>%U]8JX[79.Y"W+M/)O+NSO'OG.429=^^YS YY]]?B
M+=6J,%P)XI4TV"T%N#@839RSHJ#.*^OXH^#=G#_TU7S^6S<7(X[%F/KY<.JQ
M+^KZ8-H?*Z'H<J_O]J:.K%8UHY9)7W*A2U556)5L1&"@O/CR*@C</F%V21MW
M.':_1=)L&3B;@?!&0/A^H_&C<U5E:Z9)'3@EO&*4J+(NB)5:N,!T<!7;.ZB>
MW*9_;0[;[ H#;VG?>$ONW=YDX$KNC8/ ,O/>E'G7"L>4\KXLZXH$(RK".77$
MA+(@H3(UMS6UH)/N'636_3Y9MU(L*">HD,H#<%OE2U.IVCA:<F;-S?T&F77O
MCW77NS6*P@+JEH$8&ACA=0#6Y=X1[4LI!&-"<U#2J<KI$M\G\]YYO?:-F#=7
M)]TA9Z]W7:Z$K$MCB:M"A?W;+%&:%D0QKJDH6<VU!L[>EX7,O/UH>#OGG&<J
M92H]RK3"+"=W0DYN9!P&J37\7Q!?V4!XJ#2IM95@Q[)*2EFB(QX%I2IRSN'W
MF7/X;/AA" MS:2RU:_X:^/\NAA^ M\;S/)]Z%T),.3R<J92IE*GTO;E,.O'S
M-,9ZHV:8=;X[T_G>'6[X1J3A)M36$4^+BG!K.:FY"\2+6E>^8+RF"E4^2G=Z
M7F9FX@RUF4J92M^;;R0+Q/L6B!M.$",Y-T)51"JI"1>%(B #!6$J4,V]JLO@
M'H%$S%F(7\WQ+V:SA1Y;OYYT")SO_'3@S\Y'DPOOFQ=A[\:S_<'8QR3%J4\%
MFW/]:6#\V(?A5[I,'JTO>1=R%9&"VY(3X\^?T<F,U>M^/-.XQ(R9-\+,YQLI
MB]((5X*E0$II#.&F=L0P1HED0@#%@):% ,A\<NO>CSDN]!@TU$RE'4'<;Y6A
MM@FW,5H7WSL^QS7-GG_R4SL$X,U@>T.P7<]3*P%--:66>"\<X<Q4Q+A:DZK6
M5EECA;5L[X!5&6P?&1MGL,U4RE3*5/IQJ/3@64=9<;E/*W'#LX9]1J4KB?!"
M$NXH);7TALA0E\X+'\#R?QR:2\XP^FJ>?SH9Q]68D0?^-+#$Q=0/IEWZ7\H\
MLO%3,V3 G'"T ][D'!/*5'IT5/K&I7N7-$L]=.\6LSDV,9B]F1S"'N)2].B5
M'KH7XZ?Z?#C7HS3[&WW2(";&\^/00\EGWLQ?+\S,_W<!;_6NEA62&RDD+S8K
M_LJ":JLKHDU-"1>T)+JJ/ E> \D9,U+1O8.RRM/&'@_/9V3.5,I4RE3Z<:BT
M&RWALY:S*UK.YFQ&5RL;%"6T]C7AU%"B?5T39W1M:>F$8>7.JSDYG>GK:[J\
M]6?&3P>,[@^0K6^3CV0F4^>G9#XY_PDW9#89#=V@?83'!YXW3%;"&5C!.F:I
MX]X7)NBZ8E+42G#F67C[XIHY2O'BQXOY;*['N&,9Y&X$<D<;&4A%+;E@CI'@
M%&"<%!6IF9:D")96K.2VM@ &):=/-L=:?9US^=J,\(@B2#\*<V]INO9UG+T]
MJG0Z&<$VSI*ZDUG[IJR]5J$43*49ZBO,%IYP;C2P-F@S0*J:,QM\Y=VV(5:9
MK3-;BTJCL2. M06W-FAKJ6)EI37GEDIZ&[;.11AWQ_/KGED 8LZ*4!"A!/"\
MI8;4M)"DJH(*16 U%W+O0.U3GL5YYOLM?"]U"<J>E(62W+I*V;K2GA94<:-X
M$)GO=X3OUSNUU750C"GB:U41CB7)VFM-/!6>@Z@7=:U!ULO]HLZ,_\,P_HWB
MN$[4EJ%.&!3'?&A?@@K/54T!#:BN+N?\2QR;6:._-9>O3Z"NR[(2LE*$.^T(
M#\$0;>$W9I@S@-K"%^7> 95W,($Z<_?.<_<-F#OPLI15Y<$BK[BM0BTJ;ROJ
M2T^=J:B[KEA?'^F2.?JF-OK&I&GI>4&#($Y2X.M )3'"6,)*YTL=@#REWSL0
M66AGMMYD:^#7PDKG1<4XKT116R-HI14-SC-F;J&MOQC;T0(W[D9CY[.&?Y=(
ML1:-5+H.9566Q/&" U(H2Q3E%I1]Z2U::&7@>P=,[-/RD:-%3A+_^M'7;A*K
M+["CPJ&U\)AS>*;!:PR7Z:F;#7X_=WKN,9I9D$(,_O)R@G]MJ(??=^9'SL_)
M5,I4RE3Z<:AT$T\0$XPI77D52LUIS8R71H?"F%#RTKDOQ'ZR)^B^)W/ /=CQ
MF\.W#HQX')E%"L88X1HT0N- &2R"MES(@@?-]@Y*MLN9:9E%,Y!F*F4J/71J
MM^)"E3*8RE1<A,HP5WKM RUE5<M:W8&X^SIO2A:17SF4XZ1X^?D]?UO7K@A,
M5,15@F$_2DD4DY18;YVI:LUHX79=1NY$]O:&!V2'./V?>KS0TXM!RM N[R5#
M^Q$"8$[/?H0@ADUU7Z_J^;JJ:J]+3RJMXP0^!QCF-6"8X &HY<J"?Z/T[.\N
M//0]L75.S-YEIEXSW@O)-+"L((5P)>%%+8CBM #C/;"ZEIH!B;Y!8G9FZ$?%
MT#DE^W%P^\LU$5YQ)W$>#.%&:,(I3L8&,A+!8^$5JX%HWR@E.W/\H^)X0SU8
MK77)A:!<,>!V8/!:2U8%6UAC,L?O",>OR7=)*^^<+(G"'[PP%=%!6J(+;7W@
MJA#2IF1L<5<=^S++[S#+YS3LQ\W?QVL2W5@OC0+6EI6K":]X270I!2FI1,@&
M_A7%?:=A9[Y^>+[."=B/CY>7"=A-E$ 5SBIF*P+$B%&"BIBJJDB@"DOA2D-Q
MCN/])V!GAGY4#%URQ8-2DA:UX,9*K0I;U+QV(+N#\V5.O7[,&+$6293&!Z%J
M34K.0*$WG)%:24D\J/F%DS4K"IE2KXO'K-#O1-[UM8.-;OBAO79S"8*?CZR^
MGJ+],'#RTL\'0V#7,]]1'Q;]H^1@Y$R93*5,I4RE'X=*-U ?K0JJK)RJ05WD
MT@3C5*E+46C->*E-%?N)EFT_T?)J/1)DS8LH:OXUF<VR.GAWZN"?&[TVM.>E
M\)82:3&@(QPE=>DX$3P47@GC/ M@,>X7Y:V5P<S!&6<SE6Y5S"*%H;4J"Z8I
MKT-EX$\/AGKEC62"TFL [26.]17$S1F]]P"\&\T2>%%[40E#3%"*<"_ #B^<
M(@Y'4!1<2FT8(.\N)_1F5OY:E<EYQVH;%&?><%>(NK"B=KSB!0L%,^6-5:97
MTTD8SK.^=/=LN]:Y 'NH,PY\6M2:$HZEYRHX08RKJ"E"<#4FL8+"1#<[J>^:
M*-Z)A/S'V9O@>'[JI_#89^=3?^K'L^$'/Q@!]]TF9__Q(5X>L)JIE*F4J92I
ME*FT2U2ZB5'-2R.<<+KR6G/*I%&AM%[84I45%XY_O5$==82G?15A:6.#P7T<
MWNA/6^/BK_04=)ZLR-^=(F\WVH^6M;>>!TEL90O0XV4 %1ZL<1N"IY*K*DBS
M=U#NLRV.SQMGOF7&WT'&OS]OVE<S?O:UW0FO;_C:6$6="KPB!:]+PH-01'$1
M2*UYS4M6EK*V>P>49D[_+CG]#KQMM^#T+,?OEK?7'').!N.-X@1^X/QF(8@N
M&(WI;<RP8%E@49"SV_C2[YV]=R)?[7'ZXE:EYF#8B,W90'<#1'-+T!UP-^=P
M4:92IE*F4J92IE*FTLY2Z=NZ4+Y<$O@*GF#BP*::>CWSSWSZ-QM--S*:3C8=
M(M)HS[6F1#/#"6>5)4I(1TKK:54(II6OL0AHYU,8,N_N3 I2YMU[XMTUAT?@
M0=(R%*2N6$UX;4NBN"E)70K.I56E>"2\F]./OIK/?_/GBZD]!7X:Z+$;3/U\
M./7HZ,!9*79R=C;!%4WL^Q\K'^ERI_#65J%!.U!=*B>4-=QR8YB6U#+E"BF"
M9%>&?C=[AN*6+VGC#L?NMT@:]VPQQ2KH"(FOF[5D(+P^$'Y^WK43;2.X"M"I
M*JPGH:X%X4%;0$0+OS'!+*/:VK+8.^!;FHGND-LW1W5R>LVCH])-8F_4E:XV
MM9?<UXBP*A2\=AK^8L"@2M]8S;P>QOY;CQ99U[PIQ+Y<@UA::0N8"F:B5QZ
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M%4A+\)_.T<MW[?MK# "<K*UCUEN(B],65U;P)H8/YEV&<AL\GB\//%@DW4@
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M/"5HV5$B-"VF?TL'$7X[3$VLHS&V;(V7/$VS&&C&S#90!"8Q#SB6%75U!@,
M>:1M]/IC" !G\>+._ 6WJ!V4VWWZ\.A-1Z!X6>,MCO1<EBGAGB]0AX3C/$8M
M9-MXW"\1;%DPWNEP*_=//>ZV*'6Q<]5T>@$7^1BS55L]-47ON\E#J0\X_GJ1
M4G>># Z[ 41M+MF5&]UN9TRS'<Y\>]ZCTHP%1^M9AZCAS>9@52(:-.5:S6BV
MJ#YL#E:+6]7T]3!^-/1-9Y75[5AV1<&)V'"A6&Z4U+YM&O12HV]5L_WMQ4W[
M_4K^R;1+[,6. *,)QMR_D&9P"<]L&]?U&%#P#[]R1GMXGX3X2=../^6S@OB*
M*E2L7\<LZ65V=&0:_$[*S\>Y63ZF_VKGIB@?<=AMA+M4[X&W:.G4G/$1'-J0
M6K_XS:J6=F$^#M]#T6>G0Q/KQ3O^;FR?E(5R"A]!U&[3SS"CK?=\RYN?+698
M*WD:SV&3"&<\7GFU6NX2LW']L-R^4."^N]DC*\PO7HUP:-7886/4\]Q?+C:\
M_?SG6^:UY,K5I&0*G43,DUIX24*IRZ)0M4%/\6XZ?5K*1G;JR/JP[I^5-?EV
M32OE1!$X9O/]+N#2TXV[+'%L7 ^29/E72J ^.U^D5A!Q($]4S\U%2KF>3S4N
MA,0FCVVY'#;[6?:(6,P\QG%&(-]A/:C'(=R@UK^R6?#PE@P_D=.A S;]Z8=A
MB:,WSS\=O?OU;<$4HZ[0P A2$4X=)TJ8FC#C:BZ*FM:6@;4T!&GOQ\UI0^C_
M$I 5E5&<LR)HRS@M6,V-Y+HH:F6M9H;?!LA^CV3]US#XO4$:B0@W!)0%,O[D
M%M./<.S ;OK!\"T2\_/A6TFML-P(8D!\$"Z<)%I7DA2TI"986XFRW#N8GPZ1
M:>, ^G7G6F/W#D>NZX<#:AEHY4D<[F?F:??[Y>?G;T6I9<E@@ZG@P#R*>F >
MK8BURC%6U8&&"O=[ZOTU6:>VSFM?%)Y6BLM0&JJ<LG +7@M;&9]9YUY(:=\&
M*4.0&#\NN2.\-H& _D4)K1QWU$D36(4X^,%_@7$:F37M"<-8WS )\X]Q^GM;
M,X0-VU,[]C1-Z@QTYU2(M^QGU'(A?!BLKJ7;">[SI1-D+->A#D*QLN9E+;54
M0C *RD[IJ%$NGZ"[/T$7QV]^?5L902D  1$T,(Q ED3+JB*T+L'T-RK4 B3I
M#+U17SA"83$%(V<Q[2>[=*?IRX-P=6#2::5 E:TXHU9IIV@H%:UJ9?3MQ&Y?
M.SN*^M8/.+"G>/D,ZU^XDY)Q4GDF06&BG&A0;PC.P:*V!OCW]=[!OY!GX_R$
MOOAL"MK;XLA&9XU^/3\]6\)!TH\CWV\,4^L:L:!>O=(G,T4./_C1)$$/G*:N
MQ4YL!)H<H@2[3;20E-H&Z_-HAWQN.Q%VM?19I[XA$M"7[UZ\]=(+:BM+J 8)
MPBNGB*JM)[9R@ $5+X77-U,+0B$!P;F7U%=<<Z4"I<8[JY@-H>(9U.^'E"=O
M2UW4M7*6!(MMZ6L%C&Z!E)))X'I3LZJR0,K+(/U!IPO\?3)QZ&B-TRO:2,9A
M=#S_\.Z@X@C4]YI+#0IW#7*:@OK.0DE4"(:PRAEM95&PS;G?1:D*6Y;:!J!+
M,(613GIE:C!W<<B)^4Y*']NS$^5!RA7N1</2(7I8Y].JB[H;V+8U9MMT>&[\
MSDUTMS>0U<*7FX[PVWHO[3=CIP=Z-)NT=8N-+QN;Y*9$(AM7@-[D;I^:*$\W
M9*E9I=OL.+V<=Q"KNE/'B-%%$JXG#3&>##JRK 6(_2>+S[S2$R>L/%>G::PV
MED.W7!N+:A[@R:#MB;3^'-U-E_7HL?7M\&2<GJD; 952;6#G3X?G*PGD.!AX
M,HOJ!MX;A,M[>/]G7,W3*38TQT_$/U^?QMZ!2RTXIH=C@ J^ (<XQ;M[93XG
M($X;)T7,?]*SU%\<.YYAS+![O[>-RZ]O/FW4CD8 C\O6BTB?I@-.,U>ORQ/K
M%+<83US9XT22IO?';&G>I8/J>SO_^&),U]K)&%+"M09,M/"-_HC[BU'"I;:)
MC?ICTZ#4BRMTPP22)3V/&C&:U.,%>H-O1T=D?LST3ED/H"BGV&A#G72/CO/Z
MZ\#57<XC6Y]U>2+[A_CR1UT"0#/&[>Q\Y./0[6F[LK4%Q87'7ISX7"=?3Y5>
M:EZ88$-_[-00NS/@#30\!2HZJ?';QAH:?.M/S>SWZ%X=2;E:(+XT,C8[7ZX1
MK-_*^^N?=-G1,AI&P[/-QTDG!R ?%&?4C-OV:.<33+H<KE(!*[BMCK,+(AW0
M_.KU\XQMZ%O9U$UPF4^')R<^[CCZ!9",UBZFC[&@:%4>QZJ:Q%JITT<"1B3(
M;-9UQH+=3"2[8M;'IMS2:X<"OQ^G(,8O(E?'M(H80C[K0N!]+M=;F5N#@7S1
M=O>Y[O+PCMWI(GBZ-K6 F+7334997\NU+K"YRB?=\-T^V\Q:+X#O-5>/T'$I
M+YXA(5$E:5.JY^AN;*<,Z=DD]8Y<O\"RP_I'/VWG:"SB],E?^U1O-W4X_C 9
M?4A* Q +J0/JR6(Y>JGOOYBU>0?8:[B9KOO>7Z3^_]/EN"2/#XV))2VY-D\+
M/OP*4ERYVXGY6X)U?2ZM=YA"LJQ [IX#;]'+4DF @:RP#SAHIY.N93WV?QJV
MF81C!QK3- 50F]P;S'M!7:G-9VG3]=(AZ)IF-'-2DFJ*:(2->-LW$Y8\1A2!
M8X//LG9N8A:'\3T<AM/YWXT3UE,J<"Q%&F4*/()7C,4$B.7=K*?)>=O>SER<
MZUF3FM(!%)Z;_BW:P32XWTU%(W +J/#S-"RU61N>A?]N/@3*FU^69W(3C%:^
M<YG:L3;II!FI,##8L:[57):C37I%D[V\KA1@Q[YM$Y#F;6>8S6\U'TBC8%HX
M:>[8AP&#<\6:=C!-3NK^,A\5;]YK_PKG.K);-&M2X\@F2Q-[$8^;QI-HRR26
MBW=JTK<BBJ<1++-57&O9J)MSE8Z8=P1H/=4G2XNH\70VYE;LI#X; ";!IJ1N
M5&MS//K65--IMKG$D\'1VIXN4:'CY#@I9]88H.<+ V8+'A;4 5V>/'&C\@:9
MRQMR>4._[.#*<H4UQYVK35GS(%U54BX*42NMR[HHE' V""LO*V^XTN&WD^4-
M*ZW!^QC95:TM$=1@5UOX_0S[.I^/DD1J\]?/0/OKJ3PI<S*B_-]BMGM,$VD2
M*]MVX_LIEW-_)<.K'UE*+[0I],]_?O'FV6&;HIUF?YK)Y/U2?^O:<W?@^_@T
MF\.M4CT-\5N9MS=?Z\':V#_K]@RZ_+"I0JNUS#OIUQ^.^N:T-\HM;7M4,!N/
M@88#X EL[7G2+U:'NWW9Y-IFAN_')L^;UM>3P8NP]2FVF7+MDT7?3+>$_:WC
M#_L[USSME[;9HT:WW.&^TW1U$<N1F>L+_A -PM5=?GRG\?JZZ+H*FC*VKS2?
M<+-[<>.DJ%ZJ948WU[(O]A9*1\?+EQQ%UUO3TD>P<AH;.L(A16<VVE!Z/+_$
MN].8&+%/5./OA0-UF>^IUS:U#WZQS3%.93"K48&F0??:TZ,B'7M6=YKVUC$W
MFSKC_088GZ$V'W<@!Q2+HW>_O[7>J5KZBNA:!<)K;8C1CA.I:\^"%\+ZC8E8
ME.FRY,QHS(RM)5.%+T C,8ZJP+6HOY. XO*L]%3 %\L^OP_>R& YY#1I&UU5
MR 1=F5$DMJ$^MWR6K<.2?AJLC@R=?=3G7<]4_"45>W63D3!"MI@WQ6 X"_.\
MK67"#LSHY,$K-*]AN95S,7V^X[[DK00PT]'MT^/+Y<?;42J3,>FMO[?J99"B
MN?_RNS';"'9EFHI(OS#Y,6J6P["8IFA+M/-Q%T\G<4?;F_7@?/-Q$*>C#V<$
M"N;HHBD@ O$4ZW-7TIW6+IN<!HN4[]3?'T1^[$F=:C.QO&?1MG)H!JO'!P9A
M!$KP23M&-D4YD_NM-W_=3-PP63;=[&%\[ ;IDT<.OMV,XND_6!R%U$S-Z;V,
M"T;%I>NST*X5VV5[%[.L6@F]GR9E+D=@-M.IFP$/RVLT-7AX[>WTCI(<78:+
M1HJUMWB$8<BN/!.'!BR2*WHY)#1)T*8YV"IKQK$"Z*3I,MEZ,9N4J8M-^6&G
M>EZB-IFNO4HJZ-5S[$R2&J2G&00I8-=?TY:;ST^GD\7)*0[T2T>D'9^R',&U
MOV)\I6XBK<^YB_EU7_Q"6Y-]Y.Z/."1=-U-06U4?_D D@MV'J]G9TNCJ^K:;
MY< ^A_L1AP&U&!F1#?2G,98$-O695Z%D9)K6B7\&/!4NFG[Q_3WJ=J]GD_9;
MB6#*;-.$&J_4FU+0]H"+_4']26]\;6K-W,N*7$7JN&M;,+HI->RM&E4=TD80
MN]. :VHXUU_&KIL'87.(,$)/#+O$SSAOYLLZY+2"^'R=6%K96[3Z4)>-EXM+
M6>J079R@/XWE\3']82SZ7)F(MB(3^V.G]*R;EC-=;3 T7['D7BQ/61R1,VJT
M];B#RXKQ&,6-T@-9>-I56UN0@UC,G$:(X!@?W>>#1N%O]S_A])),<5Q,NE.,
MYB]QXY+!D--EM7/3X'VULG8-R];M^=[*TEBF69O)@L<SML)MN"2E%G>?;LL8
MQGK>L"8.ET@K;Y\GU>G"(<?BOL.F34;J\]-7#%8#+ENVN==O8VTNT/;IEL.S
M,^^&3?+$BXVE-[K%UEU/5?3().ULH-ZTLV[%RXY'FWNZ>;/5,N-+EKQ2XX]
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MG..8@AY=S.$?=VK5&VP[,YR"XQPZ'TWDY (!2LGS&E!H/H&=<]+9&NNDO5M
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M^"4?U:E\.JG,^E"+O[5H$4OU"'-YGN5G7Z75YSV-3I-8]S;)0$H]X*')IT'
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MA]I;)CFU2-/ B&E(@;10L+K6%T)27AE,GCPK5Z2KYY/.6XL'<C0<-?P[&=>
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M #JL6?PQ@ZV#@G402IJ6'-C@?7MAW9R ]X/KCA-0&:.MLP@Z.%+ A?:U?MB
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ME0A6A0 9BS2Q1,%RVMGC=@4YB(U8&[$V8KUS8FV9W/?"H]WY\+,A;3*#=B@
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ME' @I>8V"'JXUN[L:;5T)*-ANVGM+9)QOS9Z-Y+AO$_6$;K152.]9%+;;>;
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M>$C 60ADLC@2]($YX-&J4I2M-LO.GNE)^^(&\RU6ZUNP8?5H[P0;=!8JL6!
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M0D=;D)XL"!%=-5\\.)4"_<F3\CJBE[5EDUDZ*M%R+_J"^2O&7=T*[*UE4^_
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M\O?3^=-HK'0C5EKL1ZEEQ&25!YYL)@5$>+ 8Z5462%H).F7*E>G#_]%\F-L
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ML,IDE0BOPM?Y,CP:<()T"RYIQPKGK4YY9X\OAN(::+<"M"LU"1IH[PBT'0O
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M]L\H&F!?MQH?,P=D BZ=!#,S+8RM9IH%0'A2B/%\-._!Z18.D!@V\V85_ 4
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M3;[BU\]W%O+EQ>/BCHGU9U-7RU9& 0\6<P22RXDY7 MLM%186I>\#X1[6J/
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M%X-*ZS2 :H?SLR%=;0"M$?5F#" II<79BZRB%H!Z,2 7<EMX(H6FR>7V4F
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MVK'+0@;DB\%6( JZ*XM!&J?)W/VUEV UOF_T+L_/<RV>0;)\*?7R7T#*Z&1
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M,$Y:I@27UBP2PZ\J%E%Y6?R0M(#:TJ\S]&I97"D8_CX'PR(8Y5Q*B$8!,&S
M+C)":92SZ#41*A"^6EZ LH1RI3UE+' /XIC91*05T4?,;%B^#GPMBY^.")C
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M<D6H]E33Q((R6 62:G!];G"=5<2ID21Y9Q'%P2/N54"&.(&DHI'#\?NH:-7
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ME.J94$.2BSJL]YU#DUKKHJS4E- )X;V*@>KL)_:6?:]F>WKD;AS!C1%9)RU
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M:GJFYA"F::?SDLCK%"WYS%A(!PQ*^D3!9UW-2#<F0S8F9MN3KWY!81' <'*
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M5X(%*Z2&ZH!FH"PB!).$UUIZV0[E/?Y"BU[\.=#BS^XY#(H_-I7*0KY&+5Z
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M5G,H8KB>1F>;/;'-1J+)",'HV^8Q*NTX VV 1!+M.ZI,XI2V^]MI.V"VZ<Q
MFJT6BG64J)2-!I67UK0C3(0I?K#,T!E@1P;8W$WJZMHQ)4 R60)F\A R$3 6
M]KFB(<AJ2^6^SC/IX'\T\-_\T'J1!..?X6*<,T\_[3#Y<*B^E3@0)E)@!3FM
M.F^B@EB" \U&"LZR<,MS[I)E\LE86?UY;P+6:Y I*2KA;"9;2*9.N4>[EG3
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ME88]8C$9BM>FNB*)(;(T(&.-0U)$54*O_>RUG\<G6'9>V2^O;(B8*6?=A"I
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MRH65!6-L6P!=ZR/@=.5!\J3.SJ7O!-@)\.0)\.%V1W4"?#Q9<FO_4W".1*5
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M4-*85*!8H^3CW.W9H7X(BNP-J/?P94\4L%F<7*(UFA4$$=MI\M$!.:F!J5#
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M;0Q44U-91C.#-KI4KY.BMOL[F&_ +'/RC#!DF;0SPD,RPH9<JJ)0I@0$%;(
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M"KN6G$KIR[8T8II#2*0@[-,A[$2PQ"C%.=<)>6H$XL$+9%4$W\LP(JERDK@
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MOM()<P:Z4YV$YI;[G&( KR'D#F/@KB?N5M8YOVE?Z9S"R46,$V*\^+BO25!
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MSE?CU)2#HY$$J4,I9Y>)2]X2E!PUN,X:$"4HA,N*UD>&UIMHQ?< UZH5+P?
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M4F%C=E) D(EJ2Z.V22I)1:8B\ \O2S\HHXQ<Y5L<HA3QKQM&3?V. ]O'3^,
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M(FFSG=,=N7.\<]H^^NVP_?(-;^\]_])^]\?'_YX>T/9I_& A1$%+.D\C#9$
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MF*X"^&D"^"'L_ K@VP!X/O.M8BK0HC/K#&C'4R#>6$HT]5KZX 'ENK$M[6H
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M1Z$B^5$A^0%<(LL \I-.E'Q_ )_WG8!GVINHRH&  O!LB.7:XWH-5@>63"X
MK\7,GC[6E^0:J%A?':S/+>;&>\I+-@\132"2:DT\59)H1'K@22GKPRIB?<UB
MCV[K+EB/O.X/Y2XX1U35O?F#U/1F,1@G4U;6%^*H,$0JJ='.0#5$>$$9PZ6(
M1;ZQ+6Z3$[)6:5AA-#^4RZ"B>2EHGE,TI.%,@7%$.T&)="$1SY0AY7RQ,A1B
M2')C6RUNR%8TKRR:'X';X HP5VMB*2"?]QSH#%R+ $24T%G)F"->A$QX@"2\
MHRG07$LLK0/<'\AS4.%^IW"?3P MHTLEY4 4.J&&[C3Q.3F2(C*]#U+&K%<1
M[NL0:-#^EJ;!CUHO(<)Q@,%DS,7"X<"_ZWE-!'5_ _1D%H$[/ ?U_7PPE=AO
M1.QO%UPO:'0+%QDCC#).T/@VQ'GJ"7-.IR2B9U%M; MVZX1Z2T?/ ^\=51ZM
M//J8CEI5'ETNC\X[O8"*\A^Q3I53"$P09YDGRN+"&*2/N02]"64JCU8>K3SZ
M2'R0E4?OFD?G_8HQ6903".(%*S4=(R5!9D:45DZ%%(3-=AFGN2J-5AJM-/IP
M!\8JC2Z71N?4T>A4=$Q9$E4P1&85B<LV$*&\M"8;*E58QH&QE:'1BXF>Y_+&
M_FVVV9KJ^0%2/;=A]#N^HI\Z<<H,+_K#4;L_VH?1-V)8^XS/^.\/980USYSP
M9('(%!VQJ!810P&\T%HZ[>8S/LLDI0T.6'!>.A%MHME8FCA7WBDGOI_Q>7@A
MY;./<7P\[C;9GOM-"L[8/SX9P&'9M/L$Y;O]8VC]H]L?#O_9&AWZ4>O0X^>]
M_J@5 'JMP9D\2V[H<G._!^4M_=R\]&0Z$?#;S4S KPQ++<L!W&TNZ;\=I)I+
M^K'E/*YMK;FD:R[IFDOZ;X>BYI)^LMEK:]K?FDNZ3JI5&;@US"5=[*@X&OM!
MQW=G9M&![_1J3NGUS-+U$&?;+O&Z?C/C&^7GQ7DC_G5CP^/,_17GZ? _.&5A
M^#/D_@#V_)>GXY#=.Y [1V_8SMX?1_OOWM+]H\/#_;WT<??7]L?VZ<?3]WNO
MON[L?12[+Q8<LOB>@Z_MEV^_M']MXW.P;;_^<MCF;^0^?R-V]]K=G;W77W;W
MHKPLWW04W"M!*<DF<2)CB,2!T$1RF;T3R=L0-K:U6<*IF)79LJH9"BOW/=!)
MP,I]#\E]\]D+#4HO&4J2]X)(*BAR'Y4EH9!QQ>&*?R#W\<4TU)7[*O<]:NZ[
MEYBE(783_ZH<N$(<.!_79+(VGF=-A(F&2)D=L;$D= WX'WC'8M'_:B+^2H/K
M3H,_''-4:7 %:7!.%=0B<98R)5)#)E($1UP00$#SJ!TDRW,H99<>"P^NP_G2
MWP>=_J"%-W_J1&C% :3.:,TR63\B[UTCK3\GPBKQ5"\:>9UCL*=^0OY>F&TQ
MZS4W CQU@CB1T,CUC)+ 8D*;5](8C52!KF1ZO9I*\_&<X:L$L$H$,)\B TF?
M:2E1H;&!2!N0"J*T!&> 0Q/>4:MD)8 U(( [/'RV' *H0+\1T.==.<+)1"6:
M+RDD2R0$3KQ+D20#(1@KK>04;9@*\2<,\;L[&%4A_A 0GUO+J3<&N'6HPBL@
M4B9.0G"2!,>L""8DKF!C>UFGIVJ6[!LGN@K-5&^-_)=;Y;RZZ":JAV/O88!6
M>PVXGSBM97JJ*^G_&.DO9B&G- 4E-! 5K48#SB+I4Q:),]H*X<#$N.00K4>0
M=F Y&WB562NSWHL+K3+K2C#K?!TYP3(/*I.2E8#(["*QF@7";39&"^&I%<L-
M *O,6IEU79CUL;@F*Y_^*)_.>R!S@*AE+G5U?2 RV$B"XXHP&ZDNN;ACB$MP
M3U1*K91:*7657<&54G^84N<39AF1M(V>) AH_'O@Q*)$20K*ZV12!(^4*N63
MX=3;)<QR]Y PZYKYJDK>HO/YB689A/H!>SU)]8,@:2&"$'\-QLZ^<C)-AG%2
M"HJT/OMAZW]6+=)K^NGN66<NQF_TQL<D]4=D^OQ'3P,_GBAKYTO[Y?X'"(9#
M!DL<*S#6F1.O09$LC9.<TF 5W=AFFY(M[L^V?"_=: +<2Z1/G0#7GP![.Q^L
M%CQ:80AC)5-:9H'X9"0!FUT4V:=@>9D ]I),W)=M)6VV"HB;J5&$N=D:P/ $
M\/N?H/MUZT[R]/U(HL#'0]?/FYQOEP_S9BOBDN4[O3EF/O3I;RB^I*MKP9<(
MP^;QY;:6'PYA--QJ_3F.A]=^4"/I[#N#UB??'</<P\H_5V.)F.9Q:DIAO>N,
M#K_'&,/7O5?-T.SFAER:KCP_.!@ 7H??!_TCG-"7,LWZDLEI>^_@0Y!*2Q85
M$2R49-0ETD?;1%04TD%,,B=[J5)XXZ7D,4R4[R]*ZSQ5CMY^8$);)I0G7H9,
M)..,A!08\3A7& LJ<XE3A2[,E+D%I?4:J0:5^W+M'!N>D=?)#*RWX\#O/>81
M,F"9UU?3V&63NI+>93.9M5_&#Q'56JU2J>P)@4@1-0E,!Q("3YHJ(V.DCXCT
M?F!NG/VUWG-A[\T'+0, 3XYP8![G O<$#2A*P @KDPPL>7,-5KNHI=Y-?FGH
M?CJ76QKE-SX^:5CQ[;!DEW_AN[&L79W>P=XA+*Y\:Y]F>O?EJP\\)##E.":/
M7!*9C$7H.TY8!F=5,L[(,)\V^F&3JM_ 1S3Y B3B/\' 'Y3$TF=SI#4>3A)=
MQV_3I/$87;;*%F^2[W:GR^E"BNI'8Q$^JMS6:HNIJR^O2P[FQ])6NV7-CTGK
M^]>$6WY^\]+6Z[5G;;("/]*$SE.M;]*YFN"Z)KA^NBEU:R[BFN"Z3JI5&;CU
M2W#]LC.,S4&L@1_!#R6#64J&KT<4.=0;E_VNI7C Y#4VD"_Z/\YY/Q9<'S-1
M_H&2/'-X$?Y(72"3.**^VC]ZQ7;>O?_X_M>W='?O@!97Q^[>FR]M_L?'_7?O
M.[M[OQSO[$7Q?CZ.Z*C;V=E[^^7]\1\?W^^]4;O8GYV7KU3[Y2OQ_E=L__%K
MM?-N_TO[-'V\+,^S5Y%&;BGA*$,B54[$4IGQ+VJR-TY&#1O;:,TN.3KS3@*%
M'@) _^<ZB]!-(S\K(UV7D7XLIJ4RT@HQTOSA&Y8=]8X1B8L+D1"!>.\HH3ZR
M+(+A6I12H%MFT8U?&:DRTH,STH^=6:F,M#J,M%#C'4Q(,0J2F"B:418D< N$
M"T"J<DI);1H=Z=95WBLC54:Z T;ZH2,?E9%6B)'F="1KG<JF[ T[&HET3A)G
MO"11LZ1=,E*+5'0DZ2HC78.1UB$K<@%>"88KM:RA-YS6E.[% ?CACWG$GF#F
MM)5U>A7I[>87YV3W>BJZ2J8W(]/%3,@*4$LWQA)A!2<RQ$!\=)Q8%H230EA-
MD4S%%KVUP;F<_&D/SY<U/^/3=&15EEDBR\RK;(8"!609)Z-$EE&66"L#B3Z#
M]T(XIG)EF<HR3]\Y55EF>2PS[ZH*&=47R1712MA2MDL0KXLOW9L8;= ,/*TL
M4UGFZ3N<*LLLD646JF(),,9EHJ2VY9B-+ YQ2C1H,"I;GZRO++-N,5:OOIQ,
MSF@.IJZF 8S&@UYK>BQ^>B#S-L%73YXX;>:)QA L]TEZ$2WHJ'-FGAK!G,R7
MGB>[A$'+X;);L>=NGDESPJ-_-*+<[5URUK"RZ+58=#%_<TQ1!$M#28-7:@M2
M@18A> )<Z^086.I05]-;:EFA5X^>11]@Y_#)4TZ@/J"%X!-'6Y G[XJ>!MDZ
M%D"&H!K*83/*N5IIJY2SBI0SK[AQ92%)1H0&1V0,E 29,O%9E"JG,GFA2B0#
M758D0Z6<2CD+E./!RBB]R5%%J;+SH&0V$=DGL1B5K5K.(Z:<A>"I@.L()(%$
M4RHHYQA)2"H1D8$K%K..UC5:SF)^LTHYE7*6I>4XF9C2G@;'9%+.I9"T5XD*
M"S085[6<QTPY<UJ.L=%8M*)(Y,4)SHTC+EM&E+6XUL1( T^%<N2M:QX^%<I9
MAP"HU^4@)@Q'TXKP)6/*#Q\&7!='_BJ$/KV;YL%Y/DF#,Q/CBYD4:T3IS3GS
M[8(S2GKNN"]9U&(R1-*22BEF1;S.+( Q/CC8V)9;E]2\65.7?MTX?)I!4)5O
M[H1OYBO6,NYH]DVF<^0;I36QT@I4U"3U,6?'I2Q;B/;6GJC*-Y5O5CD<JO+-
M7?#-O!N*%_O?1DX$3P'U&S3T76"2&&\]0!)4Z"9DP=[ZQ$SEF\HWJQP85?GF
M3OAFP0?EE!)H2GE4<X@$&XE-S!'4;)RU%*UH%C:VV9;2E6\N*_#49(/]UX74
MRY>5?3J7+W;Z:,/QW2?]89.2_MD "@H^P;>,KO_G8@K@:3Y8^NT6'X;][GAT
M]2T+V;T>*$DP8521B^ESS_\\''S+#W< ) S ?R0^8WN?^>YG_W6X\:^+^78[
M/7)^#!^N^_Q:W7_5A4^^%Z'U_\!W1X>;K=>].)>Y>P5;W>Z/\&&C?NL%4G4Y
M1=O4=?FET\.N='RW]><(/SC&%@Y;_YA.=4C_O$S*<UB8T+0'QA,#XWUT,L;L
M(7('*NGHM%%43-:CYJ'/2T4FSJ7S47,A#)49P$LNO;'<&*.<]+!Q5^G/9TO9
MMQ3H;1A-UZH7_>&H)CC?*4<3@P>TDAUQGG,B#<7UQ'M!J/%"2ZH2!_UH$YR7
MD\C]7C/5^[G5@U+?;M#I)YQELS3F$U=].:;<':=)QO-1<^<Y[ R_(08?TVGJ
M3%Z5Y?QI)1G7<LMROM:)NQ];6Z_WU&MF.[Y&VM+'EIGT.BE=GW#WEYSM][%U
MGS[A,Q/?30%_>=+S&_9[::F.?SC2:'T;N5X!%*B?W\8]\=2JS5_6Q=7VO-R@
MZ-DMCR1=I_K9F0L2Y]6C+V$V*PS??OE7![^';?RKV\9W[!^]/]S%=NV^W"G_
MI^^/]C^__W7_=,'Q>/R*MM^]1M.P^_']N[=\!]O5/GZ%[3R0.Z?E_W\<MX]^
M_OC^J'UI-AN=M&=!6\+1=B121R!! 2<:+?NHC.:!YHUMM2+;JLO<::@4]$0I
MZ)9'E"H%W34%S:>ZX2)D"9I((P*165)BA0 B<@Q6:9O!EE0WBQ4Y*P55"EI-
M"G)1\JP$I4($:9*UW GC@F0,<"2L;BB(SBB(5@JZ9PJ:#_<PUC)M+1!(P1/I
M="*..E2*'(= 4]8VIHUM>>LS1TNDH*?E[OB[%!%GJ2'6,BO$/U;+ #L[DG3U
M8:1*1-<AHL4D#TP;#X8;DEFT1,:B"_GL"6BM%!- 74G(A<);8*)_WO,II'KV
M\$[@>P_&2X7O\N [9\JPQ*2R)A!-M212"DJ\Y8P$#<8F",(I@?"]Q):I\'T2
M\+T'Q;_"=VGPG3<#6**H*CE*%,,?,GI- E!%= :5+/(RS5#@NYAAZ4'@NPZ[
M2'] [!_T\(;4PJ$>^T&)>NOVAS]F CS!P/$[L0"&V%_\ZQJ!Y,=]'*/3::Z"
M7WVG-_P/"@<J%]V,BQ9/V')E(@M)D,R#(-(G12SCEGBO<M+*!# 9N6A%XL'K
M$9 5W<FH2+Y_),\9!<HS%U#Q)R;3IF9N(%X(31PPKPP'IH/9V%Z5D_(5R2NZ
M(5"1?.](GK</%*I29:N V%!2L'*%2$Z)$<E2,CRXQ))$)*_23N7?V BSL'1L
M+'P?_(_YF^NP5W+AI?B02#I?R&$G)>@]JT#_+M#C:.?%!.B[>Q]I^W3_ ]?:
M4\8$\9)9(G/B) CJB$E2&)FMT$[7(5_JD$O#.%BOB/'"HY;$(BD[K\0H_&F"
MXJPY7E:'?'E#'I7EFB5'M"Z'CIW&^8ZV!A$^EGHP4>M2E^%/&(VZS8FIBWZ7
M2W^MAT=X19TQWWQE;1@5O:^H?2_'L-?_)L,AJUK@36$S'RS"<T!]/A'/@1+D
M+4U0]7-$207",L=%+M5T5R0-?]WH>>R>F0KKNX'UG)M&6"I-H)* -:CS42D1
MX,R3A+(+RGOJ2XHQ?FN':X7UZL+Z/MTT%=9W NN%A/)2>W#9DI(E$DTY)TE0
M C5=9K0.(E,E&<+ZUGF\ZK[NC4#9OCI_PTW=9-<Z?OF$0^BOW__5YNE[CG*]
M-E'C5/U].E//99RIQ'PC8CY8,*,H$RH:XPD+W!")IA,)PJ/2E9%(K7$EZ'YC
M>W%7[/JA-C?%QXJ?!JH\MWX\=Y]V9N6YY?#<?.IJ)[TV*A"=52+%OB"60R32
M,PD (L9@-[;EH@):B:X2W=H0W7U:WI7HED)T\Y:V8SD(%S()EJ)"9YDC-H,@
M(7.TP),$%]7&]JV"I^^+Z*86^*PALUDM)PG_'C3#D, NI?ZXY!Q<X3Q(3ZN5
M3\LA<WEJL=W1(0QNEUCLNM& ]1GK$9+T)PP^=2+<+ '8=?<95JZWUU?S+NOB
M:FMR-U#D;EFM]SHGX*;S:J*TY?[@V)?<U%]&SW+G"R1R"H-^5>9NI,R]:A2Y
MB8<N2NR[^L"-#CFIDAA,*2*=$\0:[@E(R9R(7"03-[;_[_]G480_K=#FR9(T
MBLI/3Y2?;EG:]\;\5'GHACRT<Y&'4@G]S+QLV"I-9 Z.! J,* /&R9B$BW)C
M>S$?1F6@RD"KR4!*(>7@LIDRJDK)@>>).6J3RT+99.D2<@14!KH- [V]R$ !
M++<I!L)3 "(5M\19Q4DN>5,E8YHGNEH,]+3\%3^07KH>/+Q'<ZQF(OQQMOFZ
M8'<9YI1+I;ZM $]D DDLE92 X^"S%XDZMK&]2ID(ZV'AQV>B5,S>"K-S-DI4
MWO)L5*D1BQJ"B)IX'0J$37;&"&Z%NRR4J6+VR6#V'I3ZBME;879.J]?4(#B3
M(P&T+R?X [&6XC^UR0 :#(VF9-I<(="NPYY13?E[\]B9>]#Q:]+!93'1Z8+&
M'W#!P%5#$9Y*SE]#.?'&,R*CR=)'";A\7'KPK.8,?1+PO0=UO\)WB?"=4_Y%
M3%$[--B=R*A(6!F(<XAAGKDUF@O7G&.H\'VJ\+T'S;_"=XGPG;,#4D[>*VN(
M<DD0J44F-AA+2O2#L-9K;]2EV?EJRM\[ M_Y_'6E1O?)H-,?M(:S8+)+SX@^
M<4?$/5L#/YAJ\/<BJ'-;CR\:456*NAE%L04#08./F2M'J NV; D($JC$:9V%
M9T*D0#W;V+Y-38'J65QA0"_!/JB ?EA SYD,F4F-_Z&FX2D"6@0T'E+DQ>+W
M7#'P+/D*Z"<+Z"58#!70#POH.2."Z\@A,DHB2$6D5)%XSS6A3#BT+2B-)27<
MXJ;]@P!Z';81EI%>YN)YL4EW+CLRMK;'E9<_0$^'X^_3"JOGF9?!ZGS![HHL
MJ10]D&0<(Y)R1VP,CA@M%4AFN7 E(Z"XO6MH>1!:\:#U2J:53%?; JYDNB0R
MG;-YK7,\0 +"1"QI<"PEWBA+2EE,FHV@)MM+:V=4,JUD6LGT<7H?*IDNB4SG
M_ UH2O#, [*GU91((5$SY856L\R>@LC2 I+I$JJ$/SR9-NZ*?XT\OA1_I\ZG
M[5FOVN-CG%QQ^]_XX:PCQWYPT.G-VNMFC-;I)>@A6FQ#L/<,45X@^G(\P)%H
MC0ZA]17\8-@";%)JO80(QP$&DZA2P39;Q1QL?K*6[Z7R!]UL?896IQ?'@P'>
M,NJ/?+<UO%B6 QO:SZW_N0$/X-N%C=E) 4$FJBV-VB:I)!69BL!K98H;\\+[
M_Q[2>/Q7S[]SX]VC]N'^WB]'.^_>RO91/-T_?8-XWY$[QSNG[:/?D#O>\/;>
M\R_M=W\@QK%=ISL?J-5:4A=)D"6#EBJI J4.1*ELO*/)*,,NK2RQ>2/):QN5
M1O/56.6D8M2K' .G1B>OLV>Q%B^X9\G'#UES7(Z-(Q%RB?ST,"D]I3U(DQE$
M'M2E060-1]Q$^ *4<%&4A=U*EZ(S ,9$G8%Q@.AKBOM[%?[NRS<? J[E7$=#
MHN3ER)\O(4B!$H-+0DPREO-_EZ:HWVP-8%A"PSJ?H/MUL^6'K>[X^(0,Q\>M
M$_^U&=X6?,&5O"PU9>D9GDO)U$R=SOECM/CC^*3?:V[#U:1WJ1.]?"_W!ZV(
MBS:*M'RQ/QZT3E#>PZV9>K'4%=9>:X&=.Y?1* H7](0E+'^3"0_=3\_^C(>0
MQEW8S<^'.-PG11[#MT-(KWLO?#>.NWZ$R_W>(5RN N\5=68/&_-SMQ\_KMV\
M/Z!X[0/C/M,4-$G(=:B[\D <=9Q0QBAW5B2;Y48+D!U.<-1'@W$I '>EKJ=7
M1]=#L;<F7X!$/&JW_@#*,9;9/&F-<:(@]%KQVU1IX/E]Q/EN=P*SEA^4Y^&'
MW6[_\_#9Q4G_/6VXI*\L4^],[Y]H[S@P77\RA&>S/WZ:E='L])KN-3?]=/%Q
M_S][[][<YFVT#W\5CM\^[[0S@8K#XN0\XYDTCONX4\E-8S=U_\GL @N;MB2J
ME!3'_O2_!27Y0,F.%3$R)6*2D27>Y$W@!JYK#]B#/SBGN2^>_\GEKU]-Z]'S
M;I]NZ9-DNM,CQ]-O/KV\M;BT9(V<7 NPE:S]Z&6]93YZ[5.WS5LQN-]TUT]?
M\P ;/];/N^NO'$!?HN;B)XZD"W?)=CU>FF4!=7&%S2Y&/J.NYBV>OMGLZ>L/
MIG^[PC NGO0_>/^PVR-7*BM[OF[OQQU-:U1<^#8-<A/2#NY/#XM,X6@RQR/>
ML/R"C_H/]H^[<W*US9?@,Z(6/[2IWK.H+C:GSM;NG[)T;]T)RMY0N^KD>&'V
M9OMQW=M^_.SU]E\?[#VZ_YW>?O%$/]W;>2XVE=^Y_Q!DK'O;>SN[.\O'"R^V
M?]FQ3W]Y=/_AJZ<_/H7MQ]^_[N-[:K][_?3-2[G/\Q>/_BK?:Y_H?[]Y>*XS
M$^K2; Q-!4VD 'M3)C&0%:&U)=CH8^MQ+UMQ38HC? G$_,_O6B%]L,R56Q\-
MEEDWEEGJBY1LH,;&*!=C5I *J*QM4C%P<%2#;N ZRUP0$C)89K#,BECFBGV'
M!LNL&<LL-R7RR;(UO8)] 51 )?6PLZ8R6DHQ^T*.[]QS6^;*]5MO"\O<+K_$
MQ3/NV.H'5_V\B_</3U+-I_MESGCXVVR_FUOKXJ;;?GTM'[5OWUO)AZ<+.=CS
M<NRY?<X2Y%AU,#ZKEDB+)5B<H@RDC&N>$:)QH73VU%>V!%=3(^/+L^>HK[,)
MEN#@G!5RSI)=Z!PR::][($RO=D%9(6M45%A>]<67$ ;G#,[9-+MP<,[J.&?9
M2BPM5XRMFX5.K$0.)'I.=:H62YQBR1YQ<,Z5K,0;>"+XKA;QJ;GXKB9Q#\.Z
M2F'B37&OK9^Y>+:H?Y_M/WO,\[VSFHI+]10'E7X6E7Y_SF3L94^+ST5Y"[4[
MW)KJ4E/ID*EF;W760J5^2]OA<!MN_<TQ&0?OK)AWELS&;%W6)@KOL!>S,?BB
MR >CA'1D X7&V*NHAZTX>&?PS@:9C8-W5LL[RZ:CBY%U@:2(75!0=50Y "K7
M9"]P$W4HNCOWXI8[7R9H0WEG$PX8WW6G7-2<Z_D]OSFL=%-<;NMG*_YXFL/U
MS4D*U]L&7&=K.D(T+L^@3\Y9C)&K#9&M<IY9@8T+YUM5UE!VS#I']-WYEJZL
MN=T6Y]MP^&^"Q3C8YW=AG^7C1HBEB.!1R5E_&NQ.8%7%9)I04XH!!OL,]MDT
MNW&PS^_!/LO6(^:"Q;JD*HC& [77"_ 9%?N8BBB[);HPV.<"Z_%L$&?OA)/:
M!BMV:8U[K.8>M\ODOSC7^='1<YZO)--Y7?*$U_H>FQ" ,%*2/U=_NF*Y_9'&
MLU9ZTK/S/B*LFHUQ2C1BT9-"T;U&HI.M%S!%9W2LO<GJ%IPODK:A7O9QNO<[
M^(BN5H=^L,RZL<R2+\C49'1IK++K]5=U_PU+5%DL-!=-Y !PYY[9RH-E!LO\
M;BQSQ0+M@V76C&66?3XV^M3+_:KF:E+@:_?YH%%%I$LJJ5C7%H4/\H@8N)7N
M@Y&2?-MMOY&JLRKV?'G>$HS:.DI>I<)60=1!M#42'<VA:.#9V51@I.J,\[I-
MLP0'YZR0<Y;L0BC1:@Y5M6R#V(40%040W8U+(Q$T4%D/SAF<LVEVX>"<U7'.
MLI780C2:=%8A&%)B&0KGM 1*QX:5,#I=\N"<D9(\4I)OO+DX4G162:7?O3K7
MR)M+@J"S5I1Z3G(Q32%DKX*S#;VV:$KKN8$P/&[#K[]!-N,@GE43SU+3:X2J
M9:V+<C$X(1Y=%.I%M*=#S11:[=5'PU88E=0'\6R0X3B(9]7$L]0@VI860RY5
M)<A6@0^L2/ND2DNED+$ D'M6\M6MQ]M"/)MPQCBRDF^#N3@R<WX'"OWEG-$8
M- ?,/O3*\5X!HU/$Y!5%GS)%ZTMWP)DM?[XI\X8ZX(;3?Q.,QD$_OP_]+)F.
MGIQ)O2\R.NY-P3FKG*(3T]'&DL$3-7/GGMY*<=#/H)_-,1T'_?P^]+-D0#KR
M[#6A<J9$48&$>7I/+N5[QQPA'XZ].Y?92E?NFW-;Z&=A0/YYT2C]WFDG]M,G
MLW.\)U]0/MV9?9UZUR]:U7.=/&?</7I>>K?Y11/ZHSGOGQP]GK:P/YI-]A@/
MC^4-O7T]GYU.+MX]:Y.#.:MM >;B%G\\>CX[Y,FKY[-%__K]F=BAQW.YY='N
MZPG+<DY[8_K>Z/[M1^@TF_9/D]DBN_;L[PG*[8_GD_M<N+/6R99SYJM)M\'.
MQK0GMY[4?E#Z"@\GER.^XH"-#=HXJD"UYEJH&!953(/1%7YZ^!NMO?];/--O
M97:=S1[W)]HIZYN31[XC W@P[>SUE'%^\WGL/_]^KLO>O_;QQWS\Z,7.\Z>/
M'[S8_O$)[+PH;YZ^^=YLO]D&X;(W.R_^]GSG_O=VY_$WO^S\^,^7_W[S_9N=
M^T]_LH"I1" %.;("(1^5<Z@*,R00">10BQ&6+O)C_<]B*\DJN:\FKZ9'SR<X
M>3;'>HR[?<'ZQN_;=TUVQ9/=(WGS$7]D=YC-W@F/[F__%"AS:LZI)*J(@HBH
MD$-1#@K++B%K&>_<@RU_T4Z@UPM^>BV8.EOQ4U+^<'UM(DHZ I3FP1LD N<H
MHD6V)%]PH;/GU]:V(_DCZ_I/QO*<#\]6_^WKF[C&CY_)&K>4?"#E8^SG]*VI
M!*8ON<;(J4!!OG//:N>71>O69+5R2_[]J.!:7Z%EL+D2/>GD'9@6,R(;]@28
MC<[,0VC]WMO8/'K\]*>%OR9#4"W4H,!P+X%/6?5J/N!;,Z$?OH2+J6KU0NMW
MVQ5#:'UB)UBY]I,N4"M7I]!$KX!LZ8%').I+#(VRJYK:E856+Q*FL_<^^@QB
ME^<L2UTIYII=\M4-H?6[K?'._6<_60,<D;2JZ+("UT1>E6!5-C8QU93(U$\(
M+1$L?'CR).L'@JJ+DL-C>B&2J6.^/,?]9SR9[B\V13L^$EFQ]=8 79B;-\&\
M_,>[*-6>W;A[7$5L3V3D/#^<MJD\@[WI+UT$\W^/IT>O)X<LXG9Z-.7#K^3]
M/\NC6@C(3HKR%*:_] _@47_+^^^=H#S&$^E[]/I _I8;OONT7"[SV:'\(X^Z
M/U2Y*I\]FLU//KC+/_/NXC,%#Z9'N#M]<Y*.V=4&_&6Z)_.=[,[VGZDCGN^=
MA>!VXD:Q>(_[(SZYQR) =WKX<NM$U'<5Y=6I^TKAB?]J<B0KQ4<3W-V=E9-O
MZ3?J ?7]]U/=X?W@WLGTLFI!0PTN>P@UBV9;4D:?>EE+&T*).?J+!8#]=9(X
M]=_)H!XO9O'-VTG\@^=%'H-,<).%P)-7._>_$8+0-C"!TM";J(:"*LNS5YIB
M@F)J#=V&=>?]^/]S$0@NM_2RG,4VR%Z+=>HYHYA*-AO,->;<6AM+__LM_8N'
M/W&CIEVN2GLK!DV*5I$5=<!ZGX#)0.@&C4\7Z8$?X[:O%AQUN6W@?''&9I\;
M&' UY)A=1F.M)VR :6R#WVT;=(.@-FO$=!7MH.;0*YR#PEJU,E7'1-:S;[TG
MU@6[0"2.2(9/B+)3T?+=,E&(())5G(L ?T_,GHK6.MOK*D?Y8%.)U!'1M+\L
M1/=$T1#CHQWOU\/3[Y5M*5K(@IKD7:<#>/!147Q^($?SA:G[X:8NL_G!;)'5
M0K/^7?W+%P)/]2.#Q7>^D]]3,3SE)=&0SS[6SX\6G^G:T9.M'[8FSV8B8??[
M^T^'^.CC^L#9R*;[,B[<+[R 3U\&D;4?Z%A]B?JUZ?[QXDL_T+I.-9UH114Z
MF!U.^QONSKD?9_W,7[^:UJ/G9Z=P[WWJ5$G3[SZ"=#C;/3[Z^$?>.Q;I(!.\
M?QEM3AD=U-(#>N_G\[=E6@^$!Q3)NK]4V&2\=W'W%;X^O//G#[5645G??X9?
M;OKVLZ;_G6AYB]UR8BE]-7FX7SZNDZ_+J'=FW;P09OE6,#/;G=:%Z?%@NB]3
MF0K6?SB2%TYP\<?3K<[U3Q>M\A(63LC=6L@H!I!S44-C1A"=(R8;8[=/1=Y-
MWM[TFZ/>]H.<#3V+NG&%A%[^2\$8*X:S873VSJ<-FR^T\RL?RD+*<SL\$'G9
M^I&D,%Q7W7GO8'?VFOD#W;U+[5[:17;XLUWY5.?31:D7,0_DSW<<>9'EL^"U
MPO,C%-X]P/G1OAA+SZ<'0E<GA]]G)'SSS,%N$KTWH\/)\]ENG?PLSV)V?/B.
MJ^5I\7SW=0]8/36"#H_+<_E=C"_9L?((NN#HC^E#5I_,IKN+EY_)6_OCQOTN
MLB9_E:69]Q7[:B$O+GRF;P\IYUR9]_JY[HE0ZDYC$1*'36[17YSMR[HMG'7]
M7K*Y#[L!**/N?SX[^::SK]B:/-GO:[_P-<MN.!WI0D:<^*6[N+]X/$<S,47E
M37AP,)_]LO 8R!?_X:.:X/%A70XFJP" 38< +):'S:FZAJDFBMHSUHO50!66
M]< '.)W_"W>/^>&[I_V=8+IOUL?/\>@LB(-W1"/LZ[5XLVB$/SR7IW?V!+Y=
M/("33[_5$</FJ8CZT>-B=GJ0QYOM5SO?_,087 QB+W"SW N>>I5S-JI6"IRK
M1NSNX_,%X1>[\S+;H6E?@W"M&"+"O"Z3 S%)G,V1BB./B^UP+J1P;(??=3L\
M%8OAFY]TBUQ,0H48Q&PH.8D:[+Q*+4<7BDX<>D/R"_; T<?.E_KNZ.OYE;!-
M%UI=)]U]?0-=B-\L1,+%LUSP^;R[V1;D/>E">B&=A9%E[W>]Z\Q8.&<"G(B"
M)<?;J;@1N?[!8=[IZUN3G=D'OKG%][YO)BVIB O6G_5'-BLO;^"S_\?%C^>=
MNW7IPIS%0.O23O9E$YH0T2[0/SE&%4)X-IO+EXLAAUT+.CZ8G2S"6^?IB^/Z
M;.'OE=O-1#GM#_6MI)WN'QP?77B@*]_S[LNVA@'W20,N#@-N8PVXRU+.A0;?
MKQIP2P:?UXZAM>A2*A"-IRH6(Y&'1(FL#:M^JNFS'NJ'%M0GCEO[>6XJ+8-C
M@JI#TB6D"AZT:]J1_8SCUA_*<Z['N_RHO?.7/FKO^U+%KG@LW_@7N?IRXU2@
M9W*?9S^Q-2[9E%5C[DE82?@'(ZFB33 I%TLE+&\M46_D=6N]*PDBZH1<??0M
M-MM<3'1'3,6"!QW+\V/^@C;O._&T4$1Z6-!'-(^/BE9Z??+;F2!]_>[L\DPT
M?E09_&K"OW2/9S>H"QX^_^!L=;HO2@IWT<W3G]^9O7N] O3AI![W$)0_M_EL
M;T+SV4LQ4Q<:Y?'N(I]45!Z<[//I*/O<+F.1 $9?*0;YGR&F@.A:$?,44P8M
MMLFO&:B\^_/2(<5;V^3^,3^0,?_E9,B;;&"8[<=/?[(4JV[-*5>T5T+#0>56
MDZI!>^NII)R:&!CG<QM/CI_>;9]WP0ME%Z=[AQ-9]J/=4_$C,HJZ>V5:)XL-
M<^%&ECWRQ^O>)-\NQOK#NZ$^GOV%_R'C['MD<5!PNG^6*A)LX':QV_>W?\(B
MCQHK*WGV18&#K%+T8I223X'ER6O?.R.</\/^TU<+91\/)VTFLNZ5J"2'S).N
MPDSB5Y/___]+(BN_[BB=+&#ZU>(5\_5).$6M"WT:.Z/)"WLG6L><G^%\L?FZ
M&5 [WA=OZSOI??[[T]TS<;[(RGBGKHM%,N_I)[MX<,AWSW[YNDX/Q99[?7>Z
MOR#MQ8>^_E O\@?G4E 6:M+)Y7?Z[I8^T7E/"PJ<?O/IY:W%I:7$F)-K/FS)
MCO[H9;UE/GKM4[=-6RE^_.JG[OKI:QY@C/4&C=5^UEU_I13&)5JZ?:(XQHD%
M=3WY7,L6P,4-_/Z^H(Z'GY%3>LN?P,8_@A-E^>%&/XC'_;3I%E?(N7C69^;2
MY,Q2NDJ&^:FB<30[N-LS6A>NFLG9'-:EN>88Y)<;Y.VJ6'PQHLY.#$[MJ<F)
M077W=RWZ-^ZQ/O>X75+C(U6YER-V?MOVO@EME\<]?A<*/ZD=8[>L7_.MO@BM
M?;?1KU(F\L*".6LWX3]<:8KK7<#D$DY7'1U#]-;F"!!\Q"(OY(H^:TZN?22#
MX'RLT*=2"-Z%#_TX/7H^?7?EV],3CF\69Q WWAE[6MSGU<Z+IZ]V[/?PU':?
M_#=Z^\5#N<^#Z=,73][L[.U,MU\\V-MY4?S.Z^7B/M_8G1??N/_<?_[B/R^>
M_"+S>;W=G;H__FTJWVN?VH>OMW]\:G?>O'3_?O/]N19JA$G;E*QB8U#UDTM%
ME.5/HM*<":4$?><>I#7I<KM*=6;PTRWE)Z!BL!G*R7N(UJ/\EH61F@Y.H_Y(
MDOOOQ$\G1Q4RJE^.[B[RN-0;GL\&;UV6MY;:L-5F:_#-JNR#[1$!664,7GEH
MM=CD6^EGEOT R=BO!W<-[KHAW.6<!DH5HC$)L+A,#"9[@SYYQ]H-[KIYW+7<
MSDV'T@*5H,B8J$!4+95;J\H$LAI:J+KYP5V#N]9B;I?@KN2CU[%42XO@STRY
ML6M4/$47M0_#+EQCCEK6KY*S58Q#A;'7K7*NJ<2V*BJB5+>"7G2L=;,+5^1>
MOC'^MP?GTO1']XZ/<A,6%LV*A)L(-'GT)A1K8W&,6N-'ZMX,;OKRW/3DG,\J
M:S'Q/!4A(^N[SXH50@!E3 G@/8-UO1XUG"^B\47*48^"]+\'H(,6R60)1;%
MJ"WD#+8 B-D4*-J/53,:AM): _WU,M!C"Q:L,E18@4V@"&+KU6"=,9HJ4UB9
MH33 OKY@KZ!]3$BF) (#*0&ZW%S1%=DF:P?8;Q[8E[TB[ PAD%>:4<#NR*@4
MY<_BT+M"0;N$ ^P; ':G2XE@4FGR3_.$)B*!"[E% QGB4-77&-1+$MS6JFU.
M5GF*1D%FHY"AE^NO)AKTW*"LFZJ^:6$\V^^5]?M-#H1;V#OY/"OU+&XK&]4G
M'WK=5M+$$&.-B4S">+T',X.5+L%*3\\Y$(J/M44BI74058/8JTPA*8N6R?5^
M(M7=N>?6R;<Y>J&O&,]$ 2F#I2IFI3$A%=D2&$DL"Y,B_FKF\# IUA#G2]H'
ME6QU3$6)'2$X;Q94ZAVCM$.;BY@5QIA;?- ZP/ZNV"%F@D;H(@/$1E!RT+H$
M"R75H@?8;Q[8E_T':5%"*!;E*$0Q-711% HI-B$XYVU!&P?8-P'LKB53*GE?
M&#BXA,%:,*PU4]/U>L,_!Z@O!^HE">[!1&,IJ9I*$DT=H\)*+ *]^EI:]M'R
MFFGJFY#D]M$*_R/9;5/NL6E>LK^^;2%QU7B;C1#"+=7HJ%9'!D#;F@"*+;KX
M'#*$<+TY8D/C7H%P?G;.C08A1XYD%.K:5&\GIA!<M[8S^.9M*BT-C7L#P)Z;
M311"LZ$UR%ET-='/''J3K.P%PJ%QKS&HSVG<FF+!I"@[5&!U4,FAF-$-&FF+
MS3D!M87SY?T&H&\-H"%:P)K9)M: #;/F "%B$F-,C.CK/8(?TGLE0%_VEUE9
M1]U -C:@ )W1J!PT*,+J2E_ZZ(=S?!/ 'FS+5(I)M='".1ZC)V=U$IGNG?GL
M3D!#>G\!4"])[\@]XSUFE5LP(KU[@G2Q1GD3&@6;0L.X;M)[T])VOGW;W7(D
M[OPZ.XG"F6K 5+%8H&C)>!\+ZYB=+R:/8@XWCK5>GH_'81^AY*QT\D$!4E 9
M(JHDNZ=FXNQ6>$X_0G_7&.PN^J@M5%L"1%_(Y)BKBU&GD#B,#.)U!O62*I**
M\2T*17(Q6@$UK7+%J()VQ5BL: J+*A+7*?1W 'K5B3L%LH9L:@P(R5/*NAGP
M";"G<[CKM2V&]%X)T)<=":*&%5E3H]#I)M+;. &Z_$9%IQ);9E-'EMXF@-W9
MZEVT"4WU4"-EL3IK=1H3U8K77+MH@/IRH%Z6WCG8FH4BDZZH0,>BL-J@&$&W
MEA(QAW63WIL6DK#8]ZI/J_>>'T$)OUZXMKAL12>%X!HXE\EF@QC!E*:)[?6:
M%T,;60%Q??>JD]:)/Z& O-?_9#,D#(Y5*:*30 E%4<N@F$KDC$[TDW&NL0EH
MMS9KI&J\,Q[ $?7 \%1RR:P#^^L-^A^HOB2JMS]$=0W1%>.S$OB*D1&B52@
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MZIN0Y/:@BZV)2+$>=S"2W3;Q'IOF)?OK3$:SOZA9=L5XFXT0P@DM."O476P
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M@F^(2*%83?'.O7R^A>0 ].T!M$-OHH]14X)"0$C9VTRN<"0NXRC@1@+]R8=
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M9=V:Z4U9J5#TH\;FS6.M\]VCC8YD=6!58N\>'7U0J(-5F)#8%]%$>'6-#$<
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M]CFK-8;_Q]Z;-C>5)&V@?T7A>.\;/1%.NO8%)AQ! ]TO<\<&&O?TP)>.6K'
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MD2N:LP]"!V9-L"0JJA)12ONFTC*UU;1?D6DO9BA9(@(1WB9P7J%I;Z,&'V6
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M2? \-(7_\77.3E%5[(:%"X17NJ&]0KQ"NZ$*\8\(\939P)T+P@L!3"H)PN<
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M0G?VF-VU7RG$N^1 STT,]]Y\Q%@Z%U(1HUV(,64,A9R9X3R#I-Z!* Z11<T
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MD_XI-B,E*WA,&FQ@&83/# PO+1,#1R3(T>N,YHS:)5)4Z=]<Z6\5F7%-^JN
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MY\$GM"D(1:-"*.6]L-L:65)!XGZC+:HMT2:DF*93+,ZAM1X,.I4@/$O@M19
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M!JS+$5RD.EE#LN!D:;DL5<K;*^6+L@I56=^_-$\S!BP3KP@'?(&R'$D :VP
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M?WAP=/#T W]S^$Z\0%6/YSO?__-?'_[[Z8-\\>HO;17QSE@@ 7^(E&@IP2E
M.$6HCXQ(0W?VC)K-C.@,C]!\Z#C?1WU75%&Q$RZ5(DKETQ32B4^#L=;F=+=3
M9KYH1%1LXY:ZO<^F5,>[(7X'%UF);1FKNV+*=#^B7AVKP'\YE-7!Q?ATEV=#
M*/CZ=1YT]J\JV>N66K'-AF,+*Z9A&'3]V*(Z<A\;$ZI3PK08>30LKE=GY+K'
MN\T[]%'G_*@;CE"!H_P5=3LJ3WW1G/%=ZJ5!<\[F$<Z[HZ-NKS,Z1Q\N=4Y0
M6(Z&1:K**)TT-XQ#$5+WXUBC#SYV$8R;!QTU0MG_B$(U>-!Y'$*_L>R.+W;'
M7W;O4<6/+BY/5L5TL\7TV:?]]_N+R.D55!];FHT&G5B4GVU27*MEA/&#$V6
M"X ^F#(AQZ<^.#M!S1.6L+2F%E- N_KL.+W(3]S9, U?9#1*T/ :)I3QYO?S
MWOR%G0_Q%G\Y[H</6[=RRGE?_46UU9ZH"$8K7"]*,G#:X/+Q#%<1-5IJN8-
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M,6;_?_;>O:FMY6@?_2H4Y_V=REO%.'/IN>V<HLH[8((K$F%O82+]0\W52$C
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M"'(R];KTH*E_9LVE.O7W37UG=4=3R107CF0E- 9:61*'X14&6H%R16,,DI=
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M9)ZO\>851"!E'VSI/<@%7DP8X(99R[D/@C'AJA-X#4Y@4CLD&.>R!$>,DH$
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M=,C-@6XMB8L^H*>..B/7,N#"XK*\9SO^*<3U361B'@>SFHGY)=ST$DB;L*-
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MXEZR>K'%6BO#4EE_T1Y\'+17?A^5S&ION[U7[JDUVH3V=ANO]['9R$>[RT$
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M/%&Z9$0Q8B@";9%(I[VW+ONHW;Q!LV9#'T@W'><Q:G2*5BF@@9L23PAO10P
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MA1>.NY](!>\VGVW^2>^UL)[?UG^_-$AP31%C1;14@M[[\[3N&C-.;*1J*\]
M*<-Z?Y"C*WD]??&/A=<ZK\91?P^_WNLG=WK]UR-[*<?:#O['RM'L=&?P9JQW
M%[?C":[Z<#*#F\TF@U>3,9TA[ P9_%R-X56P%(U:1;!_9#KX+K"Z-=^OH_+2
M6?"BMI1YR4!T.!,+GC@I=*D2+5,3YW'NF/5:@FZZ-Z,Z8.%2T!&I807/BEQD
MI6'P*R7AG\KQ1=*?R_H$N"2<F;*Q(ZJQ@07_P,37Z/>A7=T;C<A]'533@1R8
MJK9Z-I@H(+=L(N-KV65G8#]J"P(+U-E@=FH'TQ[,Q Y]\O/__/.G 0B_>G(%
M$@YN/S;T^;NYFE:FDO7UX%5M334;_"QU-0(98J>;V?#)[N"?=G!BQ[:6H]$U
M[.)T#GOAV^?FXZD%M0]<.B;>_0[KQ9+X1^)D^CO[\7O:P"[YT.[7X (V=#*%
M+1F\ N$O*Z(%[-_4#OQ1.)?7@U-Y:8%NH!E& V<E]N?!-7(V@ \F5]/!G$X,
M+,':<]I\_U.\8'P]F,$^X-\G\WHPN2!Z Y'^ 0N2\/C9VCM*NL7@=#("I;;V
MYO,+N _^<Z*]T0.L TL'RIWB4D_E^,0.X'7P/-63T<!>8L $N0,8<'(U/JFE
ML>%EPRV5A6?#)?"S2SN=X2D?^,MJ8-/QR>[@^?'-T7CPLU7U',^!V$%HA71G
M<&4]"YG!_[U/8S,.<TA3:4" \4RFRF4YBXLR<<+&MDS(9$WC)!8WFZR+?7AP
M*NW>.5@\S[\_81$*^J</AQ_,V5_'N+[1&:SS_'#_7Z=_[?_K[/"7W]*##_KC
MT2]_@8UY=MV#@HX//YU<'UP-<U4:886,TB11$4_2/))&%#BI1+N<2R[0PER7
M0AG(DY/:GF Q_$5=@=*Z *TE:8.1V^_7>?DPDG_3G9>/Q 2?#DZ&S*6BM#*/
ML!\,W(Q21*5@)C(\5WF>ZIB;! $8RW50*D&F!3R5?/ =RKF@&NB#!?VP<R])
M8$NGG-":,5OP1"<JM:I0)4N-TK'+TL^7!/_)[NLC<0@[O!JJV!@3@_N9,)L"
MFY1QI#*=1+E-RS(SC)4%Y5KC+RTH'L816T'Q^6P0'^P-<\U4RED<29';B&N=
M894RBZ043.3P?P+!+?CZ=ND%09&F2X("/E@2%&A"W4=8I")/@!]M(L"%*10L
MB!O-"Z%%5EB6/H+9L!46MW()CG\26<9+;D!..,,CSG4)PB+6D;:QBA-=\D)K
M%!;KQDL\JK!X&$=LA<4C" M@@[*(G8T+'2DI!.@,Y2*9L2*2-M<@*+@LI073
M<I>M <-9%!;9LK#(EH0%\ &Z;^CX34_MR($7=U(!P;S3/VU"*;N#AGB#X--U
M!@I&#"[D-75X3NUY%<GQ>.Z=8' CP>^3]11_U3DY)*#VYB=SN)U YK12GPZN
MX<(=8,-S>*!&Q[>YPOM$ZY;0B#ZZ8?=R]UX1R_I+@G_=MB:6-8OZ$UW8F<60
MQ@2\;$LKNZ@GVEHS)9_^:E*?X4^UO*BP*P*?% (%<&?P[:DMMO'R=^!V>C3'
M6/#.0('O/9[,!J/JO,(@UVSB(RH.J(:WA&5*_>]YY>.N\-O:PGN35PQ?34\G
M]<Q'$_"9BX6-;10&?C*OP1F?DJN-C("O2\2?Z#-<UW0NX8;P>IY+9+WPH]#S
M^0P#-N!X[UMM4?P-&-$S(<<;-[$R.Q@0.<>X1S6[]MM^'YUJTB).G&0BSAUW
M62:=AK^71ML,&\C2)A<?WY(]6A2AO[?[;K9>^8+H//CPFN.PBTRSW%H=%0RQ
M+9E*(N%L'H%[SHR1L2IR<,C665G W3.0=_Y@*3F2(5R%3'\_Y?DPTF^5Y^=S
M0'9X,DS36"J9Q%$N!7" R74D$'M:")8IX5CBD .2W7*MI;T^8OL\A=OAY-(+
M-]X3;@^(*DI3%#;#ND)9XJ1#I=*R<#(57&8(;QKXF<5\&U7\'-,O/?IM6.2E
M<@Y,/S ?-,JO/"I++/8$*2)-FN8FQXD>7]K^?QC)MR+L\YF @_V?)#9SA4HC
M6Z;@"VI@AS+1,F*:.UVD><X1="#;36\-%B39_<*&+G8)S\HL3\N2BX1+KF*9
M.YOE+&$R%]NC_BA4/KO&L;$L*Z7(923R4@*50665SB21$8@1DJJR+,#9S]>9
M*H]YU!]&\NU1_WPFN#HX&1:ZY+%V190ZPR+P[+-(,LNC,N4:,?Y,FI=XU-?E
MD9;B@LF]XWXF!OF29\PY&W-5*&64%DF")<-9D679]K0_CDQ'LY0GTEDD;RJ-
MB#B&@DN>Y&BE&M#R-B_*;(-C\IBG_6$DWY[VSS_M'P^NAH4M<\$YHM-QL.Z<
M0HAKGD6E1KC40O,B2S>.#UX,["4/C=Q-;:A"N6.0; ^8;M1$R([T;$+ADIM"
M9.$'O0C9?&I]L&EL9Y\7')O.X9%RNHV"/::C>""O!RQ_[ B88F"YEH5)F$JX
M$K9,,E6ZPN6Q%"J)@V$19RS?1L >0<9<'QV3!RFM=6F1JJ@H2E T.A618CDH
MFKPP>6)L:HODQ<MU$R$?+P+V,-)OM<SG<P _! [0EFEK2K IF8MX$K,(H; B
M*4J;EI:; M&)TPWIH_^D")A714GY>?$O5Z1&QU*"PY:"A5Z6,4MDYI),I*E*
MBB1P,T_*K9G\.;R+9G(A78)-C!&XHF7$XPR,(\LDV,I.FB0V1:S00OK2\:^'
MD7PKP#Z;"<X^'NX-3:I4F3$>%1+AU1.'574%R#/P7F1:@IF<T%CCV\WD!SC%
M*5"XA <G:69X)C,I\C).C$L, Q>-R^UI?QQ"7QUB""QAQM@R4@*=8BUU5#(I
M(I%(71:JY&D!A"Z^>+7+@TB^/>V?SP37!R=#$R=,XJ"GN'!@KEB<R*8+%PG!
M=:S @LSC%$][=FNT^^]SBLEC\BYQFV6[R2?N7>1MD:U;_/2M1T]DHA<+;C%V
MN 2:W4>GY*6VI15,QB;E.3,2Y)W"'M0\-UD<&]]*#/Y0MEZGV-$E29??80'G
MU)_SS>N2U^GA\<'0ED)RP>)(E<*"I9"P2*8JCW1NR\S9E/-4;% @?6>W4R&?
MY?8^C,Q;/?) !C@"!I L9K;(7608=F%@YKS4B8@2\!HR^*A4J49?=QT+])7'
M8ET?:P@?^J:7DN.Z2.,XB<LR3;F*\U(P9DV6,.=TXG(VW&_(''7TOCFFU1SK
M?3O5=45__?8(R@Z.?\N&4J>@]8LL$KDHP";,DZC,X ^5ED*4L<TRF;]XB7V(
M)(_]ON$)AE-K_PW*&I41]EPWG8,W6XJD?D-O(8J"1L;O#*B+56I=8[P %>)\
MC%%1*O?$ [F[VES_+)4<J.H!*WIJ[@$ADD3IA(O"94E:\%B#^<RX 9'LN( S
M(6V0?"DKMD[3?8]%=K3_VY!IGNC<J,AB(0C710**SIE(Z#1Q:0QB+B[^AF[#
MA]%YJ^$>1/DW5P?'>IC95"1.N:@H8Y"'RH(\9-9%>5'R1,96)1@1BW?Y[<5
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M?]*H8CSKP0=9D@<;G(Z?]][]Y"5#3W6#\>0OP_N0>O>>0G<%33'%RJE0D=4
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M:.:GX 43,32>3>E 32X:WP+_N=/&M6D6X=I/*,9%^%G3T\A7&?F5A7L0;6Q
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MSK['2]><S7]LZ[S7+':;)ACAS>M7AU?/!@X6#S24?M=F7^%X5/#]SJ [WIM
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MP4XOROK<>*Q5%#:QXXDMQ*DY N_/58I5/+#^,HPQ>&O/\E<*RAP^V>=XZ2D
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M4I/]YF2ZX]_*QQ]6G/12.&FQ7%0= SP&\Y2/ 2SWABGGD&0AQU3:''!"/>B
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M]_(F$(:2:EOPM68 76Y\VV)Q8#Y U.#K(/UM6-I>23G\65_A&)CV8!.PZ'C
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M?.'2N'>0&4E02Y$).6<'U!ZD#7<($YXRF\5@/=B\T\KO\S@Y*Z)\):*Y^^D
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M0Q#0?4*<.XZTT@9)G:@-C(9 @3 TG@[3FB_10VHO)-%4:6&X  51).\H5C*
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M,!&"S(<_55C1RX7[\SH6*[@_)MQ+/DCIG0M66 3\GM4X1E"._43>&DXH3P%
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MWE( V].]PX]X_\]MO//GN[/]K?VC_:W7G9U/,-KN'MYOSX(L@/&GCZ?;AWL
MMJ_;\)PC %J^O_6OHU;W_='VGQ\%@#, ^OON?\X_TM;6E\]8*\* R2).O <6
M2S&R7@7DHHF:VAAX,K-E>!*.5F@%G)DQ3@+63&!!06PR(E#LYFH%358?%+5Q
MQ5XXRW<H%O3SI\[,4G@,=$&]BIX;Q35\AQ%)C29:4Q-^5&NF1DZ W0GX3%6@
MQJ7V ^H.# ]*?JAP\!C@**NX %PG@VF;XVQ@F>+7]^6A\08M5P]ZV_ICE@RG
MSKXQ'6;WS.1H#*\5<X:E\KF@\VE_$."-+@0A_.)H](W8V?S,J8I2,89$5GU
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MX^G92FH8P9HVX5LGPZL@:P>C7AQ4;UP9.[_:SLGX3(_QYZ@RH1Y84!(JW#T
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M8WW)E1/O+;?>6HNYCM+ 3XR!<E-BQE"V1,F_D.OMR'5&N.<L$!*Q0=A:#4(
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M>S=CLH/8Z??>?RLQ<B5&[GZ0_]>!!73U9Z6HW"W3QRR\.),F6)*X%-0J31B
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MZ<G.@/]Q1NPS ,PH;S=^&< 9'?2(#E)RFGXZO-6 P71/6\_'!G]J[BA5@\&
M1J1#_19*:2-MA%_U4@@3%P@2*PO%9I*F+?D&6.7^>12PI3?=P7,O-?.V]/=P
M:U]] KOGV4'2V<AFHZG4@F7)<ZW&:8$%\<N3VV$5<9PX[<5![09XPR#'[Q3L
M"*V.+.1TX8$GXT 7O%0L",&XH8F08<S#B+DQ9C\.YW.&]BV:W?[&]J6WK_6_
MVROX8[<E3T&O:'3SDV+Z\KF<<SZU17H(X_CZP_6D&R611"*D+F*>%Z$XU">6
M212$<:AXH"VWH!*YD^>4"WOA8*5=$4CE>Y2!L>N&(O:QQR.<2$5I[!N&F,.=
M:AEB10QQ=?"#8HZC6$7:LXX1PTJA2&","%?,3:3G,A7I@^MHJEMVOOUBV+U7
M* 7]LC M4%'+$Z02OPJSX:X=[W$H1>,P!*"*O(A3AFD2)R[F4I)84A:+.'PJ
ME'JY?(?AG3\\(;FDB8LBKJLX <51F$B&?!SYON=1(K$ (,)+@*& >!XF >";
M9(QP/R:,4.91BN.8<O?)8.@%K_CQ_K<?B4]9&+D4*<_U$9.P]F$2<A2!SJ P
M#=PH]@!IHFDK_A"<Z2\)*G2?$8VR6)LY'7[ZPSON+FI=3=>$*UH5[KM*9F):
MQ8#:(DPM_5@0X7F2)YA)ET4"]&W89V%_Y2KQR6IA[$-A.-FM=0;#P[/%#]<7
M) HI10*,$]VWC:+82P1*5$)Q(E0@%$ <CBHNFZPHN3#*X5"%H7)!F)*$!9[/
M=7D;S.$O&89Q$*P6Y2Q#W,T0\/G7'R%GTI>N0F :P9['180BG7$<N; 5QHI0
M6#5@"+^"IS0!<WAG400TGM]2NRJ=?'?I5(MPFZ=\0)G("]V0,I]Y,0E(HK!+
MB< R"OC\\-,6/^O:_Y_E!V:DEH5FL=#Q_N&/, "-/(D#T-1#74C:\U$$ZBSR
MA:\DHTGHTGCG/:T$T60OR(4AA1,_9%(DOB<P& ."@V'/F>L2A@7Q(G=^2+&+
M//\B__S!,?,DV.;(C62(6)#$*-8!C@'F/A/2Q8%):JZ$X60PQ0-@XAG&+6J'
M/8_3AD:V3MNYYK<.C#N%8<E270.-.^TX[;B17O9\U[E)TT^35/!6!ZQ&J:Z5
MF8GV)V= L_2ZJ&#4?Y(Y&S5^M"&5KK!@X97]BD?]ZV$HH!;&M_,HE;VCK>LL
M;6>%/?N+-WHX/;A9]H\FC<)IG,G]!]V6B=6Y(]O-5 !!M'_PJINEN4P+^89I
MFY.RPM=;>N.KSGY_T&G+N&OSGD<U[_GE)WS+8T,M7<<#9IHXP!X9>S;D:"YC
M/(L(SNG$&N7*Z8'D)=>5K!%H!KUNY\9Q_C;3<;LPJ'<WJ>S4>SD90W>5;.T.
M;N%QWFYT.[-O&8J/%TJ7=5X3^R-,/31&H*&?]:PWH&M^J5"<*?X3\03&^Y8W
M;OAMOO-F5,Y!R(=IN+[ID[FF?]!0OPRO% ?TQ>'_3!3;E%'K8#0#$7N 1CH9
MPVA@_4X^QEXMO?>O^J$VKZ>M\IT0O5&1Y/<'"8U@XK6."N>7E_JX'X!$\+P^
MA*X+!FDO/?'_+LNH#Z=?8 K? =IW2Y0\3D[Z1S2[E_H4R^H^,T+FW!K82+!:
MH&.*!$6^KJHF?!=^<V-$9.!CUX\(U?T.:<6-)BLK:^$RY\*P;\'67!YS#\<G
MC7'4R(FL'-_?S.X_/0:KZGP']NQF^CV@2:B\8US191S,VD[0=!SF03D6^;';
MZ6:JQYA?"GWEV:0!/CGWX>.S;S_"1(E01 '"3+F@>3.&HD#J$'6=BJ!<&A!/
M<Y\W[7AL1!6\274(A2H@;2I?:L4+EI,N,P(YQ)L<@7QX=G!4V"11U=G[:[?V
MZ>#4.:PYN[5]9__P=/?3R<'!T4'M[-3Y?GCVE[.[MW?\K7:VJS\XKO7^/*Q]
M,C=\/*SMUO8.=S_K6_<^'Y]^.SF8-_1HDTP9,":R,ILJ5JKEM-J.J//6I3*:
MN0Z:27.NHUL*U<"$$A8:\\!^ 9#2L64&PTQDUW!,6))F36WA#'T$3QU$N\A^
M-N&TT*UY&8]M.N,YT2XPW3&@P?'G4\-!7TZ.]P[V@6U.%PA96],,#F!#ZO9#
MK@8)H%J9[&3M1F'U?LG:0DF]DL\OX$5OJ#S+=#R4-HMU9N%@SG<= %5@1Y6J
ML"[S[K7*?J4F8E,3Q$A+";V@IZ77@P8E($)-$^>KY6I81]#?[-53E3@'OY7H
M&L/V.$E R\N* &/SW4!O+[^K]$QWE22%.=P:V-1E6*BYOQ].UQO&0 "--M!?
MS>O^:NKY2P4B6Z2]G'0;RL&4(^R]4J][KSCX7>"&LRLZ5>>#"93K7IM0.5!*
M!L2L/'2&>G1E[HUYY+QCSX9H8O(S@6U ,0)%HP@WAL$W]1:IM9:LZ.G>3V1P
M"C->7V5\*Z]&UTD,FU+#IL3K@58'-\(^7 YTD#=41-7F0\PS2L!#6*TR"*\R
M'':X5EK>J'%B*NTX*:C(.V.4FT& ^%93LDR4[9'!W'ZC'!VXJ?<'(&8S[<R@
MCHE:%:+;+(\1C,>MW6R":BO,!_#*%0A8+^ZCC&O5$?(-'9]9,I168G/CZBO"
MQ?6[^D2X>Y?;,+0_ZM.M[]\KBBIJ%C3]Q'2L>PG])F!WB%PGO7#QWC27.H-P
M+C ?*VGQ;#:AHR&&?<BN8CXLL@%@)52?O=M#[#WX?J"#M8?VD*G>+9,XTLL$
MV2L,B'Y4>9H;)ZP.S-8Q53I^"BQ2#HI@7C?Y'/#6)M?-N(K0ZV$ *7E)#//2
M8%R#G)!>-/LX]_4&8:0S[X(YK4.\]9"&-JQ)=-4N]*%I&!:?8&SSD$$ZA3;+
MP;J"0?&\W>)E5[%!KE0I\@6J-=+>^4"Y+.-OFS9)3:AB";7CNK^J@TOS@8_.
M4/EW.>+!(_I9+FFA<6?2#*^? 33OU(O=(2_S:ZYADQ.]4)2A_<"@]JOT=2%O
MUV7@>6ENFB57+?-^'1FO]&CRWD8Q3$:IX+Z&@?2L\%J8@'B>9D5&4L,< .BX
MO:'R%^8:@-6>^[ROZY2Y.Z-T?P?#[(_SKH4TPQM]3Z;*P>NM)A\-A"X2Z.9:
ML1DK4BF7G7=ZAT#%U$S7:5  #*%')V.&%"N]WDT.$S')>%,>7WJ,_@P2;08[
M8DD^'?C?SB:II;\%BLU%L@'O QE^Z3/]MK$<^_MB1XD>9;JMWJ T,07LCGFI
MXW1S59J;O16=)3KE AN2@4W9D&4QD($&5R!,+T]CVFH\PRRA#TKP;E%-)&UI
MJQT6T1RM#9)C-&^,RW)%F_1 &9T*5@=MQ>17]7"MXNBLM &/RJ[1:U26P5)H
M,SWC70W> &-:. U;M-H=H]"9956RZNP:MH/UU[DBF@&&$'X"6000KL=-91+I
MHG"Z5.B\%S"?'Z.L78O0 IKG9?K-5'OTW@WH+HN[ZDQ14(MW&F33P41]BTED
MJ0&%@4I2Z 33% E,C'YQF15'8QEOJIMV]M-Y15Q,M9Z3=X?2=W5&)TB5$<A3
MK?VTC2%TG%WRUC#FZHO/@,OE#8C1( _TGA/#M;(1]C3>]$C8O(O:E>$]I6ZR
M>T<LR[E66Z_8 #/N#+=]E"*V+J5KT:5^_]]Q]F9V0:^7&'#@/V' P>Q%N&<3
MH)NS"1QDK;Q3R,[_X\WK=\YYNPNL^OGSE\I4F5S(GU\QD@ZJ@8GKT8\;\81-
ME9TQ%;:79:-KK-U38DU+J'E?(V_W0%@75="O[]4_**,95)QU35B2?@+VS!-H
MI:<(+G\KFE$8J%.'#W9;K6[?'Z*'\+$-EBEVT?\N=$Y4?J3K:'J&F\K6%CVA
M-E4V=0T'?IVKM[U?WFD]NL%OWZ8MPQOFIG>CCX?'373MT,Q;?%U*1115 Y=H
MP2A[AI0O+F6F:F1FK&AH\1T+JLP-9G[M5O&#OB/5(/0>=.>]@PWG>NP]#506
M[)/2KVG:QYVG+A3\9CV..O/NTY6\>]Z)E_ X\?/3&BFR>_AYG31Q_K?J?%CC
M](^_[9\<['[[S]BV.[N"^D/%;0USFUYHV4+(-D+(W^N4H;]J:X60@ZJS5@3]
M_/FPMCL%0.[K?+9 P?+-[7ZF2S2ELN?@G7'.N7P,6L&$EPRJV[&\@Z7\!Q;2
MF;;:$R?7(\294C5_ T^@]P8A:!/VV/$]Y\W/QU%[3^R=B;*;]X"T".,0)BA8
M.G)0Q+Q3UZ6IFG!__>Y:YL4CS&AZ!RGZ),[8S/JD0,<F9T->-UT"[Z<^X!F*
MG>G?4%EL^/-:Q-[:.+)GQNNB?@-/R<G 4_*E\)0,@O.!1[/F!LUK!@\6A[6G
M=5C;,D>R[Q+]T-95#TW W] YX6+I+YNR?L?7:<NX=I>/*.M;O'X?A-(3-W5I
MAEQ\\X+)W2ZOAYVMX.EG*\L]5"F.:O2Q9?'XUT7@RM[QZ7%_M*]-<)VIG%'P
M1.6NF)?2/?BZ'\&BH5#[^1N-P7ESKYIMY4&Q+7-2>V(BFR1T,_G3.&V'F;0R
M[92D+$;:DCR3_?4M$;7G,1Y"UF-3%A7>4T+4JV\MP_\FARV'1?^RMWO\X75E
MTC5=EEQT@%7+()'I:S]GR9?RC,D\>C08=,3QG9HV6*9R\C7 K&KE!8<4G^9#
MV-OK5%R632A*O^1U)VFT;\KSI[*<XV!O+]J4I/VBE&E;SN%1'QYZR^0&CE:A
M[,_ R07(M8[Y;>B]KA]1I??!WSK?^Q"N<[#W2A05B0?1K7=ZY76 2U8<$W.=
ME?1O5]=#-O'7)53KNC;JKH/23=E;/I@"/WIQREUF@T8\N[SC^,''T#GNE(B^
MQP;P&>:"YZ2=D;/Z64'K\S]X]-Q%&6@Q$]-?+A;).DL/J#K'AJ=+BA3'R:E)
MIBV96+-P>Z!A3#]@FW=&?<37DF10T^3[F7*RLQ)LAH[L^H!J0- 0OM#;1^*Q
MA\_[S!WE'M:+WML;9(E- ^MOU=.JDRAIRC#G8),6B8FF7G,?7H8JHYK2S&4Y
MZ4$MYW+U3P?WZROZH9I#^WKOD69.FX0(L[-)VBW=74K)P3+.O_.963IG)OAR
M\&VYA/U@^6M36UY'XZA,!]X71#=OTA'P<5EI?TJ4!(]UDLM-79G:80^19QVR
M,5")9FI$F[]4QT.K4R))0;D"M8H(*K,&)GE@ 6CJ!4+U@U%T<>HB17= J!O%
M?QK04[]!@$&#[.ALWA(P>YD>Y0,FLWB&P7@F=(YHD/W8K*)2]1#WZ(>9".JB
MH-QH^L^-ZE?>UOI"/P2V!%V19J+;U%02979RK!JI^J4&Z24%C<O8'5UU?(@Q
MX_X&.J26;Q+K3-_W]W6(>1&JJNGX>2@8T_@)ML7,W.WE##]@,S,%Y@TOY<L*
MIW^R^,^RS4##]#A0UR;5:%K;A:KS* HM$FN/%XZUKTP-MJ^L)MI>]*/MR<8%
MV\^[FHL$Y(M5!^2+D8!\^J3A^)49\?CCK+[:>/R7&.P8/(=@1W\C,B&,K$]F
M0U06 &"=WJ"3&DIQ<<I.(<"P(\D1@/*-O%W1F'RE1%^"M?BKD?3X48U,-^(Q
MI5!*U\Q$6;-1U;"?>JM'%2OM(8*I *C\V]5)I_%@ZD-'1=K62,MYF[C*,O!Z
MT)=$RRQLHB-F1W^G:8]H>_K%IE-*VM;[P[QJF#]VKD9Q4"7KTUG>Y#-C,TQH
MK#,6%3LQR_4,^Q 6$K8$O32Y=D6:OS9D;-/]>!:XAX [O .X%REG$NQL'-QO
M1-V>#U7G^.RO@Q/GL/;Q^.1H]^SPN/8<J^[4VJUIP#HG>T3NIE>[*9=+E]KL
M5T=R3@X^[9[LZP)*L'8'AY]JSM_?3@Y/]P_W]#*>.F=_[9XY7TX._CFHG<$"
MGWXY*+YX@0M,IRWPT^/<] 7^LGL"ZW-XN'#)RUEI3?-2Q7\>;(]=S?8GP+W'
M)Z<5Y^ _!WO?S@[_.7"./WX\W#LX*<H_[1V??#D^V3T[<#X=_W-PHJN)W5%
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MN2MT(46+6$V-U;F0(FLV6:Q\%D&B-GM]<X"R^6"@/%%Y)TM%IP^3WUJ <LL
MR16F0UF0M""Y?)!45J'<=IQL/1@GORA36,3$ BX9*%>8@&^!T@+E\H$RL4"Y
MJ4"Y<!W7(LC+L P)QTQOW0I#5U1:G=E-W,TPNV$GL$!I@7+90'EI@7+K@;+Y
M(*!<Q.Q>#"179W9;D+0@N0*0K%N0W'J0;#T()!>RN1=#R=79W!8E+4JN "53
MBY);AI)8#YX-)U;!: %;FH A.-=PMT*[&V^(2HDM6%JP7#I87EFPW'JP; W
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MA_P_,\^@[T*@>4\,GC4"+4E[*"@^0)J/OVJIA9F%8.9\0D6@;A(HYD7()Q+
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MAFFL6"7HT?Y+@[<ZNRUYT"-_35F'Z8* @R?4@E )@8D(D(L9 (YT&8I(DJ"
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M/P7]H0O?9/!HZ2!G)D86%R_%Q#^L?9QLL%T.]U2/UG!POML?UWPV@&L!=1Y
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MVDBSL[]W1OMQ4/D+D8M?NH"67R>&^')ME/=3+I_T[#I^G5M7@2C/N'^7S[F
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M *ZSEL.=8R02'8$!]+2+H>#_:>-_?BTUBWKP4.30L'FB%L'*2!&3!,A!QH2
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MR"BYFJ.W47(+RHYSTCR%-@^($[MO15Z+JI;(I#.NZ LB#Y*8*U7&G:CXR'!
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M9.2OYH/;X._(34C05$@\3V:8"=_'%8[IDL0HI>R:,GC_PN>Z[!6)H"*TWG@
M.W?2HY'MFJNNP 07=3WIYGFA="U2^$7G0G?/NV^ .H@)S,)V*]J(S<A>S8_7
MQ-Z1+^W<]%!TF>OB)9$KE*)=E2$=WHV)RV>:^R]'H.IGWHNR.P_Z.]0&[9*
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MRKZ_;Y&:7T[X'"?<A%VB7W_X7U!+ P04    " "*A4]66=#H13 I  !IGP$
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MJ%=<KY51\K'8Z!6(PARHD MX@Q$P<(XI**=SZ^2Y+3"&Y/(>).Q64]WDX)9
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MF2#UPW)L?>+6"ON0?-?F7'S,BNU-X$WV/EZ=A.EG0DNJX]4<\WA91S&;=GO
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M76XOH1Y)\VD>:H_CJV/148Q.&*\=&,<-J&@Y85(9LF226[26\]:%^SO VH5
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M7W($[;7!6B3.K'IR#G90A^6T#9."CY?ICO[>YO7Z)88%_OU/_Q]02P,$%
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M^_RZC::U/\>N$;^+5::-6!MVB+J<'WD,GR8C>MKT[(48Z!08FE)G19Z#,ER
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M>3=,Y9UVL\&+,W4E[7Q9"J;S7*FWY2A/YL<T<R,Y9,Z9(0^Z1#&_=$^!YRJ
M3[%H'J0(JR6*T(!7=(%^NM2#5;$\X9A"+^)NN)NL@N_\35@%X3HQABT58Q^!
MAG[87$-5MJ"BH?&Y!M+H?4J6'*7HZK&3%^0WZ9A 8U*FOD?>K50@^XB5Y8Y0
MQ&/1E748V+&.7)Z8GN^)(@9BU3+(N@1045AP10J0HD1-(LID-^UBS[F!:W>V
M2%^\KK,;;4-*PX#'ZE@Q_QQ&M5_3.6#%23 Q1I#9U#/#9,!KIR%G7QML.2O3
M???:M-6B&^">H2IM0T\/$9,K:1JO)MWO^!>Y;_4V^7J\VTW&]&TZ:[DU7YR=
M"D*+2$:>X22:( ALEAH0#<88-'K18S+/PP"?L&G</R$]N- ?Z7.7"GZNT:M@
MZNGT;1F>_1R^]4CCI"<.>EA=EF(+VANE,8,S.=**AZ[>9!\@ZJ@3"J:5:!U:
MV9U>/' 2MV>U6$?T?6PV%Y/]4'/@0I>G?WRNK1V),,;,.<C(HS J1+!!&5"9
MT4Y<4_6RM%(9KUG&U@W-5@*V^QC<]AS>CLTV)N!.$[>'WJD_A^EP^K:\ZW!*
MK\@\/?]HG#\,C\?#,DQA/+OR,DU&PS3$Z2_UL&(TO8YVI7:J6PS6K,-JJPG?
M:+HJK0E%DR-MN%;)R5"L$\%RJUF*"N-@BW$W6R!(^IL,^N8B*<YGGR(C(UTE
M35Y9U@GH+9& VDKD0CM[\^[S6X1OBZ%!,QNR.&??WHWJ..-< _"?ZU[PQQ3+
MZ>C-L. @>*NDX;R>JM%<LTT0@N:@@ZW'\$(&USJ_=P58NUL8=ZHG2_K@-"6H
MAW2(.R'^@I\[3,-PMH_,/DTRR8)9*7)!L+PV,@W,@8^TX!M&VTEQP>3FK8#7
MP??<M6I;RGI)KYC.NF&:87X1II\([.OQ%SPW9Q<W@N:<I!!6@20[A2 Z"YY%
M#=GJE,A0<=ZV;N.V JQGHDRM"6IXM%;E<GX!?)TNSDM@/G9A/*VWRD[&T_=5
M3I/R*@R[>:'<I+R8C&H:01=&_XZC_'%R^=_?CM],PGB@M63%%P')&@U*EC O
M=*IUP)$EF9DW:85=OS&L ]>U?1/90QB+A'<R/#V9OL>$PR\UA'<T&DW^JB8Y
M>>F_3$[CC#;X<T%.!TFQ(%-Q]8BJAO<B>6"N7AI3C.<N2&93ZPRB]1 >N ;N
M@+:&*29G[\NHE-/J@EUBG=X+-H:8N3((VOL"RD8.P:.'(C5GA4D7A5]I:5MS
MX -7G?[)Z*%1VS)L\]2Z*_@7N[O+RG%%>WKV48#2Y'NXF!@(+TCUE95&M4YU
M70/>@6M7WX3UT,;ME\H!YI]Q3-_,JA-R-**=>CP_QSQS.\B]I3W[Z*16>_XW
M_HZS7TGP4Y)D;4>'TX$K21E/6W;2]0Y+Z>O-:4Z 9JP@N251Z>9]<+9&_4PT
M<<?T]M$CKI;-QYMM68ZZKM[_5!V;G[]=?N1=^%9_=51[(;P[[ROUCAPBK(T*
M+DI7WF&7ZJL7 N:BG =3. ?EZF6\:#F4(GW1]<7CS:NI>YO-,U'H1Z(./;2M
M^RUT?V(5& GR*,^;:DSIIY=?ZRQQH).V.=<;IA)G)+EZ(PU/&H(3D07$@.6^
M.P W:H)P+Z)GHG -:6G8F*Z*Y!U)@63QKIO,<.YY'Y5"SZW6Q0MZ X[2[-_G
MYTFOQ]/3KEHC],G:3*U[A3@0FCMOF8"H:M&GH:4]QB(AQ9!Y4M$%4U;P+[;!
M<. *M%.*6G:YVQ8XF1(DQUH=.$CH>,@^@ CU#NL4(T3I+9 9K%,VI;"H>]:R
M2S3?]:T/VOKH>7>SQ/!*25DU:--P-I!.Y1),!A9D!.63@]HQ'5 H;9RDU^;>
M*W%;E'3>1G7@&M83/7WTLWO[&;M09_YFWC7MY',8=O,V.O46$^&,*)ZF772]
MQ21$#Z'J.,N,]O*254JM[?[[\#P3K6E&21\=XMY,QL<?L3NI/>P&12J545C(
M'&M/@Z(A%E5O:)#"(9,U4M-8/ZZ._TST86.1+^%_ZZM<:-W"KL/\,7REV<]C
M=6^&(0Y'\U.J6KFZ.#VM(=]Z$RAR= 24&[+W44#)07E>'$K66C=6Q?9,]*87
MJI;HU-9A^R7]&5UR-+HND)',*<7G%>_!@Q?<Z2B3=;QYV\D]7LJ\WTC1=N)?
MHA$;!]LWE,-9,8DSN=2,#?"A"%"6"W#.,\BQY*Q=3IK;%7RH3<?ON]/AWGRE
MG1"R[ZZ)M2[M?0V-SNL)I"ZIZ%* 62=!&55O!Q49O!/:9RF-*RT*2B\&W'4Y
MUNYHG6PKWL:UQ7,0BTX\*\!HV)G@RM"[;S^PH?!OTK>%Y'HDTNHH6"D1M*O7
M7'B;P,FL(?DD,$2KR9=^"@3>TQ*@+7_K"*PQ;[^1I$Y.3Q:*Q%0MQLE@#7FR
M2D<.WD8&QF1)9@>S3+98:*\-NMM:ZHW%/FDAL\:%];^%KU> ").T"=$!1YFA
MWH$&,9!5P977F3OIU6HI- ^1=W70)TC>QC+K(3']O*3^PR?$V9OZZ8MN(I:G
MNG) ]*%64#+:U',R(#RSF9&#&'GK,/%=6 [>&&I*1@\M I?A6G006@%93R7K
M=Z/:3^%Z&_964(DM1+^C%>0<(:U@1HN2@9#42\^-A&A<!(,F9>%$,:QUT&;7
M2O% U?JN=6(=B?=7IC[]?3+#::U/J-EPKX9C@DL+Y64.Y\_?+K^OI=ISD60?
MDG(N@/2,@6)204",P"(+V2"/,3=/P-T"[[/9E79&:@_U*=<1G;\DJV#J:<]:
MAF=/;59VQNJM,_!&E/12IKD$F^<J*F\"%'I+:$U5"0)GENQ\FV-06A7?OBYS
M5VKR4->51Z4EZS#1@W;<67#\\[>+.5L6O9+U$D+E:0-61D"@E18D$^A5,#XU
M3^E? =:SV:M:4]2PFNU!B%<4?16(/>U0*\#;SX;5G-I556=+7G:Y$%V!6C.!
MA,P<F+ )""X#CX%#0N:$B2%DME+#W*>@.@]L8H]!<]:AHP\G_70XRF>I^(MO
M7Y]\[B9?SGJF+5K)AYRSB//NB[2_,NX@UHBF-,$G=%IRV3SFMPJPW?</:T[I
M31>^.1\]],2I=4*G,^PN)K_HHQ:9C8EY<(6L.<7)%G!!"\A2%5E08FR>!7H'
ME,-3C!8R[V']>'7:D61/.YR;_U_K=PLE5=)Q4Z(C>]S1/Z%X\(HI$(+$$%T1
M*%N';>Y&<W@*T4CR/9P*?)B4V5^APU_P"XXF5Y6U;J1220NN7LRN#"IPUN+<
M#[32QRQS\TMF[P)S>!K11NX]!-OFZ>DU;W#)5J:<*A:9 <P9R:D+$;PPM1::
M,U=<( FTWC/N@7-X2M%*]CTXO.MU[BW<:R8M[6S>%5K9R/OWA1=PO!A>+_$6
M-PO?#KM1^O["_KW1UD.CEZ7]?E?!]+V=^N8TKM(W>Q,.=M9.77%O9)108KU%
M3XI"]I-,8 NJ)+TIC+7N1O9$VZDW5XMU1+^W=NK%&66EK/>7%/*Y1*#]6-/J
M*14*LKO)%6]NLSRI=NKK<+A1._5U"&B<V+C2C5LIRN28Y%!XO8%&:PM!9@_!
MQ"2<#![M2ODM3_!JP[T4##0GI6%;L#6N25H%X?<+$#=@<_U+[3:AHG'^^ZI7
M-0J7:1G4P$RMV.*,@].) QKAG"Q<HGCN%R#VK"OK,+!C';EUUUY0/@L70EU7
M4]V;%?A$HL!@,%O.C%0K>='/X0+$M7C=Y@+$=4CIX3CGXJJU&Q=4G]^8%)E1
MWF<H@@PY54($9R0CXXX'[:/1F3>/V=X'Z. -FO:T]-!#<OE=YJN ZBFPLA30
M?B(K#8F;]"7U'GSGY>"D<8'\/4:,!7H#@I7@#9.@H[0VDR^8L'4L98>J\$ P
M9=>:L(ZP>\F2O=[%ZGQ[XYEA\3& MY:\=<D4.$^+KE&H:^,0'7CKV^>6(]E]
M?*0!30]T"MM QG>:$'U<,'<Z);33Z5$B24SG#YV^IBUT?#RLEPM,IS@[^UM7
M.YUM?+/<!J.TNU)NVRG>N$M.F: C&9I29:X":J^88(X59D-.-L?!)@-NFR5V
M:\0W%]U",*+/*I)W93PG&Z=>\QQ\A) ]>5V8BN.M,YOOP[-U1DM5!1R1]9[O
M$BH?L"@UH=*@5+TU*IEZ97G-N@G2<&N%$,VSN5?!M?L%KIEFW$IO:4U##X[3
M L@9UC?+L/X3A\>?9IB/OF 7CO'*O78:K7*!<Y*&J,)!"8%6?\B*7O@D)5>K
MQ6W6.D38'.\!J=;.:.O!Q'H]/A?]_:_&P!A=;#0&Z!V0H#SW$%114)"GPE$R
MZTMC[5H1V@$I4A]D-,S'JY&+CY-9&-T)3,4B3<H1-,IZ?Y/5X.N]%,ZA=5)I
M15\>,+T>'.0 ^&XKR!X2[#ZD3YA/1_BV++,-?_YVY:>SN)2.1E@>%9"?2:YG
MX Q\<1*L#YZ6,*N9S:V#>FMB[+M+7N^K0Z^D[+L+WG4S;>D>^O.WW\+_G70O
M1F%Z%N_(!NW\3H<D:@=K'B0X[@QD'3"EZ%GDS1/"5X>WZ[CR;M1DJ57=GJX^
M*@ONAGH)]/=P<E$IO@+<GF+/:T+=3U2Z-^I75[%FO#T"=3.&++K,"Z1<2\XU
M1[+I+ ,1HG9&<LY4ZZ#FHU"S!R+>CU7+UJ&K!^UZ<3J=34[J;86C^>GA]-/P
M\R)TF[14R&R Q.IM<%%'\$D5$)@E_;[(G%JWD;@'SN[-]5ZIO%E%UXB'7HHJ
MQ[,NI-EI&+VOP8<%K*"U32XF,-G06Y*- &=9 %%#7RZ[(@IOK1[+H1RX:C20
M?P\KQ[P;_ZW)GY<!)_(K42.X4J^S$H*@E2R Q\A]2L(PT;HDYAXXAZT>K7CH
MH=[R,@RUVKZ;4I"6\U"[&7A03%F(J$C!N;8AQ^"":[WAK GQ6?AB?=*V>RU;
M^L*M KDGGVP#N/OQRWI5@_54KAF'O1Y\K [=)Q:BX@Z2-8XL.L?!)9V@^*01
M1=*\M+Y9Z-&HW0-^VF/7NG6HZT';W@Q3%>3X^.BXPVLUTTQY8T.2@-Y78/7N
M;L$SA&A"4E:)E)O7J]\%9O<65^]4WJQ>;\+#OA.>?@]=-\\';YOA=.NQO:8T
MW3^)&SE,0NEDBC4B%::B+(%5)6!H.")F)9;F,-T:H<>D)2YR5D8)0)L4*!D#
MA.Q\+2@TBC$C5&Q]%M%GTM+YM>S3CY/S(\G%8#C]M:NW04:R34.1]!(6R4 A
M.;"1/%LH)05T/CN76F?Q/X3ID1T,KZ,1MQJ]M11_#[&EE9*I0G6-41"\H"/M
M\\J!BY8$D)C20H1$TOB>T[:-FC2G88\)1D(ZR6DI!W0U_PZ%@^B8!!%*"8XQ
M5G+K\X^GF6"TC<+T048/H8%?)Y/\UW TND@Z/NUJ)=2\[&V 13A7HH2@I25L
M14!,,8.6CE9 IY2WK0M [L-S0-K13.P]9"0ML+T[[=*G,,7+ KDK#48&4C*M
MN=.T&28D(YY<RZAM!)E<\:PV>4BMLQ17 G: 2M*.B!XZ@2U #AA-23"&D%RD
MF>KJU2D?@6/(B64?M&J=%+T8^P Y7TN</33?NKE?_8ZSU^,T.JU=;2\PALRM
ML[19R4#+DZK9_(X'#CY84V+@2*M5<T/B85P'I [-:6C8'67CDQ=OA698.!3A
MR>1A18+SM--QE5!8(PO&UEO'D\Q@W49Q>B7EL62P+IG:/.+-+5.JF 0^D\Q4
M] Q<( _>VYA,K<XC@?8?(7I2IZ%KT7^K\?GV-/32'_\VK#-S>Q'>7@5@7Q<=
M/@1N3_<=MJ!R!?78GH>]*(Q"KFPUL[T0]3Q-DV<6R-9FVI<LI.1EM3NH'[^B
M/'0'XE[T9!WQ]Z ?'\@]Q^G;\GJ<AU^&^91V]F^O3T["C'X?1LL6VO,#+TU2
MR=5%L\D76EQSACAOUNQ0HC2&B]#ZQ&)3K(_"=MZ&]IMVT"XXZ[.QTP+BAS.3
M:=&[-7+!D@=C TFD(#F':#,(JYUD(4H16SM>]P)Z%F9..TKZN+CA#,OY&[,*
MF)X,FVM ]MS$:7NB;JTFVTJYEVWI*BA,C!=D5;DSJ[<%<UHL)0>IH\XL&)YT
MZR27'5"^:K.FGAE?1[@-F:Y%S+].OF W7C+'15(-8X5VR0*)%P=*Q]J1*GJ0
MW 29LE6*/92HLL(PNS</MB!@TH_T&N[V%=H\._TZ&DM[E$NZ@-4\@;*,@]>J
M=C[511>:?Q)\!2YO/_FITK>EC/KH-C\:705U48CDE='&6Y"*23)5R8R)AC1*
MVA)B3B4PV[R]_%(D3Y'IAK)MW(KCBAWYGQBZLQ)(C<PS%\'6MD5*H0;:33*@
M,#D6HYWB9867=,FC#]J:;B'.AH?>2^ LBIM7 +3<AEZ%YWW8QTU$?S>-6\BM
ML:VT'%C"$@6R M[["LQ("$(8L ZML3EZX5;957=(Y!U6[VYX7$=<_?+WKAM.
M%JB\2TYJCV2\SZNV6 (OR5 +-B:5&)/^9N[:*B1>&6%W&V<CT=]-Y*9RVT?.
M_=O/L^')\+_GE=VOZ\/GV>33ER>?1Y-OB!^Q.QF.YW]],9G.IMMGXV\X8/,\
M_183OY'![QG*XFD'9L:KI'54PONDC14Y.5'"8,NQM^TT/)UUIVDVSWBKSST:
M9_H==E_PS<71M\>D$]9*I10RJ$QF7N0:(1ERV(,KT=G6*0*KX-J^R_*5,<X?
M/D FT&E;H!1Z*U4MC(E91<@E!)$2>E]:9UDNP[%[CZ&Y)MQNN+REN'L(["_J
M#5Y-NFOP!F0M!\ZY <YJ=\J:-TX+?8;"BS%8F!'-+]B]"\L!JD(3L??2=_VV
MBIZE ;\>IZY> /L+GGT=:!5Y)$SD0]=B/(D"G+&TCR,FD;ESUK<N\E@=W0&J
M3$_4]'#XLW2=R]S;XG6FN2*M<UF1L1=0T6(GG3)%H(FM*Z@?WE:VR2Z\]O0Y
MV:,PPSPW3<[B$3DPM-)I2$SJ&L45$(Q34!=V)B7W+K1NJK(&O%WE%/;^8O1%
MR6-)*[S_-(F;HHS*CJ8@4YV1 Z\9O?I991&CI'>L>?_5QWWVWE@+UCIV7X>-
MWL]>5P'S7(_=UR+JWD/83:3<_[&[$\KEA, ('ED B8$C#QP4!A5SLIZ+YJO"
M(S]V;\?X.L)M'(I\/3[&\7#R_NOUT\? K7'>A-HGC.:F/&VD/ 6((DF?T 3R
M'%8(0RY_^M[/[M81]Z2IK/H_6T]!.UW+LS%96WL"(NEGUF!]$=HH%T)0*S#W
M",_6-V1M2QGM.,V%1^E"#K2HE&A 5;5R-=68YV!D$I+LUU7B_X\]S65#+EM*
MK_$1^HO)R0D9E\,P^O 9ZY?9M^488XZ,:2YKUP0!JL@(+ID(G@S%D!WSRJ_"
M\*KC/56J>Y%G#]7D]WBC<RLAJ,)MR@&L#;5G1L[@JG)J@<H'6YC UKGQ#T Z
M=(>J)2,]!+,^TN=NB&!QJ?,*P'IRK^X$M1]7JRF%DS[EWX/C=3? ;&T*7# H
M2LS;@->K? AEJ5>R>E3"BM9'*#M6C <<LOWHQ3IB[^/RXO/CZ@]8;WP;)SS?
M^)P5&,G3($>#5V/'&G#2*B@YHV6:?-'0NOOZ'5!V;V,T(NOFS<4-)/V(DDL:
M]G9<=81=I8^LU?%1EJRY(9=/&ZND\CXE[UR4"5G(6:B'\D4:-W]<Z?S"<"DQ
M6@FIWM6FF(H06"D@@^$*7>*:MXZW[3Q!Y+KE]WJ<3KON[/M!\8)A/:9V'LG^
MD_1=R(R!D%:&8NFELZTOL5T1VB,]"%Y'7^XUF!N1TD-FR3685X%=A&EK&2RM
M(/BVJ]>:=[2HD%GQ!<]^^;(N"M/::N;E^)1<R_E;/N"8A0T^ U>6@Q*2W--Z
MGNR<-I[<4_2VUU/D1O,X=*W<!]W[S89QS%JG$J]=L<CF$,S3RV8,%.<\O8,E
MLIO9W-^S89JI6SMJ^BB%7B..@L9DIE4 XPKI.]9+0,@4 I^+RAX=+ZEUT[JG
MFC&RC?+T1<G3R!A!9X/"8" FA22YI.F[+$!H;9ETG#-LO8<^^8R1M;1@K8R1
M==C80=K PV">:\;(6D0]D#^POI1[ISY9KD4T&7)2Y"UX-."-+) %ETY%'4)L
MG?;_V#-&VC&^CG ;GV"O?# G"5\@ZPAXF;>,9P&\X!JT2\$SSWV,-VK%G_1!
MYUJ4;'+0N8X\&^>9W)7Y0I:19DP3(L*A B_@R5"J![PB9QM*OMD__0EE"6W*
M9P-9-7YCEV3 N!@Q%$DKT?Q:2&451-(M8$&6')-T<J4TD\>7);0I:UO*J'$R
MR4-Y+MKS*'V][2PY2=9C3D!H#$BC@RDILLCLT\\2VI3+EM+;0\:(U31=RRRM
M[O40DY/R^4)^:92BT,RM<&6'M:'/P:%JR<A.,T96 ?8]8V1M"E?.#-A$_CO-
M&+$UPZYV*.+U2%S)("#$%('3)I8"^1RRM#Y'>UH9(SWIQ1IBWV'&2)22W 8C
M($E&:Z0+-&V5(T1$ED7-8A"M7?(GD#&R%EDK9HRL(^G&OMJ[=R]?GWP.P^Z*
MQ5.2M8&,*6"T38(R.M<01 :9E#?",C)F_0KVXI)'/W4B6TBLL;OVIAXRW0)D
M-0;%HH"HZF49CB;GR;8!9:.. ;--.JY X=*''P*)VTOM3LNMA\RMU^,O>'[!
MU8MZL#VN^]*;R?BX]J2Y\L>C+V$XJO;MJTGW(8RVR.3:=L1FF5U-IW[S;E_F
M$4W63/.D0H[>,V:)>26<=%'B8-O!6YW<WGS^!TST$LR&.'US>3U.22SQ(LBC
MJ7L(LEI?R!UHGZT,GLOD6M_RLA; K5N,WI)QG%T.<W0RZ6;#_S[S\7X.4[+5
MO*D!=$LK,2?_49E43VA10HH9:4=U16/KP^QU,>XA9-*;3MUJ6]HG7SWDBSV
M-Z73D]-Y%&%^#_(?XXX6JCJ!7TGL/V.9=/@Q?!U(;6A-J6Y!K&<VNC!PN=Y%
MAB[H**)1V+KG1A/@SU@3>V"VCP[+&T[B#?UT.0F14N:(@BP:2^92LA$\9QIL
M,-GHDIR\V19];^IY#?AW]6S); ]!QQN@;TSI:#2:_%6M._KY18=Y.*O@!\4@
M"2TAN%B+/4NN<14L((51UG'N3&B=";0)SD-6OMYYZ^%$Y&Z97)_-@&4>7/0!
M"JO1.G+>(+JL('@1DM:BXNUYM;L+VR'K5"_\W-:CK>]JOE_WS\Z)#!H?1$G
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MW/AN7+M/Z'^2.MB<XD=< B U,LE3I->I'J#4 CTG45;]8DAFI5?-#\\?8PE
M*Z(?3O=?1^#[R=]>!>'W=/^U>%P_D7L3$O94'<*E]I8),(F3)^H<>1'($T0A
MBJ55%I5[ONG^/6O).K+?6;J_95D8IC2(J%R]#M=!M"F!#0YSIOU8VM9594\G
MW7\MQE9*]U]'W+M+]\_"^^@Q@A&U89@ETRL$YD':' I3TO#F=\ ]H73_;;2@
M@<![6 KN2#*.4MJD2X2L"YGAPAL(R7-(,6:CHLC*M&Z'_H2RNK=1@P8"WU-_
MHM]#UY$4OK1I0G3K:;UD;-\+^49^MM72,1YI;W=.A52\5!QML%(G$2P+@_L>
MW/_U2I<^LE.%">TD%"<Y>38ET\Y!BT?F(9M<"L?8VG);"^#V/=8F"3'/@]]G
MT:3[KVL;.)>TT20+AH($4E"#\XE>GER"82%E+UK7H*R+\;'?9K:.3MUNNM8C
M7XU;.OY^6J56^\]=VF3?KL8./H79+\/\^V1&L\JG"<_;EDB&DH20:(>NQ9E<
M! BR=IWVIBC'30Y:KW#$L>'PAZ@]NV*CCQK)R7C6A30[#:.W<30\GML&@ZSI
M+7!!0S:%D#%/EIQP-0$_:"95[4O7O#AR&9!#5)9VDN\AU?=H.L6SD/?/I+S3
MTZY:)>_Q^'14_^.4S$7E(D<&N5YKKP+9C#X' \E&QYR11?/6:4$/0#ID%6G)
M1@^)MD<I=:=XY:QDT;LFX?#+V=U]5JK,?08R/DF'-6,0H_$@%&J7O/=9MDYG
M?!#402M,4T9Z2(*],N%)&&-^%8;=?X31*<GFQ61$:HU=& V<1B41%11MJE.J
M2@U9^AJ\%#(Z:W5H?:7O2L .677:,],P9;4:6%< DJL['!_/.S73!DH$3-_7
MW7-2+D!/KH"NZ^?'R>5_?SNN,QS$9)CVZ, PRVA_-0E\\/2C35G%;#.MH2N8
MP8UA':**[9N]ABFLEQ4QGR?3X6QZMK+2VT(2N_$"'<U>A*[[1E.=SVE08DF:
MRU*#80(4^@B!.PM).<82XY*'U@D9ZZ,\1/7;$6<-DUU7J[LZ&HTF?U6+D'Y^
MT6$>SN;)W0JYU4Y9D(K5;K6%/ A5;%VGT0GE="JMZYHVP7G8FM8S;PU385?#
M?):'HJ+P+HI:C<]JXILS$()$\E"+U]$(PU+K"_]6@+7[E++]ZL_Z7#R6Y*\S
M?_;#9)3_&!.,H^,.\2PX-GF/GT^[]"E,<1$[>X?=<)*G\QP&IZ7/]>++S&H!
M-),:7&$>='(,O3?28VN'8%.L^THD:ZXS2V,1/7/70X!S ]SGE[>L KRG)+2-
M0>\G-VTWNK&]0FY![*/23$_ZH@PYX.0%U?::S(!/SM=\=)-4$B6&UJ>FCTPC
M'TB#>V(*N0Z?/2CB M/;+]B-A\>?9HL$4,]RT%)!GM]/)F0 S^IN%,F]#M;K
M[%L'^^^ LGMG84=DWKH#>GLF>KW#YB*KU,7L&9H",9::Z^417$0$K@(9$K8D
M%EM;9(\G:;]O6VM+>?=P+KA")MDJ"+_G[*_%X_K9V)N0L)^<?84A,VWJE9=8
M:C<6 =&5 BB5"-P4'14[$#59/V>_9RU91_:[:]&?%7>%(S"ER/3"V@C%6 9)
M>9Y2DJRDUG'+IY.SOQ9CJ[7H7T/</9@4M2_X(E\X"<,5328Z-(0D: CU2#H4
MF:SDBH7F.267HQ\<VQL*MH?7_(\/OTZJ'5NG>G2,XW2>,WFK;L"('!+/$F32
MJN;!)0C2.# Q!ZN"$/GREMQ&"K JMH-3CUY(:6APUK/BCY^&77X7NFOYDPM8
M)6927PE:U(8A/I)9C20*85QR)FFM;D:"EY[:WS/$P5#>4I0-L\<JK/<TQYH*
M>Z%MT22)*I'WY61->^0%7(@2F&52.2TMBV4%6F\^]Z"XW$IH/>1RO<?I,--$
MAV'TVZ2;'8=C_#FD/S'?6DL$"YB8CF 2J[E"7(!72+:&34Y'Y[+QIO$"OS*X
M@U&1?FGIH?_@>TSU4?F/<9J,\USH8?3N/+1VF1)]>??AVU*/5A>?R'-/R3JK
M18D1,$56^R,;>@=*!(O(Z=THJKC61](M<!]JY&KGG/:0UOP ]DODOTXF>?JV
M^X#=EV$B::;_.AUVN(@#KS*+GN)A;6:PGYC9[C7HIH6\/_K[<,+:S$8@F8?D
M$M#>4-/&$XL0+/= SH#(4GD12NL=_#$K\0,1O4/1X758;WRUQ7V."^U/W,];
MD'I!UE%1#GPAX\65F +M63;D59R%1^4#[H.Q%?W$=<3=N,3UMLL3C?3)2!!.
MD,DJ:::^T$L1,^H<>8SJ9F.71^HG[IGOK01[YZO>0].&7[ ;?IFW)W@U'-,'
MR*MY/9[.NM.SW@63,P$NKDD/H_J,#Y\09V^J8E4*Q_GE=#8\J1.^*#"8OBWW
M/WCSOA![!MRL]<1C$OR-[A9>6,NDP<R35AA+D$5JR;G!E+QW?+!G[-LF8B_&
M>'.13!RUR5R3DQY\O4B7LPS.<D:F 6;/G!7!M#:_EL#8/L5\\<CK% R84[K4
M8RCT@7:8+#VX3+,52%,C3Y0KV;I%SUU8=K\3;,OW[>3Q!E+NX<3ORKMS65IX
M^<MYPM4@&Q-=#@@ZH*2)1[(U'"_ C$^HI4Y<MB]>>1C7(6E%(^GWX*O>@',!
M]*R)_##$X6@X^S8P4:8D1#IO,T8^$GAC.&05!(O.>*;:WR^V"K)#TI)F#/20
MC+:*+I^M>;0"OBVE_GA<F\C/KE0R%T>X+3DTPM4"4AH%O(YD.<L81 C)A]C?
MEKHY[D/2L1VQUT.(^($Y7+XIP=@0LH[ E2.<+"1P07+0)NB8><PN]&?9W(_M
MX#5I,Q9Z."A= NGZRGJV^PI67"PE0:P;K]*DV"YY"Y)TG$>?4VH>8UT-V2%I
M2C,&>C@0756?'UP=DQ*<IUI%S)0"54VXD*T#S4N,A@469>O.MZVP'Y*N[9#%
M7EI<+""?'0NG@-[9E $SPWI;H0:/64-D-I:L;2"/LC>EVFFA=W\:L;XD'TOI
M]K]C/AZ.CW_!Z?!X?!8CJX=4)62,M6EPC()63)?(#C..' ,M/0L&;2FM?;'E
M2/:74+$%MY/F,N[!*[^-ZOSL815</24XW(5I/RD++7A[4!6V$/HNE0)-"BS+
M (G9>CVD5^",);C""1Z4\+9Y%<=NE>&!H_]=ZL(ZLNXE7'<&"//1]!SCY6'(
M^;%B2"EH+C,8QTV-%-6F-O6VT&"Y*HP)I]O[OP_"VKV1V8;#6W9%6P)Z"/K_
M/AGG"Y2+H^:"6*.$M9B93"F7D:;L(Z"G=\':F#QOW>)\"8P#T8%M!=Q[\>?9
M'406&??: (NHZP4QAJSGX.C'*)E&2]_KQI0_IFKQ=B;BEK+=3V7X*@B_5X:O
MQ>,&M[EM0,)^*L-S,HQS+FDYK%?2,/*RG= ":/$R.6+*,;7>'YY.97C/6K*.
M[/NZPHFVM'3:=;5 <=Z$Y1Q:S?7Q*",MEL[3+DEKIV,HP2G.&+/*!-4Z/'X/
MG$=9-K06>\LN<VH@^L89H#>O&IM4F&?@YM\NPJF754U<U\)F*T"XS*&FO-3#
M'@^^A"BQN&!NYDHM31%=>^"#T8C^Q=[#RG''E72^\)RR\"!2=7I,5. =F]]Q
M9KPFPSOEUGO)$[H#<)OUHH' >[!&E_>ZR-H$:0U9ZT4D4$4X<$4$\%)9EX0C
M[^OYMA;91@FV%W>OR1F7T9#WP^F?<_O)YX"$B@&SO-9,%P->T*86;(HNYNB$
M:[T@W(?G$'S29O+N51<6URW5]V#1J6\%;#WYI??AVH]'VH[%.]6C$06]9IXN
MP8B:.;0A@DZUC8[3F:Q?(\&D*(532D;77T[RKM3C 4]T/]JQCN1[B57,L*/M
MLQ9+??@K?%YTS@I!2]K$( GK:+I9@K=,0K:J9IF%P'3K?E7+D>PS5V9;MFZ%
M)K86=0^G%V\_7[&3M.5>&9NK;E<L4D"]Z1BRL")C-"G$UITFKHY_0&1O+-:^
M(DZ+^2WLUQ@]=X[4+(0 2I#]ZIFRM<;2<)6B0M$Z?6X)C$,B?$LA]^$HGI+3
M@HMV.S9[1/1@E,B@=) 0N-:0I2+59$Z;V-HIN#K^ 3&]L5A[L/U?$HB<,=]?
MM+EHAJ:<8]R2VZ/)D%'<<P@R"!#D"M7D#&U%ZQZ$Z^ [(!7IC98[,_=W7I;^
MX?3D)-3B_;>GL^DLS.^[NT@&KFD V%N!^1I#[ZA4?%-AW"CZ=BPY;E71C'-5
M?/;)<!%4\"AEB4P^4/2]!HKVY=LL)1>+MU!T\*"\=_70+H&3KG9H#=;S_CS(
M-[V7;\ML4I)<D?5F:'HQU;)1LNA,=BX9D5+!_@HR'V/Y]CI\KUR^O8Z4^RW?
MKD'?JP[;@)M0(BH-QO/:/"0FB,HED(4K$[-D(;7VB.^!<T@ZL)VL^_"7/N/X
MS'];F 73?W;#&2W5+[]^'G9G:6V$L]YG6+2I-I^,Q1)0<N"C)!>/Y&(%%J%E
M:GWW]\K@GKZ*],-#K\7:9R<-W$45BN;@D-5,:*D@LEC !^2B!"50MC:T'U$9
M49M587U)/O(R(H%:FQ UJ-KA3JFDP*,UX*VA/8XKC<T+%A]W&=%:W*Y61K2.
MC'=9,;(*KN=<1K06;ZN6CFPB]%TJ1?!*)T?K9.")\+%HP/$H:\UE<8*\_AA:
M6Y1/H8RH%UU81]9[*B/*-I;:$AVT%P31:%V#Q0B1YRS02*G5\RXC6HO##<J(
MUB&@5^=SR?%SUC(&5R045G-7K-/D$<D,W!,R'Y/VJ?5-8D\AI6<;$Z*9O'MU
M*)8$IE?!]CVE9VT6UTG:V(2"G:?T6(UH,($6N5YN1.^&2T&#4-X5)/\,>7]+
MQE-(Z>E-.]:1?..6XE?#:.\Q(0',K^B?=Q,28OWF_V W>4<++@DB'"\.,:.U
M]0@J@)"Y)K,R X'9!);)'&5 YMDJY00;#?[83OW6X6ZR2\$W+CI9"GARVLT!
MOQW/\=*76Y"=%[2KL@Q%*';68=5'(R!G=$($G_U-KV5U77EX^$/6EL;"W\'*
M\O&OR1PQ?;U3Q>N575XF)!'% (H[!T&5!)XSX:Q6GF':4%]6&/Z ]:6U\!N:
ML0]!?C4_];D#LXLN"G014LBF^O\20E(%I"8;7[ 0HY9;*LQ]XS\#C6DF_H8)
M37=B)HK/-M'Y=TLA"RV$S=:#5+2!JA@D^$Q.83&6%=1!6:\VU9B'AS]DA6DL
M_![ZCKX>I\D)?I@1ZFK<OUE<;E -?#-?_+RLB54U_5(GF)]+U:1J$Y/,.;<^
MAKL'SB'$3%I)NX=,R#N@G;\5JX#KK3W'/<#VU9FC$8VKJ<<6'/12\7(?R"PP
M1*\%&%JZ0*7D(1A9:T8-_24G7J)]^@KR8$^.?>C'.J)O[-R09?3QT^1T&L9D
M)!&R;_2+179N\NB=+Z!#O4':6@%!: ^<L>"\,X(VP!6,B[M'V$?!=#,:)LUE
MV#C,<0L5N=4+YTAKX;$6A4OTI,G*DC,M"Q DH7) S_E&S%Z,<+#,;B;#OM_9
MA;))C#%R!<9)4K;L:HR$3&%M/3DVJ42'&]%ZX)QN(+W&$8,KD%X.CS_-$!?U
M<\($$66RP((E4!%K0RC2-\]+05I 5/9\/4JO#W" I&XAP3N-\YW7F-S_UQNE
M#1<?>3>9SM'U57[2!M6.*E-Z$.&-HI44@PJ:)QM34"K$:+4M5AB&UA7:V1\H
M6FD#L'WJQ?1HG,\S18X2_6G>_.67X;1FDIYV.'USD>]J"RO&10G:)'*HO1+@
M3;'@$M,)F0X>^[O_9@/ #:\PFU=MO"US<G)]^, 98Y+0FJR\6LP6G85H;(#_
MQ]Z7-C>5).W^HHRH??D(-#W##;HA@+X3]Y,B:P.]8R1>26::^?4W2_*&+=E:
MJHYDFXX.VMANG:<RGU.56;DY;Y1DP6,)O)LP[N(YYN5<;R[=,]CL,+TT-L'K
M._R]OL-?EN]P//]Z?K:$&7 ^GF/ZG_.+6<RC'!Q3F6O(41HZ]ZKQP0BD\%'G
M8(RW6UGD6S_P.;"CGP:Z)K1L+Y[5K2;1VABF$+QV=9!,O88N=1U,"FE++AI;
M=U_>&^SPQ1G'VXIZZO%4"C[63E>N=V4\Z#JLK] 2I 5EF  7H@"2K%4E:EE\
MZW:NF[ </_K0E0G3#AKIL+^MPW7A\VV#K%.$8C.JXX0GVFAO"TH<(/IAR6&\
M2<G6QA#)!%!)<? .$8R408K:;9*WKC,=FA0/A"2&YL0N$N_ A;?3R>=/>?;U
MMQPNRQ.$BZZ&:$'2NF@_9 H<\P8D(O(D:3^4K0^3NRB&MYA;Z6C:5, ;7:3!
M[\A>EY(C^7I_3B=7E3.7OS]_-[EUT4@G+WWG[#S5BOL_\^(?=2#CV^E\OOK=
MRT:ZW5JW]$4[T)W:@"*_==?&3:D>&K<YHBI:>"^P"&2,&\EIIWO@KJTO\ ZN
M7WWDV^58]DNO1%K-9$W5]R&056CJ'790H;:&R*7XE+0>HA#J+K)VKN_E1[^;
MW.B3DA<CVNE$*CR"0$$GG54&@I7DGZ$G0UFCT=@Z->%!4"=R@W(83S9[KRU4
MT;54\!+@U4O[KJS>XG>S5].OWV:TLY%]5655O_FZ[B;S,7E7KR<DN%4'C9$6
M3FLM8VUA1XZ^*61!,2V!UZZ%5I/L3.NFGTT7\$PX.)2*A[K6NUS7RQ\79]&'
M?+9$._\R_O;RQX8(Z<L?FVJZ5K<&.3.FN8X08^"@F. U?NW!""&=3J78/.CY
MT'1U1[TX[,7ODZ+$J5PIWENX:$U@*3D#6= ?*BL)*(0"[[/5(EJ=FWN"IUT,
M?EH4VJ7.?!=5#EU O VV7W7F.VMQETKB?50P-$V4]:QPY>JPYSJMSTMPG'DH
M14B66-)!]7-+'D.=>3=V["+YX49'B"R]#I(, HGU&LWD.A \0)12*9*$":;]
M:,M',#IB)VUM-SIB%U'W&!VQIN4]\IIG$@E#*)YL0AL!+;> T=,ZC8OMAZ&?
M_ER!0U1_J)"[]$>],=M"96YBR0@:62+3B%"1113K'RDZ&[4UK1,O3GADR$&:
MWE>LO4='1&8+[3 9F%!U["4/@(E)T)+'3/N,$ZIUY\H3'AUQB(KW%NNQ1T=P
M4Q+3)H'-]<+3104A,@;"BJP3=UJ$UM<JCWATQ"$4Z::6@8NOK1-:.J] \%)E
M4!(@!H2<C44MDU2I=<K"21=?G_0=12M%=CB)[J^4V0;<K[KNG=6X4]WN/CH8
MO*Z;&2F$#8;T&$MM'IH@%.LAR>P<CQ%S\T[]CZNNNQ\_=A%]XQK1VUD+]QRE
M3&91=TK@L?:]D9E\Z20T"*$=1FV<$+<LG+6U!]L_\=2*#G=2T[2[C$\GP^I/
MG,V6/^R5%'7G 0/E,=V_L%NI1[Y@\:4$;1E3S(0ZM5)BXEEIC\2.!U*/[CSK
MF!5[VC"I56VCYV0$16L %P6#DE*0C(MH5;]A3@-6["U?SXL)2[BL"5ODV=?Q
ML@]VNL[\&I$4T"'M_=K06Z\2.10.F87D671,,AMN=Y=>O_<]_*@3R=7HPI2?
M-L7&4N^:1/2"-N[%J^D9.2%YAF?OPMGX\_)D^#3]D!?GL\DKG']Y5PK]UL@G
MSK+F"A)3@D"3&^2$2Z"=P1!RS)+W*W;= >AS(-IPFNQ@KK^8QG$U&2JBW\^F
M_UG6JKZZJDR\])%?%%K))_Q[Q(7AWI)$M#6U6[.R9)ZH#%ISGH4O":-L3+P=
M(3XGRO747I=+A.OXV4^0+X%^FKZL70_/<#X?EW%.OYW/2(!_D@W$Q1_3R>++
MO*9]>B%+P&S(*2JE=KL)X+)$, E16>%8PM QM+D_\N=$S2/HNL/M_/YUD\ED
M([)R8*T.H#QY6EA%*9/-T1N'-O0;/O<D*Z';G,T]]7@J:8L;1CJIPK)3M>&;
MSB1 $0)X;DB*(AO+@O.%M4X).=71=UU9L-V0O%VT,>0\M&UP/><A>3OI;=O!
M:/L(?4A2&)3%1%L@)D;X0I& *6D0W*M<C!+>M X\/X8A>5VXL(NL.W#@S^DD
M78UINPQP^R1KP!R\J'Z#$ E"D YDB*9(*TJ^/0S@8/6O@7%"0_!VTM&TK8 '
M&GIW?WQ\27]=O+2&3+",1H,J!!VS=\"%9HIEFYD8Y +W0:3/R^ 80)L=+@?6
MP+IXV;8!UM<BN0OJ=,H?6FMV_3'52"W];)8U &-!+*4@E*@JP,0AH!; N=+6
M.X4FMKXG&I@O>]1#'(TNNVBC TUNWD$1P*MALYA"H56:K"RH* ,XP^FK8*)&
M)HL+I3%%U@(YFFESJ**FK:7<N.OE!9":;7$^7[*["%N2*@Z4*AP4KY-YG-60
M3;$B!VZDV::[Y9T/?AXVQN$R;3RMZB<P%PS>!LYZ@^%A51_C^&\@]$WJ.T!B
MC9/$UL%RF>6BZATO)@%*DX,4I$W@D?!*[Y5DVW2<'TR!&\[C_OK;15"M!T!<
M9%740^0"C<QU5COGD#SYL*H67:+2$7*)0A5D'LLVPR;O?O)PQV0304^;26G(
M-+RK9N]77_R1L1X;RY/EY8^W^7L^^WTZ6V8YS"]^EEXLKG[]W>3%AQS/9S6>
M][*V-MX_8Z\?EF;)?0.)ZU8>(%.B.,^35LDK3A:;4MS%["4W3FJI1OU@'5C2
M=OGYJP>3H?)VC&%\MC11+F&\FUP]FG[AS^ED]A.2ZYB@5!JML(;>/[)05=T^
M7:'7T10M=/3T8]?:Q6NZ@!9>#3V@_N?U_YZ3'7CVT[B&:Y-O9#2G#<4CN)R1
MK'K'P 46(=D20[3)QN8W^%N#&][[.1X+UWE,[378X8[XQ7=Z^ZO?0)O&1T+Y
ML0ICY5CDL+C^VXCGZN$AH8LFD5UCZEVV1N BR<2C9E*TSDW<%MMS)EH7_36V
M)>L;L/AQ$TO*3K,0P"J=B?.2%NP4(U>)^U+[W^=HMK D;W_N<^3!P?+M<.>_
M[*IPV0/X1B_344#.I;41 NUJM,!$%G9R""%*C=()IW/K^36;L#Q'KC353X>T
MO&L&_S.?I1?SZUSK&P;L*!7F35$6BJO].90,$!1Y;<4+;@M&HG[K%+RM@#UG
M1K777(>"^EN9_/-1-)D[9PHP5WN2:YG B5A *!50EY)R\^WH-H;G3)J#]'&7
M'[HQ/VZTA+TS&6]](UA6QWH*JVCU-=TCT=GK;)V6X#T&17LK<ZW#3H=B/F;N
M^CY:OY]"?576HTYG*8)U;F&TVJ?@"L%A=52L48!9,(A.!3JC=6H_]W CF.>\
M2;71T%WJF':[U0W1C(C,PKK,P'CEZ&7ROC;'(:=/>R-=3CF5?A6$-X \9\H<
MKIF[=+'MZ?)C]]U2*2-SS *R9I8H7R+XXC@4'C2/47O7_+:Q!>YC'G)[4^!!
M4G767X?3[@KE#:&LO1+-P2OI.1!6!:IP 2AJ&:WB6EDE@C>M6W!O">TY;VL]
MM'>79.[@2X3X):?SLTPOQ57,JWS,WY#>@?PBQMHR8/[RQQ_X/]/9*_K6Y^GL
M1QWZ<'D+LDJBL=(ZFY0$SYD!%92"H(V&P)E4V?I@=.L(5!/@0]7\G0XMA]?W
MJ=0#7JWWY8_K2>YCVNMG\<LJ$+Q,2/%<"RS90,I"U&:G]#YBU*"+L#E('T7S
MIL';(3M6:MT1&'-[*VVON1['];H4@[MX+_)>M@';*9U_)Z#'2?'OH?%-I.JF
MKJ-S+%H1A:27S#.RG95D&I"E"%(8LBV4L24U[Y5\?&X]4 YP<M3:14L]*?5F
M\NU\,5]*@%^DK$N9>'+D?&&=+Z>0DZ&1=0(A&3/%16ESZW$:]\ YHC?17I&;
M*'.@%CJDO*R#)JXJ-IV*R60PRM-;DB.=[U$D6KS46F>I;.B6>787SG,CR#Y:
M&&@'D9?3(:*1205//JTA[GKAP'$NP86D$W,^9=;\;F(SG.=&D'VTT*7CU94O
M0/_'\GAE0?FB2P(9+:U4T$'K)4J0Y,=R@X%.W]:\N(OB^7I4!VJD.T<N5CW^
M+]X80[(-PF[]U1]"=ZPFZX?I\5Y:-%-"EP;K#R*-"FD#K9DS0G(RF^A41&,9
M6!=L+$COA_-/A"8/MEH?FB6[R+Y+Y.3OG/[ Q462U>48(\>5K'T?G:Y#*7(@
MBUK6425!&*]5$MJV#L>M!7*,9NMM-78GU'&HN#NX+;>S?"]1:1V#MPC&5 N9
M60M>,P_TO2A3S+K8UDE'ZY$\.18T$'CC1/IEXN[:RO!+;#SGZ$6 I*MG[7V
M8 V"S#HKZ9+TMX<7KTVL?^@Y3T;5S87:*YO^1I;VU;B'E)!6!M[XNMSD(&1O
M(1>OBXS:^>9M4-8C>3)D:"CP#LGQ:^8^+ T?.G4*LJ#)]ZUW)8(SVHYD@A)R
MP*7_'9M?::Z'\GR]SQ:ZZ4"93S.<S$N>U?#\QSS[/H[CR><;R4(WMKKZ(LW7
M_^CB*F>;M71R5ENNXTCAOQ8$F9Z8=COX.6W75#@+,7M@UCA0AA=P"3G]D3+3
MM&,7V[J]Y>DS]:%@XLD3=0>E=B#H7Q__,?V>9Y.E8#YG GF[T/;RAMIYR6H;
M$/(5%7D)R9+;6(L<&%><K)-@;>NLFVVQ#6^P'8\!TP'4U\'7OXGSX[?I9#Z=
MY?2ZSE[X-AO/-V#VFGO'58*8$F$6)@ R%,"C<$%XD8MN'8+8!^<O^O53:X^K
M1\(X_CRY!EY!7D SY !S7PIH*Y!D(1FY1$Q#22%@8(FIW'KTP#UPGC&Q6BFI
MP_7%7Q^7=0I51.^G-3\XXMG'\Y#&W\?5(KEB>60!2U20>&TAR02K(7]RL9DH
MUB@6 FL=W-@.V3-F50?5=?!R7TUGWZ;5U5^[>]KBN4,1@0M9!Z\Z!SY9^DKE
M'+7D6J74F%?W GK&=&JGJ [- 3[D^3C10FG5?TQGB\_X.;_$^.^<[@ UEA0N
MA :C4VW85*_^A19 WE'./F-QMO5.M36X9\RN/@KLT&;@U?3KUSR+#^-$;1+/
M3 %ZX:L/X@&-9I"9D<9$SPQOG>V\+;9GS+,NZNM0'WX1UEJSTTHE4_%20(Z6
MUP(]!IAHNQ4<F8CH20*Z1^3HUW'804$=2L5?_QV_X.1S)DFEG'X_GZ3K6Q&;
MD'$),DD#*M48B142DC(">:UE-JW]O8U@GC%SVBBH8>UM#:/7?7$ZV90S89/V
MA2@<G*M-D='6QF(1A)-,^N*5Y[>VG+5Y"?<]XQGRH:G8[]+!'[J1O%_F5.05
MN)LTS8%XBU;6=J?TAZN')"L2O$?!8E#:R=:Y"YNP/$/:-%7/FAO'@V^_7^)9
M;<G]\4O.B[?UMR\'\TEF:(<KQ.(ZR$3II,!S3TOF4KI"ECR97(UYLPG+\TUV
M:**=#A[\.ER7/?FW0-8I=V$SJN-D(K31WA:4.$#T':(8]R!TW/LL= )T=2Z6
M<PR\Y0IBUCY[78MC6R=0#4V*!X+^0W-B%XEWX,*J_>W-=B6K:Z%DHC*Z]B%<
M%DA[00>>*V"T"9K5J?2J=2+U>B3#FR2M=+6VS_!!@NX06U^BNIR/L1IDEJTD
MDR="7E4IDK\=6 G@A=;*,\,\MDX4N@/B:2E];_%N?-U[3L3YD..4[.NS\5(&
M[\JG+_EE_CR>3%:-BUY/TK)ET5)<9(YO/UOEKSE]M2Q<?4/_+,M8&PS-.0;<
M]G-UCB[T6Z-W"D\"2V'9&J]0"^^32BPRDXCO+HC149&?TG2>Y )YE59 ""K5
M^ D"%HU@ A>%):7IO6Z=]7%*TWEN@5GS^)4V)],P)_^^.EQ+9?[,FU=X%L]7
M4SH_3,_JS*;_X"R-R-#R5B@$^J)6%V4-3B8.B:D2K&59VFX=2CJLY[$W3-R%
MZQL;&!R;)SU[J-QH _&O\>++G<7,?U[-STM?"F8U&T 8*:*T 4SD9'(8,CY<
M# )R<(PL#JN2;%[+VG@-1^?Z$1FV1<.HP>@Q4)NR/==S.:C[S22>G9/Y\6;R
M&F?5=)CS$9.9F2(0/%H'RM-&@\Q&4#$H'YD@?;1V1(99V:]7XY2IU"'K\Z:Q
MO+VX?UK5C?;6M,#IUWS=T_KM>+X8(?<96=2T0EZG[5IR5W6Q$% %GEA-1NQF
MAG9;U:\7Y50IU*.DM^=6L+R'>37]^FU&/CBMN5:V5Q'4WQII;DV*+D H=4BQ
M# R<X@:RL9BBE%%H]9@.FOL6^^N5>F2$ZQ ;;+CP]^>S^ 7G>3Z**@CKG8*L
M."=-F$R:< QBXJPF^'F6NC76;KB.7^_'Z="D0[IQPS75^;+SD0N<Q&L8)"[T
M1;/^P#V=G,B9#R1CT<WN:K2&7Y0_#7IT2'MNN9Z\6*Q&-LQ'*649E?)@N,N@
M#(O@O%:@,E<,19$83MA@NK&27]0_):ITR-YNN*JK3,4WD\5TU7]WE'4N&D.A
M]SE&<ID$!T2F@=$)1Z^W#=&?L-&S9D6_7HA3I$Z'P5 ]5O?N?/&N7"R/!R9U
M*1:D-"3YF"V$6LHHF518 DL&NT7N^BSIUZMQDN3ID*G?/%XCC7&1&P&,U1I>
M;2)X@0Y2,MZ6Q+5BCRN<URU-X-6RE.?-Y*_)+./9^+\Y75ZMC")&X3$:")&+
M.OR 00AHP2DCC>4FYG*D7(#-H(^^9YQ^P+^1QGN&.0_:?E<E!MZB8LXCR,+J
M# \1 ;E7=;QV2#H&W7X@0D/XCW..XO&S57;7_<E,4]S0^<Y&9&@(/">O#A2:
MN@QMP0IN-0_!1=V^R?I)]5<]&C.V[+*ZBX9.O6?E-FOYU65U$U%;$*1G\\I]
MM'OJC.4H@BZQ@'-!@^+9 Z8B(2BTGD5ZNT5K(_7TF;IGE]63(>HN2NU T/L[
M17$NO2%;& P+9.5P'H $0PBM=SK$1')J?1?_E%MZ[:3KG5IZ[:*H#CG*VW>$
M*M()YED&5"A!)68A%.XA"[06M3:YM.ZT]%Q:>AW"KCX*[+)?;=D32A9N,R*2
M0U_;:-,;0*Z:Y\#)^"W6,9%LZP8ZSZ2EUV&[6 ?U]9H$L[YYHA)"RD+F@JXQ
MQQ03.,88%,LE<\A5D5UJEW\=AQT4U"'3=$-_H)Q0"&X<A)@1%#&8UNHER!AK
M4EY2WK6^VWB2S9L.X4P#U6Q,F.Q9-/T*9[,?)#.<I!L3Z)?AK.E:6?TY7=X(
M$<"?BV!?U3[H9^-$5F2Z69/>H%)Z,(SMRZ./(]Y;-=%:>QZ,%BX*5*5$SVS1
M1ALNI?1,XVAXN*=4"&T,!B,9&0'((BB'&8(WIF8U1*V4L,IUCL\=MQ!ZU=]C
M.OG\*<^^WAB8-BHQBN)% A],;6")B;;";$%;I[.R7O/<.O:S"<MCCT?NPK'U
M_5<.U$^/XN%,GX-G_UP6!^#D)4[^_2(MM\/Y]=#5C^=?O^+LQV_GN0;QQY-W
MD_S_,L[>E9]V!=HF1AJ9<T4RH..2K'(N!7A%!A9:IZ0ID=')W/HU;+J"Y\S1
M(W*AZT7 >_Q6K3@K33 H(04DPU#[^J*188@N9Q>L-TRVOZK\"<)SYM8AVNC@
MOI/)D^?O\<<R$,J+9J%.]5'>+Z<(UYP/@F93%,:CUZ+YE>/-YS]G6NRMAR[#
M2^A8GBUJ16J]-Z 5U_72(3UR1>182H"$J$!%30X@HXV-,1Z=19:L;=TC=R.8
MY\R6-AHZ[9K&^QH)&(D*#>=0(C*R%:4&YVH?-^6RD\L)V+F7D_.T>U(<T^HZ
M/>[T+'T\0-ZKM*54C JHZF"K6&=_8P'GHX*2$[*0G36J]<R?9N ?9RIC$W8/
MJO>3262\OG^[\7;_/LO_>YXG\<<RT22$X$JBU7#'R>JQN::,<@$9M><F:X;]
M&@UMAG4B"8Y#\643:QOI;: V6%< +V(AVT#LE,&X!;PC)2:V5NT6QWD+O1R)
M0IP++R+Y9%R[6BA8$J Q#&3A3!AI%!G83X4Z#V4*G@!S=E''0(R9W]Q_+T/L
M.2OA'=F90@FH)7W@#+GSCF#Z;+'P-$1?BC70CNAIM%+K%K0Y5"<#=2F=?[B%
M,>? 8TZFAD *J,!*G8J2P0:+3EGN<O,QB]O@>B:D.40;/3>;ES^NOOSG.,_H
M(5]6X>SEELNPE( B@$V6MEQC)3@2 :CH@O+)(<=NQ6WW(OME0C?67L_>F#??
M@[MX+]ZX;< .:$]O!'ITR[J9QK?9MIJJ:RBC:2-H84PFI!FT2YDL2*G!JQR@
M:(5*!\$M;QY!/SZWMC>]3X-:NVBI)Z56%\-+"?#+4YMEE[0)D-5JT"2=VL$[
ML$Y'EUB.'EL'J^Z!<QJF4R-%;J+,@5KH:6W?@"8N"S1LR-EQ#DQD0^^&54!G
M.8-06/ ^:!94Z\F-]\!Y;@391PL#[2#R<G)Q,+%XK2'(4!-W:+48DB!/T6>.
MRA)_NUG4=^$\-X+LHX6-EG&'K/-5)^%/^'>>_XFS&2[&W_/^^>'W?5JS3.ZM
M(=_*N?;(H\R\)B.1%Y0"6J5\$ 2&">6,&]WWP8>]GU>?_&HZ69!75OW^ZXB<
M#<(PQR,P;\CUYR$"^J0@Q5A*U#5%O'4,]%Y A^Y&O^629^25TL??\%5'5J6$
MBNRY( OMD2IP""DXR(:+Y%D41;8^J=8C&7X/:J?_VWM. UEW,%ANH%I=6]S
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MUG"0GCE0VI%5QI(%R9V5M,\*F5LGZ=T!<>CI>OF!'Z9G9[^OVNR/=#)9B%S
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M+XX2R4AER*GVNMX.9JG!%R8 9<Q:L*1%\YYFCSB,=PCQ^NGEQ,-XS"1I9-2
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M[&W5#NS89I3)?AH8)*1U=2%6T5GI(DI/+C+S9$$4,B.0:04\N62#))GX_O-
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MV*9JY*'G/(ZTGYVT>SO7K)64&Y<(WX?M<FK'%NC69_?LS(5CI.FTU]"6JC]
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M/!U;1AE>YX+DU#H9>#N2XU/\GE(>H"/)[95>1+*5](856VM\!'FO+J=Z]ZJ
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M8\P@''JNHL72R:+I >$(:#.6 K80I\E-U&5H^_X-\LMDOOQQ!5B[8GT!;JP
M9;4$5[@%P1/ST5D4<B??:8=G'Q%5!A/Y%H[TB@BO 5>T'1"_NR9VLL%+E0%E
MBC4T(.@,)?B":8)M+7)O=N#)KL\_(JX,*OHM?.D5"=X\0A\ ?'U?YB5'YKT!
MS9'D8BW)*D?Z:W(E6E8T;A;9=S)=NCS["'@RN,BW<*17R/<J O"X0[>!6@0F
M+5,%2I:$6M"1&:UG4).K@^92<*VZ$&5? ,? EE&$OX4RO:*]5Z@?3]U8H;X1
MH_:8F0\RTAY83?-"'ITS*8$/EFNC @^1[<*9G1$<$VF&%?\6UK2)]:XL\PZX
M;X2.$@^R2 XE(J<S5&IPG 5(P@1#IZD*ODOVS/X(CHDUPXI_"VMZ17H)1>>+
MC0O8-T)'W#.><XTV)F-!!3*[:FDQ)!>RB$;+Y'F7PIL>&(Z .:.I8 MW>H5]
M;U/^P>/U]]FUA^=T%-[1_JA5;3@I5 "O3 +#8N&Q5/YW28'8[^E'P)<1Q+Z%
M*6T"O<3UAW(+5WBOC;!LK*-SDT-*=4B<4Y:.4YDA^RBT=);9W(DI>SW]&)@R
MO-BWY.3UBN_>A/S@(7J!^49&F"W.D^-O@,4J)%^;71C-(.HZ.%9:*VV7J\>]
M 1P97X83_A;*](KL[H;ZAK6NO*T5KYI.3&](3*'>? D'Y-IE%5RRK-.4NWV?
M_],19D_1;^%+KRCOU?EY&4+J#!IC5K*X .@C28DK#BX[#IR<OHC%!Y\[73KN
M^?QCX,L8HM_"ES91W@X&^@KW3?L<N6-*6@V<&5G+>'6=<^MK@$ 5=-XBZW(S
MT ?#,?!F+!5LX4Z_Z.\:^*/W&BO8-V_9C>22&R&@A%5R,EH((0G0TE@F%*UE
M<Y#UP\S9&<$Q\698\6]A3;]TW^MTGLKCQW?*FW?LM$\RE3R$)&.=,1S Q9JA
M@44B<=VPO%LEW,X0CH W8RE@"W%ZQ8 [%_']/BE7@0$9F35!!& A(^V/EMR]
MH"5HQY(M7$G..I7:[O'LHZ+*0"+?PI%>$=];N8(/,[LBOKYIC\SHHA-97L73
M.9J=@6A%@IQ#=HPI(?S.F9H[//^HN#*@Z+?PI5^4=]L9N@7M=?R(:732A0BF
M1@149!&\J'W"T/#H931*[N17=WWP$3!D6&%OH4:OL.[ZYN)1;^XVY*#H8TQF
M8%TMP--!@E.:+"VAHD1IHV-=3)3]GGX$)!E![%M*9MN$=1^_'5VAOGFG;K4F
M6[N L[4NW)(A[ITOH$7QGA''0Z>2DOT1' %C1A+_%M;TBNQ6JWH%>TWS7<H:
MK"9+'#W(4L>+<SHWH_1U!',H29GHM H=:-,#PA'P9BP%;"%.DT3>JTC1(S<9
M5WND1*NS)]"%Z;I'$O(8& -9IW21J:6['4W[/O\(*#.*Z+?P10XZO^QMF-<9
MNM^PW[2R.Q_3=#;9PR W)I$I:;A*W!MME8J1A2*S"=RD*&M.B3S9^HG#S!UC
MF%32LD"0LKK#]3:("0E&>5N<Y8:PWI;N4YT[]CL2&\/IO\_.\(]9F/X6IO_]
M(J\4MOA'6)[/2;^X^'A^=A;F/^AM^,_)\LMD2G9<G<'\KOP63NNO?OR"N'P5
MEGC",?N(7 -&+FMVCX(07.W=RWF=Z6YRLHT%TW8%A][0]N/89F>] VKUL-/3
M?%3&>L<!6:K7M)*,/YXY""VE#]S'+/6@+^9#Z(Z#6P-I8X@A"K3>=^7E'/-D
M^7M(D]/)\L<_PO?)V?G9;[/Y?/;G9/KY9?A*/UG^. D:@PP*H5A%')=.@V=T
MI(=HLC'*D@_:>DO?!=]Q<&<PC0PQE&T+UM_#9'XYY/3%V>Q\NGQWOEPLR30D
MW"?):%<""8;QVKA:.@:N#A@3+!IN=8KD48S H(<P'B^+FFFF<>^UNOX/=!J?
M?5W)>07M)-86V444T#S9.K.$D=-"$O FU9;I5NA-*VFKT[;MLY^WAIM(;/")
M;<0Y7./RUJ+@!9*IG="9L1!--+62Q@O."W=Q6'OC&LOSUGQ323=L9K:'U9.3
M1N6R@AA*M7ITA)!8 .8$,B]3TLTMB7UMT-WE\/K[DG;4\\GB2WW2NU*??*DA
MCEBPE ST!:=U)P4^DJN@M$@!M:D#XQNO^WXTQ_$V-))VPV9;VU=[O5^_PD6:
M3U9?UN)"7_,&:D3,T2LK$%R( 3)SP?%B95*MIQ5W@'4<S&@M_X8-MJ[(&^:G
M/S[@U_#C@KP7X[E6X]@S%T)[;2$85SL,L@(..5GZ2MN:2\V5$:VWBGO1' <A
M&DF[8<.L-;*_DT@6?\P6"UR\FV[;T0@@TI&9,K DB*A*T-E>>WL%)!N/#GAD
M0C6FPZ.@CH,5;67?LC?6?1O9U_-Y^A(6F&_8?ES02B/1UF:70"%#"#HH$%YH
MJQPZNSDOK_E!L@76<3"DM?Q;ML':CO'E[!M.PW1Y\ZB3IB"*(,'3P0;*>@$^
M)0],"I>C+3:8UO/X'@5UC/SH*_N6#; >1OAR=O;U=%+O,4YD1HR>.Q#):E#9
M<Z@S/R%8%:3.@5N)HY#C&M,Q<V-/R;?N=;4Y7?"^,',1$I-C$9P5H>8+1?!*
M"$@FRI"S*G00=@C&=7S<\U;\4')MV<-JO>X-G"?!IR"S\*!]G5090@'/R'6V
M0?JD-#<JY\:[P :$YZW[%G)MV7CJZC;@QF#2_\2:+HCYQ3><A\]X,Q!V(FB9
MWEL/0;!JZ"8%KHYBX2QXP6(P!+CU]4PW:,?!BR'TT++EU'V'UM7LX5KLL/@R
M.\WTO3I"O*81?9J'>H/T*OQ8\!.?!#=E9=G@:N"3@: 4 X\V&N-=U&+88/\.
M8(^#4^/HJG6+JK?G55+ORG9L)\EZ*:RO4^<T"20&<K:M5A"R<SKZZ,(FC;8G
M^C[XE.>M_\92;-E'JCLUKR]=WI6/RUGZ[_?S2:(U3#Y_KCW)@[2":0-)%P%*
M, 9D+"%(E+QZ3"CRL+=$.T-^WI0ZA-Y:=Z7Z!X;%^1PK< (YF>43QR6+R2)8
M4]N2U!ZQL?;_9*IPJ56IA=\=]I(['_R\==U?5JV[1%URZH)N==;RI]DUM4Z0
MK" 4P@'SGEPE9<E##H$L:DY(7?&6F2Z-<Q]\R//7:#L9MFSH].B^4B]F)F3\
MUDQ:?J*-L$5%#XHY3G\@DG_,%5BBIF>FL+C9)&.X;?\6LN?-CP&UT+*;TW:8
MERG9/U:YU@3&,8,64O::H 5%%D[Q@#II\K2]E($-2I";:(Z1%'M+NW6;I@J
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MKCP*ZCA(TE;V6]C1.SZYIO'[,,DG+IHZML) "J[6T2H+,=A2\_NY%<4F$L5
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ME_T (^=N!N4O$>DLBBMD.M6YGF39)@V1JP3&>J,9RSPYWY@-=U$<A_I[2G>
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MC$:*H, +4\L(/0*Y90%*'9@2HK?<=LF^W_?YQ\"7,42_A2^] K57QC=A?N3
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MQU0GC=6YT._/Y^E+6."U3%Z<U9#<"1U-0MG$($F/-75)02C< AKKHD*A^>;
MS";#4A_"=&0L::J" 49';.QW+U*:G]?I@3]6,CFA#<W:J#1$&VBSP\)KFZP(
M,GN7!?=.NO;3=!]"='3T:";^QJTQ'UCZ1=RWU+G!(21:;+TGDCY5N\D 2R&3
MWZ<M=BJ(?.PY#14>3D\/8&DV%>0VL_,O=<%Y^6_I=+9 <LB7\W.\_B8]C_SU
MUZ>K&-W?_KK S_6+/GE ?Y#\/X>J@Y>TH:W"?*@=3YIK8#G429.1@[-607$R
MJF@=T[Y%BNG=)X]]$=)>H;-F@FV<[G4;S8T,ZBZ8&F:.WH=C_%S1OOJY5]4]
MA3N6XBWM?.05!^"A8N.N3I8E=UES02>3M2SS%OE\XRK\@7S/,?2]BTP;3_!X
M,5U^P;,WT_0OW_[E]?>O<W)9/J;YY.MR4;^W;A*$*J>"9'=HK),JM8 8BH/B
M?<[6J"P[]5#I\JQQ\S+;:&0VH#@;UXI\"'1*K4A,WJ>+22M24ZD5SJ9 J-V?
MC#<B)ZZ]%)VF 3[R'E\]\*@.Z?W$V# 0= 5BW<FX XR&Q_&-1X]_ N\I_$WU
M]9!<X[/V)ARC8R[!&1"!D;/G6('H<@#)9.!:<Y9$> X*?.!$;:N_70366&__
M($F=G9]=MXRH YT+T,E!N[I6'")/ HS4M,/'Q)C4#31WZZ'CGI9[BWW60F:-
M3\)_A.\W@/"82I$ET/:O.2CD#D(T&:1B);O:[-MWNDI]3'DW'_H,E;>WS :X
M*?L[K?C6D?[;C[>A!M]76XM-F&*P 4J4JQ$0!6@WB9 5F5B,!5&ZF3<[Q"P?
M!'0TYD][\0]PYW$;W"6PM6G? =I N9L/P#I,!F=#)3Y(C_X:&'P#N0W1>86F
M>F<ZLE3[/]6#B4N0]&)HDWP6I74JW^CD>"2G\S#<V$7PC4,A[[^$^5E(/[[.
M)XF@K4=.Y114" ZX\AI4+ C1. &:(XLN,K2QR_RFK1\^?IYF,]'/6LJM<3[4
M.SH?5T&=<+HV58H306@)A5>#)WD.WF!M(ID=1XD^N-A!B7<^^#@4V$]>][Z%
M0V39AJ^393C]N)RE__Y(M*,/^'IYI]XGS;;#I[;+L]UU"1N)MFB9SDI9+#F1
MNE7P1?MLHG0.K0KRI,L#FA1 G(;%XEWY-,>P.)__6#WOCZN+4E.$SHYHB,'3
M^:!K)J3*$:P)7@D6E(ZMB[8[P.I?($:?=BW/3&;U!UQ.YIA?G<]K)>6J\'XE
M=3HBG3;<%P7210_*\@"!/"\HUI:$PG"+S9MO[8#O8$4"S7ASMY!L(.TT/I^Z
MX7SQC7;ES_B>3E4\0592$D:#M*+4'#(RMU1B8$*27M&[GS:#2]N[E._\Y.-A
MR0B2'Z*G6R?$%TFIF6<AG>9@E OU7E)"P$RB$3EX7XRS3AYDPQDY1_AI[3>[
MZV: A.$-J._GL\_S</8!JQP)Z8OSY9?9?/+_,%__SD5J(C]!E1"%8*!5[94G
MD@)7@@'.M!>&,6EBZTC:_FB/GF1#:6Z (-PVF5S$'676F'(24+*Q=8QS@*B#
M!AY%L"5F;;IEBNU J7O!#)U:.!9/VDC[T*F%#[3NO @[A<BXC@E8U Q4-JJV
MV13T1TQ21,_=Y@3<8VMVW4C/'5M>[R+O43L;=P'V<[>\WDEUG5L<[R/W48E1
M;(Y%*@=.^7JGQ>LH  *HD9>DBC::-^_2\BQ:7@_#AUW$/5K+:X%.96D0I$3R
M[;TCPR?4?'UAK+1.A&R:.T)/O>7U3HKJU/)Z%RF/VHKA1@#T;9C/5XTQVT2'
M[WS<(&'AAT%OQ(,#ERX@.LYC4BZ;X%@L08D86!%"I9,'/[EG()C$-_N!^!'G
MWR8)5Y&UWZHG7!N!T':UNE1X<;KZ(/KJ7?F :?9Y6KV5"]_XY6RQO%%=$[/(
M6I.;(FLS=A51@Y>%$\%H9:RHZ%*GY+==@L9ME]![/]O^?-+:]//*PO[MQ_6O
M7%:(O?@SS//;\_I.OBL7T<UKK_"$;$*MDI)@JB>H//E_GMD(P=2A>UP8U;Q<
MO/DB#N#5'Y#9=W;?@W)BB#9[^RYH]<=_U"+K=7"-GY@D;0HUJF$XG4*!6XA1
MUQ'IC(XU40LU\E/A]Q;\OZA]$"8T3AU9':[O5KTR:YWW20K%)N\2:%96%4*%
MS"[#(:'#Q)-7V75I-;3QL3\G5_K*=XAH^E8YG(C@3([>0@G9UA'(-7RG(A&0
MBU!4T$$U=SNV(ODYB=)0.P-$PSM)Z%/X_AM.25_+VE#DYD]>?Z]?X@GY5#$K
M(< 5K$&^DB (G6@]+$B1#5->'<)$?A3YS\W) VA_@#XA>Q_7%UOWXO5WG*?)
M A=OIA<2_C0CS_3-=#F?3!>3='%3:BWW-9.I#N.B-3)E(.3B(#HO:JOHJ'1K
M)W",=?W<_']RS&G8*&6]QE=8<#['3*_QY?M:7^,;ILO5*O))9$$+*1RY7*5V
M#8OD@87,H#;=QXHWF4[%8CN0? =X/S=7A]+C7<KM/>)M6_NQ[0 +4[J(Z"![
M-*#("(*8(YD^Z)C-044C6D\'?A34STVOMCH;8+3.2CKQ\;TZWK-75[<<\WJC
M_CU,YJOMF9](+S*)QX,5M=P7 T)4)$3DI@14DG&-0YSL ZSEYZ;PDV#( ,,>
M^EHI?Z=?7%Z9**ONLB<IZVQ<2B!XK(8Z*G")C!++D[ *HY0X".G;+N,7WP_)
MB[M4]Z.$(][.IM]6K^IJ,8N5S7WSYU7$;V?+_X/+:^&?*!FR%D)",EF JNFN
M,;@$Q7GM''<QAM8)&(,MYN>F_=/@R)90_8%OH#[@_YQ/%I/E6C#K"XA([ZXS
M&<$53G9;2!I"80X,\ER24I''UK;V( OYN5E_>&YL87S_1*E&E\C?PN2T9IO^
M/INO3K43[<@#UCY R@SI'$N%7F5=P+- ]ILA>ZZT+O0;:BV_>']PAFRA_MZW
M=:N+P\<\E7B/IW+9ZN9B323KM:8N&W87+PUY(QRTCJP.*B1!VSK2RGFRZU*A
MEWSC&F;[!>\P\'Y.(C\5?6_A\-ZWA_W6=-%KZTHWYW&QZD5)_WHUZB1APJ*<
M *%EG:5%?@B990I8"<8(YYRQ8E 2/XSO%XL/JO$M-#[<!>+EZWGOPD3DP:!&
M",[4\DIR*%SM28.,&Z892\(_F4O#1];R<]+^23%D"_5[WP[N'3-]?U7Y2;IY
M5VI3M]ET=7% PD_T6R?(C..)*RB*T](4"HA&,^!1)B-Y0&6>3%S]T=7\HO\3
M8,F6%Z#W7>4*S)O%XGQ;.XXK':P0K]=R&J8+,KW(.5:.@)KD01$5P6G,P$1.
MC@?R)$+K.59[0OW)J3N"?K?PLO=UYZO)MTG&:5[0ZU3]U@N+G\"OD)_H%'04
MH:9<Q4(B<72"^&CI#ZZUB($\V]9!O8<1_=PL:ZBM+63J?8.XAG>)[A59'I]F
MO^'[,,FOPH]_S*;++R^F^?]@F)](;XOD(D)"1?MQM 6"81%,SL5KZ803K?>U
M[NA^D6P +6XA7.][O,WWX=5J,FV5S?P.5H_<^\PU9"8-J"0]!)X5..6<K-6:
ML7E^^@[P?E%N"#UNJ7[HU;OLS335SA/X9KJ],<VZRNPBYSYD[D-2G)PN5;=C
M&<$92V^'Y<89'I1679JG[O30GY-'P^IF"XMZWTC=S(.K9F.MBK[EN)QHD@-Y
MY20'Q04H9G7M6$!D+YDQ;QV7H74#Q4=!_9SL&D9G6UC5OS0K?<%\?DJHVLCM
MHK4.R<469A-HH6NW:XG@O)>@,JK$G,LHF_= &V(AHS6[>D*</3PCGDI3K56@
MZ*H?C(])"Z$+9%ES+5,)X&TFOSMH)ZTKJH36UN M (=JH/4$^#!KI9<A.NH\
M%H!?/)C_LEH&>4ZG8?HVG*V;SW19TU#=N@98SV$:??6@R:Z7+&/I^+GPE]?"
M2IX<:%L;,^9Z_:^%@\*X,4Y9$;'U!/3GP]M'^I$]<=KNHMH!Z/H!%\OY)"TQ
MK^SG?Y)"%A\^_O-J.*'A#'F HK0'DDT@0]IFP* 59FZURZUCA \".D!#LX/K
M?#:4PAIWE2>3I,SF9]4E.UOU!EV)Y^M%1_/ZZL6@0RQ8(*$D;&@"1&L1K$"6
M@I'6I(U-;/LDFT>>\\NN:ZZ-ABU,'L-V^89T0;?=8-N9,X<PJ=IKJ*/J>XBW
M];2KQU%R'7B*AM/FR"(H1CM:9-P!8\&KD@/#V'?#.(!=<FC=[R+5QCI_477S
M:49_JLOS*CAF)0\9HK(65$ &'HL%QTIA,N5H?.J@XCL?/)ZA,(349ZU$UGAF
M[?7D9*1C1SJK(0O%01G$:L$D<"8['ZT7&#N%QI_J]/:G=ZCO+_^&S:0V!_EV
M@7%\8]]W$OX]8\/WD5S#W?C.%/HLBD4IP;NZ/<5<\U15!/(8DC8E"]>M2^NA
M%=AI['L+_>TBL,9ZNSW"G P%5R(CC\^0&ZE8J77<Y$M&3-$EVE:PM-#<$QG[
MOI/8[QW[OHO,&A^AMT>8%^]$%-R L\: <H: R.QJSY7"0V1:JT[W>L]C[/O>
MRMM;9@,$S-:AG-5.(K51(5L.QM<N>((1AZ(/( UM,,D5:[!UV<?-Y_^RBGIK
M98 NA1O!OBYH!KI[>@JW1OMKYAX5]Q#K@-O!)2ID@C8CIL&S1*CH?(&@&0?!
ML1A4@FO3NMO]$[AB&4K'NTBS<:CBWH*!M?VNG&2V"-#%T2F$-D 4TH+-W/(2
M1?&XD9:_-7#QR&/&O^_HHX'9,.(;8@+ /3.*%+-,\"S J$BP8K3@A(E@HF92
MN,R-:U[&^;3&NSV]H[V%K@;HMGK_I*,NP'[NT7 [J:[S*+!]Y#[J:+C 0G8%
M-02>1)V'&L!I+H 7)X/GA;'-?@?/C1![CH8;A@^[B'NTT7!*9)Y3\I M.:XJ
M1X)'(,$Y)VRDS3#JYN-BGOIHN)T4U6DTW"Y2;IP&<7/<V8K<FMM8C).0E)6U
M[CE!':8+(0>A'!V%HN@.EN+FY_XR$'I+NV%#[$TLE\SN@F:'-(:[3Q@_;:&?
MQ.]170]Q-?;[MJ"2F%62V8#UM4#<US'F-M563$Y*YY.TV&68TEC*>R#M8$C=
M[2*E(4[;"N7FQG/#V0PZ"<8* \YKSJ?B$KQ,#&K7+%ZR$4RUKN-Z ,ZXJ0E]
M-;6MR4(#,0_@TS^<&&E34D[6Z4M>(RB)9&,4(2&7HB,KRDC>NDWD$\ED'8 %
M[40]U$YPT?AZ?>_$A1"E2'#&!U",ENIS'9(1K!<\RL!$\Q:AFR">M;[[B?3>
M[-$!9B^_2.G\[/PT$#7?+;_@O&Y5<_HM.AN_X1^SQ:+:H-,T.9U<VJ2?OF#]
MG=FTIG*_*X_^^_WG.(\&K=E,Z,,(<V.^M"S!,_( #1TC2I48N-0EEF2#DH%'
M?S(:RK[;$CVAI@7^<555BE)*3,Y"6MUDRYJ"@MX!TR47PT+(O/EHY#LH>A=U
M/B2^-U,BTTJ(-]OR?@RGY#2F\SDQ$Q<O\G^=+Y85TUM<DG;"]Q.>3=*RCIGC
MJ=1;!PM1H(>B2RWA+FAUZQ;^ RSC "&6?AR[4Q=Z8-4.8"3>MXY_3N>T^=70
MQ+_/3O-D^OGO).^ZN'?3&\N93Q;THYO=Q:[6Y84R(@<+6C)1 QBT+JDRF)0R
MHL# 56L;8ZBU/'O>/@DE#V#9/O02TB%W&A:+29E<1-NN7[W:*^/%NY=O+M_.
M=^5ZK5<+0RLEF>4"C(L65'8)0N3U.I8IHXK6NOF0H,$6<[3T'5?-#6N^NBQL
MIT.$H> AH !1:B)A\0:"5QI2)L.0):.+:=TZXI=1<$@E-BQA&-*X875P(LNV
M]H51M3%: A^UA."R(A?&A^A;&_2#VZV#27;ULT]?PO03DC,V#_,?;\Z^ALE\
M!66V?#G'/%G67USC>H5Q>8W[)"E$VL8XR,0Y*(86O/$:BD%$KZ7TNAQ&V#U7
M]NRWB"=(@ $2@!Z"7U'76=%U,MFJ2<#[V;RJ\,WT(8&LUTG?.3VO]NGEOWJQ
M7,XG\7Q9W]]/L[>S:>W/1/HE9)_?3)<XIZ=<O>!E-E_<>L%/2BQ!!,>!K%-1
M6U[$.M2R0'*U(9JV)<I!7)-G()MG_ZH]%T'O1,(!!E6/M"59F8)!,F)\K&FM
M7*NJ2@6(1F?#)4?6VH\ZQ)FTA_QG:5(__658?/G]=/;GOV/^C"\O@!/.M2/^
MHA"15IZV%5HZ5T D5D!97?..;?T#F4A&DNO2.E5N1XC/?NL84B4#S$9^B-RW
MEG +^!U_>9KK6D2R*3A=$\*TK=7XJS8Y"6SAF=9!UH-MW=>H)?YGS[V#*7.
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MUF+KV^W^)NDR$V/5]X^VWOOR,^Y/KR%Y7/[U]??:@@I/<O':9R/ AB! F23
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M/(+U\.0B( ZX#:RH2DP=@R;[),>V>"=M$4X[U[I+X"D\YV<#NPK[L2'XQGT
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M6:>0S1*FQ4TL9W->8]63039US)Z?>;I=G3T@M5AHDBSIIW6/ %V[241U6[E
M?Y&NS@Z.ZIR(*S04S[F6^>I"K.A."3@*4Y'?J?C*[#(TX&V;N:?S0&S3;KGU
M:S[J8NQG:+< .<RXG\7_7N_Q@9+//;D2ZOR7*Q)"CVGJP"KZB[=M6ZT7#QCU
M0=,I9:@F[C<M2'X"X> Q[F1)36_T%_CMI>^+BUE\,.+3-'TA:NC;S7$=L;#I
MK!EL%F/Q;F <&Q1#,[4JB6R1"N'H<,HMV^015M[!>4\[E9W[QQS$FQ_]Y#C0
M:B[CS8W/"K:[K!%U'K=B703^^)W-]C-1-_)1\;+_^<!\Z(T4P7V>])*$ST?O
M4+C@=Q"MVEH"=*"MGIJEPG5K"J1H2!33-HE\BO\F\ZR=1CZ*F;G57,(([H<4
M\[1.*,>N!^NTD4,=8;XEV/9[,EEY[ P\&D<'-C]>-^NF\%?B+(FU+4LP ]<3
M5.VV?<F9)+$TYTN)R(]:UH@60UC\B0/XPZ7>I1WR'I7;L:E<V-VWF0XLP"'F
M*[44/JE9?\I9U%&/1L7G5\G37%,".HZ]9(TQ'PHS.QL.FJ2R*\,PZJP3Y32B
M2B<Y1:/A@H:^^Z%KV-!W,@%5-C_!X# J.W6YW![AB=:E\$T26\JKPK5514UN
M;)!L47U>KD?.<JW_OL>\U7C;=M\9&K_IA>XM5HRJ5CJEFZ%>#@Q"FR;E9I/D
MQN^[^8A"JFR*:D%/T[A"-6\_ F]60OG,K8FNW>8@/OBY@)1.5>D/*@;+[@"X
M+3R^\_!H"T4.^0)V)I !K46?PD4_W]\/RITS2\"7^S&#([Q)YBMJ5@:<D;$@
M'?0*+,.ROEJL 54 )A@JACNU0ID=B K#YS2U._;/X0Q.Z%0%WHF<A74=7BK=
MG,C9^XAX 6>.N?LSCQ.OX&NI8/$P[8X>MY:FEQ^Z&4+ _J3Q$29183#%3TMF
MQR3+A]SLJ\)OM'!$\R/D*#;44MKY[T1O_&*T+U*YU][#:SPD>O',PU?O[FN^
M#YTFR!V(B:N\QSM8Y;=5TX&S5#_-U*W#ZJ/'-JDV6]?[>G<Y"\O*\A)G%YPN
MZU\HL<R(ZI7._)2YRR5PJ$D^06M/O1[@840*)W(:&=[=.!#$&PR4O;W4SC-_
M+@DRY2@6KL$4UJL1XB<O &&#9.;W^FNX*#M8V91KL?V$"Y,PG8)MBW<(S>6%
M$PD)*KFQ%6?HP,NCG0ZKF2(C%"4?A>JXB]MWOTA)RO^2$%3;C#B"^6@0_/39
MS)V'4:?#6075AN4*=@"?,D0WBHMRA7C])DJ/J!OC7/+KKR]*O[O8H;[N17J/
MCZEL)_13-X,R,^LST_JJ!JU0+]6E<@48B:Y&: WC358-V)!=^Y2\WQ94X.S3
M5ZCNTRJ:]88.!'JI;QS3^D+@."PR?63%\4E\2".J=>AM;*W>P#0!@CRXAN"@
M ]CK*.K)7;(H-![ZKV,"F72@L7MHUZDAA0ZP'Z)BZ$"M.25#-1ZQ.JM(Y4V:
M2=I$_&U@3QBR'P2/V=*PFNY(*>9859Y^E:DZ^JQS,O*52E_??57VK*'Y)U+#
M)QMI OM@"E_.GNF "H0+W4$'!)T'7/SYO@TLC?KKU\LFB7*IF[0^;@GOOU&W
MH71XO*B\J*C U/C%QX=,RW87KZC'2^3D&JG6+/J*<18*J%^WH07O*ES<UFL,
M-B#KKY7ED F_=>U]#PM/"5AA/!!/^\?0[: JF3#W-151687=);Q]OBNG,-_-
MBUKW++QZC)A,)O+55$@YZ*44N A6A4N2)G5T-ZXC>:AKTNSVXQ+P)=>?+?:X
M^!AGR]*![Z_;OX9M?-@Q7^,CKBSBN+NLQ24WEE/:M:03+KCC' ]X'S\_WN)W
MYO7]$&&R^9H 0O-JROTQ6^WGS%4FMW$#V*+/ZBQP%?(FHZ8Q:..KG)9F\=$K
M;Q'YUI.@XJY2JFM+?T'!#X$46U#/3L5A7&?KSFE2 I%3EV0^DV'=>6VW>VSG
M^U6^"Z]"%C4%^/T=I64E\C""X*?<R"DI:I:&KW?9JG>5W]/."\K#]O-6VID"
M>GZ:$X7@%R S1L8UT;IDZ(M^"CIQ(=^ANCK6)2BZ4 I6FL"+<K#]SL@V$DF$
MLT&GKIY07I;;LMNIV8(2C)ZY^9\GJU1PC/R$R9<&9-L+QGV"N@R674XVZU<Z
MM<O!%:) /DGK7B7?<,%J21(5,]A"J\9N/TM(1")463I*QVY(>9\(!+P3P::-
M,C--;"VI&M?,(ZMB-$4AX;=RF]+E1?#3XI"ZA>JNA6%"Y9ZGS2"%A_^25TE=
M6@68HQKZJOGJSYDK*Q(\V LSS.<LJPY,;^R?]91_BUYR2'IROR3K7>Q)W9OH
M=#KP%/TKN 4C5N+46%X5UM8L3^XM^M4F<%;KK>XE,41U.X-/=VMKOLIU&:C8
MB"MR6)=O_4W9HL8AG&Q=\;4=$Y;K"_6#C>#L/O'OM%+W3HG+)\S4TJKBXI7V
M=2%Y"$<IB)R*X;?6&Z+OY]+]SWW!A"&.[2B&:@%#C?(?M6O&Q_P-/5O8+SJ>
M]DBB]E)>,%=[@FIJ.PN;3\+[QVE9#JH)Q2ZGG9.-\H\C9<^D!Q>QG=Y30XL*
MO4YVB(H]4]-'^;&B/"KXUFNZD+"_ODJVGH3=(^HLOM10"AH(N&[POM/[@L++
M@A_YB7=61=+#Q=E%FY2(DRR+J0SH/@:=T: #53*=I>#VDL&;.6U<4_G/01;K
MP[$O@J_P\B.:,D?V=I8'6WY6#"K])CB<GY6#%JNC(Q#,C;[$4-PL 1F!KGX5
M&YXXJSQQW(E:*,H!OK;+94]C)Q/;=8:FUBF2M7?#SLE?7SKWABH E2&@L2AV
MDIX>03%RK4J3V2C,8+ $S]/NYIYF>F-S ^(5*%/ZS+SO07_1-GQ#;@I!6$2+
M-0ONI]51#ERM)')P3??Q1B//W)57R7YC"M7#CNHG#P6D)--R7%6GQ$?<5#0O
M;[B*WQK42>5\+Y;3-3-W22H+C9V>L-]S'(*KP52&55Q%U?#$3"2SS9AM-K!_
M+$R!.7/FA=]BCGVY"FFCI? T02?D'-NIX[Y:3TI&E[96?P8$6E#?4&,0SG/4
M;"U0HU6.GE"L\L-R%Z4\( /"?BV^]?--\?<2'>8#IB0468QBEH8#K3/AXNY\
M>SSDD2_B=K@X__3<&2_$I!N:#C"A)SA(W[#'/E=3^R.LT",2"[R5Q1#;G\8Z
M GCQ_.W=V<T#D5WT(36-#NBJ.,@E/\PI5"N%_A.XYM[MI3%64*I"2WTC! JB
M\%W!'T\H1JZ)76)!=+0P("G_)LD/TJ5X^((!^__T!0[;G>B A"<"JT(S58&!
M]J;D^S:TPE:48?V]R+^=VC #)LF .M%<I,7V^NKI/9FQ9RJBP85^4-X)7E/'
MEHG>%I7#)!V#'^6&EA,;(BV#1H?A)J/@.9X0.F #H@,W5;P*5T%;QQBXI>P?
M&YN$Y,6/"*W_!"C7!=,!$NT+X_PXRFH!29-1;5U;H7NB%0R@OPPM@<S ([OU
M9O4V'> G*3!L'E&UJU]LQ9SM<G_))/R6F?$A$[1AA*1.[-/[PDB!71ZBOVS*
M>K-&W5O9ILRD=B2;M4_75A5.]>Q5BFYUX%:7(0PJU'H3?C% K[W>,2IW<FEO
MW"_#3;RTT2!/;RM;UGA733P8^]UW7R\4,_.^(F"Q343Q]3,M2:OJS$(G@=\!
M0[]FKD5T^>_] ',<:CPA?(X^'"D=7%G\H*OR9+I"8Y\F 2&B::%6$!JG5,Z_
M[Z!MZ$"DX31#)>T:A@"N"*(/HCV/47"7LB80,]484OT6M=ED'$QBT!LI]!A>
M@[:]@(A%52]V*,9/"47>(#XY=/O^2E7>]U1HIV2"#:N=L!>K\)P_6@#]4Y'D
M,TD'J/S7/2B"M71 2(]RS9T.T*+%:VF<UG0@IJPH,!YZ5Z-J+G$',>=PX:JD
M^Y;Y03J4PMMOD3R$CVC(+Z2.+$2OX2?/QB(77'?PG7#12B(RPM>6\UZL@7VA
M5:_KY014TG AS7=;:*V8S/6=K$:YU4#4[(Y^C#T^JNCX1L_E\41=4@ROQ>(&
MK7HW"9;I]#K?FF_]:4.Q%+9M*.F:3:7># A) 07^L<_A9L3F<.E"4J#"IP\;
MQJ_[?[Y$=160_&WJ"3\P>2M[1O:-Y5_B%P39A'T>MN\*[.Y3^/=Q4(HDHYKO
M3)^R:J_HZ_#+<G(0"\D[R?]VPX3!PIH-88^@@1$EY<I2)O6,1=:"EXC+Q6LB
MIS$,[EQ-9&"G'1"OY:5@6[.O\E52-3LLR)9$, =AFB3+W8$C+.X]'RW%O=<K
M(+W$ZM>>:AT_N)RP$V<18F'.0%TLO:1DF"5!:[-=B'>SD3"YJOL2"79*N2PS
M-_60X78:?W8TF\\AVO2(]GJ$\,:&4@VPT\)?15Y: U>%:6<$P=^PG3A/*"%K
MS6[ _T !H_V[&$I-0Q5KR:,KP3/O_P CG!P)4T!J6Q$?U1*MEA1TF)G\B^,B
M>/+FF;VSKOAK5"0U%/Z'>Y13,W;T+Y[>\M4,R+!:],*5GY:X!][[]@<8BAS:
M3&'*VZIJDU$+@0'7X(-%(=6:#=WCE21$2[/4B-3U)Q5#[NX/#OFCWC-0+TNB
M;J*NG[JCNLP4)H0FM>Q1!M,@ZF:()"=N&]37FHKWM7T%9\"9*Y(>'VME2]WV
MXO0:/H#GF]D'=R_X05DU0"!DLT* =GOE17*(WH/:4(?=V!Y5)'E1A=SKP>+W
M6>^X;'FGR*O;QB^*6 'F(0&2-D&Q,R% ""\3IK(:P3-AL5*S]6TQNWL!6"3<
M-X03I$I>E[VZ_+GGT4^DU6+_0=WR7J5R7VG?17Q!=O2!"5;+A<$[P@/.37=.
M5UYM\I=V<?>Q?#1\^DUL4ONK9R&FW^$:V#5_"C]SYQY-@/H>9GB\+#O$,FMH
MYI:G9>J-;I".K@H)#PU,V ZQG';%](+ R-IJL[40<89=273@;3X!3?6N8P0D
M-[2\FC3_'XWBG3";2CM4RXG_(E@%>X*?-/A44U-I8MW";73 OJU[I5V:]@1;
MBGU'^XK8<J,#)Q!KG!Z,-(DM-E]XC\1#1FA.PT,DJ24!4@+9WDK/G@R!Z<:?
M'8]\X'R,#CB/6"(7NC!NJT3PWB!#V$^D*#KPB(<.9"<VK462MG>HQHL+H':[
M_&CSC>ZUE<YF)LJU"UZ0R#4O"-7S+D4&/8D8&Z+=$6I'DX76$#NWS.$A%-F@
M]#%$M]069.\'UH'(MJZ.7YY/^'1RA754<[JMO.@CB+0>4# 7O0>9$+KS5H>:
MUWRZ5;)B<WC*=W+2AHUMRX58/FS^\U'IVOD)5\6>[:+I\;O4,7("69%T;H)!
M>UM S,M7>PHS+HL6?M!5-;@<98."89;M<NU<R5<#ZB>Z04R-G,56GY^XG3LF
M=N3$F.1-T;#-.JX@4[@]-&V\/RVX<H5!@JP?9D?+,]] ]T^3Y"4PTD&0]O63
M8CK*6/-8S;MRI^G S_Y%Z$?3/T]@CS[Y.9_8AUOXS+1EG[CQ,W/BO6[[CLF!
M.?K=Q.H;#&KNAX8#]54IU07NB\VG\%!S-!Z1M7Z[O"7=,A"6&4[B#70O%70<
M?_6&29,5HO5%(FGA#R.J0*^5H:KF,D_71';>6U(=O]\I,S97??E#CE?+Y_;C
M#U^ &?R?S"-G_&D2$8DV670NK,N%>.<S$M%;BBO#L,EO_VSI+_VMOXH%XX;\
MZ<#.O74,P6J:8@LB+#?0@4-9OVF2@@?M8B/8X]T>DG:$#O1L[@7T@QNWI!C:
MG2,-MX05++-('+OVQ'=;(A=QKK# UNX;C\.7I+SG(NOW+!(]KY\(,I\&__-D
MR+\5".O!;H=AC[5Q\S74P:D^[NA"HCRE_\7:AMV/%='7/Z2CV@OWV20Q'[G9
MI_4+2=:ZC>\6K&-D';TW>MAIO@<D#$&_8;T=?+*4F/D\7Y4Q'33+2B)5V58(
M,C126YK;Z,G:;5LD!,X-^-!U,>*\]J^O>Y@E_YF"X=SO/TJ]=OF-H<I!D7]#
M.8[:M#KPE$#^/PT^P:XFC('$]L'!;O#S 0H*CTQFJ2PGH[DI?\WLT %X+AT(
M+YQ!'XHI@RBG6NE I_F,W]XN.$-T@MR]C4ZFM412* A_"M\(;2!E"]4,)E1K
M,#*I=D08'0A3 Y.*P#B7 'E:)!<;'6#U1!!-2>)-F$;$-=7:?>2BWAX+>!%/
MQLP@R;K0KX@;03(Q58J\O1>"=*OS7= GN21_378KW0CBY4\W;;*GW12:WF4(
ML,,'34<0] >MNYK!_6"B8LV?)YK0G-1N2J@B9I5QVZ5SS1ZG(BSN;D3[5R.-
MPLVM4M/,P*C_#/S8_-\?$:('\PE@[?D<HM1^!4:&@=URH>R.!/.N$:)IH_ @
M#'(L[=L]O])O#Z6+((6BHC26$/G=T,:^O2B2:"[M)_1X-3?GRE&W#<CFFN+=
MN0D;V>O0):^;XJTJ!S]LHP]S?=6?[3@-S3XEN[C+>Q.Z,+<0,YG0ZJX/.<LG
M*9>(R1^3Y<5>+=6']ZTCCWNY32(Y_'D?9*I+#8&Y*+HD7S1%C@C/PJ%Y+?3S
M5Y+=31.ZOZY2+D:2DB)/QU=_-Y]^?&F'6!5XMG($/'PP;GKV%JR'%O'R.)-8
MM!5%G^1-?@BS)D$=!.)C\)RU0X^%#11NFJU(2\0L''D0?/Y(??])1.NM9E77
M43?WYG-A!F;"3D-KC^/HP&;V)V1!)^Q=Q04]E7=)S8BY8,Y+^6XFX'O-JC $
M(;)%\;A!<4#:O0<9;](,+PMR>?M-)O$-:5H0KJ>.D+2)4&W2R(SXE4XX*"TD
M8Q9&*&<U"-2;CFI9^HI0"F70>--91;X5VL41Q^'=[T:;YL/GU!-7]AR3=0\K
M>5VG$8_!XP;&)"'BQ6G##^Z*C0IH0_'J]5@YV\1;?I\&"E9:TD]J$? % D/6
MTO?::]D"2V%-QW'(A4)G^=O4F.P$:Z_0:SR9NN==YY /#Z;WB"1S.L"IO>>/
MM9H"J9K\+"^><+.ID6+[;KP;6W?X$AJ71.6TM>X,=%-H[*G0EA.>%'YR.2&4
M&P<-AX)HI_H(D7BV: VYI;ZC<7CJNS?PIZ(+K\F46$R\ZUJ%R'YL@58J>IAX
MA<//)5LSF,:^20R:P'ET"X8]:+ V%+(L3YU:T#_!(Z)R.8>/#@"/Z, 1- >I
M$%^,BD+Q-.K-IF5/N1>'*/28K118K$%)'.N@<*^6I*7G^E ]D9-QSF;652F3
M5#C;^Q75HR=>;\*9*5?39A<[ISE)]U7L!;."8CS[*)?.3\K#CY629C%^C(@N
MKXX8GU*)F.*WP,>Q'BD0!H(!^>T4&KLM ;V>NAA%.VVK36Y0ZTIYL@:>S\'-
M2RUEL5%.8.[(XZ_4TP;K/]4@%_J]F2')*-7GQWI:Y\QQF'5UPE>/5PBQ1DO<
MXNM.EUJDMU,7L_57_V[DPQ/31:G47G0"(U0^@BLH=."4ABAWC(:ZVV) Y<VH
M6NLN+=<)NY*PD>'Y%.R%Z]'=LIT7-.&636?S#X1BLU>&&OWUYN;A631&%:_Q
M2\!S<RQG,A'S<@4S9D.T5&K*&QL\HPINY1QK0!XQ%18&!P!ZZNB^9:FG&0G#
M.86M9L*G#^_+"SR\V2H6*K]&?'_'_OP69(XL(2XRF'/Q*>KGB&- 3$>]^2L?
MUPQKZV&WJM++8YS???U/QRLS#Z/FIS \,$6R$<R,X)B9? V,K.XS4.L:?EF6
M>OOF4M:6$*',NXL."% <B'(.;SNU9$949E'//<HR;T/W'Z1SMYA_[SZ#4FU2
M\>C8E7@DZBP.<:76(EP<J%F-;F[VV<H)I.LZ%VH>M9KXGL?E/YHX#7S<8@U^
M"U4>T EQ$+G4/O1@N90'_\.K4.:\>W\.9@8%VO*A,?)HF3_X\,SJWE6,V+^.
M-2LRLE@@,G^EWUN1QK<+%J(#[NB#:QYB= #; 3T\*]\J/_6O0VN7$!L[5*&Y
M@&I,E*(9?/9?\=%_!)D"_@DRH<C.B-Y!V&TZ\/DU(W_J0VO^=<QN3YL2> @O
MV-[FQJ%-.N7WH7L^C,1ZE+!*ZR2#J">32,90!HVHS*>\48R$[BG^8B3N5VAM
M+1J_IM$S##Z!@*0(2.$NC.O%^X!?"WY^^ZCXQ@5%:7'>V4MWG:A+APCL%2BG
M^2:X"Q0>!.Y"109A7E57T8';S4CVRR_LV/7.RRW6UW!CI)K@LI0GI.NSBB]I
M:DV$_M?K5J*O+:J$.+B3? 7AEO::P[2'<Q(Z'F_Q4E;1.3*;>EMTX(537#8.
M_+3&:0#UV6G]I3/!;LOC**D-ETV(SU)-<PNZ^2C_AZ?P9SJ0Z=;U_&?LOLIA
M2NY*C=4"ZB@MPY]K-ZEM,WIV_*:TEV+1YYEH6O!J.0'<I2@&4_FMH3C;9*T=
M%V\E?[WVSL3*AW$$C^YUV7@Y]U)59TVR$HX8_RY0N@PY541$CK/ME1#TUL@Y
M1H>YE"#D:P:%R7GJE\B:J=LM2D0IA%AB@"#S^1-U9#,8E"A0/ &%W<9FLHE:
MGJF_%"$1Z7C%SM;;5V5N4[,#K3$HWB\=:_G^,#$(*WX\8K I<-(/NN!F<FEP
M>(",(3C-CL81:W%3;V>_,_#MP*94Q^C\RV#G2&Z^X$)*%W?0-G@B!Z>!$00[
M-;F+RFI0K?6D3*MT;"H#'QY$:WYSH'WB(/'MG:1^N@CGH!B%:6,"'0GYK_,,
M7-_?$[QD9/1KP51\Z]9G\9M[ H>'+9=.QX:ULC;&FK([?,F5=6-87ZHF3B?Z
MT]"T(T*C>@5:Z=$M3P?&]F<STV9C+,87>ARG[U6:=8\K3(@.(ZHN"0<7H)]0
MZS%/8C!A4W+U#.J\-@YE<7E[2OR13=PU/W6EVFR^?8B1W]ZI@W/-"QEW+<95
MK;J@(\@CQAGL8QO(:6@D@E=#G6C=MI=YAM!<>*(PS^:B=M>TLMND>%#QB1FL
M(?1E,Q,I=W8ZO#YK6$-FEG.=8_F+7]6[HAY-<:U5;D?6IA\3- X58OU4]]IZ
MF841J7M<>NCQME8C +Y[8#4F8*HXJ:^R6+>J?2F\:;?P<+/ 1;#>\!TVI?;2
MV/BMW/DO7SP3LN-SWQ/81AM-<,CU&,+^;'^GFWG+.->V@:^K!-E@L:VU@ >E
M]&C#+U8"3N@5XZ"DD9+(MR@ZI,:K 96=J1&%KAEM_0'1OT'0\X -&:_220KN
M$$&&^_:)V^LW)';?+__@5%OW"I?CJ\YB;G@ARLM@O&]JV2WEX$/?)5A?TE/$
M31_S-[0^L#@8][&99YEV-O.K@?C=JU=3>NSE^8Q>N =$S13V:/A(APTV6-#D
M B[KJZAA.X/DM3Y\7XDA5;IM'_V&4NW;/JF^\1QZ_MJ5?%7#4K-%]*DNX_L0
M75]E,ZTF/!=GVRK3J&\:EZR-4R_9X:O.@OVIB2^Q>*G\@NRL6X:V9[;/-H E
M*/ID88I+(U&P^#EW._7N'8>&I('VSHC[<V'[5/GK-.$<O#^5;]* 1F;PP!CT
M^+C\4G*PK;P7NIO2KTK60OG!SR/:^6'N##867(B8?OZ/'9Y_ZON2K75 $R-T
M( $.7@"-[9 KB09_FS;G7V\C2YM"4V(8Y.82K3]_$O7G-2IU. MI&\<=W>CD
MC>?FLGUZS\[RIGACRM%C"<FZTEPE0<S0YRX)5>-NOY^J7F];*5ZYFVY:)-_9
M,>L07;1J:%E9GZ2B*_::8M%(C:9=[?6]@FZ?O%.L?GHS!DL]G"8YD<4I3P;@
MT@$F]YH(@CD>3J[%5OW*WP8>\3C>_^9)!5BP:SH":XU;#6;S4.1!NH%B7L9&
M6[0L.DWS2I^6!NV'!!>CMFA=T-!WM&\.OU,Y4NI9>[6##OB6?UTL2D=VIU)P
M) 8Y85DBH0A[*\Y5G$\IKCEA[]*,VGXST7Y++X(WD@4.\3I![VVZFODFPQJ#
MKR36B&2XV2W.G*B> ?.2O!QC3 FT_+R>_*/N)7-(.G#K2-$R36A4Q?*5F97A
M[MRGF;--#0WP&^8[["J-YIQ1C_7U<@K /SYP)34U.,I*OC[,9K+KWR/7$G9W
M&2G5DPXX*2Y0N+L\(L",S-DY'374\I/DZ,8)><LRO1I8$_<@L^'.U/2-/(PV
MV!'ZR[\-7$EYLVJ>B&@SQ -JPV52G +E4@E'O&NI^.1#'W2N+%I1('56R> M
M#OG$S[C-Y--F X=L=J-]E?P, ^?+^J_5SJ*B)2X0-F,TN#_VE4+UW4>M8J]V
M:G-%^MP7[W"*<&#(%$UNBUYMFW4*+RIJ]Q:IRK$22P3S8W#16JJ( <UAS.87
M#*D>C(N&_Z/+@+Y_^M32[";T^@J#+F) VVJ(RN5]IT3:5SK GC:#;L$<)[G,
M\IPH^$PMOF<3"A\Z_WLF >M^B\IO7FJL ]N]FUBLJNZ^JRG;J2LG_]%81^"#
M7@^B6HC"MWV3U!GH.PLY!N&.@)E?M OX /ZY:3WRXI0>> H(^^V/[O=XC:K
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MD>]1(QPA_A[ @"I+/!C_UFK%Q^@/ U7^O^GNXFM\\PR6LD&PX+7L@*[#[N%
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M,X/#'.D/8VR0RZ_U19!C%G@DC;<22?H!/&06+GI%BK],L,UB*7OC'?*P]T5
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MU$6VWO4<6XX/>N:Z#/;:FMUI[&%I5C[<\CW:2F41[UBF1JSBO Q[ ^KL"Y]
M7J,^PQ/@Q_3/(SO-]'6=2#YF/KDU[8T!)6'N%R@MXIQN0\?<H<$O;OB%VPO
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M"!;"T2Y_L<5*3&K0XPLE]=_DEO<Y-:B+?\Y/F<V,JB+Y@G7KL0:Z@C1.)X*
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MEF-S9?M<:[9]%1;.'A3!H2YM_ZTT,A>I>$4Y0='>Q>><Q4=SR$*FA9F1W$N
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M[2RAKU<Y\97GH7Z^QEO-^+M3)QM51$?K1Z3E1#;-5TZDC;>'D;+Q+5@81?"
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M^"F=LJ;_HWR/#M X')9K\71@BV%%4OQBE*_:5R7),XLZGKM'G$P?W?L0,V,
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MKK07BN^(_GI0N=80[O_E]C>S5+9AAM.BBM$/:YJ6^ #657^*T 0-EH9%4D-
M"3'.Z4W%Y7=K(^-U^0ZWBQ_4S]K$O?3W4W+:[N,P;ILG,S--8U$4X>*EW(16
M>;*5SZ+VXY.;,(ZP/'%SW+[6LGOT!=?Z5/83H3\AY_T[>XV2@]3W<K>,R-<C
MS*B-:NBG<(X(+Y_264_EI:0"#46G*Q,_T@Z&!;[7#M_\N)LE,MO"\-WL2*0N
MJAN.MX;-BA-+2"A0^\$[4I24>3K#99-N^S/7"L+-.:*O- C"GK]9NHOC.*HU
MW\>T"ZW+W<HB7R+!EPK+") 5TQZY:=R61X-]K>"'^<7TW<$J?$4Y5]A"R^K"
M>*MKY\/I'AA)'H;CRRLM7D97^]@>\;F@6'<*OO4PNX92<2?=]8'DZ^Q)_(V[
M$L*H!R0JH8L(%E!T-.7\Y$XM!M",HQT-<UFT=,?/_BG5Z4V!4>KOZQ*-SUX*
M0$G4!%D#>O'_MCUO'4Y2Z*,47GU+!V[Y\%(9RN?12PG-J^T00F@/+Z>WAIU&
MJ./;[)SB>QY1Z2ISK67'F5)AAU<\I"(/[5*1G4Y!DC KZJ?]8Y5!OUJ>HZLJ
M3%]P<?TJ2.DU  DZZM\V1OC_-_&R33H2*@U"9B-T%QH!"JU/;CNTE-06R'=Y
M(CM)GFR &,B#)%!N+SML1\#>PQYQY;75EP=S)0HLCW'TRNY6_R_LO7=<DU^R
M/_X@(" ETCM!0% 1$*0H+:#21 11Z1 %I J(M  A09 J14! 09HH2!?I-?2J
M]"8H(4%%FB1(B20DW[AWOZ^[^_G<[][=^[N_O;M[^>/]#TSF/,]Y9N;,F9DS
MAUOK"UOPUX8<@DQV(K(8MHL)MISY^*G8-3TO[FC5 ^+,WH+Y) 7 72Y1BX?L
M2..>J)@8>"C,N]'U*G#?SFR0;\\%#2!GW7<"\2IK@D0M5RRH:M5*_[&;ZN'"
M8@L='Z] CN=\7V,F>APO^+]=;'S3\Z5WC7=-GFCE JEQ[G!LJ7I;,])L^&*M
M>DI1S4ZLSAZ4+B%>D;S T?#M9GI64\+T^C/BF>6<&FB[K6''#\:R;>+=>9>@
MA^%DC?+)JR/&4)F>:RT)WJG<A#JB'.DR?F/-E7C)VEU%1&1R,7;@RU8%N^NA
M3S^46O>K],;I1Y^H/E^\SW;/" AV)O$DS*] 9C,[Q]Z_K\[FK-E47:#Q"Z@/
M\4DAQ*Z2 9+*?H.2<1@9U$0(6 S1'&SG=,6WIGCM9)YQ"%TZ<O&"Q5&?Y\D^
M&7ONY",J1*E!(A0NCD,G: J_5"V,K8[6'+>/O2!\W?C9Q:=/:C7O^3<>[C47
MMFIE)-!2?0QZ0C>1C^")C!)(C[R%>E.5-#]MB%>JWIE6#9:W'Z@_-<></&<A
MXA-V5DMXN!M*D));=\<W=>MU9:O4CVSOWVM+Z]FTO<HXT_-L]J5N[+G^)?Z*
M4;E'\^!)^*^J]PV\9E1YA,#79[@I:VF\4+;]_@L-%<=Z)%8PM6$#^I0" "1.
MXD7$1VBUSG!"N@6>X:%OUM5-M2QHUYY-G4#(JV9&;CKE=Z4J]?$WN;7MSSEK
M6*$<$(IP2#J6H6U8D"#9<T'6+Q%DMZP\]K%OZ%*R=;-W597P^TC1Y*O&00 I
M@JI.\GU%1(M5F@1F@BG>_.-^P0159=S7$PFGQ7[ME![_VBD9M'V3%QW^JH,P
M@1\CE.&E=H0(X]ZEUB[7EA'256$>JJN&^.-/,@543EE:7A1W.%'*;^%,FPR"
ME,Z?P*'C4%X@@N1G*=.W"<.]>^_S)D1K7.)+O7P\8,2CTCE/]).X37O!S69#
MYW-!7-2G$1HHPZ >C8;_*)M_VN50:?@8DE1>0F9V5Y!KRZ&Y8,VA$J-2O/?
M_0QU[D3 68C@OV'C99=.M'#+J99:-\#-CV,I0)<,0/!IG_7['.04E3<W:\CX
M[*N9JU2"E(RXK)C)'8?PS8<+RH#FNS_ZC;6$07+/!]16PA1*!>6VK^'G-1>
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MVJ$78<YMFF <\L$6!6!PM;K9@HHLO9M^->KJR58Y4<GW<6P!CL[G^^\F^Z1
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MEH!YKG:23XZ6;N]S?,O+,9XXQM%Y4I>MZ0GNWL#+X =V#A2 Y3J.DQP#"J<
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MT?!+^[6M]*33/ZYW@3FKZ>H3CZTK$A/KA@I'>CV%'^P]@,J1=*C&;9PDBZ,
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M*>+7G3.&P Z'!]CMC#^\\CZY5TWN8G 9X)GFT//;"/"0C29+;Y7"HC7-XO7
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M\*?J -+-.F<BN^[5#;W6=%5CJ,(T)BUOC#X"K:HKZJT>\6<#(>Q(: :7*>D
MU&YK6M:NQ+&*X:U_<K*L"B<2DKW[3,CXA-\%[!AF&+"D&B(N E.'>O H,2>,
M9%**>U5M/=?KG-%LQ TLZ<S)A3E!"#X5"T(J^&S7OA5LU?B0>@"Z3:K*>C+I
MCX@[!MGC527#.Z" %"X&H?YR/Z4-+#Z^5L3E\W5B]?>8H),>7J:P7KAQ<<]^
M/P#Y[0XL;(W<2!FE1T[8D56\(UV/C!"EVY/G)B?=Q=_9!$T9?<HMVBG+9O Q
M$<"+'9--*=P\+*"TJEY#IX!0'])^??_]F0O?=1*N4K)YAR?E.I%\C/&Y(\@K
M/GR T?R1>!^4LNCKWGK3O"6_P,,M-E^]OP=I[UM6_L^;'R;U@X#--H8TO0PC
MMV+UK,S%[_,*\B2)F/&K"IH2Z;11[2-S33/)^CU'Y\NG9C[S =H__RN+Y?\/
MUX#^\VR&_^RZ(-I8)Z_PK+XA3=/%R:Q'?ECYG@'KF?>9(-;ZLD"4<Q8@UQ7
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M[U'V^V.(GOZV8L&Y (JNL_QR->;K>LRW7,^R/C2@CW)5FJK;'/F)%0S9J#\
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M:$_ VZ2YX855[@-IRY'CL[8;C*T?BO.I.Z8YD]]J_E].A8,[='@'$.ZYO7D
M^OIP-5W%5J+_7E7LTJG]G"#>7]8GS-B9[Q:$X!,AAY R/C@-Q8S/WNSF+V^D
M7*L_.UU;I*>XRTI_-S&$N4(^ -'X91=@K?[F5 \"/.H%#:I0K@ _D]2[(I*6
M1?%2:]G=#AO".C#Q87N&.F6)7HIZ.G--7&E>(NOS\S<7:SJ"._?M:],TWV\*
MNG3[B_:YQP]LR:U"F #12BF4<79+ 8$B^%NW6+JVS3[D^SR!MM"\]KU^+2 &
M;3ZW(VL^M%Y=Q%'L*7I#:;W IF+*YGJ%D=2^RM?3Z!)$(]F#P8$FL<_W9UTA
MI9+>%"A!W$C%6/LN^M<V_0-0W/:FK@2.5$L) ES)7R8<2)"8*CA?N0W1U?DU
MUME@UUN47Y;&8>#+C=2EW6&FCA*PW5IK6DB[2/X1BEW$IG.7YI<4V)[5.!QO
M(JV\D& /OKD-'("<P%-0BE+\8_)3V]-U@PH_?V N5#-&O[YX>1)^(C'@2NNM
M(T<IV;Q3JW+;L@0P[51O6UI*H@M9MCEE4GY:[KF.Q'N;:] WRMUWXOR%?_B7
MD5(H#8 VN>L[NF46,K@KMZ(L:)IF[N)MO'[ZO7Q8ILH)M"]H=__?X\+_L.7?
M\@LNR=N#<3M]'DR/R&36@2&B;X"VQ3\7<OQO?<FQ=TEHD3;;8-PV0%B'U2B3
M?%L;S*A2/JITB.P?RRSV91.6(;&H=@&0!5DF+W."AUC-UI*".]*019HM'HX.
MGYMN\P\!A@BLAJS9*NL)U^*FPL-/^>(XP55@HB5IBO)T #FW@#YNX.(C)5@U
M6.*N2I^%+'\XO2R\X.>JZ_NU3($>A8+_N$3IQ-$>YDYZJQR 6K>=G%+X?BA,
MSAAH\73<JSP,4[R%KM\^QAIZI2P:(\ LS&<8%Q!60.!G +W0'_%TJ"1M)>T7
M 6NJ?W>D&^)MDGPC+C9ZPJYYJPL^# V%'$6*,OIT6+)NDS I^8!^VU@A)6IJ
M(O?HT\FK:?->5Y^PDS5?7A$2,V/OL^*E\:L3#&H[N>T[,Z5&/=&GG&M3$F!Z
M!.HR!^>-=9NW0Z42#L=NL_=V<6,_T%G)Z92W@#GUM#?_8).!OSUA3<AN:Z>?
M9\4LNR[#,B"9LA)]3LMM[\XK%0/$0ZHUJ@56-<-.Q @!TB=\?^;TW?6NH$BY
MVKF%K0\J]Q5K:@:DBLD%IY$A$U0&1R\93JDE*P-AY*R'HTV03ZO'9!.6[YTU
MA=W1#SI\![O_GOSA4C1+S.=>76&P",05'0NKK8V"$9;;N'G-!FF:/DDB$I&+
MTX\ZXKAFITFG='R$;W2^G*I3W86N)S(9:ARIM@U5[ITROS )]+='U3S8.=?B
MJCC8,*]KZ":$JCKD*6H=6E:%Y$*PD936]PCG:)IX*.^44S+D?.8]T5+%Z6,^
MB3>1SJ*K+R\%@.;K>)DO]VJ!31R B*<8TN28:DHUC][ CI;MK!NX^7O8"R/T
MWO,>78D_</C)C"8S/7Z]PS?YKRR8?8D\ @*]!(D7R75@+@]HL7XR+?9.L1ZF
M07+;&!54\P83;\OQQKA+1%@"L__ XLMA?#J2L Q6_)_@!1*A'GYA=FL50E2X
M>==7B,#U*P=580$K>:7#C(T@?P:34U;75/.&,\Z["&+ 58GQ/@MRJ6<:K\LF
MA?:)#QZ ZF;-F$BLA/%W3-0.<Q*AHWY*@O7K-R#F2_Z]1P;I"MK6C(:&% 1X
MH_/>0N@F3/QY5M4?H@_58]5\Q9:]:K3X\OE'[10,7TCQBX7#](G-AY7=G?K?
M3VQOQ291F,&+ LYL-H,#?!_@$&X]"W*-JOS00N_2U\&WPV,+NKNCE:KRH26/
M "969C.@9V&..A^ QF<%&^!"TQ-E24<R")H.UN?*!WR67UAK+\PQS?R //KW
MC)I=KA7)$88B,.AZ'YUZ%DW SMZ:6.;UD"*:KYX4U2(TXF9TV  !D@#E*FEO
MM(HNUY;)$:HZ(1NN6O164"&^6]V\9@-5E\NK!TMC:#&=] 6!!,C%ZF'($]YV
MB,NXP\5JD^*)JPTYYZ]T4JY]TRR^:>B[TX%B_SMHC'+FG=2W0K?#3FI=8T@\
M#+7:[A#<_/Q<E/?*C?OI3N!I+[3$.Y;=N4XX(,_>TA\VZU_P5F%7*;PA[:G<
M0\FJBFE-X5^B#7]NC'LNXQ;Z^5$M^I#GT,DBBRQ=P#YGQBEY<RL=>F1E4_N[
MY&^'AL<_P-2U7YQ4&+Z?Q@_%H]L@4IOM%K@Y/M6G;<*JA8A&W=DBN 2+Q)"P
M!FX\4Y2$B<'/G!67TQV2?ZVM*"%5,>R:,"MT )JYSF*$/\>ZQ4K TOB5%I0Z
MOIE34?/]4=FDMNFX[?2BT-%=8\B<).58[)*%= -NBHF.4/B4 Q +X_B>H+J$
M*$KL.1E/;^S@433W0E@'?%W05I?F"^PO&WMGQN8/@58/O<BNK*@)_3ETF*\#
M#A>ZL7!G\+X1R(^S_'_B@4SF3V/.QN3$WQ\,M+ 0/BR1'>EY@F6[M@,+R&XV
MHZ(QKR>Q 2]>E]R\E5CHC=) 4-$6=J?X^AN++#O I[#X",LQABNN32G\HLVY
M'E/UCN-"<[%9*\I!')#='B-LP1K;"18 1=F<\J+('H!L#D <US/%JA?WLEW2
M[G9JNM'Q@=#R:+K<I,[?Q::NN3 IW+Q7VZ^XES(C- 4='LC:Y+-%9E=]9Z=L
M-)*,CLHJ[VK)BI5 8!0 5.[,JH#CFP)GOJHFV9$?')8O)/IN4!8'CBBU0J:F
M\):=:"EQWJY]S]@")=9;.(ZO=3/T47["4\CNCS1,@ 7/QW>A=U6._G;9YIU?
MIO$I&7S;WL"(>%/63!*_.&-DWCZZ#LW./%U<M!O3_PU!FV-#N<+'2Z(Q(HGM
MEB)LA=^S>!ZA7%;:>4Q$KPE]WG6,0%:Q4/T-D-<1<G_/./'N:JO,3R=#FM]8
MC;_=,[?]O3&F?D-OL4FI7KCQL5"'?P$)S>"T9L*\Y<1C2!4HQ^HK%D;P_'M&
MZ[W,6?>S_!Z=A]\.L(^\N^\G?@UWKS)TX_N2:*-Q"L*CF3 XLG.A+4@G:6N9
MV$-]HT\54@_^I,.%$H+.2[YN055U1#9_]=']L*=R2J;O2G.GQ@#[J.=_U/ K
M"X 0]N9VF;AH:XV)C2[\NCP'R!=04!W0XT OXR1[*KTLQSG-:!Q+.-N51#'>
M_+6M3D<OS5%HKI-J>P][9D) =-2GO^CJ'YY"EP;4R2)*40<@3BWI!6]YV"UT
MNX@#YI/\8MR-Q]O'+YHV<X_+"C?_O!0X%*#Y__B8S?_U:J48/7H)%I^+XH$\
MHQ*AK6I;,.^H+F>W-8K-V2NS"CK/;G51(L2#@KM=(X7(VRSQ6<?I<2A\R:P$
M[O(/)G05@;NM-T'=/:2R!!0^7%QI?(A]4W&TVXFDW%AS<J.=QXEUIR;RQ2OY
M\J(<=D-A"_,XH\_%<!&@UPCP(8C#VF=/8]"F@Z_3'1L;&][A99Q4D+D[H%?&
MH%=.K&Z1>Q *$Q\'O?7VHF#(G;6$$M%6W_Q Q=2"#+U2I8*8,8/MN]K92OK;
MP8#E&#.O8<> 8087&PG6S%#!-5W]NX=!U';&Z<_VRM;TQ(.)*OZFNY=?D),;
M[YHER?"SM BSYCE8,SWKK,-A\\B $[#N(N0^#JC)LH].1._1LGDQOS^[;>"'
MB<\:_F7%[9W<9.?W%PP#GE8*-(,.&:N2EMO1@+Q2"X052-B\,52,T%\ 5WQ_
MXF]D7/OV8;>1N6C/A<IH<ES=E6Z9QW&\#4YEI^AI6)?^,'#ULP@O/WS&37?_
MIR=F?T^^NR8Z93;GF<JJ4I&U*:VR'+T<24G[/QY *]/D%K)XO9<4KL%XUMZ(
M3/OZ+Z;Y3SUX)-_*%?Y30G;R]IBP,/M8K=P"+#;K$,V:JDW3QP*;)*DVHL<T
M<KL3Q4OXWE+:RJ'@?BAP:[KT(>9.LDP<AV+%;B8SB8/"$3*DN?4U!_(;\6L+
M]X8W\ZG<-5$OBICXHM95?FQ(\DI,W+%*@9@ZZ3>_IEEV!*.T/ B;+),3CP"T
M]=<!XJ;;_->:1+.Z!Q8N$3S2$29\R?8#O-?\+$]2;],LQC!'$>QD5 Q-F["B
M=:?8^=0G:_^K)U.-G4\>BQ5<NM@IU#WE,QG3O0HYJ2.%N 8P0Y1-'A@6=?(]
M^6O]C9&(6TS!U5,:EV70F<;IG&)XMZ1N>5U.$&<P)8MB#=C/PX-1+ A)_ %(
MR#NDZ<Z\@N)$PIJ9LX1><GS&$TM4:H*JG4AB]%LQG@#6+7 KA.T Y P!SH=%
M?20K151S1<$XY<-ZQU2ON_BKC'+\>D'$2=C;1W]>#)#0]2D;@T] *0])7>LI
MI!' O"U%T.H=SO+(]IU1)669A@]?2HDY;\U.L-WYP).;8+P#"8?PT2Z2"EIQ
M2&DRLMZ!0.0?>6;=NW)-T>]";'%7Q6<9RA'L!=1S)4!.,$KGW.I=;UF\6L9G
MYU,I<,K]L;%#^R5D+=>:"(_%X/%M23Q:GJP+]F2,@FM3_HKV?;>VL:5249UL
MZGJ$#$4#EUBC[\/J<H=>_\(\N7K_.:T)U^1'O8%JN:/U<E\MT45&0J#V_:EA
MXL.2'9LK+^^7.D#6GC9WS]0WK.M>*86T0#B0)VC:F,0.2)5E[+,Q3Z^X:?4
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M[Z>0_=@:2V*;^\FY*,<QXH[P])64#DOV6\/#LF$FJF8W%C03!#[P^)JQ3Z:
MJ]G7?:C'5[97,$?#;GX;DX9=N*$EZ:;*U>,>6&,]YEIP^)7$BUCOLO>8\ZB6
M)YASB.LCH1&DK)8QC+!+\A9Q*5GZR^I=]2OGTJ\_CJ>=D5D9^U; A+I\+LVS
M$EM*R#/>969DS_$VM?3<LO$7VS,/MX;J_I@+4\KJD:=H'( ?"0JE"@8V@7.]
MGZM\E# 1=1#XSD[;>?=K46>],P B>1DV#J=4TLM4SZEFA4^&?LP=UX2;9(G"
M-"[KBX47XQ2$6W[?89?-K-Z=:\D"I-&M<-;W2EH>7YYG':\^T>(D'A,2ZWL
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M5=?)"AZ*<D!'3-JB"R97K!S*WJH^P%>6!]J%GCGUBO8Y$G1GG0V$?()JX3\
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M70B/0N-\Y/ <3UYLYYK9,Q(JPO)[U=$'J/S?1K(>Y[HDOG6 _$[^E06S\3@
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M$-)UNMIP=Q-0L)!:]@N/222\W?K$/C!],^^]X]!E'496+N1_5/<Z:!+T)*0
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MFN[=VBQUNJ$ >A@VOK09;ZYT2%(%<,]=1;K'XQ^E+N_CZ+.L2[# *4QT</S
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MY8"JLLL?,IV**\6>6U$_V'!-"[8!"7[<?NB:93"0+<P3V*E?G .VQB"".]L
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M[E=3R3JIKP&.#Z+S9-/,=::PY81VC>%LALM@/OUM0OLVX* 3LWG#6K*_K*G
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M.PL,D)5\5$Z-/VO@.O^2XJS!6PHBK'[YA[PDT_6]I]/%<^7%5A%CT9>\@8@
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M0:]"L0P?+:\;#]8GL%V'MS0Q[]@[1,B5>9Y,%V]6'FJTHC3$=3)[VD-""-L
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M[ R._2G0>A;Q"U2-I [05>^4,VT#/WF$1WZ&>CC)X&K[ALW< 7HWU,8J)$/
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M Z"J#D8(4>4$K%^RY(K8NK3,Y^W#3(?+E<=",OR+<"#Y'(TK?_\EV/B: (7
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MDI+\4Q;&UW<IT+X-B@%>:E8S-GNBTS=_651HJ%C6U4; )R=AY/IUT;DP4#0
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M&\M%6X0V;8P;W@G4J?$U,&TS+5T\JRX;&L&G)YD6.J*2JAZCD\JRC8A!8=+
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M\Y" N1Z3;M/AP"NB3?L X(]]0('4/B %L@]X=N=/QZ9H^G9UH@^#%Z,IX'U
MLU7'/B#ZH(@G#7^-%H9NV0=03JW"2,, /X;?2+^1?B/]1OJ_"<GT)V1-&[_3
MW "B/^PSG31/#% N92XU\,(X2<^9^U97Q2,Z,Y-DC^4],F8QWE'"1HET7.X!
M^"(H8#5:'ISV$$9MT_EWKR&P?4"+E!_G/N"S,OZ@&P"K+XBFJ$.1]VH"[DG
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MHH"D)[I[\]E8\J2EKDVC3]HGZ[EC.]![-"9('-T_,0!.\C6ARKS"ZIRR2/L
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M.8EJXDL29PV.$#5TM(==;>LJ:B/7.[GS[#4[F.-\F,5^6?+\0E.X=YI3-][
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M>["HX]>(#Z^R#RQ93)UA;X=?!OG ZD(!ZG;8 !$6$U#T##LAM@W]QPGPT4^
M-PI_\8Y_#I_[%Y=DRYC.ST\\R),@H7BD-+ AB'%M8Z*0Q@K,HI@02C[-;H0T
MG*S$!Q.S+SVP6JP-.C9B<.FXE>Y[3<?7ZF\G6B1QCK,YU'<P3"Q-@&0[JP_B
M]KLU:DUH_^30K=@0Z>+6[T3HRCV9Y:"6"PBXFJ1-PUNW^:]A(#P=.,21Q73Q
M2$/4@.VPS&R=I<A=1J8AAB&E3B/JB$ 3S]=_W0]_#CO1<-;[,0;UV@/"1T+=
MC]3KJQBC=.8F)MOVVVHOKW<PW'^N5U)6#8\&LVS)Q:"/4JYA(%PM\TZOVDJ#
MLXR.-HF=S'Q_B>*(-?-%J!LQQ0:A3U0 HR$<+T%"WC8_IQU3>\JFKCQ@D'R<
MV8XYSIAYY(: BKUZ>B6IF^""74.NU="5E@H!%;Q5?(^LVFM46UTNF'5G-YR;
M+LU&SR_].ID\KL,<-R6J[2M'X4;.SG\EGZ;U6YVFIC9(=!,M]=>T$O53KUZ_
M@XY3.B%%,Y_J^((@6T$$/!']&LQ$5SQ?,$W5!<2[52PBXV==N+1@6)\LS))]
M1-OS@X-*4M49!Y WAX]D'+ -%@SCT92F>]^78(ZRU[1'*G8UN^?/.>^=2 "5
M.5>-JYT7\[-5Z=0#?+ML O)QV6'$=+3#V/S\2/XYI.ZFVH1E5>UE3.!KV;H,
M=GS7^UW)!YN:0<=9I'KIEE3O.+ 97HELF>_?#GZHUFIRLS=SI;_]6-7S^!W#
MG=DG[)WIWA+'&$!Q8%;:&3^+/P9P]8W6\A;G?,<KY(L69EQ*="FT3+C^8K)*
MDRA_]XH\AW'HC 6 >H[^R4!:*TV56H+![P,H$IH:Y0,R6P%M?FH%K4N/97K@
M6X$RUA^@%P).B!W2;3=3_@CM@.'U/L@%BBH,4EP)ERQ+";>_9G>5+TW<?A?S
MY-%['_.TG\9.YK?9H@L8C&ZO7]QCP*8]]?[04FM54F6:ZHBJC%DT7[[PSNW1
MS*>ZFGNDAR_>U(<IYO[KK'L&X]>\X&V*,6RA&K9;71Q*O-7_A%MFVB[UVHYX
M."SFACH3Z%X JTBVS^@:,U[G&O4SE(L4VIBZ&5PUE-'*IZ6LD=W\Z\32>A%#
MNX_ /;JU]BN%<H*O;8T02F/%E9 0C<H.^X"KPV)?ANP3Y!J($,?HK,/ 6N,W
M&U:3PJ(A=2LTELSGIAA8M*M02XJ2 ;7Z/)^5MU(+-)HM(]@.[-UJ^_P*QJ>E
M1G$!CC?8!T1:A#:APALN4-]"99HXW\S.SJ(-D?6[&++6O05+]A9VGM;'WV^_
M#E<YW"6]+=72(#) D?@TMEA[.LTU:TGIH@SOB,DSEL_!S-K&C  CYEDTA5>Z
M>0\62"<'.\BL'\O+M]<1NE8I5'.R.:5&;R%,OX/P).0BG.A"M&U6320E-DZ<
M_Y37FN[P*5=+H]4MT\WJU./#HE/ITH2=/YH&2IW"H,DG/NT#!KH+AJA5,,SG
M1-)*LZII$SH0Z75\Z:[9Y-CRWMSG+Q^,; 7S*Y",:4&4DI:4RW<V?U8S]\%$
M4)AX&+NFO#-S&YB]3F\?P"+A++$&=BA'6JZ=>]3(B?]<RS]<#D^*>*Z41_=K
M#T3DC!\7_F@[K^8%@F:]7"Q%)[>VQUHXV6:D:\#Z6TK7S+S.O1WS#X!?2#&N
M*5B3$HV1HDTZBC\N>VF6MU*]'')33L9/^;RP8_P%R394R8+4"S$UHZV?I6"S
M?\WB.EA6,$(W+C<(_!@6BJ3)$W(RB2+G)W_&G&ET6I\72PHY\6UF+;#]"N"X
M+B!^D><GNE)JE9Q%-T&8*C<8G=,?*/.Q+BPA?]0HF>8!$R]L!.B9,"9$X>H!
M?G-TQ:0ULJYY&MJ$PB=XG]X@&[9X(5,]<[TT&G0_&-K<K%+%W!Q9U5JJ6.!7
M3*/;$$ZUTV1YYY%B[->TLYFCIU/(%KI*V@72GP'?%C;>$4^H8*Q]?ES9=">=
MAK1?K@,7>;<0C4B5=D%9*9Y[4'@^@)"\&SP7SAQR0RC[P=,7)SNG*O?",Q>)
MHB(#Q0H]Y[O0!H-/9LUD5]?$S3Z'*/+?OVYT*$"5X0HH#(0WECT]BH6MU5"_
M8K^EW!XZ7_1$<4GPPB'J%S7$.\#ZK3,=P^$:*SL<:HL_TI$)94W MZ<<X@-8
MJCLE]QAF4,?I-E1I%PH_FBSJ-A=%<NZ6Y'BV\, N8A6%R8#@C0HW8E(S*6(D
M9=F>WI#S]I;2TSJ&-RZM))2RR6*,E.G*4T4@CK #)3&ORA8/*8]\F9HT$&FK
M^%:FK7!+0$3WF[W$&Y;+ATTXBO$+S7L[42_=>9U5C\!]9Q\*7K89K-3+,*FN
MU#LB+!$?'[]KA\OO#:'S"PQEH7MK&+G5W1QOWUE>U.GL?#7JYTE=F[+SD4<9
M(HT3"^.>&ZK=3RAL[/:7_AMM 9 =O1/<39!RR&L[ B1Z6\+>=IY%=@T+D9]?
MOS>@DOEMZEF"+X!5DFTKE0"<Y".Z#**<W5_O=01)<6D5W]"<_(S6!>,FMAG&
M]%9C6&^L;-:H?#O!\ M.X1E8W@>T0TH;@A'>%FL>P*/=16/HF0<6E$[9CW%=
M8BG@*7D]X&SG0S[*<5&\'OGDN 6(X\$BPK5@.GGH-'(3-XQLP#Z-IEC?+Z);
MYH/"GHB#V<_6%)?(UE10!,P>%:GJY\7WRGW"IG10,8CC5+!99"&?R7)_U<*=
MS@D(/XOTUDQS\^3-4F19657(CQ\SBB%"OB]9A74SV0HR ^A>HPI_!K"E=W)2
MK_+ WV$2-'!IN2,;U)/G9"7&U7RH8)KWAB< YM-7LWU^F!SIX^.>:][KY:7N
M6?7EQD"W^@\N"6T!!P=U $ R<9#GCRB*!BJFF\8&..\N?"J[0O5:^06L+5M1
MQ]).83:U'NQN\(+XF7"7<I)T%8G4Y$Q?<A75/^%>X1WB/T;W87>%2BM?U>Q^
MB (PS-#ONTT#P#NP#7*\0=A[I47PX8^JVNDR;\<6:ZZDZ+[X.22CR*U(F0#8
MZ+F]:S16,EW<J(-@!W8..1Y2B;3_O5E_BDK"G7#Q 5OK[YSIP=^P/T5\C'>?
M6P[1?3IPH*82"436](8U[P,X_:[.B(VL_9(Q6:O2'OA\3LE"LMZ.M??[[2.S
MA9L%HPW_G!KZKV\#\>\7U-G/FTZ.7.] #'PMVA<S?:VY25/441[V>-ES3@M5
M\YAE=E/I!\!8+,M?P&Q=K&P7]JF!B3#RFG"I6142H2Y78+FBRI'+DCY"'"\K
MR47F/=)BNLT6IP5X(TVX1(P@>;T@V\*:].M\L')'(986#] /]1_S3.TZFEBR
M*T@P2W]C/Y5_*^#95Q65IDRR-(V^TYQ@3#K=*=LV/.R-UF^@^Y6V:^DF-=@:
MU(BE7B/9N.KV].13;S7[!R]VS*^ K]-E/!=2YDY1T&GR)/ &/E[P7FB^V.GE
M4(KH]7&)ZG7MF%%YN'AY]VU>^Z^#@92VM!$(OA_,--BRM[V0AD.P2GIZ%4L[
MZ'<_L#F:[B/%:)L.M9]Z5L>V5][8H-JG>=I;1Y^@$[RM[_]8:PC+/3$SJ60\
M1-P^QB*6WW2718Q3&WJ'-@1E'P%CTD!5#L$$>%/R71# .W7VQM?!-9I9TW/V
MN?A51N!,6SJ#,'!:$$!]57*O \Y6=Y)PC0RB'4=S.-'$:!WU!E=;UOK"-7M5
MMSQZEX',C&(8D]P@/^,<[Y7F6G#8EF6\3Y;SR#.(^11 Y_VQ,!$AYO@F85%M
MEW_]84=?S/.05CG2.6(Y_BNQ?53]U"SH6"0XY)7B5*KLU+G7B-8PDO)R(R9_
M65S$*#!M>$\#"^%QI%W&SZ0A%@6C&Q"?ER\4MV6O%8;&.(X]U:*E:1T6=<$C
M9W6:/] I;$@DD_(S2$K$$:%PA*) L9L;ZP5]HBZE4BA4.QYG)/31G?FC"6K5
MG6SGW4WD):7D^6F0@G.7&9N:MYH*'5/8#-H3-9^ZB8ET7.W2-'UP8>%P@#_=
M"F:Z3WTKA%-N?DL*Q7Z].Z.(?R)[*4QGX_P6(27Y8HS^C1?B9)^ 0V:F/G2Q
MGJ<6IA _DD3<>1$O3Q%Z0X)>0<N*H+ZO8Z>F89/:][Y2*Z" -G\Y+.R$XXPZ
M_@<<X:@:7%7ZV=E(AHA,_B%Z-M.ZB7E+;)-#"]$I%Z7*D4V';*-6*_2"2*\&
M;/'E;;$2^H_=-+6>K.<L?^?X\-FFK%U#O31=, !L+9U Z&B&'*'<'*K3R//.
M;7D%_>J+)?<BEU[,7!4I=FA7EEOT_!A5\-'^?DR@]LB3.NW,,><)U^;II=$1
MPK3E YVTLM9E ?['I7>!.%/'OY/RQ/B+VX3.^"IG* L5H7X-&\OK_=0)?JQB
M<OSEV4_WT3 G!?DR11Q7&B;NA> "RXE\&0ZZ7D$ O4-O$1Q"K8L6D<2]G$08
MVY3%C,4WR0C',7MSLZ=:/*13>7Z"PS!7Q"00IYT;L%YL@9EVWIL+O(6NK8M0
MRPC[M"?W3O+!10RO0.-/3]07NOIJFG4?Z^U0!G,TB$\Z@_"!_J49#8-NMNZ5
MCEY"7S;;0]-JYG BT$W*^#$&(HC"$TLTAW>D'ZD@M6'/V$6VT8!1BF2+.?OT
M)DOO.*X?)/Z4P[9SCVG+$3N&8U+$G$!B#HG/NF#& $0Y+:@TK6:%?,"X$+PK
MQ4@NRYM>Y%>-_6I%SEP1!,>H*[OD.R%-4D>""RQ9K:N#D\W.6WM@ K_9BXW^
M=*AQ@=%O<#FU5FQH+;-Z'Q"L-3L['LU@3SY:_4N"L:ZJ[(+UU*<[\?-T 0XK
MT6^#L_H)X5#<WNZM5F+X&7CA"E0XK>3EAY6\:WI.$L>.YVZ*"0=T%5WH8EF6
M=?O44!DR/Z.=.F-G+A'/83P4]0;XZ4CVW\B<.UNF&]<^H-L5EE%^21C ?-<
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M%V2?L/ &4;:IAD!M'(.H68U\)N764:E<,1Q2Z3("&/1>8K&V0I^A.%7D\H?
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M-^47K0SF36F3WQ8!CT:W#PR[4W[DFL^)#H4DC:O7S\EM(ZL*R5P<GHF+\@U
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M+K-"F4UJA1]YY0:LWMO=7EV_MO!.$[QXTJO=6<1C6!%D5D-V!C@QR%F63OE
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M'5'L</5Q%05?N15AT>;H\O-- OE5=;=%K?:^P0X2S\T'7!;YIB,: C_WYTH
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M9;)7"_ 0,^A X;"Q[;V'O-\R_@3T@O'6T]M\<7J9.EU?3AL_Q4#>JQ@R-([
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M!75W*K_<-/B"V'K[LW(ZZWI[L"!U3G%UPTS7D0+(XD?)34;3.UT&SJN,Y);
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M=]UXPC_J6/!]IWP$ XACJ:ES;PXAZPZ@&!DVL-J7HK-TM*''! >E!(@9\S"
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M9['LAQ 70[_[@]33O'4?UZS\RZ?S*L9EQ=_,0E:CS_ OQNNQ_V:1@+WW&(?
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M!'N+Q==/]KV?ZVEM)4D8WY]/?M)V])@X2521Q!SZ8LU&WBSEP:"Z AY6-6<
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M\K3T;?5.7%[Y9M<D>M__JF/FAP"X(_8A?/\R\C78C6-&-(ZU"90^B;&#SI'
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M/]TOUC G"]YX_;K.G^I*H#;<['<MF5R*R'-.E:V3(.8-,F_04#+@'";\75,
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M05TUGN[LTEG)BGLA/H>O78JFW*;M!#V1A7S3?AS(1HOD+CX9K/ET2<EQ^@@
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M2Q<ZJ^"57^.]R;QDKKY3,Z059MG?TG+Z)=M2*.+--&%]/YLV@GLP)?);'<M
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MX!1DWQCGO?%BH8S,T(;R+S$I^1Y22KP[6J<VT,K@+BY;2B_VE8?]0W>9(.!
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MRPZ./BI8?]$B=@=%>)C'3 7\HR [@H,*V/$'X09T.6GA$KH#2-*DB%,!2VN
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M3^J#MFR%D"01">6ZR'*L_HF4<1&+ *:QG_J<)S+UC-K]#!5@;L2$?O(][X^
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M2*_Q])@M(3-_)L8.O=&JP3=:-]#7'_0 T$=[_>^U(( :A0O0XJ!^V"*Q?9+
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MQ%1(1@B"B(7Z0(\K0PPS"EF8",HXY1X.3<,&^C>>&\EULM6-8<W# )YA=?K
M?R@"(S./F?)6!_C[-!UT5/_L1I,=RN\3OW_\OO?O]AMV=46TC_K4Z<.'#T3G
MF2I,Q=VJV#9@%X$7AFDHH*1IH.P2XBL+13E!48"DX"11QHDTW9H[/=S<7LNF
M9%PM,E R7X!::K 5V_*@P1#TT_MJ;J$<^?U^)13--\7<HCG1]E>'&9"K AA
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MA"-& [O.)2=&G)]ON:E$D37%&RORW3XU\#C*9DS@$+F166$#V;%ZETY#_DV
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MUC.:O]&)_>R\V%ZQFI[>/9M[\W!HW1TGP4XQ32Y37D>5=_H$URG@WYO..LG
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M*?SPZ[W1<CJ\Z;S/,FZ$TE6)2[LL/>..]K:[?G!L(6T+I*HMW ?UI.;+1_O
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M45QR3)%?5>GV :?F,[^0%UB!P5[>3H=%+R+N1E(A<1R8FOI V*$<M!LNP2I
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M?F[^P5DB(-4)AY2QB$0BRDB$_?;KAA%T:OQR4 0\VLIPHCHR;7?EV$Z9ZD/
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M"F8<97;ACK,+/S6[U,J"G;:@J6Y9NV<"QG9?;TW!Z",MS][6^%XKNJ&MTK(
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MB[3TVF0Z/<S46.IZ/@??-O=J!0ZEN-<=>^.= =:-@_K#-3#?E *"2D)0BCA
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MY38SC&B#@2> "OX7JNQ"%]71B2M@:^J;6=VH= 5JI4!3*[!9@DJO<$0?".!
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M7*:,YVD2>1%D5T&FQJ2?MF7EIX>]"F5W!UO:[L>]6JFR%JQO%X>.)G)CD3&
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ME/,X0GGL568^F'5&G(E>F*6RQMXX+F8!TORVN .;>V6KIA3+(0SEMM8)#?_
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M/3_-)^M9(G6J-,T@1XI"',<QI#B.8(8EC3G-=)HY9;ZTC#&U(,I.3%#)63?
MM9*Z\7$;G.VD&@BDH9G1'Q]G6G- X 0WF<78;W?+IW\W5U>T9'XXL%';/4>A
M% >E=KS@\M5N7I\]R%>F7+PWGL?=<F6/2%<%?%E&5):B"%));3-RS"#+TLR\
M[ A1Q;)89D[M-B^.-+D7_>0Y6/LOV#?LJ%1X]BR6?!ET-^\J")2#.TH!4?3V
M?RXB%,B5.3_.J%[)175?.QB7+^A&)U_M'=?W-ZNES=*7[Y[_6"OY>?'M4:W,
M6G9Q=RTVQ5/EU.Q:^5"=9#@3 LHLSB'F2D+*\ABB1*@D2R,2IUZMW?Q%F!H!
M[44%;"^K'\%T,(,;\PP+[L"49$L96.G!3GR[.?^+U0#82.X!]H,6@[1DZ@YB
M(-;J(,"H=-8=H-<\U^-./1-'WSWO?_R/PHRV$O?/98&PZY_%>A9C+*4F$N8"
M28B%3B$EF$#."9%1$C&2>_6!<QMV:D1WB'.!O;!E;OG7Z[^;-\](W#6#M!U]
M-ZX+C^G _-8'SNZII$[HA$XF;1_T;=))G8 XFU#J=G4W4JH[W>W;,]4I];5K
M/J.9C/)8("B)C"%.M8!$4O-/DC$LM5(8X]EFN6%S-S)J'\Z+A/:##O?6_+!C
M %&W8+2;MIVV:B]@[$8YX9 ;F&IV'2L;'> ^[MKQO;O4CL^;:]Q@"<0Q%P8;
ME5O<%'_-*8Y7^=>TV+5R^VX6C=5A+R5__+6\618V+/6D[/__EUHM;Y1YS!8;
M=J?J0QM$\EPJ1B!C<09QAE+;FX<9[T?F),M3C=+(M=A%5R&FYOSL>R1:1<!.
M$V!4 :4NP"I2_6/5 0=].I30Z6RY=MX:RQX#L]F_ABG<2W*,89*1:G5T-TV8
MVAM]H6PIRM'YUJ-5Z^BK?+.,1^][=9FNUMN5/1]J$VW8XMGNF]HE_JX&A8@H
MB@F*H<*401P9#YBK"-GNES%.!(TRJMQGI=:QIC?YU.*"6EZP%[@3I;4#[3*)
M!(-O\+EB3.1\.#\8@J-1>P\D/4G<"9M6KFZ_PXB4[*3*2^9UN\2?8+\4C!?S
M8O/\:;GZ8V%K9KV?L^+!GM&O?]BG+M9KD!OS\-RSM3K\83T3.:9"9 K2/.-F
M<:"HH>$D@5QD.I5<QI(DKC0<1**ID?6^\*-9S_%BP:J3)C:P]U@+W\A6]Z@!
M%\9\E\E]=*,,/ 7L]0%&(5!I!"I-RII9NQ\/Z>*[V,A.K\;?1K>7^Y0RNMU&
MFGA&LI_7%!44ZY:)+,PXHTUW06%I3HIA;]SC*-C-<EZ(Y_OEW%QGVV2O9R2*
M42XY@9)3!3$1.32+% RQ)EJG,>.Q0#Y[@Z>'F=HD5QW(>6R(">:UC;S3'\X
MZQ:#[P_7P--/A513PK(A?<#L\78(0AX8.AYD_",_9Q4]>6CG_+<[[LTM'QZ6
MB]O-4OQ/><!^_6V[66^,<U<L[F:& 80@"85,4FVH(,\AS4@,!8IPRGF<YM*+
M"MH&FQHA5+*"M17V"JQ+<<'R(*_G]EP;S(Z;<X' &WIKKL+MML*MDO0*?',
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M&7YYXB?&6RU*.H'5LA3I=K_ G=$_Z_H7)?_.YEO5Z#6UZ_4]BV4<H8P)J)'
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M8$J1FJ9W.A#7NH";Z]G$?*8>RS:CU:&O+*,/ZMONSD2]->HU*=:+:C%=/@E
MC=\E-Q.M"Y!/S*(7W7ZT*=(%"-WYS\G][":W8E7.?R4_LN?U<]O30>+41Y3
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M*5]]6I?KE;A78[+79H59S"./^#P(/4A$Q"%B,84TB!)(/)0PZE%)A-4Z[]R
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M^%1"1'T:8T)HPN/6DS6CHT'E[>'_#DQH?U\IL<!ZHPS0\\H,+)0>H%2* #\
MSY4J=KPVK-G->/'ZIIQ0,O!67;#5%VA-0*OQ#'SNFKU6>_:FAH/^OCN.'L5
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M1!(:DE@:U;7K*\#47(;P%S^(_JL)*XV\/@&,?<QPFL+& '=@)JL#$^L@1:6
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M=^FW2+@GK]5T])#?L'^OU4!MS+HHOHCR3KXGQ5/S%S['+)0X3A@4S LA$CR
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M.8\H#22)(>>(011[/J210-J9BJ54](E18AI!LG?WJ;W16P'!2RTA^.F_CL?
M&\!W/M;C(E"&=XU:/!KA+L'"/,+B(DQ&BILX\*R4>=T=9I$7^N#LF:S^)<JF
M'J,NH94_/ZMO%[HRFIMHB:,XG8B!V+]FM,B&H^)VXQ6.?^G2OI1?1%E7G<M8
MLUC539F_Y.7_B'(; KC3^I +Y)% 4BA$&BBW!DE(4B^&*>%"J)5D&@K:MSUE
M'X%LWH3Q,K3JQ*Q"MZ9<K'G5HQ+<,/4>KNN^8G5,K^YGN1)/8EGH&*//>5&
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M!@9[K_S/T./UFY'>KP3/RD^$51N)-S^R8AXE*<.QCZ&DD8"(^\K+C[T8)F&
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MY*Q82].&@K=><I5:UJI;K%J0R68MK'X)1+UR_ANM=^YG37:UW=QF:S.SR6E
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M/ G^0VWZA;X^C\!?M9@.7L7@X3COF$T!\LBV2,G4A$-K)8#6 F@U0*,'4(H
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M&;-3"1B==M=%SXZ,RQ>,I)VMG6A\1K:WXPZ-.[OSY:#ZXG^^0))I&:(OA^R
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M.JCK<?B$^_W*)_5=F).TCSHQM;?JL#E+T\\WI\B$<YG$80#3 "=JDZ!)E/(
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M5IFQY>W8LG9LFVFU%@VKM&JZ/CGD0#R]<G56C&W7Z_KD1'T(5"CO1IQP8:[
MCWMA'"CUI-Z=K,6CDJ 67K_2G$\"LFEV,5IL[2Z]E-23*W3IY]#C"PUN>C)G
MZ%+EN][0Q6T-95E:%T^F_E.'(*6H_FFNRT).21!Q!G%,,$2IKM 4T !REDK)
MU2K*H]R-6NET9W,[)MC+VJ'^ 5K:0=>0O3C;74OZ0F_DQ>XX<+ZO+&W \,:(
MU-/5Q#1(YY4^Y#ZR>&<(A^B=*(O5MY_?Q5TG]SF262XI2J#RL2E$E!&81T+
M@%*:QI3$&;4B8SO=Q=SLA#[U7:[*;S]!(^8@1LFC8)[WC2^':&1CL!/0/SHN
M=)J7HC096^8KM'RQ8/;IWTMR>?3%"3DL^P1_25'9^^2 "Q>Q^1M1KK0F9A;5
M3?FI*)4C7I#EWHI6"T)HQAF)(4&Q\H^D#"$)D@S&*4U#P8(L2JRMG4V'<[-]
M2F;PR]((_"NXT]+K'8QL)==;D59TA_-Z&^13E$9QDDG(A+[7HC&')"81%$F"
MPH1&'.>Q0\$"KP,P?1D"/0[U,(!?S##\.M4XA!(%.<4AI!@SB/(PA21).0Q(
MS+E4BSY/^>))K.GJ+>9 M^/_/\X"BXM"SXB.?2NHH*P1W $Z$90.MWV>(9WJ
M:L\#M&Z79 XX]=V(V30SW?67@U(O[KI<WAMVDO.WU8K_*);+WXM2?-Z(AVHA
MDI2%&<Y@BG)=W3$*((TP5MX*3\(TS_),.F6:'_0P-W^D%1#\I44$1D;'<YI#
M%.T.9R["9F2KZ@:+\U',2=4]G;\<MC_IH<M)]5Z?M)Q^<-B$_M[F1=[(]Z2Z
M_[1<_:BN:64.AA<RRX(XHA'4A!$0"1Y!3 B'-$68HH3$E#@=S?9U-K=IOI/5
M5.14T@(C+OBK%=AQSO<";3?]?<$W]D7D<.2<S8(-))XL1&]7DQH+&Z5?VPVK
M=P8$NVQ6[)\WAN=>[4$?%J&@<1Y'$60QBB%B20!QG! 8A9+@,,?*HF#;PXI7
M;<_/0"CQP*JNT*!#S*Y,.(/#GN$U>.=W6A= ,OJDUVC4H@$MVW 8',($AL,Q
MT8;('A:W"_'CBO?=<[]Z8[KKZ^.BOKB5/O&(NSDRE>_J0+Y-R[1$LRA"6<(@
M)RR$""49)#PE4.11RM(@0T%&;4W2D?;G9I;J@I*MC -N0HYA>-XR78C,R-9I
M%%#L[=2%X$QDJUQ!<K)8/1#T6*UC;TUFN7I$[EJOOL>&[<EV]/6?R\?MIOI=
M/(EEV'QT+,:$9H3!G.=J2T:E<K"2E,(XP:$@(HJRU,K!LNAK;I;-R 8^#^3E
MZP/5;OOE":J13=V^ ,45J 6] C5RX0A$>Q:8>-I^]?4TZ>[+0N77FR^;5RXT
M%7\(HB,R]3+Q7\7F_L]R12NQ?M+1UG6GWX36KU@69A7YIMD7UT5Y]XY4167X
M2K^3I:@6%*<R09+"!,4I1!%/( T9AS&1>2;B*.-\5Z3=T<)X$G' ]>C8.T$M
MUD!KY&O<'$W8E&,QO=WK: =^*/5 5[_&*H*7&NIZBXV.P"AY5=,W7X'^T1UN
M,3T/@6\SZTN\M['-GL$]:=!]]S,TOEH6I>#O1*E^V&B^F6O."]VAOON3J_6#
MZ=WQN-FQU1G9@D9RT(@.M.QJ/N^D!QWQ1SF6'@B=MUABM]XG#B\>!,UAQ/&P
M9KQ-,*;VY)JO0W"S =2D;&MQ+\K*!$'K'-(O8O-U7:S6WY5!*)AXOZHV[]="
M"?G.I-[<DI\+DC$B L2A)(A!E&4QI(0(Y6UE.0I(FC#B='D^DIQSVPD:<4%5
MRUMG2_W"C,B.E2W&&M?!!G;JT7H;0[S7$M2'3B_T!+_4FOX*="#+%:A'N]$7
MO#>C7:O\ZU6;QJ;4'M5Z^QR7\:R\%RG?>C7P";7%JN&UNV&KB^GX]IZ4M^+A
M<;4FZ^=]0;<ZEJM#6/!5DWVNRL_E*7'U&TJFYKGKS69=T.U&>Z2WJZ]DK=JX
M?B+%4O^#$K]2[N>^%,,B0'&8"XE@%&$.41*I[7_ *$P"C!(J$8X2XA#R/#\-
M!YP>3!)<O2IAO8(96O%5V81/&!83N%'(P4T+G28A:[ S0< =9I,KL"$_P2\-
M@_FORCJ:#]UM49S/8%FNH_,1>$9+;[VPZB\'[&#I%B*M@;GJ4B&II;966I/Q
M'%N8Z_58@;-_LHN/3@ZO$5)K?(L15"!!O<GM5'SQMU3/;^@]K>XS4FQ2AV!&
M>I_P(68HX3"WPYQ!W<BO=3V,>KM<\N_%75G(@A'5,V.:MZ(H[W3U'U9TBY+B
MF"(N$@)EQ'1N5*@<!8%3&&4$)W&.,DYRNYP<'^*XV-UI\G6,-IIYKJN/J0#3
MT0CL50*M3FYK]45C:+>Z3C4N(Z^']8"L7@T(.3\@(]6E]0&KI[7F(E$F71U\
M@/;:GGMITSU4[9-: KZNBG)SJT91Z+_]MUBOO@KUN9>;#UMQ^V-U>[_:5NH+
MO?VA_NE9/]+$*Y DH!2Q'(;J!XA"BB 1(H$Y(BP+TC0( ZN*N!?*,;=CP>2W
M. G^ _"M .H;3P:$>5TR*/W6=$*HQ[YHU3L!HP8P>@#S#UH3T*@"E"Y *0-:
M;4"M3OWDM*-B'Z0WT>A,5?_LLE'R$_3G =*>X,!+6I\LB- #!-U@0Q_-#=LM
M?!$;G3C2,(WS=\]_5KKD\:Y2_#7;%$_UJ4U*:)*%,=;76#%$49#!/$H)3)*,
MT1@3%+-HL5EMR-)N9V#?M=.*M!-@Q&,]L0%,9T ]-K+KP@&K5FY =H*[>?T.
M8R&S-(A"%NH4/@%13)DN_((ADS)%H8PH"9U2^$8:BXGX*]YV+.SV6^,@/+)3
MH,$UJ7Y?.^#^HB4'1?DKV D/KL_#[+R5<D?,T\;)H>-)MTGN@+S>% UHX5)J
M2!,-52U8C(*$(0(1P^J/%.<0$QG#/$EHDO,L0!EQ.UAZW<7\#HLZ;(;$B#B4
M]K'!T#;\8#@NH\<-[  QLHU!Z?A2:>\TCDWS;T3=^%*YTW2-KYX;<(RAQMPX
MI-\UX7"_0WI?K#?/QG%M-F<9">(PP0AF--+\ KER%.,008$#AD04D8Q;.2>7
M"C(W5P7]ENT/,N)XR);YDF&Q.,F8".RQCS)42\TFV2ABM4DV^C2;ZHD'QN$P
M8Z(!FJR:^V4#Y>DXPP.H?><9ES0_W8&&!Q!>G&CX:&\@]PV[%WR[%#?R^SU9
M"TJJNKBR**LF6K_:K M=P]-DJ%^7_-6_Z.IZ5>,*/]^:2]O=Y5J29W&@:X-$
M(0\@2G(,\U"7"HDR%(>16O!21S]V3''GYQ-_WSX\Z)"5E01?5N9"7>TE]PJ!
MFEFAU487[%IN35&F@V>,VHYD/6-^&7;>^5Q&>^0EV"@'WVGMP%?R;$*3KM=K
M]8A)JKDZ'$YMVX^.\=7^:_C+Z M&N;B=8F!\41:-*>JTE$<3@'Y F31%GP-7
M+EW'HRVRLJL"VA;TJ.HJ'A]TFO'J44^C5Q:(14F>BH!!PKG4A\((TE#]E5$A
M:433*,32B=?M(G'FMOM22TE=*$=;FJ^DX&W1I(X&5T"?>*JUZ9O8%=QU7&(N
M&T++162R@1E]F5"*P%UQJWT5[ITN5T=&:=QUP NVOBS]9<),:\N] '=@K?VT
M.LP>?RZ585+&_QO9B)9>[^^"WPG-QVM"/%?OQ#?!EJ2J"ED(KKYDY:M^4=V'
MT1^FK*BR)XN0"$1YG,(TSD*(@I1 $M(8IFDF@S2)& \"%[OL1ZRYV>=;?7';
MUE13)ICH*K'%OVK+H$O"FPIEI9[S+PNWZOID9+FL;P&EP@+<:S <]P:>QMK.
M@$\_@B,;\E8AH#7:LX,"HQ306H%?M%Z_ZF0"*D!7-U K![1V((Q K9]9BOV9
M=;^(>S+OGH2:U,S[!?*UN??<^H7L._4U2D,&P6]>\3P<L$*\)(4P*]%"^=U1
M'"8QQ''(("(804QS#DG*2$J16@;<?'*/LLUM >A2O=3:M8POIKCE 9'+(?O+
M*_*7QD\<RBCF8?3M5H,W&M.Q;V$F'\[AI#W^@/?-U^-!LK>AZO$'Z4F6'H]=
M#%LHWI/'0CFMQ;_J$Z2MLI+?5W+S@ZR%J9.]D'&41R(-89 D"*(HSR%-I812
M1DD>JP6 )E8DM;8=SLVD=^0U?!Y-3>-NP6$EAJ;NX9WMO2Z1W&CE9KK/CH>=
M/?:)\LA&M@MP*RMHA;T"1EQ_]M(6&$]&\&QWDUHV6^5?FROK]]QL$!?%XD-S
M37]=EENR_&:*>2](P$60HABFF0@ARCB&A"491&E,2!HE@8@S&YMSJH.YV9A6
M1E +"6HI[0S'21#[#84/:$8V#(ZH6)N"<ZH?F?J58+_=K9[^MWJUGO7JA_UD
M/]G@))/[G#KM9#[[G/OD_5W<D>7'<E-LGDTA;R1SB3@)8,)E#)%@"<R#%,.(
MIU$JLBA(9&0[;U^U/;<I:\0#M7Q.%=&/X79^JEZ QLBSU 4(IREZ0N5!L_-U
M6Y--S!-*=.?DJ4>&^?-?-86#R1.NV=^5Q[H6FZ(F CTDF:I^+PA5^PD=+_]E
M55\OEIL%2U/*622@S.-<5_;ED(H<PSA(4I+QA&&&W+B6O<AE]=E/2K"\EPTL
M]Q*[N?Q^ALQN7S#=,$QD?1KYGJ_ <4:_O=3^]A!>0?2TT? CTZ2[$:\POMZR
M^&U\((W-ME+=5)7:,]&B;&F65W>EWDA]YJJ#0A;Z#*<^!;IF_[-5 G(E<T<:
M]3OELG%]DZ!^\5$]\D26PA2?IH1CS84?HHA"E$=JET2S$&8\YP2'$8N9T[G\
MN.+.S8'3$E[5%ZYB+Z6)K*E,2(<NG-9EL'.DOQEW[.VL_7Q&=.1EH%44=#0U
MO/F-KJ"K;'N4WZIKQKRC,&@TOJHO@?5O.UI[Y-F99'1\,?&,*^RT7#V3 '_
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M8W+7[@M3D5#,0@11DN80R3"#.6$8B@BE,D,BD:DUJ>- &>9F#5LU@-8#M(J
M_4Y2_V1VD%H;L%=GP)9^Z+"=/V298#!&-I3_#N-@?ZPRP7A,=*0R>%S\G*%<
M"&3/^<G0EB<[.[E0]>ZYR:5-#?/:3UPM?%&JUQ6I=^&--W*W;V@3##_^W.A(
M.KI4+U:;!8EREHDT@0%.U/*51RDD>:;^2",<Y1$.!48NKKQ'V>:VHO5=Y^WU
MNP([#;7_O]\VMTJ"O_9J@H^ELC5U,K_C>8//C\!NS_!&0SOR^OAFH^J\"1D!
M?T\[$Y^23;I=&0'2UWN8,;H8<$&L=E&J<9-AWI($JJU)PH($RBBARO)G')(
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MX4:<.H(K#^5!\(+I"61D5Q[=L];M"E!Q5Y3:;=9G&<^"K-W\O.$C2<(0IV&
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MW/:Q$T??/E7F,-#VV=\'5@*O-^?K^X=2WIDN)R9-P#2";:H(5W<?5NL?)E5
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M;S(F$J&(9]J HZ:T7Y9"G,4$$AJ+*.*$!=+I?/CE8>9FO1UN7W:1%@-S4X_
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MQ 0U1&8#BCC$7"8P32,1<T5$Z-;FPF7PV7%D*SOPFS[F-!]V]#@6RB-SHC7
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M&C8R ;REU=TN*<_59'D!1H:35&9Q""/-GJ:R:08I3R/]*E+.4$B")"2.!N%
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M84:J67V/K])CJI8?/#0*U"V_UT8%P-M.+*N]$O9GD#-!W>+P>":2SHBO.T1
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MG]_3>-7:-?NZ,%O]VL]CSO6J]2H7==N&5A]0*S0XJ,-MRBPI:OQI&/L0I=7
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MOM>K[3)A/) AEC . @01IQG$$B-("6%)%">*XL2M;8.C!'-;YVH%8*<!V*D
M=CHLP-L5S>]!W;#\KT8+5S>T\SQ9^GW&1']LCT\-_+N3P'<*6&(_H$;.0/R\
MU;)Q'7_BFC,#X3FL#3/T0>Y1^!\UO=[6 [VEE?RF']!^4DH2(6F6P2BBVL)/
M8P1)G$8P(9)GC&8((:O&UZ<&F1N[[>4$1E!'^CH)YVF&\@72R"3DC(]3U/XY
M "X(XC_ZZ,EB^L\IUP_Q/WOMH'@HD\SSILE;,WD\[8_59YJ+?;&\* TR$>K/
M/#,MJE"6(+/75S"(P@"Q. HSQAQ+@%L.;?6:3U^BNY,5/&AAG<)ZK/ ^OPWW
M"=^T67ZMG'6"']CA:*2VJ> W&%*G8"G?T$ZT3?8#L6O<DPM8IT.?K)XT9?23
MBVK/ J"<;G5G[@_ZI?F\SHO-A_R[-/__7[)<O]O*;S_6W^[6VXJ:^CEJ\ZC_
MW7EI,Q7&+ Y@JDTTB%B:02)0"'F,,\HP-U%2MEY:Y]'G9M*AWY(D^!<@MA)$
M01(-<.:Y3\!Y4A\5UK'/N?230"T\,)(W_V/D!UH!H"4&G0J@UJ'^U12PVQ/_
MJ/!/M 0,F08_*\%@]$ZL">[/G&QU&*QN?YT8_I +HV8_ZN7I6O]8+5D4,"0E
M@4&0Z@U]QB3$2H60,<JH2K(4A6XM: ^&F!OW]UI?&1E!+>30D-@]D);.QHO@
M&=N;Z(;,\-#7 ^5]Q[ON!WB=(-<#!8]&MAY>.>S3;AH%FHPI67;&YE4A:J][
M==V4-!-U8OH2A3A5&$NH4M-UFN$(8HP#_=TSF25"A''H5"35?NBY4<&[O)3<
ML:2A ]!VE# .?"-315_H_1;3F!6-W* 3? '.@.S,(NYX>6(7AX$G91UW0)ZS
MT8 G#"TO8D(23;C2!ZU&$]7_A]S<K46O//0GN;E1[_+OYCA#5#?EN[S:%]]:
ML@S)) @49$IJ@T5;+)":TB-$<!D&2:#I*W,K97&I2'-CM3:'Y6D4Z%J!:LNJ
M7.2TM,[I]#AM=EPX[62,S)&-,FT$9Y.!V$Y-HU*_:OT"F.0)/4D[O?1W!9YH
MYK,6AB^4O57'N%B@B>ME^ +PL(*&MR?/K?W7IW6M@12?MK5C)HHIPB$)(.'F
M4,D4[&<X#6#"4L43&H9AFBT?ZG8EVEHN-Y;[SZGD=R&:YUJ,QSD[(0$U]2AO
M\Z(P@>::6![:%DI?I'E9N+FD*0E;P]'8;G\6N7-.UF3OBPST"I\D"*K(=(P1
M*H$DE0IFBNM]2ZK2.!/M^_*^$'_[MZ738:)W19H>P_\;O"66;I@YSOO8WIW)
M^K;M,- _UBC\'1JR'9FXV3=<>R[W_R8-U8Y,QW0-TXX),"2]YB'?T%7-HVW<
M5R1(0&+,H4"!7LO2".O]JY!0Q8J$BF)" F6?,O/\\7/;D+82=B7HG<+GC@!X
M_C#U,EA&YN(1$'%)#[D$F<E2/IP0<LSD. ; R>R,@YLFS+@X)O#3+(JC5PW;
M"W9E&IN>D7IK:IH1R'>R^>\RR9)$)&$$4\3T!@[S#-*,AE IR@2622Q2IS2(
MT\/-C=2NQ/_:GFLY. 15.P/6'U8C,UTGZ*+MX0LZ6<$OG;0>LYOM8/%DTYT9
M;%)#S$[QY]:3Y5W#V..*ZX6BR==J.M5K ZV4=]I&R[_+O9^K=F:92F&LJA,9
M+#^ @4^?T9?1TZ#=13W1 3QQ'^_\PZ;&X%^=-A[/YB_$T],G-52*2;^U"Z%Z
M_A%>^KB!]5J.EVEN#J_C# D>A@@F@<(0(28ARTQ[Q%#&::K"(&'(J97JF0'G
MMKX?*>+_P4N!^+/HVY&@3TQ'9KL/)XN_+T MK\<R)Y;(^*IB<FZX:8N46"I_
M4(/$]KZ!1TMRM3+%WV4A2[JZ*L25N-<C&CK;Z#'?_S3^&[E,J1 \2AG$49!!
M%),(DDCSD!)A0E,9X8A%3A&)5L/.C7Y:J1?@MI&[]KS3)Y(#V8CNZ(JWFP5+
M/[IW;,=V@G>P_MZ#]:G0X/T96-V=UDXH^?(XVPTZK;O8"8@#7Z_;W>Z.VD]Y
M(>MP;!.&W?V_WAMQO<E_&I7][8?^U>-7^5T67>?Y1'*<)@%,:1I#%,@ $D5"
MR*6*>4RSB"=6)8<OE&-N-$9^"X+@7Q9MIDV4#4CYN&16SKN))\)Z9%HS6K1I
M'W6RQ_Y_6E4.TS\:=4"MS\2S8N^JGFAV)O)I7SQ+][Z:D7C"]H2[_)*G3^97
M]P!!WP'OXW$7U#!Z=ZPV2+\T2!2$I/T,0Y810;($IFF4F4-( 5FJ=_@1DUPP
M*61 K!J=7"+$W-:KLP5UGA0R,F_]P+Y*@V;,TB@?>1[&-M'/3\'3DD9&BQ$:
M-5T"H\_21JXB3%_=:"!(+Q8X&OJL@6<45:47?O&YE/?Y]K[ZSS+?;&2Q5&$B
M628BDQQ/-3/B&)(0IS ,XAA+FJH(8[=2U"\/Y/+535-?NI43/+2"NI':$3@M
M3W0NAFCL YL6FTY"T(KH\1#F) 2^SEA>'F3:(Y23BAZ<D)R^>MBG_UXIR3>[
M(Y9O].<7NI&F5G[!\U5>D] [*;:\R5])HEA*%$<PD"2 B+(08I(DT'3/Q8Q(
MA"/I4 )IF!16'\/TU9#,F:3\*>\?3+:1MM)DM:G]:F*7RU)*+FO/O^AT69A0
M8V,8NS&,XZS9,<\(DS!1MZ).\.ZPV,R$D1T\%7X!WNUQ_WP&=V?6&@:?)S9S
M''Q2EAL&S'/V&_B48:QXH[]*_<3BMNX"^26_O=O<J#^KYA1HB=-8;_*)A %.
MJ:D#%T :"P(3E:2IU,92B*W"5JU&F]O6<"=LW=M1+D M+UPKJ"5NSC'=N.PT
MUG;4Y0W!D9GJ$O"<"<D*%$_\<WJL2>G&2NWG[&)WT\#=U7>:KTR3H0_K\BM=
MR7>2;;Z:=A9U\>Y>W$M]NKQO:6'"7=Y(M2X-V2UYI&0H*8%ZUT5-/UX"B=#F
M%TV$8HF,(YG$ RPO+\+-U"!K8E=ZK60^UAV"'#=S7F;/<N\WV61,5>R2;<!>
M@078*0BUL-"H6'NQ=@& +\[8 K!:-V/6>=QD^L3:UY[4BTS3;F%]PGBPX_7Z
M</>3\%ZR>5[(.E6JV@W_K+MBBA2/6))J*U!(B!C/((E5!@5/ H5BGK+4NE^Z
MP[AS,P][HIO2&VVJY'[2[(]67< _?\ ]$J0C$^@S-!NYP5YPE]Z5%P%L?U8]
M$M 3G4W[!-SI&'H ;">.G5V>-MDQ\P 5^\?*0VX?+66C/8E$:1K2,%%0Q(1!
MI*BVQP/)H!"9E)0FG#.K/A#.(\^-]IVR. :>%=M/BZ6U/0;88Q^^W+R]!E>;
MILY-S42;-?A,R[I:I?>S7V>$ILM_>8U37F<X!N2X>#G/W9T:?Y7E]YS+ZHL)
ML=G*)8MC%:@(09[5'2P""0F/(ABP3 4AXEDJG8+*CPTT-WKZ(A_69?.]5/*V
M6=[7.U]<V0CM7 WN",AI)K(,$PPY10HB&B-($Q,#&^*,<)HF) O<CLU]P#S-
MP?D^3*43%;2R>@+7CMI] #:Z:>^,U( *=Z=A\%:W[L@P$U>C.ZWL88VY,]</
MX]X7./W3>M/;2F42:SJ0"D9))B!B,88DXPF, QP'@JH@39Q.C\X-.#<N/F<J
MMC9BHXD;:YS%WHX]?"(Z,HN<LK*-S'J_ZG.GZHJ0)X(Y.]RD1&.K_'/"L;[/
MC7B$S)=76Y'K&?N0E_?78LE0(-(DD5#)+#8521)C@&20A*DD:<0SA%,;ACEX
M\NRHI!$.&.G ]3L[LCC$ZS0K7(3"V-M!2P"L/_"CRK[P)5>2_W:[_OYO^I[F
M(]8_[+_=PR=-\I$>5:#[&H]?,&R]-QT(;U1=*'++-]M2;RBZ4E0RBB,F8TA#
MK/<!BC-(!0UA&@I%.)(1Q4Z;K:,CS>VS-(*:(AUOML935U5U2<3[_+^[2/9\
MDS<IIL,Z(!]'W&YY]X+CR!]V!^$3*4?H6GP6"T\K^/%Q)EVZSZK[?,T^?X/[
M8OVN/<KXIG<?56Z^B<8]L60TH4&0(8@S0B&20D"BE-"L(5"&4T5):'6$>&J0
MN7%%)R?8"PH:2>U7\Z. GE_8?< T,A4,0,AIN3\'P:"5_^A#)S,"SJG5MP?.
M7CO,-#CL?VF2\TTUZ0];S26R^T-3C[4R*3W??JR7.$PBA:,4\D0&F@9H $F
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M95N?&6[BU&L[Y0_SL"WO<]\C/G5^K]4GJ4?BY@A,--TD5F]7-+^O-NLW32O
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M#F,ADCC,DS#B3E6#;0>>&]-4+X BFX,"C@Z@->)V?#,&CB.33RWR9@M:,B]
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M*9=C23&/9, Y#()4$6$B(HA3*6$B49(02CE.K#H9.XTZ-V(\*>=ZE!M4@B^
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MPS)/(0^R/ IDA+!PZFIT89RYT6HC)K@5VX=B7>UT]FNS? E92YH<CM?8U-=
M=1!QA%[+5V#P14D71IF69KI5/:&.*Y?W3"-4W@/19P'^$*04QT.8NN#S4GE=
MA 88P2 7'*(<A3 G3,(XRG(I\@PCZ50VO&NPN1'#059@A%V UEEC+:]C7F$7
MS'8$X0N\D5FB-V[N>886@/A*-NP::MJ,0PNE3](.;;[3<YNCT%T8U[S\3)YT
M?9%JE:*<VJ^ZQ\%2A%E  YI#%@491"'*(0W5XBY+PR2(6<1Y[$0@W</-C4(.
MTH):W$7=I$Y[_<"([+B?T8VVY4:&-PS'WL$8 )_[QH45*KYV++H'FW:KPDKQ
MDST*NV_UK-"UV[#_^[$L]X*_,TDHU<Z'N75Y<(/T19_5LW:O..VS>G#*)<DX
MR?19!XEU8YE<+6%RA',8(XKR6(0B"9RB2#WEF!L-&0E!I0>H%#GL %:Z.-;G
MZFD>.WJ: /21>>LZW@MP7$N9BQM5@-'%8V&N86#Z*LS54XII"W,-@^JD,-?
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MA50=AIXXVNH.RFD@ML<]>I8(>]AL=_4NXHW4!V7U&#I25$>#U9*:4DYY (7
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MUJP0I8X7?15,MZ=2O]5+ 8D(R83>\T^R!"*<YY!@]1/%*5$^%L\"DKMP@^W
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M2E@@$P[SB&"(0IG#'.<""L:C-..1C%'H0C%NP\^-;AKIP?8@_@*01@$@-UO
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M%KQ=D;*\D;=;0<K]]LET//A#.?,?=^*A7'+,\T#&_U]UU]H;-XYEO^^O$+#
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MX-[G7-8E^(7OKTFU+S'=;Z(D@3AC&,1A'  8A!AD*(D!86$F-YTL$&$RO>Y
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M)SJ'%\U*OP1'"^7:M%MT45Z;\A<,@+6*.<[8N,,_:Y<C;52'-(P8CC @%!(
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M;#_+5UCM4_=L?=7>%T;Z5.VE*:]8Z$;H?*IU2?"JOI(]KJJ)3[% TN:F 0D
M# @#69)*FSOAB"49RWQB97,;];HV#CD*K5,F=<3^S]939&R-5K-!,&,5Y]#.
MS#!.4+7WEK%!R94/BU&?RWJ6V,#PPM_#ZN6Q+I]%N6>'4J\[G]NR]3I?J6R\
M^LJ5HODVUW^_$74=^X[S^UW19M]_O-,9,,,LBR/NA\ / P$@8BJ6F".0<1A
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M8UG*I[T=?]UX3S87S-?[3YPI+TMUV'>07^OCZ7V\YYN,PC2@(0.<<@0@XR%
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MJT^KZ]B[[&$0>5[YSU,D.PIH7!0O;8JCZVE)&CE?39 S#,@13 ZV2D6!-UH
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M*:>X6D]$CCH5<@D%K\,YC$2(*?':LD=R.MXC"ZV?'^S2,&S-24]0.4G0(W#
M;XN%K.7F\>C[.DB9E+->+Z?Q?%W+1#\M:GY^,5\3%?3%SU=<2^:KX:SC9'@W
MW]"1S\@,&%T\BJ"4:_ZXJ@WEPY:Q/)G]ZEVI([!Y#^7U)LP8;6+0D*1)H%BA
MK:E3A&R9,T%[F45KW^PAF@Y+83WS@LZ6>FF&LZ>=,O&^4\<77$]3F-WDY;21
M$S<__!3S)^YAY2F'47")QB:?06M#]M'5VBF-"-EGJ;VV:,QS'$9QLRO5;O>J
M%V?5?/\7YI>+U55QM)2*FV UN*2Q=HRF6$;&#-(&C(YQYT3KL_?Q5 Z=JV^,
MJ-L5,KVJ;02.X@,<SF:+/ZJ-J&]KB;CINH;;5R77)BE>K^4+C[5!J*DSC9%!
MB=$K+I)RS:MJ3B!WZ(N"8:':3)&/QZS?8':.G^NA\^FIH+N].;<K=!,Z65.5
M2%X(J,0*.$;.,'GE3F?)DBVMGR@>1>C0%Q3CL:Q'*N^9&M?MCCW:<5U+5 K)
M$E3 *E]O:P<7YPEEAL0\ OOZ2,SV>/TQ0A-[I#I' -Z;%0N;<=,OSM=?%LNZ
M,2>B,%%BB,"#4J!D"N C5Y"Q6!&S"2JW/OSOIVCH"Y">P==0'2,%UYO5ZIPX
M23HC<L= IUJ=9W2$8!,'8<D5,2PE+?HM0MJF9NA[D % =80:1@JH=^?KU3K,
M:WYT(EV*QH@$PA$G'3N>60$Q2^>MD=%AZZ[)#Y T]+W) - Z5B$CP-=61=;[
ML'RW[.27N^*L][CLV)L4HYCU%#=Y1898<>?!2ZE ,O);N25'E:?&&#N K*&O
M0GK&66O%C MKM\YY37$Z\]Z!#UK4"H= HM()BM-.*\Z5Y*VS@O>0,^Q#WZ?$
MUDF*&".F+HYY9R-GI@00L4;41=1V5'4F0X["%LQH2NLWXW>0,O"[WJ<'TQ$:
M&".0M@]UX0)C 168KJ&+<1F<$@Q2[2,:%"+:UAF+^^@9^!'OTT/J6%TTPU7O
MUZ]7,ETMRJ8 \,1KUST?[.FZ]2'2&UVS;CY]M=@5T#1GZ$S.4&2J(Y!MK=&M
M[=Z*\([9+&)J[9W>0<KIU>'?<'Z.U^VQ962)A9+!JEJ<)6.!("EJ-01_PUAT
M@K=.&>S2,.Q%: N=WR[[/D'*HRBNO>RY^6O7@;-V-)!,H[>2_+40ZBAFSR&&
M%$$'EUU.Y+3%UMT";Q$Q+%).T^H=\V:/$_# \V7?+Q?Y/*TO!#+):(5*GH$L
MD2BOUY].2@3C%&?)<J%W\]E[I\K>_.JP=\Y-='VBJ$;@L78O!S86<F*5MM%P
M!$]H)-+K&'9/G!AT)4BKI%.M#\&MY8>]TVVZ]8\5ZJ '0\7RNZ^X#+49P"6:
MF2<?N^A2KTKJ' 3RD[N673:I$BG =S[I S;^[G>'O0MMMO5/$M<(JH?I4+J>
MYW>!5Q:]1)Y=[6;$ZEU9!I^\I."KED87QFWS%S9[R!CVOK*I,3A5R -[ D3^
M7\)TOJKW]11#SZ^"]3=S$L[Y9A*DI_#<8BJ 1M;["J_!>>8A1"]*#MYY5 >8
MB4/6&O;2L9GI:"[6$?@2E\*9%!V,2=X YW32*<T5Q(0"G(L*A0F:]-Y3R#GL
MQ6%3PW&4.$=PJESV8=Q N\[\W,R7N99*%#IY]"0&51_9V* A2@K$@[7<"A?I
M#&WM:#Y(U+#12!\YBK9Z&(%]V1XS<\G<U3BC-YM2LB[0#BYXQHVF;:9JVICL
M9F2!@<W&,<^-BKXUO@ZE;=@$1V-([&8\^M#/*))EM=+V7:F31;OG7+C\-DVX
M^DB<3IB6I6@A@0GM0'DZK1W9=LB9!6E4EJ[Y67<W-<,:L7[1U4@'([!C'[%[
M<_H7$M<RS.H8FGPVG4^KC-;3;W@YCDU[8V(BWP%]#2:E$N#)ZX.HN+=!,1UL
MZZJLPR@;-E/3+\IZT,T($'?YO/F2?$\[PUKE@>=$Y*?,(8B(D((ATUP<*Z5U
M9X0=$H;- /6+H5.D/0*P7+POZ93QKNR.VIXD"DE+9 *R")*,K=04CSH+4C#E
M8N!>Z>9#A^^E:-A<4;]0:JB+$2#K1L;CU^\U<WH^77W95('4!R0384PH CED
M'CRH&"G4I4 91.+,:L6-YZTKKAXD:MB,4[_X:JN1\3Q_O%-JDZ"]5Z:F7FU]
M"Z*U !>-!^%$R+ZPZ)H_S;F3F&&35?TBJXT&1I#.NNZD]II$N&F6?4[[Y.+R
M9S%?_8)EL<2K01&XHHVT#*2^Z3PL?[Q9X]GJCFXSZ#"EXC*([!().+KZ'MY4
M>;O(18DEM09CC^P,&Q?TD4(;B^Y'LPV(Q8M]?+&_)[&&WE'1@2!+ !58!A=8
M 6.-SX9.B9A;=SF^@Y1A0XK^X'>:S$?@]KU?+LKFP>^D2"PB4"A4,M&KHC04
M"@D-U@IID\P]=,6X7GW80*$/@!PIV1&8D^Y6_-*X'M29K0BGO$D)C!,(*L<(
MSI#O@!@\F4S.K6S]N.?11 X;*O2!L'[U-)Z X0:?$^V*5#DH2$D1#T+5X0,I
M W,B%OISD57K1ELW"!@V,.@=1X^2[PB,U65S[\LWD[^$U31=B87.7,V]<,!2
MZ6I[ZV.W6OMI51#T9UX%V1@L]Q(T[)O6/L#33OXC\(;V,C,QF#1/D4BGP)J"
M8N,@6E]'QM/YG;/(1CX)B(:]GVZHZ$,@]"BICQ ZKZ:S\W5M1\$+*X%[L%K4
MO141HJ?(P"@E@G/%2NYZ!L\%*<->0#\=?(Z1_ @ M/4F\M7TVS3C/%^SA&E&
M_ZIO;H4)7B9 BB1!U4Z-SC$-P8<H?0I(@4;SBH:'Z1KV.7T?QUIS;3S/EZI[
MYE;<9.BD9ZO[OOX$;U@?9*I]W^#-*MU QUMK7^$U<)Y"JG/4E*S3CHJ#H.IL
M-2>,+Q2RE>:1S2-);)EM$CD0MPQ"*/YB2*H4%GA(.4C&,E.MVUD^,MOT%,_K
MF^/BOBS4(R0^@O/PD+DY9)&GBSH&?(EA5>UR]^\KP3E=K+5, 1W[M3TL2<]U
M P."]4Z$E*1I7:5U.M6C:??;.S:?6,.CJ%:]C^?=QIQ;+3OS?YYO'BE=38P2
MN0A![(%FM0T9R@ ^"5/O&5)"'3"JUJ4^K6@?UOH^->H> ?K> ##P.[677\+\
M,_'YVV*^:3!;^5_,-U;F[&N8+BMGEZ4NUR_RKN>C.2-#UG7T2^2\5KH@!)L9
MV"@-.>%<Z50><$*;$#*L<1X(ND^OPI&['R_#ZLOKV>*/?\?\&6N95K=Y"RW^
MH8:&J]6T3-,&%?-<>>=80C>J2#M3DQJ!G##K,Z2H&,;,0BJM,X@MZ1^V>&3$
M!KM7((Q\$[RO?] QUOW4^P7)&M?39><]7E1#O)^%^;ZSJSB/W>QPYXL$E6OB
M1) M2 :YY4:EK%LG17MB9=C"EA%OC:>"QWBNJ>^3!CET./T\W\PM23\^+8EQ
MDOZ%8:B_FVU <UL8.1=,=$""S Y)0;Y 5-J!4"X$S00ONG593C^<#%OB,^*M
M\D3@&/EY<L53\O2_.@<@,$Z[/T@!L7@)Q*B-3!O$YG?VS>94/\5<FU'D91ZE
MI1&4B3R^5LJ[P"E409",:]I:@4- 'P&Y<,4RBF5,ZY:P_=2T/<7<FMXQV:_^
MGH<3<75,/6)FK@Y*V&(""&D\N5(FDU,5(@BA,!FKLS&MKUD:LS":\3BCL+M]
MZ7X\.V"/ *YS2))<FDR1,T:O0'G:T\Z3]\.ESL$CU[ZTOM"YAYS1S-CI'9FM
M=/)\IB7?J!>XR/*L6I8^7'WS*0H>]C/0OLSA:J'K&AP?)6/: O>&4$<',@0R
M.^#1^Z"*K?.[^ZMIN$5/ S>R?O/]<E%K@O(O/WY?(06,5\TF7U#8]FUS8W,I
M@930%&\H,..J%@E5/T1(!+3>)T7_23>_J'L\E:,IB#@-07N\QC[5-8*(>JN^
M(T3'K?,>F*X7@JP8<"%ET"C(V25#K%7[26'CJ*CI6\]W%]4\1N@C@,MU"FGU
M:?$!R6M,TQG>"*X^+1XK2N5=]'4^J,W*@@K<@1/1@[0Y"6-LB+ZUC>^#CV'O
M=I\8PH,#X3FTSE79(S-%@>18_682=7!T]$17BC:*_I?, _Y?T]:YO=G/X='P
MV/:[CU'->&+;FST+?OW'^73]XZ^X_E(O':XJ)B;!H7+&R$T^7\7"P3/:W,PD
M[Y0GQZ?Y(-F#"!O60(X&H_TI<SQ ?85$ .VY3KE;?:YJT[V4ZD7N8MYU"^4B
M%54"9&\S;<,@P8=D0 MAO,[>ZQ@;0_5 TH:]KAD=6/M0Z C\V5<7R][5C4,H
M&Q2:.KJ^OB8S&2$$QL&R[ RS+EC7NF?9 R0->V4S0ERV4^ H"KROBR'?E;>+
M^>>WTV^8-RT!_QUG^?5B20*=2-I4-N8$64@Z%;3(X#*S8&P.46'*OGUGGD,(
M&_:R973H;*_,$=C,R^>WV%T7T&;K]#LQKD@CN =C#%G^%!F$6E2"*0B&T;F4
M6]?D[:=DV&N5T6&P@;K&81AWRJJV)/8R?)VNP^RZT"HJEBUG8%*LHYJL@:!%
M FY]U%%(RVT/K?<.I&[8_B^C@V=/:AV!G;S-&<D;I]_JG7OMZ55*ZB9$NCK_
M1X@(0;D ]1F#YX5)L9L;Z@&C6P0-/L>U%Q0\"+9C57)JJ-T3PCXM0YV!??WP
M:\*E4HQQ!"L\[4V-"9Q*OK:T]TPR@\'VC[-;9 T^D6<8M)VFGI%BKBL[NCX>
M-MW+O4,KI4U09[Z HE@+HA!UQ'NV&)FU 5N/3CF,LL$;V0Z#O).5-)[<XFWF
MWLQ7Y\M:T/)V&N)TMME9%-QGQ036!ZU(S#ER<%-1%%HI9R7SDK'6\<AAE W>
MRW88!)ZLI%&Z=)?YI\LIL;6)CQ9:@_:!PBHOR)1'7=NJ>X&6>V5DZX3A@T0-
MWAMW&,"=HII18NU%2HMS"MS>AQ_58;U\&G<ESNV-I;.3NL9@B3'R98E%<(6<
M"VNB+$[+Y+"'UMW'$SQX=]UA,-J72D>)WZU.^A?\=D7 6W]\'8U-R#710I);
M4HHDQS@:3ANU&/#!)5\,.2NN]9S'TR@>O*_O4,=Z3TH=:]+QQOZ\D&V]^?0L
M9FM+@F#J..#LNGXJ'KB/,0B4T;/^ 7L7=8/W#1Y#U'.DLD81=A]>WC=15D;C
MZ)Q0DF(YE15"R$'40>."MICWL7G'V,.I&S;\?N(BR9Z4-H[GL/LXVQ0N[1<D
M,FE=<1Z*8KJ.AG+@N/0@B^;HLHDAMZY*>SR5HVF>]R3O&%JI:P3>)OD>%Y=:
M+](_SJ=U;--U#9U.B4F3!)BB)*B2ZU2R&"!E;G+6J$)H#;W[Z!GE6X=F6-A]
MZ]!*,<,G(&MQ,8DM(>95E>LJS'!1L"O<#/-<IM\QGX5U3>W_6%VG^,G511*<
M RXXN33&*@A)>PA2&5\LLX+O/*'>6P7^^)5'^2"A-<Z>0"EC,&\7'-9*X;]N
MN"$NWB_QZ\7VJH]WPVRV>E?N;@(Y\<XYYGD!3-U8.MIS460-3!OKC2<M8>NG
MA$T('Z73V)O!?')5CP#?MT.WEXO9C,SV,LQJI=SO<]+Q-7MO<5[O42=!RY2D
MI_!0U9Z04ED(CM.F]BI[5[)UNG5WBN,H'?;.YXD1_ 3*'$5,?LNU^>5\-9UC
M?774Y<"JS"_^2YYP9P-W&"AZI!!2\7K1GP-"*1ZCTRZQU#HA_QCZAKTC&MHG
M;:6X<<*2Q/H5E^L?M5WBNDYKIC_]6G]DHHIR5I=Z)18ST*\YQ(STCR(CRB@P
MQ-95&H=3-^R5T-"0;*.T40&2O)1MYZ9+SNZ1YX2ER))V-?W+D/Y19$W.2I"!
MU2?QD1???+3'XT@<]JYG(&CVH;Y1X/-P>4X$0Y6,#6"5K:\Q=6T*QVO3?&9$
MRCK*YN4=AU,W["7/$Z.R)Z6--[=^\8Q]KR!SEMEI<IACKK<'=51T*%R"C2G(
M8(T6OO6#A\=3.9H&J$^26V^EKA$$Y]M6_\-5&N)=G8-VALO:6>%](%]EXKP@
MF'@&*E?#'\CF>U^O^*,T1FJ5M&S=\?1 TD:9<6^&D'L22*W4-3(4OEFMSFLI
MZ>95Y2=<GKW"N)X8+G@.L4!6*9%G+ 0$[0*@%LG;E)/@K=\Z/$S5*+/P3X&]
M!DH:10W0]AZZP4DN$;WR#D+PQ(EP!J*M[ A4Q2>=LFW=,.TN6D:9(>\+9$T4
M,HK(8WN[?/RR6*ZO6'%*QY",!BD=N<;"BCJ]6M>,J/6<%:-BZR;V=Q(SRN3U
M4UBPXU4R@O-R>Y?<9(0TKZUS""XJVB89:Q-?2>%1L=9[QK)I_E+_3F)&F7=^
M"L-UO$I&8;ENW_'<NM"Y* >>Z,R]\\@A,Y9J@V=)7%8_4WJL[2TINFH]<_QP
MZD:99.X+?STI;03&;D_I[_EZM0X=3R^_8/K[:H]0)UK2GK..A,E8(9,NZ]V.
MC^0PN%(PB.*%[1V:AU ZRH3ST\&TN3)' -FMM#J="^?+](58W43IB_G']2+]
M?>+(ZC,Z&0"E4,11L> $!4V!I4*N+HK@FM?K/$C5*+/,O7F#;94TBJ/[_94/
M\FI:A3C/M1"3%ZW(K=4I95#<($0M&$1N$RH7L[1]52=LD7$0M/Q_,V@=JX9Q
M8&D[6JK;X=W7JJ[5K]]KII'D-W$AV8 Q $O5D4BJ/N[."$4$YB*J;)J/P7J0
MJ,/2P>R_"]":ZFA$)^<'G'6%W8M/X?O?INLO7Q:SZB'48LC]/<^$S4Y:RVJW
M 0M*,47;B]?*B2P$:EE#L)ZLW&-I/0RB_VVN+)Y"H\,_(-BW([<\C*ZB8I]G
M*[TQ!44!A[Q65&1&+H82D%,N%)X%AJQUF/)($@^#ZW_'6X[6^AN!?3U<FA/%
MN'"F&$!5.2LN5<X<;<+D%'I57_,,5GAP&"C_N]R*]*2U$13$_$KA>UJ_*[]^
MI_!K_AD_D#5^-Z_,UO^OA9'?PFQS?) <IXEL=5?!.\\W_V#K)R?:&ADDU^"*
MJ"_/NHJ/I$$Z$R1+V@C=^NZN!S9&,[^U;4G-T H?@0T^B=G]<\CI][/SZDYM
MBW4CZHDO(?&0*?#DG/PH"C/!%^G!R&*<S"$'UKJN\6DY',T4V+8[9<0P&<'!
M<9K%H#.7>2,U)(O$;&)T0!;CR8F+(J$.%K'U;)+^#X.G&"<[(H@_2HE'(_9K
MMY%( LOU"'!KHS)1! G!VTA.I$P0I$[@*1HFR6=M1>N,6_^X[>UN:Z2X?8P2
M3\3MK_/M7/#33D;N#IC5=+Z9?G63H=/F(^]\^2FF)-_'3/M9R5TJMR;(R.?<
MK'@%6UM<$)Z<6V_K3:A4#)RW"5 HE1FSW++6]X8'$7;RY)'+13YU-0JY2 S9
M6\CUF; R:#;/1Y*VBHMB0FA>[GN3@M%,/6Z$A5NC0XZ7]PA"J"OJ-Q*I>>/%
MO&N@\'VZFJ#':+(.D)RLG8<U.0:AEHYJA208):)NG5.]EZ"18.D(3=\%FI/%
M/@(,[?#P:G$6IO-)E%(P+!F\1P%**-I=I0X]09XXA4;>I-;/IO<2,A+,G*[H
MW?S/R5(? 72V:D3^BF<1EQ/#-<.,&EP6)!)M-,0D& @M"[.8F0ZMSZM;1 P+
MF0:*W?6R3Y+R"&#R(N=I%7]]E37-;^8734HOF DRVNR\!)8R&6*4$IPAWI0W
M7F6*39)O;6GN)6C8QTSMX=-.^B. T@=<DSPP_QJ6\^G\\^J""UE28H%V@(N5
MBQ(2Q,@BN8').DGL^1Z>*>VC9-A'2NW!TT#>(T#-BY3.S\Z[NHON KM*:$E!
M[WPU_8:;-MZ7EE4FPTT4($PW,]T6\#'1D9Y5D$XKDVSK-TD'$S?L35@/AJD7
MK8P ;K\MB/CYFKY*/_'YS9R^C*OU!2^9YZ(U(UZ*M:"8JA?3SD%2:*Q-0CK7
M.G5Y'SW#7AJU!U4SV0^(H]5R/7FYV1JT$S;W4IN+K'?E15YTI8U= !(RY\Q0
M#%MBK<LN7('GJO9YCT7S($4H![E.M. 6CNAWUQ@ZE):1=)4^/K;O1>@C!]'E
M?O,^)4N11'1,UJE!%%CHF$!C4J:*T!\V ?Y$& T9\/>C_4= ZPA5C!Q<UV-X
M+ZROB('@8!ED70*H*"RX(@5(4:(FD68ZW9_"6NW0-5[ '8.)QUBS4Q3T+,"'
M^9<PJ_=;%PPJ3H*,,8+,QH-RR8#73D/.'I.PSLIT4)/\)@C<(6Z8 W0T,#Q%
M52-P^;=FCK]>+'_#/RZFGM7GQLO%G'Z9-G>HW2'B5!";,6>&R]J6B)C+4@.B
MP1B#1B]:9TD?1>!(VIB=?E'3GUI&@+E/]'/7V^@RGZ>]41HS.),C[1NLQ4 A
M0-11)Q1,J^:5,?OH&#8'WZ/:%XUU, (<70OG8WV 'I9Y]?O76OI!FF;,7# 5
M>11&A0@V*+/IIQ:1?INEK?,D-,O8>O;;080-B[33]7\[*=98&2- V)5%?SN=
MXQOZY6H2L['!>@59Q-H7U4OPT@1@Y&K*))"A[ZTVX8J*D;PM:%B0<)R QP"1
M^OAQM=4$8T(!AT:-"HKP2/XF3Q1D2P1GR0%$"E58:'V2W2)B)-4'1VIU%R0G
MB7@TE<.W"\$FNKXO-+4)MRP4+!@NP)=HZ1\H?<C*VM"Z-_!M*D:2 6V$E=.$
M/!JP_'4Z7]2Q6)<7 1,T,5L=%-BB&1#1"KS%"":RD+7PEL76;LPN#2.)KMH
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M YRL_]L7_:>+?-Q&H3:TFZXO"QA>+KKG-S@_\DG>?5]K:$(.)KI=T';7>GL
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M2WD1:_]-3'UY17Q>_%A9=UR<&FYU<-R#T;%0C,4+A"3HUQ0)58QS%UL?"VQ
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M9_EW@)W?KA[[.?Q-PEH>WKZ=A#@Y7UZUOIM-TW7Z0+T_L!@!.3KBBQN*I5!
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M@0A1.R,Y9ZIUM]4M21P7EX-!97-([JVW#F#Y\G)Q,?M:6SJ<+U6W^#+Y=MV
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M]N\\H1L([**VQT&PJPP[<"*>O!OF(F=EE "T2=&N&0.$[#QH+$8Q9H0:K.O
MS@F0@]VBCWUCL)M:NJC;NQK^NO@\NSITO&8/%[_/ZQ2EJ (/13I(19)[ABR0
M>Z8UE)(".I^=2ZWO#9ZCJ;OSVAWU/QM0%1W8KXU2.4.M1$-![(3:)%$I!RY:
M$EAB2@L1$DFOU^S:<=(8]X%8<Y5T +--L^*$=))C5H"N9@ZC<! =A8<BE!)<
M/5"Z[T'];[KB7F ;0C$=X.WWV2S_-3D_OVE%=3FO,YN0',U\BD4X5R+YJIK<
M"46_0DPQ@Y:.++53REO9&&1/T=-Q<N,^R&JF@H[@].%RGKZ$!=Z. 3O)_[I<
M7"Q=@E,IF=;U-C;6>V 5C8>H;0297*%0V2B;6F>C;418'PVE!P-8.Z5TA+13
M1B*@!R D%TDRNA8"*A^!8\B)91^T:EU2<OWL/KHC#X:7K43;1?QW?U=^AQ=O
MING\,A/6;[@*F5MG:4N6@0RIJI57C@<./EA38N!(=K6YZ_0\77TT"Q[ ;VJL
MDN/(XG__[6+R=?*?Y;>^(:]QLLQ_7[SZ^NU\]@.Q#I&Y2C-^.5M<-)C@N.,#
M!\C\;\%ZHYJ C[BXF%^FBZ5'=3+-R^94F$\24;3JKWN=XET\2@H($= XBA4U
MT^1QJ7IH+UDHFK9 ;-UO8F/BVE4+//+(I1Y69XDY,+22O(#$I*ZI" *"<:H.
M6*&_2.[)[1RL4.!9\L8]*QL&38\7#+355@<^V]-)5MP4VF2R(^IE'>L3'7A-
MSH?,*HL894#5O-'NWFF-!Z@;: R#K3(:M]%)#P#[.1?#">4R!3.,V""W)3%P
M*&H4'53,R7KR:_ZI&8U;*?;IC,8MI#SRC?2;Z1E.)[./?_^<CA6X-<Z;4'N[
MD2R4MQ!Y"A!%DCZA"5C8,U[8X]_>5?[B-JJ:-97;R)I?DX27@G:ZW@E@LK;V
MCT1:"UF#]45HHUP(06V@]<Z3%G?4^)[RZCQSF4?I0@YD_$HTH"J$7:V.XCD8
MF81,]/- F<N'2DO<$0<M)3DR*%[.OG[%>9J$\T_?L/YS\6,]3S%'QC27]8I0
M@"HR@DLF@B=7*F3'O/*;H&/3YXV<;-($)H/(M@-_\B?7NSK<2_=[@?/ON/2B
M@BK<IAS VE OEW,&5Q>"%JA\L(4);)VW] Q)O=1B#1NTM-1+!S#[3)^[)[*K
M!9FM38$+!D6)9>?TVMZ$N"G:1^-1"2M:YRL]2DQ'AR_[JGPVA/P[ -+U&>LG
MK&V[I@FOS*ZS B/YYN2:\[I-6P-.6@4E9[1,4^076O>M?X24<4'42-&S]E+O
M #Q/K+#;JR"/22>LG8-3(#GEXBCFTPCDZ+$0:,4YV_KJ?A.Z>BD%&6W;VTU#
MO:'NBIE3)&OMM"U0"DMU1IB$F%6$7*J8$GI?6B<>K:.CVQUO1VT_!:==1+\S
M?+XMDYL^783Y1=.\[]>S^4],G<J"@7.ROIS59I4U\3-Z,O"%%V.P,"/R4/G>
M]VD9US,?'$Q-5-#/X-YU:V.5DO=FFN88%O@;KOX]U2KR2*R U+6_N40!SM@$
M'C&)S)VSOG72]^;4C;LQCF+"&JBI;QR>9NYM\3J3B)!L=%:>W =49*BE4Z8(
M-''09(5MML?!3J[&V1ZW$?V>V^.K:1XY6ZEA^]%-GW"X?*2#-"7=/&5$Q:!R
MD!%84;61+0_@I4 (%#S*G%-*Q@ZYIGM)0$)C,M,J@'&%W 6LTQRXH6@\%Y7K
MS/626J?S_H()2-N@:9\$I&VTU4&P^71.!#H;% 9#FX5"4"QI>I4%"*TMDXYS
MUCP'\!=)0-H*!ELE(&VCDQX ]M-U6K)<BV@RY*0T*(\&O)$%,BU"IZ(.(;8^
MQCB:!*2M%/MD M(V4CZ6.VA)_ 0E&/"R+%UE9+\%UZ!="IYY[F,,SWA>S>^@
M#Y2DM)4Z=[F#WD:VG2:L&:XT8YHX(+I5X 6\2[S>U8N<;2CY?EUFZX2U Z4O
M[8J%!G+K+V'-Q8BA2+*8RXFTRE+423@&%F3),4DG-\I:VC%A[4")2KMJ?$]Y
M=9ZPICV/TM>AG<E)\J]R J+>@#0ZF)(BB\QNH/H6"6L'RD3:%0<M)=F!/_E<
MUH/5)![++.U@->N!$]!]L1*B%(4D984K![R./:X$I'V"EI9ZZ0!FC^=%V)KU
M5UM9\IH<H600$&**P,F*ID".NBRMYT4>:0+25BK?. %I&_EW *3'4F&BE.1H
M&P%),EIK+I"85(X0$5D6-1%&M(Z$CRP!:2M%;YB M(W41_: /GQX]>;KMS"9
MW]FK2[(VD!L C$PU**-S/2S(()/R1EA&+IS?P.M9\]7C;E)M0=!">B,K_VV]
MH'W @-48%(L"HJI=!QP)P]/>#,I&'0-FF^Z/*EZK_K5?/F[(TQX ^TNP@\UC
MHQM=PZ7$2/MJJF,>%5,1 BL%9 WND:)YS5L7=?Y:"8@#N;V[::@WU/TLL3?3
M=%DIJJ]/BQ<,:^*2\T@1J:17(3,&0EH9BK5,V]:>\(:D=>L7[XB)IT#72$&]
MX>XN(S?W)G7.59I]Q??SE[.O1.87G"XFWW'UQU<U06%1^^J\FEY^Q?E2WZ<<
ML[#!9^#*TN(6DH&KB2K.:>-I;T%O!\T,:L3'$>1*-D/T&*KO#?Y/9^XY9JU3
MB=?F8^3)"N9I89-/6YSSM-Y+9/=G!?QO@N4@4&VGIM8)EH-DQ[V9?L>K[H@O
MZQ*=5NF^G4W/:@NK.V^>? ^3\^I;O9[-/X7S/;+E]GUBP^RYILPWRJ:[^]B;
M3"=,R@1G*;SQMDY6(' GH8%KRPT+PB#'QL9A#1G[6L/?,%Y\0MH(5FE<]V2Z
M<MP-&A]$210;UO7%/(>H10(F>0B>0OOH6N_M&Y UKO.Y+R+NF[O6>NA@H[T5
M43UV6!Y5>TE$UBX>SBS+_(D-^I.&$!DZ)KQ-H362'E(Q+G":*_I!V\N]I-X=
M;E[2KGLVFU^E45^=+XD@N)7%0E++B,M)XH@<@!*\#@Z9#JJU8_8\5;T8I-WT
M_B2,]E9"![!Z/?D;\Q_AXFKE71]6*Q^"1@K6K9&@;/$0,XOT2C@AG,K\?FY+
M@\$9:PCI"3S[:_O!O(Q]1=\%?J;DKD["^9MIC4RJL%8C>D50VC,!O$8Z*F*$
MR"7)J:2@;4"5<NOZB4=(&??P8NB-K87\.X#1YWF8+NC)"XIJ/E%0.TD4W[XO
M:[A;U+6X6/_6U:V-SC6-4!2@@)H1[S&#]]&!%*7HI K/S8>QM*1_7*/7!%#W
M\RG&TFX'R/[STVT.W,D9$E.X^-DH7!E^;U [712(G!RH+&NC$LN@%!L]9BUT
M:ATY;TK;R$D:HZ%G=@!5=@;13]]FT\6,:'@UI0=\FT\6C_"8(AJM2H:$F>Q!
M1@DAN #19>X+!IU2ZUYKN] Y<FI)C] =1,4=P)A\*IR<36\9K4Q=L8+%*A0A
M@U L@PK>0?!< *W3()E@SO+F <WCY(R<[M(+*%LIK /L_?EI>5=81?IA=DZ+
M*(7S3Y<Q3[Y/%G5,['4-A H8633 A:[3Z'*I7?$$)!-2"5Q&VSQI83/*QJTU
MZ :1 ZBQ W"^G,V_S>;$UUHKGVF5I40"RCK58P9M("BE(%J>62P*C6G=D^E)
M@L:=^M8-%-LIK0,$?L3%))-@2$I_S.879^$,7X3T;\P/&(NRA"B,A!AY :4S
M,6:+@:BCMS'7/C$#Y!-N1MRX\^6Z0>8PRNP I;<ER\_PI;0N69A$6,+JG-#"
M<X$G<-F%XF,0L?DDDTUI&W=L73<8'425'4!T65=[<G8V7^7=W+EOORFH](')
M7-M@)5IR"CDMONC!V"*KT)(TH3$TGZ-I(TBZ7QZ23577 11OD]SOWVK<+K*W
MMS,K2V*)%P'&U=HG9'7 $7>@?;:2(CN97.L ?"L"QPW)A[XE&DY7'0#Q8<K;
M3\+\2AO Y#^KA-X785$S $SM=F,S1!X1E$DU 1,EI)B1!>Z*QM8]S;:EL9=>
M4\WA,CN@[OK'9DJ77R^7Y1._SV>+Q9_3.8;SRO#OM-N\P#*;T^+_^U1JXQ%K
M!7.LS9ET8>2?U/&\Z(*.(AJ%K:> -B&\E^8#(Z-X "T?,;3?TF^W3(N4,D<4
MH*PECRK9")XS#3:8;'1)3K+6MYY-".^EP+!7:.^NY7Z:/3_ME9V<G\_^JJGZ
M]/M+HG%R47D^+09)U@G!Q9I>6'+M0(&%0@2CK./<F>;)O+O0.7)SH8/A=W =
M]@/7QT7YLQ!.6>;!11^@L-H:)>E8KW05!"]"TEI4-@>VN8_1-N[A_WAFM8FN
MFCD%0Y=OW9R"O Z3^?\)YY=X,EVW@=2SF-L<V1^W8GDS/9G^_-$/L\6DTMFD
MV.L ] U3&G9HP0Y82$9P-T56;Z$(1<#/'KPW'(PUVNB4>!2NL9$Z>"'9>DG?
MZ.[ZW,=F4RR"YL74S:C6T6N*>&W6HB2E8_.67_M3W4OB_FYXVLZ):*[%#H*[
M-74S,13-:J&,=US6LN5:ZB UH$:3?4A!Y-:77L=5I=8>!\\7L6VCE.Y@M;:B
M1IFB B./.Z&B>%%$XHAQ#3(XX31FRT/K%II'6,2VE=ZW+V+;1@D=P.J12JI0
MKTQ$!+2UX7"=GNVCM< \4A#G/4^J=8;R<1:Q;:7MS8K8MA!]%_A97_-B34"3
M# /-* )36#(0]0(H[K/26NFS:'TX>81%;(/O>RW4TP'*FF8B>&UE3KSF1UL/
MBG,%H:"&0)2;$K!PU;J#ZZ]?X[85H(:L<=M&NQT@>^/"J,(+,ZD.Z:.=H$Y;
MIIU&BU#3:9!$;D5N/DCX'UCCMA5Z=JUQVT:5G4%TXP(H%CF7D=%^I0K6J0<>
M7!U4BE%F5$:ZHEK?N__#:]Q:07<0%7< XZ=*IA)*YHN0$+E+M"*UH>B0<2!_
M/GB7C=:A=?N7?T:-VSZ@;*6P#K"W:7%4\B9)<O*9U8ZX4@DHCK0@BS H/#=!
MM^[\\8^K<=O/3#978P?@?+I<"IE#7I0"F3,QP\BQC\%)8$46;ZSGS+2^0_FG
MU+CM \5V2NL @9N719'73,Q0A,ESJ6T1!<*R6T0,,7*9A7)#S(O_Q]6X[8/,
M8939 4HW+HP2Y(4L:Z*<"G4\FQ;@A350F)?*^*QR\T:N_\ :M_VLYP"J[ "B
MSQ9*%9F=%+;4$V0&"IV'2+("YB2/0= ?FM<2_8-JW/:!9%/5=0#%[1("130Q
MVZQ "5%G:&<#+O+:@#V($%3BQ3<?6/^KU+@-?HDTG"H[P.G3LGTY(T=F>CF[
M7*R7\EM<+#Y_"5,N_J!/?EF\NZQK]7VY?G]Q2EZ-L8+,@>8B@S*A@(^FCNP.
MDLFB&;>^,;('9NF8"NRV N-6J6N'1<8OMU!.)0^RD 3 NEK<P@HY_ZIPVCK)
M+A4>E0BMS[K:<G!,%7K]+(.M]+XSZK_C/,ZZQ/V=LJ]EO0RKXRL9::;J 504
M'KRLOTKC0W(YF-*ZH&10AHZIN*^?5;$/*O:MHNI@D5R+X?V\CN7!^<.]TJ/4
M-A0-.6:R&JZ._N6!@4=EE$[.6M77;O$L2\=413C>0FF+C*/WHNZ+XY29D(W5
M'G@FQA5ZA!B%JNT4523%"&'Z7A?'5+78SS+82N^_@!=UG__[^Z6R=3"-$<!=
MJ./AF03G38#"A3$E<2UMZT:<@S(T[E72L:Z*?5#1T(L:O 3X;FN?DVF^.>E[
MM#3UQ8\JREK+=QG.K]]N4^[;EI:!2GL'%-B 9;Q&*HYHZVFM)<\F9EI3@070
M)MOBJI.3CZ",=Q-CLCJB3B6B4X*XQ,) !4N>G%:E'E%+%YFT,;8^*=V8N%X*
MD79#QRX'^MOKI /O>DVY7_)>YRPT))],3;:VM#U9#]EKPQ,CWEQK5/56>SN0
MNI\OL=U&]MVA9VV]G]4YAE0GT]@<Z@VOJ0.H7:W\2U9;'K)K[6@>88GM5GK?
MOL1V&R5T *OU=9[>6N8Q<8BVCC\,*,!Q$<E7=137&55B:-UM^#A+;+?2]D8E
MMMN(O@/\;!>.12F,BT% B/56T?,(P6L'25NE' 5K*%OGZ[;/I!CUVFS_K7 X
MC74 QZ?[;]TNMO^>7'R93-]/\?]BF-^$7*>)JR(%>:M*J-I1!DG"S ;(' NW
MCK8.TSK39S^*^_?==H325GW5FNJUBQ/)3?D]*;1VB-W/7^:SR[,OKR??EYPO
M;EE77+A<C >Q#,64-/4PEEX9C-HSSDP>NA'KSL3W;XX/B^ZVVCX^H%>&KWC_
MC--[K(N(R@3!@*E:]LG)A7*Q% C<&D3A @^MHY]FQ!]38L+!@-Y,V\<'](?\
M1EK7S!@$Z=4RUS] "";3#I9S9,B<XZW;9^U'\3&E$!P,TOOI]:AP7#VQV>7%
MI\GT[!QO;BGNMC ]I6#6<BX+Y%3%GJI79I*E4"8'YX,K6;9NY-6.^F/*#3B4
MY]U0WT> ]3O=G#573DD2,,NU970N"%&0@$GFQOB(DN+T@R)YR\[;G=S6#X?3
M'76U^XG&["*<CW>B\=.E\JFRR7!&ZZZ8I$!)"GP]\@ I(EK4@2D^IIU=3_6X
MQ:"]X+:Y?H_ KCX?[_[,OJ8X0&6NP+(ZO*_0CA(0$82SM-EPAJEY17-3!L:M
M,>T/Z>VU?GR@7Q/[_LR^\$4;IF-M+X2UX)9!-%&#TTGGA+IHW3K_IBD#&X'>
M_\- WU3KQP?Z]3Q'%WSR-4).LF83YPA>HX:D!,]"9.^;-P[?G^K-[F78/PS?
M^ROXJ$#]:$A\;U$KKE@1"(E8K0DI#()F!I"V-RV4=[:,=7"]&0>;@?T?=@O9
M6/%= O_9J:Z8<C3,(G"56-VT.#C!'3 6,*#3)?'6K2N'F<C["UXR-E5>LX.2
MH>L37E[.JUI>_<_E3SGU3>H-GOGN8>H'MF%HP'J J$H=5YX!)4^@@I?@(EDU
MU%*RI (G$/5?#_!'F/^;!!<?9EPY[;DFMP0P*')29,P0I0J C):<+FB=:3TE
MZ5%B>LF*W$W[]^U2&YEWD'OVV/2!D*74CHC/,=0:-$[FVRI#KZS,5EFE96O_
M;I]I(X,!IY&B-QPBLHW4NW"NFC9[BY9'U(8#J^T9E"%OP55' 8UTN:3$9/-$
MQE]_C,A6D!IRC,@VVNT"VZ_^3E_"] Q)"N1^O+Z<YIMFP-K34E=USFXD5C#A
MJE+,2J<DBRF@;]UBYE%B?J%1(5LA9#:$LD;<D,E'7S91G4WO>\57? 1=''.<
M@PD402F5 P1%VX^T1=@2_,-&HP_<_N>>\0O-[M@%2TU5T(%O]V$^^1XN<,7,
MW25AT8LH@@&MR&%1H4CPF=A"8YT,LL0@6V^TC]'R"TWFV,=\-5%5!Y!;YR[?
M/0F**3*,D&0M/$NULY /&KSRW&CMC,36\?:3!(UK[X8)+=II8.3-\+X-/LTE
M8'"V@&6Q=O=T#H(@3]8JF0I'C"FS#3; ^]_;7WRYH[IFC6373.]#'XO^$?XU
MFU]7N%;C_ XO;M]^,Z7_@TW.2+=YT# 'ICNS.N#I:0A**2-IEY,^@?*>0] B
M0?#.6T^P8*EU%#1H-Y7[\OR(WV;S"\PG7V>7], 7/Z[D_V-EI+7$Z&*USZ[^
M\!@@%I> -FPC32)70+?>S':EM;^SUVVP\W@M\( :Z\"76M,& B-SAC,!1*FB
M6+;6V=?T22/0&V2YE-BZ.6&_K5>&U/[SG5BV445W8%K?%H*C-"0-(&>!!&1=
M &_K92U)2:+#2!(<%%Q'T8EE*[WOT(EE"R5T *OU[4"<TMX:E,!XE9&V"1S2
M#X&6"4ZQL,;6>9Y'VHEE&VUOU(EE&]%W@)]'#MI8=BQRIB!BL*!R1O#H-9#'
M(%5&EG3SPM$>3T0'1E #X7< H9=A\>5DFNL_E:'OX1QO1SQAH% YUS[O65'<
MFZVCV%DIL%8*7YQS6K:>\?X4/>.>=@X,IV:*Z !4R]EA:R:&%:FD)J$XVNK)
MD:R3R)QAH.F5RCICBH,,>]MMQ-M@A>H# ZF!\#N T Z!RNW!GV**R1 U>(FT
MC0=>("AK@"=IH];,8FD=Z.U#;R\];PX8$AY,O1U ^3Z'[_#BE MR-'4]P5&.
M5J-%!T%RLN\\6JDP!B&&._V[(>/HSB)VQ,"C@>1N"ND04[>_O_K[&TX7>&H<
M9YD5#BD9"4K6S@M.U9M0%RP7D4LQW&'7(T0=G:$;!F_[*:N+^4IK+E!.B_.H
M&9= 43(YJ74LL:^M%K)FJ,G72**Y>[>&C%[Z:AT88_LJY&BN+8G1W\-DNJ@3
M-7#Q?GKGK2:WE1M\_S"7E-LR-N#=I$2C"JL#G:/EH+2TX% JX)AIF]16.-VZ
M9^^@=Y-5KE6L/PGU*EG$.D:A58;:" 94C#72LHD,<<K$953,#->>^'&Z>CE[
MW0T3CWO[C331E0=V<[DA-3+)4P2M35SYD$ZBK A@J*SPJOG!?;_WBZTT_?Q=
MXC9B[PXX:X]_D$N*1I@ DSA2>.T,K36>( I1;$*'ROWO7>)V>M_^+G$;)70
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M31+1'(L'96R"8+F%D#S)Q;CD=.N3V%U'\HW3&F(?V.PK\!XP<W<$I4)N4L%
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M&4)008+*K&ZEYAY0!&N#UF1)M1XFT7;BR7E,SSL&F<,HLP.4[CPF0Q9N,80
M;KV\BDX;Q.@Y<+*6BG5,9-NZS[_IQ)/S&*9WW.TY@"H[@.CV(1I6"2%EJ<ZE
MJZGEE,$QQJ!8+ID+7!4Y2%_:P4_X><S/.P:$;935 >JV3#W '(3@QD%,M6Z?
M3@O)QDN0*>4D95;>M7;%CYA/<1Y#\H[!6P,U=0"VMKF8[&*QT@JZU56N0]<"
MA*(#F,A%85EIH5L/@CI]0]RI&C7&"S*-AHG^#L2!2G@1+M+EQ?K']_.+BU?S
MQ1]AD2>E!&^%"D _U+5/J,')S"$S5:*U#*4=;.WR /QT%9,])4P'21PTP$Q/
MY^?.3MI_3%>?'S"__)G[GT6U%N154;LP4B1I(YC$Z8TVFJRW% 5@=,QK:U66
MS5,0C7GHZIR,B,YMQV8,J!Q\5+[B8CK/'U9AL>KMP/R%;-HW\^7R]2Q=7&;,
MKV<OPZ*6%"SYA$EDIH@ /E@'RM/5%IA-H%)4/C%!6FP]$^,TG/T*-EO?AZL5
MK'IZG?92ST]2N%/>2 *9?\$?-8UOILO5A,QL#"QID@@GB2B;(>AB(085>69U
M;/]@/M!@7'75?=SA(>L#3CT=L"&NG76([\7\"S'WN<JH+DNM(JO_:J*Y-3FY
M"+%($I2,#)SB!M#84",O2>C6F=71F.VJ2;O#X]@U^'ZM4_KN<I$^AR4N)TE%
M8;U3@(ISTIQ!TIQCD#)G=9R]9[EUR] 0?'35<OY+GJW#(/-K'9LZ_F8Y<9&3
M.@R#S(6^[EV(W-,+'SCSD70B!K,5&_'05;O\+WE<]H?*L2THW1T67*TN\&K\
M2LXHDU(>#*_)7,,2.*\5*.2*!5%DB!V;>7<XZ:J1^M<\. ?"II].V8;"N,V;
MOYZMYNL&(3E!C46'6.@228E\2\$A!*:!T9-,=XJ-R7=LL6W@J*MN\5_R3!T+
MHRY*M(>0Q]O+U=MR+1 >F=2E6)"RCB],:"'678F2215*9-F$P=*\P[#45</P
MKWVP#@72KV;T7:7TI#$N<2. L;IB5)L$7@0'.1MO2^9:L5\C^SO8/J?_A,.S
M/U:.3/^^G#4^+X\KY\5ZJ]KKV=]G"PP7TW]COHE/3E)(PH=D("8N0,FZK#P&
M"TX9:2PW"<M()47;B>XJ9=M_W5 C[3<TO8:=2?$B+!;?B?DPR[=_]OS[^DF<
M;ZSF_7V^OJT(-S_/1G@QGRWG%]-<G[>[&S$:#*(X&8U#3)\81\"G&#FA5!T'
MK20P<NO)8+)U-[F0((()Y/E;ET3KOHP3CIPXZ*JZJ@?.Q:@82"8^)0XJA +.
M)P4%<V 1G36J]6[S9L1W4CYW+-Z&*+/>7[D]I5&>?[]C^KU:X+\N<9:^K_O/
M8XRN9&*$.T[/JL7ZP-(3AT%[;E"S,%RYVG:R.D'B:0&S#;:-M-<3(#<Q=-,J
MQ(47B4P\KET-<I4,P1@&LG FR-A2C+?N0MV!K$X V0H*.WB(Q^BE4Z@M[Y[2
MFYY%1"6\HS=E/6>.G&EPQAIPQ)9'&PK/I\@,;R"M$\BU@L0.D#M6/[W"[OT]
MGA C3YC)F5180$56ZE(U!!MM<,IRA[SU-(A=Z.HD6G!*P!VCF9[0]OS[[8]_
MG>*"B/I\Y6:NGP862HE!1+#9TM-@K 1'(B,SVD55=ZKP,-@0O$<IZP1QO9AY
MK738$S+OGK:'_-ULDC<&B2,$[3*2[2(U>(41BE9!Z2BXY8-%$W8AL).GN"%"
M=KD<FZBKKSST59IC+3-^<^4S=%F;"*B< U4M:!^] ^MT<IEA\F&PX:D/R>D$
M:>UAL UP1VJDIZON#BOB9E24C8B.<V "30U;*:#G@$$L+'H?-8LJGP!<HE<#
M[W3@.D0CG8)+7K,2HDG%:PU11E&'JD0(,0MRC3SRH"R=E<',NH?D=-*Y-@JX
M#M%(3^!JDJ UAMB7+$(,C)PS%Q#JN/Y:HI:T4L(J-W""_ 0S:;I>_-K0&3DY
M(CHX#ELWD9:41/$BDQEB2**U B<JM*#)(D%EO>;8^J(]:FMLUXF1 ^&QZ];8
M?735 >9>8:[+1?^Z[F\,L^=A]L]G>5U4L/Q;6%U///MP^>5+6'S_[1)KV=9T
M]G:&_XMA\;;\5 H05CC1@3E7) -N7'V I*"'+64(UBEI2F(E-7>DFW+0B8DZ
M.KY'Q$4'I^+'G--WX6OU"*TTT00).09=%V?50UTD!$>V?+3>,-E^F/=/))R_
M<= &E\=HI@-@_3Y?X?)=^+XVE'@A;X_78D+O:TVMK=5]Q(K-21@?O!;-AW+?
M_?ZN9@N,"*F#==(!GE[,R?18K.H0D3H1ER14Y4/BG[@B,)42(8>@0"7-(#"Z
M@!GCR=G LK6MPXI;B>FJTW[4RZN%MCJ W8EF3AD95#"<0TF!D2TM-3CGZ\)[
MATZ2.2T=MK8F^QEE=B:KYX^R,OO#4;/3-4CI_-4DFH_A3US6"37S6?4YWY;?
MK@F]\]>'E[[O_QT-2]>/9+!1Z?FFKZ8OW71>;BN$B]+6>LL@A=K"9Q,=@5(0
M=,+:W"><,*VMN0/(/'ZE\[VO^1U7MR(PML[>3 I$JF%MH1,$DRRP9'CFW'.6
M6]?R/D;/N+&JH3'T<$%S(\UT8%\\X(5^N/FSEW]^Q=F2;L[Z0&"5Y+.4%I?A
M8KG^7[PKV(DC@;I:H57;%TF@EM>HM*2;'W-)7IAD6EL0K6@?>X%X*S0]!=-3
MJ/9\(7UQ,?^COI.OYHO?YI=Q52XOZ._FES74['64N2@.T=5)0<;33R@#<,P"
M&0O"-Y\^T)Z+<0.NO<&\E;K/%O#5A+_YXTG"I$HH$A(*\HJS1/!DR(.7P1MO
M$!7V<7O?I7K<2&UG@#Y8G2,"F!RBA]R^(0>UNL*+16W1OAXU1<ZMYB(#8AUJ
M6 J'$.D7%I+VV2*FQ)[PM7;]KG%CM<U!-8B(S^/.JVX!_>^5[F;Y.<ZP3(E3
MQR+QXFJD69(14P=!TXT>@:%T<1U'R:WCM8=3.VY =\P[KH7ZSAJH+[]\O9A_
MQY_^>I*28\6F"%&@!Q5-I)M=US6ZR?J@O AC6*)[<#!N0+9#0!^MYAY!_O8K
M+HB3V:=JEJQG8Y2K\4;+B:H+2WTAV4I9H]C<0*S)/RXTM\5)S=/@"-Y.WK@C
M1$\'ST8*ZA%[=VO$7+$:K;.U7H'1.:I;'KR@M\-H\N&83*7Y /7'Z!EWF.;I
MT'6H"GJ$T[K^<&*3=IG;!+Y(8D4E!M'0K1R-*-%@L,X,;C2N*1EW;.0)+ZB]
MQ=XC>/ZRJ"/%;#1.&^M T-4))"$-/BD&&&WMUM/!*#$T>-:4C#PW\73HV5_N
M/:*G)NROM',3K9P(LOY"21)*CIFDE%,]"PR,5B[X4$<EM!XZM0-9N^'J%TBA
M'*F1?L:@;Q+9Q.8BDRN*?.FZ:#OF0J*REECA(4F-QKO6/8R;Z-@-3;] IF)?
MF?=U1]U)$=Z54*F+08/V(!G690"Q+C+TMN[*3JQ(B;GPX4"TF:AQ4U\CUB<T
MT%&WH/O+?)[_F%Y<D 1?DS9GGVJUYXW_\?/O)\XH:6,4D*.5H$)D$$2(0!=T
MEDD$*USKV4]'$]U-64(+$.T$T:$TVD^*ZZXHY[._?WC 5I*2^TSRU-(8<IG)
MD'"2V"I.")9\2M'=*^QZ*M/UU%=V4Q;0$&9#2KW;^_!^N#E\G:ZN9EM_F)?5
M'Z2.2188O#0)-#TBU9TF66**X$BL KW@,;1N&CR4UFZ2^R>[_1KKKUN<OEO,
MO^)B]?W=19BMZ*I_^:_+Z=<:*YQDIH6F<PA!$8_T_P&BBKH6DQ<OG//)#%C5
MN@N)W50'G R5;;35Q6RHS0S^'*O.R7'KB*4:JPXB0R!;HL[^-[I&DW(>,+JR
MF:AN*@!.!KE#-=*/F7>Q]59_CZOI5?=-O"EH4*ED(3S=YWE=;4@6B..20S&:
M!>:1,V/W,_GV^?IN\O'#F7^#::/;)W9C@9<5,BCG(:<@0+FDZ$QE";ID&:1E
M"OF )9Z/$]=-UOUD=]RQ&NH6>N\6^#5,;P[8<N)5TAZC@BQ2'>T<.)VGE$"(
M@LY$SW,X#>SN$=9-*OZ$EMSAFND(;K>-B7=;5!)&5")K$-%%<HSJ+""F/' 1
MLLHV.*>&*BK:1$\W2?H!P76T'CK"U#TN)#*6+6>0+2N@&/WBN"D@/$O9!)9S
M.HT;T$^^_F2WU%["/\L6<O*HOTV7] VOYHLAV\B?^)[A6\GW8;11._GMU_S8
M+'6+5<\E"HR\%HYS>N]<@NB3)701I+3C09O653B/D'/T/)JK>2:WWW#]K%]7
M%;^8SU;3V259F->%GO/9C]PB1A$22@3+8JGC=VIYE:^9%#J_3(0@L?5C>3BU
MXV;!6N'IP7R:TVBO@R?VFM/K*7</6)V49+,P9">XY$F*2B4(6CH()G,AR&((
MI?7$S2=(&GF8P8F0L1F03=34$>KF"YQ^FCUDQS,KA"X>G)=55%: %T:"U<Y(
M'U$S;%VD\@1)(Y>HC(NZ%FKJ!W4?2&]8ZWKH/]APE(+SIL10]QTDLIF-1@B^
MT+LA593)!DYR' 9[CQ,V;L9U7 0V5%D_.-PBRPDYY.1A,3I5QA!+.A(W@9ST
M;$L=YI'1B>8#"Q^E:-RLZKC(:Z&DPR$W7X6+II&4==O&0VX2_1>\J !,\4BV
MLM1 A\9 L:X(%XLJS><+/D[1N,_M4&Y%0RUT<(UM.QJ9T['C-H#G*8-*,=2*
M^PQ&YLB2*C;$UL6<QUQ<@SV90Z&HA=R;74E#1^9^'G?YMMQGO@:T+E>8GZT^
M?L9J)EP2:+]?^TFW__@]F0]- GCMR1DFSC>PV$X0#B3;+8A 5V!RDBY#71!B
MY@&D3H(;5-DT;W89,!SX0Z0_*6;+47YVX^C?:N8GE4Q<XMG$DH!K3*!D5A <
M_19E\#5I:'EL'2%LRD"_0<-]4+?U7CZYCCLP!EZ6@FDU_88_<?&S))YB60==
M?"P:C"6Y*T2RKFOR*D3CH^*"#.[6AD,#LOLU58\!\ZGUV0&$MYS?GV(/=Y[8
MB19"D:5FP.BB0"EK(88D0<LHDLBE%#98PFHW$ONU?P>X9YOHJ0,8[G+RMO+*
MH\H^<@$IJ#I9,!5Z-8($I&=#L^B\]:TQ>0R]XT:6QKP[FVBP [1N.8R_8;Y,
MZV#<!)47W 4%Q>M #-$K$'TI()EW4<N$J%O/^'F2J'&+]D]\,1ZHBV.'(9SL
M,KS#'RLF1^\R2,[H\+"Z]A65!8TFTE7O8V)C6)![ F^P<OXQ+[P#M33^2([:
MK;"!P9^8>T>_DOS?+>8K7#/YK!129MW:\H(T\RRM_KJ.U;R>D<QKZ&9=>T7*
M?H4X\2G[K$4F@Z3& JU"\&0Q@PG>%[2!67LOV;VQP61(&L=M &@-VZXT.G)7
MU)!R>(>+5#L10S;*!"4 @_2@I--UT[NH.[VL#XEQGW?IH#H!J>-V'9P;S@_1
M;W]P?_!2T>^(JV?I7Y?3Y?0JH?RE+AZ81"U05.Y2(/M<^8#@C*Z9.IN2+YHC
M"X?A>&<:QNU<.!% A]'(62+OYHA)4]!PJR"7]3)M+. 0Z8@YJT,,4:3[<^4:
M0F^?RW&X;H=^P'>(4OIUU=?%",_R_UW>]'1+;S+F8B$4XDT)X<$C'2^NB46A
M;?2Z=7O-CJ2-/,?PQ'[[48KI &^['*X'//H8#-WH''Q)"90J!4(B^UE[)45B
MDF291O#@#T/B+YGU.4IE'<!R6_E,*=&Q$M=#'AW9$HD8DLZ"<1)#$L)%U[KF
M_)BR)7Z^>9LC!-]!*>7F,[*I#G6BT4MK2P(MHB$#(01PSG@P4D7%K!?8O$YC
M=^IV0]DODGPY6CUG4S#WXG.=6/%Z]O$SKO=&U"D6:V?I;5E/W?Y[W5\]_S2K
M@\OH/[A9<_**%/1W^N3%*DQKI\>[^;6QVZ;O=2"B!FJ2/84(3U!"AXDC79\%
M4*.N.[X#!"ERS2P*IS0]S??7LO5<0G>_I'&+%E[^6=>>WZJL.FM5'_0''^<O
M_PQ?IK/U/W^/J\O%;/E^?G'QZFJSRH1QC,5[2>9U1%!&%O"6S&N2GB(O3VD7
M6YN>0_/4;Z'=/MB\?\5WA80.+-HM_$^<5_EJ3RK2JT9D"_"UJ" X2T];,D;*
MUHO8MY R+@[[PLN\O?(.QB#90M-Y_K *B]602*2+8(%A6<O2EY<7=:U5?2NO
M.ZS>K6FX^UY.C+)&L"(AQE*GJTL&SFH+C*Q ZR-GR:C3 '=/RL>M!3U'G \)
MC7ZOYLU<OR-N%QMXM@YU0'HFBU7K;8,&HB0OV<:D,_E"DCSD,8_#%KK'K3[]
M=0Y#"UCT>Q1^PWUX+B4%'YD!EN,ZX1?!<87@4E&J,).=;%W?VH+N<>M<S_$H
M# >+\2O*GC+]1 JL%*^ U:'=Y ]%\#%;".0S!6&D=;SU!(IC[/;!ZF3/$;=[
M*>](N_WE+)\PL/A[6-3 Z;<VC;0//FV84-[C1)\@!L>C+-ER"SS5<G[#)3@C
M%,G%!AM*8)A:3U8X11OK53S]$\[2]X^U5FSB+0MHZ10E4TL> V,0:AMZ3CQX
M)P,=J,&:H>X3TV_4:Q\T;$V?'27[#@S!Y^&BGMH/GQ%7M?UEK9@_I]6WBS8I
M4Q> Y@A*)@$NRPQ6<&/7JT)SZ\$WVVCI!$+'J7H^@-P[Q<]O\R_TY$^$U>B9
M,&"\H?.5# >/(=/[CC:(Y*5EK1.NVZD9%T-MM+T#A X0?0<@6E>Q_$[FY56D
MZ6K1V-_P2\0%W=+!*4E'2_,Z-9EY#T%H!3GG(F0T3(36]] CY/0'HT,T/A]&
M_/WLE/EY O<U*SG$X(LGMR+5*6'&)'"BEADP[GV26;&\2\7X$U\S;M2Y,4):
MB[6#NZ:&*M8.V_K^%<$Y:Y,%44M:E!0(7B@B7NOH<PI9V=8>P4\$=#*OHJEI
M<[B$>X+']:FA?V%=*06$L76DI><0'3,0!2;/46K7?+W!/1+&?7*.4.8V6!P@
MV9%?EM>SC&4ZFZ[P^LY+6**MJ>!8<UZ*C+6:#PY WF3P(M8;-N[PE-S_W$Y4
M?8B"YHVD-;*FWTR_$-UY76E6K@*35S*Y9L6;(D+F'I0M@LPA8L6%1-<D<SS'
MXE&67;HGG_B:<5^%5CAH*<L.7H:787%!AL^*Q/._&!;73%A%-K$R&HIS))Q2
MYV^'7&M$(D-GBLVI>8O$)D+&S>^V@$P[.7< EC=A]8 %+7QV+#B@RT#783)D
M4WGRIW+@*@J%K(C6%: ;R!@W^]D2*,?*N .8_$^XN+R2_<7%_(_JN3W_?L??
M6GOB:\.+VYPC2@6A;EY7/#)PBIC3TM =&EGQJG46<E?:.IEKUM2%&40O'>#M
M/@_7IS Y-&31:PBAD*B8DQ!9L,"\*%Z@E<*WWBNSF9)Q#>!AM+Y]D]NA*N@
M2+?'[MGEZO-\,5U]7PL&E?;"H0-,D=YF3>^UU^0NFJ)DEL$&EEH':S=3TLDL
MNZ:74@.9=XF<F_AD45H)FT&DNKW<63(%F$?@0<L4;3!<#3:I_AXMG20<C]#S
MD] Y0.@CN^9;1M\4O DS9.MB2=R!]R*2BZ U.),26('9.9MM#/>&E&_TS9_Z
MGM[ <8@FYP.)M8/[A<1!7L$TO:CE9XOOM[$&+T6,"GP22'Y!=A 5W;L^1^.T
ML%8W7X.QD9!.XOTMP--.X!V@YJ<)L/_O<C%=YNEZ M>-7ZE33$IQ8%@'P"?!
M(=BB@;$<8E9"A.:^^Q,D=>)VM4122R6,B*GE8C5Y7YN6U\^VMTZS; MD4P+Y
M"G0&'(N.Y!.48EE*87;RW.E3[Z"&?O<#,3]]82?3=)M8OH=+L@?UWU10N*(E
M]QJ,LG0BHO00"A/UMT7$XIC=K1AS%P",::$<H:S[ZCY <B,K_&_3V?3+Y9<;
MDXFHY+XD",I8,M5#37AI^D4$NL.$)]I;J/RG+QU9Z8>H;-Y"?F,K/OQYAW"C
MB^.JUN^Q.A1,H0!OF(2Z](N%4.R.X]6?4OS=+QW'I&RF^(/EUX'5N.FU>S.=
MX>L5?EE.;!2&.9Z >9-JE)#P[+.B%R^5D@C'00TVNF\309V,.Q\F)G:T!CJ
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M'*6^'V'9>.<.05LG2[J:WK6CZW#T-J#;)Z9<SO*+BS#]LGPUO2 NA/6JF%1
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MPL5XU(7:PJ1+N?KSM1:!:UA/*'9*DODA$CJT]"0T;_<[B- ^FM:'A^GP6NP
MJH^%TQ]ND_B=7K./?]#KC'^;SU:?EQ/.;;%*"4B*DU?&C(<H?*D#6XU.11N=
M6\=GCJ.XCS[Y4>_8UGH].Q3_+X;%QS_F$Z82'4_F@(>Z_U+0*?5UX4Y,27#I
MG2VI];;:@PCMHW>_-\P>HL7SA"IA#R<A9<X9&3Y>16(S^%JS4[ ."41O3&0B
MG[!K[#%2^Q@-T"5<]];D60+VU?QR,?%2AN@<@\#J7$+-,[T@3(&.AN5DLF:L
M=??Y892.$T\_![CNK<?S1"O]VPF*Z+0L&J(-=8JF]. %J^M%8W%2&\/OEQ".
M@5;ZM^/$Z,\"K?OJL>^M.^]Q-5U<3:O'&?FAJ^5[3/-9FEY<+8E<;X>Y_JNW
M\6+Z:?VGAT=8C_N^AN'6AHPWBKW^5L, F*^_LVZ6NC-W:'D+]QQB23(X*(4A
MJ,0M1*\=.)X5HE/"\];NQ&Z4M=MQ\_#[[IS[Z^IDI1BR6 OM0K3T2Q#@O/+D
M23KO4&MM;>L&X+T('#?*.@"6MB_"::VN#M[W'[=#9:<N"%^W=4GCF7>2 6.>
MTU.C(GCZD_KR:(/>.M_<E=],22\+<9JK?MY<#UVBZ;K;)J##+*V&D,G65=R(
M.D&)@42C<Q)85&B=*M]&R[B(:J'G)Z%S@- [ ,^[VE,UGUV=K9^.VW5SE3:!
M2T4&KPTV@'+10"R((&S4D4DG7/-]L$_1U!N8#M'\?$ U= "K=8W!NSD9 O<-
MX>TL>E^B(9L!I'1US)OC$.J8AU2""8Q^ZV/K8L4#R!PW<3@(^(965@=X?&A)
M_# DWMP63#GCT'M3,YZ9?HGD<_N4"FB>T;+")5>M>Z%V(JR7S1Y#VV/MM=0E
M]&[6X3[P_^]. A8A(_.1@4%6.^;)3(G:11"%$_\AR7("1WP72GMS18^&S).@
M;*Z_+E'Z@+N)\MD14Q***G2TL= ;$Y@#:41@Q=M8<NOX\@YD]8:_]NAX$I#'
MJ:J;I2</&?N BV_3A"_(-IE@]M'G@H#2D8432ITJ&!34FCKEN237K74N[E&"
MQGV4N\#=H>KI\KY[/:-/Q^5JS8VH;?\Y2#"Y&)(3DIRD%X!6!:E$TMX-#[:[
M%(U;\M4%V@Y64)=P>R"X]?S+:;Q<CU1]_KW^FW=TLT[3]&N8K2;%ILASTN"<
M0E!DMT"T7D-$5DJR23O6.IAW--'CUGQU =HAU=PEKI_5":Z+:;CX2YC.UMM&
M5,K6.C*^D[$.E*DS5))7( 571LND6?.NA1W(&K? JPML'J>J?OH&=SAU[\+W
M&M8B.7[ U>IB'>.:V.S1J^) Y+I7(@L&P?H$7'.,T=+?\-:]"@>2.FYY5Q=@
M;:_2+J_/!VS>U(^\"],\*<&S%(2#Z%($Y8P%KW5-6]6P6I8L1'EZQ-XE<=S2
MKCZ1>K *S^J*G1B3T3 >Z<0%7YO.)7F &D$[KJ33(C@U CC':<SN&Y![J:KI
MQL$351E>"7GY>O8J3!?_$RXN\6U96SQ'+GL[])L&K2P\@-G3UA0B+]*96G/M
MK*)'.2&Y,W3O\1*+0!U\3*W'+_=84TCV,^,H+* O-0EA?*TDSA "5SR1G2UY
M:P_^UZLIW =+Q]44[J.N#DS)+35.ACONC#?DS-6%/%QY<!8C,*&C+B[XD&QC
MT)U_3>%>JM^MIG ?/72)INLZ$R6*UL4',+I:#LH%\)EQ2%HD98+W9%G\)]<4
M[J7G76L*]Q%Z!^!YLIB-3-N<6%0@7:FS;&NK2U 13. V,DOW>_/U6F=:4[B7
MYO>M*=Q'#1W ZI R-8U:1?)HP,IH:O>6K=5(L2:,4G;.BYQ;Y_%^G9K"8\ W
MM+(ZP.-NI4?:5E>^ED<6LB"4KD7F61CPVC.GF>0J#N_\G'E-X3'V6'LM=0F]
MF[#2QAC W=!23,B%4@$*MW3(E+=TZ=?K/]O$T!E15.NW]W!J>W-)CX;.SK6%
M3?78)6(W<C@I,N8HT8*W=69/$@4\EPRT(.-9,)[]"8+(&TGK#8O#(.5)@!ZO
MMH[K#9]=K9_%U>5B]G9VA[_@N,PB%TB.Q*=\X. BSX Q<ZV3C]A\A/ONU/5:
MB7AB9#917I=7Y;V:H9=?OE[,OZ]7(_O:#E: "U$'G.F:2V0"DK6.#'25$(='
MY1;B>BU8/#$H6ZBN2TS^$-X3%6V9E\(,,9F%2J"*-A"0?A$\I&@B0X;#EW_M
M2FVO%8LG1NT@RNT2QC]JAY9W7HR<@].6%T#M%4E3<XA9!*!3:S R&10?_F+=
M2%JO98LG!NCQ:AN_MJ8.[]]:K+$N%KH5ZH3Y;)R/'*P3$92ID_:1CIV(D6F!
M,A)K3]0N[/%UO98;#@*RH=0P/L#V=>)"*;$4'L S]* TV<G1T&6N>6)9<!U=
M:#V=LZ7O/4)581>^]SYJ.\=BKM]Q]>S+_'*V>CVK"TCJ+#VR2I;SBVFNY^1Y
MN*B?\^$S-B[M.N1[!RWT.EH0@Y5]79&UGG'W:3;]=Z7L+C6WU3M6&E902Y!<
ME*O^ I?IIR20KE%T7)7A*^YW)/:TQ6&8 W<L,A"925#2.(C1(9BHN?#&R21:
MU^F<=7'8$(@[KEYL'PUVX IMJ5])&+5308#50H-B2D%TAIXNEHD-HWR0JC$.
MS[]>;"_5[U8OMH\>ND33=0T!FD!F,9)HF"6+.84(3IH,4B2'KC:&-R_U.:MZ
ML;WTO&N]V#Y"[P \3Q<J11Y"4 [(F&:@7"G@>'"@74XE2Y>T:#T+YTSKQ?;2
M_-[U8GNHH0-8'5*"1 =.T$%4(-DZ5806 K$%EL=L..<*?>OKZM>I%SL&?$,K
MJP,\[EA.(J4)CMZ"3(<-5-VNZ9A5X+EAT0B/P0X_>>3,Z\6.L<?::ZE+Z%W%
MCE[-%W>#G;_/9^ER4?4Q8<&7Y(,&661=5D@,!E7/E@T\)L/J.N'A/?7'B>S-
M)ST:*$^7.#346@>PO+8X;G;2_GS];SCH+Z[8?#,-<7HQ74UQ.:F1=Z.0@U+%
MTU$O&4)T=;.+3CK$:'QJ/;+S>*I[*]AI#=P3Z_783,LH6+[#[)T#++4P2,82
MR%![B'Q.X)G(8)C,-F (I?D*GR:$]U;M,S:BC]=N%Z#>.^XZ4<;[X.G)T=+K
M^@+5N=!1@ _HO*2_*W[X'.(31/96Y',"NZ&AU@ZW&^:K<#%B^G#Y(VWV+*7+
M+Y<7]9RLS_.+^1<BXW,]Y-^P3L+Z^#FL_AJ^X>]S^AR<_1#<LV7]M_-9K3QY
M6^BSKS8H3]/UU]7AA,-D(4]/_FF2F2.K9;B<Z&/,$,_S+_@<RWR!'\.?M^DJ
M)C4:+)&.?1:@&"//E3,/*"VC!X(Q58:?^GT(Y2?.ECKMBHH(+CFZ'8NMN_(\
M.3M:NJR3XE&T7A5QWMG2H;%X9.IT#W5VX+9N6R>4?0RHD0P[DI**C/@A.='C
M[15*[5TTPZ];.KO4Z3ZJWW%]UQYZZ!)--^%T;I4U)H#QV8'2,D#47D!6Y"F$
M%)0KK3N'SRIUNI>>=TZ=[B'T#L#S9,XN)::%- BI>.(G*4_\, /9%EN<1$QQ
MH(#"V:5.]]'\OJG3?=30 :P.RL9AI(N<*0C)%%!H&?W$#3@LQABF:NGT?U.G
M X!O:&5U@,?=8B9>JE)4$L#$>M6/1?"^(-@LK! V"!'_FSH=T!YKKZ4NH;>#
M,_4[KNI,]66-6>#RUK6:H,PD2)^!R=H_$@)"-(8#>A:]XI*3Y=*#>[^%_M[<
MVJ/AM4-/^4ETW6NP?R?NWRVF=0;[[2J@%T3\=/5#$%DXIK46X+@@8]WJ#$XZ
M \D7Z[B3FJM3S$YHP,HYY&W'P']+!)SKE?^#V^"2\$D$D!%577LOZ."37\I-
MD*F0H6]B7S'<<TC>GAS6A^GSW))C_\#II\\DA6??<!$^X;/E\O++UW6O_]^7
MZ_ZR<)&JG*:S3Q\_X_5_]6.0?"U%>G9Q<>UGM$MZ#4#6H,FLH<4X6))J#\(?
M4'V;*)!TO8?L&#A3>QATW29@0@')'29=(M*9'?S":\'):9-8(ANI#+G?7M?X
M)4H-OC !=*N@%BQKT7PT]UDGL4Z.U>.26ONHMP.C9TN0G9DLC4P: KKUQ(,$
MO@YX25:F['V(QK/_)K6.4?UN2:U]]- EFJX#G3(Z5HB9&OX.)!HC232^0*&#
M*1-SLJ3_Z'[ O?2\:U)K'Z%W )XGLRG6"9%3X>1/2CI?UL8Z;3)!2-XBDZZ8
MW+I)^4R36GMI?M^DUCYJZ !6A^1)B!]3NX: 3F4!%4O=VY8S&*]BUDE[;+[N
MXM=):AT#OJ&5U0$>=PM\T-&*7'@/IN2:J8MU@(510'^H=$F2^^951;]<4NL8
M>ZR]EKJ$WCUOZC%?JO)?"W??AQ6)MF"02B>0Q"8H[A0X(4D$)80HT)*[=8*,
MUF'$]^;@'@VL7?H'!]?RN<.[,ORVU(@PV3_K/WD]2PL,2YSXJ",&9>B!J75F
M+GB(WB:(0F8CLO4EGJ"YI04KYY#)&@WZC1 PXD'8/--R#Q&\+2___(IIA?E*
M&!NFJO,2M;0J@1:!DZ>:#40K!&C#4O!68%3W.F]W'$G:E,QSR&T= O3>-'PP
MV+_A(LY[N/?OA9=?S^@8XDTNF_Z#]4,HR<7@K.X?TCS7YZ^..$$&!9$%6R2W
M\02U#&V9.H=VR-'>@N:H:/8JG&J5]I-]=3<_KD72=+?V85\][++M!N(8+)N[
MF: ?#5VI*'*#)=@B"*8Y2/!&:Q!16^2HI3?#FZ^/TWC:#*PLKIA2KQ&%J2Z&
M(6M.,0N,NYRD2T8WCZV<=0:V(;Z.RZWNH[@._-%MNX)K!3XF!\;1BZ%RT>!C
MG0Z1M++.H4M^^ :O<\NM[J7Z'7=S[Z&'+M%T'6^/.O 8:Y0&(QE)BANHO2-@
M9!!.JZ ='SY7WW%N=2\][YI;W4?H'8#GR:1>S-Y%D2,$58=\YF3 6Y2@G>&!
M)V5Y\PD$9YI;W4OS^^96]U%#![ Z)%VGDF.)1P<ZLE)'']<IC2*!T]PSQG7)
MS4N+?IW<ZC'@&UI9'>!QQZ@"<L.5#4 FA0%5ZVQ"R@J"M+HH>@V8'-XA.O/<
MZC'V6'LM=0F].YTQ$RT-XTD(NM>YK0D$XD-P!C:S8FU*PIT <G<(ZLW%/!H
M.ZR..TP;G4:X;R.2E1]+!RY(CY"9]Z"*]!"85L"SRS9*DF)SC_)QBLXBS]@4
M7@?KHU-\W6:)-N6'4M$B<4A6!U"1[O_ H@&#WB$:Z;D=_B[;3M]9I/Z:8J^1
MKGKM1OXR7ZRF_[[.7M[IN9ZDS -I* +'4I>H< E>Y0"%62N"U;7C8_BLW#;R
MSB*_UA2';335*0Q_#)V\[OROK/UVB1_G=Y;2<G+01#(ED>]>-\^3OR[ BZ+
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M./^ J]7%U7IQ/A'1>3KK&DS*M6[!>7 F9L#$4F;%*/2M]QH?2NLY=$*V!?,
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M&4HN3%OOBR[-)Q3_E&]%IV8TQX%,!Z:S>XN8S5LR3]&&7#O:AD0^I]'@B@Y
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MP/@D?,P^)=7:TWB0D&DC[89@:2?N+C!S_=3]+GS!Y?6#5M(140E D6B_\[Y
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MW.[2?E5V]6JVVO3:O;X&$=(9#+E 055'(2I=*QDX9*LDV9#SR;7>K)XE:AC
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M+<G5"@4U<S63!(J0D^.R$CJL-^1)O"H<3V$GB<K95SR+AF+VR!CH.J5&81V
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M!:,A2RU 6>_ DP+!>V:"8#Z6TDVGL>%L]?5:VHU1-,# SVH6KV9?9YG.Y8U
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M,Q*LY2189@/M._*D&6(H_IQ/X9XD=N0&YUV\"#I49Z>:R3Y?<JX?<ROMT9$
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M& $7500F5"JE."1;V[[L_18%G;@A1^KS88'[L<+M!AJOKQ95<C=,9.N553)
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MIU2@R."-#"9ZT;I7W1/D]',@#99I;J6,+O(V3\@(L[(6<P17,GE^-G (QGE
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MBAC^)G;[B_I'#$O\O__K_P-02P,$%     @ BH5/5L'%9;F=H@  1-X$ !X
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M</A=C$%+X;25 Y6+B()@H(U [J++O_?AP;[^7%]L.54W517&= W\*'PWVJ,
M6GB 8[;[OX4(<[)NM^#^".B3@.^PY[TC81">+1.$K#-)7R>36J$-0>;#JIW8
MDT-E$G;PH]NR3*-9@K'<-FAFMX3[B['NZ+NDN%4<_*2@Z #''XI5S;*JIKQ
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M>(5PVZ5B @785"<O7SRGO%;&?, 391ILD-U(B7X,1,)_W:J[:IDKW;/+,AV
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M;'#TD\FQA6=CDQ:48$D*$HF:HJUE+L=JOQ#7X$92*[@750J*1>Y(R-AI+8V
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MC5#J%DW!43MU+.UHH.\-FS0[M7IJL"\-^V7X-TE.^8PWU)2"GBLM7F.-DWA
MY (/+=:<;7?A<<F Y@FM0*Y'9A<!0??LI;CM[W3SG,W=<AX(YEE$LV3:F*1E
MS_8>549EK(<N]W0,O,+Y)+M=(O362B84@!5&8>D*] .G"(ZJE[ O5IQV%'8L
M#95",S++^8YP"CGIK0J*!+0BC;:DJZ."_*2FH]6",O)Q1'SFCI!$RIQR@8<:
M.:/ STXHCVG7%,,"F29X<G%A\(>%H<71[3+#1#75T.'I]62477>+1.= KG@
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M@\WA-VT31/J/MF(FZQ[+R5=^CJ_NL493W,30H[@JIOVBM%>"T7CZ1')$TD<
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MF:A-6,8Y#1/+G@C#NJ "T7[2,X5LV>U,Z)U(_TEN+6?H#5CL&A]]Z7K)4NS
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M"CN9*VX&TRO_G.:3O5$=2P?BV;W9G$.6G6@C1A-,)6;;B%I#(N1E.CH26"A
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M.#2KRKD'N*_@(SAYJIC2>SG(#OFL@2C.4 S@4B^;N[*2- P=F0D86>"<P41
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MP.XS9)ABG>XPWJ"_]770GXM*J):V-%.$7@J2U2"< =^B2/)1&!$!V.'#OVW
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M2))/X3:31#N1IB,,+:M)]52(>PUZL;GQP'-23219$C&[4OXE5%N^#QFB)[G
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M+JX"VV>FO%[3%OT G[,IZIO-V;!_Z[91Q-.0!['RR>:E. 3]/@AG8#/EA54
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M7HOZ-L>;\M+,%"X2?LWOA(,E<T[_U)<_T;K'4"N\*0P<I?Q63;Z2Q0>O0ZN
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M:X?WK[@XQIP@*R-((J7#Y6FVTF#JXD3'4.MXOJ#+A"Y,R\CPE*?QX-R\B_)
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M>F&_?BT^=_W6/8:Q%-F;=1O'23IWFOEA%J<%5C:J ,(I/JSZKB^',\>J6AY
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M'H4'0]0[0U(]TI;20#%U\\,A^XAL;M"%:+,M-*B7S!+09Q5YT=*(X%^V"&R
M%,V$@U_,26)M 'M)OZ&KG;N;E^C:<4* 903?"?[:;E$!\5Y0 PC.A=KD%.L)
M;+'BDC' Z3(#[XP<:'@KQ^CYY8&9VT#/@1:Y/VOF%+<O]^&2Z#S)=B?R7HLW
M*L#<S3$ALE8;G$E',<5SIF_;#KP+KL#<V5Q3_E8MSX3HS6'3'72VX,Q:1+:/
M$(^93UA,V3&^:=#.^7TD5_--0S#ZC%H)>0AP0 8]"Z0GE>/RJTI3H]J^[L'N
MT<2VCHO9-X<4W^AQVZ2!$5E_Q7>.]GQ:C*Z:*!TUXI:@@"ZV7=)Z<#(^Z"3"
M1K1! E/M82C/(RPQ_.]I_S4*^:*BD.O)W3J!R 8<^[02CC?5R:/YCMG>X;V[
M(36ME).L)S.%/<MMNM=6(PHNT +!7!YD)A.SH;FQN?XVR@T!N /V:#P_IQC"
M'M'2VI>9U%]>DZ8;NFMKY)GW>3!>M((<N7;"SLVFQOJ[K-X4[N7I)"K>\S[R
MA^/T-\EXI;.+Q(@#$+PTPQBT7*'Y^1WLK>D9HVM( N;7K:$&G].]:UV@DY,F
M&>#V=_IPA<Z[+02 +BC7&YY(35^:[7SC<?[ H<==77WDT:R,BR!17*=6%58B
M>\>GQ<&];[!L'4#P6L<PEU;]-BCR5-W92L9  VBQI1ZG-RH-C%"M4G9C>6<H
MRUQ0Z:+4UG_*]#5 X4^EB85F&UC>X\FW':QDV#,.K9*QP,^N/,/G?5K;QY1?
M$+9?":;CCM0&NU 88*$@%<$IQ.DG$L:U0R-X,3T=[[?]_7ON6-<[V[^CI40U
M&D2-DP1"[+2;(^E8#;Y=@0YQ@: -)W!0(K4,%?9JS2%(A9"4&I' ?3 IJC'#
MKD"_VX1 BY#.(6DVR(%WC8>H?M,ECV:R'MFNM(V1"I1_P&!9.$IN*(F9,:T&
M=_A-J:5%9.H[L7V(V?'ZN7J;4SK1Z73<TM.,(C9):E./MD-A3N'Z%:'UVY?X
MBT:S^.T+_-$#_2 E1@!V*+&_NDTW*XW@5NG]5L<D%\%729Y*C^^\4'.^C/I
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M:/)7R4G4M]L 1(9('Q<:KW<K*\[J3**?!=&0*NZ+.\%[*LQ#<L"X/J>,QS!
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M+)=?HN"<2K.BDGA%W39E?8<Y*_>4_3L3IGR.\J\';P(ROP.B7:$$ !AP.IF
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MVG?Y//8;1V6FYG$PJ;MB1J VT'*ES9 Z&>U%V+R[Y?RR="]*O,;Y4%&VL6W
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M<*GM@7B.-)&,YN-M;?V'?)T5*Y"&@].F8.A/=_8NPQ-XE[<?/WSY_/'77Z_
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M9/K@_HC-MRELV-[,RX,3X_('+N:JEU-F5"<+F2;%S))*;K"SY?J3M ?5+VT
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M>$XT\3W0M6RO@?D+*C)APD%+*&$VDL,FJ4E1M7 OV\/4;'&<)H$W)0(8;8>
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M:Y LN]ZH8*9JTVMEU@DW#,T,OI&[9$B=/]["DGU(DZACU9SZN<!4?_'YG#Z
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M;)&](2:3S;GUCX2 -H2PR6M-'8-[IZS>YDVX4]RX2/53? .&PM:]2<O+,S>
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M+ 14T3'3705"4F:>/'DNSWF.PRD(]@PC(X5"V98]H7/>04(*Z>_=.2?=& G
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M\UCF%:Z4=;@^ERFFC_5 ;< 6G,1$)#V2B^J7*KHD&5Z(J)V6MT+0DC/4SN*
M#G,5"S83*EQ4OU95E)%[5]D"IRBP A:B6\5I+0][/3:H&WOQ<>GQ6UO-'EN-
M1\IL7#Z'QRE+WW=F8UN5"&ZHZ68*&+LCO!O9&/KE&$H,#\'=-,B8)MO/V"/1
MGK^/5?2\;&V:BD8H12,C6[85]5Y<\+ Y0I&>#8I;II"DFPC2)[SU7$A5T@2;
MXHZIDXU:KA@W,\7X/GQDH-4\%4HR R938O .,3YKET[01;%U5+KZJ4%8/)8K
M!^3"6Z ;JI-&(EJ;XEPZ(RR!@$!-/ZE6JJ*Q)_EO$3B.FBQ=2U#XT)[;?)Q@
MR)>JPGT1;:2(#\8Y&11.@%LN+$Y 7?&7+E5!#6*E"Y)T6^M31#T4O>F(44FV
MZ'>!9&\(323P4H11K'#IA(R$\_ZB +;SA$!5&KOHO4K1B0#&1'^.(=N/4#/4
M047BP'O1%_1Q[<,QVT?XJ+&'H9J*EM.@UM>.2T^VQU@6CL!89JWG]V&IJ\C?
M"W[@Y+.( ():Q4O2#K"YIPPH$^9*C'!-='U0U,&4%0UD&7-135AWY%1K9=,)
M!2*GYE,X'H9.1E'MN((]&BH8L:U08P)/(_KG5KNR\>?S^TZV9NDJ@:)Y:A\S
MOXI>I"+X@BD^(P"!2^W>JK5\%F5OAR6PW8IQ8C%<Q]4P8.W].V1$*KSG@GC?
M!5)59.:#6&-F489B8G_<%/P4=7LB%F-J.%RZ\/?R$@!FM'CD"%VZ74T6G8<R
M/JC&@K0SXVL014/A;&HA<W&,W)L8_C8WD=&*F4BUX<UL)%[W,?TLKI4T%,FJ
MGUB!$'>(P=($4J&^HV@I4D-;UBF3'>48D$=9OVG"0\[,T%N3NA8O3*3>(V<N
MJ)>([YD8TIT?2&,4.$,]&ZT>E'CY38EP:Q>@6O_(6UFTK"QHW08RF7>-&JB;
MD5%:A#K".+G3=RP&S ;U>"NYK*O!WCHX[:*)@+E42N90TE@VD4M:5IBEN2@;
MK)$[W;HH_S-3E'5G&G>_=G0Q3]!2%<L<NMQYFWW//,<T6Z'PJ8_7BPH0+0\G
M GN,BM#S6LO+T,((/VE$.=)3\V(;@ZB13T;M?>WT:)@75JG8G%1-:>W"?.JL
M)H:KB^@A45-&HN;LD*@Y)&K>3Z/>/M4VZ[;.CNLWS@Y[\,?4>X6CX<E)4 >P
M;43MP>@P%ER!V:'&\MD[FK5J>]L3_#6OG6EKG<'Q=(KXG9NG$ELJV>@UULW,
M YRS,5'%-E)X1SWC1.N?M2O;"3]$R!Z$#(F.GH+')=:XX%(V+KB2CY8.()V5
MVX4VY1+)W/0B6R_>[K^7+4%(1:""UY3*W4J.<VO%)S*A&E7?L&DG&HTY(KOH
M3DG$XL& %/PL ?F4E0UJ3B4/+T^'K7%K4FO/*(,Y=I[LL4Z?NSP^S>SD,/4!
M<J_PCT>.0["U*9K<^#/^@.F<V-#GXF_ZV!Z^./Z<>^O2B"LB3AT;/*S]$(1J
M[,TJA!US8ETY&3S,_&,R%HX0TE?/_Z-J(<6Z]&7U!&]6&EF$,%YM A90Q3'&
M*Q1WU%R&C#)A=X)ZJ/@PAZAO*RO\;#:)VIF[O\@&O7G>A2=BB-E'DJG_HB7%
MJ_[TWU>]^]MO#UWKKGM_<_WMH7?3?W^6.UUEG!$Y3?4<*%M#/QCC^O'&=;+_
M&XCRA+A5Q=\57E6D<5BA,;V$2.B0S:#@K)EZD*^@)PM&+CV1@SL(LSZ77&TA
M,VW\UT0C'MN/=;[#WWZ-]9G[JKK(78DN<G=:%SG.F45=CT61#J$NF)]&ON[?
MHSX8*WGZZ(5*NZ5)]0S".U58(I"A$_RO[,0A29Q%PF(*0CQ#.5816E0SOC."
M/XN^C7C&/3U;HW!,J3L))7\/R<#N:1?PC_9!O5SW+KO]^Z[UJ=O=C%YI-DUN
M1GW;BL5HO[^Z2,!&%-N*QF/DR$BRUEI&JZR)%Y<XLDP"4=FQ*@FYJ2Y_&@&O
M[86 _^.FUW^P?NOV'[[=E2?BYXT=:+?<]^;/TOM5G@8E\1+)Q4<F.IK[(8<A
ML0"3DW1L\%OH!A%  H\8U=^<>UV0!4MHE0G7X@N[&"Y11['LQYH9.I<72L2%
M3"#_-)NEOA>;I7_S .?!O=7I7UF7-W=@<][>]*^Z_<LB=HXIRF<Z'5K;IU'L
M,QM?HM1%&FX3&Q/%AIP+"K* 6L2HM1@S@?S0&4R96I'VT&?P%5PQ#*FH;JZ2
M[U2@B?'%J;Q0U6_+]FH^0I*H=G08J[^5M\!7G^H]2V[A*@)E*?Y2*O+!KSZ+
M)CJ7X',&SCAG\.= 8;2=+$OV* Y9ED.69=T\P6Z<GHV].#TO;[[>7G<?NE;G
M\UVW^Q5,SO)<J@O^=,O!FMAI*,Q.40J#0'='IEED\;Z*,LL8CSM5!J0\L1*G
M+I^DHK0Y>A@&.ZE>!@]1H>JW70C.9PUWB.,:+\_7WHL]S$L9+K'ND?@$^[EM
MHHYE-_;QV5[LX_ON;]V[SL?>=>_A7P7KUGT-E_0$$P'8M :[U\6^T^.A@.&%
MT['].@K'.1-7A,,<N4(?"&Y^! !9KUC(R(DQ3@)-!,&NCI).*)"H_[7,'?$+
MH'[ -)WH V-;XAUY1)A0@A=@.)9 <JEAI"\)F)I'EOF)Y!WU?X&QJ,<(FCHN
MR"!2?_U-5<)+M* ,TA/[TWB_S;W8]_V;_O=.#_9^B<[N#NSMOL<Y0E_+5_-V
MCYS9H3.R!?!0P^S+FF:9>%@&C!1-@K6N&5K?/&HH6R%JC:D]93XDM=T,&T.H
M":VQDRW'(&X<I>1SC (VKNT.WWB+$N X)6_*SE[LRM]N'GK]SV4E/9L<N"VW
M91%N$=GZ)<B0>,J@<3V>)V!-42&D16C;UH<8^QOO$20ULYB]#LOE=*ZPB)-?
M2UC*%$?TY$0U/%U[_^SB@9^Z6'+CTQ/1*$X8UQI600/4J*_YE<F8GGM/#JH,
MIKF+&=KQ>VKL67JII,;MP[^)T:!&7R;N?,0!L&.%W7OVQD.RY&U]ENAQBM1P
M_;N)>23(O27E@%5EWI%B*ANOC7Y/5/0D1@P:XRACS ^*.S@I-R;Q2*W)@,:3
MQFBF &X84"<&KHZDLB(GL6(Z&OT)DPLT6PRZ02*Z%@E8LZYR\C&A.?*]<*JQ
M)DT=VT>R?<:S\.2+3AF@?^D>S$ 9]6R %R92JN2-?L"2P'OB^VHW.[9&MDNR
M,L"(:V)1L>+5?O$4/9Z<;N8KBICO$*U - [Z6-:Y\<:*,1JE-V5<2MX7*4!)
M9^DS8H([,9]0SX6C1O,X2S8%[7%..7^7).,M90&JAB+9_/)NXCNC(5-?RXYI
MGD4&[5Z%^F-C;ZQEQ.UX@J!U2! <$@0;4!2Y-TO,'#]+><BUV@5V"BIH4USD
M"UE_Z=U;MYW/70O^V^L_=/N(L.Q<7__+^GC=Z?\SV^D[[)E=W#,KB=C^Q]-;
M>^'!?[[YK7O7!R?>NNY\WX& >HNX/78J5Z9L46;EHR21+"!0P"SRK&%?SWQ'
M=#?!5E[^4-%'B8;6]JOR&^_GHK"[-X9W\%Q#%&M/0\KG>R'Z7[J=*Q#\^](2
MP:W&+LBV8ST[-B=TW"G<92ZQAVZ@U8&C:S?B&.N+,W4=CBB+CJU:A&.*:26;
MPA@BX*RV 6>*14YX$^WIC([S14WCE-E:2JYO?>\]]+OW]];W+]V[[LVG.%L/
M31WQG0SCX&4M\.8)CI-!.!<*AG-9Z#JG:<L)?L;MI4-8.EFJ3YSS!4S^WD3.
M,]H<77QXOV[=Z&C,<O1QP7&X_\OUS\;B\*6.^4JN6/%CWO'Y,$LT$W;LN03G
M$^"#!/^4$OSQ^EO7NKR[N6?P.OWU_DNO>WUE=>[O;RY[G;5+)[>]U ?Q+DV\
M?X;OC+;56D&/GP')O_),U0J9J1U/!9P?PIK[&];<A>.V^[]?>A][#U:GB",E
M]T9KQ!IZ;,W]N^D_W-U<7W?!M/CTJ7<-ID77DG74]P]@?G3NKM(1G_QY^7IU
M<P@D\Y#^$4X=T)_U[#;HN_C6MW?=SM>/UZO5)NZ#Q?<IT?HB:F1:D)/6/$M7
M+-<HD1</Z]:*X\"NY1HY4;.W-AK"-3TX<7B?"0Q@Q_K;GQMG'X(EK+6T('25
M=50[)I"[[^*R1>S*(W=$Y,J2D^RHUOPKH8+NL3NB1W%-0=DANP*,EU(S_5V4
MHHC.HMQ]E )Z2$#F.]BY)VHXQ(C>_PEM9&@>+T2#.[K\CBZM<*,_[MKG2NC\
MB-N_,$Q']KSCE,1<E8=/94/0P''^P$_XQ3$Z:$>CX(:(_T'0J/HQ8P Q>,CP
M+&JB/)GB7;260TAYY/@*RTC% ]- M'[')U#2 ]\&N=]X/F:^,W'#"<S BS,-
M'6T):DTU^S(Q$I][Q5:*#3L1.SSP76;?$C<K(&]BV'2M1K61VG.- A7I'NVZ
MMNA'(C;=.)MGC[=;M-4R-E@$)?Q5-EKU^#\*.>^:92.@+V&3/C%$SEA#@-QO
M85!<A-+$V,%] LJNJBH[68F=9Q8;?6I^OAW8A[RPUD"LO^);X)0$\1-0^[!7
M03H".OW%&3,] 6S^/ZA9S6S.91R^-23J.K"7QBXU[X:]C_TSL/WTP/:=)43R
MJNL+=F7BG8P9=4Y:(I7W4>/TV!J"WZGJO+P!EX$.4G0.U%&5N+S3_9UBO9*C
MELCB88'[PSIJR1X,&P/^ULNGL,<*0FNY)26.X&?N6(T3N<P*T-O:(TNF:'IL
M4;4/M^\%_3A#GMW,(T(O[$TK>;.I0"^V_-QX2\Y65V0E!0K;W&@B+D$-C15X
M-V)^][#E>;5J;8K[I1G&"YR46JUJ )+M='SOXA#?V]?X7I'25EP$9(,6X1L!
M1NM(M+D#/W*=UUTAN-A.SGOSS'!X@L]VMLE 2<XMG@E_^VXV6RIQXT86&([L
MP5PS7W269 =+UM%R6=KF%\Y-Y+''K_$\GH#_/7;_';I#]%;(&+)G+IZO1_Q@
MT9/O"Q_R=V##G7RD_LB7\KHO=Q\OCT6//DMC5!>T&?U.[Y(18HAM/%'DR7"%
M? '?@5E]<8[UXB"%9EKB6%J?W"G8:MB>\,X)\-B''3PFMTL8:JHG?1'A (-P
MF7@#RQ>N;+*Z[R8SU2*US887@?24Y:5*O(SF%Q9G!5@168$UGA#.%1<A:3.C
M82Z;R,06E)@:EJWGQAIRM0HL5%C!?#;*+-,2%Q=3$ZW(L425W3(BY>$X!,:E
M?0_CTL/4EVLY5XU3Y5/1UTAW)SCOYZ+KM8_]TL7SF7&R^*Y ^OE[2B&Y'!&#
MA@B9ER0']48=Y. _DKD!TN+@X Y"IDVJ4#^\:3AQ?.21YK+GC-#)"N$1D,+R
M^P5WV%.&QV6$#U(^6\6*M^ @88,+ET3EK*/<4;GC8A1*Z>$UE @X2CSBHWQ#
M)@H*IUVTRQ]F7PG][?6W>Z/?'I77OQ7Y-8N6BOEN6[8*UG@'KS^CY-*@">7'
MF_+Q\^5L:NV#C[]7/GXALK499;#! RHIS+OB[9\:(IVU6IV*IY)K4H]*JDH(
MZ:5F"'RE/_VWPA59GV[N)-H(2;K36*2\T*-Z88N<W"PIC45#Z"(+ESIV!]&Q
M:R<<A<=8CY2!XW/3<)4K(1-/-6"@\J-5[-N\Q!:QV%":T$WX[S%/O5XO#BO4
M?F\<"/W"!.IA^>RC(Q%]+EPPDQ7%%I0@FVHU\D[\.7I6,#ESD?L29XX/=M$)
M3-+8G@7.?\D_?,#^/F-[\5_NE$9-/_H@UD0<5+@FU'4+_!^Q-6DY^&MQ>%PT
MJ\U:&\^/.2SV?"@?+(Z6*ATM_SD?&KZ#0^@T^VO0^=D_/=RVL-O^)ZT;KQU(
M1S"SI__?GQI_2@B0M%WH_,269>[0DGM.7$)2N.P"/A@,WPLY_J_Z[(=5BY\%
M>-.4$'JS/RTY^^NFMN):477QATP^7?)5ZZ#Y5]S_B;U?N-WQCM%^AY>B N.L
M,ZF5$_E4/ZMGZZ]X9<!ZI$#U:M.0NA&?;G6][\6):M4Z%2OA3,E=^5-L."*S
M2@6TDD15Y2]  =ML/[?2Z7I;:5?7,=I(']^SD=[:1V]LHPWOHD8L+B[25<41
M".8T=^'?;(?*EL[8RS4"^N*.2EJL(L G,)_(R._XW-1TO*#NBP/;'5;$G^ $
M[ Q?[.G<?G*LV]L;X^=?OM[HK*CW,X=RAGW'&0H>P)GO#</!G(&FF(S$=D(_
MR>9=ZC_]1.)N.+8;.W!JTQ9(ROA DW'$QA&[[(GUZ-O<"<,.7.R /&=^%;$%
MX"KX?!!)^"WR>%]12RB%?[_R0_$,(=,_B12O9\TU.3V?@%-J.?OM'T%76SF"
M>":VOVG;ACPM?YA:GECHYK3LDZPSIP;@\PQ?"U/MWLQA<"OU8!/'7?I*<:Z)
M XU_Y B2Z4MX,.SP>%(TDI7N>@G-7V2GI_6_^'!'=GK7O-,I7O*?%"\K;&IB
MU;RI(EP,D9O@B?QI2;-ESBST^E;GZJJ'Y!^5MT:GM""I\Z3-LXO1WVR@5D_4
M1S#ON1T$X<09KA*LI?1O^<':5K5UWEHK6%NKUFMGQ<<ISZOU]ODFPI\MPO,4
M?-M6]?RT^$EH(/:G46"P]OV!H5,T%JQ3JW$AD@IO&SD;#S8)<Z.ID0,6CIQX
M4R_0'OC7WCF;6UR^ B)3*K55_D0FTYYO3^3VHK*%S73"TCBIK5C/5N#\GZ\\
M_])5VGI8O%9<H7D^M=3W,MR-,I=,MY0R]% )&<="M])Z'LZI >QR7B"B.9\)
M:P2,ZW!VK%=>'\Z^9\?@,F7Y(;UZV_ [ ^N\<W(.OF<*\?:NE.$.;(BS^#3S
MCC@K.S!DW! 1V07X<*<?K%KSKX3IR:Y<-D>)-,8+6RM7QB^''MQ]ZNFU).\L
M)2DX%[A?._8](EC6F=S4PTDYN;_*?4.T&HX^ARXR.DQ!/FO56@4<_9S8T%+?
M];1)Y!I#+;SZLRG(I@FS?%$@ET0A&K) <I,\[[.L_0,HZWJ1M$KYYF=/3X>5
M$=S[?W*LLP.W8_59K2^E L1V0-L9*S3."FP/O*OVX+8*T7Z&'5VX_.VR+5CN
M&YIMP49.6[#\V=R@+?AV)'$']*?16FP7V./Q8"WNGK7X:^OY];?)[MATR^$C
M"6NH75V2ZLPW">^_TQN14J*N, ''Q<=[@T\I>H"Y9C4&BBE32JWHGT;5LGI!
MC,I3 %N8\'.\X-;Q@BO AO<#C61-/# 5$*R] NZE?B[.IY)Q+Q?5BU9C'=P+
M;IQF-JQC7<C'V46U?M;^->OS3B^J;=-V$A]O"_V7B>S8ZX-TC2J@MBE/HS[>
M&C@SYD$U.J6&2W8'6B"QG^T2[7S:&5E(R%_GWYGPBF71F7>NS=O<#P;8Q<_S
M[Q6]M3)4:2G&67STVWN#G_O?ZC0Y3/0V_]WX^+XJB_JJX;-RG>OWG@!O4CS5
M&AJ7FV@U1@1N:0JSE=W]H@I8=IGJK7YZH'K;*ZJWS0C;+\/O5N;T9<5QTQ$V
M$XN+_'AKW' <SRV"&^Z-&&/KK$#*ZWP^P_;XXF)ST5@GJ/^3Q9Q3Y8_%D0?F
M,T+/. +\-H>=J)FFFL>WZY^/TKU#5QK_(4C\KB!QZR>-@1W"R+L?1FXVN8U+
MHL"_J35WV7X0F1N=1+"<BE6KGEE'[LCR_"=["K<4"2_1,VV&V7EJ"&&/ \_(
M!7'\3E]VR4FP@@=62QD8C?16.6^4C7:TFGC.,%>J\7C!9K-BKCU_G?9T%4;2
M4@-!U;).HE$8BA'U+7VC.9T9BV'DLU^> 7WGTJRPZ[:57H7'GEVL12O0K+:;
M%QNI_Z>]7G"A?J/:J!5_SL.JG==;1=?_UV+GKWXX)[XIO.PXX=P9R4M*Y2XQ
M:Z-E5?R;UZ9;+?;?J(!,W.%P[+R!=WQ_',&X+BTFATA01K12E!&%6U<7&ZQH
M/RS)SBV)T&([HF)/RP;]&E+A>ZDYC>P>*P&NS")@TJ_;@8R_?3@;6G)LM"/'
MJN7PK<Y)ZQ]KHGWV?'5,%!+UL[*]-B/"W^5R11N[1$X<?WU*C%8*5O9[&& G
MPS*'".XA+,5">GD.NWT\1"WVK44V+]/YE947_*Q0,=GN#$;[M5FYJ+0_5FJG
ME;6+<O9A;YZ9Z%V:@M5OZWM3[DLK*=F%%QCN=<AR<Y*QQ;W7*7+O+;-W=W)?
MGK=,Z>OF3I3%)0[-U.:4QTZA1\[.;M#WB8%IT;=[X)EVG#GTOXF"[\-W^_U=
MD=#&9BL972T5D!AK+KL<D%B@#FA?5.OIX(+\=,L0PUKF& X0PUV$&,;!6>UU
MY+%5F"N0$Z>6#P58.*'(A^V..C*0K!/KAM/V(D4,QM1G;/\]S<N6UTC#(3<X
MGHS^,YWJL84=Y=7 1C)EK5HPQ7K2N$5UFL>A)LWF5H'L8SDGH&-,L4=81 V:
M@=UX&(-!P#/*^ML6*(HI&->,TQ!9_'#^[/GT(["IPX#)M:YE3O^K[?\1X!VH
M(RNWD[(ZH  E2L#X1K/0#T)[2F8Z7A0X,QO?Q;H59KVXO]5Y\AV'4 6O[OR9
M&]M;%0([$.+.>;+'\A7GBTI4=0T+[T[5W^;/OA<^/5NOS_ FBQ/O%?%VX"H$
M[M"U?==A.;!JQ_A"@3-&#X*!#<&R<0AX16 ]T5Y!;-^C-US Z[W@G^.2]^(1
M^$_*'C:J=;P1/+C]@9:C3@^?^<X+#A>Y90?PTR='3JZ-'N'8H1=RIP//GPFB
MCHKUN!C;KP$U9J'^MTZ 9K,;/.,#X=/H]8;>(,3I7#HLGNO79Q=DPM1H5S&N
MP5@&H1\-H4%#<'XX_@ Q(W*H^'2ZT0P<X,%"$SYX^Z5O4K5ZB%<9NCQ.X\NL
MN>)B5\ 7B76"U\')!]5Q,O.]$9QZQC<K1FF4JQ\_5H^S*HE2:K-497E^MAI+
M?0%V9:=(?IV<"_!+:.?-Z.8BJO/3L:W6155%WV2OG$9AG7+R;LO,35GD883Z
M.MZ-\HT#:4,SKA7\;6W&Z\MF?)]/X VM69VB*5M>M,:R12O0YK!LV?_.^7<(
M&HR4('PF'S'$3G=PIX#N@\C7.9@GL!Y'OWON5--O+^X0?C]>' N9H(UG6,WU
M3(DWG,GZQ>:<C^51*YMF]]Z9S1D97&M3 .OL_:-L[E%P*Z<BRJ:S/ 2W=CZX
MM9YDY1;X<D,JFPJ,Y74!6D7FH7)NO[XWQX.6ZC&I,&^ZF-.)+0Q?.DS0X 4#
M &,#PE(%-Y=MI<K;QE@>0V 2!J(LQH<C!^QB"UG,YPZ8]S-DC[.-S54?G1'[
MK1G'V,">%F4YGVW?2/:R#G]AHN$T/#G>DV_/GK&L$GT<6#4VH;"[M"@X^C5F
M@\INV/^*FL&#* \=:VI/?I590 M>UBHM9FRWR\HF)XB)AS-]@L.ML'E)]*$X
MU1#;.SA;L%?F3@6UTZ,S\"98R$PU4!@& L4#9SS.W%-H^S:<8TY%-;YZG#M#
M+AW3+%S]"]B';H :2WA0G@_3@@IUX(5^X.@+LIFI/V]JU N[-_7@W8]I-FV0
MR#G,H_-C (8SS7Q@CYT@Q\19ZEKX$,^/&45DIIXU]F 7^!@5&H5C7EY<"]^9
MC>V!4X2SN,M*8&+_P2I@[-GLJ=G#%TQG!7*6MR64K0:Y,KLZ<62LPN2 $42B
MZ?NH3;FT$R8Q'O/#*V:V/U]DA?=4A>HP^H%0RACJ\VEE3.XT74UA%QE"U)(S
M^"*S&?K;46@,Y-O#Z'6.6%GE#9<\"N3@W\"U!XD9AV0CRI<>P2IY@S^L9V],
M."_\A!C3K>9?4;)L:Q:"X3? ""<>O.;RUP)LZ9W>A&!!#\,!!],BA17-/<^8
M(6:-\9H^F"J;V8%-G9%U]V9M+E67/:!T/,6?,L24@^YPA,,&@E-[@2PRKO-"
M&P@/ER'X&[!I:",2,#)[KC<2B#*X>K7:%GR],A*)*G+XGCQB8?/ZWD!#\M2J
M54O/C%RND+"TS6XP[1T/9!^4=N"-<2=\);9V=U@1?P(ONH.FP1Q< .OV]L;X
M^9>O-[HS=3]S!C ^J^_ T_B0@%5&7<?[*1#)-OPS9L1P0/%\ZF.83,@D)5*,
M9[,PE?/25[50E,J1>TSN_;86.(C0#T<NO,O>Y67A9D\.'<AT[4UD]>1F(N-V
MW8EBU68K51E=)))VM9Q$CFS$KY)Q:!PR#H>,PUJG!\ULS&*N%U9.6R!4 D^1
M]>$2V:ET@X)H<UX\/4MINVS[<[<IT$.E,-3#2G-?J[;SV,07]>+J2M^>Z'J9
M0(5JFGS=7-,2FX-52L/2JJ;<Z<SGN)$UAI:A'K&)G#*RO/,Y8Y4HZ)3K(0[R
MP I\%7KC%!IZ=F<8/'-\V U5ZQY_0Z\@%YP66%WYN(B],)B_['G"]JE8[DAY
MHA5IVTI_-&IL)P"!OD9 *FS."9F9[++"@\@.K%J?0A_'L/)D@N@.0M%<N3,$
M+38,)_@DHZTJ3-&R0@JM6K7L@$+MJBCG%(.%'\<A6CHVF:N/=N#"NDTQ&,&.
M#5P GPTBO^46]+)U!9:_$PQ\=T9AHBL_%*LH/)4EWF>63UF@&6S"^1:Y3+\$
MSA?]VPP!J9#C^VXA23BP)J60X3KFEJ"V@<VHM@,!V +-R;^_UY TST_2D*SM
M0MQZY^&S[S;B=T$X2S,C-P/G.B^0E;\@0W$MFS"7"9=\$B&Z2K#E-E.,4ZLV
MRC:FWK1);TE[N#-FT->6LQBK=+VY*3C#4CO=0HJE6Y05:V#TII7+,BB4YA*J
MB7^QR5S'-B"F^9,=9OO/77%FY<$01-H_?4:LEHC,X7N=%>0?Q&ZUA5/#3<BB
M=CB\=:0D<[_9Y26P<KM@)!7DFJ_'L=+<F=30.B0KZR:%C)'[[:>$LI-AAY30
M7J2$5I6K7ZP$99<J\]]@8JE;E)>J?; ^N<B]@@B$.R? 4P?$8^S.%YNQC&*Z
M?$<L(RTP%K>)L";&'<+>4Z@WQQJIZ;*#(/01YZL,J $<U*-P/"(\W)@L3BR0
MX.J>P1R+/#TX2)^$KPS. WT-/IPW 1^OBGU7;,MW@S].Z.X3/&/--3?P0KKI
M%;#9#*<\OVJ%PGC6I>\%@0XVT3X545HXRA&40A@^G R,\+$SB",PSUSXB&$^
MBE1A'L,+L6AU, X#?),*>)03=R[C 3X.G\V> ,.)<">P%$4#&3 LYJ$<]]2;
MTM#?._*DZ41#$TO)@'>!J#$L 'HBHC8J9M> '35P")8[?\6('>@X GBS$-FS
MV7@AIPP%,%8!8H53@E_9]%7L&^219/@/_!XLZLD,Y7#D>Q-ZJO8F1\$Q>N/X
M*:-L/A($&6YV1:Z^!V^_S_JHH?01?*0<Z-!W2'(OD:5TY YHQ3=3>WZ^"PP-
MC4Y!3C)(TMA;8,K\56U"TD$!!_EQ"\.]YE+R:/.^."(A1&Q6%-L?1YMEH^#
M"\W6W8%386*[4^J@&4[=R<QV42..I432=.H"2?.%BD3.&>5$A,;Q2<V(,T;
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ME/SIHH.$X<**H=O5LB%L/V9P^&ZKGG,[1J(I@ERU-[WFK;K,]P[8+,PYTL[
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M$:47(Z$,/<RI5P)!/%SN-3,)Q[89[+%+E6#F#8"2<]>[_Z=U>W=S]>WRX;[
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MZO2)K;?WN6]DVMJX5= ZUX#7.V@64+*?#BO4SA5,/$Z#$:9=GQ<S=&0&=/B
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M#TC%$(9WE"J2@%<@^\H5"&3.X(BF0B.%NI2MR#AM%"5D O<'7'C4.CT&-;5
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M[>:AU_]<)JF;N<7G]DN4/HF6;W'\0V+S4;F[+ZI9F+NEHL+F%C7@;!$"0/6
MUZAI\ ]D2[AZR7Z$K-=R$H:D=$0/IJX5"8O4Q165(H G,L.(5A,?,RBB!T1?
M\ROC[V"43Y3PJUHX/3Q_\,[I>VJT*CJ'BC45Y90C\1O5*!(OC[Y,W/F(R' 7
MQRIA)'AN$U2W]#@,:+SS;F(>\78\T*CU7]Z1HGF'UT:__S><WY)4#],[ I:#
M_ B4)J+0)TS^R<C##%(0?VO#(_7VINH0$'P[##=W!:P54VI@>#J)%9,0<>((
MDC;J2' <N<=6BP2L68\XH'6A.:*4;V0:3\&RA!$2>9*<? $P E.2[A&"_3H;
M,^*<\.2/#LY"ZD8_8$G@/?%]M9L=*ZMI@!#TQ*)BYLU^\53_#SG=$D@#(W*/
M>8:MH\9Q?"SKW+@*3O\<AT>8>U?T(M4\%*DW*FC[,5<&PTX06WQ"L>ZC1O,X
M:TD%]55.\7B7 . MK:.S8[70[YB5=4G6C!UR3U/=B>+],MY%ZU8[-;35RGYD
MW!(LN_O#:;5\R\3:*<ND#Y;)9?>>^ TN;^[NNO>W-_VK;O\REV-0.XV[I9FF
M1WW["+@^E4_HY*L4>A"0%U%(F[9%T 8'+8Z\^''XC=2V6=B!J-II./1139"M
M, RIRFBN6&G&J 9$;RJ^D(HA;$7$3[!?P4D[U.CWQZKB"5]]*H$E" 6YA:NP
M0HKLF0ISWL,M\*O/#G@I-C(<A6#,C/<Z5%Y[4_;/?N)0>;E:Y"S%@%]B<'Z%
MD$/]U'C_TY_] 27E+YJ'^IX]SD-L7G9W-O.VKG9=&3572U?&;J6QV7YT-L,N
MM=?=!ZVK;5ZS,X_5V=@!D%RB:DS$G#D\H(IK:4:DQZL"(;*RW-2G(&ZVLBF:
M(K B&I[I.-DYP%9VJO/#&82B5)K3(OEAVNUT[=[."/]^]/RX[_[6O1/$,(5Z
M6^E5*+\ @FL>N" A35F/59'CH:C<"J=C^W44CEDV!QB)829RI&#"RW\/?3<8
MN@,N_J:\W<CEZ)#D^42D.Q:2B]J#>/&=]PC'CJWU HRS-D3\<;PI\?D32A ^
M*OHH2[QBNL*"6"NP_&6:>8G69(Q2V_R.BN=6/H;*)P)5?2$ZG\DW50A9P6-J
M")SGW+>I9$&MEMJU[;*W['[00_=O^M\[/=BV.:OW<T7DVFD#S!@=*S]B EL*
M+'<_T3E@H45$AL[(1M8CV($SQZ?:#(1S>U'9SS*R84OLG5@;1$<^16-,"2I4
MX3&E/IWZWC*ECU154[1[Q3@4S=UCX/P[I#JL-T<RXE:/R]]BGW?>?K"Q?KZ!
M7=='*M;KSO<BC<0+MN)WR4A4H4/N_4#V645RM4@T N4>02IGOB.ZB"3**2HB
MOOBJ#KW[N6@BVAO#.WAN@4C9PW?E?7= )>_XOTVM0EO4*K1Y")+^S \H*0K;
M.HF2B(<X[*\=A]W6X1/O";<Z9JV9[E!K!"O4]2[2F]]?-8Q=]*WOO8=^]_[>
M^OZE>]>]^52)QPP0BD1\&\,L<A,.;,CP6D6X_*+1>J*C^YBI'Y\$UZRL7:>^
M3^M&XEIE>Q%1#0!!"33T/[9-N+GLY:8[KI$XO2D9]5JK6F(_VCIE0#\N&,=5
MI&.4S&*;G_Q_&?_DY?#,G+\M]UJ$/1 K\"YC1OG1*\[G>_7=&7=-W>XN-<5@
M5JJOS[4QFTBYLHU]^5-LR^;V"6L.N[+478FXT.)W8:/47=C8UBYL;&87-@Z[
M\.WIW"6_Y/#=X;M=_NY]997+B[UVFA+\_  9W*]0U29D[5U,=*4:9!<X6__[
MI?>Q]V!U\NWB=,VWR2!KM/3M7DXDZ_*F_W!W<WW=O;(ZGS[UKGN=AZXE^]S<
M/W3Z5YV[JWOXY%/7ZO7OO]UU^I=="T%YG7YO":E=6<N3'A6:>[?8%KV&H;-Z
M3HO9&&HLU\:_ZW:^?KPNN]P>(9!;8!11#7,('<6X#@1B7;LCQ^I-@]"G+/6E
M-YG94PRI'M$WF-/^PGVQHHL&\J(*DT*,)"-$0-EL_#?H_6.J G3@;X]C-WCF
M*P3A!!+U^X[.;CMXMJ<@0^E.W-1>2#;8EA6"4:4H5@I:LE3PJ$&5G&>)JD?&
MD>DUA:D+Y][<'J<K43'I3_>H6ET$I2A.6"J#=8.(P500G-MJHB6'+U&3*'2-
M9%PA!E/5WR8V,=3BA=NNPG4A]F-")$$0,*TJU?+.HZY00_,28B-"5P!;TU2E
MT8LHN=@H5XH1854V=7T':6VUM@+8;2HJ9Y4<E]%&49@/!TY/%SL*<3\M.769
MG/91$R'52 [%W9;%8 &(=.#YO/UT@1)08FJ_-5?P1S UIHB&C-CTH])Y(X1+
M)C^T_EEPY\R=+I\S@S<:N#/8!]H(Y2Y:G]VB=,6N>DG4K!-K22.)LGE6SK>B
M^,&VB"19R+\ *PDE0T@ET0-+R)K&5ZVI,0(#CV,2"QN"=2RW&WCF!I&"O(?[
MO<J_<9ZF=DRMI")^J&;MKU(),Z^$:L@A&>Y[EUS;CJ]</V;MY3PARR!UBUSH
MG6-1\8FC1&Q S! .QHYHG3OP_)F LF%[:X9B"8;^Z*PBA+(OL%[XEZ$W"#&+
M&&@OQ;J4QPU3-?2<@(8&KS\(_>B5L09?-M&VQX;1%:QY5Z\_1^KB\L'H<AI=
MI*.8A/.0)H?.+HUJ D4(N<*(BMQQCH+C&,\&S*\\Y[ A*4BG$\JIU4@&>/7G
MSB0 I4!R)-N*P1G\PZ4:9!"A (MV$14NV__%A1-U)8O8S(-ML$ Z#<=7YTA4
M8CQT)H0*I*)B<5X3Q1IBXKDO&^>CX75?'-Y[\D4TDK<7[P]A5X6@VP<N"KC^
M9-'*&+G@Q#T461SGJO']]U%QUT%Q,S*2C[+0+UU9MTLW3Z2RGH3!7 DU'/4N
M; DR,<=R+@CH[/B"2)\-538.6!E*XU%44416 -OGI/2(!&8L37S1^M9-F/AD
M>1(:FW_IRCZ[<N^2TGL,P9, ??[K05>-TK33H;_:(?2W7Z&_0Z3O$.G;N4A?
M?;\B?<JN:(!=<2<ZN>"QU_UA2_*8DNT+Y%\J#PP0-S"H3B4>AH@Y=9&-K:P0
M_,DH!%\H>*Y@)9DMR60IDC< ?P?-@T<[< -1#>IKTPRV-34OCO/\T*L$LJ^B
M"J2Y:/-3>,.+'+*E(2S5PHO;_JPVQ!GR!\UE9W*/>A[#S,F((UA>,9\OLO'I
MJ6S=TX^I71 *F:A3Q;O:"CK*4R #*H-GUQD)+"J&,STT[QT?WTH&8^A>^ $\
MG#UH+WH3;5AB-/MHY9_!;OPJNYB5'85OT5FW*_LO+I-"M*+P(OQ_>@*;S$</
MD$4U:O_&/O"2_F_@60Z0[2J(><BV#**(CK:"U18CG!.JC)[&2D#-\>R**2#T
M3C;<[0ED$P3RDXNQ0;@G'!2T0"X'F<KV/UM;.QZ2JG^(U*68BE S@[(5^@-'
M%L;/,8<3;WA'0NDX_+%T$/6J_ZT'O6JG;3(>MR-J+1"U2T_%!?E02T?P;[6R
M9R&/\"'O9_SOW(/WS3<IM:(LEUJS3)2_677>9ZG.*'-&,TJJ2# 2!]9'.I]!
M]UVI U7>\*-/]N#T&:>:ZD7^]N?&Q0>:8X<UY*4WF>!A'D66AV IN!3F4RTD
MG747T3KJ7-_>W=X>*PICIAZD)!&,7#. 8,<]CC&4282"+I&?SA5KQJ\7A5E9
M/ZRU%78ZK%,_A'4.89WLL([!OJA%;4HV7YN>DMI:39^O3BW?ODU3+=4NFM7:
M>7KJY,>IN8OAQ]E2*,T R H*Y=,_[?-J(\WC+#\M2_^8)?_AKG/5_=JY^Z>*
M;[U-'K>#RC4].(QX?;JYXR =5E%>]>X%/9@6L[N]N[GZ=OE0=,?9'$4Q:9JQ
MUM8+"!/,*8\B2$1.9<[NTT=@?)U]$,8;_(F-HHR2D@I>?E&OGWY0B+4K-Y#8
M '-]'5Q>@[N*Y'U '&><\/)&(T?$B\3-AM'-HOR8:BOIO4X%FB(&E#"_:-9?
M_L\ZBIHGCA<52PPH8>:*]Z:GO3Y35 F[<C@",P:/%C3463<(Y,A+!GN![BO?
M9_B.)K$=5$3 Q&6F-UPO1>:OE4@G&J19KY[/R\K( X7CFA# BR0:I 7L;?>%
MS*BHUT,DC3HF3,X\X4+>GV0TIZS+1G&H*:8<<4+8+%=K]A(XV!I]CB%C!784
M 2[L())HO)& TU'/=RKUQYYOOG4OUJ(##S?/I[D8L:A@@KEW8'N#/<7,&28U
M_<0DE=CJ*I*<5RN2I/L18,4:,Y/IHV@$.(Y0KN3]SD 'SGS=T]76"Y3A5/C-
MY(CGU*8(1/,F3$(W'BL^1I,:PQY#NB $TG&FR8A] ;?A6.:=\T0"])5ITD5#
M$@W#+'[.\OEQ<8)0B>A\H>,JID>)_<L-"*ZI\A+$2[<F%>2I'I-Z=S?"+0"[
M^C??*]8#<G2 W=2M"%G W@?Q,$G4/T;!7!D"IK(YS 3J3LE%! 4RQ]]@BQ?,
M12G,WI/GL9Y^L<<A@5QBCY/M9@:..V-$K<)2#8C.D$T !*/CT]!8&6#K!Q#V
M)V0)21*3X@44G;<#@1D.5JH3-O=^B],-;M!BR^ ;W ^Z03"V'ZR;3]+'*#LB
M?U&M)U;J;*,1Y P0>^9:W4?%%)$6$H9I)C.GM(Z$;#_Y1*0I;I'[Y.!L[,1%
M+#'-UA)LO.%P("SRE.L<DM_%P?DYCQ$-*J^J4D"5BXY?M6/KL^^%,_[K W(#
MXT@KUC6Z*/3W:, 5ZSNUYN(K/C+1K_C;MRE2F :@M/#OC/@]JA];/67+IQZA
MW^S*F3DD2.+O]V_LMHOBI6FVR0UN?J2'<J'-5^/8ND%-SE.E25IO"CX93LLS
M9LY3RV)>+/X1'/2SL<V!_ B(C8V_R)R0B<VT+$42A-;-BUZ:H_422EGXM^)G
MRBPPFB'H0D2=<U/V&H'E4S_#CR,K1C>5X]G9R#:I1'5%9,K1D*.O!5<6)B&F
M<S;IZ JJ7DING80%DU\C( @"P?#92@"S+IR!QBY.OCUTK*D]<;*MI!SU%:VB
M=/U/=:N+.*Q/W$SCV-U:WB([[GO(6NQ\UF(=L2IM \32'XT\H=-FJD/#-LR[
MCYGF7;H)9[P.E&TW5NBYU;0;I.L9A>.=UMJ5U=0_672L_[U@26BG?"Z=]!F+
M<*AD^$JYF.*L=&7\FCN$4TW2P'<?\:2D8IOHM)7A+^TPE9.K>N]R#]_0#T*;
MV2D)$B;"9&EL8Z !&E9+\:]0D=O>@1UPF;D#5I*^;,/#&!_*;8V-8NO'=9)<
M]V<+QE!$X9$#%6]:B;M!A#(,(2U">OIPG^E)=)?H.4($@YBU!O:9@)!B%$5!
M3<6U7-3YB/IB[F)6@9&C8&)Q\;GH?'(IKM8:;L_G]N"9N;++=@^6^?_RH/I8
MOL^RWH9;N1U\K7:V$UOP*G,+/L2\<:UC/!:9+5A%B7ZH**HIX8)]-97%BGJ@
M#UV21X2?,M\!;G*,+L/2+Q1EKSG.MCJ.Y]1@M:3GO?2TZ5'M.).\'D[DP!XC
M@)=ZSJIJ4WOX@F6 !!*;8%MS> L\EU[@/)J)@FTQE1[J0 R;"LV1WT0P:T'#
M:6D\)X^T(*XH#="NRWL7/;D9RWH*3_PR^I'0ILH5IW+*P=BQ498$8FZAJS[U
M\".<'L3_S\8$;*:XD5#>_.;1')/BAZD8!O(5*.TMX@=X)% B6;8EYRY6$=P3
M)C">"B<Z$L1.:QEQN.AO?V[7/GQV/+#M9L\+^%OC0\&)1.-V:&R_6]E1/7,[
M/,18,DPK^6QKIA3&XEA)*8M.2;=8R&QC8>@&<%M8T2>Q".Z J#P4QP>A4;6]
M45'GK_>(^&F-K2/5"/ QBIIBU6X\#\J-R$"38I5O^O$X0OXR"BDEIT&\'E7.
M#]/*N&I]@N>!"8K*(8H-XQU\1P\1HT= F\Z9"M!W+@NZHFU@>%#R[7 &8&K'
MH>BJ)IZ;#'[9F6L@EX#M*?UGL<DA!>;B*G%8N69=621=Z^Z?-]+#QAU5KUYL
M'9ASU,C<4I1)EJD 6\O;SU\])91:#%$+[Y-%:;:RZ:OXYF!@LZLWSHS1-$1I
M/KA2KM@5Q>P%80/?./=AJ.0V8CD)Q&WIAGP^/%+%^R2<4D']4+Y:0F05D-SY
M02+Y)$]7V0">^CV%9*<_^U[X1%W,U ' ,64[2FLG;E^)F'@</\ \2.:E_-:V
M/!$9&^'.Q'EM2WM!U :I6<+K7<IE8DX(#BK6':O: L9UQ8U,1J%Z%_R;JVB6
M NOH]=DA]0N;1PP1Y^?%M:VY,W9FSZ !*Q9&KCUVO^;8:8L(5<0:'O-D/H(6
MS[$&49>[^"+F!HQD;^1WPDA6OU>\64F[>I8&O<I/MQO2S:X*/H1T=SZDNYY@
M_0S6YEGFT9A;.49T<0FT%,'7XF;-E,(Q7I Z.554UV32DH<LP[P1C$Z+ 8LG
MLL5)=4W* I.7O-?D,833,RR>^O8MGF;FLFK1A[C?YZ(EF[*D=9-(PA9%2$US
MY&+)S?@!R41^TBJA1D4KG[P@&C$Q4E%VT<(<3TUE[YC?#9^%P4KUI? UZ5L#
M++B8'=YDFH[MRD(K4Q9ZVI+'6V(CB 8)(A *MIHBJ&#W:2SPTX@]#=N:P61L
M5[EP+B$Z!/R=@>]($]FV9K#W0=["N89! #F=< DXVG]'[K$U<&R1O FSLBVZ
MF6:$X0BH?H;YF+SGK8;:3#F$K^112%]8:2]]0@F3X;I$"(@QF7@%L49!..5F
MW8Y&ONE(LX^:<KO4@I6' O][IF2,HVYF#3B$/@<#6'9-)L?2X5B[XM;BJGMV
MW)'O0EBK5+TI;P[> Q.Q8M]A'PP(9IV@,:#W@)<I,@L)H<!0!+FNT2FAX4D$
M<)7#\DG@R?J%]+L +:SO!;3P?[YUJ*1'5&>5ST6QV\C"W)J/M%FP!/PG47YL
M\T<Q %0W:7_>5%Z=UCZ"FX;V:O0"CTBA DLL8V,:"#*BH?EW:--@)"=G )IC
M6G1.NJB\5Z?\O)<ZMCZ'H&;Q>YK;CE@9P4%\'Z,6?T H%ZZDH0<C?F\2IHB5
M.%I5F86DLIJYMZ&<]\6.HSY6WGJ*CPBMPTJ:3[W"A.I,0DIX>3RY!O"Y[[RX
MX'_R8212>!K[-!%Z@,]">8F\K_5WW&THRL)^4&S8\--,,Z7DXK2+5CHVNZ?
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ML?4HP1*BFI5CFK*N1T\.ZWL4U:_JF=?WJJ ?CFX81!@UO_RL(&C',: G4SS
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M#4UF:V=)$'.1TIV/KI\8;UL;%64C)T-L(AIUD2+NJ"+J$6OOD4OZRPL#PJ#
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M8,T1^J6KV_86@"I.A-.:@'=L(="2* G#J3N9V<0L.)830B@IQQ?L@XSLDEJ
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MX&$V*$_3P5GN6@W'5();[VJHYU>>4RD:0J>?9NMW'T\PL[W@-1C$(PM^A;Z
MU*MH2>&$^Y;6#.*V504@%0Y+A]146+)2D9(-^/H-^^*XF2J-:17AJ6_K3#^A
MT@Q39S!EG#H.YZ\. \5K62#[G.%4FS'ATCHXKEJ4_'$'@-FE:1<&@'F/H<V1
MMFW6T,Z7TD='!ROE@W1;=CV#<AM9HUW[C-][19 W%3R'J*@"@TC5)BCDWR@
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ML;2.N=?O_9/Y,3-N'ME36-\M7@K 3HM97!6 R9]7M2@K!D%/8QRHV9[F_/3
M$=:?FEC2?I)"='EZM/H>^<HYZB 0*U*-W7>^@L/8_N9][US!7^_AFU?_;-\\
MMK]VO+N[V^ED8C8JE\BMBLOF[-A%IZ#^NB1;N)AIOO;:O5@B.N\[,9 KC9M,
M:L-_SZ/ :YXVO-9AJZ7P-ON+!;Q-[>0[O*@FD5<.YRRIFQ?H"&:G!C@Z5L0
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M6N5;'AKVOV45P:L"BIL.6A+2P8QP2AGMXT-T\%  S%(C)-#N=&Q!8S)>12Y
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M$_M$.DFM[F'*.F$(9NRQ;)9<"(,&=0B,_"@8*$+W'"D"F&1+FZS_%&.FVX8
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MG\OA-.5AE[]65#@L"/[I#)X1>1;=.1@0)4BT)+2A(<,;3,9A^'!N9@6H UR
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MZ/M&318[G$LFB-1&_FNLNYV5<1B=8VYD1OP&M4[8,_^>"T]I83:[7$,X_)-
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MU\SQQBJ$>^&^18%,OR':-TP@$-V1D& @3KH;D!.*)'!PJ8960V $.1)[3>K
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MC7 )(Q"\7]>-H##Z=8)_Y:MP'"%+*LVIVH*EC&XF@)(^XL2%ZR"/^GZ84-@
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M:NJ;WB?OUB*WIGG]2@5HG(>/'VZG%TY'X'#MU?=VK8A6+^BSL@A+-[$NB#"
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M#4L\")Y"D8,0V$3?7BYR:3A"&%U9:-F@)*;]>/1H0XCJ@QY7^NU!P5)/"0)
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M>H/NL1V 6GI0Y7@)(3ZI1+>E>*W*!:H]$.5YE#)+I%[$\E8L7T1,/B9]+(U
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M_IL1VAFI-,('1/BH@GF[,US=P121&?%(0.9!.WEWH$IH)5NP=IF1S*:*ZX_
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MJ:R@FI8<ZMPJJ9'UQ.R1Q/#]F#825N'2Q2B/ASP^;*QRF"[F98'_??R\?DR
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M-00<,(;@RG_!W2X]QZK-FB2/OO='(^E-_G&0^B%IYR94P<G/B]A\X-*$'TL
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M!2QAXJ4;QZ(UV?+&'-G\)MH&;:-^KC4*;1 ^BUR!Q;KM8 H?L.% B8&R<S*
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M-C:'B:ZK*<$\JN?/M-Q@GUPPZK-*_:+!!D_H2X*M'UX3@XVNPSI8VHEM4'E
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M?,Z9G"+G+XQ'BO4@,3(E+\+(5OK/(1\^1A$!X;UZS^!<UX*=!8V&-<L3T ?
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M/)R7Y!ZQWXC"2F@&>R1. :*,UV?-BVU)/EY@JO1N*<?6[)F*8)<G2@Q=LT
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M\CR-SX-+D$MX0U@ F$^X?5;$488_R*.Z*<U__NWIRY^V>$7Q]4"WI:"NJJ
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M4R8 E__,%.31()H:_0F06=[3B'CAR%>U]3-QN&XF4)&*FJD7<U:?$RQ<PR*
MJC4I)C_#M.+6S\F3X3FAPCV"T$S ,)_!N9E2<!:S8J!0+BG3&9PU$>+PC EI
M^O!%)K5)<,I:01/_"Y"QE+!#<EP5)<P)JLJX %_5^-.^]1/\='""3TV6T9Q%
M(%VUP]S@_")LK]I@>@)[+7R(VG].?GQ>!%D!$EUB#&':9+R(...EF6=1;)*M
MG]=G@_/Z6_29MW)61'S>1Y@'0A=#9GA#L5L.D*_":E_WNSL/NN\M!=U_BTK0
M<@=4M+C_=),1?U.\<[\ [!SL/*8"'E JX![HE.>#.N48Q1M+> K6V&6)!@/I
M6M0O[0 J7H'U(H.>9:06=N)^('8')^M6.CMPKSY?QB+.KIGB6/7,<(4_I+D0
M/]$] D4KZ$GW0E5=Q)\)R4P07OB$D\]/_P,5\F;!G?'6GULOA@VN(L<,-DF#
M.]_=O _"0UM@GVV>FY?#81L]TR.&5UI$58\@<OX"5"UL$3!8%UA]D)H+VB)H
M<27@0E>&MZ$4\W5G%.Z"$UI=/SF&0;!;G;NU,=^-HES!RI"O#;,\1GR_3L2W
M;T+O+. ;# -"MB#D^WKC3/  #$BG&&_7F=(/0A2@9UK?NA-NDZ(#!/*LM*Z%
MX4MI$@[ TGH__^6W]WXTZA2&#A,$5IM)9# 6?T8B;\LVZI[P]D#PKR[.#$DY
M&0ZT:UI'>"NVS1GMM7:"C5NVH]Q?*VH=?K6P];>*1&^2?+-*RI]NIQ](_C95
MKM;HV^@AA"*4C .>E62:8:&.4G? \$_Q1_X>X+>WE]KMP".>&-%XL @$8U,-
M%=K"+CE@K-'KU5UUD8K,Z<&:31$Q,*:W#*B^\G0*^4'@(2^.$M!/23/#)VZ
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MW"QQ3<^3HJFQ.71/?J_LZ^+F>DQWJ^US-#$BST1;'X>P"'-K=&'M-2E7-'K
M9*BD>=C2Z,A6A%%P7JNJBI@IA&IU/<@WR7FXU-$*GIMK<(41*3QGKM8)0SUU
MV9C$A_;8UZ$ $B5FA:P/W$9DDT,W_()[,BZ8PX-3J>[1/%,$C5 @#D:,\C.D
MPDAA=X'?*$;>8"ROTP''&X:T')5!4+'%UVV;U2YG"93U"248'H'8_X2:@5]$
M\";H5^(DT!RH8X=B@3$6+ (#VX]\HRF5T4CYEM*<V#\LL*>IU@VO&A1AZ?*R
MU'@,/H$]A4WIJ2,.1C)P<&2^TKA0$KMQ/_NC2J.+,846YEPK.>F--=*R;AQK
MY(DFY1/Q:Z]KHR5JZ7K-FKPF@/BRZ&1+3^3Y4LF=(#'Y61*"X@[$U=*T,S.%
M[<5:*[\OO(\C]4:?1"*[*+\TZR@F$R.2D@26CMB& M:-$25HO<!H_+0+X)%?
MR3M:.$:D[B/A!)WC(O[-ZHW;*GZJ!.O:'KZQFU@;XO5U3Z7Z77I!EE6-*;C9
MZY%9/KN^F;AN<[.487:[;M13JY](H29I-<_DD!L\47-.5/#2%.6L)T$1>90A
MFZ_/%5,7:%*4A.IQQQE(3Y26?A("7@FV$)X?QH<+#;V=UD+:PW?.EI4$M:G0
MU0L=\UO&4</-N6%X!DX[#%A2J(\CM'0.]-L;+H@S8$9$JL:Y[[2!B<"X'9Z[
MQ*Q'1V]14U])F'5W('DA50V3^A-V1L&).8?SJ"$]W83VG"@[-2OXI/<#?ZH;
MQ,)@DL+N+&WS]ADF[N,)]O:.:P6CFPC5(<6#&!3G1Z0"0PD+G'N)5Q-@#I']
M"@[N[TQ*-LV@ZE=A\>S,OKR>+)O&JOP0I;5IO+C\I/U*:5V9;+HBS >_+LY:
MT6!YH!<;EFW@:B\+^!G(E>#G^1*^'(Q/V]*[&IZ>[FGBQ]HM+G^#("5,V!_2
M9MP1==K<F&WFZG"$P5N3D$XZGLVS8H'R('VY7^F@Q453"U^SMWZ?KMYFVT^"
MD2,@\]'BU;A;-SDDIW9^>A)=+95/?6C1M?O,LIC6F;'I';8ED@$K0,4.O39W
M!["YTT22&?T_&ES+OM2@/V9<4US!R8)0R*LU.8XJ=QZ([R2)>*0Y&LG:OU$Z
MOWN9+3D*?$4OW3^-#^"$.>)MW;"Q1BGT"G,I6OWC=7M;+*G7VC8E1M-,^_4.
M'52KWHI:C+:R".40Z,+;DB%-J]Q7S%J7QO/'I ;8P-B^7AS['L9!WQ47TIJ2
MF++WGCVL6.AC->6#"H8N%]+=.FIYF-\7;*7A/@GG19-Y:G<:I5D?9('._$KU
MY-QK=KD#)RELT>=^PG2?\Z?LJ*+.9]\%[HU_V/1LBC3>H\.]<9" .'&  MM\
M4AQ4:JG$3!:O/Q@1+\)LAF%,O#4?V,LWI\_D"7!SM)?3PC&ZPDE$:*KT#$\,
M.$U #5?VO8V0^<C]K5LLCTCE;_DZ!BL#WK.%DK?W258/:!RNL9_2JH*11FX:
M(B^$F$H8I:KEB,F+W*$F=@,7!9<S%PW?-+<F8Z28C&4;6$S@F2FQT04>/UWZ
MB9"<UT;8=^ ![:>'-J(G86B]>&+J2TR;XP$X*V#^Y/1WQV,'W*%"U7>N(EC/
M^KW-1-!1/BP(HXG\PN(N)U%=E L=#X;_"P'5=1$<_:'Z:R-QGK:B]7;8Z("+
MHVXXI4T/A%%=F&27[+/5HXYRTVI1VZ*H9_DA+Y3#/1H=0 $D- EN)%HJK!JJ
M7$!U;G)&1^T&)]-!(2/F):QAI P_O#G8ZSS&)<N(XDT-&[?F"Y@US#BWP<L1
M* =OC;J$YM2Z(-$$[(1UFZ@RYG/P!UCW1/1K$$43FQ[@9,LPYLT3!N?%)19Q
MAZW'IKFO U^.DO$(&]B&P?Y3T+:C=+PSNN /<.S\X9<QEL\4EYC:T(VG;NH&
MS>0EFCF%_4L0--G*<.%4;$G60*1PBH;5!)9$$6((IN2B4#L47G('E@+L_9:O
MJ%"JGJ_KHHZH9#FW,L^'$3Q>[XMS;V_U-<G);OTH'3Q()\,':4^=L@OD\-&Y
MRJ>.;B 1Z-KR0>UD0O;>G:U_0+V9*^'61J8GCG9KHA&CDZV8I!PXPCU$07IX
MV&A?C8.N/>#%4J+D@CM>R6"MBH,7KU'O$=Z=SE%X/XK&J-LHK(!!,4='K,E%
M:T[0MT/^-?'%%36:4A:5"@AI"(SQ<]D"B4VE8VLK=)&B(!7(\C9K9C %\Q1G
MM<!HU9\-^_ >_Y47^NC!$N(,O87%SFF"/_*@X)Q!6*,EG1]A4^UTALAB?..I
MO3[-Z7S)X]:UU([;! Q$CA?J0$NE(+862&O2[-%9A']YWCIH6$7L@AJW^MN^
M6Z1_$M*8>G(1%$Q^)_U35"='X*0W%?4](_;L=.8^D$[PI8N4QO!- :=\;C4A
M(JIK4M<8)Z4JO593+WDJA:M-G$6E'9XM_.\,9?C6KN@VA!43SH?>N*)%#"+\
M,\6E=?N5U]JQ%-"1X:W-Q=C'M(FFA_L1/PG?AX\E#ZV;SMCXH0)-/$)AX^(3
M!/6+&SW"+873@--\5G+:&<T/.(BMF=@QT%I&64]4(N@!_=\GT-=#^.X>!FRX
MK]F#C-8\>0S6/.Q@S:WGNT;QL"7YJ87/QM""K:?R4R\"T,I-BO]VEL> O;!I
M@0F?.;D:#\-^L(.L;8:10RA<Z^8;WGUS!SY4BS@2Q23',?ZN 9LO8S(>!CCA
M)31D=$O3$HM:DF)^,]-YZ(JK>T^<EUDW-4MX11X%0Q+UN[DNB67VD!>\@9 $
M(UM>-&[C#JDNU,=V@2\*<MN;@CL,-5'G^%\M6I'\;5W()42)B/L^B] )'@D[
M9(A: ?R 9%.I3-\'&[V4NBP8MO>C/C249!(';B,+))1>/FFM5RN*J(HU*TBR
MN+Q4"K:\L2S?"V&^<VOI\;O'[QZ_>Y!>ATT3'^P_P)*9)X]IXD?/XRM['LD*
MS\,O]E#@#;76\.BI,)Q)@;"NZ8;<;R10:XC[[QM7&CA-:R>$,TO@<L3GL,1&
M*A6\F&MJB1I2#O1A0A3GYTAJ2=2!Z12O@WUVD9:U%DVT:(Q]/-3WO4P(PUF6
M^S?)&\^R7V64]:<^0H5/)3":"S9K;5T YNFP8D$BM<PLFOL(M<5L4F2,\L44
M*?$!3+UDI0#Z*X,9?EI:A'V9>AF(O"Y%TQF+(S7U6384H$95 YH(J:+,A/)<
MK5&(I$-,:4.SYPR ).>%O8R,PLE:1J4.EO^(K1*:]5)SM9P9+UO4@'Z&28S;
MJ52'%G8@8P?9P$1W;5Q-4? Y+Z1M*LD>Y?WSX/3X=8#H!*JF(E8B3C5$F.4#
MJ3J1- J[?"?YA:EJ;(?%V0'0KOP"C&FE9,U[;*G%0'$KD);)!&^^CSR"6I#/
M7IIXIO/B4N ;.NB1].? ]#;XD^W1_!?X;Z4VZK#I#'(RAZ]7J*:)> G0:<U7
M73\OTZ*T5?IV+5KH%)H)2AEZ2Z)$V5][2=X5>=J[*C=9E*?77I.EX;26I6]5
M^G^Q<F$&?G*CM8F_P=I\@".OR#=9B(/E7= J_:.0!=;V:8H><61P:UCHV*N[
MP%A.W5+^?*Z/.- J$95993)DY- JD]E$9F?LD0SUM@'N#M5''6DJ3^)$,SPM
MNIE!!IM<")BD*SLT&RMW,,_7*M'@*VXD"<A[!+-MDZZ>/. J7Z1)@V4ZE^?4
MZX!Q\#.O).$2IX\;K7,9K22>:>T+2G]/@S=$NUJ4[8*'4;OW-E45@">0V(LO
M*2))1/\V1JEWO41KEWB1C33$U)#6 64\#UV5D]Z.Q H&2/AVK%O <Q9?[!*%
MW%VW]CV+LCLTQ)D7=K(O"8!D+M*B001%5=B1C@-BQB0N&43)I7F#BV+GA[X8
MRVIWT$($4- ))CC6'PP>DQ==GFV7E3;#JVS?$&]>9 @ ,)64?)<,*W1_PM;@
M(N Y;W;N?75A%A0%1F _%M%+^;9D\#,0'\'1(Y],'1&G$V:Z\<.ICS/HW)QD
M@XI&(\4WVN),'UI)=E,#=A,7:L+])3O>RJO3V_*/^68$[Y)GL8H;/@K#]0J9
M5BMH[VZT3=I5.-044,K.6BD,0V3<UJHE& V'K E%X2%P-MGOVYO8OX>AJU,S
MKZ7$X3F23KU\_J!B5T\?0U</*72%[N"M"M"R;1'V5")0R*1K'&%J65+!EQ%J
MN9 U?)$9,=C0*1>FPZ'TV/)1F"#*D(TXDWB9LN4K-\F1#=P1*0[AL*)QEWC(
M:_6HO)"-LF%.$,?/ZEHRKE'63D9Z98V3IA;*WUDJU:B6I@(-)&8^=#2D9R6"
MM84;LUTWX./;QJW:<]]VNG\32SAVP=O+!-M2[<H>B72 ]Y]_^I[DA[C28D[(
M4KPJHC-[VLY/8Z>DK'$08..SA9)!*.4IK=QQ'\!\%(UWT+@6V#L:80=#S^!,
ML =1M3!<-EKH?>>U+6^).G-R?0CWK>L*H3E1AIVH13AZA>@0F7T.E+G48N[#
MLJ()_3BE;E*$YE"]1.*1UHH;BLS3%$DN#<-JIZ$& P_W;"$4";$47'#ID!-#
MCY4I,3,B&7*=TNDKMCZ)[ZF4K:[]?S&H%5(8!85'FV2A6@5Q($7AM"F1A =9
MD:.-_/4-V9L)V)W')B^N$M!6_/D"ET%1R-0/Q(60%KYO@E N^'G)5[1"%4(=
MPW%KY#5%V>!"[[G4*)5>9+RR,N3?)61\5U[D.QR7"NG?Y'>5=8J:*3&3VH^#
M6-B6AT3VOA:>3IM DK.@GR] E&VE>'[;\= /(%F7A!#*%>[%V.T(]^@P<,=<
MA+2ZEJ9(CPV:("I_ZOX2]WYO]5"KC,IBK+$<:.#]J;J?3N@FEYVO/V-B-XY*
M>$&M]>[AU]M2]V[_#&^?MYT>U#WF7=B%C2&K+B<?-<0/)^SB"HG(_;T7=S\G
MT>"<4 C'ZU,(?Y'H\N?*5\>?=\O@F. 0#17LX\XL-DH*I/X^[Q 0V8\-[/S]
M@\G.@6Z>GX4*Z*/%LGWTL&RN2.74;0402>Y2=A23?;'_\O!)&/B(/K8VQ8;"
M7+*K]V=G^-"+:?FWXUC6AG)^+Q9U,KBH1ZH(K/V<8.J7PYSTHMTX-R\PU>4D
MR[\J^$<3^R-D.[O,55K\H/95=D8?1?C]R=%S[(V$^(,-'TJECO<I&(*N:A@O
ML9NF"KH31K7-?0V^^OO"W:<XUV-\;&OB8X_8K@<5( ,UV=M,X1X!;;Z"JL0\
M[.A(*C>TOCZ*N?_Q2&U<NAE_G5;:$9JB'7[N!!V6W.90R D%UPC1]VAYP#J/
MVTT_L135JY@N2[0)E*V"[!!-[5)DQ$;W;$=J<J30OZ$P"9.E4;\%MB[T@TNZ
M=>U[5&&KK9'+@+WJS 3%H*XY:+ZK.DL>\0!3<;5M!:D.\.R%GI0X)]N+I?,M
M](V!!::.R.'9;)CV-7U7:D&QKJA,T627WEI4M($<KQ<%1[K@U;XL)+E'^7'D
M1,RM":I.4=XJL8XT/;KTZXI*,Z1,E5+EWL2':F%&,3:9(<<1HRQA-_S67Z&!
M#")-=N:5YN+/6F8M4?8=C+63&C4"I\!D::C[$]X<!G:*-"!D4Q^^&;K52+8A
M02M+_B5M(G3LBE+N:,N!KQTVN3\J:IV.0CQ;5VIQ3UBSK&V7A92KMXP+(DDZ
MK1X+FZ?+%# XYC1TL*P<1U?5CF-2CU?8\O (%_&A,O89D<CKKRO%,"26-H=^
MCUE<(C8@QG1N3(OQ^KF"1)>H[:-@4N3(1DW;A/$&2K'8 C&-I6D>;W3:+*C=
M*VF'>UYDK& %S#3J;2J#Y6!F-L]\*@K.VQ1X);A$>$RA]J1 -L4BL9ZO4!J'
M#OS2PW=</VBHTG^KLMY#"\)D\4R 57F1"ZJNZRAQOW$A=;H&\9 TV'F): [R
M[;K(II ]ODO\F%"N(@U"_\_R8*6Y]YEM8%N+O5#::IF(3]>\(1M].2K'VI "
MG^SO^]BK-DAG]7U0O=*](J1\1&TP<-/E+7Q)[&8M%QD;%;94BZ5BO8%HW8<X
M0WSU. ,LH<#'^E&I B1#"V&$^4.FHIZ.VVHR'4LD4S RL)E9&0FR6O)9%",Z
M?FT3(1QI.DQV]E$?[)-*D.9G%N^E;;GVV0'D4YTN1--HH<A!.OVUF[LNO0H6
M(@SYX'5Q*SR-=WZV&MX=M>Z2\9(.]>YN7V)H\P@KBI5A+R;G>G1$5")-7-V<
M"G(1?=[RR&KOE^V"UI^!LT+>,;R59UO\O&;FMERVDQ6!49+?00BOBC#JJ\H/
MOB-$3VVW? "5O>6S9@9G3:78A8M)G^/T.'QFB"GD64A@"1'MT#;7Y3PD4N.$
MME\*?49M%@+,Q"+_D8/5DF[PN>^DX4-G XY S)5UT'.YQO9@X!L-K\S61[#N
M)!BUHEMY=T);4OW\8'[E:-O*N]S2UL 4;:N3//WOL^%V\NLV_.&S[G['3V[U
MI?;W5E3V]3)2\48LS4S:[W(ZQA6_"+#%(2)\#D1F('&QD(F]_CRM+/NGERM=
M>CYWH[Y'K'6NCF'IS7TR2XHL\8V(H^[%&&DS\<'++'5"15YJ6]WJ'%QYY.?@
M*Y27UL--69)SQ>I*?^8.<&18 SY&C[<O>GP?U,?^!NWT>JB(?*A:L/]4ZE**
M\LYW,T>!/4J^S752E<Z:#-Q*P[46;3U ]+'XM"RZ#"V^9  ?V>DKXO.TGD=U
M59@+5XT3*3X-F^MPD+K5S !U-<6H5[>)<%6RK8X*?<TH+%,RZI5">+&UL'5U
MOX?0M;.08<\XI$8[G)_=>H;@;3LJDJ+$PC H(5%4=FIF2K4L%KM0(8=!^&HN
MX3LW-$+OT=/Q?M<WV^_#-CQ869^O2,-.'^2:*84W 3G*1K"Q *Y5<4XGNZZ%
MJ[UV5RLG$=7D<,_WA5*$MH-$_?GSL$5.K)*@ 7UEE]H-@E-DD]977?%L)BF0
M;4?;$<G%^ <,1(/3]HQ22B578G/SO8+(KE-;:X3$XG;GZG-UNU)RQVM"V-.G
MA!S[O'")(->/J*)HZX8(U.V6W,,U79S$TP1CDWCA_&Y8K28MF_1EZ>+VZNBS
MI*2DCV95FSE?1JT6"=M*($7!Z+J>K44I=*Y^8[-A!2@B/U\.(S!B\-^\'76E
M*VYY>62)="MYH!T3B16./W?FG\L4K:QW<,![ 59^+W9B7%2<HC)?YCAX&$$O
MRI$NME+K8(Z:R:421!9D)E(0,F!'7T_C+CC1UO N;G)O*@8G,O33Q!3CI3K4
M)O<Z*6CJ-EFF7N"D&(T,SGA>\\9FCY>7S9ZDOF6-!@$=BR$<1(8SQ,3P$7)A
MI)*@8&^LA=>#Z/M*R=KP)\PH;SM)EF",Q)9BNBW9DF+VB"#D1'?,?>Z(7WZ+
M[=8/3]8SS\BQIK9* =L'(<2)F9J<RG@2,\N1K /G"Y-1LJA'N)(N 0BW&E$Z
MKIR1^<>YZ-PQ5Y.]E47I#+%>T0S$!OZ1I9$E<\&+7Q?2>XF#S9]3' (8'XVP
M;?A(8RD!1=PS9L&9-J<T%9B1MNB#F^IV$BK2H L'?UY41 D>$NDEQH$IC@Z&
M$4PF5PA[E/()9TN$ L0R?K!]5W'&U#O>D&Z]_U1&K4.I-=415U\$9V1^BW6(
M;[ .ML&JD&#;EUZ[0 ,,.X_(/$XL".':P8,"Y3U;#H-N,NK'B,OV15SN09^1
M_:?7ZMGUJ4T3MIK2R*+@BIBC)ARZ$%Q+NXJ"+-]*^ 4PK8OT%QD8==P/J$[;
MIM\TS9:[_%@+5ILL3*+\<]G,ZWB!O1N*\BS*TW]+KLC'QI!Q%9=P\#&E1VE[
M'62IF7H&L;LAFOKV+/T]I[+6TUIQ.5XSV.C2X]QUO2^X3FI2%_J4T#;-(+Z$
MGI=OF>[=J5AJBP%7;^]DL-^/)OK VTN'<*,!"'P,8H7@-.:P8$<T;"A<_*4D
MK69II?@4[)&6?D$DX3.O(9RM@^38D27I\(<D#<:$.5K;PZG]W1XPFDE:.;T\
M-E<J@[$*6^\6:1_GJ9L<Q+52A?&J91<BN1B1.E=;,^5)ZMX0C);DCR8YPXTG
MMV%CCI>Q#D:1%H)BDV,%&#D$!CP%VWZ!;0NS5!)PX761D+UJ\BBNW96VX=<)
M LR*%.PX<7UC#,Q*62(L!#[VCP:L+;!9692U90G>IO,&,_ 7T?*R#<9=X]8V
M:XL2X7E]8NV&X"=<C&DT9XY^7@3=_V3*Z(Q0F'E@FYVAM(?!!'9;?"XQXA2#
MVU6#1U4K&N3F/X%ES_]L:*?XSOO(*0E:!_LG$Z.[ICDR9A8G;:E3P3"*!AW@
MWKVR:5N=Z4!;'<&ZWE)K'7W#U&91;\] #;[E(_M/[]8R>LV19),X(:2><XJ,
M8C$L-S@KKKOHM]A+R9X0;B*^[HF  *AST)Q4Q2[]0O</-SD?,A.1SE][/KBA
M7^5L:-<TI]/NK>IHP=ZWS!U"P?1+DR-&!C6"8KR&7E'3PTA+P!Z\:L6D*;UT
M$REK44#:5#W48!2/4]I[2S4!_L1CIG5PMF5N-72E\>'4'0OAO>SM[S-9@4U@
M<R2.R2RT;!O?W7R9IPH7$O5 AN6-A5)7Z/O*KM'W V*:5KHI1 WW'JQTQ%.0
MI.+FF_Z.4_V=?AEW8__:,G<>+7C/-L;/L'SU'K@\$!@',D? P_#94KN ?5&B
MN,,1L<R'YY4_]#8K9X(3#$QK(Y"D<+/95+IU,&/!K\HA5C%W3FO!VFMS<QFX
M(KY($^!,G4IH] C\U,Z6<OUL5C&Q4',<]&O:5 'FRWD$(D,,A0O%EYW+BK,Z
MDR!K321ZAKOPQ7A/@QE(#DQWYY31(1:!FK9)1QQQG$V<767B,-^<@M;R;':9
M/H:2B578DVW&UQF"]DR,5N-XM#\$BL7[86C.?XY;)T^3+DT#BP_VA0U><9L2
MGD+1MCJ+MKW)\@VL\"O[36FT'GU"-G% =K8B<5TM#ZPD3S?2DD2U5D[L'^SY
MW(.=$XDR%-IALZ]HFI(A(C,HG.O$0UH;KY!+,1#O/GCX%8..=Q&.>_Y8(OO0
M0FYW77TSV)2WU8RWTQ4TLCQA4W(%O2^G<N*DH#LTMB8M0]$!Z%HKUM)2R\-^
MT&NY> 1"=&2:;-K671YWJ[@ 7]/^]UE8JF;B,9)Q2^L+CHXD:M8MS>7V:L#'
M[QZ_>_SN\;LM3,]R)]X#ZL2[__1!Y6>?/Y*F/#B+\*ZKY";#F5;!)7L1HXH2
M+#94H8YIJ^&IQ72!<28,G'"-XP[=W\-:&:Y\YYZU+EW;:0'ETZ7TH:<'LKNW
M'0SG)02[6"H#?Z1D%U[UW3^Y;<;MA^?7I;>C<4\84"-?-\^GK4VFA5HTA1X"
MW!)^B(D][OPUF!S@6BT,S54PTQ755E,&:U+0"<#QPZ+D2'&DX5FTW[O)U5*8
M7:^/*;P/NS<>[P9!,+2!3P:+,=I,OY&'#^V4:3@>WQX/B)V?B25DIJWHUX'W
M %$5OHH\JU32@(U\_1*8[5Z09.6"_$X*:Z-R&5F&W@AUW^7HZOX:4>5PWV^H
M,9RW>>TQ9MF=E^[991EU'0Y]DE%BD,+RJ$ Z<?AQ81H5%AZD4=;[WNX%?-JH
M#WY!%7K:7Y@>H2=8@<_BTZ *72MI16-G:<7DOO-H89L*1@V\A@"O\0*,NU+1
MEL_CKAD"B1]WR1#PL6>FH$&FL>M=U^ZC8J,;JTH@EJ+A_M9<352Y%431*WFB
M/24D26)>A,H0 ;Y-_1!,@$^<W=-=+*+(*BZG$:)WYI4&&Y;ZEV/1W1=*,18!
M%]LG4M5/$\W\',PX9!!/H8CB"H$1Q6<E%T*P!$-OX8*DB373+%ACD(U$FQ3B
MPRPY$9HHN'^E8:'QVLXOO[!D2?LVK<\O.U0RPY4!= @S6#BO9>>YK>&E0RS%
MOD6JV5Q=2&G, ,<\:V8A_5;Z0L*AFLY3[[Y+>]F69O&6I#PXX46,3:QH(J.J
MRT9*07#+%!,LAZ'X9 :W)3NP=[IM8DF'CB44DS^4XHF0.?DT2[GX@$T.S*;0
M"])?7B[&[Q-!<YA62Y.%4N:2\:"*_ Y/_@24U(#(_PC+5#R%9@].EGPP@9->
M;=;_**]8K%M9G=C4D5^'ZCUERUGFKZ<]$*UTP05-/$TRKU,LPM5$LXMJNZV@
M!P9^WSU,JG9B</G9A(.YX-SYB-I-R9X.\4"#=4OGS"P&0LVY7SI5HWD4P\_!
M(M96K)HG73K.M/1NZ=G?5T&)I4PULQ* 0+\EKPW[J=GA7U+?P<&QXQ<R8*EB
MM/;WK*F$XD^:%$H/M]9;X>#<:[&W*,; THM4"[G/8X3\+QBA8V8F"M#M?>4
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MKE?K]OM/T>^ZD"(:3N!77-3/+:5LZQY[T.F6:=?.>OVOD9JR]6Y^ #6R:E?
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M[B:$?FZPB1!;R?7H=&9J_U/2Q%QKKMO; ;+(2'"_F345=3VR]'G$+'C!DN8
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MU%S05L'S INS5(:WG.9$OGH.X];#(R>N0W#8'Z';)(@>+ ?1!7='E2L:I<(
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MV)O:3#:SM-%#J$F11%8P$$_YG_-TSKS*(-%4*@_7V. G+I"]RIX=6J'.%D:
M!<3IU%H<H1X6:C+:O)F43N#I8&O)I":-Z6G84M$2&NRRPL5E5YY(X3,.D \
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M%X'(0_]@P*JV3%M:$18+N,O(#$O&,$$91F:S-*'\"ZT:[AQ3GGE_6D($)BO
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M'4M].Q.<@^?6/Q]$%D1'?Y.+OM"?48[KG'T7S^5>;Q5^O8UWC^)T5Z^'OXM
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M'AGDNAU,R$@,+RGQC!3&KA'MR0"3MAX8>**(C<1N,V44>5#;O!=>7VTOH-9
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MZF\P=C0.5\WX,G%=BVD0 ?1V%@_"X# ,GH3!4QS6<XJ%:'<Q^S@W[*?L6C#
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MKP+I>X;CMJ_^_QU<?=\OZ/3)Y-+]E9J'R>.X<QX;_9N<1FRVP*<E7B]08"^
M+M$(3MKZ >G550>- V3UPJ;HJ9N"I2K'<3Y0Y;B_-THVQ6E9@@5;)+3_HE\9
M#TO:?8G-;DE@]LEC8':+ [/_/WMOV]6VDJ4-_Q6M[KN[89;#'2"0I+.>6<N
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M"L)!%$^EF+WEW<S'_D-"C3FH$Z]*T((-DCM\(/S5OMXP&J0XF4N'Q3/]<!>
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M'"2P*^'N$SR=BFM/X(5<6R-A(Q#.1W[5%D5]O-,X2A(WJ^[\54)E< AB]IV
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MRLUZ$92.DM&>[XVC!ZJ72F;>B9\$ YOIQAMY9U@LF@SB8$H;^RQ.Y9X:0+$
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MN<HQ@$65':7@= <8^&1<8,%*+H4&HG]F Y>8;B5C:#*!%88K4(BF42BL.-.
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M'"0+N*P'V2QB,T4.YCKG%GEG"K'HINF]#3O49@:R?#FZ?J64J0646A K6Y$
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M^2Y<<=%Q%Z++24PP\058)2JW=J=/7SM- 29&+X+>;&G!C9^ R[!C?(X1$N*
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M7%28"X=:0/<\7&@;3:57BJ%19*$GX%,$":],9NUBN=PWG;VI3)C<)P$UFXU
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M"]31S$,%0!D:#,"%*D[N@BGLZ5OFKXL]-9F.(^[XH3&N>,EB>+*8@S,V%ZJ
MLW0ZDEEOB6IOVB8%\_.G<K,6C_/WB^MN[TM]-L9GZ6R1S27F=@:5R,6"(N;"
MZ)8)WWF4D#ZFA)MI->G4?>,/=(P&;IV?Q6HZL=&"S)&EN<A3TRY<W#*A2G@B
M%^\Z=729@]0^P'[,KXS?@U'>4K8 SF&<'YY >.G%FSHERVY]LA=*O<=(OF,Z
MW>#E]L/<G7>(\VR^:R+70F=F&,UXFNAQZ)8^\VX.@9V,U/8X676H:-G@M<X-
M_@W'H&9_P4BS9+FQK)(BUA1K@OE_,XHPF)UDW[O@F6Z_):.DI9Z=X9F! ,HP
MN@]&E\JMF8944@V^ML]&PB$0['K')&-'!Y;NSY6;'4H96<,P!*,*1DCD!'KZ
M)5__=N^([I&"Z38=,T*3\)<W"F=AX48_8%'@/?%]G9OM&N-C@)#-W+)B$L"_
MCPP7L9YNG;J&$06[/,/>SN%N=BQ/N3$L+1R?.#X"J>I^2HZ!KG5'"VTHKK'E
M_##"^MY0=''G\&BW;$V%6V)%^7B6!. MO9UWNV:EGS$M=3Z.P2TLL_!Z<(*=
M=OI4M'=Z<775Z5]>],XZO=-ZF7M4$6#II\BCDURL%,<LGG-H?(%Z0&K-;%Y8
M;^.R_)B%G0^',8H?G4/#E.#>,U,D/4;Q$B9UOI#@K;[A\B0,EK!R#1T&S[&!
MGN.KASIYBNG.2[@*H>IT5K:8-1-N@1]]46">^EARG\)!.6[":#\IQ+9M,LD>
M>+)D QR\Q4:W']^_*D+)HR:8^-J"B=L^_,KYU;&QS'GGVFE&4Y]#+P<CEE '
M6[VF6H.<(&W'&0-?%Q@5\41F#TT^"!=+QZFV-QSGJ1M]<TRJ'VJ02O$-1\U>
M +ZT;4$JIR;M=W[O7$FI:7U$J,NP.L:\+7+](=A\/!0X+5C4_L,H'?,R#]!6
M9S(XK)#&R_^5QD$R# 9<F$,1TE' _H,FD$%<%A;Y"+PM"W>.;D#Q^4YG@&PA
MG&5!8 ''YT\H%'MCJKL]><5%$!\5 B(J,BR]Q"$<)^ AOZ.A4-*/(81>8@!^
MPH*NW]0@6(0@IR"\4N\M4,[1U;OH?6]W81O41_Y[*(Y@.<0YXL.YXQ<,U<C'
M2F60WJF*"86'4*7(HC*744!Y(G>9A@)*/\4IX 0_&;%\(76\<.6R*$!G0*=6
M\F4<AL+A)@&/FV"RCXYDQ$T3EK]%O:7VW1:BT67[9/-!ZB\7L"M[R,QSWOY>
MG]UY79*O8;I+,BU:NG!5)W H(@R2/(V5,*?FX(4M\<P?S"'3GTD'C^X8WB$*
M&OQ)\]DK^JR" 0RGQ>7;HU<5O#AN@A?U#EYLUOWJ>=^[U[U.O\]-*"\^Y_K=
M8<:-*LF&9:5V[)MI9[LE7HLTCLIUJ!HS(<BMT/3H8A'B#E['O%MI(Q98$_*G
M633]^_Z'#5N %AY&B0ZW#V2[W[\X[:Y-"K69T924P<XIF?EH5]:ZC.>,ZMQ7
M&-'S!U0KJ2WR**OW[HV,_LHRBAGUZKUK(Y-/&1"83(\(8?-9\]D:LO1IR_[8
M^T5_;)61-+Y:=7RU39YEG?_YK7O2O?;*VAELJ**:VQN>=\ W^?RY>PZ^24<W
M /?ZU^"_M*_.^HO,3)M\Q_/NYX[7[?6_7;5[I^!977R];/>Z:]6M;[;2!+OD
M[*,7?+#]5RPQI*XZ[:\GY^O [C9>I65H2RFARNDLS-V>8V?TKNF,?DH-GC"$
ML4.?8%C^-Z;PM1<-]$4MS^ENCOV/*""/_Q\4YRY!2Q7\=C,.DCNW0R01I\7*
MY5R1%EJ+?6&(Y%5W>]&P4XL_=N&G.X<$#WZ7@])RYGGIA;-HYH\7X<V8MM"-
MUSJ8BS.D)X2N#A)+T2%$5;Z9:,TL0[5>)JFHJ]B(HL/PE68FAB@[I8.<-TK'
MW!743Q+F#='-JBQ"OW )YZ;O5G&W0/TB1BZ>$$?:C/2V0]U=C^$NNL%7EFW"
MRK?)-BDX)0,D=F4R8CWB\E:LALM5V2:9TN0'\0 )2&(2Q;QK7#G(-K/70 ?=
MH-.2F=E2BL*$LVE!GVG%5+I!]7.F\$:#8 KRZXQ02W\%5K589QI6OGWOC;>$
MDF_[[U^N4^%DM]+VA Z0CH8@:,XX(U6FN1_SN-TQ37QA&T8ND-C?+>B.:%OD
MN4T2-0U9]]3V-3S89<7 G1^),WY>WNB0-/+JC0[-,4!XH>+&A_:E6$WQN&&J
MAI%*:&CP^H,TMJ^,11,%'1WMC2H@_J7X+3W6#?=7W.?%7MI;,=]$<I9OLNAV
M-S0*^<G-%7]N7\5UB%"WHP(/0 4REH&/@#2NO-J;I,G,2!X<; '(+=E!8ST"
M B&I6.C,E-.HG-6*MG $'6C//#8B27U0!=Q8VZ'22B+(V:%D'A%2BK\9Z+X5
M>H.1^KA)P=P%S=A 1*KZ646  /M-X*D)/#TC\+0Y4=UN'*F)=?VD6-=!I6-=
MQF@Y!*/E2F@_\73N_/!U%>;VWWVY\4)8TZQ#GW&]K)%M+!S\RB@%CR6Y:R&"
MW-=4-Q3*PE9Y:'K<^$F02 5%[,P-&-?4C25;Y4JODFCV=Q-)"M#HEW9SQFU:
M&L,QS,I,[+K>$*=8/3NS;?@4K:/2(3>PZC*>F37RZ:ELWM.7B1 6)4-J._"N
MOL$J\13HT,3@+E C 3]A/"]"^U[%^%8ZK$'WPC_ P]G/C>R;.,.2T53 TWMD
MP[R##?-54TEO_VW7WB)9L9'5M[$T[)OU!O9!C%X:2Y,ESF8_=0ES-K5V3!*5
M9+Q87T<C!ID>WQC.FU#!3YBISBB.N;:*(BMK\_1L1V:.0&8^!Q@(@WN"NJ7E
M"#@VL_V77R4R9C7H$*E5,*1MQH/KG\8#I6NRJ'U]EAF<!$<I_K/VX=R"L^JO
MX3&LX6ED&PB3^EZ,^EXZA3VRT/!'WA;X[RR"]]W^8%=3&_TRM6$S&S0-M U-
MGYP3.CY@WY\9?:]O>!*3C1'>X?P0?O:O?S[\\(DF1KJDGD:3"9XU-CPYA(,L
MH#"4TT7UB3/O[;3/+Z\N+W<-=Q'S0E V $;NG,\@R3=C#+41VT- C"<S4PC9
M!"":SUY%H.2@J9BH0S"D(B>$>=7V_CH8S4W)> F*NR#&@1)W?=4^ZWQM7_V7
M"7A8%@KX^//%E4>A!RQ8..OVD5V ^ECK0,3EU<79M]/U6M.[=;@;9RO/%73>
MB-]+1OB*+5-VX,!^]TD.?/B)#U*O /+:PFL_'!R\_60@*&=!HC.299WV#O;A
MEI(R3(CG@),#X%HJ\7_E9D-[,YM+,"SRT4.H;%=5FYXM>L_RWPQN=W/"^E,Y
M-(O%8L<A@Q_/6YXL6\[ZD]6A.7VXHU@ LE0J@;K ! MU5MD-$KV^:Y6R;W7#
M?$=[SP=OECWA0%I /X3*T-,YA4TYQFOO(8J'NAD[J#Z#1ID03(6V'O;4@E>[
MIP/5TA?:G9-MEL?S1YGS^LTA)?=R,N$%#D=IHK"S$+69,E J"4U0<^XL6>1"
M\S5L"TQ8AG3LQUY?)KL-#Z_IA%%Q?&X/F<#:JDJ5A"^V"7QOS,1"-T*V/LZV
M9_2=EH6+,PRZ-!0_C1R_%94QHF>B"7-Q<.,PBJT6Z0<DLW67+M&.&DU&Y@/L
M1T]QHRMU2TO^E5G9A/72P33*UUFB3N9O,"MMCR<ZZC(*BGM-)X0#,V%:HN=X
M)IO,5N6J=_&]Y5UCG2M8-IV6K"?UU,ZXUI9HU&#@&-9B M1,"!2$9(/#MJ7&
M?L@%*KVX>5EN(^EK?N^/4\($9!ZG>4D'*I@RW,[@0P;$S&(;7^+3T%@9()<C
M".PM5MKF^8GP HIF^HD "I/E3:NRZW.\2+>Q=WBTR)Q"?]PL>4HID\D7L$.O
MO8O/VGY]ZE"/WNT5<,3\S)&6]0LNI?>R$&.[%\6Z*Z7IT<>V2,=M3*PZ<HN5
M]2>G:"8!P@!-1[T2Z&F!BB088<CHW_QG6>SKBLK40:(:K#8H-))UGBQJ??$%
M&UJY?^1_KI%V"\?>\L[1[*??[12TO.]$C,Q7G#"'EOSV+42&HP04 ?[.\+V=
M@UVO:XQ']W'.@]Q;GJFI(@F3W_N/F+L?7E[*IINWL".4%V?6#G>]"]21[H0Y
M<M@-P>W!R;G#9-O"$A4O''\)#L/IV.?@JD58(@,S';DZT;(H:5:^G(Z38O9:
M\MT%P_12OF:.SL*C&BU?VPIDP:8A%.S"U_#/]J1W#<!LMLB>WRV+Q2=SAX9L
M/Q8^!PP,AS,V>^@*0OSG-U;NE%]=7V#>%%&NY2H"(^&<$4/:XR6]@:L4KOQ%
MPZ,%.+(F/%JG\&CEVL6?E!,X+K#^9VN$V()AQ;6R.@J2Q:(9<<(6M5-K/35'
M=@WKN6A)5_0"S8Z@@'PHP#@.HJ$#'97D#CZ$GA_$P0WJ9X*%6QVO0PF."M=#
M-=TWN(M'&B>IS[P]!(R0D,,B""=Q4IM/YUZL@+R=ELK;6FM=?IP5>N8KG_&C
MS/IP60V7B?C"E818$S+:L[T#4/;$ 2T()A#D*(;[A&_L7>QS1,22C T I[Y@
MF:C]E,8\R;5< W2#NW,68*"4(4S8M8X[=2>Z)HRN=GKJS&;^X([)US9M>K+L
M#1'$1D[WWREYC5=9O7JR>7MXK6J.RNVHL](==9UQZ)P>3U@8,6>-(ETF4/(6
M9 6V2:BK8-QH"]JM-XB9XD)2:CH8(P1C/#?<8UP]]N1Y76RFN_%Y!;>U;&+;
M<&*!YXG ,FK682J5_.$]5J<0@&."C8;@+?"DN(<38BH5>3);$6HM#$_)7E_]
M""W66P7G5^')M>,$RP15ZERWZEW<#$LF]2(>V:G]DN@_XY)1E<]@K'P4%T&S
MS%UE91Z^@].#T-'IF !W%%T0=<MO;N>85#5,Q3#1KT#I1?$C48E3SD[W"6+2
M<(N?@@G,IAQUWS$W\P@7_?7/'_<_?5$1V#[3NSG\=OCIR7F0R@G\0:G 7V>*
MD8O6ZLYWS!>,P$@W.6U%&?F5I2H_P(=! K>%-;N5:0X&5#%M2JD)"^9(?\N<
MB=&-M'<L;/8FF&@=/<-RL6P>AYG=01UB>=GBXW&$_*$-'N2G05Z/ZBJ'BQI5
M^J2!W8?[WP8)\19QMIG=>,S[2H6"95S);&TY>Q0>E'\]G *8VW$J//7RW'R<
MPR]=!+T&;.2X7\O,CFZOV9?XXKYWYI%XU7V+')9N$<J3Z1"O[^019P^1$3(G
M^N.$;<EJ*[9DZ:.LL#-,,'"[=&2*<FT"!*[4"W!&45@IS^4;KWQ\&3&TA>>)
MW);;Z))&I\ZIDTD:4F6FZ7*7DT #RU0_2,)N]7FH>UT103?U1I[=Q5%Z2U3U
M1F5S--"W2;O<[5N6P$#%"<:W2R_EM_;U&<:YVF J)ZRO3WA!F9M9PNNYF27&
M^N%H85VP[NE=N*ZX+\E2,^^"OP6&G2+Q=A[NJ#4E_/$-CQ"GYS[PO9D:J^D=
M*+26AR''B#V<&3*C4XF[+.$NSR5UR7Y\"6PG@^P:8B!WZR&Y*GU6D?!@@YY\
M5>'!*AQX[TH/O)55GN7.R2$\""23M3U""F1$R<)Y:**/188G.:,Z'&G!.DZL
M4I[(=B%A_XV95!!KRSH>V%1QT=!S3WB-"I(HC.-)9+(L67W/=#[ZD"56[[4/
M$IB3S/R9,*BT_\)3P!S?Q>^&S\+XEOE0G!WZ=#UP7.6$]ZA4>+O.FF9[7.G&
MGPCJ6$_$6[K-K$.[52"P# MA.R  ;8C9:#"W!['2)IWO34&J0:#2F9/M!$&<
M</$;VBO8N'B@? F?IV7Q;M>L*(0#".BVQ-S)W_/2P5 M^",/9 %K7\SL2W="
M*?N+#8I!XM#KS]9E.2Q&(7??4@['EM)V"G79"JC'"P\%_G=' 7AE;N8-.*PZ
M X--MW(BOT9Q_-60BG"](3N.6(PKUA75[NB;@[7+-&G8#"F&8XL:X"D>!)J[
M>)TIM=796O2%R74J[1L;A!*KS>>X5]UUU44)E;?&^^]O;>R*YPD,OLZ1UW*
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MH(I$F@G8HI$N^J:L*M*Q%@7B<Q*UQM&8V:=N;ES"199S8H86@N@6#:O$!%B
M+9&X=P(RRZDA@80<<WC=\7+N*A[J4O9UAF,S"1S?-+$T#+DJ.N;!,H]OE08W
MFG KO@ 6,@Q468YRPBP1H+TP3T?52#S[4TO55VI&:"7)T^DH#DJ]YOI[#-6(
MT0#$L&NH1$6B!F,_F.0%R;NA\,J,ZB?O8%R@I-E^(K?B%6B9X_((;A=YJ+I$
M1'76^=KK?NZ>KMT[NR8:QZ5UX%(=[IZ#$C/$1/M034)40M17(AH/#1HTGE#D
MBPQIMH*QA19;P"128'D/_0F<J? #/(S>0K=C&D0)*R_8TO'<^R/ ATG3=J'S
M&<3!E#>,T5=^'.AZ,Q#C=#Q;,T<AZ,:F"O@7"<R]:P)SKRDP=U# H++A0^/]
MDD.#^0VO.U=?ZYRR*L=_N,ZL@TO,Y?W8%(D5TEE3OZ'1"#,9W%D0;)V TT!8
MI8+H_;GRXZP+ZZ<P-[ )!U0 2M4Y0ZDJT]%)Q,J[W^?;)@:KI@(*?1J(U,JG
M(8.?E'#0T4W0:)R[("?="%,08'A"":6<B88FP0_XSL[QVUTX >=8L!5$W*7@
MQS2POBH:7WI">0BU3G:6HQNN"VN6+(;."<NAF^U353E[O!2BRU*.K&[;&!0M
M:/20C 9CGD=33(VGH?38&FC#P_HO(KB2-:4+3-O+ &5BYU"O;S1BDBW*">J(
M!N,MM+A@V0+7Q)MA4T8?RTL(QYI]!#U5G@./T!M'IV>#,$5\)6AWO"F\*37-
M())(A/<*I1+=,)!*$8WV\T,<G ,=X!H7^M9P^>-WT=^8>P\^<8<)E-A@;4>Y
M&C!*]TM28@T;#;RYL80\X<JA6HK<*H^T%A8,[1?@%*)X!32"OL$!K!EI!<KW
MYE.U]JHSRZ_J=.XU4->,\L :LYG.T>M;O/=.2;T1"\.N58Z:WDWIZF30Q(AO
M8]"5>]OGL>A53;>4PVURND4#?]<$+^&C$AN[T\%W!YMLMZT.7U*N2R,.I>\&
M1TOYS$"X/6,R!%C,X0O48:^ZD'SM6)%&1;L)'7<OH9XT32)ZT1[LXYTEC7!W
M,_@AKL^$Q:CU;)=7,;?#!8P.8^@U_G61L&517;Z*.2HO8VT[C*LCC'.4(5 +
MQ=0EM-%B^:'@)$$:30+HT>&0MP&Q+BB&8Y=[L3Z3\V;CD_N->LLO.UX<TTUC
M#QZ"1*U1;Y+#0RZJ8"PHT<;/TCQKC2:VZQX-XA,@9:!ED)=63FME\Z18AT1-
M5]=J0X$J9!?-A5@N)R9XMG&0_I#37E*9S7Y.2V+*@R#1+!-.$-K@^QS#QS&F
M\+FVVQ7^LJS9E?4?]30XE+1-&.\7">,=-6&\UQ;&J]CAU;('R+KX'.=\DG2M
MN!_KE0$:+5JA>L 7*@?TRPH""[*75%B@<0]^"N=.)M@&WV:7BEIH1G_HIJ'<
M0!2^<H\2,B^H5W!?MOZYRP^E[O#5Q3_;Y]?K=>ZM2ZZ2*V3\N2UH\=&<9UO&
M!>2@T U0)K(5*Y8V#@4R'?OKD->OXO-LO-\ T70=FR%LZL'9>3@\V-NG#= V
M%4LCUFBC@+9TE":4TX7I1_=GY_\<M>"==C&JJ)>LY4W':=(LQ4LMQ=[;(\)C
MWQ(I @%G4DHR<,*$DO;H$$PM*7F"R7W-,;98<M^LSXNNS^/+8QM&K;A&]='X
MW7P\M" 5AI;2+>&.8K1J;)65F_EK,8!LPLQ.P]3A98$YH\HWL#*NHKD_)NB)
M0Z$G1P ?*AA9]\?8U8@8'> 0&DLQW!1!J#9V\XSZXZJ?JQIT2*A5;MD^B^'Q
MV)W<'KCC,4?0HH<UJ5V(7)KM.,LTR%1KLA0KSVUU[;*/I7;9/RZZO6OO]T[O
M^MM5C4I >A'F V\U]8[#@IC/^$MR"OP5IF$>X-YEEN=_10%<AIL]C?&D]^-9
M"#[173"%_7O+O8AB3X')'LWICAJ.BI>8R(]?$.A&P5M9 J/8WHOZ,8($3C*T
MJ*^CIF+_[1;8ILOD?O/='7^_N,:2D?KLL<_2LRV;<LYM,J8C%I PUQBWC&M,
M[,#[QY\R+=Z<NFJNJ9HQ_-(P?%D[PN'/6F3K<#9(GDYKX>*6\?GAB?"6MG:+
M*P<+*6SMQ_S*^#T8Y2V%K85<EB<07GKQIBWSHQM(\+TPI59U<"E_1V&*7T.L
M[8>Y.^\$%(/?-0$;Q+PF3H\#GB;N=  F\3/O)A.)MY.14O2( C1E0]UZ6+@N
MGU4D?'W<A*^;\/4S!"BOVM !0MVP9_3%OU.5:&@41F@Y^.KY8/I0A)>B,*!N
MWXPB#/XF6355H&(<;A=KWDG5> (W3(@0FRM9R#53.16MD9C$7J&]N)%0<@2[
MWC$=*4<'^8ZS? [L4*K24L6$X'K!"(GK0VM;+B/TWNX=T3U2</"F8Z>_[XW"
M65BXT0_0P?">^+[.S78)=D8 .L1OYK0X!LW]^\CT(];3K5$3S/Y',TQ]YS)C
M><J-X2A8;%3D=@TUI@(1>=*0"7[ D+TW%'?;.3S:+5M3(6A943Z>)0%X2VJ.
MIU?Z&=-2?].\O-%H#\S6TTZ?2IU/+ZZN.OW+B]Y9IW=:+V\Q0&)_"] D5C\!
M DB]6R$$$T^< =&BNWDZO9?+DDL6,SX<QBB#9'L.T^F8^-KUKA^CC&%?VU!?
M2/A5WS1K)+R>$ \.-:*3*=3E%OCJH<X=8F;O$JZB/A_X(DRG&\(M\*,O"KQ;
M,#5/0?<D:OP*I+:<^/+TXNOE>>>ZX[6_7'4Z=2O.STBAA#@201L+CIH\%JV%
MC36NFR(7<5AFI9TEF+A5%S#P1(.)TFO(*2QGE6\$7=INW'!B69Z<!^QM3A@V
M3HKYI_]$VBP['VX>F;:F<XI9<\8]S631G#X57)E?<,TLFOE$VA4B8#XFFK.\
MK40D)[G[42>>8,!-RS@?;=^00Z>GPM*#!,/(B^S'\SV/H E<8C",IAI#G+U[
M:P%HJ#'.I+R6,&V6 QT+J#9IT!9PQ;HU"="R\D,5I4E&6%^!5EM&V?-[YTIJ
M@.NCS[J,'F38WB(?(\+;QT,!!8-QYC^,4N+L\T';P29@<CZLHL?+_Y7&03(,
M!ER_01(Z"M@4U<0T"&3!6A"?!89MS(F4LD<WX/3Y3M?P;"=Y#@1I@@Q^/JI$
MZOXG# ">O.(B#G$DC!MF%(N7) RRT2T#1:A-/R3]& (9)@:C*!V$])L:Y( 0
M[Q0$YE[!/BCGX.E=]+ZWN[ 7ZK,)>BB3V$0]QT8Y=TS,H1KY6#P.(CQ5,:&@
M4!-&%EVZ+M>-IH#)M,U6^LE.Q6#2(GQ5Z!-I:NQ6-2UN60.HM5M"QF:X0&X2
M\.J8KN&QT8'H8RYS^5N\ G$^^J6S'U\N8+OV, %RWOY>GVU[79)29/9",J5:
MNOI1YQ@ITP#B/(V55,_E0%\M\?X>S!'4G_ELPW7'\ Y14'$,>44"V.^; '9]
M ]CPA4W;H3WO>_>ZU^GWO>^_=:XZ%Y];6?L/@]A4*33D$V\QY\A&JFZ[VQ+S
MC=JXF;T\E*T\YHK[6V&/T>775#F[5B&0_&D63?^^_V'#I];)^;>.=WIUT><
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M1-&0O0JI;R?HL8H5PYBP/IC#R"1B<.N0=EY(F.>2E6;7EUZ1>SC,^17Q"\,
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MTOW:%_)^P0Y9=S06*^RS49U#U@3ONB(=82/.T1++J $N+(F$]/J([0;KZD>
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MKS!NPO C99J$-^!FKQC\9B:"6#:$( 5@*B>X029-#JYS$'8F[7-^)4%M!SF
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MZ=(,<^VE_R[WN?%M/41.=PP$FC-7PCV ^)HOJ*%^:__5=M>:2COQBO+Q( G
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M!H^]_<@4EJ/.,W<B&>A>GZ-QYSEJ;!F833'TO0;(')'VB,#J89[M6DS!K7-
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M)8<0+ 1QJQ0[:8DQ8UIE#<ZECLQF;;XK5;#"F*>>L;5UA%[P"XHY7ZA$>;+
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M ??@2"?)P(?I *LIGL?>?1NGG'5K^$2AX!RE11BJ4&AIF27.&*N<V&%[D^S
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MQI->6=6/_N_'HW='%\'P[D?:(QE,)\<79R>?/HW@['G__N@3G#VCP#1TG%_
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M9Q'-WTT6;.UM4[8"'2:PO"TPO0%/12\!5TXJK6 BCZ;^W:D1NX3E)RHB"UG
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M-C=V!C2Q$2D8=)EPDP'=Q5W(%%43K&R<&%8KRV5+(*$1YZ&5QG)81% C)YU
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M!K7F@UEVM($TC+^D48<FOI<'CN3E4Q:_D\OXQHH*$ALHAP$$(KS:[C++3LX
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MG7NQ+*HPV?1CE;$G\X*.9)(=##\!'QUANPE:P?#G-%\PU!T 3 R@7:3+ (8
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M:5(G3=9\\CL_@)*@AUT/=!IA6GM8-G<W8$'U+)?KP0_18CJJ*J".G(@JI/U
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M;UW#<.K5:Q^NI.863N1*E.D#AIR_A]/!8SG3F2^\A[WRWMHMKR)V<K%,WI!
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M:9!#@XJ.25,-N]'@.W]E+YH#[G# '0ZXPTUQA^>/H7G"PXX6SJS7*(C\0\J
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MY[Z%"Q1^73 [58HT9'#W7'OFV\:>?8-0$1Z9-Z;8+KJZH<-G/A'_3WO/R/#
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MV:/X;-[AS$.).?[WHLJO['_6[7;S7_\?4$L#!!0    ( (J%3U899**V\!P
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MY3RH#F&(47LP%M13XI+9:Q7$V:6,]S9!W6A<O3FK?0X\K8) /P?[;Z':3XZ
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M!P$'FU?DMF>C^%PUT!D)28^JQJ>'.[QUQCD<5?"ULH/"D-T&6#R,Z&156&/
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MQ839C!>U!V-!/;VA#4QH0NX^2Y7E*LEL?4Z%1R.=")2/44-]4P_5^R/LTR#
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M<1DHH$@R0%@&2MJ8Q$ELC 1))$G/0MI0:9MA/Z).HU4.E=3H$ 2^MFP?D2$
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M+<=N?K8^@8TW_XI,57_LP@.,4.8V=]ETQ6CCW;?B,[_1Z.]6GOX/4$L#!!0
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M66 &K_3A*8>^LPY^S%?7W1&-/2PZ_1M02P,$%     @ BH5/5KC 2@GD!
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M4"&(TZ* ;8LK170">OZM-+D8[._^M^N_T##N"M/B$@,O#N$<M,6C:?$J:*S
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MK;FZC:7:V_40AC&1G?Q<O09^);+@R_T))@]8BZ))Y/MN@Q=P\D4U]<:1BEF
M>?FYE]1Y-TP*4J3A3;-V4J"IMPO#-%.Q'=B>I730DXH?4GSHAY5Q0\X'RE;W
M1'H_ 5$E&-.E&#8EE6?>U/KJ;/LU(5]_)81YV$)^/=$&=BY6%-YE;FO-Z&GF
MYEG;\V'[G6;6H,UCS:T7FND2 S]BLUZ%VD(G$;!JB10Z1S;X2NH6+X];X&1V
M+:B6V<MQ.P^G;1.O7ZGCNU>V?4.%<&OQEBM'^0E5<J_"\RH8U"VQP=9W5O@U
M#NSKG,%5U1/Y6!T[M_'[G.2G>CZ-JU\;D?ZO.EORN1T<]\3!_O[QOX=\?BQD
MH?,2U,\G=\]AZ J[X+BN(XW[D"3TX'A%0IMW>+_,K*V7KYOZIL!^I8GJD9A9
ML)B\Z"B+:+WMX&I*F&7\U16"/&LQZ^ZZWSH\B6LYRKR6\Y()U3]E6M6AA[]U
M$*[*U.%$_<T55ZJW.7+PS>6N#S?GKO?X_PB#_B\Y7O\_4$L! A0#%     @
MBH5/5GP^0NV*- < )>!3 !               ( !     &5L=BTR,#(R,3(S
M,2YH=&U02P$"% ,4    " "*A4]6NWKH?8TG  !#W@$ $
M@ &X- < 96QV+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( (J%3U99T.A%,"D
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M,#(R,3(S,5]G,BYJ<&=02P$"% ,4    " "*A4]6_!91AM!. @#/[!< %
M            @ $5Y@H 96QV+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" "*A4]6SN<5<X!\ 0"JF!$ %               @ $7-0T 96QV+3(P,C(Q
M,C,Q7W!R92YX;6Q02P$"% ,4    " "*A4]6P<5EN9VB  !$W@0 '@
M        @ ')L0X 97AH:6)I=#$P,2TR,#(R,3(S,69O<F9O<FTN:'1M4$L!
M A0#%     @ BH5/5@^54239R@$ R%H- !X              ( !HE0/ &5X
M:&EB:70Q,#$Q+7!R:6UA<GEB;'5E8W)O+FAT;5!+ 0(4 Q0    ( (J%3U9?
MFOK=@)\! )9M#  >              "  ;<?$0!E>&AI8FET,3 Q,BUP<FEM
M87)Y8FQU97-H:2YH=&U02P$"% ,4    " "*A4]6&62BMO <  !EX@( '@
M            @ %SOQ( 97AH:6)I=#(Q+3(P,C(Q,C,Q9F]R9F]R;3$N:'1M
M4$L! A0#%     @ BH5/5DUZC:1)!   :A(  !X              ( !G]P2
M &5X:&EB:70R,RTR,#(R,3(S,69O<F9O<FTQ+FAT;5!+ 0(4 Q0    ( (J%
M3U:B/J?Q5P@  '@I   >              "  23A$@!E>&AI8FET,S$Q+3(P
M,C(Q,C,Q9F]R,3!X:RYH=&U02P$"% ,4    " "*A4]608R%/EP(  "V*0
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<;3$N:'1M4$L%!@     2 !( _@0  -P3$P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
